﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Guo, GF
   Wang, YX
   Zhang, YJ
   Chen, XX
   Lu, JB
   Wang, HH
   Jiang, C
   Qiu, HQ
   Xia, LP
AF Guo, Gui-Fang
   Wang, Yi-Xing
   Zhang, Yi-Jun
   Chen, Xiu-Xing
   Lu, Jia-Bin
   Wang, Hao-Hua
   Jiang, Chang
   Qiu, Hui-Quan
   Xia, Liang-Ping
TI Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for
   cetuximab treatment combined with chemotherapy in advanced colorectal
   cancer with wild-type KRAS: Analysis from real-world data
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE 4E-binding protein 1; Beclin-1; Microtubule-associated protein
   1A/B-light chain 3; Advanced colorectal cancer; Cetuximab efficacy;
   Prognosis
ID INCREASES DRUG-RESISTANCE; INDUCED DOWN-REGULATION; ACTIVATING
   AUTOPHAGY; 1ST-LINE TREATMENT; SURVIVAL; GROWTH; BEVACIZUMAB; THERAPY;
   KINASE; CELLS
AB BACKGROUND
   Colorectal cancer (CRC) is one of the main causes of cancer-related deaths in China and around the world. Advanced CRC (ACRC) patients suffer from a low cure rate though treated with targeted therapies. The response rate is about 50% to chemotherapy and cetuximab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR) and used for ACRC with wild-type KRAS. It is important to identify more predictors of cetuximab efficacy to further improve precise treatment. Autophagy, showing a key role in the cancer progression, is influenced by the EGFR pathway. Whether autophagy can predict cetuximab efficacy in ACRC is an interesting topic.
   AIM
   To investigate the effect of autophagy on the efficacy of cetuximab in colon cancer
   METHODS
   ACRC patients treated with cetuximab plus chemotherapy, with detailed data and tumor tissue, at Sun Yat-sen University Cancer Center from January 1, 2005, to October 1, 2015, were studied. Expression of autophagy-related proteins [Beclin1, microtubule-associated protein 1A/B-light chain 3 (LC3), and 4E-binding protein 1 (4E-BP1)] was examined by Western blot in CRC cells and by immunohistochemistry in cancerous and normal tissues. The effect of autophagy on cetuximab-treated cancer cells was confirmed by MTT assay. The associations between Beclin1, LC3, and 4E-BP1 expression in tumor tissue and the efficacy of cetuximab-based therapy were analyzed.
   RESULTS
   In CACO-2 cells exposed to cetuximab, LC3 and 4E-BP1 were upregulated, and P62 was downregulated. Autophagosome formation was observed, and autophagy increased the efficacy of cetuximab. In 68 ACRC patients, immunohistochemistry showed that Beclin1 levels were significantly correlated with those of LC3 (0.657, P < 0.001) and 4E-BP1 (0.211, P = 0.042) in ACRC tissues. LC3 was significantly overexpressed in tumor tissues compared to normal tissues (P < 0.001). In 45 patients with wild-type KRAS, the expression levels of these three proteins were not related to progression-free survival; however, the expression levels of Beclin1 (P = 0.010) and 4E-BP1 (P = 0.005), pathological grade (P = 0.002), and T stage (P = 0.004) were independent prognostic factors for overall survival (OS).
   CONCLUSION
   The effect of cetuximab on colon cancer cells might be improved by autophagy. LC3 is overexpressed in tumor tissues, and Beclin1 and 4E-BP1 could be significant predictors of OS in ACRC patients treated with cetuximab.
C1 [Guo, Gui-Fang; Wang, Yi-Xing; Chen, Xiu-Xing; Wang, Hao-Hua; Jiang, Chang; Qiu, Hui-Quan; Xia, Liang-Ping] Sun Yat Sen Univ, Canc Ctr, VIP Dept, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
   [Guo, Gui-Fang; Wang, Yi-Xing; Zhang, Yi-Jun; Chen, Xiu-Xing; Lu, Jia-Bin; Wang, Hao-Hua; Jiang, Chang; Qiu, Hui-Quan; Xia, Liang-Ping] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.
   [Guo, Gui-Fang; Wang, Yi-Xing; Zhang, Yi-Jun; Chen, Xiu-Xing; Lu, Jia-Bin; Wang, Hao-Hua; Jiang, Chang; Qiu, Hui-Quan; Xia, Liang-Ping] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhang, Yi-Jun; Lu, Jia-Bin] Sun Yat Sen Univ, Canc Ctr, Pathol Dept, Guangzhou 510060, Guangdong, Peoples R China.
RP Guo, GF (corresponding author), Sun Yat Sen Univ, Canc Ctr, VIP Dept, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
EM guogf@sysucc.org.cn
OI guo, gui fang/0000-0002-6283-7266
CR Alan P, 2016, ESMO C
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Ekstrand AI, 2010, FAM CANCER, V9, P125, DOI 10.1007/s10689-009-9293-1
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Li N, 2013, BIOCHEM BIOPH RES CO, V439, P187, DOI 10.1016/j.bbrc.2013.08.065
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Yang MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097242
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Zhang J, 2013, INT J BIOCHEM CELL B, V45, P745, DOI 10.1016/j.biocel.2012.11.001
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 29
TC 10
Z9 11
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD APR 21
PY 2019
VL 25
IS 15
BP 1840
EP 1853
DI 10.3748/wjg.v25.i15.1840
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA HU2UC
UT WOS:000465126200005
PM 31057298
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Wagh, UR
   Rupachandra, S
AF Wagh, Uttara Ravindra
   Rupachandra, S.
TI New insights of RA-V cyclopeptide as an autophagy inhibitor in human
   COLO 320DM cancer cell lines
SO INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS
LA English
DT Article
DE Apoptosis; Autophagosome; Chloroquine; Colon Cancer; Cyclopeptide;
   Rapamycin
ID APOPTOSIS; CISPLATIN; PEPTIDES; PROTEIN
AB Colon cancer is the leading cause for the malignancy in the gastrointestinal tract. Autophagy is a self-degradation process of the unnecessary, injured and aged organelles and proteins in the cell, which is followed by recovering of degraded products. Apoptosis is a programmed cell death which is characterized by membrane blebbing, chromosome condensation and nuclear fragmentation. Apoptosis and autophagy can occur frequently in a cell, predominantly in a series preceding apoptosis through autophagy by the formation of autophagosomes. In current research, the impact of autophagy inhibition and apoptosis activation were found to be the targeted strategies to treat colon cancer. This study is focused on the apoptotic potential of RA-V, a natural cyclopeptide through the inhibition of protective autophagy in colon cancer cells. Growth inhibitory properties were observed in the RA-V treated (125 mu M) colo 320DM cells using cell viability assay. RA-V induced apoptosis of colo 320DM cells at the maximum concentration of 125 mu M, which was observed using DAPI and Annexin - PI staining methods. In this study we also examined the mechanistic role of RA-V (125 mu M) in and colo 320DM cells in the presence of Rapamycin (mTOR inhibitor) and chloroquine (autophagy inhibitor) using MDC and AO staining methods.
C1 [Wagh, Uttara Ravindra; Rupachandra, S.] SRM Inst Sci & Technol, Dept Biotechnol, Chennai 603203, Tamil Nadu, India.
RP Rupachandra, S (corresponding author), SRM Inst Sci & Technol, Dept Biotechnol, Chennai 603203, Tamil Nadu, India.
EM rupachas@srmist.edu.in
CR Bastos M, 2011, BIOPHYS J, V101, pL20, DOI 10.1016/j.bpj.2011.06.038
   Chacko SM, 2015, TOXICOL REP, V2, P1213, DOI 10.1016/j.toxrep.2015.08.002
   Chen XR, 2017, RSC ADV, V7, P22270, DOI 10.1039/c7ra00056a
   Chen X, 2016, FREE RADICAL RES, V50, P744, DOI 10.3109/10715762.2016.1173689
   CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q
   Cooper KF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4701275
   Dahiya R, 2007, ARCH PHARM RES, V30, P1380, DOI 10.1007/BF02977360
   de Veer SJ, 2019, CHEM REV, V119, P12375, DOI 10.1021/acs.chemrev.9b00402
   Fan JT, 2010, BIOORGAN MED CHEM, V18, P8226, DOI 10.1016/j.bmc.2010.10.019
   Fang XY, 2013, TOXICOL APPL PHARM, V267, P95, DOI 10.1016/j.taap.2012.12.010
   Fullgrabe J, 2016, J CELL SCI, V129, P3059, DOI 10.1242/jcs.188920
   Granados-Romero J, 2017, INT, V5, P4667, DOI [10.18203/2320-6012.ijrms20174914, DOI 10.18203/2320-6012.IJRMS20174914]
   Hicks RP, 2016, BIOORGAN MED CHEM, V24, P4056, DOI 10.1016/j.bmc.2016.06.048
   Katz SJ, 2011, CURR OPIN RHEUMATOL, V23, P278, DOI 10.1097/BOR.0b013e32834456bf
   Klimaszewska-Wisniewska A, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0288-3
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lau JL, 2018, BIOORGAN MED CHEM, V26, P2700, DOI 10.1016/j.bmc.2017.06.052
   Lee K, 2016, CURR EYE RES, V41, P1367, DOI 10.3109/02713683.2015.1119856
   Lee MS, 2018, MOL CELLS, V41, P1, DOI 10.14348/molcells.2018.0400
   Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z
   Li J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20934
   Liu HY, 2013, MOLECULES, V18, P13357, DOI 10.3390/molecules181113357
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Liu XY, 2016, NEUROSCI LETT, V620, P137, DOI 10.1016/j.neulet.2016.04.001
   Lovering F, 2013, MEDCHEMCOMM, V4, P515, DOI 10.1039/c2md20347b
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Ramadoss DP, 2020, NUTR CANCER, V72, P1422, DOI 10.1080/01635581.2019.1672763
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Song LH, 2017, MOLECULES, V22, DOI 10.3390/molecules22111934
   Soysa P, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2142-8
   Swadesh S., 2020, INDIAN J BIOCHEM BIO, V57, P51
   Tazehkand MN, 2019, INDIAN J BIOCHEM BIO, V56, P169
   Wang ZT, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0120843, 10.1371/journal.pone.0141807]
   Wani ZA, 2016, FOOD CHEM TOXICOL, V87, P1, DOI 10.1016/j.fct.2015.11.016
   Xu DQ, 2015, PLANTA MED, V81, P79, DOI 10.1055/s-0034-1383356
   Yang JH, 2018, RSC ADV, V8, P23451, DOI 10.1039/c8ra04241a
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Ramirez JAZ, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106495
   Zhang X, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-84
   Zhong B, 2017, J MOL GRAPH MODEL, V72, P25, DOI 10.1016/j.jmgm.2016.12.004
NR 44
TC 1
Z9 1
U1 0
U2 0
PU NATL INST SCIENCE COMMUNICATION-NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0301-1208
EI 0975-0959
J9 INDIAN J BIOCHEM BIO
JI Indian J. Biochem. Biophys.
PD OCT
PY 2021
VL 58
IS 5
BP 426
EP 433
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA WD4EC
UT WOS:000704895000004
DA 2022-04-25
ER

PT J
AU Mosca, L
   Pagano, M
   Pecoraro, A
   Borzacchiello, L
   Mele, L
   Cacciapuoti, G
   Porcelli, M
   Russo, G
   Russo, A
AF Mosca, Laura
   Pagano, Martina
   Pecoraro, Annalisa
   Borzacchiello, Luigi
   Mele, Luigi
   Cacciapuoti, Giovanna
   Porcelli, Marina
   Russo, Giulia
   Russo, Annapina
TI S-Adenosyl-l-Methionine Overcomes uL3-Mediated Drug Resistance in p53
   Deleted Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE uL3; drug resistance; AdoMet; autophagy; apoptosis; colon cancer
ID GASTRIC-CANCER; HNRNP H1; ADENOSYLMETHIONINE; RPL3; APOPTOSIS; LIVER;
   METHYLTHIOADENOSINE; EXPRESSION; PROTEIN; GROWTH
AB Purpose: In order to study novel therapeutic approaches taking advantage of natural compounds showing anticancer and anti-proliferative effects, we focused our interest on S-adenosyl-l-methionine, a naturally occurring sulfur-containing nucleoside synthesized from adenosine triphosphate and methionine by methionine adenosyltransferase, and its potential in overcoming drug resistance in colon cancer cells devoid of p53. Results: In the present study, we demonstrated that S-adenosyl-l-methionine overcomes uL3-mediated drug resistance in p53 deleted colon cancer cells. In particular, we demonstrated that S-adenosyl-l-methionine causes cell cycle arrest at the S phase; inhibits autophagy; augments reactive oxygen species; and induces apoptosis in these cancer cells. Conclusions: Results reported in this paper led us to propose S-adenosyl-l-methionine as a potential promising agent for cancer therapy by examining p53 and uL3 profiles in tumors to yield a better clinical outcomes.
C1 [Mosca, Laura; Borzacchiello, Luigi; Cacciapuoti, Giovanna; Porcelli, Marina] Univ Campania Luigi Vanvitelli, Dept Precis Med, Via Luigi De Crecchio, I-80138 Naples, Italy.
   [Pagano, Martina; Pecoraro, Annalisa; Russo, Giulia; Russo, Annapina] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.
   [Mele, Luigi] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.
RP Porcelli, M (corresponding author), Univ Campania Luigi Vanvitelli, Dept Precis Med, Via Luigi De Crecchio, I-80138 Naples, Italy.; Russo, G; Russo, A (corresponding author), Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.
EM laura.mosca@unicampania.it; martina.pagano@unicampania.it;
   annalisa.pecoraro@unina.it; luigi.borzacchiello@unicampania.it;
   luigi.mele@unicampania.it; giovanna.cacciapuoti@unicampania.it;
   marina.porcelli@unicampania.it; giulia.russo@unina.it;
   annapina.russo@unina.it
RI Pecoraro, Annalisa/AFQ-5507-2022; Mele, Luigi/AAC-9887-2019; Russo,
   Annapina/O-7545-2015
OI Mele, Luigi/0000-0002-6008-0802; Russo, Annapina/0000-0002-7509-3702
FU Regione Campania-POR Campania FESR 2014/2020 "Combattere la resistenza
   tumorale: piattaforma integrata multidisciplinare per un approccio
   tecnologico innovativo alle oncoterapie-Campania Oncoterapie"
   [B61G18000470007]; Fondo di ricerca di base FFABR-2017; Ministero della
   Universita e della Ricerca (MIUR)Ministry of Education, Universities and
   Research (MIUR); Programme Valere 2020 (Vanvitelli per la Ricerca;
   Universita della Campania "Luigi Vanvitelli"); Department of Precision
   Medicine, Universita della Campania "Luigi Vanvitelli"
FX This research was funded by a grant from Regione Campania-POR Campania
   FESR 2014/2020 "Combattere la resistenza tumorale: piattaforma integrata
   multidisciplinare per un approccio tecnologico innovativo alle
   oncoterapie-Campania Oncoterapie" Project No. B61G18000470007 (to A.
   Russo); Fondo di ricerca di base FFABR-2017 (to A. Russo and G. Russo);
   Ministero della Universita e della Ricerca (MIUR); Programme Valere 2020
   (Vanvitelli per la Ricerca; Universita della Campania "Luigi
   Vanvitelli"); and by Intradepartmental Projects, Department of Precision
   Medicine, Universita della Campania "Luigi Vanvitelli" (to M.Porcelli).
CR Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Bertram J, 1998, EUR J CANCER, V34, P731, DOI 10.1016/S0959-8049(97)10081-8
   Bukowski K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093233
   Carotenuto P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091090
   Cave D., 2017, JSM CHEM, V5, P1049
   Chong SJF, 2014, MITOCHONDRION, V19, P39, DOI 10.1016/j.mito.2014.06.002
   Delle Cave D, 2018, J CELL PHYSIOL, V233, P1370, DOI 10.1002/jcp.26015
   Ekberg J, 2006, INT J BIOCHEM CELL B, V38, P1330, DOI 10.1016/j.biocel.2006.01.011
   Esposito D, 2014, ONCOTARGET, V5, P11737, DOI 10.18632/oncotarget.2591
   Esposito V, 2017, BBA-GEN SUBJECTS, V1861, P1213, DOI 10.1016/j.bbagen.2016.09.019
   Fernandez-Ramos D, 2020, WORLD J GASTROENTERO, V26, P5101, DOI 10.3748/wjg.v26.i34.5101
   Fiore D, 2019, CANCERS, V11, DOI 10.3390/cancers11101456
   Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Huang SB, 2013, J BIOL CHEM, V288, P33654, DOI 10.1074/jbc.M113.518134
   Hussain Z, 2013, GENET MOL RES, V12, P1106, DOI 10.4238/2013.April.10.6
   Ilisso CP, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0697-6
   Indran IR, 2011, BBA-BIOENERGETICS, V1807, P735, DOI 10.1016/j.bbabio.2011.03.010
   John Reena Rachel, 2017, Indian J Dent Res, V28, P187, DOI 10.4103/ijdr.IJDR_697_16
   Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420
   Julien O, 2017, CELL DEATH DIFFER, V24, P1380, DOI 10.1038/cdd.2017.44
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Li TWH, 2015, MOL PHARMACOL, V87, P77, DOI 10.1124/mol.114.095679
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Li TWH, 2009, MOL PHARMACOL, V76, P192, DOI 10.1124/mol.108.054411
   Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9
   Lu SC, 2008, J GASTROEN HEPATOL, V23, pS73, DOI 10.1111/j.1440-1746.2007.05289.x
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Martinez-Lopez N, 2008, BIOCHEM SOC T, V36, P848, DOI 10.1042/BST0360848
   Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev
   Mele L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03056-x
   Minici C, 2020, J STRUCT BIOL, V210, DOI 10.1016/j.jsb.2020.107462
   Mosca L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228547
   Mosca L, 2020, INT J ONCOL, V56, P1212, DOI 10.3892/ijo.2020.5011
   Mosca L, 2019, J CELL PHYSIOL, V234, P13277, DOI 10.1002/jcp.28000
   Pagano C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31570-8
   Pagliara V, 2016, ONCOTARGET, V7, P50333, DOI 10.18632/oncotarget.10385
   Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197334
   Pecoraro A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040583
   Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062143
   Pecoraro A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51723-7
   Porcelli M, 2015, BIOENGINEERED, V6, P184, DOI 10.1080/21655979.2015.1045170
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Russo A, 2006, ANN ONCOL, V17, pVII115, DOI 10.1093/annonc/mdl963
   Russo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010140
   Russo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030547
   Russo A, 2016, ONCOTARGET, V7, P79656, DOI 10.18632/oncotarget.13216
   Russo A, 2016, INT J PHARMACEUT, V511, P127, DOI 10.1016/j.ijpharm.2016.06.118
   Russo A, 2016, CELL CYCLE, V15, P41, DOI 10.1080/15384101.2015.1120926
   Russo A, 2013, CELL CYCLE, V12, P76, DOI 10.4161/cc.22963
   Russo A, 2011, NUCLEIC ACIDS RES, V39, P7576, DOI 10.1093/nar/gkr461
   Russo A, 2010, BBA-GENE REGUL MECH, V1799, P419, DOI 10.1016/j.bbagrm.2010.01.008
   Russo A, 2008, BBA-GENE REGUL MECH, V1779, P820, DOI 10.1016/j.bbagrm.2008.08.006
   Russo G, 2005, BIOCHEM J, V385, P289, DOI 10.1042/BJ20040371
   Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Zhao YQ, 2002, CANCER LETT, V185, P211, DOI 10.1016/S0304-3835(02)00264-1
NR 57
TC 10
Z9 10
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 1
AR 103
DI 10.3390/ijms22010103
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PP8VJ
UT WOS:000606133200001
PM 33374288
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Taniguchi, K
   Sakai, M
   Sugito, N
   Kumazaki, M
   Shinohara, H
   Yamada, N
   Nakayama, T
   Ueda, H
   Nakagawa, Y
   Ito, Y
   Futamura, M
   Uno, B
   Otsuki, Y
   Yoshida, K
   Uchiyama, K
   Akao, Y
AF Taniguchi, Kohei
   Sakai, Miku
   Sugito, Nobuhiko
   Kumazaki, Minami
   Shinohara, Haruka
   Yamada, Nami
   Nakayama, Tatsushi
   Ueda, Hiroshi
   Nakagawa, Yoshihito
   Ito, Yuko
   Futamura, Manabu
   Uno, Bunji
   Otsuki, Yoshinori
   Yoshida, Kazuhiro
   Uchiyama, Kazuhisa
   Akao, Yukihiro
TI PTBP1-associated microRNA-1 and-133b suppress the Warburg effect in
   colorectal tumors
SO ONCOTARGET
LA English
DT Article
DE miR-1; miR-133; Warburg effect; PTBP1; PKM
ID TRACT-BINDING-PROTEIN; KINASE MESSENGER-RNA; CANCER-CELL-GROWTH;
   PYRUVATE-KINASE; ISOFORM EXPRESSION; DOWN-REGULATION; PTB; METABOLISM;
   FEEDBACK; HYPOXIA
AB It is known that pyruvate kinase in muscle (PKM), which is a rate-limiting glycolytic enzyme, has essential roles in the Warburg effect and that expression of cancer-dominant PKM2 is increased by polypyrimidine tract-binding protein 1 (PTBP1), which is a splicer of the PKM gene. In other words, PKM2 acts as a promoter of the Warburg effect. Previously, we demonstrated that the Warburg effect was partially established by down-regulation of several microRNAs (miRs) that bind to PTBP1 and that ectopic expression of these miRs suppressed the Warburg effect. In this study, we investigated the functions of miR-1 and -133b, which are well known as muscle-specific miRs, from the viewpoint of the Warburg effect in colorectal tumors. The expression levels of miR-1 and -133b were relatively high in colon tissue except muscle and very frequently down-regulated in 75 clinical colorectal tumors samples, even in adenomas, compared with those of the adjacent normal tissue samples. The ectopic expression of these miRs induced growth suppression and autophagic cell death through the switching of PKM isoform expression from PKM2 to PKM1 by silencing PTBP1 expression both in vitro and in vivo. Also, we showed that the resultant increase in the intracellular level of reactive oxygen species (ROS) was involved in this mechanism. Furthermore, PTBP1 was highly expressed in most of the 30 clinical colorectal tumor samples examined, even in adenomas. Our results suggested that PTBP1 and PTBP1-associated miR-1 and -133b are crucial molecules for the maintenance of the Warburg effect in colorectal tumors.
C1 [Taniguchi, Kohei; Sakai, Miku; Sugito, Nobuhiko; Kumazaki, Minami; Shinohara, Haruka; Yamada, Nami; Nakayama, Tatsushi; Ueda, Hiroshi; Uno, Bunji; Akao, Yukihiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu 5011193, Japan.
   [Taniguchi, Kohei; Uchiyama, Kazuhisa] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka 5698686, Japan.
   [Nakagawa, Yoshihito] Fujita Hlth Univ, Dept Gastroenterol, Sch Med, Kutsukake Cho, Toyoake, Aichi 4701192, Japan.
   [Ito, Yuko; Otsuki, Yoshinori] Osaka Med Coll, Div Life Sci, Dept Anat & Cell Biol, Takatsuki, Osaka 5698686, Japan.
   [Futamura, Manabu; Yoshida, Kazuhiro] Gifu Univ, Dept Surg Oncol, Sch Med, Gifu 5011193, Japan.
RP Taniguchi, K (corresponding author), Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu 5011193, Japan.; Taniguchi, K (corresponding author), Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka 5698686, Japan.
EM sur144@osaka-med.ac.jp
RI Nakayama, Tatsushi/AAE-8723-2022
OI Nakayama, Tatsushi/0000-0002-0346-2089; Yamada,
   Nami/0000-0002-1220-0814; Shinohara, Haruka/0000-0001-8326-1203;
   Taniguchi, Kohei/0000-0003-0648-1370
FU Ministry of Education, Science, Sports, and Culture of JapanMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [YA-24659157, KU-15K10120]
FX The work was supported in part by a grant-in-aid for scientific research
   from the Ministry of Education, Science, Sports, and Culture of Japan
   (YA-24659157 and KU-15K10120).
CR Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88
   Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270
   Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   Coles LS, 2004, EUR J BIOCHEM, V271, P648, DOI 10.1111/j.1432-1033.2003.03968.x
   Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Doe MR, 2012, CANCER RES, V72, P949, DOI 10.1158/0008-5472.CAN-11-2371
   He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307
   He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47
   Jin W, 2000, CANCER RES, V60, P1221
   Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099
   Kuwabara Y, 2011, CIRC-CARDIOVASC GENE, V4, P446, DOI 10.1161/CIRCGENETICS.110.958975
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001
   Muraoka N, 2014, EMBO J, V33, P1565, DOI 10.15252/embj.201387605
   Nakagawa Y, 2015, INT J MOL SCI, V16, P1526, DOI 10.3390/ijms16011526
   NOGUCHI T, 1986, J BIOL CHEM, V261, P3807
   PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Schepens B, 2005, NUCLEIC ACIDS RES, V33, P6884, DOI 10.1093/nar/gki1000
   Shinohara H, 2015, CANCER LETT, V360, P28, DOI 10.1016/j.canlet.2015.01.039
   Spellman R, 2006, TRENDS BIOCHEM SCI, V31, P73, DOI 10.1016/j.tibs.2005.12.003
   Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Taniguchi K, 2015, BBA-MOL BASIS DIS, V1852, P1971, DOI 10.1016/j.bbadis.2015.06.022
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Taniguchi K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08647
   Tillmar L, 2002, MOL MED, V8, P263, DOI 10.1007/BF03402152
   Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Williams AH, 2009, CURR OPIN CELL BIOL, V21, P461, DOI 10.1016/j.ceb.2009.01.029
   Yamada N, 2014, BBA-GENE REGUL MECH, V1839, P1256, DOI 10.1016/j.bbagrm.2014.09.002
   Yamada N, 2013, TRANSL ONCOL, V6, P482, DOI 10.1593/tlo.13280
   Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001
NR 41
TC 46
Z9 50
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 5
PY 2016
VL 7
IS 14
BP 18940
EP 18952
DI 10.18632/oncotarget.8005
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5TE
UT WOS:000375699000133
PM 26980745
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Adacan, K
   Obakan Yerlikaya, P
AF Adacan, Kaan
   Obakan Yerlikaya, Pinar
TI Epibrassinolide activates AKT to trigger autophagy with polyamine
   metabolism in SW480 and DLD-1 colon cancer cell lines
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE Autophagy; epibrassinolide; polyamines; LC3; spermidine
ID ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS; KINASE
AB Epibrassinolide (EBR), a plant-derived polyhydroxylated derivative of 5 alpha-cholestane, structurally shows similarities to animal steroid hormones. According to the present study, EBR treatment triggered a significant stress response via activating ER stress, autophagy, and apoptosis in cancer cells. EBR could also increase Akt phosphorylation in vitro. While the activation of Akt resulted in cellular metabolic activation in normal cells to proceed with cell survival, a rapid stress response was induced in cancer cells to reduce survival. Therefore, Akt as a mediator of cellular survival and death decision pathways is a crucial target in cancer cells. In this study, we determined that EBR induces stress responses through activating Akt, which reduced the mTOR complex I (mTORC1) activation in SW480 and DLD-1 colon cancer cells. As a consequence, EBR triggered macroautophagy and led to lipidation of LC3 most efficiently in SW480 cells. The cotreatment of spermidine (Spd) with EBR increased lipidation of LC3 synergistically in both cell lines. We also found that EBR promoted polyamine catabolism in SW480 cells. The retention of polyamine biosynthesis was remarkable following EBR treatment. We suggested that EBR-mediated Akt activation might determine the downstream cellular stress responses to induce autophagy related to polyamines.
C1 [Adacan, Kaan; Obakan Yerlikaya, Pinar] Istanbul Kultur Univ, Sci & Literature Fac, Dept Mol Biol & Genet, Istanbul, Turkey.
RP Obakan Yerlikaya, P (corresponding author), Istanbul Kultur Univ, Sci & Literature Fac, Dept Mol Biol & Genet, Istanbul, Turkey.
EM p.obakan@iku.edu.tr
OI OBAKAN YERLIKAYA, PINAR/0000-0001-7058-955X
FU Istanbul Kultur University Scientific Project CenterIstanbul Kultur
   University
FX This study was supported by the Istanbul Kultur University Scientific
   Project Center. We gratefully thank Utku Ozbey for his technical
   assistance for the HPLC analysis.
CR Akkoc Y, 2018, TURK J GASTROENTEROL, V29, P270, DOI 10.5152/tjg.2018.150318
   Banerjee IA, 2019, MAT SCI ENG C-MATER, V97, P451, DOI 10.1016/j.msec.2018.12.037
   Coskun D, 2015, EXP CELL RES, V338, P10, DOI 10.1016/j.yexcr.2015.08.015
   Cybulsky AV, 2017, NAT REV NEPHROL, V13, P681, DOI 10.1038/nrneph.2017.129
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Esposito D, 2011, J MED CHEM, V54, P4057, DOI 10.1021/jm200028h
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Hai Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15368
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kahana C, 2009, CELL MOL LIFE SCI, V66, P2479, DOI 10.1007/s00018-009-0033-3
   Kocaturk NM, 2019, EUR J PHARM SCI, V134, P116, DOI 10.1016/j.ejps.2019.04.011
   Kuryayeva F, 2019, EPIBRASSINOLIDE PROM, V40, P10
   Lee ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057708
   Liu HY, 2009, J BIOL CHEM, V284, P31484, DOI 10.1074/jbc.M109.033936
   Menon D, 2017, J BIOL CHEM, V292, P6303, DOI 10.1074/jbc.M116.772988
   Obakan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135788
   Obakan P, 2014, AMINO ACIDS, V46, P553, DOI 10.1007/s00726-013-1574-1
   Obakan-Yerlikaya P, 2017, MOL CARCINOGEN, V56, P1603, DOI 10.1002/mc.22616
   Palavan-Unsal N., 2006, Experimental Oncology, V28, P178
   Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   Pietrocola F, 2015, CELL DEATH DIFFER, V22, P509, DOI 10.1038/cdd.2014.215
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   SINGH S, 1990, ANAL BIOCHEM, V187, P212, DOI 10.1016/0003-2697(90)90446-G
   Song S, J CELLULAR PHYSL, V233, P3867
   Wang Tian, 2005, Zhiwu Shengli yu Fenzi Shengwuxue Xuebao, V31, P637
   Yue F, 2017, CANCER RES, V77, P2938, DOI 10.1158/0008-5472.CAN-16-3462
   Zhang Z, 2012, MOL CELL BIOCHEM, V361, P249, DOI 10.1007/s11010-011-1110-0
NR 31
TC 0
Z9 0
U1 1
U2 3
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2020
VL 44
IS 6
BP 417
EP 426
DI 10.3906/biy-2005-37
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA PI9FM
UT WOS:000601387600007
PM 33402868
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU An, N
   Sun, Y
   Ma, L
   Shi, SL
   Zheng, X
   Feng, WS
   Shan, ZM
   Han, YG
   Zhao, L
   Wu, HM
AF An, Na
   Sun, Ying
   Ma, Ligang
   Shi, Shengli
   Zheng, Xiaoke
   Feng, Weisheng
   Shan, Zhiming
   Han, Yongguang
   Zhao, Le
   Wu, Huiming
TI Helveticoside Exhibited p53-dependent Anticancer Activity Against
   Colorectal Cancer
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE Colorectal cancer; Helveticoside; Apoptosis; Mitochondrial membrane
   potential; p53
ID ROS-DEPENDENT APOPTOSIS; COLON-CANCER; NATURAL-PRODUCTS; TANSHINONE IIA;
   GROWTH; CELLS; MECHANISMS; GLYCOSIDES; AUTOPHAGY; MILTIRONE
AB Background. Investigation into the anti-cancer activities of natural products and their derivatives represents an efficient approach to develop safe and effective chemotherapeutic agents for the treatment of colorectal cancer. Helveticoside is a biologically active component of the seed extract of Descurainia sophia. This compound has been reported to regulate the genes related to cell proliferation and apoptosis in lung cancer cells, however its anticancer activity has not been fully explored yet.
   Methods. Cell viability was evaluated by MTT and Trypan blue exclusion assay; cell apoptosis was measured by flow cytometry; mitochondrial membrane potential was determined by using JC1-mitochondrial membrane potential assay kit; protein levels were determined by western blot assay; in vivo tumor growth was assessed in a xenograft nude mice model.
   Results. The current study demonstrated the in vitro anti-cancer activity of helveticoside against colorectal cancer using colorectal cancer cells SW480 and HCT116. Moreover, induction of apoptosis was found to mediate the cytotoxic action of helveticoside on SW480 and HCT116 cells. Based on the decrease in the mitochondrial membrane potential, upregulation of Bax, downregulation of Bcl-2 and cleavage of caspase-3 and 9, apoptosis was induced by helveticoside via mitochondria-mediated intrinsic apoptotic signaling pathways in colorectal cancer cells. Besides, using p53-knockout SW480 cells, the cytotoxic action of helveticoside was found to be p53-dependent. More importantly, administration of helveticoside inhibited the growth of HCT116 cells derived-colorectal cancer xenograft in mice via activation of apoptosis.
   Conclusions. Helveticoside might be a potential candidate for the development of novel chemotherapeutic agents for the treatment of colorectal cancer, while the potential toxic effects of helveticoside may be worthy of further investigations. (C) 2020 IMSS. Published by Elsevier Inc.
C1 [An, Na; Ma, Ligang; Shi, Shengli; Zheng, Xiaoke; Feng, Weisheng; Han, Yongguang; Zhao, Le; Wu, Huiming] Henan Univ Chinese Med, Coll Pharm, Zhengzhou 450046, Henan, Peoples R China.
   [Sun, Ying] Henan Univ Chinese Med, Basic Med Coll, Zhengzhou, Henan, Peoples R China.
   [Zheng, Xiaoke; Feng, Weisheng] Henan Univ Chinese Med, Coconstruct Collaborat Innovat Ctr Chinese Med &, Zhengzhou, Henan, Peoples R China.
   [Shan, Zhiming] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Clin Lab,Childrens Hosp, Zhengzhou, Henan, Peoples R China.
RP Zheng, X (corresponding author), Henan Univ Chinese Med, Coll Pharm, Zhengzhou 450046, Henan, Peoples R China.
EM zhengxk.2006@163.com
RI Ma, Ligang/O-9603-2014
OI Ma, Ligang/0000-0003-3451-5291
FU National Key Research and Development Project (The Major Project for
   Research of the Modernization of TCM) [2019YFC1708802]; Henan province
   high-level personnel special support "ZhongYuan One Thousand People
   Plan''-Zhongyuan Leading Talent [ZYQR201810080]; Doctoral Scientific
   Fund Project of Henan University of Chinese Medicine [BSJJ2014-13];
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2017M622352]; Henan Province Postdoctoral Science Foundation
   [00104341]
FX This study was supported by The National Key Research and Development
   Project (The Major Project for Research of the Modernization of TCM; No.
   2019YFC1708802), Henan province high-level personnel special support
   ``ZhongYuan One Thousand People Plan''-Zhongyuan Leading Talent (No.
   ZYQR201810080), The Doctoral Scientific Fund Project of Henan University
   of Chinese Medicine (No. BSJJ2014-13), China Postdoctoral Science
   Foundation (No. 2017M622352), and Henan Province Postdoctoral Science
   Foundation (No. 00104341).
CR Bai YQ, 2016, EXP THER MED, V11, P1085, DOI 10.3892/etm.2016.2984
   Biggar RJ, 2012, CLIN CANCER RES, V18, P2133, DOI 10.1158/1078-0432.CCR-11-1389
   CHEN KK, 1962, ARCH INT PHARMACOD T, V140, P8
   Hu T, 2013, J BIOMOL RES THER, V2, P110, DOI [10.4172/21677956.1000110, DOI 10.4172/21677956.1000110]
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu T, 2015, CURR PHARM DESIGN, V21, P2960, DOI 10.2174/1381612821666150514104244
   Hu T, 2015, CHEM-BIOL INTERACT, V230, P1, DOI 10.1016/j.cbi.2015.02.006
   Kim BY, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1918-1
   Kim SJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/404713
   Li LF, 2014, INT J MOL MED, V34, P372, DOI 10.3892/ijmm.2014.1786
   Lopez-Ladzaro M, 2005, J NAT PROD, V68, P1642, DOI 10.1021/np050226l
   Miura K, 2015, EXPERT OPIN DRUG DIS, V10, P411, DOI 10.1517/17460441.2015.1018174
   Rajamanickam S, 2008, DRUG DEVELOP RES, V69, P460, DOI 10.1002/ddr.20276
   STIERLE A, 1993, SCIENCE, V260, P214, DOI 10.1126/science.8097061
   Su CC, 2008, PLANTA MED, V74, P1357, DOI 10.1055/s-2008-1081299
   Trenti A, 2014, BIOCHEM PHARMACOL, V89, P197, DOI 10.1016/j.bcp.2014.02.021
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Wang L, 2016, LIFE SCI, V151, P224, DOI 10.1016/j.lfs.2016.02.083
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang Y, 2012, INT J BIOCHEM CELL B, V44, P1813, DOI 10.1016/j.biocel.2012.06.028
   Zhou XL, 2013, PHYTOMEDICINE, V20, P367, DOI 10.1016/j.phymed.2012.09.021
NR 21
TC 2
Z9 2
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD APR
PY 2020
VL 51
IS 3
BP 224
EP 232
DI 10.1016/j.arcmed.2020.02.007
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA LS1GC
UT WOS:000536139200005
PM 32147288
DA 2022-04-25
ER

PT J
AU Lee, SH
   Lee, HS
   Lee, J
   Amarakoon, D
   Lou, ZY
   Noronha, LE
   Herald, TJ
   Perumal, R
   Smolensky, D
AF Lee, Seong-Ho
   Lee, Hee-Seop
   Lee, Jihye
   Amarakoon, Darshika
   Lou, Zhiyuan
   Noronha, Leela E.
   Herald, Thomas J.
   Perumal, Ramasamy
   Smolensky, Dmitriy
TI Polyphenol Containing Sorghum Brans Exhibit an Anti-Cancer Effect in Apc
   Min/ plus Mice Treated with Dextran Sodium Sulfate
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE high phenolic sorghum bran; colon cancer; PI3K; AMPK; autophagy; Apc
   Min; + mouse
ID GENOME-WIDE ASSOCIATION; CANCER-CELL GROWTH; NF-KAPPA-B; POTENTIAL
   IMPACT; PHYTOCHEMICALS; EXPRESSION; AUTOPHAGY; PATHWAY; ACID; LINE
AB Colon cancer (CC) is considered a high-risk cancer in developed countries. Its etiology is correlated with a high consumption of red meat and low consumption of plant-based foods, including whole grains. Sorghum bran is rich in polyphenols. This study aimed to determine whether different high-phenolic sorghum brans suppress tumor formation in a genetic CC rodent model and elucidate mechanisms. Tissue culture experiments used colorectal cancer cell lines SW480, HCT-116 and Caco-2 and measured protein expression, and protein activity. The animal model used in this study was APC Min+/mouse model combined with dextram sodium sulfate. High phenolic sorghum bran extract treatment resulted in the inhibition of proliferation and induced apoptosis in CC cell lines. Treatment with high phenolic sorghum bran extracts repressed TNF-alpha-stimulated NF-kappa B transactivation and IGF-1-stimulated PI3K/AKT pathway via the downregulation of beta-catenin transactivation. Furthermore, high-phenolic sorghum bran extracts activated AMPK and autophagy. Feeding with high-phenolic sorghum bran for 6 weeks significantly suppressed tumor formation in an APC Min/+ dextran sodium sulfate promoted CC mouse model. Our data demonstrates the potential application of high-phenolic sorghum bran as a functional food for the prevention of CC.
C1 [Lee, Seong-Ho; Lee, Hee-Seop; Lee, Jihye; Amarakoon, Darshika; Lou, Zhiyuan] Univ Maryland, Coll Agr & Nat Resources, Dept Nutr & Food Sci, College Pk, MD 20742 USA.
   [Noronha, Leela E.] ARS, Arthropod Borne Anim Dis Res Unit, USDA, Manhattan, KS 66502 USA.
   [Herald, Thomas J.; Smolensky, Dmitriy] ARS, Grain Qual & Struct Res Unit, USDA, Manhattan, KS 66502 USA.
   [Perumal, Ramasamy] Kansas State Univ, Agr Res Ctr, Hays, KS 67601 USA.
RP Lee, SH (corresponding author), Univ Maryland, Coll Agr & Nat Resources, Dept Nutr & Food Sci, College Pk, MD 20742 USA.; Smolensky, D (corresponding author), ARS, Grain Qual & Struct Res Unit, USDA, Manhattan, KS 66502 USA.
EM slee2000@umd.edu; hslee123@umd.edu; jlee1232@terpmail.umd.edu;
   darshika@umd.edu; zhiyuanlou@hotmail.com; Leela.noronha@usda.gov;
   thomasherald98@gmail.com; perumal@ksu.edu; dmitriy.smolensky@usda.gov
RI Smolensky, Dmitriy/AAD-2009-2019; Lee, Jihye/AAY-2441-2021
OI Smolensky, Dmitriy/0000-0002-8128-2681; Lee, Jihye/0000-0002-7007-7498;
   Lee, Hee-Seop/0000-0002-8500-9607; Noronha, Leela/0000-0003-2330-2215
FU USDA-ARSUnited States Department of Agriculture (USDA)USDA Agricultural
   Research Service [3020-43440-002-000-D]
FX This research and APC was funded by USDA-ARS in-house appropriated
   project number 3020-43440-002-000-D.
CR Amarakoon D, 2021, J SCI FOOD AGR, V101, P2641, DOI 10.1002/jsfa.10933
   Aruna C., 2019, BREEDING SORGHUM DIV, P1
   Awika JM, 2004, PHYTOCHEMISTRY, V65, P1199, DOI 10.1016/j.phytochem.2004.04.001
   Baek SJ, 2006, GASTROENTEROLOGY, V131, P1553, DOI 10.1053/j.gastro.2006.09.015
   Cardoso LD, 2017, CRIT REV FOOD SCI, V57, P372, DOI 10.1080/10408398.2014.887057
   Clark R, 2015, J AGR FOOD CHEM, V63, P4297, DOI 10.1021/jf506098s
   Cox S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01589
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Herald TJ, 2012, J SCI FOOD AGR, V92, P2326, DOI 10.1002/jsfa.5633
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kothari K, 2020, T ASABE, V63, P81, DOI 10.13031/trans.13465
   Lee SH, 2010, ONCOGENE, V29, P5182, DOI 10.1038/onc.2010.251
   Lee SH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2890536
   Lee SH, 2012, J NUTR BIOCHEM, V23, P646, DOI 10.1016/j.jnutbio.2011.03.009
   Li M, 2021, FOOD CHEM, V340, DOI 10.1016/j.foodchem.2020.128123
   Li WD, 2015, ONCOTARGET, V6, P7365, DOI 10.18632/oncotarget.3629
   Park JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040531
   Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004
   Ratnavathi C. V., 2019, BREEDING SORGHUM DIV, P193, DOI DOI 10.1016/B978-0-08-101879-8.00012-7
   Rhodes D, 2017, CEREAL CHEM, V94, P190, DOI [10.1094/CCHEM-03-16-0075-R, 10.1094/cchem-03-16-0075-r]
   Rhodes DH, 2014, J AGR FOOD CHEM, V62, P10916, DOI 10.1021/jf503651t
   Ritchie LE, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040330
   Ritchie LE, 2015, FEMS MICROBIOL ECOL, V91, DOI 10.1093/femsec/fiv008
   Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Smolensky D, 2018, J MED FOOD, V21, P990, DOI 10.1089/jmf.2018.0008
   Soleimani A, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144132
   Suvarna V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00916
   Turner ND, 2006, FASEB J, V20, pA599
   Uchimiya M, 2020, J AGR FOOD CHEM, V68, P12978, DOI 10.1021/acs.jafc.9b07816
   WALTER E, 1995, EUR J PHARM SCI, V3, P215, DOI 10.1016/0928-0987(95)00010-B
   Wu GC, 2017, FOOD RES INT, V97, P347, DOI 10.1016/j.foodres.2017.04.030
   Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530
   Yang LY, 2009, J AGR FOOD CHEM, V57, P1797, DOI 10.1021/jf8035066
   Yu WK, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00984
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
   Zhang YQ, 2019, FOOD SCI NUTR, V7, P949, DOI 10.1002/fsn3.886
NR 40
TC 3
Z9 3
U1 6
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 8286
DI 10.3390/ijms22158286
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV5WV
UT WOS:000681794600001
PM 34361052
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Rudolf, E
   Rezacova, K
   Cervinka, M
AF Rudolf, Emil
   Rezacova, Katerina
   Cervinka, Miroslav
TI Activation of p38 and changes in mitochondria accompany autophagy to
   premature senescence-like phenotype switch upon chronic exposure to
   selenite in colon fibroblasts
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Sodium selenite; Colonic fibroblasts; p38; Premature senescence;
   Mitochondria; Autophagy
ID COLORECTAL-CANCER CELLS; OXIDATIVE STRESS; INDUCED APOPTOSIS; SIGNALING
   PATHWAY; PROSTATE-CANCER; SODIUM-SELENITE; PROTEIN-KINASE;
   PHOSPHORYLATION; CHEMOPREVENTION; INVOLVEMENT
AB Effects of chronic exposure to supranutritional sodium selenite (Se) were investigated in colonic fibroblasts. Initially, Se did not produce any gross changes in exposed cells; however, basal levels of autophagy were transiently increased and p38 activity was stimulated. From the 3rd week onwards, Se decreased cell proliferation, with corrensponding changes in cell cycle distribution. Also, in exposed cells oxidative stress and DNA damage slowly but gradually increased along with decreasing mitochondrial function and upon continued elevated activity of p38 kinase. Towards the end of the experiment, premature senescence features became more prominent in treated cells. Pharmacological inhibition as well as gene knockdown of these processes confirmed the involvement of p38 in balancing autophagy and premature senescence in cells exposed to Se and suggests that this element may in a given time frame compromise selected cell populations in digestive system. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Rudolf, Emil; Rezacova, Katerina; Cervinka, Miroslav] Charles Univ Prague, Dept Med Biol & Genet, Fac Med Hradec Kralove, Hradec Kralove 50038, Czech Republic.
RP Rudolf, E (corresponding author), Charles Univ Prague, Dept Med Biol & Genet, Fac Med Hradec Kralove, Simkova 870, Hradec Kralove 50038, Czech Republic.
EM rudolf@lfhk.cuni.cz
RI Rudolf, Emil/B-5956-2017; Cervinka, Miroslav/R-7387-2016
OI Rudolf, Emil/0000-0002-9526-3174; Cervinka, Miroslav/0000-0001-8602-4756
FU PRVOUK [P37/01]
FX This work was supported by the program PRVOUK P37/01.
CR Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631
   Choi CH, 2012, BIOCHEM BIOPH RES CO, V418, P759, DOI 10.1016/j.bbrc.2012.01.095
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   Combs GF, 2001, BRIT J NUTR, V85, P517, DOI 10.1079/BJN2000280
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236
   Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903
   Debacq-Chainiaux F, 2010, ADV EXP MED BIOL, V694, P126
   El-Bayoumy K, 2005, MUTAT RES-FUND MOL M, V591, P224, DOI 10.1016/j.mrfmmm.2005.04.021
   Harrison PR, 1997, BIOMED ENVIRON SCI, V10, P235
   Hu YJ, 2005, J NUTR, V135, p3021S, DOI 10.1093/jn/135.12.3021S
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Irons R, 2006, J NUTR, V136, P1311, DOI 10.1093/jn/136.5.1311
   Ito M, 2011, AGING-US, V3, P1213, DOI 10.18632/aging.100418
   Jacobs ET, 2004, J NATL CANCER I, V96, P1669, DOI 10.1093/jnci/djh310
   Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129
   Kim YS, 2004, EXP MOL MED, V36, P157, DOI 10.1038/emm.2004.22
   Krishna M, 2008, CELL MOL LIFE SCI, V65, P3525, DOI 10.1007/s00018-008-8170-7
   Li J, 2003, J TRACE ELEM MED BIO, V17, P19, DOI 10.1016/S0946-672X(03)80041-X
   Luo H, 2012, CANCER LETT, V315, P78, DOI 10.1016/j.canlet.2011.10.014
   Meuillet E, 2004, J CELL BIOCHEM, V91, P443, DOI 10.1002/jcb.10728
   Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467
   Rocourt CRB, 2013, J NUTR BIOCHEM, V24, P781, DOI 10.1016/j.jnutbio.2012.04.011
   SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682
   Shilo S, 2003, ANTIOXID REDOX SIGN, V5, P273, DOI 10.1089/152308603322110850
   Ye YC, 2011, J PHARMACOL SCI, V117, P160, DOI 10.1254/jphs.11105FP
   Yu RA, 2006, BIOMED ENVIRON SCI, V19, P197
   Zhang YM, 2009, FASEB J, V23, P1358, DOI 10.1096/fj.08-110296
   Zhong WX, 2001, CANCER RES, V61, P7071
   Zou YF, 2008, CANCER BIOL THER, V7, P689, DOI 10.4161/cbt.7.5.5688
NR 31
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD NOV 18
PY 2014
VL 231
IS 1
BP 29
EP 37
DI 10.1016/j.toxlet.2014.09.006
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA AT1LU
UT WOS:000344696100004
PM 25204997
DA 2022-04-25
ER

PT J
AU Gorgulho, CM
   Krishnamurthy, A
   Lanzi, A
   Galon, J
   Housseau, F
   Kaneno, R
   Lotze, MT
AF Gorgulho, Carolina Mendonca
   Krishnamurthy, Anuradha
   Lanzi, Anastasia
   Galon, Jerome
   Housseau, Franck
   Kaneno, Ramon
   Lotze, Michael T.
TI Gutting it Out: Developing Effective Immunotherapies for Patients With
   Colorectal Cancer
SO JOURNAL OF IMMUNOTHERAPY
LA English
DT Review
DE colorectal cancer; immunotherapy; Immunoscore; autophagy;
   chemoresistance; DAMPs; HMGB1; dendritic cells; T cells; microbiome
AB Risk factors for colorectal cancer (CRC) include proinflammatory diets, sedentary habits, and obesity, in addition to genetic syndromes that predispose individuals to this disease. Current treatment relies on surgical excision and cytotoxic chemotherapies. There has been a renewed interest in immunotherapy as a treatment option for CRC given the success in melanoma and microsatellite instable (MSI) CRC. Immunotherapy with checkpoint inhibitors only plays a role in the 4%-6% of patients with MSIhigh tumors and even within this subpopulation, response rates can vary from 30% to 50%. Most patients with CRC do not respond to this modality of treatment, even though colorectal tumors are frequently infiltrated with T cells. Tumor cells limit apoptosis and survive following intensive chemotherapy leading to drug resistance and induction of autophagy. Pharmacological or molecular inhibition of autophagy improves the efficacy of cytotoxic chemotherapy in murine models. The microbiome clearly plays an etiologic role, in some or most colon tumors, realized by elegant findings in murine models and now investigated in human clinical trials. Recent results have suggested that cancer vaccines may be beneficial, perhaps best as preventive strategies. The search for therapies that can be combined with current approaches to increase their efficacy, and new knowledge of the biology of CRC are pivotal to improve the care of patients suffering from this disease. Here, we review the basic immunobiology of CRC, current "state-of-the-art" immunotherapies and define those areas with greatest therapeutic promise for the future.
C1 [Gorgulho, Carolina Mendonca; Kaneno, Ramon] Sao Paulo State Univ, UNESP, Dept Chem & Biol Sci, Inst Biosci Botucatu, Botucatu, SP, Brazil.
   [Gorgulho, Carolina Mendonca; Kaneno, Ramon] Sao Paulo State Univ, UNESP, Dept Pathol, Sch Med Botucatu, Botucatu, SP, Brazil.
   [Gorgulho, Carolina Mendonca; Lotze, Michael T.] Univ Pittsburgh, DAMP Lab, Dept Surg, Pittsburgh, PA 15213 USA.
   [Krishnamurthy, Anuradha] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA.
   [Lanzi, Anastasia; Galon, Jerome] Sorbonne Univ, Cordeliers Res Ctr, Lab Integrat Canc Immunol, League Against Canc,INSERM, Paris, France.
   [Housseau, Franck] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
RP Lotze, MT (corresponding author), Univ Pittsburgh, Dept Surg, G-27A Hillman Canc,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM lotzemt@upmc.edu
RI Mendonca Gorgulho, Carolina/L-9511-2017
OI Mendonca Gorgulho, Carolina/0000-0001-6569-8647
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA181450] Funding Source: Medline
CR Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583
   Allen J, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0621-2
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Andre T., 2020, J CLIN ONCOL, V38, pLBA4
   Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519
   Angelova M, 2018, CELL, V175, P751, DOI 10.1016/j.cell.2018.09.018
   [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210
   Arthur JC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5724
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Ascierto PA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468955
   Aubry C, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0367-5
   Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110
   Balanca CC, 2020, CANCER IMMUNOL RES, V8, P869, DOI 10.1158/2326-6066.CIR-19-0855
   Bandari SK, 2018, MATRIX BIOL, V65, P104, DOI 10.1016/j.matbio.2017.09.001
   Bilen MA, 2018, EXPERT OPIN INV DRUG, V27, P163, DOI 10.1080/13543784.2018.1427731
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Boleij A, 2015, CLIN INFECT DIS, V60, P208, DOI 10.1093/cid/ciu787
   Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Bosteels C, 2020, IMMUNITY, V52, P1039, DOI 10.1016/j.immuni.2020.04.005
   Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007
   Brusa D, 2008, VACCINE, V26, P6422, DOI 10.1016/j.vaccine.2008.08.063
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Cetin B, 2012, ASIAN PAC J CANCER P, V13, P1059, DOI 10.7314/APJCP.2012.13.3.1059
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008
   Chen J, 2017, SEMIN IMMUNOL, V32, P43, DOI 10.1016/j.smim.2017.09.006
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Chung L, 2018, CELL HOST MICROBE, V23, P203, DOI [10.1016/j.chom.2018.02.004, 10.1016/j.chom.2018.01.007]
   Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
   Cook KL, 2014, CLIN CANCER RES, V20, P3222, DOI 10.1158/1078-0432.CCR-13-3227
   COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   de Vries NL, 2020, GUT, V69, P691, DOI 10.1136/gutjnl-2019-318672
   Dejea CM, 2014, P NATL ACAD SCI USA, V111, P18321, DOI 10.1073/pnas.1406199111
   Di Nicola M, 2003, HAEMATOLOGICA, V88, P1396
   Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651
   Domingue JC, 2020, MUCOSAL IMMUNOL, V13, P413, DOI 10.1038/s41385-020-0270-1
   Donadon M, 2017, J GASTROINTEST SURG, V21, P1226, DOI 10.1007/s11605-017-3446-6
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Drewes JL, 2017, NPJ BIOFILMS MICROBI, V3, DOI 10.1038/s41522-017-0040-3
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Enamorado M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01751
   Engin AB, 2015, WORLD J GASTROENTERO, V21, P3636, DOI 10.3748/wjg.v21.i12.3636
   Eri RD, 2011, MUCOSAL IMMUNOL, V4, P354, DOI 10.1038/mi.2010.74
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Feng HP, 2002, BLOOD, V100, P4108, DOI 10.1182/blood-2002-05-1389
   FINBLOOM DS, 1985, J RHEUMATOL, V12, P692
   Franke AJ, 2019, JNCI-J NATL CANCER I, V111, P1131, DOI 10.1093/jnci/djz093
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gnoni A, 2011, CURR DRUG METAB, V12, P918, DOI 10.2174/138920011798062300
   Gobbo J, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv330
   Gorgulho CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01561
   Grady WM, 2014, TOXICOL PATHOL, V42, P124, DOI 10.1177/0192623313505155
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1
   Haas NB, 2019, CLIN CANCER RES, V25, P2080, DOI 10.1158/1078-0432.CCR-18-2204
   Harris JE, 2000, J CLIN ONCOL, V18, P148, DOI 10.1200/JCO.2000.18.1.148
   Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899
   Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206
   Housseau F, 2016, CANCER RES, V76, P2115, DOI 10.1158/0008-5472.CAN-15-0749
   Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35
   Hurtado CG, 2018, GASTROENTEROLOGY, V155, P1706, DOI 10.1053/j.gastro.2018.08.056
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166
   JANEWAY C, 1989, IMMUNOL TODAY, V10, P283, DOI 10.1016/0167-5699(89)90081-9
   Jeon J, 2018, GASTROENTEROLOGY, V154, P2152, DOI 10.1053/j.gastro.2018.02.021
   Jess T, 2012, GASTROENTEROLOGY, V143, P375, DOI 10.1053/j.gastro.2012.04.016
   Jie X, 2012, CELL BIOCHEM BIOPHYS, V62, P91, DOI 10.1007/s12013-011-9265-6
   Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kasai C, 2016, ONCOL REP, V35, P325, DOI 10.3892/or.2015.4398
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Kim HS, 2006, IMMUNOL LETT, V103, P142, DOI 10.1016/j.imlet.2005.10.021
   Kim SW, 2010, INFLAMM BOWEL DIS, V16, P1514, DOI 10.1002/ibd.21262
   Kimura T, 2013, CANCER PREV RES, V6, P18, DOI 10.1158/1940-6207.CAPR-12-0275
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2017, J CLIN ONCOL, V35
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kuniyasu H, 2005, AM J PATHOL, V166, P751, DOI 10.1016/S0002-9440(10)62296-1
   Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583
   Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354
   Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034318
   Leu AJ, 2000, CANCER RES, V60, P4324
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Long Long, 2018, Genes Cancer, V9, P176, DOI 10.18632/genesandcancer.180
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Loo CP, 2017, CELL REP, V20, P3176, DOI 10.1016/j.celrep.2017.09.006
   Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942
   Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016
   Maby P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115943
   Maby P, 2015, CANCER RES, V75, P3446, DOI 10.1158/0008-5472.CAN-14-3051
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911
   Mao L, 2017, ONCOL LETT, V14, P647, DOI 10.3892/ol.2017.6209
   Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070
   Matsuno H, 2017, INFLAMM BOWEL DIS, V23, P1524, DOI 10.1097/MIB.0000000000001204
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meisenberg C, 2017, NUCLEIC ACIDS RES, V45, P1159, DOI 10.1093/nar/gkw1026
   Mennonna D, 2017, GUT, V66, P454, DOI 10.1136/gutjnl-2015-309453
   Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mlecnik B, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx123
   Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Nars MS, 2013, INT J CANCER, V132, P2471, DOI 10.1002/ijc.27801
   Nielsen DL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091926
   Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774
   Oberg HH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01690
   Oliveira AF, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00396
   Onyeagucha BC, 2013, EXP CELL RES, V319, P2081, DOI 10.1016/j.yexcr.2013.05.009
   Osada T, 2008, CANCER IMMUNOL IMMUN, V57, P1115, DOI 10.1007/s00262-007-0441-x
   Ostberg T, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2347
   OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7
   Pages F, 2020, ANN ONCOL, V31, P921, DOI 10.1016/j.annonc.2020.03.310
   Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X
   Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503
   Paul B, 2016, IMMUNOTHERAPY-UK, V8, P693, DOI 10.2217/imt-2016-0013
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Pitt JM, 2017, ADV EXP MED BIOL, V1036, P65, DOI 10.1007/978-3-319-67577-0_5
   Prorok-Hamon M, 2014, GUT, V63, P761, DOI 10.1136/gutjnl-2013-304739
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rao HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030806
   Reissfelder C, 2015, J CLIN INVEST, V125, P739, DOI 10.1172/JCI74894
   Rhee KJ, 2009, INFECT IMMUN, V77, P1708, DOI 10.1128/IAI.00814-08
   ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008
   Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116
   Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006
   Sarshekeh AM, 2018, FUTURE ONCOL, V14, P1868, DOI 10.2217/fon-2017-0696
   Shi HZ, 2006, J IMMUNOL, V176, P2134, DOI 10.4049/jimmunol.176.4.2134
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sinicrope FA, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa023
   Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Sugiura D, 2019, SCIENCE, V364, P558, DOI 10.1126/science.aav7062
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sun HL, 2012, WORLD J GASTROENTERO, V18, P3303, DOI 10.3748/wjg.v18.i25.3303
   Sun X, 2016, WORLD J GASTROENTERO, V22, P6362, DOI 10.3748/wjg.v22.i28.6362
   Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0
   Tanaka J, 2010, DIGEST DIS SCI, V55, P1896, DOI 10.1007/s10620-009-0979-x
   Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Thomas J, 2020, CLIN COLORECTAL CANC, V19, P73, DOI 10.1016/j.clcc.2020.02.002
   Tomkovich S, 2019, J CLIN INVEST, V129, P1699, DOI 10.1172/JCI124196
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003
   Viljoen KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119462
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Vulpis E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030611
   Vulpis E, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1279372
   Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111
   Wang XM, 2007, GASTROENTEROLOGY, V132, P551, DOI 10.1053/j.gastro.2006.11.040
   Wang XM, 2008, CANCER RES, V68, P9909, DOI 10.1158/0008-5472.CAN-08-1551
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   Wilson PM, 2014, NAT REV CLIN ONCOL, V11, P282, DOI 10.1038/nrclinonc.2014.51
   WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30
   Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620
   Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yatim N, 2017, NAT REV IMMUNOL, V17, P262, DOI 10.1038/nri.2017.9
   Yu M, 2014, ONCOGENE, V33, P1538, DOI 10.1038/onc.2013.102
   Zappasodi R, 2010, CANCER RES, V70, P9062, DOI 10.1158/0008-5472.CAN-10-1825
   Zeh HJ, 2020, CLIN CANCER RES, V26, P3126, DOI 10.1158/1078-0432.CCR-19-4042
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946
   Zhao YM, 2019, J CANCER RES CLIN, V145, P3005, DOI 10.1007/s00432-019-03041-8
   Zhao YL, 2019, IMMUNITY, V51, P1059, DOI 10.1016/j.immuni.2019.11.003
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
   Zhou Q, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-13
NR 187
TC 1
Z9 1
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1524-9557
EI 1537-4513
J9 J IMMUNOTHER
JI J. Immunother.
PD FEB-MAR
PY 2021
VL 44
IS 2
BP 49
EP 62
DI 10.1097/CJI.0000000000000357
PG 14
WC Oncology; Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Research & Experimental Medicine
GA QN3DY
UT WOS:000622345900001
PM 33416261
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Rajendran, P
   Kidane, AI
   Yu, TW
   Dashwood, WM
   Bisson, WH
   Lohr, CV
   Ho, E
   Williams, DE
   Dashwood, RH
AF Rajendran, Praveen
   Kidane, Ariam I.
   Yu, Tian-Wei
   Dashwood, Wan-Mohaiza
   Bisson, William H.
   Loehr, Christiane V.
   Ho, Emily
   Williams, David E.
   Dashwood, Roderick H.
TI HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in
   colon cancer cells treated with sulforaphane and related dietary
   isothiocyanates
SO EPIGENETICS
LA English
DT Article
DE CtIP acetylation; DNA damage; HDAC inhibition; HDAC3; SIRT6; colon
   cancer; epigenetics; repair
ID HISTONE DEACETYLASE INHIBITORS; DOUBLE-STRAND BREAKS; HOMOLOGOUS
   RECOMBINATION; CRUCIFEROUS VEGETABLES; KU70 ACETYLATION;
   CHEMOPREVENTION; THERAPY; PROLIFERATION; INSTABILITY; REPRESSOR
AB Histone deacetylases (HDACs) and acetyltransferases have important roles in the regulation of protein acetylation, chromatin dynamics and the DNA damage response. Here, we show in human colon cancer cells that dietary isothiocyanates (ITCs) inhibit HDAC activity and increase HDAC protein turnover with the potency proportional to alkyl chain length, i.e., AITC < sulforaphane (SFN) < 6-SFN < 9-SFN. Molecular docking studies provided insights into the interactions of ITC metabolites with HDAC3, implicating the allosteric site between HDAC3 and its co-repressor. ITCs induced DNA double-strand breaks and enhanced the phosphorylation of histone H2AX, ataxia telangiectasia and Rad3-related protein (ATR) and checkpoint kinase-2 (CHK2). Depending on the ITC and treatment conditions, phenotypic outcomes included cell growth arrest, autophagy and apoptosis. Coincident with the loss of HDAC3 and HDAC6, as well as SIRT6, ITCs enhanced the acetylation and subsequent degradation of critical repair proteins, such as CtIP, and this was recapitulated in HDAC knockdown experiments. Importantly, colon cancer cells were far more susceptible than non-cancer cells to ITC-induced DNA damage, which persisted in the former case but was scarcely detectable in non-cancer colonic epithelial cells under the same conditions. Future studies will address the mechanistic basis for dietary ITCs preferentially exploiting HDAC turnover mechanisms and faulty DNA repair pathways in colon cancer cells vs. normal cells.
C1 [Rajendran, Praveen; Kidane, Ariam I.; Yu, Tian-Wei; Dashwood, Wan-Mohaiza; Ho, Emily; Williams, David E.; Dashwood, Roderick H.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.
   [Bisson, William H.; Williams, David E.; Dashwood, Roderick H.] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.
   [Loehr, Christiane V.] Oregon State Univ, Coll Vet Med, Corvallis, OR 97331 USA.
   [Ho, Emily] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA.
RP Rajendran, P (corresponding author), Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.
EM praveen.rajendran@oregonstate.edu
RI Löhr, C. V./AAU-4902-2020; Dashwood, Roderick/AAF-2025-2020; Rajendran,
   Praveen/AAK-9963-2021
OI Löhr, C. V./0000-0003-3787-5583; Rajendran, Praveen/0000-0002-6221-7366
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [CA090890,
   CA65525, CA122906, CA122959, CA80176, ES00210]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA122906, R01CA065525, R01CA122959, R29CA065525, P01CA090890,
   R01CA080176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [P30ES000210] Funding Source:
   NIH RePORTER
FX Supported by US National Institutes of Health grants CA090890, CA65525,
   CA122906, CA122959, CA80176 and ES00210. We thank Teresa Sawyer for help
   with EM, Andrew Hau for autophagy antibodies and the Cell Imaging and
   Analysis Core for assistance with immunocytochemistry.
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   American Cancer Society, 2013, CANC FACTS FIG 2012
   Batra S, 2010, MOL CANCER THER, V9, P1596, DOI 10.1158/1535-7163.MCT-09-1146
   Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030
   Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022
   Bisson WH, 2009, J MED CHEM, V52, P5635, DOI 10.1021/jm900199u
   CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314
   Cazaux C, 2010, B CANCER, V97, P1241, DOI 10.1684/bdc.2010.1202
   Chen CS, 2007, CANCER RES, V67, P5318, DOI 10.1158/0008-5472.CAN-06-3996
   Chernikova SB, 2012, CANCER BIOL THER, V13, P61, DOI [10.4161.cbt.13.2.18872, 10.4161/cbt.13.2.18872]
   Conti C, 2010, CANCER RES, V70, P4470, DOI 10.1158/0008-5472.CAN-09-3028
   Dashwood RH, 2006, CARCINOGENESIS, V27, P344, DOI 10.1093/carcin/bgi253
   Doyle K, 2010, J BIOL CHEM, V285, P17417, DOI 10.1074/jbc.M109.089250
   Eot-Houllier G, 2009, CANCER LETT, V274, P169, DOI 10.1016/j.canlet.2008.06.005
   Fimognari C, 2012, MUTAT RES-REV MUTAT, V750, P107, DOI 10.1016/j.mrrev.2011.12.001
   Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Herr I, 2010, CANCER TREAT REV, V36, P377, DOI 10.1016/j.ctrv.2010.01.002
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208
   Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049
   Keum YS, 2004, MUTAT RES-FUND MOL M, V555, P191, DOI 10.1016/j.mrfmmm.2004.05.024
   Lea MA, 2001, INT J CANCER, V92, P784, DOI 10.1002/ijc.1277
   Ma XD, 2006, INT J ONCOL, V28, P1287
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Nakamura K, 2010, J SYN ORG CHEM JPN, V68, P1, DOI 10.5059/yukigoseikyokaishi.68.1
   Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107
   Pappa G, 2007, MOL NUTR FOOD RES, V51, P977, DOI 10.1002/mnfr.200700115
   Rajendran P, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-4
   Rajendran P, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-68
   Rajendran P, 2011, CRIT REV BIOCHEM MOL, V46, P181, DOI 10.3109/10409238.2011.557713
   Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Rosato RR, 2008, MOL CANCER THER, V7, P3285, DOI 10.1158/1535-7163.MCT-08-0385
   Rossetto D, 2010, CLIN CANCER RES, V16, P4543, DOI 10.1158/1078-0432.CCR-10-0513
   Sekine-Suzuki E, 2008, BIOCHEM BIOPH RES CO, V377, P341, DOI 10.1016/j.bbrc.2008.09.150
   Sharma R, 2010, BIOCHEMISTRY-US, V49, P3191, DOI 10.1021/bi100104e
   Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373
   Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102
   Totrov M, 1997, PROTEINS, P215
   TOTROV M, 2001, DRUG RECEPTOR THERMO, V1, P603
   Wang LG, 2008, INT J ONCOL, V33, P375, DOI 10.3892/ijo_00000018
   Wang WT, 2011, ENVIRON SCI TECHNOL, V45, P6887, DOI 10.1021/es201443z
   Watson PJ, 2012, NATURE, V481, P335, DOI 10.1038/nature10728
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566
NR 50
TC 84
Z9 90
U1 0
U2 17
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JUN 1
PY 2013
VL 8
IS 6
BP 612
EP 623
DI 10.4161/epi.24710
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 260VR
UT WOS:000327623100006
PM 23770684
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Kim, MS
   Jeong, EG
   Ahn, CH
   Kim, SS
   Lee, SH
   Yoo, NJ
AF Kim, Min Sung
   Jeong, Eun Goo
   Ahn, Chang Hyeok
   Kim, Sung Soo
   Lee, Sug Hyung
   Yoo, Nam Jin
TI Frameshift mutation of UVRAG, an autophagy-related gene, in gastric
   carcinomas with microsatellite instability
SO HUMAN PATHOLOGY
LA English
DT Article
DE UVRAG; MSI; gastric cancer; mutation
ID TUMOR-SUPPRESSOR; INACTIVATING MUTATIONS; BECLIN-1; CANCER;
   TUMORIGENESIS; PROTEINS; DEATH; CELLS; BIF-1
AB Alteration of autophagy is involved in tumor development. Beclin 1, an important regulator of autophagy, acts as a tumor suppressor. Ultraviolet (UV) radiation resistance-associated gene (UVRAG) binds with Beclin1 and induces autophagy. There is a polyadenine tract in UVRAG gene (A10 in exon 8) that is a target for frameshift mutations in colorectal carcinomas with microsatellite instability (MSI). Functionally, colon cancer cells with the frameshift mutation of UFRAG show reduced autophagy formation and increased tumorigenicity. The aim of this study was to determine whether the frameshift mutations of UVRAG are also present in gastric carcinomas with MSI. For this, we analyzed human UVRAG exon 8 in 45 gastric carcinomas with MSI and 92 gastric carcinomas without MSI by a single-strand conformation polymorphism analysis. Overall, we detected 3 frameshift mutations of UVRAG in the polyadenine tract (3/45; 6.7%), and all of them were found in MSH-high (H) subtypes (3/32; 9.4%). The 3 mutations consisted of 2 c.708_709delA and 1 c.709delA which would result in premature stops of the UVRAG protein synthesis. The present data indicate that frameshilft mutations in the polyadenine tract in UVRAG gene are present in gastric carcinomas as well and suggest that the affected gastric cancer cells with the mutations may have a reduced autophagy activity. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Kim, Min Sung; Jeong, Eun Goo; Lee, Sug Hyung; Yoo, Nam Jin] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.
   [Ahn, Chang Hyeok] Catholic Univ Korea, Coll Med, Dept Gen Surg, Seoul 137701, South Korea.
   [Kim, Sung Soo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701, South Korea.
RP Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.
EM goldfish@catholic.ac.kr
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Boland CR, 1998, CANCER RES, V58, P5248
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Krajewska M, 1996, AM J PATHOL, V149, P1449
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145
   Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Schwartz S, 1999, CANCER RES, V59, P2995
   Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094
   Simpson AJG, 2001, TRENDS MOL MED, V7, P76, DOI 10.1016/S1471-4914(01)01916-5
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J
   Wu MS, 2000, GENE CHROMOSOME CANC, V27, P403, DOI 10.1002/(SICI)1098-2264(200004)27:4<403::AID-GCC10>3.3.CO;2-T
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 25
TC 120
Z9 131
U1 1
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD JUL
PY 2008
VL 39
IS 7
BP 1059
EP 1063
DI 10.1016/j.humpath.2007.11.013
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 320VX
UT WOS:000257264300011
PM 18495205
DA 2022-04-25
ER

PT J
AU Ling, LU
   Tan, KB
   Lin, H
   Chiu, GNC
AF Ling, L-U
   Tan, K-B
   Lin, H.
   Chiu, G. N. C.
TI The role of reactive oxygen species and autophagy in safingol-induced
   cell death
SO CELL DEATH & DISEASE
LA English
DT Article
DE ROS; autophagy; necrosis; safingol; glucose uptake inhibition
ID PROTEIN-KINASE-C; INHIBITOR SAFINGOL; CANCER CELLS; ARSENIC TRIOXIDE;
   CARCINOMA-CELLS; ENDONUCLEASE G; PHORBOL ESTER; GLIOMA-CELLS;
   COLON-CANCER; APOPTOSIS
AB Safingol is a sphingolipid with promising anticancer potential, which is currently in phase I clinical trial. Yet, the underlying mechanisms of its action remain largely unknown. We reported here that safingol-induced primarily accidental necrotic cell death in MDA-MB-231 and HT-29 cells, as shown by the increase in the percentage of cells stained positive for 7-aminoactinomycin D, collapse of mitochondria membrane potential and depletion of intracellular ATP. Importantly, safingol treatment produced time-and concentration-dependent reactive oxygen species (ROS) generation. Autophagy was triggered following safingol treatment, as reflected by the formation of autophagosomes, acidic vacuoles, increased light chain 3-II and Atg biomarkers expression. Interestingly, scavenging ROS with N-acetyl-L-cysteine could prevent the autophagic features and reverse safingol-induced necrosis. Our data also suggested that autophagy was a cell repair mechanism, as suppression of autophagy by 3-methyladenine or bafilomycin A1 significantly augmented cell death on 2-5 mu M safingol treatment. In addition, Bcl-xL and Bax might be involved in the regulation of safingol-induced autophagy. Finally, glucose uptake was shown to be inhibited by safingol treatment, which was associated with an increase in p-AMPK expression. Taken together, our data suggested that ROS was the mediator of safingol-induced cancer cell death, and autophagy is likely to be a mechanism triggered to repair damages from ROS generation on safingol treatment. Cell Death and Disease (2011) 2, e129; doi: 10.1038/cddis.2011.12; published online 10 March 2011
C1 [Ling, L-U; Tan, K-B; Lin, H.; Chiu, G. N. C.] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore.
RP Chiu, GNC (corresponding author), Natl Univ Singapore, Dept Pharm, Fac Sci, Block S4,02-09,18 Sci Dr 4, Singapore 117543, Singapore.
EM phacncg@nus.edu.sg
RI Tan, Kuan Boone/J-9756-2013; Chiu, Gigi/I-6250-2013
OI Tan, Kuan Boone/0000-0002-6523-6941; Chiu, Gigi/0000-0003-1734-3512
FU Singapore's Ministry of Education through the National University of
   Singapore (NUS)National University of Singapore [R-148-000-098-112];
   NUSNational University of Singapore
FX This work was supported by Singapore's Ministry of Education through the
   National University of Singapore (NUS) Academic Research Fund FRC-Tier 1
   grant (R-148-000-098-112). LU Ling and KB Tan are supported by NUS
   graduate research scholarship.
CR Amin HM, 2000, BRIT J HAEMATOL, V110, P552, DOI 10.1046/j.1365-2141.2000.02207.x
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   BUEHRER BM, 1993, ADV LIPID RES, V26, P59
   Carvajal RD, 2006, P AN M AM SOC CLIN, V24, P13044
   Cheng JJ, 2003, MOL CELL BIOL, V23, P163, DOI 10.1128/MCB.23.1.163-177.2003
   Cheng TJ, 2007, FOOD CHEM TOXICOL, V45, P1027, DOI 10.1016/j.fct.2006.12.014
   Coward J, 2009, AUTOPHAGY, V5, P184, DOI 10.4161/auto.5.2.7361
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Hamada M, 2006, APOPTOSIS, V11, P47, DOI 10.1007/s10495-005-3348-z
   HANNUN YA, 1986, J BIOL CHEM, V261, P2604
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hoffmann TK, 2002, ANTI-CANCER DRUG, V13, P93, DOI 10.1097/00001813-200201000-00011
   Isaev NK, 2008, BIOCHEMISTRY-MOSCOW+, V73, P149, DOI 10.1134/S0006297908020053
   Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844
   Kanzawa T, 2003, CANCER RES, V63, P2103
   KEDDERIS LB, 1995, FUND APPL TOXICOL, V25, P201, DOI 10.1006/faat.1995.1056
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Ling LU, 2009, INT J ONCOL, V35, P1463, DOI 10.3892/ijo_00000465
   Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897
   Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710
   Morales PR, 2007, DRUG CHEM TOXICOL, V30, P197, DOI 10.1080/01480540701375018
   MURRAY DK, 1990, LIFE SCI, V46, P1843, DOI 10.1016/0024-3205(90)90236-K
   NELSON DH, 1986, BIOCHEM BIOPH RES CO, V138, P463, DOI 10.1016/0006-291X(86)90303-7
   Noda T, 2009, APOPTOSIS, V14, P287, DOI 10.1007/s10495-009-0319-9
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394
   Schwartz GK, 1997, CLIN CANCER RES, V3, P1467
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shi LH, 2007, CELL RES, V17, P1030, DOI 10.1038/cr.2007.100
   Tang Y, 2011, AUTOPHAGY, V7, P235, DOI 10.4161/auto.7.2.14277
   Villena J, 2008, FREE RADICAL BIO MED, V44, P1146, DOI 10.1016/j.freeradbiomed.2007.12.017
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200
NR 40
TC 106
Z9 109
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR
PY 2011
VL 2
AR e129
DI 10.1038/cddis.2011.12
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 742UE
UT WOS:000288969700006
PM 21390063
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Singh, MP
   Park, KH
   Khaket, TP
   Kang, SC
AF Singh, Mahendra Pal
   Park, Ki Hun
   Khaket, Tejinder Pal
   Kang, Sun Chul
TI CJK-7, a Novel Flavonoid from Paulownia tomentosa Triggers Cell Death
   Cascades in HCT-116 Human Colon Carcinoma Cells via Redox Signaling
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Apoptosis; autophagy; colon cancer; natural compounds; oxidative stress;
   redox signaling
ID OXIDATIVE STRESS; GASTRIC-CANCER; APOPTOSIS; AUTOPHAGY; DAMAGE;
   MITOCHONDRIA; ACTIVATION; MECHANISMS; PREVENTION; SURVIVAL
AB Background: Colon cancer is the second most common cancer to cause death worldwide. About halfof colon cancers patients require adjuvant therapy to control relapse following surgical resection. Therefore, abolition of tumor cell progression using an effective chemotherapeutic agent holds a feasible approach to treat patients suffering from colon cancer. In the present study, we evaluated the effects of geranylated flavonoid CJK-7, isolated from Paulownia tomentosa on HCT-116 human colon carcinoma cells.
   Materials and Methods: The effects of CJK-7 as an active component on HCT-116 cells programmed cell death and its underlying molecular mechanism were examined by using MTT assay, morphological assessment, H(2)DCFDA staining, Fura-2AM staining, Hoechst-33342 staining, comet assay, Acridine orange staining, mitochondrial membrane potential (Delta Psi m) assay and Western blot analyses.
   Results and Conclusion: The results revealed that, CJK-7 was capable of inducing caspase-dependent cell death events in cancer cells. Moreover, it was involved in up-regulation of autophagy signaling as evidenced by enhanced expression of LC3I/II. We also noticed stimulated expression of endoplasmic reticulum stress markers and phosphorylation of c-Jun NH2-terminal kinase (JNK), which was associated with up-regulated expression of p53, PUMA, Atg5 and Beclin-1, and down-regulation of Bcl-2, stressing the interaction of ROS on the aforementioned signaling. Furthermore, exposure to ROS scavengers (N-acetyl-l-cysteine (NAC), and JNK-specific inhibitor SP600125) significantly reversed the effects of CJK-7 by down-regulating apoptosis and autophagy signatures in HCT-116 cancer cells. Collectively our findings clarify the ROS-dependent regulatory effect of CJK-7 on programmed cell death signaling events in HCT-116 cancer cells while depicting its virile pro-oxidant capacity.
C1 [Singh, Mahendra Pal; Khaket, Tejinder Pal; Kang, Sun Chul] Daegu Univ, Collage Engn, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.
   [Park, Ki Hun] Gyeongsan Natl Univ, Div Appl Sci, IALS, Jinju 660701, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Collage Engn, Coll Engn, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.
EM sckang@daegu.ac.kr
RI Khaket, Tej/I-6260-2015; Singh, Mahendra Pal/J-8391-2019
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [NRF 2016H1D3A1938249, NRF 2017R1D1A1B03036569, NRF
   2016R1A2B4009227]
FX This work was supported by the National Research Foundation of Korea
   (NRF) through Korea Research Fellowship Program (NRF 2016H1D3A1938249,
   NRF 2017R1D1A1B03036569 and NRF 2016R1A2B4009227).
CR Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012
   Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4
   Cho JK, 2013, BIOORGAN MED CHEM, V21, P3051, DOI 10.1016/j.bmc.2013.03.027
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Diaz-Ruiz C, 2001, HISTOL HISTOPATHOL, V16, P415, DOI 10.14670/HH-16.415
   Fang XX, 2015, EUR J CANCER, V51, P2820, DOI 10.1016/j.ejca.2015.09.010
   Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835
   Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414
   Hsu WH, 2007, ARCH TOXICOL, V81, P719, DOI 10.1007/s00204-006-0169-y
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Kumar S, 2013, SCI WORLD J, V2013
   Liu B, 2009, CANCER LETT, V275, P54, DOI 10.1016/j.canlet.2008.09.042
   Liu B, 2009, AUTOPHAGY, V5, P253, DOI 10.4161/auto.5.2.7561
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Maddalena F, 2011, CANCER RES, V71, P7659, DOI 10.1158/0008-5472.CAN-11-2172
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Ortiz MA, 2001, CANCER RES, V61, P8504
   Oyvind M. A., 2005, FLAVONOIDS CHEM BIOC, P1256
   Rahman SNSA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/257108
   Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852
   Rosenfeldt M. T., 2009, EXPERT REV MOL MED, P11
   Silva JP, 2010, DRUG DISCOV THER, V4, P144
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Slimen IB, 2014, INT J HYPERTHER, V30, P513, DOI 10.3109/02656736.2014.971446
   Sui X., 2013, CELL DEATH DIS, P4
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Zhang C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147405
NR 30
TC 5
Z9 5
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2018
VL 18
IS 3
BP 428
EP 437
DI 10.2174/1871520617666171026170009
PG 10
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA GJ0UF
UT WOS:000434969100012
PM 29076434
DA 2022-04-25
ER

PT J
AU Menon, MB
   Kotlyarov, A
   Gaestel, M
AF Menon, Manoj B.
   Kotlyarov, Alexey
   Gaestel, Matthias
TI SB202190-Induced Cell Type-Specific Vacuole Formation and Defective
   Autophagy Do Not Depend on p38 MAP Kinase Inhibition
SO PLOS ONE
LA English
DT Article
ID PROTEIN-KINASE; CANCER-CELL; IN-VIVO; MATURATION STEP; SB 203580;
   P38-ALPHA; STRESS; GROWTH; SENSITIVITY; METABOLISM
AB SB202190, a widely used inhibitor of p38 MAPK alpha and beta, was recently described to induce autophagic vacuoles and cell death in colon and ovarian cancer cells lines and, therefore, this effect was supposed to be specific for transformed cells and to open therapeutic options. Here, we demonstrate that SB202190 and the structurally related inhibitor SB203580 induce pro-autophagic gene expression and vacuole formation in various cancer and non-cancer cell lines of human, rat, mouse and hamster origin. This effect seems to induce defective autophagy leading to the accumulation of acidic vacuoles, p62 protein and lipid conjugated LC3. Using further p38 inhibitors we show that p38 MAPK inhibition is not sufficient for the autophagic response. In line with these results, expression of a SB202190-resistant mutant of p38 alpha, which significantly increases activity of the p38 pathway under inhibitory conditions, does not block SB202190-dependent vacuole formation, indicating that lack of p38 alpha activity is not necessary for this effect. Obviously, the induction of autophagic vacuole formation by SB203580 and SB202190 is due to off-target effects of these inhibitors on post-translational protein modifications, such as phosphorylation of the MAPKs ERK1/2 and JNK1/2, ribosomal protein S6, and PKB/Akt. Interestingly, the PI3K-inhibitor wortmannin induces transient vacuole formation indicating that the PI3K-PKB/Akt-mTOR pathway is essential for preventing autophagy and that cross-inhibition of this pathway by SB202190 could be the reason for the early part of the effect observed.
C1 [Menon, Manoj B.; Kotlyarov, Alexey; Gaestel, Matthias] Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany.
RP Menon, MB (corresponding author), Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany.
EM gaestel.matthias@mh-hannover.de
RI Gaestel, Matthias/A-6560-2013; Menon, Manoj B./P-1543-2015
OI Gaestel, Matthias/0000-0002-4944-4652; Menon, Manoj
   B./0000-0001-5859-0347
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG);
   Hannover Medical School
FX This work was supported by Deutsche Forschungsgemeinschaft and the
   PhD-Program of the Hannover Medical School. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bawolak MT, 2010, CAN J ANAESTH, V57, P230, DOI 10.1007/s12630-009-9220-9
   Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766
   BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Ehrhardt C., 2006, SIGNAL TRANSDUCT, V6, P179, DOI [10.1002/sita.200500073, DOI 10.1002/SITA.200500073]
   Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9
   Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Gaestel M, 2007, CURR MED CHEM, V14, P2214, DOI 10.2174/092986707781696636
   Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100
   Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hsu MY, 2002, HUMAN CELL CULTURE, P259
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kametaka S, 2007, MOL BIOL CELL, V18, P2991, DOI 10.1091/mbc.E06-12-1162
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358
   King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554
   Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395
   Laufer SA, 2003, J MED CHEM, V46, P3230, DOI 10.1021/jm030766k
   Lin R, 2011, GASTROENTEROLOGY, V140, P560, DOI 10.1053/j.gastro.2010.10.042
   Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26
   Matrone A, 2010, INT J GYNECOL CANCER, V20, P203, DOI 10.1111/IGC.0b013e3181c8ca12
   McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Menon MB, 2010, J BIOL CHEM, V285, P33242, DOI 10.1074/jbc.M110.132357
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Prick T, 2006, BIOCHEM J, V394, P153, DOI 10.1042/BJ20051243
   RONKINA N, 2010, NUCL ACIDS RES
   ROSS RA, 1983, J NATL CANCER I, V71, P741
   Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002
   Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Singh AK, 2011, CELL MOL LIFE SCI, V68, P1041, DOI 10.1007/s00018-010-0503-7
   Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304
   Son JK, 2010, CELL DEATH DIFFER, V17, P1288, DOI 10.1038/cdd.2010.9
   Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005
   Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Yang J, 2010, J CELL SCI, V123, P861, DOI 10.1242/jcs.060475
   Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
NR 53
TC 43
Z9 44
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2011
VL 6
IS 8
AR e23054
DI 10.1371/journal.pone.0023054
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 827UM
UT WOS:000295454200038
PM 21853067
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Akkoc, Y
   Berrak, O
   Arisan, ED
   Obakan, P
   Coker-Gurkan, A
   Palavan-Unsal, N
AF Akkoc, Yunus
   Berrak, Ozge
   Arisan, Elif Damla
   Obakan, Pinar
   Coker-Gurkan, Ajda
   Palavan-Unsal, Narcin
TI Inhibition of PI3K signaling triggered apoptotic potential of curcumin
   which is hindered by Bcl-2 through activation of autophagy in MCF-7
   cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Curcumin; Breast cancer; Apoptosis; PI3K; LY294002
ID COLON-CANCER CELLS; DOWN-REGULATION; BREAST-CANCER; CHEMOTHERAPEUTIC
   DRUGS; FAMILY-MEMBERS; LEUKEMIA-CELLS; KAPPA-B; DEATH; EXPRESSION;
   PATHWAYS
AB Curcumin is a natural anti-cancer agent derived from turmeric (Curcuma longa). Curcumin triggers intrinsic apoptotic cell death by activating mitochondrial permeabilization due to the altered expression of pro-and anti-apoptotic Bcl-2 family members. Phosphoinositol-3-kinase (PI3K) and Akt, key molecular players in the survival mechanism, have been shown to be associated with the Bcl-2 signaling cascade; therefore, evaluating the therapeutic efficiency of drugs that target both survival and the apoptosis mechanism has gained importance in cancer therapy. We found that Bcl-2 overexpression is a limiting factor for curcumin-induced apoptosis in highly metastatic MCF-7 breast cancer cells. Forced overexpression of Bcl-2 also blocked curcumin-induced autophagy in MCF-7 cells, through its inhibitory interactions with Beclin-1. Pre-treatment of PI3K inhibitor LY294002 enhanced curcumin-induced cell death, apoptosis, and autophagy via modulating the expression of Bcl-2 family members and autophagosome formation in MCF-7 breast cancer cells. Atg7 silencing further increased apoptotic potential of curcumin in the presence or absence of LY294002 in wt and Bcl-2+ MCF-7 cells. The findings of this study support the hypothesis that blocking the PI3K/Akt pathway may further increased curcumin-induced apoptosis and overcome forced Bcl-2 expression level mediated autophagic responses against curcumin treatment in MCF-7 cells. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Akkoc, Yunus; Berrak, Ozge; Arisan, Elif Damla; Obakan, Pinar; Coker-Gurkan, Ajda; Palavan-Unsal, Narcin] Istanbul Kultur Univ, Dept Mol Biol & Genet, TR-34156 Bakirkoy Istanbul, Turkey.
RP Arisan, ED (corresponding author), Istanbul Kultur Univ, Dept Mol Biol & Genet, Atakoy Campus, TR-34156 Bakirkoy Istanbul, Turkey.
EM d.arisan@iku.edu.tr
RI OBAKAN, PINAR/D-2836-2015; Arisan, Elif Damla/W-8682-2019;
   Rencuzogullari, Ozge/X-9954-2019; AKKOC, Yunus/AAK-8853-2020
OI Arisan, Elif Damla/0000-0002-4844-6381; AKKOC,
   Yunus/0000-0001-5379-6151; Gurkan, Ajda/0000-0003-1475-2417; Unsal
   Palavan, Narcin/0000-0002-2945-540X
FU Istanbul Kultur University Scientific Projects Support CenterIstanbul
   Kultur University
FX We are thankful to the Istanbul Kultur University Scientific Projects
   Support Center and Merve Celik for her technical assistance.
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bava SV, 2005, J BIOL CHEM, V280, P6301, DOI 10.1074/jbc.M410647200
   Beevers CS, 2006, INT J CANCER, V119, P757, DOI 10.1002/ijc.21932
   BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D
   Buchholz TA, 2003, CANCER J, V9, P33, DOI 10.1097/00130404-200301000-00007
   CAMPOS L, 1993, BLOOD, V81, P3091
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Du BY, 2006, CHEMOTHERAPY, V52, P23, DOI 10.1159/000090238
   Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Ikezoe T, 2007, LEUKEMIA RES, V31, P673, DOI 10.1016/j.leukres.2006.08.001
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Khan MA, 2012, MOL CANCER THER, V11, P1873, DOI 10.1158/1535-7163.MCT-12-0141
   Khor TO, 2006, CANCER RES, V66, P613, DOI 10.1158/0008-5472.CAN-05-2708
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029
   Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lawlor MA, 2001, J CELL SCI, V114, P2903
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638
   MIYASHITA T, 1992, CANCER RES, V52, P5407
   Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048
   Nguyen DM, 2004, J THORAC CARDIOV SUR, V127, P365, DOI 10.1016/j.jtcvs.2003.09.033
   Niizuma H, 2006, ONCOGENE, V25, P5046, DOI 10.1038/sj.onc.1209515
   Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025
   REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542
   Seo BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095588
   Shankar Sharmila, 2007, J Mol Signal, V2, P10, DOI 10.1186/1750-2187-2-10
   Shankar S, 2007, INT J ONCOL, V30, P905
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043
   Shishodia S, 2007, CURR PROB CANCER, V31, P243, DOI 10.1016/j.currproblcancer.2007.04.001
   Srivastava RK, 2007, CELL CYCLE, V6, P2953, DOI 10.4161/cc.6.23.4951
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Thongrakard V., 2014, PHYTOTHER RES
   Tsai EM, 2001, CANCER RES, V61, P8390
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200
   Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040
   WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
NR 57
TC 47
Z9 50
U1 2
U2 30
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2015
VL 71
BP 161
EP 171
DI 10.1016/j.biopha.2015.02.029
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CH6XK
UT WOS:000354179500026
PM 25960232
DA 2022-04-25
ER

PT J
AU Liu, ZY
   Liu, Y
   Long, YP
   Liu, BH
   Wang, XF
AF Liu, Zhengyong
   Liu, Yi
   Long, Yupeng
   Liu, Baohua
   Wang, Xiangfeng
TI Role of HSP27 in the multidrug sensitivity and resistance of colon
   cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE heat shock 27 kD protein 1; notch receptor 1-Akt-mTOR pathway; multidrug
   sensitivity; colon cancer
ID SHOCK-PROTEIN 27; DRUG-RESISTANCE; MOLECULAR CHAPERONE; GASTRIC-CANCER;
   VINCRISTINE; SUPPRESSION; APOPTOSIS; STATISTICS; AUTOPHAGY; AKT/MTOR
AB Multidrug resistance in cancer cells is a primary factor affecting therapeutic efficacy. Heat shock 27 kD protein 1 (HSP27) is associated with cell apoptosis and resistance to chemotherapy. However, the mechanisms underlying HSP27-associated pathways in colon cancer cells remain unclear. Therefore, the present study used short hairpin (sh) RNA to inhibit HSP27 expression in colon cancer cells in order to investigate the effects in vitro and in vivo. Flow cytometry was used to investigate cell apoptosis and a xenograft model was employed to examine the tumorigenesis. Protein expression was measured by Western blotting. The results revealed that suppression of HSP27 expression significantly increased cell apoptosis, inhibited tumor growth and enhanced sensitivity to the anti-cancer agents 5-fluorouracil (5-FU) and vincristine (VCR). shHSP27 significantly decreased the expression of notch receptor 1 and the phosphorylation level of Akt and mTOR, and enhanced the effect of 5-FU and VCR. In conclusion, HSP27 suppression enhanced the sensitivity of colon cancer cells to 5-FU and VCR, and increased colon cancer cell apoptosis with and without chemotherapy. Therefore, the development of novel therapeutic agents that inhibit the expression of HSP27 may offer a new treatment option for colon cancer.
C1 [Liu, Zhengyong; Liu, Baohua; Wang, Xiangfeng] Army Med Univ, Daping Hosp, Dept Gen Surg, 10 Changjiangzhilu Rd, Chongqing 400042, Peoples R China.
   [Liu, Yi] Army Med Univ, Daping Hosp, Dept Informat, Chongqing 400042, Peoples R China.
   [Long, Yupeng] Chinese Peoples Liberat Army, Army Hosp 958, Dept Clin Lab, Chongqing 400020, Peoples R China.
RP Liu, BH; Wang, XF (corresponding author), Army Med Univ, Daping Hosp, Dept Gen Surg, 10 Changjiangzhilu Rd, Chongqing 400042, Peoples R China.
EM LBH57268@163.com; xiangfengwang@tmmu.edu.cn
FU Chongqing Science and Technology Commission of China
   [cstc2017j-cyjAX0360]
FX The present study was supported by the Chongqing Science and Technology
   Commission of China (grant no. cstc2017j-cyjAX0360).
CR Aithal MGS, 2013, J GENET, V92, P667, DOI 10.1007/s12041-013-0284-5
   [Anonymous], 1969, JAMA, V207, P1707
   Arques O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078-0432.CCR-14-3081
   Cadona FC, 2017, NUTR CANCER, V69, P800, DOI 10.1080/01635581.2017.1324994
   Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978
   Chen X, 2016, MOL MED REP, V13, P689, DOI 10.3892/mmr.2015.4600
   Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031
   Cheng J, 2015, DIGESTION, V92, P192, DOI 10.1159/000431254
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Demel HR, 2015, AM J CANCER RES, V5, P1649
   Fan YX, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16029414
   Gan RH, 2018, CELL CYCLE, V17, P216, DOI 10.1080/15384101.2017.1395534
   Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448
   Giachino C, 2015, CANCER CELL, V28, P730, DOI 10.1016/j.ccell.2015.10.008
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Guerrero-Zotano A, 2016, CANCER METAST REV, V35, P515, DOI 10.1007/s10555-016-9637-x
   Hayashi R, 2012, ONCOL REP, V28, P1269, DOI 10.3892/or.2012.1935
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Ishida T, 2017, ONCOL REP, V38, P926, DOI 10.3892/or.2017.5734
   Jiang HP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21888
   Kilbas PO, 2019, MOL BIOL REP, V46, P847, DOI 10.1007/s11033-018-4540-x
   Kim EK, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100471
   Krawczyk Z, 2018, ANTI-CANCER AGENT ME, V18, P2093, DOI 10.2174/1871520618666180817114952
   Lee SL, 2017, CELL STRESS CHAPERON, V22, P293, DOI 10.1007/s12192-017-0774-0
   Liang HH, 2018, LIFE SCI, V209, P43, DOI 10.1016/j.lfs.2018.07.047
   Liu BW, 2018, PHYTOMEDICINE, V44, P20, DOI 10.1016/j.phymed.2018.04.025
   Liu CL, 2016, ONCOTARGET, V7, P14279, DOI 10.18632/oncotarget.7306
   Meyerhardt Jeffrey A, 2010, Clin Adv Hematol Oncol, V8, P772
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   OESTERREICH S, 1993, CANCER RES, V53, P4443
   Pandya KJ, 2004, ONCOLOGY-BASEL, V66, P118, DOI 10.1159/000077437
   Sambandam V, 2019, CLIN CANCER RES, V25, P3329, DOI 10.1158/1078-0432.CCR-18-3276
   Sartore-Bianchi A, 2016, ANN ONCOL, V27, P1456, DOI 10.1093/annonc/mdw191
   Sharma A, 2017, NANOMEDICINE-UK, V12, P2137, DOI 10.2217/nnm-2017-0184
   Shen FH, 2019, TOXICOL LETT, V300, P105, DOI 10.1016/j.toxlet.2018.10.024
   Shimada T, 2018, ONCOL REP, V39, P1119, DOI 10.3892/or.2018.6180
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sun Y, 2017, CANCER MED-US, V6, P2331, DOI 10.1002/cam4.1169
   Tang H, 2019, NEOPLASMA, V66, P187, DOI 10.4149/neo_2018_180310N167
   Wang XH, 2019, BIOSCI BIOTECH BIOCH, V83, P609, DOI 10.1080/09168451.2018.1562874
   Wang YL, 2019, LIFE SCI, V223, P22, DOI 10.1016/j.lfs.2019.03.006
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   WITTY JP, 1994, CANCER RES, V54, P4805
   Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009
   Yang YX, 2006, PROTEOMICS, V6, P2009, DOI 10.1002/pmic.200402031
   Yang ZK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0664-4
   Zeng C, 2016, APOPTOSIS, V21, P1, DOI 10.1007/s10495-015-1188-z
   Zhang YR, 2016, THERANOSTICS, V6, P558, DOI 10.7150/thno.14693
NR 49
TC 5
Z9 5
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2020
VL 19
IS 3
BP 2021
EP 2027
DI 10.3892/ol.2020.11255
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KU8AI
UT WOS:000519933800043
PM 32194698
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, SL
   Yang, ZW
   Bao, WL
   Liu, LX
   You, Y
   Wang, X
   Shao, LM
   Fu, W
   Kou, XH
   Shen, WX
   Yuan, CM
   Hu, B
   Dang, WZ
   Nandakumar, KS
   Jiang, HL
   Zheng, MY
   Shen, XY
AF Zhang, Sulin
   Yang, Zhiwen
   Bao, Weilian
   Liu, Lixin
   You, Yan
   Wang, Xu
   Shao, Liming
   Fu, Wei
   Kou, Xinhui
   Shen, Weixing
   Yuan, Congmin
   Hu, Bin
   Dang, Wenzhen
   Nandakumar, Kutty Selva
   Jiang, Hualiang
   Zheng, Mingyue
   Shen, Xiaoyan
TI SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and
   progression by controlling autophagic degradation of SRC
SO AUTOPHAGY
LA English
DT Article
DE Colorectal cancer; macroautophagy; SNX10; SRC; tumor growth
ID CHAPERONE-MEDIATED AUTOPHAGY; STAT3; EXPRESSION; INFLAMMATION;
   ACTIVATION; REVEALS; ROLES; CELLS; MODEL; IL-6
AB The non-receptor tyrosine kinase SRC is a key mediator of cellular protumorigenic signals. SRC is aberrantly over-expressed and activated in more than 80% of colorectal cancer (CRC) patients, therefore regulation of its stability and activity is essential. Here, we report a significant down regulation of SNX10 (sorting nexin 10) in human CRC tissues, which is closely related to tumor differentiation, TNM stage, lymph node metastasis and survival period. SNX10 deficiency in normal and neoplastic colorectal epithelial cells promotes initiation and progression of CRC in mice. SNX10 controls SRC levels by mediating autophagosome-lysosome fusion and SRC recruitment for autophagic degradation. These mechanisms ensure proper controlling of the activities of SRC-STAT3 and SRC-CTNNB1 signaling pathways by up-regulating SNX10 expression under stress conditions. These findings suggest that SNX10 acts as a tumor suppressor in CRC and it could be a potential therapeutic target for future development.
C1 [Zhang, Sulin; Bao, Weilian; Liu, Lixin; You, Yan; Wang, Xu; Shao, Liming; Fu, Wei; Kou, Xinhui; Yuan, Congmin; Hu, Bin; Dang, Wenzhen; Shen, Xiaoyan] Fudan Univ, Sch Pharm, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
   [Zhang, Sulin; Jiang, Hualiang; Zheng, Mingyue] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
   [Yang, Zhiwen] Shanghai Jiao Tong Univ, Affiliated Shanghai Peoples Hosp 1, Songjiang Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Shen, Weixing] Nanjing Univ Tradit Chinese Med, Translat Med Res Ctr, Nanjing, Jiangsu, Peoples R China.
   [Nandakumar, Kutty Selva] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
RP Shen, XY (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.; Zheng, MY (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
EM myzheng@simm.ac.cn; shxiaoy@fudan.edu.cn
RI Nandakumar, Kutty Selva/D-5438-2011; Bao, Weilian/AAU-5822-2021; Zheng,
   Mingyue/Z-3582-2019; Zheng, Mingyue/AAJ-8027-2020
OI Nandakumar, Kutty Selva/0000-0001-7790-8197; Zheng,
   Mingyue/0000-0002-3323-3092
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773744, 81573441, 81371923]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2018M642122]; Shanghai Sailing Program [19YF1457800]
FX This study was supported by National Natural Science Foundation of China
   (No. 81773744, 81573441 and 81371923), China Postdoctoral Science
   Foundation (NO. 2018M642122), and Shanghai Sailing Program (NO.
   19YF1457800); China Postdoctoral Science Foundation [2018M642122].
CR Benham-Pyle BW, 2016, ELIFE, V5, DOI 10.7554/eLife.19799
   Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553
   Chen DD, 2012, MOL CELL, V45, P629, DOI 10.1016/j.molcel.2011.12.036
   Chen JZ, 2014, CLIN COLORECTAL CANC, V13, P5, DOI 10.1016/j.clcc.2013.10.003
   Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374
   Daigo Y, 1999, CANCER RES, V59, P4222
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Fu MM, 2014, DEV CELL, V29, P577, DOI 10.1016/j.devcel.2014.04.015
   Gayrard C, 2018, J CELL BIOL, V217, P1063, DOI 10.1083/jcb.201706013
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738
   Herrmann A, 2007, J CELL SCI, V120, P3249, DOI 10.1242/jcs.03482
   Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kesselring R, 2016, CANCER CELL, V29, P684, DOI 10.1016/j.ccell.2016.03.014
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560
   Lieu C, 2010, CLIN COLORECTAL CANC, V9, P89, DOI 10.3816/CCC.2010.n.012
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Liu XC, 2017, GASTROENTEROLOGY, V153, P1607, DOI 10.1053/j.gastro.2017.07.044
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386
   Santos CI, 2011, BBA-REV CANCER, V1816, P38, DOI 10.1016/j.bbcan.2011.03.003
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217
   Su K, 2017, FEBS LETT, V591, P2011, DOI 10.1002/1873-3468.12688
   Talbot JJ, 2014, J AM SOC NEPHROL, V25, P1737, DOI 10.1681/ASN.2013091026
   van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460
   Whitehead J, 2008, HFSP J, V2, P286, DOI 10.2976/1.2955566
   Xu TT, 2014, PROTEINS, V82, P3483, DOI 10.1002/prot.24689
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   You Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20630
   Zhang SL, 2018, CANCER LETT, V419, P116, DOI 10.1016/j.canlet.2018.01.045
   Zhou C, 2016, ANN RHEUM DIS, V75, P1211, DOI 10.1136/annrheumdis-2014-207134
NR 42
TC 13
Z9 14
U1 1
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD APR 2
PY 2020
VL 16
IS 4
BP 735
EP 749
DI 10.1080/15548627.2019.1632122
EA JUL 2019
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KS3OZ
UT WOS:000475048000001
PM 31208298
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Wang, X
   Yang, DY
   Yang, LQ
   Zhao, WZ
   Cai, LY
   Shi, HP
AF Wang, Xin
   Yang, De-Yi
   Yang, Liu-Qing
   Zhao, Wen-Zhi
   Cai, Li-Ya
   Shi, Han-Ping
TI Anthocyanin Consumption and Risk of Colorectal Cancer: A Meta-Analysis
   of Observational Studies
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Review
DE Anthocyanins; colorectal cancer; meta-analysis
ID DIETARY FLAVONOID INTAKE; COLON-CANCER; RICH EXTRACT; CELLS;
   DELPHINIDIN; MECHANISMS; VEGETABLES; QUALITY; FRUITS; BIAS
AB This meta-analysis aimed to summarize the association between anthocyanin consumption and the risk of colorectal cancer. All relative articles were located on online databases, including PubMed, Embase, and the Cochrane Library as of June 11, 2018. Risk ratios (RRs) or odds ratio and their 95% confidence intervals (CIs) were calculated through the STATA 12.0 software package. A total of seven studies were included in the meta-analysis. A significant inverse association was found between total anthocyanin consumption and colorectal cancer risk (RR = 0.78; 95% CI, 0.64-0.95). Likewise, there was significant evidence of a relationship between anthocyanin intake and colorectal cancer in the colon site (RR = 0.81; 95% CI, 0.71-0.92); men (RR = 0.88; 95% CI, 0.81-0.95), and case-control studies (RR = 0.69; 95% CI, 0.60-0.78). A dose-response relationship was not found in this meta-analysis. The Grades of Recommendations Assessment, Development, and Evaluation quality in our study was very low. This meta-analysis indicates that anthocyanin consumption is inversely associated with the risk of colorectal cancer. Anthocyanins may play an active role in the prevention of colorectal cancer. Key teaching points: Some epidemiological studies found an inverse correlation between the high consumption of anthocyanins and low risk of colorectal cancer. Because of this structure, anthocyanins/anthocyanidins have a powerful capability of donating electrons, which can be characterized as antioxidant properties. Anthocyanins can also inhibit colon cancer by interfering in the cell cycle and inducing the effect of anti-proliferation and apoptosis. The formation of cytoplasmic vacuoles in cells also indicates that anthocyanins may induce autophagy. From the findings of nonrandomized controlled trials, anthocyanins may play an active role in the prevention of colorectal cancer.
C1 [Wang, Xin; Yang, Liu-Qing; Zhao, Wen-Zhi; Cai, Li-Ya; Shi, Han-Ping] Capital Med Univ, Dept Gastrointestinal Surg, Beijing Shijitan Hosp, Dept Oncol, Beijing, Peoples R China.
   [Wang, Xin; Yang, Liu-Qing; Zhao, Wen-Zhi; Cai, Li-Ya; Shi, Han-Ping] Capital Med Univ, Dept Clin Nutr, Beijing Shijitan Hosp, Dept Oncol, Beijing, Peoples R China.
   [Wang, Xin; Yang, Liu-Qing; Zhao, Wen-Zhi; Cai, Li-Ya; Shi, Han-Ping] Peking Univ, Clin Med Coll 9, Beijing, Peoples R China.
   [Yang, De-Yi] Cent S Univ, Dept Gastrointestinal Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.
RP Shi, HP (corresponding author), Capital Med Univ, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing Shijitan Hosp, 10 Tieyi Rd, Beijing 100038, Peoples R China.
EM shihp@vip.163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672888]; National Key Research and
   Development Program of China [2017YFC1309200]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81672888) and the National Key Research and
   Development Program of China (Project No. 2017YFC1309200).
CR Ali HM, 2016, FOOD CHEM, V194, P1275, DOI 10.1016/j.foodchem.2015.09.003
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090
   Charepalli V, 2016, CANCERS, V8, DOI 10.3390/cancers8030029
   Charepalli V, 2015, J NUTR BIOCHEM, V26, P1641, DOI 10.1016/j.jnutbio.2015.08.005
   Cho YA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00117-8
   Moraes LFD, 2019, CRIT REV FOOD SCI, V59, P59, DOI 10.1080/10408398.2017.1357533
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esselen M, 2011, MOL NUTR FOOD RES, V55, pS143, DOI 10.1002/mnfr.201000315
   Fang J, 2014, DRUG METAB REV, V46, P508, DOI 10.3109/03602532.2014.978080
   Fritz J, 2008, J AGR FOOD CHEM, V56, P8891, DOI 10.1021/jf801522x
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grosso G, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600930
   Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsu CP, 2012, J AGR FOOD CHEM, V60, P3686, DOI 10.1021/jf204619n
   Kamiloglu S, 2015, INT J MOL SCI, V16, P21555, DOI 10.3390/ijms160921555
   Liang WB, 2009, AM J CLIN NUTR, V90, P1112, DOI 10.3945/ajcn.2009.28320
   Lim S, 2013, MOL NUTR FOOD RES, V57, P1908, DOI 10.1002/mnfr.201300040
   Malik M, 2003, NUTR CANCER, V46, P186, DOI 10.1207/S15327914NC4602_12
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Mursu J, 2008, INT J CANCER, V123, P660, DOI 10.1002/ijc.23421
   Nimptsch K, 2016, AM J CLIN NUTR, V103, P184, DOI 10.3945/ajcn.115.117507
   Nunes C, 2013, FOOD FUNCT, V4, P373, DOI 10.1039/c2fo30233k
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Putta S, 2017, CURR PHARM DESIGN, V23, P6321, DOI 10.2174/1381612823666170519151801
   Renis M, 2008, BRIT J NUTR, V100, P27, DOI 10.1017/S0007114507876239
   Rossi M, 2006, CANCER EPIDEM BIOMAR, V15, P1555, DOI 10.1158/1055-9965.EPI-06-0017
   Smolinska K, 2010, ARCH MED SCI, V6, P605, DOI 10.5114/aoms.2010.14475
   Spencer JPE, 2008, BRIT J NUTR, V99, P12, DOI 10.1017/S0007114507798938
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Symonds EL, 2013, BRIT J NUTR, V109, P2117, DOI 10.1017/S0007114512004333
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsuda T, 2012, MOL NUTR FOOD RES, V56, P159, DOI 10.1002/mnfr.201100526
   Wang LS, 2008, CANCER LETT, V269, P281, DOI 10.1016/j.canlet.2008.05.020
   Woo HD, 2013, WORLD J GASTROENTERO, V19, P1011, DOI 10.3748/wjg.v19.i7.1011
   Xu M, 2016, BRIT J NUTR, V116, P1275, DOI 10.1017/S0007114516003196
   Yun JM, 2009, MOL CARCINOGEN, V48, P260, DOI 10.1002/mc.20477
   Zamora-Ros R, 2017, INT J CANCER, V140, P1836, DOI 10.1002/ijc.30582
   Zamora-Ros R, 2016, EUR J NUTR, V55, P1359, DOI 10.1007/s00394-015-0950-x
   Zamora-Ros R, 2013, CANCER CAUSE CONTROL, V24, P549, DOI 10.1007/s10552-012-9992-z
   Zhou JG, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0471-0
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515
NR 49
TC 12
Z9 12
U1 3
U2 20
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD JUL 4
PY 2019
VL 38
IS 5
BP 470
EP 477
DI 10.1080/07315724.2018.1531084
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA IF3GV
UT WOS:000472969800011
PM 30589398
DA 2022-04-25
ER

PT J
AU Shang, M
   Sun, J
AF Shang, Mei
   Sun, Jun
TI Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Autophagy; bacteria; colon cancer; colitis; lactic acid bacteria; IBD;
   inflammation; probiotics; NF-kappa B; vitamin D; VDR
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; EPITHELIAL BARRIER DYSFUNCTION;
   ANTIBIOTIC-ASSOCIATED DIARRHEA; INFLAMMATORY-BOWEL-DISEASE; D-RECEPTOR;
   LACTOBACILLUS-RHAMNOSUS; COLORECTAL-CANCER; TIGHT JUNCTION; D
   DEFICIENCY; GUT MICROBIOME
AB Vitamin D is an important factor in regulating inflammation, immune responses, and carcinoma inhibition via action of its receptor, vitamin D receptor (VDR). Recent studies have demonstrated the role of vitamin D/VDR in regulating host-bacterial interactions. Probiotics are beneficial bacteria with the power of supporting or favoring life on the host. In the current review, we will discuss the recent progress on the roles of vitamin D/VDR in gut microbiome and inflammation. We will summarize evidence of probiotics in modulating vitamin D/VDR and balancing gut microbiota in health and gastrointestinal diseases. Moreover, we will review the clinical application of probiotics in prevention and therapy of IBD or colon cancer. Despite of the gains, there remain several barriers to advocate broad use of probiotics in clinical therapy. We will also discuss the limits and future direction in scientific understanding of probiotics, vitamin D/VDR, and host responses.
C1 [Shang, Mei] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou, Guangdong, Peoples R China.
   [Shang, Mei; Sun, Jun] Univ Illinois, Dept Med, Chicago, IL USA.
RP Sun, J (corresponding author), Univ Illinois, Dept Med, Div Gastroenterol & Hepatol, 840 S Wood St,Room 704 CSB, Chicago, IL 60612 USA.
EM junsun7@uic.edu
RI Sun, Jun/S-7440-2019
OI Sun, Jun/0000-0001-7465-3133
FU NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01 DK105118]; International
   Program for Ph.D. Candidates, Sun Yat-Sen University; NATIONAL INSTITUTE
   OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R03DK089010, R01DK105118] Funding Source: NIH RePORTER
FX We would like to acknowledge the NIDDK grant R01 DK105118 (JS). Mei
   Shang is partially supported by the International Program for Ph.D.
   Candidates, Sun Yat-Sen University. We would like to thank Annika
   Agrawal for her help with proofreading of this manuscript.
CR Anderson RC, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-316
   Appleyard CB, 2011, AM J PHYSIOL-GASTR L, V301, pG1004, DOI 10.1152/ajpgi.00167.2011
   Ardesia M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/470805
   Aronsson L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013087
   Assa A, 2014, J INFECT DIS, V210, P1296, DOI 10.1093/infdis/jiu235
   Baron JA, 2015, NEW ENGL J MED, V373, P1519, DOI 10.1056/NEJMoa1500409
   Bashir M, 2016, EUR J NUTR, V55, P1479, DOI 10.1007/s00394-015-0966-2
   Bassaganya-Riera J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031238
   Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202
   Bibiloni R, 2005, AM J GASTROENTEROL, V100, P1539, DOI 10.1111/j.1572-0241.2005.41794.x
   Blanck S, 2013, DIGEST DIS SCI, V58, P1698, DOI 10.1007/s10620-012-2531-7
   Bolognani F, 2001, EUR J NUTR, V40, P293, DOI 10.1007/s394-001-8359-7
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004
   Braat H, 2004, AM J CLIN NUTR, V80, P1618, DOI 10.1093/ajcn/80.6.1618
   Caderni G, 2003, CANCER RES, V63, P2388
   Cantorna MT, 2014, EXP BIOL MED, V239, P1524, DOI 10.1177/1535370214523890
   Capurso Gabriele, 2006, Dig Liver Dis, V38 Suppl 2, pS277, DOI 10.1016/S1590-8658(07)60010-3
   Cremonini F, 2002, ALIMENT PHARM THER, V16, P1461, DOI 10.1046/j.1365-2036.2002.01318.x
   Cross HS, 2011, MOL CELL ENDOCRINOL, V347, P70, DOI 10.1016/j.mce.2011.07.022
   CASTRO Francisca DIAS DE, 2015, Arq. Gastroenterol., V52, P260, DOI 10.1590/S0004-28032015000400003
   de LeBlanc AD, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-27
   Dou RX, 2016, BRIT J NUTR, V115, P1643, DOI 10.1017/S0007114516000696
   Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246
   Ewaschuk JB, 2008, AM J PHYSIOL-GASTR L, V295, pG1025, DOI 10.1152/ajpgi.90227.2008
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Femia AP, 2002, CARCINOGENESIS, V23, P1953, DOI 10.1093/carcin/23.11.1953
   Fooks LJ, 2002, BRIT J NUTR, V88, pS39, DOI [10.1079/BJNBJN2002591, 10.1079/BJN2002628]
   Fujii T, 2006, J PEDIATR GASTR NUTR, V43, P83, DOI 10.1097/01.mpg.0000228100.04702.f8
   Fujimori S, 2007, J GASTROEN HEPATOL, V22, P1199, DOI 10.1111/j.1440-1746.2006.04535.x
   Geier MS, 2006, CANCER BIOL THER, V5, P1265, DOI 10.4161/cbt.5.10.3296
   Ghadimi D, 2010, INFLAMM BOWEL DIS, V16, P410, DOI 10.1002/ibd.21057
   Gianotti L, 2010, WORLD J GASTROENTERO, V16, P167, DOI 10.3748/wjg.v16.i2.167
   Gilliland S. E., 2008, FOOD AND AGRICULTURE
   Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com
   Hawrelak JA, 2005, DIGESTION, V72, P51, DOI 10.1159/000087637
   Hlavaty T, 2014, WORLD J GASTROENTERO, V20, P15787, DOI 10.3748/wjg.v20.i42.15787
   Hoffmann M, 2011, MOL NUTR FOOD RES, V55, P703, DOI 10.1002/mnfr.201000361
   Indrio F, 2014, JAMA PEDIATR, V168, P228, DOI 10.1001/jamapediatrics.2013.4367
   Jacouton E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138880
   Jenab M, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5500
   Jin DP, 2015, CLIN THER, V37, P996, DOI 10.1016/j.clinthera.2015.04.004
   Johnson AL, 2014, AM J PHYSIOL-ENDOC M, V307, pE674, DOI 10.1152/ajpendo.00200.2014
   Johnson-Henry KC, 2008, INFECT IMMUN, V76, P1340, DOI 10.1128/IAI.00778-07
   Jones ML, 2013, J CLIN ENDOCR METAB, V98, P2944, DOI 10.1210/jc.2012-4262
   Karczewski J, 2010, AM J PHYSIOL-GASTR L, V298, pG851, DOI 10.1152/ajpgi.00327.2009
   Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018
   Kim HJ, 2003, ALIMENT PHARM THER, V17, P895, DOI 10.1046/j.1365-2036.2003.01543.x
   Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007
   Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936
   Lam EKY, 2007, LIFE SCI, V80, P2128, DOI 10.1016/j.lfs.2007.03.018
   Lee NK, 2007, LETT APPL MICROBIOL, V44, P274, DOI 10.1111/j.1472-765X.2006.02078.x
   Lee SI, 2016, BRIT J NUTR, V115, P567, DOI 10.1017/S0007114515004857
   Lee SY, 2015, J AGR FOOD CHEM, V63, P7024, DOI 10.1021/acs.jafc.5b02183
   Li AL, 2013, BIOL PHARM BULL, V36, P202, DOI 10.1248/bpb.b12-00437
   Li YC, 2015, J STEROID BIOCHEM, V148, P179, DOI 10.1016/j.jsbmb.2015.01.011
   Liu MC, 2016, INFLAMMATION, V39, P1483, DOI 10.1007/s10753-016-0382-7
   Lu R, 2012, CURR COLORECT CANC R, V8, P57, DOI 10.1007/s11888-011-0114-1
   Ma DL, 2004, INFECT IMMUN, V72, P5308, DOI 10.1128/IAI.72.9.5308-5314.2004
   Mai CW, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00007
   Maqueda M, 2008, FEMS MICROBIOL REV, V32, P2, DOI 10.1111/j.1574-6976.2007.00087.x
   Mencarelli A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045425
   Mencarelli A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022978
   Mennigen R, 2009, AM J PHYSIOL-GASTR L, V296, pG1140, DOI 10.1152/ajpgi.90534.2008
   Mizoue T, 2008, CANCER EPIDEM BIOMAR, V17, P2800, DOI 10.1158/1055-9965.EPI-08-0369
   Moorthy G, 2009, NUTRITION, V25, P350, DOI 10.1016/j.nut.2008.09.004
   Ooi JH, 2013, J NUTR, V143, P1679, DOI 10.3945/jn.113.180794
   Park SY, 2007, AM J EPIDEMIOL, V165, P784, DOI 10.1093/aje/kwk069
   Putaala H, 2008, RES MICROBIOL, V159, P692, DOI 10.1016/j.resmic.2008.08.002
   Rahimi R, 2008, DIGEST DIS SCI, V53, P2524, DOI 10.1007/s10620-007-0171-0
   Ranji Peyman, 2015, Asian Pac J Cancer Prev, V16, P3621
   Reiff C, 2009, INFLAMM BOWEL DIS, V15, P1721, DOI 10.1002/ibd.20999
   Schlee M, 2008, CLIN EXP IMMUNOL, V151, P528, DOI 10.1111/j.1365-2249.2007.03587.x
   Shimazu T, 2012, INFECT IMMUN, V80, P276, DOI 10.1128/IAI.05729-11
   Simeoli R, 2015, J NUTR, V145, P1202, DOI 10.3945/jn.114.205989
   Slattery ML, 2007, INT J CANCER, V120, P656, DOI 10.1002/ijc.22342
   Sood A, 2009, CLIN GASTROENTEROL H, V7, P1202, DOI 10.1016/j.cgh.2009.07.016
   Spruss A, 2009, J NUTR BIOCHEM, V20, P657, DOI 10.1016/j.jnutbio.2009.05.006
   Sun J, 2016, AUTOPHAGY, V12, P1057, DOI 10.1080/15548627.2015.1072670
   Sundar IK, 2011, BIOCHEM BIOPH RES CO, V406, P127, DOI 10.1016/j.bbrc.2011.02.011
   Suo HY, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030155
   Tazzyman S, 2015, BMJ OPEN GASTROENTER, V2, DOI 10.1136/bmjgast-2015-000052
   Terry P, 2002, NUTR CANCER, V43, P39, DOI 10.1207/S15327914NC431_4
   Thomas LV, 2015, BRIT J NUTR, V114, pS1, DOI 10.1017/S0007114515004043
   Thomas MR, 2001, MAYO CLIN PROC, V76, P883
   Tien MT, 2006, J IMMUNOL, V176, P1228, DOI 10.4049/jimmunol.176.2.1228
   Torki M, 2015, DIGEST DIS SCI, V60, P3085, DOI 10.1007/s10620-015-3727-4
   Ukena SN, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001308
   Ulitsky A, 2011, JPEN-PARENTER ENTER, V35, P308, DOI 10.1177/0148607110381267
   Urbanska AM, 2009, DIGEST DIS SCI, V54, P264, DOI 10.1007/s10620-008-0363-2
   Van Guelpen B, 2006, GUT, V55, DOI 10.1136/gut.2005.085480
   Vanderpool C, 2008, INFLAMM BOWEL DIS, V14, P1585, DOI 10.1002/ibd.20525
   Vilela EG, 2008, SCAND J GASTROENTERO, V43, P842, DOI 10.1080/00365520801943354
   Wachi S, 2014, MOL NUTR FOOD RES, V58, P2080, DOI 10.1002/mnfr.201400218
   Wagnerberger S, 2013, J NUTR BIOCHEM, V24, P531, DOI 10.1016/j.jnutbio.2012.01.014
   Walsham ADS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00244
   Wang B, 2010, INT J FOOD MICROBIOL, V142, P237, DOI 10.1016/j.ijfoodmicro.2010.05.024
   Wang J, 2016, NAT GENET, V48, P1396, DOI 10.1038/ng.3695
   Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225
   Wang YZ, 2013, INT IMMUNOPHARMACOL, V15, P30, DOI 10.1016/j.intimp.2012.10.026
   Weiss G, 2010, IMMUNOLOGY, V131, P268, DOI 10.1111/j.1365-2567.2010.03301.x
   Weiss ST, 2015, AM J RESP CRIT CARE, V191, P492, DOI 10.1164/rccm.201501-0117ED
   Wu Q, 2016, APPL ENVIRON MICROB, V82, P1173, DOI 10.1128/AEM.03044-15
   Wu SP, 2015, AM J PHYSIOL-GASTR L, V309, pG341, DOI 10.1152/ajpgi.00105.2015
   Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436
   Wu YP, 2016, VET IMMUNOL IMMUNOP, V172, P55, DOI 10.1016/j.vetimm.2016.03.005
   Xie JH, 2016, J AGR FOOD CHEM, V64, P1291, DOI 10.1021/acs.jafc.5b06177
   Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200
   Yao TB, 2015, ANTIOXID REDOX SIGN, V22, P633, DOI 10.1089/ars.2014.5887
   Yoon S, 2011, GASTROENTEROLOGY, V140, pS19
   Yoon SS, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/971938
   Yoshifuji A, 2016, NEPHROL DIAL TRANSPL, V31, P401, DOI 10.1093/ndt/gfv353
   Yu HJ, 2015, WORLD J GASTROENTERO, V21, P6561, DOI 10.3748/wjg.v21.i21.6561
   Yu XY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/238035
   Zhang LY, 2005, J NUTR, V135, P1752, DOI 10.1093/jn/135.7.1752
   Zhang W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125717
   Zhao HW, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-57
   Zheng AJ, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2371-5
   Zheng B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095441
   Zhou YK, 2010, BRIT J NUTR, V104, P390, DOI 10.1017/S0007114510000474
   Zhu YM, 2011, CANCER LETT, V309, P119, DOI 10.1016/j.canlet.2011.06.004
   Zyrek AA, 2007, CELL MICROBIOL, V9, P804, DOI 10.1111/j.1462-5822.2006.00836.x
NR 121
TC 39
Z9 46
U1 4
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2017
VL 24
IS 9
BP 876
EP 887
DI 10.2174/0929867323666161202150008
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA EU0JO
UT WOS:000400697700004
PM 27915988
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Hu, XT
   Sui, XB
   Li, LL
   Huang, XF
   Rong, R
   Su, XW
   Shi, QL
   Mo, LJ
   Shu, XS
   Kuang, YY
   Tao, Q
   He, C
AF Hu, Xiaotong
   Sui, Xinbing
   Li, Lili
   Huang, Xuefeng
   Rong, Rong
   Su, Xianwei
   Shi, Qinglan
   Mo, Lijuan
   Shu, Xingsheng
   Kuang, Yeye
   Tao, Qian
   He, Chao
TI Protocadherin 17 acts as a tumour suppressor inducing tumour cell
   apoptosis and autophagy, and is frequently methylated in gastric and
   colorectal cancers
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE PCDH17; tumour suppressor gene; methylation; apoptosis; autophagy
ID CANDIDATE; MULTIPLE; DIVERSITY; GENE; NASOPHARYNGEAL; CARCINOMAS;
   ESOPHAGEAL; MECHANISM; PROTEIN; DEATH
AB Gastric and colorectal cancers are among the most common cancers worldwide and cause serious cancer mortality. Both epigenetic and genetic disruptions of tumour suppressor genes (TSGs) are frequently involved in their pathogenesis. Here, we studied the epigenetic and genetic alterations of a novel TSG-PCDH17 and its functions in the pathogenesis of these tumours. We found that PCDH17 was frequently silenced and methylated in almost all gastric and colorectal tumour cell lines as well as in similar to 95% of primary tumours, but not in normal gastric and colonic mucosa. Moreover, its deletion was detected in only 18% of gastric and 12% of colorectal cancer tissues, suggesting that epigenetic and genetic inactivation of PCDH17 are both involved in gastric and colorectal tumourigenesis. PCDH17 protein expression was significantly correlated with low tumour stage and less lymph node metastasis of gastric and colorectal cancer patients, indicating its potential as a tumour marker. Restoring PCDH17 expression inhibited tumour cell growth in vitro and in vivo through promoting apoptosis, as evidenced by increased TUNEL staining and caspase-3 activation. Furthermore, PCDH17-induced autophagy, along with increased numbers of autophagic vacuoles and up-regulated autophagic proteins Atg-5, Atg-12 and LC3B II. Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers. PCDH17 methylation is a tumour-specific event that could serve as an epigenetic biomarker for these tumours. Copyright (C) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Li, Lili; Rong, Rong; Su, Xianwei; Shu, Xingsheng; Tao, Qian] Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
   [Li, Lili; Rong, Rong; Su, Xianwei; Shu, Xingsheng; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Sui, Xinbing; Huang, Xuefeng; He, Chao] Zhejiang Univ, Dept Colorectal Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
   [Hu, Xiaotong; Shi, Qinglan; Mo, Lijuan; Kuang, Yeye; He, Chao] Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
   [Hu, Xiaotong; Shi, Qinglan; Mo, Lijuan; Kuang, Yeye; He, Chao] Zhejiang Univ, Key Lab Biotherapy Zhejiang Prov, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
RP Tao, Q (corresponding author), Chinese Univ Hong Kong, Ctr Canc, PWH, Rm 315, Shatin, Hong Kong, Peoples R China.
EM qtao@clo.cuhk.edu.hk; drhe_srrsh@sina.com
RI Hu, Xiao-tong/K-5820-2019; Tao, Qian/T-4743-2018; Li, Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30770920, 81071651, 30928012]; Zhejiang
   Provincial Natural Science Foundation of ChinaNatural Science Foundation
   of Zhejiang Province [R2100213, 2010R50046, 2009C33142, Z2090056];
   Program for Zhejiang Leading Team of ST innovation [2012R10046-03]; Hong
   Kong RGCHong Kong Research Grants Council [GRF 475009]; Group Research
   Scheme of the Chinese University of Hong Kong [3110085]
FX We thank Bert Vogelstein, Keith Robertson, Sun Young Rha, for some
   tumour cell lines. This study was supported by the National Natural
   Science Foundation of China (Grant Nos 30770920, 81071651 and 30928012),
   the Zhejiang Provincial Natural Science Foundation of China (Grant Nos
   R2100213, 2010R50046, 2009C33142 and Z2090056), the Program for Zhejiang
   Leading Team of S&T innovation (Grant No. 2012R10046-03) the Hong Kong
   RGC (Grant No. GRF 475009) and the Group Research Scheme of the Chinese
   University of Hong Kong (Grant No. 3110085).
CR Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Costa VL, 2011, EPIGENETICS-US, V6, P1120, DOI 10.4161/epi.6.9.16376
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Cummings O W, 2000, Semin Gastrointest Dis, V11, P229
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4
   Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840
   Gutierrez-Gonzalez L, 2011, GASTROENTEROLOGY, V140, P1251, DOI 10.1053/j.gastro.2010.12.051
   Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053
   Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Kim EC, 1997, GASTROENTEROL CLIN N, V26, P1, DOI 10.1016/S0889-8553(05)70280-6
   Meining A, 2001, BEST PRACT RES CL GA, V15, P983, DOI 10.1053/bega.2001.0253
   Model F, 2007, MOL CANCER RES, V5, P153, DOI 10.1158/1541-7786.MCR-06-0034
   Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006
   MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944
   Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139
   Palii SS, 2007, CRIT REV EUKAR GENE, V17, P295
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Redies C, 2005, CELL MOL LIFE SCI, V62, P2840, DOI 10.1007/s00018-005-5320-z
   Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Shamas-Din A., 2010, BIOCHIM BIOPHYS ACTA, V1813, P508
   Sui XB, 2012, MOL BIOL REP, V39, P1105, DOI 10.1007/s11033-011-0837-8
   Suzuki ST, 1996, J CELL SCI, V109, P2609
   Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
NR 39
TC 73
Z9 78
U1 1
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2013
VL 229
IS 1
BP 62
EP 73
DI 10.1002/path.4093
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 057DM
UT WOS:000312542300007
PM 22926751
DA 2022-04-25
ER

PT J
AU Singh, AK
   Verma, A
   Singh, A
   Arya, RK
   Maheshwari, S
   Chaturvedi, P
   Nengroo, MA
   Saini, KK
   Vishwakarma, AL
   Singh, K
   Sarkar, J
   Datta, D
AF Singh, Anup Kumar
   Verma, Ayushi
   Singh, Akhilesh
   Arya, Rakesh Kumar
   Maheshwari, Shrankhla
   Chaturvedi, Priyank
   Nengroo, Mushtaq Ahmad
   Saini, Krishan Kumar
   Vishwakarma, Achchhe Lal
   Singh, Kavita
   Sarkar, Jayanta
   Datta, Dipak
TI Salinomycin inhibits epigenetic modulator EZH2 to enhance death
   receptors in colon cancer stem cells
SO EPIGENETICS
LA English
DT Article
DE EZH2; cancer stem cells; death receptors; salinomycin; apoptosis
ID SMALL-MOLECULE INHIBITOR; TRAIL RESISTANCE; BREAST-CANCER; TUMOR-GROWTH;
   APOPTOSIS; HETEROGENEITY; ACTIVATION; AUTOPHAGY; TARGET
AB Drug resistance is one of the trademark features of Cancer Stem Cells (CSCs). We and others have recently shown that paucity of functional death receptors (DR4/5) on the cell surface of tumour cells is one of the major reasons for drug resistance, but their involvement in the context of in CSCs is poorly understood. By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs. Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs. Concurrently, EZH2 knockdown demonstrated increased expression of DR4/DR5, significant reduction of CSC phenotypes such as spheroid formationin-vitroand tumorigenic potentialin-vivoin colon cancer. TCGA data analysis of human colon cancer clinical samples shows strong inverse correlation between EZH2 and DR4. Taken together, this study provides an insight about epigenetic regulation of DR4 in colon CSCs and advocates that drug-resistant colon cancer can be therapeutically targeted by combining TRAIL and small molecule EZH2 inhibitors.
C1 [Singh, Anup Kumar; Verma, Ayushi; Singh, Akhilesh; Arya, Rakesh Kumar; Maheshwari, Shrankhla; Chaturvedi, Priyank; Nengroo, Mushtaq Ahmad; Saini, Krishan Kumar; Datta, Dipak] CSIR, Div Canc Biol, Cent Drug Res Inst CDRI, Lucknow, Uttar Pradesh, India.
   [Maheshwari, Shrankhla; Saini, Krishan Kumar; Datta, Dipak] Acad Sci & Innovat Res, New Delhi, India.
   [Vishwakarma, Achchhe Lal] CSIR, CDRI, SAIF, Lucknow, Uttar Pradesh, India.
   [Singh, Kavita] CSIR, CDRI, Electron Microscopy Unit, Lucknow, Uttar Pradesh, India.
   [Sarkar, Jayanta] CSIR, CDRI, Biochem Div, Lucknow, Uttar Pradesh, India.
   City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Canc Genet & Epigenet, Duarte, CA 91010 USA.
RP Datta, D (corresponding author), CSIR, CDRI, Div Canc Biol, Lucknow 226031, Uttar Pradesh, India.
EM dipak.datta@cdri.res.in
RI Sarkar, Jayanta/C-3250-2009; Singh, Anup Kumar/T-9464-2019
OI Singh, Anup Kumar/0000-0001-5180-0727; Sarkar,
   Jayanta/0000-0002-9905-7722
FU Department of Biotechnology, Ministry of Science and Technology
   [BT/AIR0568/PACE-15/18]; DST-Science and Engineering Research Board
   [EMR/2016/006935]; ICMRIndian Council of Medical Research (ICMR)
   [2019-1350]
FX This work in part was supported by the Department of Biotechnology,
   Ministry of Science and Technology [BT/AIR0568/PACE-15/18]; DST-Science
   and Engineering Research Board [EMR/2016/006935] and ICMR [2019-1350].
CR Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064
   Arya RK, 2015, SCI REP-UK, V5, DOI 10.1038/srep18457
   Benoit YD, 2013, J CELL PHYSIOL, V228, P764, DOI 10.1002/jcp.24224
   Bhatia V, 2019, CLIN CANCER RES, V25, P2755, DOI 10.1158/1078-0432.CCR-18-3230
   Boehmerle W, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.46
   Boehmerle W, 2014, J MOL MED, V92, P889, DOI 10.1007/s00109-014-1155-0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Calzolari A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094438
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Datta D, 2006, CANCER RES, V66, P9509, DOI 10.1158/0008-5472.CAN-05-4345
   De Angelis ML, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00626
   Deb G, 2014, MOL CANCER RES, V12, P639, DOI 10.1158/1541-7786.MCR-13-0546
   Dewangan J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695035
   Dillies MA, 2013, BRIEF BIOINFORM, V14, P671, DOI 10.1093/bib/bbs046
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Elias A, 2009, CLIN CANCER RES, V15, P5457, DOI 10.1158/1078-0432.CCR-09-1125
   Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945
   Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576
   Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003
   Ganesher A, 2020, EUR J MED CHEM, V188, DOI 10.1016/j.ejmech.2019.112011
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031
   Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913
   Huang XL, 2018, ACS CENTRAL SCI, V4, P760, DOI 10.1021/acscentsci.8b00257
   Jangamreddy JR, 2013, BBA-MOL CELL RES, V1833, P2057, DOI 10.1016/j.bbamcr.2013.04.011
   Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kim SH, 2016, BIOCHEM BIOPH RES CO, V473, P607, DOI 10.1016/j.bbrc.2016.03.132
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195
   Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108
   Lu Y, 2015, CHEM-BIOL INTERACT, V228, P100, DOI 10.1016/j.cbi.2014.12.002
   Maheshwari S, 2017, MOL CANCER THER, V16, P1791, DOI 10.1158/1535-7163.MCT-16-0584
   Martinez-Paniagua MA, 2011, CELL CYCLE, V10, P2792, DOI 10.4161/cc.10.16.16952
   Martins-Neves SR, 2018, PHARMACOL RES, V137, P193, DOI 10.1016/j.phrs.2018.10.011
   Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317
   Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Najumudeen AK, 2016, ONCOGENE, V35, P5248, DOI 10.1038/onc.2016.59
   Naujokat C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/950658
   Parajuli B, 2013, ANTICANCER RES, V33, P1457
   Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788
   Singh AK, 2016, CARCINOGENESIS, V37, P1027, DOI 10.1093/carcin/bgw088
   Singh AK, 2015, INT J CANCER, V136, P1991, DOI 10.1002/ijc.28804
   Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489
   Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13
   Tiwari R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14184-0
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Mai TT, 2017, NAT CHEM, V9, P1025, DOI [10.1038/NCHEM.2778, 10.1038/nchem.2778]
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   van Vlerken LE, 2013, STEM CELL TRANSL MED, V2, P43, DOI 10.5966/sctm.2012-0036
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verdoodt B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044132
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016
   Yang SZ, 2017, J BIOL CHEM, V292, P10390, DOI 10.1074/jbc.M117.786830
   Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7
   Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269
   Zhang YQ, 2008, MOL CANCER RES, V6, P1861, DOI 10.1158/1541-7786.MCR-08-0313
   Zhi QM, 2011, BIOMED PHARMACOTHER, V65, P509, DOI 10.1016/j.biopha.2011.06.006
NR 64
TC 9
Z9 9
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2021
VL 16
IS 2
BP 144
EP 161
DI 10.1080/15592294.2020.1789270
EA JUL 2020
PG 18
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA QG3HT
UT WOS:000547834800001
PM 32635858
OA Bronze, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Lo Dico, A
   Martelli, C
   Diceglie, C
   Lucignani, G
   Ottobrini, L
AF Lo Dico, Alessia
   Martelli, Cristina
   Diceglie, Cecilia
   Lucignani, Giovanni
   Ottobrini, Luisa
TI Hypoxia-Inducible Factor-1 alpha Activity as a Switch for Glioblastoma
   Responsiveness to Temozolomide
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE theranostic biomarker; hypoxia-inducible factor-1 alpha silencing;
   apoptosis; chaperone-mediated autophagy activity; temozolomide
   responsiveness
ID CHAPERONE-MEDIATED AUTOPHAGY; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA
   HIF-1-ALPHA; IMAGING BIOMARKERS; MALIGNANT GLIOMAS; COLON-CANCER;
   STEM-CELLS; IN-VITRO; SENSITIVITY; INHIBITION; EXPRESSION
AB Rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1 alpha, is a common driver of a number of the pathways involved in the aggressiveness of glioblastomas (GBMs), and it has been suggested that the reduction in this activity observed, soon after the administration of temozolomide (TMZ), can be a biomarker of an early response in GBM models. As HIF-1 alpha is a tightly regulated protein, studying the processes involved in its downregulation could shed new light on the mechanisms underlying GBM sensitivity or resistance to TMZ.
   Methods: The effect of HIF-1 alpha silencing on cell responsiveness to TMZ was assessed in four genetically different human GBM cell lines by evaluating cell viability and apoptosis- related gene balance. LAMP-2A silencing was used to evaluate the contribution of chaperone-mediated autophagy (CMA) to the modulation of HIF-1 alpha activity in TMZ-sensitive and TMZ-resistant cells.
   Results: The results showed that HIF-1 alpha but not HIF-2 alpha activity is associated with GBM responsiveness to TMZ: its downregulation improves the response of TMZ-resistant cells, while blocking CMA-mediated HIF-1 alpha degradation induces resistance to TMZ in TMZ-sensitive cells. These findings are in line with the modulation of crucial apoptosis- related genes.
   Conclusion: Our results demonstrate the central role played by HIF-1 alpha activity in determining the sensitivity or resistance of GBMs to TMZ, and we suggest that CMA is the cellular mechanism responsible for modulating this activity after TMZ treatment.
C1 [Lo Dico, Alessia; Ottobrini, Luisa] CNR, Inst Mol Bioimaging & Physiol IBFM, Milan, Italy.
   [Lo Dico, Alessia; Martelli, Cristina; Diceglie, Cecilia; Ottobrini, Luisa] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Lucignani, Giovanni] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Lucignani, Giovanni] San Paolo Hosp, Unit Nucl Med, Dept Diagnost Serv, Milan, Italy.
RP Ottobrini, L (corresponding author), CNR, Inst Mol Bioimaging & Physiol IBFM, Milan, Italy.; Ottobrini, L (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
EM luisa.ottobrini@unimi.it
RI Dico, Alessia Lo/AAK-3571-2020; Lucignani, Giovanni/C-6773-2008; lo
   dico, alessia/O-9721-2017
OI Lucignani, Giovanni/0000-0002-9674-8958; lo dico,
   alessia/0000-0002-8627-5050
FU  [GA305311]
FX The authors would like to thank Dr. G. Melillo for providing the
   U251-HRE cells and the HRE-luciferase reporter plasmid. This study was
   supported in part by the FP7-funded INSERT project (HEALTH-2012-
   INNOVATION-1, GA305311).
CR Adams JM, 2009, ACTA PHYSIOL HUNG, V96, P19, DOI 10.1556/APhysiol.96.2009.1.2
   Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030
   Bocangel DB, 2002, CLIN CANCER RES, V8, P2725
   Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4
   Costa V, 2017, ONCOTARGET, V8, P24292, DOI 10.18632/oncotarget.14464
   Diers AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068348
   Ferreira JV, 2013, AUTOPHAGY, V9, P1349, DOI 10.4161/auto.25190
   Han J, 2015, INT J CLIN EXP PATHO, V8, P12698
   Haynes HR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00047
   Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x
   Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003
   Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032
   Jensen RL, 2006, J NEURO-ONCOL, V78, P233, DOI 10.1007/s11060-005-9103-z
   Johnson DR, 2013, CURR ONCOL REP, V15, P56, DOI 10.1007/s11912-012-0279-z
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kaynar MY, 2008, J CLIN NEUROSCI, V15, P1036, DOI 10.1016/j.jocn.2007.07.080
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801
   Kong XG, 2007, J BIOL CHEM, V282, P15498, DOI 10.1074/jbc.M700704200
   Kuger S, 2014, BREAST CANCER-BASIC, V8, P39, DOI 10.4137/BCBCR.S13693
   Lanvin O, 2013, EUR J CANCER, V49, P2884, DOI 10.1016/j.ejca.2013.05.003
   Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701
   Liu Q, 2015, INT J CLIN EXP MED, V8, P22073
   Lo Dico A, 2015, EUR J NUCL MED MOL I, V42, P1093, DOI 10.1007/s00259-015-3040-7
   Lo Dico A, 2014, MOL IMAGING BIOL, V16, P210, DOI 10.1007/s11307-013-0669-0
   Lo Dico A, 2016, THERANOSTICS, V6, P1105, DOI 10.7150/thno.14700
   Lucignani G, 2007, EUR J NUCL MED MOL I, V34, P1693, DOI 10.1007/s00259-007-0569-0
   Luo ZH, 2015, NEUROPHARMACOLOGY, V89, P168, DOI 10.1016/j.neuropharm.2014.05.009
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   McLendon RE, 2003, CANCER-AM CANCER SOC, V98, P1745, DOI 10.1002/cncr.11666
   Mellai M, 2012, J NEURO-ONCOL, V107, P617, DOI 10.1007/s11060-011-0787-y
   Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133
   Miao W, 2015, MOL MED REP, V11, P4165, DOI 10.3892/mmr.2015.3255
   Minardi D, 2016, INT BRAZ J UROL, V35, P433
   Persano L, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.153
   Reszec J, 2013, J NEURO-ONCOL, V115, P119, DOI 10.1007/s11060-013-1208-1
   Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214
   Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158
   Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tabatabai G, 2010, ACTA NEUROPATHOL, V120, P585, DOI 10.1007/s00401-010-0750-6
   Tang JH, 2016, EXP CELL RES, V343, P148, DOI 10.1016/j.yexcr.2016.04.011
   Thon N, 2013, ONCOTARGETS THER, V6, P1363, DOI 10.2147/OTT.S50208
   Trisciuoglio D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011772
   van Nifterik KA, 2010, BRIT J CANCER, V103, P29, DOI 10.1038/sj.bjc.6605712
   Voss MJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-158
   Welsh SJ, 2015, THER ADV MED ONCOL, V7, P122, DOI 10.1177/1758834014566428
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wick W, 2011, NEURO-ONCOLOGY, V13, P566, DOI 10.1093/neuonc/nor039
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5
   Zhang Jihong, 2012, Curr Mol Pharmacol, V5, P102
   Zou YH, 2014, MOL MED REP, V10, P411, DOI 10.3892/mmr.2014.2151
NR 58
TC 31
Z9 31
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 2
PY 2018
VL 8
AR 249
DI 10.3389/fonc.2018.00249
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL2QY
UT WOS:000436970000003
PM 30013951
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Saadat, YR
   Khosroushahi, AY
   Movassaghpour, AA
   Talebi, M
   Gargari, BP
AF Saadat, Yalda Rahbar
   Khosroushahi, Ahmad Yari
   Movassaghpour, Ali Akbar
   Talebi, Mehdi
   Gargari, Bahram Pourghassem
TI Modulatory role of exopolysaccharides of Kluyveromyces marxianus and
   Pichia kudriavzevii as probiotic yeasts from dairy products in human
   colon cancer cells
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Probiotic yeasts; Colon cancer; Apoptosis; Ferroptosis; Signaling
   pathways; Exopolysaccharides
ID APOPTOSIS; FERROPTOSIS; STRAINS; DEATH; BIOSYNTHESIS; AUTOPHAGY; CHEESE;
   LINES
AB Colorectal cancer (CRC) is a widespread and lethal cancer throughout the world. Nowadays there is considerable debate about the efficacy of conventional methods in CRC treatment. Though targeting vital molecular pathways, as well as induction of various forms of cell death by safe probiotic yeast components are regarded as potential therapeutic modalities against CRC. Hence, here we aimed to investigate the inhibitory role of the EPSs of Kluyveromyces marxianus and Pichia kudriavzevii on different colon cancer cell lines. In this regard, several cellular and molecular experiments were performed. Here, we found that both EPSs can induce apoptosis which were confirmed by DAPI and Annexin V/PI assays. Further, our data showed that the EPSs could not act via ferroptotic pathways, however, they could hinder the AKT-1, mTOR, and JAK-1 pathways, and induce apoptosis. Therefore, the probiotic yeast EPSs present beneficial effects and may provide as a novel molecular-targeted therapeutics for combating CRC.
C1 [Saadat, Yalda Rahbar; Gargari, Bahram Pourghassem] Tabriz Univ Med Sci, Nutr Res Ctr, Tabriz, Iran.
   [Saadat, Yalda Rahbar] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Khosroushahi, Ahmad Yari] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Khosroushahi, Ahmad Yari] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Nanotechnol, Tabriz, Iran.
   [Movassaghpour, Ali Akbar; Talebi, Mehdi] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Tabriz, Iran.
   [Gargari, Bahram Pourghassem] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Dept Biochem & Diet Therapy, Tabriz, Iran.
RP Gargari, BP (corresponding author), Tabriz Univ Med Sci, Fac Nutr & Food Sci, Dept Biochem & Diet Therapy, Nutr Res Ctr, Tabriz, Iran.
EM pourghassemb@tbzmed.ac.ir
RI Rahbar Saadat, Yalda/O-8109-2017; Talebi, Mehdi/E-3808-2010
OI Rahbar Saadat, Yalda/0000-0002-3295-404X; Talebi,
   Mehdi/0000-0002-3633-2280
FU Nutrition Research Center, Tabriz University of Medical Sciences, Iran
   [1396.09.28, 5D.606013];  [97011018]
FX This project is part of a Ph.D. thesis (grant No. 1396.09.28, 5D.606013)
   funded by Nutrition Research Center, Tabriz University of Medical
   Sciences, Iran and Iran National Science Foundation (INSF) (grant No.:
   97011018).
CR Aloglu HS, 2016, INT J DAIRY TECHNOL, V69, P63, DOI 10.1111/1471-0307.12217
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Banik A, 2019, FUNG BIOL-US, P101, DOI 10.1007/978-3-030-14846-1_3
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Ceugniez A, 2017, RES MICROBIOL, V168, P575, DOI 10.1016/j.resmic.2017.03.004
   Chelliah R, 2016, YEAST, V33, P385, DOI 10.1002/yea.3181
   Chen LS, 2010, DAIRY SCI TECHNOL, V90, P537, DOI 10.1051/dst/2010001
   Eslami M, 2019, J CELL PHYSIOL, V234, P17127, DOI 10.1002/jcp.28473
   Fadda ME, 2017, LWT-FOOD SCI TECHNOL, V75, P100, DOI 10.1016/j.lwt.2016.08.020
   Fortin O, 2018, NUTR CANCER, V70, P83, DOI 10.1080/01635581.2018.1380204
   Angeli JPF, 2019, CHEM RES TOXICOL, V32, P362, DOI 10.1021/acs.chemrestox.8b00349
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Gientka I, 2015, ACTA SCI POLON-TECHN, V14, P283, DOI 10.17306/J.AFS.2015.4.29
   Greppi A, 2017, FOOD MICROBIOL, V62, P169, DOI 10.1016/j.fm.2016.09.016
   Hongmei Z., 2012, APOPTOSIS MED, P3, DOI 10.5772/50129
   Kandasamy S, 2018, FOOD MICROBIOL FOOD, P25, DOI 10.1007/978-3-319-74820-7_2
   Lachaier E, 2014, ANTICANCER RES, V34, P6417
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Madhuri K. V., 2014, ORIENT J CHEM, V30, P1401, DOI 10.13005/ojc/300362.
   Mahapatra Subhadip, 2013, Microbiol Insights, V6, P1, DOI 10.4137/MBI.S10957
   Mlimbila J. S., 2014, J BIOL AGR HEALTHCAR, V4
   Mojibi P., 2019, Iranian Journal of Pathology, V14, P41, DOI 10.30699/ijp.14.1.41
   MORELLI L, 2012, FAO WHO GUIDELINES P, V46, pS1
   Newton PT, 2019, BIOCHEM J, V476, P779, DOI 10.1042/BCJ20190020
   Ogunremi OR, 2015, J FUNCT FOODS, V17, P742, DOI 10.1016/j.jff.2015.06.031
   Pedersen LL, 2012, INT J FOOD MICROBIOL, V159, P144, DOI 10.1016/j.ijfoodmicro.2012.08.016
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Ragavan ML, 2019, ANN MICROBIOL, V69, P515, DOI 10.1007/s13213-019-1440-9
   Raman M, 2016, PROBIOTICS COLORECTA, P15, DOI DOI 10.1007/978-81-322-2586-7_2
   Saadat YR, 2019, CARBOHYD POLYM, V217, P79, DOI 10.1016/j.carbpol.2019.04.025
   Saber A, 2017, J FUNCT FOODS, V34, P408, DOI 10.1016/j.jff.2017.05.007
   Saber Gharamaleki A. A. B., 2016, INTERNATIONAL JOURNA, V10
   Senger DR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148042
   Shamekhi S, 2020, PROBIOTICS ANTIMICRO, V12, P311, DOI 10.1007/s12602-019-09528-7
   Shimada K, 2016, NAT CHEM BIOL, V12, P497, DOI [10.1038/nchembio.2079, 10.1038/NCHEMBIO.2079]
   Smith IM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167410
   Stefania Pacini M. R., 2017, AM J IMMUNOLOGY, P1, DOI [10.3844/ajisp.2017, DOI 10.3844/AJISP.2017]
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Tang SB, 2019, ONCOL LETT, V17, P159, DOI 10.3892/ol.2018.9569
   Vahed SZ, 2017, BIOMED PHARMACOTHER, V94, P1094, DOI 10.1016/j.biopha.2017.08.033
   Van Bogaert I.N.A., 2009, YEAST BIOTECHNOLOGY, P651, DOI DOI 10.1007/978-1-4020-8292-4_29
   Waluga M, 2018, J PHYSIOL PHARMACOL, V69, P325, DOI 10.26402/jpp.2018.3.02
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xie YH, 2015, BRAZ J MICROBIOL, V46, P389, DOI 10.1590/S1517-838246220131278
   Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
NR 46
TC 12
Z9 13
U1 6
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JAN
PY 2020
VL 64
AR 103675
DI 10.1016/j.jff.2019.103675
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA KE3WY
UT WOS:000508491000069
OA gold
DA 2022-04-25
ER

PT J
AU Islam, F
   Gopalan, V
   Lam, AKY
AF Islam, Farhadul
   Gopalan, Vinod
   Lam, Alfred King-yin
TI RETREG1 (FAM134B): A new player in human diseases: 15 years after the
   discovery in cancer
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE cancer; endoplasmic reticulum; FAM134B; JK1; neuronal disorder; RETREG1
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; SQUAMOUS-CELL
   CARCINOMA; AUTONOMIC NEUROPATHY; COLORECTAL-CANCER; COLON-CANCER;
   CLINICOPATHOLOGICAL SIGNIFICANCE; 3-DIMENSIONAL ARCHITECTURE; SELECTIVE
   AUTOPHAGY; MUTATIONS
AB FAM134B (family with sequence similarity 134, member B)/RETREG1 and its functional roles are relatively new in human diseases. This review aimed to summarize various functions of FAM134B since our first discovery of the gene in 2001. The protein encoded by FAM134B is a reticulophagy receptor that regulates turnover of the endoplasmic reticulum (ER) by selective phagocytosis. Absence or non-functional expression of FAM134B protein impairs ER-turnover and thereby is involved in the pathogenesis of some human diseases. FAM134B inhibition contributes to impair proteostasis in the ER due to the accumulation of misfolded or aggregated proteins, which in turn leads to compromised neuronal survival and progressive neuronal degenerative diseases. Mutations in FAM134B associated with hereditary sensory and autonomic neuropathy type IIB (HSAN IIB). Selective cleavage of FAM134B by Dengue, Zika, and West Nile virus encoded protease NS2B3 leads to the increased production of infection units, whereas upregulation of FAM134B inhibits viral replication. In cancer, FAM134B acts as a tumor suppressor and inhibit cancer growth both in-vitro and in-vivo. Pharmacological upregulation of FAM134B resulted in reduced cancer cell growth and proliferation. In addition, FAM134B mutations are common in patients with colorectal adenocarcinoma, and oesophageal squamous cell carcinoma. These mutations and expression changes of FAM134B were associated with the biological aggressiveness of these cancers. FAM134B also plays a role in allergic rhinitis, vascular dementia, and identification of stem cells. Taken together, information available in the literature suggests that FAM134B plays critical roles in human diseases, by interacting with different biological and chemical mediators, which are primarily regulated by ER turnover.
C1 [Islam, Farhadul; Gopalan, Vinod; Lam, Alfred King-yin] Griffith Univ, Sch Med, Canc Mol Pathol, Gold Coast, Qld, Australia.
   [Islam, Farhadul; Gopalan, Vinod; Lam, Alfred King-yin] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld, Australia.
   [Islam, Farhadul] Rajshahi Univ, Dept Biochem & Mol Biol, Rajshahi, Bangladesh.
RP Lam, AKY (corresponding author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.
EM a.lam@griffith.edu.au
RI Lam, Alfred/C-1652-2008; Islam, Farhadul/R-5643-2017
OI Lam, Alfred/0000-0003-2771-564X; Islam, Farhadul/0000-0001-5262-4702
FU Griffith UniversityGriffith University; Menzies Health Institute
   Queensland
FX Griffith University; Menzies Health Institute Queensland
CR Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Borgese N, 2006, CURR OPIN CELL BIOL, V18, P358, DOI 10.1016/j.ceb.2006.06.008
   Chiramel AI, 2016, J INFECT DIS, V214, pS319, DOI 10.1093/infdis/jiw270
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Cybulsky AV, 2017, NAT REV NEPHROL, V13, P681, DOI 10.1038/nrneph.2017.129
   Dai XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07189-6
   Davidson GL, 2012, J NEUROL, V259, P1673, DOI 10.1007/s00415-011-6397-y
   Duret C, 2014, MUSCLE NERVE, V49, P774, DOI 10.1002/mus.24145
   Hamasaki M, 2005, TRAFFIC, V6, P56, DOI 10.1111/j.1600-0854.2004.00245.x
   Haque MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29173
   Houlden H, 2004, CURR OPIN NEUROL, V17, P569, DOI 10.1097/00019052-200410000-00007
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4
   Islam F, 2017, MOL CARCINOGEN, V56, P238, DOI 10.1002/mc.22488
   Junjhon J, 2014, J VIROL, V88, P4687, DOI 10.1128/JVI.00118-14
   Kasem K, 2014, EXP MOL PATHOL, V97, P99, DOI 10.1016/j.yexmp.2014.06.002
   Kasem K, 2014, EXP MOL PATHOL, V97, P31, DOI 10.1016/j.yexmp.2014.05.001
   Kasem K, 2014, EXP CELL RES, V326, P166, DOI 10.1016/j.yexcr.2014.06.013
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Kobayashi S, 2015, BIOL PHARM BULL, V38, P1098, DOI 10.1248/bpb.b15-00096
   Kong M, 2011, PSYCHIAT GENET, V21, P37, DOI 10.1097/YPG.0b013e3283413496
   Kurth I., 2015, GENEREVIEWS, P1993
   Kurth I, 2009, NAT GENET, V41, P1179, DOI 10.1038/ng.464
   Lam AKY, 2012, INT J COLORECTAL DIS, V27, P1303, DOI 10.1007/s00384-012-1474-y
   Lennemann NJ, 2017, AUTOPHAGY, V13, P322, DOI 10.1080/15548627.2016.1265192
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Lipatova Z, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005390
   Melchiotti R, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-73
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Murphy SM, 2012, J NEUROL NEUROSUR PS, V83, P119, DOI 10.1136/jnnp.2010.228965
   Phillips MJ, 2016, NAT REV MOL CELL BIO, V17, P69, DOI 10.1038/nrm.2015.8
   Rao RV, 2006, CELL DEATH DIFFER, V13, P415, DOI 10.1038/sj.cdd.4401761
   Riviere JB, 2011, AM J HUM GENET, V89, P219, DOI 10.1016/j.ajhg.2011.06.013
   Rubinsztein DC, 2015, NATURE, V522, P291, DOI 10.1038/nature14532
   Scheubert L, 2011, DNA RES, V18, P233, DOI 10.1093/dnares/dsr016
   Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017
   Schuchman EH, 2010, FEBS LETT, V584, P1895, DOI 10.1016/j.febslet.2009.11.083
   Schuck S, 2009, J CELL BIOL, V187, P525, DOI 10.1083/jcb.200907074
   Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6
   Song S., 2017, J CELLULAR PHYSL
   Tang JCO, 2001, CLIN CANCER RES, V7, P1539
   Tang WK, 2007, INT J MOL MED, V19, P915
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Welsch S, 2009, CELL HOST MICROBE, V5, P365, DOI 10.1016/j.chom.2009.03.007
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   Yadav Raj Kumar, 2014, J Cancer Prev, V19, P75, DOI 10.15430/JCP.2014.19.2.75
   Yorimitsu T, 2007, TRENDS CELL BIOL, V17, P279, DOI 10.1016/j.tcb.2007.04.005
NR 50
TC 30
Z9 31
U1 1
U2 205
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2018
VL 233
IS 6
BP 4479
EP 4489
DI 10.1002/jcp.26384
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FX6JP
UT WOS:000426190900009
PM 29226326
OA Green Published
DA 2022-04-25
ER

PT J
AU Ding, ZY
   Chen, QB
   Xiong, B
   Cun, YL
   Wang, HB
   Xu, MY
AF Ding, Zheyu
   Chen, Qingbo
   Xiong, Bin
   Cun, Yingli
   Wang, Hongbo
   Xu, Mingyao
TI Angustifoline inhibits human colon cancer cell growth by inducing
   autophagy along with mitochondrial-mediated apoptosis, suppression of
   cell invasion and migration and stimulating G2/M cell cycle arrest
SO JOURNAL OF BUON
LA English
DT Article
DE angustifoline; autophagy; cell migration; colon cancer; flow cytometry
AB Purpose: The prime objective of the present study was to investigate the anticancer properties of angustifoline against COLO-205 human colon cancer cells. Its effects on cell autophagy, apoptosis, cell invasion and cell migration, and cell cycle arrest were also evaluated in the current study.
   Methods: WST-1 assay was used to study cytotoxic effects of the compound on the cell viability. Effects on apoptosis and cell cycle arrest were evaluated by flow cytometry. In vitro wound healing assay and matrigel assay were carried out to study the effects of angustifoline on cell migration and cell invasion respectively. To confirm autophagy, we evaluated the expression of several autophagy-associated proteins using Western blot assay along with transmission electron microscopy (TEM).
   Results: The findings indicated that angustifoline induced dose- and time-dependent cytotoxicity in COLO-205 human colon cancer cells along with inhibiting cancer cell colony formation. Angustifoline-treated cells exhibited cell shrinkage along with distortion of the normal cell morphology. Angustifoline-treated cells were also arrested in the G2/M phase of the cell cycle, showing strong dose-dependence. The compound also led to inhibition of cell migration and cell invasion. The results showed that treatment of these cells led to generation of autophagic cell vesicles. Furthermore, it was observed that the expression of Beclin-1 and LC3-II proteins was significantly upregulated in the angustifoline-administered COLO-205 cells.
   Conclusions: In brief, the present study hints towards the potent anticancer potential of the natural product angustifoline against COLO-205 human colon cancer cells with in depth mechanistic studies.
C1 [Ding, Zheyu; Chen, Qingbo; Wang, Hongbo; Xu, Mingyao] Hubei Canc Hosp, Dept Endoscopy, Wuhan 430079, Hubei, Peoples R China.
   [Ding, Zheyu] Colorectal Canc Clin Res Ctr Hubei Prov, Colorectal Canc Clin Res Ctr Wuhan, Wuhan 430079, Hubei, Peoples R China.
   [Xiong, Bin] Wuhan Univ, Dept Gastrointestinal Surg, Zhongnan Hosp, Wuhan 430079, Hubei, Peoples R China.
   [Cun, Yingli] Yunnan Canc Hosp, Dept Abdominal Surg, Kunming 650118, Yunnan, Peoples R China.
RP Chen, QB (corresponding author), Hubei Canc Hosp, Dept Endoscopy, Wuhan 430079, Hubei, Peoples R China.
EM CovinVichto@yahoo.com
CR Abdel-Rahman WM, 2017, CURR MOL MED, V17, P34, DOI 10.2174/1566524017666170220094705
   Alam M.M., 2017, CATHARANTHUS ROSEUS, P277
   Almosnid NM, 2018, J ETHNOPHARMACOL, V211, P224, DOI 10.1016/j.jep.2017.09.032
   Butler MS, 2014, NAT PROD REP, V31, P1612, DOI 10.1039/c4np00064a
   Che T, 2018, MOLECULES, V23, DOI 10.3390/molecules23020493
   Focaccetti C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115686
   He MM, 2015, RSC ADV, V5, P16562, DOI 10.1039/c4ra14666b
   Iqbal J, 2017, ASIAN PAC J TROP BIO, V5, P97
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025
   Roleira FMF, 2015, FOOD CHEM, V183, P235, DOI 10.1016/j.foodchem.2015.03.039
   Twilley D, 2018, NATURAL PRODUCTS DRU, V5, P139
   Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236
NR 15
TC 0
Z9 0
U1 0
U2 4
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD JAN-FEB
PY 2019
VL 24
IS 1
BP 236
EP 241
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HK7XI
UT WOS:000458202600032
PM 30941961
DA 2022-04-25
ER

PT J
AU Lu, XH
   Fu, HJ
   Chen, R
   Wang, Y
   Zhan, YY
   Song, G
   Hu, TH
   Xia, C
   Tian, XM
   Zhang, B
AF Lu, Xiaohong
   Fu, Haijing
   Chen, Rui
   Wang, Yue
   Zhan, Yanyan
   Song, Gang
   Hu, Tianhui
   Xia, Chun
   Tian, Xuemei
   Zhang, Bing
TI Phosphoinositide specific phospholipase C gamma 1 inhibition-driven
   autophagy caused cell death in human lung adenocarcinoma A549 cells in
   vivo and in vitro
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE PLC gamma 1 inhibition; autophagic cell death (ACD); lung adenocarcinoma
   A549 cells; A549 xenograft nude mice
ID PROTEIN-KINASE B; SIGNALING PATHWAY; C-ALPHA; CANCER; ERK; ACTIVATION;
   EXPRESSION; APOPTOSIS; TARGET; GROWTH
AB Our previous studies indicated that phosphoinositide specific phospholipase C gamma 1 (PLC gamma 1) was involved in autophagy induction in colon and hepatic carcinoma cells. However, whether and how PLC gamma 1 regulation in human lung adenocarcinoma is linked to autophagy remains unclear. Here, we assessed the protein expression of PLC gamma 1 in human lung adenocarcinoma tissue using immunohistochemistry assay and the relationship between PLCG1 and autophagy in The Cancer Genome Atlas Network (TCGA) using Spearman correlation analysis and GSEA software. Furthermore, the interaction between PLC gamma 1 and autophagy-related signal molecules was investigated in human lung adenocarcinoma A549 cells treated with different inhibitors or transduction with lentivirus-mediated PLC gamma 1 gene short-hairpin RNA (shRNA) vectors using MTT, clonogenicity, Transwell migration, RT-PCR, Caspase-3, mitochondrial transmembrane potential, and western blotting assays, as well as transmission electron microscope technique. Additionally, the effect of shRNA/PLC gamma 1 alone or combined with autophagic activator Lithium Chloride (LiCl) on tumor growth and metastasis was measured using immunohistochemistry and assays in A549 xenograft nude mouse model. The results showed that increased PLC gamma 1 expression occurred frequently in human lung adenocarcinoma tissue with higher grades of T in TNM staging classification. PLC gamma 1 significantly enriched in autophagic process and regulation, which negatively regulating autophagy was enriched in higher expression of PLC gamma 1 PLC gamma 1 inhibition partially reduced cell proliferation and migration of A549 cells, with an increased autophagic flux involving alterations of AMPK alpha, mTOR, and ERK levels. However, PLC gamma 1 inhibition-driven autophagy led to cell death without depending on Caspase-3 and RIP]. Additionally, the abrogation of PLC gamma 1 signaling by shRNA and combination with autophagic activator LiCl could efficaciously suppress tumor growth and metastasis in A549 xenograft nude mice, in combination with a decrease in P62 level. These findings collectively suggest that reduction of cell proliferation and migration by PLC gamma 1 inhibition could be partially attributed to PLC gamma 1 inhibition-driven autophagic cell death (ACD). It highlights the potential role of a combination between targeting PLC gamma 1 and autophagy pathway in anti-tumor therapy, which may be an efficacious new strategy to overcome the autophagy addition of tumor and acquired resistance to current therapy.
C1 [Lu, Xiaohong; Fu, Haijing; Chen, Rui; Zhan, Yanyan; Song, Gang; Hu, Tianhui; Zhang, Bing] Xiamen Univ, Canc Res Ctr, Sch Med, Fujian 361102, Peoples R China.
   [Wang, Yue; Xia, Chun] Xiamen Univ, Zhongshan Hosp, Xiamen 361004, Fujian, Peoples R China.
   [Tian, Xuemei] South China Normal Univ, Sch Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
RP Zhang, B (corresponding author), Xiamen Univ, Canc Res Ctr, Sch Med, Fujian 361102, Peoples R China.; Tian, XM (corresponding author), South China Normal Univ, Sch Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
EM tianxuemei@m.scnu.edu.cn; cristal66@xmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772533,81972091]
FX This study was funded by National Natural Science Foundation of China
   (No. 81772533,81972091). We would like to thank MS Jiqian Xia for
   statistical data analytics support.
CR Arias-del-Val J, 2019, CELL CALCIUM, V77, P68, DOI 10.1016/j.ceca.2018.12.004
   Beloueche-Babari M, 2009, MOL CANCER THER, V8, P1305, DOI 10.1158/1535-7163.MCT-09-0039
   Bermudez O, 2008, ONCOGENE, V27, P3685, DOI 10.1038/sj.onc.1211040
   Bhutia SK, 2019, PHARMACOL RES, V144, P8, DOI 10.1016/j.phrs.2019.04.001
   Bibollet-Bahena O, 2009, J NEUROCHEM, V109, P1440, DOI 10.1111/j.1471-4159.2009.06071.x
   Bortnik S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071496
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Chen QZ, 2012, FOLIA HISTOCHEM CYTO, V50, P137, DOI [10.5603/FHC.2012.0020, 10.2478/18709]
   Cheng L, 2015, J CELL MOL MED, V19, P1877, DOI 10.1111/jcmm.12559
   Classen F, 2019, EXP CELL RES, V374, P29, DOI 10.1016/j.yexcr.2018.11.004
   Dai LZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13334-y
   Dai LZ, 2015, INT J MOL SCI, V16, P28510, DOI 10.3390/ijms161226116
   Das A, 2019, J BIOL CHEM, V294, P6733, DOI 10.1074/jbc.RA119.007671
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Elliott IA, 2019, P NATL ACAD SCI USA, V116, P6842, DOI 10.1073/pnas.1812410116
   Fahlman CS, 2002, BRAIN RES, V958, P43, DOI 10.1016/S0006-8993(02)03433-9
   Fu ZP, 2018, MOL ONCOL, V12, P529, DOI 10.1002/1878-0261.12179
   Hu ZX, 2015, ONCOTARGET, V6, P31628, DOI 10.18632/oncotarget.5221
   Hwang SL, 2013, J ALLERGY CLIN IMMUN, V132, P729, DOI 10.1016/j.jaci.2013.02.018
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lattanzio R, 2013, INT J CANCER, V132, P1022, DOI 10.1002/ijc.27751
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu ZJ, 2015, INT J MOL SCI, V16, P17857, DOI 10.3390/ijms160817857
   Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005
   Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012
   Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Mukherjee AK, 2015, APOPTOSIS, V20, P1358, DOI 10.1007/s10495-015-1157-6
   Nanni M, 2018, J CELL MOL MED, V22, P668, DOI 10.1111/jcmm.13352
   Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17
   Sanduja S, 2016, ONCOGENE, V35, P5295, DOI 10.1038/onc.2016.70
   Shahnazari S, 2010, CELL HOST MICROBE, V8, P137, DOI 10.1016/j.chom.2010.07.002
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005
   Tang WQ, 2019, HEPATOL RES, V49, P559, DOI 10.1111/hepr.13309
   Timsah Z, 2015, AM J CANCER RES, V5, P3135
   Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845
   Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34
   Xie ZJ, 2010, BIOCHEM BIOPH RES CO, V397, P296, DOI 10.1016/j.bbrc.2010.05.103
   Yang JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep07697
   Yuan H, 2017, INT J ANTENN PROPAG, V2017, DOI 10.1155/2017/6759169
   Zacharias M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4640-y
   Zhan YY, 2012, NAT CHEM BIOL, V8, P897, DOI [10.1038/NCHEMBIO.1069, 10.1038/nchembio.1069]
   Zhang B. Z., 2016, COMPUTER MEASUREMENT, V6, P1
   Zhuang LH, 2014, FOLIA HISTOCHEM CYTO, V52, P178, DOI 10.5603/FHC.2014.0021
NR 51
TC 5
Z9 5
U1 2
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 8
BP 1427
EP 1440
DI 10.7150/ijbs.42962
PG 14
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA KT5KW
UT WOS:000519054300011
PM 32210730
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Thorburn, A
   Thamm, DH
   Gustafson, DL
AF Thorburn, Andrew
   Thamm, Douglas H.
   Gustafson, Daniel L.
TI Autophagy and Cancer Therapy
SO MOLECULAR PHARMACOLOGY
LA English
DT Review
ID HISTONE DEACETYLASE INHIBITORS; CHEMOTHERAPY-INDUCED APOPTOSIS;
   ENDOPLASMIC-RETICULUM STRESS; INDUCED CELL-DEATH; TARGETING AUTOPHAGY;
   COLON-CANCER; INDUCED CYTOTOXICITY; MYELOMA CELLS; HMGB1 RELEASE;
   TUMOR-CELLS
AB Autophagy is the process by which cellular material is delivered to lysosomes for degradation and recycling. There are three different types of autophagy, but macroautophagy, which involves the formation of double membrane vesicles that engulf proteins and organelles that fuse with lysosomes, is by far the most studied and is thought to have important context-dependent roles in cancer development, progression, and treatment. The roles of autophagy in cancer treatment are complicated by two important discoveries over the past few years. First, most (perhaps all) anticancer drugs, as well as ionizing radiation, affect autophagy. In most, but not all cases, these treatments increase autophagy in tumor cells. Second, autophagy affects the ability of tumor cells to die after drug treatment, but the effect of autophagy may be to promote or inhibit cell death, depending on context. Here we discuss recent research related to autophagy and cancer therapy with a focus on how these processes may be manipulated to improve cancer therapy.
C1 [Thorburn, Andrew] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA.
   [Thamm, Douglas H.; Gustafson, Daniel L.] Colorado State Univ, Flint Anim Canc Ctr, Dept Clin Sci, Ft Collins, CO 80523 USA.
RP Thorburn, A (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.
EM Andrew.Thorburn@ucdenver.edu
RI Thamm, Douglas/AAG-3672-2020; Thamm, Douglas H/I-5976-2013
OI Thamm, Douglas H/0000-0002-8914-7767
FU National Institutes of Health National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01-CA111421, R01-CA150925,
   P30-CA046934]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [P30CA046934, R01CA150925, R01CA111421]
   Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institutes of Health
   National Cancer Institute [Grants R01-CA111421, R01-CA150925, and
   P30-CA046934].
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bareford MD, 2012, CANCER BIOL THER, V13, P793, DOI 10.4161/cbt.20562
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269
   Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108
   Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   Hamed HA, 2013, CANCER BIOL THER, V14, P1039, DOI 10.4161/cbt.26110
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Hou YJ, 2011, LAB INVEST, V91, P1146, DOI 10.1038/labinvest.2011.97
   Hui B, 2012, CANCER-AM CANCER SOC, V118, P5560, DOI 10.1002/cncr.27586
   Humbert M, 2013, BIOCHEM BIOPH RES CO, V431, P264, DOI 10.1016/j.bbrc.2012.12.120
   Ikeda T, 2013, J PHARMACOL SCI, V121, P67, DOI 10.1254/jphs.12158FP
   Kang R, 2012, AM J OTOLARYNG, V33, P678, DOI 10.1016/j.amjoto.2012.05.005
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kawaguchi T, 2011, INT J ONCOL, V38, P643, DOI 10.3892/ijo.2010.882
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Ladoire S, 2012, AUTOPHAGY, V8, P1175, DOI 10.4161/auto.20353
   Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li YH, 2012, CANCER RES, V72, P3535, DOI 10.1158/0008-5472.CAN-11-3103
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu FF, 2013, ONCOL LETT, V5, P1261, DOI 10.3892/ol.2013.1154
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Palacios C, 2010, LEUKEMIA RES, V34, P1533, DOI 10.1016/j.leukres.2010.07.002
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890
   Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang Y, 2012, MOL PHARMACOL, V81, P527, DOI 10.1124/mol.111.076851
   Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269
   Thorburn A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003390
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629
   Villa-Morales M, 2012, EXPERT OPIN THER TAR, V16, P85, DOI 10.1517/14728222.2011.628937
   Walker T, 2009, MOL PHARMACOL, V76, P342, DOI 10.1124/mol.109.056523
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xie BS, 2011, INT J MOL MED, V27, P599, DOI 10.3892/ijmm.2011.607
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180
NR 105
TC 209
Z9 219
U1 4
U2 83
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD JUN
PY 2014
VL 85
IS 6
BP 830
EP 838
DI 10.1124/mol.114.091850
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AH3QR
UT WOS:000336040400001
PM 24574520
OA Green Published
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Azwar, S
   Seow, HF
   Abdullah, M
   Jabar, MF
   Mohtarrudin, N
AF Azwar, Shamin
   Seow, Heng Fong
   Abdullah, Maha
   Jabar, Mohd Faisal
   Mohtarrudin, Norhafizah
TI Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and
   Reversal Strategies in Colon Cancer Treatment
SO BIOLOGY-BASEL
LA English
DT Review
DE 5-fluorouracil; 5-FU; chemotherapy drug resistance; colon cancer;
   thymidylate synthase; thymidine phosphorylase; dihydropyrimidine
   dehydrogenase; methylenetetrahydrofolate reductase; overcoming
   chemotherapy drug resistance
ID HUMAN COLORECTAL-CANCER; LONG NONCODING RNAS; DIHYDROPYRIMIDINE
   DEHYDROGENASE; THYMIDINE PHOSPHORYLASE; STEM-CELLS; THYMIDYLATE
   SYNTHASE; DRUG-RESISTANCE; 5-FU RESISTANCE; ADJUVANT CHEMOTHERAPY;
   ACQUIRED-RESISTANCE
AB Simple Summary Acquired resistance to chemotherapy by cancer cells is the predominant factor in chemotherapy failure, which ultimately leads to disease progression and death. Recent studies have presented compelling evidence of the various mechanisms and pathways through which cancer cells have developed resistance to drugs. This review summarises the mechanisms pertaining to 5-FU resistance and discusses ongoing efforts to prevent chemotherapy resistance in cancer cells and to re-sensitise them to cancer drugs. 5-Fluorouracil (5-FU) plus leucovorin (LV) remain as the mainstay standard adjuvant chemotherapy treatment for early stage colon cancer, and the preferred first-line option for metastatic colon cancer patients in combination with oxaliplatin in FOLFOX, or irinotecan in FOLFIRI regimens. Despite treatment success to a certain extent, the incidence of chemotherapy failure attributed to chemotherapy resistance is still reported in many patients. This resistance, which can be defined by tumor tolerance against chemotherapy, either intrinsic or acquired, is primarily driven by the dysregulation of various components in distinct pathways. In recent years, it has been established that the incidence of 5-FU resistance, akin to multidrug resistance, can be attributed to the alterations in drug transport, evasion of apoptosis, changes in the cell cycle and DNA-damage repair machinery, regulation of autophagy, epithelial-to-mesenchymal transition, cancer stem cell involvement, tumor microenvironment interactions, miRNA dysregulations, epigenetic alterations, as well as redox imbalances. Certain resistance mechanisms that are 5-FU-specific have also been ascertained to include the upregulation of thymidylate synthase, dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase, and the downregulation of thymidine phosphorylase. Indeed, the successful modulation of these mechanisms have been the game plan of numerous studies that had employed small molecule inhibitors, plant-based small molecules, and non-coding RNA regulators to effectively reverse 5-FU resistance in colon cancer cells. It is hoped that these studies would provide fundamental knowledge to further our understanding prior developing novel drugs in the near future that would synergistically work with 5-FU to potentiate its antitumor effects and improve the patient's overall survival.
C1 [Azwar, Shamin; Seow, Heng Fong; Abdullah, Maha; Mohtarrudin, Norhafizah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Pathol, Serdang 43400, Malaysia.
   [Jabar, Mohd Faisal] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Surg, Serdang 43400, Malaysia.
RP Mohtarrudin, N (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Pathol, Serdang 43400, Malaysia.
EM shamin.azwar@gmail.com; shf@upm.edu.my; maha@upm.edu.my;
   faisal@upm.edu.my; norhafizahm@upm.edu.my
CR Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735
   Akasaka T, 2015, INT J ONCOL, V46, P63, DOI 10.3892/ijo.2014.2693
   Al-Obeed O, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01206-x
   Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Amstutz U, 2018, CLIN PHARMACOL THER, V103, P210, DOI 10.1002/cpt.911
   An J, 2016, J MICROBIOL BIOTECHN, V26, P1490, DOI 10.4014/jmb.1605.05024
   Andreucci E, 2019, J ENZYM INHIB MED CH, V34, P117, DOI 10.1080/14756366.2018.1532419
   Angius A, 2019, INT J MED SCI, V16, P1480, DOI 10.7150/ijms.35269
   Babaei K, 2019, BIOMEDICINE-TAIWAN, V9, P1, DOI 10.1051/bmdcn/2019090422
   Baharudin R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00047
   Bai WQ, 2015, INT J CLIN EXP PATHO, V8, P12333
   Barisciano G, 2020, BRIT J CANCER, V122, P1354, DOI 10.1038/s41416-020-0773-2
   Bassani B, 2019, CANCERS, V11, DOI 10.3390/cancers11040461
   Bauer J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-55687-6
   Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362
   Ben-Shmuel A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00275
   Benhalilou N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00795
   Bian ZH, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0008-4
   Bigagli E, 2016, CANCER BIOL THER, V17, P1062, DOI 10.1080/15384047.2016.1219815
   Botticelli A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163105
   Bower JJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0009-7
   Carter JV, 2019, ONCOL LETT, V18, P3994, DOI 10.3892/ol.2019.10753
   Chang Siyuan, 2020, Cancer Cell Int, V20, P452, DOI 10.1186/s12935-020-01541-z
   Che J, 2017, MOL CLIN ONCOL, V7, P943, DOI 10.3892/mco.2017.1436
   Chen DL, 2018, INT J CLIN EXP PATHO, V11, P4735
   Chen J, 2020, BRAZ J MED BIOL RES, V53, DOI [10.1590/1414-431X20209230, 10.1590/1414-431x20209230]
   Chen NZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222035
   Chen SW, 2019, CANCER LETT, V466, P49, DOI 10.1016/j.canlet.2019.09.006
   Chen SJ, 2020, NUTR CANCER, V72, P209, DOI 10.1080/01635581.2019.1622739
   Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936
   Chen X, 2017, CARCINOGENESIS, V38, P873, DOI 10.1093/carcin/bgx059
   Chen XL, 2019, J GENE MED, V21, DOI 10.1002/jgm.3114
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Cheng Y, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0095-0
   Christenser S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12594-8
   Dai XY, 2018, ONCOL LETT, V15, P8019, DOI 10.3892/ol.2018.8332
   Cervantes-Villagrana RD, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0205-z
   Das PK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061392
   De Falco V, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015759
   Deng JJ, 2016, INT J ONCOL, V48, P1117, DOI 10.3892/ijo.2016.3342
   Dermani FK, 2018, J CELL PHYSIOL, V233, P9538, DOI 10.1002/jcp.26874
   Dermani FK, 2018, J GASTROINTEST CANC, V49, P102, DOI 10.1007/s12029-017-0038-3
   Dlugosz-Pokorska A, 2019, MOL BIOL REP, V46, P5831, DOI 10.1007/s11033-019-05017-w
   Dominijanni Anthony, 2018, Cancer Drug Resist, V1, P48, DOI 10.20517/cdr.2018.01
   Dvorak P, 2017, J CANCER, V8, P1959, DOI 10.7150/jca.19364
   Eom DW, 2015, APPL IMMUNOHISTO M M, V23, P682, DOI 10.1097/PAI.0000000000000140
   de Campos CF, 2019, CASE REP NEUROL MED, V2019, DOI 10.1155/2019/5976410
   Falcone A, 2018, ANN ONCOL, V29, pv104, DOI [10.1093/annonc/mdy149.012, DOI 10.1093/ANNONC/MDY149.012, DOI 10.1093/annonc/mdy149.012]
   Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907
   Fang Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5953619
   Farina-Sarasqueta A, 2010, CANCER CHEMOTH PHARM, V66, P1167, DOI 10.1007/s00280-010-1403-0
   Filosto M, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110389
   Fouad MA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01173
   Francescangeli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1505-4
   Francipane MG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081817
   Fu JB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53276-1
   Gajjar KK, 2018, INT J BIOL MARKER, V33, P180, DOI 10.1177/1724600817748539
   Galle E, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-0821-z
   Gao Q, 2020, CANCER LETT, V476, P67, DOI 10.1016/j.canlet.2020.02.007
   Gasiule S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122115
   Goel G, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.592
   Goncalves-Ribeiro S, 2016, ONCOTARGET, V7, P59766, DOI 10.18632/oncotarget.11121
   Gong S, 2018, CELL PHYSIOL BIOCHEM, V47, P680, DOI 10.1159/000490022
   Goto T, 2012, ANTICANCER RES, V32, P1757
   Gu CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1962-x
   Gu JJ, 2019, ONCOL LETT, V18, P2091, DOI 10.3892/ol.2019.10474
   Gu XY, 2020, AGING-US, V12, P156, DOI 10.18632/aging.102607
   Guo FF, 2019, J ONCOL, V2019, DOI 10.1155/2019/2592419
   Guo GF, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0656-3
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Han SH, 2019, ONCOL LETT, V17, P5572, DOI 10.3892/ol.2019.10234
   Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839
   Hanna J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00478
   Hasegawa K, 2012, EUR J OBSTET GYN R B, V163, P67, DOI 10.1016/j.ejogrb.2012.03.014
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4
   HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0
   Herrera M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236016
   Hon KW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53063-y
   Hong XQ, 2018, CHINESE J CANCER RES, V30, P197, DOI 10.21147/j.issn.1000-9604.2018.02.03
   Hu HQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171428
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625
   Huang HY, 2019, ANN INDIAN ACAD NEUR, V22, P325, DOI 10.4103/aian.AIAN_34_18
   Huang K, 2020, J ONCOL, V2020, DOI 10.1155/2020/5428920
   Huang WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159927
   Huang YC, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/7587428
   Idrees M, 2019, CUREUS, V11, DOI 10.7759/cureus.4713
   Ierano C, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-4103
   Ishikawa K, 2019, ONCOL REP, V42, P2416, DOI 10.3892/or.2019.7373
   Iyer DN, 2019, WORLD J STEM CELLS, V11, P519, DOI 10.4252/wjsc.v11.i8.519
   Jahanafrooz Z, 2020, J CELL PHYSIOL, V235, P4153, DOI 10.1002/jcp.29337
   Janani Jacob, 2019, Pharmacognosy Journal, V11, P466, DOI 10.5530/pj.2019.11.73
   Jang HY, 2019, BIOCHEM PHARMACOL, V160, P110, DOI 10.1016/j.bcp.2018.12.017
   Javaid S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225056
   Jayasingam SD, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01512
   Ji ML, 2019, J CANCER, V10, P5557, DOI 10.7150/jca.35380
   Jiang GZ, 2017, GENET TEST MOL BIOMA, V21, P74, DOI 10.1089/gtmb.2016.0162
   Jiang H, 2019, ONCOL LETT, V18, P1157, DOI 10.3892/ol.2019.10395
   Jiang HF, 2019, PTERIDINES, V30, P126, DOI 10.1515/pteridines-2019-0015
   Jin SJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01225
   Jing CW, 2019, MOL MED REP, V19, P1092, DOI 10.3892/mmr.2018.9730
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9
   Jubeen F, 2019, SAUDI PHARM J, V27, P1164, DOI 10.1016/j.jsps.2019.09.013
   Kazanietz MG, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00471
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kikuchi D, 2018, ONCOL LETT, V15, P2065, DOI 10.3892/ol.2017.7559
   Kim Eun-Ji, 2018, Oncotarget, V9, P19911, DOI 10.18632/oncotarget.24952
   Kim E, 2016, CARCINOGENESIS, V37, P206, DOI 10.1093/carcin/bgv250
   Kim HG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184366
   Kim KR, 2017, ONCOL LETT, V14, P2491, DOI 10.3892/ol.2017.6414
   Knoll G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2446-8
   Koh B, 2019, ONCOL LETT, V17, P2409, DOI 10.3892/ol.2018.9836
   Kong DF, 2018, BIOMED PHARMACOTHER, V99, P176, DOI 10.1016/j.biopha.2018.01.035
   Koosha S, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116633
   Koosha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41685-1
   Kozovska Z, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4572-6
   Kryeziu K, 2019, BBA-REV CANCER, V1871, P240, DOI 10.1016/j.bbcan.2019.01.002
   Kugimiya N, 2019, ONCOL LETT, V17, P5267, DOI 10.3892/ol.2019.10181
   Kumamoto K, 2012, ONCOL LETT, V3, P983, DOI 10.3892/ol.2012.598
   La XQ, 2019, J AGR FOOD CHEM, V67, P2510, DOI 10.1021/acs.jafc.8b06665
   Latchman J, 2014, CLIN J ONCOL NURS, V18, P581, DOI 10.1188/14.CJON.581-585
   Lavitrano M, 2020, J PATHOL, V250, P134, DOI 10.1002/path.5347
   Lee JH, 2019, MOL BIOL REP, V46, P3835, DOI 10.1007/s11033-019-04826-3
   Lee J, 2016, BIOMOL THER, V24, P604, DOI 10.4062/biomolther.2016.028
   Li H, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819871300
   Li LH, 2013, EUR J CANCER, V49, P1752, DOI 10.1016/j.ejca.2012.12.013
   Li NN, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0125-3
   Li QW, 2020, CHIN J NAT MEDICINES, V18, P36, DOI 10.1016/S1875-5364(20)30003-0
   Li QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1330-9
   Li TH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012131
   Li W, 2018, TRENDS CARDIOVAS MED, V28, P157, DOI 10.1016/j.tcm.2017.10.003
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Li Y, 2016, TUMOR BIOL, V37, P14205, DOI 10.1007/s13277-016-5254-0
   Li ZL, 2020, WORLD J GASTRO ONCOL, V12, P267, DOI 10.4251/wjgo.v12.i3.267
   Liang GF, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-019-0563-2
   Liang L, 2020, ONCOL LETT, V19, P519, DOI 10.3892/ol.2019.11090
   Lin J, 2019, 821801 BIORXIV, DOI [10.1101/821801, DOI 10.1101/821801]
   Lin SY, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0399-z
   Lindskog EB, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S10226
   Liu C, 2020, CANCER LETT, V470, P29, DOI 10.1016/j.canlet.2019.11.042
   Liu G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190249
   Liu HZ, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0218-1
   Liu J, 2018, INT J CLIN EXP PATHO, V11, P5622
   Liu ML, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109250
   Liu SP, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0087-0
   Liu TT, 2019, EBIOMEDICINE, V48, P289, DOI 10.1016/j.ebiom.2019.10.003
   Liu T, 2019, NEOPLASIA, V21, P557, DOI 10.1016/j.neo.2019.03.011
   Liu TY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0770-1
   Liu WY, 2018, CANCER SCI, V109, P3294, DOI 10.1111/cas.13779
   Liu Z, 2019, DRUG DES DEV THER, V13, P3823, DOI 10.2147/DDDT.S215967
   Liu Z, 2019, ONCOTARGETS THER, V12, P2095, DOI 10.2147/OTT.S192923
   Lu CW, 2020, CANCER LETT, V476, P87, DOI 10.1016/j.canlet.2020.02.004
   Lu Y, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110381
   Lunenburg CATC, 2020, EUR J HUM GENET, V28, P508, DOI 10.1038/s41431-019-0540-0
   Ma JC, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0432-5
   Maiuthed A, 2018, CANCERS, V10, DOI 10.3390/cancers10100373
   Malesci A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1342918
   Manmuan S., 2019, Journal of Applied Pharmaceutical Science, V9, P7, DOI 10.7324/JAPS.2019.91202
   Marquez-Gonzalez RM, 2020, TOHOKU J EXP MED, V250, P109, DOI 10.1620/tjem.250.109
   Mei L, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0733-6
   Mendoza-Rodriguez MG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062130
   Meng XM, 2018, ONCOTARGETS THER, V11, P1757, DOI 10.2147/OTT.S159093
   Merloni F., 2019, CANC DRUG RESIST, V2, P787, DOI [10.20517/cdr.2018.006, DOI 10.20517/CDR.2018.006]
   Meulendijks D, 2015, LANCET ONCOL, V16, P1639, DOI 10.1016/S1470-2045(15)00286-7
   Miller TJ, 2017, PATHOLOGY, V49, P721, DOI 10.1016/j.pathol.2017.08.007
   Minegaki T, 2018, ONCOL LETT, V16, P6202, DOI 10.3892/ol.2018.9388
   Mohd-Zahid MH, 2020, RSC ADV, V10, P973, DOI 10.1039/c9ra08192e
   Mohelnikova-Duchonova B, 2014, WORLD J GASTROENTERO, V20, P10316, DOI 10.3748/wjg.v20.i30.10316
   Moody L, 2019, CANCERS, V11, DOI 10.3390/cancers11081111
   Moreira H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6793957
   Mori R, 2019, GASTRIC CANCER, V22, P497, DOI 10.1007/s10120-018-0881-3
   Mukherji D, 2019, J MED CASE REP, V13, DOI 10.1186/s13256-019-2013-z
   Mukohyama J, 2019, CANCER RES, V79, P5151, DOI 10.1158/0008-5472.CAN-18-3544
   Naghibalhossaini Fakhraddin, 2017, Acta Med Iran, V55, P751
   Nakagawa Y, 2014, ONCOL REP, V31, P2001, DOI 10.3892/or.2014.3080
   Narayan S, 2017, ONCOTARGET, V8, P57246, DOI 10.18632/oncotarget.19778
   Nie Q, 2017, CLIN PHARMACOL THER, V102, P662, DOI 10.1002/cpt.685
   Nie QH, 2019, INT J CLIN EXP MED, V12, P9380
   Nijhuis A, 2017, HUM MOL GENET, V26, P1552, DOI 10.1093/hmg/ddx059
   Nishizawa Y, 2019, ANTICANCER RES, V39, P4129, DOI 10.21873/anticanres.13571
   Nowak-Sliwinska P, 2019, BBA-REV CANCER, V1871, P434, DOI 10.1016/j.bbcan.2019.04.005
   Ntavatzikos A, 2019, WORLD J GASTRO ONCOL, V11, P551, DOI 10.4251/wjgo.v11.i7.551
   Ogawa M, 2014, ONCOL LETT, V8, P2463, DOI 10.3892/ol.2014.2574
   Okada K, 2016, ONCOL REP, V36, P1875, DOI 10.3892/or.2016.5008
   Olmeda F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51575-1
   Or CHR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051773
   Palmirotta R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00139
   PARK G.-B., 2019, CANC BIOL, DOI [10.21203/rs.2.10556/v1, DOI 10.21203/RS.2.10556/V1]
   Park GB, 2020, MOL CARCINOGEN, V59, P154, DOI 10.1002/mc.23137
   Park YY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016709
   Paschall AV, 2016, ONCOTARGET, V7, P78698, DOI 10.18632/oncotarget.12168
   Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243
   Pasello M, 2020, SEMIN CANCER BIOL, V60, P57, DOI 10.1016/j.semcancer.2019.10.004
   Pathania S, 2018, BIOMED PHARMACOTHER, V105, P53, DOI 10.1016/j.biopha.2018.05.117
   Pawlowski PH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20192847
   Perilli L, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5982-9
   Phua LC, 2013, CANCER CHEMOTH PHARM, V71, P817, DOI 10.1007/s00280-012-2054-0
   Quarni W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50917-3
   Ramesh P, 2020, APOPTOSIS, V25, P305, DOI 10.1007/s10495-020-01601-9
   Rani I, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695019
   Ratti M, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919853954
   Rehman Z, 2019, PEERJ, V7, DOI 10.7717/peerj.6309
   Ren A, 2019, INT J CANCER, V145, P154, DOI 10.1002/ijc.32079
   Ren TJ, 2020, EUR REV MED PHARMACO, V24, P1743, DOI 10.26355/eurrev_202002_20351
   Riahi-Chebbi I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36808-z
   Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8
   Romano G, 2016, ONCOTARGET, V7, P22077, DOI 10.18632/oncotarget.7895
   RUTMAN RJ, 1954, CANCER RES, V14, P119
   Sakowicz-Burkiewicz M, 2016, INT J BIOCHEM CELL B, V78, P268, DOI 10.1016/j.biocel.2016.07.024
   Salem ME, 2020, ANN ONCOL, V31, P480, DOI 10.1016/j.annonc.2019.12.007
   Schaller L, 2019, HUM GENET, V138, P1359, DOI 10.1007/s00439-019-02081-x
   Scherr AL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.233
   Shen Y, 2018, PHARMACOGENOMICS J, V18, P23, DOI 10.1038/tpj.2016.91
   Sheng NQ, 2017, ACTA BIOCH BIOPH SIN, V49, P926, DOI 10.1093/abbs/gmx094
   Shi L, 2018, J GENET GENOMICS, V45, P205, DOI 10.1016/j.jgg.2018.04.003
   Shigeta K, 2014, WORLD J SURG, V38, P3248, DOI 10.1007/s00268-014-2738-1
   Shimada T, 2018, ONCOL REP, V39, P1119, DOI 10.3892/or.2018.6180
   Shinohara H, 2017, J IMMUNOL, V199, P1505, DOI 10.4049/jimmunol.1700167
   Showalter SL, 2008, CANCER BIOL THER, V7, P986, DOI 10.4161/cbt.7.7.6181
   Sivamaruthi BS, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3535982
   Srinivas US, 2015, ONCOTARGET, V6, P12574, DOI 10.18632/oncotarget.3728
   Srivastava R, 2019, P NATL ACAD SCI USA, V116, P15469, DOI 10.1073/pnas.1904523116
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Sun L, 2017, J CANCER, V8, P2802, DOI 10.7150/jca.19142
   Sun LH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65207-6
   Sun MY, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0822-y
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Sunami E, 2020, CLIN COLORECTAL CANC, V19, P22, DOI 10.1016/j.clcc.2019.10.002
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234
   Tampellini M, 2018, FUTURE ONCOL, V14, P1223, DOI 10.2217/fon-2017-0627
   Tang XW, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819874776
   Terranova-Barberio M, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0647-5
   Tigu AB, 2020, MOLECULES, V25, DOI 10.3390/molecules25081947
   Titze-de-Almeida SS, 2020, MOL DIAGN THER, V24, P49, DOI 10.1007/s40291-019-00434-w
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Trisciuoglio D, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0055-y
   Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171
   Tsukihara H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163961
   Tsunekuni K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50968-6
   Turgeon MO, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00015
   Urushibara S, 2017, ANTICANCER RES, V37, P4085, DOI 10.21873/anticanres.11795
   Van der Kraak L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0163-8
   Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0
   Vincent A, 2019, WORLD J STEM CELLS, V11, P920, DOI 10.4252/wjsc.v11.i11.920
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wakasa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123076
   Wang B, 2018, AM J CANCER RES, V8, P2518
   Wang Dan, 2019, J Immunother Cancer, V7, P215, DOI 10.1186/s40425-019-0701-2
   Wang H, 2020, CANCER SCI, V111, P84, DOI 10.1111/cas.14253
   Wang JK, 2017, MOL MED REP, V16, P8747, DOI 10.3892/mmr.2017.7721
   Wang K, 2020, BRIT J CANCER, V123, P410, DOI 10.1038/s41416-020-0902-y
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Wang M, 2019, J CANCER, V10, P4603, DOI 10.7150/jca.32065
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang S, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/7628763
   Wang WB, 2014, WORLD J GASTROENTERO, V20, P15682, DOI 10.3748/wjg.v20.i42.15682
   Wang WT, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0748-z
   Wang YW, 2019, CANCER BIOTHER RADIO, V34, P362, DOI 10.1089/cbr.2018.2746
   Wang ZP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00309
   Wang ZY, 2020, J AGR FOOD CHEM, V68, P3850, DOI 10.1021/acs.jafc.0c00107
   Warren H.R., 2016, BIOSCI HORIZ, V9, DOI [10.1093/biohorizons/hzw005hzw005, DOI 10.1093/biohorizons/hzw005]
   Wei C, 2019, ONCOTARGETS THER, V12, P3051, DOI 10.2147/OTT.S198126
   Wei R, 2020, ANAL CELL PATHOL, V2020, DOI 10.1155/2020/6283796
   Wen SJ, 2018, ARTIF CELL NANOMED B, V46, pS896, DOI 10.1080/21691401.2018.1439835
   Wigle TJ, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050199
   Wong MCS, 2019, INTEST RES, V17, P317, DOI 10.5217/ir.2019.00021
   Wong RR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0614-x
   Wozniak M, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02913-8
   Wu HJ, 2016, BIOL OPEN, V5, P563, DOI 10.1242/bio.015008
   Xi CL, 2019, BIOCHEM BIOPH RES CO, V513, P589, DOI 10.1016/j.bbrc.2019.04.014
   Xi CL, 2018, BIOCHEM BIOPH RES CO, V503, P2286, DOI 10.1016/j.bbrc.2018.06.150
   Xiao W, 2019, MOL CANCER RES, V17, P420, DOI 10.1158/1541-7786.MCR-18-0455
   Xiao Y, 2019, CLIN CHIM ACTA, V490, P186, DOI 10.1016/j.cca.2018.09.007
   Xiao Y, 2017, ONCOTARGET, V8, P83171, DOI 10.18632/oncotarget.20487
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xiong Y, 2019, NANOMED-NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102034
   Xu F, 2020, CANCER SCI, V111, P1528, DOI 10.1111/cas.14356
   Xu GR, 2020, J CELL MOL MED, V24, P4136, DOI 10.1111/jcmm.15070
   Yadak R, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1016-6
   Yadav VK, 2020, CANCERS, V12, DOI 10.3390/cancers12061590
   Yahaya MAF, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2368249
   Yan JH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1355-0
   Yang C, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860-019-0188-1
   Yang JW, 2018, J CANCER RES THER, V14, pS1141, DOI 10.4103/0973-1482.204898
   Yang Y, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0143-3
   Yang YS, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2675-x
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yao J, 2017, J CANCER RES CLIN, V143, P419, DOI 10.1007/s00432-016-2302-5
   Yao WL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0812-3
   Ye QM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00487
   Yin WH, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/7564232
   Yoshida GJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01611-0
   Young JD, 2016, BIOCHEM SOC T, V44, P869, DOI 10.1042/BST20160038
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zawiah Mohammed, 2018, Drug Metabolism and Personalized Therapy, V33, P201, DOI 10.1515/dmpt-2018-0012
   Zhan W, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0234-z
   Zhang GL, 2020, CANCER RES TREAT, V52, P622, DOI 10.4143/crt.2019.593
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang H, 2020, EXP THER MED, V19, P3042, DOI 10.3892/etm.2020.8565
   Zhang H, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00880
   Zhang LY, 2019, ONCOL LETT, V18, P4064, DOI 10.3892/ol.2019.10741
   Zhang P, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0661-7
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1314-9
   Zhang RS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1435-2
   Zhang RN, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00378
   Zhang S, 2019, MOL CANCER RES, V17, P2196, DOI 10.1158/1541-7786.MCR-19-0436
   Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200
   Zhang YH, 2020, ONCOGENE, V39, P5214, DOI 10.1038/s41388-020-1352-y
   Zhang YH, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104717
   Zhang YJ, 2020, ONCOL LETT, V19, P3567, DOI 10.3892/ol.2020.11463
   Zhang Z, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180620
   Zhao C, 2021, BIOTECH HISTOCHEM, V96, P179, DOI 10.1080/10520295.2020.1778087
   Zhao C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04172-z
   Zhong XM, 2018, CELL PHYSIOL BIOCHEM, V45, P356, DOI 10.1159/000486816
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
   Zhu ZY, 2015, MOL CELL BIOCHEM, V400, P287, DOI 10.1007/s11010-014-2285-y
   Zizzo N, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00368
NR 319
TC 1
Z9 1
U1 14
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD SEP
PY 2021
VL 10
IS 9
AR 854
DI 10.3390/biology10090854
PG 34
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA UU9SG
UT WOS:000699131700001
PM 34571731
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Dai, S
   Yang, S
   Hu, X
   Sun, W
   Tawa, G
   Zhu, WG
   Schimmer, AD
   He, C
   Fang, BL
   Zhu, HB
   Zheng, W
AF Dai, Sheng
   Yang, Shu
   Hu, Xin
   Sun, Wei
   Tawa, Gregory
   Zhu, Wenge
   Schimmer, Aaron D.
   He, Chao
   Fang, Bingliang
   Zhu, Hongbo
   Zheng, Wei
TI 17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating
   Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon
   Cancer Cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ANTITUMOR-ACTIVITY; DOWN-REGULATION; TUMOR-CELL; APOPTOSIS; CASPASE-8;
   DEATH; EXPRESSION; INHIBITOR; MECHANISM; GENE
AB Targeting of extrinsic apoptosis pathway by TNF-related apoptosis-inducing ligand (TRAIL) is an attractive approach for cancer therapy. However, two TRAIL drug candidates failed in clinical trials due to lack of efficacy. We identified 17-hydroxy wortmannin (17-HW) in a drug repurposing screen that resensitized TRAIL'S response in the resistant colon cancer cells. The deficiency of caspase-8 in drug-resistant cells along with defects in apoptotic cell death was corrected by 17-HW, an inhibitor of PIK3C3-bedin 1 (BECN1) complex and autophagy activity. Further study found that BECN1 significantly increased in the TRAIL-resistant cells, resulting in increased autophagosome formation and enhanced autophagy flux. The extracellular domain (ECD) of BECN1 directly bound to the caspase-8 catalytic subunit (p10), leading to sequestration of caspase-8 in the autophagosome and its subsequent degradation. Inhibition of BECN1 restored the caspase-8 level and TRAIL's apoptotic response in the resistant colon cancer cells. An analysis of 120 colon cancer patient tissues revealed a correlation of a subgroup of patients (30.8%, 37/120) who have high BECN1 level and low caspase-8 level with a poor survival rate, Our study demonstrates that the increased BECN1 accompanied by enhanced autophagy activity is responsible for the TRAIL resistance, and a combination of TRAIL with a PIK3C3-BECN1 inhibitor is a promising therapeutic approach for the treatment of colon cancer.
C1 [Dai, Sheng; He, Chao; Zhu, Hongbo] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Dai, Sheng; Yang, Shu; Hu, Xin; Sun, Wei; Tawa, Gregory; Zheng, Wei] NCATS, NIH, 9800 Med Ctr Dr,MSC 3375, Bethesda, MD 20892 USA.
   [Zhu, Wenge] George Washington Univ, Med Sch, Dept Biochem & Mol Med, Washington, DC USA.
   [Schimmer, Aaron D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Fang, Bingliang] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA.
RP Dai, S (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Dai, S; Zheng, W (corresponding author), NCATS, NIH, 9800 Med Ctr Dr,MSC 3375, Bethesda, MD 20892 USA.; Zhu, HB (corresponding author), Sir Run Run Shaw Hosp, Div Colorectal Surg, 3rd East Oingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
EM daimd@zju.edu.cn; ykzhb@zju.edu.cn; wzheng@mail.nih.gov
RI dai, sheng/AGQ-0059-2022
OI Yang, Shu/0000-0001-8909-1962; Schimmer, Aaron/0000-0003-4023-3899; dai,
   sheng/0000-0002-5387-8517
FU Intramural Research Programs of the National Center for Advancing
   Translational Sciences, NIH; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81703076];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [ZIATR000018] Funding Source: NIH RePORTER
FX The authors thank the compound management group at NCATS, NIH for their
   professional support, and Dr. DeeAnn Visk, a medical writer and editor,
   for editing the manuscript. This work was supported by the Intramural
   Research Programs of the National Center for Advancing Translational
   Sciences, NIH (to W. Zheng), and a grant 81703076 from the National
   Natural Science Foundation of China (to D. Sheng).
CR Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359
   Bellail AC, 2009, REV RECENT CLIN TRIA, V4, P34, DOI 10.2174/157488709787047530
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389
   Devetzi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36532
   Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174
   DODGE JA, 1995, BIOORG MED CHEM LETT, V5, P1713, DOI 10.1016/0960-894X(95)00291-Z
   Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Harada K, 2002, CANCER RES, V62, P5897
   Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Huang RL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001862
   Huang WJ, 2012, CELL RES, V22, P473, DOI 10.1038/cr.2012.24
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656
   Ihle NT, 2004, MOL CANCER THER, V3, P763
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81
   Li Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.464
   Lim SC, 2016, INT J ONCOL, V49, P1983, DOI 10.3892/ijo.2016.3699
   Lu M, 2006, CHEM BIOL, V13, P117, DOI 10.1016/j.chembiol.2005.12.007
   Nazim UMD, 2016, ONCOTARGET, V7, P23468, DOI 10.18632/oncotarget.8048
   Nazim UM, 2015, ONCOL REP, V33, P2331, DOI 10.3892/or.2015.3869
   OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0
   Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007
   Stupack DG, 2013, CANCER LETT, V332, P133, DOI 10.1016/j.canlet.2010.07.022
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Trivedi R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00069
   Van Geelen CMM, 2010, INT J ONCOL, V37, P1031, DOI 10.3892/ijo_00000755
   Wang Yuhong, 2010, Curr Chem Genomics, V4, P57, DOI 10.2174/1875397301004010057
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Yu JW, 2009, P NATL ACAD SCI USA, V106, P8169, DOI 10.1073/pnas.0812453106
   Zhang L, 2002, GENE THER, V9, P1262, DOI 10.1038/sj.gt.3301797
   Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792
   Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007
   Zhu TM, 2006, J MED CHEM, V49, P1373, DOI 10.1021/jm050901o
NR 50
TC 1
Z9 1
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2019
VL 18
IS 7
BP 1265
EP 1277
DI 10.1158/1535-7163.MCT-18-1241
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IG1FL
UT WOS:000473535800008
PM 31092562
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wong, ASL
   Cheung, ZH
   Ip, NY
AF Wong, Alan S. L.
   Cheung, Zelda H.
   Ip, Nancy Y.
TI Molecular machinery of macroautophagy and its deregulation in diseases
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
DE Autophagy; Autophagosome; Cdk5; Endophilin B1; Post-translational
   modification; Neurodegenerative disorder
ID INTERACTING FACTOR-I; CELL-DEATH; ALPHA-SYNUCLEIN; BECLIN 1; REGULATES
   AUTOPHAGY; AXONAL-TRANSPORT; COLON-CANCER; PINK1/PARKIN-MEDIATED
   MITOPHAGY; DECREASED EXPRESSION; PROTEIN AGGREGATION
AB Macroautophagy maintains cellular homeostasis through targeting cytoplasmic contents and organelles into autophagosomes for degradation. This process begins with the assembly of protein complexes on isolation membrane to initiate the formation of autophagosome, followed by its nucleation, elongation and maturation. Fusion of autophagosomes with lysosomes then leads to degradation of the cargo. In the past decade, significant advances have been made on the identification of molecular players that are implicated in various stages of macroautophagy. Post-translational modifications of macroautophagy regulators have also been demonstrated to be critical for the selective targeting of cytoplasmic contents into autophagosomes. In addition, recent demonstration of distinct macroautophagy regulators has led to the identification of different subtypes of macroautophagy. Since deregulation of macroautophagy is implicated in diseases including neurodegenerative disorders, cancers and inflammatory disorders, understanding the molecular machinery of macroautophagy is crucial for elucidating the mechanisms by which macroautophagy is deregulated in these diseases, thereby revealing new potential therapeutic targets and strategies. Here we summarize current knowledge on the regulation of mammalian macroautophagy machineries and their disease-associated deregulation. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Wong, Alan S. L.; Cheung, Zelda H.; Ip, Nancy Y.] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Div Life Sci, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China.
RP Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Div Life Sci, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China.
EM boip@ust.hk
RI Cheung, Zelda Hiu Yee/C-1402-2012
OI Wong, Alan S.L./0000-0003-1790-3233; Ip, Nancy
   Yuk-Yu/0000-0002-2763-8907
FU Research Grants Council of Hong KongHong Kong Research Grants Council
   [HKUST 661007, 661109, 660309, 660210, 6/CRF/08]; University Grants
   Committee [AoE/B-15/01]; Hong Kong Jockey Club; Croucher Foundation
FX We apologize to authors whose work could not be discussed or cited due
   to space limitations. This work was supported in part by the Research
   Grants Council of Hong Kong (HKUST 661007, 661109, 660309, 660210, and
   6/CRF/08), the Area of Excellence Scheme of the University Grants
   Committee (AoE/B-15/01) and the Hong Kong Jockey Club. N.Y.I. and Z.H.C
   were recipients of the Croucher Foundation Senior Research Fellow and
   Croucher Foundation Fellow respectively.
CR Alegre-Abarrategui J, 2009, HUM MOL GENET, V18, P4022, DOI 10.1093/hmg/ddp346
   Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Mestre MB, 2010, AUTOPHAGY, V6, P110, DOI 10.4161/auto.6.1.10698
   Bodemann BO, 2011, CELL, V144, P253, DOI 10.1016/j.cell.2010.12.018
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Chang YY, 2010, FEBS LETT, V584, P1342, DOI 10.1016/j.febslet.2010.01.006
   Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108
   Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625
   Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Coppola D, 2008, CLIN GENITOURIN CANC, V6, P117, DOI 10.3816/CGC.2008.n.018
   Crews L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009313
   Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Dehay B, 2010, J NEUROSCI, V30, P12535, DOI 10.1523/JNEUROSCI.1920-10.2010
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Filimonenko M, 2010, MOL CELL, V38, P265, DOI 10.1016/j.molcel.2010.04.007
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009
   Geisler S, 2010, AUTOPHAGY, V6, P871, DOI 10.4161/auto.6.7.13286
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Her LS, 2008, J NEUROSCI, V28, P13662, DOI 10.1523/JNEUROSCI.4144-08.2008
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jeong H, 2009, CELL, V137, P60, DOI 10.1016/j.cell.2009.03.018
   Ju JS, 2009, J CELL BIOL, V187, P875, DOI 10.1083/jcb.200908115
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MS, 2008, APMIS, V116, P939, DOI 10.1111/j.1600-0463.2008.01091.x
   Kim SY, 2008, PATHOLOGY, V40, P553, DOI 10.1080/00313020802320440
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Knaevelsrud H, 2010, FEBS LETT, V584, P2635, DOI 10.1016/j.febslet.2010.04.041
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Kovacs AL, 2010, FEBS LETT, V584, P1335, DOI 10.1016/j.febslet.2010.02.002
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Krainc D, 2010, ARCH NEUROL-CHICAGO, V67, P388, DOI 10.1001/archneurol.2010.40
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394
   Lee JY, 2010, J CELL BIOL, V189, P671, DOI 10.1083/jcb.201001039
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Lee S, 2011, J NEUROSCI, V31, P7817, DOI 10.1523/JNEUROSCI.6412-10.2011
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinez-Vicente M, 2007, LANCET NEUROL, V6, P352, DOI 10.1016/S1474-4422(07)70076-5
   Martinez-Vicente M, 2010, NAT NEUROSCI, V13, P567, DOI 10.1038/nn.2528
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   McPhee CK, 2010, NATURE, V465, P1093, DOI 10.1038/nature09127
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mukaiyama H, 2010, FEBS LETT, V584, P1327, DOI 10.1016/j.febslet.2009.12.037
   Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113
   Noda T, 2009, CELL DEATH DIFFER, V16, P984, DOI 10.1038/cdd.2009.54
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378
   Plowey ED, 2008, J NEUROCHEM, V105, P1048, DOI 10.1111/j.1471-4159.2008.05217.x
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raben N, 2010, AUTOPHAGY, V6, P1078, DOI 10.4161/auto.6.8.13378
   Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Renna M, 2011, J CELL SCI, V124, P469, DOI 10.1242/jcs.076489
   Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742
   Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Smith DM, 2010, CELL DEATH DIFFER, V17, P1867, DOI 10.1038/cdd.2010.53
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Suzuki K, 2007, FEBS LETT, V581, P2156, DOI 10.1016/j.febslet.2007.01.096
   Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takahashi Y, 2011, AUTOPHAGY, V7, P61, DOI 10.4161/auto.7.1.14015
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Thoresen SB, 2010, EXP CELL RES, V316, P3368, DOI 10.1016/j.yexcr.2010.07.008
   Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800
   Tian Y, 2010, CELL, V141, P1042, DOI 10.1016/j.cell.2010.04.034
   Tong YR, 2010, P NATL ACAD SCI USA, V107, P9879, DOI 10.1073/pnas.1004676107
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014
   van der Vaart A, 2010, AUTOPHAGY, V6, P800, DOI 10.1091/mbc.E09-04-0345
   Vergne I, 2009, EMBO J, V28, P2244, DOI 10.1038/emboj.2009.159
   Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3
   Winslow AR, 2010, J CELL BIOL, V190, P1023, DOI 10.1083/jcb.201003122
   Wong ASL, 2011, NAT CELL BIOL, V13, P568, DOI 10.1038/ncb2217
   Xilouri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005515
   Yang DS, 2011, BRAIN, V134, P258, DOI 10.1093/brain/awq341
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu WH, 2009, AM J PATHOL, V175, P736, DOI 10.2353/ajpath.2009.080928
   Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
NR 146
TC 45
Z9 51
U1 1
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD NOV
PY 2011
VL 1812
IS 11
BP 1490
EP 1497
DI 10.1016/j.bbadis.2011.07.005
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 847DR
UT WOS:000296952600016
PM 21787863
OA Bronze
DA 2022-04-25
ER

PT J
AU Bednarczyk, M
   Fatyga, E
   Dziegielewska-Gesiak, S
   Waniczek, D
   Grabarek, B
   Zmarzly, N
   Janikowska, G
   Muc-Wierzgon, M
AF Bednarczyk, Martyna
   Fatyga, Edyta
   Dziegielewska-Gesiak, Sylwia
   Waniczek, Dariusz
   Grabarek, Beniamin
   Zmarzly, Nikola
   Janikowska, Grazyna
   Muc-Wierzgon, Malgorzata
TI The Expression Patterns of BECN1, LAMP2, and PINK1 Genes in Colorectal
   Cancer Are Potentially Regulated by Micrornas and CpG Islands: An In
   Silico Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE autophagy; colorectal cancer; expression genes; microRNAs (miRNAs); CpG
   islands
ID CHAPERONE-MEDIATED AUTOPHAGY; DNA METHYLATION; PROGNOSIS; DEGRADATION;
   MECHANISMS; SURVIVAL; GROWTH; MIRNA
AB Background: Autophagy plays a dual role of tumor suppression and tumor promotion in colorectal cancer. The study aimed to find those microRNAs (miRNAs) important in BECN1, LAMP2, and PINK1 regulation and to determine the possible role of the epigenetic changes in examined colorectal cancer using an in silico approach. Methods: A total of 44 pairs of surgically removed tumors at clinical stages I-IV and healthy samples (marginal tissues) from patients' guts were analyzed. Analysis of the obtained results was conducted using the PL-Grid Infrastructure and Statistica 12.0 program. The miRNAs and CpG islands were estimated using the microrna.org database and MethPrimer program. Results: The autophagy-related genes were shown to be able to be regulated by miRNAs (BECN1-49 mRNA, LAMP2-62 mRNA, PINK1-6 mRNA). It was observed that promotion regions containing at least one CpG region were present in the sequence of each gene. Conclusions: The in silico analysis performed allowed us to determine the possible role of epigenetic mechanisms of regulation gene expression, which may be an interesting therapeutic target in the treatment of colorectal cancer.
C1 [Bednarczyk, Martyna; Fatyga, Edyta; Dziegielewska-Gesiak, Sylwia; Muc-Wierzgon, Malgorzata] Med Univ Silesia, Dept Internal Med, PL-40055 Katowice, Poland.
   [Waniczek, Dariusz] Med Univ Silesia, SHS Katowice, Chair Gen Colorectal & Polytrauma Surg, Dept Propedeut Surg, PL-40055 Katowice, Poland.
   [Grabarek, Beniamin; Zmarzly, Nikola] Univ Technol Katowice, Fac Med Zabrze, Dept Histol Cytophysiol & Embryol, PL-40055 Katowice, Poland.
   [Janikowska, Grazyna] Med Univ Silesia, Dept Analyt Chem, PL-40055 Katowice, Poland.
RP Muc-Wierzgon, M (corresponding author), Med Univ Silesia, Dept Internal Med, PL-40055 Katowice, Poland.
EM martyna.bednarczyk@outlook.com; efatyga@sum.edu.pl; sgesiak@sum.edu.pl;
   dwaniczek@sum.edu.pl; bgrabarek7@gmail.com; nikola.zmarzly@gmail.com;
   grazynajanikowska@wp.pl; mwierzgon@sum.edu.pl
RI grabarek, beniamin/V-3630-2019
OI grabarek, beniamin/0000-0003-1633-7145; Muc-Wierzgon,
   Malgorzata/0000-0001-6562-7072; Janikowska, Grazyna/0000-0002-2839-174X;
   Bednarczyk, Martyna/0000-0001-8360-9126; Fatyga,
   Edyta/0000-0003-0389-206X; Zmarzly, Nikola/0000-0002-7833-6167;
   Waniczek, Dariusz/0000-0002-0410-8604; Dziegielewska-Gesiak,
   Sylwia/0000-0003-1019-5959
FU Medical University of Silesia Agreement [KNW-1-072/K/9/K]
FX Supported by grants from Medical University of Silesia Agreement (no.
   KNW-1-072/K/9/K).
CR Afrasanie VA, 2019, RADIOL ONCOL, V53, P265, DOI 10.2478/raon-2019-0033
   Agnihotri S, 2016, CANCER RES, V76, P4708, DOI 10.1158/0008-5472.CAN-15-3079
   Alessandrini F, 2017, SEMIN ONCOL, V44, P239, DOI 10.1053/j.seminoncol.2017.10.013
   Arias E, 2011, CURR OPIN CELL BIOL, V23, P184, DOI 10.1016/j.ceb.2010.10.009
   Bednarczyk M, 2017, J BIOL REG HOMEOS AG, V31, P923
   Bednarczyk Martyna, 2018, Oncotarget, V9, P34413, DOI 10.18632/oncotarget.26126
   Bhaskaran V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08390-z
   Bhowmick SS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200353
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chang JTH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168284
   Chen L, 2019, EXP THER MED, V17, P1476, DOI 10.3892/etm.2018.7084
   Chi KH, 2016, ONCOTARGET, V7, P58075, DOI 10.18632/oncotarget.10873
   Chu SK, 2017, EPIGENOMICS-UK, V9, P1437, DOI 10.2217/epi-2017-0046
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Davegardh C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1118-4
   Dobson JR, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0073-0
   Dunlop MG, 1997, BMJ-BRIT MED J, V314, P1882, DOI 10.1136/bmj.314.7098.1882
   Fei BY, 2016, ONCOL LETT, V11, P2271, DOI 10.3892/ol.2016.4183
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14
   Hafez MM, 2012, ASIAN PAC J CANCER P, V13, P591, DOI 10.7314/APJCP.2012.13.2.591
   Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8
   Jang K, 2014, TRANSL RES, V163, P242, DOI 10.1016/j.trsl.2013.11.005
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Kaushik S, 2015, NAT CELL BIOL, V17, P759, DOI 10.1038/ncb3166
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Kyeong S.C., 2012, EXP MOL MED, V44, P109
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li L, 2017, CANCER BIOMARK, V19, P305, DOI 10.3233/CBM-160469
   Li W, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0495-y
   Li ZD, 2008, PROG BIOCHEM BIOPHYS, V35, P1282
   Liu GK, 2019, J CANCER RES THER, V15, P278, DOI 10.4103/jcrt.JCRT_135_18
   Long JL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12900
   Lui J., 2015, PLOS ONE, V10
   Mah LY, 2012, AUTOPHAGY, V8, P18, DOI 10.4161/auto.8.1.18077
   Markou A, 2014, CLIN CHEM, V60, P197, DOI 10.1373/clinchem.2013.210542
   Mateu-Jimenez M, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-017-0437-0
   Morell C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162977
   Moreno-Mateos MA, 2013, RNA, V19, P1711, DOI 10.1261/rna.039461.113
   Napolitano G, 2015, EMBO MOL MED, V7, P158, DOI 10.15252/emmm.201404223
   O'Flanagan Ciara H, 2016, Oncoscience, V3, P1
   Polewska J, 2012, POSTEP HIG MED DOSW, V66, P921, DOI 10.5604/17322693.1021109
   Qu J, 2019, MOL THER-NUCL ACIDS, V14, P274, DOI 10.1016/j.omtn.2018.12.002
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Shin JJ, 2016, DIS MODEL MECH, V9, P1039, DOI 10.1242/dmm.023374
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Su HY, 2019, ONCOL LETT, V17, P2228, DOI 10.3892/ol.2018.9829
   Szeliski K, 2018, CENT EUR J UROL, V71, P420, DOI 10.5173/ceju.2018.1762
   Tarang S, 2014, RNA BIOL, V11, P324, DOI 10.4161/rna.28649
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   Turcotte S, 2010, CURR OPIN CELL BIOL, V22, P246, DOI 10.1016/j.ceb.2009.12.007
   Wei SH, 2014, ONCOL LETT, V7, P635, DOI 10.3892/ol.2013.1773
   Wojton Jeffrey, 2014, CNS Oncol, V3, P5, DOI 10.2217/cns.13.52
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao DH, 2016, CELL PROLIFERAT, V49, P541, DOI 10.1111/cpr.12277
   Yuan C, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00205-17
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhao Y, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1026-1
NR 62
TC 3
Z9 3
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD DEC
PY 2020
VL 9
IS 12
AR 4020
DI 10.3390/jcm9124020
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PJ9SC
UT WOS:000602096600001
PM 33322704
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhao, YT
   Shi, L
   Hu, CL
   Sang, SM
AF Zhao, Yantao
   Shi, Lei
   Hu, Changling
   Sang, Shengmin
TI Wheat Bran for Colon Cancer Prevention: The Synergy between
   Phytochemical Alkylresorcinol C21 and Intestinal Microbial Metabolite
   Butyrate
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE colorectal cancer; wheat bran; alkylresorcinols; butyrate; synergy
ID CHAIN FATTY-ACIDS; ENDOPLASMIC-RETICULUM STRESS; DIETARY FIBER INTAKE;
   COLORECTAL-CANCER; CELL-GROWTH; APOPTOSIS; AUTOPHAGY; NUTRIENTS;
   PATHWAY; ADENOMA
AB There is convincing evidence that consuming whole grains (WGs) may decrease the risk of colorectal cancer (CRC). Wheat bran (WB) is a rich source of dietary fiber and phytochemicals with health-promoting properties. However, the active components especially the interaction between different components in WG wheat have not been fully explored. Here, we investigated whether one of the major WB phytochemicals, alkylresorcinol (AR) C21, and the major active intestinal microbial metabolite of fiber, butyrate, could synergistically suppress human colon cancer cells. Our results demonstrated for the first time that the combination of C21 and butyrate synergistically inhibited the growth of human colon cancer cells and induced apoptosis. Further mechanistic studies demonstrated that the cotreatment of C21 and butyrate induced significant upregulations in cleaved Poly(ADP-ribose) polymerase (PARP), cleaved caspase 3, p53 upregulated modulator of apoptosis (PUMA), cytochrome C, lipid-conjugated membrane-bound form of microtubule-associated protein 1A/1B-light chain 3 (LC3-II), and C/EBP homologous protein (CHOP) expressions, indicating the synergistic anticancer effects of C21 and butyrate were associated with induction of apoptosis, autophagy, and ER stress pathways. Notably, the C21 concentrations in the large intestinal tract of mice treated with human relevant doses of C21, were from 0.86 to 1.78 mu mol/g, suggesting the C21 doses used in vitro may be achievable after daily WG wheat intake. These results provide novel insights into the dietary prevention of CRC regarding the potential interaction of bioactive WG wheat phytochemicals and the microbial metabolites of fiber.
C1 [Zhao, Yantao; Shi, Lei; Hu, Changling; Sang, Shengmin] North Carolina Agr & Tech State Univ, Ctr Excellence Postharvest Technol, Lab Funct Foods & Human Hlth, North Carolina Res Campus,500 Laureate Way, Kannapolis, NC 28081 USA.
   [Shi, Lei] Ningxia Med Univ, Gen Hosp, Dept Colorectal Surg, Yinchuan 750004, Peoples R China.
RP Sang, SM (corresponding author), North Carolina Agr & Tech State Univ, Ctr Excellence Postharvest Technol, Lab Funct Foods & Human Hlth, North Carolina Res Campus,500 Laureate Way, Kannapolis, NC 28081 USA.
EM ssang@ncat.edu
OI Sang, Shengmin/0000-0002-5005-3616
FU United States Department of Agriculture (USDA) National Institute of
   Food and Agriculture (NIFA) R01 grant [2018-67001-28265]
FX This work was supported by funding from The United States Department of
   Agriculture (USDA) National Institute of Food and Agriculture (NIFA) R01
   grant 2018-67001-28265 to S.S.
CR Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583
   Aune D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6617
   Ben QW, 2014, GASTROENTEROLOGY, V146, P689, DOI 10.1053/j.gastro.2013.11.003
   Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1
   CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763
   CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221
   den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012
   DeVorkin L., 2014, AUTOPHAGY CANC OTHER, P369, DOI [10.1016/B978-0-12-405529-2.00024-X, DOI 10.1016/B978-0-12-405529-2.00024-X]
   FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Fu JS, 2018, J AGR FOOD CHEM, V66, P11935, DOI 10.1021/acs.jafc.8b04442
   Fung KYC, 2011, J PROTEOME RES, V10, P1860, DOI 10.1021/pr1011125
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gomes SD, 2020, CURR MED CHEM, V27, P4087, DOI 10.2174/0929867325666180530102050
   Gross MD, 2009, AM J CLIN NUTR, V89, p1543S, DOI DOI 10.3945/AJCN.2009.26736B
   HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329
   Harris PJ, 1999, MUTAT RES-GEN TOX EN, V443, P95, DOI 10.1016/S1383-5742(99)00013-7
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S
   Kruk J, 2017, EUR FOOD RES TECHNOL, V243, P1693, DOI 10.1007/s00217-017-2890-6
   Kunzmann AT, 2015, AM J CLIN NUTR, V102, P881, DOI 10.3945/ajcn.115.113282
   Kyro C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt352
   Luo SL, 2019, J PHYSIOL BIOCHEM, V75, P53, DOI 10.1007/s13105-018-0651-z
   Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897
   Mattila P, 2005, J AGR FOOD CHEM, V53, P8290, DOI 10.1021/jf051437z
   McNabney SM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121348
   Mortensen PB, 1996, SCAND J GASTROENTERO, V31, P132, DOI 10.3109/00365529609094568
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   REDDY B, 1989, CANCER RES, V49, P4629
   REDDY BS, 1992, GASTROENTEROLOGY, V102, P1475, DOI 10.1016/0016-5085(92)91704-8
   Reddy BS, 1999, AM J MED, V106, P16, DOI DOI 10.1016/S0002-9343(98)00341-6
   Rodriguez-Carrio J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00823
   Ross AB, 2003, J AGR FOOD CHEM, V51, P4111, DOI 10.1021/jf0340456
   Ross AB, 2009, J AGR FOOD CHEM, V57, P5187, DOI 10.1021/jf900239t
   Ruemmele FM, 2003, GUT, V52, P94, DOI 10.1136/gut.52.1.94
   Samali Afshin, 2010, Int J Cell Biol, V2010, P830307, DOI 10.1155/2010/830307
   Sang SM, 2006, J AGR FOOD CHEM, V54, P9792, DOI 10.1021/jf0620665
   Sang SM, 2018, J AGR FOOD CHEM, V66, P10347, DOI 10.1021/acs.jafc.8b04110
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   SCHEPPACH W, 1995, EUR J CANCER, V31A, P1077, DOI 10.1016/0959-8049(95)00165-F
   Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035
   Stevenson L, 2012, INT J FOOD SCI NUTR, V63, P1001, DOI 10.3109/09637486.2012.687366
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tallarida RJ, 2006, J PHARMACOL EXP THER, V319, P1, DOI 10.1124/jpet.106.104117
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704
   Wolczuk K, 2011, FOLIA MORPHOL, V70, P252
   World Cancer Research Fund American Institute for Cancer Research, 2018, DIET NUTR PHYS ACT C
   Wu XQ, 2018, J CANCER, V9, P2510, DOI 10.7150/jca.25324
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhao YT, 2015, J AGR FOOD CHEM, V63, P4843, DOI 10.1021/acs.jafc.5b01246
   Zhu YD, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600852
   Zhu YD, 2014, J NUTR, V144, P114, DOI 10.3945/jn.113.184663
   Zhu YD, 2012, J AGR FOOD CHEM, V60, P8624, DOI 10.1021/jf302872a
   Zhu YD, 2011, BIOORGAN MED CHEM, V19, P3973, DOI 10.1016/j.bmc.2011.05.025
NR 58
TC 7
Z9 8
U1 5
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 20
PY 2019
VL 67
IS 46
BP 12761
EP 12769
DI 10.1021/acs.jafc.9b05666
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA JR6OX
UT WOS:000499743400017
PM 31675233
DA 2022-04-25
ER

PT J
AU Zhao, YL
   Fan, DM
   Ru, BB
   Cheng, KW
   Hu, ST
   Zhang, JW
   Li, ETS
   Wang, MF
AF Zhao, Yueliang
   Fan, Daming
   Ru, Beibei
   Cheng, Ka-Wing
   Hu, Shuting
   Zhang, Jiangwen
   Li, Edmund T. S.
   Wang, Mingfu
TI 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and
   cytoprotective autophagy in colon cancer cells
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE 6-CEPN; Anticancer; Colon cancer; RAS
ID RAS; DEATH; MODULATION; SIGNATURE; APOPTOSIS; PATHWAYS; PROTEIN
AB 6-C-(E-phenylethenyl) naringenin (6-CEPN) is a small molecule found in naringenin fortified fried beef. It has been shown to suppress colon cancer cell proliferation, but the underlying mechanisms are not fully understood. Here we demonstrate that 6-CEPN suppresses tumour cell proliferation through cell cycle arrest in G(1) phase, induces necrotic cell death and autophagy in colon cancer cells. Blockade of autophagy by knockdown of the essential autophagy proteins, Atg7 or beclin-1, resulted in aggravated cell death in response to 6-CEPN treatment. In addition, genome-wide transcriptome expression profiling by RNA-sequencing revealed that 6-CEPN-mediated gene expression pattern was extremely similar to the transcriptome response induced by a RAS inhibitor salirasib (farnesylthiosalicylic acid [FTS; salirasib]). Subsequent molecular biological and biochemical experiments demonstrated that 6-CEPN indeed strongly inhibited RAS activation, leading to the inhibition of the downstream effector pathways c-Raf/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase kinase and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin. More importantly, our computational molecular docking data showed that 6-CEPN could bind to the active site of isoprenylcysteine carboxyl methyltransferase (Icmt), a critical enzyme for the activation of RAS. Icmt activity assay showed that 6-CEPN inhibited its activity significantly. Knockdown of Icmt bysiRNA attenuated 6-CEPN-mediated autophagy and cell death. The present study demonstrates that 6-CEPN induces cell growth inhibition and cytoprotective autophagy in colon cancer cells, at least in part, though inhibition of the Icmt/RAS signalling pathways. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Zhao, Yueliang; Fan, Daming; Ru, Beibei; Hu, Shuting; Zhang, Jiangwen; Li, Edmund T. S.; Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Ka-Wing] Peking Univ, Coll Engn, Beijing, Peoples R China.
RP Wang, MF (corresponding author), Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM mfwang@hku.hk
RI Ru, Beibei/F-3830-2011; Zhang, Jiangwen/A-7654-2013; Cheng, Ka
   Wing/V-9433-2019; Wang, Mingfu/D-3136-2009; Wang, Mingfu/AAT-3292-2021
OI Zhang, Jiangwen/0000-0002-2911-8446; Wang, Mingfu/0000-0003-1469-3963;
   Cheng, Ka Wing/0000-0002-1201-312X; Fan, Daming/0000-0002-4907-9034
CR Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/fmc.11.121, 10.4155/FMC.11.121]
   Bharate SB, 2012, CURR MED CHEM, V19, P2273
   Blum R, 2005, DRUG RESIST UPDATE, V8, P369, DOI 10.1016/j.drup.2005.11.002
   Blum R, 2007, CANCER RES, V67, P3320, DOI 10.1158/0008-5472.CAN-06-4287
   Bournet B, 2016, EUR J CANCER, V54, P75, DOI 10.1016/j.ejca.2015.11.012
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Cavaliere V, 2014, EUR J CANCER, V50, P3243, DOI 10.1016/j.ejca.2014.09.012
   Chapnick DA, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-42
   Cheng K.Y., 2009, THESIS
   Cheng KW, 2008, CHEM RES TOXICOL, V21, P2026, DOI 10.1021/tx800220h
   Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Gao JH, 2009, AM J TRANSL RES, V1, P312
   Hashimoto I, 2008, EUR J CANCER, V44, P1022, DOI 10.1016/j.ejca.2008.02.043
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Kanaan Z, 2012, ANN SURG, V256, P544, DOI 10.1097/SLA.0b013e318265bd6f
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kramer K, 2003, MOL BIOL CELL, V14, P848, DOI 10.1091/mbc.E02-07-0390
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Salyan MEK, 2006, ANAL BIOCHEM, V349, P112, DOI 10.1016/j.ab.2005.10.040
   Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Schmukler E, 2013, ONCOTARGET, V4, P145
   Schreck R, 2006, INT J CANCER, V119, P2261, DOI 10.1002/ijc.22144
   Shi W, 2015, NAT IMMUNOL, V16, P663, DOI 10.1038/ni.3154
   Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560
   Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247
   Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200
   Wu WKK, 2010, AUTOPHAGY, V6, P228, DOI 10.4161/auto.6.2.11042
   Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071
   Zhang N, 2010, AUTOPHAGY, V6, P1157, DOI 10.4161/auto.6.8.13614
   Zundelevich A, 2007, MOL CANCER THER, V6, P1765, DOI 10.1158/1535-7163.MCT-06-0706
NR 37
TC 24
Z9 24
U1 1
U2 31
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD NOV
PY 2016
VL 68
BP 38
EP 50
DI 10.1016/j.ejca.2016.09.001
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EC0SS
UT WOS:000387811600005
PM 27710830
DA 2022-04-25
ER

PT J
AU Jo, YK
   Kim, SC
   Park, IJ
   Park, SJ
   Jin, DH
   Hong, SW
   Cho, DH
   Kim, JC
AF Jo, Yoon Kyung
   Kim, Seung Cheol
   Park, In Ja
   Park, So Jung
   Jin, Dong-Hoon
   Hong, Seung-Woo
   Cho, Dong-Hyung
   Kim, Jin Cheon
TI Increased Expression of ATG10 in Colorectal Cancer Is Associated with
   Lymphovascular Invasion and Lymph Node Metastasis
SO PLOS ONE
LA English
DT Article
ID UBIQUITIN-CONJUGATING ENZYME; METABOLIC STRESS; GASTRIC-CANCER;
   BREAST-CANCER; CELL-SURVIVAL; RECTAL-CANCER; AUTOPHAGY; TUMORIGENESIS;
   MACROAUTOPHAGY; DISEASE
AB Background: Autophagy has paradoxical and complex functions in cancer development, and autophagy-related genes (ATG) are key regulators in autophagy. Until now, more than 30 different ATG proteins have been identified in yeast, and their mammalian counterparts also have been reported. Although the roles of a few ATG proteins in cancer have been characterized, the role of ATG10 is almost completely unknown.
   Methodology/Principal Findings: To investigate the clinicopathological role of ATG10 in colorectal cancer, we analyzed ATG10 expression in colorectal cancer tissues and cell lines. Protein expression analysis showed that ATG10 is highly increased in colorectal cancer (tissue - 18/37 cases, 48%; cell line - 8/12 cell lines, 66%). Immunohistochemical analysis with clinicopathological features indicated a strong association of the up-regulation of ATG10 with tumor lymph node metastasis (p = 0.005) and invasion (p<0.001). Moreover, both 5-year disease free survival and overall survival rates of patients bearing tumors that did not express ATG10 were significantly higher than those of patients bearing ATG10-expressing tumors (p = 0.012).
   Conclusion/Significance: Increased expression of ATG10 in colorectal cancer is associated with lymphovascular invasion and lymph node metastasis indicating that ATG10 may be a potential prognostic maker in colorectal cancer.
C1 [Jo, Yoon Kyung; Park, So Jung; Cho, Dong-Hyung] Kyung Hee Univ, Grad Sch EW Med Sci, Gyeonggi Do, South Korea.
   [Jo, Yoon Kyung; Kim, Seung Cheol; Jin, Dong-Hoon; Hong, Seung-Woo; Kim, Jin Cheon] Asan Med Ctr, Inst Innovat Canc Res, Seoul, South Korea.
   [Kim, Seung Cheol; Park, In Ja; Kim, Jin Cheon] Univ Ulsan, Dept Surg, Coll Med, Seoul, South Korea.
   [Jin, Dong-Hoon; Hong, Seung-Woo] Univ Ulsan, Dept Oncol, Coll Med, Seoul, South Korea.
RP Cho, DH (corresponding author), Kyung Hee Univ, Grad Sch EW Med Sci, Gyeonggi Do, South Korea.
EM dhcho@khu.ac.kr; jckim@amc.seoul.kr
RI Park, In Ja/U-2371-2019
OI Park, In Ja/0000-0001-5355-3969
FU Center for Development and Commercialization of Anti-Cancer
   Therapeutics; Korean Health 21 RD Project [A062254, A102059]; Ministry
   of Health, Welfare and Family Affairs, KoreaMinistry of Health &
   Welfare, Republic of Korea; Asan Institute for Life Sciences [2011-069];
   Basic Science Research Program (the National Research Foundation, Korea)
   [2010-0009164]
FX This work was supported by the Center for Development and
   Commercialization of Anti-Cancer Therapeutics and the Korean Health 21
   R&D Project (A062254 and A102059, Ministry of Health, Welfare and Family
   Affairs, Korea), the Asan Institute for Life Sciences (2011-069), and
   the Basic Science Research Program (2010-0009164, the National Research
   Foundation, Korea). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Cho DH, 2010, MOL MED, V16, P271, DOI 10.2119/molmed.2009.00187
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Lee WS, 2012, HEPATO-GASTROENTEROL, V59, P1313, DOI 10.5754/hge11610
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002
   Mantripragada KK, 2009, GENE CHROMOSOME CANC, V48, P897, DOI 10.1002/gcc.20695
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Moschos SJ, 2010, HUM PATHOL, V41, P1286, DOI 10.1016/j.humpath.2010.02.007
   Nagtegaal ID, 2008, J CLIN ONCOL, V26, P303, DOI 10.1200/JCO.2007.12.7027
   Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056
   Oga A, 2001, CYTOMETRY, V46, P57, DOI 10.1002/1097-0320(20010215)46:1<57::AID-CYTO1038>3.3.CO;2-X
   Okamoto Y, 2003, CANCER RES, V63, P4167
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ramus SJ, 2003, CANCER RES, V63, P417
   Shiraishi K, 2001, ONCOLOGY-BASEL, V60, P151, DOI 10.1159/000055313
   Tedesco D, 2007, NEOPLASIA, V9, P601, DOI 10.1593/neo.07385
   Tilney HS, 2007, DIS COLON RECTUM, V50, P29, DOI 10.1007/s10350-006-0744-6
NR 30
TC 48
Z9 52
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52705
DI 10.1371/journal.pone.0052705
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500237
PM 23285162
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Kim, SY
   Yi, HK
   Yun, BS
   Lee, DY
   Hwang, PH
   Park, HR
   Kim, MS
AF Kim, Sun-Young
   Yi, Ho-Keun
   Yun, Bong-Sik
   Lee, Dae-Yeol
   Hwang, Pyung Han
   Park, Hae-Ryong
   Kim, Min Sun
TI The extract of the immature fruit of Poncirus trifoliata induces
   apoptosis in colorectal cancer cells via mitochondrial autophagy
SO FOOD SCIENCE AND HUMAN WELLNESS
LA English
DT Article
DE Anticancer; Autophagy; Apoptosis; Mitochondria; Poncirus trifoliata
ID GROWTH-INHIBITION; SIGNALING PATHWAY; IN-VITRO; PROLIFERATION;
   CYTOTOXICITY; MACHINERY; CT26
AB The immature fruits of Poncirus trifoliate are used as a medicine for the treatment of gastrointestinal disorders, inflammation, and allergies in East Asia. However, their effect on colon cancer cells remains unclear. We investigated the effect of the immature fruit of P. trifoliate extract on colorectal adenocarcinoma. The extract of the immature fruit of P. trifoliata inhibited the proliferation of CT-26 cells compared with untreated cells and it induced autophagy and apoptosis through the protein kinase B/mammalian target of rapamycin and 5'-AMP-activated protein kinase pathways. The number of autophagic vacuoles and autophage markers increased in response to the extract. At later time-points, apoptosis increased dose/time-dependently. In CT-26 cells pre-treated a pan-caspase inhibitor prior to P. trifoliata immature fruit extract treatment, we did not find any change in pro-caspase 3 and pro-PARP levels. Additionally, in cells pre-treated autphage inhibitor, SQSTM1/p62 and LC3AB, pro-caspase 3 and pro-PARP levels did not change. Our results indicate the molecular mechanisms that the extract of the immature fruit of P. trifoliata induces apoptosis in colorectal carcinoma cells by inducing mitochondrial autophagy. In this study, we provided a draft for further investigate the use of MEPT for colorectal cancer inhibition. (c) 2020 "Society information". Production and hosting by Elsevier B.V. on behalf of KeAiCommunications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Kim, Sun-Young; Lee, Dae-Yeol; Hwang, Pyung Han; Kim, Min Sun] Jeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Biomed Res Inst, Res Inst Clin Med, Jeonju 54907, South Korea.
   [Yi, Ho-Keun] Jeonbuk Natl Univ, Sch Dent, Inst Oral Biosci, Dept Oral Biochem, Jeonju 54907, South Korea.
   [Yun, Bong-Sik] Jeonbuk Natl Univ, Div Biotechnol, Iksan Si 54596, South Korea.
   [Yun, Bong-Sik] Jeonbuk Natl Univ, Adv Inst Environm & Biosci, Iksan Si 54596, South Korea.
   [Lee, Dae-Yeol; Hwang, Pyung Han; Kim, Min Sun] Jeonbuk Natl Univ, Dept Pediat, Med Sch, Jeonju 54907, South Korea.
   [Park, Hae-Ryong] Kyungnam Univ, Dept Food Sci & Biotechnol, Changwon Si 51767, South Korea.
RP Kim, MS (corresponding author), Jeonbuk Natl Univ Hosp, Dept Pediat, 20 Baekje Daero, Jeonju Si 54907, Jeollabuk Do, South Korea.
EM children@jbnu.ac.kr
RI Kim, Minsun/ACB-3423-2022
FU Fund of Biomedical Research Institute, Jeonbuk National University
   Hospital
FX This work was supported by Fund of Biomedical Research Institute,
   Jeonbuk National University Hospital.
CR Alayev A, 2015, J CELL BIOCHEM, V116, P450, DOI 10.1002/jcb.24997
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Castle JC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-190
   Chen JJ, 2017, ONCOTARGETS THER, V10, P811, DOI 10.2147/OTT.S125039
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Han HY, 2015, PHARMACOGN MAG, V11, pS237, DOI 10.4103/0973-1296.166056
   Han HY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/394263
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hoffmann OI, 2015, J BIOTECHNOL, V205, P14, DOI 10.1016/j.jbiotec.2015.02.029
   Hong JY, 2008, PLANTA MED, V74, P151, DOI 10.1055/s-2008-1034286
   Jeon W.Y., BMC COMPLEMENT
   Jeon WY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1877-y
   Kim BY, 2011, PHYTOTHER RES, V25, P1000, DOI 10.1002/ptr.3373
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kuntz S, 1999, EUR J NUTR, V38, P133, DOI 10.1007/s003940050054
   Lee I.J., 2008, PLANTA MED, V74, DOI [/10.1016/j.cccn.2003.10.017., DOI 10.1016/J.CCCN.2003.10.017.]
   Liu M, 2014, INT J MOL MED, V33, P1451, DOI 10.3892/ijmm.2014.1713
   Pokharel YR, 2006, CARCINOGENESIS, V27, P2483, DOI 10.1093/carcin/bgl118
   Prakash P, 2001, J NUTR, V131, P1574, DOI 10.1093/jn/131.5.1574
   Rahman A, 2015, ANTI-CANCER AGENT ME, V15, P236, DOI 10.2174/1871520614666140922122358
   Sharma N, 2016, J CANCER RES THER, V12, P248, DOI 10.4103/0973-1482.154085
   Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548
   Song X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.463
   Sun WL, 2015, NEOPLASMA, V62, P199, DOI 10.4149/neo_2015_025
   Wang C, 2014, EUR J PHARMACOL, V740, P312, DOI 10.1016/j.ejphar.2014.06.051
   World Health Organization, 2018, CANCER
   Wu S., 2015, INT J CLIN EXP PATHO, V8
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu F, 2012, NAT PROD COMMUN, V7, P1475
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
   Yi JM, 2004, CLIN CHIM ACTA, V340, P179, DOI 10.1016/j.cccn.2003.10.017
   You PT, 2018, BIOMED PHARMACOTHER, V98, P619, DOI 10.1016/j.biopha.2017.12.057
   Ziberna L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030643
NR 34
TC 2
Z9 2
U1 1
U2 7
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2213-4530
J9 FOOD SCI HUM WELL
JI Food Sci. Human Wellness
PD SEP
PY 2020
VL 9
IS 3
BP 237
EP 244
DI 10.1016/j.fshw.2020.05.001
PG 8
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA NX8KT
UT WOS:000575953600004
OA gold
DA 2022-04-25
ER

PT J
AU Lv, L
   Liu, HG
   Dong, SY
   Yang, F
   Wang, QX
   Guo, GL
   Pan, YF
   Zhang, XH
AF Lv, Lin
   Liu, Hai-Guang
   Dong, Si-Yang
   Yang, Fan
   Wang, Qing-Xuan
   Guo, Gui-Long
   Pan, Yi-Fei
   Zhang, Xiao-Hua
TI Upregulation of CD44v6 contributes to acquired chemoresistance via the
   modulation of autophagy in colon cancer SW480 cells
SO TUMOR BIOLOGY
LA English
DT Article
DE CD44v6; Colorectal cancer; Chemoresistance; Autophagy
ID COLORECTAL-CANCER; DRUG-RESISTANCE; NEOADJUVANT CHEMOTHERAPY; PROTEIN
   EXPRESSION; PROGNOSTIC IMPACT; STEM-CELLS; VARIANT 6; BECLIN 1;
   5-FLUOROURACIL; METASTASIS
AB The CD44 isoform containing variant exon v6 (CD44v6) plays an important role in the progression, metastasis, and prognosis of colorectal cancer (CRC). Recently, it was found that CD44v6 is involved in acquired drug resistance. This study aimed to investigate the molecular mechanism of CD44v6 in the resistance of CRC cells to chemotherapy. A stable CD44v6 overexpression model in SW480 cells was established via lentiviral transduction. The chemosensitivity of cells to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) was determined by cell counting kit (CCK)-8, lactate dehydrogenase (LDH) release, and colony formation assays. Immunohistochemical staining of CD44v6 was performed in human CRC tissues. The key components in cell apoptosis, drug efflux and metabolism, mismatch repair, autophagy, epithelial-mesenchymal transition (EMT), and the PI3K-Akt and MAPK-Ras-Erk1/2 pathways were assessed using flow cytometry, quantitative real-time polymerase chain reaction (PCR), and western blot assays. The CD44v6 overexpression cells showed a higher viability, a lower LDH release rate, and an increased clonogenicity than the control cells under drug treatment. Moreover, overexpression of CD44v6 resulted in enhanced autophagy flux, EMT, and phosphorylation of Akt and Erk in the presence of drugs. Furthermore, high CD44v6 expression in the primary tumor was closely associated with an early recurrence in CRC patients who underwent curative surgery and adjuvant chemotherapy. In conclusion, overexpression of CD44v6 contributes to chemoresistance in SW480 cells under cytotoxic stress via the modulation of autophagy, EMT, and activation of the PI3K-Akt and MAPK-Ras-Erk pathways.
C1 [Lv, Lin; Liu, Hai-Guang; Dong, Si-Yang; Yang, Fan; Wang, Qing-Xuan; Guo, Gui-Long; Pan, Yi-Fei; Zhang, Xiao-Hua] Wenzhou Med Univ, Dept Oncol, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
RP Zhang, XH (corresponding author), Wenzhou Med Univ, Dept Oncol, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
EM zhangxhoncology@163.com
RI Pan, Yi/AAJ-2341-2021
FU Science Foundation from the Health Bureau of Wenzhou City of Zhejiang,
   China [Y20140713]; First Affiliated Hospital of Wenzhou Medical
   University [FHY2014013]
FX This work was supported by the Science Foundation from the Health Bureau
   of Wenzhou City of Zhejiang, China (Y20140713) and by the Incubation
   Program from The First Affiliated Hospital of Wenzhou Medical University
   (FHY2014013).
CR Bendardaf R, 2004, ONCOL REP, V11, P41
   Coppola D, 1998, HUM PATHOL, V29, P627, DOI 10.1016/S0046-8177(98)80014-2
   Costa S, 2001, GYNECOL ONCOL, V80, P67, DOI 10.1006/gyno.2000.6016
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Damm S, 2010, J INVEST DERMATOL, V130, P1893, DOI 10.1038/jid.2010.45
   De Mattia E, 2015, DRUG RESIST UPDATE, V20, P39, DOI 10.1016/j.drup.2015.05.003
   Gao CJ, 2003, CARCINOGENESIS, V24, P1871, DOI 10.1093/carcin/bgg139
   Giles GI, 2005, MED CHEM, V1, P383, DOI 10.2174/1573406054368738
   Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036
   GRAZIANI A, 1991, J BIOL CHEM, V266, P22087
   Hebbard L, 2000, J CELL SCI, V113, P2619
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Jung T, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208421
   Kirschner K, 2010, ANTICANCER RES, V30, P3223
   Klingbeil P, 2009, MOL CANCER RES, V7, P168, DOI 10.1158/1541-7786.MCR-08-0207
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li J, 2012, BIOMED PHARMACOTHER, V66, P144, DOI 10.1016/j.biopha.2011.11.021
   Liu CM, 2009, CELL TISSUE RES, V336, P465, DOI 10.1007/s00441-009-0780-3
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   McCubrey JA, 2011, J CELL PHYSIOL, V226, P2762, DOI 10.1002/jcp.22647
   Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478
   Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200
   Ni J, 2014, PROSTATE, V74, P602, DOI 10.1002/pros.22775
   Niu Rui-Fang, 2002, Ai Zheng, V21, P71
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Quinones A, 2003, LIFE SCI, V72, P2975, DOI 10.1016/S0024-3205(03)00230-3
   Recio JA, 2003, CANCER RES, V63, P1576
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Rodriguez-Nieto S, 2006, CURR PHARM DESIGN, V12, P4411, DOI 10.2174/138161206779010495
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sui H, 2014, ONCOL RES TREAT, V37, P584, DOI 10.1159/000367802
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Xu ZY, 2015, INT J BIOL SCI, V11, P284, DOI 10.7150/ijbs.10248
   Yanamoto S, 2014, INT J ONCOL, V44, P1153, DOI 10.3892/ijo.2014.2289
   Zaanan A, 2015, INT J CANCER, V137, P1498, DOI 10.1002/ijc.29496
   Zlobec I, 2009, HISTOPATHOLOGY, V55, P564, DOI 10.1111/j.1365-2559.2009.03421.x
NR 48
TC 45
Z9 46
U1 1
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2016
VL 37
IS 7
BP 8811
EP 8824
DI 10.1007/s13277-015-4755-6
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU4HU
UT WOS:000382174500032
PM 26747179
DA 2022-04-25
ER

PT J
AU Yu, HL
   Huang, Y
   Ge, YM
   Hong, XP
   Lin, X
   Tang, KX
   Wang, Q
   Yang, Y
   Sun, WM
   Huang, YQ
   Luo, H
AF Yu, Hailing
   Huang, Yin
   Ge, Yanming
   Hong, Xiaopeng
   Lin, Xi
   Tang, Kexin
   Wang, Qiang
   Yang, Yang
   Sun, Weiming
   Huang, Yongquan
   Luo, Hui
TI Selenite-induced ROS/AMPK/FoxO3a/GABARAPL-1 signaling pathway modulates
   autophagy that antagonize apoptosis in colorectal cancer cells
SO DISCOVER ONCOLOGY
LA English
DT Article
DE AMPK; Apoptosis; Autophagy; FoxO3a; Selenite
ID SWITCHES AUTOPHAGY; MEDIATED CLEAVAGE; AMPK; DEGRADATION; INHIBITION;
   ACTIVATION; AMBRA1; FLUX
AB Previous studies have shown that selenium possessed chemotherapeutic effect against multiple malignant cancers, inducing diverse stress responses including apoptosis and autophagy. Selenite was previously shown to induce apoptosis and autophagy in colorectal cancer cells. However, the relationship between selenite-induced apoptosis and autophagy was not fully understood. Our results revealed a pro-survival role of selenite-induced autophagy against apoptosis in colorectal cancer cells. Real-time PCR array of autophagy-related genes showed that GABARAPL-1 was significantly upregulated in colorectal cancer cells, which was confirmed by western blot and immunofluorescence results. Knockdown of GABARAPL-1 significantly inhibited selenite-induced autophagy and enhanced apoptosis. Furthermore, we found that selenite-induced upregulation of GABARAPL-1 was caused by upregulated p-AMPK and FoxO3a level. Their interaction was correlated with involved in regulation of GABARAPL-1. We observed that activation and inhibition of AMPK influenced both autophagy and apoptosis level via FoxO3a/ GABARAPL-1 signaling, implying the pro-survival role of autophagy against apoptosis. Importantly, we corroborated these findings in a colorectal cancer xenograft animal model with immunohistochemistry and western blot results. Collectively, these results show that sodium selenite could induce ROS/AMPK/FoxO3a/GABARAPL-1-mediated autophagy and downregulate apoptosis in both colorectal cancer cells and colon xenograft model. These findings help to explore sodium selenite as a potential anti-cancer drug in clinical practices.
C1 [Yu, Hailing; Lin, Xi; Tang, Kexin; Sun, Weiming; Luo, Hui] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.
   [Yu, Hailing; Lin, Xi; Tang, Kexin; Sun, Weiming; Luo, Hui] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.
   [Wang, Qiang] Chongqing Jiaotong Univ, Green Aerotech Res Inst, Chongqing, Peoples R China.
   [Huang, Yin] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Cardiol, Zhuhai, Guangdong, Peoples R China.
   [Ge, Yanming] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Pharm, Zhuhai, Guangdong, Peoples R China.
   [Hong, Xiaopeng] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Hepatobiliary Surg, Zhuhai, Guangdong, Peoples R China.
   [Yang, Yang] Peking Union Med Coll, Inst Basic Med Sci, Beijing, Peoples R China.
   [Huang, Yongquan] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Ultrasound, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.
RP Luo, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.; Luo, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.; Huang, YQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Ultrasound, 52 Meihua Dong Rd, Zhuhai, Guangdong, Peoples R China.
EM huangyq39@mail.sysu.edu.cn; luoh53@mail.sysu.edu.cn
FU Guangdong Basic and Applied Basic Research Foundation [2015A030310479,
   2020A1515011001]; Guangdong Basic and Applied Basic Research Fund
   Regional Joint Fund-Youth Fund Project [2019A1515110457]
FX This work was supported by the Guangdong Basic and Applied Basic
   Research Foundation (2015A030310479 and 2020A1515011001), the Guangdong
   Basic and Applied Basic Research Fund Regional Joint Fund-Youth Fund
   Project (2019A1515110457).
CR Antonioli M, 2021, AUTOPHAGY, V17, P2842, DOI [10.1080/15548627.2020.1847444, 10.6084/m9.figshare.13220222.v3]
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Boyer-Guittaut M, 2014, AUTOPHAGY, V10, P986, DOI 10.4161/auto.28390
   Buzun K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115804
   Carlisle AE, 2020, NAT METAB, V2, P603, DOI 10.1038/s42255-020-0224-7
   Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004
   Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135
   Cianfanelli V, 2015, CELL CYCLE, V14, P959, DOI 10.1080/15384101.2015.1021526
   Felzen V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.181
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013
   Hiebel C, 2014, J NEUROCHEM, V131, P484, DOI 10.1111/jnc.12839
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Hurley JH, 2014, CELL, V157, P300, DOI 10.1016/j.cell.2014.01.070
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Jiang QA, 2011, MOL BIOL CELL, V22, P1167, DOI 10.1091/mbc.E10-10-0860
   Jin ZS, 2014, MOL MED REP, V10, P3099, DOI 10.3892/mmr.2014.2664
   Kralova V, 2012, TOXICOL IN VITRO, V26, P258, DOI 10.1016/j.tiv.2011.12.010
   Lee K, 2015, BIOCHEM BIOPH RES CO, V466, P289, DOI 10.1016/j.bbrc.2015.08.126
   Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3
   Nho Richard Seonghun, 2014, World J Biol Chem, V5, P346, DOI 10.4331/wjbc.v5.i3.346
   Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27
   Rozenknop A, 2011, J MOL BIOL, V410, P477, DOI 10.1016/j.jmb.2011.05.003
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Shi K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.34
   Sica V, 2015, MOL CELL, V59, P522, DOI 10.1016/j.molcel.2015.07.021
   Tooze SA, 2016, CELL, V167, P1433, DOI 10.1016/j.cell.2016.11.023
   Wang HZ, 2015, P NATL ACAD SCI USA, V112, P7015, DOI 10.1073/pnas.1507263112
   Wu P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.13
   Yang Y, 2016, ONCOL REP, V35, P1255, DOI 10.3892/or.2015.4484
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu L, 2020, CELL RES, V30, P553, DOI 10.1038/s41422-020-0361-2
   Yung MMH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-327
   Zhang YQ, 2011, CELL PHYSIOL BIOCHEM, V27, P503, DOI 10.1159/000329952
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 37
TC 0
Z9 0
U1 8
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1868-8497
EI 2730-6011
J9 DISCOV ONCOL
JI Discov. Oncol.
PD SEP 24
PY 2021
VL 12
IS 1
AR 35
DI 10.1007/s12672-021-00427-4
PG 12
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA UU6ZX
UT WOS:000698946700001
PM 35201430
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Hu, FQ
   Li, G
   Huang, CS
   Hou, ZL
   Yang, X
   Luo, XL
   Feng, YD
   Wang, GH
   Hu, JB
   Cao, ZX
AF Hu, Fuqing
   Li, Geng
   Huang, Changsheng
   Hou, Zhenlin
   Yang, Xi
   Luo, Xuelai
   Feng, Yongdong
   Wang, Guihua
   Hu, Junbo
   Cao, Zhixin
TI The autophagy-independent role of BECN1 in colorectal cancer metastasis
   through regulating STAT3 signaling pathway activation
SO CELL DEATH & DISEASE
LA English
DT Article
ID BECLIN 1; BREAST-CANCER; CELL-SURVIVAL; PROMOTES; TUMORIGENESIS;
   EXPRESSION; PHOSPHORYLATION; INHIBITION; PHENOTYPE; GROWTH
AB BECN1 is a critical regulator of autophagy, which plays important roles in tumor formation and metastasis. However, the autophagy-independent role of BECN1 and the clinical prediction value of BECN1 still need to be explored. Here, we observed significantly lower expression of BECN1 in colorectal cancers (CRCs) compared with adjacent normal colon tissue, and downregulation of BECN1 was positively related to poor prognosis in CRC patients. In addition, we found that knockdown of BECN1 markedly promoted CRC cell motility and invasion. Bioinformatics gene set enrichment analysis (GSEA) revealed that low levels of BECN1 were significantly correlated with the STAT3 signaling pathway in CRC. Consistently, knockdown of BECN1 increased the phosphorylation of STAT3 and activated the STAT3 signaling pathway in CRC cells. Furthermore, we demonstrated that STAT3 was involved in the CRC metastasis mediated by knockdown of BECN1 in vitro and in vivo. Mechanistically, knockdown of BECN1 promoted the phosphorylation of STAT3 via regulation of the interaction between STAT and JAK2 but did not inhibit autophagy. Our study revealed that BECN1 served as a negative regulator of CRC metastasis by regulating STAT3 signaling pathway activation in an autophagy-independent manner. The BECN1/JAK2/STAT3 signaling pathway can be used as a potential therapeutic target for metastatic CRC.
C1 [Hu, Fuqing; Li, Geng; Huang, Changsheng; Hou, Zhenlin; Yang, Xi; Luo, Xuelai; Feng, Yongdong; Wang, Guihua; Hu, Junbo; Cao, Zhixin] Huazhong Univ Sci & Technol, Dept Gastrointestinal Surg Ctr, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China.
RP Hu, JB; Cao, ZX (corresponding author), Huazhong Univ Sci & Technol, Dept Gastrointestinal Surg Ctr, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China.
EM jbhu@tjh.tjmu.edu.cn; zxcao@tjh.tjmu.edu.cn
FU NSFCNational Natural Science Foundation of China (NSFC) [81572725,
   81802426, 81874186, 81570525]; `973' programNational Basic Research
   Program of China [2015CB553903-1]
FX We are grateful to the members of Guihua Wang's lab and Junbo Hu's lab
   for their critical input and suggestions. This work is supported by NSFC
   (No. 81572725, No. 81802426, No. 81874186, and No. 81570525) and the
   `973' program (No. 2015CB553903-1).
CR Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010
   Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706
   Chen L, 2015, BIOCHEM BIOPH RES CO, V465, P739, DOI 10.1016/j.bbrc.2015.08.070
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996
   Hamacher-Brady A, 2012, ANTIOXID REDOX SIGN, V17, P756, DOI 10.1089/ars.2011.4410
   Hill SM, 2019, CELL DEATH DIFFER, V26, P617, DOI 10.1038/s41418-018-0254-9
   Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005
   Hurley JH, 2014, CELL, V157, P300, DOI 10.1016/j.cell.2014.01.070
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470
   Menon MB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00137
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Qian X, 2017, MOL CELL, V65, P917, DOI 10.1016/j.molcel.2017.01.027
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531
   Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594
   Shen H, 2018, J CELL BIOCHEM, V119, P7022, DOI 10.1002/jcb.26912
   Singh M, 2015, ONCOTARGET, V6, P27461, DOI 10.18632/oncotarget.4742
   Stjepanovic G, 2017, MOL CELL, V67, P528, DOI 10.1016/j.molcel.2017.07.003
   Su WM, 2019, AGING-US, V11, P4587, DOI 10.18632/aging.102071
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015
   Yang J, 2005, CANCER RES, V65, P939
   Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425
   Yin Y, 2017, CLIN CANCER RES, V23, P7375, DOI 10.1158/1078-0432.CCR-17-1283
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Zhang MY, 2019, ONCOL LETT, V17, P2441, DOI 10.3892/ol.2018.9817
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
NR 42
TC 10
Z9 10
U1 3
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 1
PY 2020
VL 11
IS 5
AR 304
DI 10.1038/s41419-020-2467-3
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LL1IP
UT WOS:000531309100002
PM 32358527
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Baliou, S
   Goulielmaki, M
   Ioannou, P
   Cheimonidi, C
   Trougakos, IP
   Nagl, M
   Kyriakopoulos, AM
   Zoumpourlis, V
AF Baliou, Stella
   Goulielmaki, Maria
   Ioannou, Petros
   Cheimonidi, Christina
   Trougakos, Ioannis P.
   Nagl, Markus
   Kyriakopoulos, Anthony M.
   Zoumpourlis, Vassilis
TI Bromamine T (BAT) Exerts Stronger Anti-Cancer Properties than Taurine
   (Tau)
SO CANCERS
LA English
DT Article
DE bromamine T; taurine; colon cancer; breast cancer
AB Simple Summary
   Taurine (Tau) has been shown to inhibit cancer growth. However, the mechanisms that underlie the growth-inhibitory effects of Tau remain obscure in both colon and breast cancer. In parallel, N-bromotaurine (TauNHBr) and a stable active bromine molecule, bromamine T (BAT), appear to exert strong anti-inflammatory effects. To our knowledge, this is the first study that evaluates the anti-cancer effects of BAT and its underlying mechanisms. To gain a comprehensive picture of the cytotoxic effect of BAT on colon and breast cancer, we compared its effect with that of Tau. Our data support that BAT exerts a superior anti-cancer effect than Tau, through the induction of cell death, probably due to the activation of distinct mitogen-activated protein kinase (MAPK) family members. Interestingly, BAT inhibits colon carcinogenesis in vivo to a greater extent than Tau. Our data significantly add to the use of BAT as a novel therapeutic modality in colon and breast cancer.
   Background: Taurine (Tau) ameliorates cancer pathogenesis. Researchers have focused on the functional properties of bromamine T (BAT), a stable active bromine molecule. Both N-bromotaurine (TauNHBr) and BAT exert potent anti-inflammatory properties, but the landscape remains obscure concerning the anti-cancer effect of BAT. Methods: We used Crystal Violet, colony formation, flow cytometry and Western blot experiments to evaluate the effect of BAT and Tau on the apoptosis and autophagy of cancer cells. Xenograft experiments were used to determine the in vivo cytotoxicity of either agent. Results: We demonstrated that both BAT and Tau inhibited the growth of human colon, breast, cervical and skin cancer cell lines. Among them, BAT exerted the greatest cytotoxic effect on both RKO and MDA-MB-468 cells. In particular, BAT increased the phosphorylation of c-Jun N-terminal kinases (JNK1/2), p38 mitogen-activated protein kinase (MAPK), and extracellular-signal-regulated kinases (ERK1/2), thereby inducing mitochondrial apoptosis and autophagy in RKO cells. In contrast, Tau exerted its cytotoxic effect by upregulating JNK1/2 forms, thus triggering mitochondrial apoptosis in RKO cells. Accordingly, colon cancer growth was impaired in vivo. Conclusions: BAT and Tau exerted their anti-tumor properties through the induction of (i) mitochondrial apoptosis, (ii) the MAPK family, and iii) autophagy, providing novel anti-cancer therapeutic modalities.
C1 [Baliou, Stella; Goulielmaki, Maria; Zoumpourlis, Vassilis] Natl Hellen Res Fdn, Inst Chem Biol, Biomed Applicat Unit, 48 Vas Constantinou Ave, Athens 11635, Greece.
   [Ioannou, Petros] Univ Hosp Heraklion, Dept Internal Med & Infect Dis, Iraklion 71110, Crete, Greece.
   [Cheimonidi, Christina; Trougakos, Ioannis P.] Natl & Kapodistrian Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece.
   [Nagl, Markus] Med Univ Innsbruck, Inst Hyg & Med Microbiol, Dept Hyg Microbiol & Publ Hlth, A-6020 Innsbruck, Austria.
   [Kyriakopoulos, Anthony M.] Nasco AD Biotechnol Lab, Dept Res & Dev, 11 Sachtouri Str, Piraeus 18536, Greece.
RP Zoumpourlis, V (corresponding author), Natl Hellen Res Fdn, Inst Chem Biol, Biomed Applicat Unit, 48 Vas Constantinou Ave, Athens 11635, Greece.
EM smpaliou@eie.gr; mgoulielmaki@eie.gr; p.ioannou@med.uoc.gr;
   chrischeim@biol.uoa.gr; itrougakos@biol.uoa.gr; m.nagl@i-med.ac.at;
   antkyriak@gmail.com; vzub@eie.gr
RI ; Trougakos, Ioannis/R-6149-2018
OI Ioannou, Petros/0000-0003-1082-5674; Nagl, Markus/0000-0002-1225-9349;
   Trougakos, Ioannis/0000-0002-6179-2772
FU I.K.Y. State Scholarship Foundation for S. Baliou's Ph.D. studies
   [2018-050-0502-13155]
FX This research was supported by I.K.Y. State Scholarship Foundation for
   S. Baliou's Ph.D. studies. The IKY code is 2018-050-0502-13155.
CR Aerts L, 2002, J PERINAT MED, V30, P281, DOI 10.1515/JPM.2002.040
   Al-Asmari AK, 2016, HUM EXP TOXICOL, V35, P10, DOI 10.1177/0960327115573597
   Anand P, 2011, Pak J Biol Sci, V14, P219, DOI 10.3923/pjbs.2011.219.225
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062
   Bae IH, 2006, ONCOL REP, V15, P1175
   Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104
   Blachier F, 2020, J NUTR, V150, p2524S, DOI 10.1093/jn/nxaa243
   Blagosklonny MV, 1996, CANCER RES, V56, P1851
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chatzakos V, 2012, LIPIDS, V47, P355, DOI 10.1007/s11745-011-3639-9
   Chen JJ, 2020, EXP CELL RES, V393, DOI 10.1016/j.yexcr.2020.112060
   Chesney R W, 1985, Adv Pediatr, V32, P1
   Choi EJ, 2015, ADV EXP MED BIOL, V803, P191, DOI 10.1007/978-3-319-15126-7_17
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Das J, 2012, AMINO ACIDS, V42, P1839, DOI 10.1007/s00726-011-0904-4
   Das J, 2011, BIOCHEM PHARMACOL, V81, P891, DOI 10.1016/j.bcp.2011.01.008
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   He F, 2018, AMINO ACIDS, V50, P1749, DOI 10.1007/s00726-018-2651-2
   HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Jana A, 2017, ONCOTARGET, V8, P37377, DOI 10.18632/oncotarget.16343
   Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440
   Jong CJ, 2012, AMINO ACIDS, V42, P2223, DOI 10.1007/s00726-011-0962-7
   Kumar S, 2019, BIOMED PHARMACOTHER, V109, P1462, DOI 10.1016/j.biopha.2018.10.182
   Kyriakopoulos Anthony M, 2020, Access Microbiol, V2, pacmi000126, DOI 10.1099/acmi.0.000126
   Lee JY, 2004, BIOL PHARM BULL, V27, P1792, DOI 10.1248/bpb.27.1792
   Li H, 2019, CHINESE MED J-PEKING, V132, P948, DOI 10.1097/CM9.0000000000000162
   Ling LU, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.12
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Liu ZQ, 2018, LIBYAN J MED, V13, DOI 10.1080/19932820.2018.1500346
   Logotheti S, 2016, TRANSL RES, V173, P58, DOI 10.1016/j.trsl.2016.03.009
   Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608
   Marcinkiewicz J, 2008, EUR J DERMATOL, V18, P433, DOI 10.1684/ejd.2008.0460
   Marcinkiewicz J, 2014, AMINO ACIDS, V46, P7, DOI 10.1007/s00726-012-1361-4
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   NAIR CGR, 1978, TALANTA, V25, P525, DOI 10.1016/0039-9140(78)80089-7
   Opstad KS, 2009, BRIT J CANCER, V100, P789, DOI 10.1038/sj.bjc.6604933
   Oudit GY, 2004, CIRCULATION, V109, P1877, DOI 10.1161/01.CIR.0000124229.40424.80
   Park SH, 2006, J MED FOOD, V9, P33, DOI 10.1089/jmf.2006.9.33
   Parvez S, 2008, BASIC CLIN PHARMACOL, V102, P382, DOI 10.1111/j.1742-7843.2008.00208.x
   Redon CE, 2009, ADV SPACE RES, V43, P1171, DOI 10.1016/j.asr.2008.10.011
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Sadzuka Y, 2009, BIOL PHARM BULL, V32, P1584, DOI 10.1248/bpb.32.1584
   Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
   Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015
   She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200
   Shimizu M, 2009, ADV EXP MED BIOL, V643, P265, DOI 10.1007/978-0-387-75681-3_27
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shukla SJ, 2010, DRUG DISCOV TODAY, V15, P997, DOI 10.1016/j.drudis.2010.07.007
   Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471
   Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243
   Storr SJ, 2013, ANTIOXID REDOX SIGN, V18, P2399, DOI 10.1089/ars.2012.4920
   Sun XY, 2017, CANCER RES, V77, P926, DOI 10.1158/0008-5472.CAN-16-0987
   Tang Y, 2015, ADV EXP MED BIOL, V803, P203, DOI 10.1007/978-3-319-15126-7_18
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tu HC, 2009, P NATL ACAD SCI USA, V106, P1093, DOI 10.1073/pnas.0808173106
   Tu S, 2018, ONCOL LETT, V15, P5473, DOI 10.3892/ol.2018.8036
   Vanitha MK, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22204
   Vanitha MK, 2016, J BIOCHEM MOL TOXIC, V30, P414, DOI 10.1002/jbt.21805
   Walczewska M, 2017, ADV EXP MED BIOL, V975, P515, DOI 10.1007/978-94-024-1079-2_41
   Wang AS, 2014, NMR BIOMED, V27, P1361, DOI 10.1002/nbm.3198
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wiseman A, 2006, MED HYPOTHESES, V67, P296, DOI 10.1016/j.mehy.2006.02.013
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182
   Yang YJ, 2013, ACTA BIOCH BIOPH SIN, V45, P359, DOI 10.1093/abbs/gmt034
   Yu J, 2009, ADV EXP MED BIOL, V643, P491, DOI 10.1007/978-0-387-75681-3_51
   Zhang XL, 2015, INT J MOL MED, V35, P218, DOI 10.3892/ijmm.2014.2002
   Zhang XL, 2014, ACTA BIOCH BIOPH SIN, V46, P261, DOI 10.1093/abbs/gmu004
   Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367
NR 83
TC 1
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN
PY 2021
VL 13
IS 2
AR 182
DI 10.3390/cancers13020182
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PX1QX
UT WOS:000611138700001
PM 33430276
OA Green Published
DA 2022-04-25
ER

PT J
AU Kim, YJ
   Kang, KS
   Choi, KC
   Ko, H
AF Kim, Young-Joo
   Kang, Ki Sung
   Choi, Kyung-Chul
   Ko, Hyeonseok
TI Cardamonin induces autophagy and an antiproliferative effect through JNK
   activation in human colorectal carcinoma HCT116 cells
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Cardamonin; Autophagy; Antiproliferation; Colorectal carcinoma; p53;
   c-Jun N-terminal kinase (JNK)
ID MEDIATED UP-REGULATION; INDUCED APOPTOSIS; DOWN-REGULATION; DEATH;
   INHIBITION; INDUCTION; EXPRESSION; SURVIVAL; MTOR
AB Cardamonin (2',4'-dihydroxy-6'-methoxychalcone) is derived from Alpinia katsumadai Hayata (Zingiberaceae), a plant that has been used in Traditional Chinese Medicine for thousands of years. Several anticancer agents have been reported to induce autophagy, which either protects cells or further sensitizes cells to drug treatment. However, the possible autophagic and antiproliferative effects of cardamonin on the human colorectal carcinoma HCT116 cell line are unclear. In the present study, experiments were conducted to determine the effects of cardamonin on cell proliferation, cell cycle distribution, and stimulation of autophagy in cultures of the HCT116 cell line. The results showed that cardamonin inhibited cell proliferation, induced G2/M phase cell cycle arrest, and enhanced autophagy in HCT116 cells. We found evidence that cardamonin-induced autophagic and antiproliferative effects are regulated by the tumor protein p53. We also found that the enhanced activation of c-Jun N-terminal kinase (JNK) by cardamonin was partially regulated by p53 and was critical for cardamonin-induced autophagic and antiproliferative effects in HCT116 cells. These findings suggest that cardamonin or other anticancer agents that increase p53/JNK-dependent stimulation of autophagy could be used to effectively treat patients with colorectal carcinoma. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Kim, Young-Joo] Korea Inst Sci & Technol, Nat Prod Res Ctr, Kangnung, Gangwon Do, South Korea.
   [Kang, Ki Sung] Gachon Univ, Coll Korean Med, Songnam, South Korea.
   [Choi, Kyung-Chul] Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Choi, Kyung-Chul] Univ Ulsan, Coll Med, Dept Pharmacol, Seoul, South Korea.
   [Ko, Hyeonseok] Dankook Univ, Coll Med, Mol Oncol Lab, Cheil Gen Hosp, Seoul, South Korea.
   [Ko, Hyeonseok] Dankook Univ, Coll Med, Womens Healthcare Ctr, Seoul, South Korea.
   [Choi, Kyung-Chul] Univ Ulsan, Coll Med, CDRC, Seoul, South Korea.
RP Ko, H (corresponding author), Dankook Univ, Coll Med, Mol Oncol Lab, Cheil Gen Hosp, Seoul, South Korea.
EM drug9054@naver.com
FU Korea Institute of Science and Technology institutional program
   [2Z04381]; Basic Science Research Programs through the National Research
   Foundation of Korea - Ministry of Education, Science and Technology
   [NRF-2012R1A1A4A01014504]
FX This work was supported by the Korea Institute of Science and Technology
   institutional program (2Z04381) and Basic Science Research Programs
   through the National Research Foundation of Korea, funded by the
   Ministry of Education, Science and Technology (NRF-2012R1A1A4A01014504).
CR Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cho M, 2009, BIOCHEM BIOPH RES CO, V390, P500, DOI 10.1016/j.bbrc.2009.09.124
   Chow YL, 2012, INT IMMUNOPHARMACOL, V12, P657, DOI 10.1016/j.intimp.2012.01.009
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Elliott A, 2008, TOXICOL APPL PHARM, V232, P169, DOI 10.1016/j.taap.2008.06.017
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim YH, 2008, FREE RADICAL BIO MED, V44, P1055, DOI 10.1016/j.freeradbiomed.2007.12.001
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liao Q, 2010, EUR J PHARMACOL, V641, P179, DOI 10.1016/j.ejphar.2010.05.024
   Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107
   Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Lopez SN, 2006, PHYTOCHEMISTRY, V67, P2152, DOI 10.1016/j.phytochem.2006.06.018
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Park KJ, 2009, BIOCHEM BIOPH RES CO, V382, P726, DOI 10.1016/j.bbrc.2009.03.095
   Park MK, 2013, LIFE SCI, V92, P154, DOI 10.1016/j.lfs.2012.11.009
   Tang Y, 2014, LIFE SCI, V99, P44, DOI 10.1016/j.lfs.2014.01.066
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Yadav VR, 2012, BRIT J PHARMACOL, V165, P741, DOI 10.1111/j.1476-5381.2011.01603.x
   Zheng Wei, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2318
NR 32
TC 37
Z9 41
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 15
PY 2015
VL 25
IS 12
BP 2559
EP 2564
DI 10.1016/j.bmcl.2015.04.054
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA CJ0EL
UT WOS:000355147300022
PM 25959811
DA 2022-04-25
ER

PT J
AU Dutta, D
   Chakraborty, B
   Sarkar, A
   Chowdhury, C
   Das, P
AF Dutta, Debasmita
   Chakraborty, Biswajit
   Sarkar, Ankita
   Chowdhury, Chinmay
   Das, Padma
TI A potent betulinic acid analogue ascertains an antagonistic mechanism
   between autophagy and proteasomal degradation pathway in HT-29 cells
SO BMC CANCER
LA English
DT Article
DE Apoptosis; Autophagy; Betulinic acid analogue; Proteasomal pathway
ID CANCER-CELLS; PROTEIN; DEATH; APOPTOSIS; EXPRESSION; CLEARANCE;
   CROSSTALK; UBIQUITIN; COMPOUND; SURVIVAL
AB Background: Betulinic acid (BA), a member of pentacyclic triterpenes has shown important biological activities like anti-bacterial, anti-malarial, anti-inflammatory and most interestingly anticancer property. To overcome its poor aqueous solubility and low bioavailability, structural modifications of its functional groups are made to generate novel lead(s) having better efficacy and less toxicity than the parent compound. BA analogue, 2c was found most potent inhibitor of colon cancer cell line, HT-29 cells with IC50 value 14.9 mu M which is significantly lower than standard drug 5-fluorouracil as well as parent compound, Betulinic acid. We have studied another mode of PCD, autophagy which is one of the important constituent of cellular catabolic system as well as we also studied proteasomal degradation pathway to investigate whole catabolic pathway after exploration of 2c on HT-29 cells.
   Methods: Mechanism of autophagic cell death was studied using fluorescent dye like acridine orange (AO) and monodansylcadaverin (MDC) staining by using fluorescence microscopy. Various autophagic protein expression levels were determined by Western Blotting, qRT-PCR and Immunostaining. Confocal Laser Scanning Microscopy (CLSM) was used to study the colocalization of various autophagic proteins. These were accompanied by formation of autophagic vacuoles as revealed by FACS and transmission electron microscopy (TEM). Proteasomal degradation pathway was studied by proteasome-Glo (TM) assay systems using luminometer.
   Results: The formation of autophagic vacuoles in HT-29 cells after 2c treatment was determined by fluorescence staining - confirming the occurrence of autophagy. In addition, 2c was found to alter expression levels of different autophagic proteins like Beclin-1, Atg 5, Atg 7, Atg 5-Atg 12, LC3B and autophagic adapter protein, p62. Furthermore we found the formation of autophagolysosome by colocalization of LAMP 1 with LC3B, LC3B with Lysosome, p62 with lysosome. Finally, as proteasomal degradation pathway downregulated after 2c treatment colocalization of ubiquitin with lysosome and LC3B with p62 was studied to confirm that protein degradation in autophagy induced HT-29 cells follows autolysosomal pathway.
   Conclusions: In summary, betulinic acid analogue, 2c was able to induce autophagy in HT-29 cells and as proteasomal degradation pathway downregulated after 2c treatment so protein degradation in autophagy induced HT-29 cells follows autolysosomal pathway.
C1 [Dutta, Debasmita; Sarkar, Ankita; Das, Padma] Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, Kolkata 700032, India.
   [Chakraborty, Biswajit; Chowdhury, Chinmay] Indian Inst Chem Biol, CSIR, Organ & Med Chem Div, Kolkata 700032, India.
RP Das, P (corresponding author), Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
EM padmadas2005@yahoo.co.in
OI Dutta, Debasmita/0000-0003-0235-4649
FU CSIR-Indian Institute of Chemical Biology through CSIR-Network Project
   TREAT [BSC-0116]
FX This research work is financially supported by CSIR-Indian Institute of
   Chemical Biology through CSIR-Network Project TREAT (BSC-0116).
CR Abnosi MH, 2012, IRAN J SCI TECHNOL A, V36, P239
   Bertram John S., 2000, Molecular Aspects of Medicine, V21, P167, DOI 10.1016/S0098-2997(00)00007-8
   Bhattacharya K, 2010, BIOCHEM PHARMACOL, V79, P361, DOI 10.1016/j.bcp.2009.09.007
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chakraborty B, 2015, EUR J MED CHEM, V102, P93, DOI 10.1016/j.ejmech.2015.07.035
   Chen C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/267350
   Chiu HW, 2011, J MOL MED, V89, P927, DOI 10.1007/s00109-011-0763-1
   Chowdhury A. R., 2002, MED SCI MONITOR, V8, P254
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Eng KE, 2012, J VIROL, V86, P5674, DOI 10.1128/JVI.06581-11
   Fan WL, 2010, AUTOPHAGY, V6, P614, DOI 10.4161/auto.6.5.12189
   Fulda S, 1997, CANCER RES, V57, P4956
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Granese B, 2013, BMC MED GENET, V6, P1
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He H, 2013, J NAT PROD, V76, P880, DOI 10.1021/np400017k
   Janji B., 2013, ROLE AUTOPHAGY CANC, P189, DOI DOI 10.5772/55388
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Li Y, 2011, CANCER RES, V71, P7481, DOI 10.1158/0008-5472.CAN-11-0940
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Lim J, 2011, AUTOPHAGY, V7, P51, DOI 10.4161/auto.7.1.13909
   Martinez-Lopez M, 2013, NAT COMMUN, V4, P1
   Mathivanan N., 2005, INT J NONI RES, V1, P1
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mitroulis I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029318
   Nag TC, 2009, ANN ANAT, V191, P556, DOI 10.1016/j.aanat.2009.08.004
   Nascimento GGF, 2000, BRAZ J MICROBIOL, V31, P247
   Owolabi OJ, 2007, AFR J BIOTECHNOL, V6, P582
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90
   Roy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071672
   Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   Thurnher D, 2003, HEAD NECK-J SCI SPEC, V25, P732, DOI 10.1002/hed.10231
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   Williams RT, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-57
   World Health Organization (WHO), 1993, HERBAL GRAM, V28, P13
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
NR 50
TC 26
Z9 28
U1 1
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 16
PY 2016
VL 16
AR 23
DI 10.1186/s12885-016-2055-1
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DA8SX
UT WOS:000368077500001
PM 26772983
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Qiao, PF
   Yao, L
   Zeng, ZL
AF Qiao, Peng-Fei
   Yao, Lei
   Zeng, Zhao-Lin
TI Catalpol-mediated microRNA-34a suppresses autophagy and malignancy by
   regulating SIRT1 in colorectal cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE colorectal cancer; catalpol; autophagy; miR-34a; SIRT1
ID FACILITATES APOPTOSIS; INHIBITS MIGRATION; COLON-CANCER; KAPPA-B; CELLS;
   PROLIFERATION; INFLAMMATION; EXPRESSION; REPRESSION; RESISTANCE
AB Colorectal cancer (CRC) is one of the most common digestive tract tumors worldwide. Catalpol exerts inhibitory effects on the progression of several cancer types by regulating microRNAs (miRs). However, the precise role and carcinostatic mechanism of catalpol on CRC cells are poorly understood which limits the application of catalpol treatment. In the present study, miR-34a and sirtuin 1 (SIRT1) expression levels were detected in CRC tissues and CRC cell lines by RT-qPCR. Computational software analysis, luciferase assays and western blotting were used to demonstrate the downstream target of miR-34a in CRC cells. Effects of catalpol on cell viability, apoptosis, autophagic flux and the miR-34a/SIRT1 axis in the CRC cells were assessed by CCK-8 assay, flow cytometry, electron microscopy and western blotting, respectively. Whether the miR-34a/SIRT1 axis participated in catalpol-mediated autophagy and apoptosis was investigated. The effects of catalpol on the miR-34a/SIRT1 axis and malignant behavior were evaluated in a rat model of azoxymethane (AOM)-induced CRC. It was revealed that miR-34a expression levels were significantly decreased while SIRT1 was overexpressed in most of the CRC tissues and all the CRC cell lines. Clinically, a low level of miR-34a was correlated with poor clinicopathological characteristics in CRC patients. Catalpol reduced cell viability, suppressed autophagy, promoted apoptosis, and regulated the expression of SIRT1 by inducing miR-34a in vitro and in vivo. The autophagy-inhibiting effect of catalpol may be a mechanism to promote apoptosis of CRC cells. miR-34a mimic transfection resulted in autophagy-suppressive activity similar to that of catalpol, while the miR-34a inhibitor attenuated the antiautophagic effects of catalpol. In conclusion, miR-34a is involved in regulating catalpol-mediated autophagy and malignant behavior by directly inhibiting SIRT1 in CRC.
C1 [Qiao, Peng-Fei; Yao, Lei; Zeng, Zhao-Lin] Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, Harbin 150086, Heilongjiang, Peoples R China.
RP Yao, L (corresponding author), Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, Harbin 150086, Heilongjiang, Peoples R China.
EM oppoigod@sina.com
FU Heilongjiang Postdoctoral Funds for Scientific Research Initiation
   [LBH-Q17129]; Science Foundation of the Health Commission of
   Heilongjiang Province [2018346]
FX The present study was supported by Heilongjiang Postdoctoral Funds for
   Scientific Research Initiation (LBH-Q17129) and the Science Foundation
   of the Health Commission of Heilongjiang Province (2018346).
CR Crespo I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050407
   Dong JY, 2019, PHARMACOL RES, V144, P66, DOI 10.1016/j.phrs.2019.04.010
   Fang CY, 2017, CANCER LETT, V410, P50, DOI 10.1016/j.canlet.2017.09.012
   Gao N, 2014, INT J MOL SCI, V15, P19394, DOI 10.3390/ijms151119394
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Lai MG, 2015, MOL MED REP, V11, P3301, DOI 10.3892/mmr.2015.3182
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li DQ, 2006, BRAIN RES, V1115, P179, DOI 10.1016/j.brainres.2006.07.063
   Liu C, 2015, MOL MED REP, V12, P7609, DOI 10.3892/mmr.2015.4361
   Liu L, 2017, ONCOL LETT, V14, P3741, DOI 10.3892/ol.2017.6580
   Liu ZG, 2018, BIOMED PHARMACOTHER, V103, P1262, DOI 10.1016/j.biopha.2018.04.156
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Qiao PF, 2015, WORLD J GASTROENTERO, V21, P12822, DOI 10.3748/wjg.v21.i45.12822
   Qiao PF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1359-x
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Sun LH, 2017, AUTOPHAGY, V13, P703, DOI 10.1080/15548627.2017.1280217
   Wang Y, 2019, DRUG DES DEV THER, V13, P243, DOI 10.2147/DDDT.S188968
   Wang ZH, 2018, BIOMED PHARMACOTHER, V103, P1708, DOI 10.1016/j.biopha.2018.03.094
   Wittekind, 2009, TNM CLASSIFICATION M
   Xiong YJ, 2017, PHARMACOL RES, V123, P73, DOI 10.1016/j.phrs.2017.05.030
   Xu Y, 2019, ONCOL REP, V42, P2355, DOI 10.3892/or.2019.7350
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Zhang HG, 2018, ONCOTARGET, V9, P3887, DOI 10.18632/oncotarget.23242
   Zhang XL, 2007, PHARMACOL BIOCHEM BE, V88, P64, DOI 10.1016/j.pbb.2007.07.004
   Zhou J, 2015, BIOCHEM BIOPH RES CO, V467, P853, DOI 10.1016/j.bbrc.2015.10.054
   Zhu PT, 2017, BIOMED PHARMACOTHER, V95, P68, DOI 10.1016/j.biopha.2017.08.049
NR 29
TC 10
Z9 10
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD APR
PY 2020
VL 43
IS 4
BP 1053
EP 1066
DI 10.3892/or.2020.7494
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LA1ZN
UT WOS:000523753100003
PM 32323786
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Liu, Y
   Zhang, Y
   Zou, JL
   Yan, LX
   Yu, XF
   Lu, P
   Wu, XN
   Li, QZ
   Gu, R
   Zhu, DL
AF Liu, Ying
   Zhang, Yan
   Zou, Jilong
   Yan, Lixin
   Yu, Xiufeng
   Lu, Peng
   Wu, Xiaonneng
   Li, Qiaozhi
   Gu, Rui
   Zhu, Daling
TI Andrographolide Induces Autophagic Cell Death and Inhibits Invasion and
   Metastasis of Human Osteosarcoma Cells in An Autophagy-Dependent Manner
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Andrographolide; Autophagy; Apoptosis; Epithelial-mesenchymal
   transition; Osteosarcoma
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLON-CANCER CELLS; NF-KAPPA-B;
   SIGNALING PATHWAY; CYCLE ARREST; LUNG-CANCER; IN-VITRO; SILICA
   NANOPARTICLES; SINGLE-INSTITUTION; DOWN-REGULATION
AB Background/Aims: Osteosarcoma (OS) is the most common primary malignant tumor of bone tissue. Although treatment effectiveness has improved, the OS survival rate has fluctuated in recent years. Andrographolide (AG) has been reported to have antitumor activity against a variety of tumors. Our aim was to investigate the effects and potential mechanisms of AG in human osteosarcoma. Methods: Cell viability and morphological changes were assessed by MTT and live/dead assays. Apoptosis was detected using Annexin V-FITC/PI double staining, DAPI, and caspase-3 assays. Autophagy was detected with mRFP-GFP-LC3 adenovirus transfection and western blot. Cell migration and invasion were detected by wound healing assay and Transwell (R) experiments. Results: AG dose-dependently reduced the viability of osteosarcoma cells. No increase in apoptosis was detected in AG-treated human OS MG63 and U-2OS cells, and the pan-caspase inhibitor z-VAD did not attenuate AG-induced cell death. However, AG induced autophagy by suppressing PI3K/Akt/mTOR and enhancing JNK signaling pathways. 3-MA and Beclin-1 siRNA could reverse the cytotoxic effects of AG. In addition, AG inhibited the invasion and metastasis of OS, and this effect could be reversed with Beclin-1 siRNA. Conclusion: AG inhibits viability and induces autophagic death in OS cells. AG-induced autophagy inhibits the invasion and metastasis of OS. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Liu, Ying; Yan, Lixin; Yu, Xiufeng; Gu, Rui; Zhu, Daling] Harbin Med Univ, Key Lab Heilongjiang Prov, Dept Biopharmaceut, Harbin, Heilongjiang, Peoples R China.
   [Liu, Ying; Yan, Lixin; Yu, Xiufeng; Gu, Rui; Zhu, Daling] Harbin Med Univ, Dept Biopharmaceut Sci, Daqing, Heilongjiang, Peoples R China.
   [Zhang, Yan; Zou, Jilong] Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed, Harbin, Heilongjiang, Peoples R China.
   [Yu, Xiufeng] Harbin Med Univ Daqing, Coll Med Lab Sci & Technol, Daqing, Heilongjiang, Peoples R China.
   [Lu, Peng] Baoquanling Cent Hosp, Dept Orthopaed, Baoquanling, Heilongjiang, Peoples R China.
   [Wu, Xiaonneng] Mudanjiang Med Univ, Affiliated Hosp 2, Dept Pharm, Mudanjiang, Heilongjiang, Peoples R China.
   [Li, Qiaozhi] Harbin Med Univ, Coll Pharm, Dept Pharmaceut Anal & Analyt Chem, Harbin, Heilongjiang, Peoples R China.
RP Zhu, DL (corresponding author), Harbin Med Univ, Coll Pharm, Dept Biopharmaceut Sci, Xinyang Rd, Daqing, Heilongjiang, Peoples R China.
EM dalingz@yahoo.com
OI daling, Zhu/0000-0001-9763-9772; Zou, Jilong/0000-0002-8037-5077
FU Youth Science Foundation of Heilongjiang Province [QC2016111]; China
   Postdoctoral Sciences FoundationChina Postdoctoral Science Foundation
   [2016M591557]; Postdoctoral Foundation of Heilongjiang Province
   [LBH-Z16241]
FX This work was supported by the Youth Science Foundation of Heilongjiang
   Province (Contract grant number: QC2016111to X.Y); China Postdoctoral
   Sciences Foundation Funded Project:(Contract grant number: 2016M591557
   to X.Y); Postdoctoral Foundation of Heilongjiang Province (Contract
   grant number: LBH-Z16241 to X.Y)
CR Abu-Ghefreh AA, 2009, INT IMMUNOPHARMACOL, V9, P313, DOI 10.1016/j.intimp.2008.12.002
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Al-Sadoon MK, 2013, CELL IMMUNOL, V284, P129, DOI 10.1016/j.cellimm.2013.07.016
   Al-Sadoon MK, 2012, CELL PHYSIOL BIOCHEM, V30, P653, DOI 10.1159/000341446
   Ayan I, 2009, CANCER TREAT RES, V152, P319, DOI 10.1007/978-1-4419-0284-9_17
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Banerjee A, 2017, ONCOTARGET, V8, P26142, DOI 10.18632/oncotarget.15393
   Banerjee A, 2016, ONCOTARGET, V7, P41432, DOI 10.18632/oncotarget.9180
   Butler DE, 2017, ONCOTARGET, V8, P56698, DOI 10.18632/oncotarget.18082
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chao HP, 2010, PLANTA MED, V76, P1827, DOI 10.1055/s-0030-1250039
   Chen GN, 2016, CELL PHYSIOL BIOCHEM, V38, P598, DOI 10.1159/000438653
   Chen JX, 2009, BIOL PHARM BULL, V32, P1385, DOI 10.1248/bpb.32.1385
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Faisham WI, 2017, ASIA-PAC J CLIN ONCO, V13, pE104, DOI 10.1111/ajco.12346
   Fekadu J, 2016, MOL NEUROBIOL, V53, P5500, DOI 10.1007/s12035-015-9453-2
   Harjotaruno S, 2007, AFR J TRADIT COMPLEM, V4, P345
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He ZJ, 2017, FOOD CHEM TOXICOL, V101, P55, DOI 10.1016/j.fct.2017.01.002
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hsieh MJ, 2015, ONCOTARGET, V6, P30831, DOI 10.18632/oncotarget.5036
   Hsu YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152770
   Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kim KW, 2013, AUTOPHAGY, V9, P1579, DOI 10.4161/auto.25987
   Kumar S, 2012, CURR MOL MED, V12, P952, DOI 10.2174/156652412802480826
   Lee YC, 2010, EUR J PHARMACOL, V632, P23, DOI 10.1016/j.ejphar.2010.01.009
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li Guo-Dong, 2009, Ai Zheng, V28, P445
   Liao HF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185021
   Liu RH, 2017, CELL PHYSIOL BIOCHEM, V41, P451, DOI 10.1159/000456598
   Luo WM, 2013, EXP THER MED, V6, P743, DOI 10.3892/etm.2013.1196
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Micalizzi DS, 2009, FUTURE ONCOL, V5, P1129, DOI 10.2217/FON.09.94
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Seibel NL, 2007, CANCER, V109, P1646, DOI 10.1002/cncr.22553
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shang YJ, 2013, ONCOL LETT, V6, P490, DOI 10.3892/ol.2013.1410
   Shen J, 2017, CELL PHYSIOL BIOCHEM, V42, P1789, DOI 10.1159/000479458
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun Y, 2010, CANCER LETT, V294, P204, DOI 10.1016/j.canlet.2010.02.001
   Tu YS, 2014, J MICROENCAPSUL, V31, P307, DOI 10.3109/02652048.2013.843727
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang L, 2016, CELL PHYSIOL BIOCHEM, V38, P2173, DOI 10.1159/000445573
   Wang ZL, 2010, BIOORGAN MED CHEM, V18, P4269, DOI 10.1016/j.bmc.2010.04.094
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Yang C, 2016, CELL PHYSIOL BIOCHEM, V40, P146, DOI 10.1159/000452532
   Yu L, 2014, ONCOL LETT, V7, P239, DOI 10.3892/ol.2013.1692
   Zhao F, 2008, J ASIAN NAT PROD RES, V10, P473, DOI 10.1080/10286020801948599
   Zhou J, 2010, BIOCHEM PHARMACOL, V79, P1242, DOI 10.1016/j.bcp.2009.12.014
   Zuo DQ, 2017, J CELL MOL MED, V21, P208, DOI 10.1111/jcmm.12957
NR 55
TC 15
Z9 15
U1 2
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 4
BP 1396
EP 1410
DI 10.1159/000485536
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FQ8KW
UT WOS:000418612700012
PM 29197865
OA gold
DA 2022-04-25
ER

PT J
AU Mouratidis, PXE
   Rivens, I
   ter Haar, G
AF Mouratidis, Petros X. E.
   Rivens, Ian
   ter Haar, Gail
TI A study of thermal dose-induced autophagy, apoptosis and necroptosis in
   colon cancer cells
SO INTERNATIONAL JOURNAL OF HYPERTHERMIA
LA English
DT Article
DE Apoptosis; autophagy; high intensity focused ultrasound; necroptosis;
   thermal dose
ID INTENSITY FOCUSED ULTRASOUND; HOMOLOGOUS RECOMBINATION; THERAPEUTIC
   APPLICATIONS; PROSTATE-CANCER; HYPERTHERMIA; NECROSIS; AGGREGATION;
   INHIBITION; MECHANISMS; PATHWAYS
AB Purpose: The pleiotropic effects of heat on cancer cells have been well documented. The biological effects seen depend on the temperature applied, and the heating duration. In this study we investigate the cytotoxic effects of heat on colon cancer cells and determine how different cell death processes such as autophagy, apoptosis and necroptosis play a role in cell response.
   Materials and methods: The thermal dose concept was used to provide a parameter that will allow comparison of different thermal treatments. Two human colon cancer cell lines, HCT116 and HT29, were subjected to ablative temperatures using a polymerase chain reaction thermal cycler. Temperature was recorded using thermocouples. Cell viability was assessed using the MTT assay. Induction of apoptosis was estimated using an enzyme-linked immunosorbent assay that detects cleaved cytoplasmic nucleosomes. Protein regulation was determined using immunoblotting. The percentage of cells undergoing apoptosis and autophagy was determined with annexin V/propidium iodide staining and a cationic amphiphilic tracer using fluorescence-activated cell sorting analysis.
   Results: Exposure of colon cancer cells to ablative thermal doses results in decreased cell viability. The cytotoxic effect of heat is associated with induction of apoptosis and autophagy, the amount depending on both the thermal dose applied and on the time elapsed after treatment. Autophagy induction is mainly seen in live cells. RIPK3 protein levels are increased after exposure of cells to heat. A necroptosis inhibitor does not affect cell viability.
   Conclusions: Autophagy, apoptosis and necroptosis are associated with the response of these cancer cell lines to supra-normal temperatures.
C1 [Mouratidis, Petros X. E.; Rivens, Ian; ter Haar, Gail] Royal Marsden Hosp, Joint Dept Phys, Div Radiotherapy & Imaging, Inst Canc Res, London SW3 6JJ, England.
RP Mouratidis, PXE (corresponding author), Royal Marsden Hosp, Joint Dept Phys, Div Radiotherapy & Imaging, Inst Canc Res London, Downs Rd, Sutton SM2 5NG, Surrey, England.
EM petros.mouratidis@icr.ac.uk
OI ter Haar, Gail/0000-0001-8909-0775
FU European Association of National Metrology Institutes (EURAMET);
   EUEuropean Commission [HLT03-REG2, HLT03 DUTy]; EPSRCUK Research &
   Innovation (UKRI)Engineering & Physical Sciences Research Council
   (EPSRC) [EP/F029217/1, EP/H046526/1] Funding Source: UKRI; Cancer
   Research UKCancer Research UK [16464] Funding Source: researchfish;
   Engineering and Physical Sciences Research CouncilUK Research &
   Innovation (UKRI)Engineering & Physical Sciences Research Council
   (EPSRC) [EP/H046526/1, EP/F029217/1] Funding Source: researchfish
FX This study was funded by the European Association of National Metrology
   Institutes (EURAMET) and the EU (Grant No.: HLT03-REG2; HLT03 DUTy). The
   authors alone are responsible for the content and writing of the paper.
CR Aptel F, 2012, INT J HYPERTHER, V28, P405, DOI 10.3109/02656736.2012.665566
   ASHFORD TP, 1962, J CELL BIOL, V12, P198, DOI 10.1083/jcb.12.1.198
   Barqawi AB, 2008, ONCOLOGY-NY, V22, P123
   Bergs JWJ, 2013, DNA REPAIR, V12, P38, DOI 10.1016/j.dnarep.2012.10.008
   Cancer Research UK, 2014, CANC STATS CANC STAT
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672
   Csoboz B, 2013, INT J HYPERTHER, V29, P491, DOI 10.3109/02656736.2013.808765
   HAYAT H, 1986, International Journal of Hyperthermia, V2, P369, DOI 10.3109/02656738609004967
   Hsu SF, 2013, INT J HYPERTHER, V29, P239, DOI 10.3109/02656736.2013.777853
   Illing R, 2007, INT J HYPERTHER, V23, P183, DOI 10.1080/02656730601173037
   Ito A, 2006, CANCER IMMUNOL IMMUN, V55, P320, DOI 10.1007/s00262-005-0049-y
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jenne JW, 2012, Z MED PHYS, V22, P311, DOI 10.1016/j.zemedi.2012.07.001
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108
   Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lepock JR, 2004, INT J HYPERTHER, V20, P115, DOI 10.1080/02656730310001637334
   Leslie TA, 2007, INT J HYPERTHER, V23, P173, DOI 10.1080/02656730601150514
   Li S, 2013, CHIN J CANCER, V32, P441, DOI 10.5732/cjc.012.10104
   Luigi M, 2013, WORLD J GASTROENTERO, V19, P7494, DOI 10.3748/wjg.v19.i43.7494
   Lynn John G., 1942, JOUR GEN PHYSIOL, V26, P179, DOI 10.1085/jgp.26.2.179
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Mouratidis PXE, 2014, ANTI-CANCER AGENT ME, V14, P1169, DOI 10.2174/1871520614666140623123006
   Nagarsekar A, 2012, AM J RESP CELL MOL, V47, P824, DOI 10.1165/rcmb.2012-0105OC
   Park H, 2008, INT J HYPERTHER, V24, P638, DOI 10.1080/02656730802253117
   Roti JLR, 1998, CELL STRESS CHAPERON, V3, P245, DOI 10.1054/csac.1998.0103
   Roti JLR, 2008, INT J HYPERTHER, V24, P3, DOI 10.1080/02656730701769841
   SAPARETO SA, 1984, INT J RADIAT ONCOL, V10, P787, DOI 10.1016/0360-3016(84)90379-1
   Serrone J, 2012, J CLIN NEUROSCI, V19, P214, DOI 10.1016/j.jocn.2011.07.003
   Takahashi A, 2004, CANCER RES, V64, P8839, DOI 10.1158/0008-5472.CAN-04-1876
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077
   ter Haar G, 2007, PROG BIOPHYS MOL BIO, V93, P111, DOI 10.1016/j.pbiomolbio.2006.07.005
   van der Kooij SM, 2012, CURR OPIN OBSTET GYN, V24, P368, DOI 10.1097/GCO.0b013e328359f10a
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   WHO, 2014, CANCER
   Zhang Y, 2011, INT J HYPERTHER, V27, P409, DOI 10.3109/02656736.2011.552087
NR 41
TC 30
Z9 31
U1 3
U2 37
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0265-6736
EI 1464-5157
J9 INT J HYPERTHER
JI Int. J. Hyperthermia
PD AUG
PY 2015
VL 31
IS 5
BP 476
EP 488
DI 10.3109/02656736.2015.1029995
PG 13
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CP6LA
UT WOS:000359997500004
PM 25974074
DA 2022-04-25
ER

PT J
AU Huang, X
   Wang, XN
   Yuan, XD
   Wu, WY
   Lobie, PE
   Wu, ZS
AF Huang, Xing
   Wang, Xiao-nan
   Yuan, Xiao-dong
   Wu, Wen-yong
   Lobie, Peter E.
   Wu, Zhengsheng
TI XIAP facilitates breast and colon carcinoma growth via promotion of p62
   depletion through ubiquitination-dependent proteasomal degradation
SO ONCOGENE
LA English
DT Article
ID APOPTOSIS PROTEINS; SIGNALING ADAPTER; AUTOPHAGY; CANCER; INHIBITOR;
   TUMORIGENESIS; BECLIN-1
AB X-linked inhibitor of apoptosis protein (XIAP) possesses a critical role in promotion of cell survival and maintenance of cellular homeostasis. In cancer, elevated XIAP expression has been associated with malignancy, poor prognosis, and treatment resistance. However, the underlying mechanisms of these effects remain unclear. XIAP has previously been proposed to promote tumor growth through suppression of autophagy. In this study, we examined the expression of XIAP and p62, two critical mediators of autophagy, in breast and colon cancer. We observed a negative correlation between XIAP and p62 expression in normal and cancer tissues of breast and colon, and that the ratio of XIAP and p62 expression determines the cancer phenotype. In vitro, we observed that XIAP interacted with p62 and also that XIAP depletion resulted in increased expression of p62. XIAP functioned as an ubiquitination E3 ligase towards p62 and suppressed p62 expression through ubiquitin-proteasomal degradation. Furthermore, XIAP enhanced cancer cell proliferation, viability, and colony formation in vitro via suppression of p62. In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo. Herein, we have therefore delineated a novel mechanism by which XIAP contributes to development and progression of breast and colon carcinoma.
C1 [Huang, Xing] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Xiao-nan; Yuan, Xiao-dong; Wu, Zhengsheng] Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China.
   [Huang, Xing] Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China.
   [Wu, Wen-yong] Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China.
   [Lobie, Peter E.] Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen, Guangdong, Peoples R China.
RP Huang, X (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China.; Wu, ZS (corresponding author), Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China.; Huang, X (corresponding author), Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China.
EM dr.huangxing@foxmail.com; woozson@yahoo.com
RI 黄, 星/AAB-2241-2019
OI 黄, 星/0000-0002-8886-2777; Wu, Zhengsheng/0000-0002-6616-2745
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81502975, 81472493, 81572305]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2016T90413, 2015M581693]; Jiangsu Planned Projects for Postdoctoral
   Research Funds [1501002A]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2242016R20027, 2242016K41045]; Anhui provincial academic and technical
   leader reserve candidate [2016H074]; Key Program of Outstanding Young
   Talents in Higher Education Institutions of Anhui [gxyqZD2016046];
   Shenzhen Development and Reform Commission Subject Construction Project
   [[2017]1434]
FX We deeply thank Dr. Bert Vogelstein (Johns Hopkins University) for
   XIAP<SUP>-/-</SUP> HCT116 and XIAP<SUP>-/-</SUP> DLD1 cell lines, Dr.
   Noboru Mizushima (The University of Tokyo) for Atg5<SUP>-/-</SUP> MEF
   cell lines, and Dr. Tao Zhu (University of Science & Technology of
   China) for breast cell lines. Especially, the author Xing Huang would
   like to express deepest thanks to Dr. Mian Wu (University of Science &
   Technology of China) for the technological training and ideological
   inspiration in his lab. This work was supported by grants from National
   Natural Science Foundation of China (81502975, 81472493, and 81572305),
   and China Postdoctoral Science Foundation (2016T90413 and 2015M581693).
   The research was funded in part by Jiangsu Planned Projects for
   Postdoctoral Research Funds (1501002A), Fundamental Research Funds for
   the Central Universities (2242016R20027 and 2242016K41045), Anhui
   provincial academic and technical leader reserve candidate (#2016H074),
   Key Program of Outstanding Young Talents in Higher Education
   Institutions of Anhui (#gxyqZD2016046) and the Shenzhen Development and
   Reform Commission Subject Construction Project ([2017]1434).
CR Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472
   Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Hung TH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012202
   Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3
   Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474
   Kong DK, 2010, MOL BIOL CELL, V21, P1335, DOI 10.1091/mbc.E09-09-0818
   LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302
   Lee HM, 2011, J IMMUNOL, V186, P1248, DOI 10.4049/jimmunol.1001954
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Merlo P, 2013, EMBO J, V32, P2187, DOI 10.1038/emboj.2013.152
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Pandey V, 2010, ENDOCRINOLOGY, V151, P909, DOI 10.1210/en.2009-0979
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Wu WY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0108-3
NR 32
TC 16
Z9 17
U1 1
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 28
PY 2019
VL 38
IS 9
BP 1448
EP 1460
DI 10.1038/s41388-018-0513-8
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA HN1KL
UT WOS:000459945800006
PM 30275562
DA 2022-04-25
ER

PT J
AU Su, CC
AF Su, Chin-Cheng
TI Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer
   cells in vivo through downregulation of P-gp and LC3-II
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE tanshinone IIA; 5-fluorouracil; Colo205; P-glycoprotein;
   microtubule-associated protein light chain 3 II; in vivo
ID INHIBITION; EXTRACT; AUTOPHAGY; DANSHEN; VITRO; ACID
AB Traditional Chinese herbal medicines are widely accepted as an option for the treatment of colorectal cancers. Danshen (Salviae miltiorrhizae Radix) is widely prescribed in traditional Chinese medicine for cardiovascular diseases. Tanshinone IIA (Tan-HA) is extracted from Danshen. Our previous studies have shown that Tan-IIA induces apoptosis in Colo205 human colon cancer cells in vitro and in vivo. In the present study, we investigated the efficacy of Tan-IIA and 5-fluorouracil (5-FU) in a Colo205 cell xenograft model. For in vivo studies, SCID mice were engrafted with Colo205 cells and from day 10 onwards were randomly divided into 3 groups and treated with 5-FU plus Tan-IIA, 5-FU plus corn oil, and the vehicle alone. At the end of a 4-week dosing schedule, the SCID mice were sacrificed and xenograft tumors were dissected for protein western blot analysis. Our results showed that the Colo205 xenograft model co-treated with Tan-IIA plus 5-FU caused a reduction in the xenograft tumor volumes and decreased P-glycoprotein (P-gp) and microtubule-associated protein light chain 3 (LC3)-II expression compared to 5-FU alone. Based on these observations, it may be possible to develop Tan-HA plus 5-FU as therapeutic agents for human colon cancer.
C1 [Su, Chin-Cheng] Changhua Christian Hosp, Dept Surg, Changhua 50006, Changhua, Taiwan.
   [Su, Chin-Cheng] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung 40402, Taiwan.
   [Su, Chin-Cheng] Mingdao Univ, Changhua 52345, Taiwan.
RP Su, CC (corresponding author), Changhua Christian Hosp, Dept Surg, 135 Nan Hsiao St, Changhua 50006, Changhua, Taiwan.
EM succ.maeva@msa.hinet.net
FU Committee on Chinese Medicine and Pharmacy, Department of Health,
   Executive Yuan, Taiwan, R.O.C. [CCMP97-RD-041]
FX This study was supported by a grant (CCMP97-RD-041) from the Committee
   on Chinese Medicine and Pharmacy, Department of Health, Executive Yuan,
   Taiwan, R.O.C.
CR Albertsson P, 2009, ACTA ONCOL, V48, P418, DOI 10.1080/02841860802409512
   Boon H, 2004, EXPERT OPIN PHARMACO, V5, P2485, DOI 10.1517/14656566.5.12.2485
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chang PN, 2006, J PHARMACOL SCI, V101, P245, DOI 10.1254/jphs.FPJ05034X
   Chau I, 2005, ANN ONCOL, V16, P549, DOI 10.1093/annonc/mdi116
   Chen AJ, 2004, J SEP SCI, V27, P569, DOI 10.1002/jssc.200301710
   Chen HC, 2004, FOOD CHEM TOXICOL, V42, P1251, DOI 10.1016/j.fct.2004.03.002
   Department of Health Executive Yuan Taipei Taiwan R.O.C, 2008, STAT CAUS DEATH, P33
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z
   Fish JM, 2006, CIRCULATION, V113, P1393, DOI 10.1161/CIRCULATIONAHA.105.601690
   Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8
   He D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-343
   Jang SI, 2006, EUR J PHARMACOL, V542, P1, DOI 10.1016/j.ejphar.2006.04.044
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li W, 2007, J IMMUNOL, V178, P3856, DOI 10.4049/jimmunol.178.6.3856
   Lin R, 2006, J ETHNOPHARMACOL, V108, P217, DOI 10.1016/j.jep.2006.05.004
   LUM BL, 1993, PHARMACOTHERAPY, V13, P88
   Su CC, 2008, PLANTA MED, V74, P1357, DOI 10.1055/s-2008-1081299
   Su CC, 2008, INT J MOL MED, V22, P357, DOI 10.3892/ijmm_00000030
   Verhoef Marja J, 2005, Integr Cancer Ther, V4, P274, DOI 10.1177/1534735405282361
   Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023
   Wang AM, 2003, ANTIMICROB AGENTS CH, V47, P1836, DOI 10.1128/AAC.47.6.1836-1841.2003
   Wei SC, 2004, J BIOMED SCI, V11, P260, DOI 10.1159/000076038
   Xu WL, 2009, NUTRITION, V25, P555, DOI 10.1016/j.nut.2008.10.019
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
NR 28
TC 31
Z9 36
U1 1
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR
PY 2012
VL 3
IS 3
BP 555
EP 559
DI 10.3892/etm.2011.441
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 893FF
UT WOS:000300340300033
PM 22969929
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Qureshi, AA
   Zuvanich, EG
   Khan, DA
   Mushtaq, S
   Silswal, N
   Qureshi, N
AF Qureshi, Asaf A.
   Zuvanich, Eleanor G.
   Khan, Dilshad A.
   Mushtaq, Shahida
   Silswal, Neerupma
   Qureshi, Nilofer
TI Proteasome inhibitors modulate anticancer and anti-proliferative
   properties via NF-kB signaling, and ubiquitin-proteasome pathways in
   cancer cell lines of different organs
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE Potent anticancer compounds; Several cancer cell lines (Hela; Liver;
   Pancreas; Prostate; Breast; Lung; Melanoma; B-lymphocytes; T-cells;
   Inflammatory biomarkers
ID PALM OIL; LIPID-PEROXIDATION; PROTEIN OXIDATION; TOCOTRIENOLS;
   AUTOPHAGY; PHARMACOKINETICS; IDENTIFICATION; APOPTOSIS; GENES
AB Background: Cancer is second most common cause of death in the United State. There are over 100 different types of cancer associated with different human organs, predominantly breast, liver, pancreas, prostate, colon, rectum, lung, and stomach. We have recently reported properties of pro-inflammatory (for treatment of various types of cancers), and anti-inflammatory (for cardiovascular disease and diabetes) compounds. The major problem associated with development of anticancer drugs is their lack of solubility in aqueous solutions and severe side effects in cancer patients. Therefore, the present study was carried out to check anticancer properties of selected compounds, mostly aqueous soluble, in cancer cell lines from different organs.
   Methods: The anticancer properties, anti-proliferative, and pro-apoptotic activity of novel naturally occurring or FDA approved, nontoxic, proteasome inhibitors/activators were compared. In addition to that, effect of delta-tocotrienol on expression of proteasome subunits (X, Y, Z, LMP7, LMP2, LMP10), ICAM-1, VCAM-1, and TNF-alpha using total RNAs derived from plasmas of hepatitis C patients was investigated.
   Results: Our data demonstrated that following compounds are very effective in inducing apoptosis of cancer cells: Thiostrepton, dexamethasone, 2-methoxyestradiol, delta-tocotrienol, quercetin, amiloride, and quinine sulfate have significant anti-proliferation properties in Hela cells (44% - 87%) with doses of 2.5-20 mu M, compared to respective controls. Anti-proliferation properties of thiostrepton, 2-methoxyestradiol, d-tocotrienol, and quercetin were 70% - 92%. However, thiostrepton, dexamethasone, 2-methoxyestradiol, delta-tocotrienol, quercetin, and quinine sulphate were effective in pancreatic, prostate, breast, lungs, melanoma, B-lymphocytes, and T-cells (Jurkat: 40% to 95%) compared to respective controls. In lung cancer cells, these compounds were effective between 5 and 40 mu M. The IC50 values of anti-proliferation properties of thiostrepton in most of these cell lines were between doses of 2.5-5 mu M, dexamethasone 2.5-20 mu M, 2-methoxyestradiol 2.5-10 mu M, delta-tocotrienol 2.5-20 mu M, quercetin 10-40 mu M, and (-) Corey lactone 40-80 mu M. In hepatitis C patients, delta-tocotrienol treatment resulted in significant decrease in the expression of pro-inflammatory cytokines.
   Conclusions: These data demonstrate effectiveness of several natural-occurring compounds with anti-proliferative properties against cancer cells of several organs of humans. Thiostrepton, dexamethasone, 2-methoxyestradiol, delta-tocotrienol and quercetin are very effective for apoptosis of cancer cells in liver, pancreas, prostate, breast, lung, melanoma, B-lymphocytes and T-cells. The results have provided an opportunity to test these compounds either individually or in combination as dietary supplements in humans for treatment of various types of cancers.
C1 [Qureshi, Asaf A.; Zuvanich, Eleanor G.; Silswal, Neerupma; Qureshi, Nilofer] Univ Missouri Kansas City, Sch Med, Dept Basic Med Sci, 2411 Holmes St, Kansas City, MO 64108 USA.
   [Khan, Dilshad A.; Mushtaq, Shahida] Armed Forces Inst Pathol, Dept Chem Pathol & Endocrinol, Rawalpindi 64000, Pakistan.
   [Khan, Dilshad A.; Mushtaq, Shahida] Natl Univ Med Sci, Rawalpindi 64000, Pakistan.
   [Qureshi, Nilofer] Univ Missouri Kansas City, Sch Pharm, Pharmacol & Toxicol, 2464 Charlotte St, Kansas City, MO 64108 USA.
RP Qureshi, AA (corresponding author), Univ Missouri Kansas City, Sch Med, Dept Basic Med Sci, 2411 Holmes St, Kansas City, MO 64108 USA.
EM qureshia@umkc.edu
OI Silswal, Neerupma/0000-0001-7151-2378
FU Advanced Medical Research, Madison, Wisconsin; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [RO1 GM50870, 3RO1 GM631S1, 5RO1 GM10263]; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM050870] Funding Source: NIH
   RePORTER
FX The study supported in part by Advanced Medical Research, Madison,
   Wisconsin and NIH funds RO1 GM50870, 3RO1 GM631S1, and 5RO1 GM10263.
CR [Anonymous], 2006, AHFS DRUG INFORM
   Bhat UG, 2008, CELL CYCLE, V7, P1851, DOI 10.4161/cc.7.12.6032
   Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593
   Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592
   Brown CH, 2009, AM J LIFESTYLE MED, V3, P337, DOI 10.1177/1559827609334983
   Brunton L, 2011, GOODMAN GILMANS PHAR, P463
   Chang JG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018643
   Chang PN, 2009, NUTR CANCER, V61, P357, DOI 10.1080/01635580802567166
   Colombo B, 2014, NEUROL SCI, V35, pS141, DOI 10.1007/s10072-014-1755-z
   Cumming RG, 2000, OPHTHALMOLOGY, V107, P450, DOI 10.1016/S0161-6420(99)00024-X
   Davies S, 2006, GYNECOL ONCOL, V101, P62, DOI 10.1016/j.ygyno.2005.09.054
   Du J, 2012, BBA-REV CANCER, V1826, P443, DOI 10.1016/j.bbcan.2012.06.003
   Fishman SM, 2000, PUBLIC HEALTH NUTR, V3, P125, DOI 10.1017/S1368980000000173
   Gartel AL, 2010, EXPERT OPIN INV DRUG, V19, P235, DOI 10.1517/13543780903563364
   Group S, 2015, MED NEWS TODAY
   Hosseini A, 2015, AVICENNA J PHYTOMEDI, V5, P84
   Hsieh TC, 2010, BIOFACTORS
   Hussein D, 2009, PANCREAS, V38, pE124, DOI 10.1097/MPA.0b013e3181a20f9c
   KAMAT JP, 1995, NEUROSCI LETT, V195, P179, DOI 10.1016/0304-3940(95)11812-B
   Kamat JP, 1997, MOL CELL BIOCHEM, V170, P131, DOI 10.1023/A:1006853419214
   Korolchuk VI, 2010, FEBS LETT, V584, P1393, DOI 10.1016/j.febslet.2009.12.047
   Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002
   Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
   Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a
   Nedelsky NB, 2008, BBA-MOL BASIS DIS, V1782, P691, DOI 10.1016/j.bbadis.2008.10.002
   Nesaretnam K, 2004, ANN NY ACAD SCI, V1031, P143, DOI 10.1196/annals.1331.014
   Pandit B, 2011, CANCER BIOL THER, V11, P43, DOI 10.4161/cbt.11.1.13854
   Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277
   Qureshi AA, 2000, J AGR FOOD CHEM, V48, P3130, DOI 10.1021/jf000099t
   Qureshi AA, 2017, J CLIN EXP RES CARDI, V3, P1
   Qureshi AA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-177
   Qureshi N, 2003, J IMMUNOL, V171, P1515, DOI 10.4049/jimmunol.171.3.1515
   Reis J, 2008, INNATE IMMUN, V14, P319, DOI 10.1177/1753425908096855
   Rubinsztein DC, 2015, J EXP MED, V212, P979, DOI 10.1084/jem.20150956
   Savouret JF, 2002, BIOMED PHARMACOTHER, V56, P84, DOI 10.1016/S0753-3322(01)00158-5
   Shen J, 2006, SHOCK, V25, P472, DOI 10.1097/01.shk.0000209554.46704.64
   Shen J, 2006, SHOCK, V25, P594, DOI 10.1097/01.shk.0000209555.46704.2d
   Stetefeld J, 2005, TRENDS BIOCHEM SCI, V30, P515, DOI 10.1016/j.tibs.2005.07.001
   Wang M, 2011, MOL CANCER THER, V10, P2287, DOI 10.1158/1535-7163.MCT-11-0536
   Yang F, 2015, FLY ASH COMPREHENSIV, V2, P3
   Yap WN, 2010, CANCER LETT, V291, P187, DOI 10.1016/j.canlet.2009.10.012
   Yap WN, 2009, BRIT J CANCER, V99, P1832
   Zheng QF, 2015, CHEM BIOL, V22, P1002, DOI 10.1016/j.chembiol.2015.06.019
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
   Ziparo E, 2013, INT J MOL SCI, V14, P12090, DOI 10.3390/ijms140612090
NR 45
TC 13
Z9 14
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD APR 2
PY 2018
VL 17
AR 62
DI 10.1186/s12944-018-0697-5
PG 26
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA GB2QG
UT WOS:000428898600001
PM 29606130
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kawakita, H
   Tsuchida, A
   Miyazawa, K
   Naito, M
   Shigoka, M
   Kyo, B
   Enomoto, M
   Wada, T
   Katsumata, K
   Ohyashiki, K
   Itoh, M
   Tomoda, A
   Aoki, T
AF Kawakita, Hideaki
   Tsuchida, Akihiko
   Miyazawa, Keisuke
   Naito, Munekazu
   Shigoka, Masatoshi
   Kyo, Bunso
   Enomoto, Masanobu
   Wada, Tatehiko
   Katsumata, Kenji
   Ohyashiki, Kazuma
   Itoh, Masahiro
   Tomoda, Akio
   Aoki, Tatsuya
TI Growth inhibitory effects of vitamin K2 on colon cancer cell lines via
   different types of cell death including autophagy and apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE colon cancer; vitamin K2; chemoprevention; autophagy; apoptosis
ID HEPATOCELLULAR-CARCINOMA; LEUKEMIA-CELLS; LUNG-CANCER; INDUCTION;
   THERAPY; LC3
AB Vitamin K2 (menaquinone-4: MK4) has been reported to inhibit cell growth and induce apoptosis in various tumor cells. We examined the effects of MK4 using three types of colon cancer cell lines: PMCO1, COLO201, and DLD-1. Exposure to MK4 was at concentrations from 5 to 50 mu M, growth inhibitory effects were observed dose-dependently in COLO201 and PMCO1, whereas the growth inhibition observed in DLD-1 was minimal. Comparison of COLO201 and PMCO1 cells exhibiting distinct growth inhibitory effects showed that cell death via apoptosis accompanied by activation of caspase-3 was induced in PMCO1, while apoptosis was not induced in COLO201. On the contrary, immunoblot assay using an anti-LC3B antibody showed autophagy induction by addition of MK4 and incubation in all three types of colon cancer cell lines. Addition of 3-methyladenine (3-MA) attenuated the growth inhibitory effect of MK4 in COLO201, whereas no influence of 3-MA was noted in PCMO1. Electron microscopy images of COLO201 showed that addition of MK4 induced an increased number of cytoplasmic autophagosomes and autolysosomes as well as morphological changes including scantiness of cytoplasm accompanied by loss of cell organelles, nuclear shrinkage, and fragmentation of cytoplasmic membrane in some cells, indicating the induction of cell death via autophagy not accompanied by the formation of apoptotic bodies in COLO201 cells. These results suggested that the response to MK4 and the way of induction of cell death vary in different colon cancer cell lines.
C1 [Tsuchida, Akihiko] Tokyo Med Univ, Dept Surg 3, Shinjuku Ku, Tokyo 1600023, Japan.
   [Miyazawa, Keisuke; Tomoda, Akio] Tokyo Med Univ, Dept Biochem, Tokyo 1600023, Japan.
   [Naito, Munekazu; Itoh, Masahiro] Tokyo Med Univ, Dept Anat, Tokyo 1600023, Japan.
   [Ohyashiki, Kazuma] Tokyo Med Univ, Dept Internal Med 1, Tokyo 1600023, Japan.
RP Tsuchida, A (corresponding author), Tokyo Med Univ, Dept Surg 3, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.
EM akihikot@tokyo-med.ac.jp
OI Kawakita (he bei), Hideaki (ying ming)/0000-0001-9654-1407
FU Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour
   and Welfare, Japan
FX This study was supported by the 'Third-Term Comprehensive Control
   Research for Cancer' conducted by the Ministry of Health, Labor and
   Welfare of Japan. The authors are indebted to Professor J. Patrick
   Barron of the International Medical Communications Center of Tokyo
   Medical University for his review of this manuscript, and would like to
   thank Ms. Ayako Hirota and Ms. Minako Suzuki for their expert technical
   assistance. We also thank Dr Tomohisa Yokoyama of M.D. Anderson Cancer
   Center, University of Texas for the kind gift of anti-LC3B Ab, and Eisai
   Co. for providing
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Enomoto M, 2007, INT J MOL MED, V20, P801
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Habu D, 2004, JAMA-J AM MED ASSOC, V292, P358, DOI 10.1001/jama.292.3.358
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lamson Davis W, 2003, Altern Med Rev, V8, P303
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Miyazawa K, 2000, LEUKEMIA, V14, P1156, DOI 10.1038/sj.leu.2401790
   Miyazawa K, 2001, LEUKEMIA, V15, P1111, DOI 10.1038/sj.leu.2402155
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   MIZUSHIMA N, 2007, AUTOPHAGY, V3, pE1
   Mizuta T, 2006, CANCER, V106, P867, DOI 10.1002/cncr.21667
   Ogawa M, 2007, INT J ONCOL, V31, P323
   Paglin S, 2001, CANCER RES, V61, P439
   SELGEN PO, 1982, P NATL ACAD SCI USA, V79, P1889
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tokita H, 2006, INT J MOL MED, V17, P235
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Yaguchi M, 1999, LEUKEMIA, V13, P144, DOI 10.1038/sj.leu.2401232
   Yokoyama T, 2005, INT J ONCOL, V26, P33
   Yokoyama T, 2008, AUTOPHAGY, V4, P629, DOI 10.4161/auto.5941
   Yoshida T, 2003, INT J ONCOL, V23, P627
NR 30
TC 18
Z9 19
U1 1
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUN
PY 2009
VL 23
IS 6
BP 709
EP 716
DI 10.3892/ijmm_00000184
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 448GV
UT WOS:000266252000002
PM 19424596
OA Bronze
DA 2022-04-25
ER

PT J
AU Park, GB
   Jeong, JY
   Kim, D
AF Park, Ga Bin
   Jeong, Jee-Yeong
   Kim, Daejin
TI Ampelopsin-induced reactive oxygen species enhance the apoptosis of
   colon cancer cells by activating endoplasmic reticulum stress-mediated
   AMPK/MAPK/XAF1 signaling
SO ONCOLOGY LETTERS
LA English
DT Article
DE ampelopsin; reactive oxygen species; ER stress; 5 ' adenosine
   monophosphate-activated protein kinase; colon cancer
ID PROTEIN-KINASE; FACTOR-1 XAF1; TUMOR-CELLS; AMPK; GROWTH; PATHWAY;
   INHIBITION; EXPRESSION; CARCINOMA; AUTOPHAGY
AB Ampelopsin (Amp) is bioactive natural product and exerts anti-cancer effects against several cancer types. The present study investigated the anti-colon cancer activity of Amp and explored its mechanism of action. The treatment of colon cancer cells with Amp resulted in the dose-and time-dependent induction of apoptosis via the activation of endoplasmic reticulum (ER) stress, 5' adenosine monophosphate-activated protein kinase (AMPK), and c-Jun N-terminal protein kinase (JNK)/p38 mitogen-activated protein kinases (MAPKs). Salubrinal, an ER stress inhibitor, prevented the upregulation of ER stress-associated proteins, including phosphorylated protein kinase RNA-like ER kinase, phosphorylated eukaryotic translation initiation factor 2 alpha, glucose-regulated protein 78, and CCAAT/enhancer-binding protein homologous protein, as well as suppressing AMPK activation and the MAPK signaling pathway. Knockdown of AMPK by RNA interference failed to block ER stress. Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells. Furthermore, reactive oxygen species (ROS)-mediated ER stress/AMPK apoptotic signaling pathway in Amp-treated colon cancer cells were markedly inhibited by treatment with N-acetyl-L-cysteine, a ROS scavenger. These results demonstrate that treatment with Amp induces the apoptotic death of colon cancer cells through ER stress-initiated AMPK/MAPK/XAF1 signaling. These results also provide experimental information for developing Amp as therapeutic drug against colon cancer.
C1 [Park, Ga Bin; Jeong, Jee-Yeong] Kosin Univ, Coll Med, Dept Biochem, 262 Gamcheon Ro, Busan 49267, South Korea.
   [Kim, Daejin] Inje Univ, Coll Med, Dept Anat, 75 Bokji Ro, Busan 47392, South Korea.
RP Jeong, JY (corresponding author), Kosin Univ, Coll Med, Dept Biochem, 262 Gamcheon Ro, Busan 49267, South Korea.; Kim, D (corresponding author), Inje Univ, Coll Med, Dept Anat, 75 Bokji Ro, Busan 47392, South Korea.
EM jyjeong@kosin.ac.kr; kimdj@inje.ac.kr
FU Basic Science Research Program of the Ministry of Education
   [NRF-2015R1D1A1A01056672]; Ministry of Science, ICT and Future Planning
   through the National Research Foundation of the Republic of Korea
   [NRF-2015R1C1A2A01053732]
FX The present study was supported by the Basic Science Research Program of
   the Ministry of Education (grant no. NRF-2015R1D1A1A01056672) and the
   Ministry of Science, ICT and Future Planning (grant no.
   NRF-2015R1C1A2A01053732) through the National Research Foundation of the
   Republic of Korea.
CR Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hsu YC, 2011, CELL SIGNAL, V23, P2013, DOI 10.1016/j.cellsig.2011.07.015
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1
   Kim A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08394
   Kim HS, 2012, APOPTOSIS, V17, P938, DOI 10.1007/s10495-012-0719-0
   Laderoute KR, 2014, J BIOL CHEM, V289, P22850, DOI 10.1074/jbc.M114.576371
   Leclerc GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074420
   Liang XY, 2015, BIOFACTORS, V41, P463, DOI 10.1002/biof.1248
   Lin YC, 2014, ONCOTARGET, V5, P298, DOI 10.18632/oncotarget.1628
   Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027
   Liu B, 2014, SCI REP-UK, V4, DOI 10.1038/srep06245
   Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003
   Murakami T, 2004, BIOFACTORS, V21, P175, DOI 10.1002/biof.552210136
   Ni F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038802
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Park GB, 2013, J IMMUNOL, V191, P6281, DOI 10.4049/jimmunol.1203442
   Qi SM, 2012, INT IMMUNOPHARMACOL, V12, P278, DOI 10.1016/j.intimp.2011.12.001
   Rigoulet M, 2011, ANTIOXID REDOX SIGN, V14, P459, DOI 10.1089/ars.2010.3363
   ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H
   Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008
   Straszewski-Chavez SL, 2007, J BIOL CHEM, V282, P13059, DOI 10.1074/jbc.M609038200
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tu SP, 2010, CANCER-AM CANCER SOC, V116, P1252, DOI 10.1002/cncr.24814
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Wang JD, 2006, J BIOL CHEM, V281, P2451, DOI 10.1074/jbc.M505890200
   Wang JD, 2006, GASTROENTEROLOGY, V130, P747, DOI 10.1053/j.gastro.2005.12.017
   Yang L, 2003, CANCER RES, V63, P6815
   Yu LF, 2007, CANCER-AM CANCER SOC, V109, P1996, DOI 10.1002/cncr.22624
   Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019
   Zhang BL, 2012, ANTI-CANCER DRUG, V23, P590, DOI 10.1097/CAD.0b013e32835019f9
   Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005
   Zheng Hong-Qiang, 2003, Ai Zheng, V22, P363
   Zhou Y, 2014, CANCER SCI, V105, P1279, DOI 10.1111/cas.12494
   Zhou Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089021
NR 48
TC 12
Z9 13
U1 1
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2017
VL 14
IS 6
BP 7947
EP 7956
DI 10.3892/ol.2017.7255
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FP0LV
UT WOS:000417293400224
PM 29250183
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, H
   Zhao, N
   Jiang, MZ
AF Zhu, Hao
   Zhao, Na
   Jiang, Maozhu
TI Isovitexin attenuates tumor growth in human colon cancer cells through
   the modulation of apoptosis and epithelial-mesenchymal transition via
   PI3K/Akt/mTOR signaling pathway
SO BIOCHEMISTRY AND CELL BIOLOGY
LA English
DT Article
DE colon cancer cells; cell proliferation; cell apoptosis;
   epithelial-mesenchymal transition (EMT); tumor-bearing mice
ID QUALITY-OF-LIFE; AUTOPHAGY; TARGETS; VITEXIN; BCL-2; BAX
AB Isovitexin, a biologically active flavone C-glycosylated derivative, has a variety of biological activities. We aimed to identify the effect of isovitexin (Isov) on colon cancer. Human colonic epithelial cells (HCECs) and cancer cells were treated with Isov and Cell Counting Kit-8 (CCK8) was used to detect cell proliferation and calculate the half-inhibitory concentration (IC50). The biological activity of cancer cells was assessed. The tumor size and volume were recorded. Protein expression levels were analyzed by western blotting. Isov inhibited cancer cell proliferation but had little cytotoxicity on HCECs. Isov significantly attenuated cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and induced cell apoptosis., This trend was blocked by insulin-like growth factor-1 (IGF-1) treatment. The expression levels of phosphorylated phosphatidylinositol 3-kinasep (p-PI3K), phosphorylated protein kinase B (p-Akt), phosphorylated mammalian target of rapamycin (p-mTOR), and B cell lymphoma-2 (Bcl-2) decreased when treated with Isov, while the levels of Bcl2-associated X (Bax) and caspase-3 significantly increased. After Isov treatment, the tumor volume and weight were decreased, and the levels of p-PI3K, p-Akt, p-mTOR, and Bcl-2 significantly decreased in tumor tissues. Our findings demonstrated that Isov inhibited cancer cell migration, invasion, and EMT. Isov may be a new potential treatment for colon cancer.
C1 [Zhu, Hao; Zhao, Na] Yantaishan Hosp, Dept Gastroenterol, Yantai 264003, Shandong, Peoples R China.
   [Jiang, Maozhu] Yantaishan Hosp, Dept Radiotherapy, Yantai 264003, Shandong, Peoples R China.
RP Zhu, H (corresponding author), Yantaishan Hosp, Dept Gastroenterol, Yantai 264003, Shandong, Peoples R China.
EM zhuhao0729@163.com
CR Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Banik K, 2019, PHARMACOL RES, V144, P192, DOI 10.1016/j.phrs.2019.04.004
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Choi JS, 2014, FOOD CHEM TOXICOL, V64, P27, DOI 10.1016/j.fct.2013.11.020
   Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y
   da Silva ICV, 2018, ANTI-CANCER AGENT ME, V18, P1405, DOI 10.2174/1871520618666180315090949
   Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126
   Findlay VJ, 2014, CANCER GENE THER, V21, P181, DOI 10.1038/cgt.2014.15
   Fu XH, 2019, INT J CANCER, V144, P2109, DOI 10.1002/ijc.31973
   Ganesan K, 2017, ANN NY ACAD SCI, V1401, P102, DOI 10.1111/nyas.13446
   Gao JY, 2011, TOXICOL APPL PHARM, V254, P221, DOI 10.1016/j.taap.2011.03.016
   Hanafi MMM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00895
   He M, 2016, FITOTERAPIA, V115, P74, DOI 10.1016/j.fitote.2016.09.011
   Lee JH, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104504
   Li CY, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172463
   Liang X, 2019, CANCER MANAG RES, V11, P8923, DOI 10.2147/CMAR.S222708
   Lin CM, 2005, PLANTA MED, V71, P748, DOI 10.1055/s-2005-871287
   Lv SX, 2018, BIOCHEM BIOPH RES CO, V496, P1047, DOI 10.1016/j.bbrc.2018.01.111
   MCDERMOTT FT, 1981, BRIT J SURG, V68, P846, DOI 10.1002/bjs.1800681206
   Mu D, 2018, J MICROBIOL BIOTECHN, V28, P1426, DOI 10.4014/jmb.1802.02014
   Narayanankutty A, 2019, CURR DRUG TARGETS, V20, P1217, DOI 10.2174/1389450120666190618123846
   Phipps E, 2008, J EVAL CLIN PRACT, V14, P254, DOI 10.1111/j.1365-2753.2007.00842.x
   Rademaker G, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0130-6
   Sun V, 2012, EUR J ONCOL NURS, V16, P276, DOI 10.1016/j.ejon.2011.06.011
   Sun X, 2019, CANCER PREV RES, V12, P653, DOI 10.1158/1940-6207.CAPR-19-0134
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Yan S, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.26
   Zhang J, 2011, PHARMACOGN MAG, V7, P35, DOI 10.4103/0973-1296.75899
   Zhu ML, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02965-w
NR 30
TC 0
Z9 0
U1 1
U2 1
PU CANADIAN SCIENCE PUBLISHING
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0829-8211
EI 1208-6002
J9 BIOCHEM CELL BIOL
JI Biochem. Cell Biol.
PD DEC
PY 2021
VL 99
IS 6
BP 741
EP 749
DI 10.1139/bcb-2021-0045
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA XD3TW
UT WOS:000722636000009
PM 34219464
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Guo, YB
   Ye, Q
   Deng, P
   Cao, YN
   He, DH
   Zhou, ZH
   Wang, C
   Zaytseva, YY
   Schwartz, CE
   Lee, EY
   Evers, BM
   Morris, AJ
   Liu, SD
   She, QB
AF Guo, Yubin
   Ye, Qing
   Deng, Pan
   Cao, Yanan
   He, Daheng
   Zhou, Zhaohe
   Wang, Chi
   Zaytseva, Yekaterina Y.
   Schwartz, Charles E.
   Lee, Eun Y.
   Evers, B. Mark
   Morris, Andrew J.
   Liu, Side
   She, Qing-Bai
TI Spermine synthase and MYC cooperate to maintain colorectal cancer cell
   survival by repressing Bim expression
SO NATURE COMMUNICATIONS
LA English
DT Article
ID C-MYC; DIFLUOROMETHYLORNITHINE DFMO; HUMAN-COLON; POLYAMINES; GENE;
   DEFICIENCY; AUTOPHAGY; MICE; TRANSCRIPTION; SENSITIVITY
AB Dysregulation of polyamine metabolism has been linked to the development of colorectal cancer (CRC), but the underlying mechanism is incompletely characterized. Here, we report that spermine synthase (SMS), a polyamine biosynthetic enzyme, is overexpressed in CRC. Targeted disruption of SMS in CRC cells results in spermidine accumulation, which inhibits FOXO3a acetylation and allows subsequent translocation to the nucleus to transcriptionally induce expression of the proapoptotic protein Bim. However, this induction is blunted by MYC-driven expression of miR-19a and miR-19b that repress Bim production. Pharmacological or genetic inhibition of MYC activity in SMS-depleted CRC cells dramatically induces Bim expression and apoptosis and causes tumor regression, but these effects are profoundly attenuated by silencing Bim. These findings uncover a key survival signal in CRC through convergent repression of Bim expression by distinct SMS- and MYC-mediated signaling pathways. Thus, combined inhibition of SMS and MYC signaling may be an effective therapy for CRC. Polyamine metabolism is frequently dysregulated in cancers. Here, the authors show that a polyamine biosynthetic enzyme, spermine synthase, is overexpressed in colorectal cancers and cooperates with MYC to prevent cancer cell apoptosis by repression of proapoptotic protein, Bim.
C1 [Guo, Yubin; Liu, Side] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.
   [Guo, Yubin; Ye, Qing; Cao, Yanan; He, Daheng; Zhou, Zhaohe; Wang, Chi; Zaytseva, Yekaterina Y.; Lee, Eun Y.; Evers, B. Mark; She, Qing-Bai] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Ye, Qing; Cao, Yanan; She, Qing-Bai] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, Lexington, KY 40506 USA.
   [Deng, Pan] Univ Kentucky, Superfund Res Ctr, Lexington, KY 40536 USA.
   [Wang, Chi] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40506 USA.
   [Zaytseva, Yekaterina Y.] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY 40506 USA.
   [Schwartz, Charles E.] Greenwood Genet Ctr, Greenwood, SC 29646 USA.
   [Lee, Eun Y.] Univ Kentucky, Coll Med, Dept Pathol & Lab Med, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA.
   [Morris, Andrew J.] Univ Kentucky, Coll Med, Div Cardiovasc Med, Lexington, KY 40506 USA.
   [Morris, Andrew J.] Univ Kentucky, Coll Med, Gill Heart Inst, Lexington, KY 40506 USA.
   [Morris, Andrew J.] Lexington Vet Affairs Med Ctr, Lexington, KY 40506 USA.
RP Liu, SD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.; She, QB (corresponding author), Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA.; She, QB (corresponding author), Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, Lexington, KY 40506 USA.
EM liuside@163.com; qing-bai.she@uky.edu
RI He, Daheng/AAR-1813-2021; Cao, Yanan/AAF-7356-2021
OI Deng, Pan/0000-0003-2974-7389; She, Qing-Bai/0000-0002-7207-0599
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA203257]; University of Kentucky [CCTS UL1TR001998];
   NIH/NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P30GM127211]; South Carolina Department of
   Disabilities and Special Needs; University of Kentucky Markey Cancer
   Center [P30CA177558, CCSG P30CA177558]
FX We thank the Markey Cancer Center's Research Communication Office for
   assistance with manuscript preparation. This work was supported by NCI
   grant R01CA203257, Start-Up funds (Q.-B.S.), pilot grants (Q.-B.S.) from
   CCSG P30CA177558 (University of Kentucky Markey Cancer Center) and CCTS
   UL1TR001998 (University of Kentucky), NIH/NIGMS grant P30GM127211
   (A.J.M.), and a grant from the South Carolina Department of Disabilities
   and Special Needs (C.E.S.). This work was also supported in part by the
   Biospecimen Procurement and Translational Pathology, Cancer Research
   Informatics, Biostatistics and Bioinformatics, and Flow Cytometry and
   Immune Monitoring Shared Resources of the University of Kentucky Markey
   Cancer Center (P30CA177558).
CR Arruabarrena-Aristorena A, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2606
   Bassiri H, 2015, TRANSL PEDIATR, V4, P226, DOI 10.3978/j.issn.2224-4336.2015.04.06
   BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804
   Bertaggia E, 2012, AM J PHYSIOL-CELL PH, V302, pC587, DOI 10.1152/ajpcell.00142.2011
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Byun JA, 2008, BIOMED CHROMATOGR, V22, P73, DOI 10.1002/bmc.898
   Casero RA, 2018, NAT REV CANCER, V18, P681, DOI 10.1038/s41568-018-0050-3
   Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598
   Cason AL, 2003, EUR J HUM GENET, V11, P937, DOI 10.1038/sj.ejhg.5201072
   CELANO P, 1989, J BIOL CHEM, V264, P8922
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dobson M, 2011, BBA-MOL CELL RES, V1813, P1453, DOI 10.1016/j.bbamcr.2011.05.001
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Forshell TP, 2010, CANCER PREV RES, V3, P140, DOI 10.1158/1940-6207.CAPR-09-0166
   Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026
   Gupta VK, 2013, NAT NEUROSCI, V16, P1453, DOI 10.1038/nn.3512
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He WL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01549
   Huang XP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11580-4
   Ikeguchi Y, 2006, J BIOCHEM, V139, P1, DOI 10.1093/jb/mvj019
   Korhonen VP, 2001, MOL PHARMACOL, V59, P231, DOI 10.1124/mol.59.2.231
   Levin Victor A, 2018, CNS Oncol, V7, pCNS16, DOI 10.2217/cns-2017-0031
   Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453
   Mackintosh CA, 2000, BIOCHEM J, V351, P439, DOI 10.1042/0264-6021:3510439
   Madeo F, 2018, SCIENCE, V359, P410, DOI 10.1126/science.aan2788
   Manna SK, 2014, GASTROENTEROLOGY, V146, P1313, DOI 10.1053/j.gastro.2014.01.017
   Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Miao HM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11716
   Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167
   Murray-Stewart Tracy, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6040112
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nilsson J, 2000, BIOCHEM J, V352, P381, DOI 10.1042/0264-6021:3520381
   Nishimura K, 2006, J BIOCHEM, V139, P81, DOI 10.1093/jb/mvj003
   Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014
   O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Olive V, 2013, ELIFE, V2, DOI 10.7554/eLife.00822
   PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C
   Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230
   Pietrocola F, 2015, CELL DEATH DIFFER, V22, P509, DOI 10.1038/cdd.2014.215
   Pignatti C, 2004, AMINO ACIDS, V27, P359, DOI 10.1007/s00726-004-0115-3
   POULIN R, 1993, J BIOL CHEM, V268, P4690
   Raj KP, 2013, BRIT J CANCER, V108, P512, DOI 10.1038/bjc.2013.15
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Saunders LR, 2006, MOL CANCER THER, V5, P2777, DOI 10.1158/1535-7163.MCT-06-0298
   SCALABRINO G, 1984, MECH AGEING DEV, V26, P149, DOI 10.1016/0047-6374(84)90090-3
   Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308
   Schwartz CE, 2011, METHODS MOL BIOL, V720, P437, DOI 10.1007/978-1-61779-034-8_28
   Seckute J, 2011, PROTEIN SCI, V20, P1836, DOI 10.1002/pro.717
   Senf SM, 2011, AM J PHYSIOL-CELL PH, V300, pC1490, DOI 10.1152/ajpcell.00255.2010
   Shao Q, 2014, CANCER RES, V74, P7090, DOI 10.1158/0008-5472.CAN-14-0305
   Snezhkina AV, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2353560
   Sun LC, 2017, ELIFE, V6, DOI 10.7554/eLife.22915
   Tabib A, 1999, INT J BIOCHEM CELL B, V31, P1289, DOI 10.1016/S1357-2725(99)00098-9
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327
   Wang J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02243-3
   Wang XW, 2017, ONCOL LETT, V13, P2867, DOI 10.3892/ol.2017.5851
   Welsh PA, 2012, CANCER BIOL THER, V13, P358, DOI 10.4161/cbt.19241
   Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575
   Ye Q, 2014, ONCOGENE, V33, P1828, DOI 10.1038/onc.2013.122
   Yue F, 2017, CANCER RES, V77, P2938, DOI 10.1158/0008-5472.CAN-16-3462
NR 67
TC 14
Z9 14
U1 3
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 26
PY 2020
VL 11
IS 1
DI 10.1038/s41467-020-17067-x
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ME9AS
UT WOS:000544947000003
PM 32591507
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, Z
   Feng, L
   Wang, JQ
   Cheng, DS
   Liu, M
   Ling, MR
   Xu, WP
   Sun, KY
AF Zhao, Zhen
   Feng, Li
   Wang, Jiqin
   Cheng, Deshan
   Liu, Mei
   Ling, Meirong
   Xu, Weiping
   Sun, Keyu
TI NPC-26 kills human colorectal cancer cells via activating AMPK signaling
SO ONCOTARGET
LA English
DT Article
DE NPC-26; colorectal cancer; AMP-activated protein kinase (AMPK);
   mitochondrion; cell death
ID PROTEIN-KINASE AMPK; INDUCED GROWTH-INHIBITION; COLON-CANCER; INDUCED
   APOPTOSIS; CYCLOSPORINE-A; IN-VITRO; METABOLISM; AUTOPHAGY; SURVIVAL;
   CONTRIBUTES
AB NPC-26 is novel mitochondrion-interfering compound. The current study tested its potential effect against colorectal cancer (CRC) cells. We demonstrated that NPC-26 induced potent anti-proliferative and cytotoxic activities against CRC cell lines (HCT116, DLD-1 and HT-29). Activation of AMP-activated protein kinase (AMPK) signaling mediated NPC-26-induced CRC cell death. AMPKa1 shRNA knockdown or dominant negative mutation abolished NPC-26-induced AMPK activation and subsequent CRC cell death. NPC-26 disrupted mitochondrial function, causing mitochondrial permeability transition pore (mPTP) opening and reactive oxygen species (ROS) production. ROS scavengers (NAC or MnTBAP) and mPTP blockers (cyclosporin A or sanglifehrin A) blocked NPC-26-induced AMPK activation and attenuated CRC cell death. Significantly, intraperitoneal injection of NPC-26 potently inhibited HCT-116 tumor growth in severe combined immuno-deficient (SCID) mice. Yet, its anti-tumor activity was significantly weakened against AMPKa1-silenced HCT-116 tumors. Together, we conclude that NPC-26 kills CRC cells possibly via activating AMPK signaling.
C1 [Zhao, Zhen] Fudan Univ, Minhang Hosp, Clin Lab, Shanghai, Peoples R China.
   [Feng, Li] Fudan Univ, Minhang Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
   [Wang, Jiqin; Cheng, Deshan; Liu, Mei; Ling, Meirong; Sun, Keyu] Fudan Univ, Minhang Hosp, Emergency Dept, Shanghai, Peoples R China.
   [Xu, Weiping] Shanghai Univ Med Hlth Sci, Shanghai, Peoples R China.
RP Sun, KY (corresponding author), Fudan Univ, Minhang Hosp, Emergency Dept, Shanghai, Peoples R China.; Xu, WP (corresponding author), Shanghai Univ Med Hlth Sci, Shanghai, Peoples R China.
EM weipingxulunwen@163.com; sunkeyulunwen@163.com
FU Shanghai medical key subject construction project [ZK2015B15]; Shanghai
   weak discipline construction plan [2016ZB0202]; Shanghai Minhang
   District science and technology research plan [2015MHZ039]
FX This work is supported by Shanghai medical key subject construction
   project (ZK2015B15), Shanghai weak discipline construction plan
   (2016ZB0202) and Shanghai Minhang District science and technology
   research plan (2015MHZ039). The funders have no role in design, in the
   collection, analysis, and interpretation of data; in the writing of the
   manuscript; and in the decision to submit the manuscript for
   publication.
CR Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715
   Brouquet A, 2013, NAT REV GASTRO HEPAT, V10, P266, DOI 10.1038/nrgastro.2013.53
   Cao C, 2008, J BIOL CHEM, V283, P28897, DOI 10.1074/jbc.M804144200
   Chen LZ, 2016, BIOCHEM BIOPH RES CO, V480, P515, DOI 10.1016/j.bbrc.2016.10.040
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Chen MB, 2015, BIOCHEM BIOPH RES CO, V463, P954, DOI 10.1016/j.bbrc.2015.06.041
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522
   Chi PI, 2013, J BIOL CHEM, V288, P3571, DOI 10.1074/jbc.M112.390245
   Chung KY, 2007, CANCER J, V13, P192, DOI 10.1097/PPO.0b013e318074d26e
   Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200
   Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042
   Dong YY, 2016, TUMOUR BIOL
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Head SA, 2015, P NATL ACAD SCI USA, V112, pE7276, DOI 10.1073/pnas.1512867112
   Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2
   Huang CH, 2009, MOL NUTR FOOD RES, V53, P1156, DOI 10.1002/mnfr.200800592
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Kang MR, 2012, ONCOL REP, V27, P1407, DOI 10.3892/or.2012.1644
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YM, 2007, ANN NY ACAD SCI, V1095, P496, DOI 10.1196/annals.1397.053
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Lv GQ, 2014, BIOCHEM BIOPH RES CO, V453, P13, DOI 10.1016/j.bbrc.2014.09.028
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Narbonne P, 2009, NATURE, V457, P210, DOI 10.1038/nature07536
   Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110
   Sauer H, 2012, INT J ONCOL, V40, P501, DOI 10.3892/ijo.2011.1230
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Shao JJ, 2012, BIOCHEM BIOPH RES CO, V423, P448, DOI 10.1016/j.bbrc.2012.05.123
   Shoshan-Barmatz V, 2015, BBA-BIOMEMBRANES, V1848, P2547, DOI 10.1016/j.bbamem.2014.10.040
   Sotgia F, 2012, CELL CYCLE, V11, P4390, DOI 10.4161/cc.22777
   Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197
   Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010
   Vakana E, 2012, J CELL BIOCHEM, V113, P404, DOI 10.1002/jcb.23369
   Wang B, 2013, SCI WORLD J, DOI 10.1155/2013/405645
   Wolpaw AJ, 2011, P NATL ACAD SCI USA, V108, pE771, DOI 10.1073/pnas.1106149108
   Yang L, 2015, EXP CELL RES, V332, P47, DOI 10.1016/j.yexcr.2014.12.017
   Yang Y, 2016, J CELL PHYSL
   Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079
   Zhang L, 2011, J BIOL CHEM, V286, P16879, DOI 10.1074/jbc.M110.186932
   Zhang WS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-338
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
   Zheng QY, 2012, BIOCH BIOPHYS RES CO
NR 48
TC 12
Z9 12
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 14
PY 2017
VL 8
IS 11
BP 18312
EP 18321
DI 10.18632/oncotarget.15436
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EO7NN
UT WOS:000396877500076
PM 28407688
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, L
   Yao, L
   Li, XY
   Chen, J
   Lou, CH
   Wang, YQ
AF Wang, Lu
   Yao, Li
   Li, Xiaoyu
   Chen, Juan
   Lou, Chenghua
   Wang, Yiqi
TI Stephanthraniline A suppresses proliferation of HCT116 human colon
   cancer cells through induction of caspase-dependent apoptosis,
   dysregulation of mitochondrial function, cell cycle arrest and
   regulation of Akt/p38 signaling pathways
SO JOURNAL OF TOXICOLOGICAL SCIENCES
LA English
DT Article
DE C-21 steroidal aglycone; Apoptosis; Cell cycle arrest; Colon cancer
ID P38 MAPK; COLORECTAL-CANCER; IN-VITRO; INHIBITION; GLYCOSIDES;
   AUTOPHAGY; PI3K/AKT; KINASES
AB Stephanthraniline A (STA) is a C-21 steroidal aglycone isolated from the stem of Stephanotis mucronata (Blanco) Merr. that exerts growth inhibition in human colon cancer cells. However, the intracellular molecular mechanisms whereby this occurs have not been well characterized. In this study, we found that STA significantly inhibits the growth of HCT116 colon cancer cells in a time- and concentration-dependent manner. The inhibitory effect of STA on cell growth was related to the induction of apoptosis. Activated caspase-3, caspase-8 and caspase-9, along with a decreased Bcl-2/Bcl-x ratio and loss of mitochondria! membrane potential (Delta psi(m)), were observed in response to STA treatment. Furthermore, treatment of HCT116 cells with STA resulted in G0/G1 phase cell cycle arrest accompanied by decreased mRNA levels of cyclin-dependent kinase 4 (CDK4), p21 and c-myc. Additionally, the inhibition of Akt signaling and activation of p38 signaling were observed after treatment with STA in HCT116 cells. These findings indicate that STA inhibits HCT116 cell growth by promoting apoptosis, the dysregulation of mitochondrial function, and cell cycle arrest.
C1 [Wang, Lu; Yao, Li; Lou, Chenghua; Wang, Yiqi] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.
   [Li, Xiaoyu] Zhejiang Acad Med Sci, Inst Mat Med, Hangzhou 310013, Zhejiang, Peoples R China.
   [Chen, Juan] Zhejiang Chinese Med Univ, Sch Basic Med Sci, Hangzhou 310053, Zhejiang, Peoples R China.
RP Lou, CH; Wang, YQ (corresponding author), Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.; Li, XY (corresponding author), Zhejiang Acad Med Sci, Inst Mat Med, Hangzhou 310013, Zhejiang, Peoples R China.
EM 775423305@qq.com; lou.chenghua@hotmail.com; wangyiqi2011@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603363, 81803806]
FX This work was financially supported by the National Natural Science
   Foundation of China (grant number #81603363, #81803806).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Afrin S, 2016, MOLECULES, V21, DOI 10.3390/molecules21020169
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Borkan SC, 2016, SEMIN NEPHROL, V36, P237, DOI 10.1016/j.semnephrol.2016.04.001
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen FY, 2012, EUR J PHARMACOL, V685, P186, DOI 10.1016/j.ejphar.2012.04.012
   Croci O, 2017, GENE DEV, V31, P2017, DOI 10.1101/gad.301184.117
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Delebinski CI, 2015, CELL PROLIFERAT, V48, P600, DOI 10.1111/cpr.12208
   El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055
   Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313
   Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576
   Han B, 2018, PHYTOMEDICINE, V48, P152, DOI 10.1016/j.phymed.2017.12.027
   Huang RH, 2017, CELL PHYSIOL BIOCHEM, V41, P1851, DOI 10.1159/000471933
   Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009
   Kim DH, 2018, PHYTOTHER RES, V32, P1975, DOI 10.1002/ptr.6126
   Li JL, 2015, J NAT PROD, V78, P1548, DOI 10.1021/np501058b
   Li JP, 2015, DRUG DES DEV THER, V9, P1627, DOI 10.2147/DDDT.S75378
   Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003
   Liu KY, 2010, ANTI-CANCER DRUG, V21, P625, DOI 10.1097/CAD.0b013e328339301c
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Peng YR, 2011, PHYTOTHER RES, V25, P631, DOI 10.1002/ptr.3312
   Roskoski R, 2019, PHARMACOL RES, V139, P471, DOI 10.1016/j.phrs.2018.11.035
   Schwarz M, 2007, APOPTOSIS, V12, P869, DOI 10.1007/s10495-007-0748-2
   Tiwari M, 2015, APOPTOSIS, V20, P1019, DOI 10.1007/s10495-015-1136-y
   Wei QW, 2013, ANIM REPROD SCI, V138, P282, DOI 10.1016/j.anireprosci.2013.02.025
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Zhou X, 2016, CHEM BIODIVERS, V13, P1484, DOI 10.1002/cbdv.201600054
NR 31
TC 1
Z9 1
U1 1
U2 2
PU JAPANESE SOC TOXICOLOGICAL SCIENCES
PI TOKYO
PA INTERNATIONAL MEDICAL INFORMATION CENTER, SHINANOMACHI RENGAKAN, 35
   SHINANO-MACHI, SHINJUKU-KU, TOKYO, 160-0016, JAPAN
SN 0388-1350
EI 1880-3989
J9 J TOXICOL SCI
JI J. Toxicol. Sci.
PY 2019
VL 44
IS 7-9
BP 523
EP 533
DI 10.2131/jts.44.523
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA KM6MM
UT WOS:000514252200008
PM 31378763
OA gold
DA 2022-04-25
ER

PT J
AU Li, BX
   Li, CY
   Peng, RQ
   Wu, XJ
   Wang, HY
   Wan, DS
   Zhu, XF
   Zhang, XS
AF Li, Bao-Xiu
   Li, Chun-Yan
   Peng, Rui-Qing
   Wu, Xiao-Jun
   Wang, Hai-Ying
   Wan, De-Sen
   Zhu, Xiao-Feng
   Zhang, Xiao-Shi
TI The expression of beclin 1 is associated with favorable prognosis in
   stage IIIB colon cancers
SO AUTOPHAGY
LA English
DT Article
DE beclin 1; prognosis; colon cancer; tumor suppressor gene;
   immunohistochemistry
ID MESSENGER-RNA EXPRESSION; AUTOPHAGY; GENE; PROTEIN
AB Beclin 1 is a key modulator bridging autophagy, apoptosis and differentiation. This study investigated the expression of beclin 1 in human colon cancers and its association with clinicopathological characteristics. A total of 115 cases of cancer tissues with intact follow-up data were obtained from colon cancer patients with stage IIIB. The expression of beclin 1 in cancer nest and adjacent normal tissue was examined with immunohistochemistry. The results showed the immunostaining of beclin 1 was distributed in plasma-membrane, cytoplasm and nucleus in tumor cells, which occurred in 98 cases (85.2%) of the 115 patients. No or modest beclin I expression was observed in adjacent noncancerous tissues. The higher level of beclin 1 expression strongly associated with longer survival. Both univariate analysis and multivariate analysis showed that the beclin I expression and invasive depth of primary mass (T stage) were independent prognostic factors. Additionally, there was no significant correlation of beclin 1 expression with clinicopathological characteristics, such as sex, age, site of primary mass, pathological classification, grade and invasive depth with the nonparametric correlation Kendall's tau-b test.
C1 [Li, Bao-Xiu; Li, Chun-Yan; Peng, Rui-Qing; Wu, Xiao-Jun; Wang, Hai-Ying; Wan, De-Sen; Zhu, Xiao-Feng; Zhang, Xiao-Shi] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China.
   [Li, Bao-Xiu; Li, Chun-Yan; Peng, Rui-Qing; Wang, Hai-Ying; Zhang, Xiao-Shi] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Wu, Xiao-Jun; Wan, De-Sen] Sun Yat Sen Univ, Ctr Canc, Dept Abdominal Oncol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhu, Xiao-Feng] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China.
RP Zhang, XS (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.
EM zxs617@hotmail.com
FU Nature Science Foundation [05001693]; Bureau of Health Foundation of
   Guangdong Province, China [B2007071]
FX This study was supported by Nature Science Foundation (05001693) and
   Bureau of Health Foundation of Guangdong Province, China (B2007071).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Chen M, 2008, AUTOPHAGY, V4, P926, DOI 10.4161/auto.6716
   Daniel F, 2007, CANCER INVEST, V25, P226, DOI 10.1080/07357900701206323
   Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713
   Huerta S, 2008, EXPERT REV MOL DIAGN, V8, P277, DOI 10.1586/14737159.8.3.277
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Karantza-Wadsworth V, 2007, AUTOPHAGY, V3, P610, DOI 10.4161/auto.4867
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu CP, 2008, CHINESE J STRUC CHEM, V27, P25
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Miracco C, 2007, INT J ONCOL, V30, P429
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang NH, 2008, CELL CYCLE, V7, P925, DOI 10.4161/cc.7.7.5621
NR 21
TC 123
Z9 126
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD APR 1
PY 2009
VL 5
IS 3
BP 303
EP 306
DI 10.4161/auto.5.3.7491
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 439KP
UT WOS:000265626300004
PM 19066461
OA Bronze
DA 2022-04-25
ER

PT J
AU Mosca, L
   Pagano, M
   Borzacchiello, L
   Mele, L
   Russo, A
   Russo, G
   Cacciapuoti, G
   Porcelli, M
AF Mosca, Laura
   Pagano, Martina
   Borzacchiello, Luigi
   Mele, Luigi
   Russo, Annapina
   Russo, Giulia
   Cacciapuoti, Giovanna
   Porcelli, Marina
TI S-Adenosylmethionine Increases the Sensitivity of Human Colorectal
   Cancer Cells to 5-Fluorouracil by Inhibiting P-Glycoprotein Expression
   and NF-kappa B Activation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE S-Adenosylmethionine; colorectal cancer; 5-Fluorouracil; multidrug
   resistance; P-glycoprotein; combination therapy
ID METHYL DONOR; COLON-CANCER; NATURAL COMPOUNDS; METHYLTHIOADENOSINE;
   APOPTOSIS; AUTOPHAGY; THERAPY
AB Colorectal cancer (CRC) is the second deadliest cancer worldwide despite significant advances in both diagnosis and therapy. The high incidence of CRC and its poor prognosis, partially attributed to multi-drug resistance and antiapoptotic activity of cancer cells, arouse strong interest in the identification and development of new treatments. S-Adenosylmethionine (AdoMet), a natural compound and a nutritional supplement, is well known for its antiproliferative and proapoptotic effects as well as for its potential in overcoming drug resistance in many kinds of human tumors. Here, we report that AdoMet enhanced the antitumor activity of 5-Fluorouracil (5-FU) in HCT 116(p53+/+) and in LoVo CRC cells through the inhibition of autophagy, induced by 5-FU as a cell defense mechanism to escape the drug cytotoxicity. Multiple drug resistance is mainly due to the overexpression of drug efflux pumps, such as P-glycoprotein (P-gp). We demonstrate here that AdoMet was able to revert the 5-FU-induced upregulation of P-gp expression and to decrease levels of acetylated NF-kappa B, the activated form of NF-kappa B, the major antiapoptotic factor involved in P-gp-related chemoresistance. Overall, our data show that AdoMet, was able to overcome 5-FU chemoresistance in CRC cells by targeting multiple pathways such as autophagy, P-gp expression, and NF-kappa B signaling activation and provided important implications for the development of new adjuvant therapies to improve CRC treatment and patient outcomes.
C1 [Mosca, Laura; Pagano, Martina; Borzacchiello, Luigi; Cacciapuoti, Giovanna; Porcelli, Marina] Univ Campania Luigi Vanvitelli, Dept Precis Med, Via Luigi De Crecchio 7, I-80138 Naples, Italy.
   [Pagano, Martina; Russo, Annapina; Russo, Giulia] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.
   [Mele, Luigi] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.
RP Cacciapuoti, G; Porcelli, M (corresponding author), Univ Campania Luigi Vanvitelli, Dept Precis Med, Via Luigi De Crecchio 7, I-80138 Naples, Italy.
EM laura.mosca@unicampania.it; martina.pagano@unicampania.it;
   luigi.borzacchiello@unicampania.it; luigi.mele@unicampania.it;
   annapina.russo@unina.it; giulia.russo@unina.it;
   giovanna.cacciapuoti@unicampania.it; marina.porcelli@unicampania.it
FU Intradepartmental Projects, Department of Precision Medicine, Universita
   della Campania "Luigi Vanvitelli"; Regione Campania-POR Campania FESR
   2014/2020 "Combattere la resistenza tumorale: piattaforma integrata
   multidisciplinare per un approccio tecnologico innovativo alle
   oncoterapie-Campania Oncoterapie" [B61G18000470007]; Fondo di ricerca di
   base FFABR-2017; Ministero della Universita e della Ricerca
   (MIUR)Ministry of Education, Universities and Research (MIUR); Programme
   Valere 2019 (Progetto competitive intra/Ateneo "GO MAGIC" Universita
   della Campania "Luigi Vanvitelli")
FX The work was partially supported by Programme Valere 2019 (Progetto
   competitive intra/Ateneo "GO MAGIC" Universita della Campania "Luigi
   Vanvitelli") and by Intradepartmental Projects, Department of Precision
   Medicine, Universita della Campania "Luigi Vanvitelli", and by a grant
   from Regione Campania-POR Campania FESR 2014/2020 "Combattere la
   resistenza tumorale: piattaforma integrata multidisciplinare per un
   approccio tecnologico innovativo alle oncoterapie-Campania Oncoterapie"
   Project N. B61G18000470007 (A.R.); Fondo di ricerca di base FFABR-2017
   (A.R. and G.R.); Ministero della Universita e della Ricerca (MIUR).
CR Abdin SM, 2021, CHEM-BIOL INTERACT, V340, DOI 10.1016/j.cbi.2021.109450
   Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583
   Ahmed M, 2020, GASTROENTEROL RES, V13, P1, DOI 10.14740/gr1239
   Beklen H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01273
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chavez-Dominguez R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.578418
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Coppola A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010286
   Delle Cave D, 2018, J CELL PHYSIOL, V233, P1370, DOI 10.1002/jcp.26015
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Ergin AD, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2020.102096
   Fernandez-Ramos D, 2020, WORLD J GASTROENTERO, V26, P5101, DOI 10.3748/wjg.v26.i34.5101
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Ganesan M, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111632
   Hussain Z, 2013, GENET MOL RES, V12, P1106, DOI 10.4238/2013.April.10.6
   Ilisso CP, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0697-6
   Ilisso CP, 2015, ENDOCRINE, V50, P212, DOI 10.1007/s12020-014-0484-7
   Katayama K, 2014, N J SCI, DOI 10.1155/2014/476974
   Li TWH, 2015, MOL PHARMACOL, V87, P77, DOI 10.1124/mol.114.095679
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Li TWH, 2009, MOL PHARMACOL, V76, P192, DOI 10.1124/mol.108.054411
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu Y, 2019, N-S ARCH PHARMACOL, V392, P615, DOI 10.1007/s00210-019-01617-2
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Magesh B, 2015, J EXP NANOSCI, V10, P828, DOI 10.1080/17458080.2014.910616
   Mahmood N, 2020, J CELL MOL MED, V24, P10322, DOI 10.1111/jcmm.15642
   Mele L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03056-x
   Mosca L, 2021, CANCERS, V13, DOI 10.3390/cancers13133264
   Mosca L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010103
   Mosca L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228547
   Mosca L, 2020, INT J ONCOL, V56, P1212, DOI 10.3892/ijo.2020.5011
   Mosca L, 2019, J CELL PHYSIOL, V234, P13277, DOI 10.1002/jcp.28000
   O'Hara M.H., 2017, J CLIN ONCOL, V15, P3614
   Pagano M, 2020, CANCERS, V12, DOI 10.3390/cancers12123665
   Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002
   Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197334
   Ramesh P, 2020, APOPTOSIS, V25, P305, DOI 10.1007/s10495-020-01601-9
   Rejhova A, 2018, EUR J MED CHEM, V144, P582, DOI 10.1016/j.ejmech.2017.12.039
   Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8
   Seelig A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.576559
   Sethy C, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111285
   Shin DW, 2020, BIOMOL THER, V28, P503, DOI 10.4062/biomolther.2020.155
   Soleimani A, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144132
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wu C, 2018, SURG ONCOL CLIN N AM, V27, P235, DOI 10.1016/j.soc.2017.11.001
   Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112
   Xiao H, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.648407
   Xie QQ, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100871
   Yan XY, 2019, J CELL MOL MED, V23, P4030, DOI 10.1111/jcmm.14288
   Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Zhu GY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.595187
   Zsigrai S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081864
NR 55
TC 1
Z9 1
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2021
VL 22
IS 17
AR 9286
DI 10.3390/ijms22179286
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UO0BW
UT WOS:000694371000001
PM 34502219
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Garcia-Princival, IMR
   Princival, JL
   da Silva, ED
   Lima, SMD
   Carregosa, JC
   Wisniewski, A
   de Lucena, CCO
   Halwass, F
   Franca, JAA
   Ferreira, LFGR
   Hernandes, MZ
   Saraiva, KLA
   Peixoto, CA
   Baratte, B
   Robert, T
   Bach, S
   Gomes, DC
   Paiva, PMG
   Marchand, P
   Rodrigues, MD
   da Silva, TG
AF Rodini Garcia-Princival, Iza Mirela
   Princival, Jefferson Luiz
   da Silva, Emmanuel Dias
   de Arruda Lima, Sandrine Maria
   Carregosa, Jhonattas Carvalho
   Wisniewski Jr, Alberto
   Oliveira de Lucena, Caio Cezar
   Halwass, Fernando
   Alves Franca, Jose Adonias
   Gomes Rebello Ferreira, Luiz Felipe
   Hernandes, Marcelo Zaldini
   Alcantara Saraiva, Karina Lidianne
   Peixoto, Christina Alves
   Baratte, Blandine
   Robert, Thomas
   Bach, Stephane
   Gomes, Dayene Correia
   Guedes Paiva, Patricia Maria
   Marchand, Pascal
   Rodrigues, Maria Desterro
   da Silva, Teresinha Goncalves
TI Streptomyces hygroscopicus UFPEDA 3370: A valuable source of the potent
   cytotoxic agent nigericin and its evaluation against human colorectal
   cancer cells
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Autophagy; Natural products; Nigericin; Protein kinases; Apoptosis
ID LUNG-CARCINOMA; JANUS KINASE; AUTOPHAGY; APOPTOSIS; ANTITUMOR;
   INHIBITION; CROSSTALK; GSK3-BETA; SURVIVAL; TARGETS
AB Streptomyces hygroscopicus UFPEDA 3370 was fermented in submerged cultivation and the biomass extract was partitioned, obtaining a fraction purified named EB1. After purification of EB1 fraction, nigericin free acid was obtained and identified. Nigericin presented cytotoxic activity against several cancer cell lines, being most active against HL-60 (human leukemia) and HCT-116 (human colon carcinoma) cell lines, presenting IC50 and (IS) values: 0.0014 mu M, (30.0) and 0.0138 mu M (3.0), respectively. On HCT-116, nigericin caused apoptosis and autophagy. In this study, nigericin was also screened both in vitro and in silico against a panel of cancer-related kinases. Nigericin was able to inhibit both JAK3 and GSK-3 beta kinases in vitro and its binding affinities were mapped through the intermolecular interactions with each target in silico.
C1 [Rodini Garcia-Princival, Iza Mirela; de Arruda Lima, Sandrine Maria; Oliveira de Lucena, Caio Cezar; Rodrigues, Maria Desterro; da Silva, Teresinha Goncalves] Univ Fed Pernambuco, Dept Antibiot, Rua Prof Moraes Rego 1235, BR-50670901 Recife, PE, Brazil.
   [Princival, Jefferson Luiz; da Silva, Emmanuel Dias; Halwass, Fernando; Alves Franca, Jose Adonias] Univ Fed Pernambuco, Dept Quim Fundamental, Av Jornalista Anibal Fernandes S-N, BR-50740560 Recife, PE, Brazil.
   [Carregosa, Jhonattas Carvalho; Wisniewski Jr, Alberto] Univ Fed Sergipe, Dept Quim, Av Marechal Rondon S-N, BR-49100000 Aracaju, Sergipe, Brazil.
   [Gomes Rebello Ferreira, Luiz Felipe; Hernandes, Marcelo Zaldini] Univ Fed Pernambuco, Dept Ciencias Farmaceut, Lab Quim Teor Med LQTM, Av Prof Artur de Sa,Cidade Univ, BR-50740521 Recife, PE, Brazil.
   [Alcantara Saraiva, Karina Lidianne; Peixoto, Christina Alves] Fundacao Oswaldo Cruz FIOCRUZ, Lab Ultraestrutura Inst Aggeu Magalhaes IAM, Recife, PE, Brazil.
   [Peixoto, Christina Alves] Fundacao Oswaldo Cruz, Inst Ciencias & Tecnol Neuroimunomodulacao INCT N, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Baratte, Blandine; Robert, Thomas; Bach, Stephane] Sorbonne Univ, Stn Biol Roscoff, Integrat Biol Marine Models Lab LBI2M, CNRS,UMR8227, F-29680 Roscoff, France.
   [Baratte, Blandine; Robert, Thomas; Bach, Stephane] Sorbonne Univ, CNRS, FR2424,Stn Biol, Kinase Inhibitor Specialized Screening Facil KISS, F-29688 Roscoff, France.
   [Gomes, Dayene Correia; Guedes Paiva, Patricia Maria] Univ Fed Pernambuco, Dept Bioquim, Rua Prof Moraes Rego SN, BR-50670420 Recife, PE, Brazil.
   [Marchand, Pascal] Univ Nantes, Cibles & Medicaments Infect & Canc, IICiMed, EA 1155, F-44000 Nantes, France.
RP da Silva, TG (corresponding author), Univ Fed Pernambuco, Dept Antibiot, Rua Prof Moraes Rego 1235, BR-50670901 Recife, PE, Brazil.
EM baratte@sd-roscoff.fr; bach@sb-roscoff.fr;
   teresinha.goncalces@pq.cnpq.br
RI Wisniewski, Alberto/AAB-9263-2021; Paiva, Patricia Maria
   Guedes/S-4038-2019; Wisniewski, Alberto/E-9639-2014; da Silva, Emmanuel
   Dias/ABA-8679-2020; Gonçalves-Silva, TERESINHA/ABE-4945-2021
OI Wisniewski, Alberto/0000-0001-6815-0265; Paiva, Patricia Maria
   Guedes/0000-0003-3467-708X; Wisniewski, Alberto/0000-0001-6815-0265; da
   Silva, Emmanuel Dias/0000-0002-9678-7164; Carregosa,
   Jhonattas/0000-0002-9789-4551
FU CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ); FACEPEFundacao de Amparo a Ciencia e Tecnologia do Estado de
   Pernambuco (FACEPE); CAPES/COFECUB programCoordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES); FACEPEFundacao de Amparo a Ciencia
   e Tecnologia do Estado de Pernambuco (FACEPE) [BFP-0109-4.03/19]
FX The authors thank CNPq, FACEPE and CAPES/COFECUB program for Financial
   support. The authors are also grateful to Central Analitica DQF from
   Federal University of Pernambuco (UFPE) for the infra structure and
   Center of Multi-users Chemistry Laboratory (CLQM) from Federal
   University of Sergipe (UFS) for the UHRMS facility, and Max Planck
   Institute for Biophysical Chemistry for the NMR spectra. The author Luiz
   F. G. R. Ferreira would like to thank the postdoctoral grant
   (BFP-0109-4.03/19) from FACEPE. The authors also thank the Canceropole
   Grand-Ouest (axis: Marine drugs, metabolism and cancer), GIS IBiSA
   (Infrastructures en Biologie Sante et Agronomie, France) and Biogenouest
   (Western France life science and environment core facility network) for
   supporting KISSf screening facility (Roscoff, France).
CR Antoszczak M, 2019, EUR J MED CHEM, V166, P32, DOI 10.1016/j.ejmech.2019.01.035
   Azoulay-Alfaguter I, 2015, ONCOGENE, V34, P4613, DOI 10.1038/onc.2014.390
   BAIBAKOV BA, 1993, INT J ONCOL, V3, P1127
   Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buchert M, 2016, ONCOGENE, V35, P939, DOI 10.1038/onc.2015.150
   Callaway T R, 2003, Curr Issues Intest Microbiol, V4, P43
   Cardellina JH, 1999, PR PHYT SOC, V43, P25
   Chen H., 2020, MICROB CELL FACT, V19, P1
   Chen H, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01301-8
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   de Santana TI, 2018, EUR J MED CHEM, V144, P874, DOI 10.1016/j.ejmech.2017.12.040
   Delano WL, PYMOL MOL GRAPHICS S
   Delle Cave D, 2018, J CELL PHYSIOL, V233, P1370, DOI 10.1002/jcp.26015
   Deng CC, 2013, INT J BIOCHEM CELL B, V45, P1997, DOI 10.1016/j.biocel.2013.06.023
   Dilip VC, 2013, INT J PHARM SCI RES, V4, P1730, DOI 10.13040/IJPSR.0975-8232.4(5).1730-42
   Durrant JD, 2011, J MOL GRAPH MODEL, V29, P888, DOI 10.1016/j.jmgm.2011.01.004
   DUTTON CJ, 1995, NAT PROD REP, V12, P165, DOI 10.1039/np9951200165
   FOSTER JW, 1981, J BACTERIOL, V148, P670, DOI 10.1128/JB.148.2.670-677.1981
   Garattini S, 2003, ANN ONCOL, V14, P813, DOI 10.1093/annonc/mdg261
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Hamaguchi H, 2018, BIOORGAN MED CHEM, V26, P4971, DOI 10.1016/j.bmc.2018.08.005
   Healy MA, 2019, J SURG ONCOL, V120, P858, DOI 10.1002/jso.25648
   Hostettmann K, 1990, METHODS PLANT BIOCH, V6, P71
   Hou T, 2008, J BIOL CHEM, V283, P30725, DOI 10.1074/jbc.M805941200
   JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0
   Jung HJ, 2017, J ETHNOPHARMACOL, V208, P253, DOI 10.1016/j.jep.2017.07.020
   Kinghorn AD, 2009, IDRUGS, V12, P189
   Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lima SMA, 2017, APPL MICROBIOL BIOT, V101, P711, DOI 10.1007/s00253-016-7886-9
   Liu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1054-0
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062844
   Lomovskaya N, 1999, J BACTERIOL, V181, P305, DOI 10.1128/JB.181.1.305-318.1999
   Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mancinelli R, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4629495
   Donato MAM, 2015, TISSUE CELL, V47, P515, DOI 10.1016/j.tice.2015.07.001
   Matsumura E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26306-7
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nairismagi ML, 2018, LEUKEMIA, V32, P1147, DOI 10.1038/s41375-017-0004-x
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Ranjan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26165
   Roskoski R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104609
   Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038
   ROTIN D, 1987, CANCER RES, V47, P1497
   Schrecengost RS, 2018, J PHARMACOL EXP THER, V365, P107, DOI 10.1124/jpet.117.245738
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Shen DY, 2013, CANCER SCI, V104, P1303, DOI 10.1111/cas.12223
   Simizu S, 1998, JPN J CANCER RES, V89, P970, DOI 10.1111/j.1349-7006.1998.tb00656.x
   STEINRAUF LK, 1968, BIOCHEM BIOPH RES CO, V33, P29, DOI 10.1016/0006-291X(68)90249-0
   Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923
   Vainchenker William, 2018, F1000Res, V7, P82, DOI 10.12688/f1000research.13167.1
   Valvezan AJ, 2012, J BIOL CHEM, V287, P3823, DOI 10.1074/jbc.M111.323337
   Vidri RJ, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.118626
   Virtanen AT, 2019, BIODRUGS, V33, P15, DOI 10.1007/s40259-019-00333-w
   Wang C, 2019, BIOTECHNOL BIOENG, V116, P3382, DOI 10.1002/bit.27158
   Wang Xuan, 2019, Cancer Drug Resist, V2, P141, DOI 10.20517/cdr.2019.10
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005
   Wu ZX, 2009, CHEM NAT COMPD+, V45, P333, DOI 10.1007/s10600-009-9350-x
   Yakisich J.S., 2017, TUMOR BIOL, V39, P1
   Zegzouti H, 2009, ASSAY DRUG DEV TECHN, V7, P560, DOI 10.1089/adt.2009.0222
   Zhou XC, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-256
NR 69
TC 0
Z9 1
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JAN 5
PY 2021
VL 333
AR 109316
DI 10.1016/j.cbi.2020.109316
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA PI1BB
UT WOS:000600832900006
PM 33285127
DA 2022-04-25
ER

PT J
AU Ljujic, M
   Mijatovic, S
   Bulatovic, MZ
   Mojic, M
   Maksimovic-Ivanic, D
   Radojkovic, D
   Topic, A
AF Ljujic, M.
   Mijatovic, S.
   Bulatovic, M. Z.
   Mojic, M.
   Maksimovic-Ivanic, D.
   Radojkovic, D.
   Topic, A.
TI ALPHA-1 Antitrypsin Affects U0126-Induced Cytotoxicity in Colon Cancer
   Cell Line (HCT116)
SO MOLECULAR BIOLOGY
LA English
DT Article
DE alpha-1 antitrypsin; apoptosis; autophagy; colon cancer cell line
   (HCT116)
ID PROGNOSTIC-SIGNIFICANCE; AUTOPHAGY; INHIBITOR; MALIGNANCY; LUNG
AB Alpha-1-antitrypsin (AAT), an acute phase protein, is the principal circulatory anti-protease. This multifunctional protein is encoded by the SERPINA1 gene. Although AAT was recognised as a potential tumour marker, its role in cancer biology remains unknown. Given that it has been demonstrated that AAT has an anti-apoptotic property against non-malignant cells, we aimed to investigate whether AAT affects apoptosis in a colon cancer cell line (HCT116). The presence of AAT in the HCT116 cell culture antagonized cytotoxicity of blockers of MEK1/2, PI3K/Akt pathways as well as NF-kappa B. The dominantly recovered cell viability was observed in the co-treatment with MEK1/2 inhibitor U0126. In addition, it was revealed that AAT almost completely abolished U0126-induced apoptosis through maintenance of the autophagy process. Our study revealed for the first time that the observed cyto-protection triggered by AAT was accompanied by sustained autophagy which opposed apoptosis. These results may contribute to understanding of the role of AAT in cancer development and evaluation of efficacy of cancer therapy.
C1 [Ljujic, M.; Radojkovic, D.] Univ Belgrade, Inst Mol Genet & Genet Engn, Belgrade, Serbia.
   [Mijatovic, S.; Bulatovic, M. Z.; Mojic, M.; Maksimovic-Ivanic, D.] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Belgrade, Serbia.
   [Topic, A.] Univ Belgrade, Fac Pharm, Inst Med Biochem, Belgrade, Serbia.
RP Topic, A (corresponding author), Univ Belgrade, Fac Pharm, Inst Med Biochem, Belgrade, Serbia.
EM aleksandra.topic1@gmail.com
OI Ljujic, Mila/0000-0003-4428-2938
FU Serbian Ministry of Education and ScienceMinistry of Education, Science
   & Technological Development, Serbia [173013, 173008]
FX This work was supported by the Serbian Ministry of Education and Science
   (grant nos. 173013 and 173008).
CR Bujanda L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051810
   Cheong H, 2015, ARCH PHARM RES, V38, P358, DOI 10.1007/s12272-015-0562-2
   de Sa SV, 2007, CLIN CANCER RES, V13, P5322, DOI 10.1158/1078-0432.CCR-06-1477
   HIGASHIYAMA M, 1992, BRIT J CANCER, V65, P300, DOI 10.1038/bjc.1992.60
   Hsu PI, 2010, CANCER EPIDEM BIOMAR, V19, P405, DOI 10.1158/1055-9965.EPI-09-0609
   Janciauskiene SM, 2011, RESP MED, V105, P1129, DOI 10.1016/j.rmed.2011.02.002
   KARASHIMA S, 1990, INT J CANCER, V45, P244, DOI 10.1002/ijc.2910450207
   Keppler D, 1996, BIOL CHEM H-S, V377, P301, DOI 10.1515/bchm3.1996.377.5.301
   Kwon CH, 2014, BRIT J CANCER, V111, P1993, DOI 10.1038/bjc.2014.490
   Li Y, 2011, J THORAC ONCOL, V6, P291, DOI 10.1097/JTO.0b013e31820213fb
   Lockett AD, 2012, MOL MED, V18, P445, DOI 10.2119/molmed.2011.00207
   Perez-Holanda S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-355
   Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
NR 15
TC 1
Z9 1
U1 3
U2 5
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD JAN
PY 2016
VL 50
IS 1
BP 153
EP 156
DI 10.1134/S002689331601012X
PG 4
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DO9XB
UT WOS:000378140200018
DA 2022-04-25
ER

PT J
AU Xu, CY
   Zhang, WL
   Liu, SQ
   Wu, WH
   Qin, MB
   Huang, J
AF Xu, Chunyan
   Zhang, Wenlu
   Liu, Shiquan
   Wu, Wenhong
   Qin, Mengbin
   Huang, Jiean
TI Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon
   cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE autophagy; sphingosine kinase 1; phosphate-extracellular
   signal-regulated kinase; colon cancer
ID SIGNALING PATHWAY; PROLIFERATION; MIGRATION; METASTASIS; EXPRESSION;
   SURVIVAL; INVASION
AB Sphingosine kinase 1 (SphK1) is a master kinase that catalyzes the synthesis of sphingosine 1 phosphate and participates in the regulation of cell proliferation and autophagy. The present study aimed to assess the effects of the activation of the SphK1/extracellular signal-regulated kinase (ERK)/phosphorylated (p-) ERK pathway in the regulation of autophagy in colon cancer (HT-29) cells. Inverted fluorescence microscopy was used to detect the expression of green fluorescent protein (GFP) in the SphK1-overexpressing HT-29 cells [SphK1(+)-HT-29] and the negative control HT-29 cells (NC-HT-29). Western blotting was used to detect the protein expression levels of SphK1, ERK1/2, p-ERK1/2, as well as those of the autophagy-associated markers LC3A, ATG5, and ULK1. Protein localization and expression of the LC3A antibody were detected by immunofluorescence. The results demonstrated that GFP was similarly expressed in SphK1(+)-HT-29 and NC-HT-29 cells. However, significantly increased SphK1 mRNA and protein expression levels were detected in SphK1(+)-HT-29 cells compared with in NC-HT-29 cells, which resulted in upregulated ERK/p-ERK. Furthermore, the protein expression levels of the three autophagy-associated markers increased. LC3A protein was localized in the cytoplasm of SphK1(+)-HT-29 cells, indicating autophagy. In summary, the findings of the present study suggested that activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer HT-29 cells.
C1 [Xu, Chunyan; Liu, Shiquan; Wu, Wenhong; Qin, Mengbin; Huang, Jiean] Guangxi Med Univ, Dept Gastroenterol, Affiliated Hosp 2, 166 Daxuedong Rd, Nanning 530007, Guangxi, Peoples R China.
   [Zhang, Wenlu] Guangxi Med Univ, Dept Resp Med, Affiliated Hosp 1, Nanning 530021, Guangxi, Peoples R China.
RP Liu, SQ; Huang, J (corresponding author), Guangxi Med Univ, Dept Gastroenterol, Affiliated Hosp 2, 166 Daxuedong Rd, Nanning 530007, Guangxi, Peoples R China.
EM poempower@163.com; 1404991727@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81460380, g81260365]; Guangxi Graduate
   Education [YCBZ2017035, YCSW2017100]
FX This work was supported by grants from the National Natural Science
   Foundation of China (grant nos. 81460380 and g81260365) and the
   Innovation Project of Guangxi Graduate Education (grant nos. YCBZ2017035
   and YCSW2017100).
CR Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511
   Almejun MB, 2017, HAEMATOLOGICA, V102, pE257, DOI 10.3324/haematol.2017.167353
   Buchegger K, 2017, PATHOL RES PRACT, V213, P476, DOI 10.1016/j.prp.2017.01.025
   Cheng YC, 2016, ONCOTARGET, V7, P29116, DOI 10.18632/oncotarget.8674
   Gao Z, 2016, INT J BIOCHEM CELL B, V74, P152, DOI 10.1016/j.biocel.2016.02.018
   Giatromanolaki Alexandra, 2013, Hematol Oncol Stem Cell Ther, V6, P20, DOI 10.1016/j.hemonc.2013.02.001
   Gonzalez-Fernandez B, 2017, BIOFACTORS, V43, P272, DOI 10.1002/biof.1342
   He ML, 2016, J NEURO-ONCOL, V127, P261, DOI 10.1007/s11060-015-2044-2
   Izumi M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030828
   Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Liu SQ, 2012, INT J COLORECTAL DIS, V27, P1569, DOI 10.1007/s00384-012-1510-y
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long JT, 2016, TUMOR BIOL, V37, P6831, DOI 10.1007/s13277-015-4542-4
   Maeda Y, 2017, J BIOCHEM, V161, P339, DOI 10.1093/jb/mvw078
   Manchon JFM, 2016, AUTOPHAGY, V12, P1418, DOI 10.1080/15548627.2016.1183082
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Miyamoto M, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e33
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Nazio F, 2017, AUTOPHAGY, V13, P967, DOI 10.1080/15548627.2017.1285473
   Nihira K, 2014, J PATHOL, V234, P277, DOI 10.1002/path.4354
   Ren H, 2016, ONCOTARGET, V7, P67277, DOI 10.18632/oncotarget.11645
   Samardzija G, 2016, ULTRASTRUCT PATHOL, V40, P240, DOI 10.1080/01913123.2016.1187689
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Wang RR, 2017, INT J MOL MED, V40, P1537, DOI 10.3892/ijmm.2017.3121
   Xu CY, 2017, INT J MOL MED, V39, P1277, DOI 10.3892/ijmm.2017.2921
   Yu Y, 2017, MOL CELL BIOCHEM, V424, P173, DOI 10.1007/s11010-016-2853-4
   Zhang L, 2016, INT J MOL MED, V37, P1254, DOI 10.3892/ijmm.2016.2521
   Zhao Y, 2017, MOL NUTR FOOD RES, V61
NR 32
TC 14
Z9 15
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2018
VL 15
IS 6
BP 9719
EP 9724
DI 10.3892/ol.2018.8588
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ3BK
UT WOS:000435149700197
PM 29928348
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Blondy, S
   David, V
   Verdier, M
   Mathonnet, M
   Perraud, A
   Christou, N
AF Blondy, Sabrina
   David, Valentin
   Verdier, Mireille
   Mathonnet, Muriel
   Perraud, Aurelie
   Christou, Niki
TI 5-Fluorouracil resistance mechanisms in colorectal cancer: From
   classical pathways to promising processes
SO CANCER SCIENCE
LA English
DT Review
DE 5-fluorouracil; colorectal cancer; resistance mechanism
ID SYNTHASE MESSENGER-RNA; CELL-LINES RESISTANT; COLON-CANCER; CONFERS
   RESISTANCE; APOPTOTIC PATHWAY; DRUG-RESISTANCE; DNA METHYLATION;
   TGF-BETA; EXPRESSION; PROMOTES
AB Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is surgery, especially for early tumor stages. When there is locoregional or distant invasion, chemotherapy can be introduced, in particular 5-fluorouracil (5-FU). However, the disease can become tolerant to these pharmaceutical treatments: resistance emerges, leading to early tumor recurrence. Different mechanisms can explain this 5-FU resistance. Some are disease-specific, whereas others, such as drug efflux, are evolutionarily conserved. These mechanisms are numerous and complex and can occur simultaneously in cells exposed to 5-FU. In this review, we construct a global outline of different mechanisms from disruption of 5-FU-metabolic enzymes and classic cellular processes (apoptosis, autophagy, glucose metabolism, oxidative stress, respiration, and cell cycle perturbation) to drug transporters and epithelial-mesenchymal transition induction. Particular interest is directed to tumor microenvironment function as well as epigenetic alterations and miRNA dysregulation, which are the more promising processes that will be the subject of much research in the future.
C1 [Blondy, Sabrina; David, Valentin; Verdier, Mireille; Mathonnet, Muriel; Perraud, Aurelie; Christou, Niki] CAPTuR Control Cell Activat Tumor Progress & Ther, Lab EA3842, Fac Med, Limoges, France.
   [David, Valentin] Univ Hosp Limoges, Dept Pharm, Limoges, France.
   [Mathonnet, Muriel; Perraud, Aurelie; Christou, Niki] Univ Hosp Limoges, Serv Chirurg Digest, Dept Digest Gen & Endocrine Surg, Limoges, France.
RP Christou, N (corresponding author), CHU Limoges, Serv Chirurg Digest Gen & Endocrinienne, Limoges, France.
EM christou.niki19@gmail.com
RI Mathonnet, Muriel/ABD-3021-2020; DAVID, Valentin/P-4483-2019; DAVID,
   Valentin/O-5067-2018
OI Mathonnet, Muriel/0000-0002-9127-3068; DAVID,
   Valentin/0000-0002-2260-6690; DAVID, Valentin/0000-0002-2260-6690;
   VERDIER, Mireille/0000-0002-8162-4856; Perraud,
   Aurelie/0000-0001-7882-0613
CR Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101
   Ambriovic-Ristov A, 2006, CURR SIGNAL TRANSD T, V1, P227, DOI 10.2174/157436206777012048
   Ambudkar SV, 2006, EUR J PHARM SCI, V27, P392, DOI 10.1016/j.ejps.2005.10.010
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Baharudin R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00047
   Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061
   Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856
   Boni V, 2010, MOL CANCER THER, V9, P2265, DOI 10.1158/1535-7163.MCT-10-0061
   Borralho PM, 2009, FEBS J, V276, P6689, DOI 10.1111/j.1742-4658.2009.07383.x
   Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362
   Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034
   Buess M, 2004, NEOPLASIA, V6, P813, DOI 10.1593/neo.04307
   Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268
   Chai HJ, 2011, ACTA BIOCH BIOPH SIN, V43, P217, DOI 10.1093/abbs/gmq125
   Chai J, 2015, IUBMB LIFE, V67, P191, DOI 10.1002/iub.1361
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chen J., 2019, LOSS SHMT2 MEDIATES, P680892
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Christou N, 2017, J CANCER RES CLIN, V143, P1177, DOI 10.1007/s00432-017-2382-x
   COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Cuezva JM, 2002, CANCER RES, V62, P6674
   Dabkeviciene D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0703-y
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064
   Deschoemaeker S, 2015, EMBO MOL MED, V7, P1350, DOI 10.15252/emmm.201505492
   Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087
   Ding L, 2015, ONCOTARGET, V6, P36441, DOI 10.18632/oncotarget.5541
   Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   Fazzone W, 2009, INT J CANCER, V125, P463, DOI 10.1002/ijc.24403
   Rubio MF, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0483-x
   Fujii Ryuta, 2003, Int J Clin Oncol, V8, P72, DOI 10.1007/s101470300013
   Goncalves-Ribeiro S, 2016, ONCOTARGET, V7, P59766, DOI 10.18632/oncotarget.11121
   Grant AJ, 2002, AM J PATHOL, V160, P1445, DOI 10.1016/S0002-9440(10)62570-9
   Griffith M, 2013, PHARMACOGENOMICS J, V13, P148, DOI 10.1038/tpj.2011.65
   Guo XX, 2008, ANTICANCER RES, V28, P9
   Han J, 2017, EXP CELL RES, V360, P328, DOI 10.1016/j.yexcr.2017.09.023
   He JX, 2014, CELL BIOCHEM BIOPHYS, V70, P1343, DOI 10.1007/s12013-014-0062-x
   Hedbrant A, 2015, INT J ONCOL, V46, P37, DOI 10.3892/ijo.2014.2696
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Humeniuk R, 2009, MOL CANCER THER, V8, P1037, DOI 10.1158/1535-7163.MCT-08-0716
   Kamoshida S, 2004, JPN J CLIN ONCOL, V34, P594, DOI 10.1093/jjco/hyh113
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38
   Lenz HJ, 1998, CLIN CANCER RES, V4, P1243
   Li QG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27157
   Li X, 2015, CURR PROTEIN PEPT SC, V16, P301, DOI 10.2174/138920371604150429153309
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Li Z, 2017, CAN RES TREAT, V50, P894
   Lin PL, 2016, FREE RADICAL BIO MED, V95, P121, DOI 10.1016/j.freeradbiomed.2016.03.014
   Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718
   Liu S, 2013, CANCER LETT, V328, P325, DOI 10.1016/j.canlet.2012.10.004
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Lopez-Diaz FJ, 2013, MOL CELL, V50, P552, DOI 10.1016/j.molcel.2013.04.029
   Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195
   Lu LL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5874127
   Lv L, 2016, TUMOR BIOL, V37, P8811, DOI 10.1007/s13277-015-4755-6
   Ma X, 2012, P NATL ACAD SCI USA, V109, P16282, DOI 10.1073/pnas.1202989109
   Marsh S, 2001, INT J ONCOL, V19, P383
   Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017
   McLean MH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015366
   Meyers M, 2005, J BIOL CHEM, V280, P5516, DOI 10.1074/jbc.M412105200
   Morawska Katarzyna, 2018, Oncotarget, V9, P11559, DOI 10.18632/oncotarget.24338
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Offer SM, 2014, MOL CANCER THER, V13, P742, DOI 10.1158/1535-7163.MCT-13-0878
   Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535-7163.MCT-04-0291
   Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115
   Romano G, 2016, ONCOTARGET, V7, P22077, DOI 10.18632/oncotarget.7895
   Rutkowski MR, 2012, CELL IMMUNOL, V278, P21, DOI 10.1016/j.cellimm.2012.06.014
   Sakowicz-Burkiewicz M, 2016, INT J BIOCHEM CELL B, V78, P268, DOI 10.1016/j.biocel.2016.07.024
   Schiavoni G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00090
   Shang JL, 2014, J CELL BIOCHEM, V115, P772, DOI 10.1002/jcb.24721
   Shen Y, 2018, PHARMACOGENOMICS J, V18, P23, DOI 10.1038/tpj.2016.91
   Shibata J, 1998, ANTICANCER RES, V18, P1457
   Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300
   Singh R, 2001, GLYCOBIOLOGY, V11, P587, DOI 10.1093/glycob/11.7.587
   SOBRERO A, 1990, J CHEMOTHERAPY, V2, P12
   Sun L, 2017, J CANCER, V8, P2802, DOI 10.7150/jca.19142
   To KKW, 2015, EXP CELL RES, V338, P222, DOI 10.1016/j.yexcr.2015.09.011
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Turkington RC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.10
   Veenstra CM, 2018, CLIN COLON RECT SURG, V31, P179, DOI 10.1055/s-0037-1602238
   Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101
   Wu HJ, 2016, BIOL OPEN, V5, P563, DOI 10.1242/bio.015008
   Xie T, 2016, ONCOTARGET, V8, P8574
   Xu WD, 2017, ONCOL LETT, V13, P3387, DOI 10.3892/ol.2017.5895
   Yao WL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0812-3
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zhang BH, 2016, ONCOL REP, V35, P1807, DOI 10.3892/or.2015.4479
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002636
   Zhang LN, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0145-7
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang X, 2016, CANCER LETT, V381, P305, DOI 10.1016/j.canlet.2016.08.004
   Zhang X, 2007, BIOCHEM CELL BIOL, V85, P337, DOI 10.1139/O07-009
   Zhang X, 2006, BBA-GENE STRUCT EXPR, V1759, P247, DOI 10.1016/j.bbaexp.2006.05.001
   Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200
   Zhang Y, 2016, J CELL MOL MED, V20, P360, DOI 10.1111/jcmm.12742
   Zhao XQ, 2015, ONCOL LETT, V10, P1287, DOI 10.3892/ol.2015.3468
   Zheng Z, 2010, HEPATO-GASTROENTEROL, V57, P1106
   Zhou JF, 2010, ONCOL REP, V23, P121, DOI 10.3892/or_00000613
   Zou ZW, 2016, MOL MED REP, V14, P4893, DOI 10.3892/mmr.2016.5812
NR 105
TC 54
Z9 55
U1 11
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD SEP
PY 2020
VL 111
IS 9
BP 3142
EP 3154
DI 10.1111/cas.14532
EA AUG 2020
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NI5TU
UT WOS:000558760900001
PM 32536012
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Hotta, M
   Sakatani, T
   Ishino, K
   Wada, R
   Kudo, M
   Yokoyama, Y
   Yamada, T
   Yoshida, H
   Naito, Z
AF Hotta, Masahiro
   Sakatani, Takashi
   Ishino, Kousuke
   Wada, Ryuichi
   Kudo, Mitsuhiro
   Yokoyama, Yasuyuki
   Yamada, Takeshi
   Yoshida, Hiroshi
   Naito, Zenya
TI Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced
   inhibition of growth in colorectal cancer cells through the
   up-regulation of death receptor 5
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; Farnesoid X receptor; Proteomics; Death receptor 5;
   Autophagy; TRAIL
ID NUCLEAR RECEPTORS; EXPRESSION; CARCINOMA; AUTOPHAGY; DR5
AB Farnesoid X receptor (FXR) exhibits critical anti-cancer functions in several types of cancer, including colorectal cancer, in vitro and in vivo. However, the underlying mechanism remains unclear. We evaluated pharmacological activation of FXR with the synthetic agonist GW4064 using comprehensive proteomic analysis in colorectal cancer cell lines (HCT116, SW480, and DLD1). Among the commonly detected proteins in all three cell lines, death receptor 5 (DR5) was the most up-regulated protein, and key autophagy-related proteins, such as microtubule-associated protein 1 light chain 3 alpha/beta (MLP3A/36) and p62 sequestosome-1 (SQSTM), were also differentially expressed. Western blot analysis showed that GW4064 stimulation induced activation of the extrinsic death signaling pathway in all cell lines and induced activation of the intrinsic death signaling pathway in DLD1 cells. Western blotting showed that DR5 up-regulation was associated with inhibition of autophagic activity. These results suggest that FXR activation induced DR5 up-regulation through inhibition of autophagic activity and the DR5-related death signaling pathway. In addition, DR5 selective ligand, also known as TRAIL, has been widely used for anti-cancer treatment in several clinical trials. Co-treatment of TRAIL with GW4064 synergistically inhibited colorectal cancer cell proliferation as compared with single treatments. To the best of our knowledge, our results provide novel insights into FXR function in cancer cell lines. These findings may contribute to a new therapeutic strategy for colorectal cancer. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Hotta, Masahiro; Sakatani, Takashi; Ishino, Kousuke; Wada, Ryuichi; Kudo, Mitsuhiro; Yokoyama, Yasuyuki; Naito, Zenya] Nippon Med Sch, Dept Integrated Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo, Japan.
   [Hotta, Masahiro; Yokoyama, Yasuyuki; Yamada, Takeshi; Yoshida, Hiroshi] Nippon Med Sch, Dept Gastrointestinal & HepatoBiliary Pancreat Su, Bunkyo Ku, 1-1-5 Sendagi, Tokyo, Japan.
   [Sakatani, Takashi] Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.
RP Sakatani, T (corresponding author), Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.
EM takashi-sakatani@nms.ac.jp
RI Ishino, Kousuke/G-8473-2018
OI Ishino, Kousuke/0000-0002-6862-9898
CR Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174
   Degirolamo C, 2011, TRENDS MOL MED, V17, P564, DOI 10.1016/j.molmed.2011.05.010
   Dermadi D, 2017, CANCER RES, V77, P3352, DOI 10.1158/0008-5472.CAN-16-2860
   Gadaleta RM, 2017, MOL ASPECTS MED, V56, P66, DOI 10.1016/j.mam.2017.04.002
   Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53
   Goncharenko-Khaider N, 2010, ONCOGENE, V29, P5523, DOI 10.1038/onc.2010.288
   Haimovici A, 2017, CELL DEATH DIFFER, V24, P866, DOI 10.1038/cdd.2017.40
   Ishino K, 2018, BIOCHEM BIOPH RES CO, V501, P668, DOI 10.1016/j.bbrc.2018.05.041
   Kanzaki A, 2016, INT J ONCOL, V48, P1007, DOI 10.3892/ijo.2016.3323
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kondo R, 2019, INT J ONCOL, V54, P1409, DOI 10.3892/ijo.2019.4710
   Lax S, 2012, INT J CANCER, V130, P2232, DOI 10.1002/ijc.26293
   Lee JM, 2014, NATURE, V516, P112, DOI 10.1038/nature13961
   Lee J, 2010, J BIOL CHEM, V285, P12604, DOI 10.1074/jbc.M109.094524
   Lew JL, 2004, J BIOL CHEM, V279, P8856, DOI 10.1074/jbc.M306422200
   Modica S, 2008, CANCER RES, V68, P9589, DOI 10.1158/0008-5472.CAN-08-1791
   Ohno T, 2012, CANCER LETT, V323, P215, DOI 10.1016/j.canlet.2012.04.015
   Park E.J., 2016, SCI REP, V6, P1
   Perimenis P., 2016, BMC CANCER, V16, P1
   Qiao X., 2018, CANCER COMMUN, V38, P1
   Romagnolo DF, 2014, ADV NUTR, V5, P373, DOI 10.3945/an.114.005868
   Seok S, 2014, NATURE, V516, P108, DOI 10.1038/nature13949
   Xie G., 2015, J CANC METASTATSIS T, V2, P24
   Xie Guofeng, 2016, J Cancer Metastasis Treat, V2, P195, DOI 10.20517/2394-4722.2016.05
NR 26
TC 4
Z9 4
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 19
PY 2019
VL 519
IS 4
BP 824
EP 831
DI 10.1016/j.bbrc.2019.09.033
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA KB3OO
UT WOS:000506409400025
PM 31561852
DA 2022-04-25
ER

PT J
AU Vanderlaag, K
   Su, YP
   Frankel, AE
   Burghardt, RC
   Barhoumi, R
   Chadalapaka, G
   Jutooru, I
   Safe, S
AF Vanderlaag, Kathy
   Su, Yunpeng
   Frankel, Arthur E.
   Burghardt, Robert C.
   Barhoumi, Rola
   Chadalapaka, Gayathri
   Jutooru, Indira
   Safe, Stephen
TI 1,1-Bis(3 '-indolyl)-1-(p-substituted phenyl) methanes induce autophagic
   cell death in estrogen receptor negative breast cancer
SO BMC CANCER
LA English
DT Article
ID PROSTATE-CANCER; 3,3'-DIINDOLYLMETHANE DIM; GROWTH-INHIBITION; CYCLE
   ARREST; GAMMA AGONISTS; UP-REGULATION; TUMOR-GROWTH; APOPTOSIS;
   ACTIVATION; COLON
AB Background: A novel series of methylene-substituted DIMs (C-DIMs), namely 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes containing t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-pPhC6H5) groups inhibit proliferation of invasive estrogen receptor-negative MDA-MB-231 and MDA-MB-453 human breast cancer cell lines with IC50 values between 1-5 uM. The main purpose of this study was to investigate the pathways of C-DIM-induced cell death.
   Methods: The effects of the C-DIMs on apoptotic, necrotic and autophagic cell death were determined using caspase inhibitors, measurement of lactate dehydrogenase release, and several markers of autophagy including Beclin and light chain associated protein 3 expression (LC3).
   Results: The C-DIM compounds did not induce apoptosis and only DIM-C-pPhCF(3) exhibited necrotic effects. However, treatment of MDA-MB-231 and MDA-MB-453 cells with C-DIMs resulted in accumulation of LC3-II compared to LC3-I protein, a characteristic marker of autophagy, and transient transfection of green fluorescent protein-LC3 also revealed that treatment with C-DIMs induced a redistribution of LC3 to autophagosomes after C-DIM treatment. In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific autophagolysosome marker, accumulated in vacuoles after C-DIM treatment, and western blot analysis of lysates from cells treated with C-DIMs showed that the Beclin 1/Bcl-2 protein ratio increased.
   Conclusion: The results suggest that C-DIM compounds may represent a new mechanism-based agent for treating drug-resistant ER-negative breast tumors through induction of autophagy.
C1 [Burghardt, Robert C.; Barhoumi, Rola] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
   [Vanderlaag, Kathy; Chadalapaka, Gayathri; Jutooru, Indira; Safe, Stephen] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
   [Su, Yunpeng; Frankel, Arthur E.] Scott & White Mem Hosp & Clin, Canc Res Inst, Temple, TX 76502 USA.
   [Safe, Stephen] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA.
RP Burghardt, RC (corresponding author), Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
EM rburghardt@cvm.tamu.edu; ssafe@cvm.tamu.edu
RI Burghardt, Robert C./AAF-4847-2021
OI Burghardt, Robert C./0000-0003-1021-8444
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA108718]; Texas
   AgriLife Research; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA108718] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health
   (R01CA108718) and Texas AgriLife Research.
CR Abdelrahim M, 2006, CARCINOGENESIS, V27, P717, DOI 10.1093/carcin/bgi270
   Bhuiyan MMR, 2006, CANCER RES, V66, P10064, DOI 10.1158/0008-5472.CAN-06-2011
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Butler R, 2000, CELL GROWTH DIFFER, V11, P49
   Chaffer CL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-53
   Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631
   Chen Y, 2005, BIOCHEM BIOPH RES CO, V337, P52, DOI 10.1016/j.bbrc.2005.09.018
   Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365
   Chintharlapalli S, 2005, MOL PHARMACOL, V68, P1782, DOI 10.1124/mol.105.017046
   Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200
   Chintharlapalli S, 2004, CANCER RES, V64, P5994, DOI 10.1158/0008-5472.CAN-04-0399
   Chintharlapalli S, 2007, CARCINOGENESIS, V28, P2337, DOI 10.1093/carcin/bgm189
   Chintharlapalli S, 2006, MOL CANCER THER, V5, P1362, DOI 10.1158/1535-7163.MCT-06-0002
   Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905
   Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61
   Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806
   Gorka M, 2005, ANTI-CANCER DRUG, V16, P777
   GRUBBS CJ, 1995, ANTICANCER RES, V15, P709
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0
   Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297
   Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kassouf W, 2006, CANCER RES, V66, P412, DOI 10.1158/0008-5472.CAN-05-2755
   Kim EJ, 2007, J NUTR, V137, P31, DOI 10.1093/jn/137.1.31
   Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795
   Kristal AR, 2002, NUTR CANCER, V42, P1, DOI 10.1207/S15327914NC421_1
   Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478
   Lamparska-Przybysz M, 2005, J Physiol Pharmacol, V56 Suppl 3, P159
   Lei P, 2006, MOL CANCER THER, V5, P2324, DOI 10.1158/1535-7163.MCT-06-0184
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Motomura W, 2000, CANCER RES, V60, P5558
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Murillo G, 2001, NUTR CANCER, V41, P17, DOI 10.1207/S15327914NC41-1&amp;2_2
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pedro M, 2006, TOXICOL LETT, V164, P24, DOI 10.1016/j.toxlet.2005.11.007
   Qin CH, 2004, MOL CANCER THER, V3, P247
   Rahman KMW, 2006, CANCER RES, V66, P4952, DOI 10.1158/0008-5472.CAN-05-3918
   Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   TANAKA T, 1992, JPN J CANCER RES, V83, P835, DOI 10.1111/j.1349-7006.1992.tb01988.x
   Vanderlaag K, 2008, BREAST CANCER RES TR, V109, P273, DOI 10.1007/s10549-007-9648-y
   Vanderlaag K, 2006, CANCER LETT, V236, P198, DOI 10.1016/j.canlet.2005.05.036
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477
   Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904
NR 61
TC 14
Z9 15
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 3
PY 2010
VL 10
AR 669
DI 10.1186/1471-2407-10-669
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 696DZ
UT WOS:000285423400001
PM 21129193
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Monti, E
   Marras, E
   Prini, P
   Gariboldi, MB
AF Monti, Elena
   Marras, Emanuela
   Prini, Pamela
   Gariboldi, Marzia Bruna
TI Luteolin impairs hypoxia adaptation and progression in human breast and
   colon cancer cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Luteolin; HIF-1; Cell death; CD44; CD47; Migration
ID INDUCIBLE FACTORS; POOR-PROGNOSIS; HIF-1-ALPHA; CYTOTOXICITY; APOPTOSIS;
   AUTOPHAGY; OVEREXPRESSION; HIF-2-ALPHA; MAINTENANCE; EXPRESSION
AB Hypoxia-inducible factors (HIFs) are the force which drives hypoxic cancer cells to a more aggressive and resistant phenotype in a number of solid tumors, including colorectal and breast cancer. Results from recent studies suggest a role for HIF-1 in immune evasion and cancer stem cell phenotype promotion, establishing HIF-1 as a potential therapeutic target. Thus, identifying new compounds that might inhibit HIF1 activity, or at least exert antiproliferative effects that are unaffected by HIF1-dependent adaptations, is an attractive goal for the management of hypoxic tumors.
   Here we show that the flavonoid luteolin exerts a significant cytotoxic effect on the colon cancer cell line HCT116 and the breast adenocarcinoma cell line MDA-MB231, by inducing both apoptotic and necrotic cell death, and that this effect is not impaired by HIF-1 activation. In these cells, luteolin also stimulates autophagy; however this seems to be part of a protective response, rather than contribute to the cytotoxic effect. Interestingly, luteolin induces a decrease in HIF-1 transcriptional activity. This is accompanied by a decrease in the levels of protein markers of stemness and invasion, and by a reduction of migratory capacity of the cells.
   Taken together, our results suggest that luteolin could be developed into a useful therapeutic agent aimed at hypoxic tumors.
C1 [Monti, Elena; Marras, Emanuela; Prini, Pamela; Gariboldi, Marzia Bruna] Univ Insubria, Dept Biotechnol & Life Sci DBSV, Via JH Dunant 3, I-21100 Varese, VA, Italy.
RP Gariboldi, MB (corresponding author), Univ Insubria, Dept Biotechnol & Life Sci DBSV, Via Manara 7, Busto Arsizio, VA, Italy.
EM marzia.gariboldi@uninsubria.it
OI gariboldi, marzia bruna/0000-0002-5683-0885
FU Universita degli Studi dell'Insubria, Fondi di Ateneo per la Ricerca
FX This study was supported by the Universita degli Studi dell'Insubria,
   Fondi di Ateneo per la Ricerca "FAR2016" and "FAR2017" (to EM and MBG).
   The funding agencies were not involved in the research plan and the
   interpretation of the data.
CR Adams A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-538
   Ajdukovic J., 2016, Experimental Oncology, V38, P9
   Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972
   Berardi DE, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/595092
   Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187
   Cai XT, 2011, TOXICOL IN VITRO, V25, P1385, DOI 10.1016/j.tiv.2011.05.009
   Chen Q, 2012, NAT PROD COMMUN, V7, P29
   Choi AY, 2011, EUR J PHARMACOL, V668, P115, DOI 10.1016/j.ejphar.2011.06.047
   de Oliveira JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134458
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gao ZJ, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317709637
   Gariboldi MB, 2015, CANCER LETT, V364, P156, DOI 10.1016/j.canlet.2015.05.008
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Gilkes DM, 2014, P NATL ACAD SCI USA, V111, pE384, DOI 10.1073/pnas.1321510111
   Han SS, 2018, CELL PHYSIOL BIOCHEM, V48, P516, DOI 10.1159/000491806
   Harhaji-Trajkovic L, 2012, PHARM RES-DORDR, V29, P2249, DOI 10.1007/s11095-012-0753-1
   Johansson E, 2017, CELL REP, V20, P1641, DOI 10.1016/j.celrep.2017.07.049
   Kasprowska-Liskiewicz D, 2017, POSTEP HIG MED DOSW, V71, P825, DOI 10.5604/01.3001.0010.4672
   Kilani-Jaziri S, 2012, DRUG CHEM TOXICOL, V35, P1, DOI 10.3109/01480545.2011.564180
   Kim MC, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4720-z
   Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078
   Lequeux A, 2019, CANCER LETT, V458, P13, DOI 10.1016/j.canlet.2019.05.021
   Liu XL, 2017, PROCEEDING OF THE PREDICTGIS 2017 WORKSHOP, P10, DOI 10.1145/3152341.3152345
   Lopez-Lazaro M, 2009, MINI-REV MED CHEM, V9, P31, DOI 10.2174/138955709787001712
   Ma ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183426
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Marceau F, 2012, TOXICOL APPL PHARM, V259, P1, DOI 10.1016/j.taap.2011.12.004
   Mathonnet M, 2014, WORLD J GASTROENTERO, V20, P4189, DOI 10.3748/wjg.v20.i15.4189
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Monti Elena, 2011, Curr Mol Pharmacol, V4, P62
   Rankin EB, 2016, TRENDS CANCER, V2, P295, DOI 10.1016/j.trecan.2016.05.006
   Ravizza R, 2009, EUR J CANCER, V45, P890, DOI 10.1016/j.ejca.2008.12.021
   Ryabaya OO, 2017, ANTI-CANCER DRUG, V28, P307, DOI 10.1097/CAD.0000000000000463
   Samanta D, 2018, P NATL ACAD SCI USA, V115, pE1239, DOI 10.1073/pnas.1718197115
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Schlie Katrin, 2011, Int J Cell Biol, V2011, P470597, DOI 10.1155/2011/470597
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Triantafyllou A, 2008, FREE RADICAL BIO MED, V44, P657, DOI 10.1016/j.freeradbiomed.2007.10.050
   Vadde R, 2017, CRIT REV ONCOL HEMAT, V113, P22, DOI 10.1016/j.critrevonc.2017.02.025
   Vlachodimitropoulou E, 2011, FREE RADICAL BIO MED, V50, P934, DOI 10.1016/j.freeradbiomed.2011.01.005
   Wang G, 2017, ONCOL REP, V37, P657, DOI 10.3892/or.2016.5309
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109
   Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1
   Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zhang DD, 2020, J CELL PHYSIOL, V235, P3626, DOI 10.1002/jcp.29252
   Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112
   Zhang Q, 2009, TOXICOL IN VITRO, V23, P797, DOI 10.1016/j.tiv.2009.04.007
   Zhang T, 2019, ADV EXP MED BIOL, V1136, P87, DOI 10.1007/978-3-030-12734-3_6
NR 51
TC 8
Z9 8
U1 4
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 15
PY 2020
VL 881
AR 173210
DI 10.1016/j.ejphar.2020.173210
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NI9LX
UT WOS:000565668300009
PM 32526242
DA 2022-04-25
ER

PT J
AU Zhang, MY
   Wang, LY
   Zhao, S
   Guo, XC
   Xu, YQ
   Zheng, ZH
   Lu, H
   Zheng, HC
AF Zhang, Mei-Ying
   Wang, Li-Yuan
   Zhao, Shuang
   Guo, Xiao-Chong
   Xu, Ying-Qi
   Zheng, Zhi-Hong
   Lu, Hang
   Zheng, Hua-Chuan
TI Effects of Beclin 1 overexpression on aggressive phenotypes of colon
   cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE colon cancer; Beclin 1; aggressive phenotypes; autophagy; gene therapy
ID PROGNOSTIC-SIGNIFICANCE; PROTEIN EXPRESSION; POOR-PROGNOSIS; AUTOPHAGY;
   TUMOR; TUMORIGENESIS; CLEAVAGE; GROWTH; LC3
AB Beclin 1 is involved in autophagy, differentiation, apoptosis and cancer progression, and functions as a haploinsufficient tumor suppressor gene. The aim of the present study was to elucidate the function of Beclin 1 in colon cancer. A Beclin 1-expressing plasmid was transfected into HCT-15 and HCT-116 cells, and the phenotypes and associated molecules were determined. Beclin 1 transfectants were subcutaneously injected into nude mice to determine tumor growth, and proliferation and apoptosis levels using Ki-67 immunostaining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), respectively. Beclin 1 overexpression inhibited viability as determined using a Cell Counting Kit-8 assay, inhibited migration and invasion as determined using a wound healing assay or Transwell assay, and lamellipodia formation by filamentous actin staining, induced autophagy as determined using electron microscopy, and light chain 3B (LC-3B) expression, and apoptosis as determined using Annexin V staining in the two cell lines (P<0.05). Beclin 1 induced G(2) arrest of HCT-15 transfectants as determined using propidium iodide staining (P<0.05), whereas HCT-116 transfectants were arrested in G(1) phase (P<0.05). The two transfectants exhibited increased expression of c-Myc, cyclin D1, -catenin, insulin-response element 1 and 78 kDa glucose-regulated protein compared with the control and mock cells as determined using the reverse transcription-quantitative polymerase chain reaction (P<0.05). Beclin 1 overexpression upregulated LC-3B and cyclin-dependent kinase 4 expression, but downregulated cyclin E expression of the cancer cell lines as determined using western blot analysis (P<0.05). Beclin 1 expression in vivo significantly suppressed the proliferation of colon cancer cells in xenograft models via inducing apoptosis by TUNEL, and inhibiting proliferation by Ki-67 expression (P<0.05). Beclin 1 overexpression may reverse aggressive phenotypes and suppress colon cancer tumor growth, and be employed as a target molecule for gene therapy of patients with colon cancer.
C1 [Zhang, Mei-Ying; Wang, Li-Yuan; Guo, Xiao-Chong; Xu, Ying-Qi; Zheng, Zhi-Hong] China Med Univ, Coll Basic Med, Lab Anim Ctr, Shenyang 110001, Liaoning, Peoples R China.
   [Zhao, Shuang; Zheng, Hua-Chuan] China Med Univ, Coll Basic Med, Dept Biochem & Mol Biol, 77 Puhe Rd, Shenyang 110001, Liaoning, Peoples R China.
   [Lu, Hang] Liaoning Med Univ, Dept Surg, Affiliated Hosp 1, Jinzhou 121001, Liaoning, Peoples R China.
RP Zheng, HC (corresponding author), China Med Univ, Coll Basic Med, Dept Biochem & Mol Biol, 77 Puhe Rd, Shenyang 110001, Liaoning, Peoples R China.
EM zheng_huachuan@hotmail.com
FU Scientific Research Fund of Liaoning Provincial Education Department
   [LJQ2014093, L2014333]; Liaoning BaiQianWan Talents Program; Outstanding
   Scientific Fund of Shengjing Hospital; Award for Liaoning Distinguished
   Professors; Shenyang Science and Technology Grand [18-013-0-59];
   National Natural Scientific Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472544, 81672700]
FX The present study was supported by A Project Supported by Scientific
   Research Fund of Liaoning Provincial Education Department (grant nos.
   LJQ2014093 and L2014333), Liaoning BaiQianWan Talents Program,
   Outstanding Scientific Fund of Shengjing Hospital, Award for Liaoning
   Distinguished Professors, Shenyang Science and Technology Grand (grant
   no. 18-013-0-59) and the National Natural Scientific Foundation of China
   (grant nos. 81472544 and 81672700).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Duan Zhen-Ling, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P239
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Jiang ZF, 2012, MOL BIOL REP, V39, P259, DOI 10.1007/s11033-011-0734-1
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Muller GA, 2010, FEBS J, V277, P877, DOI 10.1111/j.1742-4658.2009.07508.x
   Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Pajalunga D, 2008, CELL MOL LIFE SCI, V65, P8, DOI 10.1007/s00018-007-7425-z
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Shi YH, 2009, AUTOPHAGY, V5, P380, DOI 10.4161/auto.5.3.7658
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449
   Wang LH, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-46
   Wang Zan-Hong, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P860
   Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034
   Won KY, 2012, HUM PATHOL, V43, P62, DOI 10.1016/j.humpath.2011.04.007
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zheng HC, 2008, HUM PATHOL, V39, P1042, DOI 10.1016/j.humpath.2007.11.009
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 32
TC 10
Z9 12
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2019
VL 17
IS 2
BP 2441
EP 2450
DI 10.3892/ol.2018.9817
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HM5YS
UT WOS:000459551800129
PM 30675309
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Tang, YX
   Chen, K
   Luan, XX
   Zhang, JY
   Liu, RR
   Zheng, XX
   Xie, SZ
   Ke, HP
   Zhang, XN
   Chen, W
AF Tang, Yuexiao
   Chen, Ke
   Luan, Xiaorui
   Zhang, Jinyan
   Liu, Rongrong
   Zheng, Xiaoxiao
   Xie, Shangzhi
   Ke, Haiping
   Zhang, Xianning
   Chen, Wei
TI Knockdown of eukaryotic translation initiation factor 5A2 enhances the
   therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells
   by triggering lethal autophagy
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE hepatocellular carcinoma; doxorubicin; chemotherapy; autophagic cell
   death
ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELLS; COLORECTAL-CANCER;
   EIF5A2; CHEMORESISTANCE; RESISTANCE; CONTRIBUTES; INHIBITION;
   ACTIVATION; EXPRESSION
AB Hepatocellular carcinoma (HCC) is an invasive malignant neoplasm with a poor prognosis. The development of chemoresistance severely obstructs the chemotherapeutic efficiency of HCC treatment. Therefore, understanding the mechanisms of chemoresistance is important for improving the outcomes of patients with HCC. Eukaryotic translation initiation factor 5A2 (eIF5A2), which is considered to be an oncogene, has been reported to mediate chemoresistance in various types of cancer; however, its precise role in HCC remains unclear. Accumulating evidence has suggested that autophagy serves a dual role in cancer chemotherapy. The present study aimed to investigate the role of autophagy in eIF5A2-mediated doxorubicin resistance in HCC. High expression levels of eIF5A2 in human HCC tissues were observed by immunohistochemistry using a tissue microarray, which was consistent with the results of reverse transcription-quantitative PCR analysis in paired HCC and adjacent healthy tissues. HCC patient-derived tumor xenograft mouse model was used for the in vivo study, and knockdown of eIF5A2 effectively enhanced the efficacy of doxorubicin chemotherapy compared with that in the control group. Notably, eIF5A2 served as a repressor in regulating autophagy under chemotherapy. Silencing of eIF5A2 induced doxorubicin sensitivity in HCC cells by triggering lethal autophagy. In addition, 5-ethynyl-2 '-deoxyuridine, lactate dehydrogenase release assay and calcein-AM/PI staining were used to determine the enhanced autophagic cell death induced by the silencing of eIF5A2 under doxorubicin treatment. Suppression of autophagy attenuated the sensitivity of HCC cells to doxorubicin induced by eIF5A2 silencing. The results also demonstrated that knockdown of the Beclin 1 gene, which is an autophagy regulator, reversed the enhanced autophagic cell death and doxorubicin sensitivity induced by eIF5A2 silencing. Taken together, these results suggested eIF5A2 may mediate the chemoresistance of HCC cells by suppressing autophagic cell death under chemotherapy through a Beclin 1-dependent pathway, and that eIF5A2 may be a novel potential therapeutic target for HCC treatment.
C1 [Tang, Yuexiao; Luan, Xiaorui; Zhang, Jinyan; Zhang, Xianning] Zhejiang Univ, Sch Med, Inst Cell Biol, Dept Genet,Zhejiang Prov Key Lab Genet & Dev Diso, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
   [Tang, Yuexiao; Luan, Xiaorui; Zhang, Jinyan; Zheng, Xiaoxiao; Xie, Shangzhi; Chen, Wei] Zhejiang Acad Tradit Chinese Med, Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western, Hangzhou 310012, Zhejiang, Peoples R China.
   [Chen, Ke] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China.
   [Liu, Rongrong] Zhejiang Univ, Sch Med, Childrens Hosp, Div Hematol Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Ke, Haiping] Ningbo Coll Hlth Sci, Dept Biol, Ningbo 315100, Zhejiang, Peoples R China.
RP Zhang, XN (corresponding author), Zhejiang Univ, Sch Med, Inst Cell Biol, Dept Genet,Zhejiang Prov Key Lab Genet & Dev Diso, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.; Chen, W (corresponding author), Zhejiang Acad Tradit Chinese Med, Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western, Hangzhou 310012, Zhejiang, Peoples R China.
EM zhangxianning@zju.edu.cn; wei_chen@zju.edu.cn
RI Zhang, Xian-Ning/B-8412-2009
FU Zhejiang Provincial Ten Thousand Plan for Young Top Talents (2018);
   Innovative Talents Training Project of Zhejiang Health Bureau (2018);
   Key Project Co-constructed by the Zhejiang Province and Ministry
   [WKJ-ZJ-1916]; National High Technology Research and Development Program
   of ChinaNational High Technology Research and Development Program of
   China [SS2014AA020533]; Zhejiang Provincial Natural Science Foundation
   of ChinaNatural Science Foundation of Zhejiang Province [LQ13H160006];
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81302071, 81673809]
FX This study was supported by the Zhejiang Provincial Ten Thousand Plan
   for Young Top Talents (2018), the Innovative Talents Training Project of
   Zhejiang Health Bureau (2018), the Key Project Co-constructed by the
   Zhejiang Province and Ministry (grant no. WKJ-ZJ-1916), the National
   High Technology Research and Development Program of China (grant no.
   SS2014AA020533), the Zhejiang Provincial Natural Science Foundation of
   China (grant no. LQ13H160006) and the Natural Science Foundation of
   China (grant nos. 81302071 and 81673809).
CR Altman JK, 2014, CLIN CANCER RES, V20, P2400, DOI 10.1158/1078-0432.CCR-13-3218
   Bao Y, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0250-9
   Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041
   Caraglia M, 2013, AMINO ACIDS, V44, P103, DOI 10.1007/s00726-011-1182-x
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Dai CH, 2018, BBA-MOL BASIS DIS, V1864, P3786, DOI 10.1016/j.bbadis.2018.10.015
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Fang L, 2018, J CANCER, V9, P3479, DOI 10.7150/jca.26136
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Guo QQ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103111
   Hayat MA, 2016, AUTOPHAGY CANC OTHER, V1
   Hu F, 2018, CANCER LETT, V416, P24, DOI 10.1016/j.canlet.2017.12.013
   Huang PY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2714-2
   Khosravi S, 2014, BRIT J CANCER, V110, P399, DOI 10.1038/bjc.2013.688
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027
   Li Y, 2014, GASTROENTEROLOGY, V146, P1701, DOI 10.1053/j.gastro.2014.02.029
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liu Y, 2015, BREAST CANCER-TOKYO, V22, P602, DOI 10.1007/s12282-014-0526-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma MC, 2014, SCI WORLD J, DOI 10.1155/2014/160138
   Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811
   Masui A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162786
   Mathews MB, 2015, BBA-GENE REGUL MECH, V1849, P836, DOI 10.1016/j.bbagrm.2015.05.002
   Meng QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119229
   Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263
   Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769
   Schuller AP, 2017, MOL CELL, V66, P194, DOI 10.1016/j.molcel.2017.03.003
   Segala G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01948-9
   Sun DJ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12402
   Sun JC, 2018, AM J TRANSL RES, V10, P4269
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Taylor CA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-35
   Wang HB, 2013, AUTOPHAGY, V9, P1975, DOI 10.4161/auto.26152
   Wang XY, 2017, CANCER LETT, V385, P128, DOI 10.1016/j.canlet.2016.10.034
   Wu FQ, 2016, J HEPATOL, V65, P314, DOI 10.1016/j.jhep.2016.04.019
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Xue F, 2016, AM J TRANSL RES, V8, P4670
   Yamakawa K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174224
   Yang H, 2015, ONCOTARGET, V6, P26079, DOI 10.18632/oncotarget.4581
   Yang JS, 2014, CANCER SCI, V105, P219, DOI 10.1111/cas.12328
   Yao MY, 2017, EXP THER MED, V14, P2101, DOI 10.3892/etm.2017.4740
   Zeng QH, 2018, CLIN CANCER RES, V24, P445, DOI 10.1158/1078-0432.CCR-17-0419
   Zheng X, 2020, HISTOL HISTOPATHOL, V35, P579, DOI 10.14670/HH-18-186
   Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207
   Zhuang K, 2017, ONCOL RES, V25, P1399, DOI 10.3727/096504016X14823648620870
NR 49
TC 2
Z9 2
U1 1
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2020
VL 57
IS 6
BP 1368
EP 1380
DI 10.3892/ijo.2020.5143
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OY0UU
UT WOS:000593970700002
PM 33174013
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Luo, MY
   Li, HX
   Han, DH
   Yang, KZ
   Kang, L
AF Luo, Mengyu
   Li, Hongxia
   Han, Duhong
   Yang, Kaizhen
   Kang, Ling
TI Inhibition of autophagy enhances apoptosis induced by Ce6-photodynamic
   therapy in human colon cancer cells
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Photodynamic therapy; Chlorin E6; Colorectal cancer; Autophagy;
   Apoptosis
ID MEDIATED PHOTODYNAMIC THERAPY; CHLORIN E(6); RESISTANCE; PATHWAY;
   TARGET; MG-63
AB Objective: To evaluate the therapeutic effect of Chlorin e6 photodynamic therapy (Ce6-PDT) in human colorectal cancer cells and investigate the role of autophagy in Ce6-PDT. Methods: SW480 cells underwent Ce6-PDT with and without pretreatment with the autophagy inhibitor 3-methyladenine (3MA). Cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was evaluated using an Annexin V assay, using a rhodamine 123 (RH123) assay to evaluate mitochondrial membrane potential (MMP), and by measuring Caspase-3 and Bcl-2 protein expression using western blotting. Autophagy was evaluated by directly visualizing acridine orange-stained acidic vesicular organelles (AVOs) using fluorescent microscopy and by measuring LC3I/IIand Atg5 expression using western blotting. Results: Ce6-PDT decreased SW480 viability in a dose-dependent manner. Ce6-PDT induced apoptosis in SW480 cells via the mitochondrial apoptosis pathway as indicated by decreased mitochondrial membrane potential, increased Annexin V staining, and increased Caspase-3 expression. Ce6-PDT was also shown to induce autophagy as demonstrated by increased acridine-orange stained AVOs as well as increased expression of the autophagyassociated proteins Atg5. Inhibition of autophagy with 3MA potentiated SW480 cell response to Ce6-PDT and increased the rate of apoptosis in the treated cells. Conclusions: Ce6-PDT induces autophagy and apoptosis of SW480 cells in a dose-dependent manner. Inhibition of autophagy increases the apoptosis induced by Ce6-PDT. Modulation of autophagy may be a potential therapeutic target for colon cancer cells treated with Ce6-PDT.
C1 [Luo, Mengyu; Li, Hongxia; Han, Duhong; Kang, Ling] Xinjiang Med Univ, Coll Publ Hlth, 567 SHangde North Rd, Urumqi, Xinjiang, Peoples R China.
   [Yang, Kaizhen] First Peoples Hosp Urumqi, Urumqi, Xinjiang, Peoples R China.
RP Kang, L (corresponding author), Xinjiang Med Univ, Coll Publ Hlth, 567 SHangde North Rd, Urumqi, Xinjiang, Peoples R China.
EM 540802213@qq.com
FU Xinjiang Uygur Autonomous Region Natural Science Foundation
   [:2014211C003]
FX This study was supported by the Xinjiang Uygur Autonomous Region Natural
   Science Foundation (No:2014211C003) .
CR Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bai Z, 2018, CLIN TRANSL ONCOL, V20, P176, DOI 10.1007/s12094-017-1708-0
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bincoletto C, 2013, CHEM-BIOL INTERACT, V206, P279, DOI 10.1016/j.cbi.2013.09.018
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Broekgaarden M, 2015, CANCER METAST REV, V34, P643, DOI 10.1007/s10555-015-9588-7
   Burke PJ, 2017, TRENDS CANCER, V3, P857, DOI 10.1016/j.trecan.2017.10.006
   Ortiz-Lazareno PC, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-13
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cho H, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6917590
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Fujiwara N, 2015, CANCER RES, V75, P3890, DOI 10.1158/0008-5472.CAN-15-0257
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495-016-1243-4
   Kessel D, 2014, PHOTOCHEM PHOTOBIOL, V90, P1211, DOI 10.1111/php.12283
   KOSTENICH GA, 1994, J PHOTOCH PHOTOBIO B, V22, P211, DOI 10.1016/1011-1344(93)06974-8
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li KT, 2016, CANCER MED-US, V5, P3186, DOI 10.1002/cam4.895
   Lin SC, 2017, INT J BIOCHEM CELL B, V87, P54, DOI 10.1016/j.biocel.2017.04.001
   Mahmoudi K, 2019, J NEURO-ONCOL, V141, P595, DOI 10.1007/s11060-019-03103-4
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Orenstein A, 1996, BRIT J CANCER, V73, P937, DOI 10.1038/bjc.1996.185
   Rodriguez ME, 2017, PHOTOCH PHOTOBIO SCI, V16, P1631, DOI 10.1039/c7pp00161d
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Suloglu AK, 2015, CYTOTECHNOLOGY, V67, P311, DOI 10.1007/s10616-013-9688-6
   Thammasit P, 2015, J CANCER, V6, P276, DOI 10.7150/jca.10879
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   van Straten D, 2017, CANCERS, V9, DOI 10.3390/cancers9020019
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Yang KZ, 2018, PHOTODIAGN PHOTODYN, V24, P332, DOI 10.1016/j.pdpdt.2018.10.012
   Ziolkowska B, 2016, MOL MED REP, V14, P2548, DOI 10.3892/mmr.2016.5541
NR 38
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2021
VL 36
AR 102605
DI 10.1016/j.pdpdt.2021.102605
EA NOV 2021
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WZ2CZ
UT WOS:000719780700005
PM 34715368
DA 2022-04-25
ER

PT J
AU Zhang, JB
   Wang, JG
   Xu, J
   Lu, YQ
   Jiang, JK
   Wang, LM
   Shen, HM
   Xia, DJ
AF Zhang, Jianbin
   Wang, Jigang
   Xu, Jian
   Lu, Yuanqiang
   Jiang, Jiukun
   Wang, Liming
   Shen, Han-Ming
   Xia, Dajing
TI Curcumin targets the TFEB-lysosome pathway for induction of autophagy
SO ONCOTARGET
LA English
DT Article
DE Curcumin; lysosome; mTOR; TFEB; autophagy
ID SIGNALING PATHWAYS; OXIDATIVE STRESS; CELL-DEATH; IN-VITRO; MTOR;
   SUPPRESSION; INHIBITION; ACTIVATION; MECHANISMS; AMPK
AB Curcumin is a hydrophobic polyphenol derived from the herb Curcumalonga and its wide spectrum of pharmacological activities has been widely studied. It has been reported that Curcumin can induce autophagy through inhibition of the Akt-mTOR pathway. However, the effect of Curcumin on lysosome remains largely elusive. In this study, we first found that Curcumin treatment enhances autophagic flux in both human colon cancer HCT116 cells and mouse embryonic fibroblasts (MEFs). Moreover, Curcumin treatment promotes lysosomal function, evidenced by the increased lysosomal acidification and enzyme activity. Second, Curcumin is capable of suppressing the mammalian target of rapamycin (mTOR). Interestingly, Curcumin fails to inhibit mTOR and to activate lysosomal function in Tsc2(-/-)MEFs with constitutive activation of mTOR, indicating that Curcumin-mediated lysosomal activation is achieved via suppression of mTOR. Third, Curcumin treatment activates transcription factor EB (TFEB), a key nuclear transcription factor in control of autophagy and lysosome biogenesis and function, based on the following observations: (i) Curcumin directly binds to TFEB, (ii) Curcumin promotes TFEB nuclear translocation; and (iii) Curcumin increases transcriptional activity of TFEB. Finally, inhibition of autophagy and lysosome leads to more cell death in Curcumin-treated HCT116 cells, suggesting that autophagy and lysosomal activation serves as a cell survival mechanism to protect against Curcumin-mediated cell death. Taken together, data from our study provide a novel insight into the regulatory mechanisms of Curcumin on autophagy and lysosome, which may facilitate the development of Curcumin as a potential cancer therapeutic agent.
C1 [Zhang, Jianbin] Zhejiang Prov Peoples Hosp, Clin Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Jianbin; Wang, Jigang; Wang, Liming; Shen, Han-Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.
   [Zhang, Jianbin; Xu, Jian; Xia, Dajing] Zhejiang Univ, Inst Immunol, Sch Publ Hlth, Hangzhou, Zhejiang, Peoples R China.
   [Lu, Yuanqiang; Jiang, Jiukun] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
   [Shen, Han-Ming] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
RP Shen, HM (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.; Xia, DJ (corresponding author), Zhejiang Univ, Inst Immunol, Sch Publ Hlth, Hangzhou, Zhejiang, Peoples R China.; Shen, HM (corresponding author), Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
EM phsshm@nus.edu.sg; dxia@zju.edu.cn
RI SHEN, Han-Ming/B-5942-2011; Wang, Liming/M-7381-2019
OI SHEN, Han-Ming/0000-0001-7369-5227; Wang, Liming/0000-0002-5444-2424
FU Singapore National Medical Research CouncilNational Medical Research
   Council, Singapore [NMRC/1260/2010, NMRC/CIRG/1373/2013]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31471297]
FX We would like to thank Dr A Ballabio for providing the pCMV-TFEB-3X Flag
   plasmid [28] and the TFEB luciferase vector, [51] Dr. Noboru Mizushima
   (Tokyo Medical and Dental University, Japan) for the MEFs with stable
   expression of GFP-LC3, and Dr. DJ Kwiatkowski (Harvard University, USA)
   for providing the pair of Tsc2<SUP>+/+</SUP> and Tsc2<SUP>-/-</SUP>
   MEFs. This work was supported by grants from Singapore National Medical
   Research Council (NMRC/1260/2010 and NMRC/CIRG/1373/2013) to HMS and by
   a grant from the National Natural Science Foundation of China (No.
   31471297) to DX.
CR Akkoc Y, 2015, BIOMED PHARMACOTHER, V71, P161, DOI 10.1016/j.biopha.2015.02.029
   Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Basile V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053664
   Buyuklu M, 2014, EUR REV MED PHARMACO, V18, P461
   Chen QY, 2012, MOL CELL BIOCHEM, V359, P389, DOI 10.1007/s11010-011-1033-9
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Guo S, 2016, MOL MED REPORTS
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Han J, 2012, AUTOPHAGY, V8, P812, DOI 10.4161/auto.19471
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Lin JK, 2007, ADV EXP MED BIOL, V595, P227
   Lubke T, 2009, BBA-MOL CELL RES, V1793, P625, DOI 10.1016/j.bbamcr.2008.09.018
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Ng TL, 2012, CELL DEATH DIFFER, V19, P501, DOI 10.1038/cdd.2011.119
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Safe S, 2016, NATURAL PRODUCTS MEC
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Song JX, 2016, AUTOPHAGY
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Vallianou NG, 2015, ANTICANCER RES, V35, P645
   Wang C, 2014, EUR J PHARMACOL, V740, P312, DOI 10.1016/j.ejphar.2014.06.051
   Wang JG, 2016, SCI REP-UK, V6, DOI 10.1038/srep22146
   Wang K, 2016, SCI REP-UK, V6, DOI 10.1038/srep26064
   Wang Y, 2016, J LAB AUTOMATION
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Xu YJ, 2014, CELL SIGNAL, V26, P1680, DOI 10.1016/j.cellsig.2014.04.009
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang KP, 2013, J CARDIOVASC PHARM T, V18, P570, DOI 10.1177/1074248413503495
   Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044
   Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 52
TC 79
Z9 88
U1 3
U2 19
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2016
VL 7
IS 46
BP 75659
EP 75671
DI 10.18632/oncotarget.12318
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5GF
UT WOS:000389632800096
PM 27689333
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Budisan, L
   Gulei, D
   Jurj, A
   Braicu, C
   Zanoaga, O
   Cojocneanu, R
   Pop, L
   Raduly, L
   Barbat, A
   Moldovan, A
   Moldovan, C
   Tigu, AB
   Ionescu, C
   Atanasov, AG
   Irimie, A
   Berindan-Neagoe, I
AF Budisan, Liviuta
   Gulei, Diana
   Jurj, Ancuta
   Braicu, Cornelia
   Zanoaga, Oana
   Cojocneanu, Roxana
   Pop, Laura
   Raduly, Lajos
   Barbat, Alexandru
   Moldovan, Alin
   Moldovan, Cristian
   Tigu, Adrian Bogdan
   Ionescu, Calin
   Atanasov, Atanas G.
   Irimie, Alexandru
   Berindan-Neagoe, Ioana
TI Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell
   LinesPossible Implications in New Therapeutic Strategies
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE natural compounds; polyphenols; colon cancer; CAPE; Kaempferol; Morin
ID ACID PHENETHYL ESTER; LONG NONCODING RNAS; INDUCED APOPTOSIS;
   POLYPHENOLS; PROPOLIS; INVASION
AB Background: Phytochemicals are natural compounds synthesized as secondary metabolites in plants and represent an important source of molecules with therapeutic applications. Attention is accorded to their potential in anti-cancer therapies as single agents or adjuvant treatment. Herby, we evaluated the in vitro effects of a panel of natural compounds with focus on caffeic acid phenethyl ester (CAPE) and Kaempferol for the treatment of human colon cancer. Methods: We exposed two human colon cancer cell lines, RKO and HCT-116, followed by functional examination of cell viability, cell proliferation and invasion, cell cycle, apoptosis, and autophagy. Modifications in gene expression were investigated through microarray and detection of existing mutations and finding of new ones was done with the help of Next Generation Sequencing (NGS). Results: Both CAPE and Kaempferol inhibit cell proliferation, motility and invasion, and stimulate apoptosis and autophagy, concomitant with modifications in coding and noncoding genes' expression. Moreover, there are pathogenic mutations that are no longer found upon treatment with CAPE and Kaempferol. Conclusions: Our findings indicate that CAPE and Kaempferol have the ability to negatively influence the development and advancement of colon cancer in vitro by specifically altering the cells at the molecular level; this activity can be exploited in possible adjuvant therapies once the optimal dose concentration with minimal side effects but with cancer inhibitory activity is set in vivo.
C1 [Budisan, Liviuta; Jurj, Ancuta; Braicu, Cornelia; Zanoaga, Oana; Cojocneanu, Roxana; Pop, Laura; Raduly, Lajos; Barbat, Alexandru; Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, 23 Marinescu St, Cluj Napoca 400337, Romania.
   [Gulei, Diana; Moldovan, Alin; Moldovan, Cristian; Tigu, Adrian Bogdan; Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, MEDFUTURE Res Ctr Adv Med, 23 Marinescu St, Cluj Napoca 400337, Romania.
   [Ionescu, Calin] Municipal Hosp, Surg Dept 5, Cluj Napoca 400139, Romania.
   [Ionescu, Calin] Iuliu Hatieganu Univ Med & Pharm, Cluj Napoca 400000, Romania.
   [Atanasov, Atanas G.] Polish Acad Sci, Inst Genet & Anim Breeding, PL-05552 Jastrzebiec, Poland.
   [Atanasov, Atanas G.] Univ Vienna, Dept Pharmacognosy, Althanstr 14, A-1090 Vienna, Austria.
   [Irimie, Alexandru] Iuliu Hatieganu Univ Med & Pharm, Dept Oncol Surg & Gynecol Oncol 11, Cluj Napoca 400015, Romania.
   [Irimie, Alexandru] Oncol Inst Prof Dr Ion Chiricuta, Dept Surg, Cluj Napoca 400015, Romania.
   [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, 34-36 Republ St, Cluj Napoca 400015, Romania.
RP Berindan-Neagoe, I (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, 23 Marinescu St, Cluj Napoca 400337, Romania.; Berindan-Neagoe, I (corresponding author), Iuliu Hatieganu Univ Med & Pharm, MEDFUTURE Res Ctr Adv Med, 23 Marinescu St, Cluj Napoca 400337, Romania.; Ionescu, C (corresponding author), Municipal Hosp, Surg Dept 5, Cluj Napoca 400139, Romania.; Ionescu, C (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Cluj Napoca 400000, Romania.; Berindan-Neagoe, I (corresponding author), Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, 34-36 Republ St, Cluj Napoca 400015, Romania.
EM liviutabudisan@gmail.com; diana.c.gulei@gmail.com; ancajurj15@gmail.com;
   braicucornelia@yahoo.com; zanoaga.oana@gmail.com; cojocneanur@gmail.com;
   laura.ancuta.pop@gmail.com; raduly.lajos78@gmail.com;
   barbatalexandruteodor@gmail.com; alin.moldovan92@yahoo.ro;
   moldovan.cristian1994@gmail.com; adrianbogdantigu@gmail.com;
   calin.ionescu@umfcluj.ro; atanas.atanasov@univie.ac.at;
   a.irimie@umfcluj.ro; ioana.neagoe@umfcluj.ro
RI Gulei, Diana/U-2864-2017; Pop, Laura/AAY-8349-2020; Țigu, Adrian
   Bogdan/AAI-9446-2020; Berindan-Neagoe, Ioana/AAH-9854-2019; Atanasov,
   Atanas G./C-5535-2013
OI Gulei, Diana/0000-0002-3030-8626; Pop, Laura/0000-0002-5806-0220; Țigu,
   Adrian Bogdan/0000-0001-9397-0791; Atanasov, Atanas
   G./0000-0003-2545-0967; Moldovan, Cristian/0000-0003-2927-4622; Raduly,
   Lajos/0000-0002-3926-5423; Cojocneanu, Roxana-Maria/0000-0002-7450-9454;
   Moldovan, Alin/0000-0001-7159-6102
FU Project PNCDI III [29PFE/18.10.2018]; Competitivity Operational Program
   [35/01.09.2016, MySMIS 103375, 3860]; Iuliu Hatieganu University of
   Medicine and Pharmacy, Cluj-Napoca, Romania [193/2014]; Non-invasive
   intelligent systems for colorectal cancer diagnosis and prognosis based
   on circulating microRNAs integrated in the clinical workflow-INTELCOR
   [PN-II-PT-PCCA-2013-4-1959]; project "MicroRNAs biomarkers of response
   to chemotherapy and overall survival in colon cancer"-Terry Fox
   Foundation
FX This research was funded by Project PNCDI III 2015-2020 entitled
   "Increasing the performance of scientific research and technology
   transfer in translational medicine through the formation of a new
   generation of young researchers"-ECHITAS, No. 29PFE/18.10.2018,
   Competitivity Operational Program, 2014-2020, entitled "Clinical and
   economical impact of personalized targeted anti-microRNA therapies in
   reconverting lung cancer chemoresistance"-CANTEMIR, No. 35/01.09.2016,
   MySMIS 103375, PhD project Nr.3860 /Date 10.01.2014-"Control of
   apoptosis in cancer with natural phytochemical compounds. The role of
   microRNAs/siRNAs" funded by Iuliu Hatieganu University of Medicine and
   Pharmacy, Cluj-Napoca, Romania, research grant No. 193/2014;
   PN-II-PT-PCCA-2013-4-1959 "Non-invasive intelligent systems for
   colorectal cancer diagnosis and prognosis based on circulating microRNAs
   integrated in the clinical workflow-INTELCOR" and project "MicroRNAs
   biomarkers of response to chemotherapy and overall survival in colon
   cancer"-Terry Fox Foundation.
CR Ackland ML, 2005, IN VIVO, V19, P69
   Aljuffali IA, 2016, CURR PHARM DESIGN, V22, P4219, DOI 10.2174/1381612822666160620072539
   Bach DH, 2018, CANCER LETT, V419, P152, DOI 10.1016/j.canlet.2018.01.053
   Braicu C, 2017, SEMIN CANCER BIOL, V46, P84, DOI 10.1016/j.semcancer.2017.06.011
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Budisan L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061178
   Gulei D, 2018, BIOTECHNOL ADV, V36, P1779, DOI 10.1016/j.biotechadv.2017.11.003
   Gulei D, 2018, BIOCONJUGATE CHEM, V29, P635, DOI 10.1021/acs.bioconjchem.8b00003
   Gulei D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0102-8
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Han XZ, 2007, INT J MOL SCI, V8, P950, DOI 10.3390/i8090950
   Huang Q, 2017, WORLD J GASTROENTERO, V23, P5018, DOI 10.3748/wjg.v23.i27.5018
   Huang WW, 2010, MOL NUTR FOOD RES, V54, P1585, DOI 10.1002/mnfr.201000005
   Ingvarsson Sigurdur, 2005, Cancer Genomics & Proteomics, V2, P247
   Irimie AI, 2015, ACTA ODONTOL SCAND, V73, P161, DOI 10.3109/00016357.2014.986754
   Kim BW, 2008, CANCER BIOL THER, V7, P1080, DOI 10.4161/cbt.7.7.6164
   Kim MS, 2017, ONCOTARGET, V8, P41319, DOI 10.18632/oncotarget.17289
   Laura A, 2009, FRUIT VEGETABLE PHYT
   Lee KM, 2010, CARCINOGENESIS, V31, P1338, DOI 10.1093/carcin/bgq102
   Luo YX, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003552
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Na HY, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0383-x
   Obeid MA, 2017, THER DELIV, V8, P947, DOI 10.4155/tde-2017-0060
   Petric RC, 2015, ONCOTARGETS THER, V8, P2053, DOI 10.2147/OTT.S83597
   Pistol GC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127503
   Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87
   Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531
   Russo M, 2010, TOXINS, V2, P517, DOI 10.3390/toxins2040517
   Rzepecka-Stojko A, 2015, MOLECULES, V20, P9242, DOI 10.3390/molecules20059242
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Seles M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040573
   Shostak A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040873
   Son S, 2002, J AGR FOOD CHEM, V50, P468, DOI 10.1021/jf010830b
   Tang H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07953-8
   Tang WQ, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-018-0115-x
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012
   Wu WeiQiang, 2017, African Journal of Traditional, Complementary and Alternative Medicines, V14, P63
   Xiang DB, 2006, ANTI-CANCER DRUG, V17, P753, DOI 10.1097/01.cad.0000224441.01082.bb
NR 39
TC 22
Z9 22
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR 1
PY 2019
VL 20
IS 5
AR 1199
DI 10.3390/ijms20051199
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HQ6QE
UT WOS:000462542300198
PM 30857282
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Lai, MC
   Chang, CM
   Sun, HS
AF Lai, Ming-Chih
   Chang, Chiao-May
   Sun, H. Sunny
TI Hypoxia Induces Autophagy through Translational Up-Regulation of
   Lysosomal Proteins in Human Colon Cancer Cells
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA TRANSLATION; INTERNAL RIBOSOME ENTRY; INDUCIBLE FACTOR-I;
   GENE-EXPRESSION; COLORECTAL TUMORIGENESIS; CYCLE ARREST; STRESS; MTOR;
   PHOSPHORYLATION; ANGIOGENESIS
AB Hypoxia occurs in a wide variety of physiological and pathological conditions, including tumorigenesis. Tumor cells have to adapt to hypoxia by altering their gene expression and protein synthesis. Here, we showed that hypoxia inhibits translation through activation of PERK and inactivation of mTOR in human colon cancer HCT116 cells. Prolonged hypoxia (1% O-2, 16 h) dramatically inhibits general translation in HCT116 cells, yet selected mRNAs remain efficiently translated under such a condition. Using microarray analysis of polysome-associated mRNAs, we identified a large number of hypoxia-regulated genes at the translational level. Efficiently translated mRNAs during hypoxia were validated by polysome profiling and quantitative real-time RT-PCR. Pathway enrichment analysis showed that many of the up-regulated genes are involved in lysosome, glycan and lipid metabolism, antigen presentation, cell adhesion, and remodeling of the extracellular matrix and cytoskeleton. The majority of down-regulated genes are involved in apoptosis, ubiquitin-mediated proteolysis, and oxidative phosphorylation. Further investigation showed that hypoxia induces lysosomal autophagy and mitochondrial dysfunction through translational regulation in HCT116 cells. The abundance of several translation factors and the mTOR kinase activity are involved in hypoxia-induced mitochondrial autophagy in HCT116 cells. Our studies highlight the importance of translational regulation for tumor cell adaptation to hypoxia.
C1 [Lai, Ming-Chih] Chang Gung Univ, Dept Biomed Sci, Taoyuan, Taiwan.
   [Lai, Ming-Chih] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taoyuan, Taiwan.
   [Chang, Chiao-May; Sun, H. Sunny] Natl Cheng Kung Univ, Bioinformat Ctr, Tainan 701, Taiwan.
   [Sun, H. Sunny] Natl Cheng Kung Univ, Inst Mol Med, Tainan 701, Taiwan.
RP Sun, HS (corresponding author), Chang Gung Univ, Dept Biomed Sci, Taoyuan, Taiwan.
EM mclai@mail.cgu.edu.tw; hssun@mail.ncku.edu.tw
OI Sun, Sunny/0000-0002-3661-4448; Hung, Li-Man/0000-0002-6032-7668
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [NSC100-2320-B-006-021-MY3, NSC101-2627-B-006-005];
   Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital
   [CMRPD3E0012]
FX This work was supported by grants from Ministry of Science and
   Technology, Taiwan (NSC100-2320-B-006-021-MY3 to MCL and
   NSC101-2627-B-006-005 to HSS) and Chang Gung Memorial Hospital, Taiwan
   (CMRPD3E0012). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06
   Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004
   Brown JM, 2002, INT J RADIAT ONCOL, V54, P1299, DOI 10.1016/S0360-3016(02)03936-6
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Chen TM, 2014, NUCLEIC ACIDS RES, V42, P2932, DOI 10.1093/nar/gkt1286
   Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006
   Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Flamant L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-191
   Frezza C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024411
   Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He MF, 2010, INT J CANCER, V126, P266, DOI 10.1002/ijc.24694
   Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101
   Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998
   Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036
   Koritzinsky M, 2007, METHOD ENZYMOL, V435, P247, DOI 10.1016/S0076-6879(07)35013-1
   Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196
   Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948
   Kunz Manfred, 2003, Mol Cancer, V2, P23, DOI 10.1186/1476-4598-2-23
   Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lobo MR, 2013, NEURO-ONCOLOGY, V15, P1673, DOI 10.1093/neuonc/not119
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0
   PETTERSEN EO, 1986, CANCER RES, V46, P4346
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683
   Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098
   Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112
   Sun Y, 2013, AUTOPHAGY, V9, P1115, DOI 10.4161/auto.24919
   TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633
   Thomas JD, 2007, RNA, V13, P1116, DOI 10.1261/rna.534807
   van den Beucken T, 2011, RADIOTHER ONCOL, V99, P379, DOI 10.1016/j.radonc.2011.05.058
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Waldner MJ, 2010, MOL ASPECTS MED, V31, P171, DOI 10.1016/j.mam.2010.02.005
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Ye JP, 2007, AM J PHYSIOL-ENDOC M, V293, pE1118, DOI 10.1152/ajpendo.00435.2007
   Zavoral M, 2014, WORLD J GASTROENTERO, V20, P3825, DOI 10.3748/wjg.v20.i14.3825
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001
NR 60
TC 27
Z9 28
U1 2
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2016
VL 11
IS 4
AR e0153627
DI 10.1371/journal.pone.0153627
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DJ3UH
UT WOS:000374131700097
PM 27078027
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Sun, WL
   Lan, D
   Gan, TQ
   Cai, ZW
AF Sun, W. L.
   Lan, D.
   Gan, T. Q.
   Cai, Z. W.
TI Autophagy facilitates multidrug resistance development through
   inhibition of apoptosis in breast cancer cells
SO NEOPLASMA
LA English
DT Article
DE autophagy; apoptosis; multidrug resistance; breast cancer; chemotherapy
ID COLON-CANCER; HEPATOCELLULAR-CARCINOMA; DEATH; 5-FLUOROURACIL;
   MACROAUTOPHAGY; CHEMOTHERAPY; CHLOROQUINE; INDUCTION
AB Acquired multidrug resistance (MDR) is the main mechanism of chemotherapeutic drugs resistance. Nevertheless, the mechanisms of MDR are complex and still not very clear. Recently, including our previous study, several studies have revealed that macroautophagy (here referred to as autophagy) induced by anti-cancer drugs in breast cancer cells may facilitate the development of resistance to epirubicin (EPI), paclitaxel (PTX), tamoxifen or herceptin. Whereas there are a few studies on the relationship between autophagy and MDR, especially the studies designed directly employing induced resistant breast cancer cells. Based on previous study, we explored the relationship between autophagy and MDR. The results showed that induced EPI-resistant MCF-7er and SK-BR-3er cells were simultaneously resistant to PTX and vinorelbine (NVB), which demonstrated that the cells obtained MDR phenotype. Furthermore, PTX and NVB could also induce autophagy in MCF-7er and SK-BR-3er cells, and the induced autophagy protected the cells from apoptosis, which facilitated the development of resistance to PTX and NVB. Thus, autophagy promoted the development of MDR in breast cancer cells through inhibition of apoptosis. In addition, we found that P-glycoprotein (Pgp) was overexpressed in MCF-7er and SK-Br-3er cells. And we preliminarily investigated the relationship between autophagy and P-glycoprotein (Pgp). The results showed that the expression of the protein did not obviously change despite the inhibition of autophagy. Therefore, the role of Pgp in the development of MDR might be independent of autophahy. Also this finding implies that autophagy might be a target to overcome MDR in breast cancer cells, and clinical use autophagy inhibitors might be one of the important strategies for overcoming MDR in breast cancer therapy.
C1 [Sun, W. L.; Lan, D.; Gan, T. Q.; Cai, Z. W.] Guangxi Med Univ, Affiliated Hosp 1, Dept Internal Med Oncol, Nanning 530021, Guangxi, Peoples R China.
RP Sun, WL (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Internal Med Oncol, Nanning 530021, Guangxi, Peoples R China.
EM swl20022001@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81360340]; Wu Jieping Medical Foundation
   clinical research special fund [320.6750.12689]
FX This study is supported by grants from the National Natural Science
   Foundation of China (grant number 81360340) and Wu Jieping Medical
   Foundation clinical research special fund (grant number 320.6750.12689).
   We thank Professor T. Yoshimori and Ms. H. Omori (Department of Cellular
   Regulation Research Institute for Microbial Diseases, Osaka University;
   Japan) for kindly providing the pEGFP-LC3 plasmid.
CR Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139
   Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bincoletto C, 2013, CHEM-BIOL INTERACT, V206, P279, DOI 10.1016/j.cbi.2013.09.018
   Chen YS, 2011, DIS ESOPHAGUS, V24, P437, DOI 10.1111/j.1442-2050.2010.01156.x
   CHITTARANJAN S, 2014, CLIN CANC RES
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Ravikumar B, 2009, J CELL SCI, V122, P1707, DOI 10.1242/jcs.031773
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schinkel AH, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2012.09.027
   Schoenlein PV, 2009, AUTOPHAGY, V5, P400, DOI 10.4161/auto.5.3.7784
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shin SW, 2012, BBA-MOL CELL RES, V1823, P451, DOI 10.1016/j.bbamcr.2011.10.014
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397
   Xu WH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-273
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhao MY, 2011, BMB REP, V44, P601, DOI 10.5483/BMBRep.2011.44.9.601
NR 49
TC 32
Z9 36
U1 2
U2 8
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2015
VL 62
IS 2
BP 199
EP 208
DI 10.4149/neo_2015_025
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5PL
UT WOS:000362862400005
PM 25591585
OA Bronze
DA 2022-04-25
ER

PT J
AU Li, YL
   Gu, FT
   Lin, X
AF Li, Yongliang
   Gu, Feiteng
   Lin, Xi
TI The role of miR-141/Sirt1 in colon cancer
SO JOURNAL OF BUON
LA English
DT Article
DE colon cancer cells; miR-141; Sirt1; proliferation; apoptosis
ID INHIBITS IN-VITRO; MICRORNA EXPRESSION; CELL-MIGRATION; AUTOPHAGY;
   PROLIFERATION; INDUCTION; APOPTOSIS; SIRT1; TUMORIGENESIS; SURVIVAL
AB Purpose: To explore the effects of micro ribonucleic acid-141 (miR)-141 on the proliferation and apoptosis of colon cancer cells and its association with the sirtuin 1 (Sirt1) expression.
   Methods: The samples of stage I, II, III and IV colon cancer were obtained, and the miRNA expression levels was analyzed, with normal colon tissues as controls. The expression of miR-141 and miR-34 was detected via quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the cell proliferation and apoptosis in each group were detected via cell counting kit-8 (CCK8) assay, respectively. Finally, the protein expressions of Sirt1, Caspase-3 and Caspase-8 were determined using Western blotting.
   Results: The expressions of miR-141 and miR-34 (miR-34 is mentioned in previous methods. Furthermore, we found the expression of miR-141 increasing with the progression of colon cancer, which was higher in stage III than in stage I-II and also higher in stage IV than in stage III. miR-34 was also highly expressed in stage IV colon cancer in our study were up-regulated in the progression of colon cancer. Overexpression of miR-141 could promote cell proliferation (p<0.05) and inhibit apoptosis (p<0.05), while inhibition on miR-141 expression could significantly weaken cell proliferation (p<0.05) and promote apoptosis (p<0.05). The results of luciferase reporter assay showed that miR-141 obviously inhibited Sirt1 (p<0.05). SRT2183 reduced cell proliferation (p<0.05) but up-regulated the protein expressions of Sirt1, Caspase-3 and Caspase-8 (p<0.05), while EX 527 had the opposite effects (p<0.05).
   Conclusions: MiR-141 may promote proliferation and reduce apoptosis of colon cancer cells via targeting Sirt1.
C1 [Li, Yongliang; Gu, Feiteng; Lin, Xi] Putian Univ, Affiliated Hosp, Dept Gastrointestinal Surg 2, 999 Dongzhen East Rd, Putian 351100, Fujian, Peoples R China.
RP Li, YL (corresponding author), Putian Univ, Affiliated Hosp, Dept Gastrointestinal Surg 2, 999 Dongzhen East Rd, Putian 351100, Fujian, Peoples R China.
EM lylfjpt@126.com
CR Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Vega AB, 2013, ONCOL REP, V30, P320, DOI 10.3892/or.2013.2475
   Chen H, 2019, J BUON, V24, P1470
   Chen XP, 2019, J BUON, V24, P488
   Cheng HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017745
   Cruz JPM, 2018, J BUON, V23, P568
   Ding L, 2017, ONCOL LETT, V13, P1665, DOI 10.3892/ol.2017.5653
   Ding Y, 2019, J BUON, V24, P1817
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
   Ji H, 2019, J BUON, V24, P91
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kim Kwangmin, 2018, J BUON, V23, P11
   Mou LJ, 2019, J BUON, V24, P1870
   Pox CP, 2014, DIGESTION, V89, P274, DOI 10.1159/000363287
   Sakin A, 2019, J BUON, V24, P1801
   Slaby O, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-102
   Wang D, 2019, J BUON, V24, P1824
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Xiong W, 2019, J BUON, V24, P1488
   Yang LD, 2009, WORLD J SURG, V33, P638, DOI 10.1007/s00268-008-9865-5
   Yang Y, 2017, CELL PHYSIOL BIOCHEM, V41, P310, DOI 10.1159/000456162
   Yin ZH, 2019, J BUON, V24, P1464
   Yue M, 2019, J BUON, V24, P1852
   Zhang LM, 2010, CARCINOGENESIS, V31, P559, DOI 10.1093/carcin/bgp335
NR 28
TC 2
Z9 2
U1 0
U2 0
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD NOV-DEC
PY 2020
VL 25
IS 6
BP 2665
EP 2671
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PY4JJ
UT WOS:000612011800019
PM 33455111
DA 2022-04-25
ER

PT J
AU Giatromanolaki, A
   Koukourakis, MI
   Harris, AL
   Polychronidis, A
   Gatter, KC
   Sivridis, E
AF Giatromanolaki, Alexandra
   Koukourakis, Michael I.
   Harris, Adrian L.
   Polychronidis, Alexandros
   Gatter, Kevin C.
   Sivridis, Efthimios
TI Prognostic relevance of light chain 3 (LC3A) autophagy patterns in
   colorectal adenocarcinomas
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
ID TUMOR ANGIOGENESIS; EXPRESSION; GROWTH; CANCER; ASSOCIATION; SURVIVAL;
   CELLS
AB Aims The microtubule-associated protein 1 light chain 3(LC3A) is an essential component of the autophagic vacuoles, forming a reliable marker of autophagic activity. In a previous study, the authors showed that LC3A immunohistochemistry renders three patterns of autophagic expression in breast carcinomas: diffuse cytoplasmic, perinuclear and 'stone-like' intracellular structures (SLS), each with a distinct prognostic relevance.
   Methods Tumour tissues from 155 patients with stage IIA-III colorectal adenocarcinomas, treated with surgery alone, were assessed immunohistochemically for LC3A. Median values were used as cut-off points to separate groups into low and high autophagic activity. Associations with prognosis and with lactate dehydrogenase-5 (LDH5) were sought.
   Results High SLS counts were associated with metastases and poor prognosis, while the prominence of the perinuclear pattern was linked to localised disease and good prognosis. The cytoplasmic pattern was irrelevant. Furthermore, patients with increased SLS numbers, but suppressed perinuclear expression, were associated with LDH5 overexpression and had an extremely poor prognosis (3-year survival 16.5%). The prognosis improved considerably when high SLS counts were accompanied by intense perinuclear expression (3-year survival 67%) and were optimal when SLS numbers dropped below median values, irrespective of perinuclear status (3-year survival 94-100%). Multivariate analysis showed that SLS and perinuclear patterns were independent predictors of death events.
   Conclusions Perinuclear LC3A accumulation in colorectal tumour cells is a marker of good prognosis, presumably reflecting a basal autophagic activity. An abnormal or excessive autophagic response, as indicated by increased numbers of SLS, is linked to metastasis and poor prognosis.
C1 [Giatromanolaki, Alexandra; Sivridis, Efthimios] Democritus Univ Thrace, Dept Pathol, Alexandroupolis 68100, Greece.
   [Giatromanolaki, Alexandra; Koukourakis, Michael I.; Harris, Adrian L.; Polychronidis, Alexandros; Sivridis, Efthimios] Univ Gen Hosp Alexandroupolis, Alexandroupolis, Greece.
   [Koukourakis, Michael I.] Democritus Univ Thrace, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece.
   [Harris, Adrian L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Oncol Labs,Canc Res UK, Oxford OX3 9DU, England.
   [Harris, Adrian L.; Gatter, Kevin C.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
   [Harris, Adrian L.; Polychronidis, Alexandros] Democritus Univ Thrace, Dept Surg, Alexandroupolis 68100, Greece.
RP Sivridis, E (corresponding author), Democritus Univ Thrace, Dept Pathol, POB 128, Alexandroupolis 68100, Greece.
EM esivrid@med.duth.gr
RI Harris, Adrian/ABA-3343-2020
OI Harris, Adrian/0000-0003-1376-8409
CR Chen JL, 2008, J BIOL CHEM, V283, P34432, DOI 10.1074/jbc.M804239200
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Giatromanolaki A, 2004, APMIS, V112, P431, DOI 10.1111/j.1600-0463.2004.apm11207-0804.x
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Miyata S, 2006, AM J PATHOL, V168, P386, DOI 10.2353/ajpath.2006.050137
   NOVIKOFF AB, 1978, P NATL ACAD SCI USA, V75, P5039, DOI 10.1073/pnas.75.10.5039
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Samokhvalov V, 2008, AUTOPHAGY, V4, P1034, DOI 10.4161/auto.6994
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
NR 19
TC 78
Z9 82
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD OCT
PY 2010
VL 63
IS 10
BP 867
EP 872
DI 10.1136/jcp.2010.079525
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 654KY
UT WOS:000282168400002
PM 20876316
OA Green Submitted, Bronze
DA 2022-04-25
ER

PT J
AU Xie, W
   Zhang, L
   Jiao, HF
   Guan, L
   Zha, JM
   Li, XT
   Wu, M
   Wang, ZX
   Han, JH
   You, H
AF Xie, Wei
   Zhang, Lei
   Jiao, Haifeng
   Guan, Li
   Zha, Junmin
   Li, Xiaotong
   Wu, Mian
   Wang, Zhanxiang
   Han, Jiahuai
   You, Han
TI Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMA
SO AUTOPHAGY
LA English
DT Article
DE apoptosis; BBC3; chaperone-mediated autophagy; IKBKB; IKK; PUMA; TNF
ID NF-KAPPA-B; COLORECTAL-CANCER CELLS; ALPHA-INDUCED APOPTOSIS;
   ENDOPLASMIC-RETICULUM; SERUM STARVATION; PUMA; P53; ACTIVATION;
   RECEPTOR; DEGRADATION
AB Autophagy is a potentially inimical pathway and together with apoptosis, may be activated by similar stress stimuli that can lead to cell death. The molecular cues that dictate the cell fate choice between autophagy and apoptosis remain largely unknown. Here we report that the proapoptotic protein BBC3/PUMA (BCL2 binding component 3) is a bona fide substrate of chaperone-mediated autophagy (CMA). BBC3 associates with HSPA8/HSC70 (heat shock 70kDa protein 8), leading to its lysosome translocation and uptake. Inhibition of CMA results in stabilization of BBC3, which in turn sensitizes tumor cells to undergo apoptosis. We further demonstrate that upon TNF (tumor necrosis factor) treatment, IKBKB/IKK(inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase )-mediated BBC3 Ser10 phosphorylation is crucial for BBC3 stabilization via blocking its degradation by CMA. Mechanistically, Ser10 phosphorylation facilitates BBC3 translocation from the cytosol to mitochondria. BBC3 stabilization resulting from either Ser10 phosphorylation or CMA inhibition potentiates TNF-induced apoptotic cell death. Our findings thus reveal that the selective degradation of BBC3 underlies the prosurvival role of CMA and define a previously unappreciated proapoptotic role of IKBKB that acts through phosphorylation-mediated stabilization of BBC3, thereby promoting TNF-triggered apoptosis.
C1 [Xie, Wei; Zhang, Lei; Jiao, Haifeng; Guan, Li; Zha, Junmin; Li, Xiaotong; Han, Jiahuai; You, Han] Sch Life Sci, Xiamen Univ, State Key Lab Cellular Stress Biol, Innovat Ctr Cell Signaling Network, Xiamen, Fujian, Peoples R China.
   [Wu, Mian] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei, Anhui, Peoples R China.
   [Wu, Mian] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China.
   [Wang, Zhanxiang] Xiamen Univ, Affiliated Hosp 1, Dept Neurosurg, Xiamen, Fujian, Peoples R China.
RP Wang, ZX (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Neurosurg, Xiamen, Fujian, Peoples R China.
EM sjwkwzx@163.com; hyou@xmu.edu.cn
RI Han, J/G-4671-2010
OI Wu, Mian/0000-0002-2714-0500
FU National Basic Research Program of China 973 ProgramNational Basic
   Research Program of China [2015CB553802]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31300627]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [20720150066]; National Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [J1310027]; Ministry of Education of
   China 111 Project [B06016]
FX This work is supported by National Basic Research Program of China 973
   Program Grant 2015CB553802 (to H.Y.), National Natural Science
   Foundation of China Grant 31300627 (to L.Z.), Fundamental Research Funds
   for the Central Universities Grant 20720150066 (to H.Y.), by the
   National Science Foundation of China for Fostering Talents in Basic
   Research (Grant No. J1310027), and Ministry of Education of China 111
   Project B06016.
CR Callus BA, 2008, J MOL BIOL, V384, P313, DOI 10.1016/j.jmb.2008.09.041
   Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x
   Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738
   CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Cuervo AM, 2010, TRENDS ENDOCRIN MET, V21, P142, DOI 10.1016/j.tem.2009.10.003
   Dice J F, 1990, Semin Cell Biol, V1, P449
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200
   Fricker M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.38
   Kabuta T, 2008, J BIOL CHEM, V283, P23731, DOI 10.1074/jbc.M801918200
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477
   Kohli Manu, 2004, Discov Med, V4, P37
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001
   Lee SH, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.116
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025
   Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Orenstein SJ, 2013, NAT NEUROSCI, V16, P394, DOI 10.1038/nn.3350
   Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408
   Sandow JJ, 2012, CELL DEATH DIFFER, V19, P633, DOI 10.1038/cdd.2011.131
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072
   Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51
   Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367
   Yan J, 2013, CELL, V152, P304, DOI 10.1016/j.cell.2012.12.021
   Yang Q, 2009, AUTOPHAGY, V5, P1073, DOI 10.4161/auto.5.7.9824
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353
   Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1
   Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100
   Zhang L, 2012, P NATL ACAD SCI USA, V109, P20937, DOI 10.1073/pnas.1214156110
   Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084
NR 40
TC 39
Z9 41
U1 5
U2 28
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD SEP
PY 2015
VL 11
IS 9
BP 1623
EP 1635
DI 10.1080/15548627.2015.1075688
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CR8UK
UT WOS:000361629400013
PM 26212789
OA Green Published, Green Submitted, Bronze
DA 2022-04-25
ER

PT J
AU Shimozawa, M
   Anzai, S
   Satow, R
   Fukami, K
AF Shimozawa, Makoto
   Anzai, Sakiho
   Satow, Reiko
   Fukami, Kiyoko
TI Phospholipase C delta 1 negatively regulates autophagy in colorectal
   cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE PLC delta 1; Autophagy; KRAS; Colorectal cancer
ID CHEMOTHERAPY; INHIBITION; RESISTANCE; TARGET
AB Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently mutated in CRC, and KRAS mutations promote cell motility, growth, and survival. We previously revealed that the expression of phospholipase C (PLC) delta 1, one of the most basal PLCs, is down-regulated in colon adenocarcinoma, and that the KRAS signaling pathway suppresses PLC delta 1 expression. Although recent studies revealed that KRAS mutations activate autophagy in cancer cells, a relation between PLC delta 1 and autophagy remains unclear. Here, we found that PLC delta 1 overexpression suppresses the formation of autophagosomes, which are key structures of autophagy, whereas endogenous PLC delta 1 knockdown increases autophagosome formation in CRC cells. We also showed that PLC delta 1 overexpression promotes cell death under nutrient deprivation. Furthermore, PLC delta 1 overexpression suppresses the autophagy induced by the anti-cancer drug oxaliplatin and promotes cell death under oxaliplatin treatment. These data suggest that PLC delta 1 negatively regulates autophagy, and PLC delta 1 suppression contributes to the tolerance of CRC cells harboring KRAS mutations to nutrient deprivation and anti-cancer drug treatment. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Shimozawa, Makoto; Anzai, Sakiho; Satow, Reiko; Fukami, Kiyoko] Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignals, Hachioji, Tokyo 1920392, Japan.
   [Satow, Reiko; Fukami, Kiyoko] Japan Agcy Med Res & Dev, AMED CREST, Chiyoda Ku, Tokyo 1000004, Japan.
RP Fukami, K (corresponding author), Tokyo Univ Pharm & Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
EM kfukami@toyaku.ac.jp
OI Satow, Reiko/0000-0002-6339-4268
FU Japan Society for the Promotion of Science KAKENHIMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [26293071, 26860221]; MEXT-Supported Program for the Strategic Research
   Foundation at Private UniversitiesMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [17gm0710002h0405]; Ono
   Medical Research Foundation; Grants-in-Aid for Scientific
   ResearchMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [17H04051] Funding Source: KAKEN
FX We thank Dr. Y. Nakamura and Dr. A. Yoneda for constructive suggestions.
   We also thank Y. Mihana for technical assistance. This work was
   supported by Grants-in-Aid for Scientific Research (Japan Society for
   the Promotion of Science KAKENHI Grant No. 26293071) and the
   MEXT-Supported Program (17gm0710002h0405) for the Strategic Research
   Foundation at Private Universities to K.F. and a Grant-in-Aid for Young
   Scientists (Japan Society for the Promotion of Science KAKENHI Grant No.
   26860221) to R.S. This work was also supported by a Grant-in Aid from
   the Ono Medical Research Foundation.
CR Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788
   Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Moreau K, 2012, J CELL BIOL, V196, P483, DOI 10.1083/jcb.201110114
   Nakamura Y, 2017, J BIOCHEM, V161, P315, DOI 10.1093/jb/mvw094
   Pan ST, 2016, CLIN EXP PHARMACOL P, V43, P723, DOI 10.1111/1440-1681.12581
   Park JB, 2012, NAT REV CANCER, V12, P782, DOI 10.1038/nrc3379
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Satow R, 2014, P NATL ACAD SCI USA, V111, P13505, DOI 10.1073/pnas.1405374111
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Tan XJ, 2016, P NATL ACAD SCI USA, V113, P10896, DOI 10.1073/pnas.1523145113
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97
NR 25
TC 2
Z9 2
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 8
PY 2017
VL 488
IS 4
BP 578
EP 583
DI 10.1016/j.bbrc.2017.05.098
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EY4VB
UT WOS:000403974600002
PM 28528980
DA 2022-04-25
ER

PT J
AU Park, SH
   Kim, JH
   Chi, GY
   Kim, GY
   Chang, YC
   Moon, SK
   Nam, SW
   Kim, WJ
   Yoo, YH
   Choi, YH
AF Park, Shin-Hyung
   Kim, Jeong-Hwan
   Chi, Gyoo Yong
   Kim, Gi-Young
   Chang, Young-Chae
   Moon, Sung-Kwon
   Nam, Soo-Wan
   Kim, Wun-Jae
   Yoo, Young Hyun
   Choi, Yung Hyun
TI Induction of apoptosis and autophagy by sodium selenite in A549 human
   lung carcinoma cells through generation of reactive oxygen species
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Sodium selenite; Apoptosis; Autophagy; ROS; Nrf2
ID COLON-CANCER CELLS; OXIDATIVE STRESS; MITOCHONDRIAL DAMAGE; SIGNALING
   PATHWAY; GENE-EXPRESSION; DNA-DAMAGE; DUAL ROLES; CROSS-TALK; NRF2;
   ACTIVATION
AB Selenium in the form of sodium selenite has been reported to exert anti-tumor effects in several cancer cell types by inducing autophagic cell death and apoptosis mediated by reactive oxygen species (ROS). However, the exact molecular pathways underlying these effects have not been fully established. The present study used A549 human lung carcinoma cells for further investigation of the anti-cancer mechanism of sodium selenite. We showed that sodium selenite modulated both the extrinsic and intrinsic apoptotic pathways, which were interconnected by Bid truncation. We used z-VAD-fmk, a pan-caspase inhibitor, to demonstrate that sodium selenite-induced apoptosis was dependent on the activation of caspases. Sodium selenite also increased autophagy, as indicated by an increase in microtubule-associated protein light chain-3 (LC3) puncta, accumulation of LC3II, and elevation of autophagic flux. Pretreatment with bafilomycin A1 enhanced sodium selenite-induced apoptosis, indicating that sodium selenite-induced autophagy functioned as a survival mechanism. Sodium selenite treatment also resulted in generation of ROS, which abrogated mitochondrial membrane potential (MMP) and regulated both apoptosis and autophagy. Phospho-nuclear factor erythroid 2-related factor 2 (p-Nrf2) showed a ROS-dependent translocation to the nucleus, which suggested that Nrf2 might increase cell survival by suppressing ROS accumulation and apoptosis mediated by oxidative stress. Sodium selenite treatment of A549 cells therefore appeared to trigger both apoptosis and cytoprotective autophagy, which were both mediated by ROS. The data suggest that regulation of ROS generation and autophagy can be a potential strategy for treating lung cancer that is resistant to pro-apoptotic therapeutics. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Choi, Yung Hyun] Dong Eui Univ, Coll Oriental Med, Dept Biochem, Pusan 614052, South Korea.
   [Park, Shin-Hyung; Chi, Gyoo Yong] Dong Eui Univ, Coll Oriental Med, Dept Pathol, Pusan 614052, South Korea.
   [Park, Shin-Hyung; Chi, Gyoo Yong] Dong Eui Univ, Coll Oriental Med, Res Inst Oriental Med, Pusan 614052, South Korea.
   [Kim, Jeong-Hwan; Nam, Soo-Wan; Choi, Yung Hyun] Dong Eui Univ, Grad Sch, Dept Biomaterial Control, Program BK21, Pusan 614714, South Korea.
   [Kim, Gi-Young] Jeju Natl Univ, Dept Marine Life Sci, Immunobiol Lab, Cheju 690756, South Korea.
   [Chang, Young-Chae] Catholic Univ, Sch Med, Res Inst Biomed Engn, Taegu 705718, South Korea.
   [Chang, Young-Chae] Catholic Univ, Sch Med, Dept Med, Taegu 705718, South Korea.
   [Moon, Sung-Kwon] Chunju Natl Univ, Dept Biotechnol, Chungbuk 380702, South Korea.
   [Nam, Soo-Wan] Dong Eui Univ, Dept Biotechnol & Bioengn, Pusan 614714, South Korea.
   [Nam, Soo-Wan; Choi, Yung Hyun] Dong Eui Univ, Antiaging Res Ctr & Blue Bio Ind RIC, Pusan 614714, South Korea.
   [Kim, Wun-Jae] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 361763, South Korea.
   [Yoo, Young Hyun] Dong A Univ, Coll Med, Dept Anat & Cell Biol, Pusan 602714, South Korea.
   [Yoo, Young Hyun] Dong A Univ, Mitochondria Hub Regulat Ctr, Pusan 602714, South Korea.
RP Choi, YH (corresponding author), Dong Eui Univ, Coll Oriental Med, Dept Biochem, Pusan 614052, South Korea.
EM yhyoo@dau.ac.kr; choiyh@deu.ac.kr
RI Park, Shin-Hyung/O-3803-2015
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea; Ministry of Education, Science, and TechnologyMinistry of
   Education, Science and Technology, Republic of Korea [2009-0093193,
   2010-001730]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science, and Technology (2009-0093193 and 2010-001730).
CR An SH, 2011, BMB REP, V44, P211, DOI 10.5483/BMBRep.2011.44.3.211
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200
   Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004
   Cai Y, 2006, TOXICOLOGY, V218, P1, DOI 10.1016/j.tox.2005.08.024
   Chen CF, 2009, CELL RES, V19, P984, DOI 10.1038/cr.2009.60
   Chen XJ, 2012, BIOL TRACE ELEM RES, V145, P1, DOI 10.1007/s12011-011-9154-2
   Cherukuri DP, 2008, CANCER BIOL THER, V7, P697, DOI 10.4161/cbt.7.5.6088
   Choi JH, 2010, EXP MOL MED, V42, P811, DOI 10.3858/emm.2010.42.12.084
   Copple IM, 2008, TOXICOLOGY, V246, P24, DOI 10.1016/j.tox.2007.10.029
   Dziaman T, 2009, CANCER EPIDEM BIOMAR, V18, P2923, DOI 10.1158/1055-9965.EPI-09-0529
   Elrod HA, 2008, CANCER BIOL THER, V7, P163, DOI 10.4161/cbt.7.2.5335
   Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249
   Fu LP, 2011, J TRACE ELEM MED BIO, V25, P130, DOI 10.1016/j.jtemb.2011.06.001
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Gill C, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-39
   Gordeeva AV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1077, DOI 10.1023/A:1026398310003
   Hayes JD, 2006, MOL CELL, V21, P732, DOI 10.1016/j.molcel.2006.03.004
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Itoh K, 2010, ANTIOXID REDOX SIGN, V13, P1665, DOI 10.1089/ars.2010.3222
   Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231
   Kim EH, 2008, AUTOPHAGY, V4, P76, DOI 10.4161/auto.5119
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kim SY, 2011, EXP MOL MED, V43, P15, DOI 10.3858/emm.2011.43.1.002
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kwak MK, 2010, TOXICOL APPL PHARM, V244, P66, DOI 10.1016/j.taap.2009.08.028
   Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797
   Lee YK, 2010, CANCER LETT, V292, P228, DOI 10.1016/j.canlet.2009.12.005
   Letavayova L, 2006, TOXICOLOGY, V227, P1, DOI 10.1016/j.tox.2006.07.017
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Liu PL, 2005, AM J PHYSIOL-LUNG C, V289, pL739, DOI 10.1152/ajplung.00099.2005
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   McKenzie RC, 2002, ANTIOXID REDOX SIGN, V4, P339, DOI 10.1089/152308602753666398
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9
   Ren Y, 2009, BMB REP, V42, P599, DOI 10.5483/BMBRep.2009.42.9.599
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schrauzer GN, 2001, J AM COLL NUTR, V20, P1
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9
   Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200
   Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352
   Stepkowski TM, 2011, FREE RADICAL BIO MED, V50, P1186, DOI 10.1016/j.freeradbiomed.2011.01.033
   Sung BK, 2010, J BIOL CHEM, V285, P35418, DOI 10.1074/jbc.M110.172767
   Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571
   Suzuki M, 2011, CANCER CHEMOTH PHARM, V67, P1129, DOI 10.1007/s00280-010-1417-7
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
   Zhang DD, 2010, ANTIOXID REDOX SIGN, V13, P1623, DOI 10.1089/ars.2010.3301
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
NR 60
TC 102
Z9 104
U1 1
U2 44
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD AUG 3
PY 2012
VL 212
IS 3
BP 252
EP 261
DI 10.1016/j.toxlet.2012.06.007
PG 10
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 990GN
UT WOS:000307619100003
PM 22721804
DA 2022-04-25
ER

PT J
AU Huang, SB
   Sinicrope, FA
AF Huang, Shengbing
   Sinicrope, Frank A.
TI Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of
   autophagy in human colorectal cancer cells
SO AUTOPHAGY
LA English
DT Article
DE celecoxib; NSAID; ABT-737; Bcl-2; apoptosis; autophagy
ID BH3 MIMETIC ABT-737; ENDOPLASMIC-RETICULUM STRESS; DRUG-INDUCED
   APOPTOSIS; BCL-2 FAMILY-MEMBERS; SMALL-MOLECULE BCL-2; GROWTH IN-VIVO;
   CYCLOOXYGENASE-2 INHIBITOR; ENZYME-INHIBITORS; DEATH; PROTEINS
AB Apoptosis and autophagy have been shown to be negatively regulated by prosurvival Bcl-2 proteins. We determined whether the anticancer agent celecoxib, alone or combined with a small molecule Bcl-2/Bcl-x L antagonist (ABT-737), can induce autophagy in colon cancer cells. Furthermore, we determined whether inhibition of autophagy can drive colon cancer cells into apoptosis. Celecoxib was shown to induce apoptosis that was attenuated by ectopic Bcl-2 or Bax knockout. ABT-737 synergistically enhanced celecoxib-induced cytotoxicity that was primarily due to apoptosis as shown by caspase cleavage and Annexin V labeling that was attenuated by a pan caspase inhibitor (z-VAD-fmk). Celecoxib triggered conversion of the autophagosome-associated protein light chain 3 (LC3) from a cytosolic (LC3I) to a membrane-bound (LC3II) form, as shown by immunoblotting and a punctate fluorescence pattern of an ectopic GFP-LC3 protein. Celecoxib-induced conversion of LC3 was due to autophagy induction, as supported using the lysosome inhibitor, bafilomycin A1, which produced an accumulation of LC3II. ABT-737 enhanced celecoxib-induced LC3 conversion and p62/SQSTM1 degradation. Inhibition of autophagy was then studied in an effort to drive cells into apoptosis. 3-methyladenine (3-MA) blocked LC3 conversion, and 3-MA and wortmannin significantly enhanced apoptotic signaling in cells treated with celecoxib plus ABT-737. Furthermore, knockdown of Atg8/LC3B or Vps34 using siRNA attenuated p62 degradation and enhanced apoptotic signaling; Vps34 siRNA potentiated annexin V(+), PI-labeled cells induced by celecoxib + ABT-737. In conclusion, celecoxib induces apoptosis and autophagy that can both be potentiated by ABT-737. Inhibition of autophagy was shown to enhance apoptosis, suggesting a novel therapeutic strategy against colon cancer.
C1 [Sinicrope, Frank A.] Mayo Clin, Fiterman Ctr Digest Dis, Div Oncol & Gastroenterol, Rochester, MN 55905 USA.
   Mayo Clin, Mayo Canc Ctr, Rochester, MN USA.
RP Sinicrope, FA (corresponding author), Mayo Clin, Fiterman Ctr Digest Dis, Div Oncol & Gastroenterol, Rochester, MN 55905 USA.
EM sinicrope.frank@mayo.edu
FU Fraternal Order of Eagles Foundation; Fraternal Order of Eagles
   Foundation [CA113681]; NATIONAL CANCER INSTITUTEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA113681, K05CA142885] Funding
   Source: NIH RePORTER
FX Grant support: Supported in part by a Fraternal Order of Eagles
   Foundation Award and a National Cancer Institute R01 grant CA113681
   [both to F. A. S.].
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Ding HM, 2005, INT J CANCER, V113, P803, DOI 10.1002/ijc.20639
   Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200
   Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Heath-Engel HM, 2008, ONCOGENE, V27, P6419, DOI 10.1038/onc.2008.309
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hida T, 2000, CLIN CANCER RES, V6, P2006
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508
   Huang SB, 2009, CLIN CANCER RES, V15, P150, DOI 10.1158/1078-0432.CCR-08-1575
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795
   Johnson AJ, 2005, BLOOD, V105, P2504, DOI 10.1182/blood-2004-05-1957
   Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008-5472.CAN-06-0325
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006
   Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Nakata E, 2004, INT J RADIAT ONCOL, V58, P369, DOI 10.1016/j.ijrobp.2003.09.061
   Okumura K, 2008, CLIN CANCER RES, V14, P8132, DOI 10.1158/1078-0432.CCR-08-1665
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pyrko P, 2007, MOL CANCER THER, V6, P1262, DOI 10.1158/1535-7163.MCT-06-0629
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289
   Sinicrope FA, 2005, MOL CANCER THER, V4, P1475, DOI 10.1158/1535-7163.MCT-05-0137
   SINICROPE FA, 1995, CANCER RES, V55, P237
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203
   Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200
   Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139
   Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436
   van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027
   Williams CS, 2000, CANCER RES, V60, P6045
NR 56
TC 100
Z9 107
U1 0
U2 29
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD FEB 16
PY 2010
VL 6
IS 2
BP 256
EP 269
DI 10.4161/auto.6.2.11124
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 577CI
UT WOS:000276198100007
PM 20104024
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Lai, K
   Killingsworth, MC
   Lee, CS
AF Lai, K.
   Killingsworth, M. C.
   Lee, C. S.
TI The significance of autophagy in colorectal cancer pathogenesis and
   implications for therapy
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Review
ID COLON-CANCER; CELL-DEATH; BECLIN 1; INHIBITION; CHLOROQUINE; APOPTOSIS;
   5-FLUOROURACIL; LC3; DEGRADATION; EXPRESSION
AB Colorectal cancer (CRC) is one of the most common cancers in developed countries with poor survival outcome in advanced stages of the disease due to its resistance to chemotherapy and other forms of treatment. New and alternative approaches are needed to overcome the tumour cells' capacity for survival and to drive the tumour towards cell death. Autophagy is a mechanism involved in the elimination of damaged cellular components through lysosomal degradation and is capable of inducing programmed cell death. The process has recently gained much interest in understanding the pathogenesis of CRC and its potential for treatment of the disease due to its role in host protection and anticancer activity. This review describes and illustrates the fundamental mechanisms of autophagy, its importance as a prognostic marker and the current approaches to harness its protective and anticancer activity in CRC therapy.
C1 [Lai, K.; Lee, C. S.] Ingham Inst Appl Med Res, Sydney, NSW, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Univ Western Sydney, Sch Med, Discipline Pathol, Liverpool, NSW 2170, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Univ Western Sydney, Sch Med, Mol Med Res Grp, Liverpool, NSW 2170, Australia.
   [Lai, K.] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia.
   [Lai, K.; Killingsworth, M. C.] Liverpool Hosp, Electron Microscopy Lab, Sydney, NSW, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Liverpool Hosp, Dept Anat Pathol, Sydney, NSW, Australia.
   [Lee, C. S.] Univ Sydney, Bosch Inst, Dept Canc Pathol, Sydney, NSW 2006, Australia.
RP Lai, K (corresponding author), Univ Western Sydney, Sch Med, Discipline Pathol, Bldg K,Coll St, Liverpool, NSW 2170, Australia.
EM ken.lai@uws.edu.au
RI Killingsworth, Murray/O-3736-2019; Killingsworth, Murray C/G-5908-2015
OI Killingsworth, Murray/0000-0002-6125-1183; Lee, C.
   Soon/0000-0003-1058-5826
CR Abdel-Aziz AK, 2014, CHEM-BIOL INTERACT, V217, P28, DOI 10.1016/j.cbi.2014.04.007
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Chen J, 2002, CANCER J, V8, P154, DOI 10.1097/00130404-200203000-00009
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Greene LM, 2013, INT J ONCOL, V43, P927, DOI 10.3892/ijo.2013.1989
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   He G, 2014, TUMOR BIOL, V35, P1003, DOI 10.1007/s13277-013-1134-z
   Hiratsuka T, 2013, ONCOL REP, V29, P2140, DOI 10.3892/or.2013.2394
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Loven D, 2013, DRUG DISCOV TODAY, V18, P193, DOI 10.1016/j.drudis.2012.07.015
   MATHE G, 1989, BIOMED PHARMACOTHER, V43, P237, DOI 10.1016/0753-3322(89)90003-6
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rosenfeld MR, 2010, J CLIN ONCOL, V28
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
   Zhang JW, 2014, BIOCHEM PHARMACOL, V90, P265, DOI 10.1016/j.bcp.2014.05.009
NR 48
TC 29
Z9 31
U1 0
U2 18
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD OCT
PY 2014
VL 67
IS 10
BP 854
EP 858
DI 10.1136/jclinpath-2014-202529
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AQ1UA
UT WOS:000342566000003
PM 25055793
DA 2022-04-25
ER

PT J
AU Lauzier, A
   Normandeau-Guimond, J
   Vaillancourt-Lavigueur, V
   Boivin, V
   Charbonneau, M
   Rivard, N
   Scott, MS
   Dubois, CM
   Jean, S
AF Lauzier, Annie
   Normandeau-Guimond, Josiann
   Vaillancourt-Lavigueur, Vanessa
   Boivin, Vincent
   Charbonneau, Martine
   Rivard, Nathalie
   Scott, Michelle S.
   Dubois, Claire M.
   Jean, Steve
TI Colorectal cancer cells respond differentially to autophagy inhibition
   in vivo
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SPARE RESPIRATORY CAPACITY; BREAST-CANCER; GROWTH; PROGRESSION;
   EXPRESSION; MTORC1; TUMORS; PHOSPHORYLATION; METABOLISM; PHYSIOLOGY
AB Autophagy has both tumor-promoting and - suppressing effects in cancer, including colorectal cancer (CRC), with transformed cells often exhibiting high autophagic flux. In established tumors, autophagy inhibition can lead to opposite responses resulting in either tumor cell death or hyperproliferation. The functional mechanisms underlying these differences are poorly understood. The present study aimed to investigate the relationship between the autophagic capacities of CRC cells and their sensitivities to autophagy inhibition. All studied CRC cell lines showed high basal autophagic flux. However, only HCT116 and Caco-2/15 cells displayed regulated autophagic flux upon starvation. Knockdown of ATG5 (which disrupts autophagosome elongation) or RAB21 (which decreases autophagosome/lysosome fusion) had little effect on CRC cell proliferation in vitro. Nonetheless, inhibition of autophagy in vivo had a substantial cell line-dependent impact on tumor growth, with some cells displaying decreased (HCT116 and Caco-2/15) or increased (SW480 and LoVo) proliferation. RNA sequencing and Western blot analyses in hyperproliferative SW480 tumors revealed that the mTORC2 and AKT pathways were hyperactivated following autophagy impairment. Inhibition of either mTOR or AKT activities rescued the observed hyperproliferation in autophagy-inhibited SW480 and reduced tumor growth. These results highlight that autophagy inhibition can lead, in specific cellular contexts, to compensatory mechanisms promoting tumor growth.
C1 [Lauzier, Annie; Normandeau-Guimond, Josiann; Vaillancourt-Lavigueur, Vanessa; Boivin, Vincent; Charbonneau, Martine; Rivard, Nathalie; Scott, Michelle S.; Dubois, Claire M.; Jean, Steve] Univ Sherbrooke, Fac Med & Sci Sante, 3201 Rue Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.
   [Lauzier, Annie; Normandeau-Guimond, Josiann; Vaillancourt-Lavigueur, Vanessa; Charbonneau, Martine; Rivard, Nathalie; Dubois, Claire M.; Jean, Steve] Univ Sherbrooke, Dept Anat & Cell Biol, 3201 Rue Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.
   [Boivin, Vincent; Scott, Michelle S.] Univ Sherbrooke, Dept Biochem, 3201 Rue Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.
RP Jean, S (corresponding author), Univ Sherbrooke, Fac Med & Sci Sante, 3201 Rue Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.; Jean, S (corresponding author), Univ Sherbrooke, Dept Anat & Cell Biol, 3201 Rue Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.
EM steve.jean@usherbrooke.ca
RI Dubois, Claire M/K-1985-2013
OI Jean, Steve/0000-0001-6881-5781
FU Centre d'excellence en Recherche en Inflammation et Oncologie Digestive
   de l'Universite de Sherbrooke (CRIODUS); Cancer Research Society;
   Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR); Canada Research Chair in Colorectal Cancer
   [227765]; Research Chair from the Centre de recherche medicale de
   l'Universite de Sherbrooke (CRMUS); FRQS
FX We thank members of the laboratory for their helpful comments during the
   course of this work. We also thank Marie-Josee Boucher for helpful
   discussion through the progression of this work and Gaspard Reulet for
   help with RNASeq data handling. This research was supported by a seed
   grant from the Centre d'excellence en Recherche en Inflammation et
   Oncologie Digestive de l'Universite de Sherbrooke (CRIODUS), and
   operating grants from the Cancer Research Society and the Canadian
   Institutes of Health Research (CIHR) and by junior faculty salary awards
   from CIHR and Fonds de Recherche du Quebec en Sante (FRQS) to S.J. S.J.,
   C.M.D., M.S.S. and N.R. are members of the FRQS-Funded Centre de
   Recherche du CHUS. N.R. is a recipient of a Canada Research Chair in
   Colorectal Cancer and Inflammatory Cell Signaling (227765). S.J. is a
   recipient of a Research Chair from the Centre de recherche medicale de
   l'Universite de Sherbrooke (CRMUS).
CR Bas L, 2018, J CELL BIOL, V217, P3656, DOI 10.1083/jcb.201804028
   Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008
   Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x
   Coly PM, 2016, AUTOPHAGY, V12, P2344, DOI 10.1080/15548627.2016.1235125
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Del Olmo T, 2019, EMBO REP, V20, DOI 10.15252/embr.201847192
   Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51
   Driscoll DR, 2016, CANCER RES, V76, P6911, DOI 10.1158/0008-5472.CAN-16-0810
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Elgendy M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6637
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gao JQ, 2018, J CELL BIOL, V217, P3670, DOI 10.1083/jcb.201804039
   Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Jean S, 2015, EMBO REP, V16, P297, DOI 10.15252/embr.201439464
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koo J, 2015, J BIOL CHEM, V290, P14120, DOI 10.1074/jbc.M114.633057
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Matsui T, 2018, J CELL BIOL, V217, P2633, DOI 10.1083/jcb.201712058
   Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271
   Oliveira CSF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.157
   Park Deokbae, 2014, Dev Reprod, V18, P225, DOI 10.12717/devrep.2014.18.4.225
   Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019
   Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285
   Perez-Villamil B., 2012, BMC CANCER, V12, P1
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sueda T., 2016, SCI REP, V6, P1
   Thomas JD, 2014, CANCER CELL, V26, P754, DOI 10.1016/j.ccell.2014.09.008
   Tiwari R, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.23
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010
   Wang L., 2017, ONCOL LETT
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Yadava N, 2007, J NEUROSCI, V27, P7310, DOI 10.1523/JNEUROSCI.0212-07.2007
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang Z., 2013, NAT CELL BIOL, V12, P814
   Zaytseva YY, 2015, ONCOTARGET, V6, P18891, DOI 10.18632/oncotarget.3783
   Zhang XC, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00357-16
NR 79
TC 23
Z9 23
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 5
PY 2019
VL 9
AR 11316
DI 10.1038/s41598-019-47659-7
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IN5VC
UT WOS:000478743700028
PM 31383875
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yan, Z
   Zhang, B
   Huang, YY
   Qiu, HJ
   Chen, P
   Guo, GF
AF Yan, Zheng
   Zhang, Bei
   Huang, Yuanyuan
   Qiu, Huijuan
   Chen, Ping
   Guo, Gui-Fang
TI Involvement of autophagy inhibition in Brucea javanica oil
   emulsion-induced colon cancer cell death
SO ONCOLOGY LETTERS
LA English
DT Article
DE Brucea javanica oil emulsion; autophagy; apoptosis; colon cancer; light
   chain 3
ID ADVANCED SOLID TUMORS; PHASE-I TRIAL; NF-KAPPA-B; INDUCED APOPTOSIS;
   DOWN-REGULATION; INDUCTION; MTOR; HYDROXYCHLOROQUINE; DIFFERENTIATION;
   CHEMOTHERAPY
AB Brucea javanica oil emulsion (BJOE), the petroleum ether extract of B. javanica emulsified by phospholipid, is widely used in China as an anticancer agent. The extracts from B. javanica induce cancer cell death by various mechanisms; however, it is not known whether these mechanisms involve autophagy, which is an important process in cancer development and treatment. Thus, the current study. aimed to investigate whether BJOE modulates autophagy in HCT116 human colon cancer cells and whether modulation of autophagy is an anticancer mechanism of BJOE. Immunoblotting was employed to analyze the protein expression levels of microtubule-associated protein light-chain 3 (LC3), a specific protein marker of autophagy, in HCT116 cancer cells following exposure to BJOE. The apoptosis rate of the HCT116 cancer cells was detected by performing an Annexin V-fluorescein isothiocyanate/propidium iodide assay. According to the effect of BJOE administration on autophagy in the HCT116 cancer cells (induction or suppression), a functionally opposite agent (autophagy suppressor or inducer) was applied to counteract this effect, and the apoptosis rate of the cancer cells was detected again. The role of autophagy (pro-survival or pro-death) was demonstrated by comparing the rates of apoptotic cancer cells prior to and following the counteraction. The results revealed that BJOE suppressed the protein expression levels of LC3, including the LC3-I and LC3-II forms, and induced apoptosis in the HCT116 cancer cells with a high level of basal LC3. The apoptosis-inducing activity of BJOE was significantly attenuated when autophagy was induced by the administration of trehalose, an autophagy inducer. The data indicates that autophagy inhibition is involved in BJOE-induced cancer cell death, and that this inhibition may be a potential anticancer mechanism of BJOE.
C1 [Yan, Zheng; Zhang, Bei; Huang, Yuanyuan; Qiu, Huijuan; Chen, Ping; Guo, Gui-Fang] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.
   [Yan, Zheng] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhang, Bei; Huang, Yuanyuan; Qiu, Huijuan; Chen, Ping; Guo, Gui-Fang] Sun Yat Sen Univ, Ctr Canc, VIP Reg, Guangzhou 510060, Guangdong, Peoples R China.
RP Guo, GF (corresponding author), Sun Yat Sen Univ, Ctr Canc, VIP Reg, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM sysucc@163.com
RI Yan, Zheng/AFD-5256-2022
OI Yan, Zheng/0000-0001-9324-2161; guo, gui fang/0000-0002-6283-7266
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302141]; Administration of Traditional
   Chinese Medicine of Guangdong Province [20111169]; Science and
   Technology Planning Project of Guangdong Province [2010B031600317];
   Fundamental Research Funds for the Sun Yat-sen University Young Teacher
   Training Project [12ykpy56]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (no. 81302141), the Administration of
   Traditional Chinese Medicine of Guangdong Province (no. 20111169), the
   Science and Technology Planning Project of Guangdong Province (no.
   2010B031600317) and the Fundamental Research Funds for the Sun Yat-sen
   University Young Teacher Training Project (no. 12ykpy56).
CR Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011
   Cuendet M, 2004, CANCER LETT, V206, P43, DOI 10.1016/j.canlet.2003.11.011
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lau FY, 2005, INT J MOL MED, V16, P1157
   Lau ST, 2008, PHYTOTHER RES, V22, P477, DOI 10.1002/ptr.2344
   Li YB, 2013, MOL NEUROBIOL, V47, P1000, DOI 10.1007/s12035-013-8403-0
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu JH, 2009, CHEM BIODIVERS, V6, P57, DOI 10.1002/cbdv.200700409
   Lou GG, 2010, AM J CHINESE MED, V38, P613, DOI 10.1142/S0192415X10008093
   Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399
   Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040
   Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372
   Mata-Greenwood E, 2002, LEUKEMIA, V16, P2275, DOI 10.1038/sj.leu.2402696
   Moad AIH, 2013, CELL BIOCHEM BIOPHYS, V66, P567, DOI 10.1007/s12013-012-9504-5
   Murakami C, 2004, BIOORGAN MED CHEM, V12, P4963, DOI 10.1016/j.bmc.2004.06.045
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108
   Rosich L, 2012, CLIN CANCER RES, V18, P5278, DOI 10.1158/1078-0432.CCR-12-0351
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Tang QS, 2013, CANCER LETT, V336, P325, DOI 10.1016/j.canlet.2013.03.023
   Wang Quan, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2022
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Xuan Y B, 1994, Gan To Kagaku Ryoho, V21, P2421
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhang HT, 2011, EURASIP J WIREL COMM, P1, DOI 10.1186/1687-1499-2011-69
NR 37
TC 26
Z9 28
U1 1
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2015
VL 9
IS 3
BP 1425
EP 1431
DI 10.3892/ol.2015.2875
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CD2OE
UT WOS:000350918100077
PM 25663926
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Pettersen, K
   Monsen, VT
   Pettersen, CHH
   Overland, HB
   Pettersen, G
   Samdal, H
   Tesfahun, AN
   Lundemo, AG
   Bjorkoy, G
   Schonberg, SA
AF Pettersen, Kristine
   Monsen, Vivi Talstad
   Pettersen, Caroline Hild Hakvag
   Overland, Hilde Bremseth
   Pettersen, Grete
   Samdal, Helle
   Tesfahun, Almaz Nigatu
   Lundemo, Anne Goril
   Bjorkoy, Geir
   Schonberg, Svanhild A.
TI DHA-induced stress response in human colon cancer cells - Focus on
   oxidative stress and autophagy
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE n 3 PUFA; DHA; Oxidative stress; Autophagy; NFE2L2; Colon cancer
ID TRANSCRIPTION FACTOR NRF2; ENDOPLASMIC-RETICULUM STRESS; POLYUNSATURATED
   FATTY-ACIDS; COLORECTAL-CANCER; SELECTIVE AUTOPHAGY; CALCIUM
   HOMEOSTASIS; QUALITY-CONTROL; ER STRESS; PATHWAY; SURVIVAL
AB Polyunsaturated fatty acids (PUFAs) are important constituents of the diet and health benefits of omega-3/n 3 PUFAs, especially eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) have been well documented in relation to several diseases. Increasing evidence suggests that n-3 PUFAs may have anticancer activity and improve the effect of conventional cancer therapy. The mechanisms behind these effects are still unclear and need to be elucidated. We have examined the DHA-induced stress response in two human colon cancer cell lines, SW620 and Caco-2. SW620 cells are growth-inhibited at early time points by DHA, while the growth of Caco-2 cells almost remains unaffected by the same treatment. Gene expression analysis of SW620 cells treated with DHA revealed changes at early time points; transcripts involved in oxidative stress and autophagy were among the first to be differentially expressed. We find that oxidative stress is induced in both cell lines, although at different time points and to different extent. DHA induced nuclear translocation of the oxidative stress sensor NFE2L2 in both cell lines, indicating an induction of an anti-oxidative response. However, vitamin E did not counteract ROS-production or the translocation of NFE2L2 to the nucleus. Neither vitamin E nor the antioxidants butylated hydoxyanisole (BHA) and butylated hydoxytoluene (BHT) did affect the growth inhibition in SW620 cells after DHA-treatment. Also, siRNA-mediated down-regulation of NFE2L2 did not sensitize SW620 and Caco-2 cells to DHA. These results indicate that oxidative stress response is not the cause of DHA-induced cytotoxicity in SW620 cells. Using biochemical and imaging based functional assays, we found a low basal level of autophagy and no increase in autophagic flux after adding DHA to the SW620 cells. However, Caco-2 cells displayed a higher level of autophagy, both in the absence and presence of DHA. Inhibition of autophagy by siRNA mediated knock down of ATG5 and ATG7 sensitized both SW620 and Caco-2 cells to DHA. Stimulation of autophagy by rapamycin in 5W620 and Caco-2 cells resulted in decreased DHA-sensitivity and inhibition of autophagy in Caco-2 cells by chloroquine resulted in increased DHA-sensitivity. These results suggest that autophagy is important for the DHA sensitivity of colon cancer cells and imply possible therapeutic effects of this fatty acid against cancer cells with low autophagy. (C)2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
C1 [Pettersen, Kristine; Monsen, Vivi Talstad; Pettersen, Caroline Hild Hakvag; Overland, Hilde Bremseth; Pettersen, Grete; Samdal, Helle; Tesfahun, Almaz Nigatu; Lundemo, Anne Goril; Schonberg, Svanhild A.] Norwegian Univ Sci & Technol, Dept Lab Med, Childrens & Womens Hlth, Fac Med,NTNU, N-7006 Trondheim, Norway.
   [Pettersen, Kristine; Bjorkoy, Geir] Univ Coll Sor Trondelag, Dept Technol, N-7006 Trondheim, Norway.
   [Overland, Hilde Bremseth] Cent Norway Reg Hlth Author, N-7055 Stjordal, Norway.
   [Pettersen, Kristine; Bjorkoy, Geir] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Ctr Mol Inflammat Res, N-7491 Trondheim, Norway.
RP Schonberg, SA (corresponding author), Norwegian Univ Sci & Technol, Dept Lab Med, Childrens & Womens Hlth, Fac Med,NTNU, N-7006 Trondheim, Norway.
EM svanhild.schonberg@ntnu.no
OI Pettersen, Caroline/0000-0003-0658-0061; Pettersen,
   Kristine/0000-0002-6446-0984
FU Faculty of Medicine; NTNU; Norwegian Cancer SocietyNorwegian Cancer
   Society; Cancer Research Foundation at St. Olavs Hospital; Central
   Norway Regional Health Authority and The Research Council of Norway
   through "Smaforsk" grant
FX We thank Terje Johansen and Hans Krokan for discussions and comments.
   Gene expression profiling was performed at the Norwegian Microarray
   consortium (NMC) in Trondheim. We thank Cathrine Goberg Olsen for gene
   expression profiling, Turid Follestad for the statistical analysis, Lena
   Pape, Nina Beate Liabakk, Kamilla Zub and Ida Johansson for their
   experimental input. This work was supported by grants from The Faculty
   of Medicine, NTNU, the Norwegian Cancer Society, the Cancer Research
   Foundation at St. Olavs Hospital, the Central Norway Regional Health
   Authority and The Research Council of Norway through "Smaforsk" grant.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bathen TF, 2008, ANTICANCER RES, V28, P3717
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Buchberger A, 2010, MOL CELL, V40, P238, DOI 10.1016/j.molcel.2010.10.001
   CAYGILL CPJ, 1995, EUR J CANCER PREV, V4, P329, DOI 10.1097/00008469-199508000-00008
   Cockbain AJ, 2012, GUT, V61, P135, DOI 10.1136/gut.2010.233718
   Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   Dennis MD, 2013, CELL SIGNAL, V25, P2709, DOI 10.1016/j.cellsig.2013.08.038
   Dyerberg J, 1989, Arctic Med Res, V48, P47
   Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Friedland RP, 2003, ARCH NEUROL-CHICAGO, V60, P923, DOI 10.1001/archneur.60.7.923
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200
   Jensen LR, 2007, CANCER BIOL THER, V6, P1810, DOI 10.4161/cbt.6.11.4887
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kubisch J, 2013, SEMIN CANCER BIOL, V23, P252, DOI 10.1016/j.semcancer.2013.06.009
   Lin G, 2012, ONCOL REP, V27, P1527, DOI 10.3892/or.2012.1669
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842
   Malhotra JD, 2008, P NATL ACAD SCI USA, V105, P18525, DOI 10.1073/pnas.0809677105
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   NisoSantano M., 2015, EMBO J
   Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164
   Pan MH, 2008, P NATL ACAD SCI USA, V105, P5862, DOI 10.1073/pnas.0707460104
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schonberg SA, 2006, FEBS J, V273, P2749, DOI 10.1111/j.1742-4658.2006.05292.x
   Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905
   Serini S, 2011, CURR MED CHEM, V18, P4065, DOI 10.2174/092986711796957310
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Slagsvold JE, 2010, NUTR CANCER, V62, P611, DOI 10.1080/01635580903532366
   Slagsvold JE, 2009, LIPIDS, V44, P103, DOI 10.1007/s11745-008-3263-5
   Storvold GL, 2009, LIPIDS, V44, P673, DOI 10.1007/s11745-009-3324-4
   Takahashi M, 1997, CARCINOGENESIS, V18, P1337, DOI 10.1093/carcin/18.7.1337
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 56
TC 42
Z9 47
U1 1
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN
PY 2016
VL 90
BP 158
EP 172
DI 10.1016/j.freeradbiomed.2015.11.018
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CZ9CY
UT WOS:000367396600015
PM 26585906
OA Green Accepted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Zhang, ZY
   Zhang, SF
   Yang, JJ
   Yi, PJ
   Xu, PP
   Yi, M
   Peng, WJ
AF Zhang, Zheyu
   Zhang, Sifang
   Yang, Jingjing
   Yi, Pengji
   Xu, Panpan
   Yi, Min
   Peng, Weijun
TI Integrated transcriptomic and metabolomic analyses to characterize the
   anti-cancer effects of (-)-epigallocatechin-3-gallate in human colon
   cancer cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE EGCG; Colorectal cancer; Transcriptomic; Metabolomics; Glutathione
   metabolism; Glycerophospholipid metabolism
ID EPIGALLOCATECHIN GALLATE; PROLIFERATION; APOPTOSIS; GROWTH; EGCG;
   INHIBITION; AUTOPHAGY; PATHWAY
AB (-)-Epigallocatechin-3-gallate (EGCG) is the main bioactive component in tea (Camellia sinensis) catechins, and exhibits potential antitumor activity against colorectal cancer (CRC). However, the underlying mechanisms are largely unclear. We investigated the effects of EGCG on activities of CRC cells and the exact molecular mechanism. We used human colon cancer cells (HT-29) and exposed them to EGCG at various concentrations. The MTT assay, flow cytometry, and TUNEL staining were used to study the underlying mechanisms of EGCG (proliferation, apoptosis, autophagy). Western blotting was used to measure expression of marker proteins of the cell cycle, apoptosis, and autophagy. Using a combined microarray-based transcriptomic and ultra-high-performance liquid chromatography coupled with quadrupole-time-of-flight tandem mass spectrometry (UHPLC-QTOF/MS)-based metabolomic approach, we investigated the perturbed pathways induced by EGCG treatment at transcript and metabolite levels. Transcriptomic analyses showed that 486 genes were differentially expressed between untreated and EGCG-treated cells. Also, 88 differentially expressed metabolites were identified between untreated and EGCG-treated cells. The altered metabolites were involved in the metabolism of glutathione, glycerophospholipids, starch, sucrose, amino sugars, and nucleotide sugars. There was substantial agreement between the results of transcriptomics and metabolomics analyses. Our data indicate that the anticancer activity of EGCG against HT-29 cells is mediated by induction of cell-cycle arrest, apoptosis, and autophagy. EGCG modulates cancer-cell metabolic pathways. These results provide a platform for future molecular mechanistic studies of EGCG.
C1 [Zhang, Zheyu; Zhang, Sifang; Yi, Pengji; Xu, Panpan; Yi, Min; Peng, Weijun] Cent South Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Zheyu] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China.
   [Zhang, Zheyu] Guilin Med Univ, Dept Gastroenterol, Affiliated Hosp, Guilin 541001, Guangxi, Peoples R China.
   [Yang, Jingjing] Cent South Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, Changsha 410008, Hunan, Peoples R China.
RP Yi, M; Peng, WJ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM yimin66@csu.edu; pengweijun87@csu.edu.cn
RI Peng, Weijun/M-5131-2014
OI Peng, Weijun/0000-0002-4506-0942
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81273722, 81603670]; Hunan Provincial
   Natural Science Foundation of ChinaNatural Science Foundation of Hunan
   Province [2017JJ3459, 2018JJ2595]
FX This work was supported by the National Natural Science Foundation of
   China (81273722, 81603670) and the Hunan Provincial Natural Science
   Foundation of China (2017JJ3459, 2018JJ2595).
CR Adachi S, 2009, CARCINOGENESIS, V30, P1544, DOI 10.1093/carcin/bgp166
   Braicu C, 2013, J NANOSCI NANOTECHNO, V13, P632, DOI 10.1166/jnn.2013.6882
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cui Y, 2017, DNA CELL BIOL, V36, P822, DOI 10.1089/dna.2017.3805
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   de Figueiredo Junior Adiel Goes, 2018, Asian Pac J Cancer Prev, V19, P1287
   Dekant W, 2017, TOXICOL LETT, V277, P104, DOI 10.1016/j.toxlet.2017.06.008
   Fang CY, 2015, INT J MOL SCI, V16, P2530, DOI 10.3390/ijms16022530
   Gan RY, 2018, CRIT REV FOOD SCI, V58, P924, DOI 10.1080/10408398.2016.1231168
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2
   Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9
   Hu JH, 2009, J AGR FOOD CHEM, V57, P1349, DOI 10.1021/jf803143n
   Hu L, 2016, ONCOTARGET, V7, P66660, DOI 10.18632/oncotarget.11433
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Jiang GZ, 2017, ONCOTARGET, V8, P21663, DOI 10.18632/oncotarget.15523
   Joana R, 2012, BMC CANCER, V12, P280
   Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919
   Lea MA, 2014, WORLD J GASTRO ONCOL, V6, P244, DOI 10.4251/wjgo.v6.i7.244
   Li SS, 2017, CELL BIOCHEM FUNCT, V35, P209, DOI 10.1002/cbf.3265
   Liu YL, 2014, ADV CANCER RES, V122, P69, DOI 10.1016/B978-0-12-420117-0.00002-5
   Lu QY, 2015, METABOLOMICS, V11, P71, DOI 10.1007/s11306-014-0672-8
   Luo KW, 2017, J NUTR BIOCHEM, V41, P56, DOI 10.1016/j.jnutbio.2016.12.004
   Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002
   Nishimura K, 2018, BIOCHEM BIOPH RES CO, V495, P1317, DOI 10.1016/j.bbrc.2017.11.167
   Patin F, 2016, NEUROTHERAPEUTICS, V13, P905, DOI 10.1007/s13311-016-0461-3
   Pei SS, 2013, J BIOL CHEM, V288, P33542, DOI 10.1074/jbc.M113.511170
   Peter B, 2017, EUR BIOPHYS J BIOPHY, V46, P1, DOI 10.1007/s00249-016-1141-2
   Rejhova A, 2018, EUR J MED CHEM, V144, P582, DOI 10.1016/j.ejmech.2017.12.039
   Shimizu M, 2010, CHEM-BIOL INTERACT, V185, P247, DOI 10.1016/j.cbi.2010.03.036
   Shou QY, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01531
   Shu X, 2018, INT J CANCER, V143, P527, DOI 10.1002/ijc.31341
   Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39
   Sukhthankar M, 2008, GASTROENTEROLOGY, V134, P1972, DOI 10.1053/j.gastro.2008.02.095
   Tanaka T, 2011, FREE RADICAL BIO MED, V50, P1324, DOI 10.1016/j.freeradbiomed.2011.01.024
   Tang GY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246196
   van der Stok EP, 2017, NAT REV CLIN ONCOL, V14, P297, DOI 10.1038/nrclinonc.2016.199
   Wang K, 2014, EXPERT REV PROTEOMIC, V11, P179, DOI 10.1586/14789450.2014.894466
   Wang WB, 2018, J ETHNOPHARMACOL, V219, P299, DOI 10.1016/j.jep.2018.03.026
   Williams MD, 2015, ANAL BIOANAL CHEM, V407, P4581, DOI 10.1007/s00216-015-8662-x
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wu PN, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112210
   Xu DQ, 2019, AGING DIS, V10, P854, DOI 10.14336/AD.2018.1027
   Yang CG, 2016, INT J FOOD SCI NUTR, V67, P818, DOI 10.1080/09637486.2016.1198892
   Yang CS, 2016, MOLECULES, V21, DOI 10.3390/molecules21121679
   Yuan CH, 2017, ENVIRON TOXICOL, V32, P845, DOI 10.1002/tox.22284
   Zhang C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00681
   Zhang DD, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/235265
   Zhang ZY, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112371
NR 50
TC 9
Z9 9
U1 5
U2 37
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD AUG 15
PY 2020
VL 401
AR 115100
DI 10.1016/j.taap.2020.115100
PG 13
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA MO4QK
UT WOS:000551512500013
PM 32512070
DA 2022-04-25
ER

PT J
AU Matarrese, P
   Mattia, G
   Pagano, MT
   Pontecorvi, G
   Ortona, E
   Malorni, W
   Care, A
AF Matarrese, Paola
   Mattia, Gianfranco
   Pagano, Maria Teresa
   Pontecorvi, Giada
   Ortona, Elena
   Malorni, Walter
   Care, Alessandra
TI The Sex-Related Interplay between TME and Cancer: On the Critical Role
   of Estrogen, MicroRNAs and Autophagy
SO CANCERS
LA English
DT Review
DE cancer; gender; sex; sex hormones; microRNA; autophagy; tumor
   microenvironment
ID CELL LUNG-CANCER; BETA ER-BETA; HUMAN OSTEOSARCOMA SAOS-2;
   RECEPTOR-BETA; COLORECTAL-CANCER; X-CHROMOSOME; CUTANEOUS MELANOMA;
   STEROID-HORMONES; XENO-CANNIBALISM; LYMPHOMA GROWTH
AB Simple Summary Autophagy is a complex cell process that allow the cell to survive in unfavorable conditions, e.g., in the lack of nutritional elements coming from the environment. Here we focused on the role played by autophagy in the crosstalk between the microenvironment surrounding the tumor and cancer cells. This environment is in fact known as pivotal in determining the growth or the inhibition of a tumor. Cancer progression and response to therapy significantly differ between women and men and the microenvironment, in particular sex hormones and microRNAs, appears a critical factor. Four representative types of cancer, i.e., colon cancer, melanoma, lymphoma, and lung cancer showing sex/gender specificities have been described herein. We underscore that the use of a "gender tailored" approach could provide a better comprehension of the cellular and molecular mechanisms of cancer growth control contributing to the development of novel therapeutic approaches towards an increasingly personalized medicine. The interplay between cancer cells and the tumor microenvironment (TME) has a fundamental role in tumor progression and response to therapy. The plethora of components constituting the TME, such as stroma, fibroblasts, endothelial and immune cells, as well as macromolecules, e.g., hormones and cytokines, and epigenetic factors, such as microRNAs, can modulate the survival or death of cancer cells. Actually, the TME can stimulate the genetically regulated programs that the cell puts in place under stress: apoptosis or, of interest here, autophagy. However, the implication of autophagy in tumor growth appears still undefined. Autophagy mainly represents a cyto-protective mechanism that allows cell survival but, in certain circumstances, also leads to the blocking of cell cycle progression, possibly leading to cell death. Since significant sex/gender differences in the incidence, progression and response to cancer therapy have been widely described in the literature, in this review, we analyzed the roles played by key components of the TME, e.g., estrogen and microRNAs, on autophagy regulation from a sex/gender-based perspective. We focused our attention on four paradigmatic and different forms of cancers-colon cancer, melanoma, lymphoma, and lung cancer-concluding that sex-specific differences may exert a significant impact on TME/cancer interaction and, thus, tumor growth.
C1 [Matarrese, Paola; Mattia, Gianfranco; Pagano, Maria Teresa; Pontecorvi, Giada; Ortona, Elena; Care, Alessandra] Ist Super Sanita, Ctr Gender Specif Med, I-00161 Rome, Italy.
   [Malorni, Walter] Univ Roma Tor Vergata, Fac Farmacy, Dept Biol, I-00133 Rome, Italy.
   [Malorni, Walter] Univ Cattolica Sacro Cuore, Ctr Global Hlth, I-00168 Rome, Italy.
RP Malorni, W (corresponding author), Univ Roma Tor Vergata, Fac Farmacy, Dept Biol, I-00133 Rome, Italy.; Malorni, W (corresponding author), Univ Cattolica Sacro Cuore, Ctr Global Hlth, I-00168 Rome, Italy.
EM paola.matarrese@iss.it; gianfranco.mattia@iss.it;
   mariateresa.pagano@guest.iss.it; giada.pontecorvi@iss.it;
   elena.ortona@iss.it; walter.malorni@unicatt.it; alessandra.care@iss.it
RI ; Care, Alessandra/H-5090-2016
OI Pagano, Maria Teresa/0000-0002-9215-9187; matarrese,
   paola/0000-0001-5477-3752; Care, Alessandra/0000-0003-4106-3342
CR Abdrakhmanov A, 2019, BIOL CHEM, V400, P161, DOI 10.1515/hsz-2018-0210
   Akkoc Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.627023
   Albain KS, 2007, J CLIN ONCOL, V25
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523
   Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Buccarelli M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0864-7
   Bustos SO, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606436
   Bustos V, 2017, ONCOTARGET, V8, P84258, DOI 10.18632/oncotarget.20653
   Campbell-Thompson M, 2001, CANCER RES, V61, P632
   Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106
   Cha MJ, 2016, EXP CELL RES, V341, P139, DOI 10.1016/j.yexcr.2016.02.005
   Chatterjee SJ, 2011, CANCER BIOL THER, V11, P216, DOI 10.4161/cbt.11.2.13798
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Cheng SB, 2011, J BIOL CHEM, V286, P22441, DOI 10.1074/jbc.M111.224071
   Clocchiatti A, 2016, NAT REV CANCER, V16, P330, DOI 10.1038/nrc.2016.30
   Colangelo T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.29
   Costa AR, 2020, TRENDS ENDOCRIN MET, V31, P785, DOI 10.1016/j.tem.2020.07.002
   Cui CM, 2018, GENOM PROTEOM BIOINF, V16, P200, DOI 10.1016/j.gpb.2018.03.004
   de Giorgi V, 2013, BRIT J DERMATOL, V168, P513, DOI 10.1111/bjd.12056
   De Giorgi V, 2011, EXPERT REV ANTICANC, V11, P739, DOI [10.1586/ERA.11.42, 10.1586/era.11.42]
   de Giorgi V, 2009, ARCH DERMATOL, V145, P30, DOI 10.1001/archdermatol.2008.537
   de Valdivia EG, 2017, J BIOL CHEM, V292, P9932, DOI 10.1074/jbc.M116.765875
   Deng XX, 2014, NAT REV GENET, V15, P367, DOI 10.1038/nrg3687
   Dika E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111463
   Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099
   Du L, 2009, J BIOL CHEM, V284, P2383, DOI 10.1074/jbc.M804396200
   Dupuis ML., 2019, ITAL J GEND SPECIF M, V5, P11, DOI 10.1723/3148.31294
   Edvardsson K, 2013, CARCINOGENESIS, V34, P1431, DOI 10.1093/carcin/bgt067
   Felzen V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.181
   Fouad YA, 2017, AM J CANCER RES, V7, P1016
   Gabriele Lucia, 2016, Ann Ist Super Sanita, V52, P213, DOI 10.4415/ANN_16_02_13
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Ge ZX, 2019, IEEE T NANOBIOSCI, V18, P679, DOI 10.1109/TNB.2019.2940258
   Ghafouri-Fard S, 2021, AUTOPHAGY, DOI 10.1080/15548627.2021.1883881
   Gomes JPM, 2011, REV BRAS FARMACOGN, V21, P963, DOI 10.1590/S0102-695X2011005000153
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802
   Guido C, 2012, CELL CYCLE, V11, P2911, DOI 10.4161/cc.21336
   Guo QK, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181523
   Guo WN, 2017, THERANOSTICS, V7, P2231, DOI 10.7150/thno.18835
   Haas NB, 2019, CLIN CANCER RES, V25, P2080, DOI 10.1158/1078-0432.CCR-18-2204
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haupt S, 2021, NAT REV CANCER, V21, P393, DOI 10.1038/s41568-021-00348-y
   He H, 2014, FOOD CHEM TOXICOL, V71, P128, DOI 10.1016/j.fct.2014.06.007
   Hershberger PA, 2005, CANCER RES, V65, P1598, DOI 10.1158/0008-5472.CAN-04-2694
   Hsieh DJY, 2015, CELL PHYSIOL BIOCHEM, V36, P274, DOI 10.1159/000374070
   Hsu LH, 2015, CANCER SCI, V106, P51, DOI 10.1111/cas.12558
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Irelli A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070232
   Janik ME, 2014, WSPOLCZESNA ONKOL, V18, P302, DOI 10.5114/wo.2014.43938
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jiang GM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0944-z
   Joosse A, 2011, J INVEST DERMATOL, V131, P719, DOI 10.1038/jid.2010.354
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kim ER, 2014, WORLD J GASTROENTERO, V20, P9872, DOI 10.3748/wjg.v20.i29.9872
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Klein SL, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00301-y
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kobayashi Y, 2020, INT J ONCOL, V56, P999, DOI 10.3892/ijo.2020.4975
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9
   Kovats S, 2008, CELL IMMUNOL, V252, P81, DOI 10.1016/j.cellimm.2007.10.008
   Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kukurba KR, 2016, GENOME RES, V26, P768, DOI 10.1101/gr.197897.115
   Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2
   Levin ER, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2016.122
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CH, 2018, CANCER RES, V78, P5527, DOI 10.1158/0008-5472.CAN-18-0362
   Li XR, 2010, ENDOCRINOLOGY, V151, P2462, DOI 10.1210/en.2009-1150
   Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264-016-0017-x
   Lista P, 2011, J CELL MOL MED, V15, P1443, DOI 10.1111/j.1582-4934.2011.01293.x
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Ma LH, 2016, TRANSL LUNG CANCER R, V5, P202, DOI 10.21037/tlcr.2016.04.04
   Mah V, 2011, LUNG CANCER, V74, P318, DOI 10.1016/j.lungcan.2011.03.009
   Malorni W, 2007, AUTOPHAGY, V3, P75, DOI 10.4161/auto.3439
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino M, 2008, STEROIDS, V73, P853, DOI 10.1016/j.steroids.2007.12.003
   Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020
   Marzagalli M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00140
   Marzagalli M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134396
   Maselli A, 2009, FASEB J, V23, P978, DOI 10.1096/fj.08-114348
   Matarrese P, 2008, CURR PHARM DESIGN, V14, P245
   Matarrese P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1888-3
   Metcalf KJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143765
   Mitchell DL, 2014, PIGM CELL MELANOMA R, V27, P408, DOI 10.1111/pcmr.12213
   Mitkov M, 2015, MOL CELL ENDOCRINOL, V417, P94, DOI 10.1016/j.mce.2015.09.020
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Moulton VR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02279
   Muralimanoharan S, 2017, J MOL CELL CARDIOL, V108, P181, DOI 10.1016/j.yjmcc.2017.06.006
   Muscogiuri G, 2020, ENDOCRINE, V69, P441, DOI 10.1007/s12020-020-02331-3
   Niikawa H, 2008, CLIN CANCER RES, V14, P4417, DOI 10.1158/1078-0432.CCR-07-1950
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Ohata C, 2008, J DERMATOL, V35, P215, DOI 10.1111/j.1346-8138.2008.00447.x
   Orshal JM, 2004, AM J PHYSIOL-REG I, V286, pR233, DOI 10.1152/ajpregu.00338.2003
   Ortona E, 2015, ITALIAN J GENDER SPE, V1, P45, DOI DOI 10.1723/2188.23636
   Ozdemir BC, 2019, CLIN CANCER RES, V25, P4603, DOI 10.1158/1078-0432.CCR-19-0137
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Park J, 2016, STEROIDS, V115, P177, DOI 10.1016/j.steroids.2016.09.011
   Parlato S, 2021, LAB CHIP, V21, P234, DOI 10.1039/d0lc00799d
   Pierdominici M, 2017, ONCOTARGET, V8, P8522, DOI 10.18632/oncotarget.14338
   Pierdominici M, 2010, IMMUNOL LETT, V132, P79, DOI 10.1016/j.imlet.2010.06.003
   Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047
   Potzl J, 2017, INT J CANCER, V140, P2125, DOI 10.1002/ijc.30646
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Pontecorvi G, 2020, CYTOKINE GROWTH F R, V51, P75, DOI 10.1016/j.cytogfr.2019.12.010
   Qiu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03052-1
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raue R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042210
   Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575
   Rodriguez-Lara V, 2014, ARCH MED RES, V45, P158, DOI 10.1016/j.arcmed.2014.01.001
   Rohani N, 2019, CANCER RES, V79, P1952, DOI 10.1158/0008-5472.CAN-18-1604
   Roskoski R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104609
   Rothschild SI, 2017, LUNG CANCER, V107, P73, DOI 10.1016/j.lungcan.2016.06.004
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Sandbothe M, 2017, J HEPATOL, V66, P1012, DOI 10.1016/j.jhep.2017.01.004
   SANTEN RJ, 1988, EUR J CANCER CLIN ON, V24, P1811, DOI 10.1016/0277-5379(88)90090-9
   SCHIEBLER TH, 1978, CELL TISSUE RES, V192, P527
   Schmidt AN, 2006, EXP DERMATOL, V15, P971, DOI 10.1111/j.1600-0625.2006.00502.x
   Shang DT, 2021, AUTOPHAGY, V17, P1065, DOI 10.1080/15548627.2020.1752511
   Shepherd R, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604000
   Shireman JM, 2020, NEURO-ONCOLOGY, V22, P1555, DOI 10.1093/neuonc/noaa218
   Siegfried JM, 2014, SEMIN ONCOL, V41, P5, DOI 10.1053/j.seminoncol.2013.12.009
   Siegfried JM, 2009, SEMIN ONCOL, V36, P524, DOI 10.1053/j.seminoncol.2009.10.004
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Skjefstad K, 2016, STEROIDS, V113, P5, DOI 10.1016/j.steroids.2016.05.008
   Solakidi S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P240
   Solakidi S, 2005, BBA-MOL CELL RES, V1745, P382, DOI 10.1016/j.bbamcr.2005.05.010
   Somasundaram A, 2020, ADV EXP MED BIOL, V1277, P33, DOI 10.1007/978-3-030-50224-9_2
   Stabile LP, 2011, CLIN CANCER RES, V17, P154, DOI 10.1158/1078-0432.CCR-10-0992
   Stabile LP, 2005, CANCER RES, V65, P1459, DOI 10.1158/0008-5472.CAN-04-1872
   Straface E, 2009, FEBS LETT, V583, P3448, DOI 10.1016/j.febslet.2009.09.052
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Totta P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094880
   Turei D, 2015, AUTOPHAGY, V11, P155, DOI 10.4161/15548627.2014.994346
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Vara-Perez M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050493
   Wagner AD, 2019, ANN ONCOL, V30, P1914, DOI 10.1093/annonc/mdz414
   Wang FM, 2014, MOL MED REP, V10, P1509, DOI 10.3892/mmr.2014.2365
   Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081
   Wang SY, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/7565076
   Wei Y, 2019, INT J BIOL SCI, V15, P942, DOI 10.7150/ijbs.30930
   Weinberg OK, 2005, CANCER RES, V65, P11287, DOI 10.1158/0008-5472.CAN-05-2737
   Wilde L, 2017, SEMIN ONCOL, V44, P198, DOI 10.1053/j.seminoncol.2017.10.004
   Williams C, 2016, CANCER LETT, V372, P48, DOI 10.1016/j.canlet.2015.12.009
   Yakimchuk K, 2011, LEUKEMIA, V25, P1103, DOI 10.1038/leu.2011.68
   Yakimchuk K, 2014, BLOOD, V123, P2054, DOI 10.1182/blood-2013-07-517292
   Yakimchuk K, 2013, MOL CELL ENDOCRINOL, V375, P121, DOI 10.1016/j.mce.2013.05.016
   Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495-013-0867-x
   Yang ZM, 2019, J INT MED RES, V47, P4644, DOI 10.1177/0300060519871373
   Yu Y, 2019, DRUG DES DEV THER, V13, P3717, DOI 10.2147/DDDT.S225671
   Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908
   Zhang GF, 2010, MOL ENDOCRINOL, V24, P1737, DOI 10.1210/me.2010-0125
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang JA, 2016, ONCOTARGET, V7, P37420, DOI 10.18632/oncotarget.9357
   Zhang MY, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00926-1
   Zhang N, 2020, BMB REP, V53, P254, DOI 10.5483/BMBRep.2020.53.5.219
   Zhang W, 2019, EUR REV MED PHARMACO, V23, P2444, DOI 10.26355/eurrev_201903_17391
   Zhang YB, 2019, INT J MOL MED, V43, P1382, DOI 10.3892/ijmm.2019.4057
   Zhang YH, 2020, PHYTOTHER RES, V34, P349, DOI 10.1002/ptr.6525
   Zhang ZM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18755-3
NR 171
TC 4
Z9 4
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2021
VL 13
IS 13
AR 3287
DI 10.3390/cancers13133287
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TG3DJ
UT WOS:000671288400001
PM 34209162
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, JB
   Ren, XR
   Piao, HL
   Zhao, SL
   Osada, T
   Premont, RT
   Mook, RA
   Morse, MA
   Lyerly, HK
   Chen, W
AF Wang, Jiangbo
   Ren, Xiu-rong
   Piao, Hailan
   Zhao, Shengli
   Osada, Takuya
   Premont, Richard T.
   Mook, Robert A., Jr.
   Morse, Michael A.
   Lyerly, Herbert Kim
   Chen, Wei
TI Niclosamide-induced Wnt signaling inhibition in colorectal cancer is
   mediated by autophagy
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID POTENTIAL ROLE; COLON-CANCER; CELL-LINES; TARGET
AB The Wnt signaling pathway, known for regulating genes critical to normal embryonic development and tissue homeostasis, is dysregulated in many types of cancer. Previously, we identified that the anthelmintic drug niclosamide inhibited Wnt signaling by promoting internalization of Wnt receptor Frizzled 1 and degradation of Wnt signaling pathway proteins, Dishevelled 2 and beta-catenin, contributing to suppression of colorectal cancer growth in vitro and in vivo. Here, we provide evidence that niclosamide-mediated inhibition of Wnt signaling is mediated through autophagosomes induced by niclosamide. Specifically, niclosamide promotes the co-localization of Frizzled 1 or beta-catenin with LC3, an autophagosome marker. Niclosamide inhibition of Wnt signaling is attenuated in autophagosome-deficient ATG5(-/-) MEF cells or cells expressing shRNA targeting Beclin1, a critical constituent of autophagosome. Treatment with the autophagosome inhibitor 3MA blocks niclosamide-mediated Frizzled 1 degradation. The sensitivity of colorectal cancer cells to growth inhibition by niclosamide is correlated with autophagosome formation induced by niclosamide. Niclosamide inhibits mTORC1 and ULK1 activities and induces LC3B expression in niclosamide-sensitive cell lines, but not in the niclosamide-resistant cell lines tested. Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling. Our findings provide a mechanistic understanding of the role of autophagosomes in the inhibition of Wnt signaling by niclosamide and may provide biomarkers to assist selection of patients whose tumors are likely to respond to niclosamide.
C1 [Wang, Jiangbo; Ren, Xiu-rong; Piao, Hailan; Zhao, Shengli; Premont, Richard T.; Mook, Robert A., Jr.; Chen, Wei] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Osada, Takuya; Morse, Michael A.; Lyerly, Herbert Kim] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
RP Wang, JB; Chen, W (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
EM jiangbo.wang@duke.edu; w.chen@duke.edu
RI Lyerly, Herbert Kim/AAX-4925-2020
OI Lyerly, Herbert Kim/0000-0002-0063-4770; Chen, Wei/0000-0002-9934-4000
FU Clinical Oncology Research Center Development Grant [5K12-CA100639-08]; 
   [5 R01 CA172570]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA172570] Funding Source: NIH
   RePORTER
FX This work was funded, in part, by 5 R01 CA172570 (W.C.) and Clinical
   Oncology Research Center Development Grant 5K12-CA100639-08 (R.A.M.).
CR Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y
   Bhattacharyya J, 2017, NANOSCALE, V9, P12709, DOI 10.1039/c7nr01973d
   Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677
   Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001
   Chen W, 2010, AM J PHYSIOL-GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010
   Dong Y, 2010, J CARDIOVASC PHARM T, V15, P220, DOI 10.1177/1074248410370327
   Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mook RA, 2017, BIOORGAN MED CHEM, V25, P1804, DOI 10.1016/j.bmc.2017.01.046
   Mook RA, 2015, BIOORGAN MED CHEM, V23, P5829, DOI 10.1016/j.bmc.2015.07.001
   Mook RA, 2013, BIOORG MED CHEM LETT, V23, P2187, DOI 10.1016/j.bmcl.2013.01.101
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Noda T, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030052
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978
   Ren XR, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0528-9
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Wang JB, 2018, BIOORGAN MED CHEM, V26, P5435, DOI 10.1016/j.bmc.2018.09.016
   World Health Organization, 2007, SEL US ESS MED
NR 27
TC 22
Z9 22
U1 1
U2 8
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD FEB 14
PY 2019
VL 476
BP 535
EP 546
DI 10.1042/BCJ20180385
PN 3
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HQ4OX
UT WOS:000462392000007
PM 30635359
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Yang, YS
   Wen, D
   Zhao, XF
AF Yang, Yu-Shen
   Wen, Dan
   Zhao, Xue-Feng
TI Preventive and therapeutic effect of intraportal oridonin on BALb/c nude
   mice hemispleen model of colon cancer liver metastasis
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE BALb/c nude mice; colon cancer liver metastasis; hemispleen model;
   intraportal oridonin; prevention and treatment
ID ANTITUMOR-ACTIVITY; LUNG-CANCER; ANTICANCER; EXPRESSION; CISPLATIN;
   APOPTOSIS; AUTOPHAGY; PROTEIN; GROWTH
AB Background: This study is to investigate the preventive and therapeutic effect of intraportal oridonin on colorectal cancer liver metastasis (CRCLM).
   Methods: The inhibitory effect of oridonin on HT29 cells was determined by CCK-8 and MTT assays. The preventive and therapeutic effect of intraportal oridonin on CRCLM were investigated by establishing BALb/c nude mice hemispleen models of colon cancer liver metastasis. The microscopic characteristics of tumor tissues were observed by hematoxylin-eosin staining, immunohistochemistry and TUNEL staining. On the other hand, liver function enzymes, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), were detected to evaluate the hepatotoxicity of intraportal oridonin. The serum levels of tumor markers, including carcinoembryonic antigen (CEA) and a-fetoprotein (AFP), were used to investigate the intervention effect of intraportal oridonin on CRCLM.
   Results: Oridonin exerted an inhibitory effect on the proliferation of HT29 cells in vitro. Intraportal oridonin was found to effectively prevent the occurrence and formation of CRCLM, whilst intraportal oridonin can also exert a therapeutic effect on CRCLM. Additionally, liver enzymes testing indicated that intraportal oridonin possesses non-hepatotoxicity, instead can effectively alleviate liver injury caused by tumor. Furthermore, intraportal oridonin was also revealed to decrease the serum levels of AFP and CEA.
   Conclusions: Intraportal oridonin can effectively inhibit the formation of liver metastatic tumor and exert a certain degree of preventive and therapeutic effect on CRCLM. These findings indicate intraportal oridonin to be a promising anti-metastasis agent for CRCLM.
C1 [Yang, Yu-Shen; Wen, Dan; Zhao, Xue-Feng] Dalian Univ, Affiliated Xinhua Hosp, Dept Gen Surg, 156 Wansui St, Dalian 116021, Liaoning, Peoples R China.
RP Zhao, XF (corresponding author), Dalian Univ, Affiliated Xinhua Hosp, Dept Gen Surg, 156 Wansui St, Dalian 116021, Liaoning, Peoples R China.
EM zoserbong@163.com
FU Liaoning Provincial Natural Science Foundations of China [201602037]
FX This study was supported by Liaoning Provincial Natural Science
   Foundations of China (grant nos. 201602037).
CR Abdalla EK, 2009, AM J SURG, V197, P737, DOI 10.1016/j.amjsurg.2008.06.029
   ARCHER SG, 1989, BRIT J SURG, V76, P545, DOI 10.1002/bjs.1800760607
   Chua TC, 2011, J SURG ONCOL, V103, P796, DOI 10.1002/jso.21864
   Church D, 2012, DIGEST DIS, V30, P27, DOI 10.1159/000341890
   de Cuba EMV, 2012, VIRCHOWS ARCH, V461, P231, DOI 10.1007/s00428-012-1287-y
   Dong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113830
   Eftekhar E, 2014, MOL BIOL REP, V41, P459, DOI 10.1007/s11033-013-2880-0
   El-Sayyad HI, 2009, INT J BIOL SCI, V5, P466
   FARBER S, 1956, ADV CANCER RES, V4, P1, DOI 10.1016/S0065-230X(08)60721-6
   FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301
   Feng N, 2008, J DRUG TARGET, V16, P479, DOI 10.1080/10611860802200938 
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Hansen JE, 2007, CANCER RES, V67, P1769, DOI 10.1158/0008-5472.CAN-06-3783
   He ZW, 2017, ONCOL LETT, V14, P2499, DOI 10.3892/ol.2017.6421
   Hu Y, 2013, ASIAN PAC J CANCER P, V14, P3877, DOI 10.7314/APJCP.2013.14.6.3877
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107
   Kanas Gena P, 2012, Clin Epidemiol, V4, P283, DOI 10.2147/CLEP.S34285
   Kasuya H, 2005, CANCER RES, V65, P3823, DOI 10.1158/0008-5472.CAN-04-2631
   Kwan HY, 2013, J GASTROENTEROL, V48, P182, DOI 10.1007/s00535-012-0612-1
   Lee JH, 2019, MOL BIOL REP, V46, P3835, DOI 10.1007/s11033-019-04826-3
   Li Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0365-1
   Liu RX, 2018, INT J ONCOL, V53, P2091, DOI 10.3892/ijo.2018.4527
   Liu W, 2019, EJSO-EUR J SURG ONC, V45, P1349, DOI 10.1016/j.ejso.2019.04.017
   Mayo Skye C, 2009, Expert Rev Gastroenterol Hepatol, V3, P131, DOI 10.1586/egh.09.8
   Owona BA, 2015, DRUGS R&D, V15, P233, DOI 10.1007/s40268-015-0102-z
   RAMIREZ LH, 1993, BRIT J CANCER, V68, P277, DOI 10.1038/bjc.1993.328
   Shen XF, 2019, J BIOL CHEM, V294, P17471, DOI 10.1074/jbc.RA119.009801
   Soares KC, 2014, JOVE-J VIS EXP, DOI 10.3791/51677
   SUN HD, 1995, PHYTOCHEMISTRY, V38, P1451, DOI 10.1016/0031-9422(94)00815-B
   Tan W, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-27
   ul Ain N, 2019, PAK J PHARM SCI, V32, P1927
   Wang YY, 2014, ANTI-CANCER DRUG, V25, P1192, DOI 10.1097/CAD.0000000000000154
   WikiVet, 2012, MOUS BIOCH
   Xu B, 2015, ACTA BIOCH BIOPH SIN, V47, P164, DOI 10.1093/abbs/gmu134
   Xu JM, 2018, MOLECULES, V23, DOI 10.3390/molecules23020474
   Yang YC, 2015, FOOD BIOPROD PROCESS, V94, P101, DOI 10.1016/j.fbp.2015.02.001
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250
   Zhu LF, 2017, ACS OMEGA, V2, P2273, DOI 10.1021/acsomega.7b00456
NR 40
TC 0
Z9 0
U1 9
U2 15
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD MAR
PY 2021
VL 10
IS 3
BP 1324
EP +
DI 10.21037/tcr-20-3042
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RF7LI
UT WOS:000635021300013
PM 35116458
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Dai, LZ
   Chen, XL
   Lu, XH
   Wang, F
   Zhan, YY
   Song, G
   Hu, TH
   Xia, C
   Zhang, B
AF Dai, Lianzhi
   Chen, Xiaolei
   Lu, Xiaohong
   Wang, Fen
   Zhan, Yanyan
   Song, Gang
   Hu, Tianhui
   Xia, Chun
   Zhang, Bing
TI Phosphoinositide-specific phospholipase C gamma 1 inhibition induces
   autophagy in human colon cancer and hepatocellular carcinoma cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; GASTRIC-CANCER;
   LUNG-CANCER; AMPK; PATHWAY; METASTASIS; TARGET; HOMEOSTASIS; MECHANISM
AB Phosphoinositide-specific phospholipase C (PLC)gamma 1 has been reported to be involved in cancer cell proliferation and metastasis. However, whether PLC gamma 1 modulates autophagy and the underlying mechanism remains unclear. Here, we investigated the relationship between PLC gamma 1 and autophagy in the human colon cancer cell line HCT116 and hepatocellular carcinoma cell line HepG2. The results indicated that PLC gamma 1 inhibition via lentivirus-mediated transduction with shRNA/PLC gamma 1 or transient transfection with pRK5-PLC gamma 1 (Y783A) vector increased LC3B-II levels and the number of autophagic vacuoles and decreased p62 levels. Addition of an autophagy inhibitor led to LC3B and p62 accumulation. Furthermore, AMPK activation promoted the autophagy induced by PLC gamma 1 inhibition by blocking the FAK/PLC gamma 1 axis. In addition, PLC gamma 1 inhibition either blocked the mTOR/ULK1 axis or enhanced dissociation of the Beclin1-IP3R-Bcl-2 complex to induce autophagy. Taken together, our findings revealed that PLC gamma 1 inhibition induced autophagy and the FAK/PLC gamma 1 axis is a potential downstream effector of the AMPK activation-dependent autophagy signalling cascade. Both blockade of the mTOR/ULK1 axis and dissociation of the Beclin1-IP3R-Bcl-2 complex contributed to the induction of autophagy by PLC gamma 1 inhibition. Consequently, these findings provide novel insight into autophagy regulation by PLC gamma 1 in colon cancer and hepatocellular carcinoma cells.
C1 [Dai, Lianzhi; Lu, Xiaohong; Wang, Fen; Zhan, Yanyan; Song, Gang; Hu, Tianhui; Zhang, Bing] Xiamen Univ, Med Sch, Xiamen 361102, Fujian, Peoples R China.
   [Chen, Xiaolei; Xia, Chun] Xiamen Univ, Zhongshan Hosp, Xiamen 361004, Fujian, Peoples R China.
RP Zhang, B (corresponding author), Xiamen Univ, Med Sch, Xiamen 361102, Fujian, Peoples R China.; Xia, C (corresponding author), Xiamen Univ, Zhongshan Hosp, Xiamen 361004, Fujian, Peoples R China.
EM chunxia@xmu.edu.cn; cristal66@xmu.edu.cn
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81572189, 81572589, 81470793, 81472568]; Natural
   Science Foundation of Xiamen, China [3502Z20159014]
FX This study was supported by the National Science Foundation of China
   (No. 81572189, 81572589, 81470793, 81472568) and the Natural Science
   Foundation of Xiamen, China (No. 3502Z20159014).
CR Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Cho HJ, 2011, BIOCHEM BIOPH RES CO, V414, P575, DOI 10.1016/j.bbrc.2011.09.121
   Conn CS, 2011, CELL CYCLE, V10, P1940, DOI 10.4161/cc.10.12.15858
   Dai LZ, 2015, INT J MOL SCI, V16, P28510, DOI 10.3390/ijms161226116
   DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6
   Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v
   Gorentla BK, 2011, BLOOD, V117, P4022, DOI 10.1182/blood-2010-08-300731
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Hwang SL, 2013, J ALLERGY CLIN IMMUN, V132, P729, DOI 10.1016/j.jaci.2013.02.018
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Khan MT, 2010, J BIOL CHEM, V285, P16912, DOI 10.1074/jbc.M110.114207
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Klimaszewska-Wisniewska A, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0288-3
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kumar SH, 2009, J VIROL, V83, P8565, DOI 10.1128/JVI.00603-09
   Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007
   Lattanzio Rossano, 2013, Advances in Biological Regulation, V53, P309, DOI 10.1016/j.jbior.2013.07.006
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Niklaus M., 2017, ONCOTARGET
   Owen KA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004159
   Paglin S, 2001, CANCER RES, V61, P439
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17
   Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102
   Rocco A, 2012, LAB INVEST, V92, P1407, DOI 10.1038/labinvest.2012.100
   Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207
   Sandilands E, 2015, CELL SIGNAL, V27, P1816, DOI 10.1016/j.cellsig.2015.05.017
   Sanduja S, 2016, ONCOGENE, V35, P5295, DOI 10.1038/onc.2016.70
   Shahnazari S, 2010, CELL HOST MICROBE, V8, P137, DOI 10.1016/j.chom.2010.07.002
   Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005
   Tomas Nicola M, 2012, BMC Res Notes, V5, P214, DOI 10.1186/1756-0500-5-214
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Zhan YY, 2012, NAT CHEM BIOL, V8, P897, DOI [10.1038/NCHEMBIO.1069, 10.1038/nchembio.1069]
   Zhang BC, 2016, ONCOTARGET, V7, P8043, DOI 10.18632/oncotarget.6976
   Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021
   Zhuang LH, 2014, FOLIA HISTOCHEM CYTO, V52, P178, DOI 10.5603/FHC.2014.0021
NR 50
TC 14
Z9 15
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 24
PY 2017
VL 7
AR 13912
DI 10.1038/s41598-017-13334-y
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FK6FD
UT WOS:000413597800029
PM 29066806
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zheng, YC
   Zhu, GG
AF Zheng, Yingcheng
   Zhu, Guoguo
TI HMGB1 suppresses colon carcinoma cell apoptosis triggered by co-culture
   with dendritic cells via an ER stress-associated autophagy pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE HMGB1; dendritic cell; ER stress; autophagy; JNK
ID ENDOPLASMIC-RETICULUM STRESS; REGULATES AUTOPHAGY; IMMUNE-RESPONSES;
   CANCER; PROTEIN; INFLAMMATION; DISEASE; ESCAPE; TIM-3
AB High mobility group box protein 1 (HMGB1) is a versatile molecule that affects the immune system in various ways; however, its role in cancer immunity has not yet been completely elucidated. In the current study, bone marrow-derived dendritic cells from BALB/c mice and undifferentiated murine colon carcinoma CT26.WT cells were used as a cellular model to study the primary role of HMGB1 in colon cancer immunity. Annexin V and acridine orange/ethidium bromide staining was used to assess cellular apoptosis, Cell Counting kit 8 and lactate dehydrogenase assays were performed to evaluate cell viability and a monodansylcadaverine assay was used to detect autophagy. Western blot analysis was performed to detect the expression levels of proteins of interest. Endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase phosphorylation were also investigated in CT26.WT cells exposed to dendritic cells. The present results demonstrated that the CT26.WT cells underwent apoptotic cell death following co-culturing with dendritic cells. However, pretreatment with HMGB1 resulted in a significant increase in viability of the CT26.WT cells exposed to dendritic cells. Furthermore, HMGB1 promoted ER stress-induced autophagy through the activation of JNK, which inhibited the apoptosis triggered by the dendritic cells, suggesting that HMGB1 has a role in immune evasion by colon cancer cells.
C1 [Zheng, Yingcheng] Wuhan Gen Hosp Guangzhou Command, Dept Infect Control, Wuhan 430070, Hubei, Peoples R China.
   [Zhu, Guoguo] Wuhan Gen Hosp Guangzhou Command, Dept Emergency & Crit Care Med, 627 Luoyu Rd, Wuhan 430070, Hubei, Peoples R China.
RP Zhu, GG (corresponding author), Wuhan Gen Hosp Guangzhou Command, Dept Emergency & Crit Care Med, 627 Luoyu Rd, Wuhan 430070, Hubei, Peoples R China.
EM guoguoicetea@hotmail.com
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592
   Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012
   Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376
   Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   James BR, 2014, CANCER IMMUNOL IMMUN, V63, P685, DOI 10.1007/s00262-014-1548-5
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651
   Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kusume A, 2009, PATHOBIOLOGY, V76, P155, DOI 10.1159/000218331
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li CY, 2006, J IMMUNOL, V177, P5163, DOI 10.4049/jimmunol.177.8.5163
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Martinotti S, 2015, IMMUNOTARGETS THER, V4, P101, DOI 10.2147/ITT.S58064
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Tang DL, 2012, NAT IMMUNOL, V13, P808, DOI 10.1038/ni.2396
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
NR 27
TC 5
Z9 7
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2018
VL 17
IS 2
BP 3123
EP 3132
DI 10.3892/mmr.2017.8202
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT5WP
UT WOS:000423224300133
PM 29257231
OA Bronze
DA 2022-04-25
ER

PT J
AU Sena, P
   Mancini, S
   Benincasa, M
   Mariani, F
   Palumbo, C
   Roncucci, L
AF Sena, Paola
   Mancini, Stefano
   Benincasa, Marta
   Mariani, Francesco
   Palumbo, Carla
   Roncucci, Luca
TI Metformin Induces Apoptosis and Alters Cellular Responses to Oxidative
   Stress in Ht29 Colon Cancer Cells: Preliminary Findings
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal cancer cells; metformin; apoptosis; oxidative stress
ID NF-KAPPA-B; COLORECTAL-CANCER; IN-VITRO; DIABETES-MELLITUS; DUAL ROLES;
   RISK; NRF2; AUTOPHAGY; GROWTH; VIVO
AB Accumulating evidence suggests that metformin, used as an antidiabetic drug, possesses anti-cancer properties. Metformin reduced the incidence and growth of experimental tumors in vivo. In a randomized clinical trial among nondiabetic patients, metformin treatment significantly decreased the number of aberrant crypt foci compared to the untreated group with a follow-up of 1 month. In our study, HT29 cells were treated with graded concentrations of metformin, 10 mM/25 mM/50 mM for 24/48 h. We performed immunofluorescence experiments by means of confocal microscopy and western blot analysis to evaluate a panel of factors involved in apoptotic/autophagic processes and oxidative stress response. Moreover, HT29 cells treated with metformin were analyzed by a flow cytometry assay to detect the cell apoptotic rate. The results demonstrate that metformin exerts growth inhibitory effects on cultured HT29 cells by increasing both apoptosis and autophagy; moreover, it affects the survival of cultured cells inhibiting the transcriptional activation of Nuclear factor E2-related factor 2 (NRF-2) and nuclear factor-kappa B (NF-B). The effects of metformin on HT29 cells were dose- and time-dependent. These results are very intriguing since metformin is emerging as a multi-faceted drug: It has a good safety profile and is associated with low cost and might be a promising candidate for the prevention or the treatment of colorectal cancer.
C1 [Sena, Paola; Benincasa, Marta; Palumbo, Carla] Univ Modena & Reggio Emilia, Sect Human Morphol, Dept Biomed Metab & Neurosci, Via Pozzo 71, I-41125 Modena, Italy.
   [Mancini, Stefano; Mariani, Francesco; Roncucci, Luca] Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, Via Pozzo 71, I-41125 Modena, Italy.
RP Roncucci, L (corresponding author), Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, Via Pozzo 71, I-41125 Modena, Italy.
EM paola.sena@unimore.it; mancini77@cloud.com; marta.benincasa@unimore.it;
   francesco.mariani@unimore.it; carla.palumbo@unimore.it;
   luca.roncucci@unimore.it
RI Sena, Paola/G-9394-2016; Palumbo, Carla/V-5905-2019; Roncucci,
   Luca/L-1392-2016; Mancini, Stefano/B-1190-2016
OI Sena, Paola/0000-0003-4724-8786; Palumbo, Carla/0000-0003-0587-0112;
   Roncucci, Luca/0000-0002-0410-1760; Mancini, Stefano/0000-0002-7350-5603
FU Associazione per la Ricerca sui Tumori Intestinali (ARTI); Fondazione
   Cassa di Risparmio di Vignola
FX The study was supported by funds of the Associazione per la Ricerca sui
   Tumori Intestinali (ARTI) and Fondazione Cassa di Risparmio di Vignola.
   The authors wish to thank the Centro Interdipartimentale Grandi
   Strumenti (C.I.G.S.) of the University of Modena and Reggio Emilia, for
   software, instrument availability, and assistance.
CR Akhdar H, 2009, EUR J CANCER, V45, P2219, DOI 10.1016/j.ejca.2009.05.017
   Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Anderson WF, 2003, CANCER METAST REV, V22, P67, DOI 10.1023/A:1022264002228
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bodmer M, 2008, DIABETES CARE, V31, P2086, DOI 10.2337/dc08-1171
   Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Das D, 2007, DIGESTION, V76, P51, DOI 10.1159/000108394
   Eray M, 2001, CYTOMETRY, V43, P134, DOI 10.1002/1097-0320(20010201)43:2<134::AID-CYTO1028>3.0.CO;2-L
   Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041
   Frezza EE, 2006, GUT, V55, P285, DOI 10.1136/gut.2005.073163
   GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221
   He L, 2015, CELL METAB, V21, P159, DOI 10.1016/j.cmet.2015.01.003
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906
   Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004
   Jurjus A, 2016, BBA CLIN, V5, P16, DOI 10.1016/j.bbacli.2015.11.002
   Kato K, 2012, MOL CANCER THER, V11, P549, DOI 10.1158/1535-7163.MCT-11-0594
   Larsson SC, 2005, DIABETES CARE, V28, P1805, DOI 10.2337/diacare.28.7.1805
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Limburg PJ, 2005, CANCER EPIDEM BIOMAR, V14, P133
   Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002
   Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042
   Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Oudejans JJ, 2005, CELL CYCLE, V4, P526, DOI 10.4161/cc.4.4.1595
   Psaty BM, 2005, NEW ENGL J MED, V352, P1133, DOI 10.1056/NEJMe058042
   Rachakonda G, 2010, ONCOGENE, V29, P3703, DOI 10.1038/onc.2010.118
   Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461
   Satoh H, 2010, CARCINOGENESIS, V31, P1833, DOI 10.1093/carcin/bgq105
   Sena P, 2015, ONCOL REP, V34, P3222, DOI 10.3892/or.2015.4326
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Song CW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00362
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   Viennois Emilie, 2013, Transl Gastrointest Cancer, V2, P21
   Wang LW, 2008, WORLD J GASTROENTERO, V14, P7192, DOI 10.3748/wjg.14.7192
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589
NR 50
TC 33
Z9 34
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2018
VL 19
IS 5
AR 1478
DI 10.3390/ijms19051478
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GJ4BO
UT WOS:000435297000214
PM 29772687
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Liu, Y
   Zhang, B
   Cao, WB
   Wang, HY
   Niu, L
   Zhang, GZ
AF Liu, Yang
   Zhang, Bo
   Cao, Wen-Bin
   Wang, Hai-Yan
   Niu, Lei
   Zhang, Guo-Zhi
TI Study on Clinical Significance of LncRNA EGOT Expression in Colon Cancer
   and Its Effect on Autophagy of Colon Cancer Cells
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE LncRNA EGOT; colon cancer; diagnosis; autophagy
ID PROGNOSIS; NCRNA
AB Background: Colon cancer (CC) is a common digestive tract tumor, and the increase of new and dead patients every year still puzzles clinical workers. LncRNA eosinophil granule ontogeny transcript (EGOT), as a newly discovered long-chain noncoding RNA (lncRNA), is differentially expressed in other tumors, but there are fewer studies of it in colon cancer.
   Methods: The relative expression and diagnostic value of EGOT in CC were detected and analyzed by starBase online website and qRT-PCR. The patients were followed-up for five years, and Cox regression was used to analyze the independent prognostic factors of CC. The effects of EGOT overexpression (pcDNA-RGOT) on CC cell function were detected by CCK-8, transwell and flow cytometry. WB was applied to detect autophagy. The influence of knocking out EGOT (sh-EGOT) on tumor growth was observed by tumor allogeneic inhibition. The microRNA (miR) and mRNA in the downstream of EGOT were predicted and the ceRNA network map was drawn.
   Results: The online database and qRT-PCR detection showed that EGOT was highly expression in patients with CC and had good diagnostic value. The five-year survival rate of patients with high expression of EGOT decreased. EGOT and TNM staging were independent prognostic factors of patients with CC. Functional analysis revealed that the growth and invasion abilities of cells increased, and the apoptosis rate decreased after overexpression. Upregulation of EGOT inhibited autophagy of CC cells and promoted cell growth. However, the tumor in nude mice was significantly lessened after knockout of EGOT. Bioinformatic analysis showed that microRNA-33a-5p and microRNA-33b-5p had targeted binding sites with EGOT.
   Conclusion: EGOT is highly expressed in CC and has high diagnostic value. In addition, inhibition of EGOT can promote autophagy of CC cells and inhibit cell growth and metastasis, which is expected to be a potential therapeutic index.
C1 [Liu, Yang; Zhang, Bo; Cao, Wen-Bin; Zhang, Guo-Zhi] North China Univ Sci & Technol, Dept Gen Surg, Affiliated Hosp, Tangshan City 063000, Hebei, Peoples R China.
   [Wang, Hai-Yan] Chinese Peoples Liberat Army, Dept Oncol, Hosp 982, Joint Logist Support Force, Tangshan City 063000, Hebei, Peoples R China.
   [Niu, Lei] Tangshan Hong Ci Hosp Co Ltd, Dept Resp Med, Tangshan City 063000, Hebei, Peoples R China.
RP Zhang, GZ (corresponding author), North China Univ Sci & Technol, Dept Gen Surg, Affiliated Hosp, Tangshan City 063000, Hebei, Peoples R China.
EM myfypwly@163.com
CR Arnold MW, 2018, SURG ONCOL CLIN N AM, V27, pXV, DOI 10.1016/j.soc.2017.11.012
   Attallah AM, 2018, BRIT J BIOMED SCI, V75, P122, DOI 10.1080/09674845.2018.1456309
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chao YJ, 2019, MED SCI MONITOR, V25, P6581, DOI 10.12659/MSM.915100
   Clark JAM, 2020, ANIM MODEL EXP MED, V3, P103, DOI 10.1002/ame2.12111
   Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031
   Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015
   Jin L, 2017, MOL MED REP, V16, P7072, DOI 10.3892/mmr.2017.7470
   Kawasaki Y, 2019, EMBO REP, V20, DOI 10.15252/embr.201847052
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liu CH, 2020, GENE, V729, DOI 10.1016/j.gene.2019.144317
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4
   Loos F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2011-5
   Ni Y, 2020, BIOSCI REP, DOI [10.1042/BSR2019389330, DOI 10.1042/BSR2019389330]
   Orangio GR, 2018, SURG ONCOL CLIN N AM, V27, P327, DOI 10.1016/j.soc.2017.11.007
   Peng W, 2019, PATHOL ONCOL RES, V25, P883, DOI 10.1007/s12253-017-0367-3
   Slaby O, 2016, ADV EXP MED BIOL, V937, P153, DOI 10.1007/978-3-319-42059-2_8
   Wang JZ, 2019, MOL THER, V27, P1718, DOI 10.1016/j.ymthe.2019.09.001
   Wang J, 2019, ONCOL LETT, V18, P1491, DOI 10.3892/ol.2019.10425
   Weinberg BA, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0756-8
   Wu Q, 2018, J CELL PHYSIOL, V233, P6750, DOI 10.1002/jcp.26383
   Wu SM, 2019, ONCOTARGETS THER, V12, P11623, DOI 10.2147/OTT.S218308
   Wu Y, 2017, EXP THER MED, V14, P3817, DOI 10.3892/etm.2017.4949
   Xu J, 2018, ADV EXP MED BIOL, V1094, P77, DOI 10.1007/978-981-13-0719-5_8
   Xu SP, 2015, TUMOR BIOL, V36, P9807, DOI 10.1007/s13277-015-3746-y
   Xu SP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1017-z
   Yang J, 2017, BIOSCI BIOTECH BIOCH, V81, P2301, DOI 10.1080/09168451.2017.1387048
   ZHANG XP, 2019, INT J MOL SCI, V0020
   Zhao Z, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2019.116900
   Zhou FR, 2019, ONCOTARGETS THER, V12, P5767, DOI 10.2147/OTT.S215419
   Zhou R, 2019, CANCER IMMUNOL IMMUN, V68, P433, DOI 10.1007/s00262-018-2289-7
NR 32
TC 2
Z9 2
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2020
VL 12
BP 13501
EP 13512
DI 10.2147/CMAR.S285254
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PN2BU
UT WOS:000604290800001
PM 33408522
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Costelli, P
   De Stefanis, D
   Reffo, P
   Autelli, R
   Bonelli, G
   Baccino, FM
AF Costelli, Paola
   De Stefanis, Daniela
   Reffo, Patrizia
   Autelli, Riccardo
   Bonelli, Gabriella
   Baccino, Francesco M.
TI Differential modulation of TNf alpha-induced cell death by
   3-methyladenine, an autophagy inhibitor
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE apoptosis; autophagy; 3-methyladenine; TNF alpha
ID TUMOR-NECROSIS-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS;
   ISOLATED RAT HEPATOCYTES; INDUCED APOPTOSIS; PROTEIN-DEGRADATION;
   FLOW-CYTOMETRY; CANCER-CELLS; SURVIVAL; ACTIVATION; MECHANISMS
AB Cell death by apoptosis is a fundamental mechanism for the maintenance of tissue homeostasis, activated to get rid of excess, damaged, or infected cells. It may be induced by several stimuli such as growth factor withdrawal, oxidative stress, drugs, or humoral mediators such as cytokines. The present study is focused on the cytotoxic activity of TNF alpha, a pleiotropic cytokine that promotes a variety of biological effects. TNF alpha cytotoxicity depends on the cell type and state. Although apoptosis (or type I cell death) has long been considered as the paradigm, various observations have stressed the possibility that TNF alpha-induced cell death may also develop with other features. Particularly interesting, in this regard, is the possibility that TNF alpha effects include stimulation of autophagy and/or induction of autophagic (type II) cell death.
   Aim of the present study has been to investigate if TNF alpha-induced death in cell types of different origin can be modulated by interference with the autophagic process. The work has been performed on U937 (lymphoid), HT-29 (colon carcinoma), L929 (fibrosarcoma) and HTC (hepatoma) cell lines. All of them undergo apoptosis or apoptosis-like death in response to TNF alpha alone (U937, L929), or combined with transcription or translation inhibitors (HT-29, HTC). However, when TNF alpha is coupled with 3-methyladenine, a well known inhibitor of the autophagic process, the various cell lines show different behaviors: HTC cells are partially protected from TNF alpha-induced death, whereas HT-29, L929 and U937 cells are sensitized, albeit to varying degrees, since the percentage of apoptotic cells is higher than in cultures exposed to the cytokine alone.
   These results show that 3-methyladenine can modulate TNF alpha-induced death both positively and negatively, depending on the cell type. Moreover, they are consistent with the view that modulation of autophagy can be relevant to the design of therapeutic strategies aimed to reduce excess apoptosis, such as that occurring in acute hepatitis, or to enhance cell death in pathologies characterized by defective apoptosis, such as cancer.
C1 Univ Turin, Dipartimento Med & Oncol Sperimentale, I-10125 Turin, Italy.
RP Costelli, P (corresponding author), Univ Turin, Dipartimento Med & Oncol Sperimentale, Corso Raffaello 30, I-10125 Turin, Italy.
EM paola.costelli@unito.it
OI Bonelli, Gabriella/0000-0002-5164-8902
CR Anthony RS, 1998, BONE MARROW TRANSPL, V21, P441, DOI 10.1038/sj.bmt.1701134
   Autelli R, 2005, APOPTOSIS, V10, P777, DOI 10.1007/s10495-005-2944-2
   BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Bonelli G, 1996, EXP CELL RES, V228, P292, DOI 10.1006/excr.1996.0329
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bursch W, 2004, FEMS YEAST RES, V5, P101, DOI 10.1016/j.femsyr.2004.07.006
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   CHAZAUD B, 1994, EUR J CELL BIOL, V64, P15
   Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538
   Choi EK, 2006, INT IMMUNOPHARMACOL, V6, P908, DOI 10.1016/j.intimp.2006.01.007
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Dosenko V. E., 2005, Ukrainskii Biokhimicheskii Zhurnal, V77, P52
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888
   FADY C, 1995, J INTERF CYTOK RES, V15, P71, DOI 10.1089/jir.1995.15.71
   Fiers W, 1996, J INFLAMM, V47, P67
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   LASTER SM, 1988, J IMMUNOL, V141, P2629
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Martinet W, 2005, BIOTECHNOL LETT, V27, P1157, DOI 10.1007/s10529-005-0007-y
   Migheli A, 1997, NEUROGENETICS, V1, P81, DOI 10.1007/s100480050012
   Mortimore G E, 1996, Subcell Biochem, V27, P93
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826
   Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1
   Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yuan JY, 2006, MOL CELL, V23, P1, DOI 10.1016/j.molcel.2006.06.008
   Zakeri Z, 1996, MICROSC RES TECHNIQ, V34, P192
NR 48
TC 1
Z9 1
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PD NOV
PY 2006
VL 3
IS 9
BP 662
EP 667
DI 10.2174/157018006778341156
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 092SZ
UT WOS:000241118900010
DA 2022-04-25
ER

PT J
AU Cheng, TC
   Lai, CS
   Chung, MC
   Kalyanam, N
   Majeed, M
   Ho, CT
   Ho, YS
   Pan, MH
AF Cheng, Tzu-Chun
   Lai, Ching-Shu
   Chung, Min-Ching
   Kalyanam, Nagabhushanam
   Majeed, Muhammed
   Ho, Chi-Tang
   Ho, Yuan-Soon
   Pan, Min-Hsiung
TI Potent Anti-Cancer Effect of 3 '-Hydroxypterostilbene in Human Colon
   Xenograft Tumors
SO PLOS ONE
LA English
DT Article
ID CELL-CYCLE ARREST; CARCINOMA CELLS; PTEROSTILBENE; CANCER; APOPTOSIS;
   AUTOPHAGY; PATHWAYS; AGENTS; CHEMOPREVENTION; INDUCTION
AB Here we report that 3'-hydroxypterostilbene (HPSB), a natural pterostilbene analogue, was more potent than pterostilbene against the growth of human cancer cells (COLO 205, HCT-116, and HT-29) with measured IC50 values of 9.0, 40.2, and 70.9 mu M, respectively. We found that HPSB effectively inhibited the growth of human colon cancer cells by inducing apoptosis and autophagy. Autophagy occurred at an early stage and was observed through the formation of acidic vesicular organelles and microtubule-associated protein 1 light chain 3-II production. At the molecular levels, the results from western blot analysis showed that HPSB significantly down-regulated phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinases (MAPKs) signalings including decreased the phosphorylation of mammalian target of rapamycin (mTOR). Significant therapeutic effects were demonstrated in vivo by treating nude mice bearing COLO 205 tumor xenografts with HPSB (10 mg/kg i.p.). These inhibitory effects were accompanied by mechanistic down-regulation of the protein levels of cyclooxygenase-2 (COX-2), matrix metallopeptidase-9 (MMP-9), vascular endothelial growth factor (VEGF), and cyclin D1, as well as by the induction of apoptosis in colon tumors. Our findings suggest that HPSB could serve as a novel promising agent for colon cancer treatment.
C1 [Cheng, Tzu-Chun; Ho, Yuan-Soon] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
   [Lai, Ching-Shu; Chung, Min-Ching; Pan, Min-Hsiung] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10764, Taiwan.
   [Kalyanam, Nagabhushanam; Majeed, Muhammed] Sabinsa Corp, East Windsor, NJ USA.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08903 USA.
   [Ho, Yuan-Soon] Taipei Med Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ, Ctr Comprehens Canc, Taipei, Taiwan.
   [Pan, Min-Hsiung] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
RP Ho, YS (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
EM hoyuansn@tmu.edu.tw; mhpan@ntu.edu.tw
RI Pan, Min-Hsiung/AAT-8865-2021
OI Pan, Min-Hsiung/0000-0002-5188-7030
FU National Science CouncilMinistry of Science and Technology, Taiwan [NSC
   101-2628-B-022-001-MY4, 102-2628-B-002-053-MY3, NTU-103R7777]; Health
   and welfare surcharge of tobacco products [MOHW103-TD-B-111-01]
FX This study was supported by the National Science Council NSC
   101-2628-B-022-001-MY4, 102-2628-B-002-053-MY3, and NTU-103R7777 (for
   Dr. Pan) and by the Health and welfare surcharge of tobacco products
   MOHW103-TD-B-111-01 (for Dr. Ho). Sabinsa Corporation provided support
   in the form of salaries for authors NK & MM, but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The specific
   roles of these authors are articulated in the 'author contributions'
   section.
CR Berchtold MW, 2014, BBA-MOL CELL RES, V1843, P398, DOI 10.1016/j.bbamcr.2013.10.021
   Blommaart EF, 1997, HISTOCHEM J, V290, P1717
   Chen RJ, 2012, J AGR FOOD CHEM, V60, P11533, DOI 10.1021/jf302778a
   Chen WC, 2014, FOOD FUNCT, V5, P1856, DOI [10.1039/c4fo00145a, 10.1039/C4FO00145A]
   Chiu HW, 2009, AUTOPHAGY, V5, P472, DOI 10.4161/auto.5.4.7759
   Dunn WJ, 1991, J CELL BIOL, V110, P1923
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Ferrer P, 2005, NEOPLASIA, V7, P37, DOI 10.1593/neo.04337
   Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073
   Hu Y, 2014, MICROBES INFECT
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kapoor S, 2013, AM J SURG, V205, P483, DOI 10.1016/j.amjsurg.2012.10.031
   Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S
   KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85
   Ma ZJ, 2002, FITOTERAPIA, V73, P313, DOI 10.1016/S0367-326X(02)00074-6
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Pan MH, 2008, J AGR FOOD CHEM, V56, P7502, DOI 10.1021/jf800820y
   Pan MH, 2008, MOL NUTR FOOD RES, V52, P43, DOI 10.1002/mnfr.200700380
   Pan MH, 2007, J AGR FOOD CHEM, V55, P7777, DOI 10.1021/jf071520h
   Pan MH, 2009, CARCINOGENESIS, V30, P1234, DOI 10.1093/carcin/bgp121
   Rimando AM, 2002, J AGR FOOD CHEM, V50, P3453, DOI 10.1021/jf0116855
   Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525
   Tolomeo M, 2005, INT J BIOCHEM CELL B, V37, P1709, DOI 10.1016/j.biocel.2005.03.004
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
NR 26
TC 29
Z9 29
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 12
PY 2014
VL 9
IS 11
AR e111814
DI 10.1371/journal.pone.0111814
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA8CP
UT WOS:000349144400035
PM 25389774
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Vessoni, AT
   Filippi-Chiela, EC
   Menck, CFM
   Lenz, G
AF Vessoni, A. T.
   Filippi-Chiela, E. C.
   Menck, C. F. M.
   Lenz, G.
TI Autophagy and genomic integrity
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Review
DE autophagy; DNA repair; genomic integrity; oxidative stress
ID DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; BASE-EXCISION-REPAIR;
   REGULATES AUTOPHAGY; COLON-CANCER; PIECEMEAL MICROAUTOPHAGY;
   HISTONE-DEACETYLASES; SIGNALING PATHWAY; INDUCED APOPTOSIS; OXIDATIVE
   STRESS
AB DNA lesions, constantly produced by endogenous and exogenous sources, activate the DNA damage response (DDR), which involves detection, signaling and repair of the damage. Autophagy, a lysosome-dependent degradation pathway that is activated by stressful situations such as starvation and oxidative stress, regulates cell fate after DNA damage and also has a pivotal role in the maintenance of nuclear and mitochondrial genomic integrity. Here, we review important evidence regarding the role played by autophagy in preventing genomic instability and tumorigenesis, as well as in micronuclei degradation. Several pathways governing autophagy activation after DNA injury and the influence of autophagy upon the processing of genomic lesions are also discussed herein. In this line, the mechanisms by which several proteins participate in both DDR and autophagy, and the importance of this crosstalk in cancer and neurodegeneration will be presented in an integrated fashion. At last, we present a hypothetical model of the role played by autophagy in dictating cell fate after genotoxic stress.
C1 [Vessoni, A. T.; Menck, C. F. M.] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, BR-05508900 Sao Paulo, Brazil.
   [Filippi-Chiela, E. C.; Lenz, G.] Univ Fed Rio Grande do Sul, Dept Biophys, Porto Alegre, RS, Brazil.
   [Filippi-Chiela, E. C.; Lenz, G.] Univ Fed Rio Grande do Sul, Ctr Biotechnol, Porto Alegre, RS, Brazil.
RP Vessoni, AT (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
EM alexandre.vessoni@usp.br; eduardochiela@gmail.com
RI Lenz, Guido/A-7618-2008; Menck, Carlos FM/G-6321-2011; Filippi-Chiela,
   Eduardo/F-1959-2014; Vessoni, Alexandre T/L-5754-2013
OI Menck, Carlos FM/0000-0003-1941-0694; Filippi-Chiela,
   Eduardo/0000-0001-8192-3779; Vessoni, Alexandre T/0000-0001-9170-5185
CR Aamann MD, 2010, FASEB J, V24, P2334, DOI 10.1096/fj.09-147991
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098
   Bao YH, 2007, CURR OPIN GENET DEV, V17, P126, DOI 10.1016/j.gde.2007.02.010
   Batista LFZ, 2009, MOL CANCER RES, V7, P237, DOI 10.1158/1541-7786.MCR-08-0428
   Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196
   Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Cadet J, 2012, CANCER LETT, V327, P5, DOI 10.1016/j.canlet.2012.04.005
   Casorelli I, 2012, INT J ENV RES PUB HE, V9, P2636, DOI 10.3390/ijerph9082636
   Chen LH, 2011, BIOCHEM PHARMACOL, V81, P594, DOI 10.1016/j.bcp.2010.12.011
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   D'Angiolella V, 2007, CELL CYCLE, V6, P576, DOI 10.4161/cc.6.5.3934
   de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768
   Dotiwala F, 2013, P NATL ACAD SCI USA, V110, pE41, DOI 10.1073/pnas.1218065109
   Dyavaiah M, 2011, MOL CANCER RES, V9, P462, DOI 10.1158/1541-7786.MCR-10-0473
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Eccles LJ, 2011, MUTAT RES-FUND MOL M, V711, P134, DOI 10.1016/j.mrfmmm.2010.11.003
   Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629
   Ferraro E, 2008, MOL BIOL CELL, V19, P3576, DOI 10.1091/mbc.E07-09-0858
   Filipcik P, 2006, Bratisl Lek Listy, V107, P384
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Garcia-Prat L, 2013, FEBS J, V280, P4051, DOI 10.1111/febs.12221
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Greinert R, 2012, NUCLEIC ACIDS RES, V40, P10263, DOI 10.1093/nar/gks824
   Guo R, 2001, J BIOL CHEM, V285, P19308
   Guo RF, 2010, J BIOL CHEM, V285, P19308, DOI 10.1074/jbc.M110.121939
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Hughson LR, 2012, INT J CELL BIOL, V2012
   Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3
   Javle M, 2011, BRIT J CANCER, V105, P1114, DOI 10.1038/bjc.2011.382
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kao SY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-67
   Kao SY, 2009, BIOCHEM BIOPH RES CO, V382, P321, DOI 10.1016/j.bbrc.2009.03.048
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Khandelwal PJ, 2011, HUM MOL GENET, V20, P2091, DOI 10.1093/hmg/ddr091
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kraft C, 2009, BBA-MOL CELL RES, V1793, P1404, DOI 10.1016/j.bbamcr.2009.02.006
   Krick R, 2008, MOL BIOL CELL, V19, P4492, DOI 10.1091/mbc.E08-04-0363
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kruszewski M, 2005, DNA REPAIR, V4, P1306, DOI 10.1016/j.dnarep.2005.06.013
   Kumar D, 2011, NUCLEIC ACIDS RES, V39, P1360, DOI 10.1093/nar/gkq829
   Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332
   Kvam E, 2005, MOL BIOL CELL, V16, P3987, DOI 10.1091/mbc.E05-04-0290
   Lee Y, 2011, AM J PHYSIOL-HEART C, V301, pH1924, DOI 10.1152/ajpheart.00368.2011
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   Lenaz G, 2012, ADV EXP MED BIOL, V942, P93, DOI 10.1007/978-94-007-2869-1_5
   Lenz Guido, 2012, Front Biosci (Schol Ed), V4, P1017
   Leung M, 2011, MOL MED, V17, P854, DOI 10.2119/molmed.2010.00240
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Ljungman M, 2005, MUTAT RES-FUND MOL M, V577, P203, DOI 10.1016/j.mrfmmm.2005.02.014
   Ljungman M, 2010, ENVIRON MOL MUTAGEN, V51, P879, DOI 10.1002/em.20597
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Majumder S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025416
   Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70
   Marabese M, 2003, NUCLEIC ACIDS RES, V31, P6624, DOI 10.1093/nar/gkg869
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McGee MD, 2011, AGING CELL, V10, P699, DOI 10.1111/j.1474-9726.2011.00713.x
   Millen JI, 2009, AUTOPHAGY, V5, P75, DOI 10.4161/auto.5.1.7181
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moore DM, 2009, NUCLEIC ACIDS RES, V37, P6429, DOI 10.1093/nar/gkp709
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Mortensen M, 2011, AUTOPHAGY, V7, P1069, DOI 10.4161/auto.7.9.15886
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Nakabeppu Y, 2007, J NEUROSCI RES, V85, P919, DOI 10.1002/jnr.21191
   Nascimento-Ferreira I, 2011, BRAIN, V134, P1400, DOI 10.1093/brain/awr047
   Negri T, 2010, GENE CHROMOSOME CANC, V49, P901, DOI 10.1002/gcc.20798
   Nezis IP, 2010, J CELL BIOL, V190, P523, DOI 10.1083/jcb.201002035
   Ni Chonghaile T, 2011, MOL CELL, V44, P844, DOI 10.1016/j.molcel.2011.12.007
   Park YE, 2009, AUTOPHAGY, V5, P795, DOI 10.4161/auto.8901
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Prigione A, 2007, AGING CELL, V6, P619, DOI 10.1111/j.1474-9726.2007.00323.x
   Prigione A, 2007, AUTOPHAGY, V3, P377, DOI 10.4161/auto.4239
   Qiang L, 2013, J BIOL CHEM, V288, P1603, DOI 10.1074/jbc.M112.415224
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rello-Varona S, 2012, CELL CYCLE, V11, P170, DOI 10.4161/cc.11.1.18564
   Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Scheibye-Knudsen M, 2012, J EXP MED, V209, P855, DOI 10.1084/jem.20111721
   SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X
   Shanware NP, 2013, ANNU REV PHARMACOL, V53, P89, DOI 10.1146/annurev-pharmtox-010611-134717
   Shin SY, 2011, TOXICOL APPL PHARM, V254, P288, DOI 10.1016/j.taap.2011.05.003
   Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650
   Siggens L, 2012, FASEB J, V26, P2117, DOI 10.1096/fj.11-197525
   Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034
   Stevnsner T, 2002, ONCOGENE, V21, P8675, DOI 10.1038/sj.onc.1205994
   Stevnsner T, 2008, MECH AGEING DEV, V129, P441, DOI 10.1016/j.mad.2008.04.009
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Taylor R, CURR PHARM DES, V17, P2056
   TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J
   Tichy Ales, 2010, Acta Medica (Hradec Kralove), V53, P13
   True O, 2012, IMMUNOL CELL BIOL, V90, P78, DOI 10.1038/icb.2011.103
   van Loon B, 2010, DNA REPAIR, V9, P604, DOI 10.1016/j.dnarep.2010.03.004
   Vessoni AT, 2012, STEM CELLS DEV, V21, P513, DOI 10.1089/scd.2011.0526
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034
   Xie R, 2011, CANCER RES, V71, P7537, DOI 10.1158/0008-5472.CAN-11-2170
   Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zaika E, 2011, FASEB J, V25, P4406, DOI 10.1096/fj.11-192815
   Zeng X, CELL RES, V20, P665
   Zeng XH, 2008, CANCER RES, V68, P2384, DOI 10.1158/0008-5472.CAN-07-6163
   Zeng XH, 2007, CLIN CANCER RES, V13, P1315, DOI 10.1158/1078-0432.CCR-06-1517
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
NR 139
TC 109
Z9 113
U1 2
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD NOV
PY 2013
VL 20
IS 11
BP 1444
EP 1454
DI 10.1038/cdd.2013.103
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 233EL
UT WOS:000325548900005
PM 23933813
OA Green Published
DA 2022-04-25
ER

PT J
AU Deng, JY
   Tian, AL
   Pan, H
   Sauvat, A
   Leduc, M
   Liu, P
   Zhao, LW
   Zhang, S
   Chen, H
   Taly, V
   Laurent-Puig, P
   Senovilla, L
   Li, YQ
   Kroemer, G
   Kepp, O
AF Deng, Jiayin
   Tian, Ai-Ling
   Pan, Hui
   Sauvat, Allan
   Leduc, Marion
   Liu, Peng
   Zhao, Liwei
   Zhang, Shuai
   Chen, Hui
   Taly, Valerie
   Laurent-Puig, Pierre
   Senovilla, Laura
   Li, Yingqiu
   Kroemer, Guido
   Kepp, Oliver
TI Everolimus and plicamycin specifically target chemoresistant colorectal
   cancer cells of the CMS4 subtype
SO CELL DEATH & DISEASE
LA English
DT Article
ID CONSENSUS MOLECULAR SUBTYPES; PHASE-II; COLON-CANCER; IN-VITRO;
   BEVACIZUMAB; INHIBITOR; PROGNOSIS; APOPTOSIS; IMMUNE; TRIAL
AB Colorectal cancers (CRC) can be classified into four consensus molecular subtypes (CMS), among which CMS1 has the best prognosis, contrasting with CMS4 that has the worst outcome. CMS4 CRC is notoriously resistant against therapeutic interventions, as demonstrated by preclinical studies and retrospective clinical observations. Here, we report the finding that two clinically employed agents, everolimus (EVE) and plicamycin (PLI), efficiently target the prototypic CMS4 cell line MDST8. As compared to the prototypic CMS1 cell line LoVo, MDST8 cells treated with EVE or PLI demonstrated stronger cytostatic and cytotoxic effects, increased signs of apoptosis and autophagy, as well as a more pronounced inhibition of DNA-to-RNA transcription and RNA-to-protein translation. Moreover, nontoxic doses of EVE and PLI induced the shrinkage of MDST8 tumors in mice, yet had only minor tumor growth-reducing effects on LoVo tumors. Altogether, these results suggest that EVE and PLI should be evaluated for their clinical activity against CMS4 CRC.
C1 [Deng, Jiayin; Li, Yingqiu] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China.
   [Deng, Jiayin; Tian, Ai-Ling; Pan, Hui; Chen, Hui] Univ Paris Sud, Paris Saclay, Fac Med, Le Kremlin Bicetre, France.
   [Deng, Jiayin; Tian, Ai-Ling; Pan, Hui; Sauvat, Allan; Leduc, Marion; Liu, Peng; Zhao, Liwei; Zhang, Shuai; Chen, Hui; Senovilla, Laura; Kroemer, Guido; Kepp, Oliver] Univ Paris Saclay, Gustave Roussy Canc Ctr, Metab & Cell Biol Platforms, Villejuif, France.
   [Deng, Jiayin; Tian, Ai-Ling; Pan, Hui; Sauvat, Allan; Leduc, Marion; Liu, Peng; Zhao, Liwei; Zhang, Shuai; Chen, Hui; Taly, Valerie; Laurent-Puig, Pierre; Senovilla, Laura; Kroemer, Guido; Kepp, Oliver] Sorbonne Univ, Univ Paris, Inserm U1138, Ctr Rech Cordeliers,Equipe Labellisee Ligue Contr, Paris, France.
   [Deng, Jiayin; Tian, Ai-Ling; Pan, Hui; Sauvat, Allan; Leduc, Marion; Liu, Peng; Zhao, Liwei; Zhang, Shuai; Chen, Hui; Taly, Valerie; Laurent-Puig, Pierre; Senovilla, Laura; Kroemer, Guido; Kepp, Oliver] Inst Univ France, CNRS SNC 5096, Paris, France.
   [Laurent-Puig, Pierre; Senovilla, Laura] Univ Valladolid, CSIC, Unidad Excelencia Inst Biol & Genet Mol IBGM, Valladolid, Spain.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Inst Canc Paris Carpem, Pole Biol, Paris, France.
   [Kroemer, Guido] Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Jiangsu, Peoples R China.
   [Kroemer, Guido] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
RP Li, YQ (corresponding author), Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China.; Kroemer, G; Kepp, O (corresponding author), Univ Paris Saclay, Gustave Roussy Canc Ctr, Metab & Cell Biol Platforms, Villejuif, France.; Kroemer, G; Kepp, O (corresponding author), Sorbonne Univ, Univ Paris, Inserm U1138, Ctr Rech Cordeliers,Equipe Labellisee Ligue Contr, Paris, France.; Kroemer, G; Kepp, O (corresponding author), Inst Univ France, CNRS SNC 5096, Paris, France.; Kroemer, G (corresponding author), Hop Europeen Georges Pompidou, AP HP, Inst Canc Paris Carpem, Pole Biol, Paris, France.; Kroemer, G (corresponding author), Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Jiangsu, Peoples R China.; Kroemer, G (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
EM lsslyq@mail.sysu.edu.cn; kroemer@orange.fr; captain.olsen@gmail.com
RI Kepp, Oliver/N-2763-2017; laurent-puig, pierre/B-2226-2013
OI Kepp, Oliver/0000-0002-6081-9558; laurent-puig,
   pierre/0000-0001-8475-5459; Senovilla, Laura/0000-0001-6887-2436; LIU,
   Peng/0000-0002-1682-9222
FU China Scholarship CouncilChina Scholarship Council; DIM ELICIT
   initiative of the Ile de France; Institut National du Cancer
   (INCa)Institut National du Cancer (INCA) France; Ligue contre le Cancer
   (equipes labellisees, Program "Equipe labelisee LIGUE'') [EL2016.LNCC
   (VT/PLP)]; Agence National de la Recherche (ANR)-Projets blancsFrench
   National Research Agency (ANR); ANR under the frame of E-Rare-2French
   National Research Agency (ANR); ERA-Net for Research on Rare Diseases;
   AMMICa [US23/CNRS UMS3655]; Association pour la recherche sur le cancer
   (ARC)Fondation ARC pour la Recherche sur le Cancer; Association "Le
   Cancer du Sein, Parlons-en!"; Canceropole Ile-de-France; Chancelerie des
   universites de Paris (Legs Poix); Fondation pour la Recherche Medicale
   (FRM)Fondation pour la Recherche Medicale; Elior; European Research Area
   Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy
   Odyssea; European Union Horizon 2020 Project Oncobiome; Fondation
   Carrefour; INCaInstitut National du Cancer (INCA) France; Inserm (HTE);
   Institut Universitaire de France; LeDucq FoundationLeducq Foundation;
   LabEx Immuno-Oncology [ANR-18-IDEX-0001]; RHU Torino Lumiere; Seerave
   Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune
   Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine
   (CARPEM); Gustave Roussy; Universite Paris-Saclay; Plateforme Imagerie
   et Cytometrie (PFIC); UMS AMMICa INSERM [US23-CNRS 3655]
FX JD, A-LT, HP, SZ, and HC are supported by the China Scholarship Council.
   OK receives funding by the DIM ELICIT initiative of the Ile de France
   and Institut National du Cancer (INCa); GK, VT, and PLP are supported by
   the Ligue contre le Cancer (equipes labellisees, Program "Equipe
   labelisee LIGUE"; no. EL2016.LNCC (VT/PLP)); Agence National de la
   Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the
   ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655;
   Association pour la recherche sur le cancer (ARC); Association "Le
   Cancer du Sein, Parlons-en!"; Canceropole Ile-de-France; Chancelerie des
   universites de Paris (Legs Poix), Fondation pour la Recherche Medicale
   (FRM); a donation by Elior; European Research Area Network on
   Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the
   European Union Horizon 2020 Project Oncobiome; Fondation Carrefour;
   INCa; Inserm (HTE); Institut Universitaire de France; LeDucq Foundation;
   the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumiere;
   the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair
   and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research
   and Personalized Medicine (CARPEM). We are grateful to the support of
   the Gustave Roussy, Universite Paris-Saclay, Plateforme Imagerie et
   Cytometrie (PFIC), UMS AMMICa INSERM US23-CNRS 3655.
CR Altomare I, 2013, EXPERT OPIN PHARMACO, V14, P505, DOI 10.1517/14656566.2013.770473
   Altomare I, 2011, ONCOLOGIST, V16, P1131, DOI 10.1634/theoncologist.2011-0078
   Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830
   BAUM M, 1968, BRIT J CANCER, V22, P176, DOI 10.1038/bjc.1968.25
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3
   Bezu L, 2018, CELL DEATH DIFFER, V25, P1375, DOI 10.1038/s41418-017-0044-9
   Bilgin B, 2017, CURR MED RES OPIN, V33, P749, DOI 10.1080/03007995.2017.1279132
   BOS JL, 1989, CANCER RES, V49, P4682
   Bramsen JB, 2017, CELL REP, V19, P1268, DOI 10.1016/j.celrep.2017.04.045
   Bravo-San Pedro JM, 2017, METHOD ENZYMOL, V587, P71, DOI 10.1016/bs.mie.2016.10.022
   Pedro JMBS, 2021, METHODS MOL BIOL, V2267, P227, DOI 10.1007/978-1-0716-1217-0_16
   Cerrato G, 2021, CELL DEATH DIFFER, V28, P1733, DOI 10.1038/s41418-020-00699-3
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   El Sissy C, 2021, CANCERS, V13, DOI 10.3390/cancers13061281
   Enot DP, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462431
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hasskarl Jens, 2018, Recent Results Cancer Res, V211, P101, DOI 10.1007/978-3-319-91442-8_8
   Humeau J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911622
   Kepp O, 2020, AUTOPHAGY, V16, P188, DOI 10.1080/15548627.2019.1688984
   Kroemer G, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1058597
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5
   LOEB LA, 1994, CANCER RES, V54, P5059
   Loos F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2011-5
   Marisa L, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx136
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3
   Michels J, 2013, CELL CYCLE, V12, P877, DOI 10.4161/cc.24034
   Mooi JK, 2018, ANN ONCOL, V29, P2240, DOI 10.1093/annonc/mdy410
   Ng K, 2013, CLIN CANCER RES, V19, P3987, DOI 10.1158/1078-0432.CCR-13-0027
   Okita Akira, 2018, Oncotarget, V9, P18698, DOI 10.18632/oncotarget.24617
   Quarni W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50917-3
   Rello-Varona S, 2012, CELL CYCLE, V11, P170, DOI 10.4161/cc.11.1.18564
   SCHWARK WS, 1987, EPILEPSY RES, V1, P63, DOI 10.1016/0920-1211(87)90052-0
   Sica V, 2016, METHODS MOL BIOL, V1491, P1, DOI 10.1007/978-1-4939-3581-9_1
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234
   Thanki Ketan, 2017, Int Biol Biomed J, V3, P105
   Thomas J, 2020, CLIN COLORECTAL CANC, V19, P73, DOI 10.1016/j.clcc.2020.02.002
   Wang Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000462
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Zhao YY, 2013, ONCOL REP, V30, P1782, DOI 10.3892/or.2013.2627
NR 45
TC 0
Z9 0
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 21
PY 2021
VL 12
IS 11
AR 978
DI 10.1038/s41419-021-04270-x
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WK6GL
UT WOS:000709823000002
PM 34675191
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ovadje, P
   Ammar, S
   Guerrero, JA
   Arnason, JT
   Pandey, S
AF Ovadje, Pamela
   Ammar, Saleem
   Guerrero, Jose-Antonio
   Arnason, John Thor
   Pandey, Siyaram
TI Dandelion root extract affects colorectal cancer proliferation and
   survival through the activation of multiple death signalling pathways
SO ONCOTARGET
LA English
DT Article
DE cancer; oxidative stress; phytochemical composition; gene expression;
   natural health product
ID NF-KAPPA-B; SELECTIVE INDUCTION; NATURAL-PRODUCTS; APOPTOSIS; AUTOPHAGY;
   LOCALIZATION; TARAXASTEROL; MITOCHONDRIA; CASPASE-8; DISEASE
AB Dandelion extracts have been studied extensively in recent years for its antidepressant and anti-inflammatory activity. Recent work from our lab, with in-vitro systems, shows the anti-cancer potential of an aqueous dandelion root extract (DRE) in several cancer cell models, with no toxicity to non-cancer cells. In this study, we examined the cancer cell-killing effectiveness of an aqueous DRE in colon cancer cell models. Aqueous DRE induced programmed cell death (PCD) selectively in >95% of colon cancer cells, irrespective of their p53 status, by 48 hours of treatment. The anti-cancer efficacy of this extract was confirmed in in-vivo studies, as the oral administration of DRE retarded the growth of human colon xenograft models by more than 90%. We found the activation of multiple death pathways in cancer cells by DRE treatment, as revealed by gene expression analyses showing the expression of genes implicated in programmed cell death. Phytochemical analyses of the extract showed complex multi-component composition of the DRE, including some known bioactive phytochemicals such as alpha-amyrin, beta-amyrin, lupeol and taraxasterol. This suggested that this natural extract could engage and effectively target multiple vulnerabilities of cancer cells. Therefore, DRE could be a non-toxic and effective anti-cancer alternative, instrumental for reducing the occurrence of cancer cells drug-resistance.
C1 [Ovadje, Pamela; Pandey, Siyaram] Univ Windsor, Dept Chem & Biochem, Windsor, ON, Canada.
   [Ammar, Saleem; Guerrero, Jose-Antonio; Arnason, John Thor] Univ Ottawa, Dept Biol, Ottawa, ON, Canada.
   [Guerrero, Jose-Antonio] Inst Ecol AC, Red Estudios Mol Avanzados, Xalapa, Veracruz, Mexico.
RP Pandey, S (corresponding author), Univ Windsor, Dept Chem & Biochem, Windsor, ON, Canada.
EM spandey@uwindsor.ca
RI Pandey, Siyaram/AAI-5491-2020; Guerrero-Analco, José A./Q-6733-2018
OI Guerrero-Analco, José A./0000-0003-0998-757X
FU Donna Dave Couvillon; Pajama Angels, Late & John Hecht Foundation; Jesse
   & Julie Rasch Foundation
FX The authors would like to acknowledge funding/ support from the
   following individuals and agencies: Donna & Dave Couvillon, The Pajama
   Angels, Late & John Hecht Foundation, Jesse & Julie Rasch Foundation.
   The authors would also like to acknowledge the contribution of Dr.
   Andrew Brooke from the University of Guelph, for the toxicological
   analysis of dandelion root extract in mice models. The authors would
   like to acknowledge the efforts of Drs. Tirumalai and Sikorska in the
   complete editing and revamping of this manuscript.
CR BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881
   Bethge N, 2014, EPIGENETICS-US, V9, P428, DOI 10.4161/epi.27554
   Chan LL, 2012, J FLUORESC, V22, P1301, DOI 10.1007/s10895-012-1072-y
   Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004
   Chatterjee SJ, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/129045
   Denes A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.86
   Devine MJ, 2011, NAT REV CANCER, V11, P812, DOI 10.1038/nrc3150
   Donald CD, 2003, LAB INVEST, V83, P501, DOI 10.1097/01.LAB.0000063929.61760.F6
   Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x
   Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
   Foster BC, 2005, ANNU REV PHARMACOL, V45, P203, DOI 10.1146/annurev.pharmtox.45.120403.095950
   Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016
   Grespi F, 2010, CELL DEATH DIFFER, V17, P1672, DOI 10.1038/cdd.2010.97
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   Hausmann M, 2011, J BIOL CHEM, V286, P26533, DOI 10.1074/jbc.M111.265322
   He H, 2014, BRIT J CANCER, V110, P2021, DOI 10.1038/bjc.2014.93
   Hu C, 2005, PHYTOMEDICINE, V12, P588, DOI 10.1016/j.phymed.2003.12.012
   Hu C, 2003, J AGR FOOD CHEM, V51, P301, DOI 10.1021/jf0258858
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x
   Liang YC, 2013, BIOCHEM BIOPH RES CO, V431, P58, DOI 10.1016/j.bbrc.2012.12.092
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147
   Murtaza I, 2009, CANCER RES, V69, P1156, DOI 10.1158/0008-5472.CAN-08-2917
   Nascimbeni AC, 2012, CELL DEATH DIFFER, V19, P1698, DOI 10.1038/cdd.2012.52
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017
   Ovadje P, 2011, J ETHNOPHARMACOL, V133, P86, DOI 10.1016/j.jep.2010.09.005
   Ovadje P, 2012, PANCREAS, V41, P1039, DOI 10.1097/MPA.0b013e31824b22a2
   Ovadje P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030604
   Ovesna Z, 2004, NEOPLASMA, V51, P407
   Peek RM, 2004, CANCER CHEMOTH PHARM, V54, pS50, DOI 10.1007/s00280-004-0887-x
   Pike LRG, 2013, BIOCHEM J, V449, P389, DOI 10.1042/BJ20120972
   Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200
   Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P9, DOI 10.1002/mnfr.200800044
   Remple Krissy, 2011, J Vis Exp, DOI 10.3791/3659
   Rieger Aja M, 2011, J Vis Exp, DOI 10.3791/2597
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Safa A. R., 2012, Experimental Oncology, V34, P176
   Schalk JAC, 1999, MAMM GENOME, V10, P642, DOI 10.1007/s003359901062
   SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Smirnov DA, 2012, GENOME RES, V22, P332, DOI 10.1101/gr.122044.111
   Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220
   TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214
   van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101
   Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158
   Yarnell E, 2009, INTEGRATIVE MED, DOI [10.1016/j.jep.2011.02.027, DOI 10.1016/J.JEP.2011.02.027]
   Yelamos J, 2008, TRENDS MOL MED, V14, P169, DOI 10.1016/j.molmed.2008.02.003
   Zhang XM, 2012, J ETHNOPHARMACOL, V141, P206, DOI 10.1016/j.jep.2012.02.020
NR 52
TC 34
Z9 37
U1 3
U2 32
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 8
PY 2016
VL 7
IS 45
BP 73080
EP 73100
DI 10.18632/oncotarget.11485
PG 21
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB5WT
UT WOS:000387452100052
PM 27564258
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Olsen, BB
   Svenstrup, TH
   Guerra, B
AF Olsen, Birgitte B.
   Svenstrup, Tina H.
   Guerra, Barbara
TI Downregulation of protein kinase CK2 induces autophagic cell death
   through modulation of the mTOR and MAPK signaling pathways in human
   glioblastoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE glioblastoma cells; autophagy; CK2; mammalian target of rapamycin;
   extracellular signaling-regulated protein kinase 1/2; reactive oxygen
   species
ID MALIGNANT GLIOMA-CELLS; COLON-CANCER CELLS; MAMMALIAN TARGET; RADIATION;
   APOPTOSIS; PHOSPHORYLATION; INHIBITION; THERAPY; PROLIFERATION;
   MATURATION
AB Glioblastoma multiforme is the most common primary brain tumor and one of the most aggressive types of cancer in adults. Survival signaling and apoptosis resistance are hallmarks of malignant glioma cells. However, recent studies have shown that other types of cell death such as autophagy can be induced in malignant glioma cells. This suggests that stimulation of this process may be explored in new therapeutic strategies against glioblastoma multiforme. Protein kinasc CK2 is a highly conserved and constitutively active enzyme that promotes numerous cellular processes such as survival, proliferation and differentiation. CK2 has been found elevated in several malignancies including brain tumors, and to confer resistance against chemotherapeutic agents and apoptotic stimuli. Recently, we have shown that the siRNA-mediated downregulation of CK2 leads to cell death in DNA-PK-proficient human glioblastoma cells. We show, here, that lack of CK2 results in significant induction of autophagic cell death in two human glioblastoma cell lines, M059K and T98G, as indicated by the positive staining of cells with the acidotropic dye acridine orange, and the specific recruitment of microtubule-associated protein 1 light chain 3 (LC3) to autophagosome membranes. Induction of autophagy is accompanied by CK2-dependent decreased phosphorylation of p70 ribosomal S6 and AKT kinases and significantly reduced expression levels of Raptor. In contrast, phosphorylation and activity levels of ERK1/2 are enhanced suggesting an inhibition of the PI3K/AKT/mTORC1 and activation of the ERK1/2 pathways. Furthermore, si RNA-mediated silencing of CK2 results in increased mitochondrial superoxide production in both glioblastoma cell lines. However, mitochondrial reactive oxygen species release correlates with induction of autophagy only in T98G cells. Taken together, our findings identify CK2 as a novel component of the autophagic machinery and underline the potential of its downregulation to kill glioblastoma cells by overcoming the resistance to multiple anticancer agents.
C1 [Svenstrup, Tina H.; Guerra, Barbara] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark.
   [Olsen, Birgitte B.] Odense Univ Hosp, Dept Nucl Med, DK-5000 Odense, Denmark.
RP Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.
EM bag@bmb.sdu.dk
OI Olsen, Birgitte Brinkmann/0000-0002-6130-0387; Guerra,
   Barbara/0000-0003-1136-2413
FU Danish Cancer SocietyDanish Cancer Society [DP08152]
FX This study was supported by a Grant from the Danish Cancer Society
   (DP08152) to BG.
CR Breuleux M, 2009, MOL CANCER THER, V8, P742, DOI 10.1158/1535-7163.MCT-08-0668
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Cheng Y, 2008, BIOCHEM BIOPH RES CO, V376, P483, DOI 10.1016/j.bbrc.2008.09.018
   Corcelle EA, 2009, FEBS J, V276, P6084, DOI 10.1111/j.1742-4658.2009.07332.x
   Dagda RK, 2008, AUTOPHAGY, V4, P770, DOI 10.4161/auto.6458
   Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L
   Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975
   Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kreutzer JN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-440
   Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Nicolau-Galmes F, 2011, APOPTOSIS, V16, P1253, DOI 10.1007/s10495-011-0640-y
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337
   Olsen BB, 2008, MOL CELL BIOCHEM, V316, P115, DOI 10.1007/s11010-008-9817-2
   Paglin S, 2001, CANCER RES, V61, P439
   Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416
   Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916
   Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222
   St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2
   Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687
   Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wang XN, 2001, EXP CELL RES, V268, P294, DOI 10.1006/excr.2001.5292
   Wu WKK, 2011, EXP CELL RES, V317, P1353, DOI 10.1016/j.yexcr.2011.03.005
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Zhuang WZ, 2009, ACTA BIOCH BIOPH SIN, V41, P341, DOI 10.1093/abbs/gmp028
NR 41
TC 50
Z9 50
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2012
VL 41
IS 6
BP 1967
EP 1976
DI 10.3892/ijo.2012.1635
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 043YZ
UT WOS:000311587900008
PM 23007634
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Qureshi-Baig, K
   Kuhn, D
   Viry, E
   Pozdeev, VI
   Schmitz, M
   Rodriguez, F
   Ullmann, P
   Koncina, E
   Nurmik, M
   Frasquilho, S
   Nazarov, PV
   Zuegel, N
   Boulmont, M
   Karapetyan, Y
   Antunes, L
   Val, D
   Mittelbronn, M
   Janji, B
   Haan, S
   Letellier, E
AF Qureshi-Baig, Komal
   Kuhn, Diana
   Viry, Elodie
   Pozdeev, Vitaly I.
   Schmitz, Martine
   Rodriguez, Fabien
   Ullmann, Pit
   Koncina, Eric
   Nurmik, Martin
   Frasquilho, Sonia
   Nazarov, Petr V.
   Zuegel, Nikolaus
   Boulmont, Marc
   Karapetyan, Yervand
   Antunes, Laurent
   Val, Daniel
   Mittelbronn, Michel
   Janji, Bassam
   Haan, Serge
   Letellier, Elisabeth
TI Hypoxia-induced autophagy drives colorectal cancer initiation and
   progression by activating the PRKC/PKC-EZR (ezrin) pathway
SO AUTOPHAGY
LA English
DT Article
DE Autophagy; colorectal cancer; cancer stem cell; ezrin; hypoxia; protein
   kinase C; self-renewal capacity; tumor-initiating cell
ID STEM-CELLS; TARGETING AUTOPHAGY; INDUCIBLE FACTORS; SELF-RENEWAL;
   SURVIVAL; EXPRESSION; BNIP3; BREAST; DEATH; SPECIFICATION
AB In solid tumors, cancer stem cells (CSCs) or tumor-initiating cells (TICs) are often found in hypoxic niches. Nevertheless, the influence of hypoxia on TICs is poorly understood. Using previously established, TIC-enrichedpatient-derived colorectal cancer (CRC) cultures, we show that hypoxia increases the self-renewal capacity of TICs while inducing proliferation arrest in their more differentiated counterpart cultures. Gene expression data revealed macroautophagy/autophagy as one of the major pathways induced by hypoxia in TICs. Interestingly, hypoxia-induced autophagy was found to induce phosphorylation of EZR (ezrin) at Thr567 residue, which could be reversed by knocking down ATG5, BNIP3, BNIP3L, or BECN1. Furthermore, we identified PRKCA/PKC alpha as a potential kinase involved in hypoxia-induced autophagy-mediated TIC self-renewal. Genetic targeting of autophagy or pharmacological inhibition of PRKC/PKC and EZR resulted in decreased tumor-initiating potential of TICs. In addition, we observed significantly reduced in vivo tumor initiation and growth after a stable knockdown of ATG5. Analysis of human CRC samples showed that p-EZR is often present in TICs located in the hypoxic and autophagic regions of the tumor. Altogether, our results establish the hypoxia-autophagy-PKC-EZR signaling axis as a novel regulatory mechanism of TIC self-renewal and CRC progression. Autophagy inhibition might thus represent a promising therapeutic strategy for cancer patients.
C1 [Qureshi-Baig, Komal; Kuhn, Diana; Viry, Elodie; Pozdeev, Vitaly I.; Schmitz, Martine; Rodriguez, Fabien; Ullmann, Pit; Koncina, Eric; Nurmik, Martin; Haan, Serge; Letellier, Elisabeth] Univ Luxembourg, Life Sci Res Unit, Mol Dis Mech Grp, Esch Sur Alzette, Luxembourg.
   [Viry, Elodie; Janji, Bassam] Luxembourg Inst Hlth, Lab Expt Canc Res, Strassen, Luxembourg.
   [Frasquilho, Sonia; Karapetyan, Yervand; Antunes, Laurent] Integrated Biobank Luxembourg, Dudelange, Luxembourg.
   [Nazarov, Petr V.] Luxembourg Inst Hlth, Proteome & Genome Res Unit, Strassen, Luxembourg.
   [Zuegel, Nikolaus; Boulmont, Marc] Ctr Hosp Emile Mayrisch, Dept Surg, Esch Sur Alzette, Luxembourg.
   [Antunes, Laurent; Val, Daniel; Mittelbronn, Michel] LNS, Dept Anat & Mol Pathol, Dudelange, Luxembourg.
   [Mittelbronn, Michel] Univ Luxembourg, LCSB, Esch Sur Alzette, Luxembourg.
   [Mittelbronn, Michel] LIH, NORLUX Neurooncol Lab, Strassen, Luxembourg.
   [Mittelbronn, Michel] Luxembourg Ctr Neuropathol LCNP, Dudelange, Luxembourg.
RP Letellier, E (corresponding author), Univ Luxembourg, Life Sci Res Unit, 6 Ave Swing,Campus Belval, L-4367 Esch Sur Alzette, Luxembourg.
EM elisabeth.letellier@uni.lu
RI Pozdeev, Vitaly/AAA-4087-2020; , Karapetyan/AAN-1433-2020; Letellier,
   Elisabeth/I-9515-2016
OI Letellier, Elisabeth/0000-0001-8242-9393; Pozdeev,
   Vitaly/0000-0002-6526-9890; Nurmik, Martin/0000-0002-6350-0577;
   Mittelbronn, Michel/0000-0002-2998-052X; Nazarov,
   Petr/0000-0003-3443-0298; JANJI, Bassam/0000-0002-9763-0943
FU TELEVIE [28504270, R-AGR-3140, 7456517, R-AGR3377]; Fondation Cancer
   [F1R-LSC-PAU-13HY2C]; Janssen CilagJohnson & JohnsonJohnson & Johnson
   USAJanssen Biotech Inc; Fondation du Pelican de Mie and Pierre
   Hippert-Faber under Fondation de Luxembourg; CORELuxembourg National
   Research Fund [C16/BM/11282028]; POC grant [PoC18/12554295]; Fonds
   National de la Recherche (FNR) (AFR grant scheme); Fonds National de la
   Recherche (FNR) (PRIDE scheme)
FX This project was supported by the TELEVIE (28504270, R-AGR-3140) and
   Fondation Cancer (grant F1R-LSC-PAU-13HY2C) and Janssen Cilag. Dr. Komal
   Qureshi-Baig, Dr. Pit Ullmann and Martin Nurmik are supported by the
   Fonds National de la Recherche (FNR) (under the AFR grant scheme and
   PRIDE scheme) and by the Fondation du Pelican de Mie and Pierre
   Hippert-Faber under the aegis of the Fondation de Luxembourg. EV is
   supported by a TELEVIE grant (7456517, R-AGR3377). EL is supported by a
   CORE (C16/BM/11282028) and a POC grant (PoC18/12554295). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bakdash JZ, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00456
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911
   Chen HF, 2010, TISSUE ENG PT A, V16, P2901, DOI 10.1089/ten.tea.2009.0722
   Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683
   Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dubash TD, 2016, CANCER LETT, V371, P326, DOI 10.1016/j.canlet.2015.11.037
   Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020
   Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300
   Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Homma K, 2011, NUCLEIC ACIDS RES, V39, pD986, DOI 10.1093/nar/gkq995
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Kemper K, 2010, ONCOTARGET, V1, P387, DOI 10.18632/oncotarget.173
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Korkeila EA, 2011, ANTICANCER RES, V31, P4529
   Leiphrakpam PD, 2014, CELL SIGNAL, V100, P130
   Letellier E, 2017, BRIT J CANCER, V117, P1689, DOI 10.1038/bjc.2017.352
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li ZZ, 2010, CURR TOP MICROBIOL, V345, P21, DOI 10.1007/82_2010_75
   Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mgrditchian T, 2017, P NATL ACAD SCI USA, V114, pE9271, DOI 10.1073/pnas.1703921114
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moussay E, 2011, AUTOPHAGY, V7, P760, DOI 10.4161/auto.7.7.15454
   Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723
   Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094
   Ognibene M, 2011, J BIOL CHEM, V286, P29973, DOI 10.1074/jbc.M111.270785
   Qureshi-Baig K, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0602-2
   Qureshi-Baig K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146052
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2016, MOL ASPECTS MED, V47-48, P15, DOI 10.1016/j.mam.2015.09.004
   Sharif N, 2018, J OCUL PHARMACOL TH, V34, P1, DOI 10.1089/jop.2017.29037.int
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486
   Sowter HM, 2001, CANCER RES, V61, P6669
   Ullmann P, 2019, CANC LETT
   Ullmann P, 2016, ONCOTARGET
   Ullmann P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060528
   Ullmann P, 2018, CANCER RES, V78, P3793, DOI 10.1158/0008-5472.CAN-17-3003
   Vitale I, 2015, INT J DEV BIOL, V59, P95, DOI 10.1387/ijdb.150082iv
   Wang HJ, 2009, WORLD J GASTROENTERO, V15, P2016, DOI 10.3748/wjg.15.2016
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122
   Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107
   Yi B, 2015, FRONT CARDIOVASC MED, V2, P1, DOI DOI 10.3389/FCVM.2015.00010/ABSTRACT
NR 60
TC 36
Z9 36
U1 3
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD AUG 2
PY 2020
VL 16
IS 8
BP 1436
EP 1452
DI 10.1080/15548627.2019.1687213
EA NOV 2019
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NC2DU
UT WOS:000499056200001
PM 31775562
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Zhao, PF
   Yin, WM
   Wu, AH
   Tang, YS
   Wang, JY
   Pan, ZZ
   Lin, TT
   Zhang, M
   Chen, BF
   Duan, YF
   Huang, YZ
AF Zhao, Pengfei
   Yin, Weimin
   Wu, Aihua
   Tang, Yisi
   Wang, Jinyu
   Pan, Zhenzhen
   Lin, Tingting
   Zhang, Meng
   Chen, Binfan
   Duan, Yifei
   Huang, Yongzhuo
TI Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic
   Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer
   Therapy
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE albumin nanoparticles; combination therapy; mannose receptors; multidrug
   resistance; SPARC
ID TUMOR-ASSOCIATED MACROPHAGES; COLORECTAL-CANCER; SPARC EXPRESSION;
   PANCREATIC-CANCER; BOUND PACLITAXEL; NAB-PACLITAXEL; BREAST-CANCER;
   LUNG-CANCER; AUTOPHAGY; DISULFIRAM
AB Multidrug resistance (MDR) is an issue that is not only related to cancer cells but also associated with the tumor microenvironments. MDR involves the complicated cancer cellular events and the crosstalk between cancer cells and their surroundings. Ideally, an effective system against MDR cancer should take dual action on both cancer cells and tumor microenvironments. The authors find that both the drug-resistant colon cancer cells and the protumor M2 macrophages highly express two nutrient transporters, i.e., secreted protein acidic and rich in cysteine (SPARC) and mannose receptors (MR). By targeting SPARC and MR, a system can act on both cancer cells and M2 macrophages. Herein the authors develop a mannosylated albumin nanoparticles with coencapsulation of different drugs, i.e., disulfiram/copper complex (DSF/Cu) and regorafenib (Rego). The results show that combination therapy of DSF/Cu and Rego efficiently inhibits the growth of drug-resistant colon tumor, and the combination has not been reported yet for use in anticancer treatment. The system significantly improves the treatment outcomes in the animal model bearing drug-resistant tumors. The therapeutic mechanisms involve enhanced apoptosis, upregulation of intracellular ROS, anti-angiogenesis, and tumor-associated macrophage "re-education." This strategy is characterized by dual targeting to and the simultaneous action on cancer cells and M2 macrophages, with biomimetic codelivery of a novel drug combination.
C1 [Zhao, Pengfei; Yin, Weimin; Duan, Yifei; Huang, Yongzhuo] Nanchang Univ, Coll Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhao, Pengfei; Yin, Weimin; Wu, Aihua; Tang, Yisi; Wang, Jinyu; Pan, Zhenzhen; Lin, Tingting; Zhang, Meng; Chen, Binfan; Huang, Yongzhuo] Chinese Acad Sci, Shanghai Inst Mat Med, 501 Haike Rd, Shanghai 201203, Peoples R China.
   [Wu, Aihua; Tang, Yisi] Guangzhou Univ Chinese Med, Trop Med Inst, 12 Jichang Rd, Guangzhou 501450, Guangdong, Peoples R China.
   [Pan, Zhenzhen] Guangxi Univ Chinese Med, Fac Pharm, 13 Wuhe Rd, Nanning 530200, Peoples R China.
   [Lin, Tingting] Binzhou Med Univ Hosp, Dept Pharm, 661 Huanghe Rd, Binzhou 256603, Peoples R China.
RP Huang, YZ (corresponding author), Nanchang Univ, Coll Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.; Huang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, 501 Haike Rd, Shanghai 201203, Peoples R China.
EM yzhuang@simm.ac.cn
RI Huang, Yongzhuo/A-4688-2013
OI Huang, Yongzhuo/0000-0001-7067-8915
FU National Basic Research Program of China (973 Program)National Basic
   Research Program of China [2014CB931900, 2013CB932503]; NSFC,
   ChinaNational Natural Science Foundation of China (NSFC) [81373357,
   81422048, 81673382, 81521005]
FX The authors thank the National Basic Research Program of China (973
   Program 2014CB931900, 2013CB932503) and NSFC, China (81373357, 81422048,
   81673382, 81521005) for the support. The authors also thank National
   Center for Protein Science Shanghai, CAS, for the technical support at
   Electron Microscopy Facility.
CR Abou-Elkacem L, 2013, MOL CANCER THER, V12, P1322, DOI 10.1158/1535-7163.MCT-12-1162
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd
   Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97
   Byeon HJ, 2016, J CONTROL RELEASE, V225, P301, DOI 10.1016/j.jconrel.2016.01.046
   Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044
   Cen DZ, 2004, J MED CHEM, V47, P6914, DOI 10.1021/jm049568z
   Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen YC, 2014, HEPATOLOGY, V59, P1435, DOI 10.1002/hep.26790
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Correia AL, 2012, DRUG RESIST UPDATE, V15, P39, DOI 10.1016/j.drup.2012.01.006
   Desai N, 2009, TRANSL ONCOL, V2, P59, DOI 10.1593/tlo.09109
   Du D, 2014, J CONTROL RELEASE, V182, P99, DOI 10.1016/j.jconrel.2014.03.006
   Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298
   Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112
   Feng JG, 2014, CURR PHARM DESIGN, V20, P6182, DOI 10.2174/1381612820666140619123255
   Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378
   Flanagan L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.7
   Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Hayashi N, 2015, MOL CANCER THER, V14, P452, DOI 10.1158/1535-7163.MCT-14-0348
   Hidalgo M, 2015, CLIN CANCER RES, V21, P4811, DOI 10.1158/1078-0432.CCR-14-3222
   Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008
   Jiang YF, 2014, ADV MATER, V26, P8174, DOI 10.1002/adma.201403547
   Kang XJ, 2017, ACTA PHARMACOL SIN, V38, P885, DOI 10.1038/aps.2017.10
   Komiya K, 2016, ONCOTARGETS THER, V9, P6663, DOI 10.2147/OTT.S114492
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lin TT, 2016, ACS NANO, V10, P9999, DOI 10.1021/acsnano.6b04268
   Liu X, 2016, ADV MATER, V28, P1743, DOI 10.1002/adma.201504288
   Ma L, 2013, ACS NANO, V7, P9518, DOI 10.1021/nn405674m
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231
   Meester RGS, 2015, CANCER-AM CANCER SOC, V121, P2281, DOI 10.1002/cncr.29336
   Merlot AM, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00299
   Morrison BW, 2010, MELANOMA RES, V20, P11, DOI 10.1097/CMR.0b013e328334131d
   Panzarini E, 2014, MOL PHARMACEUT, V11, P2527, DOI 10.1021/mp500066v
   PARDRIDGE WM, 1995, ADV DRUG DELIVER REV, V15, P5, DOI 10.1016/0169-409X(95)00003-P
   Qiu NS, 2016, ADV MATER, V28, P10613, DOI 10.1002/adma.201603095
   Rahmani M, 2007, MOL CELL BIOL, V27, P5499, DOI 10.1128/MCB.01080-06
   Ranney DF, 2000, BIOCHEM PHARMACOL, V59, P105, DOI 10.1016/S0006-2952(99)00316-0
   Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327
   Schneeweiss A, 2014, ANTICANCER RES, V34, P6609
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Stehle G, 1997, CRIT REV ONCOL HEMAT, V26, P77, DOI 10.1016/S1040-8428(97)00015-2
   Tavallai M, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-LB-094
   Tong J, 2017, ONCOGENE, V36, P787, DOI 10.1038/onc.2016.247
   Triscott J, 2015, STEM CELLS, V33, P1042, DOI 10.1002/stem.1956
   Vaz J, 2015, PANCREAS, V44, P1024, DOI 10.1097/MPA.0000000000000409
   Vinogradov S, 2014, NANOMEDICINE-UK, V9, P695, DOI [10.2217/NNM.14.13, 10.2217/nnm.14.13]
   Vogel SM, 2001, AM J PHYSIOL-LUNG C, V281, pL1512, DOI 10.1152/ajplung.2001.281.6.L1512
   Wang ZJ, 2009, ACS NANO, V3, P4110, DOI 10.1021/nn9012274
   Weng ZQ, 2015, TOXICOLOGY, V327, P10, DOI 10.1016/j.tox.2014.11.002
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wunder A, 1997, INT J ONCOL, V11, P497
   Ying X, 2010, J CONTROL RELEASE, V141, P183, DOI 10.1016/j.jconrel.2009.09.020
NR 60
TC 93
Z9 94
U1 26
U2 341
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-301X
EI 1616-3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD NOV 24
PY 2017
VL 27
IS 44
AR 1700403
DI 10.1002/adfm.201700403
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA FN5GR
UT WOS:000416035400019
DA 2022-04-25
ER

PT J
AU Wu, J
   Zhang, DW
   Li, J
   Deng, X
   Liang, GN
   Long, Y
   He, XM
   Dai, TY
   Ren, DL
AF Wu, Jian
   Zhang, Dawei
   Li, Jun
   Deng, Xin
   Liang, Guannan
   Long, Yang
   He, Xuemei
   Dai, Tianyang
   Ren, Delian
TI MACC1 induces autophagy to regulate proliferation, apoptosis, migration
   and invasion of squamous cell carcinoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE metastasis-associated colon cancer-1; metastasis; autophagy; AMPK
   signaling; esophageal squamous cell carcinoma
ID METASTASIS; EXPRESSION; BECLIN-1; CANCER; PREDICTS; GENE; MET
AB Metastasis-associated colon cancer-1 (MACC1) plays an important role in cancer development, but the role and mechansim of MACC1 in squamous cell carcinoma (ESCC) remain unclear. In this study, we found that MACC1 expression was increased in ESCC, and correlated with lymph node metastasis. MACC1 knockdown suppresed ESCC cell proliferation, metastasis and enchanced cell apoptosis. Moreover, MACC1 knockdown inhibited ESCC cell autophagy, and 3-methyladenine was able to rescue MACC1-induced malignant phenotype of ESCC cells. Furthermore, MACC1 knockdown inactivated AMPK-ULK1 signaling pathway, and metformin could rescue MACC1-induced autophagy in ESCC cells. Collectively, this study found that upregulation of MACC1 in ESCC was associated with lymph node metastasis of patients, and MACC1 regulated ESCC cell proliferation, apoptosis, migration and invasion mainly through AMPK-ULK1 induced autophagy.
C1 [Wu, Jian; Zhang, Dawei; Li, Jun; Liang, Guannan; Long, Yang; He, Xuemei; Dai, Tianyang] South West Med Univ, Affiliated Hosp, Dept Cardiothorac Surg, Luzhou, Sichuan, Peoples R China.
   [Ren, Delian] South West Med Univ, Basic Med Coll, Dept Immunol, Luzhou 646000, Sichuan, Peoples R China.
   [Deng, Xin] Southwest Med Univ, Drug Discovery Res Ctr, Luzhou, Sichuan, Peoples R China.
   [Deng, Xin] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Cardiovasc Pharmacol, Luzhou, Sichuan, Peoples R China.
RP Ren, DL (corresponding author), South West Med Univ, Basic Med Coll, Dept Immunol, Luzhou 646000, Sichuan, Peoples R China.
EM rendelian0605@sina.com
FU Joint Fund of Technology Department, Sichuan Province [2014TSX-0102];
   Youth Foundation of Affiliated Hospital of South West Medical University
   [16025]; Sichuan Science and Technology Plan projects [2016RZ0076]
FX The authors wish to thank Mr. Biao Zhou, and KaiMing He for assistance
   in obtaining patient tissue samples. This study was supported by The
   Joint Fund of Technology Department, Sichuan Province (2014TSX-0102),
   and by Youth Foundation of Affiliated Hospital of South West Medical
   University (16025), and by Sichuan Science and Technology Plan projects
   (no. 2016RZ0076).
CR Ahn JS, 2016, ONCOTARGET, V7, P79033, DOI 10.18632/oncotarget.12986
   Carchman EH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164273
   DeVorkin L, 2017, MOL CANCER RES, V15, P250, DOI 10.1158/1541-7786.MCR-16-0132
   Guo WN, 2017, THERANOSTICS, V7, P2231, DOI 10.7150/thno.18835
   He YJ, 2016, ONCOTARGET, V7, P54537, DOI 10.18632/oncotarget.10402
   Hu D, 2017, ONCOTARGET, V8, P23841, DOI 10.18632/oncotarget.13318
   Ilm K, 2016, ONCOTARGET, V7, P53443, DOI 10.18632/oncotarget.10803
   Jia YL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.247
   Kim R, 2016, WORLD J GASTROENTERO, V22, P8389, DOI 10.3748/wjg.v22.i37.8389
   Lee E, 2016, ONCOTARGET, V7, P67919, DOI 10.18632/oncotarget.12084
   Li HY, 2015, ONCOL LETT, V9, P1989, DOI 10.3892/ol.2015.2984
   Li JL, 2017, CANCER BIOMARK, V18, P11, DOI 10.3233/CBM-160667
   Lu C, 2016, ONCOL REP, V35, P3559, DOI 10.3892/or.2016.4753
   Mao Y, 2016, ONCOTARGET, V7, P51223, DOI 10.18632/oncotarget.9981
   Qu JH, 2012, WORLD J GASTROENTERO, V18, P2995, DOI 10.3748/wjg.v18.i23.2995
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sawada G, 2016, GASTROENTEROLOGY, V150, P1171, DOI 10.1053/j.gastro.2016.01.035
   Shirahata A, 2010, ANTICANCER RES, V30, P2689
   Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018
   Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889
   Sun LF, 2015, MOL MED REP, V12, P3423, DOI 10.3892/mmr.2015.3886
   Tan WG, 2016, ONCOTARGET, V7, P84408, DOI 10.18632/oncotarget.12910
   Wang HY, 2017, ONCOTARGET, V8, P7540, DOI 10.18632/oncotarget.13602
   Weh KM, 2016, MOL CARCINOGEN, V55, P1876, DOI 10.1002/mc.22432
   Xia JL, 2016, CANCER LETT, V381, P31, DOI 10.1016/j.canlet.2016.07.014
   Xie C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064235
   Yamada E, 2016, ONCOTARGET, V7, P74612, DOI 10.18632/oncotarget.11916
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhan L, 2016, ONCOTARGET, V7, P83476, DOI 10.18632/oncotarget.13080
NR 29
TC 14
Z9 16
U1 1
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2017
VL 38
IS 4
BP 2369
EP 2377
DI 10.3892/or.2017.5889
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FI1JD
UT WOS:000411688200054
PM 28791376
OA Bronze
DA 2022-04-25
ER

PT J
AU Kaushal, JB
   Bhatia, R
   Kanchan, RK
   Raut, P
   Mallapragada, S
   Ly, QP
   Batra, SK
   Rachagani, S
AF Kaushal, Jyoti B.
   Bhatia, Rakesh
   Kanchan, Ranjana K.
   Raut, Pratima
   Mallapragada, Surya
   Ly, Quan P.
   Batra, Surinder K.
   Rachagani, Satyanarayana
TI Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting
   Hh/Gli Non-Canonical Axis of Gsk3 beta
SO CANCERS
LA English
DT Article
DE niclosamide; pancreatic cancer; apoptosis; autophagy; Hh signaling; Gsk3
   beta
ID GLYCOGEN-SYNTHASE KINASE-3; HUMAN COLON-CANCER; WNT/BETA-CATENIN;
   SIGNALING PATHWAY; CARCINOMA CELLS; IN-VITRO; AUTOPHAGY; HEDGEHOG;
   GROWTH; ACTIVATION
AB Simple Summary: The current obstacles for discovering new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the identification of new uses for approved or investigational drugs for new therapeutic purposes. Niclosamide (Nic) is a Food and Drug Administration (FDA)-approved anti-helminthic drug, reported to have anti-cancer effects, and is being assessed in various clinical trials. In the current study, we assessed the therapeutic efficacy of Nic on pancreatic cancer (PC) in vitro. Our results revealed mitochondrial stress and mTORC1-dependent autophagy as the predominant players of Nic-induced PC cell death. This study provided a novel mechanistic insight for anti-cancer efficacy of Nic by increasing p-Gsk3 beta that modulates molecular signaling(s), including inhibition of hedgehog (Hh) signaling-mediated cellular proliferation and increased apoptosis through mTORC1-dependent autophagy may prove helpful for the development of novel PC therapies.
   Abstract: Niclosamide (Nic), an FDA-approved anthelmintic drug, is reported to have anti-cancer efficacy and is being assessed in clinical trials for various solid tumors. Based on its ability to target multiple signaling pathways, in the present study, we evaluated the therapeutic efficacy of Nic on pancreatic cancer (PC) in vitro. We observed an anti-cancerous effect of this drug as shown by the G0/G1 phase cell cycle arrest, inhibition of PC cell viability, colony formation, and migration. Our results revealed the involvement of mitochondrial stress and mTORC1-dependent autophagy as the predominant players of Nic-induced PC cell death. Significant reduction of Nic-induced reactive oxygen species (ROS) and cell death in the presence of a selective autophagy inhibitor spautin-1 demonstrated autophagy as a major contributor to Nic-mediated cell death. Mechanistically, Nic inhibited the interaction between BCL2 and Beclin-1 that supported the crosstalk of autophagy and apoptosis. Further, Nic treatment resulted in Gsk3 beta inactivation by phosphorylating its Ser-9 residue leading to upregulation of Sufu and Gli3, thereby negatively impacting hedgehog signaling and cell survival. Nic induced autophagic cell death, and p-Gsk3b mediated Sufu/Gli3 cascade was further confirmed by Gsk3 beta activator, LY-294002, by rescuing inactivation of Hh signaling upon Nic treatment. These results suggested the involvement of a non-canonical mechanism of Hh signaling, where p-Gsk3 beta acts as a negative regulator of Hh/Gli1 cascade and a positive regulator of autophagymediated cell death. Overall, this study established the therapeutic efficacy of Nic for PC by targeting p-Gsk3 beta mediated non-canonical Hh signaling and promoting mTORC1-dependent autophagy and cell death.
C1 [Kaushal, Jyoti B.; Bhatia, Rakesh; Kanchan, Ranjana K.; Raut, Pratima; Batra, Surinder K.; Rachagani, Satyanarayana] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
   [Mallapragada, Surya] Iowa State Univ, Nanovaccine Inst, Dept Chem & Biol Engn, Ames, IA 50011 USA.
   [Ly, Quan P.] Univ Nebraska Med Ctr, Dept Surg Oncol, Omaha, NE 68198 USA.
   [Batra, Surinder K.] Univ Nebraska Med Ctr, Fred & Pamela Buffet Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.
RP Rachagani, S (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
EM jyoti.kaushal@unmc.edu; rocky.bhatia@unmc.edu; ranjana.kanchan@unmc.edu;
   pratima.raut@unmc.edu; suryakm@iastate.edu; qly@wnmc.edu;
   sbatra@unmc.edu; srachagani@unmc.edu
RI Kaushal, Jyoti Bala/AAR-4934-2021; Kanchan, Ranjana/AAD-6218-2022
OI Kaushal, Jyoti Bala/0000-0003-3185-4175; Batra, Surinder
   K./0000-0001-9470-9317
FU National Institutes of Health, National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01 CA247763, R21 CA238953,
   P01 CA217798, R01 CA 228524, R01 CA206444]
FX The authors and work in this manuscript are, in parts, supported by the
   National Institutes of Health, National Cancer Institute (R01 CA247763,
   R21 CA238953, P01 CA217798, R01 CA 228524, and R01 CA206444).
CR Ahn SY, 2017, ONCOTARGET, V8, P31856, DOI 10.18632/oncotarget.16255
   Al-Hadiya Badraddin M H, 2005, Profiles Drug Subst Excip Relat Methodol, V32, P67, DOI 10.1016/S0099-5428(05)32002-8
   Arend RC, 2014, GYNECOL ONCOL, V134, P112, DOI 10.1016/j.ygyno.2014.04.005
   Awaji M, 2020, FASEB J, V34, P9405, DOI 10.1096/fj.201902990R
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Beurel E, 2005, INT J ONCOL, V27, P215
   Burock S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4197-9
   Chai WH, 2020, ANTICANCER RES, V40, P1405, DOI 10.21873/anticanres.14082
   Chen LP, 2017, BIOCHEM BIOPH RES CO, V484, P416, DOI 10.1016/j.bbrc.2017.01.140
   Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001
   Chien S., TARGETING KRAS MUTAT
   Choudhry Z, 2014, ANN NEUROSCI, V21, P28, DOI 10.5214/ans.0972.7531.210109
   Chu LC, 2017, CANCER J, V23, P333, DOI 10.1097/PPO.0000000000000290
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Demishtein A, 2017, AUTOPHAGY, V13, P1697, DOI 10.1080/15548627.2017.1356549
   Ding L, 2019, CLIN CANCER RES, V25, P6452, DOI 10.1158/1078-0432.CCR-19-0799
   Dossou AS, 2019, CANCERS, V11, DOI 10.3390/cancers11101422
   Ducreux M, 2019, SEMIN ONCOL, V46, P28, DOI 10.1053/j.seminoncol.2018.12.003
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638
   Frayha GJ, 1997, GEN PHARMACOL-VASC S, V28, P273, DOI 10.1016/S0306-3623(96)00149-8
   Fujii A, 2021, CANCER SCI, V112, P1655, DOI 10.1111/cas.14858
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Honselmann KC, 2015, J PANCREAS, V16, P25, DOI 10.6092/1590-8577/2894
   Jiang LX, 2013, EXP THER MED, V5, P39, DOI 10.3892/etm.2012.744
   Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950
   Katayama Erryk S, 2020, Oncotarget, V11, P3489, DOI 10.18632/oncotarget.27727
   Kaushal JB, 2018, FREE RADICAL BIO MED, V129, P582, DOI 10.1016/j.freeradbiomed.2018.10.427
   Kaushal JB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06370-1
   Kleszcz R, 2019, ACTA POL PHARM, V76, P661, DOI 10.32383/appdr/105605
   KYRIAZIS AP, 1983, CANCER RES, V43, P4393
   Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06
   Londono-Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535-7163.MCT-13-0555
   Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714
   McCubrey JA, 2016, BBA-MOL CELL RES, V1863, P2942, DOI 10.1016/j.bbamcr.2016.09.004
   MEITNER PA, 1983, CANCER RES, V43, P5978
   Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0
   Montagnani V, 2019, CANCERS, V11, DOI 10.3390/cancers11040449
   MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507
   Mukherji A, 2008, FEBS LETT, V582, P1111, DOI 10.1016/j.febslet.2008.02.068
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Newton PT, 2019, BIOCHEM J, V476, P779, DOI 10.1042/BCJ20190020
   Niewiadomski P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020147
   Park SJ, 2011, BMB REP, V44, P517, DOI 10.5483/BMBRep.2011.44.8.517
   Parvathaneni V, 2019, DRUG DISCOV TODAY, V24, P2076, DOI 10.1016/j.drudis.2019.06.014
   PEARSON RD, 1985, ANN INTERN MED, V102, P550, DOI 10.7326/0003-4819-102-4-550
   Pesce E, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01464
   Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166
   Roca-Agujetas V, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3809308
   Roden MM, 1999, J IMMUNOL METHODS, V226, P29, DOI 10.1016/S0022-1759(99)00039-3
   Roth Marc T, 2020, F1000Res, V9, DOI 10.12688/f1000research.21981.1
   Rudrapal M., 2020, DRUG REPURPOSING HYP
   Satoh K, 2016, CLIN CANCER RES, V22, P3458, DOI 10.1158/1078-0432.CCR-15-2256
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shi LY, 2017, ONCOTARGETS THER, V10, P1767, DOI 10.2147/OTT.S129449
   Shimasaki Takeo, 2012, J Carcinog, V11, P15, DOI 10.4103/1477-3163.100866
   Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4
   Stone DM, 1999, J CELL SCI, V112, P4437
   Street W., 2019, CANC FACTS FIGURES 2, V76
   Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508
   Suliman MA, 2016, INT J MOL MED, V38, P776, DOI 10.3892/ijmm.2016.2689
   Takenaka K, 2007, BIOCHEM BIOPH RES CO, V353, P501, DOI 10.1016/j.bbrc.2006.12.058
   Trnski D, 2015, BBA-MOL BASIS DIS, V1852, P2574, DOI 10.1016/j.bbadis.2015.09.005
   Tzanakakis George N, 2003, Int J Gastrointest Cancer, V34, P27
   Wang CZ, 2018, J CANCER, V9, P4150, DOI 10.7150/jca.26948
   Wang JB, 2019, BIOCHEM J, V476, P535, DOI 10.1042/BCJ20180385
   Wang Q, 2008, CELL DEATH DIFFER, V15, P908, DOI 10.1038/cdd.2008.2
   Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078-0432.CCR-12-2895
   Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Yoon JW, 2013, MOL CANCER RES, V11, P604, DOI 10.1158/1541-7786.MCR-12-0441
   Zhang LL, 2018, WORLD J GASTROENTERO, V24, P2047, DOI 10.3748/wjg.v24.i19.2047
   Zhang SN, 2010, TUMORI J, V96, P985, DOI 10.1177/548.6520
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
   Zhang Z, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00213-8
   Zhao J, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3153-x
   Zinn R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121569
NR 79
TC 3
Z9 3
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2021
VL 13
IS 13
AR 3105
DI 10.3390/cancers13133105
PG 25
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TG1LH
UT WOS:000671172300001
PM 34206370
OA Green Published
DA 2022-04-25
ER

PT J
AU Maximchik, P
   Abdrakhmanov, A
   Inozemtseva, E
   Tyurin-Kuzmin, PA
   Zhivotovsky, B
   Gogvadze, V
AF Maximchik, Polina
   Abdrakhmanov, Alibek
   Inozemtseva, Evgeniya
   Tyurin-Kuzmin, Pyotr A.
   Zhivotovsky, Boris
   Gogvadze, Vladimir
TI 2-Deoxy-D-glucose has distinct and cell line-specific effects on the
   survival of different cancer cells upon antitumor drug treatment
SO FEBS JOURNAL
LA English
DT Article
DE apoptosis; cancer; ER stress; glycolysis; mitochondria
ID ENDOPLASMIC-RETICULUM STRESS; CISPLATIN-INDUCED APOPTOSIS; ER STRESS;
   AUTOPHAGY; INHIBITION; RADIOTHERAPY; GLYCOLYSIS; ACTIVATION; CHAPERONE;
   DEATH
AB The dependence of tumors on glycolysis for ATP generation offers a rationale for therapeutic strategies aimed at selective inhibition of the glycolytic pathway. Analysis of tumor cell responses to anticancer drugs revealed that inhibition of glycolysis by 2-deoxy-D-glucose (2-DG) generally augmented the apoptotic response; however, in HCT116 human colon carcinoma cells, apoptosis was suppressed. A comparison of neuroblastoma SK-N-BE(2) and HCT116 cells revealed, that in contrast to HCT116, in SK-N-BE(2) cells 2-DG alone was able to induce cell death. In SK-N-BE(2) cells the decrease in ATP levels upon treatment with 2-DG was more prominent because in HCT116 cells mitochondria compensated for the loss of ATP caused by glycolysis suppression. In both cells lines 2-DG triggered endoplasmic reticulum (ER) stress, assessed by the accumulation of the marker protein GRP78/BiP. Suppression of ER stress by mannose attenuated the 2-DG-induced apoptotic response in SK-N-BE(2) cells, implying that apoptosis in these cells is a consequence of ER stress induction. In HCT116 cells, ER stress stimulated autophagy, assessed by the accumulation of the lipidated form of LC3. The inhibitor of ER stress mannose attenuated autophagy and reversed 2-DG-mediated suppression of cisplatin-induced apoptosis. When autophagy in HCT116 cells was suppressed by bafilomycin, cisplatin-induced apoptosis was decreased. At the same time, stimulation of autophagy in SK-N-BE(2) cells suppressed cell death. Thus, successful treatment of tumors with conventionally used anticancer drugs should be combined with targeting metabolic pathways involved in the regulation of apoptosis, autophagy, and cellular bioenergetics.
C1 [Maximchik, Polina; Abdrakhmanov, Alibek; Inozemtseva, Evgeniya; Tyurin-Kuzmin, Pyotr A.; Zhivotovsky, Boris; Gogvadze, Vladimir] Moscow MV Lomonosov State Univ, Fac Med, Moscow, Russia.
   [Zhivotovsky, Boris; Gogvadze, Vladimir] Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.
RP Gogvadze, V (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.
EM Vladimir.Gogvadze@ki.se
RI Tyurin-Kuzmin, Pyotr A./A-8193-2014; Gogvadze, Vladimir/A-4392-2014;
   Zhivotovsky, Boris/A-4346-2014
OI Tyurin-Kuzmin, Pyotr A./0000-0002-1901-1637; Abdrakhmanov,
   Alibek/0000-0002-5315-3479; Mickols, Evgeniya/0000-0002-4044-2669;
   Zhivotovsky, Boris/0000-0002-2238-3482
FU Russian Science FoundationRussian Science Foundation (RSF)
   [14-25-00056]; Stockholm [161292]; Swedish Cancer Societies [160733];
   Swedish Childhood Cancer FoundationEuropean Commission [PR-2016-0090];
   Russian Foundation for Basic ResearchRussian Foundation for Basic
   Research (RFBR) [18-04-00720, 18-315-00327]
FX This work was supported by a grant from the Russian Science Foundation
   (14-25-00056). The work in the authors' laboratories is supported by
   grants from the Stockholm (161292) and Swedish (160733) Cancer
   Societies, the Swedish Childhood Cancer Foundation (PR-2016-0090), and
   the Russian Foundation for Basic Research (18-04-00720 to VG and
   18-315-00327 to PM). We thank Prof. Bert Vogelstein for HCT116 cells,
   Prof. Fazoil Ataullakhanov and Dr. Pyotr Makhov for plasmid containing
   LC3-GFP.
CR Bartolome A, 2012, AUTOPHAGY, V8, P1757, DOI 10.4161/auto.21994
   Bernales S, 2007, AUTOPHAGY, V3, P285, DOI 10.4161/auto.3930
   Chen R, 2011, FOLIA BIOL-PRAGUE, V57, P87
   Fouillet A, 2012, AUTOPHAGY, V8, P915, DOI 10.4161/auto.19716
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Kurtoglu M, 2007, ANTIOXID REDOX SIGN, V9, P1383, DOI 10.1089/ars.2007.1714
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453
   Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200
   Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6
   Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4
   Simons AL, 2007, INT J RADIAT ONCOL, V69, P1222, DOI 10.1016/j.ijrobp.2007.07.2343
   Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z
   Tian J, 2017, ONCOL LETT, V13, P1437, DOI 10.3892/ol.2017.5580
   Tsujimoto Y, 1997, CELL DEATH DIFFER, V4, P429, DOI 10.1038/sj.cdd.4400262
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Xi HB, 2011, CANCER CHEMOTH PHARM, V67, P899, DOI 10.1007/s00280-010-1391-0
   Xu RH, 2005, CANCER RES, V65, P613
   Yan MM, 2015, INT J CLIN EXP PATHO, V8, P10204
   Zhang LJ, 2009, MOL CELL BIOCHEM, V327, P171, DOI 10.1007/s11010-009-0055-z
   Zhang XY, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0112-3
NR 23
TC 13
Z9 18
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD DEC
PY 2018
VL 285
IS 24
BP 4590
EP 4601
DI 10.1111/febs.14687
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HE6ZH
UT WOS:000453570200005
PM 30375744
OA Bronze
DA 2022-04-25
ER

PT J
AU Parks, M
   Tillhon, M
   Dona, F
   Prosperi, E
   Scovassi, AI
AF Parks, Michele
   Tillhon, Micol
   Dona, Francesca
   Prosperi, Ennio
   Scovassi, A. Ivana
TI 2-Methoxyestradiol: New perspectives in colon carcinoma treatment
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Apoptosis; Autophagy; Cell cycle; Colon carcinoma cells;
   2-Methoxyestradiol
ID ENDOGENOUS ESTROGEN METABOLITE; CELL-CYCLE PROGRESSION; IN-VITRO;
   SUPEROXIDE-DISMUTASE; ORAL 2-METHOXYESTRADIOL; INHIBITS ANGIOGENESIS;
   MAMMALIAN METABOLITE; APOPTOSIS INDUCTION; TUMOR-GROWTH; G2/M ARREST
AB Colon carcinoma represents a major problem in oncology, since this type of cancer responds poorly to conventional chemotherapy. Many groups are actively involved in the search of new experimental strategies to bypass this problem. We investigated the effects of 2-methoxyestradiol (2-ME), which derives from the NADPH-dependent cytochrome P450 metabolism of 17 beta-estradiol. This compound has raised much interest in the past few decades for its inhibitory effects on the growth of cancer cells of different origin: however, little is known about its use on colon carcinoma-derived cell lines. In the present study, we investigated the effects of 2-ME on cell proliferation and cell cycle of two human colon carcinoma cell lines, namely HCT116 and SW613-B3. Our results showed a net anti-proliferative effect of 2-ME on both cell lines, which is accompanied by cell cycle arrest; moreover, we demonstrated that 2-ME is able to induce apoptosis as well as autophagy. This body of evidence points out that 2-ME could be considered as a promising tool against colon carcinoma. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Parks, Michele; Tillhon, Micol; Dona, Francesca; Prosperi, Ennio; Scovassi, A. Ivana] Ist Genet Mol CNR, I-27100 Pavia, Italy.
RP Scovassi, AI (corresponding author), Ist Genet Mol CNR, Via Abbiategrasso 207, I-27100 Pavia, Italy.
EM scovassi@igm.cnr.it
RI Scovassi, Anna Ivana/F-2458-2010; Prosperi, Ennio/A-3439-2014; Tillhon,
   Micol/AAQ-6994-2020
OI Scovassi, Anna Ivana/0000-0003-3484-9881; Prosperi,
   Ennio/0000-0001-5391-5157; Parks, Michael/0000-0001-8240-0603
FU Regione Lombardia, ItalyRegione Lombardia [4328, 13810096];
   AIRCFondazione AIRC per la ricerca sul cancro [5126]; Fondazione
   CariploFondazione Cariplo [2006-0734]
FX The work in the laboratory is supported by Regione Lombardia, Italy
   (Projects Metadistretti n. 4328 and ATP n. 13810096). MT is a PhD
   student from University of Pavia (Dottorato in Scienze genetiche e
   molecolari) supported by the AIRC grant 5126; FD is supported by
   Fondazione Cariplo (grant # 2006-0734). We are indebted to Prof. L. Moro
   (Universita Avogadro, Novara, Italy), and Dr. P. Lombardi (Naxospharma,
   Novate Milanese, Italy) for helpful discussion. We thank Dr. G. Mazzini
   and Dr. V. Giansanti (IGM-CNR, Pavia, Italy) for help in autophagy
   experiments. We kindly acknowledge the reviewers for stimulating us to
   improve the manuscript.
CR Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870
   Basu A, 2009, FRONT BIOSCI-LANDMRK, V14, P2170, DOI 10.2741/3369
   Bhati R, 2007, CANCER RES, V67, P702, DOI 10.1158/0008-5472.CAN-06-3406
   Bottone MG, 2003, EXP CELL RES, V290, P49, DOI 10.1016/S0014-4827(03)00312-4
   Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6
   Carothers AM, 2002, CANCER LETT, V187, P77, DOI 10.1016/S0304-3835(02)00409-3
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Dahut WL, 2006, CANCER BIOL THER, V5, P22, DOI 10.4161/cbt.5.1.2349
   Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027
   Dobos J, 2004, INT J CANCER, V112, P771, DOI 10.1002/ijc.20473
   Dona F, 2008, INT J ONCOL, V33, P613, DOI 10.3892/ijo_00000047
   Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309
   Du B, 2010, INT J PHARMACEUT, V384, P140, DOI 10.1016/j.ijpharm.2009.09.045
   Dubey RK, 2009, TRENDS ENDOCRIN MET, V20, P374, DOI 10.1016/j.tem.2009.04.007
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Fukui M, 2009, MOL CARCINOGEN, V48, P66, DOI 10.1002/mc.20458
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Gao N, 2005, ONCOGENE, V24, P3797, DOI 10.1038/sj.onc.1208530
   Giansanti V, 2008, MULTIPLE PATHWAYS CA, P135
   Giansanti V, 2010, ONCOL LETT, V1, P109, DOI 10.3892/ol_00000020
   Giansanti V, 2009, INT J BIOCHEM CELL B, V41, P1890, DOI 10.1016/j.biocel.2009.04.008
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200
   Gorrini C, 2003, INT J MOL MED, V11, P737
   Harrison MR, 2011, INVEST NEW DRUG, V29, P1465, DOI 10.1007/s10637-010-9455-x
   Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140
   Kamath K, 2006, MOL CANCER THER, V5, P2225, DOI 10.1158/1535-7163.MCT-06-0113
   Kar S, 2008, CANCER CHEMOTH PHARM, V62, P831, DOI 10.1007/s00280-007-0670-x
   Kato S, 2008, REPROD SCI, V15, P878, DOI 10.1177/1933719108324171
   Kirches E, 2009, ANTI-CANCER AGENT ME, V9, P55, DOI 10.2174/187152009787047725
   Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046
   Lakhani NJ, 2007, J PHARM SCI-US, V96, P1821, DOI 10.1002/jps.20837
   Lambert C, 2004, INT J CANCER, V108, P493, DOI 10.1002/ijc.11579
   LaVallee TM, 2003, CANCER RES, V63, P468
   Li L, 2004, ANTICANCER RES, V24, P873
   Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1
   Majer M, 2007, ANTI-CANCER AGENT ME, V7, P492, DOI 10.2174/187152007781668742
   Maran A, 2008, J CELL BIOCHEM, V104, P1937, DOI 10.1002/jcb.21758
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Mueck AO, 2010, STEROIDS, V75, P625, DOI 10.1016/j.steroids.2010.02.016
   Pasquier E, 2010, MOL CANCER THER, V9, P1408, DOI 10.1158/1535-7163.MCT-09-0894
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320
   Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508
   Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233
   Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5
   Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158
   Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058
   Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968
   Stander BA, 2010, J STEROID BIOCHEM, V119, P149, DOI 10.1016/j.jsbmb.2010.02.019
   Sutherland TE, 2007, DRUG DISCOV TODAY, V12, P577, DOI 10.1016/j.drudis.2007.05.005
   Sweeney C, 2005, CLIN CANCER RES, V11, P6625, DOI 10.1158/1078-0432.CCR-05-0440
   Tevaarwerk AJ, 2009, CLIN CANCER RES, V15, P1460, DOI 10.1158/1078-0432.CCR-08-1599
   Thaver V, 2009, CELL BIOCHEM FUNCT, V27, P205, DOI 10.1002/cbf.1557
   Ting CM, 2010, BIOCHEM PHARMACOL, V79, P825, DOI 10.1016/j.bcp.2009.10.018
   Torriglia A, 1999, CELL DEATH DIFFER, V6, P234, DOI 10.1038/sj.cdd.4400486
   Van Zijl C, 2008, CELL BIOCHEM FUNCT, V26, P632, DOI 10.1002/cbf.1489
   Wang SH, 2009, MACROMOL BIOSCI, V9, P429, DOI 10.1002/mabi.200800381
   Wood L, 2001, ANTI-CANCER DRUG DES, V16, P209
   Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951
   Zhou Q, 2011, INVEST NEW DRUG, V29, P340, DOI 10.1007/s10637-009-9383-9
   Zou HC, 2006, CLIN CANCER RES, V12, P6532, DOI 10.1158/1078-0432.CCR-06-0678
NR 68
TC 16
Z9 17
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 1
PY 2011
VL 331
IS 1
BP 119
EP 128
DI 10.1016/j.mce.2010.08.017
PG 10
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 692CT
UT WOS:000285129800014
PM 20816916
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Nakamura, Y
   Yogosawa, S
   Izutani, Y
   Watanabe, H
   Otsuji, E
   Sakai, T
AF Nakamura, Yoshitaka
   Yogosawa, Shingo
   Izutani, Yasuyuki
   Watanabe, Hirotsuna
   Otsuji, Eigo
   Sakai, Tosiyuki
TI A combination of indol-3-carbinol and genistein synergistically induces
   apoptosis in human colon cancer HT-29 cells by inhibiting Akt
   phosphorylation and progression of autophagy
SO MOLECULAR CANCER
LA English
DT Article
ID MALIGNANT GLIOMA-CELLS; PROTEIN-DEGRADATION; SOY ISOFLAVONES;
   DOWN-REGULATION; INDOLE-3-CARBINOL; CARCINOGENESIS; PATHWAY;
   CHEMOPREVENTION; GROWTH; DEATH
AB Background: The chemopreventive effects of dietary phytochemicals on malignant tumors have been studied extensively because of a relative lack of toxicity. To achieve desirable effects, however, treatment with a single agent mostly requires high doses. Therefore, studies on effective combinations of phytochemicals at relatively low concentrations might contribute to chemopreventive strategies.
   Results: Here we found for the first time that co-treatment with I3C and genistein, derived from cruciferous vegetables and soy, respectively, synergistically suppressed the viability of human colon cancer HT-29 cells at concentrations at which each agent alone was ineffective. The suppression of cell viability was due to the induction of a caspase-dependent apoptosis. Moreover, the combination effectively inhibited phosphorylation of Akt followed by dephosphorylation of caspase-9 or down-regulation of XIAP and survivin, which contribute to the induction of apoptosis. In addition, the co-treatment also enhanced the induction of autophagy mediated by the dephosphorylation of mTOR, one of the downstream targets of Akt, whereas the maturation of autophagosomes was inhibited. These results give rise to the possibility that co-treatment with I3C and genistein induces apoptosis through the simultaneous inhibition of Akt activity and progression of the autophagic process. This possibility was examined using inhibitors of Akt combined with inhibitors of autophagy. The combination effectively induced apoptosis, whereas the Akt inhibitor alone did not.
   Conclusion: Although in vivo study is further required to evaluate physiological efficacies and toxicity of the combination treatment, our findings might provide a new insight into the development of novel combination therapies/chemoprevention against malignant tumors using dietary phytochemicals.
C1 [Nakamura, Yoshitaka; Yogosawa, Shingo; Izutani, Yasuyuki; Watanabe, Hirotsuna; Sakai, Tosiyuki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.
   [Nakamura, Yoshitaka; Otsuji, Eigo] Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kamigyo Ku, Kyoto 6028566, Japan.
RP Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.
EM nakamura@koto.kpu-m.ac.jp; yogosawa@koto.kpu-m.ac.jp;
   izutani@koto.kpu-m.ac.jp; w-h123@koto.kpu-m.ac.jp;
   otsuji@koto.kpu-m.ac.jp; tsakai@koto.kpu-m.ac.jp
FU Japanese Ministry of Education, Culture, Sports, Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT); Japan Society for the Promotion of
   ScienceMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of Science
FX We would like to thank Dr. Yoshihide Tsujimoto and Dr. Yoshihiro Sowa
   for helpful comments on the manuscript. We are supported by a
   Grant-in-aid from the Japanese Ministry of Education, Culture, Sports,
   Science and Technology, and a Grant-in-aid for the Encouragement of
   Young Scientists from the Japan Society for the Promotion of Science.
CR Aggarwal BB, 2005, CELL CYCLE, V4, P1201, DOI 10.4161/cc.4.9.1993
   Alberts DS, 1999, CANCER RES, V59, P4743
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Bonnesen C, 2001, CANCER RES, V61, P6120
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Busby MG, 2002, AM J CLIN NUTR, V75, P126, DOI 10.1093/ajcn/75.1.126
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Cassidy A, 1999, CURR OPIN LIPIDOL, V10, P47, DOI 10.1097/00041433-199902000-00009
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   delPeso L, 1997, SCIENCE, V278, P687
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Gee JM, 2000, CARCINOGENESIS, V21, P2255, DOI 10.1093/carcin/21.12.2255
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009
   GRUBBS CJ, 1995, ANTICANCER RES, V15, P709
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hsu JC, 2005, CARCINOGENESIS, V26, P1896, DOI 10.1093/carcin/bgi155
   Jeong JC, 2009, NEUROCHEM RES, V34, P991, DOI 10.1007/s11064-008-9868-5
   Ju YH, 2006, CARCINOGENESIS, V27, P1292, DOI 10.1093/carcin/bgi370
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701
   Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377
   Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   KOJIMA T, 1994, CANCER RES, V54, P1446
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200
   KUIPER GG, 2004, ENDOCRINOLOGY, V139, P4252
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manson MM, 1998, CARCINOGENESIS, V19, P1829, DOI 10.1093/carcin/19.10.1829
   Marot D, 2006, GENE THER, V13, P235, DOI 10.1038/sj.gt.3302637
   MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860
   Matsuzaki Y, 2004, FEBS LETT, V576, P137, DOI 10.1016/j.febslet.2004.09.002
   MEGGOUH F, 1991, CANCER RES, V51, P1227
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x
   Oki T, 2004, FEBS LETT, V577, P55, DOI 10.1016/j.febslet.2004.09.085
   PAGLIACCI MC, 1994, EUR J CANCER, V30A, P1675, DOI 10.1016/0959-8049(94)00262-4
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Paglin S, 2001, CANCER RES, V61, P439
   Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200
   PENCE BC, 1986, JNCI-J NATL CANCER I, V77, P269
   Peterson G, 1996, CELL GROWTH DIFFER, V7, P1345
   Ramos S, 2008, MOL NUTR FOOD RES, V52, P507, DOI 10.1002/mnfr.200700326
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Reed GA, 2006, CANCER EPIDEM BIOMAR, V15, P2477, DOI 10.1158/1055-9965.EPI-06-0396
   Sarkar FH, 2006, CANCER RES, V66, P3347, DOI 10.1158/0008-5472.CAN-05-4526
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Takimoto CH, 2003, CANCER EPIDEM BIOMAR, V12, P1213
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Thiagarajan DG, 1998, AM J CLIN NUTR, V68, p1394S, DOI 10.1093/ajcn/68.6.1394S
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348
   Xing CG, 2008, ACTA BIOCH BIOPH SIN, V40, P194, DOI 10.1111/j.1745-7270.2008.00393.x
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
NR 74
TC 106
Z9 109
U1 2
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 12
PY 2009
VL 8
AR 100
DI 10.1186/1476-4598-8-100
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 526IQ
UT WOS:000272281900001
PM 19909554
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Mou, LJ
   Liang, BY
   Liu, GJ
   Jiang, JJ
   Liu, J
   Zhou, B
   Huang, JG
   Zang, N
   Liao, YY
   Ye, L
   Liang, H
AF Mou, Lianjun
   Liang, Bingyu
   Liu, Guanjun
   Jiang, Junjun
   Liu, Jie
   Zhou, Bo
   Huang, Jiegang
   Zang, Ning
   Liao, Yanyan
   Ye, Li
   Liang, Hao
TI Berbamine exerts anticancer effects on human colon cancer cells via
   induction of autophagy and apoptosis, inhibition of cell migration and
   MEK/ERK signalling pathway
SO JOURNAL OF BUON
LA English
DT Article
DE colon cancer; berbamine; autophagy; apoptosis; migration
ID PRODUCT-DERIVED COMPOUNDS; NATURAL-PRODUCTS; SYNTHETIC DERIVATIVES;
   DRUGS
AB Purpose: Berbamine is a plant-derived alkaloid with amazing and wide diversity of pharmacological properties which range from antimicrobial and anticancer. Nonetheless, the anticancer properties of Berbamine have not been thoroughly evaluated against colon cancer cells. This study was undertaken to evaluate the anticancer effects of Berbamine against the human colon cancer cell line HT-29.
   Methods: CCK-8 assay was used to determine the cell viability. DAPI and propidium iodide (PI) staining assays were used for the detection of apoptosis. Electron microscopy was used for the determination of autophagy. Wound healing assay was used to monitor cell migration. Protein expression was determined by western blotting.
   Results: The results showed that Berbamine caused a remarkable decrease in the HT-29 cell viability with an IC50 of 14 mu M, while the high IC50 of Berbamine against the normal CDD-18Co cells indicated low toxicity of this mol-ecule against the normal cells. DAPI and PI staining assays showed nuclear fragmentation, indicative of apoptosis in HT-29 cells. Berbamine also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio. Electron microscopic analysis showed that Berbamine triggered the development of autophagic vesicles in the HT-29 cells which was concomitant with the increase in protein levels of LC3B-I, ATG-5, ATG-12 and Beclin-1. Wound healing assay showed that Berbamine decreased the migration potential of the HT29 and also blocked the MEK/ERK signalling pathway in colon cancer cells.
   Conclusion: Berbamine may prove an efficient lead molecule for the development of more potent anticancer agents through semi-synthetic approaches.
C1 [Mou, Lianjun; Liang, Bingyu; Jiang, Junjun; Liu, Jie; Zhou, Bo; Huang, Jiegang; Zang, Ning; Liao, Yanyan; Ye, Li; Liang, Hao] Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, 22 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Mou, Lianjun; Liang, Bingyu; Jiang, Junjun; Liu, Jie; Zhou, Bo; Huang, Jiegang; Zang, Ning; Liao, Yanyan; Ye, Li; Liang, Hao] Guangxi Med Univ, Life Sci Inst, Guangxi Collaborat Innovat Ctr Biomed, Nanning 530021, Peoples R China.
   [Mou, Lianjun] Hainan Med Univ, Affiliated Hosp 1, Dept Pathol, Haikou 571101, Hainan, Peoples R China.
   [Liu, Guanjun] Zhengzhou Univ, Henan Prov Peoples Hosp, Peoples Hosp, Dept Oncol, Zhengzhou 450003, Henan, Peoples R China.
RP Liang, H (corresponding author), Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, 22 Shuangyong Rd, Nanning 530021, Peoples R China.; Liang, H (corresponding author), Guangxi Med Univ, Sch Publ Hlth, Guangxi Univ Key Lab Prevent & Control Highly Pre, Nanning 530021, Guangxi, Peoples R China.
EM hgotenl@yahoo.com
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f
   Butler MS, 2005, NAT PROD REP, V22, P162, DOI 10.1039/b402985m
   Duan HY, 2010, CYTOTECHNOLOGY, V62, P341, DOI 10.1007/s10616-009-9240-x
   Grynkiewicz G, 2008, PHARMACOL REP, V60, P439
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   LIU CX, 1991, PHYTOTHER RES, V5, P228, DOI 10.1002/ptr.2650050508
   Meng Z, 2013, MOL CANCER THER
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Nam S, 2012, MOL ONCOL, V6, P484, DOI 10.1016/j.molonc.2012.05.002
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132
   Rahmatullah M, 2014, J PHARM PHARM SCI, V3, P95
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Wang Guan-yu, 2007, Journal of Zhejiang University-Science B, V8, P248, DOI 10.1631/jzus.2007.B0248
   Wang GY, 2009, J ASIAN NAT PROD RES, V11, P219, DOI 10.1080/10286020802675076
   Wang S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-81
   Xie JW, 2009, EUR J MED CHEM, V44, P3293, DOI 10.1016/j.ejmech.2009.02.018
   Yang F, 2013, CANCER BIOL THER, V14, P1024, DOI 10.4161/cbt.26045
   Yang FL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0076458, 10.1371/journal.pone.0100031]
   Zhao XY, 2007, CHINESE MED J-PEKING, V120, P802, DOI 10.1097/00029330-200705010-00012
NR 22
TC 9
Z9 10
U1 0
U2 4
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD SEP-OCT
PY 2019
VL 24
IS 5
BP 1870
EP 1875
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JU6CG
UT WOS:000501762000017
PM 31786849
DA 2022-04-25
ER

PT J
AU Varela-Lopez, A
   Vera-Ramirez, L
   Giampieri, F
   Navarro-Hortal, MD
   Forbes-Hernandez, TY
   Battino, M
   Quiles, JL
AF Varela-Lopez, Alfonso
   Vera-Ramirez, Laura
   Giampieri, Francesca
   Navarro-Hortal, Maria D.
   Forbes-Hernandez, Tamara Y.
   Battino, Maurizio
   Quiles, Jose L.
TI The central role of mitochondria in the relationship between dietary
   lipids and cancer progression
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Apoptosis; Autophagy; Bioenergetics; Lipogenesis; Redox biology
ID POLYUNSATURATED FATTY-ACIDS; INDUCED PANCREATIC-CANCER; CELLS IN-VITRO;
   BREAST-CANCER; COLON-CANCER; EICOSAPENTAENOIC ACID; COLORECTAL-CANCER;
   PROSTATE-CANCER; LUNG-CANCER; INDUCED APOPTOSIS
AB Evidence demonstrates the importance of lipid metabolism and signaling in cancer cell biology. De novo lipogenesis is an important source of lipids for cancer cells, but exogenous lipid uptake remains essential for many cancer cells. Dietary lipids can modify lipids present in tumor microenvironment affecting cancer cell metabolism. Clinical trials have shown that diets rich in polyunsaturated fatty acids (PUFA) can negatively affect tumor growth. However, certain n-6 PUFAs can also contribute to cancer progression. Identifying the molecular mechanisms through which lipids affect cancer progression will provide an opportunity for focused dietary interventions that could translate into the development of personalized diets for cancer control. However, the effective mechanisms of action of PUFAs have not been fully clarified yet. Mitochondria controls ATP generation, redox homeostasis, metabolic signaling, apoptotic pathways and many aspects of autophagy, and it has been recognized to play a key role in cancer. The purpose of this review is to summarize the current evidence linking dietary lipids effects on mitochondrial aspects with consequences for cancer progression and the molecular mechanisms that underlie this association.
C1 [Varela-Lopez, Alfonso; Navarro-Hortal, Maria D.; Quiles, Jose L.] Univ Granada, Dept Physiol, Inst Nutr & Food Technol Jose Mataix Verdu, Biomed Res Ctr, Avda Conocimiento S-N, Granada 18100, Spain.
   [Vera-Ramirez, Laura] Pfizer Univ Granada & Andalusian Reg Govt, GENYO Ctr Genom & Oncol, Dept Genom Med, Granada, Spain.
   [Giampieri, Francesca; Battino, Maurizio] Univ Politecn Marche, Dept Clin Sci, I-60131 Ancona, Italy.
   [Giampieri, Francesca] King Abdulaziz Univ, Dept Biochem, Fac Sci, Jeddah, Saudi Arabia.
   [Forbes-Hernandez, Tamara Y.] CACTI Univ Vigo, CITACA, Dept Analyt & Food Chem, Nutr & Food Sci Grp, Vigo 36310, Spain.
   [Battino, Maurizio] Jiangsu Univ, Int Res Ctr Food Nutr & Safety, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Quiles, Jose L.] Univ Europea Atlantico, Res Grp Food Nutr Biochem & Hlth, Santander, Spain.
RP Quiles, JL (corresponding author), Univ Granada, Dept Physiol, Inst Nutr & Food Technol Jose Mataix Verdu, Biomed Res Ctr, Avda Conocimiento S-N, Granada 18100, Spain.
EM jlquiles@ugr.es
RI Varela-López, Alfonso/F-8055-2016; Navarro-Hortal, María
   D./AAB-9805-2019; Ramirez, Laura Vera/S-3375-2018; Quiles, José
   L./C-6911-2013
OI Varela-López, Alfonso/0000-0002-0504-5086; Ramirez, Laura
   Vera/0000-0001-9184-9875; Quiles, José L./0000-0002-9048-9086;
   Navarro-Hortal, Maria D./0000-0002-6225-8379
CR Aglago EK, 2020, CLIN GASTROENTEROL H, V18, P654, DOI 10.1016/j.cgh.2019.06.031
   Agnihotri N, 2016, BIOMED PHARMACOTHER, V82, P90, DOI [10.1016/j.biopha.2016.04.045, 10.1016/j.biopha.]
   Alberg AJ, 2013, CANCER EPIDEM BIOMAR, V22, P1374, DOI 10.1158/1055-9965.EPI-12-1424
   Alberts B., 2014, MOL BIOL CELL 6 INT
   Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Bassett JK, 2016, CANCER CAUSE CONTROL, V27, P759, DOI 10.1007/s10552-016-0753-2
   Berridge MV, 2010, MITOCHONDRION, V10, P584, DOI 10.1016/j.mito.2010.08.002
   Bhat TA, 2017, BBA-REV CANCER, V1867, P58, DOI 10.1016/j.bbcan.2016.12.002
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8
   Bollu LR, 2014, CELL CYCLE, V13, P2415, DOI 10.4161/cc.29338
   Brasky TM, 2015, AM J CLIN NUTR, V101, P824, DOI 10.3945/ajcn.114.098988
   BUCKMAN DK, 1991, CANCER LETT, V59, P257, DOI 10.1016/0304-3835(91)90150-G
   Burch TC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134206
   Butler LM, 2020, ADV DRUG DELIVER REV, V159, P245, DOI 10.1016/j.addr.2020.07.013
   Cao Y, 2016, INT J CANCER, V138, P1894, DOI 10.1002/ijc.29938
   Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483
   Chajes V, 2017, ANN ONCOL, V28, P2836, DOI 10.1093/annonc/mdx482
   CHAJES V, 1995, BREAST CANCER RES TR, V34, P199, DOI 10.1007/BF00689711
   Colquhoun A, 2002, BBA-MOL CELL BIOL L, V1583, P74, DOI 10.1016/S1388-1981(02)00162-2
   Colquhoun A, 1998, BIOCHEM MOL BIOL INT, V44, P143
   Colquhoun A, 2001, BBA-MOL CELL BIOL L, V1533, P207, DOI 10.1016/S1388-1981(01)00136-6
   Commander R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15219-7
   Cordero A, 2019, ONCOGENE, V38, P6445, DOI 10.1038/s41388-019-0893-4
   Courtney ED, 2007, INT J COLORECTAL DIS, V22, P765, DOI 10.1007/s00384-006-0240-4
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   Dai JF, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-71
   Dawaliby R, 2016, J BIOL CHEM, V291, P3658, DOI 10.1074/jbc.M115.706523
   De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045190
   Dinwiddie MT, 2016, J AM COLL NUTR, V35, P452, DOI 10.1080/07315724.2015.1032444
   Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385
   FALCONER JS, 1994, BRIT J CANCER, V69, P826, DOI 10.1038/bjc.1994.161
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Fauser JK, 2013, CHEMOTHERAPY, V59, P214, DOI 10.1159/000356067
   Ferreri C, 2020, METABOLITES, V10, DOI 10.3390/metabo10090345
   Flowers MT, 2008, PHYSIOL GENOMICS, V33, P361, DOI 10.1152/physiolgenomics.00139.2007
   Fukui M, 2013, J CELL BIOCHEM, V114, P192, DOI 10.1002/jcb.24354
   Giampieri F, 2019, ANTIOXID REDOX SIGN, V30, P577, DOI 10.1089/ars.2017.7234
   Gimple RC, 2019, CANCER DISCOV, V9, P1248, DOI 10.1158/2159-8290.CD-19-0061
   Gonzalez CA, 2010, EUR J CANCER, V46, P2555, DOI 10.1016/j.ejca.2010.07.025
   Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3
   Guaita-Esteruelas S, 2017, MOL CARCINOGEN, V56, P208, DOI 10.1002/mc.22485
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardman W Elaine, 2002, Cancer Cell Int, V2, P10, DOI 10.1186/1475-2867-2-10
   Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200
   He WM, 2019, ONCOGENE, V38, P4637, DOI 10.1038/s41388-019-0747-0
   Heukamp I, 2006, PANCREATOLOGY, V6, P96, DOI 10.1159/000090028
   Igal RA, 2016, BBA-MOL CELL BIOL L, V1861, P1865, DOI 10.1016/j.bbalip.2016.09.009
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kadochi Y, 2017, ONCOL LETT, V14, P673, DOI 10.3892/ol.2017.6195
   Kanno S, 2015, TOXICOL LETT, V232, P393, DOI 10.1016/j.toxlet.2014.11.016
   Kim HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08433-9
   Kim HY, 2016, ONCOTARGET, V7, P67111, DOI 10.18632/oncotarget.11560
   Kim M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121963
   Kim S, 2019, PROSTATE, V79, P896, DOI 10.1002/pros.23796
   Konen J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15078
   Koronowicz AA, 2018, ANTICANCER RES, V38, P2861, DOI 10.21873/anticanres.12531
   Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z
   Krycer JR, 2010, TRENDS ENDOCRIN MET, V21, P268, DOI 10.1016/j.tem.2010.01.001
   Kurahashi N, 2008, CANCER EPIDEM BIOMAR, V17, P930, DOI 10.1158/1055-9965.EPI-07-2681
   Laake I, 2013, INT J CANCER, V132, P1389, DOI 10.1002/ijc.27737
   Lamprecht SA, 2002, CARCINOGENESIS, V23, P1777, DOI 10.1093/carcin/23.11.1777
   Lappano R, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.63
   Leaver HA, 2002, PROSTAG LEUKOTR ESS, V66, P19, DOI 10.1054/plef.2001.0336
   Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794
   Li S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097330
   Liebisch G, 2013, J LIPID RES, V54, P1523, DOI 10.1194/jlr.M033506
   Lin HM, 2017, INT J CANCER, V141, P2112, DOI 10.1002/ijc.30903
   Liss MA, 2019, PROSTATE CANCER P D, V22, P244, DOI 10.1038/s41391-018-0105-2
   Liu YE, 2020, MEDCOMM, V1, P129, DOI 10.1002/mco2.16
   Lu XF, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-106
   Ludwig DS, 2018, SCIENCE, V362, P764, DOI 10.1126/science.aau2096
   Ma YB, 2018, CANCER LETT, V435, P92, DOI 10.1016/j.canlet.2018.08.006
   Magtanong L, 2019, CELL CHEM BIOL, V26, P420, DOI 10.1016/j.chembiol.2018.11.016
   Molendijk J, 2020, MOL OMICS, V16, P6, DOI 10.1039/c9mo00128j
   Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x
   MOUNTFORD CE, 1982, CANCER RES, V42, P2270
   Murphy RA, 2012, LIPIDS, V47, P363, DOI 10.1007/s11745-011-3641-2
   Nashed M, 2012, EXP BIOL MED, V237, P1007, DOI 10.1258/ebm.2012.012126
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Nindrea Ricvan Dana, 2019, Asian Pac J Cancer Prev, V20, P1321, DOI 10.31557/APJCP.2019.20.5.1321
   Nindrea Ricvan Dana, 2019, Asian Pac J Cancer Prev, V20, P327, DOI 10.31557/APJCP.2019.20.2.327
   Panigrahi DP, 2020, SEMIN CANCER BIOL, V66, P45, DOI 10.1016/j.semcancer.2019.07.015
   Peck B, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0146-8
   Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079
   Psaltopoulou T, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-127
   Quiles JL, 2020, ANTIOXID REDOX SIGN, V33, P860, DOI 10.1089/ars.2020.8051
   Ramesh G, 1998, CANCER LETT, V123, P207, DOI 10.1016/S0304-3835(97)00426-6
   Rodriguez-Enriquez S, 2010, INT J BIOCHEM CELL B, V42, P1744, DOI 10.1016/j.biocel.2010.07.010
   Roy J, 2019, J LIPID RES, V60, P375, DOI 10.1194/jlr.M088559
   Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871
   Saito K, 2018, CANCER CHEMOTH PHARM, V82, P677, DOI 10.1007/s00280-018-3655-z
   Sam MR, 2017, NUTR CANCER, V69, P64, DOI 10.1080/01635581.2017.1247884
   Schmidt JA, 2020, INT J CANCER, V146, P720, DOI 10.1002/ijc.32314
   Schonberg SA, 2006, FEBS J, V273, P2749, DOI 10.1111/j.1742-4658.2006.05292.x
   Sczaniecka AK, 2012, NUTR CANCER, V64, P1131, DOI 10.1080/01635581.2012.718033
   Shan L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046846
   Sheela DL, 2019, HUM EXP TOXICOL, V38, P753, DOI 10.1177/0960327119839185
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   So WW, 2015, NUTRIENTS, V7, P6956, DOI 10.3390/nu7085319
   SPECTOR AA, 1966, J LIPID RES, V7, P657
   Suzuki-Karasaki M, 2014, INT J ONCOL, V44, P616, DOI 10.3892/ijo.2013.2215
   Van de Sande T, 2002, CANCER RES, V62, P642
   Vera-Ramirez L, 2020, SEMIN CANCER BIOL, V60, P28, DOI 10.1016/j.semcancer.2019.07.027
   Vera-Ramirez L, 2013, CRIT REV FOOD SCI, V53, P49, DOI 10.1080/10408398.2010.521600
   Vinikoor LC, 2010, CANCER CAUSE CONTROL, V21, P171, DOI 10.1007/s10552-009-9447-3
   Vriens K, 2019, NATURE, V566, P403, DOI 10.1038/s41586-019-0904-1
   Wallace M, 2020, SEMIN CELL DEV BIOL, V108, P65, DOI 10.1016/j.semcdb.2020.02.012
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6
   WELSCH CW, 1995, INT J ONCOL, V6, P55
   Wenger FA, 2000, PROSTAG LEUKOTR ESS, V62, P329, DOI 10.1054/plef.2000.0162
   Witte TR, 2015, LIPIDS, V50, P437, DOI 10.1007/s11745-015-4011-2
   Wu Y, 2016, STEM CELLS, V34, P83, DOI 10.1002/stem.2209
   Yang T, 2013, J NUTR BIOCHEM, V24, P744, DOI 10.1016/j.jnutbio.2012.03.023
   Yao QH, 2014, MOL MED REP, V9, P401, DOI 10.3892/mmr.2013.1829
   Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116
   Zajdel A, 2015, TOXICOL IN VITRO, V30, P486, DOI 10.1016/j.tiv.2015.09.013
   Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970
NR 120
TC 3
Z9 3
U1 4
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
EI 1096-3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2021
VL 73
SI SI
BP 86
EP 100
DI 10.1016/j.semcancer.2021.01.001
EA JUN 2021
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SR7TI
UT WOS:000661248600008
PM 33434641
DA 2022-04-25
ER

PT J
AU Tian, X
   Han, Z
   Zhu, QX
   Tan, J
   Liu, WJ
   Wang, YF
   Chen, W
   Zou, YL
   Cai, YS
   Huang, SS
   Chen, AF
   Zhan, T
   Huang, M
   Liu, M
   Huang, XD
AF Tian, Xia
   Han, Zheng
   Zhu, Qingxi
   Tan, Jie
   Liu, Weijie
   Wang, Yanfen
   Chen, Wei
   Zou, Yanli
   Cai, Yishan
   Huang, Shasha
   Chen, Aifang
   Zhan, Ting
   Huang, Min
   Liu, Meng
   Huang, Xiaodong
TI Silencing of cadherin-17 enhances apoptosis and inhibits autophagy in
   colorectal cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Cadherin-17; Apoptosis; Autophagy; Colorectal cancer; Rapamycin
ID LIVER-INTESTINE-CADHERIN; HEPATOCELLULAR-CARCINOMA; METASTASIS;
   EXPRESSION; MARKER; INTEGRIN; DISEASE; PROTEIN; GENE; LC3
AB Cadherin-17 (CDH17), a structurally unique member of the non-classical cadherin family, is associated with poor survival, cell proliferation, and metastasis in colorectal cancer. However, the role of CDH17 in the apoptosis and autophagy of colorectal cancer cells remains unclear. Here, we aimed to investigate the effect of CDH17 knockdown on autophagy and apoptosis in colorectal cancer cells. We inhibited CDH17 expression in KM12SM and KM12C colorectal cancer cells by RNA interference and found that silencing of CDH17 significantly inhibited cell viability and increased apoptosis in KM12SM and KM12C cells. In addition, silencing of CDH17 significantly increased the expression of cleaved caspase-3 and Bax and decreased the expression of Bcl-2. Concurrently, silencing of CDH17 significantly inhibited the conversion of LC3-I to LC3-II and decreased the formation of LC3(+) autophagic vacuoles and the accumulation of acidic vesicular organelles, indicating that autophagy was significantly inhibited in KM12SM and KM12C cells. Additionally, treatment with the autophagy-specific activator rapamycin attenuated apoptosis in CDH17-knockdown cells and as indicated by decreased caspase-3 activity, decreased expression of cleaved caspase-3 and Bax, and increased expression of Bcl-2. In conclusion, CDH17 silencing induced apoptosis and inhibited autophagy in KM12SM and KM12C cells, and this autophagy protected the cells from apoptotic cell death.
C1 [Tian, Xia; Han, Zheng; Zhu, Qingxi; Tan, Jie; Liu, Weijie; Wang, Yanfen; Chen, Wei; Zou, Yanli; Cai, Yishan; Huang, Shasha; Chen, Aifang; Zhan, Ting; Huang, Min; Liu, Meng; Huang, Xiaodong] Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Gastroenterol, 241 Pengliuyang Rd, Wuhan 430060, Hubei, Peoples R China.
RP Liu, M; Huang, XD (corresponding author), Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Gastroenterol, 241 Pengliuyang Rd, Wuhan 430060, Hubei, Peoples R China.
EM mengliu16@sina.com; xdhuang17@sina.com
OI Huang, Xiaodong/0000-0002-5815-7655
FU Wuhan Science and Technology Bureau of Applied Basic Research Projects
   [2015060101010064]; Hubei Province Natural Science Foundation of
   ChinaNatural Science Foundation of Hubei Province [2013CFB358]; Project
   of Health and Family Planning Commission of Wuhan Municipality [WX15C09,
   WX14C18]
FX This work was supported by Wuhan Science and Technology Bureau of
   Applied Basic Research Projects (2015060101010064), Hubei Province
   Natural Science Foundation of China (2013CFB358), and Project of Health
   and Family Planning Commission of Wuhan Municipality (WX15C09 and
   WX14C18).
CR Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117
   Bartolome RA, 2014, J BIOL CHEM, V289, P34801, DOI 10.1074/jbc.M114.600502
   Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195
   Chen RY, 2012, WORLD J GASTROENTERO, V18, P7251, DOI 10.3748/wjg.v18.i48.7251
   Cyjon A, 2001, BRIT J CANCER, V85, P504, DOI 10.1054/bjoc.2001.1972
   FADEL HE, 1986, AM J OBSTET GYNECOL, V155, P544, DOI 10.1016/0002-9378(86)90276-0
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Jung R, 2004, CELL MOL LIFE SCI, V61, P1157, DOI 10.1007/s00018-004-3470-z
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236
   Kaser A, 2011, GASTROENTEROLOGY, V140, P1738, DOI 10.1053/j.gastro.2011.02.048
   Li B, 2017, MOL NEUROBIOL, V54, P1642, DOI 10.1007/s12035-015-9637-9
   Li R, 2017, INT J ONCOL, V50, P15, DOI 10.3892/ijo.2016.3783
   Li YZ, 2016, ONCOL RES, V24, P287, DOI 10.3727/096504016X14648701447779
   Lin Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091095, 10.1371/journal.pone.0104195]
   Luque-Garcia JL, 2010, PROTEOMICS, V10, P940, DOI 10.1002/pmic.200900441
   Paglin S, 2001, CANCER RES, V61, P439
   Park JH, 2011, HISTOPATHOLOGY, V58, P316, DOI 10.1111/j.1365-2559.2011.03746.x
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Su MC, 2008, MODERN PATHOL, V21, P1379, DOI 10.1038/modpathol.2008.107
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Takamura M, 2004, CANCER LETT, V212, P253, DOI 10.1016/j.canlet.2004.03.016
   Takeuchi N, 2017, MOL CLIN ONCOL, V7, P308, DOI 10.3892/mco.2017.1307
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tenesa A, 2009, NAT REV GENET, V10, P353, DOI 10.1038/nrg2574
   Wang XQ, 2005, CLIN CANCER RES, V11, P483
   Wong BW, 2003, BIOCHEM BIOPH RES CO, V311, P618, DOI 10.1016/j.bbrc.2003.10.032
   Yonemura Yutaka, 2016, Gan To Kagaku Ryoho, V43, P1435
NR 30
TC 6
Z9 7
U1 1
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2018
VL 108
BP 331
EP 337
DI 10.1016/j.biopha.2018.09.020
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HA2UZ
UT WOS:000450101800040
PM 30227326
OA hybrid
DA 2022-04-25
ER

PT J
AU Wang, L
   Wang, Y
   Lu, YY
   Zhang, QY
   Qu, XJ
AF Wang, Lu
   Wang, Yan
   Lu, Yuyin
   Zhang, Qianyun
   Qu, Xianjun
TI Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal
   adenoma growth and enhances the antitumor efficacy of interferon-gamma
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE Apc Min; mouse; ATG5; colorectal cancer; heterozygous deletion;
   intestinal adenoma; IFN-; ATG5; autophagy related gene 5; CRC;
   colorectal cancer; IFN-; Interferon-gamma; 5-FU; 5-fluorouracil; Apc;
   adenomatous polyposis coli; siRNAs; small interfering RNAs; EGFR;
   epidermal growth factor receptor; Erk; extracellular signal-regulated
   kinase; LC3; microtubule-associated protein 1 light chain 3; PCNA;
   proliferating cell nuclear antigen
ID COLORECTAL-CANCER; ADJUVANT TREATMENT; BETA-CATENIN; COLON-CANCER;
   AUTOPHAGY; CELLS; APOPTOSIS; APC
AB Autophagy related gene 5 (ATG5) was lost in 23% of the patients with colorectal cancer (CRC) and the role of loss of ATG5 in the pathogenesis of CRC remains unclear. Knockdown of ATG5 in cancer cells enhances the antitumor efficacy of lots of chemotherapeutic agents. However, there is still no animal model to validate these in vitro observations in vivo. In this study, we found that heterozygous deletion of ATG5 in Apc(Min/+) mice increased the number and size of adenomas as compared with those in Apc(Min/+)ATG5(+/+) mice. To investigate whether ATG5 deficiency could sensitize tumors to chemotherapies, we compared the antitumor effects of Interferon-gamma (IFN-) between Apc(Min/+)ATG5(+/+) and Apc(Min/+)ATG5(+/-) mice, as IFN- is a potential tumor suppressor for CRC and has been used clinically as an efficient adjuvant to chemotherapy of cancer. We revealed that heterozygous deletion of ATG5 significantly enhanced the antitumor efficacy of IFN-. Early treatment of Apc(Min/+)ATG5(+/-) mice with IFN- decreased tumor incidence rate to 16.7% and reduced the number of adenomas by 95.5% and late treatment led to regression of tumor. Moreover, IFN- treatment did not cause any evident toxic reaction. Mechanistic analysis revealed that heterozygous deletion of ATG5 activated EGFR/ERK1/2 and Wnt/-catenin pathways in adenomas of Apc(Min/+) mice and enhanced the effects of IFN--dependent inhibition of these 2 pathways. Our results demonstrate that ATG5 plays important roles in intestinal tumor growth and combination of IFN- and ATG5 deficiency or ATG5-targeted inhibition is a promising strategy for prevention and treatment of CRC.
C1 [Wang, Lu; Lu, Yuyin; Zhang, Qianyun; Qu, Xianjun] Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, Jinan 250100, Shandong, Peoples R China.
   [Wang, Yan] Shandong Acad Med Sci, Inst Mat Med, Dept Pharmacol, Jinan, Shandong, Peoples R China.
RP Qu, XJ (corresponding author), Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, Jinan 250100, Shandong, Peoples R China.
EM qxj@sdu.edu.cn
FU Natural Science Foundation of China for Research Resources [91229113]
FX This research was made possible by the Grant 91229113 from Natural
   Science Foundation of China for Research Resources.
CR An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Billiau A, 1998, ANN NY ACAD SCI, V856, P22, DOI 10.1111/j.1749-6632.1998.tb08309.x
   Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315
   Burn John, 2013, Recent Results Cancer Res, V191, P157, DOI 10.1007/978-3-642-30331-9_9
   Cao ZY, 2014, ONCOL LETT, V7, P1260, DOI 10.3892/ol.2014.1856
   Chau I, 2006, ANN ONCOL, V17, P1347, DOI 10.1093/annonc/mdl029
   DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007
   FAVROT MC, 1989, PEDIATRIE, V44, P11
   Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067
   Ge Xinhong, 2013, Indian J Dermatol, V58, P101, DOI 10.4103/0019-5154.108035
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9
   Jacoby RF, 2000, CANCER RES, V60, P5040
   Kang YJ, 2012, MOL PHARMACOL, V82, P168, DOI 10.1124/mol.112.078535
   Kudinov Y, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-4
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Li WW, 2012, J ONCOL, V2012, DOI 10.1155/2012/879623
   Macdonald JS, 1999, ONCOLOGY-NY, V13, P33
   Miyahara K, 1987, Gan To Kagaku Ryoho, V14, P411
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Nishiumi S, 2012, BIOCHEM BIOPH RES CO, V421, P768, DOI 10.1016/j.bbrc.2012.04.081
   Nordman IC, 2006, ANZ J SURG, V76, P373, DOI 10.1111/j.1445-2197.2006.03726.x
   Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626
   Park EJ, 2011, BIOSCI TRENDS, V5, P120, DOI 10.5582/bst.2011.v5.3.120
   Prabhu V, 2013, MITOCHONDRION, V13, P493, DOI 10.1016/j.mito.2012.10.010
   Rehg JE, 1996, J INFECT DIS, V174, P229, DOI 10.1093/infdis/174.1.229
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999
   Takaku K, 2002, CANCER RES, V62, P4558
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   von Reyher U, 1998, CANCER RES, V58, P526
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wils J, 2001, ANN ONCOL, V12, P13, DOI 10.1023/A:1008357725209
NR 41
TC 16
Z9 16
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAR
PY 2015
VL 16
IS 3
BP 383
EP 391
DI 10.1080/15384047.2014.1002331
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF5OQ
UT WOS:000352607000005
PM 25695667
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Wang, XF
   Zhang, C
   Yan, XM
   Lan, B
   Wang, JY
   Wei, CY
   Cao, XX
   Wang, RX
   Yao, JH
   Zhou, T
   Zhou, M
   Liu, QL
   Jiang, B
   Jiang, PF
   Kesari, S
   Lin, XJ
   Guo, F
AF Wang, Xuefeng
   Zhang, Chen
   Yan, Xiangming
   Lan, Bin
   Wang, Jianyong
   Wei, Chongyang
   Cao, Xingxin
   Wang, Renxiao
   Yao, Jianhua
   Zhou, Tao
   Zhou, Mi
   Liu, Qiaoling
   Jiang, Biao
   Jiang, Pengfei
   Kesari, Santosh
   Lin, Xinjian
   Guo, Fang
TI A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via
   Cascade Effects of Mitochondria
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELL-DEATH; AUTOPHAGY; BCL-2; APOGOSSYPOL; GOSSYPOL; ABT-737; TARGET;
   MTOR; DIFFERENTIATION; MITOPHAGY
AB Purpose: Gossypol and its analogs, through their ability to bind to and inactivate BH3 domain-containing antiapoptotic proteins, have been shown to inhibit the growth of various human cancer cells in culture and xenograft models. Here, we evaluated the antitumor efficacy of a novel gossypol derivative and BH3 mimetic ch282-5 (2-aminoethanesulfonic acid sodium-gossypolone) in colon cancer models. Several innovative combination strategies were also explored and elaborated.
   Experimental Design: Ch282-5 was synthesized by modifying the active aldehyde groups and R groups of gossypol according to a computer-aided drug design program. The stability of ch282-5 was examined by high-performance liquid chromatography, and cytotoxic effects of ch282-5 on colon cancer cells were assessed by MTS assay. Activation of mitochondrial apoptotic pathway by ch282-5 was evidenced with a series of molecular biology techniques. In vivo antitumor activity of ch282-5 and its combination with chloroquine, rapamycin, oxaliplatin, and ABT-263 was also evaluated in colon cancer xenograft models and experimental liver metastasis models.
   Results: Ch282-5 showed antiproliferative and pro-cell death activity against colon cancer cells both in vitro and in vivo, and the response to the drug correlated with inhibition of antiapoptotic Bcl-2 proteins, induction of mitochondria-dependent apoptotic pathway, and disruption of mitophagy and mTOR pathway. Ch282-5 also suppressed liver metastasis produced by intrasplenic injection of colon cancer cells. Furthermore, ch282-5 could potentiate the effectiveness of oxaliplatin and rescue ABT-263 efficacy by downregulation of Mcl-1 and elevation of platelet number.
   Conclusions: These findings provide a rational basis for clinical investigation of this highly promising BH3 mimetic in colon cancer. (C)2015 AACR.
C1 [Wang, Xuefeng; Yan, Xiangming; Wang, Jianyong; Wei, Chongyang; Liu, Qiaoling; Guo, Fang] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Adv Res Inst, Lab Tumor Targeted Therapy, 99 Haike Rd, Shanghai 201210, Peoples R China.
   [Wang, Xuefeng; Lan, Bin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 201210, Peoples R China.
   [Wang, Xuefeng; Lan, Bin] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
   [Zhang, Chen; Cao, Xingxin; Wang, Renxiao; Yao, Jianhua; Zhou, Mi; Jiang, Biao] Univ Chinese Acad Sci, Shanghai Inst Organ Chem, CAS Key Lab Synthet Chem Nat Subst, Shanghai, Peoples R China.
   [Lan, Bin; Guo, Fang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, Shanghai 200030, Peoples R China.
   [Zhou, Tao] Shanghai Univ, Acad Life Sci, Shanghai, Peoples R China.
   [Jiang, Pengfei; Kesari, Santosh; Lin, Xinjian] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Jiang, Pengfei; Kesari, Santosh; Lin, Xinjian] Univ Calif San Diego, UC San Diego Moores Canc Ctr, La Jolla, CA 92093 USA.
RP Guo, F (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Adv Res Inst, Lab Tumor Targeted Therapy, 99 Haike Rd, Shanghai 201210, Peoples R China.; Lin, XJ (corresponding author), Univ Calif San Diego, UC San Diego Moores Canc Ctr, Dept Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.
EM xlin@ucsd.edu; guof@sari.ac.cn
RI Kesari, Santosh/E-8461-2013
OI wang, xuefeng/0000-0003-3613-6113
FU Shanghai Commission for Science and Technology [11DZ1910200]; National
   Basic Research ProgramNational Basic Research Program of China
   [2011CB510106]; National High Technology Research and Development
   Program of ChinaNational High Technology Research and Development
   Program of China [2013AA032201]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31171308,
   81172208, 81472610]; Interdisciplinary Science & Youth Innovation
   Program of Shanghai Advanced Research Institute [2015Y52643232]
FX This work was supported by Shanghai Commission for Science and
   Technology (11DZ1910200), The National Basic Research Program
   (2011CB510106), The National High Technology Research and Development
   Program of China (2013AA032201), and The National Natural Science
   Foundation of China (31171308, 81172208, and 81472610) as well as a
   grant from Interdisciplinary Science & Youth Innovation Program of
   Shanghai Advanced Research Institute (2015Y52643232).
CR Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chiarini F, 2015, TRENDS PHARMACOL SCI, V36, P124, DOI 10.1016/j.tips.2014.11.004
   Dolman NJ, 2013, AUTOPHAGY, V9, P1653, DOI 10.4161/auto.24001
   Fang ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062823
   FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Gardner EE, 2014, CANCER RES, V74, P2846, DOI 10.1158/0008-5472.CAN-13-3460
   Giampietri Claudia, 2014, Int J Cell Biol, V2014, P490275, DOI 10.1155/2014/490275
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Haricharan S, 2014, MOL CELL ENDOCRINOL, V382, P560, DOI 10.1016/j.mce.2013.03.014
   Hou HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035665
   Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Jia L, 2008, CANCER CHEMOTH PHARM, V61, P63, DOI 10.1007/s00280-007-0446-3
   Kanki T, 2010, MOL MICROBIOL, V75, P795, DOI 10.1111/j.1365-2958.2009.07035.x
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kim YS, 2011, BIOCHEM PHARMACOL, V82, P216, DOI 10.1016/j.bcp.2011.04.011
   Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z
   Kitada S, 2008, BLOOD, V111, P3211, DOI 10.1182/blood-2007-09-113647
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007
   Lin YY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju012
   Liu C, 2003, CANCER RES, V63, P2957
   Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200
   Lukas J, 1996, MOL CELL BIOL, V16, P6917
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Oprea TI, 2000, J COMPUT AID MOL DES, V14, P251, DOI 10.1023/A:1008130001697
   Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416
   Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6
   Samuel T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-599
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Silke J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008730
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008
   TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110
   Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836
   Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194
   Wei J, 2009, MOL CANCER THER, V8, P904, DOI 10.1158/1535-7163.MCT-08-1050
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Winter JN, 2011, AM J PHYSIOL-CELL PH, V300, pC1172, DOI 10.1152/ajpcell.00504.2010
   Yan F, 2010, J MED CHEM, V53, P5502, DOI 10.1021/jm1001698
   Yan Y, 2009, BIOCHEM J, V417, P747, DOI 10.1042/BJ20081865
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhao P, 2010, BIOCHEM BIOPH RES CO, V395, P219, DOI 10.1016/j.bbrc.2010.03.165
   Zinn RL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-16
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 49
TC 18
Z9 20
U1 9
U2 28
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2016
VL 22
IS 6
BP 1445
EP 1458
DI 10.1158/1078-0432.CCR-15-0732
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DI2WD
UT WOS:000373358900020
PM 26515494
OA Bronze
DA 2022-04-25
ER

PT J
AU Oh, BM
   Lee, SJ
   Cho, HJ
   Park, YS
   Kim, JT
   Yoon, SR
   Lee, SC
   Lim, JS
   Kim, BY
   Choe, YK
   Lee, HG
AF Oh, Byung Moo
   Lee, Seon-Jin
   Cho, Hee Jun
   Park, Yun Sun
   Kim, Jong-Tae
   Yoon, Suk Ran
   Lee, Sang Chul
   Lim, Jong-Seok
   Kim, Bo-Yeon
   Choe, Yong-Kyung
   Lee, Hee Gu
TI Cystatin SN inhibits auranofin-induced cell death by autophagic
   induction and ROS regulation via glutathione reductase activity in
   colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID DEUBIQUITINASE INHIBITOR; CYSTEINE PROTEINASES; IN-VITRO; APOPTOSIS;
   MECHANISMS; PROTEASES; GENERATION; PATHWAYS; SURVIVAL; NEURONS
AB Cystatin SN (CST1) is a specific inhibitor belonging to the cystatin superfamily that controls the proteolytic activities of cysteine proteases such as cathepsins. Our previous study showed that high CST1 expression enhances tumor metastasis and invasiveness in colorectal cancer. Recently, auranofin (AF), a gold(I)-containing thioredoxin reductase 1 (TrxR1) inhibitor, has been used clinically to treat rheumatoid arthritis. AF is a proteasome-associated deubiquitinase inhibitor and can act as an anti-tumor agent. In this study, we investigated whether CST1 expression induces autophagy and tumor cell survival. We also investigated the therapeutic effects of AF as an anti-tumor agent in colorectal cancer (CRC) cells. We found that CRC cells expressing high levels of CST1 undergo increased autophagy and exhibit chemotherapeutic resistance to AF-induced cell death, while those expressing low levels of CST1 are sensitive to AF. We also observed that knockdown of CST1 in high-CST1 CRC cells using CST1-specific small interfering RNAs attenuated autophagic activation and restored AF-induced cell mortality. Conversely, the overexpression of CST1 increased autophagy and viability in cells expressing low levels of CST1. Interestingly, high expression of CST1 attenuates AF-induced cell death by inhibiting intracellular reactive oxygen species (ROS) generation, as demonstrated by the fact that the blockage of ROS production reversed AF-induced cell death in CRC cells. In addition, upregulation of CST1 expression increased cellular glutathione reductase (GR) activity, reducing the cellular redox state and inducing autophagy in AF-treated CRC cells. These results suggest that high CST1 expression may be involved in autophagic induction and protects from AF-induced cell death by inhibition of ROS generation through the regulation of GR activity.
C1 [Oh, Byung Moo; Lee, Seon-Jin; Cho, Hee Jun; Park, Yun Sun; Kim, Jong-Tae; Choe, Yong-Kyung; Lee, Hee Gu] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, 125 Gwahak ro, Daejeon 34141, South Korea.
   [Oh, Byung Moo; Lee, Seon-Jin; Lee, Hee Gu] Univ Sci & Technol UST, Dept Biomol Sci, Daejeon, South Korea.
   [Lee, Sang Chul; Lim, Jong-Seok] Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.
   [Kim, Bo-Yeon] Korea Res Inst Biosci & Biotechnol, World Class Inst, Ochang, South Korea.
RP Lee, HG (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, 125 Gwahak ro, Daejeon 34141, South Korea.
EM hglee@kribb.re.kr
RI Lee, Seon-Jin/AAJ-8258-2020
OI Lee, Seon-Jin/0000-0001-7214-7536
FU National Research Foundation of Korea (NRF) - Ministry of Science, ICT &
   Future Planning [NRF- 2014R1A2A2A09052492]; Creative Allied Project and
   National Agenda Project through the National Research Council of Science
   and Technology
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant by the Ministry of Science, ICT & Future Planning (NRF-
   2014R1A2A2A09052492) and by the Creative Allied Project and National
   Agenda Project through the National Research Council of Science and
   Technology.
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363
   Bhatia M, 2016, REDOX BIOL, V8, P68, DOI 10.1016/j.redox.2015.12.004
   Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Chen YF, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-15
   Choi EH, 2009, CLIN CHIM ACTA, V406, P45, DOI 10.1016/j.cca.2009.05.008
   Cox JL, 2009, FRONT BIOSCI-LANDMRK, V14, P463, DOI 10.2741/3255
   Debnath A, 2012, NAT MED, V18, P956, DOI 10.1038/nm.2758
   Dickinson DP, 2002, DNA CELL BIOL, V21, P47, DOI 10.1089/10445490252810311
   DICKINSON DP, 1994, GENOMICS, V24, P172, DOI 10.1006/geno.1994.1595
   Doka E, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1500968
   Fan C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.132
   FINKELSTEIN AE, 1976, ANN RHEUM DIS, V35, P251, DOI 10.1136/ard.35.3.251
   Fiskus W, 2014, CANCER RES, V74, P2520, DOI 10.1158/0008-5472.CAN-13-2033
   Gandin V, 2010, BIOCHEM PHARMACOL, V79, P90, DOI 10.1016/j.bcp.2009.07.023
   Gauthier Sebastien, 2011, Front Biosci (Schol Ed), V3, P541, DOI 10.2741/s170
   GLAUMANN H, 1981, INT REV CYTOL, V73, P149, DOI 10.1016/S0074-7696(08)61288-7
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Huang HB, 2016, ONCOTARGET, V7, P2796, DOI 10.18632/oncotarget.6425
   Kalinina EV, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1562, DOI 10.1134/S0006297914130082
   Kim JT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.485
   Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   LAH TT, 1993, J PERIODONTOL, V64, P485
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Li W, 2016, J CELL MOL MED, V20, P1664, DOI 10.1111/jcmm.12859
   Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046
   Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113
   Marzano C, 2007, FREE RADICAL BIO MED, V42, P872, DOI 10.1016/j.freeradbiomed.2006.12.021
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027
   Raninga PV, 2015, ONCOTARGET, V6, P15410, DOI 10.18632/oncotarget.3795
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o
   Tizon B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009819
   Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8
   Tooze SA, 2008, CURR OPIN NEUROBIOL, V18, P504, DOI 10.1016/j.conb.2008.09.015
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Turk B, 1997, BIOL CHEM, V378, P141
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067
   Watanabe S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.459
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yoneda K, 2009, INT J ONCOL, V35, P33, DOI 10.3892/ijo_00000310
NR 50
TC 23
Z9 24
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR
PY 2017
VL 8
AR e2682
DI 10.1038/cddis.2017.100
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EP5VM
UT WOS:000397447100043
PM 28300829
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Cleven, AHG
   Wouters, BG
   Schutte, B
   Spiertz, AJG
   van Engeland, M
   de Bruine, AP
AF Cleven, A. H. G.
   Wouters, B. G.
   Schutte, B.
   Spiertz, A. J. G.
   van Engeland, M.
   de Bruine, A. P.
TI Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal
   adenocarcinomas is associated with wild-type TP53 but not with BNIP3
   promoter hypermethylation or apoptosis
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE colorectal cancer; hypoxia; TP53; BNIP3; outcome
ID HYPOXIA-INDUCIBLE FACTORS; METHYLATION-SPECIFIC PCR; CELL-DEATH;
   PROGNOSTIC VALUE; CANCER PATIENTS; UP-REGULATION; COLON-CANCER; K-RAS;
   P53; GENE
AB Stromal expression of hypoxia inducible factor 2 alpha (HIF-2 alpha) and carbonic anhydrase 9 (CA9) are associated with a poorer prognosis in colorectal cancer (CRC). Tumour cell death, regulated by a hypoxic stromal microenvironment, could be of importance in this respect. Therefore, we correlated apoptosis, TP53 mutational status and BNIP3 promoter hypermethylation of CRC cells with HIF-2 alpha- and CA9-related poor outcome. In a series of 195 CRCs, TP53 mutations in exons 5-8 were analysed by direct sequencing, and promoter hypermethylation of BNIP3 was determined by methylation-specific PCR. Expressions of HIF-2 alpha, CA9, p53, BNIP3 and M30 were analysed immunohistochemically. Poorer survival of HIF-2 alpha and CA9 stromal-positive CRCs was associated with wild-type TP53 ( P = 0.001 and P = 0.0391), but not with BNIP3 methylation. Furthermore, apoptotic levels were independent of the TP53 status, but lower in unmethylated BNIP3 CRCs ( P = 0.004). It appears that wild-type TP53 in CRC cells favours the progression of tumours expressing markers for hypoxia in their stroma, rather than in the epithelial compartment. Preserved BNIP3 function in CRC cells lowers apoptosis, and may thus be involved in alternative cell death pathways, such as autophagic cell death. However, BNIP3 silencing in tumour cells does not impact on hypoxia-driven poorer prognosis. These results suggest that the biology of CRC cells can be modified by alterations in the tumour microenvironment under conditions of tumour hypoxia.
C1 [Cleven, A. H. G.; Spiertz, A. J. G.; van Engeland, M.; de Bruine, A. P.] Univ Hosp, Dept Pathol, GROW Sch Oncol & Dev Biol, NL-6202 AZ Maastricht, Netherlands.
   [Wouters, B. G.] Ontario Canc Inst, PMH, Toronto, ON M4X 1K9, Canada.
   [Schutte, B.] Univ Hosp, Dept Mol Cell Biol, GROW Sch Oncol & Dev Biol, NL-6202 AZ Maastricht, Netherlands.
RP de Bruine, AP (corresponding author), Univ Hosp, Dept Pathol, GROW Sch Oncol & Dev Biol, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM adb@lpat.azm.nl
RI Wouters, Bradly/T-1525-2017; van Engeland, Manon/A-7479-2009
OI Wouters, Bradly/0000-0002-8187-592X; van Engeland,
   Manon/0000-0002-7952-6843
CR Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231
   Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720
   Borresen-Dale AL, 1998, CLIN CANCER RES, V4, P203
   Brahimi-Horn Christiane, 2006, Bull Cancer, V93, pE73
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cleven AHG, 2007, CELL ONCOL, V29, P229
   Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514
   CRIPPS KJ, 1994, ONCOGENE, V9, P2739
   de Bruin EC, 2006, CLIN CANCER RES, V12, P6432, DOI 10.1158/1078-0432.CCR-06-0231
   Derks S, 2004, CELL ONCOL, V26, P291
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Garrity MM, 2004, J CLIN ONCOL, V22, P1572, DOI 10.1200/JCO.2004.10.042
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0
   Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jessup J, 1997, ARCH SURG-CHICAGO, V132, P374
   Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Kressner U, 1999, J CLIN ONCOL, V17, P593, DOI 10.1200/JCO.1999.17.2.593
   Lee H, 2006, MOL CELLS, V21, P1
   Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J
   Lu XG, 2006, CLIN COLORECTAL CANC, V5, P350, DOI 10.3816/CCC.2006.n.005
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Marijnen CAM, 2003, INT J RADIAT ONCOL, V57, P434, DOI 10.1016/S0360-3016(03)00580-7
   Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0
   Mollevi DG, 2007, CARCINOGENESIS, V28, P1241, DOI 10.1093/carcin/bgm012
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089
   Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657
   Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395
   Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
   Pricolo VE, 1997, ARCH SURG-CHICAGO, V132, P371
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845
   Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190
   Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0
   Tang RP, 2004, CANCER LETT, V210, P101, DOI 10.1016/j.canlet.2004.01.006
   Theodoropoulos GE, 2006, INT J COLORECTAL DIS, V21, P248, DOI 10.1007/s00384-005-0788-4
   Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012
   Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375
   Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06
   Ueno T, 2005, BIOMED PHARMACOTHER, V59, pS359, DOI 10.1016/S0753-3322(05)80078-2
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   WIGGERS T, 1988, BRIT J SURG, V75, P409, DOI 10.1002/bjs.1800750505
   Yan J, 2006, BIOCHEM BIOPH RES CO, V346, P501, DOI 10.1016/j.bbrc.2006.05.160
   Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03
NR 50
TC 12
Z9 13
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG
PY 2008
VL 99
IS 5
BP 727
EP 733
DI 10.1038/sj.bjc.6604547
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 341NB
UT WOS:000258720100009
PM 18728663
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Yan, SY
   Zhou, N
   Zhang, DR
   Zhang, KL
   Zheng, WN
   Bao, YH
   Yang, WC
AF Yan, Siyuan
   Zhou, Nan
   Zhang, Deru
   Zhang, Kaile
   Zheng, Wenao
   Bao, Yonghua
   Yang, Wancai
TI PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances
   Its Cytotoxicity in Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE PFKFB3; Oxaliplatin; autophagy; colorectal cancer; proliferation
ID DOUBLE-EDGED-SWORD; COLORECTAL-CANCER; APOPTOSIS; GLYCOLYSIS;
   RESISTANCE; PHOSPHORYLATION; NORMALIZATION; STATISTICS; REDUCTION
AB 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3), a glycolytic enzyme highly expressed in cancer cells, has been reported to participate in regulating metabolism, angiogenesis, and autophagy. Although anti-cancer drug oxaliplatin (Oxa) effectively inhibits cell proliferation and induces apoptosis, the growing resistance and side-effects make it urgent to improve the therapeutic strategy of Oxa. Although Oxa induces the autophagy process, the role of PFKFB3 in this process remains unknown. In addition, whether PFKFB3 affects the cytotoxicity of Oxa has not been investigated. Here, we show that Oxa-inhibited cell proliferation and migration concomitant with the induction of apoptosis and autophagy in SW480 cells. Both inhibition of autophagy by small molecule inhibitors and siRNA modification decreased the cell viability loss and apoptosis induced by Oxa. Utilizing quantitative PCR and immunoblotting, we observed that Oxa increased PFKFB3 expression in a time- and dose-dependent manner. Meanwhile, suppression of PFKFB3 attenuated both the basal and Oxa-induced autophagy, by monitoring the autophagic flux and phosphorylated-Ulk1, which play essential roles in autophagy initiation. Moreover, PFKFB3 inhibition further inhibited the cell proliferation/migration, and cell viability decreased by Oxa. Collectively, the presented data demonstrated that PFKFB3 inhibition attenuated Oxa-induced autophagy and enhanced its cytotoxicity in colorectal cancer cells.
C1 [Yan, Siyuan; Zhou, Nan; Zhang, Deru; Zhang, Kaile; Zheng, Wenao; Bao, Yonghua; Yang, Wancai] Jining Med Univ, Key Lab Precis Oncol Shandong Higher Educ, Inst Precis Med, Jining 272067, Peoples R China.
   [Yang, Wancai] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
RP Yan, SY; Yang, WC (corresponding author), Jining Med Univ, Key Lab Precis Oncol Shandong Higher Educ, Inst Precis Med, Jining 272067, Peoples R China.; Yang, WC (corresponding author), Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
EM yansy@mail.jnmc.edu.cn; zhounanzn720@163.com; zhangdr2613@163.com;
   zhangkaile1315@163.com; zwa2019med@163.com; baoyonghua2005@126.com;
   wyang06@uic.edu
OI Yang, Wancai/0000-0001-7437-9197
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31801169]; Teacher Research Support
   Foundation in Jining medical university [JYFC2018KJ065]; Faculty
   Start-up Funds of Jining Medical University
FX This work was supported by grants from the National Natural Science
   Foundation of China (31801169 to Yan S.), the Teacher Research Support
   Foundation in Jining medical university (JYFC2018KJ065 to Yan S.), and
   the Faculty Start-up Funds of Jining Medical University (to Yan S.).
CR Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bhattacharya SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1916-3
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997
   Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006
   Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   Du ZG, 2018, CELL REP, V22, P2677, DOI 10.1016/j.celrep.2018.02.037
   Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Fang C, 2017, CANCER MED-US, V6, P2850, DOI 10.1002/cam4.1241
   Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kumar Priyank, 2012, Cells, V1, P558, DOI 10.3390/cells1030558
   Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li SN, 2017, INT J CANCER, V141, P2571, DOI 10.1002/ijc.31022
   Lin GL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185625
   Lu Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.344
   Lu WQ, 2017, ONCOTARGET, V8, P44171, DOI 10.18632/oncotarget.17396
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868
   Mou JJ, 2018, BIOMED PHARMACOTHER, V103, P729, DOI 10.1016/j.biopha.2018.04.099
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8
   Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Wang CH, 2018, INT J MOL MED, V42, P359, DOI 10.3892/ijmm.2018.3599
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xu YM, 2014, ARTERIOSCL THROM VAS, V34, P1231, DOI 10.1161/ATVBAHA.113.303041
   Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816
   Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480
   Yan S, 2014, CANCER GENE THER, V21, P188, DOI 10.1038/cgt.2014.16
   Yan SY, 2017, ONCOTARGET, V8, P80909, DOI 10.18632/oncotarget.20757
   Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
NR 43
TC 21
Z9 21
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 21
AR 5415
DI 10.3390/ijms20215415
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JQ4VU
UT WOS:000498946100173
PM 31671668
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lai, M
   Amato, R
   La Rocca, V
   Bilgin, M
   Freer, G
   Spezia, P
   Quaranta, P
   Piomelli, D
   Pistello, M
AF Lai, Michele
   Amato, Rachele
   La Rocca, Veronica
   Bilgin, Mesut
   Freer, Giulia
   Spezia, Piergiorgio
   Quaranta, Paola
   Piomelli, Daniele
   Pistello, Mauro
TI Acid ceramidase controls apoptosis and increases autophagy in human
   melanoma cells treated with doxorubicin
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LONG-CHAIN CERAMIDES; COLON-CANCER CELLS; UP-REGULATION; SPHINGOSINE;
   INHIBITION; DEFICIENCY; TARGET; SPHINGOLIPIDS; MECHANISMS; EXPRESSION
AB Acid ceramidase (AC) is a lysosomal hydrolase encoded by the ASAH1 gene, which cleaves ceramides into sphingosine and fatty acid. AC is expressed at high levels in most human melanoma cell lines and may confer resistance against chemotherapeutic agents. One such agent, doxorubicin, was shown to increase ceramide levels in melanoma cells. Ceramides contribute to the regulation of autophagy and apoptosis. Here we investigated the impact of AC ablation via CRISPR-Cas9 gene editing on the response of A375 melanoma cells to doxorubicin. We found that doxorubicin activates the autophagic response in wild-type A375 cells, which effectively resist apoptotic cell death. In striking contrast, doxorubicin fails to stimulate autophagy in A375 AC-null cells, which rapidly undergo apoptosis when exposed to the drug. The present work highlights changes that affect melanoma cells during incubation with doxorubicin, in A375 melanoma cells lacking AC. We found that the remarkable reduction in recovery rate after doxorubicin treatment is strictly associated with the impairment of autophagy, that forces the AC-inhibited cells into apoptotic path.
C1 [Lai, Michele; Freer, Giulia; Spezia, Piergiorgio; Quaranta, Paola; Pistello, Mauro] Univ Pisa, Retrovirus Ctr, Dept Translat Med & New Technol Med & Surg, Pisa, Italy.
   [Amato, Rachele; La Rocca, Veronica] Scuola St Anna Pisa, Inst Life Sci, Pisa, Italy.
   [Bilgin, Mesut] Danish Canc Soc Res Ctr, Ctr Autophagy Recycling & Dis, Cell Death & Metab Unit, Copenhagen, Denmark.
   [Piomelli, Daniele] Univ Calif Irvine, Anat & Neurobiol, Irvine, CA 92717 USA.
   [Pistello, Mauro] Pisa Univ Hosp, Virol Unit, Pisa, Italy.
RP Lai, M (corresponding author), Univ Pisa, Retrovirus Ctr, Dept Translat Med & New Technol Med & Surg, Pisa, Italy.
EM michele.lai@unipi.it
RI Lai, Michele/AAO-3499-2021; Pistello, Mauro/AAD-4214-2022
OI Lai, Michele/0000-0001-7597-123X; 
FU "I-GENE, In-vivo Gene Editing by Nanotransducers", European call
   identifier H2020-FETOPEN-2018-2020 [862714]
FX This research was funded by "I-GENE, In-vivo Gene Editing by
   Nanotransducers", European call identifier H2020-FETOPEN-2018-2020,
   Proposal ID 862714.
CR Aflaki E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.17
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248
   Barpe DR, 2010, EUR J PHARM SCI, V41, P458, DOI 10.1016/j.ejps.2010.07.015
   Bedia C, 2011, J BIOL CHEM, V286, P28200, DOI 10.1074/jbc.M110.216382
   Bratton DL, 2011, TRENDS IMMUNOL, V32, P350, DOI 10.1016/j.it.2011.04.009
   Chang MC, 2017, ONCOTARGET, V8, P106177, DOI 10.18632/oncotarget.22425
   Chen SA, 2014, MOL CELL BIOL, V34, P3435, DOI 10.1128/MCB.01383-13
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793
   del Solar V, 2015, CHEM BIOL, V22, P1662, DOI 10.1016/j.chembiol.2015.11.004
   Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X
   Doan NB, 2017, ONCOTARGET, V8, P112662, DOI 10.18632/oncotarget.22637
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fujimura T, 2020, LIFE-BASEL, V10, DOI 10.3390/life10090208
   Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208
   Gebai A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03844-2
   Grosch S, 2012, PROG LIPID RES, V51, P50, DOI 10.1016/j.plipres.2011.11.001
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hartmann D, 2013, INT J BIOCHEM CELL B, V45, P1195, DOI 10.1016/j.biocel.2013.03.012
   Hu W, 2010, J BIOL CHEM, V285, P7964, DOI 10.1074/jbc.M109.063586
   Kakisaka K, 2012, AM J PHYSIOL-GASTR L, V302, pG77, DOI 10.1152/ajpgi.00301.2011
   Klionsky DJ, 2021, AUTOPHAGY, V17, P1, DOI 10.1080/15548627.2020.1797280
   Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200
   Lai M., 2017, Sci. Rep, V7, P1, DOI 10.1038/s41598-016-0028-x
   Lai M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063247
   Lai M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143436
   LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001
   Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7
   Lepine S, 2011, J BIOL CHEM, V286, P44380, DOI 10.1074/jbc.M111.257519
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liu FY, 2016, ONCOTARGET, V7, P83907, DOI 10.18632/oncotarget.13438
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Liu X, 2008, FRONT BIOSCI-LANDMRK, V13, P2293, DOI 10.2741/2843
   Mahdy AEM, 2009, MOL THER, V17, P430, DOI 10.1038/mt.2008.281
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ndoye A., 2016, F1000RESEARCH, P5
   Nielsen IO, 2017, METHODS MOL BIOL, V1609, P123, DOI 10.1007/978-1-4939-6996-8_12
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Para C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030616
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Realini N, 2016, J BIOL CHEM, V291, P2422, DOI 10.1074/jbc.M115.666909
   Realini N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01035
   Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034
   Schiffmann S, 2009, CARCINOGENESIS, V30, P745, DOI 10.1093/carcin/bgp061
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200
   Snider JM, 2019, J LIPID RES, V60, P819, DOI 10.1194/jlr.M089714
   Stiban J, 2015, BBA-BIOMEMBRANES, V1848, P561, DOI 10.1016/j.bbamem.2014.11.018
   Su X, 2015, NANOMEDICINE-UK, V10, P2033, DOI [10.2217/nnm.15.50, 10.2217/NNM.15.50]
   SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100
   Sun W, 2008, J INVEST DERMATOL, V128, P389, DOI 10.1038/sj.jid.5701025
   Sun Y, 2013, AUTOPHAGY, V9, P1115, DOI 10.4161/auto.24919
   Tan SF, 2017, EXPERT OPIN THER TAR, V21, P583, DOI 10.1080/14728222.2017.1322065
   Turner L., 2009, ABSTRACT 379 EFFECTS
   Turner LS, 2011, PROSTATE CANCER P D, V14, P30, DOI 10.1038/pcan.2010.47
   Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118
   Xu RJ, 2016, ONCOTARGET, V7, P18440, DOI 10.18632/oncotarget.7825
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhou J, 2012, AM J HUM GENET, V91, P5, DOI 10.1016/j.ajhg.2012.05.001
NR 62
TC 6
Z9 6
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 27
PY 2021
VL 11
IS 1
AR 11221
DI 10.1038/s41598-021-90219-1
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SN6IL
UT WOS:000658391200051
PM 34045496
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Feng, Y
   Gao, SH
   Gao, YJ
   Wang, XF
   Chen, Z
AF Feng, Ye
   Gao, Shuohui
   Gao, Yongjian
   Wang, Xuefeng
   Chen, Zhi
TI Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to
   Fluorouracil-induced apoptosis by affecting autophagy
SO ONCOTARGET
LA English
DT Article
DE colorectal carcinoma (CRC); cancer stem cells (CSCs); CD133; CD44; EphB2
ID RECEPTOR MONOCLONAL-ANTIBODIES; RECTAL-CANCER; MARKERS CD133;
   SKIN-CANCER; CD44; EXPRESSION; DISEASE; CRC; 5-FLUOROURACIL; BIOMARKERS
AB Recent reports suggest that colorectal carcinoma (CRC) may be sustained by a small subpopulation of cells, termed cancer stem cells (CSCs), which have drug resistance properties as a key reason for chemotherapy failure. The epidermal growth factor receptor (EGFR) controls CRC initiation and progression. Monoclonal antibody against EGFR (cetuximab) has been used in treatment of several cancers. However, the effects of cetuximab on CSCs in the CRC chemotherapy remain unclear. Here, we studied the effects of cetuximab on the CSC-like cells in Fluorouracil (5-FU)-treated CRC cells. CSC-like cells were independently isolated from CRC cells using CD133, CD44 or EphB2-high as markers and confirmed by tumor sphere formation assay. We found that 5-FU increased the apoptotic death of CSC-like CRC cells. Co-application of cetuximab augmented the apoptotic death of CSC-like CRC cells by 5-FU, seemingly through inhibition of 5-FU-induced increases in cell autophagy in CSC-like CRC cells. Together, our data suggest that EGFR monoclonal antibody may sensitize CSC-like CRC cells to 5-FU-induced apoptosis by affecting autophagy.
C1 [Feng, Ye; Gao, Shuohui; Gao, Yongjian; Wang, Xuefeng] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, Changchun 130033, Peoples R China.
   [Chen, Zhi] Jilin Univ, Hosp 1, Dept Nephrol, Changchun 130021, Peoples R China.
RP Chen, Z (corresponding author), Jilin Univ, Hosp 1, Dept Nephrol, Changchun 130021, Peoples R China.
EM Fengye0431@163.com
FU Jilin Province Natural Science Foundation of China [20160101115JC];
   Provincal Funds for Health Service of Jilin
FX This study was supported by Jilin Province Natural Science Foundation of
   China 20160101115JC, and the Provincal Funds for Health Service of
   Jilin.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   East JE, 2013, NAT REV GASTRO HEPAT, V10, P69, DOI 10.1038/nrgastro.2012.245
   Elsaba TMA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010714
   Galizia G, 2012, ARCH SURG-CHICAGO, V147, P18, DOI 10.1001/archsurg.2011.795
   Garza-Trevino EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Horst D, 2008, BRIT J CANCER, V99, P1285, DOI 10.1038/sj.bjc.6604664
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Huang XD, 2012, SURG ONCOL, V21, P103, DOI 10.1016/j.suronc.2011.06.001
   Humeniuk R, 2009, MOL CANCER THER, V8, P1045, DOI 10.1158/1535-7163.MCT-08-0717
   Jean GW, 2008, PHARMACOTHERAPY, V28, P742, DOI 10.1592/phco.28.6.742
   Jones C, 2013, HPB, V15, P11, DOI 10.1111/j.1477-2574.2012.00591.x
   Labianca R, 2005, ANN ONCOL, V16, P37, DOI 10.1093/annonc/mdi906
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Nagata T, 2011, ANTICANCER RES, V31, P495
   Ou JJ, 2013, STEM CELL RES, V11, P820, DOI 10.1016/j.scr.2013.05.009
   Patel DK, 2008, PHARMACOTHERAPY, V28, p31S, DOI 10.1592/phco.28.11-supp.31S
   Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095
   Petersson M, 2012, CURR MED CHEM, V19, P5984
   Pitule P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/432139
   Schulenburg A, 2007, J PATHOL, V213, P152, DOI 10.1002/path.2220
   Singh SR, 2012, CURR MED CHEM, V19, P5965
   Singh SK, 2003, CANCER RES, V63, P5821
   Srimuangwong K, 2012, WORLD J GASTROENTERO, V18, P2383, DOI 10.3748/wjg.v18.i19.2383
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   von Kleist S, 1975, J Natl Cancer Inst, V55, P555
   Wang CX, 2012, ONCOL REP, V28, P1301, DOI 10.3892/or.2012.1951
   Wang Q, 2009, HISTOPATHOLOGY, V55, P284, DOI 10.1111/j.1365-2559.2009.03378.x
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2
   Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940
   Zhang XX, 2011, PROTEIN CELL, V2, P347, DOI 10.1007/s13238-011-1058-6
NR 38
TC 8
Z9 10
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 6
PY 2016
VL 7
IS 49
BP 81402
EP 81409
DI 10.18632/oncotarget.13233
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE8LO
UT WOS:000389877500104
PM 27833077
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Kwon, J
   Lee, Y
   Jeong, JH
   Ryu, JH
   Kim, KI
AF Kwon, Junhee
   Lee, Yunkyeong
   Jeong, Ji Hye
   Ryu, Jae-Ha
   Kim, Keun Il
TI Inhibition of autophagy sensitizes lignan-induced endoplasmic reticulum
   stress-mediated cell death
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DFS; Autophagy; ER stress; AMPK signaling; TFEB; Cell death
ID ER STRESS; AMPK; COMPONENTS; ACTIVATION; PROTEIN; TFEB
AB Relationship between autophagy and endoplasmic reticulum (ER) stress and their application to treat cancer have been actively studied these days. Recently, a lignan [(-)-(2R, 3R)-1,4-O-diferuloylsecoisolariciresinol, DFS] from Alnus japonica has been found to reduce the viability of colon cancer cells. In this study, we have observed DFS-induced autophagy in a variety of cancer cell lines. In addition, DFS led to ER stress, based on the activation of unfolded protein response (UPR) transducers and an elevated expression of UPR target genes in prostate and colon cancer cells. Further investigation has shown that DFS triggered the activation of AMP-activated protein kinase (AMPK) signaling and nuclear translocation of transcription factor EB (TFEB). Furthermore, the cytotoxicity of DFS was potentiated by the co-treatment of autophagy inhibitor in these cancer cells. This study has provided a noble implication that the combination of DFS and autophagy inhibition exerts a synergistic effect in cancer treatment. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Kwon, Junhee; Lee, Yunkyeong; Kim, Keun Il] Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea.
   [Kwon, Junhee; Lee, Yunkyeong; Kim, Keun Il] Sookmyung Womens Univ, Cellular Heterogene Res Ctr, Seoul 04310, South Korea.
   [Kwon, Junhee; Lee, Yunkyeong; Kim, Keun Il] Sookmyung Womens Univ, Res Inst Womens Hlth, Seoul 04310, South Korea.
   [Jeong, Ji Hye; Ryu, Jae-Ha] Sookmyung Womens Univ, Res Ctr Cell Fate Control, Seoul 04310, South Korea.
   [Jeong, Ji Hye; Ryu, Jae-Ha] Sookmyung Womens Univ, Coll Pharm, Seoul 04310, South Korea.
RP Kim, KI (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea.; Ryu, JH (corresponding author), Sookmyung Womens Univ, Coll Pharm, Seoul 04310, South Korea.
EM ryuha@sookmyung.ac.kr; kikim@sookmyung.ac.kr
RI KIM, KEUN IL/D-2959-2011
OI Lee, Yunkyeong/0000-0001-9617-4520
FU National Research Foundation of Korea (NRF) - Korean Government (MSIP)
   [20110030074]
FX We thank Professor T. Yoshimori (Department of Genetics, Graduate School
   of Medicine, Osaka University, Japan) for kindly providing mRFP-GFP-LC3
   expressing plasmid, and Atg5 wild-type and knockout mouse embryonic
   fibroblasts (MEFs). The present study was supported by the National
   Research Foundation of Korea (NRF) Grant funded by the Korean Government
   (MSIP) (No. 20110030074).
CR Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Das G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008813
   Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4
   Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x
   Dong GZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45951
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Lin T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020409
   Liu N, 2016, J BACTERIOL, V198, P986, DOI 10.1128/JB.00868-15
   Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428
   Meares GP, 2011, MOL CELL BIOL, V31, P4286, DOI 10.1128/MCB.05668-11
   Mercer TJ, 2018, J BIOL CHEM, V293, P5386, DOI 10.1074/jbc.R117.810366
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   NOMURA M, 1975, J CHEM SOC CHEM COMM, P316, DOI 10.1039/c39750000316
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tsuru A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24217
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yan JM, 2013, CANCER CHEMOTH PHARM, V72, P799, DOI 10.1007/s00280-013-2255-1
   Ye X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02334
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 32
TC 3
Z9 3
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 28
PY 2020
VL 526
IS 2
BP 300
EP 305
DI 10.1016/j.bbrc.2020.03.081
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA LJ2XE
UT WOS:000530031800004
PM 32209256
DA 2022-04-25
ER

PT J
AU Gozuacik, D
   Akkoc, Y
   Ozturk, DG
   Kocak, M
   Agostinis, P
AF Gozuacik, Devrim
   Akkoc, Yunus
   Ozturk, Deniz Gulfem
   Kocak, Muhammed
   Agostinis, Patrizia
TI Autophagy-Regulating microRNAs and Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE autophagy; microRNA; post-transcriptional control; cancer growth;
   metastasis; chemotherapy; radiotherapy; biomarker
ID CELL LUNG-CANCER; HEPATOCELLULAR-CARCINOMA CELLS; STARVATION-INDUCED
   AUTOPHAGY; CISPLATIN-INDUCED APOPTOSIS; DOWN-REGULATION CONTRIBUTES;
   HYPOXIA-INDUCED AUTOPHAGY; BREAST-CANCER; COLON-CANCER; SELECTIVE
   AUTOPHAGY; INHIBITS AUTOPHAGY
AB Macroautophagy (autophagy herein) is a cellular stress response and a survival pathway that is responsible for the degradation of long-lived proteins, protein aggregates, as well as damaged organelles in order to maintain cellular homeostasis. Consequently, abnormalities of autophagy are associated with a number of diseases, including Alzheimers's disease, Parkinson's disease, and cancer. According to the current view, autophagy seems to serve as a tumor suppressor in the early phases of cancer formation, yet in later phases, autophagy may support and/or facilitate tumor growth, spread, and contribute to treatment resistance. Therefore, autophagy is considered as a stage-dependent dual player in cancer. microRNAs (miRNAs) are endogenous non-coding small RNAs that negatively regulate gene expression at a post-transcriptional level. miRNAs control several fundamental biological processes, and autophagy is no exception. Furthermore, accumulating data in the literature indicate that dysregulation of miRNA expression contribute to the mechanisms of cancer formation, invasion, metastasis, and affect responses to chemotherapy or radiotherapy. Therefore, considering the importance of autophagy for cancer biology, study of autophagy-regulating miRNA in cancer will allow a better understanding of malignancies and lead to the development of novel disease markers and therapeutic strategies. The potential to provide study of some of these cancer-related miRNAs were also implicated in autophagy regulation. In this review, we will focus on autophagy, miRNA, and cancer connection, and discuss its implications for cancer biology and cancer treatment.
C1 [Gozuacik, Devrim; Akkoc, Yunus; Ozturk, Deniz Gulfem; Kocak, Muhammed; Agostinis, Patrizia] Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Gent & Bioengn Program, Istanbul, Turkey.
   [Gozuacik, Devrim] Sabanci Univ, EFSUN, Istanbul, Turkey.
RP Gozuacik, D (corresponding author), Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Gent & Bioengn Program, Istanbul, Turkey.
EM dgozuacik@sabanciuniv.edu
RI Agostinis, Patrizia/ABI-1177-2020; Agostinis, Patrizia/AAO-2468-2020;
   AKKOC, Yunus/AAK-8853-2020; Devrim, Gozuacik/C-3330-2008; Öztürk, Deniz
   Gülfem/AAH-5404-2019
OI Agostinis, Patrizia/0000-0003-1314-2115; AKKOC,
   Yunus/0000-0001-5379-6151; Devrim, Gozuacik/0000-0001-7739-2346; Öztürk,
   Deniz Gülfem/0000-0002-2514-126X
FU European Union COST Action Transautophagy [CA15138]; Scientific and
   Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve
   Teknolojik Arastirma Kurumu (TUBITAK) [114Z241, 114Z982];
   TUBITAK-BIDEBTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
FX This work was supported by the European Union COST Action Transautophagy
   (CA15138) and The Scientific and Technological Research Council of
   Turkey (TUBITAK) 1001 project numbers 114Z241 and 114Z982. YA is
   supported by a TUBITAK-BIDEB 2211 scholarship for Ph. D. studies.
CR Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amodio N, 2016, MOL CANCER THER, V15, P1364, DOI [10.1158/1535-7163.MCT-15-0985-T, 10.1158/1535-7163.MCT-15-0985]
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bader AG, 2011, GENE THER, V18, P1121, DOI 10.1038/gt.2011.79
   Bao L, 2016, DNA CELL BIOL, V35, P385, DOI 10.1089/dna.2016.3259
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048
   Bhattacharya A, 2015, ONCOTARGET, V6, P2966, DOI 10.18632/oncotarget.3070
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167
   Brigger D, 2013, BIOCHEM BIOPH RES CO, V438, P283, DOI 10.1016/j.bbrc.2013.07.056
   Burke JM, 2014, RNA, V20, P1068, DOI 10.1261/rna.044537.114
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen C, 2016, CANCER MED-US, V5, P3489, DOI 10.1002/cam4.863
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen K, 2012, BIOCHEM BIOPH RES CO, V427, P138, DOI 10.1016/j.bbrc.2012.09.026
   Chen P, 2016, AM J CANCER RES, V6, P2010
   Chen SS, 2015, CELL PHYSIOL BIOCHEM, V35, P997, DOI 10.1159/000369755
   Chen X, 2016, ONCOTARGET, V7, P9222, DOI 10.18632/oncotarget.7003
   Chen YS, 2011, DIS ESOPHAGUS, V24, P437, DOI 10.1111/j.1442-2050.2010.01156.x
   Chen Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11035
   Chen Yong, 2012, Sci Rep, V2, P808, DOI 10.1038/srep00808
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choudhury S, 2013, CELL CYCLE, V12, P1022, DOI 10.4161/cc.24128
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597
   Dai FR, 2014, HUM PATHOL, V45, P1285, DOI 10.1016/j.humpath.2014.02.008
   De N, 2011, METHODS MOL BIOL, V725, P107, DOI 10.1007/978-1-61779-046-1_8
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201
   Du FJ, 2015, BIOMED PHARMACOTHER, V74, P169, DOI 10.1016/j.biopha.2015.08.005
   Duan XG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138011
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Eberhart K, 2014, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 1: MOLECULAR MECHANISMS, P179, DOI 10.1016/B978-0-12-405530-8.00013-3
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Fang C, 2012, ANN HEMATOL, V91, P553, DOI 10.1007/s00277-011-1350-9
   Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576
   Feng LF, 2014, AUTOPHAGY, V10, P1442, DOI 10.4161/auto.29486
   Feng Y, 2012, RNA, V18, P2083, DOI 10.1261/rna.033688.112
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P1164, DOI 10.1002/mc.22582
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fujiwara N, 2015, CANCER RES, V75, P3890, DOI 10.1158/0008-5472.CAN-15-0257
   Fujiya M, 2014, ONCOGENE, V33, P4847, DOI 10.1038/onc.2013.429
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371
   Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568
   Gasparini P, 2014, ONCOTARGET, V5, P1174, DOI 10.18632/oncotarget.1682
   Ge YY, 2014, ONCOTARGET, V5, P6218, DOI 10.18632/oncotarget.2189
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Goussetis DJ, 2012, BLOOD, V120, P3555, DOI 10.1182/blood-2012-01-402578
   Gozuacik D, 2008, CELL DEATH DIFFER, V15, P1875, DOI 10.1038/cdd.2008.121
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Gu H, 2016, CANCER MED-US, V5, P1174, DOI 10.1002/cam4.664
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Gundara JS, 2015, CANCER MED-US, V4, P174, DOI 10.1002/cam4.355
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo J, 2016, AM J PHYSIOL-ENDOC M, V310, pE734, DOI 10.1152/ajpendo.00444.2015
   Guo S, 2016, J INVEST DERMATOL, V136, P985, DOI 10.1016/j.jid.2015.12.041
   Guo SB, 2014, TUMOR BIOL, V35, P7025, DOI 10.1007/s13277-014-1965-2
   Guo X, 2015, ONCOTARGET, V6, P41620, DOI 10.18632/oncotarget.5871
   Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hammond SM, 2005, FEBS LETT, V579, P5822, DOI 10.1016/j.febslet.2005.08.079
   Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   Hasei J, 2013, MOL CANCER THER, V12, P314, DOI 10.1158/1535-7163.MCT-12-0869
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Hu LL, 2016, INT J ONCOL, V49, P2217, DOI 10.3892/ijo.2016.3719
   Huang DQ, 2015, ONCOTARGET, V6, P9257, DOI 10.18632/oncotarget.3288
   Huang NN, 2015, CANCER BIOL THER, V16, P941, DOI 10.1080/15384047.2015.1040963
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040
   Jagannathan S, 2015, LEUKEMIA, V29, P727, DOI 10.1038/leu.2014.279
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104
   Kaddar T, 2009, LEUKEMIA RES, V33, P1217, DOI 10.1016/j.leukres.2008.12.015
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kim KW, 2013, AUTOPHAGY, V9, P1579, DOI 10.4161/auto.25987
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Kim Y, 2015, AUTOPHAGY, V11, P796, DOI 10.1080/15548627.2015.1035503
   Korac J, 2013, J CELL SCI, V126, P580, DOI 10.1242/jcs.114926
   Korkmaz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082556
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892
   Lamb Christopher A, 2016, Small GTPases, V7, P265
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x
   Lee CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007314
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044
   Li SS, 2016, CELL RES, V26, P511, DOI 10.1038/cr.2016.19
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liao HQ, 2015, ONCOL LETT, V10, P2055, DOI 10.3892/ol.2015.3551
   Link A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042933
   Liu FF, 2013, ONCOL LETT, V5, P1261, DOI 10.3892/ol.2013.1154
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Liu XD, 2015, ONCOGENE, V34, P2450, DOI 10.1038/onc.2014.199
   Liu ZR, 2016, LIFE SCI, V149, P104, DOI 10.1016/j.lfs.2016.02.059
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lozupone F, 2015, ONCOGENE, V34, P5163, DOI 10.1038/onc.2014.437
   Lu Z, 2014, AUTOPHAGY, V10, P1071, DOI 10.4161/auto.28577
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo M, 2015, INT J CLIN EXP PATHO, V8, P5542
   Ma Y, 2013, MOL BIOL REP, V40, P469, DOI 10.1007/s11033-012-2082-1
   Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Macintosh RL, 2012, CELL CYCLE, V11, P2022, DOI 10.4161/cc.20424
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Marchesi N, 2014, J CELL PHYSIOL, V229, P1776, DOI 10.1002/jcp.24631
   Mari M, 2007, AUTOPHAGY, V3, P145, DOI 10.4161/auto.3608
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127
   Mathelier A, 2013, NUCLEIC ACIDS RES, V41, P4392, DOI 10.1093/nar/gkt112
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Meenhuis A, 2011, BLOOD, V118, P916, DOI 10.1182/blood-2011-02-336487
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mo JW, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160139
   Morgado AL, 2015, MOL NEUROBIOL, V51, P1168, DOI 10.1007/s12035-014-8794-6
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nowak J, 2009, MOL BIOL CELL, V20, P870, DOI 10.1091/mbc.E08-07-0671
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Okamura M, 2015, GENES-BASEL, V6, P124, DOI 10.3390/genes6010124
   Ono S, 2015, ONCOTARGET, V6, P7053, DOI 10.18632/oncotarget.3142
   Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040
   Overholtzer M, 2015, CURR MOL MED, V15, P802, DOI 10.2174/1566524015999151026143028
   Palumbo S, 2013, J CELL PHYSIOL, V228, P1, DOI 10.1002/jcp.24118
   Pan BZ, 2015, ONCOTARGET, V6, P32805, DOI 10.18632/oncotarget.5352
   Pan BZ, 2015, ONCOTARGET, V6, P317, DOI 10.18632/oncotarget.2787
   Pannuru P, 2014, CELL SIGNAL, V26, P2193, DOI 10.1016/j.cellsig.2014.06.014
   Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Peralta-Zaragoza O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2231-3
   Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Ran XM, 2015, INT J CLIN EXP PATHO, V8, P6617
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Ren WH, 2014, MOL CELL BIOCHEM, V390, P253, DOI 10.1007/s11010-014-1976-8
   Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Savad S, 2012, ASIAN PAC J CANCER P, V13, P873, DOI 10.7314/APJCP.2012.13.3.873
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004
   Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001
   Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085
   Sibony M, 2015, INFLAMM BOWEL DIS, V21, P2778, DOI 10.1097/MIB.0000000000000553
   Song LL, 2016, TUMOR BIOL, V37, P12161, DOI 10.1007/s13277-016-5073-3
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stojcheva N, 2016, ONCOTARGET, V7, P12937, DOI 10.18632/oncotarget.7346
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Sun KT, 2015, BONE, V73, P145, DOI 10.1016/j.bone.2014.11.026
   Sun QQ, 2015, MOL MED REP, V11, P3330, DOI 10.3892/mmr.2015.3221
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Tao J, 2015, NEUROSCIENCE, V305, P1, DOI 10.1016/j.neuroscience.2015.07.064
   Tazawa H, 2012, INT J CANCER, V131, P2939, DOI 10.1002/ijc.27589
   Tekirdag KA, 2016, HISTOL HISTOPATHOL, V31, P841, DOI 10.14670/HH-11-752
   Tekirdag KA, 2013, AUTOPHAGY, V9, P374, DOI 10.4161/auto.23117
   Tomasetti M, 2016, ONCOTARGET, V7, P36338, DOI 10.18632/oncotarget.8916
   Torisu T, 2013, NAT MED, V19, P1281, DOI 10.1038/nm.3288
   van Rooij E, 2009, DEV CELL, V17, P662, DOI 10.1016/j.devcel.2009.10.013
   Viry E, 2014, BIOCHEM PHARMACOL, V92, P31, DOI 10.1016/j.bcp.2014.07.006
   Voller D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161165
   von Muhlinen N, 2012, MOL CELL, V48, P329, DOI 10.1016/j.molcel.2012.08.024
   Wampfler J, 2015, J LEUKOCYTE BIOL, V98, P357, DOI 10.1189/jlb.1AB0514-258R
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang BY, 2016, AM J TRANSL RES, V8, P606
   Wang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep33229
   Wang K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7779
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642
   Wang W, 2016, EUR REV MED PHARMACO, V20, P92
   Wang Y, 2013, DIABETES, V62, P887, DOI 10.2337/db12-0451
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Watson AS, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.8
   Wei JL, 2015, MOL MED REP, V11, P571, DOI 10.3892/mmr.2014.2675
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002
   Wu D, 2013, INT J GYNECOL CANCER, V23, P1191, DOI 10.1097/IGC.0b013e31829ea779
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Xiao J, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-35
   Xiao JB, 2014, PLOS ONE, V9, DOI [10.1155/2014/584164, 10.1371/journal.pone.0089097, 10.1371/journal.pone.0093842]
   Xie MY, 2013, CELL, V155, P1568, DOI 10.1016/j.cell.2013.11.027
   Xie N, 2014, BIOCHEM PHARMACOL, V89, P74, DOI 10.1016/j.bcp.2014.02.019
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu QF, 2014, CLIN EXP PHARMACOL P, V41, P351, DOI 10.1111/1440-1681.12227
   Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Xu ZJ, 2015, ACTA BIOCH BIOPH SIN, V47, P571, DOI 10.1093/abbs/gmv055
   Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446
   Yang XJ, 2013, BIOCHEM BIOPH RES CO, V431, P617, DOI 10.1016/j.bbrc.2012.12.083
   Yi HQ, 2013, FEBS LETT, V587, P436, DOI 10.1016/j.febslet.2012.12.027
   Young ARJ, 2006, J CELL SCI, V119, P3888, DOI 10.1242/jcs.03172
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu XF, 2016, BIOMED PHARMACOTHER, V77, P37, DOI 10.1016/j.biopha.2015.11.005
   Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yu ZW, 2010, ORAL ONCOL, V46, P317, DOI 10.1016/j.oraloncology.2010.02.002
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeng CW, 2014, AUTOPHAGY, V10, P1726, DOI 10.4161/auto.29592
   Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491
   Zeng YC, 2015, J MOL NEUROSCI, V56, P815, DOI 10.1007/s12031-015-0514-9
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhai Z, 2013, INFLAMM BOWEL DIS, V19, P2295, DOI 10.1097/MIB.0b013e31829e71cf
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang JA, 2016, ONCOTARGET, V7, P37420, DOI 10.18632/oncotarget.9357
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zhang Y, 2014, ONCOTARGET, V5, P12291, DOI 10.18632/oncotarget.2577
   Zhang ZK, 2016, EURASIP J ADV SIG PR, DOI 10.1186/s13634-016-0309-3
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   Zhao RH, 2011, ONKOLOGIE, V34, P675, DOI 10.1159/000334552
   Zhao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120905
   Zheng B, 2012, ONCOGENE, V31, P4509, DOI 10.1038/onc.2011.581
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhou JH, 2015, EXP BIOL MED, V240, P867, DOI 10.1177/1535370214563893
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 259
TC 100
Z9 103
U1 4
U2 36
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 18
PY 2017
VL 7
AR 65
DI 10.3389/fonc.2017.00065
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES2OY
UT WOS:000399369000002
PM 28459042
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ratovitski, EA
AF Ratovitski, Edward A.
TI Tumor Protein (TP)-p53 Members as Regulators of Autophagy in Tumor Cells
   upon Marine Drug Exposure
SO MARINE DRUGS
LA English
DT Article
DE marine drugs; cancer; autophagy; p53 family members; transcription
ID BREAST-CANCER CELLS; TARGETING PATHWAYS; NATURAL-PRODUCTS; DNA-DAMAGE;
   P53 FAMILY; ANTICANCER; APOPTOSIS; DEATH; ACTIVATION; INDUCTION
AB Targeting autophagic pathways might play a critical role in designing novel chemotherapeutic approaches in the treatment of human cancers, and the prevention of tumor-derived chemoresistance. Marine compounds were found to decrease tumor cell growth in vitro and in vivo. Some of them were shown to induce autophagic flux in tumor cells. In this study, we observed that the selected marine life-derived compounds (Chromomycin A2, Psammaplin A, and Ilimaquinone) induce expression of several autophagic signaling intermediates in human squamous cell carcinoma, glioblastoma, and colorectal carcinoma cells in vitro through a transcriptional regulation by tumor protein (TP)-p53 family members. These conclusions were supported by specific qPCR expression analysis, luciferase reporter promoter assay, and chromatin immunoprecipitation of promoter sequences bound to the TP53 family proteins, and silencing of the TP53 members in tumor cells.
C1 [Ratovitski, Edward A.] Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Baltimore, MD 21231 USA.
RP Ratovitski, EA (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Baltimore, MD 21231 USA.
EM eratovi1@jhmi.edu
RI Dyshlovoy, Sergey A./B-3586-2013
OI Dyshlovoy, Sergey A./0000-0002-7155-9245
FU Flight Attendant Research Institutions grant [082469]
FX This study was supported in part by the Flight Attendant Research
   Institutions grant (#082469). E.A.R. is a Distinguished Professor of the
   Prometeo Project of the Secretariat for Higher Education, Science,
   Technology, and Innovation (SENESCYT) of the Republic of Ecuador.
CR Akl MR, 2015, MAR DRUGS, V13, P288, DOI 10.3390/md13010288
   Bailon-Moscoso N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136527
   Belaid A, 2015, CURR CANCER DRUG TAR, V15, P684, DOI 10.2174/156800961508151001102452
   Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cosway B, 2016, ORAL ONCOL, V54, P1, DOI 10.1016/j.oraloncology.2015.12.007
   Craig AL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-195
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Dyshlovoy SA, 2015, ONCOTARGET, V6, P17328, DOI 10.18632/oncotarget.4175
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Guerrero-Preston R., 2013, AUTOPHAGY CANC OTHER, V1, P251
   Guimaraes LA, 2014, MAR DRUGS, V12, P5839, DOI 10.3390/md12125839
   He Z, 2013, CELL DEATH DIFFER, V20, P1415, DOI 10.1038/cdd.2013.104
   Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2010, AGING-US, V2, P959, DOI 10.18632/aging.100249
   Jin SK, 2005, AUTOPHAGY, V1, P171, DOI 10.4161/auto.1.3.2051
   Kim TH, 2015, BBA-GEN SUBJECTS, V1850, P401, DOI 10.1016/j.bbagen.2014.11.007
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kundu S, 2014, INT J ONCOL, V45, P2331, DOI 10.3892/ijo.2014.2659
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Li J, 2010, J ASIAN NAT PROD RES, V12, P992, DOI 10.1080/10286020.2010.513034
   Lim CB, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-93
   Liu J, 2016, ADV CANCER RES, V130, P1, DOI 10.1016/bs.acr.2016.01.005
   Liu ZG, 2014, ANTI-CANCER AGENT ME, V14, P409, DOI 10.2174/187152061403140207163402
   Loughery J, 2014, NUCLEIC ACIDS RES, V42, P7664, DOI 10.1093/nar/gku501
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Mah LY, 2012, AUTOPHAGY, V8, P18, DOI 10.4161/auto.8.1.18077
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478
   Moussavou G, 2014, MAR DRUGS, V12, P4898, DOI 10.3390/md12094898
   Newman DJ, 2014, MAR DRUGS, V12, P255, DOI 10.3390/md12010255
   Pflaumf J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00285
   Ratovitski EA, 2013, CURR GENOMICS, V14, P441, DOI 10.2174/13892029113146660011
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Russo GL, 2014, MAR DRUGS, V12, P4069, DOI 10.3390/md12074069
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Vijayarathna Soundararajan, 2015, Asian Pac J Cancer Prev, V16, P6175
   Wang N., 2015, BIOMED RES INT, V2015
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Wang YX, 2015, TOXINS, V7, P3030, DOI 10.3390/toxins7083030
   White E., 2016, COLD SPRING HARB PER, V6
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242
   Zhang SF, 2014, ASIAN PAC J CANCER P, V15, P10557, DOI 10.7314/APJCP.2014.15.24.10557
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
NR 55
TC 22
Z9 22
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD AUG
PY 2016
VL 14
IS 8
AR 154
DI 10.3390/md14080154
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DV9TI
UT WOS:000383284700006
PM 27537898
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Chen, GY
   Chen, CL
   Tuan, HY
   Yuan, PX
   Li, KC
   Yang, HJ
   Hu, YC
AF Chen, Guan-Yu
   Chen, Chiu-Ling
   Tuan, Hsing-Yu
   Yuan, Pei-Xiang
   Li, Kuei-Chang
   Yang, Hong-Jie
   Hu, Yu-Chen
TI Graphene Oxide Triggers Toll-Like Receptors/Autophagy Responses In Vitro
   and Inhibits Tumor Growth In Vivo
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE graphene oxide; nanomaterials; autophagy; toll-like receptors; cancer
   therapy
ID PLURIPOTENT STEM-CELLS; BECLIN 1; TLR4-INDUCED AUTOPHAGY; SIGNALING
   PATHWAYS; INNATE IMMUNITY; CANCER-THERAPY; MACROPHAGES; ACTIVATION;
   RECEPTORS; NANOPARTICLES
AB Graphene oxide (GO) is a nanomaterial with burgeoning bioapplications, while autophagy is implicated in cancer therapy. Although induction of autophagy by nanomaterials is reported, the underlying signaling mechanism in cancer cells and how this implicates the potential of GO in cancer therapy remain obscure. Here, it is shown that GO itself can induce the toll-like receptors (TLRs) responses and autophagy in cancer cells and confer antitumor effects in mice. GO can be phagocytosed by CT26 colon cancer cells, simultaneously triggering autophagy as well as TLR-4 and TLR-9 signaling cascades. By dissecting the crosstalk between the TLRs and autophagy pathways, it is uncovered that the GO-activated autophagy is regulated through the myeloid differentiation primary response gene 88 (MyD88)- and TNF receptor-associated factor 6 (TRAF6)-associated TLR-4/9 signaling pathways. Injection of GO alone into immunocompetent mice bearing the CT26 colon tumors not only suppresses the tumor progression but also enhances cell death, autophagy, and immune responses within the tumor bed. These data altogether implicate the potential of GO as an effective nanomaterial for autophagy induction and cancer therapy.
C1 [Chen, Guan-Yu; Chen, Chiu-Ling; Tuan, Hsing-Yu; Yuan, Pei-Xiang; Li, Kuei-Chang; Yang, Hong-Jie; Hu, Yu-Chen] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
RP Hu, YC (corresponding author), Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
EM ychu@mx.nthu.edu.tw
OI Tuan, Hsing-Yu/0000-0003-2819-2270
FU National Tsing Hua University (Toward World-Class University Project)
   [102N2051E1]; National Tsing Hua University (NTHU-CGMH Joint Research
   Program) [102N2766E1]; National Science Council, TaiwanMinistry of
   Science and Technology, Taiwan [NSC 99-2221-E-007-025-MY3,
   101-2628-E-007-009-MY3, 101-2923-E-007-002-MY3]
FX The authors acknowledge the financial support from the National Tsing
   Hua University (Toward World-Class University Project 102N2051E1 and
   NTHU-CGMH Joint Research Program 102N2766E1) and National Science
   Council, Taiwan (NSC 99-2221-E-007-025-MY3, 101-2628-E-007-009-MY3, and
   101-2923-E-007-002-MY3). The authors also thank C.-S. Chiang and J-.C.
   Wu for providing cancer cells and Y.-C. Chao for TEM experiment.
CR Anand PK, 2011, J BIOL CHEM, V286, P42981, DOI 10.1074/jbc.M111.310599
   Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313
   Chen GY, 2012, BIOMATERIALS, V33, P418, DOI 10.1016/j.biomaterials.2011.09.071
   Chen GY, 2012, J VIROL, V86, P8041, DOI 10.1128/JVI.00808-12
   Chen GY, 2012, BIOMATERIALS, V33, P6559, DOI 10.1016/j.biomaterials.2012.05.064
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Feng LY, 2011, BIOMATERIALS, V32, P2930, DOI 10.1016/j.biomaterials.2011.01.002
   Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Into T, 2012, CELL SIGNAL, V24, P1150, DOI 10.1016/j.cellsig.2012.01.020
   Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li CG, 2009, J MOL CELL BIOL, V1, P37, DOI 10.1093/jmcb/mjp002
   Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]
   Fader CM, 2012, AUTOPHAGY, V8, P1741, DOI 10.4161/auto.21858
   Markovic ZM, 2012, BIOMATERIALS, V33, P7084, DOI 10.1016/j.biomaterials.2012.06.060
   Markovic ZM, 2011, BIOMATERIALS, V32, P1121, DOI 10.1016/j.biomaterials.2010.10.030
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Ng S, 2011, AUTOPHAGY, V7, P1173, DOI 10.4161/auto.7.10.16681
   Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036
   Ouyang DY, 2013, AUTOPHAGY, V9, P20, DOI 10.4161/auto.22397
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Paul PK, 2011, AUTOPHAGY, V7, P555, DOI 10.4161/auto.7.5.15102
   Petrovski G, 2011, AUTOPHAGY, V7, P321, DOI 10.4161/auto.7.3.14583
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Shi CS, 2010, AUTOPHAGY, V6, P986, DOI 10.4161/auto.6.7.13288
   Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751
   Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tsan MF, 2006, SEMIN CANCER BIOL, V16, P32, DOI 10.1016/j.semcancer.2005.07.004
   Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   Yano T, 2008, NAT IMMUNOL, V9, P908, DOI 10.1038/ni.1634
   Yue H, 2012, BIOMATERIALS, V33, P4013, DOI 10.1016/j.biomaterials.2012.02.021
   Zheng XT, 2012, MOL PHARMACEUT, V9, P615, DOI 10.1021/mp2005356
   Zhou HJ, 2012, BIOMATERIALS, V33, P6933, DOI 10.1016/j.biomaterials.2012.06.064
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
NR 43
TC 85
Z9 87
U1 3
U2 72
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD SEP
PY 2014
VL 3
IS 9
BP 1486
EP 1495
DI 10.1002/adhm.201300591
PG 10
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Science & Technology - Other Topics; Materials Science
GA AP2MY
UT WOS:000341907800018
PM 24652749
DA 2022-04-25
ER

PT J
AU Saiprasad, G
   Chitra, P
   Manikandan, R
   Sudhandiran, G
AF Saiprasad, Gowrikumar
   Chitra, Palanivel
   Manikandan, Ramar
   Sudhandiran, Ganapasam
TI Hesperidin induces apoptosis and triggers autophagic markers through
   inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian
   target of rapamycin and glycogen synthase kinase-3 beta signalling
   cascades in experimental colon carcinogenesis
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Colon cancer; Apoptosis; PI3K; Autophagy; mTOR; GSK-3 beta; Aurora-A
ID COLORECTAL-CANCER; CELL-SURVIVAL; ACTIVATION; PATHWAYS; CYCLE; P21; P53
AB Abnormalities in the homeostasis mechanisms involved in cell survival and apoptosis are contributing factors for colon carcinogenesis. Interventions of these mechanisms by pharmacologically safer agents gain predominance in colon cancer prevention. We previously reported the chemopreventive efficacy of hesperidin against colon carcinogenesis. In the present study, we aimed at investigating the potential of hesperidin over the abrogated Aurora-A coupled pro-survival phosphoinositide-3-kinase (PI3K)/Akt signalling cascades. Further, the role of hesperidin over apoptosis and mammalian target of rapamycin (mTOR) mediated autophagic responses were studied. Azoxymethane (AOM) induced mouse model of colon carcinogenesis was involved in this study. Hesperidin treatment was provided either in initiation/post-initiation mode respectively. Hesperidin significantly altered AOM mediated anti-apoptotic scenario by modulating Bax/Bcl-2 ratio together with enhanced cytochromec release and caspase-3, 9 activations. In addition, hesperidin enhanced p53-p21 axis with concomitant decrease in cell cycle regulator. Hesperidin treatment caused significant up-regulation of tumour suppressor phosphatase and tensin homologue (PTEN) with a reduction in the expression of AOM mediated p-PI3K and p-Akt. Additionally, hesperidin administration exhibited inhibition against p-mTOR expression which in turn led to stimulation of autophagic markers Beclin-1 and LC3-II. Aurora-A an upstream regulator of PI3K/Akt pathway was significantly inhibited by hesperidin. Furthermore, hesperidin administration restored glycogen synthase kinase-3 beta (GSK-3 beta) activity which in turn prevented the accumulation of oncoproteins beta-catenin, c-jun and c-myc. Taken together, hesperidin supplementation initiated apoptosis via targeted inhibition of constitutively activated Aurora-A mediated PI3K/Akt/GSK-3 beta and mTOR pathways coupled with autophagic stimulation against AOM induced colon carcinogenesis. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Saiprasad, Gowrikumar; Chitra, Palanivel; Sudhandiran, Ganapasam] Univ Madras, Dept Biochem, Cell Biol Lab, Madras 600025, Tamil Nadu, India.
   [Manikandan, Ramar] Univ Madras, Dept Zool, Madras 600025, Tamil Nadu, India.
RP Sudhandiran, G (corresponding author), Univ Madras, Dept Biochem, Cell Biol Lab, Guindy Campus, Madras 600025, Tamil Nadu, India.
EM sudhandiran@yahoo.com
RI Gowrikumar, Saiprasad/AAG-9611-2019; Sudhandiran, G/AAG-9967-2019;
   Ganapasam, Sudhandiran/AAD-4264-2021
OI Sudhandiran, G/0000-0003-0066-7801; 
FU University Grants Commission (UGC), New Delhi - IndiaUniversity Grants
   Commission, India
FX The first author G. Saiprasad thanks the University Grants Commission
   (UGC), New Delhi - India for the financial assistant in the form of UGC
   meritorious research fellowship.
CR Bianco RB, 2006, EUR J CANCER, V42, P290, DOI 10.1016/j.ejca.2005.07.034
   Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405
   Chen JZ, 2009, CANCER BIOL THER, V8, P1313, DOI 10.4161/cbt.8.14.8983
   Chitra P, 2013, TOXICOL LETT, V219, P178, DOI 10.1016/j.toxlet.2013.03.009
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Dar AA, 2009, ONCOGENE, V28, P866, DOI 10.1038/onc.2008.434
   Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Douglas CM., 2001, DESIGN ANAL EXPT
   Elkablawy MA, 2001, J PATHOL, V194, P436, DOI 10.1002/path.894
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Greenawalt J W, 1974, Methods Enzymol, V31, P310
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kamaraj S, 2009, INVEST NEW DRUG, V27, P214, DOI 10.1007/s10637-008-9159-7
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lamoral-Theys D, 2010, CURR MED CHEM, V17, P812, DOI 10.2174/092986710790712183
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097
   Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6
   Marone R, 2009, MOL CANCER RES, V7, P601, DOI 10.1158/1541-7786.MCR-08-0366
   Natarajan N., 2011, BIOMED PREV NUTR, V1, P207, DOI 10.1016/j.bionut.2011.07.001
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Park HJ, 2008, PHYTOMEDICINE, V15, P147, DOI 10.1016/j.phymed.2007.07.061
   Paulsen JE, 2005, ANTICANCER RES, V25, P3883
   Philp AJ, 2001, CANCER RES, V61, P7426
   PLOTON D, 1986, HISTOCHEM J, V18, P5, DOI 10.1007/BF01676192
   Ramos S, 2007, J NUTR BIOCHEM, V18, P427, DOI 10.1016/j.jnutbio.2006.11.004
   Reddy BS, 2004, ENVIRON MOL MUTAGEN, V44, P26, DOI 10.1002/em.20026
   Rickwood D, 2006, CELL BIOL PROTOCOLS, P71
   Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201
   Saiprasad G, 2013, INFLAMM RES, V62, P425, DOI 10.1007/s00011-013-0595-2
   Sambrook J., 1989, MOL CLONING LAB MANU, P1626
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Shanmugam MK, 2011, NUTR CANCER, V63, P161, DOI 10.1080/01635581.2011.523502
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123
   Thompson Patricia A, 2009, Expert Rev Gastroenterol Hepatol, V3, P369, DOI 10.1586/egh.09.28
   Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yao JE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-95
   Zhong Y, 2010, EUR J CANCER, V46, P3365, DOI 10.1016/j.ejca.2010.07.007
NR 52
TC 64
Z9 66
U1 1
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2014
VL 50
IS 14
BP 2489
EP 2507
DI 10.1016/j.ejca.2014.06.013
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AO6GU
UT WOS:000341449200013
PM 25047426
DA 2022-04-25
ER

PT J
AU Di Conza, G
   Cafarello, ST
   Loroch, S
   Mennerich, D
   Deschoemaeker, S
   Di Matteo, M
   Ehling, M
   Gevaert, K
   Prenen, H
   Zahedi, RP
   Sickmann, A
   Kietzmann, T
   Moretti, F
   Mazzone, M
AF Di Conza, Giusy
   Cafarello, Sarah Trusso
   Loroch, Stefan
   Mennerich, Daniela
   Deschoemaeker, Sofie
   Di Matteo, Mario
   Ehling, Manuel
   Gevaert, Kris
   Prenen, Hans
   Zahedi, Rene Peiman
   Sickmann, Albert
   Kietzmann, Thomas
   Moretti, Fabiola
   Mazzone, Massimiliano
TI The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune
   HIF1 alpha Levels and Colorectal Cancer Cell Survival under Hypoxia
SO CELL REPORTS
LA English
DT Article
ID PROLYL HYDROXYLASES; INDUCIBLE FACTOR; MAMMALIAN TARGET; AUTOPHAGY; HIF;
   INHIBITION; EXPRESSION; REDD1; DEGRADATION; PROTEIN
AB Oxygen-dependent HIF1 alpha hydroxylation and degradation are strictly controlled by PHD2. In hypoxia, HIF1 alpha partly escapes degradation because of low oxygen availability. Here, we show that PHD2 is phosphorylated on serine 125(S125) by the mechanistic target of rapamycin (mTOR) downstream kinase P70S6K and that this phosphorylation increases its ability to degrade HIF1 alpha. mTOR blockade in hypoxia by REDD1 restrains P70S6K and unleashes PP2A phosphatase activity. Through its regulatory subunit B55 alpha, PP2A directly dephosphorylates PHD2 on S125, resulting in a further reduction of PHD2 activity that ultimately boosts HIF1a accumulation. These events promote autophagy- mediated cell survival in colorectal cancer (CRC) cells. B55 alpha knockdown blocks neoplastic growth of CRC cells in vitro and in vivo in a PHD2-dependent manner. In patients, CRC tissue expresses higher levels of REDD1, B55 alpha, and HIF1 alpha but has lower phospho-S125 PHD2 compared with a healthy colon. Our data disclose a mechanism of PHD2 regulation that involves the mTOR and PP2A pathways and controls tumor growth.
C1 [Di Conza, Giusy; Cafarello, Sarah Trusso; Deschoemaeker, Sofie; Di Matteo, Mario; Ehling, Manuel; Mazzone, Massimiliano] VIB, Ctr Canc Biol, Lab Tumor Inflammat & Angiogenesis, B-3000 Leuven, Belgium.
   [Di Conza, Giusy; Cafarello, Sarah Trusso; Deschoemaeker, Sofie; Di Matteo, Mario; Ehling, Manuel; Mazzone, Massimiliano] Katholieke Univ Leuven, Ctr Canc Biol, Dept Oncol, Lab Tumor Inflammat & Angiogenesis, B-3000 Leuven, Belgium.
   [Loroch, Stefan; Zahedi, Rene Peiman; Sickmann, Albert] ISAS eV, Leibniz Inst Analyt Wissensch, D-44227 Dortmund, Germany.
   [Mennerich, Daniela; Kietzmann, Thomas] Univ Oulu, Fac Biochem & Mol Med, SF-90220 Oulu, Finland.
   [Mennerich, Daniela; Kietzmann, Thomas] Univ Oulu, Bioctr Oulu, SF-90220 Oulu, Finland.
   [Gevaert, Kris] VIB, Dept Med Prot Res, B-9000 Ghent, Belgium.
   [Gevaert, Kris] Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium.
   [Prenen, Hans] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Oncol, Digest Oncol Unit, B-3000 Leuven, Belgium.
   [Sickmann, Albert] Univ Aberdeen, Coll Phys Sci, Dept Chem, Aberdeen AB24 3UE, Scotland.
   [Sickmann, Albert] Ruhr Univ Bochum, Med Proteom Ctr, D-44801 Bochum, Germany.
   [Moretti, Fabiola] Natl Res Council Italy, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy.
RP Mazzone, M (corresponding author), VIB, Ctr Canc Biol, Lab Tumor Inflammat & Angiogenesis, B-3000 Leuven, Belgium.; Mazzone, M (corresponding author), Katholieke Univ Leuven, Ctr Canc Biol, Dept Oncol, Lab Tumor Inflammat & Angiogenesis, B-3000 Leuven, Belgium.
EM massimiliano.mazzone@vib-kuleuven.be
RI Deschoemaeker, Sofie/AAF-8321-2020; Moretti, Fabiola/I-5647-2013;
   Deschoemaeker, Sofie/AAE-1359-2022; Gevaert, Kris/D-6489-2017; Di Conza,
   Giusy/AAU-9661-2020; Sickmann, Albert/A-1010-2011; Zahedi,
   René/A-9148-2012; Gevaert, Kris/AAE-4212-2019
OI Deschoemaeker, Sofie/0000-0001-5449-282X; Moretti,
   Fabiola/0000-0002-2691-1254; Gevaert, Kris/0000-0002-4237-0283;
   Sickmann, Albert/0000-0002-2388-5265; Zahedi, René/0000-0002-4960-5460;
   Gevaert, Kris/0000-0002-4237-0283; Di Matteo, Mario/0000-0001-7811-7450;
   Di Conza, Giusy/0000-0003-1353-5867; Prenen, Hans/0000-0001-8802-7352;
   Loroch, Stefan/0000-0002-7758-0301
FU ERANET [G0D8115N]; FWOFWO [1505611N00]; FWO- Marie Curie fellowship
   [1211413N]; DFGGerman Research Foundation (DFG)European Commission [EH
   472/ 1- 1]; EVDS [419.052.173]; OxyMO [308459]
FX supported by grants from ERANET (OxyUC, G0D8115N), FWO (1505611N00),
   Stichting Tegen Kanker (2010- 169), Bundesministerium fur Bildung und
   Forschung, and the Ministerium fur ur Innovation, Wissenschaft und
   Forschung des Landes Nordrhein- Westfalen. G. D. C. is supported by a
   Pegasus FWO-Marie Curie fellowship (1211413N), M. E. by DFG (EH
   472/1-1), and S. D. by VLK (EVDS and 419.052.173). M. M. received an ERC
   starting grant (OxyMO, 308459).
CR Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432
   Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005
   Chang B, 2009, CELL CYCLE, V8, P780, DOI 10.4161/cc.8.5.7887
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10
   Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424
   Gilan O, 2015, ONCOGENE, V34, P1340, DOI 10.1038/onc.2014.460
   Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105
   Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Jia W, 2014, INT J CLIN EXP PATHO, V7, P5940
   Jokilehto T, 2010, J CELL MOL MED, V14, P758, DOI 10.1111/j.1582-4934.2010.01030.x
   Kalev P, 2012, CANCER RES, V72, P6414, DOI 10.1158/0008-5472.CAN-12-1667
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302
   Leontieva OV, 2014, P NATL ACAD SCI USA, V111, P8832, DOI 10.1073/pnas.1405723111
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mazure NM, 2009, AUTOPHAGY, V5, P868, DOI 10.4161/auto.9042
   Nishimoto A, 2014, INT J ONCOL, V44, P2077, DOI 10.3892/ijo.2014.2367
   Nunez-O'Mara A, 2015, J CELL SCI, V128, P40, DOI 10.1242/jcs.151514
   Ortmann B, 2016, J CELL SCI, V129, P191, DOI 10.1242/jcs.179911
   Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06
   Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036
   Shchors K, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.012
   Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005
   Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200
   Tsuzuki Y, 2000, CANCER RES, V60, P6248
NR 38
TC 54
Z9 55
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD FEB 14
PY 2017
VL 18
IS 7
BP 1699
EP 1712
DI 10.1016/j.celrep.2017.01.051
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EP4BG
UT WOS:000397324900012
PM 28199842
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sui, XB
   Kong, N
   Wang, X
   Fang, Y
   Hu, XT
   Xu, YH
   Chen, W
   Wang, KF
   Li, D
   Jin, W
   Lou, F
   Zheng, Y
   Hu, H
   Gong, L
   Zhou, XY
   Pan, HM
   Han, WD
AF Sui, Xinbing
   Kong, Na
   Wang, Xian
   Fang, Yong
   Hu, Xiaotong
   Xu, Yinghua
   Chen, Wei
   Wang, Kaifeng
   Li, Da
   Jin, Wei
   Lou, Fang
   Zheng, Yu
   Hu, Hong
   Gong, Liu
   Zhou, Xiaoyun
   Pan, Hongming
   Han, Weidong
TI JNK confers 5-fluorouracil resistance in p53-deficient and mutant
   p53-expressing colon cancer cells by inducing survival autophagy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCED APOPTOSIS; THERAPEUTIC TARGET; ACTIVATION; INDUCTION; DRUG;
   PHOSPHORYLATION; CHEMOTHERAPY; CHLOROQUINE; PROTEIN; KINASE
AB Deficiency or mutation in the p53 tumor suppressor gene commonly occurs in human cancer and can contribute to disease progression and chemotherapy resistance. Currently, although the pro-survival or pro-death effect of autophagy remains a controversial issue, increasing data seem to support the idea that autophagy facilitates cancer cell resistance to chemotherapy treatment. Here we report that 5-FU treatment causes aberrant autophagosome accumulation in HCT116 p53(-/-) 2 and HT- 29 cancer cells. Specific inhibition of autophagy by 3-MA, CQ or small interfering RNA treatment targeting Atg5 or Beclin 1 can potentiate the re-sensitization of these resistant cancer cells to 5-FU. In further analysis, we show that JNK activation and phosphorylation of Bcl-2 are key determinants in 5-FU-induced autophagy. Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53(-/-) 2 and HT29 cells. Taken together, our results suggest that JNK activation confers 5-FU resistance in HCT116 p53(-/-) 2 and HT29 cells by promoting autophagy as a pro-survival effect, likely via inducing Bcl-2 phosphorylation. These results provide a promising strategy to improve the efficacy of 5-FU-based chemotherapy for colorectal cancer patients harboring a p53 gene mutation.
C1 [Sui, Xinbing; Kong, Na; Wang, Xian; Fang, Yong; Xu, Yinghua; Chen, Wei; Wang, Kaifeng; Li, Da; Jin, Wei; Lou, Fang; Zheng, Yu; Hu, Hong; Gong, Liu; Zhou, Xiaoyun; Pan, Hongming; Han, Weidong] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Sui, Xinbing; Kong, Na; Wang, Xian; Hu, Xiaotong; Pan, Hongming; Han, Weidong] Biomed Res Ctr, Hangzhou 310016, Zhejiang, Peoples R China.
   [Sui, Xinbing; Kong, Na; Wang, Xian; Hu, Xiaotong; Pan, Hongming; Han, Weidong] Key Lab Biotherapy Zhejiang Prov, Hangzhou 310016, Zhejiang, Peoples R China.
RP Pan, HM (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
EM drpanhm@aliyun.com; weidong2011@163.com
RI Hu, Xiao-tong/K-5820-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81301891, 81272593, 81071651, 81071963];
   Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LQ13H160008, LQ13H160009]
FX We thank Mian Wu for providing HCT116 p5<SUP>3+/+</SUP>, HCT116
   p53<SUP>-/-</SUP> cell lines. This study is supported by grants from
   National Natural Science Foundation of China (grant No. 81301891,
   81272593, 81071651 and 81071963) and Zhejiang Provincial Natural Science
   Foundation of China (grant No. LQ13H160008 and LQ13H160009).
CR Altman BJ, 2009, AUTOPHAGY, V5, P569, DOI 10.4161/auto.5.4.8254
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Chaanine AH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.5
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Fuest M, 2012, HEPATOLOGY, V55, P408, DOI 10.1002/hep.24699
   Herszenyi L, 2010, EUR REV MED PHARMACO, V14, P249
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Hu X., 2011, J PATHOL, V229, P62
   Huang C, 2009, CANCER BIOL THER, V8, P2185, DOI 10.4161/cbt.8.22.10446
   Karpinski P, 2008, J APPL GENET, V49, P1, DOI 10.1007/BF03195243
   Kelkel M, 2012, CARCINOGENESIS, V33, P2162, DOI 10.1093/carcin/bgs240
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044254
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   NILSSON JR, 1992, J PROTOZOOL, V39, P9, DOI 10.1111/j.1550-7408.1992.tb01278.x
   Notte A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.167
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Sau A, 2012, MOL BIOSYST, V8, P994, DOI 10.1039/c1mb05295k
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Subbarayan PR, 2010, ANTICANCER RES, V30, P1149
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Xiao F, 2012, WORLD J GASTROENTERO, V18, P7348, DOI 10.3748/wjg.v18.i48.7348
   Zhao MY, 2011, BMB REP, V44, P601, DOI 10.5483/BMBRep.2011.44.9.601
   Zhu BY, 2013, INT J CANCER, V132, P2270, DOI 10.1002/ijc.27927
NR 38
TC 78
Z9 80
U1 3
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 15
PY 2014
VL 4
AR 4694
DI 10.1038/srep04694
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE8XO
UT WOS:000334286500001
PM 24733045
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, H
   Wang, P
   Sun, QH
   Ding, WX
   Yin, XM
   Sobol, RW
   Stolz, DB
   Yu, J
   Zhang, L
AF Li, Hua
   Wang, Peng
   Sun, Quanhong
   Ding, Wen-Xing
   Yin, Xiao-Ming
   Sobol, Robert W.
   Stolz, Donna B.
   Yu, Jian
   Zhang, Lin
TI Following Cytochrome c Release, Autophagy Is Inhibited during
   Chemotherapy-Induced Apoptosis by Caspase 8-Mediated Cleavage of Beclin
   1
SO CANCER RESEARCH
LA English
DT Article
ID CELL-DEATH; MEDIATED CLEAVAGE; COLORECTAL-CANCER; TUMOR-SUPPRESSOR;
   BH3-ONLY PROTEIN; PUMA; MITOCHONDRIA; TUMORIGENESIS; SURVIVAL; GENE
AB Autophagy is an evolutionarily conserved stress response mechanism that often occurs in apoptosis-defective cancer cells and can protect against cell death. In this study, we investigated how apoptosis and autophagy affect each other in cancer cells in response to chemotherapeutic treatment. We found that specific ablation of the proapoptotic function of cytochrome c, a key regulator of mitochondria-mediated apoptosis, enhanced autophagy following chemotherapeutic treatment. Induction of autophagy required Beclin 1 and was associated with blockage of Beclin 1 cleavage by caspase 8 at two sites. To investigate the role of Beclin 1 cleavage in the suppression of autophagy and cell survival, a caspase-resistant mutant of Beclin 1 was knocked into HCT116 colon cancer cells. Beclin 1 mutant knockin resulted in markedly increased autophagy and improved long-term cell survival after chemotherapeutic treatment but without affecting apoptosis and caspase activation. Furthermore, Beclin 1 mutant tumors were significantly less responsive to chemotherapeutic treatment than were wild-type tumors. These results show that chemotherapy-induced apoptosis inhibits autophagy at the execution stage subsequent to cytochrome c release through caspase 8-mediated cleavage of Beclin 1. If apoptosis fails to execute, autophagy is unleashed due to lack of Beclin 1 cleavage by caspases and can contribute to cancer cell survival and therapeutic resistance. Therefore, Beclin 1 may be a useful target for inhibiting autophagy to sensitize chemotherapy. Cancer Res; 71(10); 3625-34. (C) 2011 AACR.
C1 [Li, Hua; Wang, Peng; Sobol, Robert W.; Zhang, Lin] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Sun, Quanhong; Ding, Wen-Xing; Yin, Xiao-Ming; Yu, Jian] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Pathol, Pittsburgh, PA USA.
   [Stolz, Donna B.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
   [Sobol, Robert W.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Human Genet, Pittsburgh, PA USA.
RP Zhang, L (corresponding author), Hillman Canc Ctr, UPCI Res Pavil, Room 2-42A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM zhanglx@upmc.edu
RI Yu, Jian/A-8301-2009; LI, HUA/I-9569-2014; Zhang, Lin/A-7389-2009; Li,
   Hua/C-3126-2013; Sobol, Robert W./E-4125-2013
OI Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Sobol,
   Robert W./0000-0001-7385-3563
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA106348, CA121105, CA129829,
   U01DK085570, CA132385, GM087798, CA148629]; American Cancer
   SocietyAmerican Cancer Society [RSG-07-156-01-CNE, RSG-10-124-10-CCE];
   American Lung Association/CHEST Foundation; UPCI Cancer Center
   [CA047904]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P30CA047904, R01CA148629, R01CA129829,
   R01CA121105, R01CA106348, P20CA132385] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [U01DK085570] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R44GM087798,
   R43GM087798] Funding Source: NIH RePORTER
FX This work is supported by NIH grants CA106348, CA121105, American Cancer
   Society grant RSG-07-156-01-CNE, and the American Lung Association/CHEST
   Foundation (L. Zhang), NIH grants CA129829, U01DK085570, and American
   Cancer Society grant RSG-10-124-10-CCE (J. Yu), NIH grants CA132385,
   GM087798, and CA148629 (R.W. Sobol), and the UPCI Cancer Center Support
   grant (CA047904).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Eng C, 2009, NAT REV CLIN ONCOL, V6, P207, DOI 10.1038/nrclinonc.2009.16
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Gao WT, 2010, J BIOL CHEM, V285, P1371, DOI 10.1074/jbc.M109.054197
   Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321
   Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016
   Kolinsky K, 2009, ANTICANCER RES, V29, P91
   Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mijaljica D, 2007, AUTOPHAGY, V3, P4, DOI 10.4161/auto.3011
   Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51
   Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104
   Wang XD, 2001, GENE DEV, V15, P2922
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zhang XD, 2008, NAT METHODS, V5, P163, DOI [10.1038/nmeth1170, 10.1038/NMETH1170]
NR 42
TC 107
Z9 116
U1 1
U2 20
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2011
VL 71
IS 10
BP 3625
EP 3634
DI 10.1158/0008-5472.CAN-10-4475
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 764EH
UT WOS:000290610900020
PM 21444671
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Giatromanolaki, A
   Koukourakis, MI
   Koutsopoulos, AV
   Harris, AL
   Gatter, KC
   Sivridis, E
AF Giatromanolaki, A.
   Koukourakis, M. I.
   Koutsopoulos, A. V.
   Harris, A. L.
   Gatter, K. C.
   Sivridis, E.
TI Autophagy and hypoxia in colonic adenomas related to aggressive features
SO COLORECTAL DISEASE
LA English
DT Article
DE Autophagy; colon cancer; adenoma; hypoxia
ID COLORECTAL-CANCER; CARCINOMA SEQUENCE; PROGNOSTIC RELEVANCE; BECLIN 1;
   EXPRESSION; PATTERNS; ADENOCARCINOMAS; CARCINOGENESIS; PROGRESSION;
   NEOPLASIA
AB Aim The study investigated whether autophagic activity and hypoxia parallel the adenomacarcinoma sequence. Method The study comprised 120 tubular adenomas with high-grade dysplasia, including 22 with questionable evidence of invasion, 37 with definite stromal invasion and 29 with severely dysplastic adenoma, 10 traditional serrated adenomas and 22 classical tubular adenomas lacking aggressive features. The samples were stained immunohistochemically for autophagy (LC3A and Beclin-1) and hypoxia-inducible factor1-alpha (HIF1) markers. Results LC3A was detected as diffuse cytoplasmic staining and as dense stone-like structures (SLS) within cytoplasmic vacuoles. Beclin-1 reactivity was purely cytoplasmic, whereas that of HIF1 was both cytoplasmic and nuclear. SLS counts in noninvasive, nontransformed areas of tubular adenomas were consistently low (median SLS=0.5; 200x magnification), whereas a progressive increase was noted from areas of equivocal invasion (median SLS=1.3; 200x magnification) and intramucosal carcinoma (median SLS=1.4; 200x magnification) to unequivocal invasive foci (median SLS=2.1; 200x magnification) (P<0.0001). A similar association was shown for Beclin-1 and HIF1 expression (P<0.05). Traditional serrated adenomas yielded low SLS counts and weak HIF1 reactivity, but high cytoplasmic LC3A and Beclin-1 expression (P<0.01). Conclusion A hypoxia-driven autophagy in adenomatous polyps, when particularly intense and localized, is commonly associated with early invasion or severely dysplastic adenoma.
C1 [Giatromanolaki, A.; Koutsopoulos, A. V.; Sivridis, E.] Democritus Univ Thrace, Sch Med, Dept Pathol, Alexandroupolis 68100, Greece.
   [Giatromanolaki, A.; Koukourakis, M. I.; Koutsopoulos, A. V.; Sivridis, E.] Univ Gen Hosp Alexandroupolis, Alexandroupolis 68100, Greece.
   [Koukourakis, M. I.] Democritus Univ Thrace, Sch Med, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece.
   [Harris, A. L.] Univ Oxford, Canc Res UK, Mol Oncol Labs, Weatherall Inst Mol Med, Oxford, England.
   [Gatter, K. C.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
RP Giatromanolaki, A (corresponding author), Democritus Univ Thrace, Sch Med, POB 12, Alexandroupolis 68100, Greece.
EM agiatrom@med.duth.gr
RI Koutsopoulos, Anastasios/AAO-9498-2020; Harris, Adrian/ABA-3343-2020
OI Koutsopoulos, Anastasios/0000-0002-8430-7565; Harris,
   Adrian/0000-0003-1376-8409
FU Tumour and Angiogenesis Research Group; NIHR Oxford Biomedical Research
   CentreNational Institute for Health Research (NIHR); Cancer Research
   UKCancer Research UK [11359] Funding Source: researchfish; National
   Institute for Health ResearchNational Institute for Health Research
   (NIHR) [NF-SI-0611-10163] Funding Source: researchfish
FX We thank Mrs Kyriaki Devetzi and Mrs Giannoula Kirmizi for excellent
   technical assistance. The study was financially supported by the Tumour
   and Angiogenesis Research Group and the NIHR Oxford Biomedical Research
   Centre.
CR Arbogast S, 2011, APPL IMMUNOHISTO M M, V19, P99, DOI 10.1097/PAI.0b013e3181f1feeb
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bond JH, 1999, GASTROINTEST ENDOSC, V49, pS35, DOI 10.1016/S0016-5107(99)70523-7
   Bu XD, 2010, WORLD J GASTROENTERO, V16, P4089, DOI 10.3748/wjg.v16.i32.4089
   Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Fang JS, 2008, SEMIN CANCER BIOL, V18, P330, DOI 10.1016/j.semcancer.2008.03.011
   GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1085, DOI 10.1016/0959-8049(95)00139-A
   Giatromanolaki A, 2011, GYNECOL ONCOL, V123, P147, DOI 10.1016/j.ygyno.2011.06.023
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gimeno-Garcia AZ, 2006, EUR J CANCER, V42, P3246, DOI 10.1016/j.ejca.2006.06.025
   Greenhough A, 2010, ONCOGENE, V29, P3398, DOI 10.1038/onc.2010.94
   Groff Rachel J, 2008, Curr Gastroenterol Rep, V10, P490, DOI 10.1007/s11894-008-0090-z
   Hao XP, 1997, PATHOBIOLOGY, V65, P140, DOI 10.1159/000164115
   Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602
   Kaklamanis L, 1998, Angiogenesis, V2, P49, DOI 10.1023/A:1009002426554
   Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831
   Kim KM, 2010, AM J SURG PATHOL, V34, P667, DOI 10.1097/PAS.0b013e3181d40cb2
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Koukourakis MI, 2005, CLIN EXP METASTAS, V22, P25, DOI 10.1007/s10585-005-2343-7
   Lu DY, 2009, APPL IMMUNOHISTO M M, V17, P158, DOI 10.1097/PAI.0b013e318185d1b5
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983
   Repici A, 2009, DIS COLON RECTUM, V52, P1502, DOI 10.1007/DCR.0b013e3181a74d9b
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680
   Sivridis E, 2012, UROL ONCOL IN PRESS
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Staton CA, 2007, GUT, V56, P1426, DOI 10.1136/gut.2007.125286
   Sugumar Aravind, 2010, F1000 Med Rep, V2, P89, DOI 10.3410/M2-89
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 33
TC 13
Z9 14
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
J9 COLORECTAL DIS
JI Colorectal Dis.
PD MAY
PY 2013
VL 15
IS 5
BP E223
EP E230
DI 10.1111/codi.12147
PG 8
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA 137LC
UT WOS:000318436400003
PM 23351172
DA 2022-04-25
ER

PT J
AU Jin, HR
   Zhao, J
   Zhang, Z
   Liao, Y
   Wang, CZ
   Huang, WH
   Li, SP
   He, TC
   Yuan, CS
   Du, W
AF Jin, H. R.
   Zhao, J.
   Zhang, Z.
   Liao, Y.
   Wang, C-Z
   Huang, W-H
   Li, S-P
   He, T-C
   Yuan, C-S
   Du, W.
TI The antitumor natural compound falcarindiol promotes cancer cell death
   by inducing endoplasmic reticulum stress
SO CELL DEATH & DISEASE
LA English
DT Article
DE ER stress; falcarindiol; apoptosis; unfolded protein response;
   proteasome
ID UNFOLDED PROTEIN RESPONSE; CHEMOTHERAPY-INDUCED NAUSEA;
   MULTIPLE-MYELOMA; CONSTITUENTS; INHIBITION; APOPTOSIS; AUTOPHAGY;
   TARGET; IDENTIFICATION; GRP78/BIP
AB Falcarindiol (FAD) is a natural polyyne with various beneficial biological activities. We show here that FAD preferentially kills colon cancer cells but not normal colon epithelial cells. Furthermore, FAD inhibits tumor growth in a xenograft tumor model and exhibits strong synergistic killing of cancer cells with 5-fluorouracil, an approved cancer chemotherapeutic drug. We demonstrate that FAD-induced cell death is mediated by induction of endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR). Decreasing the level of ER stress, either by overexpressing the ER chaperone protein glucose-regulated protein 78 (GRP78) or by knockout of components of the UPR pathway, reduces FAD-induced apoptosis. In contrast, increasing the level of ER stress by knocking down GRP78 potentiates FAD-induced apoptosis. Finally, FAD-induced ER stress and apoptosis is correlated with the accumulation of ubiquitinated proteins, suggesting that FAD functions at least in part by interfering with proteasome function, leading to the accumulation of unfolded protein and induction of ER stress. Consistent with this, inhibition of protein synthesis by cycloheximide significantly decreases the accumulation of ubiquitinated proteins and blocks FAD-induced ER stress and cell death. Taken together, our study shows that FAD is a potential new anticancer agent that exerts its activity through inducing ER stress and apoptosis. Cell Death and Disease (2012) 3, e376; doi: 10.1038/cddis.2012.122; published online 23 August 2012
C1 [Jin, H. R.; Zhao, J.; Liao, Y.; Du, W.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
   [Zhang, Z.; Wang, C-Z; Yuan, C-S] Univ Chicago, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
   [Zhang, Z.; Wang, C-Z; Yuan, C-S] Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA.
   [Huang, W-H; Li, S-P] Univ Macau, State Key Lab Qual Res Chinese Med, Taipa, Peoples R China.
   [Huang, W-H; Li, S-P] Univ Macau, Inst Chinese Med Sci, Taipa, Peoples R China.
   [He, T-C] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
RP Du, W (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 E 57th St, Chicago, IL 60637 USA.
EM wei@uchicago.edu
RI Liao, Yang/M-6300-2013; Wang, Chong-Zhi/B-8337-2014
OI Wang, Chong-Zhi/0000-0002-0950-2109; Huang, Wei-Hua/0000-0003-4167-8304;
   Li, SP/0000-0003-4255-6229
FU University of Macau [NIH/NCCAM AT004418, NIH GM074197, NIH/NCI CA149275,
   DOD W81XWH-10-1-0077, UL015A]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA149275] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE
   MEDICINEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Complementary &
   Alternative Medicine [P01AT004418] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM074197]
   Funding Source: NIH RePORTER
FX We thank Drs David Ron and Laurie Glimcher for the PERK<SUP>-/-</SUP>
   and XBP1<SUP>-/-</SUP> MEFs, Dr. Jianjun Chen for the RAJI, MonoMac6,
   and KOPN-1 cells, Dr. Jinhua Xu for the MCF10A cells, Dr. Geoffrey
   Greene for the MDA-MB231 and MCF7 cells. We also thank Dr. Gopal
   Thinakaran and Gabe Gordon for reading the manuscript. This work was
   supported in part by the following grants: NIH/NCCAM AT004418, NIH
   GM074197, NIH/NCI CA149275, DOD W81XWH-10-1-0077, and UL015A from the
   University of Macau.
CR Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   Calway T, 2012, J NAT MED-TOKYO, V66, P249, DOI 10.1007/s11418-011-0602-2
   Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Deng S, 2008, PHYTOTHER RES, V22, P878, DOI 10.1002/ptr.2303
   Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Hasnain SZ, 2012, IMMUNOL CELL BIOL, V90, P260, DOI 10.1038/icb.2011.112
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   Huang WH, 2010, MOLECULES, V15, P1089, DOI 10.3390/molecules15021089
   Ito D, 2004, MOL CELL BIOL, V24, P9456, DOI 10.1128/MCB.24.21.9456-9469.2004
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019
   Little JL, 2007, CANCER RES, V67, P1262, DOI 10.1158/0008-5472.CAN-06-1794
   Liu YF, 2011, CELL RES, V21, P867, DOI 10.1038/cr.2011.75
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Metzger BT, 2008, J AGR FOOD CHEM, V56, P3554, DOI 10.1021/jf073494t
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Ohnuma T, 2011, BIOL PHARM BULL, V34, P371, DOI 10.1248/bpb.34.371
   Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   Schnell FM, 2003, ONCOLOGIST, V8, P187, DOI 10.1634/theoncologist.8-2-187
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stavri M, 2005, PHYTOTHER RES, V19, P938, DOI 10.1002/ptr.1758
   Sun S, 2010, J ETHNOPHARMACOL, V132, P280, DOI 10.1016/j.jep.2010.08.026
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829
   Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546
   Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang CZ, 2005, AM J CHINESE MED, V33, P807, DOI 10.1142/S0192415X05003429
   Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Zschocke S, 1997, PLANTA MED, V63, P203, DOI 10.1055/s-2006-957653
NR 40
TC 53
Z9 55
U1 1
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2012
VL 3
AR e376
DI 10.1038/cddis.2012.122
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 002SC
UT WOS:000308553800017
PM 22914324
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Maillet, A
   Yadav, S
   Loo, YL
   Sachaphibulkij, K
   Pervaiz, S
AF Maillet, A.
   Yadav, S.
   Loo, Y. L.
   Sachaphibulkij, K.
   Pervaiz, S.
TI A novel Osmium-based compound targets the mitochondria and triggers
   ROS-dependent apoptosis in colon carcinoma
SO CELL DEATH & DISEASE
LA English
DT Article
DE cancer therapy; novel compound; mitochondria; ROS
ID DRUG-INDUCED APOPTOSIS; CELL-DEATH; HYDROGEN-PEROXIDE; TUMOR-CELLS;
   CANCER-CELLS; ARENE COMPLEXES; JNK ACTIVATION; AUTOPHAGY; PATHWAY;
   ACIDIFICATION
AB Engagement of the mitochondrial-death amplification pathway is an essential component in chemotherapeutic execution of cancer cells. Therefore, identification of mitochondria-targeting agents has become an attractive avenue for novel drug discovery. Here, we report the anticancer activity of a novel Osmium-based organometallic compound (hereafter named Os) on different colorectal carcinoma cell lines. HCT116 cell line was highly sensitive to Os and displayed characteristic features of autophagy and apoptosis; however, inhibition of autophagy did not rescue cell death unlike the pan-caspase inhibitor z-VAD-fmk. Furthermore, Os significantly altered mitochondrial morphology, disrupted electron transport flux, decreased mitochondrial transmembrane potential and ATP levels, and triggered a significant increase in reactive oxygen species (ROS) production. Interestingly, the sensitivity of cell lines to Os was linked to its ability to induce mitochondrial ROS production (HCT116 and RKO) as HT29 and SW620 cell lines that failed to show an increase in ROS were resistant to the death-inducing activity of Os. Finally, intra-peritoneal injections of Os significantly inhibited tumor formation in a murine model of HCT116 carcinogenesis, and pretreatment with Os significantly enhanced tumor cell sensitivity to cisplatin and doxorubicin. These data highlight the mitochondria-targeting activity of this novel compound with potent anticancer effect in vitro and in vivo, which could have potential implications for strategic therapeutic drug design.
C1 [Maillet, A.; Yadav, S.; Loo, Y. L.; Sachaphibulkij, K.; Pervaiz, S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Apoptosis & Canc Biol Lab,ROS, 2 Med Dr,Bldg MD9 01-05, Singapore 117597, Singapore.
   [Pervaiz, S.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore.
   [Pervaiz, S.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.
   [Pervaiz, S.] Singapore MIT Alliance, Singapore, Singapore.
RP Pervaiz, S (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Apoptosis & Canc Biol Lab,ROS, 2 Med Dr,Bldg MD9 01-05, Singapore 117597, Singapore.
EM phssp@nus.edu.sg
RI Pervaiz, Shazib/C-4188-2015
FU National Medical Research CouncilUK Research & Innovation (UKRI)Medical
   Research Council UK (MRC); Biomedical Research Council of
   SingaporeAgency for Science Technology & Research (ASTAR); Experimental
   Therapeutics Program of the Cancer Science Institute, National
   University of Singapore, Singapore; National Medical Research CouncilUK
   Research & Innovation (UKRI)Medical Research Council UK (MRC);
   Biomedical Research Council of SingaporeAgency for Science Technology &
   Research (ASTAR); Experimental Therapeutics Program of the Cancer
   Science Institute, National University of Singapore, Singapore
FX S.P. is supported by grants from the National Medical Research Council
   and the Biomedical Research Council of Singapore, and the Experimental
   Therapeutics Program of the Cancer Science Institute, National
   University of Singapore, Singapore.
CR Ahmad KA, 2004, CANCER RES, V64, P7867, DOI 10.1158/0008-5472.CAN-04-0648
   Ahmad KA, 2003, ANN NY ACAD SCI, V1010, P365, DOI 10.1196/annals.1299.067
   Bey EA, 2007, P NATL ACAD SCI USA, V104, P11832, DOI 10.1073/pnas.0702176104
   Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026
   Clement MV, 2003, CELL DEATH DIFFER, V10, P1273, DOI 10.1038/sj.cdd.4401302
   Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271
   Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Dias N, 2005, BIOCHEM PHARMACOL, V70, P1, DOI 10.1016/j.bcp.2005.03.021
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fu Y, 2010, J MED CHEM, V53, P8192, DOI 10.1021/jm100560f
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Ghibelli L, 2010, MITOCHONDRION, V10, P604, DOI 10.1016/j.mito.2010.08.003
   Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   HALLIWELL B, 1992, J LAB CLIN MED, V119, P598
   Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211
   Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kassim SK, 1999, CLIN BIOCHEM, V32, P333, DOI 10.1016/S0009-9120(99)00026-0
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205
   Li X, 2011, TOXICOL APPL PHARM, V251, P146, DOI 10.1016/j.taap.2010.12.007
   Lim D, 2005, INVEST NEW DRUG, V23, P235, DOI 10.1007/s10637-005-6731-2
   Low ICC, 2010, ANTIOXID REDOX SIGN, V13, P807, DOI 10.1089/ars.2009.3050
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mijaljica D, 2010, METHODS MOL BIOL, V648, P93, DOI 10.1007/978-1-60761-756-3_6
   Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495
   Monneret C., 2011, ANNALES PHARMACEUTIQUES FRANCAISES, V69, P286, DOI 10.1016/j.pharma.2011.10.001
   Muhlgassner G, 2012, J INORG BIOCHEM, V116, P180, DOI 10.1016/j.jinorgbio.2012.06.003
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Neuzil J, 2013, MITOCHONDRION, V13, P199, DOI 10.1016/j.mito.2012.07.112
   Sato T, 2004, J IMMUNOL, V173, P285, DOI 10.4049/jimmunol.173.1.285
   Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Tait SWG, 2012, J CELL SCI, V125, P807, DOI 10.1242/jcs.099234
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Trejo-Solis C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-156
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Wong FY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050786
   Zhang L, 2013, J CELL BIOCHEM, V114, P697, DOI 10.1002/jcb.24411
   Zuo Y, 2009, CELL RES, V19, P449, DOI 10.1038/cr.2009.19
NR 48
TC 34
Z9 36
U1 1
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN
PY 2013
VL 4
AR e653
DI 10.1038/cddis.2013.185
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 173WE
UT WOS:000321111700004
PM 23744353
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Park, BS
   Choi, NE
   Lee, JH
   Kang, HM
   Yu, SB
   Kim, HJ
   Kang, HK
   Kim, IR
AF Park, Bong-Soo
   Choi, Nak-Eun
   Lee, Ji Hye
   Kang, Hae-Mi
   Yu, Su-Bin
   Kim, Hye-Jin
   Kang, Hyun-Kyung
   Kim, In-Ryoung
TI Crosstalk between Fisetin-induced Apoptosis and Autophagy in Human Oral
   Squamous Cell Carcinoma
SO JOURNAL OF CANCER
LA English
DT Article
DE fisetin; oral squamous cell carcinoma; apoptosis; autophagy
ID DIETARY FLAVONOID FISETIN; MALIGNANT GLIOMA-CELLS; COLON-CANCER CELLS;
   INHIBITION; INDUCTION; PATHWAYS; DEATH; ACTIVATION; BCL-2;
   MACROAUTOPHAGY
AB Fisetin (3,3-,4-,7-tetrahydroxyflavone), a naturally occurring flavonoid, has antioxidant, anti-inflammatory, and anticancer effects. Oral squamous cell carcinoma (OSCC) has a 5-year survival rate lower than that of most other carcinomas, and can create functional and aesthetic problems for the patient. New therapies for OSCC are necessary, and treatment using plant-derived natural substances has recently become a trend. It has been suggested that autophagy may play an important role in cancer therapy. Several studies demonstrated that autophagy inhibition enhances apoptotic cell death. Therefore, autophagy inhibition might be a promising therapeutic method against OSCC. Our results showed that fisetin induced apoptotic cell death in human tongue squamous cell line Ca9-22 could be enhanced by inhibition of autophagy. Thus, autophagy process in fisetin treated OSCC might presumed to play a role of pro-survival. The combination of fisetin and an effective autophagy inhibitor could be a potentially adjuvant and useful treatment for oral cancer.
C1 [Park, Bong-Soo; Choi, Nak-Eun; Kang, Hae-Mi; Yu, Su-Bin; Kim, In-Ryoung] Pusan Natl Univ, Sch Dent, Dept Oral Anat, Busandaehak Ro 49, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Lee, Ji Hye] Pusan Natl Univ, Sch Dent, Dept Oral Pathol, Busandaehak Ro 49, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Park, Bong-Soo; Lee, Ji Hye; Kang, Hae-Mi] Pusan Natl Univ, Sch Dent, BK21 PLUS Project, Busandaehak Ro 49, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Park, Bong-Soo; Lee, Ji Hye; Kim, In-Ryoung] Pusan Natl Univ, Inst Translat Dent Sci, Busandaehak Ro 49, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Kim, Hye-Jin] Dong Eui Univ, Dept Dent Hyg, Gaya 1 Dong, Busan 47230, South Korea.
   [Kang, Hyun-Kyung] Silla Univ, Dept Dent Hyg, 140 Baekyang Daero 700 Beon Gil, Busan 46958, South Korea.
RP Kim, IR (corresponding author), Pusan Natl Univ, Sch Dent, Dept Oral Anat, Busandaehak Ro 49, Yangsan Si 50612, Gyeongsangnam D, South Korea.
EM biowool@pusan.ac.kr
FU National Research Foundation of Korea (NRF) - Korea governmentNational
   Research Foundation of Korea [NRF-2017R1C1B5018034]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (No. NRF-2017R1C1B5018034).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arai Y, 2000, J NUTR, V130, P2243
   Bell RB, 2007, J ORAL MAXIL SURG, V65, P229, DOI 10.1016/j.joms.2005.11.094
   Bent S, 2008, J GEN INTERN MED, V23, P854, DOI 10.1007/s11606-008-0632-y
   Bnouham M., 2006, INT J DIABETES METAB, V14, P1
   Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009
   Casiglia Jeffrey, 2001, General Dentistry, V49, P72
   Chen YC, 2002, ARCH TOXICOL, V76, P351, DOI 10.1007/s00204-002-0346-6
   Chen Z, 2008, J ALTERN COMPLEM MED, V14, P1049, DOI 10.1089/acm.2008.0039
   COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Freier K, 2008, ORAL ONCOL, V44, P116, DOI 10.1016/j.oraloncology.2007.01.006
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Higa S, 2003, J ALLERGY CLIN IMMUN, V111, P1299, DOI 10.1067/mai.2003.1456
   Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Khan N, 2008, CARCINOGENESIS, V29, P1049, DOI 10.1093/carcin/bgn078
   Kim HE, 2008, MOL CELL, V30, P239, DOI 10.1016/j.molcel.2008.03.014
   Kim SH, 2017, PHARMACOL REP, V69, P878, DOI 10.1016/j.pharep.2017.04.007
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lall RK, 2016, MOL NUTR FOOD RES, V60, P1396, DOI 10.1002/mnfr.201600025
   LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Lo WY, 2007, CLIN CHIM ACTA, V376, P101, DOI 10.1016/j.cca.2006.06.030
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Nishida K, 2008, CIRC RES, V103, P343, DOI 10.1161/CIRCRESAHA.108.175448
   Olaku O, 2011, EUR J CANCER, V47, P508, DOI 10.1016/j.ejca.2010.11.018
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5
   Preetee Jaiswal, 2011, Research Journal of Medicinal Plant, V5, P145, DOI 10.3923/rjmp.2011.145.152
   REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1
   Shen J, 2007, BIOCHEM PHARMACOL, V73, P1901, DOI 10.1016/j.bcp.2007.03.009
   Shih YL, 2017, IN VIVO, V31, P1103, DOI 10.21873/invivo.11176
   Suh Y, 2009, CARCINOGENESIS, V30, P300, DOI 10.1093/carcin/bgn269
   Syed DN, 2014, ARCH BIOCHEM BIOPHYS, V563, P108, DOI 10.1016/j.abb.2014.06.034
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026
   Yang PM, 2012, INT J ONCOL, V40, P469, DOI 10.3892/ijo.2011.1203
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yen JH, 2017, INT J MOL SCI, V18
   Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 58
TC 20
Z9 21
U1 2
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2019
VL 10
IS 1
BP 138
EP 146
DI 10.7150/jca.28500
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HE3PM
UT WOS:000453270100016
PM 30662534
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, K
   Zhou, XT
   Wang, JQ
   Zhou, YJ
   Qi, WC
   Chen, HH
   Nie, SP
   Xie, MY
AF Zhang, Ke
   Zhou, Xingtao
   Wang, Junqiao
   Zhou, Yujia
   Qi, Wucheng
   Chen, Haihong
   Nie, Shaoping
   Xie, Mingyong
TI Dendrobium officinale polysaccharide triggers mitochondrial disorder to
   induce colon cancer cell death via ROS-AMPK-autophagy pathway
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Dendrobium officinale polysaccharide; ROS; AMPK; Autophagy;
   Mitochondrial dysfunction; ATP
ID GROWTH
AB The homeostasis between mitochondrial function and autophagy is crucial to the physiological activity of cancer cells, and its mechanism is conducive to the development of anti-tumor drugs. Here, we aimed to explore the effect and mechanism of Dendrobium officinale polysaccharide (DOP) on colon cancer cell line CT26. Our data showed that DOP significantly inhibited the proliferation of CT26 cells and elevated autophagy level. Moreover, DOP disrupted mitochondrial function through increasing reactive oxygen species (ROS) and reducing mitochondrial membrane potential (MMP), thereby impairing ATP biosynthesis, which activated AMPK/mTOR autophagy signaling. Intriguingly, the further experiments demonstrated that DOP-induced cytotoxicity, excessive autophagy and mitochondrial dysfunction were reversed after CT26 cells pretreated with antioxidant (Nacetyl-L-cysteine). Herein, these findings implied that DOP-induced mitochondrial dysfunction and cytotoxic autophagy repressed the propagation of CT26 cells via ROS-ATP-AMPK signaling, providing a new opinion for the study of antineoplastic drugs.
C1 [Zhang, Ke; Zhou, Xingtao; Wang, Junqiao; Zhou, Yujia; Qi, Wucheng; Chen, Haihong; Nie, Shaoping; Xie, Mingyong] Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, 235 Nanjing East Rd, Nanchang 330047, Jiangxi, Peoples R China.
RP Zhou, XT; Xie, MY (corresponding author), Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, 235 Nanjing East Rd, Nanchang 330047, Jiangxi, Peoples R China.
EM zhouxingtao@ncu.edu.cn; myxie@ncu.edu.cn
RI 周, 兴涛/F-2927-2019
OI 周, 兴涛/0000-0002-1902-9677; Nie, Shao-Ping/0000-0002-2412-4679
FU Chinese Academy of Food Science and Technology-Jiangzhong
   Gastrointestinal Health Special Fund [201905]; National Key Research and
   Development Program of China [2017YFC1600405]; Jiangxi Province Science
   and technology plan project [20192AEI91004, 20194AFD44002]; Project of
   State Key Laboratory of food science and technology [SKLF-ZZA-201911]
FX The financial support from Chinese Academy of Food Science and
   TechnologyJiangzhong Gastrointestinal Health Special Fund (201905) ,
   National Key Research and Development Program of China (2017YFC1600405)
   , Jiangxi Province Science and technology plan project (20192AEI91004;
   20194AFD44002) and Project of State Key Laboratory of food science and
   technology (SKLF-ZZA-201911) were gratefully acknowledged.
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bertero E, 2018, CIRC RES, V122, P1460, DOI 10.1161/CIRCRESAHA.118.310082
   Bhargava P, 2017, NAT REV NEPHROL, V13, P629, DOI 10.1038/nrneph.2017.107
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8
   Bodega G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1626654
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Burgener AV, 2019, NAT IMMUNOL, V20, P1311, DOI 10.1038/s41590-019-0482-2
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Delattre C, 2011, BRAZ ARCH BIOL TECHN, V54, P1075, DOI 10.1590/S1516-89132011000600002
   Eisner V, 2018, NAT CELL BIOL, V20, P755, DOI 10.1038/s41556-018-0133-0
   Emdad L, 2020, SEMIN CANCER BIOL, V66, P140, DOI 10.1016/j.semcancer.2019.07.013
   Guo QQ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103111
   He CX, 2016, TRENDS BIOCHEM SCI, V41, P568, DOI 10.1016/j.tibs.2016.04.004
   Hseu YC, 2020, CANCERS, V12, DOI 10.3390/cancers12102936
   Hwang HY, 2021, AUTOPHAGY, V17, P2783, DOI [10.1080/15548627.2020.1841953, 10.6084/m9.figshare.13168583.v3]
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037
   Ke Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.526349
   Khan T, 2019, CARBOHYD POLYM, V210, P412, DOI 10.1016/j.carbpol.2019.01.064
   Kirkin V, 2019, MOL CELL, V76, P268, DOI 10.1016/j.molcel.2019.09.005
   Ladabaum U, 2020, GASTROENTEROLOGY, V158, P418, DOI 10.1053/j.gastro.2019.06.043
   Li MY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1728-5
   Li WY, 2018, J FUNCT FOODS, V45, P75, DOI 10.1016/j.jff.2018.03.024
   Li X, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120253
   Li Y, 2019, AUTOPHAGY, V15, P478, DOI 10.1080/15548627.2018.1522467
   Liang J, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104417
   Lin JZ, 2020, CANCER LETT, V469, P481, DOI 10.1016/j.canlet.2019.11.014
   Liu YR, 2019, J CELL MOL MED, V23, P750, DOI 10.1111/jcmm.13897
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev-pharmtox-010716-104936
   Nunes C, 2019, CURR MED CHEM, V26, P6399, DOI 10.2174/0929867326666181213093718
   Oliveira M, 2014, FOOD FUNCT, V5, P1389, DOI 10.1039/c4fo00258j
   Onnis A, 2018, AUTOPHAGY, V14, P2117, DOI 10.1080/15548627.2018.1505153
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Park JS, 2020, AUTOPHAGY, V16, P86, DOI 10.1080/15548627.2019.1598751
   Qi WC, 2020, CARBOHYD POLYM, V237, DOI 10.1016/j.carbpol.2020.116113
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Sousa SG, 2018, CARBOHYD POLYM, V197, P515, DOI 10.1016/j.carbpol.2018.06.042
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teng JF, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104396
   Wang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02915-8
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xing X. H., 2014, BIOACTIVE CARBOHYDRA, V4, P74, DOI DOI 10.1016/J.BCDF.2014.06.004
   Xing XH, 2015, CARBOHYD POLYM, V117, P422, DOI 10.1016/j.carbpol.2014.08.121
   Yi C, 2017, DEV CELL, V41, P59, DOI 10.1016/j.devcel.2017.03.007
   Yu Y, 2018, CARBOHYD POLYM, V183, P91, DOI 10.1016/j.carbpol.2017.12.009
   Zhang CS, 2016, CELL METAB, V23, P399, DOI 10.1016/j.cmet.2016.02.017
   Zhou XT, 2019, J AGR FOOD CHEM, V67, P9831, DOI 10.1021/acs.jafc.9b03939
   Zhu YX, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119668
NR 50
TC 10
Z9 10
U1 31
U2 95
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JUL 15
PY 2021
VL 264
AR 118018
DI 10.1016/j.carbpol.2021.118018
EA APR 2021
PG 12
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Polymer Science
GA RX7OH
UT WOS:000647408500001
PM 33910741
DA 2022-04-25
ER

PT J
AU Honeggar, M
   Beck, R
   Moos, PJ
AF Honeggar, Matthew
   Beck, Robert
   Moos, Philip J.
TI Thioredoxin reductase 1 ablation sensitizes colon cancer cells to
   methylseleninate-mediated cytotoxicity
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Methylseleninic acid; Thioredoxin reductase; Selenium; Apoptosis
ID HUMAN PROSTATE-CANCER; PREVENTION TRIAL SELECT; SELENIUM
   SUPPLEMENTATION; COLORECTAL-CANCER; MAMMALIAN THIOREDOXIN; SERUM
   SELENIUM; VITAMIN-E; IN-VIVO; DEFICIENCY; ACID
AB The relationship between selenium and cancer is complex because individuals with low serum selenium levels benefit from selenium supplementation, but those with high serum selenium levels are at increased risk for other diseases. This suggests that the use of selenocompounds might be limited to particular circumstances, such as adjuvant therapy. A contributor to this dichotomy may be the activity of certain selenium containing enzymes like the cytosolic thioredoxin reductase (TR1). We evaluated the cellular response to select selenocompounds that have anticancer activity when TR1 was attenuated by siRNA in RKO colon cancer cells. Methylseleninic acid (MSA). which is a substrate for TR1, enhanced cytotoxicity to colon cancer cells when TR1 was attenuated. MSA induced stress in the endoplasmic reticulum, as measured by GRP78 protein levels. However, this pathway did not appear to account for the change in cytotoxicity when TR1 was attenuated. Instead, knockdown of the cytosolic TR plus incubation with MSA increased autophagy, as measured by LOB cleavage, and apoptosis, as measured by Annexin V and mitochondrial dysfunction. Therefore, the use of selenocompounds with anticancer activity, like MSA, might be utilized most effectively with agents that targets TR1 in chemotherapeutic applications. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Honeggar, Matthew; Beck, Robert; Moos, Philip J.] Univ Utah, Dept Pharmacol & Toxicol, LS Skaggs Pharm, Salt Lake City, UT 84112 USA.
RP Moos, PJ (corresponding author), Univ Utah, Dept Pharmacol & Toxicol, LS Skaggs Pharm, Rm 201,30 S 2000 E, Salt Lake City, UT 84112 USA.
EM philip.moos@utah.edu
OI Moos, Philip/0000-0002-8223-442X
FU USPHSUnited States Department of Health & Human ServicesUnited States
   Public Health Service [CA115616];  [P30 CA042014]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA042014, R01CA115616] Funding Source: NIH RePORTER
FX This project was supported by a USPHS Grants CA115616 (PJM) We also
   acknowledge the use of core facilities supported by P30 CA042014 awarded
   to the Huntsman Cancer Institute.
CR Baker RD, 1998, J PEDIATR GASTR NUTR, V27, P387, DOI 10.1097/00005176-199810000-00003
   Berggren M, 1997, ANTICANCER RES, V17, P3377
   Berggren MM, 1999, BIOCHEM PHARMACOL, V57, P187, DOI 10.1016/S0006-2952(98)00283-4
   Bleys J, 2008, ARCH INTERN MED, V168, P404, DOI 10.1001/archinternmed.2007.74
   Cassidy PB, 2006, CARCINOGENESIS, V27, P2538, DOI 10.1093/carcin/bgl111
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   CLARK LC, 1991, ARCH ENVIRON HEALTH, V46, P37, DOI 10.1080/00039896.1991.9937427
   Connelly-Frost A, 2009, NUTR CANCER, V61, P165, DOI 10.1080/01635580802404188
   CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U
   Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103
   Gallegos A, 1997, CANCER RES, V57, P4965
   Gromer S, 2002, J BIOL CHEM, V277, P9701, DOI 10.1074/jbc.M109234200
   HATFIELD DL, 2009, BIOCH BIOPHYS ACTA
   Hatfield DL, 2009, MOL INTERV, V9, P18, DOI 10.1124/mi.9.1.6
   Hu H, 2008, CLIN CANCER RES, V14, P1150, DOI 10.1158/1078-0432.CCR-07-4037
   Ip C, 2000, CANCER RES, V60, P2882
   Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659
   Irons R, 2006, J NUTR, V136, P1311, DOI 10.1093/jn/136.5.1311
   Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li GX, 2008, CARCINOGENESIS, V29, P1005, DOI 10.1093/carcin/bgn007
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   LOBANOV AV, 2009, BIOCH BIOPHYS ACTA
   Marshafl JR, 2008, GASTROENTEROL CLIN N, V37, P73, DOI 10.1016/j.gtc.2007.12.008
   Peters U, 2006, CANCER EPIDEM BIOMAR, V15, P315, DOI 10.1158/1055-9965.EPI-05-0471
   Peters U, 2008, MOL NUTR FOOD RES, V52, P1261, DOI 10.1002/mnfr.200800103
   Peters U, 2008, CANCER EPIDEM BIOMAR, V17, P1144, DOI 10.1158/1055-9965.EPI-07-2947
   Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285
   Saito Y, 2003, J BIOL CHEM, V278, P39428, DOI 10.1074/jbc.M305542200
   Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8
   Shamberger R J, 1971, CRC Crit Rev Clin Lab Sci, V2, P211, DOI 10.3109/10408367109151308
   Shin SH, 2007, ONCOL REP, V17, P209
   Sohn OS, 2005, CHEM-BIOL INTERACT, V151, P193, DOI 10.1016/j.cbi.2004.10.007
   Stranges S, 2007, ANN INTERN MED, V147, P217, DOI 10.7326/0003-4819-147-4-200708210-00175
   Suzuki KT, 2006, TOXICOL APPL PHARM, V217, P43, DOI 10.1016/j.taap.2006.07.006
   Suzuki KT, 2006, TOXICOL APPL PHARM, V217, P51, DOI 10.1016/j.taap.2006.07.005
   Suzuki KT, 2006, TOXICOL APPL PHARM, V217, P185, DOI 10.1016/j.taap.2006.09.006
   Suzuki KT, 2006, TOXICOL APPL PHARM, V215, P189, DOI 10.1016/j.taap.2006.02.011
   Swede H, 2003, CANCER EPIDEM BIOMAR, V12, P1248
   Trotter EW, 2002, MOL MICROBIOL, V46, P869, DOI 10.1046/j.1365-2958.2002.03216.x
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu Y, 2005, CANCER RES, V65, P9073, DOI 10.1158/0008-5472.CAN-05-2016
   Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200
   Yoo MH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001112
   Zhao R, 2002, J BIOL CHEM, V277, P39456, DOI 10.1074/jbc.M206452200
   Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399
   Zu K, 2006, ONCOGENE, V25, P546, DOI 10.1038/sj.onc.1209071
NR 47
TC 13
Z9 14
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD DEC 15
PY 2009
VL 241
IS 3
BP 348
EP 355
DI 10.1016/j.taap.2009.09.010
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 520JX
UT WOS:000271841400012
PM 19782697
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Cheng, CY
   Lin, YH
   Su, CC
AF Cheng, Chun-Yuan
   Lin, Yi-Hsiang
   Su, Chin-Cheng
TI Sann-Joong-Kuey-Jian-Tang increases the protein expression of
   microtubule-associated protein II light chain 3 in human colon cancer
   colo 205 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Sann-Joong-Kuey-Jian-Tang; microtubule-associated protein II light chain
   3; colo 205 cells; autophagy
ID AUTOPHAGY
AB Sann-Joong-Kuey-Jian-Tang (SJKJT), a traditional Chinese medicine, has been prescribed as complementary medication for colon cancer in Taiwan. However, its molecular mechanisms are not yet understood. In the present study. we investigated the effects of SJKJT oil human colon cancer colo 205 cells ill vitro. The cytotoxicity of SJKJT in colo 205 cells was evaluated using the MTT assay, and the protein expression of microtubule-associated protein 11 light chain 3 (MAP-LC3-II) was measured using Western blot analysis. The results showed that SJKJT inhibited the survival rates of colo 205 cells in a time- and dose-dependent manner, with all IC50 concentration at 24 h of 590.34 mu g/ml. In addition, SJKJT up-regulated the protein expression of MAP-LC3-II in colo 205 cells. These findings indicate that one of the molecular mechanisms by which SJKJT inhibits the proliferation of colo 205 cells ill vitro may be through the induction of the autophagic pathway. SJKJT may therefore have therapeutic potential for the treatment of human colon cancer.
C1 [Su, Chin-Cheng] Buddhist Tzu Chi Gen Hosp, Div Gen Surg, Hualien 970, Taiwan.
   [Lin, Yi-Hsiang; Su, Chin-Cheng] Tzu Chi Univ, Inst Pharmacol & Toxicol, Hualien, Taiwan.
   [Cheng, Chun-Yuan] Changhua Christian Hosp, Changhua 500, Taiwan.
   [Cheng, Chun-Yuan] Chung Shan Med Univ, Inst Med, Taichung 40201, Taiwan.
RP Su, CC (corresponding author), Buddhist Tzu Chi Gen Hosp, Div Gen Surg, 707 Sec 3,Chung Yang Rd, Hualien 970, Taiwan.
EM succ.maeva@msa.hinet.net
FU Research Section of Buddhist Tzu Chi General Hospital, Hualien, Taiwan
   [TCRD97-05]; Chen-Han Foundation for Education
FX This study was supported by grant no. TCRD97-05 from the Research
   Section of Buddhist Tzu Chi General Hospital, Hualien, Taiwan. This
   Study was supported in part by the Chen-Han Foundation for Education.
CR CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Department of Health Executive Yuan Taipei Taiwan R.O.C, 2008, STAT CAUS DEATH, P33
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   Hsu YL, 2006, BIOL PHARM BULL, V29, P2388, DOI 10.1248/bpb.29.2388
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Rauh Rolf, 2007, Chin Med, V2, P8
   Su CC, 2008, INT J MOL MED, V22, P357, DOI 10.3892/ijmm_00000030
   Wei SC, 2004, J BIOMED SCI, V11, P260, DOI 10.1159/000076038
   YA K, 2006, AUTOPHAGY, V2, P85
   YANG CH, 1994, ADV SPACE RES-SERIES, V14, P115, DOI 10.1016/0273-1177(94)90459-6
   Yang YP, 2005, ACTA PHARMACOL SIN, V26, P1421, DOI 10.1111/j.1745-7254.2005.00235.x
NR 15
TC 6
Z9 6
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP-OCT
PY 2009
VL 2
IS 5
BP 707
EP 711
DI 10.3892/mmr_00000160
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 481TU
UT WOS:000268835600004
PM 21475889
OA Bronze
DA 2022-04-25
ER

PT J
AU Delou, JMA
   Biasoli, D
   Borges, HL
AF Delou, Joao M. A.
   Biasoli, Deborah
   Borges, Helena L.
TI The Complex Link between Apoptosis and Autophagy: a Promising New Role
   for RB
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE retinoblastoma; neoplasm; autophagy; cell death; antineoplastic agents
ID PROGRAMMED CELL-DEATH; BCL-2 FAMILY PROTEINS; RETINOBLASTOMA PROTEIN;
   HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; COLON-CANCER; INDUCED
   CYTOTOXICITY; TARGETING AUTOPHAGY; MOLECULAR MACHINERY; METABOLIC STRESS
AB Physiological processes, as autophagy, proliferation and apoptosis are affected during carcinogenesis. Restoring cellular sensitivity to apoptotic stimuli, such as the antineoplastic cocktails, has been explored as a strategy to eliminate cancer cells. Autophagy, a physiological process of recycling organelles and macromolecules can be deviated from homeostasis to support cancer cells survival, proliferation, escape from apoptosis, and therapy resistance. The relationship between autophagy and apoptosis is complex and many stimuli can induce both processes. Most chemotherapeutic agents induce autophagy and it is not clear whether and how this chemotherapy-induced autophagy might contribute to resistance to apoptosis. Here, we review current strategies to sensitize cancer cells by interfering with autophagy. Moreover, we discuss a new link between autophagy and apoptosis: the tumor suppressor retinoblastoma protein (RB). Inactivation of RB is one of the earliest and more frequent hallmarks of cancer transformation, known to control cell cycle progression and apoptosis. Therefore, understanding RB functions in controlling cell fate is essential for an effective translation of RB status in cancer samples to the clinical outcome.
C1 [Delou, Joao M. A.; Biasoli, Deborah; Borges, Helena L.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Av Carlos Chagas Filho 373, BR-21949590 Rio De Janeiro, RJ, Brazil.
RP Borges, HL (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Av Carlos Chagas Filho 373, BR-21949590 Rio De Janeiro, RJ, Brazil.
EM hborges@icb.ufrj.br
RI Borges, Helena/W-7533-2019; Borges, Helena L/E-5044-2013; Borges,
   Helena/AAG-3701-2020; Delou, João Marcos/N-8760-2014
OI Borges, Helena/0000-0003-2866-4223; Borges, Helena
   L/0000-0003-2866-4223; Delou, João Marcos/0000-0003-1141-5351
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), BrazilFundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Fundacao do
   Cancer do Rio de Janeiro, Brazil
FX Deborah Biasoli, Joao M.A. Delou and Helena L. Borges are are supported
   by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), by the Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES), the Fundacao Carlos Chagas Filho de Amparo a Pesquisa
   do Estado do Rio de Janeiro (FAPERJ), and by the Fundacao do Cancer do
   Rio de Janeiro, Brazil. We thank Dr. Rossana Colla Soletti for
   constructive comments of the manuscript.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Andrusiak MG, 2012, J NEUROSCI, V32, P14809, DOI 10.1523/JNEUROSCI.1912-12.2012
   Attardi LD, 2013, GENE DEV, V27, P975, DOI 10.1101/gad.219451.113
   Avery-Kiejda KA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-203
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Berry DE, 1996, ONCOGENE, V12, P1809
   Biasoli D, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.36
   Biasoli D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.283
   Bilir A, 2001, PATHOBIOLOGY, V69, P120, DOI 10.1159/000048766
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0
   Borges HL, 2007, ONCOGENE, V26, P3868, DOI 10.1038/sj.onc.1210157
   Bosnjak M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094374
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)82148-6
   Chau BN, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000082
   Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085771
   Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465
   Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794
   CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0
   Cluzeau T, 2011, CELL CYCLE, V10, P2339, DOI 10.4161/cc.10.14.16308
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700
   de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Desai S, 2013, J BIOL CHEM, V288, P9165, DOI 10.1074/jbc.M112.422071
   Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044
   Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garcia-Garcia A, 2012, CANCER BIOL THER, V13, P1091, DOI 10.4161/cbt.21143
   Ge L, 2014, ELIFE, V3, DOI 10.7554/eLife.04135
   Goehe RW, 2012, J PHARMACOL EXP THER, V343, P763, DOI 10.1124/jpet.112.197590
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Guo Z, 2001, CANCER RES, V61, P8395
   HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x
   Hacker G, 2013, MICROBES INFECT, V15, P640, DOI 10.1016/j.micinf.2013.05.005
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HAUPT Y, 1995, ONCOGENE, V10, P1563
   Hernandez-Breijo B, 2013, TOXICOL APPL PHARM, V272, P568, DOI 10.1016/j.taap.2013.07.024
   Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Huang XD, 2007, J BIOL CHEM, V282, P29401, DOI 10.1074/jbc.M702261200
   Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026
   Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286
   JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0
   Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   KIPPS TJ, 2015, LEUKEMIA LYMPHOMA, V56, P2826, DOI DOI 10.3109/10428194.2015.1030638
   Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Knox JJ, 2008, INVEST NEW DRUG, V26, P193, DOI 10.1007/s10637-007-9104-1
   Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401
   Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kolupaeva V, 2013, FEBS J, V280, P627, DOI 10.1111/j.1742-4658.2012.08511.x
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Korah J, 2016, J BIOL CHEM, V291, P2043, DOI 10.1074/jbc.M115.678557
   Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003
   Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428
   LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin WW, 2015, SCI REP-UK, V5, DOI 10.1038/srep12362
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu XY, 2016, NEUROSCI LETT, V620, P137, DOI 10.1016/j.neulet.2016.04.001
   Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Malik SA, 2011, ONCOGENE, V30, P3918, DOI 10.1038/onc.2011.104
   Malkin D, 2011, CANCER, V2, P475, DOI [10.1177/1947601911413466, DOI 10.1177/1947601911413466]
   Manov I, 2011, FEBS J, V278, P3494, DOI 10.1111/j.1742-4658.2011.08271.x
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   McConkey DJ, 1996, ONCOGENE, V13, P1693
   Munro S, 2012, ONCOGENE, V31, P4343, DOI 10.1038/onc.2011.603
   Nakamura N, 1997, J BIOCHEM, V121, P338
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407
   O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191
   O'Brien S, 2009, J CLIN ONCOL, V27, P5208, DOI 10.1200/JCO.2009.22.5748
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Ristica B, 2014, EXP CELL RES, V326, P90, DOI 10.1016/j.yexcr.2014.05.021
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764
   Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105
   Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723
   Shen XG, 2010, COLORECTAL DIS, V12, P1213, DOI 10.1111/j.1463-1318.2009.02009.x
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001
   Sirois I, 2012, AUTOPHAGY, V8, P927, DOI 10.4161/auto.19768
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Swampillai AL, 2012, CLIN ONCOL-UK, V24, P387, DOI 10.1016/j.clon.2011.09.010
   Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263
   Tan SS, 2015, ONCOL LETT, V9, P2056, DOI 10.3892/ol.2015.2996
   Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826
   Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200
   Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Veldhoen RA, 2013, ONCOGENE, V32, P736, DOI 10.1038/onc.2012.92
   Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211
   Vogler Meike, 2014, Adv Med, V2014, P943648, DOI 10.1155/2014/943648
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246
   Yazdankhah M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.358
   Yoo SH, 2012, INT J ONCOL, V41, P1443, DOI 10.3892/ijo.2012.1585
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zeng XH, 2008, CANCER RES, V68, P2384, DOI 10.1158/0008-5472.CAN-07-6163
   Zeng XH, 2007, CLIN CANCER RES, V13, P1315, DOI 10.1158/1078-0432.CCR-06-1517
   Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931
NR 152
TC 24
Z9 26
U1 0
U2 7
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD OCT-DEC
PY 2016
VL 88
IS 4
BP 2257
EP 2275
DI 10.1590/0001-3765201620160127
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EH2FA
UT WOS:000391581800019
PM 27991962
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU D'Onofrio, N
   Cacciola, NA
   Martino, E
   Borrelli, F
   Fiorino, F
   Lombardi, A
   Neglia, G
   Balestrieri, ML
   Campanile, G
AF D'Onofrio, Nunzia
   Cacciola, Nunzio Antonio
   Martino, Elisa
   Borrelli, Francesca
   Fiorino, Ferdinando
   Lombardi, Assunta
   Neglia, Gianluca
   Balestrieri, Maria Luisa
   Campanile, Giuseppe
TI ROS-Mediated Apoptotic Cell Death of Human Colon Cancer LoVo Cells by
   Milk delta-Valerobetaine
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COLORECTAL-CANCER; SIRT6; AUTOPHAGY; CONSUMPTION; PREVENTION; PATHWAYS;
   BUFFALO; TARGET; RISK
AB delta -Valerobetaine (delta VB) is a constitutive milk metabolite with antioxidant and anti-inflammatory activities. Here, we tested the antineoplastic properties of milk delta VB on human colorectal cancer cells. CCD 841 CoN (non-tumorigenic), HT-29 (p53 mutant adenocarcinoma) and LoVo (APC/RAS mutant adenocarcinoma) cells were exposed to 3kDa milk extract, delta VB (2mM) or milk+delta VB up to 72h. Results showed a time- and dose-dependent capability of delta VB to inhibit cancer cell viability, with higher potency in LoVo cells. Treatment with milk+delta VB arrested cell cycle in G2/M and SubG1 phases by upregulating p21, cyclin A, cyclin B1 and p53 protein expressions. Noteworthy, delta VB also increased necrosis (P<0.01) and when used in combination with milk it improved its activity on live cell reduction (P<0.05) and necrosis (P<0.05). <delta>VB-enriched milk activated caspase 3, caspase 9, Bax/Bcl-2 apoptotic pathway and reactive oxygen species (ROS) production, whereas no effects on ROS generation were observed in CCD 841 CoN cells. The altered redox homeostasis induced by milk+delta VB was accompanied by upregulation of sirtuin 6 (SIRT6). SIRT6 silencing by small interfering RNA blocked autophagy and apoptosis activated by milk+delta VB, unveiling the role of this sirtuin in the ROS-mediated apoptotic LoVo cell death.
C1 [D'Onofrio, Nunzia; Martino, Elisa; Balestrieri, Maria Luisa] Univ Campania L Vanvitelli, Dept Precis Med, I-80138 Naples, Italy.
   [Cacciola, Nunzio Antonio; Neglia, Gianluca; Campanile, Giuseppe] Univ Naples Federico II, Dept Vet Med & Anim Prod, I-80137 Naples, Italy.
   [Cacciola, Nunzio Antonio] Natl Res Council CNR, Inst Sustainable Plant Protect IPSP, I-80055 Naples, Italy.
   [Borrelli, Francesca; Fiorino, Ferdinando] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, I-80131 Naples, Italy.
   [Lombardi, Assunta] Univ Naples Federico II, Dept Biol, I-80126 Naples, Italy.
RP Balestrieri, ML (corresponding author), Univ Campania L Vanvitelli, Dept Precis Med, I-80138 Naples, Italy.
EM marialuisa.balestrieri@unicampania.it
RI Borrelli, Francesca/AAC-6715-2022; D'Onofrio, Nunzia/M-2081-2019
OI D'Onofrio, Nunzia/0000-0002-5300-9530; Martino,
   Elisa/0000-0003-4070-2894; Balestrieri, Maria Luisa/0000-0001-6001-1789
FU VALERE 2019 Program University of Campania L. Vanvitelli, PSR Regione
   Campania 2014/2020 - STRABUF [B68H19005200009]; VALERE 2019 Program
   University of Campania L. Vanvitelli, PON I&C 2014-2020 - TABAREZO
   [F/200085/01-03/X45]; VALERE 2019 Program University of Campania L.
   Vanvitelli, PON I&C 2014-2020 - CAPSULE [F/200016/01-03/X45]
FX This work was supported by VALERE 2019 Program University of Campania L.
   Vanvitelli, PSR Regione Campania 2014/2020 - STRABUF -B68H19005200009,
   PON I&C 2014-2020 - TABAREZO - F/200085/01-03/X45, and PON I&C 2014-2020
   - CAPSULE - F/200016/01-03/X45.
CR Aleksandrova K, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0168-4
   Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Bakken T, 2018, BRIT J NUTR, V119, P1274, DOI [10.1017/S0007114518000752, 10.1017/s0007114518000752]
   Barrubes L, 2018, INT J CANCER, V143, P1356, DOI 10.1002/ijc.31540
   Basilicata MG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071955
   Bishayee A, 2016, SEMIN CANCER BIOL, V40-41, P1, DOI 10.1016/j.semcancer.2016.08.006
   Brijesha N, 2017, FOOD RES INT, V97, P95, DOI 10.1016/j.foodres.2017.03.037
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cho E, 2004, JNCI-J NATL CANCER I, V96, P1015, DOI 10.1093/jnci/djh185
   D'Onofrio N, 2019, J AGR FOOD CHEM, V67, P1702, DOI 10.1021/acs.jafc.8b07166
   D'Onofrio N, 2018, ANTIOXID REDOX SIGN, V28, P711, DOI 10.1089/ars.2017.7178
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Gao T, 2019, NEOPLASIA, V21, P61, DOI 10.1016/j.neo.2018.11.008
   Godos J, 2020, INT J FOOD SCI NUTR, V71, P138, DOI 10.1080/09637486.2019.1625035
   Gong YT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1029-8
   Huma N, 2018, ASIAN AUSTRAL J ANIM, V31, P287, DOI 10.5713/ajas.17.0031
   Iachettini S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1065-0
   Karkkainen O, 2018, SCI REP, P8
   Karkkainen O, 2018, AM J CLIN NUTR, V108, P971, DOI 10.1093/ajcn/nqy169
   Khan IT, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-0969-8
   Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Lerrer B, 2016, CARCINOGENESIS, V37, P108, DOI 10.1093/carcin/bgv167
   Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029
   Liu WG, 2018, ONCOL LETT, V15, P5368, DOI 10.3892/ol.2018.7989
   Lombardi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116498
   Mada SB, 2017, NUTRITION, V43-44, P21, DOI 10.1016/j.nut.2017.06.010
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   NavaneethaKrishnan S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9051542
   Park Y.W., 2013, MILK DAIRY PRODUCTS, V365, P519
   Qi J, 2018, ONCOL LETT, V16, P5829, DOI 10.3892/ol.2018.9400
   Rajoka MSR, 2017, FOOD SCI HUM WELL, V6, P121, DOI 10.1016/j.fshw.2017.07.003
   Ralston RA, 2014, CRIT REV FOOD SCI, V54, P1167, DOI 10.1080/10408398.2011.629353
   Roleira FMF, 2015, FOOD CHEM, V183, P235, DOI 10.1016/j.foodchem.2015.03.039
   Salzano A, 2019, J DAIRY SCI, V102, P7717, DOI 10.3168/jds.2019-16656
   Schwingshackl L, 2018, INT J CANCER, V142, P1748, DOI 10.1002/ijc.31198
   Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Servillo L, 2018, J AGR FOOD CHEM, V66, P8142, DOI 10.1021/acs.jafc.8b02963
   Servillo L, 2018, FOOD CHEM, V260, P193, DOI 10.1016/j.foodchem.2018.03.114
   Servillo L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084589
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Sociali G, 2019, FASEB J, V33, P3704, DOI 10.1096/fj.201800321R
   Tian JH, 2018, BIOMED PHARMACOTHER, V106, P109, DOI 10.1016/j.biopha.2018.06.070
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Van Meter M, 2014, ADV EXP MED BIOL, V818, P181, DOI 10.1007/978-1-4471-6458-6_9
   Vieira AR, 2017, ANN ONCOL, V28, P1788, DOI 10.1093/annonc/mdx171
   Vitiello M, 2017, AGEING RES REV, V35, P301, DOI 10.1016/j.arr.2016.10.008
   World Cancer Research Fund International/American Institute for Cancer Research, 2017, CONT UPD PROJ REP DI
   Yang J, 2018, PROTEIN CELL, V9, P474, DOI 10.1007/s13238-018-0543-6
   Zhang YJ, 2019, THERANOSTICS, V9, P2380, DOI 10.7150/thno.29724
NR 51
TC 16
Z9 16
U1 0
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 2
PY 2020
VL 10
IS 1
AR 8978
DI 10.1038/s41598-020-65865-6
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NB8XA
UT WOS:000560797800040
PM 32488123
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Fyrst, H
   Oskouian, B
   Bandhuvula, P
   Gong, YQ
   Byun, HS
   Bittman, R
   Lee, AR
   Saba, JD
AF Fyrst, Henrik
   Oskouian, Babak
   Bandhuvula, Padmavathi
   Gong, Yaqiong
   Byun, Hoe Sup
   Bittman, Robert
   Lee, Andrew R.
   Saba, Julie D.
TI Natural Sphingadienes Inhibit Akt-Dependent Signaling and Prevent
   Intestinal Tumorigenesis
SO CANCER RESEARCH
LA English
DT Article
ID CANCER-CELL-LINES; DIETARY SPHINGOLIPIDS; COLON-CANCER; CF1 MICE;
   IN-VIVO; SPHINGOSINE; PROTEIN; SPHINGOSINE-1-PHOSPHATE; PATHWAY;
   SPHINGOMYELIN
AB Sphingolipid metabolites regulate cell proliferation, migration, and stress responses. Alterations in sphingolipid metabolism have been proposed to contribute to carcinogenesis, cancer progression, and drug resistance. We identified a family of natural sphingolipids called sphingadienes and investigated their effects in colon cancer. We find that sphingadienes induce colon cancer cell death in vitro and prevent intestinal tumorigenesis in vivo. Sphingadienes exert their influence by blocking Akt translocation from the cytosol to the membrane, thereby inhibiting protein translation and promoting apoptosis and autophagy. Sphingadienes are orally available, are slowly metabolized through the sphingolipid degradative pathway, and show limited short-term toxicity. Thus, sphingadienes represent a new class of therapeutic and/or chemopreventive agents that blocks Akt signaling in neoplastic and preneoplastic cells. [Cancer Res 2009;69(24):9457-64]
C1 [Fyrst, Henrik; Oskouian, Babak; Bandhuvula, Padmavathi; Lee, Andrew R.; Saba, Julie D.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.
   [Gong, Yaqiong; Byun, Hoe Sup; Bittman, Robert] CUNY, Queens Coll, Flushing, NY USA.
RP Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.
EM jsaba@chori.org
OI Lee, Andrew/0000-0003-1496-9253
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [RAT005336A, CA129438, CA77528,
   GM66954, HL-083187]; NATIONAL CANCER INSTITUTEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA077528, R01CA129438] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE
   MEDICINEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Complementary &
   Alternative Medicine [R21AT005336] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R24HL083187] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM066954] Funding Source: NIH RePORTER
FX Grant support: NIH grants RAT005336A, CA129438, CA77528 and GM66954
   (J.D. Saba), and HL-083187 (R. Bittman).
CR Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje
   Berra B, 2002, EUR J CANCER PREV, V11, P193, DOI 10.1097/00008469-200204000-00013
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
   Crabbe T, 2007, TRENDS BIOCHEM SCI, V32, P450, DOI 10.1016/j.tibs.2007.09.001
   Degroote S, 2004, SEMIN CELL DEV BIOL, V15, P375, DOI 10.1016/j.semcdb.2004.03.007
   Dove WF, 1998, PHILOS T ROY SOC B, V353, P915, DOI 10.1098/rstb.1998.0256
   Fyrst H, 2008, J LIPID RES, V49, P597, DOI 10.1194/jlr.M700414-JLR200
   HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6
   Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323
   Kim RH, 2009, BBA-MOL CELL BIOL L, V1791, P692, DOI 10.1016/j.bbalip.2009.02.011
   Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05
   Lahiri S, 2007, CELL MOL LIFE SCI, V64, P2270, DOI 10.1007/s00018-007-7076-0
   Lemonnier LA, 2003, ARCH BIOCHEM BIOPHYS, V419, P129, DOI 10.1016/j.abb.2003.08.023
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Means CK, 2007, AM J PHYSIOL-HEART C, V292, pH2944, DOI 10.1152/ajpheart.01331.2006
   MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200
   Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200
   Morrow CJ, 2005, FEBS LETT, V579, P5123, DOI 10.1016/j.febslet.2005.07.096
   Nilsson A, 2006, J LIPID RES, V47, P154, DOI 10.1194/jlr.M500357-JLR200
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110
   Row LC, 2007, J NAT PROD, V70, P1214, DOI 10.1021/np070095j
   Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098
   Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Schmelz EM, 1996, CANCER RES, V56, P4936
   Schmelz EM, 2001, CANCER RES, V61, P6723
   Struckhoff AP, 2004, J PHARMACOL EXP THER, V309, P523, DOI 10.1124/jpet.103.062760
   Sugawara T, 2006, BIOSCI BIOTECH BIOCH, V70, P2906, DOI 10.1271/bbb.60318
   Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7
   Symolon H, 2004, J NUTR, V134, P1157, DOI 10.1093/jn/134.5.1157
   Tan JW, 2003, LIPIDS, V38, P81, DOI 10.1007/s11745-003-1034-8
   Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010
   Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4
   Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009
NR 42
TC 43
Z9 43
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2009
VL 69
IS 24
BP 9457
EP 9464
DI 10.1158/0008-5472.CAN-09-2341
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 534TP
UT WOS:000272920500038
PM 19934323
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Kutuk, O
   Aytan, N
   Karakas, B
   Kurt, AG
   Acikbas, U
   Temel, SG
   Basaga, H
AF Kutuk, Ozgur
   Aytan, Nurgul
   Karakas, Bahriye
   Kurt, Asli Giray
   Acikbas, Ufuk
   Temel, Sehime Gulsun
   Basaga, Huveyda
TI Biphasic ROS production, p53 and BIK dictate the mode of cell death in
   response to DNA damage in colon cancer cells
SO PLOS ONE
LA English
DT Article
ID LYSOSOMAL MEMBRANE PERMEABILIZATION; BH3-ONLY PROTEIN BIK; BCL-X-L;
   ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; OXIDATIVE STRESS; FAMILY
   PROTEINS; INDUCTION; MITOCHONDRIA; ACTIVATION
AB Necrosis, apoptosis and autophagic cell death are the main cell death pathways in multicellular organisms, all with distinct and overlapping cellular and biochemical features. DNA damage may trigger different types of cell death in cancer cells but the molecular events governing the mode of cell death remain elusive. Here we showed that increased BH3-only protein BIK levels promoted cisplatin-and UV-induced mitochondrial apoptosis and biphasic ROS production in HCT-116 wild-type cells. Nonetheless, early single peak of ROS formation along with lysosomal membrane permeabilization and cathepsin activation regulated cisplatin-and UV-induced necrosis in p53-null HCT-116 cells. Of note, necrotic cell death in p53-null HCT-116 cells did not depend on BIK, mitochondrial outer membrane permeabilization or caspase activation. These data demonstrate how cancer cells with different p53 background respond to DNA-damaging agents by integrating distinct cell signaling pathways dictating the mode of cell death.
C1 [Kutuk, Ozgur; Kurt, Asli Giray; Acikbas, Ufuk] Baskent Univ, Adana Dr Turgut Noyan Med & Res Ctr, Dept Med Genet, Sch Med, Adana, Turkey.
   [Aytan, Nurgul] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Karakas, Bahriye; Basaga, Huveyda] Sabanci Univ, Genet & Bioengn Program, Mol Biol, Istanbul, Turkey.
   [Temel, Sehime Gulsun] Uludag Univ, Dept Histol & Embryol, Sch Med, Bursa, Turkey.
   [Temel, Sehime Gulsun] Near East Univ, Sch Med, Dept Histol & Embryol, Nicosia, Northern Cyprus, Turkey.
RP Kutuk, O (corresponding author), Baskent Univ, Adana Dr Turgut Noyan Med & Res Ctr, Dept Med Genet, Sch Med, Adana, Turkey.
EM ozgurkutuk@sabanciuniv.edu
RI KUTUK, OZGUR/AAH-1671-2019; Temel, Sehime/AAG-8385-2021
OI KUTUK, OZGUR/0000-0001-9854-7220; 
FU TUBITAK, Baskent University Research Fund [SBAG-113S481]; Science
   Academy
FX This work was supported by grants from TUBITAK (SBAG-113S481), Baskent
   University Research Fund and The Science Academy. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; This work was supported by grants
   from TUBITAK (SBAG-113S481), Baskent University Research Fund and The
   Science Academy.
CR Aits S, 2015, METHOD CELL BIOL, V126, P261, DOI 10.1016/bs.mcb.2014.10.032
   Aits S, 2013, J CELL SCI, V126, P1905, DOI 10.1242/jcs.091181
   Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132
   Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019
   Bodet L, 2010, BRIT J CANCER, V103, P1808, DOI 10.1038/sj.bjc.6605981
   BOYD JM, 1995, ONCOGENE, V11, P1921
   Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8
   Brojatsch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095032
   Brunelle JK, 2009, J CELL BIOL, V187, P429, DOI 10.1083/jcb.200904049
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chinnadurai G, 2008, ONCOGENE, V27, pS20, DOI 10.1038/onc.2009.40
   Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727
   Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102
   Frame FM, 2016, CANCER MED-US, V5, P61, DOI 10.1002/cam4.553
   Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592
   Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200
   Gurley KE, 2009, EMBO REP, V10, P87, DOI 10.1038/embor.2008.214
   Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098
   Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002
   Happo L, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.42
   Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696
   Jacobson LS, 2013, J BIOL CHEM, V288, P7481, DOI 10.1074/jbc.M112.400655
   Kang MA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.134
   Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Le Pen J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.400
   Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162
   Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200
   Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340
   McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5
   Montero J, 2013, CELL DEATH DIFFER, V20, P1465, DOI 10.1038/cdd.2013.52
   Montero J, 2015, CELL, V160, P977, DOI 10.1016/j.cell.2015.01.042
   Moore VD, 2013, CANCER LETT, V332, P202, DOI 10.1016/j.canlet.2011.12.021
   Motani K, 2010, CANCER SCI, V101, P1822, DOI 10.1111/j.1349-7006.2010.01610.x
   Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214
   Oh SY, 2007, MOL CANCER THER, V6, P2178, DOI 10.1158/1535-7163.MCT-07-0111
   Okamoto K, 2015, MOL CANCER RES, V13, P659, DOI 10.1158/1541-7786.MCR-14-0476
   Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890
   Paquet C, 2005, LEUKEMIA, V19, P784, DOI 10.1038/sj.leu.2403717
   Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783
   Real PJ, 2006, FEBS LETT, V580, P5905, DOI 10.1016/j.febslet.2006.08.088
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Sarosiek KA, 2013, TRENDS CELL BIOL, V23, P612, DOI 10.1016/j.tcb.2013.08.003
   Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007
   Shin HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15798
   Song EA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081257
   Spender LC, 2009, CELL DEATH DIFFER, V16, P593, DOI 10.1038/cdd.2008.183
   Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556
   Troyano A, 2003, CELL DEATH DIFFER, V10, P889, DOI 10.1038/sj.cdd.4401249
   Tu HC, 2009, P NATL ACAD SCI USA, V106, P1093, DOI 10.1073/pnas.0808173106
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286
   Xing FQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163935
   Yamaguchi H, 2013, CLIN CANCER RES, V19, P845, DOI 10.1158/1078-0432.CCR-12-2621
NR 54
TC 12
Z9 13
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2017
VL 12
IS 8
AR e0182809
DI 10.1371/journal.pone.0182809
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD2WT
UT WOS:000407396200099
PM 28796811
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Vense, R
   Tosetti, F
   Minghelli, S
   Poggi, A
   Ferrari, N
   Benelli, R
AF Vense, Roberta
   Tosetti, Francesca
   Minghelli, Simona
   Poggi, Alessandro
   Ferrari, Nicoletta
   Benelli, Roberto
TI Celecoxib increases EGF signaling in colon tumor associated fibroblasts,
   modulating EGFR expression and degradation
SO ONCOTARGET
LA English
DT Article
DE EGFR; celecoxib; colon; fibroblast
ID EPIDERMAL-GROWTH-FACTOR; CANCER-ASSOCIATED FIBROBLASTS; FACTOR RECEPTOR
   EGFR; GENE COPY NUMBER; COLORECTAL-CANCER; SUBEPITHELIAL MYOFIBROBLASTS;
   ENDOCYTIC TRAFFICKING; ADENOMATOUS POLYPS; ASPARTIC PROTEASE;
   EPITHELIAL-CELLS
AB We previously demonstrated that non-toxic doses of Celecoxib induced the immediate phosphorylation of Erk1-2 in colon tumor associated fibroblasts (TAFs), increasing their responsiveness to epidermal growth factor (EGF). We have now identified two concomitant mechanisms explaining the EGF-Celecoxib cooperation. We found that a 24-48h Celecoxib priming increased EGF receptor (EGFR) mRNA and protein levels in colon TAFs, promoting EGF binding and internalization. Celecoxib-primed TAFs showed a reduced EGFR degradation after EGF challenge. This delay corresponded to a deferred dissociation of EEA1 from EGFR positive endosomes and the accumulation of Rab7, pro Cathepsin-D and SQSTM1/p62, suggesting a shared bottleneck in the pathways of late-endosomes/autophagosomes maturation. Celecoxib modulated the levels of target proteins similarly to the inhibitors of endosome/lysosome acidification Bafilomycin-A1 and NH4Cl. Cytoplasmic vesicles fractionation showed a reduced maturation of Cathepsin-D in late endosomes and an increased content of EGFR and Rab7 in lysosomes of Celecoxib-treated TAFs.
   Our data indicate a double mechanism mediating the increased response to EGF of colon TAFs treated with Celecoxib. While EGFR overexpression could be targeted using anti EGFR drugs, the effects on endosome trafficking and protein turnover represents a more elusive target and should be taken into account for any long-term therapy with Celecoxib.
C1 [Vense, Roberta; Minghelli, Simona; Benelli, Roberto] IRCCS AOU San Martino IST, Immunol Lab, Genoa, Italy.
   [Vense, Roberta; Tosetti, Francesca; Minghelli, Simona; Poggi, Alessandro; Ferrari, Nicoletta] IRCCS AOU San Martino IST, Mol Oncol & Angiogenesis Lab, Genoa, Italy.
RP Benelli, R (corresponding author), IRCCS AOU San Martino IST, Immunol Lab, Genoa, Italy.
EM roberto.benelli@hsanmartino.it
RI Ferrari, Nicoletta/AAG-6049-2019; Poggi, Alessandro/K-6664-2016;
   Benelli, Roberto/AAF-3143-2019; Tosetti, Francesca/AAE-5569-2021
OI Ferrari, Nicoletta/0000-0002-6027-1035; Poggi,
   Alessandro/0000-0002-1860-430X; Benelli, Roberto/0000-0002-9769-0954;
   Tosetti, Francesca/0000-0001-8772-4834
FU Compagnia di San Paolo, Ministero fondo 5 per mille Enti della Ricerca
   Sanitaria, Associazione Italiana per la Ricerca sul CancroFondazione
   AIRC per la ricerca sul cancro
FX This study was supported by grants from the Compagnia di San Paolo,
   Ministero fondo 5 per mille Enti della Ricerca Sanitaria, Associazione
   Italiana per la Ricerca sul Cancro.
CR Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200
   Amoletti JP, 2005, J EXP CLIN CANC RES, V24, P279
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Arber N, 2011, AM J GASTROENTEROL, V106, P1135, DOI 10.1038/ajg.2011.116
   Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048
   Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724
   Benelli R, 2013, CANCER LETT, V328, P73, DOI 10.1016/j.canlet.2012.09.008
   Benelli R, 2009, INT J CANCER, V124, P2989, DOI 10.1002/ijc.24305
   Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Carothers AM, 2006, CANCER RES, V66, P6432, DOI 10.1158/0008-5472.CAN-06-0992
   Carothers AM, 2010, CANCER RES, V70, P4433, DOI 10.1158/0008-5472.CAN-09-4289
   Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200
   CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586
   Chulada PC, 2000, CANCER RES, V60, P4705
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32
   Davids JS, 2010, CANCER PREV RES, V3, P348, DOI 10.1158/1940-6207.CAPR-09-0146
   de Wit R, 2000, J BIOMOL SCREEN, V5, P133, DOI 10.1177/108705710000500305
   Degasperi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087293
   Dixon Dan A, 2013, Recent Results Cancer Res, V191, P7, DOI 10.1007/978-3-642-30331-9_2
   Eden ER, 2009, BIOCHEM SOC T, V37, P173, DOI 10.1042/BST0370173
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   Frolov RV, 2014, EUR J PHARMACOL, V730, P61, DOI 10.1016/j.ejphar.2014.02.032
   Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003
   Guha S, 2008, INDIAN J BIOCHEM BIO, V45, P75
   HEMLER ME, 1980, J BIOL CHEM, V255, P6253
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1
   Irrazabal T, 2014, MOL CELL, V54, P309, DOI 10.1016/j.molcel.2014.03.039
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Khan S, 2014, COMP BIOCHEM PHYS A, V168, P1, DOI 10.1016/j.cbpa.2013.10.026
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620
   Martin M, 1996, PATHOL RES PRACT, V192, P712, DOI 10.1016/S0344-0338(96)80093-8
   Micke P, 2005, EXPERT OPIN THER TAR, V9, P1217, DOI 10.1517/14728222.9.6.1217
   MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1
   Ota S, 2002, ALIMENT PHARM THER, V16, P102, DOI 10.1046/j.1365-2036.16.s2.8.x
   Park JH, 2014, ANN ONCOL, V25, P644, DOI 10.1093/annonc/mdt593
   Park JH, 2014, CANCER TREAT REV, V40, P68, DOI 10.1016/j.ctrv.2013.05.006
   Personeni N, 2008, CLIN CANCER RES, V14, P5869, DOI 10.1158/1078-0432.CCR-08-0449
   PINTO M, 1983, BIOL CELL, V47, P323
   POULSOM R, 1992, AM J PATHOL, V141, P389
   Powell DW, 2011, ANNU REV PHYSIOL, V73, P213, DOI 10.1146/annurev.physiol.70.113006.100646
   Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183
   Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005
   Prabhu KCL, 2014, AM J SURG, V207, P712, DOI 10.1016/j.amjsurg.2013.12.019
   Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043
   Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599
   Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059
   Scott CC, 2011, BIOESSAYS, V33, P103, DOI 10.1002/bies.201000108
   Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001
   Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2
   Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012
   Sigismund S, 2013, EMBO J, V32, P2140, DOI 10.1038/emboj.2013.149
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Swamy MV, 2003, CANCER RES, V63, P5239
   Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002
   Vanlandingham PA, 2009, J BIOL CHEM, V284, P12110, DOI 10.1074/jbc.M809277200
   Viiri J, 2010, MOL VIS, V16, P1399
   Waugh MG, 2013, NAT PROTOC, V8, P2429, DOI 10.1038/nprot.2013.148
   Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19
   Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8
   XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936
NR 79
TC 11
Z9 15
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 20
PY 2015
VL 6
IS 14
BP 12310
EP 12325
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO2SZ
UT WOS:000359008200042
PM 25987127
DA 2022-04-25
ER

PT J
AU Wu, F
   Liu, F
   Dong, LM
   Yang, H
   He, XX
   Li, LL
   Zhao, LH
   Jin, SS
   Li, G
AF Wu, Fang
   Liu, Fang
   Dong, Lemei
   Yang, Han
   He, Xixi
   Li, Lili
   Zhao, Lihao
   Jin, Sisi
   Li, Gang
TI miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell
   growth via activation of AMPK signaling
SO CANCER LETTERS
LA English
DT Article
DE Molecularly-targeted therapy; microRNA; Melanoma antigen A3/A6;
   AMP-activated protein kinase
ID INDUCED APOPTOSIS; PHOSPHORYLATION; AUTOPHAGY; PATHWAY; HYPOMETHYLATION;
   EXPRESSION; MICRORNAS; COMPLEXES; FAMILY
AB AMP-activated protein kinase (AMPK) is a metabolic regulator that acts to limit the growth of cancer cells. AMPK is downregulated by melanoma antigens A3/6 (MAGEA3/6), which are cancer-specific proteins that enhance the activity of specific E3 ubiquitin ligases to ubiquitinate and degrade AMP-activated protein kinase alpha 1 (AMPK alpha 1). Here, using a bioinformatic approach, we identified a microRNA, miR-1273g-3p, that is predicted to target the 3' untranslated region (UTR) of MAGEA3/6. Analyzing miR-1273g-3p expression in human colon cancer tissues, we found a reduction in miR-1273g-3p expression correlating with increased MAGEA3/6 expression and AMPK alpha 1 downregulation. Expression of miR-1273g in HT-29 cells and primary human colon cancer cells down regulated MAGEA3/6, leading to AMPK alpha 1 upregulation, inhibition of proliferation and cell apoptosis. The anti CRC activity of miR-1273g was blocked by AMPK alpha 1 knockout. MAGEA3/6 shRNA silencing mimicked and abolished miR-1273g-induced actions in HT-29 cells. In vivo, miR-1273g-or MAGEA3/6 shRNA-expressing HT-29 tumors grew significantly slower than control tumors. We propose a novel miRNA-based mechanism, whereby miR-1273g represses MAGEA3/6 expression in human CRC cells and tissues, which may provide a novel cancer-specific therapeutic.
C1 [Wu, Fang; Dong, Lemei; He, Xixi; Jin, Sisi] Wenzhou Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Wenzhou, Peoples R China.
   [Liu, Fang] Nanjing Med Univ, Dept Neurosurg, Affiliated Changzhou Peoples Hosp 2, Changzhou, Peoples R China.
   [Yang, Han; Li, Lili; Zhao, Lihao; Li, Gang] Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, South Bai Xiang St, Wenzhou 325000, Zhejiang, Peoples R China.
RP Li, G (corresponding author), Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, South Bai Xiang St, Wenzhou 325000, Zhejiang, Peoples R China.
EM ligangwzyd@163.com
FU Natural Science Foundation of Zhejiang ProvinceNatural Science
   Foundation of Zhejiang Province [LY15H030015]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81302181]
FX This project was supported by the Natural Science Foundation of Zhejiang
   Province (LY15H030015), and by National Natural Science Foundation of
   China (81302181). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118
   Chen MB, 2018, MOL CANCER THER, V17, P1229, DOI 10.1158/1535-7163.MCT-17-1094
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chomez P, 2001, CANCER RES, V61, P5544
   Dai CP, 2017, ONCOTARGET, V8, P95810, DOI 10.18632/oncotarget.21336
   Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001
   Fox Melissa M, 2013, Genes Cancer, V4, P3, DOI 10.1177/1947601913486346
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hadad SM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-307
   Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KH, 2006, WORLD J GASTROENTERO, V12, P5651, DOI 10.3748/wjg.v12.i35.5651
   Kim YM, 2007, ANN NY ACAD SCI, V1095, P496, DOI 10.1196/annals.1397.053
   Kopsiaftis S, 2016, TRANSL ONCOL, V9, P606, DOI 10.1016/j.tranon.2016.07.007
   Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Li C, 2015, CANCER BIOL THER, V16, P34, DOI 10.4161/15384047.2014.972274
   Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876
   Liu YY, 2018, ONCOGENE, V37, P2890, DOI 10.1038/s41388-018-0184-5
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Lu XS, 2017, ONCOTARGET, V8, P988, DOI 10.18632/oncotarget.13519
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Muhammad S, 2014, WORLD J GASTROENTERO, V20, P17011, DOI 10.3748/wjg.v20.i45.17011
   Nana-Sinkam SP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0445-8
   Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110
   Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6989, DOI 10.7314/APJCP.2014.15.17.6989
   Palma S, 2016, CLIN COLORECTAL CANC, V15, P104, DOI 10.1016/j.clcc.2015.11.001
   Pan SJ, 2018, CANCER LETT, V412, P21, DOI 10.1016/j.canlet.2017.09.051
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Pineda CT, 2015, AUTOPHAGY, V11, P844, DOI 10.1080/15548627.2015.1034420
   Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034
   Shantha Kumara H M C, 2012, Cancer Immun, V12, P16
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Tarnowski M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/1987505
   Van Tongelen A, 2017, CANCER LETT, V396, P130, DOI 10.1016/j.canlet.2017.03.029
   WEBER J, 1994, CANCER RES, V54, P1766
   Ye XT, 2018, CELL PHYSIOL BIOCHEM, V45, P1205, DOI 10.1159/000487452
   Zhao Z, 2017, ONCOTARGET, V8, P18312, DOI 10.18632/oncotarget.15436
NR 46
TC 34
Z9 34
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 435
BP 1
EP 9
DI 10.1016/j.canlet.2018.07.031
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GT6WX
UT WOS:000444662700001
PM 30056111
DA 2022-04-25
ER

PT J
AU Song, J
   Seo, H
   Kim, MR
   Lee, SJ
   Ahn, S
   Song, M
AF Song, Jisu
   Seo, Heejung
   Kim, Mi-Ryung
   Lee, Sang-Jae
   Ahn, Sooncheol
   Song, Minjung
TI Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed
   KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during
   Cancer Progression
SO MOLECULES
LA English
DT Article
DE Pharbitis nil; colorectal cancer; KRAS; muscle function
ID COLON-CANCER; APOPTOSIS; PROLIFERATION; CETUXIMAB; PATHWAY; RESISTANCE;
   GLYCOSIDES; AUTOPHAGY; THERAPY; INHIBIT
AB Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven colorectal cancer (CRC) is notorious to target with drugs and has shown ineffective treatment response. The seeds ofPharbitis nil,also known as morning glory, have been used as traditional medicine in East Asia. We focused on whetherPharbitis nilseeds have a suppressive effect on mutated KRAS-driven CRC as well as reserving muscle cell functions during CRC progression. Seeds ofPharbitis nil(Pharbitissemen) were separated by chromatography and the active compound ofPharbitissemen (PN) was purified by HPLC. The compound PN efficiently suppressed the proliferation of mutated KRAS-driven CRC cells and their clonogenic potentials in a concentration-dependent manner. It also induced apoptosis of SW480 human colon cancer cells and cell cycle arrest at the G2/M phase. The CRC related pathways, including RAS/ERK and AKT/mTOR, were assessed and PN reduced the phosphorylation of AKT and mTOR. Furthermore, PN preserved muscle cell proliferation and myotube formation in cancer conditioned media. In summary, PN significantly suppressed mutated KRAS-driven cell growth and reserved muscle cell function. Based on the current study, PN could be considered as a promising starting point for the development of a nature-derived drug against KRAS-mutated CRC progression.
C1 [Song, Jisu; Seo, Heejung; Kim, Mi-Ryung; Lee, Sang-Jae; Song, Minjung] Silla Univ, Sch Med & Life Sci, Dept Food Biotechnol, Busan 46958, South Korea.
   [Song, Jisu; Ahn, Sooncheol] Pusan Natl Univ, Sch Med, Dept Med Sci, Yangsan 50612, South Korea.
   [Seo, Heejung] Pusan Natl Univ, Dept Cognomechatron Engn, Coll Nanosci & Nanotechnol, Busan 46241, South Korea.
   [Song, Minjung] Univ Cambridge, WT MRC Inst Metab Sci, Cambridge CB2 0QQ, England.
RP Song, M (corresponding author), Silla Univ, Sch Med & Life Sci, Dept Food Biotechnol, Busan 46958, South Korea.; Ahn, S (corresponding author), Pusan Natl Univ, Sch Med, Dept Med Sci, Yangsan 50612, South Korea.; Song, M (corresponding author), Univ Cambridge, WT MRC Inst Metab Sci, Cambridge CB2 0QQ, England.
EM jisu632@naver.com; ssk4623@naver.com; haha7kmr@silla.ac.kr;
   sans76@silla.ac.kr; ahnsc@pusan.ac.kr; ms2700@medschl.cam.ac.uk
FU Brain Korea 21Ministry of Education & Human Resources Development
   (MOEHRD), Republic of Korea [NRF-2016R1A1A1A05921948]; Basic Research of
   the NRF [NRF-2020R1F1A1076624]
FX This research was funded by Brain Korea 21 (NRF-2016R1A1A1A05921948) and
   by Basic Research of the NRF (NRF-2020R1F1A1076624). The APC was funded
   by NRF-2020R1F1A1076624.
CR Allaoui A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040724
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bruggeman AR, 2016, J ONCOL PRACT, V12, P1163, DOI 10.1200/JOP.2016.016832
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   de Castro GS, 2019, CANCERS, V11, DOI 10.3390/cancers11091264
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Jung DY, 2008, CHEM PHARM BULL, V56, P203, DOI 10.1248/cpb.56.203
   Jung HJ, 2017, J ETHNOPHARMACOL, V208, P253, DOI 10.1016/j.jep.2017.07.020
   Kim KH, 2014, J AGR FOOD CHEM, V62, P7746, DOI 10.1021/jf501470k
   Kim KH, 2009, J NAT PROD, V72, P1121, DOI 10.1021/np900101t
   Ko SG, 2004, BIOL PHARM BULL, V27, P1604, DOI 10.1248/bpb.27.1604
   Lee Sang-Kyu, 2018, Advances in Biological Regulation, V68, P46, DOI 10.1016/j.jbior.2018.01.001
   Lee SR, 2017, PHYTOCHEM LETT, V20, P98, DOI 10.1016/j.phytol.2017.04.019
   Lee TH, 2008, PHYTOMEDICINE, V15, P836, DOI 10.1016/j.phymed.2008.02.019
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lin YY, 2017, J ETHNOPHARMACOL, V209, P305, DOI 10.1016/j.jep.2017.08.011
   McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662
   Misale S, 2012, ANN ONCOL, V23, P24
   Mollah ML, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/249217
   Nie YP, 2017, SCI REP-UK, V7, DOI 10.1038/srep41608
   Ono M, 2010, J NAT PROD, V73, P1846, DOI 10.1021/np1004888
   Park HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081746
   Park YJ, 2016, BIOORG MED CHEM LETT, V26, P4645, DOI 10.1016/j.bmcl.2016.08.054
   Pavlidou T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182475
   Perez-Sanchez A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37173-7
   Ponnurangam S, 2013, MOL CANCER THER, V12, P598, DOI 10.1158/1535-7163.MCT-12-0907
   Seo H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010020
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Son Y, 2019, PHYTOTHER RES, V33, P1689, DOI 10.1002/ptr.6357
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Villars FO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050986
   Wang G, 2019, J ETHNOPHARMACOL, V235, P255, DOI 10.1016/j.jep.2019.02.029
   Wang QH, 2014, CARBOHYD POLYM, V102, P460, DOI 10.1016/j.carbpol.2013.11.068
   최현덕, 2017, [Journal of Life Science, 생명과학회지], V27, P225
   Zhang ZY, 2013, INT J ONCOL, V43, P289, DOI 10.3892/ijo.2013.1946
   Zhou HP, 2019, J ETHNOPHARMACOL, V239, DOI 10.1016/j.jep.2019.111903
NR 36
TC 3
Z9 3
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2020
VL 25
IS 12
AR 2864
DI 10.3390/molecules25122864
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MM5QR
UT WOS:000550211600001
PM 32580297
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chang, C
   Liu, J
AF Chang, C.
   Liu, Juan
TI Matrine Treatment Triggers Apoptosis in Colon Cancer Cells
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Matrine; colon cancer Caco-2 cells; antiproliferative
ID EXPRESSION; PROLIFERATION; BCL-2; CHEMOTHERAPY; INHIBITION; AUTOPHAGY;
   CASPASE-3; PROMOTES; INVASION; EXTRACT
AB The aim of the present study was to investigate the role of matrine, a natural alkaloid from Sophora.flavescens with antiproliferative and proapoptotic activities, in human colon cancer using in vitro studies. Caco-2 cell line was treated with increasing doses (2.0 and 32 mg/ml) of matrine for 24 h. The MTT assay was used to measure abnormal cell multiplication, while flow cytometry was applied to determine the degree of apoptosis and cell growth. Western blot analysis was also used to detect the expression of various proteins. The results indicated that matrine blocked Caco-2 cell division in a dose -dependent and time-dependent manner. Matrine triggered apoptosis and blocked mitosis by altering the protein expression levels of B-cell lymphoma-2, B-cell lymphoma-2 -associated X protein, cytochrome c, caspase-9 and caspase-3. In conclusion, matrine is found to interfere with the proliferation of colon cancer cells in vitro by triggering apoptosis through enhancing the expression of X protein, caspase-3 and caspase-9, as well as suppressing B-cell lymphoma-2 expression. Therefore, matrine is a potential natural compound that could be used in colon cancer treatment..
C1 [Chang, C.] Hubei Polytech Univ, Dept Gastroenterol, Huangshi Cent Hosp, Affiliated Hosp, Huangshi, Hubei, Peoples R China.
   [Liu, Juan] Hubei Polytech Univ, Dept Publ Hlth, Huangshi Cent Hosp, Affiliated Hosp, Huangshi, Hubei, Peoples R China.
RP Liu, J (corresponding author), Hubei Polytech Univ, Dept Publ Hlth, Huangshi Cent Hosp, Affiliated Hosp, Huangshi, Hubei, Peoples R China.
EM hubeitcm@sina.com
FU Hubei Provincial Natural Scientific Foundation of China [2013CFC061]
FX the present study was supported by the Hubei Provincial Natural
   Scientific Foundation of China (NO. 2013CFC061).
CR An Q, 2016, MOL MED REP, V14, P4042, DOI 10.3892/mmr.2016.5753
   Bergquist JR, 2016, DIS COLON RECTUM, V59, P1142, DOI 10.1097/DCR.0000000000000699
   Biaoxue Rong, 2015, World J Surg Oncol, V13, P329, DOI 10.1186/s12957-015-0729-9
   Chen JC, 2014, ANN SURG ONCOL, V21, pS555, DOI 10.1245/s10434-014-3673-y
   Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Choi BM, 2010, ARCH PHARM RES, V33, P753, DOI 10.1007/s12272-010-0515-8
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   Dumitru CA, 2011, INT J CANCER, V129, P859, DOI 10.1002/ijc.25991
   Goldsmith KC, 2012, CANCER RES, V72, P2565, DOI 10.1158/0008-5472.CAN-11-3603
   Guo JR, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0031-x, 10.1186/S40659-015-0031-X]
   Guo M, 2015, BIOMED PHARMACOTHER, V76, P107, DOI 10.1016/j.biopha.2015.10.027
   Kim H, 2012, J ETHNOPHARMACOL, V142, P253, DOI 10.1016/j.jep.2012.04.053
   Lee JH, 2012, LUNG, V190, P69, DOI 10.1007/s00408-011-9326-z
   Li HL, 2014, ONCOL REP, V32, P2118, DOI [10.3892/or_xxxxxxxx, 10.3892/or.2014.3447]
   Li HL, 2010, AM J CHINESE MED, V38, P1115, DOI 10.1142/S0192415X10008512
   Li Y, 2013, ASIAN PAC J CANCER P, V14, P4599, DOI 10.7314/APJCP.2013.14.8.4599
   Liang JM, 2013, MOLECULES, V18, P12777, DOI 10.3390/molecules181012777
   Lindner AU, 2013, CANCER RES, V73, P519, DOI 10.1158/0008-5472.CAN-12-2269
   Liu LH, 2014, INT J MOL MED, V33, P423, DOI 10.3892/ijmm.2013.1567
   Liu MC, 2011, ASN NEURO, V3, P25, DOI 10.1042/AN20100012
   Lu SJ, 2015, INT J CLIN EXP PATHO, V8, P4764
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4
   Mu HY, 2014, ONCOL REP, V32, P1087, DOI 10.3892/or.2014.3273
   Peng XC, 2016, ANN CLIN LAB SCI, V46, P457
   Philip CA, 2016, ANTICANCER RES, V36, P4865, DOI 10.21873/anticanres.11050
   Plummer JM, 2016, ANN MED SURG, V5, P52, DOI 10.1016/j.amsu.2015.12.045
   Quo L, 2013, PANMINERVA MED, V55, P291
   Rong BX, 2015, INT J CLIN EXP MED, V8, P14701
   Sanders ME, 2013, GUT, V62, P787, DOI 10.1136/gutjnl-2012-302504
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sirab N, 2013, INT J MOL SCI, V14, P14301, DOI 10.3390/ijms140714301
   Song YL, 2017, ONCOL LETT, V13, P2563, DOI 10.3892/ol.2017.5749
   Sun IC, 2010, BIOCONJUG CHEM, V21, P1939
   Wang W, 2015, ACTA PHARMACOL SIN, V36, P676, DOI 10.1038/aps.2015.24
   Wang WP, 2016, DRUG DELIV, V23, P3674, DOI 10.1080/10717544.2016.1223210
   Wells CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060725
   Wu WD, 2014, CENT EUR J IMMUNOL, V39, P299, DOI 10.5114/ceji.2014.45939
   Xie SB, 2015, INT J ONCOL, V47, P517, DOI 10.3892/ijo.2015.3023
   Yang N, 2013, PHYTOCHEMISTRY, V95, P259, DOI 10.1016/j.phytochem.2013.07.023
   Yao CP, 2017, MED SCI MONITOR, V23, P2059, DOI 10.12659/MSM.901381
   Yu B, 2014, ONCOL REP, V31, P849, DOI 10.3892/or.2013.2869
   Yu HB, 2011, J ASIAN NAT PROD RES, V13, P242, DOI 10.1080/10286020.2010.551641
   Zhang JQ, 2011, ONCOL REP, V26, P115, DOI 10.3892/or.2011.1277
   Zhang LP, 2001, LEUKEMIA RES, V25, P793, DOI 10.1016/S0145-2126(00)00145-4
   Zhang SJ, 2014, MOL BIOL REP, V41, P2101, DOI 10.1007/s11033-014-3059-z
   Zhao BW, 2012, GRAEF ARCH CLIN EXP, V250, P897, DOI 10.1007/s00417-011-1751-4
   Zhou N, 2017, MOL MED REP, V15, P442, DOI 10.3892/mmr.2016.5999
NR 49
TC 1
Z9 1
U1 0
U2 6
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250-474X
EI 1998-3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PY 2020
VL 82
SI 3
BP 59
EP 65
DI 10.36468/pharmaceutical-sciences.sp1.61
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NK8IA
UT WOS:000566973300012
DA 2022-04-25
ER

PT J
AU Kim, DH
   Sung, B
   Kang, YJ
   Hwang, SY
   Kim, MJ
   Yoon, JH
   Im, E
   Kim, ND
AF Kim, Dong Hwan
   Sung, Bokyung
   Kang, Yong Jung
   Hwang, Seong Yeon
   Kim, Min Jeong
   Yoon, Jeong-Hyun
   Im, Eunok
   Kim, Nam Deuk
TI Sulforaphane inhibits hypoxia-induced HIF-1 alpha and VEGF expression
   and migration of human colon cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE sulforaphane; colon cancer cells; HIF-1; vascular endothelial growth
   factor
ID INDUCIBLE FACTOR-1; CYCLE ARREST; INDUCED ANGIOGENESIS; OXIDATIVE
   STRESS; APOPTOSIS; CHEMOPREVENTION; METASTASIS; PROTEASOME; AUTOPHAGY;
   ALPHA
AB The effects of sulforaphane (a natural product commonly found in broccoli) was investigated on hypoxia inducible factor-1 alpha (HIF-1 alpha) expression in HCT116 human colon cancer cells and AGS human gastric cancer cells. We found that hypoxia-induced HIF-1 alpha protein expression in HCT116 and AGS cells, while treatment with sulforaphane markedly and concentration-dependently inhibited HIF-1 alpha expression in both cell lines. Treatment with sulforaphane inhibited hypoxia-induced vascular endothelial growth factor (VEGF) expression in HCT116 cells. Treatment with sulforaphane modulated the effect of hypoxia on HIF-1 alpha stability. However, degradation of HIF-1 alpha by sulforaphane was not mediated through the 26S proteasome pathway. We also found that the inhibition of HIF-1 alpha by sulforaphane was not mediated through AKT and extracellular signal-regulated kinase phosphorylation under hypoxic conditions. Finally, hypoxiainduced HCT116 cell migration was inhibited by sulforaphane. These data suggest that sulforaphane may inhibit human colon cancer progression and cancer cell angiogenesis by inhibiting HIF-1 alpha and VEGF expression. Taken together, these results indicate that sulforaphane is a new and potent chemopreventive drug candidate for treating patients with human colon cancer.
C1 [Kim, Dong Hwan; Sung, Bokyung; Kang, Yong Jung; Hwang, Seong Yeon; Kim, Min Jeong; Yoon, Jeong-Hyun; Im, Eunok; Kim, Nam Deuk] Pusan Natl Univ, Mol Inflammat Res Ctr Aging Intervent, Dept Pharm, Busan 46241, South Korea.
RP Im, E (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Pharm, Busandaehag Ro 63 Beon Gil 2, Busan 46241, South Korea.
EM eoim@pusan.ac.kr; nadkim@pusan.ac.kr
RI Sung, Bokyung/AAX-5697-2021
FU Post-doc Development Program of Pusan National University
FX This study was financially supported by the 2015 Post-doc Development
   Program of Pusan National University.
CR Balasubramanian S, 2011, MOL PHARMACOL, V80, P870, DOI 10.1124/mol.111.072363
   Boddupalli Sekhar, 2012, Frontiers in Genetics, V3, P7, DOI 10.3389/fgene.2012.00007
   Chen MC, 2013, BIOCHEM PHARMACOL, V85, P1278, DOI 10.1016/j.bcp.2013.02.009
   Chen X, 2013, BRIT J PHARMACOL, V169, P437, DOI 10.1111/bph.12133
   Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287
   Denes V, 2015, INT J CANCER, V136, P1528, DOI 10.1002/ijc.29155
   Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Gan NQ, 2010, J BIOL CHEM, V285, P35528, DOI 10.1074/jbc.M110.152686
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hu R, 2006, CARCINOGENESIS, V27, P2038, DOI 10.1093/carcin/bgl049
   Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771
   Jeon YK, 2011, BBA-PROTEINS PROTEOM, V1814, P1340, DOI 10.1016/j.bbapap.2011.05.015
   Jo GH, 2014, INT J ONCOL, V45, P1497, DOI 10.3892/ijo.2014.2536
   Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5
   Jung DB, 2011, BIOL PHARM BULL, V34, P850, DOI 10.1248/bpb.34.850
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Kim DH, 2013, INT J ONCOL, V43, P1915, DOI 10.3892/ijo.2013.2116
   Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004
   Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029
   Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221
   Matsuo Y, 2014, J HEPATO-BIL-PAN SCI, V21, P105, DOI 10.1002/jhbp.6
   Mirzoeva S, 2008, MOL CARCINOGEN, V47, P686, DOI 10.1002/mc.20421
   Naumann P, 2011, INT J ONCOL, V39, P101, DOI 10.3892/ijo.2011.1025
   Parnaud G, 2004, NUTR CANCER, V48, P198, DOI 10.1207/s15327914nc4802_10
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7
   Rudolf E, 2011, TOXICOL IN VITRO, V25, P1302, DOI 10.1016/j.tiv.2011.04.019
   Semenza GL, 2007, J MOL MED-JMM, V85, P1293, DOI 10.1007/s00109-007-0285-z
   Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79
   Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI200113374
   Semenza GL, 2007, SCI STKE, DOI DOI 10.1126/STKE.4072007CM8
   Wang M, 2014, ONCOL LETT, V8, P2407, DOI 10.3892/ol.2014.2536
   Wang M, 2012, CHINESE J PHYSIOL, V55, P134, DOI 10.4077/CJP.2012.BAA085
   Yao H, 2008, INT J CANCER, V123, P1255, DOI 10.1002/ijc.23647
   Zhang CY, 2013, BIOCHEM PHARMACOL, V85, P1398, DOI 10.1016/j.bcp.2013.02.010
   Zhang J, 2014, ONCOTARGET, V5, P9664, DOI 10.18632/oncotarget.1856
NR 38
TC 43
Z9 45
U1 2
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2015
VL 47
IS 6
BP 2226
EP 2232
DI 10.3892/ijo.2015.3200
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CX1OM
UT WOS:000365465500026
PM 26498863
OA Bronze
DA 2022-04-25
ER

PT J
AU Deroyer, C
   Renert, AF
   Merville, MP
   Fillet, M
AF Deroyer, Celine
   Renert, Anne-Francoise
   Merville, Marie-Paule
   Fillet, Marianne
TI New role for EMD (emerin), a key inner nuclear membrane protein, as an
   enhancer of autophagosome formation in the C16-ceramide autophagy
   pathway
SO AUTOPHAGY
LA English
DT Article
DE autophagy; ceramide; colon cancer cells; EMD; LEM-domain;
   phosphorylation; PRKACA
ID DREIFUSS MUSCULAR-DYSTROPHY; TO-AUTOINTEGRATION FACTOR; PROGRAMMED
   CELL-DEATH; TYROSINE-PHOSPHORYLATION; CANCER-CELLS; TRANSCRIPTIONAL
   REPRESSOR; PHOSPHOPROTEOME ANALYSIS; IN-VITRO; CERAMIDE; BARRIER
AB To date, precise roles of EMD (emerin) remain poorly described. In this paper, we investigated the role of EMD in the C16-ceramide autophagy pathway. Ceramides are bioactive signaling molecules acting notably in the regulation of cell growth, differentiation, or cell death. However, the mechanisms by which they mediate these pathways are not fully understood. We found that C16-ceramide induces EMD phosphorylation on its LEM domain through PRKACA. Upon ceramide treatment, phosphorylated EMD binds MAP1LC3B leading to an increase of autophagosome formation. These data suggest a new role of EMD as an enhancer of autophagosome formation in the C16-ceramide autophagy pathway in colon cancer cells.
C1 [Deroyer, Celine; Renert, Anne-Francoise; Fillet, Marianne] Univ Liege, GIGA R Prote Unit, Liege, Belgium.
   [Merville, Marie-Paule] Ctr Hosp Univ Liege, Dept Clin Chem, Liege, Belgium.
   [Fillet, Marianne] Univ Liege, Ctr Interfacultaire Rech Medicament, Dept Pharm, Dept Analyt Pharmaceut Chem, Liege, Belgium.
RP Fillet, M (corresponding author), Univ Liege, GIGA R Prote Unit, Liege, Belgium.
EM marianne.fillet@ulg.ac.be
OI Fillet, Marianne/0000-0002-1453-6282
FU ARCAustralian Research Council; University of LiegeUniversity of Liege
FX MP Merville is a senior research associate at the National Fund for
   Scientific Research (FR-FNRS), Belgium. This work was financially
   supported by ARC fund and Leon Fredericq grant from University of Liege.
   We thank the "Imaging Platform" (S Ormenese and G Moraes, GIGA,
   University of Liege) for the confocal imaging and the "Viral vector
   platform" (E Divalentin, GIGA, University of Liege) for stable cell
   lines generation.
CR Amanchy R, 2005, J PROTEOME RES, V4, P1661, DOI 10.1021/pr050134h
   Bandhyopadhyay U, 2007, EXP GERONTOL, V42, P120, DOI 10.1016/j.exger.2006.05.019
   Bedia C, 2011, ANTI-CANCER AGENT ME, V11, P844, DOI 10.2174/187152011797655131
   Bhutia SK, 2010, CANCER RES, V70, P3667, DOI 10.1158/0008-5472.CAN-09-3647
   Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269
   Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007
   Dbaibo GS, 1997, BIOCHEM SOC T, V25, P557, DOI 10.1042/bst0250557
   Demmerle J, 2012, J BIOL CHEM, V287, P22080, DOI 10.1074/jbc.M111.325308
   Ellis JA, 1998, J CELL SCI, V111, P781
   Fairley EAL, 1999, J CELL SCI, V112, P2571
   Furukawa K, 2003, J CELL SCI, V116, P3811, DOI 10.1242/jcs.00682
   Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105
   Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855
   Haraguchi T, 2004, EUR J BIOCHEM, V271, P1035, DOI 10.1111/j.1432-1033.2004.04007.x
   Haraguchi T, 2001, J CELL SCI, V114, P4575
   Hirano Y, 2005, J BIOL CHEM, V280, P39925, DOI 10.1074/jbc.M503214200
   Holaska JM, 2007, BIOCHEMISTRY-US, V46, P8897, DOI 10.1021/bi602636m
   Holaska JM, 2004, PLOS BIOL, V2, P1354, DOI 10.1371/journal.pbio.0020231
   Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Ito H, 2009, BBA-GENE REGUL MECH, V1789, P681, DOI 10.1016/j.bbagrm.2009.08.006
   JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6
   Lavieu G, 2007, AUTOPHAGY, V3, P45, DOI 10.4161/auto.3416
   Leach N, 2007, J VIROL, V81, P10792, DOI 10.1128/JVI.00196-07
   Lee KK, 2001, J CELL SCI, V114, P4567
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840
   Margalit A, 2005, J CELL BIOCHEM, V95, P454, DOI 10.1002/jcb.20433
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398
   Morris JB, 2007, J VIROL, V81, P4429, DOI 10.1128/JVI.02354-06
   Muchir A, 2007, HUM MOL GENET, V16, P1884, DOI 10.1093/hmg/ddm137
   Muchir A, 2007, J CLIN INVEST, V117, P1282, DOI 10.1172/JCI29042
   Mullen TD, 2012, ANTI-CANCER AGENT ME, V12, P340, DOI 10.2174/187152012800228661
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026
   Olshefski RS, 2001, INT J CANCER, V93, P131, DOI 10.1002/ijc.1301
   Palumbo S, 2013, J CELL PHYSIOL, V228, P1, DOI 10.1002/jcp.24118
   Pan C, 2008, PROTEOMICS, V8, P4534, DOI 10.1002/pmic.200800105
   Park MA, 2008, AUTOPHAGY, V4, P929, DOI 10.4161/auto.6732
   Park YE, 2009, AUTOPHAGY, V5, P795, DOI 10.4161/auto.8901
   Pattingre S, 2009, AUTOPHAGY, V5, P558, DOI 10.4161/auto.5.4.8390
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1
   Plo I, 1999, NEUROREPORT, V10, P2373, DOI 10.1097/00001756-199908020-00028
   Quan W, 2012, EXP MOL MED, V44, P81, DOI 10.3858/emm.2012.44.2.030
   Renert AF, 2009, J PROTEOME RES, V8, P4810, DOI 10.1021/pr9005316
   Roberts RC, 2006, FEBS J, V273, P4562, DOI 10.1111/j.1742-4658.2006.05464.x
   Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schlosser A, 2006, FEBS J, V273, P3204, DOI 10.1111/j.1742-4658.2006.05329.x
   Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7
   Spassieva SD, 2009, BIOCHEM J, V424, P273, DOI 10.1042/BJ20090699
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Tifft KE, 2009, J CELL SCI, V122, P3780, DOI 10.1242/jcs.048397
   Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200
   Wilkinson FL, 2003, EUR J BIOCHEM, V270, P2459, DOI 10.1046/j.1432-1033.2003.03617.x
   Yacoub A, 2010, CANCER RES, V70, P1120, DOI 10.1158/0008-5472.CAN-09-4043
   Yip SC, 2012, J CELL SCI, V125, P310, DOI 10.1242/jcs.086256
NR 66
TC 15
Z9 17
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUL
PY 2014
VL 10
IS 7
BP 1229
EP 1240
DI 10.4161/auto.28777
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AL2HG
UT WOS:000338946000006
PM 24819607
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Kuranaga, Y
   Sugito, N
   Shinohara, H
   Tsujino, T
   Taniguchi, K
   Komura, K
   Ito, Y
   Soga, T
   Akao, Y
AF Kuranaga, Yuki
   Sugito, Nobuhiko
   Shinohara, Haruka
   Tsujino, Takuya
   Taniguchi, Kohei
   Komura, Kazumasa
   Ito, Yuko
   Soga, Tomoyoshi
   Akao, Yukihiro
TI SRSF3, a Splicer of the PKM Gene, Regulates Cell Growth and Maintenance
   of Cancer-Specific Energy Metabolism in Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE energy metabolism; alternative splicing; oncogenes
ID PYRUVATE-KINASE; COLORECTAL-CANCER; HNRNP PROTEINS; MESSENGER-RNA;
   EXPRESSION; TUMOR; PROLIFERATION; TRANSLATION; REPRESSES; ISOFORM
AB Serine and arginine rich splicing factor 3 (SRSF3), an SR-rich family protein, has an oncogenic function in various kinds of cancer. However, the detailed mechanism of the function had not been previously clarified. Here, we showed that the SRSF3 splicer regulated the expression profile of the pyruvate kinase, which is one of the rate-limiting enzymes in glycolysis. Most cancer cells express pyruvate kinase muscle 2 (PKM2) dominantly to maintain a glycolysis-dominant energy metabolism. Overexpression of SRSF3, as well as that of another splicer, polypyrimidine tract binding protein 1 (PTBP1) and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), in clinical cancer samples supported the notion that these proteins decreased the Pyruvate kinase muscle 1 (PKM1)/PKM2 ratio, which positively contributed to a glycolysis-dominant metabolism. The silencing of SRSF3 in human colon cancer cells induced a marked growth inhibition in both in vitro and in vivo experiments and caused an increase in the PKM1/PKM2 ratio, thus resulting in a metabolic shift from glycolysis to oxidative phosphorylation. At the same time, the silenced cells were induced to undergo autophagy. SRSF3 contributed to PKM mRNA splicing by co-operating with PTBP1 and hnRNPA1, which was validated by the results of RNP immunoprecipitation (RIP) and immunoprecipitation (IP) experiments. These findings altogether indicated that SRSF3 as a PKM splicer played a positive role in cancer-specific energy metabolism.
C1 [Kuranaga, Yuki; Sugito, Nobuhiko; Shinohara, Haruka; Akao, Yukihiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagito, Gifu, Gifu 5011193, Japan.
   [Tsujino, Takuya; Komura, Kazumasa] Osaka Med Coll, Dept Urol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
   [Taniguchi, Kohei] Osaka Med Coll, Dept Gen & Gastroenterol Surg, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
   [Taniguchi, Kohei; Komura, Kazumasa] Osaka Med Coll, Translat Res Program, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
   [Ito, Yuko] Osaka Med Coll, Dept Anat & Cell Biol, Div Life Sci, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
   [Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, 246-2 Mizukami, Tsuruoka, Yamagata 9970017, Japan.
RP Akao, Y (corresponding author), Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagito, Gifu, Gifu 5011193, Japan.
EM v3501001@edu.gifu-u.ac.jp; v3501002@edu.gifu-u.ac.jp;
   harukashinohara313@gmail.com; uro061@osaka-med.ac.jp;
   sur144@osaka-med.ac.jp; uro051@osaka-med.ac.jp; an1006@osaka-med.ac.jp;
   soga@sfc.keio.ac.jp; yakao@gifu-u.ac.jp
OI Kuranaga, Yuki/0000-0001-7418-6520; Taniguchi, Kohei/0000-0003-0648-1370
FU Japan Agency for Medical Research and Development (AMED)Japan Agency for
   Medical Research and Development (AMED) [16cm0106202h0001]; Japan
   Society for the Promotion of ScienceMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of Science [17J02701]
FX This work was supported by the Project for Cancer Research and
   Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research
   and Development (AMED) (16cm0106202h0001 to Y.A.) and a grant-in-aid for
   a research fellow from the Japan Society for the Promotion of Science
   (17J02701 to Y.K.)
CR Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745
   CARBONEL.J, 1973, EUR J BIOCHEM, V37, P148, DOI 10.1111/j.1432-1033.1973.tb02969.x
   Chen M, 2012, NAT STRUCT MOL BIOL, V19, P346, DOI 10.1038/nsmb.2219
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   Corbo C, 2013, BIOCHEM BIOPH RES CO, V436, P1, DOI 10.1016/j.bbrc.2013.05.027
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610
   Goina E, 2008, MOL CELL BIOL, V28, P3850, DOI 10.1128/MCB.02253-07
   Guo JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14548
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4
   Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004
   Jia R, 2010, INT J BIOL SCI, V6, P806
   Kiichi Imamura T.T., 1972, J BIOCH, V71, P1043, DOI [10.1093/oxfordjournals.jbchem.a129852, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A129852]
   Kim J, 2014, CELL DEATH DIFFER, V21, P481, DOI 10.1038/cdd.2013.171
   Kuranaga Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010071
   Li JZH, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0158-3
   Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010
   Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005
   Minami K, 2017, ONCOTARGET, V8, P33064, DOI 10.18632/oncotarget.16524
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   NOGUCHI T, 1987, J BIOL CHEM, V262, P14366
   Park SK, 2016, BIOCHEM BIOPH RES CO, V470, P431, DOI 10.1016/j.bbrc.2016.01.019
   Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091
   Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m
   Sugito N, 2017, NUCLEIC ACID THER, V27, P365, DOI 10.1089/nat.2017.0673
   Sugiyama T, 2016, CANCER SCI, V107, P1767, DOI 10.1111/cas.13091
   Takai T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010179
   Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288
   Taniguchi K, 2016, ONCOTARGET, V7, P18940, DOI 10.18632/oncotarget.8005
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Taniguchi K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08647
   Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509
   Wang ZX, 2012, J MOL CELL BIOL, V4, P79, DOI 10.1093/jmcb/mjr030
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O.., 1924, BIOCHEM Z, V152, P319
   Xodo Luigi, 2008, Nucleic Acids Symp Ser (Oxf), P159, DOI 10.1093/nass/nrn081
   Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182
   Zarkavelis G, 2017, ANN GASTROENTEROL, V30, P613, DOI 10.20524/aog.2017.0191
NR 39
TC 36
Z9 38
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2018
VL 19
IS 10
AR 3012
DI 10.3390/ijms19103012
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GY9HB
UT WOS:000448951000167
PM 30279379
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Shimodaira, Y
   Takahashi, S
   Kinouchi, Y
   Endo, K
   Shiga, H
   Kakuta, Y
   Kuroha, M
   Shimosegawa, T
AF Shimodaira, Yosuke
   Takahashi, Seiichi
   Kinouchi, Yoshitaka
   Endo, Katsuya
   Shiga, Hisashi
   Kakuta, Yoichi
   Kuroha, Masatake
   Shimosegawa, Tooru
TI Modulation of endoplasmic reticulum (ER) stress-induced autophagy by
   C/EBP homologous protein (CHOP) and inositol-requiring enzyme 1 alpha
   (IRE1 alpha) in human colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ER stress; Autophagy; IRE1 alpha; CHOP
ID XBP1 MESSENGER-RNA; DISEASE; SUSCEPTIBILITY; SURVIVAL; TRIGGERS;
   ATG16L1; ATF6; IRE1; LC3
AB To explore the relationship between UPR and autophagy in intestinal epithelial cells, we investigated whether autophagy was induced by endoplasmic reticulum (ER) stress in colon cancer cell lines. We demonstrated that autophagy was induced by ER stress in HT29, SW480, and Caco-2 cells. In these cells, inositol-requiring enzyme1 alpha (IRE1 alpha) and C/EBP homologous protein (CHOP) were involved in the ER stress-autophagy pathway, and CHOP was a regulator of IRE1 alpha, protein expression. Our findings suggest that CHOP promotes IRE1 alpha and autophagy especially in ER stress conditions. This study will provide important insights into the disclosure of the ER stress-autophagy pathway. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Shimodaira, Yosuke; Kinouchi, Yoshitaka; Endo, Katsuya; Shiga, Hisashi; Kakuta, Yoichi; Kuroha, Masatake; Shimosegawa, Tooru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 9808574, Japan.
   [Takahashi, Seiichi] Iwaki Kyoritsu Gen Hosp, Dept Gastroenterol, Fukushima, Japan.
RP Shimodaira, Y (corresponding author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
EM yosuke.shimodaira@med.tohoku.ac.jp
RI Kakuta, Yoichi/H-5046-2019
OI Kakuta, Yoichi/0000-0002-7042-009X
CR Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Castillo K, 2011, EMBO J, V30, P4465, DOI 10.1038/emboj.2011.318
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Margariti A, 2013, J BIOL CHEM, V288, P859, DOI 10.1074/jbc.M112.412783
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Uddin MN, 2011, BIOCHEM BIOPH RES CO, V407, P692, DOI 10.1016/j.bbrc.2011.03.077
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
NR 24
TC 42
Z9 43
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 7
PY 2014
VL 445
IS 2
BP 524
EP 533
DI 10.1016/j.bbrc.2014.02.054
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AD4NV
UT WOS:000333228700044
PM 24565834
DA 2022-04-25
ER

PT J
AU Chen, C
   Kuo, YH
   Lin, CC
   Chao, CY
   Pai, MH
   Chiang, EPI
   Tang, FY
AF Chen, Ching
   Kuo, Yueh-Hsiung
   Lin, Cheng-Chieh
   Chao, Che-Yi
   Pai, Man-Hui
   Chiang, En-Pei Isabel
   Tang, Feng-Yao
TI Decyl caffeic acid inhibits the proliferation of colorectal cancer cells
   in an autophagy-dependent manner in vitro and in vivo
SO PLOS ONE
LA English
DT Article
ID TUMOR; COLON; GROWTH; MTOR; SUPPRESSES; PROPOLIS; BECLIN-1; ARREST;
   CAPE; AKT
AB The treatment of human colorectal cancer (CRC) cells through suppressing the abnormal survival signaling pathways has recently become a significant area of focus. In this study, our results demonstrated that decyl caffeic acid (DC), one of the novel caffeic acid derivatives, remarkedly suppressed the growth of CRC cells both in vitro and in vivo. The inhibitory effects of DC on CRC cells were investigated in an in vitro cell model and in vivo using a xenograft mouse model. CRC cells were treated with DC at various dosages (0, 10, 20 and 40 mu M), and cell survival, the apoptotic index and the autophagy level were measured using an MTT assay and flow cytometry analysis, respectively. The signaling cascades in CRC were examined by Western blot assay. The anti-cancer effects of DC on tumor growth were examined by using CRC HCT-116 cells implanted in an animal model. Our results indicated that DC differentially suppressed the growth of CRC HT-29 and HCT-116 cells through an enhancement of cell-cycle arrest at the S phase. DC inhibited the expression of cell-cycle regulators, which include cyclin E and cyclin A proteins. The molecular mechanisms of action were correlated to the blockade of the STAT3 and Akt signaling cascades. Strikingly, a high dosage of DC prompted a self-protection action through inducing cell-dependent autophagy in HCT-116 cells. Suppression of autophagy induced cell death in the treatment of DC in HCT-116 cells. DC seemed to inhibit cell proliferation of CRC differentially, and the therapeutic advantage appeared to be autophagy dependent. Moreover, consumption of DC blocked the tumor growth of colorectal adenocarcinoma in an experimental animal model. In conclusion, our results suggested that DC could act as a therapeutic agent through the significant suppression of tumor growth of human CRC cells.
C1 [Chen, Ching; Tang, Feng-Yao] China Med Univ, Dept Nutr, Biomed Sci Lab, Taichung, Taiwan.
   [Kuo, Yueh-Hsiung] China Med Univ, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan.
   [Kuo, Yueh-Hsiung] Asia Univ, Dept Biotechnol, Taichung, Taiwan.
   [Lin, Cheng-Chieh] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan.
   [Lin, Cheng-Chieh] China Med Univ Hosp, Dept Family Med, Taichung, Taiwan.
   [Lin, Cheng-Chieh] Asia Univ, Dept Healthcare Adm, Coll Hlth Sci, Taichung, Taiwan.
   [Chao, Che-Yi] Asia Univ, Dept Food Nutr & Hlth Biotechnol, Taichung, Taiwan.
   [Chao, Che-Yi] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Pai, Man-Hui] Taipei Med Univ, Sch Med, Dept Anat & Cell Biol, Coll Med, Taipei, Taiwan.
   [Chiang, En-Pei Isabel] Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, Taichung, Taiwan.
   [Chiang, En-Pei Isabel] Natl Chung Hsing Univ, Innovat & Dev Ctr Sustainable Agr IDCSA, Taichung, Taiwan.
RP Tang, FY (corresponding author), China Med Univ, Dept Nutr, Biomed Sci Lab, Taichung, Taiwan.
EM vincenttang@mail.cmu.edu.tw
RI Chiang, EnPei/K-1694-2013
OI Chiang, EnPei/0000-0002-0158-0962
FU Ministry of Science and Technology (MOST), Taiwan, R.O.C.
   [MOST-104-2320-B-039-041-MY3, 107-2320-B039-008-MY3, MOST 107-2320-B-005
   -003 MY3, 107-2621-M-005-008 -MY3, MOST1072321-B-005-009,
   108-2321-B-005-004]; China Medical University (CMU)China Medical
   University [CMU102-ASIA-23, CMU103-ASIA-20, CMU103-S46, CMU104-S-32];
   Ministry of Education (MOE) Taiwan under the Higher Education Sprout
   Project at NCHU-IDCSA
FX This research project is supported by the grant of Ministry of Science
   and Technology (MOST), Taiwan, R.O.C. under the agreements
   MOST-104-2320-B-039-041-MY3, 107-2320-B039-008-MY3, MOST 107-2320-B-005
   -003 MY3, 107-2621-M-005-008 -MY3, MOST1072321-B-005-009,
   108-2321-B-005-004, China Medical University (CMU) grant under
   agreements CMU102-ASIA-23, CMU103-ASIA-20, CMU103-S46, CMU104-S-32, and
   as well as in part by the Ministry of Education (MOE) Taiwan under the
   Higher Education Sprout Project at NCHU-IDCSA. Any results, conclusions,
   or implication described in this publication are from the author(s) of
   this manuscript and do not necessarily reflect the view of the MOST,
   MOE, Asia University and CMU.
CR Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511
   Bondi J, 2005, J CLIN PATHOL, V58, P509, DOI 10.1136/jcp.2004.020347
   Chen C, 2017, ONCOL REP, V38, P2901, DOI 10.3892/or.2017.5943
   Chiang EPI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099631
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Demestre M, 2009, PHYTOTHER RES, V23, P226, DOI 10.1002/ptr.2594
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Gonzalez-Sarrias A, 2013, FOOD CHEM, V136, P636, DOI 10.1016/j.foodchem.2012.08.023
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Huang YH, 2017, ONCOTARGET, V8, P52783, DOI 10.18632/oncotarget.17189
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058
   Lee YS, 2013, J NAT PROD, V76, P2195, DOI 10.1021/np4005135
   Liu JT, 2015, CLIN LUNG CANCER, V16, pE55, DOI 10.1016/j.cllc.2015.03.006
   Mao MT, 2017, BIOCHEM BIOPH RES CO, V490, P1244, DOI 10.1016/j.bbrc.2017.07.002
   Nazarko VY, 2013, NAT CELL BIOL, V15, P727, DOI 10.1038/ncb2797
   Park JH, 2017, CLIN CANCER RES, V23, P1698, DOI 10.1158/1078-0432.CCR-16-1416
   Pearce A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184360
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Strimpakos AS, 2009, CANCER TREAT REV, V35, P148, DOI 10.1016/j.ctrv.2008.09.006
   Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057
   Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005
   Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012
NR 25
TC 8
Z9 8
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2020
VL 15
IS 5
AR e0232832
DI 10.1371/journal.pone.0232832
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LU0VG
UT WOS:000537481000033
PM 32401800
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, SP
   Lin, HM
   Wang, D
   Li, Q
   Luo, H
   Li, GX
   Chen, XH
   Li, YQ
   Chen, P
   Zhai, BT
   Wang, WG
   Zhang, RN
   Chen, B
   Zhang, MM
   Han, XM
   Li, QJ
   Chen, LX
   Liu, Y
   Chen, XY
   Li, GH
   Xiang, Y
   Duan, T
   Feng, J
   Lou, JS
   Huang, XX
   Zhang, Q
   Pan, T
   Yan, LL
   Jin, T
   Zhang, WZ
   Zhuo, LJ
   Sun, YT
   Xie, T
   Sui, XB
AF Liu, Shuiping
   Lin, Haoming
   Wang, Da
   Li, Qiang
   Luo, Hong
   Li, Guoxiong
   Chen, Xiaohui
   Li, Yongqiang
   Chen, Peng
   Zhai, Bingtao
   Wang, Wengang
   Zhang, Ruonan
   Chen, Bi
   Zhang, Mingming
   Han, Xuemeng
   Li, Qiujie
   Chen, Liuxi
   Liu, Ying
   Chen, Xiaying
   Li, Guohua
   Xiang, Yu
   Duan, Ting
   Feng, Jiao
   Lou, Jianshu
   Huang, Xingxing
   Zhang, Qin
   Pan, Ting
   Yan, Lili
   Jin, Ting
   Zhang, Wenzheng
   Zhuo, Lvjia
   Sun, Yitian
   Xie, Tian
   Sui, Xinbing
TI PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil
   treatment by inducing apoptosis and autophagic cell death
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID TUMOR-SUPPRESSOR; PROTOCADHERIN-17
AB 5-Fluorouracil (5-FU) is known as a first-line chemotherapeutic agent against colorectal cancer (CRC), but drug resistance occurs frequently and significantly limits its clinical success. Our previous study showed that the protocadherin 17 (PCDH17) gene was frequently methylated and functioned as a tumor suppressor in CRC. However, the relationship between PCDH17 and 5-FU resistance in CRC remains unclear. Here, we revealed that PCDH17 was more highly expressed in 5-FU-sensitive CRC tissues than in 5-FU-resistant CRC tissues, and high expression of PCDH17 was correlated with high BECN1 expression. Moreover, this expression profile contributed to superior prognosis and increased survival in CRC patients. Restoring PCDH17 expression augmented the 5-FU sensitivity of CRC in vitro and in vivo by promoting apoptosis and autophagic cell death. Furthermore, autophagy played a dominant role in PCDH17-induced cell death, as an autophagy inhibitor blocked cell death to a greater extent than the pancaspase inhibitor Z-VAD-FMK. PCDH17 inhibition by siRNA decreased the autophagy response and 5-FU sensitivity. Mechanistically, we showed that c-Jun NH2-terminal kinase (JNK) activation was a key determinant in PCDH17-induced autophagy. The compound SP600125, an inhibitor of JNK, suppressed autophagy and 5-FU-induced cell death in PCDH17-reexpressing CRC cells. Taken together, our findings suggest for the first time that PCDH17 increases the sensitivity of CRC to 5-FU treatment by inducing apoptosis and JNK-dependent autophagic cell death. PCDH17 may be a potential prognostic marker for predicting 5-FU sensitivity in CRC patients.
C1 [Liu, Shuiping; Luo, Hong; Li, Guoxiong; Chen, Xiaohui; Li, Yongqiang; Chen, Peng; Zhai, Bingtao; Wang, Wengang; Zhang, Ruonan; Chen, Bi; Zhang, Mingming; Han, Xuemeng; Li, Qiujie; Chen, Liuxi; Chen, Xiaying; Li, Guohua; Xiang, Yu; Duan, Ting; Feng, Jiao; Lou, Jianshu; Huang, Xingxing; Zhang, Qin; Pan, Ting; Yan, Lili; Jin, Ting; Zhang, Wenzheng; Zhuo, Lvjia; Sun, Yitian; Xie, Tian; Sui, Xinbing] Hangzhou Normal Univ, Affiliated Hosp, Coll Med, Holist Integrat Pharm Inst & Comprehens Canc Diag, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Shuiping; Xie, Tian; Sui, Xinbing] Hangzhou Normal Univ, Key Lab Elemene Class Anticanc Chinese Med Zhejia, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Shuiping; Xie, Tian; Sui, Xinbing] Hangzhou Normal Univ, Engn Lab Dev & Applicat Tradit Chinese Med Zhejia, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Haoming] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Pancreat Surg, Guangzhou, Guangdong, Peoples R China.
   [Wang, Da] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Colorectal Surg, Hangzhou, Zhejiang, Peoples R China.
   [Li, Qiang] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Ultrasound Med, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Ying] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Sui, Xinbing] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Jiangsu, Peoples R China.
RP Xie, T; Sui, XB (corresponding author), Hangzhou Normal Univ, Affiliated Hosp, Coll Med, Holist Integrat Pharm Inst & Comprehens Canc Diag, Hangzhou, Zhejiang, Peoples R China.; Xie, T; Sui, XB (corresponding author), Hangzhou Normal Univ, Key Lab Elemene Class Anticanc Chinese Med Zhejia, Hangzhou, Zhejiang, Peoples R China.; Xie, T; Sui, XB (corresponding author), Hangzhou Normal Univ, Engn Lab Dev & Applicat Tradit Chinese Med Zhejia, Hangzhou, Zhejiang, Peoples R China.; Sui, XB (corresponding author), Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Jiangsu, Peoples R China.
EM xbs@hznu.edu.cn; hzzju@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672932, 81730108, 81874380, 81802371,
   81973635]; Zhejiang Provincial Natural Science Foundation of China for
   Distinguished Young Scholars [LR18H160001]; Zhejiang Province Science
   and Technology Project of TCM [2019ZZ016]; Zhejiang Province Medical
   Science and Technology Project [2017RC007]; Talent Project of Zhejiang
   Association for Science and Technology [2017YCGC002]; Key Project of
   Hangzhou Ministry of Science and Technology [20162013A07]; Zhejiang
   Provincial Project for the Key Discipline of Traditional Chinese
   Medicine [2017-XK-A09]; Open Project Program of Jiangsu Key Laboratory
   for Pharmacology and Safety Evaluation of Chinese Materia Medica
   [JKLPSE201807]; Project of the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD)
FX This research was supported by grants from the National Natural Science
   Foundation of China (Grant Nos. 81672932, 81730108, 81874380, 81802371,
   and 81973635), Zhejiang Provincial Natural Science Foundation of China
   for Distinguished Young Scholars (Grant No. LR18H160001), Zhejiang
   Province Science and Technology Project of TCM (Grant No. 2019ZZ016),
   Zhejiang Province Medical Science and Technology Project (Grant No.
   2017RC007), Talent Project of Zhejiang Association for Science and
   Technology (Grant No. 2017YCGC002), Key Project of Hangzhou Ministry of
   Science and Technology (Grant No. 20162013A07), Zhejiang Provincial
   Project for the Key Discipline of Traditional Chinese Medicine (Grant
   No. 2017-XK-A09), Open Project Program of Jiangsu Key Laboratory for
   Pharmacology and Safety Evaluation of Chinese Materia Medica (No.
   JKLPSE201807) and Project of the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD).
CR Baranova I, 2018, CANCER BIOMARK, V23, P125, DOI 10.3233/CBM-181493
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Byzia E, 2018, MOL CARCINOGEN, V57, P878, DOI 10.1002/mc.22808
   Costa VL, 2011, EPIGENETICS-US, V6, P1120, DOI 10.4161/epi.6.9.16376
   Gaballah HH, 2017, TOXICOL APPL PHARM, V316, P27, DOI 10.1016/j.taap.2016.12.012
   Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053
   He Y, 2019, CANCER MANAG RES, V11, P1601, DOI 10.2147/CMAR.S191102
   Henricks LM, 2017, ANN ONCOL, V28, P2915, DOI 10.1093/annonc/mdx411
   Hu XT, 2013, J PATHOL, V229, P62, DOI 10.1002/path.4093
   Kaehler C, 2014, NUCLEIC ACIDS RES, V42, P6436, DOI 10.1093/nar/gku264
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Wasserman I, 2019, CLIN CANCER RES, V25, P1948, DOI 10.1158/1078-0432.CCR-18-1726
   Yang YQ, 2012, HISTOL HISTOPATHOL, V27, P217, DOI 10.14670/HH-27.217
NR 18
TC 19
Z9 20
U1 5
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD NOV 29
PY 2019
VL 4
AR 53
DI 10.1038/s41392-019-0087-0
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA JW2CU
UT WOS:000502866600004
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, XY
   Abe-Kanoh, N
   Liu, YJ
   Zhu, BW
   Munemasa, S
   Nakamura, T
   Murata, Y
   Nakamura, Y
AF Liu, Xiaoyang
   Abe-Kanoh, Naomi
   Liu, Yujia
   Zhu, Beiwei
   Munemasa, Shintaro
   Nakamura, Toshiyuki
   Murata, Yoshiyuki
   Nakamura, Yoshimasa
TI Inhibition of phosphatidylinositide 3-kinase impairs the benzyl
   isothiocyanate-induced accumulation of autophagic molecules and Nrf2 in
   human colon cancer cells
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE autophagy; phosphatidylinositide 3-kinase; Nrf2; Keap1; benzyl
   isothiocyanate
ID PATHWAY; RESISTANCE
AB The regulating role of phosphatidylinositide 3-kinase (PI3K) in benzyl isothiocyanate (BITC)-induced Nrf2 activation, contributing to the inducible expression of cytoprotective genes, was investigated. BITC significantly enhanced the accumulation of Nrf2 as well as autophagic molecules in human colorectal cancer HCT-116 cells. Experiments using a PI3K-specific inhibitor suggested that PI3K plays the key role in the non-canonical Nrf2 activation by BITC.
C1 [Liu, Xiaoyang; Abe-Kanoh, Naomi; Liu, Yujia; Munemasa, Shintaro; Nakamura, Toshiyuki; Murata, Yoshiyuki; Nakamura, Yoshimasa] Okayama Univ, Grad Sch Environm & Life Sci, Okayama, Japan.
   [Liu, Xiaoyang; Liu, Yujia; Zhu, Beiwei] Dalian Polytech Univ, Sch Food Sci & Technol, Dalian, Peoples R China.
   [Abe-Kanoh, Naomi] Tokushima Univ, Inst Biomed Sci, Dept Food Sci, Grad Sch, Tokushima, Japan.
RP Nakamura, Y (corresponding author), Okayama Univ, Grad Sch Environm & Life Sci, Okayama, Japan.
EM yossan@cc.okayama-u.ac.jp
FU MEXT KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25292073,
   16K14928, 17H03818]; Grants-in-Aid for Scientific ResearchMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [17H03818, 17K17923] Funding Source: KAKEN
FX This study was partly supported by MEXT KAKENHI [grant number 25292073],
   [grant number16K14928], [grant number17H03818] (YN).
CR Abe N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.495
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Huang Y, 2015, J NUTR BIOCHEM, V26, P1401, DOI 10.1016/j.jnutbio.2015.08.001
   Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Nakamura Y, 2000, CANCER RES, V60, P219
   Nakamura Y, 2010, BIOSCI BIOTECH BIOCH, V74, P242, DOI 10.1271/bbb.90731
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Qin S, 2016, MOL NUTR FOOD RES, V60, P1731, DOI 10.1002/mnfr.201501017
   Sakai R, 2012, J FOOD DRUG ANAL, V20, P389
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Xiao D, 2011, PLOS ONE, V7
   Zhou XY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.34
NR 17
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PY 2017
VL 81
IS 11
BP 2212
EP 2215
DI 10.1080/09168451.2017.1374830
PG 4
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA FO1PK
UT WOS:000416535100024
PM 28934922
OA Bronze
DA 2022-04-25
ER

PT J
AU Yim, NH
   Jung, YP
   Kim, A
   Ma, CJ
   Cho, WK
   Ma, JY
AF Yim, Nam-Hui
   Jung, Young Pil
   Kim, Aeyung
   Ma, Choong Je
   Cho, Won-Kyung
   Ma, Jin Yeul
TI Oyaksungisan, a Traditional Herbal Formula, Inhibits Cell Proliferation
   by Induction of Autophagy via JNK Activation in Human Colon Cancer Cells
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID TUMOR-GROWTH; APOPTOSIS; ANGIOGENESIS; METASTASIS; PATHWAYS; EXTRACTS;
   COCKTAIL; DISEASE; HEALTH; LC3
AB Oyaksungisan (OY) is a traditional herbal formula broadly used to treat beriberi, vomiting, diarrhea, and circulatory disturbance in Asian countries from ancient times. The effect of OY on cancer, however, was not reported until now. In this study, we have demonstrated that OY inhibits cell proliferation and induces cell death via modulating the autophagy on human colon cancer cells. In HCT116 cells, OY increased the ratio of LC3-II/LC3-I, a marker of autophagy, and treatment with 3-MA, an inhibitor of autophagy, and considerably reduced the formation of autophagosomes. In addition, OY regulated mitogen-activated protein kinase (MAPK) cascades; especially, JNK activation was closely related with autophagy effect by OY in HCT116 cells. Our results indicate that autophagy induction is responsible for the antiproliferative effect by OY, despite the weak apoptosis induction in HCT116 cells. In conclusion, OY might have a potential to be developed as an herbal anticancer remedy.
C1 [Yim, Nam-Hui; Jung, Young Pil; Kim, Aeyung; Cho, Won-Kyung; Ma, Jin Yeul] Korea Inst Oriental Med KIOM, Korean Med KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
   [Ma, Choong Je] Kangwon Natl Univ, Dept Biomat Engn, Div Biosci & Biotechnol, Chunchon 200701, South Korea.
RP Cho, WK (corresponding author), Korea Inst Oriental Med KIOM, Korean Med KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM wkcho@kiom.re.kr; jyma@kiom.re.kr
RI Ma, Choong Je/H-9986-2013
OI Ma, Choong Je/0000-0001-8818-6396
FU Ministry of Education, Science and Technology (MEST), Republic of
   KoreaMinistry of Education, Science and Technology, Republic of Korea
   [K12050]
FX This work was supported by Grant K12050 awarded to the Korean Institute
   of Oriental Medicine by the Ministry of Education, Science and
   Technology (MEST), Republic of Korea. Further, the authors thank Ju Hye
   Lee for the helpful experiment in this study.
CR Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Chia JS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-175
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Duan YW, 2007, ONCOL REP, V17, P1391
   Hamamura K, 2009, ARCH ORAL BIOL, V54, P279, DOI 10.1016/j.archoralbio.2008.11.003
   Han MH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/201414
   Huerta S, 2002, CANCER RES, V62, P5204
   Je JJ, 2002, AM J CHINESE MED, V30, P561, DOI 10.1142/S0192415X0200048X
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee HJ, 2006, CARCINOGENESIS, V27, P2455, DOI 10.1093/carcin/bgl104
   Lee SE, 2012, J ETHNOPHARMACOL, V139, P541, DOI 10.1016/j.jep.2011.11.046
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li YM, 2003, AM J CHINESE MED, V31, P857, DOI 10.1142/S0192415X03001545
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Luo KW, 2011, CHEMOTHERAPY, V57, P449, DOI 10.1159/000331641
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009
   Nam NH, 2003, PHYTOTHER RES, V17, P70, DOI 10.1002/ptr.901
   Oh YC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-17
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Richardson MA, 2002, SEMIN ONCOL, V29, P531, DOI 10.1053/sonc.2002.50002
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Takara K, 2005, BIOL PHARM BULL, V28, P138, DOI 10.1248/bpb.28.138
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Vickers A, 2002, CANCER INVEST, V20, P1069, DOI 10.1081/CNV-120005926
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Watson JL, 2008, EXP MOL PATHOL, V84, P230, DOI 10.1016/j.yexmp.2008.02.002
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Zhang ZQ, 2004, ONCOGENE, V23, P3841, DOI 10.1038/sj.onc.1207496
   마충제, 2011, [Korean Journal of Pharmacognosy, 생약학회지], V42, P22
NR 34
TC 14
Z9 15
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
VL 2013
AR 231874
DI 10.1155/2013/231874
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 110UV
UT WOS:000316473300001
PM 23573119
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU An, YJ
   Quan, KT
   Gwak, J
   Ju, BG
   Na, M
   Oh, S
AF An, Younju
   Khong Trong Quan
   Gwak, Jungsug
   Ju, Bong Gun
   Na, MinKyun
   Oh, Sangtaek
TI Activation of the p53 pathway with digiferrol isolated from Rubia
   philippinensis induces cell cycle arrest, apoptosis, and autophagy in
   colon cancer cells
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID MARINE SPONGE METABOLITES; BETA-CATENIN; IN-VITRO; PROLIFERATION;
   ILIMAQUINONE; INDUCTION; COMPLEX; GROWTH; ETHYLSMENOQUINONE;
   PHOSPHORYLATION
C1 [An, Younju; Oh, Sangtaek] Kookmin Univ, PLUS Program BK21, Dept Bio & Fermentat Convergence Technol, Seoul 136702, South Korea.
   [Khong Trong Quan; Na, MinKyun] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
   [Gwak, Jungsug; Ju, Bong Gun] Sogang Univ, Dept Life Sci, Seoul 121742, South Korea.
RP Oh, S (corresponding author), Kookmin Univ, PLUS Program BK21, Dept Bio & Fermentat Convergence Technol, Seoul 136702, South Korea.; Na, M (corresponding author), Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
EM mkna@cnu.ac.kr; ohsa@kookmin.ac.kr
OI Na, MinKyun/0000-0002-4865-6506
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) grant - Korean Government [NRF-2015R1A2A2A01004599, NRF-
   2017R1A2A2A05001340]
FX This work was supported by the Basic Science Research Program
   (NRF-2015R1A2A2A01004599, NRF- 2017R1A2A2A05001340) through the National
   Research Foundation of Korea (NRF) grant funded by the Korean
   Government.
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Amado NG, 2014, J BIOL CHEM, V289, P35456, DOI 10.1074/jbc.M114.621599
   Anderson CNG, 1999, J NEUROSCI, V19, P664
   Bae SK, 2011, BIOCHEM BIOPH RES CO, V409, P75, DOI 10.1016/j.bbrc.2011.04.108
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Broz P, 2013, NAT REV IMMUNOL, V13, P551, DOI 10.1038/nri3479
   Chiu SC, 2013, PROSTATE CANCER P D, V16, P315, DOI 10.1038/pcan.2013.38
   Do MT, 2014, FOOD CHEM TOXICOL, V71, P51, DOI 10.1016/j.fct.2014.06.001
   Du L, 2013, J NAT PROD, V76, P1175, DOI 10.1021/np400320r
   Fukuda R, 2013, J BIOL CHEM, V288, P16117, DOI 10.1074/jbc.M112.442442
   Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723
   Jaamaa S, 2010, CANCER RES, V70, P8630, DOI 10.1158/0008-5472.CAN-10-0937
   Jackson CL, 2009, J CELL SCI, V122, P443, DOI 10.1242/jcs.032581
   Quan KT, 2016, J NAT PROD, V79, P2559, DOI 10.1021/acs.jnatprod.6b00489
   Kim JH, 2014, FOOD CHEM TOXICOL, V67, P87, DOI 10.1016/j.fct.2014.02.019
   Kim TD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034618
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Loughery J, 2014, NUCLEIC ACIDS RES, V42, P7664, DOI 10.1093/nar/gku501
   McLeland CB, 2011, METHODS MOL BIOL, V697, P199, DOI 10.1007/978-1-60327-198-1_21
   Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8
   Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897
   Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107
   Park S, 2014, MAR DRUGS, V12, P3231, DOI 10.3390/md12063231
   Permana D, 1999, J NAT PROD, V62, P1430, DOI 10.1021/np990101e
   Roura S, 2003, BIOCHEM BIOPH RES CO, V309, P830, DOI 10.1016/j.bbrc.2003.08.075
   Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002
   Sun Xiao-Xin, 2014, World J Biol Chem, V5, P75, DOI 10.4331/wjbc.v5.i2.75
   Taylor SC, 2013, MOL BIOTECHNOL, V55, P217, DOI 10.1007/s12033-013-9672-6
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137
NR 35
TC 4
Z9 4
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD AUG
PY 2018
VL 118
BP 514
EP 522
DI 10.1016/j.fct.2018.05.054
PG 9
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA GR5XD
UT WOS:000442714300052
PM 29842910
DA 2022-04-25
ER

PT J
AU Pandurangan, AK
   Divya, T
   Kumar, K
   Dineshbabu, V
   Velavan, B
   Sudhandiran, G
AF Pandurangan, Ashok Kumar
   Divya, Thomas
   Kumar, Kalaivani
   Dineshbabu, Vadivel
   Velavan, Bakthavatchalam
   Sudhandiran, Ganapasam
TI Colorectal carcinogenesis: Insights into the cell death and signal
   transduction pathways: A review
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Review
DE Colorectal cancer; Cell death; Apoptosis; Autophagy; Inflammation; Hippo
   signalling; Nuclear factor erythroid 2-related factor 2; Wnt signaling
ID COLON-CANCER CELLS; NF-KAPPA-B; WNT/BETA-CATENIN; DOWN-REGULATION; HIPPO
   PATHWAY; INTESTINAL HOMEOSTASIS; ANIMAL-MODELS; MOUSE MODELS; KEY
   PLAYER; TNF-ALPHA
AB Colorectal carcinogenesis (CRC) imposes a major health burden in developing countries. It is the third major cause of cancer deaths. Despite several treatment strategies, novel drugs are warranted to reduce the severity of this disease. Adenomatous polyps in the colon are the major culprits in CRC and found in 45% of cancers, especially in patients 60 years of age. Inflammatory polyps are currently gaining attention in CRC, and a growing body of evidence denotes the role of inflammation in CRC. Several experimental models are being employed to investigate CRC in animals, which include the APC(min/+) mouse model, Azoxymethane, Dimethyl hydrazine, and a combination of Dextran sodium sulphate and dimethyl hydrazine. During CRC progression, several signal transduction pathways are activated. Among the major signal transduction pathways are p53, Transforming growth factor beta, Wnt/beta-catenin, Delta Notch, Hippo signalling, nuclear factor erythroid 2-related factor 2 and Kelch-like ECH-associated protein 1 pathways. These signalling pathways collaborate with cell death mechanisms, which include apoptosis, necroptosis and autophagy, to determine cell fate. Extensive research has been carried out in our laboratory to investigate these signal transduction and cell death mechanistic pathways in CRC. This review summarizes CRC pathogenesis and the related cell death and signal transduction pathways.
C1 [Pandurangan, Ashok Kumar; Divya, Thomas; Dineshbabu, Vadivel; Velavan, Bakthavatchalam; Sudhandiran, Ganapasam] Univ Madras, Dept Biochem, Cell Biol Lab, Guindy Campus, Madras 600025, Tamil Nadu, India.
   [Pandurangan, Ashok Kumar; Kumar, Kalaivani] BS Abdur Rahman Crescent Inst Sci & Technol, Sch Life Sci, Madras 600048, Tamil Nadu, India.
RP Sudhandiran, G (corresponding author), Univ Madras, Dept Biochem, Cell Biol Lab, Guindy Campus, Madras 600025, Tamil Nadu, India.
EM sudhandiran@unom.ac.in
RI Ganapasam, Sudhandiran/AAD-4264-2021; Pandurangan, Ashok
   Kumar/M-7335-2013; Sudhandiran, G/AAG-9967-2019
OI Pandurangan, Ashok Kumar/0000-0003-2824-1757; Sudhandiran,
   G/0000-0003-0066-7801
FU Council of Scientific and Industrial research (CSIR), New DelhiCouncil
   of Scientific & Industrial Research (CSIR) - India [37 (1364)
   /09/EMR-II]
FX GS acknowledges Council of Scientific and Industrial research (CSIR),
   New Delhi for funding Colon cancer project [37 (1364) /09/EMR-II].
CR Almora-Pinedo Y, 2017, CLIN EXP GASTROENTER, V10, P327, DOI 10.2147/CEG.S142515
   Angarita FA, 2018, INT J COLORECTAL DIS, V33, P115, DOI 10.1007/s00384-017-2950-1
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Ashokkumar P, 2011, INVEST NEW DRUG, V29, P273, DOI 10.1007/s10637-009-9359-9
   Begagne E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188
   Bellam N, 2010, CANCER TREAT RES, V155, P85, DOI 10.1007/978-1-4419-6033-7_5
   Bissahoyo A, 2005, TOXICOL SCI, V88, P340, DOI 10.1093/toxsci/kfi313
   Boland PM, 2018, CA-CANCER J CLIN, V68, P217, DOI 10.3322/caac.21448
   Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94
   Burghel GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083859
   Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012
   Cao JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070057
   Cao L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0757-8
   Carr PR, 2017, EUR J EPIDEMIOL, V32, P409, DOI 10.1007/s10654-017-0275-6
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chatenoud L, 2014, ANN ONCOL, V25, P1843, DOI 10.1093/annonc/mdu206
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cho SY, 2018, ONCOL LETT, V15, P4926, DOI 10.3892/ol.2018.7911
   Choi BJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15139-5
   Christou N, 2017, ONCOL LETT, V13, P4571, DOI 10.3892/ol.2017.6063
   Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3
   Clarke PGH, 1996, ANAT EMBRYOL, V193, P81
   Colakoglu T, 2008, AM J SURG, V195, P719, DOI 10.1016/j.amjsurg.2007.05.061
   Copple IM, 2012, ADV PHARMACOL, V63, P43, DOI 10.1016/B978-0-12-398339-8.00002-1
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   de Leon MP, 2001, DIGEST LIVER DIS, V33, P372
   Deng YH, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0500-2
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Edelmann L, 2004, AM J MED GENET C, V129C, P91, DOI 10.1002/ajmg.c.30021
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Fortin J, 2016, CANCER CELL, V29, P429, DOI 10.1016/j.ccell.2016.03.020
   Freeman HJ, 2013, WORLD J GASTROENTERO, V19, P8468, DOI 10.3748/wjg.v19.i46.8468
   Fulda S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00029
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2016, CELL MOL LIFE SCI, V73, P2405, DOI 10.1007/s00018-016-2209-y
   Gatza CE, 2011, NEOPLASIA, V13, P758, DOI 10.1593/neo.11528
   Gerola S, 2014, GENE CHROMOSOME CANC, V53, P769, DOI 10.1002/gcc.22185
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Goel S, 2015, CURR CLIN PHARMACOL, V10, P73, DOI 10.2174/1574884708666131111204440
   Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7
   Guo LW, 2015, INT J ONCOL, V46, P1444, DOI 10.3892/ijo.2015.2877
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Hatano S, 2013, INT SURG, V98, P114, DOI 10.9738/CC131
   Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036
   Hsieh JS, 2005, AM SURGEON, V71, P336
   Huang GX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12644-5
   Iacopetta B, 2010, ASIA-PAC J CLIN ONCO, V6, P260, DOI 10.1111/j.1743-7563.2010.01335.x
   Irvine KD, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019224
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3
   Jin DC, 2017, ONCOTARGET, V8, P97787, DOI 10.18632/oncotarget.22081
   JOBST K, 1967, NEOPLASMA, V14, P435
   Johnson RL, 2013, CANCER METAST REV, V32, P39, DOI 10.1007/s10555-012-9404-6
   Kaklamani Virginia G, 2004, Expert Rev Anticancer Ther, V4, P649, DOI 10.1586/14737140.4.4.649
   Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kim EC, 1997, GASTROENTEROL CLIN N, V26, P1, DOI 10.1016/S0889-8553(05)70280-6
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kim M, 2014, BMB REP, V47, P540, DOI 10.5483/BMBRep.2014.47.10.177
   KOESTNER AW, 1977, INT J CANCER, V20, P418, DOI 10.1002/ijc.2910200314
   Kohno H, 2005, CANCER SCI, V96, P69, DOI 10.1111/j.1349-7006.2005.00020.x
   Konsavage WM, 2012, J BIOL CHEM, V287, P11730, DOI 10.1074/jbc.M111.327767
   KOSIK KS, 1989, ANN MED, V21, P109, DOI 10.3109/07853898909149195
   Kranenburg O, 2015, CANCER DISCOV, V5, P115, DOI 10.1158/2159-8290.CD-14-1456
   Kroemer G, 2014, CELL RES, V24, P1280, DOI 10.1038/cr.2014.133
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P53959, DOI 10.18632/oncotarget.9796
   Kumar M, 2016, CYTOTECHNOLOGY, V68, P531, DOI 10.1007/s10616-015-9897-2
   Lazarova DL, 2016, J CELL MOL MED, V20, P989, DOI 10.1111/jcmm.12850
   Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev
   Letai A, 2015, CLIN CANCER RES, V21, P5015, DOI 10.1158/1078-0432.CCR-15-1204
   Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137
   Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84
   Liang K, 2014, SAUDI J GASTROENTERO, V20, P188, DOI 10.4103/1319-3767.133025
   Lin MC, 2011, J AGR FOOD CHEM, V59, P11304, DOI 10.1021/jf202433f
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Lord R, 2018, WORLD J GASTROENTERO, V24, P1167, DOI 10.3748/wjg.v24.i10.1167
   MAEKAWA A, 1988, J CANCER RES CLIN, V114, P473, DOI 10.1007/BF00391494
   Magalhaes B, 2012, EUR J CANCER PREV, V21, P15, DOI 10.1097/CEJ.0b013e3283472241
   Maida M, 2017, EXPERT REV ANTICANC, V17, P1131, DOI 10.1080/14737140.2017.1392243
   Manigandan K, 2015, BIOCHIMIE, V119, P103, DOI 10.1016/j.biochi.2015.10.014
   Manne U, 2011, CANCER BIOMARK, V9, P235, DOI 10.3233/CBM-2011-0160
   Marques-Vidal P, 2006, CLIN NUTR, V25, P14, DOI 10.1016/j.clnu.2005.09.008
   Marshman E, 2001, J PATHOL, V195, P285
   Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Masuda T, 2017, CANCERS, V9, DOI 10.3390/cancers9090124
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003
   Mesa MA, 2013, AUTOIMMUN DIS, V2013, DOI 10.1155/2013/651497
   Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398
   Mirone G, 2016, J CELL PHYSIOL, V231, P1097, DOI 10.1002/jcp.25206
   Miyaki M, 1999, CANCER RES, V59, P4506
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Murff HJ, 2012, AM J CLIN NUTR, V95, P703, DOI 10.3945/ajcn.111.024000
   MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944
   Nagashima S, 2017, CURR DRUG TARGETS, V18, P447, DOI 10.2174/1389450117666160112115641
   Nakata M, 2009, PEDIATR RES, V66, P149, DOI 10.1203/PDR.0b013e3181aa304a
   NARISAWA T, 1976, CANCER RES, V36, P505
   Newmark HL, 2009, CARCINOGENESIS, V30, P88, DOI 10.1093/carcin/bgn229
   NEWMARK HL, 1990, JNCI-J NATL CANCER I, V82, P491, DOI 10.1093/jnci/82.6.491
   Nievelstein RAJ, 1998, TERATOLOGY, V57, P70, DOI 10.1002/(SICI)1096-9926(199802)57:2<70::AID-TERA5>3.0.CO;2-A
   Niture SK, 2014, FREE RADICAL BIO MED, V66, P36, DOI 10.1016/j.freeradbiomed.2013.02.008
   Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0
   Oshima H, 2015, CANCER RES, V75, P766, DOI 10.1158/0008-5472.CAN-14-2036
   Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x
   Pan P, 2018, SURG ONCOL CLIN N AM, V27, P243, DOI 10.1016/j.soc.2017.11.002
   Pandurangan AK, 2013, J ENVIRON PATHOL TOX, V32, P131, DOI 10.1615/JEnvironPatholToxicolOncol.2013007522
   Perse M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/473964
   POLLARD M, 1987, PROSTATE, V11, P219, DOI 10.1002/pros.2990110303
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Rajendran P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0132-y
   Raskov H, 2014, WORLD J GASTROENTERO, V20, P18151, DOI 10.3748/wjg.v20.i48.18151
   Reichling T, 2005, CANCER RES, V65, P166
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Risio M, 1996, CANCER RES, V56, P4910
   Robinson JR, 2017, CANCER EPIDEMIOL, V48, P92, DOI 10.1016/j.canep.2017.04.003
   Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016
   ROTTER V, 1991, ADV CANCER RES, V57, P257
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Ruzzo A, 2010, CURR CANCER DRUG TAR, V10, P68, DOI 10.2174/156800910790980205
   Santucci M, 2015, J MED CHEM, V58, P4857, DOI 10.1021/jm501615v
   Schmidt EM, 2018, J EXP MED, V215, P1693, DOI 10.1084/jem.20171455
   Schoefl R, 2015, DIGEST DIS, V33, P38, DOI 10.1159/000366034
   Schwingshackl L, 2018, INT J CANCER, V142, P1748, DOI 10.1002/ijc.31198
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sinicrope FA, 1999, CLIN CANCER RES, V5, P1793
   Skovierova H, 2018, INT J MOL MED, V41, P1187, DOI 10.3892/ijmm.2017.3320
   Slattery ML, 1998, INT J EPIDEMIOL, V27, P382, DOI 10.1093/ije/27.3.382
   Subramaniam Renuka, 2016, Cancer Res Front, V2, P1
   Tamas K, 2015, CANCER TREAT REV, V41, P671, DOI 10.1016/j.ctrv.2015.06.007
   Tanaka Takuji, 2009, J Carcinog, V8, P5
   Tariq H, 2018, WORLD J ONCOL, V9, P35, DOI 10.14740/wjon1073w
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x
   Vande Walle L, 2016, CURR BIOL, V26, pR568, DOI 10.1016/j.cub.2016.02.019
   Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611
   Wang DH, 2011, P NATL ACAD SCI USA, V108, P10272, DOI 10.1073/pnas.1017668108
   Williams JG, 2013, COLORECTAL DIS, V15, P1, DOI 10.1111/codi.12262
   Witold K, 2018, REP PRACT ONCOL RADI, V23, P75, DOI 10.1016/j.rpor.2017.12.003
   Wondrak GT, 2010, MOLECULES, V15, P3338, DOI 10.3390/molecules15053338
   Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009
   Xie X, 2015, BRIT J PHARMACOL, V172, P3929, DOI 10.1111/bph.13184
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486
   Yang Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-48
   Yantiss RK, 2009, AM J SURG PATHOL, V33, P572, DOI 10.1097/PAS.0b013e31818afd6b
   Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568
   Yao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.221
   Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410
   Zhang T, 2013, INT J MED SCI, V10, P191, DOI 10.7150/ijms.4929
   Zhang T, 2011, INT J COLORECTAL DIS, V26, P109, DOI 10.1007/s00384-010-1034-2
   Zhang WJ, 2018, EUR J PHARMACOL, V825, P75, DOI 10.1016/j.ejphar.2018.02.019
   Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013
NR 161
TC 41
Z9 45
U1 1
U2 15
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD SEP 15
PY 2018
VL 10
IS 9
BP 244
EP 259
DI 10.4251/wjgo.v10.i9.244
PG 16
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA GT7SA
UT WOS:000444727800004
PM 30254720
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Ren, NSX
   Ji, M
   Tokar, EJ
   Busch, EL
   Xu, XJ
   Lewis, D
   Li, XC
   Jin, AW
   Zhang, YP
   Wu, WKK
   Huang, WC
   Li, LP
   Fargo, DC
   Keku, TO
   Sandler, RS
   Li, XL
AF Ren, Natalie S. X.
   Ji, Ming
   Tokar, Erik J.
   Busch, Evan L.
   Xu, Xiaojiang
   Lewis, DeAsia
   Li, Xiangchun
   Jin, Aiwen
   Zhang, Yanping
   Wu, William K. K.
   Huang, Weichun
   Li, Leping
   Fargo, David C.
   Keku, Temitope O.
   Sandler, Robert S.
   Li, Xiaoling
TI Haploinsufficiency of SIRT1 Enhances Glutamine Metabolism and Promotes
   Cancer Development
SO CURRENT BIOLOGY
LA English
DT Article
ID CARE OUTCOMES RESEARCH; CELL-SURVIVAL; P53; TUMORIGENESIS; ACTIVATION;
   EXPRESSION; MUTATIONS; PROTECTS; GAIN
AB SIRT1, the most conserved mammalian NAID(+)-dependent protein deacetylase, plays a vital role in the regulation of metabolism, stress responses, and genome stability. However, the role of SIRT1 in the multi-step process leading to transformation and/or tumorigenesis, as either a tumor suppressor or tumor promoter, is complex and may be dependent upon the context in which SIRT1 activity is altered, and the role of SIRT1 in tumor metabolism is unknown. Here, we demonstrate that SIRT1 dose-dependently regulates cellular glutamine metabolism and apoptosis, which in turn differentially impact cell proliferation and cancer development. Heterozygous deletion of Sirt1 induces c-Myc expression, enhancing glutamine metabolism and subsequent proliferation, autophagy, stress resistance, and cancer formation. In contrast, homozygous deletion of Sirt1 triggers cellular apoptotic pathways, increases cell death, diminishes autophagy, and reduces cancer formation. Consistent with the observed dose dependence in cells, intestine-specific Sirt1 heterozygous mice have enhanced intestinal tumor formation, whereas intestine-specific Sirt1 homozygous knockout mice have reduced development of colon cancer. Furthermore, SIRT1 reduction, but not deletion, is associated with human colorectal tumors, and colorectal cancer patients with low protein expression of SIRT1 have a poor prognosis. Taken together, our findings indicate that the dose-dependent regulation of tumor metabolism and possibly apoptosis by SIRT1 mechanistically contribute to the observed dual roles of SIRT1 in tumorigenesis. Our study highlights the importance of maintenance of a suitable SIRT1 dosage for metabolic and tissue homeostasis, which will have important implications in SIRT1-small-molecule-activator/inhibitor-based therapeutic strategies for cancers.
C1 [Ren, Natalie S. X.; Ji, Ming; Lewis, DeAsia; Li, Xiaoling] NIEHS, Signal Transduct Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Tokar, Erik J.] Natl Toxicol Program, Stem Cell Toxicol Grp, Res Triangle Pk, NC 27709 USA.
   [Busch, Evan L.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Xu, Xiaojiang; Fargo, David C.] NIEHS, Integrat Bioinformat Branch, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Huang, Weichun; Li, Leping] NIEHS, Biostat & Computat Biol Branch, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Li, Xiangchun; Wu, William K. K.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.
   [Li, Xiangchun; Wu, William K. K.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Jin, Aiwen; Zhang, Yanping] Univ North Carolina Chapel Hill, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
   [Jin, Aiwen; Zhang, Yanping] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Keku, Temitope O.; Sandler, Robert S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC 27599 USA.
   [Busch, Evan L.] Harvard Med Sch, Channing Div Network Med, Dept Med, Boston, MA 02115 USA.
   [Busch, Evan L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Busch, Evan L.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Li, XL (corresponding author), NIEHS, Signal Transduct Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM lix3@niehs.nih.gov
RI Li, Leping/F-6497-2019; xu, Xiaojiang/AAT-3851-2020; Wu, William
   K.K./A-3277-2009; Li, Xiaoling/A-2994-2015
OI Li, Leping/0000-0003-4208-0259; xu, Xiaojiang/0000-0001-5758-6581; Wu,
   William K.K./0000-0002-5662-5240; Li, Xiaoling/0000-0001-5920-7784
FU Intramural Research Program of National Institute of Environmental
   Health Sciences [Z01 ES102205]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30DK034987,
   U01CA93326]; National Cancer InstituteUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [5T32CA009001, 3P30CA016086]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA016086, T32CA009001, U01CA093326] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK056350, P30DK034987] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [ZIAES101765, P30ES010126, ZIAES102205, ZIAES102925,
   ZICES102445] Funding Source: NIH RePORTER
FX We thank Drs. Anton Jetten and Dmitry Gordenin and members of the
   Xiaoling Li laboratory for critical reading of the manuscript. We also
   thank Dr. Yi Fang and Ms. Qing Xu for technical support, Dr. E. Terence
   Adams from Integrated Laboratory Systems for histopathologic evaluation
   of colon tumors developed in mice, and Stephanie Cohen (image analysis)
   and Yongjuan Xia and Gabriela De la Cruz (staining) in the UNC
   Translational Pathology Laboratory (TPL) for expert technical
   assistance. This research was supported by the Intramural Research
   Program of National Institute of Environmental Health Sciences to
   Xiaoling Li (Z01 ES102205) and was also supported, in part, by
   extramural grants from the NIH (P30DK034987 and U01CA93326). E.L.B. was
   supported in part by a grant from the National Cancer Institute
   (5T32CA009001). The UNC TPL is supported in part by grants from the
   National Cancer Institute (3P30CA016086).
CR Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020
   Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014
   Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x
   Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124
   Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562
   Busch EL, 2016, CLIN EXP METASTAS, V33, P53, DOI 10.1007/s10585-015-9757-7
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889
   Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147
   Eng CH, 2010, AUTOPHAGY, V6, P968, DOI 10.4161/auto.6.7.13082
   Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002
   Kang M, 2013, CANCER BIOMARK, V13, P359, DOI 10.3233/CBM-130366
   Kazgan N, 2014, GASTROENTEROLOGY, V146, P1006, DOI 10.1053/j.gastro.2013.12.029
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501
   Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005
   Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020
   Lin Zhenghong, 2013, Genes Cancer, V4, P97, DOI 10.1177/1947601912475079
   Lo Sasso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102495
   Malin JL, 2006, SUPPORT CARE CANCER, V14, P837, DOI 10.1007/s00520-005-0902-8
   Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109
   Ming M, 2015, ONCOGENE, V34, P281, DOI 10.1038/onc.2013.583
   Nazeer FI, 2011, ONCOGENE, V30, P3073, DOI 10.1038/onc.2011.29
   Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025
   Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160
   Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105
   Purushotham A, 2012, FASEB J, V26, P656, DOI 10.1096/fj.11-195172
   Qiang L, 2015, CELL REP, V11, P1797, DOI 10.1016/j.celrep.2015.05.025
   Rathore MG, 2012, INT J BIOCHEM CELL B, V44, P1448, DOI 10.1016/j.biocel.2012.05.011
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   Schug TT, 2011, ANN MED, V43, P198, DOI 10.3109/07853890.2010.547211
   Song NY, 2012, ANN NY ACAD SCI, V1271, P10, DOI 10.1111/j.1749-6632.2012.06762.x
   Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
   Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013
NR 45
TC 28
Z9 31
U1 1
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD FEB 20
PY 2017
VL 27
IS 4
BP 483
EP 494
DI 10.1016/j.cub.2016.12.047
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA EL6IF
UT WOS:000394724600018
PM 28162896
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Roh, SA
   Choi, EY
   Cho, DH
   Yoon, YS
   Kim, TW
   Kim, YS
   Kim, JC
AF Roh, Seon Ae
   Choi, Eun Young
   Cho, Dong Hyung
   Yoon, Yong Sik
   Kim, Tae Won
   Kim, Yong Sung
   Kim, Jin Cheon
TI Characterization of biological responses of colorectal cancer cells to
   anticancer regimens
SO JOURNAL OF THE KOREAN SURGICAL SOCIETY
LA English
DT Article
DE Colorectal neoplasms; Chemotherapy; Pharmacological biomarkers
ID UP-REGULATION; CHEMOTHERAPY; APOPTOSIS; DEATH; AUTOPHAGY;
   IMMUNOGENICITY; RESISTANCE; SEQUENCE; THERAPY; AGENTS
AB Purpose: Identification of subgroups of patients who differ in their response to treatment could help to establish which of the best available chemotherapeutic options are best, based on biological activity. In metastatic colorectal cancer (CRC), novel molecular-targeted agents that act on pathways that regulate cell growth, the cell cycle, apoptosis, angiogenesis, and invasion are being developed. Here, we employed an in vitro chemosensitivity assay to evaluate the biological efficacy of conventional monotherapies and combination chemotherapy with targeted drugs. Methods: The chemosensitivities of 12 CRC cell lines to the established regimens FOLFOX (5-fluorouracil [5-FU] leucovorin + oxaliplatin) and FOLFIRI (5-FU + leucovorin + irinotecan) and to therapy with these regimens in combination with the biologically targeted drugs bevacizumab or cetuximab were comparatively evaluated for their effects on apoptotic and autophagic cell death processes, angiogenesis, and invasion. Results: Each of the chemotherapeutic regimens promoted apoptotic cell death and invasion. All drug regimens caused significantly greater apoptotic cell death with activation of caspase-3 in SW480 cells compared to other cells, effects that were associated with a remarkable reduction in matrix metalloproteinase-9 activity. The FOLFOX regimen more effectively promoted apoptotic cell death, angiogenesis, and invasion than the FOLFIRI regimen. Combination therapy with FOLFOX/FOLFIRI regimen and bevacizumab produced a moderate angiogenesis-blocking effect in most cell lines. Conclusion: The results validate our in vitro chemosensitivity assay, and suggest that it may be applied to help determine adequate regimens in individual CRC patients based on the biological characteristics of their tumors.
C1 [Roh, Seon Ae; Choi, Eun Young; Yoon, Yong Sik; Kim, Jin Cheon] Univ Ulsan, Dept Surg, Coll Med, Asan Med Ctr, Seoul 138736, South Korea.
   [Roh, Seon Ae; Choi, Eun Young; Yoon, Yong Sik; Kim, Jin Cheon] Asan Inst Life Sci, Lab Canc Biol & Genet, Seoul, South Korea.
   [Cho, Dong Hyung] Kyung Hee Univ, Grad Sch EW Med Sci, Yongin, South Korea.
   [Kim, Tae Won] Univ Ulsan, Dept Oncol, Coll Med, Asan Med Ctr, Seoul 138736, South Korea.
   [Kim, Yong Sung] Korea Res Inst Biosci & Biotechnol, Div Med Genet, Taejon, South Korea.
RP Kim, JC (corresponding author), Univ Ulsan, Dept Surg, Coll Med, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea.
EM jckim@amc.seoul.kr
CR Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Baker EA, 2002, EUR J SURG ONCOL, V28, P24, DOI 10.1053/ejso.2001.1179
   Baker EA, 2003, EUR J CANCER, V39, P981, DOI 10.1016/S0959-8049(03)00065-0
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Danese S, 2006, GASTROENTEROLOGY, V130, P2060, DOI 10.1053/j.gastro.2006.03.054
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Fujita H, 2007, ONCOL REP, V18, P1129
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339
   Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551
   Ju JH, 2007, INT J COLORECTAL DIS, V22, P855, DOI 10.1007/s00384-007-0293-z
   Kelly C, 2007, SURG ONCOL, V16, P65, DOI 10.1016/j.suronc.2007.04.006
   Kim J, 2009, INT J COLORECTAL DIS, V24, P209, DOI 10.1007/s00384-008-0590-1
   Kohne CH, 2009, ONCOLOGIST, V14, P478, DOI 10.1634/theoncologist.2008-0202
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562
   Leman ES, 2008, J CELL BIOCHEM, V104, P1988, DOI 10.1002/jcb.21363
   Lesterhuis WJ, 2010, BRIT J CANCER, V103, P1415, DOI 10.1038/sj.bjc.6605935
   Lubbe WJ, 2006, CLIN CANCER RES, V12, P1876, DOI 10.1158/1078-0432.CCR-05-2686
   Nannizzi S, 2010, CANCER CHEMOTH PHARM, V66, P547, DOI 10.1007/s00280-009-1195-2
   Rochette PJ, 2005, J MOL BIOL, V352, P44, DOI 10.1016/j.jmb.2005.06.033
   Sabharwal A, 2007, EXPERT REV ANTICANC, V7, P477, DOI 10.1586/14737140.7.4.477
   Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584
   Sun QL, 2008, INT IMMUNOPHARMACOL, V8, P1854, DOI 10.1016/j.intimp.2008.08.009
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Toscano F, 2008, ONCOGENE, V27, P4161, DOI 10.1038/onc.2008.52
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Waldner MJ, 2010, MOL ASPECTS MED, V31, P171, DOI 10.1016/j.mam.2010.02.005
   West NJ, 2009, CANCER EPIDEM BIOMAR, V18, P1680, DOI 10.1158/1055-9965.EPI-09-0006
NR 30
TC 4
Z9 8
U1 0
U2 2
PU KOREAN SURGICAL SOCIETY
PI SEOUL
PA 3304HO, 101 DONG, BROWNSTONE SEOUL, 335, JUNGMIN-DONG, JUNG-GU, SEOUL,
   100-859, SOUTH KOREA
SN 2233-7903
J9 J KOREAN SURG SOC
JI J. Korean Surg. Soc.
PD JUL
PY 2012
VL 83
IS 1
BP 21
EP 29
DI 10.4174/jkss.2012.83.1.21
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 967QI
UT WOS:000305922500004
PM 22792530
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Vallianou, NG
   Evangelopoulos, A
   Schizas, N
   Kazazis, C
AF Vallianou, Natalia G.
   Evangelopoulos, Angelos
   Schizas, Nikos
   Kazazis, Christos
TI Potential Anticancer Properties and Mechanisms of Action of Curcumin
SO ANTICANCER RESEARCH
LA English
DT Review
DE Curcumin; anti-cancer properties; autophagy; transcription factors;
   bioavailability; review
ID ENDOPLASMIC-RETICULUM STRESS; FACTOR-KAPPA-B; SIGNALING INDUCES
   APOPTOSIS; CONSTITUTIVE ACTIVATION; IN-VIVO; BIOLOGICAL EVALUATION;
   CELL-LINES; ANTIINFLAMMATORY PROPERTIES; CHEMOPREVENTIVE AGENTS; COLON
   CARCINOGENESIS
AB Curcumin, a yellow substance belonging to the polyphenols superfamily, is the active component of turmeric, a common Indian spice, which is derived from the dried rhizome of the Curcuma longa plant. Numerous studies have demonstrated that curcumin possesses anti-oxidant, antiinflammatory and anticancerous properties. The purpose of this review is to focus on the anti-tumor effects of curcumin. Curcumin inhibits the STAT3 and NF-kappa B signaling pathways, which play key-roles in cancer development and progression. Also, inhibition of Sp-1 and its housekeeping gene expressions may serve as an important hypothesis to prevent cancer formation, migration, and invasion. Recent data have suggested that curcumin may act by suppressing the Sp-1 activation and its downstream genes, including ADEM10, calmodulin, EPHB2, HDAC4, and SEPP1 in a concentration-dependent manner in colorectal cancer cell lines; these results are consistent with other studies, which have reported that curcumin could suppress the Sp-1 activity in bladder cancer and could decrease DNA binding activity of Sp-1 in non-small cell lung carcinoma cells. Recent data advocate that ER stress and autophagy may as well play a role in the apoptosis process, which is induced by the curcumin analogue B19 in an epithelial ovarian tumor cell line and that autophagy inhibition could increase curcumin analogue-induced apoptosis by inducing severe ER stress. The ability of curcumin to induce apoptosis in tumor cells and its anti-angiogenic potential will be discussed in this review.
C1 [Vallianou, Natalia G.; Schizas, Nikos] Evangelismos Gen Hosp, Athens, Greece.
   [Evangelopoulos, Angelos] Roche Diagnost, Athens, Greece.
   [Kazazis, Christos] Univ Leicester, Samos, Greece.
RP Vallianou, NG (corresponding author), 5 Pyramidon Str, Athens 19005, Greece.
EM natalia.vallianou@hotmail.com
CR Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054
   Adams BK, 2004, BIOORGAN MED CHEM, V12, P3871, DOI 10.1016/j.bmc.2004.05.006
   Agrawal DK, 2010, MED RES REV, V30, P818, DOI 10.1002/med.20188
   Ahn KS, 2008, CANCER RES, V68, P4406, DOI 10.1158/0008-5472.CAN-07-6696
   Aigner S, 1998, FASEB J, V12, P1241, DOI 10.1096/fasebj.12.12.1241
   [Anonymous], 2014, NUTR CANC, V66, P1015
   Anthwal A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/524161
   Anuchapreeda S, 2012, J NANOTECHNOL, V2012, DOI 10.1155/2012/270383
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Arzuman L, 2014, ANTICANCER RES, V34, P5453
   Bala V, 2013, J CONTROL RELEASE, V172, P48, DOI 10.1016/j.jconrel.2013.07.022
   Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988
   Bharti AC, 2002, ANN NY ACAD SCI, V973, P392, DOI 10.1111/j.1749-6632.2002.tb04671.x
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151
   Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4
   Chadalapaka G, 2008, CANCER RES, V68, P5345, DOI 10.1158/0008-5472.CAN-07-6805
   Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035
   Chen C C, 2013, EVID-BASED COMPL ALT, V2013
   Chen HW, 2008, CANCER RES, V68, P7428, DOI 10.1158/0008-5472.CAN-07-6734
   Chiablaem K, 2014, ANTICANCER RES, V34, P1857
   Cho H, 2012, NANOMED-NANOTECHNOL, V8, P228, DOI 10.1016/j.nano.2011.06.009
   Cho SG, 2009, CANCER RES, V69, P7062, DOI 10.1158/0008-5472.CAN-09-0476
   Clarke R, 2012, CANCER RES, V72, P1321, DOI 10.1158/0008-5472.CAN-11-3213
   Da-Lozzo EJ, 2013, CARBOHYD POLYM, V93, P279, DOI 10.1016/j.carbpol.2012.02.036
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Das M, 2013, MOL PHARM, V19
   Davie JR, 2008, ADV ENZYME REGUL, V48, P189, DOI 10.1016/j.advenzreg.2007.11.016
   Dayton A, 2010, CANCER BIOL THER, V10, P1027, DOI 10.4161/cbt.10.10.13250
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Du ZY, 2011, BIOSCI BIOTECH BIOCH, V75, P2351, DOI 10.1271/bbb.110547
   Duprez J, 2011, BIOCHEM BIOPH RES CO, V415, P294, DOI 10.1016/j.bbrc.2011.10.048
   Esmaili M, 2011, LWT-FOOD SCI TECHNOL, V44, P2166, DOI 10.1016/j.lwt.2011.05.023
   Gamero AM, 2004, CANCER CELL, V5, P111, DOI 10.1016/S1535-6108(04)00028-5
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Grabacka MM, 2014, PHARMACEUTICALS-BASE, V7, P913, DOI 10.3390/ph7090913
   Greten FR, 2002, GASTROENTEROLOGY, V123, P2052, DOI 10.1053/gast.2002.37075
   Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003
   Hsu CH, 2007, ADV EXP MED BIOL, V595, P471
   Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931
   HUANG MT, 1992, CARCINOGENESIS, V13, P2183, DOI 10.1093/carcin/13.11.2183
   HUANG MT, 1994, CANCER RES, V54, P5841
   HUANG MT, 1988, CANCER RES, V48, P5941
   Huq F, 2014, ANTICANCER RES, V34, P541
   Jurenka JS, 2009, ALTERN MED REV, V14, P141
   Kapakos G, 2012, INDIAN J BIOCHEM BIO, V49, P306
   Karthikeyan NS, 2011, MED CHEM RES, V20, P81, DOI 10.1007/s00044-009-9284-7
   Kasdagly M, 2014, NUTRITION, V30, P1242, DOI 10.1016/j.nut.2014.02.016
   Kim YS, 2007, J CARDIOVASC PHARM, V50, P41, DOI 10.1097/FJC.0b013e31805559b9
   Kirito K, 2002, INT J HEMATOL, V75, P51, DOI 10.1007/BF02981979
   KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6
   Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325
   KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4
   Lee HE, 2013, ORAL ONCOL, DOI [10.1016/j.oraloncology.2013.11.006, DOI 10.1016/J.0RAL0NC0L0GY.2013.11.006.]
   Lee JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023756
   Lee KH, 2009, EUR J MED CHEM, V44, P3195, DOI 10.1016/j.ejmech.2009.03.020
   Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Liang GA, 2009, BIOORGAN MED CHEM, V17, P2623, DOI 10.1016/j.bmc.2008.10.044
   Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X
   Lou Z, 2005, CANCER RES, V65, P1007
   Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006
   Masuda M, 2002, CANCER RES, V62, P3351
   Masuda T, 2001, J AGR FOOD CHEM, V49, P2539, DOI 10.1021/jf001442x
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Mora LB, 2002, CANCER RES, V62, P6659
   Novakovic M, 2014, PHYTOCHEMISTRY, V97, P46, DOI 10.1016/j.phytochem.2013.11.001
   Ohori H, 2006, MOL CANCER THER, V5, P2563, DOI 10.1158/1535-7163.MCT-06-0174
   Park W, 2013, CANCER PREV RES, V6, P387, DOI 10.1158/1940-6207.CAPR-12-0410
   Paul NK, 2014, EUR J MED CHEM, V87, P461, DOI 10.1016/j.ejmech.2014.09.090
   Qi XX, 2013, NANOSCALE, V5, P8925, DOI 10.1039/c3nr03262k
   Qu WL, 2013, INT J BIOL SCI, V9, P766, DOI 10.7150/ijbs.5711
   Rahmani AH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/761608
   RAO CV, 1995, CANCER RES, V55, P259
   Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004
   Robinson TP, 2003, BIOORG MED CHEM LETT, V13, P115, DOI 10.1016/S0960-894X(02)00832-6
   Roder S, 2001, EXP HEMATOL, V29, P694, DOI 10.1016/S0301-472X(01)00637-3
   Sahu A, 2011, J BIOMATER APPL, V25, P619, DOI 10.1177/0885328209357110
   Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263
   Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Shi Q, 2001, CANCER RES, V61, P4143
   Shishodia S, 2007, ADV EXP MED BIOL, V595, P127
   Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479
   Soukasene S, 2011, ACS NANO, V5, P9113, DOI 10.1021/nn203343z
   Strimpakos AS, 2008, ANTIOXID REDOX SIGN, V10, P511, DOI 10.1089/ars.2007.1769
   Subramaniam D, 2008, CANCER RES, V68, P1962, DOI 10.1158/0008-5472.CAN-07-6011
   Teow HM, 2013, INT J PHARMACEUT, V441, P701, DOI 10.1016/j.ijpharm.2012.10.024
   To KF, 2004, BRIT J CANCER, V91, P1335, DOI 10.1038/sj.bjc.6602133
   Ucisik MH, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-37
   Wagh A, 2013, NANOMED-NANOTECHNOL, V9, P449, DOI 10.1016/j.nano.2012.10.009
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Wang HM, 2012, BIOMATERIALS, V33, P5848, DOI 10.1016/j.biomaterials.2012.04.047
   Yadav B, 2010, BIOORGAN MED CHEM, V18, P6701, DOI 10.1016/j.bmc.2010.07.063
   Zannetti A, 2000, CANCER RES, V60, P1546
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang PC, 2013, ACS NANO, V7, P5965, DOI 10.1021/nn401667z
   Zhao CG, 2010, BIOORGAN MED CHEM, V18, P2388, DOI 10.1016/j.bmc.2010.03.001
   Zheng A, 2013, CURR CANC DRUG TARGE
   Zhou DY, 2013, CHEM PHARM BULL, V61, P1149
   Zhou T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107876
   Zlotogorski A, 2013, ORAL ONCOL, V49, P187, DOI 10.1016/j.oraloncology.2012.09.015
   Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4
NR 106
TC 189
Z9 199
U1 5
U2 95
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD FEB
PY 2015
VL 35
IS 2
BP 645
EP 651
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB4LG
UT WOS:000349598600005
PM 25667441
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Blyufer, A
   Lhamo, S
   Tam, C
   Tariq, I
   Thavornwatanayong, T
   Mahajan, SS
AF Blyufer, Angelina
   Lhamo, Sonam
   Tam, Cassey
   Tariq, Iffat
   Thavornwatanayong, Thongthai
   Mahajan, Shahana S.
TI Riluzole: A neuroprotective drug with potential as a novel anti-cancer
   agent (Review)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Review
DE riluzole; glutamate secretion and signaling; reactive oxygen species;
   DNA damage; apoptosis; cell cycle arrest; combination therapy
ID AMYOTROPHIC-LATERAL-SCLEROSIS; CANCER-CELLS; DISEASE PROGRESSION;
   SIGNALING PATHWAYS; OXIDATIVE STRESS; GLIOMA-CELLS; GLUTAMATE; MELANOMA;
   PROLIFERATION; EXPRESSION
AB Riluzole, a glutamate release inhibitor, has been in use for the treatment of amyotrophic lateral sclerosis for over two decades since its approval by the Food and Drug Administration. Recently, riluzole has been evaluated in cancer cells and indicated to block cell proliferation and/or induce cell death. Riluzole has been proven effective as an anti-neoplastic drug in cancers of various tissue origins, including the skin, breast, pancreas, colon, liver, bone, brain, lung and nasopharynx. While cancer cells expressing glutamate receptors frequently respond to riluzole treatment, numerous types of cancer cell lacking glutamate receptors unexpectedly responded to riluzole treatment as well. Riluzole was demonstrated to interfere with glutamate secretion, growth signaling pathways, Ca2+ homeostasis, glutathione synthesis, reactive oxygen species generation and integrity of DNA, as well as autophagic and apoptotic pathways. Of note, riluzole is highly effective in inducing cell death in cisplatin-resistant lung cancer cells. Furthermore, riluzole pretreatment sensitizes glioma and melanoma to radiation therapy. In addition, in triple-negative breast cancer, colorectal cancer, melanoma and glioblastoma, riluzole has synergistic effects in combination with select drugs. In an effort to highlight the therapeutic potential of riluzole, the current study reviewed the effect and outcome of riluzole treatment on numerous cancer types investigated thus far. The mechanism of action and the various molecular pathways affected by riluzole are discussed.
C1 [Blyufer, Angelina; Lhamo, Sonam; Tam, Cassey; Tariq, Iffat; Mahajan, Shahana S.] CUNY, Dept Med Lab Sci, Hunter Coll, 425 East,25th St, New York, NY 10010 USA.
   [Thavornwatanayong, Thongthai; Mahajan, Shahana S.] CUNY, PhD Program Biol, Grad Ctr, New York, NY 10016 USA.
   [Mahajan, Shahana S.] CUNY, PhD Program Biochem, Grad Ctr, New York, NY 10016 USA.
   [Mahajan, Shahana S.] Weill Cornell Med Coll, Brain Mind Res Inst, New York, NY 10021 USA.
RP Mahajan, SS (corresponding author), CUNY, Dept Med Lab Sci, Hunter Coll, 425 East,25th St, New York, NY 10010 USA.
EM smahajan@hunter.cuny.edu
FU National Institute of General Medical Sciences, National Institute of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [1 SC1 GM131929-01A1]; City University of New
   York [62504 00 50]
FX The study was funded by the following grants: National Institute of
   General Medical Sciences, National Institute of Health (grant no. 1 SC1
   GM131929-01A1) and the Professional Staff Congress and The City
   University of New York (grant no. 62504 00 50).
CR Akamatsu K, 2009, ANTICANCER RES, V29, P2195
   Basu AK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040970
   Bellingham MC, 2011, CNS NEUROSCI THER, V17, P4, DOI 10.1111/j.1755-5949.2009.00116.x
   Beltran-Parrazal L, 2003, BRIT J PHARMACOL, V140, P881, DOI 10.1038/sj.bjp.0705491
   Benavides-Serrato A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010344
   Biechele TL, 2010, CHEM BIOL, V17, P1177, DOI 10.1016/j.chembiol.2010.08.012
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y
   Cerchio R, 2020, MELANOMA RES, V30, P303, DOI 10.1097/CMR.0000000000000652
   Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645
   Cheah BC, 2010, CURR MED CHEM, V17, P1942, DOI 10.2174/092986710791163939
   Choi KY, 2011, P NATL ACAD SCI USA, V108, P15219, DOI 10.1073/pnas.1107304108
   Cowan Robert W, 2012, Front Endocrinol (Lausanne), V3, P89, DOI 10.3389/fendo.2012.00089
   Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S
   Dolfi SC, 2017, ONCOTARGET, V8, P44639, DOI 10.18632/oncotarget.17961
   Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x
   Falzone L, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01300
   Fortunato A, 2017, CELL ONCOL, V40, P367, DOI 10.1007/s13402-017-0328-6
   Grant P, 2010, J CHILD ADOL PSYCHOP, V20, P309, DOI 10.1089/cap.2010.0009
   Groeneveld GJ, 2008, CLIN PHARMACOL THER, V83, P718, DOI 10.1038/sj.clpt.6100382
   Groeneveld GJ, 2003, NEUROLOGY, V61, P1141, DOI 10.1212/01.WNL.0000090459.76784.49
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Hemendinger RA, 2012, TOXICOL APPL PHARM, V258, P208, DOI 10.1016/j.taap.2011.10.022
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432-1033.2003.03907.x
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335
   Inoue-Shibui A, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1299-1
   Jan CR, 2002, PHARMACOLOGY, V66, P120, DOI 10.1159/000063798
   Janaky R, 1999, J NEUROCHEM, V73, P889, DOI 10.1046/j.1471-4159.1999.0730889.x
   Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200
   Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x
   Kamal T, 2015, CELL SIGNAL, V27, P1860, DOI 10.1016/j.cellsig.2015.05.004
   Kennedy L, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101429
   Khan Atif J, 2019, Oncotarget, V10, P2824, DOI 10.18632/oncotarget.26854
   Khan AJ, 2011, CLIN CANCER RES, V17, P1807, DOI 10.1158/1078-0432.CCR-10-1276
   Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3
   Lacomblez L, 2002, AMYOTROPH LATERAL SC, V3, P23, DOI 10.1080/146608202317576507
   Le Liboux A, 1999, J CLIN PHARMACOL, V39, P480
   Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126
   Lee HJ, 2011, CLIN CANCER RES, V17, P7080, DOI 10.1158/1078-0432.CCR-11-0098
   Lemieszek MK, 2018, ANTI-CANCER AGENT ME, V18, P565, DOI 10.2174/1871520618666180228152713
   Liao S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171256
   Lin WY, 2020, AM J CANCER RES, V10, P3106
   Linder B, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8040082
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2
   Mehnert JM, 2018, PIGM CELL MELANOMA R, V31, P534, DOI 10.1111/pcmr.12694
   Miller RG, 2003, AMYOTROPH LATERAL SC, V4, P191
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Muir A, 2017, ELIFE, V6, DOI 10.7554/eLife.27713
   Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Poupon L, 2018, NEUROPHARMACOLOGY, V140, P43, DOI 10.1016/j.neuropharm.2018.07.026
   Prickett TD, 2012, CLIN CANCER RES, V18, P4240, DOI 10.1158/1078-0432.CCR-11-1217
   Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950
   Pucci C, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.961
   Raghubir M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00439-8
   Raghubir M, 2020, ONCOL REP, V43, P169, DOI 10.3892/or.2019.7420
   Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2
   Rampersaud S, 2016, NANO LETT, V16, P7357, DOI 10.1021/acs.nanolett.6b02577
   Reiner A, 2018, NEURON, V98, P1080, DOI 10.1016/j.neuron.2018.05.018
   Rosenberg SA, 2015, TRANSL ONCOL, V8, P1, DOI 10.1016/j.tranon.2014.11.001
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Seol HS, 2016, CANCER LETT, V382, P157, DOI 10.1016/j.canlet.2016.08.028
   Sharma MK, 2010, BIOCHEM BIOPH RES CO, V391, P91, DOI 10.1016/j.bbrc.2009.10.168
   Shin SS, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0098-7
   Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4
   Sorenson EJ, 2006, NEUROLOGY, V67, P2260, DOI 10.1212/01.wnl.0000249182.09143.20
   Sperling S, 2017, ONCOTARGET, V8, P96697, DOI 10.18632/oncotarget.18043
   Speyer CL, 2017, BREAST CANCER RES TR, V166, P407, DOI 10.1007/s10549-017-4435-x
   Speyer CL, 2016, BREAST CANCER RES TR, V157, P217, DOI 10.1007/s10549-016-3816-x
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Sun L, 2020, J CANCER, V11, P3089, DOI 10.7150/jca.41217
   Sun RL, 2021, J CELL BIOCHEM, V122, P934, DOI 10.1002/jcb.29533
   Urbani A, 2000, EUR J NEUROSCI, V12, P3567, DOI 10.1046/j.1460-9568.2000.00242.x
   Wadosky KM, 2019, PROSTATE, V79, P140, DOI 10.1002/pros.23719
   Wall BA, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12327
   Wall BA, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12207
   Wangpaichitr M, 2017, ONCOTARGET, V8, P49275, DOI 10.18632/oncotarget.17568
   Willard SS, 2013, INT J BIOL SCI, V9, P728, DOI 10.7150/ijbs.6475
   Wokke J, 1996, LANCET, V348, P795, DOI 10.1016/S0140-6736(96)03181-9
   Yamada T, 2021, J NEUROSURG, V134, P701, DOI 10.3171/2019.12.JNS192682
   Ye ZC, 1999, CANCER RES, V59, P4383
   Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999
   Yip D, 2009, CLIN CANCER RES, V15, P3896, DOI 10.1158/1078-0432.CCR-08-3303
   Yu LMJ, 2017, NEUROPHARMACOLOGY, V115, P193, DOI 10.1016/j.neuropharm.2016.02.011
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zona C, 1998, NEUROSCIENCE, V85, P931, DOI 10.1016/S0306-4522(97)00604-0
NR 93
TC 0
Z9 0
U1 3
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2021
VL 59
IS 5
AR 95
DI 10.3892/ijo.2021.5275
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WR6YK
UT WOS:000714643600001
PM 34713302
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Sun, YM
   Liu, Z
   Zou, X
   Lan, YD
   Sun, XJ
   Wang, X
   Zhao, SR
   Jiang, CC
   Liu, H
AF Sun, Yiming
   Liu, Zhe
   Zou, Xue
   Lan, Yadong
   Sun, Xiaojin
   Wang, Xiu
   Zhao, Surong
   Jiang, Chenchen
   Liu, Hao
TI Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article
DE 3-Bromopyruvate; ATP; Apoptosis; Autophagy; Necroptosis
ID CYTOCHROME-C; AUTOPHAGY; APOPTOSIS; PROMOTES; GLYCOLYSIS; INHIBITOR;
   NECROSIS; PROTEIN; MITOCHONDRIA; THERAPY
AB 3-Bromopyruvate (3BP) is an energy-depleting drug that inhibits Hexokinase II activity by alkylation during glycolysis, thereby suppressing the production of ATP and inducing cell death. As such, 3BP can potentially serve as an anti-tumorigenic agent. Our previous research showed that 3BP can induce apoptosis via AKT /protein Kinase B signaling in breast cancer cells. Here we found that 3BP can also induce colon cancer cell death by necroptosis and apoptosis at the same time and concentration in the SW480 and HT29 cell lines; in the latter, autophagy was also found to be a mechanism of cell death. In HT29 cells, combined treatment with 3BP and the autophagy inhibitor 3-methyladenine (3-MA) exacerbated cell death, while viability in 3BP-treated cells was enhanced by concomitant treatment with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone (z-VAD-fmk) and the necroptosis inhibitor necrostatin (Nec)-1. Moreover, 3BP inhibited tumor growth in a SW480 xenograft mouse model. These results indicate that 3BP can suppress tumor growth and induce cell death by multiple mechanisms at the same time and concentration in different types of colon cancer cell by depleting cellular energy stores.
C1 [Sun, Yiming; Liu, Zhe; Zou, Xue; Sun, Xiaojin; Wang, Xiu; Zhao, Surong; Liu, Hao] Bengbu Med Coll, Fac Pharm, Bengbu 233000, Anhui, Peoples R China.
   [Lan, Yadong] Bengbu Med Coll, Affiliated Hosp 1, Dept Surg Oncol, Bengbu 233004, Peoples R China.
   [Jiang, Chenchen] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia.
RP Liu, H (corresponding author), Bengbu Med Coll, Fac Pharm, Bengbu 233000, Anhui, Peoples R China.
EM liuhao6886@foxmail.com
FU Natural Science Foundation of Anhui provinceNatural Science Foundation
   of Anhui Province [1508085MH166]; National Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81372899,
   81000992]; Foundation of Bengbu Medical College [Byycx1432]
FX This work was supported by the Natural Science Foundation of Anhui
   province (No. 1508085MH166), the National Science Foundation of China
   (No. 81372899, No. 81000992) and the Foundation of Bengbu Medical
   College (No. Byycx1432).
CR BELLAIRS R, 1961, J ANAT, V95, P54
   Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7
   Chen Z, 2009, BBA-BIOENERGETICS, V1787, P553, DOI 10.1016/j.bbabio.2009.03.003
   Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Ferraro E, 2008, MOL BIOL CELL, V19, P3576, DOI 10.1091/mbc.E07-09-0858
   Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Ganapathy-Kanniappan S, 2010, CURR PHARM BIOTECHNO, V11, P510, DOI 10.2174/138920110791591427
   Geschwind JFH, 2002, CANCER RES, V62, P3909
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Levy AG, 2012, INVEST NEW DRUG, V30, P191, DOI 10.1007/s10637-010-9551-y
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu XH, 2009, CHINESE MED J-PEKING, V122, P1681, DOI 10.3760/cma.j.issn.0366-6999.2009.14.014
   Liu Z, 2014, ANTI-CANCER DRUG, V25, P447, DOI 10.1097/CAD.0000000000000081
   Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x
   Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Ota S, 2013, TARGET ONCOL, V8, P145, DOI 10.1007/s11523-013-0273-x
   Parks SK, 2013, J CELL PHYSIOL, V228, P1854, DOI 10.1002/jcp.24346
   Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186
   SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306
   Shoshan MC, 2012, J BIOENERG BIOMEMBR, V44, P7, DOI 10.1007/s10863-012-9419-2
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Takahashi A, 2012, AM J PATHOL, V180, P517, DOI 10.1016/j.ajpath.2011.11.001
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Thapa RJ, 2013, P NATL ACAD SCI USA, V110, pE3109, DOI 10.1073/pnas.1301218110
   Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O, 1928, SCIENCE, V68, P437, DOI 10.1126/science.68.1767.437
   Xu RH, 2005, CANCER RES, V65, P613
   Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhang Qianwen, 2014, Genes Cancer, V5, P100
   Zhang XD, 2009, ANTICANCER RES, V29, P1443
   Zuo XM, 2011, MOL PHARMACOL, V80, P476, DOI 10.1124/mol.111.072322
NR 50
TC 35
Z9 40
U1 0
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145-479X
EI 1573-6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD AUG
PY 2015
VL 47
IS 4
BP 319
EP 329
DI 10.1007/s10863-015-9612-1
PG 11
WC Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Cell Biology
GA CP9DC
UT WOS:000360192900003
PM 26054380
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Lindner, P
   Christensen, SB
   Nissen, P
   Moller, JV
   Engedal, N
AF Lindner, Paula
   Christensen, Soren Brogger
   Nissen, Poul
   Moller, Jesper Vuust
   Engedal, Nikolai
TI Cell death induced by the ER stressor thapsigargin involves death
   receptor 5, a non-autophagic function of MAP1LC3B, and distinct
   contributions from unfolded protein response components
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Thapsigargin; SERCA; Unfolded protein response; DR5; Caspase-8; PERK;
   ATF4; CHOP; IRE1; XBP1s; JNK; LC3B; Cell death; Apoptosis; Autophagy
ID ENDOPLASMIC-RETICULUM STRESS; PROSTATE-CANCER CELLS; INDUCED APOPTOSIS;
   CASPASE-8 ACTIVATION; INTERACTING PROTEIN; CALCIUM-BINDING; CA2+
   DEPLETION; KINASE; INHIBITION; PATHWAY
AB Background Cell death triggered by unmitigated endoplasmic reticulum (ER) stress plays an important role in physiology and disease, but the death-inducing signaling mechanisms are incompletely understood. To gain more insight into these mechanisms, the ER stressor thapsigargin (Tg) is an instrumental experimental tool. Additionally, Tg forms the basis for analog prodrugs designed for cell killing in targeted cancer therapy. Tg induces apoptosis via the unfolded protein response (UPR), but how apoptosis is initiated, and how individual effects of the various UPR components are integrated, is unclear. Furthermore, the role of autophagy and autophagy-related (ATG) proteins remains elusive. Methods To systematically address these key questions, we analyzed the effects of Tg and therapeutically relevant Tg analogs in two human cancer cell lines of different origin (LNCaP prostate- and HCT116 colon cancer cells), using RNAi and inhibitory drugs to target death receptors, UPR components and ATG proteins, in combination with measurements of cell death by fluorescence imaging and propidium iodide staining, as well as real-time RT-PCR and western blotting to monitor caspase activity, expression of ATG proteins, UPR components, and downstream ER stress signaling. Results In both cell lines, Tg-induced cell death depended on death receptor 5 and caspase-8. Optimal cytotoxicity involved a non-autophagic function of MAP1LC3B upstream of procaspase-8 cleavage. PERK, ATF4 and CHOP were required for Tg-induced cell death, but surprisingly acted in parallel rather than as a linear pathway; ATF4 and CHOP were independently required for Tg-mediated upregulation of death receptor 5 and MAP1LC3B proteins, whereas PERK acted via other pathways. Interestingly, IRE1 contributed to Tg-induced cell death in a cell type-specific manner. This was linked to an XBP1-dependent activation of c-Jun N-terminal kinase, which was pro-apoptotic in LNCaP but not HCT116 cells. Molecular requirements for cell death induction by therapy-relevant Tg analogs were identical to those observed with Tg. Conclusions Together, our results provide a new, integrated understanding of UPR signaling mechanisms and downstream mediators that induce cell death upon Tg-triggered, unmitigated ER stress.
C1 [Lindner, Paula; Engedal, Nikolai] Univ Oslo, Ctr Mol Med Norway NCMM, Nordic EMBL Partnership Mol Med, POB 1137, N-0318 Oslo, Norway.
   [Lindner, Paula; Nissen, Poul] Aarhus Univ, Danish Res Inst Translat Neurosci DANDRITE, Dept Mol Biol & Genet, Nordic EMBL Partnership Mol Med, Aarhus, Denmark.
   [Christensen, Soren Brogger] Univ Copenhagen, Dept Drug Design & Pharmacol, Copenhagen, Denmark.
   [Moller, Jesper Vuust] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
RP Engedal, N (corresponding author), Univ Oslo, Ctr Mol Med Norway NCMM, Nordic EMBL Partnership Mol Med, POB 1137, N-0318 Oslo, Norway.
EM k.n.engedal@ncmm.uio.no
RI Christensen, Søren Brøgger/H-4526-2019; Engedal, Nikolai/AAJ-8951-2020;
   Lindner, Paula/A-5234-2017
OI Christensen, Søren Brøgger/0000-0002-5773-6874; Engedal,
   Nikolai/0000-0003-3718-3464; Lindner, Paula/0000-0003-0734-6429
FU Research Council of NorwayResearch Council of Norway; University of Oslo
   [230686]; Nansen Foundation; Anders Jahre Foundation; Lundbeck
   FoundationLundbeckfonden [R191-2015-1512]
FX This work was generously supported by grants (to NE) from the Research
   Council of Norway and the University of Oslo (grant number 230686), the
   Nansen Foundation, and the Anders Jahre Foundation. PL is supported by a
   grant from The Lundbeck Foundation (to PN and NE; grant number
   R191-2015-1512). The funding bodies did not influence or take part in
   the design of the study, the collection, analysis, and interpretation of
   data, or in the writing of the manuscript.
CR Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171
   Arshad M, 2013, J BIOL CHEM, V288, P8726, DOI 10.1074/jbc.M112.368829
   Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Botbol Y, 2015, AUTOPHAGY, V11, P1864, DOI 10.1080/15548627.2015.1089374
   Brown M, 2016, J CELL SCI, V129, P2317, DOI 10.1242/jcs.179127
   Cao XM, 2011, FASEB J, V25, P1353, DOI 10.1096/fj.10-170480
   Chen HY, 2016, BIOMED PHARMACOTHER, V77, P108, DOI 10.1016/j.biopha.2015.12.010
   Chen YN, 2013, TRENDS CELL BIOL, V23, P547, DOI 10.1016/j.tcb.2013.06.005
   Coe H, 2009, GEN PHYSIOL BIOPHYS, V28, pF96
   Das CK, 2018, CANCER METAST REV, V37, P749, DOI 10.1007/s10555-018-9727-z
   Deegan S, 2014, AUTOPHAGY, V10, P1921, DOI 10.4161/15548627.2014.981790
   Denmeade SR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003886
   Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Dufour F, 2017, ONCOTARGET, V8, P9974, DOI 10.18632/oncotarget.14285
   Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167
   Engedal N, 2013, AUTOPHAGY, V9, P1475, DOI 10.4161/auto.25900
   Estornes Y, 2012, CELL DEATH DIFFER, V19, P1482, DOI 10.1038/cdd.2012.22
   Fink EE, 2018, CELL REP, V25, P212, DOI 10.1016/j.celrep.2018.09.013
   Fusakio ME, 2016, MOL BIOL CELL, V27, P1536, DOI 10.1091/mbc.E16-01-0039
   Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002
   Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53
   Gozuacik D, 2008, CELL DEATH DIFFER, V15, P1875, DOI 10.1038/cdd.2008.121
   Gupta S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000410
   Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973
   He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hu FL, 2014, APOPTOSIS, V19, P210, DOI 10.1007/s10495-013-0914-7
   Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006
   Humeres C, 2014, TOXICOL IN VITRO, V28, P1443, DOI 10.1016/j.tiv.2014.07.013
   Isaacs JT, 2013, CANCER RES, V73, P1386, DOI 10.1158/0008-5472.CAN-12-2730
   Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598
   Jakobsen CM, 2001, J MED CHEM, V44, P4696, DOI 10.1021/jm010985a
   Janssen S, 2006, PROSTATE, V66, P358, DOI 10.1002/pros.20348
   Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2
   Jo DG, 2004, MOL CELL BIOL, V24, P9763, DOI 10.1128/MCB.24.22.9763-9770.2004
   Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886
   Kim B, 2017, ANAT CELL BIOL, V50, P293, DOI 10.5115/acb.2017.50.4.293
   Kim JY, 2011, FEBS LETT, V585, P2144, DOI 10.1016/j.febslet.2011.05.034
   Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034
   Klee M, 2009, EMBO J, V28, P1757, DOI 10.1038/emboj.2009.90
   Lam M, 2018, CELL DEATH DIFFER, V25, P1530, DOI 10.1038/s41418-018-0155-y
   Laussmann MA, 2011, CELL DEATH DIFFER, V18, P1584, DOI 10.1038/cdd.2011.27
   Lerner AG, 2012, CELL METAB, V16, P250, DOI 10.1016/j.cmet.2012.07.007
   Levy O, 2016, BIOMATERIALS, V91, P140, DOI 10.1016/j.biomaterials.2016.03.023
   Li TL, 2015, J BIOL CHEM, V290, P11108, DOI 10.1074/jbc.M115.645333
   Li WM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01609-x
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017
   Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312
   Luhr M, 2019, J BIOL CHEM, V294, P8197, DOI 10.1074/jbc.RA118.002829
   Ma B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0889-x
   Mahalingam D, 2016, BRIT J CANCER, V114, P986, DOI 10.1038/bjc.2016.72
   Mahalingam D, 2019, CANCERS, V11, DOI 10.3390/cancers11060833
   Martin-Perez R, 2014, CANCER RES, V74, P1766, DOI 10.1158/0008-5472.CAN-13-1747
   Maurel M, 2014, TRENDS BIOCHEM SCI, V39, P245, DOI 10.1016/j.tibs.2014.02.008
   Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317
   Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Munoz-Pinedo C, 2018, CELL DEATH DIFFER, V25, P226, DOI 10.1038/cdd.2017.155
   Napoletano F, 2019, TRENDS CELL BIOL, V29, P323, DOI 10.1016/j.tcb.2018.12.007
   Doan NTQ, 2015, CURR PHARM DESIGN, V21, P5501, DOI 10.2174/1381612821666151002112824
   Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pan JA, 2011, MOL CELL BIOL, V31, P3158, DOI 10.1128/MCB.05460-11
   Pihan P, 2017, CELL DEATH DIFFER, V24, P1478, DOI 10.1038/cdd.2017.82
   Pike LRG, 2013, BIOCHEM J, V449, P389, DOI 10.1042/BJ20120972
   Pinski J, 2001, CANCER RES, V61, P6372
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5
   Sehgal P, 2017, J BIOL CHEM, V292, P19656, DOI 10.1074/jbc.M117.796920
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Shin GC, 2016, AUTOPHAGY, V12, P2451, DOI 10.1080/15548627.2016.1239002
   Shvets E, 2011, AUTOPHAGY, V7, P683, DOI 10.4161/auto.7.7.15279
   Sohoel H, 2006, BIOORGAN MED CHEM, V14, P2810, DOI 10.1016/j.bmc.2005.12.001
   Szalai P, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2835
   Szalai P, 2018, CELL CALCIUM, V76, P48, DOI 10.1016/j.ceca.2018.09.005
   Szalai P, 2015, EXP CELL RES, V333, P21, DOI 10.1016/j.yexcr.2015.02.003
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tay KH, 2014, CELL SIGNAL, V26, P287, DOI 10.1016/j.cellsig.2013.11.008
   Thomas M, 2005, J BIOL CHEM, V280, P21264, DOI 10.1074/jbc.M500144200
   Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857
   Tomar D, 2013, BBA-MOL CELL RES, V1833, P3134, DOI 10.1016/j.bbamcr.2013.08.021
   Tungteakkhun SS, 2010, J VIROL, V84, P1453, DOI 10.1128/JVI.01331-09
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   van Vliet AR, 2017, MOL CELL, V65, P885, DOI 10.1016/j.molcel.2017.01.020
   Wang SB, 2016, BRIT J PHARMACOL, V173, P2402, DOI 10.1111/bph.13516
   Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470
   Winther AML, 2010, J BIOL CHEM, V285, P28883, DOI 10.1074/jbc.M110.136242
   Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Yuan X, 2017, ONCOTARGET, V8, P21626, DOI 10.18632/oncotarget.15451
   Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14
   Zeng LF, 2009, P NATL ACAD SCI USA, V106, P8326, DOI 10.1073/pnas.0903197106
   Zlotorynski E, 2014, NAT REV MOL CELL BIO, V15, P498, DOI 10.1038/nature13401(2014)
NR 106
TC 20
Z9 21
U1 5
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478-811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD JAN 27
PY 2020
VL 18
IS 1
AR 12
DI 10.1186/s12964-019-0499-z
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KK3IO
UT WOS:000512640000001
PM 31987044
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zhao, C
   Qiu, SZ
   He, J
   Peng, Y
   Xu, HM
   Feng, ZQ
   Huang, HL
   Du, YL
   Zhou, YJ
   Nie, YQ
AF Zhao, Chong
   Qiu, ShaoZhuang
   He, Jie
   Peng, Yao
   Xu, Haoming
   Feng, Zhiqiang
   Huang, Hongli
   Du, Yanlei
   Zhou, Yongjian
   Nie, Yuqiang
TI Prodigiosin impairs autophagosome-lysosome fusion that sensitizes
   colorectal cancer cells to 5-fluorouracil-induced cell death
SO CANCER LETTERS
LA English
DT Article
DE Prodigiosin; Colorectal cancer; Autophagy flux; Chemotherapy; Apoptosis
ID PROTEASOME INHIBITION; STEM-CELLS; OXALIPLATIN; HYDROXYCHLOROQUINE;
   COMBINATION; SUPPRESSION; APOPTOSIS; THERAPY; PATHWAY; MTORC1
AB Chemotherapy failure is a major cause of recurrence and poor prognosis in colorectal cancer (CRC) patients. Inhibition of autophagy is a promising strategy to augment the cytotoxicity of chemotherapeutic agents. We identified prodigiosin, a secondary metabolite produced by various bacteria, as a novel autophagy inhibitor that interfered with the autophagic flux in CRC cells by blocking autophagosome-lysosome fusion and lysosomal cathepsin maturation, resulting in the accumulation of LC3B-II and SQSTM. Suppression of autophagy by prodigiosin sensitized the CRC cells to 5-fluorouracil (5-Fu) in vitro, and the combination treatment markedly reduced cancer cell viability partly via caspase-dependent apoptosis. Furthermore, prodigiosin and 5-Fu synergistically inhibited CRC xenograft growth in vivo without any adverse effects. In conclusion, prodigiosin inhibits late stage autophagy and sensitizes tumor cells to 5-Fu, indicating its therapeutic potential in CRC.
C1 [Zhao, Chong; Qiu, ShaoZhuang; He, Jie; Peng, Yao; Xu, Haoming; Feng, Zhiqiang; Huang, Hongli; Du, Yanlei; Zhou, Yongjian; Nie, Yuqiang] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Guangzhou Digest Dis Ctr, Dept Gastroenterol, Guangzhou 510180, Peoples R China.
   [Zhao, Chong; Qiu, ShaoZhuang; He, Jie; Peng, Yao; Xu, Haoming; Feng, Zhiqiang; Huang, Hongli; Du, Yanlei; Zhou, Yongjian; Nie, Yuqiang] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Gastroenterol, Guangzhou 510180, Peoples R China.
RP Nie, YQ (corresponding author), South China Univ Technol, Affiliated Hosp 2, Guangzhou Peoples Hosp 1, Guangzhou 510180, Peoples R China.
EM eynieyuqiang@scut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81871905, 81700486]; Guangzhou Science,
   Technology and Innovation Commission [201906010052]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities [2017Q113]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81871905, No. 81700486), the Guangzhou Science, Technology
   and Innovation Commission (201906010052), and the Fundamental Research
   Funds for the Central Universities (2017Q113).
CR Bartlett BJ, 2011, AUTOPHAGY, V7, P572, DOI 10.4161/auto.7.6.14943
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cartwright TH, 2012, CLIN COLORECTAL CANC, V11, P155, DOI 10.1016/j.clcc.2011.11.001
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Cheng SY, 2018, APOPTOSIS, V23, P314, DOI 10.1007/s10495-018-1456-9
   Chiu WJ, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100321
   Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Darshan N, 2015, J FOOD SCI TECH MYS, V52, P5393, DOI 10.1007/s13197-015-1740-4
   Espona-Fiedler M, 2012, BIOCHEM PHARMACOL, V83, P489, DOI 10.1016/j.bcp.2011.11.027
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hurley JH, 2014, CELL, V157, P300, DOI 10.1016/j.cell.2014.01.070
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037
   Katunuma N., 2010, J SIGNAL TRANSDUCT
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levy JMM, 2017, ELIFE, V6, DOI 10.7554/eLife.19671
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lu L, 2011, EUR J PHARMACOL, V658, P242, DOI 10.1016/j.ejphar.2011.02.043
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mei LF, 2015, BRIT J PHARMACOL, V172, P2232, DOI 10.1111/bph.13045
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961
   Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5
   O'Connell MJ, 2009, J CLIN ONCOL, V27, P3082, DOI 10.1200/JCO.2009.22.2919
   Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Perez-Tomas R, 2010, CURR MED CHEM, V17, P2222, DOI 10.2174/092986710791331103
   Prabhu VV, 2016, CANCER RES, V76, P1989, DOI 10.1158/0008-5472.CAN-14-2430
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016
   Rosenfeld MR, 2010, J CLIN ONCOL, V28
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wang ZY, 2016, P NATL ACAD SCI USA, V113, P13150, DOI 10.1073/pnas.1616336113
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Zhao C, 2016, ONCOGENE, V35, P5916, DOI 10.1038/onc.2016.114
   Zheng K, 2016, AUTOPHAGY, V12, P1593, DOI 10.1080/15548627.2016.1192751
   Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11
   Zhou J, 2012, AUTOPHAGY, V8, P338, DOI 10.4161/auto.18721
NR 49
TC 10
Z9 10
U1 6
U2 39
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUL 1
PY 2020
VL 481
BP 15
EP 23
DI 10.1016/j.canlet.2020.03.010
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LG7QS
UT WOS:000528291300002
PM 32184145
DA 2022-04-25
ER

PT J
AU Nahdi, A
   Hammami, I
   Kouidhi, W
   Chargui, A
   Ben Ammar, A
   Hamdaoui, MH
   El May, A
   El May, M
AF Nahdi, Afef
   Hammami, Imen
   Kouidhi, Wided
   Chargui, Abderrahman
   Ben Ammar, Awatef
   Hamdaoui, Mohamed Hedi
   El May, Ahmed
   El May, Michele
TI Protective effects of crude garlic by reducing iron-mediated oxidative
   stress, proliferation and autophagy in rats
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE Garlic; Iron supplementation; Oxidative stress; Proliferation;
   Autophagy; Electron microscopy
ID INDUCED CELL-DEATH; COLORECTAL-CANCER; NEOPLASTIC-CELLS; OVERLOAD;
   DAMAGE; TOXICITY; CARCINOGENESIS; APOPTOSIS; FERRITIN; OXIDANT
AB The impact of garlic, known for its antioxidant activities, on iron metabolism has been poorly investigated. The aim of this work was to study the effect of crude garlic pre-treatment on iron-mediated lipid peroxidation, proliferation and autophagy for 5 weeks. Rats were fed distilled water or garlic solution (1 g/kg body weight) by gavage for the first 3 weeks as pre-treatment and received a basal diet supplemented or not with ferrous sulfate (650 mg Fe/kg diet) for the last 2 weeks of treatment. Immunohistochemistry labeling and ultrastuctural observations were used to evaluate the iron deleterious effects in the liver. Iron supplementation induced cell proliferation predominantly in non parenchymal cells comparing to hepatocytes, but not apoptosis. In addition, iron was accumulated within the hepatic lysosomes where it triggers autophagy as evidenced by the formation of autophagic vesicles detected by LC3-II staining. It also induced morphologic alterations of the mitochondrial membranes due to increased lipid peroxidation as shown by elevated iron and malondialdehyde concentrations in serum and tissues. Garlic pre-treatment reduced iron-catalyzed lipid peroxidation by decreasing the malondialdehyde level in the liver and colon and by enhancing the status of antioxidants. In addition, garlic reduced the iron-mediated cell proliferation and autophagy by lowering iron storage in the liver and protected mitochondrial membrane. Based on these results, garlic treatment significantly prevented iron-induced oxidative stress, proliferation and autophagy at both biochemical and histological levels due to its potent free radical scavenging and antioxidant properties.
C1 [Nahdi, Afef; Hammami, Imen; Kouidhi, Wided; Chargui, Abderrahman; El May, Michele] Fac Med, Lab Histol Embryol & Cell Biol, Res Unit UR 08 07 01, Tunis 1007, Tunisia.
   [Ben Ammar, Awatef] Fac Med, Electron Microscopy Lab, Tunis 1007, Tunisia.
   [Hamdaoui, Mohamed Hedi] High Sch Hlth Sci & Techn, Res Unit Nutr Anaemia & Trace Element Bioavailabi, Tunis 1006, Tunisia.
   [El May, Ahmed] Salah Azaiez Inst, Lab Immunohistocytol, Tunis 1006, Tunisia.
RP El May, M (corresponding author), Fac Med, Lab Histol Embryol & Cell Biol, Res Unit UR 08 07 01, 15 Rue Djebel Lakhdar, Tunis 1007, Tunisia.
EM elmay_michele@yahoo.fr
RI Kouidhi, Wided/J-1840-2014
FU Tunisian Ministry of Higher Education and Scientific Research
FX We are grateful to the Tunisian Ministry of Higher Education and
   Scientific Research for its financial support.
CR ADRIAN J, 1981, TECHNIQUE ANAL CONTR, P393
   Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5
   Agarwal MK, 2007, FOOD CHEM TOXICOL, V45, P1634, DOI 10.1016/j.fct.2007.02.029
   Anoush M, 2009, Pak J Biol Sci, V12, P765, DOI 10.3923/pjbs.2009.765.771
   Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   Arivazhagan S, 2000, PHYTOTHER RES, V14, P291, DOI 10.1002/1099-1573(200006)14:4&lt;291::AID-PTR570&gt;3.0.CO;2-Y
   Balasenthil S, 1999, CANCER DETECT PREV, V23, P534, DOI 10.1046/j.1525-1500.1999.99050.x
   Balasenthil S, 2000, NUTR RES, V20, P1581, DOI 10.1016/S0271-5317(00)00242-6
   Banerjee SK, 2002, LIFE SCI, V70, P1509, DOI 10.1016/S0024-3205(01)01514-4
   Blachier F, 2007, CAN J PHYSIOL PHARM, V85, P185, DOI 10.1139/Y07-007
   Borch-Iohnsen B, 2009, J COMP PATHOL, V141, P27, DOI 10.1016/j.jcpa.2009.02.001
   Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214
   Brown KE, 2006, TRANSL RES, V148, P55, DOI 10.1016/j.trsl.2006.03.002
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cabantchik ZI, 2005, BEST PRACT RES CL HA, V18, P277, DOI 10.1016/j.beha.2004.10.003
   Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4
   El Hajji H, 2006, FREE RADICAL RES, V40, P303, DOI 10.1080/10715760500484351
   Farinati F, 2001, J VIRAL HEPATITIS, V8, P34, DOI 10.1046/j.1365-2893.2001.00267.x
   Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060
   GABORIAU F, 2005, GASTROEN CLIN BIOL, V29, P900
   Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148
   Gao XS, 2009, J BIOL CHEM, V284, P4767, DOI 10.1074/jbc.M806235200
   Garner B, 1998, FREE RADICAL RES, V29, P103, DOI 10.1080/10715769800300121
   Garner B, 1997, FREE RADICAL RES, V27, P487, DOI 10.3109/10715769709065788
   Glei M, 2002, MUTAT RES-GEN TOX EN, V519, P151, DOI 10.1016/S1383-5718(02)00135-3
   Gutierrez L, 2006, J INORG BIOCHEM, V100, P1790, DOI 10.1016/j.jinorgbio.2006.06.010
   Gutierrez L, 2009, BBA-MOL BASIS DIS, V1792, P541, DOI 10.1016/j.bbadis.2009.03.007
   Hamdaoui MH, 2005, ANN NUTR METAB, V49, P118, DOI 10.1159/000084745
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   Heath ALM, 2003, NUTR REV, V61, P45, DOI 10.1301/nr.2003.febr.45-62
   IANCU TC, 1992, ELECTRON MICROSC REV, V5, P209, DOI 10.1016/0892-0354(92)90011-E
   Inoue H, 2003, DIGEST DIS SCI, V48, P570, DOI 10.1023/A:1022553119715
   Iqbal M, 1998, FOOD CHEM TOXICOL, V36, P485, DOI 10.1016/S0278-6915(98)00008-8
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013
   Lafay S, 2005, INT J VITAM NUTR RES, V75, P119, DOI 10.1024/0300-9831.75.2.119
   Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9
   Levine S. A., 1996, ANTIOXIDANT ADAPTATI
   Liu Y, 2002, WORLD J GASTROENTERO, V8, P363
   Lukianova OA, 2005, CURR OPIN CHEM BIOL, V9, P145, DOI 10.1016/j.cbpa.2005.02.006
   Lund EK, 1999, AM J CLIN NUTR, V69, P250
   Lyoumi S, 2007, BLOOD, V109, P811, DOI 10.1182/blood-2006-04-014142
   MENA P, 1991, INT J SPORTS MED, V12, P563, DOI 10.1055/s-2007-1024734
   MOREL I, 1990, BIOCHEM PHARMACOL, V39, P1647, DOI 10.1016/0006-2952(90)90107-V
   Moridani MY, 2003, FREE RADICAL BIO MED, V34, P243, DOI 10.1016/S0891-5849(02)01241-8
   Nahdi A, 2010, NUTR RES, V30, P85, DOI 10.1016/j.nutres.2010.01.004
   Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016/j.taap.2004.06.021
   Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P619, DOI 10.1016/j.fct.2007.09.088
   Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0
   Rauen U, 2004, J HEPATOL, V40, P607, DOI 10.1016/j.jhep.2003.12.021
   Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7
   Saravanan G, 2004, J ETHNOPHARMACOL, V94, P155, DOI 10.1016/j.jep.2004.04.029
   Sener G, 2003, LIFE SCI, V73, P81, DOI 10.1016/S0024-3205(03)00236-4
   Senesse P, 2004, NUTR CANCER, V49, P66, DOI 10.1207/s15327914nc4901_9
   Temme EHM, 2002, EUR J CLIN NUTR, V56, P379, DOI 10.1038/sj.ejcn.1601309
   Walter PB, 2002, P NATL ACAD SCI USA, V99, P2264, DOI 10.1073/pnas.261708798
   Wurzelmann JI, 1996, CANCER EPIDEM BIOMAR, V5, P503
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6
   Zhou YJ, 2005, LIFE SCI, V76, P2763, DOI 10.1016/j.lfs.2004.07.035
NR 60
TC 16
Z9 21
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD OCT
PY 2010
VL 41
IS 4-5
BP 233
EP 245
DI 10.1007/s10735-010-9283-5
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 735XC
UT WOS:000288452900007
PM 20700633
DA 2022-04-25
ER

PT J
AU Wang, XJ
   Yu, J
   Wong, SH
   Cheng, ASL
   Chan, FKL
   Ng, SSM
   Cho, CH
   Sung, JJY
   Wu, WKK
AF Wang, Xiao J.
   Yu, Jun
   Wong, Sunny H.
   Cheng, Alfred S. L.
   Chan, Francis K. L.
   Ng, Simon S. M.
   Cho, Chi H.
   Sung, Joseph J. Y.
   Wu, William K. K.
TI A novel crosstalk between two major protein degradation systems
   Regulation of proteasomal activity by autophagy
SO AUTOPHAGY
LA English
DT Article
DE autophagy; proteasome; chloroquine; protein degradation; SQSTM1
ID CANCER CELLS; INHIBITION; MACROAUTOPHAGY; STRESS; NEURODEGENERATION;
   PATHWAY; DISEASE; HDAC6
AB Eukaryotes have two major intracellular protein degradation pathways, namely the ubiquitin-proteasome system (UPS) and autophagy. Inhibition of proteasomal activities has been previously shown to induce autophagy, indicating a coordinated and complementary relationship between these two systems. However, little is known about the regulation of the UPS by autophagy. In this study, we showed for the first time that proteasomes were activated in response to pharmacological inhibition of autophagy as well as disruption of autophagy-related genes by RNA interference under nutrient-deficient conditions in cultured human colon cancer cells. The induction was evidenced by the increased proteasomal activities and the upregulation of proteasomal subunits, including the proteasome 5 subunit, PSMB5. Co-inhibition of the proteasome and autophagy also synergistically increased the accumulation of polyubiquitinated proteins. Collectively, our findings suggest that proteasomes are activated in a compensatory manner for protein degradation upon autophagy inhibition. Our studies unveiled a novel regulatory mechanism between the two protein degradation pathways.
C1 [Wang, Xiao J.; Yu, Jun; Wong, Sunny H.; Cheng, Alfred S. L.; Chan, Francis K. L.; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Xiao J.; Yu, Jun; Wong, Sunny H.; Cheng, Alfred S. L.; Chan, Francis K. L.; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Xiao J.; Yu, Jun; Wong, Sunny H.; Cheng, Alfred S. L.; Chan, Francis K. L.; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Xiao J.; Yu, Jun; Wong, Sunny H.; Cheng, Alfred S. L.; Chan, Francis K. L.; Sung, Joseph J. Y.; Wu, William K. K.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Simon S. M.] Chinese Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Cho, Chi H.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
RP Wu, WKK (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
EM junyu@cuhk.edu.hk; jjysung@cuhk.edu.hk; wukakei@cuhk.edu.hk
RI Wong, Sunny H/N-3754-2015; Cho, Chi Hin/C-6543-2014; Wu, William
   K.K./A-3277-2009; Ng, Simon S. M./M-1219-2018; Yu, Jun/D-8569-2015;
   Cheng, Alfred SL/C-3327-2014; Chan, Francis K. L./F-4851-2010; Sung,
   Joseph J. Y./R-3203-2018
OI Wong, Sunny H/0000-0002-3354-9310; Cho, Chi Hin/0000-0002-7658-3260; Wu,
   William K.K./0000-0002-5662-5240; Ng, Simon S. M./0000-0002-5389-9297;
   Yu, Jun/0000-0001-5008-2153; Cheng, Alfred SL/0000-0003-2345-6951; Chan,
   Francis K. L./0000-0001-7388-2436; Sung, Joseph J.
   Y./0000-0003-3125-5199; WANG, Echo/0000-0001-6229-5690
FU Research Fund for the Control of Infectious Diseases/Health and Medical
   Research Fund [11100082, 12110332]; CUHK Direct Grant for Research
   [2041734]
FX Work in the authors' laboratory is supported by Research Fund for the
   Control of Infectious Diseases/Health and Medical Research Fund
   (11100082 and 12110332) and CUHK Direct Grant for Research (2041734).
CR Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011
   CUERVO AM, 1995, EUR J BIOCHEM, V227, P792, DOI 10.1111/j.1432-1033.1995.tb20203.x
   Engelender S, 2012, AUTOPHAGY, V8, P418, DOI 10.4161/auto.19085
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Kardosh A, 2008, CANCER RES, V68, P843, DOI 10.1158/0008-5472.CAN-07-5555
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moorthy AK, 2006, EMBO J, V25, P1945, DOI 10.1038/sj.emboj.7601081
   Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200
   Pandey UB, 2007, AUTOPHAGY, V3, P643, DOI 10.4161/auto.5050
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Qiao LY, 2009, NEUROSCI LETT, V456, P15, DOI 10.1016/j.neulet.2009.03.085
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Wenger T, 2012, AUTOPHAGY, V8, P350, DOI [10.4161/auto.8.3.18806, 10.4161/auto.18806]
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Wu WKK, 2010, AUTOPHAGY, V6, P228, DOI 10.4161/auto.6.2.11042
   Wu WK, 2010, CANC LETT, V293, P15, DOI 10.1016/j.canlet.2009.12.00220133049
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
NR 30
TC 115
Z9 119
U1 3
U2 22
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 1
PY 2013
VL 9
IS 10
BP 1500
EP 1508
DI 10.4161/auto.25573
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 260EY
UT WOS:000327579000006
PM 23934082
OA Bronze
DA 2022-04-25
ER

PT J
AU Coriat, R
   Marut, W
   Leconte, M
   Ba, LB
   Vienne, A
   Chereau, C
   Alexandre, J
   Weill, B
   Doering, M
   Jacob, C
   Nicco, C
   Batteux, F
AF Coriat, R.
   Marut, W.
   Leconte, M.
   Ba, L. B.
   Vienne, A.
   Chereau, C.
   Alexandre, J.
   Weill, B.
   Doering, M.
   Jacob, C.
   Nicco, C.
   Batteux, F.
TI The organotelluride catalyst LAB027 prevents colon cancer growth in the
   mice
SO CELL DEATH & DISEASE
LA English
DT Article
DE tellurium; colon cancer; mice; reactive oxygen species; oxaliplatin
ID SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; CELL-DEATH;
   BUTHIONINE SULFOXIMINE; IMMUNOMODULATOR AS101; PHASE-I; GLUTATHIONE;
   ROS; APOPTOSIS
AB Organotellurides are newly described redox-catalyst molecules with original pro-oxidative properties. We have investigated the in vitro and in vivo antitumoral effects of the organotelluride catalyst LAB027 in a mouse model of colon cancer and determined its profile of toxicity in vivo. LAB027 induced an overproduction of H2O2 by both human HT29 and murine CT26 colon cancer cell lines in vitro. This oxidative stress was associated with a decrease in proliferation and survival rates of the two cell lines. LAB027 triggered a caspase-independent, ROS-mediated cell death by necrosis associated with mitochondrial damages and autophagy. LAB027 also synergized with the cytotoxic drug oxaliplatin to augment its cytostatic and cytotoxic effects on colon cancer cell lines but not on normal fibroblasts. The opposite effects of LAB027 on tumor and on non-transformed cells were linked to differences in the modulation of reduced glutathione metabolism between the two types of cells. In mice grafted with CT26 tumor cells, LAB027 alone decreased tumor growth compared with untreated mice, and synergized with oxaliplatin to further decrease tumor development compared with mice treated with oxaliplatin alone. LAB027 an organotelluride catalyst compound synergized with oxaliplatin to prevent both in vitro and in vivo colon cancer cell proliferation while decreasing the in vivo toxicity of oxaliplatin. No in vivo adverse effect of LAB027 was observed in this model. Cell Death and Disease (2011) 2, e191; doi: 10.1038/cddis.2011.73; published online 11 August 2011
C1 [Coriat, R.; Marut, W.; Leconte, M.; Vienne, A.; Chereau, C.; Alexandre, J.; Weill, B.; Nicco, C.; Batteux, F.] Univ Paris 05, Fac Med, Hop Cochin, AP HP,Lab Immunol,EA 1833, F-75679 Paris 14, France.
   [Ba, L. B.; Doering, M.; Jacob, C.] Univ Saarland, Div Bioorgan Chem, Sch Pharm, D-66123 Saarbrucken, Germany.
RP Batteux, F (corresponding author), Univ Paris 05, Immunol Lab, UPRES EA 1833, 24 Rue Faubourg St Jacques, F-75679 Paris 14, France.
EM frederic.batteux@cch.aphp.fr
RI ALEXANDRE, JEROME/O-8350-2017; Coriat, Romain/O-7902-2017; Nicco,
   Carole/O-8169-2017; Nicco, Carole/X-6726-2019; Batteux,
   Frederic/O-7889-2017
OI Nicco, Carole/0000-0001-8211-2556; Nicco, Carole/0000-0001-8211-2556;
   Batteux, Frederic/0000-0002-1265-7996
FU European CommunityEuropean Commission [FP7/2007-2013, 215009]
FX This research has been funded by a grant from the European Community's
   Seventh Framework Program (FP7/2007-2013) under grant agreement no
   (215009). The authors thank Ms Agnes Colle for editing the manuscript
   and Ms Marie Mianowski for reviewing the manuscript.
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Alexandre J, 2006, J NATL CANCER I, V98, P236, DOI 10.1093/jnci/djj049
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217
   BAILEY HH, 1994, J CLIN ONCOL, V12, P194, DOI 10.1200/JCO.1994.12.1.194
   Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789
   BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q
   Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094
   Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S
   CARLBERG I, 1985, METHOD ENZYMOL, V113, P484
   Cullen JJ, 2003, CANCER RES, V63, P1297
   Diaz-Rubio E, 1998, ANN ONCOL, V9, P105, DOI 10.1023/A:1008200825886
   Frei GM, 2008, BRIT J DERMATOL, V158, P578, DOI 10.1111/j.1365-2133.2007.08414.x
   GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070
   Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063
   Halliwell B., 2007, FREE RADICALS BIOL M
   HAMAGUCHI K, 1993, CANCER RES, V53, P5225
   Hayun M, 2006, BIOCHEM PHARMACOL, V72, P1423, DOI 10.1016/j.bcp.2006.06.015
   Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5
   Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5
   Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4
   Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102
   Joza N, 2002, TRENDS GENET, V18, P142, DOI 10.1016/S0168-9525(01)02618-X
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Laurent A, 2005, CANCER RES, V65, P948
   Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z
   Mecklenburg S, 2009, ORG BIOMOL CHEM, V7, P4753, DOI 10.1039/b907831b
   MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659
   Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525
   Okun E, 2007, FEBS J, V274, P3159, DOI 10.1111/j.1742-4658.2007.05842.x
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   RICE GC, 1986, CANCER RES, V46, P6105
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shabaan S, 2009, CHEM COMMUN, P4702, DOI 10.1039/b823149d
   SKAPEK SX, 1988, CANCER RES, V48, P2764
   SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0
   Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276
   Sredni B, 1996, INT J CANCER, V65, P97, DOI 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Trejo-Gonz?lez N.L., 2015, REV PERUANA MEDICINA, V32, P457, DOI [10.17843/rpmesp.2015.323.1674, DOI 10.17843/RPMESP.2015.323.1674, DOI 10.1016/0003-2697(71)90370-8]
   Zhang Y, 2002, CANCER RES, V62, P1205
NR 45
TC 16
Z9 16
U1 0
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2011
VL 2
AR e191
DI 10.1038/cddis.2011.73
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 811VQ
UT WOS:000294244700005
PM 21833029
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chira, S
   Raduly, L
   Braicu, C
   Jurj, A
   Cojocneanu-Petric, R
   Pop, L
   Pileczki, V
   Ionescu, C
   Berindan-Neagoe, I
AF Chira, Sergiu
   Raduly, Lajos
   Braicu, Cornelia
   Jurj, Ancuta
   Cojocneanu-Petric, Roxana
   Pop, Laura
   Pileczki, Valentina
   Ionescu, Calin
   Berindan-Neagoe, Ioana
TI Premature senescence activation in DLD-1 colorectal cancer cells through
   adjuvant therapy to induce a miRNA profile modulating cellular death
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE colorectal cancer; adjuvant therapy; cell death; senescence; exosomal
   miRNAs pattern
ID DEUTERIUM-DEPLETED WATER; CARCINOMA-CELLS; MICRORNA REGULATORS;
   PROSTATE-CANCER; DOWN-REGULATION; HEAVY-WATER; IN-VITRO; APOPTOSIS;
   EXPRESSION; PROLIFERATION
AB Cancer, and particularly colon cancer, is associated with an increasing number of cases resistant to chemotherapy. One approach to overcome this, and to improve the prognosis and outcome of patients, is the use of adjuvant therapy alongside the standard chemotherapy regiment. In the present study, the effect of deuterium-depleted water (DDW) as a potential modulator of adjuvant therapy on DLD-1 colorectal cancer models was assessed. A number of functionality assays were performed, including MTT, apoptosis and autophagy, and mitochondria' activity and senescence assays, in addition to assessing the capacity to modify the pattern of released miRNA via microarray technology. No significant effect on cell viability was identified, but an increase in mitochondria' activity and a weak pro-apoptotic effect were observed in the treated DLD-1 cells cultured in DDW-prepared medium compared with those grown in standard conditions (SC). Furthermore, the findings revealed the capacity of DDW medium to promote senescence to a higher degree compared with SC. The exosome-released miRNA pattern was significantly modified for the cells maintained in DDW compared with those maintained in SC. These findings suggest that DDW may serve as an adjuvant treatment; however, a better understanding of the underlying molecular mechanism of action will be useful for developing novel and efficient therapeutic strategies, in which the transcriptomic pattern serves an important role.
C1 [Chira, Sergiu; Raduly, Lajos; Braicu, Cornelia; Jurj, Ancuta; Cojocneanu-Petric, Roxana; Pop, Laura; Pileczki, Valentina; Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca 400337, Romania.
   [Raduly, Lajos] Univ Agr Sci & Vet Med, Fac Vet Med, Dept Pathophysiol, Cluj Napoca 400372, Romania.
   [Ionescu, Calin] Iuliu Hatieganu Univ Med & Pharm, Dept Surg, 23 Marinescu St, Cluj Napoca 40015, Romania.
   [Ionescu, Calin] Iuliu Hatieganu Univ Med & Pharm, Municipal Clin Hosp, Dept Surg, Cluj Napoca 400337, Romania.
   [Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, MEDFUTURE Res Ctr Adv Med, Cluj Napoca 400337, Romania.
   [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca 400015, Romania.
RP Ionescu, C (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Dept Surg, 23 Marinescu St, Cluj Napoca 40015, Romania.
EM calin.ionescu@umfcluj.ro
RI Chira, Sergiu/AAD-4885-2020; Pileczki, Valentina/ABB-6273-2020; Pop,
   Laura/AAY-8349-2020; Berindan-Neagoe, Ioana/AAH-9854-2019
OI Chira, Sergiu/0000-0001-6075-7468; Pop, Laura/0000-0002-5806-0220;
   Cojocneanu, Roxana-Maria/0000-0002-7450-9454; Raduly,
   Lajos/0000-0002-3926-5423
FU research grant 'New strategies for improving life quality and survival
   in cancer patients: Molecular and clinical studies of the tumor genome
   in deuterium-depleted water treatment augmentation-GenCanD';
   Iuliu-Hatieganu University of Medicine and Pharmacy (Cluj-Napoca,
   Romania) [128/2014, PN-II-PT-PCCA-2013-4-2166]
FX The present study is part of the research grant 'New strategies for
   improving life quality and survival in cancer patients: Molecular and
   clinical studies of the tumor genome in deuterium-depleted water
   treatment augmentation-GenCanD'. The research grant was supplied by
   Iuliu-Hatieganu University of Medicine and Pharmacy (Cluj-Napoca,
   Romania; grant no. 128/2014; PN-II-PT-PCCA-2013-4-2166).
CR Basov A. A., 2014, Voprosy Pitaniya, V83, P43
   Benson AB, 2014, J NATL COMPR CANC NE, V12, P1028, DOI 10.6004/jnccn.2014.0099
   Berindan-Neagoe I, 2013, J GASTROINTEST LIVER, V22, P37
   Bian XJ, 2014, TUMOR BIOL, V35, P11571, DOI 10.1007/s13277-014-2462-3
   Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130
   Braicu C, 2013, CHIRURGIA-BUCHAREST, V108, P849
   Braicu C, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2984-8
   Braicu C, 2015, INT J NANOMED, V10, P791, DOI 10.2147/IJN.S72904
   Braicu C, 2014, CURR PHARM DESIGN, V20, P6565, DOI 10.2174/1381612820666140826153529
   Braicu C, 2013, CURR MED CHEM, V20, P3561
   Braicu C, 2013, MOL CELL BIOCHEM, V381, P61, DOI 10.1007/s11010-013-1688-5
   Bu HJ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2398696
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Carrato Alfredo, 2008, Gastrointest Cancer Res, V2, pS42
   Cerella C, 2016, CURR DRUG TARGETS, V17, P405, DOI 10.2174/1389450116666150202155915
   Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529
   Cong FS, 2010, EXP THER MED, V1, P277, DOI 10.3892/etm_00000043
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Geretto M, 2017, AM J CANCER RES, V7, P1350
   Gibalova L, 2012, TOXICOL IN VITRO, V26, P435, DOI 10.1016/j.tiv.2012.01.014
   Gibbings D, 2013, AUTOPHAGY, V9, P781, DOI 10.4161/auto.23694
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Goncharuk VV, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-103
   Gorospe M, 2011, TRENDS GENET, V27, P233, DOI 10.1016/j.tig.2011.03.005
   Grootaert MOJ, 2015, AUTOPHAGY, V11, P2014, DOI 10.1080/15548627.2015.1096485
   Gyongyi Z, 2013, NUTR CANCER, V65, P240, DOI 10.1080/01635581.2013.756533
   Hartmann J, 2005, ANTICANCER RES, V25, P3407
   Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520
   Irimie AI, 2017, INT J NANOMED, V12, P4593, DOI 10.2147/IJN.S133219
   Irimie AI, 2016, MOL CELL BIOCHEM, V419, P75, DOI 10.1007/s11010-016-2751-9
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kushner DJ, 1999, CAN J PHYSIOL PHARM, V77, P79, DOI 10.1139/cjpp-77-2-79
   Ling H, 2016, GUT, V65, P977, DOI 10.1136/gutjnl-2015-309372
   Mahon KL, 2011, ENDOCR-RELAT CANCER, V18, pR103, DOI 10.1530/ERC-10-0343
   Piechota M, 2016, ONCOTARGET, V7, P81099, DOI 10.18632/oncotarget.12752
   Pileczki V, 2013, INT J MOL SCI, V14, P411, DOI 10.3390/ijms14010411
   Pistol GC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127503
   Prodromaki E, 2015, CELL ONCOL, V38, P307, DOI 10.1007/s13402-015-0231-y
   Qu B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16552-6
   Ramalingam Satish, 2015, Curr Pharmacol Rep, V1, P141
   Rehakova R, 2016, PHYSIOL RES, V65, pS401, DOI 10.33549/physiolres.933440
   Roninson IB, 2003, CANCER RES, V63, P2705
   Taranu I, 2015, TOXICOL LETT, V232, P310, DOI 10.1016/j.toxlet.2014.10.022
   Wang HQ, 2013, BIOMED PHARMACOTHER, V67, P489, DOI 10.1016/j.biopha.2013.02.001
   Yoshikawa R, 2001, CANCER RES, V61, P1029
   Zhao YS, 2015, HAEMATOLOGICA, V100, P194, DOI 10.3324/haematol.2014.109769
NR 46
TC 6
Z9 8
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2018
VL 16
IS 2
BP 1241
EP 1249
DI 10.3892/etm.2018.6324
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GR1GO
UT WOS:000442280500107
PM 30116375
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Chen, LL
   Han, HT
   Amin, A
   Zhang, L
   Ma, SL
AF Chen, Lili
   Han, Haote
   Amin, Awais
   Zhang, Lin
   Ma, Shenglin
TI Hydrolysis product of Nigella A obtained from Nigella glandulifera Freyn
   seeds promotes apoptosis and AMPK-mediated autophagy in human colon
   cancer SW620 cells
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article
DE nigella A; nigella B; apoptosis; autophagy; AMPK; mTOR
ID TRITERPENOID SAPONINS; PROSTATE-CANCER; DEATH; ROOTS; LC3
AB Nigella B (NB) is the hydrolysis product of Nigella A (NA), which is extracted from the seeds of Nigella glandulifera Freyn. NB has several beneficial characteristics, including antiproliferative activity against several cancer cell lines. In this study, we analyzed the in vitro and in vivo anticancer activity of both NA and NB as well as the potential molecular mechanisms behind the actions of NB. We found that NB treatment led to autophagy and soft apoptosis in colon cancer cells (SW620). NA treatment had no effect on either. Further study showed that NB treatment in SW620 cells led to inhibited phosphorylated mammalian target of rapamycin (p-mTOR) expression but increased phosphorylated-5' adenosine monophosphate protein kinase (AMPK) expression, a key regulator of autophagy. This suggests that the AMPK-mTOR pathway plays a crucial role in autophagy induction. Separate in vivo studies using NA (40 mg/kg, intragastric administration (i.g.)) and NB (40 mg/kg, i.g.) resulted in inhibited tumor growth in nude mice by 42.82% and 37.20% respectively, when compared with vehicle-administered animals. In vitro tumor protein expression was consistent with its expression in vitro. Taken together, our results reveal an anticancer function for NA and NB in colon cancer and support the use of NA as an antitumor prodrug, and NB as a novel therapeutic drug.
C1 [Chen, Lili; Ma, Shenglin] Wenzhou Med Univ, Wenzhou 325035, Peoples R China.
   [Chen, Lili] Wenzhou Med Univ, Huangyan Hosp, Wenzhou 318020, Peoples R China.
   [Han, Haote; Amin, Awais; Zhang, Lin] Zhejiang Univ, Dept Biomed Engn, Key Lab Biomed Engn, Minist Educ, Hangzhou 310028, Peoples R China.
   [Han, Haote; Amin, Awais; Zhang, Lin] Zhejiang Univ, Zhejiang Malaysia Joint Res Ctr Tradit Med, Hangzhou 310028, Peoples R China.
   [Ma, Shenglin] Hangzhou First Peoples Hosp, Dept Oncol, Hangzhou 310006, Zhejiang, Peoples R China.
RP Ma, SL (corresponding author), Wenzhou Med Univ, Wenzhou 325035, Peoples R China.; Zhang, L (corresponding author), Zhejiang Univ, Dept Biomed Engn, Key Lab Biomed Engn, Minist Educ, Hangzhou 310028, Peoples R China.; Zhang, L (corresponding author), Zhejiang Univ, Zhejiang Malaysia Joint Res Ctr Tradit Med, Hangzhou 310028, Peoples R China.; Ma, SL (corresponding author), Hangzhou First Peoples Hosp, Dept Oncol, Hangzhou 310006, Zhejiang, Peoples R China.
EM zhanglin@zju.edu.cn; mashenglin@medmail.com.cn
FU Zhejiang-Malaysia Joint Research Center for Traditional Medicine
   [2016C04005]; Jiangsu Provincial Natural Science Foundation of
   ChinaNatural Science Foundation of Jiangsu Province [BK20161269]
FX This work was supported by Zhejiang-Malaysia Joint Research Center for
   Traditional Medicine (2016C04005) and the Jiangsu Provincial Natural
   Science Foundation of China (BK20161269).
CR Ali BH, 2003, PHYTOTHER RES, V17, P299, DOI 10.1002/ptr.1309
   Beretta GD, 2001, EUR J SURG ONCOL, V27, P595, DOI 10.1053/ejso.2001.1128
   Bursch W, 2000, J CELL SCI, V113, P1189
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   de Almagro MC, 2015, SEMIN CELL DEV BIOL, V39, P56, DOI 10.1016/j.semcdb.2015.02.002
   DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837
   Fico G, 2004, PHYTOTHER RES, V18, P468, DOI 10.1002/ptr.1454
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Han HT, 2017, ARCH BIOL SCI, V69, P481, DOI 10.2298/ABS160902123H
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li W, 2014, BIOMOL THER, V22, P334, DOI 10.4062/biomolther.2014.047
   Lin LT, 2010, VIROLOGY, V402, P1, DOI 10.1016/j.virol.2010.03.026
   Liu JY, 2012, MOLECULES, V17, P5520, DOI 10.3390/molecules17055520
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com
   Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040
   Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008
   Suarez Y, 2003, MOL CANCER THER, V2, P863
   Sun YP, 2014, ONCOL REP, V32, P1243, DOI 10.3892/or.2014.3282
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Zhao M, 2016, PHYTOCHEMISTRY, V130, P228, DOI 10.1016/j.phytochem.2016.05.009
NR 30
TC 3
Z9 3
U1 0
U2 5
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2018
VL 70
IS 4
BP 603
EP 612
DI 10.2298/ABS171108021C
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA HD0GX
UT WOS:000452187000001
OA gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Kitajima, S
   Thummalapalli, R
   Barbie, DA
AF Kitajima, Shunsuke
   Thummalapalli, Rohit
   Barbie, David A.
TI Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE KRAS; Inflammation; NF-kappa B; STAT3; Cytokines; Autophagy
ID MOUSE COLON TUMORS; PROMOTES T-CELL; COLORECTAL-CANCER; LUNG-CANCER;
   PANCREATIC-CANCER; BOWEL-DISEASE; ACTIVATION; MUTATIONS; AUTOPHAGY;
   STAT3
AB While important strides have been made in cancer therapy by targeting certain oncogenes, KRAS, the most common among them, remains refractory to this approach. In recent years, a deeper understanding of the critical importance of inflammation in promoting KRAS-driven oncogenesis has emerged, and applies across the different contexts of lung, pancreatic, and colorectal tumorigenesis. Here we review why these tissue types are particularly prone to developing KRAS mutations, and how inflammation conspires with KRAS signaling to fuel carcinogenesis. We discuss multiple lines of evidence that have established NF-kappa B, STAT3, and certain cytokines as key transducers of these signals, and data to suggest that targeting these pathways has significant clinical potential. Furthermore, recent work has begun to uncover how inflammatory signaling interacts with other KRAS regulated survival pathways such as autophagy and MAPK signaling, and that co-targeting these multiple nodes may be required to achieve real benefit. In addition, the impact of KRAS associated inflammatory signaling on the greater tumor microenvironment has also become apparent, and taking advantage of this inflammation by incorporating approaches that harness T cell anti-tumor responses represents another promising therapeutic strategy. Finally, we highlight the likelihood that the genomic complexity of KRAS mutant tumors will ultimately require tailored application of these therapeutic approaches, and that targeting inflammation early in the course of tumor development could have the greatest impact on eradicating this deadly disease. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kitajima, Shunsuke; Thummalapalli, Rohit; Barbie, David A.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
   [Thummalapalli, Rohit] Harvard Med Sch, Div Hlth Sci & Technol, 25 Shattuck St, Boston, MA 02115 USA.
RP Barbie, DA (corresponding author), 450 Brookline Ave,D819, Boston, MA 02215 USA.
EM shunsuke_kitajima@dfci.harvard.edu; rohit_thummalapalli@hms.harvard.edu;
   dbarbie@partners.org
FU strategic young researcher overseas visits program for accelerating
   brain circulation [NCI-R01 CA190394-01, NCI-K08 CA138918-01A1]; Gloria
   T. Maheu Fund for Lung Cancer Research; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [K08CA138918,
   R01CA190394] Funding Source: NIH RePORTER
FX This work was supported by the strategic young researcher overseas
   visits program for accelerating brain circulation (S.K.), NCI-R01
   CA190394-01 (D.B.), NCI-K08 CA138918-01A1 (D.B.), and the Gloria T.
   Maheu Fund for Lung Cancer Research (D.B.).
CR Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Basseres Daniela S, 2014, Genes Cancer, V5, P41
   Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290
   Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010
   Becker AE, 2014, WORLD J GASTROENTERO, V20, P11182, DOI 10.3748/wjg.v20.i32.11182
   Brown JB, 2010, GASTROENTEROLOGY, V138, P595, DOI 10.1053/j.gastro.2009.10.038
   Calles A, 2015, J THORAC ONCOL, V10, P1726, DOI 10.1097/JTO.0000000000000687
   Collins MA, 2014, GASTROENTEROLOGY, V146, P822, DOI 10.1053/j.gastro.2013.11.052
   Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908
   Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743
   de Lange KM, 2015, J AUTOIMMUN, V64, P91, DOI 10.1016/j.jaut.2015.07.013
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Fritz JM, 2010, J THORAC ONCOL, V5, P254, DOI 10.1097/JTO.0b013e3181c8ce04
   Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008
   Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002
   Golay HG, 2014, EXPERT REV ANTICANC, V14, P869, DOI 10.1586/14737140.2014.928596
   Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Guibert N, 2015, CURR MOL MED, V15, P418, DOI 10.2174/1566524015666150505161412
   Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250
   Hurwitz H. I., 2015, J CLIN ONCOL
   Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030
   Joshi NS, 2015, IMMUNITY, V43, P579, DOI 10.1016/j.immuni.2015.08.006
   Keenan BP, 2014, GASTROENTEROLOGY, V146, P1784, DOI 10.1053/j.gastro.2014.02.055
   Kim JY, 2013, P NATL ACAD SCI USA, V110, P12414, DOI 10.1073/pnas.1220674110
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439
   LaRusch J, 2011, CURR OPIN GASTROEN, V27, P467, DOI 10.1097/MOG.0b013e328349e2f8
   Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019
   Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Liu S., 2016, INT J CANC
   Maier HJ, 2013, ONCOGENE, V32, P2690, DOI 10.1038/onc.2012.272
   Maltzman T, 1997, CARCINOGENESIS, V18, P2435, DOI 10.1093/carcin/18.12.2435
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Mathew R, 2014, MOL CELL, V55, P916, DOI 10.1016/j.molcel.2014.07.019
   McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490
   Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462
   Nistal E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00220
   Ostrow SL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21927
   Pardanani A, 2013, LEUKEMIA, V27, P1322, DOI 10.1038/leu.2013.71
   Qu ZX, 2015, CANCER RES, V75, P3209, DOI 10.1158/0008-5472.CAN-14-3042
   Ranger GS, 2014, ANTICANCER RES, V34, P6277
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036
   Rosenthal A, 2014, EXPERT OPIN PHARMACO, V15, P1265, DOI 10.1517/14656566.2014.913024
   Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375
   Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008
   Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236
   Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117
   Tan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080885
   Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777
   Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188
   Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2016, CANCER IMMUNOL RES, V4, P520, DOI 10.1158/2326-6066.CIR-15-0235
   Zhang YQ, 2013, CANCER RES, V73, P6359, DOI 10.1158/0008-5472.CAN-13-1558-T
   Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318
   Zhu ZH, 2014, PHARMACOGENOMICS, V15, P1507, DOI [10.2217/PGS.14.108, 10.2217/pgs.14.108]
   Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646
NR 76
TC 48
Z9 48
U1 2
U2 20
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD OCT
PY 2016
VL 58
BP 127
EP 135
DI 10.1016/j.semcdb.2016.06.009
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA DV9TD
UT WOS:000383284000015
PM 27297136
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, M
   Zhu, JY
   Chen, S
   Qing, Y
   Wu, D
   Lin, YM
   Luo, JZ
   Han, W
   Li, YQ
AF Wang, Min
   Zhu, Jing-Yu
   Chen, Shuo
   Qing, Ying
   Wu, Dong
   Lin, Ying-Min
   Luo, Ji-Zhuang
   Han, Wei
   Li, Yan-Qing
TI Effects of co-treatment with sulforaphane and autophagy modulators on
   uridine 5 '-diphospho-glucuronosyltransferase 1A isoforms and cytochrome
   P450 3A4 expression in Caco-2 human colon cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE uridine 5 '-diphospho-glucuronosyltransferase 1A; Caco-2 cells;
   sulforaphane; chemoprevention; cytochrome P450 3A4; autophagy
ID PREGNANE X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; PHENETHYL
   ISOTHIOCYANATE; INDUCED APOPTOSIS; GENE-EXPRESSION; INHIBITION;
   INDUCTION; METABOLISM; PREVENTION; GLUCURONOSYLTRANSFERASES
AB Sulforaphane (SFN), which is highly enriched in cruciferous vegetables, has been investigated for its cancer chemopreventive properties and ability to induce autophagy. Uridine 5'-diphospho (UDP)-glucuronosyltransferase (UGT)1A induction is one of the mechanisms that is responsible for the cancer chemopreventive activity of SFN. The current study. demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction. These results indicate that targeting autophagy modulation may be a promising strategy for increasing the chemopreventive effects of SFN in cases of colon cancer.
C1 [Wang, Min; Qing, Ying; Lin, Ying-Min] Shandong Univ, Qi Lu Hosp, Dept Geriatr & Gastroenterol, Key Lab Prote Shandong, Jinan 250012, Shandong, Peoples R China.
   [Zhu, Jing-Yu] Shandong Univ, Jinan Cent Hosp, Dept Gastroenterol, Jinan 250013, Shandong, Peoples R China.
   [Chen, Shuo] China Japan Friendship Hosp, Dept Gastroenterol, Beijing, Peoples R China.
   [Chen, Shuo] Peking Union Med Coll, Grad Sch, Beijing 100029, Peoples R China.
   [Chen, Shuo] Chinese Acad Med Sci, Beijing 100029, Peoples R China.
   [Wu, Dong] Shandong Univ, Qi Lu Hosp, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China.
   [Luo, Ji-Zhuang] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
   [Han, Wei; Li, Yan-Qing] Shandong Univ, Qi Lu Hosp, Dept Gastroenterol, Jinan 250012, Shandong, Peoples R China.
RP Wang, M (corresponding author), Shandong Univ, Qi Lu Hosp, Dept Geriatr & Gastroenterol, Key Lab Prote Shandong, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
EM doctorminmin@163.com
OI Qing, Ying/0000-0001-6763-6204
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81372681]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81372681).
CR Bozina N, 2009, ARH HIG RADA TOKSIKO, V60, P217, DOI 10.2478/10004-1254-60-2009-1885
   Buckley DB, 2009, DRUG METAB DISPOS, V37, P847, DOI 10.1124/dmd.108.024190
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Collett NP, 2010, SEMIN ONCOL, V37, P258, DOI 10.1053/j.seminoncol.2010.06.014
   Gardner-Stephen D, 2004, DRUG METAB DISPOS, V32, P340, DOI 10.1124/dmd.32.3.340
   Gross-Steinmeyer K, 2010, TOXICOL SCI, V116, P422, DOI 10.1093/toxsci/kfq135
   Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Jakubikova J, 2005, BIOCHEM PHARMACOL, V69, P1543, DOI 10.1016/j.bcp.2005.03.015
   Kamdem LK, 2006, CHEM RES TOXICOL, V19, P577, DOI 10.1021/tx050358e
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038
   Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Maheo K, 1997, CANCER RES, V57, P3649
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Naumann P, 2011, INT J ONCOL, V39, P101, DOI 10.3892/ijo.2011.1025
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Saracino MR, 2007, NUTR CANCER, V59, P121, DOI 10.1080/01635580701458178
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Strassburg C, 2008, CRIT REV CL LAB SCI, V45, P485, DOI [10.1080/10408360802374624, 10.1080/10408360802374624 ]
   Sugatani J, 2004, BIOCHEM PHARMACOL, V67, P989, DOI 10.1016/j.bcp.2003.11.002
   Svehlikova V, 2004, CARCINOGENESIS, V25, P1629, DOI 10.1093/carcin/bgh169
   Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164
   Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733
   Wang Min, 2005, Zhonghua Yi Xue Za Zhi, V85, P819
   Wang M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057045
   Wang M, 2012, CHINESE J PHYSIOL, V55, P134, DOI 10.4077/CJP.2012.BAA085
   Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100
   Zhou CC, 2007, MOL PHARMACOL, V71, P220, DOI 10.1124/mol.106.029264
NR 33
TC 12
Z9 13
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2014
VL 8
IS 6
BP 2407
EP 2416
DI 10.3892/ol.2014.2536
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU9YT
UT WOS:000345948600009
PM 25364403
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Ding, WX
   Ni, HM
   Gao, WT
   Hou, YF
   Melan, MA
   Chen, XY
   Stolz, DB
   Shao, ZM
   Yin, XM
AF Ding, Wen-Xing
   Ni, Hong-Min
   Gao, Wentao
   Hou, Yi-Feng
   Melan, Melissa A.
   Chen, Xiaoyun
   Stolz, Donna B.
   Shao, Zhi-Ming
   Yin, Xiao-Ming
TI Differential effects of endoplasmic reticulum stress-induced autophagy
   on cell survival
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MISFOLDED PROTEINS; DEATH; APOPTOSIS; INHIBITION; DISSECTION; DISEASE;
   ABSENCE; ROLES; BAX
AB Autophagy is a cellular response to adverse environment and stress, but its significance in cell survival is not always clear. Here we show that autophagy could be induced in the mammalian cells by chemicals, such as A23187, tunicamycin, thapsigargin, and brefeldin A, that cause endoplasmic reticulum stress. Endoplasmic reticulum stress-induced autophagy is important for clearing polyubiquitinated protein aggregates and for reducing cellular vacuolization in HCT116 colon cancer cells and DU145 prostate cancer cells, thus mitigating endoplasmic reticulum stress and protecting against cell death. In contrast, autophagy induced by the same chemicals does not confer protection in a normal human colon cell line and in the non-transformed murine embryonic fibroblasts but rather contributes to cell death. Thus the impact of autophagy on cell survival during endoplasmic reticulum stress is likely contingent on the status of cells, which could be explored for tumor-specific therapy.
C1 Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA.
   Fudan Univ, Dept Surg, Canc Hosp, Shanghai 200032, Peoples R China.
RP Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.
EM xmyin@pitt.edu
RI Chen, Xiaoyun/K-4786-2019
OI Melan, Melissa/0000-0001-6088-7801
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA111456, CA83817] Funding Source: Medline; NINDS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [NS45252] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA111456,
   R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS045252]
   Funding Source: NIH RePORTER
CR Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200
   Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73
   Kamimoto T, 2006, J BIOL CHEM, V281, P4467, DOI 10.1074/jbc.M509409200
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139
   KOUROKU Y, 2006, CELL DEATH DIFF 0623
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004
   Perlmutter DH, 1999, LAB INVEST, V79, P623
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961
   Yoneda T, 2002, GENE DEV, V16, P1307, DOI 10.1101/gad.1000902
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
NR 40
TC 382
Z9 406
U1 3
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 16
PY 2007
VL 282
IS 7
BP 4702
EP 4710
DI 10.1074/jbc.M609267200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 140CX
UT WOS:000244482000051
PM 17135238
OA hybrid
DA 2022-04-25
ER

PT J
AU Hiratsuka, T
   Inomata, M
   Kon, Y
   Yokoyama, S
   Shiraishi, N
   Kitano, S
AF Hiratsuka, Takahiro
   Inomata, Masafumi
   Kon, Yohei
   Yokoyama, Shigeo
   Shiraishi, Norio
   Kitano, Seigo
TI DHL-TauZnNa, a newly synthesized alpha-lipoic acid derivative, induces
   autophagy in human colorectal cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE DHL-TauZnNa; antioxidant; alpha-lipoic acid derivative; G2/M arrest;
   autophagy
ID OXYGEN SPECIES GENERATION; JNK ACTIVATION; IN-VIVO; PANCREATIC-CANCER;
   APOPTOSIS; DEATH; INHIBITION; PATHWAYS; PROTEINS; THERAPY
AB In recent years, several antioxidant substances have been found to have an antiproliferative effect on various types of carcinomas. alpha-lipoic acid (ALA) induces apoptosis in several types of cancer cell lines, but it is difficult to apply alpha-lipoic acid in clinical use as it is easily oxidized and unstable. Recently, we succeeded in synthesizing the alpha-lipoic acid derivative sodium N-[6,8-dimercaptooctanoyl]-2-aminoethanesulfonate zinc complex (DHL-TauZnNa), which has highly stable antioxidant effects. We investigated whether DHL-TauZnNa elicits its antiproliferative effects in vivo and in vitro by inducing apoptosis, autophagy or cell cycle arrest, and we analyzed the expression of proteins related to these phenomena and their phosphorylation in HT-29 human colon cancer cells. Subcutaneously administered DHL-TauZnNa treatment applied daily for 41 days significantly inhibited tumor growth by 43% in a xenograft mouse model (P=0.0271). DHL-TauZnNa significantly reduced cell viability over that of controls in the trypan-blue exclusion test in a time- and dose-dependent manner (P<0.05). DHL-TauZnNa increased the proportion of cells in S phase and decreased that of cells in G0/G1 phase in the cell cycle analysis of HT-29 cells. Although DHL-TauZnNa did not increase caspase-3/7 activity and DNA fragmentation in flow cytometry analysis, it increased the expression of microtubule-associated protein light chain 3-II. Autophagosomes and autolysosomes were observed by electron microscopy in the cytoplasm of HT-29 cells treated with DHL-TauZnNa. These results suggest that DHL-TauZnNa inhibited the proliferation of HT-29 cells through the mechanisms of G2/M cell cycle arrest and autophagy but not that of apoptosis. The newly synthesized ALA derivative DHL-TauZnNa may be expected to become a novel cancer therapeutic strategy through its induction of autophagy.
C1 [Hiratsuka, Takahiro; Inomata, Masafumi; Kon, Yohei; Shiraishi, Norio] Oita Univ, Fac Med, Dept Gastroenterol Surg, Yufu City, Oita 8795593, Japan.
   [Yokoyama, Shigeo] Oita Univ, Fac Med, Dept Diagnost Pathol, Yufu City, Oita 8795593, Japan.
   [Kitano, Seigo] Oita Univ, Oita 8701124, Japan.
RP Hiratsuka, T (corresponding author), Oita Univ, Fac Med, Dept Gastroenterol Surg, 1-1 Idaigaoka,Hasama Machi, Yufu City, Oita 8795593, Japan.
EM htakahiru@oita-u.ac.jp
OI Hiratsuka, Takahiro/0000-0002-6483-6013
FU Japan Society for the Promotion of Science (JSPS)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [23591967]
FX We would like to express our gratitude to Dr Kazumi Ogata, who
   synthesized and provided the drugs used in this study, and to Ms. Yuiko
   Asou, Ms. Aiko Yasuda and Ms. Kaori Sakai for their technical
   assistance. This study was supported in part by Grants-in-Aid for
   Scientific Research (C) from the Japan Society for the Promotion of
   Science (JSPS) (no. 23591967).
CR ALTMAN SA, 1993, BIOTECHNOL PROGR, V9, P671, DOI 10.1021/bp00024a017
   Bock BC, 2010, J BIOL CHEM, V285, P21644, DOI 10.1074/jbc.M109.096628
   Bretthauer M, 2011, J INTERN MED, V270, P87, DOI 10.1111/j.1365-2796.2011.02399.x
   Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796
   Chen SY, 2011, AUTOPHAGY, V7, P217, DOI 10.4161/auto.7.2.14212
   Du JA, 2010, CLIN CANCER RES, V16, P509, DOI 10.1158/1078-0432.CCR-09-1713
   Duan WJ, 2011, BIOL PHARM BULL, V34, P47, DOI 10.1248/bpb.34.47
   Gamrekelashvili J, 2007, J IMMUNOL, V178, P1573, DOI 10.4049/jimmunol.178.3.1573
   Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004
   Hind D, 2008, Health Technol Assess, V12, piii
   Inokuma T, 2009, HEPATO-GASTROENTEROL, V56, P343
   Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Li M, 2009, CANCER INVEST, V27, P251, DOI 10.1080/07357900802254016
   Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004
   Makhov P, 2011, PROSTATE, V71, P1413, DOI 10.1002/pros.21357
   Novotny L, 2008, NEOPLASMA, V55, P81
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Shi DY, 2008, FEBS LETT, V582, P1667, DOI 10.1016/j.febslet.2008.04.021
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Viola G, 2012, BIOCHEM PHARMACOL, V83, P16, DOI 10.1016/j.bcp.2011.09.017
   Wenzel U, 2005, APOPTOSIS, V10, P359, DOI 10.1007/s10495-005-0810-x
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Zhang Y, 2012, CLIN EXP MED, V12, P97, DOI 10.1007/s10238-011-0146-5
NR 30
TC 10
Z9 11
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2013
VL 29
IS 6
BP 2140
EP 2146
DI 10.3892/or.2013.2394
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 148GO
UT WOS:000319232800008
PM 23588820
OA Bronze
DA 2022-04-25
ER

PT J
AU Li, CW
   Zhu, GD
   Cui, ZH
   Zhang, JH
   Zhang, ST
   Wei, YL
AF Li, Congwen
   Zhu, Guodong
   Cui, Zihong
   Zhang, Jihong
   Zhang, Shengting
   Wei, Yunlin
TI The strong inhibitory effect of combining anti-cancer drugs AT406 and
   rocaglamide with blue LED irradiation on colorectal cancer cells
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Colorectal cancer; Blue LED irradiation; Multi-targeted anticancer
   drugs; Inhibitory effect
ID ORALLY-ACTIVE ANTAGONIST; LIGHT-EMITTING DIODE; APOPTOSIS PROTEINS;
   MULTIPLE INHIBITOR; COLON-CANCER; RESISTANCE; CASPASE-8; POTENT; IAPS
AB There is still no satisfying method to treat colorectal cancer (CRC) currently. Inspired by cocktail therapy, the combination of 465 nm blue LED irradiation and two multi-target anticancer agents AT406 and Rocaglamide has been investigated as an innovative way to treat colorectal cancer cells in vitro. It showed a strong inhibitory effect on colorectal cancer cells, and its side effects on human normal cells are negligible. When applied to HCT116 cells, it can achieve an apoptotic rate up to 95%. It is also seen to significantly inhibit proliferation of HT29 cells. Furthermore, little to no cell inhibition or damage of normal MRC-5 cells were seen after treatment. The combination of blue LED irradiation and two anti-cancer drugs causes apoptosis of colorectal cancer cells by activating the apoptotic pathway, inhibiting autophagy and proliferation pathways as well as the production of reactive oxygen species (ROS).
C1 [Li, Congwen; Zhu, Guodong; Cui, Zihong; Zhang, Shengting; Wei, Yunlin] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Yunnan, Peoples R China.
   [Zhang, Jihong] Kunming Univ Sci & Technol, Med Sch, Kunming 650500, Yunnan, Peoples R China.
RP Zhang, ST; Wei, YL (corresponding author), Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Yunnan, Peoples R China.
EM 747585404@qq.com; weiyunlin18@163.com
CR Becker MS, 2016, ONCOTARGET, V7, P51908, DOI 10.18632/oncotarget.10188
   Brunckhorst MK, 2012, CANCER BIOL THER, V13, P804, DOI 10.4161/cbt.20563
   Cai Q, 2011, J MED CHEM, V54, P2714, DOI 10.1021/jm101505d
   CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624
   Chen Z, 2018, CELL PHYSIOL BIOCHEM, V49, P2035, DOI 10.1159/000493714
   Choi SR, 2000, INT J ONCOL, V17, P141
   Chubb D, 2015, J CLIN ONCOL, V33, P426, DOI 10.1200/JCO.2014.56.5689
   Agnol MAD, 2009, LASER MED SCI, V24, P909, DOI 10.1007/s10103-009-0648-5
   Dietrich JB, 1997, ARCH PHYSIOL BIOCHEM, V105, P125, DOI 10.1076/apab.105.2.125.12927
   ENNEVER JF, 1983, J PEDIATR-US, V103, P295, DOI 10.1016/S0022-3476(83)80370-9
   Greco C, 2007, CANCER-AM CANCER SOC, V109, P1227, DOI 10.1002/cncr.22542
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   Haga Raquel B, 2016, Small GTPases, V7, P207
   Hnasko TS, 2015, METHODS MOL BIOL, V1318, P87, DOI 10.1007/978-1-4939-2742-5_9
   Jiang YS, 2016, BIOCHEM BIOPH RES CO, V478, P293, DOI 10.1016/j.bbrc.2016.07.011
   Kamata E, 2017, ANTICANCER RES, V37, P6097, DOI 10.21873/anticanres.12058
   Kumagai T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101405
   Li Robert, 2016, React Oxyg Species (Apex), V1, P9, DOI 10.20455/ros.2016.803
   Ling Y., 2020, CURR MED CHEM
   Luan Z, 2015, MOL MED REP, V11, P203, DOI 10.3892/mmr.2014.2718
   Mahalingam D, 2019, CANCERS, V11
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nalli AD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35908-0
   Oberoi-Khanuja TK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.311
   Oh PS, 2016, INT J BIOCHEM CELL B, V70, P13, DOI 10.1016/j.biocel.2015.11.004
   Oh PS, 2015, J PHOTOCH PHOTOBIO B, V142, P197, DOI 10.1016/j.jphotobiol.2014.12.006
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Reinhold T, 2007, PLANT J, V50, P293, DOI 10.1111/j.1365-313X.2007.03049.x
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Tamas K, 2015, CANCER TREAT REV, V41, P671, DOI 10.1016/j.ctrv.2015.06.007
   Toubai T, 2017, BLOOD ADV, V1, P1517, DOI 10.1182/bloodadvances.2017004242
   Tummers B, 2017, IMMUNOL REV, V277, P76, DOI 10.1111/imr.12541
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Walker NA, 2007, J ATHL TRAINING, V42, P530
   Wang BC, 2016, AM J TRANSL RES, V8, P1047
   Waris Gulam, 2006, J Carcinog, V5, P14
   Wu Y, 2017, CANCER LETT, V389, P70, DOI 10.1016/j.canlet.2016.12.010
   Yao C, 2018, AUTOPHAGY, V14, P1831, DOI 10.1080/15548627.2018.1489946
   Zhao XG, 2016, BIOCHEM BIOPH RES CO, V479, P166, DOI 10.1016/j.bbrc.2016.08.121
   Zhuang JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051464
NR 40
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2020
VL 30
AR 101797
DI 10.1016/j.pdpdt.2020.101797
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LZ0BX
UT WOS:000540895900108
PM 32360851
DA 2022-04-25
ER

PT J
AU Kretowski, R
   Stypulkowska, A
   Cechowska-Pasko, M
AF Kretowski, Rafal
   Stypulkowska, Anna
   Cechowska-Pasko, Marzanna
TI Efficient apoptosis and necrosis induction by proteasome inhibitor:
   bortezomib in the DLD-1 human colon cancer cell line
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Apoptosis; Bortezomib; DLD-1; Necrosis; ORP150; NF-kappa B
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS;
   MULTIPLE-MYELOMA CELLS; ER STRESS; 26S PROTEASOME; MESSENGER-RNA;
   RESISTANCE; AUTOPHAGY; THERAPY; GROWTH
AB The inhibition of the 26S proteasome evokes endoplasmic reticulum stress, which has been shown to be implicated in the antitumoral effects of proteasome inhibitors. The cellular and molecular effects of the proteasome inhibitor-bortezomib-on human colon cancer cells are as yet poorly characterized. Bortezomib selectively induces apoptosis in some cancer cells. However, the nature of its selectivity remains unknown. Previously, we demonstrated that, in contrast to normal fibroblasts, bortezomib treatment evoked strong effect on apoptosis of breast cancer cells incubated in hypoxic and normoxic conditions. The study presented here provides novel information on the cellular effects of bortezomib in DLD-1 colon cancer cells line. We observe twofold higher percentage of apoptotic cells incubated for 48 h with 25 and 50 nmol/l of bortezomib in hypoxic conditions and four-, fivefold increase in normoxic conditions in comparison to control cells, incubated without bortezomib. It is of interest that bortezomib evokes strong effect on necrosis of DLD-1 colon cancer cell line. We observe the sixfold increase in necrosis of DLD-1 cells incubated with 25 or 50 nmol/l of bortezomib for 48 h in hypoxia and fourfold increase in normoxic conditions in comparison to adequate controls. We suggest that bortezomib may be candidates for further evaluation as chemotherapeutic agents for human colon cancer.
C1 [Kretowski, Rafal; Stypulkowska, Anna; Cechowska-Pasko, Marzanna] Med Univ Bialystok, Dept Pharmaceut Biochem, PL-15222 Bialystok, Poland.
RP Cechowska-Pasko, M (corresponding author), Med Univ Bialystok, Dept Pharmaceut Biochem, Mickiewicza 2A, PL-15222 Bialystok, Poland.
EM r.kretowski@umb.edu.pl; mapasko@tlen.pl
RI Cechowska-Pasko, M/X-9940-2019; Cechowska-Pasko, Marzanna/W-4203-2018;
   Kretowski, Rafal/T-4037-2018; Krętowski, Rafał/AAF-6745-2019
OI Cechowska-Pasko, Marzanna/0000-0002-2806-399X; Krętowski,
   Rafał/0000-0002-6548-5083; Stypulkowska, Anna/0000-0003-0224-3383
CR Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004
   Brown JM, 2007, METHOD ENZYMOL, V435, P297, DOI 10.1016/S0076-6879(07)35015-5
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Crawford LJ, 2012, MULT MYELOMA, DOI [10.5772/31679, DOI 10.5772/31679]
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Fennell DA, 2008, ONCOGENE, V27, P1189, DOI 10.1038/sj.onc.1210744
   Frankland-Searby S, 2012, BBA-REV CANCER, V1825, P64, DOI 10.1016/j.bbcan.2011.10.003
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Fribley A, 2006, CANCER BIOL THER, V5, P745, DOI 10.4161/cbt.5.7.2971
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322
   Han YH, 2010, DRUG CHEM TOXICOL, V33, P403, DOI 10.3109/01480540903524350
   Han YH, 2010, CHEM-BIOL INTERACT, V184, P319, DOI 10.1016/j.cbi.2010.01.033
   Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200
   Hideshima T, 2001, CANCER RES, V61, P3071
   Janen SB, 2010, GLIA, V58, P1766, DOI 10.1002/glia.21047
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Kretowski R, 2014, MOL CELL BIOCHEM, V389, P177, DOI 10.1007/s11010-013-1939-5
   Kusaczuk M, 2013, CURR PHARM DESIGN, V19, P2807, DOI 10.2174/1381612811319150016
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Laussmann MA, 2011, CELL DEATH DIFFER, V18, P1584, DOI 10.1038/cdd.2011.27
   Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Morgillo F, 2011, LUNG CANCER, V71, P283, DOI 10.1016/j.lungcan.2010.06.005
   Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Ruschak AM, 2011, J NATL CANCER I, V103, P1007, DOI 10.1093/jnci/djr160
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Soti C, 2003, AGING CELL, V2, P39, DOI 10.1046/j.1474-9728.2003.00031.x
   Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1
   Tseng LM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3175
   Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 42
TC 12
Z9 14
U1 1
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2015
VL 398
IS 1-2
BP 165
EP 173
DI 10.1007/s11010-014-2216-y
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AT7BF
UT WOS:000345090500017
PM 25292312
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Song, CF
   Xu, W
   Wu, HK
   Wang, XT
   Gong, QY
   Liu, C
   Liu, JW
   Zhou, L
AF Song, Changfeng
   Xu, Wen
   Wu, Hongkun
   Wang, Xiaotong
   Gong, Qianyi
   Liu, Chang
   Liu, Jianwen
   Zhou, Lin
TI Photodynamic therapy induces autophagy-mediated cell death in human
   colorectal cancer cells via activation of the ROS/JNK signaling pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID IN-VIVO; APOPTOSIS; PHOTOSENSITIZERS; INHIBITION; MECHANISMS; CARCINOMA;
   EFFICACY; SAFETY; HEAD; NECK
AB Evidence has shown that m-THPC and verteporfin (VP) are promising sensitizers in photodynamic therapy (PDT). In addition, autophagy can act as a tumor suppressor or a tumor promoter depending on the photosensitizer (PS) and the cancer cell type. However, the role of autophagy in m-THPC- and VP-mediated PDT in in vitro and in vivo models of human colorectal cancer (CRC) has not been reported. In this study, m-THPC-PDT or VP-PDT exhibited significant phototoxicity, inhibited proliferation, and induced the generation of large amounts of reactive oxygen species (ROS) in CRC cells. From immunoblotting, fluorescence image analysis, and transmission electron microscopy, we found extensive autophagic activation induced by ROS in cells. In addition, m-THPC-PDT or VP-PDT treatment significantly induced apoptosis in CRC cells. Interestingly, the inhibition of m-THPC-PDT-induced autophagy by knockdown of ATG5 or ATG7 substantially inhibited the apoptosis of CRC cells. Moreover, m-THPC-PDT treatment inhibited tumorigenesis of subcutaneous HCT116 xenografts. Meanwhile, antioxidant treatment markedly inhibited autophagy and apoptosis induced by PDT in CRC cells by inactivating JNK signaling. In conclusion, inhibition of autophagy can remarkably alleviate PDT-mediated anticancer efficiency in CRC cells via inactivation of the ROS/JNK signaling pathway. Our study provides evidence for the therapeutic application of m-THPC and VP in CRC.
C1 [Song, Changfeng; Xu, Wen; Wang, Xiaotong; Gong, Qianyi; Liu, Jianwen] East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Song, Changfeng; Xu, Wen; Wang, Xiaotong; Gong, Qianyi; Liu, Jianwen] East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China.
   [Wu, Hongkun; Liu, Chang; Zhou, Lin] Naval Med Univ, Changzheng Hosp, Dept Lab Med, Shanghai 200003, Peoples R China.
RP Liu, JW (corresponding author), East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.; Liu, JW (corresponding author), East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China.; Zhou, L (corresponding author), Naval Med Univ, Changzheng Hosp, Dept Lab Med, Shanghai 200003, Peoples R China.
EM liujian@ecust.edu.cn; lynnzhou36@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82072371, 81873050, 81803082, 81772283];
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M632046]; Shanghai Science and Technology
   CommitteeShanghai Science & Technology Committee [15PJD004]; Shanghai
   Municipal Commission of Health and Family Planning [2018BR35]
FX This work was supported by the National Natural Science Foundation of
   China (Grant nos. 82072371, 81873050, 81803082, and 81772283), the China
   Postdoctoral Science Foundation (Grant no. 2018M632046), the Shanghai
   Science and Technology Committee (Grant no. 15PJD004), and Shanghai
   Municipal Commission of Health and Family Planning (Grant no. 2018BR35).
CR Abdulrehman G, 2018, LASER MED SCI, V33, P1581, DOI 10.1007/s10103-018-2524-7
   Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Aniogo EC, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0815-0
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P1, DOI 10.1016/S1572-1000(05)00030-X
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   de Visscher SAHJ, 2013, ORAL ONCOL, V49, P192, DOI 10.1016/j.oraloncology.2012.09.011
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Domagala A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4126-y
   Durbec M, 2013, EUR ARCH OTO-RHINO-L, V270, P1433, DOI 10.1007/s00405-012-2083-7
   Calixto GMF, 2016, MOLECULES, V21, DOI 10.3390/molecules21030342
   Gheewala T, 2017, ONCOTARGET, V8, P30524, DOI 10.18632/oncotarget.15496
   Han XB, 2018, CELL PHYSIOL BIOCHEM, V48, P1616, DOI 10.1159/000492283
   Han XBB, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.242
   Huang LY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6374-x
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495-016-1243-4
   Jin J, 2018, CELL PHYSIOL BIOCHEM, V48, P765, DOI 10.1159/000491905
   Jones HJ, 2003, BRIT J CANCER, V89, P398, DOI 10.1038/sj.bjc.6601101
   Kessel D, 2007, PHOTOCHEM PHOTOBIOL, V83, P1024, DOI 10.1111/j.1751-1097.2007.00088.x
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kozako T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4710-1
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lange C, 2019, CANCERS, V11, DOI 10.3390/cancers11050702
   Liang CS, 2016, ONCOTARGET, V7, P31401, DOI 10.18632/oncotarget.8919
   Liu XH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1173-4
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Lu JJ, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.11.118001
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Moosavi MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143559
   Naidoo C, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818791795
   Nelke KH, 2014, POSTEP HIG MED DOSW, V68, P119, DOI 10.5604/17322693.1088044
   Ning ST, 2016, ACS APPL MATER INTER, V8, P17793, DOI 10.1021/acsami.6b04403
   Ouyang GQ, 2018, PHOTODIAGN PHOTODYN, V21, P396, DOI 10.1016/j.pdpdt.2018.01.010
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Shafirstein G, 2016, ANN AM THORAC SOC, V13, P265, DOI 10.1513/AnnalsATS.201509-650FR
   Shi GG, 2018, EXP THER MED, V16, P2751, DOI 10.3892/etm.2018.6447
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Su LY, 2017, AUTOPHAGY, V13, P1496, DOI 10.1080/15548627.2017.1332549
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sun HT, 2018, MED SCI MONITOR, V24, P6178, DOI 10.12659/MSM.910201
   van Straten D, 2017, CANCERS, V9, DOI 10.3390/cancers9020019
   Wang C, 2011, BIOMATERIALS, V32, P6145, DOI 10.1016/j.biomaterials.2011.05.007
   Wang JZ, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20176079, 10.1590/1414-431x20176079]
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Yang L, 2017, ACTA BIOMATER, V54, P271, DOI 10.1016/j.actbio.2017.03.012
   Zhang J, 2018, ACTA PHARM SIN B, V8, P137, DOI 10.1016/j.apsb.2017.09.003
   Zhu B, 2019, INT J BIOL SCI, V15, P12, DOI 10.7150/ijbs.27156
NR 51
TC 12
Z9 12
U1 12
U2 25
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 31
PY 2020
VL 11
IS 10
AR 938
DI 10.1038/s41419-020-03136-y
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OP4MT
UT WOS:000588056500001
PM 33130826
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Pattingre, S
   Petiot, A
   Codogno, P
AF Pattingre, S
   Petiot, A
   Codogno, P
TI Analyses of G alpha-interacting protein and activator of
   G-protein-signaling-3 functions in macroautophagy
SO REGULATORS OF G-PROTEIN SIGNALING, PT B
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID ISOLATED RAT HEPATOCYTES; LYSOSOMOTROPIC AGENT MONODANSYLCADAVERINE;
   CONTROLS AUTOPHAGIC SEQUESTRATION; CANCER HT-29 CELLS; SIGNALING
   PATHWAYS; REGULATOR AGS3; CULTURED RAT; VACUOLE; DEGRADATION; GAIP
AB Macroautophagy or autophagy is an ubiquitous and conserved degradative pathway of cytosolic components, macromolecules or organelles, into the lysosome. By using biochemical and microscopic methods, which allow one to measure the rate of autophagy, the role of two regulators of G(i3) protein activity, activator of G-protein-signaling-3 (AGS3) and Galpha-interacting protein (GAIP), was studied in the control of autophagy in human colon cancer HT-29 cells. In HT-29 cells, autophagy is under the control of the G(i3) protein and, when bound to the GTP, the Galpha(i3) protein inhibits autophagy, whereas it stimulates autophagy when bound to the GDP. GAIP, which enhances the intrinsic GTPase-activating protein activity of the Galpha(i3) protein, stimulates autophagy by favoring the GDP-bound form of Galpha(i3). We showed that GAIP is phosphorylated on its serine 151 and that this phosphorylation is dependent on the presence of amino acids that modulate Raf-1 activity, the kinase upstream of Erk1/2. AGS3, a guanine nucleotide dissociation inhibitor, stimulates autophagy by binding Galpha(i3) proteins. The intracellular localization of AGS3 (Golgi apparatus and endoplasmic reticulum, two membranes known to be at the origin of autophagosomes) is consistent with its role in autophagy.
C1 SW Med Sch, Div Infect Dis, Dallas, TX 75390 USA.
   INSERM U504, Inst Andre Lwofff, F-94807 Villejuif, France.
RP Pattingre, S (corresponding author), SW Med Sch, Div Infect Dis, Dallas, TX 75390 USA.
RI Codogno, Patrice/G-1384-2013
OI Codogno, Patrice/0000-0002-5492-3180; Pattingre,
   Sophie/0000-0001-6284-6050; PETIOT, Anne/0000-0001-8038-470X
CR Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8
   Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Bursch W, 2000, J CELL SCI, V113, P1189
   CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x
   CODOGNO P, 2003, AUTOPHAGY, P26
   De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364
   DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527
   HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   KADOWAKI M, 1994, J BIOL CHEM, V269, P3703
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1
   KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Niemann A, 2000, J HISTOCHEM CYTOCHEM, V48, P251, DOI 10.1177/002215540004800210
   Niemann A, 2001, J HISTOCHEM CYTOCHEM, V49, P177, DOI 10.1177/002215540104900205
   NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.biochem.63.1.949
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200
   Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200
   Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200
   PUNNONEN EL, 1993, EUR J CELL BIOL, V61, P54
   PUNNONEN EL, 1994, EUR J CELL BIOL, V65, P14
   RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897
   RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   STOWARD PJ, 1991, HISTOCHEMISTRY THEOR, V3, P1
   STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115
   Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x
   Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202
   Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8
   van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545
   Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497
NR 54
TC 48
Z9 54
U1 0
U2 2
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2004
VL 390
BP 17
EP 31
PG 15
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA BBF50
UT WOS:000225235700002
PM 15488168
DA 2022-04-25
ER

PT J
AU Assumpcao, JAF
   Magalhaes, KG
   Correa, JR
AF Fagundes Assumpcao, Jose Antonio
   Magalhaes, Kelly Grace
   Correa, Jose Raimundo
TI The role of ppar gamma and autophagy in ros production, lipid droplets
   biogenesis and its involvement with colorectal cancer cells modulation
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colorectal cancer; Autophagy; PPAR; ROS; Lipid bodies; Cancer stem cells
ID ACTIVATED RECEPTOR-GAMMA; TUMOR-SUPPRESSOR; UP-REGULATION; INHIBITION;
   MTOR; INFLAMMATION; APOPTOSIS; PTEN; AGONISTS; STRESS
AB Background: In cancer cells, autophagy can act as both tumor suppressor, when autophagic event eliminates cellular contends which exceeds the cellular capacity of regenerate promoting cell death, and as a pro-survival agent removing defective organelles and proteins and helping well-established tumors to maintain an accelerated metabolic state while still dealing with harsh conditions, such as inflammation. Many pathways can coordinate the autophagic process and one of them involves the transcription factors called PPARs, which also regulate cellular differentiation, proliferation and survival. The PPAR. activation and autophagy initiation seems to be interrelated in a variety of cell types.
   Methods: Caco-2 cells were submitted to treatment with autophagy and PPAR gamma modulators and the relationship between both pathways was determined by western blotting and confocal microscopy. The effects of such modulations on Caco-2 cells, such as lipid bodies biogenesis, cell death, proliferation, cell cycle, ROS production and cancer stem cells profiling were analyzed by flow cytometry.
   Results: PPAR. and autophagy pathways seem to be overlap in Caco-2 cells, modulating each other in different ways and determining the lipid bodies biogenesis. In general, inhibition of autophagy by 3-MA leaded to reduced cell proliferation, cell cycle arrest and, ultimately, cell death by apoptosis. In agreement with these results, ROS production was increased in 3-MA treated cells. Autophagy also seems to play an important role in cancer stem cells profiling. Rapamycin and 3-MA induced epithelial and mesenchymal phenotypes, respectively.
   Conclusions: This study helps to elucidate in which way the induction or inhibition of these pathways regulate each other and affect cellular properties, such as ROS production, lipid bodies biogenesis and cell survive. We also consolidate autophagy as a key factor for colorectal cancer cells survival in vitro, pointing out a potential side effect of autophagic inhibition as a therapeutic application for this disease and demonstrate a novel regulation of PPAR. expression by inhibition of PI3K III.
C1 [Fagundes Assumpcao, Jose Antonio; Magalhaes, Kelly Grace; Correa, Jose Raimundo] Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil.
RP Assumpcao, JAF (corresponding author), Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil.
EM zeassumpcao@gmail.com
RI Magalhaes, Kelly G/A-6966-2010; Assumpção, José AF/P-6588-2018;
   Magalhaes, Kelly Grace/L-6081-2019; Correa, Jose R/K-6270-2012
OI Magalhaes, Kelly G/0000-0002-7435-5272; Assumpção, José
   AF/0000-0002-2836-1583; Magalhaes, Kelly Grace/0000-0002-7435-5272;
   Correa, Jose R/0000-0003-2752-5395
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq-Brazil)Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPQ)
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq-Brazil).
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Aires V, 2014, MOL NUTR FOOD RES, V58, P1785, DOI 10.1002/mnfr.201300962
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Blas-Garcia A, 2010, HEPATOLOGY, V52, P115, DOI 10.1002/hep.23647
   Bordonaro M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115068
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898
   Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27
   Cerquetti L, 2011, EXP CELL RES, V317, P1397, DOI 10.1016/j.yexcr.2011.02.014
   Chateau D, 2005, J CELL PHYSIOL, V202, P767, DOI 10.1002/jcp.20173
   Chen XS, 2013, MOL CANCER RES, V11, P1269, DOI 10.1158/1541-7786.MCR-13-0212
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Coppede F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318
   Fang F, 2015, ONCOL LETT, V9, P1439, DOI 10.3892/ol.2015.2849
   Ferlay J SI, 2013, IARC CANCERBASE, V11
   FUCCI A, 2012, PPAR RES, DOI DOI 10.1155/2012/242498
   Garza-Trevino EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004
   Gibson SB, 2013, METHOD ENZYMOL, V528, P217, DOI 10.1016/B978-0-12-405881-1.00013-6
   Girnun G, 2009, GASTROENTEROLOGY, V136, P1157, DOI 10.1053/j.gastro.2009.02.022
   Gracz AD, 2013, STEM CELLS, V31, P2024, DOI 10.1002/stem.1391
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Hafner C, 2005, CURR CANCER DRUG TAR, V5, P393, DOI 10.2174/1568009054863591
   Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kang JH, 2012, J BIOL CHEM, V287, P15661, DOI 10.1074/jbc.M112.358473
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lee SJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/327167
   Lei YL, 2015, MED RES REV, V35, P306, DOI 10.1002/med.21330
   Lin CF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/787924
   Liu K, 2013, CELL DEATH DIFFER, V20, P3, DOI 10.1038/cdd.2012.63
   Mahmood DFD, 2011, J BIOL CHEM, V286, P28858, DOI 10.1074/jbc.M111.273292
   Manninen P, 2013, J CROHNS COLITIS, V7, P551
   Muller G, 2008, BRIT J PHARMACOL, V154, P901, DOI 10.1038/bjp.2008.146
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Oliveira LR, 2014, HEAD NECK-J SCI SPEC, V36, P1718, DOI 10.1002/hed.23527
   Park JI, 2012, PPAR RES, V2012, DOI 10.1155/2012/876418
   Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1
   Pellerito O, 2014, APOPTOSIS, V19, P1029, DOI 10.1007/s10495-014-0985-0
   Randall-Demllo S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00301
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1
   Ryoo HD, 2012, COLD SPRING HARB PER, V4, P1
   Schaaf MBE, 2013, RADIOTHER ONCOL, V108, P529, DOI 10.1016/j.radonc.2013.06.015
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Sekiya M, 2008, BIOCHEM BIOPH RES CO, V375, P602, DOI 10.1016/j.bbrc.2008.08.068
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Sreevalsan S, 2013, CURR COLORECT CANC R, V9, P350, DOI 10.1007/s11888-013-0190-5
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Vaiopoulos AG, 2014, BBA-MOL BASIS DIS, V1842, P971, DOI 10.1016/j.bbadis.2014.02.006
   Vaiopoulos AG, 2013, J MOL MED, V91, P1029, DOI 10.1007/s00109-013-1045-x
   Wang JF, 2014, WORLD J GASTROENTERO, V20, P4106, DOI 10.3748/wjg.v20.i14.4106
   Weng JR, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/935675
   Yan S, 2014, CANCER GENE THER, V21, P188, DOI 10.1038/cgt.2014.16
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang KJ, 2014, WORLD J GASTROENTERO, V20, P4167, DOI 10.3748/wjg.v20.i15.4167
   Zhang W, 2006, CANCER BIOL THER, V5, P1008, DOI 10.4161/cbt.5.8.2887
   Zhang Y, 2012, ONCOL REP, V27, P1599, DOI 10.3892/or.2012.1681
   Zhao H, 2014, BBA-GEN SUBJECTS, V1840, P545, DOI 10.1016/j.bbagen.2013.09.005
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou J, 2009, INT J BIOCHEM CELL B, V41, P2334, DOI 10.1016/j.biocel.2009.06.007
NR 71
TC 17
Z9 18
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD SEP 15
PY 2017
VL 17
AR 82
DI 10.1186/s12935-017-0451-5
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FG9YP
UT WOS:000410796400001
PM 28932171
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Denisenko, TV
   Pivnyuk, AD
   Zhivotovsky, B
AF Denisenko, Tatiana V.
   Pivnyuk, Anastasia D.
   Zhivotovsky, Boris
TI p53-Autophagy-Metastasis Link
SO CANCERS
LA English
DT Review
DE autophagy; apoptosis; p53; cancer; metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR P53; AUTOPHAGIC
   CELL-DEATH; MUTANT P53; CANCER-CELLS; REGULATES AUTOPHAGY; MEDIATED
   REGULATION; SIGNALING PATHWAYS; COLORECTAL-CANCER; STRESS RESPONSES
AB The tumor suppressor p53 as the guardian of the genome plays an essential role in numerous signaling pathways that control the cell cycle, cell death and in maintaining the integrity of the human genome. p53, depending on the intracellular localization, contributes to the regulation of various cell death pathways, including apoptosis, autophagy and necroptosis. Accumulated evidence suggests that this function of p53 is closely involved in the process of cancer development. Here, present knowledge concerning a p53-autophagy-metastasis link, as well as therapeutic approaches that influence this link, are discussed.
C1 [Denisenko, Tatiana V.; Pivnyuk, Anastasia D.; Zhivotovsky, Boris] Moscow MV Lomonosov State Univ, Fac Med, Moscow 119991, Russia.
   [Zhivotovsky, Boris] Karolinska Inst, Div Toxicol, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.
RP Zhivotovsky, B (corresponding author), Moscow MV Lomonosov State Univ, Fac Med, Moscow 119991, Russia.; Zhivotovsky, B (corresponding author), Karolinska Inst, Div Toxicol, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.
EM de_tanya@yahoo.com; a.pivnuk@gmail.com; Boris.Zhivotovsky@ki.se
RI Denisenko, Tatyana/U-9986-2018; Zhivotovsky, Boris/A-4346-2014
OI Zhivotovsky, Boris/0000-0002-2238-3482
FU Russian Science FoundationRussian Science Foundation (RSF)
   [14-25-00056]; Stockholm Cancer Society [161292]; Swedish Cancer
   SocietySwedish Cancer Society [160733]; Swedish Childhood Cancer
   FoundationEuropean Commission [PR2016-0090]; Swedish Research
   CouncilSwedish Research CouncilEuropean Commission [521-2014-2258]
FX This work was supported by Russian Science Foundation (grant number
   14-25-00056). The work in the authors' laboratories is being supported
   from the Stockholm (grant number 161292) and Swedish (grant number
   160733) Cancer Societies, the Swedish Childhood Cancer Foundation (grant
   number PR2016-0090), the Swedish Research Council (grant number
   521-2014-2258).
CR Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alizadeh J, 2018, BBA-MOL CELL RES, V1865, P749, DOI 10.1016/j.bbamcr.2018.02.007
   Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200
   Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x
   Ashcroft M, 1999, MOL CELL BIOL, V19, P1751
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11
   Aylon Y, 2011, CURR OPIN GENET DEV, V21, P86, DOI 10.1016/j.gde.2010.10.002
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Bar J, 2010, SEMIN CELL DEV BIOL, V21, P47, DOI 10.1016/j.semcdb.2009.11.006
   Bauer MR, 2016, P NATL ACAD SCI USA, V113, pE5271, DOI 10.1073/pnas.1610421113
   Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935
   Belaid A, 2013, CANCER RES, V73, P4311, DOI 10.1158/0008-5472.CAN-12-4142
   Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619
   Bhat P, 2018, BIOCHEM PHARMACOL, V147, P170, DOI 10.1016/j.bcp.2017.11.021
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831
   Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841
   Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200
   Chan TA, 2000, GENE DEV, V14, P1584
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373
   Cheng BC, 2017, INT J ONCOL, V50, P964, DOI 10.3892/ijo.2017.3861
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choudhury S, 2013, CELL CYCLE, V12, P1022, DOI 10.4161/cc.24128
   Cordani M, 2016, MOL ONCOL, V10, P1008, DOI 10.1016/j.molonc.2016.04.001
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373
   Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120
   Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001
   Galluzzi L, 2010, CELL CYCLE, V9, P250, DOI 10.4161/cc.9.2.10493
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Geng YD, 2017, BIOCHEM PHARMACOL, V142, P71, DOI 10.1016/j.bcp.2017.06.134
   Gilardini Montani MS, 2017, CELL ONCOL, V40, P167, DOI 10.1007/s13402-017-0314-z
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x
   Gudkov Andrei V, 2011, Genes Cancer, V2, P503, DOI 10.1177/1947601911409747
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hager KM, 2014, CARCINOGENESIS, V35, P740, DOI 10.1093/carcin/bgt487
   Harris CR, 2009, ONCOGENE, V28, P3857, DOI 10.1038/onc.2009.246
   Hemmati PG, 2008, ONCOGENE, V27, P6707, DOI 10.1038/onc.2008.193
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jakhar R, 2016, CANCER LETT, V372, P89, DOI 10.1016/j.canlet.2015.12.024
   Jiang YH, 2011, CANCER RES, V71, P2959, DOI 10.1158/0008-5472.CAN-10-4077
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Ku BM, 2013, FASEB J, V27, P3487, DOI 10.1096/fj.12-224220
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200
   Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394
   Lee YJ, 2017, MOL MED REP, V16, P2133, DOI 10.3892/mmr.2017.6789
   Levrero M, 2000, J CELL SCI, V113, P1661
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li H, 2009, J BIOL CHEM, V284, P1748, DOI 10.1074/jbc.M807821200
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lin CJ, 2016, TOXICOL APPL PHARM, V304, P59, DOI 10.1016/j.taap.2016.05.018
   Lin SY, 2013, INT J ONCOL, V43, P1817, DOI 10.3892/ijo.2013.2109
   Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376
   Liu DSH, 2015, GUT, V64, P1506, DOI 10.1136/gutjnl-2015-309770
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007
   Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   Mittal D, 2010, EMBO J, V29, P2242, DOI 10.1038/emboj.2010.94
   MIYASHITA T, 1995, CELL, V80, P293
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mleczak A, 2013, CELL SIGNAL, V25, P1, DOI 10.1016/j.cellsig.2012.09.010
   Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4
   Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059
   Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026
   Nikiforov MA, 1996, ONCOGENE, V13, P1709
   Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004
   Park JS, 2013, ARTHRITIS RHEUM-US, V65, P949, DOI 10.1002/art.37841
   Pflaumf J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00285
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136
   Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778
   Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Saha MN, 2013, MOL CANCER THER, V12, P2331, DOI 10.1158/1535-7163.MCT-12-1166
   Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019
   Salim KY, 2016, ONCOTARGET, V7, P41363, DOI 10.18632/oncotarget.9133
   Sanz-Moreno V, 2009, CELL CYCLE, V8, P1484, DOI 10.4161/cc.8.10.8490
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Starobinets H, 2013, NATURE, V504, P225, DOI 10.1038/nature12841
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tang DL, 2011, ANTIOXID REDOX SIGN, V15, P2185, DOI 10.1089/ars.2010.3666
   Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Thiery JP, 2013, CANCER CELL, V23, P272, DOI 10.1016/j.ccr.2013.03.004
   THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541
   Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4
   Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335
   Wang N, 2018, J CELL PHYSIOL, V233, P2434, DOI 10.1002/jcp.26118
   Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875
   Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991
   Wei B, 2016, J PHARMACOL SCI, V131, P77, DOI 10.1016/j.jphs.2016.03.001
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wei SC, 2016, TRENDS CELL BIOL, V26, P111, DOI 10.1016/j.tcb.2015.09.009
   Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu L, 2016, INT J BIOL MACROMOL, V85, P217, DOI 10.1016/j.ijbiomac.2015.11.014
   Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200
   Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208
   Xu JA, 2017, REDOX BIOL, V12, P198, DOI 10.1016/j.redox.2017.02.017
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZZ, 2017, EBIOMEDICINE, V19, P49, DOI 10.1016/j.ebiom.2017.04.017
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Yeudall WA, 2012, CARCINOGENESIS, V33, P442, DOI 10.1093/carcin/bgr270
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang L, 2017, LEUKEMIA LYMPHOMA, V58, P1777, DOI 10.1080/10428194.2016.1266625
   Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079
   Zhang WW, 2018, HUM GENE THER, V29, P160, DOI 10.1089/hum.2017.218
   Zheng SJ, 2005, DIABETES, V54, P1423, DOI 10.2337/diabetes.54.5.1423
   Zi D, 2015, INT J MOL SCI, V16, P27228, DOI 10.3390/ijms161126018
NR 178
TC 24
Z9 26
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2018
VL 10
IS 5
AR 148
DI 10.3390/cancers10050148
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ3JY
UT WOS:000435191400021
PM 29783720
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Ganesan, T
   Sinniah, A
   Chik, Z
   Alshawsh, MA
AF Ganesan, Thanusha
   Sinniah, Ajantha
   Chik, Zamri
   Alshawsh, Mohammed Abdullah
TI Punicalagin Regulates Apoptosis-Autophagy Switch via Modulation of
   Annexin A1 in Colorectal Cancer
SO NUTRIENTS
LA English
DT Article
DE pomegranate; annexin A1; colorectal neoplasms; apoptosis; autophagy
ID PROGRAMMED CELL-DEATH; ELLAGIC ACID; DNA-DAMAGE; POLYPHENOLS;
   INHIBITION; METABOLISM
AB Punicalagin (PU), a polyphenol extracted from pomegranate (Punica granatum) husk is proven to have anti-cancer effects on different types of cancer including colorectal cancer (CRC). Its role in modulating endogenous protein as a means of eliciting its anti-cancer effects, however, has not been explored to date. Hence, this study aimed to investigate the role of PU in modulating the interplay between apoptosis and autophagy by regulating Annexin A1 (Anx-A1) expression in HCT 116 colorectal adenocarcinoma cells. In the study, selective cytotoxicity, pro-apoptotic, autophagic and Anx-A1 downregulating properties of PU were shown which indicate therapeutic potential that this polyphenol has against CRC. Autophagy flux analysis via flow cytometry showed significant autophagosomes degradation in treated cells, proving the involvement of autophagy. Proteome profiling of 35 different proteins in the presence and absence of Anx-A1 antagonists in PU-treated cells demonstrated a complex interplay that happens between apoptosis and autophagy that suggests the possible simultaneous induction and inhibition of these two cell death mechanisms by PU. Overall, this study suggests that PU induces autophagy while maintaining basal level of apoptosis as the main mechanisms of cytotoxicity via the modulation of Anx-A1 expression in HCT 116 cells, and thus has a promising translational potential.
C1 [Ganesan, Thanusha; Sinniah, Ajantha; Chik, Zamri; Alshawsh, Mohammed Abdullah] Univ Malaya, Dept Pharmacol, Fac Med, Kuala Lumpur 50603, Malaysia.
RP Sinniah, A (corresponding author), Univ Malaya, Dept Pharmacol, Fac Med, Kuala Lumpur 50603, Malaysia.
EM thanushaganesan@gmail.com; ajantha.sinniah@um.edu.my;
   zamrichik@ummc.edu.my; alshaweshmam@um.edu.my
RI Alshawsh, Mohammed Abdullah/B-2887-2010; Ganesan, Thanusha
   M/AAJ-6469-2021; Sinniah, Ajantha/L-5684-2017; Chik, Zamri/C-1208-2010
OI Alshawsh, Mohammed Abdullah/0000-0001-8342-5183; Sinniah,
   Ajantha/0000-0002-7572-9926; Chik, Zamri/0000-0003-1770-8382; Ganesan,
   Thanusha/0000-0002-6514-4123
FU Ministry of Higher EducationScience and Technology Development Fund
   (STDF)Ministry of Higher Education & Scientific Research (MHESR)
   [FRGS/1/2019/SKK10/UM/02/2]; University of MalayaUniversiti Malaya
   [BK015-2017]
FX This work is supported by FRGS/1/2019/SKK10/UM/02/2 and BK015-2017 grant
   from the Ministry of Higher Education and University of Malaya,
   respectively.
CR Abdulhadi HL., 2015, EGYPT J BASIC APPL S, V2, P247, DOI [10.1016/j.ejbas.2015.09.004, DOI 10.1016/j.ejbas.2015.09.004, DOI 10.1016/J.EJBAS.2015.09.004]
   Adaramoye O, 2017, CHEM-BIOL INTERACT, V274, P100, DOI 10.1016/j.cbi.2017.07.009
   Cerda B, 2003, EUR J NUTR, V42, P18, DOI 10.1007/s00394-003-0396-4
   Cheng X, 2016, RSC ADV, V6, P68485, DOI 10.1039/c6ra13431a
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fouad YA, 2017, AM J CANCER RES, V7, P1016
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Gonzalez-Sarrias A, 2014, EUR J NUTR, V53, P853, DOI 10.1007/s00394-013-0589-4
   Grootaert C, 2015, NUTRIENTS, V7, P9229, DOI 10.3390/nu7115462
   Kozovska Z, 2014, BIOMED PHARMACOTHER, V68, P911, DOI 10.1016/j.biopha.2014.10.019
   Kuribayashi K, 2008, ADV EXP MED BIOL, V615, P201, DOI 10.1007/978-1-4020-6554-5_10
   Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.jnutbio.2005.09.004
   LIAN WS, 2018, CELL DEATH DIS, V0009
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527
   Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033
   Nazzaro F, 2012, CURR OPIN BIOTECH, V23, P182, DOI 10.1016/j.copbio.2011.10.001
   Onozawa H, 2017, ONCOL REP, V37, P235, DOI 10.3892/or.2016.5234
   Parisi JD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010051
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Sajid M, 2019, NEW LOOK TO PHYTOMEDICINE: ADVANCEMENTS IN HERBAL PRODUCTS AS NOVEL DRUG LEADS, P597, DOI 10.1016/B978-0-12-814619-4.00024-0
   Santiago-O'Farrill JM, 2018, ONCOTARGET, V9, P1602, DOI 10.18632/oncotarget.20308
   Sato Y, 2011, EXP THER MED, V2, P239, DOI 10.3892/etm.2011.210
   Seeram NP, 2005, J NUTR BIOCHEM, V16, P360, DOI 10.1016/j.jnutbio.2005.01.006
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   UK World Cancer Research Fund, 2018, COLORECTAL CANC
   Vecchi L, 2018, BBA-MOL CELL RES, V1865, P1368, DOI 10.1016/j.bbamcr.2018.06.010
   Wang SG, 2013, ACTA PHARMACOL SIN, V34, P1411, DOI 10.1038/aps.2013.98
   Wang Y, 2016, REPRODUCTION, V151, P97, DOI 10.1530/REP-15-0287
   White JP, 2018, STEM CELL REP, V11, P425, DOI 10.1016/j.stemcr.2018.06.014
   Yaidikar L, 2015, MOL CELL BIOCHEM, V402, P141, DOI 10.1007/s11010-014-2321-y
   Yao X, 2017, NUTR RES, V47, P63, DOI 10.1016/j.nutres.2017.09.001
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zorova LD, 2018, ANAL BIOCHEM, V552, P50, DOI 10.1016/j.ab.2017.07.009
NR 38
TC 6
Z9 6
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2020
VL 12
IS 8
AR 2430
DI 10.3390/nu12082430
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA OA5RX
UT WOS:000577843200001
PM 32823596
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kim, J
   Choi, S
   Kim, JO
   Kim, KK
AF Kim, Jaewhan
   Choi, Sunkyung
   Kim, Jong Ok
   Kim, Kee K.
TI Autophagy-mediated upregulation of cytoplasmic claudin 1 stimulates the
   degradation of SQSTM1/p62 under starvation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID HUNTINGTON-DISEASE; TIGHT JUNCTIONS; CANCER; ULK1; PHOSPHORYLATION;
   PROMOTES; MODELS; FAMILY; CELLS; LC3
AB Claudin 1, a major tight junction protein, is highly expressed in various types of tumors such as thyroid, breast, and colorectal cancers. Moreover, claudin 1 is frequently found in the cytoplasm in various types of tumor cells. However, the cytoplasmic function of claudin 1 in tumors still remains largely unknown. Here, we investigated the novel function of cytoplasmic claudin 1 in autophagy. The mRNA expression level of claudin 1 was higher in several types of tumors than in normal tissues. Furthermore, colon tumor tissues showed increased autophagy compared with the adjacent normal tissues. Both endogenous and exogenous claudin 1 showed a cytoplasmic punctate staining pattern and were co-stained with the lysosome-associated membrane protein 1 (LAMP1). Importantly, autophagy-induced conditions, including starvation, increased the protein stability of claudin 1. Moreover, the increased level of claudin 1 stimulated autophagy by decreasing the level of the autophagy substrate, sequestosome1/p62 (SQSTM1), under autophagy-inducing conditions; activation of AMP-activated protein kinase (AMPK) and inhibition of mammalian target of rapamycin (mTOR). Taken together, we demonstrate that the novel function of cytoplasmic claudin 1 is related to autophagy. This study is the first to show a cytoplasmic function of claudin 1 as an autophagy regulator and provides the evidence that claudin 1 mediated autophagy regulation is an integral part of the mechanism by which claudin 1 regulates cancer progression. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Kim, Jaewhan; Choi, Sunkyung; Kim, Kee K.] Chungnam Natl Univ, Coll Nat Sci, Dept Biochem, Daejeon 34134, South Korea.
   [Kim, Jong Ok] Catholic Univ Korea, Daejeon St Marys Hosp, Dept Pathol, Daejeon 34943, South Korea.
RP Kim, KK (corresponding author), Chungnam Natl Univ, Coll Nat Sci, Dept Biochem, Daejeon 34134, South Korea.; Kim, JO (corresponding author), Catholic Univ Korea, Daejeon St Marys Hosp, Dept Pathol, Daejeon 34943, South Korea.
EM jkim@catholic.ac.kr; kimkk@cnu.ac.kr
RI Kim, Kee/F-8784-2011
OI Kim, Keekwang/0000-0002-1088-3383
FU National Research Foundation of Korea through the Ministry of Education
   [NRF-2015R1C1A1A02036324]
FX This work was supported by the National Research Foundation of Korea
   within the Basic Science Research Program through the Ministry of
   Education under Grant NRF-2015R1C1A1A02036324.
CR Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bergamini E, 2003, BIOMED PHARMACOTHER, V57, P203, DOI 10.1016/S0753-3322(03)00048-9
   Bhat AA, 2016, EXP CELL RES, V349, P119, DOI 10.1016/j.yexcr.2016.10.005
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543
   Findley MK, 2009, IUBMB LIFE, V61, P431, DOI 10.1002/iub.175
   Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122
   Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-186
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Martin DDO, 2015, TRENDS NEUROSCI, V38, P26, DOI 10.1016/j.tins.2014.09.003
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Takahashi S, 2009, J CELL SCI, V122, P985, DOI 10.1242/jcs.040055
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu YC, 2011, NEUROSIGNALS, V19, P163, DOI 10.1159/000328516
   Zhao ZH, 2017, MED SCI MONITOR, V23, P2906, DOI 10.12659/MSM.904177
   Zwanziger D, 2015, ENDOCR-RELAT CANCER, V22, P819, DOI 10.1530/ERC-14-0502
NR 29
TC 12
Z9 13
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 29
PY 2018
VL 496
IS 1
BP 159
EP 166
DI 10.1016/j.bbrc.2018.01.017
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FU7YF
UT WOS:000424068000026
PM 29307823
DA 2022-04-25
ER

PT J
AU Bae, H
   Lee, W
   Song, J
   Hong, T
   Kim, MH
   Ham, J
   Song, G
   Lim, W
AF Bae, Hyocheol
   Lee, Woonghee
   Song, Jisoo
   Hong, Taeyeon
   Kim, Myung Hyun
   Ham, Jiyeon
   Song, Gwonhwa
   Lim, Whasun
TI Polydatin Counteracts 5-Fluorouracil Resistance by Enhancing Apoptosis
   via Calcium Influx in Colon Cancer
SO ANTIOXIDANTS
LA English
DT Article
DE polydatin; colon cancer; calcium; apoptosis; 5-fluorouracil
ID ENDOPLASMIC-RETICULUM STRESS; ER STRESS; INTRACELLULAR CA2+; AUTOPHAGY;
   CELLS; INDUCE; INJURY
AB Colon cancer is a disease with a high prevalence rate worldwide, and for its treatment, a 5-fluorouracil (5-FU)-based chemotherapeutic strategy is generally used. However, conventional anticancer agents have some limitations, including the development of drug resistance. Therefore, there has recently been a demand for the improvement of antitumor agents using natural products with low side effects and high efficacy. Polydatin is a natural active compound extracted from an annual plant, and widely known for its anticancer effects in diverse types of cancer. However, it is still not clearly understood how polydatin ameliorates several drawbacks of standard anticancer drugs by reinforcing the chemosensitivity against 5-FU, and neither are the intrinsic mechanisms behind this process. In this study, we examined how polydatin produces anticancer effects in two types of colon cancer, called HCT116 and HT-29 cells. Polydatin has the ability to repress the progression of colon cancer, and causes a modification of distribution in the cell cycle by a flow cytometry analysis. It also induces mitochondrial dysfunctions through oxidative stress and the loss of mitochondrial membrane potential. The present study investigated the apoptosis caused by the disturbance of calcium regulation and the expression levels of related proteins through flow cytometry and immunoblotting analysis. It was revealed that polydatin suppresses the signaling pathways of the mitogen-activated protein kinase (MAPK) and PI3K/AKT. In addition, it was shown that polydatin combined with 5-FU counteracts drug resistance in 5-FU-resistant cells. Therefore, this study suggests that polydatin has the potential to be developed as an innovative medicinal drug for the treatment of colon cancer.
C1 [Bae, Hyocheol] Kyung Hee Univ, Coll Life Sci, Dept Oriental Biotechnol, Yongin 17104, South Korea.
   [Lee, Woonghee; Ham, Jiyeon; Song, Gwonhwa] Korea Univ, Coll Life Sci & Biotechnol, Inst Anim Mol Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.
   [Song, Jisoo; Hong, Taeyeon; Lim, Whasun] Kookmin Univ, Coll Sci & Technol, Dept Food & Nutr, Seoul 02707, South Korea.
   [Kim, Myung Hyun] Sookmyung Womens Univ, Dept Food & Nutr, Seoul 04310, South Korea.
RP Song, G (corresponding author), Korea Univ, Coll Life Sci & Biotechnol, Inst Anim Mol Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.; Lim, W (corresponding author), Kookmin Univ, Coll Sci & Technol, Dept Food & Nutr, Seoul 02707, South Korea.
EM bhc7@khu.ac.kr; cleverwhl@korea.ac.kr; js_song97@kookmin.ac.kr;
   taeyeon97@kookmin.ac.kr; kimmh@sookmyung.ac.kr; glorijy76@korea.ac.kr;
   ghsong@korea.ac.kr; wlim@kookmin.ac.kr
RI Lim, Whasun/AAP-3156-2020; Bae, Hyocheol/AAS-7245-2021
OI Lim, Whasun/0000-0002-1328-0465; Bae, Hyocheol/0000-0002-9643-7797
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2019R1A2C2089914, 2021R1A2C2005841, 2021R1C1C1009807]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT). (No.
   2019R1A2C2089914& 2021R1A2C2005841& 2021R1C1C1009807).
CR Bae H, 2020, MAR DRUGS, V18, DOI 10.3390/md18010045
   Chen SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176501
   Chen XT, 2019, J CELL MOL MED, V23, P4290, DOI 10.1111/jcmm.14320
   Cho YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19173-2
   Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638
   Entezar-Almahdi E, 2020, INT J NANOMED, V15, P5445, DOI 10.2147/IJN.S257700
   Fournier E, 2004, EUR J PHARM BIOPHARM, V57, P189, DOI 10.1016/s0939-6411(03)00146-2
   Gardner BM, 2011, SCIENCE, V333, P1891, DOI 10.1126/science.1209126
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Han KS, 2001, J NEUROCHEM, V78, P230, DOI 10.1046/j.1471-4159.2001.00394.x
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   He PY, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114345
   Hogg SJ, 2015, OBSTET GYNECOL INT, V2015, DOI 10.1155/2015/279591
   Huang ZS, 1999, WORLD J GASTROENTERO, V5, P41
   Hwang Jimmy J, 2004, Oncology (Williston Park), V18, P26
   Jiang CQ, 2020, J NAT MED-TOKYO, V74, P533, DOI 10.1007/s11418-020-01399-5
   Jiang J, 2019, ONCOL LETT, V17, P4505, DOI 10.3892/ol.2019.10123
   Kerkhofs M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0179-0
   Kim KY, 2013, J CELL BIOCHEM, V114, P1124, DOI 10.1002/jcb.24455
   Krishnaiah YSR, 2003, EUR J PHARM SCI, V19, P355, DOI 10.1016/S0928-0987(03)00139-8
   Lai SL, 2018, PHYTOMEDICINE, V42, P144, DOI 10.1016/j.phymed.2018.03.027
   Lee JY, 2020, CANCERS, V12, DOI 10.3390/cancers12061459
   Lee M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060957
   Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453
   Ling YN, 2016, CLIN SCI, V130, P1641, DOI 10.1042/CS20160082
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu HH, 2011, J CELL BIOCHEM, V112, P3695, DOI 10.1002/jcb.23303
   Liu Z, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-71
   Marsh S, 2005, INVEST NEW DRUG, V23, P533, DOI 10.1007/s10637-005-4021-7
   Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163
   Moon D, 2013, J SURG RES, V180, P208, DOI 10.1016/j.jss.2012.04.027
   Ricci AJ, 1998, J NEUROSCI, V18, P8261
   Riviere C, 2007, BIOORGAN MED CHEM, V15, P1160, DOI 10.1016/j.bmc.2006.09.069
   Salazar M, 2011, METHOD ENZYMOL, V489, P297, DOI 10.1016/B978-0-12-385116-1.00017-0
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sobhakumari A, 2013, TOXICOL APPL PHARM, V272, P736, DOI 10.1016/j.taap.2013.07.013
   Sun DP, 2013, CANCER BIOTHER RADIO, V28, P320, DOI 10.1089/cbr.2012.1327
   Wilhelm M, 2016, CLIN COLORECTAL CANC, V15, P381, DOI 10.1016/j.clcc.2016.04.001
   Xiong QP, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153301
   Xu SC, 2020, CELL SIGNAL, V75, DOI 10.1016/j.cellsig.2020.109733
   Yang Haihong, 2010, J Thorac Dis, V2, P52
   Ye J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12252-3
   Zhang YS, 2014, ONCOL LETT, V7, P295, DOI 10.3892/ol.2013.1696
   Zhao WJ, 2019, J CELL BIOCHEM, V120, P17481, DOI 10.1002/jcb.29012
NR 46
TC 1
Z9 1
U1 4
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD SEP
PY 2021
VL 10
IS 9
AR 1477
DI 10.3390/antiox10091477
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA UV1NP
UT WOS:000699254800001
PM 34573109
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Smith, E
   Palethorpe, HM
   Tomita, Y
   Pei, JXV
   Townsend, AR
   Price, TJ
   Young, JP
   Yool, AJ
   Hardingham, JE
AF Smith, Eric
   Palethorpe, Helen M.
   Tomita, Yoko
   Pei, Jinxin, V
   Townsend, Amanda R.
   Price, Timothy J.
   Young, Joanne P.
   Yool, Andrea J.
   Hardingham, Jennifer E.
TI The Purified Extract from the Medicinal Plant Bacopa monnieri,
   Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by
   Inducing Cell Cycle Arrest and Apoptosis
SO CELLS
LA English
DT Article
DE Bacopa monnieri; bacopaside II; colorectal cancer; anti-tumour agents;
   aquaporin-1; cell cycle arrest; apoptosis
ID TRITERPENE SAPONINS; GLYCOSIDES; AUTOPHAGY
AB Aquaporin-1 (AQP1), a transmembrane pore-forming molecule, facilitates the rapid movement of water and small solutes across cell membranes. We have previously shown that bacopaside II, an extract from the medicinal herb Bacopa monnieri, blocks the AQP1 water channel and impairs migration of cells that express AQP1. The aim of this study was to further elucidate the anti-tumour potential of bacopaside II in colon cancer cells. Expression of AQP1 in HT-29, SW480, SW620 and HCT116 was determined by quantitative PCR and western immunoblot. Cells were treated with bacopaside II, and morphology, growth, autophagy, cell cycle and apoptosis assessed by time-lapse microscopy, crystal violet, acridine orange, propidium iodide (PI) and annexin V/PI staining respectively. AQP1 expression was significantly higher in HT-29 than SW480, SW620 and HCT116. Bacopaside II significantly reduced growth at >20 mu M for HT-29 and >15 mu M for SW480, SW620 and HCT116. Inhibition of HT-29 at 20 mu M was primarily mediated by G0/G1 cell cycle arrest, and at 30 mu M by G2/M arrest and apoptosis. Inhibition of SW480, SW620 and HCT116 at >15 mu M was mediated by G2/M arrest and apoptosis. These results are the first to show that bacopaside II inhibits colon cancer cell growth by inducing cell cycle arrest and apoptosis.
C1 [Smith, Eric; Palethorpe, Helen M.; Tomita, Yoko; Hardingham, Jennifer E.] Queen Elizabeth Hosp, Basil Hetzel Inst, Mol Oncol, Woodville South, SA 5011, Australia.
   [Smith, Eric; Palethorpe, Helen M.; Tomita, Yoko; Pei, Jinxin, V; Townsend, Amanda R.; Price, Timothy J.; Young, Joanne P.; Yool, Andrea J.; Hardingham, Jennifer E.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5000, Australia.
   [Townsend, Amanda R.; Price, Timothy J.] Queen Elizabeth Hosp, Med Oncol, Woodville South, SA 5011, Australia.
RP Hardingham, JE (corresponding author), Queen Elizabeth Hosp, Basil Hetzel Inst, Mol Oncol, Woodville South, SA 5011, Australia.; Hardingham, JE (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5000, Australia.
EM eric.smith@adelaide.edu.au; helen.palethorpe@adelaide.edu.au;
   yoko.tomita@sa.gov.au; jinxin.pei@adelaide.edu.au;
   amanda.townsend@sa.gov.au; timothy.price@sa.gov.au;
   joanne.young@adelaide.edu.au; andrea.yool@adelaide.edu.au;
   jenny.hardingham@sa.gov.au
RI Palethorpe, Helen Marie/AAC-4219-2022; Yool, Andrea/AAK-9907-2020;
   Smith, Eric/ABG-7104-2020
OI Palethorpe, Helen Marie/0000-0003-3803-5113; Yool,
   Andrea/0000-0003-1283-585X; Smith, Eric/0000-0003-2958-3492; Tomita,
   Yoko/0000-0001-7934-2203
CR Aguiar S, 2013, REJUV RES, V16, P313, DOI 10.1089/rej.2013.1431
   Blanc L, 2009, BLOOD, V114, P3928, DOI 10.1182/blood-2009-06-230086
   Chakravarty AK, 2002, CHEM PHARM BULL, V50, P1616, DOI 10.1248/cpb.50.1616
   Das DN, 2016, PHYTOTHER RES, V30, P1794, DOI 10.1002/ptr.5682
   Dorward HS, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0310-6
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fosang AJ, 2015, J BIOL CHEM, V290, P29692, DOI 10.1074/jbc.E115.000002
   Garai S, 1996, PHYTOCHEMISTRY, V42, P815, DOI 10.1016/0031-9422(95)00936-1
   Mallick MN, 2017, PHARMACOGN MAG, V13, pS595, DOI 10.4103/pm.pm_397_16
   Mallick MN, 2015, J PHARM BIOALLIED SC, V7, P325, DOI 10.4103/0975-7406.168038
   Paglin S, 2001, CANCER RES, V61, P439
   Palethorpe HM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030653
   Palethorpe HM, 2017, DIGEST DIS SCI, V62, P3402, DOI 10.1007/s10620-017-4794-5
   Pei JXV, 2016, MOL PHARMACOL, V90, P496, DOI 10.1124/mol.116.105882
   Peng L, 2010, PHYTOTHER RES, V24, P864, DOI 10.1002/ptr.3034
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Singh R, 2015, XENOBIOTICA, V45, P741, DOI 10.3109/00498254.2015.1017752
   Sivaramakrishna C, 2005, PHYTOCHEMISTRY, V66, P2719, DOI 10.1016/j.phytochem.2005.09.016
   Smith E, 2016, DIGEST DIS SCI, V61, P433, DOI 10.1007/s10620-015-3909-0
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Young PE, 2014, J CANCER, V5, P262, DOI 10.7150/jca.7988
   Zhou Y, 2007, J NAT PROD, V70, P652, DOI 10.1021/np060470s
NR 22
TC 28
Z9 29
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2018
VL 7
IS 7
AR 81
DI 10.3390/cells7070081
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GO7BG
UT WOS:000440209500018
PM 30037060
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU He, QL
   Li, ZQ
   Yin, JB
   Li, YL
   Yin, YT
   Lei, X
   Zhu, W
AF He, Qinglian
   Li, Ziqi
   Yin, Jinbao
   Li, Yuling
   Yin, Yuting
   Lei, Xue
   Zhu, Wei
TI Prognostic Significance of Autophagy-Relevant Gene Markers in Colorectal
   Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; autophagy; prognostic model; splicing; markers
ID COLON-CANCER; SIGNATURE; IDENTIFICATION; VALIDATION; DEATH; CELLS
AB Background
   Colorectal cancer (CRC) is a common malignant solid tumor with an extremely low survival rate after relapse. Previous investigations have shown that autophagy possesses a crucial function in tumors. However, there is no consensus on the value of autophagy-associated genes in predicting the prognosis of CRC patients. This work screens autophagy-related markers and signaling pathways that may participate in the development of CRC, and establishes a prognostic model of CRC based on autophagy-associated genes.
   Methods
   Gene transcripts from the TCGA database and autophagy-associated gene data from the GeneCards database were used to obtain expression levels of autophagy-associated genes, followed by Wilcox tests to screen for autophagy-related differentially expressed genes. Then, 11 key autophagy-associated genes were identified through univariate and multivariate Cox proportional hazard regression analysis and used to establish prognostic models. Additionally, immunohistochemical and CRC cell line data were used to evaluate the results of our three autophagy-associated genes EPHB2, NOL3, and SNAI1 in TCGA. Based on the multivariate Cox analysis, risk scores were calculated and used to classify samples into high-risk and low-risk groups. Kaplan-Meier survival analysis, risk profiling, and independent prognosis analysis were carried out. Receiver operating characteristic analysis was performed to estimate the specificity and sensitivity of the prognostic model. Finally, GSEA, GO, and KEGG analysis were performed to identify the relevant signaling pathways.
   Results
   A total of 301 autophagy-related genes were differentially expressed in CRC. The areas under the 1-year, 3-year, and 5-year receiver operating characteristic curves of the autophagy-based prognostic model for CRC were 0.764, 0.751, and 0.729, respectively. GSEA analysis of the model showed significant enrichment in several tumor-relevant pathways and cellular protective biological processes. The expression of EPHB2, IL-13, MAP2, RPN2, and TRAF5 was correlated with microsatellite instability (MSI), while the expression of IL-13, RPN2, and TRAF5 was related to tumor mutation burden (TMB). GO analysis showed that the 11 target autophagy genes were chiefly enriched in mRNA processing, RNA splicing, and regulation of the mRNA metabolic process. KEGG analysis showed enrichment mainly in spliceosomes. We constructed a prognostic risk assessment model based on 11 autophagy-related genes in CRC.
   Conclusion
   A prognostic risk assessment model based on 11 autophagy-associated genes was constructed in CRC. The new model suggests directions and ideas for evaluating prognosis and provides guidance to choose better treatment strategies for CRC.
C1 [He, Qinglian; Li, Ziqi; Yin, Jinbao; Yin, Yuting; Lei, Xue; Zhu, Wei] Guangdong Med Univ, Dept Pathol, Dongguan, Peoples R China.
   [Li, Yuling] Southern Med Univ, Dongguan Peoples Hosp, Dept Pathol, Dongguan, Peoples R China.
RP Zhu, W (corresponding author), Guangdong Med Univ, Dept Pathol, Dongguan, Peoples R China.
EM zhuwei@gdmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472275, 81702399]; Guangdong Basic and
   Applied Basic Research Foundation [2020A151501303, 2014A030313542,
   2017A030313618]
FX This work was supported by the National Natural Science Foundation of
   China (81472275, 81702399) and the Guangdong Basic and Applied Basic
   Research Foundation (2020A151501303, 2014A030313542, 2017A030313618).
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bi CY, 2018, ONCOL REP, V40, P283, DOI 10.3892/or.2018.6434
   Cao H, 2016, ONCOTARGET, V7, P61183, DOI 10.18632/oncotarget.11282
   Cheng L, 2021, INT J MED SCI, V18, P88, DOI 10.7150/ijms.49449
   Chukkapalli S, 2014, EXP CELL RES, V320, P233, DOI 10.1016/j.yexcr.2013.10.022
   Cordani M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8794612
   Dehmelt L, 2005, GENOME BIOL, V6
   Dickinson JD, 2016, AUTOPHAGY, V12, P397, DOI 10.1080/15548627.2015.1056967
   Ding R, 2016, AUTOPHAGY, V12, P737, DOI 10.1080/15548627.2016.1155009
   Drucker A, 2013, TRANSL ONCOL, V6, P520, DOI 10.1593/tlo.13385
   Duan L, 2015, ONCOTARGET, V6, P23135, DOI 10.18632/oncotarget.5218
   Fabrizio DA, 2018, J GASTROINTEST ONCOL, V9, P610, DOI 10.21037/jgo.2018.05.06
   Ferretta A, 2016, BBA-MOL CELL RES, V1863, P2710, DOI 10.1016/j.bbamcr.2016.08.007
   Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706
   Freihen V, 2020, INT J CANCER, V146, P2229, DOI 10.1002/ijc.32644
   Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005
   Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8
   Gong H, 2018, ONCOL REP, V39, P1090, DOI 10.3892/or.2018.6199
   Guan J, 2016, EXP THER MED, V12, P2815, DOI 10.3892/etm.2016.3713
   Guo F, 2018, BRAIN PATHOL, V28, P3, DOI 10.1111/bpa.12545
   Hall TM, 2018, CURR OPIN PHARMACOL, V41, P12, DOI 10.1016/j.coph.2018.04.003
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   He YL, 2018, J CELL BIOL, V217, P315, DOI 10.1083/jcb.201701049
   Hildebrand JM, 2011, IMMUNOL REV, V244, P55, DOI 10.1111/j.1600-065X.2011.01055.x
   Huang LS, 2019, AGING-US, V11, P6674, DOI 10.18632/aging.102167
   Huang RH, 2017, CELL PHYSIOL BIOCHEM, V41, P1851, DOI 10.1159/000471933
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Ishii M, 2011, HISTOCHEM CELL BIOL, V136, P345, DOI 10.1007/s00418-011-0849-4
   Jang BG, 2018, J PATHOL TRANSL MED, V52, P298, DOI 10.4132/jptm.2018.06.29
   Jensen MA, 2017, BLOOD, V130, P453, DOI 10.1182/blood-2017-03-735654
   Kandouz M, 2010, CELL CYCLE, V9, P398, DOI 10.4161/cc.9.2.10505
   Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0
   Kautto EA, 2017, ONCOTARGET, V8, P7452, DOI 10.18632/oncotarget.13918
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Kumar Priyank, 2012, Cells, V1, P558, DOI 10.3390/cells1030558
   Kuranaga Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103012
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362
   Li HP, 2017, ONCOTARGET, V8, P72633, DOI 10.18632/oncotarget.20005
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x
   Li WL, 2016, EXP THER MED, V11, P1259, DOI 10.3892/etm.2016.3054
   Liu Min, 2017, Neurogenesis (Austin), V4, pe1313646, DOI 10.1080/23262133.2017.1313646
   Liu SY, 2008, BIOCHEM BIOPH RES CO, V366, P520, DOI 10.1016/j.bbrc.2007.11.179
   Lu XX, 2018, MOL PHARMACOL, V94, P1412, DOI 10.1124/mol.118.113423
   Luo XJ, 2019, INT J CANCER, V145, P1475, DOI 10.1002/ijc.32253
   Mo H, 2016, BIOCHEM BIOPH RES CO, V478, P74, DOI 10.1016/j.bbrc.2016.07.090
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Niu YN, 2014, ASIAN PAC J CANCER P, V15, P2153, DOI 10.7314/APJCP.2014.15.5.2153
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Opdam FJM, 2000, J CELL SCI, V113, P2725
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Pandurangan AK, 2018, WORLD J GASTRO ONCOL, V10, P244, DOI 10.4251/wjgo.v10.i9.244
   Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7
   Qian K, 2018, INT J ONCOL, V53, P1083, DOI 10.3892/ijo.2018.4443
   Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501
   Rahim SAA, 2017, BRIT J CANCER, V117, P813, DOI 10.1038/bjc.2017.263
   Salem AF, 2012, CELL CYCLE, V11, P4174, DOI 10.4161/cc.22376
   Schulte RR, 2019, MOL PHARMACOL, V95, P490, DOI 10.1124/mol.118.114314
   Sena P, 2015, ONCOL REP, V34, P3222, DOI 10.3892/or.2015.4326
   Sohn EJ, 2016, INT J MOL MED, V38, P225, DOI 10.3892/ijmm.2016.2596
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Tanabe H, 2011, INT J ONCOL, V39, P33, DOI 10.3892/ijo.2011.1011
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tauriello DVF, 2016, TRENDS CANCER, V2, P495, DOI 10.1016/j.trecan.2016.08.001
   Tsukahara T, 2015, BIORESEARCH OPEN ACC, V4, P319, DOI 10.1089/biores.2015.0018
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Verzella D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2399-y
   Wang H, 2018, ARTIF CELL NANOMED B, V46, pS293, DOI 10.1080/21691401.2017.1423494
   Wlcek K, 2011, CANCER BIOL THER, V11, P801, DOI 10.4161/cbt.11.9.15176
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Zhang J, 2019, J CELL PHYSIOL, V234, P12800, DOI 10.1002/jcp.27914
   Zhao LY, 2020, CANCER GENE THER, V27, P461, DOI 10.1038/s41417-019-0118-6
   Zhou CX, 2017, ONCOTARGET, V8, P14736, DOI 10.18632/oncotarget.14718
   Zhou L, 2019, BIOCHEM BIOPH RES CO, V509, P966, DOI 10.1016/j.bbrc.2019.01.048
   Zhou Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00878
NR 81
TC 1
Z9 1
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 15
PY 2021
VL 11
AR 566539
DI 10.3389/fonc.2021.566539
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RU3CV
UT WOS:000645027700001
PM 33937013
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, WKK
   Volta, V
   Cho, CH
   Wu, YC
   Li, HT
   Yu, L
   Li, ZJ
   Sung, JJY
AF Wu, William Ka Kei
   Volta, Viviana
   Cho, Chi Hin
   Wu, Ya Chun
   Li, Hai Tao
   Yu, Le
   Li, Zhi Jie
   Sung, Joseph Jao Yiu
TI Repression of protein translation and mTOR signaling by proteasome
   inhibitor in colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Proteasome; Colon cancer; Proliferation; Protein translation; Mammalian
   target of rapamycin
ID MAMMALIAN TARGET; DEGRADATION; MG-132; P53; UBIQUITINATION;
   PROLIFERATION; MECHANISMS; BORTEZOMIB; APOPTOSIS; AUTOPHAGY
AB Protein homeostasis relies on a balance between protein synthesis and protein degradation. The ubiquitin-proteasome system is a major catabolic pathway for protein degradation. In this respect, proteasome inhibition has been used therapeutically for the treatment of cancer. Whether inhibition of protein degradation by proteasome inhibitor can repress protein translation via a negative feedback mechanism, however, is unknown. In this study, proteasome inhibitor MG-132 lowered the proliferation of colon cancer cells HT-29 and SW1116. In this connection, MG-132 reduced the phosphorylation of mammalian target of rapamycin (mTOR) at Ser2448 and Ser2481 and the phosphorylation of its downstream targets 4E-BP1 and p70/p85 S6 kinases. Further analysis revealed that MG-132 inhibited protein translation as evidenced by the reductions of S-35-methionine incorporation and polysomes/80S ratio. Knockdown of raptor, a structural component of mTOR complex 1, mimicked the anti-proliferative effect of MG-132. To conclude, we demonstrate that the inhibition of protein degradation by proteasome inhibitor represses mTOR signaling and protein translation in colon cancer cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Wu, William Ka Kei; Cho, Chi Hin; Yu, Le; Sung, Joseph Jao Yiu] Chinese Univ Hong Kong, Fac Med, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Sung, Joseph Jao Yiu] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Wu, William Ka Kei; Cho, Chi Hin; Wu, Ya Chun; Li, Hai Tao; Yu, Le; Li, Zhi Jie] Chinese Univ Hong Kong, Fac Med, Dept Pharmacol, Hong Kong, Hong Kong, Peoples R China.
   [Volta, Viviana] Ist Sci San Raffaele, DiBiT, Mol Histol & Cellular Growth Unit, Milan, Italy.
RP Cho, CH (corresponding author), Chinese Univ Hong Kong, Fac Med, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
EM wukakei@cuhk.edu.hk; chcho@cuhk.edu.hk; joesung@cuhk.edu.hk
RI Cho, Chi Hin/C-6543-2014; Wu, William K.K./A-3277-2009; Sung, Joseph J.
   Y./R-3203-2018
OI Cho, Chi Hin/0000-0002-7658-3260; Wu, William K.K./0000-0002-5662-5240;
   Sung, Joseph J. Y./0000-0003-3125-5199; Volta,
   Viviana/0000-0001-9999-3732
FU Hong Kong Research Grants CouncilHong Kong Research Grants Council
   [CUHK7499/05M]
FX This work was supported by the Hong Kong Research Grants Council
   (CUHK7499/05M).
CR Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265
   Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546
   Boccadoro M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-18
   Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166
   Chang YC, 1998, CELL GROWTH DIFFER, V9, P79
   Drakos E, 2009, LEUKEMIA, V23, P784, DOI 10.1038/leu.2008.348
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Maki CG, 1996, CANCER RES, V56, P2649
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Rodriguez MS, 1996, ONCOGENE, V12, P2425
   Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003
   Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340
   Shao JY, 2004, CANCER RES, V64, P229, DOI 10.1158/0008-5472.CAN-03-1859
   Wu WKK, 2008, BRIT J PHARMACOL, V154, P632, DOI 10.1038/bjp.2008.115
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V371, P209, DOI 10.1016/j.bbrc.2008.04.059
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271
   Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018
   Zhang WG, 2008, CANCER INVEST, V26, P1032, DOI 10.1080/07357900802104997
NR 31
TC 18
Z9 22
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 4
PY 2009
VL 386
IS 4
BP 598
EP 601
DI 10.1016/j.bbrc.2009.06.080
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 476RS
UT WOS:000268462100010
PM 19540199
DA 2022-04-25
ER

PT J
AU Revelant, G
   Huber-Villaume, S
   Dunand, S
   Kirsch, G
   Schohn, H
   Hesse, S
AF Revelant, Germain
   Huber-Villaume, Sophie
   Dunand, Sandrine
   Kirsch, Gilbert
   Schohn, Herve
   Hesse, Stephanie
TI Synthesis and biological evaluation of novel
   2-heteroarylimino-1,3-thiazolidin-4-ones as potential anti-tumor agents
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Thiazolidinone; Thiophene; Thiazole; Antiproliferative activity; Colon
   cancer
ID CANCER-CELLS; THIAZOLIDINONE DERIVATIVES; 4-THIAZOLIDINONES; INHIBITORS;
   AUTOPHAGY; DESIGN
AB A series of 35 heteroarylimino-1,3-thiazolidinones with three sites of functionalization were synthesized and their antiproliferative properties were studied. The in vitro screening by MTT assay was performed against five cancer cell lines (human colon cancer cell lines HT29, HCT116 and SW620 and breast cancer cell lines MCF7 and MDA-MB-231). It was observed that N3-substituted thiazolidinones had moderate activities whereas 5-benzylidene thiazolidinones showed promising activities. To investigate the mechanism of action, detailed biological studies of six selected compounds (those presenting the lower mitotic index) were carried out on the human colon cancer HT29 cell line. Cell cycle assay revealed that those compounds induced cell accumulation in G2/M and in subG0/G1 phases of cell cycle. Moreover, dissipation of mitochondria membrane potential was observed as well as redox changes in treated cells. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Revelant, Germain; Dunand, Sandrine; Kirsch, Gilbert; Hesse, Stephanie] Univ Lorraine, Equipe HECRIN 3, UMR CNRS 7565, Struct & React Syst Mol Complexes, F-57070 Metz Technople, France.
   [Huber-Villaume, Sophie; Schohn, Herve] Univ Lorraine, Equipe 2MIC 5, UMR CNRS 7565, Struct & React Syst Mol Complexes, F-57070 Metz, France.
RP Hesse, S (corresponding author), Univ Lorraine, Equipe HECRIN 3, UMR CNRS 7565, Struct & React Syst Mol Complexes, 1 Blvd Arago, F-57070 Metz Technople, France.
EM herve.schohn@univ-lorraine.fr; stephanie.hesse@univ-lorraine.fr
FU Ministere de l'Enseignement Superieur et de la Recherche
FX We thank the 'Ministere de l'Enseignement Superieur et de la Recherche'
   for Ph.D. grants to G.R. and S. H.-V.
CR Abdillahi I, 2010, SYNTHESIS-STUTTGART, P2543, DOI 10.1055/s-0029-1218780
   Deep A, 2014, ARAB J CHEM, V7, P287, DOI 10.1016/j.arabjc.2010.10.032
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Jain AK, 2012, BIOORGAN MED CHEM, V20, P3378, DOI 10.1016/j.bmc.2012.03.069
   Lewicki K, 2006, TALANTA, V70, P876, DOI 10.1016/j.talanta.2006.02.009
   Liu ZH, 2007, DEV CELL, V12, P484, DOI 10.1016/j.devcel.2007.03.016
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maccari R, 2014, EUR J MED CHEM, V81, P1, DOI 10.1016/j.ejmech.2014.05.003
   Nikalje APG, 2014, BIOORG MED CHEM LETT, V24, P5558, DOI 10.1016/j.bmcl.2014.11.016
   Niture SK, 2010, TOXICOL APPL PHARM, V244, P37, DOI 10.1016/j.taap.2009.06.009
   Omar K, 2010, BIOORGAN MED CHEM, V18, P426, DOI 10.1016/j.bmc.2009.10.041
   Ottana R, 2005, BIOORG MED CHEM LETT, V15, P3930, DOI 10.1016/j.bmcl.2005.05.093
   Pasquier E, 2006, DRUG RESIST UPDATE, V9, P74, DOI 10.1016/j.drup.2006.04.003
   Revelant G, 2011, TETRAHEDRON, V67, P9352, DOI 10.1016/j.tet.2011.09.134
   Revelant G, 2010, SYNTHESIS-STUTTGART, P3319, DOI 10.1055/s-0030-1257867
   Teraishi F, 2005, CANCER RES, V65, P6380, DOI 10.1158/0008-5472.CAN-05-0575
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tripathi AC, 2014, EUR J MED CHEM, V72, P52, DOI 10.1016/j.ejmech.2013.11.017
   UNANGST PC, 1994, J MED CHEM, V37, P322, DOI 10.1021/jm00028a017
   Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103
   Vicini P, 2008, BIOORGAN MED CHEM, V16, P3714, DOI 10.1016/j.bmc.2008.02.001
   Wang SB, 2011, EUR J MED CHEM, V46, P3509, DOI 10.1016/j.ejmech.2011.05.017
   Wu JF, 2014, FOOD CHEM TOXICOL, V64, P307, DOI 10.1016/j.fct.2013.12.006
   Xie T, 1996, BIOCHEM PHARMACOL, V51, P771, DOI 10.1016/0006-2952(95)02394-1
   Xu S., 2006, MED CHEM, P597
   Zhou HY, 2008, J MED CHEM, V51, P1242, DOI 10.1021/jm7012024
NR 27
TC 29
Z9 29
U1 0
U2 17
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD APR 13
PY 2015
VL 94
BP 102
EP 112
DI 10.1016/j.ejmech.2015.02.053
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CH0RU
UT WOS:000353730900010
PM 25757093
DA 2022-04-25
ER

PT J
AU Matsumoto, N
   Yoshikawa, K
   Shimada, M
   Kurita, N
   Sato, H
   Iwata, T
   Higashijima, J
   Chikakiyo, M
   Nishi, M
   Kashihara, H
   Takasu, C
   Eto, S
   Takahashi, A
   Akutagawa, M
   Emoto, T
AF Matsumoto, Noriko
   Yoshikawa, Kozo
   Shimada, Mitsuo
   Kurita, Nobuhiro
   Sato, Hirohiko
   Iwata, Takashi
   Higashijima, Jun
   Chikakiyo, Motoya
   Nishi, Masaaki
   Kashihara, Hideya
   Takasu, Chie
   Eto, Shohei
   Takahashi, Akira
   Akutagawa, Masatake
   Emoto, Takahiro
TI Effect of Light Irradiation by Light Emitting Diode on Colon Cancer
   Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Light-emitting diode; colon cancer; HT29; HCT116 cells
ID RED-LIGHT; AUTOPHAGY; GROWTH; DEATH; LASER; APOPTOSIS; PATHWAYS; THERAPY
AB Background/Aim: Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation. Materials and Methods: Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively. Results: Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells. Conclusion: LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway.
C1 [Matsumoto, Noriko; Yoshikawa, Kozo; Shimada, Mitsuo; Kurita, Nobuhiro; Sato, Hirohiko; Iwata, Takashi; Higashijima, Jun; Chikakiyo, Motoya; Nishi, Masaaki; Kashihara, Hideya; Takasu, Chie; Eto, Shohei] Univ Tokushima, Inst Hlth Biosci, Dept Surg, Tokushima 7708503, Japan.
   [Takahashi, Akira] Univ Tokushima, Inst Hlth Biosci, Dept Prevent Environm & Nutr, Tokushima 770, Japan.
   [Akutagawa, Masatake; Emoto, Takahiro] Univ Tokushima, Inst Sci & Technol, Dept Life Syst, Tokushima 770, Japan.
RP Yoshikawa, K (corresponding author), Univ Tokushima, Inst Hlth Biosci, Dept Surg, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM yoshikawa.kozo@tokushima-u.ac.jp
CR Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x
   de Sousa APC, 2013, LASER MED SCI, V28, P981, DOI 10.1007/s10103-012-1187-z
   Agnol MAD, 2009, LASER MED SCI, V24, P909, DOI 10.1007/s10103-009-0648-5
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Fiandalo M. V., 2012, Experimental Oncology, V34, P165
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Greco C, 2007, CANCER-AM CANCER SOC, V109, P1227, DOI 10.1002/cncr.22542
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kim EK, 2010, BIOCHIM BIOPHYS ACTA, V1802, P396, DOI DOI 10.1016/J.BBADIS.2009.12.009
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103-008-0550-6
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Ohara M, 2002, JPN J CANCER RES, V93, P551, DOI 10.1111/j.1349-7006.2002.tb01290.x
   Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282
   Reinhold T, 2007, PLANT J, V50, P293, DOI 10.1111/j.1365-313X.2007.03049.x
   Schindl A, 1999, J AM ACAD DERMATOL, V40, P481, DOI 10.1016/S0190-9622(99)70503-7
   Seo YK, 2014, LASER MED SCI, V29, P245, DOI 10.1007/s10103-013-1322-5
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Vinck EM, 2005, PHOTOMED LASER SURG, V23, P167, DOI 10.1089/pho.2005.23.167
   Walker NA, 2007, J ATHL TRAINING, V42, P530
   Xavier M, 2010, LASER SURG MED, V42, P553, DOI 10.1002/lsm.20896
   Zhang L, 2009, J RADIAT RES, V50, P109, DOI 10.1269/jrr.08003
NR 29
TC 17
Z9 17
U1 1
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2014
VL 34
IS 9
BP 4709
EP 4716
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP1VS
UT WOS:000341860700010
PM 25202048
DA 2022-04-25
ER

PT J
AU Jing, ZL
   He, XY
   Jia, ZR
   Sa, YL
   Yang, BL
   Liu, P
AF Jing, Zuolei
   He, Xinyuan
   Jia, Zhirong
   Sa, Yunli
   Yang, Bolin
   Liu, Ping
TI NCAPD2 inhibits autophagy by regulating Ca2+/CAMKK2/AMPK/mTORC1 pathway
   and PARP-1/SIRT1 axis to promote colorectal cancer
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; NCAPD2; Autophagy; PARP-1/SIRT1; CAMKK/AMPK pathway
ID CHROMOSOME 12P13 LOCUS; CELL-DEATH; PROTEIN; MTOR; TUMORIGENESIS;
   CONDENSATION; METABOLISM; INTERACTS; HOMOLOG; DISEASE
AB Non-SMC condensin I complex subunit D2 (NCAPD2) is one of the three non-SMC subunits in condensin I. Previous studies have shown that NCAPD2 plays an important role in the chromosome condensation and segregation. However, its role in the development of colorectal cancer (CRC) and specific molecular mechanisms still need to be further studied. Here we show that NCAPD2 inhibits autophagy and blocks autophagic flux via Ca2+/CAMKK/AMPK/mTORC1 pathway and PARP-1/SIRT1 axis. NCAPD2 acts as a tumor promoter both in vitro and in vivo. NCAPD2 knockout suppresses colorectal cancer development in AOM/DSS induced mice model. Therefore, our findings support a role for NCAPD2 in autophagy to promote CRC development and highlight NCAPD2 as a potential target for CRC therapy.
C1 [Jing, Zuolei; He, Xinyuan; Jia, Zhirong; Sa, Yunli; Liu, Ping] Nanjing Normal Univ, Coll Life Sci, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China.
   [Yang, Bolin] Nanjing Univ Chinese Med, Dept Colorectal Surg, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.
RP Jing, ZL; Liu, P (corresponding author), Nanjing Normal Univ, Coll Life Sci, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM Jingzuolei0212@163.com; liuping0805@njnu.edu.cn
OI Jing, Zuolei/0000-0002-0749-2197; Liu, Ping/0000-0001-5366-4618
FU National Natural Science Foundation of China (NNSFC)National Natural
   Science Foundation of China (NSFC) [81872104, 81472415]
FX This work was supported by the National Natural Science Foundation of
   China (NNSFC) (grant no. 81872104 and 81472415) .
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Aventaggiato M, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107748
   Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004
   Birrer MJ, 2011, PLOS ONE, V6
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Choi S, 2014, BIOCHEM BIOPH RES CO, V443, P56, DOI 10.1016/j.bbrc.2013.11.044
   East DA, 2013, AUTOPHAGY, V9, P1710, DOI 10.4161/auto.25367
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Feng YC, 2015, TRENDS CELL BIOL, V25, P354, DOI 10.1016/j.tcb.2015.02.002
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004
   Heale JT, 2006, MOL CELL, V21, P837, DOI 10.1016/j.molcel.2006.01.036
   Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102
   Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hughes WE, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0802-6
   Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200
   Kalyan A, 2018, J GASTROINTEST ONCOL, V9, P160, DOI 10.21037/jgo.2018.01.17
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee JH, 2008, NEUROGENETICS, V9, P127, DOI 10.1007/s10048-008-0122-8
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li Y, 2009, DEMENT GERIATR COGN, V27, P508, DOI 10.1159/000218740
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Neufert C, 2021, NAT PROTOC, V16, P61, DOI 10.1038/s41596-020-00412-1
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241
   Sun B, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0054-1
   Sun T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8215
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wen X, 2020, SEMIN CANCER BIOL, V66, P3, DOI 10.1016/j.semcancer.2019.11.005
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Yang YZ, 2019, J BIOL CHEM, V294, P772, DOI 10.1074/jbc.RA118.005166
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu JJ, 2009, ANN NY ACAD SCI, V1173, pE10, DOI 10.1111/j.1749-6632.2009.04952.x
   Zhang P, 2014, GENOME, V57, P253, DOI 10.1139/gen-2014-0032
   Zhang YJ, 2020, AM J PATHOL, V190, P37, DOI 10.1016/j.ajpath.2019.09.014
NR 48
TC 2
Z9 2
U1 6
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD NOV 1
PY 2021
VL 520
BP 26
EP 37
DI 10.1016/j.canlet.2021.06.029
EA JUL 2021
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UR7MB
UT WOS:000696927600003
PM 34229059
DA 2022-04-25
ER

PT J
AU Wang, YY
   Zhao, Z
   Zhuang, J
   Wu, XX
   Wang, ZZ
   Zhang, B
   Gao, G
   Zhang, YP
   Guo, CL
   Xia, QX
AF Wang, Yuanyuan
   Zhao, Zhi
   Zhuang, Jing
   Wu, Xinxin
   Wang, Zhizhong
   Zhang, Bing
   Gao, Ge
   Zhang, Yinping
   Guo, Caili
   Xia, Qingxin
TI Prognostic Value of Autophagy, Microsatellite Instability, and KRAS
   Mutations in Colorectal Cancer
SO JOURNAL OF CANCER
LA English
DT Article
DE Beclin 1; LC3; MSI; KRAS; prognosis; CRC
ID CLINICAL-PRACTICE GUIDELINES; WILD-TYPE KRAS; COLON-CANCER; STAGE-II;
   BRAF; CHEMOTHERAPY; SURVIVAL; REPAIR; 5-FLUOROURACIL; FLUOROURACIL
AB Introduction: Autophagy plays pivotal role in various tumors, including colorectal cancer (CRC). Microsatellite instability (MSI) and KRAS mutations are also involved in response to the adjuvant therapy of CRC. We aimed to investigate the relationships among autophagy, KRAS mutations, MSI, clinicopathological parameters, and prognosis in CRC patients. Methods and Results: We tested 200 CRC tumors for autophagy-related protein expression (Beclin 1 and LC3), MSI status, and KRAS mutations. Results: Expression of Beclin 1 and LC3 was higher in CRC, with Beclin 1 significantly correlating with the depth of invasion, whereas LC3 was not associated with clinicopathological parameters. Patients expressing the LC3 proteins experienced a shorter overall survival (OS) after surgery with adjuvant therapy, especially in the MSS/L-CRC subgroup and the mutated KRAS subgroup. MSS/L-CRC patients with KRAS mutations positively expressed the LC3 protein and suffered a shorter OS than LC3 non-expressing patients. In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, the positive expression of LC3 correlated with worse OS compared to patients who did not express LC3. Sequencing showed BRCA1/2 as the most variant genes in all patients. Nevertheless, deleterious variations were more frequent in patients with MSI-H CRC. Conclusions: High LC3 protein expression shows a certain prognostic value in CRC patients. LC3, the MSI status, and KRAS mutations must be considered when selecting an adjuvant therapy for CRC. The detection of these indexes is of great significance to identify high-risk patients who would benefit from autophagy-related anticancer drugs or help to explore more effective treatment options for patients who are resistant to conventional chemotherapy or relapse.
C1 [Wang, Yuanyuan; Zhang, Bing; Gao, Ge; Zhang, Yinping; Xia, Qingxin] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Pathol, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
   [Zhao, Zhi] Henan Univ, Yihe Hosp, Dept Pathol, 69 Agr East Rd, Zhengzhou 450008, Peoples R China.
   [Zhuang, Jing] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Gen Surg, 127 Dongming Rd, Zhengzhou 450008, Peoples R China.
   [Wu, Xinxin; Wang, Zhizhong] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Mol Pathol, 127 Dongming Rd, Zhengzhou 450008, Peoples R China.
   [Guo, Caili] Zhengzhou Univ, Affiliated Childrens Hosp, Dept Crit Care Med, 255 Gangdu Rd,Dongsan St, Zhengzhou 450008, Peoples R China.
RP Xia, QX (corresponding author), Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Pathol, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.; Guo, CL (corresponding author), Zhengzhou Univ, Affiliated Childrens Hosp, Dept Crit Care Med, 255 Gangdu Rd,Dongsan St, Zhengzhou 450008, Peoples R China.
EM guocaili8888@163.com; tudou414135404@163.com
FU Medical Technology Research and Development Program of Henan Province
   [201701029, 182102310343]
FX This work was supported by The Medical Technology Research and
   Development Program of Henan Province [grant numbers 201701029,
   182102310343].
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061
   Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bertagnolli MM, 2011, J CLIN ONCOL, V29, P3153, DOI 10.1200/JCO.2010.33.0092
   Boland CR, 1998, CANCER RES, V58, P5248
   Boussios S, 2019, J PERS MED, V9, DOI 10.3390/jpm9010012
   Chatterjee N, 2017, ENVIRON MOL MUTAGEN, V58, P235, DOI 10.1002/em.22087
   Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201
   Guidoboni M, 2001, AM J PATHOL, V159, P297, DOI 10.1016/S0002-9440(10)61695-1
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Jeong SY, 2003, DIS COLON RECTUM, V46, P1069, DOI 10.1007/s10350-004-7282-x
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kadowaki S, 2015, WORLD J GASTROENTERO, V21, P1275, DOI 10.3748/wjg.v21.i4.1275
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Klingbiel D, 2015, ANN ONCOL, V26, P126, DOI 10.1093/annonc/mdu499
   Koustas E, 2019, AM J CLIN ONCOL-CANC, V42, P767, DOI 10.1097/COC.0000000000000592
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li WH, 2019, INT J CLIN EXP PATHO, V12, P957
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Liou JM, 2011, INT J COLORECTAL DIS, V26, P1387, DOI 10.1007/s00384-011-1229-1
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Niu WB, 2019, ONCOL LETT, V17, P332, DOI 10.3892/ol.2018.9611
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Provenzale D, 2020, J NATL COMPR CANC NE, V18, P1313, DOI 10.6004/jnccn.2020.0048
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC
   Riely GJ, 2008, J MOL DIAGN, V10, P493, DOI 10.2353/jmoldx.2008.080105
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Sena P, 2015, ONCOL REP, V34, P3222, DOI 10.3892/or.2015.4326
   Sinicrope FA, 2012, CLIN CANCER RES, V18, P1506, DOI 10.1158/1078-0432.CCR-11-1469
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wang YY, 2019, ONCOL LETT, V18, P5577, DOI 10.3892/ol.2019.10915
   Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821
   Watanabe T, 2013, JPN J CLIN ONCOL, V43, P706, DOI 10.1093/jjco/hyt062
   Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015
   Wu JY, 2006, INT J CANCER, V118, P1215, DOI 10.1002/ijc.21428
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Zhang XC, 2013, WORLD J GASTRO ONCOL, V5, P12, DOI 10.4251/wjgo.v5.i2.12
   Zhang YL, 2017, J GENET, V96, P283, DOI 10.1007/s12041-017-0774-y
   Zhang YQ, 2012, INT J CANCER, V131, P83, DOI 10.1002/ijc.26346
NR 51
TC 3
Z9 3
U1 0
U2 1
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2021
VL 12
IS 12
BP 3515
EP 3528
DI 10.7150/jca.51430
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RZ4TW
UT WOS:000648591100010
PM 33995628
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhu, DR
   Chen, C
   Xia, YZ
   Kong, LY
   Luo, JG
AF Zhu, Dongrong
   Chen, Chen
   Xia, Yuanzheng
   Kong, Ling-Yi
   Luo, Jianguang
TI A Purified Resin Glycoside Fraction from Pharbitidis Semen Induces
   Paraptosis by Activating Chloride Intracellular Channel-1 in Human Colon
   Cancer Cells
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE Pharbitidis Semen; resin glycoside; paraptosis; CLIC1; cytoplasmic
   vacuolization
ID SEEDS; AUTOPHAGY; DEATH
AB Pharbitidis Semen has worldwide recognition in traditional medicine for the treatment of several illnesses apart from its purgative properties, and it is also reported to show anticancer effect. However, limited pharmacological studies are available on the extract or resin glycosides fraction of Pharbitidis Semen. The purpose of this study was to determine the mechanism of the colon cancer cell cytotoxic effect of a purified resin glycoside fraction from Pharbitidis Semen (RFP). Our results showed that the RFP-induced cell death was mediated by the caspase-independent and autophagy-protective paraptosis, a type of cell death that is characterized by the accumulation of cytoplasmic vacuoles and mitochondria swelling. RFP significantly stimulated endoplasmic reticulum stress, inhibited proteasome-dependent degradation, and activated the MAPK signaling pathway in human colon cancer cell lines. Furthermore, we found that RFP activated chloride intracellular channel-1 (CLIC1) and increased the intracellular Cl-concentration. Blockage of CLIC1 by DIDS (disodium 4,4'-diisothiocyanato-2,2'-stilbenedisulfonate hydrate) attenuated cell death, cytoplasmic vacuolization, and endoplasmic reticulum stress, suggesting that CLIC1 acts as a critical early signal in RFP-induced paraptosis. In conclusion, results obtained indicated that the cytotoxic effect of RFP in colon cancer cells was the outcome of paraptosis mediated by activation of CLIC1.
C1 [Zhu, Dongrong; Chen, Chen; Xia, Yuanzheng; Kong, Ling-Yi; Luo, Jianguang] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Dongrong; Chen, Chen; Xia, Yuanzheng; Kong, Ling-Yi; Luo, Jianguang] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.
RP Kong, LY; Luo, JG (corresponding author), China Pharmaceut Univ, Nanjing 210009, Jiangsu, Peoples R China.
EM cpu_lykong@126.com; luojg@cpu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573570]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD); Program for
   Chang Jiang Scholars and Innovative Research Team in UniversityProgram
   for Changjiang Scholars & Innovative Research Team in University
   (PCSIRT) [IRT_15R63]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported financially by the National Natural Science Foundation of
   China (No. 81573570), the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD), and the Program for Chang
   Jiang Scholars and Innovative Research Team in University (IRT_15R63).
CR Bai LJ, 2017, TETRAHEDRON, V73, P2863, DOI 10.1016/j.tet.2017.03.059
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Bury M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.85
   Chen C, 2017, MOL CARCINOGEN, V56, P2692, DOI 10.1002/mc.22712
   Cruz-Morales S, 2016, J NAT PROD, V79, P3093, DOI 10.1021/acs.jnatprod.6b00782
   Diederich M, 2016, SEMIN CANCER BIOL, V40-41, P4, DOI 10.1016/j.semcancer.2016.06.001
   Edwards JC, 2010, FEBS LETT, V584, P2102, DOI 10.1016/j.febslet.2010.01.037
   Fan BY, 2015, J FUNCT FOODS, V19, P141, DOI 10.1016/j.jff.2015.09.027
   Hoa NT, 2007, J TECH METHODS PATHO, V87, P115, DOI [10.1038/labinvest.3700506, DOI 10.1038/LABINVEST.3700506]
   Lee D, 2016, PHARMACOL THERAPEUT, V162, P120, DOI 10.1016/j.pharmthera.2016.01.003
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429
   ONO M, 1990, CHEM PHARM BULL, V38, P1892, DOI 10.1248/cpb.38.1892
   Ono M, 2010, J NAT PROD, V73, P1846, DOI 10.1021/np1004888
   Pereda-Miranda R, 2003, CURR TOP MED CHEM, V3, P111, DOI 10.2174/1568026033392534
   Pereda-Miranda R., 2009, Revista Latinoamericana de Quimica, V37, P144
   Pereda-Miranda R, 2010, PROG CHEM ORG NAT PR, V92, P77, DOI 10.1007/978-3-211-99661-4_2
   Rencurosi A, 2004, ANGEW CHEM INT EDIT, V43, P5918, DOI 10.1002/anie.200460327
   Samadder P, 2009, BIOCHEM CELL BIOL, V87, P401, DOI [10.1139/o08-147, 10.1139/O08-147]
   Sawadogo WR, 2012, BIOCHEM PHARMACOL, V84, P1225, DOI 10.1016/j.bcp.2012.07.021
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.217
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Yoon MJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.85
   Yoon MJ, 2010, FREE RADICAL BIO MED, V48, P713, DOI 10.1016/j.freeradbiomed.2009.12.016
   Zahreddine H, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00028
   Zhang C, 2015, INT J MOL SCI, V16, P14979, DOI 10.3390/ijms160714979
NR 28
TC 5
Z9 5
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JAN 7
PY 2019
VL 18
DI 10.1177/1534735418822120
PG 13
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA HN8YF
UT WOS:000460483500001
PM 30614302
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zheng, BA
   Yu, XJ
   Chai, R
AF Zheng, Bo'an
   Yu, Xiaojun
   Chai, Rui
TI Myotubularin-Related Phosphatase 3 Promotes Growth of Colorectal Cancer
   Cells
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID CARCINOMA CELLS; AUTOPHAGY; APOPTOSIS; DEATH; EXPRESSION; INHIBITORS;
   PATHWAYS; MTMR3
AB Due to changes in lifestyle, particularly changes in dietary habits, colorectal cancer (CRC) increased in recent years despite advances in treatment. Nearly one million new cases diagnosed worldwide and half a million deaths make CRC a leading cause of cancer mortality. In the present study, we aimed to investigate the role of myotubularin-related phosphatase 3 (MTMR3) in CRC cell growth via lentivirus-mediated small interfering RNA (siRNA) transduction in human colon cancer cell lines HCT116 and SW1116. The effect of MTMR3 knockdown on cell growth was evaluated by MTT, colony formation, and flow cytometry assays. The effect of MTMR3 knockdown on cell apoptosis was evaluated by flow cytometry with Annexin V/7-AAD double staining. The activation of apoptotic markers, Bad and PARP, was detected using Intracellular Signaling Array. Knockdown of MTMR3 resulted in a significant reduction in cell proliferation in both HCT116 and SW1116 cells. Moreover, knockdown of MTMR3 led to S phase cell cycle arrest. Furthermore, knockdown of MTMR3 induced cell apoptosis via phosphorylation of Bad and cleavage of PARP. These results indicate that MTMR3 may play an important role in the progression of CRC and suggest that siRNA mediated silencing of MTMR3 could be an effective tool in CRC treatment.
C1 [Zheng, Bo'an; Chai, Rui] Zhejiang Prov Peoples Hosp, Dept Colorectal Surg, Hangzhou 310014, Zhejiang, Peoples R China.
   [Yu, Xiaojun] Zhejiang Prov Peoples Hosp, Dept Surg Gastroenterol, Hangzhou 310014, Zhejiang, Peoples R China.
RP Chai, R (corresponding author), Zhejiang Prov Peoples Hosp, Dept Colorectal Surg, Hangzhou 310014, Zhejiang, Peoples R China.
EM ruichaidr@163.com
CR Aparo S, 2012, CRIT REV ONCOL HEMAT, V83, P47, DOI 10.1016/j.critrevonc.2011.08.006
   Bialik S, 2010, TRENDS BIOCHEM SCI, V35, P556, DOI 10.1016/j.tibs.2010.04.008
   Bolocan A, 2012, CHIRURGIA-BUCHAREST, V107, P555
   Chang KH, 2013, ONCOL LETT, V6, P1435, DOI 10.3892/ol.2013.1548
   Clague MJ, 2005, TRAFFIC, V6, P1063, DOI 10.1111/j.1600-0854.2005.00338.x
   Do Yoo Y, 2004, ONCOL REP, V12, P667
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758
   Gurzu S, 2013, ROM J MORPHOL EMBRYO, V54, P241
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kuo YZ, 2014, ORAL DIS, V20, pe65, DOI 10.1111/odi.12133
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Lorenzo O, 2005, J CELL SCI, V118, P2005, DOI 10.1242/jcs.02325
   Lorenzo O, 2006, J CELL SCI, V119, P2953, DOI 10.1242/jcs.03040
   Luo ZG, 2012, CANCER RES, V72, P3360, DOI 10.1158/0008-5472.CAN-12-0388
   Ma D, 2014, ANTI-CANCER DRUG, V25, P406, DOI 10.1097/CAD.0000000000000068
   Puglisi MA, 2013, WORLD J GASTROENTERO, V19, P2997, DOI 10.3748/wjg.v19.i20.2997
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Taguchi-Atarashi N, 2010, TRAFFIC, V11, P468, DOI 10.1111/j.1600-0854.2010.01034.x
   Uversky Alexey V, 2013, F1000Res, V2, P190, DOI 10.12688/f1000research.2-190.v1
   Wang YC, 2013, WORLD J GASTROENTERO, V19, P5159, DOI 10.3748/wjg.v19.i31.5159
   Wei P., 2013, J TRANSL MED, VII
   Wei SH, 2014, ONCOL LETT, V7, P635, DOI 10.3892/ol.2013.1773
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wolmarans E, 2014, CELL MOL BIOL LETT, V19, P98, DOI 10.2478/s11658-014-0183-7
NR 30
TC 8
Z9 8
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2014
AR 703804
DI 10.1155/2014/703804
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AR4PO
UT WOS:000343568900001
PM 25215329
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU New, J
   Subramaniam, D
   Ramalingam, S
   Enders, J
   Sayed, AAA
   Ponnurangam, S
   Standing, D
   Ramamoorthy, P
   O'Neil, M
   Dixon, DA
   Saha, S
   Umar, S
   Gunewardena, S
   Jensen, RA
   Thomas, SM
   Anant, S
AF New, Jacob
   Subramaniam, Dharmalingam
   Ramalingam, Satish
   Enders, Jonathan
   Sayed, Afreen Asif Ali
   Ponnurangam, Sivapriya
   Standing, David
   Ramamoorthy, Prabhu
   O'Neil, Maura
   Dixon, Dan A.
   Saha, Subhrajit
   Umar, Shahid
   Gunewardena, Sumedha
   Jensen, Roy A.
   Thomas, Sufi Mary
   Anant, Shrikant
TI Pleotropic role of RNA binding protein CELF2 in autophagy induction
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE autophagy; colorectal cancer; radiotherapy; RNA binding protein
ID CANCER CELLS; DEATH; GUIDELINES; RADIATION; ASSAYS
AB We previously reported that ionizing radiation (IR) mediates cell death through the induction of CUGBP elav-like family member 2 (CELF2), a tumor suppressor. CELF2 is an RNA binding protein that modulates mRNA stability and translation. Since IR induces autophagy, we hypothesized that CELF2 regulates autophagy-mediated colorectal cancer (CRC) cell death. For clinical relevance, we determined CELF2 levels in The Cancer Genome Atlas (TCGA). Role of CELF2 in radiation response was carried out in CRC cell lines by immunoblotting, immunofluorescence, autophagic vacuole analyses, RNA stability assay, quantitative polymerase chain reaction and electron microscopy. In vivo studies were performed in a xenograft tumor model. TCGA analyses demonstrated that compared to normal tissue, CELF2 is expressed at significantly lower levels in CRC, and is associated with better overall 5-year survival in patients receiving radiation. Mechanistically, CELF2 increased levels of critical components of the autophagy cascade including Beclin-1, ATG5, and ATG12 by modulating mRNA stability. CELF2 also increased autophagic flux in CRC. IR significantly induced autophagy in CRC which correlates with increased levels of CELF2 and autophagy associated proteins. Silencing CELF2 with siRNA, mitigated IR induced autophagy. Moreover, knockdown of CELF2 in vivo conferred tumor resistance to IR. These studies elucidate an unrecognized role for CELF2 in inducing autophagy and potentiating the effects of radiotherapy in CRC.
C1 [New, Jacob; Enders, Jonathan; Thomas, Sufi Mary] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Lawrence, KS 66045 USA.
   [New, Jacob; Thomas, Sufi Mary] Univ Kansas, Med Ctr, Dept Otolaryngol, Lawrence, KS 66045 USA.
   [Subramaniam, Dharmalingam; Ramalingam, Satish; Sayed, Afreen Asif Ali; Ponnurangam, Sivapriya; Standing, David; Ramamoorthy, Prabhu; Thomas, Sufi Mary; Anant, Shrikant] Univ Kansas, Med Ctr, Dept Canc Biol, Lawrence, KS 66045 USA.
   [O'Neil, Maura; Jensen, Roy A.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Lawrence, KS 66045 USA.
   [Dixon, Dan A.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.
   [Saha, Subhrajit] Univ Kansas, Med Ctr, Dept Radiat Oncol, Lawrence, KS 66045 USA.
   [Umar, Shahid] Univ Kansas, Med Ctr, Dept Gen Surg, Lawrence, KS 66045 USA.
   [Gunewardena, Sumedha] Univ Kansas, Med Ctr, Dept Mol Integrat Physiol, Lawrence, KS 66045 USA.
RP Thomas, SM; Anant, S (corresponding author), Dept Canc Biol, 3901 Rainbow Blvd,MS 1071, Kansas City, KS 66160 USA.; Thomas, SM; Anant, S (corresponding author), Dept Otolaryngol, 3901 Rainbow Blvd,MS 1071, Kansas City, KS 66160 USA.
EM sthomas7@kumc.edu; sanant@kumc.edu
RI Anant, Shrikant/AAF-8020-2020; SAHA, SUBHRAJIT/AAJ-9272-2021
OI SAHA, SUBHRAJIT/0000-0002-7287-073X; New, Jacob/0000-0003-0707-9324
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30CA168524,
   CA227838, CA182872, U01AI138323]; Kansas Bioscience Authority; Thomas P.
   O'Sullivan IV, and Marina O'Sullivan Family Fund; Braden's Hope
   Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA182872, P30CA168524, R01CA190291,
   R01CA227838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI138323] Funding Source:
   NIH RePORTER
FX National Cancer Institute; NIH, Grant/Award Numbers: P30CA168524,
   CA227838, CA182872, U01AI138323; Kansas Bioscience Authority; Thomas P.
   O'Sullivan IV, and Marina O'Sullivan Family Fund; Braden's Hope
   Foundation
CR Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Blech-Hermoni Y, 2013, DEV DYNAM, V242, P767, DOI 10.1002/dvdy.23959
   Chulada PC, 2000, CANCER RES, V60, P4705
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44
   Jakstaite A, 2016, LANGENBECK ARCH SURG, V401, P99, DOI 10.1007/s00423-015-1364-1
   Kai M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030310
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46
   Martinez NM, 2015, GENE DEV, V29, P2054, DOI 10.1101/gad.267245.115
   Maskey D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3130
   Mohseni N, 2009, AUTOPHAGY, V5, P329, DOI 10.4161/auto.5.3.7444
   Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1
   Natarajan G, 2008, AM J PHYSIOL-GASTR L, V294, pG1235, DOI 10.1152/ajpgi.00037.2008
   Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X
   Palumbo S, 2013, J CELL PHYSIOL, V228, P1, DOI 10.1002/jcp.24118
   Ramalingam Satish, 2012, Immunogastroenterology, V1, P27
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Stojcheva N, 2016, ONCOTARGET, V7, P12937, DOI 10.18632/oncotarget.7346
   Subramaniam D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016958
   Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421
   Wen YF, 2014, CELL REP, V7, P488, DOI 10.1016/j.celrep.2014.03.009
   Wu LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02992-7
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
NR 27
TC 8
Z9 8
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD AUG
PY 2019
VL 58
IS 8
BP 1400
EP 1409
DI 10.1002/mc.23023
PG 10
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA IH1UG
UT WOS:000474276900006
PM 31020708
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Hu, YT
   Qian, YC
   Wei, JS
   Jin, T
   Kong, XX
   Cao, HF
   Ding, KF
AF Hu, Yeting
   Qian, Yucheng
   Wei, Jingsun
   Jin, Tian
   Kong, Xiangxing
   Cao, Hongfeng
   Ding, Kefeng
TI The Disulfiram/Copper Complex Induces Autophagic Cell Death in
   Colorectal Cancer by Targeting ULK1
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE disulfiram; autophagy; ULK1; CRISPR library; colorectal cancer
ID INHIBITION; DRUG; CHEMOTHERAPY; APOPTOSIS
AB Colorectal cancer (CRC) is highly prevalent worldwide, but there has been limited development of efficient and affordable treatment. Induced autophagy has recently been recognized as a novel therapeutic strategy in cancer treatment, and disulfiram (DSF), a well-known antialcohol drug, is also found to inhibit tumor growth in various malignancies. Recently, DSF has been reported to induce excessive autophagy in oral squamous cells; however, little is known about whether it can induce autophagy and suppress proliferation in CRC. In this study, we investigate the effect of DSF with copper (DSF/Cu) on CRC both in vitro and in vivo and find that the combination significantly inhibits CRC cell viability and mainly induces autophagy instead of apoptosis. Furthermore, we use whole genome CRISPR library screening and identify a new mechanism by which DSF triggers autophagy by ULK1. Overall, these findings provide a potential CRC treatment.
C1 [Hu, Yeting; Qian, Yucheng; Wei, Jingsun; Jin, Tian; Kong, Xiangxing; Cao, Hongfeng; Ding, Kefeng] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent,Sch Med, Hangzhou, Peoples R China.
   [Ding, Kefeng] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.
RP Ding, KF (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent,Sch Med, Hangzhou, Peoples R China.; Ding, KF (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.
EM dingkefeng@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802750, 81772545, 82072624]; Key
   Technology Research and Development Program of Zhejiang Province
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81802750, 81772545, 82072624) and the Key
   Technology Research and Development Program of Zhejiang Province (No.
   2021C01180).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Cen DZ, 2004, J MED CHEM, V47, P6914, DOI 10.1021/jm049568z
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   Guo XX, 2010, CANCER LETT, V290, P104, DOI 10.1016/j.canlet.2009.09.002
   Huang JY, 2019, J NEURO-ONCOL, V142, P537, DOI 10.1007/s11060-019-03125-y
   Huang X, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-020-00295-7
   Iljin K, 2009, CLIN CANCER RES, V15, P6070, DOI 10.1158/1078-0432.CCR-09-1035
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jiang K, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-020-01816-3
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lewison E F, 1977, Prog Clin Biol Res, V12, P47
   Li YQ, 2020, CANCERS, V12, DOI 10.3390/cancers12010138
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Nechushtan H, 2015, ONCOLOGIST, V20, P366, DOI 10.1634/theoncologist.2014-0424
   Ren XY, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102122
   Said ES, 2021, EUR J PHARMACOL, V912, DOI 10.1016/j.ejphar.2021.174511
   SELLERS EM, 1981, NEW ENGL J MED, V305, P1255
   Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016
   Tardito S, 2011, J AM CHEM SOC, V133, P6235, DOI 10.1021/ja109413c
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Udristioiu A, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108892
   Wang Z, 2021, ORAL DIS, V27, P1148, DOI 10.1111/odi.13652
   Wu X, 2018, EUR J PHARMACOL, V827, P1, DOI 10.1016/j.ejphar.2018.02.039
   Xia HJ, 2021, NAT REV CANCER, V21, P281, DOI 10.1038/s41568-021-00344-2
   Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126
NR 25
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 23
PY 2021
VL 12
AR 752825
DI 10.3389/fphar.2021.752825
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XK7VN
UT WOS:000727668400001
PM 34887757
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Henidi, HA
   Al-Abd, AM
   Al-Abbasi, FA
   BinMahfouz, HA
   El-Deeb, IM
AF Henidi, Hanan A.
   Al-Abd, Ahmed M.
   Al-Abbasi, Fahad A.
   BinMahfouz, Hawazen A.
   El-Deeb, Ibrahim M.
TI Design and synthesis of novel phenylaminopyrimidines with
   antiproliferative activity against colorectal cancer
SO RSC ADVANCES
LA English
DT Article
ID SELECTIVE INHIBITOR; KINASE INHIBITORS; ACTIVATION; AUTOPHAGY; POTENT;
   ARREST
AB New phenylaminopyrimidine (PAP) derivatives have been designed and synthesised as potential tyrosine kinase inhibitors for the treatment of cancer. The synthesized compounds share a general structure and vary in the substitution pattern at position-2 of the pyridine ring. Several derivatives have demonstrated potent anticancer activities against HCT-116, HT-29 and LS-174T colorectal cancer cells. Furthermore, a number of hits showed good selectivity to Src-kinase. The cytotoxic mechanisms of these compounds were also investigated by studying their effects on cell-cycle distribution. Among all the compounds examined, compound 8b (with a terminal pyridin-3-yl moiety at the pyridine ring) showed the highest inhibitory selectivity towards src-kinase, which was coupled with cell cycle arrest, and apoptotic and autophagic interference, in colorectal cancer cells. This report introduces a novel category of PAP derivatives with promising kinase inhibitory and anticancer effects against colon cancer.
C1 [Henidi, Hanan A.; Al-Abbasi, Fahad A.; BinMahfouz, Hawazen A.] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia.
   [Al-Abd, Ahmed M.] Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, Ajman, U Arab Emirates.
   [Al-Abd, Ahmed M.] Natl Res Ctr, Div Med, Dept Pharmacol, Giza, Egypt.
   [El-Deeb, Ibrahim M.] Royal Coll Surg Ireland Med Univ Bahrain, Busaiteen, Bahrain.
   [El-Deeb, Ibrahim M.] Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia.
RP Al-Abd, AM (corresponding author), Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, Ajman, U Arab Emirates.; Al-Abd, AM (corresponding author), Natl Res Ctr, Div Med, Dept Pharmacol, Giza, Egypt.; El-Deeb, IM (corresponding author), Royal Coll Surg Ireland Med Univ Bahrain, Busaiteen, Bahrain.; El-Deeb, IM (corresponding author), Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia.
EM ahmedmalabd@pharma.asu.edu.eg; i.el-deeb@griffith.edu.au
OI Al-Abbasi, Fahad/0000-0001-5609-4913; Al-Abd, Ahmed/0000-0001-7872-4867
FU Royal College of Surgeons in Ireland-Medical University of Bahrain
   [BR00063]
FX This research was supported by the Royal College of Surgeons in
   Ireland-Medical University of Bahrain (Grant number BR00063). The
   authors are grateful for Dr Marc Devocelle and Ms Siobhan O'Flaherty for
   their assistance in characterising the synthesized compounds using
   spectroscopy facility in RCSI (Royal College of Surgeons in Ireland).
CR Alsanea N, 2015, ANN SAUDI MED, V35, P196, DOI 10.5144/0256-4947.2015.196
   Bashmail HA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30046-z
   Bazarbashi Shouki, 2017, Asian Pac J Cancer Prev, V18, P2437, DOI 10.22034/APJCP.2017.18.9.2437
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839
   DeRemer DL, 2008, CLIN THER, V30, P1956, DOI 10.1016/j.clinthera.2008.11.014
   DiPaola RS, 2002, CLIN CANCER RES, V8, P3311
   El-Deeb IM, 2008, MOLECULES, V13, P818, DOI 10.3390/molecules13040818
   El-Deeb IM, 2010, B KOREAN CHEM SOC, V31, P1848, DOI 10.5012/bkcs.2010.31.7.1848
   El-Deeb IM, 2010, BIOORGAN MED CHEM, V18, P3961, DOI 10.1016/j.bmc.2010.04.029
   El-Deeb IM, 2010, BIOORGAN MED CHEM, V18, P3860, DOI 10.1016/j.bmc.2010.04.037
   Fernandez A, 2007, J CLIN INVEST, V117, P4044, DOI 10.1172/JCI32373
   Finocchiaro G, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.43
   Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Levinson NM, 2014, NAT CHEM BIOL, V10, P127, DOI [10.1038/NCHEMBIO.1404, 10.1038/nchembio.1404]
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Niwa T, 2007, ANAL CHEM INSIGHTS, V2, P93
   Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920
   Nuijen B, 2000, INT J PHARM, V194, P261, DOI 10.1016/S0378-5173(99)00389-0
   Patterson H, 2014, CLIN EXP IMMUNOL, V176, P1, DOI 10.1111/cei.12248
   Rapecki S, 2002, J PHARMACOL EXP THER, V303, P1325, DOI 10.1124/jpet.102.038380
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037
   Troiani T, 2012, BRIT J CANCER, V106, P1648, DOI 10.1038/bjc.2012.129
   Xu XH, 2001, J BIOL CHEM, V276, P43221, DOI 10.1074/jbc.M104446200
   Xu XM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-33
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JUL 10
PY 2019
VL 9
IS 37
BP 21578
EP 21586
DI 10.1039/c9ra03359a
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA II8ZO
UT WOS:000475483100063
OA gold
DA 2022-04-25
ER

PT J
AU Ren, F
   Shu, GS
   Liu, GL
   Liu, DC
   Zhou, JP
   Yuan, LW
   Zhou, JP
AF Ren, Feng
   Shu, Guoshun
   Liu, Ganglei
   Liu, Dongcai
   Zhou, Jiapeng
   Yuan, Lianwen
   Zhou, Jianping
TI Knockdown of p62/sequestosome 1 attenuates autophagy and inhibits
   colorectal cancer cell growth
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Colorectal cancer; p62/sequestosome 1; Autophagy; Knockdown
ID HEPATOCELLULAR-CARCINOMA; SELECTIVE AUTOPHAGY; DEFICIENT MICE; P62;
   OVEREXPRESSION; TUMORIGENESIS; P62/SQSTM1; UBIQUITIN; TUMORS
AB p62/sequestosome-1 is a multifunctional adapter protein implicated in selective autophagy, cell signaling pathways, and tumorigenesis, and plays an important role at the crossroad between autophagy and cancer. But, the connection between autophagy and cancer is complex and in some cases contradictory. Human colorectal cancer tissues from patients were analyzed for expression of p62 and Microtubule-associated protein light chain 3 (LC3, an autophagosome marker) using immunostaining, western blotting, real-time PCR, and confocal microscopy. To study the effects of p62 on autophagy and cell growth, shRNA for p62 was applied and cell growth curve was monitored in human colorectal cancer cell. In vivo experiments were done using the mouse xenograft model. We showed that up-regulated expression of p62 and LC3 in colorectal cancer tissues. We also demonstrated that specifically knockdown the expression of p62 showed significantly inhibitory effects not only on autophagy activation, but also on tumor growth both in vitro and xenograft tumors model. The ectopic overexpression of p62 and autophagy activation contributes to colorectal tumorigenesis. p62 and autophagy will be therapy targets for the treatment of colorectal cancer.
C1 [Ren, Feng; Shu, Guoshun; Liu, Ganglei; Liu, Dongcai; Zhou, Jiapeng; Yuan, Lianwen; Zhou, Jianping] Cent S Univ, Xiangya Hosp 2, Dept Geriatr Surg, Changsha 410011, Hunan, Peoples R China.
RP Zhou, JP (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Geriatr Surg, 139 RenMin Rd, Changsha 410011, Hunan, Peoples R China.
EM jpz2013@126.com
FU Hunan Provincial Science and Technology Department [2013TT2022]
FX This work was supported by Grants No. 2013TT2022 from Hunan Provincial
   Science and Technology Department.
CR Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Myung Park J, 2012, CANCER BIOL THER, V14, P100
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Stumptner C, 1999, AM J PATHOL, V154, P1701, DOI 10.1016/S0002-9440(10)65426-0
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Viiri J, 2010, MOL VIS, V16, P1399
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zheng QW, 2011, CIRC RES, V109, P296, DOI 10.1161/CIRCRESAHA.111.244707
NR 26
TC 38
Z9 39
U1 4
U2 29
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2014
VL 385
IS 1-2
BP 95
EP 102
DI 10.1007/s11010-013-1818-0
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 264EG
UT WOS:000327859200011
PM 24065390
DA 2022-04-25
ER

PT J
AU Talero, E
   Garcia-Maurino, S
   Avila-Roman, J
   Rodriguez-Luna, A
   Alcaide, A
   Motilva, V
AF Talero, Elena
   Garcia-Maurino, Sofia
   Avila-Roman, Javier
   Rodriguez-Luna, Azahara
   Alcaide, Antonio
   Motilva, Virginia
TI Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and
   Cancer
SO MARINE DRUGS
LA English
DT Review
DE chronic inflammation; colon cancer; skin cancer; chemoprevention;
   microalgae
ID NF-KAPPA-B; POLYUNSATURATED FATTY-ACIDS; INDUCED COLON CARCINOGENESIS;
   INDUCED SKIN CARCINOGENESIS; ACTIVATED PROTEIN-KINASE; SQUAMOUS-CELL
   CARCINOMAS; INDUCED OXIDATIVE DAMAGE; CAROTENE-RICH ALGA; BETA-CAROTENE;
   EICOSAPENTAENOIC ACID
AB The risk of onset of cancer is influenced by poorly controlled chronic inflammatory processes. Inflammatory diseases related to cancer development include inflammatory bowel disease, which can lead to colon cancer, or actinic keratosis, associated with chronic exposure to ultraviolet light, which can progress to squamous cell carcinoma. Chronic inflammatory states expose these patients to a number of signals with tumorigenic effects, including nuclear factor kappa B (NF-B) and mitogen-activated protein kinases (MAPK) activation, pro-inflammatory cytokines and prostaglandins release and ROS production. In addition, the participation of inflammasomes, autophagy and sirtuins has been demonstrated in pathological processes such as inflammation and cancer. Chemoprevention consists in the use of drugs, vitamins, or nutritional supplements to reduce the risk of developing or having a recurrence of cancer. Numerous in vitro and animal studies have established the potential colon and skin cancer chemopreventive properties of substances from marine environment, including microalgae species and their products (carotenoids, fatty acids, glycolipids, polysaccharides and proteins). This review summarizes the main mechanisms of actions of these compounds in the chemoprevention of these cancers. These actions include suppression of cell proliferation, induction of apoptosis, stimulation of antimetastatic and antiangiogenic responses and increased antioxidant and anti-inflammatory activity.
C1 [Talero, Elena; Avila-Roman, Javier; Rodriguez-Luna, Azahara; Alcaide, Antonio; Motilva, Virginia] Univ Seville, Fac Pharm, Dept Pharmacol, E-41012 Seville, Spain.
   [Garcia-Maurino, Sofia] Univ Seville, Dept Plant Biol & Ecol, Fac Biol, E-41012 Seville, Spain.
RP Talero, E (corresponding author), Univ Seville, Fac Pharm, Dept Pharmacol, E-41012 Seville, Spain.
EM etalero@us.es; sgarma@us.es; javieravila@us.es; arodriguez53@us.es;
   aalcaide@us.es; motilva@us.es
RI Rodriguez-Luna, Azahara/AAS-2533-2021; Talero, Elena/I-2613-2015;
   Avila-Roman, Javier/B-5337-2017; García-Mauriño, Sofía/E-6707-2010
OI Rodriguez-Luna, Azahara/0000-0002-1529-7674; García-Mauriño,
   Sofía/0000-0002-7698-5112; Avila-Roman, Francisco
   Javier/0000-0001-9766-8178
FU Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de
   AndaluciaJunta de Andalucia [P12-AGR-430]
FX This work was supported by Consejeria de Economia, Innovacion, Ciencia y
   Empleo, Junta de Andalucia (grant number P12-AGR-430).
CR Abd El-Baky HH, 2010, J SCI FOOD AGR, V90, P299, DOI 10.1002/jsfa.3815
   Actis Giovanni C., 2014, Inflammation & Allergy Drug Targets, V13, P217
   Adarme-Vega TC, 2014, MAR DRUGS, V12, P3381, DOI 10.3390/md12063381
   Aherne GW, 1996, CANCER CHEMOTH PHARM, V38, P225, DOI 10.1007/s002800050475
   Ahmad I, 2015, PLANT BIOTECHNOL J, V13, P540, DOI 10.1111/pbi.12278
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Andrianasolo EH, 2007, PURE APPL CHEM, V79, P593, DOI 10.1351/pac200779040593
   Aranda E, 2012, CURR MOL MED, V12, P50, DOI 10.2174/156652412798376099
   Astner S, 2007, SKIN PHARMACOL PHYS, V20, P283, DOI 10.1159/000107576
   Augustsson K, 2003, CANCER EPIDEM BIOMAR, V12, P64
   Avila-Roman J, 2014, BRIT J NUTR, V112, P1055, DOI 10.1017/S0007114514001895
   Bae SY, 2006, INT IMMUNOPHARMACOL, V6, P473, DOI 10.1016/j.intimp.2005.09.009
   Balachandran P, 2006, INT IMMUNOPHARMACOL, V6, P1808, DOI 10.1016/j.intimp.2006.08.001
   Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005
   Bandaranayake WM, 1998, NAT PROD REP, V15, P159
   Banskota AH, 2014, PHYTOCHEMISTRY, V101, P101, DOI 10.1016/j.phytochem.2014.02.004
   Banskota AH, 2013, NAT PROD RES, V27, P1084, DOI 10.1080/14786419.2012.717285
   Barcelos RCS, 2015, J DERMATOL SCI, V79, P298, DOI 10.1016/j.jdermsci.2015.06.015
   Baron JA, 2010, CANCER PREV RES, V3, P573, DOI 10.1158/1940-6207.CAPR-10-0050
   Barros MP, 2014, NUTRIENTS, V6, P1293, DOI 10.3390/nu6031293
   Battie C, 2014, EXP DERMATOL, V23, P7, DOI 10.1111/exd.12388
   Begum H, 2016, CRIT REV FOOD SCI, V56, P2209, DOI 10.1080/10408398.2013.764841
   BENAMOTZ A, 1988, BRIT J NUTR, V59, P443, DOI 10.1079/BJN19880053
   Benavente CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042276
   Bernardo PH, 2004, J MED CHEM, V47, P4958, DOI 10.1021/jm049625o
   Berwick Marianne, 2014, Adv Exp Med Biol, V810, P342
   Besaratinia A, 2007, P NATL ACAD SCI USA, V104, P5953, DOI 10.1073/pnas.0610534104
   Bhupathiraju SN, 2013, AM J CLIN NUTR, V98, P1514, DOI 10.3945/ajcn.113.066381
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bian QN, 2012, ADV EXP MED BIOL, V723, P43, DOI 10.1007/978-1-4614-0631-0_7
   Bird P.R., 2000, TOXICOL LETT, V112-113, P295
   BLACK HS, 1992, PHOTOCHEM PHOTOBIOL, V56, P195, DOI 10.1111/j.1751-1097.1992.tb02147.x
   Campelo APBS, 2015, ACTA CIR BRAS, V30, P430, DOI 10.1590/S0102-865020150060000009
   Bosco N, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-81
   Brown GT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090776
   Brown M.R., 2002, ADV AQUACULTURE NUTR
   BROWN MR, 1992, J APPL PHYCOL, V4, P205, DOI 10.1007/BF02161206
   Bruno A, 2005, EUR J PHARMACOL, V524, P159, DOI 10.1016/j.ejphar.2005.09.023
   Camera E, 2009, EXP DERMATOL, V18, P222, DOI 10.1111/j.1600-0625.2008.00790.x
   Cansell MS, 2007, INT J PHARMACEUT, V343, P277, DOI 10.1016/j.ijpharm.2007.04.014
   Cao C, 2009, J CELL MOL MED, V13, P3632, DOI 10.1111/j.1582-4934.2008.00453.x
   Carballo-Cardenas EC, 2003, BIOMOL ENG, V20, P139, DOI 10.1016/S1389-0344(03)00040-6
   Cardus A, 2013, CARDIOVASC RES, V97, P571, DOI 10.1093/cvr/cvs352
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Carreto JI, 2011, MAR DRUGS, V9, P387, DOI 10.3390/md9030387
   Cazzonelli CI, 2011, FUNCT PLANT BIOL, V38, P833, DOI 10.1071/FP11192
   Cha KH, 2008, J AGR FOOD CHEM, V56, P10521, DOI 10.1021/jf802111x
   Cha TS, 2011, J MICROBIOL METH, V84, P430, DOI 10.1016/j.mimet.2011.01.005
   Chaganty S, 2004, J NAT PROD, V67, P1403, DOI 10.1021/np0499665
   Chaiter Y, 2009, CANCER CAUSE CONTROL, V20, P1327, DOI 10.1007/s10552-009-9354-7
   Challouf R, 2011, BRAZ ARCH BIOL TECHN, V54, P831, DOI 10.1590/S1516-89132011000400024
   Chen AC, 2013, PATHOLOGY, V45, P331, DOI 10.1097/PAT.0b013e32835f515c
   Chen CR, 2012, BIORESOURCE TECHNOL, V104, P828, DOI 10.1016/j.biortech.2011.11.083
   Chen F, 2005, J CHROMATOGR A, V1064, P183, DOI 10.1016/j.chroma.2004.12.065
   Chen GY, 2011, GASTROENTEROLOGY, V141, P1986, DOI 10.1053/j.gastro.2011.10.002
   Chene G, 2007, BBA-MOL CELL BIOL L, V1771, P576, DOI 10.1016/j.bbalip.2007.02.014
   Cheng JL, 2003, CANCER LETT, V193, P17, DOI 10.1016/S0304383502007176
   Chetty P, 2015, DERMATOLOGY THER, V5, P19, DOI 10.1007/s13555-015-0070-9
   Chinembiri TN, 2014, MOLECULES, V19, P11679, DOI 10.3390/molecules190811679
   Cho S, 2010, DERMATOLOGY, V221, P160, DOI 10.1159/000305548
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi SK, 2008, J MICROBIOL BIOTECHN, V18, P1990, DOI 10.4014/jmb.0800.489
   Choi SR, 2014, EXP DERMATOL, V23, P718, DOI 10.1111/exd.12515
   Choi SY, 2006, BIOFACTORS, V27, P137, DOI 10.1002/biof.5520270112
   Chun KS, 2011, MOL CARCINOGEN, V50, P439, DOI 10.1002/mc.20728
   Clarens AF, 2010, ENVIRON SCI TECHNOL, V44, P1813, DOI 10.1021/es902838n
   Colombo D, 2000, CANCER LETT, V161, P201, DOI 10.1016/S0304-3835(00)00610-8
   Colombo D, 2013, CARBOHYD RES, V373, P64, DOI 10.1016/j.carres.2013.03.007
   Colombo D, 2011, EUR J MED CHEM, V46, P1827, DOI 10.1016/j.ejmech.2011.02.043
   Conde FR, 2004, PHOTOCH PHOTOBIO SCI, V3, P960, DOI 10.1039/b405782a
   Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757
   Cordero BF, 2011, MAR DRUGS, V9, P1607, DOI 10.3390/md9091607
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j
   Crupi Pasquale, 2013, Rapid Commun Mass Spectrom, V27, P1027, DOI 10.1002/rcm.6531
   Das UN, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-19
   Davidi L, 2014, PLANT PHYSIOL, V164, P2139, DOI 10.1104/pp.113.235119
   Davis WJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00024
   Raposo MFD, 2015, MAR DRUGS, V13, P2967, DOI 10.3390/md13052967
   de los Reyes C, 2014, PHYTOCHEMISTRY, V102, P152, DOI 10.1016/j.phytochem.2014.03.011
   Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Pham DNT, 2013, AM J CLIN NUTR, V98, P413, DOI 10.3945/ajcn.113.060996
   Divya SP, 2015, TOXICOL APPL PHARM, V284, P92, DOI 10.1016/j.taap.2015.02.003
   Dominguez A, 2005, AQUACULTURE, V250, P424, DOI 10.1016/j.aquaculture.2005.08.005
   Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385
   Drexler SK, 2012, P NATL ACAD SCI USA, V109, P18384, DOI 10.1073/pnas.1209171109
   Etchegaray JP, 2013, CURR TOP MED CHEM, V13, P2991, DOI 10.2174/15680266113136660213
   Feagan BG, 2008, JAMA-J AM MED ASSOC, V299, P1690, DOI 10.1001/jama.299.14.1690
   Feingold KR, 2007, J LIPID RES, V48, P2531, DOI 10.1194/jlr.R700013-JLR200
   Fennell BJ, 2003, J ANTIMICROB CHEMOTH, V51, P833, DOI 10.1093/jac/dkg151
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   FISCHER MA, 1991, PHOTOCHEM PHOTOBIOL, V54, P381, DOI 10.1111/j.1751-1097.1991.tb02031.x
   Foster JG, 2012, PHARMACOL REV, V64, P1027, DOI 10.1124/pr.110.004051
   Franz AK, 2013, ACS CHEM BIOL, V8, P1053, DOI 10.1021/cb300573r
   Fu WQ, 2013, APPL MICROBIOL BIOT, V97, P2395, DOI 10.1007/s00253-012-4502-5
   Fujita F, 2000, Gan To Kagaku Ryoho, V27, P451
   Gagez A.L., 2012, CURR BIOACT COMPD, V8, P109, DOI [10.1016/j.nbt.2015.03.016., DOI 10.1016/J.NBT.2015.03.016]
   Garcia-Maurino S, 2012, CURR PHARM DESIGN, V18, P3853, DOI 10.2174/138161212802083653
   Gasparoto TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107170
   Geerling BJ, 2000, EUR J CLIN NUTR, V54, P514, DOI 10.1038/sj.ejcn.1601049
   Gehin A, 2006, ENVIRON TOXICOL PHAR, V22, P27, DOI 10.1016/j.etap.2005.11.003
   GENSLER HL, 1991, NUTR CANCER, V15, P97, DOI 10.1080/01635589109514117
   Giampieri F, 2014, MOLECULES, V19, P7798, DOI 10.3390/molecules19067798
   Goh L P Jr, 2009, Malays J Nutr, V15, P77
   Goldenberg Gary, 2014, J Clin Aesthet Dermatol, V7, P28
   Gonzalez S, 2003, J INVEST DERMATOL, V121, P399, DOI 10.1046/j.1523-1747.2003.12355.x
   Gordon Randy, 2013, Semin Oncol Nurs, V29, P160, DOI 10.1016/j.soncn.2013.06.002
   Gravitz L., 2011, NATURE, V471, P5
   Grether-Beck S, 2014, PHOTODERMATOL PHOTO, V30, P167, DOI 10.1111/phpp.12111
   Grune T, 2010, J NUTR, V140, p2268S, DOI 10.3945/jn.109.119024
   Guedes AC, 2011, MAR DRUGS, V9, P625, DOI 10.3390/md9040625
   Gunasekera SP, 2008, J NAT PROD, V71, P887, DOI 10.1021/np0706769
   Gupta NK, 2012, ENVIRON TOXICOL PHAR, V34, P941, DOI 10.1016/j.etap.2012.08.001
   Gustafsson A, 2010, INT J ONCOL, V36, P469, DOI 10.3892/ijo_00000521
   Gutierrez M, 2008, J NAT PROD, V71, P1099, DOI 10.1021/np800121a
   Guzman S, 2003, PHYTOTHER RES, V17, P665, DOI 10.1002/ptr.1227
   Habeeb BS, 2011, CANCER SCI, V102, P999, DOI 10.1111/j.1349-7006.2011.01902.x
   Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Hama S, 2012, J PHARM SCI-US, V101, P2909, DOI 10.1002/jps.23216
   Han JW, 2015, INT J MOL SCI, V16, P8102, DOI 10.3390/ijms16048102
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Hartog A, 2015, J NUTR BIOCHEM, V26, P227, DOI 10.1016/j.jnutbio.2014.10.011
   Hatae N, 2014, MED CHEM RES, V23, P4956, DOI 10.1007/s00044-014-1061-6
   Hayashi O., 2004, Nutritional Sciences, V7, P31
   Hengstermann S, 2008, CLIN NUTR, V27, P571, DOI 10.1016/j.clnu.2008.01.007
   Hensler S, 2013, CANCER J, V19, P517, DOI 10.1097/PPO.0000000000000010
   Heo SJ, 2009, TOXICOL IN VITRO, V23, P1123, DOI 10.1016/j.tiv.2009.05.013
   Heo SJ, 2009, J PHOTOCH PHOTOBIO B, V95, P101, DOI 10.1016/j.jphotobiol.2008.11.011
   Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Horvath G, 2015, J MOL NEUROSCI, V56, P113, DOI 10.1007/s12031-014-0472-7
   Hosokawa M, 2004, BBA-GEN SUBJECTS, V1675, P113, DOI 10.1016/j.bbagen.2004.08.012
   Hossain Z, 2005, IN VITRO CELL DEV-AN, V41, P154, DOI 10.1290/0409058.1
   Hu B, 2011, CELL CYCLE, V10, P1936, DOI 10.4161/cc.10.12.16008
   Hwang E, 2014, MAR BIOTECHNOL, V16, P361, DOI 10.1007/s10126-013-9554-8
   Hwang H, 2006, INT J CANCER, V119, P2742, DOI 10.1002/ijc.22147
   Ibrahim A, 2011, CLIN NUTR, V30, P678, DOI 10.1016/j.clnu.2011.05.002
   Irigoien X, 2004, NATURE, V429, P863, DOI 10.1038/nature02593
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Ivan ALM, 2014, J PHOTOCH PHOTOBIO B, V138, P124, DOI 10.1016/j.jphotobiol.2014.05.010
   Jahns P, 2012, BBA-BIOENERGETICS, V1817, P182, DOI 10.1016/j.bbabio.2011.04.012
   Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685
   Jansen Rick J, 2013, J Gastrointest Cancer, V44, P152, DOI 10.1007/s12029-012-9441-y
   Jeon BK, 2015, ARCH PHARM RES, V38, P1552, DOI 10.1007/s12272-014-0482-6
   Jiang Q, 2003, FASEB J, V17, P816, DOI 10.1096/fj.02-0877com
   Jiang Q, 2002, FREE RADICAL BIO MED, V33, P1534, DOI 10.1016/S0891-5849(02)01091-2
   Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097
   Jin E, 2003, J MICROBIOL BIOTECHN, V13, P165
   Jin XJ, 2010, J KOREAN MED SCI, V25, P930, DOI 10.3346/jkms.2010.25.6.930
   Jo WS, 2010, FOOD SCI BIOTECHNOL, V19, P1519, DOI 10.1007/s10068-010-0216-6
   JOHNSON EA, 1991, CRIT REV BIOTECHNOL, V11, P297, DOI 10.3109/07388559109040622
   Jowett SL, 2004, GUT, V53, P1479, DOI 10.1136/gut.2003.024828
   Jung S, 2013, CANCER CAUSE CONTROL, V24, P705, DOI 10.1007/s10552-013-0151-y
   Jusoh M, 2015, PHYTOCHEMISTRY, V111, P65, DOI 10.1016/j.phytochem.2014.12.022
   JYONOUCHI H, 1995, J NUTR, V125, P2483
   Kabat GC, 2012, EUR J CLIN NUTR, V66, P549, DOI 10.1038/ejcn.2011.207
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kagan ML, 2015, FOOD FUNCT, V6, P186, DOI 10.1039/c4fo00591k
   Kanai T, 2013, CURR DRUG TARGETS, V14, P1392, DOI 10.2174/13894501113149990006
   Kang HS, 2012, PHYTOCHEMISTRY, V79, P109, DOI 10.1016/j.phytochem.2012.03.005
   Kang HS, 2011, J NAT PROD, V74, P1597, DOI 10.1021/np2002226
   Kang KH, 2013, CURR PROTEIN PEPT SC, V14, P212
   Kansu E, 2014, HEMATOLOGY, V19, P433, DOI 10.1179/1024533214Z.000000000322
   Karahan B, 2015, INT J CLIN EXP PATHO, V8, P4044
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kaskel P, 2015, J EUR ACAD DERMATOL, V29, P134, DOI 10.1111/jdv.12488
   Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737
   Kaulmann A, 2012, BRIT J NUTR, V108, P963, DOI 10.1017/S0007114511006349
   Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052
   Kawee-ai A, 2014, NAT PROD COMMUN, V9, P921
   Khanavi M, 2012, PHARMACOGN MAG, V8, P60, DOI 10.4103/0973-1296.93327
   Kilian O, 2011, P NATL ACAD SCI USA, V108, P21265, DOI 10.1073/pnas.1105861108
   Kim HH, 2005, J LIPID RES, V46, P1712, DOI 10.1194/jlr.M500105-JLR200
   Kim JA, 2013, CURR PROTEIN PEPT SC, V14, P177
   Kim MS, 2013, PHOTOCHEM PHOTOBIOL, V89, P911, DOI 10.1111/php.12061
   Kim SR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.460
   Kim S, 2014, J PHOTOCH PHOTOBIO B, V141, P301, DOI 10.1016/j.jphotobiol.2014.10.012
   Kim SB, 2015, INT J MOL MED, V35, P1411, DOI 10.3892/ijmm.2015.2120
   Kim W, 2010, PROG LIPID RES, V49, P250, DOI 10.1016/j.plipres.2010.01.002
   Kim Y, 2011, J NUTR SCI VITAMINOL, V57, P216, DOI 10.3177/jnsv.57.216
   Kobayashi M, 1997, JPN J CANCER RES, V88, P316, DOI 10.1111/j.1349-7006.1997.tb00383.x
   Koh SJ, 2014, J GASTROEN HEPATOL, V29, P502, DOI 10.1111/jgh.12435
   Kriegl L, 2012, ONCOTARGET, V3, P1182
   Krishnaswamy R, 2010, FREE RADICAL BIO MED, V49, P50, DOI 10.1016/j.freeradbiomed.2010.03.016
   Kropotova ES, 2014, PATHOL ONCOL RES, V20, P707, DOI 10.1007/s12253-014-9751-4
   Kruk J, 2014, ASIAN PAC J CANCER P, V15, P561, DOI 10.7314/APJCP.2014.15.2.561
   Kumar SR, 2013, MAR DRUGS, V11, P5130, DOI 10.3390/md11125130
   Kune G.A., 1992, NUTR CANC, V18, P233
   Kunz M, 2014, EUR J CELL BIOL, V93, P1, DOI 10.1016/j.ejcb.2013.12.002
   Kupcinskas L, 2008, PHYTOMEDICINE, V15, P391, DOI 10.1016/j.phymed.2008.04.004
   Kwan JC, 2010, J NAT PROD, V73, P463, DOI 10.1021/np900614n
   Lagarde D, 2000, APPL ENVIRON MICROB, V66, P64, DOI 10.1128/AEM.66.1.64-72.2000
   Lavy A, 2003, INFLAMM BOWEL DIS, V9, P372, DOI 10.1097/00054725-200311000-00005
   Lea MA, 2010, FUTURE ONCOL, V6, P993, DOI 10.2217/FON.10.53
   Leao PN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069562
   Lee I, 2015, BIORESOURCE TECHNOL, V191, P1, DOI 10.1016/j.biortech.2015.04.124
   Lee J, 2000, P SOC EXP BIOL MED, V223, P170, DOI 10.1046/j.1525-1373.2000.22323.x
   LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903
   Leenders M, 2014, INT J CANCER, V135, P2930, DOI 10.1002/ijc.28938
   Li B, 2006, BIOTECHNOL APPL BIOC, V43, P155, DOI 10.1042/BA20050142
   Lin JH, 2015, BIORESOURCE TECHNOL, V184, P421, DOI 10.1016/j.biortech.2014.09.099
   Lin JR, 2014, CANCER BIOTHER RADIO, V29, P257, DOI 10.1089/cbr.2014.1647
   Lin Y, 2014, J ASIAN NAT PROD RES, V16, P800, DOI 10.1080/10286020.2014.929573
   Linington RG, 2008, J NAT PROD, V71, P22, DOI 10.1021/np070280x
   Liu H, 2013, CHEM-EUR J, V19, P6774, DOI 10.1002/chem.201203667
   Liu J, 2014, MAR DRUGS, V12, P3487, DOI 10.3390/md12063487
   Liu ZG, 2015, FOOD CHEM TOXICOL, V82, P12, DOI 10.1016/j.fct.2015.04.025
   Llewellyn CA, 2010, MAR DRUGS, V8, P1273, DOI 10.3390/md8041273
   Lopez-Camarillo C, 2012, INT J MOL SCI, V13, P142, DOI 10.3390/ijms13010142
   Lopez-Lazaro M, 2009, ANTI-CANCER AGENT ME, V9, P517, DOI 10.2174/187152009788451806
   Lopez-Urrutia A, 2006, P NATL ACAD SCI USA, V103, P8739, DOI 10.1073/pnas.0601137103
   LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655
   Lou YR, 2011, CARCINOGENESIS, V32, P1078, DOI 10.1093/carcin/bgr074
   Lu MS, 2015, EUR J NUTR, V54, P619, DOI 10.1007/s00394-014-0743-7
   MacDougall KM, 2011, ANAL BIOANAL CHEM, V401, P2609, DOI 10.1007/s00216-011-5376-6
   Maeda H, 2005, BIOCHEM BIOPH RES CO, V332, P392, DOI 10.1016/j.bbrc.2005.05.002
   Maeda N, 2005, J NUTR BIOCHEM, V16, P121, DOI 10.1016/j.jnutbio.2004.08.005
   Maeda N, 2009, FOOD CHEM, V112, P205, DOI 10.1016/j.foodchem.2008.05.059
   Maeda N, 2008, LIPIDS, V43, P741, DOI 10.1007/s11745-008-3202-5
   Maeda N, 2013, EXP THER MED, V5, P17, DOI 10.3892/etm.2012.792
   Campos PMBGM, 2012, EUR J PHARM BIOPHARM, V82, P580, DOI 10.1016/j.ejpb.2012.08.009
   Malhotra P, 2013, TUMOR BIOL, V34, P1901, DOI 10.1007/s13277-013-0734-y
   Mancebo Silvia E., 2014, Reviews on Environmental Health, V29, P265, DOI 10.1515/reveh-2014-0041
   Mannisto S, 2007, AM J EPIDEMIOL, V165, P246, DOI 10.1093/aje/kwk009
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Maoka T, 2012, MAR DRUGS, V10, P1391, DOI 10.3390/md10061391
   Markou G, 2015, BIORESOURCE TECHNOL, V196, P459, DOI 10.1016/j.biortech.2015.08.007
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Matsui MS, 2003, APPL BIOCHEM BIOTECH, V104, P13, DOI 10.1385/ABAB:104:1:13
   Matsumoto Y, 2000, TRANSPLANT P, V32, P2051, DOI 10.1016/S0041-1345(00)01554-2
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   McCarty Mark F, 2015, Mo Med, V112, P72
   McCusker M, 2014, EUR J CANCER, V50, P774, DOI 10.1016/j.ejca.2013.12.013
   McCusker MM, 2010, CLIN DERMATOL, V28, P440, DOI 10.1016/j.clindermatol.2010.03.020
   McDaniel JC, 2011, WOUND REPAIR REGEN, V19, P189, DOI 10.1111/j.1524-475X.2010.00659.x
   Meireles LA, 2003, J AGR FOOD CHEM, V51, P2237, DOI 10.1021/jf025952y
   Mendiola JA, 2008, J SUPERCRIT FLUID, V43, P484, DOI 10.1016/j.supflu.2007.07.021
   MERCURIO AM, 1984, J EXP MED, V160, P1114, DOI 10.1084/jem.160.4.1114
   Miao XP, 2015, ASIAN PAC J TROP MED, V8, P147, DOI 10.1016/S1995-7645(14)60306-0
   Ming M, 2015, ONCOGENE, V34, P281, DOI 10.1038/onc.2013.583
   Ming M, 2014, EXP DERMATOL, V23, P207, DOI 10.1111/exd.12323
   Ming ME, 2011, J INVEST DERMATOL, V131, P1401, DOI 10.1038/jid.2011.83
   Mizushina Y, 2012, ONCOL REP, V28, P821, DOI 10.3892/or.2012.1893
   Mobraten K., 2014, J RECEPT SIG TRANSD, V24, P1
   Mobraten K, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-101
   Montaser R, 2011, PHYTOCHEMISTRY, V72, P2068, DOI 10.1016/j.phytochem.2011.07.014
   Mooberry SL, 2003, INT J CANCER, V104, P512, DOI 10.1002/ijc.10982
   Motilva V, 2011, J PINEAL RES, V51, P44, DOI 10.1111/j.1600-079X.2011.00915.x
   Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414
   Murtaugh MA, 2005, CANCER EPIDEM BIOMAR, V14, P1224, DOI 10.1158/1055-9965.EPI-04-0681
   Nagendraprabhu P, 2011, INVEST NEW DRUG, V29, P207, DOI 10.1007/s10637-009-9342-5
   Nauroth JM, 2010, LIPIDS, V45, P375, DOI 10.1007/s11745-010-3406-3
   Nidhi B, 2015, FOOD FUNCT, V6, P450, DOI [10.1039/c4fo00606b, 10.1039/C4FO00606B]
   Nindl I, 2007, BRIT J DERMATOL, V156, P34, DOI 10.1111/j.1365-2133.2007.07857.x
   Nishio S, 2008, CANCER SCI, V99, P113, DOI 10.1111/j.1349-7006.2007.00636.x
   Nomoto K, 1983, Gan To Kagaku Ryoho, V10, P781
   Norsker NH, 2011, BIOTECHNOL ADV, V29, P24, DOI 10.1016/j.biotechadv.2010.08.005
   O'Connor PM, 2010, INFLAMM BOWEL DIS, V16, P1411, DOI 10.1002/ibd.21217
   Obata T, 1999, CLIN EXP ALLERGY, V29, P1129
   Okuyama Y, 2014, INT J CLIN ONCOL, V19, P87, DOI 10.1007/s10147-013-0520-2
   Pal A, 2013, NUTR CANCER, V65, P78, DOI 10.1080/01635581.2013.785005
   Pal HC, 2015, PHOTOCHEM PHOTOBIOL, V91, P225, DOI 10.1111/php.12337
   Palombo P, 2007, SKIN PHARMACOL PHYS, V20, P199, DOI 10.1159/000101807
   Palozza P, 2005, J NUTR, V135, P129, DOI 10.1093/jn/135.1.129
   Palozza P, 2009, CANCER LETT, V283, P108, DOI 10.1016/j.canlet.2009.03.031
   Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18
   Parrish CC, 1998, PHYTOCHEMISTRY, V47, P783, DOI 10.1016/S0031-9422(97)00661-4
   PASCAL RR, 1994, HUM PATHOL, V25, P1160, DOI 10.1016/0046-8177(94)90032-9
   Pasquet V, 2011, MAR DRUGS, V9, P819, DOI 10.3390/md9050819
   Peng J, 2011, MAR DRUGS, V9, P1806, DOI 10.3390/md9101806
   Pereira AR, 2012, CHEMBIOCHEM, V13, P810, DOI 10.1002/cbic.201200007
   Pilkington SM, 2014, MOL NUTR FOOD RES, V58, P580, DOI 10.1002/mnfr.201300405
   Pilkington SM, 2013, AM J CLIN NUTR, V97, P646, DOI 10.3945/ajcn.112.049494
   Piplani H, 2013, BBA-GEN SUBJECTS, V1830, P5142, DOI 10.1016/j.bbagen.2013.07.011
   Piplani H, 2012, EUR J CANCER PREV, V21, P511, DOI 10.1097/CEJ.0b013e328351c69d
   Plaza M, 2010, J PHARMACEUT BIOMED, V51, P450, DOI 10.1016/j.jpba.2009.03.016
   Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175
   Pongcharoen S, 2013, BIOL RES, V46, P39, DOI 10.4067/S0716-97602013000100006
   Prabhu PN, 2009, FUND CLIN PHARMACOL, V23, P225, DOI 10.1111/j.1472-8206.2009.00669.x
   Prasad R, 2014, INT J ONCOL, V44, P1199, DOI 10.3892/ijo.2014.2275
   Prokopiou EM, 2010, MOL MED REP, V3, P309, DOI 10.3892/mmr_00000256
   Proksch P, 2002, APPL MICROBIOL BIOT, V59, P125, DOI 10.1007/s00253-002-1006-8
   Pugh N, 2001, PLANTA MED, V67, P737, DOI 10.1055/s-2001-18358
   Raff JD, 2009, P NATL ACAD SCI USA, V106, P13647, DOI 10.1073/pnas.0904195106
   Rahman S, 2008, CHEM-BIOL INTERACT, V172, P195, DOI 10.1016/j.cbi.2007.11.017
   Raju J, 2005, INT J CANCER, V113, P798, DOI 10.1002/ijc.20640
   Ramos Ana A., 2011, Algae, V26, P3, DOI 10.4490/algae.2011.26.1.003
   Ramos-e-Silva M, 2012, CLIN DERMATOL, V30, P277, DOI 10.1016/j.clindermatol.2011.08.025
   Rao AR, 2013, J AGR FOOD CHEM, V61, P3842, DOI 10.1021/jf304609j
   Rao SK, 2010, J BIOL CHEM, V285, P32512, DOI 10.1074/jbc.M110.150490
   Rasmussen RS, 2007, ADV FOOD NUTR RES, V52, P237, DOI 10.1016/S1043-4526(06)52005-4
   Rees D, 2006, AM J CLIN NUTR, V83, P331
   Reynoso-Camacho R, 2011, NUTR CANCER, V63, P39, DOI 10.1080/01635581.2010.516477
   Rhodes LE, 2003, CARCINOGENESIS, V24, P919, DOI 10.1093/carcin/bgg038
   RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0
   Rizwan M, 2011, BRIT J DERMATOL, V164, P154, DOI 10.1111/j.1365-2133.2010.10057.x
   Romay C, 2003, CURR PROTEIN PEPT SC, V4, P207, DOI 10.2174/1389203033487216
   Rumi G, 2000, J PHYSIOL-PARIS, V94, P159, DOI 10.1016/S0928-4257(00)00159-5
   Ryu J, 2014, INT J MOL MED, V34, P796, DOI 10.3892/ijmm.2014.1815
   Sadovskaya I, 2014, CARBOHYD POLYM, V111, P139, DOI 10.1016/j.carbpol.2014.04.077
   Saini MK, 2012, NUTR CANCER, V64, P409, DOI 10.1080/01635581.2012.655402
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199
   Salvador-Reyes LA, 2015, J NAT PROD, V78, P486, DOI 10.1021/np500931q
   Samarakoon K, 2012, FOOD RES INT, V48, P948, DOI 10.1016/j.foodres.2012.03.013
   Scrivo R, 2011, AUTOIMMUN REV, V10, P369, DOI 10.1016/j.autrev.2010.12.006
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Serini S, 2012, CURR ALZHEIMER RES, V9, P913, DOI 10.2174/156720512803251147
   Serravallo M, 2013, ARCH DERMATOL RES, V305, P269, DOI 10.1007/s00403-013-1320-2
   Shahbakhti H, 2004, PHOTOCHEM PHOTOBIOL, V80, P231, DOI 10.1562/2004-01-27-RA-066.1
   Sharma K, 2015, BIOTECHNOL BIOENG, V112, P1243, DOI 10.1002/bit.25544
   Shi XM, 2002, BIOTECHNOL PROGR, V18, P723, DOI 10.1021/bp0101987
   Shimoda H, 2010, J PHARM PHARMACOL, V62, P1137, DOI 10.1111/j.2042-7158.2010.01139.x
   Shnyder SD, 2007, INT J ONCOL, V31, P353
   Shukla Y, 2011, ANN NY ACAD SCI, V1229, P162, DOI 10.1111/j.1749-6632.2011.06104.x
   Simmons TL, 2009, J NAT PROD, V72, P1011, DOI 10.1021/np9001674
   Singh D, 2013, BIORESOURCE TECHNOL, V143, P308, DOI 10.1016/j.biortech.2013.06.006
   Singh M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/243452
   Sinha RP, 2007, J PHOTOCH PHOTOBIO B, V89, P29, DOI 10.1016/j.jphotobiol.2007.07.006
   Smith W, 2005, CRIT REV ONCOL HEMAT, V55, P143, DOI 10.1016/j.critrevonc.2005.02.003
   Song H, 2011, INT IMMUNOPHARMACOL, V11, P2208, DOI 10.1016/j.intimp.2011.10.002
   Soontornchaiboon W, 2012, BIOL PHARM BULL, V35, P1137, DOI 10.1248/bpb.b12-00187
   Spencer L, 2009, EUR J CANCER, V45, P2077, DOI 10.1016/j.ejca.2009.04.026
   Sporn MB, 2011, NATURE, V471, pS10, DOI 10.1038/471S10a
   Stahl W, 2012, AM J CLIN NUTR, V96, p1179S, DOI 10.3945/ajcn.112.034819
   Storey A, 2005, J INVEST DERMATOL, V124, P248, DOI 10.1111/j.0022-202X.2004.23543.x
   Subramanian B, 2002, ANTI-CANCER DRUG, V13, P1061, DOI 10.1097/00001813-200211000-00010
   Sue S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/737621
   Suetsuna K, 2001, MAR BIOTECHNOL, V3, P305, DOI 10.1007/s10126-001-0012-7
   Suganuma K, 2010, J DERMATOL SCI, V58, P136, DOI 10.1016/j.jdermsci.2010.02.009
   Suh HJ, 2003, PHOTOCHEM PHOTOBIOL, V78, P109, DOI 10.1562/0031-8655(2003)078<0109:MGPBSA>2.0.CO;2
   Suh SS, 2014, MAR DRUGS, V12, P5174, DOI 10.3390/md12105174
   Sun LQ, 2014, FOOD CHEM, V160, P1, DOI 10.1016/j.foodchem.2014.03.067
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Sun YP, 2009, PROSTAG LEUKOTR ESS, V81, P357, DOI 10.1016/j.plefa.2009.09.004
   Sun YY, 2014, CARBOHYD POLYM, V113, P22, DOI 10.1016/j.carbpol.2014.06.058
   Takai E, 2011, RADIAT RES, V175, P358, DOI 10.1667/RR2375.1
   Talero E, 2011, INFLAMM BOWEL DIS, V17, P696, DOI 10.1002/ibd.21420
   Tanaka T, 1995, CARCINOGENESIS, V16, P2957, DOI 10.1093/carcin/16.12.2957
   Tartar A, 2003, INT J SYST EVOL MICR, V53, P1719, DOI 10.1099/ijs.0.02559-0
   Tartar A, 2002, INT J SYST EVOL MICR, V52, P273, DOI 10.1099/00207713-52-1-273
   Thomas NV, 2013, MAR DRUGS, V11, P146, DOI 10.3390/md11010146
   Tominaga K, 2012, ACTA BIOCHIM POL, V59, P43
   Trekli MC, 2003, FREE RADICAL BIO MED, V34, P456, DOI 10.1016/S0891-5849(02)01303-5
   TREVITHICK JR, 1992, ARCH BIOCHEM BIOPHYS, V296, P575, DOI 10.1016/0003-9861(92)90613-2
   Trivedi PP, 2015, EUR J NUTR, V54, P639, DOI 10.1007/s00394-014-0745-5
   Ueno R, 2003, FEMS MICROBIOL LETT, V223, P275, DOI 10.1016/S0378-1097(03)00394-X
   Umemura K, 2003, BIOCHEM PHARMACOL, V66, P481, DOI 10.1016/S0006-2952(03)00281-8
   Urikura I, 2011, BIOSCI BIOTECH BIOCH, V75, P757, DOI 10.1271/bbb.110040
   Uzair B, 2012, SCI WORLD J, P1, DOI 10.1100/2012/179782
   van Beelen VA, 2009, FOOD CHEM TOXICOL, V47, P316, DOI 10.1016/j.fct.2008.11.014
   van Dam RM, 2000, AM J CLIN NUTR, V71, P135
   VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P407, DOI 10.1001/archderm.122.4.407
   Varela JC, 2015, PHOTOSYNTH RES, V125, P423, DOI 10.1007/s11120-015-0149-2
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753-4887.2010.00287.x
   Wallingford SC, 2013, CANCER EPIDEM BIOMAR, V22, P1900, DOI 10.1158/1055-9965.EPI-13-0434
   Wang F, 2009, CURR OPIN PHARMACOL, V9, P389, DOI 10.1016/j.coph.2009.06.005
   Wang GZ, 2015, CANCER LETT, V363, P60, DOI 10.1016/j.canlet.2015.04.005
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Wang XQ, 2013, BIOTECHNOL PROGR, V29, P681, DOI 10.1002/btpr.1725
   Wang ZJ, 2012, NUTR CANCER, V64, P798, DOI 10.1080/01635581.2012.690927
   Weerawatanakorn M, 2014, FOOD FUNCT, V5, P257, DOI 10.1039/c3fo60332f
   Wells JW, 2015, CURR PROBL DERMATOL, V46, P36, DOI 10.1159/000366533
   Wendland BE, 2001, AM J CLIN NUTR, V74, P259
   Werner RN, 2013, BRIT J DERMATOL, V169, P502, DOI 10.1111/bjd.12420
   Wheller L, 2015, CURR PROBL DERMATOL, V46, P58, DOI 10.1159/000366536
   Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098
   Wrasidlo W, 2008, P NATL ACAD SCI USA, V105, P2313, DOI 10.1073/pnas.0712198105
   Wright TJ, 2013, CLIN EXP DERMATOL, V38, P421, DOI 10.1111/ced.12138
   Wu NL, 2010, EXP DERMATOL, V19, pE173, DOI 10.1111/j.1600-0625.2009.01036.x
   Xu JL, 2010, ANAL CHIM ACTA, V663, P60, DOI 10.1016/j.aca.2010.01.026
   Yaakob Z, 2014, J BIOL RES-THESSALON, V21, DOI 10.1186/2241-5793-21-6
   Yakovleva I, 2004, COMP BIOCHEM PHYS B, V139, P721, DOI 10.1016/j.cbpc.2004.08.016
   Yamane K, 2013, APPL ENVIRON MICROB, V79, P924, DOI 10.1128/AEM.01685-12
   Yang CA, 2015, J AUTOIMMUN, V61, P1, DOI 10.1016/j.jaut.2015.05.001
   Yang F, 2014, DRUG DES DEV THER, V8, P1789, DOI 10.2147/DDDT.S62530
   Yasui Y, 2011, CHEM-BIOL INTERACT, V193, P79, DOI 10.1016/j.cbi.2011.05.006
   Yates CM, 2014, PHARMACOL THERAPEUT, V141, P272, DOI 10.1016/j.pharmthera.2013.10.010
   Yoon HS, 2014, J MED FOOD, V17, P810, DOI 10.1089/jmf.2013.3060
   Yoshida E, 2006, J INVEST DERMATOL, V126, P1633, DOI 10.1038/sj.jid.5700236
   Yoshihara N, 2014, J DERMATOL, V41, P311, DOI 10.1111/1346-8138.12439
   Yoshihisa Y, 2014, EXP DERMATOL, V23, P178, DOI 10.1111/exd.12347
   Yu T, 2015, J MOL MED, V93, P31, DOI 10.1007/s00109-014-1225-3
   Yu XH, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00056
   Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414
   Yurko-Mauro K, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0109-z
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zhang LW, 2007, J PHOTOCH PHOTOBIO B, V86, P240, DOI 10.1016/j.jphotobiol.2006.10.006
   Zheng J, 2014, MAR DRUGS, V12, P4214, DOI 10.3390/md12074214
   Zheng J, 2013, BIOMOL THER, V21, P270, DOI 10.4062/biomolther.2013.030
   Zheng LH, 2011, MAR DRUGS, V9, P1840, DOI 10.3390/md9101840
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 396
TC 102
Z9 106
U1 5
U2 90
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD OCT
PY 2015
VL 13
IS 10
BP 6152
EP 6209
DI 10.3390/md13106152
PG 58
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV0YO
UT WOS:000363980000008
PM 26437418
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Lebovitz, CB
   Bortnik, SB
   Gorski, SM
AF Lebovitz, Chandra B.
   Bortnik, Svetlana B.
   Gorski, Sharon M.
TI Here, There Be Dragons: Charting Autophagy-Related Alterations in Human
   Tumors
SO CLINICAL CANCER RESEARCH
LA English
DT Review
ID HUMAN BREAST-CANCER; BECLIN 1; MAMMALIAN TARGET; SIGNALING PATHWAYS;
   COLON-CANCER; PROGNOSTIC-SIGNIFICANCE; MONITORING AUTOPHAGY; REDUCED
   EXPRESSION; RAPAMYCIN PATHWAY; POOR-PROGNOSIS
AB Macroautophagy (or autophagy) is a catabolic cellular process that is both homeostatic and stress adaptive. Normal cells rely on basal levels of autophagy to maintain cellular integrity (via turnover of long-lived proteins and damaged organelles) and increased levels of autophagy to buoy cell survival during various metabolic stresses (via nutrient and energy provision through lysosomal degradation of cytoplasmic components). Autophagy can function in both tumor suppression and tumor progression, and is under investigation in clinical trials as a novel target for anticancer therapy. However, its role in cancer pathogenesis has yet to be fully explored. In particular, it remains unknown whether in vitro observations will be applicable to human cancer patients. Another outstanding question is whether there exists tumor-specific selection for alterations in autophagy function. In this review, we survey reported mutations in autophagy genes and key autophagy regulators identified in human tumor samples and summarize the literature regarding expression levels of autophagy genes and proteins in various cancer tissues. Although it is too early to draw inferences from this collection of in vivo studies of autophagy-related alterations in human cancers, their results highlight the challenges that must be overcome before we can accurately assess the scope of autophagy's predicted role in tumorigenesis. Clin Cancer Res; 18(5); 1214-26. (C)2012 AACR.
C1 [Lebovitz, Chandra B.; Bortnik, Svetlana B.; Gorski, Sharon M.] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada.
   [Bortnik, Svetlana B.; Gorski, Sharon M.] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC V5Z 1M9, Canada.
   [Lebovitz, Chandra B.; Gorski, Sharon M.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.
RP Gorski, SM (corresponding author), BC Canc Agcy, Genome Sci Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.
EM sgorski@bcgsc.ca
RI Gorski, Sharon M/E-9375-2012
OI Gorski, Sharon M/0000-0002-3821-8289; Lebovitz,
   Chandra/0000-0002-8679-0431
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [GPG102167]
FX Canadian Institutes of Health Research (New Investigator award and team
   grant GPG102167 to S.M.G.).
CR Abou Youssif T, 2011, CANCER-AM CANCER SOC, V117, P290, DOI 10.1002/cncr.25402
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Annovazzi L, 2009, ANTICANCER RES, V29, P3087
   Bakarakos P, 2010, HISTOPATHOLOGY, V56, P876, DOI 10.1111/j.1365-2559.2010.03570.x
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525
   Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Colosetti P, 2009, AUTOPHAGY, V5, P1092, DOI 10.4161/auto.5.8.9889
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   de Haan CAM, 2010, AUTOPHAGY, V6, P994, DOI 10.4161/auto.6.7.13309
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hara T, 2009, AUTOPHAGY, V5, P85, DOI 10.4161/auto.5.1.7180
   Hardt M, 2011, GENES CELLS, V16, P141, DOI 10.1111/j.1365-2443.2010.01482.x
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jiang ZF, 2012, MOL BIOL REP, V39, P259, DOI 10.1007/s11033-011-0734-1
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Klebig C, 2005, CANCER RES, V65, P394
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lang SA, 2007, INT J CANCER, V120, P1803, DOI 10.1002/ijc.22442
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li XY, 2011, J NEURO-ONCOL, V103, P453, DOI 10.1007/s11060-010-0424-1
   Li YM, 2012, AM J MED SCI, V343, P155, DOI 10.1097/MAJ.0b013e31821f978d
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370
   Liu Quan, 2008, Ai Zheng, V27, P25
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Martin SJ, 2011, AUTOPHAGY, V7, P922, DOI 10.4161/auto.7.8.15821
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1784, DOI 10.4161/cc.10.11.15674
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mavrommati I, 2011, CURR MED CHEM, V18, P2743, DOI 10.2174/092986711796011247
   Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Miracco C, 2007, INT J ONCOL, V30, P429
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Mutee AF, 2010, INT J LAB MED, V4, P1
   Negri T, 2010, GENE CHROMOSOME CANC, V49, P901, DOI 10.1002/gcc.20798
   Neufeld TP, 2010, CURR OPIN CELL BIOL, V22, P157, DOI 10.1016/j.ceb.2009.11.005
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   Nomura H, 2009, HUM PATHOL, V40, P83, DOI 10.1016/j.humpath.2008.06.018
   Othman EQG, 2009, J CLIN LAB ANAL, V23, P249, DOI 10.1002/jcla.20309
   Qian HL, 2005, WORLD J GASTROENTERO, V11, P1788
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018
   Roberts SS, 2009, PATHOL ONCOL RES, V15, P645, DOI 10.1007/s12253-009-9165-x
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shen Yang, 2008, Ai Zheng, V27, P595
   Shi YH, 2009, AUTOPHAGY, V5, P380, DOI 10.4161/auto.5.3.7658
   Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058
   Shpilka T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-226
   Shvets E, 2008, AUTOPHAGY, V4, P1054, DOI 10.4161/auto.6823
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Sivridis E, 2011, MELANOMA RES, V21, P188, DOI 10.1097/CMR.0b013e328346612c
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947
   Sivridis E, 2010, AUTOPHAGY, V6, P830, DOI 10.4161/auto.6.6.12588
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Tickoo SK, 2011, BJU INT, V107, P844, DOI 10.1111/j.1464-410X.2010.09517.x
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   Wang Zan-Hong, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P860
   Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zheng QW, 2011, CIRC RES, V109, P296, DOI 10.1161/CIRCRESAHA.111.244707
   Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112
NR 120
TC 22
Z9 23
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 1
PY 2012
VL 18
IS 5
BP 1214
EP 1226
DI 10.1158/1078-0432.CCR-11-2465
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 902LW
UT WOS:000301040700006
PM 22253413
DA 2022-04-25
ER

PT J
AU Liu, J
   Yang, MP
   Kong, R
   Chen, H
   Wang, YW
   Pan, SH
   Jiang, HC
   Sun, B
AF Liu, Ji
   Yang, Maopeng
   Kong, Rui
   Chen, Hua
   Wang, Yongwei
   Pan, Shangha
   Jiang, Hongchi
   Sun, Bei
TI Icotinib Enhances Bufalin-Induced Apoptosis via the Suppression of
   PI3K/Akt Signaling Pathway in Human Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Colon cancer; PI3K/Akt; bufalin; icotinib; apoptosis
ID CBL-B; GROWTH; INHIBITION; RESISTANCE; AUTOPHAGY
AB This study sought to uncover whether icotinib can enhance bufalin-induced apoptosis of human colon cancer cells and the roles of PI3K/Akt signaling pathway in the apoptosis. The cell proliferation of human colon cancer cell lines RKO, HT29, CACO-2 and SW480 treated by bufalin was detected by MTT assay. Then, the apoptosis rate of RKO and SW480 cells treated by bufalin alone and combination of bufalin and icotinib was detected by flow cytometry. Afterwards, the levels of Cbl-b, p-AKT, p-ERK, PARP, Bax and Bcl-2 in RKO and SW480 cells were determined by Western blotting. Additionally, the effect of K-Ras silencing on the synergy of bufalin and icotinib was assessed. Bufalin decreased RKO, HT29, CACO-2 and SW480 (EX12 mutation) cell viability in a dose dependent manner and induced apoptosis of RKO and SW480 cells in vitro. In the cells treated by combination of bufalin and icotinib, the levels of Cbl-b, cleaved PARP and Bax were increased, while the levels of p-Akt and Bcl-2 were reduced, comparing with that in the bufalin treated cells. Furthermore, K-Ras silencing (including EX12 mutated K-Ras and wild-type K-Ras) did not significantly affect the apoptosis rate of cells treated by the combination of bufalin and icotinib. Icotinib synergizes with bufalin to induce the apoptosis of colon cancer cells through PI3K/Akt signal pathway and regulating the apoptosis related proteins (Bcl-2, Cbl-b, cleaved PARP and Bax). K-Ras may not participate in the combination of bufalin and icotinib induced apoptosis in human colon cancer cells.
C1 [Liu, Ji; Kong, Rui; Chen, Hua; Wang, Yongwei; Jiang, Hongchi; Sun, Bei] Harbin Med Univ, Affiliated Hosp 1, Dept Pancreat & Biliary Surg, Harbin 150001, Peoples R China.
   [Yang, Maopeng] Harbin Med Univ, Affiliated Hosp 3, Dept Med Oncol, Harbin 150001, Peoples R China.
   [Pan, Shangha] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Key Lab Hepatosplen Surg, Harbin 150001, Peoples R China.
RP Sun, B (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Pancreat & Biliary Surg, Harbin 150001, Peoples R China.
CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361
   Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870
   Garcia-Alfonso P, 2014, ANGIOGENESIS, V17, P805, DOI 10.1007/s10456-014-9433-6
   Guerrero S, 2000, CANCER RES, V60, P6750
   Harashima N, 2012, CANCER IMMUNOL IMMUN, V61, P667, DOI 10.1007/s00262-011-1132-1
   Kang XH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/243859
   Khoo BY, 2010, INT J MOL SCI, V11, P2188, DOI 10.3390/ijms11052188
   Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614
   Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6
   Li W, 2011, INT J MOL SCI, V12, P668, DOI 10.3390/ijms12010668
   Mu XD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/726375
   Nakao R, 2009, MOL CELL BIOL, V29, P4798, DOI 10.1128/MCB.01347-08
   Park IH, 2010, INVEST NEW DRUG, V28, P791, DOI 10.1007/s10637-009-9319-4
   Qu XJ, 2009, FEBS LETT, V583, P2255, DOI 10.1016/j.febslet.2009.05.054
   Sahlberg SH, 2012, INT J ONCOL, V40, P176, DOI 10.3892/ijo.2011.1177
   Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805
   Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106
   Takezawa K, 2011, CLIN CANCER RES, V17, P2140, DOI 10.1158/1078-0432.CCR-10-2798
   Tashiro J, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-145
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yang C. L., 2013, J XINXIANG MED U, V30, P622
   Zhao QO, 2011, LUNG CANCER, V73, P195, DOI 10.1016/j.lungcan.2010.11.007
   Zhu ZT, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-228
   Zhu ZT, 2012, INT J MOL SCI, V13, P2025, DOI 10.3390/ijms13022025
NR 27
TC 1
Z9 1
U1 0
U2 7
PU ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET
PI FAISALABAD
PA 308-LASANI TOWN, SARGODHA RD, FAISALABAD, 38090, PAKISTAN
SN 1811-7775
EI 1812-5700
J9 INT J PHARMACOL
JI Int. J. Pharmacol.
PY 2015
VL 11
IS 8
BP 910
EP 919
DI 10.3923/ijp.2015.910.919
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DC4TY
UT WOS:000369214400003
DA 2022-04-25
ER

PT J
AU Siri, M
   Behrouj, H
   Dastghaib, S
   Zamani, M
   Likus, W
   Rezaie, S
   Hudecki, J
   Khazayel, S
   Los, MJ
   Mokarram, P
   Ghavami, S
AF Siri, Morvarid
   Behrouj, Hamid
   Dastghaib, Sanaz
   Zamani, Mozhdeh
   Likus, Wirginia
   Rezaie, Sedigheh
   Hudecki, Jacek
   Khazayel, Saeed
   Los, Marek J.
   Mokarram, Pooneh
   Ghavami, Saeid
TI Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite
   Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux
   Inhibition
SO ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
LA English
DT Article
DE 5-Fluorouracil; Casein kinase 1 alpha inhibitor; Colorectal cancer;
   Combination treatment; Autophagy; Chemoresistance
ID UNFOLDED PROTEIN RESPONSE; DRUG-RESISTANCE; CYCLIN D1; COLON-CANCER;
   AUTOPHAGY; MECHANISMS; APOPTOSIS; GROWTH; MULTIPLE; ABCG2
AB Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H). Given the importance of autophagy and multi-drug-resistant (MDR) proteins in chemotherapy resistance, as well as the role of casein kinase 1-alpha (CK1 alpha) in the regulation of autophagy, we tested the combined effect of 5-FU and CK1 alpha inhibitor (D4476) on HCT116 cells as a model of MSI-H colorectal cancer. To achieve this goal, the gene expression of Beclinl and MDR genes, ABCG2 and ABCC3 were analyzed using quantitative real-time polymerase chain reaction. We used immunoblotting to measure autophagy flux (LC3, p62) and flow cytometry to detect apoptosis. Our findings showed that combination treatment with 5-FU and D4476 inhibited autophagy flux. Moreover, 5-FU and D4476 combination therapy induced G2, S and G1 phase arrests and it depleted mRNA of both cell proliferation-related genes and MDR-related genes (ABCG2, cyclin DI and c-myc). Hence, our data indicates that targeting of CK1 alpha may increase the sensitivity of HCT116 cells to 5-FU. To our knowledge, this is the first description of sensitization of CRC cells to 5-FU chemotherapy by CK1 alpha inhibitor.
C1 [Siri, Morvarid; Zamani, Mozhdeh; Los, Marek J.; Mokarram, Pooneh; Ghavami, Saeid] Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.
   [Siri, Morvarid; Behrouj, Hamid; Dastghaib, Sanaz; Rezaie, Sedigheh; Mokarram, Pooneh] Shiraz Univ Med Sci, Sch Med, Dept Biochem, POB 1167, Shiraz, Iran.
   [Dastghaib, Sanaz] Shiraz Univ Med Sci, Endocrinol & Metab Res Ctr, Shiraz, Iran.
   [Likus, Wirginia] Med Univ Silesia, Sch Hlth Sci Katowice, Dept Anat, Ul Medykow 18, PL-40762 Katowice, Poland.
   [Hudecki, Jacek] Med Univ Silesia, Sch Med Katowice, Laryngol Dept, Katowice, Poland.
   [Khazayel, Saeed] Kermanshah Univ Med Sci, Dept Res & Technol, Kermanshah, Iran.
   [Los, Marek J.] Pomeranian Med Univ, Dept Pathol, Unii Lubelskiej 1, PL-71344 Szczecin, Poland.
   [Ghavami, Saeid] Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.
   [Ghavami, Saeid] Katowice Sch Technol, Fac Med, Katowice, Poland.
   [Ghavami, Saeid] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
RP Los, MJ; Mokarram, P; Ghavami, S (corresponding author), Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.; Mokarram, P (corresponding author), Shiraz Univ Med Sci, Sch Med, Dept Biochem, POB 1167, Shiraz, Iran.; Los, MJ (corresponding author), Pomeranian Med Univ, Dept Pathol, Unii Lubelskiej 1, PL-71344 Szczecin, Poland.; Ghavami, S (corresponding author), Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.; Ghavami, S (corresponding author), Katowice Sch Technol, Fac Med, Katowice, Poland.; Ghavami, S (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
EM mjelos@gmail.com; mokaram2@gmail.com; saeid.ghavami@umanitoba.ca
RI Mokarram, Pooneh/E-1613-2012; Behrouj, Hamid/AAC-1604-2022; Dastghaib,
   Sanaz/ABD-5899-2021
OI Mokarram, Pooneh/0000-0002-9717-0473; Dastghaib,
   Sanaz/0000-0001-8553-9221; Likus, Wirginia/0000-0002-4738-6102; Ghavami,
   Saeid/0000-0001-5948-508X; Los, Marek/0000-0001-9518-1411
FU Shiraz University of Medical Sciences [97-01-01-18115]; National
   Institute for Medical Research Development (NIMAD) [943267]
FX This study was supported financially by Shiraz University of Medical
   Sciences [Grant No.: 97-01-01-18115]. This project was also supported by
   the National Institute for Medical Research Development (NIMAD) Grant
   No: 943267.
CR Aghaei M, 2021, LIFE-BASEL, V11, DOI 10.3390/life11010001
   Ahmadi M, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165968
   Alizadeh J, 2018, BBA-MOL CELL RES, V1865, P749, DOI 10.1016/j.bbamcr.2018.02.007
   Alizadeh J, 2017, SCI REP-UK, V7, DOI 10.1038/srep44841
   Amaravadi RK, 2015, J CLIN INVEST, V125, P1393, DOI 10.1172/JCI81504
   An Y, 2009, EXPERT OPIN DRUG MET, V5, P1529, DOI 10.1517/17425250903228834
   Auger C, 2021, CANCERS, V13, DOI 10.3390/cancers13051039
   Behrouj H, 2021, CAN J PHYSIOL PHARM, V99, P284, DOI 10.1139/cjpp-2020-0449
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532
   Brun P, 2020, J ALLERGY CLIN IMMUN, V146, P1210, DOI 10.1016/j.jaci.2020.03.013
   Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8
   Carrino M, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0179-1
   Chen J, 2021, ONCOGENE, V40, P3974, DOI 10.1038/s41388-021-01815-4
   Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018
   Cheong JK, 2011, INT J BIOCHEM CELL B, V43, P465, DOI 10.1016/j.biocel.2010.12.004
   Christowitz C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5939-z
   Dastghaib S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112339
   Desantis V, 2018, TRANSL ONCOL, V11, P1350, DOI 10.1016/j.tranon.2018.08.014
   Ding R, 2016, AUTOPHAGY, V12, P737, DOI 10.1080/15548627.2016.1155009
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Emami A, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172616
   Fletcher JI, 2016, DRUG RESIST UPDATE, V26, P1, DOI 10.1016/j.drup.2016.03.001
   Ghavami S, 2014, BBA-MOL CELL RES, V1843, P1259, DOI 10.1016/j.bbamcr.2014.03.006
   Ghavami S, 2012, AM J PHYSIOL-LUNG C, V302, pL420, DOI 10.1152/ajplung.00312.2011
   Ghavami S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016523
   Ghavami S, 2009, BBA-MOL CELL RES, V1793, P546, DOI 10.1016/j.bbamcr.2009.01.002
   Ghiringhelli F, 2015, BIOMED J, V38, P111, DOI 10.4103/2319-4170.130923
   Hasanabady MH, 2016, J BIOSCIENCES, V41, P313, DOI 10.1007/s12038-016-9601-5
   Hashemi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053075
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Jahanafrooz Z, 2020, J CELL PHYSIOL, V235, P4153, DOI 10.1002/jcp.29337
   Janovska P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239026
   Jaromy M, 2021, EUR J PHARMACOL, V897, DOI 10.1016/j.ejphar.2021.173956
   Jiang SJ, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0236-z
   Jung JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62823-0
   Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329
   Karami Shima, 2020, Asian Pac J Cancer Prev, V21, P3115, DOI 10.31557/APJCP.2020.21.10.3115
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Khunweeraphong N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094806
   Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081604
   Kiruthiga C, 2020, CANCERS, V12, DOI 10.3390/cancers12030562
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Knippschild U, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00096
   Kobayashi M, 2016, CANCER SCI, V107, P1776, DOI 10.1111/cas.13097
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kugimiya N, 2015, J CELL MOL MED, V19, P1569, DOI 10.1111/jcmm.12531
   Kwan BLY, 2016, AUTOPHAGY IN CURRENT TRENDS IN CELLULAR PHYSIOLOGY AND PATHOLOGY, P435, DOI 10.5772/64274
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li N, 2021, NANOSCALE ADV, V3, P1656, DOI 10.1039/d0na00990c
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu CX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246184
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lorzadeh S, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118926
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manni S, 2017, ONCOTARGET, V8, P14604, DOI [10.18632/oncotarget.14678, 10.18632/oncotarget.14654]
   Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Meiyanto Edy, 2018, Asian Pac J Cancer Prev, V19, P49, DOI 10.22034/APJCP.2018.19.1.49
   Mele L, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102043
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8
   Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830
   Petitprez A, 2013, INT J ONCOL, V42, P1644, DOI 10.3892/ijo.2013.1868
   Petroni G, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1745038
   Qie S, 2016, J MOL MED, V94, P1313, DOI 10.1007/s00109-016-1475-3
   Rebuzzi SE, 2020, CANCERS, V12, DOI 10.3390/cancers12092584
   Reima H, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035556
   Richter J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4019-0
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Rong LW, 2017, ONCOL LETT, V13, P5028, DOI 10.3892/ol.2017.6059
   Samiei E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093162
   Schittek B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-231
   Shojaei S, 2020, FEBS J, V287, P1005, DOI 10.1111/febs.15069
   Symonds LK, 2019, GASTROENTEROL REP, V7, P301, DOI 10.1093/gastro/goz035
   Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770
   Tai CJ, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/514719, 10.1155/2013/121725]
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wang H, 2020, CURR PHARM DESIGN, V26, P1979, DOI 10.2174/1381612826666200408102305
   Wang XJ, 2018, FASEB J, V32, P37, DOI 10.1096/fj.201601393R
   Wu GY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-167
   Xu WL, 2020, ONCOL REP, V44, P1895, DOI 10.3892/or.2020.7760
   Yan JH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1355-0
   Yang JW, 2018, J CANCER RES THER, V14, pS1141, DOI 10.4103/0973-1482.204898
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Zhang F, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/324294
   Zhang HL, 2019, ONCOL LETT, V17, P4487, DOI 10.3892/ol.2019.10081
   Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/s41467-017-01968-5, 10.1038/ncomms14542]
NR 98
TC 1
Z9 1
U1 4
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0004-069X
EI 1661-4917
J9 ARCH IMMUNOL THER EX
JI Arch. Immunol. Ther. Exp.
PD DEC
PY 2021
VL 69
IS 1
AR 26
DI 10.1007/s00005-021-00629-2
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA UR9OY
UT WOS:000697070300001
PM 34536148
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Sipos, F
   Kiss, AL
   Constantinovits, M
   Tulassay, Z
   Muzes, G
AF Sipos, Ferenc
   Kiss, Anna L.
   Constantinovits, Miklos
   Tulassay, Zsolt
   Muzes, Gyoergyi
TI Modified Genomic Self-DNA Influences In Vitro Survival of HT29 Tumor
   Cells via TLR9-and Autophagy Signaling
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE HT29; Colon cancer; TLR9; Autophagy; Colonosphere; Self-DNA
ID TOLL-LIKE RECEPTORS; NF-KAPPA-B; CANCER STEM-CELLS;
   CPG-OLIGODEOXYNUCLEOTIDES; COLON-CANCER; LYMPHOMA-CELLS; BACTERIAL-DNA;
   UP-REGULATION; STRANDED-RNA; APOPTOSIS
AB In relation of immunobiology, the consequence of the crosstalk between TLR9-signaling and autophagy is poorly documented in HT29 cancer cells. To assess the TLR9-mediated biologic effects of modified self-DNA sequences on cell kinetics and autophagy response HT29 cells were incubated separately with intact genomic (g), hypermethylated (m), fragmented (f), and hypermethylated/fragmented (m/f) self-DNAs. Cell viability, apoptosis, cell proliferation, colonosphere-formation were determined. Moreover, the relation of TLR9-signaling to autophagy response was assayed by real-time RT-PCR, immunocytochemistry and transmission electron microscopy (TEM). After incubation with g-, m-, and m/f-DNAs cell viability and proliferation decreased, while apoptosis increased. F-DNA treatment resulted in an increase of cell survival. Methylation of self-DNA resulted in decrease of TLR9 expression, while it did not influence the positive effect of DNA fragmentation on MyD88 and TRAF6 overexpression, and TNF alpha downregulation. Fragmentation of DNA abrogated the positive effect of methylation on IRAK2, NF kappa B and IL-8 mRNA upregulations. In case of the autophagy genes and proteins, g- and f-DNAs caused significant upregulation of Beclin1, Atg16L1, and LC3B. According to TEM analyses, autophagy was present in each group of tumor cells, but to a varying degree. Incubation with m-DNA suppressed tumor cell survival by inducing features of apoptotic cell death, and activated mitophagy. F-DNA treatment enhanced cell survival, and activated macroautophagy and lipophagy. Colonospheres were only present after m-DNA incubation. Our data provided evidence for a close existing interplay between TLR9-signaling and the autophagy response with remarkable influences on cell survival in HT29 cells subjected to modified self-DNA treatments.
C1 [Sipos, Ferenc; Constantinovits, Miklos; Tulassay, Zsolt; Muzes, Gyoergyi] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi St 46, H-1088 Budapest, Hungary.
   [Kiss, Anna L.] Semmelweis Univ, Dept Human Morphol & Dev Biol, H-1094 Budapest, Hungary.
   [Tulassay, Zsolt] Hungarian Acad Sci, Mol Med Res Unit, H-1051 Budapest, Hungary.
RP Sipos, F (corresponding author), Semmelweis Univ, Dept Internal Med 2, Szentkiralyi St 46, H-1088 Budapest, Hungary.
EM dr.siposf@gmail.com
OI Sipos, Ferenc/0000-0002-2767-7746
FU Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi
   Alapprogramok (OTKA) [OTKA-K111743]; StartUp Program of Semmelweis
   University Faculty of Medicine [11720, Ikt. sz.: 5127/AOKGIE/2018,
   SE10332470]
FX Supported by the Hungarian Scientific Research Fund (OTKA-K111743 grant)
   to ZT and the StartUp Program of Semmelweis University Faculty of
   Medicine (CO No.: 11720, Ikt. sz.: 5127/AOKGIE/2018; SE10332470) to FS.
   The funders had no role in data collection, decision to publish, or
   preparation of the manuscript.
CR Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Amir M, 2011, EXPERT REV GASTROENT, V5, P159, DOI [10.1586/egh.11.4, 10.1586/EGH.11.4]
   Arunkumar N, 2013, CELL MOL IMMUNOL, V10, P360, DOI 10.1038/cmi.2013.14
   Barnie PA, 2014, BIOMED REP, V2, P374, DOI 10.3892/br.2014.257
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bertin S, 2008, MOL CELL PROTEOMICS, V7, P2311, DOI 10.1074/mcp.M800100-MCP200
   Bertin S, 2008, AUTOPHAGY, V4, P1086, DOI 10.4161/auto.7138
   Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012
   Chen GY, 2014, ADV HEALTHC MATER, V3, P1486, DOI 10.1002/adhm.201300591
   Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372
   Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174
   Cortez-Gonzalez X, 2006, DNA CELL BIOL, V25, P253, DOI 10.1089/dna.2006.25.253
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   El Andaloussi A, 2006, GLIA, V54, P526, DOI 10.1002/glia.20401
   Farias N, 2015, J NUTR BIOCHEM, V26, P818, DOI 10.1016/j.jnutbio.2015.02.002
   Furi I, 2013, SCI WORLD J, DOI 10.1155/2013/293296
   Ghadimi D, 2010, INFLAMM BOWEL DIS, V16, P410, DOI 10.1002/ibd.21057
   de Cedron MG, 2016, J LIPID RES, V57, P193, DOI 10.1194/jlr.R061812
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401
   Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784
   Into T, 2012, CELL SIGNAL, V24, P1150, DOI 10.1016/j.cellsig.2012.01.020
   Ivanov S, 2007, BLOOD, V110, P1970, DOI 10.1182/blood-2006-09-044776
   Jahr S, 2001, CANCER RES, V61, P1659
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Khorramizadeh MR, 2007, IRAN J ALLERGY ASTHM, V6, P107
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Kuo CC, 2006, J BIOL CHEM, V281, P38200, DOI 10.1074/jbc.M605439200
   Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028
   LEON SA, 1977, CANCER RES, V37, P646
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li XY, 2010, CYTOKINE, V49, P1, DOI 10.1016/j.cyto.2009.08.010
   Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   McKelvey KJ, 2011, J AUTOIMMUN, V36, P76, DOI 10.1016/j.jaut.2010.11.001
   Mehta P, 2014, CURR OPIN IMMUNOL, V26, P69, DOI 10.1016/j.coi.2013.10.012
   Meng QB, 2012, MOL CELL BIOCHEM, V371, P177, DOI 10.1007/s11010-012-1434-4
   Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mochida K, 2015, NATURE, V522, P359, DOI 10.1038/nature14506
   Moga E, 2008, EXP HEMATOL, V36, P69, DOI 10.1016/j.exphem.2007.08.012
   Mouliere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023418
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Pedersen G, 2005, CLIN EXP IMMUNOL, V141, P298, DOI 10.1111/j.1365-2249.2005.02848.x
   Peng Zhang, 2013, Mol Cell Biochem, V377, P87, DOI 10.1007/s11010-013-1573-2
   Pradere JP, 2014, ONCOGENE, V33, P3485, DOI 10.1038/onc.2013.302
   Qi XF, 2013, MOL IMMUNOL, V54, P327, DOI 10.1016/j.molimm.2013.01.001
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Radogna F, 2016, ONCOGENE, V35, P3839, DOI 10.1038/onc.2015.455
   Ruckdeschel K, 2002, J IMMUNOL, V168, P4601, DOI 10.4049/jimmunol.168.9.4601
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Shimosato T, 2006, CELL MICROBIOL, V8, P485, DOI 10.1111/j.1462-5822.2005.00640.x
   Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sozzi G, 2001, CANCER RES, V61, P4675
   Sun H, 2014, INT J BIOCHEM CELL B, V53, P195, DOI 10.1016/j.biocel.2014.04.010
   Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555
   Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457
   Tuomela J, 2013, BREAST CANCER RES TR, V142, P477, DOI 10.1007/s10549-013-2762-0
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wei JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049567
   Widlak P, 2009, CELL MOL LIFE SCI, V66, P263, DOI 10.1007/s00018-008-8472-9
   Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8
   Xu L, 2010, IMMUNOL LETT, V127, P93, DOI 10.1016/j.imlet.2009.10.002
   Xue F, 2016, CANCER LETT, V371, P38, DOI 10.1016/j.canlet.2015.11.022
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yao F, 2013, TUMOR BIOL, V34, P3201, DOI 10.1007/s13277-013-0890-0
   Yu L, 2008, CANCER IMMUNOL IMMUN, V57, P1271, DOI 10.1007/s00262-008-0459-8
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhang YY, 2014, CANCER IMMUNOL IMMUN, V63, P357, DOI 10.1007/s00262-014-1518-y
   Zhong L, 2013, TUMOR BIOL, V34, P231, DOI 10.1007/s13277-012-0543-8
NR 88
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD OCT
PY 2019
VL 25
IS 4
BP 1505
EP 1517
DI 10.1007/s12253-018-0544-z
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA JH3JE
UT WOS:000492663100027
PM 30465163
DA 2022-04-25
ER

PT J
AU Gariboldi, MB
   Taiana, E
   Bonzi, MC
   Craparotta, I
   Giovannardi, S
   Mancini, M
   Monti, E
AF Gariboldi, Marzia B.
   Taiana, Elisa
   Bonzi, Maria Chiara
   Craparotta, Ilaria
   Giovannardi, Stefano
   Mancini, Monica
   Monti, Elena
TI The BH3-mimetic obatoclax reduces HIF-1 alpha levels and HIF-1
   transcriptional activity and sensitizes hypoxic colon adenocarcinoma
   cells to 5-fluorouracil
SO CANCER LETTERS
LA English
DT Article
DE HIF-1; Obatoclax; Drug resistance; 5-Fluorouracil; Colon cancer;
   Oxaliplatin
ID HIPPEL-LINDAU PROTEIN; INDUCED APOPTOSIS; FAMILY INHIBITOR;
   DRUG-RESISTANCE; DOWN-REGULATION; CANCER-CELLS; BCL-XL; GX15-070;
   TUMORS; ALPHA
AB Activation of hypoxia-inducible factor (HIF)-1 is a feature of hypoxic solid tumors that has been associated with drug resistance, mainly due to disruption of Bcl-2 family dynamics. Resetting the balance in favor of proapoptotic family members is an attractive therapeutic goal that has been pursued by developing BH3-mimetic compounds. In the present study we evaluated the response of human colon adenocarcinoma cells to the BH3-mimetic obatoclax (OBX), in terms of growth arrest, apoptosis and autophagy, in the presence or absence of HIF-1 alpha-stabilizing conditions; its possible effect on HIF-1 alpha expression and HIF-1 activity; and the possibility to improve the response of colon cancer cells to cytotoxic chemotherapeutics by combining them with OBX. Colon cancer cell response to the BH3-mimetic was unmodified by HIF-1 activation and OBX induced a decrease in HIF-1 alpha protein levels and HIF-1 transcriptional activity, probably by decreasing HIF-1 alpha synthesis and facilitating a VHL-independent proteasomal degradation pathway. Finally, a chemosensitizing effect of OBX with respect to 5-fluorouracil or oxaliplatin treatment was observed, highlighting the possibility that patients with hypoxic colon tumors might benefit from combined regimens including OBX. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Gariboldi, Marzia B.; Taiana, Elisa; Bonzi, Maria Chiara; Craparotta, Ilaria; Giovannardi, Stefano; Mancini, Monica; Monti, Elena] Univ Insubria, Div Biomed Res, Dept Theoret & Appl Sci, I-21052 Busto Arsizio, Varese, Italy.
RP Monti, E (corresponding author), Univ Insubria, Div Biomed Res, Dept Theoret & Appl Sci, Via A da Giussano 10, I-21052 Busto Arsizio, Varese, Italy.
EM elena.monti@uninsubria.it
RI Craparotta, Ilaria/ABG-6626-2021; Gariboldi, Marzia Bruna/U-1331-2019
OI Craparotta, Ilaria/0000-0002-0846-9634; Taiana,
   Elisa/0000-0003-4940-1318; Mancini, Monica/0000-0003-4128-9018;
   gariboldi, marzia bruna/0000-0002-5683-0885
CR Acoca S, 2011, PROTEINS, V79, P2624, DOI 10.1002/prot.23083
   Adamski J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065304
   Chen N, 2009, J BIOL CHEM, V284, P10004, DOI 10.1074/jbc.M805997200
   Comerford KM, 2002, CANCER RES, V62, P3387
   Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798
   Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615
   Cruickshanks N, 2012, MOL PHARMACOL, V81, P748, DOI 10.1124/mol.112.077586
   Dasmahapatra G, 2012, MOL CANCER THER, V11, P1122, DOI 10.1158/1535-7163.MCT-12-0021
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Espona-Fiedler M, 2012, BIOCHEM PHARMACOL, V83, P489, DOI 10.1016/j.bcp.2011.11.027
   Flamant L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-191
   Gariboldi MB, 2007, CANCER LETT, V258, P181, DOI 10.1016/j.canlet.2007.08.019
   Harrison LRE, 2011, J CLIN INVEST, V121, P1075, DOI 10.1172/JCI43505
   Jona A, 2011, EXP HEMATOL, V39, P1007, DOI 10.1016/j.exphem.2011.07.002
   Klymenko T, 2011, MOL CANCER THER, V10, P2373, DOI 10.1158/1535-7163.MCT-11-0326
   Koehler BC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106571
   Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002
   Kong XG, 2007, J BIOL CHEM, V282, P15498, DOI 10.1074/jbc.M700704200
   Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919
   Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200
   Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658
   Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3
   Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360
   Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197
   Mayes PA, 2011, CANCER RES, V71, P5265, DOI 10.1158/0008-5472.CAN-11-1383
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Monti Elena, 2011, Curr Mol Pharmacol, V4, P62
   Muller A, 2013, INT J CANCER, V133, P1813, DOI 10.1002/ijc.28206
   Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104
   Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006
   Peter B, 2014, J LEUKOCYTE BIOL, V95, P95, DOI 10.1189/jlb.1112609
   Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Rahmani M, 2012, BLOOD, V119, P6089, DOI 10.1182/blood-2011-09-378141
   Ravizza R, 2009, EUR J CANCER, V45, P890, DOI 10.1016/j.ejca.2008.12.021
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Schimmer AD, 2008, CLIN CANCER RES, V14, P8295, DOI 10.1158/1078-0432.CCR-08-0999
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shore Gordon C, 2005, Hematology Am Soc Hematol Educ Program, P226
   Tang Y, 2012, MOL PHARMACOL, V81, P527, DOI 10.1124/mol.111.076851
   Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243
   Vogler M, 2009, CELL DEATH DIFFER, V16, P1030, DOI 10.1038/cdd.2009.48
   Witters LM, 2007, ONCOL REP, V17, P465
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937
NR 47
TC 17
Z9 18
U1 1
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD AUG 10
PY 2015
VL 364
IS 2
BP 156
EP 164
DI 10.1016/j.canlet.2015.05.008
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CL7GL
UT WOS:000357140400008
PM 25979228
DA 2022-04-25
ER

PT J
AU Morselli, E
   Tasdemir, E
   Maiuri, MC
   Galluzzi, L
   Kepp, O
   Criollo, A
   Vicencio, JM
   Soussi, T
   Kroemer, G
AF Morselli, Eugenia
   Tasdemir, Ezgi
   Maiuri, Maria Chiara
   Galluzzi, Lorenzo
   Kepp, Oliver
   Criollo, Alfredo
   Vicencio, Jose Miguel
   Soussi, Thierry
   Kroemer, Guido
TI Mutant p53 protein localized in the cytoplasm inhibits autophagy
SO CELL CYCLE
LA English
DT Article
DE Bcl-2; cancer; GFP-LC3; human colon carcinoma HCT 116 cells; MDM2; p53
   hot-spot mutations
ID DNA-BINDING DOMAIN; HUMAN CANCER; CELL-SURVIVAL; INSTABILITY; DAMAGE;
   MDM2
AB The knockout, knockdown or chemical inhibition of p53 stimulates autophagy. Moreover, autophagy-inducing stimuli such as nutrient depletion, rapamycin or lithium cause the depletion of cytoplasmic p53, which in turn is required for the induction of autophagy. Here, we show that retransfection of p53(-/-) HCT 116 colon carcinoma cells with wild type p53 decreases autophagy down to baseline levels. Surprisingly, one third among a panel of 22 cancer-associated p53 single amino acid mutants also inhibited autophagy when transfected into p53(-/-) cells. Those variants of p53 that preferentially localize to the cytoplasm effectively repressed autophagy, whereas p53 mutants that display a prominently nuclear distribution failed to inhibit autophagy. The investigation of a series of deletion mutants revealed that removal of the DNA-binding domain from p53 fails to interfere with its role in the regulation of autophagy. Altogether, these results identify the cytoplasmic localization of p53 as the most important feature for p53-mediated autophagy inhibition. Moreover, the structural requirements for the two biological activities of extranuclear p53, namely induction of apoptosis and inhibition of autophagy, are manifestly different.
C1 [Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France.
   [Morselli, Eugenia; Tasdemir, Ezgi; Maiuri, Maria Chiara; Galluzzi, Lorenzo; Kepp, Oliver; Criollo, Alfredo; Vicencio, Jose Miguel; Kroemer, Guido] Univ Paris 11, Orsay, France.
   [Maiuri, Maria Chiara] Univ Naples Federico II, Fac Sci Biotecnol, Naples, Italy.
   [Soussi, Thierry] Univ Paris 06, Paris, France.
   [Soussi, Thierry] Canc Ctr Karolinska, Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
RP Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.
EM kroemer@igr.fr
RI Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/K-2709-2012; KROEMER,
   Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi,
   Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/AAH-3286-2021
OI Galluzzi, Lorenzo/0000-0003-2257-8500; KROEMER,
   Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Criollo,
   Alfredo/0000-0002-2737-7751; soussi, thierry/0000-0001-8184-3293
FU EUEuropean Commission; Institut National contre le Cancer (INCa)Institut
   National du Cancer (INCA) France; CONICYT, ChileComision Nacional de
   Investigacion Cientifica y Tecnologica (CONICYT); CancerfondenSwedish
   Cancer Society; Swedish Research CouncilSwedish Research CouncilEuropean
   Commission; EMBOEuropean Molecular Biology Organization (EMBO); Ligue
   Nationale contre le Cancer (equipe labellisee)Ligue nationale contre le
   cancer; European CommissionEuropean CommissionEuropean Commission Joint
   Research Centre; Agence Nationale pour la RechercheFrench National
   Research Agency (ANR); Canceropole Ile-de-FranceRegion Ile-de-France
FX We thank Dr. B. Vogelstein (John Hopkins University, Bethesda, USA) for
   WT and p53<SUP>-/-</SUP> HCT 116 cells. E. M. is recipient of a Ph.D.
   student fellowship from the EU Apop-Train network. E. T. receives a
   Ph.D. student fellowship from Institut National contre le Cancer (INCa).
   J. M. V. and A. C. are recipients of Ph. D. student fellowships from
   CONICYT, Chile. The work of T. S. is supported by Cancerfonden and the
   Swedish Research Council (VR). O. K. is funded by an EMBO Ph. D.
   fellowship. G. K. is supported by the Ligue Nationale contre le Cancer
   (equipe labellisee), European Commission (Active p53, RIGHT, Apo-Sys,
   Apop-Train), Agence Nationale pour la Recherche, Canceropole
   Ile-de-France, and INCa.
CR Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Castedo M, 2006, ANN NY ACAD SCI, V1090, P35, DOI 10.1196/annals.1378.004
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Demma MJ, 2004, J BIOL CHEM, V279, P45887, DOI 10.1074/jbc.M401854200
   Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Lassus P, 1999, ONCOGENE, V18, P4699, DOI 10.1038/sj.onc.1202841
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MAIURI MC, 2008, CELL DEATH IN PRESS
   MARSTON NJ, 1994, ONCOGENE, V9, P2707
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571
   Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280
   Soussi T, 2006, NAT REV CANCER, V6, P83, DOI 10.1038/nrc1783
   Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001
   Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908
   Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200
   Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438
   Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030
NR 37
TC 194
Z9 206
U1 3
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD OCT 1
PY 2008
VL 7
IS 19
BP 3056
EP 3061
DI 10.4161/cc.7.19.6751
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 363JG
UT WOS:000260263000019
PM 18818522
OA Bronze
DA 2022-04-25
ER

PT J
AU Tan, YZ
   Peng, C
   Hu, CJ
   Li, HX
   Li, WB
   He, JL
   Li, YZ
   Zhang, H
   Zhang, RQ
   Wang, LX
   Cao, ZX
AF Tan, Yu-Zhu
   Peng, Cheng
   Hu, Chang-Jiang
   Li, Hong-Xiang
   Li, Wen-Bing
   He, Jun-Lin
   Li, Yu-Zhi
   Zhang, Hai
   Zhang, Ruo-Qi
   Wang, Li-Xia
   Cao, Zhi-Xing
TI Iridoids from Valeriana jatamansi induce autophagy-associated cell death
   via the PDK1/Akt/mTOR pathway in HCT116 human colorectal carcinoma cells
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE Valeriana jatamansi; Caprifoliaceae; Iridoids; Cytotoxicity;
   PDK1/Akt/mTOR
ID NATURAL-PRODUCTS; PLUS CETUXIMAB; ROOTS; PI3K/AKT/MTOR; CANCER;
   SESQUITERPENOIDS; MUTATIONS; DIVERSITY; DRUGS
AB Chlorovaltrates U-W (1-3), three previously undescribed iridoids, together with four known analogues were isolated from the roots of Valeriana jatamansi. Their structures were elucidated by means of spectroscopic analyses (HRESIMS, NMR). The cytotoxicity of all isolates was evaluated. Compounds 5-7 exhibited selective cytotoxicity against HCT116 cells, with IC50 values of 9.3, 1.7 and 2.2 mu M, respectively. The preliminary mechanistic study revealed that, the cytotoxicity effect of 6 was attributed to Akt/mTOR activation blockade via inhibition of PDK1 phosphorylation. Meanwhile, compound 6 could induce autophagosome formation in HCT116 cells via suppressing its downstream Akt/mTOR. These findings show that compound 6 could be of great importance to the development of anti-colon cancer agents.
C1 [Tan, Yu-Zhu; Peng, Cheng; He, Jun-Lin; Li, Yu-Zhi; Zhang, Hai; Zhang, Ruo-Qi; Wang, Li-Xia; Cao, Zhi-Xing] Chengdu Univ Tradit Chinese Med, State Key Lab Breeding Base Systemat Res Dev & Ut, Chengdu 611137, Sichuan, Peoples R China.
   [Tan, Yu-Zhu; Peng, Cheng; Hu, Chang-Jiang; He, Jun-Lin; Li, Yu-Zhi; Zhang, Hai; Zhang, Ruo-Qi; Wang, Li-Xia; Cao, Zhi-Xing] Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu 611137, Sichuan, Peoples R China.
   [Li, Hong-Xiang] Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, Chengdu 611137, Sichuan, Peoples R China.
   [Li, Wen-Bing] Sichuan New Green Med Sci & Technol Dev Co Ltd, Key Lab Qual Control & Efficacy Evaluat Tradit Ch, Pengzhou 611930, Peoples R China.
RP Peng, C; Cao, ZX (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Breeding Base Systemat Res Dev & Ut, Chengdu 611137, Sichuan, Peoples R China.
EM pengchengchengdu@126.com; caozhixing007@163.com
RI Hai, Zhang/AAE-3173-2019
OI Hu, Changjiang/0000-0002-6080-5594
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703693, 81503346]; key fund project for
   Education Department of Sichuan [18ZA0181]; Youth Science and Technology
   Innovative Research Team fund project of Sichuan [2016TD0006]; Fund
   Project of Science and Technology of Chengdu [2016-HM01-00457-SF]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 81703693, 81503346), the key fund project for
   Education Department of Sichuan (No. 18ZA0181), the Youth Science and
   Technology Innovative Research Team fund project of Sichuan (No.
   2016TD0006), and the Fund Project of Science and Technology of Chengdu
   [No. 2016-HM01-00457-SF].
CR BECKER H, 1984, PLANTA MED, V50, P245, DOI 10.1055/s-2007-969689
   BOUNTHANH C, 1981, PLANTA MED, V41, P21, DOI 10.1055/s-2007-971668
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893
   Fernandez S, 2004, PHARMACOL BIOCHEM BE, V77, P399, DOI 10.1016/j.pbb.2003.12.003
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Jillson I, 2015, J CANCER EDUC, V30, P284, DOI 10.1007/s13187-015-0813-4
   Li YD, 2013, HELV CHIM ACTA, V96, P424, DOI 10.1002/hlca.201100465
   Lin S, 2015, J ASIAN NAT PROD RES, V17, P455, DOI 10.1080/10286020.2015.1041933
   Lin S, 2013, PHYTOCHEMISTRY, V85, P185, DOI 10.1016/j.phytochem.2012.08.015
   Lin S, 2010, J NAT PROD, V73, P1723, DOI 10.1021/np100426j
   Lin S, 2010, J NAT PROD, V73, P632, DOI 10.1021/np900795c
   Liu F. L., 2010, PHARM CLIN RES, V20, P356
   Liu YH, 2017, FITOTERAPIA, V123, P73, DOI 10.1016/j.fitote.2017.09.011
   Ma CH, 2015, J ETHNOPHARMACOL, V168, P349, DOI 10.1016/j.jep.2015.03.068
   Mathela CS, 2005, CHEM BIODIVERS, V2, P1174, DOI 10.1002/cbdv.200590087
   Ming DS, 1997, TETRAHEDRON LETT, V38, P5205, DOI 10.1016/S0040-4039(97)01112-X
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sun JZ, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3738
   Sun Y, 2018, BIOMED PHARMACOTHER, V104, P817, DOI 10.1016/j.biopha.2018.04.136
   Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021
   Tan YZ, 2016, PHYTOCHEM LETT, V17, P177, DOI 10.1016/j.phytol.2016.07.020
   Tang YP, 2002, J NAT PROD, V65, P1949, DOI 10.1021/np0203335
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Van C.E., 2010, ANN ONCOL, V21, P155
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Verma RS, 2011, CHEM BIODIVERS, V8, P1921, DOI 10.1002/cbdv.201100059
   Wang RJ, 2017, PHYTOCHEMISTRY, V141, P156, DOI 10.1016/j.phytochem.2017.05.010
   Xu J, 2012, NAT PROD RES, V26, P1996, DOI 10.1080/14786419.2011.636747
   Xu J, 2011, FITOTERAPIA, V82, P1133, DOI 10.1016/j.fitote.2011.07.013
   Xu J, 2011, FITOTERAPIA, V82, P849, DOI 10.1016/j.fitote.2011.04.012
   Xu ZL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0645-4
   Yu LL, 2005, HELV CHIM ACTA, V88, P1059, DOI 10.1002/hlca.200590077
   Zhang B, 2017, RSC ADV, V7, P31899, DOI 10.1039/c6ra27478a
   Zhang W., 2010, Patent No. [101829080A, 101829080]
   Zhang XM, 2018, NAT PROD RES, V32, P2071, DOI 10.1080/14786419.2017.1360881
NR 43
TC 8
Z9 10
U1 1
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0045-2068
EI 1090-2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD JUN
PY 2019
VL 87
BP 136
EP 141
DI 10.1016/j.bioorg.2019.03.020
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA HZ7IC
UT WOS:000469026400015
PM 30884307
DA 2022-04-25
ER

PT J
AU Zhang, XY
   Xu, RT
   Feng, WJ
   Xu, JP
   Liang, YL
   Mu, JH
AF Zhang, Xianyi
   Xu, Runtao
   Feng, Wenjing
   Xu, Jiapeng
   Liang, Yulong
   Mu, Jinghui
TI Autophagy-related genes contribute to malignant progression and have a
   clinical prognostic impact in colon adenocarcinoma
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE colon adenocarcinoma; autophagy; The Cancer Genome Atlas; GTEx; DAPK1;
   ATG4B; SERPINA1; risk signature
ID CANCER; METABOLISM; RESISTANCE
AB Autophagy has an important role in regulating tumor cell survival. However, the roles of autophagy-related genes (ARGs) during colon adenocarcinoma (COAD) progression and their prognostic value have remained elusive. The present study aimed to identify the correlation between ARGs and the progression of COAD, as well as the prognostic significance of ARGs. The transcriptome pro?les and the corresponding clinicopathological information of patients with COAD were downloaded from The Cancer Genome Atlas and Genotype-Tissue Expression databases. A list of ARGs was obtained from the Human Autophagy Database and bioinformatics analysis was performed to investigate the functions of these ARGs. Statistical analyses of these genes were performed to identify independent prognostic markers. The selected prognostic markers were then validated in 15 patients with COAD via immunohistochemistry. Differentially expressed ARGs between normal and tumor tissues were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed that the differentially expressed ARGs were mainly enriched in toxoplasmosis and pathways in cancer. The ATG4B, DAPK1 and SERPINA1 genes were determined to be associated with COAD progression. In addition, a risk signature was proposed that may serve as an independent prognostic marker. In conclusion, ATG4B, DAPK1 and SERPINA1 are crucial participants in tumorigenesis of COAD. The present study may promote the development of novel treatment strategies for COAD.
C1 [Zhang, Xianyi; Xu, Runtao; Feng, Wenjing; Xu, Jiapeng; Liang, Yulong; Mu, Jinghui] Hebei Med Univ, Hosp 3, Dept Gen Surg, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
RP Mu, JH (corresponding author), Hebei Med Univ, Hosp 3, Dept Gen Surg, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
EM jinghuimutgy@163.com
CR Akkoc Y, 2018, TURK J GASTROENTEROL, V29, P270, DOI 10.5152/tjg.2018.150318
   [Anonymous], 2018, AM FAM PHYS, V97
   Auberger P, 2017, BLOOD, V129, P547, DOI 10.1182/blood-2016-07-692707
   Bhat P, 2018, BIOCHEM PHARMACOL, V147, P170, DOI 10.1016/j.bcp.2017.11.021
   Chan LL, 2015, CLIN BIOCHEM, V48, P962, DOI 10.1016/j.clinbiochem.2015.04.022
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Erickson LA, 2018, MAYO CLIN PROC, V93, P669, DOI 10.1016/j.mayocp.2018.03.010
   Fu YY, 2019, AUTOPHAGY, V15, P295, DOI 10.1080/15548627.2018.1517073
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gomes LR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112351
   Griffith OL, 2006, J CLIN ONCOL, V24, P5043, DOI 10.1200/JCO.2006.06.7330
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Han YY, 2018, INT J ONCOL, V52, P1057, DOI 10.3892/ijo.2018.4270
   Kriegsmann M, 2017, BBA-PROTEINS PROTEOM, V1865, P858, DOI 10.1016/j.bbapap.2016.11.018
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lachaux A, 2014, REV MAL RESPIR, V31, P357, DOI 10.1016/j.rmr.2013.10.651
   Li M, 2020, CANCER GENE THER, V27, P715, DOI 10.1038/s41417-019-0143-5
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Liu PF, 2017, CELL PHYSIOL BIOCHEM, V44, P728, DOI 10.1159/000485286
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Mitchell EL, 2017, CURR PATHOBIOL REP, V5, P243, DOI 10.1007/s40139-017-0147-5
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Rosen AW., 2016, UGESKRLAEGER, V178
   Singh P, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00046
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Wan LD, 2019, GUT, V68, P118, DOI 10.1136/gutjnl-2017-314983
   Wang ZN, 2016, METHODS MOL BIOL, V1418, P111, DOI 10.1007/978-1-4939-3578-9_6
   White A, 2017, CANCER-AM CANCER SOC, V123, P5014, DOI 10.1002/cncr.31076
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Yuan WZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184959
NR 34
TC 1
Z9 1
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2021
VL 22
IS 3
AR 932
DI 10.3892/etm.2021.10364
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA TK7BL
UT WOS:000674309500001
PM 34306201
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ghecham, A
   Senator, A
   Pawlowska, E
   Bouafia, W
   Blasiak, J
AF Ghecham, Abdelmoudjib
   Senator, Abderrahmane
   Pawlowska, Elzbieta
   Bouafia, Waffa
   Blasiak, Janusz
TI Epigenetic modifiers, 5-aza-2 '-deoxycytidine and valproic acid,
   differentially change viability, DNA damage and gene expression in
   metastatic and non-metastatic colon cancer cell lines
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE epigenetic modifiers; anticancer therapy; 5-Aza-dC; VPA; colorectal
   cancer; metastatic and non-metastatic cancer cells; DNA damage; gene
   expression
ID NF-KAPPA-B; HISTONE DEACETYLASE INHIBITION; ACUTE MYELOID-LEUKEMIA;
   METHYLATION; COMBINATION; AZACITIDINE; DECITABINE; THERAPY;
   DEMETHYLATION; MECHANISMS
AB DNA methylation and histone modifications are major components of cellular epigenetic pattern determining gene expression. Cancer cells have their own epigenetic array, which can be different in cells of primary and metastatic tumors. In the work presented here, we investigated effects of 1 mM valproic acid (VPA), a histone deacetylase inhibitor, and 0.2 mu M 5-aza-2'-deoxycytidine (5-aza-dC), a DNA demethylation agent, singly or in combination in two colorectal cancer cell lines: Caco-2 (non- metastatic) and LoVo (metastatic). Cell viability, DNA damage and mRNA expression of the CDC25C (cell division cycle 25C), CDKN1A (cyclin dependent kinase inhibitor 1A) and CHEK1 (checkpoint kinase 1), SQSTM1 (p62, sequestosome 1), ULK1 (unc-51 like autophagy activating kinase 1), RELA (RELA proto-oncogene, NF-KB subu- nit) and TP53BP1 (tumor protein p53 binding protein 1) genes important for cell cycle regulation, autophagy and cancer progression were investigated. Both drugs induced a moderate decrease in cell viability and a significant DNA damage in both cell lines. The LoVo cells were more sensitive to VPA and combined treatment than Caco-2. The LoVo cells also showed higher expression of genes that are often associated with more aggressive tumors than the Caco-2 cells and treatment with modifiers had increased this difference. In conclusion, 5-aza-dC and VPA can induce different effects in metastatic and non-metastatic cancer cell lines and this may be important in determination of an epigenetic profile responsible for metastatic properties of cancer cells.
C1 [Ghecham, Abdelmoudjib] Univ Batna 2, Biotechnol Lab Bioact Mol & Cellular Physiopathol, Fac Life Sci, Batna, Algeria.
   [Senator, Abderrahmane; Bouafia, Waffa] Univ Batna 2, Fac Life Sci, Batna, Algeria.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, Lodz, Poland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Lodz, Poland.
RP Blasiak, J (corresponding author), Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Pawlowska,
   Elzbieta/0000-0002-5373-4783; Abderrahmane, Senator/0000-0002-3472-0538
CR Al-Temaimi RA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050598
   Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942
   Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169
   Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Caswell DR, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0900-y
   De Greef K, 2016, WORLD J GASTROENTERO, V22, P7215, DOI 10.3748/wjg.v22.i32.7215
   DREWINKO B, 1979, CANCER RES, V39, P2630
   Elshafay A, 2019, CNS DRUGS, V33, P239, DOI 10.1007/s40263-019-00606-6
   Fiskus W, 2017, LEUKEMIA, V31, P1658, DOI 10.1038/leu.2017.77
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Gobble RM, 2011, CANCER RES, V71, P2697, DOI 10.1158/0008-5472.CAN-10-3588
   Habano W, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-81
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   Hu Xin, 2010, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V24, P678
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Jung Y, 2007, J MOL MED, V85, P1137, DOI 10.1007/s00109-007-0216-z
   Khan C, 2012, THER ADV HEMATOL, V3, P355, DOI 10.1177/2040620712464882
   Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016
   Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lobbezoo DJA, 2016, ANN ONCOL, V27, P256, DOI 10.1093/annonc/mdv544
   Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955
   Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591-019-0376-8
   Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Papi A, 2012, ANTICANCER RES, V32, P2855
   Pawlowska E, 2014, INT J MOL SCI, V15, P16649, DOI 10.3390/ijms150916649
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4
   Raynal NJM, 2017, MOL CANCER THER, V16, P397, DOI 10.1158/1535-7163.MCT-16-0588
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229
   Schuh AC, 2017, CRIT REV ONCOL HEMAT, V116, P159, DOI 10.1016/j.critrevonc.2017.05.010
   Schulpis KH, 2006, TOXICOLOGY, V217, P228, DOI 10.1016/j.tox.2005.10.004
   Seelan RS, 2018, DRUG METAB REV, V50, P193, DOI 10.1080/03602532.2018.1437446
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Strey CW, 2011, EXP THER MED, V2, P301, DOI 10.3892/etm.2011.202
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9
   Tung EWY, 2011, REPROD TOXICOL, V32, P255, DOI 10.1016/j.reprotox.2011.05.020
   van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002
   Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545
   Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559
   Yao Hongliang, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P1080, DOI 10.3969/j.issn.1672-7347.2010.10.008
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhao L, 2018, CURR TOP MED CHEM, V18, P2395, DOI 10.2174/1568026619666181224095449
NR 51
TC 2
Z9 2
U1 0
U2 1
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2019
VL 66
IS 3
BP 355
EP 360
DI 10.18388/abp.2019_2814
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IY4XT
UT WOS:000486397000017
PM 31284710
OA gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, T
   Qi, YL
   Liao, MJ
   Xu, M
   Bower, KA
   Frank, JA
   Shen, HM
   Luo, J
   Shi, XL
   Chen, G
AF Zhang, Tao
   Qi, Yuanlin
   Liao, Mingjun
   Xu, Mei
   Bower, Kimberley A.
   Frank, Jacqueline A.
   Shen, Han-Ming
   Luo, Jia
   Shi, Xianglin
   Chen, Gang
TI Autophagy Is a Cell Self-Protective Mechanism Against Arsenic-Induced
   Cell Transformation
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE arsenic; autophagy; oxidative stress; transformation; tumorigenesis
ID MOLECULAR-MECHANISMS; OXIDATIVE STRESS; NEURONAL DEATH; ACTIVATION;
   CANCER; BECLIN-1; TUMORIGENESIS; GENERATION; DAMAGE; MOUSE
AB Subchronic exposure to arsenic increases the incidence of human cancers such as skin, lung, colon, and rectal cancer. The mechanism for arsenic-induced tumorigenesis is still not clear. It is generally believed that DNA damage and genomic instability, generated by arsenic-promoted oxidative stress, account largely for this process. The major sources of reactive oxygen species (ROS) are arsenic-damaged mitochondria. Autophagy is a catabolic process functioning in turnover of long-lived proteins and dysfunctional organelles such as mitochondria. Defects of autophagy under stress conditions promote genomic instability and increase the risk of tumorigenesis. In the present study using a human bronchial epithelial cell line, BEAS-2B cells, we investigated the role of autophagy in arsenic-induced cell transformation, an important step in arsenic tumorigenesis. Our results show that subchronic arsenic exposure induces BEAS-2B cell transformation accompanied with increased ROS generation and autophagy activation. However, the patterns for ROS and autophagy alteration are different. Arsenic exposure generated a prolonged and steady increase of ROS levels, whereas the activation of autophagy, after an initial boost by arsenic administration, decreases in response to subchronic arsenic exposure, although the activity is still higher than a nontreated control. Further stimulation of autophagy increases mitochondria turnover and decreases ROS generation and arsenic-induced cell transformation. Contrarily, inhibition of autophagy activity decreases mitochondria turnover and enhances arsenic-induced ROS generation and cell transformation. In addition, the mammalian target of rapamycin signaling pathway is involved in arsenic-mediated autophagy activation. Our results suggest that autophagy is a cell self-protective mechanism against arsenic-induced cell transformation.
C1 [Zhang, Tao; Qi, Yuanlin; Liao, Mingjun; Xu, Mei; Bower, Kimberley A.; Frank, Jacqueline A.; Luo, Jia; Chen, Gang] Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40536 USA.
   [Zhang, Tao] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350004, Fujian, Peoples R China.
   [Qi, Yuanlin] Fujian Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Fuzhou 350004, Fujian, Peoples R China.
   [Shen, Han-Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore.
   [Shi, Xianglin] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.
RP Chen, G (corresponding author), Univ Kentucky, Coll Med, Dept Internal Med, 125 Hlth Sci Res Bldg,1095 Vet Dr, Lexington, KY 40536 USA.
EM gangchen6@uky.edu
RI Luo, Jia/E-4674-2012; SHEN, Han-Ming/B-5942-2011; Shi,
   Xianglin/B-8588-2012
OI Luo, Jia/0000-0002-6968-3618; SHEN, Han-Ming/0000-0001-7369-5227; Qi,
   Yuanlin/0000-0002-5253-9732
FU American Cancer SocietyAmerican Cancer Society [RSG-11-116-01-CNE]
FX American Cancer Society [RSG-11-116-01-CNE to G.C.].
CR Airoldi I, 2007, P NATL ACAD SCI USA, V104, P3996, DOI 10.1073/pnas.0609028104
   Benbrahim-Tallaa L, 2005, TOXICOL APPL PHARM, V206, P288, DOI 10.1016/j.taap.2004.11.017
   Carames B, 2010, ARTHRITIS RHEUM-US, V62, P791, DOI 10.1002/art.27305
   Carpenter RL, 2011, BIOCHEM BIOPH RES CO, V414, P533, DOI 10.1016/j.bbrc.2011.09.102
   Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje
   Chen G, 2008, J NEUROSCI RES, V86, P937, DOI 10.1002/jnr.21540
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Choi KC, 2010, J NEUROCHEM, V112, P366, DOI 10.1111/j.1471-4159.2009.06463.x
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kimura S, 2009, METHOD ENZYMOL, V452, P1, DOI 10.1016/S0076-6879(08)03601-X
   Krebiehl G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009367
   Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Ling M, 2012, FREE RADICAL BIO MED, V52, P1508, DOI 10.1016/j.freeradbiomed.2012.02.020
   Liu L, 2011, J PHARMACOL EXP THER, V339, P451, DOI 10.1124/jpet.111.180505
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, AUTOPHAGY, V3, P502, DOI 10.4161/auto.4605
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Partridge MA, 2007, CANCER RES, V67, P5239, DOI 10.1158/0008-5472.CAN-07-0074
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Santra A, 2007, TOXICOL APPL PHARM, V220, P146, DOI 10.1016/j.taap.2006.12.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Stipanuk MH, 2009, NUTR REV, V67, P677, DOI 10.1111/j.1753-4887.2009.00252.x
   Sun H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017982
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Wang C, 2011, ACTA BIOCH BIOPH SIN, V43, P425, DOI 10.1093/abbs/gmr028
   Wang X, 2011, TOXICOL SCI, V123, P399, DOI 10.1093/toxsci/kfr180
   Wang Y, 2007, CANCER RES, V67, P3698, DOI 10.1158/0008-5472.CAN-06-4000
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wikstrom JD, 2009, INT J BIOCHEM CELL B, V41, P1914, DOI 10.1016/j.biocel.2009.06.006
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang WY, 2011, TOXICOL IN VITRO, V25, P979, DOI 10.1016/j.tiv.2011.03.009
   Zhang Z, 2011, TOXICOL APPL PHARM, V256, P114, DOI 10.1016/j.taap.2011.07.016
   Zhang ZL, 2012, MOL CELL BIOCHEM, V365, P243, DOI 10.1007/s11010-012-1265-3
NR 45
TC 60
Z9 63
U1 0
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD DEC
PY 2012
VL 130
IS 2
BP 298
EP 308
DI 10.1093/toxsci/kfs240
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 040FN
UT WOS:000311307600009
PM 22869613
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Russo, R
   Cassiano, MGV
   Ciociaro, A
   Adornetto, A
   Varano, GP
   Chiappini, C
   Berliocchi, L
   Tassorelli, C
   Bagetta, G
   Corasaniti, MT
AF Russo, Rossella
   Cassiano, Maria Gilda Valentina
   Ciociaro, Antonella
   Adornetto, Annagrazia
   Varano, Giuseppe Pasquale
   Chiappini, Carlotta
   Berliocchi, Laura
   Tassorelli, Cristina
   Bagetta, Giacinto
   Corasaniti, Maria Tiziana
TI Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in
   SH-SY5Y Neuroblastoma Cells
SO PLOS ONE
LA English
DT Article
ID COLON-CANCER CELLS; IN-VITRO ACTIVITY; RAT; GROWTH; COMPLEX; DEATH;
   PREVENTION; INHIBITION; MECHANISM; SIGNALS
AB Bergamot (Citrus bergamia, Risso et Poiteau) essential oil (BEO) is a well characterized, widely used plant extract. BEO exerts anxiolytic, analgesic and neuroprotective activities in rodents through mechanisms that are only partly known and need to be further investigated. To gain more insight into the biological effects of this essential oil, we tested the ability of BEO (0.005-0.03%) to modulate autophagic pathways in human SH-SY5Y neuroblastoma cells. BEO-treated cells show increased LC3II levels and appearance of dot-like formations of endogenous LC3 protein that colocalize with the lysosome marker LAMP-1. Autophagic flux assay using bafilomycin A1 and degradation of the specific autophagy substrate p62 confirmed that the observed increase of LC3II levels in BEO-exposed cells is due to autophagy induction rather than to a decreased autophagosomal turnover. Induction of autophagy is an early and not cell-line specific response to BEO. Beside basal autophagy, BEO also enhanced autophagy triggered by serum starvation and rapamycin indicating that the underlying mechanism is mTOR independent. Accordingly, BEO did not affect the phosphorylation of ULK1 (Ser757) and p70(S6K) (Thr389), two downstream targets of mTOR. Furthermore, induction of autophagy by BEO is beclin-1 independent, occurs in a concentration-dependent manner and is unrelated to the ability of BEO to induce cell death. In order to identify the active constituents responsible for these effects, the two most abundant monoterpenes found in the essential oil, d-limonene (125-750 mu M) and linalyl acetate (62.5-375 mu M), were individually tested at concentrations comparable to those found in 0.005-0.03% BEO. The same features of stimulated autophagy elicited by BEO were reproduced by d-limonene, which rapidly increases LC3II and reduces p62 levels in a concentration-dependent manner. Linalyl acetate was ineffective in replicating BEO effects; however, it greatly enhanced LC3 lipidation triggered by d-limonene.
C1 [Russo, Rossella; Adornetto, Annagrazia; Varano, Giuseppe Pasquale; Bagetta, Giacinto] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Sect Preclin & Translat Pharmacol, I-87036 Cosenza, Italy.
   [Cassiano, Maria Gilda Valentina; Ciociaro, Antonella; Chiappini, Carlotta; Berliocchi, Laura; Corasaniti, Maria Tiziana] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tassorelli, Cristina] Univ Pavia, Headache Sci Ctr, Natl Neurol Inst C Mondino, I-27100 Pavia, Italy.
   [Tassorelli, Cristina] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy.
RP Russo, R (corresponding author), Univ Calabria, Dept Pharm Hlth & Nutr Sci, Sect Preclin & Translat Pharmacol, I-87036 Cosenza, Italy.
EM rossella.russo@unical.it; mtcorasa@unicz.it
RI Tassorelli, Cristina/AAC-1483-2019; Adornetto, Annagrazia/AAG-5467-2020;
   Bagetta, Giacinto/E-8402-2012; Bagetta, Giacinto/N-9716-2018;
   Corasaniti, Maria Tiziana/N-1332-2015
OI Tassorelli, Cristina/0000-0003-1513-2113; Adornetto,
   Annagrazia/0000-0003-1869-2642; Bagetta, Giacinto/0000-0001-8540-6218;
   Bagetta, Giacinto/0000-0001-8540-6218; Corasaniti, Maria
   Tiziana/0000-0001-6472-0697; Russo, Rossella/0000-0001-8758-6523;
   Berliocchi, Laura/0000-0002-3014-1838
CR Amantea D, 2009, INT REV NEUROBIOL, V85, P389, DOI 10.1016/S0074-7742(09)85027-7
   Bagetta G, 2010, FITOTERAPIA, V81, P453, DOI 10.1016/j.fitote.2010.01.013
   Banerjee R, 2010, TRENDS NEUROSCI, V33, P541, DOI 10.1016/j.tins.2010.09.001
   Berliocchi L, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-83
   Berliocchi L, 2011, FOOD CHEM TOXICOL, V49, P2780, DOI 10.1016/j.fct.2011.08.017
   Bicas JL, 2011, FOOD CHEM TOXICOL, V49, P1610, DOI 10.1016/j.fct.2011.04.012
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chaudhary SC, 2012, HUM EXP TOXICOL, V31, P798, DOI 10.1177/0960327111434948
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Corasaniti MT, 2007, BRIT J PHARMACOL, V151, P518, DOI 10.1038/sj.bjp.0707237
   Cosentino M, 2014, PHYTOTHER RES
   CROWELL PL, 1991, J BIOL CHEM, V266, P17679
   Dugo P, 2000, J PHARMACEUT BIOMED, V24, P147, DOI 10.1016/S0731-7085(00)00400-3
   ELSON CE, 1988, CARCINOGENESIS, V9, P331, DOI 10.1093/carcin/9.2.331
   Manuele MG, 2010, CANCER INVEST, V28, P135, DOI 10.3109/07357900903179583
   Manuele MG, 2009, PHYTOTHER RES, V23, P1011, DOI 10.1002/ptr.2743
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Itani WS, 2008, CANCER BIOL THER, V7, P1765, DOI 10.4161/cbt.7.11.6740
   Jia SS, 2013, ONCOL REP, V29, P349, DOI 10.3892/or.2012.2093
   Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karlson J, 1996, ANTI-CANCER DRUG, V7, P422, DOI 10.1097/00001813-199606000-00008
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Laird K, 2012, J HOSP INFECT, V80, P61, DOI 10.1016/j.jhin.2011.04.008
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   MALTZMAN TH, 1989, CARCINOGENESIS, V10, P781, DOI 10.1093/carcin/10.4.781
   Miller JA, 2013, CANCER PREV RES, V6, P577, DOI 10.1158/1940-6207.CAPR-12-0452
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mondello L, 1993, FLAVOUR FRAG J, V8, P17, DOI 10.1002/ffj.2730080105
   Mondello Luigi, 1995, Flavour and Fragrance Journal, V10, P33, DOI 10.1002/ffj.2730100106
   Morrone LA, 2007, PHARMACOL RES, V55, P255, DOI 10.1016/j.phrs.2006.11.010
   Murthy KNC, 2012, LIFE SCI, V91, P429, DOI 10.1016/j.lfs.2012.08.016
   Ndao DH, 2012, PSYCHO-ONCOLOGY, V21, P247, DOI 10.1002/pon.1898
   Rabi Thangaiyan, 2009, J Carcinog, V8, P9, DOI 10.4103/1477-3163.51368
   Romano L, 2005, J ANTIMICROB CHEMOTH, V55, P110, DOI 10.1093/jac/dkh503
   Rombola L, 2009, FUNCT NEUROL, V24, P107
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Russo R, 2013, FITOTERAPIA, V89, P48, DOI 10.1016/j.fitote.2013.05.014
   Saiyudthong S, 2011, PHYTOTHER RES, V25, P858, DOI 10.1002/ptr.3325
   Sakurada T, 2009, INT REV NEUROBIOL, V85, P237, DOI 10.1016/S0074-7742(09)85018-6
   Sanguinetti M, 2007, J ANTIMICROB CHEMOTH, V59, P305, DOI 10.1093/jac/dkl473
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Verzera A, 2003, J AGR FOOD CHEM, V51, P206, DOI 10.1021/jf0206872
   Verzera A., 1996, Perfumer & Flavorist, V21, P19
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
NR 49
TC 27
Z9 28
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 24
PY 2014
VL 9
IS 11
AR e113682
DI 10.1371/journal.pone.0113682
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AX2IM
UT WOS:000346766900064
PM 25419658
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Tao, XX
   Yan, YF
   Lu, LM
   Chen, B
AF Tao, Xiangxiang
   Yan, Yifeng
   Lu, Linming
   Chen, Bing
TI HDAC10 expression is associated with DNA mismatch repair gene and is a
   predictor of good prognosis in colon carcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE colon cancer; HDAC10; prognosis; tissue microarray; immunohistochemistry
ID CANCER PATIENTS; POOR-PROGNOSIS; AUTOPHAGY; DEACETYLATION
AB Despite increasing evidence of the involvement of histone deacetylase (HDAC) 10 in cancer tumorigenesis, the potential role of HDAC10 in colon cancer remains unclear. Oncomine database analysis revealed that HDAC10 mRNA was significantly upregulated in colon cancer. In an independent cohort, consistent with mRNA expression levels, constitutively high HDAC10 expression was observed in the cytoplasm and nucleus compared with in adjacent normal tissues (cytoplasm, 93.12 +/- 12.98 vs. 31.65 +/- 26.50%; nucleus, 84.16 +/- 19.23 vs. 68.64 +/- 19.00%). Cytoplasmic HDAC expression correlated with gender (r=0.265; P<0.05), lymph node metastasis (N stage; r=0.256; P<0.05) and distant metastasis (M stage; r=0.331; P<0.05) in paracarcinoma tissues. Cytoplasmic HDAC10 expression in tumors was not associated with the four DNA mismatch repair genes examined, but was negatively correlated with mutL homolog 1 (MLH1) (r=-0.244; P<0.05), mutS homolog (MSH)2 (r=-0.410; P<0.01) and MSH6 (r=-0.240; P<0.05) in paracarcinoma tissues. Similarly, nuclear HDAC10 expression was negatively correlated with MLH1 expression (r=-0.288; P<0.05). The findings of the current study suggest that HDAC10 expression is associated with good prognosis in colon cancer tissues and poor prognosis in paracarcinoma tissues with a potential involvement in DNA mismatch repair.
C1 [Tao, Xiangxiang; Lu, Linming; Chen, Bing] Wannan Med Coll, Dept Pathol, 22 Wenchang West Rd, Wuhu 241001, Anhui, Peoples R China.
   [Yan, Yifeng] Wannan Med Coll, Dept Forens Pathol, Wuhu 241001, Anhui, Peoples R China.
RP Chen, B (corresponding author), Wannan Med Coll, Dept Pathol, 22 Wenchang West Rd, Wuhu 241001, Anhui, Peoples R China.
EM 281993214@qq.com
CR Bauer KM, 2012, MOL CARCINOGEN, V51, P411, DOI 10.1002/mc.20804
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Clocchiatti A, 2011, J CELL MOL MED, V15, P1833, DOI 10.1111/j.1582-4934.2011.01321.x
   Fan WX, 2015, INT J CLIN EXP MED, V8, P3734
   Islam MM, 2017, GYNECOL ONCOL, V144, P613, DOI 10.1016/j.ygyno.2017.01.009
   Jin ZL, 2014, INT J CLIN EXP PATHO, V7, P5872
   Kotian S, 2011, J BIOL CHEM, V286, P7722, DOI 10.1074/jbc.C110.194233
   Lai IL, 2010, J BIOL CHEM, V285, P7187, DOI 10.1074/jbc.M109.061861
   Lee JH, 2010, MOL CELLS, V30, P107, DOI 10.1007/s10059-010-0094-z
   Li YX, 2015, MOL CELL BIOL, V35, P3547, DOI 10.1128/MCB.00400-15
   Oehme I, 2013, AUTOPHAGY, V9, P2163, DOI 10.4161/auto.26450
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395
   Park BL, 2007, BIOCHEM BIOPH RES CO, V363, P776, DOI 10.1016/j.bbrc.2007.09.026
   Petrelli F., 2016, JAMA ONCOL
   Pinto G, 2016, J NUTR BIOCHEM, V27, P171, DOI 10.1016/j.jnutbio.2015.08.031
   Powers J, 2016, METHODS MOL BIOL, V1436, P129, DOI 10.1007/978-1-4939-3667-0_10
   Radhakrishnan R, 2015, J BIOL CHEM, V290, P22795, DOI 10.1074/jbc.M114.612945
   Song CL, 2013, J BIOL CHEM, V288, P28021, DOI 10.1074/jbc.M113.498758
   Wang XJ, 2014, KIDNEY INT, V86, P712, DOI 10.1038/ki.2014.111
   Yang YW, 2016, ONCOTARGET, V7, P59388, DOI 10.18632/oncotarget.10673
   Yuan ZG, 2010, J BIOL CHEM, V285, P39329, DOI 10.1074/jbc.M110.179333
NR 22
TC 9
Z9 9
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2017
VL 14
IS 4
BP 4923
EP 4929
DI 10.3892/ol.2017.6818
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FK0DU
UT WOS:000413151300151
PM 29085502
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, B
   Liu, LT
AF Zhang, Bo
   Liu, Lantao
TI Autophagy is a double-edged sword in the therapy of colorectal cancer
SO ONCOLOGY LETTERS
LA English
DT Review
DE autophagy; Beclin 1; chemotherapy; colorectal cancer; apoptosis
AB Colorectal cancer is one of the leading causes of cancer-associated mortality worldwide. The limitations of colorectal cancer treatment include various types of multidrug resistance and the contingent damage to neighboring normal cells caused by chemotherapy. Macroautophagy/autophagy and apoptosis are essential mechanisms involved in cancer cell regulation of chemotherapy. Autophagy can either cause cancer cell death or promote tumor survival during colorectal cancer. Given that autophagy is involved in chemotherapy of colorectal cancer, an improved insight into the potential interactions between apoptosis and autophagy is crucial. The present review aimed to summarize the involvement of autophagy in the regulation of colorectal cancer and its association with chemotherapy. Furthermore, the role of natural product extraction, novel chemicals and small molecules, as well as radiation, which induce autophagy in colorectal cancer cells, were reviewed. Finally, the present review aimed to provide an outlook for the regulation of autophagy as a novel approach to the treatment of cancer, particularly chemotherapy-resistant colorectal cancer.
C1 [Zhang, Bo; Liu, Lantao] Beijing Inst Occupat Dis Prevent & Treatment, Med Lab Radiat Res, 50 Yikesong Rd, Beijing 100093, Peoples R China.
   [Zhang, Bo] Jinzhou Med Univ, Coll Food Sci & Engn, Jinzhou 121000, Liaoning, Peoples R China.
RP Liu, LT (corresponding author), Beijing Inst Occupat Dis Prevent & Treatment, Med Lab Radiat Res, 50 Yikesong Rd, Beijing 100093, Peoples R China.
EM lantao.liu@163.com
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Athamneh K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11202-3
   Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427
   Beccafico S, 2015, CARCINOGENESIS, V36, P1071, DOI 10.1093/carcin/bgv098
   Bellezza I, 2020, CELL MOL LIFE SCI, V77, P3547, DOI 10.1007/s00018-020-03476-0
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bravo-San Pedro JM, 2015, AUTOPHAGY, V11, P452, DOI 10.1080/15548627.2015.1017191
   Burman C, 2010, SEMIN IMMUNOPATHOL, V32, P397, DOI 10.1007/s00281-010-0222-z
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Chen MJ, 2016, INT J ONCOL, V49, P316, DOI 10.3892/ijo.2016.3514
   Chen YJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2004-4
   Cheng ZY, 2019, TRENDS ENDOCRIN MET, V30, P658, DOI 10.1016/j.tem.2019.07.009
   Chifenti Barbara, 2013, Clin Exp Reprod Med, V40, P33, DOI 10.5653/cerm.2013.40.1.33
   Choi PR, 2015, INT J ONCOL, V47, P563, DOI 10.3892/ijo.2015.3031
   Coker-Gurkan A, 2015, ONCOL REP, V33, P2761, DOI 10.3892/or.2015.3918
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Dai LZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13334-y
   Dai S, 2019, MOL CANCER THER, V18, P1265, DOI 10.1158/1535-7163.MCT-18-1241
   Ding Z., 2019, J BUON, V24, P130
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Emanuele S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101490
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Guaman-Ortiz LM, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/1565306
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Gurkan AC, 2018, CELL ONCOL, V41, P297, DOI 10.1007/s13402-017-0369-x
   Helgason GV, 2013, ESSAYS BIOCHEM, V55, P133, DOI [10.1042/bse0550133, 10.1042/BSE0550133]
   Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Hussain A, 2016, MOL CARCINOGEN, V55, P2135, DOI 10.1002/mc.22457
   Jiang F, 2018, INT J MOL MED, V42, P1295, DOI 10.3892/ijmm.2018.3712
   Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329
   Kou JY, 2017, ONCOTARGET, V8, P81591, DOI 10.18632/oncotarget.20189
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li DD, 2016, ONCOTARGET, V7, P80842, DOI 10.18632/oncotarget.13099
   Lignitto L, 2019, CELL, V178, P316, DOI 10.1016/j.cell.2019.06.003
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Liu D, 2017, CHIN J INTEGR MED, V23, P312, DOI 10.1007/s11655-016-2271-1
   Liu YX, 2018, BIOCHEM BIOPH RES CO, V498, P246, DOI 10.1016/j.bbrc.2018.01.091
   Lu R, 2019, FASEB J, V33, P11845, DOI 10.1096/fj.201900727R
   Luan YP, 2018, INT J MOL MED, V41, P1305, DOI 10.3892/ijmm.2017.3337
   Luo H, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0270-9
   Ma YM, 2015, ACTA PHARMACOL SIN, V36, P517, DOI 10.1038/aps.2014.157
   Maraming P, 2019, J CELL PHYSIOL, V234, P22116, DOI 10.1002/jcp.28774
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Menon MB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00137
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mou LJ, 2019, J BUON, V24, P1870
   Moura AF, 2018, TOXICOL IN VITRO, V47, P129, DOI 10.1016/j.tiv.2017.11.014
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Ouyang GQ, 2018, PHOTODIAGN PHOTODYN, V21, P396, DOI 10.1016/j.pdpdt.2018.01.010
   Pal I, 2015, EUR J PHARMACOL, V765, P217, DOI 10.1016/j.ejphar.2015.08.039
   Pandurangan AK, 2018, ARCH MED SCI, V14, P1281, DOI 10.5114/aoms.2018.76935
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Potocnjak I, 2020, TOXICOL IN VITRO, V66, DOI 10.1016/j.tiv.2020.104852
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Rothenberg C, 2010, HUM MOL GENET, V19, P3219, DOI 10.1093/hmg/ddq231
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Roy Badal Chandra, 2019, Oncotarget, V10, P2340, DOI 10.18632/oncotarget.26684
   Saad ED, 2020, CANCERS, V12, DOI 10.3390/cancers12113442
   Satoh J, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-68
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Shao LN, 2016, MOL MED REP, V13, P2661, DOI 10.3892/mmr.2016.4820
   Shen H, 2018, J CELL BIOCHEM, V119, P7022, DOI 10.1002/jcb.26912
   Shiratori H, 2019, ONCOL REP, V42, P377, DOI 10.3892/or.2019.7134
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sommerer C, 2016, KIDNEY DIS-BASEL, V2, P120, DOI 10.1159/000449394
   Song JR, 2011, J CELL BIOCHEM, V112, P3406, DOI 10.1002/jcb.23274
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Talero E, 2016, INT IMMUNOPHARMACOL, V35, P248, DOI 10.1016/j.intimp.2016.03.046
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Towers CG, 2019, DEV CELL, V50, P690, DOI 10.1016/j.devcel.2019.07.010
   Trivedi PP, 2016, MOL CARCINOGEN, V55, P255, DOI 10.1002/mc.22274
   Tschan MP, 2010, J INTERN MED, V268, P410, DOI 10.1111/j.1365-2796.2010.02266.x
   Tuncer S, 2020, FEBS J, V287, P2504, DOI 10.1111/febs.15152
   Vasilevskaya IA, 2016, MOL CANCER RES, V14, P753, DOI 10.1158/1541-7786.MCR-16-0035
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wang D, 2019, J BUON, V24, P1824
   Wasik AM, 2014, INT REV CEL MOL BIO, V308, P167, DOI 10.1016/B978-0-12-800097-7.00005-1
   Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005
   Wu H, 2019, DIGEST ENDOSC, V31, P508, DOI 10.1111/den.13353
   Wu MY, 2021, AUTOPHAGY, V17, P1096, DOI 10.1080/15548627.2020.1741332
   Xie QQ, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100871
   Xie ZY, 2018, BIOCHIMIE, V147, P55, DOI 10.1016/j.biochi.2017.12.013
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xiong W, 2019, J BUON, V24, P1488
   Xiong Y, 2019, MED SCI MONITOR, V25, P6015, DOI 10.12659/MSM.916116
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yoshimoto T, 2018, ANN GASTROENT SURG, V2, P154, DOI 10.1002/ags3.12055
   You PT, 2018, BIOMED PHARMACOTHER, V98, P619, DOI 10.1016/j.biopha.2017.12.057
   Young LN, 2016, P NATL ACAD SCI USA, V113, P8224, DOI 10.1073/pnas.1603650113
   Yu ZY, 2018, ONCOL LETT, V15, P3127, DOI 10.3892/ol.2017.7677
   Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068
   Ramirez JAZ, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106495
   Zhang MY, 2019, ONCOL LETT, V17, P2441, DOI 10.3892/ol.2018.9817
   Zhang P, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0661-7
   Zhang R, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317703984
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
   Zhou W, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00068
   Zhu JH, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7203584
   Ziolkowska B, 2016, MOL MED REP, V14, P2548, DOI 10.3892/mmr.2016.5541
NR 111
TC 4
Z9 4
U1 8
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2021
VL 21
IS 5
AR 378
DI 10.3892/ol.2021.12639
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RC6VQ
UT WOS:000632936600001
PM 33777202
OA Green Published, gold
DA 2022-04-25
ER

PT S
AU Chen, LX
   Zhou, YX
   Sun, QH
   Zhou, JC
   Pan, HM
   Sui, XB
AF Chen, Liuxi
   Zhou, Yuxia
   Sun, Qiuhua
   Zhou, Jichun
   Pan, Hongming
   Sui, Xinbing
BE Galluzzi, L
   Vitale, I
TI Regulation of Autophagy by MiRNAs and Their Emerging Roles in
   Tumorigenesis and Cancer Treatment
SO MIRNAS IN AGING AND CANCER
SE International Review of Cell and Molecular Biology
LA English
DT Review; Book Chapter
ID HEPATOCELLULAR-CARCINOMA CELLS; HYPOXIA-INDUCED AUTOPHAGY;
   DOWN-REGULATION; INHIBITING AUTOPHAGY; COLORECTAL-CANCER; NUCLEAR
   EXPORT; MICRORNA GENES; RNA-INTERFERENCE; CERVICAL-CANCER;
   FAMILY-MEMBERS
AB Autophagy is a conserved catabolic process for the degradation and recycling of cytosolic components or organelles through a lysosome-dependent pathway. Autophagy can be induced in response to multiple stress conditions, such as nutrient deprivation, hypoxia, energy depletion, etc. As a result, autophagy can regulate many biological processes, including cell survival, metabolism, differentiation, senescence, and cell death. MicroRNAs (MiRNAs) are small noncoding molecules that regulate gene expression by silencing mRNA targets. MiRNA dysregulation exhibits great regulatory potential during organismal development, hematopoiesis, immunity, cell proliferation and death, and autophagy. Recently, increasing studies have linked MiRNAs to autophagic regulation during cancer initiation and development. Although the relationship between MiRNAs and autophagy is quite complicated and has not been well elucidated, MiRNAs may underlie key aspects of autophagy and cancer biology. Increasing evidence shows that MiRNAs play important roles as both oncogenic MiRNAs and tumor suppressive MiRNAs in cancer initiation and development. Thus, understanding the novel relationship between MiRNAs and autophagy may allow us to develop promising cancer biomarkers and therapeutic targets.
C1 [Chen, Liuxi; Zhou, Jichun; Pan, Hongming; Sui, Xinbing] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Yuxia] Shandong Maternal & Child Hlth Hosp, Jinan, Shandong, Peoples R China.
   [Sun, Qiuhua; Sui, Xinbing] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China.
RP Zhou, JC; Pan, HM; Sui, XB (corresponding author), Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.; Sui, XB (corresponding author), Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China.
EM zjc@live.com; drpanhm@aliyun.com; hzzju@aliyun.com
RI Zhou, Jichun/Q-8646-2019
OI Zhou, Jichun/0000-0002-0727-4034
CR Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bernard A, 2013, DEV CELL, V25, P116, DOI 10.1016/j.devcel.2013.04.004
   Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chang Y, 2012, AUTOPHAGY, V8, P1833, DOI 10.4161/auto.21796
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen X, 2016, ONCOTARGET, V7, P9222, DOI 10.18632/oncotarget.7003
   Chen Yong, 2012, Sci Rep, V2, P808, DOI 10.1038/srep00808
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Clarke PGH, 2012, AUTOPHAGY, V8, P867, DOI 10.4161/auto.20380
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602
   Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131
   Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070
   Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102
   Feng LF, 2014, AUTOPHAGY, V10, P1442, DOI 10.4161/auto.29486
   Feng YC, 2015, TRENDS CELL BIOL, V25, P354, DOI 10.1016/j.tcb.2015.02.002
   Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Gaur S, 2015, ONCOTARGET, V6, P29161, DOI 10.18632/oncotarget.4971
   Ge YY, 2014, ONCOTARGET, V5, P6218, DOI 10.18632/oncotarget.2189
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Guo JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140745
   Guo X, 2015, ONCOTARGET, V6, P41620, DOI 10.18632/oncotarget.5871
   Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043
   Han ML, 2012, CANCER SCI, V103, P1058, DOI 10.1111/j.1349-7006.2012.02281.x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harmalkar M, 2015, J MOL NEUROSCI, V57, P197, DOI 10.1007/s12031-015-0602-x
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Inguscio Valentina, 2012, Cells, V1, P464, DOI 10.3390/cells1030464
   Izzotti A, 2016, AM J CANCER RES, V6, P1461
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim J, 2014, INT J PHOTOENERGY, V2014, DOI 10.1155/2014/324859
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lan SH, 2014, AUTOPHAGY, V10, P1687, DOI 10.4161/auto.29959
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044
   Li X., 2014, BIORESOUR BIOPROC, V1, P1, DOI DOI 10.1007/S10404-014-1340-Z
   Liang C, 2015, ONCOTARGET, V6, P14440, DOI 10.18632/oncotarget.3885
   Lin F, 2015, EUR J GYNAECOL ONCOL, V36, P432
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nam YH, 2011, EURASIP J WIREL COMM, DOI 10.1186/1687-1499-2011-184
   Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407
   Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200
   Peralta-Zaragoza O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2231-3
   Piletic K, 2016, ARCH TOXICOL, V90, P2405, DOI 10.1007/s00204-016-1815-7
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954
   Shen SN, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-69
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004
   Song LL, 2016, TUMOR BIOL, V37, P12161, DOI 10.1007/s13277-016-5073-3
   Sorel Oceane, 2016, BioMolecular Concepts, V7, P229, DOI 10.1515/bmc-2016-0017
   Stiuso P, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.8
   Stojcheva N, 2016, ONCOTARGET, V7, P12937, DOI 10.18632/oncotarget.7346
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tanaka K, 2015, CARCINOGENESIS, V36, P894, DOI 10.1093/carcin/bgv067
   Tazawa H, 2012, INT J CANCER, V131, P2939, DOI 10.1002/ijc.27589
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep33229
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang Z. M., 2014, J NONLINEAR FUNCT AN, DOI DOI 10.1007/978-3-319-01796-9_
   Wei RX, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160238
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497
   Yang XJ, 2013, BIOCHEM BIOPH RES CO, V431, P617, DOI 10.1016/j.bbrc.2012.12.083
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 144
TC 23
Z9 24
U1 2
U2 24
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1937-6448
BN 978-0-12-811869-6; 978-0-12-811868-9
J9 INT REV CEL MOL BIO
JI Int. Rev. Cell Mol. Biol.
PY 2017
VL 334
BP 1
EP 26
DI 10.1016/bs.ircmb.2017.03.003
PG 26
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Geriatrics &
   Gerontology
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Geriatrics &
   Gerontology
GA BI7LN
UT WOS:000414404700001
PM 28838537
DA 2022-04-25
ER

PT J
AU Guo, JB
   Ma, YB
   Peng, XQ
   Jin, HY
   Liu, JG
AF Guo, Jianbo
   Ma, Yingbo
   Peng, Xueqiang
   Jin, Hongyuan
   Liu, Jingang
TI LncRNA CCAT1 promotes autophagy via regulating ATG7 by sponging miR-181
   in hepatocellular carcinoma
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE autophagy-related gene 7; autophagy; colon cancer associated transcript
   1; hepatocellular carcinoma; long noncoding RNA
ID LONG NONCODING RNAS; CANCER; PROLIFERATION; EXPRESSION
AB Background Hepatocellular carcinoma (HCC) is a significant clinical challenge, and the mechanisms underlying HCC pathogenesis remain incompletely understood. Colon cancer associated transcript 1 (CCAT1), is one novel long noncoding RNA (lncRNA) which is upregulated in HCC. Autophagy is a vital process in HCC progression, and it is unknown whether CCAT1 regulates autophagy in HCC. Materials and methods Immunofluorescence staining and transmission electron microscopy were used to analyze autophagy activity. Luciferase assay was performed to confirm miRNA-181a-5p (miR-181a-5p) bind CCAT1 and ATG7. Results CCAT1 levels were higher in tissue and cell lines of HCC. In function research, we found that CCAT1 facilitates HCC cell autophagy and cell proliferation. Our results show that, mechanistically, CCAT1 promotes autophagy through functioning as a sponge for miR-181a-5p, and then regulating ATG7 expression. Conclusion Our findings indicate CCAT1 may play a role in regulating autophagy by sponging miR-181a-5p in HCC.
C1 [Guo, Jianbo; Ma, Yingbo; Peng, Xueqiang; Jin, Hongyuan; Liu, Jingang] China Med Univ, Affiliated Hosp 4, Dept Gen Surg, Shenyang 110032, Liaoning, Peoples R China.
RP Liu, JG (corresponding author), China Med Univ, Affiliated Hosp 4, Dept Gen Surg, Shenyang 110032, Liaoning, Peoples R China.
EM liujg0347@126.com
CR Bhardwaj N, 2016, J TRANSPLANT, V2016, DOI 10.1155/2016/7926264
   Chen S, 2013, CLIN CANCER RES, V19, P6853, DOI 10.1158/1078-0432.CCR-13-1617
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063
   Deng L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0136-7
   Dou CQ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697572
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9
   Granito A, 2017, LANCET ONCOL, V18, pE101, DOI 10.1016/S1470-2045(16)30569-1
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   He XL, 2014, TUMOR BIOL, V35, P12181, DOI 10.1007/s13277-014-2526-4
   He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021
   Huang JL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0841-x
   Hui X, 2013, BIOMED RES INT, V2013
   Long B, 2018, BIOCHEM BIOPH RES CO, V495, P312, DOI 10.1016/j.bbrc.2017.11.030
   Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541
   Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547
   Ozawa T, 2017, ANN ONCOL, V28, P1882, DOI 10.1093/annonc/mdx248
   Sacco R, 2017, J HEPATOCELL CARCINO, V4, P105, DOI 10.2147/JHC.S103661
   Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001
   Shi LX, 2016, VIRUS RES, V223, P131, DOI 10.1016/j.virusres.2016.06.008
   Sun JF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0771-x
   Suzuki K, 2013, J CELL SCI, V126, P2534, DOI 10.1242/jcs.122960
   Wu YY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0715-7
   Xin XR, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0843-8
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Ye RF, 2018, BIOMED PHARMACOTHER, V105, P962, DOI 10.1016/j.biopha.2018.06.065
   Zhu Hua-Qiang, 2015, Asian Pac J Cancer Prev, V16, P5181
   Zhu HQ, 2015, INT J CLIN EXP PATHO, V8, P5427
NR 30
TC 22
Z9 25
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2019
VL 120
IS 10
BP 17975
EP 17983
DI 10.1002/jcb.29064
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IU4IQ
UT WOS:000483551100149
PM 31218739
DA 2022-04-25
ER

PT J
AU Mokri, N
   Sepehri, Z
   Faninam, F
   Khaleghi, S
   Kazemi, NM
   Hashemi, M
AF Mokri, Negin
   Sepehri, Zahra
   Faninam, Farnaz
   Khaleghi, Sepideh
   Kazemi, Negar Motakef
   Hashemi, Mehrdad
TI Chitosan-coated Zn-metal-organic framework nanocomposites for effective
   targeted delivery of LNA-antisense miR-224 to colon tumor: in vitro
   studies
SO GENE THERAPY
LA English
DT Article; Early Access
ID DRUG-DELIVERY; G4 DENDRIMER; CANCER; PROLIFERATION; NANOPARTICLES;
   EXPRESSION; CELLS; APOPTOSIS; INVASION
AB Nowadays, nano-compartments are considered as an effective drug delivery system (DDS) for cancer therapy. Targeted delivery of therapeutic agents is an advantageous approach by which cancer cells can be targeted without harming normal cells, and eliminates the negative effects of conventional therapies such as chemotherapy. In this research, a novel zinc-based nanoscale metal-organic framework (Zn-NMOF) coated with folic acid (FA) functionalized chitosan (CS) has been constructed and applied as efficient delivery of LNA (locked nucleic acid)-antisense miR-224 to colon cancer cell lines. LNA-antisense miR-224 as a therapeutic sequence was able to considerably block highly expressed miR-224 and downregulated cancer cell growth. The prepared nano-complex was characterized by analytical devices such as FT-IR, UV-Vis spectrophotometry, DLS, TEM, and XRD. The size range of NMOF-CS-FA-LNA-antisense miR-224 (MCFL224) nano-complex was obtained nearly at 200 nm. The entrapment efficiency of LNA-antisense miR-224 was calculated 72 +/- 5% and a significant release profile of LNA-antisense miR-224 was observed at first 6 h (about 50%). Then, in vitro assays were implemented on HCT116 (folic acid receptor-positive colon cancer cell line) and CRL1831 (normal colon cell line) to evaluate the therapeutic efficiency of the MCFL224 nano-complex. In these investigations, decreased cell viability (14.22 +/- 0.3% after 72 h treatment), increased apoptotic and autophagy-related genes expression level (BECLIN1: 34-folds, BAX: 36-folds, mTORC1: 10-folds, and Caspase-9: 9-folds more than control), higher cell cycle arrest in sub-G1 phase (19.53% of cells in sub-G1 phase), and more apoptosis analyses (late apoptosis: 67.7%) were evaluated in colon cancer cells treated with MCFL224 nano-complex. Results remarkably indicate the inhibited growth of colon cancer cells and induced cell apoptosis which suggests MCFL224 as a promising nanocomposite for colon cancer therapy.
C1 [Mokri, Negin; Khaleghi, Sepideh] Islamic Azad Univ, Tehran Med Sci, Fac Adv Sci & Technol, Dept Biotechnol, Tehran, Iran.
   [Sepehri, Zahra; Faninam, Farnaz] Islamic Azad Univ, North Tehran Branch, Dept Life Sci, Fac Biol, Tehran, Iran.
   [Kazemi, Negar Motakef] Islamic Azad Univ, Dept Med Nanotechnol, Fac Adv Sci & Technol, Tehran Med Sci, Tehran, Iran.
   [Hashemi, Mehrdad] Islamic Azad Univ, Dept Genet, Fac Adv Sci & Technol, Tehran Med Sci, Tehran, Iran.
RP Khaleghi, S (corresponding author), Islamic Azad Univ, Tehran Med Sci, Fac Adv Sci & Technol, Dept Biotechnol, Tehran, Iran.
EM s.khaleghi@iautmu.ac.ir
OI Khaleghi, Sepideh/0000-0002-1817-3116; Hashemi,
   Mehrdad/0000-0003-0627-6991
CR Abazari R, 2018, INORG CHEM, V57, P13364, DOI 10.1021/acs.inorgchem.8b01955
   Ali MEA, 2018, SEP SCI TECHNOL, V53, P2870, DOI 10.1080/01496395.2018.1489845
   Bwatanglang IB, 2016, J COLLOID INTERF SCI, V480, P146, DOI 10.1016/j.jcis.2016.07.011
   Chalati T, 2011, J MATER CHEM, V21, P2220, DOI 10.1039/c0jm03563g
   Chen Y, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8070486
   Cosco D, 2015, SCI REP-UK, V5, DOI 10.1038/srep17579
   Daryasari MP, 2016, RSC ADV, V6, P105578, DOI 10.1039/c6ra23182a
   Deng XW, 2014, BIOMATERIALS, V35, P4333, DOI 10.1016/j.biomaterials.2014.02.006
   Ding SC, 2020, MATER TODAY, V37, P112, DOI 10.1016/j.mattod.2020.02.001
   Duan JJ, 2015, MACROMOLECULES, V48, P2706, DOI 10.1021/acs.macromol.5b00117
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ghaffar I, 2019, MAT SCI ENG C-MATER, V105, DOI 10.1016/j.msec.2019.110111
   Hajiashrafi S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02152
   Hidalgo T, 2017, SCI REP-UK, V7, DOI 10.1038/srep43099
   Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867
   Huang L, 2012, BIOCHEM BIOPH RES CO, V425, P127, DOI 10.1016/j.bbrc.2012.07.025
   Jiang YW, 2012, MOL MED REP, V5, P890, DOI 10.3892/mmr.2012.776
   Ju EG, 2020, ACS NANO, V14, P476, DOI 10.1021/acsnano.9b06333
   Karsy Michael, 2012, Genes Cancer, V3, P3, DOI 10.1177/1947601912448068
   Krishna M, 2017, J CLIN EPIGENET, V3, P38, DOI [10.21767/2472-1158.100072, DOI 10.21767/2472-1158.100072]
   Kumari R, 2020, J CONTROL RELEASE, V319, P135, DOI 10.1016/j.jconrel.2019.12.041
   Levy JMM, 2020, CELL DEATH DIFFER, V27, P843, DOI [10.1038/s41418-019-0474, 10.1038/s41418-019-0474-7]
   Liang K, 2017, CHEM COMMUN, V53, P1249, DOI 10.1039/c6cc09680h
   Liao WT, 2013, CLIN CANCER RES, V19, P4662, DOI 10.1158/1078-0432.CCR-13-0244
   Lin Q, 2015, MOL MED REP, V12, P5709, DOI 10.3892/mmr.2015.4185
   Liu L, 2019, DALTON T, V48, P6951, DOI 10.1039/c9dt00503j
   Mombini S, 2019, INT J BIOL MACROMOL, V140, P278, DOI 10.1016/j.ijbiomac.2019.08.046
   Murad H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0315-4
   Narmani A, 2020, BIOMED MICRODEVICES, V22, DOI 10.1007/s10544-020-00485-5
   Narmani A, 2019, DRUG DEVELOP RES, V80, P404, DOI 10.1002/ddr.21545
   Narmani A, 2019, J DRUG DELIV SCI TEC, V50, P278, DOI 10.1016/j.jddst.2019.01.037
   Narmani A, 2018, PROCESS BIOCHEM, V69, P178, DOI 10.1016/j.procbio.2018.01.014
   Narmani A, 2018, J DRUG DELIV SCI TEC, V44, P457, DOI 10.1016/j.jddst.2018.01.011
   Narmani A, 2018, PROCESS BIOCHEM, V65, P46, DOI 10.1016/j.procbio.2017.10.009
   Narmani A, 2017, COLLOID SURFACE B, V159, P232, DOI 10.1016/j.colsurfb.2017.07.089
   Rezvani M, 2018, INT J BIOL MACROMOL, V113, P1287, DOI 10.1016/j.ijbiomac.2018.02.141
   Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194
   SPECIFICATIONS Q., 2000, TRANSF REAG
   Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023
   Tekie FSM, 2015, INT J BIOL MACROMOL, V81, P828, DOI 10.1016/j.ijbiomac.2015.09.014
   Towers CG, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201909033
   Tu L, 2017, MAT SCI ENG C-MATER, V72, P177, DOI 10.1016/j.msec.2016.10.052
   Wang L, 2013, INORG CHEM, V52, P5119, DOI 10.1021/ic400019r
   Wang XG, 2015, NANOSCALE, V7, P16061, DOI 10.1039/c5nr04045k
   Wu DJ, 2020, CARBOHYD POLYM, V238, DOI 10.1016/j.carbpol.2020.116126
   Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304
   Yang L, 2015, CATAL SCI TECHNOL, V5, P2777, DOI 10.1039/c4cy01609b
   Yousefi M, 2020, ADV COLLOID INTERFAC, V278, DOI 10.1016/j.cis.2020.102125
   Zheng HQ, 2016, J AM CHEM SOC, V138, P962, DOI 10.1021/jacs.5b11720
   Zhuang J, 2014, ACS NANO, V8, P2812, DOI 10.1021/nn406590q
   Zou MJ, 2012, CELL SIGNAL, V24, P1722, DOI 10.1016/j.cellsig.2012.04.009
NR 51
TC 1
Z9 1
U1 8
U2 16
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
DI 10.1038/s41434-021-00265-7
EA JUN 2021
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA SP0YT
UT WOS:000659399600002
PM 34108628
DA 2022-04-25
ER

PT J
AU Priault, M
   Hue, E
   Marhuenda, F
   Pilet, P
   Oliver, L
   Vallette, FM
AF Priault, Muriel
   Hue, Erika
   Marhuenda, Fanny
   Pilet, Paul
   Oliver, Lisa
   Vallette, Francois M.
TI Differential Dependence on Beclin 1 for the Regulation of Pro-Survival
   Autophagy by Bcl-2 and Bcl-xL in HCT116 Colorectal Cancer Cells
SO PLOS ONE
LA English
DT Article
ID 3-KINASE COMPLEX; APOPTOTIC DEATH; MECHANISMS; PROTEINS; DEPRIVATION;
   MACROAUTOPHAGY; NOMENCLATURE; PROGRESSION; INHIBITION; HOMOLOG
AB Autophagy is described to be involved in homeostasis, development and disease, both as a survival and a death process. Its involvement in cell death proceeds from interrelationships with the apoptotic pathway. We focused on survival autophagy and investigated its interplays with the apoptotic machinery. We found that while Mcl-1 remained ineffective, Bcl-2 and BclxL were required for starved cells to display a fully functional autophagic pathway as shown by proteolysis activity and detection of autophagic vesicles. Such pro-autophagic functions of Bcl-2 and Bcl-xL were independent of Bax. However they appeared to operate through non redundant mechanisms as Bcl-xL wielded a tighter control than Bcl-2 over the regulation of autophagy: unlike Bcl-2, Bcl-xL and Atg7 manipulation yielded identical phenotypes suggesting they could be components of the same signalling pathway; Bcl-xL subcellular localisation was modified upon starvation, and importantly Bcl-xL acted independently of Beclin 1. Still an intact BH3-binding site was required for Bcl-xL to stimulate a fully functional autophagic pathway. This study highlights that, in addition to their well-established anti-death function during apoptosis, Bcl-2 and Bcl-xL have a broader role in cell survival. Should Bcl-2 and Bcl-xL stand at the cross-roads between pro-survival and pro-death autophagy, this study introduces the new concept that the regulation of autophagy by Bcl-2 and Bcl-xL is adjusted according to its survival or death outcome.
C1 [Priault, Muriel] CNRS, IBGC, UMR 5095, Bordeaux, France.
   [Priault, Muriel] Univ Bordeaux 2, F-33076 Bordeaux, France.
   [Hue, Erika; Marhuenda, Fanny; Oliver, Lisa; Vallette, Francois M.] INSERM, UMR 892, Nantes, France.
   [Hue, Erika; Marhuenda, Fanny; Oliver, Lisa; Vallette, Francois M.] Univ Nantes, Fac Med, Nantes, France.
   [Pilet, Paul] INSERM, UMR 791, Nantes, France.
RP Priault, M (corresponding author), CNRS, IBGC, UMR 5095, Bordeaux, France.
EM muriel.priault@ibgc.cnrs.fr
RI Paul, Pilet/A-3755-2015; Vallette, Francois/N-2361-2018; Oliver, Lisa
   J/L-3070-2015; Vallette, Francois M/K-9047-2015
OI Oliver, Lisa J/0000-0002-5588-7564; Vallette, Francois
   M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519; Priault,
   Muriel/0000-0001-8193-0389; HUE, Erika/0000-0001-6930-3606
FU Institut National de la Santeet de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS)Centre
   National de la Recherche Scientifique (CNRS); Universitede Nantes,
   Universitede Bordeaux, the Conseil Regional d'Aquitaine; Agence
   Nationale pour la RechercheFrench National Research Agency (ANR)
FX This work was supported by the Institut National de la Santeet de la
   Recherche Medicale (INSERM), the Centre National de la Recherche
   Scientifique (CNRS), Universitede Nantes, Universitede Bordeaux, the
   Conseil Regional d'Aquitaine (to UMR 5095), and the Agence Nationale
   pour la Recherche (project MABA to F. V.). M. P. was supported by a
   post-doctoral fellowship from INSERM. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x
   Cardenas-Aguayo MD, 2003, J HEMATOTH STEM CELL, V12, P735
   Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   Falcon-Perez JM, 2005, J CELL SCI, V118, P5243, DOI 10.1242/jcs.02633
   Fengsrud M, 2000, BIOCHEM J, V352, P773, DOI 10.1042/0264-6021:3520773
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   LUO S, 2009, CELL DEATH DIFFER
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Niemann A, 2001, J HISTOCHEM CYTOCHEM, V49, P177, DOI 10.1177/002215540104900205
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   SCHWORER CM, 1979, P NATL ACAD SCI USA, V76, P3169, DOI 10.1073/pnas.76.7.3169
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
NR 43
TC 37
Z9 38
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 18
PY 2010
VL 5
IS 1
AR e8755
DI 10.1371/journal.pone.0008755
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 545EJ
UT WOS:000273715000013
PM 20090905
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Xiong, K
   Zhou, Y
   Karges, J
   Du, KJ
   Shen, JC
   Lin, MW
   Wei, FM
   Kou, JF
   Chen, Y
   Ji, LN
   Chao, H
AF Xiong, Kai
   Zhou, Ying
   Karges, Johannes
   Du, Kejie
   Shen, Jinchao
   Lin, Mingwei
   Wei, Fangmian
   Kou, Junfeng
   Chen, Yu
   Ji, Liangnian
   Chao, Hui
TI Autophagy-Dependent Apoptosis Induced by Apoferritin-Cu(II)
   Nanoparticles in Multidrug-Resistant Colon Cancer Cells
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE antitumor; apoferritin; autophagy-dependent apoptosis; copper(II)
   complex; multidrug resistance
ID IRIDIUM(III) COMPLEXES; INHIBITION; ENCAPSULATION; RELEASE; PROTEIN;
   STRESS; DESIGN; COPPER; DEATH
AB Chemotherapy continues to be the most commonly applied strategy for cancer. Despite the impressive clinical success obtained with several drugs, increasing numbers of (multi)drug-resistant tumors are reported. To overcome this shortcoming, novel drug candidates and delivery systems are urgently needed. Herein, a therapeutic copper polypyridine complex encapsulated in natural nanocarrier apoferritin is reported. The generated nanoparticles showed higher cytotoxicity toward various (drugresistant) cancer cell lines than noncancerous cells. The study of the mechanism revealed that the compound triggers cell autophagy-dependent apoptosis. Promisingly, upon injection of the nanodrug conjugate into the bloodstream of a mouse model bearing a multidrug-resistant colon tumor, a strong tumor growth inhibition effect was observed. To date, this is the first study describing the encapsulation of a copper complex in apoferritin that acts by autophagy-dependent apoptosis.
C1 [Xiong, Kai; Zhou, Ying; Du, Kejie; Shen, Jinchao; Lin, Mingwei; Wei, Fangmian; Kou, Junfeng; Chen, Yu; Ji, Liangnian; Chao, Hui] Sun Yat Sen Univ, Sch Chem, MOE Key Lab Bioinorgan & Synthet Chem, Guangzhou 510275, Peoples R China.
   [Karges, Johannes] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
RP Chen, Y; Chao, H (corresponding author), Sun Yat Sen Univ, Sch Chem, MOE Key Lab Bioinorgan & Synthet Chem, Guangzhou 510275, Peoples R China.
EM chenyu63@mail.sysu.edu.cn; ceschh@mail.sysu.edu.cn
OI Xiong, kai/0000-0002-8170-0273; jinchao, shen/0000-0002-8436-9360;
   Karges, Johannes/0000-0001-5258-0260
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21525105, 21778079, 21977126]; Pearl River
   S&T Nova Program of Guangzhou [201806010136]; Guangdong Natural Funds
   for Distinguished Young Scientists [2021B1515020102]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 21525105, 21778079, and 21977126), the Pearl River S&T Nova
   Program of Guangzhou (No. 201806010136), and Guangdong Natural Funds for
   Distinguished Young Scientists (No. 2021B1515020102). The authors thank
   Dr. Susan E Bates for the SW620 and SW620 AD300 cell lines (Columbia
   University, New York).
CR Assaraf YG, 2019, DRUG RESIST UPDATE, V46, DOI 10.1016/j.drup.2019.100645
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   BLESSING RH, 1995, ACTA CRYSTALLOGR A, V51, P33, DOI 10.1107/S0108767394005726
   Chen MH, 2019, CHEM SCI, V10, P3315, DOI 10.1039/c8sc04520h
   Chow MJ, 2016, CHEM SCI, V7, P4117, DOI 10.1039/c6sc00268d
   da Silva PB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050745
   Deng ZQ, 2020, J AM CHEM SOC, V142, P7803, DOI 10.1021/jacs.0c00221
   Fan YY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4504-5
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao ZB, 2012, J CONTROL RELEASE, V162, P45, DOI 10.1016/j.jconrel.2012.05.051
   Ghosh S, 2016, ACS APPL MATER INTER, V8, P30824, DOI 10.1021/acsami.6b11798
   Gu Y, 2017, CANCER CELL, V32, P115, DOI 10.1016/j.ccell.2017.06.001
   Guan RL, 2021, INORG CHEM FRONT, V8, P1788, DOI 10.1039/d0qi01430c
   Guan RL, 2018, CHEM SCI, V9, P5183, DOI 10.1039/c8sc01142g
   Gupte A, 2009, CANCER TREAT REV, V35, P32, DOI 10.1016/j.ctrv.2008.07.004
   Heger Z, 2014, NANOMEDICINE-UK, V9, P2233, DOI [10.2217/NNM.14.119, 10.2217/nnm.14.119]
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Huang P, 2017, BIOMATERIALS, V125, P23, DOI 10.1016/j.biomaterials.2017.02.018
   Kelly RJ, 2013, ANN ONCOL, V24, P2601, DOI 10.1093/annonc/mdt249
   Kenny RG, 2019, CHEM REV, V119, P1058, DOI 10.1021/acs.chemrev.8b00271
   Laussmann MA, 2011, CELL DEATH DIFFER, V18, P1584, DOI 10.1038/cdd.2011.27
   Lelievre P, 2020, CANCERS, V12
   Li X, 2016, ACS APPL MATER INTER, V8, P22756, DOI 10.1021/acsami.6b07038
   Liang JW, 2014, J INORG BIOCHEM, V141, P17, DOI 10.1016/j.jinorgbio.2014.08.006
   Lu X, 2020, J MED CHEM, V63, P9154, DOI 10.1021/acs.jmedchem.9b02047
   Ouyang C, 2018, CHEM COMMUN, V54, P6268, DOI 10.1039/c8cc02795a
   Ramasamy T, 2017, DRUG DELIV, V24, P1262, DOI 10.1080/10717544.2017.1373163
   Reina-Campos M, 2019, CANCER CELL, V35, P385, DOI 10.1016/j.ccell.2019.01.018
   Robke L, 2018, CHEM SCI, V9, P3014, DOI 10.1039/c7sc05040b
   Santini C, 2014, CHEM REV, V114, P815, DOI 10.1021/cr400135x
   Shanbhag VC, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118893
   Sheldrick G. M., 1997, SHELXS97
   Shen JL, 2017, NANO LETT, V17, P2913, DOI 10.1021/acs.nanolett.7b00132
   Simovic AR, 2019, COORDIN CHEM REV, V398, DOI 10.1016/j.ccr.2019.07.008
   Stefanini S, 1996, ARCH BIOCHEM BIOPHYS, V325, P58, DOI 10.1006/abbi.1996.0007
   Sulkshane P, 2017, ONCOTARGET, V8, P60060, DOI 10.18632/oncotarget.11085
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Tan CP, 2010, J MED CHEM, V53, P7613, DOI 10.1021/jm1009296
   Villemin E, 2019, NAT REV CHEM, V3, P261, DOI 10.1038/s41570-019-0088-0
   Wang JL, 2017, ONCOTARGET, V8, P84559, DOI 10.18632/oncotarget.19187
   Wang K, 2019, ANGEW CHEM INT EDIT, V58, P4638, DOI 10.1002/anie.201900387
   Wang S, 2020, J MED CHEM, V63, P15979, DOI 10.1021/acs.jmedchem.0c01741
   Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011
   Wang ZG, 2019, CHEM-US, V5, P3151, DOI 10.1016/j.chempr.2019.08.021
   Wei WJ, 2017, THERANOSTICS, V7, P987, DOI 10.7150/thno.17322
   Wu KJ, 2020, ACS APPL BIO MATER, V3, P2017, DOI 10.1021/acsabm.9b01156
   Xie JN, 2017, ACS APPL MATER INTER, V9, P14281, DOI 10.1021/acsami.7b02622
   Xie LN, 2021, J INORG BIOCHEM, V217, DOI 10.1016/j.jinorgbio.2021.111380
   Xiong K, 2020, ANGEW CHEM INT EDIT, V59, P16631, DOI 10.1002/anie.202006089
   Xue R, 2019, J CELL MOL MED, V23, P7810, DOI 10.1111/jcmm.14658
   Yang GJ, 2018, ANGEW CHEM INT EDIT, V57, P13091, DOI 10.1002/anie.201807305
   Yang Z, 2007, CHEM COMMUN, P3453, DOI 10.1039/b705326f
   Yao HZ, 2020, INORG CHEM, V59, P11823, DOI 10.1021/acs.inorgchem.0c01880
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yuan H, 2021, ANGEW CHEM INT EDIT, V60, P8174, DOI 10.1002/anie.202014959
   Zhang C, 2020, INORG CHEM FRONT, V7, P1864, DOI 10.1039/d0qi00224k
   Zhang WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09566-3
   Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77
   Zhang ZL, 2019, J MED CHEM, V62, P10630, DOI 10.1021/acs.jmedchem.9b00939
   Zhao XH, 2019, CANCER CELL, V35, P752, DOI 10.1016/j.ccell.2019.04.005
   Zhao XB, 2018, ACS APPL MATER INTER, V10, P6608, DOI 10.1021/acsami.7b16910
   Zhou BR, 2020, SEMIN CANCER BIOL, V66, P89, DOI 10.1016/j.semcancer.2019.03.002
   Zhou YC, 2018, SMALL, V14, DOI 10.1002/smll.201702446
NR 63
TC 2
Z9 2
U1 18
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
EI 1944-8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 25
PY 2021
VL 13
IS 33
BP 38959
EP 38968
DI 10.1021/acsami.1c07223
EA AUG 2021
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA UK2DJ
UT WOS:000691785200003
PM 34379404
DA 2022-04-25
ER

PT J
AU Hu, CE
   Gan, J
AF Hu, Cheng-En
   Gan, Jun
TI TRIM37 promotes epithelial-mesenchymal transition in colorectal cancer
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE tripartite motif containing 37; colorectal cancer;
   epithelial-mesenchymal transition
ID PROTEINS REGULATE AUTOPHAGY; COLON-CANCER; MULIBREY NANISM; CROSSROADS;
   METASTASIS
AB There is substantial research on the oncogenic role of tripartite motif containing 37 (TRIM37); however, its importance in colorectal cancer (CRC) remains to be elucidated. The present study used reverse transcription -quantitative polymerase chain reaction, immunohistochemistry and western blotting to detect the expression level of TRIM37 in CRC. The importance of TRIM37 in cell proliferation, invasion and metastasis of CRC were investigated through overexpressing or knocking -down of TRIM37 in CRC cell lines, to observe its function. The present study revealed that TRIM37 was overexpressed in human CRC tissues. High TRIM37 expression resulted in increased CRC proliferation, migration and invasion. Mechanistically, it was confirmed that TRIM37 enhanced invasion and metastasis of CRC via the epithelial-mesenchymal transition pathway. In conclusion, the present study suggested that TRIM3 may contribute to CRC and act as a potential therapeutic target for CRC treatment.
C1 [Hu, Cheng-En; Gan, Jun] Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Wurumuqizhong Rd, Shanghai 200040, Peoples R China.
RP Gan, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Wurumuqizhong Rd, Shanghai 200040, Peoples R China.
EM jungan2015@163.com
CR Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001
   Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262
   Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Fan Q, 2015, ONCOL REP, V34, P1787, DOI 10.3892/or.2015.4143
   Fu BJ, 2012, AM J CLIN PATHOL, V138, P356, DOI 10.1309/AJCPVT7LC4CRPZSK
   Godde NJ, 2010, J MAMMARY GLAND BIOL, V15, P149, DOI 10.1007/s10911-010-9180-2
   Jiang JX, 2016, TUMOR BIOL, V37, P2629, DOI 10.1007/s13277-015-4078-7
   Jiang JX, 2015, BIOCHEM BIOPH RES CO, V464, P1120, DOI 10.1016/j.bbrc.2015.07.089
   Kallijarvi J, 2002, AM J HUM GENET, V70, P1215, DOI 10.1086/340256
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Karlberg S, 2009, MODERN PATHOL, V22, P570, DOI 10.1038/modpathol.2009.13
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee OH, 2015, BBA-MOL CELL RES, V1853, P409, DOI 10.1016/j.bbamcr.2014.11.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mandell MA, 2014, AUTOPHAGY, V10, P2387, DOI 10.4161/15548627.2014.984278
   Mandell MA, 2014, DEV CELL, V30, P394, DOI 10.1016/j.devcel.2014.06.013
   Pasquier J, 2015, J ONCOL, V2015, DOI 10.1155/2015/792182
   Qiu F, 2015, INT J CLIN EXP PATHO, V8, P5053
   Rubin MA, 2014, CANCER DISCOV, V4, P1262, DOI 10.1158/2159-8290.CD-14-1075
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Tejpar S, 2010, ONCOLOGIST, V15, P390, DOI 10.1634/theoncologist.2009-0233
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Wang Y, 2015, BIOCHEM BIOPH RES CO, V463, P458, DOI 10.1016/j.bbrc.2015.05.117
   Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186
   Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012
   Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048
   Zoni E, 2015, J ONCOL, V2015, DOI 10.1155/2015/198967
NR 31
TC 24
Z9 24
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2017
VL 15
IS 3
BP 1057
EP 1062
DI 10.3892/mmr.2017.6125
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EP1VS
UT WOS:000397173000008
PM 28098873
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Lan, L
   Liu, H
   Smith, AR
   Appelman, C
   Yu, J
   Larsen, S
   Marquez, RT
   Wu, XQ
   Liu, FY
   Gao, P
   Gowthaman, R
   Karanicolas, J
   De Guzman, RN
   Rogers, S
   Aube, J
   Neufeld, KL
   Xu, L
AF Lan, Lan
   Liu, Hao
   Smith, Amber R.
   Appelman, Carl
   Yu, Jia
   Larsen, Sarah
   Marquez, Rebecca T.
   Wu, Xiaoqing
   Liu, Frank Y.
   Gao, Philip
   Gowthaman, Ragul
   Karanicolas, John
   De Guzman, Roberto N.
   Rogers, Steven
   Aube, Jeffrey
   Neufeld, Kristi L.
   Xu, Liang
TI Natural product derivative Gossypolone inhibits Musashi family of
   RNA-binding proteins
SO BMC CANCER
LA English
DT Article
DE Gossypolone; Musashi; RNA-binding protein; Colon cancer; Liposomes
ID STEM-CELL MARKERS; PEGYLATED LIPOSOMAL DOXORUBICIN; IN-VITRO;
   PROSTATE-CANCER; MYELOID-LEUKEMIA; EXPRESSION; CARCINOMA; MSI2;
   (-)-GOSSYPOL; AUTOPHAGY
AB Background: The Musashi (MSI) family of RNA-binding proteins is best known for the role in post-transcriptional regulation of target mRNAs. Elevated MSI1 levels in a variety of human cancer are associated with up-regulation of Notch/Wnt signaling. MSI1 binds to and negatively regulates translation of Numb and APC (adenomatous polyposis coli), negative regulators of Notch and Wnt signaling respectively.
   Methods: Previously, we have shown that the natural product (-)-gossypol as the first known small molecule inhibitor of MSI1 that down-regulates Notch/Wnt signaling and inhibits tumor xenograft growth in vivo. Using a fluorescence polarization (FP) competition assay, we identified gossypolone (Gn) with a > 20-fold increase in Ki value compared to (-)-gossypol. We validated Gn binding to MSI1 using surface plasmon resonance, nuclear magnetic resonance, and cellular thermal shift assay, and tested the effects of Gn on colon cancer cells and colon cancer DLD-1 xenografts in nude mice.
   Results: In colon cancer cells, Gn reduced Notch/Wnt signaling and induced apoptosis. Compared to (-)-gossypol, the same concentration of Gn is less active in all the cell assays tested. To increase Gn bioavailability, we used PEGylated liposomes in our in vivo studies. Gn-lip via tail vein injection inhibited the growth of human colon cancer DLD-1 xenografts in nude mice, as compared to the untreated control (P < 0.01, n = 10).
   Conclusion: Our data suggest that PEGylation improved the bioavailability of Gn as well as achieved tumor-targeted delivery and controlled release of Gn, which enhanced its overall biocompatibility and drug efficacy in vivo. This provides proof of concept for the development of Gn-lip as a molecular therapy for colon cancer with MSI1/MSI2 overexpression.
C1 [Lan, Lan; Liu, Hao; Smith, Amber R.; Appelman, Carl; Yu, Jia; Larsen, Sarah; Marquez, Rebecca T.; Wu, Xiaoqing; Liu, Frank Y.; De Guzman, Roberto N.; Neufeld, Kristi L.; Xu, Liang] Univ Kansas, Dept Mol Biosci, 4002 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.
   [Gao, Philip] NIH COBRE Prot Struct & Funct, Prot Prod Grp, Lawrence, KS USA.
   [Gowthaman, Ragul] Univ Kansas, Ctr Computat Biol, Lawrence, KS 66045 USA.
   [Yu, Jia] Southeast Univ, Sch Chem & Chem Engn, Nanjing, Jiangsu, Peoples R China.
   [Karanicolas, John] Fox Chase Canc Ctr, Program Mol Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Rogers, Steven; Aube, Jeffrey] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Xu, Liang] Univ Kansas, Canc Ctr, Dept Radiat Oncol, Kansas City, KS 66160 USA.
   [Liu, Hao] Southwest Med Univ, Sch Pharm, Luzhou City, Peoples R China.
RP Xu, L (corresponding author), Univ Kansas, Dept Mol Biosci, 4002 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.; Xu, L (corresponding author), Univ Kansas, Canc Ctr, Dept Radiat Oncol, Kansas City, KS 66160 USA.
EM xul@ku.edu
RI Liu, Hao/J-1911-2014
OI Liu, Hao/0000-0003-2343-4998; Neufeld, Kristi/0000-0003-3653-9385;
   Gowthaman, Ragul/0000-0002-0008-6401
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA178831,
   CA191785, AI074856]; NIH COBRE-PSF at KUUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P30
   GM110761]; Department of Defense Breast Cancer Research Program
   Breakthrough Level II grantUnited States Department of Defense
   [BC151845]; Kansas Bioscience Authority Rising Star Award; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA191785, R01CA178831] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI074856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [P30GM110761] Funding Source: NIH
   RePORTER
FX This study was supported in part by National Institutes of Health grants
   R01 CA178831 and CA191785 (to LX, JA, KN); AI074856 (to R.N.D.); NIH
   COBRE-PSF at KU (P30 GM110761) Pilot Project, Department of Defense
   Breast Cancer Research Program Breakthrough Level II grant BC151845, and
   Kansas Bioscience Authority Rising Star Award (to LX). No involvement of
   the funding bodies in any part of the study.
CR Aly RM, 2015, INT J LAB HEMATOL, V37, P272, DOI 10.1111/ijlh.12284
   Baek SE, 2014, J CONTROL RELEASE, V196, P234, DOI 10.1016/j.jconrel.2014.10.018
   Battelli C, 2006, MOL CELL NEUROSCI, V31, P85, DOI 10.1016/j.mcn.2005.09.003
   Blackstaffe L, 1997, MELANOMA RES, V7, P364, DOI 10.1097/00008390-199710000-00002
   Byers RJ, 2011, BLOOD, V118, P2857, DOI 10.1182/blood-2011-04-346767
   Charlesworth A, 2006, EMBO J, V25, P2792, DOI 10.1038/sj.emboj.7601159
   Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857
   Dodou K, 2005, BIOORGAN MED CHEM, V13, P4228, DOI 10.1016/j.bmc.2005.04.026
   Fan LF, 2010, INT J COLORECTAL DIS, V25, P17, DOI 10.1007/s00384-009-0791-2
   Farid A, 2001, PHARM BIOL, V39, P120
   Fox RG, 2016, NATURE, V534, P407, DOI 10.1038/nature17988
   Gabizon A, 1997, DRUGS, V54, P15, DOI 10.2165/00003495-199700544-00005
   GILBERT NE, 1995, LIFE SCI, V57, P61, DOI 10.1016/0024-3205(95)00243-Y
   Glazer RI, 2012, FRONT BIOSCI-LANDMRK, V17, P54, DOI 10.2741/3915
   Griner LN, 2010, CANCER BIOL THER, V10, P979, DOI 10.4161/cbt.10.10.14010
   GU Y, 1991, RES COMMUN CHEM PATH, V72, P27
   Guo K, 2017, CLIN CANCER RES, V23, P687, DOI 10.1158/1078-0432.CCR-16-1064
   HAAS RH, 1965, J ORG CHEM, V30, P4111, DOI 10.1021/jo01023a031
   Hou T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1826-4
   Hsu WH, 2014, NUCL MED BIOL, V41, P765, DOI 10.1016/j.nucmedbio.2014.05.142
   Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001
   Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171
   Kaeda J, 2015, LEUKEMIA LYMPHOMA, V56, P2105, DOI 10.3109/10428194.2014.981175
   Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435
   Katanasaka Y, 2010, INT J CANCER, V127, P2685, DOI 10.1002/ijc.25276
   Kawahara H, 2008, J CELL BIOL, V181, P639, DOI 10.1083/jcb.200708004
   Kharas MG, 2010, NAT MED, V16, P903, DOI 10.1038/nm.2187
   KIM IC, 1984, CONTRACEPTION, V30, P253, DOI 10.1016/0010-7824(84)90088-X
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kudinov AE, 2016, P NATL ACAD SCI USA, V113, P6955, DOI 10.1073/pnas.1513616113
   Lan L., 2015, MOL ONCOL
   Li DW, 2011, ANN SURG ONCOL, V18, P2074, DOI 10.1245/s10434-011-1567-9
   Li K, 2015, BIOMATERIALS, V39, P131, DOI 10.1016/j.biomaterials.2014.10.073
   Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035
   Li L, 2013, CLIN CANCER RES, V19, P6703, DOI 10.1158/1078-0432.CCR-13-0621
   Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Liang Xu, [Small molecule antagonists of Bcl-2 family proteins, US patent], Patent No. [8163805 B2, 8163805B2]
   Liu H, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2784-5
   Liu H, 2014, J MATER CHEM B, V2, P5238, DOI 10.1039/c4tb00539b
   Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7
   Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X
   Ohyama T, 2012, NUCLEIC ACIDS RES, V40, P3218, DOI 10.1093/nar/gkr1139
   Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551
   Paoluzzi L, 2008, BLOOD, V111, P5350, DOI 10.1182/blood-2007-12-129833
   Park JW, 2002, BREAST CANCER RES, V4, P93
   Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140
   Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x
   Rezza A, 2010, J CELL SCI, V123, P3256, DOI 10.1242/jcs.065284
   Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499
   Sakakibara S, 2001, J NEUROSCI, V21, P8091, DOI 10.1523/JNEUROSCI.21-20-08091.2001
   Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130
   Seigel GM, 2007, MOL VIS, V13, P823
   Shan W, 2015, NAT COMMUN, V6
   Shelley MD, 1999, CANCER LETT, V135, P171, DOI 10.1016/S0304-3835(98)00302-4
   Sheng W, 2017, FASEB J
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Smith AR, 2015, ONCOTARGET, V6, P12558, DOI 10.18632/oncotarget.3726
   Spears E, 2011, J BIOL CHEM, V286, P4946, DOI 10.1074/jbc.C110.205922
   Sugiyama-Nakagiri Y, 2006, AM J PATHOL, V168, P80, DOI 10.2353/ajpath.2006.050469
   Sureban SM, 2008, GASTROENTEROLOGY, V134, P1448, DOI 10.1053/j.gastro.2008.02.057
   Takahashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053540
   Thol F, 2013, ANN HEMATOL, V92, P315, DOI 10.1007/s00277-012-1637-5
   Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034
   Uphoff CC, 2011, METHODS MOL BIOL, V731, P93, DOI 10.1007/978-1-61779-080-5_8
   Wang XY, 2013, ONCOTARGET, V4, P739, DOI 10.18632/oncotarget.1034
   Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221
   Wu DC, 2012, BIOMED MICRODEVICES, V14, P497, DOI 10.1007/s10544-011-9626-3
   Wu XQ, 2010, BIOORGAN MED CHEM, V18, P3812, DOI 10.1016/j.bmc.2010.04.046
   Yang T, 2007, INT J PHARMACEUT, V338, P317, DOI 10.1016/j.ijpharm.2007.02.011
   Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108
   Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475
   YU YW, 1987, J ETHNOPHARMACOL, V20, P65
   Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X
   Zhang XQ, 2010, ASIAN J ANDROL, V12, P390, DOI 10.1038/aja.2009.87
NR 79
TC 14
Z9 14
U1 5
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 10
PY 2018
VL 18
AR 809
DI 10.1186/s12885-018-4704-z
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GQ1QY
UT WOS:000441412500002
PM 30097032
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Mikula, M
   Najjar, S
   El Jabbour, T
   Dalvi, S
   Umrau, K
   Li, H
   Koo, BH
   Lee, H
AF Mikula, Michael
   Najjar, Saleh
   El Jabbour, Tony
   Dalvi, Siddhartha
   Umrau, Kavita
   Li, Hua
   Koo, Brandon H.
   Lee, Hwajeong
TI Increased Cytoplasmic Yes-associated Protein (YAP) Expression in
   Mismatch Repair Protein-Proficient Colorectal Cancer With High-grade
   Tumor Budding and Reduced Autophagy Activity
SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
LA English
DT Article
DE YAP; autophagy; p62; tumor budding; colon
ID EPITHELIAL-MESENCHYMAL TRANSITION; HIPPO PATHWAY; EMT; APOPTOSIS; SWITCH
AB Yes-associated protein (YAP) is a transcriptional coactivator regulated by autophagy that stimulates colorectal cancer (CRC) progression through activation of epithelial-mesenchymal transition (EMT), represented by tumor budding. The associations between these components in CRC are unknown. Archived surgically resected CRCs with known mismatch repair protein (MMR) status were retrieved (n=81; 2010 to 2016). Electronic medical records were reviewed for clinicopathologic variables including pathologic TNM stage and clinical stage. Tumor budding was graded according to consensus guidelines. Cytoplasmic and nuclear YAP and p62 (autophagy substrate) immunoreactivity were semiquantitatively scored within tumor samples. The Student t test, Fisher exact test, chi(2) test, and Spearman correlation coefficient were performed with P<0.05 as a significance level. MMR proficiency (MMR-P) status correlated with high-grade tumor budding. The extent of cytoplasmic YAP staining and pathologic N stage was associated with tumor budding in multivariate analysis. Cytoplasmic YAP expression correlated with higher cytoplasmic p62 expression, suggesting an inverse correlation between autophagy activation and cytoplasmic YAP expression. Nuclear YAP expression correlated with pathologic N stage and clinical stage. A correlation between MMR-P status and tumor budding, combined with correlations between cytoplasmic YAP, tumor budding and p62 raise the possibility of 2 distinct neoplastic pathways concerning autophagy and YAP; one displaying relative activation of YAP and EMT, being commonly observed in MMR-P, and another with less active YAP and EMT, but active autophagy, being commonly seen in MMR-deficient CRC. Nuclear YAP staining could be useful in prognostication.
C1 [Mikula, Michael] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Mikula, Michael; Koo, Brandon H.] Albany Med Coll, Albany, NY 12208 USA.
   [Najjar, Saleh; El Jabbour, Tony; Dalvi, Siddhartha; Umrau, Kavita; Li, Hua; Lee, Hwajeong] Albany Med Ctr, Dept Pathol & Lab Med, Albany, NY 12208 USA.
RP Lee, H (corresponding author), 47 New Scotland Ave,MC81, Albany, NY 12208 USA.
EM leeh5@amc.edu
RI Umrau, Kavita/AAA-2597-2022
CR Amin MB., 2017, AJCC CANC STAGING MA, V8th ed.
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070
   Hewish M, 2010, NAT REV CLIN ONCOL, V7, P197, DOI 10.1038/nrclinonc.2010.18
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Le Corre D, 2019, EBIOMEDICINE, V46, P94, DOI 10.1016/j.ebiom.2019.07.036
   Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z
   Ling HH, 2017, EXP CELL RES, V350, P218, DOI 10.1016/j.yexcr.2016.11.024
   Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep45523
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Ou CL, 2017, ONCOTARGET, V8, P75727, DOI 10.18632/oncotarget.20155
   Park J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10729-5
   Pino MS, 2010, GASTROENTEROLOGY, V138, P1406, DOI 10.1053/j.gastro.2009.12.010
   Platel V, 2019, J ONCOL, V2019, DOI 10.1155/2019/8361945
   Sakabe M, 2017, P NATL ACAD SCI USA, V114, P10918, DOI 10.1073/pnas.1704030114
   Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004
   Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539
   Wang Y, 2013, TUMOR BIOL, V34, P2169, DOI 10.1007/s13277-013-0751-x
   Weinstein N, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00040
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wierzbicki PM, 2015, FOLIA HISTOCHEM CYTO, V53, P105, DOI 10.5603/FHC.a2015.0015
   Zlobec I, 2018, NAT REV CANCER, V18, P203, DOI 10.1038/nrc.2018.1
   Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199
NR 31
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1541-2016
EI 1533-4058
J9 APPL IMMUNOHISTO M M
JI Appl. Immunohistochem.
PD APR
PY 2021
VL 29
IS 4
BP 305
EP 312
DI 10.1097/PAI.0000000000000888
PG 8
WC Anatomy & Morphology; Medical Laboratory Technology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Medical Laboratory Technology; Pathology
GA RY2PL
UT WOS:000647759200011
PM 33264106
DA 2022-04-25
ER

PT J
AU Kakiuchi, Y
   Kuroda, S
   Kanaya, N
   Kumon, K
   Tsumura, T
   Hashimoto, M
   Yagi, C
   Sugimoto, R
   Hamada, Y
   Kikuchi, S
   Nishizaki, M
   Kagawa, S
   Tazawa, H
   Urata, Y
   Fujiwara, T
AF Kakiuchi, Yoshihiko
   Kuroda, Shinji
   Kanaya, Nobuhiko
   Kumon, Kento
   Tsumura, Tomoko
   Hashimoto, Masashi
   Yagi, Chiaki
   Sugimoto, Ryoma
   Hamada, Yuki
   Kikuchi, Satoru
   Nishizaki, Masahiko
   Kagawa, Shunsuke
   Tazawa, Hiroshi
   Urata, Yasuo
   Fujiwara, Toshiyoshi
TI Local oncolytic adenovirotherapy produces an abscopal effect via
   tumor-derived extracellular vesicles
SO MOLECULAR THERAPY
LA English
DT Article
ID CANCER; EXOSOMES; TROPISM; MODULATION; RADIATION; DELIVERY
AB Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), and occasionally observed therapeutic effects on distal tumors after local treatment in immunodeficient mice. In this study, we hypothesized that EVs may be involved in the abscopal effect of OBP-301. EVs isolated from the supernatant of HCT116 human colon carcinoma cells treated with OBP-301 were confirmed to contain OBP-301, and they showed cytotoxic activity (apoptosis and autophagy) similar to OBP-301. In bilateral subcutaneous HCT116 and CT26 tumor models, intratumoral administration of OBP-301 produced potent antitumor effects on tumors that were not directly treated with OBP-301, involving direct mediation by tumor-derived EVs containing OBP-301. This indicates that immune activation is not the main factor in this abscopal effect. Moreover, tumor-derived EVs exhibited high tumor tropism in orthotopic HCT116 rectal tumors, in which adenovirus E1A and adenovirus type 5 proteins were observed in metastatic liver tumors after localized rectal tumor treatment. In conclusion, local treatment with OBP-301 has the potential to produce abscopal effects via tumor-derived EVs.
C1 [Kakiuchi, Yoshihiko; Kuroda, Shinji; Kanaya, Nobuhiko; Kumon, Kento; Tsumura, Tomoko; Hashimoto, Masashi; Yagi, Chiaki; Sugimoto, Ryoma; Hamada, Yuki; Kikuchi, Satoru; Nishizaki, Masahiko; Kagawa, Shunsuke; Tazawa, Hiroshi; Fujiwara, Toshiyoshi] Okayama Univ, Dept Gastroenterol Surg, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
   [Kuroda, Shinji; Tazawa, Hiroshi] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama 7008558, Japan.
   [Kikuchi, Satoru; Kagawa, Shunsuke] Okayama Univ Hosp, Minimally Invas Therapy Ctr, Okayama 7008558, Japan.
   [Urata, Yasuo] Oncolys BioPharma Inc, Tokyo 1050001, Japan.
RP Kuroda, S (corresponding author), Okayama Univ, Dept Gastroenterol Surg, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM shinkuro@okayama-u.ac.jp
RI TAZAWA, Hiroshi/B-2247-2011
OI TAZAWA, Hiroshi/0000-0003-4658-1050; Masashi,
   Hashimoto/0000-0002-0329-5110; Kuroda, Shinji/0000-0002-4484-1253
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP20K17617]
FX The authors would like to thank Tomoko Sueishi, Tae Yamanishi, and Yuko
   Hoshijima for excellent technical support. This work was supported by
   JSPS KAKENHI (grant no. JP16K19893 to S. Kuroda) and JSPS KAKENHI (grant
   no. JP20K17617 to Y.K.).
CR Aoyama K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14717-x
   Brooks ED, 2019, NAT REV CLIN ONCOL, V16, P123, DOI 10.1038/s41571-018-0119-7
   Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244
   Costafreda MI, 2020, NAT MICROBIOL, V5, P1096, DOI 10.1038/s41564-020-0740-y
   Fujita Y, 2016, CANCER SCI, V107, P385, DOI 10.1111/cas.12896
   Fujiwara T, 2019, ANN GASTROENT SURG, V3, P396, DOI 10.1002/ags3.12270
   Garofalo M, 2019, THERANOSTICS, V9, P5681, DOI 10.7150/thno.34824
   Hashimoto Y, 2008, CANCER SCI, V99, P385, DOI 10.1111/j.1349-7006.2007.00665.x
   Havunen R, 2018, MOL THER-ONCOLYTICS, V11, P109, DOI 10.1016/j.omto.2018.10.005
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Iguchi Y, 2016, BRAIN, V139, P3187, DOI 10.1093/brain/aww237
   Kanaya N, 2020, MOL THER, V28, P794, DOI 10.1016/j.ymthe.2020.01.003
   Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3
   Kepp O, 2020, NAT REV CLIN ONCOL, V17, P49, DOI 10.1038/s41571-019-0272-7
   Kim SM, 2017, J CONTROL RELEASE, V266, P8, DOI 10.1016/j.jconrel.2017.09.013
   Kojima T, 2010, ANN SURG, V251, P1079, DOI 10.1097/SLA.0b013e3181deb69d
   Kooijmans SAA, 2016, PHARMACOL RES, V111, P487, DOI 10.1016/j.phrs.2016.07.006
   Kuroda S, 2014, GENE THERAPY OF CANCER: TRANSLATIONAL APPROACHES FROM PRECLINICAL STUDIES TO CLINICAL IMPLEMENTATION, 3RD EDITION, P171, DOI 10.1016/B978-0-12-394295-1.00012-3
   Kuroda S, 2010, CANCER RES, V70, P9339, DOI 10.1158/0008-5472.CAN-10-2333
   Lai RC, 2013, BIOTECHNOL ADV, V31, P543, DOI 10.1016/j.biotechadv.2012.08.008
   Longo V, 2019, CANCERS, V11, DOI 10.3390/cancers11040539
   Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Ludwig N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194684
   MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234
   Morales-Kastresana A, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1597603
   Morales-Kastresana A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01731-2
   Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262
   Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6
   Nishida-Aoki N, 2017, MOL THER, V25, P181, DOI 10.1016/j.ymthe.2016.10.009
   Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016
   Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824
   Ramakrishnaiah V, 2013, P NATL ACAD SCI USA, V110, P13109, DOI 10.1073/pnas.1221899110
   Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292
   Urabe F, 2020, AM J PHYSIOL-CELL PH, V318, pC29, DOI 10.1152/ajpcell.00280.2019
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Dongen HM, 2016, MICROBIOL MOL BIOL R, V80, P369, DOI 10.1128/MMBR.00063-15
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9
   Yamamoto T, 2019, SCI TECHNOL ADV MAT, V20, P746, DOI 10.1080/14686996.2019.1629835
   Yang Y, 2018, CELL RES, V28, P862, DOI 10.1038/s41422-018-0060-4
NR 40
TC 4
Z9 4
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD OCT 6
PY 2021
VL 29
IS 10
BP 2920
EP 2930
DI 10.1016/j.ymthe.2021.05.015
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA WI4HY
UT WOS:000708324600008
PM 34023506
DA 2022-04-25
ER

PT J
AU Saponaro, C
   Sergio, S
   Coluccia, A
   De Luca, M
   La Regina, G
   Mologni, L
   Famiglini, V
   Naccarato, V
   Bonetti, D
   Gautier, C
   Gianni, S
   Vergara, D
   Salzet, M
   Fournier, I
   Bucci, C
   Silvestri, R
   Passerini, CG
   Maffia, M
   Coluccia, AML
AF Saponaro, Concetta
   Sergio, Sara
   Coluccia, Antonio
   De Luca, Maria
   La Regina, Giuseppe
   Mologni, Luca
   Famiglini, Valeria
   Naccarato, Valentina
   Bonetti, Daniela
   Gautier, Candice
   Gianni, Stefano
   Vergara, Daniele
   Salzet, Michel
   Fournier, Isabelle
   Bucci, Cecilia
   Silvestri, Romano
   Passerini, Carlo Gambacorti
   Maffia, Michele
   Coluccia, Addolorata Maria Luce
TI beta-catenin knockdown promotes NHERF1-mediated survival of colorectal
   cancer cells: implications for a double-targeted therapy
SO ONCOGENE
LA English
DT Article
ID SMALL-MOLECULE INHIBITION; REGULATORY FACTOR-1; NUCLEAR NHERF1; PROTEIN;
   GROWTH; COLON; PTEN; PHOSPHORYLATION; ASSOCIATION; ACTIVATION
AB Nuclear activated beta-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring different Wnt/beta-catenin pathway mutations in APC/KRAS or beta-catenin/KRAS genes, and both genetic and pharmacological knockdown approaches, we show that oncogenic beta-catenin signaling negatively regulates the expression of NHERF1 (Na+/H+ exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or downregulated in early dysplastic adenomas to exacerbate nuclear beta-catenin activity. Chromatin immunoprecipitation (ChIP) assays demonstrated that beta-catenin represses NHERF1 via TCF4 directly, while the association between TCF1 and the Nherf1 promoter increased upon beta-catenin knockdown. To note, the occurrence of a cytostatic survival response in settings of single beta-catenin-depleted CRC cells was abrogated by combining NHERF1 inhibition via small hairpin RNA (shRNA) or RS5517, a novel PDZ1-domain ligand of NHERF1 that prevented its ectopic nuclear entry. Mechanistically, dual NHERF1/beta-catenin targeting promoted an autophagy-to-apoptosis switch consistent with the activation of Caspase-3, the cleavage of PARP and reduced levels of phospho-ERK1/2, Beclin-1, and Rab7 autophagic proteins compared with beta-catenin knockdown alone. Collectively, our data unveil novel beta-catenin/TCF-dependent mechanisms of CRC carcinogenesis, also offering preclinical proof of concept for combining beta-catenin and NHERF1 pharmacological inhibitors as a mechanism-based strategy to augment apoptotic death of CRC cells refractory to current Wnt/beta-catenin-targeted therapeutics.
C1 [Saponaro, Concetta; Sergio, Sara; Vergara, Daniele; Maffia, Michele; Coluccia, Addolorata Maria Luce] Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy.
   [Saponaro, Concetta] IRCCS Ist Tumori Giovanni Paolo II, Funct Biomorphol Lab, Bari, Italy.
   [Sergio, Sara; De Luca, Maria; Vergara, Daniele; Bucci, Cecilia; Maffia, Michele; Coluccia, Addolorata Maria Luce] Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy.
   [Coluccia, Antonio; La Regina, Giuseppe; Famiglini, Valeria; Naccarato, Valentina; Silvestri, Romano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Drug Chem & Technol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Mologni, Luca; Passerini, Carlo Gambacorti] Univ Milano Bicocca, San Gerardo Hosp, Dept Clin Med, I-20052 Monza, Italy.
   [Bonetti, Daniela; Gautier, Candice; Gianni, Stefano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Biochem, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Salzet, Michel; Fournier, Isabelle] U1192 Lab Prote Reponse Inflammatoire & Spectrome, F-59000 Lille, France.
RP Coluccia, AML (corresponding author), Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy.; Coluccia, AML (corresponding author), Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy.
EM michele.maffia@unisalento.it; malu.coluccia@unisalento.it
RI Coluccia, Antonio/K-3114-2018; FOURNIER, Isabelle/H-9195-2015; Vergara,
   Daniele/K-3831-2014; sergio, sara/AAC-3849-2019; SERGIO,
   SARA/AAL-4019-2021; La Regina, Giuseppe/I-2161-2012; Saponaro,
   Concetta/K-7886-2018; Salzet, Michel/A-7675-2011; MAFFIA,
   MICHELE/AAC-2943-2020; BUCCI, CECILIA/F-6699-2012; Mologni,
   Luca/AAC-1065-2022
OI Coluccia, Antonio/0000-0002-7940-8206; FOURNIER,
   Isabelle/0000-0003-1096-5044; Vergara, Daniele/0000-0002-2396-7674; La
   Regina, Giuseppe/0000-0003-3252-1161; Salzet,
   Michel/0000-0003-4318-0817; BUCCI, CECILIA/0000-0002-6232-6183; Mologni,
   Luca/0000-0002-6365-5149; Sergio, Sara/0000-0002-4490-4189
FU Italian Association for Cancer Research (AIRC)-Investigator Grant (IG)
   [14236]; Italian Grant PRIN 2015 [2015FCHJ8E]; European Union's Horizon
   2020 Research and Innovation program under the Marie Sklodowska-Curie
   grant [675341]; AIRC IG 2016 [19068]; Apulia Regione Cluster Project
   SISTEMA [T7WGSJ3]; Veronesi Foundation fellowship
FX We thank Dr. Hans Clevers (Hubrecht Laboratory, Utrecht, The
   Netherlands) for providing the pcDNA<INF>6</INF>TR and pTER vectors. We
   gratefully acknowledge funding from Italian Association for Cancer
   Research (AIRC)-Investigator Grant (IG) 2014 No. 14236 (AMLC). This work
   was partially supported by Italian Grant PRIN 2015 (2015FCHJ8E) (RS),
   European Union's Horizon 2020 Research and Innovation program under the
   Marie Sklodowska-Curie grant agreement No. 675341 (SG), AIRC IG 2016 No.
   19068 (CB) and Apulia Regione Cluster Project SISTEMA No. T7WGSJ3 (MM).
   MDL was recipient of a Veronesi Foundation fellowship. We warmly thank
   Dr. Antonio Danieli for his technical assistance.
CR Bellizzi A, 2011, HISTOPATHOLOGY, V58, P1086, DOI 10.1111/j.1365-2559.2011.03844.x
   Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80
   Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683
   Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617
   Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   De Luca M, 2014, J CELL SCI, V127, P2697, DOI 10.1242/jcs.142604
   Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x
   Du GF, 2016, ONCOTARGET, V7, P29440, DOI 10.18632/oncotarget.8751
   Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976
   Fitzpatrick JM, 2014, BIOCHEMISTRY-US, V53, P5916, DOI 10.1021/bi500368k
   Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031
   Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611
   Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031
   Georgescu MM, 2016, NEOPLASIA, V18, P512, DOI 10.1016/j.neo.2016.07.003
   Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004
   Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063
   Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780
   Ho-Bouldoires THN, 2015, FREE RADICAL BIO MED, V89, P34, DOI 10.1016/j.freeradbiomed.2015.07.011
   Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330
   Ivarsson Y, 2007, J BIOL CHEM, V282, P8568, DOI 10.1074/jbc.M611026200
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534
   Karn T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028403
   Korb Oliver, 2007, Swarm Intelligence, V1, P115, DOI 10.1007/s11721-007-0006-9
   Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239
   Liu H, 2015, AUTOPHAGY, V11, P2323, DOI 10.1080/15548627.2015.1074372
   Malfettone A, 2012, EXP MOL PATHOL, V92, P296, DOI 10.1016/j.yexmp.2012.03.004
   Mamonova T, 2012, BIOCHEMISTRY-US, V51, P3110, DOI 10.1021/bi201213w
   Mangia A, 2012, ONCOL REP, V28, P889, DOI 10.3892/or.2012.1895
   Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000
   Mayasundari A, 2008, BIOORG MED CHEM LETT, V18, P942, DOI 10.1016/j.bmcl.2007.12.038
   Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324
   Mologni L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051449
   Pan Y, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1616
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Saponaro C, 2014, CANCER BIOMARK, V14, P177, DOI 10.3233/CBM-130329
   Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-362
   Song GJ, 2015, J BIOL CHEM, V290, P2879, DOI 10.1074/jbc.M114.609768
   Song LL, 2015, CLIN COLORECTAL CANC, V14, P133, DOI 10.1016/j.clcc.2015.02.001
   Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2
   Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tsui V., 2014, AMBER
   van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865
   Vaquero J, 2017, ONCOGENE, V36, P3067, DOI 10.1038/onc.2016.462
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Wheeler DS, 2011, ONCOGENE, V30, P32, DOI 10.1038/onc.2010.389
   Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102
NR 50
TC 13
Z9 13
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN 14
PY 2018
VL 37
IS 24
BP 3301
EP 3316
DI 10.1038/s41388-018-0170-y
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA GJ6XB
UT WOS:000435526600009
PM 29551770
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Yang, X
   Zheng, YT
   Rong, W
AF Yang, Xiao
   Zheng, Yao-tun
   Rong, Wei
TI Sevoflurane induces apoptosis and inhibits the growth and motility of
   colon cancer in vitro and in vivo via inactivating Ras/Raf/MEK/ERK
   signaling
SO LIFE SCIENCES
LA English
DT Article
DE Sevoflurane; Colon cancer; Growth; Motility; ERK signaling pathway
ID EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; VOLATILE
   ANESTHETICS; CELL-DEATH; BREAST; EXPRESSION; SURGERY; RAF/MEK/ERK;
   PATHWAY; EMT
AB Aims: To investigate the effects of sevoflurane on proliferation, cell cycle, apoptosis, autophagy, invasion and epithelial-mesenchymal transition of colon cancer cell line SW480, and to explore its possible mechanism.
   Materials and methods: SW480 and SW620 cells were treated with a mixture of 95% O-2+5% CO2 containing different concentrations of sevoflurane (1.7% SAV, 3.4% SAV and 5.1% SAV) for 6 h. Meanwhile, we performed a rescue experiment by treating cells with the ERK pathway activator LM22B-10 prior to treatment of cells with 5.1% sevoflurane.
   Key findings: High concentration (5.1%) of sevoflurane significantly inhibited the proliferation and invasion of cells, causing G0/G1 phase arrest and promoted apoptosis and autophagy. 5.1% sevoflurane can participate in the regulation of EMT by regulating the expression of E-cadherin, Vimentin and N-cadherin proteins. LM22B-10 promoted proliferation and invasion of cancer cells and inhibited apoptosis and autophagy, while 5.1% sevoflurane could reverse the effect of LM22B-10 on the biological characteristics of cells. Sevoflurane can significantly inhibit tumor growth in SW480 cells transplanted nude mice. Moreover, 5.1% sevoflurane significantly increased the expression of p-Raf, p-MEK1/2, and p-ERK1/2 in SW480 cells and tumor tissues without affecting p-JNK and p-p38 proteins, meanwhile, 5.1% sevoflurane can inhibit the activation of ERK signaling pathway by LM22B-10 in vitro and in vivo.
   Significance: Sevoflurane can inhibit the proliferation and invasion of colon cancer cells, induce apoptosis and autophagy, and participate in the regulation of epithelial-mesenchymal transition, which may be related to its inhibition of the ERK signaling pathway.
C1 [Yang, Xiao; Zheng, Yao-tun; Rong, Wei] Weihai Cent Hosp, Dept Anesthesiol, Unit18-2,Wenhua Rd, Weihai 264400, Shandong, Peoples R China.
RP Rong, W (corresponding author), Weihai Cent Hosp, Dept Anesthesiol, Unit18-2,Wenhua Rd, Weihai 264400, Shandong, Peoples R China.
EM rongweirw123@126.com
CR Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brozovic G, 2008, EUR J ANAESTH, V25, P642, DOI 10.1017/S0265021508004171
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chang CY, 2015, IUBMB LIFE, V67, P869, DOI 10.1002/iub.1445
   Chen HH, 2017, MOL MED REP, V16, P5807, DOI 10.3892/mmr.2017.7366
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Choi CH, 2010, FREE RADICAL BIO MED, V49, P245, DOI 10.1016/j.freeradbiomed.2010.04.014
   Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55
   Dang Y., 2018, CAN J GASTROENTEROL, P1
   Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458
   Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17
   Delfini MC, 2009, DEV BIOL, V333, P229, DOI 10.1016/j.ydbio.2009.05.544
   Ecimovic P, 2013, ANTICANCER RES, V33, P4255
   Ethier C, 2007, APOPTOSIS, V12, P2037, DOI 10.1007/s10495-007-0127-z
   Guo L., 2017, JIANGSU AGR SCI, V45, P24
   Hu XL, 2017, CANCER LETT, V397, P83, DOI 10.1016/j.canlet.2017.03.033
   Huitink JM, 2010, ANESTH ANALG, V111, P1411, DOI 10.1213/ANE.0b013e3181fa3533
   Kim JH, 2014, EXP CELL RES, V327, P340, DOI 10.1016/j.yexcr.2014.08.001
   Kvolik S, 2005, LIFE SCI, V77, P2369, DOI 10.1016/j.lfs.2004.12.052
   Kvolik S, 2009, ACTA ANAESTH SCAND, V53, P1192, DOI 10.1111/j.1399-6576.2009.02036.x
   Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460
   Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li H, 2017, ONCOL LETT, V14, P5865, DOI 10.3892/ol.2017.6924
   Li NY, 2013, SURGERY, V154, P404, DOI 10.1016/j.surg.2013.05.012
   Li QR, 2018, NEUROSCI RES, V130, P47, DOI 10.1016/j.neures.2017.08.004
   Liang H, 2012, J ANESTH, V26, P381, DOI 10.1007/s00540-011-1317-y
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Lucchinetti E, 2009, ANESTH ANALG, V109, P1117, DOI 10.1213/ANE.0b013e3181b5a277
   MITSUHATA H, 1995, INT J IMMUNOPHARMACO, V17, P529, DOI 10.1016/0192-0561(95)00026-X
   Moradkhani MR, 2018, DRUG RES, V68, P125, DOI 10.1055/s-0043-119071
   Nishiwada T, 2015, J ANESTH, V29, P805, DOI 10.1007/s00540-015-2025-9
   Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841
   Pape M, 2006, ANESTH ANALG, V103, P173, DOI 10.1213/01.ane.0000222634.51192.a4
   Peng J, 2017, GUT, V66, P984, DOI 10.1136/gutjnl-2016-312986
   Ribatti D, 2017, EXP CELL RES, V353, P1, DOI 10.1016/j.yexcr.2017.02.041
   Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257
   Robles-Escajeda E, 2016, CELL ONCOL, V39, P265, DOI 10.1007/s13402-016-0272-x
   Saini KS, 2013, CANCER TREAT REV, V39, P935, DOI 10.1016/j.ctrv.2013.03.009
   Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011
   Schmukler E, 2013, ONCOTARGET, V4, P145
   Shi QY, 2015, BRIT J ANAESTH, V114, P825, DOI 10.1093/bja/aeu402
   Siekmann W, 2017, COLORECTAL DIS, V19, pO186, DOI 10.1111/codi.13643
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017
   Sun HZ, 2016, J CLIN LAB ANAL, V30, P1175, DOI 10.1002/jcla.22000
   Suter D, 2007, ANESTH ANALG, V104, P638, DOI 10.1213/01.ane.0000255046.06058.58
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tavare AN, 2012, INT J CANCER, V130, P1237, DOI 10.1002/ijc.26448
   von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001
   Wang J.Y., 2012, INT J ANESTHESIOL RE, V33, P314
   Wang J, 2016, GENES DIS, V3, P3, DOI 10.1016/j.gendis.2016.01.002
   Watanabe K, 2013, BRIT J ANAESTH, V110, P637, DOI 10.1093/bja/aes469
   Williams CS, 2011, J CLIN INVEST, V121, P4056, DOI 10.1172/JCI44228
   Wu AB, 2016, BIOMED PHARMACOTHER, V82, P290, DOI 10.1016/j.biopha.2016.04.008
   Xu HM, 2018, AM J TRANSL RES, V10, P1703
   Xu Y, 2017, MOL MED REP, V16, P7829, DOI 10.3892/mmr.2017.7519
   Xu ZH, 2014, J BUON, V19, P466
   Yang SF, 2017, ONCOL LETT, V13, P1041, DOI 10.3892/ol.2017.5557
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Zhang L, 2015, INT J CLIN EXP MED, V8, P19412
   Zhang XX, 2018, J CELL BIOCHEM, V119, P2864, DOI 10.1002/jcb.26461
   Zhou X, 2015, EUR REV MED PHARMACO, V19, P4087
   Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143
NR 65
TC 23
Z9 24
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD DEC 15
PY 2019
VL 239
AR 116916
DI 10.1016/j.lfs.2019.116916
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JU0IH
UT WOS:000501363000029
PM 31626792
DA 2022-04-25
ER

PT J
AU Pan, ZP
   Li, X
   Wang, YJ
   Jiang, QL
   Jiang, L
   Zhang, M
   Zhang, N
   Wu, FB
   Liu, B
   He, G
AF Pan, Zhaoping
   Li, Xiang
   Wang, Yujia
   Jiang, Qinglin
   Jiang, Li
   Zhang, Min
   Zhang, Nan
   Wu, Fengbo
   Liu, Bo
   He, Gu
TI Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives
   as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors
   Induce Autophagic Cell Death in Colorectal Carcinoma Cells
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID BET BROMODOMAIN; HDAC INHIBITORS; SMALL-MOLECULE; IN-VITRO; PRELIMINARY
   BIOACTIVITY; CANCER STATISTICS; BRD4; DESIGN; POTENT; LEUKEMIA
AB Bromodomain-containing protein 4 (BRD4) and histone deacetylases (HDAC) are both attractive epigenetic targets in cancer and other chronic diseases. Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives are discovered as selective BRD4-HDAC dual inhibitors. Compound 17c is the most potent inhibitor for BRD4 and HDAC with IC50 values at nanomolar levels, as well as the expression level of c-Myc, and increases the acetylation of histone H3. Moreover, 17c presents inhibitory effects on the proliferation of colorectal carcinoma (CRC) cells via inducing autophagic cell death. It also has a good pharmacokinetic profile in rats and oral bioavailability of 40.5%. In the HCT-116 xenograft in vivo models, 17c displays potent inhibitory efficiency on tumor growth by inducing autophagic cell death and suppressing IL6-JAK-STAT signaling pathways. Our results suggest that the BRD4-HDAC dual inhibition might be an attractive therapeutic strategy for CRC.
C1 [Jiang, Qinglin; Jiang, Li; Zhang, Min] Chengdu Med Coll, Sch Pharm, Chengdu 610500, Peoples R China.
   [Jiang, Qinglin; Jiang, Li; Zhang, Min] Chengdu Med Coll, Sichuan Prov Coll Key Lab Struct Specif Small Mol, Chengdu 610500, Peoples R China.
   [Pan, Zhaoping; Li, Xiang; Wang, Yujia; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Pan, Zhaoping; Li, Xiang; Wang, Yujia; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu] Sichuan Univ, West China Hosp, Dept Urol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Nan; Liu, Bo; He, Gu] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
RP Jiang, QL (corresponding author), Chengdu Med Coll, Sch Pharm, Chengdu 610500, Peoples R China.; Jiang, QL (corresponding author), Chengdu Med Coll, Sichuan Prov Coll Key Lab Struct Specif Small Mol, Chengdu 610500, Peoples R China.; Liu, B; He, G (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Liu, B; He, G (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, Chengdu 610041, Sichuan, Peoples R China.; Liu, B; He, G (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
EM jpl_cmc@163.com; liubo2400@163.com; hegu@scu.e.cu
RI He, Gu/G-5446-2015
OI He, Gu/0000-0002-1536-8882
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21772131, 81603065, 81673455]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2016M602696, 2016M592679]; National Science and Technology Major
   Project of the Ministry of Science and Technology of China
   [2018ZX09735005]; Fundamental Research Funds for the Science &
   Technology department of Sichuan Province [2019YFSY0004]
FX This work was supported by grants from National Natural Science
   Foundation of China (grant nos. 21772131, 81603065 and 81673455), China
   Postdoctoral Science Foundation (nos 2016M602696 and 2016M592679),
   National Science and Technology Major Project of the Ministry of Science
   and Technology of China (No. 2018ZX09735005) and the Fundamental
   Research Funds for the Science & Technology department of Sichuan
   Province (2019YFSY0004).
CR Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Bailey D, 2010, J AM COLL CARDIOL, V55, P2580, DOI 10.1016/j.jacc.2010.02.035
   Bonazzoli E, 2018, CLIN CANCER RES, V24, P4845, DOI 10.1158/1078-0432.CCR-18-0864
   Campbell GR, 2018, J BIOL CHEM, V293, P5808, DOI 10.1074/jbc.RA118.002353
   Chen C, 2017, EUR J MED CHEM, V133, P11, DOI 10.1016/j.ejmech.2017.03.064
   Chen T, 2017, SCI REP-UK, V7, DOI 10.1038/srep44543
   Delcuratolo M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005366
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Fischer PM, 2017, MED RES REV, V37, P314, DOI 10.1002/med.21409
   Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770
   Gosmini R, 2014, J MED CHEM, V57, P8111, DOI 10.1021/jm5010539
   Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013
   Guan P, 2014, BIOORGAN MED CHEM, V22, P5766, DOI 10.1016/j.bmc.2014.09.039
   Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976
   He SP, 2020, ANGEW CHEM INT EDIT, V59, P3028, DOI 10.1002/anie.201915896
   Hu XM, 2014, J BIOL CHEM, V289, P23154, DOI 10.1074/jbc.M114.570812
   Iftner T, 2017, VIRUS RES, V231, P76, DOI 10.1016/j.virusres.2016.12.006
   Jang JE, 2017, CLIN CANCER RES, V23, P2781, DOI 10.1158/1078-0432.CCR-16-1903
   Jia YP, 2013, ACTA PHARMACOL SIN, V34, P65
   Ke BW, 2016, MED RES REV, V36, P983, DOI 10.1002/med.21398
   Li XY, 2017, EUR J MED CHEM, V134, P185, DOI 10.1016/j.ejmech.2017.03.069
   Li ZC, 2013, NUCLEIC ACIDS RES, V41, P277, DOI 10.1093/nar/gks976
   Liu ZQ, 2018, EUR J MED CHEM, V151, P450, DOI 10.1016/j.ejmech.2018.04.006
   Lutz L, 2016, AM J CANCER RES, V6, P664
   McDaniel KF, 2017, J MED CHEM, V60, P8369, DOI 10.1021/acs.jmedchem.7b00746
   Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212
   Mrazek A, 2013, J AM COLL SURGEONS, V217, pS133, DOI 10.1016/j.jamcollsurg.2013.07.310
   Muller S, 2014, MEDCHEMCOMM, V5, P288, DOI 10.1039/c3md00291h
   Nagarajan S, 2017, NUCLEIC ACIDS RES, V45, P3130, DOI 10.1093/nar/gkw1276
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Neele AE, 2015, EUR J PHARMACOL, V763, P79, DOI 10.1016/j.ejphar.2015.03.101
   Noguchi-Yachide T, 2016, CHEM PHARM BULL, V64, P540, DOI 10.1248/cpb.c16-00225
   Ouyang L, 2017, J MED CHEM, V60, P9990, DOI 10.1021/acs.jmedchem.7b00275
   Ozer HG, 2018, CANCER DISCOV, V8, P458, DOI 10.1158/2159-8290.CD-17-0902
   Pan DQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101772
   Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292
   Roel M, 2016, ONCOTARGET, V7, P83071, DOI 10.18632/oncotarget.13068
   Saijo K, 2015, CANCER SCI, V106, P208, DOI 10.1111/cas.12585
   Sakakibara N., 2013, PLOS PATHOG, V9
   Sakamaki JI, 2017, AUTOPHAGY, V13, P2006, DOI 10.1080/15548627.2017.1364822
   Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041
   Shao MF, 2017, BIOORG MED CHEM LETT, V27, P4051, DOI 10.1016/j.bmcl.2017.07.054
   Shen CY, 2015, ONCOTARGET, V6, P8397, DOI 10.18632/oncotarget.3108
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Slyskova J, 2012, CLIN CANCER RES, V18, P5878, DOI 10.1158/1078-0432.CCR-12-1380
   Stolfa DA, 2014, J MOL BIOL, V426, P3442, DOI 10.1016/j.jmb.2014.03.007
   Vidler LR, 2013, J MED CHEM, V56, P8073, DOI 10.1021/jm4011302
   Wang JH, 2014, MEDCHEMCOMM, V5, P1887, DOI 10.1039/c4md00203b
   Wang L, 2015, BIOORGAN MED CHEM, V23, P4364, DOI 10.1016/j.bmc.2015.06.024
   Wen X, 2017, AUTOPHAGY, V13, P1801, DOI 10.1080/15548627.2017.1364334
   Wu QJ, 2014, NANOSCALE, V6, P11940, DOI 10.1039/c4nr02978j
   Wu SY, 2016, CELL REP, V16, P1733, DOI 10.1016/j.celrep.2016.07.001
   Yang ZZ, 2017, ONCOTARGET, V8, P29138, DOI 10.18632/oncotarget.16251
   Younes A, 2011, LANCET ONCOL, V12, P1222, DOI 10.1016/S1470-2045(11)70265-0
   Zang J, 2017, BIOORGAN MED CHEM, V25, P2666, DOI 10.1016/j.bmc.2016.12.001
   Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001
   Zhang TN, 2016, ONCOTARGET, V7, P42225, DOI 10.18632/oncotarget.9944
   Zhang ZM, 2016, BIOORG MED CHEM LETT, V26, P2931, DOI 10.1016/j.bmcl.2016.04.034
   Zhao YJ, 2013, J MED CHEM, V56, P7498, DOI 10.1021/jm4014407
NR 60
TC 25
Z9 25
U1 18
U2 85
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 9
PY 2020
VL 63
IS 7
BP 3678
EP 3700
DI 10.1021/acs.jmedchem.9b02178
PG 23
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA LE0HG
UT WOS:000526405300018
PM 32153186
DA 2022-04-25
ER

PT J
AU Cheng, KW
   Wong, CC
   Alston, N
   Mackenzie, GG
   Huang, LQ
   Ouyang, NT
   Xie, G
   Wiedmann, T
   Rigas, B
AF Cheng, Ka Wing
   Wong, Chi C.
   Alston, Ninche
   Mackenzie, Gerardo G.
   Huang, Liqun
   Ouyang, Nengtai
   Xie, Gang
   Wiedmann, Timothy
   Rigas, Basil
TI Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED PROTEIN-KINASE;
   COLON-CANCER; IBUPROFEN MDC-917; OXIDATIVE STRESS; AUTOPHAGY; SURVIVAL;
   GROWTH; APOPTOSIS; OXT-328
AB Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome first-pass metabolism and produce high levels of intact drug in lung tumors. Here, we developed a system for aerosolization of phospho-sulindac and evaluated the antitumor efficacy of inhaled phospho-sulindac in an orthotopic model of human non-small cell lung cancer (A549 cells). We found that administration by inhalation delivered high levels of phospho-sulindac to the lungs and minimized its hydrolysis to less active metabolites. Consequently, inhaled phospho-sulindac (6.5 mg/kg) was highly effective in inhibiting lung tumorigenesis (75%; P < 0.01) and significantly improved the survival of mice bearing orthotopic A549 xenografts. Mechanistically, phospho-sulindac suppressed lung tumorigenesis by (i) inhibiting EGF receptor (EGFR) activation, leading to profound inhibition of Raf/MEK/ERK and PI3K/AKT/mTOR survival cascades; (ii) inducing oxidative stress, which provokes the collapse of mitochondrial membrane potential and mitochondria-dependent cell death; and (iii) inducing autophagic cell death. Our data establish that inhalation delivery of phospho-sulindac is an efficacious approach to the control of lung cancer, which merits further evaluation. (C)2013 AACR.
C1 [Cheng, Ka Wing; Wong, Chi C.; Alston, Ninche; Mackenzie, Gerardo G.; Huang, Liqun; Ouyang, Nengtai; Xie, Gang; Rigas, Basil] SUNY Stony Brook, Canc Prevent Div, Stony Brook, NY 11794 USA.
   [Ouyang, Nengtai] Medicon Pharmaceut Inc, Stony Brook, NY USA.
   [Wiedmann, Timothy] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA.
RP Rigas, B (corresponding author), SUNY Stony Brook, Canc Prevent Div, HSC, T-17 Room 080, Stony Brook, NY 11794 USA.
EM basil.rigas@stonybrookmedicine.edu
RI Cheng, Ka Wing/V-9433-2019; Mackenzie, Gerardo G/AAW-5114-2020; Wong,
   Chi Chun/C-4636-2016
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA139454, R41CA162683]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA139454, R43CA165448] Funding Source: NIH RePORTER
FX This work was supported by NIH grants R01CA139454 and R41CA162683.
CR Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226
   Bhoopathi P, 2010, CELL DEATH DIFFER, V17, P1529, DOI 10.1038/cdd.2010.28
   Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002
   Brasky TM, 2012, J THORAC ONCOL, V7, P1503, DOI 10.1097/JTO.0b013e3182641bdc
   Castonguay A, 1997, CARCINOGENESIS, V18, P491, DOI 10.1093/carcin/18.3.491
   Dahl AR, 2000, CLIN CANCER RES, V6, P3015
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Doki Y, 1999, BRIT J CANCER, V79, P1121, DOI 10.1038/sj.bjc.6690178
   Duperron C, 1997, CARCINOGENESIS, V18, P1001, DOI 10.1093/carcin/18.5.1001
   Fulzele SV, 2006, PHARM RES-DORDR, V23, P2094, DOI 10.1007/s11095-006-9074-6
   Gong H. C., 2011, INT J PROTEOMICS, V2011, DOI DOI 10.1155/2011/215496
   Harris RE, 2002, ONCOL REP, V9, P693
   Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563
   Hosokawa M, 2008, MOLECULES, V13, P412, DOI 10.3390/molecules13020412
   Huang LQ, 2011, CANCER RES, V71, P7617, DOI 10.1158/0008-5472.CAN-11-2349
   Huang LQ, 2010, CARCINOGENESIS, V31, P1982, DOI 10.1093/carcin/bgq149
   Kang JH, 2012, J BIOL CHEM, V287, P15661, DOI 10.1074/jbc.M112.358473
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Mackenzie GG, 2011, CANCER PREV RES, V4, P1052, DOI 10.1158/1940-6207.CAPR-11-0067
   Mackenzie GG, 2010, GASTROENTEROLOGY, V139, P1320, DOI 10.1053/j.gastro.2010.06.044
   Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev
   Morton CL, 2000, CANCER RES, V60, P4206
   Naito A, 2008, INT J CANCER, V122, P1506, DOI 10.1002/ijc.23235
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Rigas B, 2008, BRIT J CANCER, V98, P1157, DOI 10.1038/sj.bjc.6604225
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Sahin U, 2007, FEBS LETT, V581, P41, DOI 10.1016/j.febslet.2006.11.074
   Scagliotti GV, 2004, CLIN CANCER RES, V10, p4227S, DOI 10.1158/1078-0432.CCR-040007
   Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474
   She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006
   Shivapurkar N, 2003, J CELL BIOCHEM, V88, P885, DOI 10.1002/jcb.10440
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125
   SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550
   Sun Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3105
   Sun Y, 2011, J PHARMACOL EXP THER, V338, P775, DOI 10.1124/jpet.111.183533
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   TATSUMURA T, 1993, BRIT J CANCER, V68, P1146, DOI 10.1038/bjc.1993.495
   Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8
   Wattenberg LW, 1997, CANCER RES, V57, P5489
   Wong CC, 2012, J PHARMACOL EXP THER, V340, P422, DOI 10.1124/jpet.111.188508
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Xie G, 2012, BRIT J PHARMACOL, V165, P2152, DOI 10.1111/j.1476-5381.2011.01705.x
   Xie G, 2011, J PHARMACOL EXP THER, V337, P876, DOI 10.1124/jpet.111.180224
NR 50
TC 11
Z9 12
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2013
VL 12
IS 8
BP 1417
EP 1428
DI 10.1158/1535-7163.MCT-13-0006-T
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 198FU
UT WOS:000322908400004
PM 23645590
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Belovejdov, V
   Dikov, D
   Auriault, M
   Copie-Bergman, C
   Sarafian, V
AF Belovejdov, Veselin T.
   Dikov, Dorian I.
   Auriault, Marie L.
   Copie-Bergman, Christiane
   Sarafian, Victoria S.
TI Uterine leiomyoma with massive lymphoid infiltrate after colon cancer
   chemotherapy: an immunohistochemical investigation with special
   reference to lysosome-associated membrane protein expression
SO CENTRAL EUROPEAN JOURNAL OF MEDICINE
LA English
DT Article
DE Uterine leiomyoma with massive lymphoid infiltrate; Colon cancer;
   Immunohistochemistry; LAMPs
ID LYMPHOCYTIC INFILTRATION; SIMULATING LYMPHOMA; HORMONE AGONIST;
   CELL-DEATH; AUTOPHAGY
AB Uterine leiomyoma with massive lymphoid infiltration is a rare morphologic phenomenon. We describe the first case of uterine leiomyoma with lymphoid infiltration observed in a patient after chemotherapy for sigmoid cancer. We performed immunohistochemical analysis with a panel of antibodies to several markers. Detection of CD20, CD3, Ki67, CD68 and Epstein-Barr virus nuclear antigen assisted in the differential diagnosis and partial elucidation of the pathogenesis. In addition, we examined the lysosome-associated membrane proteins LAMP-1 and LAMP-2 for the first time in this lesion. Their expression was elevated, indicating enhanced autophagy, an indirect sign of degenerative changes in this benign tumor characterized by massive lymphoid infiltration.
C1 [Belovejdov, Veselin T.] Med Univ Plovdiv, Dept Gen & Clin Pathol, Plovdiv 4002, Bulgaria.
   Ctr Hosp Lagny Marne La Vallee, Serv Anatom & Cytol Pathol, F-77405 Lagny Sur Marne, France.
   Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France.
   Med Univ Plovdiv, Dept Biol, Plovdiv 4002, Bulgaria.
RP Belovejdov, V (corresponding author), Med Univ Plovdiv, Dept Gen & Clin Pathol, Plovdiv 4002, Bulgaria.
EM vesbel@abv.bg
CR Bardsley V, 1998, HISTOPATHOLOGY, V33, P80, DOI 10.1046/j.1365-2559.1998.00451.x
   Botsis D, 1999, EUR J GYNAECOL ONCOL, V20, P61
   Bozzini N, 2003, ACTA OBSTET GYN SCAN, V82, P330, DOI 10.1034/j.1600-0412.2003.00049.x
   Chuang SS, 2001, PATHOL RES PRACT, V197, P135, DOI 10.1078/0344-0338-5710024
   COLGAN TJ, 1993, HUM PATHOL, V24, P1073, DOI 10.1016/0046-8177(93)90186-K
   CROW J, 1995, INT J GYNECOL PATHOL, V14, P235, DOI 10.1097/00004347-199507000-00007
   Cuervo AM, 2000, J CELL SCI, V113, P4441
   FERRY JA, 1989, INT J GYNECOL PATHOL, V8, P263, DOI 10.1097/00004347-198909000-00010
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511
   Ito F, 2001, FERTIL STERIL, V75, P125, DOI 10.1016/S0015-0282(00)01660-5
   Laforga JBM, 1999, HISTOPATHOLOGY, V34, P471
   McClean G, 2003, INT J SURG PATHOL, V11, P339, DOI 10.1177/106689690301100417
   Ohmori T, 2002, HISTOPATHOLOGY, V41, P276
   Paik SS, 2004, PATHOL INT, V54, P343, DOI 10.1111/j.1440-1827.2004.01629.x
   Resta L, 2004, Pathologica, V96, P35
   Saglam A, 2005, INT J GYNECOL CANCER, V15, P167
   Sarafian VS, 2007, APMIS, V115, P701, DOI 10.1111/j.1600-0463.2007.apm_576.x
   Ueda M, 1997, INT J CANCER, V71, P668, DOI 10.1002/(SICI)1097-0215(19970516)71:4<668::AID-IJC25>3.0.CO;2-6
   Wei SZ, 2004, GYNECOL ONCOL, V95, P409, DOI 10.1016/j.ygyno.2004.07.058
   Yoshimatsu K, 2008, ANTICANCER RES, V28, P373
NR 21
TC 0
Z9 0
U1 0
U2 1
PU SCIENDO
PI WARSAW
PA DE GRUYTER POLAND SP Z O O, BOGUMILA ZUGA 32A STR, 01-811 WARSAW, POLAND
SN 1895-1058
EI 1644-3640
J9 CENT EUR J MED
JI Cent. Eur. J. Med.
PD MAR
PY 2009
VL 4
IS 1
BP 54
EP 58
DI 10.2478/s11536-009-0016-7
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 406MP
UT WOS:000263299900008
DA 2022-04-25
ER

PT J
AU Chen, J
   Na, RS
   Xiao, C
   Wang, X
   Wang, YP
   Yan, DW
   Song, GH
   Liu, XI
   Chen, JY
   Lu, HJ
   Chen, CY
   Tang, HM
   Zhuang, GH
   Fan, GJ
   Peng, ZH
AF Chen, Jian
   Na, Risi
   Xiao, Chao
   Wang, Xiao
   Wang, Yupeng
   Yan, Dongwang
   Song, Guohe
   Liu, Xueni
   Chen, Jiayi
   Lu, Huijun
   Chen, Chunyan
   Tang, Huamei
   Zhuang, Guohong
   Fan, Guangjian
   Peng, Zhihai
TI The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal
   cancer by upregulating autophagy
SO ONCOGENE
LA English
DT Article
ID GLYCINE; COLON; METABOLISM; METASTASIS; SERINE; CELLS; PKM2; RISK; GENE
AB 5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting the binding of p53 and HDM2. Under 5-FU treatment, SHMT2 depletion promotes autophagy and inhibits apoptosis. Autophagy inhibitors decrease low SHMT2-induced 5-FU resistance in vitro and in vivo. Finally, the lethality of 5-FU treatment to CRC cells was enhanced by treatment with the autophagy inhibitor chloroquine in patient-derived and CRC cell xenograft models. Taken together, our findings indicate that autophagy induced by low SHMT2 levels mediates 5-FU resistance in CRC. These results reveal the SHMT2-p53 interaction as a novel therapeutic target and provide a potential opportunity to reduce chemoresistance.
C1 [Chen, Jian] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China.
   [Na, Risi; Tang, Huamei; Peng, Zhihai] Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China.
   [Xiao, Chao] Fu Dan Univ, Sch Med, Hua Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Wang, Xiao] Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Hosp 5, Zhuhai, Peoples R China.
   [Wang, Yupeng; Song, Guohe] Fu Dan Univ, Sch Med, Zhong Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Yan, Dongwang; Liu, Xueni; Chen, Jiayi; Fan, Guangjian] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China.
   [Lu, Huijun] Guigang City Peoples Hosp, Dept Pathol, Guigang, Guangxi, Peoples R China.
   [Chen, Chunyan] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Pathol, Shanghai, Peoples R China.
   [Tang, Huamei; Zhuang, Guohong; Peng, Zhihai] Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.
RP Tang, HM; Peng, ZH (corresponding author), Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China.; Fan, GJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China.; Tang, HM; Zhuang, GH; Peng, ZH (corresponding author), Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.
EM tanghuamei2014@163.com; zhgh@xmu.edu.cn; ytfan@126.com;
   pengzhihai1958@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81530044, 81802343, 81871931, 81602069,
   81220108021, 81702337, 81602616]; Medical Guidance Project of Shanghai
   Science and Technology Commission [17411968200, 19QA1407100]; Natural
   Science Foundation of Shanghai MunicipalityNatural Science Foundation of
   Shanghai [16ZR1427700, 16CR2008A]; National Science and Technology Major
   Project of China [2017ZX10203206]
FX We acknowledge the National Natural Science Foundation of China
   (81530044, 81802343, 81871931, 81602069, 81220108021, 81702337,
   81602616), the Medical Guidance Project of Shanghai Science and
   Technology Commission (17411968200, 19QA1407100), and the Natural
   Science Foundation of Shanghai Municipality (16ZR1427700). Shanghai
   3-year action plan to promote the clinical skills and clinical
   innovation capacity of municipal hospitals (No. 16CR2008A). National
   Science and Technology Major Project of China Grant 2017ZX10203206.
CR Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004
   Anderson DD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005839
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bao XR, 2016, ELIFE, V5, DOI 10.7554/eLife.10575
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chen DT, 2012, J GASTROINTEST SURG, V16, P905, DOI 10.1007/s11605-011-1815-0
   Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277-015-3800-9
   Chowdhury RM, 2018, J STOMATOL ORAL MAXI, V119, P37, DOI 10.1016/j.jormas.2017.11.001
   Fan GJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20208-x
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Harris I, 2012, CELL RES, V22, P447, DOI 10.1038/cr.2011.203
   Hashizume O, 2015, SCI REP-UK, V5, DOI 10.1038/srep10434
   Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Kelemen Linda E., 2012, Frontiers in Genetics, V3, P33, DOI 10.3389/fgene.2012.00033
   Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557
   Long M, 2017, TRENDS ENDOCRIN MET, V28, P818, DOI 10.1016/j.tem.2017.09.001
   Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Ning SL, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/4369253
   Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265
   Pezze PD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13254
   Piffoux M, 2021, BRIT J CANCER, V124, P333, DOI 10.1038/s41416-020-01039-5
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Ron-Harel N, 2016, CELL METAB, V24, P104, DOI 10.1016/j.cmet.2016.06.007
   Ryan BM, 2014, INT J CANCER, V134, P1399, DOI 10.1002/ijc.28457
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sanz-Pamplona R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-46
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Son SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16886-2
   Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Thandi RS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17310-5
   Walden M, 2019, NATURE, V570, P194, DOI 10.1038/s41586-019-1232-1
   Wei Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06812-y
   Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415
   Xiao C, 2018, CANCER SCI, V109, P1075, DOI 10.1111/cas.13516
   Xu MY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007071
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912
   Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053
   Zheng H, 2013, CELL REP, V5, P180, DOI 10.1016/j.celrep.2013.08.025
NR 55
TC 3
Z9 3
U1 8
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN 10
PY 2021
VL 40
IS 23
BP 3974
EP 3988
DI 10.1038/s41388-021-01815-4
EA MAY 2021
PG 15
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA SQ8GV
UT WOS:000650652500001
PM 33990700
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Jeong, S
   Yun, HK
   Jeong, YA
   Jo, MJ
   Kang, SH
   Kim, JL
   Kim, DY
   Park, SH
   Kim, BR
   Na, YJ
   Lee, SI
   Kim, HD
   Kim, DH
   Oh, SC
   Lee, DH
AF Jeong, Soyeon
   Yun, Hye Kyeong
   Jeong, Yoon A.
   Jo, Min Jee
   Kang, Sang Hee
   Kim, Jung Lim
   Kim, Dae Yeong
   Park, Seong Hye
   Kim, Bo Ram
   Na, Yoo Jin
   Lee, Sun Il
   Kim, Han Do
   Kim, Dae Hyun
   Oh, Sang Cheul
   Lee, Dae-Hee
TI Cannabidiol-induced apoptosis is mediated by activation of Noxa in human
   colorectal cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Marijuana extract; Bcl-2 protein family; ROS; Apoptotic cell death;
   Colon cancer
ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; ER STRESS; CANNABINOIDS;
   DEATH; MECHANISMS; ROS; AUTOPHAGY; PATHWAY
AB Cannabidiol (CBD), one of the compounds present in the marijuana plant, has anti-tumor properties, but its mechanism is not well known. This study aimed to evaluate the apoptotic action of CBD in colorectal cancer (CRC) cells, and focused on its effects on the novel pro-apoptotic Noxa-reactive oxygen species (ROS) signaling pathway. CBD experiments were performed using the CRC cell lines HCT116 and DLD-1. CBD induced apoptosis by regulating many pro- and anti-apoptotic proteins, of which Noxa showed significantly higher expression. To understand the relationship between Noxa and CBD-induced apoptosis, Noxa levels were downregulated using siRNA, and the expression of apoptosis markers decreased. After ROS production was blocked, the level of Noxa also decreased, suggesting that ROS is involved in the regulation of Noxa, which along with ROS is a well-known pro-apoptotic signaling agents. As a result, CBD induced apoptosis in a Noxa-and-ROS-dependent manner. Taken together, the results obtained in this study re-demonstrated the effects of CBD treatment in vivo, thus confirming its role as a novel, reliable anticancer drug.
C1 [Jeong, Soyeon; Kim, Jung Lim; Kim, Bo Ram; Oh, Sang Cheul; Lee, Dae-Hee] Korea Univ, Coll Med, Guro Hosp, Dept Oncol, Seoul, South Korea.
   [Yun, Hye Kyeong; Jeong, Yoon A.; Jo, Min Jee; Kim, Dae Yeong; Park, Seong Hye; Na, Yoo Jin; Oh, Sang Cheul; Lee, Dae-Hee] Korea Univ, Grad Sch Med, Coll Med, Seoul 08308, South Korea.
   [Kang, Sang Hee; Lee, Sun Il] Korea Univ, Coll Med, Guro Hosp, Dept Surg, Seoul, South Korea.
   [Kim, Han Do; Kim, Dae Hyun] Kaiyon Bio Tech Co Ltd, 226 Gamasan Ro, Seoul 08308, South Korea.
RP Lee, DH (corresponding author), Korea Univ, Med Ctr, Dept Internal Med, Coll Med,Div Oncol Hematol, Seoul 08308, South Korea.; Oh, SC (corresponding author), Korea Univ, Guro Hosp, Dept Internal Med, Div Oncol Hematol, 148 Gurodong Gil, Seoul 08308, South Korea.
EM sachoh@korea.ac.kr; neogene@korea.ac.kr
OI Kang, Sanghee/0000-0002-6097-8831
FU National Research Foundation of Korea - Korea government (MSIP)
   [NRF-2017R1D1A1B03030703]; Business for Cooperative R & D between
   Industry, Academy, and Research Institute [C0566291]; Korea University
   Grant
FX This work was supported by the National Research Foundation of Korea
   grant funded by the Korea government (MSIP) (NRF-2017R1D1A1B03030703)
   and supported by the Business for Cooperative R & D between Industry,
   Academy, and Research Institute funded Korea Small and Medium Business
   Administration in 20 (C0566291) and a Korea University Grant.
CR Banerjee A, 2017, ONCOTARGET, V8, P26142, DOI 10.18632/oncotarget.15393
   Chakravarti B, 2014, ONCOTARGET, V5, P5852, DOI 10.18632/oncotarget.2233
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Ehrhardt H, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.53
   Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188
   Hatsugai N, 2012, PLANT CELL PHYSIOL, V53, P1768, DOI 10.1093/pcp/pcs119
   Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034
   Jeong S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-481
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613
   Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940
   Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Nabissi M, 2013, CARCINOGENESIS, V34, P48, DOI 10.1093/carcin/bgs328
   Narita T, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.98
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x
   Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46
   Ramer R, 2013, MOL CANCER THER, V12, P69, DOI 10.1158/1535-7163.MCT-12-0335
   Saha SK, 2013, EUR J PHARMACOL, V714, P239, DOI 10.1016/j.ejphar.2013.06.009
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200
   Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603
   Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359
   Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sreevalsan S, 2011, ANTICANCER RES, V31, P3799
   Sun SS, 2017, REDOX BIOL, V11, P577, DOI 10.1016/j.redox.2016.12.029
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   Velasco G, 2016, CURR ONCOL, V23, pS23, DOI 10.3747/co.23.3080
   Velasco G, 2016, PROG NEURO-PSYCHOPH, V64, P259, DOI 10.1016/j.pnpbp.2015.05.010
   Velasco G, 2012, NAT REV CANCER, V12, P436, DOI 10.1038/nrc3247
   Yang YJ, 2017, CELL PHYSIOL BIOCHEM, V42, P929, DOI 10.1159/000478647
   Yuan YG, 2015, LAB INVEST, V95, P1374, DOI 10.1038/labinvest.2015.118
   Zhang DX, 2007, AM J PHYSIOL-HEART C, V292, pH2023, DOI 10.1152/ajpheart.01283.2006
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 37
TC 47
Z9 47
U1 6
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2019
VL 447
BP 12
EP 23
DI 10.1016/j.canlet.2019.01.011
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HO1ZT
UT WOS:000460711900002
PM 30660647
DA 2022-04-25
ER

PT J
AU Kwatra, D
   Subramaniam, D
   Ramamoorthy, P
   Standing, D
   Moran, E
   Velayutham, R
   Mitra, A
   Umar, S
   Anant, S
AF Kwatra, Deep
   Subramaniam, Dharmalingam
   Ramamoorthy, Prabhu
   Standing, David
   Moran, Elizabeth
   Velayutham, Ravichandiran
   Mitra, Ashim
   Umar, Shahid
   Anant, Shrikant
TI Methanolic Extracts of Bitter Melon Inhibit Colon Cancer Stem Cells by
   Affecting Energy Homeostasis and Autophagy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; MOMORDICA-CHARANTIA; ELEOSTEARIC ACID; STROMAL
   CELLS; IDENTIFICATION; APOPTOSIS; CURCUMIN; PROLIFERATION; NEOPLASIA;
   AGENTS
AB Bitter melon fruit is recommended in ancient Indian and Chinese medicine for prevention/treatment of diabetes. However its effects on cancer progression are not well understood. Here, we have determined the efficacy of methanolic extracts of bitter melon on colon cancer stem and progenitor cells. Both, whole fruit (BMW) and skin (BMSk) extracts showed significant inhibition of cell proliferation and colony formation, with BMW showing greater efficacy. In addition, the cells were arrested at the S phase of cell cycle. Moreover, BMW induced the cleavage of LC3B but not caspase 3/7, suggesting that the cells were undergoing autophagy and not apoptosis. Further confirmation of autophagy was obtained when western blots showed reduced Bcl-2 and increased Beclin-1, Atg 7 and 12 upon BMW treatment. BMW reduced cellular ATP levels coupled with activation of AMP activated protein kinase; on the other hand, exogenous additions of ATP lead to revival of cell proliferation. Finally, BMW treatment results in a dose-dependent reduction in the number and size of colonospheres. The extracts also decreased the expression of DCLK1 and Lgr5, markers of quiescent, and activated stem cells. Taken together, these results suggest that the extracts of bitter melon can be an effective preventive/therapeutic agent for colon cancer.
C1 [Kwatra, Deep; Subramaniam, Dharmalingam; Ramamoorthy, Prabhu; Standing, David; Moran, Elizabeth; Umar, Shahid; Anant, Shrikant] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA.
   [Subramaniam, Dharmalingam; Ramamoorthy, Prabhu; Standing, David; Umar, Shahid; Anant, Shrikant] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66160 USA.
   [Velayutham, Ravichandiran] Vels Univ, Dept Pharmacognosy, Madras 600117, Tamil Nadu, India.
   [Mitra, Ashim] Univ Missouri, Dept Pharmaceut Sci, Kansas City, MO 64108 USA.
RP Anant, S (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd MS 3040, Kansas City, KS 66160 USA.
EM sanant@kumc.edu
RI Anant, Shrikant/AAF-8020-2020
OI Pearsall, Elizabeth/0000-0003-1013-6238; Standing,
   David/0000-0003-3153-4374
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DK062265, CA109269, CA135559]; Thomas
   O'Sullivan Foundation; NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA168524-01]; Cancer Center; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA109269, P30CA168524, R01CA135559] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01DK062265] Funding Source: NIH RePORTER
FX This work was supported by the NIH Grants DK062265, CA109269, and
   CA135559 to S. Anant and Grant support from the Thomas O'Sullivan
   Foundation and NCI-designated The University of Kansas Cancer Center
   (P30CA168524-01). S. Anant is an Eminent Scientist of the Kansas
   Biosciences Authority. The author would also like to acknowledge the
   Flow Cytometry Core Laboratory, which is sponsored in part by the Cancer
   Center. They also thank all members of the Anant Laboratory for their
   discussion during the course of this study.
CR Akihisa T, 2007, J NAT PROD, V70, P1233, DOI 10.1021/np068075p
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Basch E, 2003, AM J HEALTH-SYST PH, V60, P356, DOI 10.1093/ajhp/60.4.356
   Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Dhar A., 2012, NUTRACEUTICALS CANC, P11
   Erlanson-Albertsson Charlotte, 2011, Lakartidningen, V108, P2713
   Filippi-Chiela EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020849
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Fujishima Y, 2011, ARCH BIOCHEM BIOPHYS, V506, P223, DOI 10.1016/j.abb.2010.12.009
   Goel A, 2010, NUTR CANCER, V62, P919, DOI 10.1080/01635581.2010.509835
   Grossmann ME, 2009, CANCER PREV RES, V2, P879, DOI 10.1158/1940-6207.CAPR-09-0088
   Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Huang MY, 2012, DNA CELL BIOL, V31, P43, DOI 10.1089/dna.2011.1264
   JILKA C, 1983, CANCER RES, V43, P5151
   Jordan CT, 2009, CELL STEM CELL, V4, P203, DOI 10.1016/j.stem.2009.02.003
   Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212
   Kemper K, 2010, ONCOTARGET, V1, P387, DOI 10.18632/oncotarget.173
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Lee-Huang S, 2000, ANTICANCER RES, V20, P653
   Leung L, 2009, BRIT J NUTR, V102, P1703, DOI 10.1017/S0007114509992054
   Li CJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/261971
   Mandong B M, 2011, Niger J Med, V20, P399
   May R, 2008, STEM CELLS, V26, P630, DOI 10.1634/stemcells.2007-0621
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005
   Nagasawa H, 2002, AM J CHINESE MED, V30, P195, DOI 10.1142/S0192415X02000302
   Nerurkar P, 2010, PHARM RES-DORDR, V27, P1049, DOI 10.1007/s11095-010-0057-2
   Nerurkar PV, 2008, BRIT J NUTR, V100, P751, DOI 10.1017/S0007114508937430
   Ray RB, 2010, CANCER RES, V70, P1925, DOI 10.1158/0008-5472.CAN-09-3438
   Rocco A, 2012, J CELL PHYSIOL, V227, P2686, DOI 10.1002/jcp.23013
   Ru P, 2011, CANCER PREV RES, V4, P2122, DOI 10.1158/1940-6207.CAPR-11-0376
   Shoshan M. C., CURRENT PHA IN PRESS
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Subramaniam D, 2008, CANCER RES, V68, P1962, DOI 10.1158/0008-5472.CAN-07-6011
   Tatrai P, 2012, BIOCHEM BIOPH RES CO, V422, P28, DOI 10.1016/j.bbrc.2012.04.088
   Thomasset SC, 2007, INT J CANCER, V120, P451, DOI 10.1002/ijc.22419
   Tsuzuki T, 2004, CARCINOGENESIS, V25, P1417, DOI 10.1093/carcin/bgh109
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Xiong SD, 2009, INT J CANCER, V125, P774, DOI 10.1002/ijc.24325
   Yin Jun, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P99, DOI 10.2174/187153008784534330
   Yu JM, 2005, FOOD CHEM, V90, P199, DOI 10.1016/j.foodchem.2004.03.048
NR 48
TC 42
Z9 43
U1 0
U2 28
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
VL 2013
AR 702869
DI 10.1155/2013/702869
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 106UQ
UT WOS:000316170600001
PM 23533514
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Sivaprasad, U
   Basu, A
AF Sivaprasad, U.
   Basu, A.
TI Inhibition of ERK attenuates autophagy and potentiates tumour necrosis
   factor-alpha-induced cell death in MCF-7 cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE TNF; autophagy; ERK 1/2; U0126
ID PROTEIN-KINASE-C; COLON-CANCER CELLS; INDUCED APOPTOSIS; SIGNALING
   PATHWAYS; IN-VITRO; ACTIVATION; INDUCTION; MACROAUTOPHAGY; GROWTH; TRAIL
AB The role of autophagy in cell death is under considerable debate. The process of autophagy has been shown to lead to either cell survival or cell death depending on cell type and stimulus. In the present study, we determined the contribution of ERK1/2 signalling to autophagy and cell death induced by tumour necrosis factor-alpha (TNF) in MCF-7 breast cancer cells. Treatment of MCF-7 cells with TNF caused a time-dependent increase in ERK1/2 activity. There was an induction of autophagy and cleavage of caspase-7, -8, -9 and PARP. Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells. These data suggest that TNF-induces autophagy through ERK1/2 and that inhibition of autophagy increases cellular sensitivity to TNF.
C1 [Basu, A.] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.
   Inst Canc Res, Ft Worth, TX USA.
RP Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM abasu@hsc.unt.edu
OI Basu, Alakananda/0000-0002-1656-0788
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA071727] Funding Source: NIH RePORTER; NCI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA71727, R01 CA071727] Funding Source: Medline
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200
   Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q
   Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x
   Chang NS, 1997, AM J PHYSIOL-CELL PH, V273, pC1987, DOI 10.1152/ajpcell.1997.273.6.C1987
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   GHAVAMI S, 2007, J CELL MOL MED
   Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Harhaji L, 2007, EUR J PHARMACOL, V568, P248, DOI 10.1016/j.ejphar.2007.04.029
   Hetz CA, 2005, BIOCHEM CELL BIOL, V83, P579, DOI 10.1139/o05-065
   Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7
   Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885
   Kim R, 2005, ONCOL REP, V14, P595
   Klionsky DJ, 2005, AUTOPHAGY, V1, P59, DOI 10.4161/auto.1.1.1536
   Kuribayashi K, 2006, CANCER BIOL THER, V5, P763, DOI 10.4161/cbt.5.7.3228
   Lee CY, 2001, DEVELOPMENT, V128, P1443
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007
   Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x
   Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933
   Martinet W, 2005, BIOTECHNOL LETT, V27, P1157, DOI 10.1007/s10529-005-0007-y
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Prins JB, 1998, BIOSCIENCE REP, V18, P329, DOI 10.1023/A:1020261316486
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Sivaprasad U, 2007, CELL DEATH DIFFER, V14, P851, DOI 10.1038/sj.cdd.4402077
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826
   Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906
   Wang XJ, 2004, J BIOL CHEM, V279, P45855, DOI 10.1074/jbc.M405147200
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
NR 51
TC 107
Z9 112
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2008
VL 12
IS 4
BP 1265
EP 1271
DI 10.1111/j.1582-4934.2008.00282.x
PG 7
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 336IU
UT WOS:000258358300024
PM 18266953
OA Green Published
DA 2022-04-25
ER

PT J
AU Wang, Y
   Li, YZ
   Yang, L
   Yin, DX
AF Wang, Yang
   Li, Yezhou
   Yang, Li
   Yin, Dexin
TI Intermittent low dose irradiation enhances the effectiveness of radio-
   and chemo-therapy for human colorectal adenocarcinoma cell line HT-29
SO ONCOLOGY REPORTS
LA English
DT Article
DE low dose irradiation; colorectal adenocarcinoma; chemotherapy;
   radiotherapy; cell signaling
ID COLON-CANCER CELLS; 5-FLUOROURACIL RESISTANCE; IONIZING-RADIATION;
   LEVEL; RADIORESISTANCE; PERSPECTIVES; MECHANISMS; AUTOPHAGY; HORMESIS;
   P53
AB Low dose irradiation (LDIR) induces hormesis and adaptive response in organism and mammalian cell lines. Notably, LDIR generates distinct biological effects in cancer cells from normal cells, e.g., it may affect the growth of cancer cells via the activation of certain cell signaling pathway, which does not exist in normal cells. Therefore, LDIR is considered as a promising assistant method of clinical cancer therapy. In this study, we chose human colorectal adenocarcinoma cell line HT-29 as the experimental model, and investigated the differential biological effects between 250 mGy single dose LDIR and 250 mGy intermittent LDIR pretreatments in high dose irradiation (HDIR) radiotherapy and 5-fluorouracil (5-FU) based chemotherapy. Through the cell growth assays, we observed that 250 mGy intermittent LDIR pretreatment significantly increased the killing effect of both radiotherapy and chemotherapy. Western blotting results showed that intermittent LDIR pretreatment apparently activated the ATM/p53 (ataxia telangiectasia mutated, ATM) pathway in radiotherapy; it also activated ERK and p38MAPK pathways in chemotherapy. When we used chemical inhibitors to block the ATM/p53 or p38MAPK pathways, the intermittent LDIR induced cell growth inhibitions were reversed. However, blockage of ERK pathway could not affect the cell growth inhibiton in chemotherapy. Taken together, our findings evaluated the intermittent LDIR as a potential valuable method that can enhance the effectiveness of radiotherapy and chemotherapy, especially in the radio- or chemo-resistant tumor types.
C1 [Wang, Yang; Yang, Li] FAW Gen Hosp, Dept Gastroenterol, Changchun 130011, Jilin, Peoples R China.
   [Li, Yezhou; Yin, Dexin] Jilin Univ, Dept Vasc Surg, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
RP Yin, DX (corresponding author), Jilin Univ, Dept Vasc Surg, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.
EM jlucjuhyd@163.com
CR Brazina J, 2015, CELL CYCLE, V14, P375, DOI 10.4161/15384101.2014.988019
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Feinendegen LE, 2005, BRIT J RADIOL, V78, P3, DOI 10.1259/bjr/63353075
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Guo M, 2015, BIOMED PHARMACOTHER, V76, P107, DOI 10.1016/j.biopha.2015.10.027
   Hafner MF, 2016, VISC MED, V32, P172, DOI 10.1159/000446486
   Liang XY, 2016, DOSE-RESPONSE, V14, DOI 10.1177/1559325815622174
   Lin K, 2012, CLIN CANCER RES, V18, P4191, DOI 10.1158/1078-0432.CCR-11-2936
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   LUCKEY TD, 1982, HEALTH PHYS, V43, P771, DOI 10.1097/00004032-198212000-00001
   OLIVIERI G, 1984, SCIENCE, V223, P594, DOI 10.1126/science.6695170
   Shin YK, 2009, ELECTROPHORESIS, V30, P2182, DOI 10.1002/elps.200800806
   Su XL, 2014, GENET MOL RES, V13, P2513, DOI 10.4238/2014.January.17.5
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Tang FR, 2015, INT J RADIAT BIOL, V91, P13, DOI 10.3109/09553002.2014.937510
   Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Yang GZ, 2016, ONCOTARGET, V7, P71856, DOI 10.18632/oncotarget.12379
   Yang GZ, 2016, INT J CANCER, V139, P2157, DOI 10.1002/ijc.30235
   Yang XD, 2015, AM J CANCER RES, V5, P545
NR 20
TC 4
Z9 4
U1 1
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2017
VL 38
IS 1
BP 591
EP 597
DI 10.3892/or.2017.5679
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EY6JR
UT WOS:000404089500068
PM 28560404
OA Bronze
DA 2022-04-25
ER

PT J
AU Fuel, M
   Mesas, C
   Martinez, R
   Ortiz, R
   Quinonero, F
   Prados, J
   Porres, JM
   Melguizo, C
AF Fuel, Marco
   Mesas, Cristina
   Martinez, Rosario
   Ortiz, Raul
   Quinonero, Francisco
   Prados, Jose
   Porres, Jesus M.
   Melguizo, Consolacion
TI Antioxidant and antiproliferative potential of ethanolic extracts from
   Moringa oleifera, Tropaeolum tuberosum and Annona cherimola in
   colorrectal cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Moringa oleifera; Tropaeolum tuberosum; Annona cherimola; Ethanolic
   extract; Colon cancer; 5-Fluorouracil
ID IN-VITRO; OXIDATIVE DAMAGE; CONSTITUENTS; ACETOGENINS; MECHANISMS;
   RESISTANCE; INHIBITORS; MURICATA; LEAVES; GREEN
AB Moringa oleifera, Tropaeolum tuberosum and Annona cherimola are medicinal plants traditionally used in Ecuador. However, their therapeutic properties are not completely known. We analyzed chromatographically ethanolic extracts of the seeds of M. oleifera, A. cherimola and the tubers of T. tuberosum; all presented a high content of polyphenols. The extract of A. cherimola showed the highest antioxidant activity and M. oleifera had the highest capacity to enhance the activity of detoxifying enzymes such as glutathione S-transferase and quinone oxidoreductase. The antitumor effect of these extracts was evaluated in vitro with colorectal cancer (CRC) cell lines T84, HCT-15, SW480 and HT-29, as well as with cancer stem cells (CSCs). A. cherimola and M. oleifera extracts presented the lowest IC50 in T-84 and HCT-15 (resistant) cells, respectively, as well as the highest level of inhibition of proliferation in multicellular tumor spheroids of HCT-15 cells. The inhibitory effect on CSCs is noteworthy because in vivo, these cells are often responsible for cancer recurrences and resistance to chemotherapy. Moreover, all extracts showed a synergistic activity with 5-Fu. The antiproliferative mechanism of the extracts was related to overexpression of caspases 9, 8 and 3 and increased production of reactive oxygen species. In addition, we observed cell death by autophagy in M. oleifera and T. tuberosum extracts. Therefore, these ethanolic extracts are excellent candidates for future molecular analysis of the presence of bioactive compounds and in vivo studies which could improve colon cancer therapy.
C1 [Fuel, Marco; Mesas, Cristina; Ortiz, Raul; Quinonero, Francisco; Prados, Jose; Melguizo, Consolacion] Univ Granada, Ctr Biomed Res CIBM, Inst Biopathol & Regenerat Med IBIMER, Granada 18100, Spain.
   [Mesas, Cristina; Ortiz, Raul; Quinonero, Francisco; Prados, Jose; Melguizo, Consolacion] Univ Granada, Fac Med, Dept Anat & Embryol, Granada 18071, Spain.
   [Mesas, Cristina; Ortiz, Raul; Quinonero, Francisco; Prados, Jose; Melguizo, Consolacion] Inst Biosanitario Granada Ibs GRANADA, Granada 18014, Spain.
   [Martinez, Rosario; Porres, Jesus M.] Univ Almeria, NIF B04847216, Cellbitec SL, Sci Headquarters Almeria Technol Pk, Almeria 04128, Spain.
   [Martinez, Rosario; Porres, Jesus M.] Univ Granada, Biomed Res Ctr CIBM, Inst Nutr & Food Technol INyTA, Dept Physiol, Granada 18100, Spain.
RP Prados, J (corresponding author), Univ Granada, Ctr Biomed Res CIBM, Inst Biopathol & Regenerat Med IBIMER, Granada 18100, Spain.
EM jcprados@ugr.es
RI Herrera, Marco Fuel/AAG-9237-2020; Quiñonero, Francisco/T-3165-2018;
   Melguizo Alonso, Consolacion/E-9842-2016
OI Herrera, Marco Fuel/0000-0002-4170-2899; Quiñonero,
   Francisco/0000-0002-9087-8161; Mesas, Cristina/0000-0001-6369-5485;
   Melguizo Alonso, Consolacion/0000-0003-3990-806X
FU Granada Universit [CTS-107, AGR145]; 2018 Research Initiation Grants
   Program for Master Students of the Vice-Rectorate for Research and
   Knowledge Transfer of the University of Granada
FX This research was funded by the CTS-107 and AGR145 Groups from the
   Granada University. M. Fuel obtained all plants of the study from
   Ecuador. A part of this study has been funded by the 2018 Research
   Initiation Grants Program for Master Students of the Vice-Rectorate for
   Research and Knowledge Transfer of the University of Granada.
CR Akinlolu AA, 2021, INT J HEALTH SCI-IJH, V15, P26
   Al-Shammari A.M, 2021, INT J DRUG DELIV TEC, V11, P21, DOI [10.25258/ijddt.11.1.4, DOI 10.25258/IJDDT.11.1.4]
   Anaya-Esparza LM, 2020, FOOD RES INT, V138, DOI 10.1016/j.foodres.2020.109775
   Antony P, 2016, DRUG DES DEV THER, V10, P1399, DOI 10.2147/DDDT.S103216
   Ticona LA, 2020, CHEMISTRYSELECT, V5, P11825, DOI 10.1002/slct.202003062
   Ticona LA, 2020, PHYTOCHEMISTRY, V177, DOI 10.1016/j.phytochem.2020.112435
   Ticona LNA, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2019.112152
   Bailon-Moscoso N, 2015, MED CHEM RES, V24, P2283, DOI 10.1007/s00044-015-1335-7
   Bao JL, 2017, AM J CHINESE MED, V45, P1513, DOI [10.1142/S0192415X17500823, 10.1142/s0192415x17500823]
   Barhoi D, 2021, J AM COLL NUTR, V40, P70, DOI 10.1080/07315724.2020.1735572
   Baruah TJ, 2018, MOL BIOL REP, V45, P1219, DOI 10.1007/s11033-018-4275-8
   Baskaran R, 2016, FOOD RES INT, V82, P121, DOI 10.1016/j.foodres.2016.02.001
   Berkenbosch L, 2013, BMC MED EDUC, V13, DOI [10.1186/1472-6882-13-212, 10.1186/1472-6920-13-25]
   Bhadresha KP, 2022, NUTR CANCER, V74, P1023, DOI 10.1080/01635581.2021.1933099
   Cabeza Laura, 2021, Biology (Basel), V10, DOI 10.3390/biology10020134
   Calzada F, 2017, PHARMACOGN RES, V9, P1, DOI 10.4103/0974-8490.199781
   Cao XC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1244-6
   Caparica R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020233
   Chen HJ, 2018, ONCOL REP, V39, P921, DOI 10.3892/or.2018.6191
   Chirinos R, 2008, FOOD CHEM, V111, P98, DOI 10.1016/j.foodchem.2008.03.038
   Cuellar-Nunez ML, 2021, FOOD RES INT, V144, DOI 10.1016/j.foodres.2021.110318
   De Raphaelli C.O., 2021, PHYTOMED PLUS, V1, P100112, DOI [10.1016/j.phyplu.2021.100112, DOI 10.1016/J.PHYPLU.2021.100112, 10.1016/j. phyplu.2021.100112]
   Dhakad AK, 2019, PHYTOTHER RES, V33, P2870, DOI 10.1002/ptr.6475
   Truong DH, 2019, J FOOD QUALITY, DOI 10.1155/2019/8178294
   Dong ZL, 2017, MOLECULES, V22, DOI 10.3390/molecules22091466
   Du GJ, 2012, NUTRIENTS, V4, P1679, DOI 10.3390/nu4111679
   Famurewa AC, 2019, S AFR J BOT, V127, P96, DOI 10.1016/j.sajb.2019.08.038
   Fan DS, 2016, FITOTERAPIA, V113, P69, DOI 10.1016/j.fitote.2016.07.006
   Foster K, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03130-z
   Gill BS, 2016, TUMOR BIOL, V37, P14271, DOI 10.1007/s13277-016-5291-8
   Gupta S., 2020, BIOACT NAT PROD DRUG, DOI [10.1007/978-981-15-1394-7_5, DOI 10.1007/978-981-15-1394-7_5]
   Haykal T, 2019, TOXINS, V11, DOI 10.3390/toxins11090506
   Hedrick TL, 2021, SURGERY, V169, P1280, DOI 10.1016/j.surg.2020.10.038
   Henc I, 2017, INT IMMUNOPHARMACOL, V49, P148, DOI 10.1016/j.intimp.2017.05.034
   Herranz-Lopez Maria, 2018, Medicines (Basel), V6, DOI 10.3390/medicines6010006
   Iriti M, 2017, PHYTOTHER RES, V31, P1529, DOI 10.1002/ptr.5878
   Priya MJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1855249
   Justino AB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55779-3
   Kapravelou G, 2015, J SCI FOOD AGR, V95, P1207, DOI 10.1002/jsfa.6809
   Katarina A, 2011, INDONESIAN J CANC CH, V1, P124, DOI [10.14499/indonesianjcanchemoprev1iss2pp124-128, DOI 10.14499/INDONESIANJCANCHEMOPREV1ISS2PP124-128, 10.14499/indonesianjcanchemoprev1iss2pp124, DOI 10.14499/INDONESIANJCANCHEMOPREV1ISS2PP124]
   Khalil M, 2021, NUTR CANCER, V73, P1193, DOI 10.1080/01635581.2020.1792517
   Khan T, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010047
   Kuete V, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3361-4
   Kuruppu AI, 2019, SAUDI PHARM J, V27, P565, DOI 10.1016/j.jsps.2019.02.004
   Lam Moringa oleifera, 2020, NAT PROD RES, P1, DOI [10.1080/14786419.2020.1837804, DOI 10.1080/14786419.2020.1837804]
   Lee DY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050743
   Lee M, 2021, J CLIN PATHOL, DOI 10.1136/jclinpath-2021-207406
   Lezoul NE, 2020, MOLECULES, V25, DOI 10.3390/molecules25204672
   Li BH, 2014, COMPUT BIOL MED, V53, P19, DOI 10.1016/j.compbiomed.2014.05.007
   Li YQ, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03225-1
   Liu XL, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0214-y
   Mannino G, 2020, MOLECULES, V25, DOI 10.3390/molecules25112612
   Mesas C, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020566
   Moghadamtousi SZ, 2015, INT J MOL SCI, V16, P15625, DOI 10.3390/ijms160715625
   Fisall UFM, 2021, MOL BIOL REP, V48, P4465, DOI 10.1007/s11033-021-06466-y
   Mwamatope Bonface, 2021, Anticancer Agents Med Chem, DOI 10.2174/1871520621666210708122037
   Mwitari P., 2018, EUR J MED PLANTS, V23, P1, DOI [10.9734/EJMP/2018/41021, DOI 10.9734/EJMP/2018/41021]
   Nuzzo G, 2019, MAR DRUGS, V17, DOI 10.3390/md17010058
   Olatunde OO, 2021, INT J FOOD SCI TECH, V56, P2804, DOI 10.1111/ijfs.14917
   Qin JJ, 2016, J BIOMED RES, V30, P322, DOI 10.7555/JBR.30.20160018
   Quilez AM, 2018, J ETHNOPHARMACOL, V225, P244, DOI 10.1016/j.jep.2018.06.014
   Rady I, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1826170
   Rahman HS, 2021, CURR DRUG TARGETS, V22, P977, DOI 10.2174/1389450122666210405105206
   Ramos LPA, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.112049
   Rana A, 2014, NAT PROD RES, V28, P593, DOI 10.1080/14786419.2014.886207
   Ren YL, 2019, J NAT PROD, V82, P657, DOI 10.1021/acs.jnatprod.9b00018
   Salsabila IA, 2021, IRAN J PHARM RES, V20, P57, DOI 10.22037/ijpr.2020.112485.13788
   Sawicki T, 2021, CANCERS, V13, DOI 10.3390/cancers13092025
   Siddiqui S, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13720
   Silva C.R.Espinoza, 2019, EVALUACION INVITRO C
   Sridhar N, 2015, INDIAN J PHARMACOL, V47, P177, DOI 10.4103/0253-7613.153425
   Sultana B, 2009, MOLECULES, V14, P2167, DOI 10.3390/molecules14062167
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Surowiak AK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22095036
   Pacheco MT, 2019, FOOD CHEM, V301, DOI 10.1016/j.foodchem.2019.125268
   Thummar Vipul R, 2016, J Tradit Complement Med, V6, P383
   Thanh TTV, 2019, NAT PROD COMMUN, V14, DOI 10.1177/1934578X19850969
   Tundis R, 2008, Z NATURFORSCH C, V63, P347
   Van Kiem P, 2008, CHEM PHARM BULL, V56, P1270, DOI 10.1248/cpb.56.1270
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wang J, 2020, FITOTERAPIA, V146, DOI 10.1016/j.fitote.2020.104675
   Waseem Y, 2018, CUREUS, V10, DOI 10.7759/cureus.3628
   Wu JJ, 2010, STEROIDS, V75, P734, DOI 10.1016/j.steroids.2010.05.002
   Wu Q, 2018, J AGR FOOD CHEM, V66, P7181, DOI 10.1021/acs.jafc.8b02420
   Xie J., EVID-BASED COMPL ALT, V2021, P1, DOI [10.1155/2021, DOI 10.1155/2021]
   Xu YB, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8080296
   Xu YB, 2021, PHYTOCHEM ANALYSIS, V32, P698, DOI 10.1002/pca.3016
   Ye Wei-Jian, 2018, Zhongguo Zhong Yao Za Zhi, V43, P3150, DOI 10.19540/j.cnki.cjcmm.20180423.002
   Zhang H, 2019, ACTA PHARM SIN B, V9, P516, DOI 10.1016/j.apsb.2018.12.006
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang QA, 2011, J NAT PROD, V74, P152, DOI 10.1021/np100428u
   Zhang YQ, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/9806160
   Zhao LL, 2019, MOL MED REP, V20, P802, DOI 10.3892/mmr.2019.10282
   Zhu JX, 2018, CHINESE CHEM LETT, V29, P1261, DOI 10.1016/j.cclet.2017.11.042
NR 94
TC 1
Z9 1
U1 14
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2021
VL 143
AR 112248
DI 10.1016/j.biopha.2021.112248
EA SEP 2021
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA WD4HD
UT WOS:000704903000004
PM 34649364
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chang, HW
   Liu, PF
   Tsai, WL
   Hu, WH
   Hu, YC
   Yang, HC
   Lin, WY
   Weng, JR
   Shu, CW
AF Chang, Hsueh-Wei
   Liu, Pei-Feng
   Tsai, Wei-Lun
   Hu, Wan-Hsiang
   Hu, Yu-Chang
   Yang, Hsiu-Chen
   Lin, Wei-Yu
   Weng, Jing-Ru
   Shu, Chih-Wen
TI Xanthium strumarium Fruit Extract Inhibits ATG4B and Diminishes the
   Proliferation and Metastatic Characteristics of Colorectal Cancer Cells
SO TOXINS
LA English
DT Article
DE medicinal plant; autophagy; ATG4B; colorectal cancer
ID PROTECTIVE AUTOPHAGY; PROMOTES; GEMCITABINE; PROGRESSION; MECHANISMS;
   MIGRATION; AKT/MTOR; INVASION; DEATH
AB Autophagy is an evolutionarily conserved pathway to degrade damaged proteins and organelles for subsequent recycling in cells during times of nutrient deprivation. This process plays an important role in tumor development and progression, allowing cancer cells to survive in nutrient-poor environments. The plant kingdom provides a powerful source for new drug development to treat cancer. Several plant extracts induce autophagy in cancer cells. However, little is known about the role of plant extracts in autophagy inhibition, particularly autophagy-related (ATG) proteins. In this study, we employed S-tagged gamma-aminobutyric acid receptor associated protein like 2 (GABARAPL2) as a reporter to screen 48 plant extracts for their effects on the activity of autophagy protease ATG4B. Xanthium strumarium and Tribulus terrestris fruit extracts were validated as potential ATG4B inhibitors by another reporter substrate MAP1LC3B-PLA(2). The inhibitory effects of the extracts on cellular ATG4B and autophagic flux were further confirmed. Moreover, the plant extracts significantly reduced colorectal cancer cell viability and sensitized cancer cells to starvation conditions. The fruit extract of X. strumarium consistently diminished cancer cell migration and invasion. Taken together, the results showed that the fruit of X. strumarium may have an active ingredient to inhibit ATG4B and suppress the proliferation and metastatic characteristics of colorectal cancer cells.
C1 [Chang, Hsueh-Wei] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 80708, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 80708, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr, Kaohsiung 80708, Taiwan.
   [Liu, Pei-Feng; Yang, Hsiu-Chen] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 81362, Taiwan.
   [Tsai, Wei-Lun] Kaohsiung Vet Gen Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung 813, Taiwan.
   [Hu, Wan-Hsiang] Kaohsiung Chang Gung Mem Hosp, Dept Colorectal Surg, Kaohsiung 83341, Taiwan.
   [Hu, Wan-Hsiang] Chang Gung Univ, Coll Med, Kaohsiung 83341, Taiwan.
   [Hu, Yu-Chang] Kaohsiung Vet Gen Hosp, Dept Radiat Oncol, Kaohsiung 81362, Taiwan.
   [Lin, Wei-Yu] Kinmen Hosp, Dept Pharm, Kinmen 89142, Taiwan.
   [Weng, Jing-Ru] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan.
   [Shu, Chih-Wen] I Shou Univ, Sch Med Int Students, Kaohsiung 82445, Taiwan.
RP Weng, JR (corresponding author), Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan.; Shu, CW (corresponding author), I Shou Univ, Sch Med Int Students, Kaohsiung 82445, Taiwan.
EM changhw@kmu.edu.tw; pfliu@vghks.gov.tw; tsaiwl@yahoo.com.tw;
   gary.hu0805@msa.hinet.net; ychu81@gmail.com; mini16610@gmail.com;
   u8557006@gmail.com; jrweng@mail.nsysu.edu.tw; cwshu@isu.edu.tw
RI Shu, Chih-Wen/AAE-9652-2019
OI Liu, Pei-Feng/0000-0002-7849-8940; Chang, Hsueh-Wei/0000-0003-0068-2366;
   Shu, Chih-Wen/0000-0002-7774-0002
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [106-2311-B-075B-001,
   106-2320-B-110-003-MY3, 107-2311-B-214-003]; Kaohsiung Veterans General
   Hospital [VGHNSU108-006]; Kaohsiung Medical University Research Center
   [KMU-TC108A03]
FX Ministry of Science and Technology: 106-2311-B-075B-001,
   106-2320-B-110-003-MY3, and 107-2311-B-214-003; Kaohsiung Veterans
   General Hospital: VGHNSU108-006; the Kaohsiung Medical University
   Research Center (KMU-TC108A03).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Bosc D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29900-x
   Catanzaro E, 2018, TOXINS, V10, DOI 10.3390/toxins10110469
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537
   Gali-Muhtasib H, 2015, APOPTOSIS, V20, P1531, DOI 10.1007/s10495-015-1169-2
   Giansanti F, 2018, TOXINS, V10, DOI 10.3390/toxins10020082
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Huang NC, 2017, PEERJ, V5, DOI 10.7717/peerj.3448
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kou XJ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090927
   Li H, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2046-z
   Li M, 2011, J BIOL CHEM, V286, P7327, DOI 10.1074/jbc.M110.199059
   Li W, 2017, ONCOL REP, V37, P3459, DOI 10.3892/or.2017.5637
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Liu PF, 2017, CELL PHYSIOL BIOCHEM, V44, P728, DOI 10.1159/000485286
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Ojha R, 2016, BBA-MOL CELL RES, V1863, P347, DOI 10.1016/j.bbamcr.2015.12.002
   Pan SY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/627375
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Schaeffer D, 2014, MOL CELL BIOL, V34, P3486, DOI 10.1128/MCB.00694-14
   Shakeri A, 2019, J CELL PHYSIOL, V234, P5643, DOI 10.1002/jcp.27404
   Shu CW, 2011, J BIOMOL SCREEN, V16, P174, DOI 10.1177/1087057110392996
   Shu CW, 2010, AUTOPHAGY, V6, P936, DOI 10.4161/auto.6.7.13075
   Sun R, 2016, BIOMATERIALS, V103, P44, DOI 10.1016/j.biomaterials.2016.06.038
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Toshima T, 2014, J GASTROENTEROL, V49, P907, DOI 10.1007/s00535-013-0835-9
   Wang J, 2018, ONCOTARGETS THER, V11, P7777, DOI 10.2147/OTT.S159095
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291
   Xu DQ, 2017, SLAS DISCOV, V22, P338, DOI 10.1177/1087057116639202
   Yang XY, 2018, INT J ONCOL, V53, P215, DOI 10.3892/ijo.2018.4376
   Yu LH, 2017, MOL MED REP, V15, P2339, DOI 10.3892/mmr.2017.6241
   Zhao GM, 2016, ONCOL REP, V35, P1065, DOI 10.3892/or.2015.4413
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 38
TC 14
Z9 16
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6651
J9 TOXINS
JI Toxins
PD JUN
PY 2019
VL 11
IS 6
DI 10.3390/toxins11060313
PG 16
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA II6UE
UT WOS:000475328000010
PM 31159487
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Dey, DK
   Chang, SN
   Vadlamudi, Y
   Park, JG
   Kang, SC
AF Dey, Debasish Kumar
   Chang, Sukkum Ngullie
   Vadlamudi, Yellamandayya
   Park, Jae Gyu
   Kang, Sun Chul
TI Synergistic therapy with tangeretin and 5-fluorouracil accelerates the
   ROS/JNK mediated apoptotic pathway in human colorectal cancer cell
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Oxidative stress; Mitochondria; DNA damage; Apoptosis; Colon cancer
ID WEISSELLA-CONFUSA DD-A7; HUMAN BREAST; IN-VITRO; COLON; PROLIFERATION;
   MECHANISMS; ARREST; DAMAGE; ACID
AB Synergistic therapy is emerging as a promising strategy for improving the chemotherapeutic efficacy of anticancer drugs. Addition of adjuvants with standard anticancer drugs has shown successful reduction of adverse side effects. The synthetic drug 5-Fluorouracil (5-FU) shows several side effects upon prolonged chemotherapy, thereby restricting its long-term clinical application. Several studies have reported anticancer potential and anti-inflammatory activity of tangeretin (TAN) towards mammalian cells. Therefore, we investigate whether the combination of TAN with 5-FU increases their anticancer potential against colorectal cancer. In this study, we examined the synergistic activity of TAN and 5-FU on the viability of several human cancer and normal cells. Several possible mechanistic pathways were screened, and found that co-exposure of TAN and 5-FU accelerates oxidative-stress and increases endogenous-ROS generation, which sequentially triggers the DNA damage response and activates the apoptotic pathway, by down-regulating autophagy and DNA repair system in HCT-116 cells. TAN and 5-FU co-treatment also remarkably reduces the mitochondrial membrane potential, and sequentially decreases ATPase activity. Collectively, results indicate that combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway. To our knowledge gained from literature, this study is the first to describe synergistic activity of TAN and 5-FU against colorectal cancer cells.
C1 [Dey, Debasish Kumar; Chang, Sukkum Ngullie; Vadlamudi, Yellamandayya; Kang, Sun Chul] Daegu Univ, Dept Biotechnol, Gyongsan 38453, South Korea.
   [Park, Jae Gyu] Pohang Technopk Fdn, Adv Bio Convergence Ctr, Pohang 37668, Gyeongbuk, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Dept Biotechnol, Gyongsan 38453, South Korea.; Park, JG (corresponding author), Pohang Technopk Fdn, Adv Bio Convergence Ctr, Pohang 37668, Gyeongbuk, South Korea.
EM jaegpark@gmail.com; sckang@daegu.ac.kr
RI Dey, Debasish/AAP-6607-2020
OI Dey, Debasish/0000-0001-5429-0216; Chang, Sukkum
   Ngullie/0000-0001-8391-8041
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF2019R1A2B501070543, 2019H1D3A1A01103012]
FX This research was supported by the National Research Foundation of Korea
   grant, NRF2019R1A2B501070543 and 2019H1D3A1A01103012.
CR Anderson-Hanley C, 2003, J INT NEUROPSYCH SOC, V9, P967, DOI 10.1017/S1355617703970019
   Arafa ESA, 2009, CANCER RES, V69, P8910, DOI 10.1158/0008-5472.CAN-09-1543
   Bhardwaj M, 2017, ONCOTARGET, V8, P112426, DOI 10.18632/oncotarget.20113
   Bivik C, 2008, APOPTOSIS, V13, P1111, DOI 10.1007/s10495-008-0240-7
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chang SN, 2019, FOOD CHEM TOXICOL, V132, DOI 10.1016/j.fct.2019.110699
   Dai W, 2016, TUMOR BIOL, V37, P6307, DOI 10.1007/s13277-015-4501-0
   Das G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008813
   Datla KP, 2001, NEUROREPORT, V12, P3871, DOI 10.1097/00001756-200112040-00053
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Dey DK, 2020, SCI TOTAL ENVIRON, V737, DOI 10.1016/j.scitotenv.2020.139704
   Dey DK, 2020, MICROBIOL RES, V237, DOI 10.1016/j.micres.2020.126489
   Dey DK, 2019, LWT-FOOD SCI TECHNOL, V111, P663, DOI 10.1016/j.lwt.2019.05.089
   Dey DK, 2019, MICROB PATHOGENESIS, V128, P119, DOI 10.1016/j.micpath.2018.12.048
   Farhat A, 2014, CHEM BIODIVERS, V11, P469, DOI 10.1002/cbdv.201300347
   Focaccetti C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115686
   Goodwin Rachel A, 2009, Clin Colon Rectal Surg, V22, P251, DOI 10.1055/s-0029-1242465
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Guo JJ, 2015, BANGL J PHARMACOL, V10, P937, DOI 10.3329/bjp.v10i4.23699
   Gurunathan S, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9081089
   Lee HS, 2016, GUT LIVER, V10, P340, DOI 10.5009/gnl15465
   Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549
   Li SH, 2018, APOPTOSIS, V23, P356, DOI 10.1007/s10495-018-1460-0
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Masi G, 2006, ANN ONCOL, V17, P1249, DOI 10.1093/annonc/mdl119
   MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936
   Morley KL, 2007, CANCER LETT, V251, P168, DOI 10.1016/j.canlet.2006.11.016
   Pan MH, 2002, CARCINOGENESIS, V23, P1677, DOI 10.1093/carcin/23.10.1677
   Satari A, 2019, ADV PHARM BULL, V9, P462, DOI 10.15171/apb.2019.055
   Shafiya Rafiq, 2018, Journal of the Saudi Society of Agricultural Sciences, V17, P351
   Singh MP, 2019, CANCERS, V11, DOI 10.3390/cancers11070986
   Sivandzade F, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3128
   Spagnol ST, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146244
   Surichan S, 2018, TOXICOL IN VITRO, V50, P274, DOI 10.1016/j.tiv.2018.04.001
   Thomas S.A., 2016, CANC CELL MICROENVIR, V3, pE1266, DOI DOI 10.14800/CCM.1266
   Ting YW, 2015, J FUNCT FOODS, V15, P264, DOI 10.1016/j.jff.2015.03.034
   Vanhoecke BW, 2005, IN VIVO, V19, P103
   Walle T, 2007, SEMIN CANCER BIOL, V17, P354, DOI 10.1016/j.semcancer.2007.05.002
   Wei GJ, 2019, AAPS J, V21, DOI 10.1208/s12248-019-0345-7
   Wigmore PM, 2010, ADV EXP MED BIOL, V678, P157
   WOHLHUETER RM, 1980, J CELL PHYSIOL, V104, P309, DOI 10.1002/jcp.1041040305
   Xiang GG, 2013, FOOD CHEM TOXICOL, V53, P352, DOI 10.1016/j.fct.2012.12.020
   Xu S, 2019, INT IMMUNOPHARMACOL, V72, P402, DOI 10.1016/j.intimp.2019.04.039
   Yu IS, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/9450754
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
NR 45
TC 15
Z9 15
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD SEP
PY 2020
VL 143
AR 111529
DI 10.1016/j.fct.2020.111529
PG 14
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA NE6SV
UT WOS:000562731900021
PM 32619557
DA 2022-04-25
ER

PT J
AU Luo, W
   Liu, QA
   Chen, XW
   Liu, HJ
   Quan, B
   Lu, JL
   Zhang, K
   Wang, XL
AF Luo, Wen
   Liu, Qingan
   Chen, Xinwen
   Liu, Haijun
   Quan, Bin
   Lu, Jinli
   Zhang, Ke
   Wang, Xiangling
TI FXYD6 Regulates Chemosensitivity by Mediating the Expression of Na plus
   /K plus -ATPase alpha 1 and Affecting Cell Autophagy and Apoptosis in
   Colorectal Cancer
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID III COLON-CANCER; NA+/K+-ATPASE; CARDIOTONIC STEROIDS; IRINOTECAN;
   SIGNATURE; IDENTIFICATION; ESTABLISHMENT; FLUOROURACIL; CHEMOTHERAPY;
   OXALIPLATIN
AB Purpose. Chemoresistance is a challenge of improving chemotherapeutic efficacy and prolonging survival time for patients with colorectal cancer (CRC); it is the major cause of frequent recurrence, rapid metastasis, and poor prognosis for CRC patients. FXYD6 is a regulator of Na+/K+-ATPase which is depressed in chemoresistant CRC patients. However, the biological roles of FXYD6 on regulating chemoresistance in CRC are still unclear. Methods. GSE3964 and GSE69657 from GEO DataSets were used to analyze the relationship of genes and chemoresistance. The FXYD6 expression level was detected by western blotting and real-time PCR and also analyzed from TCGA DataSet. To investigate the functional role of FXYD6 and ATP-alpha 1, FXYD6 and ATP-alpha 1 functional cell models were constructed. Drug sensitivity and cell proliferation were performed by MTT assay. Autophagy and apoptosis were conducted by autophagy fluorescence analysis and flow cytometric analysis, respectively. Autophagy and apoptosis markers were tested by western blotting. Results. FXYD6 was downregulated in CRC resistant patients and irinotecan- (Iri-) resistant SW620 cells (SW620/Iri). FXYD6 silence inhibited cell apoptosis and enhanced prosurvival autophagy, whereas FXYD6 overexpression produced the opposite effect which alleviated the drug resistance to irinotecan and oxaliplatin of CRC cells. FXYD6 regulates chemosensitivity by mediating the expression of Na+/K+-ATPase alpha 1 and affecting cell autophagy and apoptosis in colorectal cancer. Conclusion. FXYD6 functions as a chemosensitivity regulator which may predict the curative effect of chemotherapy in colorectal cancer.
C1 [Luo, Wen; Liu, Qingan; Chen, Xinwen; Liu, Haijun; Quan, Bin; Lu, Jinli; Zhang, Ke; Wang, Xiangling] Changde First Peoples Hosp, Dept Gen Surg, Changde 415000, Hunan, Peoples R China.
RP Liu, QA (corresponding author), Changde First Peoples Hosp, Dept Gen Surg, Changde 415000, Hunan, Peoples R China.
EM ji17483chundu@163.com; lqapwas98@163.com; chuang864676qic@163.com;
   huiyi352148ship@163.com; pu500351bozhang@163.com;
   ao5014703laotunfe@163.com; zhihuan0433811y@163.com;
   huan64376xiongha@163.com
FU Project of Changde Science and Technology Bureau of Hunan Province in
   China [2017S040]
FX This work was supported by the Project of Changde Science and Technology
   Bureau of Hunan Province in China (2017S040).
CR Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Chen XF, 2014, ONCOL LETT, V7, P393, DOI 10.3892/ol.2013.1727
   Clausen MV, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00371
   Cui XY, 2017, MOLECULES, V22, DOI 10.3390/molecules22060990
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gao Q, 2014, PROTEIN CELL, V5, P532, DOI 10.1007/s13238-014-0045-0
   Geering K, 2006, AM J PHYSIOL-RENAL, V290, pF241, DOI 10.1152/ajprenal.00126.2005
   Geng F, 2017, CANCER BIOTHER RADIO, V32, P149, DOI 10.1089/cbr.2017.2210
   Goncalves-de-Albuquerque CF, 2017, MOLECULES, V22, DOI 10.3390/molecules22040578
   Gong FM, 2011, ANTI-CANCER DRUG, V22, P500, DOI 10.1097/CAD.0b013e3283408596
   Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386
   Huang CY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1019-6
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kocaturk NM, 2019, EUR J PHARM SCI, V134, P116, DOI 10.1016/j.ejps.2019.04.011
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Lauf PK, 2015, AM J PHYSIOL-CELL PH, V308, pC51, DOI 10.1152/ajpcell.00287.2014
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Lu XR, 2013, CANCER BIOTHER RADIO, V28, P552, DOI 10.1089/cbr.2012.1431
   Mijatovic T, 2012, PHARM PAT ANAL, V1, P91, DOI [10.4155/PPA.12.3, 10.4155/ppa.12.3]
   Mijatovic T, 2013, PLANTA MED, V79, P189, DOI 10.1055/s-0032-1328243
   Mijatovic T, 2009, CANCER LETT, V282, P30, DOI 10.1016/j.canlet.2009.02.048
   Mukhopadhyay R, 2018, J VIROL, V92, DOI 10.1128/JVI.01861-17
   Noguchi M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2724-5
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pommier Y, 2009, CHEM REV, V109, P2894, DOI 10.1021/cr900097c
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Sakai H, 2004, FEBS LETT, V563, P151, DOI 10.1016/S0014-5793(04)00292-3
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sartore-Bianchi A, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv306
   Shi Q, 2018, NEW ENGL J MED, V379, P396, DOI 10.1056/NEJMc1805498
   Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011
   Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang XY, 2017, AM J TRANSL RES, V9, P4652
   Wei L, 2019, CELL ONCOL, V42, P757, DOI 10.1007/s13402-019-00466-8
   Wu MW, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00790
   Yaghoubi N, 2019, BIOMED PHARMACOTHER, V110, P312, DOI 10.1016/j.biopha.2018.11.105
   Zeino M, 2015, J STEROID BIOCHEM, V150, P97, DOI 10.1016/j.jsbmb.2015.03.008
   Zhang L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00467
NR 42
TC 1
Z9 1
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUN 9
PY 2021
VL 2021
AR 9986376
DI 10.1155/2021/9986376
PG 15
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA SX0PE
UT WOS:000664913500005
PM 34212047
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Sharma, N
   Kumar, A
   Sharma, PR
   Qayum, A
   Singh, SK
   Dutt, P
   Paul, S
   Gupta, V
   Verma, MK
   Satti, NK
   Vishwakarma, R
AF Sharma, Neha
   Kumar, Ashok
   Sharma, P. R.
   Qayum, Arem
   Singh, Shashank K.
   Dutt, Prabhu
   Paul, Satya
   Gupta, Vivek
   Verma, M. K.
   Satti, N. K.
   Vishwakarma, R.
TI A new clerodane furano diterpene glycoside from Tinospora cordifolia
   triggers autophagy and apoptosis in HCT-116 colon cancer cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Tinospora cordifolia; DAPI (4 '-6-Diamidino-2-phenylindole); Apoptosis;
   HCT116; MMP potential; ROS
ID EXTRACT INDUCES APOPTOSIS; EX HOOK F; ANTIPROLIFERATIVE ACTIVITY;
   ANTITUMOR-ACTIVITY; MEDICINAL-PLANTS; MCF-7 CELLS; DEATH; BERBERINE;
   PATHWAY; LINES
AB Ethnophatmacological relevance: Tinospora cordifolia is a miraculous ayurvedic herb used in the treatment of innumerable diseases such as diabetes, gonorrhea, secondary syphilis, anaemia, rheumatoid arthritis, dermatological diseases, cancer, gout, jaundice, asthma, leprosy, in the treatment of bone fractures, liver & intestinal disorders, purifies the blood, gives new life to the whole body; (rejuvenating herb) and many more. Recent studies have revealed the anticancer potential of this plant but not much work has been done on the anticancer chemical constituents actually responsible for its amazing anticancer effects. This prompted us to investigate this plant further for new potent anticancer molecules.
   Aim of the study: The present study was designed to isolate and identify new promising anticancer candidates from the aqueous alcoholic extract of T. cordifolia using bioassay-guided fractionation.
   Materials and methods: The structures of the isolated compounds were determined on the basis of spectroscopic data interpretation and that of new potent anticancer molecule, TC-2 was confirmed by a single-crystal X-ray crystallographic analysis of its corresponding acetate. The in vitro anti-cancer activity of TC-2 was evaluated by SRB assay and the autophagic activity was investigated by immunofluorescence microscopy. Annexin-V FITC and PI dual staining was applied for the detection of apoptosis. The studies on Mitochondrial Membrane potential and ROS (Reactive oxygen species) production were also done.
   Results: Bioassay guided fractionation and purification of the aqueous alcoholic stem extract of Tinospora cordifolia led to the isolation of a new clerodane furano diterpene glycoside (TC-2) along with five known compounds i.e. cordifolioside A (beta-D-Glucopyranoside,4-(3-hydroxy-l-propeny1)- 2,6-dimethoxyphenyl 3-O-D-apio-beta-D-furanosyl) (TC-1), beta-Sitosterol(TC-3), 2 beta,3 beta:15,16-Diepoxy- 4 alpha, 6 beta-dihydroxy-13(16),14-clerodadiene-17,12:18,1-diolide (TC-4), ecdysterone(TC-5) and tinosporoside(TC-6). TC-2 emerged as a potential candidate for the treatment of colon cancer.
   Conclusion: The overall study on the bioassay guided isolation of T.cordifolia identified and isolated a new clerodane furano diterpenoid that exhibited anticancer activity via induction of mitochondria mediated apoptosis and autophagy in HCT116 cells. We have reported a promising future candidate for treating colon cancer.
C1 [Sharma, Neha; Dutt, Prabhu; Satti, N. K.; Vishwakarma, R.] CSIR, Indian Inst Integrat Med, Nat Prod Chem Div, Jammu 180001, India.
   [Sharma, Neha; Verma, M. K.] CSIR, Indian Inst Integrat Med, Analyt Chem Div Instrumentat, Jammu 180001, India.
   [Kumar, Ashok; Sharma, P. R.; Qayum, Arem; Singh, Shashank K.] CSIR, Indian Inst Integrat Med, Canc Pharmacol Div, Jammu 180001, India.
   [Paul, Satya] Univ Jammu, Dept Chem, Jammu 180006, India.
   [Gupta, Vivek] Univ Jammu, Postgrad Dept Phys, Jammu 180006, India.
   [Kumar, Ashok; Sharma, P. R.; Qayum, Arem; Singh, Shashank K.] AcSIR Acad Sci & Innovat Res, Jammu Campus, Jammu, India.
RP Satti, NK (corresponding author), CSIR, Indian Inst Integrat Med, Nat Prod Chem Div, Jammu 180001, India.
EM nksatti@rediffmail.com
RI Sharma, Neha/AAN-2750-2021; Jani, Arpit/B-5376-2017; Clark,
   James/C-2064-2012
OI Sharma, Neha/0000-0001-9771-3549; Clark, James/0000-0002-5860-2480;
   Paul, Satya/0000-0002-9859-3371; singh, shashank/0000-0001-8532-7421
FU Department of Science and Technology, New DelhiDepartment of Science &
   Technology (India) [GAP-1168]
FX This work was supported by the Department of Science and Technology
   (GAP-1168), New Delhi.
CR Acharya BR, 2009, BIOCHEMISTRY-US, V48, P6963, DOI 10.1021/bi900152k
   Adhvaryu MR, 2008, AFR J TRADIT COMPLEM, V5, P409
   Ahmed SM, 2006, J CHROMATOGR SCI, V44, P504, DOI 10.1093/chromsci/44.8.504
   Bai J, 2015, PLOS ONE, V10, P1371, DOI DOI 10.1371/J0URNAL.P0NE.0118286
   Balachandran P, 2005, PHARMACOL RES, V51, P19, DOI 10.1016/j.phrs.2004.04.010
   BHATT R P, 1987, Journal of Economic and Taxonomic Botany, V9, P139
   BISSET NG, 1983, PLANTA MED, V48, P275, DOI 10.1055/s-2007-969933
   Chaudhary R, 2008, J ENVIRON PATHOL TOX, V27, P233, DOI 10.1615/JEnvironPatholToxicolOncol.v27.i3.70
   Chauhan K., 1995, SUCHITRA AYURVED, V47, P840
   CHI CW, 1994, LIFE SCI, V54, P2099, DOI 10.1016/0024-3205(94)00719-5
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Dai ZJ, 2008, WORLD J GASTROENTERO, V14, P7321, DOI 10.3748/wjg.14.7321
   Dash B., 1987, DIAGNOSIS TREATMENT, P437
   Farrugia, 1997, J APPL CRYSTALLOGR, V30, P565, DOI [DOI 10.1107/S0021889897003117, 10.1107/S0021889897003117]
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   FUKUDA N, 1993, LIEBIGS ANN CHEM, P491
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Grover JK, 2000, J ETHNOPHARMACOL, V73, P461, DOI 10.1016/S0378-8741(00)00319-6
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Jagetia GC, 2006, EVID-BASED COMPL ALT, V3, P267, DOI 10.1093/ecam/nel011
   Jagetia GC, 2006, BIOL PHARM BULL, V29, P460, DOI 10.1248/bpb.29.460
   Jeyachandran R, 2003, Anc Sci Life, V23, P40
   Kapil A, 1997, J ETHNOPHARMACOL, V58, P89, DOI 10.1016/S0378-8741(97)00086-X
   Khare CP., 2007, INDIAN MED PLANTS, VFirst Edition
   Khuda M.Q.I., 1964, SCI RES, V1, P177, DOI 10.1016%2Fj.heliyon.2019.e02437
   Kirtikar KR, 1975, INDIAN MED PLANTS, VI
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kumar A, 2016, TUMOR BIOL, V37, P13121, DOI 10.1007/s13277-016-5160-5
   Kumar A, 2016, CELL BIOCHEM FUNCT, V34, P69, DOI 10.1002/cbf.3166
   KUMAR S, 2000, J MED AROM PLANT SCI, V22, P61
   Leyon PV, 2004, J ETHNOPHARMACOL, V90, P233, DOI 10.1016/j.jep.2003.09.046
   Manosroi J, 2006, CANCER LETT, V235, P114, DOI 10.1016/j.canlet.2005.04.021
   Mathew S, 1999, FITOTERAPIA, V70, P35, DOI 10.1016/S0367-326X(98)00017-3
   Mhaiskar V.B., 1980, RHEUMATISM, V16, P35
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Nardelli M., 1995, J APPL CRYSTALLOGR, V28, P659, DOI [DOI 10.1107/S0021889895007138, 10.1107/S0021889895007138]
   Nowacki L, 2015, PHYTOTHER RES, V29, P1964, DOI 10.1002/ptr.5491
   Ortiz LMG, 2015, ACTA BIOCH BIOPH SIN, V47, P824, DOI 10.1093/abbs/gmv077
   Phan VK, 2010, FITOTERAPIA, V81, P485, DOI 10.1016/j.fitote.2010.01.005
   Prakashananda S., 1992, CHEMEXCIL, P319
   Premanath R., 2010, J AM SCI, V6, P736
   Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726
   Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6
   Ren GW, 2015, J NAT MED-TOKYO, V69, P522, DOI 10.1007/s11418-015-0918-4
   Rout GR, 2006, Z NATURFORSCH C, V61, P118
   Sarma D.N.K., 2009, J PHARM SCI RES, V1, P26
   SHAH G L, 1984, Journal of Economic and Taxonomic Botany, V5, P753
   Shah G. L., 1983, J EC TAXONOMIC BOT, V4, P141
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   SINGH K K, 1983, Journal of Economic and Taxonomic Botany, V4, P829
   Singh N, 2005, IMMUNOPHARM IMMUNOT, V27, P1, DOI 10.1081/IPH-200051287
   Singh S. S., 2003, Indian Journal of Pharmacology, V35, P83
   Sinha K., 2004, INDIAN J TRAD KNOWLE, V3, P257
   Sohni YR, 1996, J ETHNOPHARMACOL, V54, P119, DOI 10.1016/S0378-8741(96)01457-2
   Spek AL, 2009, ACTA CRYSTALLOGR D, V65, P148, DOI 10.1107/S090744490804362X
   Sudha P, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-5
   Tirtha Sada Shiva, 2005, AYURVEDA ENCY NATURA
   Torricelli C., 2012, EVID-BASED COMPL ALT, V2012, P11
   Verma M, 2008, CHEM-BIOL INTERACT, V171, P45, DOI 10.1016/j.cbi.2007.08.010
   Williamson E., 2002, MAJOR HERBS AYURVEDA
   Xuan HZ, 2016, BIOORG MED CHEM LETT, V26, P570, DOI 10.1016/j.bmcl.2015.11.072
   Zhang HF, 2013, SCI REP-UK, V3, DOI 10.1038/srep02615
   ZHAO TF, 1991, PLANTA MED, V57, P505, DOI 10.1055/s-2006-960188
NR 64
TC 14
Z9 14
U1 2
U2 74
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 30
PY 2018
VL 211
BP 295
EP 310
DI 10.1016/j.jep.2017.09.034
PG 16
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA FN9XJ
UT WOS:000416395900027
PM 28962889
DA 2022-04-25
ER

PT J
AU Oliveira, I
   Nunes, A
   Lima, A
   Borralho, P
   Rodrigues, C
   Ferreira, RB
   Ribeiro, AC
AF Oliveira, Isabel
   Nunes, Antonio
   Lima, Ana
   Borralho, Pedro
   Rodrigues, Cecilia
   Ferreira, Ricardo Boavida
   Ribeiro, Ana Cristina
TI New Lectins from Mediterranean Flora. Activity against HT29 Colon Cancer
   Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE lectins; glycosylated receptors; HT29 colon cancer cells; antitumor
   activity
ID CONCANAVALIN-A; PLANT-PROTEINS; IN-VITRO; AUTOPHAGY; INDUCTION;
   APOPTOSIS; DEATH; MMP-9
AB Experiments conducted in vitro and in vivo, as well as some preclinical trials for cancer therapeutics, support the antineoplastic properties of lectins. A screening of antitumoral activity on HT29 colon cancer cells, based on polypeptide characterization and specific lectin binding to HT29 cells membrane receptors, was performed in order to assess the bioactivities present in four Mediterranean plant species: Juniperus oxycedrus subsp. oxycedrus, Juniperus oxycedrus subsp. badia, Arbutus unedo and Corema album. Total leaf proteins from each species were evaluated with respect to cell viability and inhibitory activities on HT29 cells (cell migration, matrix metalloproteinase -MMP proteolytic activities). A discussion is presented on a possible mechanism justifying the specific binding of lectins to HT29 cell receptors. All species revealed the presence of proteins with affinity to HT29 cell glycosylated receptors, possibly explaining the differential antitumor activity exhibited by the two most promising species, Juniperus oxycedrus subsp. badia and Arbutus unedo.
C1 [Oliveira, Isabel; Nunes, Antonio; Ribeiro, Ana Cristina] Univ Lisbon, Fac Pharm, Dept Toxicol & Bromatol Sci DCTB, P-1649003 Lisbon, Portugal.
   [Oliveira, Isabel; Nunes, Antonio; Lima, Ana; Ferreira, Ricardo Boavida; Ribeiro, Ana Cristina] Univ Lisbon, Inst Super Agron, Linking Landscape Environm Agr & Food LEAF, P-1349017 Lisbon, Portugal.
   [Borralho, Pedro; Rodrigues, Cecilia] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, P-1649003 Lisbon, Portugal.
RP Ribeiro, AC (corresponding author), Univ Lisbon, Fac Pharm, Dept Toxicol & Bromatol Sci DCTB, P-1649003 Lisbon, Portugal.; Ribeiro, AC (corresponding author), Univ Lisbon, Inst Super Agron, Linking Landscape Environm Agr & Food LEAF, P-1349017 Lisbon, Portugal.
EM ioliveira2@campus.ul.pt; filipe_estesl@yahoo.com; agusmaolima@gmail.com;
   borralhopm@gmail.com; cmprodrigues@ff.ulisboa.pt;
   rbferreira@isa.ulisboa.pt; acribeiro@ff.ulisboa.pt
RI Ribeiro, Ana Cristina/AAA-6457-2020; Borralho, Pedro/AAJ-2829-2021;
   Rodrigues, Cecilia MP/M-3572-2013; Ribeiro, Ana Cristina/A-6769-2017;
   Borralho, Pedro/C-2727-2011
OI Rodrigues, Cecilia MP/0000-0002-4829-754X; Lima,
   Ana/0000-0001-8251-6286; Ribeiro, Ana Cristina/0000-0001-9555-5735;
   Borralho, Pedro/0000-0003-4488-7240; Ferreira, Ricardo
   Boavida/0000-0002-5027-7564
FU Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science
   and TechnologyEuropean Commission [UID/AGR/4129]
FX Fundacao para a Ciencia e a Tecnologia, UID/AGR/4129.
CR BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75
   De Mejia EG, 2005, CRIT REV FOOD SCI, V45, P425, DOI 10.1080/10408390591034445
   Dubois B, 1998, FEBS LETT, V427, P275, DOI 10.1016/S0014-5793(98)00449-9
   FAYE L, 1985, ANAL BIOCHEM, V149, P218, DOI 10.1016/0003-2697(85)90498-1
   Fu LL, 2011, INT J BIOCHEM CELL B, V43, P1442, DOI 10.1016/j.biocel.2011.07.004
   Gokaslan ZL, 1998, CLIN EXP METASTAS, V16, P721, DOI 10.1023/A:1006580728338
   Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597
   Hauselmann I, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00028
   Jacobs AK, 1999, PLANT PATHOL, V48, P325, DOI 10.1046/j.1365-3059.1999.00343.x
   Jordinson M, 1999, GUT, V44, P709, DOI 10.1136/gut.44.5.709
   Khan F., 2002, MED SCI MONITOR, V8, P293
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lei HY, 2007, AUTOPHAGY, V3, P402, DOI 10.4161/auto.4280
   Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g
   Liu B, 2009, CANCER LETT, V275, P54, DOI 10.1016/j.canlet.2008.09.042
   de-Freitas JCM, 2016, ONCOTARGET, V7, P19395, DOI 10.18632/oncotarget.6283
   Morelli C, 2004, J CELL PHYSIOL, V199, P126, DOI 10.1002/jcp.10450
   Nakajima K, 2015, CANCER MED-US, V4, P293, DOI 10.1002/cam4.342
   Ozturk M, 2011, J SCI FOOD AGR, V91, P867, DOI 10.1002/jsfa.4258
   Padler-Karavani V, 2014, CANCER LETT, V352, P102, DOI 10.1016/j.canlet.2013.10.005
   Park JJ, 2013, GUT LIVER, V7, P629, DOI 10.5009/gnl.2013.7.6.629
   Peiris D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138345
   Podlech O, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/501796
   Poiroux G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061232
   Ribeiro A.C., 2018, STUDIES NATURAL PROD, P2
   Ribeiro A, 2012, CARBOHYD RES, V352, P206, DOI 10.1016/j.carres.2012.01.024
   Roy B, 2014, CHEM-BIOL INTERACT, V210, P96, DOI 10.1016/j.cbi.2014.01.003
   Shi Z, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020228
   Silva MCC, 2014, BBA-GEN SUBJECTS, V1840, P2262, DOI 10.1016/j.bbagen.2014.03.009
   Silva Redinaldo dos Santos, 2009, Acta Amaz., V39, P255, DOI 10.1590/S0044-59672009000200002
   Sodhi A, 2007, INT IMMUNOPHARMACOL, V7, P1403, DOI 10.1016/j.intimp.2007.07.004
   Souza MA, 2013, GLYCOCONJUGATE J, V30, P641, DOI 10.1007/s10719-012-9464-4
   Tavares Wilson R, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030081
   Toth Marta, 2012, Methods Mol Biol, V878, P121, DOI 10.1007/978-1-61779-854-2_8
   Van Slambrouck S, 2007, BIOCHEM J, V401, P689, DOI 10.1042/BJ20060944
   Vercoutter-Edouart AS, 2008, PROTEOMICS, V8, P3236, DOI 10.1002/pmic.200800151
   Very N, 2018, ONCOTARGET, V9, P1380, DOI 10.18632/oncotarget.22377
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   Yang J, 2017, BIOMED PHARMACOTHER, V96, P1199, DOI 10.1016/j.biopha.2017.11.098
   Yau T, 2015, MOLECULES, V20, P3791, DOI 10.3390/molecules20033791
   Yu LG, 2001, J CELL PHYSIOL, V186, P282, DOI 10.1002/1097-4652(200102)186:2&lt;282::AID-JCP1028&gt;3.0.CO;2-2
NR 43
TC 6
Z9 6
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN 2
PY 2019
VL 20
IS 12
AR 3059
DI 10.3390/ijms20123059
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IG4ED
UT WOS:000473756000209
PM 31234551
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Bai, LY
   Weng, JR
   Chiu, CF
   Wu, CY
   Yeh, SP
   Sargeant, AM
   Lin, PH
   Liao, YM
AF Bai, Li-Yuan
   Weng, Jing-Ru
   Chiu, Chang-Fang
   Wu, Chia-Yung
   Yeh, Su-Peng
   Sargeant, Aaron M.
   Lin, Po-Han
   Liao, Yu-Min
TI OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute
   myeloid leukemia through reactive oxygen species-mediated apoptosis
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE OSU-A9; Indole-3-carbinol; Acute myeloid leukemia; Reactive oxygen
   species; Glutathione
ID PROSTATE-CANCER CELLS; DIETARY INDOLE-3-CARBINOL; MECHANISMS; AUTOPHAGY;
   PROTEIN; AGENT; DEATH
AB Indole-3-carbinol (I3C) is a broadly targeted phytochemical shown to prevent carcinogenesis in animal studies and to suppress the proliferation of cancer cells of human breast, colon, prostate, and endometrium. Here we demonstrate that OSU-A9, an I3C derivative with improved anticancer potency, induces cytotoxicity in acute myeloid leukemia (AML) cell lines (HL-60 and THP-1) and primary leukemia cells from AML patients in a dose-responsive manner. Normal human bone marrow cells were less sensitive to OSU-A9 than leukemia cells. OSU-A9 induces caspase activation, PARP cleavage, and autophagy but not autophagic cell death. Interestingly, pretreatment of AML cell lines and primary AML cells with N-acetylcysteine or glutathione rescues them from apoptosis (and concomitant PARP cleavage) and Akt hypophosphorylation, implicating a key role of reactive oxygen species (ROS) in OSU-A9-related cytotoxicity. Importantly, the anticancer utility of OSU-A9 is extended in vivo as it, administered intraperitoneally, suppresses the growth of THP-1 xenograft tumors in athymic nude mice without obvious toxicity. This study shows that ROS-mediated apoptosis contributes to the anticancer activity of OSU-A9 in AML cell lines and primary AML cells, and thus should be considered in the future assessment of its translational value in AML therapy. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bai, Li-Yuan; Chiu, Chang-Fang; Yeh, Su-Peng; Lin, Po-Han; Liao, Yu-Min] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung 40402, Taiwan.
   [Chiu, Chang-Fang] China Med Univ Hosp, Ctr Canc, Taichung 40402, Taiwan.
   [Bai, Li-Yuan; Chiu, Chang-Fang; Yeh, Su-Peng] China Med Univ, Sch Med, Coll Med, Taichung 40402, Taiwan.
   [Weng, Jing-Ru; Wu, Chia-Yung] China Med Univ, Dept Biol Sci & Technol, Taichung 40402, Taiwan.
   [Sargeant, Aaron M.] Charles River Labs, Preclin Serv, Spencerville, OH 45887 USA.
RP Bai, LY (corresponding author), China Med Univ Hosp, Dept Med, Div Hematol & Oncol, 2 Yude Rd, Taichung 40402, Taiwan.
EM lybai6@gmail.com
RI Lin, Po-Han/AEU-8550-2022; Weng, Jing-Ru/L-1743-2013
OI Lin, Po-Han/0000-0001-6066-398X; 
FU Taiwan Department of Health, China Medical University Hospital Cancer
   Research of Excellence [DOH102-TD-C-111-005]; National Science
   CouncilMinistry of Science and Technology, Taiwan [NSC
   101-2314-B-039-021-MY2, NSC 101-2320-B-039-029-MY2]; China Medical
   University Hospital [DMR-99-304, DMR-101-008]
FX We thank Dr. Chun-Ru Chien of China Medical University Hospital for the
   statistical assistance. This work was supported in part by grants from
   the Taiwan Department of Health, China Medical University Hospital
   Cancer Research of Excellence (DOH102-TD-C-111-005), National Science
   Council grants (NSC 101-2314-B-039-021-MY2, NSC 101-2320-B-039-029-MY2)
   and China Medical University Hospital (DMR-99-304, DMR-101-008).
CR Bredholt T, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-101
   Cabello CM, 2007, CURR OPIN INVEST DR, V8, P1022
   Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507
   Dasmahapatra G, 2006, BLOOD, V107, P232, DOI 10.1182/blood-2005-06-2302
   Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057
   Ekiz HA, 2012, CRIT REV ONCOL HEMAT, V81, P275, DOI 10.1016/j.critrevonc.2011.03.009
   Fang J, 2009, ADV DRUG DELIVER REV, V61, P290, DOI 10.1016/j.addr.2009.02.005
   Galleron S, 1999, CELL BIOL INT, V23, P637, DOI 10.1006/cbir.1999.0424
   GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007
   Hatchi E, 2011, J EXP MED, V208, P1403, DOI 10.1084/jem.20101995
   Hsu JC, 2006, BIOCHEM PHARMACOL, V72, P1714, DOI 10.1016/j.bcp.2006.08.012
   Jin L, 1999, CANCER RES, V59, P3991
   KOJIMA T, 1994, CANCER RES, V54, P1446
   Lindsay D G, 1999, J Nutr Health Aging, V3, P84
   Oganesian A, 1997, CANCER LETT, V118, P87, DOI 10.1016/S0304-3835(97)00235-8
   Omar HA, 2009, MOL PHARMACOL, V76, P957, DOI 10.1124/mol.109.058180
   Reed GA, 2005, CANCER EPIDEM BIOMAR, V14, P1953, DOI 10.1158/1055-9965.EPI-05-0121
   Safe S, 2008, CANCER LETT, V269, P326, DOI 10.1016/j.canlet.2008.04.021
   Sawayama Y, 2008, LEUKEMIA, V22, P956, DOI 10.1038/leu.2008.8
   Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Weng JR, 2008, CANCER LETT, V262, P153, DOI 10.1016/j.canlet.2008.01.033
   Weng JR, 2007, CANCER RES, V67, P7815, DOI 10.1158/0008-5472.CAN-07-0794
   Weng JR, 2010, ORAL ONCOL, V46, P748, DOI 10.1016/j.oraloncology.2010.08.005
   Weng JR, 2009, CARCINOGENESIS, V30, P1702, DOI 10.1093/carcin/bgp202
   Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827
NR 26
TC 23
Z9 23
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV 15
PY 2013
VL 86
IS 10
BP 1430
EP 1440
DI 10.1016/j.bcp.2013.09.002
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 245AZ
UT WOS:000326432600004
PM 24041743
DA 2022-04-25
ER

PT J
AU Tao, FF
   Zhang, YR
   Zhang, ZQ
AF Tao, Fangfang
   Zhang, Yanrong
   Zhang, Zhiqian
TI The Role of Herbal Bioactive Components in Mitochondria Function and
   Cancer Therapy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID GANODERMA-ATRUM POLYSACCHARIDE; THYMOQUINONE INDUCES APOPTOSIS; INDUCED
   OXIDATIVE STRESS; AUTOPHAGIC CELL-DEATH; INHIBITS TUMOR-GROWTH; MEDIATED
   APOPTOSIS; COLON-CANCER; IN-VITRO; ANTITUMOR-ACTIVITY; GINSENOSIDE RB1
AB Mitochondria are highly dynamic double-membrane organelles which play a well-recognized role in ATP production, calcium homeostasis, oxidation-reduction (redox) status, apoptotic cell death, and inflammation. Dysfunction of mitochondria has long been observed in a number of human diseases, including cancer. Targeting mitochondria metabolism in tumors as a cancer therapeutic strategy has attracted much attention for researchers in recent years due to the essential role of mitochondria in cancer cell growth, apoptosis, and progression. On the other hand, a series of studies have indicated that traditional medicinal herbs, including traditional Chinese medicines (TCM), exert their potential anticancer effects as an effective adjunct treatment for alleviating the systemic side effects of conventional cancer therapies, for reducing the risk of recurrence and cancer mortality and for improving the quality of patients' life. An amazing feature of these structurally diverse bioactive components is that majority of them target mitochondria to provoke cancer cell-specific death program. The aim of this review is to summarize the in vitro and in vivo studies about the role of these herbs, especially their bioactive compounds in the modulation of the disturbed mitochondrial function for cancer therapy.
C1 [Tao, Fangfang] Zhejiang Chinese Med Univ, Basic Med Coll, Dept Immunol & Microbiol, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhang, Yanrong] Hebei Med Univ, Hosp 3, Dept Vasc Surg, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Zhiqian] Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.
RP Zhang, YR (corresponding author), Hebei Med Univ, Hosp 3, Dept Vasc Surg, Shijiazhuang, Hebei, Peoples R China.; Zhang, ZQ (corresponding author), Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.
EM zhangyanrong@hebmu.edu.cn; zhangzq@sustech.edu.cn
RI Zhang, Zhiqian/P-7746-2018
OI Zhang, Zhiqian/0000-0003-1226-4807; tao, fang fang/0000-0002-2090-2701
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302896]; Zhejiang TCM Science and
   Technology Program [2019ZQ013]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2015M581292]
FX This work was supported by National Natural Science Foundation of China
   (no. 81302896), Zhejiang TCM Science and Technology Program (no.
   2019ZQ013), and China Postdoctoral Science Foundation grant (no.
   2015M581292).
CR Anderson AS, 2013, EXP CELL RES, V319, P1431, DOI 10.1016/j.yexcr.2013.02.017
   Bat-Chen W, 2010, NUTR CANCER, V62, P947, DOI 10.1080/01635581.2010.509837
   Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591
   Cao L, 2016, ONCOL REP, V36, P2245, DOI 10.3892/or.2016.5044
   Catania A, 2013, BREAST CANCER RES TR, V141, P55, DOI 10.1007/s10549-013-2667-y
   Chakraborty D, 2012, EUR J PHARMACOL, V694, P20, DOI 10.1016/j.ejphar.2012.08.001
   Chan GCF, 2013, CLIN REV ALLERG IMMU, V44, P262, DOI 10.1007/s12016-012-8322-2
   Chan SF, 2017, ENVIRON TOXICOL, V32, P550, DOI 10.1002/tox.22259
   Chang HW, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00634
   Chen MC, 2015, J AGR FOOD CHEM, V63, P1540, DOI 10.1021/jf5054063
   Choi S, 2011, J CELL BIOCHEM, V112, P330, DOI 10.1002/jcb.22932
   Chu YL, 2012, J AGR FOOD CHEM, V60, P8363, DOI 10.1021/jf301298y
   Conners R, 2005, MOL BIOCHEM PARASIT, V142, P137, DOI 10.1016/j.molbiopara.2005.03.015
   Devassy JG, 2015, NUTR REV, V73, P155, DOI 10.1093/nutrit/nuu064
   Devika PT, 2008, J APPL TOXICOL, V28, P938, DOI 10.1002/jat.1357
   Dimas K, 2000, PHARMACOL RES, V42, P475, DOI 10.1006/phrs.2000.0716
   Du YF, 2015, INT J ONCOL, V47, P2064, DOI 10.3892/ijo.2015.3202
   Duan ZG, 2017, FOOD FUNCT, V8, P3723, DOI [10.1039/c7fo00385d, 10.1039/C7FO00385D]
   El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002/ijc.21205
   Gao CX, 2016, SCI REP-UK, V6, DOI 10.1038/srep36114
   Gao X, 2018, J CELL BIOCHEM, V119, P4967, DOI 10.1002/jcb.26742
   Gao YJ, 2014, CANCER LETT, V349, P15, DOI 10.1016/j.canlet.2014.03.015
   Ghosh K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168488
   Gogada R, 2011, CELL CYCLE, V10, P4128, DOI 10.4161/cc.10.23.18292
   Gonzalez-Burgos E, 2017, FOOD CHEM TOXICOL, V109, P38, DOI 10.1016/j.fct.2017.08.013
   Guitard R, 2016, FOOD CHEM, V213, P284, DOI 10.1016/j.foodchem.2016.06.038
   Ha TK, 2017, BIOMED PHARMACOTHER, V91, P378, DOI 10.1016/j.biopha.2017.04.100
   He F, 2007, J CARDIOVASC PHARM, V50, P314, DOI 10.1097/FJC.0b013e3180cab12e
   Hossain Dewan Md Sakib, 2012, Front Biosci (Schol Ed), V4, P335
   Huo HZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154605
   Inokuma T, 2009, HEPATO-GASTROENTEROL, V56, P343
   Kimoto T, 2001, ANTICANCER RES, V21, P221
   Kong JM, 2018, TOXICOL APPL PHARM, V342, P1, DOI 10.1016/j.taap.2018.01.011
   Kumar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160783
   Lee JH, 2010, CANCER LETT, V290, P68, DOI 10.1016/j.canlet.2009.08.027
   Lee YK, 2009, ANN NY ACAD SCI, V1171, P489, DOI 10.1111/j.1749-6632.2009.04699.x
   Li J, 2017, CAN J PHYSIOL PHARM, V95, P787, DOI 10.1139/cjpp-2016-0548
   Li R, 2017, BIOMED PHARMACOTHER, V95, P771, DOI 10.1016/j.biopha.2017.08.127
   Li W, 2008, XENOBIOTICA, V38, P1551, DOI 10.1080/00498250802503359
   Li WJ, 2013, CANCER SCI, V104, P143, DOI 10.1111/cas.12051
   Li WJ, 2011, J AGR FOOD CHEM, V59, P3707, DOI 10.1021/jf1049497
   Li Y, 2014, BIOMED CHROMATOGR, V28, P193, DOI 10.1002/bmc.3000
   Li YP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5130-y
   Liu M, 2017, TOXINS, V9, DOI 10.3390/toxins9070208
   Liu XB, 2013, BIOL PHARM BULL, V36, P988, DOI 10.1248/bpb.b13-00021
   Luo RL, 2016, ANTI-CANCER AGENT ME, V16, P802, DOI 10.2174/1871520616666151111115443
   Ma ZJ, 2018, EUR J PHARMACOL, V821, P1, DOI 10.1016/j.ejphar.2017.12.027
   Manju V, 2002, J Biochem Mol Biol Biophys, V6, P387, DOI 10.1080/1025814021000036115
   Mayola E, 2011, APOPTOSIS, V16, P1014, DOI 10.1007/s10495-011-0625-x
   Meiyanto E, 2014, ASIAN PAC J CANCER P, V15, P179, DOI 10.7314/APJCP.2014.15.1.179
   Mirzoeva S, 2008, MOL CARCINOGEN, V47, P686, DOI 10.1002/mc.20421
   Mishra A, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.525
   Miyata Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24010193
   Mohanan P, 2018, J GINSENG RES, V42, P123, DOI 10.1016/j.jgr.2017.01.008
   Mou SF, 2017, ONCOL LETT, V14, P4937, DOI 10.3892/ol.2017.6739
   Murakami C, 2002, BIOSCI BIOTECH BIOCH, V66, P1559, DOI 10.1271/bbb.66.1559
   Nigam N, 2010, CANCER CHEMOTH PHARM, V65, P687, DOI 10.1007/s00280-009-1074-x
   Ning DL, 2018, ONCOL LETT, V16, P3545, DOI 10.3892/ol.2018.9085
   Nishikawa Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134137
   Pandita A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107154
   Paramasivam A, 2012, TOXICOL LETT, V213, P151, DOI 10.1016/j.toxlet.2012.06.011
   Park BH, 2016, ONCOTARGET, V7, P63870, DOI 10.18632/oncotarget.11563
   Peng YF, 2019, ONCOL LETT, V17, P1139, DOI 10.3892/ol.2018.9691
   Piao XM, 2018, INT J MOL MED, V42, P1018, DOI 10.3892/ijmm.2018.3647
   Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575
   Salim LZA, 2013, MOLECULES, V18, P11219, DOI 10.3390/molecules180911219
   Sehrawat A, 2019, MITOCHONDRION, V47, P282, DOI 10.1016/j.mito.2019.01.003
   Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001
   Seydi E, 2016, BASIC CLIN PHARMACOL, V119, P249, DOI 10.1111/bcpt.12572
   Shen L, 2017, MED SCI MONITOR, V23, P223, DOI 10.12659/MSM.902704
   Shih YW, 2009, J AGR FOOD CHEM, V57, P3490, DOI 10.1021/jf900124r
   Silva MD, 2018, TOXICOL IN VITRO, V50, P75, DOI 10.1016/j.tiv.2018.02.020
   Sun F, 2012, NUTR CANCER, V64, P599, DOI 10.1080/01635581.2012.665564
   Szliszka E, 2012, INT J ONCOL, V41, P818, DOI 10.3892/ijo.2012.1527
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   Tomeh MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051033
   Wang DD, 2017, BIOCHEM BIOPH RES CO, V493, P521, DOI 10.1016/j.bbrc.2017.08.158
   Wang JY, 2018, EUR REV MED PHARMACO, V22, P7492, DOI 10.26355/eurrev_201811_16290
   Wang JY, 2015, INT J ONCOL, V46, P1507, DOI 10.3892/ijo.2015.2869
   Wang M, 2017, MOL MED REP, V16, P9165, DOI 10.3892/mmr.2017.7710
   Wang YQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23092334
   Watson DG, 2013, CELL SIGNAL, V25, P1011, DOI 10.1016/j.cellsig.2013.01.002
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Xia SX, 2018, BIOCHEM BIOPH RES CO, V503, P2363, DOI 10.1016/j.bbrc.2018.06.162
   Xia T, 2017, MOL MED REP, V15, P3591, DOI 10.3892/mmr.2017.6459
   Xu L, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/378684
   Xu XD, 2015, ONCOL RES TREAT, V38, P117, DOI 10.1159/000375435
   Xue X, 2011, TOXICOL LETT, V205, P47, DOI 10.1016/j.toxlet.2011.05.003
   Yan YJ, 2019, EUR J PHARMACOL, V842, P10, DOI 10.1016/j.ejphar.2018.10.025
   Yang G, 2012, PHYTOTHER RES, V26, P1667, DOI 10.1002/ptr.4632
   Yang JZ, 2017, APMIS, V125, P134, DOI 10.1111/apm.12650
   Yu XM, 2016, INT J MOL MED, V38, P861, DOI 10.3892/ijmm.2016.2676
   Yuan JH, 2007, PHARMACOLOGY, V80, P269, DOI 10.1159/000106447
   Zhang J, 2017, ONCOTARGET, V8, P91223, DOI 10.18632/oncotarget.20077
   Zhang MZ, 2018, CHEM-BIOL INTERACT, V292, P65, DOI 10.1016/j.cbi.2018.06.013
   Zhang QZ, 2006, MOL CANCER THER, V5, P1227, DOI 10.1158/1535-7163.MCT-05-0490
   Zhang R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0641-7
   Zhang SS, 2014, J AGR FOOD CHEM, V62, P9296, DOI 10.1021/jf503250d
   Zhang SS, 2014, FOOD CHEM TOXICOL, V68, P239, DOI 10.1016/j.fct.2014.03.020
   Zhang SS, 2014, J AGR FOOD CHEM, V62, P1581, DOI 10.1021/jf4053012
   Zhang SS, 2013, FOOD CHEM, V136, P1213, DOI 10.1016/j.foodchem.2012.08.090
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhao L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.563
   Zhou CX, 2016, TUMOR BIOL, V37, P3135, DOI 10.1007/s13277-015-4134-3
   Zhou GZ, 2018, BIOMED PHARMACOTHER, V103, P391, DOI 10.1016/j.biopha.2018.04.086
   Zhou H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0865-5
   Zhou P, 2019, MOL CELL PROBE, V43, P1, DOI 10.1016/j.mcp.2018.12.001
   Zhou QM, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0453-3
   Zhou YY, 2018, CELL PHYSIOL BIOCHEM, V45, P2548, DOI 10.1159/000488273
   Zhu XF, 2018, ONCOTARGETS THER, V11, P3521, DOI 10.2147/OTT.S159236
   Zhuang JH, 2016, ANTI-CANCER DRUG, V27, P312, DOI 10.1097/CAD.0000000000000340
   Zou XJ, 2016, J PHARMACOL SCI, V131, P233, DOI 10.1016/j.jphs.2016.04.017
NR 112
TC 13
Z9 13
U1 6
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2019
VL 2019
AR 3868354
DI 10.1155/2019/3868354
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA IF3RQ
UT WOS:000473001000001
PM 31308852
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Brachtendorf, S
   Wanger, RA
   Birod, K
   Thomas, D
   Trautmann, S
   Wegner, MS
   Fuhrmann, DC
   Brune, B
   Geisslinger, G
   Grosch, S
AF Brachtendorf, Sebastian
   Wanger, Ruth Anna
   Birod, Kerstin
   Thomas, Dominique
   Trautmann, Sandra
   Wegner, Marthe-Susanna
   Fuhrmann, Dominik C.
   Bruene, Bernhard
   Geisslinger, Gerd
   Groesch, Sabine
TI Chemosensitivity of human colon cancer cells is influenced by a
   p53-dependent enhancement of ceramide synthase 5 and induction of
   autophagy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE Sphingolipid; Chemoresistance; shRNA; Oxaliplatin; 5-Fluorouracil
ID LONG-CHAIN CERAMIDES; UP-REGULATION; CARCINOMA CELLS; MESSENGER-RNA;
   HUMAN BREAST; DNA-DAMAGE; P53; APOPTOSIS; ACTIVATION; PROTEIN
AB Resistance against chemotherapy is a life-threatening complication in colon cancer therapy. To increase response rate, new additional targets that contribute to chemoresistance are still needed to be explored. Ceramides, which belong to the group of sphingolipids, are well-known regulators of cell death and survival, respectively. Here, we show that in human wild-type ((wt)) p53 HCT-116 colon cancer cells treatment with oxaliplatin or 5-fluorouracil (5-FU) leads to a strong increase in ceramide synthase 5 (CerS5) expression and C-16:0-ceramide levels, which was not shown in HCT-116 lacking p53 expression (HCT-116 p53(-/-)). The increase in CerS5 expression occurs by stabilizing CerS5 mRNA at the 3'-UTR. By contrast, in the p53-deficient cells CerS2 expression and CerS2-related C-24:0- and C-24:1-ceramide levels were elevated which is possibly related to enhanced polyadenylation of the CerS2 transcript in these cells. Stable knockdown of CerS5 expression using CerS5-targeting shRNA led to an increased sensitivity of HCT-116 p53(wt) cells, but not of p53(-/-) cells, to oxaliplatin and 5-FU. Enhanced sensitivity was accompanied by an inhibition of autophagy and inhibition of mitochondrial respiration in these cells. However, knockdown of CerS2 had no significant effects on chemosensitivity of both cell lines.
   In conclusion, in p53(wt) colon cancer cells chemosensitivity against oxaliplatin or 5-FU could be enhanced by downregulation of CerS5 expression leading to reduced autophagy and mitochondrial respiration.
C1 [Brachtendorf, Sebastian; Wanger, Ruth Anna; Birod, Kerstin; Thomas, Dominique; Trautmann, Sandra; Wegner, Marthe-Susanna; Geisslinger, Gerd; Groesch, Sabine] Goethe Univ Frankfurt, Fac Med, Inst Clin Pharmacol, Frankfurt, Germany.
   [Geisslinger, Gerd] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol TMP, Frankfurt, Germany.
   [Fuhrmann, Dominik C.; Bruene, Bernhard] Goethe Univ Frankfurt, Inst Biochem 1, Fac Med, Frankfurt, Germany.
RP Grosch, S (corresponding author), Goethe Univ, Inst Clin Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM groesch@em.uni-frankfurt.de
RI Fuhrmann, Dominik/AAG-2145-2022
OI Fuhrmann, Dominik/0000-0002-4902-9387
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [SFB 1039/2]; DFGGerman Research Foundation (DFG)European Commission
   [GR2011/3-2, WE 5825/1-1]; August Scheidel- and Heinrich and Fritz
   Riese-Stiftung
FX This work was supported by the Deutsche Forschungsgemeinschaft (DFG)
   [SFB 1039/2]; DFG project [GR2011/3-2]; DFG project [WE 5825/1-1] and
   the August Scheidel- and Heinrich and Fritz Riese-Stiftung.
CR Barthelmes J, 2015, BRAIN BEHAV IMMUN, V46, P280, DOI 10.1016/j.bbi.2015.02.010
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Coban N, 2017, TURK KARDIYOL DERN A, V45, P118, DOI 10.5543/tkda.2016.82389
   Darmon SK, 2012, RNA BIOL, V9, P1255, DOI 10.4161/rna.21957
   Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180
   Deroyer C, 2014, AUTOPHAGY, V10, P1229, DOI 10.4161/auto.28777
   Divakaruni AS, 2014, METHOD ENZYMOL, V547, P309, DOI 10.1016/B978-0-12-801415-8.00016-3
   Eskandari MR, 2015, XENOBIOTICA, V45, P79, DOI 10.3109/00498254.2014.942809
   Fekry B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146618
   Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502
   Fitzgerald S, 2015, J PATHOL CLIN RES, V1, P54, DOI 10.1002/cjp2.5
   Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004
   Ghosh T, 2008, NUCLEIC ACIDS RES, V36, P6318, DOI 10.1093/nar/gkn624
   Gosejacob D, 2016, J BIOL CHEM, V291, P6989, DOI 10.1074/jbc.M115.691212
   Grosch S, 2012, PROG LIPID RES, V51, P50, DOI 10.1016/j.plipres.2011.11.001
   Grosch S, 2005, BIOCHEM PHARMACOL, V69, P831, DOI 10.1016/j.bcp.2004.11.026
   Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Harami-Papp H, 2016, ONCOTARGET, V7, P67183, DOI 10.18632/oncotarget.11594
   Hartmann D, 2013, INT J BIOCHEM CELL B, V45, P1195, DOI 10.1016/j.biocel.2013.03.012
   Hartmann D, 2012, INT J BIOCHEM CELL B, V44, P620, DOI 10.1016/j.biocel.2011.12.019
   Heffernan-Stroud LA, 2011, ADV ENZYME REGUL, V51, P219, DOI 10.1016/j.advenzreg.2010.10.003
   Hernandez-Tiedra S, 2016, AUTOPHAGY, V12, P2213, DOI 10.1080/15548627.2016.1213927
   Hoeferlin LA, 2013, J BIOL CHEM, V288, P12880, DOI 10.1074/jbc.M113.461798
   Hunten S, 2015, MOL CELL PROTEOMICS, V14, P2609, DOI 10.1074/mcp.M115.050237
   Ke RH, 2014, J NEURO-ONCOL, V118, P369, DOI 10.1007/s11060-014-1441-2
   Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200
   Law BA, 2018, FASEB J, V32, P1403, DOI 10.1096/fj.201700300R
   Li Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.215
   Licatalosi DD, 2010, NAT REV GENET, V11, P75, DOI 10.1038/nrg2673
   Liu YY, 2011, CANCER RES, V71, P2276, DOI 10.1158/0008-5472.CAN-10-3107
   Maier TJ, 2005, FASEB J, V19, P1353, DOI 10.1096/fj.04-3274fje
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mesicek J, 2010, CELL SIGNAL, V22, P1300, DOI 10.1016/j.cellsig.2010.04.006
   Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291
   Mizutani Y, 2008, J LIPID RES, V49, P2356, DOI 10.1194/jlr.M800158-JLR200
   Mizutani Y, 2006, BIOCHEM J, V398, P531, DOI 10.1042/BJ20060379
   Moser CV, 2016, BIOCHEM PHARMACOL, V103, P64, DOI 10.1016/j.bcp.2015.12.016
   Montgomery MK, 2016, BBA-MOL CELL BIOL L, V1861, P1828, DOI 10.1016/j.bbalip.2016.08.016
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914
   Nazeer FI, 2011, ONCOGENE, V30, P3073, DOI 10.1038/onc.2011.29
   Nemoto S, 2009, J BIOL CHEM, V284, P10422, DOI 10.1074/jbc.M900735200
   Oertel S, 2017, CELL MOL LIFE SCI, V74, P3039, DOI 10.1007/s00018-017-2518-9
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Panjarian S, 2008, PROSTAG OTH LIPID M, V86, P41, DOI 10.1016/j.prostaglandins.2008.02.004
   Pewzner-Jung Y, 2010, J BIOL CHEM, V285, P10911, DOI 10.1074/jbc.M109.077610
   Pewzner-Jung Y, 2010, J BIOL CHEM, V285, P10902, DOI 10.1074/jbc.M109.077594
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Russo SB, 2012, J CLIN INVEST, V122, P3919, DOI 10.1172/JCI63888
   Schiffmann S, 2010, BIOCHEM PHARMACOL, V80, P1632, DOI 10.1016/j.bcp.2010.08.012
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130
   Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044
   Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200
   Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580
   Tommasino C, 2015, APOPTOSIS, V20, P645, DOI 10.1007/s10495-015-1102-8
   Walker T, 2009, MOL PHARMACOL, V76, P342, DOI 10.1124/mol.109.056523
   Wegner MS, 2014, BIOCHEM PHARMACOL, V92, P577, DOI 10.1016/j.bcp.2014.10.007
   White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468
   Winer LSP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109916
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935
   Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016
NR 67
TC 23
Z9 23
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 0006-3002
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD OCT
PY 2018
VL 1863
IS 10
BP 1214
EP 1227
DI 10.1016/j.bbalip.2018.07.011
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA GU5EY
UT WOS:000445310000006
PM 30059758
DA 2022-04-25
ER

PT J
AU Psahoulia, FH
   Moumtzi, S
   Roberts, ML
   Sasazuki, T
   Shirasawa, S
   Pintzas, A
AF Psahoulia, Faiy H.
   Moumtzi, Sophy
   Roberts, Michael L.
   Sasazuki, Takehiko
   Shirasawa, Senji
   Pintzas, Alexander
TI Quercetin mediates preferential degradation of oncogenic Ras and causes
   autophagy in Ha-RAS-transformed human colon cells
SO CARCINOGENESIS
LA English
DT Article
ID HUMAN CANCER; K-RAS; N-RAS; GROWTH; ACTIVATION; PROTEIN; CARCINOMA;
   KINASE; LINES; MACROAUTOPHAGY
AB Several food polyphenols act as chemopreventers by reducing the incidence of many types of cancer, especially in colon epithelia. In this study, we have investigated whether the flavonoid quercetin can modulate cell proliferation and survival by targeting key molecules and/or biological processes responsible for tumor cell properties. The effect of quercetin on the expression of Ras oncoproteins was specifically studied using systems of either constitutive or conditional expression of oncogenic RAS in human epithelial cells. Our findings suggest that quercetin inhibits cell viability as well as cancer cell properties like anchorage-independent growth. These findings were further supported at the molecular level, since quercetin treatment resulted in a preferential reduction of Ras protein levels in cell lines expressing oncogenic Ras proteins. Notably, in cells that only express wild-type Ras or in those where the oncogenic Ras allele was knocked out, quercetin had no evident effects upon Ras levels. We have shown that quercetin drastically reduces half-life of oncogenic Ras but has no effect when the cells are treated with a proteasome inhibitor. Moreover, in Ha-RAS-transformed cells, quercetin induces autophagic processes. Since quercetin downregulates the levels of oncogenic Ras in cancer cells, we propose that this flavonoid could act as a chemopreventive agent for cancers with frequent mutations of RAS genes.
C1 Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, Athens 11635, Greece.
   Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan.
   Univ Thessaly, Dept Med, Sch Hlth Sci, Larisa 41222, Greece.
RP Pintzas, A (corresponding author), Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, Athens 11635, Greece.
EM apint@eie.gr
OI Roberts, Michael/0000-0001-7387-1155
CR Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000
   AVILA MA, 1994, CANCER RES, V54, P2424
   Bellone G, 2001, CANCER RES, V61, P2200
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   BOS JL, 1989, CANCER RES, V49, P4682
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5
   Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538
   CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4
   de Both NJ, 1999, BRIT J CANCER, V81, P934, DOI 10.1038/sj.bjc.6690790
   Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632
   Dihal AA, 2006, CANCER LETT, V238, P248, DOI 10.1016/j.canlet.2005.07.007
   Ferry DR, 1996, CLIN CANCER RES, V2, P659
   Food nutrition and the prevention of cancer: a global perspective, 1999, NUTRITION, V15, P523, DOI DOI 10.1016/S0899-9007(99)00021-0
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gustin DM, 2002, CANCER METAST REV, V21, P323, DOI 10.1023/A:1021271229476
   HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8
   HOSOKAWA N, 1990, INT J CANCER, V45, P1119, DOI 10.1002/ijc.2910450622
   Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035
   Lynch EA, 2006, MOL BIOL CELL, V17, P2236, DOI 10.1091/mbc.E05-08-0779
   Manson MM, 2003, TRENDS MOL MED, V9, P11, DOI 10.1016/S1471-4914(02)00002-3
   Marais R, 1996, CANCER SURV, V27, P101
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004
   QUINCOCES AF, 1995, CELL GROWTH DIFFER, V6, P271
   RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326
   Ranelletti FO, 2000, INT J CANCER, V85, P438, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;438::AID-IJC22&gt;3.0.CO;2-F
   Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003
   Roberts ML, 2006, INT J CANCER, V118, P616, DOI 10.1002/ijc.21386
   Rolli-Derkinderen M, 2005, CIRC RES, V96, P1152, DOI 10.1161/01.RES.0000170084.88780.ea
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   STAVRIC B, 1994, CLIN BIOCHEM, V27, P245, DOI 10.1016/0009-9120(94)90025-6
   Svegliati S, 2005, J BIOL CHEM, V280, P36474, DOI 10.1074/jbc.M502851200
   ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
NR 41
TC 94
Z9 101
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAY
PY 2007
VL 28
IS 5
BP 1021
EP 1031
DI 10.1093/carcin/bgl232
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 162WX
UT WOS:000246121300016
PM 17148506
OA hybrid
DA 2022-04-25
ER

PT J
AU Choi, EJ
   Lee, JH
   Kim, MS
   Song, SY
   Yoo, NJ
   Lee, SH
AF Choi, Eun Ji
   Lee, Ju Hwa
   Kim, Min Sung
   Song, Sang Yong
   Yoo, Nam Jin
   Lee, Sug Hyung
TI Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1,
   ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Tumor suppressor gene; Frameshift mutation; Colon cancer; Microsatellite
   instability
ID PROTEIN-KINASE-C; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS;
   EXPRESSION; GENE; SYSTEM
AB Both NRIP1 and DOK1 genes are considered candidate tumor suppressor genes (TSGs). Also, cell polarity-related genes PARD3, PRKCI and DLGAP3, and autophagy-related genes ULK1 and ULK2 genes are considered to play crucial roles in tumorigenesis. The aim of our study was to find whether these genes were mutated in colorectal cancer (CRC). In a genome database, we observed that each of these genes harbored mononucleotide repeats in the coding sequences, which could be mutated in cancers with high microsatellite instability (MSI-H). For this, we studied 124 CRCs for the frameshift mutations of these genes and their intratumoral heterogeneity (ITH). NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 harbored 18 (22.8%), 2 (2.5%), 2 (2.5%), 2 (2.5%), 5 (6.3%), 2 (2.5%) and 2 (2.5%) of 79 CRCs with MSI-H, respectively. However, we found no such mutations in microsatellite stable (MSS) cancers in the nucleotide repeats. We also studied ITH for the frameshift mutations in 16 cases of CRCs and detected that the frameshift mutations of NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 showed regional ITH in 5 (31.3%), 2 (12.5%), 0 (0%), 0 (0%), 1 (6.3%), 1 (6.3%) and 3 (18.8%) cases, respectively. Our data exhibit that candidate cancer-related genes NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 harbor mutational ITH as well as the frameshift mutations in CRC with MSI-H. Also, the results suggest that frameshift mutations of these genes might play a role in tumorigenesis through their inactivation in CRC.
C1 [Choi, Eun Ji; Lee, Ju Hwa; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
   [Song, Sang Yong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea.
RP Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
EM suhulee@catholic.ac.kr
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [2012R1A5A2047939, 2016R1D1A1B01007490]
FX This study was supported by grants from National Research Foundation of
   Korea (2012R1A5A2047939and 2016R1D1A1B01007490).
CR Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527
   Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.0.CO;2-J
   Choi EJ, 2017, PATHOL ONCOL RES, V23, P145, DOI 10.1007/s12253-016-0112-3
   Choi YJ, 2017, J PATHOL, V241, P57, DOI 10.1002/path.4819
   Choi YJ, 2014, PATHOL ONCOL RES, V20, P965, DOI 10.1007/s12253-014-9781-y
   Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827
   Docquier A, 2010, CLIN CANCER RES, V16, P2959, DOI 10.1158/1078-0432.CCR-09-3153
   Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jo YS, 2016, PATHOL ONCOL RES, V22, P769, DOI 10.1007/s12253-016-0070-9
   Jung SH, 2016, P NATL ACAD SCI USA, V113, P10672, DOI 10.1073/pnas.1606946113
   Lapierre M, 2014, J CLIN INVEST, V124, P1899, DOI 10.1172/JCI65178
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   MAZZARELLA R, 1995, GENOMICS, V26, P629, DOI 10.1016/0888-7543(95)80190-W
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Murphy KM, 2006, J MOL DIAGN, V8, P305, DOI 10.2353/jmoldx.2006.050092
   Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183
   Welch JM, 2004, J COMP NEUROL, V472, P24, DOI 10.1002/cne.20060
   Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148
NR 21
TC 10
Z9 10
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD OCT
PY 2018
VL 24
IS 4
BP 827
EP 832
DI 10.1007/s12253-017-0297-0
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA GS8QP
UT WOS:000443977800014
PM 28844109
DA 2022-04-25
ER

PT J
AU Pattingre, S
   Bauvy, C
   Codogno, P
AF Pattingre, S
   Bauvy, C
   Codogno, P
TI Amino acids interfere with the ERK1/2-dependent control of
   macroautophagy by controlling the activation of Raf-1 in human colon
   cancer HT-29 cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CONTROLS AUTOPHAGIC SEQUESTRATION; ALPHA-INTERACTING PROTEIN; ISOLATED
   RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; OKADAIC ACID; KINASE
   ACTIVATION; PHOSPHATASE 2A; IN-VIVO; PHOSPHORYLATION; INHIBITION
AB Activation of ERK1/2 stimulates macroautophagy in the human colon cancer cell line HT-29 by favoring the phosphorylation of the Galpha-interacting protein (GAIP) in an amino acid-dependent manner (Ogier-Denis, E., Pattingre, S., El Benna, J., and Codogno, P. (2000) J. Biol. Chem. 275, 39090-39095). Here we show that ERK1/2 activation by aurintricarboxylic acid (ATA) treatment induces the phosphorylation of GAIP in an amino acid-dependent manner. Accordingly, ATA challenge increased the rate of macroautophagy, whereas epidermal growth factor did not significantly affect macroautophagy and GAIP phosphorylation status. In fact, ATA activated the ERK1/2 signaling pathway, whereas epidermal growth factor stimulated both the ERK1/2 pathway and the class I phosphoinositide 3-kinase pathway, known to decrease the rate of macroautophagy. Amino acids interfered with the ATA-induced macroautophagy by inhibiting the activation of the kinase Raf-1. The role of the Ras/Raf-1/ERK1/2 signaling pathway in the GAIP- and amino acid-dependent control of macroautophagy was confirmed in HT-29 cells expressing the Ras(G12V, T35S) mutant. Similar to the protein phosphatase 2A inhibitor okadaic acid, amino acids sustained the phosphorylation of Ser(259), which is involved in the negative regulation of Raf-1. In conclusion, these results add a novel target to the amino acid signaling-dependent control of macroautophagy in intestinal cells.
C1 INSERM, U504, F-94807 Villejuif, France.
RP Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.
RI Codogno, Patrice/G-1384-2013
OI Codogno, Patrice/0000-0002-5492-3180; Pattingre,
   Sophie/0000-0001-6284-6050; Ogier-Denis, Eric/0000-0002-0057-7593
CR Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127
   Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400
   BALLARD FJ, 1985, EXP CELL RES, V157, P172, DOI 10.1016/0014-4827(85)90160-0
   BLANKSON H, 1995, EXP CELL RES, V218, P522, DOI 10.1006/excr.1995.1187
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235
   Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578
   Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64
   Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8
   Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856
   Franch HA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134903
   Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200
   Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255
   Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4
   HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633
   HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x
   Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817
   HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550
   HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521
   Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1
   Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65
   Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464
   Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438
   Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3
   Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7
   Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8
   van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561
   Waguri S, 1999, ARCH HISTOL CYTOL, V62, P423, DOI 10.1679/aohc.62.423
   White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439
   Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050
   Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741
NR 56
TC 228
Z9 244
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 9
PY 2003
VL 278
IS 19
BP 16667
EP 16674
DI 10.1074/jbc.M210998200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 677QG
UT WOS:000182818600030
PM 12609989
OA hybrid
DA 2022-04-25
ER

PT J
AU Chen, H
   Tang, XC
   Liu, T
   Jing, L
   Wu, JH
AF Chen, Hai
   Tang, Xiaocheng
   Liu, Ting
   Jing, Liang
   Wu, Junhui
TI Zingiberene inhibits in vitro and in vivo human colon cancer cell growth
   via autophagy induction, suppression of PI3K/AKT/mTOR Pathway and
   caspase 2 deactivation
SO JOURNAL OF BUON
LA English
DT Article
DE colon cancer; zingiberene; autophagy; caspases proliferation
ID NATURAL-PRODUCTS; DRUGS; SESQUITERPENE; AGENTS
AB Purpose: Colon cancer (CC) is one of the deadly malignancies and the second most frequent cancer in the world. The development of drug resistance and dearth of the viable drug options form a serious obstacle in the treatment of CC. Herein, the anticancer potential of Zingiberene was examined against the CC cells.
   Methods: The proliferation rate of the CC cells was assessed by cell counting assay. Autophagy was detected by transmission electron microscopy (TEM). The transfected cells were then treated with varied concentrations of Zingiberene (0, 10, 20 and 40 mu M) for 24 h and monitored by fluorescent microscopy. Cell cycle analysis was performed by flow cytometry. Protein expression was determined by immunoblotting.
   Results: Zingiberene could considerably inhibit the proliferation of CC cells. The anticancer activity of Zingiberene against the HT-29 CC cells was found to be due to induction of autophagy. The Zingiberene triggered autophagy was also linked with increase in the expression of LC3-II and decrease in p62 expression. However, no apparent effects were observed on the LC3-I expression. Moreover, it was found that zingiberine also caused activation of autophagy-related caspases in the HT-29 cells. Further, it was found that Zingiberene could inhibit the mTOR/PI3K/AKT signalling pathway in the CC cells. Zingiberene also suppressed the weight and volume of the xenografted tumors concentration-dependently.
   Conclusions: These results indicate that Zingiberene may inhibit the growth of CC in vitro and in vivo and may be used for the development of systemic therapy against CC.
C1 [Chen, Hai; Tang, Xiaocheng; Liu, Ting; Jing, Liang; Wu, Junhui] Cent S Univ, Xiangya Hosp 3, Dept Gastrointestinal Surg, Changsha 410000, Hunan, Peoples R China.
RP Wu, JH (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Gastrointestinal Surg, Changsha 410000, Hunan, Peoples R China.
EM howyver@yahoo.com
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   BALANDRIN MF, 1985, SCIENCE, V228, P1154, DOI 10.1126/science.3890182
   BRUCE WR, 1966, JNCI-J NATL CANCER I, V37, P233
   Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f
   Chan ML, 2015, N-S ARCH PHARMACOL, V388, P1223, DOI 10.1007/s00210-015-1152-z
   Chen MH, 2019, CHEM-BIOL INTERACT, V299, P1, DOI 10.1016/j.cbi.2018.11.009
   Cragg GM, 2000, EXPERT OPIN INV DRUG, V9, P2783, DOI 10.1517/13543784.9.12.2783
   Cudjoe E.K., 2019, TARGETING CELL SURVI, P259
   Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016/j.drudis.2010.06.002
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Habib SHM, 2008, CLINICS, V63, P807, DOI 10.1590/S1807-59322008000600017
   Millar JG, 1998, J NAT PROD, V61, P1025, DOI 10.1021/np9800699
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Kreuger MRO, 2012, ANTI-CANCER DRUG, V23, P883, DOI 10.1097/CAD.0b013e328356cad9
   Ramakrishnan R., 2013, IJMPS, V3, P11
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang B, 2018, BIOCHEM BIOPH RES CO, V499, P156, DOI 10.1016/j.bbrc.2018.03.091
   Zhang Siyuan, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P239, DOI 10.2174/1568011053765976
NR 21
TC 7
Z9 8
U1 1
U2 6
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD JUL-AUG
PY 2019
VL 24
IS 4
BP 1470
EP 1475
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IR7BT
UT WOS:000481595900020
PM 31646793
DA 2022-04-25
ER

PT J
AU Zheng, XJ
   Xie, GX
   Jia, W
AF Zheng, Xiaojiao
   Xie, Guoxiang
   Jia, Wei
TI Metabolomic profiling in colorectal cancer: opportunities for
   personalized medicine
SO PERSONALIZED MEDICINE
LA English
DT Review
DE biomarkers; colorectal cancer; drug discovery; early diagnosis;
   metabolomic profiling; personalized medicine; staging; treatment
ID CHAIN FATTY-ACIDS; MAS NMR-SPECTROSCOPY; COLON-CANCER;
   CELL-PROLIFERATION; PROSTATE-CANCER; GENE-EXPRESSION; SERUM;
   IDENTIFICATION; PROTEOMICS; AUTOPHAGY
AB Colorectal cancer (CRC) is one of the most common types of cancer in the world, with high prevalence and mortality. Understanding the alterations of cancer metabolism and identifying reliable biomarkers would facilitate the development of novel technologies of CRC screening and early diagnosis, as well as new approaches to providing personalized medicine. Metabolomics, as an emerging molecular phenotyping approach, provides a clinical platform technology with an unprecedented amount of metabolic readout information, which is ideal for theranostic biomarker discovery. Metabolic signatures can link the unique pathophysiological states of patients to personalized health monitoring and intervention strategies. This article presents an overview of the metabolomic studies of CRC with a focus on recent advances in the biomarker discovery in serum, urine, fecal water and tissue samples for cancer diagnosis. The development and application of metabolomics towards personalized medicine, including early diagnosis, cancer staging, treatment and drug discovery are also discussed.
C1 [Zheng, Xiaojiao; Jia, Wei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Ctr Translat Med, Shanghai 200233, Peoples R China.
   [Zheng, Xiaojiao; Jia, Wei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Lab Diabet Mellitus, Dept Endocrinol & Metab, Shanghai 200233, Peoples R China.
   [Xie, Guoxiang; Jia, Wei] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA.
   [Jia, Wei] Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Comm, Shanghai 201203, Peoples R China.
RP Jia, W (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Ctr Translat Med, Shanghai 200233, Peoples R China.
EM wjia@cc.hawaii.edu
RI Xie, Guoxiang/F-3022-2016; Jia, Wei/AAN-5102-2020
OI Xie, Guoxiang/0000-0002-0951-4150; Jia, Wei/0000-0002-3739-8994
FU Metabolic Disease Biobank, Shanghai Jiao Tong University Affiliated
   Sixth People's Hospital; E-institutes of Shanghai Municipal Education
   Commission [E03008]; Program for Professor of Special Appointment
   (Eastern Scholar) at Shanghai Institutions of Higher Learning [2011-50,
   085ZY1205]; Shanghai Science and Technology funds [12DZ2295004]
FX The authors are thankful for the support of the Metabolic Disease
   Biobank, Shanghai Jiao Tong University Affiliated Sixth People's
   Hospital. This work was funded in part by E-institutes of Shanghai
   Municipal Education Commission (E03008), the Program for Professor of
   Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher
   Learning (No. 2011-50), 085ZY1205 and Shanghai Science and Technology
   funds (12DZ2295004). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Abrahams E, 2005, AM J PHARMACOGENOMIC, V5, P345, DOI 10.2165/00129785-200505060-00002
   Abrahamse SL, 1999, CARCINOGENESIS, V20, P629, DOI 10.1093/carcin/20.4.629
   Andre N, 2005, GUT, V54, P1194, DOI 10.1136/gut.2004.062745
   Ang CS, 2011, BIOMED CHROMATOGR, V25, P82, DOI 10.1002/bmc.1528
   Aziz Q, 1998, GASTROENTEROLOGY, V114, P559, DOI 10.1016/S0016-5085(98)70540-2
   Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W
   Backshall A, 2011, CLIN CANCER RES, V17, P3019, DOI 10.1158/1078-0432.CCR-10-2474
   Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802
   Bertini I, 2012, CANCER RES, V72, P356, DOI 10.1158/0008-5472.CAN-11-1543
   Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547
   Bisogno T, 1998, EUR J BIOCHEM, V254, P634, DOI 10.1046/j.1432-1327.1998.2540634.x
   BOFFA LC, 1992, CANCER RES, V52, P5906
   Boger DL, 1998, CURR PHARM DESIGN, V4, P303
   Boros LG, CURR CANC DRUG TARGE, V3, P445
   BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983
   Chae YK, 2010, B KOREAN CHEM SOC, V31, P379, DOI 10.5012/bkcs.2010.31.02.379
   Chan ECY, 2009, J PROTEOME RES, V8, P352, DOI 10.1021/pr8006232
   Chen JL, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/125890
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Chen WX, 2011, CHINESE J CHEM, V29, P2511, DOI 10.1002/cjoc.201180423
   Cheng Y, 2012, J PROTEOME RES, V11, P1354, DOI 10.1021/pr201001a
   Claudino WM, 2012, CRIT REV ONCOL HEMAT, V84, P1, DOI 10.1016/j.critrevonc.2012.02.009
   Connolly JM, 1997, NUTR CANCER, V29, P114, DOI 10.1080/01635589709514611
   Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525
   Droge W, 2004, MECH AGEING DEV, V125, P161, DOI 10.1016/j.mad.2003.12.003
   Farshidfar F, 2012, GENOME MED, V4, DOI 10.1186/gm341
   Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27
   Griffin JL, 2004, NAT REV CANCER, V4, P551, DOI 10.1038/nrc1390
   HAGUE A, 1995, EUR J CANCER PREV, V4, P359, DOI 10.1097/00008469-199510000-00005
   Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   Jimenez B, 2013, J PROTEOME RES, V12, P959, DOI 10.1021/pr3010106
   Kaddurah-Daouk R, 2008, ANNU REV PHARMACOL, V48, P653, DOI 10.1146/annurev.pharmtox.48.113006.094715
   Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5
   Kim YS, 2008, J MICROBIOL BIOTECHN, V18, P1109
   Kleivi K, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-2
   Kogan NM, 2005, MINI-REV MED CHEM, V5, P941, DOI 10.2174/138955705774329555
   Komori T, 2004, J EXP CLIN CANC RES, V23, P521
   Kondo Y, 2011, BIOMARK MED, V5, P451, DOI [10.2217/BMM.11.41, 10.2217/bmm.11.41]
   Kouskoumvekaki I, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/525497
   KRIAT M, 1993, J LIPID RES, V34, P1009
   LaPointe LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029059
   Leddin D, 2004, CAN J GASTROENTEROL, V18, P93, DOI 10.1155/2004/983459
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137
   Lindon JC, 2005, NAT BIOTECHNOL, V23, P833, DOI 10.1038/nbt0705-833
   Ma YL, 2012, ANN SURG, V255, P720, DOI 10.1097/SLA.0b013e31824a9a8b
   Mal M, 2012, ANAL BIOANAL CHEM, V403, P483, DOI 10.1007/s00216-012-5870-5
   Mal M, 2009, RAPID COMMUN MASS SP, V23, P487, DOI 10.1002/rcm.3898
   Marshafl JR, 2008, GASTROENTEROL CLIN N, V37, P73, DOI 10.1016/j.gtc.2007.12.008
   Martinez-Garcia M, 2007, MAR DRUGS, V5, P52, DOI 10.3390/md503052
   Mazzanti R, 2006, AM J PHYSIOL-GASTR L, V290, pG1329, DOI 10.1152/ajpgi.00563.2005
   McGarr SE, 2005, J CLIN GASTROENTEROL, V39, P98
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Monleon D, 2009, NMR BIOMED, V22, P342, DOI 10.1002/nbm.1345
   Nambiar PR, 2010, MUTAT RES-FUND MOL M, V693, P3, DOI 10.1016/j.mrfmmm.2010.07.008
   Nicholson JK, 2012, EXPERT OPIN DRUG MET, V8, P135, DOI 10.1517/17425255.2012.646987
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Nishiumi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040459
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   O'Leary BA, 2004, J GASTROEN HEPATOL, V19, P38, DOI 10.1111/j.1440-1746.2004.03177.x
   Oliver SG, 2002, PHILOS T R SOC B, V357, P17, DOI 10.1098/rstb.2001.1049
   Patsos HA, BIOCH SOC T 4, V33, P712
   Piotto M, 2009, METABOLOMICS, V5, P292, DOI 10.1007/s11306-008-0151-1
   Pouillart PR, 1998, LIFE SCI, V63, P1739, DOI 10.1016/S0024-3205(98)00279-3
   Qiu YP, 2010, J PROTEOME RES, V9, P1627, DOI 10.1021/pr901081y
   Qiu YP, 2009, J PROTEOME RES, V8, P4844, DOI 10.1021/pr9004162
   Rex DK, 2009, AM J GASTROENTEROL, V104, P739, DOI 10.1038/ajg.2009.104
   Righi V, 2009, J PROTEOME RES, V8, P1859, DOI 10.1021/pr801094b
   Ritchie SA, 2013, INT J CANCER, V132, P355, DOI 10.1002/ijc.27673
   Ritchie SA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-59
   Ritchie SA, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-140
   Ritchie SA, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-13
   Robertson DG, 2011, TOXICOL SCI, V120, pS146, DOI 10.1093/toxsci/kfq358
   Roblick UJ, 2004, CELL MOL LIFE SCI, V61, P1246, DOI 10.1007/s00018-004-4049-4
   Romero R, 2006, BJOG-INT J OBSTET GY, V113, P118, DOI 10.1111/j.1471-0528.2006.01150.x
   Saric J, 2008, J PROTEOME RES, V7, P352, DOI 10.1021/pr070340k
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shrubsole MJ, 2012, CANCER PREV RES, V5, P336, DOI 10.1158/1940-6207.CAPR-11-0426
   Solmi R, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-250
   Sun JC, 2013, PERS MED, V10, P149, DOI [10.2217/PME.13.8, 10.2217/pme.13.8]
   Tan BB, 2013, J PROTEOME RES, V12, P3000, DOI 10.1021/pr400337b
   Tessem MB, 2010, J PROTEOME RES, V9, P3664, DOI 10.1021/pr100176g
   Thomas EA, 1997, P NATL ACAD SCI USA, V94, P14115, DOI 10.1073/pnas.94.25.14115
   Wang HL, 2010, FUTURE ONCOL, V6, P1395, DOI 10.2217/FON.10.107
   Wang M, 2005, PHYTOTHER RES, V19, P173, DOI 10.1002/ptr.1624
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188
   Williams MD, 2013, ANAL BIOANAL CHEM, V405, P5013, DOI 10.1007/s00216-013-6777-5
   Wishart DS., 2010, J BIOMOL TECH, V21, pS6
   Yang YJ, 1999, CLIN BIOCHEM, V32, P405, DOI 10.1016/S0009-9120(99)00036-3
   Zarbo RJ, 2005, ARCH PATHOL LAB MED, V129, P1237
   Zhao LA, 2010, FEBS J, V277, P4195, DOI 10.1111/j.1742-4658.2010.07808.x
   Zheng XJ, 2011, J PROTEOME RES, V10, P5512, DOI 10.1021/pr2007945
NR 94
TC 6
Z9 6
U1 2
U2 40
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1741-0541
EI 1744-828X
J9 PERS MED
JI Pers. Med.
PD SEP
PY 2013
VL 10
IS 7
BP 741
EP 755
DI 10.2217/PME.13.73
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AI8PX
UT WOS:000337184100015
PM 29768755
DA 2022-04-25
ER

PT J
AU Sundaramoorthy, P
   Baskaran, R
   Mishra, SK
   Jeong, KY
   Oh, SH
   Yoo, BK
   Kim, HM
AF Sundaramoorthy, Pasupathi
   Baskaran, Rengarajan
   Mishra, Siddhartha Kumar
   Jeong, Keun-Yeong
   Oh, Seung Hyun
   Yoo, Bong Kyu
   Kim, Hwan Mook
TI Novel self-micellizing anticancer lipid nanoparticles induce cell death
   of colorectal cancer cells
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Nanoparticle; Self-micellizing anticancer lipid; Apoptosis; Autophagy;
   Colorectal cancer
ID LIPOSOMAL NANOPARTICLES; ANTITUMOR EFFICACY; DELIVERY; THERAPY;
   CHEMOTHERAPY; PLATFORM; SPHINGOLIPIDS; IRINOTECAN; RESISTANCE; APOPTOSIS
AB In the present study, we developed a novel drug-like self-micellizing anticancer lipid (SMAL), and investigated its anticancer activity and effects on cell death pathways in human colorectal cancer (CRC) cell lines.-Three self-assembled nanoparticles were prepared, namely, SMAL102 (lauramide derivative), SMAL104 (palmitamide derivative), and SMAL108 (stearamide derivative) by a thin-film hydration technique, and were characterized for physicochemical and biological parameters. SMAL102 were nanosized (160.23 +/- 8.11 nm) with uniform spherical shape, while SMAL104 and SMAL108 did not form spherical shape but formed large size nanoparticles and irregular in shape. Importantly, SMAL102 showed a cytotoxic effect towards CRC cell lines (HCT116 and HT-29), and less toxicity to a normal colon fibroblast cell line (CCD-18Co). Conversely, SMAL104 and SMAL108 did not have an anti-proliferative effect on CRC cell lines. SMAL102 nanoparticles were actively taken up by CRC cell lines, localized in the cell membrane, and exhibited remarkable cytotoxicity in a concentration-dependent manner. The normal colon cell line showed significantly less cellular uptake and non-cytotoxicity as compared with the CRC cell lines. SMAL102 nanoparticles induced caspase-3, caspase-9, and PARP cleavage in HT-29 cells, indicating the induction of apoptosis; whereas LOB was activated in HCT116 cells, indicating autophagy-induced cell death. Collectively, these results demonstrate that SMAL102 induced cell death via activation of apoptosis and autophagy in CRC cell lines. The present study could be a pioneer for further preclinical and clinical development of such compounds. (c) 2015 Elsevier B.V. All rights reserved.
C1 [Sundaramoorthy, Pasupathi; Baskaran, Rengarajan; Mishra, Siddhartha Kumar; Jeong, Keun-Yeong; Oh, Seung Hyun; Yoo, Bong Kyu; Kim, Hwan Mook] Gachon Univ, Gachon Inst Pharmaceut Sci, Inchon 406840, South Korea.
   [Mishra, Siddhartha Kumar] Dr Harisingh Gour Cent Univ, Sch Biol Sci, Dept Zool, Sagar 470003, India.
RP Kim, HM (corresponding author), Gachon Univ, Gachon Inst Pharmaceut Sci, Inchon 406840, South Korea.
EM hwanmook@gachon.ac.kr
RI Mishra, Siddhartha Kumar/A-4344-2016; Jeong, Keun-Yeong/B-8845-2015;
   Sundaramoorthy, Pasupathi/I-4307-2019; Oh, Seung/AAN-6744-2021
OI Mishra, Siddhartha Kumar/0000-0003-1627-1377; Jeong,
   Keun-Yeong/0000-0002-4933-3493; Sundaramoorthy,
   Pasupathi/0000-0003-1045-093X; 
FU Gachon Institute of Pharmaceutical Sciences Research Fund, Gachon
   University, Republic of Korea
FX This research was supported by the Gachon Institute of Pharmaceutical
   Sciences Research Fund 2014, Gachon University and the Republic of
   Korea. We thank Dr. Thiruganesh Ramasamy (Yeungnam University, South
   Korea) for his valuable help in proofreading the manuscript.
CR Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Dhule SS, 2014, MOL PHARMACEUT, V11, P417, DOI 10.1021/mp400366r
   Haidar ZS., 2011, J BIONANOSCI, V5, P143
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Holovati JL, 2008, CELL PRESERV TECHNOL, V6, P207, DOI 10.1089/cpt.2008.0008
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063
   Kolishetti N, 2010, P NATL ACAD SCI USA, V107, P17939, DOI 10.1073/pnas.1011368107
   Krasnici S, 2003, INT J CANCER, V105, P561, DOI 10.1002/ijc.11108
   Markman JL, 2013, ADV DRUG DELIVER REV, V65, P1866, DOI 10.1016/j.addr.2013.09.019
   Min KH, 2008, J CONTROL RELEASE, V127, P208, DOI 10.1016/j.jconrel.2008.01.013
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Perche F., 2013, J DRUG DELIV, V2013, P1
   Ramasamy T, 2015, CHEM COMMUN, V51, P5758, DOI 10.1039/c5cc00482a
   Ramasamy T, 2015, PHARM RES-DORDR, V32, P1947, DOI 10.1007/s11095-014-1588-8
   Ramasamy T, 2014, ACTA BIOMATER, V10, P5116, DOI 10.1016/j.actbio.2014.08.021
   Ramasamy T, 2014, J MATER CHEM B, V2, P6324, DOI 10.1039/c4tb00867g
   Ruttala HB, 2015, COLLOID SURFACE B, V128, P419, DOI 10.1016/j.colsurfb.2015.02.040
   Ruttala HB, 2015, PHARM RES-DORDR, V32, P1002, DOI 10.1007/s11095-014-1512-2
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701
   Yoon Goo, 2013, Journal of Pharmaceutical Investigation, V43, P353, DOI 10.1007/s40005-013-0087-y
NR 25
TC 15
Z9 15
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD NOV 1
PY 2015
VL 135
BP 793
EP 801
DI 10.1016/j.colsurfb.2015.08.039
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA CZ9IB
UT WOS:000367410200097
PM 26342325
DA 2022-04-25
ER

PT J
AU Mainz, L
   Rosenfeldt, MT
AF Mainz, Laura
   Rosenfeldt, Mathias T.
TI Autophagy and cancer - insights from mouse models
SO FEBS JOURNAL
LA English
DT Review
DE autophagy; cancer; chloroquine; mouse models; treatment
ID DOUBLE-EDGED-SWORD; PANCREATIC-CANCER; AKT INHIBITION; COLON-CANCER;
   CELL-DEATH; PTEN LOSS; IN-VITRO; CHLOROQUINE; TUMORIGENESIS; MUTANTS
AB (Macro-)autophagy is an evolutionary conserved self-digestion program' that serves to maintain cellular metabolism and is implicated in many pathological processes such as cancer. In recent years, an increasing number of studies in murine cancer models have provided a plethora of sometimes conflicting results about the role of autophagy in cancer biology. This review summarizes these studies and raises awareness that there are situations in which autophagy blockage might indeed reduce tumor growth, but that sometimes the exact opposite is the case. It is therefore vital to mimic patient conditions in preclinical mouse experiments as thoroughly as possible before commencing clinical trials.
C1 [Rosenfeldt, Mathias T.] Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
   Univ Wurzburg, Germany & Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.
RP Rosenfeldt, MT (corresponding author), Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
EM mathias.rosenfeldt@uni-wuerzburg.de
RI Rosenfeldt, Mathias/ABE-4736-2022
OI Rosenfeldt, Mathias/0000-0001-7650-8458
FU German Research FoundationGerman Research Foundation (DFG) [FOR2314]
FX This work was supported by a grant of the German Research Foundation to
   MTR as part of FOR2314.
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amaravadi R, 2014, CANCER DISCOV, V4, P873, DOI 10.1158/2159-8290.CD-14-0618
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaya C, 2015, FEBS LETT, V589, P3343, DOI 10.1016/j.febslet.2015.09.021
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bokobza SM, 2014, ONCOTARGET, V5, P4765, DOI 10.18632/oncotarget.2017
   Boya P, 2013, NAT CELL BIOL, V15, P1017, DOI 10.1038/ncb2815
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   Guldberg P, 1997, CANCER RES, V57, P3660
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591
   Hill R, 2010, CANCER RES, V70, P7114, DOI 10.1158/0008-5472.CAN-10-1649
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Ito H, 2005, INT J ONCOL, V26, P1401
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li VSW, 2012, GASTROENTEROLOGY, V143, P30, DOI 10.1053/j.gastro.2012.05.017
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.264
   Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Rosenfeldt MT, 2017, CELL DEATH DIFFER, V24, P1303, DOI 10.1038/cdd.2016.120
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301
   THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5
   Tooze S. A., 2014, MEMBRANE TRAFFICKING, V1270, P155
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wei HJ, 2009, J BIOL CHEM, V284, P6004, DOI 10.1074/jbc.M806375200
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Yoshii SR, 2016, DEV CELL, V39, P116, DOI 10.1016/j.devcel.2016.09.001
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Yue Z, 2003, P NATL ACAD SCI USA, V100, P1
NR 82
TC 23
Z9 23
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD MAR
PY 2018
VL 285
IS 5
BP 792
EP 808
DI 10.1111/febs.14274
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FY8VL
UT WOS:000427143000001
PM 28921866
OA Bronze
DA 2022-04-25
ER

PT J
AU Gong, YZ
   Ma, H
   Ruan, GT
   Zhu, LC
   Liao, XW
   Wang, S
   Yan, L
   Huang, W
   Huang, KT
   Xie, HL
   Zhu, GZ
   Wang, XK
   Liao, C
   Gao, F
AF Gong, Yi-Zhen
   Ma, Hui
   Ruan, Guo-Tian
   Zhu, Li-Chen
   Liao, Xi-Wen
   Wang, Shuai
   Yan, Ling
   Huang, Wei
   Huang, Ke-Tuan
   Xie, Hailun
   Zhu, Guang-Zhi
   Wang, Xiang-Kun
   Liao, Cun
   Gao, Feng
TI Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in
   colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort
SO JOURNAL OF CANCER
LA English
DT Article
DE CXCL1; COAD; Diagnosis; Prognosis; Biomarker; GSEA
ID FALSE DISCOVERY RATE; COLORECTAL-CANCER; GRO-ALPHA; STAGE-II;
   EXPRESSION; CXCL1; ANGIOGENESIS; BIOMARKER; BETA; SET
AB Objective: The objective was to identify and validate C-X-C motif chemokine ligand 1(CXCL1) for diagnosis and prognosis in colon adenocarcinoma (COAD).
   Methods: Our current study had enrolled one The Cancer Genome Atlas (TCGA) cohort and two Guangxi cohorts to identify and verify the diagnostic and prognostic values of CXCL1 in COAD. Functional enrichment was performed by gene set enrichment analysis (GSEA).
   Results: In TCGA cohort, the expression of CXCL1 was significantly up-regulated in tumor tissues and decreased as the tumor stage developed. The receiver operating characteristic (ROC) curve showed that CXCL1 had a high diagnostic value for COAD. The result of Kaplan-Meier survival analysis showed that CXCL1 gene expression (P=0.045) was significantly correlated with overall survival (OS) of COAD. Results of Guangxi cohort also verified the diagnostic value of CXCL1 in COAD, and sub-group survival analyses also suggested that patients with high CXCL1 expression were related to a favorable OS (Corrected P=0.005). GSEA revealed that CXCL1 high expression phenotype was related to cytokine activity, cell apoptosis, P53 regulation pathway, and regulation of autophagy in COAD.
   Conclusions: In this study, we found that CXCL1 gene might be a potential diagnostic biomarker for COAD, and might serve as a prognostic biomarker for specific subgroup of COAD.
C1 [Gong, Yi-Zhen; Ma, Hui; Ruan, Guo-Tian; Wang, Shuai; Yan, Ling; Huang, Wei; Xie, Hailun; Liao, Cun; Gao, Feng] Guangxi Med Univ, Dept Colorectal & Anal Surg, Affiliated Hosp 1, 6 ShuangYong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Zhu, Li-Chen] Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning, Guangxi Zhuang, Peoples R China.
   [Liao, Xi-Wen; Huang, Ke-Tuan; Zhu, Guang-Zhi; Wang, Xiang-Kun] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning, Guangxi Zhuang, Peoples R China.
RP Gao, F (corresponding author), Guangxi Med Univ, Dept Colorectal & Anal Surg, Affiliated Hosp 1, 6 ShuangYong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM gaofeng@gxmu.edu.cn
FU Innovation Project of Guangxi Graduate Education [YCBZ2020048]; Basic
   Ability Improvement Project for Middle-aged and Young Teachers in
   Colleges and Universities in Guangxi [2020KY12026]
FX The present study was supported by the Innovation Project of Guangxi
   Graduate Education (YCBZ2018036), The Basic Ability Improvement Project
   for Middle-aged and Young Teachers in Colleges and Universities in
   Guangxi (2020KY12026) and Innovation Project of Guangxi Graduate
   Education (YCBZ2020048).
CR Abdulla MH, 2017, ONCOL REP, V37, P3175, DOI 10.3892/or.2017.5576
   Amin MB, 2017, AJCC CANC STAGING MA, P20
   BECKER S, 1994, AM J PHYSIOL, V266, pL278, DOI 10.1152/ajplung.1994.266.3.L278
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cabrero-de las Heras S, 2018, WORLD J GASTROENTERO, V24, P4738, DOI 10.3748/wjg.v24.i42.4738
   Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x
   Chen JJ, 2017, CANCER BIOL MED, V14, P42, DOI 10.20892/j.issn.2095-3941.2016.0082
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Dai J, 2016, ONCOTARGET, V7, P87147, DOI 10.18632/oncotarget.13515
   Divella R, 2017, ANTICANCER RES, V37, P4867, DOI 10.21873/anticanres.11895
   Feng X, 2018, CANCER MED-US, V7, P2339, DOI 10.1002/cam4.1480
   Garborg K, 2015, SURG CLIN N AM, V95, P979, DOI 10.1016/j.suc.2015.05.007
   Garcia-Larsen V, 2019, EUR J CLIN NUTR, V73, P366, DOI 10.1038/s41430-018-0234-7
   Hashimoto Y, 2016, EPIGENOMICS-UK, V8, P685, DOI 10.2217/epi-2015-0013
   HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732
   Hsu YL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082427
   Huang EY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4254-4
   Huang SC, 2017, BIOMED J, V40, P39, DOI 10.1016/j.bj.2017.01.004
   Katkoori VR, 2017, ONCOTARGET, V8, P76574, DOI 10.18632/oncotarget.20580
   Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4
   Liu ZY, 2019, THERANOSTICS, V9, P3659, DOI 10.7150/thno.32126
   Miyake M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-322
   MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797
   Nakamura Y, 2018, ONCOLOGIST, V23, P1310, DOI 10.1634/theoncologist.2017-0621
   Noda M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200315
   Ogawa R, 2019, CLIN CANCER RES, V25, P2887, DOI 10.1158/1078-0432.CCR-18-3684
   Oladipo O, 2011, BRIT J CANCER, V104, P480, DOI 10.1038/sj.bjc.6606055
   OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153
   Pita-Fernandez S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2717-z
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   Rong MH, 2014, UPSALA J MED SCI, V119, P19, DOI 10.3109/03009734.2013.856970
   Rosenberg EE, 2014, TUMOR BIOL, V35, P3237, DOI 10.1007/s13277-013-1423-6
   Shinkins B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171810
   Soreide K, 2007, CELL ONCOL, V29, P301
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3
   Uchiyama K, 2018, J GASTROENTEROL, V53, P1179, DOI 10.1007/s00535-018-1448-0
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Vries MHM, 2015, ANGIOGENESIS, V18, P163, DOI 10.1007/s10456-014-9454-1
   Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199
   Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124
   Wen Y, 2006, CLIN CANCER RES, V12, P5951, DOI 10.1158/1078-0432.CCR-06-0736
   Wu YY, 2017, ONCOL LETT, V13, P129, DOI 10.3892/ol.2016.5425
   Zhang AH, 2014, CANCER LETT, V345, P17, DOI 10.1016/j.canlet.2013.11.011
   Zhang Y, 2016, ONCOTARGETS THER, V9, P4959, DOI 10.2147/OTT.S105225
   Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhuo CH, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180580
NR 50
TC 0
Z9 0
U1 1
U2 1
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2021
VL 12
IS 18
BP 5506
EP 5518
DI 10.7150/jca.51524
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XA7YV
UT WOS:000720858900003
PM 34405013
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Lee, SJ
   Lee, HJ
   Jung, YH
   Kim, JS
   Choi, SH
   Han, HJ
AF Lee, Sei-Jung
   Lee, Hyun Jik
   Jung, Young Hyun
   Kim, Jun Sung
   Choi, Sang Ho
   Han, Ho Jae
TI Melatonin inhibits apoptotic cell death induced by Vibrio vulnificus
   VvhA via melatonin receptor 2 coupling with NCF-1
SO CELL DEATH & DISEASE
LA English
DT Article
ID COLON-CANCER CELLS; JNK1-MEDIATED PHOSPHORYLATION; EXTRACELLULAR
   CYTOLYSIN; SIGNALING PATHWAY; EPITHELIAL-CELLS; JNK ACTIVATION; NADPH
   OXIDASES; PROTEIN-KINASE; NOX FAMILY; AUTOPHAGY
AB Melatonin, an endogenous hormone molecule, has a variety of biological functions, but a functional role of melatonin in the infection of Gram-negative bacterium Vibrio vulnificus has yet to be described. In this study, we investigated the molecular mechanism of melatonin in the apoptosis of human intestinal epithelial (HCT116) cells induced by the hemolysin (VvhA) produced by V. vulnificus. Melatonin (1 mu M) significantly inhibited apoptosis induced by the recombinant protein (r) VvhA, which had been inhibited by the knockdown of MT2. The rVvhA recruited caveolin-1, NCF-1, and Rac1 into lipid rafts to facilitate the production of ROS responsible for the phosphorylation of PKC and JNK. Interestingly, melatonin recruited NCF-1 into non-lipid rafts to prevent ROS production via MT2 coupling with Gaq. Melatonin inhibited the JNK-mediated phosphorylation of c-Jun responsible for Bax expression, the release of mitochondrial cytochrome c, and caspase-3/-9 activation during its promotion of rVvhA-induced apoptotic cell death. In addition, melatonin inhibited JNK-mediated phosphorylation of Bcl-2 responsible for the release of Beclin-1 and Atg5 expression during its promotion of rVvhA-induced autophagic cell death. These results demonstrate that melatonin signaling via MT2 triggers recruitment of NCF-1 into non-lipid rafts to block ROS production and JNK-mediated apoptotic and autophagic cell deaths induced by rVvhA in intestinal epithelial cells.
C1 [Lee, Sei-Jung] Daegu Haany Univ, Dept Pharmaceut Engn, Gyongsan 38610, South Korea.
   [Lee, Hyun Jik; Jung, Young Hyun; Kim, Jun Sung; Han, Ho Jae] Seoul Natl Univ, Dept Vet Physiol, Coll Vet Med, Res Inst Vet Sci, Seoul 08826, South Korea.
   [Lee, Hyun Jik; Jung, Young Hyun; Kim, Jun Sung; Han, Ho Jae] Seoul Natl Univ, PLUS Program Creat Vet Sci Res BK21, Seoul 08826, South Korea.
   [Choi, Sang Ho] Seoul Natl Univ, Natl Res Lab Mol Microbiol & Toxicol, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Choi, Sang Ho] Seoul Natl Univ, Ctr Food Safety & Toxicol, Seoul 08826, South Korea.
RP Han, HJ (corresponding author), Seoul Natl Univ, Dept Vet Physiol, Coll Vet Med, Res Inst Vet Sci, Seoul 08826, South Korea.; Han, HJ (corresponding author), Seoul Natl Univ, PLUS Program Creat Vet Sci Res BK21, Seoul 08826, South Korea.
EM hjhan@snu.ac.kr
RI Lee, Sei-Jung/V-8772-2019
OI Choi, Sang Ho/0000-0003-3865-1039
FU National R&D Program through the National Research Foundation of Korea
   (NRF) - Ministry of Science and ICT [NRF-2017M3A9F3047062]; Basic
   Science Research Program through the NRF - Ministry of Education
   [NRF-2016R1D1A1B03930458]; Korea Institute of Planning and Evaluation
   for Technology in Food, Agriculture and Forestry (IPET) through
   Agriculture, Food and Rural Affairs Research Center Support Program -
   Ministry of Agriculture, Food and Rural Affairs (MAFRA), Republic of
   Korea [710012-03-1-SB110]
FX This research was supported by National R&D Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Science and
   ICT (NRF-2017M3A9F3047062) and Basic Science Research Program through
   the NRF funded by the Ministry of Education (NRF-2016R1D1A1B03930458);
   and Korea Institute of Planning and Evaluation for Technology in Food,
   Agriculture and Forestry (IPET) through Agriculture, Food and Rural
   Affairs Research Center Support Program, funded by Ministry of
   Agriculture, Food and Rural Affairs (MAFRA)(710012-03-1-SB110), Republic
   of Korea.
CR Bahr I, 2012, J PINEAL RES, V53, P390, DOI 10.1111/j.1600-079X.2012.01009.x
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Chen LJ, 2014, BIOCHEMISTRY-US, V53, P2827, DOI 10.1021/bi500092e
   Crane JK, 2005, CELL DEATH DIFFER, V12, P115, DOI 10.1038/sj.cdd.4401531
   Czabotar PE, 2010, CURR PHARM DESIGN, V16, P3132
   Elgaml A, 2017, MICROBIOL IMMUNOL, V61, DOI 10.1111/1348-0421.12465
   Fang FC, 2011, MBIO, V2, DOI 10.1128/mBio.00141-11
   Fu J, 2011, J PINEAL RES, V51, P104, DOI 10.1111/j.1600-079X.2011.00867.x
   Garcia-Santos G, 2006, J PINEAL RES, V41, P130, DOI 10.1111/j.1600-079X.2006.00342.x
   GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985
   Hardeland R, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12377
   HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195
   Horseman MA, 2011, INT J INFECT DIS, V15, pE157, DOI 10.1016/j.ijid.2010.11.003
   Hu W, 2017, BRIT J PHARMACOL, V174, P754, DOI 10.1111/bph.13751
   Jeong HG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002581
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kaneko Y, 2011, J PINEAL RES, V50, P272, DOI 10.1111/j.1600-079X.2010.00837.x
   Ki MR, 2008, AM J PHYSIOL-GASTR L, V294, pG635, DOI 10.1152/ajpgi.00281.2007
   Kim WH, 2008, CELL IMMUNOL, V253, P81, DOI 10.1016/j.cellimm.2008.05.003
   Kohchi C, 2009, ANTICANCER RES, V29, P817
   Kolliputi N, 2009, AM J PHYSIOL-LUNG C, V297, pL6, DOI 10.1152/ajplung.90381.2008
   Lee HY, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12379
   Lee HY, 2014, J PINEAL RES, V57, P262, DOI 10.1111/jpi.12165
   Lee SJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.19
   Lee SJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00352
   Lee SJ, 2014, J PINEAL RES, V57, P393, DOI 10.1111/jpi.12179
   Lee WJ, 2009, GENE DEV, V23, P2260, DOI 10.1101/gad.1858709
   Leon J, 2014, J PINEAL RES, V56, P415, DOI 10.1111/jpi.12131
   Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658
   Leto TL, 2006, ANTIOXID REDOX SIGN, V8, P1549, DOI 10.1089/ars.2006.8.1549
   Li PL, 2007, ANTIOXID REDOX SIGN, V9, P1457, DOI 10.1089/ars.2007.1667
   Lindsay J, 2011, BBA-MOL CELL RES, V1813, P532, DOI 10.1016/j.bbamcr.2010.10.017
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897
   Monturiol-Gross L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086475
   Neish AS, 2013, FREE RADICAL RES, V47, P950, DOI 10.3109/10715762.2013.833331
   Nogueira CV, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000478
   Nougayrede JP, 2004, CELL MICROBIOL, V6, P1097, DOI 10.1111/j.1462-5822.2004.00421.x
   Park JH, 2011, J BACTERIOL, V193, P2062, DOI 10.1128/JB.00110-11
   Peschke E, 2010, BEST PRACT RES CL EN, V24, P829, DOI 10.1016/j.beem.2010.09.001
   Reiter RJ, 2003, J PINEAL RES, V34, P79, DOI 10.1034/j.1600-079X.2003.2e114.x
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Santofimia-Castano P, 2015, FREE RADICAL BIO MED, V87, P226, DOI 10.1016/j.freeradbiomed.2015.06.033
   Sareila O, 2013, J LEUKOCYTE BIOL, V93, P427, DOI 10.1189/jlb.1211588
   Sareila O, 2011, ANTIOXID REDOX SIGN, V15, P2197, DOI 10.1089/ars.2010.3635
   Slauch JM, 2011, MOL MICROBIOL, V80, P580, DOI 10.1111/j.1365-2958.2011.07612.x
   Song EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep27080
   Srinivasan V, 2012, RECENT PATENTS ENDOC, V6, P30, DOI 10.2174/187221412799015317
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tekbas OF, 2008, J PINEAL RES, V44, P222, DOI 10.1111/j.1600-079X.2007.00516.x
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   WRIGHT AC, 1991, INFECT IMMUN, V59, P192, DOI 10.1128/IAI.59.1.192-197.1991
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yamasaki E, 2006, J BIOL CHEM, V281, P11250, DOI 10.1074/jbc.M509404200
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhu YF, 2017, AM J TRANSL RES, V9, P3422
NR 57
TC 10
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN 19
PY 2018
VL 9
AR 48
DI 10.1038/s41419-017-0083-7
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FZ1PO
UT WOS:000427349600007
PM 29352110
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Fu, Q
   Cheng, J
   Zhang, JD
   Zhang, YL
   Chen, XB
   Xie, JG
   Luo, SX
AF Fu, Qiang
   Cheng, Jing
   Zhang, Jindai
   Zhang, Yonglei
   Chen, Xiaobing
   Xie, Jianguo
   Luo, Suxia
TI Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells
   to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy
SO ONCOLOGY REPORTS
LA English
DT Article
DE miR-218; YEATS4; colorectal cancer; chemosensitivity; autophagy; cell
   apoptosis
ID TUMOR-SUPPRESSIVE MICRORNA-218; DRUG-RESISTANCE; HMGB1-MEDIATED
   AUTOPHAGY; MULTIDRUG-RESISTANCE; LUNG-CANCER; EXPRESSION; CARCINOMA;
   PATHWAY; OXALIPLATIN; SURVIVIN
AB Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Deregulation of microRNAs (miRNAs) has been reported to participate in CRC progression. In the present study, we observed downregulation of miR-218 and upregulation of YEATS domain containing 4 (YEATS4) in CRC tissues and in multidrug-resistant HCT-116/L-OHP cells compared with these levels in normal tissues and parental HCT-116 cells, respectively. The results indicated that miR-218 overexpression significantly decreased the IC50 value of oxaliplatin (L-OHP) in the HCT-116/L-OHP cells, and suppression of miR-218 significantly enhanced the IC50 of L-OHP in the HCT-116 cells. Flow cytometric analysis showed that miR-218 overexpression alone promoted cell apoptosis in the HCT-116/L-OHP cells, which was further enhanced in response to L-OHP, and miR-218 inhibition decreased cell apoptosis in the HCT-116 cells following treatment with L-OHP. Western blot analysis indicated that, compared with the small increase observed in HCT-116 cells, the relative LC3 II level in HCT-116/L-OHP cells after lysosome inhibition via chloroquine (CQ) was markedly upregulated following L-OHP treatment, suggesting induction of autophagy. Exposure of HCT-116/L-OHP cells to L-OHP after control mimic transfection increased autophagic flux, as reflected by increased LC3 II levels, while miR-218 overexpression partly reversed L-OHP-mediated LC3 II accumulation. Additionally, both miR-218 overexpression and CQ treatment promoted L-OHP-induced HCT-116/L-OHP cell apoptosis. Molecularly, our results confirmed that miR-218 directly targets the YEATS4 gene and inhibits YEATS4 expression. Furthermore, YEATS4 overexpression without the 3'-untranslated region (3'-UTR) restored miR-218-inhibited YEATS4 and LC3 II expression, and abolished miR-218-stimulated cell viability loss and cell apoptosis increase in response to L-OHP. In conclusion, miR-218 sensitized HCT-116/L-OHP cells to L-OHP-induced cell apoptosis via inhibition of cytoprotective autophagy by targeting YEATS4 expression.
C1 [Fu, Qiang; Zhang, Jindai; Zhang, Yonglei; Xie, Jianguo] Zhengzhou Univ, Affiliated Tumor Hosp, Tumor Hosp Henan Prov, Dept Gastrointestinal Surg, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
   [Chen, Xiaobing; Luo, Suxia] Zhengzhou Univ, Affiliated Tumor Hosp, Tumor Hosp Henan Prov, Dept Digest Oncol, Zhengzhou 450008, Henan, Peoples R China.
   [Cheng, Jing] Zhengzhou Univ, Affiliated Cent Hosp, Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou 450007, Henan, Peoples R China.
RP Xie, JG (corresponding author), Zhengzhou Univ, Affiliated Tumor Hosp, Tumor Hosp Henan Prov, Dept Gastrointestinal Surg, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
EM jianguo_xie@126.com
CR Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754
   Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619
   Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712
   Faltejskova P, 2012, INT J COLORECTAL DIS, V27, P1401, DOI 10.1007/s00384-012-1461-3
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817
   Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271
   Gao XC, 2014, CANCER LETT, V353, P25, DOI 10.1016/j.canlet.2014.07.011
   He XQ, 2012, MOL MED, V18, P1491, DOI 10.2119/molmed.2012.00304
   Hu YH, 2015, BREAST CANCER RES TR, V151, P269, DOI 10.1007/s10549-015-3372-9
   Kim YR, 2015, ONCOTARGET, V6, P31030, DOI 10.18632/oncotarget.5208
   Li PL, 2015, CARCINOGENESIS, V36, P1484, DOI 10.1093/carcin/bgv145
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Park JH, 2006, MOL CELL BIOL, V26, P4006, DOI 10.1128/MCB.02185-05
   Pikor LA, 2013, CANCER RES, V73, P7301, DOI 10.1158/0008-5472.CAN-13-1897
   Ran XM, 2015, INT J CLIN EXP PATHO, V8, P6617
   Sakitani K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1789-5
   Shi Y, 2015, J CELL MOL MED, V19, P535, DOI 10.1111/jcmm.12435
   Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635
   Stiegelbauer V, 2014, WORLD J GASTROENTERO, V20, P11727, DOI 10.3748/wjg.v20.i33.11727
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Tao K, 2015, AM J TRANSL RES, V7, P616
   Wang KY, 2014, IUBMB LIFE, V66, P645, DOI 10.1002/iub.1317
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Xie LL, 2015, BLOOD REV, V29, P33, DOI 10.1016/j.blre.2014.09.005
   Xu K, 2012, EXP CELL RES, V318, P2168, DOI 10.1016/j.yexcr.2012.04.014
   Yamamoto N, 2013, INT J ONCOL, V42, P1523, DOI 10.3892/ijo.2013.1851
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yu H, 2013, INT J CLIN EXP PATHO, V6, P2904
   Zarogoulidis P, 2015, CELL SIGNAL, V27, P1576, DOI 10.1016/j.cellsig.2015.04.009
   Zhang XL, 2015, INT J CLIN EXP PATHO, V8, P6397
   Zhong XH, 2015, BIOCHEM BIOPH RES CO, V466, P206, DOI 10.1016/j.bbrc.2015.09.008
NR 37
TC 21
Z9 22
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2016
VL 36
IS 6
BP 3682
EP 3690
DI 10.3892/or.2016.5195
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED2DG
UT WOS:000388653200072
PM 27779719
OA Bronze
DA 2022-04-25
ER

PT J
AU Muzes, G
   Kiss, AL
   Tulassay, Z
   Sipos, F
AF Muzes, Gyorgyi
   Kiss, Anna L.
   Tulassay, Zsolt
   Sipos, Ferenc
TI Cell-free DNA-induced alteration of autophagy response and
   TLR9-signaling: Their relation to amelioration of DSS-colitis
SO COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
DE Cell-free DNA; DSS-colitis; TLR9; Beclin1; ATG16L1; LC3B; Autophagy;
   Inflammation; Spleen index
ID TOLL-LIKE RECEPTORS; DOUBLE-EDGED SWORDS; NUCLEIC-ACIDS;
   ULCERATIVE-COLITIS; IMMUNE ACTIVATION; OXIDATIVE STRESS; DENDRITIC
   CELLS; INNATE; CANCER; MECHANISMS
AB Background: The influence of cell-free DNA (fDNA) administration on the TLR9-autophagy regulatory crosstalk within inflammatory circumstances remains unclear.
   Aims: To examine the immunobiologic effects of iv. fDNA injection on the TLR9-mediated autophagy response in murine DSS-colitis.
   Methods: Different types of modified fDNAs were administered to DSS-colitic mice. Disease and histological activities, spleen index were measured. Changes of the TLR9-associated and autophagy-related gene expression profiles of lamina proprial cells and splenocytes were assayed by quantitative real-time PCR, and validated by immunohistochemistries. Ultrastructural changes of the colon were examined by transmission electron microscopy (TEM).
   Results: A single intravenous injection of colitic fDNA (C-DNA) exhibited beneficial clinical and histological effects on DSS-colitis, compared to normal (N-DNA). C-DNA administration displayed a more prominent impact on the outcome of the TLR9-autophagy response than N-DNA. C-DNA resulted in a decreased spleen index in DSS-colitic mice. C-DNA treatment of normal mice resulted in a downregulation of Beclin1 and ATG16L1 mRNA and protein expression in the colon. These as well as LC3B were downregulated in the spleen. In contrast, the Beclin1, ATG16L1 and LC3B gene and protein expressions were upregulated in both the colon and the spleen by C-DNA injection. Moreover, C-DNA administration to DSS-colitic mice resulted in a remarkable increase of epithelial autophagic vacuoles representing an intensified macroautophagy.
   Conclusions: The effect of intravenously administered fDNA on the TLR9-mediated autophagy response is expressly dependent on the origin of fDNA (i.e. inflammatory or not) and on the characteristics of the local immunobiologic milieu (i.e. inflammatory or not, as well).
C1 [Muzes, Gyorgyi; Tulassay, Zsolt; Sipos, Ferenc] Semmelweis Univ, Dept Internal Med 2, H-1088 Budapest, Hungary.
   [Tulassay, Zsolt] Hungarian Acad Sci, Mol Med Res Unit, H-1051 Budapest, Hungary.
   Semmelweis Univ, Dept Human Morphol & Dev Biol, H-1094 Budapest, Hungary.
RP Muzes, G (corresponding author), Semmelweis Univ, Dept Internal Med 2, Immunol & Internal Med, Szentkiralyi St 46, H-1088 Budapest, Hungary.
EM muzes.gyorgyi@med.semmelweis-univ.hu
OI Sipos, Ferenc/0000-0002-2767-7746
FU Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi
   Alapprogramok (OTKA) [OTKA-K111743]
FX This study was funded by the Hungarian Scientific Research Fund
   (OTKA-K111743 grant) to ZT. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Hernandez-Trejo JA, 2016, BIOCHEM J, V473, P3805, DOI 10.1042/BCJ20160390
   Berglund M, 2009, CELL IMMUNOL, V259, P27, DOI 10.1016/j.cellimm.2009.05.009
   Chen G., 2016, BIOL CHEM
   Chen KQ, 2017, BRAIN BEHAV IMMUN, V59, P200, DOI 10.1016/j.bbi.2016.10.002
   Chiu HW, 2015, CANCER LETT, V365, P229, DOI 10.1016/j.canlet.2015.05.025
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Cueto-Sola M, 2013, INT ARCH ALLERGY IMM, V162, P214, DOI 10.1159/000353596
   Cui J, 2014, HUM VACC IMMUNOTHER, V10, P3270, DOI 10.4161/21645515.2014.979640
   Dadakhujaev S, 2010, NEUROSCI LETT, V472, P47, DOI 10.1016/j.neulet.2010.01.053
   Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Deng XB, 2013, TOXICOL IN VITRO, V27, P1762, DOI 10.1016/j.tiv.2013.05.004
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6
   Duijvestein M, 2011, STEM CELLS, V29, P1549, DOI 10.1002/stem.698
   Egger B, 2000, DIGESTION, V62, P240, DOI 10.1159/000007822
   Gao H, 2016, BIOCHEM BIOPH RES CO, V473, P311, DOI 10.1016/j.bbrc.2016.03.101
   Gosu V, 2012, MOLECULES, V17, P13503, DOI 10.3390/molecules171113503
   Gould TJ, 2015, J THROMB HAEMOST, V13, pS82, DOI 10.1111/jth.12977
   Hart AL, 2005, GASTROENTEROLOGY, V129, P50, DOI 10.1053/j.gastro.2005.05.013
   Hindryckx P, 2010, LAB INVEST, V90, P566, DOI 10.1038/labinvest.2010.37
   Howe R, 2009, CLIN IMMUNOL, V131, P317, DOI 10.1016/j.clim.2008.12.003
   Inomata M, 2012, CELL MOL LIFE SCI, V69, P963, DOI 10.1007/s00018-011-0819-y
   Into T, 2012, CELL SIGNAL, V24, P1150, DOI 10.1016/j.cellsig.2012.01.020
   Ishii KJ, 2005, INT J CANCER, V117, P517, DOI 10.1002/ijc.21402
   Ishii KJ, 2004, CURR OPIN MOL THER, V6, P166
   Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719
   Kawagoe T, 2008, NAT IMMUNOL, V9, P684, DOI 10.1038/ni.1606
   Knaevelsrud H, 2010, FEBS LETT, V584, P2635, DOI 10.1016/j.febslet.2010.04.041
   Kohler C, 2011, ANTICANCER RES, V31, P2623
   Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee JS, 2009, BIOSCI BIOTECH BIOCH, V73, P1732, DOI 10.1271/bbb.90035
   Lei N, 2016, MOL MED REP, V14, P1002, DOI 10.3892/mmr.2016.5310
   LEON SA, 1977, CANCER RES, V37, P646
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Liu C, 2015, CHEM-BIOL INTERACT, V242, P327, DOI 10.1016/j.cbi.2015.10.022
   Lu KF, 2014, AUTOPHAGY, V10, P2381, DOI 10.4161/15548627.2014.981919
   Mehta P, 2014, CURR OPIN IMMUNOL, V26, P69, DOI 10.1016/j.coi.2013.10.012
   Moore MN, 2007, AQUAT TOXICOL, V84, P80, DOI 10.1016/j.aquatox.2007.06.007
   Moss BL, 2012, J BIOL CHEM, V287, P31359, DOI 10.1074/jbc.M112.364018
   Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629
   MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184
   Muzes G, 2014, CURR DRUG TARGETS, V15, P743, DOI 10.2174/1389450115666140522120427
   Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698
   O'Brien CE, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0065-0
   Park JH, 2013, TOXICOL APPL PHARM, V268, P55, DOI 10.1016/j.taap.2013.01.013
   Pei F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.397
   Pricolo VE, 1996, J SURG RES, V66, P6, DOI 10.1006/jsre.1996.0364
   Qin L., 2016, ONCOTARGET, V21
   Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019
   Rauh P, 2003, DIGEST DIS, V21, P363, DOI 10.1159/000075361
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004
   Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x
   Sipos F, 2014, PATHOL ONCOL RES, V20, P867, DOI 10.1007/s12253-014-9766-x
   STEINMAN CR, 1975, J CLIN INVEST, V56, P512, DOI 10.1172/JCI108118
   Strobaek D, 2013, BRIT J PHARMACOL, V168, P432, DOI 10.1111/j.1476-5381.2012.02143.x
   Swarup V, 2007, FEBS LETT, V581, P795, DOI 10.1016/j.febslet.2007.01.051
   Takahashi W, 2013, CRIT CARE, V17, DOI 10.1186/cc12839
   TAN EM, 1966, J CLIN INVEST, V45, P1732, DOI 10.1172/JCI105479
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   van Dieren JM, 2006, INFLAMM BOWEL DIS, V12, P311, DOI 10.1097/01.MIB.0000209787.19952.53
   Velde AAT, 2006, INFLAMM BOWEL DIS, V12, P995, DOI 10.1097/01.mib.0000227817.54969.5e
   Volik S, 2016, MOL CANCER RES, V14, P898, DOI 10.1158/1541-7786.MCR-16-0044
   Wang CH, 2010, INFLAMM BOWEL DIS, V16, P1751, DOI 10.1002/ibd.21266
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Yan HY, 2015, INT J CLIN EXP MED, V8, P20245
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yao J, 2015, WORLD J GASTROENTERO, V21, P6572, DOI 10.3748/wjg.v21.i21.6572
   Zhang H., 2017, IMMUNOBIOLOGY
   Zhu JM, 2010, J INEQUAL APPL, DOI 10.1155/2010/520240
   Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344
NR 76
TC 7
Z9 7
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0147-9571
EI 1878-1667
J9 COMP IMMUNOL MICROB
JI Comp. Immunol. Microbiol. Infect. Dis.
PD JUN
PY 2017
VL 52
BP 48
EP 57
DI 10.1016/j.cimid.2017.06.005
PG 10
WC Immunology; Microbiology; Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Veterinary Sciences
GA FA2MJ
UT WOS:000405275200009
PM 28673462
DA 2022-04-25
ER

PT J
AU Zhao, MN
   Liu, Q
   Gong, YC
   Xu, XH
   Zhang, C
   Liu, XJ
   Zhang, CB
   Guo, HY
   Zhang, XY
   Gong, YQ
   Shao, CS
AF Zhao, Minnan
   Liu, Qiao
   Gong, Yanchao
   Xu, Xiuhua
   Zhang, Chen
   Liu, Xiaojie
   Zhang, Caibo
   Guo, Haiyang
   Zhang, Xiyu
   Gong, Yaoqin
   Shao, Changshun
TI GSH-dependent antioxidant defense contributes to the acclimation of
   colon cancer cells to acidic microenvironment
SO CELL CYCLE
LA English
DT Article
DE acidic microenvironment; antioxidant defense; CD44; colorectal cancer;
   GSH; GSR
ID HUMAN-MELANOMA CELLS; CELLULAR ADAPTATION; OXIDATIVE STRESS;
   MAMMALIAN-CELLS; HUMAN-TUMORS; PH; PROGRESSION; PROMOTES; SENESCENCE;
   AUTOPHAGY
AB Due to increased glycolysis and poor local perfusion, solid tumors are usually immersed in an acidic microenvironment. While extracellular acidosis is cytotoxic, cancer cells eventually become acclimated to it. While previous studies have addressed the acute effect of acidosis on cancer cells, little is known about how cancer cells survive chronic acidosis. In this study we exposed colorectal cancer (CRC) cells (HCT15, HCT116 and LoVo) to acidic pH (pH 6.5) continuously for over three months and obtained CRC cells that become acclimated to acidic pH, designated as CRC-acidosis-acclimated or CRC-AA. We unexpectedly found that while acute exposure to low pH resulted in an increase in the level of intracellular reactive oxygen species (ROS), CRC-AA cells exhibited a significantly reduced level of ROS when compared to ancestor cells. CRC-AA cells were found to maintain a higher level of reduced glutathione, via the upregulation of CD44 and glutathione reductase (GSR), among others, than their ancestor cells. Importantly, CRC-AA cells were more sensitive to agents that deplete GSH. Moreover, downregulation of GSR by RNA interference was more deleterious to CRC-AA cells than to control cells. Together, our results demonstrate a critical role of glutathione-dependent antioxidant defense in acclimation of CRC cells to acidic extracellular pH.
C1 [Zhao, Minnan; Liu, Qiao; Gong, Yanchao; Xu, Xiuhua; Zhang, Chen; Liu, Xiaojie; Zhang, Caibo; Guo, Haiyang; Zhang, Xiyu; Gong, Yaoqin; Shao, Changshun] Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ, 44 W Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Zhao, Minnan; Liu, Qiao; Gong, Yanchao; Xu, Xiuhua; Zhang, Chen; Liu, Xiaojie; Zhang, Caibo; Guo, Haiyang; Zhang, Xiyu; Gong, Yaoqin; Shao, Changshun] Shandong Univ, Sch Med, Dept Mol Med & Genet, 44 W Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Shao, Changshun] Rutgers State Univ, Human Genet Inst New Jersey, Dept Genet, Piscataway, NJ USA.
RP Shao, CS (corresponding author), Shandong Univ, Sch Med, Dept Mol Med & Genet, 44 W Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
EM changshun.shao@gmail.com
RI Shao, Changshun/AAD-8977-2022
OI Shao, Changshun/0000-0003-2618-9342; guo, haiyang/0000-0001-5503-6922
FU National Basic Research Program of China (973 Program)National Basic
   Research Program of China [2011CB966200]; National Natural Science
   Foundation Research Grants [81372241, 81572785, 81330050]; State Program
   of National Natural Science Foundation of China for Innovative Research
   GroupNational Natural Science Foundation of China (NSFC) [81321061]
FX This study was supported by National Basic Research Program of China
   (973 Program) grant (2011CB966200), National Natural Science Foundation
   Research Grants (81372241,81572785 and 81330050), and State Program of
   National Natural Science Foundation of China for Innovative Research
   Group (81321061).
CR Amend SR, 2015, ONCOTARGET, V6, P9669, DOI 10.18632/oncotarget.3430
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796
   Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811
   Gerweck LE, 1996, CANCER RES, V56, P1194
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514
   Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019
   Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   LaMonte G, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-23
   Leontieva OV, 2011, AGING-US, V3, P1078, DOI 10.18632/aging.100402
   Liu Q, 2015, MOL CANCER THER, V14, P355, DOI 10.1158/1535-7163.MCT-14-0634
   Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214
   MEISTER A, 1994, J BIOL CHEM, V269, P9397
   MORITA T, 1992, MUTAT RES, V268, P297, DOI 10.1016/0027-5107(92)90235-T
   Peppicelli S, 2015, CELL CYCLE, V14, P3088, DOI 10.1080/15384101.2015.1078032
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575
   Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Seo YJ, 2009, CANCER RES, V69, P7285, DOI 10.1158/0008-5472.CAN-09-0624
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wei Z, 2015, FREE RADICAL BIO MED, V79, P1, DOI 10.1016/j.freeradbiomed.2014.11.010
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660
   Wojtkowiak JW, 2012, CANCER RES, V72, P3938, DOI 10.1158/0008-5472.CAN-11-3881
   Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c
   Xu B, 2014, MUTAT RES-FUND MOL M, V770, P1, DOI 10.1016/j.mrfmmm.2014.08.004
NR 34
TC 24
Z9 26
U1 2
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2016
VL 15
IS 8
BP 1125
EP 1133
DI 10.1080/15384101.2016.1158374
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DK5YO
UT WOS:000374997400018
PM 26950675
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Chen, L
   Meng, Y
   Sun, Q
   Zhang, ZY
   Guo, XQ
   Sheng, XT
   Tai, GH
   Cheng, HR
   Zhou, YF
AF Chen, Lei
   Meng, Yue
   Sun, Qi
   Zhang, Zhongyu
   Guo, Xiaoqing
   Sheng, Xiaotong
   Tai, Guihua
   Cheng, Hairong
   Zhou, Yifa
TI Ginsenoside compound K sensitizes human colon cancer cells to
   TRAIL-induced apoptosis via autophagy-dependent and -independent DR5
   upregulation
SO CELL DEATH & DISEASE
LA English
DT Article
ID DEATH RECEPTOR 5; NF-KAPPA-B; CCAAT/ENHANCER-BINDING-PROTEIN; LIGAND
   TRAIL; HOMOLOGOUS PROTEIN; MEDIATED APOPTOSIS; DOWN-REGULATION;
   MELANOMA-CELLS; IN-VIVO; METABOLITE
AB Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent cancer cell-specific apoptosis-inducing cytokine with little toxicity to most normal cells. However, acquired resistance of cancer cells to TRAIL is a roadblock. Agents that can either potentiate the effect of TRAIL or overcome resistance to TRAIL are urgently needed. This article reports that ginsenoside compound K (CK) potentiates TRAIL-induced apoptosis in HCT116 colon cancer cells and sensitizes TRAIL-resistant colon cancer HT-29 cells to TRAIL. On a cellular mechanistic level, CK downregulated cell survival proteins including Mcl-1, Bcl-2, surviving, X-linked inhibitor of apoptosis protein and Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein, upregulated cell pro-apoptotic proteins including Bax, tBid and cytochrome c, and induced the cell surface expression of TRAIL death receptor DR5. Reduction of DR5 levels by siRNAs significantly decreases CK-and TRAIL-mediated apoptosis. Importantly, our results indicate, for the first time, that DR5 upregulation is mediated by autophagy, as blockade of CK-induced autophagy by 3-MA, LY294002 or Atg7 siRNAs substantially decreases DR5 upregulation and reduces the synergistic effect. Furthermore, CK-stimulated autophagy is mediated by the reactive oxygen species-c-Jun NH2-terminal kinase pathway. Moreover, we found that p53 and the C/EBP homologous (CHOP) protein is also required for DR5 upregulation but not related with autophagy. Our findings contribute significantly to the understanding of the mechanism accounted for the synergistic anticancer activity of CK and TRAIL, and showed a novel mechanism related with DR5 upregulation.
C1 [Chen, Lei; Meng, Yue; Sun, Qi; Zhang, Zhongyu; Guo, Xiaoqing; Sheng, Xiaotong; Tai, Guihua; Cheng, Hairong; Zhou, Yifa] Northeast Normal Univ, Sch Life Sci, Jilin Prov Key Lab Chem & Biol Changbai Mt Nat Dr, 5268 Renmin St, Changchun 130024, Peoples R China.
RP Cheng, HR; Zhou, YF (corresponding author), Northeast Normal Univ, Sch Life Sci, Jilin Prov Key Lab Chem & Biol Changbai Mt Nat Dr, 5268 Renmin St, Changchun 130024, Peoples R China.
EM chenghr893@nenu.edu.cn; zhouyf383@nenu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302172, 31170770]; Doctoral Fund of
   Ministry of Education of ChinaMinistry of Education, China
   [20120043130001]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2014T70270]; Key Scientific Program of
   Jilin Province [20140101122JC]
FX This work was supported by the National Natural Science Foundation of
   China (no. 81302172 and no. 31170770), the Doctoral Fund of Ministry of
   Education of China (no. 20120043130001), the China Postdoctoral Science
   Foundation (no. 2014T70270) and the Key Scientific Program of Jilin
   Province (no. 20140101122JC).
CR Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Camidge DR, 2010, CLIN CANCER RES, V16, P1256, DOI 10.1158/1078-0432.CCR-09-1267
   Chae S, 2009, J AGR FOOD CHEM, V57, P5777, DOI 10.1021/jf900331g
   Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8
   Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416
   Cheng HR, 2012, CELL CYCLE, V11, P3312, DOI 10.4161/cc.21670
   Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200
   Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174
   Dolloff NG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001384
   Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Gupta SC, 2011, J BIOL CHEM, V286, P1134, DOI 10.1074/jbc.M110.191379
   Hasegawa H, 1997, ARCH PHARM RES, V20, P539, DOI 10.1007/BF02975208
   Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936
   Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416
   Hou W, 2008, AUTOPHAGY, V4, P940, DOI 10.4161/auto.6769
   Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200
   Kannappan R, 2010, MOL CANCER THER, V9, P2196, DOI 10.1158/1535-7163.MCT-10-0277
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim AD, 2010, ENVIRON TOXICOL PHAR, V30, P134, DOI 10.1016/j.etap.2010.04.008
   Kim H, 2006, CANCER RES, V66, P1740, DOI 10.1158/0008-5472.CAN-05-1568
   Kim HK, 2013, J GINSENG RES, V37, P451, DOI 10.5142/jgr.2013.37.451
   Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200
   Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236
   Lee IK, 2010, INT J MOL SCI, V11, P4916, DOI 10.3390/ijms11124916
   Lee JC, 2011, EUR J PHARMACOL, V670, P96, DOI 10.1016/j.ejphar.2011.08.006
   Lee JY, 2013, MOL CANCER THER, V12, P274, DOI 10.1158/1535-7163.MCT-12-0054
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950
   Prasad S, 2011, CANCER RES, V71, P538, DOI 10.1158/0008-5472.CAN-10-3121
   Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096
   Sheikh MS, 1998, CANCER RES, V58, P1593
   Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tian XB, 2011, J BIOL CHEM, V286, P29408, DOI 10.1074/jbc.M110.197665
   Trivedi R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00069
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141
   Yodkeeree S, 2009, CANCER RES, V69, P6581, DOI 10.1158/0008-5472.CAN-09-1161
   Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693
   Yuan BZ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-140
NR 46
TC 60
Z9 63
U1 7
U2 40
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2016
VL 7
AR e2334
DI 10.1038/cddis.2016.234
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DU2YP
UT WOS:000382077800013
PM 27512955
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Mohamed, A
   Ayman, A
   Deniece, J
   Wang, TT
   Kovach, C
   Siddiqui, MT
   Cohen, C
AF Mohamed, Amr
   Ayman, Alkhoder
   Deniece, Johnson
   Wang, Tengteng
   Kovach, Charles
   Siddiqui, Momin T.
   Cohen, Cynthia
TI P62/Ubiquitin IHC expression correla ec with clinicopathologic
   parameters and outcome in gastrointestinal carcinomas
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE P62; ubiquitin; immunohistochemical expression; GI carcinoma
ID E3 UBIQUITIN LIGASES; BINDING PROTEIN P62; CANCER; PATHWAY
AB P62 and ubiquitin are small regulatory proteins demonstrated to have implications in the prognosis and survival of various malignancies including: hepatocellular, breast, ovarian, and some gastrointestinal carcinomas. Several trials studied the link of their activity to the extrinsic apoptosis pathway and showed that their autophagy modification has a critical stand point in tumorigenesis.These findings explain their vital role in controlling the process of cell death and survival. It has been shown recently that p62 and ubiquitin overexpression in different types of cancers, such as triple negative breast and ovarian cancers, have directly correlated with incidence of distant metastases. We aim to evaluate p62/ubiquitin expression in gastrointestinal carcinomas of gastric, colonic, and pancreatic origin, and correlate with annotated clinicopathologic data. In gastric carcinoma (61), positive p62 nuclear expression was noted in 57% and cytoplasmic in 61%, while positive ubiquitin was nuclear expressed in 68.8%, and cytoplasmic in 29.5%. In colon carcinoma (45), positive p62 nuclear expression was noted in 29% and cytoplasmic in 71%, while positive ubiquitin was nuclear in 58% and cytoplasmic in 44%. In pancreatic cancer (18), positive p62 nuclear expression was noted in 78% and cytoplasmic in 56%, while positive ubiquitin was nuclear in 83% and cytoplasmic in 72%. Normal gastric (6), colon (4), and pancreatic (4) tissues were negative for both P62 and ubiquitin (nuclear and cytoplasmic staining <20%). Ubiquitin high expression was associated with more lymph node metastases in colon (4.14 vs 1.70, P=0.04), and pancreatic adenocarcinomas (3.07 vs 0.33, P= 0.03). Also, ubiquitin high expression was associated with worse pancreatic adenocarcinoma overall survival (1.37 vs 2.26 mos, P= 0.04). In addition, gastric cancer patients with high p62 expression tend to have more poorly differentiated grade when compared to those with low expression (21 vs 17, P= 0.04) but less lymph node metastases (2.77 vs 5.73, P=0.01). P62 and ubiquitin expression did not correlate with other clinicopathologic parameters in gastric, colon or pancreatic denocarcinomas. The results suggest that p62 and ubiquitin are highly expressed in gastric, colonic, and pancreatic carcinomas. High ubiquitin expression was noted to have an impact on number of lymph node metastases in patients with colon and pancreatic adenocarcinomas, but on overall survival only in patients with pancreatic adenocarcinoma. Also, P62 high expression is correlated with poor differentiation, but less lymph node metastases, in gastric carcinoma.
C1 [Mohamed, Amr; Ayman, Alkhoder; Kovach, Charles; Siddiqui, Momin T.; Cohen, Cynthia] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Mohamed, Amr; Deniece, Johnson] Morehouse Sch Med, Dept Med, Atlanta, GA 30310 USA.
   [Wang, Tengteng] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
RP Mohamed, A (corresponding author), 1371 Keys Crossing Dr NE, Atlanta, GA 30391 USA.
EM amohamed@msm.edu
OI Siddiqui, Momin/0000-0002-1812-8729
CR Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19
   Casiano CA, 2006, MOL CELL PROTEOMICS, V5, P1745, DOI 10.1074/mcp.R600010-MCP200
   Chen C, 2006, MOL CANCER RES, V4, P695, DOI 10.1158/1541-7786.MCR-06-0182
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Genini D, 2008, PPAR RES, V2008, DOI 10.1155/2008/195065
   GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11
   Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Lu ML, 2001, AM J PATHOL, V159, P945, DOI 10.1016/S0002-9440(10)61770-1
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376
   Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101
NR 16
TC 27
Z9 28
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 30
PY 2015
VL 5
AR 70
DI 10.1158/1541-7786.MCR-06-0182; 10.3389/fonc.2015.00070
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CO3UD
UT WOS:000359084600001
PM 25870850
DA 2022-04-25
ER

PT J
AU Robertson, H
   Dinkova-Kostova, AT
   Hayes, JD
AF Robertson, Holly
   Dinkova-Kostova, Albena T.
   Hayes, John D.
TI NRF2 and the Ambiguous Consequences of Its Activation during Initiation
   and the Subsequent Stages of Tumourigenesis
SO CANCERS
LA English
DT Review
DE NRF2; KEAP1; Cullin 3; ATF4; oxidative stress; reactive oxygen species;
   antioxidant; adaptation; glutathione; thioredoxin; NADPH generation;
   pentose phosphate pathway; proteasome; autophagy; drug metabolism;
   chemoprevention; chemotherapy; bioactivation; quinone-containing drugs;
   drug resistance; oncogene; tumour suppressor; initiation; progression;
   metastasis; recurrent disease; lung; oesophagus; liver; head and neck;
   stomach; bladder; colon; rectum
ID GLUTATHIONE-S-TRANSFERASE; TRANSCRIPTION FACTOR NRF2; COMPREHENSIVE
   MOLECULAR CHARACTERIZATION; INDUCED LUNG CARCINOGENESIS; HIGH
   CATALYTIC-ACTIVITY; CUL3-BASED E3 LIGASE; ALDO-KETO REDUCTASES;
   OXIDATIVE STRESS; NAD(P)H-QUINONE OXIDOREDUCTASE; GENOMIC
   CHARACTERIZATION
AB Simple Summary
   Transcription factor NRF2 controls expression of antioxidant and detoxification genes. Normally, the activity of NRF2 is tightly controlled in the cell, and is continuously adjusted to ensure that cells are protected against endogenous chemicals and environmental agents that perturb the intracellular antioxidant/pro-oxidant balance (i.e., redox) that must be maintained for them to grow and survive in an appropriate manner. This tight control of NRF2 is achieved by a repressor protein called KEAP1 that perpetually targets NRF2 protein for degradation under normal conditions, but is unable to do so when challenged with oxidants or thiol-reactive chemicals. In the context of cancer, it is well known that drugs that stimulate short-term and reversible activation of NRF2 can provide protection for a limited period against exposure to chemicals that cause cancer. However, it is also becoming widely recognised that permanent hyper-activation of NRF2 resulting from somatic mutations in the gene that encodes NRF2, or in genes associated with its degradation, is frequently observed in certain cancers and associated with poor outcome. In this article, we provide a critical overview of the literature describing the seemingly ambiguous contributions that NRF2 makes to the development of cancer. In particular, we describe the range of genetic and other mechanisms that are responsible for the upregulation of NRF2 in tumours, and highlight shortcomings in our knowledge of how frequently this occurs in different types of cancer. Moreover, we discuss how upregulation of NRF2 might aid the growth and survival of tumours, whether NRF2 upregulation in particular types of cancer is associated with mutations in specific oncogenes, and at what stage of cancer development this is likely to occur. Lastly, we discuss therapeutic strategies that have been proposed that selectively target tumours in which NRF2 is permanently activated with a view to overcoming NRF2-associated drug resistance.
   NF-E2 p45-related factor 2 (NRF2, encoded in the human by NFE2L2) mediates short-term adaptation to thiol-reactive stressors. In normal cells, activation of NRF2 by a thiol-reactive stressor helps prevent, for a limited period of time, the initiation of cancer by chemical carcinogens through induction of genes encoding drug-metabolising enzymes. However, in many tumour types, NRF2 is permanently upregulated. In such cases, its overexpressed target genes support the promotion and progression of cancer by suppressing oxidative stress, because they constitutively increase the capacity to scavenge reactive oxygen species (ROS), and they support cell proliferation by increasing ribonucleotide synthesis, serine biosynthesis and autophagy. Herein, we describe cancer chemoprevention and the discovery of the essential role played by NRF2 in orchestrating protection against chemical carcinogenesis. We similarly describe the discoveries of somatic mutations in NFE2L2 and the gene encoding the principal NRF2 repressor, Kelch-like ECH-associated protein 1 (KEAP1) along with that encoding a component of the E3 ubiquitin-ligase complex Cullin 3 (CUL3), which result in permanent activation of NRF2, and the recognition that such mutations occur frequently in many types of cancer. Notably, mutations in NFE2L2, KEAP1 and CUL3 that cause persistent upregulation of NRF2 often co-exist with mutations that activate KRAS and the PI3K-PKB/Akt pathway, suggesting NRF2 supports growth of tumours in which KRAS or PKB/Akt are hyperactive.
   Besides somatic mutations, NRF2 activation in human tumours can occur by other means, such as alternative splicing that results in a NRF2 protein which lacks the KEAP1-binding domain or overexpression of other KEAP1-binding partners that compete with NRF2. Lastly, as NRF2 upregulation is associated with resistance to cancer chemotherapy and radiotherapy, we describe strategies that might be employed to suppress growth and overcome drug resistance in tumours with overactive NRF2.
C1 [Robertson, Holly; Dinkova-Kostova, Albena T.; Hayes, John D.] Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Cellular Med, Dundee DD1 9SY, Scotland.
   [Robertson, Holly] Wellcome Trust Sanger Inst, Wellcome Genome Campus, Cambridge CB10 1SA, England.
RP Hayes, JD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Cellular Med, Dundee DD1 9SY, Scotland.
EM hr6@sanger.ac.uk; A.DinkovaKostova@dundee.ac.uk; j.d.hayes@dundee.ac.uk
OI Dinkova-Kostova, Albena/0000-0003-0316-9859
FU Medical Research CouncilUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC)European Commission [MR/N009851/1, MR/T014644/1];
   Biotechnology and Biological Sciences Research CouncilUK Research &
   Innovation (UKRI)Biotechnology and Biological Sciences Research Council
   (BBSRC) [BB/L01405X/1]; Cancer Research UKCancer Research UK
   [C20953/A18644]; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [MR/T014644/1, MR/N009851/1] Funding Source: UKRI
FX Our work was supported by the Medical Research Council (MR/N009851/1 and
   MR/T014644/1, awarded to ATD-K and J.D.H.), the Biotechnology and
   Biological Sciences Research Council (Industrial CASE PhD studentship
   BB/L01405X/1, awarded to J.D.H.) and Cancer Research UK (C20953/A18644,
   awarded to ATD-K).
CR Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006
   Agyeman AS, 2012, BREAST CANCER RES TR, V132, P175, DOI 10.1007/s10549-011-1536-9
   Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
   Akdemir B, 2017, MOL CANCER RES, V15, P1570, DOI 10.1158/1541-7786.MCR-17-0232
   Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Anzalone AV, 2020, NAT BIOTECHNOL, V38, P824, DOI 10.1038/s41587-020-0561-9
   Arbour KC, 2018, CLIN CANCER RES, V24, P334, DOI 10.1158/1078-0432.CCR-17-1841
   Badgley MA, 2020, SCIENCE, V368, P85, DOI 10.1126/science.aaw9872
   Baeissa HM, 2016, BIOCHEM SOC T, V44, P925, DOI 10.1042/BST20160001
   Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]
   Baird L, 2021, MOL CELL BIOL, V41, DOI 10.1128/MCB.00473-20
   Baird L, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00377-20
   Baird L, 2013, P NATL ACAD SCI USA, V110, P15259, DOI 10.1073/pnas.1305687110
   Barrera-Rodriguez R, 2018, BIOMED REP, V9, P375, DOI 10.3892/br.2018.1143
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   BEALL HD, 1994, CANCER RES, V54, P3196
   BEALL HD, 1995, MOL PHARMACOL, V48, P499
   Becks L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-540
   BENSON AM, 1979, CANCER RES, V39, P2971
   BENSON AM, 1978, CANCER RES, V38, P4486
   BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216
   Berenblum I, 1935, J PATHOL BACTERIOL, V40, P549, DOI 10.1002/path.1700400312
   Berenblum I, 1931, J PATHOL BACTERIOL, V34, P731, DOI 10.1002/path.1700340604
   Best SA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12164-y
   Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006
   Bollong MJ, 2018, NATURE, V562, P600, DOI 10.1038/s41586-018-0622-0
   Bowman BM, 2020, J PATHOL, V252, P125, DOI 10.1002/path.5504
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   CHA YN, 1978, CANCER RES, V38, P4496
   CHA YN, 1982, CANCER RES, V42, P2609
   Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943
   Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320
   Chang CH, 2014, MOL PHARMACOL, V85, P849, DOI 10.1124/mol.113.090654
   Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
   Chen S, 1997, J BIOL CHEM, V272, P1437, DOI 10.1074/jbc.272.3.1437
   Choi EJ, 2017, ONCOGENE, V36, P5285, DOI 10.1038/onc.2017.153
   Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010
   Chorley BN, 2012, NUCLEIC ACIDS RES, V40, P7416, DOI 10.1093/nar/gks409
   Chung CH, 2015, ANN ONCOL, V26, P1216, DOI 10.1093/annonc/mdv109
   Cloer EW, 2019, CANCER RES, V79, P889, DOI 10.1158/0008-5472.CAN-18-2723
   COLES B, 1985, DRUG METAB REV, V15, P1307, DOI 10.3109/03602538409029962
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Crabtree HG, 1941, CANCER RES, V1, P39
   CRABTREE HG, 1945, CANCER RES, V5, P346
   Crawford DR, 2017, CARCINOGENESIS, V38, P717, DOI 10.1093/carcin/bgx048
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573-018-0008-x
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004
   Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063
   Danson SJ, 2011, ANN ONCOL, V22, P1653, DOI 10.1093/annonc/mdq638
   Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156
   DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421
   Dietlein F, 2020, NAT GENET, V52, P208, DOI 10.1038/s41588-019-0572-y
   Dinkova-Kostova AT, 2006, CANCER LETT, V240, P243, DOI 10.1016/j.canlet.2005.09.012
   Dinkova-Kostova AT, 2010, J BIOL CHEM, V285, P33747, DOI 10.1074/jbc.M110.163485
   Dinkova-Kostova AT, 2010, PHOTOCH PHOTOBIO SCI, V9, P597, DOI 10.1039/b9pp00130a
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   DOCK L, 1984, CARCINOGENESIS, V5, P841, DOI 10.1093/carcin/5.6.841
   Duan FG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2031-1
   Dziunycz PJ, 2014, J INVEST DERMATOL, V134, P1998, DOI 10.1038/jid.2014.77
   ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350
   Escoll M, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101425
   Evans Michael, 2013, Br J Nurs, V22, pS15
   Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099
   Fan Z, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.65
   FARBER E, 1984, CANCER RES, V44, P5463
   Fernandez-Caggiano M, 2016, J BIOL CHEM, V291, P10399, DOI 10.1074/jbc.M115.699850
   Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z
   Fox DB, 2020, NAT METAB, V2, P318, DOI 10.1038/s42255-020-0191-z
   FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668
   Fukutomi T, 2014, MOL CELL BIOL, V34, P832, DOI 10.1128/MCB.01191-13
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gagliardi M, 2020, CELL CYCLE, V19, P2411, DOI 10.1080/15384101.2020.1806426
   Gamcsik MP, 2012, BIOMARKERS, V17, P671, DOI 10.3109/1354750X.2012.715672
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gills JJ, 2006, CANCER LETT, V236, P72, DOI 10.1016/j.canlet.2005.05.007
   Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017
   Goldstein LD, 2016, CELL REP, V16, P2605, DOI 10.1016/j.celrep.2016.08.010
   Gong ML, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00568-z
   Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549
   GRANTHAM PH, 1973, FOOD COSMET TOXICOL, V11, P209, DOI 10.1016/S0015-6264(73)80487-0
   Guengerich FP, 2001, CHEM RES TOXICOL, V14, P727, DOI 10.1021/tx010005p
   Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo WC, 2005, CANCER RES, V65, P10006, DOI 10.1158/0008-5472.CAN-05-2029
   Guo WC, 2006, MOL PHARMACOL, V70, P1194, DOI 10.1124/mol.106.025643
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hanada N, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-66
   Haque E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155378
   Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019
   Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042
   Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655
   Hayashi M, 2020, CANCER RES, V80, P3331, DOI 10.1158/0008-5472.CAN-19-2888
   Hayashi M, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aba0443
   HAYES JD, 1991, BIOCHEM J, V279, P385, DOI 10.1042/bj2790385
   HAYES JD, 1992, BIOCHEM J, V285, P173, DOI 10.1042/bj2850173
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   HAYES JD, 1993, CANCER RES, V53, P3887
   Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033
   Hayes JD, 1998, CHEM-BIOL INTERACT, V112, P51, DOI 10.1016/S0009-2797(97)00151-8
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Hayes JD, 2017, CANCER CELL, V32, P539, DOI 10.1016/j.ccell.2017.10.009
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   He F, 2020, J HEPATOL, V72, P1182, DOI 10.1016/j.jhep.2020.01.023
   Hensing T, 2014, ADV EXP MED BIOL, V799, P85, DOI 10.1007/978-1-4614-8778-4_5
   Hiebert P, 2018, DEV CELL, V46, P145, DOI 10.1016/j.devcel.2018.06.012
   Higgins LG, 2009, TOXICOL APPL PHARM, V237, P267, DOI 10.1016/j.taap.2009.03.005
   Hourihan JM, 2013, ANTIOXID REDOX SIGN, V19, P465, DOI 10.1089/ars.2012.4944
   Huang XM, 2012, CANCER RES, V72, P3038, DOI 10.1158/0008-5472.CAN-11-3135
   Hwang B, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0071-8
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184
   Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jarvis RM, 2012, FREE RADICAL BIO MED, V53, P1522, DOI 10.1016/j.freeradbiomed.2012.08.001
   Jessen C, 2020, ONCOGENE, V39, P6841, DOI 10.1038/s41388-020-01477-8
   Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124
   Jiang H, 2018, CANCER LETT, V438, P154, DOI 10.1016/j.canlet.2018.09.004
   Jin Y, 2007, ANNU REV PHARMACOL, V47, P263, DOI 10.1146/annurev.pharmtox.47.120505.105337
   Johnson WW, 1997, BIOCHEMISTRY-US, V36, P3056, DOI 10.1021/bi962537o
   JUDAH DJ, 1993, BIOCHEM J, V292, P13, DOI 10.1042/bj2920013
   Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149
   Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575
   Kasala ER, 2016, PHARMACOL REP, V68, P310, DOI 10.1016/j.pharep.2015.08.014
   KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581
   Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005
   Kawasaki Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1008-4
   Kelly VP, 2000, CANCER RES, V60, P957
   KENSLER TW, 1986, CANCER RES, V46, P3924
   KENSLER TW, 1987, CANCER RES, V47, P4271
   Kim J, 2015, CLIN CANCER RES, V21, P4514, DOI 10.1158/1078-0432.CCR-14-1215
   Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805
   Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653
   Kitano Y, 2018, J PATHOL, V244, P346, DOI 10.1002/path.5021
   Kitson RRA, 2013, NAT CHEM, V5, P307, DOI [10.1038/NCHEM.1596, 10.1038/nchem.1596]
   Knox RJ, 2000, CANCER RES, V60, P4179
   KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4661, DOI 10.1016/0006-2952(88)90335-8
   KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4671, DOI 10.1016/0006-2952(88)90336-X
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006
   Kombairaju Ponvijay, 2012, J Carcinog, V11, P8, DOI 10.4103/1477-3163.98459
   Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006
   Kudo Y, 2020, CANCER CELL, V38, P247, DOI 10.1016/j.ccell.2020.05.018
   Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200
   Lan AX, 2016, ONCOTARGET, V7, P53502, DOI 10.18632/oncotarget.10609
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   LeBoeuf SE, 2020, CELL METAB, V31, P339, DOI 10.1016/j.cmet.2019.11.012
   Lee K, 2020, CANCERS, V12, DOI 10.3390/cancers12082128
   Lee S, 2012, FREE RADICAL BIO MED, V53, P807, DOI 10.1016/j.freeradbiomed.2012.05.038
   Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z
   LEVIN W, 1976, P NATL ACAD SCI USA, V73, P3867, DOI 10.1073/pnas.73.11.3867
   Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106
   Li R, 2018, CELL PHYSIOL BIOCHEM, V49, P1717, DOI 10.1159/000493615
   Li T, 2020, CANCER SCI, V111, P1156, DOI 10.1111/cas.14321
   Li XC, 2004, J BIOL CHEM, V279, P54750, DOI 10.1074/jbc.M410073200
   Lim PJ, 2019, NAT METAB, V1, P519, DOI 10.1038/s42255-019-0063-6
   Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935
   Liu J, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/305861
   Liu M, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150092
   Liu PF, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000620
   Liu Y, 2019, JNCI-J NATL CANCER I, V111, P1033, DOI 10.1093/jnci/djy230
   Liu OG, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00166-2
   Long M, 2015, CANCER PREV RES, V8, P444, DOI 10.1158/1940-6207.CAPR-14-0359
   Lu BC, 2016, ONCOL LETT, V12, P4333, DOI 10.3892/ol.2016.5269
   Luo L, 2018, FREE RADICAL BIO MED, V115, P361, DOI 10.1016/j.freeradbiomed.2017.12.010
   Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212
   Martin-Hurtado A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50356-0
   Martinez VD, 2015, HEAD NECK-J SCI SPEC, V37, P727, DOI 10.1002/hed.23663
   Maruyama A, 2008, ARCH BIOCHEM BIOPHYS, V477, P139, DOI 10.1016/j.abb.2008.06.004
   McMahon M, 2001, CANCER RES, V61, P3299
   McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200
   McMahon M, 2010, P NATL ACAD SCI USA, V107, P18838, DOI 10.1073/pnas.1007387107
   McMahon M, 2006, J BIOL CHEM, V281, P24756, DOI 10.1074/jbc.M601119200
   MEECHAN RJ, 1953, CANCER RES, V13, P802
   MILLER EC, 1966, PHARMACOL REV, V18, P805
   MILLER EC, 1958, CANCER RES, V18, P469
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Miyamoto N, 2011, INVEST OPHTH VIS SCI, V52, P1226, DOI 10.1167/iovs.10-5775
   MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nabeshima T, 2020, AM J PHYSIOL-GASTR L, V318, pG419, DOI 10.1152/ajpgi.00296.2019
   Nadal E, 2019, J THORAC ONCOL, V14, P1881, DOI 10.1016/j.jtho.2019.08.005
   Namani A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3907-z
   NEWBERNE PM, 1969, CANCER RES, V29, P236
   Ngo HKC, 2017, CANCER RES, V77, P4797, DOI 10.1158/0008-5472.CAN-16-3538
   O'Cathail SM, 2020, CANCER GENET-NY, V248, P1, DOI 10.1016/j.cancergen.2020.08.006
   Ohkoshi A, 2013, CANCER PREV RES, V6, P149, DOI 10.1158/1940-6207.CAPR-12-0401-T
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185
   Okazaki K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19593-0
   Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024
   Orru C, 2020, CANCERS, V12, DOI 10.3390/cancers12082305
   Orru C, 2018, J HEPATOL, V69, P635, DOI 10.1016/j.jhep.2018.05.010
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Parkinson EI, 2015, ACCOUNTS CHEM RES, V48, P2715, DOI 10.1021/acs.accounts.5b00365
   Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005
   PEARSON WR, 1983, J BIOL CHEM, V258, P2052
   PEARSON WR, 1988, J BIOL CHEM, V263, P13324
   Penning TM, 2014, CHEM RES TOXICOL, V27, P1901, DOI 10.1021/tx500298n
   Perez S, 2017, FREE RADICAL BIO MED, V104, P75, DOI 10.1016/j.freeradbiomed.2016.12.048
   Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033
   Petrelli A, 2014, HEPATOLOGY, V59, P228, DOI 10.1002/hep.26616
   Phillips RM, 2019, CANCER CHEMOTH PHARM, V83, P1183, DOI 10.1007/s00280-019-03812-7
   Pink JJ, 2000, J BIOL CHEM, V275, P5416, DOI 10.1074/jbc.275.8.5416
   Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186
   Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726
   Polonen P, 2019, ONCOGENE, V38, P7473, DOI 10.1038/s41388-019-0956-6
   PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965
   PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281
   PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232
   Raghunath A, 2018, CANCERS, V10, DOI 10.3390/cancers10120481
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108
   Reszka E, 2014, J CANCER RES CLIN, V140, P1723, DOI 10.1007/s00432-014-1733-0
   RICHARDSON HL, 1952, CANCER RES, V12, P356
   Richters A, 2020, WORLD J UROL, V38, P1895, DOI 10.1007/s00345-019-02984-4
   Rolfs F, 2015, CANCER RES, V75, P4817, DOI 10.1158/0008-5472.CAN-15-0614
   Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220
   Sasaki H, 2013, ONCOL LETT, V6, P719, DOI 10.3892/ol.2013.1427
   Sasaki Y, 2016, WORLD J GASTROENTERO, V22, P2284, DOI 10.3748/wjg.v22.i7.2284
   Satoh H, 2016, CANCER RES, V76, P3088, DOI 10.1158/0008-5472.CAN-15-1584
   Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499
   Sayin VI, 2017, ELIFE, V6, DOI 10.7554/eLife.28083
   Schafer M, 2014, EMBO MOL MED, V6, P442, DOI 10.1002/emmm.201303281
   Scheffler M, 2015, ONCOTARGET, V6, P1315, DOI 10.18632/oncotarget.2834
   Seo DC, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-75
   Shaw AT, 2011, P NATL ACAD SCI USA, V108, P8773, DOI 10.1073/pnas.1105941108
   Shen T, 2015, ANTIOXID REDOX SIGN, V23, P651, DOI 10.1089/ars.2014.6074
   Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105
   Shibata T, 2011, NEOPLASIA, V13, P864, DOI 10.1593/neo.11750
   Shin SM, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/763257
   SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019
   Siegel D, 1998, CLIN CANCER RES, V4, P2065
   SIEGEL D, 1990, CANCER RES, V50, P7483
   Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651
   Slocum SL, 2011, ARCH TOXICOL, V85, P273, DOI 10.1007/s00204-011-0675-4
   Sobotta MC, 2015, NAT CHEM BIOL, V11, P64, DOI 10.1038/nchembio.1695
   Song SJ, 2020, MOL CANCER RES, V18, P1777, DOI 10.1158/1541-7786.MCR-20-0082
   Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176
   Soriano FX, 2009, MOL CELLS, V27, P279, DOI 10.1007/s10059-009-0050-y
   SPARNINS VL, 1982, J NATL CANCER I, V68, P493
   SPARNINS VL, 1982, CANCER RES, V42, P1205
   SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711
   Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430
   Starcher CL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01575
   Stocker S, 2018, NAT CHEM BIOL, V14, P148, DOI 10.1038/nchembio.2536
   Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251
   Suzuki T, 2019, CELL REP, V28, P746, DOI 10.1016/j.celrep.2019.06.047
   Taguchi K, 2016, TOXICOL SCI, V152, P40, DOI 10.1093/toxsci/kfw065
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Taguchi K, 2010, MOL CELL BIOL, V30, P3016, DOI 10.1128/MCB.01591-09
   Taheri Z, 2020, REP BIOCHEM MOL BIOL, V9, P33, DOI 10.29252/rbmb.9.1.33
   Takahashi N, 2018, CANCER CELL, V33, P985, DOI 10.1016/j.ccell.2018.05.001
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261
   Tang XM, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0314-y
   Tang XW, 2011, FREE RADICAL BIO MED, V50, P1599, DOI 10.1016/j.freeradbiomed.2011.03.008
   Tao SS, 2018, MOL CARCINOGEN, V57, P182, DOI 10.1002/mc.22745
   Tarantini S, 2018, J GERONTOL A-BIOL, V73, P853, DOI 10.1093/gerona/glx177
   Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021
   TEW KD, 1994, CANCER RES, V54, P4313
   THAKKER DR, 1976, P NATL ACAD SCI USA, V73, P3381, DOI 10.1073/pnas.73.10.3381
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006
   Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07
   Torrente L, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101365
   Towers CG, 2019, DEV CELL, V50, P690, DOI 10.1016/j.devcel.2019.07.010
   Tsuchida K, 2017, FREE RADICAL BIO MED, V103, P236, DOI 10.1016/j.freeradbiomed.2016.12.041
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   ULLAND BM, 1973, FOOD COSMET TOXICOL, V11, P199, DOI 10.1016/S0015-6264(73)80486-9
   Vartanian S, 2016, MOL CELL PROTEOMICS, V15, P1220, DOI 10.1074/mcp.M115.055509
   Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Wakabayashi N, 2015, FREE RADICAL BIO MED, V88, P158, DOI 10.1016/j.freeradbiomed.2015.05.017
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104
   WATTENBE.LW, 1966, CANCER RES, V26, P1520
   WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379
   WATTENBERG LW, 1978, CANCER RES, V38, P1410
   WATTENBERG LW, 1974, JNCI-J NATL CANCER I, V52, P1583, DOI 10.1093/jnci/52.5.1583
   WATTENBERG LW, 1970, CANCER RES, V30, P1922
   WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425
   WATTENBERG LW, 1968, CANCER RES, V28, P934
   WATTENBERG LW, 1985, CANCER RES, V45, P1
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Williams GM, 1999, FOOD CHEM TOXICOL, V37, P1027, DOI 10.1016/S0278-6915(99)00085-X
   Wimuttisuk W, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-28
   Wu KC, 2011, TOXICOL SCI, V123, P590, DOI 10.1093/toxsci/kfr183
   Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yang F, 2019, EMBO J, V38, DOI 10.15252/embj.2019101964
   Yang QL, 2020, FREE RADICAL RES, V54, P790, DOI 10.1080/10715762.2019.1642472
   Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516
   Yu S, 2018, ANTI-CANCER AGENT ME, V18, P388, DOI 10.2174/1871520617666171103112019
   Zavattari P, 2015, HEPATOLOGY, V62, P851, DOI 10.1002/hep.27790
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zhang D, 2018, ANTIOXID REDOX SIGN, V29, P1535, DOI 10.1089/ars.2017.7201
   Zhang DD, 2020, NAT PROD REP, V37, P797, DOI 10.1039/c9np00061e
   Zhang JZ, 2018, THORAC CANCER, V9, P726, DOI 10.1111/1759-7714.12640
   ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147
   Zhong Y, 2013, MOL CARCINOGEN, V52, P824, DOI 10.1002/mc.21921
   Zuo J, 2020, THORAC CANCER, V11, P738, DOI 10.1111/1759-7714.13326
NR 318
TC 14
Z9 14
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC
PY 2020
VL 12
IS 12
AR 3609
DI 10.3390/cancers12123609
PG 48
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PJ6TO
UT WOS:000601897600001
PM 33276631
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Asghari, MH
   Ghobadi, E
   Moloudizargari, M
   Fallah, M
   Abdollahi, M
AF Asghari, Mohammad Hossein
   Ghobadi, Emad
   Moloudizargari, Milad
   Fallah, Marjan
   Abdollahi, Mohammad
TI Does the use of melatonin overcome drug resistance in cancer
   chemotherapy?
SO LIFE SCIENCES
LA English
DT Review
DE Cancer; Chemotherapy; Drug resistance; Melatonin
ID HUMAN HEPATOCELLULAR-CARCINOMA; NIGHT-SHIFT WORK; ENDOPLASMIC-RETICULUM
   STRESS; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; MULTIDRUG-RESISTANCE;
   ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; OXIDATIVE STRESS;
   COLORECTAL-CANCER
AB Our knowledge regarding the implications of melatonin in the therapy of numerous medical conditions, including cancer is constantly expanding. Melatonin can variably affect cancer pathology via targeting several key aspects of any neoplastic condition, including the very onset of carcinogenesis as well as tumor growth, differentiation, and dissemination. Numerous studies have examined the effects of melatonin in the context of various cancers reporting the enhanced efficacy of chemo/radiotherapy in combination with this compound. Reduced sensitivity and also resistance of cancer cells to antineoplastic agents are common events which might arise as a result of genomic instability of the malignant cells. Genetic mutations provide numerous mechanisms for these cells to resist cytotoxic therapies. Melatonin, due to its pleitropic effects, is able to correct these alterations in favour of sensitization to antineoplastic agents as evident by increased response to treatment via modulating the expression and phosphorylation status of drug targets, the reduced clearance of drugs by affecting their metabolism and transport within the body, decreased survival of malignant cells via altering DNA repair and telomerase activity, and enhanced responsiveness to cell death-associated mechanisms such as apoptosis and autophagy. These effects are presumably governed by melatonin's interventions in the main signal transduction pathways such as Akt and MAPK, independent of its antioxidant properties. Possessing such a signaling altering nature, melatonin can considerably affect the drug-resistance mechanisms employed by the malignant cells in breast, lung, hepatic, and colon cancers as well as different types of leukemia which are the subject of the current review.
C1 [Asghari, Mohammad Hossein] Babol Univ Med Sci, Dept Pharmacol, Fac Med, Babol Sar, Iran.
   [Ghobadi, Emad] Univ Tehran Med Sci, Dept Toxicol & Pharmacol, Fac Pharm, Tehran, Iran.
   [Moloudizargari, Milad] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Student Res Comm, Tehran, Iran.
   [Fallah, Marjan] Mazandaran Univ Med Sci, Dept Pharmacol & Toxicol, Student Res Comm, Fac Pharm, Sari, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Toxicol & Dis Grp, Pharmaceut Sci Res Ctr, Tehran, Iran.
RP Abdollahi, M (corresponding author), Univ Tehran Med Sci, Fac Pharm, Tehran 1417614411, Iran.; Abdollahi, M (corresponding author), Univ Tehran Med Sci, Pharmaceut Sci Res Ctr, Tehran 1417614411, Iran.
EM Mohammad@TUMS.Ac.Ir
RI Moloudizargari, Milad/AAC-5979-2019; Abdollahi, Mohammad/B-9232-2008;
   Fallah, Marjan/AAN-5771-2021
OI Moloudizargari, Milad/0000-0002-9125-9944; Abdollahi,
   Mohammad/0000-0003-0123-1209; Fallah, Marjan/0000-0003-0101-5426;
   Asghari, Mohammad Hossein/0000-0003-2981-879X
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Alonso-Gonzalez C, 2015, J PINEAL RES, V58, P189, DOI 10.1111/jpi.12205
   Asghari M.H., 2017, ARCH TOXICOL, P1
   Asghari MH, 2017, LIFE SCI, V185, P38, DOI 10.1016/j.lfs.2017.07.020
   Asghari MH, 2017, J PHARM PHARMACOL, V69, P236, DOI 10.1111/jphp.12682
   Asghari MH, 2017, EXPERT OPIN DRUG MET, V13, P545, DOI 10.1080/17425255.2016.1214712
   Bandyopadhyay D, 2002, J PINEAL RES, V33, P1, DOI 10.1034/j.1600-079X.2002.01107.x
   Barrenetxe J, 2004, J PHYSIOL BIOCHEM, V60, P61, DOI 10.1007/BF03168221
   BARTSCH C, 1985, J PINEAL RES, V2, P121, DOI 10.1111/j.1600-079X.1985.tb00633.x
   Batrakova EV, 2001, BRIT J CANCER, V85, P1987, DOI 10.1054/bjoc.2001.2165
   Blask DE, 1999, BIOL SIGNAL RECEPT, V8, P49
   Bosch TM, 2006, CLIN PHARMACOKINET, V45, P253, DOI 10.2165/00003088-200645030-00003
   Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342
   Brzozowska I, 2014, CURR PHARM DESIGN, V20, P4807
   Callaghan R, 2014, DRUG METAB DISPOS, V42, P623, DOI 10.1124/dmd.113.056176
   Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075
   Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P20
   Carlberg C, 2000, ANN NY ACAD SCI, V917, P387
   Casado-Zapico S, 2011, J PINEAL RES, V50, P345, DOI 10.1111/j.1600-079X.2010.00850.x
   Casado-Zapico S, 2010, J PINEAL RES, V48, P72, DOI 10.1111/j.1600-079X.2009.00727.x
   Cheng YD, 2013, EUR J PHARMACOL, V715, P219, DOI 10.1016/j.ejphar.2013.05.017
   Chuffa LGA, 2016, ENDOCR-RELAT CANCER, V23, P65, DOI 10.1530/ERC-15-0463
   Chuffa LGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081676
   COLEMAN MP, 1992, EUR J CANCER, V28A, P501, DOI 10.1016/S0959-8049(05)80087-5
   Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x
   Dauchy RT, 2014, CANCER RES, V74, P4099, DOI 10.1158/0008-5472.CAN-13-3156
   Davis S, 2001, JNCI-J NATL CANCER I, V93, P1557, DOI 10.1093/jnci/93.20.1557
   Deng WG, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M610579200
   Dolberg OT, 1998, AM J PSYCHIAT, V155, P1119, DOI 10.1176/ajp.155.8.1119
   Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Facciola G, 2001, EUR J CLIN PHARMACOL, V56, P881, DOI 10.1007/s002280000245
   Fan LL, 2010, WORLD J GASTROENTERO, V16, P1473, DOI 10.3748/wjg.v16.i12.1473
   Fan LL, 2013, J PINEAL RES, V55, P184, DOI 10.1111/jpi.12061
   Fan LL, 2013, J PINEAL RES, V55, P174, DOI 10.1111/jpi.12060
   Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006
   Fic M, 2007, IN VIVO, V21, P513
   Fic M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071396
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Futagami M, 2001, GYNECOL ONCOL, V82, P544, DOI 10.1006/gyno.2001.6330
   Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x
   Garcia-Santos G, 2012, BRIT J CANCER, V106, P1288, DOI 10.1038/bjc.2012.66
   Garrido P, 2015, J CELL PHYSIOL, V230, P191, DOI 10.1002/jcp.24698
   Ghobadi E, 2017, EXPERT OPIN DRUG MET, V13, P525, DOI 10.1080/17425255.2017.1277205
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gradinaru D, 2012, TOXICOL LETT, V213, P316, DOI 10.1016/j.toxlet.2012.07.014
   Granzotto M, 2001, J PINEAL RES, V31, P206, DOI 10.1034/j.1600-079X.2001.310303.x
   Hao JJ, 2017, AM J CANCER RES, V7, P13
   Hardeland R, 2009, BIOFACTORS, V35, P183, DOI 10.1002/biof.23
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Holysz H, 2013, TUMOR BIOL, V34, P1371, DOI 10.1007/s13277-013-0757-4
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   HUETHER G, 1993, EXPERIENTIA, V49, P665, DOI 10.1007/BF01923948
   HUETHER G, 1994, ANN NY ACAD SCI, V719, P146, DOI 10.1111/j.1749-6632.1994.tb56826.x
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x
   Jaworek J, 2003, J PINEAL RES, V34, P40, DOI 10.1034/j.1600-079X.2003.02937.x
   Jin X, 2010, EXP MOL MED, V42, P574, DOI 10.3858/emm.2010.42.8.058
   Jung JH, 2013, EVID BASED COMPLEMEN, V2013
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kang S, 2010, BIOCHEM BIOPH RES CO, V396, P731, DOI 10.1016/j.bbrc.2010.05.004
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Keshet GI, 2008, BIOCHEM BIOPH RES CO, V368, P930, DOI 10.1016/j.bbrc.2008.02.022
   Kilic M, 2007, ONCOGENE, V26, P2027, DOI 10.1038/sj.onc.1210008
   Kim JH, 2012, J PINEAL RES, V52, P244, DOI 10.1111/j.1600-079X.2011.00935.x
   Klement GL, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00113
   Kliukiene J, 2001, BRIT J CANCER, V84, P397, DOI 10.1054/bjoc.2000.1617
   Koh W, 2011, J PINEAL RES, V50, P367, DOI 10.1111/j.1600-079X.2010.00852.x
   Korkmaz A, 2009, BREAST CANCER RES TR, V115, P13, DOI 10.1007/s10549-008-0103-5
   Lee Y. C., 2012, GROUP, V10, P7
   Lee YJ, 2014, INT J MOL SCI, V15, P11941, DOI 10.3390/ijms150711941
   Leja-Szpak A, 2010, J PINEAL RES, V49, P248, DOI 10.1111/j.1600-079X.2010.00789.x
   LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060
   Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068
   Lipinska N., 2017, CELL MOL LIFE SCI, P1
   Lippert TH, 2011, INT J MED SCI, V8, P245, DOI 10.7150/ijms.8.245
   Liu B, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0260-7
   Liu TC, 2005, J PINEAL RES, V39, P91, DOI 10.1111/j.1600-079X.2005.00223.x
   Lu JJ, 2016, ONCOTARGET, V7, P2985, DOI 10.18632/oncotarget.6407
   Lu YX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.330
   Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410
   Majidinia M, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12416
   Mamillapalli R, 2008, J BIOL CHEM, V283, P24435, DOI 10.1074/jbc.M801738200
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Mao LL, 2016, J PINEAL RES, V60, P167, DOI 10.1111/jpi.12298
   Martin V, 2013, BRIT J CANCER, V108, P2005, DOI 10.1038/bjc.2013.188
   Martin V, 2010, CANCER LETT, V287, P216, DOI 10.1016/j.canlet.2009.06.016
   Mayo JC, 2005, ENDOCRINE, V27, P169, DOI 10.1385/ENDO:27:2:169
   MEIJER C, 1992, CANCER RES, V52, P6885
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   MOLIS TM, 1993, INT J ONCOL, V3, P687
   Moloudizargari M, 2017, AGEING RES REV, V40, P64, DOI 10.1016/j.arr.2017.09.005
   Moretti RM, 2000, ONCOL REP, V7, P347
   Mozaffari S, 2011, CURR PHARM DESIGN, V17, P4372, DOI 10.2174/138161211798999357
   Mozaffari S, 2010, CURR PHARM DESIGN, V16, P3646, DOI 10.2174/138161210794079254
   Nooshinfar E, 2016, BIOMED PHARMACOTHER, V83, P456, DOI 10.1016/j.biopha.2016.07.004
   Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001
   Panzer A, 1997, J PINEAL RES, V22, P184, DOI 10.1111/j.1600-079X.1997.tb00322.x
   Pechanova O, 2014, INT J MOL SCI, V15, P17920, DOI 10.3390/ijms151017920
   Peres MFP, 2006, EXPERT OPIN INV DRUG, V15, P367, DOI 10.1517/13543784.15.4.367
   POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x
   Prieto-Dominguez N, 2016, J PINEAL RES, V61, P396, DOI 10.1111/jpi.12358
   Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374
   Reiter RJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040843
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Reiter RJ, 2010, CURR NEUROPHARMACOL, V8, P194, DOI 10.2174/157015910792246236
   Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   Rodriguez-Garcia A, 2013, J PINEAL RES, V54, P33, DOI 10.1111/j.1600-079X.2012.01017.x
   Romero A, 2014, J PINEAL RES, V56, P343, DOI 10.1111/jpi.12132
   Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103
   Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004
   Ruiz-Rabelo JF, 2007, J PINEAL RES, V43, P270, DOI 10.1111/j.1600-079X.2007.00472.x
   Salavaty A, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0043-5
   Sanchez-Barcelo EJ, 2010, CURR MED CHEM, V17, P2070, DOI 10.2174/092986710791233689
   Sanchez-Barcelo EJ, 2003, ENDOCR-RELAT CANCER, V10, P153, DOI 10.1677/erc.0.0100153
   Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077
   Schernhammer ES, 2005, J NATL CANCER I, V97, P1084, DOI 10.1093/jnci/dji190
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Shin JS, 2012, PATHOLOGY, V44, P209, DOI 10.1097/PAT.0b013e3283511cd5
   Siu SWF, 2002, PROSTATE, V52, P106, DOI 10.1002/pros.10098
   Srinivasan V, 2008, INTEGR CANCER THER, V7, P189, DOI 10.1177/1534735408322846
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tahan G, 2011, DIGEST DIS SCI, V56, P715, DOI 10.1007/s10620-010-1364-5
   Tamarkin L., 1981, MELATONIN INHIBITION
   Tan DX, 1998, BIOCHEM BIOPH RES CO, V253, P614, DOI 10.1006/bbrc.1998.9826
   Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165
   Tricoire H, 2003, REPRODUCTION, P311
   Ullah MF, 2008, ASIAN PAC J CANCER P, V9, P1
   Um HJ, 2011, J PINEAL RES, V50, P359, DOI 10.1111/j.1600-079X.2010.00851.x
   Viedma-Rodriguez R, 2014, ONCOL REP, V32, P3, DOI 10.3892/or.2014.3190
   Viswanathan AN, 2007, CANCER RES, V67, P10618, DOI 10.1158/0008-5472.CAN-07-2485
   Vriend J, 2016, BBA-REV CANCER, V1865, P176, DOI 10.1016/j.bbcan.2016.02.004
   Wang J, 2013, J NANOMATER, V2013, P4, DOI DOI 10.1016/J.ENZMIC
   Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wei JY, 2015, J PINEAL RES, V58, P429, DOI 10.1111/jpi.12226
   Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x
   WILSON ST, 1992, J CLIN ENDOCR METAB, V75, P669, DOI 10.1210/jc.75.2.669
   WURTMAN RJ, 1963, SCIENCE, V142, P1071, DOI 10.1126/science.142.3595.1071
   Xiang SL, 2015, J PINEAL RES, V59, P60, DOI 10.1111/jpi.12239
   Yamamori T, 2010, NUCLEIC ACIDS RES, V38, P832, DOI 10.1093/nar/gkp1039
   Yao Yixin, 2014, J Carcinog Mutagen, V5
   Yu X, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12323
   Yun M, 2014, CELL PHYSIOL BIOCHEM, V34, P865, DOI 10.1159/000366305
   Yun SM, 2016, MOL CELL ENDOCRINOL, V422, P64, DOI 10.1016/j.mce.2015.11.016
   Zawilska JB, 2009, PHARMACOL REP, V61, P383, DOI 10.1016/S1734-1140(09)70081-7
   Zha LX, 2012, J PINEAL RES, V52, P322, DOI 10.1111/j.1600-079X.2011.00946.x
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhdanova IV, 2001, J CLIN ENDOCR METAB, V86, P4727, DOI 10.1210/jc.86.10.4727
NR 153
TC 37
Z9 37
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD MAR 1
PY 2018
VL 196
BP 143
EP 155
DI 10.1016/j.lfs.2018.01.024
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FX1YG
UT WOS:000425851500018
PM 29374563
DA 2022-04-25
ER

PT J
AU Kim, DH
   Shin, EA
   Kim, B
   Shim, BS
   Kim, SH
AF Kim, Dong Hee
   Shin, Eun Ah
   Kim, Bonglee
   Shim, Bum Sang
   Kim, Sung-Hoon
TI Reactive oxygen species-mediated phosphorylation of p38 signaling is
   critically involved in apoptotic effect of Tanshinone I in colon cancer
   cells
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE caspase-3; colon cancer; p38; reactive oxygen species; Tanshinone I
ID MAPK ACTIVATION; ADJUVANT CHEMOTHERAPY; ROS GENERATION; PATHWAY;
   AUTOPHAGY; ROLES; DEATH
AB Though Tanshinone I (Tan I), a phenolic compound from Salvia miltiorrhiza, is known to have anticancer activity in several cancers, its anticancer mechanisms are not fully understood in colon cancer cells. Thus, in the present study, the underlying molecular mechanism of Tan I was explored in HCT116 and HT29 colorectal cancer cells (CRCs). Here, Tan I suppressed viability in HCT116 and HT29 cells in a time- and dose-dependent manner. Also, Tan I increased the number of terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL)-positive cells and sub-G1 population in HCT116 and HT29 cells. Consistently, Tan I cleaved poly (adenosine diphosphate-ribose) polymerase (PARP) and caspase-8, caspase-3, attenuated the expression of Bid and activated tBid as a caspase-8 substrate and activated phosphorylation of p38 MAPK in HCT116and HT29 cells. Of note, Tan I generated reactive oxygen species (ROS) and conversely an ROS scavenger, N-acetyl-(L)-cysteine, reversed ROS production, PARP cleavage, caspase-3 activation, and p38 MAPK phosphorylation induced by Tan I in HCT116 cells. Furthermore, p38 MAPK inhibitor SB203580 reduced cytotoxicity, increase of TUNEL-positive cells, cleavages of PARP and caspase-3 induced by Tan I in HCT116 cells. Overall, our findings for the first time suggest that ROS-dependent activation of p38 MAPK and caspase-3 is critically involved in Tan I induced apoptosis in CRCs as a potent anticancer agent.
C1 [Kim, Dong Hee; Shin, Eun Ah; Kim, Bonglee; Shim, Bum Sang; Kim, Sung-Hoon] Kyung Hee Univ, Coll Korean Med, Seoul, South Korea.
RP Kim, SH (corresponding author), Kyung Hee Univ, Canc Mol Targeted Herbal Res Ctr, Coll Korean Med, 1 Hoegi Dong, Seoul 02447, South Korea.
EM sungkim7@khu.ac.kr
RI Kim, Bonglee/AAH-9077-2020; Shim, Bum-sang/AAH-9081-2020
OI Kim, Bonglee/0000-0002-8678-156X; kim, sunghoon/0000-0003-2423-1973
FU Cooperative Research Program for Agriculture Science and Technology
   DevelopmentRural Development Administration (RDA) [PJ01317002]; National
   Research Foundation of KoreaNational Research Foundation of Korea
   [2017R1A2A1A17069297]
FX Cooperative Research Program for Agriculture Science and Technology
   Development, Grant/Award Number: PJ01317002; National Research
   Foundation of Korea, Grant/Award Number: 2017R1A2A1A17069297
CR Bonjer HJ, 2005, LANCET ONCOL, V6, P477, DOI 10.1016/S1470-2045(05)70221-7
   Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106
   Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8
   Burz C, 2009, ACTA ONCOL, V48, P811, DOI 10.1080/02841860902974175
   Chang ZQ, 2014, TUMOR BIOL, V35, P753, DOI 10.1007/s13277-013-1102-7
   Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040
   Fang SH, 2011, MOL CELL BIOCHEM, V347, P175, DOI 10.1007/s11010-010-0626-z
   Hua X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09636-w
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jing XP, 2016, CANCER CHEMOTH PHARM, V77, P1171, DOI 10.1007/s00280-016-3034-6
   Kasibhatla S., 2006, COLD SPRING HARBOR P, V2006, DOI [10. 1101/pdb. prot4463, DOI 10.1101/PDB.PR0T4463]
   Kim BM, 2007, BIOCHEM BIOPH RES CO, V363, P745, DOI 10.1016/j.bbrc.2007.09.024
   Kim EJ, 2016, BIOMOL THER, V24, P623, DOI 10.4062/biomolther.2016.023
   Kim HS, 2015, PHARM BIOL, V53, P212, DOI 10.3109/13880209.2014.913297
   Lee DS, 1999, BIOSCI BIOTECH BIOCH, V63, P2236, DOI 10.1271/bbb.63.2236
   Lee WYW, 2009, CANCER LETT, V285, P46, DOI 10.1016/j.canlet.2009.04.040
   Liu B, 2009, CANCER LETT, V275, P54, DOI 10.1016/j.canlet.2008.09.042
   Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097245
   Lu MJ, 2016, INT J ONCOL, V49, P603, DOI 10.3892/ijo.2016.3565
   Martenson JA, 2004, J CLIN ONCOL, V22, P3277, DOI 10.1200/JCO.2004.01.029
   Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165
   Nizamutdinova IT, 2008, INT J ONCOL, V33, P485, DOI 10.3892/ijo_00000031
   Park JH, 2014, NEUROCHEM RES, V39, P1300, DOI 10.1007/s11064-014-1312-4
   Probin V, 2007, FREE RADICAL BIO MED, V42, P1858, DOI 10.1016/j.freeradbiomed.2007.03.020
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Shin EA, 2014, ONCOTARGET, V5, P5624, DOI 10.18632/oncotarget.2152
   Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Weh KM, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-1898
   Woo KS, 2013, EVID-BASED COMPL ALT, V2013, P1
   Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349
   Yamaguchi K, 2017, METHODS MOL BIOL, V1578, P309, DOI 10.1007/978-1-4939-6859-6_26
   Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080464
   Zhang Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep30146
   Zhong YJ, 2017, TOXICON, V137, P106, DOI 10.1016/j.toxicon.2017.07.018
   Zhou L, 2017, INT J IMMUNOPATH PH, V30, P123, DOI 10.1177/0394632017703274
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488
   Zhu YY, 2017, BIOMED PHARMACOTHER, V87, P527, DOI 10.1016/j.biopha.2016.12.095
NR 38
TC 9
Z9 9
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD OCT
PY 2018
VL 32
IS 10
BP 1975
EP 1982
DI 10.1002/ptr.6126
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GW0NW
UT WOS:000446565300010
PM 29876988
DA 2022-04-25
ER

PT J
AU Li, S
   Liu, JY
   Zheng, XJ
   Ren, LW
   Yang, YH
   Li, W
   Fu, WQ
   Wang, JH
   Du, GH
AF Li, Sha
   Liu, Jinyi
   Zheng, Xiangjin
   Ren, Liwen
   Yang, Yihui
   Li, Wan
   Fu, Weiqi
   Wang, Jinhua
   Du, Guanhua
TI Tumorigenic bacteria in colorectal cancer: mechanisms and treatments
SO CANCER BIOLOGY & MEDICINE
LA English
DT Review
DE Colorectal cancer; microbiota; tumorigenic mechanism; genotoxicity;
   cancer pathways; tumor immunity
ID DOUBLE-STRAND BREAKS; FACTOR-KAPPA-B; FUSOBACTERIUM-NUCLEATUM; GENOTOXIN
   COLIBACTIN; COLON TUMORIGENESIS; EPITHELIAL-CELLS; GUT MICROBIOTA;
   UP-REGULATION; EXPRESSION; PROTEIN
AB Colorectal cancer (CRC) is the third most common and the second most fatal cancer. In recent years, more attention has been directed toward the role of gut microbiota in the initiation and development of CRC. Some bacterial species, such as Fusobacterium nucleatum, Escherichia colt, Bacteroides fragilis, Enterococcus faecalis, and Salmonella sp. have been associated with CRC, based upon sequencing studies in CRC patients and functional studies in cell culture and animal models. These bacteria can cause host DNA damage by genotoxic substances, including colibactin secreted by pks + Escherichia coli, B. fragilis toxin (BFT) produced by Bacteroides and typhoid toxin (TT) from Salmonella. These bacteria can also indirectly promote CRC by influencing host-signaling pathways, such as E-cadherin/beta-catenin, TLR4/MYD88/NF-kappa B, and SMO/RAS/p38 MAPK. Moreover, some of these bacteria can contribute to CRC progression by helping tumor cells to evade the immune response by suppressing immune cell function, creating a proinflammatory environment, or influencing the autophagy process. Treatments with the classical antibacterial drugs, metronidazole or erythromycin, the antibacterial active ingredients, M13@ Ag (electrostatically assembled from inorganic silver nanoparticles and the protein capsid of bacteriophage M13), berberine, and zerumbone, were found to inhibit tumorigenic bacteria to different degrees. In this review, we described progress in elucidating the tumorigenic mechanisms of several CRC-associated bacteria, as well as progress in developing effective antibacterial therapies. Specific bacteria have been shown to be active in the oncogenesis and progression of CRC, and some antibacterial compounds have shown therapeutic potential in bacteria-induced CRC. These bacteria may be useful as biomarkers or therapeutic targets for CRC.
C1 [Li, Sha; Liu, Jinyi; Zheng, Xiangjin; Ren, Liwen; Yang, Yihui; Li, Wan; Fu, Weiqi; Wang, Jinhua; Du, Guanhua] State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.
   [Li, Sha; Liu, Jinyi; Zheng, Xiangjin; Ren, Liwen; Yang, Yihui; Li, Wan; Fu, Weiqi; Wang, Jinhua; Du, Guanhua] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Key Lab Drug Target Res & Drug Screen, Beijing 100050, Peoples R China.
RP Wang, JH; Du, GH (corresponding author), State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.; Wang, JH; Du, GH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Key Lab Drug Target Res & Drug Screen, Beijing 100050, Peoples R China.
EM wjh@imm.ac.cn; dugh@imm.ac.cn
FU CAMS Innovation Fund for Medical Sciences [2016-I2M-3-007]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81803584]; Technology Major Projects for "Major New
   Drugs Innovation and Development" [2018ZX09711001005-025,
   2018ZX09711001-012]; Inner Mongolian Natural Science Foundation
   [2018LH08032]
FX This work was supported by the CAMS Innovation Fund for Medical Sciences
   (Grant No. 2016-I2M-3-007), the National Natural Science Foundation of
   China (Grant No. 81803584), the Technology Major Projects for "Major New
   Drugs Innovation and Development" (Grant Nos. 2018ZX09711001005-025 and
   2018ZX09711001-012), and the Inner Mongolian Natural Science Foundation
   (Grant No. 2018LH08032)
CR Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006
   Aleksandrov R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081853
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Bai F, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000169
   Baxter NT, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0290-3
   Boleij A, 2011, CLIN INFECT DIS, V53, P870, DOI 10.1093/cid/cir609
   Bossuet-Greif N, 2018, MBIO, V9, DOI 10.1128/mBio.02393-17
   Bossuet-Greif N, 2016, MOL MICROBIOL, V99, P897, DOI 10.1111/mmi.13272
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buc E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056964
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Chan JL, 2019, MUCOSAL IMMUNOL, V12, P164, DOI 10.1038/s41385-018-0085-5
   Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547
   Chen YY, 2020, THERANOSTICS, V10, P323, DOI 10.7150/thno.38870
   Chowdhury S, 2019, NAT MED, V25, P1057, DOI 10.1038/s41591-019-0498-z
   Chung L, 2018, CELL HOST MICROBE, V23, P203, DOI [10.1016/j.chom.2018.02.004, 10.1016/j.chom.2018.01.007]
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107
   de Almeida CV, 2018, THER ADV GASTROENTER, V11, DOI 10.1177/1756284818783606
   Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648
   Dejea CM, 2014, P NATL ACAD SCI USA, V111, P18321, DOI 10.1073/pnas.1406199111
   Dong X, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1590
   Dower Christopher M, 2018, Autophagy, V14, P1110, DOI 10.1080/15548627.2018.1450020
   Eklof V, 2017, INT J CANCER, V141, P2528, DOI 10.1002/ijc.31011
   Fais T, 2018, TOXINS, V10, DOI 10.3390/toxins10040151
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ganesan K, 2019, CANCERS, V11, DOI 10.3390/cancers11101592
   Gao R, 2017, EUR J CLIN MICROBIOL, V36, P757, DOI 10.1007/s10096-016-2881-8
   Gao ZG, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00020
   Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108
   Guo SH, 2018, CLIN CHEM, V64, P1327, DOI 10.1373/clinchem.2018.289728
   Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010
   Hale VL, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0586-6
   Hamada T, 2019, J PATHOL, V247, P615, DOI 10.1002/path.5236
   Hamada T, 2018, CANCER IMMUNOL RES, V6, P1327, DOI 10.1158/2326-6066.CIR-18-0174
   Hamada T, 2017, J GASTROENTEROL, V52, P265, DOI 10.1007/s00535-016-1272-3
   Hamoya T, 2017, J CLIN BIOCHEM NUTR, V60, P199, DOI 10.3164/jcbn.16-107
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He ZY, 2010, WORLD J GASTROENTERO, V16, P4670, DOI 10.3748/wjg.v16.i37.4670
   Healy AR, 2017, J AM CHEM SOC, V139, P14817, DOI 10.1021/jacs.7b07807
   Healy AR, 2016, J AM CHEM SOC, V138, P15563, DOI 10.1021/jacs.6b10354
   HIBBERD AA, 2017, BMJ OPEN GASTROENTER, V4, DOI DOI 10.1136/BMJGAST-2017-000145
   Hwang S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030857
   Jasemi S, 2020, GUT PATHOG, V12, DOI 10.1186/s13099-020-00366-5
   Kasai C, 2016, ONCOL REP, V35, P325, DOI 10.3892/or.2015.4398
   Kim JM, 2005, EUR J IMMUNOL, V35, P2648, DOI 10.1002/eji.200526321
   Kim JM, 2008, EUR J IMMUNOL, V38, P2190, DOI 10.1002/eji.200838191
   Kitajima S, 2018, CLIN CANCER RES, V24, P1243, DOI 10.1158/1078-0432.CCR-17-3597
   Komiya Y, 2019, GUT, V68, P1335, DOI 10.1136/gutjnl-2018-316661
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Kwong TNY, 2018, GASTROENTEROLOGY, V155, P383, DOI 10.1053/j.gastro.2018.04.028
   Lawrence GW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030924
   Lee SA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00566
   Lee-Six H, 2019, NATURE, V574, P532, DOI 10.1038/s41586-019-1672-7
   Li LY, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00806-z
   Li ZR, 2019, NAT CHEM, V11, P880, DOI 10.1038/s41557-019-0317-7
   Liang QY, 2017, CLIN CANCER RES, V23, P2061, DOI 10.1158/1078-0432.CCR-16-1599
   Liu L, 2018, CLIN GASTROENTEROL H, V16, P1622, DOI 10.1016/j.cgh.2018.04.030
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Ma B, 2019, J CELL MOL MED, V23, P4514, DOI 10.1111/jcmm.14332
   Martin OCB, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13099
   McCarthy AJ, 2015, INFECT IMMUN, V83, P3704, DOI 10.1128/IAI.00716-15
   Mehta RS, 2017, JAMA ONCOL, V3, P921, DOI 10.1001/jamaoncol.2016.6374
   Micenkova L, 2017, INT J MED MICROBIOL, V307, P182, DOI 10.1016/j.ijmm.2017.02.003
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377
   Miyamoto S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040826
   Mughini-Gras L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189721
   Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059
   Ogino S, 2019, ANNU REV PATHOL-MECH, V14, P83, DOI 10.1146/annurev-pathmechdis-012418-012818
   Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031
   Orberg ET, 2017, MUCOSAL IMMUNOL, V10, P421, DOI 10.1038/mi.2016.53
   Payros D, 2014, GUT MICROBES, V5, P313, DOI 10.4161/gmic.28932
   Perillo F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155389
   Pleguezuelos-Manzano C, 2020, NATURE, V580, P269, DOI 10.1038/s41586-020-2080-8
   Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Santaolalla R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063298
   Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610
   Sears CL, 2014, J CLIN INVEST, V124, P4166, DOI 10.1172/JCI72334
   Shang AQ, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0517-1
   Shi CZ, 2016, GUT, V65, P1470, DOI 10.1136/gutjnl-2014-308455
   Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sinha R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152126
   Song JM, 2013, NATURE, V499, P350, DOI 10.1038/nature12377
   Temoin S, 2012, FEBS LETT, V586, P1, DOI 10.1016/j.febslet.2011.10.047
   Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819
   Tomkovich S, 2017, CANCER RES, V77, P2620, DOI 10.1158/0008-5472.CAN-16-3472
   Tsoi H, 2017, GASTROENTEROLOGY, V152, P1419, DOI 10.1053/j.gastro.2017.01.009
   Vizcaino MI, 2015, NAT CHEM, V7, P411, DOI [10.1038/NCHEM.2221, 10.1038/nchem.2221]
   Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478
   Wang JW, 2018, NEOPLASIA, V20, P499, DOI 10.1016/j.neo.2018.03.001
   Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109
   Wang XM, 2007, GASTROENTEROLOGY, V132, P551, DOI 10.1053/j.gastro.2006.11.040
   Wang XM, 2015, GUT, V64, P459, DOI 10.1136/gutjnl-2014-307213
   Wang XM, 2013, CANCER PREV RES, V6, P206, DOI 10.1158/1940-6207.CAPR-12-0350
   Wang XM, 2012, GASTROENTEROLOGY, V142, P543, DOI 10.1053/j.gastro.2011.11.020
   Wang XM, 2008, CANCER RES, V68, P9909, DOI 10.1158/0008-5472.CAN-08-1551
   Warren RL, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-16
   Wick EC, 2014, INFLAMM BOWEL DIS, V20, P821, DOI 10.1097/MIB.0000000000000019
   Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785
   Wong SH, 2017, GUT, V66, P1441, DOI 10.1136/gutjnl-2016-312766
   Wu SG, 2004, INFECT IMMUN, V72, P5832, DOI 10.1128/IAI.72.10.5832-5839.2004
   Wu SG, 1998, P NATL ACAD SCI USA, V95, P14979, DOI 10.1073/pnas.95.25.14979
   Wu SG, 2003, GASTROENTEROLOGY, V124, P392, DOI 10.1053/gast.2003.50047
   Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xie YH, 2017, EBIOMEDICINE, V25, P32, DOI 10.1016/j.ebiom.2017.10.005
   Xue MZ, 2019, SCIENCE, V365, P1000, DOI 10.1126/science.aax2685
   Xue MZ, 2018, BIOCHEMISTRY-US, V57, P6391, DOI 10.1021/acs.biochem.8b01023
   Xue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0389-0
   Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Ye XC, 2017, CANCER PREV RES, V10, P398, DOI 10.1158/1940-6207.CAPR-16-0178
   Ye ZD, 2007, AM J PATHOL, V171, P882, DOI 10.2353/ajpath.2007.070220
   Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zackular JP, 2014, CANCER PREV RES, V7, P1112, DOI 10.1158/1940-6207.CAPR-14-0129
   Zamani S, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00449
   Zeller G, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145645
   Zhang WL, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00930
   Zitvogel L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010473
   Zoller J, 2020, GUT MICROBES, V11, P1790, DOI 10.1080/19490976.2020.1775464
NR 129
TC 1
Z9 1
U1 10
U2 10
PU CHINA ANTI-CANCER ASSOC
PI TIANJIN
PA TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL  TI-YUAN-BEI, HUANHU XI LU,
   HEXIQU, TIANJIN, 300060, PEOPLES R CHINA
SN 2095-3941
J9 CANCER BIOL MED
JI Cancer Biol. Med.
PD FEB
PY 2022
VL 19
IS 2
BP 147
EP 162
DI 10.20892/j.issn.2095-3941.2020.0651
EA SEP 2021
PG 16
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA YR4LH
UT WOS:000729398400001
PM 34586760
OA gold
DA 2022-04-25
ER

PT J
AU Valdes, A
   Artemenko, KA
   Bergquist, J
   Garcia-Canas, V
   Cifuentes, A
AF Valdes, Alberto
   Artemenko, Konstantin A.
   Bergquist, Jonas
   Garcia-Canas, Virginia
   Cifuentes, Alejandro
TI Comprehensive Proteomic Study of the Antiproliferative Activity of a
   Polyphenol-Enriched Rosemary Extract on Colon Cancer Cells Using
   Nanoliquid Chromatography-Orbitrap MS/MS
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE antiproliferative activity; foodomics; colon cancer; dimethyl labeling;
   HT-29 cells; mass spectrometry; quantitative proteomics; rosemary
   extract
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ER-STRESS;
   CARNOSIC ACID; TRANSCRIPTION FACTOR; IN-VITRO; AUTOPHAGY; PATHWAY; P62;
   NRF2
AB In this work, a proteomics strategy based on nanoliquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) using an Orbitrap high-resolution mass spectrometer together with stable isotope dimethyl labeling (DML) is applied to quantitatively examine relative changes in the protein fraction of HT-29 human colon cancer cells treated with different concentrations of a polyphenol-enriched rosemary extract over the time. The major objective of this study was to gain insights into the antiproliferative mechanisms induced by rosemary polyphenols. Using this methodology, 1909 and 698 proteins were identified and quantified in cell extracts. The polyphenol-enriched rosemary extract treatment changed the expression of several proteins in a time- and concentration-dependent manner. Most of the altered proteins are implicated, in the activation of Nrf2 transcription factor and the unfolded protein response. In conclusion, rosemary polyphenols induced proteomic changes that were related to the attenuation of aggresome formation and activation of autophagy to alleviate cellular stress..
C1 [Valdes, Alberto; Garcia-Canas, Virginia; Cifuentes, Alejandro] CSIC, Inst Food Sci Res CIAL, Lab Food, Calle Nicolas Cabrera 9, Madrid 28049, Spain.
   [Artemenko, Konstantin A.; Bergquist, Jonas] Uppsala Univ, Dept Chem BMC, Analyt Chem, Husargatan 3, S-75124 Uppsala, Sweden.
   [Artemenko, Konstantin A.; Bergquist, Jonas] Uppsala Univ, SciLifeLab, Husargatan 3, S-75124 Uppsala, Sweden.
RP Garcia-Canas, V (corresponding author), CSIC, Inst Food Sci Res CIAL, Lab Food, Calle Nicolas Cabrera 9, Madrid 28049, Spain.; Bergquist, J (corresponding author), Uppsala Univ, Dept Chem BMC, Analyt Chem, Husargatan 3, S-75124 Uppsala, Sweden.; Bergquist, J (corresponding author), Uppsala Univ, SciLifeLab, Husargatan 3, S-75124 Uppsala, Sweden.
EM jonas.bergquist@kemi.uu.se; virginia.garcia@csic.es
RI Cifuentes, Alejandro/B-4715-2011; Garcia-Cañas, Virginia/H-4037-2012;
   Valdés, Alberto/C-3454-2019
OI Cifuentes, Alejandro/0000-0002-7464-0217; Garcia-Cañas,
   Virginia/0000-0001-6728-4325; Valdés, Alberto/0000-0002-7901-5816;
   Bergquist, Jonas/0000-0002-4597-041X
FU Ministerio de Economia y Competitividad, SpainSpanish Government
   [AGL2014-53609-P]; Comunidad de MadridComunidad de Madrid
   [S2013/ABI-2728]; Ministerio de Economia y CompetitividadSpanish
   Government [BES-2012-057014]; Swedish Research CouncilSwedish Research
   CouncilEuropean Commission [2011-4423, 2015-4870]
FX This work was supported by the projects AGL2014-53609-P (Ministerio de
   Economia y Competitividad, Spain) and S2013/ABI-2728 (Comunidad de
   Madrid). A.V. thanks the Ministerio de Economia y Competitividad for his
   FPI predoctoral fellowship (BES-2012-057014). The Swedish Research
   Council (2011-4423 and 2015-4870; J.B.) is acknowledged for financial
   support.
CR Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264
   Barni MV, 2012, ONCOL REP, V27, P1041, DOI 10.3892/or.2012.1630
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Boersema PJ, 2009, NAT PROTOC, V4, P484, DOI 10.1038/nprot.2009.21
   Brewer AC, 2013, ANTIOXID REDOX SIGN, V18, P1114, DOI 10.1089/ars.2012.4914
   Bruning A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00047
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Cheng X, 2014, INT J MOL MED, V34, P772, DOI 10.3892/ijmm.2014.1822
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Dodson M, 2015, BIOCHEM J, V469, P347, DOI 10.1042/BJ20150568
   Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041
   Garcia-Canas V, 2012, ANAL CHEM, V84, P10150, DOI 10.1021/ac301680q
   Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x
   Gonzalez-Vallinas M, 2015, NUTR CANCER, V67, P1221, DOI 10.1080/01635581.2015.1082110
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Herrero M, 2010, J CHROMATOGR A, V1217, P2512, DOI 10.1016/j.chroma.2009.11.032
   Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976
   Holmes P., 1999, INT J AROMATHER, V9, P62, DOI [10.1016/S0962-4562(98)80021-0, DOI 10.1016/S0962-4562(98)80021-0]
   Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091
   Ibanez C, 2012, J CHROMATOGR A, V1248, P139, DOI 10.1016/j.chroma.2012.06.008
   Ibarra A, 2011, BRIT J NUTR, V106, P1182, DOI 10.1017/S0007114511001620
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Ishida Y, 2014, HUM CELL, V27, P68, DOI 10.1007/s13577-013-0083-6
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kang JH, 2011, BIOCHEM BIOPH RES CO, V407, P581, DOI 10.1016/j.bbrc.2011.03.067
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Korolchuk VI, 2010, FEBS LETT, V584, P1393, DOI 10.1016/j.febslet.2009.12.047
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lafleur MA, 2013, TOXICOL PATHOL, V41, P235, DOI 10.1177/0192623312470764
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025
   Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934
   Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757
   Moreno S, 2006, FREE RADICAL RES, V40, P223, DOI 10.1080/10715760500473834
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200
   Paine MG, 2005, FEBS LETT, V579, P5029, DOI 10.1016/j.febslet.2005.08.010
   Peng CH, 2007, BIOSCI BIOTECH BIOCH, V71, P2223, DOI 10.1271/bbb.70199
   Petiwala SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089772
   Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200
   Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x
   Shen D, 2011, CELL BIOCHEM BIOPHYS, V60, P173, DOI 10.1007/s12013-010-9138-4
   Shimodaira Y, 2014, BIOCHEM BIOPH RES CO, V445, P524, DOI 10.1016/j.bbrc.2014.02.054
   Sjodin MOD, 2013, J CHROMATOGR B, V928, P83, DOI 10.1016/j.jchromb.2013.03.027
   Sovolyova N, 2014, BIOL CHEM, V395, P1, DOI 10.1515/hsz-2013-0174
   Sui P, 2013, J PROTEOME RES, V12, P2245, DOI 10.1021/pr4001064
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024
   Valdes A, 2015, J FUNCT FOODS, V15, P429, DOI 10.1016/j.jff.2015.03.043
   Valdes A, 2014, ANAL CHEM, V86, P9807, DOI 10.1021/ac502401j
   Valdes A, 2013, GENES NUTR, V8, P43, DOI 10.1007/s12263-012-0311-9
   Valdes A, 2012, ELECTROPHORESIS, V33, P2314, DOI 10.1002/elps.201200133
   Verfaillie Tom, 2010, Int J Cell Biol, V2010, P930509, DOI 10.1155/2010/930509
   Waters Katrina M., 2006, Briefings in Functional Genomics & Proteomics, V5, P261, DOI 10.1093/bfgp/ell019
   Xiang QS, 2015, INT J FOOD SCI NUTR, V66, P76, DOI 10.3109/09637486.2014.953452
   Yao Tso-Pang, 2010, Genes Cancer, V1, P779
   Yeung Y.G., 2010, CURR PROTOC PROTEIN, V16, DOI 10.1002/0471140864.ps1612s59
NR 70
TC 26
Z9 28
U1 2
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD JUN
PY 2016
VL 15
IS 6
BP 1971
EP 1985
DI 10.1021/acs.jproteome.6b00154
PG 15
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DN8HG
UT WOS:000377319200021
PM 27103343
DA 2022-04-25
ER

PT J
AU Kumar, A
   Singh, B
   Sharma, PR
   Bharate, SB
   Saxena, AK
   Mondhe, DM
AF Kumar, Ashok
   Singh, Baljinder
   Sharma, Parduman R.
   Bharate, Sandip B.
   Saxena, Ajit K.
   Mondhe, D. M.
TI A novel microtubule depolymerizing colchicine analogue triggers
   apoptosis and autophagy in HCT-116 colon cancer cells
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE colchicine analogue; cytotoxicity; tubulin; reactive oxygen species;
   apoptosis; autophagy
ID VASCULAR-TARGETING AGENT; DEATH; INDUCTION; DERIVATIVES; PROGRESSION;
   ZD6126
AB Colchicine is a tubulin-binding natural product isolated from Colchicum autumnale. Here we report the in vitro anticancer activity of C-ring modified semi-synthetic derivative of colchicine; N-[(7S)-1,2,3-trimethoxy-9-oxo-10-(4-phenyl-piperidin-1-yl)-5,6,7,9 tetrahydrobenzo[a]heptalen-7-yl]acetamide (4h) on colon cancer HCT-116 cell line. The compound 4h was screened for anti-proliferative activity against different human cancer cell lines and was found to exhibit higher cytotoxicity against colon cancer cell lines HCT-116 and Colo-205 with IC50 of 1 and 0.8M respectively. Cytotoxicity of the compound to the normal fR2 breast epithelial cells and normal HEK293 human embryonic kidney cells was evaluated in concentration and time-dependent manner to estimate its selectivity for cancer cells which showed much better selectivity than that of colchicine. Compound 4h induced cell death in HCT-116 cells by activating apoptosis and autophagy pathways. Autophagy inhibitor 3-MA blocked the production of LC3-II and reduced the cytotoxicity in response to 4h, but did not affect apoptosis, suggesting thereby that these two were independent events. Reactive oxygen species scavenger ascorbic acid pretreatment not only decreased the reactive oxygen species level but also reversed 4h induced cytotoxicity. Treatment with compound 4h depolymerized microtubules and the majority of cells arrested at the G2/M transition. Together, these data suggest that 4h has better selectivity and is a microtubule depolymerizer, which activates dual cell-death machineries, and thus, it could be a potential novel therapeutic agent in cancer therapy. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [Kumar, Ashok; Sharma, Parduman R.; Mondhe, D. M.] Indian Inst Integrat Med, CSIR, Canc Pharmacol Div, Jammu 180001, India.
   [Kumar, Ashok; Singh, Baljinder; Sharma, Parduman R.; Bharate, Sandip B.; Mondhe, D. M.] Indian Inst Integrat Med, CSIR, Acad Sci & Innovat Res AcSIR, Jammu 180001, India.
   [Singh, Baljinder] Indian Inst Integrat Med, CSIR, Nat Prod Chem Div, Jammu 180001, India.
   [Bharate, Sandip B.] Indian Inst Integrat Med, CSIR, Med Chem Div, Jammu 180001, India.
   [Saxena, Ajit K.] Amity Univ, Lucknow, Uttar Pradesh, India.
RP Sharma, PR; Mondhe, DM (corresponding author), Indian Inst Integrat Med, CSIR, Canc Pharmacol Div, Jammu 180001, India.
EM prsharma@iiim.ac.in; dmmondhe@iiim.res.in
RI Bharate, Sandip B/B-7104-2018; Singh, Baljinder/W-6314-2018
OI Singh, Baljinder/0000-0003-2828-5768
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India); CSIRCouncil of Scientific & Industrial
   Research (CSIR) - India
FX We thank our Director Dr. Ram A. Vishwakarma for encouraging us to
   complete this work. Ashok Kumar is thankful to Department of Science and
   Technology, Government of India for INSPIRE fellowship. Baljinder Singh
   thanks the CSIR 12th FYP project for fellowship.
CR Acharya BR, 2009, BIOCHEMISTRY-US, V48, P6963, DOI 10.1021/bi900152k
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Bains M, 2009, METHOD ENZYMOL, V453, P145, DOI 10.1016/S0076-6879(08)04007-X
   Ben-Chetrit E, 1998, SEMIN ARTHRITIS RHEU, V28, P48, DOI 10.1016/S0049-0172(98)80028-0
   Cerquaglia C., 2005, Current Drug Targets - Inflammation and Allergy, V4, P117
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Craig WJ, 1997, J AM DIET ASSOC, V97, pS199, DOI 10.1016/S0002-8223(97)00765-7
   Craig WJ, 1999, AM J CLIN NUTR, V70, p491S, DOI 10.1093/ajcn/70.3.491s
   Davis PD, 2002, CANCER RES, V62, P7247
   Dini L, 2005, TISSUE CELL, V37, P379, DOI 10.1016/j.tice.2005.06.006
   Dubey KK, 2010, PROCESS BIOCHEM, V45, P1036, DOI 10.1016/j.procbio.2010.03.014
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Ferlay J, 2013, GLOBOCAN V1 0 CANC I
   Fournier-Dit-Chabert J, 2012, BIOORG MED CHEM LETT, V22, P7693, DOI 10.1016/j.bmcl.2012.09.104
   Gelmi ML, 1999, J MED CHEM, V42, P5272, DOI 10.1021/jm981134e
   Goto H, 2004, CLIN CANCER RES, V10, P7671, DOI 10.1158/1078-0432.CCR-04-1171
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Kim Sung-Kuk, 2013, Exp Mol Med, V45, pe19, DOI 10.1038/emm.2013.38
   KNYRIM K, 1977, VIRCHOWS ARCH B, V25, P309
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Koppikar SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-210
   Korolchuk VI, 2011, AUTOPHAGY, V7, P927, DOI 10.4161/auto.7.8.15862
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724
   Larocque K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087064
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   LI DH, 1980, CHINESE MED J-PEKING, V93, P188
   Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046
   Lidar M, 2007, NETH J MED, V65, P318
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Pasquier E, 2007, CURR CANCER DRUG TAR, V7, P566, DOI 10.2174/156800907781662266
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6
   RINGEL I, 1988, BIOCHEM PHARMACOL, V37, P2487, DOI 10.1016/0006-2952(88)90380-2
   RINGEL I, 1991, J MED CHEM, V34, P3334, DOI 10.1021/jm00115a026
   Salido M, 2001, CELL BIOL INT, V25, P499, DOI 10.1006/cbir.2000.0763
   Schlesinger N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006190
   Singh B, 2015, ORG BIOMOL CHEM, V13, P5674, DOI 10.1039/c5ob00406c
   Stevenson RP, 2012, J CELL SCI, V125, P1073, DOI 10.1242/jcs.093799
   TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022
   Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233
NR 43
TC 21
Z9 25
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0263-6484
EI 1099-0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD MAR
PY 2016
VL 34
IS 2
BP 69
EP 81
DI 10.1002/cbf.3166
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DF5YI
UT WOS:000371428500003
PM 26919061
DA 2022-04-25
ER

PT J
AU Lee, JW
   Jeong, EG
   Lee, SH
   Yoo, NJ
   Lee, SH
AF Lee, Jong Woo
   Jeong, Eun Goo
   Lee, Sung Hak
   Yoo, Nam Jin
   Lee, Sug Hyung
TI Somatic mutations of BECN1, an autophagy-related gene, in human cancers
SO APMIS
LA English
DT Article
DE BECN1; autophagy; mutation; cancer
ID TUMOR-SUPPRESSOR; INACTIVATING MUTATIONS; BECLIN-1; TUMORIGENESIS;
   APOPTOSIS; PROTEIN; DEATH
AB Evasion of programmed cell death (PCD) is one of the hallmarks of human cancers. It is well known that not only apoptosis, but also autophagy, acts as an action mechanism of PCD. BECN1 protein is a key regulator of autophagic PCD. The BECN1 gene that encodes BECN1 protein acts as a haploinsufficient tumor-suppressor gene. However, to date, data on BECN1 mutation in human cancer tissues are lacking. To explore the possibility that somatic mutation of the BECN1 gene might contribute to the development of human cancers, we analyzed the entire coding region and all splice sites of the human BECN1 gene for detection of somatic mutations in 180 gastric carcinomas, 94 breast carcinomas, 50 acute leukemias, 50 colorectal carcinomas, 50 hepatocellular carcinomas, and 124 non-small cell lung cancers by single-strand conformation polymorphism (SSCP) and DNA sequencing. Overall, we detected 11 somatic mutations of the BECN1 gene, including 3 missense mutations (N8K, P350R and R389C) in coding sequences and 8 mutations in introns. The mutations were observed in five gastric, three colorectal, one lung and one breast carcinoma (s). We expressed the three mutations (N8K, P350R and R389C) in HT1080 cells, and found that two (P350R and R389C) of them showed only slightly decreased cell death activities compared to the wild-type BECN1. This is the first report on BECN1 gene mutations in human cancer tissues, and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis.
C1 Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.
RP Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
EM suhulee@catholic.ac.kr
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   BERG JM, 2002, BIOCHEMISTRY-US, P18
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   KRAWCZAK M, 1992, HUM GENET, V90, P41
   Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145
   Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 22
TC 30
Z9 32
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
J9 APMIS
JI APMIS
PD JUN
PY 2007
VL 115
IS 6
BP 750
EP 756
DI 10.1111/j.1600-0463.2007.apm_640.x
PG 7
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 173ZJ
UT WOS:000246910700009
PM 17550384
DA 2022-04-25
ER

PT J
AU Ma, XK
   Wang, MH
   Zheng, N
   Wang, GY
   Zhuang, JH
   Ye, Y
   Xia, W
AF Ma, Xiaokun
   Wang, Menghan
   Zheng, Ni
   Wang, Guoyu
   Zhuang, Juhua
   Ye, Ying
   Xia, Wei
TI Apatinib inhibits the proliferation of colon cancer cells by
   down-regulating the VEGFR2-PLC-ERK1/2 pathway
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Colon cancer; apatinib; apoptosis; VEGFR2-PLC-ERK1/2 pathway
ID CYCLE ARREST; APOPTOSIS; AUTOPHAGY; TRIAL
AB Objective: To analyze the effect of apatinib on colon cancer cells via the VEGFR2-PLC-ERK1/2 pathway. Methods: Human colon cancer cell line LS174T in the logarithmic phase of growth were treated with apatinib solution at concentrations of 0, 25, 50, and 100 mol/L for 24, 48, and 72 hours, respectively. CCK-8 detected cell proliferation, flow cytometry evaluated the cell apoptosis and cell cycle. Western blot was used to detect the phosphorylation of key enzymes in VEGFR2-PLC-ERK1/2 pathway and expression of related apoptotic proteins. Results: Compared with 0 mol/L, the absorbance of LS174T cells at 25, 50, and 100 mol/L decreased significantly after 24, 48, and 72 h of cell culture (P < 0.05); and the inhibitory effect of apatinib on colon cancer cells was increased in a dose/time-dependent manner. The apoptosis rate of the control group was (6.55 +/- 1.08)% which is significantly different from (12.58 +/- 1.36)% (24 h), (18.85 +/- 1.37)% (48 h) and (25.74 +/- 143)% (72 h) in the 100 mol/L apatinib group (P < 0.05). Apatinib-induced apoptosis exhibited a time-dependent relationship. Compared with the control group, the 100 mol/L apatinib group showed a decrease in S-phase and G2/M-phase cells and an increase in G0/G1-phase cells (P < 0.05), while the expression of pPCL and pERK1/2 proteins in the 100 mol/L apatinib group decreased at 24, 48, and 72 h (P < 0.05). Conclusion: Apatinib can inhibit the proliferation of colon cancer cells and accelerate apoptosis, which was related to the inhibition of phosphorylation of key proteases in the VEGFR2-PLC-ERK1/2 pathway.
C1 [Ma, Xiaokun; Wang, Menghan; Zheng, Ni; Wang, Guoyu; Zhuang, Juhua; Xia, Wei] Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Dept Nucl Med, 358 Datong Rd, Shanghai 200120, Peoples R China.
   [Ye, Ying] Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Cent Lab, 358 Datong Rd, Shanghai 200120, Peoples R China.
RP Xia, W (corresponding author), Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Dept Nucl Med, 358 Datong Rd, Shanghai 200120, Peoples R China.; Ye, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Cent Lab, 358 Datong Rd, Shanghai 200120, Peoples R China.
EM yy49453324@163.com; wxeiia00@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873178, 81904036]; Science and Technology
   Development Fund of Shanghai Pudong New Area [PKJ2017-Y14]; Special Fund
   for Health of Pudong Health and Family Planning Commission of Shanghai
   [PW2018E-02]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 81873178 and No. 81904036), Science and
   Technology Development Fund of Shanghai Pudong New Area (PKJ2017-Y14),
   Special Fund for Health of Pudong Health and Family Planning Commission
   of Shanghai (PW2018E-02), Science and Technology Development Fund of
   Shanghai Pudong New Area (No. PKJ2017-Y14).
CR Chen P, 2006, CANCER RES, V66, P83
   Chen ZC, 2018, ONCOL LETT, V15, P1559, DOI 10.3892/ol.2017.7475
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Deng MM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1421-y
   Gali-Muhtasib HU, 2018, CANCER CHEMOTH PHARM, V81, P627, DOI 10.1007/s00280-017-3515-2
   Huijbers A, 2018, J SURG ONCOL, V117, P1043, DOI 10.1002/jso.24998
   Karthikeyan C, 2018, BIOORG MED CHEM LETT, V28, P2244, DOI 10.1016/j.bmcl.2018.05.045
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Li T, 2017, CHIN J PATHOPHYS, V8, P231
   Liang Shu, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P871
   de las Hazas MCL, 2017, J AGR FOOD CHEM, V65, P6467, DOI 10.1021/acs.jafc.6b04933
   Meng C, 2017, J PRACTICAL MED, V33, P3858
   Meng W, 2018, CHINESE J COMP MED, V28, P96
   Meyerhardt JA, 2006, J CLIN ONCOL, V24, P3535, DOI 10.1200/JCO.2006.06.0863
   Quan MJ, 2018, WORLD LATEST MED INF, V18
   Suenaga M, 2018, ANTICANCER RES, V38, P1741, DOI 10.21873/anticanres.12410
   Sun J, 2017, MOL MED REP, V15, P3485, DOI 10.3892/mmr.2017.6426
   van den Broek Evert, 2018, Oncotarget, V9, P29445, DOI 10.18632/oncotarget.25655
   Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263
   Zhao TF, 2018, IUBMB LIFE, V70, P60, DOI 10.1002/iub.1704
   Zhou K, 2019, ACTA PHARMACOL SIN, V40, P556, DOI 10.1038/s41401-018-0058-y
NR 21
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2020
VL 13
IS 7
BP 5464
EP 5469
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA MW8VH
UT WOS:000557309800104
DA 2022-04-25
ER

PT J
AU Kaluderovic, MR
   Mojic, M
   Gomez-Ruiz, S
   Mijatovic, S
   Maksimovic-Ivanic, D
AF Kaluderovic, Milena R.
   Mojic, Marija
   Gomez-Ruiz, Santiago
   Mijatovic, Sanja
   Maksimovic-Ivanic, Danijela
TI Anticancer Activity of Organogallium(III) Complexes in Colon Cancer
   Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Apoptosis; autophagy; cell division; cisplatin; cytotoxic activity;
   organogallium(III) complexes
ID GALLIUM(III) COMPLEXES; INSIGHT; DEATH
AB In vitro antitumor activity of various organogallium(III) complexes (1-8) has been tested against CT26CL25, HCT116, SW480 colon cancer cell lines. CV and MTT assays were used to assess on the antiproliferative effect of investigated organogallium(III) complexes. From the investigated complexes, the most active was found to be tetranuclear compound 8 against CT26CL25 cells. Flow cytometric analysis of the CT26CL25 cells upon the treatment with 8 was performed in order to determine the role of apoptosis, caspase activation, autophagy and proliferation rate on the cell death caused with this compound. Results indicate cytotoxic potential of the tetranuclear complex 8 by inducing caspase independent apoptosis and blocking most of the cells before first division.
C1 [Kaluderovic, Milena R.] Univ Hosp Leipzig, Dept Oral Maxillary Facial & Reconstruct Plast Su, D-04103 Leipzig, Germany.
   [Mojic, Marija; Mijatovic, Sanja; Maksimovic-Ivanic, Danijela] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Bulevar Despota Stefana 142, Belgrade 11060, Serbia.
   [Gomez-Ruiz, Santiago] Univ Rey Juan Carlos, ESCET, Dept Biol & Geol Fis & Quim Inorgan, Calle Tulipan S-N, Mostoles 28933, Madrid, Spain.
RP Kaluderovic, MR (corresponding author), Univ Hosp Leipzig, Dept Oral Maxillary Facial & Reconstruct Plast Su, D-04103 Leipzig, Germany.
EM milena.kaluderovic@medizin.uni-leipzig.de
RI Gómez-Ruiz, Santiago/E-4863-2012; Mojic, Marija/E-8729-2015
OI Gómez-Ruiz, Santiago/0000-0001-9538-8359; Mojic,
   Marija/0000-0002-4906-9880
FU Ministry of Education, Science and Technological Development, Republic
   of Serbia [173013]; Ministerio de Economia y Competitividad, Spain
   [CTQ2012-30762]; Universidad Rey Juan Carlos-Banco de Santander
   (Excellence group QUINANOAP, Convocatoria de ayudas a la Actividad de
   Grupos de Excelencia Investigadora)
FX We gratefully acknowledge financial support from the Ministry of
   Education, Science and Technological Development, Republic of Serbia
   (#173013) and Ministerio de Economia y Competitividad, Spain (Grant no.
   CTQ2012-30762) and of Universidad Rey Juan Carlos-Banco de Santander
   (Excellence group QUINANOAP, Convocatoria de ayudas a la Actividad de
   Grupos de Excelencia Investigadora).
CR Arnesano F, 2009, COORDIN CHEM REV, V253, P2070, DOI 10.1016/j.ccr.2009.01.028
   Bernstein LR, 1998, PHARMACOL REV, V50, P665
   Ceballos-Torres J, 2014, CHEM-EUR J, V20, P10811, DOI 10.1002/chem.201400300
   Chen D, 2007, CANCER RES, V67, P9258, DOI 10.1158/0008-5472.CAN-07-1813
   Chitambar CR, 2007, J PHARMACOL EXP THER, V322, P1228, DOI 10.1124/jpet.107.126342
   Chitambar CR, 2006, MOL CANCER THER, V5, P2834, DOI 10.1158/1535-7163.MCT-06-0285
   Chitambar CR, 2012, FUTURE MED CHEM, V4, P1257, DOI [10.4155/FMC.12.69, 10.4155/fmc.12.69]
   CHITAMBAR CR, 1987, CANCER RES, V47, P3929
   Fischer-Fodor E, 2014, METALLOMICS, V6, P833, DOI 10.1039/c3mt00278k
   Gallego B, 2011, INVEST NEW DRUG, V29, P932, DOI 10.1007/s10637-010-9449-8
   Gomez-Ruiz S., 2012, BIOINORG CHEM APPL, V2012, P14, DOI DOI 10.1155/2012/140284
   Gomez-Ruiz S, 2009, J ORGANOMET CHEM, V694, P2191, DOI 10.1016/j.jorganchem.2009.02.027
   GREEN MA, 1989, NUCL MED BIOL, V16, P435
   Hadjikakou SK, 2009, COORDIN CHEM REV, V253, P235, DOI 10.1016/j.ccr.2007.12.026
   Hambley TW, 2007, DALTON T, P4929, DOI 10.1039/b706075k
   Hartinger CG, 2009, CHEM SOC REV, V38, P391, DOI 10.1039/b707077m
   HIGBY DJ, 1974, CANCER, V33, P1219, DOI 10.1002/1097-0142(197405)33:5<1219::AID-CNCR2820330505>3.0.CO;2-U
   Jakupec MA, 2004, CURR TOP MED CHEM, V4, P1575, DOI 10.2174/1568026043387449
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Kaluderovic GN, 2011, CURR MED CHEM, V18, P4738
   Kaluderovic MR, 2011, J INORG BIOCHEM, V105, P164, DOI 10.1016/j.jinorgbio.2010.10.013
   Kaluderovic MR, 2010, EUR J MED CHEM, V45, P519, DOI 10.1016/j.ejmech.2009.10.038
   Kang WQ, 2005, CARCINOGENESIS, V26, P1129, DOI 10.1093/carcin/bgi045
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Ludwig G, 2014, CHEMMEDCHEM, V9, P1586, DOI 10.1002/cmdc.201300479
   Ludwig G, 2013, DALTON T, V42, P3771, DOI 10.1039/c3dt33064h
   Mijatovic S, 2005, CELL MOL LIFE SCI, V62, P589, DOI 10.1007/s00018-005-4425-8
   NARASIMHAN J, 1992, BIOCHEM PHARMACOL, V44, P2403, DOI 10.1016/0006-2952(92)90686-D
   Ott I, 2007, ARCH PHARM, V340, P117, DOI 10.1002/ardp.200600151
   Pantelic N, 2015, EUR J MED CHEM, V90, P766, DOI 10.1016/j.ejmech.2014.12.019
   Perez-Quintanilla D, 2009, CHEM-EUR J, V15, P5588, DOI 10.1002/chem.200900151
   Strohfeldt K, 2008, CHEM SOC REV, V37, P1174, DOI 10.1039/b707310k
NR 32
TC 8
Z9 8
U1 1
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2016
VL 16
IS 3
BP 359
EP 364
DI 10.2174/1871520615666151007160319
PG 6
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA DI4UG
UT WOS:000373494300008
PM 26443026
DA 2022-04-25
ER

PT J
AU Sousa, ML
   Preto, M
   Vasconcelos, V
   Linder, S
   Urbatzka, R
AF Sousa, Maria Ligia
   Preto, Marco
   Vasconcelos, Vitor
   Linder, Stig
   Urbatzka, Ralph
TI Antiproliferative Effects of the Natural Oxadiazine Nocuolin A Are
   Associated With Impairment of Mitochondrial Oxidative Phosphorylation
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE natural products; cyanobacteria; spheroids; colon cancer; ant-cancer
   drugs; mitochondria; autophagy
ID CONNECTIVITY MAP; TUMOR-CELLS; ANTICARCINOMA ACTIVITY; BRENTUXIMAB
   VEDOTIN; CYANOBACTERIA; MARINE; DRUG; TARGET; EXPRESSION; INHIBITOR
AB Natural products are interesting sources for drug discovery. The natural product oxadiazine Nocuolin A (NocA) was previously isolated from the cyanobacterial strain Nodularia sp. LEGE 06071 and here we examined its cytotoxic effects against different strains of the colon cancer cell line HCT116 and the immortalized epithelial cell line hTERT RPE-1. NocA was cytotoxic against colon cancer cells and immortalized cells under conditions of exponential growth but was only weakly active against non-proliferating immortalized cells. NocA induced apoptosis by mechanism(s) resistant to overexpression of BCL family members. Interestingly, NocA affected viability and induced apoptosis of HCT116 cells grown as multicellular spheroids. Analysis of transcriptome profiles did not match signatures to any known compounds in CMap but indicated stress responses and induction of cell starvation. Evidence for autophagy was observed, and a decrease in various mitochondrial respiration parameter within 1 h of treatment. These results are consistent with previous findings showing that nutritionally compromised cells in spheroids are sensitive to impairment of mitochondrial energy production due to limited metabolic plasticity. We conclude that the antiproliferative effects of NocA are associated with effects on mitochondrial oxidative phosphorylation.
C1 [Sousa, Maria Ligia; Vasconcelos, Vitor] Univ Porto, Fac Sci, Porto, Portugal.
   [Sousa, Maria Ligia; Preto, Marco; Vasconcelos, Vitor; Urbatzka, Ralph] Interdisciplinary Ctr Marine & Environm Res, Porto, Portugal.
   [Linder, Stig] Karolinska Inst, Dept Oncol & Pathol, Canc Ctr Karolinska, Stockholm, Sweden.
   [Linder, Stig] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.
RP Urbatzka, R (corresponding author), Interdisciplinary Ctr Marine & Environm Res, Porto, Portugal.
EM rurbatzka@ciimar.up.pt
RI Sousa, Maria Lígia/AAC-9071-2020; Vasconcelos, Vitor/A-8933-2008;
   Urbatzka, Ralph/G-8907-2013
OI Sousa, Maria Lígia/0000-0003-0012-7493; Vasconcelos,
   Vitor/0000-0003-3585-2417; Urbatzka, Ralph/0000-0001-7476-9195; Correia
   Preto, Marco Aurelio/0000-0002-9697-5579
FU Structured Program of R&D&I INNOVMAR-Innovation and Sustainability in
   the Management and Exploitation of Marine Resources - Northern Regional
   Operational Program (NORTE2020) through the European Regional
   Development Fund (ERDF) [NORTE-01-0145-FEDER-000035]; project
   CYANCAN-Uncovering the cyanobacterial chemical diversity: the search for
   novel anticancer compounds - NORTE 2020, Portugal 2020
   [PTDC/MEDQUI/30944/2017]; European Union through the ERDF; Foundation
   for Science and Technology; FCTPortuguese Foundation for Science and
   TechnologyEuropean Commission [SFRH/BPD/112287/2015,
   SFRH/BD/108314/2015]
FX This research was supported by the Structured Program of R&D&I
   INNOVMAR-Innovation and Sustainability in the Management and
   Exploitation of Marine Resources (reference NORTE-01-0145-FEDER-000035,
   Research Line NOVELMAR), funded by the Northern Regional Operational
   Program (NORTE2020) through the European Regional Development Fund
   (ERDF). The project was additionally supported the project
   CYANCAN-Uncovering the cyanobacterial chemical diversity: the search for
   novel anticancer compounds (reference PTDC/MEDQUI/30944/2017)
   co-financed by NORTE 2020, Portugal 2020, and the European Union through
   the ERDF, and by Foundation for Science and Technology through national
   funds. RU was supported by the FCT postdoc grant SFRH/BPD/112287/2015
   and MS by the FCT PhD grant SFRH/BD/108314/2015.
CR Almeida JR, 2017, SCI REP-UK, V7, DOI 10.1038/srep42424
   Bajaj S, 2015, EUR J MED CHEM, V97, P124, DOI 10.1016/j.ejmech.2015.04.051
   Balaji S, 2013, ALGAL RES, V2, P278, DOI 10.1016/j.algal.2013.03.002
   BERNAL SD, 1983, SCIENCE, V222, P169, DOI 10.1126/science.6623064
   Brito A, 2015, ALGAL RES, V9, P218, DOI 10.1016/j.algal.2015.03.016
   Brnjic S, 2014, ANTIOXID REDOX SIGN, V21, P2271, DOI 10.1089/ars.2013.5322
   Bui HTN, 2007, J NAT PROD, V70, P499, DOI 10.1021/np060324m
   Carbone M, 2011, ORG LETT, V13, P2516, DOI 10.1021/ol200234r
   Carter GT, 2011, NAT PROD REP, V28, P1783, DOI 10.1039/c1np00033k
   Dahms HU, 2006, BIOFOULING, V22, P317, DOI 10.1080/08927010600967261
   de Claro RA, 2012, CLIN CANCER RES, V18, P5845, DOI 10.1158/1078-0432.CCR-12-1803
   Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0
   Eakins J, 2016, TOXICOL IN VITRO, V34, P161, DOI 10.1016/j.tiv.2016.03.016
   Ehrenreich IM, 2005, APPL ENVIRON MICROB, V71, P7401, DOI 10.1128/AEM.71.11.7401-7413.2005
   Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X
   Freitas S, 2016, MAR DRUGS, V14, DOI 10.3390/md14090158
   Freitas S, 2016, TOXICON, V119, P140, DOI 10.1016/j.toxicon.2016.05.016
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hernlund E, 2012, EUR J CANCER, V48, P396, DOI 10.1016/j.ejca.2011.11.013
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   Herrmann R, 2008, J BIOMOL SCREEN, V13, P1, DOI 10.1177/1087057107310442
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   Johansson K, 2017, ANTIOXID REDOX SIGN, V26, P229, DOI 10.1089/ars.2015.6419
   Katz J, 2011, CLIN CANCER RES, V17, P6428, DOI 10.1158/1078-0432.CCR-11-0488
   Kim KW, 2016, CANC DRUG DISCOVERY, P113
   Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9
   Kotai J., 1972, INSTRUCTIONS PREPARA
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Linington RG, 2008, J NAT PROD, V71, P22, DOI 10.1021/np070280x
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mohareb RM, 2011, BIOORGAN MED CHEM, V19, P2707, DOI 10.1016/j.bmc.2011.02.051
   Osswald J, 2007, ENVIRON INT, V33, P1070, DOI 10.1016/j.envint.2007.06.003
   Pitaval A, 2010, J CELL BIOL, V191, P303, DOI 10.1083/jcb.201004003
   Ramos V, 2018, J APPL PHYCOL, V30, P1437, DOI 10.1007/s10811-017-1369-y
   Ribeiro T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188817
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Simmons TL, 2008, J NAT PROD, V71, P1544, DOI 10.1021/np800110e
   Singh RK, 2011, J ANTIBIOT, V64, P401, DOI 10.1038/ja.2011.21
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Sun XC, 1996, CLIN CANCER RES, V2, P1335
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Voracova K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172850
   Wang X, 2016, SCI REP-UK, V6, DOI 10.1038/srep26979
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Wenzel C, 2014, EXP CELL RES, V323, P131, DOI 10.1016/j.yexcr.2014.01.017
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhang XM, 2011, BIOORGAN MED CHEM, V19, P6518, DOI 10.1016/j.bmc.2011.08.013
   Zhang XN, 2015, INT J MOL SCI, V16, P27313, DOI 10.3390/ijms161126020
   Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295
NR 58
TC 6
Z9 6
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 3
PY 2019
VL 9
AR 224
DI 10.3389/fonc.2019.00224
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HR8RP
UT WOS:000463427000001
PM 31001482
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Deng, J
   Wang, Y
   Lei, J
   Lei, W
   Xiong, JP
AF Deng, Jun
   Wang, Yi
   Lei, Jun
   Lei, Wan
   Xiong, Jian Ping
TI Insights into the involvement of noncoding RNAs in 5-fluorouracil drug
   resistance
SO TUMOR BIOLOGY
LA English
DT Review
DE microRNA; long noncoding RNA; 5-fluorouracil; drug resistance
ID COLON-CANCER CELLS; HEPATOCELLULAR-CARCINOMA CELLS; DIHYDROPYRIMIDINE
   DEHYDROGENASE EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA-21
   INDUCES RESISTANCE; HUMAN COLORECTAL-CANCER; HUMAN GASTRIC-CANCER;
   DOWN-REGULATION; THYMIDYLATE SYNTHASE; TUMOR-SUPPRESSOR
AB 5-Fluorouracil is a classic chemotherapeutic drug that is widely used to treat various cancers. However, patients often exhibit primary or acquired drug resistance during treatment with 5-fluorouracil chemotherapy. 5-Fluorouracil resistance is a multifactorial event that involves abnormal enzyme metabolism, transport deregulation, cell cycle disorders, apoptosis resistance, and mismatch repair deficiency. Despite advancements in bioresearch technologies in the past several decades, the molecular mechanisms of 5-fluorouracil resistance have not been completely clarified. Recently, microarray analyses have shown that noncoding RNAs (i.e. microRNAs and long noncoding RNAs) play a vital role in 5-fluorouracil resistance in multiple cancer cell lines. These noncoding RNAs can function as oncogenes or tumor suppressors, contributing to 5-fluorouracil drug resistance. In this review, we discuss the effects of microRNAs on 5-fluorouracil sensitivity via targeting of metabolic enzymes, the cell cycle, apoptosis, autophagy, the epithelial-mesenchymal transition, and cancer stem cells. In particular, we focus on summarizing current knowledge on the molecular mechanisms through which long noncoding RNAs mediate 5-fluorouracil drug resistance. Moreover, we describe the specific microRNAs that may function as markers for prediction of chemotherapeutic response to 5-fluorouracil. This review will help to improve the current understanding of how to reverse 5-fluorouracil resistance and may facilitate the establishment of new strategies for alleviating drug resistance in the future.
C1 [Deng, Jun; Wang, Yi; Lei, Jun; Lei, Wan; Xiong, Jian Ping] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China.
RP Deng, J; Xiong, JP (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China.
EM dengjun19871106@126.com; junjungege@outlook.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81160281, 81441083]; Jiangxi Province Talent
   555 Project; National Natural Science Foundation of Jiangxi Province
   [20152ACB20024, 20151BBG70228]
FX This work was supported by the National Natural Science Foundation of
   China (grant nos 81160281 and 81441083), the Jiangxi Province Talent 555
   Project, and the National Natural Science Foundation of Jiangxi Province
   (grant nos 20152ACB20024 and 20151BBG70228).
CR Amankwatia EB, 2015, BRIT J CANCER, V112, P1480, DOI 10.1038/bjc.2015.125
   Ashkenazi A, 2015, J CLIN INVEST, V125, P487, DOI 10.1172/JCI80420
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bedi U, 2014, ONCOTARGET, V5, P2016, DOI 10.18632/oncotarget.1875
   Besbes S, 2015, ONCOTARGET, V6, P12862, DOI 10.18632/oncotarget.3868
   Boni V, 2010, MOL CANCER THER, V9, P2265, DOI 10.1158/1535-7163.MCT-10-0061
   Chai J, 2015, IUBMB LIFE, V67, P191, DOI 10.1002/iub.1361
   Chen BH, 2013, J CHEMOTHERAPY, V25, P229, DOI 10.1179/1973947813Y.0000000092
   Chen Q, 2013, ASIAN PAC J CANCER P, V14, P7421, DOI 10.7314/APJCP.2013.14.12.7421
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048
   Deng J, 2015, TUMOR BIOL, V36, P6823, DOI 10.1007/s13277-015-3364-8
   Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064
   Devaud N, 2013, FAM CANCER, V12, P301, DOI 10.1007/s10689-013-9633-z
   Di Gesualdo F, 2014, ONCOTARGET, V5, P10976, DOI 10.18632/oncotarget.2770
   Diaz T, 2014, J SURG ONCOL, V109, P676, DOI 10.1002/jso.23572
   Dong L, 2015, TUMOR BIOL, V36, P6973, DOI 10.1007/s13277-015-3415-1
   Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399-0004.2008.01076.x
   Ferracin M, 2015, ONCOTARGET, V6, P14545, DOI 10.18632/oncotarget.3859
   Gotanda K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-369
   Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214
   Han YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-932
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He JX, 2014, CELL BIOCHEM BIOPHYS, V70, P1343, DOI 10.1007/s12013-014-0062-x
   He XD, 2015, ONCOTARGET, V6, P2302, DOI 10.18632/oncotarget.2955
   Hirota T, 2012, LUNG CANCER, V77, P16, DOI 10.1016/j.lungcan.2011.12.018
   Hou N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114779
   Hudson WH, 2014, NAT REV MOL CELL BIO, V15, P749, DOI 10.1038/nrm3884
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Jakob C, 2004, J PATHOL, V204, P562, DOI 10.1002/path.1663
   Jiang JX, 2014, MOL MED REP, V10, P995, DOI 10.3892/mmr.2014.2271
   Jiang LL, 2015, ONCOTARGET, V6, P8286, DOI 10.18632/oncotarget.3221
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kim SA, 2015, ARCH PHARM RES, V38, P239, DOI 10.1007/s12272-014-0528-9
   Kim T, 2015, ONCOTARGET, V6, P18780, DOI 10.18632/oncotarget.3909
   Kjersem JB, 2014, MOL ONCOL, V8, P59, DOI 10.1016/j.molonc.2013.09.001
   Kurokawa K, 2012, J GASTROENTEROL, V47, P883, DOI 10.1007/s00535-012-0547-6
   Lee H, 2014, MOL CELLS, V37, P540, DOI 10.14348/molcells.2014.0151
   Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103
   Li S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0549-0
   Li T, 2015, ONCOL REP, V33, P607, DOI 10.3892/or.2014.3646
   Liao HZ, 2015, ONCOTARGET, V6, P8914, DOI 10.18632/oncotarget.3563
   Liao JM, 2014, J MOL CELL BIOL, V6, P206, DOI 10.1093/jmcb/mju018
   Lin CW, 2015, ONCOTARGET, V6, P8434, DOI 10.18632/oncotarget.3020
   Lin XJ, 2015, LANCET ONCOL, V16, P804, DOI 10.1016/S1470-2045(15)00048-0
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lopes-Rodrigues V, 2014, INT J CANCER, V135, P253, DOI 10.1002/ijc.28500
   Martinez BV, 2015, ONCOTARGET, V6, P19246, DOI 10.18632/oncotarget.4266
   Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104
   Mitsuhashi K, 2015, ONCOTARGET, V6, P22114, DOI 10.18632/oncotarget.4294
   Nandy SB, 2015, ONCOTARGET, V6, P17366, DOI 10.18632/oncotarget.3953
   Nie J, 2012, CARCINOGENESIS, V33, P220, DOI 10.1093/carcin/bgr245
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Noguchi T, 2004, CLIN CANCER RES, V10, P7100, DOI 10.1158/1078-0432.CCR-04-0337
   Offer SM, 2014, MOL CANCER THER, V13, P742, DOI 10.1158/1535-7163.MCT-13-0878
   Patel K, 2012, ONCOTARGET, V3, P678
   Perez-Carbonell L, 2015, BRIT J CANCER, V113, P83, DOI 10.1038/bjc.2015.168
   PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292
   Rhodes LV, 2015, ONCOTARGET, V6, P16638, DOI 10.18632/oncotarget.3184
   Sacconi A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.160
   Shang JL, 2014, J CELL BIOCHEM, V115, P772, DOI 10.1002/jcb.24721
   Shang Y, 2014, ONCOGENE, V33, P3267, DOI 10.1038/onc.2013.297
   Shen WW, 2013, J MOL MED, V91, P989, DOI 10.1007/s00109-013-1037-x
   Shi L, 2015, CELL PHYSIOL BIOCHEM, V35, P2333, DOI 10.1159/000374036
   Shi XF, 2015, TUMOR BIOL, V36, P503, DOI 10.1007/s13277-015-3106-y
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523
   Tang HF, 2014, PHARMAZIE, V69, P287, DOI 10.1691/ph.2014.3849
   Tang J, 2014, BIOCHEM BIOPH RES CO, V447, P210, DOI 10.1016/j.bbrc.2014.03.135
   Tomimaru Y, 2010, BRIT J CANCER, V103, P1617, DOI 10.1038/sj.bjc.6605958
   Tong FY, 2014, DIGEST DIS SCI, V59, P24, DOI 10.1007/s10620-013-2887-3
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Wan LY, 2015, BIOCHEM BIOPH RES CO, V457, P125, DOI 10.1016/j.bbrc.2014.11.039
   Wang BD, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-98
   Wang H, 2014, BRIT J CANCER, V111, P339, DOI 10.1038/bjc.2014.157
   Wang J, 2015, ONCOTARGET, V6, P19456, DOI 10.18632/oncotarget.3318
   Wang LJ, 2015, ONCOTARGET, V6, P5932, DOI 10.18632/oncotarget.3465
   Weirauch U, 2013, NEOPLASIA, V15, P783, DOI 10.1593/neo.13172
   Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030
   Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501
   Xiao J, 2014, INT J CLIN EXP PATHO, V7, P7442
   Xiong Wei, 2015, Asian Pac J Cancer Prev, V16, P3395
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020
   Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451
   Yang XY, 2012, ONCOL REP, V27, P250, DOI 10.3892/or.2011.1472
   Yin J, 2011, PHARMAZIE, V66, P975, DOI 10.1691/ph.2011.1548
   Yin JH, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-71
   Yu X, 2015, ONCOTARGET, V6, P23297, DOI 10.18632/oncotarget.4195
   Yu YJ, 2013, TRANSL ONCOL, V6, P180, DOI 10.1593/tlo.12397
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang PF, 2016, ONCOTARGET, V7, P35284, DOI 10.18632/oncotarget.9169
   Zhang XF, 2015, ONCOTARGET, V6, P4144, DOI 10.18632/oncotarget.2864
   Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252
   Zhang Y, 2015, ONCOTARGET, V6, P6737, DOI 10.18632/oncotarget.3253
   Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110
   Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T
   Zhao Y, 2015, TARGET ONCOL, V10, P535, DOI 10.1007/s11523-015-0360-2
NR 102
TC 22
Z9 24
U1 4
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2017
VL 39
IS 4
AR 697553
DI 10.1177/1010428317697553
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QD
UT WOS:000400268800038
PM 28381160
OA gold
DA 2022-04-25
ER

PT J
AU Zeya, B
   Nafees, S
   Imtiyaz, K
   Uroog, L
   Fakhri, KU
   Rizvi, MMA
AF Zeya, Bushra
   Nafees, Sana
   Imtiyaz, Khalid
   Uroog, Laraib
   Fakhri, Khalid Umar
   Rizvi, M. Moshahid A.
TI Diosmin in combination with naringenin enhances apoptosis in colon
   cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE colon cancer; flavonoids; naringenin; diosmin; apoptosis; inflammatory
   pathway
ID NF-KAPPA-B; INFLAMMATION; ANTIOXIDANT; ACTIVATION; CARCINOMA;
   MECHANISMS; FLAVONOIDS; HALLMARKS; AUTOPHAGY; SYNERGISM
AB Colon cancer is one of the most commonly diagnosed malignancies, which begins as a polyp and grows to become cancer. Diosmin (DS) and naringenin (NR) are naturally occurring flavonoids that exhibit various pharmacological activities. Although several studies have illustrated the effectiveness of these flavonoids as anti-cancerous agents individually, the combinatorial impact of these compounds has not been explored. In the present study, the combined effect of DS and NR (DiNar) in colon cancer cell lines HCT116 and SW480 were assessed by targeting apoptosis and inflammatory pathways. The MTT assay was used to evaluate the effect of DiNar on cell proliferation, while Chou-Talalay analysis was employed to determine the combination index of DS and NR. Moreover, flow cytometry was used to monitor cell cycle arrest and population study. The onset of apoptosis was assessed by DAPI staining, DNA fragmentation, and Annexin V-fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI). The expression levels of apoptotic pathway markers, Bcl-2, Bax, caspase3, caspase8, caspase9 and p53, and inflammatory markers, NF-kappa beta, IKK-alpha and IKK-beta, were assessed using western blotting and reverse transcription-quantitative PCR. These results suggested that DiNar treatment acts synergistically and induces cytotoxicity with a concomitant increase in chromatin condensation, DNA fragmentation and cell cycle arrest in the G0/G1 phase. Annexin V-FITC/PI apoptosis assay also showed increased number of cells undergoing apoptosis in the DiNar treatment group. Furthermore, the expression of apoptosis and inflammatory markers was also more effectively regulated under the DiNar treatment. Thereby, these findings demonstrated that DiNar treatment could be a potential novel chemotherapeutic alternative in colon cancer.
C1 [Zeya, Bushra; Nafees, Sana; Imtiyaz, Khalid; Uroog, Laraib; Fakhri, Khalid Umar; Rizvi, M. Moshahid A.] Jamia Millia Islamia, Genome Biol Lab, Dept Biosci, Ramanujan Block, Delhi 110025, India.
RP Rizvi, MMA (corresponding author), Jamia Millia Islamia, Genome Biol Lab, Dept Biosci, Ramanujan Block, Delhi 110025, India.
EM rizvijmi@gmail.com
CR Ahamad MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110003
   Ahmad, 2014, J BIOL ACTIVE PRODUC, V4, P158, DOI DOI 10.1080/22311866.2014.933084
   American Cancer Society, 2021, COL CANC FACTS FIG
   Arul D, 2013, PATHOL ONCOL RES, V19, P763, DOI 10.1007/s12253-013-9641-1
   Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x
   Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269
   Bleiberg H, 2012, ACTA GASTRO-ENT BELG, V75, P14
   Bodduluru LN, 2016, INT IMMUNOPHARMACOL, V30, P102, DOI 10.1016/j.intimp.2015.11.036
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4
   Huang YY, 2021, J CELL MOL MED, V25, P1480, DOI 10.1111/jcmm.16237
   Jurisicova A, 1996, MOL HUM REPROD, V2, P93, DOI 10.1093/molehr/2.2.93
   Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Key TJ, 2011, BRIT J CANCER, V104, P6, DOI 10.1038/sj.bjc.6606032
   Khan KH, 2014, CRIT REV ONCOL HEMAT, V90, P200, DOI 10.1016/j.critrevonc.2013.12.012
   Khan N, 2019, INT J CANCER, V145, P3022, DOI 10.1002/ijc.32367
   Kojima M, 2004, ANTICANCER RES, V24, P675
   Lakatos PL, 2008, WORLD J GASTROENTERO, V14, P3937, DOI 10.3748/wjg.14.3937
   Lee H, 2014, ANN SURG ONCOL, V21, P1641, DOI 10.1245/s10434-013-3477-5
   Lewinska A, 2017, TOXICOL LETT, V265, P117, DOI 10.1016/j.toxlet.2016.11.018
   Lewinska A, 2015, TOXICOL IN VITRO, V29, P417, DOI 10.1016/j.tiv.2014.12.005
   Liu L, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0243-6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Mills CC, 2018, CANCER RES, V78, P320, DOI 10.1158/0008-5472.CAN-17-2782
   Mir IA, 2015, NUTR CANCER, V67, P27, DOI 10.1080/01635581.2015.976320
   Mishra J, 2013, CRIT REV ONCOL HEMAT, V86, P232, DOI 10.1016/j.critrevonc.2012.09.014
   Morgan D M, 1998, Methods Mol Biol, V79, P179
   Nafees S, 2018, ARCH MED RES, V49, P226, DOI 10.1016/j.arcmed.2018.09.008
   Naso L, 2016, BIOORGAN MED CHEM, V24, P4108, DOI 10.1016/j.bmc.2016.06.053
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Park HJ, 2017, FOOD CHEM TOXICOL, V99, P1, DOI 10.1016/j.fct.2016.11.008
   Park JH, 2008, FOOD CHEM TOXICOL, V46, P3684, DOI 10.1016/j.fct.2008.09.056
   Patel K, 2018, CHIN J INTEGR MED, V24, P551, DOI 10.1007/s11655-014-1960-x
   Ren WY, 2003, MED RES REV, V23, P519, DOI 10.1002/med.10033
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Shi XY, 2021, J CELL MOL MED, V25, P2563, DOI 10.1111/jcmm.16226
   Silambarasan T, 2012, EUR J PHARMACOL, V679, P81, DOI 10.1016/j.ejphar.2011.12.040
   Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Totta P, 2004, IUBMB LIFE, V56, P491, DOI 10.1080/15216540400010792
   Dung TD, 2012, FOOD CHEM, V132, P2065, DOI 10.1016/j.foodchem.2011.11.149
   Verhoeyen ME, 2002, J EXP BOT, V53, P2099, DOI 10.1093/jxb/erf044
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Xu ZX, 2018, TOXICOLOGY, V410, P231, DOI 10.1016/j.tox.2018.08.013
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang N, 2009, CANCER SCI, V100, P2459, DOI 10.1111/j.1349-7006.2009.01340.x
NR 54
TC 0
Z9 0
U1 6
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2022
VL 47
IS 1
AR 4
DI 10.3892/or.2021.8215
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XA0NT
UT WOS:000720355800001
PM 34738632
DA 2022-04-25
ER

PT J
AU Zeng, XH
   Yan, T
   Schupp, JE
   Seo, YJ
   Kinsella, TJ
AF Zeng, Xuehuo
   Yan, Tao
   Schupp, Jane E.
   Seo, Yuji
   Kinsella, Timothy J.
TI DNA mismatch repair initiates 6-thioguanine-induced autophagy through
   p53 activation in human tumor cells
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CANCER-CELLS; COLORECTAL-CANCER; DEATH; DAMAGE; CYTOTOXICITY;
   INSTABILITY; APOPTOSIS; MUTATION; ARREST; SYSTEM
AB Purpose: We investigate the roles of DNA mismatch repair (MMR) and p53 in mediating the induction of autophagy in human tumor cells after exposure to 6-thioguanine (6-TG), a chemotherapy drug recognized by MMR. We also examine how activation of autophagy affects apoptosis (type I cell death) after MMR processing of 6-TG.
   Experimental Design: Using isogenic pairs of MLH1(-)/MLH1(+) human colorectal cancer cells (HCT116) and MSH2(-)/MSH2(+) human endometrial cancer cells (HEC59), we initially measure activation of autophagy for up to 3 days after 6-TG treatment using LC3, a specific marker of autophagy. We then assess the role of p53 in autophagic signaling of 6-TG MMR processing using both pifithrin-alpha cotreatment to chemically inhibit p53 transcription and small hairpin RNA inhibition of p53 expression. Finally, we use Atg5 small hairpin RNA inhibition of autophagy to assess the effect on apoptosis after MMR processing of 6-TG.
   Results: We find that MMR is required for mediating autophagy in response to 6-TG treatment in these human tumor cells. We also show that p53 plays an essential role in signaling from MMR to the autophagic pathway. Finally, our results indicate that 6-TG-induced autophagy inhibits apoptosis after MMR processing of 6-TG.
   Conclusions: These data suggest a novel function of MMR in mediating autophagy after a chemical (6-TG) DNA mismatch damage through p53 activation. The resulting autophagy inhibits apoptosis after MMR processing of 6-TG.
C1 Univ Hosp Cleveland, Dept Radiat Oncol, Case Integrat Canc BiolProgram, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA.
RP Kinsella, TJ (corresponding author), Univ Hosp Cleveland, Dept Radiat Oncol, Case Integrat Canc BiolProgram, Case Comprehens Canc Ctr, LTR6068,11100 Euclid Ave, Cleveland, OH 44106 USA.
EM timothy.kinsella@uhhospitals.org
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA112963, CA050595] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA050595] Funding Source: NIH RePORTER
CR AQUILINA G, 1993, CARCINOGENESIS, V14, P2097, DOI 10.1093/carcin/14.10.2097
   Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052
   Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216
   Clodfelter JE, 2005, NUCLEIC ACIDS RES, V33, P3323, DOI 10.1093/nar/gki646
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011
   Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Jacob S, 2001, CANCER RES, V61, P6555
   Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1
   Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424
   Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077
   Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298
   Paglin S, 2001, CANCER RES, V61, P439
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   UMAR A, 1994, J BIOL CHEM, V269, P14367
   Umar A, 1997, CANCER RES, V57, P3949
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Yan T, 2003, CLIN CANCER RES, V9, P2327
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430
NR 42
TC 60
Z9 64
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2007
VL 13
IS 4
BP 1315
EP 1321
DI 10.1158/1078-0432.CCR-06-1517
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 140JO
UT WOS:000244501100033
PM 17317843
OA Bronze
DA 2022-04-25
ER

PT J
AU Manogaran, P
   Beeraka, NM
   Huang, CY
   Padma, VV
AF Manogaran, Prasath
   Beeraka, Narasimha Murthy
   Huang, Chih-Yang
   Padma, Viswanadha Vijaya
TI Neferine and isoliensinine enhance 'intracellular uptake of cisplatin'
   and induce 'ROS-mediated apoptosis' in colorectal cancer cells - A
   comparative study
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Cisplatin; Neferine; Isoliensinine; Colon cancer HCT-15 cells
ID STRAWBERRY TREE HONEY; NELUMBO-NUCIFERA; SIGNALING PATHWAYS; AUTOPHAGY;
   PROLIFERATION; INHIBITION; ACTIVATION; GENERATION; KINASE
AB Cisplatin (CDDP) is a potent platinum-based chemotherapeutic agent used to treat solid tumors including colorectal cancer via inducing cytotoxicity. CDDP usage is limited due to the chemoresistance and associated adverse effects. A combinatorial regimen of phytochemicals with anticancer activity along with approved anticancer drugs seems to be a hopeful strategy against cancer treatment. Lotus-derived compounds such as neferine and isoliensinine have proven significant chemosensitizing activity in different cancer cells. Present study aims to compare chemosensitizing activity/anticancer potential of neferine/isoliensinine in combinatorial regimen with CDDP. Results documented that neferine/isoliensinine with CDDP augmented 'intracellular uptake of cisplatin' consequently apoptosis in HCT-15 cells exemplified by 'apoptotic morphological changes', 'S phase cell cycle arrest', 'ROS mediated oxidative stress' with the concomitant escalation in intracellular calcium & dissipation of MMP and activation of MAPK/PI3K/AKT pathway'. Furthermore, isoliensinine combination with CDDP exclusively enhanced CDDP uptake and induced more ROS-mediated apoptosis compared to other treatment regimens. Combination regimens induced downregulation of Bcl2 and upregulation of cytochrome c, caspase 3, 9, PARP cleavage indicating apoptosis induction through the intrinsic pathway. Thus, the results of the present study suggest that CDDP combination with neferine/isoliensinine augments the anticancer potential of CDDP in an additive manner and decrease CDDP dose requirement.
C1 [Manogaran, Prasath; Beeraka, Narasimha Murthy; Padma, Viswanadha Vijaya] Bharathiar Univ, Translat Res Lab, Dept Biotechnol, Coimbatore, Tamil Nadu, India.
   [Huang, Chih-Yang; Padma, Viswanadha Vijaya] China Med Univ, Lifu Teaching Bldg 12F,91 Hsueh Shih Rd, Taichung 40402, Taiwan.
RP Padma, VV (corresponding author), Bharathiar Univ, Dept Biotechnol, Coimbatore 641046, Tamil Nadu, India.
EM vvijayapadma@rediffmail.com
RI Manogaran, Prasath/AAX-3974-2020
OI Huang, Chih-Yang/0000-0003-2347-0411; Beeraka,
   Narasimha/0000-0001-6879-7835; Manogaran, Prasath/0000-0001-6105-7818
FU DST-SERB [SB/SO/HS/075/2013]; DST-FISTDepartment of Science & Technology
   (India); UGC-SAPUniversity Grants Commission, India
FX We acknowledge our sincere thanks to DST-SERB (Funding ref. no.
   SB/SO/HS/075/2013) for their financial support to this entire study and
   DST-FIST& UGC-SAP for supporting the Department.
CR Afrin S, 2019, J FUNCT FOODS, V57, P439, DOI 10.1016/j.jff.2019.04.035
   Afrin S, 2019, J FUNCT FOODS, V57, P477, DOI 10.1016/j.jff.2019.04.037
   Afrin S, 2018, FOOD FUNCT, V9, P2158, DOI [10.1039/c8fo00165k, 10.1039/C8FO00165K]
   Afrin S, 2018, FOOD FUNCT, V9, P2145, DOI [10.1039/C8FO00164B, 10.1039/c8fo00164b]
   Allen JT, 2001, RESP RES, V3, DOI 10.1186/rr162
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   CAO JG, 2004, CHINESE GERMAN J CLI, V3, P93
   Chen L, 2008, FREE RADICAL BIO MED, V45, P1035, DOI 10.1016/j.freeradbiomed.2008.07.011
   Eid W, 2017, J CELL BIOCHEM, V118, P3472, DOI 10.1002/jcb.26006
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   He GD, 2016, BIOCHEM BIOPH RES CO, V469, P1075, DOI 10.1016/j.bbrc.2015.12.100
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406
   Kalimuthu S, 2013, INT J MOL SCI, V14, P2334, DOI 10.3390/ijms14022334
   Kesavan A, 2015, EUR J PHARM BIOPHARM, V96, P255, DOI 10.1016/j.ejpb.2015.08.001
   Kilari D, 2016, WORLD J CLIN ONCOL, V7, P106, DOI 10.5306/wjco.v7.i1.106
   Koosha S, 2016, INT J MED SCI, V13, P374, DOI 10.7150/ijms.14485
   Li H, 2017, BIOCHEM BIOPH RES CO, V484, P694, DOI 10.1016/j.bbrc.2017.01.180
   Li QQ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0424-4
   Li W, 2018, FOOD CHEM TOXICOL, V121, P156, DOI 10.1016/j.fct.2018.08.030
   Lu HX, 2006, J IMMUNOL, V177, P1171, DOI 10.4049/jimmunol.177.2.1171
   Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162
   Mukherjee PK, 2009, J PHARM PHARMACOL, V61, P407, DOI 10.1211/jpp/61.04.0001
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003
   Omabe M., 2011, INT J BIOTECHNOL BIO, V7, P229
   Poornima P, 2014, FOOD CHEM TOXICOL, V68, P87, DOI 10.1016/j.fct.2014.03.008
   Poornima P, 2013, FOOD CHEM, V141, P3598, DOI 10.1016/j.foodchem.2013.05.138
   Poornima P, 2013, FOOD CHEM, V136, P659, DOI 10.1016/j.foodchem.2012.07.112
   Riahi-Chebbi I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36808-z
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Selvi SK, 2017, FOOD CHEM TOXICOL, V103, P28, DOI 10.1016/j.fct.2017.02.020
   Shu GW, 2015, J AGR FOOD CHEM, V63, P8793, DOI 10.1021/acs.jafc.5b02993
   Sivalingam KS, 2017, J CELL BIOCHEM, V118, P2865, DOI 10.1002/jcb.25937
   Vallejo M.J., 2017, OXIDATIVE MED CELLUL, V2017
   XIAOJUNHUA, 2005, ACTA PHARM SIN, V40, P105
   Xiong YQ, 2003, ACTA PHARMACOL SIN, V24, P332
   Xu LM, 2016, TUMOR BIOL, V37, P8721, DOI 10.1007/s13277-015-4737-8
   Yang XZ, 2017, J AGR FOOD CHEM, V65, P7168, DOI 10.1021/acs.jafc.7b01964
   Yu ZS, 2016, PHARM BIOL, V54, P2026, DOI 10.3109/13880209.2016.1139601
   Zakraoui O, 2017, MOL CARCINOGEN, V56, P18, DOI 10.1002/mc.22470
   Zhang X, 2015, SCI REP-UK, V5, DOI [10.1038/srep09803, 10.1038/srep09940]
   Zhang XY, 2012, EUR J PHARMACOL, V677, P47, DOI 10.1016/j.ejphar.2011.12.035
   Zhao YL, 2019, FOOD FUNCT, V10, P2729, DOI [10.1039/C8FO02315H, 10.1039/c8fo02315h]
   Zhao YL, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600437
NR 43
TC 9
Z9 9
U1 2
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD OCT
PY 2019
VL 132
AR 110652
DI 10.1016/j.fct.2019.110652
PG 9
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA IW0JB
UT WOS:000484647100002
PM 31255669
DA 2022-04-25
ER

PT S
AU Dudkowska, M
   Staniak, K
   Bojko, A
   Sikora, E
AF Dudkowska, Magdalena
   Staniak, Karolina
   Bojko, Agnieszka
   Sikora, Ewa
BE Gewirtz, DA
   Fisher, PB
TI The role of autophagy in escaping therapy-induced polyploidy/senescence
SO AUTOPHAGY AND SENESCENCE IN CANCER THERAPY
SE Advances in Cancer Research
LA English
DT Review; Book Chapter
ID COLON-CANCER CELLS; CELLULAR SENESCENCE; DOWN-REGULATION; TUMOR-CELLS;
   IONIZING-RADIATION; PRO-SENESCENCE; STEM-LIKE; IN-VITRO; POLYPLOIDY;
   MTOR
AB Autophagy is an evolutionarily conserved process necessary to maintain cell homeostasis in response to various forms of stress such as nutrient deprivation and hypoxia as well as functioning to remove damaged molecules and organelles. The role of autophagy in cancer varies depending on the stage of cancer. Cancer therapeutics can also simultaneously evoke cancer cell senescence and ploidy increase. Both cancer cell senescence and polyploidization are reversible by depolyploidization giving rise to the progeny. Autophagy activation may be indispensable for cancer cell escape from senescence/polyploidy. As cancer cell polyploidy is proposed to be involved in cancer origin, the role of autophagy in polyploidization/depolyploidization of senescent cancer cells seems to be crucial. Accordingly, this review is an attempt to understand the complicated interrelationships between reversible cell senescence/polyploidy and autophagy.
C1 [Dudkowska, Magdalena; Staniak, Karolina; Bojko, Agnieszka; Sikora, Ewa] Polish Acad Sci, Lab Mol Bases Aging, Nencki Inst Expt Biol, Warsaw, Poland.
RP Sikora, E (corresponding author), Polish Acad Sci, Lab Mol Bases Aging, Nencki Inst Expt Biol, Warsaw, Poland.
EM e.sikora@nencki.edu.pl
RI Bojko, Agnieszka/AAH-7914-2020; Staniak, Karolina Anna/AAB-5958-2022
OI Bojko, Agnieszka/0000-0002-8680-3300; Staniak, Karolina
   Anna/0000-0001-8236-4665; Sikora, Ewa/0000-0002-1111-1748
FU National Science CentreNational Science Centre, Poland
   [UMO-2015/17/B/NZ3/03531]
FX This work was supported by the National Science Centre, grant
   UMO-2015/17/B/NZ3/03531 for E.S.
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Ambrosio S, 2020, CANCERS, V12, DOI 10.3390/cancers12071793
   Amend SR, 2019, PROSTATE, V79, P1489, DOI 10.1002/pros.23877
   Aqbi Hussein F, 2018, Oncotarget, V9, P22113, DOI 10.18632/oncotarget.25197
   Bahar E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091558
   Barnard RA, 2016, J PHARMACOL EXP THER, V358, P282, DOI 10.1124/jpet.116.233908
   Belden WJ, 2008, CELL, V134, P212, DOI 10.1016/j.cell.2008.07.010
   Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476
   Bharadwaj D, 2020, CYTOKINE GROWTH F R, V52, P68, DOI 10.1016/j.cytogfr.2019.11.002
   Bialik S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215152
   Bielski CM, 2018, NAT GENET, V50, P1189, DOI 10.1038/s41588-018-0165-1
   Bishop E, 2018, CANCER CHEMOTH PHARM, V82, P913, DOI 10.1007/s00280-018-3669-6
   Bojko A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176084
   Bojko A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121501
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   Campisi J, 2011, SEMIN CANCER BIOL, V21, P354, DOI 10.1016/j.semcancer.2011.09.001
   Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005
   Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918
   Chitikova ZV, 2014, CELL CYCLE, V13, P1424, DOI 10.4161/cc.28402
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Cianfanelli V, 2015, J CELL SCI, V128, P2003, DOI 10.1242/jcs.168153
   Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174
   Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   CORDONCARDO C, 1995, AM J PATHOL, V147, P545
   Costa JR, 2016, ONCOTARGET, V7, P41203, DOI 10.18632/oncotarget.9754
   Coward J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00123
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Das S, 2020, FREE RADICAL BIO MED, V152, P715, DOI 10.1016/j.freeradbiomed.2020.01.015
   Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044
   Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Devitt A, 2011, J LEUKOCYTE BIOL, V90, P447, DOI 10.1189/jlb.0211095
   Dewhurst SM, 2014, CANCER DISCOV, V4, P175, DOI 10.1158/2159-8290.CD-13-0285
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034
   Erenpreisa J, 2017, SENESCENCE PHYSL PAT
   Erenpreisa J, 2012, AUTOPHAGY, V8, P1877, DOI 10.4161/auto.21610
   Erenpreisa J, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-92
   Erenpreisa J, 2011, CELL BIOL INT, V35, P687, DOI 10.1042/CBI20100762
   Flynn Alyssa La Belle, 2019, J Cancer Metastasis Treat, V5, DOI 10.20517/2394-4722.2019.13
   Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053
   Gewirtz DA, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9010012
   Gewirtz DA, 2016, CANCER RES, V76, P5610, DOI 10.1158/0008-5472.CAN-16-0722
   Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005
   Gosselin K, 2009, CANCER RES, V69, P7917, DOI 10.1158/0008-5472.CAN-08-2510
   Grasso D, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00146
   Gui X, 2019, NATURE, V567, P262, DOI 10.1038/s41586-019-1006-9
   Han BA, 2020, AGING-US, V12, P13318, DOI 10.18632/aging.103437
   Harrison SJ, 2012, EPIGENOMICS-UK, V4, P571, DOI [10.2217/EPI.12.52, 10.2217/epi.12.52]
   Ianzini F, 2009, CANCER RES, V69, P2296, DOI 10.1158/0008-5472.CAN-08-3364
   Ikari S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230156
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jakhar R, 2018, MOL CANCER RES, V16, P1625, DOI 10.1158/1541-7786.MCR-18-0024
   Jiang YH, 2020, J MOL CELL CARDIOL, V138, P115, DOI 10.1016/j.yjmcc.2019.11.155
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Kalejs M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-6
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kawabata T, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0166-y
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Kondratskyi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.156
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kucharewicz K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0383-6
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Kwon Y, 2017, MOL CELLS, V40, P607, DOI 10.14348/molcells.2017.0151
   Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71
   Lenain C, 2015, CARCINOGENESIS, V36, P1263, DOI 10.1093/carcin/bgv124
   Li M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122083
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Li ZY, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000288
   Li ZY, 2016, ONCOTARGET, V7, P39705, DOI 10.18632/oncotarget.9451
   Lin HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060516
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu JS, 2020, SEMIN CANCER BIOL, V60, P380, DOI 10.1016/j.semcancer.2019.09.005
   Liu JS, 2018, SEMIN CANCER BIOL, V53, P1, DOI 10.1016/j.semcancer.2018.07.004
   Liu LY, 2009, CELL CYCLE, V8, P1616, DOI 10.4161/cc.8.10.8577
   Liu XW, 2010, PHARMACOL RES, V62, P416, DOI 10.1016/j.phrs.2010.07.002
   Liu ZJ, 2011, BLOOD, V117, P4106, DOI 10.1182/blood-2010-07-293092
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lundberg G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059268
   Luo MS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021163
   Ma DC, 2009, J CELL PHYSIOL, V219, P31, DOI 10.1002/jcp.21647
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428
   Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167
   Mirzayans R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041308
   Mirzayans R, 2018, CANCERS, V10, DOI 10.3390/cancers10040118
   Mirzayans R, 2013, INT J MOL SCI, V14, P22409, DOI 10.3390/ijms141122409
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Morgan MJ, 2018, P NATL ACAD SCI USA, V115, pE8479, DOI 10.1073/pnas.1706526115
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Mosieniak G, 2010, CURR PHARM DESIGN, V16, P734, DOI 10.2174/138161210790883714
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Nakamura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08729-6
   Nakamura S, 2018, MOL CELLS, V41, P65, DOI 10.14348/molcells.2018.2333
   Napolitano G, 2016, J CELL SCI, V129, P2475, DOI 10.1242/jcs.146365
   Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057
   Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407
   Neurohr GE, 2019, CELL, V176, P1083, DOI 10.1016/j.cell.2019.01.018
   Odle RI, 2020, MOL CELL, V77, P228, DOI 10.1016/j.molcel.2019.10.016
   Oku M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800008
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Orr-Weaver TL, 2015, TRENDS GENET, V31, P307, DOI 10.1016/j.tig.2015.03.011
   Ovadya Y, 2014, BIOGERONTOLOGY, V15, P627, DOI 10.1007/s10522-014-9529-9
   Patel NH, 2020, BIOCHEM PHARMACOL, V175, DOI 10.1016/j.bcp.2020.113896
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Prata Larissa G P Langhi, 2018, Semin Immunol, V40, P101275, DOI 10.1016/j.smim.2019.04.003
   Puertollano R, 2018, EMBO J, V37, DOI 10.15252/embj.201798804
   Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Sabath N, 2020, P NATL ACAD SCI USA, V117, P31902, DOI 10.1073/pnas.2018138117
   Sabisz M, 2009, CELL CYCLE, V8, P3208, DOI 10.4161/cc.8.19.9758
   Saleh T, 2020, CANCERS, V12, DOI 10.3390/cancers12040822
   Saleh T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041427
   Salmina K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082779
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Sharma S, 2014, MOL ONCOL, V8, P469, DOI 10.1016/j.molonc.2013.12.014
   Sikora Ewa, 2022, Semin Cancer Biol, V81, P83, DOI 10.1016/j.semcancer.2020.11.015
   Sikora E, 2019, AGEING RES REV, V55, DOI 10.1016/j.arr.2019.100941
   Sikora E, 2016, CURR DRUG TARGETS, V17, P377, DOI 10.2174/1389450116666151019094724
   Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002
   Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011
   Sorokina IV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14901-z
   Sosa MS, 2013, ADV EXP MED BIOL, V734, P73, DOI 10.1007/978-1-4614-1445-2_5
   Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537
   Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Visconti R, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0433-9
   Walen KH, 2005, CELL BIOL INT, V29, P1057, DOI 10.1016/j.cellbi.2005.10.016
   Walen KH, 2004, IN VITRO CELL DEV-AN, V40, P150
   Wang Q, 2013, INT J CANCER, V132, P1505, DOI 10.1002/ijc.27810
   Was H, 2018, CANCER BIOL THER, V19, P63, DOI 10.1080/15384047.2017.1385675
   Was H, 2017, ONCOTARGET, V8, P9303, DOI 10.18632/oncotarget.14066
   White-Gilbertson S, 2020, ADV CANCER RES, V148, P201, DOI 10.1016/bs.acr.2020.03.001
   Wilde L, 2018, BIOCHEM J, V475, P1939, DOI 10.1042/BCJ20170847
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9
   Yang SH, 2011, AUTOPHAGY, V7, P912, DOI 10.4161/auto.7.8.15762
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yim WWY, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0141-7
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96
   Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319
   Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021
   Zheng K, 2019, THERANOSTICS, V9, P104, DOI 10.7150/thno.30308
NR 165
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-230X
EI 2162-5557
BN 978-0-12-824158-5
J9 ADV CANCER RES
JI Adv.Cancer Res.
PY 2021
VL 150
BP 209
EP 247
DI 10.1016/bs.acr.2021.01.004
PG 39
WC Biochemistry & Molecular Biology; Oncology; Cell Biology
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology
GA BS3EB
UT WOS:000709860300006
PM 33858597
DA 2022-04-25
ER

PT J
AU Seiwert, N
   Neitzel, C
   Stroh, S
   Frisan, T
   Audebert, M
   Toulany, M
   Kaina, B
   Fahrer, J
AF Seiwert, Nina
   Neitzel, Carina
   Stroh, Svenja
   Frisan, Teresa
   Audebert, Marc
   Toulany, Mahmoud
   Kaina, Bernd
   Fahrer, Jorg
TI AKT2 suppresses pro-survival autophagy triggered by DNA double-strand
   breaks in colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID CYTOLETHAL DISTENDING TOXIN; MAMMALIAN TARGET; IONIZING-RADIATION;
   DAMAGE RESPONSE; TUMOR-CELLS; APOPTOSIS; P53; RAPAMYCIN; MULTIPLE;
   KINASE
AB DNA double-strand breaks (DSBs) are critical DNA lesions, which threaten genome stability and cell survival. DSBs are directly induced by ionizing radiation (IR) and radiomimetic agents, including the cytolethal distending toxin (CDT). This bacterial genotoxin harbors a unique DNase-I-like endonuclease activity. Here we studied the role of DSBs induced by CDT and IR as a trigger of autophagy, which is a cellular degradation process involved in cell homeostasis, genome protection and cancer. The regulatory mechanisms of DSB-induced autophagy were analyzed, focusing on the ATM-p53-mediated DNA damage response and AKT signaling in colorectal cancer cells. We show that treatment of cells with CDT or IR increased the levels of the autophagy marker LC3B-II. Consistently, an enhanced formation of autophagosomes and a decrease of the autophagy substrate p62 were observed. Both CDT and IR concomitantly suppressed mTOR signaling and stimulated the autophagic flux. DSBs were demonstrated as the primary trigger of autophagy using a DNase I-defective CDT mutant, which neither induced DSBs nor autophagy. Genetic abrogation of p53 and inhibition of ATM signaling impaired the autophagic flux as revealed by LC3B-II accumulation and reduced formation of autophagic vesicles. Blocking of DSB-induced apoptotic cell death by the pan-caspase inhibitor Z-VAD stimulated autophagy. In line with this, pharmacological inhibition of autophagy increased cell death, while ATG5 knockdown did not affect cell death after DSB induction. Interestingly, both IR and CDT caused AKT activation, which repressed DSB-triggered autophagy independent of the cellular DNA-PK status. Further knockdown and pharmacological inhibitor experiments provided evidence that the negative autophagy regulation was largely attributable to AKT2. Finally, we show that upregulation of CDT-induced autophagy upon AKT inhibition resulted in lower apoptosis and increased cell viability. Collectively, the findings demonstrate that DSBs trigger pro-survival autophagy in an ATM-and p53-dependent manner, which is curtailed by AKT2 signaling.
C1 [Seiwert, Nina; Neitzel, Carina; Stroh, Svenja; Kaina, Bernd; Fahrer, Jorg] Univ Med Ctr Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.
   [Frisan, Teresa] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.
   [Audebert, Marc] Univ Toulouse, Toxalim Res Ctr Food Toxicol, INRA UMR1331, ENVT,INP Purpan,UPS, Toulouse 3, France.
   [Toulany, Mahmoud] Univ Tubingen, Div Radiobiol & Mol Environm Res, Dept Radiat Oncol, Tubingen, Germany.
   [Toulany, Mahmoud] German Canc Consortium DKTK, Partnersite Tuebingen, Heidelberg, Germany.
   [Toulany, Mahmoud] German Canc Res Ctr, Heidelberg, Germany.
RP Fahrer, J (corresponding author), Univ Med Ctr Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.
EM fahrer@uni-mainz.de
RI Frisan, Teresa/H-8444-2019; Seiwert, Nina/ABD-2627-2020; AUDEBERT, Marc
   A/C-1153-2008; Kaina, Bernd/AAE-4692-2020
OI Frisan, Teresa/0000-0002-1209-0942; Seiwert, Nina/0000-0003-2169-3670;
   AUDEBERT, Marc A/0000-0001-7898-6912; 
FU University Medical Center Mainz (MAIFOR) [972 8716]; Johannes-Gutenberg
   University Mainz (Stufe I) [973 8807]; German Research Foundation
   (DFG)German Research Foundation (DFG) [FA 1034/3-1, DFG TO 685/2-1]
FX This work was supported by the University Medical Center Mainz (MAIFOR,
   grant no. 972 8716), the Johannes-Gutenberg University Mainz (Stufe I,
   grant no. 973 8807) and the German Research Foundation (DFG-FA 1034/3-1;
   DFG TO 685/2-1). We are grateful to Dr. Bert Vogelstein (John Hopkins
   University, Baltimore, MD, USA), Dr. Eric Hendrickson (University of
   Minnesota, Minneapolis, MN, USA) and Dr. Thomas Brunner (University of
   Konstanz, Konstanz, Germany) for providing cell lines.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030
   Audebert M, 2011, ARCH TOXICOL, V85, P1463, DOI 10.1007/s00204-011-0721-2
   Belluz Del Bel L, 2016, PLOS PATHOG, V12
   Bezine E, 2014, CELLS-BASEL, V3, P592, DOI 10.3390/cells3020592
   Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105
   Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024
   Chaachouay H, 2015, RADIOTHER ONCOL, V116, P409, DOI 10.1016/j.radonc.2015.08.012
   Chen JY, 2008, NUCLEIC ACIDS RES, V36, P3781, DOI 10.1093/nar/gkn302
   Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200
   Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885
   Corre I, 2010, MUTAT RES-REV MUTAT, V704, P61, DOI 10.1016/j.mrrev.2010.01.014
   Correa RJM, 2014, CARCINOGENESIS, V35, P1951, DOI 10.1093/carcin/bgu049
   Cortes-Bratti X, 2001, J BIOL CHEM, V276, P5296, DOI 10.1074/jbc.M008527200
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dorsam B, 2015, ARCH TOXICOL, V89, P1829, DOI 10.1007/s00204-014-1434-0
   Fahrer J, 2014, DNA REPAIR, V18, P31, DOI 10.1016/j.dnarep.2014.03.002
   Fahrer J, 2013, BIOCONJUGATE CHEM, V24, P595, DOI 10.1021/bc300563c
   Fedor Y, 2013, CELL MICROBIOL, V15, P1, DOI 10.1111/cmi.12028
   Frisan T, 2016, BBA-BIOMEMBRANES, V1858, P567, DOI 10.1016/j.bbamem.2015.08.016
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Ge ZM, 2005, INFECT IMMUN, V73, P3559, DOI 10.1128/IAI.73.6.3559-3567.2005
   Goder A, 2015, CARCINOGENESIS, V36, P817, DOI 10.1093/carcin/bgv070
   Graillot V, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00034
   Guerra L, 2005, CELL MICROBIOL, V7, P921, DOI 10.1111/j.1462-5822.2005.00520.x
   Guidi R, 2013, CELL MICROBIOL, V15, P98, DOI 10.1111/cmi.12034
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263
   Hosokawa N, 2006, FEBS LETT, V580, P2623, DOI 10.1016/j.febslet.2006.04.008
   Kaushik S, 2015, NAT MED, V21, P1406, DOI 10.1038/nm.4001
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Lillich M, 2012, BIOCONJUGATE CHEM, V23, P1426, DOI 10.1021/bc300041z
   Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mimmler M, 2016, NUCLEIC ACIDS RES, V44, P10259, DOI 10.1093/nar/gkw791
   Mladenov E, 2016, SEMIN CANCER BIOL, V37-38, P51, DOI 10.1016/j.semcancer.2016.03.003
   Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427
   Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Roukos V, 2014, NAT CELL BIOL, V16, P293, DOI 10.1038/ncb2941
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Thompson LH, 2012, MUTAT RES-REV MUTAT, V751, P158, DOI 10.1016/j.mrrev.2012.06.002
   Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003
   Vessoni AT, 2013, CELL DEATH DIFFER, V20, P1444, DOI 10.1038/cdd.2013.103
   Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200
   White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
NR 62
TC 23
Z9 24
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2017
VL 8
AR e3019
DI 10.1038/cddis.2017.418
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FG1JB
UT WOS:000409550500057
PM 28837154
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Schmukler, E
   Wolfson, E
   Elazar, Z
   Kloog, Y
   Pinkas-Kramarski, R
AF Schmukler, Eran
   Wolfson, Eya
   Elazar, Zvulun
   Kloog, Yoel
   Pinkas-Kramarski, Ronit
TI Continuous treatment with FTS confers resistance to apoptosis and
   affects autophagy
SO PLOS ONE
LA English
DT Article
ID CELL-DEATH; AURORA KINASE; CANCER CELLS; TUMOR-GROWTH; RAS; INHIBITION;
   DEGRADATION; P62/SQSTM1; MECHANISMS; ARREST
AB High percentage of human cancers involves alteration or mutation in Ras proteins, including the most aggressive malignancies, such as lung, colon and pancreatic cancers. FTS (Salirasib) is a farnesylcysteine mimetic, which acts as a functional Ras inhibitor, and was shown to exert anti-tumorigenic effects in vitro and in vivo. Previously, we have demonstrated that short-term treatment with FTS also induces protective autophagy in several cancer cell lines. Drug resistance is frequently observed in cancer cells exposed to prolonged treatment, and is considered a major cause for therapy inefficiency. Therefore, in the present study, we examined the effect of a prolonged treatment with FTS on drug resistance of HCT-116 human colon cancer cells, and the involvement of autophagy in this process. We found that cells grown in the presence of FTS for 6 months have become resistant to FTSinduced cell growth inhibition and cell death. Furthermore, we discovered that the resistant cells exhibit altered autophagy, reduced apoptosis and changes in Ras-related signaling pathways following treatment with FTS. Moreover we found that while FTS induces an apoptosis-related cleavage of p62, the FTS-resistant cells were more resistant to apoptosis and p62 cleavage.
C1 [Schmukler, Eran; Wolfson, Eya; Kloog, Yoel; Pinkas-Kramarski, Ronit] Tel Aviv Univ, Dept Neurobiol, Ramat Aviv, Israel.
   [Elazar, Zvulun] Weizmann Inst Sci, Dept Biol Chem, Rehovot, Israel.
RP Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiol, Ramat Aviv, Israel.
EM lironit@post.tau.ac.il
OI Pinkas-Kramarski, Ronit/0000-0002-1000-369X
FU Israel Science FoundationIsrael Science Foundation [848/12]; Israel
   Cancer Association; Kauffman Prostate Cancer Research Fund
FX This work was supported by the Israel Science Foundation (grant No.
   848/12), the Israel Cancer Association and by the Kauffman Prostate
   Cancer Research Fund.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/fmc.11.121, 10.4155/FMC.11.121]
   Biran A, 2011, INT J CANCER, V128, P691, DOI 10.1002/ijc.25367
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d
   Haklai R, 2008, CANCER CHEMOTH PHARM, V61, P89, DOI 10.1007/s00280-007-0451-6
   Halaschek-Wiener J, 2000, MOL MED, V6, P693, DOI 10.1007/BF03402049
   He W, 2013, AM J TRANSL RES, V5, P359
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Jiang ZH, 2014, ONCOL REP, V31, P1249, DOI 10.3892/or.2014.2986
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200
   Moscat J, 2009, EMBO REP, V10, P804, DOI 10.1038/embor.2009.172
   Norman JM, 2010, AUTOPHAGY, V6, P1042, DOI 10.4161/auto.6.8.13337
   Rotblat B, 2008, METHOD ENZYMOL, V439, P467, DOI 10.1016/S0076-6879(07)00432-6
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Schmukler E, 2014, ONCOTARGET, V5, P173, DOI 10.18632/oncotarget.1500
   Schmukler E, 2013, ONCOTARGET, V4, P145
   Shi J, 2014, CELL DEATH DIFFER, V21, P1432, DOI 10.1038/cdd.2014.58
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Wolfson E, 2015, BIOL CELL, V107, P130, DOI 10.1111/boc.201400087
   Yuan CX, 2015, DRUG DES DEV THER, V9, P487, DOI 10.2147/DDDT.S74127
   Zeng RX, 2014, CELL BIOL INT, V38, P1221, DOI 10.1002/cbin.10311
NR 31
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 2
PY 2017
VL 12
IS 2
AR e0171351
DI 10.1371/journal.pone.0171351
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN7DB
UT WOS:000396161200131
PM 28151959
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, XG
   Huang, ZL
   Chen, Y
   Zhou, J
   Hu, SQ
   Zhi, QM
   Song, SD
   Wang, YN
   Wan, DW
   Gu, W
   Zhou, H
   Zhang, B
   Cao, W
   He, SB
AF Zhu, Xinguo
   Huang, Zhilong
   Chen, Yan
   Zhou, Jian
   Hu, Shuiqing
   Zhi, Qiaoming
   Song, Shiduo
   Wang, Yanan
   Wan, Daiwei
   Gu, Wen
   Zhou, Hao
   Zhang, Bo
   Cao, Wei
   He, Songbing
TI Effect of CLN3 silencing by RNA interference on the proliferation and
   apoptosis of human colorectal cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Colorectal cancer; CLN3; RNA interference; Proliferation; Apoptosis
ID BATTEN-DISEASE PROTEIN; COLON-CANCER; AUTOPHAGY; EXPRESSION; CERAMIDE;
   THERAPY; KINASE; DEATH; GENE
AB Apoptosis constitutes a system for the removal of aged, or damaged cells, which is regulated by the interplay of pro-apoptotic and antiapoptotic proteins. Previous study has shown that Juvenile Batten disease protein, CLN3, is antiapoptotic gene in NT2 neuronal precursor cells and a few types of cancers. However, in colorectal cancer, whether CLN3 also play its antiapoptotic role and the effect of targeted controlling CLN3 on the biological behavior of human colorectal cancer cell is unknown. We employed the sequence-specific siRNA silencing the CLN3 gene and investigated its effects on growth and apoptosis of colorectal cancer HCT116 cells, which has highest elevation of CLN3 expression among four colorectal cancer cell lines. After CLN3 specific siRNA transfection, mRNA and protein expression levels of CLN3 in HCT116 cells were noticeably decreased. Moreover, CLN3-siRNA inhibited the proliferation of colorectal cancer cells, promoted their apoptosis and induced G0/G1 cell cycle arrest. Our current study demonstrated that CLN3 was expressed in colorectal cancer cells at a high frequency. Moreover, CLN3 down-regulation with RNA interference can inhibit proliferation, apoptosis, and cell cycle progression of colorectal cancer cells. Our study represented a potential new approach to understanding the role of CLN3 in cancer and provides a potential novel strategy colorectal cancer therapy. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Zhu, Xinguo; Huang, Zhilong; Chen, Yan; Zhou, Jian; Zhi, Qiaoming; Song, Shiduo; Gu, Wen; Zhou, Hao; Cao, Wei; He, Songbing] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
   [Hu, Shuiqing] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Clin Labs, Shanghai 200011, Peoples R China.
   [Wang, Yanan] Nanjing Med Univ, Affiliated Hosp, Suzhou Municipal Hosp, Dept Clin Lab, Suzhou 215006, Peoples R China.
   [Wan, Daiwei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gen Surg, Guangzhou 510000, Guangdong, Peoples R China.
   [He, Songbing] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China.
   [He, Songbing] Washington Univ, Sch Med, St Louis, MO 63110 USA.
RP He, SB (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.
EM captain_hsb@163.com
FU Nature Science Foundation of ChinaNational Natural Science Foundation of
   China (NSFC) [81201905, 81100023]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2013M540374]; Nature
   Science Research Grants in University of Jiangsu Province of China
   [12KJB320009]; Medical Science and Technology Development Foundation of
   Jiangsu Province of China [H201209]; Innovation Program of Shanghai
   Municipal Education CommissionInnovation Program of Shanghai Municipal
   Education Commission [12YZ050]; Shanghai Postdoctoral Scientific Program
   of China [13R21415200]; Science and Technology Bureau of Suzhou City of
   China [SYS201220]; Government Overseas Scholarship from Department of
   Education of Jiangsu Province of China
FX This study was supported by Project of Nature Science Foundation of
   China (81201905, 81100023), China Postdoctoral Science Foundation
   (2013M540374), Nature Science Research Grants in University of Jiangsu
   Province of China (12KJB320009), Project of Medical Science and
   Technology Development Foundation of Jiangsu Province of China
   (H201209), Innovation Program of Shanghai Municipal Education Commission
   (12YZ050), Shanghai Postdoctoral Scientific Program of China
   (13R21415200) and Science and Technology Research Project of in Science
   and Technology Bureau of Suzhou City of China (SYS201220) and sponsored
   by Government Overseas Scholarship from Department of Education of
   Jiangsu Province of China.
CR Brenner H, 2013, LANCET, P61649
   Burotto M, 2012, COLORECTAL CANCER, V1, P433, DOI [10.2217/CRC.12.52, 10.2217/crc.12.52]
   Carpinteiro A, 2008, CANCER LETT, V264, P1, DOI 10.1016/j.canlet.2008.02.020
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cui JZ, 2013, BBA-REV CANCER, V1836, P15, DOI 10.1016/j.bbcan.2013.02.003
   He SB, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-109
   Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014
   Jain K, 2013, AM J CANCER RES, V3, P251
   Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X
   Ledeen RW, 2006, BBA-MOL CELL BIOL L, V1761, P588, DOI 10.1016/j.bbalip.2006.04.010
   LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0
   Lotze MT, 2013, CANCER J, V19, P341, DOI 10.1097/PPO.0b013e31829da0d6
   Merritt WM, 2010, CANCER RES, V70, P2571, DOI 10.1158/0008-5472.CAN-09-2536
   Narayan SB, 2006, MOL GENET METAB, V88, P178, DOI 10.1016/j.ymgme.2006.01.011
   Persaud-Sawin DANW, 2002, HUM MOL GENET, V11, P2129, DOI 10.1093/hmg/11.18.2129
   Phillips SN, 2005, J NEUROSCI RES, V79, P573, DOI 10.1002/jnr.20367
   Puranam KL, 1999, MOL GENET METAB, V66, P294, DOI 10.1006/mgme.1999.2834
   Rakheja D, 2004, BIOCHEM BIOPH RES CO, V317, P988, DOI 10.1016/j.bbrc.2004.03.146
   Rylova SN, 2002, CANCER RES, V62, P801
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siskind LJ, 2008, J BIO L CHEM, V51, P66
   Van Overloop H, 2007, BIOCHEM BIOPH RES CO, V364, P169, DOI 10.1016/j.bbrc.2007.09.117
   Wan DW, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0378-6
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou J, 2013, TOXICOL LETT, V222, P139, DOI 10.1016/j.toxlet.2013.07.022
NR 25
TC 14
Z9 14
U1 1
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2014
VL 68
IS 3
BP 253
EP 258
DI 10.1016/j.biopha.2013.12.010
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AG4NA
UT WOS:000335395400001
PM 24556023
DA 2022-04-25
ER

PT J
AU Pawlak, A
   Strzadala, L
   Kalas, W
AF Pawlak, Alicja
   Strzadala, Leon
   Kalas, Wojciech
TI Non-genomic effects of the NR4A1/Nur77/TR3/NGFIB orphan nuclear receptor
SO STEROIDS
LA English
DT Review
DE NR4A1; Nuclear receptor; Non-genomic; Cancer; Apoptosis; Autophagy
ID AUTOPHAGIC CELL-DEATH; ENDOPLASMIC-RETICULUM; ER STRESS; BCL-XL; K-RAS;
   NUR77; APOPTOSIS; GENE; TRANSLOCATION; TR3/NUR77
AB The orphan nuclear receptor NR4A1/Nur77/TR3/NGFIB acts primarily as a transcription factor to regulate the expression of multiple genes. However, increasing research attention has recently been given to non-genomic activities of NR4A1. The first description of a non-genomic action of NR4A1 referred to the conversion of anti-apoptotic Bcl-2 into a pro-apoptotic protein by direct interaction with NR4A1. In response to certain apoptotic stimuli, NR4A1 translocates from the nucleus to the mitochondrial outer membrane (MOM) where it associates with Bcl-2 and thereby causes apoptosis. Afterwards, it appeared that NR4A1 could also bind and convert other anti-apoptotic Bcl-2 family members. The latest studies indicate a significant role of NR4A1 in the process of autophagy. For example, a new NR4A1-mediated pathway specific for melanoma cells has been described where NR4A1 interacts with the adenine nucleotide translocase 1 (ANTI.) on the mitochondrial inner membrane (MIM) leading to induction of the autophagy pathway. Moreover, NR4A1 interaction with cytoplasmic p53 may also contribute to the induction of autophagy. In addition to mitochondria, NR4A1 could be translocated to the outer membrane of the endoplasmic reticulum (ER) and associate with Bcl-2 or translocon-associated protein subunit gamma (TRAP gamma) causing ER stress-induced apoptosis. NR4A1 also contributes to the proteasomal degradation of p-catenin in colon cancer cells in vitro and in vivo, as well as to the stabilization of hypoxia-inducible factor-1 alpha (HIF-1 alpha) under non-hypoxic conditions. This review summarizes research findings on non-genomic effects of NR4A1 in normal and cancer cells. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Pawlak, Alicja; Strzadala, Leon; Kalas, Wojciech] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland.
   [Kalas, Wojciech] Jan Dlugosz Univ Czestochowa, PL-42200 Czestochowa, Poland.
RP Pawlak, A (corresponding author), Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Rudolfa Weigla 12, PL-53114 Wroclaw, Poland.
EM alicja.pawlak@iitd.pan.wroc.pl; strzadal@iitd.pan.wroc.pl;
   kalas@iitd.pan.wroc.pl
RI Kałas, Wojciech/AAB-4469-2019
OI Kałas, Wojciech/0000-0003-2656-5192; Strzadala, Leon/0000-0002-7323-2254
FU NCN Grant [2011/01/B/NZ4/00938]
FX This study was supported by NCN Grant No. 2011/01/B/NZ4/00938.
CR Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269
   Berthon A, 2014, HUM MOL GENET, V23, P889, DOI 10.1093/hmg/ddt484
   Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012
   Bouzas-Rodriguez J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046422
   Chang LF, 2011, J SURG ONCOL, V103, P442, DOI 10.1002/jso.21809
   Chen HZ, 2013, INT J BIOCHEM CELL B, V45, P1600, DOI 10.1016/j.biocel.2013.04.026
   Choi JW, 2004, CANCER RES, V64, P35, DOI 10.1158/0008-5472.CAN-03-0145
   Corazzari M, 2013, SEMIN CANCER BIOL, V23, P337, DOI 10.1016/j.semcancer.2013.07.001
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de Medina P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2835
   Ferlini C, 2009, CANCER RES, V69, P6906, DOI 10.1158/0008-5472.CAN-09-0540
   Flaig R, 2005, J BIOL CHEM, V280, P19250, DOI 10.1074/jbc.M413175200
   Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095
   Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2
   Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358
   Hardwick J.M., 2013, COLD SPRING HARB PER, V5
   HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444
   Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505
   Kang SA, 2010, BIOCHEM PHARMACOL, V80, P867, DOI 10.1016/j.bcp.2010.04.026
   Kim BY, 2008, EXP MOL MED, V40, P71, DOI 10.3858/emm.2008.40.1.71
   Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002
   Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003
   Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955
   Kurakula K, 2014, BBA-MOL CELL RES, V1843, P2543, DOI 10.1016/j.bbamcr.2014.06.010
   Lee SO, 2014, MOL CANCER RES, V12, P527, DOI 10.1158/1541-7786.MCR-13-0567
   Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159
   Liang B, 2007, EXP CELL RES, V313, P2833, DOI 10.1016/j.yexcr.2007.04.032
   Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X
   Lin PC, 2008, J NEUROCHEM, V106, P1017, DOI 10.1111/j.1471-4159.2008.05432.x
   Liu H, 2013, SEMIN CANCER BIOL, V23, P352, DOI 10.1016/j.semcancer.2013.06.008
   Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Luciano F, 2007, BLOOD, V109, P3849, DOI 10.1182/blood-2006-11-056879
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maxwell MA, 2006, NUCL RECEPT SIGNALIN, V4
   MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9
   Mohan HM, 2012, CLIN CANCER RES, V18, P3223, DOI 10.1158/1078-0432.CCR-11-2953
   Pearen MA, 2010, MOL ENDOCRINOL, V24, P1891, DOI 10.1210/me.2010-0015
   Segala G, 2013, CANC RES S8, V73
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618
   Silvente-Poirot S, 2013, 3 ENOR S OXYSTEROLS, P38
   Sommer N, 2013, BBA-MOL CELL RES, V1833, P3104, DOI 10.1016/j.bbamcr.2013.08.018
   Stasik I, 2007, BBA-MOL CELL RES, V1773, P1483, DOI 10.1016/j.bbamcr.2007.05.011
   Sun Z, 2012, ONCOGENE, V31, P2653, DOI 10.1038/onc.2011.448
   Sung PJ, 2013, P NATL ACAD SCI USA, V110, P20593, DOI 10.1073/pnas.1306431110
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   To SKY, 2012, EXPERT OPIN THER TAR, V16, P573, DOI 10.1517/14728222.2012.680958
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/NCHEMBIO.1406, 10.1038/nchembio.1406]
   Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645
   Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384
   Wilson AJ, 2003, CANCER RES, V63, P5401
   Wilson AJ, 2013, CANCER RES, V73, P4758, DOI 10.1158/0008-5472.CAN-12-4560
   WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0
   Wu H, 2011, FASEB J, V25, P192, DOI 10.1096/fj.10-166462
   Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583
   Zhao BX, 2006, EMBO J, V25, P5703, DOI 10.1038/sj.emboj.7601435
NR 58
TC 33
Z9 33
U1 3
U2 66
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-128X
EI 1878-5867
J9 STEROIDS
JI Steroids
PD MAR
PY 2015
VL 95
BP 1
EP 6
DI 10.1016/j.steroids.2014.12.020
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CC1IK
UT WOS:000350094200001
PM 25555471
DA 2022-04-25
ER

PT J
AU Zhang, DS
   Fei, Q
   Li, J
   Zhang, C
   Sun, Y
   Zhu, CY
   Wang, FZ
   Sun, YM
AF Zhang, Dongsheng
   Fei, Qiang
   Li, Juan
   Zhang, Chuan
   Sun, Ye
   Zhu, Chunyan
   Wang, Fengzhen
   Sun, Yueming
TI 2-Deoxyglucose Reverses the Promoting Effect of Insulin on Colorectal
   Cancer Cells In Vitro
SO PLOS ONE
LA English
DT Article
ID TARGETING SURVIVIN; DIABETES-MELLITUS; PROSTATE-CANCER; COLON-CANCER;
   2-DEOXY-D-GLUCOSE; METABOLISM; AUTOPHAGY; GLUCOSE; INHIBITION;
   GLYCOLYSIS
AB An increased risk of colorectal cancer is related to the development of metabolic syndromes including hyperglycemia, and hyperinsulinemia. The high circulatory levels of glucose and/or insulin or the application of exogenous insulin may promote carcinogenesis, cancer progression and metastasis, which can be attributed to the Warburg effect or aerobic glycolysis. We attempted to resolve these existing questions by applying the glucose analog 2-deoxyglucose (2DG). According to the in vitro studies we performed, the glycolysis of colorectal cancer cells could be interrupted by 2DG as it decreased the cellular productions of ATP and lactate. In addition, 2DG induced apoptosis and cell cycle arrest, and inhibited proliferation, migration and invasion of these cells. Since insulin can stimulate the cellular uptake of hexose, including 2DG, the combination of 2DG and insulin improved the cytotoxicity of 2DG and meanwhile overcame the cancer-promoting effects of insulin. This in vitro study provided a viewpoint of 2DG as a potential therapeutic agent against colorectal cancer, especially for patients with concomitant hyperinsulinemia or treated with exogenous insulin.
C1 [Zhang, Dongsheng; Fei, Qiang; Li, Juan; Zhang, Chuan; Sun, Ye; Zhu, Chunyan; Sun, Yueming] Nanjing Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, Nanjing, Jiangsu, Peoples R China.
   [Fei, Qiang; Li, Juan; Zhang, Chuan; Sun, Ye; Zhu, Chunyan] Nanjing Med Univ, Sch Clin Med 1, Nanjing, Jiangsu, Peoples R China.
   [Wang, Fengzhen] China Pharmaceut Univ, Dept Pharmaceut, Nanjing, Jiangsu, Peoples R China.
RP Sun, YM (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, Nanjing, Jiangsu, Peoples R China.
EM jssunym@126.com
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX This study was funded by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD). No potential conflicts of
   interest were disclosed.
CR Alexandru Oana, 2014, Curr Health Sci J, V40, P27, DOI 10.12865/CHSJ.40.01.05
   Altieri DC, 2013, CANCER LETT, V332, P225, DOI 10.1016/j.canlet.2012.03.005
   Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074
   Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   Chen JZ, 2011, J GASTROINTEST ONCOL, V2, P27, DOI 10.3978/j.issn.2078-6891.2010.028
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Cheong JH, 2011, MOL CANCER THER, V10, P2350, DOI 10.1158/1535-7163.MCT-11-0497
   Choi Y, 2011, CANCER BIOL THER, V12, P989, DOI 10.4161/cbt.12.11.18364
   Chuang IC, 2015, LIFE SCI, V139, P52, DOI 10.1016/j.lfs.2015.08.002
   DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837
   Draznin B, 2010, DIABETOLOGIA, V53, P229, DOI 10.1007/s00125-009-1558-6
   Dwarakanath BS, 2009, J CANCER RES THER, V5, P21, DOI 10.4103/0973-1482.55136
   El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466
   Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184
   Gao C, 2011, AUTOPHAGY, V7, P334, DOI 10.4161/auto.7.3.14072
   Giammarioli AM, 2012, INT J CANCER, V131, pE337, DOI 10.1002/ijc.26420
   Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S
   Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457
   Janssen JAMJL, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00079
   Kanwar JR, 2011, DRUG DISCOV TODAY, V16, P485, DOI 10.1016/j.drudis.2011.04.001
   Kennedy CR, 2013, CANCER LETT, V336, P299, DOI 10.1016/j.canlet.2013.03.020
   Kerr Caroline A, 2009, BMC Res Notes, V2, P164, DOI 10.1186/1756-0500-2-164
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310
   Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   Li LJ, 2014, ASIAN PAC J CANCER P, V15, P3123, DOI 10.7314/APJCP.2014.15.7.3123
   Maher JC, 2005, PANCREAS, V30, pE34, DOI 10.1097/01.mpa.0000153327.46945.26
   Mei ZB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091818
   Pantano F, 2013, CANCER BIOL THER, V14, P467, DOI 10.4161/cbt.24346
   Priebe A, 2011, GYNECOL ONCOL, V122, P389, DOI 10.1016/j.ygyno.2011.04.024
   Qin JZ, 2010, BIOCHEM BIOPH RES CO, V401, P293, DOI 10.1016/j.bbrc.2010.09.054
   Ralser M, 2008, P NATL ACAD SCI USA, V105, P17807, DOI 10.1073/pnas.0803090105
   Ramirez-Peinado S, 2011, CANCER RES, V71, P6796, DOI 10.1158/0008-5472.CAN-11-0759
   Sandhu MS, 2002, J NATL CANCER I, V94, P972
   Schultz-Klarr S, 1994, J Assoc Acad Minor Phys, V5, P152
   Sottnik JL, 2011, CLIN EXP METASTAS, V28, P865, DOI 10.1007/s10585-011-9417-5
   Sun G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/708183
   Takahashi A, 1996, BRAIN RES, V734, P116, DOI 10.1016/S0006-8993(96)00621-X
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013
   Watts R, 2014, BIOCHEM CELL BIOL, V92, P226, DOI 10.1139/bcb-2014-0004
   Wilcox Gisela, 2005, Clin Biochem Rev, V26, P19
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Xi HB, 2011, CANCER CHEMOTH PHARM, V67, P899, DOI 10.1007/s00280-010-1391-0
   Yin SN, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-91
   Zagorodna O, 2012, ONCOGENE, V31, P2738, DOI 10.1038/onc.2011.454
   Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003
NR 52
TC 17
Z9 17
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 3
PY 2016
VL 11
IS 3
AR e0151115
DI 10.1371/journal.pone.0151115
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG0EB
UT WOS:000371735200165
PM 26939025
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Liu, J
   Liu, X
   Qian, JQ
   Meng, C
   Zhu, P
   Hang, JY
   Wang, YL
   Xiong, B
   Qiu, XD
   Zhu, WZ
   Yang, YM
   Zhang, YN
   Ling, Y
AF Liu, Ji
   Liu, Xin
   Qian, Jianqiang
   Meng, Chi
   Zhu, Peng
   Hang, Jiaying
   Wang, Yaling
   Xiong, Biao
   Qiu, Xiaodong
   Zhu, Weizhong
   Yang, Yumin
   Zhang, Yanan
   Ling, Yong
TI Development of pH/Glutathione-Responsive Theranostic Agents Activated by
   Glutathione S-Transferase pi for Human Colon Cancer
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TUMOR MICROENVIRONMENT; DNA-BINDING; ANTICANCER; APOPTOSIS; AUTOPHAGY;
   INFLAMMATION; RESISTANCE; ANALOGS; DESIGN; ALPHA
AB Two novel theranostic agents HJTA and HJTB have been designed and synthesized by covalently linking a beta-carboline derivative, with antitumor activities and pH-responsive fluorescence, with a 2-exomethylenecyclohexanone moiety, which can be activated by the tumor-targeting glutathione (GSH)/glutathione S-transferase pi (GST pi). These agents showed pH- and GSH-dual-responsive fluorescence in tumor cells but not in normal cells. Importantly, HJTA selectively illuminated tumor tissue for up to 7 h and generated precise visualization of orthotopic colonic tumors through the blood circulation system in intraoperative mice. Furthermore, HJTA exhibited potent and selective antiproliferative activities and colonic tumor inhibition in mice. Finally, HJTA induced great cancer cell apoptosis and autophagy by regulating the expression of apoptotic and autophagic proteins. Therefore, this pH/GSH-dual-responsive fluorescent probe with cancer-targeting therapeutic activity provides a novel tool for precise diagnosis and tumor treatment, therefore broadening the impact of multifunctional agents as theranostic precision medicines.
C1 [Liu, Ji; Liu, Xin; Qian, Jianqiang; Meng, Chi; Zhu, Peng; Hang, Jiaying; Wang, Yaling; Xiong, Biao; Qiu, Xiaodong; Zhu, Weizhong; Yang, Yumin; Zhang, Yanan; Ling, Yong] Nantong Univ, Sch Pharm, Nantong 226001, Peoples R China.
   [Liu, Ji; Liu, Xin; Qian, Jianqiang; Meng, Chi; Zhu, Peng; Hang, Jiaying; Wang, Yaling; Xiong, Biao; Qiu, Xiaodong; Zhu, Weizhong; Yang, Yumin; Zhang, Yanan; Ling, Yong] Nantong Univ, Jiangsu Prov Key Lab Inflammat & Mol Drug Target, Nantong 226001, Peoples R China.
   [Zhu, Peng; Wang, Yaling; Ling, Yong] Nantong Univ, Coinnovat Ctr Neuroregenerat, Minist Educ & Jiangsu Prov, Key Lab Neuroregenerat, Nantong 226001, Peoples R China.
RP Zhang, YN; Ling, Y (corresponding author), Nantong Univ, Sch Pharm, Nantong 226001, Peoples R China.; Zhang, YN; Ling, Y (corresponding author), Nantong Univ, Jiangsu Prov Key Lab Inflammat & Mol Drug Target, Nantong 226001, Peoples R China.; Ling, Y (corresponding author), Nantong Univ, Coinnovat Ctr Neuroregenerat, Minist Educ & Jiangsu Prov, Key Lab Neuroregenerat, Nantong 226001, Peoples R China.
EM zhangyanan@gmail.com; Lyyy111@sina.com
OI zhu, peng/0000-0002-4148-9135
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31830028, 21977058]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018 T110533, 2016
   M590488, 1601136B]; Project of "Jiangsu Six Peaks of Talent"
   [2016-SWYY-CXTD-008, 2014-SWYY-044]; Project of "Jiangsu 333 high-level
   talents", Jiangsu Province Innovation Project of Postgraduate Training
   [KYCX19 2086]; Applied Research Projects of Nantong City [MS12018079,
   JC2018125]; Jiangsu Province Postdoctoral Science Foundation [2018
   T110533, 2016 M590488, 1601136B]
FX This work was financially supported by the Natural Science Foundation of
   China (Nos. 31830028 and 21977058), China and Jiangsu Province
   Postdoctoral Science Foundation (2018 T110533, 2016 M590488, and
   1601136B), the Project of "Jiangsu Six Peaks of Talent"
   (2016-SWYY-CXTD-008 and 2014-SWYY-044), the Project of "Jiangsu 333
   high-level talents", Jiangsu Province Innovation Project of Postgraduate
   Training (KYCX19 2086), and Applied Research Projects of Nantong City
   (MS12018079 and JC2018125).
CR AGHIL O, 1992, ANTI-CANCER DRUG DES, V7, P67
   Chatterjee A, 2018, CANCER LETT, V433, P33, DOI 10.1016/j.canlet.2018.06.028
   Chen DQ, 2018, J AM CHEM SOC, V140, P7373, DOI 10.1021/jacs.7b12025
   DIILIO C, 1985, CANCER LETT, V29, P37, DOI 10.1016/0304-3835(85)90120-X
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796
   Feng LL, 2018, ACS NANO, V12, P11000, DOI 10.1021/acsnano.8b05042
   Gao M, 2017, CHEM SOC REV, V46, P2237, DOI 10.1039/c6cs00908e
   Hamilton DS, 2003, J AM CHEM SOC, V125, P15049, DOI 10.1021/ja030396p
   Hamilton DS, 2002, ORG LETT, V4, P1209, DOI 10.1021/ol025650h
   Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z
   Hengstler JG, 1998, CANCER LETT, V128, P105, DOI 10.1016/S0304-3835(98)00059-7
   Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kamal A, 2015, BIOORGAN MED CHEM, V23, P5511, DOI 10.1016/j.bmc.2015.07.037
   Kong C, 2019, ACS NANO, V13, P4049, DOI 10.1021/acsnano.8b08246
   Kotoku N, 2011, ORG LETT, V13, P3514, DOI 10.1021/ol201327u
   Kovvuri J, 2018, EUR J MED CHEM, V143, P1563, DOI 10.1016/j.ejmech.2017.10.054
   Ling BP, 2019, ACS APPL MATER INTER, V11, P11157, DOI 10.1021/acsami.8b22487
   Ling Y, 2019, EUR J MED CHEM, V168, P515, DOI 10.1016/j.ejmech.2019.02.054
   Ling Y, 2015, J MED CHEM, V58, P9214, DOI 10.1021/acs.jmedchem.5b01052
   LIU Z, 2014, ANGEW CHEM, V126, P4022, DOI DOI 10.1002/ANGE.201311161
   Lu YP, 2016, EUR J PHARMACOL, V771, P130, DOI 10.1016/j.ejphar.2015.12.026
   Ma WL, 2019, ACS OMEGA, V4, P15240, DOI 10.1021/acsomega.9b01863
   MELHUISH WH, 1961, J PHYS CHEM-US, V65, P229, DOI 10.1021/j100820a009
   Ngabire D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092016
   Ni H, 2017, MED CHEM RES, V26, P2861, DOI 10.1007/s00044-017-1985-8
   Nie XK, 2015, J APPL TOXICOL, V35, P851, DOI 10.1002/jat.3084
   OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2
   Qiao CM, 2018, ADV MATER, V30, DOI 10.1002/adma.201705054
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Song QL, 2017, NANO LETT, V17, P6366, DOI 10.1021/acs.nanolett.7b03186
   Sun FH, 2019, BIOCHEM PHARMACOL, V162, P142, DOI 10.1016/j.bcp.2018.10.021
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Uthaman Saji, 2018, Biomater Res, V22, P22, DOI 10.1186/s40824-018-0132-z
   Wang F, 2017, BIOMED PHARMACOTHER, V92, P672, DOI 10.1016/j.biopha.2017.05.129
   Wang Q, 2018, CANCER LETT, V438, P17, DOI 10.1016/j.canlet.2018.08.028
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Yin GX, 2019, ANGEW CHEM INT EDIT, V58, P4557, DOI 10.1002/anie.201813935
   Zhang PF, 2018, J AM CHEM SOC, V140, P14980, DOI 10.1021/jacs.8b09396
   Zhao ZL, 2013, ANGEW CHEM INT EDIT, V52, P7487, DOI 10.1002/anie.201302557
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zou Y, 2018, J MED CHEM, V61, P1821, DOI 10.1021/acs.jmedchem.7b01096
NR 44
TC 7
Z9 6
U1 7
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 10
PY 2020
VL 63
IS 17
BP 9271
EP 9283
DI 10.1021/acs.jmedchem.0c00354
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA NR3WG
UT WOS:000571493400022
PM 32787089
DA 2022-04-25
ER

PT J
AU Li, JC
   Frederick, ALM
   Jin, Y
   Guo, C
   Xiao, H
   Wood, RJ
   Liu, ZH
AF Li, Jinchao
   Frederick, Armina-Lyn M.
   Jin, Yu
   Guo, Chi
   Xiao, Hang
   Wood, Richard J.
   Liu, Zhenhua
TI The Prevention of a High Dose of Vitamin D or Its Combination with
   Sulforaphane on Intestinal Inflammation and Tumorigenesis in Apc(1638N)
   Mice Fed a High-Fat Diet
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE colorectal cancer; inflammation; obesity; sulforaphane; vitamin D
ID HISTONE DEACETYLASE INHIBITORS; SERUM 25-HYDROXYVITAMIN D;
   NECROSIS-FACTOR-ALPHA; COLORECTAL-CANCER; INDUCED APOPTOSIS; MOUSE
   MODELS; TNF-ALPHA; IN-VITRO; COLON; AUTOPHAGY
AB Scope The previous study shows that obesity-promoted inflammation is responsible for the activation of the intestinal tumorigenic Wnt-signaling. The present study aims to test a dietary strategy, dietary supplementation with a high dose of vitamin D (VD) or its combination with sulforaphane (SFN) to inhibit intestinal inflammation and obesity-associated tumorigenesis. Methods and results Apc(1638N) mice are randomly divided into four groups: LF, a low-fat diet (10 kcal% fat) with 200 IU VD; HF, a high-fat diet (60 kcal% fat) with 200 IU VD; HFD, a high-fat diet with 5000 IU VD; and HFDS, a high-fat diet plus 5000 IU VD and 0.23 g SFN per approximate to 4000 kcal. VD administration decreased tumor incidence and size, and the co-administration with SFN (HFDS) magnified the effects. Inflammation and Wnt-signaling are suppressed by VD. The addition of SFN decreased the activity of histone deacetylase (HDAC) and increased autophagy. Conclusion The administration of VD, at 5000 IU level, exerts an anti-inflammatory property and leads to suppressed intestinal Wnt-signaling and tumorigenesis in obese mice. The molecular function of SFN on a high dose of VD supplementation, although displayed on the inhibition of HDAC and the activation of autophagy, needs further investigation.
C1 [Li, Jinchao; Frederick, Armina-Lyn M.; Jin, Yu; Guo, Chi; Wood, Richard J.; Liu, Zhenhua] Univ Massachusetts, Dept Nutr, Sch Publ Hlth & Hlth Sci, Amherst, MA 01002 USA.
   [Jin, Yu] China Med Univ, Shengjing Hosp, Dept Gastroenterol, Shenyang 110004, Liaoning, Peoples R China.
   [Guo, Chi] Hunan Univ, Dept Mol Med, Changsha 410006, Hunan, Peoples R China.
   [Xiao, Hang] Univ Massachusetts, Dept Food Sci, Amherst, MA 01002 USA.
   [Liu, Zhenhua] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02153 USA.
RP Liu, ZH (corresponding author), Univ Massachusetts, Dept Nutr, Sch Publ Hlth & Hlth Sci, Amherst, MA 01002 USA.
EM zliu@nutrition.umass.edu
RI Xiao, Hang/Y-2797-2019
OI Liu, Zhenhua/0000-0001-8439-055X; Xiao, Hang/0000-0001-6194-2796
FU USDAUnited States Department of Agriculture (USDA) [2014-67017-21762,
   MAS00514]; Dean's Incentive Grant, School of Public Health and Health
   Sciences
FX J.L. performed all the experiments. A.M.F., Y.J., and C.G. contributed
   to the collection, interpretation, and analysis of data throughout the
   experiment; all authors contributed to the discussion. Z.L., H.X., and
   R.J.W. designed the research and directed the project. J.L. and Z.L.
   wrote the manuscript. All authors reviewed the manuscript. This project
   was supported in part by USDA grants (2014-67017-21762 and MAS00514,
   Z.L. and R.J.W., respectively) and a Dean's Incentive Grant, School of
   Public Health and Health Sciences (Z.L.)
CR Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Banwell CM, 2004, J STEROID BIOCHEM, V89-90, P245, DOI 10.1016/j.jsbmb.2004.03.081
   Baron JA, 2015, NEW ENGL J MED, V373, P1519, DOI 10.1056/NEJMoa1500409
   Brunner RL, 2011, NUTR CANCER, V63, P827, DOI 10.1080/01635581.2011.594208
   Coskun M, 2014, CARCINOGENESIS, V35, P1185, DOI 10.1093/carcin/bgu037
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X
   Dickinson SE, 2015, MOL CARCINOGEN, V54, P1513, DOI 10.1002/mc.22224
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Fleet JC, 2008, J NUTR, V138, P1114, DOI 10.1093/jn/138.6.1114
   Fleet JC, 2008, MOL ASPECTS MED, V29, P388, DOI 10.1016/j.mam.2008.07.003
   Flood A, 2008, AM J CLIN NUTR, V88, P176, DOI 10.1093/ajcn/88.1.176
   Garland CF, 2011, ANTICANCER RES, V31, P607
   Gorham ED, 2007, AM J PREV MED, V32, P210, DOI 10.1016/j.amepre.2006.11.004
   Grant WB, 2012, ANTICANCER RES, V32, P223
   Gunter MJ, 2006, J NUTR BIOCHEM, V17, P145, DOI 10.1016/j.jnutbio.2005.06.011
   Hales CM, 2018, JAMA-J AM MED ASSOC, V319, P1723, DOI 10.1001/jama.2018.3060
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Hopkins MH, 2011, CANCER PREV RES, V4, P1645, DOI 10.1158/1940-6207.CAPR-11-0105
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Hoyer-Hansen M, 2010, TRENDS MOL MED, V16, P295, DOI 10.1016/j.molmed.2010.04.005
   Hummel DM, 2013, J STEROID BIOCHEM, V136, P284, DOI 10.1016/j.jsbmb.2012.09.003
   Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S
   Jenab M, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5500
   Larriba MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023524
   Jo C, 2014, FEBS LETT, V588, P3081, DOI 10.1016/j.febslet.2014.06.036
   Kaler P, 2009, ONCOGENE, V28, P3892, DOI 10.1038/onc.2009.247
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Khanim FL, 2004, ONCOGENE, V23, P6712, DOI 10.1038/sj.onc.1207772
   Kim BG, 2016, SCI REP-UK, V6, DOI 10.1038/srep36215
   Kim HN, 2014, CANCER LETT, V351, P41, DOI 10.1016/j.canlet.2014.03.037
   Lappe J, 2017, JAMA-J AM MED ASSOC, V317, P1234, DOI 10.1001/jama.2017.2115
   Lee JE, 2011, CANCER PREV RES, V4, P735, DOI 10.1158/1940-6207.CAPR-10-0289
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu HR, 2017, J MOL MED, V95, P553, DOI 10.1007/s00109-016-1502-4
   Liu ZH, 2012, J NUTR BIOCHEM, V23, P1207, DOI 10.1016/j.jnutbio.2011.07.002
   Malinen M, 2008, NUCLEIC ACIDS RES, V36, P121, DOI 10.1093/nar/gkm913
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Mousa A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010804
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Ng K, 2014, CURR COLORECT CANC R, V10, P339, DOI 10.1007/s11888-014-0238-1
   Ng K, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3506
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105
   Ramos EJB, 2003, SURGERY, V134, P329, DOI 10.1067/msy.2003.267
   Rashid SF, 2001, ONCOGENE, V20, P1860, DOI 10.1038/sj.onc.1204269
   Rautiainen S, 2016, NAT REV ENDOCRINOL, V12, P407, DOI 10.1038/nrendo.2016.54
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Selting KA, 2016, VET COMP ONCOL, V14, P295, DOI 10.1111/vco.12101
   Seuter S, 2013, NUCLEIC ACIDS RES, V41, P110, DOI 10.1093/nar/gks959
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8
   Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035
   Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010
   Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x
   Tavera-Mendoza LE, 2017, P NATL ACAD SCI USA, V114, pE2186, DOI 10.1073/pnas.1615015114
   Tong WM, 1999, ONCOL RES, V11, P77
   Uday S, 2017, CURR OSTEOPOROS REP, V15, P293, DOI 10.1007/s11914-017-0383-y
   Wactawski-Wende J, 2006, NEW ENGL J MED, V354, P684, DOI 10.1056/NEJMoa055222
   Wang JR, 2008, J BIOL CHEM, V283, P25596, DOI 10.1074/jbc.M801716200
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   Xu L, 2016, INT J CLIN EXP PATHO, V9, P4505
   Yang K, 1998, CANCER RES, V58, P5713
   Zhang Y, 2012, J IMMUNOL, V188, P2127, DOI 10.4049/jimmunol.1102412
NR 70
TC 7
Z9 7
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD FEB
PY 2019
VL 63
IS 4
AR 1800824
DI 10.1002/mnfr.201800824
PG 10
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA HL7EY
UT WOS:000458902400003
PM 30447137
OA Bronze
DA 2022-04-25
ER

PT J
AU Xu, ZY
   Chen, L
   Xiao, ZG
   Zhu, YH
   Jiang, H
   Jin, Y
   Gu, C
   Wu, YL
   Wang, L
   Zhang, W
   Zuo, J
   Zhou, DX
   Luan, JJ
   Shen, J
AF Xu Zhenyu
   Chen Lu
   Xiao Zhangang
   Zhu Yanhong
   Jiang Hui
   Jin Yan
   Gu Cheng
   Wu Yilai
   Wang Lin
   Zhang Wen
   Zuo Jian
   Zhou Dexi
   Luan Jiajie
   Shen Jing
TI Potentiation of the anticancer effect of doxorubicinin drug-resistant
   gastric cancer cells by tanshinone IIA
SO PHYTOMEDICINE
LA English
DT Article
DE Tanshinone IIA; Multidrug resistance protein 1; Autophagy; Drug
   resistance; Gastric cancer
ID ROS-DEPENDENT APOPTOSIS; COLON-CANCER; MULTIDRUG-RESISTANCE;
   MOLECULAR-MECHANISMS; SALVIA-MILTIORRHIZA; P-GP; DIHYDROTANSHINONE;
   AUTOPHAGY; CRYPTOTANSHINONE; INHIBITION
AB Background: Gastric cancer is the fifth commonest cancer and the third cause of cancer-related deaths all over the world. The effectiveness of chemotherapy is still limited by drug resistance in gastric cancer. Tanshinones, abietane diterpenes isolated from the traditional Chinese medicine Danshen (Salvia miltiorrhiza), have exhibited versatile anticancer activities in particular the ability to overcome drug resistance in different cancers.
   Purpose: The current study aimed to explore the capacity of tanshinone IIA, the most abundant tanshinone found in the plant Danshen, to overcome drug resistance of gastric cancer cells to a commonly used anticancer drug doxorubicin.
   Study design: Sensitivity of cell lines to doxorubicin was determined by MTT assay. Doxorubicin resistant gastric cancer cell lines was established by step selection with increasing concentrations of doxorubicin. Cell cycle arrest, apoptosis and doxorubicin efflux were analyzed by flow cytometry. The expression of MRP1 was determined by realtime PCR and western-blot.
   Results: Based on the IC50 values of doxorubicin, we identified the doxorubicin-sensitive gastric cancer cell lines SNU-719 and SNU-610 as well as the cell lines relatively resistant to doxorubicin including SNU-638, SNU-668, SNU-216 and SNU-620. We also established two drug-resistant cell lines SNU-719R and SNU-610R. Despite the fact that tanshinone IIA alone showed no cytotoxicity on these gastric cells, we found the potentiation of the anticancer effect of doxorubicin in drug-resistant gastric cancer cells by tanshinone IIA. Furthermore, using doxorubicin-sensitive cell line SNU-719 and doxorubicin-resistant cell lines SNU-719R and SNU-620, we revealed the pivotal roles of MRP1. Its overexpression impaired cell cycle arrest and suppressed apoptosis in the development of both intrinsic and acquired drug resistance in gastric cancer cells to doxorubicin. Importantly, inhibition of MRP1 function enhanced cell cycle arrest, increased apoptosis and induced autophagic cell death which contributed to the capability of tanshinone IIA to potentiate the anticancer effect of doxorubicin in drugresistant gastric cancer cells.
   Conclusion: Tanshinone IIA is an interesting agent with potential to treat drug-resistant gastric cancer in combination therapy.
C1 [Xu Zhenyu; Chen Lu; Zhu Yanhong; Jiang Hui; Gu Cheng; Wu Yilai; Wang Lin; Zhang Wen; Zuo Jian; Zhou Dexi; Luan Jiajie] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.
   [Xiao Zhangang; Shen Jing] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Sichuan, Peoples R China.
   [Jin Yan] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Gastrointestinal Surg, Wuhu, Anhui, Peoples R China.
RP Luan, JJ (corresponding author), Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China.; Shen, J (corresponding author), Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Sichuan, Peoples R China.
EM luanjiajie757@163.com; crystal_stray@126.com
RI Jiajie, Luan/AAM-2206-2021; 周, 德喜/ABF-6374-2020
OI Jiajie, Luan/0000-0002-3499-1944; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81602240, 81503093, 81602166, 81672444];
   University Natural Science Research Project of Anhui ProvinceNatural
   Science Foundation of Anhui Province [KJ2016A732]; Talent Research Fund
   of Yijiahan Hospital [YR201504]; Joint Funds of the Southwest Medical
   University Luzhou [2016LZXNYD-T01, 2017LZXNYD-Z05, 2017LZXNYD-J09]
FX This work was supported by the National Natural Science Foundation of
   China (Grant nos. 81602240, 81503093, 81602166, and 81672444), the
   University Natural Science Research Project of Anhui Province
   (KJ2016A732), the Talent Research Fund of Yijiahan Hospital (YR201504),
   the Joint Funds of the Southwest Medical University & Luzhou
   (2016LZXNYD-T01, 2017LZXNYD-Z05 and 2017LZXNYD-J09).
CR Bae S, 2010, AM J PHYSIOL-HEART C, V299, pH1374, DOI 10.1152/ajpheart.00168.2010
   Chen J, 2012, ONCOL REP, V27, P523, DOI 10.3892/or.2011.1524
   Chen XP, 2014, MED RES REV, V34, P768, DOI 10.1002/med.21304
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
   Deeley RG, 2006, FEBS LETT, V580, P1103, DOI 10.1016/j.febslet.2005.12.036
   Ding LJ, 2016, ENVIRON TOXICOL PHAR, V46, P264, DOI 10.1016/j.etap.2016.07.021
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Hu T, 2013, J BIOMOL RES THER, V2, P110, DOI [10.4172/21677956.1000110, DOI 10.4172/21677956.1000110]
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu T, 2015, CURR PHARM DESIGN, V21, P2960, DOI 10.2174/1381612821666150514104244
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hu T, 2015, CHEM-BIOL INTERACT, V230, P1, DOI 10.1016/j.cbi.2015.02.006
   Hu T, 2014, PHYTOMEDICINE, V21, P1264, DOI 10.1016/j.phymed.2014.06.013
   Jing Jing, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P391
   Lee CY, 2008, MOL CANCER THER, V7, P3527, DOI 10.1158/1535-7163.MCT-07-2288
   Li K, 2017, BIOMED PHARMACOTHER, V96, P371, DOI 10.1016/j.biopha.2017.10.016
   Li LF, 2014, INT J MOL MED, V34, P372, DOI 10.3892/ijmm.2014.1786
   Li XQ, 2015, EUR J MED CHEM, V101, P560, DOI 10.1016/j.ejmech.2015.06.049
   Lu Q, 2009, INT J MOL MED, V24, P773, DOI 10.3892/ijmm_00000291
   Nakanishi T, 2012, CHIN J CANCER, V31, P73, DOI 10.5732/cjc.011.10320
   Riquelme I, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030424
   Shi WJ, 2016, WORLD J GASTRO ONCOL, V8, P673, DOI 10.4251/wjgo.v8.i9.673
   Shinoda C, 2005, INT J CANCER, V117, P21, DOI 10.1002/ijc.21094
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Wang L, 2016, LIFE SCI, V151, P224, DOI 10.1016/j.lfs.2016.02.083
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang P., 2015, EVID BASED COMPLEMEN, V2015
   Won SH, 2010, BIOL PHARM BULL, V33, P1828, DOI 10.1248/bpb.33.1828
   Xu M, 2013, ASIAN PAC J CANCER P, V14, P173, DOI 10.7314/APJCP.2013.14.1.173
   Xu ZY, 2017, CHEM-BIOL INTERACT, V273, P48, DOI 10.1016/j.cbi.2017.06.003
   Yu J, 2017, ONCOL REP, V37, P1394, DOI 10.3892/or.2017.5408
   Zhang DX, 2010, FUTURE ONCOL, V6, P527, DOI [10.2217/fon.10.21, 10.2217/FON.10.21]
   Zhou XL, 2013, PHYTOMEDICINE, V20, P367, DOI 10.1016/j.phymed.2012.09.021
NR 33
TC 33
Z9 36
U1 2
U2 28
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC 1
PY 2018
VL 51
BP 58
EP 67
DI 10.1016/j.phymed.2018.05.012
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HB9UH
UT WOS:000451438300007
PM 30466628
DA 2022-04-25
ER

PT J
AU Chatterji, P
   Williams, PA
   Whelan, KA
   Samper, FC
   Andres, SF
   Simon, LA
   Parham, LR
   Mizuno, R
   Lundsmith, ET
   Lee, DSM
   Liang, S
   Wijeratne, HRS
   Marti, S
   Chau, L
   Giroux, V
   Wilkins, BJ
   Wu, GD
   Shah, P
   Tartaglia, GG
   Hamilton, KE
AF Chatterji, Priya
   Williams, Patrick A.
   Whelan, Kelly A.
   Samper, Fernando C.
   Andres, Sarah F.
   Simon, Lauren A.
   Parham, Louis R.
   Mizuno, Rei
   Lundsmith, Emma T.
   Lee, David S. M.
   Liang, Shun
   Wijeratne, H. R. Sagara
   Marti, Stefanie
   Chau, Lillian
   Giroux, Veronique
   Wilkins, Benjamin J.
   Wu, Gary D.
   Shah, Premal
   Tartaglia, Gian G.
   Hamilton, Kathryn E.
TI Posttranscriptional regulation of colonic epithelial repair by RNA
   binding protein IMP1/IGF2BP1
SO EMBO REPORTS
LA English
DT Article
DE colonic repair; IGF2BP1; IMP1; inflammatory bowel disease; RNA binding
   protein
ID MYC MESSENGER-RNA; PANETH CELL PHENOTYPES; CODING REGION; CRD-BP;
   QUANTITATIVE PREDICTIONS; IMP1 PROMOTES; IN-VITRO; AUTOPHAGY; GROWTH;
   TRANSLATION
AB RNA binding proteins, including IMP1/IGF2BP1, are essential regulators of intestinal development and cancer. Imp1 hypomorphic mice exhibit gastrointestinal growth defects, yet the specific role for IMP1 in colon epithelial repair is unclear. Our prior work revealed that intestinal epithelial cell-specific Imp1 deletion (Imp1(Delta IEC)) was associated with better regeneration in mice after irradiation. Here, we report increased IMP1 expression in patients with Crohn's disease and ulcerative colitis. We demonstrate that Imp1(Delta IEC) mice exhibit enhanced recovery following dextran sodium sulfate (DSS)-mediated colonic injury. Imp1(Delta IEC) mice exhibit Paneth cell granule changes, increased autophagy flux, and upregulation of Atg5. In silico and biochemical analyses revealed direct binding of IMP1 to MAP1LC3B, ATG3, and ATG5 transcripts. Genetic deletion of essential autophagy gene Atg7 in Imp1(Delta IEC) mice revealed increased sensitivity of double-mutant mice to colonic injury compared to control or Atg7 single mutant mice, suggesting a compensatory relationship between Imp1 and the autophagy pathway. The present study defines a novel interplay between IMP1 and autophagy, where IMP1 may be transiently induced during damage to modulate colonic epithelial cell responses to damage.
C1 [Chatterji, Priya; Andres, Sarah F.; Mizuno, Rei; Chau, Lillian; Wu, Gary D.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Williams, Patrick A.; Simon, Lauren A.; Parham, Louis R.; Hamilton, Kathryn E.] Univ Penn, Dept Pediat, Childrens Hosp Philadelphia, Perelman Sch Med,Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
   [Whelan, Kelly A.] Temple Univ, Dept Pathol & Lab Med, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Whelan, Kelly A.; Marti, Stefanie] Temple Univ, Fels Inst Canc Res & Mol Biol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Samper, Fernando C.; Marti, Stefanie; Tartaglia, Gian G.] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Barcelona, Spain.
   [Samper, Fernando C.; Tartaglia, Gian G.] Univ Pompeu Fabra, Barcelona, Spain.
   [Lundsmith, Emma T.] Thomas Jefferson Univ, Thomas Jefferson Med Coll, Philadelphia, PA 19107 USA.
   [Lee, David S. M.] Univ Penn, Genom & Computat Biol Grad Grp, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Liang, Shun; Wijeratne, H. R. Sagara; Shah, Premal] Rutgers State Univ, Dept Genet, New Brunswick, NJ USA.
   [Giroux, Veronique] Univ Sherbrooke, Dept Anat & Cell Biol, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada.
   [Wilkins, Benjamin J.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Shah, Premal] Human Genet Inst New Jersey, Piscataway, NJ USA.
   [Tartaglia, Gian G.] ICREA, Barcelona, Spain.
RP Hamilton, KE (corresponding author), Univ Penn, Dept Pediat, Childrens Hosp Philadelphia, Perelman Sch Med,Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
EM hamiltonk1@email.chop.edu
RI Hamilton, Kathryn/AAA-9643-2022; Tartaglia, Gian Gaetano/K-1229-2014
OI Tartaglia, Gian Gaetano/0000-0001-7524-6310; Shah,
   Premal/0000-0002-8424-4218
FU National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001878. NIH K01DK100485];
   Crohn's and Colitis Foundation Career Development Award; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R03DK114463, P30DK050306, T32CA115299-09,
   R01DK056645, K08DK099379, F32DK107052, K01DK103953, R03DK118304,
   R01GM103591, R35GM124976]; Institute for Translational Medicine and
   Therapeutics of the Perelman School of Medicine at the University of
   Pennsylvania; pilot grant program; Children's Hospital of Philadelphia
   Research Institute; European Union through the European Research Council
   [RIBOMY_LOME_309545]; Spanish Ministry of Economy and
   CompetitivenessSpanish Government [BFU2014-55054-P]; AGAURAgencia de
   Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR) [2014 SGR 00685];
   Spanish Ministry of Economy and CompetitivenessSpanish Government;
   Centro de Excelencia Severo Ochoa 2013-2017 [SEV-2012-0208]; HHMI
   Medical Research Fellows Program; Fonds de Recherche en Sante du
   QuebecFonds de la Recherche en Sante du Quebec [P-Giroux-27692,
   P-Giroux-31601]; NIGMSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [T32GM008216-29]; Human Genetics
   Institute of New Jersey; Rutgers University; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [T32CA115299] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR001878]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK099379,
   P30DK050306, K01DK100485, R01DK056645, R03DK114463, R03DK118304,
   K01DK103953, F32DK107052] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R35GM124976, R01GM103591,
   T32GM008216] Funding Source: NIH RePORTER
FX We wish to thank Dr. Anil K. Rustgi (UPenn) and laboratory for support,
   discussions, and technical input. We thank UPenn Core Facilities:
   Molecular Pathology and Imaging, Human and Microbial Analytic
   Repository, Cell Culture/iPS, Flow Cytometry, and Electron Microscopy.
   We thank Dr. Donita Brady (UPenn) and laboratory for technical advice.
   We thank also Drs. T. Stappenbeck, A. Rodriguez, P. Vedula, L. Ghanem,
   and Y. Barash for discussions and advice. We thank Drs. Speigelman and
   Noubissi for Imp1-floxed mice. Research reported in this publication was
   supported by the National Center for Advancing Translational Sciences of
   the National Institutes of Health under Award Number UL1TR001878. NIH
   K01DK100485 (KEH), Crohn's and Colitis Foundation Career Development
   Award (KEH), NIH R03DK114463 (KEH); Institute for Translational Medicine
   and Therapeutics of the Perelman School of Medicine at the University of
   Pennsylvania (KEH); NIH P30DK050306 and its pilot grant program (KEH);
   start-up funds from the Children's Hospital of Philadelphia Research
   Institute (KEH); NIH T32CA115299-09 (SFA); NIH R01DK056645 (PC, RM,
   SFA); NIH K08DK099379 (BJW); European Union Seventh Framework Programme
   (FP7/2007-2013), through the European Research Council and
   RIBOMY_LOME_309545 (GGT), the Spanish Ministry of Economy and
   Competitiveness (BFU2014-55054-P and fellowship to FCS), AGAUR (2014 SGR
   00685), the Spanish Ministry of Economy and Competitiveness, Centro de
   Excelencia Severo Ochoa 2013-2017' (SEV-2012-0208), NIH F32DK107052
   (SFA), NIH K01DK103953 (KAW), NIH R03DK118304 (KAW), HHMI Medical
   Research Fellows Program (ETL), and Fonds de Recherche en Sante du
   Quebec (P-Giroux-27692 and P-Giroux-31601), NIH R01GM103591 (GDW). NIH
   R35GM124976 (SL, HRSW, PS), NIGMS T32GM008216-29 (SWF), start-up funds
   from Human Genetics Institute of New Jersey and Rutgers University (SL,
   HRSW, PS).
CR Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Ascano M, 2012, WIRES RNA, V3, P159, DOI 10.1002/wrna.1103
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Bellucci M, 2011, NAT METHODS, V8, P444, DOI 10.1038/nmeth.1611
   BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642
   Burger E, 2018, CELL HOST MICROBE, V23, P177, DOI 10.1016/j.chom.2018.01.001
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Carja O, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1873-8
   Chatterji P, 2018, GENE DEV, V32, P1020, DOI 10.1101/gad.314369.118
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Cirillo D, 2017, NAT METHODS, V14, P5, DOI 10.1038/nmeth.4100
   Cirillo D, 2013, RNA, V19, P129, DOI 10.1261/rna.034777.112
   Conway AE, 2016, CELL REP, V15, P666, DOI 10.1016/j.celrep.2016.03.052
   Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116
   Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716
   Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007
   Fakhraldeen SA, 2015, J BIOL CHEM, V290, P13386, DOI 10.1074/jbc.M115.655175
   Gu W, 2008, MOL CELL BIOL, V28, P4963, DOI 10.1128/MCB.00266-08
   Gu W, 2012, J CELL SCI, V125, P81, DOI 10.1242/jcs.086132
   Haberman Y, 2014, J CLIN INVEST, V124, P3617, DOI 10.1172/JCI75436
   Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009
   Hamilton KE, 2015, MOL CANCER RES, V13, P1478, DOI 10.1158/1541-7786.MCR-15-0224
   Hamilton Kathryn E, 2015, Cold Spring Harb Protoc, V2015, P354, DOI 10.1101/pdb.prot078303
   Hamilton KE, 2013, CARCINOGENESIS, V34, P2647, DOI 10.1093/carcin/bgt217
   Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004
   Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z
   Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535
   Hubstenberger A, 2017, MOL CELL, V68, P144, DOI 10.1016/j.molcel.2017.09.003
   Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115
   Jin SH, 2018, CELL RES, V28, P955, DOI 10.1038/s41422-018-0069-8
   Jonson L, 2007, MOL CELL PROTEOMICS, V6, P798, DOI 10.1074/mcp.M600346-MCP200
   Kijima T, 2019, CELL MOL GASTROENTER, V7, P73, DOI 10.1016/j.jcmgh.2018.09.003
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093
   Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002
   Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022
   Liu TC, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91917
   Liu TC, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86907
   Liu TC, 2014, INFLAMM BOWEL DIS, V20, P646, DOI 10.1097/01.MIB.0000442838.21040.d7
   Madison BB, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005408
   Madison BB, 2013, GENE DEV, V27, P2233, DOI 10.1101/gad.224659.113
   Manieri NA, 2012, GASTROENTEROLOGY, V143, P110, DOI 10.1053/j.gastro.2012.03.037
   Matsuzawa-Ishimoto Y, 2017, J EXP MED, V214, P3687, DOI 10.1084/jem.20170558
   McGlincy NJ, 2017, METHODS, V126, P112, DOI 10.1016/j.ymeth.2017.05.028
   Merves JF, 2016, AM J GASTROENTEROL, V111, P151, DOI 10.1038/ajg.2015.404
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   Nishino J, 2013, ELIFE, V2, DOI 10.7554/eLife.00924
   Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839
   Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008-5472.CAN-09-1500
   Parham LR, 2019, AM J PHYSIOL-GASTR L, V316, pG197, DOI 10.1152/ajpgi.00403.2017
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158
   RUNGE S, J BIOL CHEM, V275, P2956
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Stappenbeck TS, 2017, GASTROENTEROLOGY, V152, P322, DOI 10.1053/j.gastro.2016.10.003
   Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071
   Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111
   Subtelny AO, 2014, NATURE, V508, P66, DOI 10.1038/nature13007
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   Tu HC, 2015, GENE DEV, V29, P1074, DOI 10.1101/gad.256693.114
   VanDussen KL, 2014, GASTROENTEROLOGY, V146, P200, DOI 10.1053/j.gastro.2013.09.048
   Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039
   Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517
   Washington MK, 2013, GASTROENTEROLOGY, V144, P705, DOI 10.1053/j.gastro.2013.01.067
   Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909
   Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341
   Yousefi M, 2016, J CELL BIOL, V215, P401, DOI 10.1083/jcb.201604119
   Zhong Y, 2017, BIOINFORMATICS, V33, P139, DOI 10.1093/bioinformatics/btw585
NR 71
TC 8
Z9 8
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD JUN
PY 2019
VL 20
IS 6
AR e47074
DI 10.15252/embr.201847074
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IF3HX
UT WOS:000472972600007
PM 31061170
OA Green Submitted, Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Li, C
   Xu, HL
   Chen, XL
   Chen, JJ
   Li, X
   Qiao, G
   Tian, Y
   Yuan, R
   Su, SN
   Liu, XH
   Lin, XK
AF Li, Cong
   Xu, Huanli
   Chen, Xiaoliang
   Chen, Jijun
   Li, Xiao
   Qiao, Gan
   Tian, Ye
   Yuan, Ru
   Su, Shuonan
   Liu, Xiaohui
   Lin, Xiukun
TI Aqueous extract of clove inhibits tumor growth by inducing autophagy
   through AMPK/ULK pathway
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE AMPK; anticancer; aqueous extract of clove; autophagy; traditional
   Chinese medicine
ID TRADITIONAL CHINESE MEDICINE; SYZYGIUM-AROMATICUM
AB Cloves (Syzygium aromaticum), a traditional Chinese medicinal herb, displays broad biological activity. In the present study, the aqueous extract of clove (AEC) was prepared, and its anticancer affects were studied. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium (MTS) analysis revealed that AEC was able to inhibit cancer cell growth in vitro on several cancer cell lines; the IC50 is around 150 mu g/ml for human pancreatic ASPC-1 and human colon HT-29 cancer cells. Treatment of the cancer cells with AEC also diminished the colony formation significantly in both human pancreatic ASPC-1 cancer cells and human colon HT-29 cancer cells. In vivo study revealed that AEC inhibited the tumor growth significantly in HT-29 xenograft mice model. Transmission electron microscope, flow cytometry assay, and fluorescence microscope analysis confirmed that AEC is capable of inducing cell autophagy. Further study showed that AMPK/ULK pathway plays an important role in AEC-induced autophagy in cancer cells. Analysis of AEC components was performed by liquid chromatograph mass spectrometer approach, and more than nine constitutes were identified in AEC fraction. The study provides evidence that AEC has potential to be developed as a novel anticancer agent or as an adjuvant in cancer chemotherapy.
C1 [Li, Cong; Xu, Huanli; Li, Xiao; Qiao, Gan; Tian, Ye; Yuan, Ru; Su, Shuonan; Liu, Xiaohui; Lin, Xiukun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100069, Peoples R China.
   [Chen, Xiaoliang] Shanxi Datong Univ, Basic Med Sch, Datong, Peoples R China.
   [Chen, Jijun] Chinese Acad Sci, Kunming Inst Bot, Kunming, Yunnan, Peoples R China.
RP Lin, XK (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100069, Peoples R China.
EM xiukunlin@126.com
OI Lin, Xiukun/0000-0002-0306-4953
FU National innovative drug development projects of China
   [2014ZX-09102043-001]; Sichuan Sci. and Tech Dept., China [17GJHZ0074,
   2017HH0104]; Zibo Development Program of Sci. & Tech, in Shandong, China
   [2016kj100048]; Department of Sci and Tech in Shandong Province of China
   [ZR2017MH027, 2018YYSP025, ZR2017MH117, 2016GSF201183]; National Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81773776, 81573457]
FX National innovative drug development projects of China, Grant/Award
   Number: 2014ZX-09102043-001; Sichuan Sci. and Tech Dept., China,
   Grant/Award Numbers: 17GJHZ0074 and 2017HH0104; Zibo Development Program
   of Sci. & Tech, in Shandong, China, Grant/Award Number: 2016kj100048;
   Department of Sci and Tech in Shandong Province of China, Grant/Award
   Numbers: ZR2017MH027, 2018YYSP025, ZR2017MH117 and 2016GSF201183;
   National Science Foundation of China, Grant/Award Numbers: 81773776 and
   81573457
CR Banerjee S, 2006, CARCINOGENESIS, V27, P1645, DOI 10.1093/carcin/bgi372
   Chan HYL, 2014, EUR J ONCOL NURS, V18, P445, DOI 10.1016/j.ejon.2014.05.005
   Cortes-Rojas Diego Francisco, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P90, DOI 10.1016/S2221-1691(14)60215-X
   Draz H, 2017, CELL SIGNAL, V40, P172, DOI 10.1016/j.cellsig.2017.09.006
   Ezzat SM, 2012, Z NATURFORSCH C, V67, P266, DOI 10.5560/ZNC.2012.67c0266
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lee MS, 2017, MOL CARCINOGEN, V56, P2578, DOI 10.1002/mc.22702
   Leng JCF, 2014, J CANCER EDUC, V29, P56, DOI 10.1007/s13187-013-0542-5
   Li CA, 2017, PHYTOMEDICINE, V28, P10, DOI 10.1016/j.phymed.2017.02.008
   Liu HZ, 2013, ONCOL RES, V21, P247, DOI 10.3727/096504014X13946388748910
   Pourgholami MH, 1999, J ETHNOPHARMACOL, V64, P167, DOI 10.1016/S0378-8741(98)00121-4
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Qi FH, 2011, INT IMMUNOPHARMACOL, V11, P342, DOI 10.1016/j.intimp.2010.12.007
   Tian Y, 2018, PHYTOTHER RES, V32, P1320, DOI 10.1002/ptr.6064
   Wang CY, 2014, AM J CHINESE MED, V42, P543, DOI 10.1142/S0192415X14500359
   Wu Q, 2018, FOOD FUNCT, V9, P1736, DOI 10.1039/c7fo01964e
   Yamagata K, 2018, MOL CELL BIOCHEM, V441, P9, DOI 10.1007/s11010-017-3171-1
NR 19
TC 11
Z9 15
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUL
PY 2019
VL 33
IS 7
BP 1794
EP 1804
DI 10.1002/ptr.6367
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IM3RP
UT WOS:000477912800005
PM 30993793
DA 2022-04-25
ER

PT J
AU Potocnjak, I
   Simic, L
   Gobin, I
   Vukelic, I
   Domitrovic, R
AF Potocnjak, Iva
   Simic, Lidija
   Gobin, Ivana
   Vukelic, Iva
   Domitrovic, Robert
TI Antitumor activity of luteolin in human colon cancer SW620 cells is
   mediated by the ERK/FOXO3a signaling pathway
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Colon cancer SW620 cells; Luteolin; Mitogen-activated protein kinase;
   Forkhead box O3a; Apoptosis; Autophagy
ID MESENCHYMAL TRANSITION; AUTOPHAGY; APOPTOSIS; FOXO3A; INHIBITION;
   PROLIFERATION; ANTIOXIDANT; CISPLATIN
AB The aim of this study was to investigate the mechanism of the anticancer activity of luteolin in metastatic human colon cancer SW620 cells. Luteolin dose-dependently reduced the viability and proliferation of SW620 cells and increased the expression of antioxidant enzymes. The expression of antiapoptotic protein Bcl-2 decreased whereas the expression of proapoptotic proteins Box and caspase-3 increased by luteolin treatment, resulting in increased poly (ADP-ribose) polymerase (PARP) cleavage and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positivity. Luteolin also increased the expression of autophagic proteins Beclin-1, autophagy-related protein 5 (Atg5) and microtubule-associated protein 1A/1B-light chain 3 beta-I/II (LC3B-I/II), while the usage of 3-methyladenine suggested a prosurvival role of autophagy. Moreover, treatment with luteolin induced reversal of the epithelial-mesenchymal transition process through the suppression of the wingless-related integration site protein (Wnt)/beta-catenin pathway. The cytotoxic activity of luteolin coincided with the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and forkhead box O3a (FOXO3a). Treatment with the mitogen-activated protein kinase kinase (MEK) inhibitor PD0325901 inhibited ERK-dependent FOXO3a phosphorylation, resulting in increased FOXO3a expression and apoptosis, with the suppression of autophagy. The results of the current study suggest the antitumor activity of luteolin in SW620 cells through the ERK/FOXO3a-dependent mechanism, as well as its antimetastatic potential.
C1 [Potocnjak, Iva; Simic, Lidija; Vukelic, Iva; Domitrovic, Robert] Univ Rijeka, Fac Med, Dept Med Chem Biochem & Clin Chem, B Branchetta 20, Rijeka 51000, Croatia.
   [Gobin, Ivana] Univ Rijeka, Fac Med, Dept Microbiol & Parasitol, Rijeka, Croatia.
RP Domitrovic, R (corresponding author), Univ Rijeka, Fac Med, Dept Med Chem Biochem & Clin Chem, B Branchetta 20, Rijeka 51000, Croatia.
EM robert.domitrovic@uniri.hr
RI Vukelić, Iva/R-8489-2018; Potočnjak, Iva/Q-9579-2018; Gobin,
   Ivana/O-6889-2018
OI Vukelić, Iva/0000-0002-4244-5206; Potočnjak, Iva/0000-0002-0815-2805;
   Gobin, Ivana/0000-0002-8956-4675
FU University of Rijeka [13.06.1.2.24, 13.06.2.2.60]
FX This research was supported by grants from the University of Rijeka
   (Projects 13.06.1.2.24 and 13.06.2.2.60).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Ashokkumar P, 2011, INVEST NEW DRUG, V29, P273, DOI 10.1007/s10637-009-9359-9
   Bi W, 2018, FOOD FUNCT, V9, P2809, DOI 10.1039/c8fo00054a
   Brandt R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10954-y
   Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864
   Chakrabarti M, 2016, APOPTOSIS, V21, P312, DOI 10.1007/s10495-015-1198-x
   Chen H, 2016, ASIAN PAC J TROP MED, V9, P46, DOI 10.1016/j.apjtm.2015.12.010
   Cheng ZY, 2019, TRENDS ENDOCRIN MET, V30, P658, DOI 10.1016/j.tem.2019.07.009
   de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Domitrovic R, 2013, TOXICOLOGY, V310, P115, DOI 10.1016/j.tox.2013.05.015
   Domitrovic R, 2009, TOXICOL APPL PHARM, V241, P311, DOI 10.1016/j.taap.2009.09.001
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507
   de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Hewitt RE, 2000, J PATHOL, V192, P446
   Imran M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108612
   Juan TK, 2018, ONCOL LETT, V15, P7716, DOI 10.3892/ol.2018.8286
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang JI, 2016, BIOMOL THER, V24, P320, DOI 10.4062/biomolther.2015.145
   Kang Kyoung Ah, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0238-y
   Kang KA, 2017, INT J ONCOL, V51, P1169, DOI 10.3892/ijo.2017.4091
   Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037
   Kustiawan PM, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0139-4
   Lee Y, 2019, BIOCHEM BIOPH RES CO, V517, P617, DOI 10.1016/j.bbrc.2019.07.073
   Lin CN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1114-3
   Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001
   Liu J, 2016, TUMOR BIOL, V37, P8181, DOI 10.1007/s13277-015-4668-4
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mascotti K, 2000, TRANSFUSION, V40, P693, DOI 10.1046/j.1537-2995.2000.40060693.x
   Meng J.R., 2010, PLOS ONE, V5
   Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Paglin S, 2001, CANCER RES, V61, P439
   Pai SG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0471-6
   Redondo-Blanco S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00109
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281
   Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s-0028-1088314
   Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014
   Shimoi K, 1998, FEBS LETT, V438, P220, DOI 10.1016/S0014-5793(98)01304-0
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Taylor S, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0156-6
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128
   Verschooten L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048264
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
   Zhu WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115087
NR 54
TC 17
Z9 18
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD AUG
PY 2020
VL 66
AR 104852
DI 10.1016/j.tiv.2020.104852
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA LS1AM
UT WOS:000536124600018
PM 32268164
DA 2022-04-25
ER

PT J
AU Zaanan, A
   Park, JM
   Tougeron, D
   Huang, SB
   Wu, TT
   Foster, NR
   Sinicrope, FA
AF Zaanan, Aziz
   Park, Jae Myung
   Tougeron, David
   Huang, Shengbing
   Wu, Tsung-Teh
   Foster, Nathan R.
   Sinicrope, Frank A.
TI Association of beclin 1 expression with response to neoadjuvant
   chemoradiation therapy in patients with locally advanced rectal
   carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE beclin 1; rectal cancer; chemoradiation; autophagy; biomarker
ID PATHOLOGICAL COMPLETE RESPONSE; POSTOPERATIVE CHEMORADIOTHERAPY;
   PREOPERATIVE CHEMORADIATION; PROGNOSTIC IMPACT; CANCER; AUTOPHAGY;
   5-FLUOROURACIL; RADIOTHERAPY; INHIBITION; RESISTANCE
AB Beclin 1 is an essential regulator of autophagy that is induced in response to cellular stress and serves to maintain cell survival in established tumors. We recently demonstrated that Beclin 1 suppression can sensitize colorectal cancer cells to radiation-induced DNA damage and apoptosis. Therefore, we hypothesized that the level of Beclin 1 expression may be associated with radiation sensitivity in vivo. We determined the association of Beclin 1 expression in pretreatment rectal cancer tissues with response to neoadjuvant chemoradiation in surgical resection specimens. Stages II and III (n=96) rectal adenocarcinoma patients were treated with neoadjuvant chemoradiation followed by surgical resection with curative intent. Beclin 1 was analyzed by immunohistochemistry and the expression level was dichotomized at the median value with categorization into low and high groups. We identified 56 (58.3%) and 40 (41.7%) patients whose tumors had high- versus low-level Beclin 1 expression, respectively. Rectal cancers with high versus low Beclin 1 expression were significantly less likely to be downstaged after chemoradiation treatment (45% [25/55] vs. 58% [22/38]; p=0.02). In a multivariable analysis adjusted for age, sex, histological grade and baseline tumor node metastasis (TNM) stage, the impact of Beclin 1 expression on tumor downstaging remained statistically significant (p=0.03). The association of the level of Beclin 1 expression with the rate of tumor downstaging after chemoradiation is consistent with in vitro data, and suggests that Beclin 1 may be a predictive biomarker for the efficacy of chemoradiation in patients with rectal cancer.
   What's new? Patients with nonmetastatic rectal cancer routinely receive chemotherapy and radiation before surgery. However, a predictive marker for the efficacy of chemoradiation is lacking. Here, the authors show that the essential autophagy protein Beclin 1 -known to protect against radiation-induced DNA damage- could be such a predictive marker. In locally advanced rectal cancer patients, high-level Beclin 1 expression in pretreatment tumor tissues was associated with a significantly reduced rate of tumor downstaging after chemoradiation and vice versa, supporting a new role of Beclin 1 as a clinical biomarker.
C1 [Zaanan, Aziz; Park, Jae Myung; Tougeron, David; Huang, Shengbing; Sinicrope, Frank A.] Mayo Clin, Dept Med, Rochester, MN 55905 USA.
   [Zaanan, Aziz; Park, Jae Myung; Tougeron, David; Huang, Shengbing; Wu, Tsung-Teh; Foster, Nathan R.; Sinicrope, Frank A.] Mayo Canc Ctr, Rochester, MN 55905 USA.
   [Wu, Tsung-Teh] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN 55905 USA.
   [Foster, Nathan R.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Sinicrope, Frank A.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.
RP Sinicrope, FA (corresponding author), Mayo Clin, Dept Med, 200 First St SW, Rochester, MN 55905 USA.
EM sinicrope.frank@mayo.edu
RI tougeron, david/ABF-3217-2020
OI tougeron, david/0000-0002-8065-9635; Zaanan, Aziz/0000-0001-8372-5653
FU National Cancer Institute Senior Scientist Award [K05CA-142885];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [K05CA142885, P30CA015083] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK084567] Funding Source: NIH RePORTER
FX Grant sponsor: National Cancer Institute Senior Scientist Award; Grant
   number: K05CA-142885
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Capirci C, 2008, INT J RADIAT ONCOL, V72, P99, DOI 10.1016/j.ijrobp.2007.12.019
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chen YS, 2013, PATHOL RES PRACT, V209, P562, DOI 10.1016/j.prp.2013.06.006
   Chetty R, 2012, J CLIN PATHOL, V65, P865, DOI 10.1136/jclinpath-2012-201054
   Firat E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047357
   Garcia-Aguilar J, 2011, ANN SURG, V254, P486, DOI 10.1097/SLA.0b013e31822b8cfa
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Janjan NA, 2001, AM J CLIN ONCOL-CANC, V24, P107, DOI 10.1097/00000421-200104000-00001
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kikuchi M, 2009, BRIT J CANCER, V101, P116, DOI 10.1038/sj.bjc.6605105
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   MacGregor TP, 2012, J CLIN PATHOL, V65, P867, DOI 10.1136/jclinpath-2012-200958
   Marusch F, 2011, ENDOSCOPY, V43, P425, DOI 10.1055/s-0030-1256111
   Negri FV, 2008, BRIT J CANCER, V98, P143, DOI 10.1038/sj.bjc.6604131
   Park IJ, 2012, J CLIN ONCOL, V30, P1770, DOI 10.1200/JCO.2011.39.7901
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202
   Stipa F, 2006, ANN SURG ONCOL, V13, P1047, DOI 10.1245/ASO.2006.03.053
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Theodoropoulos G, 2002, DIS COLON RECTUM, V45, P895, DOI 10.1007/s10350-004-6325-7
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
NR 29
TC 13
Z9 14
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP
PY 2015
VL 137
IS 6
BP 1498
EP 1502
DI 10.1002/ijc.29496
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM6OT
UT WOS:000357808900030
PM 25708267
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Elamin, KM
   Motoyama, K
   Higashi, T
   Yamashita, Y
   Tokuda, A
   Arima, H
AF Elamin, Khaled M.
   Motoyama, Keiichi
   Higashi, Taishi
   Yamashita, Yuki
   Tokuda, Azumi
   Arima, Hidetoshi
TI Dual targeting system by supramolecular complex of folate-conjugated
   methyl-beta-cyclodextrin with adamantane-grafted hyaluronic acid for the
   treatment of colorectal cancer
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Dual targeting; Folate receptor; CD44; Methyl beta cyclodextrin;
   Hyaluronic acid; Supramolecular complex
ID DRUG-DELIVERY; CELLULAR UPTAKE; IN-VIVO; NANOPARTICLES; CELLS;
   AUTOPHAGY; MICE; INVOLVEMENT; ACTIVATION; THERAPY
AB In our previous study, we demonstrated that folate-appended methyl cyclodextrin (FA-M-beta-CyD) was a promising antitumor agent for the treatment of folate receptor-alpha (FR-alpha)-expressing tumors. In the present study, to enhance the antitumor effect of FA-M-beta-CyD against FR-alpha- and CD44-expressing colorectal cancer cells, we synthesized a dual targeting supramolecular complex composed of FA-M-beta-CyD and adamantane-grafted hyaluronic acid (Ad-HA). The supramolecular complex of Ad-HA/FA-M-beta-CyD showed higher cytotoxic activity in HCT116 cells (FR-alpha (+), CD44 (+)), a human colon cancer cell line, than FA-M-beta-CyD alone. In addition, the cytotoxic activity of Ad-HA/FA-M-beta-CyD was significantly impaired by the addition of FA and HA, as inhibitors of FR-alpha and CD44, respectively. Furthermore, tetramethylrhodamine isothiocyanate (TRITC)-labeled FA-M-beta-CyD was efficiently internalized into HCT116 cells through supramolecular complexation with Ad-HA, compared to that of TRITC-FA-M-beta-CyD alone. Additionally, Ad-HA/FA-M-beta-CyD induced mitophagy in HCT116 cells. These results suggest that Ad-HA/FA-M-beta-CyD targeted HCT116 cells, as well as induced mitophagy-mediated cell death. Notably, an intravenous injection of the Ad-HA/FA-M-beta-CyD complex in a mouse model of colorectal cancer significantly ameliorated the growth of tumor polyps. Collectively, these results suggest that Ad-HA/FA-M-beta-CyD has antiproliferation effects in tumors, based on the dual targeting activity. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Elamin, Khaled M.; Motoyama, Keiichi; Higashi, Taishi; Yamashita, Yuki; Tokuda, Azumi; Arima, Hidetoshi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.
   [Arima, Hidetoshi] Kumamoto Univ, Program Leading Grad Sch HIGO Hlth Life Sci Inter, Kumamoto, Japan.
RP Arima, H (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.
EM arimah@gpo.kumamoto-u.ac.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16K08198]; Japan Agency for Medical Research
   and Development (AMED)Japan Agency for Medical Research and Development
   (AMED) [10801104]; Center for Clinical and Translational Research of
   Kyushu University [A103]; Ministry of Health, Labour and WelfareMinistry
   of Health, Labour and Welfare, Japan [24-0003]
FX This work was partially supported by a Grant-in-Aid for Scientific
   Research (C) from the Japan Society for the Promotion of Science
   (16K08198), the Japan Agency for Medical Research and Development (AMED,
   10801104), the Center for Clinical and Translational Research of Kyushu
   University (A103), and the Ministry of Health, Labour and Welfare
   24-0003.
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Arima H, 2005, BIOCHEM PHARMACOL, V70, P1506, DOI 10.1016/j.bcp.2005.08.021
   Badwaik V, 2016, MOL PHARMACEUT, V13, P1176, DOI 10.1021/acs.molpharmaceut.6b00078
   Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Contreras-Ruiz L, 2011, MOL VIS, V17, P279
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Elamin KM, 2018, CHEM PHARM BULL, V66, P277, DOI 10.1248/cpb.c17-00824
   Grosse PY, 1998, BRIT J CANCER, V78, P1165, DOI 10.1038/bjc.1998.648
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hou XY, 2017, BIOMATERIALS, V124, P195, DOI 10.1016/j.biomaterials.2016.12.032
   Jokerst JV, 2011, ACCOUNTS CHEM RES, V44, P1050, DOI 10.1021/ar200106e
   Jono H, 2011, BIOCHEM J, V437, P35, DOI 10.1042/BJ20110041
   Kameyama K, 2017, INT J NANOMED, V12, P3433, DOI 10.2147/IJN.S133482
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Miyake H, 1998, J UROLOGY, V160, P1562, DOI 10.1016/S0022-5347(01)62613-2
   Motoyama K, 2005, FEBS LETT, V579, P1707, DOI 10.1016/j.febslet.2005.01.076
   Motoyama K, 2017, BEILSTEIN J ORG CHEM, V13, P10, DOI 10.3762/bjoc.13.2
   Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018
   Oh EJ, 2010, J CONTROL RELEASE, V141, P2, DOI 10.1016/j.jconrel.2009.09.010
   Onodera R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04417
   Onodera R, 2013, INT J PHARMACEUT, V452, P116, DOI 10.1016/j.ijpharm.2013.04.071
   Onodera R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01104
   Onodera R, 2011, J INCL PHENOM MACRO, V70, P321, DOI 10.1007/s10847-010-9843-z
   Oommen OP, 2016, ACS APPL MATER INTER, V8, P20614, DOI 10.1021/acsami.6b06823
   Suzuki M, 2002, BBA-MOL CELL RES, V1591, P37, DOI 10.1016/S0167-4889(02)00246-X
   Termsarasab U, 2013, INT J PHARMACEUT, V441, P373, DOI 10.1016/j.ijpharm.2012.11.018
   Vite CH, 2015, SCI TRANSL MED, V7
   Xu XY, 2015, TRENDS MOL MED, V21, P223, DOI 10.1016/j.molmed.2015.01.001
   Yang DS, 2017, HUM MOL GENET, V26, P843, DOI 10.1093/hmg/ddx001
   Yang Y, 2016, BIOCONJUGATE CHEM, V27, P2834, DOI 10.1021/acs.bioconjchem.6b00606
   Yokoo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141946
   Yoo JW, 2011, ADV DRUG DELIVER REV, V63, P1247, DOI 10.1016/j.addr.2011.05.004
   Zhang MZ, 2016, CANCER RES, V76, P7208, DOI 10.1158/0008-5472.CAN-16-1681
   Zimmer S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6100
NR 39
TC 12
Z9 12
U1 7
U2 103
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD JUL 1
PY 2018
VL 113
BP 386
EP 394
DI 10.1016/j.ijbiomac.2018.02.149
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA GG2EP
UT WOS:000432503100045
PM 29486262
DA 2022-04-25
ER

PT J
AU Iovine, B
   Guardia, F
   Irace, C
   Bevilacqua, MA
AF Iovine, Barbara
   Guardia, Francesca
   Irace, Carlo
   Bevilacqua, Maria Assunta
TI L-carnosine dipeptide overcomes acquired resistance to 5-fluorouracil in
   HT29 human colon cancer cells via downregulation of HIF1-alpha and
   induction of apoptosis
SO BIOCHIMIE
LA English
DT Article
DE Hypoxia-inducible factor-1; 5-Fluorouracil; L-carnosine;
   Chemoresistance; Apoptosis; Multi-drug resistance
ID SHOCK-PROTEIN 27; MULTIDRUG-RESISTANCE; HYPOXIA; THERAPY; HIF-1-ALPHA;
   SENSITIVITY; SUPPRESSION; MECHANISMS; EXPRESSION; AUTOPHAGY
AB Hypoxia-inducible factor (HIF-1 alpha) protein is over-expressed in many human cancers and is a major cause of resistance to drugs. HIF-1 alpha up-regulation decreases the effectiveness of several anticancer agents, including 5-fluorouracil (5-FU), because it induces the expression of drug efflux transporters, alters DNA repair mechanisms and modifies the balance between pro- and antiapoptotic factors. These findings suggest that inhibition of HIF-1 alpha activity may sensitize cancer cells to cytotoxic drugs. We previously reported that L-carnosine reduces HIF-1 alpha expression by inhibiting the proliferation of colon cancer cells. In the present study we investigated the effect of L-carnosine on HT29 colon cancer cells with acquired resistance to 5-FU. We found that L-carnosine reduces colon cancer cell viability, decreases HIF-1 alpha and multi-drug resistant protein MDR1-pg expression, and induces apoptosis. Moreover, the L-carnosine/5-FU combination lowers the expression of some chemoresistance markers. The combination index evaluated in vitro on the HT29-5FU cell line by median drug effect analysis reveals a significant synergistic effect. (C) 2016 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Iovine, Barbara; Guardia, Francesca; Bevilacqua, Maria Assunta] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Via Sergio Pansini 5, I-80131 Naples, Italy.
   [Irace, Carlo] Univ Naples Federico II, Dipartimento Farm, Via Domenico Montesano 49, I-80131 Naples, Italy.
RP Iovine, B (corresponding author), Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM barbara.iovine@unina.it
CR Cecconi D, 2009, PROTEOMICS, V9, P1952, DOI 10.1002/pmic.200701089
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen N, 2009, J BIOL CHEM, V284, P10004, DOI 10.1074/jbc.M805997200
   Comerford KM, 2002, CANCER RES, V62, P3387
   Di Gennaro E, 2009, CANCER BIOL THER, V8, P782, DOI 10.4161/cbt.8.9.8118
   Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Gomez-Monterrey I, 2013, J AMINO ACIDS, V2013
   Hayashi R, 2012, ONCOL REP, V28, P1269, DOI 10.3892/or.2012.1935
   Iovine B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096755
   Iovine B, 2012, CANCER LETT, V315, P122, DOI 10.1016/j.canlet.2011.07.021
   Iovine B, 2009, BIOCHIMIE, V91, P364, DOI 10.1016/j.biochi.2008.10.017
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Koh MY, 2010, RECENT RESULTS CANC, V180, P15, DOI 10.1007/978-3-540-78281-0_3
   Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Li S, 2015, CURR TOP MED CHEM, V15, P720, DOI 10.2174/1568026615666150302105343
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mirjolet JF, 2000, BRIT J CANCER, V83, P1380, DOI 10.1054/bjoc.2000.1455
   Mistry P, 2001, CANCER RES, V61, P749
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nardinocchi L, 2010, PLOS ONE, V12
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Ravizza R, 2009, EUR J CANCER, V45, P890, DOI 10.1016/j.ejca.2008.12.021
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Silva R., 2015, PHARMACOL THERAPEUT, V123, P149
   Tsuruta M, 2008, ONCOL REP, V20, P1165, DOI 10.3892/or_00000125
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   Vitiello G, 2015, J MATER CHEM B, V3, P3011, DOI 10.1039/c4tb01807a
   Wang XF, 2007, LEUKEMIA RES, V31, P989, DOI 10.1016/j.leukres.2006.09.001
NR 32
TC 12
Z9 12
U1 0
U2 17
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD AUG
PY 2016
VL 127
BP 196
EP 204
DI 10.1016/j.biochi.2016.05.010
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DR7LZ
UT WOS:000380082500022
PM 27234614
DA 2022-04-25
ER

PT J
AU Li, YH
   Yu, YL
   Kang, L
   Lu, Y
AF Li, Yuhua
   Yu, Yalu
   Kang, Ling
   Lu, Ying
TI Effects of chlorin e6-mediated photodynamic therapy on human colon
   cancer SW480 cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Colorectal cancer; chlorin e6; photodynamic therapy; SW480 cells
ID SUBCELLULAR-LOCALIZATION; COLORECTAL-CANCER; AUTOPHAGY; DEATH;
   APOPTOSIS; E(6); MITOCHONDRIAL; RESISTANCE; ARREST
AB Objective: This study is to investigate the antitumor effects and possible mechanisms of chlorin e6-mediated photodynamic therapy (Ce6-PDT) on human colon cancer SW480 cells. Methods: SW480 cells were treated with Ce6, followed by photodynamic irradiation. Subcellular localization of Ce6 in SW480 cells was observed with confocal laser scanning microscopy (LSCM). Reactive oxygen species (ROS) levels were monitored with fluorescence microscopy. Cell proliferation and apoptosis were detected by the MTT assay and flow cytometry, respectively. Scratch test and colony formation assay were employed to analyze the cell migration ability and colony formation ability. Results: LSCM showed that, in SW480 cells, Ce6 was evenly distributed within the ER and lysosomes, with nearly no distribution in the mitochondria and nuclei. When SW480 cells were subjected to Ce6-PDT, the ROS levels would be elevated, in a dose-dependent manner. Moreover, Ce6-PDT treatment could inhibit the cell proliferation and enhance the apoptotic process, in SW480 cells. However, Ce6 treatment alone without photodynamic irradiation could not induce any significant differences in the cell proliferation and apoptosis. In addition, the migration ability and colony formation ability of SW480 cells were decreased by Ce6-PDT treatment at appropriate dosages. Conclusion: Ce6-PDT treatment could enhance ROS production and apoptosis, inhibit cell proliferation, decrease migration ability and colony formation ability, in SW480 cells, in a dose-dependent manner. These findings might provide experimental evidence for the application of Ce6-PDT in clinical treatment of colorectal cancer.
C1 [Li, Yuhua; Kang, Ling; Lu, Ying] Xinjiang Med Univ, Coll Publ Hlth, Dept Occupat & Environm Hlth, Urumqi 830011, Xinjiang, Peoples R China.
   [Yu, Yalu] Xinjiang Med Univ, Coll Publ Hlth, Cent Lab, Urumqi 830011, Xinjiang, Peoples R China.
RP Kang, L (corresponding author), Xinjiang Med Univ, Coll Publ Hlth, Dept Occupat & Environm Hlth, 393 Xinyi Rd, Urumqi 830011, Xinjiang, Peoples R China.
EM lingkang12201@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81060186]; Xinjiang Uygur Autonomous Region
   Natural Science Foundation [2014211C003]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81060186) and the Xinjiang Uygur Autonomous Region Natural
   Science Foundation (No. 2014211C003).
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Galanou MC, 2008, PHOTOCHEM PHOTOBIOL, V84, P1073, DOI 10.1111/j.1751-1097.2008.00392.x
   Garg AD, 2010, APOPTOSIS, V15, P1050, DOI 10.1007/s10495-010-0479-7
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x
   Kessel D, 2007, PHOTOCHEM PHOTOBIOL, V83, P1024, DOI 10.1111/j.1751-1097.2007.00088.x
   KOSTENICH GA, 1994, J PHOTOCH PHOTOBIO B, V22, P211, DOI 10.1016/1011-1344(93)06974-8
   Lee LS, 2010, PHOTODIAGN PHOTODYN, V7, P213, DOI 10.1016/j.pdpdt.2010.08.005
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   Mojzisova H, 2007, BBA-BIOMEMBRANES, V1768, P2748, DOI 10.1016/j.bbamem.2007.07.002
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nitsche Ulrich, 2011, Ann Surg, V254, P793, DOI 10.1097/SLA.0b013e3182369101
   Oliveira CS, 2011, FREE RADICAL BIO MED, V51, P824, DOI 10.1016/j.freeradbiomed.2011.05.023
   Orenstein A, 1996, BRIT J CANCER, V73, P937, DOI 10.1038/bjc.1996.185
   Peng Q, 1996, ULTRASTRUCT PATHOL, V20, P109, DOI 10.3109/01913129609016306
   Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2
   Sasnauskiene A, 2009, AUTOPHAGY, V5, P743, DOI 10.4161/auto.5.5.8701
   Sheleg SV, 2004, PHOTODERMATOL PHOTO, V20, P21, DOI 10.1111/j.1600-0781.2004.00078.x
   Wang JB, 2007, HEPATO-GASTROENTEROL, V54, P718
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Yoo JO, 2012, INT REV CEL MOL BIO, V295, P139, DOI 10.1016/B978-0-12-394306-4.00010-1
NR 24
TC 24
Z9 27
U1 1
U2 18
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2014
VL 7
IS 12
BP 4867
EP 4876
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AZ6BP
UT WOS:000348303600026
PM 25663983
DA 2022-04-25
ER

PT J
AU Wang, AT
   Ding, L
   Wu, ZQ
   Ding, R
   Teng, XL
   Wang, FX
   Hu, ZL
   Chen, L
   Yu, XY
   Zou, Q
AF Wang, Aiting
   Ding, Lei
   Wu, Zhongqiu
   Ding, Rui
   Teng, Xiao-Lu
   Wang, Feixiang
   Hu, Zhilin
   Chen, Lei
   Yu, Xiaoyan
   Zou, Qiang
TI ZFP91 is required for the maintenance of regulatory T cell homeostasis
   and function
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID IFN-GAMMA; AUTOPHAGY; METABOLISM; SURVIVAL; STABILIZES; EXPRESSION;
   NETWORKS; CANCER; GENE
AB Autophagy programs the metabolic and functional fitness of regulatory T reg) cells to establish immune tolerance, yet the mechanisms governing autophagy initiation in T reg cells remain unclear. Here, we show that the E3 ubiquitin ligase ZFP91 facilitates autophagy activation to sustain T reg cell metabolic programming and functional integrity. T reg cell-specific deletion of Zfp91 caused T reg cell dysfunction and exacerbated colonic inflammation and inflammation-driven colon carcinogenesis. TCR-triggered autophagy induction largely relied on T reg cell-derived ZFP91 to restrict hyperglycolysis, which is required for the maintenance of T reg cell homeostasis. Mechanistically, ZFP91 rapidly translocated from the nucleus to the cytoplasm in response to TCR stimulation and then mediated BECN1 ubiquitination to promote BECN1-PIK3C3 complex formation. Therefore, our results highlight a ZFP91-dependent mechanism promoting TCR-initiated autophagosome maturation to maintain T reg cell homeostasis and function.
C1 [Wang, Aiting; Wu, Zhongqiu; Ding, Rui; Teng, Xiao-Lu; Wang, Feixiang; Hu, Zhilin; Yu, Xiaoyan; Zou, Qiang] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes,Shanghai, Hongqiao Int Inst Med,Tongren Hosp,Dept Immunol &, Shanghai, Peoples R China.
   [Ding, Lei; Chen, Lei] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Inst Immunol,Dept Immunol & Microbiol, Shanghai, Peoples R China.
RP Yu, XY; Zou, Q (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes,Shanghai, Hongqiao Int Inst Med,Tongren Hosp,Dept Immunol &, Shanghai, Peoples R China.; Chen, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Inst Immunol,Dept Immunol & Microbiol, Shanghai, Peoples R China.
EM lei.chen@sjtu.edu.cn; yuxy@shsmu.edu.cn; qzou1984@sjtu.edu.cn
OI Teng, Xiao-Lu/0000-0002-8490-4570; Wang, Aiting/0000-0003-3177-9961;
   Zou, Qiang/0000-0002-1362-2007
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81930040, 31922025, 31870884, 31900631];
   Shanghai Municipal Health and Family Planning Commission [2018YQ08];
   Natural Science Foundation of ShanghaiNatural Science Foundation of
   Shanghai [19ZR1445700]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81930040, 31922025, 31870884, 31900631), the
   Shanghai Municipal Health and Family Planning Commission (2018YQ08), and
   the Natural Science Foundation of Shanghai (19ZR1445700).
CR Alon R, 2017, IMMUNITY, V47, P805, DOI 10.1016/j.immuni.2017.11.006
   Campbell C, 2020, CELL METAB, V31, P18, DOI 10.1016/j.cmet.2019.09.010
   Chen D, 2020, THERANOSTICS, V10, P8558, DOI 10.7150/thno.44873
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012
   Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820
   Jin XJ, 2010, J BIOL CHEM, V285, P30539, DOI 10.1074/jbc.M110.129551
   Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444
   Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017
   Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384
   Li CY, 2006, J IMMUNOL, V177, P5163, DOI 10.4049/jimmunol.177.8.5163
   Li XH, 2017, J EXP MED, V214, P1093, DOI 10.1084/jem.20161105
   Masui K, 2013, CELL METAB, V18, P726, DOI 10.1016/j.cmet.2013.09.013
   Mi CL, 2018, BRIT J PHARMACOL, V175, P4338, DOI 10.1111/bph.14493
   Newton R, 2016, NAT IMMUNOL, V17, P618, DOI 10.1038/ni.3466
   Parekh VV, 2013, J IMMUNOL, V190, P5086, DOI 10.4049/jimmunol.1202071
   Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706
   Ren JZ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000270
   Saravia J, 2020, CELL RES, V30, P328, DOI 10.1038/s41422-020-0301-1
   Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Takahashi R, 2011, J EXP MED, V208, P2055, DOI 10.1084/jem.20110428
   Tang DE, 2020, CARCINOGENESIS, V41, P56, DOI 10.1093/carcin/bgz085
   Unoki M, 2003, INT J ONCOL, V22, P1217
   Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365
   West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896
   Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020
   Xu SH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0525-x
   Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025
   Yu XY, 2018, J EXP MED, V215, P2463, DOI 10.1084/jem.20180397
   Zeng H, 2017, CURR OPIN IMMUNOL, V46, P103, DOI 10.1016/j.coi.2017.04.005
   Zheng TT, 2018, P NATL ACAD SCI USA, V115, pE12313, DOI 10.1073/pnas.1814705115
   Zou Q, 2015, CELL REP, V13, P2470, DOI 10.1016/j.celrep.2015.11.046
   Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885
NR 37
TC 3
Z9 4
U1 2
U2 7
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD FEB 1
PY 2021
VL 218
IS 2
AR e20201217
DI 10.1084/jem.20201217
PG 14
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA QI4UT
UT WOS:000618975300005
PM 33355624
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Sasaki, K
   Tsuno, NH
   Sunami, E
   Tsurita, G
   Kawai, K
   Okaji, Y
   Nishikawa, T
   Shuno, Y
   Hongo, K
   Hiyoshi, M
   Kaneko, M
   Kitayama, J
   Takahashi, K
   Nagawa, H
AF Sasaki, Kazuhito
   Tsuno, Nelson H.
   Sunami, Eiji
   Tsurita, Giichiro
   Kawai, Kazushige
   Okaji, Yurai
   Nishikawa, Takeshi
   Shuno, Yasutaka
   Hongo, Kumiko
   Hiyoshi, Masaya
   Kaneko, Manabu
   Kitayama, Joji
   Takahashi, Koki
   Nagawa, Hirokazu
TI Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
   colon cancer cells
SO BMC CANCER
LA English
DT Article
ID OLD DRUG; AUTOPHAGY; APOPTOSIS; GROWTH; INHIBITION; INDUCTION; DEATH;
   LYMPHOMA; KINASES; ARREST
AB Background: Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs. It has been shown to inhibit cell growth and/or to induce cell death in various types of cancer. 5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-FU develops through various mechanisms. Here, we focused on the combination of CQ as a mechanism to potentiate the inhibitory effect of 5-FU on human colon cancer cells.
   Methods: HT-29 cells were treated with CQ and/or 5-FU, and their proliferative ability, apoptosis and autophagy induction effects, and the affection of the cell cycle were evaluated. The proliferative ability of HT-29 was analyzed by the MTS assay. Apoptosis was quantified by flow-cytometry after double-staining of the cells with AnnexinV/PI. The cell cycle was evaluated by flow-cytometry after staining of cells with PI. Autophagy was quantified by flow-cytometry and Western blot analysis. Finally, to evaluate the fate of the cells treated with CQ and/or 5-FU, the colony formation assay was performed.
   Results: 5-FU inhibited the proliferative activity of HT-29 cells, which was mostly dependent on the arrest of the cells to the G0/G1-phase but also partially on apoptosis induction, and the effect was potentiated by CQ pretreatment. The potentiation of the inhibitory effect of 5-FU by CQ was dependent on the increase of p21(Cip1) and p27(Kip1) and the decrease of CDK2. Since CQ is reported to inhibit autophagy, the catabolic process necessary for cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective mechanism against chemotherapeutic agents, we also analyzed the induction of autophagy in HT-29. HT-29 induced autophagy in response to 5-FU, and CQ inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-FU.
   Conclusion: Our findings suggest that the combination therapy with CQ should be a novel therapeutic modality to improve efficacy of 5-FU-based chemotherapy, possibly by inhibiting autophagy-dependent resistance to chemotherapy.
C1 [Sasaki, Kazuhito; Tsuno, Nelson H.; Sunami, Eiji; Tsurita, Giichiro; Kawai, Kazushige; Nishikawa, Takeshi; Shuno, Yasutaka; Hongo, Kumiko; Hiyoshi, Masaya; Kaneko, Manabu; Kitayama, Joji; Nagawa, Hirokazu] Univ Tokyo, Fac Med Sci, Dept Surg Oncol, Tokyo 1138655, Japan.
   [Tsuno, Nelson H.; Okaji, Yurai; Takahashi, Koki] Univ Tokyo, Fac Med Sci, Dept Transfus Med, Tokyo 1138655, Japan.
RP Sasaki, K (corresponding author), Univ Tokyo, Fac Med Sci, Dept Surg Oncol, Tokyo 1138655, Japan.
EM sasakik-sur@h.u-tokyo.ac.jp
RI Kawai, Kazushige/AAF-4334-2020
OI Kawai, Kazushige/0000-0002-5881-0036
CR Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ashktorab H, 2005, DIGEST DIS SCI, V50, P1025, DOI 10.1007/s10620-005-2698-2
   Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243
   BIJNSDORP IV, 2009, INT J CANC
   CHOI S, CANC LETT
   Dang CV, 2008, J CLIN INVEST, V118, P15, DOI 10.1172/JCI34503
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   FRAILE RJ, 1980, CANCER RES, V40, P2223
   Grivicich I, 2005, CHEMOTHERAPY, V51, P93, DOI 10.1159/000085617
   Hu C, 2008, BIOORGAN MED CHEM, V16, P7888, DOI 10.1016/j.bmc.2008.07.076
   Jiang PD, 2008, CELL PHYSIOL BIOCHEM, V22, P431, DOI 10.1159/000185488
   LI J, 2005, EUR J CANCER, V46, P1900
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Munshi A, 2009, CANCER, V115, P2380, DOI 10.1002/cncr.24288
   NISHIKAWA T, 2009, ANN SURG ONCOL
   PAN J, CANC LETT, V293, P167
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X
   Rahim R, 2009, ANTI-CANCER DRUG, V20, P736, DOI 10.1097/CAD.0b013e32832f4e50
   Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Tasdemir Ezgi, 2008, V445, P29, DOI 10.1007/978-1-59745-157-4_3
   Tasdemir E, 2007, CELL CYCLE, V6, P2263, DOI 10.4161/cc.6.18.4681
   WONG CH, PLOS ONE, V5, pE9996
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Xu R, 2006, HISTOL HISTOPATHOL, V21, P867, DOI 10.14670/HH-21.867
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18
NR 34
TC 235
Z9 252
U1 1
U2 42
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 15
PY 2010
VL 10
AR 370
DI 10.1186/1471-2407-10-370
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 661GG
UT WOS:000282713100001
PM 20630104
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sun, T
   Ming, L
   Yan, YM
   Zhang, Y
   Xue, HK
AF Sun, Ting
   Ming, Liang
   Yan, Yunmeng
   Zhang, Yan
   Xue, Haikuo
TI Beclin 1 acetylation impairs the anticancer effect of aspirin in
   colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE aspirin; autophagy; Beclin 1; acetylation; colorectal cancer
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B; SALICYLIC-ACID;
   MONITORING AUTOPHAGY; POTENTIAL ROLE; BREAST-CANCER; APOPTOSIS; RISK;
   INHIBITION; PREVENTION
AB Regular use of aspirin can reduce cancer incidence, recurrence, metastasis and cancer-related mortality. Aspirin suppresses proliferation and induces apoptosis and autophagy in colorectal cancer cells, but the precise mechanism is not clear. In this study, we demonstrated that aspirin induced autophagosome formation in colorectal cancer cells, but autophagic degradation was blocked through aspirin-mediated Beclin 1 acetylation. Blocked autophagic degradation weakened aspirin-induced cell death. Collectively, our findings indicate the dual roles of aspirin on autophagy, and demonstrate a new mechanism by which Beclin 1 acetylation impairs the anticancer effect of aspirin in colorectal cancer cells.
C1 [Sun, Ting; Ming, Liang; Yan, Yunmeng; Zhang, Yan; Xue, Haikuo] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Key Clin Lab Henan Prov, Zhengzhou 450052, Henan, Peoples R China.
   [Sun, Ting; Ming, Liang; Yan, Yunmeng; Zhang, Yan; Xue, Haikuo] Zhengzhou Univ, Dept Lab Med, Zhengzhou 450001, Henan, Peoples R China.
RP Ming, L (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Key Clin Lab Henan Prov, Zhengzhou 450052, Henan, Peoples R China.; Ming, L (corresponding author), Zhengzhou Univ, Dept Lab Med, Zhengzhou 450001, Henan, Peoples R China.
EM mingliangzzu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31501123]; Youth Innovation Fund of the
   First Affiliated Hospital of Zhengzhou University
FX This research was supported by National Natural Science Foundation of
   China (Grant No. 31501123) and the Youth Innovation Fund of the First
   Affiliated Hospital of Zhengzhou University.
CR Ai GQ, 2016, TUMOR BIOL, V37, P1727, DOI 10.1007/s13277-015-3959-0
   Alfonso LF, 2009, INT J ONCOL, V34, P597, DOI 10.3892/ijo_00000185
   Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0
   Carrat F, 2014, CLIN RES HEPATOL GAS, V38, P9, DOI 10.1016/j.clinre.2013.09.007
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   Choi HW, 2015, MOL MED, V21, P526, DOI 10.2119/molmed.2015.00148
   Dachineni R, 2016, MOL CANCER RES, V14, P241, DOI 10.1158/1541-7786.MCR-15-0360
   Dikshit P, 2006, J BIOL CHEM, V281, P29228, DOI 10.1074/jbc.M602629200
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913
   Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Goel A, 2003, CLIN CANCER RES, V9, P383
   Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345
   Harris RE, 2007, INT J BIOL SCI, V3, P328
   Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   LECOMTE M, 1994, J BIOL CHEM, V269, P13207
   Luciani MG, 2007, CARCINOGENESIS, V28, P2207, DOI 10.1093/carcin/bgm101
   Marimuthu S, 2011, INT J ONCOL, V39, P1273, DOI 10.3892/ijo.2011.1113
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   McCaffrey P, 2006, LANCET ONCOL, V7, P16, DOI 10.1016/S1470-2045(05)70523-4
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   O'Hara A, 2014, J CELL SCI, V127, P3659, DOI 10.1242/jcs.149328
   Ranjan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26165
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   Sun T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8215
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   VANE JR, 1990, STROKE, V21, P12
   Wang JG, 2015, SCI REP-UK, V5, DOI 10.1038/srep07896
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 43
TC 4
Z9 5
U1 2
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 26
PY 2017
VL 8
IS 43
BP 74781
EP 74790
DI 10.18632/oncotarget.20367
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FI2HT
UT WOS:000411760400115
PM 29088823
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhou, QM
   Zhao, Y
   Fu, XH
   Chen, QQ
   Tang, YQ
   Gao, XP
AF Zhou, Qiming
   Zhao, Yan
   Fu, Xiaohong
   Chen, Qianqi
   Tang, Yueqiang
   Gao, Xiaoping
TI Naturally occurring triterpene Lupane exerts anticancer effects on
   colorectal cancer cells via induction of apoptosis and autophagy and
   suppresses cell migration and invasion by targeting MMP-9
SO JOURNAL OF BUON
LA English
DT Article
DE Lupane; anticancer; apoptosis; proliferation; cell cycle arrest; flow
   cytometry
ID SECONDARY METABOLITES; SAPONINS; DRUGS
AB Purpose: This study was undertaken with a purpose to examine the anticancer effects of Lupane against human colorectal cancer.
   Methods: The SW48 colorectal cell line and CDD18Co normal colon cell line were used in this study. The CCK8 assay was used to determine cell proliferation while acridine orange (AO)/ethidium bromide (EB) and DAPI staining assays were used to detect apoptosis. Wound healing and transwell assays were used to detect the cell migration and invasion. Western blotting was used to determine protein expression.
   Results: Lupane inhibited the proliferation of colorectal cancer cells and the level of inhibition followed dose-dependent pattern. The antiproliferative role of Lupane was exerted via induction of apoptotic cell death. Western blot showed that the expression of Bcl-2 was decreased and that of Bax was increaced. Lupane also prompted the autophagy of the SW48 colorectal cancer cells and enhanced the expression of LC3-II. However, the expression of p62 was depleted. The treatment of Lupane also resulted to inhibition of the migratory potential of cancer cells as revealed by the wound healing assay. The invasion of SW48 cancer cells was also suppressed and was associated with suppression of metalloproteinase-9 (MMP-9) expression.
   Conclusion: The results indicate the anticancer potential of Lupane against the colorectal cancer growth and propagation. The study envisages the importance of natural compounds for their usage against human cancers.
C1 [Zhou, Qiming; Zhao, Yan; Fu, Xiaohong; Chen, Qianqi; Tang, Yueqiang; Gao, Xiaoping] Huazhong Univ Sci & Technol Union, Shenzhen Hosp, Canc Ctr, Shenzhen 518052, Peoples R China.
RP Zhou, QM (corresponding author), Huazhong Univ Sci & Technol Union, Shenzhen Hosp, 89 Taoyuan Rd, Shenzhen 518052, Peoples R China.
EM zqm1977122@163.com
FU Basic Research Projects of Shenzhen Knowledge Innovation Program
   [JCYj20180302144716002]
FX Funding from Basic Research Projects of Shenzhen Knowledge Innovation
   Program (NO. JCYj20180302144716002) is acknowledged.
CR Carpenter SR, 2009, P NATL ACAD SCI USA, V106, P1305, DOI 10.1073/pnas.0808772106
   Cipollini ML, 1997, AM NAT, V150, P346, DOI 10.1086/286069
   Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004
   Cmoch P, 2008, CARBOHYD RES, V343, P995, DOI 10.1016/j.carres.2008.02.011
   Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018
   Just MJ, 1998, PLANTA MED, V64, P404, DOI 10.1055/s-2006-957469
   Kommera H, 2010, EUR J MED CHEM, V45, P3346, DOI 10.1016/j.ejmech.2010.04.018
   Luo J, 2002, ACTA PHARM SIN, V7, P6
   Oparin A. I., 2003, ORIGIN LIFE
   Phillips DR, 2006, CURR OPIN PLANT BIOL, V9, P305, DOI 10.1016/j.pbi.2006.03.004
   Pichersky E, 2000, TRENDS PLANT SCI, V5, P439, DOI 10.1016/S1360-1385(00)01741-6
   Prakash C. V. S., 2012, Research Journal of Pharmaceutical Sciences, V1, P23
   Raja A, 2010, INT J PHARMACOL, V6, P360
   Rajandeep Kaur, 2011, Journal of Natural Product and Plant Resources, V1, P119
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Thimmappa R, 2014, ANNU REV PLANT BIOL, V65, P225, DOI 10.1146/annurev-arplant-050312-120229
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   WINK M, 1988, THEOR APPL GENET, V75, P225, DOI 10.1007/BF00303957
   Ye YQ, 2017, J MED CHEM, V60, P6353, DOI 10.1021/acs.jmedchem.7b00679
NR 19
TC 2
Z9 2
U1 1
U2 3
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAR-APR
PY 2020
VL 25
IS 2
BP 884
EP 889
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NE1TJ
UT WOS:000562380000014
PM 32521882
DA 2022-04-25
ER

PT J
AU Gornowicz, A
   Szymanowska, A
   Mojzych, M
   Bielawski, K
   Bielawska, A
AF Gornowicz, Agnieszka
   Szymanowska, Anna
   Mojzych, Mariusz
   Bielawski, Krzysztof
   Bielawska, Anna
TI The Effect of Novel
   7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine
   Sulfonamide Derivatives on Apoptosis and Autophagy in DLD-1 and HT-29
   Colon Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal cancer; apoptosis; autophagy; anticancer agents; roscovitine;
   5-fluorouracil
ID 1,2,4-TRIAZINE DERIVATIVES; PLATINUM(II) COMPLEX; SILDENAFIL ANALOGS;
   ROSCOVITINE; TYROSINASE; ANTI-MUC1
AB The discovery of cytotoxic drugs is focused on designing a compound structure that directly affects cancer cells without an impact on normal cells. The mechanism of anticancer activity is mainly related with activation of apoptosis. However, recent scientific reports show that autophagy also plays a crucial role in cancer cell progression. Thus, the objective of this study was to synthesize 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine utilizing nucleophilic substitution reaction at the position N1. The biological activity of tested compounds was assessed in DLD-1 and HT-29 cell lines. The induction of apoptosis was confirmed by Annexin V binding assay and acridine orange/ethidium bromide staining. The loss of mitochondrial membrane potential and caspase-8 activity was estimated using cytometer flow analysis. The concentration of p53, LC3A, LC3B and beclin-1 was measured using the ELISA technique. Our study revealed that anticancer activity of 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine derivatives is related with initiation of apoptosis occur on the intrinsic pathway with mitochondrial membrane decrease and extrinsic with increase of activity of caspase-8. Moreover, a decrease in beclin-1, LC3A, and LC3B were observed in two cell lines after treatment with novel compounds. This study showed that novel 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine derivatives might be a potential strategy in colon cancer treatment.
C1 [Gornowicz, Agnieszka; Szymanowska, Anna; Bielawska, Anna] Med Univ Bialystok, Dept Biotechnol, PL-15222 Bialystok, Poland.
   [Mojzych, Mariusz] Siedlce Univ Nat Sci & Humanities, Dept Chem, PL-08110 Siedlce, Poland.
   [Bielawski, Krzysztof] Med Univ Bialystok, Dept Synth & Technol Drugs, PL-15222 Bialystok, Poland.
RP Gornowicz, A (corresponding author), Med Univ Bialystok, Dept Biotechnol, PL-15222 Bialystok, Poland.
EM agnieszka.gornowicz@umb.edu.pl; anna.szymanowska@umb.edu.pl;
   mmojzych@yahoo.com; kbiel@umb.edu.pl; anna.bielawska@umb.edu.pl
RI Mojzych, Mariusz/AAC-7302-2020
OI Mojzych, Mariusz/0000-0002-9884-6068; Gornowicz,
   Agnieszka/0000-0002-0945-7870; Szymanowska, Anna/0000-0003-4783-3336
FU Ministry of Science and Higher Education from the "Innovation Incubator
   2.0" program from the European Regional Development Fund
   [II2.0/2019/UD/01]; Medical University of Bialystok
   [SUB/2/DN/20/002/2229]
FX This research was funded by Ministry of Science and Higher Education
   from the "Innovation Incubator 2.0" program from the European Regional
   Development Fund, grant number II2.0/2019/UD/01. This research was
   funded by Medical University of Bialystok, grant number
   SUB/2/DN/20/002/2229.
CR Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058
   Bracht K, 2010, BRIT J CANCER, V103, P340, DOI 10.1038/sj.bjc.6605780
   Cascioferro S, 2017, EUR J MED CHEM, V142, P328, DOI 10.1016/j.ejmech.2017.08.009
   Cicenas J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.61
   Czajkowska A, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9153403
   Gariboldi MB, 2015, CANCER LETT, V364, P156, DOI 10.1016/j.canlet.2015.05.008
   Gornowicz A, 2019, ONCOL REP, V42, P1391, DOI 10.3892/or.2019.7256
   Gornowicz A, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701641
   Gornowicz A, 2015, MOL CELL BIOCHEM, V408, P103, DOI 10.1007/s11010-015-2486-z
   Gornowicz A, 2014, MOL CELL BIOCHEM, V392, P161, DOI 10.1007/s11010-014-2018-2
   Gucky T, 2009, EUR J MED CHEM, V44, P891, DOI 10.1016/j.ejmech.2008.05.026
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Karczmarzyk Z, 2007, J MOL STRUCT, V829, P22, DOI 10.1016/j.molstruc.2006.06.003
   Koustas E, 2018, WORLD J GASTRO ONCOL, V10, P367, DOI 10.4251/wjgo.v10.i11.367
   Kumar R, 2014, MINI-REV MED CHEM, V14, P168, DOI 10.2174/1389557514666140131111837
   Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333
   Lepiarczyk M, 2015, ARCH PHARM RES, V38, P628, DOI 10.1007/s12272-014-0444-z
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   LINDNER HJ, 1972, CHEM BER-RECL, V105, P1949, DOI 10.1002/cber.19721050619
   Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516
   Mamolo MG, 2000, FARMACO, V55, P590, DOI 10.1016/S0014-827X(00)00074-4
   Matysiak J, 2017, COMPUT BIOL CHEM, V71, P57, DOI 10.1016/j.compbiolchem.2017.09.006
   Miyamoto K, 1996, HETEROCYCLES, V43, P1513, DOI [10.3987/COM-96-7494, DOI 10.3987/COM-96-7494]
   Mojzych M, 2005, MOLECULES, V10, P1298, DOI 10.3390/10101298
   Mojzych M, 2004, HETEROCYCLES, V63, P1829
   Mojzych M., 2019, Polish Patent Application, Patent No. [PCT/PL2019/000110, 2019000110]
   Mojzych M, 2020, MOLECULES, V25, DOI 10.3390/molecules25010221
   Mojzych M, 2018, MED CHEM, V14, P53, DOI 10.2174/1573406413666171020114924
   Mojzych M, 2017, J ENZYM INHIB MED CH, V32, P99, DOI 10.1080/14756366.2016.1238362
   Mojzych M, 2015, BIOORGAN MED CHEM, V23, P1421, DOI 10.1016/j.bmc.2015.02.026
   Mojzych M, 2014, BIOORGAN MED CHEM, V22, P6616, DOI 10.1016/j.bmc.2014.10.009
   Mojzych M, 2014, J MOL STRUCT, V1067, P147, DOI 10.1016/j.molstruc.2014.03.025
   Mojzych M, 2014, BIOORGAN MED CHEM, V22, P2643, DOI 10.1016/j.bmc.2014.03.029
   Mojzych M, 2014, EUR J MED CHEM, V78, P217, DOI 10.1016/j.ejmech.2014.03.054
   Mojzych M, 2011, J CHEM SOC PAKISTAN, V33, P698
   Mojzych M, 2011, J CHEM SOC PAKISTAN, V33, P123
   Mullick P, 2009, ACTA POL PHARM, V66, P379
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pawowska N., 2018, NEW DRUGS, V36, P970, DOI 10.1007/s10637-018-0584-y 29549610
   Qian MJ, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0154-5
   Smirnov VV, 1997, FEMS MICROBIOL LETT, V153, P357, DOI 10.1016/S0378-1097(97)00274-7
   Supuran CT, 2017, MOLECULES, V22, DOI 10.3390/molecules22101642
   Traini R, 2010, MOL CANCER THER, V9, P2007, DOI 10.1158/1535-7163.MCT-10-0257
   Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0
   Wang L, 2013, LIFE SCI, V93, P344, DOI 10.1016/j.lfs.2013.07.007
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110
NR 49
TC 6
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 15
AR 5221
DI 10.3390/ijms21155221
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MZ3GG
UT WOS:000559010100001
PM 32717981
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lu, Y
   Zhang, XJ
   Wang, JY
   Chen, KS
AF Lu, Yan
   Zhang, Xiujuan
   Wang, Jiayue
   Chen, Kaoshan
TI Exopolysaccharides isolated from Rhizopus nigricans induced colon cancer
   cell apoptosis in vitro and in vivo via activating the AMPK pathway
SO BIOSCIENCE REPORTS
LA English
DT Article
ID PROTEIN-KINASE; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; PHOSPHORYLATION;
   POLYSACCHARIDES; AUTOPHAGY; ANTITUMOR; RAPTOR; GROWTH; MTOR
AB Colorectal cancer (CRC) is a leading cause of cancer-related human deaths. The exopolysaccharide (EPS1-1), isolated from Rhizopus nigricans, has been described as exhibiting anti-tumor and pro-apoptotic activity against CRC, although the underlying mechanism is poorly understood. Herein, we investigate how EPS1-1 induces apoptosis of CRC cells in vitro and in vivo. Our results show that, in vitro, EPS1-1 suppressed cell growth and facilitated apoptosis in a dose- and time-dependent manner by activating the AMP-activated protein kinase (AMPK) pathway in mouse colon cancer CT26 cells. However, treatment with small interfering RNAs (siRNAs) targeting AMPK alpha or with compound C, an AMPK inhibitor, interfered with the pro-apoptosis effects of EPS1-1. We also show that EPS1-1 initiated the release of reactive oxygen species (ROS) and liver kinase B1 (LKB1), both of which are necessary signals for AMPK activation. Furthermore, EPS1-1-mediated apoptosis is regulated by inactivation of mammalian target of rapamycin complex 1 (mTORC1) and activation of the jun-NH2 kinase (JNK)-p53 signaling axis dependent on AMPK activation. In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues. Collectively, these findings suggest that EPS1-1-induced apoptosis relies on the activation of the AMPK pathway. The present study provides evidence suggesting that EPS1-1 may be an effective target for development of novel CRC therapeutic agents.
C1 [Lu, Yan; Zhang, Xiujuan; Wang, Jiayue; Chen, Kaoshan] Shandong Univ, Sch Life Sci, Qingdao 266000, Peoples R China.
   [Chen, Kaoshan] Shandong Univ, Natl Glycoengn Res Ctr, Qingdao 266000, Peoples R China.
   [Chen, Kaoshan] Wannan Med Coll, Anhui Prov Engn Res Ctr Polysaccharide Drugs, Anhui Prov Key Lab Act Biol Macromol, Drug Res & Dev Ctr,Sch Pharm, Wuhu 241002, Peoples R China.
RP Chen, KS (corresponding author), Shandong Univ, Sch Life Sci, Qingdao 266000, Peoples R China.; Chen, KS (corresponding author), Shandong Univ, Natl Glycoengn Res Ctr, Qingdao 266000, Peoples R China.; Chen, KS (corresponding author), Wannan Med Coll, Anhui Prov Engn Res Ctr Polysaccharide Drugs, Anhui Prov Key Lab Act Biol Macromol, Drug Res & Dev Ctr,Sch Pharm, Wuhu 241002, Peoples R China.
EM ksc313@126.com
FU National Key Research and Development Program of China [2018YFA0902000];
   Major Program of Shandong Province (Key Technology) [2015ZDJS04002];
   Major State Basic Research Development Program of China (973
   Program)National Basic Research Program of China [2012CB822102]; High
   Technology Research and Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [2012AA021501]; Natural Science Foundation of Education Department
   of Anhui Province [KJ2018ZD025]
FX This work was supported by the National Key Research and Development
   Program of China [grant number 2018YFA0902000]; the Major Program of
   Shandong Province (Key Technology) [grant number 2015ZDJS04002]; the
   Major State Basic Research Development Program of China (973 Program)
   [grant number 2012CB822102]; the High Technology Research and
   Development Program of China (863 Program) [grant number 2012AA021501];
   and the Natural Science Foundation of Education Department of Anhui
   Province [grant number KJ2018ZD025].
CR Callejas BE, 2019, INT J CANCER, V145, P3126, DOI 10.1002/ijc.32626
   Canedo-Antelo M, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00333
   Cao JF, 2016, BIOORG MED CHEM LETT, V26, P2098, DOI 10.1016/j.bmcl.2016.02.012
   Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/NCHEMBIO.610, 10.1038/nchembio.610]
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen GC, 2013, CARBOHYD POLYM, V97, P800, DOI 10.1016/j.carbpol.2013.05.068
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Cui HY, 2016, FOOD FUNCT, V7, P1616, DOI 10.1039/c6fo00027d
   Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Draz H, 2017, CELL SIGNAL, V40, P172, DOI 10.1016/j.cellsig.2017.09.006
   Duan WX, 2017, CANCER LETT, V385, P225, DOI 10.1016/j.canlet.2016.10.019
   Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001
   Feregrino-Perez AA, 2008, J AGR FOOD CHEM, V56, P8737, DOI 10.1021/jf8007162
   Guan W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01137
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   Hinchy EC, 2018, J BIOL CHEM, V293, P17208, DOI 10.1074/jbc.RA118.002579
   Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Irrcher I, 2009, AM J PHYSIOL-CELL PH, V296, pC116, DOI 10.1152/ajpcell.00267.2007
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Ji XL, 2018, INT J BIOL MACROMOL, V114, P1127, DOI 10.1016/j.ijbiomac.2018.03.186
   Jing YS, 2014, CARBOHYD POLYM, V102, P288, DOI 10.1016/j.carbpol.2013.11.061
   Khan AS, 2017, NAT REV UROL, V14, P164, DOI 10.1038/nrurol.2016.272
   Kim JH, 2013, CELL SIGNAL, V25, P805, DOI 10.1016/j.cellsig.2012.12.005
   Kim MJ, 2010, J BIOL CHEM, V285, P14617, DOI 10.1074/jbc.M109.085456
   Kim WH, 2007, CELL SIGNAL, V19, P791, DOI 10.1016/j.cellsig.2006.10.004
   Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002
   Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100
   Li WD, 2015, MOL CARCINOGEN, V54, P1096, DOI 10.1002/mc.22179
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   Liu SY, 2018, CANCER LETT, V416, P11, DOI 10.1016/j.canlet.2017.12.008
   Liu XF, 2014, APOPTOSIS, V19, P1532, DOI 10.1007/s10495-014-1025-9
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001
   Lu ZY, 2017, CHEM-BIOL INTERACT, V277, P62, DOI 10.1016/j.cbi.2017.08.011
   Mungai PT, 2011, MOL CELL BIOL, V31, P3531, DOI 10.1128/MCB.05124-11
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   Pan SJ, 2018, CANCER LETT, V412, P21, DOI 10.1016/j.canlet.2017.09.051
   Park KJ, 2009, BIOCHEM BIOPH RES CO, V382, P726, DOI 10.1016/j.bbrc.2009.03.095
   Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Shukla K, 2017, CANCER LETT, V411, P57, DOI 10.1016/j.canlet.2017.09.031
   Song G, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.01.054
   Sun DN, 2017, CANCER LETT, V406, P105, DOI 10.1016/j.canlet.2017.06.029
   Tedesco I, 2001, J NUTR BIOCHEM, V12, P505, DOI 10.1016/S0955-2863(01)00164-4
   Wang Q, 2019, INT J BIOL SCI, V15, P24, DOI 10.7150/ijbs.28633
   Wang XH, 2016, INT J CHEM ENG, V2016, DOI 10.1155/2016/5217802
   Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001
   WINDER WW, 1996, AM J PHYSIOL, V270, pE29
   Wu F, 2018, CANCER LETT, V435, P1, DOI 10.1016/j.canlet.2018.07.031
   Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200
   Yang XH, 2019, LIFE SCI, V219, P20, DOI 10.1016/j.lfs.2018.12.052
   Yu WQ, 2016, INT J BIOL MACROMOL, V82, P299, DOI 10.1016/j.ijbiomac.2015.10.005
   Yu ZD, 2016, CARBOHYD POLYM, V148, P318, DOI 10.1016/j.carbpol.2016.04.068
   Yue LL, 2012, CARBOHYD POLYM, V88, P1326, DOI 10.1016/j.carbpol.2012.02.015
   Zeng J, 2018, THERANOSTICS, V8, P109, DOI 10.7150/thno.20356
   Zhan PP, 2017, MOL CARCINOGEN, V56, P1427, DOI 10.1002/mc.22603
   Zhu L, 2016, INT IMMUNOPHARMACOL, V36, P218, DOI 10.1016/j.intimp.2016.04.033
   Zong AZ, 2012, CARBOHYD POLYM, V90, P1395, DOI 10.1016/j.carbpol.2012.07.026
NR 65
TC 1
Z9 1
U1 3
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JAN 14
PY 2020
VL 40
AR BSR20192774
DI 10.1042/BSR20192774
PN 1
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KC9TM
UT WOS:000507514600001
PM 31894839
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kocaturk, NM
   Akkoc, Y
   Kig, C
   Bayraktar, O
   Gozuacik, D
   Kutlu, O
AF Kocaturk, Nur Mehpare
   Akkoc, Yunus
   Kig, Cenk
   Bayraktar, Oznur
   Gozuacik, Devrim
   Kutlu, Ozlem
TI Autophagy as a molecular target for cancer treatment
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the European-Federation-of-Pharmaceutical-Sciences
   (EUFEPS)
CY MAY 24-26, 2018
CL Athens, GREECE
SP European Federat Pharmaceut Sci
DE Autophagy; Cancer; Therapeutic agents
ID ENDOPLASMIC-RETICULUM STRESS; STARVATION-INDUCED AUTOPHAGY; TYROSINE
   KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTORS; CELL-DEATH; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLASE; MAMMALIAN TARGET;
   COLON-CANCER
AB Autophagy is an evolutionarily conserved catabolic mechanism, by which eukaryotic cells recycle or degrades internal constituents through membrane-trafficking pathway. Thus, autophagy provides the cells with a sustainable source of biomolecules and energy for the maintenance of homeostasis under stressful conditions such as tumor microenvironment. Recent findings revealed a close relationship between autophagy and malignant transformation. However, due to the complex dual role of autophagy in tumor survival or cell death, efforts to develop efficient treatment strategies targeting the autophagy/cancer relation have largely been unsuccessful. Here we review the two-faced role of autophagy in cancer as a tumor suppressor or as a pro-oncogenic mechanism. In this sense, we also review the shared regulatory pathways that play a role in autophagy and malignant transformation. Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed.
C1 [Kocaturk, Nur Mehpare; Gozuacik, Devrim; Kutlu, Ozlem] Sabanci Univ, Nanotechnol Res & Applicat Ctr SUNUM, Orta Mah Univ Cad 27, TR-34956 Istanbul, Turkey.
   [Akkoc, Yunus; Gozuacik, Devrim] Sabanci Univ, Mol Biol Genet & Bioengn Program, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey.
   [Kig, Cenk] Istanbul Yeni Yuzyil Univ, Fac Med, TR-34010 Istanbul, Turkey.
   [Bayraktar, Oznur] Okan Univ, Dept Med Biol & Genet, Fac Med, Istanbul, Turkey.
RP Kutlu, O (corresponding author), Sabanci Univ, Nanotechnol Res & Applicat Ctr SUNUM, Orta Mah Univ Cad 27, TR-34956 Istanbul, Turkey.
EM ozlemkutlu@sabanciuniv.edu
RI Abdulsalam, Raghad/AAR-5226-2021; kig, cenk/ABI-4009-2020; Kocaturk,
   Nur/V-3125-2018; Devrim, Gozuacik/C-3330-2008; AKKOC,
   Yunus/AAK-8853-2020
OI kig, cenk/0000-0002-6318-5001; Kocaturk, Nur/0000-0002-4452-9913;
   Devrim, Gozuacik/0000-0001-7739-2346; AKKOC, Yunus/0000-0001-5379-6151;
   Kutlu, Ozlem/0000-0002-3769-2536
FU Scientific and Technological Research Council of Turkey
   (TUBITAK)-1001Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
   [114Z836]; TUBITAK-BIDEB 2211Turkiye Bilimsel ve Teknolojik Arastirma
   Kurumu (TUBITAK)
FX This work was supported by Scientific and Technological Research Council
   of Turkey (TUBITAK)-1001 Grant number: 114Z836. YA is supported by
   TUBITAK-BIDEB 2211 Scholarships for his PhD studies.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672
   Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878
   Adiseshaiah PP, 2013, CANCER LETT, V337, P254, DOI 10.1016/j.canlet.2013.04.034
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   Akkoc Y, 2015, BIOMED PHARMACOTHER, V71, P161, DOI 10.1016/j.biopha.2015.02.029
   Alexander A, 2010, AUTOPHAGY, V6, P672, DOI 10.4161/auto.6.5.12509
   Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   An H, 2018, NAT CELL BIOL, V20, P135, DOI 10.1038/s41556-017-0007-x
   Antar A, 2015, CL LYMPH MYELOM LEUK, V15, P298, DOI 10.1016/j.clml.2014.12.005
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Awada A, 2011, DRUG TODAY, V47, P335, DOI 10.1358/dot.2011.47.5.1584110
   Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098
   Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461
   Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bialik S., 2006, ANNU REV BIOCHEM, DOI [10.1146/annurev.biochem.75.103004, DOI 10.1146/ANNUREV.BIOCHEM.75.103004]
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591
   Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200
   Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107
   Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387
   Carew J. S., 2007, BLOOD, DOI [10.1182/blood-2006;10:050260, DOI 10.1182/BLOOD-2006;10:050260]
   Carroll B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02746-z
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chan CH, 2019, MOL CANCER RES, V17, P555, DOI 10.1158/1541-7786.MCR-18-0551
   Chano T, 2002, GENE, V291, P29, DOI 10.1016/S0378-1119(02)00585-1
   Chaturvedi AK, 2010, CANCER EPIDEM BIOMAR, V19, P1498, DOI 10.1158/1055-9965.EPI-09-1261
   Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200
   Chen HD, 2015, INT J CANCER, V137, P12, DOI 10.1002/ijc.29180
   Chen N, 2013, AUTOPHAGY, V9, P1214, DOI 10.4161/auto.24870
   Chen YS, 2011, DIS ESOPHAGUS, V24, P437, DOI 10.1111/j.1442-2050.2010.01156.x
   Chen Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11035
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cheng X, 2014, INT J MOL MED, V34, P772, DOI 10.3892/ijmm.2014.1822
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Chiao MT, 2013, AUTOPHAGY, V9, P1509, DOI 10.4161/auto.25664
   Chinen Y, 2014, CANCER RES, V74, P7418, DOI 10.1158/0008-5472.CAN-14-1420
   Choi MS, 2013, EXP DERMATOL, V22, P491, DOI 10.1111/exd.12175
   Choudhury S, 2013, CELL CYCLE, V12, P1022, DOI 10.4161/cc.24128
   Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Chu YL, 2012, J AGR FOOD CHEM, V60, P8363, DOI 10.1021/jf301298y
   Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752
   Cuppens T, 2017, CLIN CANCER RES, V23, P1274, DOI 10.1158/1078-0432.CCR-16-2149
   Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038
   Dan HC, 2014, J BIOL CHEM, V289, P25227, DOI 10.1074/jbc.M114.554881
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Del Bel M, 2017, J AM CHEM SOC, V139, P6819, DOI 10.1021/jacs.7b02829
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Desideri E, 2012, AUTOPHAGY, V8, P1769, DOI 10.4161/auto.22037
   Di HF, 2016, DRUG DEV IND PHARM, V42, P2038, DOI 10.1080/03639045.2016.1190743
   Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111
   Du GJ, 2012, NUTRIENTS, V4, P1679, DOI 10.3390/nu4111679
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Dupere-Richer D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.210
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604
   Eberhart K, 2014, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 1: MOLECULAR MECHANISMS, P179, DOI 10.1016/B978-0-12-405530-8.00013-3
   Eliopoulos AG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00204
   Ellmerich S, 2000, CARCINOGENESIS, V21, P753, DOI 10.1093/carcin/21.4.753
   Elzinga BM, 2013, AM J HEMATOL, V88, P455, DOI 10.1002/ajh.23428
   Emadi A, 2010, BLOOD REV, V24, P191, DOI 10.1016/j.blre.2010.04.001
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Estfan B, 2013, AM J CLIN ONCOL-CANC, V36, P319, DOI 10.1097/COC.0b013e3182468039
   Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584
   Feng YC, 2016, AUTOPHAGY, V12, P648, DOI 10.1080/15548627.2016.1157237
   Ferguson LR, 2015, SEMIN CANCER BIOL, V35, pS5, DOI 10.1016/j.semcancer.2015.03.005
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Fremont L., 2001, ANTIOXID REDOX SIGN, DOI [10.1089/152308601317203567, DOI 10.1089/152308601317203567]
   Fu JH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-68
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Fulda S., 2015, ONCOGENE, DOI [10.1038/onc.2014, DOI 10.1038/ONC.2014]
   Fullgrabe J, 2016, J CELL SCI, V129, P3059, DOI 10.1242/jcs.188920
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Gao JH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0595-y
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Gao YP, 2017, ONCOTARGET, V8, P7420, DOI 10.18632/oncotarget.14558
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gaur S, 2015, ONCOTARGET, V6, P29161, DOI 10.18632/oncotarget.4971
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Gorshtein A, 2009, ENDOCR-RELAT CANCER, V16, P1017, DOI 10.1677/ERC-08-0269
   Gorzalczany Y, 2011, CANCER LETT, V310, P207, DOI 10.1016/j.canlet.2011.07.002
   Goussetis DJ, 2012, BLOOD, V120, P3555, DOI 10.1182/blood-2012-01-402578
   Goussetis DJ, 2010, J BIOL CHEM, V285, P29989, DOI 10.1074/jbc.M109.090530
   Gowda Saralamma Venu Venkatarame, 2018, Oncotarget, V9, P5993, DOI 10.18632/oncotarget.23202
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Greene LM, 2013, INT J ONCOL, V43, P927, DOI 10.3892/ijo.2013.1989
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Horikawa I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5706
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hsu K. F., 2009, AUTOPHAGY, DOI [10.4161/auto.5.4, DOI 10.4161/AUTO.5.4]
   Hu ZD, 2016, MOL MED REP, V14, P1567, DOI 10.3892/mmr.2016.5437
   Huang HH, 2015, EMBO J, V34, P154, DOI 10.15252/embj.201489083
   Huang YD, 2014, APOPTOSIS, V19, P371, DOI 10.1007/s10495-013-0919-2
   Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087
   Huijbers A, 2012, ENDOCR-RELAT CANCER, V19, pL15, DOI 10.1530/ERC-11-0302
   Hung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3111
   Hurley PJ, 2007, CELL CYCLE, V6, P414, DOI 10.4161/cc.6.4.3886
   Hurvitz SA, 2013, BREAST DIS, V24, P79, DOI [10.1016/j.breastdis.2013.01.007, DOI 10.1016/J.BREASTDIS.2013.01.007, 10.1016/j.breastdis.2013.01.00758.]
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jiang Hao, 2009, J Exp Ther Oncol, V8, P25
   Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jiang XW, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98921
   Joshi P, 2012, COLLOID SURFACE B, V95, P195, DOI 10.1016/j.colsurfb.2012.02.039
   Jung C. H., 2011, AUTOPHAGY, DOI [10.4161/auto.7.10, DOI 10.4161/AUTO.7.10]
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Karras S, 2014, EXPERT OPIN DRUG MET, V10, P469, DOI 10.1517/17425255.2014.885015
   Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X
   Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kharaziha P, 2015, ONCOTARGET, V6, P37066, DOI 10.18632/oncotarget.5797
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Kim HK, 2013, J GINSENG RES, V37, P451, DOI 10.5142/jgr.2013.37.451
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MS, 2011, APMIS, V119, P802, DOI 10.1111/j.1600-0463.2011.02812.x
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kocaturk NM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00128
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kriegenburg F, 2018, CURR BIOL, V28, pR512, DOI 10.1016/j.cub.2018.02.034
   Krishnan S, 2014, COLORECTAL DIS, V16, P672, DOI 10.1111/codi.12662
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kumar B, 2015, BIOCHIMIE, V118, P26, DOI 10.1016/j.biochi.2015.07.016
   Lakshmaiah KC, 2014, J CANCER RES THER, V10, P469, DOI 10.4103/0973-1482.137937
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196
   Lawson LD, 2005, J AGR FOOD CHEM, V53, P1974, DOI 10.1021/jf048323s
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706
   Lin J, 2014, AUTOPHAGY, V10, P2006, DOI 10.4161/auto.36293
   Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370
   Liu B, 2009, CANCER LETT, V275, P54, DOI 10.1016/j.canlet.2008.09.042
   Liu B, 2010, BIOCHIMIE, V92, P1934, DOI 10.1016/j.biochi.2010.08.009
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu F, 2010, BLOOD, V116, P4806, DOI 10.1182/blood-2010-06-288589
   Liu FF, 2013, ONCOL LETT, V5, P1261, DOI 10.3892/ol.2013.1154
   Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0721-9
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Liu ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135236
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Luchenko VL, 2014, MOL ONCOL, V8, P1379, DOI 10.1016/j.molonc.2014.05.001
   Luque-Cabal M, 2016, CLIN MED INSIGHTS-ON, V10, P21, DOI 10.4137/CMO.S34537
   Lv TT, 2018, ACTA BIOMATER, V76, P257, DOI 10.1016/j.actbio.2018.06.034
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597
   Macintosh RL, 2012, CELL CYCLE, V11, P2022, DOI 10.4161/cc.20424
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Mao K, 2017, AUTOPHAGY, V13, P223, DOI 10.1080/15548627.2016.1267075
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2521, DOI 10.4161/cc.10.15.16584
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mauthe M, 2011, AUTOPHAGY, V7, P1448, DOI 10.4161/auto.7.12.17802
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487
   Mazzoni E, 2015, CANCER-AM CANCER SOC, V121, P708, DOI 10.1002/cncr.29137
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Meek DW, 2015, BIOCHEM J, V469, P325, DOI 10.1042/BJ20150517
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Memar O. M., 1995, J MOL MED, DOI [10.1007/BF00196354, DOI 10.1007/BF00196354]
   Mercer TJ, 2018, J BIOL CHEM, V293, P5386, DOI 10.1074/jbc.R117.810366
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mita M, 2008, EXPERT OPIN INV DRUG, V17, P1947, DOI 10.1517/13543780802556485 
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Molejon MI, 2013, AUTOPHAGY, V9, P933, DOI 10.4161/auto.24390
   Molejon MI, 2013, SCI REP-UK, V3, DOI 10.1038/srep01055
   Mortensen M, 2011, AUTOPHAGY, V7, P1069, DOI 10.4161/auto.7.9.15886
   Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Mughini-Gras L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189721
   Murthy HN, 2014, APPL MICROBIOL BIOT, V98, P6243, DOI 10.1007/s00253-014-5801-9
   Nag SA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00025
   Nagelkerke A, 2014, BBA-REV CANCER, V1846, P277, DOI 10.1016/j.bbcan.2014.07.006
   Nagy JA, 2010, SEMIN THROMB HEMOST, V36, P321, DOI 10.1055/s-0030-1253454
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   O'Reilly S, 2014, J BIOL CHEM, V289, P9952, DOI 10.1074/jbc.M113.545822
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   ODonovan T. R., 2011, AUTOPHAGY, DOI [10.4161/auto.7.6, DOI 10.4161/AUTO.7.6]
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ohta T., 1998, J PATHOL, DOI [10.1002/(SICI)1096-9896(199807)185:33.0.CO;2-9, DOI 10.1002/(SICI)1096-9896(199807)185:33.0.CO;2-9]
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Oku M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800008
   Onal G, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0521-7
   Opipari A. W., 2004, CANCER RES, DOI [10.1158/0008-5472.CAN-03-240, DOI 10.1158/0008-5472.CAN-03-240]
   Oral O, 2016, HISTOL HISTOPATHOL, V31, P479, DOI 10.14670/HH-11-714
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Panzarini E, 2014, MOL PHARMACEUT, V11, P2527, DOI 10.1021/mp500066v
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Papinski D, 2014, AUTOPHAGY, V10, P1338, DOI 10.4161/auto.28971
   Park EJ, 2015, BBA-MOL BASIS DIS, V1852, P1071, DOI 10.1016/j.bbadis.2015.01.014
   Park JM, 2016, AUTOPHAGY, V12, P547, DOI 10.1080/15548627.2016.1140293
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pelt J, 2018, PHARMACOL THERAPEUT, V191, P43, DOI 10.1016/j.pharmthera.2018.06.007
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Phillip CJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-145
   Piacentini M, 2015, INT J DEV BIOL, V59, P5, DOI 10.1387/ijdb.150167mp
   Pignochino Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1363-1
   Pike LRG, 2013, BIOCHEM J, V449, P389, DOI 10.1042/BJ20120972
   Poh ZX, 2015, EUR J GASTROEN HEPAT, V27, P638, DOI 10.1097/MEG.0000000000000341
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706
   Puleston DJ, 2014, IMMUNOLOGY, V141, P1, DOI 10.1111/imm.12165
   Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021
   Qiu B, 2015, SEMIN CELL DEV BIOL, V43, P3, DOI 10.1016/j.semcdb.2015.08.005
   Qiu GZ, 2017, TRENDS PHARMACOL SCI, V38, P669, DOI 10.1016/j.tips.2017.05.002
   Qu H., 2013, INT J CLIN EXP PATHO, DOI [10.1371/journal.pone.0059154, DOI 10.1371/JOURNAL.PONE.0059154]
   Rahmani AH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/761608
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Ren NSX, 2017, CURR BIOL, V27, P483, DOI 10.1016/j.cub.2016.12.047
   Rijkaart DC, 2012, LANCET ONCOL, V13, P78, DOI 10.1016/S1470-2045(11)70296-0
   Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778
   Roos S, 2013, HUM MOL GENET, V22, P2411, DOI 10.1093/hmg/ddt094
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Scarlatti F, 2008, AUTOPHAGY, V4, P1083, DOI 10.4161/auto.7068
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Selvaraj S, 2016, MOL CARCINOGEN, V55, P818, DOI 10.1002/mc.22324
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Serrano-Oviedo L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200878
   Shao S, 2014, INT J ONCOL, V44, P1661, DOI 10.3892/ijo.2014.2313
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Sharma K, 2014, EXCLI J, V13, P178
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Shen CT, 2014, ENDOCR-RELAT CANCER, V21, P253, DOI 10.1530/ERC-13-0438
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shi K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.34
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Shpilka T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-226
   SHUIN T, 1994, CANCER RES, V54, P2852
   Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun Y, 2011, ASIAN PAC J CANCER P, V12, P1269
   Svajger U, 2012, INT REV IMMUNOL, V31, P202, DOI 10.3109/08830185.2012.665108
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Tang JY, 2015, PATHOL ONCOL RES, V21, P301, DOI 10.1007/s12253-014-9821-7
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   de Souza CRT, 2018, WORLD J GASTROENTERO, V24, P4928, DOI 10.3748/wjg.v24.i43.4928
   Tekirdag KA, 2016, HISTOL HISTOPATHOL, V31, P841, DOI 10.14670/HH-11-752
   Till Andreas, 2012, Int J Cell Biol, V2012, P512721, DOI 10.1155/2012/512721
   Tiwari AK, 2009, BIOCHEM PHARMACOL, V78, P153, DOI 10.1016/j.bcp.2009.04.002
   Mai TT, 2012, CANCER LETT, V321, P144, DOI 10.1016/j.canlet.2012.01.045
   Tripathi R, 2014, J CELL MOL MED, V18, P2275, DOI 10.1111/jcmm.12386
   Tsuboyama K, 2016, SCIENCE, V354, P1036, DOI 10.1126/science.aaf6136
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Tuloup-Minguez V, 2011, AUTOPHAGY, V7, P27, DOI 10.4161/auto.7.1.13851
   Uehara N, 2012, CANCER LETT, V315, P112, DOI 10.1016/j.canlet.2011.07.032
   Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006
   Upadhyay RK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/869269
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Varambally S., 2008, SCIENCE, DOI [10.1126/science.1165395.(80), DOI 10.1126/SCIENCE.1165395.(80)]
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   Vera-Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04070-6
   Vessoni AT, 2013, CELL DEATH DIFFER, V20, P1444, DOI 10.1038/cdd.2013.103
   Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   von Muhlinen N, 2013, AUTOPHAGY, V9, P784, DOI 10.4161/auto.23698
   Wagle N, 2014, NEW ENGL J MED, V371, P1426, DOI 10.1056/NEJMoa1403352
   Wan HY, 2018, ADV SCI, V5, DOI 10.1002/advs.201700585
   Wang CR, 2013, NAT NEUROSCI, V16, P532, DOI 10.1038/nn.3365
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Wang N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/934207
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   Wang ZL, 2016, INT J ONCOL, V48, P2558, DOI 10.3892/ijo.2016.3468
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Wei PF, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/49/495101
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Weng JQ, 2014, ORAL ONCOL, V50, P983, DOI 10.1016/j.oraloncology.2014.06.020
   West A. C., 2014, J CLIN INVEST, DOI [10.1172/JCI69738.30, DOI 10.1172/JCI69738.30]
   Wileman T, 2013, ESSAYS BIOCHEM, V55, P153, DOI [10.1042/BSE0550153, 10.1042/bse0550153]
   Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017
   Wolfram J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14221-2
   Wu EQ, 2010, CURR MED RES OPIN, V26, P61, DOI 10.1185/03007990903396469
   Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008-5472.CAN-04-3137
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Wu YN, 2013, INT J NANOMED, V8, P3321, DOI 10.2147/IJN.S47742
   Wu YM, 2018, CANCER RES, V78, P671, DOI 10.1158/0008-5472.CAN-17-1327
   Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Xie ZG, 2014, MOL MED REP, V10, P1103, DOI 10.3892/mmr.2014.2281
   Xiong XX, 2015, INT J ONCOL, V47, P1321, DOI 10.3892/ijo.2015.3103
   Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711
   Xu P, 2011, GENE DEV, V25, P310, DOI 10.1101/gad.1984311
   Yang S, 2014, J LEUKOCYTE BIOL, V95, P563, DOI 10.1189/jlb.0713412
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008
   Yazdankhah M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.358
   Yin YC, 2015, CELL PHYSIOL BIOCHEM, V35, P945, DOI 10.1159/000369751
   Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang Q, 2009, AUTOPHAGY, V5, P1107, DOI 10.4161/auto.5.8.9842
   Zhao Chuankuo, 2018, Oncotarget, V9, P30704, DOI 10.18632/oncotarget.25694
   Zhao Jun, 2014, Cancer Biology Medicine, V11, P64, DOI 10.7497/j.issn.2095-3941.2014.01.006
   Zhou J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087161
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
   Zhou WC, 2015, ONCOTARGET, V6, P37300, DOI 10.18632/oncotarget.5836
   Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015
   Zhu AX, 2011, CANCER-AM CANCER SOC, V117, P5094, DOI 10.1002/cncr.26165
   Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
   Zhu XL, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.59
   Zhu YP, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/5787218
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210
   2015, J BIOL CHEM, V290, P1749, DOI DOI 10.1074/JBC.M115.660498
NR 391
TC 96
Z9 102
U1 20
U2 64
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD JUN 15
PY 2019
VL 134
BP 116
EP 137
DI 10.1016/j.ejps.2019.04.011
PG 22
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Pharmacology & Pharmacy
GA HY4ER
UT WOS:000468081200010
PM 30981885
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Lee, YC
   Su, CY
   Lin, YF
   Lin, CM
   Fang, CY
   Lin, YK
   Hsiao, M
   Chen, CL
AF Lee, Yu-Chieh
   Su, Chia-Yu
   Lin, Yuan-Feng
   Lin, Chun-Mao
   Fang, Chih-Yeu
   Lin, Yen-Kuang
   Hsiao, Michael
   Chen, Chi-Long
TI Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is
   associated with better survival in stage II colorectal cancer patients
   receiving chemotherapy
SO ONCOTARGET
LA English
DT Article
DE colorectal carcinoma; lysosomal acid phosphatase 2; 5-FU; chemotherapy
ID GENE-EXPRESSION PROFILE; COLON-CANCER; ADJUVANT CHEMOTHERAPY; PREDICTS
   RECURRENCE; CELL-PROLIFERATION; TARGETING PTEN; POOR-PROGNOSIS;
   CARCINOMA; METASTASIS; AUTOPHAGY
AB Colorectal cancer (CRC) is one of the leading cancers worldwide. Surgery is the main therapeutic modality for stage II CRC. However, the implementation of adjuvant chemotherapy remains controversial and is not universally applied so far. In this study, we found that the protein expression of lysosomal acid phosphatase 2 (ACP2) was increased in CRC and that stage II CRC patients with high ACP2 expression showed a poorer outcome than those with low ACP2 expression (p = 0.004). To investigate this discrepancy, we analyzed the relation between ACP2 expression and several clinical cofactors.
   Among patients who received chemotherapy, those with an high expression of ACP2 showed better survival in both stage II and III CRC than those with low ACP2 expression. In stage II CRC patients, univariate analysis showed ACP2 expression and T stage to be cofactors significantly associated with overall survival (ACP2: p = 0.006; T stage: p = 0.034). Multivariate Cox proportion hazard model analysis also revealed ACP2 to be an independent prognostic factor for overall survival (ACP2: p = 0.006; T stage: p = 0.041). Furthermore, ACP2-knockdown CRC cells showed an increase in chemoresistance to 5-FU treatment and increased proliferation marker in the ACP2 knockdown clone.
   Taken together, our results suggested that ACP2 is an unfavorable prognostic factor for stage II CRC and may serve as a potential chemotherapy-sensitive marker to help identify a subset of stage II and III CRC patients for whom chemotherapy would improve survival.
C1 [Lee, Yu-Chieh] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
   [Su, Chia-Yu; Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Lin, Yuan-Feng] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan.
   [Lin, Chun-Mao] Taipei Med Univ, Sch Med, Dept Biochem, Taipei, Taiwan.
   [Chen, Chi-Long] Taipei Med Univ, Coll Med, Dept Pathol, Taipei, Taiwan.
   [Chen, Chi-Long] Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan.
   [Fang, Chih-Yeu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan.
   [Lin, Yen-Kuang] Taipei Med Univ, Ctr Biostat, Taipei, Taiwan.
   [Lee, Yu-Chieh] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan.
   [Hsiao, Michael] Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan.
RP Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, Taipei, Taiwan.; Chen, CL (corresponding author), Taipei Med Univ, Coll Med, Dept Pathol, Taipei, Taiwan.; Chen, CL (corresponding author), Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan.; Hsiao, M (corresponding author), Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan.
EM mhsiao@gate.sinica.edu.tw; chencl@tmu.edu.tw
RI Su, Chia-Yi/L-5378-2016; Fang, Chih-Yeu/AAH-5170-2021; Hsiao,
   Michael/U-6238-2019
OI Su, Chia-Yi/0000-0002-9483-4510; Fang, Chih-Yeu/0000-0002-8280-3012;
   Hsiao, Michael/0000-0001-8529-9213; Lin, Chun-Mao/0000-0002-8366-4026
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT); Academia SinicaAcademia
   Sinica - Taiwan [MOST 104-0210-01-09-02, MOST 105-0210-01-13-01]; Health
   and Welfare surcharge of tobacco products from the Ministry of Health
   and Welfare to the Comprehensive Cancer center of Taipei Medical
   University [MOHW105-TDU-B-212-134001]
FX We thank Miss Tracy Tsai for her assistance in immunohistochemistry
   experiments, Jennifer Liu for her assistance in cell culture experiments
   and Dr. YuanHung Wang (Department Medical Research, Shuang Ho Hospital,
   Taipei Medical University) for statistical analysis support. We would
   also like to thank the Ministry of Science and Technology and Academia
   Sinica for their financial support (MOST 104-0210-01-09-02 and MOST
   105-0210-01-13-01 to M. Hsiao). This work was also funded by the Health
   and Welfare surcharge of tobacco products (MOHW105-TDU-B-212-134001)
   from the Ministry of Health and Welfare to the Comprehensive Cancer
   center of Taipei Medical University.
CR Chi JY, 2015, ONCOTARGET, V6, P23987, DOI 10.18632/oncotarget.4364
   COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108
   Giraldez MD, 2013, INT J CANCER, V132, P1090, DOI 10.1002/ijc.27747
   Fang WL, 2012, WORLD J SURG, V36, P2131, DOI 10.1007/s00268-012-1652-7
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Gou WF, 2015, ONCOTARGET, V6, P19552, DOI 10.18632/oncotarget.3735
   GRIFFIN MR, 1987, CANCER-AM CANCER SOC, V60, P2318, DOI 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO;2-B
   Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304
   Holle AW, 2016, ADV DRUG DELIVER REV, V97, P270, DOI 10.1016/j.addr.2015.10.007
   Isacoff WH, 1997, WORLD J SURG, V21, P748, DOI 10.1007/s002689900301
   Katagiri H, 2015, INT J ONCOL, V47, P2037, DOI 10.3892/ijo.2015.3191
   Kelder W, 2006, EXPERT REV ANTICANC, V6, P785, DOI 10.1586/14737140.6.5.785
   Kopetz S, 2015, ONCOLOGIST, V20, P127, DOI 10.1634/theoncologist.2014-0325
   Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
   Kumar A, 2015, CANCER-AM CANCER SOC, V121, P527, DOI 10.1002/cncr.29072
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Lee YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132579
   Li HH, 2015, INT J ONCOL, V47, P1379, DOI 10.3892/ijo.2015.3144
   Lin CC, 2012, INT J COLORECTAL DIS, V27, P277, DOI 10.1007/s00384-011-1341-2
   Lin TC, 2015, J PATHOL, V237, P50, DOI 10.1002/path.4552
   Liu K, 2015, ONCOL REP, V34, P1003, DOI 10.3892/or.2015.4030
   Mannan AU, 2004, NEUROGENETICS, V5, P229, DOI 10.1007/s10048-004-0197-9
   Melquist S, 2007, AM J HUM GENET, V80, P769, DOI 10.1086/513320
   NADLER HL, 1970, NEW ENGL J MED, V282, P302, DOI 10.1056/NEJM197002052820604
   Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Somoza-Martin JM, 2005, J ORAL MAXIL SURG, V63, P786, DOI 10.1016/j.joms.2005.02.014
   Su CY, 2015, ONCOTARGET, V6, P18602, DOI 10.18632/oncotarget.4329
   Thu Kelsie L, 2014, Oncoscience, V1, P326
   WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   You YN, 2015, SURG ONCOL, V24, P61, DOI 10.1016/j.suronc.2015.02.001
NR 32
TC 0
Z9 0
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 14
PY 2017
VL 8
IS 7
BP 12120
EP 12132
DI 10.18632/oncotarget.14552
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EK8QB
UT WOS:000394187400119
PM 28076332
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Peng, QL
   Lin, KS
   Chang, T
   Zou, L
   Xing, PF
   Shen, YT
   Zhu, YQ
AF Peng, Qiliang
   Lin, Kaisu
   Chang, Tao
   Zou, Li
   Xing, Pengfei
   Shen, Yuntian
   Zhu, Yaqun
TI Identification of genomic expression differences between right-sided and
   left-sided colon cancer based on bioinformatics analysis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colon cancer; location; differentially expressed genes; bioinformatics
   analysis
ID INHIBITORS; STATISTICS; AUTOPHAGY; MUTATION; STRESS; GENES; PCNA
AB Introduction: More and more findings have demonstrated that right-sided colon cancers (RCC) and left-sided colon cancers (LCC) are distinct clinical and biological entities and suggest that they should be treated as different diseases. However, the reasons why RCC and LCC harbor different clinical and biological features remain unclear.
   Materials and methods: To identify the genomic expression differences between RCC and LCC and uncover the mechanisms underlying these differences, we chose the gene expression profiles of GSE14333 from the Gene Expression Omnibus (GEO) database as an object of study. Then, a systematic and integrative bioinformatics analysis was performed to research the possible mechanism of the differentially expressed (DE) genes from the Gene Expression Omnibus dataset including gene ontology (GO) analysis, pathway enrichment analysis, protein-protein interaction (PPI) network construction, and module analysis. Totally, we extracted 3,793 DE genes from samples of colon cancer including 1,961 genes upregulated in RCC and 1,832 genes upregulated in LCC from the selected dataset.
   Results: The results of GO and pathway enrichment analysis indicated that RCC and LCC could predispose to different pathways regulated by different genes. Based on the PPI network, PCNA, TP53, HSP90AA1, CSNK2A1, UBB, LRRK2, ABL1, PRKACA, CAV1, and JUN were identified as the key hub genes. Also, significant modules were screened from the PPI network.
   Conclusion: In conclusion, the present study indicated that the identified genes and pathways may promote new insights into the underlying molecular mechanisms contributing to the difference between RCC and LCC and might be used as specific therapeutic targets and prognostic markers for the personalized treatment of RCC and LCC.
C1 [Peng, Qiliang; Zou, Li; Xing, Pengfei; Shen, Yuntian; Zhu, Yaqun] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, San Xiang Rd 1055, Suzhou 215004, Jiangsu, Peoples R China.
   [Peng, Qiliang; Zou, Li; Xing, Pengfei; Shen, Yuntian; Zhu, Yaqun] Soochow Univ, Inst Radiotherapy & Oncol, Suzhou, Peoples R China.
   [Peng, Qiliang; Zou, Li; Xing, Pengfei; Shen, Yuntian; Zhu, Yaqun] Suzhou Key Lab Radiat Oncol, Suzhou, Peoples R China.
   [Lin, Kaisu] Nantong Rich Hosp, Dept Oncol, Nantong, Peoples R China.
   [Chang, Tao] Sixth Peoples Hosp Kunshan, Dept Gen Surg, Kunshan, Peoples R China.
RP Zhu, YQ (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, San Xiang Rd 1055, Suzhou 215004, Jiangsu, Peoples R China.
EM szzhuyaqun@sina.com
FU Second Affiliated Hospital of Soochow University [XKQ2015005]; Suzhou
   Science and Technology Development Program [SZS201509]; Suzhou Clinical
   Medical Center Construction Project [Szzxj201503]; Jiangsu Medical
   Innovation Team [CXDT-37]
FX This study was supported by the Second Affiliated Hospital of Soochow
   University Preponderant Clinic Discipline Group Project funding
   (XKQ2015005), Suzhou Science and Technology Development Program
   (SZS201509), Suzhou Clinical Medical Center Construction Project
   (Szzxj201503), and Jiangsu Medical Innovation Team (CXDT-37).
CR Bae JS, 2016, AM J PATHOL, V186, P3297, DOI 10.1016/j.ajpath.2016.08.007
   Bauer KM, 2012, MOL CARCINOGEN, V51, P411, DOI 10.1002/mc.20804
   Brighenti E, 2015, ONCOTARGET, V6, P38617, DOI 10.18632/oncotarget.5775
   Brozovich FV, 2016, PHARMACOL REV, V68, P476, DOI 10.1124/pr.115.010652
   Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250
   Dey N, 2017, PHARMACOL THERAPEUT, V175, P91, DOI 10.1016/j.pharmthera.2017.02.037
   Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073
   Goh G, 2014, NAT GENET, V46, P613, DOI 10.1038/ng.2956
   Ha TK, 2012, AUTOPHAGY, V8, P1684, DOI 10.4161/auto.21487
   Harris MA, 2006, NUCLEIC ACIDS RES, V34, pD322, DOI 10.1093/nar/gkj021
   Hu BL, 2015, AUTOPHAGY, V11, P503, DOI 10.1080/15548627.2015.1017184
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jang M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41541
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kuramochi H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2400-4
   Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038
   Lewis R, 2015, LANCET ONCOL, V16, pE482, DOI 10.1016/S1470-2045(15)00271-5
   Li N, 2013, MOL CANCER THER, V12, P1848, DOI 10.1158/1535-7163.MCT-13-0048
   Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418
   Logan CV, 2014, NAT GENET, V46, P188, DOI 10.1038/ng.2851
   Loupakis F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju427
   Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424
   Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Oh C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02623
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Petrelli F, JAMA ONCOL
   Rouette A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34019
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sourbier C, 2014, CANCER CELL, V26, P840, DOI 10.1016/j.ccell.2014.10.005
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang Y, 2017, CANCER LETT, V391, P12, DOI 10.1016/j.canlet.2017.01.010
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039
   Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004
   Weiss JM, 2011, J CLIN ONCOL, V29, P4401, DOI 10.1200/JCO.2011.36.4414
   Weygant N, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-103
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
NR 42
TC 8
Z9 8
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2018
VL 11
BP 609
EP 618
DI 10.2147/OTT.S154207
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA FV0WZ
UT WOS:000424283200002
PM 29430186
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Maraming, P
   Klaynongsruang, S
   Boonsiri, P
   Peng, SF
   Daduang, S
   Leelayuwat, C
   Pientong, C
   Chung, JG
   Daduang, J
AF Maraming, Pornsuda
   Klaynongsruang, Sompong
   Boonsiri, Patcharee
   Peng, Shu-Fen
   Daduang, Sakda
   Leelayuwat, Chanvit
   Pientong, Chamsai
   Chung, Jing-Gung
   Daduang, Jureerut
TI The cationic cell-penetrating KT2 peptide promotes cell membrane defects
   and apoptosis with autophagy inhibition in human HCT 116 colon cancer
   cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE antimicrobial peptide; apoptosis; autophagy; cationic cell-penetrating
   KT2; membrane permeability
ID ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL ACTIVITY; ARGININE; RICH;
   MECHANISMS; LYSINE; SELECTIVITY; LEUKEMIA; DESIGN
AB The anticancer activity of cationic antimicrobial peptides (AMPs) has become more interesting because some AMPs have selective recognition against cancer cells. However, their antitumor properties and underlying mechanisms in cancer cells have not been clearly understood. In this study, we evaluated the effects of KT2 (lysine/tryptophan-rich AMP) on the cellular uptake and internalization mechanism, cell viability, surface charge of the cell membrane, membrane integrity, apoptotic cell death, and autophagy in human HCT 116 colon cancer cells. We found that KT2 interacted with the cell membrane of HCT 116 cells and was internalized into HCT 116 cells via clathrin-mediated and caveolae-mediated endocytosis mechanisms. The interaction of KT2 with cells caused cell membrane structure change, elevated membrane permeability, and KT2 also affected the lipid component. The results of atomic force microscopy showed cellular membrane defects of KT2-treated cells. The internalized KT2 induced nuclear condensation and apoptotic cell death. It elevated the apoptotic factor levels including those of cytochrome c and apoptosis-inducing factor. Furthermore, KT2 inhibited autophagy by the suppression of autophagy-related 5, autophagy-related 7, autophagy-related 16 like 1, and Beclin-1 proteins. In conclusion, these results revealed the cytotoxicity of cationic KT2 against HCT 116 cells and may help to clarify the interactions between cationic AMPs and cancer cells.
C1 [Maraming, Pornsuda] Khon Kaen Univ, Grad Sch, Biomed Sci Program, Khon Kaen, Thailand.
   [Klaynongsruang, Sompong] Khon Kaen Univ, Fac Sci, Prot & Prote Res Ctr Commercial & Ind Purposes Pr, Dept Biochem, Khon Kaen, Thailand.
   [Boonsiri, Patcharee] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand.
   [Peng, Shu-Fen; Chung, Jing-Gung] China Med Univ, Dept Biol Sci & Technol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
   [Peng, Shu-Fen] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Daduang, Sakda] Khon Kaen Univ, Fac Pharmaceut Sci, Div Pharmacognosy & Toxicol, Khon Kaen, Thailand.
   [Leelayuwat, Chanvit; Daduang, Jureerut] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen 40002, Thailand.
   [Pientong, Chamsai] Khon Kaen Univ, HPV & EBV & Carcinogenesis Res Grp, Khon Kaen, Thailand.
RP Chung, JG (corresponding author), China Med Univ, Dept Biol Sci & Technol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Daduang, J (corresponding author), Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen 40002, Thailand.
EM jgchung@mail.cmu.edu.tw; jurpoo@kku.ac.th
OI Klaynongsruang, Sompong/0000-0003-2872-1291; Maraming,
   Pornsuda/0000-0002-5937-0917; Daduang, Jureerut/0000-0003-0977-4144
FU China Medical University, Taichung, TaiwanChina Medical University
   [CMU107-ASIA-17]; National Research Council of ThailandNational Research
   Council of Thailand (NRCT) [2558]; Khon Kaen University (Synchrotron
   Light Research Institute) [2559-KKU-SLRI-01-09]; Royal Golden Jubilee
   (RGJ) Ph.D. Scholarship [PHD/0014/2558]; Khon Kaen University
   [61004605]; Synchrotron Light Research Institute [2559-KKU-SLRI-01-09]
FX China Medical University, Taichung, Taiwan, Grant/Award Number:
   CMU107-ASIA-17; National Research Council of Thailand, Grant/Award
   Numbers: grant no. 2558, 2558; Khon Kaen University (Synchrotron Light
   Research Institute), Grant/Award Number: grant no. 2559-KKU-SLRI-01-09;
   The Royal Golden Jubilee (RGJ) Ph.D. Scholarship, Grant/Award Number:
   PHD/0014/2558; Khon Kaen University, Grant/Award Number: 61004605;
   Synchrotron Light Research Institute, Grant/Award Number:
   2559-KKU-SLRI-01-09
CR Alves AC, 2016, BBA-BIOMEMBRANES, V1858, P2231, DOI 10.1016/j.bbamem.2016.06.025
   Amand HL, 2012, BBA-BIOMEMBRANES, V1818, P2669, DOI 10.1016/j.bbamem.2012.06.006
   Anunthawan T, 2013, BIOORG MED CHEM LETT, V23, P4657, DOI 10.1016/j.bmcl.2013.06.005
   Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423
   Baxter AA, 2017, CELL MOL LIFE SCI, V74, P3809, DOI 10.1007/s00018-017-2604-z
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866
   Chen CX, 2014, BIOMATERIALS, V35, P1552, DOI 10.1016/j.biomaterials.2013.10.082
   Chou HT, 2008, INT J ANTIMICROB AG, V32, P130, DOI 10.1016/j.ijantimicag.2008.04.003
   Chu HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126390
   Cutrona KJ, 2015, FEBS LETT, V589, P3915, DOI 10.1016/j.febslet.2015.11.002
   Dai YX, 2017, AMINO ACIDS, V49, P1601, DOI 10.1007/s00726-017-2453-y
   Del Bello B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057236
   Deslouches B, 2017, ONCOTARGET, V8, P46635, DOI 10.18632/oncotarget.16743
   Felicio MR, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00005
   Gaspar D, 2015, BBA-MOL CELL RES, V1853, P308, DOI 10.1016/j.bbamcr.2014.11.006
   Ghosh P, 2018, J CELL PHYSIOL, V233, P1041, DOI 10.1002/jcp.25958
   Gondim ACS, 2017, J INORG BIOCHEM, V175, P179, DOI 10.1016/j.jinorgbio.2017.07.011
   Guzman-Rodriguez JJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/735087
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hsiao YT, 2018, ENVIRON TOXICOL, V33, P821, DOI 10.1002/tox.22568
   Jiao YN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0646-4
   Jin L, 2016, J MED CHEM, V59, P1791, DOI 10.1021/acs.jmedchem.5b01264
   Jobin ML, 2015, BBA-BIOMEMBRANES, V1848, P593, DOI 10.1016/j.bbamem.2014.11.013
   Juks C, 2017, FASEB J, V31, P975, DOI 10.1096/fj.201600811R
   Kim HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11719
   Lee J, 2015, J MICROBIOL BIOTECHN, V25, P759, DOI 10.4014/jmb.1411.11058
   Li JG, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00073
   Li M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030332
   Liu XL, 2016, J MED CHEM, V59, P5238, DOI 10.1021/acs.jmedchem.5b02016
   Ma SH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0940-9
   Mader JS, 2007, EXP CELL RES, V313, P2634, DOI 10.1016/j.yexcr.2007.05.015
   Mader JS, 2005, MOL CANCER THER, V4, P612, DOI 10.1158/1535-7163.MCT-04-0077
   Maijaroen S, 2018, ENVIRON TOXICOL PHAR, V62, P164, DOI 10.1016/j.etap.2018.07.007
   Mishra B, 2017, CURR OPIN CHEM BIOL, V38, P87, DOI 10.1016/j.cbpa.2017.03.014
   Mishra B, 2016, ACS MED CHEM LETT, V7, P117, DOI 10.1021/acsmedchemlett.5b00433
   Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001
   Nur-E-Kamal A, 2004, J BIOL CHEM, V279, P24911, DOI 10.1074/jbc.C400051200
   Paredes-Gamero EJ, 2012, BBA-GEN SUBJECTS, V1820, P1062, DOI 10.1016/j.bbagen.2012.02.015
   Patathananone S, 2016, ENVIRON TOXICOL, V31, P986, DOI 10.1002/tox.22108
   Polanski J, 2016, ONCOTARGETS THER, V9, P1023, DOI 10.2147/OTT.S100685
   Rattanata N, 2016, INT J NANOMED, V11, P3347, DOI 10.2147/IJN.S109795
   Reinhardt A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050701
   Rejman J, 2005, MOL THER, V12, P468, DOI 10.1016/j.ymthe.2005.03.038
   Ren SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063641
   Ricciardi V, 2017, BIOSENSORS-BASEL, V7, DOI 10.3390/bios7040057
   Schweizer F, 2009, EUR J PHARMACOL, V625, P190, DOI 10.1016/j.ejphar.2009.08.043
   Shagaghi N, 2016, WORLD J MICROB BIOT, V32, DOI 10.1007/s11274-015-1986-z
   Su YC, 2013, AMINO ACIDS, V44, P821, DOI 10.1007/s00726-012-1421-9
   Wang C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08963-2
   Wesen E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02227-9
   Xia LJ, 2016, ONCOL LETT, V12, P57, DOI 10.3892/ol.2016.4601
   Yarbrough VL, 2015, HUM REPROD UPDATE, V21, P353, DOI 10.1093/humupd/dmu065
   Zhang P, 2017, ORG BIOMOL CHEM, V15, P9379, DOI 10.1039/c7ob02233f
   Zhang Y, 2009, SMALL, V5, P1990, DOI 10.1002/smll.200900520
NR 56
TC 15
Z9 15
U1 4
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2019
VL 234
IS 12
BP 22116
EP 22129
DI 10.1002/jcp.28774
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA IV6KF
UT WOS:000484376600058
PM 31073999
DA 2022-04-25
ER

PT J
AU Casanova, MR
   Azevedo-Silva, J
   Rodrigues, LR
   Preto, A
AF Casanova, Marta R.
   Azevedo-Silva, Joao
   Rodrigues, Ligia R.
   Preto, Ana
TI Colorectal Cancer Cells Increase the Production of Short Chain Fatty
   Acids by Propionibacterium freudenreichii Impacting on Cancer Cells
   Survival
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE colorectal cancer; Propionibacterium freudenreichii; probiotic; short
   chain fatty acids; acetate; propionate
ID LACTATE METABOLISM; PROTEOMIC ANALYSIS; SODIUM-BUTYRATE; SUBSP
   SHERMANII; COLON-CANCER; IN-VIVO; APOPTOSIS; AUTOPHAGY; MICROBIOTA;
   MITOCHONDRIA
AB Propionibacterium freudenreichii is a commercially relevant bacterium with probiotic potential.This bacterium can exert protective effects particularly against colorectal cancer (CRC), via the production of short chain fatty acids (SCFA), namely acetate and propionate. In this work, we aimed to evaluate the performance and adaptation capacity of P. freudenreichii to a simulated digestive stress using different culture media, namely YEL, Basal medium, Mimicking the Content of the Human Colon medium (MCHC) and DMEM. The effect of the fermented culture broth on CRC cells survival and of CRC cells conditioned media on the bacteria performance was also evaluated. Basal medium was found to be the best for P. freudenreichii to produce SCFA. MCHC medium, despite being the medium in which lower amounts of acetate and propionate were produced, showed higher acetate and propionate yields as compared to other media. We also observed that the presence of lactate in CRC cells conditioned growth medium resulting from cell metabolism, leads to an increased production of SCFA by the bacteria. The bacterial fermented broth successfully inhibited CRC cells proliferation and increased cell death. Our results showed for the first time that P. freudenreichii performance might be stimulated by extracellular lactate produced by CRC metabolic switch also known as "Warburg effect," where cancer cells "ferment" glucose into lactate. Additionally, our results suggest that P. freudenreichii could be potentially used as a probiotic in CRC prevention at early stages of the carcinogenesis process and might help in CRC therapeutic approaches.
C1 [Casanova, Marta R.; Rodrigues, Ligia R.] Univ Minho, Ctr Biol Engn, Braga, Portugal.
   [Casanova, Marta R.; Azevedo-Silva, Joao; Preto, Ana] Univ Minho, Dept Biol, Ctr Mol & Environm Biol, Braga, Portugal.
RP Preto, A (corresponding author), Univ Minho, Dept Biol, Ctr Mol & Environm Biol, Braga, Portugal.
EM apreto@bio.uminho.pt
RI Rodrigues, Ligia R/C-3151-2009; Preto, Ana/H-8112-2012; Casanova,
   Marta/AAL-5693-2020
OI Rodrigues, Ligia R/0000-0001-9265-0630; Preto, Ana/0000-0002-7302-0630;
   Casanova, Marta/0000-0002-9413-7977; Azevedo-Silva,
   Joao/0000-0003-1754-9254
FU FEDER through POFC-COMPETE; FCTPortuguese Foundation for Science and
   TechnologyEuropean Commission [PEst-OE/BIA/UI4050/2014]; FCT I.P
   [UID/BIO/04469/2013, RECI/BBB-EBI/0179/2012, FCOMP-01-0124-FEDER-027462,
   UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569)]; ERDF through the
   COMPETE2020-Programa Operacional Competitividade e Internacionalizacao
   (POCI); Norte Portugal Regional Operational Programme (NORTE 2020),
   under the PORTUGAL 2020 Partnership Agreement, through the European
   Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-00009]
FX The authors acknowledge the financial support from the FEDER through
   POFC-COMPETE and by FCT through project PEst-OE/BIA/UI4050/2014. This
   work was supported by FCT I.P. through the strategic funding of
   UID/BIO/04469/2013 unit and project ref. RECI/BBB-EBI/0179/2012 (project
   number FCOMP-01-0124-FEDER-027462). This work was also supported by the
   strategic programme UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569)
   funded by national funds through the FCT I.P. and by the ERDF through
   the COMPETE2020-Programa Operacional Competitividade e
   Internacionalizacao (POCI). This article is a result of the project
   EcoAgriFood NORTE-01-0145-FEDER-00009, supported by Norte Portugal
   Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020
   Partnership Agreement, through the European Regional Development Fund
   (ERDF).
CR Aktipis CA, 2013, NAT REV CANCER, V13, P883, DOI 10.1038/nrc3606
   Amorim R, 2015, CANCER LETT, V365, P68, DOI 10.1016/j.canlet.2015.05.015
   Anand P, 2008, PHARM RES-DORDR, V25, P2097, DOI 10.1007/s11095-008-9661-9
   Annison G, 2003, J NUTR, V133, P3523, DOI 10.1093/jn/133.11.3523
   Augenlicht LH, 2002, J NUTR, V132, p3804S, DOI 10.1093/jn/132.12.3804S
   Azcarate-Peril MA, 2011, AM J PHYSIOL-GASTR L, V301, pG401, DOI 10.1152/ajpgi.00110.2011
   Bassaganya-Riera J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034676
   Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1
   Blouin JM, 2011, INT J CANCER, V128, P2591, DOI 10.1002/ijc.25599
   Borowicki A, 2011, NUTR CANCER, V63, P151, DOI 10.1080/01635581.2010.516874
   Cencic A, 2010, NUTRIENTS, V2, P611, DOI 10.3390/nu2060611
   Cousin FJ, 2012, J AGR FOOD CHEM, V60, P7917, DOI 10.1021/jf302245m
   Cousin FJ, 2012, FOOD MICROBIOL, V32, P135, DOI 10.1016/j.fm.2012.05.003
   CROW VL, 1986, APPL ENVIRON MICROB, V52, P359, DOI 10.1128/AEM.52.2.359-365.1986
   Dalmasso M, 2011, INT J FOOD MICROBIOL, V145, P113, DOI 10.1016/j.ijfoodmicro.2010.11.037
   Das L, 2012, J FOOD SCI TECH MYS, V49, P173, DOI 10.1007/s13197-011-0269-4
   Deborde C, 2000, APPL ENVIRON MICROB, V66, P2012, DOI 10.1128/AEM.66.5.2012-2020.2000
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   GIBSON GR, 1994, FEMS MICROBIOL LETT, V118, P121, DOI 10.1016/0378-1097(94)90606-8
   HAGUE A, 1995, EUR J CANCER PREV, V4, P359, DOI 10.1097/00008469-199510000-00005
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hester CM, 2015, WORLD J GASTROENTERO, V21, P2759, DOI 10.3748/wjg.v21.i9.2759
   Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935
   Lan A, 2008, BRIT J NUTR, V100, P1251, DOI 10.1017/S0007114508978284
   Lan A, 2007, BRIT J NUTR, V97, P714, DOI 10.1017/S0007114507433001
   Lan A, 2007, APOPTOSIS, V12, P573, DOI 10.1007/s10495-006-0010-3
   Lee JS, 2012, J BIOTECHNOL, V161, P34, DOI 10.1016/j.jbiotec.2012.05.011
   Lee JS, 2012, BIOTECHNOL PROGR, V28, P349, DOI 10.1002/btpr.1512
   Lee J, 2015, HEMATOL ONCOL CLIN N, V29, P1, DOI 10.1016/j.hoc.2014.09.005
   Leverrier P, 2004, ARCH MICROBIOL, V181, P215, DOI 10.1007/s00203-003-0646-0
   Leverrier P, 2003, APPL ENVIRON MICROB, V69, P3809, DOI 10.1128/AEM.69.7.3809-3818.2003
   Marques C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.29
   Oliveira CSF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.157
   Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1
   Saraoui T, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-911
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tedelind S, 2007, WORLD J GASTROENTERO, V13, P2826, DOI 10.3748/wjg.v13.i20.2826
   Thierry A, 2011, INT J FOOD MICROBIOL, V149, P19, DOI 10.1016/j.ijfoodmicro.2011.04.026
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wargovich MJ, 2010, CANCER METAST REV, V29, P503, DOI 10.1007/s10555-010-9240-5
   Yamamoto M, 2016, GENES ENVIRON, V38, DOI 10.1186/s41021-016-0038-8
   Zhu YM, 2011, CANCER LETT, V309, P119, DOI 10.1016/j.canlet.2011.06.004
NR 44
TC 21
Z9 22
U1 3
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD MAY 24
PY 2018
VL 5
AR 44
DI 10.3389/fnut.2018.00044
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GK7GA
UT WOS:000436363900001
PM 29881727
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, L
   Zhao, WM
   Yang, XH
   Sun, ZQ
   Jin, HZ
   Lei, C
   Jin, B
   Wang, HJ
AF Liu, Lin
   Zhao, Wei-Min
   Yang, Xin-Hui
   Sun, Zhen-Qiang
   Jin, Hui-Zhen
   Lei, Cheng
   Jin, Bo
   Wang, Hai-Jiang
TI Effect of inhibiting Beclin-1 expression on autophagy, proliferation and
   apoptosis in colorectal cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE colorectal cancer; HCT116 cells; Beclin-1; small interfering RNA;
   autophagy; proliferation; apoptosis
ID BCL-X-L; CELL-DEATH; TUMOR-SUPPRESSOR; GENE; PHOSPHORYLATION;
   MACROAUTOPHAGY; TUMORIGENESIS; PATHOGENESIS; MECHANISMS; INDUCTION
AB The present study aimed to investigate the molecular mechanisms and effect of Beclin-1 on autophagy, proliferation and apoptosis in the colorectal cancer (CRC) HCT116 and SW620 cells. Beclin-1 was silenced by RNA interference (RNAi) in HTC116 and SW620 cells. Reverse transcription-polymerase chain reaction and western blot were used to measure the expression of Beclin-1. The percentage of apoptotic cells was analyzed by cell counting kit-8 (CCK-8) and flow cytometry (FCM). Cell cycle and cell proliferation were analyzed by FCM and the MTT assay. The present study created 3 groups in the two cell lines, consisting of the targeting siRNA (TS) group, in which Beclin-1 was partially silenced, non-specific siRNA (NS) group and control group (CG; without transfection). By siRNA transfection, the mRNA and protein level of Beclin-1 in the TS group were significantly inhibited compared with the NS group and CG (P<0.05). After 0, 24, 48 and 72 h, the survival rate of the cells in the TS group was significantly decreased compared with the survival rate of the cells in the NS group and CG, as detected by CCK-8 methods (P<0.05). FCM and MTT results showed the apoptotic rate of the cells in the TS group was significantly decreased compared with the rate in the NS group and CG (P<0.05), and the proliferation of the cells in the NS group was evidently increased compared with the CG. In conclusion, Beclin-1 played an important role in regulating autophagy, proliferation and apoptosis in HCT116 and SW620 cells. The inhibition of Beclin-1 by RNAi suppressed the autophagic activity and proliferation, but promoted apoptosis in CRC cells. Beclin-1 was the new target of gene therapy for CRC.
C1 [Liu, Lin; Zhao, Wei-Min; Yang, Xin-Hui; Sun, Zhen-Qiang; Jin, Hui-Zhen; Lei, Cheng; Jin, Bo; Wang, Hai-Jiang] Xinjiang Med Univ, Canc Hosp, Dept Abdominal Surg, 789 Suzhou East St, Urumqi 830011, Xinjiang, Peoples R China.
RP Wang, HJ (corresponding author), Xinjiang Med Univ, Canc Hosp, Dept Abdominal Surg, 789 Suzhou East St, Urumqi 830011, Xinjiang, Peoples R China.
EM wanghaijang_l@163.com
CR Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Galadari S, 2015, APOPTOSIS, V20, P689, DOI 10.1007/s10495-015-1109-1
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ren JS, 2010, ASIAN PAC J CANCER P, V11, P1587
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Won KY, 2015, PATHOL RES PRACT, V211, P308, DOI 10.1016/j.prp.2014.11.005
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
NR 25
TC 13
Z9 16
U1 3
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2017
VL 14
IS 4
BP 4319
EP 4324
DI 10.3892/ol.2017.6687
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FK0DU
UT WOS:000413151300061
PM 28989537
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Gao, Q
   Bi, PD
   Luo, D
   Guan, Y
   Zeng, WL
   Xiang, HY
   Mi, QL
   Yang, GY
   Li, XM
   Yang, B
AF Gao, Qian
   Bi, Pinduan
   Luo, Ding
   Guan, Ying
   Zeng, Wanli
   Xiang, Haiying
   Mi, Qili
   Yang, Guangyu
   Li, Xuemei
   Yang, Bin
TI Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective
   effect in colitis mouse model
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Ulcerative colitis; Nicotine; Autophagy; AMPK/mTOR pathway
ID INFLAMMATORY-BOWEL-DISEASE; SODIUM-INDUCED COLITIS; ULCERATIVE-COLITIS;
   APOPTOSIS; PATHOGENESIS; CELLS; PROLIFERATION; ACTIVATION; INSIGHTS;
   CANCER
AB Epidemiological studies have shown that cigarette smoking is beneficial in ulcerative colitis and that nicotine may be responsible for this effect. However, the mechanism remains unclear. In a previous study, nicotine was found to induce autophagy in intestinal cells. Here, we evaluated the effect of nicotine-induced autophagy in a dextran sodium sulfate (DSS)-induced colitis mouse model. C57BL/6 adult male mice drank DSS water solution freely for seven consecutive days, and then tap water was administered. The effect of nicotine treatment was examined in the DSS model, including colon length, disease severity, histology of the colon tissue, and inflammation levels. Moreover, autophagy levels were detected by Western blot analysis (LC3II/LC3I, p62, and beclin-1). The levels of DSS-induced colitis were significantly decreased following nicotine treatment. The disease activity score, body weight, histologic damage scores, and the level of colonic inflammatory factors of nicotine-treated mice all decreased compared to those of the control mice. Additionally, nicotine enhanced the expression of LC3II/LC3I and beclin-1 but decreased the p62 protein level. Inhibiting autophagy by 3-MA attenuated the protective effects of nicotine on colitis. Additionally, both in vitro and in vivo experiments showed changes in AMPK-mTOR-P70S6K during this process. These results suggest that nicotine improved colitis by regulating autophagy and provided a protective effect against DSS-induced colitis.
C1 [Gao, Qian; Guan, Ying; Zeng, Wanli; Xiang, Haiying; Mi, Qili; Yang, Guangyu; Li, Xuemei] China Tobacco Yunnan Ind Co Ltd, Yunnan Key Lab Tobacco Chem, R&D Ctr, Kunming, Yunnan, Peoples R China.
   [Bi, Pinduan; Luo, Ding; Yang, Bin] Kunming Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China.
RP Yang, B (corresponding author), 295 Xichang Rd, Kunming, Yunnan, Peoples R China.; Li, XM (corresponding author), 41 Keyi Rd, Kunming 650106, Yunnan, Peoples R China.
EM lixuem@ynzy-tobacco.com; allan11182@163.com
FU Yunnan Key Laboratory of Tobacco Chemistry Project [2017539200340397]
FX This work was supported by the Yunnan Key Laboratory of Tobacco
   Chemistry Project [Grant No. 2017539200340397].
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   AlSharari SD, 2013, J PHARMACOL EXP THER, V344, P207, DOI 10.1124/jpet.112.198796
   Amre D, 2007, ARTIFICIAL CELLS, CELL ENGINEERING AND THERAPY, P454, DOI 10.1533/9781845693077.4.454
   An ZB, 2007, J BIOL CHEM, V282, P26793, DOI 10.1074/jbc.M703701200
   Araki Y, 2010, ONCOL REP, V24, P869, DOI 10.3892/or_00000932
   Bastida G, 2011, WORLD J GASTROENTERO, V17, P2740, DOI [10.3748/wjg.v17.i22.2734, 10.3748/wjg.v17.i22.2740]
   Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861
   Birrenbach T, 2004, INFLAMM BOWEL DIS, V10, P848, DOI 10.1097/00054725-200411000-00019
   Bodas M, 2016, FREE RADICAL BIO MED, V97, P441, DOI 10.1016/j.freeradbiomed.2016.06.017
   Castillo G, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.095701
   Cosnes J, 2009, DIGEST DIS, V27, P516, DOI 10.1159/000233291
   Fukada A, 2002, J PHARMACOL EXP THER, V302, P532, DOI 10.1124/jpet.102.034629
   Hao X., 2015, INT J CLIN EXP MED, V8
   Hayashi S, 2014, AM J PHYSIOL-GASTR L, V307, pG968, DOI 10.1152/ajpgi.00346.2013
   Hooper KM, 2017, J CROHNS COLITIS, V11, P118, DOI 10.1093/ecco-jcc/jjw127
   Hosomi S, 2015, CURR OPIN GASTROEN, V31, P81, DOI 10.1097/MOG.0000000000000144
   Iida T, 2017, WORLD J GASTROENTERO, V23, P1944, DOI 10.3748/wjg.v23.i11.1944
   Ke P, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00695
   Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006
   Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727
   Lakhan SE, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-129
   Lankarani KB, 2017, SCAND J GASTROENTERO, V52, P468, DOI 10.1080/00365521.2016.1259655
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579
   Lu XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080602
   Mizushima N, 2007, GENES DEV, V21
   Mofarrahi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047265
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Ng WK, 2016, INTEST RES, V14, P111, DOI 10.5217/ir.2016.14.2.111
   Nunes T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/218493
   Pelissier-Rota MA, 2015, INT J BIOCHEM CELL B, V65, P239, DOI 10.1016/j.biocel.2015.06.013
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Qin Z., 2016, J MOL MED, V31, P998
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Sepehrimanesh M., 2017, ULCERATIVE COLITIS P
   Summers AE, 2003, LIFE SCI, V72, P2091, DOI 10.1016/S0024-3205(03)00089-4
   Vetuschi A, 2002, DIGEST DIS SCI, V47, P1447, DOI 10.1023/A:1015931128583
   Wang ZY, 2019, ATHEROSCLEROSIS, V284, P1, DOI 10.1016/j.atherosclerosis.2019.02.008
   Ward MA, 2016, AM J PHYSIOL-GASTR L, V310, pG973, DOI 10.1152/ajpgi.00017.2016
   Xia L., 2015, NICOTINE EXERTS PROT
   Xiong HB, 2004, J BIOL CHEM, V279, P10776, DOI 10.1074/jbc.M313416200
   Zhao XL, 2018, INT J BIOCHEM CELL B, V100, P30, DOI 10.1016/j.biocel.2018.05.001
NR 42
TC 12
Z9 13
U1 4
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD FEB 1
PY 2020
VL 317
AR 108943
DI 10.1016/j.cbi.2020.108943
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA KN4NR
UT WOS:000514815900008
PM 31926917
DA 2022-04-25
ER

PT J
AU Roberts, JL
   Poklepovic, A
   Booth, L
AF Roberts, Jane L.
   Poklepovic, Andrew
   Booth, Laurence
TI Curcumin interacts with sildenafil to kill GI tumor cells via
   endoplasmic reticulum stress and reactive oxygen/nitrogen species
SO ONCOTARGET
LA English
DT Article
DE sildenafil; autophagy; chaperone; death receptor; ER stress
ID PDE5 INHIBITORS ENHANCE; HUMAN COLORECTAL-CANCER; NITRIC-OXIDE; TYROSINE
   NITRATION; GM-CSF; PATHWAY; GROWTH; ACTIVATION; EXPRESSION; PROMOTES
AB The present studies focused on the ability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil to enhance the anti-cancer properties of clinically relevant concentrations of the dietary diarylheptanoid curcumin. In gastrointestinal tumor cells, sildenafil and curcumin interacted in a greater than additive fashion to kill. Inhibition of the extrinsic apoptotic pathway suppressed killing by similar to 50%, as did blockade of the intrinsic apoptotic pathway. Sildenafil and curcumin reduced mTORC1 and mTORC2 activity and increased Beclin1 levels and the numbers of autophagosomes and autolysosomes in cells in a PERK-eIF2 alpha-dependent fashion. Knock down of Beclin1 or ATG5 partially suppressed killing. In contrast, stable knock out of ATG16-L1 unexpectedly enhanced killing, an effect not altered by Beclin1/ATG5 knock down. Curcumin and sildenafil exposure reduced the expression of MCL-1, BCL-XL, thioredoxin and superoxide dismutase 2 (SOD2) in an eIF2 alpha-dependent fashion. Curcumin and sildenafil interacted in a greater than additive fashion to increase the levels of reactive oxygen species; knock down of thioredoxin or SOD2 enhanced killing and overexpression of thioredoxin or SOD2 suppressed killing. In vivo, curcumin and sildenafil interacted to suppress the growth of colon cancer tumors. Multiplex analyses of plasma taken after drug exposure at animal nadir indicated that the levels of M-CSF, CXCL-9, PDGF and G-CSF were significantly increased by [curcumin + sildenafil] and that expression of CXCL1 and CCL5 were significantly reduced. Cells isolated from in vivo treated [curcumin + sildenafil] tumors were resistant to in vitro [curcumin + sildenafil] exposure, a phenotype that was blocked by the colon cancer therapeutic regorafenib.
C1 [Roberts, Jane L.; Poklepovic, Andrew; Booth, Laurence] Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Roberts, Jane L.; Booth, Laurence] Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
RP Booth, L (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Booth, L (corresponding author), Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
EM laurence.booth@vcuhealth.org
FU Universal Inc.; Dr. H.F. Young and Betts family fund;  [R01CA192613];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA192613] Funding Source: NIH RePORTER
FX Support for the present study was funded from the Universal Inc. Chair
   in Signal Transduction Research and R01CA192613. Thanks to Dr. H.F.
   Young and the Betts family fund for support in the purchase of the
   Hermes Wiscan instrument. Thanks to Dr. David. L. Boone for providing
   the HCT116 cell clones.
CR Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376
   Aliper AM, 2014, CANCER MED-US, V3, P737, DOI 10.1002/cam4.239
   Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x
   Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258
   Babykutty S, 2012, CLIN EXP METASTAS, V29, P471, DOI 10.1007/s10585-012-9464-6
   Booth L, 2017, ONCOTARGET, V8, P1449, DOI 10.18632/oncotarget.13640
   Booth L, 2016, ONCOTARGET, V7, P40398, DOI 10.18632/oncotarget.9752
   Booth L, 2016, ONCOTARGET, V7, P23608, DOI 10.18632/oncotarget.8281
   Booth L, 2016, ONCOTARGET, V7, P12975, DOI 10.18632/oncotarget.7349
   Booth L, 2015, J CELL PHYSIOL, V230, P1982, DOI 10.1002/jcp.24977
   Booth L, 2015, J CELL PHYSIOL, V230, P1661, DOI 10.1002/jcp.24919
   Booth L, 2015, J CELL PHYSIOL, V230, P1115, DOI 10.1002/jcp.24843
   Carreras MC, 2007, AM J PHYSIOL-CELL PH, V292, pC1569, DOI 10.1152/ajpcell.00248.2006
   Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401
   Curry JM, PLOS ONE, V3, P3405
   Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003
   Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Gota VS, 2010, J AGR FOOD CHEM, V58, P2095, DOI 10.1021/jf9024807
   Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97
   Kitadai Y, 2006, INT J CANCER, V119, P2567, DOI 10.1002/ijc.22229
   Kocher A, 2016, MOL NUTR FOOD RES, V60, P1555, DOI 10.1002/mnfr.201501034
   Langtry HD, 1999, DRUGS, V57, P967, DOI 10.2165/00003495-199957060-00015
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4
   Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200
   Lev-Ari S, 2005, CLIN CANCER RES, V11, P6738, DOI 10.1158/1078-0432.CCR-05-0171
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Luedke E, 2012, SURGERY, V152, P431, DOI 10.1016/j.surg.2012.05.035
   Messer JS, 2013, BMJ OPEN, V3
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Nakamura Y, 2008, ANN SURG ONCOL, V15, P2129, DOI 10.1245/s10434-008-9943-9
   Niedzwiecki A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090552
   Oladipo O, 2011, BRIT J CANCER, V104, P480, DOI 10.1038/sj.bjc.6606055
   Otani T, 1999, CELL IMMUNOL, V198, P111, DOI 10.1006/cimm.1999.1589
   Rahimi HR, 2016, AVICENNA J PHYTOMEDI, V6, P383
   Roberts JL, 2015, J CELL PHYSIOL, V230, P2552, DOI 10.1002/jcp.25014
   Roberts JL, 2014, CANCER BIOL THER, V15, P758, DOI 10.4161/cbt.28553
   Schiborr C, 2014, MOL NUTR FOOD RES, V58, P516, DOI 10.1002/mnfr.201300724
   Schmidt P, 2003, EUR J PHARMACOL, V468, P167, DOI 10.1016/S0014-2999(03)01674-1
   Sharma RA, 2001, CLIN CANCER RES, V7, P1894
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shehzad A, 2010, DRUG FUTURE, V35, P113, DOI 10.1358/dof.2010.035.02.1426640
   Siamwala JH, 2010, FEBS LETT, V584, P3415, DOI 10.1016/j.febslet.2010.06.039
   Sorokin A, 2016, CURR MED CHEM, V23, P2559, DOI 10.2174/0929867323666160729105312
   Steward WP, 2008, MOL NUTR FOOD RES, V52, P1005, DOI 10.1002/mnfr.200700148
   Strumberg D, 2012, EXPERT OPIN INV DRUG, V21, P879, DOI 10.1517/13543784.2012.684752
   Sun SS, 2004, CELL STRESS CHAPERON, V9, P76
   Suzuki S, 1998, TOHOKU J EXP MED, V185, P223, DOI 10.1620/tjem.185.223
   Tavallai M, 2015, J CELL PHYSIOL, V230, P2281, DOI 10.1002/jcp.24961
   Trinchieri Giorgio, 1992, Progress in Growth Factor Research, V4, P355, DOI 10.1016/0955-2235(92)90016-B
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Tunctan B, 2013, NITRIC OXIDE-BIOL CH, V33, P18, DOI 10.1016/j.niox.2013.05.001
   Uemura Y, 2006, INT J MOL MED, V18, P365
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Wang S.L., 2012, J NANOMATER, V2012, P5, DOI DOI 10.1371/J0URNAL.P0NE.0035101
   Yakovlev VA, 2007, BIOCHEMISTRY-US, V46, P11671, DOI 10.1021/bi701107z
   Yakovlev VA, 2010, J RECEPT SIG TRANSD, V30, P420, DOI 10.3109/10799893.2010.513991
   ZEH HJ, 1993, J IMMUNOTHER, V14, P155, DOI 10.1097/00002371-199308000-00012
   Zhu B, 2005, J CELL BIOCHEM, V94, P336, DOI 10.1002/jcb.20286
NR 65
TC 14
Z9 14
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 21
PY 2017
VL 8
IS 59
BP 99451
EP 99469
DI 10.18632/oncotarget.19807
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1TR
UT WOS:000419561600030
PM 29245915
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Huang, ZJ
   Fang, WL
   Liu, WH
   Wang, L
   Liu, B
   Liu, SM
   Liu, SJ
AF Huang, Zhenjun
   Fang, Weilun
   Liu, Weihua
   Wang, Li
   Liu, Bin
   Liu, Shiming
   Liu, Shaojun
TI Aspirin induces Beclin-1-dependent autophagy of human hepatocellular
   carcinoma cell
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE aspirin; autophagy; hepatocellular carcinoma cells; Beclin-1;
   AMP-activated protein kinase; mammalian target of rapamycin
ID CANCER STEM-CELLS; ACTIVATED PROTEIN-KINASE; LOW-DOSE ASPIRIN;
   COLORECTAL-CANCER; BREAST-CANCER; GROWTH; PATHWAY; COMBINATION;
   EXPRESSION; MECHANISM
AB Aspirin not only reduces the incidence of hepatocellular carcinoma (HCC) but also plays a synergistic role with chemotherapy for HCC treatment. However, the underlying mechanisms remain incompletely elucidated. Given that autophagy triggers cancer cell death, the present study examined the autophagic effect of aspirin on HCC cells. Results showed that aspirin increased LC3II/LC3I ratio, decreased p62 expression, and enhanced autophagic flux (autophagosome and autolysosome puncta) in Hep3B, HepG2, or SMMC-7721 cells, reflecting the autophagy of HCC cells. The autophagic effects of aspirin depended on Beclin-1 expression. Aspirin disrupted the interaction between Bcl-2 and Beclin-1. In addition to activating the AMP-activated protein kinase, c-Jun N-terminal kinase, and Glycogen synthase kinase-3 pathways, aspirin inhibited the mammalian-target-of rapamycin- S6K1/4E-BP1 signaling. Aspirin induced autophagy of HCC cell. This study contributes to understanding the chemoprotective and inhibitory effects of aspirin on HCC development.
C1 [Huang, Zhenjun; Fang, Weilun; Liu, Weihua; Wang, Li; Liu, Bin; Liu, Shiming; Liu, Shaojun] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Inst Cardiovasc Dis, Guangzhou 510260, Guangdong, Peoples R China.
   [Huang, Zhenjun] Guangzhou Med Univ, Affiliated Hosp 1, Expt Ctr, Guangzhou 510700, Guangdong, Peoples R China.
RP Liu, SJ (corresponding author), Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Inst Cardiovasc Dis, Guangzhou 510260, Guangdong, Peoples R China.
EM shaojunliu@gzhmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81570259, 81400234]; Science and Technology
   Planning Project of Guangdong Province, China [2014A020212327,
   2016A020215163]; Elite Programme of The Second Affiliated Hospital of
   Guangzhou Medical University [52010205-035]
FX This study was supported by research grants from National Natural
   Science Foundation of China (No. 81570259, 81400234), Science and
   Technology Planning Project of Guangdong Province, China (No.
   2014A020212327, 2016A020215163) and Elite Programme of The Second
   Affiliated Hospital of Guangzhou Medical University (No. 52010205-035).
CR Akbari-Birgani S, 2016, DRUG DISCOV TODAY, V21, P836, DOI 10.1016/j.drudis.2016.03.004
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577
   Bos CL, 2006, ONCOGENE, V25, P6447, DOI 10.1038/sj.onc.1209658
   Chang ET, 2009, CANCER EPIDEM BIOMAR, V18, P976, DOI 10.1158/1055-9965.EPI-08-1130
   Chen W, 2009, BIOCHEM BIOPH RES CO, V390, P142, DOI 10.1016/j.bbrc.2009.09.083
   Cieslar-Pobuda A, 2015, ONCOTARGET, V6, P29753, DOI 10.18632/oncotarget.4995
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Ding JH, 2014, EUR J HAEMATOL, V93, P329, DOI 10.1111/ejh.12352
   Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4
   Gao M, 2016, ONCOTARGET, V7, P16349, DOI 10.18632/oncotarget.7648
   Goel A, 2003, CLIN CANCER RES, V9, P383
   Henry WS, 2017, CANCER RES, V77, P790, DOI 10.1158/0008-5472.CAN-16-2400
   Holmes MD, 2011, BREAST CANCER RES TR, V130, P657, DOI 10.1007/s10549-011-1651-7
   Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200
   Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692
   King TS, 2015, EUR J PHARMACOL, V762, P299, DOI 10.1016/j.ejphar.2015.06.001
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li JH, 2016, AM J CANCER RES, V6, P2109
   Li L, 2016, ONCOL LETT, V12, P93, DOI 10.3892/ol.2016.4607
   Li XF, 2013, BIOCHEM BIOPH RES CO, V436, P259, DOI 10.1016/j.bbrc.2013.05.088
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078-0432.CCR-15-0198
   Likus W, 2016, DRUG RESIST UPDATE, V25, P13, DOI 10.1016/j.drup.2016.02.001
   Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032
   Liu L, 2017, ONCOTARGET, V8, P57707, DOI 10.18632/oncotarget.17202
   Liu WH, 2016, EUR J PHARMACOL, V776, P19, DOI 10.1016/j.ejphar.2016.02.056
   Ma SS, 2012, J BIOL CHEM, V287, P22521, DOI 10.1074/jbc.M111.321349
   Mc Menamin UC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1910-9
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moris D, 2016, BREAST CARE, V11, P339, DOI 10.1159/000452315
   Pennarun B, 2013, J PATHOL, V229, P410, DOI 10.1002/path.4138
   Petrick JL, 2015, CANCER PREV RES, V8, P1156, DOI 10.1158/1940-6207.CAPR-15-0126
   Sitia G, 2013, J HEPATOL, V59, P1135, DOI 10.1016/j.jhep.2013.05.040
   Skriver C, 2016, CANCER CAUSE CONTROL, V27, P1067, DOI 10.1007/s10552-016-0785-7
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang JG, 2015, SCI REP-UK, V5, DOI 10.1038/srep07896
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wood NJ, 2007, INT J GYNECOL CANCER, V17, P447, DOI 10.1111/j.1525-1438.2007.00867.x
   Xie YC, 2015, AUTOPHAGY, V11, P28, DOI 10.4161/15548627.2014.984267
   Yi C, 2012, SCIENCE, V336, P474, DOI 10.1126/science.1216990
   Zhang C, 2015, J CELL MOL MED, V19, P408, DOI 10.1111/jcmm.12461
   Zhao QQ, 2016, ONCOL LETT, V12, P2804, DOI 10.3892/ol.2016.5017
   Zong M, 2016, EUR J PHARMACOL, V791, P137, DOI 10.1016/j.ejphar.2016.07.050
NR 43
TC 19
Z9 23
U1 3
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 15
PY 2018
VL 823
BP 58
EP 64
DI 10.1016/j.ejphar.2018.01.031
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FX2KG
UT WOS:000425888100008
PM 29408091
DA 2022-04-25
ER

PT J
AU Wu, YP
   Tang, L
   Wang, BK
   Sun, QM
   Zhao, PW
   Li, WF
AF Wu, Yanping
   Tang, Li
   Wang, Baikui
   Sun, Qiming
   Zhao, Pengwei
   Li, Weifen
TI The role of autophagy in maintaining intestinal mucosal barrier
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE autophagy; intestinal mucosal barrier; IECs; intestinal diseases;
   therapy
ID GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; PANETH CELL
   AUTOPHAGY; STEM-CELLS; EPITHELIAL-CELLS; COLORECTAL-CANCER; OXIDATIVE
   STRESS; CROHN-DISEASE; COLON-CANCER; NECROTIZING ENTEROCOLITIS
AB The intestinal mucosal barrier is the first line to defense against luminal content penetration and performs numerous biological functions. The intestinal epithelium contains a huge surface that is lined by a monolayer of intestinal epithelial cells (IECs). IECs are dominant mediators in maintaining intestinal homeostasis that drive diverse functions including nutrient absorption, physical segregation, secretion of antibacterial peptides, and modulation of immune responses. Autophagy is a cellular self-protection mechanism in response to various stresses, and accumulating studies have revealed its importance in participating physiological processes of IECs. The regulatory effects of autophagy depend on the specific IEC types. This review aims to elucidate the myriad roles of autophagy in regulating the functions of different IECs (stem cells, enterocytes, goblet cells, and Paneth cells), and present the progress of autophagy-targeting therapy in intestinal diseases. Understanding the involved mechanisms can provide new preventive and therapeutic strategies for gastrointestinal dysfunction and diseases.
C1 [Wu, Yanping; Tang, Li; Wang, Baikui; Li, Weifen] Zhejiang Univ, Key Lab Mol Anim Nutr, Minist Educ, Coll Anim Sci, Hangzhou, Zhejiang, Peoples R China.
   [Sun, Qiming; Zhao, Pengwei] Zhejiang Univ, Sch Med, Dept Biochem, Hangzhou 310058, Zhejiang, Peoples R China.
RP Zhao, PW (corresponding author), Zhejiang Univ, Sch Med, Dept Biochem, Hangzhou 310058, Zhejiang, Peoples R China.; Li, WF (corresponding author), Zhejiang Univ, Coll Anim Sci, Key Lab Mol Anim Nutr, Hangzhou 310058, Zhejiang, Peoples R China.
EM zhaopengwei625@163.com; wfli@zju.edu.cn
OI Wang, Baikui/0000-0001-5283-7337
FU National High-Tech R&D Program (863) of ChinaNational High Technology
   Research and Development Program of China [2013AA102803D]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31472128, 31672460]
FX National High-Tech R&D Program (863) of China, Grant/Award Number: No.
   2013AA102803D; National Natural Science Foundation of China, Grant/Award
   Numbers: 31472128, No. 31672460
CR Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arrieta MC, 2009, GUT, V58, P41, DOI 10.1136/gut.2008.150888
   Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546
   Billmann-Born S, 2011, EUR J CELL BIOL, V90, P593, DOI 10.1016/j.ejcb.2010.10.015
   Botti-Millet J, 2016, AM J PHYSIOL-CELL PH, V311, pC351, DOI 10.1152/ajpcell.00129.2016
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bretin A, 2016, AUTOPHAGY, V12, P770, DOI 10.1080/15548627.2016.1156823
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Burger E, 2018, CELL HOST MICROBE, V23, P177, DOI 10.1016/j.chom.2018.01.001
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Cederlund A, 2011, FEBS J, V278, P3942, DOI 10.1111/j.1742-4658.2011.08302.x
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chung HC, 2012, CELL, V149, P1578, DOI 10.1016/j.cell.2012.04.037
   Clark JA, 2006, AM J PHYSIOL-GASTR L, V291, pG938, DOI 10.1152/ajpgi.00090.2006
   Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Delorme-Axford E, 2018, AUTOPHAGY, V14, P365, DOI 10.1080/15548627.2017.1401425
   Deplancke B, 2001, AM J CLIN NUTR, V73, p1131S
   Deretic V, 2008, DEV CELL, V15, P641, DOI 10.1016/j.devcel.2008.10.009
   Duan JL, 2015, FREE RADICAL RES, V49, P210, DOI 10.3109/10715762.2014.993627
   Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fritz T, 2011, GUT, V60, P1580, DOI 10.1136/gut.2009.206466
   Gardet A, 2012, CURR OPIN IMMUNOL, V24, P522, DOI 10.1016/j.coi.2012.08.001
   Garrison AP, 2009, AM J PHYSIOL-GASTR L, V296, pG643, DOI 10.1152/ajpgi.90588.2008
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giepmans BNG, 2009, BBA-BIOMEMBRANES, V1788, P820, DOI 10.1016/j.bbamem.2008.07.015
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Hooper KM, 2017, J CROHNS COLITIS, V11, P118, DOI 10.1093/ecco-jcc/jjw127
   Hooper LV, 2010, NAT REV IMMUNOL, V10, P159, DOI 10.1038/nri2710
   Ishibashi K, 2012, MOL BIOL CELL, V23, P3193, DOI 10.1091/mbc.E12-01-0010
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Johansson MEV, 2009, J PROTEOME RES, V8, P3549, DOI 10.1021/pr9002504
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009
   Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x
   Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu B, 2013, AM J PHYSIOL-GASTR L, V305, pG573, DOI 10.1152/ajpgi.00071.2013
   Liu ZZ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/352723
   Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028
   Martens EC, 2018, NAT REV MICROBIOL, V16, P457, DOI 10.1038/s41579-018-0036-x
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathis D, 2012, IMMUNOL REV, V245, P239, DOI 10.1111/j.1600-065X.2011.01084.x
   Maynard AA, 2010, AM J PHYSIOL-GASTR L, V299, pG614, DOI 10.1152/ajpgi.00076.2010
   McElroy SJ, 2013, NEONATOLOGY, V103, P10, DOI 10.1159/000342340
   McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549
   McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010
   Mei Y, 2015, BBA-MOL BASIS DIS, V1852, P243, DOI 10.1016/j.bbadis.2014.05.005
   Metcalfe C, 2014, CELL STEM CELL, V14, P149, DOI 10.1016/j.stem.2013.11.008
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001
   Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044
   Na HJ, 2018, BIOCHEM BIOPH RES CO, V498, P18, DOI 10.1016/j.bbrc.2018.02.191
   Nagy P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23065-3
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   Naves JE, 2015, J CROHNS COLITIS, V9, pS98
   Neal MD, 2013, J IMMUNOL, V190, P3541, DOI 10.4049/jimmunol.1202264
   Negroni A, 2016, INFLAMM RES, V65, P803, DOI 10.1007/s00011-016-0964-8
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Nighot P, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1171284
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683
   Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016
   Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005
   Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Ra EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11726
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Reggiori F, 2017, J MOL BIOL, V429, P486, DOI 10.1016/j.jmb.2017.01.002
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Roda G, 2010, WORLD J GASTROENTERO, V16, P4264, DOI 10.3748/wjg.v16.i34.4264
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Ruart M, 2019, J HEPATOL, V70, P458, DOI 10.1016/j.jhep.2018.10.015
   Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sandler NG, 2011, GASTROENTEROLOGY, V141, P1220, DOI 10.1053/j.gastro.2011.06.063
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shaffiey S., 2014, J SURG RES, V186, P650
   Shakeri A, 2019, J CELL PHYSIOL, V234, P5643, DOI 10.1002/jcp.27404
   Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   Singh V, 2017, J BIOL CHEM, V292, P1847, DOI 10.1074/jbc.M116.759456
   Snoeck V, 2005, MICROBES INFECT, V7, P997, DOI 10.1016/j.micinf.2005.04.003
   SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183
   Stappenbeck TS, 2009, GASTROENTEROLOGY, V137, P30, DOI 10.1053/j.gastro.2009.05.013
   Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133
   Suh HW, 2017, CURR MED CHEM, V24, P898, DOI 10.2174/0929867323666161202151856
   Thachil E, 2012, GASTROENTEROLOGY, V142, pS682
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Tiwari S., 2018, J CANADIAN ASS GASTR, V1, P459, DOI [10.1093/jcag/gwy008.265, DOI 10.1093/JCAG/GWY008.265]
   Treveil A, 2019, J CROHNS COLITIS, V13, pS31, DOI 10.1093/ecco-jcc/jjy222.043
   Tsuboyama K, 2016, SCIENCE, V354, P1036, DOI 10.1126/science.aaf6136
   Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653
   Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105
   van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145
   Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020
   Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485
   Wang SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00693
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Wildenberg ME, 2017, MUCOSAL IMMUNOL, V10, P352, DOI 10.1038/mi.2016.65
   Wittkopf N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/278059
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Wu YP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00469
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Yang Y, 2015, AMINO ACIDS, V47, P2177, DOI 10.1007/s00726-014-1844-6
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yilmaz OH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010157
   Zhang H, 2017, IMMUNOBIOLOGY, V222, P831, DOI 10.1016/j.imbio.2017.03.002
   Zhang LZ, 2019, MOL MED REP, V19, P3053, DOI 10.3892/mmr.2019.9974
   Zhu Y, 2008, J PHYSIOL-LONDON, V586, P1977, DOI 10.1113/jphysiol.2007.149310
NR 147
TC 24
Z9 25
U1 5
U2 65
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2019
VL 234
IS 11
BP 19406
EP 19419
DI 10.1002/jcp.28722
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA IM5EX
UT WOS:000478018200026
PM 31020664
DA 2022-04-25
ER

PT J
AU Yao, DH
   Wang, PQ
   Zhang, J
   Fu, LL
   Ouyang, L
   Wang, JH
AF Yao, Dahong
   Wang, Peiqi
   Zhang, Jin
   Fu, Leilei
   Ouyang, Liang
   Wang, Jinhui
TI Deconvoluting the relationships between autophagy and metastasis for
   potential cancer therapy
SO APOPTOSIS
LA English
DT Review
DE Autophagy; Metastasis; Anti-metastatic agent; Cancer therapy
ID BREAST-CANCER; BECLIN 1; CELL-DEATH; COLORECTAL-CANCER; GASTRIC-CANCER;
   TUMOR PROGRESSION; HEPATOCELLULAR-CARCINOMA; MEDIATED SUPPRESSION;
   PULMONARY METASTASIS; SELECTIVE AUTOPHAGY
AB Autophagy is a highly conserved lysosome-dependent degradation process that may digest some long-lived proteins and damaged organelles. As an essential homeostasis maintaining system in normal cells, autophagy plays a key role in several pathological settings, especially cancer. Metastasis, known as a crucial hallmark of cancer progression, is the primary cause of cancer lethality. The role of autophagy in metastasis is quite complex as supportive evidence has indicated both pro-metastatic and anti-metastatic functions of autophagy. Autophagy can inhibit metastasis by restricting necrosis and mediating autophagic cell death, whereas it may also promote metastasis by enhancing cancer cell fitness in response to stress. Moreover, the function of autophagy is context- and stage-dependent. Specifically, during the early steps of metastasis, autophagy mainly serves as a suppressor, while it plays a pro-metastatic role in the later steps. Here, we focus on highlighting the dual roles of autophagy in metastasis and address the molecular mechanisms involved in this process, which may provide a new insight into cancer biology. While, we also summarize several anti-metastatic agents manipulating autophagy, in the hope of shedding light on exploration of potential novel drugs for future cancer therapy.
C1 [Yao, Dahong; Zhang, Jin; Fu, Leilei; Ouyang, Liang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Yao, Dahong; Zhang, Jin; Fu, Leilei; Ouyang, Liang] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.
   [Yao, Dahong; Wang, Jinhui] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China.
   [Wang, Peiqi] Sichuan Univ, West China Sch Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
RP Fu, LL; Ouyang, L (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.; Fu, LL; Ouyang, L (corresponding author), Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.
EM leilei_fu@163.com; ouyangliang@scu.edu.cn
RI Ouyang, Liang/A-2751-2010; Zhang, Jin/AAK-7593-2021
OI Ouyang, Liang/0000-0001-5537-8834; 
FU Key Projects of the National Science and Technology Pillar Program
   [2012BAI30B02]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81160543, 81260628,
   81303270, 81172374]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2015M580794]
FX This work was supported in part by grants from the Key Projects of the
   National Science and Technology Pillar Program (No. 2012BAI30B02),
   National Natural Science Foundation of China (Nos. 81160543, 81260628,
   81303270 and 81172374) and China Postdoctoral Science Foundation (No.
   2015M580794).
CR Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242
   Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bhattacharya A, 2015, ONCOTARGET, V6, P2966, DOI 10.18632/oncotarget.3070
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Buricchi F, 2007, CELL ADHES MIGR, V1, P33, DOI 10.4161/cam.3911
   Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chang L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.415
   Chen KL, 2012, CANCER LETT, V317, P89, DOI 10.1016/j.canlet.2011.11.015
   Chen L, 2011, CARCINOGENESIS, V32, P986, DOI 10.1093/carcin/bgr065
   Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380
   Chen TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023317
   Chen Y, 2014, MED IMAGE ANAL, V18, P1, DOI 10.1016/j.media.2013.08.003
   Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023
   Chiu HW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076340
   Chun J, 2013, J CELL BIOCHEM, V114, P456, DOI 10.1002/jcb.24386
   D'Anneo A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.415
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Debnath J, 2008, AUTOPHAGY, V4, P351, DOI 10.4161/auto.5523
   DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0
   DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
   Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036
   Gaur S, 2015, ONCOTARGET, V6, P29161, DOI 10.18632/oncotarget.4971
   Ge J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110293
   Ge XY, 2014, PLOS ONE, V7
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Giovannetti E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt346
   Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gou WF, 2015, ONCOTARGET, V6, P19552, DOI 10.18632/oncotarget.3735
   Gou WF, 2015, ONCOTARGET, V6, P19841, DOI 10.18632/oncotarget.3734
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Guo JY, 2015, TOXICOL LETT, V234, P201, DOI 10.1016/j.toxlet.2015.02.016
   Guo WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070910
   Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189
   Han B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107204
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hashimoto I, 2008, EUR J CANCER, V44, P1022, DOI 10.1016/j.ejca.2008.02.043
   He SS, 2015, AUTOPHAGY, V11, P1939, DOI 10.1080/15548627.2015.1086523
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Huang YH, 2014, AUTOPHAGY, V10, P1787, DOI 10.4161/auto.29989
   Ishima Y, 2015, CANCER SCI, V106, P194, DOI 10.1111/cas.12577
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Khan M, 2016, J CELL MOL MED, V20, P389, DOI 10.1111/jcmm.12749
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050624
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Leung T, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3574
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liao CC, 2013, AUTOPHAGY, V9, P5, DOI 10.4161/auto.22379
   Lin C, 2015, APPL MICROBIOL BIOT, V99, P8487, DOI 10.1007/s00253-015-6565-6
   Lin JJ, 2014, MAR DRUGS, V12, P4783, DOI 10.3390/md12094783
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864
   Liu H, 2015, AUTOPHAGY, V11, P2323, DOI 10.1080/15548627.2015.1074372
   Liu TX, 2015, MOL CANCER THER, V14, P429, DOI 10.1158/1535-7163.MCT-14-0548
   Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lu YT, 2015, AUTOPHAGY, V11, P2213, DOI 10.1080/15548627.2015.1108507
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo HM, 2014, ACS NANO, V8, P4334, DOI 10.1021/nn405989n
   Lv Q, 2012, AUTOPHAGY, V8, P1675, DOI 10.4161/auto.21438
   Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Maroni P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.465
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakaya Y, 2013, CANCER LETT, V341, P9, DOI 10.1016/j.canlet.2013.02.037
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pang LY, 2015, VET J, V205, P154, DOI 10.1016/j.tvjl.2014.12.029
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Peng JM, 2012, BRIT J PHARMACOL, V165, P479, DOI 10.1111/j.1476-5381.2011.01581.x
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628
   Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671
   Sahni S, 2014, J BIOL CHEM, V289, P9692, DOI 10.1074/jbc.M113.529511
   Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105
   Shteingauz NIA, 2015, AUTOPHAGY, V11, P2387, DOI 10.1080/15548627.2015.1115174
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549-012-2080-y
   Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Tian ML, 2011, CANCER BIOL THER, V12, P896, DOI 10.4161/cbt.12.10.17679
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Wu PF, 2015, EXP DERMATOL, V24, P930, DOI 10.1111/exd.12805
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Wu XY, 2013, TUMOR BIOL, V34, P713, DOI 10.1007/s13277-012-0599-5
   Yang M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-43
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Yuan J, 2015, METALLOMICS, V7, P896, DOI 10.1039/c5mt00010f
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhang H, 2014, CELL PHYSIOL BIOCHEM, V33, P991, DOI 10.1159/000358670
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhang RY, 2016, TUMOR BIOL, V37, P3479, DOI 10.1007/s13277-015-4086-7
   Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185
   Zheng HC, 2015, ONCOTARGET, V6, P19685, DOI 10.18632/oncotarget.4081
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 134
TC 17
Z9 17
U1 0
U2 29
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD JUN
PY 2016
VL 21
IS 6
BP 683
EP 698
DI 10.1007/s10495-016-1237-2
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DL3XC
UT WOS:000375565900002
PM 27003389
DA 2022-04-25
ER

PT J
AU Xue, Q
   Wang, P
   Wang, XB
   Zhang, K
   Liu, QH
AF Xue, Qin
   Wang, Pan
   Wang, Xiaobing
   Zhang, Kun
   Liu, Quanhong
TI Targeted inhibition of p38MAPK-enhanced autophagy in SW620 cells
   resistant to photodynamic therapy-induced apoptosis
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE PDT; p38MAPK; ROS; Autophagy; Apoptosis
ID COLORECTAL-CANCER CELLS; PROTEIN-KINASES; MAP KINASE; P38; ACTIVATION;
   DEATH; TUMORIGENESIS; SENESCENCE; HYPERICIN; EFFICACY
AB Photodynamic therapy (PDT) is a promising and noninvasive treatment that can induce apoptosis, autophagy, or both depending on the cell phenotype. In this work, chlorin e6 (Ce6) was used to photosensitize human colorectal cancer SW620 cells. In cells, apparent autophagy and apoptosis with dependence on intracellular reactive oxygen species (ROS) generation were detected. p38MAPK activation followed by ROS generation might be a core component in Ce6 mediate PDT (Ce6-PDT)-induced autophagy and apoptosis signaling pathway. By using p38MAPK siRNA, the results showed a marked enhancement on cell apoptosis in Ce6-PDT with increased annexin (+) apoptotic cells, nuclear condensation, caspase-3, and PARP cleavage. Besides, impairment of p38MAPK also promoted the autophagic response to photodamage as indicated by conversion of LC3 and monodansyl cadaverine (MDC) labeling patterns. It appears that Ce6-PDT induced ROS production involving activation of p38MAPK, probably to prevent SW620 cells from photodamage. Moreover, autophagy inhibitor 3-methyladenine/bafilomycin A1 greatly aggravated Ce6-PDT-induced apoptosis in SW620 cells with knockdown of p38MAPK. Taken together, this study suggests that autophagy could represent a promising field in cancer treatment and p38MAPK may be a potential therapeutic target to enhance the efficacy on clinical evaluation for the treatment of colorectal cancer.
C1 [Xue, Qin; Wang, Pan; Wang, Xiaobing; Zhang, Kun; Liu, Quanhong] Shaanxi Normal Univ, Coll Life Sci, Minist Educ,Key Lab Med Resources & Nat Pharmaceu, Natl Engn Lab Resource Developing Endangered Chin, Xian 710062, Shaanxi, Peoples R China.
   [Xue, Qin] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian 710032, Peoples R China.
RP Zhang, K (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Minist Educ,Key Lab Med Resources & Nat Pharmaceu, Natl Engn Lab Resource Developing Endangered Chin, Xian 710062, Shaanxi, Peoples R China.
EM zkxian@snnu.edu.cn; lshaof@snnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472846]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [GK201502009]
FX This work was supported by the National Natural Science Foundation of
   China (no. 81472846) and the Fundamental Research Funds for the Central
   Universities (GK201502009).
CR Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788
   Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200
   Barberi-Heyob M, 2004, INT J ONCOL, V24, P951
   Bhuvaneswari R, 2011, LASER SURG MED, V7, P769
   Burmistrova O, 2011, CANCER LETT, V309, P71, DOI 10.1016/j.canlet.2011.05.018
   Burns CJ, 2000, BIOCHEM BIOPH RES CO, V268, P541, DOI 10.1006/bbrc.2000.2179
   Chin WWL, 2006, J PHOTOCH PHOTOBIO B, V84, P103, DOI 10.1016/j.jphotobiol.2006.02.002
   Crescenzi E, 2006, MOL CANCER THER, V5, P776, DOI 10.1158/1535-7163.MCT-05-0425
   Magalhaes PVDS, 2013, AUST NZ J PSYCHIAT, V47, P564, DOI 10.1177/0004867413481631
   Davids LM, 2011, CANCER TREAT REV, V37, P465, DOI 10.1016/j.ctrv.2010.11.007
   De Dosso S, 2009, CANCER TREAT REV, V35, P160, DOI 10.1016/j.ctrv.2008.10.001
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Firczuk M, 2011, FRONT BIOSCI-LANDMRK, V16, P208, DOI 10.2741/3684
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Ha YM, 2009, CANCER LETT, V277, P48, DOI 10.1016/j.canlet.2008.11.020
   HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x
   HERMAN PS, 1973, LANCET, V1, P209
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   KOCHUBEEV GA, 1988, BIOFIZIKA+, V33, P471
   Kopetz S, 2008, ONCOLOGY-NY, V22, P260
   Krammer B, 2012, CURR MED CHEM, V19, P793, DOI 10.2174/092986712799034842
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Luo Y, 2011, EXP GERONTOL, V46, P860, DOI 10.1016/j.exger.2011.07.005
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Noodt BB, 1996, BRIT J CANCER, V74, P22, DOI 10.1038/bjc.1996.310
   Ol'shevskaya VA, 2009, BIOORGAN MED CHEM, V17, P1297, DOI 10.1016/j.bmc.2008.12.016
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Siboni G, 2003, CANCER LETT, V196, P57, DOI 10.1016/S0304-3835(03)00207-6
   vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031
   Wang HP, 2013, ULTRASOUND MED BIOL, V39, P1713, DOI 10.1016/j.ultrasmedbio.2013.03.017
   Whitacre CM, 2000, CLIN CANCER RES, V6, P2021
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Yu JH, 2013, INT J MED SCI, V10, P707, DOI 10.7150/ijms.5726
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 41
TC 3
Z9 3
U1 1
U2 26
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
EI 1435-604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD SEP
PY 2015
VL 30
IS 7
BP 1967
EP 1975
DI 10.1007/s10103-015-1770-1
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Surgery
GA CQ8NA
UT WOS:000360863300019
PM 26254783
DA 2022-04-25
ER

PT J
AU Bajbouj, K
   Schulze-Luehrmann, J
   Diermeier, S
   Amin, A
   Schneider-Stock, R
AF Bajbouj, Khuloud
   Schulze-Luehrmann, Jan
   Diermeier, Stefanie
   Amin, Amr
   Schneider-Stock, Regine
TI The anticancer effect of saffron in two p53 isogenic colorectal cancer
   cell lines
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ANTITUMOR-ACTIVITY; OXIDATIVE STRESS; AUTOPHAGY; BIOLOGY; CROCIN;
   CHEMOPREVENTION; APOPTOSIS; EXTRACT; PROTEIN; P73
AB Background: Saffron extract, a natural product, has been shown to induce apoptosis in several tumor cell lines. Nevertheless, the p53-dependency of saffron's mechanism of action in colon cancer remains unexplored.
   Material and methods: In order to examine saffron's anti-proliferative and pro-apoptotic effects in colorectal cancer cells, we treated two p53 isogenic HCT116 cell lines (HCT wildtype and HCT p53-/-) with different doses of the drug and analyzed cell proliferation and apoptosis in a time-dependent manner. MTT viability and crystal violet assays were performed in order to determine the effective dose of saffron on both cell lines. The cell cycle progress was examined by Flow cytometric analysis. Apoptosis was assessed using Annexin-PI-staining and Western Blotting for caspase 3 and PARP cleavage. Autophagy was determined by Western Blotting of the light chain 3 (LC3)-II and Beclin 1 proteins. The protein content of phospho-H2AX (gamma H2AX), a sensor of DNA double strand breaks, was also analyzed by Western Blotting.
   Results: Saffron extract induced a p53-dependent pattern of cell cycle distribution with a full G2/M stop in HCT116 p53 wildtype cells. However, it induced a remarkable delay in S/G2 phase transit with entry into mitosis in HCT116 p53-/- cells. The apoptotic Pre-G1 cell fraction as well as Annexin V staining and caspase 3 cleavage showed a more pronounced apoptosis induction in HCT116 p53 wildtype cells. Obviously, the significantly higher DNA-damage, reflected by gamma H2AX protein levels in cells lacking p53, was coped by up-regulation of autophagy. The saffron-induced LC3-II protein level was a remarkable indication of the accumulation of autophagosomes, a response to the cellular stress condition of drug treatment.
   Conclusions: This is the first study showing the effect of saffron in HCT116 colorectal cancer cells with different p53 status. Saffron induced DNA-damage and apoptosis in both cell lines. However, autophagy has delayed the induction of apoptosis in HCT116 p53-/- cells. Considering the fact that most tumors show a functional p53 inactivation, further research is needed to elucidate the long-term effects of saffron in p53-/- tumors.
C1 [Bajbouj, Khuloud; Amin, Amr; Schneider-Stock, Regine] UAE Univ, Fac Sci, Dept Biol, Al Ain, U Arab Emirates.
   [Schulze-Luehrmann, Jan; Diermeier, Stefanie; Schneider-Stock, Regine] Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany.
   [Amin, Amr] Cairo Univ, Dept Zool, Cairo, Egypt.
RP Schneider-Stock, R (corresponding author), UAE Univ, Fac Sci, Dept Biol, Al Ain, U Arab Emirates.
EM regine.schneider-stock@uk-erlangen.de
RI Amin, Amr/I-2137-2019; Schneider-Stock, Regine/H-8863-2012
OI Amin, Amr/0000-0001-8888-1102; Bajbouj, Khuloud/0000-0001-7344-6095
FU Emirates Foundation [2009-079]
FX This study was funded in-part by Emirates Foundation Grant # 2009-079
   for AA. Authors are also grateful to Adrian Koch for his excellent
   technical assistance.
CR Abdullaev FI, 2004, CANCER DETECT PREV, V28, P426, DOI 10.1016/j.cdp.2004.09.002
   Abdullaev FI, 1997, ARCH LATINOAM NUTR, V47, P195
   Amin A, 2007, RECENT PAT ANTI-CANC, V2, P109, DOI 10.2174/157489207780832414
   Amin A, 2011, HEPATOLOGY, V54, P857, DOI 10.1002/hep.24433
   Aung H H, 2007, Exp Oncol, V29, P175
   Bathaie SZ, 2007, DNA CELL BIOL, V26, P533, DOI 10.1089/dna.2007.0598
   Cantero-Munoz P, 2011, CANCER LETT, V306, P121, DOI 10.1016/j.canlet.2011.02.020
   Chryssanthi DG, 2011, PLANTA MED, V77, P146, DOI 10.1055/s-0030-1250178
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Das I, 2010, ACTA HISTOCHEM, V112, P317, DOI 10.1016/j.acthis.2009.02.003
   Deng Ying, 2002, Zhongguo Zhongyao Zazhi, V27, P565
   Deo B., 2003, CROP FOOD RES, V20, P1
   Dufresne C, 1997, PLANTA MED, V63, P150, DOI 10.1055/s-2006-957633
   Facchini PJ, 2001, ANNU REV PLANT PHYS, V52, P29, DOI 10.1146/annurev.arplant.52.1.29
   Ghadrdoost B, 2011, EUR J PHARMACOL, V667, P222, DOI 10.1016/j.ejphar.2011.05.012
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Harrison S, 2011, SURG-J R COLL SURG E, V9, P200, DOI 10.1016/j.surge.2011.01.011
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Holstein SA, 2004, LIPIDS, V39, P293, DOI 10.1007/s11745-004-1233-3
   Iriti M., 2004, Current Topics in Nutraceutical Research, V2, P47
   Kern A, 2002, INT J ONCOL, V21, P243
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Li J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-215
   Liu RH, 2004, J NUTR, V134, p3479S, DOI 10.1093/jn/134.12.3479S
   Melnyk J. P., 2010, Food Research International, V43, P1981, DOI 10.1016/j.foodres.2010.07.033
   Mousavi SH, 2009, FOOD CHEM TOXICOL, V47, P1909, DOI 10.1016/j.fct.2009.05.017
   NAIR SC, 1995, CANCER BIOTHERAPY, V10, P257, DOI 10.1089/cbr.1995.10.257
   NAIR SC, 1991, CANCER LETT, V57, P109, DOI 10.1016/0304-3835(91)90203-T
   Premkumar K, 2003, PHYTOTHER RES, V17, P614, DOI 10.1002/ptr.1209
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Tavakkol-Afshari J, 2008, FOOD CHEM TOXICOL, V46, P3443, DOI 10.1016/j.fct.2008.08.018
   Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001
   Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757
   Zheng YQ, 2007, BRAIN RES, V1138, P86, DOI 10.1016/j.brainres.2006.12.064
NR 36
TC 45
Z9 49
U1 3
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 28
PY 2012
VL 12
AR 69
DI 10.1186/1472-6882-12-69
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 031MV
UT WOS:000310646700001
PM 22640402
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Terzuoli, E
   Nannelli, G
   Frosini, M
   Giachetti, A
   Ziche, M
   Donnini, S
AF Terzuoli, Erika
   Nannelli, Ginevra
   Frosini, Maria
   Giachetti, Antonio
   Ziche, Marina
   Donnini, Sandra
TI Inhibition of cell cycle progression by the hydroxytyrosol-cetuximab
   combination yields enhanced chemotherapeutic efficacy in colon cancer
   cells
SO ONCOTARGET
LA English
DT Article
DE hydroxytyrosol; cetuximab; colon cancer; cell cycle; AIF-dependent
   apoptosis
ID VIRGIN OLIVE OIL; MILL. BARK EXTRACT; HL60 CELLS; GROWTH; APOPTOSIS;
   KINASE; STRESS; DIHYDROXYPHENYLETHANOL; DIFFERENTIATION; PROLIFERATION
AB Hydroxytyrosol (HT), a polyphenol of olive oil, downregulates epidermal growth factor (EGFR) expression and inhibits cell proliferation in colon cancer (CC) cells, with mechanisms similar to that activated by the EGFR inhibitor, cetuximab. Here, we studied whether HT treatment would enhance the cetuximab inhibitory effects on cell growth in CC cells.
   HT-cetuximab combination showed greater efficacy in reducing cell growth in HT-29 and WiDr cells at concentrations 10 times lower than when used as single agents. This reduction was clearly linked to cell cycle blockade, occurring at G(2)/M phase. The cell cycle arrest in response to combination treatment is related to cyclins B, D1, and E, and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 down-regulation, and to the concomitant over-expression of CDK inhibitors p21 and p27. HT and cetuximab stimulated a caspase-independent cell death cascade, promotedtranslocation of apoptosis-inducing factor (AIF) from mitochondria to nucleus and activated the autophagy process.
   Notably, normal colon cells and keratinocytes were less susceptible to combo induced cell death and EGFR downregulation.
   These results suggest a potential role of diet, containing olive oil, during cetuximab chemotherapy of colon tumor. HT may be a competent therapeutic agent in CC enhancing the effects of EGFR inhibitors.
C1 [Terzuoli, Erika; Nannelli, Ginevra; Frosini, Maria; Giachetti, Antonio; Ziche, Marina; Donnini, Sandra] Univ Siena, Dept Life Sci, I-53100 Siena, Italy.
RP Ziche, M; Donnini, S (corresponding author), Univ Siena, Dept Life Sci, I-53100 Siena, Italy.
EM marina.ziche@unisi.it; sandra.donnini@unisi.it
RI Donnini, Sandra/K-9252-2019; Terzuoli, Erika/M-7346-2016
OI Donnini, Sandra/0000-0001-6617-1644; Ziche, Marina/0000-0002-9564-214X;
   FROSINI, MARIA/0000-0002-4452-8128; Terzuoli, Erika/0000-0001-9248-4505
FU Associazione Italiana sul Cancro (AIRC)Fondazione AIRC per la ricerca
   sul cancro [IG10731]; Consorzio per la tutela dell'Olio Extravergine di
   Oliva Toscano IGP; Regione Toscana, bando Nutraceutica, OlivaPlus
   Project; AIRCFondazione AIRC per la ricerca sul cancro
FX This work was supported by Associazione Italiana sul Cancro (AIRC) under
   Grant IG10731 MZ (Marina Ziche); Consorzio per la tutela dell'Olio
   Extravergine di Oliva Toscano IGP, and Regione Toscana, bando
   Nutraceutica 2014, OlivaPlus Project (Sandra Donnini). ET and GN are
   supported by AIRC.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Brizi C, 2016, J CELL BIOCHEM, V117, P510, DOI 10.1002/jcb.25302
   Catalan U, 2015, MOL NUTR FOOD RES, V59, P2523, DOI 10.1002/mnfr.201500361
   Coccia A, 2016, ONCOL REP, V36, P3095, DOI 10.3892/or.2016.5150
   Corona G, 2009, MOL NUTR FOOD RES, V53, P897, DOI 10.1002/mnfr.200800269
   Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com
   Fabiani R, 2006, J NUTR, V136, P614, DOI 10.1093/jn/136.3.614
   Fabiani R, 2008, J NUTR, V138, P42, DOI 10.1093/jn/138.1.42
   Fabiani R, 2009, MOL NUTR FOOD RES, V53, P887, DOI 10.1002/mnfr.200800376
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   GRANA X, 1995, ONCOGENE, V11, P211
   Guichard C, 2006, CARCINOGENESIS, V27, P1812, DOI 10.1093/carcin/bgl009
   Hillestrom PR, 2006, FREE RADICAL BIO MED, V41, P1133, DOI 10.1016/j.freeradbiomed.2006.06.013
   Holcmann M, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2015.1004969
   Huang YF, 2017, ONCOTARGET, V8, P40264, DOI 10.18632/oncotarget.16828
   Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032
   KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Kim E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.269
   Krall AS, 2017, NATURE, V546, P357, DOI 10.1038/nature22504
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Manna C, 1999, J NUTR BIOCHEM, V10, P159, DOI 10.1016/S0955-2863(98)00085-0
   Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x
   Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018
   Omar Syed Haris, 2010, Saudi Pharm J, V18, P111, DOI 10.1016/j.jsps.2010.05.005
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Perez-Jimenez F, 2005, EUR J CLIN INVEST, V35, P421, DOI 10.1111/j.1365-2362.2005.01516.x
   Perez-Torres M, 2006, J BIOL CHEM, V281, P40183, DOI 10.1074/jbc.M607958200
   Psaltopoulou T, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-127
   Santulli C, 2017, J CELL BIOCHEM, V118, P839, DOI 10.1002/jcb.25760
   Terzuoli E, 2016, MOL NUTR FOOD RES, V60, P519, DOI 10.1002/mnfr.201500498
   Terzuoli E, 2010, CLIN CANCER RES, V16, P4207, DOI 10.1158/1078-0432.CCR-10-0156
NR 32
TC 21
Z9 21
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 10
PY 2017
VL 8
IS 47
BP 83207
EP 83224
DI 10.18632/oncotarget.20544
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FJ4DA
UT WOS:000412683900127
PM 29137335
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Noureldein, MH
   Eid, AA
AF Noureldein, Mohamed H.
   Eid, Assaad A.
TI Gut microbiota and mTOR signaling: Insight on a new pathophysiological
   interaction
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE Gut microbiota; mTOR; Butyrate; Obesity; Diabetes; Colon cancer
ID CONJUGATED LINOLEIC-ACID; CHAIN FATTY-ACIDS; REGULATORY T-CELLS; EXTENDS
   LIFE-SPAN; HEPATIC LIPOGENESIS; COMMENSAL BACTERIA; LIPID-METABOLISM;
   GENE-EXPRESSION; COLON-CANCER; AUTOPHAGY
AB The gut microbiota plays a substantial role in regulating the host metabolic and immune functions. Dysbiosis, resulting from disruption of gut microbiota, predisposes many morbid pathologies like obesity and its associated comorbidities, diabetes and inflammatory conditions including some types of cancer. There are numerous proposed signaling pathways through which alterations in gut microbiota and its metabolites can disturb the host's normal physiological functions. Interestingly, many of these processes happen to be controlled by the mammalian target of rapamycin (mTOR). The mTOR pathway responds to environmental changes and regulates accordingly many intracellular processes such as transcription, translation, cell growth, cytoskeletal organization and autophagy. In this review, we aim to highlight the cross-talk between the gut microbiota and the mTOR pathway and discuss how this emerging field of research gives a beautiful insight into how the mentioned crosstalk impacts the body's homeostasis thus leading to undesirable complications including obesity, diabetes, colon and pancreatic cancer, immune system malfunctioning and ageing. Although there are a limited number of studies investigating the crosstalk between the gut microbiota and the mTOR pathway, the results obtained so far are enough to elucidate the key role of the mTOR signaling in microbiota-associated metabolic and immune regulations.
C1 Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon.
   Amer Univ Beirut, Med Ctr, Beirut, Lebanon.
RP Eid, AA (corresponding author), Amer Univ Beirut, Fac Med, POB 11-0236, Beirut 1107 2020, Lebanon.; Eid, AA (corresponding author), Amer Univ Beirut, Med Ctr, Dept Anat Cell Biol & Physiol Sci, POB 11-0236, Beirut 1107 2020, Lebanon.
EM ae94@aub.edu.lb
CR Alexander KL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181866
   An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803
   Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726
   Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469
   Azain MJ, 2000, J NUTR, V130, P1548
   Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104
   Barbara G, 2005, AM J GASTROENTEROL, V100, P2560, DOI 10.1111/j.1572-0241.2005.00230.x
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Bissonauth V, 2006, J NUTR BIOCHEM, V17, P597, DOI 10.1016/j.jnutbio.2005.10.010
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200
   Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7
   Canani RB, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-4
   Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]
   Canfora EE, 2015, NAT REV ENDOCRINOL, V11, P577, DOI 10.1038/nrendo.2015.128
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198
   Chin RM, 2014, NATURE, V510, P397, DOI 10.1038/nature13264
   Choi YJ, 2000, J NUTR, V130, P1920, DOI 10.1093/jn/130.8.1920
   Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200
   Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200
   Cook SI, 1998, ALIMENT PHARM THER, V12, P499, DOI 10.1046/j.1365-2036.1998.00337.x
   Corl BA, 2003, J NUTR, V133, P2893, DOI 10.1093/jn/133.9.2893
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cummings J.H., 1983, SCAND J GASTROENTE S, V93, P89
   Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175
   Druart C, 2013, BRIT J NUTR, V110, P998, DOI 10.1017/S0007114513000123
   Du M, 2003, LIPIDS, V38, P505, DOI 10.1007/s11745-003-1091-z
   Eid S, 2016, ANTIOXID REDOX SIGN, V25, P703, DOI 10.1089/ars.2015.6562
   Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268
   Feng YJ, 2012, ANN NY ACAD SCI, V1258, P71, DOI 10.1111/j.1749-6632.2012.06572.x
   Ferramosca A, 2006, J LIPID RES, V47, P1994, DOI 10.1194/jlr.M600138-JLR200
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Glover-Cutter KM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003701
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   Gwang-woong G, 2013, J MICROBIOL BIOTECHN, V23, P1569, DOI 10.4014/jmb.1308.08008
   Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015
   HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322
   Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Hovhannisyan G, 2009, TOXICOL IN VITRO, V23, P1028, DOI 10.1016/j.tiv.2009.06.011
   Huang J., 2009, COMPLEX INTERPLAY AK
   Hurez V, 2015, AGING CELL, V14, P945, DOI 10.1111/acel.12380
   Ide T, 2005, DIABETES, V54, P412, DOI 10.2337/diabetes.54.2.412
   Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jung MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep30887
   Kang KH, 2003, BIOCHEM BIOPH RES CO, V303, P795, DOI 10.1016/S0006-291X(03)00413-3
   Kelley DS, 2002, LIPIDS, V37, P725, DOI 10.1007/s11745-002-0954-7
   KEPLER CR, 1966, J BIOL CHEM, V241, P1350
   Kim EJ, 2002, AM J PHYSIOL-GASTR L, V283, pG357, DOI 10.1152/ajpgi.00495.2001
   Kim MK, 2012, J FOOD DRUG ANAL, V20, P241
   Kimura I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2852
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2012, J LIPIDS, V2012, DOI 10.1155/2012/571281
   Lisse TS, 2011, FASEB J, V25, P937, DOI 10.1096/fj.10-172577
   Martin S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002894
   Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008
   Mercken EM, 2014, AGING CELL, V13, P787, DOI 10.1111/acel.12220
   Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613
   Miller A, 2003, LIPIDS, V38, P623, DOI 10.1007/s11745-003-1107-8
   Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031
   Mizunuma M, 2014, AGING CELL, V13, P869, DOI 10.1111/acel.12248
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Panebianco C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040331
   Pant K, 2017, CHEM-BIOL INTERACT, V273, P99, DOI 10.1016/j.cbi.2017.06.001
   PARIZA MW, 1991, ADV EXP MED BIOL, V289, P269
   PARIZA MW, 1990, BASIC LIFE SCI, V52, P167
   Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44
   Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017
   Pezze PD, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002469
   Quigley EMM, 2011, J NEUROGASTROENTEROL, V17, P140, DOI 10.5056/jnm.2011.17.2.140
   Rathmell JC, 2012, IMMUNOL REV, V249, P5, DOI 10.1111/j.1600-065X.2012.01158.x
   Robida-Stubbs S, 2012, CELL METAB, V15, P713, DOI 10.1016/j.cmet.2012.04.007
   Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545
   Ryu JH, 2008, SCIENCE, V319, P777, DOI 10.1126/science.1149357
   Scharlau D, 2009, MUTAT RES-REV MUTAT, V682, P39, DOI 10.1016/j.mrrev.2009.04.001
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278
   Shiels PG, 2017, NAT REV NEPHROL, V13, P471, DOI 10.1038/nrneph.2017.78
   Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Smith SB, 2006, ANIM SCI J, V77, P478, DOI 10.1111/j.1740-0929.2006.00375.x
   Sommer F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085254
   Sonnenberg GF, 2012, IMMUNITY, V37, P601, DOI 10.1016/j.immuni.2012.10.003
   Su ND, 2003, LIPIDS, V38, P615, DOI 10.1007/s11745-003-1106-9
   Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3
   Szymczyk B, 2000, J SCI FOOD AGR, V80, P1553, DOI [10.1002/1097-0010(200008)80:10<1553::AID-JSFA650>3.0.CO;2-Z, 10.1002/1097-0010(200008)80:10&lt;1553::AID-JSFA650&gt;3.0.CO;2-Z]
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tang Y, 2011, AUTOPHAGY, V7, P235, DOI 10.4161/auto.7.2.14277
   Tanti J.-F., 2012, FRONT ENDOCRINOL, V3
   Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650
   Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Vyas D., 2011, J NUTR METAB, V2012
   Wang SJ, 2013, BRAIN RES, V1492, P122, DOI 10.1016/j.brainres.2012.11.027
   Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002
   Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158
   Yuan MS, 2012, J BIOL CHEM, V287, P29579, DOI 10.1074/jbc.M112.386854
   Zeng H, 2015, TRENDS IMMUNOL, V36, P3, DOI 10.1016/j.it.2014.08.003
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhou Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.588
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 113
TC 35
Z9 42
U1 4
U2 24
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD MAY
PY 2018
VL 118
BP 98
EP 104
DI 10.1016/j.micpath.2018.03.021
PG 7
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology
GA GK9AE
UT WOS:000436528000013
PM 29548696
DA 2022-04-25
ER

PT J
AU Marmol, I
   Jimenez-Moreno, N
   Ancin-Azpilicueta, C
   Osada, J
   Cerrada, E
   Rodriguez-Yoldi, MJ
AF Marmol, Ines
   Jimenez-Moreno, Nerea
   Ancin-Azpilicueta, Carmen
   Osada, Jesus
   Cerrada, Elena
   Jesus Rodriguez-Yoldi, Maria
TI A Combination of Rosa Canina Extracts and Gold Complex Favors Apoptosis
   of Caco-2 Cells by Increasing Oxidative Stress and Mitochondrial
   Dysfunction
SO ANTIOXIDANTS
LA English
DT Article
DE apoptosis; autophagy; colorectal cancer; rosehip; gold complex; ROS
ID CISPLATIN RESISTANCE; POLYPHENOLS; CANCER; NECROPTOSIS; AUTOPHAGY; LINE
AB Given the alarming increase in colorectal cancer (CRC) worldwide, novel therapies are urgently needed. Plant-derived extracts have gained considerable interest in the last years due to their strong anticancer effect mediated by their unique bioactive compounds. Specifically, rosehips from Rosa canina have been successfully tested against several cancer models, including colon cancer. Moreover, gold derivatives are a promising alternative to the current platinum-based drugs commonly used in CRC chemotherapy due to their lack of affinity for DNA. Herein we have investigated the antitumor potential of a drug combination made of acidic polyphenols extracted from R. canina and the gold complex (Au(C equivalent to C-2-NC5H4) (PTA)) in Caco-2 cell line as a model of CRC. The combination triggered strong apoptosis mediated by a blockage of the autophagic flux, which might be a consequence of a reactive oxygen species (ROS) increase and mitochondrial dysfunctionality. Our results suggest that the clinical application of plant polyphenols might enhance the anticancer effect of metallodrugs and reduce drug exposure time and therefore its side effects.
C1 [Marmol, Ines; Jesus Rodriguez-Yoldi, Maria] Univ Zaragoza, Dept Pharmacol & Physiol, Vet Fac, E-50009 Zaragoza, Spain.
   [Jimenez-Moreno, Nerea; Ancin-Azpilicueta, Carmen] Univ Publ Navarra, Dept Sci, INAMAT, Pamplona 31006, Spain.
   [Osada, Jesus] Univ Zaragoza, Dept Biochem & Mol Biol, Vet Fac, E-50009 Zaragoza, Spain.
   [Osada, Jesus; Jesus Rodriguez-Yoldi, Maria] Ctr Invest Biomed Red Obesidad & Nutr CIBERobn, IIS Aragon, IA2, ISCIII, Zaragoza 50009, IA, Spain.
   [Cerrada, Elena] Univ Zaragoza, Sci Fac, Dept Inorgan Chem, E-50009 Zaragoza, Spain.
RP Rodriguez-Yoldi, MJ (corresponding author), Univ Zaragoza, Dept Pharmacol & Physiol, Vet Fac, E-50009 Zaragoza, Spain.; Rodriguez-Yoldi, MJ (corresponding author), Ctr Invest Biomed Red Obesidad & Nutr CIBERobn, IIS Aragon, IA2, ISCIII, Zaragoza 50009, IA, Spain.; Cerrada, E (corresponding author), Univ Zaragoza, Sci Fac, Dept Inorgan Chem, E-50009 Zaragoza, Spain.
EM ines.marmol9@gmail.com; nerea.jimenez@unavarra.es; ancin@unavarra.es;
   josada@unizar.es; ecerrada@unizar.es; mjrodyol@unizar.es
RI ; CERRADA, ELENA/K-6790-2014
OI Rodriguez Yoldi, Maria Jesus/0000-0002-3595-7668; Jimenez-Moreno,
   Nerea/0000-0002-8065-5220; Marmol, Ines/0000-0002-3136-2480; CERRADA,
   ELENA/0000-0003-2457-3674
FU Ministerio de Economia y Competitividad, Gobierno de Espana
   [SAF2016-75441-R, CTQ2016-75816-C2-1-P]; CIBERobn [CB06/03/1012];
   Gobierno de Aragon (Fondos FEDER "otra manera de hacer Europa")
   [B16-17R, E07-17R]; SUDOE (Redvalue) [SOE1/PI/E0123]; Proyecto ELENA
   [EFA 220/11 ELENA]
FX This work was supported by grants from Ministerio de Economia y
   Competitividad, Gobierno de Espana (SAF2016-75441-R and
   CTQ2016-75816-C2-1-P), CIBERobn (CB06/03/1012), Gobierno de Aragon
   (B16-17R and E07-17R, Fondos FEDER "otra manera de hacer Europa"), SUDOE
   (Redvalue, SOE1/PI/E0123) and Proyecto ELENA (EFA 220/11 ELENA).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Brahmi D, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-111
   Chen DS, 2016, BBA-REV CANCER, V1865, P228, DOI 10.1016/j.bbcan.2016.03.003
   Ci YQ, 2016, MOLECULES, V21, DOI 10.3390/molecules21121634
   Czyzowska A, 2015, J FOOD COMPOS ANAL, V39, P62, DOI 10.1016/j.jfca.2014.11.009
   Demers-Lamarche J, 2016, J BIOL CHEM, V291, P10263, DOI 10.1074/jbc.M115.695825
   Di Nunzio M, 2018, FOOD RES INT, V113, P392, DOI 10.1016/j.foodres.2018.07.025
   Divya MK, 2016, PHARM BIOL, V54, P2149, DOI 10.3109/13880209.2016.1149494
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Hamza AA, 2016, ANDROLOGIA, V48, P211, DOI 10.1111/and.12435
   He RZ, 2018, TOXICOL APPL PHARM, V356, P159, DOI 10.1016/j.taap.2018.08.003
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Ivanova D, 2019, ANTICANCER RES, V39, P3745, DOI 10.21873/anticanres.13523
   Jimenez S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159136
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7
   Marmol I., 2018, ADV HLTH DIS, V1, P67
   Marmol I, 2019, CANCERS, V11, DOI 10.3390/cancers11060780
   Marmol I, 2017, J INORG BIOCHEM, V176, P123, DOI 10.1016/j.jinorgbio.2017.08.020
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061137
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Matsuzawa-Ishimoto Y, 2017, J EXP MED, V214, P3687, DOI 10.1084/jem.20170558
   Mohan A, 2013, ANTI-CANCER AGENT ME, V13, P281, DOI 10.2174/1871520611313020015
   Nardon C, 2014, ANTICANCER RES, V34, P487
   Natoli M, 2012, TOXICOL IN VITRO, V26, P1243, DOI 10.1016/j.tiv.2012.03.009
   Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6
   Sanchez-de-Diego C, 2017, J INORG BIOCHEM, V166, P108, DOI 10.1016/j.jinorgbio.2016.11.009
   Shen HM, 2012, EXP CELL RES, V318, P1304, DOI 10.1016/j.yexcr.2012.02.006
   Stamelos VA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150696
   Tang XL, 2017, J PHARMACOL SCI, V135, P1, DOI 10.1016/j.jphs.2017.06.006
   Vergara E, 2010, ORGANOMETALLICS, V29, P2596, DOI 10.1021/om100300a
   Yarijani ZM, 2018, BIOMED PHARMACOTHER, V106, P1767, DOI 10.1016/j.biopha.2018.07.115
   Zeller P, 2015, EUR J PHARM SCI, V72, P1, DOI 10.1016/j.ejps.2015.02.013
   Zhang PY, 2015, CELL BIOCHEM BIOPHYS, V73, P649, DOI 10.1007/s12013-015-0558-z
   Zhang YW, 2015, BIOMED PHARMACOTHER, V69, P285, DOI 10.1016/j.biopha.2014.12.016
   Zhao Liang, 2010, Front Biosci (Elite Ed), V2, P241, DOI 10.2741/e86
NR 35
TC 6
Z9 6
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JAN
PY 2020
VL 9
IS 1
AR 17
DI 10.3390/antiox9010017
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA KJ6EF
UT WOS:000512151700083
PM 31878141
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Cheng, Y
   Zhang, HQ
   Qu, LJ
   He, Y
   Routledge, MN
   Gong, YY
   Qiao, BL
AF Cheng, Ying
   Zhang, Huiqin
   Qu, Lejing
   He, Ying
   Routledge, Michael N.
   Gong, Yun Yun
   Qiao, Boling
TI Identification of rhein as the metabolite responsible for toxicity of
   rhubarb anthraquinones
SO FOOD CHEMISTRY
LA English
DT Article
DE Rhubarb anthraquinones; Colonic toxicities; Melanosis coli; Rhein
   accumulation; Apoptosis; Autophagy
ID MELANOSIS-COLI; LAXATIVE USE; EXTRACT
AB Rhubarb is a popular food in Europe with laxative properties attributed to anthraquinones. Long term usage of rhubarb anthraquinones has been linked to colonic toxicity, including the formation of melanosis coli, which is associated with increased risk of colon cancer. The major purgative anthraquinone in rhubarb is thought to be sennoside A, which is metabolised by colonic microflora. Here, we sought to identify the toxic metabolite responsible for melanosis coli in rats dosed with rhubarb anthraquinones for up to 90 days. Three metabolites were detected in rat faeces using HPLC. Of these, rhein was identified as the metabolite that accumulated most over time. Fecal flora from treated rats were capable of greater biotransformation of sennoside A to rhein compared to that from control rats. Cell culture experiments suggested that apoptosis and autophagy induced by rhein is the likely mechanism of chronic toxicity of rhubarb anthraquinones.
C1 [Cheng, Ying; Zhang, Huiqin; Qu, Lejing; He, Ying; Qiao, Boling] Northwest Univ, Minist Educ, Key Lab Resource Biol & Modern Biotechnol Western, Xian 710069, Peoples R China.
   [Cheng, Ying; Zhang, Huiqin; Qu, Lejing; He, Ying; Qiao, Boling] Northwest Univ, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China.
   [Routledge, Michael N.] Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England.
   [Routledge, Michael N.] Jiangsu Univ, Sch Food & Biol Engn, Zhenjiang, Jiangsu, Peoples R China.
   [Gong, Yun Yun] Univ Leeds, Sch Food Sci & Nutr, Leeds LS2 9JT, W Yorkshire, England.
RP Qiao, BL (corresponding author), Northwest Univ, Minist Educ, Key Lab Resource Biol & Modern Biotechnol Western, Xian 710069, Peoples R China.; Routledge, MN (corresponding author), Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England.
EM M.N.Routledge@leeds.ac.uk; y.gong@leeds.ac.uk; bolingq@nwu.edu.cn
RI Gong, Yun Yun/L-7094-2016; Routledge, Michael/N-7413-2017
OI Gong, Yun Yun/0000-0003-4927-5526; Routledge,
   Michael/0000-0001-9139-2182
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973452]; Scientific Research Foundation of
   Shaanxi Provincial Key Laboratory [2018SZS-41]
FX This work was supported by National Natural Science Foundation of China
   (81973452) and Scientific Research Foundation of Shaanxi Provincial Key
   Laboratory (2018SZS-41).
CR Biernacka-Wawrzonek D, 2017, GASTROENTEROL REV, V12, P22, DOI 10.5114/pg.2016.64844
   Camilleri M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.95
   Cao YX, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103210
   Chen JY, 2011, CHIN J INTEGR MED, V17, P525, DOI 10.1007/s11655-011-0786-z
   Cirillo C, 2015, PHYTOTHER RES, V29, P1488, DOI 10.1002/ptr.5410
   Coyne JD, 2013, INT J SURG PATHOL, V21, P261, DOI 10.1177/1066896912468212
   DEWITTE P, 1988, J PHARM PHARMACOL, V40, P652
   Esposito F, 2016, PHYTOMEDICINE, V23, P1383, DOI 10.1016/j.phymed.2016.08.001
   Jimenez OE, 2017, GASTROENT HEPAT-BARC, V40, P93, DOI 10.1016/j.gastrohep.2016.01.004
   Huang ZH, 2019, J CHROMATOGR B, V1104, P59, DOI 10.1016/j.jchromb.2018.10.008
   Kunkel J, 2009, INT J COLORECTAL DIS, V24, P595, DOI 10.1007/s00384-008-0625-7
   Li PJ, 2017, BIOMED PHARMACOTHER, V91, P425, DOI 10.1016/j.biopha.2017.04.109
   Li XA, 2015, MOL MED REP, V12, P5807, DOI 10.3892/mmr.2015.4126
   Liu ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186668
   Malik EM, 2016, MED RES REV, V36, P705, DOI 10.1002/med.21391
   Mandawgade SD, 2016, CURR DRUG DELIV, V13, P83, DOI 10.2174/1567201812666150713104031
   Matsumoto M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031700
   Nesheiwa T. Z., 2020, MELANOSIS COLI
   NUSKO G, 1993, PHARMACOLOGY, V47, P234, DOI 10.1159/000139863
   Sanchez MI, 2011, CAN J SURG SB, V25, P11, DOI DOI 10.1155/2011/974573
   Song R, 2011, BIOMED CHROMATOGR, V25, P417, DOI 10.1002/bmc.1467
   Sun H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00247
   Sun SW, 2005, J PHARMACEUT BIOMED, V36, P995, DOI 10.1016/j.jpba.2004.08.039
   Wang SF, 2018, PEERJ, V6, DOI 10.7717/peerj.4483
   Willems M, 2003, NETH J MED, V61, P22
   Yokoyama S, 2017, ANN DERMATOL, V29, P414, DOI 10.5021/ad.2017.29.4.414
   Zhou YX, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/578107
NR 27
TC 7
Z9 8
U1 13
U2 58
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD NOV 30
PY 2020
VL 331
AR 127363
DI 10.1016/j.foodchem.2020.127363
PG 10
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA NA4RW
UT WOS:000559806600008
PM 32590269
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Kapral, M
   Wawszczyk, J
   Weglarz, L
AF Kapral, Malgorzata
   Wawszczyk, Joanna
   Weglarz, Ludmila
TI Regulation of MicroRNA-155 and Its Related Genes Expression by Inositol
   Hexaphosphate in Colon Cancer Cells
SO MOLECULES
LA English
DT Article
DE IP6; miRNAs; miR-155; FOXO3a; HIF-1 alpha; ELK3; colon cancer
ID APOPTOTIC DEATH; INHIBITS GROWTH; G1 ARREST; MIR-155; IP6;
   PROLIFERATION; INVASION; PHYTOCHEMICALS; INFLAMMATION; MODULATION
AB Inositol hexaphosphate (IP6), a natural dietary component, has been found as an antitumor agent by stimulating apoptosis and inhibiting cancer cell proliferation, their migration, and metastasis in diverse cancers including colon cancer. However, molecular mechanisms of its action have not been well understood. In recent years, microRNAs (miRNAs) have been reported to play important roles in a broad range of biologic processes, such as cell growth, proliferation, apoptosis, or autophagy. These small noncoding molecules regulate post-transcriptional expression of targets genes via degradation of transcript or inhibition of protein synthesis. Aberrant expression and/or dysregulation of miRNAs have been characterized during tumor development and progression, thus, they are potential molecular targets for cancer prevention. The aim of this study was to investigate the effect of IP6 on the miRNAs expression profile in Caco-2 colon cancer cells. 84 miRNAs were analyzed in Caco-2 cells treated with 2.5 mM and 5 mM IP6 by the use of PCR (Polymerase Chain Reaction) array. The effect of 5 mM IP6 on selected potential miR-155 targets was determined by real-time (RT)-qPCR and ELISA (quantitative Polymerase Chain Reaction and Enzyme-Linked Immunosorbent Assay )method. The results indicated alteration in the specific 10 miRNA expression in human colon cancer cells following their treatment with 5 mM IP6. It down-regulated 8 miRNAs (miR-155, miR-210, miR-144, miR-194, miR-26b, miR-126, miR-302c, and miR-29a) and up-regulated 2 miRNAs (miR-223 and miR-196b). In silico analysis revealed that FOXO3a, HIF-1 alpha, and ELK3 mRNAs are those of predicted targets of miR-155. IP6 at the concentration of 5 mM markedly induced FOXO3a and HIF-1a genes' expression at both mRNA and protein level and decreased the amount of ELK3 mRNA as well as protein concentration in comparison to the control. In conclusion, the present study indicates that one of the mechanisms of antitumor potential of IP6 is down-regulation of the miR-155 expression in human colon cancer cells. Moreover, the expression of genes that are targeted by miRNA are also modulated by IP6.
C1 [Kapral, Malgorzata; Wawszczyk, Joanna; Weglarz, Ludmila] Med Univ Silesia, Fac Pharmaceut Sci Sosnowiec, Dept Biochem, Jednosci 8, PL-41200 Sosnowiec, Poland.
RP Kapral, M (corresponding author), Med Univ Silesia, Fac Pharmaceut Sci Sosnowiec, Dept Biochem, Jednosci 8, PL-41200 Sosnowiec, Poland.
EM mkapral@sum.edu.pl; jwawszczyk@sum.edu.pl; lweglarz@sum.edu.pl
OI Kapral, Malgorzata/0000-0001-5189-1171; Wawszczyk,
   Joanna/0000-0001-8739-3342
FU Medical University of Silesia (Katowice, Poland) [KNW-1-090/K/8/I,
   KNW-1-018/K/7/I]
FX This research was funded by grants No. KNW-1-090/K/8/I, KNW-1-018/K/7/I
   from the Medical University of Silesia (Katowice, Poland).
CR Agarwal C, 2004, NEOPLASIA, V6, P646, DOI 10.1593/neo.04232
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bizzarri M, 2016, INT J ENDOCRINOL, V2016, DOI 10.1155/2016/5616807
   Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028
   Cao HL, 2018, J CANCER RES THER, V14, P604, DOI 10.4103/0973-1482.175432
   Chen ZL, 2014, J CELL PHYSIOL, V229, P545, DOI 10.1002/jcp.24492
   Chun KS, 2013, GUT LIVER, V7, P137, DOI 10.5009/gnl.2013.7.2.137
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Correa TAF, 2019, NUTRITION, V59, P150, DOI 10.1016/j.nut.2018.08.010
   Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914
   Dou HQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00877
   Ferry S, 2002, CARCINOGENESIS, V23, P2031, DOI 10.1093/carcin/23.12.2031
   Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006
   Fu M, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050286
   Gao YW, 2018, ONCOL LETT, V15, P4781, DOI 10.3892/ol.2018.7976
   Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104
   Grases F, 1999, ANTICANCER RES, V19, P3717
   Gu M, 2009, CANCER RES, V69, P9465, DOI 10.1158/0008-5472.CAN-09-2805
   He B, 2015, MOL MED REP, V11, P2355, DOI 10.3892/mmr.2014.2994
   Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017
   Jariwalla RJ, 1999, ANTICANCER RES, V19, P3699
   Kandzari Stanley J, 2013, Curr Urol, V6, P199, DOI 10.1159/000343539
   Kapral M, 2017, MOLECULES, V22, DOI 10.3390/molecules22101657
   Kapral M, 2014, ACTA POL PHARM, V71, P987
   Kong SY, 2016, ONCOTARGET, V7, P65137, DOI 10.18632/oncotarget.11427
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Kumazaki M, 2013, J NUTR BIOCHEM, V24, P1849, DOI 10.1016/j.jnutbio.2013.04.006
   Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1
   Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y
   Li YH, 2015, WORLD J GASTROENTERO, V21, P9262, DOI 10.3748/wjg.v21.i31.9262
   Liu GY, 2015, INT J CLIN EXP PATHO, V8, P1402
   Liu J, 2015, BIOTECHNOL BIOTEC EQ, V29, P840, DOI 10.1080/13102818.2015.1043946
   Liu N, 2018, EUR REV MED PHARMACO, V22, P101, DOI 10.26355/eurrev_201801_14106
   Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3
   Matejuk A, 2010, CURR CANCER THER REV, V6, P1, DOI 10.2174/157339410790596443
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Owen RW, 1996, GUT, V38, P591, DOI 10.1136/gut.38.4.591
   Phuah NH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/804510
   Raimondi L, 2020, CURR MED CHEM, V27, P187, DOI 10.2174/0929867325666180629153141
   Ranjan A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204981
   Riffo-Campos AL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121987
   Robertson ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113050
   Roy S, 2009, CANCER RES, V69, P1166, DOI 10.1158/0008-5472.CAN-08-3115
   Russo M, 2010, TOXINS, V2, P517, DOI 10.3390/toxins2040517
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Singh RP, 2003, CARCINOGENESIS, V24, P555, DOI 10.1093/carcin/24.3.555
   Svrcek M, 2013, CARCINOGENESIS, V34, P828, DOI 10.1093/carcin/bgs408
   Tantivejkul K, 2003, ANTICANCER RES, V23, P3671
   Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Vucenik I, 2005, BREAST CANCER RES TR, V91, P35, DOI 10.1007/s10549-004-6456-5
   Vucenik I, 2003, J NUTR, V133, p3778S, DOI 10.1093/jn/133.11.3778S
   Vucenik I, 2006, NUTR CANCER, V55, P109, DOI 10.1207/s15327914nc5502_1
   Weglarz L, 2006, ACTA BIOCHIM POL, V53, P349
   Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34
   Yang LK, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7149296
   Zhu XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124266
NR 60
TC 7
Z9 7
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2019
VL 24
IS 22
AR 4153
DI 10.3390/molecules24224153
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JU2TU
UT WOS:000501529700142
PM 31744065
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Dent, P
   Booth, L
   Roberts, JL
   Poklepovic, A
   Hancock, JF
AF Dent, Paul
   Booth, Laurence
   Roberts, Jane L.
   Poklepovic, Andrew
   Hancock, John F.
TI (Curcumin plus sildenafil) enhances the efficacy of 5FU and anti-PD1
   therapies in vivo
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE 5FU; autophagy; chaperone; colon cancer; HDAC; immunotherapy
ID K-RAS; INHIBITORS; PLASMA
AB We have extended our analyses of (curcumin+sildenafil) biology. The drug combination caused vascularization and degradation of mutant K-RAS that correlated with reduced phosphorylation of ERK1/2, AKT T308, mTORC1, mTORC2, ULK1 S757, STAT3, STAT5, and NF kappa B and increased phosphorylation of eIF2 alpha, ATM, AMPK alpha, ULK1 S317; all concomitant with elevated ATG13 S318 phosphorylation and autophagosome formation. Prior studies with drug combinations utilizing sildenafil have delineated an ATM-AMPK-ULK1 S317 pathway and an AKT-mTOR-ULK1 S757 pathway as modules which control ATG S318 phosphorylation and autophagosome formation. The knockdown of PKG reduced cell killing as well as reducing drug-enhanced phosphorylation of ATM, AMPK alpha, and ATG13. In the absence of PKG, no significant increase in ULK1 S317 phosphorylation was observed. In a Beclin1-dependent fashion, the drug combination reduced the expression of multiple histone deacetylase (HDAC) proteins, including HDAC2 and HDAC3. Molecular knockdown of HDAC2, HDAC3, and especially (HDAC2+HDAC3) significantly reduced the expression of PD-L1 and elevated expression of Class I human major histocompatibility complex. In vivo, (curcumin+sildenafil) enhanced the efficacy of 5-flurouracil against CT26 colorectal tumors. Prior exposure of established CT26 tumors to (curcumin+sildenafil) significantly enhanced the efficacy of a subsequently administered anti-PD-1 antibody. Collectively our data argue that (curcumin+sildenafil) has the potential in several settings to be an efficacious neoadjuvant therapy for colon cancer.
C1 [Dent, Paul; Booth, Laurence; Roberts, Jane L.; Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA USA.
   [Dent, Paul; Booth, Laurence; Roberts, Jane L.] Virginia Commonwealth Univ, Dept Mol Biol, Richmond, VA USA.
   [Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Hancock, John F.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.
RP Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23298 USA.
EM paul.dent@vcuhealth.org
FU Commonwealth Health Research Board [236-04-18]; Massey Cancer Center;
   Universal Inc.; Chair in Signal Transduction Research
FX Commonwealth Health Research Board, Grant/Award Number: 236-04-18;
   Massey Cancer Center; Universal Inc. Chair in Signal Transduction
   Research
CR Asher GN, 2017, J CLIN PHARMACOL, V57, P185, DOI 10.1002/jcph.806
   Booth L, 2019, CANCER BIOL THER, V20, P700, DOI 10.1080/15384047.2018.1551747
   Booth L, 2019, CANCER BIOL THER, V20, P109, DOI 10.1080/15384047.2018.1507258
   Booth L, 2019, J CELL PHYSIOL, V234, P4874, DOI 10.1002/jcp.27276
   Booth L, 2018, ADV CANCER RES, V137, P1, DOI 10.1016/bs.acr.2017.11.004
   Booth Laurence, 2018, Oncotarget, V9, P6062, DOI 10.18632/oncotarget.23681
   Booth L, 2018, CANCER BIOL THER, V19, P797, DOI 10.1080/15384047.2018.1472190
   Booth L, 2018, CANCER BIOL THER, V19, P132, DOI 10.1080/15384047.2017.1394556
   Booth L, 2017, ONCOTARGET, V8, P90262, DOI 10.18632/oncotarget.21660
   Cho KJ, 2016, MOL CELL BIOL, V36, P3086, DOI 10.1128/MCB.00365-16
   Cuomo J, 2011, J NAT PROD, V74, P664, DOI 10.1021/np1007262
   Dei Cas M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092147
   Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hsieh C.Y., 2001, ANTICANCER RES, V21, pe2900
   Kalyan A, 2018, J GASTROINTEST ONCOL, V9, P160, DOI 10.21037/jgo.2018.01.17
   Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4
   Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2
   Oladipo O, 2011, BRIT J CANCER, V104, P480, DOI 10.1038/sj.bjc.6606055
   Qi XM, 2014, ONCOTARGET, V5, P4269, DOI 10.18632/oncotarget.2001
   Roberts JL, 2017, ONCOTARGET, V8, P99451, DOI 10.18632/oncotarget.19807
   Spallanzani A, 2018, J CANC METASTASIS TR, V4, P28, DOI [10.20517/2394-4722.2018.31, DOI 10.20517/2394-4722.2018.31]
   Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
NR 26
TC 13
Z9 13
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2020
VL 235
IS 10
BP 6862
EP 6874
DI 10.1002/jcp.29580
EA JAN 2020
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA MZ8KE
UT WOS:000509608000001
PM 31985048
DA 2022-04-25
ER

PT J
AU Gao, TY
   Liu, XX
   He, BS
   Pan, YQ
   Wang, SK
AF Gao, Tianyi
   Liu, Xiangxiang
   He, Bangshun
   Pan, Yuqin
   Wang, Shukui
TI RETRACTED: Long non-coding RNA 91H regulates IGF2 expression by
   interacting with IGF2BP2 and promotes tumorigenesis in colorectal cancer
   (Retracted article. See vol. 49, pg. 681, 2021)
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE lncRNA 91H; IGF2; IGF2BP2; CRC
ID CONTRIBUTES; PROGRESSION; SURVIVAL; INSULIN; FAMILY; CELLS; COLON
AB 91H, a long non-coding antisense transcripts located on the position of the H19/IGF2 locus had been suggested to play a critical role in tumour development. However, little study had proved the mechanism in colorectal cancer (CRC). Hence, we performed this study to deeply explore the mechanism of lncRNA 91H in tumour progression. The expression of lncRNA 91H was first detected in CRC tissues and cells which was higher in vitro and in vivo than normal cells or tissues and CRC patients with high lncRNA 91H expression usually had a high risk in tumour metastasis (p < .05). Then, monodansylcadaverine (MDC) staining, scratch wound, migration and invasion assays were conducted which showed to that reduced lncRNA 91H would greatly affect tumour migration, invasion and autophagy. Finally, by RNA pull down and RNA-binding protein immunoprecipitation (RIP) assay, a significant interaction was found between lncRNA 91H and IGF2BP2 which was proved to play an important role in CRC IGF2 expression. All these results suggested lncRNA 91H promotes IGF2 expression by interacting with IGF2BP2 which would provide a new strategy in finding potential CRC diagnostic biomarkers and therapeutic targets.
C1 [Gao, Tianyi; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Lab, 68 Changle Rd, Nanjing 210006, Jiangsu, Peoples R China.
   [Liu, Xiangxiang; He, Bangshun; Pan, Yuqin] Nanjing Med Univ, Nanjing Hosp 1, Cent Lab, Nanjing, Peoples R China.
RP Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Lab, 68 Changle Rd, Nanjing 210006, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, 68 Changle Rd, Nanjing 210006, Jiangsu, Peoples R China.
EM sk_wang@njmu.edu.cn
OI Gao, Tianyi/0000-0003-2155-7839; Reis, AlessanRSS/0000-0001-8486-7469
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472027, 81172141, 81200401, 81903034];
   Development of Nanjing Medical Science and Technology Foundation
   [YKK17123]
FX This project was supported by grants from The National Nature Science
   Foundation of China under Grant Nos. [81472027], [81172141], [81200401],
   [81903034], and The Development of Nanjing Medical Science and
   Technology Foundation to Tianyi Gao under Grant No. [YKK17123].
CR Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050
   Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07
   Bigagli E, 2016, CELL ONCOL, V39, P545, DOI 10.1007/s13402-016-0299-z
   Brouwer-Visser J, 2015, CYTOKINE GROWTH F R, V26, P371, DOI 10.1016/j.cytogfr.2015.01.002
   Dai N, 2017, ELIFE, V6, DOI [10.7554/eLife.27155.001, 10.7554/eLife.27155]
   Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022
   Gao TY, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0506-2
   Gao TY, 2015, MOL CARCINOGEN, V54, P359, DOI 10.1002/mc.22106
   Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197
   Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846
   Kolligs FT, 2016, VISC MED, V32, P158, DOI 10.1159/000446488
   Lederer M, 2014, SEMIN CANCER BIOL, V29, P3, DOI 10.1016/j.semcancer.2014.07.006
   Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103551
   Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004
   Liu L, 2017, ONCOTARGET, V8, P57707, DOI 10.18632/oncotarget.17202
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   Onyango P, 2011, P NATL ACAD SCI USA, V108, P16759, DOI 10.1073/pnas.1110904108
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Shimizu T, 2014, CANCER RES, V74, P6531, DOI 10.1158/0008-5472.CAN-14-0914
   Unger C, 2017, ONCOGENE, V36, P5341, DOI 10.1038/onc.2017.116
   Vennin C, 2017, CANCER LETT, V385, P198, DOI 10.1016/j.canlet.2016.10.023
   Xia WK, 2016, ONCOTARGETS THER, V9, P4645, DOI 10.2147/OTT.S103376
   Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445
NR 26
TC 19
Z9 20
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD JAN 1
PY 2020
VL 48
IS 1
BP 664
EP 671
DI 10.1080/21691401.2020.1727491
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA KO4UE
UT WOS:000515545800001
PM 32070145
OA gold
DA 2022-04-25
ER

PT J
AU Vasilevskaya, IA
   Selvakumaran, M
   Roberts, D
   O'Dwyer, PJ
AF Vasilevskaya, Irina A.
   Selvakumaran, Muthu
   Roberts, David
   O'Dwyer, Peter J.
TI JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to
   Chemotherapy
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID COLON-CANCER CELLS; JNK1-MEDIATED PHOSPHORYLATION; BCL-XL; APOPTOSIS;
   KINASE; STRESS; JUN; RESISTANCE; TARGET; DEATH
AB Inhibition of hypoxia-induced stress signaling through JNK potentiates the effects of oxaliplatin. The JNK pathway plays a role in both autophagy and apoptosis; therefore, it was determined how much of the effect of JNK inhibition on oxaliplatin sensitivity is dependent on its effect on autophagy. We studied the impact of JNK isoform downregulation in the HT29 colon adenocarcinoma cell line on hypoxia-and oxaliplatin-induced responses. Electron microscopic analyses demonstrated that both oxaliplatin-and hypoxia-induced formations of autophagosomes were reduced significantly in HT29 cells treated with the JNK inhibitor SP600125. The role of specific JNK isoforms was defined using HT29-derived cell lines stably expressing dominant-negative constructs for JNK1 and JNK2 (HTJ1.3 and HTJ2.2, respectively). These cell lines demonstrated that functional JNK1 is required for hypoxia-induced autophagy and that JNK2 does not substitute for it. Inhibition of autophagy in HTJ1.3 cells also coincided with enhancement of intrinsic apoptosis. Analysis of Bcl2-family proteins revealed hyperphosphorylation of Bcl-XL in the HTJ1.3 cell line, but this did not lead to the expected dissociation from Beclin 1. Consistent with this, knockdown of Bcl-XL in HT29 cells did not significantly affect the induction of autophagy, but abrogated hypoxic resistance to oxaliplatin due to the faster and more robust activation of apoptosis.
   Implications: These data suggest that balance between autophagy and apoptosis is shifted toward apoptosis by downregulation of JNK1, contributing to oxaliplatin sensitization. These findings further support the investigation of JNK inhibition in colorectal cancer treatment. (C) 2016 AACR.
C1 [Vasilevskaya, Irina A.; Selvakumaran, Muthu; Roberts, David; O'Dwyer, Peter J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Roberts, David] Modbury Hosp, Adelaide, SA, Australia.
RP Vasilevskaya, IA (corresponding author), Univ Penn, 1020 BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM vasilevs@mail.med.upenn.edu
FU NCI, NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA139003, RO1CA158377]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA139003, R01CA158377]
   Funding Source: NIH RePORTER
FX This study was supported in part by R01CA139003 and RO1CA158377 from
   NCI, NIH.
CR Arena G, 2013, CELL DEATH DIFFER, V20, P920, DOI 10.1038/cdd.2013.19
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Benard A, 2014, APOPTOSIS, V19, P1769, DOI 10.1007/s10495-014-1042-8
   Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Galluzzi L, 2011, ANTIOXID REDOX SIGN, V15, P1691, DOI 10.1089/ars.2010.3504
   Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028
   Karakashev SV, 2015, CANCER MANAG RES, V7, P253, DOI 10.2147/CMAR.S58285
   Kutuk O, 2008, CURR MOL MED, V8, P102
   Lin ZY, 2014, FREE RADICAL BIO MED, V72, P296, DOI 10.1016/j.freeradbiomed.2014.04.004
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Picco Vincent, 2013, Genes Cancer, V4, P360, DOI 10.1177/1947601913486347
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Raciti M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.167
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Rakitina TV, 2007, BIOCHEM PHARMACOL, V73, P1715, DOI 10.1016/j.bcp.2007.01.037
   Rakitina TV, 2003, CANCER RES, V63, P8600
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028
   Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Span PN, 2015, SEMIN NUCL MED, V45, P101, DOI 10.1053/j.semnuclmed.2014.10.002
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun QJ, 2015, HISTOL HISTOPATHOL, V30, P51, DOI 10.14670/HH-30.51
   Tamura Y, 2009, ONCOGENE, V28, P107, DOI 10.1038/onc.2008.368
   Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349
   Tu QQ, 2014, ACTA PHARMACOL SIN, V35, P504, DOI 10.1038/aps.2013.170
   Vasilevskaya I, 2003, DRUG RESIST UPDATE, V6, P147, DOI 10.1016/S1368-7646(03)00043-8
   Vasilevskaya IA, 2008, MOL PHARMACOL, V74, P246, DOI 10.1124/mol.107.044644
   Vasilevskaya IA, 2015, CLIN CANCER RES, V21, P4143, DOI 10.1158/1078-0432.CCR-15-0352
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   Wang JF, 2012, CELL CYCLE, V11, P2159, DOI 10.4161/cc.20672
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhang Q, 2015, NAT IMMUNOL, V16, P458, DOI 10.1038/ni.3130
NR 50
TC 20
Z9 21
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD AUG
PY 2016
VL 14
IS 8
BP 753
EP 763
DI 10.1158/1541-7786.MCR-16-0035
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DU5WJ
UT WOS:000382283900008
PM 27216154
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Pan, HT
   Wang, YJ
   Na, K
   Wang, Y
   Wang, L
   Li, ZH
   Guo, CJ
   Guo, DD
   Wang, XY
AF Pan, Haitao
   Wang, Yujie
   Na, Kun
   Wang, Ying
   Wang, Lu
   Li, Zhenhao
   Guo, Chengjie
   Guo, Dandan
   Wang, Xingya
TI Autophagic flux disruption contributes to Ganoderma lucidum
   polysaccharide-induced apoptosis in human colorectal cancer cells via
   MAPK/ERK activation
SO CELL DEATH & DISEASE
LA English
DT Article
ID BECLIN 1; BECLIN-1-INDEPENDENT AUTOPHAGY; TARGETING AUTOPHAGY; OXIDATIVE
   STRESS; INHIBITION; IMPAIRS; DEATH; MITOCHONDRIA; DEGRADATION;
   DYSFUNCTION
AB Targeting autophagy may serve as a promising strategy for cancer therapy. Ganoderma lucidum polysaccharide (GLP) has been shown to exert promising anti-cancer effects. However, the underlying mechanisms remain elusive. Whether GLP regulates autophagy in cancer has never been reported. In this study, GLP induced the initiation of autophagy in colorectal cancer (CRC) HT-29 and HCT116 cells, as evidenced by enhanced level of LC3-II protein, GFP-LC3 puncta, and increased formation of double membrane vacuoles. However, GLP treatment caused marked increase of p62 expression. Addition of late stage autophagy inhibitor, chloroquine (CQ), further enhanced LC3-II and p62 level, as well as increased autophagosome accumulation, suggesting a blockage of autophagic flux by GLP in CRC cells. We then found GLP blocked autophagosome and lysosome fusion as determined by mRFP-GFP-LC3 colocalization analysis. Mechanistic study revealed that GLP-induced disruption of autophagosome-lysosome fusion is due to reduced lysosome acidification and lysosomal cathepsin activities. Cell viability and flow cytometry assays revealed that GLP-induced autophagosome accumulation is responsible for GLP-induced apoptosis in CRC cells. In line with this, inhibition of autophagy initiation by 3-methyladenine (3-MA), an early stage autophagy inhibitor, attenuated GLP-induced apoptosis. In contrast, suppression of autophagy at late stage by CQ enhanced the anti-cancer effect of GLP. Furthermore, we demonstrated that GLP-induced autophagosome accumulation and apoptosis is mediated via MAPK/ERK activation. Finally, GLP inhibited tumor growth and also inhibited autophagic flux in vivo. These results unveil new molecular mechanism underlying anti-cancer effects of GLP, suggesting that GLP is a potent autophagy inhibitor and might be useful in anticancer therapy.
C1 [Pan, Haitao; Wang, Yujie; Na, Kun; Wang, Ying; Wang, Lu; Guo, Chengjie; Guo, Dandan; Wang, Xingya] Zhejiang Chinese Med Univ, Dept Pharmaceut Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Li, Zhenhao] Zhejiang Shouxiangu Inst Rare Med Plant, 12,Huanglong 3rd Rd, Wuyi 321200, Zhejiang, Peoples R China.
RP Wang, XY (corresponding author), Zhejiang Chinese Med Univ, Dept Pharmaceut Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
EM xywang@zcmu.edu.cn
OI Wang, Xingya/0000-0001-6986-3240
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81473397]; Science and Technology Department
   of Zhejiang Province Foundation [2019C02100]
FX We thank Dr. Thomas E. Eling at the National Institute of Environmental
   Health Sciences (NIEHS) for proofreading this manuscript. We also thank
   Junying Li and Li Xie at the Bio-ultrastructure Analysis Laboratory of
   Agrobiology and Environmental Sciences of Zhejiang University for
   providing technique support for TEM analysis. This study was supported
   by the National Natural Science Foundation of China (grant no.
   81473397), and the Science and Technology Department of Zhejiang
   Province Foundation (2019C02100).
CR Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7
   Athamneh K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11202-3
   Batra P, 2013, INT J MED MUSHROOMS, V15, P127, DOI 10.1615/IntJMedMushr.v15.i2.20
   Bi YK, 2016, TUMOR BIOL, V37, P3549, DOI 10.1007/s13277-015-4125-4
   Bishop KS, 2015, PHYTOCHEMISTRY, V114, P56, DOI 10.1016/j.phytochem.2015.02.015
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Button RW, 2017, J BIOL CHEM, V292, P13599, DOI 10.1074/jbc.M117.782276
   Button RW, 2016, ONCOTARGET, V7, P5157, DOI 10.18632/oncotarget.6986
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Chen X, 2016, SCI REP-UK, V6, DOI 10.1038/srep28423
   Cheng SJ, 2015, INTEGR CANCER THER, V14, P249, DOI 10.1177/1534735414568721
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cina DP, 2012, J AM SOC NEPHROL, V23, P412, DOI 10.1681/ASN.2011070690
   Cooper KF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4701275
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Elgendy M, 2015, AUTOPHAGY, V11, P581, DOI 10.1080/15548627.2015.1029836
   Elgendy M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6637
   FONG D, 1986, P NATL ACAD SCI USA, V83, P2909, DOI 10.1073/pnas.83.9.2909
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Grotemeier A, 2010, CELL SIGNAL, V22, P914, DOI 10.1016/j.cellsig.2010.01.015
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Hau AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065250
   He W, 2018, CELL PHYSIOL BIOCHEM, V45, P1506, DOI 10.1159/000487576
   Jakhar R, 2016, CANCER LETT, V372, P89, DOI 10.1016/j.canlet.2015.12.024
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Jiang YF, 2017, BIOMED PHARMACOTHER, V96, P865, DOI 10.1016/j.biopha.2017.09.060
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kladar NV, 2016, EUR J CANCER PREV, V25, P462, DOI 10.1097/CEJ.0000000000000204
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kuo HH, 2016, ONCOTARGET, V7, P38078, DOI 10.18632/oncotarget.9348
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li ZQ, 2018, BIOCHEM BIOPH RES CO, V496, P294, DOI 10.1016/j.bbrc.2018.01.037
   Limpert AS, 2018, TRENDS PHARMACOL SCI, V39, P1021, DOI 10.1016/j.tips.2018.10.004
   Liu C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-622
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Liu L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41862
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Loyd AL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01557
   Ma HT, 2015, PHYTOCHEMISTRY, V114, P109, DOI 10.1016/j.phytochem.2015.02.017
   Manzoni C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35106
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Masuelli L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356151
   Mittal S, 2017, PART FIBRE TOXICOL, V14, DOI 10.1186/s12989-017-0194-4
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Na K, 2017, INT J ONCOL, V50, P1541, DOI 10.3892/ijo.2017.3939
   RICHO GR, 1994, J BIOL CHEM, V269, P14806
   Schaffner I, 2018, NEURON, V99, P1188, DOI 10.1016/j.neuron.2018.08.017
   Shen H, 2018, J CELL BIOCHEM, V119, P7022, DOI 10.1002/jcb.26912
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Smith DM, 2010, CELL DEATH DIFFER, V17, P1867, DOI 10.1038/cdd.2010.53
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Sun L, 2015, AM J CANCER RES, V5, P2626
   Tammineni P, 2017, AUTOPHAGY, V13, P982, DOI 10.1080/15548627.2017.1291114
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wilde L, 2018, BIOCHEM J, V475, P1939, DOI 10.1042/BCJ20170847
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Wu KK, 2018, INT J ONCOL, V53, P2356, DOI 10.3892/ijo.2018.4578
   Xiong X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111242
   Yang HR, 2018, INT J MED MUSHROOMS, V20, P727, DOI [10.1615/IntJMedMushrooms.2018026983, 10.1615/intjmedmushrooms.2018026983]
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Zeng PJ, 2018, J CELL MOL MED, V22, P3278, DOI 10.1111/jcmm.13613
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
   Zhao XY, 2017, CARBOHYD POLYM, V171, P136, DOI 10.1016/j.carbpol.2017.05.014
   Zhao Y, 2013, AUTOPHAGY, V9, P794, DOI 10.4161/auto.23918
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
   Zhou J, 2012, AUTOPHAGY, V8, P338, DOI 10.4161/auto.18721
NR 76
TC 51
Z9 56
U1 15
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 11
PY 2019
VL 10
AR 456
DI 10.1038/s41419-019-1653-7
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IC6ZO
UT WOS:000471121800004
PM 31186406
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kang, XJ
   Wang, HY
   Peng, HG
   Chen, BF
   Zhang, WY
   Wu, AH
   Xu, Q
   Huang, YZ
AF Kang, Xue-jia
   Wang, Hui-yuan
   Peng, Hui-ge
   Chen, Bin-fan
   Zhang, Wen-yuan
   Wu, Ai-hua
   Xu, Qin
   Huang, Yong-zhuo
TI Codelivery of dihydroartemisinin and doxorubicin in mannosylated
   liposomes for drug-resistant colon cancer therapy
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE human colon cancer; multidrug resistance; doxorubicin;
   dihydroartemisinin; combination therapy; tumor-targeted delivery;
   mannosylated liposome; mannose receptor
ID BREAST-CANCER; CELLS; AUTOPHAGY; APOPTOSIS; MECHANISMS; STRATEGIES;
   MORTALITY
AB Multidrug resistance (MDR) is a major hurdle in cancer chemotherapy and makes the treatment benefits unsustainable. Combination therapy is a commonly used method for overcoming MDR. In this study we investigated the anti-MDR effect of dihydroartemisinin (DHA), a derivative of artemisinin, in combination with doxorubicin (Dox) in drug-resistant human colon tumor HCT8/ADR cells. We developed a tumor-targeting codelivery system, in which the two drugs were co-encapsulated into the mannosylated liposomes (Manliposomes). The Man-liposomes had a mean diameter of 158.8 nm and zeta potential of -15.8 mV. In the HCT8/ADR cells that overexpress the mannose receptors, the Man-liposomes altered the intracellular distribution of Dox, resulting in a high accumulation of Dox in the nuclei and thus displaying the highest cytotoxicity (IC50=0.073 mu g/mL) among all the groups. In a subcutaneous HCT8/ADR tumor xenograft model, administration of the Man-liposomes resulted in a tumor inhibition rate of 88.59%, compared to that of 47.46% or 70.54%, respectively, for the treatment with free Dox or free Dox+ DHA. The mechanisms underlying the anti-MDR effect of the Manliposomes involved preferential nuclear accumulation of the therapeutic agents, enhanced cancer cell apoptosis, downregulation of Bcl-xl, and the induction of autophagy.
C1 [Kang, Xue-jia; Wu, Ai-hua; Xu, Qin] Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou 510405, Guangdong, Peoples R China.
   [Kang, Xue-jia; Wang, Hui-yuan; Peng, Hui-ge; Chen, Bin-fan; Zhang, Wen-yuan; Wu, Ai-hua; Huang, Yong-zhuo] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
RP Xu, Q (corresponding author), Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou 510405, Guangdong, Peoples R China.; Huang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
EM xuqin@gzucm.edu.cn; yzhuang@simm.ac.cn
RI Huang, Yongzhuo/A-4688-2013
OI Huang, Yongzhuo/0000-0001-7067-8915
FU 973 Program, ChinaNational Basic Research Program of China
   [2014CB931900, 2013CB932503]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81373357,
   81422048, 81402883, 81521005, 81673382]; Scientific Research and
   Equipment Development Project, Chinese Academy of Sciences [YZ201437]
FX This work was supported by the 973 Program, China (2014CB931900 and
   2013CB932503) and the National Natural Science Foundation of China
   (81373357, 81422048, 81402883, 81521005, and 81673382). It was also
   partially supported by the Scientific Research and Equipment Development
   Project, Chinese Academy of Sciences (YZ201437).
CR Al-Harbi S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0460-8
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Arnold M, 2016, GUT
   Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747
   Chen H, 2010, J CANCER RES CLIN, V136, P897, DOI 10.1007/s00432-009-0731-0
   Chen WQ, 2016, CHINESE J CANCER RES, V28, P1, DOI 10.3978/j.issn.1000-9604.2016.02.08
   Feng X, 2014, BIOCHEM BIOPH RES CO, V444, P376, DOI 10.1016/j.bbrc.2014.01.053
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Geldenhuys WJ, 2015, THER DELIV, V6, P961, DOI [10.4155/TDE.15.32, 10.4155/tde.15.32]
   Hayashi N, 2015, MOL CANCER THER, V14, P452, DOI 10.1158/1535-7163.MCT-14-0348
   HERZOG CE, 1992, J NATL CANCER I, V84, P711, DOI 10.1093/jnci/84.9.711
   Hu CJ, 2014, CANCER BIOL THER, V15, P279, DOI 10.4161/cbt.27223
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Lai HC, 2013, INVEST NEW DRUG, V31, P230, DOI 10.1007/s10637-012-9873-z
   Li C, 2014, CLIN TRANSL ONCOL, V16, P593, DOI 10.1007/s12094-014-1169-7
   Li SG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057604
   Lin RY, 2016, CANCER LETT, V381, P165, DOI 10.1016/j.canlet.2016.07.033
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Ontikatze T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00116
   Panzarini E, 2014, MOL PHARMACEUT, V11, P2527, DOI 10.1021/mp500066v
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Takano Y, 1996, J CANCER RES CLIN, V122, P166, DOI 10.1007/BF01366957
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Vredenburg MR, 2001, JNCI-J NATL CANCER I, V93, P1234, DOI 10.1093/jnci/93.16.1234
   Wang HX, 2014, J CONTROL RELEASE, V192, P47, DOI 10.1016/j.jconrel.2014.06.051
   Wang P, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/767136
   Wang S, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-219
   Wu GS, 2013, PHARMACOL REP, V65, P453, DOI 10.1016/S1734-1140(13)71021-1
   Zhang ZS, 2015, ONCOL LETT, V10, P379, DOI 10.3892/ol.2015.3183
NR 30
TC 45
Z9 45
U1 4
U2 52
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD JUN
PY 2017
VL 38
IS 6
SI SI
BP 885
EP 896
DI 10.1038/aps.2017.10
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA EW5EB
UT WOS:000402526900013
PM 28479604
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Raju, GSR
   Pavitra, E
   Merchant, N
   Lee, H
   Prasad, GLV
   Nagaraju, GP
   Huh, YS
   Han, YK
AF Raju, G. Seeta Rama
   Pavitra, E.
   Merchant, Neha
   Lee, Hoomin
   Prasad, Ganji Lakshmi Vara
   Nagaraju, Ganji Purnachandra
   Huh, Yun Suk
   Han, Young-Kyu
TI Targeting autophagy in gastrointestinal malignancy by using
   nanomaterials as drug delivery systems
SO CANCER LETTERS
LA English
DT Review
DE Autophagy; Nanomaterial; Gastric cancer; Pancreatic cancer; Liver cancer
ID HEPATOCELLULAR-CARCINOMA CELLS; HYPOXIA-INDUCED AUTOPHAGY; ESOPHAGEAL
   CANCER-CELLS; COLON-CANCER; SIGNALING PATHWAYS; VACUOLATING CYTOTOXIN;
   ESOPHAGOGASTRIC CANCER; OXIDE NANOPARTICLES; GROWTH-INHIBITION; INDUCE
   AUTOPHAGY
AB Autophagy is a conserved catabolic process involving large protein degradation by a ubiquitous auto-phagosomic signaling pathway, which is essential for cellular homeostasis. It is triggered by environmental factors such as stress, lack of nutrients, inflammation, and eliminating intracellular pathogens. Although the mechanisms underlying autophagy are still unclear, increasing evidence illuminates the magnitude of autophagy in a wide range of physiological processes and human diseases. Simultaneously, research community has focused on the triggering of autophagy by the internalization of engineered nanomaterials, which indicates a new line of revolution in cancer cure. However, most studies on nanoparticle-induced autophagy focus on brain, breast, and cervical cancers; limited reports are available on gastrointestinal (GI) cancers. Therefore, the aim of this mini review is to discuss in detail the role of autophagy in GI malignancy and the status of research on nanoparticle-induced autophagy. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Raju, G. Seeta Rama; Han, Young-Kyu] Dongguk Univ Seoul, Dept Energy & Mat Engn, Seoul 04620, South Korea.
   [Pavitra, E.; Lee, Hoomin; Huh, Yun Suk] Inha Univ, Dept Biol Engn, BSRC, 100 Inha Ro, Incheon 22212, South Korea.
   [Merchant, Neha; Nagaraju, Ganji Purnachandra] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
   [Prasad, Ganji Lakshmi Vara] Dr LV Prasad Diagnost & Res Lab, Hyderabad 500004, Telangana, India.
RP Han, YK (corresponding author), Dongguk Univ Seoul, Dept Energy & Mat Engn, Seoul 04620, South Korea.; Huh, YS (corresponding author), Inha Univ, Dept Biol Engn, BSRC, 100 Inha Ro, Incheon 22212, South Korea.; Nagaraju, GP (corresponding author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
EM pganji@emory.edu; yunsukhuh@inha.ac.kr; ykenergy@dongguk.edu
RI Merchant, Neha/AAW-3369-2021; Nagaraju, Purnachandra/D-4193-2011;
   Pavitra, E./A-1005-2014; Raju, Ganji Seeta Rama/D-3428-2011
OI Nagaraju, Purnachandra/0000-0002-4989-5234; Pavitra,
   E./0000-0002-8066-6309; Raju, Ganji Seeta Rama/0000-0002-3170-7506
FU Ministry of Science, ICT & Future Planning [2016R1A2B4013374,
   2014R1A5A1009799]
FX The authors are grateful for the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by the Ministry
   of Science, ICT & Future Planning (2016R1A2B4013374 and
   2014R1A5A1009799).
CR Abdel-Aziz AK, 2014, CHEM-BIOL INTERACT, V217, P28, DOI 10.1016/j.cbi.2014.04.007
   Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   Aghajan M, 2012, J GASTROEN HEPATOL, V27, P10, DOI 10.1111/j.1440-1746.2011.07008.x
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Berasain Carmen, 2011, Cancers (Basel), V3, P2444, DOI 10.3390/cancers3022444
   Bhanot UK, 2009, LAB INVEST, V89, P489, DOI 10.1038/labinvest.2009.19
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen HI, 2016, PATHOL ONCOL RES, V22, P699, DOI 10.1007/s12253-016-0051-z
   Chen J, 2002, CANCER J, V8, P154, DOI 10.1097/00130404-200203000-00009
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen SA, 2014, MOL CELL BIOL, V34, P3435, DOI 10.1128/MCB.01383-13
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   Dizdaroglu M, 2012, CANCER LETT, V327, P26, DOI 10.1016/j.canlet.2012.01.016
   Dong L, 2013, ADV FUNCT MATER, V23, P5930, DOI 10.1002/adfm.201203767
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240
   Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ferreira RM, 2014, BEST PRACT RES CL GA, V28, P1003, DOI 10.1016/j.bpg.2014.09.004
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gil J, 2008, J APPL GENET, V49, P193, DOI 10.1007/BF03195612
   Greene LM, 2013, INT J ONCOL, V43, P927, DOI 10.3892/ijo.2013.1989
   Gukovskaya AS, 2012, AM J PHYSIOL-GASTR L, V303, pG993, DOI 10.1152/ajpgi.00122.2012
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Guo XL, 2014, CANCER LETT, V346, P278, DOI 10.1016/j.canlet.2014.01.011
   Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He G, 2014, TUMOR BIOL, V35, P1003, DOI 10.1007/s13277-013-1134-z
   He XX, 2012, ONCOGENE, V31, P3357, DOI 10.1038/onc.2011.500
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890
   Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li L, 2012, FREE RADICAL BIO MED, V53, P1399, DOI 10.1016/j.freeradbiomed.2012.07.011
   Li PY, 2012, CANCER LETT, V314, P213, DOI 10.1016/j.canlet.2011.09.031
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Li XJ, 2016, J BIOMED NANOTECHNOL, V12, P948, DOI 10.1166/jbn.2016.2232
   Liebmann C, 2011, MOL CELL ENDOCRINOL, V331, P222, DOI 10.1016/j.mce.2010.04.008
   Lin J, 2016, SMALL, V12, P5759, DOI 10.1002/smll.201601903
   Liu DL, 2015, ONCOL LETT, V9, P2278, DOI 10.3892/ol.2015.3047
   Liu Y, 2012, J PHARMACOL SCI, V118, P423, DOI 10.1254/jphs.11181FP
   Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183
   Liu Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09375-y
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Lordick F, 2004, BRIT J SURG, V91, P540, DOI 10.1002/bjs.4575
   Lu C, 2016, ONCOL REP, V35, P3559, DOI 10.3892/or.2016.4753
   Lu Y, 2013, ADV FUNCT MATER, V23, P1534, DOI 10.1002/adfm.201202233
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Mareninova OA, 2015, CELL MOL GASTROENTER, V1, P678, DOI 10.1016/j.jcmgh.2015.07.006
   MATHE G, 1989, BIOMED PHARMACOTHER, V43, P237, DOI 10.1016/0753-3322(89)90003-6
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McGowan PM, 2009, FUTURE ONCOL, V5, P1083, DOI 10.2217/FON.09.73
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Mishra AR, 2016, TOXICOL SCI, V150, P473, DOI 10.1093/toxsci/kfw011
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   O'Sullivan GC, 1999, GASTROENTEROLOGY, V116, P543, DOI 10.1016/S0016-5085(99)70175-7
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Panzarini E, 2014, MOL PHARMACEUT, V11, P2527, DOI 10.1021/mp500066v
   Panzarini Elisa, 2013, Cancers (Basel), V5, P296, DOI 10.3390/cancers5010296
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Peek RM, 2016, HELICOBACTER PYLORI, P403
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Qin YR, 2015, TOXICOLOGY, V327, P62, DOI 10.1016/j.tox.2014.10.011
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raju D, 2012, GASTROENTEROLOGY, V142, P1160, DOI 10.1053/j.gastro.2012.01.043
   Raju D, 2010, AUTOPHAGY, V6, P138, DOI 10.4161/auto.6.1.10222
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Ryan P, 2004, J SURG RES, V117, P121, DOI 10.1016/j.jss.2003.12.008
   Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086
   Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Song W, 2017, ACTA BIOMATER, V58, P196, DOI 10.1016/j.actbio.2017.05.038
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.35
   Suzuki R, 2014, ANTICANCER RES, V34, P4685
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W
   Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029
   Terebiznik MR, 2009, AUTOPHAGY, V5, P370, DOI 10.4161/auto.5.3.7663
   Tian Y, 2015, CELL DEATH DIFFER, V22, P1025, DOI 10.1038/cdd.2014.201
   Tomic S, 2017, BIOMATERIALS, V146, P13, DOI 10.1016/j.biomaterials.2017.08.040
   Tzeng CW, 2016, PHYTOMEDICINE, V23, P528, DOI 10.1016/j.phymed.2016.02.010
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
   Wands JR, 2014, HEPATOLOGY, V60, P452, DOI 10.1002/hep.27081
   Wang BS, 2014, MOL CARCINOGEN, V53, P514, DOI 10.1002/mc.22003
   Wang FZ, 2016, MOL PHARMACEUT, V13, P1298, DOI 10.1021/acs.molpharmaceut.5b00879
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Weh KM, 2016, MOL CARCINOGEN, V55, P1876, DOI 10.1002/mc.22432
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wei PF, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/49/495101
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Wu DH, 2014, TUMOR BIOL, V35, P12225, DOI 10.1007/s13277-014-2531-7
   Wu YN, 2011, BIOMATERIALS, V32, P4565, DOI 10.1016/j.biomaterials.2011.03.006
   Xu MY, 2013, FOOD CHEM TOXICOL, V59, P703, DOI 10.1016/j.fct.2013.06.059
   Xue F, 2016, CANCER LETT, V371, P38, DOI 10.1016/j.canlet.2015.11.022
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang C, 2016, TUMOR BIOL, V37, P15489, DOI 10.1007/s13277-015-3775-6
   Yang SH, 2011, AUTOPHAGY, V7, P912, DOI 10.4161/auto.7.8.15762
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang Y, 2016, TUMOR BIOL, V37, P1853, DOI 10.1007/s13277-015-3974-1
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yu YB, 2014, J HAZARD MATER, V270, P176, DOI 10.1016/j.jhazmat.2014.01.028
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916
   Zhang Hui-Qing, 2015, Asian Pac J Cancer Prev, V16, P3907
   Zhang XD, 2016, MOL PHARMACEUT, V13, P2578, DOI 10.1021/acs.molpharmaceut.6b00405
   Zhang YJ, 2012, NAT MATER, V11, P817, DOI [10.1038/NMAT3363, 10.1038/nmat3363]
   Zheng K, 2016, AUTOPHAGY, V12, P1593, DOI 10.1080/15548627.2016.1192751
   Zheng W, 2016, NANOMEDICINE-UK, V11, P1417, DOI 10.2217/nnm-2016-0040
   Zhou W, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/16/165102
   Zhu BS, 2015, MOL MED REP, V11, P1891, DOI 10.3892/mmr.2014.2926
   Zhu LY, 2017, NANOSCALE, V9, P5489, DOI 10.1039/c6nr08188f
NR 161
TC 16
Z9 16
U1 5
U2 60
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 419
BP 222
EP 232
DI 10.1016/j.canlet.2018.01.044
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FY8GN
UT WOS:000427102300022
PM 29355658
DA 2022-04-25
ER

PT J
AU Margalef, P
   Colomer, C
   Villanueva, A
   Montagut, C
   Iglesias, M
   Bellosillo, B
   Salazar, R
   Martinez-Iniesta, M
   Bigas, A
   Espinosa, L
AF Margalef, Pol
   Colomer, Carlota
   Villanueva, Alberto
   Montagut, Clara
   Iglesias, Mar
   Bellosillo, Beatriz
   Salazar, Ramon
   Martinez-Iniesta, Maria
   Bigas, Anna
   Espinosa, Lluis
TI BRAF-induced tumorigenesis is IKK alpha-dependent but NF-kappa
   B-independent
SO Science Signaling
LA English
DT Article
ID COLORECTAL-CANCER; RAF INHIBITORS; GENE-EXPRESSION; PROSTATE-CANCER; MEK
   INHIBITION; MAPK PATHWAY; KINASE-ALPHA; COLON-CANCER; ACTIVATION;
   MELANOMA
AB KRAS mutations contribute to cell proliferation and survival in numerous cancers, including colorectal cancers (CRC). One pathway through which mutant KRAS acts is an inflammatory pathway that involves the kinase IKK and activates the transcription factor NF-kappa B. BRAF, a kinase that is downstream of KRAS, is mutated in a subset of CRC and is predictive of poor prognosis and therapeutic resistance. We found that, in contrast to mutant KRAS, mutant BRAF (BRAF(V600E)) did not trigger NF-kappa B activation but instead triggered the phosphorylation of a proteolytic fragment of IKK alpha (p45-IKK alpha) in CRC cells. BRAF(V600E) CRC cells had a high abundance of phosphorylated p45-IKK alpha, which was decreased by a RAF inhibitor. However, the abundance and DNA binding of NF-kappa B in these cells were unaffected by the RAF inhibitor, and expression of BRAF(V600E) in human embryonic kidney-293T cells did not activate an NF-kappa B reporter. Moreover, BRAF-induced transformation of NIH-3T3 cells and BRAF-dependent transcription required phosphorylation of p45-IKK alpha. The kinase TAK1, which was associated with the endosomal compartment, phosphorylated p45-IKK alpha. Inhibition of endosomal vacuolar adenosine triphosphatase (V-ATPase) with chloroquine or bafilomycin A1 blocked p45-IKK alpha phosphorylation and induced apoptosis in BRAF-mutant CRC cells independent of autophagy. Treating mice with V-ATPase inhibitors reduced the growth and metastasis of BRAF(V600E) xenograft tumors in the cecum of mice.
C1 [Margalef, Pol; Colomer, Carlota; Bigas, Anna; Espinosa, Lluis] Inst Hosp del Mar Invest Med IMIM, Barcelona 08003, Spain.
   [Villanueva, Alberto; Martinez-Iniesta, Maria] Inst Catala Oncol, Inst Invest Biomed Bellvitge IDIBELL, Lab Recerca Translac, Barcelona 08907, Spain.
   [Montagut, Clara] Univ Pompeu Fabra, IMIM, Dept Oncol, Barcelona 08003, Spain.
   [Iglesias, Mar; Bellosillo, Beatriz] IMIM, Dept Pathol, Barcelona 08003, Spain.
   [Salazar, Ramon] Bellvitge Hosp, Dept Oncol, Barcelona 08907, Spain.
RP Espinosa, L (corresponding author), Inst Hosp del Mar Invest Med IMIM, Parc Recerca Biomed Barcelona, Barcelona 08003, Spain.
EM lespinosa@imim.es
RI Espinosa, Lluis/ABA-4564-2020; Bigas, Anna/A-7457-2014
OI Espinosa, Lluis/0000-0002-2897-4099; Martinez-Iniesta,
   Maria/0000-0001-6252-6671; Bigas, Anna/0000-0003-4801-6899
FU Formacion de Profesorado Universitario (FPU)Spanish Government
   [AP2009-2892]; Instituto de Salud Carlos III-FEDER grant [PI13/00448];
   RTICCS/FEDEREuropean Commission [RD12/0036/0054, RD09/0076/00036]; Pla
   Director d'Oncologia de Catalunya (XBTC); AGAURAgencia de Gestio D'Ajuts
   Universitaris de Recerca Agaur (AGAUR) [SGR23]
FX P.M. is a recipient of a Formacion de Profesorado Universitario (FPU)
   fellowship (AP2009-2892), and L.E. is an investigator at the Carlos III
   program. This work was further supported by Instituto de Salud Carlos
   III-FEDER grants PI13/00448, AGAUR (SGR23), and RTICCS/FEDER
   (RD12/0036/0054 and RD09/0076/00036) and "Xarxa de Bancs de tumors"
   sponsored by the Pla Director d'Oncologia de Catalunya (XBTC).
CR Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648
   Mulero MC, 2013, CANCER CELL, V24, P151, DOI 10.1016/j.ccr.2013.06.003
   Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104
   Fernandez-Majada V, 2007, CELL CYCLE, V6, P1748, DOI 10.4161/cc.6.14.4429
   Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200
   Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010
   Holderfield M, 2013, CANCER CELL, V23, P594, DOI 10.1016/j.ccr.2013.03.033
   Jin HO, 2013, BIOCHEM BIOPH RES CO, V437, P463, DOI 10.1016/j.bbrc.2013.06.106
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Lamoureux F, 2013, AUTOPHAGY, V9, P1119, DOI 10.4161/auto.24921
   Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Maier HJ, 2013, ONCOGENE, V32, P2690, DOI 10.1038/onc.2012.272
   Margalef P, 2012, CELL REP, V2, P840, DOI 10.1016/j.celrep.2012.08.028
   Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462
   Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787
   Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111
   Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prajapati S, 2006, CELL CYCLE, V5, P2371, DOI 10.4161/cc.5.20.3359
   Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576
NR 40
TC 18
Z9 19
U1 0
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD APR 21
PY 2015
VL 8
IS 373
AR ra38
DI 10.1126/scisignal.2005886
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CG6AI
UT WOS:000353376900003
PM 25900832
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Senawong, T
   Wongphakham, P
   Saiwichai, T
   Phaosiri, C
   Kumboonma, P
AF Senawong, Thanaset
   Wongphakham, Paweena
   Saiwichai, Thussanee
   Phaosiri, Chanokbhorn
   Kumboonma, Pakit
TI Histone deacetylase inhibitory activity of hydroxycapsaicin, a synthetic
   derivative of capsaicin, and its cytotoxic effects against human colon
   cancer cell lines
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE Capsaicin; apoptosis; cell-cycle arrest; cytotoxicity; HDAC inhibitor;
   colon cancer
ID HOT CHILI-PEPPERS; CYCLE ARREST; APOPTOSIS; ACTIVATION; AUTOPHAGY;
   DEATH; INDUCTION; THERAPY; DIHYDROCAPSAICIN; INFLAMMATION
AB Capsaicin possesses cytotoxic/anticancer activity and shares some common structural features, including a benzene ring and a long hydrophobic carbon tail, with the histone deacetylase (HDAC) inhibitors trichostatin A and suberoylanilide hydroxamic acid. The aims of this study were to investigate HDAC inhibitory and cytotoxic activities of a synthetic derivative of capsaicin, hydroxycapsaicin (6-hydroxy-N-(4-hydroxy-3-methoxybenzyl)-8-methylnonenamide), in colon cancer cell lines. Hydroxycapsaicin inhibited HDAC activity in vitro (IC50 = 72 mu M) much more effectively than the prototype capsaicin (IC50 > 13.1 mM) and also exhibited HDAC inhibitory activity in human cells (HeLa cells). MTT assay demonstrated that hydroxycapsaicin was less toxic than capsaicin against both cancer and noncancer cells; however, hydroxycapsaicin, with greater HDAC inhibitory activity, was more effective than capsaicin at inducing apoptosis in colon cancer cell lines, especially in HCT116 cells. Hydroxycapsaicin appeared to induce less apoptotic cell death than capsaicin in Vero cells. Moreover, only hydroxycapsaicin induced S-phase cell-cycle arrest in both HT29 and HCT116 cells. The current study demonstrates that hydroxycapsaicin can act as a novel HDAC inhibitor, which would lead to a promising strategy for the development of safe and effective chemotherapeutic drugs from the abundant natural capsaicin of chili pepper.
C1 [Senawong, Thanaset; Wongphakham, Paweena; Saiwichai, Thussanee] Khon Kaen Univ, Dept Biochem, Fac Sci, Khon Kaen, Thailand.
   [Phaosiri, Chanokbhorn; Kumboonma, Pakit] Khon Kaen Univ, Dept Chem, Fac Sci, Khon Kaen, Thailand.
   [Senawong, Thanaset; Phaosiri, Chanokbhorn] Khon Kaen Univ, Nat Prod Res Unit, Fac Sci, Khon Kaen 40002, Thailand.
   [Senawong, Thanaset] Khon Kaen Univ, Food & Prod Chem Anal Res Grp, Fac Sci, Khon Kaen 40002, Thailand.
RP Senawong, T (corresponding author), Khon Kaen Univ, Dept Biochem, Fac Sci, Khon Kaen, Thailand.
EM sthanaset@kku.ac.th
RI Phaosiri, Chanokbhorn/AAF-7797-2020
OI Phaosiri, Chanokbhorn/0000-0002-0108-0204
FU Khon Kaen University
FX This work was supported by Khon Kaen University through a Researcher
   Training Grant (to TS). We are thankful to Professor Nison Sattayasai
   and Associate Professor Veerapol Kukongviriyapan, Khon Kaen University,
   Thailand, for technical advice and coordination for the use of
   microplate spectrofluorometer, respectively.
CR Ahn S, 2014, MOL CELLS, V37, P257, DOI 10.14348/molcells.2014.2384
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Bromberg Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057149
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Cheriyath V, 2011, BRIT J CANCER, V104, P957, DOI 10.1038/bjc.2011.42
   Choi CH, 2010, FREE RADICAL BIO MED, V49, P245, DOI 10.1016/j.freeradbiomed.2010.04.014
   Choi CH, 2010, MOL PHARMACOL, V78, P114, DOI 10.1124/mol.110.063495
   Creppy EE, 2000, ARCH TOXICOL, V74, P40, DOI 10.1007/s002040050650
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de Jong PR, 2014, J CLIN INVEST, V124, P3793, DOI 10.1172/JCI72340
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4
   Ghosh AK, 2010, CANCER LETT, V287, P142, DOI 10.1016/j.canlet.2009.06.007
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199
   Jin JZ, 2014, INT J BIOL SCI, V10, P285, DOI 10.7150/ijbs.7730
   Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Knotkova H, 2008, CLIN J PAIN, V24, P142, DOI 10.1097/AJP.0b013e318158ed9e
   Kretzner L, 2011, CANCER RES, V71, P3912, DOI 10.1158/0008-5472.CAN-10-2259
   Kumboonma P, 2010, THESIS KHON KAEN U K
   Lee EJ, 2010, FREE RADICAL BIO MED, V48, P1133, DOI 10.1016/j.freeradbiomed.2010.01.034
   Lin CH, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-46
   Liu NC, 2012, J AGR FOOD CHEM, V60, P2758, DOI 10.1021/jf204869w
   LOPEZCARRILLO L, 1994, AM J EPIDEMIOL, V139, P263, DOI 10.1093/oxfordjournals.aje.a116993
   Luo XJ, 2011, EUR J PHARMACOL, V650, P1, DOI 10.1016/j.ejphar.2010.09.074
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Martinez-Iglesias O, 2008, CLIN TRANSL ONCOL, V10, P395, DOI 10.1007/s12094-008-0221-x
   Mehta RG, 2014, TURK J BIOL, V38, P839, DOI 10.3906/biy-1405-42
   Messeguer A, 2006, CURR NEUROPHARMACOL, V4, P1, DOI 10.2174/157015906775202995
   Nascimento PLA, 2014, MOLECULES, V19, P5434, DOI 10.3390/molecules19045434
   Ocker Matthias, 2010, World J Biol Chem, V1, P55, DOI 10.4331/wjbc.v1.i5.55
   Oh SH, 2009, J PHARMACOL EXP THER, V329, P112, DOI 10.1124/jpet.108.144113
   Poolman RA, 1998, J MOL CELL CARDIOL, V30, P2121, DOI 10.1006/jmcc.1998.0808
   Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157
   Reilly CA, 2003, TOXICOL SCI, V73, P170, DOI 10.1093/toxsci/kfg044
   Reinbach HC, 2009, CLIN NUTR, V28, P260, DOI 10.1016/j.clnu.2009.01.010
   Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260
   Saito M, 2013, CURR OPIN LIPIDOL, V24, P71, DOI 10.1097/MOL.0b013e32835a4f40
   Senawong T, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-232
   Surh YJ, 2002, J NATL CANCER I, V94, P1263, DOI 10.1093/jnci/94.17.1263
   Thoennissen NH, 2010, ONCOGENE, V29, P285, DOI 10.1038/onc.2009.335
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182
   Yang ZH, 2010, UROLOGY, V75, P735, DOI 10.1016/j.urology.2009.03.042
   Zhang J, 2003, LEUKEMIA RES, V27, P275, DOI 10.1016/S0145-2126(02)00164-9
   Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686
   Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102
NR 49
TC 5
Z9 5
U1 1
U2 8
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2015
VL 39
IS 3
BP 370
EP 379
DI 10.3906/biy-1409-60
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA CK6SM
UT WOS:000356358200003
OA Bronze, Green Submitted
DA 2022-04-25
ER

PT J
AU Milczarek, M
   Pogorzelska, A
   Wiktorska, K
AF Milczarek, Malgorzata
   Pogorzelska, Anna
   Wiktorska, Katarzyna
TI Synergistic Interaction between 5-FU and an Analog of
   Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model
SO MOLECULES
LA English
DT Article
DE 5-fluorouracil; isothiocyanates; sulforaphane; synergistic effect
ID CELL-CYCLE; GROWTH-INHIBITION; APOPTOSIS; 5-FLUOROURACIL; AUTOPHAGY;
   COMBINATION; ACID; OXALIPLATIN; SENSITIZES; METABOLITE
AB Combination therapy is based on the beneficial effects of pharmacodynamic interaction (synergistic or additive) between combined drugs or substances. A considerable group of candidates for combined treatments are natural compounds (e.g., isothiocyanates) and their analogs, which are tested in combination with anticancer drugs. We tested the anticancer effect of the combined treatment of isothiocyanate 2-oxohexyl isothiocyanate and 5-fluorouracil in colon and prostate cancer cell lines. The type of interaction was described using the Chou-Talalay method. The cytostatic and cytotoxic activities of the most promising combined treatments were investigated. In conclusion, we showed that combined treatment with 5-fluorouracil and 2-oxohexyl isothiocyanate acted synergistically in colon cancer. This activity is dependent on the cytostatic properties of the tested compounds and leads to the intensification of their individual cytotoxic activity. The apoptotic process is considered to be the main mechanism of cytotoxicity in this combined treatment.
C1 [Milczarek, Malgorzata; Pogorzelska, Anna; Wiktorska, Katarzyna] Natl Med Inst, Dept Drug Biotechnol & Bioinformat, 30-34 Chelmska St, PL-00725 Warsaw, Poland.
RP Milczarek, M; Wiktorska, K (corresponding author), Natl Med Inst, Dept Drug Biotechnol & Bioinformat, 30-34 Chelmska St, PL-00725 Warsaw, Poland.
EM m.milczarek@nil.gov.pl; a.pogorzelska@nil.gov.pl; k.wiktorska@nil.gov.pl
OI Pogorzelska, Anna/0000-0002-4006-2682; Wiktorska,
   Katarzyna/0000-0002-2731-9535; Milczarek, Malgorzata/0000-0003-1209-9477
FU National Science Center, PolandNational Science Centre, Poland
   [N/NZ5/02634]; National Medicines Institute, Warsaw, Poland
FX This research was funded by the National Science Center, Poland, grant
   number N/NZ5/02634, and by the National Medicines Institute, Warsaw,
   Poland, from statutory funding.
CR Akhtar R, 2014, WORLD J GASTRO ONCOL, V6, P177, DOI 10.4251/wjgo.v6.i6.177
   Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Bose C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193918
   Carnesecchi S, 2004, CANCER LETT, V215, P53, DOI 10.1016/j.canlet.2004.06.019
   Chan JY, 2008, CANCER BIOL THER, V7, P1305, DOI 10.4161/cbt.7.8.6302
   Chionh F, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008398.pub2
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   de Vos F Y F L, 2010, Ther Adv Med Oncol, V2, P381, DOI 10.1177/1758834010376185
   Dey DK, 2020, FOOD CHEM TOXICOL, V143, DOI 10.1016/j.fct.2020.111529
   Druskovic M, 2006, CROAT MED J, V47, P832
   Fulda S, 2004, ONCOGENE, V23, P6702, DOI 10.1038/sj.onc.1207630
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gatouillat G, 2010, J CELL BIOCHEM, V110, P893, DOI 10.1002/jcb.22601
   Gonzalez-Sarrias A, 2015, FOOD FUNCT, V6, P1460, DOI [10.1039/C5FO00120J, 10.1039/c5fo00120j]
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hoffmann JC, 2009, MOL CELL BIOL, V29, P4431, DOI 10.1128/MCB.02261-07
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V332, P433, DOI 10.1016/j.bbrc.2005.04.143
   Jiang D, 2017, ONCOL REP, V37, P594, DOI 10.3892/or.2016.5246
   Jung GR, 2007, BASIC CLIN PHARMACOL, V101, P277, DOI 10.1111/j.1742-7843.2007.00115.x
   Jung Hsuan, 2003, Chang Gung Med J, V26, P250
   Kallifatidis G, 2011, MOL THER, V19, P188, DOI 10.1038/mt.2010.216
   Kaminski BM, 2011, CANCER CHEMOTH PHARM, V67, P1167, DOI 10.1007/s00280-010-1413-y
   Lee WY, 2015, NUTR CANCER, V67, P275, DOI 10.1080/01635581.2015.989374
   Lin JY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71970-3
   Liu XY, 2017, BIOCHEM BIOPH RES CO, V491, P209, DOI 10.1016/j.bbrc.2017.07.078
   Mhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211
   Milczarek M, 2018, MOLECULES, V23, DOI 10.3390/molecules23113040
   Milczarek M, 2018, FOOD CHEM TOXICOL, V111, P1, DOI 10.1016/j.fct.2017.10.056
   Milczarek M, 2011, ACTA POL PHARM, V68, P331
   Misiewicz I, 2003, ONCOL REP, V10, P2045
   Misiewicz I, 2005, ONCOL REP, V13, P659
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Mukherjee S, 2009, J ENVIRON PATHOL TOX, V28, P269, DOI 10.1615/JEnvironPatholToxicolOncol.v28.i4.30
   Mukhtar E, 2016, MOL CANCER THER, V15, P2863, DOI 10.1158/1535-7163.MCT-16-0515
   Overbeeke R, 1998, APOPTOSIS, V3, P115, DOI 10.1023/A:1009649025439
   Paciello F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57965-0
   Parrish AB, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008672
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Piedbois P, 2004, J CLIN ONCOL, V22, P3766, DOI 10.1200/JCO.2004.03.104
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Plotnikov A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77028-8
   SCHMID H, 1948, HELV CHIM ACTA, V31, P1497, DOI 10.1002/hlca.19480310608
   Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc1887
   Shahsavari Z, 2016, TUMOR BIOL, V37, P4479, DOI 10.1007/s13277-015-4258-5
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Wang CZ, 2015, NUTRIENTS, V7, P799, DOI 10.3390/nu7020799
   Yang D, 2015, CANCER CHEMOTH PHARM, V76, P575, DOI 10.1007/s00280-015-2749-0
   Yang YS, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2675-x
   Yu L, 2017, INT J MED SCI, V14, P356, DOI 10.7150/ijms.18382
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
NR 50
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAY
PY 2021
VL 26
IS 10
AR 3019
DI 10.3390/molecules26103019
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SI8CV
UT WOS:000655058900001
PM 34069385
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Pool, H
   Campos-Vega, R
   Herrera-Hernandez, MG
   Garcia-Solis, P
   Garcia-Gasca, T
   Sanchez, IC
   Luna-Barcenas, G
   Vergara-Castaneda, H
AF Pool, Hector
   Campos-Vega, Rocio
   Guadalupe Herrera-Hernandez, Maria
   Garcia-Solis, Pablo
   Garcia-Gasca, Teresa
   Sanchez, Isaac Cornelius
   Luna-Barcenas, Gabriel
   Vergara-Castaneda, Heyde
TI Development of genistein-PEGylated silica hybrid nanomaterials with
   enhanced antioxidant and antiproliferative properties on HT29 human
   colon cancer cells
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Colorectal cancer; genistein; PEGylated silica nanoparticles; hybrid
   nanomaterials; antiproliferative effects; mechanisms of programmed cell
   death
ID DRUG-DELIVERY; HYDROGEN-PEROXIDE; IN-VITRO; NANOPARTICLES; APOPTOSIS;
   ENCAPSULATION; AUTOPHAGY; TOXICITY; CAPACITY; RELEASE
AB The anticancer use of genistein (Gen) has been severely limited due to its low water solubility, low bioavailability, and instability under experimental conditions. To overcome these limitations, we propose a formulation of a hybrid nanomaterial (HNM) based upon the incorporation of Gen into PEGylated silica nanoparticles (PEG-SiNPs) (Gen-PEG-SiHNM), where their physicochemical and biological effects on HT29 cells were evaluated. Genistein-loaded PEGylated silica hybrid nanomaterials were obtained by a simple end effective aqueous dispersion method. Physicochemical properties were determined by its mean particle size, surface charge, amount of cargo, spectroscopic properties, release profiles and aqueous solubility. In vitro biological performance was carried out by evaluating its antioxidant capacity and elucidating its antiproliferative mechanistic. Results showed that small (ca. 33 nm) and spherical particles were obtained with positive surface charge (+9.54 mV). Infrared analyses determined that encapsulation of genistein was successfully achieved with an efficiency of 51%; it was observed that encapsulation process enhanced the aqueous dispersibility of genistein and cumulative release of genistein was pH-dependent. More important, after encapsulation data showed that Gen potentiated its antioxidant and antiproliferative effects on HT29 human colon cancer cells by the modulation of endogenous antioxidant enzymes and H2O2 production, which simultaneously activated two different processes of cell death (apoptosis and autophagy), unlike free genistein that only activated one (apoptosis) in a lower proportion. Overall, our data support that Gen-PEG-SiHNM could be potentially used as alternative treatment for colorectal cancer in a near future.
C1 [Pool, Hector; Luna-Barcenas, Gabriel] Inst Politecn Nacl, Unidad Queretaro, Ctr Invest & Estudios Avanzados CINVESTAV, Juriquilla 76230, Queretaro, Mexico.
   [Campos-Vega, Rocio] Univ Autonoma Queretaro, Fac Quim, Dept Invest & Posgrad Alimentos, Queretaro 76010, Mexico.
   [Guadalupe Herrera-Hernandez, Maria] INIFAP, Unidad Biotecnol, Campo Expt Bajio, Celaya 38110, Guanajuato, Mexico.
   [Garcia-Solis, Pablo; Vergara-Castaneda, Heyde] Univ Autonoma Queretaro, Fac Med, Dept Invest Biomed, Queretaro 76176, Queretaro, Mexico.
   [Garcia-Gasca, Teresa] Univ Autonoma Queretaro, Fac Ciencias Nat, Juriquilla 76230, Queretaro, Mexico.
   [Sanchez, Isaac Cornelius] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.
RP Pool, H (corresponding author), Inst Politecn Nacl, Unidad Queretaro, Ctr Invest & Estudios Avanzados CINVESTAV, Juriquilla 76230, Queretaro, Mexico.
EM gabriel.luna@cinvestav.mx; hayvergarac@gmail.com
RI Luna-Barcenas, Gabriel/B-7243-2016; Garcia-Solis, Pablo/B-8572-2013;
   Luna-Barcenas, Gabriel/B-4433-2011
OI Luna-Barcenas, Gabriel/0000-0002-1162-6928; Garcia-Solis,
   Pablo/0000-0002-7483-0555; Reyes Pool, Hector/0000-0002-6742-3839
FU National Council of Science and Technology (CONACYT) of MexicoConsejo
   Nacional de Ciencia y Tecnologia (CONACyT)
FX Authors would like to thank The National Council of Science and
   Technology (CONACYT) of Mexico for postdoctoral fellowships and partial
   support for this work. We also thank MSc Araceli Mauricio and MSc
   Lourdes Palma-Tirado for the technical support in DRIFT and TEM
   analyses, respectively.
CR Ahmed F, 2006, MOL PHARMACEUT, V3, P340, DOI 10.1021/mp050103u
   Akl MA, 2013, J NANOMED NANOTECHNO, V4
   Bielecki A, 2011, NUTR CANCER, V63, P139, DOI 10.1080/01635581.2010.516867
   Bishayee K, 2015, MOL CELLS, V38, P518, DOI 10.14348/molcells.2015.2339
   Bolling BW, 2012, J FOOD SCI, V77, pH69, DOI 10.1111/j.1750-3841.2011.02538.x
   Cancino J, 2013, TOXICOL LETT, V219, P18, DOI 10.1016/j.toxlet.2013.02.009
   Castillo PM, 2014, BEILSTEIN J NANOTECH, V5, P1312, DOI 10.3762/bjnano.5.144
   Chang PY, 2013, INT J ONCOL, V43, P1141, DOI 10.3892/ijo.2013.2050
   Chen BD, 2016, THERANOSTICS, V6, P1887, DOI 10.7150/thno.16358
   Chen F., 2013, FOOD SCI HUM WELL, V2, P124, DOI [10.1016/j.fshw.2013.06.001, DOI 10.1016/J.FSHW.2013.06.001]
   Choi JN, 2009, J MICROBIOL BIOTECHN, V19, P1348, DOI 10.4014/jmb.0903.0114
   Desai V, 2017, BIOMED RES INT, V2017, P1
   Di Felice G, 2017, INT J NANOMED, V12, P4493, DOI 10.2147/IJN.S134630
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Fantini M, 2015, INT J MOL SCI, V16, P9236, DOI 10.3390/ijms16059236
   Gao S, 2010, MINI-REV MED CHEM, V10, P550, DOI 10.2174/138955710791384081
   Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Hami Z, 2014, DARU, V22, DOI 10.1186/2008-2231-22-30
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hu H, 2011, J MATER CHEM, V21, P6576, DOI 10.1039/c0jm03915b
   Jeong Chul-Ho, 2016, J Cancer Prev, V21, P13, DOI 10.15430/JCP.2016.21.1.13
   Kim IY, 2015, NANOMED-NANOTECHNOL, V11, P1407, DOI 10.1016/j.nano.2015.03.004
   Lagoa R, 2011, BBA-BIOENERGETICS, V1807, P1562, DOI 10.1016/j.bbabio.2011.09.022
   Li Y, 2014, BIOMATERIALS, V35, P8467, DOI 10.1016/j.biomaterials.2014.06.032
   Lohan SB, 2015, EUR J PHARM BIOPHARM, V89, P201, DOI 10.1016/j.ejpb.2014.12.008
   Lopez-Lazaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029
   Lu CC, 2012, J MATER CHEM, V22, P19806, DOI 10.1039/c2jm34327d
   Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   Majoul N, 2015, APPL SURF SCI, V331, P388, DOI 10.1016/j.apsusc.2015.01.107
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   Meirow D, 2001, HUM REPROD UPDATE, V7, P535, DOI 10.1093/humupd/7.6.535
   Mileo AM, 2015, OXID MED CELL LONGEV, V2016, P1
   Mousa Shaker A, 2011, Cancers (Basel), V3, P2888, DOI 10.3390/cancers3032888
   Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017
   Ortiz R, 2012, RECENT PAT ANTI-CANC, V7, P297, DOI 10.2174/157489212801820093
   Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o
   Pandit NT, 2011, INDIAN J PHARM SCI, V73, P184, DOI 10.4103/0250-474X.91583
   Parhi P, 2012, DRUG DISCOV TODAY, V17, P1044, DOI 10.1016/j.drudis.2012.05.010
   Pinho E, 2014, CARBOHYD POLYM, V101, P121, DOI 10.1016/j.carbpol.2013.08.078
   Pool H, 2012, J NANOMATER, V2012, DOI 10.1155/2012/145380
   Pool H, 2013, FOOD FUNCT, V4, P162, DOI 10.1039/c2fo30042g
   Prietsch RF, 2014, MOL CELL BIOCHEM, V390, P235, DOI 10.1007/s11010-014-1974-x
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Si HY, 2010, J NANOSCI NANOTECHNO, V10, P2325, DOI 10.1166/jnn.2010.1913
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Teng X, 2015, J NANOSCI NANOTECHNO, V15, P3773, DOI 10.1166/jnn.2015.9270
   Tollis S, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-149
   Uskokovic V, 2012, BIOMATERIALS, V33, P1663, DOI 10.1016/j.biomaterials.2011.11.010
   Vergara-Castaneda H, 2016, J COLLOID INTERF SCI, V466, P44, DOI 10.1016/j.jcis.2015.12.011
   Wu JG, 2010, J CHEM ENG DATA, V55, P5286, DOI 10.1021/je100261w
   Wu TS, 2014, INHAL TOXICOL, V26, P128, DOI 10.3109/08958378.2013.871762
   Xie GP, 2010, ARCH TOXICOL, V84, P183, DOI 10.1007/s00204-009-0488-x
   Xu ZJ, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-015-2869-9
   Yamamoto T, 2007, J CONTROL RELEASE, V123, P11, DOI 10.1016/j.jconrel.2007.07.008
   Yang KC, 2009, MOL CARCINOGEN, V48, P420, DOI 10.1002/mc.20480
   Yu M, 2012, INT J MOL SCI, V13, P5554, DOI 10.3390/ijms13055554
   Zhu Q, 2011, MICROPOR MESOPOR MAT, V141, P199
   Zhu QL, 2002, NUTR CANCER, V42, P131, DOI 10.1207/S15327914NC421_18
   Zhu YF, 2011, MICROPOR MESOPOR MAT, V141, P199, DOI 10.1016/j.micromeso.2010.11.013
NR 62
TC 25
Z9 25
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 8
BP 2306
EP +
PG 19
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GS5QU
UT WOS:000443724100007
PM 30210672
DA 2022-04-25
ER

PT J
AU Yi, JY
   Jung, YJ
   Choi, SS
   Hwang, J
   Chung, E
AF Yi, Jae Youn
   Jung, Yu-Jin
   Choi, Sun Shim
   Hwang, Jungjin
   Chung, Eunkyung
TI Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Imiquimod; TLR7; Autophagy; Anti-tumoral activity; TNF-alpha; Apoptosis;
   Caco-2 cells
ID RESPONSE MODIFIER IMIQUIMOD; VIRAL RECOGNITION; DENDRITIC CELLS;
   CANCER-THERAPY; APOPTOSIS; DEATH; IMIDAZOQUINOLINES; CARCINOMA;
   INDUCTION; MELANOMA
AB Imiquimod (IMQ) is recognized as a topical immune response modifier compound that enhances immune responses with anti-viral and anti-tumoral activities. Its anti-tumoral effects have been previously demonstrated in a variety of cancer cells, and were identified as indirect responses mediated by the immune modulation Of cutaneous dendritic cells. Recently, the pro-apoptotic activities Of IMQ occuring Via the modulation of bcl-2 family have been reported in several tumor cells. In this Study, we first observed IMQ-initiated autophagy determined by vesicular organelle formation and the generation of LC3-II in Caco-2 human colonic adenocarcinoma cells, which expressing functional TLR7. Additionally, IMQ-induced autophagy resulted in cell death Occurring independently of molecular changes of apoptotic markers. Loxoribine also induced autophagy and autophagy-induced cell death at less potent than IMQ. Moreover. the activation of autophagy by rapamycin induced enhanced cell death in TNF-alphatreated Caco-2 cells, which were autophagy and cell death-resistant. Our results led LIS to Conclude that IMQ exerts a direct effect oil the anti-tumoral activity of Caco-2 cells via autophagy-induced cell death. In conclusion, the modulation of autophagy might be applied in a potential cancer therapy for (be treatment of colon cancer cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Chung, Eunkyung] Hallym Univ, Dept Biomed Sci, Chunchon 200702, South Korea.
   [Yi, Jae Youn] Korea Inst Radiol & Med Sci, Lab Modulat Radiobiol Response, Seoul 139706, South Korea.
   [Jung, Yu-Jin] Kangwon Natl Univ, Med & Biomat Res Ctr, Chunchon 200701, South Korea.
   [Jung, Yu-Jin] Kangwon Natl Univ, Dept Biol, Chunchon 200701, South Korea.
   [Choi, Sun Shim] Kangwon Natl Univ, Dept Mol & Med Biotechnol, Chunchon 200701, South Korea.
   [Hwang, Jungjin] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea.
RP Chung, E (corresponding author), Hallym Univ, Dept Biomed Sci, 39 Hallymdaehak Gil, Chunchon 200702, South Korea.
EM chungek@hallym.ac.kr
RI Hwang, Jung Jin/F-3424-2014
FU Korean Government MOEHRDMinistry of Education & Human Resources
   Development (MOEHRD), Republic of KoreaKorean Government
   [KRF-2006-003-C00220]; Nuclear Research Development Program of the Korea
   Science and Engineering Foundation KOSEFKorea Science and Engineering
   Foundation [M2070600005-08BO600-00510]; Korean Ministry of Science and
   TechnologyMinistry of Science and Technology (MOST) Korea [2007-00324]
FX This work was supported by the Korea Research Foundation Grant funded by
   the Korean Government (MOEHRD, Basic Research Promotion Fund,
   KRF-2006-003-C00220), Nuclear Research Development Program of the Korea
   Science and Engineering Foundation KOSEF (M2070600005-08BO600-00510),
   and National Nuclear Research & Development Program of the Korean
   Ministry of Science and Technology (2007-00324).
CR CHEN N, 2009, BIOCH BIOPH IN PRESS
   Cheng Y, 2008, BIOCHEM BIOPH RES CO, V376, P483, DOI 10.1016/j.bbrc.2008.09.018
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Garland SM, 2003, CURR OPIN INFECT DIS, V16, P85, DOI 10.1097/00001432-200304000-00004
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Iwasaki A, 2007, AUTOPHAGY, V3, P354, DOI 10.4161/auto.4114
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee JR, 2007, CLIN EXP DERMATOL, V32, P541, DOI 10.1111/j.1365-2230.2007.02453.x
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Meyer T, 2003, BRIT J DERMATOL, V149, P9, DOI 10.1046/j.0366-077X.2003.05632.x
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Schon MP, 2008, ONCOGENE, V27, P190, DOI 10.1038/sj.onc.1210913
   Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x
   Schon M, 2007, CURR MED CHEM, V14, P681, DOI 10.2174/092986707780059625
   Schon M, 2003, J NATL CANCER I, V95, P1138, DOI 10.1093/jnci/djg016
   Schon MP, 2004, J INVEST DERMATOL, V122, P1266, DOI 10.1111/j.0022-202X.2004.22528.x
   Schwartz MJ, 2009, UROLOGY, V73, P1156, DOI 10.1016/j.urology.2008.02.010
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   Smith EB, 2007, J UROLOGY, V177, P2347, DOI 10.1016/j.juro.2007.01.112
   Sullivan TP, 2003, DERMATOL SURG, V29, P1181, DOI 10.1111/j.1524-4725.2003.29399.x
   Vidal D, 2004, BRIT J DERMATOL, V151, P656, DOI 10.1111/j.1365-2133.2004.06094.x
NR 26
TC 27
Z9 28
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 28
PY 2009
VL 386
IS 3
BP 455
EP 458
DI 10.1016/j.bbrc.2009.06.046
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 474DH
UT WOS:000268262100008
PM 19527683
DA 2022-04-25
ER

PT J
AU Chen, YQ
   Gibson, SB
AF Chen, Yongqiang
   Gibson, Spencer B.
TI Three dimensions of autophagy in regulating tumor growth: cell
   survival/death, cell proliferation, and tumor dormancy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Autophagy; Cell survival; Cell death; Proliferation; Tumor dormacy;
   Tumor growth
ID STARVATION-INDUCED AUTOPHAGY; CANCER-CELLS; UROKINASE RECEPTOR;
   SUPPRESSES PROLIFERATION; PROSTATE-CANCER; HUMAN CARCINOMA;
   COLON-CANCER; DEATH; AMPK; MECHANISMS
AB Autophagy is an intracellular lysosomal degradation process involved in multiple facets of cancer biology. Various dimensions of autophagy are associated with tumor growth and cancer progression, and here we focus on the dimensions involved in regulation of cell survival/cell death, cell proliferation and tumor dormancy. The first dimension of autophagy supports cell survival under stress within tumors and under certain contexts drives cell death, impacting tumor growth. The second dimension of autophagy promotes proliferation through directly regulating cell cycle or indirectly maintaining metabolism, increasing tumor growth. The third dimension of autophagy facilitates tumor cell dormancy, contributing to cancer treatment resistance and cancer recurrence. The intricate relationship between these three dimensions of autophagy influences the extent of tumor growth and cancer progression. In this review, we summarize the roles of the three dimensions of autophagy in tumor growth and cancer progression, and discuss unanswered questions in these fields.
C1 [Chen, Yongqiang; Gibson, Spencer B.] Univ Manitoba, CancerCare Manitoba Res Inst, CancerCare Manitoba, Winnipeg, MB, Canada.
   [Gibson, Spencer B.] Univ Manitoba, Rady Fac Hlth Sci, Dept Biochem & Med Genet, Winnipeg, MB, Canada.
RP Chen, YQ (corresponding author), Univ Manitoba, CancerCare Manitoba Res Inst, CancerCare Manitoba, Winnipeg, MB, Canada.
EM ychen2@cancercare.mb.ca
RI Chen, Yongqiang/ABF-6081-2021
OI Chen, Yongqiang/0000-0003-2309-5674
FU CancerCare Manitoba Foundation
FX This work was supported by a grant from the CancerCare Manitoba
   Foundation awarded to S.B.G.
CR Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820
   Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863
   Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Chen J, 2018, J CELL BIOCHEM, V119, P2368, DOI 10.1002/jcb.26400
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen Y., 2017, SM J CANC SCI, V1, p1002S
   Chen YQ, 2021, AUTOPHAGY, DOI [10.6084/m9.figshare.16635159.v1, 10.1080/15548627.2021.1973338]
   Chen YQ, 2021, CANCERS, V13, DOI 10.3390/cancers13051038
   Chen YQ, 2016, AUTOPHAGY, V12, P1029, DOI 10.1080/15548627.2016.1164357
   Chen YQ, 2014, J BIOL CHEM, V289, P1164, DOI 10.1074/jbc.M113.526335
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Choi HK, 2018, J BONE MINER RES, V33, P2021, DOI 10.1002/jbmr.3530
   De Angelis ML, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00626
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   Dhimolea E, 2021, CANCER CELL, V39, P240, DOI 10.1016/j.ccell.2020.12.002
   Di Nardo A, 2014, HUM MOL GENET, V23, P3865, DOI 10.1093/hmg/ddu101
   Ding WX, 2015, AM J PHYSIOL-CELL PH, V308, pC246, DOI 10.1152/ajpcell.00375.2014
   Duan FS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64880-x
   Fukuda T, 2015, GYNECOL ONCOL, V137, P538, DOI 10.1016/j.ygyno.2015.03.053
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95
   Garnica P, 2019, EUR J MED CHEM, V175, P234, DOI 10.1016/j.ejmech.2019.04.074
   Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342
   Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hamurcu Z, 2018, J CANCER RES CLIN, V144, P415, DOI 10.1007/s00432-017-2557-5
   Han B, 2017, ONCOTARGET, V8, P86227, DOI 10.18632/oncotarget.21043
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He L, 2017, CELL PHYSIOL BIOCHEM, V44, P532, DOI 10.1159/000485089
   Hen O, 2020, SEMIN CANCER BIOL, V60, P157, DOI 10.1016/j.semcancer.2019.09.002
   Henson E, 2017, CANCERS, V9, DOI 10.3390/cancers9040027
   Huang W, 2019, CANCER MANAG RES, V11, P10275, DOI 10.2147/CMAR.S226828
   Inoue Kazushi, 2015, Sign Transduct Insights, V4, P1, DOI 10.4137/STI.S30306
   Jahangiri L, 2021, CANCERS, V13, DOI 10.3390/cancers13061239
   Jiang K, 2022, PROTEIN CELL, V13, P336, DOI 10.1007/s13238-020-00809-4
   Jung S, 2020, EXP MOL MED, V52, P921, DOI 10.1038/s12276-020-0455-4
   Jutten B, 2018, AUTOPHAGY, V14, P283, DOI 10.1080/15548627.2017.1409926
   Kajarabille N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194968
   Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651
   Kheloufi M, 2015, HEPATOLOGY, V62, P657, DOI 10.1002/hep.27597
   Kim TW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0930-1
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Law BYK, 2017, ONCOTARGET, V8, P30077, DOI 10.18632/oncotarget.15616
   Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8
   Li ZY, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000288
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Liang C, 2010, CELL DEATH DIFFER, V17, P1807, DOI 10.1038/cdd.2010.115
   Liao YN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1165-4
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009
   Linder B, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8040082
   Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7
   Liu J, 2020, DRUG DES DEV THER, V14, P1813, DOI 10.2147/DDDT.S239247
   Liu PF, 2017, CELL PHYSIOL BIOCHEM, V44, P728, DOI 10.1159/000485286
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Long M, 2020, SEMIN CANCER BIOL, V66, P12, DOI 10.1016/j.semcancer.2019.05.016
   Loukil Abdelhalim, 2015, World J Biol Chem, V6, P346, DOI 10.4331/wjbc.v6.i4.346
   Loukil A, 2014, J CELL SCI, V127, P2145, DOI 10.1242/jcs.139188
   Lv F, 2021, EUR J PHARMACOL, V900, DOI 10.1016/j.ejphar.2021.174069
   Ma SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182921
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051
   Mehrpour M., 2012, ATLAS GENET CYTOGENE, V16, P165
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Menon MB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00137
   Miller DR, 2021, DEV CELL, V56, P906, DOI 10.1016/j.devcel.2021.02.010
   Mohan N, 2016, MOL CANCER THER, V15, P1321, DOI 10.1158/1535-7163.MCT-15-0741
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090
   Nah J, 2020, J CLIN INVEST, V130, P2978, DOI 10.1172/JCI132366
   Nahm JH, 2020, CANCER RES TREAT, V52, P1273, DOI 10.4143/crt.2020.032
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Noguchi M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2724-5
   Pan HJ, 2016, BMC BIOCHEM, V17, DOI 10.1186/s12858-016-0069-6
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ranganathan AC, 2006, CANCER BIOL THER, V5, P729, DOI 10.4161/cbt.5.7.2968
   Recasens A, 2019, TRENDS PHARMACOL SCI, V40, P128, DOI 10.1016/j.tips.2018.12.004
   Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018
   Ribatti D, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100773
   Rossari F, 2020, CELL ONCOL, V43, P155, DOI 10.1007/s13402-019-00467-7
   Schaaf MB, 2019, CELL DEATH DIFFER, V26, P665, DOI 10.1038/s41418-019-0287-8
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Sencan S, 2021, MOL CELL BIOCHEM, V476, P2075, DOI 10.1007/s11010-021-04063-y
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Sosa MS, 2013, ADV EXP MED BIOL, V734, P73, DOI 10.1007/978-1-4614-1445-2_5
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Talukdar S, 2019, ADV CANCER RES, V141, P43, DOI 10.1016/bs.acr.2018.12.002
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Torisu K, 2016, AGING CELL, V15, P187, DOI 10.1111/acel.12423
   Vera-Ramirez L, 2020, SEMIN CANCER BIOL, V60, P28, DOI 10.1016/j.semcancer.2019.07.027
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vuppalapati KK, 2015, J BONE MINER RES, V30, P2249, DOI 10.1002/jbmr.2575
   Wang CR, 2013, NAT NEUROSCI, V16, P532, DOI 10.1038/nn.3365
   Wang JY, 2012, J NEURO-ONCOL, V106, P473, DOI 10.1007/s11060-011-0692-4
   Webber JL, 2010, AUTOPHAGY, V6, P292, DOI 10.4161/auto.6.2.11128
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Weidenfeld K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00381
   Wu SY, 2018, HEPATOLOGY, V68, P141, DOI 10.1002/hep.29781
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1113-9
   Xu C, 2019, ONCOGENE, V38, P1832, DOI 10.1038/s41388-018-0556-x
   Xu M, 2018, BBA-MOL BASIS DIS, V1864, P3605, DOI 10.1016/j.bbadis.2018.08.024
   Xu W, 2018, CELL PHYSIOL BIOCHEM, V46, P226, DOI 10.1159/000488425
   Yan YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37052
   Yang JL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.574720
   Yang XH, 2018, CANCER BIOL THER, V19, P706, DOI 10.1080/15384047.2018.1451277
   Ye CL, 2018, ONCOL LETT, V15, P3221, DOI 10.3892/ol.2017.7667
   Yeh AC, 2015, CANCER RES, V75, P5014, DOI 10.1158/0008-5472.CAN-15-1370
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]
   Yu C, 2020, HAEMATOLOGICA, V105, P1285, DOI 10.3324/haematol.2018.212027
   Zhang JH, 2015, REDOX BIOL, V4, P242, DOI 10.1016/j.redox.2015.01.003
   Zhang SJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.656554
   Zheng K, 2019, THERANOSTICS, V9, P104, DOI 10.7150/thno.30308
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 136
TC 1
Z9 1
U1 12
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD DEC 1
PY 2021
VL 1867
IS 12
AR 166265
DI 10.1016/j.bbadis.2021.166265
EA SEP 2021
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA US0VF
UT WOS:000697154300019
PM 34487813
DA 2022-04-25
ER

PT J
AU Lan, L
   Appelman, C
   Smith, AR
   Yu, J
   Larsen, S
   Marquez, RT
   Liu, H
   Wu, XQ
   Gao, P
   Roy, A
   Anbanandam, A
   Gowthaman, R
   Karanicolas, J
   De Guzman, RN
   Rogers, S
   Aube, J
   Ji, M
   Cohen, RS
   Neufeld, KL
   Xu, L
AF Lan, Lan
   Appelman, Carl
   Smith, Amber R.
   Yu, Jia
   Larsen, Sarah
   Marquez, Rebecca T.
   Liu, Hao
   Wu, Xiaoqing
   Gao, Philip
   Roy, Anuradha
   Anbanandam, Asokan
   Gowthaman, Ragul
   Karanicolas, John
   De Guzman, Roberto N.
   Rogers, Steven
   Aube, Jeffrey
   Ji, Min
   Cohen, Robert S.
   Neufeld, Kristi L.
   Xu, Liang
TI Natural product (-)-gossypol inhibits colon cancer cell growth by
   targeting RNA-binding protein Musashi-1
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE RNA binding protein; Wnt; Notch; Musashi-1; Colon cancer
ID STEM-CELL; IN-VITRO; PROSTATE-CANCER; EXPRESSION; GOSSYPOL; MARKER;
   FAMILY; IDENTIFICATION; PROLIFERATION; APOPTOSIS
AB Musashi-1 (MSI1) is an RNA-binding protein that acts as a translation activator or repressor of target mRNAs. The best-characterized MSI1 target is Numb mRNA, whose encoded protein negatively regulates Notch signaling. Additional MSI1 targets include the mRNAs for the tumor suppressor protein APC that regulates Wnt signaling and the cyclin-dependent kinase inhibitor P21(WAF-1). We hypothesized that increased expression of NUMB, P21 and APC, through inhibition of MSI1 RNA-binding activity might be an effective way to simultaneously downregulate Wnt and Notch signaling, thus blocking the growth of a broad range of cancer cells. We used a fluorescence polarization assay to screen for small molecules that disrupt the binding of MSI1 to its consensus RNA binding site. One of the top hits was (-)-gossypol (Ki = 476 +/- 273 nM), a natural product from cottonseed, known to have potent anti-tumor activity and which has recently completed Phase IIb clinical trials for prostate cancer. Surface plasmon resonance and nuclear magnetic resonance studies demonstrate a direct interaction of (-)-gossypol with the RNA binding pocket of MSI1. We further showed that (-)-gossypol reduces Notch/Wnt signaling in several colon cancer cell lines having high levels of MSI1, with reduced SURVIVIN expression and increased apoptosis/autophagy. Finally, we showed that orally administered (-)-gossypol inhibits colon cancer growth in a mouse xenograft model. Our study identifies (-)-gossypol as a potential small molecule inhibitor of MSI1-RNA interaction, and suggests that inhibition of MSI1's RNA binding activity may be an effective anti-cancer strategy. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Lan, Lan; Appelman, Carl; Smith, Amber R.; Yu, Jia; Larsen, Sarah; Marquez, Rebecca T.; Liu, Hao; Wu, Xiaoqing; Gowthaman, Ragul; Karanicolas, John; De Guzman, Roberto N.; Neufeld, Kristi L.; Xu, Liang] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.
   [Gao, Philip] Univ Kansas, COBRE Prot Prod Grp, Lawrence, KS 66045 USA.
   [Roy, Anuradha] Univ Kansas, High Throughput Screening Lab, Lawrence, KS 66045 USA.
   [Anbanandam, Asokan] Univ Kansas, BioNMR Core Facil, Lawrence, KS 66045 USA.
   [Gowthaman, Ragul; Karanicolas, John] Univ Kansas, Ctr Bioinformat, Lawrence, KS 66045 USA.
   [Rogers, Steven; Aube, Jeffrey] Univ Kansas, Ctr Canc Expt Therapeut, Ctr Biomed Res Excellence, Lawrence, KS 66045 USA.
   [Aube, Jeffrey] Univ Kansas, Specialized Chem Ctr, Lawrence, KS 66045 USA.
   [Aube, Jeffrey] Univ Kansas, Ctr Chem Methodol & Lib Dev, Lawrence, KS 66045 USA.
   [Aube, Jeffrey] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA.
   [Ji, Min] Southeast Univ, Sch Chem & Chem Engn, Nanjing, Jiangsu, Peoples R China.
   [Cohen, Robert S.] Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA.
   [Xu, Liang] Univ Kansas, Ctr Canc, Dept Radiat Oncol, Kansas City, KS USA.
RP Xu, L (corresponding author), Univ Kansas, Dept Mol Biosci, 4002 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.
EM xul@ku.edu
RI Wu, Xiaoqing/D-3569-2016; LAN, LAN/N-8872-2018; Liu, Hao/J-1911-2014
OI Wu, Xiaoqing/0000-0003-2076-4107; Liu, Hao/0000-0003-2343-4998; Roy,
   Anuradha/0000-0002-1057-1443; Neufeld, Kristi/0000-0003-3653-9385;
   Gowthaman, Ragul/0000-0002-0008-6401; Aube, Jeffrey/0000-0003-1049-5767
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA178831];
   K-INBRE Bridging Grant [P20 GM103418]; Kansas Bioscience Authority
   Rising Star Award; University of Kansas Cancer Center Pilot Grant; NIH
   COBRE at KU CCET Pilot Project [P30 RR030926]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01 AI074856]; University of Kansas Bold Aspiration Strategic
   Initiative Award; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA178831] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [P30RR030926] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI074856] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P20GM103418,
   P30GM110761] Funding Source: NIH RePORTER
FX This study was supported in part by National Institutes of Health grant
   R01 CA178831 (to L. X., K. N., J. A.), K-INBRE (P20 GM103418) Bridging
   Grant; Kansas Bioscience Authority Rising Star Award, and University of
   Kansas Cancer Center Pilot Grant (to L. X.); NIH COBRE at KU CCET Pilot
   Project (P30 RR030926 to K. N.), NIH R01 AI074856 (to R. N. D.), and the
   University of Kansas Bold Aspiration Strategic Initiative Award (to L.
   X. and K. N.). The sponsors had no role in the study design, in the
   collection, analysis, and interpretation of data.
CR Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956
   Battelli C, 2006, MOL CELL NEUROSCI, V31, P85, DOI 10.1016/j.mcn.2005.09.003
   Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999
   Charlesworth A, 2006, EMBO J, V25, P2792, DOI 10.1038/sj.emboj.7601159
   Cheng Qiuying, 2012, Int J Biochem Mol Biol, V3, P179
   Clingman CC, 2014, ELIFE, V3, DOI 10.7554/eLife.02848
   COYLE T, 1994, J NEURO-ONCOL, V19, P25, DOI 10.1007/BF01051046
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Estrada DF, 2009, J BIOL CHEM, V284, P8645, DOI 10.1074/jbc.M808081200
   Fan LF, 2010, INT J COLORECTAL DIS, V25, P17, DOI 10.1007/s00384-009-0791-2
   Harper S, 2011, METHODS MOL BIOL, V681, P259, DOI 10.1007/978-1-60761-913-0_14
   Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001
   Johnson Bruce A, 2004, Methods Mol Biol, V278, P313
   Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435
   Kawahara H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199166
   Keshmiri-Neghab H, 2014, PHARM BIOL, V52, P124, DOI 10.3109/13880209.2013.832776
   Ko CH, 2007, INT J CANCER, V121, P1670, DOI 10.1002/ijc.22910
   Kuwako K, 2010, NEURON, V67, P407, DOI 10.1016/j.neuron.2010.07.005
   Li DW, 2011, ANN SURG ONCOL, V18, P2074, DOI 10.1245/s10434-011-1567-9
   Li L., 2014, GASTROENTEROLOGY
   Li L, 2013, CLIN CANCER RES, V19, P6703, DOI 10.1158/1078-0432.CCR-13-0621
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7
   Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333
   Minuesa G, 2014, COMB CHEM HIGH T SCR, V17, P596, DOI 10.2174/1386207317666140609122714
   Miyanoiri Y, 2003, J BIOL CHEM, V278, P41309, DOI 10.1074/jbc.M306210200
   Mohammad RM, 2005, PANCREAS, V31, P317, DOI 10.1097/01.mpa.0000179731.46210.01
   Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ohyama T, 2012, NUCLEIC ACIDS RES, V40, P3218, DOI 10.1093/nar/gkr1139
   Okano H, 2005, EXP CELL RES, V306, P349, DOI 10.1016/j.yexcr.2005.02.021
   Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551
   Pagano JM, 2011, RNA, V17, P14, DOI 10.1261/rna.2428111
   Paoluzzi L, 2008, BLOOD, V111, P5350, DOI 10.1182/blood-2007-12-129833
   Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140
   Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x
   Rezza A, 2010, J CELL SCI, V123, P3256, DOI 10.1242/jcs.065284
   Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130
   Seigel GM, 2007, MOL VIS, V13, P823
   Siddall NA, 2006, P NATL ACAD SCI USA, V103, P8402, DOI 10.1073/pnas.0600906103
   Spears E, 2011, J BIOL CHEM, V286, P4946, DOI 10.1074/jbc.C110.205922
   Sugiyama-Nakagiri Y, 2006, AM J PATHOL, V168, P80, DOI 10.2353/ajpath.2006.050469
   Sureban SM, 2008, GASTROENTEROLOGY, V134, P1448, DOI 10.1053/j.gastro.2008.02.057
   Takahashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053540
   The Regents of the University of Michigan Georgetown University, 2012, Patent No. [US8163805, 8163805, 8163805 B2]
   Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034
   Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221
   Wolter KG, 2006, NEOPLASIA, V8, P163, DOI 10.1593/neo.05691
   Wu XQ, 2010, BIOORGAN MED CHEM, V18, P3812, DOI 10.1016/j.bmc.2010.04.046
   Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108
   Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475
   Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X
   Zhang XQ, 2010, ASIAN J ANDROL, V12, P390, DOI 10.1038/aja.2009.87
NR 55
TC 74
Z9 77
U1 5
U2 49
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD AUG
PY 2015
VL 9
IS 7
BP 1406
EP 1420
DI 10.1016/j.molonc.2015.03.014
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP4XB
UT WOS:000359884800015
PM 25933687
OA Green Accepted, hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Zheng, F
   Yang, WJ
   Sun, KJ
   Wan, XM
   Man, N
   Wen, LP
AF Zheng, Fang
   Yang, Wen-Jun
   Sun, Ke-Jing
   Wan, Xiao-Mei
   Man, Na
   Wen, Long-Ping
TI Hoechst 33342-induced autophagy protected HeLa cells from
   caspase-independent cell death with the participation of ROS
SO FREE RADICAL RESEARCH
LA English
DT Article
DE Hoechst 33342; autophagy; caspase-independent cell death; ROS
ID MALIGNANT GLIOMA-CELLS; 33342 INDUCES APOPTOSIS; COLON-CANCER CELLS; I
   IN-VIVO; ARSENIC TRIOXIDE; MACROAUTOPHAGY; INDUCTION; GENES; DEGRADATION
AB Autophagy, an evolutionarily-conserved intracellular organelle and protein degradation process, may exhibit drastically different effects on cell survival depending on the particular environmental and culturing conditions. Hoechst 33342 (HO), a fluorescent dye widely used for staining DNA, has been reported to induce apoptosis in mammalian cells. Here we showed that, in addition to caspase-independent cell death, HO also induced autophagy in HeLa cells, as evidenced by the accumulation of autophagosomes, LC3 form conversion and LC3 puncta formation in a cell line stably expressing GFP-LC3. HO treatment led to generation of reactive oxygen species (ROS), and inhibition of ROS with N-acetyl-L-cysteine (NAC) abrogated both autophagy and caspase-independent cell death. Finally, autophagy played a protective role against caspase-independent cell death, as cell death induced by HO was enhanced under pharmacological and siRNA-mediated genetic inhibition of autophagy.
C1 [Wen, Long-Ping] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
   [Wen, Long-Ping] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China.
RP Wen, LP (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
EM manna@mail.ustc.edu.cn; lpwen@ustc.edu.cn
OI Wen, Longping/0000-0003-0384-4578
FU Chinese Ministry of Sciences [2007CB935800, 2010CB912804]; Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [30721002, 31071211, 30830036, 31170966, 31101020]; Chinese
   Academy of SciencesChinese Academy of Sciences [KSCX2-YW-R-139];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [WK2070000008]; Scientific
   and Technological Major Special Project [2009ZX09103-650]
FX We thank Noboru Mizushima for providing LC3 plasmid. This work was
   supported by grants from the Chinese Ministry of Sciences 973 Program
   (2007CB935800, 2010CB912804), Natural Science Foundation of China
   (#30721002, #31071211, #30830036, #31170966, #31101020), Knowledge
   Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-139),
   the Fundamental Research Funds for the Central Universities
   (WK2070000008) and Scientific and Technological Major Special Project
   (2009ZX09103-650).
CR Bergmann A, 2007, CELL, V131, P1032, DOI 10.1016/j.cell.2007.11.027
   Chen Y, 2005, BIOCHEM BIOPH RES CO, V337, P52, DOI 10.1016/j.bbrc.2005.09.018
   Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8
   KIECHLE FL, 1999, ARAB J LAB MED, V25, P151
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013
   L'hoste S, 2009, FREE RADICAL BIO MED, V46, P1017, DOI 10.1016/j.freeradbiomed.2008.12.009
   Lee SJ, 2011, AM J RESP CELL MOL, V45, P867, DOI 10.1165/rcmb.2010-0352OC
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Loos B, 2009, AUTOPHAGY, V5, P590, DOI 10.4161/auto.5.5.8479
   Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761
   Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Orvedahl A, 2010, CELL HOST MICROBE, V7, P115, DOI 10.1016/j.chom.2010.01.007
   Ou Y, 2009, CHEM-BIOL INTERACT, V179, P103, DOI 10.1016/j.cbi.2008.10.039
   Paglin S, 2001, CANCER RES, V61, P439
   Paris I, 2011, TOXICOL SCI, V121, P376, DOI 10.1093/toxsci/kfr060
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tzeng YW, 2010, FREE RADICAL BIO MED, V49, P839, DOI 10.1016/j.freeradbiomed.2010.06.004
   Wallington-Beddoe CT, 2011, AUTOPHAGY, V7, P707, DOI 10.4161/auto.7.7.15154
   Wang YJ, 2008, J BIOL CHEM, V283, P4766, DOI 10.1074/jbc.M706666200
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang XB, 1999, ARCH PATHOL LAB MED, V123, P921
   Zhang XB, 1998, J CLIN LIGAND ASSAY, V21, P62
   Zhang XB, 1997, ANN CLIN LAB SCI, V27, P260
NR 39
TC 3
Z9 3
U1 2
U2 21
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-5762
J9 FREE RADICAL RES
JI Free Radic. Res.
PD JUN
PY 2012
VL 46
IS 6
BP 740
EP 749
DI 10.3109/10715762.2012.670701
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 939RW
UT WOS:000303832700004
PM 22375792
DA 2022-04-25
ER

PT J
AU Was, H
   Barszcz, K
   Czarnecka, J
   Kowalczyk, A
   Bernas, T
   Uzarowska, E
   Koza, P
   Klejman, A
   Piwocka, K
   Kaminska, B
   Sikora, E
AF Was, Halina
   Barszcz, Kamila
   Czarnecka, Joanna
   Kowalczyk, Agata
   Bernas, Tytus
   Uzarowska, Ewelina
   Koza, Paulina
   Klejman, Agata
   Piwocka, Katarzyna
   Kaminska, Bozena
   Sikora, Eva
TI Bafilomycin A1 triggers proliferative potential of senescent cancer
   cells in vitro and in NOD/SCID mice
SO ONCOTARGET
LA English
DT Article
DE colon cancer; chemotherapy; senescence; autophagy; angiogenesis
ID ACCELERATED CELLULAR SENESCENCE; ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS;
   SELF-RENEWAL; MITOTIC CATASTROPHE; BETA-GALACTOSIDASE; CYCLE ARREST;
   TUMOR-CELLS; AUTOPHAGY; POLYPLOIDY
AB Anticancer therapies that induce DNA damage tend to trigger senescence in cancer cells, a process known as therapy-induced senescence (TIS). Such cells may undergo atypical divisions, thus contributing to tumor re-growth. Accumulation of senescent cancer cells reduces survival of patients after chemotherapy. As senescence interplays with autophagy, a dynamic recycling process, we sought to study whether inhibition of autophagy interferes with divisions of TIS cells. We exposed human colon cancer HCT116 cells to repeated cycles of a chemotherapeutic agent doxorubicin (doxo) and demonstrated induction of hallmarks of TIS (e.g. growth arrest, hypertrophy, poliploidization and secretory phenotype) and certain properties of cancer stem cells (increased NANOG expression, percentages of CD24+ cells and side population). Colonies of small and highly proliferative progeny appeared shortly after drug removal. Treatment with bafilomycin A1 (BAF A1), an autophagy inhibitor, postponed short term in vitro cell re-population. It was associated with reduction in the number of diploid and increase in the number of poliploid cells. In a long term, a pulse of BAF A1 resulted in reactivation of autophagy in a subpopulation of HCT116 cells and increased proliferation. Accordingly, the senescent HCT116 cells treated with BAF A1 when injected into NOD/SCID mice formed tumors, in contrast to the controls.
   Our results suggest that senescent cancer cells that appear during therapy, can be considered as dormant cells that contribute to cancer re-growth, when chemotherapeutic treatment is stopped. These data unveil new mechanisms of TIS-related cancer maintenance and re-population, triggered by a single pulse of BAF A1 treatment.
C1 [Was, Halina; Barszcz, Kamila; Czarnecka, Joanna; Sikora, Eva] Polish Acad Sci, Nencki Inst Expt Biol, Lab Mol Basis Ageing, PL-02093 Warsaw, Poland.
   [Was, Halina; Barszcz, Kamila; Czarnecka, Joanna; Kaminska, Bozena] Polish Acad Sci, Nencki Inst Expt Biol, Mol Neurobiol Lab, PL-02093 Warsaw, Poland.
   [Kowalczyk, Agata; Piwocka, Katarzyna] Polish Acad Sci, Nencki Inst Expt Biol, Lab Cytometry, PL-02093 Warsaw, Poland.
   [Bernas, Tytus] Polish Acad Sci, Nencki Inst Expt Biol, Lab Imaging Tissue Struct & Funct, PL-02093 Warsaw, Poland.
   [Uzarowska, Ewelina; Koza, Paulina; Klejman, Agata] Polish Acad Sci, Nencki Inst Expt Biol, Lab Anim Models, PL-02093 Warsaw, Poland.
   [Koza, Paulina] Polish Acad Sci, Nencki Inst Expt Biol, Neurobiol Lab, PL-02093 Warsaw, Poland.
RP Was, H (corresponding author), Polish Acad Sci, Nencki Inst Expt Biol, Lab Mol Basis Ageing, PL-02093 Warsaw, Poland.; Was, H (corresponding author), Polish Acad Sci, Nencki Inst Expt Biol, Mol Neurobiol Lab, PL-02093 Warsaw, Poland.
EM h.was@nencki.gov.pl
RI Klejman, Agata/AAC-1844-2021; Kaminska, Bozena/B-2915-2014; Kaminska,
   Bozena/H-4592-2011; Czarnecka-Herok, Joanna/ABD-8148-2020
OI Klejman, Agata/0000-0001-6083-9957; Kaminska,
   Bozena/0000-0002-2642-4616; Sikora, Ewa/0000-0002-1111-1748; Piwocka,
   Katarzyna/0000-0001-6676-5282; Koza, Paulina/0000-0001-8311-4027; Was,
   Halina/0000-0003-2743-0337; Kominek, Agata/0000-0003-1567-9442;
   Czarnecka-Herok, Joanna/0000-0002-7287-3615
FU Foundation for Polish ScienceFoundation for Polish ScienceEuropean
   Commission; European Union under the European Social Fund
   [125/UD/SKILLS/2013]; Ministry of Science and Higher EducationMinistry
   of Science and Higher Education, PolandEuropean Commission [IP2012
   062172]; National Science CenterNational Science Centre, Poland
   [2013/09/B/NZ3/01389, 2012/05/E/ST2/02180]; EU FP7 Project BIO-IMAGINE:
   BIO-IMAGing in research INnovation and Education [264173]; Ministry of
   Science and Higher EducationMinistry of Science and Higher Education,
   PolandEuropean Commission
FX This work was supported by the Foundation for Polish Science co-financed
   by the European Union under the European Social Fund (grant
   125/UD/SKILLS/2013), the Ministry of Science and Higher Education (grant
   IP2012 062172), and the National Science Center (grants
   2013/09/B/NZ3/01389 and 2012/05/E/ST2/02180). H.W. is the recipient of a
   fellowship from EU FP7 Project BIO-IMAGINE: BIO-IMAGing in research
   INnovation and Education, GA No. 264173 that was obtained by Nencki
   Institute of Experimental Biology. H.W. is the recipient of a
   scholarship for young and outstanding investigators from the Ministry of
   Science and Higher Education.
CR Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Blagosklonny MV, 2012, AGING-US, V4, P159, DOI 10.18632/aging.100443
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Elmore LW, 2005, CLIN CANCER RES, V11, P2637, DOI 10.1158/1078-0432.CCR-04-1462
   Erenpreisa J, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-92
   Erenpreisa J, 2011, CELL BIOL INT, V35, P687, DOI 10.1042/CBI20100762
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Gerashchenko BI, 2016, HISTOCHEM CELL BIOL, V145, P497, DOI 10.1007/s00418-016-1415-x
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Gewirtz DA, 2014, J CELL PHYSIOL, V229, P6, DOI 10.1002/jcp.24420
   Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922
   Gire V, 2015, CELL CYCLE, V14, P297, DOI 10.1080/15384101.2014.1000134
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hasan MR, 2011, INT J CANCER, V129, P2115, DOI 10.1002/ijc.26179
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Ivanov A, 2013, J CELL BIOL, V202, P129, DOI 10.1083/jcb.201212110
   Jones KA, 2016, NEURO-ONCOLOGY, V18, P667, DOI 10.1093/neuonc/nov243
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Krtolica A, 2003, Adv Gerontol, V11, P109
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Kurz DJ, 2000, J CELL SCI, V113, P3613
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Leontieva OV, 2013, CELL CYCLE, V12, P3063, DOI 10.4161/cc.26130
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Rajaraman R, 2005, CELL BIOL INT, V29, P1084, DOI 10.1016/j.cellbi.2005.10.003
   Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Singh R, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-4
   Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011
   Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663
   te Poele RH, 2002, CANCER RES, V62, P1876
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Wang Q, 2013, INT J CANCER, V132, P1505, DOI 10.1002/ijc.27810
   Wang Q, 2011, INT J CANCER, V128, P1546, DOI 10.1002/ijc.25482
   Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033
   Weichert W, 2005, CLIN CANCER RES, V11, P6574, DOI 10.1158/1078-0432.CCR-05-0606
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wu P. C., 2012, Experimental Oncology, V34, P298
   Wu PC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.47
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Young ARJ, 2010, CURR OPIN CELL BIOL, V22, P234, DOI 10.1016/j.ceb.2009.12.005
   Zhang D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/432652
   Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96
   Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319
NR 70
TC 26
Z9 26
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 7
PY 2017
VL 8
IS 6
BP 9303
EP 9322
DI 10.18632/oncotarget.14066
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EK8NX
UT WOS:000394181800035
PM 28030837
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Manogaran, P
   Somasundaram, B
   Viswanadha, VP
AF Manogaran, Prasath
   Somasundaram, Bharath
   Viswanadha, Vijaya Padma
TI Reversal of cisplatin resistance by neferine/isoliensinine and their
   combinatorial regimens with cisplatin-induced apoptosis in
   cisplatin-resistant colon cancer stem cells (CSCs)
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE cisplatin resistant colon cancer stem cells (CSCs); colorectal cancer
   (CRC); isoliensinine; neferine; PI3K; pAKT; mTOR & apoptosis
ID PI3K/AKT/MTOR PATHWAY; MULTIDRUG-RESISTANCE; IN-VITRO; NEFERINE;
   CURCUMIN; AUTOPHAGY; GEFITINIB; BLOCKADE
AB Cisplatin chemotherapy to the colorectal cancer cells (CRCs) is accompanied by dose-limiting adverse effects along with the acquisition of drug resistance implicating low therapeutic outcomes. The present study is aimed to evaluate the chemosensitizing efficacy of neferine/isoliensinine or combinatorial regimen of neferine/isoliensinine with cisplatin against CSCs (cisplatin resistant colon stem cells). CSCs were developed using pulse exposure of cisplatin to parental HCT-15 cells. Neferine/isoliensinine or combinatorial regimens of Neferine/isoliensinine and cisplatin exhibited a stronger cytotoxic activity against CSCs compared to control. IC50 doses were found to be 6.5 mu M for neferine, 12.5 mu M for isoliensinine, and 120 mu M for cisplatin respectively. Furthermore, the combinatorial regimen of a low dose of cisplatin (40 mu M) with 4 mu M neferine/8 mu M isoliensinine induced cell death in a synergistic manner as described by isobologram. Neferine/isoliensinine could confer extensive intracellular reactive oxygen species generation in CSCs. Neferine/isoliensinine or combinatorial regimens dissipated mitochondrial membrane potential and enhanced intracellular [Ca2+]i, which were measured by spectroflurimetry. Furthermore, these combinatorial regimens induced a significant increase in the sub G0 phase of cell cycle arrest and PI uptake and alleviated the expression of ERCC1 in CSCs. Combinatorial regimens or neferine/isoliensinine treatments downregulated the cell survival protein expression (PI3K/pAkt/mTOR) and activated mitochondria-mediated apoptosis by upregulating Bax, cytochrome c, caspase-3, and PARP cleavage expression while downregulating the BCl-2 expression in CSCs. Our study confirms the chemosensitizing efficacy of neferine/isoliensinine or combinatorial regimens of neferine/isoliensinine with a low dose of cisplatin against CSCs.
C1 [Manogaran, Prasath; Somasundaram, Bharath; Viswanadha, Vijaya Padma] Bharathiar Univ, Dept Biotechnol, Translat Res Lab, Coimbatore 641046, Tamil Nadu, India.
RP Viswanadha, VP (corresponding author), Bharathiar Univ, Dept Biotechnol, Translat Res Lab, Coimbatore 641046, Tamil Nadu, India.
EM vvijayapadma@rediffmail.com
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR) [2017-3490/SCR-BMS]
FX Indian Council of Medical Research, Grant/Award Number: File no.
   2017-3490/SCR-BMS
CR Baskaran R, 2016, BIOFACTORS, V42, P407, DOI 10.1002/biof.1286
   Berghmans T, 2017, Rev Med Brux, V38, P175
   Cavazzoni A, 2012, CANCER LETT, V323, P77, DOI 10.1016/j.canlet.2012.03.034
   Chan MM, 2018, CANCER LETT, V433, P53, DOI 10.1016/j.canlet.2018.06.034
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Chen Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060572
   Cho Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00764
   Coombs MRP, 2016, CANCER LETT, V380, P424, DOI 10.1016/j.canlet.2016.06.023
   Janmaat ML, 2003, CLIN CANCER RES, V9, P2316
   Jaudan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191523
   Jiao LJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46524
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lu WD, 2013, CLINICS, V68, P694, DOI 10.6061/clinics/2013(05)18
   Manogaran P, 2021, CANCER INVEST, V39, P349, DOI 10.1080/07357907.2021.1894569
   Matsui, 2016, MEDICINE, V95, P8
   Morgan RG, 2018, BRIT J CANCER, V118, P1410, DOI 10.1038/s41416-018-0118-6
   O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Poornima P, 2014, FOOD CHEM TOXICOL, V68, P87, DOI 10.1016/j.fct.2014.03.008
   Poornima P, 2013, FOOD CHEM, V141, P3598, DOI 10.1016/j.foodchem.2013.05.138
   Poornima P, 2013, FOOD CHEM, V136, P659, DOI 10.1016/j.foodchem.2012.07.112
   Raghavan S, 2015, BIOORG MED CHEM LETT, V25, P3601, DOI 10.1016/j.bmcl.2015.06.068
   Ramasamy TS, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0241-x
   Ranjan A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204981
   Rayburn Elizabeth R, 2009, Mol Cell Pharmacol, V1, P29
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sivalingam KS, 2017, J CELL BIOCHEM, V118, P2865, DOI 10.1002/jcb.25937
   Skarkova V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030234
   Song BC, 2013, J SURG RES, V185, P399, DOI 10.1016/j.jss.2013.05.093
   Takebe N, 2010, CLIN CANCER RES, V16, P3106, DOI 10.1158/1078-0432.CCR-09-2934
   Tang XQ, 2005, ACTA PHARMACOL SIN, V26, P1009, DOI 10.1111/j.1745-7254.2005.00149.x
   Tong YX, 2019, EXP THER MED, V18, P3793, DOI 10.3892/etm.2019.8027
   Tsai MS, 2011, MOL PHARMACOL, V80, P136, DOI 10.1124/mol.111.071316
   Wang M, 2019, INT J BIOL SCI, V15, P1200, DOI 10.7150/ijbs.33710
   Wang SH, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2300-z
   Xiong YQ, 2003, ACTA PHARMACOL SIN, V24, P332
   Xu LM, 2016, TUMOR BIOL, V37, P8721, DOI 10.1007/s13277-015-4737-8
   Yano S, 2006, J AGR FOOD CHEM, V54, P5203, DOI 10.1021/jf0607361
   Yilmazer Acelya, 2018, Biotechnology Reports, V17, P24, DOI 10.1016/j.btre.2017.11.004
   Zhao ZQ, 2016, ONCOL LETT, V12, P63, DOI 10.3892/ol.2016.4606
   Zhou J, 2013, TOXICOL LETT, V222, P139, DOI 10.1016/j.toxlet.2013.07.022
NR 41
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD MAR
PY 2022
VL 36
IS 3
AR e22967
DI 10.1002/jbt.22967
EA DEC 2021
PG 18
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA ZS3SP
UT WOS:000731265600001
PM 34921482
DA 2022-04-25
ER

PT J
AU Guo, BQ
   Xiong, XP
   Hasani, S
   Wen, YA
   Li, AT
   Martinez, R
   Skaggs, AT
   Gao, TY
AF Guo, Bianqin
   Xiong, Xiaopeng
   Hasani, Sumati
   Wen, Yang-An
   Li, Austin T.
   Martinez, Rebecca
   Skaggs, Ashley T.
   Gao, Tianyan
TI Downregulation of PHLPP induced by endoplasmic reticulum stress promotes
   eIF2 alpha phosphorylation and chemoresistance in colon cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID CELL MOTILITY; PHOSPHATASE; EXPRESSION; AKT; TRANSLATION; INHIBITION;
   RESISTANCE; SURVIVAL; CREP
AB Aberrant activation of endoplasmic reticulum (ER) stress by extrinsic and intrinsic factors contributes to tumorigenesis and resistance to chemotherapies in various cancer types. Our previous studies have shown that the downregulation of PHLPP, a novel family of Ser/Thr protein phosphatases, promotes tumor initiation, and progression. Here we investigated the functional interaction between the ER stress and PHLPP expression in colon cancer. We found that induction of ER stress significantly decreased the expression of PHLPP proteins through a proteasome-dependent mechanism. Knockdown of PHLPP increased the phosphorylation of eIF2 alpha as well as the expression of autophagy-associated genes downstream of the eIF2 alpha/ATF4 signaling pathway. In addition, results from immunoprecipitation experiments showed that PHLPP interacted with eIF2 alpha and this interaction was enhanced by ER stress. Functionally, knockdown of PHLPP improved cell survival under ER stress conditions, whereas overexpression of a degradation-resistant mutant PHLPP1 had the opposite effect. Taken together, our studies identified ER stress as a novel mechanism that triggers PHLPP downregulation; and PHLPP-loss promotes chemoresistance by upregulating the eIF2 alpha/ATF4 signaling axis in colon cancer cells.
C1 [Guo, Bianqin] Chongqing Univ, Chongqing Key Lab Translat Res Canc Metastasis &, Canc Hosp, Chongqing 400030, Peoples R China.
   [Xiong, Xiaopeng; Hasani, Sumati; Wen, Yang-An; Skaggs, Ashley T.; Gao, Tianyan] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Hasani, Sumati; Skaggs, Ashley T.; Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Li, Austin T.] Paul Laurence Dunbar High Sch, Lexington, KY USA.
   [Martinez, Rebecca] Univ Kentucky, Coll Agr Food & Environm, Agr & Med Biotechnol Program, Lexington, KY USA.
   [Li, Austin T.] Princeton Univ, Princeton, NJ 08544 USA.
RP Gao, TY (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.; Gao, TY (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
EM tianyan.gao@uky.edu
OI , Ashley Skaggs/0000-0001-6732-1640
FU Chongqing Science and Technology CommissionNatural Science Foundation
   Project of CQ CSTC [cstc2020jcyj-msxmX0907]; National Science Foundation
   Graduate Research Fellowship AwardNational Science Foundation (NSF)
   [1839289]; NRSAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [F31CA260840];
   Biostatistics and Bioinformatics, Biospecimen Procurement and
   Translational Pathology, Flow Cytometry and Immune Monitoring, and Redox
   Metabolism Shared Resource Facilities of the University of Kentucky
   Markey Cancer Center [P30CA177558];  [R01CA133429]
FX This work was supported by R01CA133429 (TG). BG was supported by funding
   from Chongqing Science and Technology Commission
   (cstc2020jcyj-msxmX0907). ATS was supported by the National Science
   Foundation Graduate Research Fellowship Award (#1839289). SH was
   supported by NRSA F31CA260840 predoctoral fellowship. The studies were
   conducted with support provided by the Biostatistics and Bioinformatics,
   Biospecimen Procurement and Translational Pathology, Flow Cytometry and
   Immune Monitoring, and Redox Metabolism Shared Resource Facilities of
   the University of Kentucky Markey Cancer Center (P30CA177558). The
   summary diagram was created with BioRender.com.
CR Arias E, 2015, MOL CELL, V59, P270, DOI 10.1016/j.molcel.2015.05.030
   Avril T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.72
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008
   Gardner BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013169
   Grzechnik AT, 2016, BIOCHEM SOC T, V44, P1675, DOI 10.1042/BST20160170
   Hou JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036252
   Humeau J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2642-6
   Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075
   Kawashima AT, 2021, MOL CELL BIOL, V41, DOI 10.1128/MCB.00333-20
   Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003
   Li X, 2009, MOL CELL BIOL, V29, P6192, DOI 10.1128/MCB.00681-09
   Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450
   Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11
   Liu JY, 2011, J BIOL CHEM, V286, P6510, DOI 10.1074/jbc.M110.183087
   Lv DQ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1711-1
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x
   Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Reid DW, 2016, MOL CELL BIOL, V36, P1868, DOI 10.1128/MCB.00190-16
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Smith AJ, 2016, ONCOTARGET, V7, P7801, DOI 10.18632/oncotarget.6848
   Stevens PD, 2018, CANCER RES, V78, P4839, DOI 10.1158/0008-5472.CAN-17-3629
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suljagic M, 2010, LEUKEMIA, V24, P2063, DOI 10.1038/leu.2010.201
   Wang HM, 2019, THORAC CANCER, V10, P2124, DOI 10.1111/1759-7714.13196
   Wen YA, 2019, CELL DEATH DIFFER, V26, P1955, DOI 10.1038/s41418-018-0265-6
   Wen YA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0330-6
   Wen YA, 2015, BBA-MOL BASIS DIS, V1852, P2013, DOI 10.1016/j.bbadis.2015.07.012
   Wen YA, 2013, MOL CELL BIOL, V33, P4594, DOI 10.1128/MCB.00695-13
   Xiong XP, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.103
   Xiong XP, 2016, J BIOL CHEM, V291, P25167, DOI 10.1074/jbc.M116.740639
   Zhou JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119405
NR 36
TC 0
Z9 0
U1 3
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 18
PY 2021
VL 12
IS 11
AR 960
DI 10.1038/s41419-021-04251-0
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WI6VR
UT WOS:000708496600006
PM 34663797
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yang, MP
   Zhao, H
   Guo, L
   Zhang, QY
   Zhao, L
   Bai, SP
   Zhang, MH
   Xu, SQ
   Wang, FJ
   Wang, XH
   Zhao, B
AF Yang, Maopeng
   Zhao, Hong
   Guo, Li
   Zhang, Qingyuan
   Zhao, Ling
   Bai, Shuping
   Zhang, Minghui
   Xu, Sanqi
   Wang, Fujing
   Wang, Xiaohong
   Zhao, Bin
TI Autophagy-based survival prognosis in human colorectal carcinoma
SO ONCOTARGET
LA English
DT Article
DE Colorectal carcinoma; autophagy; Beclin 1; LC 3B; Bcl-xL
ID MALIGNANT PHENOTYPE; THERAPEUTIC TARGET; POOR-PROGNOSIS; CHROMOSOME 17Q;
   BECLIN 1; TUMOR; EXPRESSION; PROGRESSION; ENERGY; MITOCHONDRIA
AB The role of autophagy in cancers is controversial. Here we aim to determine the prognostic significance of autophagy in colorectal carcinoma patients, thereby allowing more rational development of therapeutic strategies. Through transmission electron microscopy, our data first demonstrated high frequency of defective mitochondria was strongly associated with poor overall survival in colorectal carcinoma. Next immunohistochemical study showed the expressions of Beclin 1, LC3B and Bcl-xL in both the center of tumor and adjacent noncancerous mucosal region were also correlated with overall survivals. We developed an autophagy signature for prognosis based on these three major autophagic proteins, further analysis suggested it was an independent prognostic biomarker and had its value even within single clinical stage. Combined TNM stage and this signature could significantly improve the accuracy of survival prognosis. To validate these immunohistochemical results, an internal testing cohort and an independent population were also included. Our findings suggest that autophagy plays an important role in the clinical cancer progression. Therefore autophagic proteins may be valuable prognostic biomarkers in the therapy of colorectal carcinoma and possibly other types of cancers.
C1 [Yang, Maopeng; Zhao, Hong; Guo, Li; Zhang, Qingyuan; Zhao, Ling; Bai, Shuping; Zhang, Minghui; Xu, Sanqi; Wang, Xiaohong] Harbin Med Univ, Dept Med Oncol, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China.
   [Wang, Fujing] Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China.
   [Zhao, Bin] Harbin Med Univ Daqing, Coll Basic Med, Harbin, Heilongjiang, Peoples R China.
RP Wang, FJ (corresponding author), Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China.
EM fujingwang@yeah.net; drxiaohongwang@163.com; bin.science@gmail.com
CR Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Eskelinen EL, 2011, AUTOPHAGY, V7, P935, DOI 10.4161/auto.7.9.15760
   GAO X, 1995, ONCOGENE, V11, P1241
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342
   Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lin HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060516
   Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P4208, DOI 10.4161/cc.10.24.18487
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   SAITO H, 1993, CANCER RES, V53, P3382
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Yang HI, 2011, LANCET ONCOL, V12, P568, DOI 10.1016/S1470-2045(11)70077-8
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhao H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0475-1
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537
NR 44
TC 34
Z9 34
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 30
PY 2015
VL 6
IS 9
BP 7084
EP 7103
DI 10.18632/oncotarget.3054
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF8GI
UT WOS:000352793800045
PM 25762626
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Packiriswamy, N
   Coulson, KF
   Holcombe, SJ
   Sordillo, LM
AF Packiriswamy, Nandakumar
   Coulson, Kari F.
   Holcombe, Susan J.
   Sordillo, Lorraine M.
TI Oxidative stress-induced mitochondrial dysfunction in a normal colon
   epithelial cell line
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Colon cancer cell line; CRL. 1790 cells; Inflammation; Mitochondria;
   Microbial stimulation; Interleukin-8; Autophagy
ID INFLAMMATORY-BOWEL-DISEASE; ESCHERICHIA-COLI; METABOLIC STRESS;
   CANCER-CELLS; DNA-DAMAGE; TNF-ALPHA; IN-VITRO; EXPRESSION; BARRIER; ACID
AB AIM
   To determine how a normal human colon cell line reacts to microbial challenge as a way to study oxidative stress-induced responses associated with inflammatory bowel disease.
   METHODS
   Normal human colon epithelial cells (ATCC (R) CRL. 1790 T) were stimulated with either heat killed E. coli or heat killed murine cecal contents (HKC) and examined for several relevant biomarkers associated with inflammation and oxidative stress including cytokine production, mitochondrial autophagy and oxidant status. TNF alpha, IL-1 beta and IL-8 protein concentrations were measured within the supernatants. Fluorescent microscopy was performed to quantify the production of reactive oxygen species (ROS) using an oxidation responsive fluorogenic probe. Mitochondrial morphology and mitochondrial membrane potential was assessed by dual staining using COXIV antibody and a dye concentrating in active mitochondria. Mitochondrial ROS scavenger was used to determine the source of ROS in stimulated cells. Autophagy was detected by staining for the presence of autophagic vesicles. Positive controls for autophagy and ROS/RNS experiments were treated with rapamycin and chloroquine. Mitochondrial morphology, ROS production and autophagy microscopy experiments were analyzed using a custom acquisition and analysis microscopy software (ImageJ).
   RESULTS
   Exposing CRL. 1790 cells to microbial challenge stimulated cells to produce several relevant biomarkers associated with inflammation and oxidative stress. Heat killed cecal contents treatment induced a 10-12 fold increase in IL-8 production by CRL. 1790 cells compared to unstimulated controls at 6 and 12 h (P < 0.001). Heat killed E. coli stimulation resulted in a 4-5 fold increase in IL-8 compared to the unstimulated control cells at each time point (P < 0.001). Both heat killed E. coli and HKC stimulated robust ROS production at 6 (P < 0.001), and 12 h (P < 0.01). Mitochondrial morphologic abnormalities were detected at 6 and 12 h based on reduced mitochondrial circularity and decreased mitochondrial membrane potential, P < 0.01. Microbial stimulation also induced significant autophagy at 6 and 12 h, P < 0.01. Lastly, blocking mitochondrial ROS generation using mitochondrial specific ROS scavenger reversed microbial challenge induced mitochondrial morphologic abnormalities and autophagy.
   CONCLUSION
   The findings from this study suggest that CRL. 1790 cells may be a useful alternative to other colon cancer cell lines in studying the mechanisms of oxidative stress events associated with intestinal inflammatory disorders.
C1 [Packiriswamy, Nandakumar; Coulson, Kari F.; Holcombe, Susan J.; Sordillo, Lorraine M.] Michigan State Univ, Dept Large Anim Clin Sci, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA.
RP Sordillo, LM (corresponding author), Michigan State Univ, Dept Large Anim Clin Sci, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA.
EM sordillo@msu.edu
RI Packiriswamy, Nandakumar/S-9400-2019
OI Sordillo, Lorraine/0000-0001-8873-3134; Packiriswamy,
   Nandakumar/0000-0002-8415-9187
FU Detroit, Michigan
FX Supported by an endowment from the Matilda R. Wilson Fund in Detroit,
   Michigan.
CR Arasaki K, 2015, DEV CELL, V32, P304, DOI 10.1016/j.devcel.2014.12.011
   Babcook MA, 2014, MOL CANCER THER, V13, P2288, DOI 10.1158/1535-7163.MCT-14-0451
   Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012
   BRATTAIN MG, 1981, CANCER RES, V41, P1751
   Burkewitz K, 2015, CELL, V160, P842, DOI 10.1016/j.cell.2015.02.004
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Daig R, 2000, GUT, V46, P350, DOI 10.1136/gut.46.3.350
   Gao J, 2014, J CELL BIOL, V207, P213, DOI 10.1083/jcb.201403129
   Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013
   Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com
   Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9
   Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0
   Halliwell B, 2007, BIOCHEM SOC T, V35, P1147, DOI 10.1042/BST0351147
   Johansson MEV, 2014, GUT, V63, P281, DOI 10.1136/gutjnl-2012-303207
   JUMARIE C, 1991, J CELL PHYSIOL, V149, P24, DOI 10.1002/jcp.1041490105
   Kathiria AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031231
   Kaur Gurvinder, 2012, Spermatogenesis, V2, P1
   Koh SJ, 2015, J PHARMACOL EXP THER, V352, P455, DOI 10.1124/jpet.114.217844
   Korolkova OY, 2015, CLIN MED INSIGHTS-GA, V8, P29, DOI 10.4137/CGast.S20612
   Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409
   Lewis K, 2008, AM J PHYSIOL-GASTR L, V294, pG669, DOI 10.1152/ajpgi.00382.2007
   MacVicar TDB, 2014, J CELL SCI, V127, P2313, DOI 10.1242/jcs.144337
   Mashukova A, 2011, MOL CELL BIOL, V31, P756, DOI 10.1128/MCB.00811-10
   Nazli A, 2004, AM J PATHOL, V164, P947, DOI 10.1016/S0002-9440(10)63182-3
   Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661
   Novak EA, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00062
   Ocuin LM, 2011, J LEUKOCYTE BIOL, V89, P423, DOI 10.1189/jlb.0810479
   Packiriswamy N, 2016, INFECT IMMUN, V84, P1633, DOI 10.1128/IAI.00051-16
   Pan CP, 2009, MOL CELL PROTEOMICS, V8, P443, DOI 10.1074/mcp.M800258-MCP200
   Picard M, 2013, AM J PHYSIOL-REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012
   Raza Y, 2014, PATHOL ONCOL RES, V20, P839, DOI 10.1007/s12253-014-9762-1
   Reddy KVK, 2016, INT IMMUNOPHARMACOL, V35, P29, DOI 10.1016/j.intimp.2016.03.019
   Scarpa M, 2013, EUR J CANCER, V49, P254, DOI 10.1016/j.ejca.2012.05.015
   SIDDIQUI KM, 1984, IN VITRO CELL DEV B, V20, P859
   Song IS, 2015, GASTROENTEROLOGY, V149, P1006, DOI 10.1053/j.gastro.2015.06.007
   TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221
   Walczak K, 2011, SCAND J GASTROENTERO, V46, P903, DOI 10.3109/00365521.2011.579159
   Wang ZQ, 2015, INFLAMM BOWEL DIS, V21, P1894, DOI 10.1097/MIB.0000000000000421
   Zhao DY, 2016, J AGR FOOD CHEM, V64, P2238, DOI 10.1021/acs.jafc.5b05742
NR 39
TC 11
Z9 12
U1 1
U2 6
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 21
PY 2017
VL 23
IS 19
BP 3427
EP 3439
DI 10.3748/wjg.v23.i19.3427
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA EV6QY
UT WOS:000401897100006
PM 28596679
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Shi, WN
   Cui, SX
   Song, ZY
   Wang, SQ
   Sun, SY
   Yu, XF
   Li, Y
   Zhang, YH
   Gao, ZH
   Qu, XJ
AF Shi, Wen-Na
   Cui, Shu-Xiang
   Song, Zhi-Yu
   Wang, Shu-Qing
   Sun, Shi-Yue
   Yu, Xin-Feng
   Li, Ye
   Zhang, Yu-Hang
   Gao, Zu-Hua
   Qu, Xian-Jun
TI Overexpression of SphK2 contributes to ATRA resistance in colon cancer
   through rapid degradation of cytoplasmic RXR alpha by K48/K63-linked
   polyubiquitination
SO ONCOTARGET
LA English
DT Article
DE sphingosine kinase 2 (SphK2); retinoid therapy resistance; cytoplasmic
   RXR alpha; polyubiquitination
ID RETINOID-X-RECEPTORS; CELL LUNG-CANCER; SELECTIVE AUTOPHAGY; NUCLEAR
   EXPORT; UBIQUITIN; ACID; EXPRESSION; GROWTH; APOPTOSIS; KINASE
AB The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that is mainly located in the nucleus and endoplasmic reticulum. Unlike well- studied sphingosine kinase 1 (SphK1) located in the cytosol, little has yet understood the functions of SphK2. Here we show that SphK2 overexpression contributes to the resistance of all-trans retinoic acid (ATRA) therapy in colon cancer through rapid degradation of cytoplasmic retinoid X receptor alpha (RXR alpha) by lysine 48 (K48)- and lysine 63 (K63)-based polyubiquitination. Human colonic adenocarcinoma HCT-116 cells transfected with SphK2 (HCT-116(Sphk2) cells) demonstrate resistance to ATRA therapy as determined by in vitro and in vivo assays. Sphk2 overexpression increases the ATRA-induced nuclear RXRa export to cytoplasm and then rapidly degrades RXRa through the polyubiquitination pathway. We further show that Sphk2 activates the ubiquitin-proteasome system through the signal mechanisms of (1) K48-linked proteosomal degradation and (2) K63-linked ubiquitin-dependent autophagic degradation. These results provide new insights into the biological functions of Sphk2 and the molecular mechanisms that underlie the Sphk2-mediated resistance to retinoid therapy.
C1 [Shi, Wen-Na; Song, Zhi-Yu; Wang, Shu-Qing; Sun, Shi-Yue; Yu, Xin-Feng; Li, Ye; Zhang, Yu-Hang; Qu, Xian-Jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.
   [Cui, Shu-Xiang] Capital Med Univ, Sch Publ Hlth, Dept Toxicol & Sanit Chem, Beijing Key Lab Environm Toxicol, Beijing, Peoples R China.
   [Gao, Zu-Hua] McGill Univ, Dept Pathol, Montreal, PQ, Canada.
RP Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.; Gao, ZH (corresponding author), McGill Univ, Dept Pathol, Montreal, PQ, Canada.
EM zu-hua.gao@mcgill.ca; quxj@ccmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81373436, 81373435, 91229113]; Beijing
   Science Foundation [7142017]; Research Institute of the McGill
   University Health Centre
FX This work was supported by the National Natural Science Foundation of
   China (81373436, 81373435 and 91229113) and the Beijing Science
   Foundation (7142017). We thank the Research Institute of the McGill
   University Health Centre for their financial support.
CR Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   Brabender J, 2005, CARCINOGENESIS, V26, P525, DOI 10.1093/carcin/bgi006
   Brtko Julius, 2007, Central European Journal of Public Health, V15, P3
   Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004
   Carapuca EF, 2016, J PATHOL, V239, P286, DOI 10.1002/path.4727
   Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014
   Chiao MT, 2013, AUTOPHAGY, V9, P1509, DOI 10.4161/auto.25664
   Cras A, 2012, CLIN CANCER RES, V18, P442, DOI 10.1158/1078-0432.CCR-11-0510
   Dawson MI, 2012, BBA-MOL CELL BIOL L, V1821, P21, DOI 10.1016/j.bbalip.2011.09.014
   El Magraoui F, 2015, CELLS-BASEL, V4, P596, DOI 10.3390/cells4040596
   Gao GL, 2013, BIOSCI TRENDS, V7, P56, DOI 10.5582/bst.2013.v7.1.56
   Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7
   Huang FT, 2013, P NATL ACAD SCI USA, V110, P15722, DOI 10.1073/pnas.1308014110
   Ju J, 2015, AM J TRANSL RES, V7, P856
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Korchnak AC, 2009, CELL SIGNAL, V21, P1620, DOI 10.1016/j.cellsig.2009.06.008
   Kunkel GT, 2013, NAT REV DRUG DISCOV, V12, P688, DOI 10.1038/nrd4099
   Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200
   Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009
   Li X, 2016, ONCOGENE, V35, P4881, DOI 10.1038/onc.2016.20
   Lim KL, 2011, NEUROBIOL DIS, V43, P9, DOI 10.1016/j.nbd.2010.08.001
   Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X
   Liu HP, 2013, INT J CANCER, V132, P2667, DOI 10.1002/ijc.27929
   Lok GTM, 2012, NUCLEIC ACIDS RES, V40, P196, DOI 10.1093/nar/gkr655
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Richter B, 2016, P NATL ACAD SCI USA, V113, P4039, DOI 10.1073/pnas.1523926113
   Sun DF, 2012, CANCER LETT, V319, P182, DOI 10.1016/j.canlet.2012.01.012
   Sun E, 2016, TUMOR BIOL, V37, P473, DOI 10.1007/s13277-015-3818-z
   Tarantino N, 2014, J CELL BIOL, V204, P231, DOI 10.1083/jcb.201307172
   van de Pavert SA, 2014, NATURE, V508, P123, DOI 10.1038/nature13158
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wang QS, 2014, TUMOR BIOL, V35, P363, DOI 10.1007/s13277-013-1051-1
   Weathington NM, 2013, CELL SIGNAL, V25, P1792, DOI 10.1016/j.cellsig.2013.05.003
   Zeng JZ, 2006, CARCINOGENESIS, V27, P1991, DOI 10.1093/carcin/bgl046
   Zhang L, 2016, TUMOR BIOL, V37, P8455, DOI 10.1007/s13277-015-4700-8
   Zhang XK, 2016, ACTA BIOCH BIOPH SIN, V48, P49, DOI 10.1093/abbs/gmv104
   Zhao R, 2015, BIOSCI TRENDS, V9, P367, DOI 10.5582/bst.2015.01168
NR 40
TC 18
Z9 19
U1 4
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 13
PY 2017
VL 8
IS 24
BP 39605
EP 39617
DI 10.18632/oncotarget.17174
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EX5VX
UT WOS:000403311900124
PM 28465486
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Cheng, CY
   Lin, YH
   Su, CC
AF Cheng, Chun-Yuan
   Lin, Yi-Hsiang
   Su, Chin-Cheng
TI Anti-tumor activity of Sann-Joong-Kuey-Jian-Tang alone and in
   combination with 5-fluorouracil in a human colon cancer colo 205 cell
   xenograft model
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Sann-Joong-Kyuy-Jian-Tang; 5-fluorouracil; colo 205 cell xenograft
   model; microtubule-associated protein light chain 3
ID TRADITIONAL CHINESE MEDICINE; PROTEIN EXPRESSION; IN-VITRO; AUTOPHAGY;
   CYCLE
AB Malignant tumors are the leading cause of death in Taiwan; among these, colon cancer ranks third as I cause of cancer-related death. Sann-Joong-Kuey-Jian-Tang (SJKJT), a traditional Chinese medicinal prescription, has been used to treat lymph node diseases and infectious lesions, and exhibits cytotoxic activity in many cancer cell lines. Our previous Studies demonstrated that SJKJT inhibits the proliferation of human colon cancer colo 205 cells in vitro. The aim of this study was to evaluate the anti-tumor activity of SJKJT alone and in combination with 5-fluorouracil (5-FU) in vivo. SCID mice bearing human colon cancer colo 205 cell xenografts were administered SJKJT alone (30 mg/kg daily, p.o.), SJKJT (30 mg/kg daily, p.o.) in combination with 5-FU (30 mg/kg weekly, i.p.), or vehicle alone. At the end of the 4-week dosing schedule, the tumor and animal body weights were individually measured. The SCID mice were sacrificed with CO, inhalation, the xenograft tumors were dissected, and the protein expression of microtubule-associated protein light chain 3 (MAP-LC3-II) in colo 205 xenograft tumors was measured by Western blotting. In the control, SJKJT-, and SJKJT Plus 5-FU-treated mice, the tumor weights were 6.37 +/- 2.57, 0.43 +/- 0.35 and 1.63 +/- 0.46 g, and the mice body weights were 29 +/- 0.55, 29 +/- 2.71 and 27 +/- 0.77 g, respectively. Treatment with SJKJT resulted in a reduction in tumor weight compared with the control group, indicating that SJKJT inhibits tumor growth in a colo 205 xenograft model. SJKJT also increased LC3-II protein expression as compared to the controls. The present study shows that SJKJT alone or in combination with 5-FU has a positive effect on the treatment of SCID mice hearing human colon cancer colo 205 cell xenografts. This suggests that SJKJT has therapeutic potential in the treatment of human colon cancer.
C1 [Cheng, Chun-Yuan] Chun Shan Med Univ, Inst Med, Taichung 40201, Taiwan.
   [Cheng, Chun-Yuan] Changhua Christian Hosp, Changhua 500, Taiwan.
   [Lin, Yi-Hsiang; Su, Chin-Cheng] Tzu Chi Univ, Inst Pharmacol & Toxicol, Hualien 97004, Taiwan.
   [Su, Chin-Cheng] Buddhist Tzu Chi Gen Hosp, Div Gen Surg, Hualien 97004, Taiwan.
RP Su, CC (corresponding author), Buddhist Tzu Chi Gen Hosp, Div Gen Surg, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan.
EM succ.maeva@msa.hinet.net
FU Research Section of the Buddhist Tzu Chi General Hospital, Hualien,
   Taiwan [TCRD97-05]
FX This Study was Supported by grant no. TCRD97-05 from the Research
   Section of the Buddhist Tzu Chi General Hospital, Hualien, Taiwan,
   R.O.C.
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen HC, 2004, FOOD CHEM TOXICOL, V42, P1251, DOI 10.1016/j.fct.2004.03.002
   Cheng CY, 2010, MOL MED REP, V3, P63, DOI 10.3892/mmr_00000219
   Cheng CY, 2009, MOL MED REP, V2, P707, DOI 10.3892/mmr_00000160
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Department of Health Executive Yuan Taipei Taiwan R.O.C, 2008, STAT CAUS DEATH, P33
   Efferth T, 2008, MOL CANCER THER, V7, P152, DOI 10.1158/1535-7163.MCT-07-0073
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Hsu YL, 2006, BIOL PHARM BULL, V29, P2388, DOI 10.1248/bpb.29.2388
   James K, 1999, J NATL CANCER I, V91, P523, DOI 10.1093/jnci/91.6.523
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Parekh HS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-21
   Rauh Rolf, 2007, Chin Med, V2, P8
   Su CC, 2008, INT J MOL MED, V22, P357, DOI 10.3892/ijmm_00000030
NR 16
TC 6
Z9 6
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR-APR
PY 2010
VL 3
IS 2
BP 227
EP 231
DI 10.3892/mmr_00000244
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 559KD
UT WOS:000274822200005
PM 21472226
DA 2022-04-25
ER

PT J
AU Pelissier-Rota, MA
   Pelosi, L
   Meresse, P
   Jacquier-Sarlin, MR
AF Pelissier-Rota, Marjolaine A.
   Pelosi, Ludovic
   Meresse, Patrick
   Jacquier-Sarlin, Muriel R.
TI Nicotine-induced cellular stresses and autophagy in human cancer colon
   cells: A supportive effect on cell homeostasis via up-regulation of
   Cox-2 and PGE(2) production
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Nicotine; Colorectal cancer; Autophagy; Cox-2; PGE(2); Cell homeostasis
ID ENDOPLASMIC-RETICULUM STRESS; INFLAMMATORY-BOWEL-DISEASE; UNFOLDED
   PROTEIN RESPONSE; NF-KAPPA-B; CYCLOOXYGENASE-2 EXPRESSION;
   GROWTH-FACTOR; VAGUS NERVE; ACETYLCHOLINE-RECEPTORS; ULCERATIVE-COLITIS;
   OXIDATIVE STRESS
AB Nicotine, one of the active components in cigarette smoke, has been described to contribute to the protective effect of smoking in ulcerative colitis (UC) patients. Furthermore, the nicotinic acetylcholine receptor alpha 7 subunit (alpha 7nAChR) expressed on immune cells, is an essential regulator of inflammation. As intestinal epithelial cells also express alpha 7nAChR, we investigated how nicotine could participate in the homeostasis of intestinal epithelial cells. First, using the human adenocarcinoma cell line HT-29, we revealed that nicotine, which triggers an influx of extracellular Ca2+ following alpha 7nAChR stimulation, induces mitochondrial reactive oxygen species (ROS) production associated with a disruption of the mitochondrial membrane potential and endoplasmic reticulum stress. This results in caspase-3 activation, which in turn induces apoptosis. Additionally, we have shown that nicotine induces a P13-K dependent up-regulation of cyclooxygenase-2 (Cox-2) expression and prostaglandin E2 (PGE(2)) production. In this context, we suggest that this key mediator participates in the cytoprotective effects of nicotine against apoptosis by stimulating autophagy in colon cancer cells. Our results provide new insight into one potential mechanism by which nicotine could protect from UC and suggest an anti-inflammatory role for the cholinergic pathway at the epithelial cell level. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Pelissier-Rota, Marjolaine A.; Jacquier-Sarlin, Muriel R.] INSERM, Equipe Stress & Interact Neurodigest, U836, F-38042 Grenoble 09, France.
   [Pelissier-Rota, Marjolaine A.; Jacquier-Sarlin, Muriel R.] Univ Grenoble 1, Grenoble Inst Neurosci, F-38041 Grenoble 09, France.
   [Pelosi, Ludovic] CNRS, Equipe Genom & Evolut Microorganismes, UMR 5163, F-38042 Grenoble 9, France.
   [Pelosi, Ludovic] Univ Grenoble 1, Lab Adaptat & Pathogen Microorganismes, F-38041 Grenoble 09, France.
   [Meresse, Patrick] Univ Grenoble 1, Ctr Univ Biol Expt, F-38041 Grenoble 09, France.
RP Jacquier-Sarlin, MR (corresponding author), Grenoble Inst Neurosci, Ctr Rech, INSERM, Equipe Stress & Interact Neurodigest,U836, Site Sante BP 170 La Tronche, F-38042 Grenoble 9, France.
EM muriel.jacquier-sarlin@ujf-grenoble.fr
RI Pelosi, Ludovic/AAB-9832-2020; Jacquier-Sarlin, Muriel/ABF-4923-2021
OI Pelosi, Ludovic/0000-0002-4198-5681; Jacquier-Sarlin,
   Muriel/0000-0001-8501-7511
FU Association pour la Recherche sur le CancerFondation ARC pour la
   Recherche sur le CancerAustralian Research CouncilEuropean Commission;
   Ligue Nationale contre le CancerLigue nationale contre le cancer;
   Universite Joseph Fourier; Ministre de la Recherche et de l'Enseignement
   Superieur
FX The authors gratefully acknowledge grant support from Association pour
   la Recherche sur le Cancer, Ligue Nationale contre le Cancer and the
   Universite Joseph Fourier. Pelissier-Rota is the recipient of a
   fellowship from the Ministre de la Recherche et de l'Enseignement
   Superieur.
CR Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008
   Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Bernstein CN, 2005, GASTROENTEROLOGY, V129, P827, DOI 10.1053/j.gastro.2005.06.021
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   Bonaz B, 2013, NEUROGASTROENT MOTIL, V25, P208, DOI 10.1111/nmo.12076
   Borovikova LV, 2000, AUTON NEUROSCI-BASIC, V85, P141, DOI 10.1016/S1566-0702(00)00233-2
   Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200
   Cardinale A, 2012, CRIT REV TOXICOL, V42, P68, DOI 10.3109/10408444.2011.623150
   Catassi A, 2008, MUTAT RES-REV MUTAT, V659, P221, DOI 10.1016/j.mrrev.2008.04.002
   Chartier NT, 2011, EXP CELL RES, V317, P1422, DOI 10.1016/j.yexcr.2011.03.009
   Chartier NT, 2006, J CELL SCI, V119, P31, DOI 10.1242/jcs.02698
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   Cosnes J, 2004, BEST PRACT RES CL GA, V18, P481, DOI 10.1016/j.bpg.2003.12.003
   Csordas G, 2009, BBA-BIOENERGETICS, V1787, P1352, DOI 10.1016/j.bbabio.2009.06.004
   Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006
   Decuypere JP, 2011, AUTOPHAGY, V7, P1472, DOI 10.4161/auto.7.12.17909
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Elander N, 2008, BIOCHEM BIOPH RES CO, V372, P249, DOI 10.1016/j.bbrc.2008.05.026
   FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842
   Frucht H, 1999, CLIN CANCER RES, V5, P2532
   Gellert C, 2012, ARCH INTERN MED, V172, P837, DOI 10.1001/archinternmed.2012.1397
   Gheorghe C, 2004, EUR J GASTROEN HEPAT, V16, P1153, DOI 10.1097/00042737-200411000-00012
   Ghia JE, 2006, GASTROENTEROLOGY, V131, P1122, DOI 10.1053/j.gastro.2006.08.016
   Giordano S, 2014, REDOX BIOL, V2, P82, DOI 10.1016/j.redox.2013.12.013
   Gong K, 2012, J BIOL CHEM, V287, P35576, DOI 10.1074/jbc.M112.370585
   Green J T, 1997, Expert Opin Investig Drugs, V6, P17, DOI 10.1517/13543784.6.1.17
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017
   Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054
   Ho YC, 2006, ACTA PHARMACOL SIN, V27, P409, DOI 10.1111/j.1745-7254.2006.00286.x
   Hoie O, 2007, AM J GASTROENTEROL, V102, P1692, DOI 10.1111/j.1572-0241.2007.01265.x
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kathiria AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031231
   Kefalakes H, 2009, EUR J CLIN PHARMACOL, V65, P963, DOI 10.1007/s00228-009-0719-3
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200
   Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Lalier L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-153
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Leone V, 2007, AM J PHYSIOL-GASTR L, V293, pG673, DOI 10.1152/ajpgi.00584.2006
   Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634
   Loffler I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-380
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   McGilligan VE, 2007, FOOD CHEM TOXICOL, V45, P1593, DOI 10.1016/j.fct.2007.02.021
   McGilligan VE, 2007, INFLAMM BOWEL DIS, V13, P108, DOI 10.1002/ibd.20020
   Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007
   Mokbel M, 1998, GASTROEN CLIN BIOL, V22, P858
   Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200
   Nys K, 2013, NAT REV GASTRO HEPAT, V10, P395, DOI 10.1038/nrgastro.2013.66
   Okada F, 2000, LAB INVEST, V80, P1617, DOI 10.1038/labinvest.3780172
   Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C
   Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037
   Pelissier-Rota M., 2013, J CANC THER, V04, P1116, DOI DOI 10.4236/JCT.2013.46128
   Picciotto MR, 2008, FRONT BIOSCI-LANDMRK, V13, P492, DOI 10.2741/2695
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202
   Raufman JP, 2008, CANCER RES, V68, P3573, DOI 10.1158/0008-5472.CAN-07-6810
   Raufman JP, 2011, BIOCHEM BIOPH RES CO, V415, P319, DOI 10.1016/j.bbrc.2011.10.052
   Rissanen A, 2006, BRAIN RES, V1087, P60, DOI 10.1016/j.brainres.2006.02.095
   Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Russo P, 2012, LIFE SCI, V91, P1087, DOI 10.1016/j.lfs.2012.05.003
   Sandborn WJ, 1999, AM J GASTROENTEROL, V94, P1161, DOI 10.1111/j.1572-0241.1999.01059.x
   Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541
   Scharl M, 2012, INFLAMM BOWEL DIS, V18, P1287, DOI 10.1002/ibd.21891
   Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590
   Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254
   Sheehan KM, 2004, EUR J GASTROEN HEPAT, V16, P619, DOI 10.1097/00042737-200406000-00017
   Shin VY, 2005, MOL CANCER RES, V3, P607, DOI 10.1158/1541-7786.MCR-05-0106
   Shkoda A, 2007, GASTROENTEROLOGY, V132, P190, DOI 10.1053/j.gastro.2006.10.030
   Si J, 2007, J BIOL CHEM, V282, P16244, DOI 10.1074/jbc.M700297200
   Sonoshita M, 2002, CANCER RES, V62, P6846
   TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167
   van der Heide F, 2009, INFLAMM BOWEL DIS, V15, P1199, DOI 10.1002/ibd.20884
   Van Haasteren G., J RECEPTOR SIGNAL TR, V19, P481
   Von Rosenvinge Erik C, 2011, Cancers (Basel), V3, P971, DOI 10.3390/cancers3010971
   Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Wang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074185
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Yang WL, 2000, CARCINOGENESIS, V21, P1789, DOI 10.1093/carcin/21.10.1789
   Yuan X, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/474272
   Yuzefovych LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054059
   Zhu YT, 2012, EXP CELL RES, V318, P2520, DOI 10.1016/j.yexcr.2012.07.021
   Zhu YT, 2012, EXP CELL RES, V318, P2116, DOI 10.1016/j.yexcr.2012.05.027
NR 103
TC 29
Z9 33
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD AUG
PY 2015
VL 65
BP 239
EP 256
DI 10.1016/j.biocel.2015.06.013
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CN9XM
UT WOS:000358804400026
PM 26100595
DA 2022-04-25
ER

PT J
AU Ji, LY
   Fu, JH
   Hao, J
   Ji, Y
   Wang, HY
   Wang, ZY
   Wang, P
   Xiao, H
AF Ji, Liyun
   Fu, Jihong
   Hao, Jie
   Ji, Yin
   Wang, Huiyu
   Wang, Zeyuan
   Wang, Peng
   Xiao, Hua
TI Proteomics analysis of tissue small extracellular vesicles reveals
   protein panels for the reoccurrence prediction of colorectal cancer
SO JOURNAL OF PROTEOMICS
LA English
DT Article
DE Small extracellular vesicles; Reoccurence; Colorectal cancer;
   parallel&nbsp; reaction monitoring; Protein&nbsp; panel
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; COLON-CANCER; STAGE-II; CELL;
   RECURRENCE; EXPRESSION; MARKER; METASTASIS; AUTOPHAGY
AB Many stage II/III colorectal cancer (CRC) patients might relapse after routine treatment and there is a great need of reliable biomarkers for predicting its reoccurrence risk. Small extracellular vesicles (sEVs) could regulate many pathophysiological processes of diseases, which are promising source for biomarker discovery. In this study, we implemented a MS-based workflow that utilizes data-dependent acquisition (DDA) for discovery and parallel reaction monitoring (PRM) for validation of high relapse risk related biomarkers. We compared the protein profiling of sEVs from CRC tissues and paired adjacent tissues in relapsed group (n = 5) and non-relapsed group (n = 5). 417 and 1140 proteins were differentially expressed between the tumor tissues and adjacent tissues in relapsed group and non-relapsed group, respectively. Bioinformatics analysis showed that immunity of the relapsed patients (Z-score - 0.69) was relatively poorer than the non-relapsed patients (Z-score 2.59), while chronic inflammatory response was activated (Z-score 3.0), which might enhance the reoccurrence risk. Four proteins (HLA-DPA1, S100P, NUP205, PCNA) showed significant expressions in the adjacent tissues of the relapsed group by PRM validation. ROC analysis of HLA-DPA1 (AUC = 0.96) achieved the best classification accuracy in separating the relapsed group and the non-relapsed group. Our data demonstrate that tissue-derived sEVs harbor prognostic proteomic signatures of CRC. Significance: In this research, our proteomics analysis of tissue sEVs revealed that poor immunity as well as chronic inflammatory of the CRC relapsed patient likely lead to poor prognosis and high risk of reoccurrence. The significant expression levels of four proteins (HLA-DPA1, S100P, NUP205, PCNA) in the adjacent tissues of the relapsed group might be used to predict the risk of relapse in postoperative follow-ups.
C1 [Ji, Liyun; Wang, Huiyu; Wang, Zeyuan; Xiao, Hua] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci, Shanghai 200240, Peoples R China.
   [Fu, Jihong] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Colorectal Surg, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
   [Hao, Jie] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China.
   [Ji, Yin; Wang, Peng] Jiangsu Simcere Pharmaceut Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Nanjing 210042, Peoples R China.
RP Xiao, H (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci, Shanghai 200240, Peoples R China.; Wang, P (corresponding author), Jiangsu Simcere Pharmaceut Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Nanjing 210042, Peoples R China.
EM peng.wang@simceregroup.com; huaxiao@sjtu.edu.cn
RI Xiao, Hua/I-7429-2013
OI Xiao, Hua/0000-0002-2831-0436
FU Natural Science Foundation of ShanghaiNatural Science Foundation of
   Shanghai [21ZR1433200]; National Key Research and Development Program of
   China [2017YFC1200204]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [21675110,
   21305087]; Key Scientific Project of Shanghai Jiao Tong University
   [TMSK-2020-130, YG2017MS80, YG2015QN45, ZH2018QNA65]; Recruitment
   Program of Global Youth Experts of China; National High-tech R&D Program
   of China (863 Program)National High Technology Research and Development
   Program of China [2014AA020545]
FX This work was supported by grants from the Natural Science Foun-dation
   of Shanghai (No. 21ZR1433200) , the National Key Research and
   Development Program of China (No. 2017YFC1200204) , the National Natural
   Science Foundation of China (No. 21675110, No. 21305087) ; and the Key
   Scientific Project of Shanghai Jiao Tong University (No. TMSK-2020-130,
   No. YG2017MS80, No. YG2015QN45, No. ZH2018QNA65) ; H.X. is supported by
   the Recruitment Program of Global Youth Experts of China and National
   High-tech R&D Program of China (863 Program, No.2014AA020545) .
CR Baniyash M, 2014, CANCER IMMUNOL IMMUN, V63, P11, DOI 10.1007/s00262-013-1468-9
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Belizario JE, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9523628
   Bockelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cheng JW, 2007, J BIOL CHEM, V282, P30535, DOI 10.1074/jbc.M704829200
   Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Di Falco MR, 2018, METHODS MOL BIOL, V1775, P93, DOI 10.1007/978-1-4939-7804-5_9
   Fu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.509
   Gao QZ, 2020, ONCOGENE, V39, P3926, DOI 10.1038/s41388-020-1266-8
   Gardiner C, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.19671
   Gingery A, 2017, ENDOCRINOLOGY, V158, P3354, DOI 10.1210/en.2016-1871
   Gonzalez LC, 2016, BIOGERONTOLOGY, V17, P71, DOI 10.1007/s10522-015-9593-9
   Hagos Y., J PHARM SCI-US, V103
   Hiramoto-Yamaki N, 2010, J CELL BIOL, V190, P461, DOI 10.1083/jcb.201005141
   Hu YH, 2019, AM J CANCER RES, V9, P1061
   Huang LP, 2020, J CELL PHYSIOL, V235, P4834, DOI 10.1002/jcp.29361
   Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37
   Kim YH, 2014, J KOREAN MED SCI, V29, P351, DOI 10.3346/jkms.2014.29.3.351
   Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Labade AS, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0106-0
   Lamb CA, 2016, EMBO J, V35, P281, DOI 10.15252/embj.201592695
   Lawson JS, 1999, LANCET, V354, P1787, DOI 10.1016/S0140-6736(99)04936-3
   Loilome W, 2012, PARASITOL INT, V61, P136, DOI 10.1016/j.parint.2011.07.003
   Maguire A, 2014, WORLD J GASTROENTERO, V20, P9850, DOI 10.3748/wjg.v20.i29.9850
   Malkas LH, 2006, P NATL ACAD SCI USA, V103, P19472, DOI 10.1073/pnas.0604614103
   Mao ZM, 2018, CANCER LETT, V414, P222, DOI 10.1016/j.canlet.2017.11.024
   Matsumoto A, 2018, METHODS MOL BIOL, V1840, P307, DOI 10.1007/978-1-4939-8691-0_21
   Min L, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1643670
   Mishra SK, 2018, AUTOPHAGY, V14, P862, DOI 10.1080/15548627.2017.1393129
   Miyoshi N, 2010, ONCOL REP, V23, P505, DOI 10.3892/or_00000662
   Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x
   Notas G, 2013, MOL ONCOL, V7, P595, DOI 10.1016/j.molonc.2013.02.012
   O'Connell MJ, 2008, J CLIN ONCOL, V26, P2336, DOI 10.1200/JCO.2007.15.8261
   Pathan M, 2019, NUCLEIC ACIDS RES, V47, pD516, DOI 10.1093/nar/gky1029
   Patriarca S, 2017, EPIDEMIOL PREV, V41, P140, DOI 10.19191/EP17.2.P140.034
   Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Rauniyar N, 2017, BIOMARK INSIGHTS, V12, DOI 10.1177/1177271917710948
   Rauniyar N, 2015, INT J MOL SCI, V16, P28566, DOI 10.3390/ijms161226120
   Reece MM, 2018, ANZ J SURG, V88, P1163, DOI 10.1111/ans.14870
   Reeves ME, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-562
   Roy S, 2017, MOL CELL, V67, P84, DOI 10.1016/j.molcel.2017.05.020
   Rui X, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6391-9
   Ryuk JP, 2014, ANN SURG TREAT RES, V86, P143, DOI 10.4174/astr.2014.86.3.143
   Samuel Glenson, 2020, Oncotarget, V11, P2995, DOI 10.18632/oncotarget.27678
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Shen WL, 2019, BIOENGINEERED, V10, P459, DOI 10.1080/21655979.2019.1676485
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tao Y, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00233
   Urushibara S, 2017, ANTICANCER RES, V37, P4085, DOI 10.21873/anticanres.11795
   van der Stok EP, 2017, NAT REV CLIN ONCOL, V14, P297, DOI 10.1038/nrclinonc.2016.199
   Vannucci Luca, 2011, Front Biosci (Schol Ed), V3, P1421
   Walbrecq G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145071
   Walker AS, 2014, J CANCER, V5, P272, DOI 10.7150/jca.8871
   Wang GJ, 2008, J IMMUNOL, V181, P5242, DOI 10.4049/jimmunol.181.8.5242
   Wang Q, 2012, ONCOL REP, V28, P303, DOI 10.3892/or.2012.1794
   Xia ZY, 2019, J CANCER, V10, P864, DOI 10.7150/jca.27663
   Yao HL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54188-w
   Yi X, 2012, J BIOL CHEM, V287, P21045, DOI 10.1074/jbc.M112.355321
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1314-9
   Zhang XS, 2016, CELL CYCLE, V15, P1134, DOI 10.1080/15384101.2016.1158375
NR 69
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1874-3919
EI 1876-7737
J9 J PROTEOMICS
JI J. Proteomics
PD OCT 30
PY 2021
VL 249
AR 104347
DI 10.1016/j.jprot.2021.104347
EA SEP 2021
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA UR1FG
UT WOS:000696501000001
PM 34384913
DA 2022-04-25
ER

PT J
AU Nishikawa, T
   Tsuno, NH
   Okaji, Y
   Sunami, E
   Shuno, Y
   Sasaki, K
   Hongo, K
   Kaneko, M
   Hiyoshi, M
   Kawai, K
   Kitayama, J
   Takahashi, K
   Nagawa, H
AF Nishikawa, Takeshi
   Tsuno, Nelson H.
   Okaji, Yurai
   Sunami, Eiji
   Shuno, Yasutaka
   Sasaki, Kazuhito
   Hongo, Kumiko
   Kaneko, Manabu
   Hiyoshi, Masaya
   Kawai, Kazushige
   Kitayama, Joji
   Takahashi, Koki
   Nagawa, Hirokazu
TI The inhibition of autophagy potentiates anti-angiogenic effects of
   sulforaphane by inducing apoptosis
SO ANGIOGENESIS
LA English
DT Article
DE Autophagy; Endothelial cells; Sulforaphane; Apoptosis; 3-Methyladenine;
   Angiogenesis
ID CELL-CYCLE ARREST; COLON-CANCER; CRUCIFEROUS VEGETABLES; GROWTH;
   ISOTHIOCYANATES; PROLIFERATION; ENDOTHELIUM; PROGRESSION; BROCCOLI;
   ENZYMES
AB Sulforaphane (SUL), a kind of isothiocyanate, has recently been focused due to its strong pro-apoptotic effect on cancer cells as well as tumor vascular endothelial cells (ECs). And recently, we demonstrated the induction of autophagy by colon cancer cells as a protective mechanism against SUL. In the present study, we aimed to investigate the possible role of autophagy induction by ECs as a defense mechanism against SUL.
   Human umbilical vein endothelial cells (HUVECs) were used as the in vitro model of angiogenic ECs. The induction of autophagy was evaluated by the detection of acidic vesicular organelles (AVOs) by flow-cytometry, after the staining with acridine orange, as well as the detection of light chain 3(LC3) by Western blot. Finally, the functional implication of autophagy inhibition and SUL treatment in ECs was investigated by their ability to form vascular-like structures on Matrigel.
   Treatment of HUVECs with relatively low concentrations of SUL for 16 h resulted in the evident formation of AVOs and the recruitment of LC3 to autophagosomes, the pathognomonic features of autophagy. Co-treatment of cells with the specific autophagy inhibitor (3-methyladenine) potentiated the proapoptotic effect of SUL. And inhibition of autophagy potentiated the inhibitory effect of SUL on the ability of ECs to form capillary-like structures.
   Similar to cancer cells, ECs induced autophagy in response to the pro-apoptotic agent, SUL, and the inhibition of autophagy potentiated the pro-apoptotic effect. These findings open premises for the use of autophagy inhibitors in combination with anti-angiogenic agents.
C1 [Nishikawa, Takeshi; Tsuno, Nelson H.; Sunami, Eiji; Shuno, Yasutaka; Sasaki, Kazuhito; Hongo, Kumiko; Kaneko, Manabu; Hiyoshi, Masaya; Kawai, Kazushige; Kitayama, Joji; Nagawa, Hirokazu] Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Tsuno, Nelson H.; Okaji, Yurai; Takahashi, Koki] Univ Tokyo, Dept Transfus Med, Fac Med, Tokyo 1138655, Japan.
RP Nishikawa, T (corresponding author), Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM takn-tky@umin.ac.jp
RI Kawai, Kazushige/AAF-4334-2020
OI Kawai, Kazushige/0000-0002-5881-0036
CR Asakage Masahiro, 2006, Angiogenesis, V9, P83, DOI 10.1007/s10456-006-9034-0
   Bertl E, 2006, MOL CANCER THER, V5, P575, DOI 10.1158/1535-7163.MCT-05-0324
   Bonnesen C, 2001, CANCER RES, V61, P6120
   CAREW JS, 2009, J CELL MOL MED
   Chiao JW, 2002, INT J ONCOL, V20, P631
   Dong ZW, 2009, TOXICOL IN VITRO, V23, P105, DOI 10.1016/j.tiv.2008.11.003
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Gewirtz DA, 2009, RADIOTHER ONCOL, V92, P323, DOI 10.1016/j.radonc.2009.05.022
   Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Jackson SJT, 2007, VASC PHARMACOL, V46, P77, DOI 10.1016/j.vph.2006.06.015
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   NGUYEN TMB, 2009, J CELL MOL MED
   Nishikawa T, 2009, ANN SURG ONCOL, V16, P534, DOI 10.1245/s10434-008-0215-5
   Okaji Y, 2004, CANCER SCI, V95, P85, DOI 10.1111/j.1349-7006.2004.tb03175.x
   Okaji Y, 2008, EUR J CANCER, V44, P383, DOI 10.1016/j.ejca.2007.10.018
   Pappa G, 2007, MOL NUTR FOOD RES, V51, P977, DOI 10.1002/mnfr.200700115
   Shan Y, 2006, INT J ONCOL, V29, P883
   Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178
   Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200
   Tsuboi Y, 2009, J NEUROSURG, V110, P594, DOI 10.3171/2008.8.JNS17648
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
NR 27
TC 43
Z9 44
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD SEP
PY 2010
VL 13
IS 3
BP 227
EP 238
DI 10.1007/s10456-010-9180-2
PG 12
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 652BX
UT WOS:000281976900004
PM 20694744
DA 2022-04-25
ER

PT J
AU Liang, CY
   Jung, JU
AF Liang, Chengyu
   Jung, Jae U.
TI Autophagy genes as tumor suppressors
SO CURRENT OPINION IN CELL BIOLOGY
LA English
DT Article
ID CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; MICROSATELLITE INSTABILITY;
   METABOLIC STRESS; CROHNS-DISEASE; SACCHAROMYCES-CEREVISIAE; REGULATES
   AUTOPHAGY; PROTEIN COMPLEX; CANCER CELLS; COLON-CANCER
AB Autophagy, originally described as a universal lysosome-dependent bulk degradation of cytoplasmic components upon nutrient deprivation, has since been shown to influence diverse aspects of homeostasis and is implicated in a wide variety of pathological conditions, including cancer. The list of autophagy-related (Atg) genes associated with the initiation and progression of human cancer as well as with responses to cancer therapy continues to grow as these genes are being discovered. However, whether Atg genes work through their expected mechanisms of autophagy regulation and/or through as-yet-undefined functions in the development of cancer remains to be further clarified. Here we review recent advances in the knowledge of the molecular basis of autophagy genes and their biological outputs during tumor development. A better understanding of the mechanistic link between cellular autophagy and tumor growth control may ultimately better human cancer treatments.
C1 [Liang, Chengyu; Jung, Jae U.] Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Liang, CY (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA.
EM chengyu.liang@usc.edu
OI LIANG, CHENGYU/0000-0001-6082-2143
FU U.S. Public Health ServiceUnited States Department of Health & Human
   ServicesUnited States Public Health Service [CA140964, AI083841];
   Leukemia & Lymphoma Society of USA; Wright Foundation; Baxter
   Foundation; Fletcher Jones Foundation; Hastings Foundation; Korean GRL
   Program [K20815000001];  [CA82057];  [CA91819];  [CA31363];  [CA115284];
   [A1073099]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA140964, R01CA115284, R01CA082057,
   R01CA031363, R01CA091819] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI073099, R21AI083841] Funding Source: NIH RePORTER
FX We apologize to all scientists whose work could not be cited here due to
   limited space. We thank Stacy Lee for her critical reading of the
   manuscript. This work was partly supported by U.S. Public Health Service
   grants CA140964, AI083841, the Leukemia & Lymphoma Society of USA, the
   Wright Foundation, and the Baxter Foundation (C. Liang) and CA82057,
   CA91819, CA31363, CA115284, A1073099, Fletcher Jones Foundation,
   Hastings Foundation, and Korean GRL Program K20815000001 (JUJ).
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Balakrishnan A, 2006, GENE CHROMOSOME CANC, V45, P883, DOI 10.1002/gcc.20352
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   BYUN JY, 2009, CARCINOGENESIS
   Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08
   Chang YY, 2009, MOL BIOL CELL, V20, P2004, DOI 10.1091/mbc.E08-12-1250
   Chia WJ, 2009, BBA-REV CANCER, V1795, P110, DOI 10.1016/j.bbcan.2008.10.001
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Day TW, 2009, MINI-REV MED CHEM, V9, P741, DOI 10.2174/138955709788452748
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   GALLUZZI L, 2009, MOL ASPECTS MED
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936
   Harrison B, 2008, J BIOL CHEM, V283, P9999, DOI 10.1074/jbc.M706040200
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kraft C, 2009, BBA-MOL CELL RES, V1793, P1404, DOI 10.1016/j.bbamcr.2009.02.006
   Kuballa P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003391
   LEE JS, 2009, NAT CELL BIOL
   Lee WC, 1996, CANCER RES, V56, P4297
   Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine Beth, 2003, Harvey Lect, V99, P47
   LIANG C, 2008, NAT CELL BIOL
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Massey DCO, 2007, AUTOPHAGY, V3, P649, DOI 10.4161/auto.5075
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Nakamura N, 1997, J BIOL CHEM, V272, P11344
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Obara K, 2006, MOL BIOL CELL, V17, P1527, DOI 10.1091/mbc.E05-09-0841
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2
   Schildhaus HU, 2005, INT J ONCOL, V26, P1493
   Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Takahashi Y, 2008, AUTOPHAGY, V4, P121, DOI 10.4161/auto.5265
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang M, 2009, BIOSCIENCE REP, V29, P193, DOI 10.1042/BSR20090032
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 80
TC 58
Z9 61
U1 0
U2 7
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0955-0674
J9 CURR OPIN CELL BIOL
JI Curr. Opin. Cell Biol.
PD APR
PY 2010
VL 22
IS 2
BP 226
EP 233
DI 10.1016/j.ceb.2009.11.003
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 598NS
UT WOS:000277845300016
PM 19945837
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Yan, L
   Gong, YZ
   Shao, MN
   Ruan, GT
   Xie, HL
   Liao, XW
   Wang, XK
   Han, QF
   Zhou, X
   Zhu, LC
   Gao, F
   Gan, JL
AF Yan, Ling
   Gong, Yi-Zhen
   Shao, Meng-Nan
   Ruan, Guo-Tian
   Xie, Hai-Lun
   Liao, Xi-Wen
   Wang, Xiang-Kun
   Han, Quan-Fa
   Zhou, Xin
   Zhu, Li-Cheng
   Gao, Feng
   Gan, Jia-Liang
TI Distinct diagnostic and prognostic values of gamma-aminobutyric acid
   type A receptor family genes in patients with colon adenocarcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE gamma-aminobutyric acid type A receptor; mRNA; colon adenocarcinoma;
   diagnosis; prognosis
ID MEMBRANE-POTENTIAL DIFFERENCES; COLORECTAL-CANCER RISK; CYTOSCAPE
   PLUGIN; CELL-MIGRATION; EXPRESSION; GROWTH; METABOLISM; AUTOPHAGY;
   ADHESION; TISSUES
AB In the present study, the significance ofGABA(A)genes in colon adenocarcinoma (COAD) were investigated from the view of diagnosis and prognosis. All data were achieved from The Cancer Genome Atlas. Overall survival was analyzed by the Kaplan-Meier analyses and Cox regression model and the hazard ratios and 95% confidence interval were calculated for computation. The Database for Annotation, Visualization and Integrated Discovery, and the Biological Networks Gene Ontology (BiNGO) softwares were applied to assess the biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) was used for pathway analysis to predict the biological function ofGABA(A)genes. The associated Gene Ontology and KEGG pathways were conducted by Gene Set Enrichment Analysis (GSEA). From receiver operating characteristics curves analysis, it was found that the expression ofGABR, gamma-aminobutyric acid type A receptorGABRA2, GABRA3, GABRB2, GABRB3, GABRG2, GABRG3, GABRD, GABREwere correlated with COAD occurrence [P<0.0001, area under the curve (AUC)>0.7]. The low expression of theGABRB1, GABRD, GABRPandGABRQin genes after tumor staging adjustment were positively correlated with the overall survival rate [P=0.049, hazard ratio (HR)=1.517, 95% confidence interval (CI)=1.001-2.297; P=0.006, HR=1.807, 95% CI=1.180-2.765; P=0.005, HR=1.833, 95% CI=1.196-2.810; P=0.034, HR=1.578, 95% CI=1.036-2.405). GSEA showed enrichment of cell matrix adhesion, integrin binding, angiogenesis, endothelial growth factor and endothelial migration regulation in patients with COAD withGABRDoverexpression.GABRB1, GABRD, GABRP and GABRQwere associated with the prognostic factors of COAD. The expression levels ofGABRA2, GABRA3, GABRB2, GABRB3, GABRG2, GABRDandGABREmay allow differentiation between tumor tissues and adjacent normal tissues.
C1 [Yan, Ling; Gong, Yi-Zhen; Ruan, Guo-Tian; Xie, Hai-Lun; Gao, Feng; Gan, Jia-Liang] Guangxi Med Univ, Dept Colorectal & Anal Surg, Affiliated Hosp 1, 6 Shuang Yong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Shao, Meng-Nan] Guangxi Med Univ, Life Sci Inst, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Liao, Xi-Wen; Wang, Xiang-Kun; Han, Quan-Fa; Zhou, Xin] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Zhu, Li-Cheng] Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning 530021, Guangxi Zhuang, Peoples R China.
RP Gan, JL (corresponding author), Guangxi Med Univ, Dept Colorectal & Anal Surg, Affiliated Hosp 1, 6 Shuang Yong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM gjl5172@163.com
FU Innovation Project of Guangxi Graduate Education [JGY2019052];
   Self-financing Scientific Research Project of Guangxi Zhuang Autonomous
   Region Health Commission, China [Z20180959]
FX The present study was supported by the Innovation Project of Guangxi
   Graduate Education (grant no. JGY2019052) and Self-financing Scientific
   Research Project of Guangxi Zhuang Autonomous Region Health Commission,
   China (grant no. Z20180959).
CR Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7
   Bautista W, 2014, CAN J PHYSIOL PHARM, V92, P85, DOI 10.1139/cjpp-2013-0226
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Campbell PT, 2007, CANCER EPIDEM BIOMAR, V16, P1735, DOI 10.1158/1055-9965.EPI-06-1059
   Chen Zhi-ao, 2012, Cancer Biology Medicine, V9, P90, DOI 10.3969/j.issn.2095-3941.2012.02.002
   Darlison MG, 2005, CELL MOL NEUROBIOL, V25, P607, DOI 10.1007/s10571-005-4004-4
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P890, DOI 10.1038/nrc2965
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Fedirko V, 2011, ANN ONCOL, V22, P1958, DOI 10.1093/annonc/mdq653
   Fessler E, 2016, TRENDS CANCER, V2, P505, DOI 10.1016/j.trecan.2016.07.008
   Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312
   Gross AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142618
   Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715
   Hackett CS, 2014, CELL REP, V9, P1034, DOI 10.1016/j.celrep.2014.09.046
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   IJspeert JEG, 2015, NAT REV GASTRO HEPAT, V12, P401, DOI 10.1038/nrgastro.2015.73
   Jiang SH, 2019, GUT, V68, P1994, DOI 10.1136/gutjnl-2018-317479
   Kawauchi T, 2012, INT J MOL SCI, V13, P4564, DOI 10.3390/ijms13044564
   Kimura C, 2013, BBA-GEN SUBJECTS, V1830, P4470, DOI 10.1016/j.bbagen.2013.05.009
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Lee E, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.2
   Li YH, 2012, WORLD J GASTROENTERO, V18, P2704, DOI 10.3748/wjg.v18.i21.2704
   Liao XW, 2018, CANCER MANAG RES, V10, P2537, DOI 10.2147/CMAR.S168351
   Ludvigsson JF, 2015, J CLIN IMMUNOL, V35, P182, DOI 10.1007/s10875-014-0124-2
   MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Malmberg KJ, 2017, SEMIN IMMUNOL, V31, P20, DOI 10.1016/j.smim.2017.08.002
   Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355
   Minuk GY, 2007, HEPATOLOGY, V45, P735, DOI 10.1002/hep.21562
   Mizumoto S, 2015, CURR OPIN STRUC BIOL, V34, P35, DOI 10.1016/j.sbi.2015.06.004
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562
   Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701
   Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497
   NAYEEM N, 1994, J NEUROCHEM, V62, P815
   Neelands TR, 1999, MOL PHARMACOL, V56, P598, DOI 10.1124/mol.56.3.598
   Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Okegawa T, 2004, ACTA BIOCHIM POL, V51, P445
   Park SH, 2014, CELL SIGNAL, V26, P1506, DOI 10.1016/j.cellsig.2014.03.017
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sarathi A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5838-3
   Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sung HY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.62
   Symmans WF, 2005, ENDOCR-RELAT CANCER, V12, P1059, DOI 10.1677/erc.1.01051
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203
   Takehara A, 2007, CANCER RES, V67, P9704, DOI 10.1158/0008-5472.CAN-07-2099
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tian JD, 2004, J IMMUNOL, V173, P5298, DOI 10.4049/jimmunol.173.8.5298
   Tu HP, 2014, J RHEUMATOL, V41, P749, DOI 10.3899/jrheum.130870
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Willis CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103966
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Zafrakas M, 2006, INT J CANCER, V118, P1453, DOI 10.1002/ijc.21517
   Zhang YA, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0288-6
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
NR 62
TC 6
Z9 6
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2020
VL 20
IS 1
BP 275
EP 291
DI 10.3892/ol.2020.11573
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MG4OT
UT WOS:000546013100028
PM 32565954
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Jang, YM
   Park, NY
   Rostgaard-Hansen, AL
   Huang, JJ
   Jiang, Q
AF Jang, Yumi
   Park, Na-Young
   Rostgaard-Hansen, Agnetha Linn
   Huang, Jianjie
   Jiang, Qing
TI Vitamin E metabolite 13 '-carboxychromanols inhibit pro-inflammatory
   enzymes, induce apoptosis and autophagy in human cancer cells by
   modulating sphingolipids and suppress colon tumor development in mice
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Cancer; Sphingolipid; Vitamin E metabolites; Autophagy; Apoptosis
ID LONG-CHAIN CARBOXYCHROMANOLS; GAMMA-TOCOPHEROL; DIHYDROCERAMIDE
   DESATURASE; NATURAL FORMS; CERAMIDE; ACID; AZOXYMETHANE; TOCOTRIENOL;
   PATHWAY; CARCINOGENESIS
AB Vitamin E forms are substantially metabolized to various carboxychromanols including 13'-carboxychromanols (13'-COOHs) that are found at high levels in feces. However, there is limited knowledge about functions of these metabolites. Here we studied delta T-13'-COOH and delta TE-13'-COOH, which are metabolites of delta-tocopherol and delta-tocotrienol, respectively. delta TE-13'-COOH is also a natural constituent of a traditional medicine Garcinia Kola. Both 13'-COOHs are much stronger than tocopherols in inhibition of pro-inflammatory and cancer promoting cyclooxygenase-2 (COX-2) and delta-lipoxygenase (5-LOX), and in induction of apoptosis and autophagy in colon cancer cells. The anticancer effects by 13'-COOHs appeared to be partially independent of inhibition of COX-2/5-LOX. Using liquid chromatography tandem mass spectrometry, we found that 13'-COOHs increased intracellular dihydrosphingosine and dihydroceramides after short-time incubation in HCT-116 cells, and enhanced ceramides while decreased sphingomyelins during prolonged treatment. Modulation of sphingolipids by 13'-COOHs was observed prior to or coinciding with biochemical manifestation of cell death. Pharmaceutically blocking the increase of these sphingolipids partially counteracted 13'-COOH-induced cell death. Further, 13'-COOH inhibited dihydroceramide desaturase without affecting the protein expression. In agreement with these mechanistic findings, delta TE-13'-COOH significantly suppressed the growth and multiplicity of colon tumor in mice. Our study demonstrates that 13'-COOHs have anti-inflammatory and anticancer activities, may contribute to in vivo anticancer effect of vitamin E forms and are promising novel cancer prevention agents. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Jang, Yumi; Park, Na-Young; Rostgaard-Hansen, Agnetha Linn; Huang, Jianjie; Jiang, Qing] Purdue Univ, Dept Nutr Sci, 700 W State St,Stone Hall G1A, W Lafayette, IN 47907 USA.
RP Jiang, Q (corresponding author), Purdue Univ, Dept Nutr Sci, 700 W State St,Stone Hall G1A, W Lafayette, IN 47907 USA.
EM qjiang@purdue.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R21CA152588,
   R01AT006882]; NIH via Purdue Center for Cancer Research [P30CA023168];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R21CA152588, P30CA023168] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Complementary & Alternative Medicine
   [R01AT006882] Funding Source: NIH RePORTER
FX The authors would like to thank Amber S Jannasch for helps with LC-MS/MS
   analyses of sphingolipids. This study was in part supported by grants
   R21CA152588 and R01AT006882 (to QJ) from National Institutes of Health.
   This project was also partially supported by NIH grant P30CA023168 via
   Purdue Center for Cancer Research.
CR Adegbehingbe Olayinka O, 2008, J Orthop Surg Res, V3, P34, DOI 10.1186/1749-799X-3-34
   Bardowell SA, 2012, J LIPID RES, V53, P2667, DOI 10.1194/jlr.M030734
   Bardowell SA, 2012, J BIOL CHEM, V287, P26077, DOI 10.1074/jbc.M112.373597
   Birringer M, 2010, FREE RADICAL BIO MED, V49, P1315, DOI 10.1016/j.freeradbiomed.2010.07.024
   Freiser H, 2009, J NUTR, V139, P884, DOI 10.3945/jn.108.103309
   Gopalan A, 2012, MOL NUTR FOOD RES, V56, P1803, DOI 10.1002/mnfr.201200350
   Guan F, 2012, CANCER PREV RES, V5, P644, DOI 10.1158/1940-6207.CAPR-11-0521
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Henry Brian, 2013, Handb Exp Pharmacol, P77, DOI 10.1007/978-3-7091-1368-4_4
   Heravi RE, 2011, EUR J PHARM SCI, V44, P479, DOI 10.1016/j.ejps.2011.09.005
   JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jiang Q, 2004, P NATL ACAD SCI USA, V101, P17825, DOI 10.1073/pnas.0408340102
   Jiang Q, 2007, J LIPID RES, V48, P1221, DOI 10.1194/jlr.D700001-JLR200
   Jiang Q, 2015, J LIPID RES, V56, P2217, DOI 10.1194/jlr.D061663
   Jiang Q, 2014, FREE RADICAL BIO MED, V72, P76, DOI 10.1016/j.freeradbiomed.2014.03.035
   Jiang Q, 2013, FREE RADICAL BIO MED, V65, P1069, DOI 10.1016/j.freeradbiomed.2013.08.187
   Jiang Q, 2012, INT J CANCER, V130, P685, DOI 10.1002/ijc.26054
   Jiang Q, 2008, P NATL ACAD SCI USA, V105, P20464, DOI 10.1073/pnas.0810962106
   Jiang ZY, 2011, J IMMUNOL, V186, P1173, DOI 10.4049/jimmunol.1002342
   Ju J, 2009, CANCER PREV RES, V2, P143, DOI 10.1158/1940-6207.CAPR-08-0099
   Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200
   Maloney DJ, 2005, ORG LETT, V7, P4297, DOI 10.1021/ol051849t
   Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091
   Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009
   Mohammed A, 2011, CANCER PREV RES, V4, P2015, DOI 10.1158/1940-6207.CAPR-11-0233
   Moya-Camarena SY, 2011, NUTRACEUTICALS CANC, P323
   Newmark HL, 2006, NUTR CANCER, V56, P82, DOI 10.1207/s15327914nc5601_11
   OKAZAKI T, 1994, J BIOL CHEM, V269, P4070
   Rahmaniyan M, 2011, J BIOL CHEM, V286, P24754, DOI 10.1074/jbc.M111.250779
   Rainsford KD, 2001, J PHYSIOL-PARIS, V95, P11, DOI 10.1016/S0928-4257(01)00004-3
   Ruangsiriluk W, 2012, J LIPID RES, V53, P1459, DOI 10.1194/jlr.M020941
   Schiffmann S, 2009, J LIPID RES, V50, P32, DOI 10.1194/jlr.M800122-JLR200
   Shakor ABA, 2014, BBA-MOL CELL BIOL L, V1841, P1672, DOI 10.1016/j.bbalip.2014.09.006
   Siddique MM, 2013, MOL CELL BIOL, V33, P2353, DOI 10.1128/MCB.00226-13
   Signorelli P, 2009, CANCER LETT, V282, P238, DOI 10.1016/j.canlet.2009.03.020
   Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200
   Tavolari S, 2008, CARCINOGENESIS, V29, P371, DOI 10.1093/carcin/bgm265
   Terashima K, 1997, HETEROCYCLES, V45, P1559
   Triola G, 2003, J ORG CHEM, V68, P9924, DOI 10.1021/jo030141u
   Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421
   Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809
   Wang Y, 2015, J IMMUNOL, V195, P126, DOI 10.4049/jimmunol.1403149
   Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200
NR 44
TC 31
Z9 31
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JUN
PY 2016
VL 95
BP 190
EP 199
DI 10.1016/j.freeradbiomed.2016.03.018
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DM2IH
UT WOS:000376169800016
PM 27016075
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Li, YL
   Yang, J
   Wang, HY
   Qiao, W
   Guo, YF
   Zhang, ST
   Guo, YJ
AF Li, Yilong
   Yang, Jie
   Wang, Hengyang
   Qiao, Wei
   Guo, Yongfeng
   Zhang, Shengtao
   Guo, Yajuan
TI FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation
   and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE FNDC3B; colorectal cancer; proliferation; invasion; microRNA; PI3K/mTOR
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLON-CANCER; APOPTOSIS; METASTASIS;
   STATISTICS; AUTOPHAGY; MIGRATION; PATHWAY; FAD104
AB Background: Fibronectin type III domain containing 3B (FNDC3B) acts as an oncogene in various cancers, and abnormal expression of FNDC3B has been found in colorectal cancer (CRC). Our study aimed to illustrate the role of FNDC3B in CRC development.
   Methods: Through RT-qPCR and western blotting assays, the mRNA and protein expressions of target genes were measured. CCK-8 and MTT methods were used to detect cell proliferation. Invasion ability was determined using Transwell assay. TargetScan platform and luciferase reporter gene assay were performed to predict and validate the bindings between FNDC3B and miR-125a-5p or miR-217. Besides, the expression correlationwas measured by Pearson'sCorrelation analysis.
   Results: We found that FNDC3B was significantly upregulated in CRC tissues and tumor cell lines, and high expression of FNDC3B predicted a poor survival outcome. The bindings between FNDC3B and miR-125a-5p and miR-217 were respectively at the motifs of CUCAGGG and AUGCAGU. MiR-125a-5p and miR-217 were downregulated in CRC tissues, and both were negatively correlated with FNDC3B expression. Subsequently, the downregulated miR-125a-5p and miR-217 were confirmed as contributors FNDC3B upregulation in CRC. A loss-of-function assay demonstrated that FNDC3B knockdown inhibited the proliferation of CRC cells, while FNDC3B overexpression promoted the proliferation and invasion of tumor cells. Besides, we validated that PI3K/mTOR signaling was involved in the regulation of FNDC3B on the proliferation and invasion of CRC cells.
   Conclusion: Generally, our findings demonstrated that FNDC3B facilitated cell proliferation and invasion via PI3K/mTOR signaling, and further promoted CRC progression. The novel miR-125a-5p/FNDC3B and miR-217/FNDC3B axes might be new targets for CRC prognosis and therapy.
C1 [Li, Yilong; Yang, Jie; Wang, Hengyang; Qiao, Wei; Guo, Yongfeng; Zhang, Shengtao; Guo, Yajuan] Ninth Hosp Xian, Dept Gen Surg 1, Xian 710054, Shaanxi, Peoples R China.
RP Guo, YJ (corresponding author), Ninth Hosp Xian, 151 Eastern Sect South Second Ring Rd, Xian 710054, Shaanxi, Peoples R China.
EM yajuanguo123@163.com
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bian YZ, 2019, CANCER BIOL THER, V20, P886, DOI 10.1080/15384047.2019.1579959
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Chen S, 2017, ONCOL LETT, V14, P6671, DOI 10.3892/ol.2017.7044
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Conza GD, 2017, CELL REP, V18, P1699, DOI [10.1016/j.celrep.2017.01.051, DOI 10.1016/J.CELREP.2017.01.051]
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Duan SY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0980-3
   Gao Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0362-4
   Jiang QG, 2014, MOL BIOL REP, V41, P3359, DOI 10.1007/s11033-014-3198-2
   Kishimoto K, 2011, EXP CELL RES, V317, P2110, DOI 10.1016/j.yexcr.2011.06.003
   Kishimoto K, 2010, BIOCHEM BIOPH RES CO, V397, P187, DOI 10.1016/j.bbrc.2010.05.077
   Li JZ, 2018, MOL THER-NUCL ACIDS, V10, P426, DOI 10.1016/j.omtn.2017.12.022
   Lin CH, 2016, ONCOTARGET, V7, P49498, DOI 10.18632/oncotarget.10374
   Liu HY, 2017, CANCER GENE THER, V24, P244, DOI 10.1038/cgt.2017.8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nishizuka M, 2009, EXP CELL RES, V315, P809, DOI 10.1016/j.yexcr.2008.12.013
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Sun XL, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22028
   Tang JJ, 2014, ONCOTARGET, V5, P10778, DOI 10.18632/oncotarget.2502
   Tong ZG, 2015, BIOMED PHARMACOTHER, V75, P129, DOI 10.1016/j.biopha.2015.07.036
   Verhoeff SR, 2016, INT J CANCER, V139, P187, DOI 10.1002/ijc.30053
   Wang HY, 2016, BRIT J HAEMATOL, V172, P987, DOI 10.1111/bjh.13552
   Xu HS, 2017, BIOMED PHARMACOTHER, V87, P405, DOI 10.1016/j.biopha.2016.12.100
   Ye H, 2018, CHIN MED, V9, P720
   Yin Y, 2016, ONCOTARGET, V7, P86755, DOI 10.18632/oncotarget.13550
   Ying-Zi L, 2014, INT J ONCOL, V45, P104, DOI [10.3892/ijo.2014.2392, DOI 10.3892/IJO.2014.2392]
   Zhang N, 2016, ONCOL LETT, V12, P4589, DOI 10.3892/ol.2016.5249
   Zhang T, 2018, WORLD J GASTROENTERO, V24, P3538, DOI 10.3748/wjg.v24.i31.3538
   Zhang XL, 2015, INT J MOL MED, V35, P1301, DOI 10.3892/ijmm.2015.2126
   Zhang Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0753-1
   Zhong ZM, 2018, ONCOL REP, V39, P1853, DOI 10.3892/or.2018.6231
NR 33
TC 6
Z9 6
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 3501
EP 3510
DI 10.2147/OTT.S226520
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA OH7SZ
UT WOS:000582795100001
PM 32431508
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Huang, CY
   Chiang, SF
   Chen, WTL
   Ke, TW
   Chen, TW
   You, YS
   Lin, CY
   Chao, KSC
AF Huang, Chih-Yang
   Chiang, Shu-Fen
   Chen, William Tzu-Liang
   Ke, Tao-Wei
   Chen, Tsung-Wei
   You, Ying-Shu
   Lin, Chen-Yu
   Chao, K. S. Clifford
TI HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for
   chemoresistance through RAGE in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID GLYCATION END-PRODUCTS; ADVANCED RECTAL-CANCER; DRUG-RESISTANCE;
   AUTOPHAGY; FISSION; EXPRESSION; AMPHOTERIN; PROGRESSION; RECEPTOR;
   OXALIPLATIN
AB Dysfunctional mitochondria have been shown to enhance cancer cell proliferation, reduce apoptosis, and increase chemoresistance. Chemoresistance develops in nearly all patients with colorectal cancer, leading to a decrease in the therapeutic efficacies of anticancer agents. However, the effect of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission on chemoresistance in colorectal cancer is unclear. Here, we found that the release of high-mobility group box 1 protein (HMGB1) in conditioned medium from dying cells by chemotherapeutic drugs and resistant cells, which triggered Drp1 phosphorylation via its receptor for advanced glycation end product (RAGE). RAGE signals ERK1/2 activation to phosphorylate Drp1 at residue S616 triggerring autophagy for chemoresistance and regrowth in the surviving cancer cells. Abolishment of Drp1 phosphorylation by HMGB1 inhibitor and RAGE blocker significantly enhance sensitivity to the chemotherapeutic treatment by suppressing autophagy. Furthermore, patients with high phospho-Drp1(Ser616) are associated with high risk on developing tumor relapse, poor 5-year disease-free survival (DFS) and 5-year overall survival (OS) after neoadjuvant chemoradiotherapy (neoCRT) treatment in locally advanced rectal cancer (LARC). Moreover, patients with RAGE-G82S polymorphism (rs2070600) are associated with high phospho-Drp1(Ser616) within tumor microenvironment. These findings suggest that the release of HMGB1 from dying cancer cells enhances chemoresistance and regrowth via RAGE-mediated ERK/Drp1 phosphorylation.
C1 [Huang, Chih-Yang] China Med Univ, China Med Univ Hosp, Translat Res Core, Taichung 40402, Taiwan.
   [Huang, Chih-Yang] HungKuang Univ, Dept Nutr, Taichung 43302, Taiwan.
   [Chiang, Shu-Fen; You, Ying-Shu; Lin, Chen-Yu; Chao, K. S. Clifford] China Med Univ, China Med Univ Hosp, Canc Ctr, Taichung 40402, Taiwan.
   [Chen, William Tzu-Liang; Ke, Tao-Wei] China Med Univ, China Med Univ Hosp, Dept Colorectal Surg, Taichung 40402, Taiwan.
   [Chen, Tsung-Wei] China Med Univ, China Med Univ Hosp, Dept Pathol, Taichung 40402, Taiwan.
   [Huang, Chih-Yang] China Med Univ, Grad Inst Basic Med Sci, Taichung 40402, Taiwan.
   [Huang, Chih-Yang] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.
   [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
   [Huang, Chih-Yang] China Med Univ, China Med Univ Hosp, Med Res Ctr Exosomes & Mitochondria Related Dis, Taichung 40402, Taiwan.
RP Huang, CY (corresponding author), China Med Univ, China Med Univ Hosp, Translat Res Core, Taichung 40402, Taiwan.; Huang, CY (corresponding author), HungKuang Univ, Dept Nutr, Taichung 43302, Taiwan.; Huang, CY (corresponding author), China Med Univ, Grad Inst Basic Med Sci, Taichung 40402, Taiwan.; Huang, CY (corresponding author), China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.; Huang, CY (corresponding author), China Med Univ, China Med Univ Hosp, Med Res Ctr Exosomes & Mitochondria Related Dis, Taichung 40402, Taiwan.
EM cyhuag@mail.cmu.edu.tw
RI Chen, William Tzu-Liang/ABA-5673-2021; Huang, Kevin
   Chih-Yang/Q-4862-2016
OI Huang, Kevin Chih-Yang/0000-0002-0266-3233; Huang,
   Chih-Yang/0000-0003-2347-0411
FU National Core Facility Program for Biotechnology Grants of MOST [MOST
   1042319- B-001-001-]; Ministry of Health and Welfare, Taiwan
   [MOHW107-TDU-B-212-123004]; Health and welfare surcharge of tobacco
   products, China Medical University Hospital Cancer Research Center of
   Excellence (Taiwan) [MOHW107-TDU-B-212-114024]; China Medical University
   Hospital, Taiwan [DMR-107-126]; Translation Research Core, China Medical
   University Hospital
FX The experiments and data analysis were performed using the Medical
   Research Core Facilities Center, Office of Research & Development at
   China Medical University, Taichung, Taiwan. We are grateful for the
   tissue microarray (TMA) support from the Translation Research Core,
   China Medical University Hospital. The lentivirus carrying shRNAs were
   obtained from the National Core Facility for Manipulation of Gene
   Function by RNAi, miRNA, miRNA sponges, and CRISPR/Genomic Research
   Center, Academia Sinica and supported by the National Core Facility
   Program for Biotechnology Grants of MOST (MOST 1042319- B-001-001-).
   This work was supported by grants from the Ministry of Health and
   Welfare, Taiwan (MOHW107-TDU-B-212-123004), Health and welfare surcharge
   of tobacco products, China Medical University Hospital Cancer Research
   Center of Excellence (MOHW107-TDU-B-212-114024, Taiwan) and China
   Medical University Hospital, Taiwan (DMR-107-126).
CR Adlard JW, 2002, LANCET ONCOL, V3, P75, DOI 10.1016/S1470-2045(02)00648-4
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Amornsupak K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-955
   Bhawal UK, 2005, ONCOLOGY-BASEL, V69, P246, DOI 10.1159/000087910
   Cai JY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.370
   Chao KSC, 2016, INT J RADIAT ONCOL, V96, pS108, DOI 10.1016/j.ijrobp.2016.06.265
   Czura CJ, 2001, J ENDOTOXIN RES, V7, P315, DOI 10.1177/09680519010070041401
   Fu L, 2017, ONCOGENE, V36, P2724, DOI 10.1038/onc.2016.425
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001
   Hofmann MA, 2002, GENES IMMUN, V3, P123, DOI 10.1038/sj.gene.6363861
   Huang CY, 2018, CANCER IMMUNOL IMMUN, V67, P551, DOI 10.1007/s00262-017-2109-5
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318
   Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x
   Inoue-Yamauchi A, 2012, BIOCHEM BIOPH RES CO, V421, P81, DOI 10.1016/j.bbrc.2012.03.118
   Jin BY, 2011, MED ONCOL, V28, pS373, DOI 10.1007/s12032-010-9662-5
   Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuniyasu H, 2003, INT J CANCER, V104, P722, DOI 10.1002/ijc.11016
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034318
   Li X, 2016, INFLAMMATION, V39, P96, DOI 10.1007/s10753-015-0227-9
   Lin TY, 2015, BIOMEDICINE-TAIWAN, V5, P33, DOI 10.7603/s40681-015-0005-x
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Liu LY, 2011, AUTOPHAGY, V7, P112, DOI 10.4161/auto.7.1.14005
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016
   Osawa M, 2007, BBA-GEN SUBJECTS, V1770, P1468, DOI 10.1016/j.bbagen.2007.07.003
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Prieto J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11124
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543
   Sasahira T, 2005, VIRCHOWS ARCH, V446, P411, DOI 10.1007/s00428-005-1210-x
   Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tanaka A, 2008, MOL CELL, V29, P409, DOI 10.1016/j.molcel.2008.02.005
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang DL, 2009, AM J RESP CELL MOL, V41, P651, DOI 10.1165/rcmb.2008-0119OC
   Wang KCW, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.112.100388
   Wang L, 2015, ONCOL REP, V34, P2969, DOI 10.3892/or.2015.4278
   Wang XY, 2018, BIOMEDICINE-TAIWAN, V8, P26, DOI 10.1051/bmdcn/2018080104
   Wieder SY, 2015, J INVEST DERMATOL, V135, P2544, DOI 10.1038/jid.2015.196
   Xia WJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0442-5
   Zhan DT, 2018, ARCH ORAL BIOL, V87, P86, DOI 10.1016/j.archoralbio.2017.12.011
   Zhang RG, 2015, TUMOR BIOL, V36, P8585, DOI 10.1007/s13277-015-3617-6
   Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494
   Zheng MH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16010
NR 50
TC 59
Z9 60
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 26
PY 2018
VL 9
AR 1004
DI 10.1038/s41419-018-1019-6
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GV6YY
UT WOS:000446268400002
PM 30258050
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, HH
   Tang, JL
   Li, C
   Kong, JL
   Wang, JY
   Wu, YH
   Xu, EP
   Lai, MD
AF Zhang, Honghe
   Tang, Jinlong
   Li, Chen
   Kong, Jianlu
   Wang, Jingyu
   Wu, Yihua
   Xu, Enping
   Lai, Maode
TI MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting
   apoptosis in colorectal cancer cells
SO CANCER LETTERS
LA English
DT Article
DE MiR-22; 5-FU; Autophagy; Apoptosis; Colorectal cancer
ID BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; IN-VITRO; 5-FLUOROURACIL;
   RESISTANCE; MICRORNAS; SUPPRESSOR; SURVIVAL; CHEMOTHERAPY; GENES
AB Autophagy has become one of the most important mechanisms of chemotherapy resistance by supporting the survival of tumor cells under metabolic and therapeutic stress. Here, we showed that miR-22 inhibited autophagy and promoted apoptosis to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment both in vitro and in vivo. B-cell translocation gene 1 (BTG1) was identified as a new target of miR-22, which could reverse the inhibition of autophagy induced by miR-22. Thus, miR-22 may function as an important switch between autophagy and apoptosis to regulate 5-FU sensitivity through post-transcriptional silencing of BTG1. Promisingly, miR-22 could be considered as both a predictor of 5-FU sensitivity for personalized treatment and a therapeutic target for colorectal cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Honghe; Tang, Jinlong; Li, Chen; Kong, Jianlu; Wang, Jingyu; Wu, Yihua; Xu, Enping; Lai, Maode] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Tang, Jinlong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Jingyu] First Hosp Jiaxing, Dept Pathol, Jiaxing, Peoples R China.
   [Zhang, Honghe; Li, Chen; Kong, Jianlu; Xu, Enping; Lai, Maode] Key Lab Dis Prote Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
RP Xu, EP (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
EM lmp@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81090421, 81171938, 81201557, 81302455];
   Natural Science Foundation of ZhejiangNatural Science Foundation of
   Zhejiang Province [LY12H16017]
FX This research is supported by National Natural Science Foundation of
   China (81090421, 81171938, 81201557 and 81302455) and Natural Science
   Foundation of Zhejiang (LY12H16017). We thank Prof Wei Liu (College of
   Medicine, Zhejiang University) for providing the GFP-LC3 plasmid. We
   also thank Prof. Lain Charles Bruce (College of Medicine, Zhejiang
   University) for English language assistance.
CR Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Bar N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010859
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214
   Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li B, 2013, ONCOL REP, V29, P1932, DOI 10.3892/or.2013.2300
   Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu LH, 2010, TOXICOL IN VITRO, V24, P1168, DOI 10.1016/j.tiv.2010.02.016
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888
   Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   REMMELE W, 1987, PATHOLOGE, V8, P138
   ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x
   Shang JL, 2014, J CELL BIOCHEM, V115, P772, DOI 10.1002/jcb.24721
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Tan GY, 2012, BIOCHEM BIOPH RES CO, V417, P546, DOI 10.1016/j.bbrc.2011.11.160
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919
   Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x
   Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100
   Yamakuchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020291
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 51
TC 119
Z9 125
U1 2
U2 47
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JAN 28
PY 2015
VL 356
IS 2
BP 781
EP 790
DI 10.1016/j.canlet.2014.10.029
PN B
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AZ1NL
UT WOS:000348005500051
PM 25449431
DA 2022-04-25
ER

PT J
AU Kamarudin, MNA
   Sarker, MMR
   Zhou, JR
   Parhar, I
AF Kamarudin, Muhamad Noor Alfarizal
   Sarker, Md. Moklesur Rahman
   Zhou, Jin-Rong
   Parhar, Ishwar
TI Metformin in colorectal cancer: molecular mechanism, preclinical and
   clinical aspects
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Review
DE Metformin; Colorectal cancer; Cancer; Type 2 diabetes mellitus;
   Chemopreventive; Anticancer
ID TRAIL-INDUCED APOPTOSIS; ABERRANT CRYPT FOCI; COLON-CANCER;
   DIABETES-MELLITUS; PANCREATIC-CANCER; MCL-1 DEGRADATION;
   PROSTATE-CANCER; REDUCED RISK; DOUBLE-BLIND; IN-VITRO
AB Growing evidence showed the increased prevalence of cancer incidents, particularly colorectal cancer, among type 2 diabetic mellitus patients. Antidiabetic medications such as, insulin, sulfonylureas, dipeptyl peptidase (DPP) 4 inhibitors and glucose-dependent insulinotropic peptide (GLP-1) analogues increased the additional risk of different cancers to diabetic patients. Conversely, metformin has drawn attention among physicians and researchers since its use as antidiabetic drug exhibited beneficial effect in the prevention and treatment of cancer in diabetic patients as well as an independent anticancer drug. This review aims to provide the comprehensive information on the use of metformin at preclinical and clinical stages among colorectal cancer patients. We highlight the efficacy of metformin as an anti-proliferative, chemopreventive, apoptosis inducing agent, adjuvant, and radio-chemosensitizer in various colorectal cancer models. This multifarious effects of metformin is largely attributed to its capability in modulating upstream and downstream molecular targets involved in apoptosis, autophagy, cell cycle, oxidative stress, inflammation, metabolic homeostasis, and epigenetic regulation. Moreover, the review highlights metformin intake and colorectal cancer risk based on different clinical and epidemiologic results from different gender and specific population background among diabetic and non-diabetic patients. The improved understanding of metformin as a potential chemotherapeutic drug or as neo-adjuvant will provide better information for it to be used globally as an affordable, well-tolerated, and effective anticancer agent for colorectal cancer.
C1 [Kamarudin, Muhamad Noor Alfarizal; Parhar, Ishwar] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, BRIMS, Bandar Sunway 47500, Selangor, Malaysia.
   [Sarker, Md. Moklesur Rahman] State Univ Bangladesh, Dept Pharm, 77 Satmasjid Rd, Dhaka 1205, Bangladesh.
   [Sarker, Md. Moklesur Rahman] Hlth Med Sci Res Ltd, 3-1 Block F, Dhaka 1207, Bangladesh.
   [Zhou, Jin-Rong] Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Kamarudin, MNA (corresponding author), Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, BRIMS, Bandar Sunway 47500, Selangor, Malaysia.; Sarker, MMR (corresponding author), State Univ Bangladesh, Dept Pharm, 77 Satmasjid Rd, Dhaka 1205, Bangladesh.
EM MuhamadNoor.Alfarizal@monash.edu; moklesur2002@yahoo.com
RI Sarker, Moklesur Rahman/AAH-9492-2019; KAMARUDIN, MUHAMAD NOOR
   ALFARIZAL/S-3187-2018; Sarker, Moklesur Rahman/G-2396-2014
OI Sarker, Moklesur Rahman/0000-0001-9795-0608; Sarker, Moklesur
   Rahman/0000-0002-0787-0944; Kamarudin, Alfarizal/0000-0003-2505-1018
FU Brain Research Institute Monash Sunway (BRIMS); Jeffrey Cheah School of
   Medicine and Health Sciences, Monash University Malaysia
FX The authors would like to thank the funding from Brain Research
   Institute Monash Sunway (BRIMS) and Jeffrey Cheah School of Medicine and
   Health Sciences, Monash University Malaysia.
CR Abdel-Rahman O, 2019, CLIN TRANSL ONCOL, V21, P512, DOI 10.1007/s12094-018-1939-8
   Abu el Maaty MA, 2017, MOL CARCINOGEN, V56, P2486, DOI 10.1002/mc.22696
   Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   Amable G, 2019, INT J BIOCHEM CELL B
   Balsells M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h102
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769
   Bishnoi R, 2019, CANCER MED-US, V8, P3918, DOI 10.1002/cam4.2278
   Bodmer M, 2012, CANCER EPIDEM BIOMAR, V21, P280, DOI 10.1158/1055-9965.EPI-11-0992-T
   Bordini HP, 2016, MOL CARCINOG
   Bozzi F, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0475-z
   Bradley MC, 2018, CANCER EPIDEM BIOMAR, V27, P525, DOI 10.1158/1055-9965.EPI-17-0424
   Bugianesi E, 2005, AM J GASTROENTEROL, V100, P1082, DOI 10.1111/j.1572-0241.2005.41583.x
   Cantoria MJ, 2014, METABOLOMICS, V10, P91, DOI 10.1007/s11306-013-0555-4
   Cardel M, 2014, CANCER MED-US, V3, P1458, DOI 10.1002/cam4.306
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chang CH, 2012, J CLIN ENDOCR METAB, V97, pE1170, DOI 10.1210/jc.2012-1162
   Chang Y-C, 2015, J CARDIOLOGY THERAPY, V2, P386
   Cho S-Y, 2013, EVID-BASED COMPL ALT, P2013
   Cho YH, 2014, INTEST RES, V12, P139, DOI 10.5217/ir.2014.12.2.139
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Cossor FI, 2013, CANCER EPIDEMIOL, V37, P742, DOI 10.1016/j.canep.2013.04.015
   Cufi S, 2013, ONCOTARGET, V4, P1484, DOI 10.18632/oncotarget.1234
   de Bruijn KMJ, 2013, BRIT J SURG, V100, P1421, DOI 10.1002/bjs.9229
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Elmaci I, 2016, BIOCHEM GENET, V54, P573, DOI 10.1007/s10528-016-9754-9
   Farmer RE, 2019, INT J EPIDEMIOL, V48, P527, DOI 10.1093/ije/dyz005
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Feng YH, 2012, INT J MOL MED, V29, P920, DOI 10.3892/ijmm.2012.910
   Forouzandeh F, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001202
   Franciosi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071583
   Fransgaard T, 2016, ANN SURG ONCOL, V23, P1569, DOI 10.1245/s10434-015-5028-8
   Garrett CR, 2012, BRIT J CANCER, V106, P1374, DOI 10.1038/bjc.2012.71
   Geagea Alice Gerges, 2019, Oncotarget, V10, P1284, DOI 10.18632/oncotarget.26641
   GIOVANNUCCI E, 1993, GASTROENTEROLOGY, V105, P130, DOI 10.1016/0016-5085(93)90018-8
   Glueck CJ, 2002, FERTIL STERIL, V77, P520, DOI 10.1016/S0015-0282(01)03202-2
   Godsland IF, 2010, CLIN SCI, V118, P315, DOI 10.1042/CS20090399
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2006, GASTROENTEROLOGY, V131, P973, DOI 10.1053/j.gastro.2006.07.032
   Henderson D, 2017, AM J MED SCI, V354, P246, DOI 10.1016/j.amjms.2017.05.006
   Higurashi T, 2016, LANCET ONCOL, V17, P475, DOI 10.1016/S1470-2045(15)00565-3
   Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Huang WS, 2018, J CELL BIOCHEM, V119, P6943, DOI 10.1002/jcb.26898
   Ibanez L, 2006, J CLIN ENDOCR METAB, V91, P2068, DOI 10.1210/jc.2005-2329
   Inzucchi SE, 2014, JAMA-J AM MED ASSOC, V312, P2668, DOI 10.1001/jama.2014.15298
   Jain D, 2016, J GASTROINTEST CANC, V47, P404, DOI DOI 10.1007/s12029-016-9842-4
   Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012
   Jeong YK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143596
   Jia YL, 2015, CANCER MED-US, V4, P1730, DOI 10.1002/cam4.521
   Jin HY, 2016, ONCOL LETT, V11, P3197, DOI 10.3892/ol.2016.4339
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Jung YS, 2017, J GASTROEN HEPATOL, V32, P957, DOI 10.1111/jgh.13639
   Kanadiya MK, 2013, J DIABETES COMPLICAT, V27, P463, DOI 10.1016/j.jdiacomp.2013.04.010
   Kast RE, 2017, ONCOTARGET, V8, P60727, DOI 10.18632/oncotarget.18337
   Khawaja MR, 2016, CANCER CHEMOTH PHARM, V77, P973, DOI 10.1007/s00280-016-3009-7
   Kim YH, 2015, INTEST RES, V13, P145, DOI 10.5217/ir.2015.13.2.145
   Koh SJ, 2014, J GASTROEN HEPATOL, V29, P502, DOI 10.1111/jgh.12435
   Kowall B, 2015, PHARMACOEPIDEM DR S, V24, P865, DOI 10.1002/pds.3823
   Lee Dong Jun, 2012, Korean J Gastroenterol, V60, P355
   Lee JH, 2012, DIGEST LIVER DIS, V44, P1042, DOI 10.1016/j.dld.2012.06.007
   Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20
   Leone A, 2014, CANCER TREAT RES, V159, P355, DOI 10.1007/978-3-642-38007-5_21
   Li W, 2015, CANCER PREV RES, V8, P139, DOI 10.1158/1940-6207.CAPR-14-0128
   Liu FF, 2017, ONCOTARGET, V8, P16017, DOI 10.18632/oncotarget.13762
   Loubiere C, 2015, ONCOTARGET, V6, P15652, DOI 10.18632/oncotarget.3404
   Mansourian M, 2018, EXCLI J, V17, P45, DOI 10.17179/excli2017-993
   Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7
   Mazzotti A, 2016, DIGEST LIVER DIS
   Mc Menamin UC, 2016, INT J CANCER, V138, P369, DOI 10.1002/ijc.29720
   Mei ZB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091818
   Do MT, 2014, FREE RADICAL BIO MED, V74, P21, DOI [10.1016/j.freeradbiomed2014.06.010, 10.1016/j.freeradbiomed.2014.06.010]
   Miranda VC, 2016, CLIN COLORECTAL CANC, V15, P321, DOI 10.1016/j.clcc.2016.04.011
   Montales MTE, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0499-6
   Moon HS, 2013, ENDOCR-RELAT CANCER, V20, P849, DOI 10.1530/ERC-13-0240
   Mussin N, 2017, J KOREAN MED SCI, V32, P1385, DOI 10.3346/jkms.2017.32.9.1385
   MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944
   Nangia-Makker P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084369
   Ngwuluka NC, 2016, AAPS PHARMSCITECH, P1
   Nie ZH, 2016, PHARM BIOL, V54, P2636, DOI 10.1080/13880209.2016.1176057
   Noto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033411
   Oh BY, 2016, J CANCER RES CLIN, V142, P1377, DOI 10.1007/s00432-016-2148-x
   Park SH, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-3497
   Park SH, 2016, ONCOTARGET, V7, P59503, DOI 10.18632/oncotarget.11147
   Park S, 2015, J INVEST MED, V63, P882, DOI 10.1097/JIM.0000000000000233
   Paulus JK, 2016, CANCER EPIDEM BIOMAR, V25, P1418, DOI 10.1158/1055-9965.EPI-16-0312
   Petrera M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5126-7
   Qiu H, 2013, DIABETES OBES METAB, V15, P349, DOI 10.1111/dom.12036
   Ramjeesingh R, 2016, CURR ONCOL, V23, pE116, DOI 10.3747/co.23.2809
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Richard SM, 2015, J CANCER RES THER, V11, P336, DOI 10.4103/0973-1482.157317
   Rosato V, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00210
   Rowan JA, 2008, NEW ENGL J MED, V359, P106
   Saber MM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2157-9
   Sabit Hussein, 2018, Asian Pac J Cancer Prev, V19, P2991
   Salani B, 2014, ENDOCR-RELAT CANCER, V21, pR461, DOI 10.1530/ERC-14-0284
   Sehdev A, 2015, CANCER-AM CANCER SOC, V121, P1071, DOI 10.1002/cncr.29165
   Sena P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051478
   Shafiee MN, 2014, GYNECOL ONCOL, V132, P248, DOI 10.1016/j.ygyno.2013.10.028
   Shikata K, 2013, CANCER SCI, V104, P9, DOI 10.1111/cas.12043
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singh P.P., 2015, ASCO M ABSTR S, V33, P3531
   Singh S, 2013, CANCER EPIDEM BIOMAR, V22, P2258, DOI 10.1158/1055-9965.EPI-13-0429
   Skinner HD, 2013, CANCER MED-US, V2, P99, DOI 10.1002/cam4.54
   Spillane S, 2013, CANCER EPIDEM BIOMAR, V22, P1364, DOI 10.1158/1055-9965.EPI-13-0347
   Suhaimi NAM, 2017, MOL CANCER THER, V16, P2035, DOI 10.1158/1535-7163.MCT-16-0793
   Sui XB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097781
   Thakkar B, 2013, METABOLISM, V62, P922, DOI 10.1016/j.metabol.2013.01.014
   Nguyen TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38778-2
   Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x
   Tsai CC, 2015, WORLD J GASTROENTERO, V21, P4169, DOI 10.3748/wjg.v21.i14.4169
   Tseng CH, 2012, EUR J ENDOCRINOL, V167, P409, DOI 10.1530/EJE-12-0369
   Tsilidis KK, 2014, DIABETES CARE, V37, P2522, DOI 10.2337/dc14-0584
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Vargas AJ, 2012, NUTR CLIN PRACT, V27, P613, DOI 10.1177/0884533612454885
   Vernieri C, 2019, ONCOLOGIST, V24, P385, DOI 10.1634/theoncologist.2018-0442
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178
   Yeung S, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0087-z
   Zaafar DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100562
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zell JA, 2015, CANC PREV RES, pA21
   Zhang C, 2019, MOL MED REP, V19, P1203, DOI 10.3892/mmr.2018.9765
   Zhang YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081264
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
   Zhou Xiao-zhi, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P1935
NR 129
TC 47
Z9 48
U1 2
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD DEC 12
PY 2019
VL 38
IS 1
AR 491
DI 10.1186/s13046-019-1495-2
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JV9ZH
UT WOS:000502718400003
PM 31831021
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, BK
   Nam, SW
   Min, BS
   Ban, HS
   Paik, S
   Lee, K
   Im, JY
   Lee, Y
   Park, JT
   Kim, SY
   Kim, M
   Lee, H
   Won, M
AF Kim, Bo-Kyung
   Nam, Soon Woo
   Min, Byung Soh
   Ban, Hyun Seung
   Paik, Soonmyung
   Lee, Kyeong
   Im, Joo-Young
   Lee, Youngjoo
   Park, Joon-Tae
   Kim, Seon-Young
   Kim, Mirang
   Lee, Hongsub
   Won, Misun
TI Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the
   V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
ID INDUCED APOPTOSIS; ROCK INHIBITOR; COLON-CANCER; AUTOPHAGY; PROTEIN;
   SCREEN; ACTIVATION; THERAPY; MEMBERS; GROWTH
AB BACKGROUND: The IDF-11774, a novel clinical candidate for cancer therapy, targets HSP70 and inhibits mitochondrial respiration, resulting in the activation of AMPK and reduction in HIF-1 alpha accumulation.
   METHODS: To identify genes that have synthetic lethality to IDF-11774, RNA interference screening was conducted, using pooled lentiviruses expressing a short hairpin RNA library.
   RESULTS: We identified ATP6V0C, encoding the V0 subunit C of lysosomal V-ATPase, knockdown of which induced a synergistic growth-inhibitory effect in HCT116 cells in the presence of IDF-11774. The synthetic lethality of IDF-11774 with ATP6V0C possibly correlates with IDF-11774-mediated autolysosome formation. Notably, the synergistic effect of IDF-11774 and the ATP6V0C inhibitor, bafilomycin A1, depended on the PIK3CA genetic status and Bcl-2 expression, which regulates autolysosome formation and apoptosis. Similarly, in an experiment using conditionally reprogramed cells derived from colorectal cancer patients, synergistic growth inhibition was observed in cells with low Bcl-2 expression.
   CONCLUSIONS: Bcl-2 is a biomarker for the synthetic lethal interaction of IDF-11774 with ATP6V0C, which is clinically applicable for the treatment of cancer patients with IDF-11774 or autophagy-inducing anti-cancer drugs.
C1 [Kim, Bo-Kyung; Im, Joo-Young; Lee, Youngjoo; Kim, Seon-Young; Kim, Mirang; Won, Misun] KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea.
   [Nam, Soon Woo] Catholic Univ Korea, Incheon St Marys Hosp, 56 Dongsuro Bupyunggu, Incheon 06591, South Korea.
   [Min, Byung Soh; Paik, Soonmyung] Yonsei Univ, Serverance Biomed Sci Inst, Coll Med, Seoul 03722, South Korea.
   [Ban, Hyun Seung] KRIBB, Metab Regulat Res Ctr, Daejeon 34141, South Korea.
   [Lee, Kyeong] Dongguk Univ Seoul, Coll Pharm, Goyang 410820, South Korea.
   [Park, Joon-Tae; Lee, Hongsub] ILDONG Pharmaceut Co Ltd, Drug Discovery Team, Hwaseong 445811, Hwaseong, South Korea.
   [Won, Misun] Korea Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Funct Genom, 217 Gajeong Ro, Daejeon 34113, South Korea.
RP Won, M (corresponding author), KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea.; Won, M (corresponding author), Korea Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Funct Genom, 217 Gajeong Ro, Daejeon 34113, South Korea.
EM misun@kribb.re.kr
RI ; Ban, Hyun Seung/F-9526-2014
OI Paik, Soonmyung/0000-0001-9688-6480; Ban, Hyun Seung/0000-0002-2698-6037
FU KRIBB Initiative program [KGM4751713]; National Research Foundation
   (NRF) [NRF-2017R1A2B2011936, NRF-2018R1A5A2023127]; Health Technology RD
   [HI13C2162]
FX This work was supported by the KRIBB Initiative program (KGM4751713),
   National Research Foundation (NRF) (NRF-2017R1A2B2011936 and
   NRF-2018R1A5A2023127) and Health Technology R&D (HI13C2162).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ban HS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.235
   Ban HS, 2016, BIOCONJUGATE CHEM, V27, P1911, DOI 10.1021/acs.bioconjchem.6b00305
   Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Cartwright TH, 2012, CLIN COLORECTAL CANC, V11, P155, DOI 10.1016/j.clcc.2011.11.001
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Dai BB, 2013, CANCER RES, V73, P5532, DOI 10.1158/0008-5472.CAN-13-0712
   Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
   Diehl Paul, 2014, Drug Discov Today Technol, V11, P11, DOI 10.1016/j.ddtec.2013.12.002
   Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805
   Goldberg RM, 2006, ONCOLOGIST, V11, P981, DOI 10.1634/theoncologist.11-9-981
   Im JY, 2016, BBA-GENE REGUL MECH, V1859, P1449, DOI 10.1016/j.bbagrm.2016.07.003
   Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011
   Khorashad JS, 2015, BLOOD, V125, P1772, DOI 10.1182/blood-2014-08-588855
   Kim BK, 2014, BBA-GENE REGUL MECH, V1839, P364, DOI 10.1016/j.bbagrm.2014.03.004
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Leung AWY, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0546-y
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   Liu-Sullivan N, 2011, ONCOTARGET, V2, P1
   Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822
   Mangieri LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093257
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108
   Min H, 2014, CANCER CHEMOTH PHARM, V74, P167, DOI 10.1007/s00280-014-2451-7
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Olsen MH, 2015, INT J CANCER, V136, P2476, DOI 10.1002/ijc.29288
   Palechor-Ceron N, 2013, AM J PATHOL, V183, P1862, DOI 10.1016/j.ajpath.2013.08.009
   Perez-Sayans M, 2009, INT J ONCOL, V34, P1513, DOI 10.3892/ijo_00000280
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Ragazzoni Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.53
   Schonherr M, 2014, PIGM CELL MELANOMA R, V27, P418, DOI 10.1111/pcmr.12216
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Srivas R, 2016, MOL CELL, V63, P514, DOI 10.1016/j.molcel.2016.06.022
   Tsuboyama K, 2016, SCIENCE, V354, P1036, DOI 10.1126/science.aaf6136
   Wan G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.345
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu JY, 2012, CARCINOGENESIS, V33, P2432, DOI 10.1093/carcin/bgs277
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
NR 45
TC 10
Z9 10
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD NOV 27
PY 2018
VL 119
IS 11
BP 1347
EP 1357
DI 10.1038/s41416-018-0289-1
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HC2LS
UT WOS:000451634100006
PM 30420612
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Tan, ML
   Tan, HK
   Oon, CE
   Kuroyanagi, M
   Muhammad, TST
AF Tan, Mei Lan
   Tan, Heng Kean
   Oon, Chern Ein
   Kuroyanagi, Masanori
   Muhammad, Tengku Sifzizul Tengku
TI Identification of genes involved in the regulation of
   14-deoxy-11,12-didehydroandrographolide-induced toxicity in T-47D
   mammary cells
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE 14-Deoxy-11,12-didehydroandrographolide; Cytotoxic; Gene expression;
   Autophagic; Apoptotic
ID ANDROGRAPHIS-PANICULATA EXTRACT; MAJOR DITERPENOID CONSTITUENTS;
   BREAST-CANCER CELLS; DOWN-REGULATION; BINDING-PROTEIN; COLON-CANCER;
   CYCLE ARREST; TRANSCRIPTIONAL ACTIVITY; MICROARRAY ANALYSIS; INDUCED
   APOPTOSIS
AB 14-Deoxy-11,12-didehydroandrographolide is one of the principle compounds of the medicinal plant, Andrographis paniculata Nees. This study explored the mechanisms of 14-deoxy-11,12-didehydroandrographolide-induced toxicity and non-apoptotic cell death in T-47D breast carcinoma cells. Gene expression analysis revealed that 14-deoxy-11,12-didehydroandrographolide exerted its cytotoxic effects by regulating genes that inhibit the cell cycle or promote cell cycle arrest. This compound regulated genes that are known to reduce/inhibit cell proliferation, induce growth arrest and suppress cell growth. The growth suppression activities of this compound were demonstrated by a downregulation of several genes normally found to be over-expressed in cancers. Microscopic analysis revealed positive monodansylcadaverine (MDC) staining at 8 h, indicating possible autophagosomes. TEM analysis revealed that the treated cells were highly vacuolated, thereby suggesting that 14-deoxy-11,12-didehydroandrographolide may cause autophagic morphology in these cells. This morphology may be correlated with the concurrent expression of genes known to affect lysosomal activity, ion transport, protein degradation and vesicle transport. Interestingly, some apoptotic-like bodies were found, and these bodies contained multiple large vacuoles, suggesting that this compound is capable of eliciting a combination of apoptotic and autophagic-like morphological characteristics. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Tan, Mei Lan; Tan, Heng Kean; Muhammad, Tengku Sifzizul Tengku] Minist Sci Technol & Innovat Malaysia, Malaysian Inst Pharmaceut & Nutraceut, Halaman Bukit Gambir 11700, Pulau Pinang, Malaysia.
   [Tan, Mei Lan] Univ Sains Malaysia, Adv Med & Dent Inst, George Town, Malaysia.
   [Oon, Chern Ein] Univ Oxford, Mol Oncol Labs, Canc Res UK, Weatherall Inst Mol Med,John Radcliffe Hosp, Oxford OX1 2JD, England.
   [Kuroyanagi, Masanori] Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa 7692193, Japan.
   [Muhammad, Tengku Sifzizul Tengku] Univ Malaysia Terengganu, Fac Sci & Technol, Kuala Terengganu 21030, Terengganu, Malaysia.
RP Tan, ML (corresponding author), Minist Sci Technol & Innovat Malaysia, Malaysian Inst Pharmaceut & Nutraceut, Halaman Bukit Gambir 11700, Pulau Pinang, Malaysia.
EM tanml@usm.my
RI Oon, Chern E/B-3684-2013; Lan, Tan Mei/E-3500-2012; Muhammad, Tengku
   Sifzizul Tengku/AAW-7767-2021
OI Oon, Chern E/0000-0002-4685-6408; Lan, Tan Mei/0000-0001-6565-699X;
   Tengku Muhammad, Tengku Sifzizul/0000-0002-9275-7988
FU Fundamental Research Grant Scheme (FRGS); Higher Education Ministry
   Malaysia; R&D Initiatives Grant; Ministry of Science, Technology and
   Innovation MalaysiaMinistry of Energy, Science, Technology, Environment
   and Climate Change (MESTECC), Malaysia
FX This work was fully supported by the Fundamental Research Grant Scheme
   (FRGS), Higher Education Ministry Malaysia and partly supported by the
   R&D Initiatives Grant, Ministry of Science, Technology and Innovation
   Malaysia.
CR Aarhus M, 2008, J NEURO-ONCOL, V88, P251, DOI 10.1007/s11060-008-9569-6
   Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002
   Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37
   Apostolou A, 2008, EXP CELL RES, V314, P2454, DOI 10.1016/j.yexcr.2008.05.001
   Aruga J, 2003, GENE, V315, P87, DOI 10.1016/S0378-1119(03)00715-7
   Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103
   Balachandran P, 2005, PHARMACOL RES, V51, P19, DOI 10.1016/j.phrs.2004.04.010
   Barret B., 2007, INTEGRATIVE MED, P1238
   Bates S, 1996, ONCOGENE, V13, P1103
   Bouvard D, 2007, DEVELOPMENT, V134, P2615, DOI 10.1242/dev.000877
   Buanne P, 1998, GENOMICS, V51, P233, DOI 10.1006/geno.1998.5260
   Camarero N, 2006, MOL CANCER RES, V4, P645, DOI 10.1158/1541-7786.MCR-05-0267
   Cattaneo M, 2004, GENE, V326, P149, DOI 10.1016/j.gene.2003.10.021
   Chang KT, 2008, FOOD CHEM TOXICOL, V46, P1079, DOI 10.1016/j.fct.2007.11.002
   Cheung HY, 2005, PLANTA MED, V71, P1106, DOI 10.1055/s-2005-873128
   Chinni SR, 2008, MOL CANCER RES, V6, P446, DOI 10.1158/1541-7786.MCR-07-0117
   Chiou WF, 2000, BRIT J PHARMACOL, V129, P1553, DOI 10.1038/sj.bjp.0703191
   CHOUDHURY BR, 1987, PLANTA MED, P135, DOI 10.1055/s-2006-962655
   CHOUDHURY BR, 1984, METHOD FIND EXP CLIN, V6, P481
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   Engstrom LD, 2004, NEOPLASIA, V6, P660, DOI 10.1593/neo.04244
   Fayolle C, 2008, J INVEST DERMATOL, V128, P196, DOI 10.1038/sj.jid.5700963
   Feys T, 2007, HAEMATOLOGICA, V92, P913, DOI 10.3324/haematol.11073
   Forough R, 2003, INT J BIOL MARKER, V18, P89, DOI 10.1177/172460080301800201
   Gakiopoulou H, 2007, BRIT J CANCER, V97, P1124, DOI 10.1038/sj.bjc.6603992
   Galiova G, 2008, EUR J CELL BIOL, V87, P291, DOI 10.1016/j.ejcb.2008.01.013
   Garcia JM, 2007, CLIN CANCER RES, V13, P6351, DOI 10.1158/1078-0432.CCR-07-0882
   Geethangili M., 2008, PHYTOTHER RES
   Germaniuk-Kurowska A, 2007, CANCER RES, V67, P11789, DOI 10.1158/0008-5472.CAN-07-2721
   Gouble A, 2002, CANCER RES, V62, P1489
   Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475
   Guo L, 2010, J ENVIRON SCI HEAL C, V28, P60, DOI 10.1080/10590500903585416
   Ha SA, 2004, CLIN CANCER RES, V10, P8386, DOI 10.1158/1078-0432.CCR-04-1029
   Han YQ, 2008, MOL CANCER RES, V6, P1347, DOI 10.1158/1541-7786.MCR-07-2179
   HANDA SS, 1990, INDIAN J MED RES-B, V92, P276
   Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022
   Ho JC, 2006, INT J CANCER, V119, P1330, DOI 10.1002/ijc.22005
   Hsu LC, 2006, ONCOGENE, V25, P5517, DOI 10.1038/sj.onc.1209563
   Hu HM, 2008, J ORTHOP RES, V26, P886, DOI 10.1002/jor.20597
   Hurst DR, 2008, J BIOL CHEM, V283, P7438, DOI 10.1074/jbc.M709446200
   Ignatiuk A, 2006, J BIOL CHEM, V281, P5956, DOI 10.1074/jbc.M510032200
   Jain DC, 2000, J PHARMACEUT BIOMED, V22, P705, DOI 10.1016/S0731-7085(99)00297-6
   Jeong MH, 2004, CELL RES, V14, P295, DOI 10.1038/sj.cr.295
   KAPIL A, 1993, BIOCHEM PHARMACOL, V46, P182, DOI 10.1016/0006-2952(93)90364-3
   Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209
   Kim K, 2008, J BIOL CHEM, V283, P9113, DOI 10.1074/jbc.M708205200
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kremer BE, 2007, CELL, V130, P837, DOI 10.1016/j.cell.2007.06.053
   Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006
   Kucherlapati M, 2007, ONCOGENE, V26, P6297, DOI 10.1038/sj.onc.1210453
   Kumar RA, 2004, J ETHNOPHARMACOL, V92, P291, DOI 10.1016/j.jep.2004.03.004
   Kurehara H, 2007, INT J ONCOL, V30, P421
   Li JL, 2007, EUR J PHARMACOL, V568, P31, DOI 10.1016/j.ejphar.2007.04.027
   Li XQ, 2007, CANCER SCI, V98, P1592, DOI 10.1111/j.1349-7006.2007.00565.x
   Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106
   Liu K, 2007, MOL BIOL CELL, V18, P487, DOI 10.1091/mbc.E06-07-0592
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Lu J, 2008, BIOCHEM BIOPH RES CO, V369, P948, DOI 10.1016/j.bbrc.2008.02.122
   Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002
   Martinez-Arribas F, 2006, J CELL BIOCHEM, V97, P1275, DOI 10.1002/jcb.20725
   Mathur M, 2007, ONCOGENE, V26, P277, DOI 10.1038/sj.onc.1209783
   MATSUDA T, 1994, CHEM PHARM BULL, V42, P1216, DOI 10.1248/cpb.42.1216
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Myojin R, 2004, BIOL REPROD, V71, P926, DOI 10.1095/biolreprod.104.028159
   Nickeleit I, 2008, CANCER CELL, V14, P23, DOI 10.1016/j.ccr.2008.05.016
   Nishikawa Y, 1997, BIOCHEM J, V321, P537, DOI 10.1042/bj3210537
   Novellino L, 2008, CELL SIGNAL, V20, P872, DOI 10.1016/j.cellsig.2007.12.024
   Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839
   Olayioye MA, 2005, J BIOL CHEM, V280, P27436, DOI 10.1074/jbc.M413330200
   Pole, 2006, AYURVEDIC MED PRINCI
   PURI A, 1993, J NAT PROD, V56, P995, DOI 10.1021/np50097a002
   RANA A C, 1991, Archives of Pharmacal Research (Seoul), V14, P93, DOI 10.1007/BF02857822
   Reyes BAS, 2006, J ETHNOPHARMACOL, V105, P196, DOI 10.1016/j.jep.2005.10.018
   Richard DJ, 2008, NATURE, V453, P677, DOI 10.1038/nature06883
   SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3
   Schwartz B, 2007, ONCOGENE, V26, P4049, DOI 10.1038/sj.onc.1210193
   Sheeja K, 2007, IMMUNOPHARM IMMUNOT, V29, P81, DOI 10.1080/08923970701282726
   Sheeja K, 2007, INT IMMUNOPHARMACOL, V7, P211, DOI 10.1016/j.intimp.2006.10.002
   Shen Kai-kai, 2009, Yaoxue Xuebao, V44, P973
   Shiratsuchi A, 1999, J BIOL CHEM, V274, P5901, DOI 10.1074/jbc.274.9.5901
   Singha PK, 2003, FITOTERAPIA, V74, P692, DOI [10.1016/S0367-326X(03)00159-X, 10.1016/s0367-326X(03)00159-X]
   Singha PK, 2007, J ETHNOPHARMACOL, V111, P13, DOI 10.1016/j.jep.2006.10.026
   Solomon S, 2007, MOL CELL BIOL, V27, P2324, DOI 10.1128/MCB.02300-06
   Song H, 2004, J BIOCHEM, V135, P331, DOI 10.1093/jb/mvh040
   Steen RL, 2003, J CELL SCI, V116, P2237, DOI 10.1242/jcs.00432
   Tan ML, 2005, PHARM BIOL, V43, P501, DOI 10.1080/13880200500220557
   Tang W., 1992, CHINESE DRUGS PLANT
   Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200
   Thisoda P, 2006, EUR J PHARMACOL, V553, P39, DOI 10.1016/j.ejphar.2006.09.052
   Tompkins VS, 2007, J BIOL CHEM, V282, P1322, DOI 10.1074/jbc.M609612200
   Tsai TC, 2005, J BIOL CHEM, V280, P20000, DOI 10.1074/jbc.M412169200
   Tvrdik D, 2007, FOLIA BIOL-PRAGUE, V53, P207
   Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106
   Varma A., 2009, ANDROGRAPHOLIDE NEW
   Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200
   Waring JF, 2001, TOXICOL LETT, V120, P359, DOI 10.1016/S0378-4274(01)00267-3
   Waters MD, 2004, NAT REV GENET, V5, P936, DOI 10.1038/nrg1493
   Webley SD, 2000, BRIT J CANCER, V83, P792, DOI 10.1054/bjoc.2000.1358
   Wilson MD, 2008, MOL CELL BIOL, V28, P1503, DOI 10.1128/MCB.01565-07
   Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583
   Wu Y, 2007, ONCOGENE, V26, P765, DOI 10.1038/sj.onc.1209835
   Yang ZM, 2007, ENDOCRINOLOGY, V148, P1340, DOI 10.1210/en.2006-0716
   Yano M, 2004, INT J CANCER, V112, P8, DOI 10.1002/ijc.20407
   Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918
   Zhao F, 2008, J ASIAN NAT PROD RES, V10, P473, DOI 10.1080/10286020801948599
NR 105
TC 7
Z9 7
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 2012
VL 50
IS 2
BP 431
EP 444
DI 10.1016/j.fct.2011.11.001
PG 14
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA 904SS
UT WOS:000301218800047
PM 22101062
DA 2022-04-25
ER

PT J
AU Lee, SH
   Jeong, EG
   Yoo, NJ
   Lee, SH
AF Lee, Sung Hak
   Jeong, Eun Goo
   Yoo, Nam Jin
   Lee, Sug Hyung
TI Mutational and expressional analysis of BNIP3, a pro-apoptotic Bcl-2
   member, in gastric carcinomas
SO APMIS
LA English
DT Article
DE BNIP3; expression; mutation; gastric carcinoma; apoptosis
ID CELL-DEATH; INTERACTING PROTEIN; SOMATIC MUTATIONS; COLON CANCERS; BH3
   DOMAIN; GENE; MITOCHONDRIAL; HYPOXIA; METHYLATION; MARKER
AB Cell death deregulation is a hallmark of human cancers. BNIP3 was initially identified as a proapoptotic member of the Bcl-2 family and plays an important role in apoptosis, necrosis and autophagy. The aim of this study was to see whether alterations of BNIP3 protein expression and somatic mutation of the BNIP3 gene are characteristics of human cancers. We analyzed the expression of BNIP3 protein in 60 gastric adenocarcinomas by immunohistochemistry. In addition, we analyzed BNIP3 mutation in the DNA sequences encoding BH3 (Bcl-2 homology3) and TM (transmembrane) domains that are important in the cell death function of BNIP3 by single-strand conformation polymorphism (SSCP) in 48 colorectal, 48 gastric, and 48 breast carcinomas, and 48 acute leukemias. By immunohistochemistry, BNIP3 protein was detected in 40 of the 60 carcinomas (67%). Both early and advanced gastric carcinomas expressed BNIP3. There was no significant association between BNIP3 expression and clinicopathologic characteristics, including invasion, metastasis and stage. In contrast to the cancer cells, epithelial cells in normal gastric mucosa showed no or weak expression of BNIP3. Mutational analysis revealed BNIP3 mutation in neither the BH3 nor the TM domain, suggesting that BNIP3 mutation in these domains is not a direct target of inactivation in gastric, colorectal and breast carcinomas, and acute leukemias. Increased expression of BNIP3 in the malignant gastric epithelial cells compared to the normal mucosal epithelial cells suggests that BNIP3 expression might play a role in gastric carcinoma development.
C1 Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.
RP Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
EM suhulee@catholic.ac.kr
CR Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547
   Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Kondo S, 2000, CANCER RES, V60, P4328
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666
   Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145
   Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Nam NJ, 2002, APMIS, V110, P825, DOI 10.1034/j.1600-0463.2002.1101109.x
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065
   Soung YH, 2004, HUM GENET, V115, P112, DOI 10.1007/s00439-004-1129-3
   Soung YH, 2005, CANCER RES, V65, P815
   Sowter HM, 2001, CANCER RES, V61, P6669
   Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5
   Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415
NR 29
TC 11
Z9 12
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD NOV
PY 2007
VL 115
IS 11
BP 1274
EP 1280
DI 10.1111/j.1600-0643.2007.00795.x
PG 7
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 239JJ
UT WOS:000251514300011
PM 18092960
DA 2022-04-25
ER

PT J
AU Sun, XF
   Zhu, MJ
AF Sun, Xiaofei
   Zhu, Mei-Jun
TI AMP-activated protein kinase: a therapeutic target in intestinal
   diseases
SO OPEN BIOLOGY
LA English
DT Review
DE AMPK; absorption; barrier function; colorectal cancer; intestinal
   health; intestinal inflammation
ID FATTY-ACID OXIDATION; TIGHT JUNCTION PROTEINS; HUMAN SKELETAL-MUSCLE;
   COLON-CANCER CELLS; INDUCED APOPTOSIS; GUT MICROBIOTA; EPITHELIAL
   DIFFERENTIATION; GLUCOSE-ABSORPTION; GROWTH-INHIBITION;
   PEPTIDE-TRANSPORT
AB Adenosine monophosphate (AMP)-activated protein kinase (AMPK), a highly conserved energy sensor, has a crucial role in cardiovascular, neurodegenerative and inflammatory diseases, as well as in cancer and metabolic disorders. Accumulating studies have demonstrated that AMPK activation enhances paracellular junctions, nutrient transporters, autophagy and apoptosis, and suppresses inflammation and carcinogenesis in the intestine, indicating an essential role of AMPK in intestinal health. AMPK inactivation is an aetiological factor in intestinal dysfunctions. This review summarizes the favourable outcomes of AMPK activation on intestinal health, and discusses AMPK as a potential therapeutic target for intestinal diseases.
C1 [Sun, Xiaofei; Zhu, Mei-Jun] Washington State Univ, Sch Food Sci, Pullman, WA 99164 USA.
   [Sun, Xiaofei; Zhu, Mei-Jun] Univ Idaho, Sch Food Sci, Moscow, ID 83844 USA.
RP Zhu, MJ (corresponding author), Washington State Univ, Sch Food Sci, Pullman, WA 99164 USA.; Zhu, MJ (corresponding author), Univ Idaho, Sch Food Sci, Moscow, ID 83844 USA.
EM meijun.zhu@wsu.edu
RI Sun, Xiaofei/S-9786-2018
OI Sun, Xiaofei/0000-0002-4835-9309
FU Washington State University Agricultural Research Center Emerging
   Research Issues Internal Competitive [10A-3057-8640];  [NIHR15HD073864]
FX This work was partially supported by NIHR15HD073864 and Washington State
   University Agricultural Research Center Emerging Research Issues
   Internal Competitive grant no. (10A-3057-8640).
CR Al-Khalili L, 2004, AM J PHYSIOL-CELL PH, V286, pC1410, DOI 10.1152/ajpcell.00444.2003
   Almaca J, 2009, PFLUG ARCH EUR J PHY, V458, P713, DOI 10.1007/s00424-009-0660-4
   Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919
   Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200
   Aoki K, 2011, CANCER RES, V71, P593, DOI 10.1158/0008-5472.CAN-10-2842
   Au A, 2002, BIOCHEM J, V367, P247, DOI 10.1042/BJ20020393
   Baba Y, 2009, CLIN CANCER RES, V15, P4665, DOI 10.1158/1078-0432.CCR-09-0401
   Bai AP, 2010, BIOCHEM PHARMACOL, V80, P1708, DOI 10.1016/j.bcp.2010.08.009
   Ben-Shlomo S, 2011, J HEPATOL, V54, P1214, DOI 10.1016/j.jhep.2010.09.032
   Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173
   Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604
   Bland ML, 2010, DEV BIOL, V344, P293, DOI 10.1016/j.ydbio.2010.05.010
   Bosi E, 2006, DIABETOLOGIA, V49, P2824, DOI 10.1007/s00125-006-0465-3
   Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132
   Breen DM, 2008, BIOCHEM BIOPH RES CO, V374, P117, DOI 10.1016/j.bbrc.2008.06.104
   Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006
   Brusq JM, 2006, J LIPID RES, V47, P1281, DOI 10.1194/jlr.M600020-JLR200
   Buhner S, 2006, GUT, V55, P342, DOI 10.1136/gut.2005.065557
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Carvalho BM, 2012, DIABETOLOGIA, V55, P2823, DOI 10.1007/s00125-012-2648-4
   Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x
   Cottreau J, 2012, EXPERT REV GASTROENT, V6, P17, DOI [10.1586/egh.11.87, 10.1586/EGH.11.87]
   Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45
   Duca FA, 2015, NAT MED, V21, P506, DOI 10.1038/nm.3787
   Eamin EE, 2013, J NUTR, V143, P1872, DOI 10.3945/jn.113.179549
   EE HC, 1995, AM J PATHOL, V147, P586
   Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063388
   Escaffit F, 2006, BIOCHEM BIOPH RES CO, V342, P66, DOI 10.1016/j.bbrc.2006.01.128
   Everard A, 2011, DIABETES, V60, P2775, DOI 10.2337/db11-0227
   FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375
   FERRARIS RP, 1989, ANNU REV PHYSIOL, V51, P125, DOI 10.1146/annurev.ph.51.030189.001013
   Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326
   Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104
   Fu X, 2013, MOL CELL BIOL, V33, P4517, DOI 10.1128/MCB.01078-13
   Gabler NK, 2009, J NUTR BIOCHEM, V20, P17, DOI 10.1016/j.jnutbio.2007.11.009
   Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9
   Gerondalds S, 2014, NAT IMMUNOL, V15, P15, DOI 10.1038/ni.2785
   Goirand F, 2007, J PHYSIOL-LONDON, V581, P1163, DOI 10.1113/jphysiol.2007.132589
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guo SH, 2013, AM J PATHOL, V182, P375, DOI 10.1016/j.ajpath.2012.10.014
   H-d Yuan, 2010, APOPTOSIS, V2, P6
   Hallows KR, 2010, AM J PHYSIOL-RENAL, V298, pF1067, DOI 10.1152/ajprenal.00005.2010
   Hallows KR, 2005, CURR OPIN NEPHROL HY, V14, P464, DOI 10.1097/01.mnh.0000174145.14798.64
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005
   Harmel E, 2014, ENDOCRINOLOGY, V155, P873, DOI 10.1210/en.2013-1750
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   Hollander D, 1999, Curr Gastroenterol Rep, V1, P410, DOI 10.1007/s11894-999-0023-5
   Horman S, 2008, J BIOL CHEM, V283, P18505, DOI 10.1074/jbc.M802053200
   Hou YQ, 2011, BRIT J NUTR, V106, P357, DOI 10.1017/S0007114511000249
   Huang SL, 2012, DIABETOLOGIA, V55, P1469, DOI 10.1007/s00125-011-2366-3
   Hutber CA, 1997, AM J PHYSIOL-ENDOC M, V272, pE262, DOI 10.1152/ajpendo.1997.272.2.E262
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Hwang JT, 2006, CANCER RES, V66, P10057, DOI 10.1158/0008-5472.CAN-06-1814
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V332, P433, DOI 10.1016/j.bbrc.2005.04.143
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195
   Ichikawa-Tomikawa N, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/253048
   Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159
   Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627
   Ix JH, 2010, J AM SOC NEPHROL, V21, P406, DOI 10.1681/ASN.2009080820
   JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kamada N, 2005, J IMMUNOL, V175, P6900, DOI 10.4049/jimmunol.175.10.6900
   Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200
   Kefas BA, 2004, BIOCHEM PHARMACOL, V68, P409, DOI 10.1016/j.bcp.2004.04.003
   Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155
   Kennedy DJ, 2002, PFLUG ARCH EUR J PHY, V445, P139, DOI 10.1007/s00424-002-0910-1
   Kim AY, 2010, MOL ENDOCRINOL, V24, P1441, DOI 10.1210/me.2009-0498
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Kim HJ, 2010, J AGR FOOD CHEM, V58, P8643, DOI 10.1021/jf101510z
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2
   King TD, 2006, BIOCHEM PHARMACOL, V71, P1637, DOI 10.1016/j.bcp.2006.03.005
   Koh SJ, 2014, J GASTROEN HEPATOL, V29, P502, DOI 10.1111/jgh.12435
   Kojima T, 2009, HISTOL HISTOPATHOL, V24, P1463, DOI 10.14670/HH-24.1463
   Kongsuphol P, 2009, PFLUG ARCH EUR J PHY, V457, P1071, DOI 10.1007/s00424-008-0577-3
   Konopka AR, 2016, CELL REP, V15, P1394, DOI 10.1016/j.celrep.2016.04.024
   Lee HJ, 2005, TOXICOL APPL PHARM, V203, P124, DOI 10.1016/j.taap.2004.08.004
   Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828
   Lee YK, 2009, ANN NY ACAD SCI, V1171, P489, DOI 10.1111/j.1749-6632.2009.04699.x
   Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531
   Lenzen S, 1996, BIOCHEM PHARMACOL, V51, P893, DOI 10.1016/0006-2952(95)02243-0
   Li WD, 2015, MOL CARCINOGEN, V54, P1096, DOI 10.1002/mc.22179
   Mahmood K, 2013, EUR J INTERN MED, V24, P20, DOI 10.1016/j.ejim.2012.10.011
   Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030
   Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208
   Manzo-Avalos S, 2010, INT J ENV RES PUB HE, V7, P4281, DOI 10.3390/ijerph7124281
   Mao JM, 2013, DIABETES, V62, P3736, DOI 10.2337/db13-0035
   Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003
   McDaniel SS, 2001, J APPL PHYSIOL, V91, P2322, DOI 10.1152/jappl.2001.91.5.2322
   Meddings J, 2008, GUT, V57, P438, DOI 10.1136/gut.2007.143172
   Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848
   Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440
   Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a
   Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324
   Muanprasat C, 2015, BIOCHEM PHARMACOL, V96, P225, DOI 10.1016/j.bcp.2015.05.016
   Nava P, 2004, J CELL SCI, V117, P5509, DOI 10.1242/jcs.01425
   Neurath MF, 2017, NAT REV GASTRO HEPAT, V14, P269, DOI 10.1038/nrgastro.2016.208
   Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052
   Nielsen OH, 2003, SCAND J GASTROENTERO, V38, P180, DOI 10.1080/00365520310000672
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638
   Peralta C, 2001, HEPATOLOGY, V34, P1164, DOI 10.1053/jhep.2001.29197
   Pieri M, 2010, AM J PHYSIOL-GASTR L, V299, pG136, DOI 10.1152/ajpgi.00014.2010
   Randall-Demllo S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00301
   Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200
   Rogers AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069050
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297
   Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643
   Saitoh M, 2004, BIOCHEM PHARMACOL, V67, P2005, DOI 10.1016/j.bcp.2004.01.020
   Sakar Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007935
   Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003
   Seyfried TN, 2014, CARCINOGENESIS, V35, P515, DOI 10.1093/carcin/bgt480
   Shen SC, 2003, J CELL BIOCHEM, V89, P1044, DOI 10.1002/jcb.10559
   Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142
   SINGHAL RL, 1995, BIOCHEM BIOPH RES CO, V208, P425, DOI 10.1006/bbrc.1995.1355
   Stainier DYR, 2005, SCIENCE, V307, P1902, DOI 10.1126/science.1108709
   Suchankova G, 2005, BIOCHEM BIOPH RES CO, V326, P851, DOI 10.1016/j.bbrc.2004.11.114
   Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156
   Suh E, 1996, MOL CELL BIOL, V16, P619
   Sun XF, 2017, CELL DEATH DIFFER, V24, P819, DOI 10.1038/cdd.2017.14
   Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200
   Takeda J, 2013, FOOD CHEM, V138, P2140, DOI 10.1016/j.foodchem.2012.12.026
   Talley N.J., 1999, GUT, V45, P1137
   Teixeira TFS, 2012, NUTR RES, V32, P637, DOI 10.1016/j.nutres.2012.07.003
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089
   Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541
   Turer E, 2017, P NATL ACAD SCI USA, V114, pE1273, DOI 10.1073/pnas.1621400114
   Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193
   Van Klinken BJW, 1999, GUT, V44, P387, DOI 10.1136/gut.44.3.387
   Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215
   Walker J, 2005, BIOCHEM J, V385, P485, DOI 10.1042/BJ20040694
   Wang H, 2012, WORLD J GASTROENTERO, V18, P2180, DOI 10.3748/wjg.v18.i18.2180
   Wang K, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050272
   Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242
   Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005
   Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133
   Xue YS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168670
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yano T, 2013, J CELL BIOL, V203, P605, DOI 10.1083/jcb.201304194
   Yasuda Y, 2010, CANCER SCI, V101, P1701, DOI 10.1111/j.1349-7006.2010.01579.x
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P17272, DOI 10.1073/pnas.0608531103
   Zhang X, 2015, SCI REP-UK, V5, DOI [10.1038/srep09803, 10.1038/srep09940]
NR 165
TC 27
Z9 27
U1 4
U2 9
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
EI 2046-2441
J9 OPEN BIOL
JI Open Biol
PD AUG
PY 2017
VL 7
IS 8
AR 170104
DI 10.1098/rsob.170104
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FF2XK
UT WOS:000408759900004
PM 28835570
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ba, MC
   Long, H
   Wang, S
   Wu, YB
   Zhang, BH
   Yan, ZF
   Yu, FH
   Cui, SZ
AF Ba, Ming-Chen
   Long, Hui
   Wang, Shuai
   Wu, Yin-Bing
   Zhang, Bo-Huo
   Yan, Zhao-Fei
   Yu, Fei-Hong
   Cui, Shu-Zhong
TI Hyperthermia enhances radiosensitivity of colorectal cancer cells
   through ROS inducing autophagic cell death
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE autophagy; cvolorectal cancer; hyperthermia; radiotherapy; ROS
ID INTRAPERITONEAL CHEMOTHERAPY; OXIDATIVE-STRESS; MILD HYPERTHERMIA;
   DOWN-REGULATION; RECTAL-CANCER; BREAST-CANCER; APOPTOSIS; SENSITIVITY;
   THERAPY; MODULATION
AB Hyperthermia (HT) enhances the anti-cancer effects of radiotherapy (RT), but the precise biochemical mechanisms involved are unclear. This study was aim to investigate if mild HT sensitizes colorectal cancer cells to RT through reactive oxygen species (ROS)-inducing autophagic cell death in a mice model of HCT116 human colorectal cancer. HCT116 mice model were randomly divided into five groups: mock group, hyperthermia group (HT), radiotherapy group (RT), HT+RT group, and HT+RT +N-acetyl L-cysteine (NAC) group (HT+CT+NAC). After four weeks of treatment, cancer growth inhibition, rate and mitochondrial membrane potential were measured with MTT and JC-1 assays, respectively, while ROS were estimated fluorimetrically. The relationship of these parameters to expressions of autophagy-related genes Beclin1, LC3B, and mTOR was analyzed. Gene expression was measured by Real-Time polymerase chain reaction (RT-PCR). There were significant increases in ROS levels and mitochondrial membrane potential in the HT+RT group. ROS levels in the HT+RT group increased more significantly than in any other group. In contrast, ROS levels in the HT+RT+NAC group were significantly decreased relative to the HT+RT group. The number of autophagic bodies in HT+RT group was higher than that of mock group. There were significant increases in the expression of Beclin1 and LC3B genes, while mTOR expression was significantly decreased in the HT+CT group. Treatment with NAC reversed the pattern of these changes. These results indicate that HT enhances the radiosensitivity of colorectal cancer cells to RT through ROS inducing autophagic cell death.
C1 [Ba, Ming-Chen; Wang, Shuai; Wu, Yin-Bing; Zhang, Bo-Huo; Yan, Zhao-Fei; Yu, Fei-Hong; Cui, Shu-Zhong] Guangzhou Med Univ, Canc Hosp & Inst, Intracelom Hypertherm Perfus Therapy Ctr, Guangzhou, Guangdong, Peoples R China.
   [Long, Hui] Guangzhou Dermatol Inst, Dept Pharm, Guangzhou 510095, Guangdong, Peoples R China.
RP Long, H (corresponding author), Guangzhou Dermatol Inst, Dept Pharm, Guangzhou 510095, Guangdong, Peoples R China.; Ba, MC (corresponding author), Guangzhou Med Univ, Canc Hosp, Intracelom Hypertherm Perfus Therapy Ctr, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.
EM medbamc@126.com; bil368@163.com
FU Guangzhou Key Medical Discipline Construction Project [2006Z1-E6041];
   Guangdong Science and Technology Plan Project [2009A030301013];
   Guangzhou Science Technology and Innovation Commission [2014Y2-00152,
   2014Y2-00548]
FX Guangzhou Key Medical Discipline Construction Project, Grant number:
   2006Z1-E6041; Guangdong Science and Technology Plan Project, Grant
   number: 2009A030301013; Guangzhou Science Technology and Innovation
   Commission, Grant numbers: 2014Y2-00152, 2014Y2-00548
CR Aladag I, 2016, J LARYNGOL OTOL, V130, P440, DOI 10.1017/S0022215116000992
   ARMOUR EP, 1993, CANCER RES, V53, P2740
   Atkinson RL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001447
   Baratti D, 2014, DIS COLON RECTUM, V57, P858, DOI 10.1097/DCR.0000000000000149
   Barsukov YA, 2013, COLORECTAL DIS, V15, P1107, DOI 10.1111/codi.12281
   Cao Y, 2016, HEMATOLOGY, V21, P613, DOI 10.1080/10245332.2016.1165446
   Chen F, 2008, CELL BIOL INT, V32, P715, DOI 10.1016/j.cellbi.2008.02.010
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   Cho YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057172
   Choi J, 2013, HISTOPATHOLOGY, V62, P275, DOI 10.1111/his.12002
   Cui K, 2004, PROG NEURO-PSYCHOPH, V28, P771, DOI 10.1016/j.pnpbp.2004.05.023
   Devun F, 2014, RADIOLOGY, V270, P736, DOI 10.1148/radiol.13130805
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Failli A, 2009, TUMORI J, V95, P343
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X
   HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N
   Imaoka T, 2016, INT J RADIAT BIOL, V92, P289, DOI 10.3109/09553002.2016.1152413
   Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kattan Z, 2008, BREAST CANCER RES TR, V108, P203, DOI 10.1007/s10549-007-9597-5
   Klaver YLB, 2013, STRAHLENTHER ONKOL, V189, P256, DOI 10.1007/s00066-012-0282-1
   Lehmann K, 2012, ANN SURG, V256, P730, DOI 10.1097/SLA.0b013e3182737517
   Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Ma GX, 2016, CHEM-BIOL INTERACT, V253, P1, DOI 10.1016/j.cbi.2016.04.028
   Masunaga S, 1997, JPN J CANCER RES, V88, P770, DOI 10.1111/j.1349-7006.1997.tb00449.x
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nicco C, 2005, BIOMED PHARMACOTHER, V59, P169, DOI 10.1016/j.biopha.2005.03.009
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schroeder C, 2012, INT J HYPERTHER, V28, P707, DOI 10.3109/02656736.2012.722263
   Senturker S, 1997, FEBS LETT, V416, P286, DOI 10.1016/S0014-5793(97)01226-X
   Siegel EM, 2014, DIS COLON RECTUM, V57, P941, DOI 10.1097/DCR.0000000000000160
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Toth S, 2002, CELL TISSUE RES, V309, P409, DOI 10.1007/s00441-001-0506-7
   Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035
   Wang CC, 2007, SURGERY, V142, P384, DOI 10.1016/j.surg.2007.03.013
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Yang L, 2011, W INDIAN MED J, V60, P107
   Yorimitsu T, 2007, TRENDS CELL BIOL, V17, P279, DOI 10.1016/j.tcb.2007.04.005
   Zhang J, 2015, BIO-MED MATER ENG, V26, pS2259, DOI 10.3233/BME-151532
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zhu JJ, 2016, LIFE SCI, V151, P115, DOI 10.1016/j.lfs.2016.02.014
NR 48
TC 5
Z9 5
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2018
VL 119
IS 4
BP 3763
EP 3774
DI 10.1002/jcb.26615
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FX6IO
UT WOS:000426187500072
PM 29240246
DA 2022-04-25
ER

PT J
AU Yu, ZY
   Wang, Z
   Lee, KY
   Yuan, P
   Ding, J
AF Yu, Zhao-Yan
   Wang, Zi
   Lee, Ke-Yue
   Yuan, Ping
   Ding, Jie
TI Effect of silencing colon cancer-associated transcript 2 on the
   proliferation, apoptosis and autophagy of gastric cancer BGC-823 cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE gastric cancer; long non-coding RNA; colon cancer-associated transcript
   2; POU domain class 5 transcription factor 1B; apoptosis; autophagy
ID NONCODING RNA CCAT2; POOR-PROGNOSIS; SUSCEPTIBILITY; METAANALYSIS;
   METASTASIS; BECLIN-1; PATHWAY; GROWTH; 8Q24
AB The role of long non-coding RNAs (lncRNAs) in the carcinogenesis and progression of tumors has been receiving increasing attention. Colon cancer-associated transcript 2 (CCAT2), a type of oncogenic lncRNA, is regarded as a novel biomarker of poor prognosis and metastasis in various types of cancer. However, the molecular contributions of CCAT2 to gastric cancer (GC) progression remain largely unclear. The aim of the present study was to demonstrate the effect of silencing CCAT2 on the biological behavior of GC BGC-823 cells and illustrate the potential underlying molecular mechanisms. A short hairpin RNA interference plasmid pRNAT-U6.1-CCAT2 targeting CCAT2 was successfully constructed. At 48 h after transfection with the interference plasmid, the survival rate of BGC-823 cells was significantly decreased, as determined by the MTT assay. In addition, RT-qPCR results revealed that CCAT2 gene expression was effectively suppressed by the transfection, while POU domain class 5 transcription factor 1B (POU5F1B) gene expression was significantly decreased. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay further revealed that the apoptotic index was significantly higher in the interference group. Western blot analysis also demonstrated that the expression of beclin-1 protein was significantly increased, whereas the expression levels of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) proteins were downregulated in the interference group. In conclusion, CCAT2 was able to positively regulate the expression of POU5F1B gene. Furthermore, silencing of CCAT2 gene inhibited the proliferation of BGC-823 cells, as well as induced apoptosis and autophagy in BGC-823 cells, by suppression of the PI3K/mTOR signaling pathways.
C1 [Yu, Zhao-Yan; Yuan, Ping; Ding, Jie] Guizhou Prov Peoples Hosp, Dept Gen Surg, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
   [Wang, Zi] Guizhou Prov Peoples Hosp, Dept Oncol, Guiyang 550002, Guizhou, Peoples R China.
   [Lee, Ke-Yue] Guizhou Prov Peoples Hosp, Dept Hepatobiliary Surg, Guiyang 550002, Guizhou, Peoples R China.
RP Ding, J (corresponding author), Guizhou Prov Peoples Hosp, Dept Gen Surg, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
EM djofgzsy@163.com
FU Guizhou Provincial Fund Project of Science and Technology [(2015)2095];
   Science and Technology Fund Projects of Guizhou Provincial Health and
   Family Planning Commission [gzwjkj2015-1-019]; Joint Fund Project of
   Guizhou Provincial Science and Technology Agency [(2015)7170]
FX This study was supported by grants from the Guizhou Provincial Fund
   Project of Science and Technology [grant no. (2015)2095], the Science
   and Technology Fund Projects of Guizhou Provincial Health and Family
   Planning Commission (grant no. gzwjkj2015-1-019), and the Joint Fund
   Project of Guizhou Provincial Science and Technology Agency [grant no.
   (2015)7170].
CR Barry KH, 2014, CANCER PREV RES, V7, P1282, DOI 10.1158/1940-6207.CAPR-14-0132
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   Breyer JP, 2014, AM J HUM GENET, V94, P395, DOI 10.1016/j.ajhg.2014.01.019
   Brisbin AG, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-156
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chen SF, 2016, BIOMED PHARMACOTHER, V82, P583, DOI 10.1016/j.biopha.2016.05.017
   Fan YH, 2017, CLIN CHIM ACTA, V466, P120, DOI 10.1016/j.cca.2017.01.016
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547
   He YY, 2014, TUMOR BIOL, V35, P7317, DOI 10.1007/s13277-014-2060-4
   Huang SY, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0499-x
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Liu M, 2014, INT J MOL MED, V33, P1451, DOI 10.3892/ijmm.2014.1713
   Liu Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061322
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ouyang Shaobo, 2016, Zhonghua Kou Qiang Yi Xue Za Zhi, V51, P286, DOI 10.3760/cma.j.issn.1002-0098.2016.05.007
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Redis RS, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1166308
   Redis RS, 2016, MOL CELL, V61, P520, DOI 10.1016/j.molcel.2016.01.015
   Sun WL, 2016, J CANCER RES CLIN, V142, P2231, DOI 10.1007/s00432-016-2183-7
   Wang CY, 2015, INT J CLIN EXP PATHO, V8, P779
   Wang YJ, 2016, AM J CANCER RES, V6, P2651
   [余招焱 Yu Zhaoyan], 2015, [中国普通外科杂志, Chinese Journal of General Surgery], V24, P1389
   Zhang M, 2016, WORLD J GASTROENTERO, V22, P6610, DOI 10.3748/wjg.v22.i29.6610
   Zhang R, 2016, ONCOL LETT, V12, P1233, DOI 10.3892/ol.2016.4770
   Zhao XN, 2011, ASIAN PAC J CANCER P, V12, P397
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou N, 2016, ONCOL LETT, V12, P132, DOI 10.3892/ol.2016.4580
NR 28
TC 21
Z9 24
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2018
VL 15
IS 3
BP 3127
EP 3132
DI 10.3892/ol.2017.7677
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD9FK
UT WOS:000430818300055
PM 29435046
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Soria, NGC
   Aga, DS
   Atilla-Gokcumen, GE
AF Soria, N. G. Chavez
   Aga, D. S.
   Atilla-Gokcumen, G. E.
TI Lipidomics reveals insights on the biological effects of copper oxide
   nanoparticles in a human colon carcinoma cell line
SO MOLECULAR OMICS
LA English
DT Article
ID SPECTROMETRY-BASED METABOLOMICS; CUO NANOPARTICLES; TOXICITY;
   TRIACYLGLYCEROLS; MECHANISM; AUTOPHAGY; BEHAVIOR; LIPIDS
AB Engineered nanomaterials have unique properties compared to their bulk counterparts. Copper oxide nanoparticles (CuO NPs) are one example of nanomaterials used in a wide range of consumer products due to their conductivity and biocidal properties. While CuO NPs can induce toxicity in various organisms, their interactions with different organisms and how they affect cellular homeostasis is yet to be fully understood. In this work, the toxicity of CuO NPs was evaluated in different human cell lines (colorectal carcinoma, cervical cancer, embryonic kidney, and lung fibroblast), showing a dose-dependent toxicity. An untargeted lipidomics approach using liquid chromatography-quadrupole time of flight mass spectrometry was employed in a human colon carcinoma cell line to investigate the impact of CuO NP exposure at the cellular level. A 24 h CuO NP exposure at 2.5 and 5 mu g mL(-1) resulted in upregulation of different metabolites: triacylglycerols, phosphatidylcholines, and ceramides accumulated. The most profound increase in a dose-dependent manner was observed in ceramides, specifically in C18:0, C18:1, and C22:0 species, with up to similar to 10 fold accumulations. Further experiments suggested that activation of autophagy and oxidative stress could be responsible for the toxicity observed in these cell lines. Increases in the level of glutathione oxide (similar to 7 fold) also supported the activation of oxidative stress upon CuO NP treatment. Based on the changes in different metabolites induced by CuO NP exposure and previous studies from our laboratory, we propose that autophagy and oxidative stress could play a role in CuO NP-induced toxicity.
C1 [Soria, N. G. Chavez; Aga, D. S.; Atilla-Gokcumen, G. E.] SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA.
RP Aga, DS; Atilla-Gokcumen, GE (corresponding author), SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA.
EM dianaaga@buffalo.edu; ekinatil@buffalo.edu
OI Aga, Diana/0000-0001-6512-7713; Chavez Soria, Nita/0000-0003-2303-6914
FU National Science FoundationNational Science Foundation (NSF)
   [CHE1506295, CHE-0959565, MCB1817468]
FX We acknowledge the support from the National Science Foundation grant
   CHE1506295 (to D. S. A.) and MCB1817468 (to G. E. A.-G.). We would like
   to thank the Instrument Center, specifically Dr Valerie Frerichs (UB,
   Department of Chemistry). This work utilized Inductively Coupled Plasma
   Mass Spectrometry instrument that was purchased with funding from
   National Science Foundation (CHE-0959565). We also would like to thank
   Yueling Qin (UB, Department of Chemistry) for his help with TEM.
CR Bhattacharya K, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-17
   Bondarenko O, 2013, ARCH TOXICOL, V87, P1181, DOI 10.1007/s00204-013-1079-4
   Boyles MSP, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0160-6
   Chang YN, 2012, MATERIALS, V5, P2850, DOI 10.3390/ma5122850
   Cho EJ, 2013, MOL PHARMACEUT, V10, P2093, DOI 10.1021/mp300697h
   Circu ML, 2012, BBA-MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gawande MB, 2016, CHEM REV, V116, P3722, DOI 10.1021/acs.chemrev.5b00482
   Hosokawa M., 2007, NANOPARTICLE TECHNOL
   Jiang WH, 2014, BBA-MOL CELL BIOL L, V1841, P783, DOI 10.1016/j.bbalip.2013.09.005
   Kaplan JH, 2016, BIOPHYS J, V110, P7, DOI 10.1016/j.bpj.2015.11.025
   Khan I., 2017, ARAB J CHEM, DOI [10.1016/j.arabjc.2017.05.011, DOI 10.1016/J.ARABJC.2017.05.011]
   Kitchin KT, 2017, PART FIBRE TOXICOL, V14, DOI 10.1186/s12989-017-0230-4
   Klaine SJ, 2008, ENVIRON TOXICOL CHEM, V27, P1825, DOI 10.1897/08-090.1
   Kung ML, 2015, NANOSCALE, V7, P1820, DOI 10.1039/c4nr05843g
   Laha D, 2014, BBA-GEN SUBJECTS, V1840, P1, DOI 10.1016/j.bbagen.2013.08.011
   Li NS, 2018, BIOCHEMISTRY-US, V57, P72, DOI 10.1021/acs.biochem.7b00975
   Li N, 2016, ACS CHEM BIOL, V11, P2583, DOI 10.1021/acschembio.6b00410
   Li XB, 2009, NANOMED-NANOTECHNOL, V5, P473, DOI 10.1016/j.nano.2009.01.013
   Lizardo DY, 2018, BIOCHEMISTRY-US, V57, P22, DOI 10.1021/acs.biochem.7b00862
   Lopez-Serrano A, 2014, ANAL METHODS-UK, V6, P38, DOI 10.1039/c3ay40517f
   Matich EK, 2016, ALGAL RES, V19, P146, DOI 10.1016/j.algal.2016.08.009
   Mishra AK, 2014, APPLICATION OF NANOTECHNOLOGY IN WATER RESEARCH, P1, DOI 10.1002/9781118939314
   Mohammad, 2015, NANOTECHNOLOGY PLANT
   Nowack B, 2007, ENVIRON POLLUT, V150, P5, DOI 10.1016/j.envpol.2007.06.006
   Ortelli S, 2017, ENVIRON SCI-NANO, V4, P1264, DOI [10.1039/c6en00601a, 10.1039/C6EN00601A]
   Sabuncu AC, 2012, COLLOID SURFACE B, V95, P96, DOI 10.1016/j.colsurfb.2012.02.022
   Schnackenberg L. K., 2012, NANOTOXICITY METHODS, P141, DOI [10.1007/978-1-62703-002-1_10, DOI 10.1007/978-1-62703-002-1_10]
   Sekhon BS, 2014, NANOTECHNOL SCI APPL, V7, P31, DOI 10.2147/NSA.S39406
   Semisch A, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-10
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Simonet BM, 2009, ANAL BIOANAL CHEM, V393, P17, DOI 10.1007/s00216-008-2484-z
   Soria NGC, 2017, ENVIRON SCI-NANO, V4, P1944, DOI [10.1039/c7en00555e, 10.1039/C7EN00555E]
   Srivastava A. K, 2014, OXIDE NANOSTRUCTURES
   Storck EM, 2018, ANNU REV BIOCHEM, V87, P839, DOI 10.1146/annurev-biochem-062917-012448
   Sun TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043442
   Tautenhahn R, 2012, NAT BIOTECHNOL, V30, P826, DOI 10.1038/nbt.2348
   TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913
   Wongrakpanich A, 2016, ENVIRON SCI-NANO, V3, P365, DOI 10.1039/c5en00271k
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Zhu ZJ, 2013, NAT PROTOC, V8, P451, DOI 10.1038/nprot.2013.004
NR 42
TC 13
Z9 15
U1 2
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2515-4184
J9 MOL OMICS
JI Mol. Omics
PD FEB 1
PY 2019
VL 15
IS 1
BP 30
EP 38
DI 10.1039/c8mo00162f
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HM6HN
UT WOS:000459574900009
PM 30560257
DA 2022-04-25
ER

PT J
AU Holloway, KR
   Calhoun, TN
   Saxena, M
   Metoyer, CF
   Kandler, EF
   Rivera, CA
   Pruitt, K
AF Holloway, Kimberly R.
   Calhoun, Tara N.
   Saxena, Madhurima
   Metoyer, Cheynita F.
   Kandler, Ethan F.
   Rivera, Chantal A.
   Pruitt, Kevin
TI SIRT1 regulates Dishevelled proteins and promotes transient and
   constitutive Wnt signaling
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE breast cancer; colon cancer; cambinol; beta-catenin; sirtuin 2
ID BONE MORPHOGENETIC PROTEIN-4; BETA-CATENIN; CANCER-CELLS;
   COLORECTAL-CANCER; PATHWAY ACTIVATION; PROSTATE-CANCER; COLON-CANCER;
   LUNG-CANCER; DNA-DAMAGE; CYCLIN D1
AB Sirtuin 1 (SIRT1) is a class III histone deacetylase that deacetylates histone and nonhistone proteins to regulate gene transcription and protein function. Because SIRT1 regulates very diverse responses such as apoptosis, insulin sensitivity, autophagy, differentiation, and stem cell pluripotency, it has been a challenge to reconcile how it orchestrates such pleiotropic effects. Here we show that SIRT1 serves as an important regulator of Wnt signaling. We demonstrate that SIRT1 loss of function leads to a significant decrease in the levels of all three Dishevelled (Dvl) proteins. Furthermore, we demonstrate that SIRT1 and Dvl proteins complex in vivo and that inhibition of SIRT1 leads to changes in gene expression of Wnt target genes. Finally, we demonstrate that Wnt-stimulated cell migration is inhibited by a SIRT1 inhibitor. Because the three mammalian Dvl proteins serve as key messengers for as many as 19 Wnt ligands, SIRT1-mediated regulation of Dvl proteins may explain the diverse physiological responses observed in different cellular contexts. Previously, SIRT1 had only been shown to mediate the epigenetic silencing of Wnt antagonists. In contrast, here we report that SIRT1 regulates Dvl protein levels and Wnt signaling in several cellular contexts. These findings demonstrate that SIRT1 is a regulator of transient and constitutive Wnt signaling.
C1 [Holloway, Kimberly R.; Calhoun, Tara N.; Saxena, Madhurima; Kandler, Ethan F.; Rivera, Chantal A.; Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA.
   [Holloway, Kimberly R.; Calhoun, Tara N.; Saxena, Madhurima; Metoyer, Cheynita F.; Kandler, Ethan F.; Rivera, Chantal A.; Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Shreveport, LA 71130 USA.
   [Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA.
RP Pruitt, K (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA.
EM kpruit@lsuhsc.edu
FU Feist-Weiller Cancer Center
FX Our research was supported by an intramural grant to K.P. from the
   Feist-Weiller Cancer Center.
CR Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004
   Coussens M, 2008, PLOS ONE, V3, DOI [10.1371/journal.pone.0001571, 10.1371/journal.pone.0002640]
   Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905
   Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020
   Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050
   Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807
   Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20
   Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091
   Kang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006611
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Kim JS, 2002, CANCER RES, V62, P2744
   Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee YN, 2008, CELL SIGNAL, V20, P443, DOI 10.1016/j.cellsig.2007.11.005
   Liang XJ, 2008, MOL CANCER RES, V6, P1499, DOI 10.1158/1541-7786.MCR-07-2130
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Ma PP, 2006, MOL REPROD DEV, V73, P774, DOI 10.1002/mrd.20468
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003
   Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200
   Najdi R, 2009, ONCOGENE, V28, P4133, DOI 10.1038/onc.2009.271
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Qiang L, 2007, MOL CELL BIOL, V27, P4698, DOI 10.1128/MCB.02279-06
   Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Samarzija I, 2009, BIOCHEM BIOPH RES CO, V386, P449, DOI 10.1016/j.bbrc.2009.06.033
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Shimazu T, 2007, J BIOL CHEM, V282, P4470, DOI 10.1074/jbc.M609745200
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200
   Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Uematsu K, 2003, CANCER RES, V63, P4547
   Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018
   Wang S, 2006, CURR BIOL, V16, P2239, DOI 10.1016/j.cub.2006.09.034
   Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227
   Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388
   Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085
NR 54
TC 82
Z9 85
U1 1
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 18
PY 2010
VL 107
IS 20
BP 9216
EP 9221
DI 10.1073/pnas.0911325107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 598GH
UT WOS:000277822600037
PM 20439735
OA Green Published
DA 2022-04-25
ER

PT J
AU Sun, X
   Shu, YH
   Yan, PY
   Huang, HL
   Gao, RL
   Xu, MT
   Lu, LQ
   Tian, JK
   Huang, DS
   Zhang, JB
AF Sun, Xin
   Shu, Yuhan
   Yan, Peiyi
   Huang, Hongliang
   Gao, Ruilan
   Xu, Mengting
   Lu, Liqin
   Tian, Jingkui
   Huang, Dongsheng
   Zhang, Jianbin
TI Transcriptome profiling analysis reveals that ATP6V0E2 is involved in
   the lysosomal activation by anlotinib
SO CELL DEATH & DISEASE
LA English
DT Article
ID MOLECULAR-CLONING; NUCLEAR-PROTEIN; PHASE-II; AUTOPHAGY; MTORC1;
   MULTICENTER; DEGRADATION; EXPRESSION; CANCER; TRIAL
AB Anlotinib is a receptor tyrosine kinase inhibitor with potential anti-neoplastic and anti-angiogenic activities. It has been approved for the treatment of non-small-cell lung cancer. Lysosomes are acidic organelles and have been implicated in various mechanisms of cancer therapeutics. However, the effect of anlotinib on lysosomal function has not been investigated. In the present study, anlotinib induces apoptosis in human colon cancer cells. Through transcriptome sequencing, we found for the first time that anlotinib treatment upregulates ATP6V0E2 (ATPase H(+)Transporting V0 Subunit E2) and other lysosome-related genes expression in human colon cancer. In human colon cancer, we validated that anlotinib activates lysosomal function and enhances the fusion of autophagosomes and lysosomes. Moreover, anlotinib treatment is shown to inhibit mTOR (mammalian target of rapamycin) signaling and the activation of lysosomal function by anlotinib is mTOR dependent. Furthermore, anlotinib treatment activates TFEB, a key nuclear transcription factor that controls lysosome biogenesis and function. We found that anlotinib treatment promotes TFEB nuclear translocation and enhances its transcriptional activity. When TFEB or ATP6V0E2 are knocked down, the enhanced lysosomal function and autophagy by anlotinib are attenuated. Finally, inhibition of lysosomal function enhances anlotinib-induced cell death and tumor suppression, which may be attributed to high levels of ROS (reactive oxygen species). These findings suggest that the activation of lysosomal function protects against anlotinib-mediated cell apoptosis via regulating the cellular redox status. Taken together, our results provide novel insights into the regulatory mechanisms of anlotinib on lysosomes, and this information could facilitate the development of potential novel cancer therapeutic agents that inhibit lysosomal function.
C1 [Sun, Xin; Lu, Liqin; Zhang, Jianbin] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Oncol, Peoples Hosp, Hangzhou, Peoples R China.
   [Shu, Yuhan; Xu, Mengting; Tian, Jingkui] Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Hangzhou, Peoples R China.
   [Yan, Peiyi] Shanghai Putuo Dist Peoples Hosp, Dept Clin Lab, Shanghai, Peoples R China.
   [Huang, Hongliang] Guangdong Pharmaceut Univ, Sch Biosci & Biopharmaceut, Guangzhou, Peoples R China.
   [Huang, Hongliang] Guangdong Pharmaceut Univ, Ctr Bioresources & Drug Discovery, Guangzhou, Peoples R China.
   [Gao, Ruilan] Zhejiang Chinese Med Univ, Inst Hematol Res, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Huang, Dongsheng; Zhang, Jianbin] Hangzhou Med Coll, Clin Res Inst, Key Lab Tumor Mol Diag & Individualized Med Zheji, Peoples Hosp, Hangzhou, Peoples R China.
RP Zhang, JB (corresponding author), Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Oncol, Peoples Hosp, Hangzhou, Peoples R China.; Tian, JK (corresponding author), Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Hangzhou, Peoples R China.; Huang, DS; Zhang, JB (corresponding author), Hangzhou Med Coll, Clin Res Inst, Key Lab Tumor Mol Diag & Individualized Med Zheji, Peoples Hosp, Hangzhou, Peoples R China.
EM tjk@zju.edu.cn; dshuang@zju.edu.cn; zhangjianbin@hmc.edu.cn
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LR18H160002]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31701199, 81703907]; Traditional Chinese Medicine Scientific Research
   Fund Project of Zhejiang Province [2018ZB010]; Zhejiang Provincial
   Program in Medicine and Health Sciences and Technology [2018253645];
   Zhejiang Provincial Outstanding Talent Project of Ten Thousand Talents
   Program, Zhejiang Provincial Qianjiang Talents Program
FX This work was supported by research grants from Zhejiang Provincial
   Natural Science Foundation of China (LR18H160002), National Natural
   Science Foundation of China (31701199), Traditional Chinese Medicine
   Scientific Research Fund Project of Zhejiang Province (2018ZB010),
   Zhejiang Provincial Program in Medicine and Health Sciences and
   Technology (2018253645), Zhejiang Provincial Outstanding Talent Project
   of Ten Thousand Talents Program, Zhejiang Provincial Qianjiang Talents
   Program to Z.J. and National Natural Science Foundation of China
   (81703907) to S.X.
CR Azimi I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15474-7
   Blake-Palmer KG, 2007, GENE, V393, P94, DOI 10.1016/j.gene.2007.01.020
   Bodrikov V, 2017, EXP NEUROL, V289, P31, DOI 10.1016/j.expneurol.2016.12.007
   Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020
   Cespedes Feliciano EM, 2016, J CLIN ONCOL, V34, P3664, DOI 10.1200/JCO.2016.67.4473
   Chi Y, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.11503
   Chi YHBL, 2018, CLIN CANCER RES, V24, P5233, DOI 10.1158/1078-0432.CCR-17-3766
   Coe IR, 1997, GENOMICS, V45, P459, DOI 10.1006/geno.1997.4928
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Dang SP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0245-4
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hamalisto S, 2016, CURR OPIN CELL BIOL, V39, P69, DOI 10.1016/j.ceb.2016.02.009
   Hamilton Z, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.535
   Han BH, 2018, BRIT J CANCER, V118, P654, DOI 10.1038/bjc.2017.478
   He CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21524
   HORIKAWA I, 1995, BIOCHEM BIOPH RES CO, V208, P999, DOI 10.1006/bbrc.1995.1433
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369
   Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446
   KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0
   Li XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.433
   Liang LJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1093-3
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0721-9
   MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241
   Marchitti SA, 2007, BIOCHEM BIOPH RES CO, V356, P792, DOI 10.1016/j.bbrc.2007.03.046
   MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Ruan XH, 2019, ENDOCR-RELAT CANCER, V26, P153, DOI 10.1530/ERC-17-0558
   Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, AUTOPHAGY, V7, P1379, DOI 10.4161/auto.7.11.17166
   Sha YB, 2017, EMBO J, V36, P2544, DOI 10.15252/embj.201796699
   Shen GS, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0664-7
   Si XY, 2018, LUNG CANCER, V122, P32, DOI 10.1016/j.lungcan.2018.05.013
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Slater R, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-59
   [苏雨栋 Su Yudong], 2018, [中国肺癌杂志, Chinese Journal of Lung Cancer], V21, P428
   Sun Y, 2016, J CLIN ONCOL S, V34, P6015
   Taurin S, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3244
   Valdivia CR, 2009, AM J PHYSIOL-HEART C, V297, pH1446, DOI 10.1152/ajpheart.00513.2009
   Wang Y, 2019, ONCOTARGETS THER, V12, P2809, DOI 10.2147/OTT.S195364
   Xie CY, 2018, CANCER SCI, V109, P1207, DOI 10.1111/cas.13536
   Yan PY, 2018, AM J CHINESE MED, V46, P673, DOI [10.1142/S0192415X18500350, 10.1142/s0192415x18500350]
   Yu R, 2019, EMBO J, V38, DOI 10.15252/embj.201899748
   Zhang JB, 2018, AUTOPHAGY, V14, P1043, DOI 10.1080/15548627.2018.1447290
   Zhang JB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0571-4
   Zhang JB, 2016, ONCOTARGET, V7, P75659, DOI 10.18632/oncotarget.12318
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
   Zhitomirsky B, 2017, ONCOTARGET, V8, P45117, DOI 10.18632/oncotarget.15155
   Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004
   Zhou AP, 2019, ONCOLOGIST, V24, pE702, DOI 10.1634/theoncologist.2018-0839
   Zhou AP, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e16082
   Zhou J, 2013, AUTOPHAGY, V9, P803, DOI 10.4161/auto.23965
   Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11
NR 62
TC 4
Z9 4
U1 6
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 24
PY 2020
VL 11
IS 8
AR 702
DI 10.1038/s41419-020-02904-0
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NK8MF
UT WOS:000566984200002
PM 32839434
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhao, J
   Dong, JN
   Wang, HG
   Zhao, M
   Sun, J
   Zhu, WM
   Zuo, LG
   Gong, JF
   Li, Y
   Gu, LL
   Li, N
   Li, JS
AF Zhao, Jie
   Dong, Jian-Ning
   Wang, Hong-Gang
   Zhao, Mingli
   Sun, Jing
   Zhu, Wei-Ming
   Zuo, Lu-Gen
   Gong, Jian-Feng
   Li, Yi
   Gu, Li-Li
   Li, Ning
   Li, Jie-Shou
TI Docosahexaenoic Acid Attenuated Experimental Chronic Colitis in
   Interleukin 10-Deficient Mice by Enhancing Autophagy Through Inhibition
   of the mTOR Pathway
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE Crohn's disease; interleukin 10-deficient mice; docosahexaenoic acid;
   autophagy; mTOR pathway
ID INFLAMMATORY BOWEL DISEASES; POLYUNSATURATED FATTY-ACIDS;
   CROHNS-DISEASE; EICOSAPENTAENOIC ACID; CELLS; CANCER; APOPTOSIS;
   IMMUNITY; OMEGA-3-FATTY-ACIDS; MODULATION
AB Background: In the battle against Crohn's disease, autophagy stimulation is a promising therapeutic optionone both new and newly rediscovered. In experimental models, docosahexaenoic acid (DHA)a long-chain polyunsaturated fatty acidhas been demonstrated to be useful in the treatment of inflammatory bowel disease through inhibition of the nuclear factor-B pathway. However, the impact of DHA on autophagy in the colon remains unclear. Methods: Mice were divided into 3 groups: wild type (placebo), the interleukin 10 knockout group (IL-10(-/-), placebo), and the DHA group (IL-10(-/-), DHA). DHA was administered to IL-10(-/-) mice by gavage at a dosage of 35.5 mg/kg/d for 2 weeks. The severity of colitis, expression of proinflammatory cytokines, expression/distribution of LC3B, and mTOR signaling pathway were evaluated in the proximal colon tissues collected from all mice at the end of the experiment. Results: DHA administration ameliorated experimental colitis in the IL-10(-/-) mice, as demonstrated by decreased proinflammatory cytokines (TNF- and IFN-), reduced infiltration of inflammatory cells, and lowered histologic scores of the proximal colon mucosa. Moreover, in the DHA-treated mice, enhanced autophagy was observed to be associated with (1) increased expression and restoration of the distribution integrity of LC3B in the colon and (2) inhibition of the mTOR signaling pathway. Conclusion: This study showed that DHA therapy could attenuate experimental chronic colitis in IL-10(-/-) mice by triggering autophagy via inhibition of the mTOR pathway.
C1 [Zhao, Jie; Dong, Jian-Ning; Wang, Hong-Gang; Zhao, Mingli; Sun, Jing; Zhu, Wei-Ming; Zuo, Lu-Gen; Gong, Jian-Feng; Li, Yi; Gu, Li-Li; Li, Ning; Li, Jie-Shou] Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
RP Zhu, WM (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM zhuweimingtg@163.com
FU National Ministry of Health for Digestive Disease [201002020]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81200263, 81170365, 81270006]; Jiangsu Provincial
   Special Program of Medical Science [BL2012006]
FX This work was supported in part by funding from the National Ministry of
   Health for Digestive Disease (grant 201002020), the National Natural
   Science Foundation of China (grants 81200263, 81170365, 81270006), and
   Jiangsu Provincial Special Program of Medical Science (BL2012006).
CR Andrade-Vieira R, 2013, CANCER BIOL THER, V14, P1050, DOI 10.4161/cbt.26206
   Borrelli O, 2006, CLIN GASTROENTEROL H, V4, P744, DOI 10.1016/j.cgh.2006.03.010
   Cabre E, 2012, BRIT J NUTR, V107, pS240, DOI 10.1017/S0007114512001626
   Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009
   Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x
   Calder PC, 2010, CLIN NUTR, V29, P5, DOI 10.1016/j.clnu.2009.11.003
   Chen R, 2014, J CELL BIOL, V206, P173, DOI 10.1083/jcb.201403009
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Coulombe F, 2009, LANCET, V374, P769, DOI 10.1016/S0140-6736(09)61576-2
   Deretic V, 2011, IMMUNOL REV, V240, P92, DOI 10.1111/j.1600-065X.2010.00995.x
   EI-Sharkawy H, 2010, J PERIODONTOL, V81, P1635, DOI 10.1902/jop.2010.090628
   ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501
   Eom JM, 2010, BIOCHEM BIOPH RES CO, V391, P903, DOI 10.1016/j.bbrc.2009.11.161
   Froslie KF, 2007, GASTROENTEROLOGY, V133, P412, DOI 10.1053/j.gastro.2007.05.051
   Fukui M, 2013, J CELL BIOCHEM, V114, P192, DOI 10.1002/jcb.24354
   Garcia-Maurino S, 2012, CURR PHARM DESIGN, V18, P3853, DOI 10.2174/138161212802083653
   Goettel JA, 2011, GASTROENTEROLOGY, V140, P265, DOI 10.1053/j.gastro.2010.09.041
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hsu HC, 2014, EUR J NUTR, V53, P541, DOI 10.1007/s00394-013-0562-2
   Huang SC, 2014, NEUROSCI LETT, V580, P125, DOI 10.1016/j.neulet.2014.08.011
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kiss MHB, 2008, J CLIN IMMUNOL, V28, pS84, DOI 10.1007/s10875-008-9179-2
   Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007
   Li Y, 2010, MOL IMMUNOL, V47, P2467, DOI 10.1016/j.molimm.2010.06.007
   Marcuzzi A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/297501
   Marion-Letellier R, 2013, INFLAMM BOWEL DIS, V19, P205, DOI [10.1002/ibd.23001, 10.1097/MIB.0b013e3182810122]
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   Ng SC, 2012, INFLAMM BOWEL DIS, V18, P1164, DOI 10.1002/ibd.21845
   Nys K, 2013, NAT REV GASTRO HEPAT, V10, P395, DOI 10.1038/nrgastro.2013.66
   Pang YX, 2014, FOOD CHEM TOXICOL, V69, P163, DOI 10.1016/j.fct.2014.04.010
   Plantinga TS, 2012, CURR OPIN PHARMACOL, V12, P497, DOI 10.1016/j.coph.2012.01.017
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Singh UP, 2003, J IMMUNOL, V171, P1401, DOI 10.4049/jimmunol.171.3.1401
   Stappenbeck TS, 2011, AUTOPHAGY, V7, P355, DOI [10.4161/auto.7.4.13074, 10.4161/auto.7.2.13074]
   Stewart M, 2011, J PEDIATR GASTR NUTR, V52, P38, DOI 10.1097/MPG.0b013e3181e2c724
   VanNoolen L, PROSTAGLANDINS LEUKO
   Weylandt KH, 2012, PROSTAG OTH LIPID M, V97, P73, DOI 10.1016/j.prostaglandins.2012.01.005
   Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957
   Yamada H, 2008, ARTERIOSCL THROM VAS, V28, P2173, DOI 10.1161/ATVBAHA.108.171736
   Yuk JM, 2012, EXP MOL MED, V44, P99, DOI 10.3858/emm.2012.44.2.032
   Zhou XJ, 2012, AUTOPHAGY, V8, P1286, DOI 10.4161/auto.21212
NR 43
TC 12
Z9 12
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD JUL
PY 2017
VL 41
IS 5
BP 824
EP 829
DI 10.1177/0148607115609308
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA FC1WU
UT WOS:000406629400012
PM 26407598
DA 2022-04-25
ER

PT J
AU Wu, JC
   Wang, FZ
   Tsai, ML
   Lo, CY
   Badmaev, V
   Ho, CT
   Wang, YJ
   Pan, MH
AF Wu, Jia-Ching
   Wang, Fang-Zong
   Tsai, Mei-Ling
   Lo, Chih-Yu
   Badmaev, Vladimir
   Ho, Chi-Tang
   Wang, Ying-Jan
   Pan, Min-Hsiung
TI Se-Allylselenocysteine induces autophagy by modulating the AMPK/mTOR
   signaling pathway and epigenetic regulation of PCDH17 in human
   colorectal adenocarcinoma cells
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Autophagy; DNA methylation; Epigenetic; Se-allylselenocysteine; PCDH17
ID DNA METHYLTRANSFERASE 1; SELENOAMINO ACIDS; CANCER PREVENTION;
   TUMOR-SUPPRESSOR; GASTRIC-CANCER; SELENIUM; DEATH; APOPTOSIS;
   METHYLATION; ACTIVATION
AB Scope: Selenium ( Se)-conjugated compounds have been established as anti-carcinogenic compounds. The use of chemicals as cancer chemotherapeutic agents to induce programmed cell death (PCD) involves genetic and epigenetic modifications. In this study, we investigated the underlying molecular mechanisms of Se-allylselenocysteine (ASC)-induced PCD and protocadherin 17 (PCDH17) expression in HT-29 cells.
   Methods and results: Cell viability analysis indicated that the ability of ASC to induce cancer cell death was greater than that of Se-methylselenocysteine in colorectal cancer cells. ASC also decreased global DNA methylation levels via downregulation of DNA methyltransferase 1 expression. The autophagic cell death is the cause in ASC-induced cytotoxicity that was inhibited by pretreatment with autophagy inhibitor. At the molecular level, ASC induced PCDH17 expression through decreased PCDH17 promoter hypermethylation. PCDH17 is also an important role in ASC-induced autophagy by HT-29 transfected with PCDH17 shRNA or expression plasmid. Our western blot analysis showed that ASC significantly induced autophagy via the AMPK/mTOR pathway that was also regulated PCDH17 expression. Additionally, we used the HT-29 tumor xenograft models to confirm the ability of ASC inhibited tumor growth.
   Conclusion: These results reveal that ASC is an effective inducer of autophagy through regulating the AMPK/mTOR and PCDH17 expression via epigenetic modification.
C1 [Wu, Jia-Ching; Wang, Ying-Jan] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 70101, Taiwan.
   [Wang, Fang-Zong; Tsai, Mei-Ling] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung, Taiwan.
   [Lo, Chih-Yu] Natl Chiayi Univ, Dept Food Sci, Chiayi 60004, Taiwan.
   [Badmaev, Vladimir] Amer Med Holdings Inc, New York, NY USA.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08903 USA.
   [Wang, Ying-Jan] Asia Univ, Dept Biomed Informat, Taichung, Taiwan.
   [Wang, Ying-Jan; Pan, Min-Hsiung] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Pan, Min-Hsiung] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
   [Pan, Min-Hsiung] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10764, Taiwan.
RP Pan, MH (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
EM mhpan@ntu.edu.tw
RI Pan, Min-Hsiung/AAT-8865-2021
OI Pan, Min-Hsiung/0000-0002-5188-7030
FU National Taiwan UniversityNational Taiwan University [NTU-104R7777];
   Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [101-2628-B-022-001-MY4,
   102-2628-B-002-053-MY3]
FX This study was supported by the National Taiwan University NTU-104R7777;
   Ministry of Science and Technology101-2628-B-022-001-MY4,
   102-2628-B-002-053-MY3
CR Aryal P, 2014, FEBS J, V281, P4644, DOI 10.1111/febs.12969
   CAI XJ, 1995, J AGR FOOD CHEM, V43, P1754, DOI 10.1021/jf00055a002
   Cheishvili D, 2015, BRIT J PHARMACOL, V172, P2705, DOI 10.1111/bph.12885
   Cheng YC, 2015, EXP BIOL MED, V240, P467, DOI 10.1177/1535370214553772
   Coffin JC, 2000, TOXICOL SCI, V58, P243, DOI 10.1093/toxsci/58.2.243
   Commandeur JNM, 2001, ADV EXP MED BIOL, V500, P105
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Feldman J.P., 2009, J APPL QUANT METHODS, V4, P455
   Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657
   Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053
   Hu XT, 2013, J PATHOL, V229, P62, DOI 10.1002/path.4093
   Ip C, 1999, ANTICANCER RES, V19, P2875
   Jia Y, 2013, CHIN J CANCER, V32, P21, DOI 10.5732/cjc.011.10245
   Jiang WQ, 2001, CANCER LETT, V162, P167, DOI 10.1016/S0304-3835(00)00647-9
   Joseph J, 2013, NUTRIENTS, V5, P340, DOI 10.3390/nu5020340
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Larsen EH, 2001, J ANAL ATOM SPECTROM, V16, P1403, DOI 10.1039/b106355n
   Larsen EH, 2006, ANAL BIOANAL CHEM, V385, P1098, DOI 10.1007/s00216-006-0535-x
   Liu Man, 2013, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V29, P809
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Michalska-Kacymirow M, 2014, ANAL BIOANAL CHEM, V406, P3717, DOI 10.1007/s00216-014-7742-7
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Pan MH, 2011, MOL NUTR FOOD RES, V55, P723, DOI 10.1002/mnfr.201000481
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Ren J, 2011, CELL SIGNAL, V23, P1082, DOI 10.1016/j.cellsig.2011.02.003
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Sanmartin C, 2012, INT J MOL SCI, V13, P9649, DOI 10.3390/ijms13089649
   Sheng Y, 2013, BIOCHEM BIOPH RES CO, V432, P5, DOI 10.1016/j.bbrc.2013.01.106
   Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13
   Sui XB, 2012, MOL BIOL REP, V39, P1105, DOI 10.1007/s11033-011-0837-8
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   't Hoen PAC, 2002, BIOCHEM PHARMACOL, V63, P1843, DOI 10.1016/S0006-2952(02)00987-5
   Tanida I, 2012, AUTOPHAGY, V8, P88, DOI 10.4161/auto.8.1.18339
   van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107
   Walczak M, 2013, AUTOPHAGY, V9, P424, DOI 10.4161/auto.22931
   Wang Juan, 2008, Ai Zheng, V27, P119
   Wang XB, 2014, J INT MED RES, V42, P292, DOI 10.1177/0300060513504364
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Wu SB, 2014, BBA-GEN SUBJECTS, V1840, P1331, DOI 10.1016/j.bbagen.2013.10.034
   Yang YQ, 2012, HISTOL HISTOPATHOL, V27, P217, DOI 10.14670/HH-27.217
   Yie YY, 2015, MOL CELL BIOCHEM, V402, P63, DOI 10.1007/s11010-014-2314-x
   Zhang YX, 2012, NUCLEIC ACIDS RES, V40, P4850, DOI 10.1093/nar/gks159
   Zhao SY, 2015, J CELL MOL MED, V19, P630, DOI 10.1111/jcmm.12476
NR 46
TC 21
Z9 21
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD DEC
PY 2015
VL 59
IS 12
BP 2511
EP 2522
DI 10.1002/mnfr.201500373
PG 12
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA DA3WJ
UT WOS:000367730600015
PM 26395119
DA 2022-04-25
ER

PT J
AU Lin, S
   Wang, HB
   Yang, WJ
   Wang, AG
   Geng, C
AF Lin, Sen
   Wang, Hongbo
   Yang, Wenjuan
   Wang, Aiguang
   Geng, Chao
TI Silencing of Long Non-Coding RNA Colon Cancer-Associated Transcript 2
   Inhibits the Growth and Metastasis of Gastric Cancer Through Blocking
   mTOR Signaling
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colon cancer-associated transcript 2; gastric cancer; mammalian target
   of rapamycin; apoptosis; autophagy
ID PROMOTES CELL-PROLIFERATION; CCAT2 PROMOTES; THERAPEUTIC TARGET;
   AUTOPHAGY; EXPRESSION; APOPTOSIS
AB Purpose: This study aimed to evaluate the specific role of colon cancer-associated transcript 2 (CCAT2) on gastric cancer (GC), and reveal the potential regulatory mechanism relating to mammalian target of rapamycin (mTOR) signaling.
   Methods: The expression of CCAT2 was detected in GC tissues and cells by quantitative real-time PCR (qRT-PCR), and its relation with the pathologic characteristics of GC patients was analyzed. HGC-27 and SGC-7901 cells were transfected with siRNA-CCAT2 to silence CCAT2, and HGC-27 cells were then treated with an mTOR agonist Leucine (Leu) to activate mTOR signaling. The cell proliferation was evaluated by cell viability and colony formation. The cell cycle and apoptosis, and the migration and invasion abilities were detected by Flow cytometry, and Transwell assay, respectively. The expression of PCNA (proliferation marker), Snail, N-cadherin, E-cadherin (invasion markers), P53, Caspase-8, Bcl-2 (apoptosis markers), LC3-II/LC3-I, ATG3, p62 (autophagy makers), phosphorylated mTOR (p-mTOR), p-AKT, and p-p70S6K (mTOR signaling markers) were detected by Western blot.
   Results: CCAT2 was upregulated in GC tissues and cells, and positively associated with the maximum tumor diameter, lymphatic metastasis, TNM staging, and low overall survival rate (P < 0.05). siRNA-CCAT2 transfection significantly inhibited the viability, colony formation, and migration and invasion abilities, blocked the cell cycle in G0/G1 phase, and promoted the apoptosis and autophagy of SGC-7901 and HGC-27 cells (P < 0.05). In addition, siRNA-CCAT2 transfection significantly upregulated P53, Caspase-8, LC3-II/LC3-I and ATG3, and downregulated PCNA, Bcl-2, p62, p-mTOR, p-AKT and p-p70S6K in SGC-7901 and HGC-27 cells (P < 0.05). siRNA-CCAT2 reversed the tumor-promoting effect of mTOR signaling activation on HGC-27 cells (P < 0.05).
   Conclusion: Silencing of CCAT2 inhibited the proliferation, migration and invasion, and promoted the apoptosis and autophagy of GC cells through blocking mTOR signaling.
C1 [Lin, Sen; Wang, Hongbo] Shandong Univ, Hosp 2, Dept Gastroenterol, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China.
   [Yang, Wenjuan] Jinan Cent Hosp, Dept Nursing, Jinan 250013, Shandong, Peoples R China.
   [Wang, Aiguang] Qianfoshan Hosp Shandong Prov, Dept Oncol, Jinan 250014, Shandong, Peoples R China.
   [Geng, Chao] Shouguang Peoples Hosp, Dept Gastroenterol, Shouguang City 262799, Shandong, Peoples R China.
RP Lin, S (corresponding author), Shandong Univ, Hosp 2, Dept Gastroenterol, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China.
EM linsen334@163.com
CR Al-Batran SE, 2012, INT J CANCER, V130, P491, DOI 10.1002/ijc.26396
   An JY, 2010, INT J CANCER, V126, P2904, DOI 10.1002/ijc.24872
   Chang TK, 2013, NAT CELL BIOL, V15, P1067, DOI 10.1038/ncb2804
   Deng X, 2017, BIOMED PHARMACOTHER, V91, P1160, DOI 10.1016/j.biopha.2017.05.030
   Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065
   Gu Y, 2015, FUTURE ONCOL, V11, P2427, DOI 10.2217/fon.15.175
   Hewitt G, 2016, AUTOPHAGY, V12, P1917, DOI 10.1080/15548627.2016.1210368
   Huang JY, 2013, ANN SURG ONCOL, V20, P3927, DOI 10.1245/s10434-013-3021-7
   Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kaur A, 2017, INFLAMMOPHARMACOLOGY, V25, P293, DOI 10.1007/s10787-017-0336-1
   Kui W, 2011, AUTOPHAGY, V7, P13, DOI [10.4161/auto.7.5.14845, DOI 10.4161/AUTO.7.5.14845]
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Li Z, 2016, CELL PROLIFERAT, V49, P471, DOI 10.1111/cpr.12269
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Liu K, 2016, AUTOPHAGY, V12, P2000, DOI 10.1080/15548627.2016.1212786
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Murayama T, 2009, BRIT J CANCER, V100, P782, DOI 10.1038/sj.bjc.6604915
   Ruan R, 2018, EUR REV MED PHARMACO, V22, P2978, DOI 10.26355/eurrev_201805_15053
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/BST0290684
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Wang BD, 2018, ONCOL LETT, V15, P3369, DOI 10.3892/ol.2017.7669
   Wang CY, 2015, INT J CLIN EXP PATHO, V8, P779
   Wang YJ, 2016, AM J CANCER RES, V6, P2651
   Wu SW, 2017, MINERVA MED, V108, P317, DOI 10.23736/S0026-4806.17.04703-6
   Wu YouXing, 2016, Chinese Journal of Cancer Biotherapy, V23, P52
   Wu ZJ, 2017, EUR REV MED PHARMACO, V21, P706
   Xie P, 2017, CANCER BIOMARK, P1
   Xin Y, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12342
   Yamashita K, 2011, WORLD J GASTROENTERO, V17, P3390, DOI 10.3748/wjg.v17.i29.3390
   Ye YW, 2011, J SURG ONCOL, V104, P76, DOI 10.1002/jso.21896
   Yi JH, 2017, ONCOTARGET, V8, P96656, DOI 10.18632/oncotarget.3750
   Yu ZY, 2018, ONCOL LETT, V15, P3127, DOI 10.3892/ol.2017.7677
NR 36
TC 9
Z9 10
U1 1
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 337
EP 349
DI 10.2147/OTT.S220302
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA KC7ZB
UT WOS:000507390200001
PM 32021279
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zeng, XL
   Chen, SZ
   Yang, Y
   Ke, Z
AF Zeng, Xianliang
   Chen, Sizeng
   Yang, Yang
   Ke, Zhao
TI Acylated and unacylated ghrelin inhibit atrophy in myotubes co-cultured
   with colon carcinoma cells
SO ONCOTARGET
LA English
DT Article
DE cancer cachexia; ghrelin; co-culture; calpain; myotube
ID SKELETAL-MUSCLE ATROPHY; CALPAIN INHIBITORS; MYOSTATIN; DEGRADATION;
   PROTEOLYSIS; PATHWAY; DIFFERENTIATION; MECHANISM; AUTOPHAGY; MODEL
AB Cancer cachexia is a result of increased protein degradation and decreased protein synthesis. The multifunctional circulating hormone ghrelin promotes synthesis and inhibits degradation of muscle protein, but its mechanism of action is not fully understood. Here, we investigated whether co-culturing C2C12 myotubes with CT26 colon carcinoma cells induces myotube atrophy, and whether acylated ghrelin (AG) and unacylated ghrelin (UnAG) had anti-atrophic effects. We found that co-culture induced myotube atrophy and increased tumor necrosis factor-alpha (TNF-alpha) and myostatin concentrations in the culture medium. Moreover, co-culture down-regulated myogenin and MyoD expression, inhibited the Akt signaling, up-regulated ubiquitin E3 ligase expression, and activated the calpain system and autophagy in myotubes. Both AG and UnAG inhibited these changes. Our study describes a novel in vitro model that can be employed to investigate cancer cachexia, and our findings suggest a possible use for AG and UnAG in treating cancer cachexia.
C1 [Zeng, Xianliang; Chen, Sizeng; Yang, Yang; Ke, Zhao] Fujian Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Fuzhou 350005, Fujian, Peoples R China.
RP Chen, SZ (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Fuzhou 350005, Fujian, Peoples R China.
EM chensz04871@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272465]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81272465).
CR Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829
   Chopin L, 2011, MOL CELL ENDOCRINOL, V340, P65, DOI 10.1016/j.mce.2011.04.013
   Clavel S, 2010, MOL CELL BIOL, V30, P470, DOI 10.1128/MCB.00666-09
   DeBoer MD, 2008, NUTRITION, V24, P806, DOI 10.1016/j.nut.2008.06.013
   Donkor IO, 2011, EXPERT OPIN THER PAT, V21, P601, DOI 10.1517/13543776.2011.568480
   Donohoe CL, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/601434
   Du J, 2005, INT J BIOCHEM CELL B, V37, P2147, DOI 10.1016/j.biocel.2005.03.012
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7
   Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
   Filigheddu N, 2007, MOL BIOL CELL, V18, P986, DOI 10.1091/mbc.E06-05-0402
   Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018
   Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988
   Granata R, 2007, ENDOCRINOLOGY, V148, P512, DOI 10.1210/en.2006-0266
   Guillory B, 2013, VITAM HORM, V92, P61, DOI 10.1016/B978-0-12-410473-0.00003-9
   Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787
   Huang JR, 2016, PHYSIOL RES, V65, P547, DOI 10.33549/physiolres.933087
   Ibrahim RM, 2008, J ANIM SCI, V86, P1426, DOI 10.2527/jas.2007-0618
   Johns N, 2013, INT J BIOCHEM CELL B, V45, P2215, DOI 10.1016/j.biocel.2013.05.032
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lenk K, 2013, J CACHEXIA SARCOPENI, V4, P63, DOI 10.1007/s13539-012-0085-3
   Lin XY, 2017, ONCOL REP, V37, P1601, DOI 10.3892/or.2017.5396
   Lokireddy S, 2012, BIOCHEM J, V446, P23, DOI 10.1042/BJ20112024
   Lokireddy S, 2011, MOL ENDOCRINOL, V25, P1936, DOI 10.1210/me.2011-1124
   Molfino A, 2014, CURR OPIN CLIN NUTR, V17, P471, DOI 10.1097/MCO.0000000000000075
   Molfino A, 2013, EXPERT OPIN BIOL TH, V13, P465, DOI 10.1517/14712598.2013.748031
   Penna F, 2013, AM J PATHOL, V182, P1367, DOI 10.1016/j.ajpath.2012.12.023
   Pereira C, 2005, INT J BIOCHEM CELL B, V37, P1948, DOI 10.1016/j.biocel.2005.05.009
   Porporato PE, 2013, J CLIN INVEST, V123, P611, DOI 10.1172/JCI39920
   Reano S, 2014, CURR OPIN CLIN NUTR, V17, P236, DOI 10.1097/MCO.0000000000000049
   Rodriguez A, 2012, DIABETOLOGIA, V55, P3038, DOI 10.1007/s00125-012-2671-5
   Sandri M, 2008, PHYSIOLOGY, V23, P160, DOI 10.1152/physiol.00041.2007
   Shenkman BS, 2015, ARCH BIOCHEM BIOPHYS, V584, P36, DOI 10.1016/j.abb.2015.07.011
   Sheriff S, 2012, MOL CELL ENDOCRINOL, V351, P286, DOI 10.1016/j.mce.2011.12.021
   Smith IJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE762, DOI 10.1152/ajpendo.90226.2008
   Smith IJ, 2007, EXP PHYSIOL, V92, P561, DOI 10.1113/expphysiol.2006.035790
   Smith IJ, 2011, MUSCLE NERVE, V43, P410, DOI 10.1002/mus.21893
   Tardif N, 2013, AM J CLIN NUTR, V98, P1485, DOI 10.3945/ajcn.113.063859
   Trendelenburg AU, 2009, AM J PHYSIOL-CELL PH, V296, pC1258, DOI 10.1152/ajpcell.00105.2009
   Tsubouchi H, 2014, EUR J PHARMACOL, V743, P1, DOI 10.1016/j.ejphar.2014.09.025
   Voss JO, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/714230
   Wohlers LM, 2013, AM J PHYSIOL-ENDOC M, V304, pE1199, DOI 10.1152/ajpendo.00617.2012
   Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326
   Yoshida T, 2010, AM J PHYSIOL-HEART C, V298, pH1565, DOI 10.1152/ajpheart.00146.2010
NR 43
TC 7
Z9 7
U1 2
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 22
PY 2017
VL 8
IS 42
BP 72872
EP 72885
DI 10.18632/oncotarget.20531
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH9DW
UT WOS:000411509400120
PM 29069832
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zhou, WJ
   Xu, G
   Wang, YQ
   Xu, Z
   Liu, XF
   Xu, X
   Ren, GJ
   Tian, KL
AF Zhou, Wenjing
   Xu, Gang
   Wang, Yunqiu
   Xu, Ziao
   Liu, Xiaofei
   Xu, Xia
   Ren, Guijie
   Tian, Keli
TI Oxidative stress induced autophagy in cancer associated fibroblast
   enhances proliferation and metabolism of colorectal cancer cells
SO CELL CYCLE
LA English
DT Article
DE autophagy; Colorectal cancer; co-culture; metabolism; oxidative stress;
   NAC; 3-MA
ID CARCINOMA-ASSOCIATED FIBROBLASTS; BREAST-CANCER; TUMOR MICROENVIRONMENT;
   STROMAL FIBROBLASTS; PHENOTYPE; GROWTH; CHEMOTHERAPY; CAVEOLIN-1;
   THERAPY
AB Tumors are comprised of malignant cancer cells and stromal cells which constitute the tumor microenvironment (TME). Previous studies have shown that cancer associated fibroblast (CAF) in TME is an important promoter of tumor initiation and progression. However, the underlying molecular mechanisms by which CAFs influence the growth of colorectal cancer cells (CRCs) have not been clearly elucidated. In this study, by using a non-contact co-culture system between human colorectal fibroblasts (CCD-18-co) and CRCs (LoVo, SW480, and SW620), we found that fibroblasts existing in tumor microenvironment positively influenced the metabolism of colorectal cancer cells, through its autophagy and oxidative stress pathway which were initially induced by neighboring tumor cells. Therefore, our data provided a novel possibility to develop fibroblasts as a potential target to treat CRC.
C1 [Zhou, Wenjing; Wang, Yunqiu; Liu, Xiaofei; Xu, Xia; Ren, Guijie; Tian, Keli] Shandong Univ, Sch Med, Dept Biochem & Mol Biol, Jinan, Shandong, Peoples R China.
   [Zhou, Wenjing] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.
   [Zhou, Wenjing] Shandong Univ, Brain Sci Res Inst, Jinan, Peoples R China.
   [Xu, Gang] PLA, Hosp 456, Dept Gastroenterol, Jinan, Shandong, Peoples R China.
   [Xu, Ziao] Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China.
RP Tian, KL (corresponding author), Shandong Univ, Sch Med, Dept Biochem & Mol Biol, Jinan, Shandong, Peoples R China.
EM tiankeli@sdu.edu.cn
RI Zhou, Wenjing/O-5814-2018
OI Zhou, Wenjing/0000-0002-4932-9312
FU Natural Science Foundation of Shandong ProvinceNatural Science
   Foundation of Shandong Province [ZR2014HM087]
FX This work was supported by the Natural Science Foundation of Shandong
   Province (ZR2014HM087). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bensinger SJ, 2012, SEMIN CELL DEV BIOL, V23, P352, DOI 10.1016/j.semcdb.2012.02.003
   Casey TM, 2008, BREAST CANCER RES TR, V110, P39, DOI 10.1007/s10549-007-9684-7
   Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599
   Chaudhri VK, 2013, MOL CANCER RES, V11, P579, DOI 10.1158/1541-7786.MCR-12-0437-T
   Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025
   Fujii N, 2012, J ORAL PATHOL MED, V41, P444, DOI 10.1111/j.1600-0714.2012.01127.x
   Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116
   Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384
   Hayward SW, 2001, CANCER RES, V61, P8135
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Jia CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063243
   Jia YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110455
   Kabir TD, 2016, AGING-US, V8, P1608, DOI 10.18632/aging.100987
   Khan K, 2014, WORLD J GASTROENTERO, V20, P12391, DOI 10.3748/wjg.v20.i35.12391
   Ko H, 2016, J CONTROL RELEASE, V234, P68, DOI 10.1016/j.jconrel.2016.05.009
   Lampiasi N, 2012, CANCER LETT, V322, P35, DOI 10.1016/j.canlet.2012.02.008
   Leontieva OV, 2011, AGING-US, V3, P1078, DOI 10.18632/aging.100402
   Li T, 2013, WORLD J GASTROENTERO, V19, P5615, DOI 10.3748/wjg.v19.i34.5615
   Li X, 2014, CARCINOGENESIS, V35, P1362, DOI 10.1093/carcin/bgu046
   Lisanti MP, 2013, CELL CYCLE, V12, P2723, DOI 10.4161/cc.25695
   Liu LX, 2016, EXP THER MED, V11, P1279, DOI 10.3892/etm.2016.3029
   Martinez-Outschoorn U, 2014, SEMIN ONCOL, V41, P195, DOI 10.1053/j.seminoncol.2014.03.002
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048
   Mercier I, 2012, AM J PATHOL, V181, P278, DOI 10.1016/j.ajpath.2012.03.017
   Montero AJ, 2011, DRUGS, V71, P1385, DOI 10.2165/11592590-000000000-00000
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Peiris-Pages M, 2015, AGING-US, V7, P816, DOI 10.18632/aging.100808
   Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875
   Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P289, DOI 10.4161/cc.23109
   Shaker H, 2016, THROMB RES, V140, pS184, DOI 10.1016/S0049-3848(16)30154-2
   Shi Y, 2015, AUTOPHAGY, V11, P769, DOI 10.1080/15548627.2015.1034411
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sotgia F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2892
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432-0436.2002.700905.x
   Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248
   WARBURG O, 1956, SCIENCE, V124, P269
   Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613
   Xue T, 2016, THERANOSTICS, V6, P773, DOI 10.7150/thno.14394
NR 43
TC 30
Z9 33
U1 3
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2017
VL 16
IS 1
BP 73
EP 81
DI 10.1080/15384101.2016.1252882
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EI8EC
UT WOS:000392737300016
PM 27841696
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Susmi, TF
   Rahman, A
   Khan, MMR
   Yasmin, F
   Islam, MS
   Nasif, O
   Alharbi, SA
   Batiha, GE
   Hossain, MU
AF Susmi, Tasmina Ferdous
   Rahman, Atikur
   Khan, Md. Moshiur Rahman
   Yasmin, Farzana
   Islam, Md. Shariful
   Nasif, Omaima
   Alharbi, Sulaiman Ali
   Batiha, Gaber El-Saber
   Hossain, Mohammad Uzzal
TI Prognostic and clinicopathological insights of phosphodiesterase 9A gene
   as novel biomarker in human colorectal cancer
SO BMC CANCER
LA English
DT Article
DE PDE9A gene; Colorectal cancer; Methylation; Pathways; Biomarker
ID DOWN-REGULATION; MESSENGER-RNA; EXPRESSION; CGMP; DATABASE; SURVIVAL;
   FAMILY; HYPERMETHYLATION; IDENTIFICATION; PROLIFERATION
AB Background PDE9A (Phosphodiesterase 9A) plays an important role in proliferation of cells, their differentiation and apoptosis via intracellular cGMP (cyclic guanosine monophosphate) signaling. The expression pattern of PDE9A is associated with diverse tumors and carcinomas. Therefore, PDE9A could be a prospective candidate as a therapeutic target in different types of carcinoma. The study presented here was designed to carry out the prognostic value as a biomarker of PDE9A in Colorectal cancer (CRC). The present study integrated several cancer databases with in-silico techniques to evaluate the cancer prognosis of CRC. Results The analyses suggested that the expression of PDE9A was significantly down-regulated in CRC tissues than in normal tissues. Moreover, methylation in the DNA promoter region might also manipulate PDE9A gene expression. The Kaplan-Meier curves indicated that high level of expression of PDE9A gene was associated to higher survival in OS, RFS, and DSS in CRC patients. PDE9A demonstrated the highest positive correlation for rectal cancer recurrence with a marker gene CEACAM7. Furtheremore, PDE9A shared consolidated pathways with MAPK14 to induce survival autophagy in CRC cells and showed interaction with GUCY1A2 to drive CRPC. Conclusions Overall, the prognostic value of PDE9A gene could be used as a potential tumor biomarker for CRC.
C1 [Susmi, Tasmina Ferdous; Rahman, Atikur; Khan, Md. Moshiur Rahman; Yasmin, Farzana] Jashore Univ Sci & Technol, Fac Biol Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh.
   [Rahman, Atikur] Jiangnan Univ, Sch Biotechnol, Dept Fermentat Engn, Wuxi, Jiangsu, Peoples R China.
   [Islam, Md. Shariful] Hokkaido Univ, Grad Sch Life Sci, Dept Reprod & Dev Biol, Sapporo,5 Chome Kita 8 Jonishi, Sapporo, Hokkaido 0600808, Japan.
   [Islam, Md. Shariful] Univ Kentucky, Dept Biol, 101 TH Morgan Bldg, Lexington, KY 40506 USA.
   [Nasif, Omaima] King Saud Univ, King Khalid Univ Hosp, Coll Med, Dept Physiol, POB 2925, Riyadh 11461, Saudi Arabia.
   [Alharbi, Sulaiman Ali] King Saud Univ, Coll Sci, Dept Bot & MicroBiol, POB 2455, Riyadh 11451, Saudi Arabia.
   [Batiha, Gaber El-Saber] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour 22511, Albeheira, Egypt.
   [Hossain, Mohammad Uzzal] Natl Inst Biotechnol, Bioinformat Div, Dhaka 1349, Bangladesh.
RP Islam, MS (corresponding author), Hokkaido Univ, Grad Sch Life Sci, Dept Reprod & Dev Biol, Sapporo,5 Chome Kita 8 Jonishi, Sapporo, Hokkaido 0600808, Japan.; Islam, MS (corresponding author), Univ Kentucky, Dept Biol, 101 TH Morgan Bldg, Lexington, KY 40506 USA.
EM sharifbge@uky.edu
OI Susmi, Tasmina Ferdous/0000-0002-2628-2371; Rahman,
   Atikur/0000-0002-2022-711X
FU King Saud University (KSU)King Saud University [RSP-2020/257]; King Saud
   University, Riyadh, Saudi ArabiaKing Saud University
FX This study is supported by King Saud University (KSU), Researchers
   Supporting Project number (RSP-2020/257), King Saud University, Riyadh,
   Saudi Arabia.
CR Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67
   Andreeva SG, 2001, J NEUROSCI, V21, P9068, DOI 10.1523/JNEUROSCI.21-22-09068.2001
   Azevedo MF, 2014, ENDOCR REV, V35, P195, DOI 10.1210/er.2013-1053
   Bian QL, 2019, ONCOL LETT, V18, P5043, DOI 10.3892/ol.2019.10866
   Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cesarini V, 2017, ONCOTARGET, V8, P13223, DOI 10.18632/oncotarget.14656
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen FJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13528-0
   Cui XR, 2018, CELL PHYSIOL BIOCHEM, V50, P41, DOI 10.1159/000493956
   Damian Szklarczyk, 2016, Nucleic acids research
   Das V, 2017, BIOMED PHARMACOTHER, V87, P8, DOI 10.1016/j.biopha.2016.12.064
   De Las Rivas J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000807
   Dorner-Ciossek C, 2017, Adv Neurobiol, V17, P231, DOI 10.1007/978-3-319-58811-7_9
   Doubeni CA, 2018, GUT, V67, P291, DOI 10.1136/gutjnl-2016-312712
   Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673
   Fajardo AM, 2014, CANCERS, V6, P436, DOI 10.3390/cancers6010436
   Feng HL, 2018, BRIT J CANCER, V118, P224, DOI 10.1038/bjc.2017.363
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Freitas M, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1415-9
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gemei M., 2015, BIOMARK CANC, P685
   Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8
   Guipponi M, 1998, HUM GENET, V103, P386, DOI 10.1007/s004390050838
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hassan Muhammad Radzi Abu, 2016, Asian Pac J Cancer Prev, V17, P3575
   Hou GX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174515
   Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883
   Hussain SA, 2013, JPN J CLIN ONCOL, V43, P1159, DOI 10.1093/jjco/hyt140
   Idos GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60255-4
   Kerachian MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59690-0
   Kobaek-Larsen M, 2000, COMPARATIVE MED, V50, P16
   Krishnan MS, 2016, HDB SUPPORTIVE PALLI
   Lee DI, 2015, NATURE, V519, P472, DOI 10.1038/nature14332
   Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002
   Li DJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00394
   Loweth AC, 1997, FEBS LETT, V400, P285, DOI 10.1016/S0014-5793(96)01392-0
   Messick CA, 2010, SURGERY, V147, P713, DOI 10.1016/j.surg.2009.10.056
   Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18
   Ng JMK, 2015, INT J MOL SCI, V16, P2472, DOI 10.3390/ijms16022472
   O'Keefe SJD, 2016, NAT REV GASTRO HEPAT, V13, P691, DOI 10.1038/nrgastro.2016.165
   Ouyang S, 2020, ONCOL LETT, V20, P828, DOI 10.3892/ol.2020.11597
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Park SJ, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0514-7
   Pinto EM, 2020, CANCERS, V12, DOI 10.3390/cancers12020506
   Rahman MR, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55010020
   Rauluseviciute I, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-0657-6
   Raza AM., 2016, J CURR ADV MED RES, V3, P22, DOI [10.3329/jcamr.v3i1.29388, DOI 10.3329/JCAMR.V3I1.29388]
   Razmkhah F, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0147-8
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rivu SF, 2017, CANCER EPIDEMIOL, V49, P46, DOI 10.1016/j.canep.2017.05.005
   Rotimi SO, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00714
   Safran M, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq020
   Saravani R, 2012, CELL PROLIFERAT, V45, P199, DOI 10.1111/j.1365-2184.2012.00819.x
   Sato T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059444
   Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642
   Shen LL, 2010, J CLIN ONCOL, V28, P605, DOI 10.1200/JCO.2009.23.4781
   Shimojo T, 1999, EXP CELL RES, V247, P38, DOI 10.1006/excr.1998.4310
   Singh N, 2014, LIFE SCI, V106, P1, DOI 10.1016/j.lfs.2014.04.007
   Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234
   Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553
   Song W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9022
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun HD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27837-9
   Swiderska M, 2014, WSPOLCZESNA ONKOL, V18, P1, DOI 10.5114/wo.2013.39995
   Szarek E, 2014, HORM METAB RES, V46, P863, DOI 10.1055/s-0034-1389916
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   THOMPSON J, 1994, J BIOL CHEM, V269, P32924
   Thompson J, 1997, CANCER RES, V57, P1776
   Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877
   Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
   Wu Y, 2020, CANCER MED-US
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
   Xue CL, 2019, ONCOL LETT, V18, P2877, DOI 10.3892/ol.2019.10665
   Yan P, 2018, PEERJ, V6, DOI 10.7717/peerj.6092
   Yi JM, 2011, CLIN CANCER RES, V17, P1535, DOI 10.1158/1078-0432.CCR-10-2509
   Yu YJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1379-5
   Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105
   Zheng H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00068
NR 85
TC 1
Z9 1
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 20
PY 2021
VL 21
IS 1
AR 577
DI 10.1186/s12885-021-08332-3
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SM3MV
UT WOS:000657514700001
PM 34016083
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chiacchiera, F
   Simone, C
AF Chiacchiera, Fulvio
   Simone, Cristiano
TI Inhibition of p38 alpha unveils an AMPK-FoxO3A axis linking autophagy to
   cancer-specific metabolism
SO AUTOPHAGY
LA English
DT Article
DE p38 alpha; FoxO3A; ATG transcription; AMPK; HIF1 alpha; colorectal
   cancer
ID CELL-DEATH; DISEASE
AB Autophagy is an essential process for the maintenance of cellular and metabolic homeostasis. Indeed, it is required for the recovery of ATP-generating substrates in cells subjected to different types of stress insults. Thus, the activity of the autophagic machinery strongly depends on the metabolic status of the cell.(1) It has been proposed that this principle applies not only to normal, but also to cancer cells,(2) despite the profound differences in their metabolism. Cancer cells predominantly produce ATP through the constitutive activation of aerobic glycolysis, a process that generally relies on the stabilization and activation of the transcription factor HIF1 alpha, which regulates the expression of glycolytic genes.(3) We recently showed that p38 alpha is required to sustain the expression of HIF1 alpha target genes, and that its inhibition causes a rapid drop in ATP levels in colorectal cancer cells (CRCs). This acute energy need triggers AMPK-dependent nuclear accumulation of FoxO3A and subsequent activation of its transcriptional program, leading to sequential induction of autophagy, cell cycle arrest and cell death. In vivo, pharmacological blockade of p38 alpha has both a cytostatic and cytotoxic effect on colorectal neoplasms, associated with nuclear enrichment of FoxO3A and expression of its target genes p21 and PTEN.(4) Our data suggest that CRCs impaired in their glycolytic metabolism trigger autophagy as a reversible recovery mechanism and undergo cell cycle arrest; however, the persistence of the stress insults inevitably leads to cell death.
C1 [Chiacchiera, Fulvio; Simone, Cristiano] Consorzio Mario Negri Sud, Lab Signal Dependent Transcript, Dept Translat Pharmacol, I-66030 Santa Maria Imbaro, Ch, Italy.
RP Simone, C (corresponding author), Consorzio Mario Negri Sud, Lab Signal Dependent Transcript, Dept Translat Pharmacol, I-66030 Santa Maria Imbaro, Ch, Italy.
EM simone@negrisud.it
RI Simone, Cristiano/K-3452-2018; Chiacchiera, Fulvio/K-6740-2016;
   Chiacchiera, Fulvio/ABD-6137-2020
OI Simone, Cristiano/0000-0002-2628-7658; Chiacchiera,
   Fulvio/0000-0003-3830-2090; 
FU IRC (Italian Foundation for Cancer Research) fellowship; 'My First
   Grant'; Italian Association for Cancer ResearchFondazione AIRC per la
   ricerca sul cancro
FX We thank Dr. Francesco Paolo Jori for his helpful discussion during the
   preparation of the manuscript and editorial assistance; Dr. Francesca
   Demarchi and Dr. Tamara Copetti (C.I.B., Trieste, Italy) for providing
   the MAP1LC3 antisera. Dr. Chiacchiera is supported by a FIRC (Italian
   Foundation for Cancer Research) fellowship. This work was partially
   supported by a 'My First Grant' (to C.S.) from the Italian Association
   for Cancer Research.
CR CHIACCHIERA F, 2009, CELL DEATH IN PRESS
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Meijer AJ, 2009, AUTOPHAGY, V5, P3, DOI 10.4161/auto.5.1.7207
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
NR 14
TC 63
Z9 64
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 1
PY 2009
VL 5
IS 7
BP 1030
EP 1033
DI 10.4161/auto.5.7.9252
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 531TH
UT WOS:000272691100013
PM 19587525
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Khan, A
   Wani, MY
   Al-Bogami, AS
   Subramanian, K
   Kandhavelu, J
   Ruff, P
   Penny, C
AF Khan, Amber
   Wani, Mohmmad Younus
   Al-Bogami, Abdullah Saad
   Subramanian, Kumar
   Kandhavelu, Jeyalakshmi
   Ruff, Paul
   Penny, Clement
TI Anticancer Activity of Novel Gabexate Mesilate Mimetics in Colorectal
   Cancer Cells
SO CHEMISTRYSELECT
LA English
DT Article
DE Antitumor agents; Cell cycle; Colorectal cancer; Gabexate mesilate; High
   mobility group box 1
ID COLON-CANCER; HMGB1; AUTOPHAGY; SURVIVORSHIP; THERAPY; PATHWAY
AB Despite there being significant advances in colorectal cancer (CRC) treatments, recurrence and chemoresistance remain a challenge in the treatment of patients. During the process of autophagy, cancer cells acquire anoikis resistance and escape chemotherapy. High Mobility Group Box 1 (HMGB1) protein is a key mediator of autophagy and can be exploited to develop effective targeted anticancer therapies. Gabexate mesilate (GM) used in the treatment of pancreatitis is both a synthetic inhibitor of HMGB1 and of metastasis. Structural analogues of GM hold promise to suppress HMGB1 functionality to arrest cancer growth, recurrence and resistance mechanisms. We synthesized structural GM mimetics (GMMs) and evaluated their anticancer activity. Considering the critical role of HMGB1 in the cell cycle, we analyzed cell cycle response to active GMMs in CRC cells in a Muse flow cell analyzer. Docking studies were further performed to predict the binding modes and affinity of active GMM for HMGB1. A total of thirteen GMMs were synthesized and their anticancer activity was evaluated on each of the SW480, HT29 and DLD1 CRC cell lines. Of the 13-novel synthetic GMMs assessed, A1, A2, A3 and A6 were found to be the most active, with anticancer inhibitory concentrations (IC80) of 250-500 mu g/mL. Treatment with active GMMs resulted in CRC cells being arrested mainly in preparatory phases of the cell cycle. Docking studies established that the active GMMs possessed specific binding affinity with the target, compared to the inactive GMM.
C1 [Khan, Amber; Subramanian, Kumar; Kandhavelu, Jeyalakshmi; Ruff, Paul; Penny, Clement] Univ Witwatersrand, Dept Internal Med, Fac Hlth Sci, 7 York Rd, ZA-2193 Johannesburg, South Africa.
   [Wani, Mohmmad Younus; Al-Bogami, Abdullah Saad] Univ Jeddah, Chem Dept, Fac Sci, POB 80327, Jeddah 21589, Saudi Arabia.
RP Penny, C (corresponding author), Univ Witwatersrand, Dept Internal Med, Fac Hlth Sci, 7 York Rd, ZA-2193 Johannesburg, South Africa.
EM clempenny@yahoo.co.uk
RI Wani, Mohammad Younus/E-3909-2018; Wani, Mohmmad Younus/AAJ-5016-2020;
   Kandhavelu, Jeyalakshmi/AAL-8279-2020; Al-Bogami, Abdullah S/H-7774-2012
OI Wani, Mohammad Younus/0000-0002-1838-1337; Wani, Mohmmad
   Younus/0000-0002-1838-1337; Kandhavelu, Jeyalakshmi/0000-0003-3511-3040
FU Medical Research Council (MRC) of South AfricaUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC); National Research Foundation
   (NRF) of South AfricaNational Research Foundation - South Africa
   [99554]; Wits Faculty of Health Sciences Griffin Trust Fund
FX The study was supported by funding from the Medical Research Council
   (MRC) of South Africa to the Wits/MRC Common Epithelial Cancer Research
   Centre. AK is grateful to the National Research Foundation (NRF) of
   South Africa [Grant number: 99554] for research funding and bursary and
   to the Wits Faculty of Health Sciences Griffin Trust Fund for financial
   assistance.
CR Brandi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041347
   DESCHNER EE, 1987, PREV MED, V16, P580, DOI 10.1016/0091-7435(87)90075-2
   EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7
   Frick MA, 2017, CANCER-AM CANCER SOC, V123, P1860, DOI 10.1002/cncr.30527
   Guglielmi V, 2017, EUR REV MED PHARMACO, V21, P5268, DOI 10.26355/eurrev_201711_13851
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hidaka S, 2011, J SURG RES, V165, P142, DOI 10.1016/j.jss.2009.05.039
   Ke SB, 2015, INT J ONCOL, V46, P1051, DOI 10.3892/ijo.2014.2793
   Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034318
   Li QL, 2014, ONCOTARGET, V5, P6387, DOI 10.18632/oncotarget.2201
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Livesey KM, 2012, AUTOPHAGY, V8, P846, DOI 10.4161/auto.19891
   Makhoul R, 2015, CLIN COLON RECT SURG, V28, P262, DOI 10.1055/s-0035-1564435
   Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001
   Nishiyama T, 2012, AM J EMERG MED, V30, P1219, DOI 10.1016/j.ajem.2011.06.003
   Ozeki T, 2010, INT J CLIN EXP PATHO, V3, P710
   Poznic M, 2009, J BIOSCIENCES, V34, P305, DOI 10.1007/s12038-009-0034-2
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095
   Smolarczyk R, 2012, POSTEP HIG MED DOSW, V66, P913, DOI 10.5604/17322693.1021108
   Sun XF, 2014, AUTOPHAGY, V10, P1873, DOI 10.4161/auto.32184
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Waki K, 2016, CANCER SCI, V107, P1721, DOI 10.1111/cas.13084
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wu TY, 2016, ONCOTARGET, V7, P50417, DOI 10.18632/oncotarget.10413
   Yamaguchi H, 2012, BIOINFORMATION, V8, P1147, DOI 10.6026/97320630081147
   Yang H, 2015, MOL MED, V21, pS6, DOI 10.2119/molmed.2015.00087
   Yoon WH, 2004, CLIN CANCER RES, V10, P4517, DOI 10.1158/1078-0432.CCR-04-0084
   Zhang ZX, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0166-1
   Zhao XL, 2017, J PATHOL, V243, P376, DOI 10.1002/path.4958
NR 32
TC 0
Z9 0
U1 0
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2365-6549
J9 CHEMISTRYSELECT
JI ChemistrySelect
PD JUN 29
PY 2018
VL 3
IS 24
BP 6942
EP 6948
DI 10.1002/slct.201800629
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA GL0RT
UT WOS:000436798700033
DA 2022-04-25
ER

PT J
AU Xie, RY
   Wang, J
   Liu, XH
   Wu, LQ
   Zhang, H
   Tang, WM
   Li, YQ
   Xiang, L
   Peng, Y
   Huang, XT
   Bai, Y
   Liu, GN
   Li, AM
   Wang, YD
   Chen, Y
   Ren, YX
   Li, GX
   Gong, W
   Liu, SD
   Wang, JD
AF Xie, Ruyi
   Wang, Jing
   Liu, Xuehua
   Wu, Liqing
   Zhang, Hui
   Tang, Weimei
   Li, Yueqiao
   Xiang, Li
   Peng, Ying
   Huang, Xiaoting
   Bai, Yang
   Liu, Guangnan
   Li, Aimin
   Wang, Yadong
   Chen, Ye
   Ren, Yuexin
   Li, Guoxin
   Gong, Wei
   Liu, Side
   Wang, Jide
TI RUFY3 interaction with FOXK1 promotes invasion and metastasis in
   colorectal cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DOMAIN-CONTAINING PROTEIN; FYVE-FINGER; RUN DOMAIN; EFFECTOR;
   IDENTIFICATION; TUMORIGENESIS; EXPRESSION; AUTOPHAGY; COMPLEX; RABIP4
AB RUFY3 is highly expressed in brain tissue and has a role in neuronal development. Transcriptional factor FOXK1 is involved in cell growth and metabolism. We knew that RUFY3 or FOXK1 has been correlated with the malignant of tumor cells. However, the role of these molecules in colorectal cancer (CRC) progression remains unknown. We investigated the protein expression levels by Western blot, immunofluorescence and immunohistochemistry analyses. The migration and invasive abilities of CRC cells were assessed using shRNA-mediated inhibition in vitro and in vivo. We showed that RUFY3 expression was up-regulated in CRC compared with its expression in a normal human colon cell line (FHC). RUFY3 suppression inhibited anchorage independent cell tumorigenesis. RUFY3 induced elevated expression of eight major oncogenes. Moreover, RUFY3 physically interacts with FOXK1 in CRC. A positive correlation was observed between the expression patterns of RUFY3 and FOXK1. Furthermore, RUFY3 and FOXK1 expression were correlated with tumor progression and represented significant predictors of overall survival in CRC patients. SiRNA-mediated repression of FOXK1 in RUFY3-overexpressing cells reversed the epithelial-mesenchymal transition (EMT) and metastatic phenotypes. In vivo, FOXK1 promoted RUFY3-mediated metastasis via orthotopic implantation. These findings suggest that the RUFY3-FOXK1 axis might promote the development and progression of human CRC.
C1 [Xie, Ruyi; Wang, Jing; Liu, Xuehua; Wu, Liqing; Zhang, Hui; Tang, Weimei; Li, Yueqiao; Xiang, Li; Peng, Ying; Huang, Xiaoting; Bai, Yang; Liu, Guangnan; Li, Aimin; Wang, Yadong; Chen, Ye; Ren, Yuexin; Gong, Wei; Liu, Side; Wang, Jide] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.
   [Liu, Xuehua] First Peoples Hosp Shunde, Dept Gastroenterol, Foshan 528300, Peoples R China.
   [Zhang, Hui] Southern Med Univ, Hexian Mem Affiliated Hosp, Dept Gastroenterol, Guangzhou 511400, Guangdong, Peoples R China.
   [Xiang, Li] Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen 518172, Peoples R China.
   [Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou 510515, Guangdong, Peoples R China.
RP Liu, SD; Wang, JD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.
EM liuside@163.com; jidewang55@163.com
FU National Natural Science Funds of ChinaNational Natural Science
   Foundation of China (NSFC) [81672875, 81272761]; President Foundation of
   Nanfang Hospital, Southern Medical University [2012B009, 2013Z007];
   high-level topic-matching funds of Nanfang Hospital [201347, G201227];
   Guangzhou Pilot Project of Clinical and Translational Research Center
   (early gastrointestinal cancer) [7415696196402]
FX This study was supported by grants from the National Natural Science
   Funds of China (81672875 & 81272761), 'President Foundation of Nanfang
   Hospital, Southern Medical University' (2012B009, 2013Z007), and
   high-level topic-matching funds of Nanfang Hospital (201347 and
   G201227). Guangdong Provincial Key Laboratory of Gastroenterology,
   Department of Gastroenterology, Nanfang Hospital, Southern Medical
   University; Guangzhou Pilot Project of Clinical and Translational
   Research Center (early gastrointestinal cancer, No. 7415696196402).
CR Bowman CJ, 2014, NAT CELL BIOL, V16, P1202, DOI 10.1038/ncb3062
   Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998
   Dunkelberg JC, 2001, DNA CELL BIOL, V20, P403, DOI 10.1089/104454901750361460
   Fukuda M, 2011, CELL STRUCT FUNCT, V36, P155, DOI 10.1247/csf.11001
   Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197
   Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657
   He J, 2009, PROTEINS, V76, P852, DOI 10.1002/prot.22392
   Ivan V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048142
   Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x
   Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200
   Mori T, 2007, J BIOL CHEM, V282, P19884, DOI 10.1074/jbc.M700770200
   Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737
   Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082
   Peng Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.225
   Shi XZ, 2012, BIOCHEM J, V446, P349, DOI 10.1042/BJ20120563
   Terawaki S, 2015, J CELL BIOL, V210, P1133, DOI 10.1083/jcb.201501059
   Tian LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12357
   Vukmirica J, 2006, J BIOL CHEM, V281, P36360, DOI 10.1074/jbc.M602920200
   Wang G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.50
   Wang S, 2003, BIOCHEM GENET, V41, P13, DOI 10.1023/A:1020918411532
   Wang WQ, 2015, DEV CELL, V32, P707, DOI 10.1016/j.devcel.2015.01.031
   Wei Z, 2014, J NEUROCHEM, V130, P678, DOI 10.1111/jnc.12740
   Wu Y., 2016, ONCOTARGET
   Yamamoto H, 2010, MOL BIOL CELL, V21, P2746, DOI 10.1091/mbc.E10-01-0074
   Yan Q, 2015, ONCOTARGET, V6, P25402, DOI 10.18632/oncotarget.4517
   Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335
   Yoshida H, 2010, INT J BIOL SCI, V6, P187
   Zhang WJ, 2011, EUR J CANCER, V47, P121, DOI 10.1016/j.ejca.2010.07.045
NR 30
TC 19
Z9 21
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 16
PY 2017
VL 7
AR 3709
DI 10.1038/s41598-017-04011-1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EX7FN
UT WOS:000403413700071
PM 28623323
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Islam, F
   Gopalan, V
   Law, S
   Tang, JCO
   Lam, AKY
AF Islam, Farhadul
   Gopalan, Vinod
   Law, Simon
   Tang, Johnny Cheuk-on
   Lam, Alfred King-yin
TI FAM134B promotes esophageal squamous cell carcinoma in vitro and its
   correlations with clinicopathologic features
SO HUMAN PATHOLOGY
LA English
DT Article
DE Esophagus; FAM134B; JK1; RETREG1; Squamous cell carcinoma
ID COLORECTAL-CANCER; COLON-CANCER; OVEREXPRESSION; EXPRESSION; JK1;
   MUTATIONS; GENE
AB Family with sequence similarity 134, member B (FAM134B) is an autophagy regulator of endoplasmic reticulum first discovered to be involved in the pathogenesis of esophageal squamous cell carcinoma (ESCC). The present study examined the functional behavior of FAM134B in cancer cells and the association of FAM134B expression with clinicopathologic factors in patients with ESCC. Expression at both the mRNA and protein levels was investigated using real-time polymerase chain reaction and immunohistochemistry. The results were correlated with the clinical and pathological features of the patients. In addition, in vitro functional assays were used to investigate the roles of FAM134B in ESCC cells in response to gene silencing with shRNA lentiviral particles. Overexpression of FAM134B mRNA and protein was present in 31.2% (n = 29/93) and 36.6% (n = 41/112), respectively, in tumors, whereas downregulation occurred in 39.8% (n = 37/93) and 63.4% (n = 71/112), respectively. Expression of FAM134B protein in ESCC correlated with histologic grade (P =.002) and pathologic stage (P =.012). In vitro suppression of FAM134B in ESCC induced significant reductions of cell proliferation and colony formation (P <.05). In addition, suppression of FAM134B caused reduction of wound healing, migration, and invasion capacities of ESCC. To conclude, FAM134B could play crucial roles in the initiation and progression of ESCC, and FAM134B protein expression has potential predictive value. Therefore, development of strategies targeting FAM134B could have therapeutic value in the management of patients with ESCC. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Islam, Farhadul; Gopalan, Vinod; Lam, Alfred King-yin] Griffith Univ, Sch Med, Dept Canc Mol Pathol, Gold Coast, Qld, Australia.
   [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh.
   [Law, Simon] Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.
   [Tang, Johnny Cheuk-on] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Lo Ka Chung Ctr Nat Anticanc Drug Dev, State Key Lab Chirosci, Hong Kong, Peoples R China.
RP Tang, JCO (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, 11 Yuk Choi Rd, Hong Kong, Peoples R China.; Lam, AKY (corresponding author), Griffith Med Sch, Gold Coast Campus, Gold Coast, Qld 4222, Australia.
EM bccotang@polyu.edu.hk; a.lam@griffith.edu.au
RI Lam, Alfred/C-1652-2008; Law, Simon/C-4324-2009; Tang, Johnny
   Cheuk-on/W-7214-2019; Tang, Johnny C. O./M-9639-2014; Islam,
   Farhadul/R-5643-2017
OI Lam, Alfred/0000-0003-2771-564X; Law, Simon/0000-0002-6518-5806; Tang,
   Johnny Cheuk-on/0000-0002-4261-3206; Tang, Johnny C.
   O./0000-0002-4261-3206; Islam, Farhadul/0000-0001-5262-4702
FU Griffith UniversityGriffith University; Menzies Health Institute
   Queensland, Gold Coast, Queensland, Australia
FX This project was supported by a student scholarship from Griffith
   University and funding from Menzies Health Institute Queensland
   (Chamier's family donation), Gold Coast, Queensland, Australia.
CR Chan D, 2013, WORLD J GASTROENTERO, V19, P2772, DOI 10.3748/wjg.v19.i18.2772
   Dai W, 2017, J PATHOL, V242, P500, DOI 10.1002/path.4925
   Dai XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07189-6
   Fatima S, 2006, INT J MOL MED, V17, P159
   Gopalan V, 2016, EXP CELL RES, V348, P146, DOI 10.1016/j.yexcr.2016.09.010
   Hamilton S. R., 2010, WHO CLASSIFICATION T, V134
   Haque MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29173
   Hu YC, 2000, CANCER GENET CYTOGEN, V118, P112, DOI 10.1016/S0165-4608(99)00193-4
   Islam F, 2018, MOL CARCINOGEN, V57, P1480, DOI 10.1002/mc.22871
   Islam F, 2018, INT J BIOL MACROMOL, V117, P1050, DOI 10.1016/j.ijbiomac.2018.06.021
   Islam F, 2018, METHODS MOL BIOL, V1756, P247, DOI 10.1007/978-1-4939-7734-5_21
   Islam F, 2018, GENE CHROMOSOME CANC, V57, P240, DOI 10.1002/gcc.22525
   Islam F, 2018, J CELL PHYSIOL, V233, P4479, DOI 10.1002/jcp.26384
   Islam F, 2018, EXP MOL PATHOL, V104, P98, DOI 10.1016/j.yexmp.2018.01.006
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Islam F, 2017, HUM PATHOL, V62, P141, DOI 10.1016/j.humpath.2017.01.014
   Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4
   Islam F, 2017, MOL CARCINOGEN, V56, P238, DOI 10.1002/mc.22488
   Kasem K, 2014, EXP MOL PATHOL, V97, P99, DOI 10.1016/j.yexmp.2014.06.002
   Kasem K, 2014, EXP MOL PATHOL, V97, P31, DOI 10.1016/j.yexmp.2014.05.001
   Kasem K, 2014, EXP CELL RES, V326, P166, DOI 10.1016/j.yexcr.2014.06.013
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Lam AK, 2015, ESOPHAGEAL CANC PREV, P25
   Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2
   Lam KY, 2001, J PATHOL, V195, P435, DOI 10.1002/path.984
   Lam KY, 1997, CHINESE MED J-PEKING, V110, P459
   Lee KTW, 2018, EUR J CELL BIOL, V97, P230, DOI 10.1016/j.ejcb.2018.03.002
   Lehrbach Dárcio Matenhauer, 2003, Arq. Gastroenterol., V40, P256, DOI 10.1590/S0004-28032003000400011
   Rice T.W., 2017, AJCC CANC STAGING SY, P185
   Saremi N, 2018, METHODS MOL BIOL, V1756, P105, DOI 10.1007/978-1-4939-7734-5_10
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C
   Tang JCO, 2001, CLIN CANCER RES, V7, P1539
   Tang WK, 2007, INT J MOL MED, V19, P915
   Wahab R, 2018, EXP MOL PATHOL, V104, P71, DOI 10.1016/j.yexmp.2018.01.004
   Xu WW, 2015, ONCOTARGET, V6, P1790, DOI 10.18632/oncotarget.2781
NR 35
TC 16
Z9 16
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD MAY
PY 2019
VL 87
BP 1
EP 10
DI 10.1016/j.humpath.2018.11.033
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA IA4GX
UT WOS:000469523100001
PM 30794892
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Zajac, J
   Kostrhunova, H
   Novohradsky, V
   Vrana, O
   Raveendran, R
   Gibson, D
   Kasparkova, J
   Brabec, V
AF Zajac, Juraj
   Kostrhunova, Hana
   Novohradsky, Vojtech
   Vrana, Oldrich
   Raveendran, Raji
   Gibson, Dan
   Kasparkova, Jana
   Brabec, Viktor
TI Potentiation of mitochondrial dysfunction in tumor cells by conjugates
   of metabolic modulator dichloroacetate with a Pt(IV) derivative of
   oxaliplatin
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Platinum-dichloroacetate conjugates; Mitochondrial dysfunction; Glucose
   metabolism; Autophagy; 5-Fluorouracil; Cancer therapy
ID IN-VITRO CYTOTOXICITY; PLATINUM(IV) COMPLEXES; INCREASES SENSITIVITY;
   ANTITUMOR-ACTIVITY; COLORECTAL-CANCER; MOLECULAR-BASIS; HUMAN COLON;
   CISPLATIN; 5-FLUOROURACIL; RESISTANCE
AB The molecular and cellular mechanisms of enhanced toxic effects in tumor cells of the Pt(IV) derivatives of antitumor oxaliplatin containing axial dichloroacetate (DCA) ligands were investigated. DCA ligands were chosen because DCA has shown great potential as an apoptosis sensitizer and anticancer agent reverting the Wartburg effect. In addition, DCA reverses mitochondrial changes in a wide range of cancers, promoting tumor cell apoptosis in a mitochondrial-dependent pathway. We demonstrate that (i) the transformation of oxaliplatin to its Pt(IV) derivatives containing axial DCA ligands markedly enhances toxicity in cancer cells and helps overcome inherent and acquired resistance to cisplatin and oxaliplatin; (ii) a significant fraction of the intact molecules of DCA conjugates with Pt(IV) derivative of oxaliplatin accumulates in cancer cells where it releases free DCA; (iii) mechanism of biological action of the Pt(IV) derivatives of oxaliplatin containing DCA ligands is connected with the effects of DCA released in cancer cells from the Pt(IV) prodrugs on mitochondria and metabolism of glucose; (iv) treatments with the Pt(IV) derivatives of oxaliplatin containing DCA ligands activate an autophagic response in human colorectal cancer cells; (v) the toxic effects in cancer cells of the Pt(IV) derivatives of oxaliplatin containing DCA ligands can be potentiated if cells are treated with these prodrugs in combination with 5-fluorouracil. These properties of the Pt(IV) derivatives of oxaliplatin containing DCA ligands provide opportunities for further development of new platinum-based agents with the capability of killing cancer cells resistant to conventional antitumor platinum drugs used in the clinic. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Zajac, Juraj; Kostrhunova, Hana; Novohradsky, Vojtech; Vrana, Oldrich; Brabec, Viktor] Acad Sci Czech Republ, Inst Biophys, Vvi, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
   [Zajac, Juraj; Kasparkova, Jana] Palacky Univ, Fac Sci, Dept Biophys, 17 Listopadu 12, CZ-77146 Olomouc, Czech Republic.
   [Raveendran, Raji; Gibson, Dan] Hebrew Univ Jerusalem, Sch Pharm, Inst Drug Res, IL-91120 Jerusalem, Israel.
RP Brabec, V (corresponding author), Acad Sci Czech Republ, Inst Biophys, Vvi, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
EM brabec@ibp.cz
RI Brabec, Viktor/H-1946-2014; Kostrhunová, Hana/H-1934-2014
OI Brabec, Viktor/0000-0002-8233-1393; Kostrhunová,
   Hana/0000-0003-2706-6491
FU Czech Science FoundationGrant Agency of the Czech Republic [14-21053S];
   Ministry of Education, Youth and Sports of the Czech RepublicMinistry of
   Education, Youth & Sports - Czech Republic [LH14317, LD14019]; Palack
   University (IGAPrF) [2015 025]; Israel Science foundationIsrael Science
   Foundation [1332/10]
FX This work was supported by the Czech Science Foundation (Grant
   14-21053S) and the Ministry of Education, Youth and Sports of the Czech
   Republic (Grant LH14317). J.Z. and J.K. also acknowledge the support
   from the Ministry of Education, Youth and Sports of the Czech Republic
   (Grant LD14019) and from the student project of Palack University
   (IGAPrF 2015 025). D.G. acknowledges the support of the Israel Science
   foundation (grant 1332/10). The authors also acknowledge that their
   participation in the EU COST Action CM1105 enabled them to exchange
   regularly the most recent ideas in the field of platinum anticancer
   drugs with several European colleagues.
CR Berindan-Neagoe I, 2013, J GASTROINTEST LIVER, V22, P37
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Choi S, 1998, INORG CHEM, V37, P2500, DOI 10.1021/ic971047x
   CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Dai YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092962
   deBraud F, 1998, AM J CLIN ONCOL-CANC, V21, P279, DOI 10.1097/00000421-199806000-00015
   Dhar S, 2009, P NATL ACAD SCI USA, V106, P22199, DOI 10.1073/pnas.0912276106
   Di Francesco AM, 2002, CELL MOL LIFE SCI, V59, P1914, DOI 10.1007/PL00012514
   Duan Y, 2013, ONCOTARGETS THER, V6, P189, DOI 10.2147/OTT.S40992
   ELLIS LT, 1995, AUST J CHEM, V48, P793, DOI 10.1071/CH9950793
   Failli A, 2011, J BIOL REG HOMEOS AG, V25, P575
   FAN SJ, 1995, CANCER RES, V55, P1649
   Fiebiger W, 2011, CLIN TRANSL ONCOL, V13, P43, DOI 10.1007/s12094-011-0615-z
   Garcia-Cano J, 2015, ONCOTARGET, V6, P15551, DOI 10.18632/oncotarget.3902
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gramatica P, 2010, J BIOL INORG CHEM, V15, P1157, DOI 10.1007/s00775-010-0676-4
   Hall MD, 2012, METALLOMICS, V4, P568, DOI 10.1039/c2mt20053h
   Hall MD, 2004, J INORG BIOCHEM, V98, P1614, DOI 10.1016/j.jinorgbio.2004.05.017
   Hall MD, 2002, COORDIN CHEM REV, V232, P49, DOI 10.1016/S0010-8545(02)00026-7
   Hambley TW, 1999, J INORG BIOCHEM, V77, P3, DOI 10.1016/S0162-0134(99)00133-6
   Johnstone TC, 2013, ACS NANO, V7, P5675, DOI 10.1021/nn401905g
   Kadoyama K, 2012, INT J MED SCI, V9, P33, DOI 10.7150/ijms.9.33
   KELLAND LR, 1994, CANCER RES, V54, P5618
   Kelland LR, 1999, J INORG BIOCHEM, V77, P111, DOI 10.1016/S0162-0134(99)00141-5
   Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6
   Lin G, 2014, BRIT J CANCER, V111, P375, DOI 10.1038/bjc.2014.281
   Liu Z, 2011, INORG CHEM, V50, P5777, DOI 10.1021/ic200607j
   LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419
   Mani S, 2000, ONCOLOGY-NY, V14, P52
   Novohradsky V, 2014, J INORG BIOCHEM, V140, P72, DOI 10.1016/j.jinorgbio.2014.07.004
   Oldfield SP, 2007, J MED CHEM, V50, P5227, DOI 10.1021/jm0708275
   Olszewski U, 2010, CLIN PHARMACOL-ADV A, V2, P177, DOI 10.2147/CPAA.S11795
   Pan James G, 2007, Sci STKE, V2007, ppe14
   PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8
   Pathak RK, 2014, ACS CHEM BIOL, V9, P1178, DOI 10.1021/cb400944y
   Platts JA, 2006, J INORG BIOCHEM, V100, P1199, DOI 10.1016/j.jinorgbio.2006.01.035
   Raymond E, 2002, MOL CANCER THER, V1, P227
   Raymond E, 1997, ANTI-CANCER DRUG, V8, P876, DOI 10.1097/00001813-199710000-00009
   Raymond E, 1998, SEMIN ONCOL, V25, P4
   Raymond E, 2001, B CANCER, V88, pS26
   Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Tong JT, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/740564
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   WEISS RB, 1993, DRUGS, V46, P360, DOI 10.2165/00003495-199346030-00003
   Wexselblatt E, 2015, CHEM-EUR J, V21, P3108, DOI 10.1002/chem.201405467
   Xie J, 2011, INT J ONCOL, V38, P409, DOI 10.3892/ijo.2010.851
   Xuan Y, 2014, EXP CELL RES, V321, P219, DOI 10.1016/j.yexcr.2013.12.009
   Xue X, 2012, MOL PHARMACEUT, V9, P634, DOI 10.1021/mp200571k
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang SZ, 2006, CANCER RES, V66, P8847, DOI 10.1158/0008-5472.CAN-06-0769
   Zheng MF, 2013, CANCER CHEMOTH PHARM, V72, P1031, DOI 10.1007/s00280-013-2281-z
NR 57
TC 46
Z9 48
U1 3
U2 63
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD MAR
PY 2016
VL 156
BP 89
EP 97
DI 10.1016/j.jinorgbio.2015.12.003
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DE6UP
UT WOS:000370769400010
PM 26780576
DA 2022-04-25
ER

PT J
AU Li, B
   Shi, C
   Li, B
   Zhao, JM
   Wang, L
AF Li, Bai
   Shi, Chong
   Li, Bo
   Zhao, Jing-Ming
   Wang, Lei
TI The effects of Curcumin on HCT-116 cells proliferation and apoptosis via
   the miR-491/PEG10 pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE cell apoptosis; cell proliferation; Curcumin; miR-491; PEG10
ID MICRORNA EXPRESSION; IMPRINTED GENE; CANCER; PEG10; AUTOPHAGY;
   INVOLVEMENT; SURVIVAL
AB Paternally expressed gene-10 (PEG10) could participate in several carcinomas and might be regulated by miR-491. To now, miR-491 was found to play an important role in the sensitivity and mechanism of drug usage in the treatment of colorectal cancer, and drug resistance is a key factor to affect the disease healing. In this study, miR-491, PEG10, Wnt1, and -catenin expression levels and their correlation with colorectal cancer were assessed in cancer tissues and adjacent parts. And the target relationship between PEG10 and miR-491 was verified. Meanwhile, the impaction of Curcumin on miR-491, PEG10, and Wnt/-catenin signaling pathway were analyzed in HCT-116 cells. The effects of PEG10 and Curcumin on human HCT-116 cells proliferation and apoptosis were investigated by MTT and flow cytometry assay. Results showed that the expression of miR-491 in colon cancer tissues was decreased, but PEG10, Wnt1, and -catenin were higher than that in adjacent tissues. The PEG10 gene 3 UTR could combine with miR-491 seed sequence and miR-491 overexpression could cause a decrease in PEG10, Wnt1, and -catenin levels in human HCT-116 cells. Furthermore, PEG10 overexpression increased the expression levels of Wnt1 and -catenin, thereby promoting cell proliferation and inhibiting apoptosis. In addition, Curcumin could up-regulate miR-491, inhibit PEG10, and Wnt/-catenin signaling pathway. Consequently, Curcumin reduced HCT-116 cells proliferation and promoted cells apoptosis via the miR-491/PEG10 pathway. In conclusion, PEG10 was a target gene of miR-491, miR-491/PEG10 strengthen the sensitivity of Curcumin in HCT-116 cells proliferation and apoptosis, which might act as an ideal diagnostic biomarker treatment methods.
C1 [Li, Bai; Wang, Lei] Jilin Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, 71 Xinmin St, Changchun, Jilin, Peoples R China.
   [Shi, Chong; Zhao, Jing-Ming] Changchun Univ Chinese Med, Afflicted Hosp, Dept Anorectal Surg, Changchun, Jilin, Peoples R China.
   [Li, Bo] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, Changchun, Jilin, Peoples R China.
RP Wang, L (corresponding author), Jilin Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, 71 Xinmin St, Changchun, Jilin, Peoples R China.
EM leiwang_jlu@163.com
RI Li, Bo/AAA-8968-2020
OI Li, Bo/0000-0002-7294-6888; Jingming, Zhao/0000-0002-1019-1029
CR Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen TL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004945
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Huang ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep40382
   Ip WK, 2007, CANCER LETT, V250, P284, DOI 10.1016/j.canlet.2006.10.012
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Liu SG, 2013, ONCOL LETT, V5, P1639, DOI 10.3892/ol.2013.1251
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143
   O'Connell JB, 2004, DIS COLON RECTUM, V47, P2064, DOI 10.1007/s10350-004-0738-1
   Okabe H, 2003, CANCER RES, V63, P3043
   Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494
   Safe S, 2016, PHYTOTHER RES, V30, P1723, DOI 10.1002/ptr.5669
   Sahu PK, 2016, EUR J MED CHEM, V121, P510, DOI 10.1016/j.ejmech.2016.05.037
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Voortman J, 2010, CANCER RES, V70, P8288, DOI 10.1158/0008-5472.CAN-10-1348
   Wang YW, 2016, JALA-J LAB AUTOM, V21, P723, DOI 10.1177/2211068216655524
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Yoshibayashi H, 2007, ONCOL REP, V17, P549
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 36
TC 27
Z9 29
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2018
VL 119
IS 4
BP 3091
EP 3098
DI 10.1002/jcb.26449
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FX6IO
UT WOS:000426187500010
PM 29058812
DA 2022-04-25
ER

PT J
AU Le, XF
   Bast, RC
AF Le, Xiao-Feng
   Bast, Robert C., Jr.
TI Src family kinases and paclitaxel sensitivity
SO CANCER BIOLOGY & THERAPY
LA English
DT Review
DE Src; SFK; paclitaxel; dasatinib; ovarian cancer; drug sensitivity;
   resistance
ID GROWTH-FACTOR RECEPTOR; MICROTUBULE-ASSOCIATED PROTEIN; BETA-TUBULIN
   GENE; OVARIAN-CANCER CELLS; HUMAN BREAST-CANCER; C-SRC; TYROSINE KINASE;
   MULTIDRUG-RESISTANCE; LUNG-CANCER; FYN KINASE
AB Src-family Kinases (SFKs) participate in the regulation of proliferation, differentiation, apoptosis, autophagy, adhesion, migration, invasion and angiogenesis in normal and cancer cells. Abnormal expression of SFKs has been documented in cancers that arise in breast, colon, ovary, melanocyte, gastric mucosa, head and neck, pancreas, lung and brain. Targeting SFKs in cancer cells has been shown to be a promising therapeutic strategy in solid tumors, particularly in ovarian, colon and breast cancers. Paclitaxel is one of most widely used chemotherapeutic agents for the management of ovarian, breast, lung and head and neck cancers. As a microtubule-stabilizing agent, paclitaxel possesses both mitosis-dependent and mitosis-independent activities against cancer cells. A variety of mechanisms such as deregulation of P-glycoprotein, alteration of tubulin isotypes, alteration of microtubule-regulatory proteins, deregulation of apoptotic signaling pathways, mutation of tubulins and overexpression of copper transporters have been implicated in the development of primary or secondary resistance to paclitaxel. By affecting cancer cell survival, proliferation, autophagy, microtubule stability, motility, and/or angiogenesis, SFKs interact with mechanisms that regulate paclitaxel sensitivity. Inhibition of SFKs can potentiate the anti-tumor activity of paclitaxel by enhancing apoptosis, autophagy and microtubule stability. Based on pre-clinical observations, administration of SFK inhibitors in combination with paclitaxel could improve treatment for ovarian, breast, lung and head and neck cancers. Identification and validation of predictive biomarkers could also permit personalization of the therapy.
C1 [Le, Xiao-Feng; Bast, Robert C., Jr.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
RP Le, XF (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
EM xfle@mdanderson.org; rbast@mdanderson.org
RI Bast, Robert C/E-6585-2011
OI Bast, Robert C/0000-0003-4621-8462
FU Anne and Henry Zarrow Foundation; National Foundation for Cancer
   Research; NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50
   CA83639, CCSG P30 CA16672]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA016672, P50CA083639]
   Funding Source: NIH RePORTER
FX We are grateful to the Anne and Henry Zarrow Foundation, Mr. and Mrs.
   Stuart Zarrow, the National Foundation for Cancer Research, the MD
   Anderson SPORE in Ovarian Cancer NCI P50 CA83639 and the MD Anderson NCI
   CCSG P30 CA16672 for their support in preparing this review.
CR Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   Ahluwalia MS, 2010, CANCER LETT, V298, P139, DOI 10.1016/j.canlet.2010.08.014
   Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014
   Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328
   Alli E, 2002, CANCER RES, V62, P6864
   Bellarosa D, 2005, ANTICANCER RES, V25, P2119
   Belotti D, 1996, CLIN CANCER RES, V2, P1843
   Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200
   BROOKS HD, 2010, CANCER IN PRESS
   BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0
   BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171
   Cantiani L, 2007, CANCER RES, V67, P7675, DOI 10.1158/0008-5472.CAN-06-4697
   Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528
   Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378
   Chen T, 2005, MOL CANCER THER, V4, P217
   Cheung CHA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-43
   Debernardis D, 1997, CANCER RES, V57, P870
   Dehm SM, 2004, BIOCHEM CELL BIOL, V82, P263, DOI 10.1139/o03-077
   DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014
   Dimple C, 2008, CANCER RES, V68, P4902, DOI 10.1158/0008-5472.CAN-07-5698
   Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061
   Egloff AM, 2008, SEMIN ONCOL, V35, P286, DOI 10.1053/j.seminoncol.2008.03.008
   Elsberger B, 2010, BRIT J CANCER, V103, P899, DOI 10.1038/sj.bjc.6605829
   ERSHLER MA, 1995, FEBS LETT, V375, P50, DOI 10.1016/0014-5793(95)01154-7
   Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291
   Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x
   Fojo T, 2007, ANN ONCOL, V18, pV3, DOI 10.1093/annonc/mdm172
   FORNIER MN, 2011, ANN ONCOL IN PRESS
   Frasson M, 2009, BBA-MOL CELL RES, V1793, P239, DOI 10.1016/j.bbamcr.2008.10.001
   Furukawa T, 2008, CURR MED CHEM, V15, P3268, DOI 10.2174/092986708786848479
   Gan PP, 2007, CANCER RES, V67, P9356, DOI 10.1158/0008-5472.CAN-07-0509
   GAN PP, MOL CANC THER, V9, P1339
   George JA, 2005, CANCER RES, V65, P10381, DOI 10.1158/0008-5472.CAN-05-1822
   Giaccone G, 2008, ANN ONCOL, V19, P1219, DOI 10.1093/annonc/mdn048
   Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118
   Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Goldspiel BR, 1997, PHARMACOTHERAPY, V17, pS110
   Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875
   Griffiths GJ, 2004, J BIOL CHEM, V279, P46113, DOI 10.1074/jbc.M408550200
   Gruber D, 2001, CELL MOTIL CYTOSKEL, V49, P115, DOI 10.1002/cm.1026
   GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23
   Hage-Sleiman R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-135
   Han LY, 2006, CANCER RES, V66, P8633, DOI 10.1158/0008-5472.CAN-06-1410
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hasegawa S, 2002, INT J CANCER, V101, P46, DOI 10.1002/ijc.10575
   Hiscox S, 2008, EXPERT OPIN THER TAR, V12, P757, DOI 10.1517/14728222.12.6.757 
   Horwitz S. B., 1994, ANN ONCOL, V5, pS3, DOI DOI 10.1093/ANN0NC/5.SUPPL_4.S3
   Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55
   Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633
   Huang RYJ, 2008, INT J CANCER, V123, P801, DOI 10.1002/ijc.23579
   Iancu C, 2000, CANCER RES, V60, P3537
   IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3
   Inagaki K, 2005, J BIOL CHEM, V280, P31428, DOI 10.1074/jbc.M501406200
   Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012
   Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001
   JACOBS C, 1983, CANCER RES, V43, P1696
   Jeong KJ, 2008, EXP MOL MED, V40, P607, DOI 10.3858/emm.2008.40.6.607
   Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507
   Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J
   Kim CH, 2006, INT J CANCER, V118, P1692, DOI 10.1002/ijc.21573
   Kim HS, 2011, CLIN CANCER RES, V17, P1713, DOI 10.1158/1078-0432.CCR-10-2081
   Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129
   KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916
   Komlodi-Pasztor E, 2011, NAT REV CLIN ONCOL, V8, P244, DOI [10.1038/nrclinonc.2010.228, 10.1038/nrclinonc.2010.228-c2]
   Konecny GE, 2009, BRIT J CANCER, V101, P1699, DOI 10.1038/sj.bjc.6605381
   Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226
   Kuo MT, 2007, CANCER METAST REV, V26, P71, DOI 10.1007/s10555-007-9045-3
   Landen CN, 2006, J NATL CANCER I, V98, P1558, DOI 10.1093/jnci/djj414
   Le XF, 2010, CANCER-AM CANCER SOC, V116, P4980, DOI 10.1002/cncr.25426
   Le XF, 2008, CELL CYCLE, V7, P3747, DOI 10.4161/cc.7.23.7212
   Lee D, 2006, CLIN LUNG CANCER, V7, P381, DOI 10.3816/CLC.2006.n.020
   Lee FYF, 2008, CLIN CANCER RES, V14, P8123, DOI 10.1158/1078-0432.CCR-08-0025
   Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307
   Leung ELH, 2009, MOL CANCER RES, V7, P923, DOI 10.1158/1541-7786.MCR-09-0003
   Levi M, 2010, MOL CELL ENDOCRINOL, V314, P228, DOI 10.1016/j.mce.2009.08.027
   Levi M, 2010, CELL CYCLE, V9, P1577, DOI 10.4161/cc.9.8.11299
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7
   Lim RWL, 2000, J BIOL CHEM, V275, P20578, DOI 10.1074/jbc.M001887200
   Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200
   LINN SC, 1995, ANN ONCOL, V6, P679, DOI 10.1093/oxfordjournals.annonc.a059284
   Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779
   Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845
   Lu CH, 2010, CANCER BIOL THER, V9, P176, DOI 10.4161/cbt.9.3.10635
   Lu J, 2009, CLIN CANCER RES, V15, P1326, DOI 10.1158/1078-0432.CCR-08-0954
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luttrell Louis M., 2006, V332, P3
   Mangala LS, 2009, CLIN CANCER RES, V15, P3770, DOI 10.1158/1078-0432.CCR-08-2306
   Martello LA, 2003, CANCER RES, V63, P1207
   Martinez-Balibrea E, 2009, INT J CANCER, V124, P2905, DOI 10.1002/ijc.24273
   Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4
   MAZURENKO NN, 1991, VOP ONKOL+, V37, P683
   Metzger-Filho O, 2009, EXPERT OPIN INV DRUG, V18, P1183, DOI 10.1517/13543780903119167
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669
   Morgan Liam, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P273, DOI 10.2174/187153008786848295
   MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735
   NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4
   Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446
   Naramoto H, 2007, INT J ONCOL, V30, P393
   Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200
   Oguri T, 2008, MOL CANCER THER, V7, P1150, DOI 10.1158/1535-7163.MCT-07-2088
   Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026
   Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934
   OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773
   Owatari S, 2007, CANCER RES, V67, P4860, DOI 10.1158/0008-5472.CAN-06-3096
   PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358
   Pengetnze Y, 2003, BIOCHEM BIOPH RES CO, V309, P377, DOI 10.1016/j.bbrc.2003.08.012
   Penson RT, 2004, GYNECOL ONCOL, V93, P98, DOI 10.1016/j.ygyno.2003.11.053
   Pusztai L, 2009, J CLIN ONCOL, V27, P4287, DOI 10.1200/JCO.2008.21.6887
   Qian XL, 2009, CANCER CELL, V16, P246, DOI 10.1016/j.ccr.2009.07.031
   Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106
   Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012
   ROTHSCHILD SI, CLIN LUNG CANC, V11, P238
   Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102
   Sale S, 2002, MOL CANCER THER, V1, P215
   SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0
   SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561
   Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323
   Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382
   Shahzad MMK, 2009, CANCER BIOL THER, V8, P1027, DOI 10.4161/cbt.8.11.8523
   Shajahan AN, 2007, J BIOL CHEM, V282, P5934, DOI 10.1074/jbc.M608857200
   Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214
   Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620
   Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200
   Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481
   STOVER DR, 1994, J BIOL CHEM, V269, P26885
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Sun Yang, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P557, DOI 10.3969/j.issn.1672-7347.2010.06.004
   Tabuchi Y, 2009, INT J ONCOL, V34, P313, DOI 10.3892/ijo_00000153
   Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353
   Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200
   Teneriello MG, 2009, J CLIN ONCOL, V27, P1426, DOI 10.1200/JCO.2008.18.9548
   Teoh D, 2011, GYNECOL ONCOL, V121, P187, DOI 10.1016/j.ygyno.2010.11.017
   THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Tran TA, 2009, BIOCHEM BIOPH RES CO, V379, P304, DOI 10.1016/j.bbrc.2008.12.073
   Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P11, DOI 10.1016/S0169-5002(01)00291-4
   van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147
   Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N
   Vispe S, 2009, MOL CANCER THER, V8, P2780, DOI 10.1158/1535-7163.MCT-09-0549
   Wakahara K, 2004, J CELL BIOCHEM, V93, P437, DOI 10.1002/jcb.20160
   Wanaski SP, 2003, BIOCHEMISTRY-US, V42, P42, DOI 10.1021/bi012097n
   Wang XD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r255
   Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130
   Wen XF, 2006, ONCOGENE, V25, P6986, DOI 10.1038/sj.onc.1209685
   Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wiener JR, 1999, CLIN CANCER RES, V5, P2164
   Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851
   Wiesen KM, 2007, CANCER LETT, V257, P227, DOI 10.1016/j.canlet.2007.07.022
   Wilson GR, 2006, BRIT J CANCER, V95, P1410, DOI 10.1038/sj.bjc.6603444
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Yin SH, 2007, MOL CANCER THER, V6, P2798, DOI 10.1158/1535-7163.MCT-06-0791
   Yin SH, 2010, MOL CANCER THER, V9, P327, DOI 10.1158/1535-7163.MCT-09-0674
   Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947
   Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3
   Zamora-Leon SP, 2005, J BIOL CHEM, V280, P1962, DOI 10.1074/jbc.M411380200
   Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658
   Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706
   Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504
   Zheng R, 2005, CLIN EXP METASTAS, V22, P195, DOI 10.1007/s10585-005-7768-5
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
   Zou CF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-22
NR 170
TC 66
Z9 71
U1 2
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD AUG 15
PY 2011
VL 12
IS 4
BP 260
EP 269
DI 10.4161/cbt.12.4.16430
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 806WN
UT WOS:000293847500002
PM 21646863
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Khorsandi, L
   Saki, G
   Bavarsad, N
   Mombeini, M
AF Khorsandi, L.
   Saki, G.
   Bavarsad, N.
   Mombeini, M.
TI Silymarin induces a multi-targeted cell death process in the human colon
   cancer cell line HT-29
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Necroptosis; Apoptosis; Autophagy; Silymarin; Colon cancer
ID REACTIVE OXYGEN; STEM-CELLS; AUTOPHAGY; APOPTOSIS; NECROPTOSIS;
   INHIBITION; SILIBININ; DIFFERENTIATION; NANOPARTICLES; CURCUMIN
AB This study investigated the Silymarin (SM) effects on growth of HT-29 human colon cancer cell line and its cellular death mechanism. HT-29 cells were treated by 25 mM/ml of SM for 48 h. HT-29 cells were also pretreated with 10 mmol zVAD (apoptosis inhibitor), 10 mmol 3-MA (autophagy inhibitor) and 3 mmol Nec (necroptosis inhibitor) for evaluation cell death induced by apoptosis, outophagy and necroptosis. MTT and clonogenicity assays revealed that the SM without inhibitors induced a significant decrease in cell viability and proliferation of HT-29 cells (p < 0.05). SM in presence of Nec and 3-MA significantly decreased viability and proliferation of HT-29 cells. Apoptotic indexes were significantly increased compare to other groups. SM in presence of zVAD and 3-MA significantly decreased viability and proliferation of HT-29 cells, and expression of RIPK1 and RIPK3 in compare to absence the inhibitors. Necroptotic index was also increased. zVAD could not completely blocked apoptosis. This indicate that SM may stimulate both caspase-dependent and caspase-independent apoptotic pathways. SM in presence of zVAD and Nec significantly decreased cell viability and proliferation of HT-29 cells in compare to control and other experimental groups. LC3-II positive cells were significantly increased in this group in compare to the control and SM without inhibitors treatment. Our results revealed that the high SM toxicity to HT-29 cells depends on multiple cell death pathways, which involved mainly autophagy. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Khorsandi, L.; Saki, G.] Ahvaz Jundishapur Univ Med Sci, Cell & Mol Res Ctr, POB 61335, Ahvaz, Iran.
   [Khorsandi, L.; Saki, G.; Mombeini, M.] Ahvaz Jundishapur Univ Med Sci, Fac Med, Dept Anat Sci, Ahvaz, Iran.
   [Bavarsad, N.] Ahvaz Jundishapur Univ Med Sci, Dept Pharmaceut, Fac Med, Nanotechnol Res Ctr, Ahvaz, Iran.
RP Khorsandi, L (corresponding author), Ahvaz Jundishapur Univ Med Sci, Cell & Mol Res Ctr, POB 61335, Ahvaz, Iran.
EM khorsandi_cmrc@yahoo.com
RI Khorsandi, Layasadat/R-3901-2017; saki, ghasem/M-3341-2018; Bavarsad,
   Neda/P-8663-2015
OI Khorsandi, Layasadat/0000-0002-3391-3055; saki,
   ghasem/0000-0001-5268-8407; Bavarsad, Neda/0000-0002-7872-0273
FU research council of Ahvaz Jundishapur University of Medical sciences
   [CMRC-95034]
FX This paper is a part Ms. C thesis of Maryam Mombeini and was supported
   by a Grant (CMRC-95034) from the research council of Ahvaz Jundishapur
   University of Medical sciences.
CR Abenavoli L, 2010, PHYTOTHER RES, V24, P1423, DOI 10.1002/ptr.3207
   Agarwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062852
   Akhtar R, 2014, NUTR HOSP, V29, P388, DOI 10.3305/nh.2014.29.2.7080
   Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   Duan WJ, 2010, J PHARMACOL SCI, V113, P48, DOI 10.1254/jphs.09315FP
   Echeverry N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.124
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fan L, 2014, EUR J PHARMACOL, V743, P79, DOI 10.1016/j.ejphar.2014.09.019
   Fan SM, 2011, FREE RADICAL RES, V45, P1307, DOI 10.3109/10715762.2011.618186
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20
   Jiang YY, 2011, EUR J PHARMACOL, V659, P7, DOI 10.1016/j.ejphar.2010.12.043
   Kalla PK, 2014, ADV BIOL RES, V8, P57, DOI DOI 10.5829/idosi.abr.2014.8.2.82286
   Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123
   Khorsandi L, 2017, ENVIRON SCI POLLUT R, V24, P5595, DOI 10.1007/s11356-016-8325-2
   Khorsandi L, 2015, CELL TISSUE RES, V361, P745, DOI 10.1007/s00441-015-2140-9
   Khosropanah MH, 2016, IRAN J PHARM RES, V15, P231
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V468, P151, DOI 10.1016/j.bbrc.2015.10.143
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Li IH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116565
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Lin CY, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.65
   Meng MB, 2016, ONCOTARGET, V7, P57391, DOI 10.18632/oncotarget.10548
   Montgomery A, 2016, J CANCER, V7, P1250, DOI 10.7150/jca.15690
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Mouratidis P. X., 2011, J PHARM SCI, V117, P160
   Mouratidis PXE, 2013, NUTR CANCER, V65, P1086, DOI 10.1080/01635581.2013.850963
   Nikoletopoulou V., 2015, INT J HYPERTHER, V31, P476
   Nugues AL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.347
   Orazizadeh M, 2015, CELL J, V17, P412
   Polito L, 2016, PHYTOMEDICINE, V23, P32, DOI 10.1016/j.phymed.2015.11.006
   Polito L, 2009, INT J BIOCHEM CELL B, V41, P1055, DOI 10.1016/j.biocel.2008.09.021
   Pugsley HR, 2017, METHODS, V112, P147, DOI 10.1016/j.ymeth.2016.05.022
   Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007
   Soleimani M, 2014, CELL J, V16, P43
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Toyoda-Hokaiwado N, 2011, CARCINOGENESIS, V32, P1512, DOI 10.1093/carcin/bgr130
   Ullen A, 2010, INT J ONCOL, V37, P15, DOI 10.3892/ijo_00000648
   Wallenberg M., 2009, INT J BIOCHEM CELL B, V41, P1055
   Wang Hai-Yu, 2015, Asian Pac J Cancer Prev, V16, P2569
   Wang Y, 2014, NEUROSCIENCE, V266, P91, DOI 10.1016/j.neuroscience.2014.02.007
   Ye LH, 2012, ANAT REC, V295, P417, DOI 10.1002/ar.21528
   Ye Y. C., 2016, AUTOPHAGY, V12, P659
NR 45
TC 9
Z9 10
U1 0
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2017
VL 94
BP 890
EP 897
DI 10.1016/j.biopha.2017.08.015
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FP6MU
UT WOS:000417741000100
PM 28810529
DA 2022-04-25
ER

PT J
AU Verdoodt, B
   Vogt, M
   Schmitz, I
   Liffers, ST
   Tannapfel, A
   Mirmohammadsadegh, A
AF Verdoodt, Berlinda
   Vogt, Markus
   Schmitz, Inge
   Liffers, Sven-Thorsten
   Tannapfel, Andrea
   Mirmohammadsadegh, Alireza
TI Salinomycin Induces Autophagy in Colon and Breast Cancer Cells with
   Concomitant Generation of Reactive Oxygen Species
SO PLOS ONE
LA English
DT Article
ID DEATH; APOPTOSIS; KINASE; RESISTANCE; ROLES; ROS; METASTASIS;
   ACTIVATION; EXPRESSION; CROSSTALK
AB Background: Salinomycin is a polyether ionophore antibiotic that has recently been shown to induce cell death in human cancer cells displaying multiple mechanisms of drug resistance. The underlying mechanisms leading to cell death after salinomycin treatment have not been well characterized. We therefore investigated the role of salinomycin in caspase dependent and independent cell death in colon cancer (SW480, SW620, RKO) and breast cancer cell lines (MCF-7, T47D, MDA-MB-453).
   Methodology/Principal Findings: We detected features of apoptosis in all cell lines tested, but the executor caspases 3 and 7 were only strongly activated in RKO and MDA-MB-453 cells. MCF-7 and SW620 cells instead presented features of autophagy such as cytoplasmic vacuolization and LC3 processing. Caspase proficient cell lines activated autophagy at lower salinomycin concentrations and before the onset of caspase activation. Salinomycin also led to the formation of reactive oxygen species (ROS) eliciting JNK activation and induction of the transcription factor JUN. Salinomycin mediated cell death could be partially inhibited by the free radical scavenger N-acetyl-cysteine, implicating ROS formation in the mechanism of salinomycin toxicity.
   Conclusions: Our data indicate that, in addition to its previously reported induction of caspase dependent apoptosis, the initiation of autophagy is an important and early effect of salinomycin in tumor cells.
C1 [Verdoodt, Berlinda; Vogt, Markus; Schmitz, Inge; Liffers, Sven-Thorsten; Tannapfel, Andrea; Mirmohammadsadegh, Alireza] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany.
RP Mirmohammadsadegh, A (corresponding author), Ruhr Univ Bochum, Inst Pathol, Univ Str 150, Bochum, Germany.
EM alireza.mirmohammadsadegh@rub.de
FU Ministry for Innovation, Science and Research of Nordrhein-Westfalen;
   Protein Research Unit Ruhr within Europe, PURE
FX This work was funded by the Ministry for Innovation, Science and
   Research of Nordrhein-Westfalen, and by the Protein Research Unit Ruhr
   within Europe, PURE. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   DALTON AJ, 1955, ANAT REC, V121, P281
   DANFORTH HD, 1977, POULTRY SCI, V56, P926, DOI 10.3382/ps.0560926
   Daugschies A, 1998, VET PARASITOL, V76, P163, DOI 10.1016/S0304-4017(97)00203-3
   Duan WJ, 2011, BIOL PHARM BULL, V34, P47, DOI 10.1248/bpb.34.47
   Ferguson HA, 2003, J BIOL CHEM, V278, P45793, DOI 10.1074/jbc.M307979200
   Fuchs D, 2010, BIOCHEM BIOPH RES CO, V394, P1098, DOI 10.1016/j.bbrc.2010.03.138
   Fuchs D, 2009, BIOCHEM BIOPH RES CO, V390, P743, DOI 10.1016/j.bbrc.2009.10.042
   Ghosh D, 2011, J PROTEOME RES, V10, P4373, DOI 10.1021/pr2005617
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551
   Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Moretti L, 2007, AUTOPHAGY, V3, P142, DOI 10.4161/auto.3607
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197
   Oak PS, 2012, INT J CANCER, V131, P2808, DOI 10.1002/ijc.27595
   Riccioni R, 2010, BLOOD CELL MOL DIS, V45, P86, DOI 10.1016/j.bcmd.2010.03.008
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schneider M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-96
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Takeda K, 2003, CELL STRUCT FUNCT, V28, P23
   Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016
   Temkin V, 2007, IMMUNOL REV, V220, P8, DOI 10.1111/j.1600-065X.2007.00560.x
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 45
TC 69
Z9 74
U1 3
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2012
VL 7
IS 9
AR e44132
DI 10.1371/journal.pone.0044132
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 014PP
UT WOS:000309388400019
PM 23028492
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Sun, WL
AF Sun, Wei-Liang
TI Ambra1 in autophagy and apoptosis: Implications for cell survival and
   chemotherapy resistance (Review)
SO ONCOLOGY LETTERS
LA English
DT Review
DE activating molecule in beclin 1-regulated autophagy protein 1;
   autophagy; apoptosis; chemotherapy; resistance
ID BREAST-CANCER CELLS; BECLIN 1; COLON-CANCER; HEPATOCELLULAR-CARCINOMA;
   REGULATES AUTOPHAGY; MULTIDRUG-RESISTANCE; THERAPEUTIC TARGET; INHIBITS
   AUTOPHAGY; DEATH; 5-FLUOROURACIL
AB Increasing studies suggest that autophagy has a protective role in cancer treatment and may even be involved in chemotherapy resistance. Nevertheless, the mechanism of autophagy in cancer treatment and drug resistance has not yet been established. There is a complex association between autophagy and apoptosis. Accordingly, these two processes can mutually regulate and transform to determine the fate of a cell, depending on the context. Activating molecule in Beclin 1-regulated autophagy protein 1 (Ambra1) is an important factor at the crossroad between autophagy and apoptosis. The expression level and intracellular distributions of Ambra1 may control the balance and conversion between autophagy and apoptosis, and modify the effectiveness of chemotherapy. Therefore, Ambra1 may provide a novel target for cancer treatment, particularly for overcoming anticancer drug resistance. The present review focuses on the role of Ambra1 in autophagy and apoptosis and assesses the implications for cell survival and chemotherapy resistance.
C1 [Sun, Wei-Liang] Guangxi Med Univ, Dept Internal Med Oncol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
RP Sun, WL (corresponding author), Guangxi Med Univ, Dept Internal Med Oncol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
EM swl20022001@hotmail.com
FU National Natural Science Foundation of China (Beijing, China)National
   Natural Science Foundation of China (NSFC) [81360340]; Wu Jieping
   Medical Foundation clinical research special fund (Beijing, China)
   [320.6750.12689]
FX The present study is supported by grants front the National Natural
   Science Foundation of China (Beijing, China; grant no. 81360340) and the
   Wu Jieping Medical Foundation clinical research special fund (Beijing,
   China; grant no. 320.6750.12689).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Chen YS, 2011, DIS ESOPHAGUS, V24, P437, DOI 10.1111/j.1442-2050.2010.01156.x
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Corazzari M, 2012, AUTOPHAGY, V8, P1255, DOI 10.4161/auto.20671
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Di Bartolomeo S, 2010, J CELL BIOL, V191, P155, DOI 10.1083/jcb.201002100
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   FEDORKO M, 1967, J CLIN INVEST, V46, P1932, DOI 10.1172/JCI105683
   Fimia GM, 2013, ONCOGENE, V32, P3311, DOI 10.1038/onc.2012.455
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090151
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lee YJ, 2012, INT J MED SCI, V9, P881, DOI 10.7150/ijms.5011
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Ravikumar B, 2009, J CELL SCI, V122, P1707, DOI 10.1242/jcs.031773
   Rubinsztein DC, 2012, CURR BIOL, V22, pR29, DOI 10.1016/j.cub.2011.11.034
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schoenlein PV, 2009, AUTOPHAGY, V5, P400, DOI 10.4161/auto.5.3.7784
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shin SW, 2012, BBA-MOL CELL RES, V1823, P451, DOI 10.1016/j.bbamcr.2011.10.014
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun WL, 2015, NEOPLASMA, V62, P199, DOI 10.4149/neo_2015_025
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Tooze SA, 2011, EMBO J, V30, P1185, DOI 10.1038/emboj.2011.75
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Xia PY, 2014, CELL RES, V24, P943, DOI 10.1038/cr.2014.85
   Xia PY, 2013, EMBO J, V32, P2685, DOI 10.1038/emboj.2013.189
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397
   Xu WH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-273
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Yazdankhah M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.358
   Zhao MY, 2011, BMB REP, V44, P601, DOI 10.5483/BMBRep.2011.44.9.601
NR 77
TC 19
Z9 20
U1 5
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2016
VL 12
IS 1
BP 367
EP 374
DI 10.3892/ol.2016.4644
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DR5RN
UT WOS:000379960200062
PM 27347152
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Mosieniak, G
   Adamowicz, M
   Alster, O
   Jaskowiak, H
   Szczepankiewicz, AA
   Wilczynski, GM
   Ciechomska, IA
   Sikora, E
AF Mosieniak, Grazyna
   Adamowicz, Marek
   Alster, Olga
   Jaskowiak, Hubert
   Szczepankiewicz, Andrzej A.
   Wilczynski, Grzegorz M.
   Ciechomska, Iwona A.
   Sikora, Ewa
TI Curcumin induces permanent growth arrest of human colon cancer cells:
   Link between senescence and autophagy
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Senescence; Autophagy; Curcumin; p53; Polyploidy
ID NF-KAPPA-B; CELLULAR SENESCENCE; MITOTIC CATASTROPHE; DNA FRAGMENTATION;
   APOPTOTIC PATHWAY; DOWN-REGULATION; TUMOR-CELLS; IN-VITRO; P53;
   EXPRESSION
AB Curcumin, a natural polyphenol derived from the rhizome of Curcuma longa, is a potent anticancer agent, which restricts tumor cell growth both in vitro and in vivo. Thus far curcumin was shown to induce death of cancer cells. This study reports the induction of cellular senescence of human colon cancer cells HCT116 upon curcumin treatment. The SA-beta-galactosidase activation was observed both in p53+/+ and p53-/- cells, however the latter ones were less sensitive to the prosenescent activity of curcumin. Upregulation of p53 and p21 proteins was observed in p53+/+ HCT116, while p53-independent induction of p21 was noticed in p53-/- HCT116. Moreover, the senescence of HCT116 cells was accompanied by autophagy, that was confirmed by electron microscopy observations of autophagosomes in the curcumin-treated cells as well as LC3-II expression, punctue staining of LC3 and increased content of acidic vacuoles. Inhibition of autophagy, due to the diminished expression of ATG5 by RNAi decreased the number of senescent cells induced by curcumin, but did not lead to increased cell death. Altogether, we demonstrated a new antitumor activity of curcumin leading to cancer cell senescence and revealed the presence of a functional link between senescence and autophagy in curcumin-treated cells. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Mosieniak, Grazyna; Adamowicz, Marek; Alster, Olga; Jaskowiak, Hubert; Sikora, Ewa] PAS, Nencki Inst Expt Biol, Lab Mol Bases Aging, PL-02093 Warsaw, Poland.
   [Szczepankiewicz, Andrzej A.; Wilczynski, Grzegorz M.] PAS, Nencki Inst Expt Biol, Lab Mol & Syst Neuromotphol, PL-02093 Warsaw, Poland.
   [Ciechomska, Iwona A.] PAS, Nencki Inst Expt Biol, Lab Transcript Regulat, PL-02093 Warsaw, Poland.
RP Mosieniak, G (corresponding author), PAS, Nencki Inst Expt Biol, Lab Mol Bases Aging, PL-02093 Warsaw, Poland.
EM g.mosieniak@nencki.gov.pl
RI Ciechomksa, Iwona/R-4706-2016
OI Ciechomksa, Iwona/0000-0002-8068-0020; Mosieniak,
   Grazyna/0000-0001-7957-1241; Sikora, Ewa/0000-0002-1111-1748;
   Wilczynski, Grzegorz/0000-0001-6667-0291; Szczepankiewicz,
   Andrzej/0000-0002-1502-3147
FU Ministry of Science and Higher EducationMinistry of Science and Higher
   Education, PolandEuropean Commission [N301 008 32/0549]; National Center
   of ScienceNational Science Centre, Poland [2011/01/M/NZ1/01597]
FX This work was supported by the Ministry of Science and Higher Education
   (grant N301 008 32/0549) and by National Center of Science (grant
   2011/01/M/NZ1/01597).
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bielak-Zmijewska A, 2004, CANCER CHEMOTH PHARM, V53, P179, DOI 10.1007/s00280-003-0705-x
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573
   Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078
   Choi BH, 2008, CANCER RES, V68, P1369, DOI 10.1158/0008-5472.CAN-07-5222
   Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Das T, 2010, MOL CELL BIOCHEM, V336, P85, DOI 10.1007/s11010-009-0269-0
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Glienke W, 2010, CANCER INVEST, V28, P166, DOI 10.3109/07357900903287006
   Gosselin K, 2009, AM J PATHOL, V174, P423, DOI 10.2353/ajpath.2009.080332
   Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   Holy JM, 2002, MUTAT RES-GEN TOX EN, V518, P71, DOI 10.1016/S1383-5718(02)00076-1
   Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240
   Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Liu HL, 2005, ACTA PHARMACOL SIN, V26, P603, DOI 10.1111/j.1745-7254.2005.00081.x
   Mackenzie GG, 2008, INT J CANCER, V123, P56, DOI 10.1002/ijc.23477
   Magalska A, 2006, ACTA BIOCHIM POL, V53, P531
   Magalska A, 2006, INT J CANCER, V119, P1811, DOI 10.1002/ijc.22055
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mosieniak G, 2010, CURR PHARM DESIGN, V16, P734, DOI 10.2174/138161210790883714
   Mosieniak G, 2006, FEBS LETT, V580, P4653, DOI 10.1016/j.febslet.2006.07.038
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Paglin S, 2001, CANCER RES, V61, P439
   Patschan S, 2008, AM J PHYSIOL-HEART C, V294, pH1119, DOI 10.1152/ajpheart.00713.2007
   Piwocka K, 2002, ANN NY ACAD SCI, V973, P250, DOI 10.1111/j.1749-6632.2002.tb04643.x
   Prasad CP, 2009, CHEM-BIOL INTERACT, V181, P263, DOI 10.1016/j.cbi.2009.06.012
   Prencipe M, 2009, BRIT J CANCER, V101, P1900, DOI 10.1038/sj.bjc.6605419
   Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Schmitt CA, 1999, J PATHOL, V187, P127
   Shankar S, 2007, INT J ONCOL, V30, P905
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518
   Shishodia S, 2007, CURR PROB CANCER, V31, P243, DOI 10.1016/j.currproblcancer.2007.04.001
   Sikora E, 2006, MOL CANCER THER, V5, P927, DOI 10.1158/1535-7163.MCT-05-0360
   Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002
   Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011
   Song G, 2005, BRAZ J MED BIOL RES, V38, P1791, DOI 10.1590/S0100-879X2005001200007
   Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227
   Sung B, 2009, MOL CANCER THER, V8, P959, DOI 10.1158/1535-7163.MCT-08-0905
   Teiten MH, 2011, INT J ONCOL, V38, P603, DOI 10.3892/ijo.2011.905
   Villegas I, 2008, MOL NUTR FOOD RES, V52, P1040, DOI 10.1002/mnfr.200700280
   Watson JL, 2010, MOL CARCINOGEN, V49, P13, DOI 10.1002/mc.20571
   Wolanin K, 2006, MOL CANCER RES, V4, P457, DOI 10.1158/1541-7786.MCR-05-0172
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Young ARJ, 2010, CURR OPIN CELL BIOL, V22, P234, DOI 10.1016/j.ceb.2009.12.005
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
NR 60
TC 94
Z9 100
U1 0
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUN
PY 2012
VL 133
IS 6
BP 444
EP 455
DI 10.1016/j.mad.2012.05.004
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 978SE
UT WOS:000306765300008
PM 22613224
DA 2022-04-25
ER

PT J
AU Xu, JL
   Yuan, L
   Tang, YC
   Xu, ZY
   Xu, HD
   Cheng, XD
   Qin, JJ
AF Xu, Jing-Li
   Yuan, Li
   Tang, Yan-Cheng
   Xu, Zhi-Yuan
   Xu, Han-Dong
   Cheng, Xiang-Dong
   Qin, Jiang-Jiang
TI The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE gastric cancer; autophagy; chemoresistance; ncRNAs; natural products;
   inhibitor and activator
ID CELL-CYCLE PROGRESSION; MESENCHYMAL TRANSITION; SUPPRESSES AUTOPHAGY;
   COLON-CANCER; APOPTOSIS; MIGRATION; RESISTANCE; INVASION; PATHWAY; DEATH
AB Gastric cancer is the third most common cause of cancer-related death worldwide. Drug resistance is the main inevitable and vital factor leading to a low 5-year survival rate for patients with gastric cancer. Autophagy, as a highly conserved homeostatic pathway, is mainly regulated by different proteins and non-coding RNAs (ncRNAs) and plays dual roles in drug resistance of gastric cancer. Thus, targeting key regulatory nodes in the process of autophagy by small molecule inhibitors or activators has become one of the most promising strategies for the treatment of gastric cancer in recent years. In this review, we provide a systematic summary focusing on the relationship between autophagy and chemotherapy resistance in gastric cancer. We comprehensively discuss the roles and molecular mechanisms of multiple proteins and the emerging ncRNAs including miRNAs and lncRNAs in the regulation of autophagy pathways and gastric cancer chemoresistance. We also summarize the regulatory effects of autophagy inhibitor and activators on gastric cancer chemoresistance. Understanding the vital roles of autophagy in gastric cancer chemoresistance will provide novel opportunities to develop promising therapeutic strategies for gastric cancer.
C1 [Xu, Jing-Li; Yuan, Li; Xu, Zhi-Yuan; Xu, Han-Dong; Cheng, Xiang-Dong; Qin, Jiang-Jiang] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China.
   [Xu, Jing-Li; Yuan, Li; Xu, Zhi-Yuan; Xu, Han-Dong; Cheng, Xiang-Dong; Qin, Jiang-Jiang] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China.
   [Xu, Jing-Li; Yuan, Li; Xu, Han-Dong] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Peoples R China.
   [Tang, Yan-Cheng] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tsai, Hong Kong, Peoples R China.
RP Cheng, XD; Qin, JJ (corresponding author), Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China.; Cheng, XD; Qin, JJ (corresponding author), Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China.
EM chengxd516@126.com; zylysjtu@hotmail.com
RI Qin, Jiangjiang/AAM-9553-2020
OI Qin, Jiangjiang/0000-0002-8559-616X; Cheng,
   Xiangdong/0000-0003-1470-2831; yuan, li/0000-0002-6245-9437
FU Natural Science Foundation of Zhejiang ProvinceNatural Science
   Foundation of Zhejiang Province [LY18H290006]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81903842, 81973634]; Program of Zhejiang Provincial TCM Sci-tech Plan
   [2018ZY006, 2020ZZ005]
FX This study was supported by Natural Science Foundation of Zhejiang
   Province (LY18H290006), National Natural Science Foundation of China
   (81903842 and 81973634), and Program of Zhejiang Provincial TCM Sci-tech
   Plan (2018ZY006 and 2020ZZ005).
CR Abdrakhmanov A, 2020, TRENDS BIOCHEM SCI, V45, P347, DOI 10.1016/j.tibs.2019.11.006
   Abdu K, 2020, NUCLEOS NUCLEOT NUCL, V39, P1108, DOI 10.1080/15257770.2020.1764971
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Anerillas C, 2020, GEROSCIENCE, V42, P397, DOI 10.1007/s11357-020-00183-3
   Bakula D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15637
   Balvers RK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0427-y
   Barroso-Chinea P, 2020, AUTOPHAGY, V16, P1279, DOI 10.1080/15548627.2019.1668606
   Biagioni A, 2019, CANCER METAST REV, V38, P537, DOI 10.1007/s10555-019-09803-7
   Boosani CS, 2019, EXPERT OPIN THER PAT, V29, P881, DOI 10.1080/13543776.2019.1669562
   Cai CZ, 2021, AUTOPHAGY, V17, P1112, DOI 10.1080/15548627.2020.1760623
   Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8
   Cao YJ, 2019, CLIN CHIM ACTA, V489, P10, DOI 10.1016/j.cca.2018.11.028
   Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005
   Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767
   Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0950-x
   Chen ZH, 2019, J CELL PHYSIOL, V234, P5904, DOI 10.1002/jcp.26777
   Cheng CY, 2019, VET RES, V50, DOI 10.1186/s13567-019-0697-0
   Chi CW, 2019, P NATL ACAD SCI USA, V116, P556, DOI 10.1073/pnas.1808618116
   Chollat-Namy M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1950-1
   Corona AK, 2018, TRENDS CELL BIOL, V28, P869, DOI 10.1016/j.tcb.2018.07.001
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Dandawate P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57940-9
   Diao JJ, 2015, NATURE, V520, P563, DOI 10.1038/nature14147
   Dong XQ, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.87
   Du XM, 2018, EXP THER MED, V15, P599, DOI 10.3892/etm.2017.5354
   Dutta P, 2020, CANCERS, V12, DOI 10.3390/cancers12051317
   Dutta S, 2019, FOOD CHEM TOXICOL, V128, P240, DOI 10.1016/j.fct.2019.04.012
   Emanuele S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101490
   Fan J, 2016, CELL PHYSIOL BIOCHEM, V38, P1063, DOI 10.1159/000443057
   Fawal MA, 2015, DEV CELL, V33, P67, DOI 10.1016/j.devcel.2015.02.010
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Gao AB, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104990
   Gao S, 2018, AGING-US, V10, P2113, DOI 10.18632/aging.101534
   Gomez-Osuna A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103417
   Gu YF, 2020, ANTI-CANCER DRUG, V31, P385, DOI 10.1097/CAD.0000000000000886
   Guardia CM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107837
   Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x
   Hao QY, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00589-8
   Hempen CH, 2020, BUNDESGESUNDHEITSBLA, V63, P570, DOI 10.1007/s00103-020-03132-9
   Hollenstein DM, 2020, CURR OPIN CELL BIOL, V65, P50, DOI 10.1016/j.ceb.2020.02.012
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Hsiao YH, 2019, PHYTOMEDICINE, V62, DOI 10.1016/j.phymed.2019.152964
   Hu WL, 2019, ADV EXP MED BIOL, V1206, P127, DOI 10.1007/978-981-15-0602-4_6
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang HJ, 2018, INT J ONCOL, V53, P2769, DOI 10.3892/ijo.2018.4593
   Jamali Z, 2020, IUBMB LIFE, V72, P1306, DOI 10.1002/iub.2277
   Jiang H, 2019, ONCOL LETT, V18, P6829, DOI 10.3892/ol.2019.10997
   Jiang SY, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1584
   Jin W, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051256
   Jo MJ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5957-x
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Kim BR, 2020, J CANCER, V11, P460, DOI 10.7150/jca.34773
   Kim BW, 2018, AUTOPHAGY, V14, P2104, DOI 10.1080/15548627.2018.1504716
   Kim TW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0658-y
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Koh YC, 2020, J FOOD DRUG ANAL, V28, P14, DOI 10.1016/j.jfda.2019.11.001
   Lei YY, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109896
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li J, 2020, PATHOL ONCOL RES, V26, P1725, DOI 10.1007/s12253-019-00753-7
   Li M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2579-9
   Li XG, 2013, CLIN CANCER RES, V19, P2917, DOI 10.1158/1078-0432.CCR-12-3258
   Li Y, 2020, EUR REV MED PHARMACO, V24, P5101, DOI 10.26355/eurrev_202005_21203
   Li YH, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20170982
   Lin Y, 2017, MOL MED REP, V15, P2451, DOI 10.3892/mmr.2017.6289
   Liu B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0994-x
   Liu FH, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.920981
   Liu HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2656-0
   Liu HM, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104738
   Liu SX, 2020, NONLINEAR ANAL-MODEL, V25, P1, DOI 10.15388/namc.2020.25.15717
   Liu T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00408
   LIU YC, 2020, CELLS-BASEL, V9, DOI DOI 10.3390/CELLS9061331
   Lopez-Contreras F, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01670
   Lorincz P, 2020, J MOL BIOL, V432, P2462, DOI 10.1016/j.jmb.2019.10.028
   Lu RQ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819864311
   Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200
   Lystad AH, 2019, AUTOPHAGY, V15, P1485, DOI 10.1080/15548627.2019.1618100
   Mao K, 2011, CIRC RES, V108, P787, DOI 10.1161/RES.0b013e3182194c29
   Mele L, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102043
   Moon HJ, 2019, ONCOL RES, V27, P835, DOI 10.3727/096504019X15517850319579
   Moosavi MS, 2020, PATHOL ONCOL RES, V26, P615, DOI 10.1007/s12253-019-00646-9
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Murugan AK, 2019, SEMIN CANCER BIOL, V59, P92, DOI 10.1016/j.semcancer.2019.07.003
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Nazim UM, 2020, INT J MOL MED, V46, P280, DOI 10.3892/ijmm.2020.4566
   Nie YL, 2020, AM J MED SCI, V359, P287, DOI 10.1016/j.amjms.2020.02.007
   Nobili A, 2020, J PATHOL, V251, P113, DOI 10.1002/path.5436
   Ouyang L, 2017, AUTOPHAGY, V13, P777, DOI 10.1080/15548627.2017.1283470
   Pan XK, 2018, CURR MED SCI, V38, P1018, DOI 10.1007/s11596-018-1978-y
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Parikh C, 2012, P NATL ACAD SCI USA, V109, P19368, DOI 10.1073/pnas.1204384109
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pei GQ, 2018, CELL PHYSIOL BIOCHEM, V46, P847, DOI 10.1159/000488742
   Perez-Montoyo H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030614
   Petroni G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2349-8
   Poursheikhani A, 2020, CELL ONCOL, V43, P961, DOI 10.1007/s13402-020-00528-2
   Qi YY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1089-2
   Qi YY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5810-2
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508
   Qin JJ, 2018, GENES DIS, V5, P204, DOI 10.1016/j.gendis.2018.07.002
   Qin JJ, 2013, EUR J MED CHEM, V68, P473, DOI 10.1016/j.ejmech.2013.07.018
   Qin JJ, 2017, CHIN J NAT MEDICINES, V15, P401, DOI 10.1016/S1875-5364(17)30062-6
   Qiu L, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2019.117234
   Ranek MJ, 2019, NATURE, V566, P264, DOI 10.1038/s41586-019-0895-y
   Ratti M, 2020, TARGET ONCOL, V15, P261, DOI 10.1007/s11523-020-00717-x
   Reggiori F, 2017, J MOL BIOL, V429, P486, DOI 10.1016/j.jmb.2017.01.002
   Russi S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153736
   Sanchez-Martin P, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.118613
   Santos-Laso A, 2020, LIVER INT, V40, P1670, DOI 10.1111/liv.14485
   Sato E, 2019, ANTICANCER RES, V39, P6585, DOI 10.21873/anticanres.13874
   Seetha A, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22433
   Shi XS, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911047
   Stanga D, 2019, TRAFFIC, V20, P325, DOI 10.1111/tra.12640
   Suarez-Cabrera C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31326-4
   Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199
   Sun Y, 2017, CANCER MED-US, V6, P2331, DOI 10.1002/cam4.1169
   Thrift AP, 2020, CLIN GASTROENTEROL H, V18, P534, DOI 10.1016/j.cgh.2019.07.045
   Tian HJ, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00375
   Tian L, 2018, ONCOTARGET, V9, P4886, DOI 10.18632/oncotarget.23513
   Tsai CY, 2020, ONCOLOGIST, V25, pE1021, DOI 10.1634/theoncologist.2019-0419
   VALLECILLOHERNA.J, 2018, DRUGS SCI REPORTS, V8, P3593, DOI DOI 10.1038/s41598-018-21455-1
   Wang HW, 2020, BIOENGINEERED, V11, P510, DOI 10.1080/21655979.2020.1754038
   Wei F, 2017, INT J ONCOL, V51, P1383, DOI 10.3892/ijo.2017.4134
   Wu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0935-8
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xiao F, 2020, DRUG DEVELOP RES, V81, P544, DOI 10.1002/ddr.21650
   Xin L, 2019, J CANCER RES CLIN, V145, P2507, DOI 10.1007/s00432-019-03015-w
   Xu JX, 2020, ARCH BIOCHEM BIOPHYS, V684, DOI 10.1016/j.abb.2020.108314
   Xu WX, 2018, INT J BIOL SCI, V14, P1054, DOI 10.7150/ijbs.25349
   Xu WX, 2018, AM J TRANSL RES, V10, P1229
   Xu ZY, 2018, PHYTOMEDICINE, V51, P58, DOI 10.1016/j.phymed.2018.05.012
   Yang LQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00565
   You Q, 2020, J BUON, V25, P308
   Young LN, 2019, P NATL ACAD SCI USA, V116, P21508, DOI 10.1073/pnas.1911612116
   Yu Y, 2017, MOL CELL BIOCHEM, V424, P173, DOI 10.1007/s11010-016-2853-4
   Yuan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01219-0
   Yuan L, 2019, J CANCER, V10, P6439, DOI 10.7150/jca.32873
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zeng X, 2020, CURR MOL MED, V20, P667, DOI 10.2174/1566524020666200226124336
   Zhang C, 2020, BRIT J PHARMACOL, V177, P3240, DOI 10.1111/bph.15046
   Zhang F, 2019, ONCOL LETT, V18, P6221, DOI 10.3892/ol.2019.10976
   Zhang XY, 2019, AUTOPHAGY, V15, P1787, DOI 10.1080/15548627.2019.1596480
   Zhang XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01171-z
   Zhang Y, 2020, ENERGY SCI ENG, V5, P1, DOI DOI 10.1016/J.LFS.2020.117280
   Zhang YJ, 2018, CANCER SCI, V109, P3865, DOI 10.1111/cas.13808
   Zhao R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00348
   Zhong B, 2018, ONCOL LETT, V15, P755, DOI 10.3892/ol.2017.7380
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou S, 2020, INT J MOL MED, V45, P1305, DOI 10.3892/ijmm.2020.4520
   Zhu JX, 2013, FITOTERAPIA, V84, P40, DOI 10.1016/j.fitote.2012.09.026
NR 153
TC 13
Z9 13
U1 5
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD DEC 3
PY 2020
VL 8
AR 621428
DI 10.3389/fcell.2020.621428
PG 17
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA PF8JS
UT WOS:000599294500001
PM 33344463
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, Y
   Fu, LL
   Wen, X
   Liu, B
   Huang, J
   Wang, JH
   Wei, YQ
AF Chen, Y.
   Fu, L. L.
   Wen, X.
   Liu, B.
   Huang, J.
   Wang, J. H.
   Wei, Y. Q.
TI Oncogenic and tumor suppressive roles of microRNAs in apoptosis and
   autophagy
SO APOPTOSIS
LA English
DT Article
DE Apoptosis; Autophagy; Oncogenic microRNA; Tumor suppressive microRNA
ID LUNG ADENOCARCINOMA CELLS; DOWN-REGULATION; UP-REGULATION; REGULATES
   AUTOPHAGY; PROMOTES APOPTOSIS; BREAST-CANCER; INHIBITS AUTOPHAGY; INDUCE
   APOPTOSIS; COLON-CANCER; EXPRESSION
AB MicroRNAs (miRNAs), small and non-coding endogenous RNAs similar to 22 nucleotides (nt) in length, have been known to regulate approximately 30 % of human gene expression at the post-transcriptional and translational levels. Accumulating data have demonstrated that certain miRNAs could exert an oncogenic and/or tumor suppressive function and might play essential roles in the regulation of apoptosis and autophagy in cancer. In this review, we summarize that certain oncogenic and tumor suppressive miRNAs could modulate apoptotic pathways in different types of cancer. Subsequently, we demonstrate that other miRNAs might play regulatory roles in the autophagic pathways of cancer. A limited number of oncogenic/tumor suppressive miRNAs could regulate apoptosis and autophagy, respectively, and cooperatively. Taken together, these findings would provide a new clue to elucidate more apoptotic and/or autophagic mechanisms of miRNAs for designing potential novel therapeutic strategies in cancer.
C1 [Chen, Y.; Wen, X.; Liu, B.; Wei, Y. Q.] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Fu, L. L.] Sichuan Univ, Coll Life Sci, Chengdu 610064, Peoples R China.
   [Huang, J.] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China.
   [Wang, J. H.] Xinjiang Med Univ, Coll Pharm, Urumqi 830011, Peoples R China.
RP Liu, B (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
EM liubo2400@163.com; 13504051049@163.com
RI Wen, Xin/ADT-4758-2022
OI Wen, Xin/0000-0001-6513-8623
FU National 973 Basic Research Program of ChinaNational Basic Research
   Program of China [2010CB529900]; Key Projects of the National Science
   and Technology Pillar Program [2012BAI30B02]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81160543, 81260628, 81303270, 81172374]; West China Hospital-Chengdu
   Science and Technology Department Translational Medicine Innovation
   Foundation [ZH13039]; Shenyang Pharmaceutical University Scientific
   Research Fund [ZCJJ2013407]
FX We thank Dr. Yan Cheng (Pennsylvania State University) for her critical
   review on this manuscript. We are also grateful to the revision of this
   manuscript by Elsevier Webshop. This work was supported by grants from
   the National 973 Basic Research Program of China (No. 2010CB529900), the
   Key Projects of the National Science and Technology Pillar Program (No.
   2012BAI30B02), the National Natural Science Foundation of China (Nos.
   81160543, 81260628, 81303270 and 81172374), the West China
   Hospital-Chengdu Science and Technology Department Translational
   Medicine Innovation Foundation (No. ZH13039), and the Shenyang
   Pharmaceutical University Scientific Research Fund (No. ZCJJ2013407).
CR Adlakha YK, 2011, CELL MOL LIFE SCI, V68, P1415, DOI 10.1007/s00018-010-0528-y
   Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Cai CK, 2012, ONCOL REP, V28, P1764, DOI 10.3892/or.2012.1995
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Castagnino P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056140
   Chang KH, 2011, EJSO-EUR J SURG ONC, V37, P597, DOI 10.1016/j.ejso.2011.04.001
   Chang Y, 2012, AUTOPHAGY, V8, P1833, DOI 10.4161/auto.21796
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010
   Chen LJ, 2011, CANCER LETT, V309, P62, DOI 10.1016/j.canlet.2011.05.017
   Chen WX, 2013, TUMOR BIOL, V34, P1361, DOI 10.1007/s13277-013-0750-y
   Chen Z, 2012, J CELL BIOCHEM, V113, P3229, DOI 10.1002/jcb.24200
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109
   Ciuffreda L, 2010, CURR CANCER DRUG TAR, V10, P484, DOI 10.2174/156800910791517172
   Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597
   Dar AA, 2011, J BIOL CHEM, V286, P16606, DOI 10.1074/jbc.M111.227611
   Dong J, 2011, ARCH MED RES, V42, P8, DOI 10.1016/j.arcmed.2011.01.006
   Dou LP, 2013, ONCOTARGETS THER, V6, P1153, DOI 10.2147/OTT.S45376
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Eto K, 2014, ANN SURG ONCOL, V21, P343, DOI 10.1245/s10434-013-3325-7
   Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fujiya M, 2014, ONCOGENE, V33, P4847, DOI 10.1038/onc.2013.429
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170
   Gocek E, 2011, CANCER RES, V71, P6230, DOI 10.1158/0008-5472.CAN-11-1717
   Gong J, 2013, ONCOGENE, V32, P3071, DOI 10.1038/onc.2012.318
   Grunder E, 2011, EUR J CANCER, V47, P2479, DOI 10.1016/j.ejca.2011.06.041
   Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449
   Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269
   Hao JW, 2012, ONCOL REP, V27, P1504, DOI 10.3892/or.2012.1652
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Hiroki E, 2012, INT J CANCER, V131, pE395, DOI 10.1002/ijc.27345
   Hou ZB, 2012, MED ONCOL, V29, P886, DOI 10.1007/s12032-011-9862-7
   Huang F, 2013, ASIAN PAC J CANCER P, V14, P5915, DOI 10.7314/APJCP.2013.14.10.5915
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Krell J, 2013, EPIGENOMICS-UK, V5, P417, DOI [10.2217/EPI.13.41, 10.2217/epi.13.41]
   Lawrie CH, 2007, BRIT J HAEMATOL, V137, P503, DOI 10.1111/j.1365-2141.2007.06611.x
   Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Levati L, 2011, PIGM CELL MELANOMA R, V24, P538, DOI 10.1111/j.1755-148X.2011.00857.x
   Ling N, 2013, ONCOL REP, V30, P2111, DOI 10.3892/or.2013.2685
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu J, 2014, TUMOR BIOL, DOI [10.1002/j.1532-2149.2014.00455.x, DOI 10.1002/J.1532-2149.2014.00455.X]
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Liu L, 2010, MOL MED REP, V5, P753
   Luo L, 2012, MED ONCOL, V29, P1681, DOI 10.1007/s12032-011-0085-8
   Majid S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067686
   Majid S, 2011, CANCER RES, V71, P2611, DOI 10.1158/0008-5472.CAN-10-3666
   Meenhuis A, 2011, BLOOD, V118, P916, DOI 10.1182/blood-2011-02-336487
   Meunier L, 2012, ENDOCRINOLOGY, V153, P1936, DOI 10.1210/en.2011-1109
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Molitoris JK, 2011, MOL ENDOCRINOL, V25, P409, DOI 10.1210/me.2010-0402
   Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143
   Olive V, 2013, ELIFE, V2, DOI 10.7554/eLife.00822
   Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001
   Paik JH, 2011, CLIN CANCER RES, V17, P4761, DOI 10.1158/1078-0432.CCR-11-0494
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214
   Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429
   Satzger I, 2012, EXP DERMATOL, V21, P509, DOI 10.1111/j.1600-0625.2012.01510.x
   Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018
   Seoudi AM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002122
   Shahbazi Jeyran, 2013, Frontiers in Genetics, V4, P80, DOI 10.3389/fgene.2013.00080
   Shang JL, 2014, J CELL BIOCHEM, V115, P772, DOI 10.1002/jcb.24721
   Shen J, 2012, PANCREATOLOGY, V12, P91, DOI 10.1016/j.pan.2012.02.008
   Shi GD, 2013, GLIA, V61, P504, DOI 10.1002/glia.22451
   Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369
   Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024
   Tait SWG, 2012, J CELL SCI, V125, P807, DOI 10.1242/jcs.099234
   Tanaka N, 2013, ONCOL REP, V29, P2169, DOI 10.3892/or.2013.2351
   Tanaka Y, 2012, PLOS ONE, V7
   Tu YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075872
   Ugalde AP, 2011, EMBO J, V30, P2219, DOI 10.1038/emboj.2011.124
   Ugras S, 2011, CANCER RES, V71, P5659, DOI 10.1158/0008-5472.CAN-11-0890
   Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003697
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang P, 2013, MOL ONCOL, V7, P334, DOI 10.1016/j.molonc.2012.10.011
   Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x
   Weeraratne SD, 2011, NEURO-ONCOLOGY, V13, P165, DOI 10.1093/neuonc/noq179
   Wen X, 2013, FREE RADICAL BIO MED, V65, P402, DOI 10.1016/j.freeradbiomed.2013.07.013
   Xiang Q, 2013, PHARMAZIE, V68, P274, DOI 10.1691/ph.2013.2759
   Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Zaman MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031060
   Zhai H, 2013, ONCOGENE, V32, P1570, DOI 10.1038/onc.2012.167
   Zhai HY, 2013, CELL CYCLE, V12, P246, DOI 10.4161/cc.23273
   Zhang CM, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-79
   Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229
   Zhang CZ, 2010, INT J ONCOL, V37, P1621, DOI 10.3892/ijo_00000816
   Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530
   Zhang JG, 2011, J THORAC ONCOL, V6, P671, DOI 10.1097/JTO.0b013e318208eb35
   Zhang J, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975
   Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2
   Zheng YX, 2012, FEBS LETT, V586, P2396, DOI 10.1016/j.febslet.2012.05.054
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
   Zhou P, 2012, DIGEST DIS SCI, V57, P1171, DOI 10.1007/s10620-012-2099-2
   Zhu DX, 2012, CARCINOGENESIS, V33, P1294, DOI 10.1093/carcin/bgs179
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 117
TC 62
Z9 65
U1 0
U2 29
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD AUG
PY 2014
VL 19
IS 8
BP 1177
EP 1189
DI 10.1007/s10495-014-0999-7
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AK5TZ
UT WOS:000338490600001
PM 24850099
DA 2022-04-25
ER

PT J
AU Deng, Z
   Liu, Q
   Wang, MM
   Wei, HK
   Peng, J
AF Deng, Zhao
   Liu, Qi
   Wang, Miaomiao
   Wei, Hong-Kui
   Peng, Jian
TI GPA Peptide-Induced Nur77 Localization at Mitochondria Inhibits
   Inflammation and Oxidative Stress through Activating Autophagy in the
   Intestine
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID FISH SKIN GELATIN; BOWEL-DISEASE; EXPERIMENTAL COLITIS;
   EPITHELIAL-CELLS; IMMUNITY; UBIQUITINATION; PATHOGENESIS; THERAPY;
   CANCER; GENE
AB Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. Nur77, belongs to the NR4A subfamily of nuclear hormone receptors, plays a critical role in controlling the pathology of colitis. The aim of this study is to investigate the protection effect and mechanism of Gly-Pro-Ala (GPA) peptide, isolated from fish skin gelatin hydrolysate, in a mouse model of dextran sulfate sodium- (DSS-) induced colitis and intestinal epithelial cells (IECs) stimulated by lipopolysaccharide (LPS). In vivo, GPA treatment alleviates DSS-induced weight loss, disease activity index (DAI) increase, colon length shortening, and colonic pathological damage. Production of proinflammatory cytokines, ROS, and MDA is significantly decreased by GPA treatment. In vitro, GPA significantly inhibits proinflammatory cytokine production, cytotoxicity, ROS, and MDA in IECs. Furthermore, GPA induces autophagy to suppress inflammation and oxidative stress. GPA promotes Nur77 translocation from the nucleus to mitochondria where it facilitates Nur77 interaction with TRAF6 and p62, leading to the induction of autophagy. In addition, GPA contributed to the maintenance of tight junction architecture in vivo and in vitro. Taken together, GPA, as a Nur77 modulator, could exert anti-inflammatory and antioxidant effects by inducing autophagy in IECs, suggesting that GPA may be promising for the prevention of colitis.
C1 [Deng, Zhao; Liu, Qi; Wang, Miaomiao; Wei, Hong-Kui; Peng, Jian] Huazhong Agr Univ, Coll Anim Sci & Technol, Dept Anim Nutr & Feed Sci, Wuhan 430070, Peoples R China.
   [Wei, Hong-Kui; Peng, Jian] Cooperat Innovat Ctr Sustainable Pig Prod, Wuhan 430070, Hubei, Peoples R China.
RP Wei, HK; Peng, J (corresponding author), Huazhong Agr Univ, Coll Anim Sci & Technol, Dept Anim Nutr & Feed Sci, Wuhan 430070, Peoples R China.; Wei, HK; Peng, J (corresponding author), Cooperat Innovat Ctr Sustainable Pig Prod, Wuhan 430070, Hubei, Peoples R China.
EM weihongkui@mail.hzau.edu.cn; pengjian@mail.hzau.edu.cn
RI deng, zhao/AAK-6182-2021
OI deng, zhao/0000-0002-7025-4976
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31972578]; Hubei Province Technology
   Innovation Special Major Project [2019ABA081]; Modern Agricultural
   Industry Technology System [CARS-35]; Basic Scientific Research
   Operating Expenses of Central Universities [2662017PY017]
FX We thank the Department of Animal Nutrition and Feed Science (Huazhong
   Agricultural University) for their help. This research was supported by
   the National Natural Science Foundation of China (31972578), the Hubei
   Province Technology Innovation Special Major Project (2019ABA081), the
   Modern Agricultural Industry Technology System (CARS-35), and the Basic
   Scientific Research Operating Expenses of Central Universities
   (2662017PY017).
CR Aviello G, 2018, MUCOSAL IMMUNOL, V11, P1011, DOI 10.1038/s41385-018-0021-8
   Banno A, 2019, AM J PATHOL, V189, P482, DOI 10.1016/j.ajpath.2018.10.002
   Bashashati M, 2015, CURR DRUG TARGETS, V16, P199, DOI 10.2174/1389450116666150120104012
   Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132
   Bressler B, 2015, GASTROENTEROLOGY, V148, P1035, DOI 10.1053/j.gastro.2015.03.001
   Chalamaiah M, 2018, FOOD CHEM, V245, P205, DOI 10.1016/j.foodchem.2017.10.087
   Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x
   Cheng ZK, 2011, EUR HEART J, V32, P2179, DOI 10.1093/eurheartj/ehq496
   Cordani M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8794612
   Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055
   CROCKETT E, 2017, FASEB J S1, V0031, P00786
   De Silva S, 2005, ARTHRITIS RHEUM-US, V52, P333, DOI 10.1002/art.20736
   Deng Z, 2020, FOOD FUNCT, V11, P414, DOI [10.1039/c9fo02165e, 10.1039/C9FO02165E]
   Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385
   Eisenstein M, 2018, NATURE, V563, pS34, DOI 10.1038/d41586-018-07277-1
   Farrell RJ, 2002, LANCET, V359, P331, DOI 10.1016/S0140-6736(02)07499-8
   Friedrich M, 2019, IMMUNITY, V50, P992, DOI 10.1016/j.immuni.2019.03.017
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Gurung P, 2015, TRENDS MOL MED, V21, P193, DOI 10.1016/j.molmed.2014.11.008
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hu MJ, 2017, MOL CELL, V66, P141, DOI 10.1016/j.molcel.2017.03.008
   Huang Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708689
   Hwang JR, 2014, PLACENTA, V35, pA91, DOI 10.1016/j.placenta.2014.06.294
   Iida T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010007
   Kanzleiter T, 2010, DIABETOLOGIA, V53, P1174, DOI 10.1007/s00125-010-1703-2
   Karin M, 2009, IMMUNOL REV, V228, P225, DOI 10.1111/j.1600-065X.2008.00755.x
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kimura T, 2017, AUTOPHAGY, V13, P997, DOI 10.1080/15548627.2017.1309485
   Korzenik JR, 2006, NAT REV DRUG DISCOV, V5, P197, DOI 10.1038/nrd1986
   Kovacs-Nolan J, 2012, BBA-GEN SUBJECTS, V1820, P1753, DOI 10.1016/j.bbagen.2012.07.007
   Kumar S, 2019, AGING-US, V11, P4145, DOI 10.18632/aging.102043
   Kurakula K, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02400-2018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li L, 2015, NAT CHEM BIOL, V11, P339, DOI [10.1038/NCHEMBIO.1788, 10.1038/nchembio.1788]
   Lu R, 2019, FASEB J, V33, P11845, DOI 10.1096/fj.201900727R
   MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442
   Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008
   Martinez-Alvarez O, 2015, FOOD RES INT, V73, P204, DOI 10.1016/j.foodres.2015.04.005
   McGuckin MA, 2009, INFLAMM BOWEL DIS, V15, P100, DOI 10.1002/ibd.20539
   Mottawea W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13419
   Moura FA, 2015, REDOX BIOL, V6, P617, DOI 10.1016/j.redox.2015.10.006
   Novak EA, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00062
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Olivera P, 2019, NAT REV GASTRO HEPAT, V16, P312, DOI 10.1038/s41575-019-0102-5
   Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777
   Plichta DR, 2019, CELL, V178, P1041, DOI 10.1016/j.cell.2019.07.045
   Rangaraju S, 2010, J NEUROSCI, V30, P11388, DOI 10.1523/JNEUROSCI.1356-10.2010
   Rath E, 2018, NAT REV GASTRO HEPAT, V15, P497, DOI 10.1038/s41575-018-0021-x
   Rezaie A, 2007, DIGEST DIS SCI, V52, P2015, DOI 10.1007/s10620-006-9622-2
   Serra G, 2018, REDOX BIOL, V17, P348, DOI 10.1016/j.redox.2018.05.006
   Shi ZL, 2019, AGING-US, V11, P12177, DOI 10.18632/aging.102559
   Snezhkina AV, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6175804
   VIDAL K, 1993, J IMMUNOL METHODS, V166, P63, DOI 10.1016/0022-1759(93)90329-6
   Vikram A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3451528
   Wang JR, 2014, CARCINOGENESIS, V35, P2474, DOI 10.1093/carcin/bgu157
   Wang LH, 2019, FASEB J, V33, P8935, DOI 10.1096/fj.201802769RR
   Wang R, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4703253
   Welcker K, 2004, EUR J MED RES, V9, P456
   Wu H, 2016, J PATHOL, V238, P457, DOI 10.1002/path.4670
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Yin HM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.357
   Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106
   Zhang H, 2015, BBA-MOL BASIS DIS, V1852, P792, DOI 10.1016/j.bbadis.2014.12.023
   Zhang M, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00942
   Zheng LF, 2018, J FUNCT FOODS, V51, P104, DOI 10.1016/j.jff.2018.08.033
   Zheng LF, 2018, J AGR FOOD CHEM, V66, P11601, DOI 10.1021/acs.jafc.8b02840
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 67
TC 7
Z9 7
U1 6
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 21
PY 2020
VL 2020
AR 4964202
DI 10.1155/2020/4964202
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NL0PK
UT WOS:000567127900001
PM 32904539
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Izdebska, M
   Zielinska, W
   Halas-Wisniewska, M
   Grzanka, A
AF Izdebska, Magdalena
   Zielinska, Wioletta
   Halas-Wisniewska, Marta
   Grzanka, Alina
TI Involvement of Actin in Autophagy and Autophagy-Dependent Multidrug
   Resistance in Cancer
SO CANCERS
LA English
DT Review
DE autophagy; actin; cancer; multidrug resistance
ID CELL-DEATH; ARP2/3 COMPLEX; COLON-CANCER; INDEPENDENT FUNCTIONS;
   MAMMALIAN AUTOPHAGY; INHIBITS AUTOPHAGY; REQUIRE AUTOPHAGY; LIR MOTIF;
   IN-VITRO; MEMBRANE
AB Currently, autophagy in the context of cancer progression arouses a lot of controversy. It is connected with the possibility of switching the nature of this process from cytotoxic to cytoprotective and vice versa depending on the treatment. At the same time, autophagy of cytoprotective character may be one of the factors determining multidrug resistance, as intensification of the process is observed in patients with poorer prognosis. The exact mechanism of this relationship is not yet fully understood; however, it is suggested that one of the elements of the puzzle may be a cytoskeleton. In the latest literature reports, more and more attention is paid to the involvement of actin in the autophagy. The role of this protein is linked to the formation of autophagosomes, which are necessary element of the process. However, based on the proven effectiveness of manipulation of the actin pool, it seems to be an attractive alternative in breaking autophagy-dependent multidrug resistance in cancer.
C1 [Izdebska, Magdalena; Zielinska, Wioletta; Halas-Wisniewska, Marta; Grzanka, Alina] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Fac Med, Dept Histol & Embryol, PL-85092 Bydgoszcz, Poland.
RP Izdebska, M (corresponding author), Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Fac Med, Dept Histol & Embryol, PL-85092 Bydgoszcz, Poland.
EM mizdebska@cm.umk.pl
RI Hałas-Wiśniewska, Marta/AAI-4961-2020
OI Halas-Wisniewska, Marta/0000-0002-1264-0481; Zielinska,
   Wioletta/0000-0002-3065-0931; Izdebska, Magdalena/0000-0002-9395-0886
FU Nicolaus Copernicus University in Torun, Faculty of Medicine, Collegium
   Medicum in Bydgoszcz [163]
FX The present study was co supported via research tasks within the
   framework of statutory activities no. 163 (Nicolaus Copernicus
   University in Torun, Faculty of Medicine, Collegium Medicum in
   Bydgoszcz).
CR Afzal S, 2015, P NATL ACAD SCI USA, V112, P1119, DOI 10.1073/pnas.1423588112
   Anwar T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050475
   APLIN A, 1992, J CELL PHYSIOL, V152, P458, DOI 10.1002/jcp.1041520304
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Baranowska K, 2016, ONCOTARGET, V7, P70845, DOI 10.18632/oncotarget.12226
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556
   Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264
   Chen HZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1278-9
   Cheng CY, 2017, J BIOL REG HOMEOS AG, V31, P645
   Chiu YH, 2018, INT J ONCOL, V53, P1967, DOI 10.3892/ijo.2018.4523
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Coutts AS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8888
   Das G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008813
   Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5
   Devereaux K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076405
   Dietrich S, 2013, BIOL CHEM, V394, P1649, DOI 10.1515/hsz-2013-0176
   Djavaheri-Mergny M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020103
   Dominguez R, 2011, ANNU REV BIOPHYS, V40, P169, DOI 10.1146/annurev-biophys-042910-155359
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Du BY, 2017, INT J CLIN EXP PATHO, V10, P6071
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Fernandez AF, 2018, NATURE, V558, P136, DOI 10.1038/s41586-018-0162-7
   Flouriot G, 2014, BIOCHEM J, V461, P257, DOI 10.1042/BJ20131240
   Foerster F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.363
   Frudd K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02352-z
   Gagat M, 2013, INT J MOL MED, V32, P115, DOI 10.3892/ijmm.2013.1357
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026
   Gong C, 2017, J CONTROL RELEASE, V266, P272, DOI 10.1016/j.jconrel.2017.09.042
   Gong ZW, 2018, J CELL BIOL, V217, P635, DOI 10.1083/jcb.201606095
   Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Grzanka D, 2013, ACTA HISTOCHEM, V115, P775, DOI 10.1016/j.acthis.2013.04.002
   Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189
   Han MW, 2014, ANTICANCER RES, V34, P1449
   Hara F, 2007, J BACTERIOL, V189, P2039, DOI 10.1128/JB.01454-06
   Hasegawa J, 2016, EMBO J, V35, P1853, DOI 10.15252/embj.201593148
   Heng YW, 2010, INT J BIOCHEM CELL B, V42, P1622, DOI 10.1016/j.biocel.2010.04.007
   Hieke N, 2015, AUTOPHAGY, V11, P1471, DOI 10.1080/15548627.2015.1068488
   HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0
   Hong NH, 2015, J CELL BIOL, V210, P753, DOI 10.1083/jcb.201412127
   Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296
   Hu XH, 2019, J CELL BIOL, V218, P251, DOI 10.1083/jcb.201802157
   Ishibashi K, 2011, AUTOPHAGY, V7, P1500, DOI 10.4161/auto.7.12.18025
   Izdebska M, 2019, INT J ONCOL, V54, P1099, DOI 10.3892/ijo.2018.4668
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kaewpiboon C, 2014, INT J ONCOL, V44, P1233, DOI 10.3892/ijo.2014.2297
   Kaliszczak M, 2018, BRIT J CANCER, V119, P1278, DOI 10.1038/s41416-018-0232-5
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kast DJ, 2017, CURR BIOL, V27, pR318, DOI 10.1016/j.cub.2017.02.061
   Kast DJ, 2015, AUTOPHAGY, V11, P1702, DOI 10.1080/15548627.2015.1073434
   Kast DJ, 2015, CURR BIOL, V25, P1791, DOI 10.1016/j.cub.2015.05.042
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   King JS, 2013, MOL BIOL CELL, V24, P2714, DOI 10.1091/mbc.E13-02-0092
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Ktistakis NT, 2017, AUTOPHAGY, V13, P2015, DOI 10.1080/15548627.2017.1367473
   Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lee HO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131464
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Lee SH, 2010, MOL CELLS, V29, P311, DOI 10.1007/s10059-010-0053-8
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li M, 2011, J BIOL CHEM, V286, P7327, DOI 10.1074/jbc.M110.199059
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Li YY, 2015, J CANCER, V6, P382, DOI 10.7150/jca.11187
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Mack HID, 2012, AUTOPHAGY, V8, P1197, DOI 10.4161/auto.20586
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mi N, 2015, NAT CELL BIOL, V17, P1112, DOI 10.1038/ncb3215
   Molinie N, 2018, PHYSIOL REV, V98, P215, DOI 10.1152/physrev.00006.2017
   Monastyrska I, 2009, BIOL REV, V84, P431, DOI 10.1111/j.1469-185X.2009.00082.x
   Moreau K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9045
   Moreau K, 2012, J CELL BIOL, V196, P483, DOI 10.1083/jcb.201110114
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Newman DJ, 2004, J NAT PROD, V67, P1216, DOI 10.1021/np040031y
   Olsvik HL, 2015, J BIOL CHEM, V290, P29361, DOI 10.1074/jbc.M115.686915
   Aguilera MO, 2012, AUTOPHAGY, V8, P1590, DOI 10.4161/auto.21459
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Papadopulos A, 2017, MOL CELL NEUROSCI, V84, P93, DOI 10.1016/j.mcn.2017.05.006
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Pei B, 2015, J IMMUNOL, V194, P5872, DOI 10.4049/jimmunol.1402154
   Pietrocola F, 2017, AUTOPHAGY, V13, P2163, DOI 10.1080/15548627.2017.1310356
   Piquereau J, 2013, AUTOPHAGY, V9, P1837, DOI 10.4161/auto.26502
   Piras A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0292-9
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rahim SAA, 2017, BRIT J CANCER, V117, P813, DOI 10.1038/bjc.2017.263
   Rai S, 2019, AUTOPHAGY, V15, P599, DOI 10.1080/15548627.2018.1534507
   RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rottner K, 2010, TRENDS CELL BIOL, V20, P650, DOI 10.1016/j.tcb.2010.08.014
   Russo AJ, 2016, MOL BIOL CELL, V27, P967, DOI 10.1091/mbc.E15-07-0508
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Saint-Martin A, 2019, CANCERS, V11, DOI 10.3390/cancers11060755
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Schuh M, 2011, NAT CELL BIOL, V13, P1431, DOI 10.1038/ncb2353
   Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Slobodkin MR, 2013, ESSAYS BIOCHEM, V55, P51, DOI [10.1042/BSE0550051, 10.1042/bse0550051]
   Soltany-Rezaee-Rad M, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/185035
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Stanley RE, 2014, TRENDS CELL BIOL, V24, P73, DOI 10.1016/j.tcb.2013.07.008
   Stehn JR, 2013, CANCER RES, V73, P5169, DOI 10.1158/0008-5472.CAN-12-4501
   Tan MD, 2018, FREE RADICAL RES, V52, P872, DOI 10.1080/10715762.2018.1485075
   Tooze SA, 2016, CELL, V167, P1433, DOI 10.1016/j.cell.2016.11.023
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   van Haastert PJM, 2017, MOL BIOL CELL, V28, P922, DOI 10.1091/mbc.E16-10-0733
   Van Helleputte L, 2018, NEUROBIOL DIS, V111, P59, DOI 10.1016/j.nbd.2017.11.011
   VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7
   Veltman DM, 2010, MOL BIOL CELL, V21, P2880, DOI 10.1091/mbc.E10-04-0372
   Wang HZ, 2015, P NATL ACAD SCI USA, V112, P7015, DOI 10.1073/pnas.1507263112
   Wang J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0747-0
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0731-5
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Xia PY, 2013, EMBO J, V32, P2685, DOI 10.1038/emboj.2013.189
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Yang MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097242
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang XY, 2018, INT J ONCOL, V53, P215, DOI 10.3892/ijo.2018.4376
   Yeo SK, 2018, AUTOPHAGY, V14, P1214, DOI 10.1080/15548627.2018.1460010
   Zavodszky E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4828
   Zhan L, 2016, ONCOTARGET, V7, P83476, DOI 10.18632/oncotarget.13080
   Zhang Q, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-99
   Zhang Q, 2017, GENE, V608, P79, DOI 10.1016/j.gene.2017.01.014
   ZHANG Y, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/cells8020146
   Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990
   Zientara-Rytter K, 2016, AUTOPHAGY, V12, P2512, DOI 10.1080/15548627.2016.1236877
NR 139
TC 8
Z9 10
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2019
VL 11
IS 8
AR 1209
DI 10.3390/cancers11081209
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IV7HU
UT WOS:000484438000169
PM 31434275
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Xie, X
   Zhao, Y
   Ma, CY
   Xu, XM
   Zhang, YQ
   Wang, CG
   Jin, J
   Shen, X
   Gao, JL
   Li, N
   Sun, ZJ
   Dong, DL
AF Xie, Xin
   Zhao, Yu
   Ma, Chun-Yan
   Xu, Xiao-Ming
   Zhang, Yan-Qiu
   Wang, Chen-Guang
   Jin, Jing
   Shen, Xin
   Gao, Jin-Lai
   Li, Na
   Sun, Zhi-Jie
   Dong, De-Li
TI Dimethyl fumarate induces necroptosis in colon cancer cells through GSH
   depletion/ROS increase/MAPKs activation pathway
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID PERMEABILITY TRANSITION PORE; NRF2 ANTIOXIDANT PATHWAY; MYELOID-LEUKEMIA
   CELLS; GLUTATHIONE DEPLETION; COLORECTAL-CANCER; ACID-ESTERS; IN-VITRO;
   APOPTOSIS RESISTANCE; DRUG-RESISTANCE; DEATH
AB Background and PurposeDimethyl fumarate (DMF) is a newly approved drug for the treatment of relapsing forms of multiple sclerosis and relapsing-remitting multiple sclerosis. Here, we investigated the effects of DMF and its metabolites mono-methylfumarate (MMF and methanol) on different gastrointestinal cancer cell lines and the underlying molecular mechanisms involved.
   Experimental ApproachCell viability was measured by the MTT or CCK8 assay. Protein expressions were measured by Western blot analysis. LDH release, live- and dead-cell staining, intracellular GSH levels, and mitochondrial membrane potential were examined by using commercial kits.
   Key ResultsDMF but not MMF induced cell necroptosis, as demonstrated by the pharmacological tool necrostatin-1, transmission electron microscopy, LDH and HMGB1 release in CT26 cells. The DMF-induced decrease in cellular GSH levels as well as cell viability and increase in reactive oxygen species (ROS) were inhibited by co-treatment with GSH and N-acetylcysteine (NAC) in CT26 cells. DMF activated JNK, p38 and ERK MAPKs in CT26 cells and JNK, p38 and ERK inhibitors partially reversed the DMF-induced decrease in cell viability. GSH or NAC treatment inhibited DMF-induced JNK, p38, and ERK activation in CT26 cells. DMF but not MMF increased autophagy responses in SGC-7901, HCT116, HT29 and CT26 cancer cells, but autophagy inhibition did not prevent the DMF-induced decrease in cell viability.
   Conclusion and ImplicationsDMF but not its metabolite MMF induced necroptosis in colon cancer cells through a mechanism involving the depletion of GSH, an increase in ROS and activation of MAPKs.
C1 [Xie, Xin; Zhao, Yu; Ma, Chun-Yan; Xu, Xiao-Ming; Zhang, Yan-Qiu; Wang, Chen-Guang; Jin, Jing; Shen, Xin; Gao, Jin-Lai; Li, Na; Dong, De-Li] Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Key Lab Cardiovasc Res,Minist Educ, Harbin 150086, Heilongjiang, Peoples R China.
   [Sun, Zhi-Jie] Harbin Engn Univ, Ctr Biomed Mat & Engn, Harbin, Peoples R China.
RP Dong, DL (corresponding author), Harbin Med Univ, Dept Pharmacol, Baojian Rd 157, Harbin 150086, Heilongjiang, Peoples R China.
EM dongdeli@ems.hrbmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81373406, 81421063]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81373406, 81421063).
CR Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451
   Ashrafian H, 2012, CELL METAB, V15, P361, DOI 10.1016/j.cmet.2012.01.017
   BERGER SJ, 1994, CANCER RES, V54, P4077
   Burness CB, 2014, CNS DRUGS, V28, P373, DOI 10.1007/s40263-014-0155-5
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Chromik J, 2014, CANCER LETT, V344, P101, DOI 10.1016/j.canlet.2013.10.018
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   El-Mesery M, 2015, BRIT J PHARMACOL, V172, P1222, DOI 10.1111/bph.12998
   Forster A, 2013, EXP DERMATOL, V22, P719, DOI 10.1111/exd.12247
   Fox RJ, 2014, CURR MED RES OPIN, V30, P251, DOI 10.1185/03007995.2013.849236
   Franco R, 2012, ANTIOXID REDOX SIGN, V17, P1694, DOI 10.1089/ars.2012.4553
   Fulda S, 2014, SEMIN CELL DEV BIOL, V35, P51, DOI 10.1016/j.semcdb.2014.07.002
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Ghods Ali J, 2013, Surg Neurol Int, V4, P160, DOI 10.4103/2152-7806.123656
   Gill AJ, 2013, CRIT REV IMMUNOL, V33, P307, DOI 10.1615/critrevimmunol.2013007247
   Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289
   Gu B, 2005, ANTI-CANCER DRUG, V16, P167, DOI 10.1097/00001813-200502000-00008
   Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511
   HELD KD, 1988, RADIAT RES, V115, P495, DOI 10.2307/3577299
   Hu X, 2007, AUTOPHAGY, V3, P490, DOI 10.4161/auto.4592
   Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149
   Kirlin WG, 1999, J NUTR, V129, P1827, DOI 10.1093/jn/129.10.1827
   Krishnaiah YSR, 2012, PHARM DEV TECHNOL, V17, P521, DOI 10.3109/10837450.2012.696268
   Kuo LM, 2014, MOLECULES, V19, P3327, DOI 10.3390/molecules19033327
   Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003
   Lehmann JCU, 2007, J INVEST DERMATOL, V127, P835, DOI 10.1038/sj.jid.5700686
   Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386
   Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050
   Loewe R, 2006, CANCER RES, V66, P11888, DOI 10.1158/0008-5472.CAN-06-2397
   Mailloux RJ, 2013, TRENDS BIOCHEM SCI, V38, P592, DOI 10.1016/j.tibs.2013.09.001
   NIBBERING PH, 1993, J INVEST DERMATOL, V101, P37, DOI 10.1111/1523-1747.ep12358715
   Panczyk M, 2014, WORLD J GASTROENTERO, V20, P9775, DOI 10.3748/wjg.v20.i29.9775
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   PERRY RR, 1993, CANCER, V72, P783, DOI 10.1002/1097-0142(19930801)72:3<783::AID-CNCR2820720325>3.0.CO;2-U
   Petrosillo G, 2009, AM J PHYSIOL-HEART C, V297, pH1487, DOI 10.1152/ajpheart.00163.2009
   Rostami-Yazdi M, 2010, ARCH DERMATOL RES, V302, P531, DOI 10.1007/s00403-010-1061-4
   Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132
   Schmidt TJ, 2007, BIOORGAN MED CHEM, V15, P333, DOI 10.1016/j.bmc.2006.09.053
   Sheng Y, 2014, BRIT J PHARMACOL, V171, P4970, DOI 10.1111/bph.12821
   Sheng Y, 2013, BIOCHEM BIOPH RES CO, V432, P5, DOI 10.1016/j.bbrc.2013.01.106
   Silhavy J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101906
   Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320
   Valero T, 2010, J INVEST DERMATOL, V130, P1087, DOI 10.1038/jid.2009.368
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014
   Werdenberg D, 2003, BIOPHARM DRUG DISPOS, V24, P259, DOI 10.1002/bdd.364
   Wierinckx A, 2005, J NEUROIMMUNOL, V166, P132, DOI 10.1016/j.jneuroim.2005.05.013
   Wilms H, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-30
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Yamazoe Y, 2009, CELL BIOL INT, V33, P1087, DOI 10.1016/j.cellbi.2009.06.027
   Yan CL, 2013, TOXICOL APPL PHARM, V266, P9, DOI 10.1016/j.taap.2012.11.001
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   You BR, 2010, TOXICOL IN VITRO, V24, P1356, DOI 10.1016/j.tiv.2010.04.009
   Zhang HL, 2009, J IMMUNOL, V182, P6993, DOI 10.4049/jimmunol.0802502
   Zhang LY, 2014, BIOCHEM BIOPH RES CO, V450, P697, DOI 10.1016/j.bbrc.2014.06.039
NR 57
TC 79
Z9 80
U1 6
U2 45
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD AUG
PY 2015
VL 172
IS 15
BP 3929
EP 3943
DI 10.1111/bph.13184
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CM8LN
UT WOS:000357952500018
PM 25953698
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Nkune, NW
   Kruger, CA
   Abrahamse, H
AF Nkune, Nkune W.
   Kruger, Cherie A.
   Abrahamse, Heidi
TI Possible Enhancement of Photodynamic Therapy (PDT) Colorectal Cancer
   Treatment when Combined with Cannabidiol
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Colorectal Cancer (CRC); combinative treatment; Cannabis sativa;
   Cannabidiol (CBD); Photodynamic Therapy (PDT); targeted therapy
ID COLON-CANCER; INDUCED APOPTOSIS; DRUG-DELIVERY; ZINC PHTHALOCYANINE;
   RADIATION-THERAPY; TARGETED THERAPY; RECTAL-CANCER; STAGE-II;
   NANOPARTICLES; AUTOPHAGY
AB Colorectal Cancer (CRC) has a high mortality rate and is one of the most difficult diseases to manage due to tumour resistance and metastasis. The treatment of choice for CRC is reliant on the phase and time of diagnosis. Despite several conventional treatments available to treat CRC (surgical excision, chemo-, radiation and immune-therapy), resistance is a major challenge, especially if it has metastasized. Additionally, these treatments often cause unwanted adverse side effects and so it remains imperative to investigate alternative combination therapies.
   Photodynamic Therapy (PDT) is a promising treatment modality for the primary treatment of CRC, since it is non-invasive, has few side effects and selectively damages only cancerous tissues, leaving adjacent healthy structures intact. PDT involves three fundamentals: a Photosensitizer (PS) drug localized in tumour tissues, oxygen, and light. Upon PS excitation using a specific wavelength of light, an energy transfer cascade occurs, that ultimately yields cytotoxic species, which in turn induces cell death. Cannabidiol (CBD) is a cannabinoid compound derived from the Cannabis sativa plant, which has shown to exert anticancer effects on CRC through different pathways, inducing apoptosis and so inhibiting tumour metastasis and secondary spread.
   This review paper highlights current conventional treatment modalities for CRC and their limitations, as well as discusses the necessitation for further investigation into unconventional active nanoparticle targeting PDT treatments for enhanced primary CRC treatment. This can be administered in combination with CBD, to prevent CRC secondary spread and enhance the synergistic efficacy of CRC treatment outcomes, with less side effects.
C1 [Nkune, Nkune W.; Kruger, Cherie A.; Abrahamse, Heidi] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, Johannesburg, South Africa.
RP Kruger, CA (corresponding author), Univ Johannesburg, Fac Hlth Sci, Dept Laser Res Ctr, POB 17011, Johannesburg, South Africa.
EM cherier@uj.ac.za
RI Nkune, Nkune Williams/AAK-1713-2021; ABRAHAMSE, HEIDI/U-7763-2019;
   Kruger, Cherie Ann/H-2004-2016
OI Nkune, Nkune Williams/0000-0003-3746-707X; ABRAHAMSE,
   HEIDI/0000-0001-5002-827X; Kruger, Cherie Ann/0000-0002-4556-9132
FU South African Research Chairs Initiative of the Department of Science
   and Technology; South African Research Chairs Initiative of the National
   Research Foundation of South Africa [98337]; National Research
   Foundation Thuthuka Fund [TTK180409318735]; Cancer Association of South
   Africa (CANSA) Research Funding Grant; University of Johannesburg;
   National Laser Centre; National Research Foundation of South Africa
   (CSIR-DST); CSIR-DST InterBursary Programme
FX This work is based on the research supported by the South African
   Research Chairs Initiative of the Department of Science and Technology
   and National Research Foundation of South Africa (Grant No 98337),
   National Research Foundation Thuthuka Fund (Grant No TTK180409318735)
   and Cancer Association of South Africa (CANSA) Research Funding Grant.
   The authors sincerely thank the University of Johannesburg, the National
   Laser Centre and the National Research Foundation of South Africa
   (CSIR-DST) for their financial grant support, as well as the CSIR-DST
   InterBursary Programme for postgraduate student monetary support.
CR Abdulrehman G, 2018, LASER MED SCI, V33, P1581, DOI 10.1007/s10103-018-2524-7
   Abrahamse, 2019, TARGETED PHOTODYNAMI
   Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942
   Ahluwalia A, 2014, CURR PHARM DESIGN, V20, P1041, DOI 10.2174/1381612819999131218175905
   Aung TN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030656
   Aviello G, 2012, J MOL MED, V90, P925, DOI 10.1007/s00109-011-0856-x
   Babu A, 2013, J NANOMATER, V2013, DOI 10.1155/2013/863951
   Banerjee A, 2017, ONCOTARGET, V8, P26142, DOI 10.18632/oncotarget.15393
   Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Baskaran Rengarajan, 2018, Biomater Res, V22, P25, DOI 10.1186/s40824-018-0140-z
   Bazak R, 2015, J CANCER RES CLIN, V141, P769, DOI 10.1007/s00432-014-1767-3
   Benarba B, 2018, BIOMED PHARMACOTHER, V107, P408, DOI 10.1016/j.biopha.2018.08.006
   Benov L, 2015, MED PRIN PRACT, V24, P14, DOI 10.1159/000362416
   Bi Y, 2016, CURR DRUG METAB, V17, P763, DOI 10.2174/1389200217666160619191853
   Birgisson H, 2007, ACTA ONCOL, V46, P504, DOI 10.1080/02841860701348670
   Bostad M, 2015, J CONTROL RELEASE, V206, P37, DOI 10.1016/j.jconrel.2015.03.008
   Brar G, 2017, AM J HEMATOL-ONCOL, V13, P4
   Bruheim K, 2010, INT J RADIAT ONCOL, V76, P1005, DOI 10.1016/j.ijrobp.2009.03.010
   Calavia PG, 2018, PHOTOCH PHOTOBIO SCI, V17, P1534, DOI 10.1039/c8pp00271a
   Cheasley D, 2015, TRANSL CANCER RES, V4, P235, DOI 10.3978/j.issn.2218-676X.2015.05.02
   Colombeau L, 2016, TOP CURR CHEM, V370, P113, DOI 10.1007/978-3-319-22942-3_4
   Danaee H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189953
   de Freitas L.F., 2016, NANOBIOMATERIALS ANT, P1, DOI DOI 10.1016/B978-0-323-42864-4.00001-4
   de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108
   Denlinger CS, 2009, J NATL COMPR CANC NE, V7, P883, DOI 10.6004/jnccn.2009.0058
   Dienstmann R, 2017, ANN ONCOL, V28, P1023, DOI 10.1093/annonc/mdx052
   Geng F, 2017, CANCER BIOTHER RADIO, V32, P149, DOI 10.1089/cbr.2017.2210
   Gianfaldoni Serena, 2017, Open Access Maced J Med Sci, V5, P521, DOI 10.3889/oamjms.2017.122
   Gong HY, 2019, EXP THER MED, V17, P41, DOI 10.3892/etm.2018.6901
   Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3
   Hatakeyama T, 2013, ONCOL REP, V29, P911, DOI 10.3892/or.2013.2220
   Hodgkinson N., 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317734691
   Honarman M., 2019, COMP CLIN PATHOL, V28, P165, DOI [10.1007/s00580-018-2810-6, DOI 10.1007/s00580-018-2810-6]
   Hong EJ, 2016, ACTA PHARM SIN B, V6, P297, DOI 10.1016/j.apsb.2016.01.007
   Huang YJ, 2019, J CLIN NEUROSCI, V63, P13, DOI 10.1016/j.jocn.2019.02.019
   Jaffray D.A., 2015, DIS CONTROL PRIORITI, V3rd
   Jeong S, 2019, CANCERS, V11, DOI 10.3390/cancers11060781
   Jeong S, 2019, CANCER LETT, V447, P12, DOI 10.1016/j.canlet.2019.01.011
   Kawczyk-Krupka A, 2018, PHOTODIAGN PHOTODYN, V23, P240, DOI 10.1016/j.pdpdt.2018.07.007
   Kawczyk-Krupka A, 2016, PHOTODIAGN PHOTODYN, V13, P158, DOI 10.1016/j.pdpdt.2015.07.175
   Kenyon J, 2018, ANTICANCER RES, V38, P5831, DOI 10.21873/anticanres.12924
   Kim JH, 2017, RADIAT ONCOL J, V35, P295, DOI 10.3857/roj.2017.00395
   Kim JH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1514-4
   Kim JL, 2019, CANCERS, V11, DOI 10.3390/cancers11050642
   Kruger CA, 2018, MOLECULES, V23, DOI 10.3390/molecules23102628
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Kwiatt M, 2013, CLIN COLON RECT SURG, V26, P112, DOI 10.1055/s-0033-1348050
   Lee SY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7590245
   Li PT, 2015, J DENT SCI, V10, P74, DOI 10.1016/j.jds.2013.10.005
   Li YH, 2014, INT J CLIN EXP MED, V7, P4867
   Lin BR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137053
   Lombardo D, 2019, J NANOMATER, V2019, DOI 10.1155/2019/3702518
   Lukhele ST, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1280-0
   Magee MS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1227897
   Mansoori B, 2019, PHOTODIAGN PHOTODYN, V26, P395, DOI 10.1016/j.pdpdt.2019.04.033
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Massi P, 2013, BRIT J CLIN PHARMACO, V75, P303, DOI 10.1111/j.1365-2125.2012.04298.x
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mishra J, 2013, CRIT REV ONCOL HEMAT, V86, P232, DOI 10.1016/j.critrevonc.2012.09.014
   Muhamad N, 2018, INT J NANOMED, V13, P3921, DOI 10.2147/IJN.S165210
   Naderi J., 2019, J CANC RES THER
   Naidoo C, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818791795
   Nakayama G, 2013, GASTROINTEST TUMORS, V1, P25, DOI 10.1159/000354995
   Nombona N, 2011, DALTON T, V40, P11876, DOI 10.1039/c1dt11151e
   O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x
   Ohhara Y, 2016, WORLD J GASTRO ONCOL, V8, P642, DOI 10.4251/wjgo.v8.i9.642
   Oniszczuk A, 2016, BIOMED PHARMACOTHER, V83, P912, DOI 10.1016/j.biopha.2016.07.058
   Ouyang GQ, 2018, PHOTODIAGN PHOTODYN, V21, P396, DOI 10.1016/j.pdpdt.2018.01.010
   Palaghia M, 2015, JURNALUL CHIR, V10, P249
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Peng CL, 2018, PHOTODIAGN PHOTODYN, V23, P111, DOI 10.1016/j.pdpdt.2018.06.008
   Pietersz GA, 2017, NANOMEDICINE-UK, V12, P1873, DOI 10.2217/nnm-2017-0043
   Portilho FA, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-41
   Rajabi M, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020034
   Rejhova A, 2018, EUR J MED CHEM, V144, P582, DOI 10.1016/j.ejmech.2017.12.039
   Rentsch M, 2016, VISC MED, V32, P184, DOI 10.1159/000446490
   Rizvi SAA, 2018, SAUDI PHARM J, V26, P64, DOI 10.1016/j.jsps.2017.10.012
   Romano B, 2014, PHYTOMEDICINE, V21, P631, DOI 10.1016/j.phymed.2013.11.006
   Sanovic R, 2011, PHOTODIAGN PHOTODYN, V8, P291, DOI 10.1016/j.pdpdt.2011.04.003
   Sekhejane PR, 2014, INT J PHOTOENERGY, V2014, DOI 10.1155/2014/383027
   Senapati S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0004-3
   Shams M, 2015, CANCER IMMUNOL IMMUN, V64, P287, DOI 10.1007/s00262-014-1633-9
   Sharma M., 2014, Pharmacology and Pharmacy, V5, P806, DOI 10.4236/pp.2014.58091
   Shida D, 2019, ANN SURG ONCOL, V26, P1358, DOI 10.1245/s10434-019-07209-x
   Shirasu N, 2013, ANTICANCER RES, V33, P2823
   Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Sledzinski P, 2018, CANCER MED-US, V7, P765, DOI 10.1002/cam4.1312
   Soares MD, 2011, INT J NANOMED, V6, P227, DOI 10.2147/IJN.S15860
   Solinas M, 2012, BRIT J PHARMACOL, V167, P1218, DOI 10.1111/j.1476-5381.2012.02050.x
   St Denis TG, 2013, BIOANALYSIS, V5, P1099, DOI [10.4155/bio.13.37, 10.4155/BIO.13.37]
   Sueki F, 2019, PHOTODIAGN PHOTODYN, V27, P95, DOI 10.1016/j.pdpdt.2019.05.012
   Sukumar UK, 2013, INT NANO LETT, V3, DOI 10.1186/2228-5326-3-45
   Sun WJ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-63
   Taieb J, 2019, CANCER TREAT REV, V75, P1, DOI 10.1016/j.ctrv.2019.02.002
   Tanaka M, 2011, ANTICANCER RES, V31, P763
   Tombe S, 2013, NEW J CHEM, V37, P679, DOI 10.1039/c2nj40984d
   Varghese A, 2015, CLIN COLON RECT SURG, V28, P256, DOI 10.1055/s-0035-1564430
   Viswanath B, 2016, INT J NANOMED, V11, P2491, DOI 10.2147/IJN.S108715
   Wang JM, 2018, DRUG DELIV, V25, P1319, DOI 10.1080/10717544.2018.1477857
   Wang JC, 2018, BBA-MOL CELL RES, V1865, P1105, DOI 10.1016/j.bbamcr.2018.05.007
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wu HY, 2018, FREE RADICAL BIO MED, V124, P311, DOI 10.1016/j.freeradbiomed.2018.06.023
   Wu HY, 2010, TOXICOL LETT, V195, P68, DOI 10.1016/j.toxlet.2010.02.012
   Yang KZ, 2018, PHOTODIAGN PHOTODYN, V24, P332, DOI 10.1016/j.pdpdt.2018.10.012
   Zeng J, 2017, WORLD J GASTROENTERO, V23, P1780, DOI 10.3748/wjg.v23.i10.1780
   Zhou ZJ, 2016, CHEM SOC REV, V45, P6597, DOI 10.1039/c6cs00271d
   Zhu B, 2019, INT J BIOL SCI, V15, P12, DOI 10.7150/ijbs.27156
NR 111
TC 7
Z9 7
U1 7
U2 20
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2021
VL 21
IS 2
BP 137
EP 148
DI 10.2174/1871520620666200415102321
PG 12
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA QK4KN
UT WOS:000620356100003
PM 32294046
OA hybrid
DA 2022-04-25
ER

PT J
AU Zhou, W
   Liu, LB
   Xue, YX
   Zheng, J
   Liu, XB
   Ma, J
   Li, Z
   Liu, YH
AF Zhou, Wei
   Liu, Libo
   Xue, Yixue
   Zheng, Jian
   Liu, Xiaobai
   Ma, Jun
   Li, Zhen
   Liu, Yunhui
TI Combination of Endothelial-Monocyte-Activating Polypeptide-II with
   Temozolomide Suppress Malignant Biological Behaviors of Human
   Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR
   Signal Pathway
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Article
DE EMAP-II; TMZ; GSCs; autophagy; microRNAs; MiR-590-3p; MACC1
ID EPITHELIAL-MESENCHYMAL TRANSITION; GLIOMA-CELLS; CANCER-CELLS;
   HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; IN-VITRO; REGULATES
   AUTOPHAGY; COLORECTAL-CANCER; MACC1 EXPRESSION; EMAP II
AB This study aims to investigate the effect of Endothelial-Monocyte-Activating Polypeptide-II (EMAP-II) combined with temozolomide (TMZ) upon glioblastoma stem cells (GSCs) and its possible molecular mechanisms. In this study, combination of EMAP-II with TMZ inhibited cell viability, migration and invasion in GSCs, and autophagy inhibitor 3-methyl adenine (3-MA) and chloroquine (CQ) partly reverse the anti-proliferative effect of the combination treatment. Autophagic vacuoles were formed in GSCs after the combination therapy, accompanied with the up-regulation of LC3-II and Beclin-1 as well as the down-regulation of p62/SQSTM1. Further, miR-590-3p was up-regulated and Metastasis-associated in colon cancer 1 (MACC1) was down-regulated by the combination treatment in GSCs; MiR-590-3p overexpression and MACC1 knockdown up-regulated LC3-II and Beclin-1 as well as down-regulated p62/SQSTM1 in GSCs; MACC1 was identified as a direct target of miR-590-3p, mediating the effects of miR-590-3p in the combination treatment. Furthermore, the combination treatment and MACC1 knockdown decreased p-PI3K, p-Akt, p-mTOR, p-S6 and p-4EBP in GSCs; PI3K/Akt agonist insulin-like growth factor-1(IGF-1) partly blocked the effect of the combination treatment. Moreover, in vivo xenograft models, the mice given stable overexpressed miR-590-3p cells and treated with EMAP-II and TMZ had the smallest tumor sizes, besides, miR-590-3p + EMAP-II + TMZ up-regulated the expression level of miR-590-3p, LC3-II and Beclin-1 as well as down-regulated p62/SQSTM1. In conclusion, these results elucidated anovel molecular mechanism of EMAP-II in combination with TMZ suppressed malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs.
C1 [Zhou, Wei; Zheng, Jian; Liu, Xiaobai; Li, Zhen; Liu, Yunhui] China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang, Peoples R China.
   [Zhou, Wei; Zheng, Jian; Liu, Xiaobai; Li, Zhen; Liu, Yunhui] Liaoning Res Ctr Translat Med Nervous Syst Dis, Shenyang, Peoples R China.
   [Liu, Libo; Xue, Yixue; Ma, Jun] China Med Univ, Dept Neurobiol, Coll Basic Med, Shenyang, Peoples R China.
   [Liu, Libo; Xue, Yixue; Ma, Jun] China Med Univ, Minist Publ Hlth China, Key Lab Cell Biol, Shenyang, Peoples R China.
   [Liu, Libo; Xue, Yixue; Ma, Jun] China Med Univ, Minist Educ China, Key Lab Med Cell Biol, Shenyang, Peoples R China.
RP Liu, YH (corresponding author), China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang, Peoples R China.; Liu, YH (corresponding author), Liaoning Res Ctr Translat Med Nervous Syst Dis, Shenyang, Peoples R China.
EM liuyh_cmuns@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672511, 81372484, 81402573, 81573010];
   Liaoning Science and Technology Plan Project [2015225007]; Shenyang
   Science and Technology Plan Projects [F15-199-1-30, F15-199-1-57];
   outstanding scientific fund of Shengjing hospital [201304]
FX This work is supported by grants from the National Natural Science
   Foundation of China (81672511, 81372484, 81402573 and 81573010),
   Liaoning Science and Technology Plan Project (No. 2015225007), Shenyang
   Science and Technology Plan Projects (Nos. F15-199-1-30 and
   F15-199-1-57) and outstanding scientific fund of Shengjing hospital (No.
   201304).
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001
   Auffinger B, 2015, EXPERT REV NEUROTHER, V15, P741, DOI 10.1586/14737175.2015.1051968
   Awasthi N, 2010, CANCER BIOL THER, V10, P99, DOI 10.4161/cbt.10.1.12169
   Bak DH, 2016, EXP THER MED, V11, P2153, DOI 10.3892/etm.2016.3196
   Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249
   Cao Yiting, 2010, Genes Cancer, V1, P50
   Carew Jennifer S, 2008, Biologics, V2, P201
   Chen CM, 2015, INT J MOL MED, V36, P1244, DOI 10.3892/ijmm.2015.2332
   Chen JJ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00128
   Chen J, 2014, TUMOR BIOL, V35, P6293, DOI 10.1007/s13277-014-1821-4
   Feng JY, 2015, ONCOL REP, V33, P713, DOI 10.3892/or.2014.3642
   Filippi-Chiela EC, 2015, AUTOPHAGY, V11, P1099, DOI 10.1080/15548627.2015.1009795
   Gammell P, 2007, CYTOTECHNOLOGY, V53, P55, DOI 10.1007/s10616-007-9049-4
   Gao S, 2009, CHINESE MED J-PEKING, V122, P1260, DOI 10.3760/cma.j.issn.0366-6999.2009.11.005
   Gewirtz DA, 2014, BIOCHEM PHARMACOL, V90, P208, DOI 10.1016/j.bcp.2014.05.016
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Huang N, 2015, ONCOTARGET, V6, P15222, DOI 10.18632/oncotarget.3835
   Huang NN, 2015, CANCER BIOL THER, V16, P941, DOI 10.1080/15384047.2015.1040963
   Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604
   KAO J, 1994, J BIOL CHEM, V269, P25106
   Kim SS, 2015, NANOMED-NANOTECHNOL, V11, P301, DOI 10.1016/j.nano.2014.09.005
   Kim Y, 2015, BMB REP, V48, P371, DOI 10.5483/BMBRep.2015.48.7.121
   Lashford LS, 2002, J CLIN ONCOL, V20, P4684, DOI 10.1200/JCO.2002.08.141
   Li Z, 2015, J MOL NEUROSCI, V57, P11, DOI 10.1007/s12031-015-0604-8
   Liu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0302-1
   Liu J, 2014, BIOCHEM PHARMACOL, V89, P477, DOI 10.1016/j.bcp.2014.04.014
   Ma J, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00074
   Maiese K, 2013, TRENDS MOL MED, V19, P51, DOI 10.1016/j.molmed.2012.11.001
   Mendez I, 2001, CAN J NEUROL SCI, V28, P61
   Mineo M, 2016, CELL REP, V15, P2500, DOI 10.1016/j.celrep.2016.05.018
   Misra UK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051735
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   Pang HY, 2015, BIOCHEM BIOPH RES CO, V468, P739, DOI 10.1016/j.bbrc.2015.11.025
   Reznikov A. G., 2007, Experimental Oncology, V29, P267
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Roy B, 2014, CHEM-BIOL INTERACT, V210, P96, DOI 10.1016/j.cbi.2014.01.003
   Santoni M, 2012, ANTICANCER RES, V32, P1099
   Schwarz MA, 2005, EXP CELL RES, V311, P229, DOI 10.1016/j.yexcr.2005.09.008
   Schwarz RE, 2010, CANCER BIOL THER, V9, P632, DOI 10.4161/cbt.9.8.11265
   Shang Chao, 2015, Asian Pac J Cancer Prev, V16, P195
   Shi L, 2015, TUMOR BIOL, V36, P7107, DOI 10.1007/s13277-015-3427-x
   Shimokawa H, 2011, J THORAC CARDIOV SUR, V141, P895, DOI 10.1016/j.jtcvs.2010.09.044
   Soritau O, 2011, J BUON, V16, P282
   Stahlhut Espinosa Carlos E, 2006, Yale J Biol Med, V79, P131
   Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889
   Sun DW, 2015, INT J CLIN EXP MED, V8, P4769
   Tezcan G, 2014, CELL MOL NEUROBIOL, V34, P679, DOI 10.1007/s10571-014-0050-0
   Tso JL, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0459-1
   Tunca B, 2012, J CANCER RES CLIN, V138, P1831, DOI 10.1007/s00432-012-1261-8
   Yang T, 2014, TUMOR BIOL, V35, P815, DOI 10.1007/s13277-013-1112-5
   Yao YL, 2015, MOL ONCOL, V9, P640, DOI 10.1016/j.molonc.2014.11.003
   Yao YM, 2015, CELL PHYSIOL BIOCHEM, V35, P983, DOI 10.1159/000369754
   Yousef BA, 2016, BIOMED PHARMACOTHER, V79, P112, DOI 10.1016/j.biopha.2016.02.003
   Yu ZY, 2015, ONCOTARGET, V6, P32930, DOI 10.18632/oncotarget.5405
   Yu ZY, 2015, CANCER LETT, V367, P58, DOI 10.1016/j.canlet.2015.07.007
   Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022
   Zhang RT, 2016, ONCOL REP, V35, P2466, DOI 10.3892/or.2016.4585
   Zhang Y, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-23
   Zhou J, 2012, ONCOL RES, V20, P197, DOI 10.3727/096504013X13589503482734
   Zhou RJ, 2015, INT J MOL MED, V36, P1159, DOI 10.3892/ijmm.2015.2312
   Zou YH, 2014, MOL MED REP, V10, P411, DOI 10.3892/mmr.2014.2151
NR 63
TC 19
Z9 19
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD MAR 13
PY 2017
VL 10
AR 68
DI 10.3389/fnmol.2017.00068
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EN5RD
UT WOS:000396062300001
PM 28348518
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Lin, PL
   Tang, HH
   Wu, SY
   Shaw, NS
   Su, CL
AF Lin, Pin-Lun
   Tang, Han-Hsuan
   Wu, Shan-Ying
   Shaw, Ning-Sing
   Su, Chun-Li
TI Saponin Formosanin C-Induced Ferritinophagy and Ferroptosis in Human
   Hepatocellular Carcinoma Cells
SO ANTIOXIDANTS
LA English
DT Article
DE formosanin C; hepatocellular carcinoma; ferroptosis; autophagy;
   ferritinophagy
ID COLORECTAL-CANCER CELLS; NF-KAPPA-B; IRON HOMEOSTASIS; AUTOPHAGY;
   APOPTOSIS; DEGRADATION; DEATH; ACSL4; CYTOTOXICITY; ACTIVATION
AB Ferroptosis, a recently discovered form of iron-dependent cell death, requires an increased level of lipid-reactive oxygen species (ROS). Ferritinophagy, a ferritin degradation pathway, depends on a selective autophagic cargo receptor (NCOA4). By screening various types of natural compounds, formosanin C (FC) was identified as a novel ferroptosis inducer, characterized by attenuations of FC-induced viability inhibition and lipid ROS formation in the presence of ferroptosis inhibitor. FC also induced autophagic flux, evidenced by preventing autophagic marker LC3-II degradation and increasing yellow LC3 puncta in tandem fluorescent-tagged LC3 (mRFP-GFP) reporter plasmid (ptfLC3) transfected cells when combined with autophagic flux inhibitor. It is noteworthy that FC-induced ferroptosis and autophagic flux were stronger in HepG2 cells expressing higher NCOA4 and lower ferritin heavy chain 1 (FTH1) levels, agreeing with the results of gene expression analysis using CTRP and PRISM, indicating that FTH1 expression level exhibited a significant negative correlation with the sensitivity of the cells to a ferroptosis inducer. Confocal and electron microscopy confirmed the pronounced involvement of ferritinophagy in FC-induced ferroptosis in the cells with elevated NCOA4. Since ferroptosis is a non-apoptotic form of cell death, our data suggest FC has chemotherapeutic potential against apoptosis-resistant HCC with a higher NCOA4 expression via ferritinophagy.
C1 [Lin, Pin-Lun; Su, Chun-Li] Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 106, Taiwan.
   [Tang, Han-Hsuan; Wu, Shan-Ying; Su, Chun-Li] Natl Taiwan Normal Univ, Sch Life Sci, Grad Program Nutr Sci, Taipei 106, Taiwan.
   [Wu, Shan-Ying] Taipei Med Univ, Sch Med, Dept Microbiol & Immunol, Coll Med, Taipei 110, Taiwan.
   [Shaw, Ning-Sing] Natl Taiwan Univ, Dept Biochem Sci & Technol, Coll Life Sci, Taipei 106, Taiwan.
RP Su, CL (corresponding author), Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 106, Taiwan.; Su, CL (corresponding author), Natl Taiwan Normal Univ, Sch Life Sci, Grad Program Nutr Sci, Taipei 106, Taiwan.; Shaw, NS (corresponding author), Natl Taiwan Univ, Dept Biochem Sci & Technol, Coll Life Sci, Taipei 106, Taiwan.
EM sp940921@gate.sinica.edu.tw; 60751001s@ntnu.edu.tw;
   shanyingwu@tmu.edu.tw; nsshaw@ntu.edu.tw; chunlisu@ntnu.edu.tw
OI Tang, Han-Hsuan/0000-0002-9034-3597; Lin, Pin-lun/0000-0001-5313-7180;
   Su, Chun-Li/0000-0001-7617-2077
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 105-2320-B-003-003, 105-2514-S-003-006,
   106-2320-B-003-006-MY3, 106-2514-S-003-006]; National Taiwan Normal
   University, Taiwan [10502, 10602]
FX This work was supported by grants from the Ministry of Science and
   Technology, Taiwan (MOST 105-2320-B-003-003, 105-2514-S-003-006,
   106-2320-B-003-006-MY3, and 106-2514-S-003-006) and National Taiwan
   Normal University, Taiwan (10502 and 10602).
CR Bellelli R, 2016, CELL REP, V14, P411, DOI 10.1016/j.celrep.2015.12.065
   Cao Y, 2001, CANCER RES, V61, P8429
   Chen JR, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0226-z
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   CHIANG HC, 1992, ANTICANCER RES, V12, P1475
   Day SH, 2002, J NAT PROD, V65, P379, DOI 10.1021/np0101651
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   FENWICK DE, 1983, J SCI FOOD AGR, V34, P186, DOI 10.1002/jsfa.2740340212
   Fernando W, 2019, CANCER LETT, V452, P168, DOI 10.1016/j.canlet.2019.03.022
   Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Kang R, 2017, CURR PATHOBIOL REP, V5, P153, DOI 10.1007/s40139-017-0139-5
   Kazan HH, 2017, BIOMETALS, V30, P629, DOI 10.1007/s10534-017-0037-7
   Kim SE, 2016, NAT NANOTECHNOL, V11, P977, DOI 10.1038/nnano.2016.164
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Krstic J., 2018, INT J MOL SCI, V19
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Lee JC, 2005, CARCINOGENESIS, V26, P1716, DOI 10.1093/carcin/bgi133
   Lee JC, 2009, CANCER SCI, V100, P503, DOI 10.1111/j.1349-7006.2008.01057.x
   Li YY, 2014, CHEM-BIOL INTERACT, V220, P193, DOI 10.1016/j.cbi.2014.06.023
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liu HS, 2011, MOL PHARMACOL, V80, P638, DOI 10.1124/mol.111.072512
   Liu J, 2016, BIOORG MED CHEM LETT, V26, P4970, DOI 10.1016/j.bmcl.2016.09.005
   Ma SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182921
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Mancias JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10308
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Manz DH, 2016, ANN NY ACAD SCI, V1368, P149, DOI 10.1111/nyas.13008
   RAVIKUMAR PR, 1979, J PHARM SCI, V68, P900, DOI 10.1002/jps.2600680731
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sun XJ, 2017, MED SCI MONITOR, V23, P4343, DOI 10.12659/MSM.906639
   Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251
   Weber RA, 2020, MOL CELL, V77, P645, DOI 10.1016/j.molcel.2020.01.003
   Wei GF, 2018, EUR J MED CHEM, V157, P759, DOI 10.1016/j.ejmech.2018.08.036
   Won SJ, 2018, J CELL PHYSIOL, V233, P497, DOI 10.1002/jcp.25910
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Wu CC, 2008, J NAT PROD, V71, P246, DOI 10.1021/np070507o
   WU RT, 1990, INT J IMMUNOPHARMACO, V12, P777
   Wu SY, 2011, NEOPLASIA, V13, P1171, DOI 10.1593/neo.11888
   Wu XY, 2015, ONCOTARGET, V6, P44849, DOI 10.18632/oncotarget.6438
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859
   Yang M, 2015, ONCOL REP, V33, P2190, DOI 10.3892/or.2015.3836
   Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
   Zhang YJ, 2015, MOLECULES, V20, P21138, DOI 10.3390/molecules201219753
NR 53
TC 12
Z9 13
U1 12
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2020
VL 9
IS 8
AR 682
DI 10.3390/antiox9080682
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA NM4YZ
UT WOS:000568105200001
PM 32751249
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, MY
   Gou, WF
   Zhao, S
   Mao, XY
   Zheng, ZH
   Takano, Y
   Zheng, HC
AF Zhang, Mei-Ying
   Gou, Wen-Feng
   Zhao, Shuang
   Mao, Xiao-Yun
   Zheng, Zhi-Hong
   Takano, Yasuo
   Zheng, Hua-Chuan
TI Beclin 1 Expression is Closely Linked to Colorectal Carcinogenesis and
   Distant Metastasis of Colorectal Carcinoma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal carcinoma; Beclin 1; tumorigenesis; pathogenesis; prognosis
ID TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; PROGNOSTIC-SIGNIFICANCE;
   PROTEIN EXPRESSION; REDUCED EXPRESSION; CERVICAL-CANCER; AUTOPHAGY GENE;
   APOPTOSIS; TUMORIGENESIS; CHEMOTHERAPY
AB Beclin 1 participates in development, autophagy, differentiation, anti-apoptosis, neurodegeneration, tumorigenesis and cancer progression. The roles of Beclin 1 in colorectal carcinogenesis and its subsequent progression are still unclear. Here, the mRNA and protein expression of Beclin 1 were determined in colorectal carcinoma and matched mucosa by Reverse transcriptase-polymerase chain reaction and Western blot. Immunohistochemistry and in situ hybridization (ISH) were performed on tissue microarryer with colorectal carcinoma, adenoma and mucosa. The expression of Beclin 1 mRNA and protein was found to be higher in colorectal carcinoma than matched mucosa by real-time PCR and Western blot (p < 0.05). According to the ISH data, Beclin 1 expression was lower in colorectal non-neoplastic mucosa (NNM) than adenoma and carcinoma (p < 0.05). Immunohistochemically, primary carcinoma showed stronger Beclin 1 expression than NNM and metastatic carcinoma in the liver (p < 0.05). Beclin 1 protein expression was negatively related to liver and distant metastasis (p < 0.05), but not correlated with age, sex, depth of invasion, lymphatic or venous invasion, lymph node metastasis, tumor-node-metastasis (TNM) staging, differentiation or serum carcinoembryonic antigen (CEA) concentration (p > 0.05). Survival analysis indicated that Beclin 1 expression was not linked to favorable prognosis of the patients with colorectal carcinoma (p > 0.05). Cox's model indicated that depth of invasion and distant metastasis were independent prognostic factors for colorectal carcinomas (p < 0.05). It was suggested that Beclin 1 expression is closely linked to colorectal carcinogenesis and distant metastasis of colorectal carcinoma.
C1 [Zhang, Mei-Ying; Zheng, Zhi-Hong] China Med Univ, Lab Anim Ctr, Shenyang 110001, Peoples R China.
   [Gou, Wen-Feng; Zhao, Shuang; Zheng, Hua-Chuan] China Med Univ, Coll Basic Med, Dept Biochem & Mol Biol, Shenyang 110001, Peoples R China.
   [Mao, Xiao-Yun] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Shenyang 110001, Peoples R China.
   [Takano, Yasuo] Kanagawa Canc Ctr, Clin Res Inst, Yokohama, Kanagawa 2410815, Japan.
RP Zheng, HC (corresponding author), China Med Univ, Coll Basic Med, Dept Biochem & Mol Biol, Shenyang 110001, Peoples R China.
EM zhmeiying@hotmail.com; xiaogouaeiou@163.com; zhaoshuang1235@163.com;
   maoxiaoyun@126.com; zhihongzheng@163.com;
   ytakano@gancen.asahi.yokohama.jp; zheng_huachuan@hotmail.com
FU Shenyang Outstanding Talent Foundation of China; Shenyang Science and
   Technology Grant [F10-149-9-25, F11-264-1-10]; Liaoning Science and
   Technology Grant; National Natural Scientific Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81172371,
   81201886]; Ministry of Education, Culture, Sports and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [23659958]
FX This study was supported by: Shenyang Outstanding Talent Foundation of
   China; Shenyang Science and Technology Grant (F10-149-9-25;
   F11-264-1-10); Liaoning Science and Technology Grant; National Natural
   Scientific Foundation of China (81172371; 81201886) and Grant-in aid for
   Scientific Research from the Ministry of Education, Culture, Sports and
   Technology of Japan (23659958).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Bosman FT, 2010, WHO CLASSIFICATION T
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Duan Zhen-Ling, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P239
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Jiang Z. F., 2012, MOL BIOL REP, V43, P62
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651
   Kim HS, 2011, PATHOL RES PRACT, V207, P247, DOI 10.1016/j.prp.2011.02.007
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Kumada T, 2004, MODERN PATHOL, V17, P1141, DOI 10.1038/modpathol.3800165
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Okura R, 2011, EUR J DERMATOL, V21, P1002, DOI 10.1684/ejd.2011.1516
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Shi YH, 2009, AUTOPHAGY, V5, P380, DOI 10.4161/auto.5.3.7658
   Sobin L H, 2002, TNM CLASSIFICATION M, V6th
   Song H, 2004, WORLD J GASTROENTERO, V10, P509, DOI 10.3748/wjg.v10.i4.509
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Wang Zan-Hong, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P860
   Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034
   Wang ZH, 2011, INT J GYNECOL PATHOL, V30, P400, DOI 10.1097/PGP.0b013e31820f874a
   Yu M, 2013, TUMOR BIOL, V34, P1071, DOI 10.1007/s13277-013-0648-8
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhao Y, 2014, TUMOR BIOL, V35, P1955, DOI 10.1007/s13277-013-1261-6
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 34
TC 24
Z9 27
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2014
VL 15
IS 8
BP 14372
EP 14385
DI 10.3390/ijms150814372
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AO7GD
UT WOS:000341519600073
PM 25196438
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Talbert, E
   Metzger, G
   He, W
   Guttridge, D
AF Talbert, Erin E.
   Metzger, Gregory A.
   He, Wei A.
   Guttridge, Denis C.
TI Modeling human cancer cachexia in colon 26 tumor-bearing adult mice
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article
DE Muscle wasting; Ubiquitin ligases; Autophagy; Muscle regeneration
ID SKELETAL-MUSCLE; WEIGHT-LOSS; ADENOCARCINOMA; REJUVENATION;
   CHEMOTHERAPY; DYSFUNCTION
AB Muscle wasting is a profound side effect of advanced cancer. Cancer-induced cachexia decreases patient quality of life and is associated with poor patient survival. Currently, no clinical therapies exist to treat cancer-induced muscle wasting. Although cancers commonly associated with cachexia occur in older individuals, the standard animal models used to elucidate the causes of cachexia rely on juvenile mice.
   In an effort to better model human cancer cachexia, we determined whether cachectic features seen in young mice could be achieved in adult, pre-sarcopenic mice following colon 26 (C-26) tumor cell inoculation.
   Both young and adult mice developed similar-sized tumors and progressed to cachexia with similar kinetics, as evidenced by losses in body mass, and adipose and skeletal muscle tissues. Proteolytic signaling, including proteasome and autophagy genes, was also increased in muscles from both young and adult tumor-bearing animals. Furthermore, tumor-associated muscle damage and activation of Pax7 progenitor cells was induced in both young and adult mice.
   Although cancer cachexia generally occurs in older individuals, these data suggest that the phenotype and underlying mechanisms can be effectively modeled using the currently accepted protocol in juvenile mice.
C1 [Talbert, Erin E.; Metzger, Gregory A.; He, Wei A.; Guttridge, Denis C.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
   [Talbert, Erin E.; Metzger, Gregory A.; He, Wei A.; Guttridge, Denis C.] Ohio State Univ, Coll Med, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA.
RP Guttridge, D (corresponding author), Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, 460 W 12th Ave, Columbus, OH 43210 USA.
EM erin.talbert@osumc.edu; gregory.metzger@osumc.edu; wei.he@osumc.edu;
   denis.guttridge@osumc.edu
RI He, Wei/J-6275-2016; Talbert, Erin/AAM-5535-2020
OI Talbert, Erin/0000-0003-4587-0950; Guttridge, Denis/0000-0002-7276-6609
FU Ohio State Comprehensive Cancer Center; Ohio State Cancer Genetics NIH
   T32 training grant [T32 CA106196]; NIHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R01
   CA180057]; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA180057] Funding Source: NIH RePORTER
FX We thank Katherine Ladner for technical assistance and The Ohio State
   Comprehensive Cancer Center for support for this project. EET is Weiss
   Postdoctoral Fellow and is supported by the Ohio State Cancer Genetics
   NIH T32 training grant, T32 CA106196. Further support was provided by an
   NIH grant, R01 CA180057 to DCG.
CR Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004
   Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174
   American Cancer Society, 2013, CANC FACTS FIG 2013
   Andreyev HJN, 1998, EUR J CANCER, V34, P503, DOI 10.1016/S0959-8049(97)10090-9
   Aulino P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-363
   Bernet JD, 2014, NAT MED, V20, P265, DOI 10.1038/nm.3465
   Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012
   Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Cosgrove BD, 2014, NAT MED, V20, P255, DOI 10.1038/nm.3464
   DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3
   Di Marco S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1899
   Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
   Flurkey K., 2007, MOUSE BIOMEDICAL RES, V3, P637, DOI [10.1016/B978-012369454-6/50074-1, DOI 10.1016/B978-012369454-6/50074-1]
   He WA, 2013, J CLIN INVEST, V123, P4821, DOI 10.1172/JCI68523
   Lokireddy S, 2012, CELL METAB, V16, P613, DOI 10.1016/j.cmet.2012.10.005
   Murphy KT, 2012, DIS MODEL MECH, V5, P533, DOI 10.1242/dmm.008839
   Penna F, 2013, J LIPID RES, V54, P3045, DOI 10.1194/jlr.M038406
   Roberts BM, 2013, FASEB J, V27, P2600, DOI 10.1096/fj.12-222844
   Sayer AA, 2013, AGE AGEING, V42, P145, DOI 10.1093/ageing/afs191
   Taillandier D, 2004, P NUTR SOC, V63, P357, DOI 10.1079/PAR2004358
   TANAKA M, 1993, CANCER LETT, V72, P65, DOI 10.1016/0304-3835(93)90012-X
   TANAKA Y, 1990, CANCER RES, V50, P2290
   Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008
   Tisdale MJ, 2004, J CELL BIOCHEM, V93, P871, DOI 10.1002/jcb.20246
   Tsoli M, 2013, TRENDS ENDOCRIN MET, V24, P174, DOI 10.1016/j.tem.2012.10.006
   Zhang GH, 2011, EMBO J, V30, P4323, DOI 10.1038/emboj.2011.292
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
NR 28
TC 46
Z9 47
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2190-5991
EI 2190-6009
J9 J CACHEXIA SARCOPENI
JI J. Cachexia Sarcopenia Muscle
PD DEC
PY 2014
VL 5
IS 4
BP 321
EP 328
DI 10.1007/s13539-014-0141-2
PG 8
WC Geriatrics & Gerontology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; General & Internal Medicine
GA AU1WC
UT WOS:000345407100010
PM 24668658
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Qiao, XR
   Wang, XF
   Shang, Y
   Li, Y
   Chen, SZ
AF Qiao, Xinran
   Wang, Xiaofei
   Shang, Yue
   Li, Yi
   Chen, Shu-zhen
TI Azithromycin enhances anticancer activity of TRAIL by inhibiting
   autophagy and up-regulating the protein levels of DR4/5 in colon cancer
   cells in vitro and in vivo
SO CANCER COMMUNICATIONS
LA English
DT Article
DE Azithromycin; TRAIL; Apoptosis; Autophagy; Colon cancer
ID INDUCED APOPTOSIS; DOWN-REGULATION; DEATH; CHLOROQUINE; INDUCTION;
   CLARITHROMYCIN; ANTIBIOTICS; BORTEZOMIB; RESISTANCE; CELECOXIB
AB Background: Azithromycin is a member of macrolide antibiotics, and has been reported to inhibit the proliferation of cancer cells. However, the underlying mechanisms are not been fully elucidated. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively targets tumor cells without damaging healthy cells. In the present study, we examined whether azithromycin is synergistic with TRAIL, and if so, the underlying mechanisms in colon cancers.
   Methods: HCT-116, SW480, SW620 and DiFi cells were treated with azithromycin, purified TRAIL, or their combination. A sulforhoddamine B assay was used to examine cell survival. Apoptosis was examined using annexin V-FITC/PI staining, and autophagy was observed by acridine orange staining. Western blot analysis was used to detect protein expression levels. In mechanistic experiments, siRNAs were used to knockdown death receptors (DR4, DR5) and LC-3B. The anticancer effect of azithromycin and TRAIL was also examined in BALB/c nude mice carrying HCT-116 xenografts.
   Results: Azithromycin decreased the proliferation of HCT-116 and SW480 cells in a dose-dependent manner. Combination of azithromycin and TRAIL inhibited tumor growth in a manner that could not be explained by additive effects. Azithromycin increased the expressions of DR4, DR5, p62 and LC-3B proteins and potentiated induction of apoptosis by TRAIL. Knockdown of DR4 and DR5 with siRNAs increased cell survival rate and decreased the expression of cleaved-PARP induced by the combination of azithromycin and TRAIL. LC-3B siRNA and CQ potentiated the anti-proliferation activity of TRAIL alone, and increased the expressions of DR4 and DR5.
   Conclusion: The synergistic antitumor effect of azithromycin and TRAIL mainly relies on the up-regulations of DR4 and DR5, which in turn result from LC-3B-involved autophagy inhibition.
C1 [Chen, Shu-zhen] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
   Peking Union Med Coll, Beijing 100050, Peoples R China.
RP Chen, SZ (corresponding author), Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
EM bjcsz@imb.pumc.edu.cn
OI Chen, Shu-zhen/0000-0003-4881-0558; , xinran/0000-0003-0909-7155; qiao,
   xinran/0000-0002-0354-3364
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81373437, 81621064]; CAMS Innovation Fund
   for Medical Sciences (CIFMS) [2016-I2M-02-002]
FX The manuscript was supported by grants from the National Natural Science
   Foundation of China (81373437 and 81621064) and CAMS Innovation Fund for
   Medical Sciences (CIFMS) (2016-I2M-02-002).
CR Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Chen SZ, 2007, MOL PHARMACOL, V72, P1269, DOI 10.1124/mol.107.037465
   Chu DJ, 2014, GENET MOL RES, V13, P2796, DOI 10.4238/2014.April.14.8
   Cousin FJ, 2016, ONCOTARGET, V7, P7161, DOI 10.18632/oncotarget.6881
   Das S, 2017, ONCOTARGET, V8, P248, DOI 10.18632/oncotarget.11335
   Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174
   Eisenblatter M, 2008, EUR J CLIN MICROBIOL, V27, P1087, DOI 10.1007/s10096-008-0547-x
   Hwang JS, 2015, TUMOR BIOL, V36, P8819, DOI 10.1007/s13277-015-3629-2
   Jeong JW, 2015, PHYTOTHER RES, V29, P1516, DOI 10.1002/ptr.5402
   Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90
   Karl I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.528
   Kauntz H, 2011, APOPTOSIS, V16, P1042, DOI 10.1007/s10495-011-0631-z
   Kim SW, 2016, ONCOTARGET, V7, P4356, DOI 10.18632/oncotarget.5374
   Komatsu S, 2012, INT J ONCOL, V40, P1029, DOI 10.3892/ijo.2011.1317
   Lamb R, 2015, ONCOTARGET, V6, P4569, DOI 10.18632/oncotarget.3174
   Lippai M, 2017, CELL BIOL TOXICOL, V33, P145, DOI 10.1007/s10565-016-9374-5
   Liu F, 2014, ACTA PHARMACOL SIN, V35, P645, DOI 10.1038/aps.2014.3
   Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322
   Liu XY, 2015, CANCER RES, V75, P1736, DOI 10.1158/0008-5472.CAN-14-2199
   Liu YJ, 2014, ONCOL REP, V32, P1257, DOI 10.3892/or.2014.3317
   Lv XQ, 2015, ONCOL REP, V34, P1289, DOI 10.3892/or.2015.4091
   Moriya S, 2013, INT J ONCOL, V42, P1541, DOI 10.3892/ijo.2013.1870
   Mukai S, 2016, INT J ONCOL, V48, P45, DOI 10.3892/ijo.2015.3237
   Park EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22921
   Shi XD, 2016, ARCH VIROL, V161, P2197, DOI 10.1007/s00705-016-2896-6
   Timur M, 2015, ANTI-CANCER AGENT ME, V15, P99
   van Nuffel AMT, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.513
   Zhang ZY, 2015, J PHARMACOL SCI, V127, P83, DOI 10.1016/j.jphs.2014.11.003
   Zheng SM, 2014, ANTIMICROB AGENTS CH, V58, P6675, DOI 10.1128/AAC.02904-14
   Zhou Xuezhang, 2012, Cancers (Basel), V4, P1318, DOI 10.3390/cancers4041318
NR 30
TC 22
Z9 22
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2523-3548
J9 CANCER COMMUN
JI Cancer Commun.
PD JUL 3
PY 2018
VL 38
AR 43
DI 10.1186/s40880-018-0309-9
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM7HG
UT WOS:000438353700001
PM 29970185
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, XM
   Yang, ZJ
   Xie, Q
   Zhang, ZK
   Zhang, H
   Ma, JY
AF Huang, Xuan-mei
   Yang, Zhi-jie
   Xie, Qing
   Zhang, Zi-kang
   Zhang, Hua
   Ma, Jun-ying
TI Natural products for treating colorectal cancer: A mechanistic review
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Natural products; Colorectal cancer; Anti-cancer effects; Molecular
   mechanisms; Regulation networks
ID CELL-CYCLE ARREST; FLUOROURACIL PLUS LEUCOVORIN; MOLECULAR PATHOLOGICAL
   EPIDEMIOLOGY; EPITHELIAL-MESENCHYMAL TRANSITION; ENHANCED
   ANTITUMOR-ACTIVITY; FACTOR-KAPPA-B; COLON-CANCER; PHASE-II; INDUCE
   APOPTOSIS; ANTIPROLIFERATIVE ACTIVITY
AB Colorectal cancer (CRC) is one of the most common types of cancers in humans and is closely linked to the global cancer-related mortalities worldwide. Molecular pathological epidemiology studies can reveal the risk factors of CRC and contribute to biomarker research and precision medicine. The current clinical treatment for CRC mainly involves surgery and chemotherapy. However, because of the occurrence of side effects and the emergence of drug resistance, there is an urgent need to find new and more effective drugs for CRC treatment. An increasing number of studies have demonstrated that many natural products possess effective anti-CRC effects and may serve as alternative chemotherapy agents for CRC treatment. In this review, we summarize the natural products with anti-CRC effects from different sources based on the chemical structures such as alkaloids, polysaccharides, polyphenols, terpenoid, unsaturated fatty acids, and discuss the natural product-derived drugs used clinically for colorectal cancer treatment. Furthermore, natural products of marine origin are also discussed for their enormous potential to serve as the candidate drugs. Notably, we generalize the experiment-based molecular mechanisms and the regulatory networks whereby natural products exert anticancer effects on cell proliferation, metastasis, apoptosis, autophagy, and angiogenesis.
C1 [Huang, Xuan-mei; Xie, Qing; Zhang, Zi-kang; Zhang, Hua] Guangdong Med Univ, Marine Biomed Res Inst, Inst Lab Med, Guangdong Prov Key Lab Med Mol Diagnost, Dongguan 523808, Peoples R China.
   [Yang, Zhi-jie; Ma, Jun-ying] Chinese Acad Sci, South China Sea Inst Oceanol, RNAM Ctr Marine Microbiol, CAS Key Lab Trop Marine Bioresources & Ecol,Guang, Guangzhou 510301, Guangdong, Peoples R China.
RP Zhang, H (corresponding author), Guangdong Med Univ, Marine Biomed Res Inst, Inst Lab Med, Guangdong Prov Key Lab Med Mol Diagnost, Dongguan 523808, Peoples R China.; Ma, JY (corresponding author), Chinese Acad Sci, South China Sea Inst Oceanol, RNAM Ctr Marine Microbiol, CAS Key Lab Trop Marine Bioresources & Ecol,Guang, Guangzhou 510301, Guangdong, Peoples R China.
EM 1837766853@qq.com; yzjie6@126.com; 1048271414@qq.com; 1119129766@qq.com;
   huazhang@gdmu.edu.cn; majunying@scsio.ac.cn
RI Zhang, Hua/AAF-3999-2020; Zhang, Hua/AAA-2164-2022
OI Zhang, Hua/0000-0001-9731-2737; Ma, Junying/0000-0002-0641-7291
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870046, 81741166]; Natural Science
   Foundation of Guangdong ProvinceNational Natural Science Foundation of
   Guangdong Province [2016A030312014, 2018A0303130005, 2015A03313528];
   Special Support Program for Training High-Level Talents in Guangdong
   [201528018]; Fund of the School of Laboratory Medicine of Guangdong
   Medical University
FX This work was supported by the National Natural Science Foundation of
   China (31870046 and 81741166), the Natural Science Foundation of
   Guangdong Province (2016A030312014, 2018A0303130005 and 2015A03313528),
   the Special Support Program for Training High-Level Talents in Guangdong
   (201528018) and Fund of the School of Laboratory Medicine of Guangdong
   Medical University.
CR Abaza MSI, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1358-8
   Abdel-Lateff A, 2016, Z NATURFORSCH C, V71, P29, DOI 10.1515/znc-2015-0160
   Aires V, 2013, MOL NUTR FOOD RES, V57, P1170, DOI 10.1002/mnfr.201200766
   Al-kasspooles MF, 2013, INVEST NEW DRUG, V31, P871, DOI 10.1007/s10637-012-9919-2
   Altomare I, 2013, EXPERT OPIN PHARMACO, V14, P505, DOI 10.1517/14656566.2013.770473
   Amin ARMR, 2015, SEMIN CANCER BIOL, V35, pS55, DOI 10.1016/j.semcancer.2015.02.005
   Angulo P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0373-z
   Anwar A, 2018, MOL BIOL REP, V45, P1339, DOI 10.1007/s11033-018-4294-5
   Asif M, 2016, TOXICOL LETT, V257, P84, DOI 10.1016/j.toxlet.2016.05.027
   Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8
   Bach DH, 2015, MAR DRUGS, V13, P6962, DOI 10.3390/md13116962
   Bahrami A, 2018, J CELL BIOCHEM, V119, P2460, DOI 10.1002/jcb.25950
   Bajetta E, 2004, ONCOLOGY-BASEL, V66, P132, DOI 10.1159/000077439
   Becerril-Espinosa A, 2012, REV BIOL MAR OCEANOG, V47, P317, DOI 10.4067/S0718-19572012000200013
   Benarba B, 2018, BIOMED PHARMACOTHER, V107, P408, DOI 10.1016/j.biopha.2018.08.006
   Benelli R, 2018, TRANSL RES, V196, P42, DOI 10.1016/j.trsl.2018.01.003
   Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138
   Bishayee A, 2010, CANCER TREAT REV, V36, P43, DOI 10.1016/j.ctrv.2009.10.002
   Bondarev I M, 1980, Probl Tuberk, P36
   Buhrmann C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101073
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Cai YC, 2014, J NAT MED-TOKYO, V68, P53, DOI 10.1007/s11418-013-0766-z
   Carbone A, 2015, MAR DRUGS, V13, P460, DOI 10.3390/md13010460
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chan CK, 2016, MOLECULES, V21, DOI 10.3390/molecules21030385
   Chao CY, 2013, CARCINOGENESIS, V34, P1843, DOI 10.1093/carcin/bgt131
   Chen C, 2017, MOL CARCINOGEN, V56, P2692, DOI 10.1002/mc.22712
   Chen JX, 2015, MAR DRUGS, V13, P6259, DOI 10.3390/md13106259
   Chen L, 2017, CHIN J NAT MEDICINES, V15, P576, DOI [10.3724/SP.J.1009.2017.00576, 10.1016/S1875-5364(17)30085-7]
   Chen MC, 2015, J AGR FOOD CHEM, V63, P1540, DOI 10.1021/jf5054063
   Chen XH, 2015, EUR J PHARMACOL, V764, P124, DOI 10.1016/j.ejphar.2015.07.008
   Chen XX, 2017, J AGR FOOD CHEM, V65, P1566, DOI 10.1021/acs.jafc.6b05376
   Cheng L, 2014, INT J ONCOL, V45, P757, DOI 10.3892/ijo.2014.2449
   Cheraghi O, 2016, PHYTOMEDICINE, V23, P398, DOI 10.1016/j.phymed.2016.01.015
   Chevallier C, 2003, ORG LETT, V5, P3737, DOI 10.1021/ol035476c
   Chu C, 2013, FUND CLIN PHARMACOL, V27, P434, DOI 10.1111/j.1472-8206.2012.01035.x
   Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709
   Creemers GJ, 1997, SEMIN ONCOL, V24, pS42
   Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5
   Dia VP, 2016, SCI REP-UK, V6, DOI 10.1038/srep33532
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Ellebaek E, 2012, SCAND J GASTROENTERO, V47, P315, DOI 10.3109/00365521.2012.640831
   Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020
   Eo HJ, 2016, BIOMOL THER, V24, P380, DOI 10.4062/biomolther.2015.154
   Escargueil AE, 2008, J CELL SCI, V121, P1275, DOI 10.1242/jcs.023259
   Esmaeelian B, 2014, MAR DRUGS, V12, P17, DOI 10.3390/md12010017
   Esmaeelian B, 2013, MAR DRUGS, V11, P3802, DOI 10.3390/md11103802
   Farokhi F, 2013, MAR DRUGS, V11, P1304, DOI 10.3390/md11041304
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fiore D, 2016, CANCER BIOL THER, V17, P849, DOI 10.1080/15384047.2015.1078028
   Font A, 2002, LUNG CANCER, V37, P213, DOI 10.1016/S0169-5002(02)00081-8
   Freitas S, 2016, TOXICON, V119, P140, DOI 10.1016/j.toxicon.2016.05.016
   Fu JS, 2018, J AGR FOOD CHEM, V66, P11935, DOI 10.1021/acs.jafc.8b04442
   Fuggetta MP, 2006, J EXP CLIN CANC RES, V25, P189
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Go RE, 2016, J BIOMED RES, V30, P234, DOI 10.7555/JBR.30.2016K0004
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Goldwasser F, 2000, ANN ONCOL, V11, P1463, DOI 10.1023/A:1026535824044
   Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4
   Gu MC, 2017, ONCOTARGET, V8, P87379, DOI 10.18632/oncotarget.20972
   Gunasekera SP, 2016, J NAT PROD, V79, P1867, DOI 10.1021/acs.jnatprod.6b00203
   Haller DG, 2008, J CLIN ONCOL, V26, P4544, DOI 10.1200/JCO.2008.17.1249
   Hamada T, 2019, J PATHOL, V247, P615, DOI 10.1002/path.5236
   Hamano H, 2019, SUPPORT CARE CANCER, V27, P849, DOI 10.1007/s00520-018-4367-y
   Han MS, 2017, INT J COLORECTAL DIS, V32, P1223, DOI 10.1007/s00384-017-2782-z
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hansen E, 2015, CURR PHARM BIOTECHNO, V17, P71, DOI 10.2174/1389201016666150817095537
   Hatae N, 2014, MED CHEM RES, V23, P4956, DOI 10.1007/s00044-014-1061-6
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hidalgo MA, 2005, BRIT J PHARMACOL, V144, P680, DOI 10.1038/sj.bjp.0706105
   Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282
   Holch JW, 2019, EUR J CANCER, V106, P115, DOI 10.1016/j.ejca.2018.10.001
   Horita Y, 2012, INT J CLIN ONCOL, V17, P604, DOI 10.1007/s10147-011-0331-2
   Hosokawa M, 2004, BBA-GEN SUBJECTS, V1675, P113, DOI 10.1016/j.bbagen.2004.08.012
   Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725
   Hsuan SW, 2016, EUR J NUTR, V55, P491, DOI 10.1007/s00394-015-0866-5
   Hu F, 2015, J PHARMACOL SCI, V128, P27, DOI 10.1016/j.jphs.2015.04.003
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang YH, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12451
   Iihara H, 2019, CANCER CHEMOTH PHARM, V83, P393, DOI 10.1007/s00280-018-3736-z
   Ikeguchi M, 2011, ONCOL LETT, V2, P319, DOI 10.3892/ol.2011.254
   Jayasekara H, 2017, INT J CANCER, V140, P1485, DOI 10.1002/ijc.30568
   Jespers W, 2017, MOLECULES, V22, DOI 10.3390/molecules22111945
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jing Z, 2016, ONCOTARGET, V7, P61509, DOI 10.18632/oncotarget.11385
   Johnson JJ, 2007, CANCER LETT, V255, P170, DOI 10.1016/j.canlet.2007.03.005
   KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
   Kamiyama H, 2005, J CANCER RES CLIN, V131, P205, DOI 10.1007/s00432-004-0642-z
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Keum N, 2014, INT J CANCER, V135, P1940, DOI 10.1002/ijc.28840
   Kim EJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-96
   Kim WK, 2018, BIOCHEM PHARMACOL, V152, P71, DOI 10.1016/j.bcp.2018.03.009
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kolman Ada, 2004, Curr Opin Investig Drugs, V5, P657
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kumar MS, 2018, BIOMED PHARMACOTHER, V105, P233, DOI 10.1016/j.biopha.2018.05.142
   Kumazaki M, 2014, PHYTOMEDICINE, V21, P1070, DOI 10.1016/j.phymed.2014.04.006
   Kustiawan PM, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0139-4
   Lee KC, 2011, J ETHNOPHARMACOL, V135, P678, DOI 10.1016/j.jep.2011.03.068
   Lee RM, 2019, J SURG ONCOL, V119, P549, DOI 10.1002/jso.25431
   Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453
   Lemieszek MK, 2017, FOOD FUNCT, V8, P1830, DOI [10.1039/C6FO01626J, 10.1039/c6fo01626j]
   Li G, 2018, MED RES REV, V38, P1255, DOI 10.1002/med.21474
   Li H, 2017, ACTA PHARMACOL SIN, V38, P252, DOI 10.1038/aps.2016.101
   Li J, 2015, ONCOTARGETS THER, V8, P427, DOI 10.2147/OTT.S76116
   Li M, 2018, PHYTOMEDICINE, V46, P131, DOI 10.1016/j.phymed.2018.03.065
   Li Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0632-2
   Li YH, 2015, WORLD J GASTROENTERO, V21, P9262, DOI 10.3748/wjg.v21.i31.9262
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Lin LC, 2018, MAR DRUGS, V16, DOI 10.3390/md16080252
   Lin XB, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0708-7
   Lin YW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030507, 10.1371/journal.pone.0052490]
   Liu BXZ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-412
   Liu HP, 2018, MOL MED REP, V17, P5837, DOI 10.3892/mmr.2018.8617
   Liu KC, 2016, AM J CHINESE MED, V44, P1289, DOI 10.1142/S0192415X16500725
   Liu LQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020506
   Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310
   Liu Y, 2016, APOPTOSIS, V21, P1398, DOI 10.1007/s10495-016-1297-3
   Liu YG, 2015, ONCOTARGETS THER, V8, P1061, DOI 10.2147/OTT.S81442
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Maehara Y, 2012, SURG TODAY, V42, P8, DOI 10.1007/s00595-011-0075-7
   Mahajan P, 2016, J PHARM PHARMACOL, V68, P1331, DOI 10.1111/jphp.12609
   Mao J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0442-y
   MARINELLI A, 1991, BRIT J CANCER, V64, P74, DOI 10.1038/bjc.1991.242
   Matsubara T, 2019, MAR DRUGS, V17, DOI 10.3390/md17010003
   Minker C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/154164
   Miyata T, 2007, J PHARMACOL SCI, V103, P127, DOI 10.1254/jphs.CPJ06016X
   Morgan JB, 2015, MAR DRUGS, V13, P1552, DOI 10.3390/md13031552
   Mouchiroud L, 2010, BIOFACTORS, V36, P377, DOI 10.1002/biof.127
   Mutiah Roihatul, 2018, Asian Pac J Cancer Prev, V19, P1457, DOI 10.22034/APJCP.2018.19.6.1457
   Nakagawa H, 2001, J CANCER RES CLIN, V127, P258, DOI 10.1007/s004320000190
   Nauroth JM, 2010, LIPIDS, V45, P375, DOI 10.1007/s11745-010-3406-3
   Neoh CA, 2018, MOLECULES, V23, DOI 10.3390/molecules23010058
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Newman DJ, 2004, J NAT PROD, V67, P1216, DOI 10.1021/np040031y
   Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Ondrouskova E., 2019, KLIN ONKOL, V29, P12
   PALMIERI G, 1991, J CHEMOTHERAPY, V3, P55
   Palozza P, 2009, CANCER LETT, V283, P108, DOI 10.1016/j.canlet.2009.03.031
   Park GH, 2016, FOOD CHEM TOXICOL, V95, P142, DOI 10.1016/j.fct.2016.07.008
   Patt YZ, 2007, AM J CLIN ONCOL-CANC, V30, P350, DOI 10.1097/COC.0b013e31804b40bb
   Peng L, 2018, AM J GASTROENTEROL, V113, P1788, DOI 10.1038/s41395-018-0209-2
   Poindessous V, 2003, INT J ONCOL, V23, P1347
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Qiu SL, 2017, ONCOL LETT, V14, P5540, DOI 10.3892/ol.2017.6889
   Rammelkamp CH, 1943, J CLIN INVEST, V22, P649, DOI 10.1172/JCI101437
   Rea DW, 2005, ANN ONCOL, V16, P1123, DOI 10.1093/annonc/mdi227
   Reyes-Zurita FJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146178
   Rho JR, 2009, ORG LETT, V11, P5590, DOI 10.1021/ol902223m
   Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6
   Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643
   Rougier P, 1997, J CLIN ONCOL, V15, P251, DOI 10.1200/JCO.1997.15.1.251
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Saliba F, 1998, J CLIN ONCOL, V16, P2745, DOI 10.1200/JCO.1998.16.8.2745
   Sastre J, 2003, ANTI-CANCER DRUG, V14, P543, DOI 10.1097/00001813-200308000-00006
   Sharma SH, 2018, BIOMED PHARMACOTHER, V100, P367, DOI 10.1016/j.biopha.2018.02.035
   Shen T, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/210736
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   Shi MD, 2008, CHEM-BIOL INTERACT, V174, P201, DOI 10.1016/j.cbi.2008.06.006
   Shin MS, 2017, INT J BIOL MACROMOL, V103, P1327, DOI 10.1016/j.ijbiomac.2017.05.055
   Shin SJ, 2008, CANCER CHEMOTH PHARM, V61, P75, DOI 10.1007/s00280-007-0447-2
   Shiragami R, 2013, INT J ONCOL, V43, P431, DOI 10.3892/ijo.2013.1978
   Singh R, 2008, ANTI-CANCER AGENT ME, V8, P603, DOI 10.2174/187152008785133074
   Sithara T, 2018, J AGR FOOD CHEM, V66, P602, DOI 10.1021/acs.jafc.7b04472
   Sobrero A, 2009, NAT REV CLIN ONCOL, V6, P248, DOI 10.1038/nrclinonc.2009.43
   Soontornchaiboon W, 2012, BIOL PHARM BULL, V35, P1137, DOI 10.1248/bpb.b12-00187
   Sophonnithiprasert T, 2015, INT J ONCOL, V47, P2188, DOI 10.3892/ijo.2015.3204
   Stingl JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-360
   Su CC, 2006, ANTICANCER RES, V26, P4379
   Su M, 2017, DRUG DES DEV THER, V11, P3333, DOI 10.2147/DDDT.S140354
   Sugawara T, 2007, BIOSCI BIOTECH BIOCH, V71, P1069, DOI 10.1271/bbb.60597
   Sun DD, 2018, BIOMED PHARMACOTHER, V101, P107, DOI 10.1016/j.biopha.2018.02.062
   Sun WJ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-63
   Suzuki H, 2014, BIOCHEM BIOPH RES CO, V455, P35, DOI 10.1016/j.bbrc.2014.07.007
   Tarhouni-Jabberi S, 2017, MAR DRUGS, V15, DOI 10.3390/md15070221
   Timotheadou E, 2005, TUMORI J, V91, P309, DOI 10.1177/030089160509100404
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Trisciuoglio D, 2008, J NATL CANCER I, V100, P1233, DOI 10.1093/jnci/djn239
   Tsai HL, 2017, MAR DRUGS, V15, DOI 10.3390/md15040122
   Tsai KD, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060318
   Tsutsumi N, 2011, ONCOL LETT, V2, P791, DOI 10.3892/ol.2011.336
   Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097
   Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259
   Wang WC, 2016, BIOCHEM PHARMACOL, V121, P8, DOI 10.1016/j.bcp.2016.09.024
   Wasserman E, 1999, J CLIN ONCOL, V17, P1751, DOI 10.1200/JCO.1999.17.6.1751
   Wasserman I, 2019, CLIN CANCER RES, V25, P1948, DOI 10.1158/1078-0432.CCR-18-1726
   Watson JL, 2008, EXP MOL PATHOL, V84, P230, DOI 10.1016/j.yexmp.2008.02.002
   Weidner C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152398
   Wen CY, 2015, INT J ONCOL, V47, P1663, DOI 10.3892/ijo.2015.3166
   Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594
   Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761
   Woynarowski JM, 1998, MOL PHARMACOL, V54, P770, DOI 10.1124/mol.54.5.770
   Xie S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0035-3
   Xu DG, 2015, ANAT REC, V298, P376, DOI 10.1002/ar.23045
   Xu RH, 2018, LANCET ONCOL, V19, P660, DOI 10.1016/S1470-2045(18)30140-2
   Yamamoto T, 2015, ONCOL REP, V33, P1579, DOI 10.3892/or.2015.3777
   Yamaoka Y, 2018, J GASTROENTEROL, V53, P517, DOI 10.1007/s00535-017-1382-6
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yan H, 2014, HUM EXP TOXICOL, V33, P522, DOI 10.1177/0960327113497771
   Yan H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095609
   Yang HL, 2019, J CELL PHYSIOL, V234, P10747, DOI 10.1002/jcp.27749
   Yang WS, 2019, CANCER PREV RES, V12, P283, DOI 10.1158/1940-6207.CAPR-18-0279
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Yoshida GJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0436-9
   Yu H, 2017, INT J ONCOL, V50, P161, DOI 10.3892/ijo.2016.3794
   Yuan L, 2017, J PROTEOMICS, V161, P1, DOI 10.1016/j.jprot.2017.04.005
   Yun SH, 2012, CLIN CANCER RES, V18, P5934, DOI 10.1158/1078-0432.CCR-12-0655
   Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407
   Zhang HJ, 2017, J NAT PROD, V80, P1798, DOI 10.1021/acs.jnatprod.7b00004
   Zhang LL, 2008, INFLAMM RES, V57, P388, DOI 10.1007/s00011-007-7240-x
   Zhang RW, 2014, J BIOL CHEM, V289, P6394, DOI 10.1074/jbc.M113.513960
   Zhang S, 2011, CLIN CANCER RES, V17, P4439, DOI 10.1158/1078-0432.CCR-10-3109
   Zhang XH, 2016, INT J CANCER, V139, P2232, DOI 10.1002/ijc.30293
   Zhang YL, 2017, ONCOL REP, V38, P3319, DOI 10.3892/or.2017.6042
   Zhang Y, 2014, CELL BIOCHEM BIOPHYS, V69, P303, DOI 10.1007/s12013-013-9799-x
   Zhang ZY, 2014, NUTRIENTS, V6, P2668, DOI 10.3390/nu6072668
   Zhu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056407
NR 220
TC 47
Z9 48
U1 17
U2 61
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2019
VL 117
AR 109142
DI 10.1016/j.biopha.2019.109142
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IM2EA
UT WOS:000477804500082
PM 31238258
OA gold
DA 2022-04-25
ER

PT J
AU Xiang, XC
   Tian, YH
   Hu, JN
   Xiong, R
   Bautista, M
   Deng, L
   Yue, QJ
   Li, YQ
   Kuang, W
   Li, JF
   Liu, K
   Yu, CL
   Feng, G
AF Xiang, Xiaocong
   Tian, Yunhong
   Hu, Jiani
   Xiong, Rong
   Bautista, Matthew
   Deng, Li
   Yue, Qiuju
   Li, Yuqi
   Kuang, Wei
   Li, Junfeng
   Liu, Kang
   Yu, Chunlei
   Feng, Gang
TI Fangchinoline exerts anticancer effects on colorectal cancer by inducing
   autophagy via regulation AMPK/mTOR/ULK1 pathway
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Fangchinoline; Autophagy; Apoptosis; AMPK; Colorectal cancer
ID LETHAL; MTOR
AB Autophagy has become a promising target for cancer therapy. Fangchinoline (Fan) has been shown to exert anticancer effects in some types of cancers. However, the anticancer effects on colorectal cancer (CRC) and the underlying mechanisms have never been elucidated. More specifically, regulation of autophagy in CRC by Fan has never been reported before. In the present study, Fan was found to induce apoptosis and autophagic flux in the CRC cell lines HT29 and HCT116, which was reflected by the enhanced levels of LC3-II protein and p62 degradation, and the increased formation of autophagosomes and puncta formation by LC3-II. Meanwhile, combination with the early-stage autophagy inhibitor 3-methyladenine (3-MA) but not the late-stage autophagy inhibitor chloroquine (CQ) further increased Fan-induced cell death, which suggested the cytoprotective function of autophagy induced by Fan in both HT29 and HCT116 cells. Moreover, Fan treatment demonstrated a dose- and time-dependently increase in the phosphorylation of AMPK and decrease in the phosphorylation of mammalian target of rapamycin (mTOR) and ULK1, leading to the activation of the AMPK/mTOR/ULK1 signaling pathway. Furthermore, in the HT29 xenograft model, Fan inhibited tumor growth in vivo. These results indicate that Fan inhibited CRC cell growth both in vitro and in vivo and revealed a new molecular mechanism involved in the anticancer effect of Fan on CRC, suggesting that Fan is a potent autophagy inducer and might be a promising anticancer agent.
C1 [Xiang, Xiaocong; Xiong, Rong; Deng, Li; Yue, Qiuju; Liu, Kang; Feng, Gang] Nanchong Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Inst Tissue Engn & Stem Cells,Canc Biotherapy Key, Nanchong 637000, Peoples R China.
   [Li, Yuqi; Kuang, Wei; Yu, Chunlei] North Sichuan Med Coll, Sch Pharm, Inst Mat Med, Nanchong 637000, Peoples R China.
   [Tian, Yunhong] Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Dept Gen Surg, Nanchong 637000, Peoples R China.
   [Li, Junfeng] Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Dept Cardiothorac Surg, Nanchong 637000, Peoples R China.
   [Hu, Jiani; Bautista, Matthew] Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA.
RP Feng, G (corresponding author), Nanchong Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Inst Tissue Engn & Stem Cells,Canc Biotherapy Key, Nanchong 637000, Peoples R China.; Yu, CL (corresponding author), North Sichuan Med Coll, Sch Pharm, Inst Mat Med, Nanchong 637000, Peoples R China.
EM yuchunlei@nsmc.edu.cn; fenggang@nsmc.edu.cn
OI Bautista, Matthew/0000-0002-4510-2719
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81903026]; Science and Technology Department
   of Sichuan Province Foundation [20YYJC2624]; Ministry of Education
   "Chunhui Plan" cooperative scientific research project [12]; Bureau of
   Science and Technology and Intellectual Property of Nanchong
   [19SXHZ0304, 18SXHZ0375]; Scientific Research Project of the Health
   Commission of Sichuan Province [19PJ224]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81903026) , the Science and Technology Department of Sichuan
   Province Foundation (No. 20YYJC2624) , The Ministry of Education
   "Chunhui Plan" cooperative scientific research project (No. 12) , the
   Bureau of Science and Technology and Intellectual Property of Nanchong
   (No. 19SXHZ0304 and No. 18SXHZ0375) and the Scientific Research Project
   of the Health Commission of Sichuan Province (No. 19PJ224) .
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Fontana F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020460
   Gu YP, 2020, AGEING RES REV, V59, DOI 10.1016/j.arr.2020.101036
   Guo BY, 2015, J DRUG TARGET, V23, P266, DOI 10.3109/1061186X.2014.992898
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Iachettini S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1065-0
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lee HS, 2017, TOXICOL APPL PHARM, V332, P32, DOI 10.1016/j.taap.2017.07.017
   Li T, 2020, BIOCHEM PHARMACOL, V175, DOI 10.1016/j.bcp.2020.113921
   Lin SR, 2020, BRIT J PHARMACOL, V177, P1409, DOI 10.1111/bph.14816
   Liu CG, 2018, P NATL ACAD SCI USA, V115, P13075, DOI 10.1073/pnas.1809681115
   Losier TT, 2019, AUTOPHAGY, V15, P1489, DOI 10.1080/15548627.2019.1618640
   Margeta M, 2020, ANNU REV PATHOL-MECH, V15, P261, DOI 10.1146/annurev-pathmechdis-012419-032618
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Pal R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5425
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Saitsu H, 2013, NAT GENET, V45, P445, DOI 10.1038/ng.2562
   Segala G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01948-9
   Serhan N, 2020, CANCERS, V12, DOI 10.3390/cancers12071725
   Sharif T, 2019, AUTOPHAGY, V15, P686, DOI 10.1080/15548627.2018.1548547
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170
   Sun YX, 2018, CIRCULATION, V138, P2247, DOI 10.1161/CIRCULATIONAHA.117.032821
   Tian F, 2015, INT J ONCOL, V46, P2355, DOI 10.3892/ijo.2015.2959
   Ueno T, 2017, NAT REV GASTRO HEPAT, V14, P170, DOI 10.1038/nrgastro.2016.185
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Xiang XC, 2019, ONCOL REP, V42, P2600, DOI 10.3892/or.2019.7376
   Xiang XC, 2018, CELL CYCLE, V17, P1310, DOI 10.1080/15384101.2018.1480208
   Xing ZB, 2013, PHYTOTHER RES, V27, P1790, DOI 10.1002/ptr.4936
   Yang J, 2020, EUR J MED CHEM, V186, DOI 10.1016/j.ejmech.2019.111898
   Yu C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.199
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhou XN, 2017, BIOCHEM PHARMACOL, V142, P58, DOI 10.1016/j.bcp.2017.06.133
NR 46
TC 3
Z9 3
U1 9
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR
PY 2021
VL 186
AR 114475
DI 10.1016/j.bcp.2021.114475
EA MAR 2021
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RN5UA
UT WOS:000640416200005
PM 33609560
OA hybrid
DA 2022-04-25
ER

PT J
AU Zeng, CJ
   Matsuda, K
   Jia, WH
   Chang, J
   Kweon, SS
   Xiang, YB
   Shin, AS
   Jee, SH
   Kim, DH
   Zhang, B
   Cai, QY
   Guo, XY
   Long, JR
   Wang, N
   Courtney, R
   Pan, ZZ
   Wu, C
   Takahashi, A
   Shin, MH
   Matsuo, K
   Matsuda, F
   Gao, YT
   Oh, JH
   Kim, S
   Jung, KJ
   Ahn, YO
   Ren, ZF
   Li, HL
   Wu, J
   Shi, JJ
   Wen, WQ
   Yang, G
   Li, BS
   Ji, BT
   Brenner, H
   Schoen, RE
   Kury, S
   Gruber, SB
   Schumacher, FR
   Stenzel, SL
   Casey, G
   Hopper, JL
   Jenkins, MA
   Kim, HR
   Jeong, JY
   Park, JW
   Tajima, K
   Cho, SH
   Kubo, M
   Shu, XO
   Lin, DX
   Zeng, YX
   Zheng, W
AF Zeng, Chenjie
   Matsuda, Koichi
   Jia, Wei-Hua
   Chang, Jiang
   Kweon, Sun-Seog
   Xiang, Yong-Bing
   Shin, Aesun
   Jee, Sun Ha
   Kim, Dong-Hyun
   Zhang, Ben
   Cai, Qiuyin
   Guo, Xingyi
   Long, Jirong
   Wang, Nan
   Courtney, Regina
   Pan, Zhi-Zhong
   Wu, Chen
   Takahashi, Atsushi
   Shin, Min-Ho
   Matsuo, Keitaro
   Matsuda, Fumihiko
   Gao, Yu-Tang
   Oh, Jae Hwan
   Kim, Soriul
   Jung, Keum Ji
   Ahn, Yoon-Ok
   Ren, Zefang
   Li, Hong-Lan
   Wu, Jie
   Shi, Jiajun
   Wen, Wanqing
   Yang, Gong
   Li, Bingshan
   Ji, Bu-Tian
   Brenner, Hermann
   Schoen, Robert E.
   Kuery, Sebastien
   Gruber, Stephen B.
   Schumacher, Fredrick R.
   Stenzel, Stephanie L.
   Casey, Graham
   Hopper, John L.
   Jenkins, Mark A.
   Kim, Hyeong-Rok
   Jeong, Jin-Young
   Park, Ji Won
   Tajima, Kazuo
   Cho, Sang-Hee
   Kubo, Michiaki
   Shu, Xiao-Ou
   Lin, Dongxin
   Zeng, Yi-Xin
   Zheng, Wei
CA GECCO
   Colorectal Transdisciplinary
   CCFR
TI Identification of Susceptibility Loci and Genes for Colorectal Cancer
   Risk
SO GASTROENTEROLOGY
LA English
DT Article
DE Epidemiology; Single Nucleotide Polymorphisms; Colon Cancer; eQTL
ID GENOME-WIDE ASSOCIATION; SOCS BOX; SCAN; METAANALYSIS; AUTOPHAGY;
   VARIANTS; TFEB; DYSREGULATION; RAD21; MITF
AB BACKGROUND & AIMS: Known genetic factors explain only a small fraction of genetic variation in colorectal cancer (CRC). We conducted a genome-wide association study to identify risk loci for CRC. METHODS: This discovery stage included 8027 cases and 22,577 controls of East-Asian ancestry. Promising variants were evaluated in studies including as many as 11,044 cases and 12,047 controls. Tumor-adjacent normal tissues from 188 patients were analyzed to evaluate correlations of risk variants with expression levels of nearby genes. Potential functionality of risk variants were evaluated using public genomic and epigenomic databases. RESULTS: We identified 4 loci associated with CRC risk; P values for the most significant variant in each locus ranged from 3.92 x 10(-8) to 1.24 x 10(-12): 6p21.1 (rs4711689), 8q23.3 (rs2450115, rs6469656), 10q24.3 (rs4919687), and 12p13.3 (rs11064437). We also identified 2 risk variants at loci previously associated with CRC: 10q25.2 (rs10506868) and 20q13.3 (rs6061231). These risk variants, conferring an approximate 10%-18% increase in risk per allele, are located either inside or near protein-coding genes that include transcription factor EB (lysosome biogenesis and autophagy), eukaryotic translation initiation factor 3, subunit H (initiation of translation), cytochrome P450, family 17, subfamily A, polypeptide 1 (steroidogenesis), splA/ryanodine receptor domain and SOCS box containing 2 (proteasome degradation), and ribosomal protein S2 (ribosome biogenesis). Gene expression analyses showed a significant association (P < .05) for rs4711689 with transcription factor EB, rs6469656 with eukaryotic translation initiation factor 3, subunit H, rs11064437 with splA/ryanodine receptor domain and SOCS box containing 2, and rs6061231 with ribosomal protein S2. CONCLUSIONS: We identified susceptibility loci and genes associated with CRC risk, linking CRC predisposition to steroid hormone, protein synthesis and degradation, and autophagy pathways and providing added insight into the mechanism of CRC pathogenesis.
C1 [Zeng, Chenjie; Zhang, Ben; Cai, Qiuyin; Guo, Xingyi; Long, Jirong; Wang, Nan; Courtney, Regina; Wu, Jie; Shi, Jiajun; Wen, Wanqing; Yang, Gong; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Epidemiol,Dept Med,Vanderbilt Epidemiol Ctr, Nashville, TN 37203 USA.
   [Matsuda, Koichi] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Technol, Tokyo, Japan.
   [Jia, Wei-Hua; Pan, Zhi-Zhong; Zeng, Yi-Xin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
   [Chang, Jiang; Wu, Chen; Lin, Dongxin] Chinese Acad Med Sci, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China.
   [Chang, Jiang; Wu, Chen; Lin, Dongxin] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Kweon, Sun-Seog; Shin, Min-Ho] Chonnam Natl Univ, Dept Prevent Med, Sch Med, Gwangju, South Korea.
   [Kweon, Sun-Seog] Chonnam Natl Univ, Jeonnam Reg Canc Ctr, Hwasun Hosp, Hwasun, South Korea.
   [Xiang, Yong-Bing; Gao, Yu-Tang; Li, Hong-Lan] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
   [Shin, Aesun] Natl Canc Ctr, Mol Epidemiol Branch, Goyang Si, South Korea.
   [Shin, Aesun; Ahn, Yoon-Ok] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
   [Jee, Sun Ha; Kim, Soriul; Jung, Keum Ji] Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Inst Hlth Promot, Seoul 120749, South Korea.
   [Kim, Dong-Hyun; Jeong, Jin-Young] Hallym Univ, Coll Med, Dept Social & Prevent Med, Okcheon Dong, South Korea.
   [Wang, Nan] Fourth Mil Med Univ, Tangdu Hosp, Gen Dept, Xian, Shaanxi, Peoples R China.
   [Takahashi, Atsushi; Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan.
   [Matsuo, Keitaro] Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi, Japan.
   [Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan.
   [Oh, Jae Hwan; Park, Ji Won] Natl Canc Ctr, Ctr Colorectal Canc, Goyang Si, South Korea.
   [Ren, Zefang] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China.
   [Li, Bingshan] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37203 USA.
   [Ji, Bu-Tian] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   [Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
   [Brenner, Hermann] Natl Ctr Tumor Dis NCT, Div Prevent Oncol, Heidelberg, Germany.
   [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany.
   [Brenner, Hermann] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
   [Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Med & Epidemiol, Pittsburgh, PA USA.
   [Kuery, Sebastien] CHU Nantes, Gen Med Serv, F-44035 Nantes 01, France.
   [Gruber, Stephen B.; Schumacher, Fredrick R.; Stenzel, Stephanie L.; Casey, Graham] Univ So Calif, USC Norris Comprehens Canc Ctr, Los Angeles, CA USA.
   [Hopper, John L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Jenkins, Mark A.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Kim, Hyeong-Rok] Chonnam Natl Univ, Sch Med, Dept Surg, Gwangju, South Korea.
   [Park, Ji Won] Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea.
   [Tajima, Kazuo] Mie Univ, Grad Sch Med, Dept Publ Hlth & Occupat Med, Tsu, Mie, Japan.
   [Cho, Sang-Hee] Chonnam Natl Univ, Sch Med, Dept Hematooncol, Gwangju, South Korea.
RP Zheng, W (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, 2525 West End Ave,8th Floor, Nashville, TN 37203 USA.
EM wei.zheng@vanderbilt.edu
RI Kweon, Sun-Seog/AAZ-4732-2021; Schmit, Stephanie/AAW-8980-2020; Brenner,
   Hermann/ABE-6383-2020; Schumacher, Fredrick/R-6043-2019; Brenner,
   Hermann/B-4627-2017; Hoffmeister, Michael/T-7187-2019; Gallinger,
   Steven/E-4575-2013; Shin, Aesun/E-9145-2014; Zheng, Wei/O-3351-2013;
   Jenkins, Mark/P-7803-2015; Matsuo, Keitaro/H-6758-2019; Schmit,
   Stephanie L./AAC-5916-2019; KÜRY, Sébastien/G-5971-2015; Moreno,
   Victor/A-1697-2010; Matsuda, Koichi/D-4597-2011
OI Kweon, Sun-Seog/0000-0003-2378-8550; Brenner,
   Hermann/0000-0002-6129-1572; Schumacher, Fredrick/0000-0002-3073-7463;
   Brenner, Hermann/0000-0002-6129-1572; Hoffmeister,
   Michael/0000-0002-8307-3197; Shin, Aesun/0000-0002-6426-1969; Zheng,
   Wei/0000-0003-1226-070X; Jenkins, Mark/0000-0002-8964-6160; Matsuo,
   Keitaro/0000-0003-1761-6314; Schmit, Stephanie L./0000-0001-5931-1194;
   KÜRY, Sébastien/0000-0001-5497-0465; SHI, JIAJUN/0000-0001-5194-0009;
   Harrison, Tabitha/0000-0002-4173-7530; Caan, Bette/0000-0002-5803-310X;
   Long, Jirong/0000-0002-7433-9766; Zeng, Chenjie/0000-0002-0149-5661; Wu,
   Chen/0000-0003-4954-1011; Lin, Dongxin/0000-0002-8723-8868; Moreno,
   Victor/0000-0002-2818-5487; Jung, Keum Ji/0000-0003-4993-0666; Jee, Sun
   Ha/0000-0001-9519-3068; Matsuda, Koichi/0000-0001-7292-2686
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01CA188214,
   R37CA070867, R01CA124558, P50CA095103, R01CA148667]; Vanderbilt
   University School of Medicine; Vanderbilt-Ingram Cancer Center
   [P30CA068485]; Shanghai Women's Health Study (US NIH) [R37CA070867,
   UM1CA182910]; Shanghai Men's Health Study (US NIH) [R01CA082729,
   UM1CA173640]; Shanghai Breast and Endometrial Cancer Studies (US
   NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA064277, R01CA092585]; Shanghai
   Colorectal Cancer Study 3 (US NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01CA188214,
   R37CA070867]; Guangzhou Colorectal Cancer Study (National Key Scientific
   and Technological Project) [2011ZX09307-001-04;]; Guangzhou Colorectal
   Cancer Study (National Basic Research Program) [2011CB504303]; Guangzhou
   Colorectal Cancer Study (Natural Science Foundation of China)National
   Natural Science Foundation of China (NSFC) [81072383]; Japan BioBank
   Colorectal Cancer Study (Ministry of Education, Culture, Sports, Science
   and Technology of the Japanese government)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT); Hwasun Cancer
   Epidemiology Study-Colon and Rectum Cancer (HCES-CRC) [HCRI15011-1];
   Japanese Ministry of Education, Culture, Sports, Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [17015018, 221S0001]; Korea-NCC (National
   Cancer Center) Colorectal Cancer Study (Basic Science Research Program
   through the National Research Foundation of Korea [2010-0010276,
   2013R1A1A2A10008260]; National Cancer Center Korea [0910220]; KCPS-II
   Colorectal Cancer Study (National R&D Program for Cancer Control
   [1220180]; KCPS-II Colorectal Cancer Study (Seoul RD Program) [10526];
   GECCO; CORECT; GECCO (US NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01CA137088,
   R01CA059045]; DALS (US NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA048998]; DACHS
   (German Federal Ministry of Education and Research) [BR 1704/6-1, BR
   1704/6-3, BR 1704/6-4, CH 117/1-1, 01KH0404, 01ER0814]; HPFS [P01 CA
   055075, UM1 CA167552, R01 CA137178, R01 CA151993, P50 CA127003]; NHS
   [R01 CA137178, R01 CA151993, P50 CA127003, UM1 CA186107, P01 CA87969];
   OFCCR (US NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01CA074783]; PMH (US
   NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA076366]; PHS (US NIH)
   [R01CA042182]; VITAL (US NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K05CA154337]; WHI (US
   NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HHSN268201100046C, HHSN268201100001C,
   HHSN268201100002C, HHSN268201100003C, HHSN268201100004C,
   HHSN271201100004C]; PLCO (US NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [Z01CP 010200,
   U01HG004446, U01HG 004438]; National Cancer Institute as part of the
   GAME-ON consortium (US NIH) [U19CA148107]; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA81488, P30CA014089]; National Human Genome Research Institute at
   the US NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Human Genome Research
   Institute (NHGRI) [T32HG000040]; National Institute of Environmental
   Health Sciences at the US NIH [T32ES013678]; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); US
   NIH under RFAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA-95-011]; National Cancer Institute
   grant (US NIH) [U01CA122839]; Ontario Research Fund; Canadian Institutes
   of Health ResearchCanadian Institutes of Health Research (CIHR); Cancer
   Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society
   Research Institute; Ontario Institute for Cancer Research through
   Ontario Ministry of Economic Development and Innovation; Regional
   Hospital Clinical Research Program (PHRC); Regional Council of Pays de
   la LoireRegion Pays de la Loire; Groupement des Entreprises Francaises
   dans la Lutte Contre le Cancer (GEFLUC); Association Anne de Bretagne
   Genetique; Ligue Regionale Contre le Cancer (LRCC); US NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [Z01CP 010200, U01HG004446, U01HG 004438]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [U01CA074783, U01CA097735, R01CA188214, UM1CA167551, R01CA076366,
   UM1CA167552, P30CA014089, R01CA151993, P01CA055075, R01CA148667,
   U01CA074794, Z01CP010200, U01CA074799, U01CA137088, R01CA124558,
   U01CA122839, P50CA095103, P50CA127003, UM1CA173640, U01CA074800,
   UM1CA186107, U01CA164930, U19CA148107, R01CA081488, U01CA074806,
   P30CA071789, P30CA068485, R01CA082729, P01CA087969, R37CA070867,
   UM1CA182910, R01CA042182, K05CA154337, R01CA064277, R01CA048998,
   R01CA137178, R01CA059045, R01CA092585] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Human Genome Research Institute (NHGRI) [U01HG004438,
   U01HG004446, T32HG000040] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS)
   [T32ES013678] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific
   ResearchMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [25293168] Funding Source: KAKEN
FX The work at the Vanderbilt University School of Medicine was supported
   by US National Institutes of Health grants R01CA188214, R37CA070867,
   R01CA124558, P50CA095103, and R01CA148667, as well as Ingram
   Professorship and Anne Potter Wilson Chair funds from the Vanderbilt
   University School of Medicine. The Survey and Biospecimen Shared
   Resources and Vanderbilt Microarray Shared Resource are supported in
   part by the Vanderbilt-Ingram Cancer Center (P30CA068485). Studies
   (grant support) participating in the Asia Colorectal Cancer Consortium
   include the Shanghai Women's Health Study (US NIH, R37CA070867,
   UM1CA182910), Shanghai Men's Health Study (US NIH, R01CA082729,
   UM1CA173640), Shanghai Breast and Endometrial Cancer Studies (US NIH,
   R01CA064277 and R01CA092585; contributing only controls), Shanghai
   Colorectal Cancer Study 3 (US NIH, R37CA070867, R01CA188214 and Ingram
   Professorship funds), Guangzhou Colorectal Cancer Study (National Key
   Scientific and Technological Project, 2011ZX09307-001-04; National Basic
   Research Program, 2011CB504303, contributing only controls; Natural
   Science Foundation of China, 81072383, contributing only controls),
   Japan BioBank Colorectal Cancer Study (grant from the Ministry of
   Education, Culture, Sports, Science and Technology of the Japanese
   government), Hwasun Cancer Epidemiology Study-Colon and Rectum Cancer
   (HCES-CRC; grants from Chonnam National University Hwasun Hospital,
   HCRI15011-1). The Aichi Colorectal Cancer Study (Grant-in-Aid for Cancer
   Research, grant for the Third Term Comprehensive Control Research for
   Cancer and Grants-in-Aid for Scientific Research from the Japanese
   Ministry of Education, Culture, Sports, Science and Technology, 17015018
   and 221S0001), Korea-NCC (National Cancer Center) Colorectal Cancer
   Study (Basic Science Research Program through the National Research
   Foundation of Korea, 2010-0010276 and 2013R1A1A2A10008260; National
   Cancer Center Korea, 0910220), and the KCPS-II Colorectal Cancer Study
   (National R&D Program for Cancer Control, 1220180; Seoul R&D Program,
   10526).; Participating studies (grant support) in the GECCO, CORECT, and
   CCFR GWAS meta-analysis are GECCO (US NIH, U01CA137088 and R01CA059045),
   DALS (US NIH, R01CA048998), DACHS (German Federal Ministry of Education
   and Research, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1,
   01KH0404 and 01ER0814), HPFS (P01 CA 055075, UM1 CA167552, R01 CA137178,
   R01 CA151993 and P50 CA127003), NHS (UM1 CA186107, R01 CA137178, P01
   CA87969, R01 CA151993 and P50 CA127003), OFCCR (US NIH, U01CA074783),
   PMH (US NIH, R01CA076366), PHS (US NIH, R01CA042182), VITAL (US NIH,
   K05CA154337), WHI (US NIH, HHSN268201100046C, HHSN268201100001C,
   HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and
   HHSN271201100004C), and PLCO (US NIH, Z01CP 010200, U01HG004446 and
   U01HG 004438). CORECT is supported by the National Cancer Institute as
   part of the GAME-ON consortium (US NIH, U19CA148107) with additional
   support from National Cancer Institute grants (R01CA81488 and
   P30CA014089), the National Human Genome Research Institute at the US NIH
   (T32HG000040) and the National Institute of Environmental Health
   Sciences at the US NIH (T32ES013678). CCFR is supported by the National
   Cancer Institute, US NIH under RFA CA-95-011 and through cooperative
   agreements with members of the Colon Cancer Family Registry and
   principal investigators of the Australasian Colorectal Cancer Family
   Registry (US NIH, U01CA097735), Familial Colorectal Neoplasia
   Collaborative Group (US NIH, U01CA074799) (University of Southern
   California), the Mayo Clinic Cooperative Family Registry for Colon
   Cancer Studies (US NIH, U01CA074800), Ontario Registry for Studies of
   Familial Colorectal Cancer (US NIH, U01CA074783), Seattle Colorectal
   Cancer Family Registry (US NIH, U01CA074794). and the University of
   Hawaii Colorectal Cancer Family Registry (US NIH, U01CA074806). The GWAS
   work was supported by a National Cancer Institute grant (US NIH,
   U01CA122839). OFCCR was supported by a GL2 grant from the Ontario
   Research Fund, Canadian Institutes of Health Research and a Cancer Risk
   Evaluation (CaRE) Program grant from the Canadian Cancer Society
   Research Institute. T.J. Hudson and B.W. Zanke are recipients of Senior
   Investigator Awards from the Ontario Institute for Cancer Research,
   through support from the Ontario Ministry of Economic Development and
   Innovation. ASTERISK was funded by a Regional Hospital Clinical Research
   Program (PHRC) and supported by the Regional Council of Pays de la
   Loire, the Groupement des Entreprises Francaises dans la Lutte Contre le
   Cancer (GEFLUC), the Association Anne de Bretagne Genetique and the
   Ligue Regionale Contre le Cancer (LRCC). PLCO data sets were accessed
   with approval through dbGaP (CGEMS prostate cancer scan, phs000207.v1.p1
   (Yeager, M et al. Genome-wide association study of prostate cancer
   identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649);
   CGEMS pancreatic cancer scan, phs000206.v4.p3 (Amundadottir, L et al.
   Genome-wide association study identifies variants in the ABO locus
   associated with susceptibility to pancreatic cancer. Nat Genet
   2009;41:986-990, and Petersen, GM et al. A genome-wide association study
   identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1,
   1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228); and GWAS of Lung
   Cancer and Smoking, phs000093.v2.p2 (Landi MT, et al. A genome-wide
   association study of lung cancer identifies a region of chromosome 5p15
   associated with risk for adenocarcinoma. Am J Hum Genet
   2009;85:679-691), which was funded by Z01CP 010200, U01HG004446 and
   U01HG 004438 from the US NIH).
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Al-Tassan NA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10442
   Andolfo I, 2010, HAEMATOL-HEMATOL J, V95, P1244, DOI 10.3324/haematol.2009.020685
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364
   Carvajal-Carmona LG, 2011, HUM MOL GENET, V20, P2879, DOI 10.1093/hmg/ddr190
   Davis IJ, 2006, CANCER CELL, V9, P473, DOI 10.1016/j.ccr.2006.04.021
   Dunlop MG, 2012, NAT GENET, V44, P770, DOI 10.1038/ng.2293
   Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896
   Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41
   Janakiram NB, 2012, FUTURE MED CHEM, V4, P2193, DOI [10.4155/FMC.12.168, 10.4155/fmc.12.168]
   Jia WH, 2013, NAT GENET, V45, P191, DOI 10.1038/ng.2505
   Jovanovic M, 2015, SCIENCE, V347, DOI 10.1126/science.1259038
   Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Kuang ZH, 2010, J CELL BIOL, V190, P129, DOI 10.1083/jcb.200912087
   Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lemire M, 2015, HUM GENET, V134, P1249, DOI 10.1007/s00439-015-1598-6
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lin JH, 2010, JNCI-J NATL CANCER I, V102, P1746, DOI 10.1093/jnci/djq444
   Lin YS, 2009, DRUG METAB DISPOS, V37, P1295, DOI 10.1124/dmd.108.025213
   Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6
   Ma XY, 2014, GUT, V63, P326, DOI 10.1136/gutjnl-2012-304121
   Mahmood SF, 2014, CARCINOGENESIS, V35, P670, DOI 10.1093/carcin/bgt351
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Ongen H, 2014, NATURE, V512, P87, DOI 10.1038/nature13602
   Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257
   Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705
   Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020
   Pittman AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001126
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Romanoski CE, 2015, NATURE, V518, P314, DOI 10.1038/518314a
   Schumacher FR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8138
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   Tomlinson IPM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002105
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5613
   Whiffin N, 2014, HUM MOL GENET, V23, P4729, DOI 10.1093/hmg/ddu177
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Xu H, 2014, CELL REP, V9, P1781, DOI 10.1016/j.celrep.2014.10.059
   Xu J, 2013, MOL BIOL REP, V40, P5085, DOI 10.1007/s11033-013-2609-0
   Yao L, 2010, BREAST CANCER RES TR, V122, P221, DOI 10.1007/s10549-009-0679-4
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
   Zhang B, 2014, NAT GENET, V46, P533, DOI 10.1038/ng.2985
   Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253
   Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200
NR 59
TC 61
Z9 63
U1 0
U2 20
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2016
VL 150
IS 7
BP 1633
EP 1645
DI 10.1053/j.gastro.2016.02.076
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DN0TW
UT WOS:000376778800035
PM 26965516
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Greene, LM
   Wang, S
   O'Boyle, NM
   Bright, SA
   Reid, JE
   Kelly, P
   Meegan, MJ
   Zisterer, DM
AF Greene, Lisa M.
   Wang, Shu
   O'Boyle, Niamh M.
   Bright, Sandra A.
   Reid, Jane E.
   Kelly, Patrick
   Meegan, Mary J.
   Zisterer, Daniela M.
TI Combretazet-3 a novel synthetic cis-stable combretastatin
   A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy
   in colon cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE combretastatin A-4; azetidinone (beta-lactam); colon cancer
ID TARGETING AGENT COMBRETASTATIN-A4; VASCULAR DISRUPTING AGENTS;
   BETA-LACTAM ANALOG; MULTIDRUG-RESISTANCE; SOLID TUMORS; A-4; CELLS;
   DERIVATIVES; PHOSPHATE; AUTOPHAGY
AB In recent years an extensive series of synthetic combretastatin A-4 (CA-4)-azetidinone (beta-lactam) hybrids were designed and synthesised with a view to improve the stability, therapeutic efficacy and aqueous solubility of CA-4. Lead compounds containing a 3,4,5-trimethoxy aromatic ring at position 1 and a variety of substitution patterns at positions 3 and 4 of the beta-lactam ring were screened in three adenocarcinoma-derived colon cancer cell lines (CT-26, Caco-2 and the CA-4 resistant cell line, HT-29). In both CT-26 and Caco-2 cells all P-lactam analogues analysed displayed potent therapeutic efficacy within the nanomolar range. Substitution of the ethylene bridge of CA-4 with the beta-lactam ring together with the aforementioned aryl substitutions improved the therapeutic efficacy of CA-4 up to 300-fold in the combretastatin refractory HT-29 cells. The lead compound combretazet-3 (CAZ-3); chemical name [4-(3-hydroxy-4-methoxyphenyl)-3-(4-hydroxy phenyl)-1-(3,4,5-tri methoxy phenyl)azetidin-2-one] demonstrated improved chemical stability together with enhanced therapeutic efficacy as compared with CA-4 whilst maintaining the natural biological properties of CA-4. Furthermore, CAZ-3 demonstrated significant tumour inhibition in a murine model of colon cancer. Our results suggest that combretastatin-azetidinone hybrids represent an effective novel therapy for the treatment of combretastatin resistant carcinomas.
C1 [Greene, Lisa M.; Bright, Sandra A.; Reid, Jane E.; Zisterer, Daniela M.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland.
   [Wang, Shu; O'Boyle, Niamh M.; Kelly, Patrick; Meegan, Mary J.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland.
RP Greene, LM (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, 152-160 Pearse St, Dublin 2, Ireland.
EM greeneli@tcd.ie
OI Zisterer, Daniela/0000-0001-5005-1023; Reid, Jane/0000-0002-5196-8121;
   O'Boyle, Niamh/0000-0001-5660-4944
FU Health Research Board Ireland
FX We would like to thank Health Research Board Ireland for funding the
   project. We would also like to thank Sally Lee at Cyprotex Discovery,
   Ltd., (Macclesfield, UK) for carrying out the microsomal stability
   studies.
CR Beale TM, 2010, MEDCHEMCOMM, V1, P202, DOI 10.1039/c0md00095g
   Carr M, 2010, EUR J MED CHEM, V45, P5752, DOI 10.1016/j.ejmech.2010.09.033
   Delmonte A, 2009, EXPERT OPIN INV DRUG, V18, P1541, DOI 10.1517/13543780903213697
   Dowlati A, 2002, CANCER RES, V62, P3408
   Eikesdal HP, 2000, INT J RADIAT ONCOL, V46, P645, DOI 10.1016/S0360-3016(99)00451-4
   Greene LM, 2012, BIOCHEM PHARMACOL, V84, P612, DOI 10.1016/j.bcp.2012.06.005
   Greene LM, 2011, INT J MOL MED, V27, P715, DOI 10.3892/ijmm.2011.633
   Greene LM, 2010, J PHARMACOL EXP THER, V335, P302, DOI 10.1124/jpet.110.170415
   Hinnen P, 2007, BRIT J CANCER, V96, P1159, DOI 10.1038/sj.bjc.6603694
   Lee HY, 2011, J MED CHEM, V54, P8517, DOI 10.1021/jm201031f
   Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1
   Marrelli M, 2011, CURR MED CHEM, V18, P3035, DOI 10.2174/092986711796391642
   O'Boyle NM, 2011, EUR J MED CHEM, V46, P4595, DOI 10.1016/j.ejmech.2011.07.039
   O'Boyle NM, 2011, BIOORGAN MED CHEM, V19, P2306, DOI 10.1016/j.bmc.2011.02.022
   O'Boyle NM, 2010, J MED CHEM, V53, P8569, DOI 10.1021/jm101115u
   Ohsumi K, 1998, J MED CHEM, V41, P3022, DOI 10.1021/jm980101w
   Patterson DM, 2012, CLIN CANCER RES, V18, P1415, DOI 10.1158/1078-0432.CCR-11-2414
   PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881
   Romagnoli R, 2012, J MED CHEM, V55, P475, DOI 10.1021/jm2013979
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185
   Schobert R, 2011, INT J CLIN PHARM TH, V49, P71, DOI 10.5414/CPP49071
   Shan Y, 2011, CURR MED CHEM, V18, P523, DOI 10.2174/092986711794480221
NR 23
TC 21
Z9 21
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2013
VL 29
IS 6
BP 2451
EP 2458
DI 10.3892/or.2013.2379
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 148GO
UT WOS:000319232800051
PM 23564200
OA Bronze
DA 2022-04-25
ER

PT J
AU Tang, Y
   Ren, F
   Cong, X
   Kong, Y
   Tian, YX
   Xu, YF
   Fan, JH
AF Tang, Ying
   Ren, Feng
   Cong, Xi
   Kong, Ying
   Tian, Yuxiang
   Xu, Yuefei
   Fan, Jianhui
TI Overexpression of ribonuclease inhibitor induces autophagy in human
   colorectal cancer cells via the Akt/mTOR/ULK1 pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ribonuclease inhibitor; colorectal cancer; autophagy; signal pathway
ID TO-MESENCHYMAL TRANSITION; SIGNALING PATHWAY; PROTEIN; PHOSPHORYLATION;
   METASTASIS; STATISTICS; ANGIOGENIN; MTOR; AMPK
AB Ribonuclease inhibitor (RI), also termed angiogenin inhibitor, acts as the inhibitor of ribonucleolytic activity of RNase A and angiogenin. The expression of RI has been investigated in melanoma and bladder cancer cells. However, the precise role of RI in tumorigenesis, in addition to RI-induced autophagy, remains poorly understood. In the present study, it was demonstrated that RI positively regulated autophagy in human colorectal cancer (CRC) cells as indicated by an increase in light chain 3 (LC3)-II levels. Furthermore, RI regulated cell survival in HT29 cells. In addition, autophagy-associated proteins, including beclin-1 and autophagy-related protein 13, were increased in response to RI-induced autophagy, and the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR)/Unc-51 like autophagy activating kinase (ULK1) pathway may be involved in the activation of autophagy induced by RI overexpression. Taken together, the evidence of the present study indicated that the overexpression of RI induced ATG-dependent autophagy in CRC cells via the Akt/mTOR/ULK1 pathway, suggesting that the upregulation of RI activity may constitute a novel approach for the treatment of human colorectal carcinoma.
C1 [Tang, Ying] Dalian Med Univ, Affiliated Hosp 2, Dept Pathol, Dalian 116023, Liaoning, Peoples R China.
   [Ren, Feng; Cong, Xi; Kong, Ying; Tian, Yuxiang; Xu, Yuefei; Fan, Jianhui] Dalian Med Univ, Dept Biochem & Mol Biol, 9 Sout Lvshun Rd Western Sect, Dalian 116044, Liaoning, Peoples R China.
RP Fan, JH (corresponding author), Dalian Med Univ, Dept Biochem & Mol Biol, 9 Sout Lvshun Rd Western Sect, Dalian 116044, Liaoning, Peoples R China.
EM fanjh@dlmedu.edu.cn
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31400687]
FX This study was supported by a grant from the National Science Foundation
   of China (grant no. 31400687).
CR Carroll RG, 2013, CANCER CELL, V23, P425, DOI 10.1016/j.ccr.2013.04.001
   Chen JX, 2005, INT J BIOCHEM CELL B, V37, P1219, DOI 10.1016/j.biocel.2004.11.020
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Ciombor KK, 2015, ANNU REV MED, V66, P83, DOI 10.1146/annurev-med-051513-102539
   Datta D, 2013, BIOORGAN MED CHEM, V21, P4634, DOI 10.1016/j.bmc.2013.05.047
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1
   Dickson KA, 2009, BIOCHEMISTRY-US, V48, P3804, DOI 10.1021/bi9005094
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Han K, 2015, HELIYON, V1, DOI 10.1016/j.heliyon.2015.e00027
   Ji S, 2017, J CANCER, V8, P555, DOI 10.7150/jca.17205
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lin Y, 2017, MOL MED REP, V16, P4113, DOI 10.3892/mmr.2017.7114
   Liu JL, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-75
   Liu MH, 2018, INT J ONCOL, V53, P1363, DOI 10.3892/ijo.2018.4465
   McEwan PA, 2006, J STRUCT BIOL, V155, P294, DOI 10.1016/j.jsb.2006.01.016
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Pan XY, 2012, INT J BIOCHEM CELL B, V44, P998, DOI 10.1016/j.biocel.2012.03.008
   Peng Y, 2014, CELL SIGNAL, V26, P2782, DOI 10.1016/j.cellsig.2014.08.021
   Pizzo E, 2013, J CELL SCI, V126, P4308, DOI 10.1242/jcs.134551
   Qi SQ, 2015, STRUCTURE, V23, P1848, DOI 10.1016/j.str.2015.07.011
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tang Y, 2015, CLIN TRANSL ONCOL, V17, P306, DOI 10.1007/s12094-014-1228-0
   Tian Yu-Xiang, 2004, Ai Zheng, V23, P269
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
   Yao X, 2013, CELL TISSUE RES, V353, P409, DOI 10.1007/s00441-013-1638-2
   Young PG, 2019, AUTOPHAGY, V15, P941, DOI 10.1080/15548627.2019.1569915
   Zhou Ji-hong, 2012, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V28, P260
   Zhou XN, 2017, BIOCHEM PHARMACOL, V142, P58, DOI 10.1016/j.bcp.2017.06.133
   Zhuang X, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0408-x
NR 42
TC 3
Z9 3
U1 3
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2019
VL 19
IS 5
BP 3519
EP 3526
DI 10.3892/mmr.2019.10030
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HV3DH
UT WOS:000465868800016
PM 30896869
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Le, YC
   Zhang, SL
   Ni, JH
   You, Y
   Luo, KJ
   Yu, YQ
   Shen, XY
AF Le, Yunchen
   Zhang, Sulin
   Ni, Jiahui
   You, Yan
   Luo, Kejing
   Yu, Yunqiu
   Shen, Xiaoyan
TI Sorting nexin 10 controls mTOR activation through regulating amino-acid
   metabolism in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID CHAPERONE-MEDIATED AUTOPHAGY; TUMOR-SUPPRESSOR; METABOLOMICS; DISEASE;
   TARGET; LAMP2A; DEGRADATION; SUFFICIENCY; PROGRESSION; MECHANISMS
AB Amino-acid metabolism plays a vital role in mammalian target of rapamycin (mTOR) signaling, which is the pivot in colorectal cancer (CRC). Upregulated chaperone-mediated autophagy (CMA) activity contributes to the regulation of metabolism in cancer cells. Previously, we found that sorting nexin 10 (SNX10) is a critical regulator in CMA activation. Here we investigated the role of SNX10 in regulating amino-acid metabolism and mTOR signaling pathway activation, as well as the impact on the tumor progression of mouse CRC. Our results showed that SNX10 deficiency promoted colorectal tumorigenesis in male FVB mice and CRC cell proliferation and survival. Metabolic pathway analysis of gas chromatography-mass spectrometry (GC-MS) data revealed unique changes of amino-acid metabolism by SNX10 deficiency. In HCT116 cells, SNX10 knockout resulted in the increase of CMA and mTOR activation, which could be abolished by chloroquine treatment or reversed by SNX10 overexpression. By small RNA interference (siRNA), we found that the activation of mTOR was dependent on lysosomal-associated membrane protein type-2A (LAMP-2A), which is a limiting factor of CMA. Similar results were also found in Caco-2 and SW480 cells. Ultra-high-performance liquid chromatography-quadrupole time of flight (UHPLC-QTOF) and GC-MS-based untargeted metabolomics revealed that 10 amino-acid metabolism in SNX10-deficient cells were significantly upregulated, which could be restored by LAMP-2A siRNA. All of these amino acids were previously reported to be involved in mTOR activation. In conclusion, this work revealed that SNX10 controls mTOR activation through regulating CMA-dependent amino-acid metabolism, which provides potential target and strategy for treating CRC.
C1 [Le, Yunchen; Zhang, Sulin; Ni, Jiahui; You, Yan; Luo, Kejing; Yu, Yunqiu; Shen, Xiaoyan] Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China.
RP Yu, YQ; Shen, XY (corresponding author), Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China.
EM yqyu@shmu.edu.cn; shxiaoy@fudan.edu.cn
OI Le, Yunchen/0000-0003-4440-5854
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773744, 81573441]
FX This study was funded by National Natural Science Foundation of China
   (No. 81773744 and 81573441).
CR Abu-Remaileh M, 2017, SCIENCE, V358, P807, DOI 10.1126/science.aan6298
   American Cancer Society, 2015, CANC FACTS FIG
   Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003
   Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Chava S, 2017, ONCOTARGET, V8, P40019, DOI 10.18632/oncotarget.16685
   Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Cuervo AM, 2010, TRENDS ENDOCRIN MET, V21, P142, DOI 10.1016/j.tem.2009.10.003
   Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374
   Ding ZB, 2016, INT J ONCOL, V49, P2367, DOI 10.3892/ijo.2016.3754
   Dyachok J, 2016, J BIOL CHEM, V291, P22414, DOI 10.1074/jbc.M116.732511
   Ekstrand AI, 2010, FAM CANCER, V9, P125, DOI 10.1007/s10689-009-9293-1
   Farshidfar F, 2016, BRIT J CANCER, V115, P848, DOI 10.1038/bjc.2016.243
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Goedert JJ, 2014, CARCINOGENESIS, V35, P2089, DOI 10.1093/carcin/bgu131
   Han Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04994-x
   Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004
   Kim A, 2013, INT J CANCER, V133, P984, DOI 10.1002/ijc.28073
   Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123
   Li WM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01609-x
   Loos B, 2017, PROG NEUROBIOL, V156, P90, DOI 10.1016/j.pneurobio.2017.05.001
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013
   Massey A, 2004, INT J BIOCHEM CELL B, V36, P2420, DOI 10.1016/j.biocel.2004.04.010
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P89, DOI 10.1016/j.semcancer.2014.05.004
   Nappi A, 2018, CURR CANCER DRUG TAR, V18, P421, DOI 10.2174/1568009617666170209095143
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Seyfried TN, 2014, CARCINOGENESIS, V35, P515, DOI 10.1093/carcin/bgt480
   Suzuki J, 2017, BIOCHEM BIOPH RES CO, V482, P1334, DOI 10.1016/j.bbrc.2016.12.037
   Tang Y, 2017, ONCOTARGET, V8, P51970, DOI 10.18632/oncotarget.17583
   Tasset I, 2016, FEBS J, V283, P2403, DOI 10.1111/febs.13677
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Uchiyama K, 2017, J GASTROENTEROL, V52, P677, DOI 10.1007/s00535-016-1261-6
   Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132
   Weijenberg Matty P, 2013, Curr Nutr Rep, V2, P19
   Williams C, 2016, CANCER LETT, V372, P48, DOI 10.1016/j.canlet.2015.12.009
   Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32
   Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674
   Xilouri M, 2013, AUTOPHAGY, V9, P2166, DOI 10.4161/auto.26451
   You Y, 2018, J HEPATOL, V69, P129, DOI 10.1016/j.jhep.2018.01.038
   Zhang SL, 2018, CANCER LETT, V419, P116, DOI 10.1016/j.canlet.2018.01.045
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
   Zhou C, 2013, NEUROSCIENCE, V254, P361, DOI 10.1016/j.neuroscience.2013.09.045
   Zhou DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009
   Zhou J, 2017, AGING-US, V9, P583, DOI 10.18632/aging.101181
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 56
TC 12
Z9 13
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 4
PY 2018
VL 9
AR 666
DI 10.1038/s41419-018-0719-2
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GH9XW
UT WOS:000434024500002
PM 29867114
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chiacchiera, F
   Simone, C
AF Chiacchiera, Fulvio
   Simone, Cristiano
TI Signal-dependent regulation of gene expression as a target for cancer
   treatment: Inhibiting p38 alpha in colorectal tumors
SO CANCER LETTERS
LA English
DT Review
DE colorectal cancer; chromatin-associated kinase; p38; signal-dependent
   gene expression; autophagy
ID ACTIVATED PROTEIN-KINASE; AUTOPHAGIC CELL-DEATH; MALIGNANT GLIOMA-CELLS;
   NITRIC-OXIDE; HOG1 KINASE; CYCLIN-E; P38; TRANSCRIPTION; COMPLEX;
   MUTATIONS
AB In the last year, several evidences indicated that pharmacological manipulation of relevant signaling pathways could selectively affect gene expression to influence cell fate. These findings render of extreme importance the elucidation of how external stimuli are transduced to mediate chromatin modifications, resulting in a permissive or repressive environment for gene expression. These signaling cascades activate or repress the function of chromatin binding proteins that represent attractive pharmacological targets for human diseases. Actually, the closer the target is to chromatin, the more the transcriptional effect will be selective. Recent studies suggest that pharmacological manipulation of signaling pathways to modulate cell fate is indeed possible and that chromatin-associated kinases could represent an optimal target. The p38 MAPK is the prototype of this class of enzymes and its central role in the transcription process is evolutionary conserved. In this review we will focus on the possibility to inhibit p38 alpha in colorectal cancer to arrest tumor progression and induce autophagic cell death. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Chiacchiera, Fulvio; Simone, Cristiano] Consorzio Mario Negri Sud, Lab Signaldependent Transcript, DTP, I-66030 Santa Maria Imbaro, Chieti, Italy.
RP Simone, C (corresponding author), Consorzio Mario Negri Sud, Lab Signaldependent Transcript, DTP, Via Nazl 8-A, I-66030 Santa Maria Imbaro, Chieti, Italy.
EM simone@negrisud.it
RI Chiacchiera, Fulvio/ABD-6137-2020; Simone, Cristiano/K-3452-2018;
   Chiacchiera, Fulvio/K-6740-2016
OI Simone, Cristiano/0000-0002-2628-7658; Chiacchiera,
   Fulvio/0000-0003-3830-2090
FU Associazione Italiana per la Ricerca sul CancroFondazione AIRC per la
   ricerca sul cancro Funding Source: Custom
CR Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243
   Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0
   Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Boyle P, 2005, NAT CLIN PRACT ONCOL, V2, P424, DOI 10.1038/ncponc0288
   Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chow CW, 2006, CELL, V127, P887, DOI 10.1016/j.cell.2006.11.015
   Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192
   Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Compton CC, 2004, CA-CANCER J CLIN, V54, P295, DOI 10.3322/canjclin.54.6.295
   Corin I, 2006, CANCER BIOL THER, V5, P198, DOI 10.4161/cbt.5.2.2356
   Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Demarchi F, 2006, J CELL BIOL, V175, P595, DOI 10.1083/jcb.200601024
   Dunker N, 2002, GASTROENTEROLOGY, V122, P1364, DOI 10.1053/gast.2002.32991
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104
   Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5
   Forcales SV, 2005, SEMIN CELL DEV BIOL, V16, P596, DOI 10.1016/j.semcdb.2005.07.005
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283
   HACKER H, 2006, SCI STKE, P13, DOI DOI 10.1126/STKE.3572006RE13
   Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691
   HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524
   Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086
   Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Klebig C, 2005, CANCER RES, V65, P394
   Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin ZS, 2004, MOL CELL PROTEOMICS, V3, P820, DOI 10.1074/mcp.M400008-MCP200
   Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528
   Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899
   Montera M, 2000, J Med Genet, V37, pE7, DOI 10.1136/jmg.37.7.e7
   Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646
   Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Petak I, 2003, CELL DEATH DIFFER, V10, P211, DOI 10.1038/sj.cdd.4401132
   Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
   PETRELLI N, 1989, J CLIN ONCOL, V7, P1419, DOI 10.1200/JCO.1989.7.10.1419
   Prakash J, 2006, J PHARMACOL EXP THER, V319, P8, DOI 10.1124/jpet.106.106054
   Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9
   Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Resta N, 2002, Hum Mutat, V20, P78, DOI 10.1002/humu.9046
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310
   Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009
   Serra C, 2007, MOL CELL, V28, P200, DOI 10.1016/j.molcel.2007.08.021
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Simone C, 2007, CELL DEATH DIFFER, V14, P192, DOI 10.1038/sj.cdd.4402008
   Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514
   Simone C, 2002, J CLIN PATHOL-MOL PA, V55, P200, DOI 10.1136/mp.55.3.200
   Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   van den Brink GR, 2007, CANCER CELL, V11, P109, DOI 10.1016/j.ccr.2007.01.003
   van den Brink GR, 2006, GUT, V55, P912, DOI 10.1136/gut.2005.085902
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang SH, 1999, MOL CELL BIOL, V19, P4028
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   ZHANG ZG, 1992, SEMIN ONCOL, V19, P10
   Zhao M, 1999, MOL CELL BIOL, V19, P21
NR 100
TC 36
Z9 37
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 28
PY 2008
VL 265
IS 1
BP 16
EP 26
DI 10.1016/j.canlet.2008.02.061
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 313GX
UT WOS:000256730200002
PM 18395970
DA 2022-04-25
ER

PT J
AU Li, YF
   Shi, LJ
   Wang, P
   Wang, JW
   Shi, GY
   Lee, SC
AF Li, Yuan Fei
   Shi, Lin Jie
   Wang, Pu
   Wang, Jia Wen
   Shi, Guang Yi
   Lee, Shao Chin
TI Binding between ROCK1 and DCTN2 triggers diabetes-associated centrosome
   amplification in colon cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE centrosome amplification; type 2 diabetes; Rho-associated protein kinase
   1; dynactin subunit 2; colon cancer cells; functional proteomics
ID DNA-DAMAGE; COLORECTAL-CANCER; PROGNOSTIC VALUE; EXPRESSION;
   TUMORIGENESIS; AUTOPHAGY; PHASE; ROS
AB Type 2 diabetes increases the risk various types of cancer and is associated with a poor prognosis therein. There is also evidence that the disease is associated with cancer metastasis. Centrosome amplification can initiate tumorigenesis with metastasis in vivo and increase the invasiveness of cancer cells in vitro. Our previous study reported that type 2 diabetes promotes centrosome amplification via the upregulation and centrosomal translocation of Rho-associated protein kinase 1 (ROCK1), which suggests that centrosome amplification is a candidate biological link between type 2 diabetes and cancer development. In the present study, functional proteomics analysis was used to further investigate the molecular pathways underlying centrosome amplification by targeting ROCK1 binding partners. High glucose, insulin and palmitic acid were used to induce centrosome amplification, and immunofluorescent staining was employed to visualize centrosomal alterations. Combined with immunoprecipitation, mass spectrometry-based proteomics analysis was used to identify ROCK1 binding proteins, and protein complex disruption was achieved by siRNA-knockdown. In total, 1,148 ROCK1 binding proteins were identified, among which 106 proteins were exclusively associated with the treated samples, 193 were only associated with the control samples, and 849 were found in both the control and treated samples. Of the proteins with evidence of centrosomal localization, Dynactin subunit 2 (DCTN2) was confirmed to be localized to the centrosomes. Treating the cells with high glucose, insulin and palmitic acid increased the protein levels of ROCK1 and DCTN2, promoted their binding with each other, and triggered centrosome amplification. Disruption of the protein complex by knocking down ROCK1 or DCTN2 expression partially attenuated centrosome amplification, while simultaneous knockdown of both proteins completely inhibited centrosome amplification. These results suggested ROCK1-DCTN2 binding as a signal for the regulation of centrosome homeostasis, which is key for diabetes-associated centrosome amplification, and enriches our knowledge of centrosome biology. Therefore, the ROCK1-DCTN2 complex may serve as a target for inhibiting centrosome amplification both in research or future therapeutic development.
C1 [Li, Yuan Fei; Shi, Lin Jie] Shanxi Med Univ, First Hosp, Dept Oncol, 85 Jiefang South Rd, Taiyuan 030001, Shanxi, Peoples R China.
   [Shi, Lin Jie] Shaanxi Prov Canc Hosp, Intens Care Unit, Xian 710000, Shaanxi, Peoples R China.
   [Wang, Pu] Changzhi Med Univ, Changzhi 030001, Shanxi, Peoples R China.
   [Wang, Jia Wen; Shi, Guang Yi; Lee, Shao Chin] Jiangsu Normal Univ, Inst Biomed Sci, Sch Life Sci, 101 Shanghai Rd, Xuzhou 221116, Jiangsu, Peoples R China.
RP Li, YF (corresponding author), Shanxi Med Univ, First Hosp, Dept Oncol, 85 Jiefang South Rd, Taiyuan 030001, Shanxi, Peoples R China.; Lee, SC (corresponding author), Jiangsu Normal Univ, Inst Biomed Sci, Sch Life Sci, 101 Shanghai Rd, Xuzhou 221116, Jiangsu, Peoples R China.
EM liyflinda@163.com; lee_shao@hotmail.com
FU Shanxi Health Commission Research Project [09509]; Jiangsu Normal
   University [9212418102]; Department of Science and Technology of the
   Jiangsu Province [BX2019029]
FX The present study was supported by grants from the Shanxi Health
   Commission Research Project (grant no. 09509) and Jiangsu Normal
   University (grant no. 9212418102), as well as the Department of Science
   and Technology of the Jiangsu Province (grant no. BX2019029).
CR Akagi EM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-822
   Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039
   Beeharry N, 2003, MUTAT RES-FUND MOL M, V530, P27, DOI 10.1016/S0027-5107(03)00134-9
   Bommer C, 2017, LANCET DIABETES ENDO, V5, P423, DOI 10.1016/S2213-8587(17)30097-9
   Braathen GJ, 2016, ACTA NEUROL SCAND, V134, P67, DOI 10.1111/ane.12515
   Bransfield KL, 2006, MOL CARCINOGEN, V45, P157, DOI 10.1002/mc.20151
   Chan N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11777
   Chen SG, 2019, ONCOL LETT, V17, P3133, DOI 10.3892/ol.2019.9975
   D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772
   Dall TM, 2019, DIABETES CARE, V42, P1661, DOI 10.2337/dc18-1226
   Dionne LK, 2018, J CELL BIOL, V217, P2485, DOI 10.1083/jcb.201710019
   Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393
   Fan GJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9450
   Fischer U, 2008, MOL CANCER RES, V6, P576, DOI 10.1158/1541-7786.MCR-07-0283
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277
   Han X, 2016, MED SCI MONITOR, V22, P848, DOI 10.12659/MSM.895837
   Hartmann S, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00276
   He QJ, 2020, AM J PHYSIOL-CELL PH, V318, pC48, DOI 10.1152/ajpcell.00091.2019
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Landman GWD, 2008, ANTICANCER RES, V28, P1373
   Lee SC, 2015, CHINESE MED J-PEKING, V128, P1543, DOI 10.4103/0366-6999.157693
   Levine MS, 2017, DEV CELL, V40, P313, DOI 10.1016/j.devcel.2016.12.022
   Li J, 2014, J PATHOL, V234, P178, DOI 10.1002/path.4374
   Liang HL, 2019, J CELL PHYSIOL, V234, P7266, DOI 10.1002/jcp.27484
   Mahjoub MR, 2012, CURR BIOL, V22, P1628, DOI 10.1016/j.cub.2012.06.057
   Marthiens V, 2013, NAT CELL BIOL, V15, P731, DOI 10.1038/ncb2746
   Nazir Muhammad Ashraf, 2018, Open Access Maced J Med Sci, V6, P1545, DOI 10.3889/oamjms.2018.294
   Nunes P, 2013, AUTOPHAGY, V9, P550, DOI 10.4161/auto.23662
   Otto EA, 2010, NAT GENET, V42, P840, DOI 10.1038/ng.662
   Tsai NP, 2010, CELL SIGNAL, V22, P668, DOI 10.1016/j.cellsig.2009.12.001
   Wang P, 2018, CELL PHYSIOL BIOCHEM, V47, P356, DOI 10.1159/000489812
   Wang QQ, 2018, MED SCI MONITOR, V24, P3752, DOI 10.12659/MSM.910566
   Wang SJ, 2018, CANCER MANAG RES, V10, P5807, DOI 10.2147/CMAR.S183062
   World Health Organisation, 2018, FACT SHEETS
   Xu M, 2014, J CELL MOL MED, V18, P2165, DOI 10.1111/jcmm.12326
   Zhang YP, 2017, ANN HEMATOL, V96, P1485, DOI 10.1007/s00277-017-3047-1
   Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151
   Zhu B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176068
   Zucchini C, 2015, PATHOBIOLOGY, V82, P252, DOI 10.1159/000439405
NR 40
TC 0
Z9 0
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2021
VL 46
IS 1
AR 151
DI 10.3892/or.2021.8102
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SO5QV
UT WOS:000659027600001
PM 34080666
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU El-Gowily, AH
   Abosheasha, MA
AF El-Gowily, Afnan H.
   Abosheasha, Mohammed A.
TI Differential mechanisms of autophagy in cancer stem cells: Emphasizing
   gastrointestinal cancers
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Review
DE autophagy; gastrointestinal cancer; stem cells; tumour microenvironment
ID TARGETING NOTCH; SELF-RENEWAL; TUMOR-GROWTH; COLON-CANCER; THERAPEUTIC
   TARGET; EMERGING ROLE; SOLID TUMORS; PROMOTES; SURVIVAL; HEDGEHOG
AB Gastrointestinal (GI) cancers are one of the most common forms of malignancies and still are the most important cause of cancer-related mortality worldwide. Autophagy is a conserved catabolic pathway involving lysosomal degradation and recycling of whole cellular components, which is essential for cellular homeostasis. For instance, it acts as a pivotal intracellular quality control and repair mechanism but also implicated in cell reformation during cell differentiation and development. Indeed, GI cancer stem cells (CSCs) are thought to be responsible for tumour initiation, traditional therapies resistance, metastasis and tumour recurrence. Molecular mechanisms of autophagy in normal vs CSCs gain great interest worldwide. Here, we shed light on the role of autophagy in normal stem cells differentiation for embryonic progression and its role in maintaining the activity and self-renewal capacity of CSCs which offer novel viewpoints on promising cancer therapeutic strategies based on the differential roles of autophagy in CSCs.
C1 [El-Gowily, Afnan H.] Tanta Univ, Fac Sci, Dept Chem, Biochem Div, Tanta, Egypt.
   [El-Gowily, Afnan H.] Juntendo Univ, Organ & Cell Physiol Dept, Tokyo, Japan.
   [Abosheasha, Mohammed A.] Tokyo Metropolitan Univ, Grad Sch Sci, Cellular Genet Lab, Tokyo 1920397, Japan.
RP Abosheasha, MA (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Cellular Genet Lab, Tokyo 1920397, Japan.
EM mohammed-abosheasha@ed.tmu.ac.jp
RI El-Gowily, Afnan Hamdy/AAT-5472-2021; Gowily, Afnan Hamdy
   El/AAT-5497-2021; Abosheasha, Mohammed A./AAK-1682-2021
OI Gowily, Afnan Hamdy El/0000-0001-5290-7278; Abosheasha, Mohammed
   A./0000-0002-8866-0040
CR Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Balistreri CR, 2016, AGEING RES REV, V29, P50, DOI 10.1016/j.arr.2016.06.004
   Banreti A, 2013, AUTOPHAGY, V9, P819, DOI 10.4161/auto.23908
   Bao B, 2012, BBA-REV CANCER, V1826, P272, DOI 10.1016/j.bbcan.2012.04.008
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1
   Bischof J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692227
   Bissa B, 2018, CURR BIOL, V28, pR347, DOI 10.1016/j.cub.2018.03.015
   Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740
   Boya P, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146506
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chandrakesan P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0594-y
   Chen LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05911
   Chen T, 2012, CELL RES, V22, P248, DOI 10.1038/cr.2011.109
   Chhabra R, 2014, TUMOR BIOL, V35, P8395, DOI 10.1007/s13277-014-2264-7
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576
   Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767
   DeRenzo C, 2004, TRENDS CELL BIOL, V14, P420, DOI 10.1016/j.tcb.2004.07.005
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Dotse E, 2016, CYTOTECHNOLOGY, V68, P609, DOI 10.1007/s10616-014-9806-0
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Endo S, 2017, PANCREATOLOGY, V17, P990, DOI 10.1016/j.pan.2017.08.009
   Fesler A, 2017, EPIGENOMICS-UK, V9, P793, DOI 10.2217/epi-2017-0041
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Garcia-Prat L, 2017, CELL STEM CELL, V20, P593, DOI 10.1016/j.stem.2017.04.011
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Garvalov BK, 2011, J MOL MED, V89, P95, DOI 10.1007/s00109-010-0685-3
   Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086
   Han YY, 2018, INT J ONCOL, V52, P1057, DOI 10.3892/ijo.2018.4270
   Haraguchi N, 2013, INT J ONCOL, V43, P425, DOI 10.3892/ijo.2013.1955
   Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Hwang I, 2018, AGING CELL, V17, DOI 10.1111/acel.12701
   Hwang SH, 2019, BIOCHEM BIOPH RES CO, V508, P308, DOI 10.1016/j.bbrc.2018.11.139
   Ishiwata T, 2018, PATHOL ONCOL RES, V24, P797, DOI 10.1007/s12253-018-0420-x
   Jonchere Barbara, 2013, JAKSTAT, V2, pe24353, DOI 10.4161/jkst.24353
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037
   Kim WT, 2017, BMB REP, V50, P285, DOI 10.5483/BMBRep.2017.50.6.039
   Kruta M, 2018, CELL STEM CELL, V22, P281, DOI 10.1016/j.stem.2018.02.008
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lee DY, 2015, EXP NEUROBIOL, V24, P177, DOI 10.5607/en.2015.24.3.177
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li J, 2017, ONCOGENE, V36, P6725, DOI 10.1038/onc.2017.272
   Li J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2050-6
   Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162
   Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347
   Liu N, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-23
   Liu XW, 2010, PHARMACOL RES, V62, P416, DOI 10.1016/j.phrs.2010.07.002
   Liu Z, 2014, NEOPLASMA, V61, P177, DOI 10.4149/neo_2014_016
   Lu C, 2016, ONCOL REP, V35, P3559, DOI 10.3892/or.2016.4753
   Lu J, 2016, ONCOL LETT, V12, P3, DOI 10.3892/ol.2016.4609
   Matsui WH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004765
   Menendez JA, 2011, CELL CYCLE, V10, P3658, DOI 10.4161/cc.10.21.18128
   Mikhail Sameh, 2014, World J Stem Cells, V6, P606, DOI 10.4252/wjsc.v6.i5.606
   Milla LA, 2012, BIOL RES, V45, P223, DOI 10.4067/S0716-97602012000300004
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Moulis M, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100149
   Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Nosrati Anahita, 2016, Gastroenterol Hepatol Bed Bench, V9, P132
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Offei EB, 2018, HISTOCHEM CELL BIOL, V150, P721, DOI 10.1007/s00418-018-1751-0
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Ozeki N, 2017, EXP CELL RES, V352, P63, DOI 10.1016/j.yexcr.2017.01.018
   Pan TH, 2017, INT J MOL MED, V39, P9, DOI 10.3892/ijmm.2016.2815
   Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001
   Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002
   Pellegrinet L, 2011, GASTROENTEROLOGY, V140, P1230, DOI 10.1053/j.gastro.2011.01.005
   Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Pierzynowska K, 2018, METAB BRAIN DIS, V33, P989, DOI 10.1007/s11011-018-0214-6
   Ralaidovy AH, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0157-0
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rountree CB, 2008, HEPATOLOGY, V47, P1288, DOI 10.1002/hep.22141
   Sato A, 2014, STEM CELL RES, V12, P119, DOI 10.1016/j.scr.2013.09.012
   Sato F, 2015, CANCER BIOL THER, V16, P933, DOI 10.1080/15384047.2015.1040959
   Scoville DH, 2008, GASTROENTEROLOGY, V134, P849, DOI 10.1053/j.gastro.2008.01.079
   Shyh-Chang N, 2017, GENE DEV, V31, P336, DOI 10.1101/gad.293167.116
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Sotthibundhu A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0425-x
   Sousa-Victor P, 2018, INT J DEV BIOL, V62, P583, DOI 10.1387/ijdb.180041pm
   Spivak-Kroizman TR, 2013, CANCER RES, V73, P3235, DOI 10.1158/0008-5472.CAN-11-1433
   Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Taniguchi H, 2016, CANCER SCI, V107, P1556, DOI 10.1111/cas.13069
   Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Tsukamoto S, 2018, J REPROD DEVELOP, V64, P217, DOI 10.1262/jrd.2018-039
   Tsukamoto S, 2008, AUTOPHAGY, V4, P1076, DOI 10.4161/auto.7065
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang D, 2017, SEMIN CANCER BIOL, V44, P60, DOI 10.1016/j.semcancer.2017.03.010
   Wang S, 2015, CELL MOL LIFE SCI, V72, P1699, DOI 10.1007/s00018-014-1829-3
   Wang ZW, 2011, ANTICANCER RES, V31, P1105
   Wei Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1012789
   Wesselborg S, 2015, CELL MOL LIFE SCI, V72, P4721, DOI 10.1007/s00018-015-2034-8
   Wiener Z, 2014, CELL REP, V8, P1943, DOI 10.1016/j.celrep.2014.08.034
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Willet SG, 2018, EMBO J, V37, DOI 10.15252/embj.201798311
   Wu XT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10533
   Xu YH, 2014, ONCOL REP, V31, P707, DOI 10.3892/or.2013.2881
   Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024
   Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013
   Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Zakeri Z, 2015, INT J DEV BIOL, V59, P11, DOI 10.1387/ijdb.150220zz
   Zeng X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082279
   Zeng ZL, 2018, STEM CELL REV REP, V14, P71, DOI 10.1007/s12015-017-9785-6
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang CJ, 2011, J CANCER RES CLIN, V137, P1679, DOI 10.1007/s00432-011-1038-5
   Zhang LJ, 2016, NEUROSCIENCE, V337, P88, DOI 10.1016/j.neuroscience.2016.09.001
   Zhu HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-119
NR 123
TC 2
Z9 2
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0263-6484
EI 1099-0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD MAR
PY 2021
VL 39
IS 2
BP 162
EP 173
DI 10.1002/cbf.3552
EA MAY 2020
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QT0WO
UT WOS:000535923500001
PM 32468609
DA 2022-04-25
ER

PT J
AU Guaman-Ortiz, LM
   Romero-Benavides, JC
   Suarez, AI
   Torres-Aguilar, S
   Castillo-Veintimilla, P
   Samaniego-Romero, J
   Ortiz-Diaz, K
   Bailon-Moscoso, N
AF Guaman-Ortiz, Luis M.
   Romero-Benavides, Juan C.
   Suarez, Alirica I.
   Torres-Aguilar, Stephania
   Castillo-Veintimilla, Paola
   Samaniego-Romero, Jimmy
   Ortiz-Diaz, Kevin
   Bailon-Moscoso, Natalia
TI Cytotoxic Property of Grias neuberthii Extract on Human Colon Cancer
   Cells: A Crucial Role of Autophagy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID MOLECULAR-MECHANISMS; MEDICINAL-PLANTS; DEATH; DERIVATIVES; LUPEOL; P62
AB Traditional herbal medicine has become an important alternative in the treatment of various cancer types, including colon cancer, which represents one of the main health problems around the world. Therefore, the search for new therapies to counteract this disease is very active. Grias neuberthii is an endemic plant located in the Ecuadorian Amazon region, which has been used in traditional medicine for its pharmacological properties, including its ability to inhibit tumor cell growth, although scientific studies are limited. We have analyzed the effect of this plant on two colon carcinoma cell lines, that is, RKO (normal p53) and SW613-B3 (mutated p53) cells. Among several extracts obtained from various parts of G. neuberthii plant, we identified the extract with the greatest cytotoxic potential, derived from the stem bark. The cytotoxic effect was similar on both cell lines, thus indicating that it is independent of the status of p53. However, significant differences were observed after the analysis of colony formation, with RKO cells being more sensitive than SW613-B3. No evidence for apoptotic markers was recorded; nevertheless, both cell lines showed signs of autophagy after the treatment, including increased Beclin-1 and LC3-II and decreased p62. Finally, three chemical compounds, possibly responsible for the effect observed in both cell lines, were identified: lupeol (1), 3 '-O-methyl ellagic acid 4-O-beta-D-rhamnopyranoside (2), and 19-alpha-hydroxy-asiatic acid monoglucoside (3).
C1 [Guaman-Ortiz, Luis M.; Torres-Aguilar, Stephania; Samaniego-Romero, Jimmy; Ortiz-Diaz, Kevin; Bailon-Moscoso, Natalia] Univ Tecn Particular Loja, Dept Ciencias Salud, Loja 1101608, Ecuador.
   [Romero-Benavides, Juan C.; Suarez, Alirica I.; Castillo-Veintimilla, Paola] Univ Tecn Particular Loja, Dept Quim & Ciencias Exactas, Loja 1101608, Ecuador.
   [Suarez, Alirica I.] Univ Cent Venezuela, Fac Farm, Caracas 1050, Venezuela.
   [Castillo-Veintimilla, Paola] Inst Nacl Invest Salud Publ LIP, Programa Nacl Abordaje Multidisciplinario Parasit, Guayaquil 3961, Ecuador.
RP Bailon-Moscoso, N (corresponding author), Univ Tecn Particular Loja, Dept Ciencias Salud, Loja 1101608, Ecuador.
EM lmguaman@utpl.edu.ec; jcromerob@utpl.edu.ec; alirica1@yahoo.es;
   sdtorres1@utpl.edu.ec; pmcastillo@utpl.edu.ec; jpsamaniego2@utpl.edu.ec;
   koortiz@utpl.edu.ec; ncbailon@utpl.edu.ec
RI Bailon-Moscoso, Natalia/Z-1548-2019; Romero-Benavides, Juan
   Carlos/Q-9855-2018
OI Romero-Benavides, Juan Carlos/0000-0003-1660-1217; Guaman Ortiz, Luis
   Miguel/0000-0003-2919-4905; Bailon Moscoso, Natalia/0000-0003-2754-1328
FU International Centre for Genetic Engineering and Biotechnology (ICGEB),
   Trieste, Italy [ECU1601 EC]; Universidad Tecnica Particular de Loja
   (UTPL), Loja, Ecuador [PROY_CCSAL_1266]
FX This work was supported by International Centre for Genetic Engineering
   and Biotechnology (ICGEB), Trieste, Italy (ECU1601 EC) and Universidad
   Tecnica Particular de Loja (UTPL), Loja, Ecuador (PROY_CCSAL_1266). The
   authors want to thank Dr. A. Ivana Scovassi for her support in the
   observations and analysis of experimental results and reviewing the
   English version.
CR Saltos RVA, 2016, ACTA AMAZON, V46, P355, DOI 10.1590/1809-4392201600305
   Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Bailon-Moscoso N, 2016, REV BRAS FARMACOGN, V26, P44, DOI 10.1016/j.bjp.2015.08.014
   Bailon-Moscoso N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136527
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Romero-Benavides JC, 2018, MED CHEM RES, V27, P834, DOI 10.1007/s00044-017-2106-4
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   CHENG DL, 1992, PHYTOCHEMISTRY, V31, P1317, DOI 10.1016/0031-9422(92)80499-5
   Cho CW, 2006, CELL BIOL TOXICOL, V22, P393, DOI 10.1007/s10565-006-0104-2
   Das AK., 2015, ESSENTIALS BOT EXTRA, P173, DOI [10.1016/B978-0-12-802325-9.00009-4, DOI 10.1016/B978-0-12-802325-9.05001-1]
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Frion-Herrera Y, 2019, FITOTERAPIA, V136, DOI 10.1016/j.fitote.2019.104173
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gomez-Sanchez R, 2016, DATA BRIEF, V7, P641, DOI 10.1016/j.dib.2016.02.085
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Jamal A.K., 2008, SCIENCE, V19, P45
   Jiang CT, 2019, TOXICOLOGY, V425, DOI 10.1016/j.tox.2019.152238
   Joppa LN, 2013, SCIENCE, V341, P1100, DOI 10.1126/science.1241706
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim OT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122630
   Kubisch J, 2013, SEMIN CANCER BIOL, V23, P252, DOI 10.1016/j.semcancer.2013.06.009
   Kwon HH, 2015, J INVEST DERMATOL, V135, P1491, DOI 10.1038/jid.2015.29
   Lee CH, 2013, INT J MOL SCI, V14, P6414, DOI 10.3390/ijms14036414
   Lee TK, 2007, CANCER RES, V67, P8800, DOI 10.1158/0008-5472.CAN-07-0801
   Luis L. M., 2012, CURRENT ENZYME INHIB, V7, P244, DOI [10.2174/157340811799860524, DOI 10.2174/157340811799860524]
   Lv JL, 2018, EXP THER MED, V16, P2309, DOI 10.3892/etm.2018.6435
   Lv X, 2019, J CELL BIOCHEM, V120, P18871, DOI 10.1002/jcb.29207
   Maiuri MC, 2019, CELL DEATH DIFFER, V26, P680, DOI 10.1038/s41418-019-0290-0
   Meeran MFN, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00892
   Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730
   Guaman-Ortiz LM, 2017, CURR GENOMICS, V18, P132, DOI 10.2174/1389202917666160803150639
   Ortiz LMG, 2015, ACTA BIOCH BIOPH SIN, V47, P824, DOI 10.1093/abbs/gmv077
   Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119
   Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207
   Saleem M, 2009, CANCER LETT, V285, P109, DOI 10.1016/j.canlet.2009.04.033
   Siddique HR, 2011, LIFE SCI, V88, P285, DOI 10.1016/j.lfs.2010.11.020
   Sierra MS, 2016, CANCER EPIDEMIOL, V44, pS11, DOI 10.1016/j.canep.2016.07.020
   Stroikin Y, 2007, BIOGERONTOLOGY, V8, P43, DOI 10.1007/s10522-006-9029-7
   Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012
   Vasquez-Ocmin P, 2018, J ETHNOPHARMACOL, V210, P372, DOI 10.1016/j.jep.2017.08.039
   Wang JZ, 2019, J IMMUNOTHER, V42, P321, DOI 10.1097/CJI.0000000000000281
   Yan XH, 2004, J ASIAN NAT PROD RES, V6, P271, DOI 10.1080/10286020310001595944
NR 43
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD APR 1
PY 2020
VL 2020
AR 1565306
DI 10.1155/2020/1565306
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA LE8GK
UT WOS:000526961900001
PM 32328120
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sun, J
   Feng, Y
   Wang, Y
   Ji, Q
   Cai, G
   Shi, L
   Wang, YY
   Huang, Y
   Zhang, J
   Li, Q
AF Sun, Jian
   Feng, Yu
   Wang, Yan
   Ji, Qing
   Cai, Gang
   Shi, Lei
   Wang, Yiyi
   Huang, Yan
   Zhang, Jue
   Li, Qi
TI alpha -hederin induces autophagic cell death in colorectal cancer cells
   through reactive oxygen species dependent AMPK/mTOR signaling pathway
   activation
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE colorectal cancer; alpha-hederin; autophagy; reactive oxygen species;
   AMP-activated protein kinase; mechanistic target of rapamycin signaling
ID INDUCED APOPTOSIS; NIGELLA-SATIVA; ANTICANCER ACTIVITY; ROS; SAPONIN;
   THYMOQUINONE; CONSTITUENTS; HEDERAGENIN; INHIBITION; GENERATION
AB alpha-hederin, a monodesmosidic triterpenoid saponin, had previously demonstrated strong anticancer effects. In the current study, the pharmacological mechanism of autophagic cell death induced by alpha-hederin was investigated in human colorectal cancer cells. First, through cell counting kit-8 and colony formation assays, it was demonstrated that alpha-hederin could inhibit the proliferation of HCT116 and HCT8 cell. Results of flow cytometry using fluorescein isothiocyanate Annexin V/propidium iodide and Hoechst 33258 staining indicated that alpha-hederin could induce apoptosis. Western blotting demonstrated that alpha-hederin could activate mitochondrial apoptosis signal pathway. Then, using light chain 3 lentiviral and electron microscope assay, it was demonstrated that alpha-hederin could induce autophagy in colorectal cancer cells. In addition, immunohistochemistry results from in vivo experiments also demonstrated that alpha-hederin could induce autophagy. AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) signaling was demonstrated to be activated by alpha-hederin, which could be blocked by reactive oxygen species (ROS) inhibitor NAC. Furthermore, NAC could inhibit apoptosis and autophagy induced by alpha-hederin. Finally, 3-MA (autophagy inhibitor) reduced the inhibition of alpha-hederin on cell activity, but it had no significant effect on apoptosis. In conclusion, alpha-hederin triggered apoptosis through ROS-activated mitochondrial signaling pathway and autophagic cell death through ROS dependent AMPK/mTOR signaling pathway activation in colorectal cancer cells.
C1 [Sun, Jian; Shi, Lei; Wang, Yiyi; Huang, Yan; Zhang, Jue] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Clin Lab, Shanghai 201203, Peoples R China.
   [Feng, Yu; Wang, Yan; Ji, Qing; Cai, Gang; Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, 528 Zhangheng Rd, Shanghai 201203, Peoples R China.
RP Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, 528 Zhangheng Rd, Shanghai 201203, Peoples R China.
EM zhangjue425@hotmail.com
OI Li, Qi/0000-0003-2004-6885; Sun, Jian/0000-0001-9645-4741
FU International Cooperation Key Project of the National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81520108031]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81473478]; Shanghai Academic
   Research Leader [16XD1403600]; Shanghai Rising-Star Program
   [16QA1403700]; Municipal Human Resources Development Program for
   Outstanding Leaders in Medical Disciplines in Shanghai [2017BR031];
   Shanghai University of Traditional Chinese Medicine [18LK042]
FX The present study was supported by the International Cooperation Key
   Project of the National Natural Science Foundation of China (grant no.
   81520108031), the National Natural Science Foundation of China (grant
   no. 81473478), Shanghai Academic Research Leader (grant no.
   16XD1403600), Shanghai Rising-Star Program (grant no. 16QA1403700),
   Municipal Human Resources Development Program for Outstanding Leaders in
   Medical Disciplines in Shanghai (grant no. 2017BR031) and Shanghai
   University of Traditional Chinese Medicine (grant no. 18LK042).
CR Bang SC, 2008, ARCH PHARM RES, V31, P555, DOI 10.1007/s12272-001-1192-7
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cheng L, 2014, INT J ONCOL, V45, P757, DOI 10.3892/ijo.2014.2449
   Cheng L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090848
   Claereboudt EJS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29223-x
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   DANLOY S, 1994, PLANTA MED, V60, P45, DOI 10.1055/s-2006-959406
   Delmas F, 2000, PLANTA MED, V66, P343, DOI 10.1055/s-2000-8541
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Gaillard Y, 2003, J ANAL TOXICOL, V27, P257, DOI 10.1093/jat/27.4.257
   Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886
   Gumushan-Aktas H, 2016, ONCOL LETT, V12, P2985, DOI 10.3892/ol.2016.4941
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jeong HG, 1998, BIOCHEM MOL BIOL INT, V45, P163
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Kou B, 2017, ONCOL REP, V38, P3137, DOI 10.3892/or.2017.5988
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Lee MS, 2017, MOL CARCINOGEN, V56, P2578, DOI 10.1002/mc.22702
   Li GH, 2015, ATHEROSCLEROSIS, V243, P223, DOI 10.1016/j.atherosclerosis.2015.09.020
   Li J, 2018, WORLD J GASTROENTERO, V24, P1901, DOI 10.3748/wjg.v24.i17.1901
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x
   Lorent JH, 2016, PLANTA MED, V82, P1532, DOI 10.1055/s-0042-114780
   Mao X, 2008, CELL RES, V18, P879, DOI 10.1038/cr.2008.86
   Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635
   Na AR, 2008, BIOCHEM BIOPH RES CO, V369, P672, DOI 10.1016/j.bbrc.2008.02.098
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   Ou LL, 2017, INT J NANOMED, V12, P6633, DOI 10.2147/IJN.S140526
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Randhawa MA, 2011, AM J CHINESE MED, V39, P1075, DOI 10.1142/S0192415X1100941X
   Reczek CR, 2015, CURR OPIN CELL BIOL, V33, P8, DOI 10.1016/j.ceb.2014.09.010
   Roach PJ, 2011, MOL CELL BIOL, V31, P3082, DOI 10.1128/MCB.05565-11
   Rooney S, 2005, ANTICANCER RES, V25, P2199
   Rooney S, 2005, ANTICANCER RES, V25, P4255
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508
   Sun D, 2018, BIOMED RES INT, V2548378, P2018
   Sun DD, 2018, BIOMED PHARMACOTHER, V101, P107, DOI 10.1016/j.biopha.2018.02.062
   Sun J, 2017, ONCOL REP, V38, P1420, DOI 10.3892/or.2017.5826
   Sun J, 2016, J DRUG DELIV SCI TEC, V35, P252, DOI 10.1016/j.jddst.2016.08.001
   Sun ZL, 2017, BIOMED PHARMACOTHER, V85, P303, DOI 10.1016/j.biopha.2016.11.030
   Swamy SMK, 2003, MOL CELL BIOCHEM, V245, P127, DOI 10.1023/A:1022807207948
   TAKECHI M, 1990, PHYTOCHEMISTRY, V29, P451, DOI 10.1016/0031-9422(90)85095-W
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wu AG, 2017, PHARMACOL RES, V115, P25, DOI 10.1016/j.phrs.2016.11.002
   Xie J, 2015, TUMOR BIOL, V36, P1279, DOI 10.1007/s13277-014-2754-7
   Xu Ling, 2011, Chin J Cancer, V30, P490, DOI 10.5732/cjc.010.10518
   Zha QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124355
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhan YJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103221
   Zhu R, 2015, SCI REP-UK, V5, DOI 10.1038/srep17904
NR 59
TC 31
Z9 31
U1 4
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2019
VL 54
IS 5
BP 1601
EP 1612
DI 10.3892/ijo.2019.4757
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HS5GM
UT WOS:000463899800010
PM 30896843
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Carew, JS
   Medina, EC
   Esquivel, JA
   Mahalingam, D
   Swords, R
   Kelly, K
   Zhang, H
   Huang, P
   Mita, AC
   Mita, MM
   Giles, FJ
   Nawrocki, ST
AF Carew, Jennifer S.
   Medina, Ernest C.
   Esquivel, Juan A., II
   Mahalingam, Devalingam
   Swords, Ronan
   Kelly, Kevin
   Zhang, Hui
   Huang, Peng
   Mita, Alain C.
   Mita, Monica M.
   Giles, Francis J.
   Nawrocki, Steffan T.
TI Autophagy inhibition enhances vorinostat-induced apoptosis via
   ubiquitinated protein accumulation
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; autophagy; bortezomib; proteasome; aggresome; chloroquine;
   histone deacetylase; superoxide; cancer
ID HISTONE DEACETYLASE INHIBITORS; MALIGNANT GLIOMA-CELLS; REGULATES
   AGGRESOME FORMATION; PANCREATIC-CANCER CELLS; MULTIPLE-MYELOMA;
   LEUKEMIA-CELLS; THERAPY; DEATH; PROTEASOME; BORTEZOMIB
AB Autophagy is an evolutionarily conserved cell survival pathway that enables cells to recoup ATP and other critical biosynthetic molecules during nutrient deprivation or exposure to hypoxia, which are hallmarks of the tumour microenvironment. Autophagy has been implicated as a potential mechanism of resistance to anticancer agents as it can promote cell survival in the face of stress induced by chemotherapeutic agents by breaking down cellular components to generate alternative sources of energy. Disruption of autophagy with chloroquine (CQ) induces the accumulation of ubiquitin-conjugated proteins in a manner similar to the proteasome inhibitor bortezomib (BZ). However, CQ-induced protein accumulation occurs at a slower rate and is localized to lysosomes in contrast to BZ, which stimulates rapid buildup of ubiquitinated proteins and aggresome formation in the cytosol. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) blocked BZ-induced aggresome formation, but promoted CQ-mediated ubiquitinated protein accumulation. Disruption of autophagy with CQ strongly enhanced VOR-mediated apoptosis in colon cancer cells. Accordingly, knockdown of the essential autophagy gene Atg7 also sensitized cells to VOR-induced apoptosis. Knockdown of HDAC6 greatly enhanced BZ-induced apoptosis, but only marginally sensitized cells to CQ. Subsequent studies determined that the CQ/VOR combination promoted a large increase in superoxide generation that was required for ubiquitinated protein accumulation and cell death. Finally, treatment with the CQ/VOR combination significantly reduced tumour burden and induced apoptosis in a colon cancer xenograft model. Collectively, our results establish that inhibition of autophagy with CQ induces ubiquitinated protein accumulation and VOR potentiates CQ-mediated aggregate formation, superoxide generation and apoptosis.
C1 [Carew, Jennifer S.; Medina, Ernest C.; Esquivel, Juan A., II; Mahalingam, Devalingam; Swords, Ronan; Kelly, Kevin; Mita, Alain C.; Mita, Monica M.; Giles, Francis J.; Nawrocki, Steffan T.] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78245 USA.
   [Zhang, Hui; Huang, Peng] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.
RP Nawrocki, ST (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, 14960 Omicron Dr, San Antonio, TX 78245 USA.
EM nawrocki@uthscsa.edu
FU NIH Cancer CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [CA054174]; AT&T
   Endowed Chair at The Institute for Drug Development, Cancer Therapy and
   Research Center at The University of Texas Health Science Center at San
   Antonio, TX, USA; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [P30CA054174] Funding Source: NIH
   RePORTER
FX This work was supported by the NIH Cancer Center Core Grant CA054174 and
   funds provided by the AT&T Endowed Chair at The Institute for Drug
   Development, Cancer Therapy and Research Center at The University of
   Texas Health Science Center at San Antonio, TX, USA.
CR Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476
   Fiskus W, 2008, BLOOD, V112, P2896, DOI 10.1182/blood-2007-10-116319
   GLAUMANN H, 1987, EXP MOL PATHOL, V47, P346, DOI 10.1016/0014-4800(87)90018-9
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Khraishi MM, 1996, LUPUS, V5, pS41, DOI 10.1177/096120339600500110
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Myint HY, 2004, T ROY SOC TROP MED H, V98, P73, DOI 10.1016/S0035-9203(03)00014-2
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Nawrocki ST, 2008, BLOOD, V112, P2917, DOI 10.1182/blood-2007-12-130823
   Nawrocki ST, 2007, CANCER RES, V67, P6987, DOI 10.1158/0008-5472.CAN-07-0812
   Paglin S, 2001, CANCER RES, V61, P439
   Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   Powis G, 2007, CURR OPIN PHARMACOL, V7, P392, DOI 10.1016/j.coph.2007.04.003
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Rosato RR, 2003, CANCER RES, V63, P3637
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548
   Selvakumar E, 2005, MOL CELL BIOCHEM, V272, P179, DOI 10.1007/s11010-005-7322-4
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tiwari M, 2008, CARCINOGENESIS, V29, P600, DOI 10.1093/carcin/bgm264
NR 45
TC 152
Z9 159
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2010
VL 14
IS 10
BP 2448
EP 2459
DI 10.1111/j.1582-4934.2009.00832.x
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 672OS
UT WOS:000283596400011
PM 19583815
OA Green Accepted, Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Yadav, SS
   Kumar, M
   Varshney, A
   Yadava, PK
AF Yadav, Suresh Singh
   Kumar, Manoj
   Varshney, Akhil
   Yadava, Pramod Kumar
TI KLF4 sensitizes the colon cancer cell HCT-15 to cisplatin by altering
   the expression of HMGB1 and hTERT
SO LIFE SCIENCES
LA English
DT Article
DE KLF4; Cisplatin; And chemo-resistance
ID STEM-CELLS; COLORECTAL-CANCER; DOWN-REGULATION; PROMOTES
   CHEMORESISTANCE; 1ST-LINE TREATMENT; DRUG-RESISTANCE; AUTOPHAGY; ARREST;
   CYCLE; FLUOROURACIL
AB Aims: Insensitivity of cancer cells to therapeutic drugs is the most daunting challenge in cancer treatment. The mechanism of developing chemo-resistance is only partly understood to date. In continuation of some earlier reports, we hypothesize that KLF4, a key transcription factors that also has a crucial role in maintaining the stemness in cancer cells, may offer a basis for chemo-resistance.
   Main methods: Sensitivity of cells to cisplatin was analyzed by cell proliferation, colony formation, and cell growth assay. Cell cycle analysis and immunophenotyping were used to measure cell cycle arrest and level of reactive oxygen species respectively. Immunoblotting was used to analyze the change in expression hTERT and HMGB1 involved in KLF4 mediated cisplatin resistance.
   Key findings: We found that KLF4 expression sensitizes cancer cell to cisplatin cytotoxicity. Further, KLF4 promotes the cisplatin-mediated G2/M cell cycle arrest while KLF4 knocked down induces cisplatin-mediated S-phase arrest compared to control. Decreased level of reactive oxygen species (ROS) in cisplatin-treated and KLF4 knocked down HCT-15 cells compared to vector control, accounting for increased cell survival. Immuno-blotting showed that KLF4 positively regulates expression of the survival proteins hTERT and HMGB1 while in presence of cisplatin, expression of HMGB1 and hTERT is negatively regulated by KLF4.
   Significance: This study suggests the involvement of KLF4-HMGB1/hTERT signaling in offering the basis for chemo-resistance in colon cancer cells and KLF4 overexpression as a probable strategy for sensitizing drug-resistant cancer cells to chemotherapy. The present study opens up new avenues for cancer research and therapeutics.
C1 [Yadav, Suresh Singh] Weizmann Inst Sci, Herzl St 234, IL-76100 Rehovot, Israel.
   [Varshney, Akhil] Univ Virginia, Ctr Adv Vis Sci, 415 Lane Rd, Charlottesville, VA 22908 USA.
   [Kumar, Manoj; Yadava, Pramod Kumar] Jawaharlal Nehru Univ, Sch Life Sci, Appl Mol Biol Lab, New Delhi 110067, India.
   [Kumar, Manoj] IISER, Berhampur 760010, Odisha, India.
RP Yadava, PK (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Appl Mol Biol Lab, New Delhi 110067, India.
EM pky0200@mail.jnu.ac.in
OI Varshney, Akhil/0000-0003-0759-0982; Yadava, Pramod/0000-0003-2395-1274
FU University grant commission (UGC) IndiaUniversity Grants Commission,
   India; Jawaharlal Nehru University, New Delhi
FX We acknowledge the University grant commission (UGC) India for the
   post-doctoral fellowship and contingency to SSY. We also acknowledge the
   Jawaharlal Nehru University, New Delhi for providing the working space
   and financial assistance.
CR Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609
   Boulikas T, 2003, ONCOL REP, V10, P1663
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   BURDON RH, 1990, FREE RADICAL RES COM, V11, P65, DOI 10.3109/10715769009109669
   Butler SJ, 2017, BIOCHEM BIOPH RES CO, V490, P29, DOI 10.1016/j.bbrc.2017.05.176
   Chen ZC, 2018, ONCOL LETT, V15, P1559, DOI 10.3892/ol.2017.7475
   Coban EA, 2017, EXP CELL RES, V352, P393, DOI 10.1016/j.yexcr.2017.02.030
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413
   DiPaola RS, 2002, CLIN CANCER RES, V8, P3311
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Haney S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064946
   Huang J, 2016, CANCER SCI, V107, P242, DOI 10.1111/cas.12864
   Islam F, 2015, EXP CELL RES, V335, P135, DOI 10.1016/j.yexcr.2015.04.018
   Jia YS, 2012, CANCER CHEMOTH PHARM, V69, P377, DOI 10.1007/s00280-011-1708-7
   Ke SB, 2015, INT J ONCOL, V46, P1051, DOI 10.3892/ijo.2014.2793
   Lau E, 2009, MOL BIOL CELL, V20, P3953, DOI 10.1091/mbc.E09-01-0022
   Lewis K. A., 2010, MOL CANCER, V8, P855
   Li X, 2005, CELL MOL LIFE SCI, V62, P894, DOI 10.1007/s00018-005-5027-1
   Lin CC, 2011, MOL CELL BIOL, V31, P2513, DOI 10.1128/MCB.01189-10
   Lin JT, 2013, EXP CELL RES, V319, P2216, DOI 10.1016/j.yexcr.2013.06.003
   Liu CC, 2015, MOL CARCINOGEN, V54, P889, DOI 10.1002/mc.22161
   Liu SG, 2016, ONCOL RES, V24, P81, DOI 10.3727/096504016X14597766487717
   Lund RJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01624-4
   Mao MT, 2017, BIOCHEM BIOPH RES CO, V490, P1244, DOI 10.1016/j.bbrc.2017.07.002
   Qi Y, 2012, BIOCHEM BIOPH RES CO, V420, P699, DOI 10.1016/j.bbrc.2012.03.086
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780
   Sangster-Guity N, 2011, ONCOGENE, V30, P2526, DOI 10.1038/onc.2010.624
   Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362
   Scott NA, 2009, COLORECTAL DIS, V11, P245, DOI 10.1111/j.1463-1318.2008.01636.x
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Sussman RT, 2007, CANCER BIOL THER, V6, P1490, DOI 10.4161/cbt.6.9.4905
   Tai SK, 2011, CANCER SCI, V102, P895, DOI 10.1111/j.1349-7006.2011.01859.x
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Tentes IK, 2010, EXP CELL RES, V316, P3172, DOI 10.1016/j.yexcr.2010.09.003
   Thomassen I, 2013, DIS COLON RECTUM, V56, P1373, DOI 10.1097/DCR.0b013e3182a62d9d
   Varshney A, 2014, GENE, V547, P211, DOI 10.1016/j.gene.2014.06.018
   Wang BJ, 2017, BIOCHEM BIOPH RES CO, V484, P486, DOI 10.1016/j.bbrc.2017.01.062
   Wang L, 2015, ONCOL REP, V34, P2969, DOI 10.3892/or.2015.4278
   Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619
   Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Yang LC, 2012, LEUKEMIA LYMPHOMA, V53, P315, DOI 10.3109/10428194.2011.616962
   Zhang L, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0270-x
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhang ZP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07204-w
   Zhao TD, 2015, ONCOTARGET, V6, P35908, DOI 10.18632/oncotarget.5468
   Zhou J, 2016, BIOCHEM BIOPH RES CO, V470, P445, DOI 10.1016/j.bbrc.2016.01.014
   Zou L., 2013, COLD SPRING HARB PER, V5
NR 54
TC 17
Z9 18
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD MAR 1
PY 2019
VL 220
BP 169
EP 176
DI 10.1016/j.lfs.2019.02.005
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HL0RF
UT WOS:000458400900019
PM 30716337
DA 2022-04-25
ER

PT J
AU Ke, P
   Shao, BZ
   Xu, ZQ
   Chen, XW
   Liu, C
AF Ke, Ping
   Shao, Bo-Zong
   Xu, Zhe-Qi
   Chen, Xiong-Wen
   Liu, Chong
TI Intestinal Autophagy and Its Pharmacological Control in Inflammatory
   Bowel Disease
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE autophagy; Paneth cell; macrophage; goblet cell; inflammatory bowel
   disease; immune reaction
ID ENDOPLASMIC-RETICULUM STRESS; GENOME-WIDE ASSOCIATION; AMELIORATES
   EXPERIMENTAL COLITIS; CHAPERONE-MEDIATED AUTOPHAGY; COLORECTAL-CANCER
   CELLS; PREVENTS MUCOSAL INJURY; AMBIENT AIR-POLLUTION; NF-KAPPA-B;
   CROHNS-DISEASE; VITAMIN-D
AB Intestinal mucosal barrier, mainly composed of the intestinal mucus layer and the epithelium, plays a critical role in nutrient absorption as well as protection from pathogenic microorganisms. It is widely acknowledged that the damage of intestinal mucosal barrier or the disturbance of microorganism balance in the intestinal tract contributes greatly to the pathogenesis and progression of inflammatory bowel disease (IBD), which mainly includes Crohn's disease and ulcerative colitis. Autophagy is an evolutionarily conserved catabolic process that involves degradation of protein aggregates and damaged organelles for recycling. The roles of autophagy in the pathogenesis and progression of IBD have been increasingly studied. This present review mainly describes the roles of autophagy of Paneth cells, macrophages, and goblet cells in IBD, and finally, several potential therapeutic strategies for IBD taking advantage of autophagy.
C1 [Ke, Ping; Shao, Bo-Zong; Xu, Zhe-Qi; Chen, Xiong-Wen; Liu, Chong] Second Mil Med Univ, Dept Pharmacol, Shanghai, Peoples R China.
RP Chen, XW; Liu, C (corresponding author), Second Mil Med Univ, Dept Pharmacol, Shanghai, Peoples R China.
EM xchen001@gmail.com; wanlc2004@aliyun.com
RI Chen, Xiongwen/D-5988-2012
OI Chen, Xiongwen/0000-0002-3829-5815
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670260]; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL088243] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Natural Science
   Foundation of China (81670260).
CR Abderrazak A, 2015, CIRCULATION, V131, P1061, DOI 10.1161/CIRCULATIONAHA.114.013730
   Abreu MT, 2004, GUT, V53, P1129, DOI 10.1136/gut.2003.036657
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Ananthakrishnan AN, 2011, INFLAMM BOWEL DIS, V17, P1138, DOI 10.1002/ibd.21455
   Antoni L, 2014, WORLD J GASTROENTERO, V20, P1165, DOI 10.3748/wjg.v20.i5.1165
   Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069
   Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89
   Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192
   Baxt LA, 2015, GASTROENTEROLOGY, V149, P553, DOI 10.1053/j.gastro.2015.06.046
   Beltran CJ, 2010, INFLAMM BOWEL DIS, V16, P1097, DOI 10.1002/ibd.21175
   Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546
   Billmann-Born S, 2011, EUR J CELL BIOL, V90, P593, DOI 10.1016/j.ejcb.2010.10.015
   Birrenbach T, 2004, INFLAMM BOWEL DIS, V10, P848, DOI 10.1097/00054725-200411000-00019
   Bisicchia E, 2013, CELL MOL LIFE SCI, V70, P2191, DOI 10.1007/s00018-012-1253-5
   Blaney GP, 2009, ANN NY ACAD SCI, V1173, P384, DOI 10.1111/j.1749-6632.2009.04875.x
   Boyapati RK, 2016, MUCOSAL IMMUNOL, V9, P567, DOI 10.1038/mi.2016.14
   Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x
   BreuerKatschinski BD, 1996, EUR J GASTROEN HEPAT, V8, P225, DOI 10.1097/00042737-199603000-00007
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Canonico B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165780
   Cederlund A, 2011, FEBS J, V278, P3942, DOI 10.1111/j.1742-4658.2011.08302.x
   Chen GY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005357
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406
   Cheng YL, 2015, IMMUNOLOGY, V145, P258, DOI 10.1111/imm.12442
   Cosnes J, 1996, GASTROENTEROLOGY, V110, P424, DOI 10.1053/gast.1996.v110.pm8566589
   Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666
   Crotzer VL, 2005, P NATL ACAD SCI USA, V102, P7779, DOI 10.1073/pnas.0503088102
   de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111
   Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102
   Deretic V, 2016, J LEUKOCYTE BIOL, V100, P969, DOI 10.1189/jlb.4MR0216-079R
   Deuring JJ, 2014, GUT, V63, P1081, DOI 10.1136/gutjnl-2012-303527
   Dorfel D, 2005, BLOOD, V105, P3199, DOI 10.1182/blood-2004-09-3556
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Dumortier J, 2008, INFLAMM BOWEL DIS, V14, P874, DOI 10.1002/ibd.20395
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   El Bakali J, 2015, ACS MED CHEM LETT, V6, P198, DOI 10.1021/ml500439x
   El-Khider F, 2016, DIGEST DIS, V34, P27, DOI 10.1159/000442921
   Fen ZG, 2016, DIABETES, V65, P2966, DOI 10.2337/db16-0317
   Gutierrez MG, 2007, P NATL ACAD SCI USA, V104, P1829, DOI 10.1073/pnas.0601437104
   Gao SY, 2016, BIOORG CHEM, V69, P121, DOI 10.1016/j.bioorg.2016.10.005
   Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010
   Giles EM, 2017, MUCOSAL IMMUNOL, V10, P184, DOI 10.1038/mi.2016.44
   Goto Y, 2012, IMMUNOL REV, V245, P147, DOI 10.1111/j.1600-065X.2011.01078.x
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han Y., 2014, J ADV SIGNAL PROCESS, V2014, P1, DOI DOI 10.1097/PAT.0000000000000125
   Hansson GC, 2012, CURR OPIN MICROBIOL, V15, P57, DOI 10.1016/j.mib.2011.11.002
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep28370
   Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Hooper KM, 2017, J CROHNS COLITIS, V11, P118, DOI 10.1093/ecco-jcc/jjw127
   Hosomi S, 2015, CURR OPIN GASTROEN, V31, P81, DOI 10.1097/MOG.0000000000000144
   Huang YH, 2018, GUT, V67, P307, DOI 10.1136/gutjnl-2016-311909
   Huber LA, 2016, CURR OPIN CELL BIOL, V39, P8, DOI 10.1016/j.ceb.2016.01.006
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   HUME DA, 1984, ANAT REC, V210, P503, DOI 10.1002/ar.1092100311
   Hviid A, 2011, GUT, V60, P49, DOI 10.1136/gut.2010.219683
   Ito M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8360
   Jada SR, 2008, BRIT J PHARMACOL, V155, P641, DOI 10.1038/bjp.2008.368
   Jia ZY, 2015, INT IMMUNOPHARMACOL, V29, P552, DOI 10.1016/j.intimp.2015.09.029
   Jing Z, 2016, ONCOTARGET
   Jo YK, 2017, CANCER LETT, V385, P21, DOI 10.1016/j.canlet.2016.11.002
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Johansson MEV, 2014, CELL HOST MICROBE, V15, P251, DOI 10.1016/j.chom.2014.02.014
   Johansson MEV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041009
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kaplan GG, 2010, AM J GASTROENTEROL, V105, P2412, DOI 10.1038/ajg.2010.252
   Kaser A, 2011, GASTROENTEROLOGY, V140, P1738, DOI 10.1053/j.gastro.2011.02.048
   Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1
   Kaser A, 2009, SEMIN IMMUNOL, V21, P156, DOI 10.1016/j.smim.2009.01.001
   Ke P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155076
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kouznetsova L, 1999, JPEN-PARENTER ENTER, V23, P136, DOI 10.1177/0148607199023003136
   Lapaquette P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/398483
   Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x
   Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462-5822.2009.01381.x
   Larsson JMH, 2011, INFLAMM BOWEL DIS, V17, P2299, DOI 10.1002/ibd.21625
   Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111
   Lee HY, 2016, AUTOPHAGY, V12, P1390, DOI 10.1080/15548627.2016.1184799
   Lewis GJ, 2011, INFLAMM BOWEL DIS, V17, P1387, DOI 10.1002/ibd.21499
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li W, 2011, PHYS RES INT, P1, DOI [10.1155/2011/791545, DOI 10.1155/2011/791545]
   Li WM, 2011, CELL MOL LIFE SCI, V68, P749, DOI 10.1007/s00018-010-0565-6
   Li YX, 2016, AM J PHYSIOL-LUNG C, V311, pL970, DOI 10.1152/ajplung.00161.2016
   Lim WC, 2005, NAT CLIN PRACT GASTR, V2, P308, DOI 10.1038/ncpgasthep0215
   Lin LJ, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00320
   Liu B, 2013, AM J PHYSIOL-GASTR L, V305, pG573, DOI 10.1152/ajpgi.00071.2013
   Liu N, 2016, KIDNEY DIS-BASEL, V2, P37, DOI 10.1159/000444841
   Liu W, 2014, INT IMMUNOPHARMACOL, V20, P337, DOI 10.1016/j.intimp.2014.03.015
   Liu XT, 2016, BIOCHEM PHARMACOL, V112, P37, DOI 10.1016/j.bcp.2016.05.002
   Ma YL, 2011, J CLIN ONCOL, V29, P3775, DOI 10.1200/JCO.2011.35.7566
   Maeda S, 2007, BIOCHEM BIOPH RES CO, V360, P394, DOI 10.1016/j.bbrc.2007.06.065
   Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020
   Massey DCO, 2008, GUT, V57, P1294, DOI 10.1136/gut.2008.157297
   Matsuda C, 2007, CLIN EXP IMMUNOL, V148, P348, DOI 10.1111/j.1365-2249.2007.03345.x
   Mazzini E, 2014, IMMUNITY, V40, P248, DOI 10.1016/j.immuni.2013.12.012
   McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010
   Meuwis M-A, 2013, J Crohns Colitis, V7, pe678, DOI 10.1016/j.crohns.2013.06.008
   Moran AP, 2011, GUT, V60, P1412, DOI 10.1136/gut.2010.212704
   Muller AJ, 2012, CELL HOST MICROBE, V11, P19, DOI 10.1016/j.chom.2011.11.013
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Mutalib M, 2014, J CROHNS COLITIS, V8, P1730, DOI 10.1016/j.crohns.2014.08.014
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Negroni A, 2016, INFLAMM RES, V65, P803, DOI 10.1007/s00011-016-0964-8
   Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17
   Newsholme P, 2001, J NUTR, V131, p2515S, DOI 10.1093/jn/131.9.2515S
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Ouellette AJ, 2010, CURR OPIN GASTROEN, V26, P547, DOI 10.1097/MOG.0b013e32833dccde
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Pavel M, 2017, FEBS J, V284, P672, DOI 10.1111/febs.13931
   Pearson JP, 2010, INT J INFLAMM, V2010, DOI 10.4061/2010/321426
   Pelissier-Rota MA, 2015, INT J BIOCHEM CELL B, V65, P239, DOI 10.1016/j.biocel.2015.06.013
   Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339
   Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z
   Qualls JE, 2006, J LEUKOCYTE BIOL, V80, P802, DOI 10.1189/jlb.1205734
   Randall-Demllo S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00301
   Reinisch W, 2008, AM J GASTROENTEROL, V103, P2284, DOI 10.1111/j.1572-0241.2008.02024.x
   Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rocha JDB, 2015, NAT IMMUNOL, V16, P898, DOI 10.1038/ni.3255
   Roda G, 2010, WORLD J GASTROENTERO, V16, P4264, DOI 10.3748/wjg.v16.i34.4264
   Ruiz PA, 2017, GUT, V66, P1216, DOI 10.1136/gutjnl-2015-310297
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002
   Salim SY, 2014, GUT MICROBES, V5, P215, DOI 10.4161/gmic.27251
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shaker ME, 2014, CHEM-BIOL INTERACT, V210, P26, DOI 10.1016/j.cbi.2013.12.007
   Shao BZ, 2016, ACTA PHARMACOL SIN, V37, P150, DOI 10.1038/aps.2015.87
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shao BZ, 2014, CNS NEUROSCI THER, V20, P1021, DOI 10.1111/cns.12349
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Simmons JD, 2000, GUT, V47, P211, DOI 10.1136/gut.47.2.211
   Singh UP, 2012, TOXICOL APPL PHARM, V258, P256, DOI 10.1016/j.taap.2011.11.005
   STEIN WH, 1954, J BIOL CHEM, V211, P915
   Storr MA, 2009, INFLAMM BOWEL DIS, V15, P1678, DOI 10.1002/ibd.20960
   Strisciuglio C, 2013, J CROHNS COLITIS, V7, P534, DOI 10.1016/j.crohns.2012.08.009
   Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587
   Suh HW, 2017, CURR MED CHEM, V24, P898, DOI 10.2174/0929867323666161202151856
   Sukhotnik I, 2007, DIGEST DIS SCI, V52, P1497, DOI 10.1007/s10620-006-9629-8
   Sun J, 2016, AUTOPHAGY, V12, P1057, DOI 10.1080/15548627.2015.1072670
   Sun Y, 2015, BIOCHEM PHARMACOL, V94, P142, DOI 10.1016/j.bcp.2015.02.002
   Swaid F, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-53
   Swidsinski A, 2009, J PHYSIOL PHARMACOL, V60, P61
   Talero E, 2014, CURR PHARM DESIGN, V20, P4816
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Tosiek MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10888
   Tourteau A, 2013, BIOORGAN MED CHEM, V21, P5383, DOI 10.1016/j.bmc.2013.06.010
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   van de Veerdonk FL, 2014, AUTOPHAGY, V10, P1141, DOI 10.4161/auto.28638
   VANFURTH R, 1972, B WORLD HEALTH ORGAN, V46, P845
   Varghese GP, 2015, MOL MED REP, V11, P4579, DOI 10.3892/mmr.2015.3236
   Vitali R, 2011, AM J GASTROENTEROL, V106, P2029, DOI 10.1038/ajg.2011.231
   Wallace KL, 2014, WORLD J GASTROENTERO, V20, P6, DOI 10.3748/wjg.v20.i1.6
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Weber B, 2011, EUR J IMMUNOL, V41, P773, DOI 10.1002/eji.201040965
   Wells JM, 2011, P NATL ACAD SCI USA, V108, P4607, DOI 10.1073/pnas.1000092107
   WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107
   Wittkopf N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/278059
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Wumesh KC, 2014, NATURE, V507, P243, DOI 10.1038/nature12967
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Xilouri M, 2016, AGEING RES REV, V32, P13, DOI 10.1016/j.arr.2016.07.001
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Zhang C, 2015, TUMOR BIOL, V36, P8359, DOI 10.1007/s13277-015-3578-9
   Zhang QH, 2013, AUTOPHAGY, V9, P451, DOI 10.4161/auto.23691
   Zhang YC, 2012, PLOS ONE, V7, DOI [10.1155/2012/583417, 10.1371/journal.pone.0044465]
   Zhao J, 2017, JPEN-PARENTER ENTER, V41, P824, DOI 10.1177/0148607115609308
   Zhao J, 2015, INT IMMUNOPHARMACOL, V26, P221, DOI 10.1016/j.intimp.2015.03.033
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou J, 2006, BIOCHEM PHARMACOL, V72, P132, DOI 10.1016/j.bcp.2006.04.019
   Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026
NR 188
TC 37
Z9 38
U1 5
U2 33
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 9
PY 2017
VL 7
AR 695
DI 10.3389/fimmu.2016.00695
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA EG9HC
UT WOS:000391368500001
PM 28119697
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Miao, YF
   Zhang, YW
   Chen, YL
   Chen, LB
   Wang, FY
AF Miao, Yufeng
   Zhang, Youwei
   Chen, Yonglin
   Chen, Longbang
   Wang, Fangyu
TI GABARAP is Overexpressed in Colorectal Carcinoma and Correlates with
   Shortened Patient Survival
SO HEPATO-GASTROENTEROLOGY
LA English
DT Article
DE gamma-aminobutyric acid type A (GABAA) receptor-associated protein;
   Autophagy; Colorectal cancer
ID ACTIVATED PROTEIN-KINASE; AUTOPHAGY; CANCER; CELLS; EXPRESSION; GATE-16;
   SYSTEM; HEALTH; LC3
AB Background/Aims: gamma-aminobutyric acid type A (GABAA) receptor associated protein (GABARAP), the mammalian homologue of yeast Atg8, is involved in autophagosome formation during autophagy. The aim of this study is to explore the expression and its prognostic significance in comparison with various clinicopathological predictors of survival.
   Methodology: GABARAP protein expression was determined by immunohistochemistry in 103 colorectal cancers. Cytoplasmic immunoreactivity was scored semiquantitatively. The results were analyzed in correlation with various clinicopathological variables, including patient survival. Chi-square test and Kaplan-Meier survival analysis were applied.
   Results: The expression of GABARAP was significantly higher in colorectal cancers than that in adjacent matched nontumor tissues (51.5% vs 33.0%, p<0.01). Increased expression of GABARAP expression in colorectal cancers was significantly correlated with a low grade of differentiation and shortened overall survival (p<0.05). There were no significant differences between the expression of GABARAP and age, gender, stage, tumor size, location of primary tumor, and lymph node invasion.
   Conclusions: Our data demonstrated that GABARAP is frequently expressed in colorectal cancer. Overexpression of GABARAP is a new independent prognostic marker, which is associated with poor differentiation as well as shortened overall survival.
C1 [Miao, Yufeng; Wang, Fangyu] Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Peoples R China.
   [Miao, Yufeng; Zhang, Youwei; Chen, Longbang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Gastroenterol & Hepatol, Nanjing 210002, Peoples R China.
   [Chen, Yonglin] Lanzhou Univ, Sch Basic Med Sci, Dept Pathol, Lanzhou 730000, Peoples R China.
RP Wang, FY (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Peoples R China.
EM wangfy65@gmail.com
FU Nanjing Military Command [07M076]
FX This work was supported by the Science and Technology Innovation Program
   of Nanjing Military Command (No. 07M076).
CR Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200
   Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240
   Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Klebig C, 2005, CANCER RES, V65, P394
   Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256
   Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Roberts SS, 2004, J CLIN ONCOL, V22, P4127, DOI 10.1200/JCO.2004.02.032
   Roberts SS, 2009, PATHOL ONCOL RES, V15, P645, DOI 10.1007/s12253-009-9165-x
   Scriven P, 2007, J MOL MED, V85, P331, DOI 10.1007/s00109-006-0150-5
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   White A, 2007, CHEM WORLD-UK, V4, P34
NR 25
TC 26
Z9 27
U1 0
U2 2
PU H G E UPDATE MEDICAL PUBLISHING S A
PI ATHENS
PA PO BOX 17257, ATHENS GR-10024, GREECE
SN 0172-6390
J9 HEPATO-GASTROENTEROL
JI Hepato-Gastroenterol.
PD MAR-APR
PY 2010
VL 57
IS 98
BP 257
EP 261
PG 5
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA 612XD
UT WOS:000278938200015
PM 20583424
DA 2022-04-25
ER

PT J
AU Ji, S
   Tang, SN
   Li, K
   Li, ZW
   Liang, WF
   Qiao, X
   Wang, Q
   Yu, SW
   Ye, M
AF Ji, Shuai
   Tang, Shunan
   Li, Kai
   Li, Ziwei
   Liang, Wenfei
   Qiao, Xue
   Wang, Qi
   Yu, Siwang
   Ye, Min
TI Licoricidin inhibits the growth of SW480 human colorectal adenocarcinoma
   cells in vitro and in vivo by inducing cycle arrest, apoptosis and
   autophagy
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Licoricidin; Colorectal cancer; Cycle arrest; Apoptosis; Autophagy; AMPK
ID GLYCYRRHIZA-URALENSIS; ETHANOL EXTRACT; ISOLIQUIRITIGENIN; DEATH; YEAST;
   ROOT
AB Licorice (Glycyrrhiza uralensis Fisch.) possesses significant anti-cancer activities, but the active ingredients and underlying mechanisms have not been revealed. By screening the cytotoxic activities of 122 licorice compounds against SW480 human colorectal adenocarcinoma cells, we found that licoricidin (LCD) inhibited SW480 cell viability with an IC50 value of 7.2 mu M. Further studies indicated that LCD significantly induced G1/S cell cycle arrest and apoptosis in SW480 cells, accompanied by inhibition of cyclins/CDK1 expression and activation of caspase-dependent pro-apoptotic signaling. Meanwhile, LCD promoted autophagy in SW480 cells, and activated AMPK signaling and inhibited Akt/mTOR pathway. Overexpression of a dominant-negative AMPK alpha 2 abolished LCD-induced inhibition of Akt/mTOR, autophagic and pro-apoptotic signaling pathways, and significantly reversed loss of cell viability, suggesting activation of AMPK is essential for the anti-cancer activity of LCD. In vivo anti-tumor experiments indicated that LCD (20 mg/kg, i.p.) significantly inhibited the growth of SW480 xenografts in nude mice with an inhibitory rate of 43.5%. In addition, we obtained the glycosylated product LCDG by microbial transformation, and found that glycosylation slightly enhanced the in vivo anti-cancer activities of LCD. This study indicates that LCD could inhibit SW480 cells by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Ji, Shuai; Tang, Shunan; Li, Kai; Li, Ziwei; Liang, Wenfei; Qiao, Xue; Wang, Qi; Yu, Siwang; Ye, Min] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Ji, Shuai] Xuzhou Med Univ, Sch Pharm, Jiangsu Key Lab New Drug Res & Clin Pharm, 209 Tongshan Rd, Xuzhou 221004, Peoples R China.
RP Yu, SW; Ye, M (corresponding author), Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM swang_yu@bjmu.edu.cn; yemin@bjmu.edu.cn
RI yu, Siwang/AAL-8059-2020
OI Qiao, Xue/0000-0002-8771-7877; Yu, Siwang/0000-0002-3336-202X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81173644, 81222054, 81472657]
FX This work was supported by National Natural Science Foundation of China
   (No. 81173644, No. 81222054, No. 81472657).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Chinese Pharmacopoeia Commission, 2010, PHARMACOPOEIA PEOPLE, V1, P255
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Fiore C, 2005, J ETHNOPHARMACOL, V99, P317, DOI 10.1016/j.jep.2005.04.015
   Huang W, 2014, FITOTERAPIA, V94, P36, DOI 10.1016/j.fitote.2014.01.016
   Hydbring P, 2016, NAT REV MOL CELL BIO, V17, P280, DOI 10.1038/nrm.2016.27
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jeong, 2016, CANC PREV, V21, P26, DOI DOI 10.15430/JCP.2016.21.1.26
   Ji S, 2016, RSC ADV, V6, P20791, DOI 10.1039/c6ra00072j
   Ji S, 2016, J NAT PROD, V79, P281, DOI 10.1021/acs.jnatprod.5b00877
   Jo EH, 2005, CANCER LETT, V230, P239, DOI 10.1016/j.canlet.2004.12.038
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Khan R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056020
   Kim JK, 2006, BIOCHEM BIOPH RES CO, V345, P1215, DOI 10.1016/j.bbrc.2006.05.035
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Kummar S, 2011, CLIN COLORECTAL CANC, V10, P85, DOI 10.1016/j.clcc.2011.03.003
   Li PY, 2012, CANCER LETT, V314, P213, DOI 10.1016/j.canlet.2011.09.031
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Mae T, 2003, J NUTR, V133, P3369, DOI 10.1093/jn/133.11.3369
   Oganesyan KR, 2002, B EXP BIOL MED+, V134, P135, DOI 10.1023/A:1021123928740
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Pan K, 2012, MOL MED, V18, P507, DOI 10.2119/molmed.2011.00319
   Park SY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060934
   Park SY, 2010, BRIT J NUTR, V104, P1272, DOI 10.1017/S0007114510002114
   Prietsch RF, 2014, MOL CELL BIOCHEM, V390, P235, DOI 10.1007/s11010-014-1974-x
   Song W, 2017, ANAL CHEM, V89, P3146, DOI 10.1021/acs.analchem.6b04919
   Stewart PM, 2009, J CLIN INVEST, V119, P760, DOI 10.1172/JCI38936
   Takahashi T, 2004, CANCER SCI, V95, P448, DOI 10.1111/j.1349-7006.2004.tb03230.x
   Wang ZY, 2001, NUTR CANCER, V39, P1, DOI 10.1207/S15327914nc391_1
   Xu XH, 2014, HYPERTENSION, V63, P490, DOI 10.1161/HYPERTENSIONAHA.113.02219
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zeng JF, 1998, PHYTOCHEMISTRY, V47, P903, DOI 10.1016/S0031-9422(97)00633-X
   Zhang QY, 2009, J CHROMATOGR A, V1216, P1954, DOI 10.1016/j.chroma.2008.07.072
   Zhao HX, 2014, TOXICOL APPL PHARM, V279, P311, DOI 10.1016/j.taap.2014.07.001
NR 36
TC 32
Z9 33
U1 3
U2 49
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUL 1
PY 2017
VL 326
BP 25
EP 33
DI 10.1016/j.taap.2017.04.015
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA EW6BH
UT WOS:000402589700004
PM 28416456
DA 2022-04-25
ER

PT J
AU Luo, Y
   Chihara, Y
   Fujimoto, K
   Sasahira, T
   Kuwada, M
   Fujiwara, R
   Fujii, K
   Ohmori, H
   Kuniyasu, H
AF Luo, Yi
   Chihara, Yoshitomo
   Fujimoto, Kiyohide
   Sasahira, Tomonori
   Kuwada, Masaomi
   Fujiwara, Rina
   Fujii, Kiyomu
   Ohmori, Hitoshi
   Kuniyasu, Hiroki
TI High mobility group box 1 released from necrotic cells enhances regrowth
   and metastasis of cancer cells that have survived chemotherapy
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE HMGB1; Necrosis; Apoptosis; TLR4; RAGE
ID GLYCATION END-PRODUCTS; COLON-CANCER; COLORECTAL-CANCER; REGULATES
   AUTOPHAGY; HMGB PROTEINS; LINOLEIC-ACID; EXPRESSION; AMPHOTERIN;
   RECEPTOR; GROWTH
AB The role of the high mobility group box 1 (HMGB1) protein in chemotherapy-induced cell death was examined. CT26 mouse colon cancer cells were treated with trichostatin A (TSA; apoptosis inducer) or doxorubicin (DXR; necrosis inducer). DXR increased HMGB1 concentration in CT26 cell culture medium, whereas TSA did not. In a CT26 bilateral subcutaneous tumour model, DXR or TSA was injected in a single tumour. After injection, serum HMGB1 concentration in DXR-treated mice was 10 times higher than that in TSA-treated mice. After DXR treatment, the contralateral and remnant tumours showed more pronounced growth than did those treated with TSA. In mouse models, lung and liver metastasis was enhanced by DXR but not by TSA. DXR-enhanced metastasis was abrogated by anti-HMGB1 antibody treatment. In a cancer dormancy model, DXR induced regrowth of quiescent CT26 cells. HMGB1 induced tumour necrosis factor-a secretion via Toll-like receptor (TLR) 4 in U937 monocytes; however, HMGB1 decreased the number of U937 cells, resulting in restriction of immune activation via receptor for advanced glycation endproducts (RAGE). RAGE showed a more pronounced effect on nuclear factor kappa B activation than did TLR4 in CT26 cells. These findings suggest that HMGB1 released from necrotic cancer cells treated with a necrosis inducer enhances regrowth and metastasis of remnant cancer cells via RAGE activation. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Luo, Yi; Chihara, Yoshitomo; Sasahira, Tomonori; Fujiwara, Rina; Fujii, Kiyomu; Ohmori, Hitoshi; Kuniyasu, Hiroki] Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 6348521, Japan.
   [Chihara, Yoshitomo; Fujimoto, Kiyohide; Kuwada, Masaomi] Nara Med Univ, Dept Urol, Kashihara, Nara 6348521, Japan.
RP Kuniyasu, H (corresponding author), Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM cooninh@zb4.so-net.ne.jp
FU Japan Society for the Promotion of Science, JapanMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science; Ministry of Health, Labour and Welfare,
   JapanMinistry of Health, Labour and Welfare, Japan
FX This work was supported in part by Grant-in-Aid for Scientific Research
   from Japan Society for the Promotion of Science, Japan, and Grant-in-Aid
   for Scientific Research from Ministry of Health, Labour and Welfare,
   Japan.
CR Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Bhawal UK, 2005, ONCOLOGY-BASEL, V69, P246, DOI 10.1159/000087910
   Czura CJ, 2001, J ENDOTOXIN RES, V7, P315, DOI 10.1177/09680519010070041401
   Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197
   Fujii K, 2009, CELL PROLIFERAT, V42, P701, DOI 10.1111/j.1365-2184.2009.00624.x
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kuniyasu H, 2000, AM J PATHOL, V157, P1523, DOI 10.1016/S0002-9440(10)64790-6
   Kuniyasu H, 2005, AM J PATHOL, V166, P751, DOI 10.1016/S0002-9440(10)62296-1
   Kuniyasu H, 2003, ONCOL REP, V10, P1863
   Kuniyasu H, 2003, INT J CANCER, V104, P722, DOI 10.1002/ijc.11016
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Kusume A, 2009, PATHOBIOLOGY, V76, P155, DOI 10.1159/000218331
   LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051
   Liu AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035379
   Luo Y, 2010, EUR J CANCER, V46, P791, DOI 10.1016/j.ejca.2009.11.011
   Moriwaka Y, 2010, PATHOBIOLOGY, V77, P17, DOI 10.1159/000272950
   Ohmori H, 2008, PATHOBIOLOGY, V75, P226, DOI 10.1159/000132383
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Pallier C, 2003, MOL BIOL CELL, V14, P3414, DOI 10.1091/mbc.E02-09-0581
   Parkkinen J, 1993, J BIOL CHEM, V268, P685
   RAUVALA H, 1987, J BIOL CHEM, V262, P16625
   Sasahira T, 2005, J EXP CLIN CANC RES, V24, P69
   Sasaki T, 2006, INT J CANCER, V118, P593, DOI 10.1002/ijc.21393
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007
   Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Yamamoto K, 2006, PATHOBIOLOGY, V73, P317, DOI 10.1159/000099127
NR 34
TC 69
Z9 74
U1 0
U2 27
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD FEB
PY 2013
VL 49
IS 3
BP 741
EP 751
DI 10.1016/j.ejca.2012.09.016
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 076HM
UT WOS:000313947100022
PM 23040637
DA 2022-04-25
ER

PT J
AU de Bruin, EC
   Mederna, JP
AF de Bruin, Elza C.
   Mederna, Jan Paul
TI Apoptosis and non-apoptotic deaths in cancer development and treatment
   response
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Apoptosis; Autophagy; Mitotic catastrophe; Necrosis; Tumorigenesis;
   Treatment response; Radiotherapy
ID NECROTIC CELL-DEATH; TUMOR-NECROSIS-FACTOR; RADIATION-INDUCED AUTOPHAGY;
   PROTEIN CONJUGATION SYSTEM; FLICE-INHIBITORY PROTEIN; MALIGNANT
   GLIOMA-CELLS; RECTAL-CANCER; COLORECTAL-CARCINOMA; MITOTIC CATASTROPHE;
   DNA-DAMAGE
AB Resistance to apoptosis is closely linked to tumorigenesis, as it enables malignant cells to expand even in a stressful environment. Celts resistant to apoptosis are also assumed to be resistant to anti-cancer therapies. Apoptosis has therefore taken a central position in cell death research. However, its contribution to treatment success is highly debated for solid tumors. It becomes more and more clear that cells can also die by non-apoptotic mechanisms, such as autophagy, mitotic catastrophe and necrosis. In this review, we summarize the current knowledge regarding the molecular pathways that underlie these apoptotic and non-apoptotic death pathways, and discuss the clinical data that have now accumulated to evaluate their rotes in tumor development and cancer treatment. (C) 2008 Elsevier Ltd. All. rights reserved.
C1 [de Bruin, Elza C.; Mederna, Jan Paul] Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, NL-1105 AZ Amsterdam, Netherlands.
RP Mederna, JP (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM E.C.deBruin@amc.uva.nl; J.P.Medema@amc.uva.nl
OI Medema, Jan Paul/0000-0003-3045-2924
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Abend M, 2003, INT J RADIAT BIOL, V79, P927, DOI 10.1080/09553000310001632958
   Adell GCE, 2001, CANCER, V91, P1870, DOI 10.1002/1097-0142(20010515)91:10<1870::AID-CNCR1208>3.0.CO;2-1
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317
   Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185
   Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280
   Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028
   Bendardaf R, 2003, ONCOLOGY-BASEL, V64, P435, DOI 10.1159/000070304
   Bertagnolli MM, 2007, LANCET ONCOL, V8, P439, DOI 10.1016/S1470-2045(07)70139-0
   Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374
   Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0
   Brown EJ, 2000, GENE DEV, V14, P397
   Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560
   Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Burns TF, 2001, J BIOL CHEM, V276, P37879
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245
   Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356
   Chen JG, 2002, CANCER RES, V62, P1935
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982
   Cho D, 2007, CLIN CANCER RES, V13, p758S, DOI 10.1158/1078-0432.CCR-06-1986
   Chollet P, 2006, CLIN BREAST CANCER, V7, P336, DOI 10.3816/CBC.2006.n.047
   Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200
   Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   de Bruin EC, 2006, CLIN CANCER RES, V12, P6432, DOI 10.1158/1078-0432.CCR-06-0231
   de Heer P, 2007, CLIN CANCER RES, V13, P2955, DOI 10.1158/1078-0432.CCR-06-2042
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Duffy MJ, 2007, CANCER LETT, V249, P49, DOI 10.1016/j.canlet.2006.12.020
   Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Elkablawy MA, 2001, J PATHOL, V194, P436, DOI 10.1002/path.894
   Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627
   Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225
   Hilska M, 2005, DIS COLON RECTUM, V48, P2197, DOI 10.1007/s10350-005-0202-x
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Hyer ML, 2006, CLIN CANCER RES, V12, P5929, DOI 10.1158/1078-0432.CCR-06-2098
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jahr S, 2001, CANCER RES, V61, P1659
   Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kawai Ken, 2005, Int J Gastrointest Cancer, V35, P197, DOI 10.1385/IJGC:35:3:197
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kawasaki H, 2001, CANCER, V91, P2026, DOI 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim CH, 2007, J CELL PHYSIOL, V211, P371, DOI 10.1002/jcp.20941
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809
   Kondo S, 2000, CANCER RES, V60, P4328
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455
   Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003
   Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X
   Langlois NEI, 1997, J PATHOL, V182, P392
   Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008
   Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307
   Lens SMA, 2006, CURR OPIN CELL BIOL, V18, P616, DOI 10.1016/j.ceb.2006.08.016
   Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200
   Linder S, 2004, CANCER LETT, V214, P1, DOI 10.1016/j.canlet.2004.06.032
   Lopez-Sanchez N, 2007, MOL CANCER RES, V5, P47, DOI 10.1158/1541-7786.MCR-06-0233
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516
   MARINO G, 2007, J BIOL CHEM
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8
   Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033
   Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126
   Michael-Robinson JM, 2001, GUT, V48, P360, DOI 10.1136/gut.48.3.360
   Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889
   MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314
   MOLZ L, 1989, GENETICS, V122, P773
   Moretti L, 2007, AUTOPHAGY, V3, P142, DOI 10.4161/auto.3607
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200
   Noguchi T, 2003, ONCOL REP, V10, P827
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Olofsson MH, 2007, CLIN CANCER RES, V13, P3198, DOI 10.1158/1078-0432.CCR-07-0009
   OTTERSDORF T, 2005, NATURE, V435, P677
   Paglin S, 2001, CANCER RES, V61, P439
   Peter Marcus E, 2004, Biochem J, V382, pe1
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024
   Rodel C, 2002, INT J RADIAT ONCOL, V52, P294, DOI 10.1016/S0360-3016(01)02643-8
   Rodel F, 2002, STRAHLENTHER ONKOL, V178, P426, DOI 10.1007/s00066-002-1003-y
   Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028
   Romagnoli M, 2007, LEUKEMIA, V21, P1070, DOI 10.1038/sj.leu.2404602
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914
   Rupa JD, 2003, CANCER-AM CANCER SOC, V97, P2404, DOI 10.1002/cncr.11366
   Ruth AC, 2000, CANCER RES, V60, P2576
   Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645
   Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670
   Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542
   Schwandner O, 2000, DIS COLON RECTUM, V43, P1227, DOI 10.1007/BF02237426
   Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Sinicrope FA, 1999, CLIN CANCER RES, V5, P1793
   Smith FM, 2006, EJSO-EUR J SURG ONC, V32, P55, DOI 10.1016/j.ejso.2005.09.010
   Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359
   Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9
   Strauss SJ, 2007, CANCER RES, V67, P2783, DOI 10.1158/0008-5472.CAN-06-3254
   Sugao Y, 2000, INT J SURG PATHOL, V8, P123, DOI 10.1177/106689690000800207
   Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0
   Takai H, 2000, GENE DEV, V14, P1439
   Takemasa I, 2000, CANCER RES, V60, P3043
   Tannapfel A, 1998, INT J RADIAT ONCOL, V41, P585, DOI 10.1016/S0360-3016(98)00076-5
   TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263
   Tu SP, 2005, GASTROENTEROLOGY, V128, P361, DOI 10.1053/j.gastro.2004.11.058
   Vagefi Parsia A, 2005, Clin Colorectal Cancer, V4, P313, DOI 10.3816/CCC.2005.n.003
   Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919
   Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477
   Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602
   Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X
   Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Weichert W, 2005, WORLD J GASTROENTERO, V11, P5644, DOI 10.3748/wjg.v11.i36.5644
   Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585
   Xu YR, 2006, J BIOL CHEM, V281, P27389, DOI 10.1074/jbc.M602355200
   Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088
   Zhou XD, 2005, WORLD J GASTROENTERO, V11, P2482, DOI 10.3748/wjg.v11.i16.2482
   Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904
NR 164
TC 214
Z9 220
U1 1
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD DEC
PY 2008
VL 34
IS 8
BP 737
EP 749
DI 10.1016/j.ctrv.2008.07.001
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 386EW
UT WOS:000261866100008
PM 18722718
DA 2022-04-25
ER

PT J
AU Liang, HH
   Huang, CY
   Chou, CW
   Makondi, PT
   Huang, MT
   Wei, PL
   Chang, YJ
AF Liang, Hung-Hua
   Huang, Chien-Yu
   Chou, Ching-Wen
   Makondi, Precious Takondwa
   Huang, Ming-Te
   Wei, Po-Li
   Chang, Yu-Jia
TI Heat shock protein 27 influences the anti-cancer effect of curcumin in
   colon cancer cells through ROS production and autophagy activation
SO LIFE SCIENCES
LA English
DT Article
DE Colorectal cancer; Resistance; Curcumin; HSP27; Apoptosis; Autophagy;
   Reactive oxygen species
ID METASTATIC COLORECTAL-CANCER; RANDOMIZED CONTROLLED-TRIAL; PERSONALIZED
   MEDICINE; PROSTATE-CANCER; CYCLE ARREST; APOPTOSIS; HSP27; SURVIVAL;
   ANTIOXIDANT; RADIOSENSITIVITY
AB The problem of therapeutic resistance and chemotherapeutic efficacy is tricky and critical in the management of colorectal cancer (CRC). Curcumin is a promising anti-cancer agent. Heat shock protein 27 (HSP27) is correlated with CRC progression and is said to affect CRC response to different therapies. However, the role of HSP27 on the therapeutic efficacy of curcumin remains unknown. HSP27 was silenced using small hairpin RNA (shRNA) technique. The cytotoxic and apoptotic effects of curcumin were assessed by sulforhodamine B (SRB) colorimetric assay, flow cytometric cell cycle analysis, and annexin V/propidium iodide (PI) double-labeling assays. Total reactive oxygen species (ROS)/superoxide and autophagy detection were performed, and the levels of apoptosis-related proteins were examined by Western blotting. It was found that the silencing of HSP27 (HSP27-KD) resulted in increased treatment resistance to curcumin in CRC cells. In addition, cell cycle analysis showed that the curcumin treatment caused cell cycle arrest at the G2/M phase in the control group, and apoptosis was reduced in the HSP27-KD group. Curcumin treatment also resulted in a decrease in anti-apoptotic proteins, p-Akt, Akt, Bcl-2 and p-Bad, and increase in pro-apoptotic proteins Bad and c-PARP levels in the control cells but not in the HSP27-KD cells. This was also followed by low reactive oxygen/nitrogen species (ROS/RNS), superoxide and autophagy induction levels in the HSP27-KD cells as compared to the control cells. Therefore, as silencing of HSP27 increases curcumin resistance by reducing apoptosis and reactive oxidative stress production, HSP27 is a potential selective target for curcumin treatment in CRC.
C1 [Liang, Hung-Hua; Chou, Ching-Wen; Chang, Yu-Jia] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Huang, Chien-Yu; Wei, Po-Li] Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei, Taiwan.
   [Huang, Chien-Yu; Huang, Ming-Te] Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan.
   [Makondi, Precious Takondwa] Taipei Med Univ, Coll Med, Int PhD Program Med, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Wan Fang Hosp, Div Colorectal Surg, Dept Surg, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Dept Med Res, Canc Res Ctr, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Dept Med Res, Translat Lab, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Div Colorectal Surg, Dept Surg, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan.
RP Huang, CY; Chang, YJ (corresponding author), 250 Wu Xing St, Taipei, Taiwan.
EM b8501133@tmu.edu.tw; cyh@tmu.edu.tw; b101102137@tmu.edu.tw;
   mthuant@tmu.edu.tw; poliwei@tmu.edu.tw; r5424012@tmu.edu.tw
FU Taipei Medical University [TMU106-AE1-B03]
FX This work was funded by Taipei Medical University (TMU106-AE1-B03)
CR Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1
   Andre F, 2013, PHARMACOGENOMICS, V14, P931, DOI [10.2217/PGS.13.79, 10.2217/pgs.13.79]
   Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Chang YJ, 2015, TUMOR BIOL, V36, P633, DOI 10.1007/s13277-014-2640-3
   Chang YJ, 2011, ANN SURG ONCOL, V18, P2395, DOI 10.1245/s10434-011-1597-3
   Chen W, 2018, J CELL MOL MED, V22, P2283, DOI 10.1111/jcmm.13510
   Chen X, 2016, MOL MED REP, V13, P689, DOI 10.3892/mmr.2015.4600
   Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1
   Des Guetz G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007046.pub2
   Diaz Z, 2013, MODERN PATHOL, V26, P1413, DOI 10.1038/modpathol.2013.81
   Doshi BM, 2009, CELL STRESS CHAPERON, V14, P445, DOI 10.1007/s12192-008-0098-1
   Elyaman W, 2002, MOL BRAIN RES, V109, P233, DOI 10.1016/S0169-328X(02)00582-X
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427
   Hao CF, 2018, J BUON, V23, P205
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Hou AW, 2016, ONCOTARGETS THER, V9, P315, DOI 10.2147/OTT.S95831
   Huang CY, 2016, TUMOR BIOL, V37, P4295, DOI 10.1007/s13277-015-4254-9
   Hung CS, 2017, ONCOTARGET, V8, P54978, DOI 10.18632/oncotarget.18989
   Hung CS, 2012, ANN SURG ONCOL, V19, P3547, DOI 10.1245/s10434-012-2393-4
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455
   Kajstura M, 2007, CYTOM PART A, V71A, P125, DOI 10.1002/cyto.a.20357
   Lee JR, 2017, J CANCER RES CLIN, V143, P2257, DOI 10.1007/s00432-017-2466-7
   Li G, 2017, BIOMED PHARMACOTHER, V94, P974, DOI 10.1016/j.biopha.2017.07.148
   Li W, 2017, Zhonghua Zhong Liu Za Zhi, V39, P490, DOI 10.3760/cma.j.issn.0253-3766.2017.07.003
   Liang HH, 2013, TUMOR BIOL, V34, P3209, DOI 10.1007/s13277-013-0891-z
   Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026
   Ling YH, 1996, MOL PHARMACOL, V49, P832
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lu H, 2016, ONCOL RES, V23, P119, DOI 10.3727/096504015X14496932933656
   Lu Y, 2016, MOL THER, V24, P364, DOI 10.1038/mt.2015.165
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441
   Panahi Y, 2015, CLIN NUTR, V34, P1101, DOI 10.1016/j.clnu.2014.12.019
   Panahi Yunes, 2016, Journal of Dietary Supplements, V13, P209, DOI 10.3109/19390211.2015.1008611
   Panahi Y, 2014, PHYTOTHER RES, V28, P1461, DOI 10.1002/ptr.5149
   Panahi Y, 2012, ANN CLIN BIOCHEM, V49, P580, DOI 10.1258/acb.2012.012040
   Rashmi R, 2003, FEBS LETT, V538, P19, DOI 10.1016/S0014-5793(03)00099-1
   Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840
   Rossi A, 2014, CANCER TREAT REV, V40, P485, DOI 10.1016/j.ctrv.2013.09.012
   Ruers T, 2002, EUR J CANCER, V38, P1023, DOI 10.1016/S0959-8049(02)00059-X
   de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675
   Sahebkar A, 2015, NAT PROD RES, V29, P491, DOI 10.1080/14786419.2014.956212
   Sahebkar A, 2013, PHYTOTHER RES, V27, P1883, DOI 10.1002/ptr.4952
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Stope MB, 2014, ONCOL REP, V32, P2380, DOI 10.3892/or.2014.3492
   Subramaniam D, 2008, AM J PHYSIOL-GASTR L, V294, pG1025, DOI 10.1152/ajpgi.00602.2007
   Subramaniam D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016958
   Tebbutt NC, 2002, EUR J CANCER, V38, P1000, DOI 10.1016/S0959-8049(02)00062-X
   Tsai JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091331
   Tsuruta M, 2008, ONCOL REP, V20, P1165, DOI 10.3892/or_00000125
   Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Wadlow RC, 2010, CANCER-AM CANCER SOC, V116, P3537, DOI 10.1002/cncr.25155
   Wang QR, 2014, INT J ONCOL, V44, P858, DOI 10.3892/ijo.2013.2237
   Wei PL, 2016, TUMOR BIOL, V37, P8219, DOI 10.1007/s13277-015-4669-3
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Yu J, 2011, ASIAN PAC J CANCER P, V12, P1925
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zhuang J, 2006, CELL DEATH DIFFER, V13, P1263, DOI 10.1038/sj.cdd.4401952
NR 63
TC 20
Z9 24
U1 2
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2018
VL 209
BP 43
EP 51
DI 10.1016/j.lfs.2018.07.047
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GS5SE
UT WOS:000443730000006
PM 30056019
DA 2022-04-25
ER

PT J
AU Marchal, JA
   Carrasco, E
   Ramirez, A
   Jimenez, G
   Olmedo, C
   Peran, M
   Agil, A
   Conejo-Garcia, A
   Cruz-Lopez, O
   Campos, JM
   Garcia, MA
AF Antonio Marchal, Juan
   Carrasco, Esther
   Ramirez, Alberto
   Jimenez, Gema
   Olmedo, Carmen
   Peran, Macarena
   Agil, Ahmad
   Conejo-Garcia, Ana
   Cruz-Lopez, Olga
   Maria Campos, Joaquin
   Angel Garcia, Maria
TI Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis
   and synergizes with IFN alpha triggering apoptosis, autophagy and
   senescence
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE seven-member heterocycles; purines; IC50; interferon cytokine; cell
   death; breast and colon cancer cells
ID BREAST-CANCER CELLS; INTERFERON-ALPHA; ANTICANCER ACTIVITY;
   PROTEIN-KINASE; WILD-TYPE; DEATH; P53; MELANOMA; IMMUNOTHERAPY;
   CHLOROQUINE
AB Bozepinib [(RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin- 3-yl]-9H-purine] is a potent antitumor compound that is able to induce apoptosis in breast cancer cells. In the present study, we show that bozepinib also has antitumor activity in colon cancer cells, showing 50% inhibitory concentration (IC50) values lower than those described for breast cancer cells and suggesting great potential of this synthetic drug in the treatment of cancer. We identified that the double-stranded RNA-dependent protein kinase (PKR) is a target of bozepinib, being upregulated and activated by the drug. However, p53 was not affected by bozepinib, and was not necessary for induction of apoptosis in either breast or colon cancer cells. In addition, the efficacy of bozepinib was improved when combined with the interferon-alpha (IFN alpha) cytokine, which enhanced bozepinib-induced apoptosis with involvement of protein kinase PKR. Moreover, we report here, for the first time, that in combined therapy, IFNa induces a clear process of autophagosome formation, and prior treatment with chloroquine, an autophagy inhibitor, is able to significantly reduce IFN alpha/bozepinib-induced cell death. Finally, we observed that a minor population of caspase 3-deficient MCF-7 cells persisted during long-term treatment with lower doses of bozepinib and the bozepinib/IFN alpha combination. Curiously, this population showed beta-galactosidase activity and a percentage of cells arrested in S phase, that was more evident in cells treated with the bozepinib/IFN alpha combination than in cells treated with bozepinib or IFNa alone. Considering the resistance of some cancer cells to conventional chemotherapy, combinations enhancing the diversity of the cell death outcome might succeed in delivering more effective and less toxic chemotherapy.
C1 [Antonio Marchal, Juan; Carrasco, Esther; Ramirez, Alberto; Jimenez, Gema; Olmedo, Carmen; Peran, Macarena] Univ Granada, Ctr Biomed Res, Biopathol & Regenerat Med Inst, Granada, Spain.
   [Antonio Marchal, Juan; Jimenez, Gema] Univ Granada, Fac Med, Dept Human Anat & Embryol, Granada, Spain.
   [Ramirez, Alberto; Peran, Macarena] Univ Jaen, Dept Hlth Sci, Jaen, Spain.
   [Olmedo, Carmen; Angel Garcia, Maria] Virgen de las Nieves Univ Hosp, Expt Surg Res Unit, E-18012 Granada, Spain.
   [Agil, Ahmad] Univ Granada, Fac Med, Dept Pharmacol, Granada, Spain.
   [Agil, Ahmad] Univ Granada, Fac Med, Ctr Neurosci, Granada, Spain.
   [Conejo-Garcia, Ana; Cruz-Lopez, Olga; Maria Campos, Joaquin] Univ Granada, Fac Pharm, Dept Pharmaceut & Organ Chem, Granada, Spain.
   [Angel Garcia, Maria] Virgen de las Nieves Univ Hosp, Dept Oncol, E-18012 Granada, Spain.
RP Garcia, MA (corresponding author), Hosp Univ Virgen de las Nieves, E-18012 Granada, Spain.
EM jmarchal@ugr.es; mangelgarcia@ugr.es
RI Cruz-Lopez, Olga/F-3060-2017; Marchal, Juan Antonio/M-4305-2014; Agil,
   Ahmad/D-9620-2014; Peran, Macarena/I-5225-2016; Garcia, Maria Angel
   MA/I-5116-2016; Rosa, Joaquín/L-8436-2014; García, Ana
   Conejo/I-5087-2018; Jiménez, Gema/O-7778-2017
OI Marchal, Juan Antonio/0000-0002-4996-8261; Peran,
   Macarena/0000-0001-7562-2347; Garcia, Maria Angel
   MA/0000-0003-2003-3769; Rosa, Joaquín/0000-0002-9035-8123; García, Ana
   Conejo/0000-0001-5776-7315; Jiménez, Gema/0000-0002-9803-879X; Agil,
   Ahmad/0000-0003-0164-9648; Ramirez Rivera, Alberto/0000-0002-7661-6974;
   Cruz-Lopez, Olga/0000-0002-9807-4061
FU Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria FEDER
   funds [CP08/0063, PI10/02295, PI10/00592]
FX We gratefully acknowledge Jaime Lazuen for providing excellent technical
   assistance with the cytometry studies and Manuela Exposito for
   statistical assistance. We also thank staff from the Experimental
   Surgery Research Unit, and Pablo Bueno for support with equipment. This
   work was supported in part by grants from the Instituto de Salud Carlos
   III (Fondo de Investigacion Sanitaria FEDER funds, CP08/0063,
   PI10/02295, and PI10/00592).
CR Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3
   Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887
   Backus HHJ, 2003, EUR J CANCER, V39, P1310, DOI 10.1016/S0959-8049(03)00204-1
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Dal Col J, 2012, CANCER RES, V72, P1825, DOI 10.1158/0008-5472.CAN-11-2505
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001
   Desai MM, 2011, GASTROENTEROLOGY, V141, P674, DOI 10.1053/j.gastro.2011.04.060
   Diaz-Gavilan M, 2006, J ORG CHEM, V71, P1043, DOI 10.1021/jo052167m
   Diaz-Gavilan M, 2008, CHEMMEDCHEM, V3, P127, DOI 10.1002/cmdc.200700180
   ESTEBAN M, 1974, EUR J BIOCHEM, V45, P567, DOI 10.1111/j.1432-1033.1974.tb03583.x
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255
   Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Hasselbalch HC, 2011, CURR DRUG TARGETS, V12, P387
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618
   Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540
   Kirkwood J, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.33078
   Kong Y., 2011, J AGING RES, V2011, DOI [10.4061/2011/963172, DOI 10.4061/2011/963172]
   Konstantakou EG, 2009, INT J ONCOL, V35, P401, DOI 10.3892/ijo_00000353
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Li QF, 2008, MOL CANCER RES, V6, P770, DOI 10.1158/1541-7786.MCR-07-0114
   Lopez-Cara LC, 2011, EUR J MED CHEM, V46, P249, DOI 10.1016/j.ejmech.2010.11.011
   Mansilla S, 2012, ANTI-CANCER AGENT ME, V12, P226, DOI 10.2174/187152012800228805
   Martinez-Rivera M, 2012, BIOCHEM PHARMACOL, V83, P1049, DOI 10.1016/j.bcp.2011.12.026
   Nakamura M, 2007, J HEPATOL, V46, P77, DOI 10.1016/j.jhep.2006.07.032
   Negrier S, 2011, LANCET ONCOL, V12, P673, DOI 10.1016/S1470-2045(11)70124-3
   Nunez MC, 2008, CURR MED CHEM, V15, P2614, DOI 10.2174/092986708785909021
   Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76
   Philchenkov A, 2004, EXP ONCOL, V26, P82
   Simonsson B, 2011, CURR DRUG TARGETS, V12, P420, DOI 10.2174/138945011794815301
   Tarhini AA, 2012, J IMMUNOL, V189, P3789, DOI 10.4049/jimmunol.1290060
   Tarhini AA, 2012, J CLIN ONCOL, V30, P322, DOI 10.1200/JCO.2011.37.5394
   Upreti M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.43
   VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yang XH, 2001, CANCER RES, V61, P348
   Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x
   Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 44
TC 17
Z9 19
U1 0
U2 22
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 1301
EP 1313
DI 10.2147/DDDT.S51354
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 241FH
UT WOS:000326151300001
PM 24194639
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Jeong, YK
   Oh, JY
   Yoo, JK
   Lim, SH
   Kim, EH
AF Jeong, Youn Kyoung
   Oh, Ju Yeon
   Yoo, Jae Kuk
   Lim, Sun Ha
   Kim, Eun Ho
TI The Biofunctional Effects of Mesima as a Radiosensitizer for
   Hepatocellular Carcinoma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mesima; HCC; radiation; radiosensitivity
ID PHELLINUS-LINTEUS; APOPTOSIS; POLYSACCHARIDE; METASTASIS; MUSHROOMS;
   INVASION; GROWTH; ARREST; CELLS
AB The tropical basidiomycete fungus Phellinus linteus (Mesima) exhibits anti-tumor, anti-angiogenic, and immunomodulatory properties in various cancers including prostate, colon, and lung cancer along with melanoma by, for example, inducing apoptosis or cell cycle arrest. However, whether medina also facilitates treatment of hepatocellular carcinoma (HCC), the third global cause of cancer deaths, remains unknown. Here, we examined its potential as a radiosensitizer in HCC radiotherapy using human HCC Hep3B and HepG2 cell lines and xenograft tumors. Mesima pretreatment significantly enhanced HCC cell radiosensitivity in vitro and the combination of mesima + radiation treatment significantly reduced xenograft tumor growth and size in vivo compared to those with single treatments. Mechanistically, mesima significantly enhanced radiotherapy efficiency by inhibiting tumor cell survival through inducing apoptosis (assessed via annexin V), impairing cell cycle regulation (shown by flow cytometry), and reducing radiation-induced DNA damage repair (measured via gamma-H2AX foci). Combination treatment also facilitated autophagic cell death beyond that from single treatments (assessed by quantifying stained acidic vesicular organelles), and diminished tumor cell metastatic potentials (shown by wound and Transwell assays). These findings support the synergistic anti-tumor effects of mesima combined with radiation and suggest scientific evidence for mesima as a radiosensitizer in HCC.
C1 [Jeong, Youn Kyoung] Korea Inst Radiol & Med Sci, Radiat Nonclin Ctr, Seoul 01812, South Korea.
   [Oh, Ju Yeon] Korea Univ, Sch Life Sci & Biotechnol, Lab Biochem, Seoul 136701, South Korea.
   [Yoo, Jae Kuk] Han Kook Shin Yak Pharmaceut Co Ltd, Nonsan 33023, South Korea.
   [Lim, Sun Ha; Kim, Eun Ho] Daegu Catholic Univ, Sch Med, Dept Biochem, 33,17 Gil, Daegu 705718, South Korea.
RP Kim, EH (corresponding author), Daegu Catholic Univ, Sch Med, Dept Biochem, 33,17 Gil, Daegu 705718, South Korea.
EM amy3523@kirams.re.kr; ojo5295@naver.com; yjk125@daum.net;
   sunha112@cu.ac.kr; eh140149@cu.ac.kr
FU Korea Institute of Radiological and Medical Sciences (KIRAMS)
   [51313-2017, 51314-2019]
FX This study was supported by private contract project (51313-2017,
   51314-2019) from the Korea Institute of Radiological and Medical
   Sciences (KIRAMS).
CR Borchers AT, 1999, P SOC EXP BIOL MED, V221, P281, DOI 10.1046/j.1525-1373.1999.d01-86.x
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   CHICHARA G, 1969, NATURE, V222, P687, DOI 10.1038/222687a0
   Collett NP, 2010, SEMIN ONCOL, V37, P258, DOI 10.1053/j.seminoncol.2010.06.014
   Collins L, 2006, BRIT J CANCER, V95, P282, DOI 10.1038/sj.bjc.6603277
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Guo JJ, 2007, MOL CARCINOGEN, V46, P144, DOI 10.1002/mc.20275
   Han SB, 1999, IMMUNOPHARMACOLOGY, V41, P157, DOI 10.1016/S0162-3109(98)00063-0
   Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687
   Kim EH, 2016, ONCOTARGET, V7, P65125, DOI 10.18632/oncotarget.11372
   Leber MF, 2009, INT J ONCOL, V34, P881, DOI 10.3892/ijo_00000214
   Lee HJ, 2005, BIOL PHARM BULL, V28, P27, DOI 10.1248/bpb.28.27
   Li G, 2004, CANCER LETT, V216, P175, DOI 10.1016/j.canlet.2004.07.014
   Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Sliva D, 2010, EXP THER MED, V1, P407, DOI 10.3892/etm_00000063
   Song KS, 1995, CHEM PHARM BULL, V43, P2105, DOI 10.1248/cpb.43.2105
   Song KS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-307
   Wasser SP, 2002, APPL MICROBIOL BIOT, V60, P258, DOI 10.1007/s00253-002-1076-7
NR 23
TC 5
Z9 5
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2020
VL 21
IS 3
AR 871
DI 10.3390/ijms21030871
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KY4PQ
UT WOS:000522551603025
PM 32013255
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Al-Bari, MAA
   Xu, PY
AF Al-Bari, Md Abdul Alim
   Xu, Pingyong
TI Molecular regulation of autophagy machinery by mTOR-dependent and
   -independent pathways
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Review
DE macroautophagy; autophagy regulation; mTOR signaling; amino acid
   sensing; calcium channel; TRPML; miRNA
ID ACTIVATED PROTEIN-KINASE; ER CA2+ DEPLETION; CELL-DEATH; CANCER CELLS;
   ENDOPLASMIC-RETICULUM; AMINO-ACIDS; AMPK PHOSPHORYLATION;
   COLORECTAL-CANCER; RAG GTPASES; ION-CHANNEL
AB Macroautophagy is a lysosomal degradative pathway or recycling process that maintains cellular homeostasis. This autophagy involves a series of sequential processing events, such as initiation; elongation and nucleation of the isolation membrane; cargo recruitment and maturation of the autophagosome (AP); transport of the AP; docking and fusion of the AP with a late endosome or lysosome; and regeneration of the lysosome by the autophagic lysosomal reformation cycle. These events are critically coordinated by the action of a set of several key components, including autophagy-related proteins (Atg), and regulated by intricate networks, such as mechanistic target of rapamycin (mTOR), a master regulator of autophagy, as well as mTOR-independent signaling pathways. Among mTOR-independent pathways, the transient receptor potential (TRP) calcium ion channel TRPML (mucolipin) subfamily is emerging as an important signaling channel to modulate lysosomal biogenesis and autophagy. This review discusses the recent advances in elucidating the molecular mechanisms and regulation of the autophagy process. Understanding these mechanisms may ultimately allow scientists and clinicians to control this process in order to improve human health.
C1 [Al-Bari, Md Abdul Alim] Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
   [Xu, Pingyong] Chinese Acad Sci, Inst Biophys, Key Lab RNA Biol, Beijing, Peoples R China.
   [Xu, Pingyong] Chinese Acad Sci, Inst Biophys, Beijing Key Lab Noncoding RNA, Beijing, Peoples R China.
RP Al-Bari, MAA (corresponding author), Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
EM alimalbari347@ru.ac.bd
RI Al-Bari, Abdul Alim/AAT-4301-2020; Al-Bari, Md. Abdul Alim/C-2946-2018
OI Al-Bari, Md. Abdul Alim/0000-0002-1777-3662
CR Agarwal S, 2015, J BIOL CHEM, V290, P27473, DOI 10.1074/jbc.M115.665133
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044
   Bootman MD, 2018, CELL CALCIUM, V70, P32, DOI 10.1016/j.ceca.2017.08.005
   Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030
   Carroll B, 2016, ELIFE, V5, DOI 10.7554/eLife.11058
   Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Cheng KT, 2008, J BIOL CHEM, V283, P12935, DOI 10.1074/jbc.C800008200
   Choi S, 2014, BIOCHEM BIOPH RES CO, V443, P56, DOI 10.1016/j.bbrc.2013.11.044
   Chung KM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00116
   Coblentz J, 2014, BIOCHEM J, V457, P361, DOI 10.1042/BJ20130647
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Cormerais Y, 2018, J BIOL CHEM, V293, P2877, DOI 10.1074/jbc.RA117.001342
   Cuajungco MP, 2016, PFLUG ARCH EUR J PHY, V468, P177, DOI 10.1007/s00424-015-1732-2
   Decuypere JP, 2011, AUTOPHAGY, V7, P1472, DOI 10.4161/auto.7.12.17909
   Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001
   Decuypere JP, 2011, BBA-MOL CELL RES, V1813, P1003, DOI 10.1016/j.bbamcr.2010.11.023
   Di Paola S, 2018, CELL CALCIUM, V69, P112, DOI 10.1016/j.ceca.2017.06.006
   Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dong X. S., 2010, CPWR DATA BRIEFS, V2, P1, DOI DOI 10.1038/NC0MMS1037
   East DA, 2013, AUTOPHAGY, V9, P1710, DOI 10.4161/auto.25367
   Efeyan A, 2013, BIOCHEM SOC T, V41, P902, DOI 10.1042/BST20130063
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ezeani M, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00083
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fliniaux I, 2018, CELL CALCIUM, V69, P4, DOI 10.1016/j.ceca.2017.07.002
   Fracchiolla D, 2018, EMBO J, V37, DOI 10.15252/embj.201798895
   Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51
   Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721
   Gu X, 2017, SCIENCE, V358, P813, DOI 10.1126/science.aao3265
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Gulati P, 2008, CELL METAB, V7, P456, DOI 10.1016/j.cmet.2008.03.002
   Gurusamy N, 2009, ANTIOXID REDOX SIGN, V11, P1975, DOI [10.1089/ars.2009.2524, 10.1089/ARS.2009.2524]
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jang M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30977-7
   Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472
   Jia GH, 2015, BBA-MOL BASIS DIS, V1852, P219, DOI 10.1016/j.bbadis.2014.06.025
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kim HJ, 2009, TRAFFIC, V10, P1157, DOI 10.1111/j.1600-0854.2009.00924.x
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kishino A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02960-1
   Kondratskyi A, 2018, AUTOPHAGY, V14, P3, DOI 10.1080/15548627.2017.1384887
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Laker RC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00520-9
   Leipnitz G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19543-3
   Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x
   Li RJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19360
   Li XR, 2016, NAT CELL BIOL, V18, P404, DOI 10.1038/ncb3324
   Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002
   Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200
   Margariti A, 2013, J BIOL CHEM, V288, P859, DOI 10.1074/jbc.M112.412783
   Martin TD, 2014, MOL CELL, V53, P209, DOI 10.1016/j.molcel.2013.12.004
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Mazar J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013779
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710
   Milkereit R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8250
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Monkkonen T, 2018, AUTOPHAGY, V14, P190, DOI 10.1080/15548627.2017.1345412
   Munch C, 2018, NAT CELL BIOL, V20, P122, DOI 10.1038/s41556-018-0036-0
   Nakanishi A, 2017, J BIOL CHEM, V292, P19804, DOI 10.1074/jbc.M117.805085
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Nwadike C, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00023-18
   Onyenwoke RU, 2015, BIOCHEM J, V470, P331, DOI 10.1042/BJ20150219
   Ozturk DG, 2019, AUTOPHAGY, V15, P375, DOI 10.1080/15548627.2018.1531197
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Petit CS, 2013, J CELL BIOL, V202, P1107, DOI 10.1083/jcb.201307084
   Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200
   Powis K, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2015.49
   Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122
   Prakriya M, 2015, PHYSIOL REV, V95, P1383, DOI 10.1152/physrev.00020.2014
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Raffaello A, 2016, TRENDS BIOCHEM SCI, V41, P1035, DOI 10.1016/j.tibs.2016.09.001
   Raiborg C, 2015, EMBO J, V34, P1848, DOI 10.15252/embj.201591481
   Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107
   Rockel JS, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.17
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Sabatini DM, 2017, P NATL ACAD SCI USA, V114, P11818, DOI 10.1073/pnas.1716173114
   Salsman J, 2017, SCI REP-UK, V7, DOI 10.1038/srep45038
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Saxton RA, 2016, NATURE, V536, P229, DOI 10.1038/nature19079
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Sehgal P, 2017, J BIOL CHEM, V292, P19656, DOI 10.1074/jbc.M117.796920
   Semenza GL, 2011, BBA-MOL CELL RES, V1813, P1263, DOI 10.1016/j.bbamcr.2010.08.006
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shao D, 2014, CELL METAB, V19, P232, DOI 10.1016/j.cmet.2013.12.013
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Sil P, 2018, CURR OPIN IMMUNOL, V50, P21, DOI 10.1016/j.coi.2017.10.004
   Song YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20162-1
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Szalai P, 2018, CELL CALCIUM, V76, P48, DOI 10.1016/j.ceca.2018.09.005
   Tedeschi V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46708-5
   Valladares D, 2018, BBA-MOL BASIS DIS, V1864, P3685, DOI 10.1016/j.bbadis.2018.08.042
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547
   Venugopal B, 2009, J CELL PHYSIOL, V219, P344, DOI 10.1002/jcp.21676
   Vergarajauregui S, 2011, J CELL SCI, V124, P459, DOI 10.1242/jcs.076240
   Vergarajauregui S, 2009, J BIOL CHEM, V284, P36357, DOI 10.1074/jbc.M109.047241
   Vervliet T, 2017, BIOCHEM PHARMACOL, V132, P133, DOI 10.1016/j.bcp.2017.03.011
   Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang P, 2017, MOL MED REP, V16, P2107, DOI 10.3892/mmr.2017.6794
   Wang P, 2018, J BIOL CHEM, V293, P4110, DOI 10.1074/jbc.RA117.001294
   Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132
   Wang WY, 2015, P NATL ACAD SCI USA, V112, pE1373, DOI 10.1073/pnas.1419669112
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674
   Wong CO, 2012, CURR BIOL, V22, P1616, DOI 10.1016/j.cub.2012.06.055
   Wyant GA, 2017, CELL, V171, P642, DOI 10.1016/j.cell.2017.09.046
   Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016
   Yang ZD, 2016, J IRON STEEL RES INT, V23, P808, DOI 10.1016/S1006-706X(16)30124-8
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu YH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1484152
   Yuan J, 2015, AUTOPHAGY, V11, P1081, DOI 10.1080/15548627.2015.1040970
   Yuan JP, 2007, NAT CELL BIOL, V9, P636, DOI 10.1038/ncb1590
   Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147
   Zhang TL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01567-4
   Zhang XL, 2012, P NATL ACAD SCI USA, V109, P11384, DOI 10.1073/pnas.1202194109
   Zhang XZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10938
   Zhao Y, 2013, AUTOPHAGY, V9, P794, DOI 10.4161/auto.23918
   Ziemba BP, 2013, BIOCHEMISTRY-US, V52, P4820, DOI 10.1021/bi400488f
NR 150
TC 46
Z9 47
U1 9
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0077-8923
EI 1749-6632
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD MAY
PY 2020
VL 1467
IS 1
BP 3
EP 20
DI 10.1111/nyas.14305
EA JAN 2020
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LN6VD
UT WOS:000509412400001
PM 31985829
DA 2022-04-25
ER

PT J
AU Duarte, D
   Cardoso, A
   Vale, N
AF Duarte, Diana
   Cardoso, Armando
   Vale, Nuno
TI Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer
   Cells with Simultaneous and Sequential Combinations of Antineoplastics
   and CNS Drugs
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal cancer; breast cancer; drug synergism; antineoplastic drugs;
   drug repurposing; CNS drugs; combination therapy
ID VALPROIC ACID; ANTICANCER ACTIVITY; IN-VITRO; IMIPRAMINE BLUE;
   P-GLYCOPROTEIN; 5-FLUOROURACIL; AUTOPHAGY; VIVO; TRIFLUOPERAZINE;
   CHEMOTHERAPY
AB Several central nervous system (CNS) drugs exhibit potent anti-cancer activities. This study aimed to design a novel model of combination that combines different CNS agents and antineoplastic drugs (5-fluorouracil (5-FU) and paclitaxel (PTX)) for colorectal and breast cancer therapy, respectively. Cytotoxic effects of 5-FU and PTX alone and in combination with different CNS agents were evaluated on HT-29 colon and MCF-7 breast cancer cells, respectively. Three antimalarials alone and in combination with 5-FU were also evaluated in HT-29 cells. Different schedules and concentrations in a fixed ratio were added to the cultured cells and incubated for 48 h. Cell viability was evaluated using MTT and SRB assays. Synergism was evaluated using the Chou-Talalay, Bliss Independence and HSA methods. Our results demonstrate that fluphenazine, fluoxetine and benztropine have enhanced anticancer activity when used alone as compared to being used in combination, making them ideal candidates for drug repurposing in colorectal cancer (CRC). Regarding MCF-7 cells, sertraline was the most promising candidate alone for drug repurposing, with the lowest IC50 value. For HT-29 cells, the CNS drugs sertraline and thioridazine in simultaneous combination with 5-FU demonstrated the strongest synergism among all combinations. In MCF-7 breast cancer cells, the combination of fluoxetine, fluphenazine and benztropine with PTX resulted in synergism for all concentrations below IC50. We also found that the antimalarial artesunate administration prior to 5-FU produces better results in reducing HT-29 cell viability than the inverse drug schedule or the simultaneous combination. These results demonstrate that CNS drugs activity differs between the two selected cell lines, both alone and in combination, and support that some CNS agents may be promising candidates for drug repurposing in these types of cancers. Additionally, these results demonstrate that 5-FU or a combination of PTX with CNS drugs should be further evaluated. These results also demonstrate that antimalarial drugs may also be used as antitumor agents in colorectal cancer, besides breast cancer.
C1 [Duarte, Diana; Vale, Nuno] Ctr Hlth Technol & Serv Res CINTESIS, OncoPharma Res Grp, Rua Doutor Placido da Costa, P-4200450 Porto, Portugal.
   [Duarte, Diana] Univ Porto, Fac Pharm, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Cardoso, Armando] Ctr Hlth Technol & Serv Res CINTESIS, NeuroGen Res Grp, Rua Doutor Placido da Costa, P-4200450 Porto, Portugal.
   [Cardoso, Armando] Univ Porto, Fac Med, Dept Biomed, Unit Anat, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.
   [Vale, Nuno] Univ Porto, Fac Med, Dept Community Med Hlth Informat & Decis MEDCIDS, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.
RP Vale, N (corresponding author), Ctr Hlth Technol & Serv Res CINTESIS, OncoPharma Res Grp, Rua Doutor Placido da Costa, P-4200450 Porto, Portugal.; Vale, N (corresponding author), Univ Porto, Fac Med, Dept Community Med Hlth Informat & Decis MEDCIDS, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.
EM dianaduarte29@gmail.com; cardosoa@med.up.pt; nunovale@med.up.pt
RI Duarte, Diana/ABA-2082-2020; Cardoso, Armando/H-9733-2013
OI Duarte, Diana/0000-0003-1420-5042; Vale, Nuno/0000-0002-1283-1042;
   Cardoso, Armando/0000-0002-2967-6990
FU FEDER-Fundo Europeu de Desenvolvimento Regional funds through the
   COMPETE 2020-Operational Programme for Competitiveness and
   Internationalisation (POCI), Portugal 2020; Portuguese funds through
   Fundacao para a Ciencia e a Tecnologia (FCT)
   [IF/00092/2014/CP1255/CT0004]
FX This research was financed by FEDER-Fundo Europeu de Desenvolvimento
   Regional funds through the COMPETE 2020-Operational Programme for
   Competitiveness and Internationalisation (POCI), Portugal 2020, and by
   Portuguese funds through Fundacao para a Ciencia e a Tecnologia (FCT) in
   the framework of the project IF/00092/2014/CP1255/CT0004.
CR Abdelaleem M, 2019, ONCOL REV, V13, P37, DOI 10.4081/oncol.2019.411
   Ben-Hamo R, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0084-3
   Bertolesi GE, 2002, MOL PHARMACOL, V62, P210, DOI 10.1124/mol.62.2.210
   Bharadwaj P R, 2013, Transl Psychiatry, V3, pe332, DOI 10.1038/tp.2013.97
   Bowie M, 2015, WORLD J CLIN ONCOL, V6, P299, DOI 10.5306/wjco.v6.i6.299
   Calaf GM, 2018, ONCOL REP, V40, P2381, DOI 10.3892/or.2018.6603
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Chou YW, 2011, CANCER LETT, V311, P177, DOI 10.1016/j.canlet.2011.07.015
   De La Garza R, 2015, PROG NEURO-PSYCHOPH, V59, P40, DOI 10.1016/j.pnpbp.2015.01.009
   Duarte D, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121623
   El Ela AA, 2004, J PHARM PHARMACOL, V56, P967, DOI 10.1211/0022357043969
   Entezar-Almahdi E, 2020, INT J NANOMED, V15, P5445, DOI 10.2147/IJN.S257700
   Fond G, 2012, MED HYPOTHESES, V79, P38, DOI 10.1016/j.mehy.2012.03.026
   Fulda S, 2004, ONCOGENE, V23, P6702, DOI 10.1038/sj.onc.1207630
   Ghorab MM, 2017, EUR J MED CHEM, V134, P304, DOI 10.1016/j.ejmech.2017.04.028
   Gil-Ad I, 2008, INT J ONCOL, V33, P277, DOI 10.3892/ijo_00000007
   Grolleman JE, 2019, CANCER CELL, V35, P256, DOI 10.1016/j.ccell.2018.12.011
   Gupta SC, 2013, TRENDS PHARMACOL SCI, V34, P508, DOI 10.1016/j.tips.2013.06.005
   Gwynne WD, 2017, ONCOTARGET, V8, P32101, DOI 10.18632/oncotarget.16646
   Hallett RM, 2016, ONCOTARGET, V7, P53137, DOI 10.18632/oncotarget.10614
   Hu LX, 2012, ASIAN PAC J CANCER P, V13, P5903, DOI 10.7314/APJCP.2012.13.11.5903
   Hu QY, 2016, ADV DRUG DELIVER REV, V98, P19, DOI 10.1016/j.addr.2015.10.022
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V332, P433, DOI 10.1016/j.bbrc.2005.04.143
   Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216
   Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9
   Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024
   Jiang D, 2017, ONCOL REP, V37, P594, DOI 10.3892/or.2016.5246
   Kang S, 2017, MOL CANCER THER, V16, P217, DOI 10.1158/1535-7163.MCT-16-0169-T
   Kapoor A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056525
   Laidlaw KME, 2016, ONCOTARGET, V7, P51651, DOI 10.18632/oncotarget.10541
   Lee WY, 2015, NUTR CANCER, V67, P275, DOI 10.1080/01635581.2015.989374
   Liu SW, 2017, FEBS OPEN BIO, V7, P798, DOI 10.1002/2211-5463.12223
   Metts J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04796-1
   Miles TF, 2015, NEUROPHARMACOLOGY, V91, P103, DOI 10.1016/j.neuropharm.2014.12.018
   Mirzapur P, 2018, LIFE SCI, V205, P45, DOI 10.1016/j.lfs.2018.04.035
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Munson JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003016
   Niraula S, 2012, J CLIN ONCOL, V30, P3012, DOI 10.1200/JCO.2011.40.3824
   O'Brien FE, 2012, BRIT J PHARMACOL, V165, P289, DOI 10.1111/j.1476-5381.2011.01557.x
   Odeh LH, 2018, J CANCER RES THER, V14, pS324, DOI 10.4103/0973-1482.235349
   Oliveras-Ferraros C, 2008, INT J ONCOL, V32, P113
   Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009
   Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.442
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Rajamanickam S, 2016, CLIN CANCER RES, V22, P3524, DOI 10.1158/1078-0432.CCR-15-2535
   Roell KR, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00158
   Roney MSI, 2018, ARCH PHARM RES, V41, P384, DOI 10.1007/s12272-018-1017-3
   Saha SK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051048
   SCHLICKER E, 1994, N-S ARCH PHARMACOL, V349, P20
   Shu CH, 1997, APOPTOSIS, V2, P463, DOI 10.1023/A:1026422111457
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sogawa C, 2020, CANCERS, V12, DOI 10.3390/cancers12020523
   Sun DJ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12402
   Terranova-Barberio M, 2016, ONCOTARGET, V7, P7715, DOI 10.18632/oncotarget.6802
   Vogus DR, 2018, BIOENG TRANSL MED, V3, P49, DOI 10.1002/btm2.10082
   Wang CZ, 2015, NUTRIENTS, V7, P799, DOI 10.3390/nu7020799
   Wu CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27540
   Xu FY, 2019, AM J CANCER RES, V9, P459
   Yang WH, 2016, ONCOGENE, V35, P2287, DOI 10.1038/onc.2015.291
   Yao MJ, 2017, INT J ONCOL, V51, P587, DOI 10.3892/ijo.2017.4052
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Zhang C, 2017, ONCOL REP, V37, P1168, DOI 10.3892/or.2016.5313
   Zong D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.56
NR 64
TC 5
Z9 5
U1 3
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 14
AR 7408
DI 10.3390/ijms22147408
PG 39
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TN6ZN
UT WOS:000676380700001
PM 34299028
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, LC
   Wang, HY
   Qian, J
   Wei, GL
   Ding, R
   Hu, CH
   Fang, D
   Jiang, ZY
   Bi, L
   Song, J
   Ma, J
   Qin, FX
   Huang, XF
   Cao, M
   Huo, JG
AF Li, Lingchang
   Wang, Haiyan
   Qian, Jun
   Wei, Guoli
   Ding, Rong
   Hu, Canhong
   Fang, Dong
   Jiang, Ziyu
   Bi, Lei
   Song, Jie
   Ma, Jun
   Qin, Fengxia
   Huang, Xiaofei
   Cao, Meng
   Huo, Jiege
TI FuFangChangTai Decoction Activates Macrophages via Inducing Autophagy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID T-CELLS; IL-6; EXPRESSION; APOPTOSIS; PATHWAYS; ROLES; CD80
AB The traditional Chinese medicine decoction FuFangChangTai (FFCT) has been used in the therapy of colon cancer clinically, yielding alleviated toxicity and enhanced immunity. In our previous study, FFCT exerted its antitumor activity not only by inducing apoptosis but also by activating autophagy to eliminate tumor cells. However, its mechanism is not well understood. The purpose of this study was to investigate the relationship between macrophages activation and FFCT-induced autophagy. Results showed that FFCT could induce autophagy in colon cancer, as demonstrated by increased level of intracellular autophagy marker LC3 II in CT26.WT cells by fluorescence microscope and western blot assay. FFCT also facilitated numbers of vesicular bodies with bilayer membrane in CT26.WT cells, which were indicative of autophagosomes formation. Autophagosomes secreted by FFCT-treated CT26.WT cells can activate M1 type macrophages, accompanied with increased expression of costimulatory molecules CD86 and CD40 on the surface of RAW264.7 cells, and more inflammatory cytokines secretion, such as TNF-, IL-6, MCP-1, and IL-1. mRNA expressions of M2 macrophages markers, such as IL-10, CD206, Arg-1, and FIZZ-1, were downregulated. And this process helps regulate the polarization of macrophages and promote the immune response. These findings support a mechanism of FFCT-induced autophagy and provide novel evidence demonstrating that macrophages are involved in FFCT-induced autophagy progression.
C1 [Li, Lingchang; Wei, Guoli; Ding, Rong; Hu, Canhong; Jiang, Ziyu; Song, Jie; Qin, Fengxia; Huang, Xiaofei; Cao, Meng; Huo, Jiege] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Jiangsu, Peoples R China.
   [Li, Lingchang; Qian, Jun; Bi, Lei] Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China.
   [Wang, Haiyan] Xuzhou Tongshan Dist Hosp Tradit Chinese Med, Xuzhou, Jiangsu, Peoples R China.
   [Fang, Dong] Zhenjiang Hosp Chinese Tradit & Western Med, Zhenjiang, Jiangsu, Peoples R China.
   [Ma, Jun] Nanjing Univ Chinese Med, Huaian Affiliated Hosp, Huaian, Jiangsu, Peoples R China.
RP Cao, M; Huo, JG (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Jiangsu, Peoples R China.
EM mcao1979@163.com; huojiege@jsatcm.com
RI Li, Lingchang/AAL-4850-2021
OI Li, Lingchang/0000-0001-5520-7023
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81503574, 81673945, 81873055, 81873219];
   Natural Science Foundation of Jiangsu Province of ChinaNatural Science
   Foundation of Jiangsu Province [BK20151605]; Jiangsu Provincial TCM
   Leading Talent Project [SLJ0211]; Jiangsu Provincial Clinical Research
   Project [BL2014099]; Open subject of Jiangsu Branch of Chinese Academy
   of Chinese Medical Sciences [FY201803]
FX This study received Grants from National Natural Science Foundation of
   China (81503574, 81673945, 81873055, and 81873219); Natural Science
   Foundation of Jiangsu Province of China (BK20151605); Jiangsu Provincial
   TCM Leading Talent Project (SLJ0211); Jiangsu Provincial Clinical
   Research Project (BL2014099); Open subject of Jiangsu Branch of Chinese
   Academy of Chinese Medical Sciences (FY201803).
CR Asano K, 2011, IMMUNITY, V34, P85, DOI 10.1016/j.immuni.2010.12.011
   Bansal Megha, 2018, Commun Integr Biol, V11, P1, DOI 10.1080/19420889.2018.1467189
   Bertin-Maghit S, 2011, DIABETES, V60, P248, DOI 10.2337/db10-0104
   Chadli Loubna, 2013, Methods Mol Biol, V989, P83, DOI 10.1007/978-1-62703-330-5_8
   Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007
   Chen QH, 2018, CELL PHYSIOL BIOCHEM, V49, P2200, DOI 10.1159/000493824
   Chen S, 2015, AUTOPHAGY, V11, P2346, DOI 10.1080/15548627.2015.1109765
   Cheng J, 2012, TOXICOL MECH METHOD, V22, P512, DOI 10.3109/15376516.2012.686534
   Coperchini F, 2016, TUMOR BIOL, V37, P5569, DOI 10.1007/s13277-015-4418-7
   Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17
   [丁永芳 Ding Yongfang], 2011, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V27, P346
   Dong W, 2018, MOLECULES, V23, DOI 10.3390/molecules23081841
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   He QS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00635
   He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108
   Klein L, 2010, FEBS LETT, V584, P1405, DOI 10.1016/j.febslet.2010.01.008
   Lai Xianghong, 2018, Oncol Res, DOI 10.3727/096504018X15321979274728
   Li LC, 2011, CHIN GER J CLIN ONCO, V10, P225
   Li ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/jhep.2003.50048
   Liu B, 2013, CHIN J CANCER, V32, P113, DOI 10.5732/cjc.012.10010
   Liuzzi JP, 2014, BIOMETALS, V27, P1087, DOI 10.1007/s10534-014-9773-0
   Luo XJ, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0150-x
   Ma PF, 2017, J HEPATOL, V67, P770, DOI 10.1016/j.jhep.2017.05.022
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Mauvezin C, 2014, METHODS, V68, P134, DOI 10.1016/j.ymeth.2014.03.014
   Moreno-Fierros L, 2013, INT IMMUNOPHARMACOL, V17, P1051, DOI 10.1016/j.intimp.2013.10.005
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Onore CE, 2014, BRAIN BEHAV IMMUN, V38, P220, DOI 10.1016/j.bbi.2014.02.007
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Rekha RS, 2015, AUTOPHAGY, V11, P1688, DOI 10.1080/15548627.2015.1075110
   Sakakura K, 2016, LAB INVEST, V96, P994, DOI 10.1038/labinvest.2016.70
   Satchidanandam V, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004176
   Sebina I, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12455
   Song J, 2017, MOL CARCINOGEN, V56, P36, DOI 10.1002/mc.22471
   Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x
   VanGool SW, 1996, IMMUNOL REV, V153, P47
   Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009
   Vidyarthi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01650
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wu ZM, 2018, MOL MED REP, V17, P7875, DOI 10.3892/mmr.2018.8818
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Xu YH, 2013, ONCOL LETT, V5, P411, DOI 10.3892/ol.2012.1015
   [许珍珍 XU Zhenzhen], 2011, [中国药房, China Pharmacy], V22, P2523
   [张舒 ZHANG Shu], 2010, [中成药, Chinese Traditional Patent Medicine], V32, P374
   Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004
NR 46
TC 1
Z9 2
U1 2
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2019
VL 2019
AR 5657035
DI 10.1155/2019/5657035
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA IF3RW
UT WOS:000473001700001
PM 31308853
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Yu, HI
   Shen, HC
   Chen, SH
   Lim, YP
   Chuang, HH
   Tai, TS
   Kung, FP
   Lu, CH
   Hou, CY
   Lee, YR
AF Yu, Hui-, I
   Shen, Hui-Ching
   Chen, Shu-Hsin
   Lim, Yun-Ping
   Chuang, Hsiang-Hsun
   Tai, Tsai-Sung
   Kung, Fang-Ping
   Lu, Chieh-Hsiang
   Hou, Chia-Yi
   Lee, Ying-Ray
TI Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine
   Treatment
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE aloperine; thyroid cancer; autophagy
ID CYCLE ARREST; IN-VITRO; DERIVATIVES; APOPTOSIS; EVOLUTION; DISCOVERY;
   INJURY
AB Aloperine, an alkaloid isolated from Sophoraalopecuroides, exhibits multiple pharmacological activities including anti-inflammatory, antioxidant, antiallergic, antinociceptive, antipathogenic, and antitumor effects. Furthermore, it exerts protective effects against renal and neuronal injuries. Several studies have reported antitumor effects of aloperine against various human cancers, including multiple myeloma; colon, breast, and prostate cancers; and osteosarcoma. Cell cycle arrest, apoptosis induction, and tumorigenesis suppression have been demonstrated following aloperine treatment. In a previous study, we demonstrated antitumor effects of aloperine on human thyroid cancer cells through anti-tumorigenesis and caspase-dependent apoptosis induction via the Akt signaling pathway. In the present study, we demonstrated the modulation of the autophagy mechanism following the incubation of multidrug-resistant papillary and anaplastic human thyroid cancer cells with aloperine; we also illustrate the underlying mechanisms, including AMPK, Erk, JNK, p38, and Akt signaling pathways. Further investigation revealed the involvement of the Akt signaling pathway in aloperine-modulated autophagy in human thyroid cancer cells. These results indicate a previously unappreciated function of aloperine in autophagy modulation in human thyroid cancer cells.
C1 [Yu, Hui-, I; Chuang, Hsiang-Hsun; Tai, Tsai-Sung; Kung, Fang-Ping; Lu, Chieh-Hsiang] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med, Div Endocrinol & Metab, Chiayi 600, Taiwan.
   [Shen, Hui-Ching; Hou, Chia-Yi] Chi Mei Med Ctr, Dept Clin Pathol, Liouying 736, Taiwan.
   [Chen, Shu-Hsin; Lee, Ying-Ray] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Med Res, Chiayi 600, Taiwan.
   [Lim, Yun-Ping] China Med Univ, Coll Pharm, Dept Pharm, Taichung 404, Taiwan.
RP Lee, YR (corresponding author), Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Med Res, Chiayi 600, Taiwan.
EM 04490@cych.org.tw; huiching0105@gmail.com; 10472@cych.org.tw;
   limyp@mail.cmu.edu.tw; 04486@cych.org.tw; 04015@cych.org.tw;
   07266@cych.org.tw; 02602@cych.org.tw; 960360@mail.chimei.org.tw;
   yingray.lee@gmail.com
OI Lee, Ying-Ray/0000-0002-0349-0960
FU Ministry of Science and Technology of the Republic of China,
   TaiwanMinistry of Science and Technology, Taiwan [MOST
   108-2314-B-705-001]; Ditmanson Medical Foundation Chiayi Christian
   Hospital [R107-24]; Chi Mei Medical Center [CLFHR10836]
FX This work was supported by the grants from the Ministry of Science and
   Technology of the Republic of China, Taiwan (MOST 108-2314-B-705-001),
   Ditmanson Medical Foundation Chiayi Christian Hospital (Grant R107-24)
   and Chi Mei Medical Center (CLFHR10836). We thank Myron for the critical
   review of the manuscript.
CR Chen S, 2018, BIOMED PHARMACOTHER, V97, P45, DOI 10.1016/j.biopha.2017.09.066
   Dang Z, 2017, ACS MED CHEM LETT, V8, P1199, DOI 10.1021/acsmedchemlett.7b00376
   Dang Z, 2016, ACS MED CHEM LETT, V7, P240, DOI 10.1021/acsmedchemlett.5b00339
   Ebrahimi S, 2017, CURR MED CHEM, V24, P1321, DOI 10.2174/0929867324666170206142658
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Hu S, 2015, MOL MED, V21, P912, DOI 10.2119/molmed.2015.00056
   Kaushal GP, 2016, KIDNEY INT, V89, P779, DOI 10.1016/j.kint.2015.11.021
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lee YR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010312
   Lin WC, 2011, J AGR FOOD CHEM, V59, P184, DOI 10.1021/jf103581r
   Lin Z, 2011, BASIC CLIN PHARMACOL, V108, P304, DOI 10.1111/j.1742-7843.2010.00653.x
   Ling ZX, 2018, ONCOTARGETS THER, V11, P2735, DOI 10.2147/OTT.S165262
   Liu JS, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152843
   Ma NT, 2015, J NAT MED-TOKYO, V69, P575, DOI 10.1007/s11418-015-0928-2
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Ren DL, 2017, EXP THER MED, V13, P315, DOI 10.3892/etm.2016.3962
   Suzuki K, 2007, FEBS LETT, V581, P2156, DOI 10.1016/j.febslet.2007.01.096
   Tian DL, 2018, MOL MED REP, V18, P3699, DOI 10.3892/mmr.2018.9419
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Wang H, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0120-x
   Wang N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/934207
   Wu F, 2017, BIOMED PHARMACOTHER, V89, P632, DOI 10.1016/j.biopha.2017.02.033
   Yin WL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24565-y
   Yuan XY, 2010, EUR J PHARMACOL, V629, P147, DOI 10.1016/j.ejphar.2009.12.007
   Zhang L, 2014, INT J MOL MED, V33, P1613, DOI 10.3892/ijmm.2014.1718
   Zhang N, 2019, EBIOMEDICINE, V40, P151, DOI 10.1016/j.ebiom.2019.01.054
   Zhang X, 2018, EUR J MED CHEM, V149, P45, DOI 10.1016/j.ejmech.2018.02.061
   Zhang X, 2018, EUR J MED CHEM, V143, P1053, DOI 10.1016/j.ejmech.2017.12.002
   Zhao XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1340-8
   ZHOU CC, 1989, ACTA PHARM SINIC, V10, P360
NR 34
TC 10
Z9 10
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 21
AR 5315
DI 10.3390/ijms20215315
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JQ4VU
UT WOS:000498946100073
PM 31731481
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU O'Donovan, TR
   Rajendran, S
   O'Reilly, S
   O'Sullivan, GC
   McKenna, SL
AF O'Donovan, Tracey R.
   Rajendran, Simon
   O'Reilly, Seamus
   O'Sullivan, Gerald C.
   McKenna, Sharon L.
TI Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells
   and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo
SO PLOS ONE
LA English
DT Article
ID TUMOR STROMA MODEL; ISCHEMIA/REPERFUSION INJURY; MEMBRANE
   PERMEABILIZATION; CARDIOMYOCYTE DEATH; OXIDATIVE STRESS; FLOW-CYTOMETRY;
   INHIBITION; DEGRADATION; GROWTH; DRUG
AB Many epithelial cancers, particularly gastrointestinal tract cancers, remain poor prognosis diseases, due to resistance to cytotoxic therapy and local or metastatic recurrence. We have previously shown that apoptosis incompetent esophageal cancer cells induce autophagy in response to chemotherapeutic agents and this can facilitate their recovery. However, known pharmacological inhibitors of autophagy could not enhance cytotoxicity. In this study, we have examined two well known, clinically approved autophagy inducers, rapamycin and lithium, for their effects on chemosensitivity in apoptosis incompetent cancer cells. Both lithium and rapamycin were shown to induce autophagosomes in esophageal and colorectal cancer cells by western blot analysis of LC3 isoforms, morphology and FACS quantitation of Cyto-ID or mCherry-GFP-LC3. Analysis of autophagic flux indicates inefficient autophagosome processing in lithium treated cells, whereas rapamycin treated cells showed efficient flux. Viability and recovery was assessed by clonogenic assays. When combined with the chemotherapeutic agent 5-fluorouracil, rapamycin was protective. In contrast, lithium showed strong enhancement of non-apoptotic cell death. The combination of lithium with 5-fluorouracil or oxaliplatin was then tested in the syngenic mouse (balb/c) colorectal cancer model-CT26. When either chemotherapeutic agent was combined with lithium a significant reduction in tumor volume was achieved. In addition, survival was dramatically increased in the combination group (p < 0.0001), with > 50% of animals achieving long term cure without re-occurrence (> 1 year tumor free). Thus, combination treatment with lithium can substantially improve the efficacy of chemotherapeutic agents in apoptosis deficient cancer cells. Induction of compromised autophagy may contribute to this cytotoxicity.
C1 [O'Donovan, Tracey R.; Rajendran, Simon; O'Sullivan, Gerald C.; McKenna, Sharon L.] Natl Univ Ireland Univ Coll Cork, Leslie C Quick Lab, Cork Canc Res Ctr, BioSci Inst, Cork, Ireland.
   [O'Reilly, Seamus] Cork Univ Hosp, Dept Med Oncol, Cork, Ireland.
RP McKenna, SL (corresponding author), Natl Univ Ireland Univ Coll Cork, Leslie C Quick Lab, Cork Canc Res Ctr, BioSci Inst, Cork, Ireland.
EM s.mckenna@ucc.ie
RI McKenna, Sharon/AAD-9432-2020
OI McKenna, Sharon/0000-0002-6764-6274
FU Health Research Board [HRA_POR/2011/55]
FX Funding was provided by Health Research Board HRA_POR/2011/55.
CR Aissat N, 2008, CANCER CHEMOTH PHARM, V62, P305, DOI 10.1007/s00280-007-0609-2
   Beauchamp EM, 2013, ONCOGENE, V32, P3923, DOI 10.1038/onc.2012.567
   Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Crowley LC, 2013, ONCOL REP, V29, P2261, DOI 10.3892/or.2013.2377
   Delbaldo C, 2011, TARGET ONCOL, V6, P119, DOI 10.1007/s11523-011-0177-6
   Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146
   Dou HY, 2005, J NEUROSCI, V25, P8375, DOI 10.1523/JNEUROSCI.2164-05.2005
   Erdal E, 2005, INT J CANCER, V115, P903, DOI 10.1002/ijc.20972
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Ginet V, 2014, AUTOPHAGY, V10, P846, DOI 10.4161/auto.28264
   Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10
   Grandjean EM, 2009, CNS DRUGS, V23, P331, DOI 10.2165/00023210-200923040-00005
   Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289
   Hsin IL, 2012, BRIT J PHARMACOL, V167, P1287, DOI 10.1111/j.1476-5381.2012.02073.x
   Hundeshagen P, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-38
   Kaufmann L, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-15
   Kessler L, 2014, ENDOCR PRACT, V20, P737, DOI 10.4158/EP13504.RA
   Kitazawa M, 2008, ANN NEUROL, V64, P15, DOI 10.1002/ana.21325
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kubisch R, 2014, INT J CANCER, V134, P2478, DOI 10.1002/ijc.28562
   Lam D, 2008, MOL BIOL CELL, V19, P691, DOI 10.1091/mbc.E07-08-0823
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Loos B, 2013, AUTOPHAGY, V9, P1270, DOI 10.4161/auto.25560
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Ma XC, 2012, CIRCULATION, V125, P3170, DOI 10.1161/CIRCULATIONAHA.111.041814
   Ma XC, 2012, AUTOPHAGY, V8, P297, DOI 10.4161/auto.18658
   Malhi GS, 2012, LANCET, V379, P690, DOI 10.1016/S0140-6736(11)61703-0
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P4297, DOI 10.4161/cc.9.21.13817
   McKnight RF, 2012, LANCET, V379, P721, DOI 10.1016/S0140-6736(11)61516-X
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mrschtik M, 2015, FEBS J, V282, P1858, DOI 10.1111/febs.13253
   Nciri R, 2009, HUM EXP TOXICOL, V28, P641, DOI 10.1177/0960327109106486
   Nowicki MO, 2008, NEURO-ONCOLOGY, V10, P690, DOI 10.1215/15228517-2008-041
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243
   Pavlides S, 2010, CELL CYCLE, V9, P3485, DOI 10.4161/cc.9.17.12721
   Peng ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061457
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Ren SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063641
   Repnik U, 2014, MITOCHONDRION, V19, P49, DOI 10.1016/j.mito.2014.06.006
   Repnik U, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008755
   Ronchi A, 2010, INT J ONCOL, V37, P745, DOI 10.3892/ijo_00000724
   Rouhani M, 2014, GEN PHYSIOL BIOPHYS, V33, P235, DOI 10.4149/gpb_2013080
   Sabanci PA, 2014, NEUROL RES, V36, P189, DOI 10.1179/1743132813Y.0000000283
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Shvets E, 2008, AUTOPHAGY, V4, P621, DOI 10.4161/auto.5939
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Thakker-Varia S, 2010, J NEUROSCI, V30, P9368, DOI 10.1523/JNEUROSCI.5987-09.2010
   Vidal F, 2011, INT J ONCOL, V38, P1365, DOI 10.3892/ijo.2011.955
   Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562
   Weiner LM, 2012, NEW ENGL J MED, V366, P1156, DOI 10.1056/NEJMcibr1114526
   Wiersma VR, 2015, AUTOPHAGY, V11, P1373, DOI 10.1080/15548627.2015.1063767
   Xie M, 2014, CIRCULATION, V129, P1139, DOI 10.1161/CIRCULATIONAHA.113.002416
   Yao XF, 2014, FOOD CHEM TOXICOL, V67, P96, DOI 10.1016/j.fct.2014.02.017
   Yazlovitskaya EM, 2006, CANCER RES, V66, P11179, DOI 10.1158/0008-5472.CAN-06-2740
   Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997
   Zhou HY, 2012, CHIN J CANCER, V31, P8, DOI 10.5732/cjc.011.10281
   Zhou J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087161
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 69
TC 25
Z9 31
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2015
VL 10
IS 8
AR e0134676
DI 10.1371/journal.pone.0134676
PG 26
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO3MQ
UT WOS:000359062300058
PM 26248051
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhao, S
   Chen, SR
   Yang, XF
   Shen, DF
   Takano, Y
   Su, RJ
   Zheng, HC
AF Zhao, Shuang
   Chen, Shu-rui
   Yang, Xue-feng
   Shen, Dao-fu
   Takano, Yasuo
   Su, Rong-jian
   Zheng, Hua-chuan
TI BTG1 might be employed as a biomarker for carcinogenesis and a target
   for gene therapy in colorectal cancers
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; BTG1; carcinogenesis; aggressive phenotypes; gene
   therapy
ID CELL TRANSLOCATION GENE-1; PROGNOSTIC MARKER; TUMOR-METASTASIS;
   GASTRIC-CANCER; EXPRESSION; CARCINOMA; APOPTOSIS; LEUKEMIA;
   PATHOGENESIS; IDENTIFICATION
AB Here, BTG1 overexpression inhibited proliferation, induced differentiation, autophagy, and apoptosis in colorectal cancer cells (p<0.05). BTG1 overexpression reduced mitochondrial membrane potential and caused senescence in HCT-116 transfectants (p<0.05). BTG1-induced G(2) arrest might be related to Cyclin B1 and Cdc25B hypoexpression in HCT-15 transfectants, while G(1) arrest in HCT-116 transfectants overexpressing p21 and p27. BTG1 overexpression decreased the expression of Bcl-2, Bcl-xL, XIAP, Akt1 or survivin and increased the expression of Bax or p53 in colorectal cancer cells. BTG1-induced autophagy was dependent on Beclin-1 expression. BTG1 overexpression might weaken beta-catenin pathway in colorectal cancer cells. The chemosensitivity of BTG1 transfectants to paclitaxel, cisplatin, MG132 or SAHA was positively correlated with its apoptotic induction. There was a lower expression level of BTG1 in cancer than matched non-neoplastic mucosa by RT-PCR (p<0.05), while versa for Western blot and immunohistochemical data (p<0.05). BTG1 overexpression significantly suppressed the growth of HCT-15 and HCT-116 via inhibiting proliferation, inducing apoptosis and autophagy in nude mice. Up-regulated BTG1 expression plays an important role in colorectal carcinogenesis as a potential biomarker. BTG1 expression might reverse aggressive phenotypes, so it might be employed as a target of gene therapy for colorectal cancer.
C1 [Zhao, Shuang; Yang, Xue-feng; Shen, Dao-fu; Zheng, Hua-chuan] Jinzhou Med Univ, Canc Ctr, Key Lab Brain & Spinal Cord Injury Liaoning Prov, Affiliated Hosp 1, Jinzhou, Peoples R China.
   [Zhao, Shuang; Yang, Xue-feng; Shen, Dao-fu; Zheng, Hua-chuan] Jinzhou Med Univ, Affiliated Hosp 1, Anim Ctr, Jinzhou, Peoples R China.
   [Chen, Shu-rui] Jinzhou Med Univ, Dept Sci & Technol, Jinzhou, Peoples R China.
   [Takano, Yasuo] Tokyo Univ Technol, Sch Hlth Sci, Ohta Ku, Tokyo, Japan.
   [Su, Rong-jian; Zheng, Hua-chuan] Jinzhou Med Univ, Life Sci Inst, Jinzhou, Peoples R China.
RP Zheng, HC (corresponding author), Jinzhou Med Univ, Canc Ctr, Key Lab Brain & Spinal Cord Injury Liaoning Prov, Affiliated Hosp 1, Jinzhou, Peoples R China.; Zheng, HC (corresponding author), Jinzhou Med Univ, Affiliated Hosp 1, Anim Ctr, Jinzhou, Peoples R China.; Zheng, HC (corresponding author), Jinzhou Med Univ, Life Sci Inst, Jinzhou, Peoples R China.
EM zheng_huachuan@hotmail.com
FU President Fund of Jinzhou Medical University [XZJJ20140201,
   XZJJ20140203]; Liaoning BaiQianWan Talents Program; Scientific Research
   Fund of Liaoning Provincial Education Department [LJQ2014093]; Key
   Scientific and Technological Project of Liaoning Province [2015408001];
   National Natural Scientific Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472544]
FX We thank Dr. Xin-lu Wang (Shengjing Hospital, China Medical University)
   for her assistance of ultrasonic examination. This study was supported
   by President Fund of Jinzhou Medical University (XZJJ20140201;
   XZJJ20140203), Liaoning BaiQianWan Talents Program, A Project Supported
   by Scientific Research Fund of Liaoning Provincial Education Department
   (LJQ2014093), a Key Scientific and Technological Project of Liaoning
   Province (2015408001) and National Natural Scientific Foundation of
   China (81472544).
CR Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013
   Busson M, 2005, ONCOGENE, V24, P1698, DOI 10.1038/sj.onc.1208373
   Cancer facts and figures, 2015, CANC FACTS FIG, V26, P463
   Chauhan PS, 2012, EXP MOL PATHOL, V92, P44, DOI 10.1016/j.yexmp.2011.09.004
   Cho JW, 2004, PROTEOMICS, V4, P3456, DOI 10.1002/pmic.200400968
   Corjay MH, 1998, LAB INVEST, V78, P847
   Cosentino K, 2014, CHEM PHYS LIPIDS, V181, P62, DOI 10.1016/j.chemphyslip.2014.04.001
   Doidge R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051331
   Henderson LJ, 2011, J NEUROIMMUNE PHARM, V6, P247, DOI 10.1007/s11481-011-9266-7
   Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193
   Iwai K, 2004, BIOCHEM BIOPH RES CO, V316, P628, DOI 10.1016/j.bbrc.2004.02.095
   Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047
   Kanda M, 2015, DIGEST DIS SCI, V60, P1256, DOI 10.1007/s10620-014-3477-8
   Kanda M, 2015, INT J ONCOL, V46, P641, DOI 10.3892/ijo.2014.2762
   Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890
   Kumada T, 2004, MODERN PATHOL, V17, P1141, DOI 10.1038/modpathol.3800165
   Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034
   Lu YF, 2014, INT J ONCOL, V45, P1574, DOI 10.3892/ijo.2014.2543
   Nahta R, 2006, MOL CANCER THER, V5, P1593, DOI 10.1158/1535-7163.MCT-06-0133
   Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253
   Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147
   Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398
   Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486
   Roller C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00010
   ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x
   Sheng SH, 2014, TUMOR BIOL, V35, P3317, DOI 10.1007/s13277-013-1437-0
   Smolewski P, 2011, CURR MOL MED, V11, P633, DOI 10.2174/156652411797536723
   Stanley RE, 2014, TRENDS CELL BIOL, V24, P73, DOI 10.1016/j.tcb.2013.07.008
   Sun GG, 2014, TUMOR BIOL, V35, P9707, DOI 10.1007/s13277-014-2245-x
   Sun GG, 2014, MOL BIOL REP, V41, P5979, DOI 10.1007/s11033-014-3475-0
   Sun GG, 2014, TUMOR BIOL, V35, P2949, DOI 10.1007/s13277-013-1379-6
   Williams GH, 2012, J PATHOL, V226, P352, DOI 10.1002/path.3022
   Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919
   Zhao Y, 2013, INT J MOL SCI, V14, P19670, DOI 10.3390/ijms141019670
   Zheng HC, 2015, ONCOTARGET, V6, P19685, DOI 10.18632/oncotarget.4081
   Zhu R, 2013, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2013-59
NR 36
TC 18
Z9 18
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 31
PY 2017
VL 8
IS 5
BP 7502
EP 7520
DI 10.18632/oncotarget.10649
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5YP
UT WOS:000393295500030
PM 27447746
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Huang, W
   Zeng, C
   Liu, J
   Yuan, L
   Liu, WD
   Wang, L
   Zhu, HC
   Xu, Y
   Luo, Y
   Xie, D
   Jiang, XJ
   Ren, CP
AF Huang, Wei
   Zeng, Chong
   Liu, Jie
   Yuan, Li
   Liu, Weidong
   Wang, Lei
   Zhu, Hecheng
   Xu, Yang
   Luo, Yi
   Xie, Dan
   Jiang, Xingjun
   Ren, Caiping
TI Sodium butyrate induces autophagic apoptosis of nasopharyngeal carcinoma
   cells by inhibiting AKT/mTOR signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Nasopharyngeal carcinoma; Sodium butyrate; Autophagy; Apoptosis;
   AKT/mTOR
ID COLORECTAL-CANCER; PI3K/AKT/MTOR PATHWAY; HDAC INHIBITORS; DUAL ROLE;
   DEATH; INVOLVEMENT; ACTIVATION; CROSSTALK; LIFE; AMPK
AB Previously, we confirmed the anti-tumor effects of sodium butyrate (NaBu) in nasopharyngeal carcinoma (NPC). However, its molecular mechanisms have not be fully elucidated. In this study, we studied the effects of NaBu on autophagy and explored the relation between NaBu associated autophagy and apoptosis in NPC cells. EGFP-LC3 plasmids were introduced into NPC cells to observed the effects of NaBu on autophagy flux with or without chloroquine (CQ) addition. Autophagy markers were also detected by Western blot. Under NaBu treatment, autophagy and apoptosis markers were detected simultaneously at different time. Then, to explore the roles of autophagy in NaBu induced apoptosis, the effects of autophagy inhibition, via specific inhibitor treatment or key gene knockdown, were analyzed. At last, the upstream signaling and its roles in NaBu induced autophagy and apoptosis were also analyzed. Increased LC3 dots and LC3-II accumulation indicated that NaBu can promote autophagy flux in NPC cells. LC3-II accumulation was earlier than cleaved PARP increment suggesting autophagy activation is prior to apoptosis activation, which was validated by flow cytometry mediated apoptosis analysis. Moreover, autophagy inhibition, achieved by 3-MA treatment or BECN1 knockdown, can antagonize NaBu induced apoptosis reflecting by re-deregulated cPARP and apoptotic rates. Furthermore, NaBu treatment inhibited the AKT/mTOR axis indicated by deregulated p-AKT(S473) and p-mTOR(S2448) and ectopic AKT expression both suppressed NaBu induced autophagy and apoptosis. At last, Western blot showed that HDAC6 dependent EGFR deregulation may account for the NaBu associated AKT/mTOR inhibition. NaBu can induce autophagic apoptosis via suppressing AKT/mTOR axis in NPC cells. Our results suggest that combination of autophagy inhibitors and deacetylase inhibitors may not be recommended in NPC clinical treatment. (C) 2019 Published by Elsevier Inc.
C1 [Huang, Wei; Liu, Weidong; Wang, Lei; Ren, Caiping] Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Huang, Wei; Liu, Weidong; Wang, Lei; Ren, Caiping] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha 410008, Hunan, Peoples R China.
   [Huang, Wei; Liu, Weidong; Wang, Lei; Ren, Caiping] Cent S Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha, Hunan, Peoples R China.
   [Huang, Wei] Xiangya Hosp, Res Ctr Carcinogenesis & Targeted Therapy, Changsha, Hunan, Peoples R China.
   [Zeng, Chong] Hunan Rongjun Hosp, Dept Resp Med & Neurol, Changsha, Hunan, Peoples R China.
   [Liu, Jie] Changsha Cent Hosp, Dept Pathol, Changsha, Hunan, Peoples R China.
   [Yuan, Li] Cent S Univ, Xiangya Hosp 3, Dept Nucl Med, Changsha, Hunan, Peoples R China.
   [Zhu, Hecheng; Xu, Yang; Luo, Yi] Changsha Kexin Canc Hosp, Changsha, Hunan, Peoples R China.
   [Xie, Dan] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.
   [Jiang, Xingjun] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China.
RP Ren, CP (corresponding author), Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Ren, CP (corresponding author), Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha 410008, Hunan, Peoples R China.; Jiang, XJ (corresponding author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China.
EM jiangxj@csu.edu.cn; rencaiping@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773179, 81702924, 81272972]; Natural
   Science Foundation of Hunan Province of ChinaNatural Science Foundation
   of Hunan Province [2016JJ2172, 2018JJ3811]; National Basic Research
   Program of ChinaNational Basic Research Program of China [2010CB833605];
   Open-End Fund for the Valuable and Precision Instruments of Central
   South University
FX The present study was supported by the National Natural Science
   Foundation of China (nos. 81773179, 81702924, 81602686and 81272972), the
   Natural Science Foundation of Hunan Province of China (nos. 2016JJ2172,
   2018JJ3811), the National Basic Research Program of China(2010CB833605),
   and the Open-End Fund for the Valuable and Precision Instruments of
   Central South University.
CR Anding AL, 2015, CURR TOP DEV BIOL, V114, P67, DOI 10.1016/bs.ctdb.2015.07.012
   Bujak AL, 2015, CELL METAB, V21, P883, DOI 10.1016/j.cmet.2015.05.016
   Campbell GR, 2015, J BIOL CHEM, V290, P5028, DOI 10.1074/jbc.M114.605428
   Cao Su-Mei, 2011, Chin J Cancer, V30, P114
   Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0
   Di Fazio P, 2016, ONCOTARGET, V7, P28998, DOI 10.18632/oncotarget.8585
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Freudlsperger C, 2011, EXPERT OPIN THER TAR, V15, P63, DOI 10.1517/14728222.2011.541440
   Fu Z T, 2018, Zhonghua Zhong Liu Za Zhi, V40, P566, DOI 10.3760/cma.j.issn.0253-3766.2018.08.002
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754
   Goncalves P, 2013, CURR DRUG METAB, V14, P994
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Huang W, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0564-4
   Jiang L, 2018, BIOTECHNOL ADV, V36, P2101, DOI 10.1016/j.biotechadv.2018.09.005
   Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347
   Lee SJ, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0070-8
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8
   Li WF, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0256-x
   Li XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087767
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11614
   Liu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049418
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Lopez G, 2011, AUTOPHAGY, V7, P440, DOI 10.4161/auto.7.4.14680
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Pant K, 2017, CHEM-BIOL INTERACT, V273, P99, DOI 10.1016/j.cbi.2017.06.001
   Qu JQ, 2015, MOL CANCER THER, V14, P2653, DOI 10.1158/1535-7163.MCT-15-0461
   Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Stankov MV, 2014, LEUKEMIA, V28, P577, DOI 10.1038/leu.2013.264
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun DP, 2013, CANCER BIOTHER RADIO, V28, P320, DOI 10.1089/cbr.2012.1327
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   Tailor D, 2014, MITOCHONDRION, V16, P55, DOI 10.1016/j.mito.2013.10.004
   Verma SP, 2018, IN VITRO CELL DEV-AN, V54, P295, DOI 10.1007/s11626-018-0239-5
   Wei ZL, 2008, ONCOL REP, V20, P397, DOI 10.3892/or_00000021
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yang PM, 2011, AUTOPHAGY, V7, P107, DOI 10.4161/auto.7.1.13988
   Yeganeh B, 2018, BBA-MOL CELL RES, V1865, P364, DOI 10.1016/j.bbamcr.2017.10.014
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
   Zheng Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.211
NR 46
TC 9
Z9 11
U1 2
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 18
PY 2019
VL 514
IS 1
BP 64
EP 70
DI 10.1016/j.bbrc.2019.04.111
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA IA2QS
UT WOS:000469406800010
PM 31023529
DA 2022-04-25
ER

PT J
AU Rodrigues, BLC
   Lallo, MA
   Perez, EC
AF Colhado Rodrigues, Bridilla Luiza
   Lallo, Maria Anete
   Perez, Elizabeth Cristina
TI The Controversial Role of Autophagy in Tumor Development: A Systematic
   Review
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Review
DE Autophagocytosis; cancer; cell death; homeostasis; ATG proteins; PI3K;
   AKT; mTOR intracellular signaling pathway
ID CELL-DEATH; CANCER; SURVIVAL
AB Autophagy is a natural regulatory mechanism of the cell that eliminates unnecessary and dysfunctional cellular components to maintain homeostasis. Several authors have demonstrated that this mechanism can be induced by pathological conditions as cancer. However, their role in tumor development is still a controversial issue in cancer research. Here, we discussed the most relevant findings concerning autophagy in tumor development. In this critical review performed with studies published between 2002 and 2018, we found that the main pathway involved in the autophagy process is the PI3K/AKT/mTOR intracellular signaling pathway. Regarding their role in cancer development, breast cancer is the main study target, followed by lung, prostate and colon cancer. In these issues, 46% of the works consulted suggesting that autophagy inhibits tumor progression by favor a better antitumor response, 4% suggest that favors growth and tumor progression and, 50% of the authors failed to establish whether autophagy inhibits or favors tumor development. Herein, we concluded that depending on the study model, autophagy may favor or inhibits growth and cancer progression.
C1 [Colhado Rodrigues, Bridilla Luiza; Lallo, Maria Anete; Perez, Elizabeth Cristina] Univ Paulista, Programa Posgrad Patol Ambiental & Expt, Rua Doutor Bacelar 1212,4th Floor, BR-04026002 Sao Paulo, SP, Brazil.
   [Colhado Rodrigues, Bridilla Luiza] Inst Butantan, Lab Imunogenet, Sao Paulo, SP, Brazil.
RP Perez, EC (corresponding author), Univ Paulista, Programa Posgrad Patol Ambiental & Expt, Rua Doutor Bacelar 1212,4th Floor, BR-04026002 Sao Paulo, SP, Brazil.
EM elicristin@hotmail.com
RI Lallo, Maria A/D-5976-2012
OI Lallo, Maria Anete/0000-0003-3578-3087; Colhado Rodrigues, Bridilla
   Luiza/0000-0003-4819-429X
FU Banco Santander, grant for undergraduate student [2016/2107]; Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2017/04176-7]
FX This work was supported by Banco Santander, grant for undergraduate
   student 2016/2107; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   - FAPESP grant #2017/04176-7.
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Antunes F, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e814s
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Bhattacharjee A, 2019, J GENET GENOMICS, V46, P157, DOI 10.1016/j.jgg.2019.03.007
   Birgisdottir AB, 2019, AUTOPHAGY, V15, P1333, DOI 10.1080/15548627.2019.1581009
   Bousquet G, 2017, ONCOTARGET, V8, P35205, DOI 10.18632/oncotarget.16925
   Butler DE, 2017, ONCOTARGET, V8, P56698, DOI 10.18632/oncotarget.18082
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo W, 2016, CANCER SCI, V107, P1610, DOI 10.1111/cas.13059
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hao YQ, 2019, AUTOPHAGY, V15, P1558, DOI 10.1080/15548627.2019.1586255
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Kardideh B, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0327-6
   Leonardi M, 2019, AUTOPHAGY, V15, P312, DOI 10.1080/15548627.2018.1517855
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li N, 2019, IMMUNOL INVEST, V48, P378, DOI 10.1080/08820139.2019.1567532
   Liang Diana Hwang, 2015, J Nucl Med Radiat Ther, V6
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Lin SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071412
   Magrys A, 2018, IMMUNOL INVEST, V47, P251, DOI 10.1080/08820139.2018.1423569
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Naponelli V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/121826
   Ndoye Abibatou, 2016, F1000Res, V5, DOI 10.12688/f1000research.8347.1
   O'Donnell JS, 2018, SEMIN CANCER BIOL, V48, P91, DOI 10.1016/j.semcancer.2017.04.015
   Orvedahl A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Sharif T, 2017, AUTOPHAGY, V13, P264, DOI 10.1080/15548627.2016.1260808
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Sun L, 2015, AM J CANCER RES, V5, P2626
   Wen X, 2016, J MOL BIOL, V428, P1681, DOI 10.1016/j.jmb.2016.02.021
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Yang J, 2019, MOL THER-NUCL ACIDS, V18, P1, DOI 10.1016/j.omtn.2019.08.003
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zarzynska JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/710345
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
   Zhou YT, 2016, ACTA BIOCH BIOPH SIN, V48, P60, DOI 10.1093/abbs/gmv119
NR 52
TC 14
Z9 15
U1 1
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0139
EI 1532-4311
J9 IMMUNOL INVEST
JI Immunol. Invest.
PD MAY 18
PY 2020
VL 49
IS 4
BP 386
EP 396
DI 10.1080/08820139.2019.1682600
EA NOV 2019
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA LE0ON
UT WOS:000496602400001
PM 31726897
DA 2022-04-25
ER

PT J
AU Mena, S
   Rodriguez, ML
   Ponsoda, X
   Estrela, JM
   Jaattela, M
   Ortega, AL
AF Mena, Salvador
   Rodriguez, Maria L.
   Ponsoda, Xavier
   Estrela, Jose M.
   Jaattela, Marja
   Ortega, Angel L.
TI Pterostilbene-Induced Tumor Cytotoxicity: A Lysosomal Membrane
   Permeabilization-Dependent Mechanism
SO PLOS ONE
LA English
DT Article
ID INDUCED CELL-DEATH; CANCER-CELLS; B16 MELANOMA; DOWN-REGULATION;
   CATHEPSIN-D; RESVERATROL; AUTOPHAGY; APOPTOSIS; THERAPY; ARREST
AB The phenolic phytoalexin resveratrol is well known for its health-promoting and anticancer properties. Its potential benefits are, however, limited due to its low bioavailability. Pterostilbene, a natural dimethoxylated analog of resveratrol, presents higher anticancer activity than resveratrol. The mechanisms by which this polyphenol acts against cancer cells are, however, unclear. Here, we show that pterostilbene effectively inhibits cancer cell growth and stimulates apoptosis and autophagosome accumulation in cancer cells of various origins. However, these mechanisms are not determinant in cell demise. Pterostilbene promotes cancer cell death via a mechanism involving lysosomal membrane permeabilization. Different grades of susceptibility were observed among the different cancer cells depending on their lysosomal heat shock protein 70 (HSP70) content, a known stabilizer of lysosomal membranes. A375 melanoma and A549 lung cancer cells with low levels of HSP70 showed high susceptibility to pterostilbene, whereas HT29 colon and MCF7 breast cancer cells with higher levels of HSP70 were more resistant. Inhibition of HSP70 expression increased susceptibility of HT29 colon and MCF7 breast cancer cells to pterostilbene. Our data indicate that lysosomal membrane permeabilization is the main cell death pathway triggered by pterostilbene.
C1 [Mena, Salvador; Estrela, Jose M.; Ortega, Angel L.] Green Mol, Valencia, Spain.
   [Rodriguez, Maria L.; Estrela, Jose M.; Ortega, Angel L.] Univ Valencia, Dept Physiol, E-46100 Burjassot, Spain.
   [Ponsoda, Xavier] Univ Valencia, Dept Cell Biol, E-46100 Burjassot, Spain.
   [Jaattela, Marja] Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, Copenhagen, Denmark.
   [Jaattela, Marja] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Response, Copenhagen, Denmark.
RP Mena, S (corresponding author), Green Mol, Valencia, Spain.
EM angel.ortega@uv.es
RI Estrela, Jose/H-4449-2015; Mena, Salvador/F-6696-2016; Ortega, Angel
   L./A-4113-2014; Jäättelä, Marja/AAT-7932-2021; Rodriguez,
   Maria/A-8510-2016; Mena, Salvador/L-8780-2014; Ponsoda,
   Xavier/L-8272-2014
OI Estrela, Jose/0000-0002-2540-9190; Ortega, Angel L./0000-0002-9901-3383;
   Jäättelä, Marja/0000-0001-5950-7111; Mena, Salvador/0000-0002-6423-4741;
   Ponsoda, Xavier/0000-0002-4051-4458
FU MICINNSpanish GovernmentEuropean Commission [JC2008-00282,
   SAF2009-07729, IPT-010000-2010-21]; GV-Conselleria d'Educacio
   [GVPRE/2008/272]; Danish Cancer SocietyDanish Cancer Society; Danish
   Medical CouncilDanish Medical Research Council; Danish National Research
   FoundationDanmarks Grundforskningsfond
FX This research was supported by grants from the MICINN (JC2008-00282 ALO
   SAF2009-07729 and IPT- 010000-2010-21 to JME), the GV-Conselleria
   d'Educacio (GVPRE/2008/272 to ALO), the Danish Cancer Society (to MJ),
   the Danish Medical Council (to MJ) and the Danish National Research
   Foundation (to MJ). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Ahmad N, 2001, CLIN CANCER RES, V7, P1466
   [Anonymous], 2010, ALTERN MED REV, V15, P159
   Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056
   Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5
   Asensi M, 2011, CRIT REV CL LAB SCI, V48, P197, DOI 10.3109/10408363.2011.631268
   Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Chen RJ, 2010, MOL NUTR FOOD RES, V54, P1819, DOI 10.1002/mnfr.201000067
   Cui J, 2010, PHYTOTHER RES, V24, P1637, DOI 10.1002/ptr.3157
   Davalli P, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/984219
   Delmas D, 2011, CURR MED CHEM, V18, P1100, DOI 10.2174/092986711795029708
   Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883
   Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476
   FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402
   Ferrer P, 2005, NEOPLASIA, V7, P37, DOI 10.1593/neo.04337
   Ferrer P, 2007, J BIOL CHEM, V282, P2880, DOI 10.1074/jbc.M605934200
   Filippi-Chiela EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020849
   Gassmann P, 2008, CLIN EXP METASTAS, V25, P171, DOI 10.1007/s10585-007-9130-6
   Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666
   Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9
   Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4
   Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje
   Kairisalo M, 2011, NEUROSCI LETT, V488, P263, DOI 10.1016/j.neulet.2010.11.042
   Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Mannal PW, 2010, J GASTROINTEST SURG, V14, P873, DOI 10.1007/s11605-010-1164-4
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200
   Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774
   Pan MH, 2007, J AGR FOOD CHEM, V55, P7777, DOI 10.1021/jf071520h
   Priego S, 2008, MOL CANCER THER, V7, P3330, DOI 10.1158/1535-7163.MCT-08-0363
   PUNNONEN EL, 1990, EXP MOL PATHOL, V52, P87, DOI 10.1016/0014-4800(90)90061-H
   Rammer P, 2010, MOL CANCER THER, V9, P24, DOI 10.1158/1535-7163.MCT-09-0559
   Ruiz MJ, 2009, J AGR FOOD CHEM, V57, P3180, DOI 10.1021/jf803579e
   Schneider JG, 2010, J SURG RES, V161, P18, DOI 10.1016/j.jss.2009.06.027
   Schneider Y, 2003, INT J CANCER, V107, P189, DOI 10.1002/ijc.11344
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shukla Y, 2011, ANN NY ACAD SCI, V1215, P1, DOI 10.1111/j.1749-6632.2010.05870.x
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
NR 55
TC 74
Z9 75
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2012
VL 7
IS 9
AR e44524
DI 10.1371/journal.pone.0044524
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 001MC
UT WOS:000308463800070
PM 22957077
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Booth, L
   Roberts, JL
   Rais, R
   Cutler, RE
   Diala, I
   Lalani, AS
   Hancock, JF
   Poklepovic, A
   Dent, P
AF Booth, Laurence
   Roberts, Jane L.
   Rais, Rumeesa
   Cutler, Richard E., Jr.
   Diala, Irmina
   Lalani, Alshad S.
   Hancock, John F.
   Poklepovic, Andrew
   Dent, Paul
TI Neratinib augments the lethality of [regorafenib plus sildenafil]
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE autophagy; DNA damage; HDAC
ID K-RAS; BETA-CATENIN; INHIBITORS; ENHANCE; COMPLEX
AB Regorafenib is approved for the treatment of colorectal cancer and hepatocellular carcinoma. In the trial NCT02466802, we have discovered that regorafenib can be safely combined with the phosphodiesterase 5 inhibitor sildenafil in advanced solid tumor patients. The present studies determined whether the approved ERBB1/2/4 and RAS downregulating drug neratinib, could enhance the lethality of [regorafenib+sildenafil]. Neratinib enhanced [regorafenib+sildenafil] lethality in a greater than additive fashion in colon cancer cells. The drug combination reduced the expression of mutant K-RAS and of multiple histone deacetylase (HDAC) proteins that required autophagosome formation. It caused green fluorescent protein or red fluorescent protein-tagged forms of K-RAS V12 to localize into large intracellular vesicles. Compared with [regorafenib+sildenafil], the three-drug combination caused greater and more prolonged activation of the ATM-AMPK-ULK-1 pathway and caused a greater suppression and prolonged inactivation of mammalian target of rapamycin, AKT, and p70 S6K. Approximately 70% of enhanced lethality caused by neratinib required ataxia-telangiectasia-mutated (ATM)-AMP-dependent protein kinase (AMPK) signaling whereas knockdown of Beclin1, ATG5, FADD, and CD95 completely prevented the elevated killing effect. Exposure of cells to [regorafenib+sildenafil] reduced the expression of the checkpoint immunotherapy biomarkers programmed death-ligand 1, ornithine decarboxylase, and indoleamine 2,3-dioxygenase-1 and increased the expression of major histocompatibility complex A (MHCA), which also required autophagosome formation. Knockdown of specific HDAC proteins recapitulated the effects observed using chemical agents. In vivo, using mouse cancer models, neratinib significantly enhanced the antitumor efficacy of [regorafenib+sildenafil]. Our data support performing a new three drug Phase I trial combining regorafenib, sildenafil, and neratinib.
C1 [Booth, Laurence; Roberts, Jane L.; Rais, Rumeesa; Dent, Paul] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Biochem, Richmond, VA USA.
   [Booth, Laurence; Roberts, Jane L.; Rais, Rumeesa; Dent, Paul] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Mol Biol, Richmond, VA USA.
   [Poklepovic, Andrew] Virginia Commonwealth Univ, Med, Richmond, VA USA.
   [Cutler, Richard E., Jr.; Diala, Irmina; Lalani, Alshad S.] Puma Biotechnol Inc, Los Angeles, CA USA.
   [Cutler, Richard E., Jr.; Diala, Irmina; Lalani, Alshad S.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
   [Hancock, John F.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.
RP Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Massey Canc Ctr, POB 980035, Richmond, VA 23298 USA.
EM paul.dent@vcuhealth.org
OI Hancock, John/0000-0003-0542-4710
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01 CA192613]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA192613] Funding Source:
   NIH RePORTER
FX National Cancer Institute, Grant/Award Number: R01 CA192613
CR Booth L, 2018, CANCER BIOL THER, V19, P132, DOI 10.1080/15384047.2017.1394556
   Booth L, 2017, ONCOTARGET, V8, P90262, DOI 10.18632/oncotarget.21660
   Booth L, 2017, CANCER BIOL THER, V18, P705, DOI 10.1080/15384047.2017.1362511
   Booth L, 2017, ONCOTARGET, V8, P1449, DOI 10.18632/oncotarget.13640
   Booth L, 2016, ONCOTARGET, V7, P40398, DOI 10.18632/oncotarget.9752
   Booth L, 2016, ONCOTARGET, V7, P12975, DOI 10.18632/oncotarget.7349
   Booth L, 2014, MOL PHARMACOL, V85, P408, DOI 10.1124/mol.113.090043
   Carr BI, 2013, J CELL PHYSIOL, V228, P1344, DOI 10.1002/jcp.24291
   Cho KJ, 2016, MOL CELL BIOL, V36, P3086, DOI 10.1128/MCB.00365-16
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0
   Echavarria I, 2017, EXPERT REV ANTICANC, V17, P669, DOI 10.1080/14737140.2017.1338954
   Fiedler M, 2011, P NATL ACAD SCI USA, V108, P1937, DOI 10.1073/pnas.1017063108
   Gottardi CJ, 2008, STRUCTURE, V16, P336, DOI 10.1016/j.str.2008.02.005
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Qi XM, 2014, ONCOTARGET, V5, P4269, DOI 10.18632/oncotarget.2001
   Skarderud MR, 2018, CANCER TREAT REV, V62, P61, DOI 10.1016/j.ctrv.2017.10.011
   Tavallai M, 2015, J CELL PHYSIOL, V230, P2281, DOI 10.1002/jcp.24961
   Zhang QJ, 2009, J PHYSIOL-LONDON, V587, P3911, DOI 10.1113/jphysiol.2009.172916
NR 22
TC 24
Z9 24
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2019
VL 234
IS 4
BP 4874
EP 4887
DI 10.1002/jcp.27276
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA HK0TE
UT WOS:000457613700143
PM 30203445
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Janji, B
   Hasmim, M
   Parpal, S
   Berchem, G
   Noman, MZ
AF Janji, Bassam
   Hasmim, Meriem
   Parpal, Santiago
   Berchem, Guy
   Noman, Muhammad Zaeem
TI Firing up the cold tumors by targeting Vps34
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Autophagy; VPS34; cold; hot tumors; proinflammatory cytokines; CCL5;
   CXCL10; immune landscape; NK cells; T CD8 lymphocytes; cancer
   immunotherapy; anti-PD-1; PD-L1; melanoma; colon cancer
ID AUTOPHAGY; GROWTH
AB Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published inScience Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.
C1 [Janji, Bassam; Hasmim, Meriem; Noman, Muhammad Zaeem] Luxembourg Inst Hlth LIH, Dept Oncol, Tumor Immunotherapy & Microenvironm TIME Grp, Luxembourg, Luxembourg.
   [Parpal, Santiago] Sprint Biosci, Stockholm, Sweden.
   [Parpal, Santiago] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden.
   [Berchem, Guy] Ctr Hosp Luxembourg, Dept Hematooncol, Luxembourg, Luxembourg.
RP Janji, B (corresponding author), Luxembourg Inst Hlth, Tumor Immunotherapy & Microenvironm TIME Grp, Dept Oncol, L-1526 Luxembourg, Luxembourg.
EM bassam.janji@lih.lu; muhammadzaeem.noman@lih.lu
RI Berchem, Guy/C-9364-2014; NOMAN, Muhammmad Zaeem/AAJ-1466-2021; NOMAN,
   Muhammmad Zaeem/AAJ-1465-2021
OI Berchem, Guy/0000-0003-0157-2257; NOMAN, Muhammmad
   Zaeem/0000-0002-1837-3097; NOMAN, Muhammmad Zaeem/0000-0002-1837-3097;
   JANJI, Bassam/0000-0002-9763-0943
FU Luxembourg National Research FundLuxembourg National Research Fund
   [C18/BM/12670304/COMBATIC]; Action LIONS Vaincre le Cancer Luxembourg;
   Fondation Cancer Luxembourg [FC/2018/06]; Kriibskrank Kanner Foundation
   [2016-08-15]; Janssen Cilag Pharma; Roche pharma
FX This work was supported by grants from Luxembourg National Research Fund
   C18/BM/12670304/COMBATIC; Roche pharma and Action LIONS Vaincre le
   Cancer Luxembourg; Fondation Cancer Luxembourg (FC/2018/06); Kriibskrank
   Kanner Foundation (2016-08-15); Janssen Cilag Pharma.
CR Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110
   Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281
   Marsh T, 2015, NAT CELL BIOL, V17, P1, DOI 10.1038/ncb3089
   Mgrditchian T, 2017, P NATL ACAD SCI USA, V114, pE9271, DOI 10.1073/pnas.1703921114
   Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881
   Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
NR 10
TC 8
Z9 8
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2020
VL 9
IS 1
AR 1809936
DI 10.1080/2162402X.2020.1809936
PG 2
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA NL0ZW
UT WOS:000567155100001
PM 32939326
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Schmukler, E
   Grinboim, E
   Schokoroy, S
   Amir, A
   Wolfson, E
   Kloog, Y
   Pinkas-Kramarski, R
AF Schmukler, Eran
   Grinboim, Efrat
   Schokoroy, Sari
   Amir, Adva
   Wolfson, Eya
   Kloog, Yoel
   Pinkas-Kramarski, Ronit
TI Ras inhibition enhances autophagy, which partially protects cells from
   death
SO ONCOTARGET
LA English
DT Article
DE autophagy; Ras; transformation; signal transduction
ID COLON-CANCER CELLS; TUMOR-GROWTH; FARNESYLTHIOSALICYLIC ACID; UNANSWERED
   QUESTIONS; ONCOGENIC RAS; IN-VITRO; DEGRADATION; ANTAGONIST; PATHWAY;
   ACTIVATION
AB Autophagy, a process of regulated turnover of cellular constituents, is essential for normal growth control but may be defective under pathological conditions. The Ras/PI3K/mTOR signaling pathway negatively regulates autophagy. Ras signaling has been documented in a large number of human cancers. In this in-vitro study we examined the effect of the Ras inhibitor Salirasib (S-trans, trans-farnesylthiosalicylic acid; FTS) on autophagy induction and cell viability. We show that Ras inhibition by FTS induced autophagy in several cell lines, including mouse embryonic fibroblasts and the human cancer cell lines HeLa, HCT-116 and DLD-1. The autophagy induced by FTS seems to inhibit the cell death induced by FTS, since in the absence of autophagy the death of FTS-treated cells was enhanced. Therefore, inhibition of autophagy may promote the inhibition of tumor cell growth and the cell death mediated by FTS.
C1 [Schmukler, Eran; Grinboim, Efrat; Schokoroy, Sari; Amir, Adva; Wolfson, Eya; Kloog, Yoel; Pinkas-Kramarski, Ronit] Tel Aviv Univ, Dept Neurobiol, Ramat Aviv, Israel.
RP Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiol, Ramat Aviv, Israel.
EM lironit@post.tau.ac.il
OI Pinkas-Kramarski, Ronit/0000-0002-1000-369X
FU Israel Science FoundationIsrael Science Foundation [848/12]; Kauffman
   Prostate Cancer Research Fund
FX This work was supported by the Israel Science Foundation (Grant no.
   848/12) and by the Kauffman Prostate Cancer Research Fund.
CR Aharonson Z, 1998, BBA-MOL BASIS DIS, V1406, P40, DOI 10.1016/S0925-4439(97)00077-X
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Charette N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-256
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0
   Elad G, 1999, BBA-MOL CELL RES, V1452, P228, DOI 10.1016/S0167-4889(99)00144-5
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d
   Halaschek-Wiener J, 2000, MOL MED, V6, P693, DOI 10.1007/BF03402049
   Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003
   Harris A L, 1992, J Natl Cancer Inst Monogr, P181
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263
   McPherson RA, 2004, PROSTATE, V58, P325, DOI 10.1002/pros.10336
   Melisi D, 2004, ENDOCR-RELAT CANCER, V11, P51, DOI 10.1677/erc.0.0110051
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   SEPPLORENZINO L, 1995, CANCER RES, V55, P5302
   Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431
   TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602
   Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zundelevich A, 2007, MOL CANCER THER, V6, P1765, DOI 10.1158/1535-7163.MCT-06-0706
NR 40
TC 32
Z9 33
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN
PY 2013
VL 4
IS 1
BP 145
EP 155
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 138IB
UT WOS:000318501100016
PM 23370967
DA 2022-04-25
ER

PT J
AU de la Cruz-Morcillo, MA
   Valero, MLL
   Callejas-Valera, JL
   Arias-Gonzalez, L
   Melgar-Rojas, P
   Galan-Moya, EM
   Garcia-Gil, E
   Garcia-Cano, J
   Sanchez-Prieto, R
AF de la Cruz-Morcillo, M. A.
   Valero, M. L. L.
   Callejas-Valera, J. L.
   Arias-Gonzalez, L.
   Melgar-Rojas, P.
   Galan-Moya, E. M.
   Garcia-Gil, E.
   Garcia-Cano, J.
   Sanchez-Prieto, R.
TI P38MAPK is a major determinant of the balance between apoptosis and
   autophagy triggered by 5-fluorouracil: implication in resistance
SO ONCOGENE
LA English
DT Article
DE 5-fluorouracil; p38MAPK; autophagy; resistance; p53; apoptosis
ID ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; COLORECTAL-CANCER CELLS;
   CISPLATIN-BASED THERAPY; DNA-DAMAGE; GENE-EXPRESSION; COLON-CANCER;
   CHEMOTHERAPEUTIC-AGENTS; P53-DEPENDENT APOPTOSIS; THYMIDYLATE SYNTHASE
AB 5-Fluorouracil (5-FU), together with other drugs such as oxaliplatin, is one of the most important pharmacological agents in the treatment of colorectal cancer. Although mitogen-activated protein kinases (MAPKs) have been extensively connected with resistance to platinum compounds, no role has been established in 5-FU resistance. Here we demonstrate that p38MAPK activation is a key determinant in the cellular response to 5-FU. Thus, inhibition of p38MAPK alpha by SB203580 compound or by short-hairpin RNA interference-specific knockdown correlates with a decrease in the 5-FU-associated apoptosis and chemical resistance in both HaCaT and HCT116 cells. Activation of p38MAPK by 5-FU was dependent on canonical MAP2K, MAPK kinase (MKK)-3 and MKK6. In addition, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) showed a redundancy of function for the final activation of p38MAPK. Resistance associated with p38MAPK inhibition correlates with an autophagic response that was mediated by a decrease in p53-driven apoptosis, without effect onto p53-dependent autophagy. Moreover, the results with colorectal cancer-derived cell lines with different p53 status and patterns of resistance to 5-FU suggest that de novo and acquired resistance was controlled by similar mechanisms. In summary, our data demonstrate a critical role for the p38MAPK signaling pathway in the cellular response to 5-FU by controlling the balance between apoptosis and autophagy. Oncogene (2012) 31, 1073-1085; doi:10.1038/onc.2011.321; published online 15 August 2011
C1 [de la Cruz-Morcillo, M. A.; Valero, M. L. L.; Callejas-Valera, J. L.; Arias-Gonzalez, L.; Melgar-Rojas, P.; Galan-Moya, E. M.; Garcia-Gil, E.; Garcia-Cano, J.; Sanchez-Prieto, R.] UCLM, Oncol Mol Lab, CRIB, PCYTA, Albacete 02006, Spain.
RP Sanchez-Prieto, R (corresponding author), UCLM, Oncol Mol Lab, CRIB, PCYTA, C Almansa 14, Albacete 02006, Spain.
EM ricardo.sanchez@uclm.es
RI Romo, José A./J-3024-2012; Sanchez-Prieto, Ricardo/AAY-4271-2021;
   Prieto, Ricardo/AAZ-7221-2021; Sanchez-Prieto, Ricardo/B-6877-2008;
   Arias-González, Laura/D-9517-2016; García-Cano, Jesús/AAA-9257-2020;
   Galan-Moya, Eva M/I-2912-2015
OI Romo, José A./0000-0003-2907-580X; Sanchez-Prieto,
   Ricardo/0000-0003-0882-9780; Sanchez-Prieto,
   Ricardo/0000-0003-0882-9780; Arias-González, Laura/0000-0003-2132-9350;
   García-Cano, Jesús/0000-0002-8312-2622; Galan-Moya, Eva
   M/0000-0001-5758-7592; Garcia Gil, Elena/0000-0002-8952-0306; de la
   Cruz-Morcillo, Miguel Angel/0000-0002-6674-1333
FU Fundacion Leticia Castillejo Castillo; Ministerio de Ciencia e
   InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean
   Commission [SAF2009-07329]; European CommunityEuropean Commission
FX This work was supported by grants from Fundacion Leticia Castillejo
   Castillo and Ministerio de Ciencia e Innovacion (SAF2009-07329) to RSP.
   RSP Research Institute, and the work carried out in his laboratory,
   received support from the European Community through the regional
   development funding program (FEDER). We appreciate the comments and
   suggestions of Drs G Almazan, E de la Casa-Esperon, S Gutkind, D Arango,
   A Cuenda, A Vazquez, I Sanchez and D Garcia-Olmo.
CR Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Callejas-Valera JL, 2008, J BIOL CHEM, V283, P13450, DOI 10.1074/jbc.M709230200
   Chan A, 2009, EUR J CANCER, V45, P2253, DOI 10.1016/j.ejca.2009.04.031
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002
   Elsea CR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002355
   Ewald B, 2008, ONCOGENE, V27, P6522, DOI 10.1038/onc.2008.316
   Ewald B, 2008, CANCER RES, V68, P7947, DOI 10.1158/0008-5472.CAN-08-0971
   Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240
   Galan-Moya EM, 2008, INT J CANCER, V122, P289, DOI 10.1002/ijc.23063
   Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Habiro A, 2004, BIOCHEM BIOPH RES CO, V316, P71, DOI 10.1016/j.bbrc.2004.02.017
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200
   Jardim MJ, 2009, MOL BIOL CELL, V20, P3801, DOI 10.1091/mbc.E09-04-0303
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200
   Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.3.CO;2-N
   Koizumi K, 2005, ANTICANCER RES, V25, P3347
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09
   Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189
   Liu A, 2008, J CELL BIOCHEM, V105, P245, DOI 10.1002/jcb.21824
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Longley DB, 2002, CANCER RES, V62, P2644
   Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Mariadason JM, 2003, CANCER RES, V63, P8791
   McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009
   McDonald GT, 2010, EXP CELL RES, V316, P3197, DOI 10.1016/j.yexcr.2010.08.007
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   OConnor PM, 1997, CANCER RES, V57, P4285
   Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007
   Perfettini JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002458
   Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0
   Raftery L, 2008, SEMIN ONCOL, V35, P561, DOI 10.1053/j.seminoncol.2008.08.004
   Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024
   Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018
   Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
   Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134
   SANCHEZAREVALO LV, 2005, BIOCH J 1, V387, P231
   Specenier P, 2010, CURR OPIN ONCOL, V22, P200, DOI 10.1097/CCO.0b013e3283376e15
   Tanida I, 2008, AUTOPHAGY, V4, P131, DOI 10.4161/auto.5233
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tominaga T, 2010, INT J CANCER, V126, P1691, DOI 10.1002/ijc.24929
   Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wilsker D, 2007, MOL CANCER THER, V6, P1406, DOI 10.1158/1535-7163.MCT-06-0679
   Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Zeng XH, 2010, CELL RES, V20, P665, DOI 10.1038/cr.2010.40
   Zhao HY, 2008, CANCER RES, V68, P7035, DOI 10.1158/0008-5472.CAN-07-6496
   Zheng MH, 1999, J CANCER RES CLIN, V125, P357, DOI 10.1007/s004320050286
NR 74
TC 91
Z9 91
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2012
VL 31
IS 9
BP 1073
EP 1085
DI 10.1038/onc.2011.321
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 901EW
UT WOS:000300945900001
PM 21841826
OA Bronze
DA 2022-04-25
ER

PT J
AU Qiao, XR
   Wang, C
   Wang, WD
   Shang, Y
   Li, Y
   Ni, J
   Chen, SZ
AF Qiao, Xinran
   Wang, Chen
   Wang, Wendie
   Shang, Yue
   Li, Yi
   Ni, Jun
   Chen, Shu-zhen
TI Levamisole enhances DR4-independent apoptosis induced by TRAIL through
   inhibiting the activation of JNK in lung cancer
SO LIFE SCIENCES
LA English
DT Article
DE Levamisole; TRAIL; Cell cycle arrest; DR4; LC3B; Erk; cJUN
ID COLORECTAL-CANCER; COLON-CANCER; PHASE-III; STAGE-II; EXPRESSION; CELLS;
   AUTOPHAGY; PATHWAY
AB The headings aims: Levamisole has anti-parasite and antitumor activities, but the anti-lung cancer mechanism has not been studied. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is regarded as a promising drug because of the ability to selectively target cancer cells. However, the tolerance of cancer cells to TRAIL limits its antitumor activity. Other drugs combined with TRAIL need to be explored to enhance its antitumor activity. Based on the adjuvant anticancer effect of levamisole on anticancer drugs activity, the antitumor activity of levamisole combined with TRAIL will be investigated.
   Materials and methods: In vitro and in vivo experiments were employed to investigate the anti-tumor activity. Flow-cytometry analysis, western blotting and siRNA transfection were used to explore the molecular mechanism.
   Key findings: Levamisole decreased the proliferation of lung cancer cells in vitro and in vivo and induced cell cycle arrest in G0/G1 phase. Besides, levamisole also enhanced TRAIL-induced DR4-independent apoptosis by inhibiting the phosphorylation of cJUN. A new cellular protective pathway LC3B-DR4/Erk was also disclosed, in which levamisole only increased the expression of LC3B and then activated the phosphorylation of Erk and increased the expression of DR4, while p-Erk and DR4 inter-regulated.
   Significance: Levamisole may be used as an adjuvant of TRAIL in treating lung cancer. The discovery of LC3BDR4/Erk as a new protective pathway provides a new direction for sensitizing lung cancer cells to TRAIL.
C1 [Qiao, Xinran; Wang, Chen; Wang, Wendie; Shang, Yue; Li, Yi; Ni, Jun; Chen, Shu-zhen] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotehnol, Beijing, Peoples R China.
RP Chen, SZ (corresponding author), 1 Tiantan Xili, Beijing 100050, Peoples R China.
EM bjcsz@imb.pumc.edu.cn
OI Chen, Shu-zhen/0000-0003-4881-0558
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81621064, 81702934]; CAMS Innovation Fund
   for Medical Sciences (CIFMS) [2016-I2M-02-002, 2019-I2M-1-003];
   "Significant New Drug Development" Major Science and Technology
   Development Projects of China [2018ZX09711001-007-002]
FX The manuscript was supported by grants from the National Natural Science
   Foundation of China (81621064, 81702934), CAMS Innovation Fund for
   Medical Sciences (CIFMS, 2016-I2M-02-002, 2019-I2M-1-003), and
   "Significant New Drug Development" Major Science and Technology
   Development Projects of China (no. 2018ZX09711001-007-002).
CR Anto Endy Juli, 2019, Open Access Maced J Med Sci, V7, P1299, DOI 10.3889/oamjms.2019.299
   Boye K, 2016, CANCER MED-US, V5, P1840, DOI 10.1002/cam4.766
   Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Chen SZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-23
   Chethan GE, 2019, TROP ANIM HEALTH PRO, V51, P1455, DOI 10.1007/s11250-019-01833-1
   Drosopoulos KG, 2005, J BIOL CHEM, V280, P22856, DOI 10.1074/jbc.M412483200
   Friis Tina, 2005, Angiogenesis, V8, P25, DOI 10.1007/s10456-005-3588-0
   Friis Tina, 2013, Cancers (Basel), V5, P762, DOI 10.3390/cancers5030762
   Girnius N, 2018, ELIFE, V7, DOI 10.7554/eLife.36389
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Guo ZL, 2018, BMC CELL BIOL, V19, DOI 10.1186/s12860-018-0179-7
   Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686
   Hegde M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043632
   Ibrahim HM, 2018, BIOMED PHARMACOTHER, V106, P43, DOI 10.1016/j.biopha.2018.06.113
   Iliev D, 2018, FEBS J, V285, P3114, DOI 10.1111/febs.14601
   Karki SS, 2011, EUR J MED CHEM, V46, P2109, DOI 10.1016/j.ejmech.2011.02.064
   Kim JH, 2014, EXP CELL RES, V327, P340, DOI 10.1016/j.yexcr.2014.08.001
   Kim MK, 2015, FITOTERAPIA, V101, P162, DOI 10.1016/j.fitote.2015.01.010
   Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342
   Lim SC, 2016, INT J ONCOL, V49, P1983, DOI 10.3892/ijo.2016.3699
   Liu HJ, 2018, CELL PHYSIOL BIOCHEM, V51, P528, DOI 10.1159/000495274
   Mandrell J, 2016, CUTIS, V98, pE15
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Muhlig AK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060860
   Nageshwari B, 2017, INDIAN J CANCER, V54, P566, DOI 10.4103/ijc.IJC_349_17
   Pan HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1653-7
   Park EJ, 2014, ARCH TOXICOL, V88, P323, DOI 10.1007/s00204-013-1134-1
   Qiao XR, 2019, MAR DRUGS, V17, DOI 10.3390/md17010063
   Qiao XR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0309-9
   Ramanadham M, 2010, J IMMUNOTOXICOL, V7, P327, DOI 10.3109/1547691X.2010.514871
   Recio-Boiles A, 2016, ONCOTARGET, V7, P9890, DOI 10.18632/oncotarget.7066
   Salem FS, 2011, VET ITAL, V47, P89
   Satyavarapu EM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0989-8
   Tong YX, 2015, BIOCHEM BIOPH RES CO, V456, P86, DOI 10.1016/j.bbrc.2014.11.038
   Wang Y, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.68
   Witonsky S, 2019, J VET INTERN MED, V33, P889, DOI 10.1111/jvim.15404
   Xu YT, 2018, CANCER CHEMOTH PHARM, V81, P555, DOI 10.1007/s00280-018-3526-7
   Yan SC, 2012, J CANCER RES CLIN, V138, P1279, DOI 10.1007/s00432-012-1204-4
   Yao WL, 2016, J BIOL CHEM, V291, P21694, DOI 10.1074/jbc.M116.738302
   Yuan H, 2017, INT J ANTENN PROPAG, V2017, DOI 10.1155/2017/6759169
   Zhang LQ, 2015, CELL SIGNAL, V27, P306, DOI 10.1016/j.cellsig.2014.11.014
NR 41
TC 2
Z9 4
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118034
DI 10.1016/j.lfs.2020.118034
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3TU
UT WOS:000568714500014
PM 32621923
DA 2022-04-25
ER

PT J
AU Tsai, DH
   Chung, CH
   Lee, KT
AF Tsai, Dai-Hua
   Chung, Cheng-Han
   Lee, Kung-Ta
TI Antrodia cinnamomea induces autophagic cell death via the
   CHOP/TRB3/Akt/mTOR pathway in colorectal cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; ER STRESS; CAMPHORATA MYCELIA; INDUCED
   APOPTOSIS; FRUITING BODIES; EXPRESSION; CHOP; GENE; INHIBITION;
   INDUCTION
AB Antrodia cinnamomea, a well-known traditional medicine used in Taiwan, is a potent anticancer drug for colorectal cancer, but the upstream molecular mechanism of its anticancer effects remains unclear. In this study, A. cinnamomea extracts showed cytotoxicity in HCT116, HT29, SW480, Caco-2 and, Colo205 colorectal cancer cells. Whole-genome expression profiling of A. cinnamomea extracts in HCT116 cells was performed. A. cinnamomea extracts upregulated the expression of the endoplasmic reticulum stress marker CHOP and its downstream gene TRB3. Moreover, dephosphorylation of Akt and mTOR as well as autophagic cell death were observed. Gene expression and autophagic cell death were reversed by the knockdown of CHOP and TRB3. Autophagy inhibition but not apoptosis inhibition reversed A. cinnamomea-induced cell death. Finally, we demonstrated that A. cinnamomea extracts significantly suppressed HCT116 tumour growth in nude mice. Our findings suggest that autophagic cell death via the CHOP/TRB3/Akt/mTOR pathway may represent a new mechanism of anti-colorectal cancer action by A. cinnamomea. A. cinnamomea is a new CHOP activator and potential drug that can be used in colorectal cancer treatment.
C1 [Tsai, Dai-Hua; Lee, Kung-Ta] Natl Taiwan Univ, Dept Biochem Sci & Technol, Taipei 10617, Taiwan.
   [Chung, Cheng-Han] Yong Teng Biotechnol Co Ltd, New Taipei 22180, Taiwan.
RP Lee, KT (corresponding author), Natl Taiwan Univ, Dept Biochem Sci & Technol, Taipei 10617, Taiwan.
EM ktlee@ntu.edu.tw
CR Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887
   Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Chan YY, 2010, J ETHNOPHARMACOL, V127, P652, DOI 10.1016/j.jep.2009.12.008
   Chang CW, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/946451
   Chen LY, 2011, J AGR FOOD CHEM, V59, P11255, DOI 10.1021/jf2024215
   Dabkeviciene D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0703-y
   Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x
   Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fribley A, 2009, METHODS MOL BIOL, V559, P191, DOI 10.1007/978-1-60327-017-5_14
   Geethangili M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep108
   GUJULUVA CN, 1994, ONCOGENE, V9, P1819
   Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625
   Hansen TE, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-39
   Hseu YC, 2007, FOOD CHEM TOXICOL, V45, P1107, DOI 10.1016/j.fct.2006.12.012
   Hsiao G, 2003, J AGR FOOD CHEM, V51, P3302, DOI 10.1021/jf021159t
   Hsin IL, 2012, TOXICOL APPL PHARM, V263, P330, DOI 10.1016/j.taap.2012.07.005
   Hsu YL, 2007, FOOD CHEM TOXICOL, V45, P1249, DOI 10.1016/j.fct.2007.01.005
   Huang GJ, 2010, J AGR FOOD CHEM, V58, P7445, DOI 10.1021/jf1013764
   Huang L., 2013, OA ALTERNAT MED, V1, P7
   Itatani Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050643
   Itoh Y, 2005, CYTOKINE, V29, P275, DOI 10.1016/j.cyto.2004.11.005
   Jiang W, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-72
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Kuo MC, 2008, J ETHNOPHARMACOL, V120, P196, DOI 10.1016/j.jep.2008.08.011
   Lai Chiao-I, 2016, J Tradit Complement Med, V6, P48, DOI 10.1016/j.jtcme.2014.11.026
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li CC, 2012, BIOMEDICINE-TAIWAN, V2, P10, DOI 10.1016/j.biomed.2012.02.002
   Li YM, 2014, ACTA BIOCH BIOPH SIN, V46, P629, DOI 10.1093/abbs/gmu048
   LIEN HM, 2011, EVID-BASED COMPL ALT, DOI DOI 10.1093/ECAM/NEP230
   Lin HC, 2017, J AGR FOOD CHEM, V65, P51, DOI 10.1021/acs.jafc.6b04101
   Lu MC, 2009, ARCH TOXICOL, V83, P121, DOI 10.1007/s00204-008-0337-3
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Mitra S., 2018, EVID-BASED COMPL ALT, V2018
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Pan-Hammarstrom Q, 2006, J INTERF CYTOK RES, V26, P628, DOI 10.1089/jir.2006.26.628
   Park DK, 2013, J MED FOOD, V16, P681, DOI 10.1089/jmf.2012.2605
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Sarvaiya PJ, 2013, ONCOTARGET, V4, P2171, DOI 10.18632/oncotarget.1426
   Sheu F, 2009, J AGR FOOD CHEM, V57, P4130, DOI 10.1021/jf900469a
   Song TY, 2003, J AGR FOOD CHEM, V51, P1571, DOI 10.1021/jf0209701
   Sturm A, 2005, CYTOKINE, V29, P42, DOI 10.1016/j.cyto.2004.09.007
   Su Yu-Cheng, 2012, J Tradit Complement Med, V2, P312
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Tsai Z. T., 1985, USE EFFECT GANODERMA, V116
   Tu SH, 2012, J AGR FOOD CHEM, V60, P3612, DOI 10.1021/jf300221g
   Verfaillie T., 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/93050920145727, DOI 10.1155/2010/930509]
   Wang DZ, 2009, CURR OPIN PHARMACOL, V9, P688, DOI 10.1016/j.coph.2009.08.003
   Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278
   Wu H, 2006, PROTEOMICS, V6, P826, DOI 10.1002/pmic.200401341
   Xiao YC, 2015, CANCER LETT, V361, P22, DOI 10.1016/j.canlet.2015.02.021
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Yan WH, 2014, CELL PHYSIOL BIOCHEM, V33, P823, DOI 10.1159/000358655
   Yu CC, 2012, J NUTR BIOCHEM, V23, P900, DOI 10.1016/j.jnutbio.2011.04.015
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
   Zou CG, 2009, ENDOCRINOLOGY, V150, P277, DOI 10.1210/en.2008-0794
NR 62
TC 16
Z9 18
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 27
PY 2018
VL 8
AR 17424
DI 10.1038/s41598-018-35780-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HB8DO
UT WOS:000451315600011
PM 30479369
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shen, B
   Tan, MY
   Mu, XY
   Qin, Y
   Zhang, F
   Liu, Y
   Fan, Y
AF Shen, Bing
   Tan, Mingyue
   Mu, Xinyu
   Qin, Yan
   Zhang, Fang
   Liu, Yong
   Fan, Yu
TI Upregulated SMYD3 promotes bladder cancer progression by targeting
   BCLAF1 and activating autophagy
SO TUMOR BIOLOGY
LA English
DT Article
DE SMYD3; BCLAF1; Autophagy; Bladder cancer; Histone methyltransferases
ID HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; PROSTATE-CANCER;
   GASTRIC-CANCER; COLON-CANCER; HISTONE; OVEREXPRESSION; PROLIFERATION;
   METASTASIS; SURVIVAL
AB The recent discovery of a large number of histone methyltransferases reveals important roles of these enzymes in regulating tumor development and progression. SMYD3, a histone methyltransferase, is associated with poor prognosis of patients with prostate and gastric cancer. In the study, we attempted to investigate its putative oncogenic role on bladder cancer. Here, we report that SMYD3 frequently amplified in bladder cancer is correlated with bladder cancer progression and poor prognosis. Overexpression of SMYD3 promotes bladder cancer cell proliferation and invasion, whereas SMYD3 knockdown inhibits cancer cell growth and invasion. Mechanically, SMYD3 positively regulates the expression of BCL2-associated transcription factor 1 (BCLAF1). SMYD3 physically interacts with the promoter of BCLAF1 and upregulates its expression by accumulating di- and trimethylation of H3K4 at the BCLAF1 locus. We further show that SMYD3 overexpression in bladder cancer cells promotes autophagy activation, whereas BCLAF1 depletion inhibits SMYD3-induced autophagy. Finally, we demonstrate that SMYD3 promotes bladder cancer progression, at least in part by increasing BCLAF1 expression and activating autophagy. Our results establish a function for SMYD3 in autophagy activation and bladder cancer progression and suggest its candidacy as a new prognostic biomarker and target for clinical management of bladder cancer.
C1 [Shen, Bing; Tan, Mingyue; Mu, Xinyu; Qin, Yan; Zhang, Fang; Liu, Yong; Fan, Yu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Renal Transplantat & Urol, 100 Haining Rd, Shanghai 200080, Peoples R China.
RP Fan, Y (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Renal Transplantat & Urol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM fanyu1965@163.com
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81402086]
FX This work was funded by National Science Foundation of China (Grant No.
   81402086).
CR Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Benard A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-531
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Connor KM, 2007, CANCER RES, V67, P10260, DOI 10.1158/0008-5472.CAN-07-1204
   Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364
   Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gao SB, 2014, J HEPATOL, V61, P832, DOI 10.1016/j.jhep.2014.05.015
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kim WJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-3
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403
   Lacey JV, 2002, ENVIRON MOL MUTAGEN, V39, P82, DOI 10.1002/em.10062
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Y, 2015, TUMOR BIOL, V36, P4377, DOI 10.1007/s13277-015-3077-z
   Liu Y, 2015, TUMOR BIOL, V36, P2685, DOI 10.1007/s13277-014-2891-z
   Liu Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0404-y
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   Luo XG, 2014, CANCER LETT, V344, P129, DOI 10.1016/j.canlet.2013.10.026
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Peserico A, 2015, J CELL PHYSIOL, V230, P2447, DOI 10.1002/jcp.24975
   Riester M, 2014, CLIN CANCER RES, V20, P1873, DOI 10.1158/1078-0432.CCR-13-0759
   Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271
   Rosenberg JE, 2005, J UROLOGY, V174, P14, DOI 10.1097/01.ju.0000162039.38023.5f
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Vieira FQ, 2015, ONCOTARGET, V6, P13644, DOI 10.18632/oncotarget.3767
   Wang JF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118086
   Ying L, 2015, FEBS J, V282, P174, DOI 10.1111/febs.13116
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
NR 39
TC 34
Z9 38
U1 3
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2016
VL 37
IS 6
BP 7371
EP 7381
DI 10.1007/s13277-015-4410-2
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DM6LT
UT WOS:000376464700035
PM 26676636
DA 2022-04-25
ER

PT J
AU Ortiz, LMG
   Tillhon, M
   Parks, M
   Dutto, I
   Prosperi, E
   Savio, M
   Arcamone, AG
   Buzzetti, F
   Lombardi, P
   Scovassi, AI
AF Guaman Ortiz, Luis Miguel
   Tillhon, Micol
   Parks, Michael
   Dutto, Ilaria
   Prosperi, Ennio
   Savio, Monica
   Arcamone, Andrea G.
   Buzzetti, Franco
   Lombardi, Paolo
   Scovassi, Anna Ivana
TI Multiple Effects of Berberine Derivatives on Colon Cancer Cells
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID NATURAL ALKALOID BERBERINE; LUNG-CANCER; IN-VITRO; APOPTOSIS;
   MITOCHONDRIAL; DEATH; BINDING; GROWTH; P53; PERSPECTIVES
AB The pharmacological use of the plant alkaloid berberine is based on its antibacterial and anti-inflammatory properties; recently, anticancer activity has been attributed to this compound. To exploit this interesting feature, we synthesized three berberine derivatives, namely, NAX012, NAX014, and NAX018, and we tested their effects on two human colon carcinoma cell lines, that is, HCT116 and SW613-B3, which are characterized by wt and mutated p53, respectively. We observed that cell proliferation is more affected by cell treatment with the derivatives than with the lead compound; moreover, the derivatives proved to induce cell cycle arrest and cell death through apoptosis, thus suggesting that they could be promising anticancer drugs. Finally, we detected typical signs of autophagy in cells treated with berberine derivatives.
C1 [Guaman Ortiz, Luis Miguel; Tillhon, Micol; Parks, Michael; Dutto, Ilaria; Prosperi, Ennio; Scovassi, Anna Ivana] CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Guaman Ortiz, Luis Miguel] Univ Tecn Particular Loja, Dept Ciencias Salud, Loja 1101608, Ecuador.
   [Savio, Monica] Univ Pavia, Dept Mol Med, Immunol & Gen Pathol Unit, I-27100 Pavia, Italy.
   [Arcamone, Andrea G.; Buzzetti, Franco; Lombardi, Paolo] Naxospharma Srl, I-20026 Novate Milanese, Italy.
RP Scovassi, AI (corresponding author), CNR, Ist Genet Mol, I-27100 Pavia, Italy.
EM scovassi@igm.cnr.it
RI Prosperi, Ennio/A-3439-2014; Ortiz, Luis Miguel Guaman/X-9496-2019;
   dutto, Ilaria/AAX-9097-2020; Tillhon, Micol/AAQ-6994-2020
OI Prosperi, Ennio/0000-0001-5391-5157; Ortiz, Luis Miguel
   Guaman/0000-0003-2919-4905; Scovassi, Anna Ivana/0000-0003-3484-9881;
   Dutto, Ilaria/0000-0002-6987-6647; Parks, Michael/0000-0001-8240-0603;
   Lombardi, Paolo/0000-0002-7971-7404
FU Regione Lombardia, ItalyRegione Lombardia [13810040]; SENESCYT (Quito,
   Ecuador); Universidad Tecnica Particular de Loja (Loja, Ecuador);
   Italian AIRCFondazione AIRC per la ricerca sul cancro
FX The research was partly supported by Regione Lombardia, Italy (Project
   Plant Cell, Grant no. 13810040 to Anna Ivana Scovassi and Naxospharma).
   Luis Miguel Guaman Ortiz is a Ph.D. student (Dottorato in Genetica,
   Biologia Cellulare e Molecolare, University of Pavia, Italy) supported
   by SENESCYT (Quito, Ecuador) and Universidad Tecnica Particular de Loja
   (Loja, Ecuador); Micol Tillhon is a Postdoc supported by Italian AIRC;
   Ilaria Dutto is a Ph.D. student from IUSS, Pavia, Italy. Thanks are due
   to Dr. Francesca Aredia for the experiments with 3MA. The authors kindly
   acknowledge the reviewers for stimulating to improve the paper.
CR Albring KF, 2013, BIOFACTORS, V39, P652, DOI 10.1002/biof.1133
   Andrabi SA, 2008, ANN NY ACAD SCI, V1147, P233, DOI 10.1196/annals.1427.014
   Aredia F, 2013, APOPTOSIS, V18, P1586, DOI 10.1007/s10495-013-0898-3
   Bhadra K, 2011, MED RES REV, V31, P821, DOI 10.1002/med.20202
   Bhowmik D, 2014, SPECTROCHIM ACTA A, V120, P257, DOI 10.1016/j.saa.2013.09.081
   Bhowmik D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037939
   Bhowmik D, 2012, J PHYS CHEM B, V116, P2314, DOI 10.1021/jp210072a
   Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x
   Carpignano F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048556
   Choi MS, 2009, INT J ONCOL, V34, P1221, DOI 10.3892/ijo_00000250
   Choi MS, 2008, ANTICANCER RES, V28, P3777
   Derosa G, 2014, CURR TOP MED CHEM, V14, P200, DOI 10.2174/1568026613666131213155252
   Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309
   Fu LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069240
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Giansanti V, 2009, INT J BIOCHEM CELL B, V41, P1890, DOI 10.1016/j.biocel.2009.04.008
   Goto H, 2012, CANCER SCI, V103, P775, DOI 10.1111/j.1349-7006.2012.02212.x
   Guaman Ortiz L. M., 2013, BIOCHEM PHARMACOL, V2, P110
   He W, 2012, J PHARMACOL SCI, V119, P341, DOI 10.1254/jphs.12052FP
   Hou Q, 2011, CANCER SCI, V102, P1287, DOI 10.1111/j.1349-7006.2011.01933.x
   Huang ZJ, 2011, MINI-REV MED CHEM, V11, P1122, DOI 10.2174/138955711797655362
   Karaosmanoglu K, 2014, OMICS, V18, P42, DOI 10.1089/omi.2013.0100
   Katiyar SK, 2009, MOL CARCINOGEN, V48, P24, DOI 10.1002/mc.20453
   Kim HS, 2012, BIOCHEM PHARMACOL, V83, P385, DOI 10.1016/j.bcp.2011.11.008
   Kumar GS, 2012, J BIOSCIENCES, V37, P539, DOI 10.1007/s12038-012-9217-3
   Lee SJ, 2011, INT J ONCOL, V38, P485, DOI 10.3892/ijo.2010.878
   Li JS, 2013, LAB INVEST, V93, P354, DOI 10.1038/labinvest.2012.172
   Liu ZJ, 2009, MUTAT RES-FUND MOL M, V662, P75, DOI 10.1016/j.mrfmmm.2008.12.009
   Lo CY, 2013, BIOORG MED CHEM LETT, V23, P305, DOI 10.1016/j.bmcl.2012.10.098
   Lu JJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/485042
   Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560
   Marverti G, 2013, INT J ONCOL, V43, P1269, DOI 10.3892/ijo.2013.2045
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Murthy KNC, 2012, EUR J PHARMACOL, V688, P14, DOI 10.1016/j.ejphar.2012.05.004
   Parks M, 2011, MOL CELL ENDOCRINOL, V331, P119, DOI 10.1016/j.mce.2010.08.017
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Pierpaoli E, 2013, BIOFACTORS, V39, P672, DOI 10.1002/biof.1131
   Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161/cc.5.18.3235
   Singh IP, 2013, EXPERT OPIN THER PAT, V23, P215, DOI 10.1517/13543776.2013.746314
   Sorrentino G., 2014, FEBS LETT
   Tan Wen, 2011, Int J Nanomedicine, V6, P1773, DOI 10.2147/IJN.S22683
   Teiten MH, 2013, BIOCHEM PHARMACOL, V86, P1239, DOI 10.1016/j.bcp.2013.08.007
   Tillhon M, 2012, BIOCHEM PHARMACOL, V84, P1260, DOI 10.1016/j.bcp.2012.07.018
   Torriglia A, 1999, CELL DEATH DIFFER, V6, P234, DOI 10.1038/sj.cdd.4400486
   Vuddanda PR, 2010, EXPERT OPIN INV DRUG, V19, P1297, DOI 10.1517/13543784.2010.517745
   Wang J, 2012, INT J MOL MED, V30, P1166, DOI 10.3892/ijmm.2012.1095
   Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang YJ, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020422, 10.1371/journal.pone.0023495]
   Wang Y, 2012, MUTAT RES-FUND MOL M, V734, P20, DOI 10.1016/j.mrfmmm.2012.04.005
   Waters ML, 2002, CURR OPIN CHEM BIOL, V6, P736, DOI 10.1016/S1367-5931(02)00359-9
   Xia Q., 2013, J NATURAL MED, V68, P53
   Xiao NN, 2012, BIOCHEM BIOPH RES CO, V419, P567, DOI 10.1016/j.bbrc.2012.02.063
   Yang XL, 2013, MOL MED REP, V8, P505, DOI 10.3892/mmr.2013.1506
   Yip NKY, 2013, ONCOL REP, V30, P1107, DOI 10.3892/or.2013.2543
   Zhang L, 2012, MOLECULES, V17, P11294, DOI 10.3390/molecules171011294
NR 56
TC 38
Z9 42
U1 0
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 924585
DI 10.1155/2014/924585
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AK0JP
UT WOS:000338099100001
PM 25045712
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Li, MX
   Luo, T
   Huang, Y
   Su, JY
   Li, D
   Chen, XH
   Zhang, YF
   Huang, LH
   Li, SX
   Jiao, CW
   Li, WZ
   Xie, YZ
   Li, WD
AF Li, Muxia
   Luo, Ting
   Huang, Yong
   Su, Jiyan
   Li, Dan
   Chen, Xiaohong
   Zhang, Yifan
   Huang, Longhua
   Li, Shunxian
   Jiao, Chunwei
   Li, Wenzhi
   Xie, Yizhen
   Li, Wende
TI Polysaccharide from Pycnoporus sanguineus ameliorates dextran sulfate
   sodium-induced colitis via helper T cells repertoire modulation and
   autophagy suppression
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE autophagy; epithelium barrier; helper T cells; inflammatory bowel
   disease; Pycnoporus sanguineus
ID INFLAMMATORY-BOWEL-DISEASE; CANCER; PROLIFERATION; SULFASALAZINE;
   INHIBITION; PREVALENCE; MUSHROOM; COLON; MICE
AB Inflammatory bowel disease (IBD) is a chronic autoimmune disease associated with various risk factors. Pycnoporus sanguineus (L.) Murrill is a saprotrophic fungus used worldwide for its industrial and medical purposes. Here, polysaccharide from P. sanguineus (PPS) was explored for its antiinflammatory potential in a murine colitis model of IBD induced by dextran sulfate sodium (DSS). PPS ameliorated the colitis as manifested by the lowered disease activity index (DAI), prolonged colon, and reduced serum lipopolysaccharide (LPS). PPS recovered the histological lesion by upregulating the expressions of Zonula occludens-1 (ZO-1), E-cadherin, and proliferating cell nuclear antigen (PCNA). PPS inhibited the helper T cells (Th)-mediated immune response by decreasing the proportions of Th cells (including Th2 cells, Th17 cells, and regulatory T cells), which was accompanied with reductions on myeloperoxidase (MPO) activity and releases of several interleukins and chemokines within the colon. Moreover, PPS exhibited an evident inhibition on autophagy, in which the ratio of light chain 3 (LC3) II/I was declined, while the expression of p62 and Beclin-1 was increased. The present study highlighted important clinical implications for the treatment application of PPS against IBD, which relies on the regulation of Th cells repertoire and autophagy suppression to restore epithelium barrier.
C1 [Li, Muxia; Li, Dan; Chen, Xiaohong] Guangzhou Univ Chinese Med, Math Engn Acad Chinese Med, Guangdong Prov Key Lab New Drug Dev & Res Chinese, Guangzhou, Guangdong, Peoples R China.
   [Li, Muxia; Su, Jiyan; Li, Dan; Chen, Xiaohong; Zhang, Yifan; Huang, Longhua; Xie, Yizhen] Guangdong Acad Sci, Guangdong Inst Microbiol, Guangdong Prov Key Lab Microbial Culture Collect, State Key Lab Appl Microbiol Southern China,Guang, Guangzhou, Guangdong, Peoples R China.
   [Luo, Ting] Jinan Univ, Guangzhou, Guangdong, Peoples R China.
   [Luo, Ting; Li, Wende] Guangdong Prov Key Lab Lab Anim, Guangdong Lab Anim Monitoring Inst, 11 Fengxin Rd, Guangzhou 510663, Guangdong, Peoples R China.
   [Huang, Yong] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China.
   [Li, Dan; Chen, Xiaohong; Li, Shunxian; Jiao, Chunwei; Xie, Yizhen] Guangdong Yuewei Edible Fungi Technol Co Ltd, Guangzhou, Guangdong, Peoples R China.
   [Li, Wenzhi] Infinitus China Co Ltd, Guangzhou, Guangdong, Peoples R China.
RP Li, WD (corresponding author), Guangdong Prov Key Lab Lab Anim, Guangdong Lab Anim Monitoring Inst, 11 Fengxin Rd, Guangzhou 510663, Guangdong, Peoples R China.; Xie, YZ (corresponding author), Guangdong Inst Microbiol, Guangdong Prov Key Lab Microbial Culture Collect, State Key Lab Appl Microbiol Southern China, 100 Xianlie Zhong Rd, Guangzhou 510070, Guangdong, Peoples R China.
EM xyzgdim@sina.com; lwd@gdlami.com
FU GDAS' Special Project of Science and Technology Development
   [2019GDASYL-0105002]; Guangdong Province Innovation Team Construction
   Program on Modern Agriculture Industrial technology system [2019KJ103];
   Guangdong Province Science and Technology Innovation Strategy Special
   Fund [2018B020205001]; Guangzhou Science and Technology Plan Project
   [201604016051]; High-level Leading Talent Introduction Program of GDAS
   [2016GDASRC-0102]; Natural Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2018A0303130102, 2018A030313887]; Pearl River S&T Nova Program of
   Guangzhou [201806010078]; Provincial-level Major Scientific Research
   Projects in Regular Universities of Guangdong Province [2017KZDXM017];
   Science and Technology Planning Project of Guangdong Province
   [2017B030314171, 2018B030317001]; Science and Technology Planning
   Project of Guangzhou [201707020022]; Nanyue Microbial Talents
   Cultivation Fund of Guangdong Institute of Microbiology
   [GDIMYET20150203]
FX GDAS' Special Project of Science and Technology Development, Grant/Award
   Number: 2019GDASYL-0105002; Guangdong Province Innovation Team
   Construction Program on Modern Agriculture Industrial technology system,
   Grant/Award Number: 2019KJ103; Guangdong Province Science and Technology
   Innovation Strategy Special Fund, Grant/Award Number: 2018B020205001;
   Guangzhou Science and Technology Plan Project, Grant/Award Number:
   201604016051; High-level Leading Talent Introduction Program of GDAS,
   Grant/Award Number: 2016GDASRC-0102; Natural Science Foundation of
   Guangdong Province, Grant/Award Numbers: 2018A0303130102,
   2018A030313887; Pearl River S&T Nova Program of Guangzhou, Grant/Award
   Number: 201806010078; Provincial-level Major Scientific Research
   Projects in Regular Universities of Guangdong Province, Grant/Award
   Number: 2017KZDXM017; Science and Technology Planning Project of
   Guangdong Province, Grant/Award Numbers: 2017B030314171, 2018B030317001;
   Science and Technology Planning Project of Guangzhou, Grant/Award
   Number: 201707020022; the Nanyue Microbial Talents Cultivation Fund of
   Guangdong Institute of Microbiology, Grant/Award Number: GDIMYET20150203
CR Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X
   Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9
   Boukes GJ, 2017, S AFR J BOT, V113, P62, DOI 10.1016/j.sajb.2017.07.010
   Brest P, 2010, CURR MOL MED, V10, P486, DOI 10.2174/156652410791608252
   Brown GD, 2005, CELL MICROBIOL, V7, P471, DOI 10.1111/j.1462-5822.2005.00505.x
   Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4
   Butera A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02511
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   COLLIER HOJ, 1976, PROSTAGLANDINS, V11, P219, DOI 10.1016/0090-6980(76)90145-3
   Correa E, 2006, PHYTOTHER RES, V20, P497, DOI 10.1002/ptr.1890
   Durando M, 2017, AM J KIDNEY DIS, V70, P869, DOI 10.1053/j.ajkd.2017.05.013
   Fakhoury M, 2014, J INFLAMM RES, V7, P113, DOI 10.2147/JIR.S65979
   Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51
   Giner E, 2016, MOL NUTR FOOD RES, V60, P242, DOI 10.1002/mnfr.201500605
   Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668
   Jaszek M, 2015, INT J MED MUSHROOMS, V17, P701, DOI 10.1615/IntJMedMushrooms.v17.i8.10
   Jin BR, 2017, SCI REP-UK, V7, DOI 10.1038/srep46252
   Jouda JB, 2018, BIOORG CHEM, V80, P216, DOI 10.1016/j.bioorg.2018.06.021
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444
   Khor B, 2015, ELIFE, V4, DOI 10.7554/eLife.05920
   Li XX, 2005, J MOL MED, V83, P258, DOI 10.1007/s00109-004-0622-4
   Li YL, 2018, CELL PHYSIOL BIOCHEM, V49, P1352, DOI 10.1159/000493413
   Linard C, 2008, J PHARMACOL EXP THER, V324, P911, DOI 10.1124/jpet.107.129122
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Luk HH, 2002, EUR J PHARMACOL, V443, P197, DOI 10.1016/S0014-2999(02)01592-3
   Maria-Ferreira D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30526-2
   Matsuzawa-Ishimoto Y, 2018, ANNU REV IMMUNOL, V36, P73, DOI 10.1146/annurev-immunol-042617-053253
   Meczker A, 2018, J GASTROINTEST LIVER, V27, P189, DOI 10.15403/jgld.2014.1121.272.asa
   Mehta S, 2015, CELL TISSUE RES, V360, P749, DOI 10.1007/s00441-014-1994-6
   Mi Y, 2020, INT J BIOL MACROMOL, V147, P284, DOI 10.1016/j.ijbiomac.2020.01.072
   Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001
   Muszynska B, 2018, FOOD CHEM, V243, P373, DOI 10.1016/j.foodchem.2017.09.149
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0
   Papagianni M, 2004, BIOTECHNOL ADV, V22, P189, DOI 10.1016/j.biotechadv.2003.09.005
   Patel H, 2009, CAN J GASTROENTEROL, V23, P170, DOI 10.1155/2009/501345
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Pott J, 2018, AUTOPHAGY, V14, P1460, DOI 10.1080/15548627.2018.1450021
   Qin MM, 2016, INT J MED MUSHROOMS, V18, P227, DOI 10.1615/IntJMedMushrooms.v18.i3.50
   Reikvam DH, 2011, SCAND J GASTROENTERO, V46, P550, DOI 10.3109/00365521.2011.551887
   Sartor RB, 2011, MUCOSAL IMMUNOL, V4, P127, DOI 10.1038/mi.2010.87
   Sciarretta S, 2018, ANNU REV PHYSIOL, V80, P1, DOI 10.1146/annurev-physiol-021317-121427
   Sharma A, 2020, EUR J NUTR, V59, P2663, DOI 10.1007/s00394-019-02114-1
   Silva LCR, 2010, IMMUNOTHERAPY-UK, V2, P817, DOI 10.2217/IMT.10.67
   Smania A, 2003, PHYTOTHER RES, V17, P1069, DOI 10.1002/ptr.1304
   Solanas G, 2011, EXP CELL RES, V317, P2695, DOI 10.1016/j.yexcr.2011.07.019
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020
   Stolimenov I, 2009, BIOCHEM SOC T, V37, P605, DOI 10.1042/BST0370605
   Su JY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00829
   Szanto A, 2008, IMMUNOBIOLOGY, V213, P789, DOI 10.1016/j.imbio.2008.07.015
   Ueno A, 2018, J AUTOIMMUN, V87, P38, DOI 10.1016/j.jaut.2017.12.004
   Wells CL, 1996, GASTROENTEROLOGY, V110, P1429, DOI 10.1053/gast.1996.v110.pm8613048
   Wittkopf N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/278059
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Xie CC, 2016, AUTOPHAGY, V12, P410, DOI 10.1080/15548627.2015.1132134
   Zheng J., 2017, MOLECULES, V23, DOI 10.3390/molecules23010051
NR 59
TC 4
Z9 5
U1 4
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD OCT
PY 2020
VL 34
IS 10
BP 2649
EP 2664
DI 10.1002/ptr.6695
EA APR 2020
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OC4MU
UT WOS:000526020700001
PM 32281697
DA 2022-04-25
ER

PT J
AU Quah, SY
   Wong, CC
   Wong, HC
   Ho, KL
   Manan, NA
   Deb, PK
   Sagineedu, SR
   Stanslas, J
AF Quah, Shun Ying
   Wong, Charng Choon
   Wong, Hui Chyn
   Ho, Kok Lian
   Manan, Nizar Abdul
   Deb, Pran Kishore
   Sagineedu, Sreenivasa Rao
   Stanslas, Johnson
TI Microarray-based identification of differentially expressed genes
   associated with andrographolide derivatives-induced resistance in colon
   and prostate cancer cell lines
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Chemoresistance; SRJ09; SRJ23; Microarray analysis; Gene expression
ID FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR 4; HEME OXYGENASE-1;
   DRUG-RESISTANCE; IN-VITRO; BREAST-CANCER; STEM-CELLS;
   HEPATOCELLULAR-CARCINOMA; PROMOTES PROGRESSION; INDUCED APOPTOSIS
AB Chemoresistance poses a major hurdle to cancer treatments. Andrographolide-derived SRJ09 and SRJ23 were reported to exhibit potent, selective inhibitory activities against colon and prostate cancer cells, respectively. In this study, previously developed resistant colon (HCT-116rst09) and prostate (PC-3rst23) cancer cell lines were used to elucidate the molecular mechanisms contributing to chemoresistance. Cytotoxic effects of SRJ09 and SRJ23 on both parental and resistant cells were investigated. Cell cycle distributions in HCT-116rst09 cells following SRJ09 treatment were analysed using flow cytometry. Whole-genome microarray analysis was performed on both parental and resistant cells to obtain differential gene expression profiles. Microarray data were subjected to protein-protein interaction network, functional enrichment, and pathway analyses. Reverse transcription-polymerase chain reaction (RT-PCR) was used to validate the changes in expression levels of selected genes. Besides morphological changes, HCT-116rst09 cells showed 7.0-fold resistance to SRJ09 while PC3rst23 cells displayed a 5.5-fold resistance to SRJ23, as compared with their respective parental cells. G0/G1-phase cell cycle arrest was observed in HCT-116rst09 cells upon SRJ09 treatment. Collectively, 77 and 21 genes were found differentially modulated in HCT-116rst09 and PC-3rst23 cells, respectively. Subsequent bioinformatics analysis revealed several genes associated with FGFR4 and PI3K pathways, and cancer stemness, were chemoresistance mediators in HCT-116rst09 cells. RT-PCR confirmed the HMOX1 upregulation and ATG12 downregulation protected the PC-3rst23 cells from SRJ23 cytotoxicity. In conclusion, acquired chemoresistance to SRJ09 and SRJ23 in colon and prostate cancer cells, respectively, could be attributed to the alterations in the expression of genes such as those related to PI3K and autophagy pathways.
C1 [Quah, Shun Ying; Wong, Charng Choon; Wong, Hui Chyn; Stanslas, Johnson] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Pharmacotherapeut Unit, Serdang 43400, Selangor, Malaysia.
   [Ho, Kok Lian] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Pathol, Serdang 43400, Selangor, Malaysia.
   [Manan, Nizar Abdul] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Serdang 43400, Selangor, Malaysia.
   [Deb, Pran Kishore] Philadelphia Univ, Fac Pharm, POB 1, Amman 19392, Jordan.
   [Sagineedu, Sreenivasa Rao] Int Med Univ, Sch Pharm, Dept Pharmaceut Chem, Kuala Lumpur 57000, Malaysia.
RP Stanslas, J (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Pharmacotherapeut Unit, Serdang 43400, Selangor, Malaysia.
EM rcxjs@upm.edu.my
OI Quah, Shun Ying/0000-0002-0621-7169
FU Universiti Putra Malaysia, Malaysia through Research University Grant
   Scheme [04-01-09-0713RU, 04-02-12-2017RU]
FX This work was supported by the Universiti Putra Malaysia, Malaysia
   through Research University Grant Scheme [grant numbers 04-01-09-0713RU
   and 04-02-12-2017RU] to J. Stanslas.
CR Bao LJ, 2014, INT J CLIN EXP PATHO, V7, P1502
   Battista RA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201621
   Belounis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2906-9
   Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159
   Carlino Matteo S, 2014, Oncoscience, V1, P423
   Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2999-1
   Desai AG, 2008, CURR DRUG METAB, V9, P581, DOI 10.2174/138920008785821657
   Desnoyers L, 2008, ONCOGENE, V27, P85, DOI 10.1038/sj.onc.1210623
   Devendar P, 2015, MEDCHEMCOMM, V6, P898, DOI 10.1039/c4md00566j
   Gao LX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0478-9
   Gao W, 2008, BIOORG MED CHEM LETT, V18, P704, DOI 10.1016/j.bmcl.2007.11.054
   GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333
   Gueron G, 2009, MOL CANCER RES, V7, P1745, DOI 10.1158/1541-7786.MCR-08-0325
   Guo XX, 2008, ANTICANCER RES, V28, P9
   Han L, 2018, INT J ONCOL, V52, P2101, DOI 10.3892/ijo.2018.4363
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hill DP, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S5-S2
   Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Hu LL, 2015, ONCOL REP, V34, P2683, DOI 10.3892/or.2015.4212
   Huang EH, 2008, TRENDS MOL MED, V14, P503, DOI 10.1016/j.molmed.2008.09.005
   Hyeon J, 2013, DIGEST DIS SCI, V58, P1916, DOI 10.1007/s10620-013-2609-x
   Jada SR, 2008, BRIT J PHARMACOL, V155, P641, DOI 10.1038/bjp.2008.368
   Jada SR, 2007, PHYTOCHEMISTRY, V68, P904, DOI 10.1016/j.phytochem.2006.11.031
   Jada SR, 2006, J ENZYM INHIB MED CH, V21, P145, DOI 10.1080/14756360500499988
   Jansen PLM, 2017, HEPAT ONCOL, V4, P1, DOI 10.2217/hep-2017-0008
   Jayakumar T, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/846740
   Jo EJ, 2016, EUR J PHARMACOL, V788, P321, DOI 10.1016/j.ejphar.2016.06.052
   Kars MD, 2006, ANTICANCER RES, V26, P4559
   Laconi E, 2020, BRIT J CANCER, V122, P943, DOI 10.1038/s41416-019-0721-1
   Lang LW, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010031
   Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200
   Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011
   Lim ZF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0818-2
   Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259
   Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041
   McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040
   Michaelis M., 2019, CANC DRUG RESIST, V2, P447, DOI [DOI 10.20517/CDR.2019.005, 10.20517/cdr.2019.005]
   MINATO K, 1990, CANCER CHEMOTH PHARM, V26, P313, DOI 10.1007/BF02897284
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mujoo K, 2000, INT J GYNECOL CANCER, V10, P105, DOI 10.1046/j.1525-1438.2000.00018.x
   Nagamatsu H, 2015, PROSTATE, V75, P1092, DOI 10.1002/pros.22994
   Nanduri S, 2004, BIOORG MED CHEM LETT, V14, P4711, DOI 10.1016/j.bmcl.2004.06.090
   Naponelli V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/121826
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Paldino E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/859871
   Patil R., 2014, INT J PHARM BIO SCI, V5, P526
   Pietras A, 2011, ADV CANCER RES, V112, P255, DOI 10.1016/B978-0-12-387688-1.00009-0
   Poerwono H, 2007, INDONES J CHEM, V7, P202
   Qi LS, 2012, CANCER SCI, V103, P828, DOI 10.1111/j.1349-7006.2012.02222.x
   Rajagopal Sriram, 2003, J Exp Ther Oncol, V3, P147, DOI 10.1046/j.1359-4117.2003.01090.x
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Singh AK, 2015, INT J CANCER, V136, P1991, DOI 10.1002/ijc.28804
   Sirion U, 2012, BIOORG MED CHEM LETT, V22, P49, DOI 10.1016/j.bmcl.2011.11.085
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328
   Turkington RC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.10
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Wang DY, 2019, DIGEST DIS, V37, P214, DOI 10.1159/000494454
   Wang Xuan, 2019, Cancer Drug Resist, V2, P141, DOI 10.20517/cdr.2019.10
   Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365
   Wong C.C., 2015, THESIS U PUTRA MALAY
   Wong CC, 2016, PHARMACOL RES, V107, P66, DOI 10.1016/j.phrs.2016.02.024
   Wong H.C., 2013, THESIS U PUTRA MALAY
   Wong HC, 2014, CELL BIOL TOXICOL, V30, P269, DOI 10.1007/s10565-014-9282-5
   Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015
   Zhang XC, 2017, THORAC CANCER, V8, P655, DOI 10.1111/1759-7714.12504
   Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200
   Zhe NN, 2015, HEMATOLOGY, V20, P384, DOI 10.1179/1607845414Y.0000000212
   Zhu XF, 2015, ONCOL LETT, V10, P2974, DOI 10.3892/ol.2015.3735
NR 75
TC 1
Z9 1
U1 2
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD AUG 15
PY 2021
VL 425
AR 115605
DI 10.1016/j.taap.2021.115605
EA JUN 2021
PG 15
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA SV9LE
UT WOS:000664138800004
PM 34087331
DA 2022-04-25
ER

PT J
AU Li, B
   Wu, GL
   Dai, W
   Wang, G
   Su, HY
   Shen, XP
   Zhan, R
   Xie, JM
   Wang, Z
   Qin, ZH
   Gao, QG
   Shen, GH
AF Li, Bin
   Wu, Guo-liang
   Dai, Wei
   Wang, Gang
   Su, Hao-yuan
   Shen, Xue-ping
   Zhan, Rui
   Xie, Jia-ming
   Wang, Zhong
   Qin, Zheng-hong
   Gao, Quan-gen
   Shen, Gen-hai
TI Aescin-induced reactive oxygen species play a pro-survival role in human
   cancer cells via ATM/AMPK/ULK1-mediated autophagy
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE aescin; ROS; autophagy; apoptosis; human hepatocellular carcinoma HepG2
   cells; human colon carcinoma HCT 116 cells; 3-MA; NAC; KU-55933
ID FACTOR-KAPPA-B; BETA-ESCIN; APOPTOSIS; ROS; STRESS; INHIBITION;
   ACTIVATION; MECHANISMS; AMPK
AB Aescin, a natural mixture of triterpene saponins, has been reported to exert anticancer effect. Recent studies show that aescin increases intracellular reactive oxygen species (ROS) levels. However, whether the increased ROS play a role in the anticancer action of aescin remains to be explored. In this study, we demonstrated that aescin (20-80 mu g/mL) dose-dependently induced apoptosis and activated mammalian target of rapamycin (mTOR)-independent autophagy in human hepatocellular carcinoma HepG2 cells and colon carcinoma Ha 116 cells. The activation of autophagy favored cancer cell survival in response to aescin, as suppression of autophagy with ATG5 siRNAs or 3-methyladenine (3-MA), a selective inhibitor of autophagy, promoted aescin-induced apoptosis in vitro, and significantly enhanced the anticancer effect of aescin in vivo. Meanwhile, aescin dose-dependently elevated intracellular ROS levels and activated Ataxia-telangiectasia mutated kinase/AMP-activated protein kinase/UNC-51-like kinase-1 (ATM/AMPK/ULK1) pathway. The ROS and ATM/AMPK/ULK1 pathway were upstream modulators of the aescin-induced autophagy, as N-acetyl-L-cysteine (NAC) or ATM kinase inhibitor (KU-55933) remarkably suppressed aescin-induced autophagy and consequently promoted aescin-induced apoptosis, whereas overexpression of ATG5 partly attenuated NAC-induced enhancement in aescin-induced apoptosis. In conclusion, this study provides new insights into the roles of aescin-mediated oxidative stress and autophagy in cancer cell survival. Our results suggest that combined administration of the antioxidants or autophagic inhibitors with aescin might be a potential strategy to enhance the anticancer effect of aescin.
C1 [Li, Bin; Wu, Guo-liang; Dai, Wei; Wang, Gang; Su, Hao-yuan; Shen, Xue-ping; Zhan, Rui; Gao, Quan-gen; Shen, Gen-hai] First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
   [Xie, Jia-ming; Wang, Zhong] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
   [Qin, Zheng-hong] Soochow Univ, Dept Pharmacol, Suzhou 215123, Peoples R China.
   [Qin, Zheng-hong] Soochow Univ, Jiangsu Key Lab Translat Res & Therapy Neuropsyco, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Lab Aging & Nervous Dis,Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
RP Gao, QG; Shen, GH (corresponding author), First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.; Qin, ZH (corresponding author), Soochow Univ, Dept Pharmacol, Suzhou 215123, Peoples R China.; Qin, ZH (corresponding author), Soochow Univ, Jiangsu Key Lab Translat Res & Therapy Neuropsyco, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Lab Aging & Nervous Dis,Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
EM qinzhenhong@suda.edu.cn; wjyygqg@sohu.com; wjsgh3026@sina.com
FU Jiangsu Provincial Commission of Health and Family Planning [YG201402,
   YG201503]; Jiangsu Provincial Medical Youth Talent [QNRC2016249]; Suzhou
   Science and Technology Bureau [SYSD2013041, SYSD2016044, SYSD2017041,
   SYS201788]; Wujiang District Science and Technology Bureau [WS201301];
   Wujiang District Commission of Health and Family Planning [WWK201607,
   WWK201609]; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [81602613]
FX This work was supported by grants from the Jiangsu Provincial Commission
   of Health and Family Planning (No. YG201402, YG201503), Jiangsu
   Provincial Medical Youth Talent, (No. QNRC2016249), Suzhou Science and
   Technology Bureau (No. SYSD2013041, SYSD2016044, SYSD2017041 and
   SYS201788), Wujiang District Science and Technology Bureau (No.
   WS201301), Wujiang District Commission of Health and Family Planning
   (No. WWK201607 and WWK201609) and National Natural Science Foundation of
   China (No. 81602613).
CR Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024
   Cheng P, 2016, FREE RADICAL BIO MED, V99, P405, DOI 10.1016/j.freeradbiomed.2016.09.002
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912
   Harikumar KB, 2010, MOL PHARMACOL, V77, P818, DOI 10.1124/mol.109.062760
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Ji DB, 2011, MOL CARCINOGEN, V50, P945, DOI 10.1002/mc.20762
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mojzisova G, 2016, ACTA BIOCHIM POL, V63, P79, DOI 10.18388/abp.2015_1013
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Ni ZH, 2014, FREE RADICAL BIO MED, V70, P194, DOI 10.1016/j.freeradbiomed.2014.02.012
   Patiolla JMR, 2006, MOL CANCER THER, V5, P1459, DOI 10.1158/1535-7163.MCT-05-0495
   Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042
   Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Sirtori CR, 2001, PHARMACOL RES, V44, P183, DOI 10.1006/phrs.2001.0847
   Tan SML, 2010, J PHARMACOL EXP THER, V334, P285, DOI 10.1124/jpet.110.165498
   Xie JM, 2014, CANCER RES, V74, P5127, DOI 10.1158/0008-5472.CAN-13-3517
   Yuan SY, 2017, ONCOL REP, V37, P1002, DOI 10.3892/or.2017.5348
   Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576
   Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230
   Zhang L, 2015, FREE RADICAL BIO MED, V89, P452, DOI 10.1016/j.freeradbiomed.2015.08.030
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488
NR 33
TC 11
Z9 11
U1 1
U2 12
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD DEC
PY 2018
VL 39
IS 12
BP 1874
EP 1884
DI 10.1038/s41401-018-0047-1
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HG2DU
UT WOS:000454773800007
PM 29921885
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Cao, ZX
   Yang, YT
   Yu, S
   Li, YZ
   Wang, WW
   Huang, J
   Xie, XF
   Xiong, L
   Lei, S
   Peng, C
AF Cao, Zhi-Xing
   Yang, Yu-Ting
   Yu, Si
   Li, Yu-Zhi
   Wang, Wen-Wen
   Huang, Jing
   Xie, Xiao-Fang
   Xiong, Liang
   Lei, Song
   Peng, Cheng
TI Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis
   in human colorectal carcinoma HCT116 cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Pogostone; Autophagy; Apoptosis; Akt; mTOR
ID IN-VITRO; POGOSTEMONIS HERBA; MAMMALIAN TARGET; CANCER; ANTICANCER;
   PATHWAY; PROLIFERATION; INHIBITION; MEDICINE; PROTEIN
AB Ethnophamacological relevance: Pogostemon cablin is a medicinal herb widely used to treat gastrointestinal diseases in many Asian countries. Pogostone is an important constituent of Pogostemon cablin, and possesses various bioactivitys. In this study, we performed to investigate the anti-colorectal tumor property of Pogostone by inducing aurophagy and apoptosis in human colorectal cancer cells, and to define the potential molecular mechanisms.
   Materials and methods: In vitro, The anti-tumor activity of pogostone was assessed using MIT assay. Autophagy was monitored by transmission electron microscopy observation and mRFP-GFP-LC3 fluorescence analysis in colorectal tumor cell line. Apoptosis was measured by flow cytometry and annexinV-FITC/PI staining. The protein expressions or activition of LC3-II, AKT, mTOR, caspase-3 and caspase-7 were detected through western blotting. In vivo, the anti-tumor effect of pogostone was tested with HCT116 colorectal tumor cells transplantation tumor model. The expression of Ki-67 was determined by Immunohistochemistry staining and the apoptosis was evaluated using TUNEL assay.
   Results: In vitro, pogostone exhibits significant anti-tumor activity against human cancer cell lines, especially for HCT116 (18.7 +/- 1.93 g/ml). Transmission electron microscopy observation, mRFP-GFP-LC3 fluorescence analysis, flow cytometry and assay and western blotting detection revealed that the anti-colorectal tumor activity of pogostone was dependent on inducing autophagy and apoptosis through up-regulating the expression of LC3-II, cleaved caspase-7 and caspase-3, and decreasing the phosphorylation of AKT/mTOR. In vivo, 150 mg/kg pogostone inhibited the HCT116 tumor growth in immunodeficient mice with an inhibitory rate of 43.3%, decreased the expression of Ki67, and induced apoptosis in three days.
   Conclusion: Pogostone showed anti-colorectal tumor effects by inducing autophagy and apoptosis involving PI3K/Akt/mTOR axis. Thus, pogostone may be a promising lead compound to be further developed for cancer therapy.
C1 [Cao, Zhi-Xing; Yang, Yu-Ting; Yu, Si; Li, Yu-Zhi; Wang, Wen-Wen; Huang, Jing; Xie, Xiao-Fang; Xiong, Liang; Peng, Cheng] Chengdu Univ Tradit Chinese Med, Key Lab Standardizat Chinese Herbal Med,Minist Ed, Key Lab Breeding Base Cofounded Sichuan Prov,Phar, Key Lab Systemat Res Dev & Utilizat Chinese Med R, Chengdu, Peoples R China.
   [Cao, Zhi-Xing; Yang, Yu-Ting; Yu, Si; Li, Yu-Zhi; Wang, Wen-Wen; Huang, Jing; Xie, Xiao-Fang; Xiong, Liang; Peng, Cheng] MOST, Beijing, Peoples R China.
   [Lei, Song] West China Hosp, Dept Pathol, Chengdu, Peoples R China.
   [Wang, Wen-Wen; Huang, Jing] Chengdu Univ Tradit Chinese Med, Sch Med Technol, Chengdu, Peoples R China.
RP Peng, C (corresponding author), Chengdu Univ Tradit Chinese Med, Key Lab Standardizat Chinese Herbal Med,Minist Ed, Key Lab Breeding Base Cofounded Sichuan Prov,Phar, Key Lab Systemat Res Dev & Utilizat Chinese Med R, Chengdu, Peoples R China.; Peng, C (corresponding author), MOST, Beijing, Peoples R China.
EM pengchengchengdu@l26.com
OI Xiong, Liang/0000-0001-6222-8340
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81300437, 81403149]; Youth Scientific
   Research Fund of CDUTCM [ZRQN1450, CGPY1402]; Sichuan Province Youth
   Science and Technology Innovation Research Team project [2014TD0007,
   2016TD0006]
FX This study was supported by the National Natural Science Foundation of
   China (81300437, 81403149), Youth Scientific Research Fund of CDUTCM
   (ZRQN1450, CGPY1402), Sichuan Province Youth Science and Technology
   Innovation Research Team project (2014TD0007, 2016TD0006).
CR Arlia-Ciommo A., 2015, ONCOTARGET, V6
   Assaf AM, 2013, J ETHNOPHARMACOL, V145, P728, DOI 10.1016/j.jep.2012.11.039
   Chen HM, 2015, FITOTERAPIA, V100, P110, DOI 10.1016/j.fitote.2014.11.017
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011
   Fouche G, 2008, J ETHNOPHARMACOL, V119, P455, DOI 10.1016/j.jep.2008.07.005
   Globocan, 2012, COL CANC FACT SHEET
   Gong K, 2014, EUR J PHARMACOL, V738, P142, DOI 10.1016/j.ejphar.2014.05.034
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang SH, 2014, PEST MANAG SCI, V70, P510, DOI 10.1002/ps.3635
   Kumar P. Ashok, 2013, ASIAN PAC J CANCER P, V14, P2201
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   Li YC, 2014, J ETHNOPHARMACOL, V157, P212, DOI 10.1016/j.jep.2014.09.023
   Li YC, 2012, PHYTOMEDICINE, V20, P77, DOI 10.1016/j.phymed.2012.08.008
   Li YC, 2014, PHYTOCHEM ANALYSIS, V25, P97, DOI 10.1002/pca.2471
   Ma CH, 2015, J ETHNOPHARMACOL, V168, P349, DOI 10.1016/j.jep.2015.03.068
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P99, DOI 10.1016/j.semcancer.2014.06.001
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988
   OSAWA K, 1990, Bulletin of Tokyo Dental College, V31, P17
   Peng F, 2014, CHINESE MED J-PEKING, V127, P4001, DOI 10.3760/cma.j.issn.0366-6999.20140494
   Radhakrishnan P, 2013, CANCER RES, V73, P1118, DOI 10.1158/0008-5472.CAN-12-2545
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Shi SQ, 2014, ONCOL LETT, V8, P1087, DOI 10.3892/ol.2014.2293
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Simard S, 2013, J CANCER SURVIV, V7, P300, DOI 10.1007/s11764-013-0272-z
   Su JY, 2015, INT IMMUNOPHARMACOL, V26, P328, DOI 10.1016/j.intimp.2015.04.019
   Sun JZ, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3738
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Van C.E., 2010, ANN ONCOL, V21, P155
   Vijayaraghavan S, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-1783
   Wang QW, 2013, BIOCHEM BIOPH RES CO, V438, P186, DOI 10.1016/j.bbrc.2013.07.050
   Zhirnov O.P., 2007, CELL SIGNAL, V19, P261
   莫小路, 2004, [中药材, Journal of Chinese Medicinal Materials], V27, P805
NR 40
TC 26
Z9 32
U1 4
U2 33
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 18
PY 2017
VL 202
BP 20
EP 27
DI 10.1016/j.jep.2016.07.028
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA ET3YN
UT WOS:000400216000003
PM 27416805
DA 2022-04-25
ER

PT J
AU Mbaveng, AT
   Noulala, CGT
   Samba, ARM
   Tankeo, SB
   Abdelfatah, S
   Fotso, GW
   Happi, EN
   Ngadjui, BT
   Beng, VP
   Kuete, V
   Efferth, T
AF Mbaveng, Armelle T.
   Noulala, Cedric G. T.
   Samba, Anne R. M.
   Tankeo, Simplice B.
   Abdelfatah, Sara
   Fotso, Ghislain W.
   Happi, Emmanuel N.
   Ngadjui, Bonaventure T.
   Beng, Veronique P.
   Kuete, Victor
   Efferth, Thomas
TI The alkaloid, soyauxinium chloride, displays remarkable cytotoxic
   effects towards a panel of cancer cells, inducing apoptosis, ferroptosis
   and necroptosis
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Cancer; Cell death; Indoloquinazoline; Multidrug resistance; Natural
   product
ID GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MULTIDRUG-RESISTANCE;
   MEDICINAL-PLANTS; DRUG-RESISTANCE; MODES; TRANSPORTER; MODULATION;
   EXPRESSION; FLAVONOIDS
AB The cytotoxic potential of a naturally occurring indoloquinazoline alkaloid, soyauxinium chloride (SCHL), was determined on a broad panel of animal and human cancer cell lines, including various sensitive and drug-resistant phenotypes. The cytotoxicity, SCHL-induced autophagic, ferroptotic, and necmptotic cell death were evaluated by the resazurin reduction assay (RRA). Caspase-Glo assay was used to detect the activity of caspases using spectrophotometric analysis. Flow cytometry was applied for cell cycle analysis (PI staining), apoptosis (annexin V/PI staining), mitochondrial membrane potential (MMP) (JC-1) and reactive oxygen species (ROS) (H2DCFH-DA). SCHL and doxorubicin (reference molecule) exhibited cytotoxic effects towards the 18 cancer cell lines tested. The IC50 values obtained ranged from 3.64 mu M (towards CCRF-CEM leukemia cells) to 16.86 mu M (against the BRAF-wildtype SKMe1-505 melanoma cells for SCHL). Collateral sensitivity of the resistant HCT116 p53(-/-) colon adenocarcinoma cells to SCHL was observed as well as the normal sensitivity of CEM/ADR5000 leukemia cells, MDA-MB-231-BCRP breast adenocarcinoma cells and U87. MG Delta EGFR glioblastoma cells. SCHL induced apoptosis in CCRF-CEM cells via caspases 3/7-, 8- and 9-activation, MMP alteration and increased ROS production, and otherwise ferroptosis and necroptosis. SCHL is a prominent cytotoxic alkaloid that should be further studied to develop a novel drug to combat cancers including refractory phenotypes.
C1 [Mbaveng, Armelle T.; Tankeo, Simplice B.; Abdelfatah, Sara; Kuete, Victor; Efferth, Thomas] Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Dept Pharmaceut Biol, Staudinger Weg 5, D-55128 Mainz, Germany.
   [Mbaveng, Armelle T.; Samba, Anne R. M.; Tankeo, Simplice B.; Kuete, Victor] Univ Dschang, Fac Sci, Dept Biochem, Dschang, Cameroon.
   [Noulala, Cedric G. T.; Fotso, Ghislain W.; Ngadjui, Bonaventure T.] Univ Yaounde I, Fac Sci, Dept Organ Chem, POB 812, Yaounde, Cameroon.
   [Samba, Anne R. M.; Beng, Veronique P.] Univ Yaounde I, Fac Sci, Dept Biochem, Yaounde, Cameroon.
   [Happi, Emmanuel N.] Univ Douala, Fac Sci, Dept Chem, Douala, Cameroon.
RP Efferth, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Dept Pharmaceut Biol, Staudinger Weg 5, D-55128 Mainz, Germany.; Kuete, V (corresponding author), POB 1499, Bafoussam, Cameroon.
EM armbatsa@yahoo.fr; cedric.noulala@hotmail.fr; annecesarine@gmail.com;
   simplicetankeo@yahoo.fr; saabdelf@uni-mainz.de; ghis152001@gmail.com;
   ngeufa@yahoo.fr; ngadjuibt@yahoo.fr; v.penlap@yahoo.fr;
   kuetevictor@yahoo.fr; efferth@uni-mainz.de
FU Alexander von Humboldt FoundationAlexander von Humboldt Foundation;
   Yaounde-Bielefeld Bilateral Graduate School Natural Products with
   Antiparasite and Antibacterial Activity (YaBiNaPA) [DAAD] [57316173]
FX ATM is thankful to Alexander von Humboldt Foundation for an 18 months
   fellowship in Prof. Dr. Thomas Efferth's laboratory in Mainz, Germany,
   through the ''Georg Foster Research Fellowship for Experienced
   Researchers'' program. VK is grateful to the Alexander von Humboldt
   Foundation for the 6-month further research stay fellowship in Mainz.
   CGTN is particularly grateful to the Yaounde-Bielefeld Bilateral
   Graduate School Natural Products with Antiparasite and Antibacterial
   Activity (YaBiNaPA) [DAAD, project ID 57316173] for providing research
   facilities in Cameroon. The authors acknowledge the Institute of
   Molecular Biology gGmbH (IMB) (Mainz, Germany) for MMP measurements by
   flow cytometry.
CR Adem FA, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152853
   BASS DA, 1983, J IMMUNOL, V130, P1910
   Benlloch M, 2006, J BIOL CHEM, V281, P69, DOI 10.1074/jbc.M507471200
   Boik J., 2001, NATURAL COMPOUNDS CA
   Brahemi G, 2010, J MED CHEM, V53, P2757, DOI 10.1021/jm901757t
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Cheng JQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01355-0
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189
   [Data International Agency for Research on Cancer (IARC) World Health Organization], 2018, LAT GLOB CANC DAT CA
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382
   Efferth T., 2020, PHYTOCHEM REV, DOI [10.1007/s11101-11020-09703-11107., DOI 10.1007/S11101-11020-09703-11107]
   Efferth T, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.01.009
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Gillet JP, 2004, CANCER RES, V64, P8987, DOI 10.1158/0008-5472.CAN-04-1978
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Howley B, 2008, J CELL MOL MED, V12, P1502, DOI 10.1111/j.1582-4934.2008.00292.x
   Hwang ST, 2020, MOLECULES, V25, DOI 10.3390/molecules25061320
   Jun KY, 2015, CHEMMEDCHEM, V10, P827, DOI 10.1002/cmdc.201500068
   KIMMIG A, 1990, CANCER RES, V50, P6793
   Kuete V, 2016, PHYTOMEDICINE, V23, P856, DOI 10.1016/j.phymed.2016.04.007
   Kuete V, 2015, PHYTOMEDICINE, V22, P1247, DOI 10.1016/j.phymed.2015.10.008
   Kuete V, 2015, PHYTOMEDICINE, V22, P946, DOI 10.1016/j.phymed.2015.07.002
   Kuete V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/914813
   Kuete V, 2015, PLANTA MED, V81, P32, DOI 10.1055/s-0034-1383362
   Kuete V, 2014, PHYTOMEDICINE, V21, P1651, DOI 10.1016/j.phymed.2014.08.001
   Kuete V, 2014, INVEST NEW DRUG, V32, P1053, DOI 10.1007/s10637-014-0137-y
   Kuete V, 2014, J ETHNOPHARMACOL, V153, P207, DOI 10.1016/j.jep.2014.02.025
   Kuete V, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/285903
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mbaveng AT, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153261
   Mbaveng AT, 2020, CHEM-BIOL INTERACT, V326, DOI 10.1016/j.cbi.2020.109141
   Mbaveng AT, 2020, PHYTOMEDICINE, V70, DOI 10.1016/j.phymed.2020.153215
   Mbaveng AT, 2019, PHYTOMEDICINE, V60, DOI 10.1016/j.phymed.2019.152832
   Mbaveng AT, 2019, J ETHNOPHARMACOL, V235, P28, DOI 10.1016/j.jep.2019.01.031
   Mbaveng AT, 2018, PHYTOMEDICINE, V48, P112, DOI 10.1016/j.phymed.2017.12.016
   Mbaveng AT, 2018, PHYTOMEDICINE, V43, P78, DOI 10.1016/j.phymed.2018.03.035
   Mbaveng AT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00343
   Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724
   Navolanic PM, 2003, INT J ONCOL, V22, P237
   Nganou BK, 2019, FITOTERAPIA, V133, P193, DOI 10.1016/j.fitote.2019.01.003
   Noulala CGT, 2020, BIOCHEM SYST ECOL, V91, DOI 10.1016/j.bse.2020.104050
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Rocha GD, 2012, INT J MOL SCI, V13, P6757, DOI 10.3390/ijms13066757
   Saeed MEM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00136
   Tshitenge DT, 2018, J NAT PROD, V81, P918, DOI 10.1021/acs.jnatprod.7b01041
   Wansi JD, 2012, PLANTA MED, V78, P71, DOI 10.1055/s-0031-1280227
   Yan G, 2019, ANTICANCER RES, V39, P3585, DOI 10.21873/anticanres.13505
   Yan Y, 2018, MOL CANCER RES, V16, P212, DOI 10.1158/1541-7786.MCR-17-0215
   Yoon SS, 1997, MELANOMA RES, V7, P275, DOI 10.1097/00008390-199708000-00002
   Yoshida GJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0436-9
NR 55
TC 2
Z9 2
U1 3
U2 21
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JAN 5
PY 2021
VL 333
AR 109334
DI 10.1016/j.cbi.2020.109334
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA PI1BB
UT WOS:000600832900008
PM 33245930
DA 2022-04-25
ER

PT J
AU Ding, JJ
   Gou, Q
   Jia, X
   Liu, Q
   Jin, JH
   Shi, JJ
   Hou, YZ
AF Ding, Jiajun
   Gou, Qian
   Jia, Xiao
   Liu, Qian
   Jin, Jianhua
   Shi, Juanjuan
   Hou, Yongzhong
TI AMPK phosphorylates PPAR delta to mediate its stabilization, inhibit
   glucose and glutamine uptake and colon tumor growth
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACTIVATED-RECEPTOR-DELTA; ENDOPLASMIC-RETICULUM STRESS;
   PEROXISOME-PROLIFERATOR; ENDOTHELIAL DYSFUNCTION; LIGAND ACTIVATION;
   AUTOPHAGY; PROTEINS; PATHWAY; KINASE; IDENTIFICATION
AB Peroxisome proliferator-activated receptor delta (PPAR delta) is a nuclear receptor transcription factor that plays an important role in the regulation of metabolism, inflammation, and cancer. In addition, the nutrient-sensing kinase 5'AMP-activated protein kinase (AMPK) is a critical regulator of cellular energy in coordination with PPAR delta. However, the molecular mechanism of the AMPK/PPAR delta pathway on cancer progression is still unclear. Here, we found that activated AMPK induced PPAR delta-S50 phosphorylation in cancer cells, whereas the PPAR delta/S50A (nonphosphorylation mimic) mutant reversed this event. Further analysis showed that the PPAR delta/S50E (phosphorylation mimic) but not the PPAR delta/S50A mutant increased PPAR delta protein stability, which led to reduced p62/SQSTM1-mediated degradation of misfolded PPAR delta. Furthermore, PPAR delta-S50 phosphorylation decreased PPAR delta transcription activity and alleviated PPAR delta-mediated uptake of glucose and glutamine in cancer cells. Soft agar and xenograft tumor model analysis showed that the PPAR delta/S50E mutant but not the PPAR delta/S50A mutant inhibited colon cancer cell proliferation and tumor growth, which was associated with inhibition of Glut1 and SLC1A5 transporter protein expression. These findings reveal a new mechanism of AMPK-induced PPAR delta-S50 phosphorylation, accumulation of misfolded PPAR delta protein, and inhibition of PPAR delta transcription activity contributing to the suppression of colon tumor formation.
C1 [Ding, Jiajun; Jia, Xiao; Shi, Juanjuan; Hou, Yongzhong] Jiangsu Univ, Sch Life Sci, Zhenjiang, Jiangsu, Peoples R China.
   [Gou, Qian] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China.
   [Liu, Qian; Jin, Jianhua] Jiangsu Univ, Affiliated Wujin Peoples Hosp, Dept Oncol, Changzhou, Jiangsu, Peoples R China.
RP Shi, JJ; Hou, YZ (corresponding author), Jiangsu Univ, Sch Life Sci, Zhenjiang, Jiangsu, Peoples R China.; Shi, JJ; Hou, YZ (corresponding author), Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China.
EM sjj@ujs.edu.cn; houyz@ujs.edu.cn
OI Hou, Yongzhong/0000-0003-2019-8686
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972618, 81672711, 81872275]; Natural
   Science FoundationNational Natural Science Foundation of China (NSFC)
   [M2020002]; Changzhou Sci Tech Program [CJ20200004]; Jiangsu Commission
   of Health
FX This article contains supporting information. Acknowledgments-This work
   was supported by the National Natural Science Foundation of China
   (81972618, 81672711, 81872275) , Jiangsu Commission of Health, Natural
   Science Foundation (M2020002) , and Changzhou Sci & Tech Program (Grant
   No. CJ20200004) .
CR Aznar N, 2016, ELIFE, V5, DOI 10.7554/eLife.20795
   Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bojic LA, 2014, J LIPID RES, V55, P1254, DOI 10.1194/jlr.M046037
   Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124
   Cheang WS, 2017, DIABETES, V66, P519, DOI 10.2337/db15-1657
   Chen L, 2017, CELL REP, V18, P3143, DOI 10.1016/j.celrep.2017.03.010
   Choy KW, 2016, BIOCHEM PHARMACOL, V116, P51, DOI 10.1016/j.bcp.2016.07.013
   Ding JJ, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172425
   Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757
   Gou Q, 2020, ONCOGENE, V39, P4844, DOI 10.1038/s41388-020-1329-x
   Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5
   Hollingshead HE, 2008, CARCINOGENESIS, V29, P169, DOI 10.1093/carcin/bgm209
   Hou Y, 2014, ONCOGENE, V33, P5619, DOI 10.1038/onc.2013.504
   Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270
   Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006
   Jeong E, 2014, MOL CARCINOGEN, V53, P926, DOI 10.1002/mc.22144
   Jiang XM, 2017, ACTA PHARMACOL SIN, V38, P1512, DOI 10.1038/aps.2017.123
   Jiffry J, 2021, CLIN CANCER RES, V27, P865, DOI 10.1158/1078-0432.CCR-20-2385
   Jung TW, 2021, ADV MED SCI-POLAND, V66, P155, DOI 10.1016/j.advms.2021.01.007
   Jung TW, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0147-5
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kim YE, 2013, ANNU REV BIOCHEM, V82, P323, DOI 10.1146/annurev-biochem-060208-092442
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kramer DK, 2007, J BIOL CHEM, V282, P19313, DOI 10.1074/jbc.M702329200
   Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007
   Liu F, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113830
   Lo Re AE, 2012, J BIOL CHEM, V287, P25325, DOI 10.1074/jbc.M112.370809
   Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277
   Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Peters Jeffrey M, 2011, Drug Discov Today Dis Mech, V8, pe85
   Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009
   SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028
   Wang DZ, 2014, P NATL ACAD SCI USA, V111, P7084, DOI 10.1073/pnas.1324233111
   Yang L, 2008, DIS COLON RECTUM, V51, P318, DOI 10.1007/s10350-007-9145-8
   Yang L, 2010, ONCOGENE, V29, P516, DOI 10.1038/onc.2009.370
   Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060715
   Yang L, 2011, CLIN CANCER RES, V17, P3760, DOI 10.1158/1078-0432.CCR-10-2779
   You ML, 2018, J ONCOL, V2018, DOI 10.1155/2018/6458537
   You ML, 2015, CURR PHARM DESIGN, V21, P2956, DOI 10.2174/1381612821666150514104035
   Young CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023205
   Zhang Z, 2013, ONKOLOGIE, V36, P598, DOI 10.1159/000355328
   Zhao FQ, 2007, CURR GENOMICS, V8, P113, DOI 10.2174/138920207780368187
   Zhou DY, 2019, EUR J PHARMACOL, V842, P248, DOI 10.1016/j.ejphar.2018.10.050
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
   Zhu B, 2014, ONCOGENE, V33, P5348, DOI 10.1038/onc.2013.477
   Zuo XS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju052
   Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078
NR 58
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP
PY 2021
VL 297
IS 3
AR 100954
DI 10.1016/j.jbc.2021.100954
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA WF5RS
UT WOS:000706361700004
PM 34270958
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, L
   Meng, Y
   Guo, XQ
   Sheng, XT
   Tai, GH
   Zhang, FL
   Cheng, HR
   Zhou, YF
AF Chen, Lei
   Meng, Yue
   Guo, Xiaoqing
   Sheng, Xiaotong
   Tai, Guihua
   Zhang, Fenglei
   Cheng, Hairong
   Zhou, Yifa
TI Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis
   of via autophagy- and JNK-mediated death receptors upregulation
SO APOPTOSIS
LA English
DT Article
DE TRAIL; Gefitinib; DR4; DR5; Autophagy; JNK
ID TYROSINE KINASE INHIBITOR; PHASE-I SAFETY; ZD1839 IRESSA; RESISTANCE;
   EXPRESSION; LIGAND; COMBINATION; ANTITUMOR; ANTIBODY; FAMILY
AB Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent cancer cell-specific apoptosis-inducing cytokine with little toxicity to most normal cells. Here, we report that gefitinib and TRAIL in combination produce a potent synergistic effect on TRAIL-sensitive human colon cancer HCT116 cells and an additive effect on TRAIL-resistant HT-29 cells. Interestingly, gefitinib increases the expression of cell surface receptors DR4 and DR5, possibly explaining the synergistic effect. Knockdown of DR4 and DR5 by siRNA significantly decreases gefitinib- and TRAIL-mediated cell apoptosis, supporting this idea. Because the inhibition of gefitinib-induced autophagy by 3-MA significantly decreases DR4 and DR5 upregulation, as well as reduces gefitinib- and TRAIL-induced apoptosis, we conclude that death receptor upregulation is autophagy mediated. Furthermore, our results indicate that death receptor expression may also be regulated by JNK activation, because pre-treatment of cells with JNK inhibitor SP600125 significantly decreases gefitinib-induced death receptor upregulation. Interestingly, SP600125 also inhibits the expression CHOP, yet CHOP has no impact on death receptor expressions. We also find here that phosphorylation of Akt and ERK might also be required for TRAIL sensitization. In summary, our results indicate that gefitinib effectively enhances TRAIL-induced apoptosis, likely via autophagy and JNK- mediated death receptor expression and phosphorylation of Akt and ERK.
C1 [Chen, Lei; Meng, Yue; Guo, Xiaoqing; Sheng, Xiaotong; Tai, Guihua; Cheng, Hairong; Zhou, Yifa] Northeast Normal Univ, Sch Life Sci, Jilin Prov Key Lab Chem & Biol Changbai Mt Nat Dr, Changchun 130024, Peoples R China.
   [Zhang, Fenglei] Jilin Univ, Hosp 1, Dept Radiol, Part 2, 3302 Jilin Rd, Changchun 130024, Peoples R China.
RP Cheng, HR; Zhou, YF (corresponding author), Northeast Normal Univ, Sch Life Sci, Jilin Prov Key Lab Chem & Biol Changbai Mt Nat Dr, Changchun 130024, Peoples R China.
EM chenghr893@nenu.edu.cn; zhouyf383@nenu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302172]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2013M530959,
   2014T70270]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81302172) and the China Postdoctoral Science Foundation
   (2013M530959 & 2014T70270). We would also like to thank Prof. KH Mayo
   for critical reading and editing of this manuscript.
CR Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Camidge DR, 2010, CLIN CANCER RES, V16, P1256, DOI 10.1158/1078-0432.CCR-09-1267
   Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8
   Cheng HR, 2012, CELL CYCLE, V11, P3312, DOI 10.4161/cc.21670
   Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174
   Dolloff NG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001384
   Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503
   Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416
   Hou W, 2008, AUTOPHAGY, V4, P940, DOI 10.4161/auto.6769
   Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200
   Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236
   LoRusso PM, 2003, SEMIN ONCOL, V30, P21, DOI 10.1053/sonc.2003.50029
   Magne N, 2003, BRIT J CANCER, V89, P585, DOI 10.1038/sj.bjc.6601131
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011
   Shoeb M, 2013, FREE RADICAL BIO MED, V63, P280, DOI 10.1016/j.freeradbiomed.2013.05.039
   Shrader M, 2007, CANCER RES, V67, P1430, DOI 10.1158/0008-5472.CAN-06-1224
   Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X
   Teralshi F, 2005, FEBS LETT, V579, P4069, DOI 10.1016/j.febslet.2005.06.031
   Thamkachy R, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0505-7
   Tortora G, 2003, CLIN CANCER RES, V9, P1566
   Wakeling AE, 2002, CANCER RES, V62, P5749
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Xu Fei, 2011, Chin J Cancer, V30, P701, DOI 10.5732/cjc.011.10107
   Yan D, 2015, ONCOTARGETS THER, V8, P1603, DOI 10.2147/OTT.S73731
   Yerbes R, 2012, CELL DEATH DIFFER, V19, P1908, DOI 10.1038/cdd.2012.78
   Yuan BZ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-140
NR 36
TC 23
Z9 25
U1 1
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD NOV
PY 2016
VL 21
IS 11
BP 1291
EP 1301
DI 10.1007/s10495-016-1287-5
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DY5QM
UT WOS:000385156400008
PM 27629794
DA 2022-04-25
ER

PT J
AU Li, Y
   Cho, MH
   Lee, SS
   Lee, DE
   Cheong, H
   Choi, Y
AF Li, Yan
   Cho, Mi Hyeon
   Lee, Seon Sook
   Lee, Dong-Eun
   Cheong, Heesun
   Choi, Yongdoo
TI Hydroxychloroquine-loaded hollow mesoporous silica nanoparticles for
   enhanced autophagy inhibition and radiation therapy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Radiation therapy; Autophagy; Hydroxychloroquine; Hollow mesoporous
   silica nanoparticle; Cancer
ID TRIAL; RADIORESISTANCE; TEMOZOLOMIDE; MECHANISMS; DELIVERY; CELLS
AB Radiotherapy (RT) is a major modality for cancer treatment, along with surgery and chemotherapy. Despite its therapeutic effect, the recurrence and metastasis of tumors due to the acquired resistance of cancer cells to RT remain significant clinical problems. Therefore, it is imperative to overcome radioresistance and improve radiosensitivity in cancer patients. Here, we synthesized hydroxychloroquine (HCQ)-loaded hollow mesoporous silica nanoparticles (HMSNs) to enable effective inhibition of radiation-induced cytoprotective autophagy and enhance the therapeutic efficacy of RT. HCQ-HMSN-treated HCT116 colon cancer cells showed a 200-fold higher intracellular uptake of HCQ than that of free HCQ-treated cells, thereby effectively inhibiting the radiation-induced autophagy of cancer cells. In vivo imaging and therapy studies of a tumor xenograft model showed preferential accumulation of HCQ-HMSNs in tumor tissues and significant enhancement of RT by inhibiting autophagy in the tumor sites. Histopathology analyses of major organs, blood chemistry profiles, and changes in body weights of mice confirmed the good biocompatibility of HCQ-HMSNs.
C1 [Li, Yan; Cho, Mi Hyeon; Lee, Seon Sook; Choi, Yongdoo] Natl Canc Ctr, Res Inst, Div Translat Sci, 323 Ilsan Ro, Goyang 10408, Gyeonggi, South Korea.
   [Lee, Dong-Eun; Cheong, Heesun] Natl Canc Ctr, Res Inst, Div Canc Biol, 323 Ilsan Ro, Goyang 10408, Gyeonggi, South Korea.
RP Choi, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Translat Sci, 323 Ilsan Ro, Goyang 10408, Gyeonggi, South Korea.; Cheong, H (corresponding author), Natl Canc Ctr, Res Inst, Div Canc Biol, 323 Ilsan Ro, Goyang 10408, Gyeonggi, South Korea.
EM heesunch@ncc.re.kr; ydchoi@ncc.re.kr
OI Cho, mi hyeon/0000-0001-9429-4692; Cheong, Heesun/0000-0003-1946-107X
FU National Cancer Center grant [1910070, 2010960, 2011440]; Ministry of
   Oceans and Fisheries, Korea
FX This work was supported by the National Cancer Center grant (1910070,
   2010960, and 2011440) and by the Ministry of Oceans and Fisheries, Korea
   (the project title: Development of marine material based near infrared
   fluorophore complex and diagnostic imaging instruments).
CR Arriagada FJ, 1999, J COLLOID INTERF SCI, V211, P210, DOI 10.1006/jcis.1998.5985
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313
   Chaiswing Luksana, 2018, Critical Reviews in Oncogenesis, V23, P39, DOI 10.1615/CritRevOncog.2018025946
   Chang L, 2014, CANCER METAST REV, V33, P469, DOI 10.1007/s10555-014-9493-5
   Chen F, 2014, SCI REP-UK, V4, DOI 10.1038/srep05080
   Fang XL, 2011, NANOSCALE, V3, P1632, DOI 10.1039/c0nr00893a
   Gao Y, 2011, ACS NANO, V5, P9788, DOI 10.1021/nn2033105
   Gewirtz DA, 2014, RADIAT RES, V182, P363, DOI 10.1667/RR13774.1
   Hong Suk Ho, 2018, Journal of Pharmaceutical Investigation, V48, P3, DOI 10.1007/s40005-017-0356-2
   Hong SH, 2017, CHEM-ASIAN J, V12, P1700, DOI 10.1002/asia.201700371
   Hong SH, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa66b0
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Park Jungyoul, 2018, Journal of Biomedical and Translational Research, V19, P130
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Shi SX, 2013, NANOMEDICINE-UK, V8, P2027, DOI 10.2217/nnm.13.177
   Tam SY, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0795-y
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wang XH, 2018, INT J PHARMACEUT, V536, P1, DOI 10.1016/j.ijpharm.2017.09.007
   Wang Y, 2016, AUTOPHAGY, V12, P949, DOI 10.1080/15548627.2016.1162930
   Yin S, 2018, J CONTROL RELEASE, V288, P148, DOI 10.1016/j.jconrel.2018.08.015
NR 25
TC 17
Z9 17
U1 6
U2 65
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 10
PY 2020
VL 325
BP 100
EP 110
DI 10.1016/j.jconrel.2020.06.025
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA NA9PK
UT WOS:000560148400008
PM 32621826
DA 2022-04-25
ER

PT J
AU Liu, EY
   Ryan, KM
AF Liu, Emma Y.
   Ryan, Kevin M.
TI Autophagy and cancer - issues we need to digest
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Autophagy; Cancer; Therapy
ID RAPAMYCIN-INDUCED AUTOPHAGY; MALIGNANT GLIOMA-CELLS; TUMOR-SUPPRESSOR
   GENE; COLON-CANCER; REGULATES AUTOPHAGY; TARGETING AUTOPHAGY; METABOLIC
   STRESS; MAMMALIAN TARGET; UP-REGULATION; BECLIN 1
AB Autophagy is an evolutionarily conserved catabolic pathway that has multiple roles in carcinogenesis and cancer therapy. It can inhibit the initiation of tumorigenesis through limiting cytoplasmic damage, genomic instability and inflammation, and the loss of certain autophagy genes can lead to cancer. Conversely, autophagy can also assist cells in dealing with stressful metabolic environments, thereby promoting cancer cell survival. In fact, some cancers rely on autophagy to survive and progress. Furthermore, tumour cells can exploit autophagy to cope with the cytotoxicity of certain anticancer drugs. By contrast, it appears that certain therapeutics require autophagy for the effective killing of cancer cells. Despite these dichotomies, it is clear that autophagy has an important, if complex, role in cancer. This is further exemplified by the fact that autophagy is connected with major cancer networks, including those driven by p53, mammalian target of rapamycin (mTOR), RAS and glutamine metabolism. In this Commentary, we highlight recent advances in our understanding of the role that autophagy has in cancer and discuss current strategies for targeting autophagy for therapeutic gain. This article is part of a Minifocus on Autophagy. For further reading, please see related articles: 'Ubiquitin-like proteins and autophagy at a glance' by Tomer Shpilka et al. (J. Cell Sci. 125, 2343-2348) and 'Autophagy and cell growth - the yin and yang of nutrient responses' by Thomas Neufeld (J. Cell Sci. 125, 2359-2368).
C1 [Liu, Emma Y.; Ryan, Kevin M.] Beatson Inst Canc Res, Tumour Cell Death Lab, Glasgow G61 1BD, Lanark, Scotland.
RP Ryan, KM (corresponding author), Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
EM k.ryan@beatson.gla.ac.uk
OI Ryan, Kevin M./0000-0002-1059-9681
FU Cancer Research UKCancer Research UK; Association for International
   Cancer Research; Cancer Research UKCancer Research UK [15816] Funding
   Source: researchfish
FX Work in the Tumour Cell Death Laboratory is supported by Cancer Research
   UK and the Association for International Cancer Research.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Basciani S, 2007, FEBS LETT, V581, P5897, DOI 10.1016/j.febslet.2007.11.069
   Bodemann BO, 2011, CELL, V144, P253, DOI 10.1016/j.cell.2010.12.018
   Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006
   Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chano T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011404
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Giatromanolaki AN, 2011, MODERN PATHOL, V24, P1036, DOI 10.1038/modpathol.2011.63
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Konings IRHM, 2009, CURR CANCER DRUG TAR, V9, P439, DOI 10.2174/156800909788166556
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048
   Kroemer G, 2010, CURR OPIN CELL BIOL, V22, P121, DOI 10.1016/j.ceb.2010.02.003
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868
   Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Mujumdar N, 2010, AUTOPHAGY, V6, P997, DOI 10.4161/auto.6.7.13334
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ochi Y, 2011, ONCOL REP, V26, P805, DOI 10.3892/or.2011.1329
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schoenlein PV, 2009, AUTOPHAGY, V5, P400, DOI 10.4161/auto.5.3.7784
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wilkinson S, 2010, CURR OPIN GENET DEV, V20, P57, DOI 10.1016/j.gde.2009.12.004
   Wilkinson S, 2009, AUTOPHAGY, V5, P1068, DOI 10.4161/auto.5.7.9821
   Wilkinson S, 2009, GENE DEV, V23, P1283, DOI 10.1101/gad.521709
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
NR 124
TC 154
Z9 159
U1 0
U2 51
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD MAY 15
PY 2012
VL 125
IS 10
BP 2349
EP 2358
DI 10.1242/jcs.093708
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 970CZ
UT WOS:000306107000002
PM 22641689
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, XX
   Shen, C
   Liu, ZD
   Peng, F
   Chen, X
   Yang, G
   Zhang, DM
   Yin, ZQ
   Ma, JC
   Zheng, ZX
   Zhao, BX
   Liu, HL
   Wang, LG
   Wu, JN
   Han, DY
   Wang, KK
   Zhong, C
   Hou, X
   Zhao, WY
   Shu, MT
   Wang, XZ
   Zhao, SG
AF Wang, Xiaoxiong
   Shen, Chen
   Liu, Zhendong
   Peng, Fei
   Chen, Xin
   Yang, Guang
   Zhang, Daming
   Yin, Zhiqin
   Ma, Jichao
   Zheng, Zhixing
   Zhao, Boxian
   Liu, Huailei
   Wang, Ligang
   Wu, Jianing
   Han, Dayong
   Wang, Kaikai
   Zhong, Chen
   Hou, Xu
   Zhao, Wenyang
   Shu, Mengting
   Wang, Xinzhuang
   Zhao, Shiguang
TI Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and
   promotes ING1-induced cell cycle arrest in glioblastoma
SO CELL DEATH & DISEASE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; COLORECTAL-CANCER; MALIGNANT GLIOMA;
   TEMOZOLOMIDE; AGENT; DEATH; MECHANISMS; CANDIDATE; PATHWAYS; TARGET
AB Glioblastoma is the most common and aggressive primary brain tumor in adults. New drug design and development is still a major challenge for glioma treatment. Increasing evidence has shown that nitazoxanide, an antiprotozoal drug, has a novel antitumor role in various tumors and exhibits multiple molecular functions, especially autophagic regulation. However, whether nitazoxanide-associated autophagy has an antineoplastic effect in glioma remains unclear. Here, we aimed to explore the underlying molecular mechanism of nitazoxanide in glioblastoma. Our results showed that nitazoxanide suppressed cell growth and induced cell cycle arrest in glioblastoma by upregulating ING1 expression with a favorable toxicity profile. Nitazoxanide inhibited autophagy through blockage of late-stage lysosome acidification, resulting in decreased cleavage of ING1. A combination with chloroquine or Torin1 enhanced or impaired the chemotherapeutic effect of nitazoxanide in glioblastoma cells. Taken together, these findings indicate that nitazoxanide as an autophagy inhibitor induces cell cycle arrest in glioblastoma via upregulated ING1 due to increased transcription and decreased post-translational degradation by late-stage autophagic inhibition.
C1 [Wang, Xiaoxiong; Shen, Chen; Liu, Zhendong; Peng, Fei; Chen, Xin; Yang, Guang; Zhang, Daming; Yin, Zhiqin; Zheng, Zhixing; Zhao, Boxian; Liu, Huailei; Wang, Ligang; Wu, Jianing; Han, Dayong; Wang, Kaikai; Zhong, Chen; Hou, Xu; Zhao, Wenyang; Shu, Mengting; Wang, Xinzhuang; Zhao, Shiguang] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
   [Wang, Xiaoxiong; Shen, Chen; Liu, Zhendong; Peng, Fei; Chen, Xin; Yang, Guang; Zhang, Daming; Yin, Zhiqin; Zheng, Zhixing; Zhao, Boxian; Liu, Huailei; Wang, Ligang; Wu, Jianing; Han, Dayong; Wang, Kaikai; Zhong, Chen; Hou, Xu; Zhao, Wenyang; Shu, Mengting; Wang, Xinzhuang; Zhao, Shiguang] Harbin Med Univ, Inst Brain Sci, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
   [Wang, Xiaoxiong; Shen, Chen; Liu, Zhendong; Peng, Fei; Chen, Xin; Yang, Guang; Zhang, Daming; Yin, Zhiqin; Zheng, Zhixing; Zhao, Boxian; Liu, Huailei; Wang, Ligang; Wu, Jianing; Han, Dayong; Wang, Kaikai; Zhong, Chen; Hou, Xu; Zhao, Wenyang; Shu, Mengting; Wang, Xinzhuang; Zhao, Shiguang] Harbin Med Univ, Inst Neurosci, Sinorussian Med Res Ctr, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
   [Ma, Jichao] Harbin Med Univ, Dept Pharmacol, Coll Pharm, State Prov Key Labs Biomed Pharmaceut China, 157 Baojian St, Harbin 150001, Heilongjiang, Peoples R China.
RP Zhao, SG (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.; Zhao, SG (corresponding author), Harbin Med Univ, Inst Brain Sci, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.; Zhao, SG (corresponding author), Harbin Med Univ, Inst Neurosci, Sinorussian Med Res Ctr, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
EM guangsz@hotmail.com
RI Zhang, Daming/AAD-3489-2019
OI Zhang, Daming/0000-0003-0280-2093; Wang, Xiaoxiong/0000-0002-8949-8970
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572482, 81672486, 81402062]; Postgraduate
   Innovation Research Project (Sino-Russia Special Fund) of Harbin Medical
   University [YJSCX2017-57HYD]; Special Fund for Translational Research of
   Sino-Russia Medical Research Center in Harbin Medical University
   [CR201410]
FX This work was surpported by the National Natural Science Foundation of
   China (grant numbers 81572482, 81672486, and 81402062), Postgraduate
   Innovation Research Project (Sino-Russia Special Fund) of Harbin Medical
   University (YJSCX2017-57HYD to X.X.W.) and the Special Fund for
   Translational Research of Sino-Russia Medical Research Center in Harbin
   Medical University (grant number CR201410 to S.G.Z.).
CR Adiseshaiah PP, 2013, CANCER LETT, V337, P254, DOI 10.1016/j.canlet.2013.04.034
   Anderson VR, 2007, DRUGS, V67, P1947, DOI 10.2165/00003495-200767130-00015
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169
   Boguski MS, 2009, SCIENCE, V324, P1394, DOI 10.1126/science.1169920
   Botrugno OA, 2012, CLIN CANCER RES, V18, P2436, DOI 10.1158/1078-0432.CCR-11-0767
   Campos B, 2011, CANCER SCI, V102, P387, DOI 10.1111/j.1349-7006.2010.01792.x
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Darwish WM, 2018, EUR J PHARM SCI, V111, P526, DOI 10.1016/j.ejps.2017.10.038
   Di Santo N, 2014, MUTAT RES-FUND MOL M, V768, P16, DOI 10.1016/j.mrfmmm.2014.05.005
   Ecker Jonas, 2013, CNS Oncol, V2, P359, DOI 10.2217/cns.13.24
   Fan-Minogue H, 2013, MOL CANCER THER, V12, P1896, DOI 10.1158/1535-7163.MCT-12-1243
   FernandezHidalgo OA, 1996, BONE MARROW TRANSPL, V18, P143
   Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839
   Galluzzi L, 2008, BIOCHEM SOC T, V36, P786, DOI 10.1042/BST0360786
   Glisoni RJ, 2014, J NANOSCI NANOTECHNO, V14, P4670, DOI 10.1166/jnn.2014.8647
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hernandez JJ, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00273
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002
   Lam KKY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002691
   Lee SW, 2015, CANCER LETT, V360, P195, DOI 10.1016/j.canlet.2015.02.012
   Li ZY, 2016, NEUROCHEM RES, V41, P3192, DOI 10.1007/s11064-016-2043-5
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861
   Niikura K, 2006, DRUG NEWS PERSPECT, V19, P139, DOI 10.1358/dnp.2006.19.3.977442
   Ohba S, 2016, CURR MED CHEM, V23, P4309, DOI 10.2174/0929867323666161014132907
   Paglin S, 2001, CANCER RES, V61, P439
   Palumbo S, 2012, J CELL BIOCHEM, V113, P2308, DOI 10.1002/jcb.24102
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Senkowski W, 2015, MOL CANCER THER, V14, P1504, DOI 10.1158/1535-7163.MCT-14-0792
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tallen G, 2014, FEBS LETT, V588, P2728, DOI 10.1016/j.febslet.2014.03.011
   Tallen G, 2009, ONCOL RES, V18, P95, DOI 10.3727/096504009789954645
   Tallen UG, 2008, J NEURO-ONCOL, V86, P23, DOI 10.1007/s11060-007-9436-x
   Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5
   Tang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15961
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Venur VA, 2015, CANCER TREAT RES, V163, P103, DOI 10.1007/978-3-319-12048-5_7
   Wang XQ, 2017, ONCOTARGET, V8, P48027, DOI 10.18632/oncotarget.18227
   Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5
NR 48
TC 16
Z9 17
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 9
PY 2018
VL 9
AR 1032
DI 10.1038/s41419-018-1058-z
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GW1VA
UT WOS:000446668100006
PM 30302016
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhong, S
   Ji, DF
   Li, YG
   Lin, TB
   Lv, ZQ
   Chen, HP
AF Zhong, Shi
   Ji, Dong-Feng
   Li, You-Gui
   Lin, Tian-Bao
   Lv, Zhi-Qiang
   Chen, Hua-Ping
TI Activation of P27kip1-cyclin D1/E-CDK2 pathway by polysaccharide from
   Phellinus linteus leads to S-phase arrest in HT-29 cells
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Polysaccharide; S-phase arrest; P27kip1; Cyclins/CDK complexes
ID DEPENDENT KINASE INHIBITOR; COLON-CANCER CELLS; CYCLE ARREST; P27(KIP1);
   APOPTOSIS; DEATH; INDUCTION; ANTITUMOR; G(1)
AB Our previous study showed that polysaccharide (P1) from Phellinus linteus exhibits a significant inhibitive activity on human colorectal carcinoma cells (HT-29). However its novel molecular mechanism remains unknown. To obtain insights into P1's mechanism of action, we examined its effects on cell proliferation in vitro and in vivo, cell cycle distribution, apoptosis, autophagy, and expression of several cell cycle interrelated proteins in HT-29 cells. Interestingly, we found that volume and weight of the solid tumor significantly decreased in P1(200 mg/kg)-treated mice compared with the control. However, slightly increased the body weight of the P1 treated tumor-bearing mice, with no significant increased ALT, AST levels in serum and LPO concentration in liver and kidney indicated that P1 has no toxicity to mammals at a dose of 200 mg/kg. Furthermore, P1 caused a significantly dose-dependent increase in the S-phase cell cycle, but no apoptosis and autophagy in HT-29 cells. RT-PCR and Western blot results showed significantly down-regulated expressions of cyclin D1, cyclin E, and CDK2, as well as increased expressions of P27kip1 in P1(100 mu g/mL)-treated HT-29 cells. These results suggested that the activation of P27kip1-cyclin D1/E-CDK2 pathway is involved in P1-induced S-phase cell cycle arrest in HT-29 cells. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhong, Shi; Ji, Dong-Feng; Li, You-Gui; Lin, Tian-Bao; Lv, Zhi-Qiang] Zhejiang Acad Agr Sci, Sericultural Res Inst, Hangzhou 310021, Zhejiang, Peoples R China.
   [Chen, Hua-Ping] Hangzhou Qing Zheng Biol Sci Technol Co, Hangzhou 311700, Zhejiang, Peoples R China.
RP Ji, DF (corresponding author), 198 Shigiao Rd, Hangzhou 310021, Zhejiang, Peoples R China.
EM dong_fengji@126.com
FU earmarked fund for Modern Agro-Industry Technology Research System of
   China [CARS-22-ZJ0105]; Zhejiang Sericultural Sci-Tech Innovation Team
   [2011R50028]; Zhejiang Academy of Agricultural Science [2012R06Y01E01]
FX We are grateful to Hangzhou Biosci Biotech Co., Ltd. for their technical
   assistance. This study was supported by the earmarked fund for Modern
   Agro-Industry Technology Research System of China (CARS-22-ZJ0105), by
   the Zhejiang Sericultural Sci-Tech Innovation Team (2011R50028), and by
   the Zhejiang Academy of Agricultural Science (2012R06Y01E01).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Ajith TA, 2003, J ETHNOPHARMACOL, V84, P157, DOI 10.1016/S0378-8741(02)00292-1
   Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877
   Draetta G.F., 1997, CURR BIOL, V7, P50
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Han SB, 1999, IMMUNOPHARMACOLOGY, V41, P157, DOI 10.1016/S0162-3109(98)00063-0
   Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kim GY, 2003, BIOCHEM BIOPH RES CO, V309, P399, DOI 10.1016/j.bbrc.2003.08.018
   Kim HM, 1996, INT J IMMUNOPHARMACO, V18, P295, DOI 10.1016/0192-0561(96)00028-8
   Lee SJ, 2008, BIOCHEM PHARMACOL, V75, P2289, DOI 10.1016/j.bcp.2008.03.022
   Li G, 2004, CANCER LETT, V216, P175, DOI 10.1016/j.canlet.2004.07.014
   Li X, 2008, INT IMMUNOPHARMACOL, V8, P909, DOI 10.1016/j.intimp.2008.02.008
   Li YC, 2012, TOXICOL APPL PHARM, V263, P21, DOI 10.1016/j.taap.2012.05.018
   Li YG, 2013, SCI REP-UK, V3, DOI 10.1038/srep01377
   Li YG, 2011, INT J BIOL MACROMOL, V48, P511, DOI 10.1016/j.ijbiomac.2011.01.014
   Moon J, 2000, BIOCHEM PHARMACOL, V59, P1109, DOI 10.1016/S0006-2952(00)00235-5
   Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8
   NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   OuYang FJ, 2013, FOOD CHEM, V138, P2130, DOI 10.1016/j.foodchem.2012.10.047
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   Takai N, 2009, CANCER LETT, V277, P235, DOI 10.1016/j.canlet.2008.12.018
   Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334
   Wang XQ, 2013, PESTIC BIOCHEM PHYS, V105, P122, DOI 10.1016/j.pestbp.2012.12.008
   Zhang CX, 2006, TOXICOL APPL PHARM, V210, P236, DOI 10.1016/j.taap.2005.04.019
   Zhang M, 2008, TOXICOL LETT, V179, P1, DOI 10.1016/j.toxlet.2008.03.002
NR 30
TC 29
Z9 35
U1 0
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD NOV 25
PY 2013
VL 206
IS 2
BP 222
EP 229
DI 10.1016/j.cbi.2013.09.008
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 273GK
UT WOS:000328523100013
PM 24060681
DA 2022-04-25
ER

PT J
AU Zheng, Z
   Xu, LT
   Zhang, SF
   Li, WP
   Tou, FF
   He, QS
   Rao, J
   Shen, Q
AF Zheng, Zhi
   Xu, Liting
   Zhang, Shuofeng
   Li, Wuping
   Tou, Fangfang
   He, Qinsi
   Rao, Jun
   Shen, Qiang
TI Peiminine inhibits colorectal cancer cell proliferation by inducing
   apoptosis and autophagy and modulating key metabolic pathways
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; peiminine; natural product; metabolomics; cancer
   therapy
ID POLYUNSATURATED FATTY-ACIDS; BIOMARKERS; DISEASE; DEATH;
   ADENOSYLHOMOCYSTEINE; SIGNATURES; DIAGNOSIS; GLUTAMINE; SURVIVAL;
   IDENTIFY
AB Peiminine, a compound extracted from the bulbs of Fritillaria thunbergii and traditionally used as a medication in China and other Asian countries, was reported to inhibit colorectal cancer cell proliferation and tumor growth by inducing autophagic cell death. However, its mechanism of anticancer action is not well understood, especially at the metabolic level, which was thought to primarily account for peiminine's efficacy against cancer. Using an established metabolomic profiling platform combining ultra-performance liquid chromatography/tandem mass spectrometry with gas chromatography/mass spectrometry, we identified metabolic alterations in colorectal cancer cell line HCT-116 after peiminine treatment. Among the identified 236 metabolites, the levels of 57 of them were significantly (p < 0.05) different between peiminine-treated and - untreated cells in which 45 metabolites were increased and the other 12 metabolites were decreased. Several of the affected metabolites, including glucose, glutamine, oleate (18: 1n9), and lignocerate (24: 0), may be involved in regulation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway and in the oxidative stress response upon peiminine exposure. Peiminine predominantly modulated the pathways responsible for metabolism of amino acids, carbohydrates, and lipids. Collectively, these results provide new insights into the mechanisms by which peiminine modulates metabolic pathways to inhibit colorectal cancer cell growth, supporting further exploration of peiminine as a potential new strategy for treating colorectal cancer.
C1 [Zheng, Zhi; Xu, Liting; Li, Wuping; Tou, Fangfang; He, Qinsi; Rao, Jun] Jiangxi Canc Hosp, Jiangxi Canc Ctr, Dept Internal Med, Jiangxi Prov Key Lab Translat Med & Oncol,Div 5, Nanchang 330029, Jiangxi, Peoples R China.
   [Zheng, Zhi; Xu, Liting; Tou, Fangfang; He, Qinsi; Rao, Jun] Nanchang Univ, Sch Grad Study, Med Coll, Nanchang 330029, Jiangxi, Peoples R China.
   [Zheng, Zhi; Shen, Qiang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   [Zhang, Shuofeng] Beijing Univ Chinese Med, Dept Pharmacol, Beijing 100102, Peoples R China.
RP Rao, J (corresponding author), Jiangxi Canc Hosp, Jiangxi Canc Ctr, Dept Internal Med, Jiangxi Prov Key Lab Translat Med & Oncol,Div 5, Nanchang 330029, Jiangxi, Peoples R China.; Rao, J (corresponding author), Nanchang Univ, Sch Grad Study, Med Coll, Nanchang 330029, Jiangxi, Peoples R China.; Shen, Q (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
EM raojun1986@126.com; qshen@mdanderson.org
OI Shen, Qiang/0000-0002-1491-5434
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81260592, 81303119]; Cancer Center Support
   Grant from the NIH/NCI (MDACC) [CA016672]; Startup fund from MDACC;
   Duncan Family Institute Seed Funding Research Program; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA016672] Funding Source: NIH RePORTER
FX This work was supported by grant No. 81260592 and No. 81303119 from the
   National Natural Science Foundation of China (ZZ); in part by a Cancer
   Center Support Grant CA016672 from the NIH/NCI (MDACC); Startup fund
   from MDACC (QS); and Duncan Family Institute Seed Funding Research
   Program (QS). The authors thank Amy Ninetto, PhD, ELS, Department of
   Scientific Publications, The University of Texas MD Anderson Cancer
   Center for her editing of the manuscript.
CR Alonso-Aperte E, 2008, EUR J CLIN NUTR, V62, P295, DOI 10.1038/sj.ejcn.1602722
   Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71
   Andres Ibarra R, 2011, HPB SURG, V2011
   Aran V, 2016, CLIN COLORECTAL CANC, V15, P195, DOI 10.1016/j.clcc.2016.02.008
   Bertini I, 2012, CANCER RES, V72, P356, DOI 10.1158/0008-5472.CAN-11-1543
   Brosnan JT, 2013, AMINO ACIDS, V45, P413, DOI 10.1007/s00726-012-1280-4
   Calder PC, 2009, BIOCHIMIE, V91, P791, DOI 10.1016/j.biochi.2009.01.008
   Chan ECY, 2009, J PROTEOME RES, V8, P352, DOI 10.1021/pr8006232
   Coghlin C, 2015, PROTEOM CLIN APPL, V9, P64, DOI 10.1002/prca.201400082
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   da Silva T, 2015, ANN ONCOL, V26, DOI 10.1093/annonc/mdv233.190
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   Daye D, 2012, SEMIN CELL DEV BIOL, V23, P362, DOI 10.1016/j.semcdb.2012.02.002
   de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Gao D, 2016, J CHROMATOGR B, V1014, P17, DOI 10.1016/j.jchromb.2016.01.003
   Gao R, 2015, SCI REP-UK, V5, DOI 10.1038/srep18175
   Gilroy DW, 2004, FASEB J, V18, P489, DOI 10.1096/fj.03-0837com
   Guo H, 2013, MOL MED REP, V7, P1103, DOI 10.3892/mmr.2013.1312
   Halama A, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0576-z
   Huang Q, 2013, CANCER RES, V73, P4992, DOI 10.1158/0008-5472.CAN-13-0308
   Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jin X, 2014, ONCOTARGET, V5, P1635, DOI 10.18632/oncotarget.1744
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Li QG, 2016, INT J CANCER, V139, P2502, DOI 10.1002/ijc.30388
   Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9
   Ludwig C, 2009, MAGN RESON CHEM, V47, pS68, DOI 10.1002/mrc.2519
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704
   Mondul A, 2015, P 106 ANN M AM ASS C, P75
   O'Donovan TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134676
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rao J, 2014, METABOLOMICS, V10, P775, DOI 10.1007/s11306-014-0624-3
   Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Toiyama Y, 2013, JNCI-J NATL CANCER I, V105, P849, DOI 10.1093/jnci/djt101
   Tolstikov V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114019
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254
   Uchiyama K, 2017, J GASTROENTEROL, V52, P677, DOI 10.1007/s00535-016-1261-6
   Valli A, 2008, CLIN CHIM ACTA, V395, P106, DOI 10.1016/j.cca.2008.05.018
   Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Woodle ES, 1998, TRANSPLANTATION, V66, P681, DOI 10.1097/00007890-199809270-00001
   Wu XD, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0894-7
   Xue Y, 2015, MUTAGENESIS, V30, P303, DOI 10.1093/mutage/geu076
   Zhao GX, 2005, BIOCHEM BIOPH RES CO, V336, P909, DOI 10.1016/j.bbrc.2005.08.204
   Zheng Z, 2016, OPEN LIFE SCI, V11, P358, DOI 10.1515/biol-2016-0047
NR 53
TC 27
Z9 29
U1 4
U2 28
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 18
PY 2017
VL 8
IS 29
BP 47619
EP 47631
DI 10.18632/oncotarget.17411
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA8KD
UT WOS:000405694000076
PM 28496003
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, JG
   Zhang, JB
   Zhang, CJ
   Wong, YK
   Lim, TK
   Hua, ZC
   Liu, B
   Tannenbaum, SR
   Shen, HM
   Lin, QS
AF Wang, Jigang
   Zhang, Jianbin
   Zhang, Chong-Jing
   Wong, Yin Kwan
   Lim, Teck Kwang
   Hua, Zi-Chun
   Liu, Bin
   Tannenbaum, Steven R.
   Shen, Han-Ming
   Lin, Qingsong
TI In situ Proteomic Profiling of Curcumin Targets in HCT116 Colon Cancer
   Cell Line
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MAMMALIAN TARGET; AUTOPHAGY; RAPAMYCIN; MTOR; DERIVATIVES; MECHANISM;
   SURVIVAL; PATHWAY; PROBE
AB To date, the exact targets and mechanism of action of curcumin, a natural product with anti-inflammatory and anti-cancer properties, remain elusive. Here we synthesized a cell permeable curcumin probe (Cur-P) with an alkyne moiety, which can be tagged with biotin for affinity enrichment, or with a fluorescent dye for visualization of the direct-binding protein targets of curcumin in situ. iTRAQ (TM) quantitative proteomics approach was applied to distinguish the specific binding targets from the non-specific ones. In total, 197 proteins were confidently identified as curcumin binding targets from HCT116 colon cancer cell line. Gene Ontology analysis showed that the targets are broadly distributed and enriched in the nucleus, mitochondria and plasma membrane, and they are involved in various biological functions including metabolic process, regulation, response to stimulus and cellular process. Ingenuity Pathway Analysis (TM) (IPA) suggested that curcumin may exert its anticancer effects over multiple critical biological pathways including the EIF2, eIF4/p70S6K, mTOR signaling and mitochondrial dysfunction pathways. Functional validations confirmed that curcumin downregulates cellular protein synthesis, and induces autophagy, lysosomal activation and increased ROS production, thus leading to cell death.
C1 [Wang, Jigang; Tannenbaum, Steven R.] Singapore MIT Alliance Res & Technol SMART, Interdisciplinary Res Grp Infect Dis, Singapore 138602, Singapore.
   [Wang, Jigang; Wong, Yin Kwan; Lim, Teck Kwang; Lin, Qingsong] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.
   [Wang, Jigang; Hua, Zi-Chun] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Jianbin; Shen, Han-Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore.
   [Zhang, Chong-Jing; Liu, Bin] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117585, Singapore.
   [Tannenbaum, Steven R.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Tannenbaum, Steven R.] MIT, Dept Chem, Cambridge, MA 02139 USA.
RP Wang, JG (corresponding author), Singapore MIT Alliance Res & Technol SMART, Interdisciplinary Res Grp Infect Dis, Singapore 138602, Singapore.; Wang, JG; Lin, QS (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.; Wang, JG (corresponding author), Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.; Shen, HM (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore.
EM jigang@smart.mit.edu; han-ming_shen@nuhs.edu.sg; dbslinqs@nus.edu.sg
RI Liu, Bin/K-6445-2012; SHEN, Han-Ming/B-5942-2011; Zhang,
   Chong-Jing/AAO-5782-2021
OI Liu, Bin/0000-0002-0956-2777; SHEN, Han-Ming/0000-0001-7369-5227; Zhang,
   Chong-Jing/0000-0002-3396-9999
FU NUS research scholarshipNational University of Singapore
FX J.Z. is supported by NUS research scholarship. We thank Dr. Liqian Gao
   and Dr. Siewli Lai for critical review of this manuscript.
CR Angelo LS, 2013, BIOORGAN MED CHEM, V21, P932, DOI 10.1016/j.bmc.2012.12.008
   Basnet P, 2011, MOLECULES, V16, P4567, DOI 10.3390/molecules16064567
   Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367
   Cheng XM, 2014, CHEM COMMUN, V50, P2851, DOI 10.1039/c4cc00184b
   Ciochina R, 2014, DRUG DEVELOP RES, V75, P88, DOI 10.1002/ddr.21158
   Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463
   Firouzi Z, 2014, LIFE SCI, V98, P12, DOI 10.1016/j.lfs.2013.12.200
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Gupta SC, 2013, BIOFACTORS, V39, P2, DOI 10.1002/biof.1079
   Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a
   Han J, 2012, AUTOPHAGY, V8, P812, DOI 10.4161/auto.19471
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Kalesh KA, 2015, CHEM COMMUN, V51, P5497, DOI 10.1039/c4cc09527h
   Le Droumaguet B, 2012, ACS NANO, V6, P5866, DOI 10.1021/nn3004372
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Madden K, 2009, PROSTAG LEUKOTR ESS, V80, P9, DOI 10.1016/j.plefa.2008.10.003
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531
   Ping-Er Wang, 2012, 2012 International Conference on Biomedical Engineering and Biotechnology (iCBEB), P593, DOI 10.1109/iCBEB.2012.483
   Salem M, 2014, RSC ADV, V4, P10815, DOI 10.1039/c3ra46396f
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728
   Shi HB, 2011, CHEM COMMUN, V47, P11306, DOI 10.1039/c1cc14824a
   Shi W, 2007, ORG LETT, V9, P5461, DOI 10.1021/ol702370m
   Sun ZJ, 2011, MOL PHARMACOL, V79, P106, DOI 10.1124/mol.110.066910
   Wang JG, 2016, PHARMACOL THERAPEUT, V162, P10, DOI 10.1016/j.pharmthera.2016.01.010
   Wang J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10111
   Wang JG, 2015, INT J ANAL CHEM, V2015, DOI 10.1155/2015/763969
   Wang JG, 2015, SCI REP-UK, V5, DOI 10.1038/srep07896
   Wang JG, 2014, MOL CELL PROTEOMICS, V13, P876, DOI 10.1074/mcp.M113.029793
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Yamauchi Y, 2012, PHYTOTHER RES, V26, P1779, DOI 10.1002/ptr.4645
   Yang PY, 2012, CHEM COMMUN, V48, P835, DOI 10.1039/c1cc16178d
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zhang JB, 2014, AUTOPHAGY, V10, P901, DOI 10.4161/auto.28267
   Zhu DJ, 2014, INT J CLIN EXP PATHO, V7, P1
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 40
TC 58
Z9 64
U1 4
U2 90
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 26
PY 2016
VL 6
AR 22146
DI 10.1038/srep22146
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DE8CT
UT WOS:000370864100005
PM 26915414
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Tavera-Mendoza, L
   Wang, TT
   Lallemant, B
   Zhang, R
   Nagai, Y
   Bourdeau, R
   Calderon, MR
   Desbarats, J
   Mader, S
   White, JH
AF Tavera-Mendoza, L
   Wang, TT
   Lallemant, B
   Zhang, R
   Nagai, Y
   Bourdeau, R
   Calderon, MR
   Desbarats, J
   Mader, S
   White, JH
TI Convergence of vitamin D and retinoic acid signalling at a common
   hormone response element
SO EMBO REPORTS
LA English
DT Article
DE vitamin D; retinoic acid; nuclear receptors; autophagy; cross-talk;
   cyclin-dependent kinase inhibitors
ID SQUAMOUS CARCINOMA-CELLS; COLON-CANCER CELLS; INDUCED DIFFERENTIATION;
   ANALOG EB1089; DEPENDENT KINASES; GENE-EXPRESSION; IMMUNE-SYSTEM;
   PROLIFERATION; PROTEIN; CHEMOPREVENTION
AB Although 1,25-dihydroxyvitamin D-3 (1,25D(3)) and retinoic acid ( RA) have distinct developmental and physiological roles, both regulate the cell cycle. We provide molecular and genomic evidence that their cognate nuclear receptors regulate common genes through everted repeat TGA(C/T) TPyN8PuG(G/T) TCA (ER8) response elements. ER8 motifs were found in the promoters of several target genes of 1,25D3 and/or RA. Notably, an element was characterized in the cyclin-dependent kinase (CDK) inhibitor p19(ink4d) gene, and 1,25D(3)- or RA-induced p19(INK4D) expression. P19(ink4d) knockdown together with depletion of p27(kip1), another CDK inhibitor regulated by 1,25D3 and RA, rendered cells resistant to ligand-induced growth arrest. Remarkably, p19(INK4D)-deficient cells showed increased autophagic cell death, which was markedly enhanced by 1,25D3, but not RA, and attenuated by loss of p27(KIP1). These results show a limited crosstalk between 1,25D3 and RA signalling by means of overlapping nuclear receptor DNA binding specificities, and uncover a role for p19(INK4D) in control of cell survival.
C1 McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.
   McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada.
   McGill Univ, McGill Univ & Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
   Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada.
RP White, JH (corresponding author), McGill Univ, Dept Med, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.
EM john.white@mcgill.ca
RI white, john h/N-9782-2013
OI white, john h/0000-0002-4785-2687; Desbarats, Julie/0000-0002-2495-7152;
   Calderon, Mario R/0000-0001-6618-1789
CR Adachi M, 1997, BLOOD, V90, P126
   Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127
   Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Cobbold SP, 2003, IMMUNOL REV, V196, P109, DOI 10.1046/j.1600-065X.2003.00078.x
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Cunningham JJ, 2002, MOL CELL NEUROSCI, V19, P359, DOI 10.1006/mcne.2001.1090
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200
   Florentin E, 1996, EUR J BIOCHEM, V240, P699, DOI 10.1111/j.1432-1033.1996.0699h.x
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N
   HIRAI H, 1995, MOL CELL BIOL, V15, P2762
   Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200
   Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368
   Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026
   Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243
   Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Palmer HG, 2003, CANCER RES, V63, P7799
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913
   Thompson PD, 2002, BIOCHEM BIOPH RES CO, V299, P730, DOI 10.1016/S0006-291X(02)02742-0
   TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295
   van Rossum MM, 2000, ARCH DERMATOL RES, V292, P16, DOI 10.1007/PL00007455
   Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462
NR 31
TC 72
Z9 77
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1469-221X
J9 EMBO REP
JI EMBO Rep.
PD FEB
PY 2006
VL 7
IS 2
BP 180
EP 185
DI 10.1038/sj.embor.7400594
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 023QX
UT WOS:000236142400013
PM 16322758
OA Green Published
DA 2022-04-25
ER

PT J
AU Vallecillo-Hernandez, J
   Barrachina, MD
   Ortiz-Masia, D
   Coll, S
   Esplugues, JV
   Calatayud, S
   Hernandez, C
AF Vallecillo-Hernandez, Jorge
   Dolores Barrachina, Maria
   Ortiz-Masia, Dolores
   Coll, Sandra
   Vicente Esplugues, Juan
   Calatayud, Sara
   Hernandez, Carlos
TI Indomethacin Disrupts Autophagic Flux by Inducing Lysosomal Dysfunction
   in Gastric Cancer Cells and Increases Their Sensitivity to Cytotoxic
   Drugs
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOWN-REGULATION; COLORECTAL-CANCER;
   INDUCED APOPTOSIS; INHIBITION; DEATH; SUPPRESSION; METASTASIS;
   MECHANISM; SURVIVIN
AB NSAIDs inhibit tumorigenesis in gastrointestinal tissues and have been proposed as coadjuvant agents to chemotherapy. The ability of cancer epithelial cells to adapt to the tumour environment and to resist cytotoxic agents seems to depend on rescue mechanisms such as autophagy. In the present study we aimed to determine whether an NSAID with sensitizing properties such as indomethacin modulates autophagy in gastric cancer epithelial cells. We observed that indomethacin causes lysosomal dysfunction in AGS cells and promotes the accumulation of autophagy substrates without altering mTOR activity. Indomethacin enhanced the inhibitory effects of the lysosomotropic agent chloroquine on lysosome activity and autophagy, but lacked any effect when both functions were maximally reduced with another lysosome inhibitor (bafilomycin B1). Indomethacin, alone and in combination with chloroquine, also hindered the autophagic flux stimulated by the antineoplastic drug oxaliplatin and enhanced its toxic effect, increasing the rate of apoptosis/necrosis and undermining cell viability. In summary, our results indicate that indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes and, by doing so, increases the sensitivity of gastric cancer cells to cytotoxic agents, an effect that could be used to overcome cancer cell resistance to antineoplastic regimes.
C1 [Vallecillo-Hernandez, Jorge; Dolores Barrachina, Maria; Coll, Sandra; Vicente Esplugues, Juan; Calatayud, Sara; Hernandez, Carlos] Univ Valencia, Fac Med, Dept Farmacol, Ave Blasco Ibanez 15, Valencia 46010, Spain.
   [Vallecillo-Hernandez, Jorge; Dolores Barrachina, Maria; Ortiz-Masia, Dolores; Coll, Sandra; Vicente Esplugues, Juan; Calatayud, Sara; Hernandez, Carlos] Univ Valencia, Fac Med, CIBERehd, Ave Blasco Ibanez 15, Valencia 46010, Spain.
   [Ortiz-Masia, Dolores] Univ Valencia, Fac Med, Dept Med, Ave Blasco Ibanez 15, Valencia 46010, Spain.
   [Vicente Esplugues, Juan; Hernandez, Carlos] Hosp Dr Peset, FISABIO, Ave Cataluna 21, Valencia 46020, Spain.
RP Calatayud, S (corresponding author), Univ Valencia, Fac Med, Dept Farmacol, Ave Blasco Ibanez 15, Valencia 46010, Spain.; Calatayud, S (corresponding author), Univ Valencia, Fac Med, CIBERehd, Ave Blasco Ibanez 15, Valencia 46010, Spain.
EM sara.calatayud@uv.es
RI SAEZ, CARLOS HERNANDEZ/M-3029-2014; ORTIZ-MASIA, MARIA
   DOLORES/M-1413-2017; Esplugues, Juan/ABC-1488-2021; Barrachina,
   Maria/ABB-9683-2021; Calatayud, Sara/ABB-9665-2021
OI SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; ORTIZ-MASIA, MARIA
   DOLORES/0000-0002-7924-9962; Calatayud, Sara/0000-0001-9675-2423;
   Barrachina, Maria Dolores/0000-0002-4332-2929; Esplugues Mota, Juan
   Vicente/0000-0001-8205-021X
FU Ministerio de Economia y CompetitividadSpanish Government
   [SAF2013-43441-P]; European Regional Development Fund of the European
   Union (ERDF) [SAF2013-43441-P]; Ministerio de Economia, Industria y
   CompetitividadSpanish Government [SAF2016-80072P]; ERDFEuropean
   Commission [SAF2016-80072P]; CIBERehd [CB06/04/0071, ACCESS EHD16PI02];
   Generalitat ValencianaGeneralitat ValencianaEuropean CommissionGeneral
   Electric [PROMETEOII/2014/035]; FISABIO [UGP-14-164]; Ministerio de
   Economia y Competitividad of SpainSpanish Government [RYC-2011-09571]
FX We thank Brian Normanly for his English language editing. This work was
   supported by Ministerio de Economia y Competitividad and the European
   Regional Development Fund of the European Union (ERDF)
   [SAF2013-43441-P], Ministerio de Economia, Industria y Competitividad
   and ERDF [SAF2016-80072P], CIBERehd [CB06/04/0071 and ACCESS EHD16PI02],
   Generalitat Valenciana [PROMETEOII/2014/035] and FISABIO (UGP-14-164).
   Carlos Hernandez acknowledges support from the 'Ramon y Cajal' program
   from Ministerio de Economia y Competitividad of Spain (RYC-2011-09571).
CR Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415
   Chiou SK, 2011, BIOCHEM PHARMACOL, V81, P1317, DOI 10.1016/j.bcp.2011.03.019
   Davidson SM, 2017, ANNU REV PHARMACOL, V57, P481, DOI 10.1146/annurev-pharmtox-010715-103101
   Deharo E, 2003, BIOCHEM PHARMACOL, V66, P809, DOI 10.1016/S0006-2952(03)00396-4
   Florey O, 2015, AUTOPHAGY, V11, P88, DOI 10.4161/15548627.2014.984277
   Gewirtz DA, 2016, CANCER RES, V76, P5610, DOI 10.1158/0008-5472.CAN-16-0722
   Gowrishankar S, 2016, J CELL BIOL, V212, P617, DOI 10.1083/jcb.201602082
   Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573
   Gyparaki MT, 2014, TRENDS MOL MED, V20, P239, DOI 10.1016/j.molmed.2014.01.009
   Harada S, 2015, J PHARMACOL EXP THER, V355, P353, DOI 10.1124/jpet.115.226431
   Hernandez C, 2016, J GASTROENTEROL, V51, P691, DOI 10.1007/s00535-015-1137-1
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Jamshidi F, 2008, CELL CYCLE, V7, P917, DOI 10.4161/cc.7.7.5620
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   LALA PK, 1988, CANCER RES, V48, P1072
   Lee HJ, 2017, J CLIN BIOCHEM NUTR, V60, P55, DOI 10.3164/jcbn.16-69
   Leibowitz B, 2014, P NATL ACAD SCI USA, V111, P16520, DOI 10.1073/pnas.1415178111
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Lonnroth C, 2014, INT J ONCOL, V45, P2208, DOI 10.3892/ijo.2014.2686
   Ock CY, 2017, J MOL MED, V95, P405, DOI 10.1007/s00109-016-1491-3
   Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Restivo A, 2015, BRIT J CANCER, V113, P1133, DOI 10.1038/bjc.2015.336
   Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829
   Sahin IH, 2014, CANCER LETT, V345, P249, DOI 10.1016/j.canlet.2013.09.001
   Soon SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107866
   Sun WY, 2016, ONCOL LETT, V11, P4193, DOI 10.3892/ol.2016.4493
   Tse AKW, 2014, J INVEST DERMATOL, V134, P1397, DOI 10.1038/jid.2013.471
   Wu WKK, 2009, BIOCHEM BIOPH RES CO, V382, P79, DOI 10.1016/j.bbrc.2009.02.140
   Yu L, 2009, MOL PHARMACOL, V75, P1364, DOI 10.1124/mol.108.053546
NR 33
TC 22
Z9 22
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 26
PY 2018
VL 8
AR 3593
DI 10.1038/s41598-018-21455-1
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FX4KW
UT WOS:000426045700014
PM 29483523
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Behrouj, H
   Seghatoleslam, A
   Mokarram, P
   Ghavami, S
AF Behrouj, Hamid
   Seghatoleslam, Atefeh
   Mokarram, Pooneh
   Ghavami, Saeid
TI Effect of casein kinase 1 alpha inhibition on autophagy flux and the
   AKT/phospho-beta-catenin (S552) axis in HCT116, a RAS-mutated colorectal
   cancer cell line
SO CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE RAS oncogene; casein kinase 1 alpha; autophagy; AKT pathway;
   phospho-beta-catenin (S552)
ID UNFOLDED PROTEIN RESPONSE; WNT/BETA-CATENIN; COLON-CANCER; MTOR;
   PHOSPHORYLATION; SUPPRESSES; APOPTOSIS; PATHWAY; DEATH; AKT
AB The Wnt/beta-catenin pathway, which interferes with cell proliferation, differentiation, and autophagy, is commonly dysregulated in colorectal cancer (CRC). Mutation of the RAS oncogene is the most prevalent genetic alteration in CRC and has been linked to activation of protein kinase B (AKT) signaling. Phosphorylation of beta-catenin at Ser 552 by AKT contributes to beta-catenin stability, transcriptional activity, and increase of cell proliferation. Casein kinase 1 alpha (CK1 alpha) is an enzyme that simultaneously regulates Wnt/beta-catenin and AKT. The link of the AKT and Wnt pathway to autophagy in RAS-mutated CRC cells has not well identified. Therefore, we investigated how pharmacological CK1 alpha inhibition (D4476) is involved in regulation of autophagy, Wnt/beta-catenin, and An pathways in RAS-mutated CRC cell lines. qRT-PCR and immunoblotting experiments revealed that phospho-AKT (S473) and phospho-beta-catenin (S552) are constitutively increased in RAS-mutated CRC cell lines, in parallel with augmented CK1 alpha expression. The results also showed that D4476 significantly reduced the AKT/phospho-beta-catenin (S552) axis concomitantly with autophagy flux inhibition in RAS-mutated CRC cells. Furthermore, D4476 significantly induced apoptosis in RAS-mutated CRC cells. In conclusion, our results indicate that CK1 alpha inhibition reduces autophagy flux and promotes apoptosis by interfering with the AKT/phospho-beta-catenin (S552) axis in RAS-mutated CRC cells.
C1 [Behrouj, Hamid; Seghatoleslam, Atefeh; Mokarram, Pooneh] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
   [Mokarram, Pooneh; Ghavami, Saeid] Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.
   [Ghavami, Saeid] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
   [Ghavami, Saeid] Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.
   [Ghavami, Saeid] Katowice Sch Technol, Fac Med, Katowice, Poland.
RP Mokarram, P (corresponding author), Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.; Mokarram, P; Ghavami, S (corresponding author), Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.; Ghavami, S (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.; Ghavami, S (corresponding author), Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.; Ghavami, S (corresponding author), Katowice Sch Technol, Fac Med, Katowice, Poland.
EM mokaram2@gmail.com; saeid.ghavami@umanitoba.ca
RI Behrouj, Hamid/AAC-1604-2022
OI Ghavami, Saeid/0000-0001-5948-508X
FU Shiraz University of Medical Sciences [96-15414]; office of the
   President and Vice President for Science and Technology, Iran National
   Science Foundation (INSF) [96015616]
FX This article was adapted from the thesis written by Hamid Behrouj and
   was financially supported by Shiraz University of Medical Sciences Grant
   No. 96-15414. P. Mokarram and S. Ghavami conceived and designed the
   analysis, verified the analytical methods, monitored the data of this
   study, and drafted the manuscript. H. Behrouj contributed in data
   collection, analysis, and interpretation and in the literature search.
   A. Seghatoleslam verified the analytical methods. All authors critically
   evaluated the data and approved the final manuscript. This project was
   also supported by the office of the President and Vice President for
   Science and Technology, Iran National Science Foundation (INSF; Grant
   No. 96015616). The authors would like to thank Science Impact (Winnipeg,
   Canada) for (post-)editing themanuscript.
CR Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050
   Alizadeh J, 2017, SCI REP-UK, V7, DOI 10.1038/srep44841
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399
   Bourroul GM, 2016, EINSTEIN-SAO PAULO, V14, P135, DOI 10.1590/S1679-45082016AO3678
   Brun P, 2020, J ALLERGY CLIN IMMUN, V146, P1210, DOI 10.1016/j.jaci.2020.03.013
   Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8
   Carrino M, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0179-1
   Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018
   Cruciat CM, 2014, CURR OPIN CELL BIOL, V31, P46, DOI 10.1016/j.ceb.2014.08.003
   Rosa SCD, 2021, AUTOPHAGY, V17, P2257, DOI 10.1080/15548627.2020.1821548
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Dastghaib S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112339
   Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Eghtedardoost M, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.105896
   Emami A, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172616
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z
   Ghavami S, 2004, J LEUKOCYTE BIOL, V76, P169, DOI 10.1189/jlb.0903435
   Ghavami S, 2008, J CELL MOL MED, V12, P1005, DOI 10.1111/j.1582-4934.2008.00129.x
   Ghavami S, 2014, BBA-MOL CELL RES, V1843, P1259, DOI 10.1016/j.bbamcr.2014.03.006
   Ghavami S, 2012, AM J PHYSIOL-LUNG C, V302, pL420, DOI 10.1152/ajplung.00312.2011
   Ghavami S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016523
   Ghavami S, 2010, BBA-MOL CELL RES, V1803, P452, DOI 10.1016/j.bbamcr.2009.12.005
   Ghavami S, 2009, BBA-MOL CELL RES, V1793, P546, DOI 10.1016/j.bbamcr.2009.01.002
   Goud KI, 2020, APPL BIOCHEM BIOTECH, V190, P703, DOI 10.1007/s12010-019-03119-6
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hale CM, 2016, AUTOPHAGY, V12, P713, DOI 10.1080/15548627.2016.1147669
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Jaras M, 2014, J EXP MED, V211, P605, DOI 10.1084/jem.20131033
   Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Kuhn K, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.31
   Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lin RK, 2015, CELL PHYSIOL BIOCHEM, V35, P926, DOI 10.1159/000369749
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lodyga M, 2009, ONCOGENE, V28, P937, DOI 10.1038/onc.2008.447
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manni S, 2017, ONCOTARGET, V8, P14604, DOI [10.18632/oncotarget.14678, 10.18632/oncotarget.14654]
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Midthun L, 2019, J GASTROINTEST ONCOL, V10, P577, DOI 10.21037/jgo.2019.01.10
   Moghadam AR, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0115-9
   Mokarram P, 2019, AUTOPHAGY, V15, P2039, DOI 10.1080/15548627.2019.1606638
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Murugan AK, 2019, SEMIN CANCER BIOL, V59, P23, DOI 10.1016/j.semcancer.2019.06.007
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830
   Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037
   Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356
   Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580
   Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687
   Sheikholeslami K, 2019, CANCERS, V11, DOI 10.3390/cancers11070994
   Shojaei S, 2020, VIRULENCE, V11, P805, DOI 10.1080/21505594.2020.1780088
   Shojaei S, 2020, FEBS J, V287, P1005, DOI 10.1111/febs.15069
   STAMOS JL, 2013, COLD SPRING HARB PER, V5
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770
   Turcios L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212538
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010
   Wang JB, 2019, BIOCHEM J, V476, P535, DOI 10.1042/BCJ20180385
   Wiersma VR, 2015, AUTOPHAGY, V11, P1373, DOI 10.1080/15548627.2015.1063767
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw332
NR 80
TC 4
Z9 4
U1 1
U2 3
PU CANADIAN SCIENCE PUBLISHING
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4212
EI 1205-7541
J9 CAN J PHYSIOL PHARM
JI Can. J. Physiol. Pharmacol.
PD MAR
PY 2021
VL 99
IS 3
BP 284
EP 293
DI 10.1139/cjpp-2020-0449
PG 10
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA QX2OM
UT WOS:000629187400004
PM 33635146
DA 2022-04-25
ER

PT J
AU Martisova, A
   Sommerova, L
   Kuricova, K
   Podhorec, J
   Vojtesek, B
   Kankova, K
   Hrstka, R
AF Martisova, Andrea
   Sommerova, Lucia
   Kuricova, Katarina
   Podhorec, Jan
   Vojtesek, Borivoj
   Kankova, Katerina
   Hrstka, Roman
TI AGR2 silencing contributes to metformin-dependent sensitization of
   colorectal cancer cells to chemotherapy
SO ONCOLOGY LETTERS
LA English
DT Article
DE AGR2; diabetes mellitus; colorectal cancer; AMPK; autophagy; ROS
ID PROTEIN DISULFIDE-ISOMERASE; DIABETES-MELLITUS; ANTERIOR GRADIENT-2;
   PANCREATIC-CANCER; STEM-CELLS; PROMOTES; SURVIVAL; RISK; 5-FLUOROURACIL;
   PROLIFERATION
AB There is growing epidemiological evidence indicating an association between diabetes mellitus and the increased incidence of colorectal cancer (CRC). The preferred initial and most widely used pharmacological agent for the treatment of type 2 diabetes is metformin, which in parallel reduces the risk of CRC and improves patient prognosis. AMP-activated protein kinase (AMPK) appears to be tightly associated with the beneficial metabolic effects of metformin, serving as a cellular energy sensor activated in response to a variety of conditions that deplete cellular energy levels. Such conditions include nutrient starvation (particularly glucose), hypoxia and exposure to toxins that inhibit the mitochondrial respiratory chain complex. The aim of the present study was to determine the effect of metformin on CRC cell lines, with different levels of anterior gradient 2 (AGR2) expression, exposed to 5-fluorouracil (5-FU) and oxaliplatin, alone or in combination with metformin. AGR2 has recently emerged as a factor involved in colon carcinogenesis. In AGR2-knockout cells, markedly higher levels of phosphorylated-AMPK were observed in comparison with control cells transfected with GFP-scrambled guide RNA, which indicated that the presence of AGR2 may interfere with the metformin-dependent activation of AMPK. In addition, metformin in combination with 5-FU and oxaliplatin induced ROS production and attenuated autophagy. This effect was enhanced in AGR2-knockout cells.
C1 [Martisova, Andrea; Sommerova, Lucia; Podhorec, Jan; Vojtesek, Borivoj; Kankova, Katerina; Hrstka, Roman] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Zluty Kopec 7, Brno 65653, Czech Republic.
   [Kuricova, Katarina; Kankova, Katerina] Masaryk Univ, Fac Med, Dept Pathophysiol, Brno 62500, Czech Republic.
RP Hrstka, R (corresponding author), Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Zluty Kopec 7, Brno 65653, Czech Republic.
EM hrstka@mou.cz
RI Chalásová, Katarína/ABA-6857-2021; Hrstka, Roman/AAM-4430-2020
OI Chalásová, Katarína/0000-0003-4796-5152; Hrstka,
   Roman/0000-0002-6139-2664; Kankova, Katerina/0000-0001-9548-0630;
   Kankova, Katerina/0000-0002-5574-1768; Martisova,
   Andrea/0000-0002-0081-0498
FU Ministry of Health, Czech Republic-Conceptual Development of Research
   Organization (Masaryk Memorial Cancer Institute) [00209805]; MEYS-NPS I
   [LO1413]; GACRGrant Agency of the Czech Republic [16-14829S, 19-02014S]
FX The present study was supported by the Ministry of Health, Czech
   Republic-Conceptual Development of Research Organization (Masaryk
   Memorial Cancer Institute; grant no. 00209805), by the project MEYS-NPS
   I-LO1413 and GACR 16-14829S and 19-02014S.
CR Abdelsatir Azza Ali, 2015, Asian Pac J Cancer Prev, V16, P8053
   Alves MR, 2018, CANCER MED-US, V7, P3188, DOI 10.1002/cam4.1530
   Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12
   Ariyasu D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020382
   Arumugam T, 2015, MOL CANCER THER, V14, P941, DOI 10.1158/1535-7163.MCT-14-0470
   Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346
   de Kort S, 2017, SCI REP-UK, V7, DOI 10.1038/srep46527
   Diaz-Morales N, 2018, ANTIOXID REDOX SIGN, V28, P1562, DOI 10.1089/ars.2017.7409
   Dumartin L, 2017, ONCOGENE, V36, P3094, DOI 10.1038/onc.2016.459
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529
   Higurashi T, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00622
   Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228
   Hrstka R, 2016, MOL ONCOL, V10, P652, DOI 10.1016/j.molonc.2015.12.003
   Hrstka R, 2013, DIS MARKERS, V2013, P207, DOI 10.1155/2013/761537
   Hrstka R, 2013, CANCER LETT, V333, P187, DOI 10.1016/j.canlet.2013.01.034
   Hur KY, 2015, J DIABETES INVEST, V6, P600, DOI 10.1111/jdi.12328
   Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413
   Kim JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18762-4
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kobiela J, 2019, EXP CLIN ENDOCR DIAB, V127, P445, DOI 10.1055/a-0621-8830
   Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li ZQ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0577-z
   Ma SR, 2017, AM J TRANSL RES, V9, P507
   Madia Federica, 2012, Cells, V1, P535, DOI 10.3390/cells1030535
   Matoulkova E, 2017, EXP CELL RES, V356, P40, DOI 10.1016/j.yexcr.2017.04.011
   Maurel M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810120
   Meng FQ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5063239
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mills KT, 2013, DIS COLON RECTUM, V56, P1304, DOI 10.1097/DCR.0b013e3182a479f9
   Miranda VC, 2016, CLIN COLORECTAL CANC, V15, P321, DOI 10.1016/j.clcc.2016.04.011
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mogavero A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16149-z
   Nangia-Makker P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084369
   Ostatna V, 2014, ELECTROCHIM ACTA, V150, P218, DOI 10.1016/j.electacta.2014.10.125
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Park K, 2011, EXP MOL MED, V43, P91, DOI 10.3858/emm.2011.43.2.011
   Queiroz EAIF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098207
   Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320
   Richard SM, 2015, J CANCER RES THER, V11, P336, DOI 10.4103/0973-1482.157317
   Riedmaier AE, 2013, TRENDS PHARMACOL SCI, V34, P126, DOI 10.1016/j.tips.2012.11.005
   Riener MO, 2014, EUR J CANCER, V50, P1722, DOI 10.1016/j.ejca.2014.04.012
   Schexnayder C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113692
   Sharma A, 2014, CLIN COLORECTAL CANC, V13, P54, DOI 10.1016/j.clcc.2013.10.002
   Sun L, 2012, DIGEST DIS SCI, V57, P1586, DOI 10.1007/s10620-012-2059-x
   Tian SB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15757-z
   Tian SB, 2018, EXP CELL RES, V364, P198, DOI 10.1016/j.yexcr.2018.02.004
   Tiemann K, 2019, ONCOGENE, V38, P3003, DOI 10.1038/s41388-018-0638-9
   van de Poll-Franse LV, 2012, DIABETOLOGIA, V55, P2163, DOI 10.1007/s00125-012-2555-8
   Wang L, 2015, FREE RADICAL BIO MED, V83, P305, DOI 10.1016/j.freeradbiomed.2015.02.007
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Yang JH, 2017, J DIABETES COMPLICAT, V31, P1228, DOI 10.1016/j.jdiacomp.2017.04.012
   Yue W, 2015, SCI REP-UK, V5, DOI 10.1038/srep13390
   Zanders MMJ, 2014, DIABETES METAB, V40, P120, DOI 10.1016/j.diabet.2013.12.007
   Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029
NR 62
TC 4
Z9 4
U1 2
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2019
VL 18
IS 5
BP 4964
EP 4973
DI 10.3892/ol.2019.10800
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JW7HS
UT WOS:000503219600064
PM 31612008
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pouyafar, A
   Rezabakhsh, A
   Rahbarghazi, R
   Heydarabad, MZ
   Shokrollahi, E
   Sokullu, E
   Khaksar, M
   Nourazarian, A
   Avci, CB
AF Pouyafar, Ayda
   Rezabakhsh, Aysa
   Rahbarghazi, Reza
   Heydarabad, Milad Zadi
   Shokrollahi, Elhameh
   Sokullu, Emel
   Khaksar, Majid
   Nourazarian, Alireza
   Avci, Cigir Biray
TI Treatment of cancer stem cells from human colon adenocarcinoma cell line
   HT-29 with resveratrol and sulindac induced mesenchymal-endothelial
   transition rate
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Human cancer stem cells; Sulindac; Resveratrol; Endothelial
   differentiation; Autophagy
ID RESISTANCE
AB In the current experiment, the combined regime of resveratrol and a Wnt-3a inhibitor, sulindac, were examined on the angiogenic potential of cancer stem cells from human colon adenocarcinoma cell line HT-29 during 7days. Cancer stem cells were enriched via a magnetic-activated cell sorter technique and cultured in endothelial induction medium containing sulindac and resveratrol. Expression of endothelial markers such as the von Willebrand factor (vWF) and vascular endothelial cadherin (VE-cadherin) and genes participating in mesenchymal-to-epithelial transition was studied by real-time PCR assay. Protein levels of Wnt-3a and angiogenic factor YKL-40 were examined by western blotting. ELISA was used to determine the level of N-acetylgalactosaminyltransferase 11 (GALNT11) during mesenchymal-endothelial transition. Autophagy status was monitored by PCR array under treatment with the resveratrol plus sulindac. Results showed that resveratrol and sulindac had the potential to decrease the cell survival of HT-29 cancer cells and the clonogenic capacity of cancer stem cells compared with the control (p<0.05). The expression of VE-cadherin and vWF was induced in cancer stem cells incubated with endothelial differentiation medium enriched with resveratrol (p<0.05). Interestingly, the Wnt-3a level was increased in the presence of resveratrol and sulindac (p<0.05). YKL-40 was reduced after cell exposure to sulindac and resveratrol. The intracellular content of resistance factor GALNT11 was diminished after treatment with resveratrol (p<0.05). Resveratrol had the potential to induce the transcription of autophagy signaling genes in cancer stem cells during endothelial differentiation (p<0.05). These data show that resveratrol could increase cancer stem cell trans-differentiation toward endothelial lineage while decrease cell resistance by modulation of autophagy signaling and GALNT11 synthesis.
C1 [Pouyafar, Ayda; Rahbarghazi, Reza; Shokrollahi, Elhameh; Khaksar, Majid] Tabriz Univ Med Sci, Stem Cell Res Ctr, Imam Reza St,Golgasht St, Tabriz 5166614756, Iran.
   [Rezabakhsh, Aysa] Tabriz Univ Med Sci, Aging Res Inst, Tabriz, Iran.
   [Rahbarghazi, Reza] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Appl Cell Sci, Tabriz, Iran.
   [Heydarabad, Milad Zadi] Yasuj Univ Med Sci, Med Plants Res Ctr, Yasuj, Iran.
   [Sokullu, Emel] Izmir Katip Celebi Univ, Bioengn Dept, Izmir, Turkey.
   [Sokullu, Emel] Harvard Med Sch, Harvard MIT Hlth Sci & Technol, Div Biomed Engn, Brigham & Womens Hosp, Cambridge, MA USA.
   [Nourazarian, Alireza] Tabriz Univ Med Sci, Fac Med, Dept Biochem & Clin Labs, Golgasht St, Tabriz 5166616471, Iran.
   [Avci, Cigir Biray] Ege Univ, Fac Med, Dept Med Biol, Izmir, Turkey.
RP Rahbarghazi, R (corresponding author), Tabriz Univ Med Sci, Stem Cell Res Ctr, Imam Reza St,Golgasht St, Tabriz 5166614756, Iran.; Rahbarghazi, R (corresponding author), Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Appl Cell Sci, Tabriz, Iran.; Nourazarian, A (corresponding author), Tabriz Univ Med Sci, Fac Med, Dept Biochem & Clin Labs, Golgasht St, Tabriz 5166616471, Iran.; Avci, CB (corresponding author), Ege Univ, Fac Med, Dept Med Biol, Izmir, Turkey.
EM rezarahbardvm@gmail.com; Nourazariana@tbzmed.ac.ir; cbavci@gmail.com
RI Rahbarghazi, Reza/L-7238-2017; Avci, Cigir Biray/AAH-2300-2019;
   Rezabakhsh, Aysa/AAZ-1312-2020; Nourazarian, Alireza/G-3873-2015
OI Rahbarghazi, Reza/0000-0003-3864-9166; Avci, Cigir
   Biray/0000-0001-8251-4520; Rezabakhsh, Aysa/0000-0003-3942-7848;
   Sokullu, Emel/0000-0003-1302-1997; Nourazarian,
   Alireza/0000-0003-2082-1335
FU Tabriz University of Medical Sciences
FX This study was supported by a grant from the Tabriz University of
   Medical Sciences.
CR Akbarzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16940-y
   Bomken S, 2010, BRIT J CANCER, V103, P439, DOI 10.1038/sj.bjc.6605821
   Buhrmann C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070888
   Campagnolo P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125122
   Cilibrasi C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169854
   Della Corte CM, 2014, BIOMEDICINES, V2, P345, DOI 10.3390/biomedicines2040345
   Desiderio V, 2015, ONCOTARGET, V6, P71, DOI 10.18632/oncotarget.2698
   Druzhkova I, 2019, CLIN COLORECTAL CANC, V18, pE74, DOI 10.1016/j.clcc.2018.10.003
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Evans C, 2006, BRIT J CANCER, V94, P1412, DOI 10.1038/sj.bjc.6603104
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   HARRISON DE, 1991, BLOOD, V78, P1237
   Hope C, 2008, MOL NUTR FOOD RES, V52, pS52, DOI 10.1002/mnfr.200700448
   Huang F, 2014, EXP THER MED, V7, P1611, DOI 10.3892/etm.2014.1662
   Jia ZF, 2010, J NEURO-ONCOL, V98, P329, DOI 10.1007/s11060-009-0092-1
   Krushkal J, 2017, CANCER INFORM, V16, DOI 10.1177/1176935117747259
   Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6
   Reddivari L, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1254-2
   Rezabakhsh A, 2017, J CELL BIOCHEM, V118, P1518, DOI 10.1002/jcb.25814
   Rosello S, 2018, CANCER TREAT REV, V63, P156, DOI 10.1016/j.ctrv.2018.01.001
   Seino M, 2015, ANTICANCER RES, V35, P85
   Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017
   Wang S, 2012, HUMAN GENET EMBRYOL, VS2, P2161
   Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307
   Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568
   Zhang RR, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0249-0
   Zhang W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-593
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 29
TC 20
Z9 21
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD JUN
PY 2019
VL 376
IS 3
BP 377
EP 388
DI 10.1007/s00441-019-02998-9
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HZ6AP
UT WOS:000468934500006
PM 30758710
DA 2022-04-25
ER

PT J
AU Liu, Q
   Sun, Y
   Lv, YF
   Le, ZY
   Xin, YH
   Zhang, P
   Liu, Y
AF Liu, Qi
   Sun, Yong
   Lv, Yuefeng
   Le, Ziyu
   Xin, Yuhu
   Zhang, Ping
   Liu, Yong
TI TERT alleviates irradiation-induced late rectal injury by reducing
   hypoxia-induced ROS levels through the activation of NF-kappa B and
   autophagy
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE radiation; late rectal injury; hypoxia; telomerase reverse
   transcriptase; autophagy
ID ENDOTHELIAL GROWTH-FACTOR; CROSS-TALK; OXIDATIVE STRESS; UP-REGULATION;
   CANCER CELLS; RADIATION; TELOMERASE; MITOCHONDRIA; RESISTANCE; RESPONSES
AB The hypoxic microenvironment which is present following irradiation has been proven to promote radiation-induced injury to normal tissues. Previous studies have demonstrated that telomerase reverse transcriptase (TERT) is regulated by hypoxia, and that it plays a protective role in the process of wound repair. However, its effects on radiation-induced injury remain unclear. In this study, we examined the effects of human TERT on irradiation-induced late rectal injury in fibroblasts under hypoxic conditions. We also performed in vivo experiments. The rectums of 5-week-old female C57BL/6N mice were irradiated locally with a single dose of 25 Gy. We then examined the fibrotic changes using hematoxylin and eosin staining, and Masson's staining. The expression of hypoxia inducible factor-1 alpha (HIF-1 alpha) and TERT was analyzed by immunohistochemistry. In in vitro experiments, apoptosis, reactive oxygen species (ROS) production and the autophagy level induced by exposure to hypoxia were assayed in fibroblasts. The association between TERT, nuclear factor-kappa B (NF-kappa B) and the autophagy level was examined by western blot analysis. The antioxidant effects of TERT were examined on the basis of the ratio of glutathione to glutathione disulfide (GSH/GSSG) and mitochondrial membrane potential. Rectal fibrosis was induced significantly at 12 weeks following irradiation. The HIF-1 alpha and TERT expression levels increased in the fibrotic region. The TERT-overexpressing fibroblasts (transfected with an hTERT-expressing lentiviral vector) exhibited reduced apoptosis, reduced ROS production, a higher autophagy level, a higher GSH/GSSG ratio and stable mitochondrial membrane potential compared with the fibroblasts in which TERT had been silenced by siRNA. NF-kappa B was activated by TERT, and the inhibition of TERT reduced the autophagy level in the fibroblasts. These results demonstrate that TERT decreases cellular ROS production, while maintaining mitochondrial function and protecting the cells from hypoxia-induced apoptosis, which may thus attenuate the effects of irradiation-induced hypoxia on rectal injury following irradiation.
C1 [Liu, Qi; Sun, Yong; Xin, Yuhu; Zhang, Ping; Liu, Yong] Fudan Univ, Shanghai Canc Ctr, Canc Res Inst, 270 Dong An Rd, Shanghai 200032, Peoples R China.
   [Le, Ziyu; Liu, Yong] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China.
   [Liu, Qi; Sun, Yong; Le, Ziyu; Xin, Yuhu; Zhang, Ping; Liu, Yong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Lv, Yuefeng] Hubei Univ Med, Shiyan Taihe Hosp, Dept Obstet, Shiyan 442000, Hubei, Peoples R China.
RP Liu, Y (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Res Inst, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM drliuyong@hotmail.com
FU Scientific Research Foundation for the Returned Overseas Chinese
   Scholars from the China State Education MinistryScientific Research
   Foundation for the Returned Overseas Chinese Scholars [N130204];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81202148, 31370838]; Shanghai Pujiang
   ProgramShanghai Pujiang Program [13P1401600]; Foundation of Shanghai
   Committee of Science and Technology of China [12DZ2260100]
FX This study was supported by the Scientific Research Foundation for the
   Returned Overseas Chinese Scholars (no. N130204) from the China State
   Education Ministry, the National Natural Science Foundation of China
   (nos. 81202148 and 31370838), the Shanghai Pujiang Program (no.
   13P1401600), and the Foundation of Shanghai Committee of Science and
   Technology of China (no. 12DZ2260100).
CR Ahmed S, 2008, J CELL SCI, V121, P1046, DOI 10.1242/jcs.019372
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936
   Christofidou-Solomidou M, 2015, AM J PHYSIOL-LUNG C, V308, pL416, DOI 10.1152/ajplung.00260.2014
   De Boeck G, 2009, J PATHOL, V217, P327, DOI 10.1002/path.2500
   Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P4203, DOI 10.1002/art.23074
   GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7
   Grodsky MB, 2015, CLIN COLON RECT SURG, V28, P103, DOI 10.1055/s-0035-1547337
   Haroon ZA, 2000, ANN SURG, V231, P137, DOI 10.1097/00000658-200001000-00020
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588
   Jan HM, 2012, GENE THER, V19, P86, DOI 10.1038/gt.2011.62
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Liu Y, 2008, J RADIAT RES, V49, P261, DOI 10.1269/jrr.07099
   Liu Y, 2009, J RADIAT RES, V50, P233, DOI 10.1269/jrr.08112
   Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1
   Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004
   Nordal RA, 2004, CLIN CANCER RES, V10, P3342, DOI 10.1158/1078-0432.CCR-03-0426
   Okunieff P, 2005, INT J RADIAT ONCOL, V62, P273, DOI 10.1016/j.ijrobp.2005.01.034
   Osanai M, 2002, WOUND REPAIR REGEN, V10, P59, DOI 10.1046/j.1524-475X.2002.10506.x
   Qu Y, 2011, STROKE, V42, P3542, DOI 10.1161/STROKEAHA.111.626325
   Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029
   Sannigrahi MK, 2015, ORAL DIS, V21, P283, DOI 10.1111/odi.12254
   Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2
   Spilsbury A, 2015, J NEUROSCI, V35, P1659, DOI 10.1523/JNEUROSCI.2925-14.2015
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Sun ZY, 2015, CELL BIOCHEM BIOPHYS, V72, P115, DOI 10.1007/s12013-014-0417-3
   Xu T, 2013, NEUROCHEM RES, V38, P1914, DOI 10.1007/s11064-013-1097-x
   Yang SM, 2015, RADIAT RES, V184, P509, DOI 10.1667/RR13831.1
   Zeng M, 2013, BIOCHEM BIOPH RES CO, V436, P180, DOI 10.1016/j.bbrc.2013.05.070
   Zhang YH, 2009, ARCH BIOCHEM BIOPHYS, V489, P25, DOI 10.1016/j.abb.2009.07.017
NR 36
TC 13
Z9 15
U1 1
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2016
VL 38
IS 3
BP 785
EP 793
DI 10.3892/ijmm.2016.2673
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DU8EA
UT WOS:000382444900012
PM 27431814
OA Green Submitted, hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Ge, CC
   Wang, YX
   Feng, YL
   Wang, SZ
   Zhang, KM
   Xu, XJ
   Zhang, ZY
   Zhao, Y
   Wang, YM
   Gao, L
   Dai, FJ
   Xie, SQ
   Wang, CJ
AF Ge, Chaochao
   Wang, Yuxia
   Feng, Yongli
   Wang, Senzhen
   Zhang, Kemeng
   Xu, Xiaojuan
   Zhang, Zhiyang
   Zhao, Yuan
   Wang, Yanming
   Gao, Lei
   Dai, Fujun
   Xie, Songqiang
   Wang, Chaojie
TI Suppression of oxidative phosphorylation and IDH2 sensitizes colorectal
   cancer to a naphthalimide derivative and mitoxantrone
SO CANCER LETTERS
LA English
DT Article
DE Mitochondria; Reactive oxygen species; Autophagy; Senescence;
   Tricarboxylic acid cycle
ID MITOCHONDRIAL COMPLEX-III; INDUCED ROS PRODUCTION; CELL-DEATH;
   METABOLISM; INHIBITORS
AB Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. Oxidative phosphorylation (OXPHOS) has attracted a considerable attention in CRC. It is of great interest to explore novel therapies that inhibit OXPHOS for CRC treatment. Compound 6c is a novel naphthalimide derivative. However, the effects of 6c on CRC and the underlying mechanism are unclear. In this study, 6c suppressed CRC tumor growth and metastasis. RNA-seq data showed that 6c triggered the inhibition of OXPHOS and tricarboxylic acid cycle. 6c specifically inhibited mitochondrial complex III activity and the expression of isocitrate dehydrogenase 2 (IDH2), resulting in oxidative stress. Antioxidants reversed 6c-induced cell death, senescence, and autophagosomes formation. 6c inhibited autophagy flux; however, pretreatment with autophagy inhibitors resulted in the reduction of 6cinduced cytoplasmic vacuolization and proliferation inhibition. Moreover, combinatory treatment of 6c and mitoxantrone (MIT) showed stronger inhibitory effects on CRC compared with the single agent. Downregulation of IDH2 induced reactive oxygen species production, leading to MIT accumulation and autophagic cell death after co-treatment with 6c and MIT. In summary, our findings indicated 6c as a promising candidate for CRC treatment.
C1 [Ge, Chaochao; Feng, Yongli; Wang, Senzhen; Zhang, Zhiyang; Zhao, Yuan; Gao, Lei; Dai, Fujun; Wang, Chaojie] Henan Univ, Key Lab Nat Med & Immunoengn, Kaifeng 475004, Henan, Peoples R China.
   [Wang, Yuxia] Henan Univ, Coll Chem & Chem Engn, Kaifeng 475004, Henan, Peoples R China.
   [Wang, Senzhen; Zhang, Kemeng; Wang, Yanming; Gao, Lei; Dai, Fujun] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China.
   [Xu, Xiaojuan; Xie, Songqiang] Henan Univ, Sch Pharm, Kaifeng 475004, Henan, Peoples R China.
RP Dai, FJ; Wang, CJ (corresponding author), Henan Univ, Key Lab Nat Med & Immunoengn, Kaifeng 475004, Henan, Peoples R China.; Xie, SQ (corresponding author), Henan Univ, Sch Pharm, Kaifeng 475004, Henan, Peoples R China.
EM fjdwl@hotmail.com; xiesq@henu.edu.cn; wcjsxq@henu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703004, U1904151, 81772832, 32000271,
   22073023]; Young Backbone Teacher in Colleges and Universities of Henan
   Province [2020GGJS033]; Postdoctoral Research Foundation of ChinaChina
   Postdoctoral Science Foundation [2019M652527, 2020M672214]; Start-up
   Fund of Postdoctoral Research Program of Henan Province [1901009];
   Postgraduate Education Reform Project of Henan Province [2019SJGLX081Y];
   Innovative Research Team (in Science and Technology) in University of
   Henan Province [19IRTSTHN004]; Guangdong Provincial Key Laboratory of
   Drug Non-clinical Evaluation and Research [2018B030323024]
FX This work was supported by National Natural Science Foundation of China
   (81703004, U1904151, 81772832, 32000271and 22073023) , The Young
   Backbone Teacher in Colleges and Universities of Henan Province
   (2020GGJS033) , Postdoctoral Research Foundation of China
   (2019M652527and 2020M672214) , Start-up Fund of Postdoctoral Research
   Program of Henan Province (1901009) , Postgraduate Education Reform
   Project of Henan Province (2019SJGLX081Y) , Innovative Research Team (in
   Science and Technology) in University of Henan Province (19IRTSTHN004) ,
   and Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation
   and Research (2018B030323024) .
CR Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843
   Bernard M, 2020, AUTOPHAGY, V16, P2004, DOI 10.1080/15548627.2020.1713640
   Budanov AV, 2011, ANTIOXID REDOX SIGN, V15, P1679, DOI 10.1089/ars.2010.3530
   Cannino G, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00333
   Chang MJ, 2018, CHEM COMMUN, V54, P13531, DOI 10.1039/c8cc07934j
   Dai FJ, 2017, J MED CHEM, V60, P2071, DOI 10.1021/acs.jmedchem.6b01846
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065
   Fang J, 2009, ADV DRUG DELIVER REV, V61, P290, DOI 10.1016/j.addr.2009.02.005
   Flaig TW, 2007, INT J CANCER, V120, P2028, DOI 10.1002/ijc.22465
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Gao L, 2020, CANCERS, V12, DOI 10.3390/cancers12030528
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Huang Q, 2019, CANCER LETT, V455, P36, DOI 10.1016/j.canlet.2019.04.021
   Huang YH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00790
   Ingrassia L, 2009, CURR MED CHEM, V16, P1192, DOI 10.2174/092986709787846659
   Kaliszczak M, 2018, BRIT J CANCER, V119, P1278, DOI 10.1038/s41416-018-0232-5
   Karch J, 2017, ELIFE, V6, DOI 10.7554/eLife.30543
   Kono Y, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13030388
   Lagnado A, 2021, EMBO J, V40, DOI 10.15252/embj.2020106048
   Leary A, 2019, INVEST NEW DRUG, V37, P693, DOI 10.1007/s10637-018-0688-4
   Lee M, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101073
   Lee MH, 2014, J AM CHEM SOC, V136, P14136, DOI 10.1021/ja506301n
   Liang X, 2011, INVEST NEW DRUG, V29, P646, DOI 10.1007/s10637-010-9403-9
   Liemburg-Apers DC, 2015, ARCH TOXICOL, V89, P1209, DOI 10.1007/s00204-015-1520-y
   Liu NA, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0897-x
   Liu Y., 2021, SEMIN CANC BIOL
   Lozano-Torres B, 2021, ANAL CHEM, V93, P3052, DOI 10.1021/acs.analchem.0c05447
   Ma MT, 2013, CANCER LETT, V339, P107, DOI 10.1016/j.canlet.2013.07.016
   Martinez-Reyes I, 2020, NATURE, V585, P288, DOI 10.1038/s41586-020-2475-6
   Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973
   Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4
   Montemurro L, 2019, CANCER RES, V79, P6166, DOI 10.1158/0008-5472.CAN-19-0008
   Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024
   Park JH, 2018, REDOX BIOL, V17, P16, DOI 10.1016/j.redox.2018.04.008
   Park JB, 2016, FREE RADICAL BIO MED, V94, P36, DOI 10.1016/j.freeradbiomed.2016.02.017
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Qin JZ, 2019, J SURG RES, V233, P57, DOI 10.1016/j.jss.2018.07.068
   Shi F, 2020, MOL METAB, V36, DOI 10.1016/j.molmet.2020.02.009
   Tcheng M., BLOOD, V2021, P8551
   Toh YM, 2011, CLIN CANCER RES, V17, P5026, DOI 10.1158/1078-0432.CCR-11-0235
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang AY, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0550-8
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wen SJ, 2013, FUTURE MED CHEM, V5, P53, DOI 10.4155/fmc.12.190
   Xiao WS, 2018, ANTIOXID REDOX SIGN, V28, P251, DOI 10.1089/ars.2017.7216
   Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349
   Zhang GY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1492-6
   Zhang GH, 2016, J BIOL CHEM, V291, P4211, DOI 10.1074/jbc.M115.669978
   Zhang HM, 2011, J PINEAL RES, V50, P78, DOI 10.1111/j.1600-079X.2010.00815.x
   Zhou J, 2019, THERANOSTICS, V9, P5577, DOI 10.7150/thno.34663
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011
   Zou XH, 2017, CANCER RES, V77, P3990, DOI 10.1158/0008-5472.CAN-16-2393
NR 53
TC 1
Z9 1
U1 6
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 28
PY 2021
VL 519
BP 30
EP 45
DI 10.1016/j.canlet.2021.06.015
EA JUN 2021
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UH0VH
UT WOS:000689658000001
PM 34166768
DA 2022-04-25
ER

PT J
AU Ding, L
   Wang, LY
   Sui, LM
   Zhao, HY
   Xu, XX
   Li, TY
   Wang, XN
   Li, WJ
   Zhou, P
   Kong, L
AF Ding, Lei
   Wang, Liyong
   Sui, Leiming
   Zhao, Huanying
   Xu, Xiaoxue
   Li, Tengyan
   Wang, Xiaonan
   Li, Wenjing
   Zhou, Ping
   Kong, Lu
TI Claudin-7 indirectly regulates the integrin/FAK signaling pathway in
   human colon cancer tissue
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID CELLS; CARCINOMA; CARCINOGENESIS; AUTOPHAGY; MIGRATION; NETWORKS;
   PROTEINS; GELSOLIN; DATABASE
AB The claudin family of proteins is integral to the structure and function of tight junctions. The role of claudin-7 (Cldn-7, CLDN7) in regulating the integrin/focal adhesion kinase (FAK)/ERK signaling pathway remains poorly understood. Therefore, we investigated differences in gene expression, primarily focusing on CLDN7 and integrin/FAK/ERK signaling pathway genes, between colon cancer and adjacent normal tissues. Quantitative real-time reverse transcription-PCR and immunohistochemistry were utilized to verify the results of mRNA and protein expression, respectively. In silico analysis was used to predict co-regulation between Cldn-7 and integrin/FAK/ERK signaling pathway components, and the STRING database was used to analyze protein-protein interaction pairs among these proteins. Meta-analysis of expression microarrays in The Cancer Genome Atlas (TCGA) database was used to identify significant correlations between Cldn-7 and components of predicted genes in the integrin/FAK/ERK signaling pathway. Our results showed marked cancer stage-specific decreases in the protein expression of Cldn-7, Gelsolin, MAPK1 and MAPK3 in colon cancer samples, and the observed changes for all proteins except Cldn-7 were in agreement with changes in the corresponding mRNA levels. Cldn-7 might indirectly regulate MAPK3 via KRT8 due to KRT8 co-expression with MAPK3 or CLDN7. Our bioinformatics methods supported the hypothesis that Cldn-7 does not directly regulate any genes in the integrin/FAK/ERK signaling pathway. These factors may participate in a common network that regulates cancer progression in which the MAPK pathway serves as the central node.
C1 [Ding, Lei; Li, Tengyan; Wang, Xiaonan; Li, Wenjing] Capital Med Univ, Beijing Shijitan Hosp, Dept Oncol, Beijing 100038, Peoples R China.
   [Wang, Liyong; Sui, Leiming; Zhao, Huanying; Xu, Xiaoxue; Kong, Lu] Capital Med Univ, Dept Biochem & Mol Biol, Beijing, Peoples R China.
   [Zhou, Ping] Capital Med Univ, Inst Biomed Engn, Dept Bioinformat, Beijing, Peoples R China.
RP Ding, L (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Dept Oncol, Beijing 100038, Peoples R China.; Kong, L (corresponding author), Capital Med Univ, Inst Canc, Dept Biochem & Mol Biol, 10 Xitoutiao, Beijing 100069, Peoples R China.
EM dinglei1005@126.com; konglu@ccmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81372585, 81272406]; Scientific Research
   Program of Beijing Municipal Commission of Education [KM201410025026,
   KM201510025009, KZ201410025020]
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 81372585 and 81272406) and the Scientific Research
   Program of Beijing Municipal Commission of Education (grant no.
   KM201410025026, KM201510025009 and KZ201410025020).
CR Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385
   Bornholdt J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-65
   Bostanci O, 2014, EUR REV MED PHARMACO, V18, P2533
   Chen YL, 2005, LIFE SCI, V76, P2409, DOI 10.1016/j.lfs.2004.09.044
   Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025
   Gay F, 2008, HUM PATHOL, V39, P1420, DOI 10.1016/j.humpath.2008.02.020
   Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8
   Ha BG, 2015, INT J ONCOL, V46, P2621, DOI 10.3892/ijo.2015.2942
   Kong J, 2011, IEEE T BIO-MED ENG, V58, P3469, DOI 10.1109/TBME.2011.2169256
   Laliberte E, 2010, ECOL LETT, V13, P76, DOI 10.1111/j.1461-0248.2009.01403.x
   Liu YT, 2012, MOL MED REP, V6, P1006, DOI 10.3892/mmr.2012.1052
   Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002
   Lu QY, 2015, GRAEF ARCH CLIN EXP, V253, P669, DOI 10.1007/s00417-015-2985-3
   Lu Z, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24978
   Lu Z, 2011, EXP CELL RES, V317, P1935, DOI 10.1016/j.yexcr.2011.05.019
   Luo CW, 2014, BBA-MOL CELL RES, V1843, P2129, DOI 10.1016/j.bbamcr.2014.06.007
   Obayashi T, 2008, NUCLEIC ACIDS RES, V36, pD77, DOI 10.1093/nar/gkm840
   Ou JJ, 2013, STEM CELL RES, V11, P820, DOI 10.1016/j.scr.2013.05.009
   Radwanska A, 2012, EXP CELL RES, V318, P2312, DOI 10.1016/j.yexcr.2012.07.005
   Reddy RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147409
   ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743
   Rock A, 2011, FORENSIC SCI INT-GEN, V5, P126, DOI 10.1016/j.fsigen.2010.10.006
   Saleem S, 2009, J PATHOL, V219, P182, DOI 10.1002/path.2577
   Sewer MB, 2013, MOL CELL ENDOCRINOL, V371, P79, DOI 10.1016/j.mce.2012.11.014
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Slattery ML, 2013, NUTR CANCER, V65, P729, DOI 10.1080/01635581.2013.795599
   Suren D, 2014, MED SCI MONITOR, V20, P1255, DOI 10.12659/MSM.890598
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Urosevic J, 2014, CELL CYCLE, V13, P2641, DOI 10.4161/15384101.2014.946374
   Zhang W, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0189-x
NR 30
TC 19
Z9 22
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD AUG
PY 2016
VL 61
IS 8
BP 711
EP 720
DI 10.1038/jhg.2016.35
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DU7ZE
UT WOS:000382432300007
PM 27121327
DA 2022-04-25
ER

PT J
AU Choi, J
   Jo, M
   Lee, E
   Choi, D
AF Choi, JongYeob
   Jo, MinWha
   Lee, EunYoung
   Choi, DooSeok
TI ERK1/2 is involved in luteal cell autophagy regulation during corpus
   luteum regression via an mTOR-independent pathway
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE autophagy; luteal cell; mTOR; AKT; ERK1/2
ID ALPHA-INTERACTING PROTEIN; RIBOSOMAL S6 KINASE; COLON-CANCER CELLS;
   TUBEROUS SCLEROSIS; HORMONE ANTAGONIST; SIGNALING PATHWAY; IN-VIVO;
   APOPTOSIS; DEATH; AKT
AB Autophagy is known to be regulated by the phosphoinositide-3 kinase (PI3K)-protein kinase B (AKT) and/or mitogen-activated protein kinase 1/2 (MEK1/2)-extracellular signal-regulated kinase 1/2 (ERK1/2) pathways, leading to activation of mammalian target of rapamycin (mTOR), a major negative regulator of autophagy. However, some reports have also suggested that autophagic regulation by the PI3K-AKT and/or MEK1/2-ERK1/2 pathways may not be mediated by mTOR activity, and there is no direct evidence of the involvement of these pathways in luteal cell autophagy regulation. To elucidate the luteal cell-specific regulatory mechanisms of autophagy induction during corpus luteum (CL) regression, we evaluated whether luteal cell autophagy is regulated by the PI3K-AKT pathway and/or MEK1/2-ERK1/2 pathway and if this regulation is mediated by mTOR. We found that autophagy induction increased despite mTOR activation in luteal cells cultured with prostaglandin F2 alpha (PGF2 alpha), an important mediator of CL regression, suggesting that PGF2 alpha-induced autophagy is independent of mTOR regulation. We also found that PGF2 alpha-induced autophagy was not mediated by AKT activity, because AKT inhibition using a PI3K inhibitor (wortmannin) did not change autophagy induction or mTOR activity. In contrast, ERK1/2 activity increased in PGF2 alpha-treated luteal cells, as did the levels of autophagy induction despite increased mTOR activity. Furthermore, PGF2 alpha-mediated up-regulation of luteal cell autophagy was reversed by addition of ERK1/2 inhibitors, despite a decrease in mTOR activity. These in vitro results suggest that luteal cell autophagy is induced by increased ERK1/2 activity during CL regression, and is independent of mTOR activity. This finding was further supported by in vivo experiments in a pseudo-pregnant rat model, which showed that induction of luteal cell autophagy increased during luteal stage progression and that this was accompanied by increased ERK1/2 and mTOR activity. Taken together, our findings indicate that activation of ERK1/2 is a key event in the induction of luteal cell autophagy during CL regression which is not associated with mTOR regulation.
C1 [Choi, JongYeob; Lee, EunYoung; Choi, DooSeok] Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Infertil Clin,Sch Med, Seoul 135710, South Korea.
   [Jo, MinWha] Samsung Biochem Res Inst, Clin Res Ctr, Seoul, South Korea.
RP Choi, D (corresponding author), Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Infertil Clin,Sch Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM dooseok.choi@samsung.com
FU Samsung Biomedical Research InstituteSamsung [SBRI GLI-B2-341-2]
FX This study was supported by a grant from the Samsung Biomedical Research
   Institute [grant number SBRI GLI-B2-341-2].
CR Arvisais E, 2010, MOL ENDOCRINOL, V24, P632, DOI 10.1210/me.2009-0312
   Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200
   BEHRMAN HR, 1980, ENDOCRINOLOGY, V107, P656, DOI 10.1210/endo-107-3-656
   Berisha B, 2005, DOMEST ANIM ENDOCRIN, V29, P305, DOI 10.1016/j.domaniend.2005.02.035
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen XL, 2003, SCI CHINA SER C, V46, P273, DOI 10.1360/03yc9029
   Choi J, 2011, BIOL REPROD, V85, P465, DOI 10.1095/biolreprod.111.091314
   Corcelle EA, 2009, FEBS J, V276, P6084, DOI 10.1111/j.1742-4658.2009.07332.x
   DAVIS JS, 2002, FRONT BIOSCI, V7, P1949, DOI DOI 10.2741/DAVIS1
   Degtyarev M, 2009, AUTOPHAGY, V5, P415, DOI 10.4161/auto.5.3.7827
   Del Canto F, 2007, J CLIN ENDOCR METAB, V92, P4436, DOI 10.1210/jc.2007-0125
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Fraser HM, 1999, BIOL REPROD, V61, P1468, DOI 10.1095/biolreprod61.6.1468
   FRASER HM, 1995, J ENDOCRINOL, V147, P131, DOI 10.1677/joe.0.1470131
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Leng Y, 2001, ACTA PHARMACOL SIN, V22, P155
   Li CG, 2009, J MOL CELL BIOL, V1, P37, DOI 10.1093/jmcb/mjp002
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Mordier S, 2000, J BIOL CHEM, V275, P29900, DOI 10.1074/jbc.M003633200
   Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13
   Paglin S, 2001, CANCER RES, V61, P439
   PAYNE AH, 1980, ENDOCRINOLOGY, V106, P1424, DOI 10.1210/endo-106-5-1424
   Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101
   RUEDA BR, 1995, BIOL REPROD, V52, P305, DOI 10.1095/biolreprod52.2.305
   Saeki K, 2003, J LEUKOCYTE BIOL, V74, P1108, DOI 10.1189/jlb.0503211
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Shikone T, 1996, J CLIN ENDOCR METAB, V81, P2376, DOI 10.1210/jc.81.6.2376
   Stankiewicz M, 1996, INT J PARASITOL, V26, P445, DOI 10.1016/0020-7519(96)00003-3
   Stevens C, 2009, J BIOL CHEM, V284, P334, DOI 10.1074/jbc.M805165200
   Stocco C, 2007, ENDOCR REV, V28, P117, DOI 10.1210/er.2006-0022
   Stouffer RL, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P475
   Telleria CM, 2001, ENDOCRINE, V15, P147, DOI 10.1385/ENDO:15:2:147
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Weems CW, 2006, VET J, V171, P206, DOI 10.1016/j.tvjl.2004.11.014
   Zha XJ, 2011, CANCER LETT, V313, P211, DOI 10.1016/j.canlet.2011.09.006
NR 42
TC 21
Z9 22
U1 2
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460-2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD OCT
PY 2014
VL 20
IS 10
BP 972
EP 980
DI 10.1093/molehr/gau061
PG 9
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA AT0HT
UT WOS:000344618300005
PM 25107837
OA Bronze
DA 2022-04-25
ER

PT J
AU Schroll, MM
   Liu, X
   Herzog, SK
   Skube, SB
   Hummon, AB
AF Schroll, Monica M.
   Liu, Xin
   Herzog, Sarah K.
   Skube, Susan B.
   Hummon, Amanda B.
TI Nutrient restriction of glucose or serum results in similar proteomic
   expression changes in 3D colon cancer cell cultures
SO NUTRITION RESEARCH
LA English
DT Article
DE Nutrient restriction; Three dimensional cell culture; Autophagy;
   Apoptosis; Quantitative proteomics; Colorectal cancer
ID CALORIE RESTRICTION; PROTEIN; AUTOPHAGY; PREVENTION; GENE
AB Nutrient restriction, also known as caloric restriction, has been extensively examined for its positive impact on lifespan, immune system boost, and aging. In addition, nutrient restriction is implicated in decreasing cancer initiation and progression. Given the phenotypic changes associated with nutrient restriction, we hypothesized significant protein expression alterations must be associated with caloric restriction. To compare the molecular and phenotypic changes caused by glucose restriction and fetal bovine serum restriction there is need for an efficient model system. We establish 3-dimensional cell culture models, known as spheroids, in the HCT 116 colorectal cancer cell line as a high throughput model for studying the proteomic changes associated with nutrient restriction. Flow cytometry was used to assess apoptosis and autophagy levels in the spheroids under nutrient restriction. Isobaric tags for relative and absolute quantification and liquid chromatography tandem mass spectrometry were used to determine differential protein abundances between the nutrient restriction conditions. We identified specific proteins that have implications in cancer progression and metastasis that are differentially regulated by restriction of either glucose or serum. These proteins include the up regulation of sirtuin 1 and protein inhibitor of activated STAT 1 and down-regulation of multi-drug resistance protein and Zinc finger and BTB domain-containing protein 7A. The results indicate nutrient restriction causes lower apoptotic and higher autophagy rates in HCT 116 spheroids. In addition, proteins shown to be differentially regulated by both glucose and serum restriction were similarly regulated. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Schroll, Monica M.; Liu, Xin; Herzog, Sarah K.; Skube, Susan B.; Hummon, Amanda B.] Univ Notre Dame, Harper Canc Res Inst, Dept Chem & Biochem, Notre Dame, IN 46556 USA.
RP Hummon, AB (corresponding author), 251 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.
EM ahummon@nd.edu
OI Hummon, Amanda/0000-0002-1969-9013; Herzog, Sarah/0000-0003-3782-7389
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01GM110406];
   National Science Foundation (CAREER Award)National Science Foundation
   (NSF) [CHE-1351595]; Walther Cancer Foundation; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM110406, T32GM075762] Funding
   Source: NIH RePORTER
FX We thank the Notre Dame Mass Spectrometry and Proteomics Facility for
   their assistance. In addition, we thank Katelyn Ludwig for her
   helpfulness in procedures and data analysis and William Andrews for
   artwork assistance. This work was funded by the National Institutes of
   Health (R01GM110406), and the National Science Foundation (CAREER Award,
   CHE-1351595). The Walther Cancer Foundation provided salary support for
   ABH.
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dadakhujaev Shorafidinkhuja, 2014, Oncoscience, V1, P229
   Florey O, 2012, TRENDS CELL BIOL, V22, P374, DOI 10.1016/j.tcb.2012.04.005
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156
   Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x
   Kanfi Y, 2008, FEBS LETT, V582, P543, DOI 10.1016/j.febslet.2008.06.005
   Klement RJ, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-75
   Lee C, 2011, ONCOGENE, V30, P3305, DOI 10.1038/onc.2011.91
   Li H, 2011, IMAGING MASS SPECTRO, P8794
   Lin Zhenghong, 2013, Genes Cancer, V4, P97, DOI 10.1177/1947601912475079
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Liu X, 2013, EVALUATION THERAPEUT
   Liu X, 2015, ANAL CHEM, V87, P9508, DOI 10.1021/acs.analchem.5b00419
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203
   Meynet O, 2014, TRENDS MOL MED, V20, P419, DOI 10.1016/j.molmed.2014.05.001
   Mizushima N, 2011, ROLE ATG PROTEINS AU
   Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285
   Netherton SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013971
   Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113
   Nooter K, 1997, BRIT J CANCER, V76, P486, DOI 10.1038/bjc.1997.414
   Olivo-Marston SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094765
   Ong SE, 2005, NAT CHEM BIOL, V1, P252, DOI 10.1038/nchembio736
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Panieri E, 2010, AGING-US, V2, P487, DOI 10.18632/aging.100183
   Persidis A, 1999, NAT BIOTECHNOL, V17, P94, DOI 10.1038/5289
   Rabellino A, 2012, CANCER RES, V72, P2275, DOI 10.1158/0008-5472.CAN-11-3159
   Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105
   Romagnolo DF, 2012, J NUTR, V142, P225
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200
   Safdie FM, 2009, AGING-US, V1, P1, DOI DOI 10.18632/AGING.100114
   Stacey TTI, 2004, J CELL SCI, V117, P6071, DOI 10.1242/jcs.01526
   Sun LL, 2014, SCI REP-UK, V4, DOI 10.1038/srep04365
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   Tannenbaum A, 1942, CANCER RES, V12, P460
   Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375
   Wang J, 2006, J CHROMATOGR, P1759
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yagi R, 2011, ONCOGENE, V30, P1413, DOI 10.1038/onc.2010.522
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhang YY, 2013, CHEM REV, V113, P2343, DOI 10.1021/cr3003533
   Zhuang Y, 2014, PLOS ONE, V9
NR 50
TC 19
Z9 19
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD OCT
PY 2016
VL 36
IS 10
BP 1068
EP 1080
DI 10.1016/j.nutres.2016.08.002
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA EE0SG
UT WOS:000389288600003
PM 27865348
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Zou, Y
   Yan, C
   Zhang, HB
   Xu, JY
   Zhang, DY
   Huang, ZJ
   Zhang, YH
AF Zou, Yu
   Yan, Chang
   Zhang, Huibin
   Xu, Jinyi
   Zhang, Dayong
   Huang, Zhangjian
   Zhang, Yihua
TI Synthesis and evaluation of N-heteroaromatic ring-based analogs of
   piperlongumine as potent anticancer agents
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Piperlongumine; N-heteroaromatic ring; Solubility; Anticancer activity;
   ROS
ID DRUG DISCOVERY; DERIVATIVES; SOLUBILITY; DESIGN; CELLS
AB Piperlongumine (PL) selectively targets a wide spectrum of cancer cells and induces their death by triggering various pathways, including apoptosis, necrosis and autophagy. However, the poor solubility is a serious concern for intensive study and clinical application. We synthesized its analogs 1-9 by replacement of the trimethoxyphenyl of PL with an N-heteroaromatic ring and/or not introduction of 2-Cl. These compounds improved aqueous solubility and displayed potent anticancer activity. The most active compound 9 selectively enhanced ROS levels in colon cancer cells and inhibited the cell proliferation but sparing non-tumor colon cells. Importantly, 9 significantly repressed tumor growth in an HCT-116 xenograft mouse model, suggesting that these N-heteroaromatic ring-based analogs of PL warrant further investigation. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Zou, Yu; Yan, Chang; Zhang, Huibin; Xu, Jinyi; Zhang, Dayong; Huang, Zhangjian; Zhang, Yihua] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Zou, Yu; Yan, Chang; Zhang, Huibin; Zhang, Dayong; Huang, Zhangjian; Zhang, Yihua] China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 210009, Jiangsu, Peoples R China.
RP Huang, ZJ; Zhang, YH (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21372261, 81673305]; Jiangsu Province Funds
   for Distinguished Young Scientists [BK20160033]; Program for New Century
   Excellent Talents in UniversityProgram for New Century Excellent Talents
   in University (NCET) [NCET-13-1033]; Jiangsu Shuang Chuang team
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 21372261 and No. 81673305) and Jiangsu Province
   Funds for Distinguished Young Scientists (BK20160033). Part of the work
   was supported by the Program for New Century Excellent Talents in
   University (NCET-13-1033) and the Jiangsu Shuang Chuang team.
CR Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109
   Alelyunas YW, 2010, BIOORG MED CHEM LETT, V20, P7312, DOI 10.1016/j.bmcl.2010.10.068
   Alhassan A., 2016, PLOS ONE, V11
   Fofaria NM, 2016, INT J PHARMACEUT, V498, P12, DOI 10.1016/j.ijpharm.2015.11.045
   Gross G, 2012, INT J PHARMACEUT, V437, P103, DOI 10.1016/j.ijpharm.2012.07.071
   Kong EH, 2008, ONCOL REP, V20, P785, DOI 10.3892/or_00000075
   Ku SK, 2014, INFLAMM RES, V63, P369, DOI 10.1007/s00011-014-0708-6
   Liao Y, 2016, J MED CHEM, V59, P7974, DOI 10.1021/acs.jmedchem.6b00772
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Palucki M, 2010, J MED CHEM, V53, P5897, DOI 10.1021/jm1002638
   Park BS, 2008, PHYTOTHER RES, V22, P1195, DOI 10.1002/ptr.2432
   Punganuru SR, 2016, EUR J MED CHEM, V107, P233, DOI 10.1016/j.ejmech.2015.10.052
   Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167
   Seo YH, 2014, BIOORG MED CHEM LETT, V24, P5727, DOI 10.1016/j.bmcl.2014.10.054
   Wu YL, 2014, EUR J MED CHEM, V82, P545, DOI 10.1016/j.ejmech.2014.05.070
   Xie WH, 1997, MAR ENVIRON RES, V44, P429, DOI 10.1016/S0141-1136(97)00017-2
   Xiong XX, 2015, ACTA PHARMACOL SIN, V36, P362, DOI 10.1038/aps.2014.141
   Yan WJ, 2016, FREE RADICAL BIO MED, V97, P109, DOI 10.1016/j.freeradbiomed.2016.05.021
   Yang B, 2016, ENVIRON SCI POLLUT R, V23, P3399, DOI 10.1007/s11356-015-5544-x
   Zhang YJ, 2017, BIOORG MED CHEM LETT, V27, P2308, DOI 10.1016/j.bmcl.2017.04.035
NR 20
TC 19
Z9 20
U1 2
U2 21
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 29
PY 2017
VL 138
BP 313
EP 319
DI 10.1016/j.ejmech.2017.06.046
PG 7
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA FH6OQ
UT WOS:000411297000025
PM 28686911
DA 2022-04-25
ER

PT J
AU Liu, YQ
   Wang, GY
   Li, Y
   Zhao, Q
   Fan, LQ
   Tan, BB
   Li, BK
   Yu, B
   Xi, JC
AF Liu, Youqiang
   Wang, Guiying
   Li, Yong
   Zhao, Qun
   Fan, Liqiao
   Tan, Bibo
   Li, Baokun
   Yu, Bin
   Xi, Jinchuan
TI miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting
   Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal
   transition in colon cancer cells
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE miR-424-5p; epithelial; mesenchymal transition; 5-fluorouracil
   resistance; colon cancer; Src; focal adhesion kinase
ID EMT; INVASION; PROLIFERATION; AUTOPHAGY; MIGRATION; MARKERS; SRC
AB Objectives miR-424-5p negatively regulates various malignant biological behaviours in tumour cells. We explored the relationship between miR-424-5p and 5-fluorouracil resistance in colon cancer cells.
   Methods We developed 5-fluorouracil-resistant HT-29 cells and detected miR-424-5p expression using real-time fluorescence quantitative PCR. Cell viability was assessed using Cell Counting Kit-8 (CCK-8) assay. Immunofluorescence and western blotting were performed to determine protein levels. Apoptosis was detected by Annexin V-FITC/PI staining.
   Key findings miR-424-5p was downregulated in 5-fluorouracil-resistant HT-29 cells. A miR-424-5p mimic enhanced the sensitivity of the resistant cells to 5-fluorouracil, whereas a miR-424-5p inhibitor promoted 5-fluorouracil resistance in HT-29 cells. Furthermore, the miR-424-5p mimic downregulated vimentin and upregulated E-cadherin in 5-fluorouracil-resistant HT-29 cells, whereas the miR-424-5p inhibitor exhibited opposite effects. The miR-424-5p inhibitor significantly inhibited 5-fluorouracil-induced HT-29 cell apoptosis and Src and focal adhesion kinase phosphorylation, whereas the miR-424-5p mimic showed opposite effects. Pretreatment with Src inhibitor 1 or focal adhesion kinase inhibitor 2 blocked the increase in Src and focal adhesion kinase phosphorylation and vimentin expression level and the decrease in E-cadherin expression level in miR-424-5p inhibitor-exposed HT-29 cells.
   Conclusions miR-424-5p suppressed epithelial-mesenchymal transition by inhibiting the Src/focal adhesion kinase signalling pathway to reduce 5-fluorouracil resistance in colon cancer cells.
C1 [Liu, Youqiang; Wang, Guiying; Li, Yong; Zhao, Qun; Fan, Liqiao; Tan, Bibo; Li, Baokun; Yu, Bin; Xi, Jinchuan] Hebei Med Univ, Hosp 4, Shijiazhuang 050051, Hebei, Peoples R China.
   [Wang, Guiying] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China.
RP Li, Y (corresponding author), Hebei Med Univ, Hosp 4, Shijiazhuang 050051, Hebei, Peoples R China.
EM liyonghhm@aliyun.com
FU 2018 Hebei Province Key RD Plan [182777186]
FX This study was supported by 2018 Hebei Province Key R&D Plan (grant
   number 182777186).
CR Bozhkova Desislava M, 2019, Folia Med (Plovdiv), V61, P296, DOI 10.2478/folmed-2018-0082
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Dastmalchi N, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118239
   Demircioglu F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15104-3
   Devaud C, 2019, INT J CANCER, V145, P494, DOI 10.1002/ijc.32120
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Endo Y, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1687-4
   Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Hong X, 2019, INT J ONCOL, V54, P1676, DOI 10.3892/ijo.2019.4726
   Huang QH, 2017, NEUROSCI LETT, V661, P51, DOI 10.1016/j.neulet.2017.07.044
   Iderzorig T, 2018, BIOCHEM BIOPH RES CO, V496, P770, DOI 10.1016/j.bbrc.2018.01.069
   Kaehler C, 2014, NUCLEIC ACIDS RES, V42, P6436, DOI 10.1093/nar/gku264
   Kalbasi A, 2020, NAT REV IMMUNOL, V20, P25, DOI 10.1038/s41577-019-0218-4
   Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364
   Li W, 2016, DRUG RESIST UPDATE, V27, P14, DOI 10.1016/j.drup.2016.05.001
   Li YJ, 2019, ONCOTARGETS THER, V12, P10441, DOI 10.2147/OTT.S224325
   Liu JJ, 2018, CELL CYCLE, V17, P309, DOI 10.1080/15384101.2017.1407894
   Liu XL, 2019, MOL THER-ONCOLYTICS, V15, P248, DOI 10.1016/j.omto.2019.10.008
   Ma YX, 2016, CLIN PHARMACOKINET, V55, P1205, DOI 10.1007/s40262-016-0395-2
   Meng DX, 2018, BIOMED PHARMACOTHER, V108, P1617, DOI 10.1016/j.biopha.2018.10.005
   Odero-Marah V, 2018, ADV EXP MED BIOL, V1095, P101, DOI 10.1007/978-3-319-95693-0_6
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036
   Peng YS, 2020, CELL BIOL TOXICOL, V36, P287, DOI 10.1007/s10565-019-09509-0
   Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003
   Sahami-Fard MH, 2019, CANCER BIOMARK, V24, P291, DOI 10.3233/CBM-182171
   Suarez-Carmona M, 2017, MOL ONCOL, V11, P805, DOI 10.1002/1878-0261.12095
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Teng F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01739-z
   Wang JW, 2018, BIOMED PHARMACOTHER, V97, P1066, DOI 10.1016/j.biopha.2017.11.034
   Wang RF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0995-9
   Wazzan N, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-019-4147-8
   Wu JB, 2019, INT J BIOL SCI, V15, P1591, DOI 10.7150/ijbs.34113
   Yuan L, 2018, BIOMED PHARMACOTHER, V108, P184, DOI 10.1016/j.biopha.2018.08.165
   Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248
   Zhao J, 2014, INT BRAZ J UROL, V40, P179, DOI 10.1590/S1677-5538.IBJU.2014.02.07
NR 38
TC 1
Z9 1
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD AUG
PY 2021
VL 73
IS 8
BP 1062
EP 1070
DI 10.1093/jpp/rgab031
EA MAR 2021
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TZ0ND
UT WOS:000684172200007
PM 33793771
DA 2022-04-25
ER

PT J
AU Chen, H
   Huang, JT
   Chen, CY
   Jiang, YM
   Feng, XZ
   Liao, Y
   Yang, ZL
AF Chen, Hao
   Huang, Jintuan
   Chen, Chunyu
   Jiang, Yingming
   Feng, Xingzhi
   Liao, Yi
   Yang, Zuli
TI NGFR Increases the Chemosensitivity of Colorectal Cancer Cells by
   Enhancing the Apoptotic and Autophagic Effects of 5-fluorouracil via the
   Activation of S100A9
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; NGFR; apoptosis; autophagy; chemosensitivity
ID DEATH
AB Colorectal cancer (CRC) is currently the third leading cause of cancer-related deaths worldwide, and 5-fluorouracil (5-FU)-based chemotherapies serve as important adjuvant therapies before and after surgery for CRC. However, the efficacy of CRC chemotherapy is limited by chemoresistance, and therefore the discovery of novel markers to indicate chemosensitivity is essential. Nerve growth factor receptor (NGFR), a cell surface receptor, is involved in cell death and survival. Our previous study indicated that NGFR acts as a tumor suppressor, and high expression is associated with better outcomes in patients receiving 5-FU-based adjuvant chemotherapy after surgery. The aim of this study was to investigate the effect of NGFR on the chemotherapeutic response in CRC. Chemosensitivity was investigated using DLD1 and HCT8 cells after NGFR transfection. Apoptosis was investigated by flow cytometry. Autophagy was assessed using GFP-LC3B transient transfection. Gene expression was measured using an mRNA microarray. Beclin-1 and Bcl-2 protein expressions were assessed by western blot. NGFR and S100 calcium-binding protein A9 (S100A9) expressions in CRC patients were investigated by immunohistochemistry. The results showed that the half maximal inhibitory concentration of NGFR-transfected cells was lower than that of controls in DLD1 and HCT8 cells after 5-FU treatment, and cell viability was lower than in empty-vector cells. Tumor sizes were also smaller than in empty-vector cells in vivo. The percentages of apoptotic and autophagic cells were higher in NGFR-transfected cells. NGFR elevated the expression of S100A9 after 5-FU treatment. The combination of Bcl-2 and Beclin-1 was significantly suppressed by overexpressed NGFR. Five-year overall and disease-free survival in NGFR+/S100A9+ patients was better than in NGFR-/S100A9- patients. This study's findings suggest that NGFR may serve as a marker predicting CRC patients' chemosensitivity.
C1 [Chen, Hao; Huang, Jintuan; Chen, Chunyu; Jiang, Yingming; Liao, Yi; Yang, Zuli] Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Hosp 6, Guangzhou, Peoples R China.
   [Feng, Xingzhi] Sun Yat Sen Univ, Guangdong Inst Gastroenterol, Affiliated Hosp 6, Guangzhou, Peoples R China.
RP Yang, ZL (corresponding author), Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Hosp 6, Guangzhou, Peoples R China.
EM yangzuli@mail.sysu.edu.cn
FU National Key Clinical Discipline; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81802322,
   81772594, 81902949]; Science and Technology Program of Guangzhou
   [201803010095]; Natural Science Foundation of Guangdong Province,
   ChinaNational Natural Science Foundation of Guangdong Province
   [2019A1515011723]; Medical Scientific Research Foundation of Guangdong
   Province, China [A2019483]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [19ykpy09]
FX This work was supported by grants from the National Key Clinical
   Discipline, the National Natural Science Foundation of China (Grant no.
   81802322 & Grant no. 81772594 & Grant no. 81902949), the Science and
   Technology Program of Guangzhou (Grant no. 201803010095), Natural
   Science Foundation of Guangdong Province, China (Grant No.
   2019A1515011723), Medical Scientific Research Foundation of Guangdong
   Province, China (Grant No. A2019483) and also supported by the
   Fundamental Research Funds for the Central Universities (Grant no.
   19ykpy09).
CR Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bulk E, 2009, CLIN CANCER RES, V15, P22, DOI 10.1158/1078-0432.CCR-08-0953
   Chakravarthy R, 2016, BIOCHEM BIOPH RES CO, V478, P1541, DOI 10.1016/j.bbrc.2016.08.149
   Chen Y, 2009, J INT MED RES, V37, P281, DOI 10.1177/147323000903700201
   Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997
   Dahlmann M, 2012, ONCOTARGET, V3, P783, DOI 10.18632/oncotarget.572
   Deol YS, 2011, J BIOL CHEM, V286, P44845, DOI 10.1074/jbc.M111.225466
   Ding QQ, 2011, J CLIN INVEST, V121, P4526, DOI 10.1172/JCI45008
   Ferraro E, 2007, ARCH BIOCHEM BIOPHYS, V462, P210, DOI 10.1016/j.abb.2007.02.006
   Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170
   Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397
   Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129
   Ghavami S, 2008, BBA-MOL CELL RES, V1783, P297, DOI 10.1016/j.bbamcr.2007.10.015
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He YL, 2008, CANCER LETT, V268, P110, DOI 10.1016/j.canlet.2008.03.038
   Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394
   Jiang L, 2011, MOL MED, V17, P709, DOI 10.2119/molmed.2011.00008
   Jin HF, 2007, NEOPLASIA, V9, P471, DOI 10.1593/neo.07175
   Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje
   Khwaja F, 2006, BIOCHEM BIOPH RES CO, V341, P1184, DOI 10.1016/j.bbrc.2006.01.073
   Khwaja F, 2003, MOL CARCINOGEN, V36, P153, DOI 10.1002/mc.10106
   Khwaja FS, 2009, CANCER PREV RES, V2, P566, DOI 10.1158/1940-6207.CAPR-08-0202
   Krygier S, 2002, INT J CANCER, V98, P1, DOI 10.1002/ijc.10160
   Li CS, 2009, BIOCHEM J, V422, P363, DOI 10.1042/BJ20090465
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Marchetti D, 2004, J CELL BIOCHEM, V91, P206, DOI 10.1002/jcb.10649
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Rocha AS, 2006, HUM PATHOL, V37, P562, DOI 10.1016/j.humpath.2005.12.016
   Rossi D, 2003, HAEMATOLOGICA, V88, P212
   Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006
   Shin S, 2013, ONCOL REP, V29, P306, DOI 10.3892/or.2012.2079
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Tabassum A, 2003, INT J CANCER, V105, P47, DOI 10.1002/ijc.11038
   Truzzi F, 2008, J INVEST DERMATOL, V128, P2031, DOI 10.1038/jid.2008.21
   Tsai WC, 2006, MOL CANCER RES, V4, P539, DOI 10.1158/1541-7786.MCR-05-0266
   Yang ZL, 2015, MOL CANCER RES, V13, P107, DOI 10.1158/1541-7786.MCR-13-0247
NR 43
TC 0
Z9 0
U1 2
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 30
PY 2021
VL 11
AR 652081
DI 10.3389/fonc.2021.652081
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SB5OJ
UT WOS:000650043000001
PM 33996571
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chang, SH
   Minai-Tehrani, A
   Shin, JY
   Park, S
   Kim, JE
   Yu, KN
   Hong, SH
   Hong, CM
   Lee, KH
   Beck, GR
   Cho, MH
AF Chang, Seung-Hee
   Minai-Tehrani, Arash
   Shin, Ji-Young
   Park, Sungjin
   Kim, Ji-Eun
   Yu, Kyeong-Nam
   Hong, Seong-Ho
   Hong, Choong-Man
   Lee, Kee-Ho
   Beck, George R., Jr.
   Cho, Myung-Haing
TI Beclin1-induced Autophagy Abrogates Radioresistance of Lung Cancer Cells
   by Suppressing Osteopontin
SO JOURNAL OF RADIATION RESEARCH
LA English
DT Article
DE Osteopontin(OPN); Beclin-1(BECN1); Gamma-irradiation; p53; Angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; BREAST-CANCER; IN-VIVO; GENE;
   METASTASIS; EXPRESSION; APOPTOSIS; PROMOTER; COLON
AB Osteopontin (OPN) serves as an indicator of resistance to radiotherapy. However, the role of OPN in the development of acquired radioresistance in human lung cancer cells has not yet been fully elucidated. Therefore, the potential importance of OPN as a marker of lung cancer with a potential significant role in the development of radioresistance against repeated radiotherapy has prompted us to define the pathways by which OPN regulates lung cancer cell growth. In addition, autophagy has been reported to play a key role in the radiosensitization of cancer cells. Here, we report that increased OPN expression through induction of nuclear p53 following irradiation was inhibited by exogenous beclin-1 (BECN1). Our results clearly show that BECN1 gene expression led to induction of autophagy and inhibition of cancer cell growth and angiogenesis. Our results suggest that the induction of autophagy abrogated the radioresistance of the cancer cells. Interestingly, we showed that knockdown of OPN by lentivirus-mediated shRNA induced the autophagy of human lung cancer cell. Taken together, these results suggest that OPN and BECN1 can be molecular targets for overcoming radioresistance by controlling autophagy.
C1 [Chang, Seung-Hee; Minai-Tehrani, Arash; Shin, Ji-Young; Park, Sungjin; Kim, Ji-Eun; Yu, Kyeong-Nam; Hong, Seong-Ho; Cho, Myung-Haing] Seoul Natl Univ, Coll Vet Med, Toxicol Lab, Seoul 151742, South Korea.
   [Kim, Ji-Eun; Cho, Myung-Haing] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Nanofus Technol, Seoul 151742, South Korea.
   [Hong, Choong-Man] Osong Hlth Technol Adm Complex, Div Med Device Management, Cheongwon 363700, South Korea.
   [Lee, Kee-Ho] Korea Inst Radiol & Med Sci, Lab Radiat Mol Oncol, Seoul 139709, South Korea.
   [Beck, George R., Jr.] Emory Univ, Sch Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [Cho, Myung-Haing] Seoul Natl Univ, Grad Grp Tumor Biol, Seoul 151742, South Korea.
   [Cho, Myung-Haing] Seoul Natl Univ, Natl Inst Food & Drug Safety, Ctr Food Safety & Toxicol, Seoul 151742, South Korea.
   [Cho, Myung-Haing] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 443270, South Korea.
RP Cho, MH (corresponding author), Seoul Natl Univ, Coll Vet Med, Toxicol Lab, Seoul 151742, South Korea.
EM mchotox@snu.ac.kr
RI Cho, Myung-Haing/B-7362-2014; Beck, George/AAO-2117-2020
OI Cho, Myung-Haing/0000-0002-3993-2011; Park, Sungjin/0000-0001-5801-5537
FU National Research Foundation of the Ministry of Education, Science and
   Technology (MEST) in Korea [NRF-2012-0000102]; Research Institute for
   Veterinary Science, Seoul National University; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R03CA136059, R01CA136716] Funding Source: NIH RePORTER
FX This work was supported by the National Research Foundation
   (NRF-2012-0000102) of the Ministry of Education, Science and Technology
   (MEST) in Korea. M.H. CHO was also partially supported by the Research
   Institute for Veterinary Science, Seoul National University.
CR Agrawal D, 2002, J NATL CANCER I, V94, P513
   Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931
   Berry DL, CELL, V131, P1137
   Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126
   Chang YS, 2007, LUNG CANCER, V57, P373, DOI 10.1016/j.lungcan.2007.04.005
   CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404
   Donati V, 2005, CLIN CANCER RES, V11, P6459, DOI 10.1158/1078-0432.CCR-05-0541
   Du YL, 2009, AUTOPHAGY, V5, P663, DOI 10.4161/auto.5.5.8377
   Fedarko NS, 2001, CLIN CANCER RES, V7, P4060
   Hahnel A, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-82
   HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255
   Hirama M, 2003, CANCER LETT, V198, P107, DOI 10.1016/S0304-3835(03)00286-6
   Jaboin JJ, 2009, METHOD ENZYMOL, V453, P287, DOI 10.1016/S0076-6879(08)04014-7
   Jin H, 2008, CANCER GENE THER, V15, P275, DOI 10.1038/sj.cgt.7701116
   Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Mack PC, 2008, J CLIN ONCOL, V26, P4771, DOI 10.1200/JCO.2008.17.0662
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020
   Rangaswami H, 2007, ONCOL REP, V18, P909
   Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007
   Rieber M, 2008, CANCER BIOL THER, V7, P1561, DOI 10.4161/cbt.7.10.6540
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Senger DR, 1996, AM J PATHOL, V149, P293
   Shen CX, 2003, FEBS LETT, V539, P111, DOI 10.1016/S0014-5793(03)00209-6
   Solberg TD, 2008, INT J RADIAT ONCOL, V72, P918, DOI 10.1016/j.ijrobp.2008.06.1925
   Sun BS, 2008, HEPATOLOGY, V48, P1834, DOI 10.1002/hep.22531
   Thalmann GN, 1999, CLIN CANCER RES, V5, P2271
   Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781
   Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V
   Wai PY, 2005, CARCINOGENESIS, V26, P741, DOI 10.1093/carcin/bgi027
   Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3
NR 38
TC 33
Z9 40
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0449-3060
J9 J RADIAT RES
JI J. Radiat. Res.
PD MAY
PY 2012
VL 53
IS 3
BP 422
EP 432
DI 10.1269/jrr.11148
PG 11
WC Biology; Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Oncology; Radiology, Nuclear
   Medicine & Medical Imaging
GA 984NH
UT WOS:000307196500010
PM 22481206
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, CD
   Ma, YP
   Hu, QW
   Xie, TT
   Wu, JY
   Zeng, F
   Song, FZ
AF Wang, Changdong
   Ma, Yongping
   Hu, Qiongwen
   Xie, Tingting
   Wu, Jiayan
   Zeng, Fan
   Song, Fangzhou
TI Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy
   system induces FasL and TNFR2 mediated antitumor apoptosis in solid
   tumors
SO BMC CANCER
LA English
DT Article
DE Tumor gene therapy; Bifidobacterium; Apoptosis; Thymidine kinase;
   Ganciclovir
ID COLON-CANCER CELLS; BINDING PROTEIN-6; DELIVERY-SYSTEM; BLADDER-CANCER;
   OVARIAN-CANCER; ACTIVATION; ADENOVIRUS; DEATH; NECROPTOSIS; EXPRESSION
AB Background: Directly targeting therapeutic suicide gene to a solid tumor is a hopeful approach for cancer gene therapy. Treatment of a solid tumor by an effective vector for a suicide gene remains a challenge. Given the lack of effective treatments, we constructed a bifidobacterial recombinant thymidine kinase (BF-rTK) -ganciclovir (GCV) targeting system (BKV) to meet this requirement and to explore antitumor mechanisms.
   Methods: Bifidobacterium (BF) or BF-rTK was injected intratumorally with or without ganciclovir in a human colo320 intestinal xenograft tumor model. The tumor tissues were analyzed using apoptosis antibody arrays, real time PCR and western blot. The colo320 cell was analyzed by the gene silencing method. Autophagy and necroptosis were also detected in colo320 cell. Meanwhile, three human digestive system xenograft tumor models (colorectal cancer colo320, gastric cancer MKN-45 and liver cancer SSMC-7721) and a breast cancer (MDA-MB-231) model were employed to validate the universality of BF-rTK + GCV in solid tumor gene therapy. The survival rate was evaluated in three human cancer models after the BF-rTK + GCV intratumor treatment. The analysis of inflammatory markers (TNF-alpha) in tumor indicated that BF-rTK + GCV significantly inhibited TNF-alpha expression.
   Results: The results suggested that BF-rTK + GCV induced tumor apoptosis without autophagy and necroptosis occurrence. The apoptosis was transduced by multiple signaling pathways mediated by FasL and TNFR2 and mainly activated the mitochondrial control of apoptosis via Bid and Bim, which was rescued by silencing Bid or/and Bim. However, BF + GCV only induced apoptosis via Fas/FasL signal pathway accompanied with increased P53 expression. We further found that BF-rTK + GCV inhibited the expression of the inflammatory maker of TNF-alpha. However, BF-rTK + GCV did not result in necroptosis and autophagy.
   Conclusions: BF-rTK + GCV induced tumor apoptosis mediated by FasL and TNFR2 through the mitochondrial control of apoptosis via Bid and Bim without inducing necroptosis and autophagy. Furthermore, BF-rTK + GCV showed to repress the inflammation of tumor through downregulating TNF-alpha expression. Survival analysis results of multiple cancer models confirmed that BF-rTK + GCV system has a wide field of application in solid tumor gene therapy.
C1 [Wang, Changdong; Ma, Yongping; Hu, Qiongwen; Xie, Tingting; Wu, Jiayan; Zeng, Fan; Song, Fangzhou] Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Yi XueYuan Rd 1, Chongqing 400016, Peoples R China.
RP Ma, YP (corresponding author), Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Yi XueYuan Rd 1, Chongqing 400016, Peoples R China.
EM yongpingm@yahoo.com
FU Chongqing Science & Technology Commission (CSTC)Natural Science
   Foundation Project of CQ CSTC [2011BB5125]; National Natural Science
   Foundation of China (NSFC)National Natural Science Foundation of China
   (NSFC) [30972585]
FX This work was supported by grants from Chongqing Science & Technology
   Commission (CSTC no. 2011BB5125); The construction of pBEX plasmid was
   supported by grants from the National Natural Science Foundation of
   China (NSFC no. 30972585).
CR Asahara T, 2001, J APPL MICROBIOL, V91, P985, DOI 10.1046/j.1365-2672.2001.01461.x
   Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009
   Boucher PD, 2000, CANCER RES, V60, P1631
   Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x
   Chow WL, 2008, BRIT J NUTR, V99, P449, DOI 10.1017/S0007114507812062
   Ding ZY, 2013, TUMOR BIOL, V34, P683, DOI 10.1007/s13277-012-0596-8
   Freund CTF, 2000, ANTICANCER RES, V20, P1359
   Galheigo MR, 2016, PROSTATE, V28
   Gallicchio MA, 2001, INT J CANCER, V94, P645, DOI 10.1002/ijc.1519
   Grellier P, 2002, J ENDOCRINOL, V172, P467, DOI 10.1677/joe.0.1720467
   Iosef C, 2008, ENDOCRINOLOGY, V149, P1214, DOI 10.1210/en.2007-0959
   Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003
   Kang BPS, 2003, AM J PHYSIOL-RENAL, V285, pF1013, DOI 10.1152/ajprenal.00209.2003
   Kieback D. G., 2008, Cancer Genomics & Proteomics, V5, P311
   Kircheis R, 1992, Eur Cytokine Netw, V3, P381
   Leinonen HM, 2012, CANCER RES, V72, P6227, DOI 10.1158/0008-5472.CAN-12-1166
   Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7
   Ma YP, 2012, MICROBIOL-SGM, V158, P498, DOI 10.1099/mic.0.049932-0
   Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011
   Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b
   Matthews K, 2009, CLIN CANCER RES, V15, P4131, DOI 10.1158/1078-0432.CCR-08-3354
   Mercer KE, 2002, PROTEIN ENG, V15, P903, DOI 10.1093/protein/15.11.903
   Noy R, 2002, MOL CANCER THER, V1, P585
   Park JH, 2002, CELL IMMUNOL, V219, P22, DOI 10.1016/S0008-8749(02)00579-8
   Philippe D, 2011, INT J FOOD MICROBIOL, V149, P45, DOI 10.1016/j.ijfoodmicro.2010.12.020
   Saha S, 2016, CANCER RES, V3, P3
   Spagnoli A, 2002, J BIOL CHEM, V277, P18860, DOI 10.1074/jbc.M200218200
   Tang W, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-155
   Wang HE, 2006, J NUCL MED, V47, P1161
   Wolczyk D, 2016, CELL ONCOL, V4, P4
   Xiao X, 2014, UROLOGY, V84, DOI 10.1016/j.urology.2014.05.020
   Xu YF, 2007, CANCER GENE THER, V14, P151, DOI 10.1038/sj.cgt.7701003
   Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x
   Yazawa K, 2001, BREAST CANCER RES TR, V66, P165, DOI 10.1023/A:1010644217648
   Yildirim Z, 1999, J APPL MICROBIOL, V86, P45, DOI 10.1046/j.1365-2672.1999.00629.x
NR 35
TC 9
Z9 11
U1 2
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 27
PY 2016
VL 16
AR 545
DI 10.1186/s12885-016-2608-3
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DT0VF
UT WOS:000381200400006
PM 27464624
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Garofalo, M
   Iovine, B
   Kuryk, L
   Capasso, C
   Hirvinen, M
   Vitale, A
   Yliperttula, M
   Bevilacqua, MA
   Cerullo, V
AF Garofalo, Mariangela
   Iovine, Barbara
   Kuryk, Lukasz
   Capasso, Cristian
   Hirvinen, Mari
   Vitale, Andrea
   Yliperttula, Marjo
   Bevilacqua, Maria Assunta
   Cerullo, Vincenzo
TI Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to
   Enhance the Antitumor Activity
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID LUNG-CANCER CELLS; IN-VIVO; MODEL; PROLIFERATION; AUTOPHAGY; INHIBITION;
   ENDOSTATIN; GROWTH; MICE
AB Oncolytic viruses are able to specifically replicate, infect, and kill only cancer cells. Their combination with chemotherapeutic drugs has shown promising results due to the synergistic action of virus and drugs; the combinatorial therapy is considered a potential clinically relevant approach for cancer. In this study, we optimized a strategy to absorb peptides on the viral capsid, based on electrostatic interaction, and used this strategy to deliver an active antitumor drug. We used L-carnosine, a naturally occurring histidine dipeptide with a significant antiproliferative activity. An ad hoc modified, positively charged L-carnosine was combined with the capsid of an oncolytic adenovirus to generate an electrostatic virus-carnosine complex. This complex showed enhanced antitumor efficacy in vitro and in vivo in different tumor models. In HCT-116 colorectal and A549 lung cancer cell lines, the complex showed higher transduction ratio and infectious titer compared with an uncoated oncolytic adenovirus. The in vivo efficacy of the complex was tested in lung and colon cancer xenograft models, showing a significant reduction in tumor growth. Importantly, we investigated the molecular mechanisms underlying the effects of complex on tumor growth reduction. We found that complex induces apoptosis in both cell lines, by using two different mechanisms, enhancing viral replication and affecting the expression of Hsp27. Our system could be used in future studies also for delivery of other bioactive drugs. (C) 2016 AACR.
C1 [Garofalo, Mariangela; Kuryk, Lukasz; Capasso, Cristian; Hirvinen, Mari; Cerullo, Vincenzo] Univ Helsinki, Lab ImmunoViroTherapy, Div Pharmaceut Biosci, CDR,Fac Pharm, Helsinki 00790, Finland.
   [Garofalo, Mariangela; Iovine, Barbara; Bevilacqua, Maria Assunta] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.
   [Kuryk, Lukasz] Oncos Therapeut Ltd, Helsinki, Finland.
   [Kuryk, Lukasz] Natl Inst Hyg, Dept Virol, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland.
   [Vitale, Andrea] Univ Naples Parthenope, Dept Movement Sci & Wellness DiSMEB, Naples, Italy.
   [Vitale, Andrea] CEINGE Biotecnol Avanzate, Naples, Italy.
   [Yliperttula, Marjo] Univ Helsinki, Div Pharmaceut Biosci, Helsinki 00790, Finland.
   [Yliperttula, Marjo] Univ Helsinki, Ctr Drug Res, Helsinki 00790, Finland.
RP Cerullo, V (corresponding author), Univ Helsinki, POB 56, Helsinki 00790, Finland.
EM vincenzo.cerullo@helsinki.fi
RI Kuryk, Lukasz/D-9596-2018; Garofalo, Mariangela/Q-9469-2018; Cerullo,
   Vincenzo/B-9075-2015
OI Kuryk, Lukasz/0000-0003-1887-6361; Garofalo,
   Mariangela/0000-0002-5001-7826; Cerullo, Vincenzo/0000-0003-4901-3796
FU University of Helsinki; K. Albin Johansson Foundation; Foundation for
   the Finnish Cancer Institute; CDR; Division of Pharmaceutical
   Biosciences (University of Helsinki); Doctoral School BCMB University of
   Naples Federico II; CREME grant [CUP B25B09000050007]; Marie Curie
   Innovative Training Network (ITN) grant, ADVance [FP7-290002]
FX V. Cerullo was supported by the three-year research grant (University of
   Helsinki), K. Albin Johansson Foundation, Foundation for the Finnish
   Cancer Institute, CDR, and Division of Pharmaceutical Biosciences
   (University of Helsinki). M. Garofalo was supported by Doctoral School
   BCMB University of Naples Federico II. A. Vitale was supported by CREME
   grant, CUP B25B09000050007. L. Kuryk was supported by Marie Curie
   Innovative Training Network (ITN) grant, ADVance (FP7-290002).
CR Bertin S, 2008, AUTOPHAGY, V4, P1086, DOI 10.4161/auto.7138
   Bressy C, 2014, BIOCHEM PHARMACOL, V90, P97, DOI 10.1016/j.bcp.2014.05.003
   Capasso C, 2015, ONCOIMMUNOLOGY  1029
   Capasso C, 2014, MOL THER, V22, pS190
   Capasso C, 2014, VIRUSES-BASEL, V6, P832, DOI 10.3390/v6020832
   Cerullo V, 2012, MOL THER, V20, P2076, DOI 10.1038/mt.2012.137
   Cerullo V, 2012, ADV CANCER RES, V115, P265, DOI 10.1016/B978-0-12-398342-8.00008-2
   Cheng PH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-293
   Diaz R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-188
   Farzad L, 2014, MOL THERAPY ONCOLYTI, P1
   Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479
   Guiotto A, 2005, CURR MED CHEM, V12, P2293, DOI 10.2174/0929867054864796
   Hayashi R, 2012, ONCOL REP, V28, P1269, DOI 10.3892/or.2012.1935
   Horii Y, 2012, NEUROSCI LETT, V510, P1, DOI 10.1016/j.neulet.2011.12.058
   Iovine B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096755
   Iovine B, 2012, CANCER LETT, V315, P122, DOI 10.1016/j.canlet.2011.07.021
   Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10
   Koski A, 2010, MOL THER, V18, P1874, DOI 10.1038/mt.2010.161
   Lelj-Garolla B, 2015, MOL CANCER THER, V14, P1107, DOI 10.1158/1535-7163.MCT-14-0866
   Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mullen JT, 2003, ANN SURG ONCOL, V10, P596, DOI 10.1245/ASO.2003.07.020
   Pesonen S, 2011, MOL PHARMACEUT, V8, P12, DOI 10.1021/mp100219n
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Rajaiya J, 2012, BIOCHEMISTRY-US, V51, P5695, DOI 10.1021/bi3007127
   Renner C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-2
   Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-70
   Sjostrom J, 2001, BRIT MED J, V322, P1538, DOI 10.1136/bmj.322.7301.1538
   Wang C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-44
   Wonganan P, 2010, VIRUSES-BASEL, V2, P468, DOI 10.3390/v2020468
   Xu HR, 2011, ONCOL LETT, V2, P773, DOI 10.3892/ol.2011.334
   Yokoyama Y, 2000, CANCER RES, V60, P2190
   Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579
   Zhang ZW, 2014, J CANCER, V5, P382, DOI 10.7150/jca.8024
NR 34
TC 30
Z9 33
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD APR
PY 2016
VL 15
IS 4
BP 651
EP 660
DI 10.1158/1535-7163.MCT-15-0559
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DI6GD
UT WOS:000373596300011
PM 26861248
DA 2022-04-25
ER

PT J
AU Fang, LM
   Li, B
   Guan, JJ
   Xu, HD
   Shen, GH
   Gao, QG
   Qin, ZH
AF Fang, Li-mei
   Li, Bin
   Guan, Jun-jie
   Xu, Hai-dong
   Shen, Gen-hai
   Gao, Quan-gen
   Qin, Zheng-hong
TI Transcription factor EB is involved in autophagy-mediated
   chemoresistance to doxorubicin in human cancer cells
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE transcription factor EB (TFEB); LoVo cells; HeLa cells; doxorubicin;
   autophagy; apoptosis; chemotherapy resistance; 3-methyladenine
ID LYSOSOMAL BIOGENESIS; DRUG-RESISTANCE; ATG PROTEINS; TUMORIGENESIS;
   APOPTOSIS; BECLIN-1; GENE; INHIBITION; METABOLISM; MECHANISMS
AB Transcription factor EB (TFEB) is a master regulator of autophagy activity and lysosomal biogenesis, but its role in autophagy-mediated cell survival and chemotherapy resistance is not completely understood. In this study, we explored whether TFEB played an important role in autophagy-mediated chemotherapy resistance in human cancer LoVo and HeLa cells in vitro. Treatment of human colon cancer LoVo cells with doxorubicin (0.5 mu mol/L) induced autophagy activation and nuclear translocation of TFEB, which resulted from inactivation of the mTOR pathway. In both LoVo and HeLa cells, overexpression of TFEB enhanced doxorubicin-induced autophagy activation and significantly decreased doxorubicin-induced cell death, whereas knockdown of TFEB with small interfering RNA blocked doxorubicin-induced autophagy and significantly enhanced the cytotoxicity of doxorubicin. In LoVo cells, autophagy inhibition by 3-methyladenine (3-MA) or knockdown of autophagy-related gene Atg5 increased cell death in response to doxorubicin, and abolished TFEB overexpression-induced chemotherapy resistance, suggesting that the inhibition of autophagy made cancer cells more sensitive to doxorubicin. The results demonstrate that TFEB-mediated autophagy activation decreases the sensitivity of cancer cells to doxorubicin.
C1 [Fang, Li-mei; Guan, Jun-jie; Xu, Hai-dong; Qin, Zheng-hong] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215123, Peoples R China.
   [Fang, Li-mei; Guan, Jun-jie; Xu, Hai-dong; Qin, Zheng-hong] Soochow Univ, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Jiangsu Key Lab Translat Res & Therapy Neuropsych, Coll Pharmaceut Sci,Lab Aging & Nervous Dis, Suzhou 215123, Peoples R China.
   [Li, Bin; Shen, Gen-hai; Gao, Quan-gen] First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
RP Qin, ZH (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215123, Peoples R China.; Qin, ZH (corresponding author), Soochow Univ, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Jiangsu Key Lab Translat Res & Therapy Neuropsych, Coll Pharmaceut Sci,Lab Aging & Nervous Dis, Suzhou 215123, Peoples R China.; Gao, QG (corresponding author), First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
EM wjyygqg@sohu.com; qinzhenhong@suda.edu.cn
RI Xu, Haidong/Q-1095-2019
FU Jiangsu Provincial Commission of Health and Family Planning [YG201402,
   YG201503]; Suzhou Wujiang District Science and Technology Bureau
   [WS201301]
FX This work was supported by the Jiangsu Provincial Commission of Health
   and Family Planning 2014 (No YG201402) and 2015 (No YG201503) as well as
   by Suzhou Wujiang District Science and Technology Bureau 2013 (No
   WS201301).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bestebroer J, 2013, TRAFFIC, V14, P1029, DOI 10.1111/tra.12091
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Klionsky DJ, 2014, AUTOPHAGY, V10, P715, DOI 10.4161/auto.28813
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Pan ST, 2016, CLIN EXP PHARMACOL P, V43, P723, DOI 10.1111/1440-1681.12581
   Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sardiello M, 2009, CELL CYCLE, V8, P4021, DOI 10.4161/cc.8.24.10263
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Vitale I, 2015, INT J DEV BIOL, V59, P95, DOI 10.1387/ijdb.150082iv
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Wesselborg S, 2015, CELL MOL LIFE SCI, V72, P4721, DOI 10.1007/s00018-015-2034-8
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Xie JM, 2014, CANCER RES, V74, P5127, DOI 10.1158/0008-5472.CAN-13-3517
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yu HP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09853
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhitomirsky B, 2015, ONCOTARGET, V6, P1143, DOI 10.18632/oncotarget.2732
NR 38
TC 28
Z9 28
U1 2
U2 10
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD SEP
PY 2017
VL 38
IS 9
BP 1305
EP 1316
DI 10.1038/aps.2017.25
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA FG7EJ
UT WOS:000410575900008
PM 28603284
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Fan, XJ
   Wan, XB
   Huang, Y
   Cai, HM
   Fu, XH
   Yang, ZL
   Chen, DK
   Song, SX
   Wu, PH
   Liu, Q
   Wang, L
   Wang, JP
AF Fan, X-J
   Wan, X-B
   Huang, Y.
   Cai, H-M
   Fu, X-H
   Yang, Z-L
   Chen, D-K
   Song, S-X
   Wu, P-H
   Liu, Q.
   Wang, L.
   Wang, J-P
TI Epithelial-mesenchymal transition biomarkers and support vector machine
   guided model in preoperatively predicting regional lymph node metastasis
   for rectal cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE SVM; EMT; regional lymph node metastasis; colorectal cancer
ID COLORECTAL-CANCER; TUMOR PROGRESSION; POOR-PROGNOSIS; EXPRESSION
   PROFILE; CARCINOMA; OVEREXPRESSION; TUMORIGENESIS; AUTOPHAGY; INVASION;
   BECLIN-1
AB BACKGROUND: Current imaging modalities are inadequate in preoperatively predicting regional lymph node metastasis (RLNM) status in rectal cancer (RC). Here, we designed support vector machine (SVM) model to address this issue by integrating epithelial-mesenchymal-transition (EMT)-related biomarkers along with clinicopathological variables.
   METHODS: Using tissue microarrays and immunohistochemistry, the EMT-related biomarkers expression was measured in 193 RC patients. Of which, 74 patients were assigned to the training set to select the robust variables for designing SVM model. The SVM model predictive value was validated in the testing set (119 patients).
   RESULTS: In training set, eight variables, including six EMT-related biomarkers and two clinicopathological variables, were selected to devise SVM model. In testing set, we identified 63 patients with high risk to RLNM and 56 patients with low risk. The sensitivity, specificity and overall accuracy of SVM in predicting RLNM were 68.3%, 81.1% and 72.3%, respectively. Importantly, multivariate logistic regression analysis showed that SVM model was indeed an independent predictor of RLNM status (odds ratio, 11.536; 95% confidence interval, 4.113-32.361; P < 0.0001).
   CONCLUSION: Our SVM-based model displayed moderately strong predictive power in defining the RLNM status in RC patients, providing an important approach to select RLNM high-risk subgroup for neoadjuvant chemoradiotherapy. British Journal of Cancer (2012) 106, 1735-1741. doi:10.1038/bjc.2012.82 www.bjcancer.com Published online 26 April 2012 (C) 2012 Cancer Research UK
C1 [Fan, X-J; Huang, Y.; Fu, X-H; Yang, Z-L; Chen, D-K; Song, S-X; Wu, P-H; Wang, L.; Wang, J-P] Sun Yat Sen Univ, Affiliated Hosp 6, Gastrointestinal Inst, Guangzhou 510655, Guangdong, Peoples R China.
   [Wan, X-B] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou 510630, Guangdong, Peoples R China.
   [Cai, H-M] Sun Yat Sen Univ, Sch Informat Sci & Technol, Guangzhou 510000, Guangdong, Peoples R China.
   [Liu, Q.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China.
RP Wang, JP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Gastrointestinal Inst, Guangzhou 510655, Guangdong, Peoples R China.
EM leiwangyinghu@yahoo.com.cn; wangjpgz@yahoo.com.cn
RI Chen, Dianke/E-2248-2011; Cai, Hongmin/M-8240-2019
OI Cai, Hongmin/0000-0002-2747-7234
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30872488, 81072042, 81001086, 81000934]
FX This work was supported by National Natural Science Foundation of China
   ( No. 30872488 and 81072042 to L Wang, No. 81001086 to XJ Fan and No.
   81000934 to XB Wan).
CR Anderson Billie, 2010, Front Biosci (Elite Ed), V2, P849
   Baumgart E, 2007, CLIN CANCER RES, V13, P1685, DOI 10.1158/1078-0432.CCR-06-2330
   Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947
   Bipat S, 2004, RADIOLOGY, V232, P773, DOI 10.1148/radiol.2323031368
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Catto JWF, 2009, CLIN CANCER RES, V15, P3150, DOI 10.1158/1078-0432.CCR-08-1960
   Dietzel M, 2010, ACTA RADIOL, V51, P885, DOI 10.3109/02841851.2010.504232
   Engelen SME, 2008, EJSO-EUR J SURG ONC, V34, P776, DOI 10.1016/j.ejso.2007.10.007
   Fang WF, 2009, HEPATO-GASTROENTEROL, V56, P663
   Fritzmann J, 2009, GASTROENTEROLOGY, V137, P165, DOI 10.1053/j.gastro.2009.03.041
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Huh JW, 2010, J GASTROINTEST SURG, V14, P1074, DOI 10.1007/s11605-010-1206-y
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kwon HC, 2004, DIS COLON RECTUM, V47, P141, DOI 10.1007/s10350-003-0032-7
   Leonard GD, 2005, J CLIN ONCOL, V23, P2038, DOI 10.1200/JCO.2005.00.349
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Low G, 2008, SURG-J R COLL SURG E, V6, P222, DOI 10.1016/S1479-666X(08)80032-7
   McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237
   Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666
   MINSKY BD, 1992, J CLIN ONCOL, V10, P1218, DOI 10.1200/JCO.1992.10.8.1218
   Mocellin S, 2006, ANN SURG ONCOL, V13, P1113, DOI 10.1245/ASO.2006.03.019
   Modlin IM, 2009, ANN SURG ONCOL, V16, P487, DOI 10.1245/s10434-008-0251-1
   Mroczko B, 2007, CLIN CHIM ACTA, V380, P208, DOI 10.1016/j.cca.2007.02.037
   Okada T, 2010, GENE CHROMOSOME CANC, V49, P452, DOI 10.1002/gcc.20755
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038
   Sattlecker M, 2010, ANALYST, V135, P895, DOI 10.1039/b920229c
   Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0
   Stojadinovic Alexander, 2010, Eplasty, V10, pe25
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x
   Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Watanabe T, 2009, DIS COLON RECTUM, V52, P1941, DOI 10.1007/DCR.0b013e3181b53684
   Zhu ZH, 2009, J CLIN ONCOL, V27, P1091, DOI 10.1200/JCO.2008.16.6991
NR 37
TC 16
Z9 16
U1 1
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 22
PY 2012
VL 106
IS 11
BP 1735
EP 1741
DI 10.1038/bjc.2012.82
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 946LQ
UT WOS:000304353500005
PM 22538975
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Banerjee, A
   Banerjee, V
   Czinn, S
   Blanchard, T
AF Banerjee, Aditi
   Banerjee, Vivekjyoti
   Czinn, Steven
   Blanchard, Thomas
TI Increased reactive oxygen species levels cause ER stress and
   cytotoxicity in andrographolide treated colon cancer cells
SO ONCOTARGET
LA English
DT Article
DE andrographolide; chemotherapy; reactive oxygen species; endoplasmic
   reticulum stress; unfolded protein response
ID UNFOLDED PROTEIN RESPONSE; AIRWAY EPITHELIAL-CELLS; MEDIATED APOPTOSIS;
   DOWN-REGULATION; BREAST-TUMOR; G2/M PHASE; V-SRC; DEATH; AUTOPHAGY;
   SUPPRESSION
AB Chemotherapy continues to play an essential role in the management of many cancers including colon cancer, the third leading cause of death due to cancer in the United States. Many naturally occurring plant compounds have been demonstrated to possess anti-cancer cell activity and have the potential to supplement existing chemotherapy strategies. The plant metabolite andrographolide induces cell death in cancer cells and apoptosis is dependent upon the induction of endoplasmic reticulum stress (ER stress) leading to the unfolded protein response (UPR). The goal of the present study was to determine the mechanism by which andrographolide induces ER stress and to further evaluate its role in promoting cell death pathways. The T84 and COLO 205 cancer cell lines were used to demonstrate that andrographolide induces increased ROS levels, corresponding anti-oxidant response molecules, and reduced mitochondrial membrane potential. No increases in ROS levels were detected in control colon fibroblast cells. Andrographolide-induced cell death, UPR signaling, and CHOP, Bax, and caspase 3 apoptosis elements were all inhibited in the presence of the ROS scavenger NAC. Additionally, andrographolide-induced suppression of cyclins B1 and D1 were also reversed in the presence of NAC. Finally, Akt phosphorylation and phospho-mTOR levels that are normally suppressed by andrographolide were also expressed at normal levels in the absence of ROS. These data demonstrate that andrographolide induces ER stress leading to apoptosis through the induction of ROS and that elevated ROS also play an important role in down-regulating cell cycle progression and cell survival pathways as well.
C1 [Banerjee, Aditi; Banerjee, Vivekjyoti; Czinn, Steven; Blanchard, Thomas] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
RP Banerjee, A (corresponding author), Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
EM abanerjee@peds.umaryland.edu
FU Department of Pediatrics at the University of Maryland School of
   Medicine
FX We wish to thank the Department of Pediatrics at the University of
   Maryland School of Medicine for supporting this research.
CR Banerjee A, 2016, ONCOTARGET, V7, P41432, DOI 10.18632/oncotarget.9180
   Banerjee A, 2011, J BIOL CHEM, V286, P29127, DOI 10.1074/jbc.M110.169771
   Chao CY, 2013, CARCINOGENESIS, V34, P1843, DOI 10.1093/carcin/bgt131
   Chao HP, 2010, PLANTA MED, V76, P1827, DOI 10.1055/s-0030-1250039
   Chen W, 2012, CARCINOGENESIS, V33, P2190, DOI 10.1093/carcin/bgs264
   Chen YY, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/821813
   De Marchi U, 2004, CELL MOL LIFE SCI, V61, P2664, DOI 10.1007/s00018-004-4236-3
   Dey SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058055
   Harjotaruno S, 2007, AFR J TRADIT COMPLEM, V4, P345
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hsieh MJ, 2015, ONCOTARGET, V6, P30831, DOI 10.18632/oncotarget.5036
   Jada SR, 2006, J ENZYM INHIB MED CH, V21, P145, DOI 10.1080/14756360500499988
   Ji L, 2007, PLANTA MED, V73, P1397, DOI 10.1055/s-2007-990230
   Kim B, 2016, MOL CARCINOGEN, V55, P918, DOI 10.1002/mc.22332
   Kim TG, 2005, IN VIVO, V19, P551
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kumar D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139657
   Kumar RA, 2004, J ETHNOPHARMACOL, V92, P291, DOI 10.1016/j.jep.2004.03.004
   Kumar S, 2012, CURR MOL MED, V12, P952, DOI 10.2174/156652412802480826
   Lee YC, 2010, EUR J PHARMACOL, V632, P23, DOI 10.1016/j.ejphar.2010.01.009
   Li J, 2015, ONCOTARGETS THER, V8, P427, DOI 10.2147/OTT.S76116
   Li JL, 2007, EUR J PHARMACOL, V568, P31, DOI 10.1016/j.ejphar.2007.04.027
   Li YC, 2012, LIFE SCI, V90, P962, DOI 10.1016/j.lfs.2012.04.044
   Liang FP, 2008, J BIOL CHEM, V283, P5023, DOI 10.1074/jbc.M705877200
   Lim JCW, 2012, CLIN EXP PHARMACOL P, V39, P300, DOI 10.1111/j.1440-1681.2011.05633.x
   Lin HH, 2014, TOXICOL SCI, V139, P108, DOI 10.1093/toxsci/kfu032
   Lin HH, 2011, TOXICOL APPL PHARM, V250, P336, DOI 10.1016/j.taap.2010.11.014
   Liu SH, 2014, BIOCHEM PHARMACOL, V87, P229, DOI 10.1016/j.bcp.2013.10.014
   Lu H, 2014, ENVIRON TOXICOL PHAR, V37, P718, DOI 10.1016/j.etap.2014.01.019
   Majumdar KN, 2008, ARTHRITIS RHEUM-US, V58, P696, DOI 10.1002/art.23295
   Manikam ST, 2009, J PHARM PHARMACOL, V61, P69, DOI [10.1211/jpp/61.01.0010, 10.1211/jpp.61.01.0010]
   Nita-Lazar M, 2015, MOL IMMUNOL, V68, P194, DOI 10.1016/j.molimm.2015.08.005
   Nita-Lazar M, 2015, MOL IMMUNOL, V65, P1, DOI 10.1016/j.molimm.2014.12.010
   Satyanarayana C, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-26
   Shiu J, 2015, MUCOSAL IMMUNOL, V8, P1047, DOI 10.1038/mi.2014.132
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Tan BJ, 2013, INT J ONCOL, V42, P1605, DOI 10.3892/ijo.2013.1843
   Wong CC, 2016, PHARMACOL RES, V107, P66, DOI 10.1016/j.phrs.2016.02.024
   World Health Organization, 2002, WHO MON SEL MED PLAN
   Yang SH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/312847
   Yang S, 2010, CLIN CANCER RES, V16, P4755, DOI 10.1158/1078-0432.CCR-10-0883
   Yang TF, 2016, DRUG DES DEV THER, V10, P1389, DOI 10.2147/DDDT.S94983
   Yuan H., 2016, IEEE T CYBERNETICS, VPP, P1, DOI [10.1109/TCYB.2016.2574766, DOI 10.1109/TCYB.2016.2574766]
   Zhao F, 2008, J ASIAN NAT PROD RES, V10, P473, DOI 10.1080/10286020801948599
   Zhu YY, 2013, PROTEOMICS, V13, P169, DOI 10.1002/pmic.201200273
   Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367
NR 47
TC 62
Z9 62
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 18
PY 2017
VL 8
IS 16
BP 26142
EP 26153
DI 10.18632/oncotarget.15393
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA ES8PQ
UT WOS:000399819700030
PM 28412728
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Hu, CX
   Cao, YB
   Li, P
   Tang, XR
   Yang, MH
   Gu, SL
   Xiong, K
   Li, T
   Xiao, TB
AF Hu, Changxiao
   Cao, Yibo
   Li, Ping
   Tang, Xiaorong
   Yang, Minhui
   Gu, Shengliang
   Xiong, Kai
   Li, Tian
   Xiao, Tianbao
TI Oleanolic Acid Induces Autophagy and Apoptosis via the AMPK-mTOR
   Signaling Pathway in Colon Cancer
SO JOURNAL OF ONCOLOGY
LA English
DT Article
ID GROWTH; PHOSPHORYLATION; CELLS
AB Aims. The purpose of this study was to explore the biological functions of the mTOR and AMPK signaling pathways in colon cancer (CC). The potential molecular mechanisms by which oleanolic acid (OA) induces autophagy and apoptosis were also investigated. Methods. The biological functions of mTOR were analyzed by GeneCards, the Search Tool for the Retrieval of Interacting Genes (STRING), and the Database for Annotation, Visualization and Integrated Discovery (DAVID). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to obtain prognostic and survival data of CC patients from the Gene Expression Omnibus (GEO) database. The effects of OA on the CC cell lines HCT-116 and SW-480 were analyzed by CCK-8, colony formation assay, and high-content system (HCS) array scan. The apoptosis rate of SW-480 and HCT-116 cells was detected by flow cytometry. The mRNA and protein expression levels in HCT-116 and SW-480 cells and NCM-460 normal colonic epithelial cells were detected by RT-PCR and Western blotting. Results. mTOR was highly expressed in CC patients and acted as an oncogene. The AMPK signaling pathway mediated by mTOR predicted the poor prognosis of CC patients. OA effectively inhibited the proliferation and viability of CC cells. Furthermore, the apoptosis rate of CC cells was clearly increased following OA administration. Regarding the molecular mechanism of OA, the results indicated that mTOR and the antiapoptosis gene Bcl-2 were downregulated by OA. In addition, regulator genes of autophagy and apoptosis, including BAX, caspase-9, caspase-8, and caspase-3, were significantly upregulated by OA. Moreover, OA upregulated AMPK and its downstream proteins, including TSC2, BAX, Beclin 1, LC3B-II, and ULK1, to induce autophagy and apoptosis in CC cells. Conclusion. The findings from this study demonstrate that OA could effectively inhibit the proliferation and viability of CC cells. The anti-CC activity of OA is closely related to the activation of the AMPK-mTOR signaling pathway. Activation of AMPK and inhibition of mTOR are involved in the induction of autophagy and apoptosis by OA. OA induced autophagy and apoptosis mainly in an AMPK activation-dependent manner in CC cells.
C1 [Hu, Changxiao; Yang, Minhui; Gu, Shengliang; Xiong, Kai] Guizhou Univ Tradit Chinese Med, Coll Clin Med, 71 Baoshan North Rd, Guiyang 550001, Peoples R China.
   [Cao, Yibo; Li, Ping; Tang, Xiaorong; Xiao, Tianbao] Guizhou Univ Tradit Chinese Med, Affiliated Hosp 1, Colorectal & Anal Surg, 71 Baoshan North Rd, Guiyang 550001, Peoples R China.
   [Li, Tian] Fourth Mil Med Univ, 169 Changle West Rd, Xian 710032, Peoples R China.
RP Xiao, TB (corresponding author), Guizhou Univ Tradit Chinese Med, Affiliated Hosp 1, Colorectal & Anal Surg, 71 Baoshan North Rd, Guiyang 550001, Peoples R China.; Li, T (corresponding author), Fourth Mil Med Univ, 169 Changle West Rd, Xian 710032, Peoples R China.
EM doc_huchangxiao@163.com; 47030959@qq.com; 418835868@qq.com;
   406817855@qq.com; 2726030816@qq.com; 850712786@qq.com;
   1255354266@qq.com; fmmult@foxmail.com; prof_xiaotianbao@163.com
OI Li, Tian/0000-0002-8281-4459
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81860854, 8186150460]; Science and
   Technology Projects of Guizhou Province [7788, 7153]
FX This research was financially supported by the National Natural Science
   Foundation of China (nos. 81860854 and 8186150460) and Science and
   Technology Projects of Guizhou Province (nos. 7788, Qiankehe LH[2015]
   and 7153, Qiankehe LH[2017]).
CR Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Athamneh K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030412
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bu HQ, 2020, ONCOTARGETS THER, V13, P8533, DOI 10.2147/OTT.S262022
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051
   Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Hong DS, 2012, CLIN CANCER RES, V18, P3396, DOI 10.1158/1078-0432.CCR-11-2703
   Howell JJ, 2013, BIOCHEM SOC T, V41, P906, DOI 10.1042/BST20130041
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Janakiram NB, 2008, PHARM RES-DORDR, V25, P2151, DOI 10.1007/s11095-008-9582-7
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li J, 2002, WORLD J GASTROENTERO, V8, P493, DOI 10.3748/wjg.v8.i3.493
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   O'Brien PJ, 2006, ARCH TOXICOL, V80, P580, DOI 10.1007/s00204-006-0091-3
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024
   Peragon J, 2015, INT J MOL SCI, V16, P21681, DOI 10.3390/ijms160921681
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Reyes FJ, 2006, FEBS LETT, V580, P6302, DOI 10.1016/j.febslet.2006.10.038
   Shanmugam MK, 2014, CANCER LETT, V346, P206, DOI 10.1016/j.canlet.2014.01.016
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Song X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.463
   Speranza G, 2012, CANCER CHEMOTH PHARM, V69, P431, DOI 10.1007/s00280-011-1712-y
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8
   Wang HN, 2020, CANCER GENE THER, V27, P448, DOI 10.1038/s41417-019-0117-7
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Yang MH, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.622212
   Yang T, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117456
   Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1
   Ziberna L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030643
NR 40
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8450
EI 1687-8469
J9 J ONCOL
JI J. Oncol.
PD JUL 17
PY 2021
VL 2021
AR 8281718
DI 10.1155/2021/8281718
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TR5IU
UT WOS:000678998600001
PM 34326874
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Banfi, S
   Caruso, E
   Zaza, S
   Mancini, M
   Gariboldi, MB
   Monti, E
AF Banfi, Stefano
   Caruso, Enrico
   Zaza, Stefano
   Mancini, Monica
   Gariboldi, Marzia B.
   Monti, Elena
TI Synthesis and photodynamic activity of a panel of BODIPY dyes
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE BODIPY; Photodynamic activity; Singlet oxygen; HCT 116; Apoptosis; Heavy
   atom effect
ID RESONANCE ENERGY-TRANSFER; HIGHLY EFFICIENT; SINGLET OXYGEN; IN-VITRO;
   THERAPY; EMISSION; CANCER; CELLS; PHOTOSENSITIZERS; DERIVATIVES
AB Eight BODIPY dyes were synthesized and used as photosensitizers (PSs) on the human colon carcinoma cell line HCT116. In this panel of molecules, the structure varies in the substituents on pyrrole 2, 6 positions and on the phenyl ring at the indacene 8 position. For these compounds relevant physico-chemical parameters, such as singlet oxygen production, fluorescent quantum yield, absorbance profile and a relative rank of lipophilicity were determined.
   Our results indicate that some of these novel PSs are very effective in reducing the growth/viability of HCT116 cells when irradiated with a green LED source, whereas they are practically devoid of activity in the dark, up to 5 mu M. To evaluate whether cell death is induced under these conditions, flow cytometric analysis of the percentage of apoptotic and autophagic cells was performed on four molecules, chosen for their efficacy/structural characteristics. Our data indicate that phototoxicity likely occurs mainly through apoptotic cell death, whereas autophagy seems to play a minor role in determining cell fate. Furthermore, the relationship between singlet oxygen generation and the PS efficacy is confirmed, thus underscoring the importance of the heavy-atom effect and of the presence of an aryl substituent at dipyrromethene 8 (meso) position.
   Among the PSs here described, the most efficient BODIPY was successfully tested on three other human cancer cell lines of different tissue origin, MCF7 (breast), A2780 and A2780/CP8 (ovary, sensitive and resistant to cisplatin, respectively), yielding IC50 values comparable to those obtained on HCT116. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Banfi, Stefano; Caruso, Enrico; Zaza, Stefano; Mancini, Monica; Gariboldi, Marzia B.; Monti, Elena] Univ Insubria, Dept Theoret & Appl Sci DiSTA, I-21100 Varese, VA, Italy.
RP Banfi, S (corresponding author), Univ Insubria, Dept Theoret & Appl Sci DiSTA, Via H Dunant 3, I-21100 Varese, VA, Italy.
EM stefano.banfi@uninsubria.it
RI Gariboldi, Marzia Bruna/U-1331-2019
OI gariboldi, marzia bruna/0000-0002-5683-0885; Mancini,
   Monica/0000-0003-4128-9018
CR Atilgan S, 2006, CHEM COMMUN, P4398, DOI 10.1039/b612347c
   Banfi S, 2004, BIOORGAN MED CHEM, V12, P4853, DOI 10.1016/j.bmc.2004.07.011
   Banfi S, 2006, J MED CHEM, V49, P3293, DOI 10.1021/jm050997m
   BEHRENS BC, 1987, CANCER RES, V47, P414
   Berg K., PHOTOSENSITIZERS MED
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Colella G, 2001, BRIT J CANCER, V84, P1387, DOI 10.1054/bjoc.2001.1751
   Coskun A, 2005, ORG LETT, V7, P5187, DOI 10.1021/ol052020h
   Coskun A, 2005, J AM CHEM SOC, V127, P10464, DOI 10.1021/ja052574f
   Coskun A, 2006, J AM CHEM SOC, V128, P14474, DOI 10.1021/ja066144g
   Dost Z, 2006, TETRAHEDRON, V62, P8484, DOI 10.1016/j.tet.2006.06.082
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Erten-Ela S, 2008, ORG LETT, V10, P3299, DOI 10.1021/ol8010612
   Gorman A, 2004, J AM CHEM SOC, V126, P10619, DOI 10.1021/ja047649e
   Grosjean P, 1998, BRIT J CANCER, V77, P1989, DOI 10.1038/bjc.1998.330
   JOHNSON S, 1999, REV CONT PHARMACOTHE
   KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kochevar IE, 2000, METHOD ENZYMOL, V319, P20
   Lim SH, 2010, J MED CHEM, V53, P2865, DOI 10.1021/jm901823u
   LISSI EA, 1993, CHEM REV, V93, P699, DOI 10.1021/cr00018a004
   Liu JY, 2008, ORG LETT, V10, P5421, DOI 10.1021/ol8023677
   Loudet A, 2008, TETRAHEDRON, V64, P3642, DOI 10.1016/j.tet.2008.01.117
   MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328
   Osterloh J, 2002, J PORPHYR PHTHALOCYA, V6, P305, DOI 10.1142/S1088424602000373
   Pandey RK, 2000, J PORPHYR PHTHALOCYA, V4, P368, DOI 10.1002/(SICI)1099-1409(200006/07)4:4<368::AID-JPP244>3.0.CO;2-6
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Saki N, 2006, TETRAHEDRON, V62, P2721, DOI 10.1016/j.tet.2005.12.021
   Scalise I, 2004, J PHOTOCH PHOTOBIO A, V162, P105, DOI 10.1016/S1010-6030(03)00317-4
   Singh-Rachford TN, 2008, J AM CHEM SOC, V130, P16164, DOI 10.1021/ja807056a
   TRONCONI M, 1995, CANCER LETT, V88, P41, DOI 10.1016/0304-3835(94)03612-M
   Umezawa K, 2008, J AM CHEM SOC, V130, P1550, DOI 10.1021/ja077756j
   Wittmershaus BP, 2001, J FLUORESC, V11, P119, DOI 10.1023/A:1016629518660
   Yano S, 2011, J PHOTOCH PHOTOBIO C, V12, P46, DOI 10.1016/j.jphotochemrev.2011.06.001
   Yogo T, 2005, J AM CHEM SOC, V127, P12162, DOI 10.1021/ja0528533
   Zeng L, 2006, J AM CHEM SOC, V128, P10, DOI 10.1021/ja055064u
NR 36
TC 42
Z9 42
U1 1
U2 57
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD SEP 3
PY 2012
VL 114
BP 52
EP 60
DI 10.1016/j.jphotobiol.2012.05.010
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 987KJ
UT WOS:000307415500006
PM 22705078
DA 2022-04-25
ER

PT J
AU Deitersen, J
   El-Kashef, DH
   Proksch, P
   Stork, B
AF Deitersen, Jana
   El-Kashef, Dina H.
   Proksch, Peter
   Stork, Bjoern
TI Anthraquinones and autophagy - Three rings to rule them all?
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Review
DE Anthraquinones; Autophagy; AKT pathway; Emodin; Chemotherapy-resistance
ID EMODIN INDUCES APOPTOSIS; NF-KAPPA-B; FUNGUS STEMPHYLIUM-GLOBULIFERUM;
   ACTIVATED PROTEIN-KINASE; COLON-CANCER CELLS; ALOE-EMODIN; IN-VITRO;
   BIOACTIVE METABOLITES; ARSENIC CYTOTOXICITY; ANTIOXIDANT ACTIVITY
AB In order to overcome therapy resistance in cancer, scientists search in nature for novel lead structures for the development of improved chemotherapeutics. Anthraquinones belong to a class of tricyclic organic natural compounds with promising anti-cancer effects. Anthraquinone derivatives are rich in structural diversity, and exhibit pleiotropic properties, among which the modulation of autophagy seems promising in the context of overcoming cancer-therapy resistance. Among the most promising derivatives in this regard are emodin, aloe emodin, rhein, physcion, chrysophanol and altersolanol A. On the molecular level, these compounds target autophagy via different upstream pathways including the AKT/mTOR-axis and transcription of autophagy-related proteins. The role of autophagy is pro-survival as well as cell death-promoting, depending on derivatives and their cell type specificity. This review summarizes observed effects of anthraquinone derivatives on autophagy and discusses targeted pathways and crosstalks. A cumulative knowledge about this topic paves the way for further research on modes of action, and aids to find a therapeutic window of anthraquinones in cancer-therapy.
C1 [Deitersen, Jana; Stork, Bjoern] Heinrich Heine Univ, Inst Mol Med 1, Med Fac, Univ Str 1, D-40225 Dusseldorf, Germany.
   [El-Kashef, Dina H.; Proksch, Peter] Heinrich Heine Univ, Fac Math & Nat Sci, Inst Pharmaceut Biol & Biotechnol, Univ Str 1, D-40225 Dusseldorf, Germany.
RP Deitersen, J; Stork, B (corresponding author), Heinrich Heine Univ, Inst Mol Med 1, Med Fac, Univ Str 1, D-40225 Dusseldorf, Germany.
EM jana.deitersen@hhu.de; bjoern.stork@hhu.de
RI Proksch, Peter/AAR-4593-2020; Stork, Björn/C-2160-2011
OI Stork, Björn/0000-0002-4167-7806
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German
   Research Foundation (DFG) [315775584/STO 864/5-1, 270650915/GRK 2158]
FX We thank Michelle Klein for the technical support in the analysis of
   cell death mediated by altersolanol A. We thank the Deutsche
   Forschungsgemeinschaft (DFG, German Research Foundation) for financial
   support of the projects 315775584/STO 864/5-1 (to BS) and 270650915/GRK
   2158 (subproject 1c to PP and subproject 3b to BS).
CR Aly AH, 2008, PHYTOCHEMISTRY, V69, P1716, DOI 10.1016/j.phytochem.2008.02.013
   Aly AH, 2010, FUNGAL DIVERS, V41, P1, DOI 10.1007/s13225-010-0034-4
   Aviello G, 2010, J CELL MOL MED, V14, P2006, DOI 10.1111/j.1582-4934.2009.00815.x
   Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894
   BARNARD DL, 1992, ANTIVIR RES, V17, P63, DOI 10.1016/0166-3542(92)90091-I
   Cai Y, 2004, J AGR FOOD CHEM, V52, P7884, DOI 10.1021/jf0489116
   Cai YZ, 2006, LIFE SCI, V78, P2872, DOI 10.1016/j.lfs.2005.11.004
   CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746
   Chang CH, 1996, AM J CHINESE MED, V24, P139, DOI 10.1142/S0192415X96000189
   Chauhan S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9620
   Cheema SK, 2007, INT J PHARMACEUT, V341, P221, DOI 10.1016/j.ijpharm.2007.03.043
   Chen DX, 2016, INT IMMUNOPHARMACOL, V34, P107, DOI 10.1016/j.intimp.2016.02.023
   Chen YC, 2002, BIOCHEM PHARMACOL, V64, P1713, DOI 10.1016/S0006-2952(02)01386-2
   Chukwujekwu JC, 2006, S AFR J BOT, V72, P295, DOI 10.1016/j.sajb.2005.08.003
   Convertino M, 2009, PROTEIN SCI, V18, P792, DOI 10.1002/pro.87
   Cooper KF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4701275
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   Dan HC, 2008, J IMMUNOL, V180, P7582, DOI 10.4049/jimmunol.180.11.7582
   Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308
   Dave H, 2012, REV ANTHRAQUINONES I
   Alves CCD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079565
   Debbab A, 2009, PLANTA MED, V75, P884
   Debbab A, 2009, J NAT PROD, V72, P626, DOI 10.1021/np8004997
   Dou Fang, 2018, Chinese Pharmacological Bulletin, V34, P1555, DOI 10.3969/j.issn.1001-1978.2018.11.016
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59
   Fenig E, 2004, ONCOL REP
   Fernand VE, 2011, CHEM-BIOL INTERACT, V192, P220, DOI 10.1016/j.cbi.2011.03.013
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Gao QP, 2011, ULTRASOUND MED BIOL, V37, P1478, DOI 10.1016/j.ultrasmedbio.2011.05.846
   Gurusamy N, 2009, AUTOPHAGY, V5, P120, DOI 10.4161/auto.5.1.7303
   Harhaji L, 2007, EUR J PHARMACOL, V568, P248, DOI 10.1016/j.ejphar.2007.04.029
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He DY, 2011, BIOL PHARM BULL, V34, P1219, DOI 10.1248/bpb.34.1219
   Hindupur SK, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019141
   Hu Hao, 2015, Zhongguo Zhong Yao Za Zhi, V40, P1965
   Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094
   Huang XZ, 2008, CANCER BIOL THER, V7, P468, DOI 10.4161/cbt.7.3.5457
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Hwang DW, 2017, PANCREAS, V46, P575, DOI 10.1097/MPA.0000000000000780
   Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709
   Janeczko M, 2017, YEAST, V34, P253, DOI 10.1002/yea.3230
   Joo JH, 2011, MOL CELL, V43, P572, DOI 10.1016/j.molcel.2011.06.018
   Kamei H, 1998, CANCER BIOTHER RADIO, V13, P185, DOI 10.1089/cbr.1998.13.185
   Kamil M, 2018, ANTICANCER AGENTS ME
   Kang SC, 2008, ARCH PHARM RES, V31, P722, DOI 10.1007/s12272-001-1218-1
   Khan Irfan A, 2014, Int J Chronic Dis, V2014, P789340, DOI 10.1155/2014/789340
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kuo YC, 2001, INFLAMM RES, V50, P73, DOI 10.1007/s000110050727
   Kwak HJ, 2006, INT J CANCER, V118, P2711, DOI 10.1002/ijc.21641
   Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058
   Lee MS, 2011, PHYTOTHER RES, V25, P833, DOI 10.1002/ptr.3323
   Li L, 2017, HUAXI PHARM J, V15
   Li XJ, 2009, MOL CELL ENDOCRINOL, V307, P157, DOI 10.1016/j.mce.2009.03.006
   Lin HD, 2017, ONCOL LETT, V13, P3431, DOI 10.3892/ol.2017.5915
   Lin S, 2003, INT J ONCOL
   Liu H, 2016, ACTA PHARMACOL SIN, V37, P235, DOI 10.1038/aps.2015.114
   Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293
   Lu CC, 2010, MOL NUTR FOOD RES, V54, P967, DOI 10.1002/mnfr.200900265
   Ma J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/107671
   Mack HID, 2012, AUTOPHAGY, V8, P1197, DOI 10.4161/auto.20586
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Markovic ZS, 2009, MONATSH CHEM, V140, P1311, DOI 10.1007/s00706-009-0192-9
   Mathew R, 2009, ASSESSING METABOLIC, P53
   Mazzorana M, 2008, MOL CELL BIOCHEM, V316, P57, DOI 10.1007/s11010-008-9822-5
   Mercer TJ, 2018, J BIOL CHEM, V293, P5386, DOI 10.1074/jbc.R117.810366
   Miao LJ, 2014, TUMOR BIOL, V35, P7097, DOI 10.1007/s13277-014-1961-6
   Mijatovic S, 2004, CELL MOL LIFE SCI, V61, P1805, DOI 10.1007/s00018-004-4089-9
   Mishra PD, 2015, LETT APPL MICROBIOL, V60, P387, DOI 10.1111/lam.12384
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Monisha BA, 2016, ADV EXP MED BIOL, V928, P47, DOI 10.1007/978-3-319-41334-1_3
   Ni CH, 2014, ENVIRON TOXICOL, V29, P740, DOI 10.1002/tox.21801
   Olsen BB, 2007, INT J BIOCHEM CELL B, V39, P227, DOI 10.1016/j.biocel.2006.08.006
   Pan XP, 2018, LIFE SCI, V214, P124, DOI 10.1016/j.lfs.2018.10.064
   Pang MJ, 2016, ACTA PHARMACOL SIN, V37, P1623, DOI 10.1038/aps.2016.98
   Pecere T, 2000, CANCER RES, V60, P2800
   Raaf J, 2008, HIGH PH VALUE CRYSTA
   Ravi R, 2002, CANCER RES, V62, P4180
   Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674
   Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7
   Savarino L, 2007, CLIN ORTHOP RELAT R, P231, DOI 10.1097/BLO.0b013e3180533b5c
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Sharma V, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00147
   Shi YQ, 2001, ANTICANCER RES, V21, P2847
   Shia CS, 2010, J PHARM SCI-US, V99, P2185, DOI 10.1002/jps.21978
   Shieh DE, 2004, LIFE SCI, V74, P2279, DOI 10.1016/j.lfs.2003.09.060
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Song P, 2013, J BIOL CHEM, V288, P5732, DOI 10.1074/jbc.M112.441477
   Su YT, 2005, BIOCHEM PHARMACOL, V70, P229, DOI 10.1016/j.bcp.2005.04.026
   Subramaniam A, 2013, APOPTOSIS, V18, P1175, DOI 10.1007/s10495-013-0851-5
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tang N, 2017, MICROB PATHOGENESIS, V113, P168, DOI 10.1016/j.micpath.2017.10.031
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Teiten MH, 2013, BIOORGAN MED CHEM, V21, P3850, DOI 10.1016/j.bmc.2013.04.024
   Tekirdag K, 2018, J BIOL CHEM, V293, P5414, DOI 10.1074/jbc.R117.818237
   Teng ZH, 2007, BIOL PHARM BULL, V30, P1628, DOI 10.1248/bpb.30.1628
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Trybus W, 2017, ANTICANCER RES, V37, P6087, DOI 10.21873/anticanres.12057
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   Tu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep43790
   Tu Yue, 2014, Zhongguo Zhong Yao Za Zhi, V39, P4090
   Ueno Yoshio, 1995, Natural Toxins, V3, P129, DOI 10.1002/nt.2620030303
   Wang XF, 2007, J CARDIOVASC PHARM, V49, P253, DOI 10.1097/FJC.0b013e318033dfb3
   Wang XJ, 2005, CELL RES, V15, P511, DOI 10.1038/sj.cr.7290321
   Wang YX, 2015, CELL ONCOL, V38, P353, DOI 10.1007/s13402-015-0234-8
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wei WT, 2013, ONCOL REP, V30, P2555, DOI 10.3892/or.2013.2741
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu WJ, 2014, CHEM-BIOL INTERACT, V219, P18, DOI 10.1016/j.cbi.2014.05.006
   Xiong HR, 2011, J ETHNOPHARMACOL, V133, P718, DOI 10.1016/j.jep.2010.10.059
   Xu CF, 2011, FASEB J, V25, P2700, DOI 10.1096/fj.10-167676
   Yamada E, 2012, CELL REP, V1, P557, DOI 10.1016/j.celrep.2012.03.014
   Yang J, 2004, FREE RADICAL BIO MED, V37, P2027, DOI 10.1016/j.freeradbiomed.2004.09.016
   Yang S., 1998, DIVINE FARMERS MATER
   Yen GC, 2000, FOOD CHEM, V70, P437, DOI 10.1016/S0308-8146(00)00108-4
   Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yu XZ, 2018, PANCREAS, V47, P892, DOI 10.1097/MPA.0000000000001080
   Zhang XY, 2017, J ETHNOPHARMACOL, V201, P108, DOI 10.1016/j.jep.2016.11.007
   Zheng He-Yong, 2007, Yaoxue Xuebao, V42, P1142
   Zheng Y, 2015, J SHAANXI U SCI TECH, P134
   Zhou XM, 2014, ANTIOXID REDOX SIGN, V21, P1741, DOI 10.1089/ars.2013.5587
NR 126
TC 7
Z9 7
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD OCT 15
PY 2019
VL 27
IS 20
AR 115042
DI 10.1016/j.bmc.2019.115042
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA IY4SO
UT WOS:000486383500004
PM 31420258
OA hybrid
DA 2022-04-25
ER

PT J
AU Fattahi, Y
   Heidari, HR
   Khosroushahi, AY
AF Fattahi, Yasin
   Heidari, Hamid Reza
   Khosroushahi, Ahmad Yari
TI Review of short-chain fatty acids effects on the immune system and
   cancer
SO FOOD BIOSCIENCE
LA English
DT Review
DE Acetate; Butyrate; Capric acid; Caprylic acid; Caproic acid; Propionate
ID HISTONE DEACETYLASE INHIBITORS; PROTEIN-COUPLED RECEPTOR; NF-KAPPA-B;
   SUPPRESSES COLONIC INFLAMMATION; CYTOKINE-INDUCED VCAM-1;
   SODIUM-BUTYRATE; GUT MICROBIOTA; MEDIATED APOPTOSIS; GENE-EXPRESSION;
   METABOLITE BUTYRATE
AB Short-chain fatty acids (SCFA), as end products of indigestible-fiber-fermentation by gut-bacteria, affect inflammatory disease and cancer. SCFA are quickly absorbed in the colon through their transporters categorized as SMCT1/SLC5a8, MCT1/SLAC16a, and SCFA-HCO3 exchangers. These compounds have anti-inflammatory and anticancer properties by activating FFR2/GPR43, FFR3/GPR41, GPR109, olfactory receptor 78, and inhibiting histone deacetylases (HDAC). SCFA suppresses inflammation by influencing chemotaxis, immune cells' differentiation, and the production of cytokines from different cell types. In addition to autophagy induction ability of SCFA in cancer cells, they can also induce apoptosis in tumoral cells. SCFA has not shown significant effects on normal cells' propagation. On the other hand, previous reports showed their preventive impacts on cancer cell proliferation, which has been named the "Butyrate paradox" and discussed in terms of the "Warburg effect."
C1 [Fattahi, Yasin] Tabriz Univ Med Sci, Fac Pharm, Biotechnol Res Ctr, Student Res Comm, Tabriz, Iran.
   [Heidari, Hamid Reza; Khosroushahi, Ahmad Yari] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Heidari, Hamid Reza] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut Biotechnol, Tabriz, Iran.
   [Khosroushahi, Ahmad Yari] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Nanotechnol, Tabriz, Iran.
RP Khosroushahi, AY (corresponding author), Tabriz Univ Med Sci, Fac Adv Med Sci, Daneshgah St,POB 51548-53431, Tabriz, Iran.
EM yarikhosroushahia@tbzmed.ac.ir
RI Heidari, Hamid Reza/M-4362-2017
OI Heidari, Hamid Reza/0000-0001-7371-4977
FU Drug Applied Research Center, Tabriz University of Medical Science
   [59585]
FX This study was supported financially by the Drug Applied Research
   Center, Tabriz University of Medical Science, with the grant number of
   59585.
CR Almotairy ARZ, 2017, J INORG BIOCHEM, V177, P1, DOI 10.1016/j.jinorgbio.2017.09.009
   Aoyama M, 2010, NUTRITION, V26, P653, DOI 10.1016/j.nut.2009.07.006
   Asarat M, 2016, IMMUNOL INVEST, V45, P205, DOI 10.3109/08820139.2015.1122613
   Asarat M, 2015, INT J FOOD SCI NUTR, V66, P755, DOI 10.3109/09637486.2015.1088935
   Asarat M, 2015, IMMUNOL INVEST, V44, P678, DOI 10.3109/08820139.2015.1085389
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Bae JM, 2017, MODERN PATHOL, V30, P267, DOI 10.1038/modpathol.2016.172
   Belenguer A, 2007, APPL ENVIRON MICROB, V73, P6526, DOI 10.1128/AEM.00508-07
   Bhat MI, 2017, NUTR REV, V75, P374, DOI 10.1093/nutrit/nux001
   Bolognini D, 2016, MOL PHARMACOL, V89, P388, DOI 10.1124/mol.115.102301
   Bordonaro M., 2014, BUTYRATE FOOD SOURCE, P133
   Casanova MR, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00044
   Chambers Edward S, 2018, Curr Nutr Rep, V7, P198, DOI 10.1007/s13668-018-0248-8
   Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111
   Christiansen CB, 2018, AM J PHYSIOL-GASTR L, V315, pG53, DOI 10.1152/ajpgi.00346.2017
   Coothankandaswamy V, 2013, BIOCHEM J, V450, P169, DOI 10.1042/BJ20121248
   Correa RO, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.17
   Cousin FJ, 2016, ONCOTARGET, V7, P7161, DOI 10.18632/oncotarget.6881
   Dahl WJ, 2017, J AM COLL NUTR, V36, P127, DOI 10.1080/07315724.2016.1188737
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012
   Deng R, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0589-6
   Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Donohoe DR, 2012, MOL CELL, V48, P612, DOI 10.1016/j.molcel.2012.08.033
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Duncan SH, 2009, ENVIRON MICROBIOL, V11, P2112, DOI 10.1111/j.1462-2920.2009.01931.x
   Engels C, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00713
   Esgalhado M, 2017, FUTURE MICROBIOL, V12, P1413, DOI 10.2217/fmb-2017-0059
   Fernando WMADB, 2018, INT J FOOD SCI NUTR, V69, P144, DOI 10.1080/09637486.2017.1340932
   Ferro S, 2016, ONCOTARGET, V7, P70639, DOI 10.18632/oncotarget.12156
   Fu Zidong Donna, 2017, Curr Pharmacol Rep, V3, P101, DOI 10.1007/s40495-017-0087-0
   Fukumoto S, 2003, AM J PHYSIOL-REG I, V284, pR1269, DOI 10.1152/ajpregu.00442.2002
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Ganapathy V, 2013, CURR OPIN PHARMACOL, V13, P869, DOI 10.1016/j.coph.2013.08.006
   Gao SM, 2013, EXP HEMATOL, V41, P261, DOI 10.1016/j.exphem.2012.10.012
   Gomes S. D., 2018, CURRENT MED CHEM, V27, P4087
   Goncalves P, 2018, INFLAMM BOWEL DIS, V24, P558, DOI 10.1093/ibd/izx029
   Gupta V, 2014, CURR PHARM DESIGN, V20, P1706, DOI 10.2174/13816128113199990536
   Halaburkova A, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0359-x
   Han F, 2018, J AGR FOOD CHEM, V66, P6326, DOI 10.1021/acs.jafc.8b01891
   Harris HC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9010026
   HEERDT BG, 1994, CANCER RES, V54, P3288
   Hester CM, 2015, WORLD J GASTROENTERO, V21, P2759, DOI 10.3748/wjg.v21.i9.2759
   HIBBERD AA, 2017, BMJ OPEN GASTROENTER, V4, DOI DOI 10.1136/BMJGAST-2017-000145
   Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012
   Ho RH, 2017, BIOCHEMISTRY-US, V56, P4871, DOI 10.1021/acs.biochem.7b00508
   Hrebackova J, 2010, CURR DRUG TARGETS, V11, P361, DOI 10.2174/138945010790711923
   Hu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016221
   Hughes SA, 2007, J AGR FOOD CHEM, V55, P4589, DOI 10.1021/jf070293g
   Huuskonen J, 2004, BRIT J PHARMACOL, V141, P874, DOI 10.1038/sj.bjp.0705682
   Iannucci LF, 2016, BIOCHEM BIOPH RES CO, V480, P461, DOI 10.1016/j.bbrc.2016.10.072
   Inoue D, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00081
   Iraporda C, 2015, IMMUNOBIOLOGY, V220, P1161, DOI 10.1016/j.imbio.2015.06.004
   Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935
   Jia XY, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.613
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kasubuchi M, 2015, NUTRIENTS, V7, P2839, DOI 10.3390/nu7042839
   Kawamura T, 2009, DIGEST DIS SCI, V54, P238, DOI 10.1007/s10620-008-0348-1
   Kilner J, 2012, MOL BIOSYST, V8, P1146, DOI 10.1039/c1mb05219e
   Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188
   Kobayashi S, 2015, BIOL PHARM BULL, V38, P1098, DOI 10.1248/bpb.b15-00096
   Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041
   Kouraklis G, 2006, ONCOL REP, V15, P489
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Layden BT, 2013, TRANSL RES, V161, P131, DOI 10.1016/j.trsl.2012.10.007
   Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200
   Lee HJ, 2012, BIOMOL THER, V20, P280, DOI 10.4062/biomolther.2012.20.3.280
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Louis P, 2017, ENVIRON MICROBIOL, V19, P29, DOI 10.1111/1462-2920.13589
   Luu M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32860-x
   Manal M, 2016, BIOORG CHEM, V67, P18, DOI 10.1016/j.bioorg.2016.05.005
   Matthews GM, 2012, CHEMOTHERAPY, V58, P102, DOI 10.1159/000335672
   McLoughlin RF, 2017, AM J CLIN NUTR, V106, P930, DOI 10.3945/ajcn.117.156265
   McNabney SM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121348
   McNelis JC, 2015, DIABETES, V64, P3203, DOI 10.2337/db14-1938
   Meijer K, 2010, CURR OPIN CLIN NUTR, V13, P715, DOI 10.1097/MCO.0b013e32833eebe5
   Meissner S, 2017, J DAIRY SCI, V100, P6662, DOI 10.3168/jds.2016-12262
   Menzel T, 2004, INFLAMM BOWEL DIS, V10, P122, DOI 10.1097/00054725-200403000-00010
   Millard AL, 2002, CLIN EXP IMMUNOL, V130, P245
   Miller SJ, 2005, NUTRITION, V21, P740, DOI 10.1016/j.nut.2004.11.011
   Mima K, 2017, SURG ONCOL, V26, P368, DOI 10.1016/j.suronc.2017.07.011
   Mirmonsef P, 2012, AM J REPROD IMMUNOL, V67, P391, DOI 10.1111/j.1600-0897.2011.01089.x
   Monaco C, 2004, P NATL ACAD SCI USA, V101, P5634, DOI 10.1073/pnas.0401060101
   Morrison DJ, 2016, GUT MICROBES, V7, P189, DOI 10.1080/19490976.2015.1134082
   Mrkvicova A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210889
   Nakatani M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091220
   Nastasi C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15099-w
   Nastasi C, 2015, SCI REP-UK, V5, DOI 10.1038/srep16148
   Nawaz A, 2018, FISH SHELLFISH IMMUN, V76, P272, DOI 10.1016/j.fsi.2018.03.004
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078-0432.CCR-06-2903
   Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1
   Nurdin SU, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040355
   Ohira H, 2017, J ATHEROSCLER THROMB, V24, P660, DOI 10.5551/jat.RV17006
   Ohno H., 2015, JAPANESE J CLIN IMMU, V37, P403
   Ou JH, 2013, AM J CLIN NUTR, V98, P111, DOI 10.3945/ajcn.112.056689
   Paglin S, 2001, CANCER RES, V61, P439
   Pajak B, 2007, ADV MED SCI-POLAND, V52, P83
   Pant K, 2017, CHEM-BIOL INTERACT, V273, P99, DOI 10.1016/j.cbi.2017.06.001
   Pant K, 2017, REDOX BIOL, V12, P340, DOI 10.1016/j.redox.2017.03.006
   Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44
   Pattayil L, 2019, ANTICANCER RES, V39, P3795, DOI 10.21873/anticanres.13528
   Pessione E, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00086
   Prasad K. N., 2018, MECH AGEING DEV, VS0047-6374, P30013
   Qamar TR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091785
   Reichardt N, 2014, ISME J, V8, P1323, DOI 10.1038/ismej.2014.14
   Rios-Covian D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00185
   Riviere A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00979
   Roy Claude C, 2006, Nutr Clin Pract, V21, P351, DOI 10.1177/0115426506021004351
   Sakata T, 2019, ANIM SCI J, V90, P3, DOI 10.1111/asj.13118
   Salimi V, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0593-4
   Samuel BS, 2008, P NATL ACAD SCI USA, V105, P16767, DOI 10.1073/pnas.0808567105
   Sanford JA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah4609
   Schlormann W, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0500-4
   Scholz-Ahrens KE, 2007, J NUTR, V137, p2513S, DOI 10.1093/jn/137.11.2513S
   Schulthess J, 2019, IMMUNITY, V50, P432, DOI 10.1016/j.immuni.2018.12.018
   Serpa J, 2010, J BIOL CHEM, V285, P39211, DOI 10.1074/jbc.M110.156026
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Sharma M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01940
   Shin H, 2012, INT J ONCOL, V40, P1533, DOI 10.3892/ijo.2012.1327
   Siennicka Aldona, 2005, Ann Acad Med Stetin, V51, P117
   Silva LG, 2018, J ANIM SCI, V96, P5244, DOI 10.1093/jas/sky373
   Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007
   Singh N, 2010, J BIOL CHEM, V285, P27601, DOI 10.1074/jbc.M110.102947
   Sivaprakasam S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080856
   Sivaprakasam S, 2016, PHARMACOL THERAPEUT, V164, P144, DOI 10.1016/j.pharmthera.2016.04.007
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Steinmeyer S, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0524-2
   Stumpff F, 2018, PFLUG ARCH EUR J PHY, V470, P571, DOI 10.1007/s00424-017-2105-9
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tang Y, 2011, AUTOPHAGY, V7, P235, DOI 10.4161/auto.7.2.14277
   Tang Y, 2011, INT J CANCER, V128, P847, DOI 10.1002/ijc.25638
   Tazoe H, 2008, J PHYSIOL PHARMACOL, V59, P251
   Tedelind S, 2007, WORLD J GASTROENTERO, V13, P2826, DOI 10.3748/wjg.v13.i20.2826
   Bui TPN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10062
   Tian Y, 2018, J NUTR BIOCHEM, V57, P103, DOI 10.1016/j.jnutbio.2018.03.007
   Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67
   Tolhurst G, 2012, DIABETES, V61, P364, DOI 10.2337/db11-1019
   Hung TV, 2018, J AGR FOOD CHEM, V66, P108, DOI 10.1021/acs.jafc.7b04233
   Tuncil YE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34912-8
   Turtoi Andrei, 2015, Critical Reviews in Oncogenesis, V20, P119
   Tylichova Z, 2017, J NUTR BIOCHEM, V39, P145, DOI 10.1016/j.jnutbio.2016.09.006
   van der Beek CM, 2017, NUTR REV, V75, P286, DOI 10.1093/nutrit/nuw067
   Veprik A, 2016, FASEB J, V30, P3860, DOI 10.1096/fj.201500030R
   Vipperla K, 2013, CURR COLORECT CANC R, V9, P95, DOI 10.1007/s11888-012-0158-x
   von Engelhardt W, 2005, DEUT TIERARZTL WOCH, V112, P413
   Waldecker M, 2008, J NUTR BIOCHEM, V19, P587, DOI 10.1016/j.jnutbio.2007.08.002
   Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109
   Watson AJM, 2006, CRIT REV ONCOL HEMAT, V57, P107, DOI 10.1016/j.critrevonc.2005.06.005
   Weir TL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070803
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015
   Xiao TF, 2018, ONCOL LETT, V16, P4439, DOI 10.3892/ol.2018.9201
   Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200
   Yonezawa T, 2007, CELL SIGNAL, V19, P185, DOI 10.1016/j.cellsig.2006.06.004
   Zapolska-Downar D, 2004, J NUTR BIOCHEM, V15, P220, DOI 10.1016/j.jnutbio.2003.11.008
   Zapolska-Downar D, 2009, J PHYSIOL PHARMACOL, V60, P123
   Zhan K, 2018, IN VITRO CELL DEV-AN, V54, P311, DOI 10.1007/s11626-017-0226-2
   Zhang H, 2019, FRONT MED-PRC, V13, P461, DOI 10.1007/s11684-019-0695-7
   Zhao L, 2018, ANTI-CANCER DRUG, V29, P227, DOI 10.1097/CAD.0000000000000588
   Zhou CB, 2018, CRIT REV MICROBIOL, V44, P436, DOI 10.1080/1040841X.2018.1425671
   Zimmerman MA, 2012, AM J PHYSIOL-GASTR L, V302, pG1405, DOI 10.1152/ajpgi.00543.2011
NR 163
TC 8
Z9 8
U1 16
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-4292
EI 2212-4306
J9 FOOD BIOSCI
JI Food Biosci.
PD DEC
PY 2020
VL 38
AR 100793
DI 10.1016/j.fbio.2020.100793
PG 10
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA PC6SU
UT WOS:000597129200012
DA 2022-04-25
ER

PT J
AU Arslan, FD
   Kocak, A
   Aydin, C
   Pala, EE
   Oncel, D
   Diniz, G
   Kaya, T
   Ugurlu, L
   Degirmenci, M
   Ozkan, B
   Soysal, Y
   Said, HM
AF Arslan, Fatma Demet
   Kocak, Ayse
   Aydin, Cengiz
   Pala, Emel Ebru
   Oncel, Dilek
   Diniz, Gulden
   Kaya, Tayfun
   Ugurlu, Levent
   Degirmenci, Mustafa
   Ozkan, Bulent
   Soysal, Yasemin
   Said, Harun Muayad
TI Evaluation of potential tumor markers that may predict neoadjuvant
   treatment efficiency in rectal cancer
SO TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
LA English
DT Article
DE Beclin 1; carbonic anhydrase-9; hypoxia-inducible factor-1 alpha;
   neoadjuvant treatment; rectal cancer; Survivin
ID CARBONIC-ANHYDRASE; COLORECTAL-CANCER; CHEMORADIATION THERAPY; BECLIN 1;
   EXPRESSION; HYPOXIA; AUTOPHAGY; SURVIVIN; CHEMORADIOTHERAPY; CELLS
AB Objectives: The recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1 alpha (HIF-1 alpha) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC).
   Methods: Twenty-five patients with locally advanced RC were included in the study. Gene expression and protein levels of Beclin 1, Survivin, HIF-1 alpha, and CA9 were analyzed in fresh tissue specimens and blood samples. The relationships of these markers to tumor staging and regression grade were evaluated.
   Results: Higher blood CA9 gene expression levels and lower blood HIF-1 alpha protein levels were found in the response group according to tumor regression grade. After neoadjuvant treatment, tissue Beclin 1 and blood Survivin gene expressions and tissue CA9, blood Beclin 1 and blood HIF-1 alpha protein levels decreased significantly.
   Conclusion: Beclin 1, Survivin, HIF-1 alpha ve CA9 may help to predict the effects of the applied treatment approach.
C1 [Arslan, Fatma Demet] Univ Hlth Sci, Tepecik Training & Res Hosp, Dept Med Biochem, Gaziler St,468, TR-35180 Izmir, Turkey.
   [Kocak, Ayse; Soysal, Yasemin; Said, Harun Muayad] Dokuz Eylul Univ, Inst Hlth Sci, Dept Mol Med, Izmir, Turkey.
   [Aydin, Cengiz] Univ Hlth Sci, Tepecik Training & Res Hosp, Gen Surg Clin, Izmir, Turkey.
   [Pala, Emel Ebru; Diniz, Gulden; Kaya, Tayfun; Ugurlu, Levent] Univ Hlth Sci, Tepecik Training & Res Hosp, Med Pathol Clin, Izmir, Turkey.
   [Oncel, Dilek] Univ Hlth Sci, Tepecik Training & Res Hosp, Radiol Clin, Izmir, Turkey.
   [Degirmenci, Mustafa] Univ Hlth Sci, Tepecik Training & Res Hosp, Oncol Clin, Izmir, Turkey.
   [Ozkan, Bulent] Katip Celebi Univ, Fac Med, Dept Biostat, Izmir, Turkey.
RP Arslan, FD (corresponding author), Univ Hlth Sci, Tepecik Training & Res Hosp, Dept Med Biochem, Gaziler St,468, TR-35180 Izmir, Turkey.
EM fatmademet.arslan@gmail.com
RI Arslan, Fatma Demet/ABG-6885-2021; Said, Harun Muayad/AAZ-7299-2021;
   Arslan İnce, Fatma Demet/AAZ-5735-2021; Kocak, Ayse/W-3229-2017
OI Arslan, Fatma Demet/0000-0003-0766-0303; Diniz,
   Gulden/0000-0003-1512-7584; Kocak, Ayse/0000-0002-1510-2937
FU Scientific and Technological Research Council of TurkeyTurkiye Bilimsel
   ve Teknolojik Arastirma Kurumu (TUBITAK) [116S225]
FX The present study was funded by a grant from the Scientific and
   Technological Research Council of Turkey with the number 116S225.
CR Aklilu M, 2011, NAT REV CLIN ONCOL, V8, P649, DOI 10.1038/nrclinonc.2011.118
   Amin MB., 2017, AJCC CANC STAGING MA, V8th, P252, DOI [10.1007/978-3-319-40618-3, DOI 10.1007/978-3-319-40618-3]
   BUROKER T, 1976, DIS COLON RECTUM, V19, P660, DOI 10.1007/BF02591003
   Chen X, 2016, J CANCER, V7, P314, DOI 10.7150/jca.13332
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Gantt GA, 2013, COLORECTAL CANCER, V2, P321, DOI 10.2217/CRC.13.35
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hawk ET, 2002, SURG CLIN N AM, V82, P905, DOI 10.1016/S0039-6109(02)00046-4
   Hektoen HH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1557-6
   Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014
   Horisberger K, 2010, ONKOLOGIE, V33, P439, DOI 10.1159/000318145
   Kim HJ, 2014, ONCOL REP, V32, P2493, DOI 10.3892/or.2014.3504
   Kim K, 2011, INT J COLORECTAL DIS, V26, P1019, DOI 10.1007/s00384-011-1180-1
   Kockar F, 2012, WORLD J CLIN ONCOL, V3, P82, DOI 10.5306/wjco.v3.i6.82
   Korkeila E, 2010, SCAND J GASTROENTERO, V45, P340, DOI 10.3109/00365520903483635
   Korkeila E, 2009, BRIT J CANCER, V100, P874, DOI 10.1038/sj.bjc.6604949
   Lin SH, 2015, INT J CLIN EXP PATHO, V8, P10680
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MINSKY B, 1994, CANCER, V73, P273, DOI 10.1002/1097-0142(19940115)73:2<273::AID-CNCR2820730207>3.0.CO;2-4
   National Comprehensive Cancer Network, 2016, NCCN CLIN PRACTICE G
   Niu TK, 2010, FEBS LETT, V584, P3519, DOI 10.1016/j.febslet.2010.07.018
   Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rasheed S, 2009, BRIT J CANCER, V101, P742, DOI 10.1038/sj.bjc.6605242
   Ren DL, 2019, WORLD J GASTROENTERO, V25, P118, DOI 10.3748/wjg.v25.i1.118
   Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1
   Said HM, 2007, J NEURO-ONCOL, V81, P27, DOI 10.1007/s11060-006-9205-2
   Said HM, 2010, CURR PHARM DESIGN, V16, P3288
   Said HM, 2017, ONCOL REP, V37, P3625, DOI 10.3892/or.2017.5620
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shioya M, 2011, J RADIAT RES, V52, P821, DOI 10.1269/jrr.11117
   Sprenger T, 2011, CLIN CANCER RES, V17, P1623, DOI 10.1158/1078-0432.CCR-10-2592
   Thomas AW, 2013, PLOS ONE, V8
   Tian ML, 2011, CANCER BIOL THER, V12, P896, DOI 10.4161/cbt.12.10.17679
   Toiyama Y, 2010, CLIN ONCOL-UK, V22, P272, DOI 10.1016/j.clon.2010.01.001
   Wykoff CC, 2000, CANCER RES, V60, P7075
   Yang WL, 2012, J SURG ONCOL, V106, P680, DOI 10.1002/jso.23184
   Yao Hang, 2008, Zhonghua Wei Chang Wai Ke Za Zhi, V11, P61
   Zaanan A, 2015, INT J CANCER, V137, P1498, DOI 10.1002/ijc.29496
NR 40
TC 0
Z9 0
U1 1
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0250-4685
EI 1303-829X
J9 TURK J BIOCHEM
JI Turk. J. Biochem.
PD AUG
PY 2021
VL 46
IS 4
BP 445
EP 454
DI 10.1515/tjb-2020-0507
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA UM8XD
UT WOS:000693607700014
OA gold
DA 2022-04-25
ER

PT J
AU Enayat, S
   Ceyhan, MS
   Taskoparan, B
   Stefek, M
   Banerjee, S
AF Enayat, Shabnam
   Ceyhan, M. Seyma
   Taskoparan, Betul
   Stefek, Milan
   Banerjee, Sreeparna
TI CHNQ, a novel 2-Chloro-1,4-naphthoquinone derivative of quercetin,
   induces oxidative stress and autophagy both in vitro and in vivo
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE CHNQ; Quercetin; Colon cancer; Oxidative stress; Autophagy
ID CANCER CELL-LINES; ALDOSE REDUCTASE; TARGET; INHIBITION;
   1,4-NAPHTHOQUINONES; PHOSPHORYLATION; BIOAVAILABILITY; CYTOTOXICITY;
   CROSSTALK; MECHANISM
AB Quercetin (Qc) shows strong antitumor effects but has limited clinical application due to poor water solubility and bioavailability. In a screening of novel semi-synthetic derivatives of Qc, 3,7-dihydroxy-2-[4-(2-chloro-1,4-naphthoquinone-3-yloxy)-3-hydroxyphenyl]-5-hydroxychromen-4-one (CHNQ) could ameliorate acetic acid induced acute colitis in vivo more efficiently than Qc. Since inflammation contributes to colorectal cancer (CRC), we have hypothesized that CHNQ may have anti-cancer effects. Using CRC cell lines HCT-116 and HT-29, we report that CHNQ was three-fold more cytotoxic than Qc along with a robust induction of apoptosis. As expected from naphthoquinones such as CHNQ, a strong induction of oxidative stress was observed. This was accompanied by reactive oxygen species (ROS) induced autophagy marked by a dramatic increase in the lipidation of LC3, decreased activation of Akt/PKB, acidic vesicle accumulation and puncta formation in HCT-116 cells treated with CHNQ. Interestingly, an incomplete autophagy was observed in HT-29 cells where CHNQ treatment led to LC3 lipidation, but not the formation of acidic vacuoles. CHNQ-induced cytotoxicity, ROS formation and autophagy were also detected in vivo in Saccharomyces cerevisiae strain RDKY3615 (WinstonS288C background). Overall, we propose that CHNQ can induce cancer cell death through the induction of oxidative stress, and may be examined further as a potential chemotherapeutic drug. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Enayat, Shabnam; Ceyhan, M. Seyma; Taskoparan, Betul; Banerjee, Sreeparna] Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
   [Stefek, Milan] Slovak Acad Sci, Inst Expt Pharmacol & Toxicol, Dubravska Cesta 9, Bratislava 84104, Slovakia.
RP Banerjee, S (corresponding author), Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
EM banerjee@metu.edu.tr
RI enayat, shabnam/AGD-9425-2022; Banerjee, Sreeparna/AAZ-6742-2020
OI Banerjee, Sreeparna/0000-0003-4596-6768; Stefek,
   Milan/0000-0002-2707-8030; Taskoparan Yaglikci,
   Betul/0000-0003-1890-1547
FU TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Slovak
   Academy of SciencesSlovak Academy of Sciences [113S006]
FX The authors would like to gratefully acknowledge Dr Cagdas Devrim Son at
   METU for his help with microscopy. This work was supported by the
   TUBITAK 2513 Bilateral Cooperation Program between TUBITAK and the
   Slovak Academy of Sciences (Project no: 113S006 to MS and SB).
CR Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Pham A, 2012, BIOCHEM BIOPH RES CO, V427, P415, DOI 10.1016/j.bbrc.2012.09.080
   Araujo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006
   Astarci E, 2012, FEBS J, V279, P2966, DOI 10.1111/j.1742-4658.2012.08677.x
   AVILA MA, 1994, CANCER RES, V54, P2424
   Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258
   Cai X, 2013, CURR MED CHEM, V20, P2572, DOI 10.2174/09298673113209990120
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   de Moraes TAP, 2014, MOLECULES, V19, P13188, DOI 10.3390/molecules190913188
   Diaz-Moralli S, 2013, PHARMACOL THERAPEUT, V138, P255, DOI 10.1016/j.pharmthera.2013.01.011
   Enayat S, 2014, NUTR CANCER, V66, P999, DOI 10.1080/01635581.2014.936949
   Eum KH, 2011, MOL CELL BIOCHEM, V348, P61, DOI 10.1007/s11010-010-0638-8
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Guo Y, 2015, J NUTR BIOCHEM, V26, P201, DOI 10.1016/j.jnutbio.2014.10.008
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu Y, 2014, MICROBES INFECT, V16, P727, DOI 10.1016/j.micinf.2014.07.005
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335
   Klotz LO, 2014, MOLECULES, V19, P14902, DOI 10.3390/molecules190914902
   Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369
   Li X, 2013, ACTA PHARMACOL SIN, V34, P612, DOI 10.1038/aps.2013.23
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Milackova I, 2015, GEN PHYSIOL BIOPHYS, V34, P51, DOI 10.4149/gpb_2014028
   Milackova I, 2015, J ENZYM INHIB MED CH, V30, P107, DOI 10.3109/14756366.2014.892935
   Myung K, 2004, P NATL ACAD SCI USA, V101, P15980, DOI 10.1073/pnas.0407010101
   Okamoto K, 2011, BIOCHEM J, V440, P63, DOI 10.1042/BJ20110610
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Qi ZT, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/315896
   Ranelletti FO, 2000, INT J CANCER, V85, P438, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;438::AID-IJC22&gt;3.0.CO;2-F
   RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0
   ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2
   Sak K, 2014, NUTR CANCER, V66, P177, DOI 10.1080/01635581.2014.864418
   Schmukler E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036828
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Verma Rajeshwar P., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P41, DOI 10.2174/187152006778226512
   Veverka M, 2013, CHEM PAP, V67, P76, DOI 10.2478/s11696-012-0240-5
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zimmermann C, 2013, CELL REP, V5, P1036, DOI 10.1016/j.celrep.2013.10.024
NR 49
TC 13
Z9 16
U1 4
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD APR 15
PY 2016
VL 596
BP 84
EP 98
DI 10.1016/j.abb.2016.03.004
PG 15
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DK0UE
UT WOS:000374626900008
PM 26946942
DA 2022-04-25
ER

PT J
AU Yan, C
   Luo, L
   Goto, S
   Urata, Y
   Guo, CY
   Doi, H
   Kitazato, K
   Li, TS
AF Yan, Chen
   Luo, Lan
   Goto, Shinji
   Urata, Yoshishige
   Guo, Chang-Ying
   Doi, Hanako
   Kitazato, Kaio
   Li, Tao-Sheng
TI Enhanced autophagy in colorectal cancer stem cells does not contribute
   to radio-resistance
SO ONCOTARGET
LA English
DT Article
DE cancer stem cells; autophagy; radio-resistance
ID TUMOR MICROENVIRONMENT; RADIORESISTANCE FACTOR; OXIDATIVE STRESS;
   RECTAL-CANCER; RADIATION; THERAPY; RADIOTHERAPY; INHIBITION;
   RADIOSENSITIVITY; 5-FLUOROURACIL
AB Autophagy, an essential catabolic pathway of degrading cellular components within the lysosome, has been found to benefit the growth and therapeutic resistance of cancer cells. In this study, we investigated the role of autophagy in the radiosensitivity of cancer stem cells. By separating CD44(+)/CD133(+) cancer stem cells from parental HCT8 human colorectal cancer cells, we found a significantly higher level of autophagy in the CD44(+)/CD133(+) cells than in the parental cells. Exposure to 5 Gy of eta-ray significantly damaged both CD44(+)/CD133(+) cells and parental cells, but the radiation-induced damage did not differ between the groups. Unexpectedly, autophagy was not significantly induced by radiation exposure in the CD44(+)/CD133(+) cells and parental cells. The inhibition of autophagy by the silencing of ATG7, a factor required for autophagy at the stage of autophagosome precursor synthesis, did not significantly change the growth and radiation-induced damage in both CD44(+)/CD133(+) cells and parental cells. Although an enhanced basic level of autophagy was found in the CD44(+)/CD133(+) cancer stem cells, our data suggest that the canonical autophagy in cancer cells plays few roles, if any, in radio-sensitivity.
C1 [Yan, Chen; Luo, Lan; Goto, Shinji; Urata, Yoshishige; Guo, Chang-Ying; Doi, Hanako; Li, Tao-Sheng] Nagasaki Univ, Dept Stem Cell Biol, Grad Sch Biomed Sci, Nagasaki, Japan.
   [Guo, Chang-Ying] Jiangxi Canc Hosp, Dept Thorac Surg, Nanchang, Peoples R China.
   [Kitazato, Kaio] Nagasaki Univ, Div Mol Pharmacol Infect Agents, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki, Japan.
RP Li, TS (corresponding author), Nagasaki Univ, Dept Stem Cell Biol, Grad Sch Biomed Sci, Nagasaki, Japan.; Kitazato, K (corresponding author), Nagasaki Univ, Div Mol Pharmacol Infect Agents, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki, Japan.
EM kkholi@nagasaki-u.ac.jp; litaoshe@nagasaki-u.ac.jp
RI chang-ying, guo/F-2770-2018
OI Luo, Lan/0000-0001-7549-9852; Li, Tao-Sheng/0000-0002-7653-8873
FU Ministry of Education, Science, Sports, Culture and Technology,
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT); collaborative Research program of Atomic-bomb Disease
   Institute of Nagasaki University; Grants-in-Aid for Scientific
   ResearchMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [25462061] Funding Source: KAKEN
FX This study was supported in part by a Grant-in-Aid from the Ministry of
   Education, Science, Sports, Culture and Technology, Japan, and
   collaborative Research program of the Atomic-bomb Disease Institute of
   Nagasaki University. The funder played no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Calloni R, 2013, STEM CELLS DEV, V22, P1455, DOI 10.1089/scd.2012.0637
   Chang L, 2016, ONCOTARGET, V7, P11002, DOI 10.18632/oncotarget.6760
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Gupta AK, 2002, CLIN CANCER RES, V8, P885
   Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Krishnan S, 2006, INT J RADIAT ONCOL, V66, P762, DOI 10.1016/j.ijrobp.2006.05.063
   Kuwahara Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.56
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Moussata D, 2012, AM J PATHOL, V181, P1271, DOI 10.1016/j.ajpath.2012.06.029
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028
   Sandur SK, 2009, INT J RADIAT ONCOL, V75, P534, DOI 10.1016/j.ijrobp.2009.06.034
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schaaf MBE, 2015, RADIOTHER ONCOL, V114, P406, DOI 10.1016/j.radonc.2015.02.019
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Urata Y, 2014, BIOCHEM BIOPH RES CO, V454, P376, DOI 10.1016/j.bbrc.2014.10.090
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Yoshida T, 2012, FREE RADICAL RES, V46, P147, DOI 10.3109/10715762.2011.645207
   Yuk JM, 2010, AUTOPHAGY, V6, P46, DOI 10.4161/auto.6.1.10325
NR 40
TC 12
Z9 13
U1 1
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 19
PY 2016
VL 7
IS 29
BP 45112
EP 45121
DI 10.18632/oncotarget.8972
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8SX
UT WOS:000385402300022
PM 27129175
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Gil, J
   Pesz, KA
   Sasiadek, MM
AF Gil, Justyna
   Pesz, Karolina A.
   Sasiadek, Maria M.
TI May autophagy be a novel biomarker and antitumor target in colorectal
   cancer?
SO BIOMARKERS IN MEDICINE
LA English
DT Review
DE ATG; autophagy; autophagosome; BECN1; colorectal cancer; gene
   expression; immunohistochemistry; LC3; protein expression
ID INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; MICROSATELLITE INSTABILITY;
   FAVORABLE PROGNOSIS; DOWN-REGULATION; CROHNS-DISEASE; CELL-DEATH; BECLIN
   1; EXPRESSION; APOPTOSIS
AB Autophagy is a catabolic process associated with intracellular self-digestion of damaged organelles or redundant proteins enabling maintenance of cell homeostasis. It is accepted that impaired autophagy is closely linked to cancer development and has been extensively studied in a variety of malignancies including colorectal cancer (CRC) to elucidate its influence on carcinogenesis, metastasis and antitumor therapy response. CRC remains a great epidemiological problem because of poor 5-year survival and treatment resistance. Many studies concerning autophagy in CRC gave inconsistent and contradictory results, illustrating a multifaceted nature of this process. In this review, we focus on current knowledge of autophagy in CRC development to determinate its role as a potential prognostic and predictive biomarker as well as target in antitumor therapy.
C1 [Gil, Justyna; Pesz, Karolina A.; Sasiadek, Maria M.] Wroclaw Med Univ, Dept Genet, Wroclaw, Poland.
RP Gil, J (corresponding author), Wroclaw Med Univ, Dept Genet, Wroclaw, Poland.
EM justyna.gil@umed.wroc.pl
RI /L-5618-2019
OI /0000-0003-0991-7686; Pesz, Karolina/0000-0003-1482-1021; Sasiadek,
   Maria/0000-0002-7599-7074
FU National Science Centre (Poland) [DEC-2012/07/D/NZ5/04305]
FX This work was financed from the funds of the National Science Centre
   (Poland) decision number DEC-2012/07/D/NZ5/04305. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Biemar Frederic, 2013, Cancer Biology Medicine, V10, P183, DOI 10.7497/j.issn.2095-3941.2013.04.001
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brown JC, 2012, COMPR PHYSIOL, V2, P2775, DOI 10.1002/cphy.c120005
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Chi KH, 2015, ONCOTARGET, V6, P16735, DOI 10.18632/oncotarget.3793
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Csongei V, 2010, WORLD J GASTROENTERO, V16, P176, DOI 10.3748/wjg.v16.i2.176
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hu XT, 2013, J PATHOL, V229, P62, DOI 10.1002/path.4093
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Karpinski P, 2008, J APPL GENET, V49, P1, DOI 10.1007/BF03195243
   Klionsky DJ, 2012, AUTOPHAGY, V8, P1281, DOI 10.4161/auto.21812
   Klionsky DJ, 2012, CELL RES, V22, P783, DOI 10.1038/cr.2012.39
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   LI Jing-gang, 2009, J NATURAL RESOURCE, V5, DOI DOI 10.2514/1.52476.31
   Li YH, 2015, WORLD J GASTROENTERO, V21, P9262, DOI 10.3748/wjg.v21.i31.9262
   Li ZD, 2008, PROG BIOCHEM BIOPHYS, V35, P1282
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Lin G, 2014, BRIT J CANCER, V111, P375, DOI 10.1038/bjc.2014.281
   Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Miracco C, 2007, INT J ONCOL, V30, P429
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Mukhtar E, 2012, CURR DRUG TARGETS, V13, P1831, DOI 10.2174/138945012804545489
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P99, DOI 10.1016/j.semcancer.2014.06.001
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P89, DOI 10.1016/j.semcancer.2014.05.004
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Palomino-Morales RJ, 2009, GENES IMMUN, V10, P356, DOI 10.1038/gene.2009.25
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Platt FM, 2012, J CELL BIOL, V199, P723, DOI 10.1083/jcb.201208152
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schneider M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-96
   Serbati Nadia, 2014, BMC Res Notes, V7, P570, DOI 10.1186/1756-0500-7-570
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui XB, 2015, CANCER LETT, V360, P106, DOI 10.1016/j.canlet.2015.02.009
   Tanemura M, 2009, TRANSPL P, V41, P334, DOI 10.1016/j.transproceed.2008.10.032
   Tschan MP, 2010, J INTERN MED, V268, P410, DOI 10.1111/j.1365-2796.2010.02266.x
   Verdoodt B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044132
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White EJ, 2011, AM J CANCER RES, V1, P362
   Wojciechowska U., ZACHOROWANIA ZGONY N
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xu YH, 2013, ONCOL LETT, V5, P411, DOI 10.3892/ol.2012.1015
   Yamazaki K, 2007, J HUM GENET, V52, P575, DOI 10.1007/s10038-007-0156-z
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Zhang HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096418
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
NR 87
TC 15
Z9 18
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1752-0363
EI 1752-0371
J9 BIOMARK MED
JI Biomark. Med.
PD OCT
PY 2016
VL 10
IS 10
BP 1081
EP 1094
DI 10.2217/bmm-2016-0083
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DZ8PM
UT WOS:000386133200008
PM 27626110
DA 2022-04-25
ER

PT J
AU Lin, FF
   Song, ZF
AF Lin, Fangfang
   Song, Zhangfa
TI LNCRNA UCA1 REGULATING CELL AUTOPHAGY THROUGH AKT/MTOR SIGNAL PATHWAY
   FOR INHIBITING COLON CANCER CELL PROLIFERATION, PROMOTING CELL
   APOPTOSIS, AND INCREASING CELL CYCLE ARREST
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE lncRNA UCA1; AMPK/mTOR signaling pathway; cell autophagy; colon cancer;
   cell proliferation; apoptosis; cell cycle
AB Objective: To analyze long-chain non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) regulating cell autophagy through the protein kinase B/rapamycin target protein (AKT/mTOR) signaling pathway, which inhibits colon cancer cell proliferation and promotes apoptosis and cell cycle arrest.
   Methods: Caco-2 cells were cultured at the same concentration and transfected into si-NC, si-UCA1, and si-UCA1 + 100nmol LRAPA (autophagy inhibitor) groups. Each group was set up with four replicate wells. After 6 h, it was replaced with dual antibodies and the medium of serum to be cultured for 24 h. Cell proliferation was measured using the CCK-8 method in each group. The cell apoptosis and cell cycle changes in each group were detected using flow cytometry, away from light. The expression of microtubule-associated protein light chain 3 (LC3), p62, AKT, and mTOR of cells in each group were determined using Western blotting and PCR.
   Results: The cell proliferation of each group was the same after 24 h. After longer periods of time, the differences in cell proliferation of each group were more obvious. At 72 h, compared with the Si-nc group, the proliferation ability of the si-uca1 and si-uca1 + Rapa group decreased significantly (P < 0.05), and the proliferation ability of the si-uca1 + Rapa group increased significantly (P < 0.05). Compared with the Si-nc group, the apoptosis ability of the si-uca1 and si-uca1 + Rapa group was significantly higher (P < 0.05), and the apoptosis ability of the si-uca1 + Rapa group was significantly lower than that of the si-uca1 group (P< 0.05). In comparison to the Si-nc group, the G1 phase cells in the si-uca1 group were significantly reduced, and the S phase and G phase cells were significantly increased (P < 0.05); compared with the si-uca1 group, the G1 phase cells of the si-uca1 + Rapa group were significantly increased, and the S phase and G phase cells were significantly reduced (P< 0.05). In comparison to the Si-nc group, the expression level of LC3 and p62 in the Si UCA1 group was significantly lower, and the expression levels of Akt and mTOR were significantly higher (P < 0.05)
   Conclusion: lncRNA UCA1 may regulate cell autophagy through the AKT/mTOR signaling pathway, thereby inhibiting colon cancer cell proliferation, promoting apoptosis, and blocking the G2 phase of the cell cycle.
C1 [Lin, Fangfang] Zhejiang Univ, Med Coll, Hangzhou 310011, Peoples R China.
   [Lin, Fangfang] Jiangshan Peoples Hosp, Dept Pathol, Jiangshan 324100, Peoples R China.
   [Song, Zhangfa] Zhejiang Univ, Med Coll, Shao Yifu Hosp, Dept Anorectal Surg, Hangzhou 310016, Peoples R China.
RP Song, ZF (corresponding author), Zhejiang Univ, Med Coll, Shao Yifu Hosp, Dept Anorectal Surg, Hangzhou 310016, Peoples R China.
EM zpty71@163.com
CR Ananthanarayanan M, 2016, HEPATOLOGY, V64, P16, DOI 10.1002/hep.28525
   Cui NI, 2019, J CELL BIOCHEM, V120, P376
   Dai ZB, 2018, ONCOL REP, V40, P867, DOI 10.3892/or.2018.6512
   Hamraz M, 2020, FASEB J, V34, P222, DOI 10.1096/fj.201900706RR
   He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79
   Jahanafrooz Z, 2020, J CELL PHYSIOL, V235, P4153, DOI 10.1002/jcp.29337
   Lee KH, 2017, MOL MED REP, V15, P2163, DOI 10.3892/mmr.2017.6254
   Nakayama H, 2019, INT J ONCOL, V55, P211, DOI 10.3892/ijo.2019.4812
   Schmuck R, 2020, LANGENBECK ARCH SURG, V405, P71, DOI 10.1007/s00423-019-01850-6
   Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7
   Wang Bishi, 2015, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V31, P898
   Wang WenXia, 2017, World Forestry Research, V30, P1
   Wang Y, 2018, J CELL BIOCHEM, V119, P1841, DOI 10.1002/jcb.26345
   Xiao C, 2016, EUR REV MED PHARMACO, V20, P2819
   Xu JS, 2019, ARTIF CELL NANOMED B, V47, P2634, DOI 10.1080/21691401.2019.1614594
   Zhuang B, 2019, J MOD ONCOL, V27, P924
NR 16
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2021
VL 37
IS 1
BP 139
EP 143
DI 10.19193/0393-6384_2021_1_20
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QM4UO
UT WOS:000621776000020
DA 2022-04-25
ER

PT J
AU Jin, HR
   Du, CH
   Wang, CZ
   Yuan, CS
   Du, W
AF Jin, Hong Ri
   Du, Charles H.
   Wang, Chong-Zhi
   Yuan, Chun-Su
   Du, Wei
TI Ginseng metabolite protopanaxadiol interferes with lipid metabolism and
   induces endoplasmic reticulum stress and p53 activation to promote
   cancer cell death
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE BH3-only protein Puma and Noxa; ER stress; fatty acid synthase (FASN);
   ginseng; p53; Protopanaxadiol (PPD)
ID UNFOLDED PROTEIN RESPONSE; COLON-CANCER; COMPOUND K; INHIBITION;
   APOPTOSIS; PATHWAY; FAMILY; BCL-2
AB Protopanaxadiol (PPD), a ginseng metabolite generated by the gut bacteria, was shown to induce colorectal cancer cell death and enhance the anticancer effect of chemotherapeutic agent 5-FU. However, the mechanism by which PPD promotes cancer cell death is not clear. In this manuscript, we showed that PPD activated p53 and endoplasmic reticulum (ER) stress and induced expression of BH3-only proteins Puma and Noxa to promote cell death. Induction of Puma by PPD was p53-dependent, whereas induction of Noxa was p53-independent. On the other hand, PPD also induced prosurvival mechanisms including autophagy and expression of Bcl2 family apoptosis regulator Mcl-1. Inhibition of autophagy or knockdown of Mcl-1 significantly enhanced PPD-induced cell death. Interestingly, PPD inhibited expression of genes involved in fatty acid and cholesterol biosynthesis and induced synergistic cancer cell death with fatty acid synthase inhibitor cerulenin. As PPD-induced ER stress was not significantly affected by inhibition of new protein synthesis, we suggest PPD may induce ER stress directly through causing lipid disequilibrium.
C1 [Jin, Hong Ri; Du, Wei] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
   [Du, Charles H.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Wang, Chong-Zhi; Yuan, Chun-Su] Univ Chicago, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
   [Wang, Chong-Zhi; Yuan, Chun-Su] Univ Chicago, Dept Anesthesia & Crit Care, Box 428, Chicago, IL 60637 USA.
   [Jin, Hong Ri] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
RP Du, W (corresponding author), Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
EM wei@uchicago.edu
RI Wang, Chong-Zhi/B-8337-2014
OI Wang, Chong-Zhi/0000-0002-0950-2109; Du, Wei/0000-0003-3962-370X
FU National Institute of Health, USAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [NIH R01
   GM120046]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM120046] Funding Source: NIH RePORTER
FX National Institute of Health, Grant/Award Number: NIH R01 GM120046, USA
CR Bae EA, 2000, BIOL PHARM BULL, V23, P1481, DOI 10.1248/bpb.23.1481
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364
   Hasegawa H, 1996, PLANTA MED, V62, P453, DOI 10.1055/s-2006-957938
   Hou NS, 2014, P NATL ACAD SCI USA, V111, pE2271, DOI 10.1073/pnas.1318262111
   Jin HR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.169
   Jin HR, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.122
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019
   Little JL, 2007, CANCER RES, V67, P1262, DOI 10.1158/0008-5472.CAN-06-1794
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829
   Volmer R, 2015, CURR OPIN CELL BIOL, V33, P67, DOI 10.1016/j.ceb.2014.12.002
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang CZ, 2015, NUTRIENTS, V7, P799, DOI 10.3390/nu7020799
   Wang CZ, 2012, INT J ONCOL, V40, P1970, DOI 10.3892/ijo.2012.1399
   Zhang L, 2011, CELL DEATH DIFFER, V18, P864, DOI 10.1038/cdd.2010.152
   Zhang ZY, 2015, J PHARMACOL SCI, V127, P83, DOI 10.1016/j.jphs.2014.11.003
   Zhang ZY, 2013, INT J MOL SCI, V14, P2980, DOI 10.3390/ijms14022980
NR 25
TC 7
Z9 7
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD MAR
PY 2019
VL 33
IS 3
BP 610
EP 617
DI 10.1002/ptr.6249
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HO6UH
UT WOS:000461067400012
PM 30537241
OA Green Accepted, Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, F
   Wu, DL
   Chen, JX
   Chen, SL
   He, FR
   Fu, HS
   Wu, QH
   Liu, S
   Li, XG
   Wang, WF
AF Wang, Fei
   Wu, Dinglan
   Chen, Jianxiang
   Chen, Shiliang
   He, Fengrong
   Fu, Housheng
   Wu, Qinghui
   Liu, Shuan
   Li, Xionggen
   Wang, Weifu
TI Long non-coding RNA HOXA-AS2 promotes the migration, invasion and
   stemness of bladder cancer via regulating miR-125b/Smad2 axis
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Bladder cancer; HOXA-AS2; miR-125b; Samd2; Migration and invasion;
   Stemness
ID ANTISENSE LINCRNA HOXA-AS2; COLON-CANCER; MESENCHYMAL TRANSITION;
   APOPTOSIS; PROLIFERATION; RESISTANCE; DIHYDROTANSHINONE;
   CRYPTOTANSHINONE; STATISTICS; AUTOPHAGY
AB Long non-coding RNA HOXA-AS2 (HOXA cluster antisense RNA 2) has been reported to function as an oncogene in different types of cancers including breast cancer, liver cancer, gastric cancer and colorectal cancer, etc. However, its role in the development and progression of bladder cancer remains unknown. This study aimed to examine the expression of HOXA-AS2 in bladder cancer, to explore its role in the migration, invasion and stemness of bladder cancer cells and to further identify the potential downstream target miRNAs of HOXA-AS2 in this type of cancer. Our results firstly demonstrated the upregulation of HOXA-AS2 in both bladder cancer cells and clinical bladder tumors. Such upregulation was also positively correlated with the advanced stage, invasion and lymph node metastasis of bladder cancer as well as the expression of cancer stem cell marker OCT4 in patients. After knockdown of HOXA-AS2 in bladder cancer 5637 and T24 cells, the migration, invasion and sternness of cancer cells were significantly inhibited, indicating the capability of HOXA-AS2 to promote the migration, invasion and sternness of bladder cancer cells. Knockdown of HOXA-AS2 also suppressed in vivo tumor growth in the nude mice. Furthermore, this study also identified miR-125b as a downstream target of HOXA-AS2 and revealed the downregulation of miR-125b by HOXA-AS2 as well as the involvement of HOXA-AS2/miR-125b/Smad2 interactions in the functional role of HOXA-AS2 in mediating the migration, invasion and sternness of bladder cancer cells. Together, our findings suggest that HOXA-AS2 might be a potential biomarker and target for the diagnosis, monitoring and treatment of bladder cancer.
C1 [Wang, Fei; He, Fengrong; Fu, Housheng; Wu, Qinghui; Liu, Shuan; Wang, Weifu] Peoples Hosp Hainan Prov, Dept Urol, Haikou, Hainan, Peoples R China.
   [Wu, Dinglan] Southern Med Univ, Shenzhen Hosp, Clin Innovat & Res Ctr, Shenzhen, Peoples R China.
   [Chen, Jianxiang] Xiangnan Coll, Affiliated Hosp, Dept Urol, Cenzhou, Peoples R China.
   [Chen, Shiliang] Peoples Hosp Hainan Prov, Dept Pathol, Haikou, Hainan, Peoples R China.
   [Li, Xionggen] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Gen Practice, Shenzhen, Peoples R China.
RP Wang, WF (corresponding author), Peoples Hosp Hainan Prov, Dept Urol, Haikou, Hainan, Peoples R China.; Li, XG (corresponding author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Gen Practice, Shenzhen, Peoples R China.
EM shengshengzhu@yeah.net; szs_lxg@sina.com
OI Wu, Dinglan/0000-0002-5057-9626
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81760461]; Major Scientific and
   Technological Hainan Province [ZDZX20130036]; Hainan Province Scientific
   and Technological Cooperation Special Foundation [KJHZ2015-25]
FX This study was supported by National Natural Science Foundation of China
   (Grant no. 81760461), Major Scientific and Technological Hainan Province
   (Grant no. ZDZX20130036) and Hainan Province Scientific and
   Technological Cooperation Special Foundation (Grant no. KJHZ2015-25).
CR Chen SS, 2017, ONCOTARGET, V8, P110685, DOI 10.18632/oncotarget.22161
   Chen W, 2017, ONCOTARGETS THER, V10, P1503, DOI 10.2147/OTT.S130139
   Ding J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.84
   Fang Y, 2017, ONCOTARGET, V8, P46090, DOI 10.18632/oncotarget.17552
   Gao YN, 2018, CELL PHYSIOL BIOCHEM, V45, P131, DOI 10.1159/000486253
   Han YH, 2013, J SURG ONCOL, V107, P555, DOI 10.1002/jso.23264
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Hu T, 2014, PHYTOMEDICINE, V21, P1264, DOI 10.1016/j.phymed.2014.06.013
   Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509
   Li Y, 2017, ONCOTARGET, V8, P66668, DOI 10.18632/oncotarget.19112
   Lian YF, 2017, AM J TRANSL RES, V9, P5496
   Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012
   Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003
   Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6
   Thomas H, 2017, NAT REV GASTRO HEPAT, V14, P691, DOI 10.1038/nrgastro.2017.156
   Tong GL, 2017, AM J TRANSL RES, V9, P4545
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang FQ, 2016, CELL PHYSIOL BIOCHEM, V40, P287, DOI 10.1159/000452545
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang YH, 2018, CELL CYCLE, V17, P1637, DOI 10.1080/15384101.2018.1489174
   Xie M, 2015, ONCOTARGET, V6, P33587, DOI 10.18632/oncotarget.5599
   Xu ZY, 2017, CHEM-BIOL INTERACT, V273, P48, DOI 10.1016/j.cbi.2017.06.003
   Xue M, 2016, CANCER SCI, V107, P18, DOI 10.1111/cas.12844
   Yang HJ, 2018, J CELL MOL MED, V22, P1650, DOI 10.1111/jcmm.13442
   Yang L, 2017, NEOPLASMA, V64, P847, DOI 10.4149/neo_2017_606
   Zhang L, 2018, MOL CANCER THER, V17, P1816, DOI 10.1158/1535-7163.MCT-18-0124
   Zhao H, 2013, J CELL BIOCHEM, V114, P2375, DOI 10.1002/jcb.24586
NR 30
TC 21
Z9 23
U1 2
U2 18
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 1
PY 2019
VL 375
IS 1
BP 1
EP 10
DI 10.1016/j.yexcr.2018.11.005
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA HI7KX
UT WOS:000456636200001
PM 30412716
DA 2022-04-25
ER

PT J
AU Crighton, D
   Wilkinson, S
   Ryan, KM
AF Crighton, Diane
   Wilkinson, Simon
   Ryan, Kevin M.
TI DRAM links autophagy to p53 and programmed cell death
SO AUTOPHAGY
LA English
DT Article
DE DRAM; p53; autophagy; apoptosis; cancer
ID TUMOR-SUPPRESSOR; COLON-CANCER; BECLIN-1; PROTEIN; GENE; TUMORIGENESIS;
   APOPTOSIS; UVRAG
AB It is clear that changes in autophagy and autophagy regulators occur during tumor development and that this can have profound effects in certain tumor settings. The fact that p53, a key tumor suppressor mutated in approximately 50% of human cancers, has now also been shown to induce autophagy, has placed autophagy center stage in the minds of those interested in the development and treatment of malignant disease. p53 is a transcription factor that responds to cellular stress and prevents the propagation of cells which may otherwise form a tumor. The recent discovery, therefore, of DRAM (damage-regulated autophagy modulator) as a new p53 target which modulates autophagy is a major step forward in understanding how p53 controls autophagy and how this relates to tumor suppression. DRAM is a lysosomal protein that is not only critical for the ability of p53 to induce autophagy, but also for p53's ability to induce programmed cell death - a facet of p53 considered central to its tumor suppressive effects. The fact that DRAM is also inactivated in certain cancers underscores its importance and highlights the possibility that autophagy may have a more profound role in cancer than was first believed.
C1 Beatson Inst Canc Res, Canc Res UK Beatson Labs, Tumour Cell Death Lab, Glasgow G61 1BD, Lanark, Scotland.
RP Ryan, KM (corresponding author), Beatson Inst Canc Res, Canc Res UK Beatson Labs, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
EM k.ryan@beatson.gla.ac.uk
OI Wilkinson, Simon/0000-0003-1082-8218; Ryan, Kevin M./0000-0002-1059-9681
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458
   Crighton D, 2004, BBA-REV CANCER, V1705, P3, DOI 10.1016/j.bbcan.2004.09.001
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156
   Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 22
TC 153
Z9 162
U1 1
U2 8
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD JAN-FEB
PY 2007
VL 3
IS 1
BP 72
EP 74
DI 10.4161/auto.3438
PG 3
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 126FY
UT WOS:000243499200022
PM 17102582
OA Bronze
DA 2022-04-25
ER

PT J
AU Jing, YM
   Liang, WQ
   Liu, J
   Zhang, L
   Wei, JG
   Yang, JH
   Zhang, Y
   Huang, ZL
AF Jing, Yuanming
   Liang, Wenqing
   Liu, Jian
   Zhang, Lin
   Wei, Jianguo
   Yang, Jianhui
   Zhang, Yu
   Huang, Zongliang
TI Autophagy-mediating microRNAs in cancer chemoresistance
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Review
DE Autophagy; Cancer; Chemoresistance; Hypoxia; MicroRNA
ID CELL LUNG-CANCER; CISPLATIN-INDUCED APOPTOSIS; DRUG-RESISTANCE;
   HEPATOCELLULAR-CARCINOMA; MULTIDRUG-RESISTANCE; MOLECULAR-MECHANISMS;
   INHIBITING AUTOPHAGY; COLORECTAL-CANCER; MYELOID-LEUKEMIA;
   DOWN-REGULATION
AB Chemoresistance is a complex phenomenon responsible for failure in response to chemotherapy agents and more than 90% of deaths in cancer patients. MicroRNAs (miRNAs), as a subgroup of non-coding RNAs with lengths between 21 and 25 nucleotides, are involved in various cancer processes like chemoresistance via interacting with their target mRNAs and suppressing their expression. Autophagy is a greatly conserved procedure involving the lysosomal degradation of cytoplasmic contents and organelles to deal with environmental stresses like hypoxia and starvation. Autophagy contributes to response to chemotherapy agents: autophagy can act as a protective mechanism for mediating the resistance in response to chemotherapy or can induce autophagic cell death and mediate the sensitivity to chemotherapy. On the other hand, one of the processes targeted by microRNAs in the regulation of chemoresistance is autophagy. Hence, we studied the literatures on chemoresistance mechanisms, the miRNAs' role in cancer, and the miRNAs' role in chemoresistance by modulating autophagy.
C1 [Jing, Yuanming; Zhang, Lin; Wei, Jianguo; Yang, Jianhui; Zhang, Yu] Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Gastrointestinal Surg,Shaoxing Peoples Hosp, Shaoxing 312000, Zhejiang, Peoples R China.
   [Liang, Wenqing] Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthopaed,Shaoxing Peoples Hosp, Shaoxing 312000, Zhejiang, Peoples R China.
   [Liu, Jian] Shanghai Oriental Hepatobiliary Hosp, Dept Hepatobiliary Surg, Shanghai 200438, Peoples R China.
   [Huang, Zongliang] Tongji Univ, Sch Med, Tongji Hosp, Dept Radiol, 389 Xincun Rd, Shanghai 200065, Peoples R China.
RP Huang, ZL (corresponding author), Tongji Univ, Sch Med, Tongji Hosp, Dept Radiol, 389 Xincun Rd, Shanghai 200065, Peoples R China.
EM 5224471@qq.com; 13587342011@163.com; jianliu926@163.com;
   zhangl@usx.edu.cn; mickmouse88@163.com; yjheart@126.com;
   25216838@qq.com; zonglianghuang@tongji.edu.cn
OI Zhang, Lin/0000-0002-3767-0249
FU Nature Science Foundation of Zhejiang ProvinceNatural Science Foundation
   of Zhejiang Province [LY18H060013]; Public Welfare Application Plan
   Project of Shaoxing [2018C30109]
FX The current work was funded by Nature Science Foundation of Zhejiang
   Province (#LY18H060013 to WQL) and Public Welfare Application Plan
   Project of Shaoxing (#2018C30109 to YMJ).
CR Abedi P, 2020, BRIT J BIOMED SCI, V77, P118, DOI 10.1080/09674845.2020.1731050
   Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Allen KE, 2010, MOL CANCER THER, V9, P3126, DOI 10.1158/1535-7163.MCT-10-0397
   Ao X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.367
   Bar-Yosef T, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00196
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556
   Bhutia SK, 2010, P NATL ACAD SCI USA, V107, P22243, DOI 10.1073/pnas.1009479107
   Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741
   Boe SO, 2010, AUTOPHAGY, V6, P964, DOI 10.4161/auto.6.7.13066
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cajuso T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11770-0
   Casas C, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00177
   Chai S, 2014, ONCOTARGET, V5, P5725, DOI 10.18632/oncotarget.2167
   Chang Zhiqiang, 2014, ScientificWorldJournal, V2014, P794756, DOI 10.1155/2014/794756
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen H., 2019, J THERM SCI, V1, P1, DOI DOI 10.1016/j.biopha.2019.109277
   Chen HL, 2017, ONCOL LETT, V13, P2021, DOI 10.3892/ol.2017.5727
   Chen PH, 2018, CHEM-BIOL INTERACT, V291, P144, DOI 10.1016/j.cbi.2018.06.006
   Chen QN, 2017, ONCOTARGET, V8, P1925, DOI 10.18632/oncotarget.12461
   Chen R, 2017, MOL MED REP, V15, P1326, DOI 10.3892/mmr.2017.6149
   CHEN S, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9
   Chen Wei-Juan, 2010, Chin J Cancer, V29, P151
   Chen WX, 2019, THERANOSTICS, V9, P5739, DOI 10.7150/thno.37556
   Chen YB, 2020, APOPTOSIS, V25, P205, DOI 10.1007/s10495-019-01588-y
   Chen YQ, 2017, CELL PHYSIOL BIOCHEM, V41, P1370, DOI 10.1159/000467896
   Cheng Y, 2020, ONCOL RES FEATUR PRE
   Cui YJ, 2018, ONCOL REP, V39, P1649, DOI 10.3892/or.2018.6259
   Datta S, 2019, APOPTOSIS, V24, P414, DOI 10.1007/s10495-019-01526-y
   Derynck R, 2019, DEV CELL, V49, P313, DOI 10.1016/j.devcel.2019.04.026
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dong Z, 2014, CANCER LETT, V343, P249, DOI 10.1016/j.canlet.2013.09.034
   Dou LP, 2013, MOL BIOL REP, V40, P6811, DOI 10.1007/s11033-013-2798-6
   Du XM, 2018, EXP THER MED, V15, P599, DOI 10.3892/etm.2017.5354
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fan XL, 2017, BIOMED PHARMACOTHER, V88, P507, DOI 10.1016/j.biopha.2017.01.058
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Feng YH, 2016, BIOMED REP, V5, P395, DOI 10.3892/br.2016.747
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391
   Fletcher JI, 2016, DRUG RESIST UPDATE, V26, P1, DOI 10.1016/j.drup.2016.03.001
   Fornari F, 2017, CLIN CANCER RES, V23, P3953, DOI 10.1158/1078-0432.CCR-16-1464
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gao J, 2011, ONCOL LETT, V2, P1019, DOI 10.3892/ol.2011.413
   Gattolliat CH, 2011, BRIT J CANCER, V105, P1352, DOI 10.1038/bjc.2011.388
   GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570
   Goler-Baron V, 2012, BIOCHEM PHARMACOL, V83, P1340, DOI 10.1016/j.bcp.2012.01.033
   Goradel NH, 2019, J CELL PHYSIOL, V234, P1099, DOI 10.1002/jcp.27051
   Goradel NH, 2018, J CELL PHYSIOL, V233, P2902, DOI 10.1002/jcp.26029
   Goradel NH, 2017, TOXICOL APPL PHARM, V335, P56, DOI 10.1016/j.taap.2017.09.022
   Gottesman MM, 2016, ANNU REV PHARMACOL, V56, P85, DOI 10.1146/annurev-pharmtox-010715-103111
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Goussetis DJ, 2012, BLOOD, V120, P3555, DOI 10.1182/blood-2012-01-402578
   Guo BQ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2790-3
   Guo H, 2014, NAT COMMUN, V5, DOI [10.1038/ncomms5986, 10.1038/ncomms6276]
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Han BJ, 2019, INT J BIOL MACROMOL, V125, P544, DOI 10.1016/j.ijbiomac.2018.12.075
   Han GD, 2019, J CELL BIOCHEM, V120, P11390, DOI 10.1002/jcb.28416
   Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91
   Hatzl S, 2020, CANCERS, V12, DOI 10.3390/cancers12020496
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He XJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-218
   Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475
   Hong L, 2013, EXPERT OPIN THER TAR, V17, P1073, DOI 10.1517/14728222.2013.819853
   Hosoya N, 2014, CANCER SCI, V105, P370, DOI 10.1111/cas.12366
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Huang JC, 2017, ONCOTARGET, V9, P10483, DOI [DOI 10.18632/ONCOTARGET.23711, 10.18632/oncotarget.23711]
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Huang NN, 2015, CANCER BIOL THER, V16, P941, DOI 10.1080/15384047.2015.1040963
   HuCDF, 2010, MED SCI MONITOR, V16, P30
   Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409
   Jiang CM, 2018, BIOMED PHARMACOTHER, V97, P844, DOI 10.1016/j.biopha.2017.10.146
   Jiang KB, 2017, AM J CANCER RES, V7, P1407
   Jin F, 2018, CELL DEATH DIS, V8, pe2540
   Kartal-Yandim M, 2016, CRIT REV BIOTECHNOL, V36, P716, DOI 10.3109/07388551.2015.1015957
   Khandia R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070674
   Khordadmehr M, 2019, J CELL PHYSIOL, V234, P16861, DOI 10.1002/jcp.28368
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Lee YJ, 2012, INT J MED SCI, V9, P881, DOI 10.7150/ijms.5011
   Lei W, 2018, BMC CANCER, V18, DOI [10.1186/S12885-018-4460-0, 10.1186/s12885-018-4460-0]
   Li H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0618-0
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Li W, 2016, DRUG RESIST UPDATE, V27, P14, DOI 10.1016/j.drup.2016.05.001
   Li XF, 2014, TUMOR BIOL, V35, P6021, DOI [10.1007/s13277-014-1797-0, 10.1007/s13277-014-2426-7]
   Li YQ, 2021, SEP PURIF REV, V50, P115, DOI 10.1080/15422119.2019.1623253
   Li YS, 2016, ONCOL LETT, V12, P4203, DOI 10.3892/ol.2016.5172
   Liang L, 2020, ACTA PHARMACOL SIN B, V10, P1036, DOI 10.1016/j.apsb.2019.11.009
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liebhardt S, 2010, ANTICANCER RES, V30, P1707
   Liu JG, 2018, ONCOL REP, V39, P1631, DOI 10.3892/or.2018.6268
   Liu MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43717
   Liu X, 2015, J CANCER RES CLIN, V141, P381, DOI 10.1007/s00432-014-1765-5
   Liu ZR, 2016, LIFE SCI, V149, P104, DOI 10.1016/j.lfs.2016.02.059
   Long JP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/373574
   Lu F, 2014, INT J ONCOL, V45, P383, DOI 10.3892/ijo.2014.2390
   Lu JF, 2013, PHARMACOL RES, V76, P77, DOI 10.1016/j.phrs.2013.07.009
   Lu X, 2020, ONCOGENE, V39, P234, DOI 10.1038/s41388-019-0986-0
   Manolitsas TP, 1997, BRIT J CANCER, V75, P1398, DOI 10.1038/bjc.1997.238
   Mao L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9623412
   Meng CY, 2020, ONCOL REP, V43, P1169, DOI 10.3892/or.2020.7492
   Meng FD, 2016, CLIMATIC CHANGE, V139, P579, DOI 10.1007/s10584-016-1802-2
   Michael M, 2005, J CLIN ONCOL, V23, P205, DOI 10.1200/JCO.2005.02.120
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Nasser Hashemi G., 2017, CURRENT REGENERATIVE, V7, P46, DOI [DOI 10.2174/2468424408666180315101232, 10.2174/2468424408666180315101232]
   Naves T, 2013, BIOCHEM PHARMACOL, V85, P1153, DOI 10.1016/j.bcp.2013.01.022
   Nikolaou M, 2018, CLIN EXP METASTAS, V35, P309, DOI 10.1007/s10585-018-9903-0
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   Pan BZ, 2015, ONCOTARGET, V6, P32805, DOI 10.18632/oncotarget.5352
   Pan BZ, 2015, ONCOTARGET, V6, P317, DOI 10.18632/oncotarget.2787
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Ping W, 2018, BIOCHEM BIOPH RES CO, V495, P2482, DOI 10.1016/j.bbrc.2017.12.096
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574
   Rak B, 2017, CANCER GENOM PROTEOM, V14, P389, DOI 10.21873/cgp.20049
   Ran XM, 2015, INT J CLIN EXP PATHO, V8, P6617
   RIORDAN JR, 1979, J BIOL CHEM, V254, P2701
   Roma-Rodrigues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040840
   Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Seca H, 2013, CURR DRUG TARGETS, V14, P1135, DOI 10.2174/13894501113149990185
   Senthebane DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071586
   Sharma A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.155
   Shen CC, 2013, INT J MOL MED, V32, P448, DOI 10.3892/ijmm.2013.1399
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Si WG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0587-8
   Sishc BJ, 2017, CANCERS, V9, DOI 10.3390/cancers9070081
   Sodani K, 2012, CHIN J CANCER, V31, P58, DOI 10.5732/cjc.011.10329
   Song LQ, 2014, J CELL BIOCHEM, V115, P1234, DOI 10.1002/jcb.24665
   Sousa D, 2015, TRENDS MOL MED, V21, P595, DOI 10.1016/j.molmed.2015.08.002
   Sun D, 2018, INT J ONCOL, V52, P1491, DOI 10.3892/ijo.2018.4315
   Sun W., 2018, CELL DEATH DIS, V9, P1
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takahashi R, 2019, CANCER SCI, V110, P1140, DOI 10.1111/cas.13965
   Takenaka T, 2007, INT J CANCER, V121, P895, DOI 10.1002/ijc.22738
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tian XY, 2007, ONCOL REP, V18, P927
   Tian YF, 2018, MOL MED REP, V18, P5603, DOI 10.3892/mmr.2018.9572
   Ueda S, 2011, ANN SURG ONCOL, V18, P1204, DOI 10.1245/s10434-010-1414-4
   Um JH, 2004, EXP MOL MED, V36, P233, DOI 10.1038/emm.2004.32
   Wan LL, 2014, CANCER RES, V74, P5336, DOI 10.1158/0008-5472.CAN-14-1349
   Wang CZ, 2018, AM J TRANSL RES, V10, P3310
   Wang G, 2010, INT UROL NEPHROL, V42, P95, DOI 10.1007/s11255-009-9584-3
   Wang HY, 2014, ONCOL LETT, V8, P1492, DOI 10.3892/ol.2014.2417
   Wang JY, 2017, INT J ONCOL, V50, P345, DOI 10.3892/ijo.2016.3811
   Wang P, 2019, ORTHOP SURG, V11, P285, DOI 10.1111/os.12442
   Wang QW, 2019, CANCER MANAG RES, V11, P10327, DOI 10.2147/CMAR.S231971
   Wang TR, 2015, ONCOL LETT, V9, P967, DOI 10.3892/ol.2014.2723
   Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001
   Wang ZQ, 2014, FEBS LETT, V588, P4504, DOI 10.1016/j.febslet.2014.09.047
   Westhoff MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083128
   Wild CP, 2019, NAT REV CANCER, V19, P123, DOI 10.1038/s41568-019-0110-3
   Willoughby CE, 2019, J CLIN INVEST, V130
   Wu L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00137
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Xiong J, 2017, ONCOTARGET, V8, P6555, DOI 10.18632/oncotarget.14149
   Xu CG, 2016, EUR REV MED PHARMACO, V20, P4362
   Xu HT, 2018, ONCOL LETT, V15, P9142, DOI 10.3892/ol.2018.8463
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju162
   Xu X, 2018, J CANCER, V9, P3557, DOI 10.7150/jca.26350
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yamakuchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020291
   Yang C, 2017, CELL PHYSIOL BIOCHEM, V44, P843, DOI 10.1159/000485351
   Yang N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.358
   Yang X, 2017, CELL PHYSIOL BIOCHEM, V43, P1126, DOI 10.1159/000481754
   Ye L, 2017, MOL THER-NUCL ACIDS, V7, P453, DOI 10.1016/j.omtn.2017.05.006
   Yong X, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/605045
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yu PN, 2014, INT J CANCER, V134, P542, DOI 10.1002/ijc.28399
   Yu X, 2015, MOL CANCER, V14, P1, DOI DOI 10.1186/S12943-015-0480-4
   Yu XF, 2016, BIOMED PHARMACOTHER, V77, P37, DOI 10.1016/j.biopha.2015.11.005
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yu Y, 2019, DRUG DES DEV THER, V13, P3717, DOI 10.2147/DDDT.S225671
   Yu ZY, 2015, CANCER LETT, V367, P58, DOI 10.1016/j.canlet.2015.07.007
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zahreddine H, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00028
   Zargar Amin, 2019, Chronic Dis Transl Med, V5, P258, DOI 10.1016/j.cdtm.2019.11.001
   Zhang GQ, 2016, BIOCHEM BIOPH RES CO, V469, P189, DOI 10.1016/j.bbrc.2015.11.099
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   ZHANG KH, 2018, ENVIRON TECHNOL, V3, P1, DOI DOI 10.1109/jphot.2018.2841968
   Zhang XD, 2010, ACTA PHARMACOL SIN, V31, P1208, DOI 10.1038/aps.2010.151
   Zhang XF, 2019, BIOCHEM BIOPH RES CO, V510, P508, DOI 10.1016/j.bbrc.2019.01.109
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zhang YF, 2016, ONCOL REP, V36, P480, DOI 10.3892/or.2016.4828
   Zhang Y, 2017, TRANSL ONCOL, V10, P410, DOI 10.1016/j.tranon.2017.03.003
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   Zhao SC, 2015, J BUON, V20, P588
   Zhao S, 2017, ONCOTARGET, V8, P7502, DOI 10.18632/oncotarget.10649
   Zhao XR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02690
   Zhao Z, 2012, AUTOPHAGY, V8, P1392, DOI 10.4161/auto.21035
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
   Zhong ZP, 2014, MOL MED REP, V10, P2575, DOI 10.3892/mmr.2014.2494
   Zhu HG, 2020, EXP THER MED, V19, P1797, DOI 10.3892/etm.2020.8418
   Zhu JW, 2013, EMBO MOL MED, V5, P353, DOI 10.1002/emmm.201201760
   Zhu K, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S7-S8
   Zhuang ZH, 2017, ONCOL REP, V38, P2051, DOI 10.3892/or.2017.5899
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 208
TC 12
Z9 12
U1 5
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742-2091
EI 1573-6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD DEC
PY 2020
VL 36
IS 6
BP 517
EP 536
DI 10.1007/s10565-020-09553-1
EA SEP 2020
PG 20
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Toxicology
GA OQ9IO
UT WOS:000565177200001
PM 32875398
DA 2022-04-25
ER

PT J
AU Zhu, FX
   Wang, XT
   Zeng, HQ
   Yin, ZH
   Ye, ZZ
AF Zhu, Fang-Xiao
   Wang, Xiao-Tao
   Zeng, Hui-Qiong
   Yin, Zhi-Hua
   Ye, Zhi-Zhong
TI A predicted risk score based on the expression of 16 autophagy-related
   genes for multiple myeloma survival
SO ONCOLOGY LETTERS
LA English
DT Article
DE multiple myeloma; autophagy; autophagy-related genes; survival
ID SET ENRICHMENT ANALYSIS; BREAST-CANCER; COLON-CANCER; CELLS; HYPOXIA;
   MACROAUTOPHAGY; RESISTANCE; INHIBITION; PATHWAY
AB \ Autophagy has an important role in the pathogenesis of plasma cell development and multiple myeloma (MM); however, the prognostic role of autophagy-related genes (ARGs) in MM remains undefined. In the present study, the expression profiles of 234 ARGs were obtained from a Gene Expression Omnibus dataset (accession GSE24080), which contains 559 samples of patients with MM analyzed with 54,675 probes. Univariate Cox regression analysis identified 55 ARGs that were significantly associated with event-free survival of MM. Furthermore, a risk score with 16 survival-associated ARGs was developed using multivariate Cox regression analysis, including ATIC, BNIP3L, CALCOCO2, DNAJB1, DNAJB9, EIF4EBP1, EVA1A, FKBP1B, FOXO1, FOXO3, GABARAP, HIF1A, NCKAP1, PRKAR1A and SUPT20H, was constructed. Using this prognostic signature, patients with MM could be separated into high- and low-risk groups with distinct clinical outcomes. The area under the curve values for the receiver operating characteristic curves were 0.740, 0.741 and 0.712 for 3, 5 and 10 years prognosis predictions, respectively. Notably, the prognostic role of this risk score could be validated with another four independent cohorts (accessions: GSE57317, GSE4581, GSE4452 and GSE4204). In conclusion, ARGs may serve vital roles in the progression of MM, and the ARGs-based prognostic model may provide novel ideas for clinical applications in MM.
C1 [Zhu, Fang-Xiao; Zeng, Hui-Qiong; Yin, Zhi-Hua; Ye, Zhi-Zhong] Shenzhen Futian Hosp Rheumat Dis, Dept Rheumatol, 22 Nonglin Rd, Shenzhen 518040, Guangdong, Peoples R China.
   [Wang, Xiao-Tao] Guilin Med Coll, Affiliated Hosp 2, Dept Hematol, Guilin 541001, Guangxi, Peoples R China.
RP Ye, ZZ (corresponding author), Shenzhen Futian Hosp Rheumat Dis, Dept Rheumatol, 22 Nonglin Rd, Shenzhen 518040, Guangdong, Peoples R China.
EM yezhizhong2000@163.com
FU Program of Scientific and Technology Project (Guilin Science Research
   and Technology Development) [2016012706-2]; Sanming Project of Medicine
   in Shenzhen [SZSM201602087]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81460038];
   Guangxi Natural Science Foundation of China [2017GXNSFAA198178];
   Shenzhen Futian Public Welfare Scientific Research Project [FTWS2017020,
   FTWS2018005]
FX The present study was supported by the Program of Scientific and
   Technology Project (Guilin Science Research and Technology Development;
   grant no. 2016012706-2), Sanming Project of Medicine in Shenzhen (grant
   no. SZSM201602087), National Natural Science Foundation of China (grant
   no. 81460038), Guangxi Natural Science Foundation of China (grant no.
   2017GXNSFAA198178) and Shenzhen Futian Public Welfare Scientific
   Research Project (grant nos. FTWS2017020 and FTWS2018005).
CR Bednarczyk M, 2017, J BIOL REG HOMEOS AG, V31, P923
   Boga JA, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12534
   Bosseler M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061551
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chen D, 2018, ONCOL LETT, V15, P7104, DOI 10.3892/ol.2018.8206
   Coudre C, 2016, CELL CYCLE, V15, P2174, DOI 10.1080/15384101.2016.1196302
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   De Bruyne E, 2010, BLOOD, V115, P2430, DOI 10.1182/blood-2009-07-232801
   Desantis V, 2018, TRANSL ONCOL, V11, P1350, DOI 10.1016/j.tranon.2018.08.014
   Du L, 2017, CELL PHYSIOL BIOCHEM, V42, P673, DOI 10.1159/000477885
   Duan X, 2018, APOPTOSIS, V23, P587, DOI 10.1007/s10495-018-1489-0
   Feldmann A, 2017, BIOCHEM BIOPH RES CO, V486, P738, DOI 10.1016/j.bbrc.2017.03.112
   Filippi I, 2018, CELL PHYSIOL BIOCHEM, V46, P203, DOI 10.1159/000488423
   Gandolfi S, 2018, BLOOD, V132, P1114, DOI 10.1182/blood-2017-05-693606
   Guillaume JD, 2019, METHODS MOL BIOL, V1862, P151, DOI 10.1007/978-1-4939-8769-6_11
   Han Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04994-x
   Han XB, 2018, CELL PHYSIOL BIOCHEM, V48, P1616, DOI 10.1159/000492283
   Han YY, 2018, INT J ONCOL, V52, P1057, DOI 10.3892/ijo.2018.4270
   He RQ, 2018, CELL PHYSIOL BIOCHEM, V48, P1355, DOI 10.1159/000492094
   Ianniciello A, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00120
   Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536
   Jacomin AC, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080112
   Jiao YN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0646-4
   Jin SH, 2018, ONCOL REP, V39, P2473, DOI 10.3892/or.2018.6370
   Kinoshita S, 2018, ONCOL LETT, V15, P9450, DOI 10.3892/ol.2018.8501
   Kishino A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02960-1
   Li WL, 2016, EXP THER MED, V11, P1259, DOI 10.3892/etm.2016.3054
   Li XY, 2018, CELL PHYSIOL BIOCHEM, V47, P2589, DOI 10.1159/000491655
   Liang L, 2018, CELL PHYSIOL BIOCHEM, V48, P475, DOI 10.1159/000491778
   Liang Y, 2017, EXP THER MED, V14, P2367, DOI 10.3892/etm.2017.4779
   Liang ZG, 2018, CANCER MANAG RES, V10, P4125, DOI 10.2147/CMAR.S176536
   Lin P, 2018, EBIOMEDICINE, V34, P46, DOI 10.1016/j.ebiom.2018.07.040
   Lin P, 2018, CELL PHYSIOL BIOCHEM, V48, P1953, DOI 10.1159/000492519
   Lin P, 2018, INT J ONCOL, V53, P603, DOI 10.3892/ijo.2018.4404
   Lin Peng, 2018, Oncotarget, V9, P17368, DOI 10.18632/oncotarget.24089
   Liu MH, 2018, INT J ONCOL, V53, P1363, DOI 10.3892/ijo.2018.4465
   Liu XL, 2016, INT J ONCOL, V49, P1469, DOI 10.3892/ijo.2016.3623
   Liu XF, 2017, ONCOTARGET, V8, P87307, DOI 10.18632/oncotarget.20263
   Lu DF, 2018, CELL PHYSIOL BIOCHEM, V48, P2517, DOI 10.1159/000492690
   Lu XX, 2016, MOL MED REP, V13, P1172, DOI 10.3892/mmr.2015.4646
   Luo XM, 2018, INT J ONCOL, V53, P904, DOI 10.3892/ijo.2018.4442
   Ma RY, 2018, J CELL MOL MED, V22, P5955, DOI 10.1111/jcmm.13865
   Ma YB, 2018, EXP THER MED, V15, P4671, DOI 10.3892/etm.2018.5999
   Mei HL, 2018, INT J MOL MED, V42, P2676, DOI 10.3892/ijmm.2018.3857
   Miki Y, 2018, NEUROSCI LETT, V684, P35, DOI 10.1016/j.neulet.2018.06.052
   Moussay E, 2011, AUTOPHAGY, V7, P760, DOI 10.4161/auto.7.7.15454
   Muz B, 2017, LEUKEMIA LYMPHOMA, V58, P2916, DOI 10.1080/10428194.2017.1319052
   Ni Y, 2018, J INT MED RES, V46, P596, DOI 10.1177/0300060517693719
   Niu GH, 2018, MED SCI MONITOR, V24, P2758, DOI 10.12659/MSM.905140
   Ostaszewski M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2314-z
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110
   Raje NS, 2019, CLIN CANCER RES, V25, P12, DOI 10.1158/1078-0432.CCR-18-1537
   Seegmiller AC, 2011, ARCH PATHOL LAB MED, V135, P770, DOI 10.1043/2009-0691-OA.1
   Shen JK, 2013, ONCOL REP, V30, P425, DOI 10.3892/or.2013.2431
   Shen M, 2018, REDOX BIOL, V18, P138, DOI 10.1016/j.redox.2018.07.004
   Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285
   Viziteu E, 2016, BRIT J CANCER, V114, P519, DOI 10.1038/bjc.2016.20
   Wang CY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05449-1
   Wang J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29199-8
   Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356
   Wang P, 2017, MOL MED REP, V16, P2107, DOI 10.3892/mmr.2017.6794
   Wang X, 2017, CELL PHYSIOL BIOCHEM, V43, P2535, DOI 10.1159/000484506
   Wang ZG, 2017, ONCOL REP, V37, P3010, DOI 10.3892/or.2017.5511
   Wu JS, 2018, ONCOL REP, V40, P3381, DOI 10.3892/or.2018.6747
   Wu YQ, 2018, ONCOTARGETS THER, V11, P5621, DOI 10.2147/OTT.S176744
   Yang H, 2018, ONCOL REP, V40, P3346, DOI 10.3892/or.2018.6715
   Yin SS, 2018, MOL MED REP, V18, P2798, DOI 10.3892/mmr.2018.9236
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang DS, 2018, MED SCI MONITOR, V24, P2218, DOI 10.12659/MSM.906195
   Zhang HX, 2017, ONCOTARGET, V8, P60987, DOI 10.18632/oncotarget.17719
   Zhang R, 2018, AM J TRANSL RES, V10, P2636
   Zhang W, 2017, EXP THER MED, V14, P973, DOI 10.3892/etm.2017.4623
   Zhao YX, 2019, ONCOL REP, V41, P27, DOI 10.3892/or.2018.6780
   Zheng LQ, 2018, ONCOL LETT, V15, P4837, DOI 10.3892/ol.2018.7971
   Zheng ZH, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130742
   Zhou Y, 2008, LEUKEMIA LYMPHOMA, V49, P1945, DOI 10.1080/10428190802304966
   Zhu BY, 2018, ONCOL LETT, V15, P6094, DOI 10.3892/ol.2018.8157
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
   Zhu SM, 2017, MOL MED REP, V16, P5471, DOI 10.3892/mmr.2017.7253
   Zhuang Y, 2017, LEUKEMIA RES, V59, P97, DOI 10.1016/j.leukres.2017.06.002
   Zyla J, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1674-0
NR 84
TC 12
Z9 12
U1 4
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2019
VL 18
IS 5
BP 5310
EP 5324
DI 10.3892/ol.2019.10881
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JW7HS
UT WOS:000503219600099
PM 31612041
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wawszczyk, J
   Jesse, K
   Szewerniak, A
   Kapral, M
   Weglarz, L
AF Wawszczyk, Joanna
   Jesse, Katarzyna
   Szewerniak, Aleksandra
   Kapral, Malgorzata
   Weglarz, Ludmila
TI THE INDUCTION OF CYTOTOXICITY BY PTEROSTILBENE IN VARIOUS HUMAN CANCER
   CELL LINES
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE pterostilbene; cytotoxic activity; SRB assay; cancer cell lines
ID CYCLE ARREST; APOPTOSIS; RESVERATROL; ANTIOXIDANT; ANTICANCER; AUTOPHAGY
AB Pterostilbene is a naturally occurring compound found primarily in blueberries and grapes. It has been found to possess several biological activities such as antioxidative and anti-inflammatory. The study evaluated the cytotoxic activity of pterostilbene in various human cancer cell lines, i.e., melanoma (A2058, C32), colon carcinoma (HT-29, SW1116), breast adenocarcinoma (MCF-7, SKBR3) and ovary adenocarcinoma (SKOV3). The cells were treated with pterostilbene concentrations ranging from 5 to 75 mu M for 72 h. The cytotoxicity of pterostilbene was evaluated using the Sulforhodamine B assay and expressed as a percentage of that of untreated control cells. The concentration of pterostilbene required for 50% reduction of cell viability (IC50) was calculated from log dose-response curves. The results of this study showed that pterostilbene exerted dosedependent cytotoxic effect on cancer cells. Among the all cell lines tested, the C32 melanoma cells were the most sensitive to the cytotoxic effect of pterostilbene (IC50 similar to 10 mu M) and SW1116 colon cancer cells showed the lowest sensitivity (IC50 similar to 70 mu M).
C1 [Wawszczyk, Joanna] Dept Biochem, Jednosci 8, PL-41200 Sosnowiec, Poland.
   Med Univ Silesia, Sch Pharm, Div Lab Med Sosnowiec, Katowice, Poland.
RP Wawszczyk, J (corresponding author), Dept Biochem, Jednosci 8, PL-41200 Sosnowiec, Poland.
EM jwawszczyk@sum.edu.pl
OI Wawszczyk, Joanna/0000-0001-8739-3342; Kapral,
   Malgorzata/0000-0001-5189-1171
FU Medical University of Silesia (Katowice, Poland) [KNW-2-013/N/5/K,
   KNW-2-I18/D/6/N]
FX This work was supported by grants no. KNW-2-013/N/5/K and
   KNW-2-I18/D/6/N from the Medical University of Silesia (Katowice,
   Poland).
CR Alosi JA, 2010, J SURG RES, V161, P195, DOI 10.1016/j.jss.2009.07.027
   Sirerol JA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3128951
   Benlloch M, 2016, ANTIOXID REDOX SIGN, V24, P974, DOI 10.1089/ars.2015.6437
   BERGHE WV, 2012, PHARMACOL RES, V65, P565, DOI DOI 10.1016/J.PHRS.2012.03.007
   Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051
   Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P980, DOI 10.1177/0960327110383625
   Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P977, DOI 10.1177/0960327110383623
   Chen RJ, 2010, MOL NUTR FOOD RES, V54, P1819, DOI 10.1002/mnfr.201000067
   Chiou YS, 2011, J AGR FOOD CHEM, V59, P2725, DOI 10.1021/jf2000103
   Dewi NI, 2015, CYTOTECHNOLOGY, V67, P671, DOI 10.1007/s10616-014-9758-4
   Dong J, 2016, EUR J GYNAECOL ONCOL, V37, P342, DOI 10.12892/ejgo3024.2016
   Elsayed Elsayed Ahmed, 2015, Asian Pac J Cancer Prev, V16, P4671
   Ferrer P, 2005, NEOPLASIA, V7, P37, DOI 10.1593/neo.04337
   Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043
   Guo LY, 2016, ONCOL REP, V36, P3233, DOI 10.3892/or.2016.5151
   Harun Z, 2012, ASIAN PAC J CANCER P, V13, P6403, DOI 10.7314/APJCP.2012.13.12.6403
   Kapetanovic IM, 2011, CANCER CHEMOTH PHARM, V68, P593, DOI 10.1007/s00280-010-1525-4
   Kondratyuk TP, 2011, MOL NUTR FOOD RES, V55, P1249, DOI 10.1002/mnfr.201100122
   Kong YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37417
   Lee H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162335
   Ma ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08547-0
   McCormack D, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/575482
   McCormack D, 2012, J SURG RES, V173, pE53, DOI 10.1016/j.jss.2011.09.054
   Mena S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044524
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Parasramka MA, 2012, J ONCOL, V2012, DOI 10.1155/2012/709739
   Paul S, 2010, EUR J MED CHEM, V45, P3702, DOI 10.1016/j.ejmech.2010.05.019
   Remsberg CM, 2008, PHYTOTHER RES, V22, P169, DOI 10.1002/ptr.2277
   Riche DM, 2013, J TOXICOL-US, V2013, DOI 10.1155/2013/463595
   Schneider JG, 2009, AM J SURG, V198, P679, DOI 10.1016/j.amjsurg.2009.07.014
   Siddiqa A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-129
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sun Y, 2016, MOL NUTR FOOD RES, V60, P1924, DOI 10.1002/mnfr.201500989
   Turati F, 2015, BRIT J NUTR, V113, pS102, DOI 10.1017/S0007114515000148
   Vo NT, 2010, CARCINOGENESIS, V31, P2074, DOI 10.1093/carcin/bgp199
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Wang YJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0441-z
   Zielinska-Przyjemska M, 2017, TOXICOL IN VITRO, V43, P69, DOI 10.1016/j.tiv.2017.06.004
   2017, DRUG CHEM TOXICOL, V40, P36, DOI DOI 10.3109/01480545.2016.1169542
NR 39
TC 0
Z9 0
U1 0
U2 7
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00-238 WARSAW, POLAND
SN 0001-6837
EI 2353-5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD SEP-OCT
PY 2018
VL 75
IS 5
BP 1161
EP 1166
DI 10.32383/appdr/83592
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HX3UR
UT WOS:000467319200011
OA Bronze
DA 2022-04-25
ER

PT J
AU Al-Bari, MAA
   Ito, Y
   Ahmed, S
   Radwan, N
   Ahmed, HS
   Eid, N
AF Al-Bari, Md Abdul Alim
   Ito, Yuko
   Ahmed, Samrein
   Radwan, Nada
   Ahmed, Hend S.
   Eid, Nabil
TI Targeting Autophagy with Natural Products as a Potential Therapeutic
   Approach for Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE autophagy; natural products; anticancer drugs; mTOR signaling; autophagy
   modulators; resveratrol; omega-3 PUFAs
ID CELL-CYCLE ARREST; DEACETYLASE INHIBITOR TRICHOSTATIN;
   ENDOPLASMIC-RETICULUM STRESS; STARVATION-INDUCED AUTOPHAGY; ROTTLERIN
   INDUCES AUTOPHAGY; UBIQUITIN-PROTEASOME SYSTEM; EXERTS
   ANTITUMOR-ACTIVITY; ACTIVATED PROTEIN-KINASE; COLON-CANCER;
   CYTOPROTECTIVE AUTOPHAGY
AB Macro-autophagy (autophagy) is a highly conserved eukaryotic intracellular process of self-digestion caused by lysosomes on demand, which is upregulated as a survival strategy upon exposure to various stressors, such as metabolic insults, cytotoxic drugs, and alcohol abuse. Paradoxically, autophagy dysfunction also contributes to cancer and aging. It is well known that regulating autophagy by targeting specific regulatory molecules in its machinery can modulate multiple disease processes. Therefore, autophagy represents a significant pharmacological target for drug development and therapeutic interventions in various diseases, including cancers. According to the framework of autophagy, the suppression or induction of autophagy can exert therapeutic properties through the promotion of cell death or cell survival, which are the two main events targeted by cancer therapies. Remarkably, natural products have attracted attention in the anticancer drug discovery field, because they are biologically friendly and have potential therapeutic effects. In this review, we summarize the up-to-date knowledge regarding natural products that can modulate autophagy in various cancers. These findings will provide a new position to exploit more natural compounds as potential novel anticancer drugs and will lead to a better understanding of molecular pathways by targeting the various autophagy stages of upcoming cancer therapeutics.
C1 [Al-Bari, Md Abdul Alim] Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
   [Ito, Yuko] Osaka Med & Pharmaceut Univ, Dept Gen & Gastroenterol Surg, 27 Daigaku Machi, Takatsuki 5698686, Japan.
   [Ahmed, Samrein] Sheffield Hallam Univ, Coll Hlth & Wellbeing & Life Sci, Dept Biosci & Chem, City Campus,Howard St, Sheffield S1 1WB, S Yorkshire, England.
   [Radwan, Nada; Eid, Nabil] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Anat, Al Ain 17666, U Arab Emirates.
   [Ahmed, Hend S.] Omdurman Ahlia Univ, Fac Med, Dept Hematol & Blood Transfus, Lab Sci, Khartoum 786, Sudan.
RP Eid, N (corresponding author), United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Anat, Al Ain 17666, U Arab Emirates.
EM alimalbari347@ru.ac.bd; yuko.ito@ompu.ac.jp; Samrein.Ahmed@shu.ac.uk;
   NadaA.Radwan@outlook.com; hind.salaheldien@gmail.com;
   nabileidm@uaeu.ac.ae
RI Al-Bari, Md. Abdul Alim/C-2946-2018
OI Al-Bari, Md. Abdul Alim/0000-0002-1777-3662; Eid Moustafa,
   Nabil/0000-0002-2938-2618
CR Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076
   Al-Bari MAA, 2020, ANN NY ACAD SCI, V1467, P3, DOI 10.1111/nyas.14305
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Alaufi OM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13357-5
   Almajali B, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14040369
   Almatroodi SA, 2021, MOLECULES, V26, DOI 10.3390/molecules26051315
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Tran AT, 2015, EUR J NUTR, V54, P265, DOI 10.1007/s00394-014-0707-y
   Arguello G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084220
   Ashrafizadeh M, 2020, PHYTOTHER RES, V34, P911, DOI 10.1002/ptr.6577
   Asokan SM, 2018, LIFE SCI, V199, P60, DOI 10.1016/j.lfs.2018.02.032
   Astanina E, 2021, MOL ONCOL, V15, P327, DOI 10.1002/1878-0261.12867
   Bai M, 2020, EUR J MED CHEM, V198, DOI 10.1016/j.ejmech.2020.112362
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bashmail HA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30046-z
   Bawadood AS, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110302
   Bhardwaj M, 2018, ONCOTARGET, V9, P3278, DOI 10.18632/oncotarget.22890
   Bin Ali A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025268
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Buldak RJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123309
   Cai JX, 2014, PHYTOMEDICINE, V21, P1725, DOI 10.1016/j.phymed.2014.08.007
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Chen LY, 2017, ONCOTARGET, V8, P11937, DOI 10.18632/oncotarget.14442
   Chen MJ, 2016, INT J ONCOL, V49, P316, DOI 10.3892/ijo.2016.3514
   Chen MC, 2015, J AGR FOOD CHEM, V63, P1540, DOI 10.1021/jf5054063
   Chen Y, 2018, MOL CELLS, V41, P45, DOI 10.14348/molcells.2018.2265
   Chen YY, 2018, ONCOL REP, V40, P2260, DOI 10.3892/or.2018.6619
   Choi HS, 2013, TUBERC RESPIR DIS, V75, P9, DOI 10.4046/trd.2013.75.1.9
   Collins MP, 2020, BBA-BIOMEMBRANES, V1862, DOI 10.1016/j.bbamem.2020.183341
   Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5
   Cuanalo-Contreras K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194666
   D'Eliseo Donatella, 2017, Genes Cancer, V8, P426, DOI 10.18632/genesandcancer.131
   Dai CH, 2021, J CELL PHYSIOL, V236, P4538, DOI 10.1002/jcp.30172
   Das Gupta D, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113842
   Dasari S, 2020, PHYTOTHER RES, V34, P2366, DOI 10.1002/ptr.6687
   Della Sala G, 2018, MAR DRUGS, V16, DOI 10.3390/md16120467
   Deng LJ, 2020, J LEUKOCYTE BIOL, V108, P493, DOI 10.1002/JLB.3MR0320-444R
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Deng ZQ, 2020, AUTOPHAGY, V16, P917, DOI 10.1080/15548627.2019.1644076
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Pham DC, 2018, MOLECULES, V23, DOI 10.3390/molecules23123110
   Dischler NM, 2019, J NAT PROD, V82, P532, DOI 10.1021/acs.jnatprod.8b00923
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Du J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607757
   Eid N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030283
   Eid N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00100
   Eid N, 2017, WORLD J HEPATOL, V9, P349, DOI 10.4254/wjh.v9.i7.349
   Eid N, 2013, J HEPATOL, V59, P398, DOI 10.1016/j.jhep.2013.03.038
   Endo S, 2018, BIOCHEM BIOPH RES CO, V497, P437, DOI 10.1016/j.bbrc.2018.02.105
   Enogieru AB, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6241017
   Farkas T, 2011, J BIOL CHEM, V286, P38904, DOI 10.1074/jbc.M111.269134
   Feng C, 2012, INT J CANCER, V131, P1445, DOI 10.1002/ijc.27365
   Feng Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01356
   Fracchiolla D, 2017, AUTOPHAGY, V13, P978, DOI 10.1080/15548627.2016.1277311
   Fujiki H, 2018, MOL CELLS, V41, P73, DOI 10.14348/molcells.2018.2227
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gao AM, 2018, CHEM-BIOL INTERACT, V280, P45, DOI 10.1016/j.cbi.2017.11.020
   Gao GZ, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111262
   Gao L, 2018, MOL MED REP, V17, P4345, DOI 10.3892/mmr.2018.8446
   Geng JF, 2017, AUTOPHAGY, V13, P639, DOI 10.1080/15548627.2017.1280646
   Geng XR, 2018, BIOCHEM BIOPH RES CO, V498, P99, DOI 10.1016/j.bbrc.2018.02.205
   Ghasemi S, 2021, PHYTOTHER RES, V35, P3649, DOI 10.1002/ptr.7059
   Ghirga F, 2021, ORG CHEM FRONT, V8, P996, DOI 10.1039/d0qo01210f
   Ghosh S, 2014, PHYTOTHER RES, V28, P1153, DOI 10.1002/ptr.5107
   Gilardini Montani MS, 2017, CELL ONCOL, V40, P167, DOI 10.1007/s13402-017-0314-z
   Giordano C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072279
   Gong L, 2016, INT J ONCOL, V49, P2538, DOI 10.3892/ijo.2016.3748
   Greene LM, 2012, BIOCHEM PHARMACOL, V84, P612, DOI 10.1016/j.bcp.2012.06.005
   Gross SP, 2007, CURR BIOL, V17, pR478, DOI 10.1016/j.cub.2007.04.025
   Gu W, 2017, NEOPLASMA, V64, P674, DOI 10.4149/neo_2017_504
   Guo JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140745
   Guo YB, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/7517431
   Guzman EA, 2011, INVEST NEW DRUG, V29, P777, DOI 10.1007/s10637-010-9422-6
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Han YH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010066
   Harder BG, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0116-z
   Hashemzaei M, 2017, EUR J PHARMACOL, V802, P44, DOI 10.1016/j.ejphar.2017.02.038
   Hashimoto M, 2003, J RADIAT RES, V44, P151, DOI 10.1269/jrr.44.151
   Haspel J, 2011, AUTOPHAGY, V7, P629, DOI 10.4161/auto.7.6.15100
   He M, 2016, FITOTERAPIA, V115, P74, DOI 10.1016/j.fitote.2016.09.011
   Heng YQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.671180
   Heo YA, 2019, DRUGS, V79, P767, DOI 10.1007/s40265-019-01120-1
   Holczer M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6721530
   Horibe A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051061
   Hotte SJ, 2019, CLIN GENITOURIN CANC, V17, P201, DOI 10.1016/j.clgc.2019.03.005
   Hsiao YT, 2018, AM J CHINESE MED, V46, P1145, DOI 10.1142/S0192415X1850060X
   Hu MJ, 2017, MOL CELL, V66, P141, DOI 10.1016/j.molcel.2017.03.008
   Hua F, 2017, J ASIAN NAT PROD RES, V19, P305, DOI 10.1080/10286020.2017.1304385
   Huang XM, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109142
   Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e
   Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200
   Islam MS, 2019, EUR J MED CHEM, V162, P109, DOI 10.1016/j.ejmech.2018.11.001
   Ito Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073749
   Jang MS, 2017, ONCOTARGET, V8, P115068, DOI 10.18632/oncotarget.22858
   Jang YM, 2017, J NUTR BIOCHEM, V46, P49, DOI 10.1016/j.jnutbio.2017.04.003
   Jayasooriya RGPT, 2018, FOOD CHEM TOXICOL, V121, P648, DOI 10.1016/j.fct.2018.09.057
   Jeong S, 2019, CANCERS, V11, DOI 10.3390/cancers11070982
   Jia SN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1366-y
   Jiang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0680-z
   Jiang SL, 2019, ACTA PHARMACOL SIN, V40, P919, DOI 10.1038/s41401-018-0165-9
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Jung S, 2020, EXP MOL MED, V52, P921, DOI 10.1038/s12276-020-0455-4
   Kallifatidis G, 2013, MAR DRUGS, V11, P3500, DOI 10.3390/md11093500
   Kan WLT, 2013, INT J CANCER, V132, P707, DOI 10.1002/ijc.27694
   Karatoprak GS, 2020, MOLECULES, V25, DOI 10.3390/molecules25112560
   Karve S, 2012, P NATL ACAD SCI USA, V109, P8230, DOI 10.1073/pnas.1120508109
   Kast DJ, 2017, CURR BIOL, V27, pR318, DOI 10.1016/j.cub.2017.02.061
   Kaul R, 2019, J NAT PROD, V82, P680, DOI 10.1021/acs.jnatprod.9b00105
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kennedy BK, 2014, TRANSL RES, V163, P456, DOI 10.1016/j.trsl.2013.11.007
   Khalifa SAM, 2019, MAR DRUGS, V17, DOI 10.3390/md17090491
   Khan N, 2019, CHEM-BIOL INTERACT, V307, P167, DOI 10.1016/j.cbi.2019.04.035
   Kim N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/239764
   Kim S, 2018, ONCOL REP, V39, P239, DOI 10.3892/or.2017.6101
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Krols M, 2016, J CELL BIOL, V214, P367, DOI 10.1083/jcb.201607124
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lambert IH, 2020, AM J PHYSIOL-CELL PH, V318, pC581, DOI 10.1152/ajpcell.00460.2019
   Lamming DW, 2013, J CLIN INVEST, V123, P980, DOI 10.1172/JCI64099
   Landais E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060725
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Law BYK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56675-6
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Lee JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64871-y
   Lee YK, 2017, EMBO J, V36, P1100, DOI 10.15252/embj.201696315
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Li CY, 2019, MED SCI MONITOR, V25, P2852, DOI 10.12659/MSM.913771
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li H, 2017, ACTA PHARMACOL SIN, V38, P252, DOI 10.1038/aps.2016.101
   Li JJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00746
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Li Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00334
   Li TY, 2017, BIOMED PHARMACOTHER, V93, P208, DOI 10.1016/j.biopha.2017.06.038
   Li YL, 2014, TOXICOL APPL PHARM, V274, P319, DOI 10.1016/j.taap.2013.11.018
   Lichota A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113533
   Lima RT, 2016, MOLECULES, V21, DOI 10.3390/molecules21101343
   Lin CW, 2019, ENVIRON TOXICOL, V34, P983, DOI 10.1002/tox.22769
   Lin LT, 2019, MOLECULES, V24, DOI 10.3390/molecules24112102
   Lin YN, 2019, J CELL BIOCHEM, V120, P9820, DOI 10.1002/jcb.28262
   Lindner P, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0499-z
   Liou YF, 2019, ENVIRON TOXICOL, V34, P1208, DOI 10.1002/tox.22822
   Liu CM, 2021, PHARMAZIE, V76, P225, DOI 10.1691/ph.2021.1301
   Liu HY, 2019, ANTI-CANCER DRUG, V30, P347, DOI 10.1097/CAD.0000000000000724
   Liu JH, 2021, PHARMACOLOGY, V106, P60, DOI 10.1159/000507937
   Liu M, 2021, MOL ONCOL, V15, P2084, DOI 10.1002/1878-0261.12936
   Liu SP, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03148-8
   Liu T, 2015, ONCOTARGET, V6, P7992, DOI 10.18632/oncotarget.3505
   Liu WP, 2019, AM J TRANSL RES, V11, P6952
   Liu XH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1173-4
   Liu XW, 2017, ONCOL REP, V38, P271, DOI 10.3892/or.2017.5648
   Liu YS, 2007, J BIOL CHEM, V282, P2505, DOI 10.1074/jbc.M609603200
   Liu Y, 2021, PATHOL RES PRACT, V222, DOI 10.1016/j.prp.2021.153455
   Lopes TZ, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109794
   Luan F, 2020, J PHARM PHARMACOL, V72, P1491, DOI 10.1111/jphp.13339
   Lyu L, 2021, PHYTOTHER RES, V35, P4007, DOI 10.1002/ptr.7117
   Ma LK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00097
   Madeo F, 2015, J CLIN INVEST, V125, P85, DOI 10.1172/JCI73946
   Maioli E, 2018, ARCH BIOCHEM BIOPHYS, V645, P50, DOI 10.1016/j.abb.2018.03.009
   Mani R, 2018, PHYTOCHEMISTRY, V145, P187, DOI 10.1016/j.phytochem.2017.09.016
   MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4
   Messeha SS, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051718
   Mohan N, 2011, NEUROSCI LETT, V502, P24, DOI 10.1016/j.neulet.2011.07.016
   Monti MC, 2014, BBA-PROTEINS PROTEOM, V1844, P713, DOI 10.1016/j.bbapap.2014.02.003
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev-pharmtox-010716-104936
   Morishita H, 2017, AUTOPHAGY, V13, P757, DOI 10.1080/15548627.2016.1278094
   Mosca L, 2021, DRUG RESIST UPDATE, V54, DOI 10.1016/j.drup.2020.100742
   Moskot M, 2014, J BIOL CHEM, V289, P17054, DOI 10.1074/jbc.M114.555300
   Mostofa AGM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00295
   Mukhtar E, 2014, MOL CANCER THER, V13, P275, DOI 10.1158/1535-7163.MCT-13-0791
   Musial C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010123
   Nakamura M, 2010, INT J ONCOL, V37, P815, DOI 10.3892/ijo_00000731
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   NAKANISHI S, 1992, J BIOL CHEM, V267, P2157
   Nazim UM, 2020, INT J ONCOL, V56, P1152, DOI 10.3892/ijo.2020.5012
   Nazim UM, 2019, MOL MED REP, V19, P984, DOI 10.3892/mmr.2018.9757
   Nazim UM, 2019, INT J MOL MED, V43, P701, DOI 10.3892/ijmm.2018.3994
   Nedelsky NB, 2008, BBA-MOL BASIS DIS, V1782, P691, DOI 10.1016/j.bbadis.2008.10.002
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Park BS, 2019, J CANCER, V10, P138, DOI 10.7150/jca.28500
   Park HJ, 2020, NUTR RES PRACT, V14, P478, DOI 10.4162/nrp.2020.14.5.478
   Park SY, 2018, CANCER EPIDEM BIOMAR, V27, P928, DOI 10.1158/1055-9965.EPI-18-0093
   Pazhouhi M, 2016, IRAN J BASIC MED SCI, V19, P890
   Pei XD, 2021, EUR J NUTR, V60, P2781, DOI 10.1007/s00394-020-02440-9
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953
   Pietrocola F, 2014, CELL CYCLE, V13, P1987, DOI 10.4161/cc.28929
   Pinto MMM, 2021, MOLECULES, V26, DOI 10.3390/molecules26020431
   Pitz MW, 2015, NEURO-ONCOLOGY, V17, P1270, DOI 10.1093/neuonc/nou365
   Pizato N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061199
   Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Pous C, 2011, NAT CELL BIOL, V13, P342, DOI 10.1038/ncb0411-342
   Prietsch RF, 2014, MOL CELL BIOCHEM, V390, P235, DOI 10.1007/s11010-014-1974-x
   Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287
   Qiu W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.84
   Qu WL, 2013, INT J BIOL SCI, V9, P766, DOI 10.7150/ijbs.5711
   Raha S, 2020, AM J CHINESE MED, V48, P679, DOI 10.1142/S0192415X20500342
   Rahman MA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.639628
   Ramesh G, 2020, J PHARM PHARMACOL, V72, P1893, DOI 10.1111/jphp.13354
   Ray A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137614
   Ren B, 2017, ONCOTARGET, V8, P93039, DOI 10.18632/oncotarget.21750
   Ren GW, 2015, J NAT MED-TOKYO, V69, P522, DOI 10.1007/s11418-015-0918-4
   Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095
   Rovito D, 2015, BBA-GEN SUBJECTS, V1850, P2185, DOI 10.1016/j.bbagen.2015.08.004
   Ruan CX, 2020, ONCOL LETT, V20, P623, DOI 10.3892/ol.2020.11604
   Saeed M, 2019, CRIT REV FOOD SCI, V59, P3293, DOI 10.1080/10408398.2018.1489368
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Sameiyan E, 2019, EUR J PHARMACOL, V852, P244, DOI 10.1016/j.ejphar.2019.04.001
   Sanchez-Wandelmer J, 2015, J CELL SCI, V128, P185, DOI 10.1242/jcs.158758
   Sarkaria JN, 1998, CANCER RES, V58, P4375
   Sasaki T, 2017, AUTOPHAGY, V13, P386, DOI 10.1080/15548627.2016.1256934
   Sasazawa Y, 2012, ACS CHEM BIOL, V7, P892, DOI 10.1021/cb200492h
   Sato E, 2019, ANTICANCER RES, V39, P6585, DOI 10.21873/anticanres.13874
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Selvi SK, 2017, FOOD CHEM TOXICOL, V103, P28, DOI 10.1016/j.fct.2017.02.020
   Shabalala S, 2017, LIFE SCI, V180, P160, DOI 10.1016/j.lfs.2017.05.003
   Shao JL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061664
   Shen T, 2015, ANTIOXID REDOX SIGN, V23, P651, DOI 10.1089/ars.2014.6074
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Son Y, 2019, PHYTOTHER RES, V33, P1689, DOI 10.1002/ptr.6357
   Sundarraj K, 2021, NUTR CANCER, V73, P2502, DOI 10.1080/01635581.2020.1836241
   Suzuki R, 2014, ANTICANCER RES, V34, P4685
   Takahashi H, 2017, ONCOGENE, V36, P4267, DOI 10.1038/onc.2017.59
   Tan H, 2019, J BUON, V24, P1143
   Tan RH, 2018, FOOD FUNCT, V9, P6180, DOI 10.1039/c8fo01617h
   Tan XF, 2019, IN VITRO CELL DEV-AN, V55, P703, DOI 10.1007/s11626-019-00387-8
   Tang DF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22257-1
   Tang Yancheng, 2021, [Acta Pharmaceutica Sinica B, 药学学报], V11, P3966
   Tao L, 2014, PHYTOMEDICINE, V21, P1473, DOI 10.1016/j.phymed.2014.05.001
   Tian L, 2019, MOLECULES, V24, DOI 10.3390/molecules24061091
   Tian SS, 2018, PHYTOTHER RES, V32, P908, DOI 10.1002/ptr.6030
   Tisi R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111535
   Tiwari RV, 2015, MOL CELL BIOCHEM, V408, P123, DOI 10.1007/s11010-015-2488-x
   Wang B, 2018, BIOCHEM BIOPH RES CO, V499, P156, DOI 10.1016/j.bbrc.2018.03.091
   Wang GX, 2017, CANCER BIOL THER, V18, P584, DOI 10.1080/15384047.2017.1345386
   Wang HS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.438
   Wang JX, 2020, CHEM-BIOL INTERACT, V331, DOI 10.1016/j.cbi.2020.109279
   Wang J, 2020, CANCER MED-US, V9, P7268, DOI 10.1002/cam4.3356
   Wang K, 2020, CARCINOGENESIS, V41, P804, DOI 10.1093/carcin/bgz140
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02915-x
   Wang LH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122983
   Wang M, 2020, INT J MOL MED, V46, P1816, DOI 10.3892/ijmm.2020.4714
   Wang S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.485
   Wang SF, 2016, J ETHNOPHARMACOL, V194, P861, DOI 10.1016/j.jep.2016.10.069
   Wang TK, 2020, MOLECULES, V25, DOI 10.3390/molecules25245971
   Wang Y, 2020, CANCER MANAG RES, V12, P695, DOI 10.2147/CMAR.S242329
   Wang YT, 2021, INTEGR CANCER THER, V20, DOI 10.1177/1534735421996822
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Watanabe-Asano T, 2014, BIOCHEM BIOPH RES CO, V445, P334, DOI 10.1016/j.bbrc.2014.01.180
   Wedel S, 2018, MOLECULES, V23, DOI 10.3390/molecules23051219
   Wozniak M, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02913-8
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Wu JJ, 2015, EUR J PHARMACOL, V762, P449, DOI 10.1016/j.ejphar.2015.06.032
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Wu MS, 2014, MOL CARCINOGEN, V53, pE119, DOI 10.1002/mc.22053
   Wu N, 2018, J CANCER, V9, P987, DOI 10.7150/jca.22861
   Wu XN, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101569
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xiaokaiti Y, 2020, ADV EXP MED BIOL, V1207, P709, DOI 10.1007/978-981-15-4272-5_53
   Xie SB, 2015, INT J ONCOL, V47, P517, DOI 10.3892/ijo.2015.3023
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu LM, 2016, TUMOR BIOL, V37, P8721, DOI 10.1007/s13277-015-4737-8
   Xu SW, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104660
   Xu XD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020370
   Xue DF, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5649174
   Yam C, 2018, CLIN CANCER RES, V24, P22, DOI 10.1158/1078-0432.CCR-17-1807
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yami A, 2020, J ETHNOPHARMACOL, V253, DOI 10.1016/j.jep.2019.112504
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang XH, 2018, CANCER BIOL THER, V19, P706, DOI 10.1080/15384047.2018.1451277
   Yang YL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054736, 10.1371/journal.pone.0067755, 10.1371/journal.pone.0055384]
   Yang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174021
   Ye LY, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0410-1
   Yessenkyzy A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051344
   Yin B, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111664
   Yin ZH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6940953
   Yuan N, 2015, HAEMATOLOGICA, V100, P345, DOI 10.3324/haematol.2014.113324
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
   Zhang CJ, 2021, ACTA PHARMACOL SIN, V42, P1472, DOI 10.1038/s41401-020-00572-6
   Zhang JB, 2016, ONCOTARGET, V7, P75659, DOI 10.18632/oncotarget.12318
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
   Zhang L, 2015, FOOD FUNCT, V6, P3464, DOI [10.1039/c5fo00671f, 10.1039/C5FO00671F]
   Zhang Q, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110245
   Zhang Q, 2018, CANCER LETT, V432, P144, DOI 10.1016/j.canlet.2018.05.049
   Zhang RN, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00378
   Zhang SF, 2014, ASIAN PAC J CANCER P, V15, P10557, DOI 10.7314/APJCP.2014.15.24.10557
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhang X, 2016, MOL MED REP, V14, P4489, DOI 10.3892/mmr.2016.5792
   Zhang XS, 2021, FOOD CHEM TOXICOL, V148, DOI 10.1016/j.fct.2020.111957
   Zhang XL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000252
   Zhang YJ, 2018, CANCER SCI, V109, P3865, DOI 10.1111/cas.13808
   Zhao Q, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0208-0
   Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185
   Zhao YL, 2016, EUR J CANCER, V68, P38, DOI 10.1016/j.ejca.2016.09.001
   Zheng XW, 2015, CANCER BIOL THER, V16, P1407, DOI 10.1080/15384047.2015.1070990
   Zheng YF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8781690
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhou T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107876
   Zhu SL, 2017, ONCOTARGET, V8, P109135, DOI 10.18632/oncotarget.22629
   Zientara-Rytter K, 2018, AUTOPHAGY, V14, P1074, DOI 10.1080/15548627.2018.1454238
   Zou SH, 2018, EUR REV MED PHARMACO, V22, P3010, DOI 10.26355/eurrev_201805_15058
   Zou YM, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6199-7
NR 313
TC 1
Z9 1
U1 21
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2021
VL 22
IS 18
AR 9807
DI 10.3390/ijms22189807
PG 66
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UV8TR
UT WOS:000699744000001
PM 34575981
OA Green Published, gold, Green Accepted
DA 2022-04-25
ER

PT J
AU Necchi, V
   Sommi, P
   Vanoli, A
   Manca, R
   Ricci, V
   Solcia, E
AF Necchi, Vittorio
   Sommi, Patrizia
   Vanoli, Alessandro
   Manca, Rachele
   Ricci, Vittorio
   Solcia, Enrico
TI Proteasome Particle-Rich Structures Are Widely Present in Human
   Epithelial Neoplasms: Correlative Light, Confocal and Electron
   Microscopy Study
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; HELICOBACTER-PYLORI;
   REGULATED KINASES; RAS MUTATIONS; CAGA PROTEIN; CANCER; CARCINOMA;
   AUTOPHAGY; BRAF
AB A novel cytoplasmic structure has been recently characterized by confocal and electron microscopy in H. pylori-infected human gastric epithelium, as an accumulation of barrel-like proteasome reactive particles colocalized with polyubiquitinated proteins, H. pylori toxins and the NOD1 receptor. This proteasome particle-rich cytoplasmic structure (PaCS), a sort of focal proteasome hyperplasia, was also detected in dysplastic cells and was found to be enriched in SHP2 and ERK proteins, known to play a role in H. pylori-mediated gastric carcinogenesis. However, no information is available on its occurrence in neoplastic growths. In this study, surgical specimens of gastric cancer and various other human epithelial neoplasms have been investigated for PaCSs by light, confocal and electron microscopy including correlative confocal and electron microscopy (CCEM). PaCSs were detected in gastric cohesive, pulmonary large cell and bronchioloalveolar, thyroid papillary, parotid gland, hepatocellular, ovarian serous papillary, uterine cervix and colon adenocarcinomas, as well as in pancreatic serous microcystic adenoma. H. pylori bodies, their virulence factors (VacA, CagA, urease, and outer membrane proteins) and the NOD1 bacterial proteoglycan receptor were selectively concentrated inside gastric cancer PaCSs, but not in PaCSs from other neoplasms which did, however, retain proteasome and polyubiquitinated proteins reactivity. No evidence of actual microbial infection was obtained in most PaCS-positive neoplasms, except for H. pylori in gastric cancer and capsulated bacteria in a colon cancer case. Particle lysis and loss of proteasome distinctive immunoreactivities were seen in some tumour cell PaCSs, possibly ending in sequestosomes or autophagic bodies. It is concluded that PaCSs are widely represented in human neoplasms and that both non-infectious and infectious factors activating the ubiquitin-proteasome system are likely to be involved in their origin. PaCS detection might help clarify the role of the ubiquitin-proteasome system in carcinogenesis.
C1 [Necchi, Vittorio; Vanoli, Alessandro; Solcia, Enrico] Univ Pavia, Dept Human Pathol & Genet, I-27100 Pavia, Italy.
   [Necchi, Vittorio] Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy.
   [Sommi, Patrizia; Manca, Rachele; Solcia, Enrico] Fdn IRCCS Policlin San Matteo, Serv Anat Pathol, Pavia, Italy.
   [Sommi, Patrizia; Ricci, Vittorio] Univ Pavia, Dept Physiol, I-27100 Pavia, Italy.
RP Necchi, V (corresponding author), Univ Pavia, Dept Human Pathol & Genet, Via Palestro 3, I-27100 Pavia, Italy.
EM vricci@unipv.it; solciae@smatteo.pv.it
RI Vanoli, Alessandro/J-4469-2016
OI Vanoli, Alessandro/0000-0002-2976-7032
FU Italian Ministry of HealthMinistry of Health, Italy; University of Pavia
FX This work was supported by grants from the Italian Ministry of Health to
   Fondazione IRCCS Policlinico San Matteo (to ES) and from the University
   of Pavia (to VR). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Brose MS, 2002, CANCER RES, V62, P6997
   Denk H, 2006, J PATHOL, V208, P653, DOI 10.1002/path.1946
   FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463
   Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Handa O, 2007, BIOCHEM PHARMACOL, V73, P1697, DOI 10.1016/j.bcp.2006.10.022
   Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433
   Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
   Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409
   Keates S, 2007, J INFECT DIS, V196, P95, DOI 10.1086/518440
   Kimura ET, 2003, CANCER RES, V63, P1454
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Kuboki Y, 2010, MODERN PATHOL, V23, P1127, DOI 10.1038/modpathol.2010.97
   Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200
   Necchi V, 2007, GASTROENTEROLOGY, V132, P1009, DOI 10.1053/j.gastro.2007.01.049
   Necchi V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009716
   RIVETT J, 1992, J HISTOCHEM CITOCHEM, V40, P1165
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Schmitz KJ, 2007, VIRCHOWS ARCH, V450, P151, DOI 10.1007/s00428-006-0342-y
   Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036
   Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521
   Szeto J, 2006, AUTOPHAGY, V2, P189, DOI 10.4161/auto.2731
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
NR 25
TC 17
Z9 17
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2011
VL 6
IS 6
AR e21317
DI 10.1371/journal.pone.0021317
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 778VR
UT WOS:000291737600059
PM 21695063
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Hussain, A
   Qazi, AK
   Mupparapu, N
   Kumar, A
   Mintoo, MJ
   Mahajan, G
   Sharma, PR
   Singh, SK
   Bharate, SB
   Zargar, MA
   Ahmed, QN
   Mondhe, DM
   Vishwakarma, RA
   Hamid, A
AF Hussain, Aashiq
   Qazi, Asif Khurshid
   Mupparapu, Nagaraju
   Kumar, Ashok
   Mintoo, Mubashir Javeed
   Mahajan, Girish
   Sharma, Parduman Raj
   Singh, Shashank Kumar
   Bharate, Sandip B.
   Zargar, Mohmmad Afzal
   Ahmed, Qazi Naveed
   Mondhe, Dilip Manikrao
   Vishwakarma, Ram A.
   Hamid, Abid
TI A novel PI3K axis selective molecule exhibits potent tumor inhibition in
   colorectal carcinogenesis
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE PI3K; signaling; inhibitor; therapeutics; colorectal cancer
ID KRAS P.G13D MUTATION; PLUS IRINOTECAN; CANCER; PATHWAY; LEUCOVORIN;
   FLUOROURACIL; CHEMOTHERAPY; IDELALISIB; APOPTOSIS; AUTOPHAGY
AB Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is responsible for initiation, chemo-resistance, and poor prognosis of colorectal cancer (CRC). Therefore, PI3K pathway inhibition can provide a plausible way of attaining CRC treatment. We report PI3K target specific synthesis and selection of a potent molecule, that is, 2,3-dihydro-2-(naphthalene-1-yl) quinazolin-4(1H)-one (DHNQ) from quinazolinone series based on the structural activity relationship after evaluation in diverse cancers. This molecule inhibited the PI3K enzyme activity and transcriptional as well as translational expression levels in colorectal cancer (CRC) models. This was associated with subsequent decrease in phosphorylation of its downstream effector proteins, that is, p-Akt((Ser-473)) and p-mTORC1((Ser-2448)) and decreased ERK signaling. Furthermore, DHNQ decreased expression of cyclins that caused G(1) arrest and decreased Bcl-2/Bax ratio after mitochondrial membrane potential loss, reactive oxygen species generation, and an increase in cytosolic Ca2+ loads that is responsible for the decreased CRC cell proliferation and survival. These biochemical changes triggered apoptotic cell death with altered autophagic Beclin-1 and LC3 expression. It seemed that the PI3K-Akt signaling regulated apoptosis and autophagy through different mechanisms but mTORC1 mediated autophagy appeared not to be involved in the cell death induction by DHNQ. The molecule also showed significant anticancer efficacy in in vivo tumor models without any mortality indicating its non-toxic nature with possible clinical significance. Overall, the selective elucidation of DHNQ molecular mechanism will provide the possible strategies for the clinical development in CRC that may respond to this specific, potent and novel P13K inhibitor. (c) 2016 Wiley Periodicals, Inc.
C1 [Hussain, Aashiq; Qazi, Asif Khurshid; Kumar, Ashok; Mintoo, Mubashir Javeed; Mahajan, Girish; Sharma, Parduman Raj; Singh, Shashank Kumar; Mondhe, Dilip Manikrao; Hamid, Abid] Indian Inst Integrat Med, CSIR, Canc Pharmacol Div, Canal Rd, Jammu 180001, India.
   [Mupparapu, Nagaraju; Bharate, Sandip B.; Ahmed, Qazi Naveed; Vishwakarma, Ram A.] Indian Inst Integrat Med, CSIR, Div Med Chem, Jammu, India.
   [Singh, Shashank Kumar; Bharate, Sandip B.; Ahmed, Qazi Naveed; Mondhe, Dilip Manikrao; Vishwakarma, Ram A.; Hamid, Abid] Govt India, Acad Sci & Innovat Res, CSIR, New Delhi, India.
   [Zargar, Mohmmad Afzal] Univ Kashmir, Dept Biochem, Srinagar, Jammu & Kashmir, India.
RP Hamid, A (corresponding author), Indian Inst Integrat Med, CSIR, Canc Pharmacol Div, Canal Rd, Jammu 180001, India.; Hamid, A (corresponding author), Govt India, Acad Sci & Innovat Res, CSIR, New Delhi, India.
EM ahdar@iiim.ac.in
RI Jani, Arpit/B-5376-2017; Zargar, Mohammad/G-7393-2018; Bharate, Sandip
   B/B-7104-2018
OI Zargar, Mohammad/0000-0002-2844-7141; singh,
   shashank/0000-0001-8532-7421; Mupparapu, Nagaraju/0000-0003-2900-7479;
   Ahmed, Qazi Naveed/0000-0002-6890-7587
FU CSIRCouncil of Scientific & Industrial Research (CSIR) - India
   [BSC-0205]
FX Grant sponsor: CSIR grant; Grant number: BSC-0205
CR Bharate SB, 2012, ARKIVOC, P308, DOI 10.3998/ark.5550190.0013.826
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50
   Deng T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0752-z
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8
   IARC, 2012, GLOBOCAN 2012
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majeed R, 2016, MOL CARCINOGEN, V55, P964, DOI 10.1002/mc.22339
   Mao C, 2013, CANCER-AM CANCER SOC, V119, P714, DOI 10.1002/cncr.27804
   Miller BW, 2015, CLIN CANCER RES, V21, P1525, DOI 10.1158/1078-0432.CCR-14-2522
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Qazi AK, 2015, CANCER LETT, V359, P47, DOI 10.1016/j.canlet.2014.12.034
   Qazi AK, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-36
   Qazi AK, 2013, ANTI-CANCER AGENT ME, V13, P1552, DOI 10.2174/1871520613666131125123241
   Shrotriya S, 2015, MOL CARCINOGEN, V54, P1734, DOI 10.1002/mc.22246
   Shugg RPP, 2013, J BIOL CHEM, V288, P35346, DOI 10.1074/jbc.M113.507525
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Stark AK, 2015, CURR OPIN PHARMACOL, V23, P82, DOI 10.1016/j.coph.2015.05.017
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
NR 33
TC 7
Z9 7
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2016
VL 55
IS 12
BP 2135
EP 2155
DI 10.1002/mc.22457
PG 21
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA EC1GY
UT WOS:000387854100021
PM 26764221
DA 2022-04-25
ER

PT J
AU Guo, C
   Liu, P
   Deng, GL
   Han, Y
   Chen, YH
   Cai, CJ
   Shen, H
   Deng, GP
   Zeng, S
AF Guo, Cao
   Liu, Ping
   Deng, Ganlu
   Han, Ying
   Chen, Yihong
   Cai, Changjing
   Shen, Hong
   Deng, Gongping
   Zeng, Shan
TI Honokiol induces ferroptosis in colon cancer cells by regulating GPX4
   activity
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Honokiol (HNK); ferroptosis; reactive oxygen species (ROS); colon cancer
   (CC); GPX4
ID CYCLE ARREST; IN-VITRO; DEATH; IRON; APOPTOSIS; AUTOPHAGY; PROGRESSION;
   INHIBITION; MECHANISMS; RESISTANCE
AB Colon cancer (CC) is a prevalent malignancy worldwide. Approaches to specifically induce tumor cell death have historically been a popular research topic. Honokiol (HNK), which exhibits highly efficient and specific anticancer effects, is a biphenolic compound found in Magnolia grandiflora. In the present study, we aim to study the effect of HNK on CC cells and elucidate the potential underlying mechanisms. Seven CC cell lines (RKO, HCT116, SW48, HT29, LS174T, HCT8, and SW480) were used. Cells were exposed to HNK and subjected to a series of assays to evaluate characteristics such as cellular activity, reactive oxygen species (ROS) levels and ferroptosis-related protein expression levels. Lentiviral transduction was also used to verify molecular mechanisms in vivo and in vitro. We here observed that HNK reduced the viability of CC cell lines by increasing ROS and Fe2+ levels. Transmission electron microscopy revealed HNK-induced changes in mitochondrial morphology. HNK decreased the activity of Glutathione Peroxidase 4 (GPX4) but did not affect system Xc-. Thus, our datas indicated that HNK can induce ferroptosis in CC cells by reducing the activity of GPX4. As a potential therapeutic drug, HNK showed good anticancer effects through diverse signal transduction mechanisms and multiple pathways.
C1 [Guo, Cao; Liu, Ping; Han, Ying; Chen, Yihong; Cai, Changjing; Shen, Hong; Zeng, Shan] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China.
   [Guo, Cao; Shen, Hong] Cent South Univ, Xiangya Hosp, Key Lab Mol Radiat Oncol Hunan Prov, Changsha 410008, Peoples R China.
   [Guo, Cao; Liu, Ping; Han, Ying; Chen, Yihong; Cai, Changjing; Shen, Hong; Zeng, Shan] Cent South Univ, Natl Clin Res Ctr Geriatr Disorders, Xiangya Hosp, Changsha 410008, Peoples R China.
   [Deng, Ganlu] Guangxi Med Univ, Affiliated Hosp 1, Dept Oncol, Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Deng, Gongping] Hainan Med Univ, Dept Emergency, Hainan Gen Hosp, Hainan Affiliated Hosp, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.
RP Zeng, S (corresponding author), Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China.; Deng, GP (corresponding author), Hainan Med Univ, Dept Emergency, Hainan Gen Hosp, Hainan Affiliated Hosp, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.
EM denggong-ping@hainmc.edu.cn; zengshan2000@csu.edu.cn
RI Cai, Changjing/ABA-4542-2021; Shen, Hong/N-9734-2019
OI Shen, Hong/0000-0002-6456-8231
FU National Key R&D Program of China [2018YFC1313300]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81070362, 81172470, 81372629, 81772627, 81874073, 81974384,
   81902500]; Nature Science Foundation of Hunan ProvinceNatural Science
   Foundation of Hunan Province [2015JC3021, 2016JC2037]; CSCO Cancer
   Research Foundation [Y-HR2019-0182, Y-2019Genecast-043]
FX This study was supported by grants from National Key R&D Program of
   China (No. 2018YFC1313300), National Natural Science Foundation of China
   (No.: 81070362, 81172470, 81372629, 81772627, 81874073, 81974384 &
   81902500), key projects from the Nature Science Foundation of Hunan
   Province (No. 2015JC3021 & 2016JC2037), two projects from CSCO Cancer
   Research Foundation (No. Y-HR2019-0182 & Y-2019Genecast-043). All animal
   experiments and procedures were directed and approved by the
   Experimental Animal Ethics Committee of Central South University.
CR Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064
   Balan M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05455-1
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1
   Dachert J, 2016, ONCOTARGET, V7, P63779, DOI 10.18632/oncotarget.11687
   De Felici M, 2015, INT J DEV BIOL, V59, P1, DOI 10.1387/ijdb.150168md
   Deng GL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0828-x
   Deng GL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41616
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Doll S, 2017, IUBMB LIFE, V69, P423, DOI 10.1002/iub.1616
   Fanzani A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081718
   Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011
   Godugu C, 2017, COLLOID SURFACE B, V153, P208, DOI 10.1016/j.colsurfb.2017.01.038
   Guo SC, 2019, BLOOD, V133, P1888, DOI 10.1182/blood-2018-10-879585
   Hahm ER, 2007, MOL CANCER THER, V6, P2686, DOI 10.1158/1535-7163.MCT-07-0217
   Hall N, 2009, MOL NUTR FOOD RES, V53, P49, DOI 10.1002/mnfr.200700527
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   Huang KM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0166-5
   Huo HZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154605
   Jelinek A, 2018, FREE RADICAL BIO MED, V117, P45, DOI 10.1016/j.freeradbiomed.2018.01.019
   Latunde-Dada GO, 2017, BBA-GEN SUBJECTS, V1861, P1893, DOI 10.1016/j.bbagen.2017.05.019
   Lin CJ, 2016, TOXICOL APPL PHARM, V304, P59, DOI 10.1016/j.taap.2016.05.018
   Lin RY, 2016, CANCER LETT, V381, P165, DOI 10.1016/j.canlet.2016.07.033
   Liu J, 2020, CELL CHEM BIOL, V27, P420, DOI 10.1016/j.chembiol.2020.02.005
   Lorincz T, 2015, PATHOL ONCOL RES, V21, P1115, DOI 10.1007/s12253-015-9946-3
   Lu CH, 2017, PHARMACOL RES, V115, P288, DOI 10.1016/j.phrs.2016.11.038
   Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y
   Pan J, 2016, MOL NUTR FOOD RES, V60, P1383, DOI 10.1002/mnfr.201501007
   Pan J, 2014, CANCER PREV RES, V7, P1149, DOI 10.1158/1940-6207.CAPR-14-0091
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Prasad R, 2016, ADV EXP MED BIOL, V928, P245, DOI 10.1007/978-3-319-41334-1_11
   Sehm T, 2016, ONCOTARGET, V7, P36021, DOI 10.18632/oncotarget.8651
   Shimada K, 2016, NAT CHEM BIOL, V12, P497, DOI [10.1038/nchembio.2079, 10.1038/NCHEMBIO.2079]
   Xavier CPR, 2016, CURR CANCER DRUG TAR, V16, P226, DOI 10.2174/1568009616666151113120705
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xie YC, 2016, BIOCHEM BIOPH RES CO, V473, P775, DOI 10.1016/j.bbrc.2016.03.052
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Ye Z, 2020, AM J CANCER RES, V10, P1182
   Zhu YX, 2016, CELL PHYSIOL BIOCHEM, V40, P297, DOI 10.1159/000452546
NR 41
TC 2
Z9 2
U1 4
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2021
VL 11
IS 6
BP 3039
EP 3054
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TA4KS
UT WOS:000667218200012
PM 34249443
DA 2022-04-25
ER

PT J
AU Yu, CH
   Chu, SC
   Yang, SF
   Hsieh, YS
   Lee, CY
   Chen, PN
AF Yu, Ching-Han
   Chu, Shu-Chen
   Yang, Shun-Fa
   Hsieh, Yih-Shou
   Lee, Chih-Yi
   Chen, Pei-Ni
TI Induction of apoptotic but not autophagic cell death by Cinnamomum
   cassia extracts on human oral cancer cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE apoptosis; autophagy; Cinnamomum cassia; oral cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; CARCINOMA-CELLS; CYCLE ARREST;
   PROTEASE ACTIVITIES; IN-VITRO; INVASION; INHIBITION; GROWTH; FAK;
   EXPRESSION
AB Cinnamomum cassia has been widely studied in different fields to reveal its antidiabetic, antidepressive, antiviral, anti-inflammatory, antiosteoporotic, and anticancer effects. Its antimalignant activities have been explored in lung cancer, breast cancer, colorectal cancer, and even oral cancer, but the detailed signaling mechanism and effects of this plant on animal models needto be clarified. In the current study, C. cassia extract (CCE) was used to investigate the antitumorigenesis mechanism in vitro and in vivo. The major constituents of CCE used in this study were coumarin, cinnamic acid, and cinnamic aldehyde. CCE reduced the viability, number, and colony formation of human oral cancer cells, and induced their apoptosis. Caspase-3 activation, Bcl-2 reduction, and phosphatidylserine inversion were involved in CCE-stimulated apoptosis. CCE also enhanced the expression of autophagic markers, including acidic vesicular organelle, microtubule-associated protein 1 light chain 3-I, autophagy-related protein 14, rubicon, and p62. The combined treatment of CCE and caspase inhibitor significantly restored mitochondrial membrane potential ((m)) and cell viability. However, the combined treatment of CCE and autophagy inhibitor further reduced the cell viability indicating that autophagy might be a survival pathway of CCE-treated SASVO3 cells. In contrast, CCE treatment for 12 days did not adversely affect SASVO3 tumor-bearing nude mice. CCE also elicited dose-dependent effects on the decrease in tumor volume, tumor weight, and Ki-67 expression. These results suggested that CCE showed the potential for the complementary treatment of oral caner.
C1 [Yu, Ching-Han] Chung Shan Med Univ, Sch Med, Dept Physiol, Taichung, Taiwan.
   [Yu, Ching-Han; Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Chu, Shu-Chen] Cent Taiwan Univ Sci & Technol, Inst & Dept Food Sci, Taichung, Taiwan.
   [Yang, Shun-Fa] Chung Shan Med Univ, Med, Taichung, Taiwan.
   [Hsieh, Yih-Shou; Lee, Chih-Yi; Chen, Pei-Ni] Chung Shang Med Univ, Inst Biochem Microbiol & Immunol, 110,Sect 1,Chien Kuo N Rd, Taichung 402, Taiwan.
   [Hsieh, Yih-Shou; Chen, Pei-Ni] Chung Shan Med Univ Hosp, Clin Lab, Taichung, Taiwan.
RP Chen, PN (corresponding author), Chung Shang Med Univ, Inst Biochem Microbiol & Immunol, 110,Sect 1,Chien Kuo N Rd, Taichung 402, Taiwan.
EM peini@csmu.edu.tw
RI Yang, Shun-Fa/AAN-1519-2020
OI Yang, Shun-Fa/0000-0002-0365-7927
FU Ministry of Science and Technology TaiwanMinistry of Science and
   Technology, Taiwan [MOST 106-2320-B-040 -016, MOST
   106-2320-B-040-020-MY3]
FX Ministry of Science and Technology Taiwan, Grant/Award Numbers: MOST
   106-2320-B-040 -016, MOST 106-2320-B-040-020-MY3
CR Anantharaju PG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186208
   BOXENBAUM H, 1995, J CLIN PHARMACOL, V35, P957, DOI 10.1002/j.1552-4604.1995.tb04011.x
   Chang WL, 2017, ENVIRON TOXICOL, V32, P456, DOI 10.1002/tox.22250
   Chen CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-100
   Chen PN, 2005, NUTR CANCER, V53, P232, DOI 10.1207/s15327914nc5302_12
   Chen PN, 2011, J AGR FOOD CHEM, V59, P3836, DOI 10.1021/jf1049408
   Chen PN, 2006, J DENT RES, V85, P220, DOI 10.1177/154405910608500303
   Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031864
   Chu SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101579
   Fatima M, 2016, J MICROBIOL BIOTECHN, V26, P151, DOI 10.4014/jmb.1508.08024
   Goswami SK, 2014, J SEX MED, V11, P1475, DOI 10.1111/jsm.12535
   Ho YS, 2001, INT J CANCER, V91, P393, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1070&gt;3.0.CO;2-#
   Hsieh YS, 2013, FOOD CHEM TOXICOL, V62, P908, DOI 10.1016/j.fct.2013.10.021
   Hsin IL, 2011, AUTOPHAGY, V7, P873, DOI 10.4161/auto.7.8.15698
   Hu FW, 2012, MOL NUTR FOOD RES, V56, P1247, DOI 10.1002/mnfr.201200150
   Huang SF, 2016, FOOD CHEM TOXICOL, V94, P1, DOI 10.1016/j.fct.2016.05.009
   Huh JE, 2015, PHYTOTHER RES, V29, P30, DOI 10.1002/ptr.5218
   INGS RMJ, 1990, XENOBIOTICA, V20, P1201, DOI 10.3109/00498259009046839
   Jacobson JJ, 2012, HEAD NECK ONCOL, DOI 10.1186/1758-3284-4-15
   Kim EC, 2015, BIOSCI BIOTECH BIOCH, V79, P617, DOI 10.1080/09168451.2014.993917
   Kim SH, 2017, ONCOTARGET, V8
   Kumar M., 2017, ANTICANCER AGENTS ME, V18
   Lee MA, 2013, J NAT PROD, V76, P1278, DOI 10.1021/np400216m
   Liao JC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429320
   Lin CY, 2017, ENVIRON TOXICOL, V32, P1878, DOI 10.1002/tox.22410
   Lu KH, 2016, FOOD CHEM TOXICOL, V97, P177, DOI 10.1016/j.fct.2016.09.006
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448
   Mohammadzadeh M, 2013, INTEGR CANCER THER, V12, P496, DOI 10.1177/1534735413485417
   Park CH, 2018, ENDOCRINOL METAB, V33, P121, DOI 10.3803/EnM.2018.33.1.121
   Park GH, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2096-x
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   Rad SK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145216
   Ranasinghe P, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2192-0
   Shen ZP, 2017, MED SCI MONITOR, V23, P2096, DOI 10.12659/MSM.901183
   Shin WY, 2017, J ETHNOPHARMACOL, V205, P173, DOI 10.1016/j.jep.2017.03.043
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Song MY, 2017, AM J CHINESE MED, V45, P1017, DOI [10.1142/S0192415X17500549, 10.1142/s0192415x17500549]
   Tian F, 2017, BIOCHEM BIOPH RES CO, V493, P1260, DOI 10.1016/j.bbrc.2017.09.136
   WONG DYK, 1990, J ORAL MAXIL SURG, V48, P385, DOI 10.1016/0278-2391(90)90436-6
   Wu CN, 2017, INT J BIOCHEM CELL B, V84, P58, DOI 10.1016/j.biocel.2017.01.005
   Wu HC, 2018, INT J MED SCI, V15, P115, DOI 10.7150/ijms.22293
   Zada W, 2016, NAT PROD RES, V30, P1212, DOI 10.1080/14786419.2015.1047776
   Zhou Z, 2017, MED SCI MONITOR, V23, P462, DOI 10.12659/MSM.903170
NR 43
TC 13
Z9 13
U1 2
U2 55
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2019
VL 234
IS 4
BP 5289
EP 5303
DI 10.1002/jcp.27338
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA HK0TE
UT WOS:000457613700178
PM 30317581
DA 2022-04-25
ER

PT J
AU Wang, N
   Feng, YB
AF Wang, Ning
   Feng, Yibin
TI Elaborating the Role of Natural Products-Induced Autophagy in Cancer
   Treatment: Achievements and Artifacts in the State of the Art
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID CELL LUNG-CANCER; ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA
   CELLS; GASTRIC ADENOCARCINOMA CELLS; IN-VITRO; PROTECTIVE AUTOPHAGY;
   COLON-CANCER; CYTOPROTECTIVE AUTOPHAGY; APOPTOTIC MECHANISMS; MITOTIC
   CATASTROPHE
AB Autophagy is a homeostatic process that is highly conserved across different types of mammalian cells. Autophagy is able to relieve tumor cell from nutrient and oxidative stress during the rapid expansion of cancer. Excessive and sustained autophagy may lead to cell death and tumor shrinkage. It was shown in literature that many anticancer natural compounds and extracts could initiate autophagy in tumor cells. As summarized in this review, the tumor suppressive action of natural products-induced autophagy may lead to cell senescence, provoke apoptosis-independent cell death, and complement apoptotic cell death by robust or target-specific mechanisms. In some cases, natural products-induced autophagy could protect tumor cells from apoptotic death. Technical variations in detecting autophagy affect data quality, and study focus should be made on elaborating the role of autophagy in deciding cell fate. In vivo study monitoring of autophagy in cancer treatment is expected to be the future direction. The clinical-relevant action of autophagy-inducing natural products should be highlighted in future study. As natural products are an important resource in discovery of lead compound of anticancer drug, study on the role of autophagy in tumor suppressive effect of natural products continues to be necessary and emerging.
C1 [Wang, Ning; Feng, Yibin] Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Ning; Feng, Yibin] Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen 518057, Peoples R China.
RP Feng, YB (corresponding author), Univ Hong Kong, Sch Chinese Med, 10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
EM yfeng@hku.hk
FU Research Council of the University of Hong KongUniversity of Hong Kong
   [10401764, 104002889, 104002587]; Research Grant Committee (RGC) of Hong
   Kong SAR of China (RGC General Research Fund) [10500362]; Wong's
   Donation for Modern Oncology of Chinese Medicine [20006276]; Gala Family
   Trust for Immunology and Stem Cell Research of Natural Products
   [200007008]; Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302808]
FX The study was financially supported by grants from the Research Council
   of the University of Hong Kong (Project codes 10401764, 104002889, and
   104002587), the Research Grant Committee (RGC) of Hong Kong SAR of China
   (RGC General Research Fund, Project code 10500362), Wong's Donation for
   Modern Oncology of Chinese Medicine (Project code 20006276), Gala Family
   Trust for Immunology and Stem Cell Research of Natural Products (Project
   code 200007008), and Natural Science Foundation of China (Project code
   81302808).
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Bui-Xuan NH, 2010, J ETHNOPHARMACOL, V131, P95, DOI 10.1016/j.jep.2010.06.007
   Chang KH, 2013, ONCOL LETT, V6, P1435, DOI 10.3892/ol.2013.1548
   Chen JL, 2014, INTEGR CANCER THER, V13, P226, DOI 10.1177/1534735414520970
   Chen MJ, 2013, ONCOL REP, V29, P430, DOI 10.3892/or.2012.2131
   Chiang YY, 2013, INT J MOL MED, V32, P577, DOI 10.3892/ijmm.2013.1441
   Chow HHS, 2010, CANCER PREV RES, V3, P1168, DOI 10.1158/1940-6207.CAPR-09-0155
   Chow SE, 2012, J CELL BIOCHEM, V113, P3476, DOI 10.1002/jcb.24224
   De A., 2013, PLOS ONE, V8
   Deng Q, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.324
   Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146
   DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437
   Dong YH, 2014, AUTOPHAGY, V10, P296, DOI 10.4161/auto.27210
   Eom JM, 2010, BIOCHEM BIOPH RES CO, V391, P903, DOI 10.1016/j.bbrc.2009.11.161
   Farkas T, 2009, AUTOPHAGY, V5, P1018, DOI 10.4161/auto.5.7.9443
   Filippi-Chiela EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020849
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088140
   Hau AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065250
   He CC, 2010, AUTOPHAGY, V6, P642, DOI 10.4161/auto.6.5.12092
   He H, 2013, J ETHNOPHARMACOL, V148, P544, DOI 10.1016/j.jep.2013.04.051
   Hou Q, 2011, CANCER SCI, V102, P1287, DOI 10.1111/j.1349-7006.2011.01933.x
   Hsieh MJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/134512
   Hsui CM, 2013, INT J ONCOL, V43, P338, DOI 10.3892/ijo.2013.1942
   Hu FL, 2014, APOPTOSIS, V19, P210, DOI 10.1007/s10495-013-0914-7
   Huo JG, 2013, PHYTOMEDICINE, V20, P159, DOI 10.1016/j.phymed.2012.10.001
   Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077
   Jin CY, 2013, INT J ONCOL, V43, P1943, DOI 10.3892/ijo.2013.2143
   Jung CH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/385219
   Kallifatidis G, 2013, MAR DRUGS, V11, P3500, DOI 10.3390/md11093500
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Kaushik G, 2012, AM J SURG, V204, P868, DOI 10.1016/j.amjsurg.2012.09.001
   Kim A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098703
   Kim A, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-233
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Kundu S, 2014, INT J ONCOL, V45, P2331, DOI 10.3892/ijo.2014.2659
   Kuo YF, 2010, FREE RADICAL BIO MED, V49, P214, DOI 10.1016/j.freeradbiomed.2010.04.005
   Kwatra D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/702869
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Law BYK, 2010, MOL CANCER THER, V9, P718, DOI 10.1158/1535-7163.MCT-09-0700
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Lee H.-W., 2014, BMB REPORTS
   Lee MY, 2013, ONCOL REP, V29, P2072, DOI 10.3892/or.2013.2334
   Leone RD, 2013, TRENDS ENDOCRIN MET, V24, P209, DOI 10.1016/j.tem.2013.01.008
   Li B, 2013, INT J GYNECOL CANCER, V23, P803, DOI 10.1097/IGC.0b013e31828c9581
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Liu J, 2012, J PHARM PHARMACOL, V64, P146, DOI 10.1111/j.2042-7158.2011.01371.x
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Liu WK, 2012, J NAT PROD, V75, P586, DOI 10.1021/np2008158
   Lu C, 2014, J CELL BIOCHEM, V115, P1458, DOI 10.1002/jcb.24808
   Ma D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028780
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Man K, 2010, CLIN CANCER RES, V16, P967, DOI 10.1158/1078-0432.CCR-09-1487
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Marzetti E, 2009, CLIN GERIATR MED, V25, P715, DOI 10.1016/j.cger.2009.07.002
   Maskey D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3130
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mei W, 2014, PLOS ONE, V9
   Meng ZQ, 2009, CANCER-AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602
   Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952
   Miao Q, 2013, INT J MOL SCI, V14, P1370, DOI 10.3390/ijms14011370
   Nkandeu DS, 2013, CELL BIOCHEM FUNCT, V31, P566, DOI 10.1002/cbf.2937
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Pedro M, 2006, TOXICOL LETT, V164, P24, DOI 10.1016/j.toxlet.2005.11.007
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Poornima P, 2013, FOOD CHEM, V141, P3598, DOI 10.1016/j.foodchem.2013.05.138
   Popat R, 2013, BRIT J HAEMATOL, V160, P714, DOI 10.1111/bjh.12154
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Qiu W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.84
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rasul A, 2012, ONCOL REP, V27, P1481, DOI 10.3892/or.2012.1694
   Rasul A, 2012, INT J ONCOL, V40, P1153, DOI 10.3892/ijo.2011.1277
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Roy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071672
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Shen SY, 2014, INT J BIOL SCI, V10, P212, DOI 10.7150/ijbs.8056
   Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004
   Tai CJ, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/514719, 10.1155/2013/121725]
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Tian FF, 2011, AUTOPHAGY, V7, P985, DOI 10.4161/auto.7.9.16012
   Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427
   Torricelli C, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/980658
   Tsai SC, 2012, INT J ONCOL, V41, P1431, DOI 10.3892/ijo.2012.1579
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang M, 2014, NUTR CANCER, V66, P435, DOI 10.1080/01635581.2013.878738
   Wang N, 2013, BBA-MOL CELL RES, V1833, P2890, DOI 10.1016/j.bbamcr.2013.07.018
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358
   Wang YJ, 2014, TOXICOL LETT, V226, P182, DOI 10.1016/j.toxlet.2014.02.003
   Wang YY, 2013, TOXICOL IN VITRO, V27, P1928, DOI 10.1016/j.tiv.2013.06.001
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Williams RT, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-57
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
   Wu EJ, 2014, CANCER BIOL THER, V15, P473, DOI 10.4161/cbt.27824
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xie R, 2011, CANCER RES, V71, P7537, DOI 10.1158/0008-5472.CAN-11-2170
   Xu MY, 2013, FOOD CHEM TOXICOL, V59, P703, DOI 10.1016/j.fct.2013.06.059
   Xu WS, 2014, AM J CHINESE MED, V42, P243, DOI 10.1142/S0192415X14500165
   Yamamoto M, 2010, ONCOL LETT, V1, P489, DOI 10.3892/ol_00000086
   Yan CH, 2006, TOXICON, V47, P521, DOI 10.1016/j.toxicon.2006.01.010
   Yan G, 2014, NUTR CANCER, V66, P506, DOI 10.1080/01635581.2013.780627
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yim NH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/231874
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Yun SM, 2014, PHYTOTHER RES, V28, P458, DOI 10.1002/ptr.5015
   Zhan YH, 2012, ASIAN PAC J CANCER P, V13, P2739, DOI 10.7314/APJCP.2012.13.6.2739
   Zhang DM, 2013, CARCINOGENESIS, V34, P1331, DOI 10.1093/carcin/bgt060
   Zhang L, 2014, BIOCHEM BIOPH RES CO, V450, P247, DOI 10.1016/j.bbrc.2014.05.101
   Zhao S, 2012, INT J MOL MED, V30, P939, DOI 10.3892/ijmm.2012.1066
   Zhou GZ, 2014, MOL MED REP, V10, P441, DOI 10.3892/mmr.2014.2183
   Zhou J, 2013, ANTI-CANCER DRUG, V24, P928, DOI 10.1097/CAD.0b013e328364e8d3
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 129
TC 28
Z9 28
U1 1
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 934207
DI 10.1155/2015/934207
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CD9BF
UT WOS:000351390100001
PM 25821829
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Wang, JW
   Wang, XH
   Liu, K
   Gu, L
   Yu, L
   Han, L
   Meng, ZJ
AF Wang, Jianwen
   Wang, Xuehai
   Liu, Kai
   Gu, Li
   Yu, Lei
   Han, Li
   Meng, Zhaojin
TI Suppressing UVRAG Induces Radiosensitivity by Triggering Lysosomal
   Membrane Permeabilization in Hypopharyngeal Squamous Cell Carcinoma
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE UVRAG; autophagy; radiosensitivity; hypopharyngeal squamous cell
   carcinoma; lysosomal membrane permeabilization
ID COLORECTAL-CANCER; AUTOPHAGY; ACTIVATION; CISPLATIN; APOPTOSIS;
   INDUCTION
AB Introduction: Radiotherapy is one of the most important methods in the treatment of patients with hypopharyngeal squamous cell carcinoma (HSCC). However, radioresistance will be developed after repeated irradiation. Among many key factors contributing to radioresistance, enhanced autophagy is recognized as one of the most important. The ultraviolent irradiation resistance-associated gene (UVRAG) is reported to be a crucial gene involved in the process of autophagy. Here, we test whether UVRAG has effect on the radioresistance of HSCC.
   Methods: HSCC cell line Fadu cells were treated with irradiation to test levels of autophagy. Tumor tissues from primary and recurrent HSCC patients were tested by immunohistochemistry. Then, we knocked down UVRAG to test its role in cell growth and the malignant behaviors. Response of cells to treatment was examined using LDH release assay, immunofluorescence, Western blot analysis and colony formation.
   Results: We found that irradiation induced autophagy in Fadu cells. Immunohistochemistry of primary and irradiated HSCC tumor tissues showed that UVRAG was upregulated after irradiation treatment. Inhibiting UVRAG with siRNA interfered cell growth, cell cycle, malignant behaviors and autophagic flux in Fadu cells. Knocking down UVRAG increased DNA damage and cell death induced by irradiation. Finally, we found that inhibiting UVRAG induced lysosomal membrane permeabilization, which contributed to radiosensitization of Fadu cells.
   Conclusion: Our findings supported the oncogenic properties of UVRAG in HSCC and inhibiting UVRAG increased radiosensitivity in HSCC by triggering lysosomal membrane permeabilization. Therefore, UVRAG might be a promising target in the treatment of HSCC.
C1 [Wang, Jianwen; Wang, Xuehai; Liu, Kai; Gu, Li; Yu, Lei; Han, Li; Meng, Zhaojin] Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Otolaryngol, Weihai 264200, Shandong, Peoples R China.
RP Wang, XH (corresponding author), Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Otolaryngol, Weihai 264200, Shandong, Peoples R China.
EM xuehai581@163.com
FU Medical Science Technology Development Program of Shandong Province
   [2018WS103]
FX This work was supported by the Medical Science Technology Development
   Program of Shandong Province (2018WS103).
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chang VHS, 2017, RADIOTHER ONCOL, V122, P476, DOI 10.1016/j.radonc.2017.01.001
   Datta S, 2019, APOPTOSIS, V24, P414, DOI 10.1007/s10495-019-01526-y
   Dhar SK, 2018, ONCOGENE, V37, P6225, DOI 10.1038/s41388-018-0404-z
   Feng X, 2019, AUTOPHAGY, V15, P1130, DOI 10.1080/15548627.2019.1570063
   Huang Y, 2020, CLIN SCI, V134, P853, DOI 10.1042/CS20191235
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Janoray G, 2020, EUR J CANCER, V133, P86, DOI 10.1016/j.ejca.2020.04.009
   Jo YK, 2018, ANTICANCER RES, V38, P271, DOI 10.21873/anticanres.12218
   Lee TG, 2020, ANTICANCER RES, V40, P2537, DOI 10.21873/anticanres.14224
   Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027
   Li Q, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1029-4
   Li YS, 2018, CANCER BIOMARK, V22, P495, DOI 10.3233/CBM-171137
   Lin JF, 2017, DRUG DES DEV THER, V11, P1517, DOI 10.2147/DDDT.S126464
   Liu C, 2020, ORAL ONCOL, V100, DOI 10.1016/j.oraloncology.2019.104469
   Meng QC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1244-z
   Munson MJ, 2015, EMBO J, V34, P2272, DOI 10.15252/embj.201590992
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   QUACH C, 2019, NAT COMMUN, V10, DOI DOI 10.1038/S41467-019-13475-W17
   Ramos-Garcia P, 2017, ORAL ONCOL, V72, P7, DOI 10.1016/j.oraloncology.2017.04.016
   RODRIGUEZABREU D, 2020, J CLIN ONCOL, V38
   Sharma M, 2018, AUTOPHAGY, V14, P1239, DOI 10.1080/15548627.2018.1474312
   Song Y, 2020, AUTOPHAGY, V16, P387, DOI 10.1080/15548627.2019.1709768
   Tsou YA, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6083-5
   Wang F, 2018, CLIN CANCER RES, V24, P3176, DOI 10.1158/1078-0432.CCR-17-3435
   Wang HY, 2020, ONCOTARGETS THER, V13, P497, DOI 10.2147/OTT.S237410
   Wang XH, 2017, BIOMED PHARMACOTHER, V96, P899, DOI 10.1016/j.biopha.2017.12.011
   Yang YF, 2016, MOL CELL, V62, P507, DOI 10.1016/j.molcel.2016.04.014
   Yin XC, 2011, AUTOPHAGY, V7, P1242, DOI 10.4161/auto.7.10.16507
   Yin XC, 2011, EMBO REP, V12, P727, DOI 10.1038/embor.2011.79
   Zhan YT, 2020, J CANCER, V11, P4193, DOI 10.7150/jca.39354
   ZHANG X, 2017, J EXP CLIN CANC RES, V36, DOI DOI 10.1186/S13046-017-0588-Z6
   Zhang X, 2018, CANCER LETT, V439, P39, DOI 10.1016/j.canlet.2018.08.029
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
   Zhou W, 2020, J CELL BIOCHEM, V121, P2027, DOI 10.1002/jcb.29437
NR 36
TC 1
Z9 1
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 10275
EP 10285
DI 10.2147/OTT.S270433
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA OC9XL
UT WOS:000579509400002
PM 33116608
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ramirez, JAZ
   Romagnoli, GG
   Falasco, BF
   Gorgulho, CM
   Fogolin, CS
   dos Santos, DC
   Junior, JPA
   Lotze, MT
   Ureshino, RP
   Kaneno, R
AF Zamame Ramirez, Jofer Andree
   Romagnoli, Graziela Gorete
   Falasco, Bianca Francisco
   Gorgulho, Carolina Mendonca
   Fogolin, Carla Sanzochi
   dos Santos, Daniela Carvalho
   Araujo Junior, Joao Pessoa
   Lotze, Michael Thomas
   Ureshino, Rodrigo Portes
   Kaneno, Ramon
TI Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer
   cells enhances DC maturation and T cell responses induced by tumor cell
   lysate
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Autophagy; Cancer; Colorectal; Chemotherapy; Dendritic cells; Cytotoxic
   T cells
ID ANTIGEN PRESENTATION; INDUCED APOPTOSIS; 5-FLUOROURACIL; INHIBITION;
   DEGRADATION; EXPRESSION; INDUCTION; CD4(+); DEATH; ASSAY
AB Autophagy is an important mechanism for tumor escape, allowing tumor cells to recover from the damage induced by chemotherapy, radiation therapy, and immunotherapy and contributing to the development of resistance. The pharmacological inhibition of autophagy contributes to increase the efficacy of antineoplastic agents. Exposing tumor cells to low concentrations of select autophagy-inducing antineoplastic agents increases their immunogenicity and enhances their ability to stimulate dendritic cell (DC) maturation. We tested whether the application of an autophagy-inhibiting agent, chloroquine (CQ), in combination with low concentrations of 5-fluorouracil (5-FU) increases the ability of tumor cells to induce DC maturation. DCs sensitized with the lysate of HCT-116 cells previously exposed to such a combination enhanced the DC maturation/activation ability. These matured DCs also increased the allogeneic responsiveness of both CD4+ and CD8 + T cells, which showed a greater proliferative response than those from DCs sensitized with control lysates. The T cells expanded in such cocultures were CD69+ and PD-1- and produced higher levels of IFN-gamma and lower levels of IL-10, consistent with the preferential activation of Th1 cells. Cocultures of autologous DCs and lymphocytes improved the generation of cytotoxic T lymphocytes, as assessed by the expression of CD107a, perforin, and granzyme B. The drug combination increased the expression of genes related to the CEACAM family (BECN1, ATGs, MAPLC3B, ULK1, SQSTM1) and tumor suppressors (PCBP1). Furthermore, the decreased expression of genes related to metastasis and tumor progression (BNIP3, BNIP3L, FOSL2, HES1, LAMB3, LOXL2, NDRG1, P4HA1, PIK3R2) was noted. The combination of 5-FU and CQ increases the ability of tumor cells to drive DC maturation and enhances the ability of DCs to stimulate T cell responses.
C1 [Zamame Ramirez, Jofer Andree; Romagnoli, Graziela Gorete; Falasco, Bianca Francisco; Gorgulho, Carolina Mendonca; Fogolin, Carla Sanzochi; Araujo Junior, Joao Pessoa; Kaneno, Ramon] Sao Paulo State Univ, Inst Biosci Botucatu, Dept Chem & Biol Sci, UNESP, Campus Rubiao Jr,Rua Prof Dr Plinio Pinto e Silva, BR-18618691 Botucatu, SP, Brazil.
   [Zamame Ramirez, Jofer Andree; Romagnoli, Graziela Gorete; Gorgulho, Carolina Mendonca] Sao Paulo State Univ, Sch Med Botucatu, Dept Pathol, UNESP, Botucatu, SP, Brazil.
   [dos Santos, Daniela Carvalho] Sao Paulo State Univ, Ctr Electron Microscopy, Inst Biosci Botucatu, UNESP, Botucatu, SP, Brazil.
   [Lotze, Michael Thomas] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.
   [Ureshino, Rodrigo Portes] Univ Fed Sao Paulo, Dept Biol Sci, UNIFESP, Sao Paulo, SP, Brazil.
RP Kaneno, R (corresponding author), Sao Paulo State Univ, Inst Biosci Botucatu, Dept Chem & Biol Sci, UNESP, Campus Rubiao Jr,Rua Prof Dr Plinio Pinto e Silva, BR-18618691 Botucatu, SP, Brazil.
EM rskaneno@yahoo.com.br
RI Araujo Jr, Joao Pessoa/Q-3043-2019; Ureshino, Rodrigo P/C-4095-2014;
   Ureshino, Rodrigo/ABC-5150-2020; Carvalho dos Santos,
   Daniela/E-3102-2012; Mendonca Gorgulho, Carolina/L-9511-2017; Zamame
   Ramirez, Jofer Andree/P-5163-2015
OI Araujo Jr, Joao Pessoa/0000-0002-9153-1485; Ureshino, Rodrigo
   P/0000-0003-3371-3376; Ureshino, Rodrigo/0000-0003-3371-3376; Carvalho
   dos Santos, Daniela/0000-0001-8062-104X; Mendonca Gorgulho,
   Carolina/0000-0001-6569-8647; Zamame Ramirez, Jofer
   Andree/0000-0002-1196-6893
FU CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES); Brazilian Council for Research CNPq, Brazil; Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX This research did not receive any specific grant from funding agencies
   in the public, commercial, or not for profit sectors. JAZR and CMG were
   recipients of doctorate scholarships from CAPES and the Brazilian
   Council for Research CNPq, Brazil. GGR was the recipient of a
   postdoctoral fellowship from CAPES. BFF and CSF were the recipients of
   scientific initiation scholarships from the Sao Paulo Research
   Foundation (FAPESP).
CR Aarntzen EHJG, 2013, CANCER RES, V73, P19, DOI 10.1158/0008-5472.CAN-12-1127
   Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Andre T., 2004, CLIN COLON CANC S1, V4, P22
   Aquino A, 2000, ANTICANCER RES, V20, P3475
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bryceson YT, 2010, METHODS MOL BIOL, V612, P335, DOI 10.1007/978-1-60761-362-6_23
   Burleson GR, 2010, METHODS MOL BIOL, V598, P195, DOI 10.1007/978-1-60761-401-2_14
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   Cockerham LR, 2014, AIDS, V28, P1749, DOI 10.1097/QAD.0000000000000314
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   De Almeida CV, 2017, ONCOL REP, V38, P561, DOI 10.3892/or.2017.5692
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Grimaldi A, 2015, CANCER BIOL THER, V16, P567, DOI 10.1080/15384047.2015.1018494
   GrohBrandt N., 2009, GEBURTSH FRAUENHEILK, V5, P214
   Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Guery L., 2015, BIOMED RES INT, V20, P31
   Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Kaneno R, 2011, CELL ONCOL, V34, P97, DOI 10.1007/s13402-010-0005-5
   Kaneno R, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-58
   Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2
   Kucharewicz K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0383-6
   Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moon EK, 2015, ANTIMICROB AGENTS CH, V59, P4020, DOI 10.1128/AAC.05165-14
   Patsoukis N, 2012, CELL CYCLE, V11, P4305, DOI 10.4161/cc.22135
   Pitt JM, 2017, ADV EXP MED BIOL, V1036, P65, DOI 10.1007/978-3-319-67577-0_5
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Saude M.d., 2019, EST, P120
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Sharma N, 2012, CANCER LETT, V326, P143, DOI 10.1016/j.canlet.2012.07.029
   Shurin GV, 2009, J IMMUNOL, V183, P137, DOI 10.4049/jimmunol.0900734
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Sundar R, 2015, THER ADV MED ONCOL, V7, P85, DOI 10.1177/1758834014567470
   Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911
   Vanmeerbeek I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1703449
   Wang XJ, 2015, ONCOTARGET, V6, P44688, DOI 10.18632/oncotarget.5975
   Yang JW, 2018, J CANCER RES THER, V14, pS1141, DOI 10.4103/0973-1482.204898
   Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
   Zitvogel L, 2009, J CLIN INVEST, V119, P2127, DOI 10.1172/JCI39991
NR 54
TC 8
Z9 8
U1 5
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2020
VL 84
AR 106495
DI 10.1016/j.intimp.2020.106495
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA LY3SB
UT WOS:000540446500070
PM 32298965
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Liang, CY
   Feng, PH
   Ku, BS
   Oh, BH
   Jung, JU
AF Liang, Chengyu
   Feng, Pinghui
   Ku, Bonsu
   Oh, Byung-Ha
   Jung, Jae U.
TI UVRAG - A new player in autophagy and tumor cell growth
SO AUTOPHAGY
LA English
DT Article
DE UVRAG; autophagy; tumor suppression; Beclin 1; Bcl-2
ID COLON-CANCER; GENE; INHIBITION; BECLIN-1; PROTEIN; CLONING
AB Autophagy has a well-documented role in the maintenance of homeostasis and the response to stressful environments and it is often deregulated in various human diseases including cancer. The regulation of the Beclin 1-PI3KC3 complex lipid kinase activity is a critical element in the autophagy signaling pathway. Previous studies(1) have demonstrated that Beclin 1-PI3KC3-mediated autophagy is negatively regulated by a proto-oncogene Bcl-2. We have recently identified a novel coiled-coil UVRAG tumor suppressor candidate, which positively engages in Beclin 1-dependent autophagy. UVRAG interacts with Beclin 1, leading to activation of autophagy and thereof inhibition of tumorigenesis. This finding adds a new player to the emerging picture of the autophagy network, underscoring the importance of the coordinated activity between Bcl-2 and UVRAG in the regulation of Beclin 1-PI3KC3-mediated autophagy and tumor cell control.
C1 Harvard Univ, Sch Med, Tumor Virol Div, New England Primat Res Ctr, Southborough, MA 01772 USA.
   Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, New England Primat Res Ctr, Southborough, MA 01772 USA.
   Pohang Univ Sci & Technol, Ctr Biomol Recognit, Dept Life Sci, Pohang, South Korea.
RP Jung, JU (corresponding author), Harvard Univ, Sch Med, Tumor Virol Div, New England Primat Res Ctr, POB 9102,1 Pine Hill Dr, Southborough, MA 01772 USA.
EM jae_jung@hms.harvard.edu
RI Oh, Byung-Ha/C-2061-2011
OI Ku, Bonsu/0000-0003-1784-8975
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Ito H, 2005, INT J ONCOL, V26, P1401
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   LIANG PFC, 2006, UVRAG NATURE CELL BI, V8, P688
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Perelman B, 1997, GENOMICS, V41, P397, DOI 10.1006/geno.1997.4623
   Proikas-Cezanne T, 2004, ONCOGENE, V23, P9314, DOI 10.1038/sj.onc.1208331
   Susan PP, 2001, J CELL PHYSIOL, V187, P48, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1050>3.3.CO;2-9
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 17
TC 55
Z9 57
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JAN-FEB
PY 2007
VL 3
IS 1
BP 69
EP 71
DI 10.4161/auto.3437
PG 3
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 126FY
UT WOS:000243499200021
PM 17106237
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhang, SH
   Zhang, YY
   Cheng, Q
   Ma, ZQ
   Gong, GW
   Deng, ZM
   Xu, K
   Wang, GY
   Wei, YS
   Zou, XP
AF Zhang, Shihu
   Zhang, Yiyang
   Cheng, Qing
   Ma, Zhaoqun
   Gong, Guanwen
   Deng, Zhengming
   Xu, Kun
   Wang, Gaoyuan
   Wei, Yousong
   Zou, Xiaoping
TI Silencing protein kinase C zeta by microRNA-25-5p activates AMPK
   signaling and inhibits colorectal cancer cell proliferation
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer (CRC); protein kinase C zeta (PKC zeta); AMP-activated
   protein kinase (AMPK); microRNA-25-5p; cell proliferation
ID INDUCED APOPTOSIS; REGULATES APOPTOSIS; EPITHELIAL-CELLS; ENERGY STRESS;
   AUTOPHAGY; GROWTH; EXPRESSION; PATHWAY; PHOSPHORYLATION; SURVIVAL
AB Developing novel strategies against human colorectal cancer (CRC) cells is needed. Activation of AMP-activated protein kinase (AMPK) could possibly inhibit CRC cells. Protein kinase C zeta (PKC zeta) is an AMPK negative regulator. Here we found that PKC zeta expression was significantly elevated in human colon cancer tissues and CRC cells. PKC zeta upregulation was correlated with AMPK in-activation and mTOR complex 1 (mTORC1) over-activation. Reversely, PKC zeta shRNA knockdown activated AMPK signaling and inhibited HT-29 cell proliferation. Significantly, downregulation of microRNA-25-5p (miR-25-5p), a PKC zeta-targeting miRNA, could be the cause of PKC zeta upregulation. Exogenous expression of miR-25-5p silenced PKC zeta to activate AMPK signaling, which inhibited HT-29 cell proliferation. In vivo studies showed that HT-29 xenograft growth in mice was inhibited after expressing PKC zeta shRNA or miR-25-5p. Collectively, PKC zeta could be a novel oncogenic protein of human CRC. PKC zeta silence, by targeted-shRNA or miR-25-5p expression, activates AMPK and inhibits HT-29 cell proliferation.
C1 [Zhang, Shihu; Ma, Zhaoqun; Gong, Guanwen; Deng, Zhengming; Xu, Kun; Wang, Gaoyuan; Wei, Yousong] Nanjing Univ Chinese Med, Dept Gen Surg, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Yiyang; Zou, Xiaoping] Nanjing Med Univ, Digest Dept, Affiliated Drum Tower Clin Med Sch, Nanjing, Jiangsu, Peoples R China.
   [Cheng, Qing] Nanjing Med Univ, Dept Obstet & Gynaecol, Obstet & Gynecol Hosp, Nanjing, Jiangsu, Peoples R China.
RP Wei, YS (corresponding author), Nanjing Univ Chinese Med, Dept Gen Surg, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.; Zou, XP (corresponding author), Nanjing Med Univ, Digest Dept, Affiliated Drum Tower Clin Med Sch, Nanjing, Jiangsu, Peoples R China.
EM weiyousongnanjlw@yeah.net; zouxiaopingmunj@163.com
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC)
FX This work is partly supported by the National Science Foundation of
   China.
CR Accordi B, 2013, LEUKEMIA, V27, P1019, DOI 10.1038/leu.2012.338
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen MB, 2016, ONCOTARGET, V7, P17047, DOI 10.18632/oncotarget.7742
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522
   Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21
   Deepa SS, 2011, MOL ENDOCRINOL, V25, P1773, DOI 10.1210/me.2011-0082
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fan JB, 2017, ONCOTARGET, V8, P3226, DOI 10.18632/oncotarget.13698
   Gao W, 2014, CLIN SCI, V127, P571, DOI 10.1042/CS20140010
   Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164
   Guo DK, 2015, NEUROSCI BULL, V31, P469, DOI 10.1007/s12264-015-1543-7
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hsu YF, 2012, BBA-GEN SUBJECTS, V1820, P104, DOI 10.1016/j.bbagen.2011.11.011
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Jia XJ, 2016, NEUROSCI BULL, V32, P512, DOI 10.1007/s12264-016-0061-6
   Kang MR, 2012, ONCOL REP, V27, P1407, DOI 10.3892/or.2012.1644
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YM, 2007, ANN NY ACAD SCI, V1095, P496, DOI 10.1196/annals.1397.053
   Li Z, 2016, EURASIP J WIREL COMM, DOI 10.1186/s13638-016-0554-z
   Liang PZ, 2015, NEUROSCI BULL, V31, P435, DOI 10.1007/s12264-015-1545-5
   Liu WD, 2017, ONCOTARGET, V8, P10543, DOI 10.18632/oncotarget.14454
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Lu XS, 2017, ONCOTARGET, V8, P988, DOI 10.18632/oncotarget.13519
   Lv GQ, 2014, BIOCHEM BIOPH RES CO, V453, P13, DOI 10.1016/j.bbrc.2014.09.028
   Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Min H, 2014, CANCER CHEMOTH PHARM, V74, P167, DOI 10.1007/s00280-014-2451-7
   Muhammad S, 2014, WORLD J GASTROENTERO, V20, P17011, DOI 10.3748/wjg.v20.i45.17011
   Narbonne P, 2009, NATURE, V457, P210, DOI 10.1038/nature07536
   Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6989, DOI 10.7314/APJCP.2014.15.17.6989
   Palta M, 2014, NAT REV CLIN ONCOL, V11, P182, DOI 10.1038/nrclinonc.2014.43
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156
   Vakana E, 2012, J CELL BIOCHEM, V113, P404, DOI 10.1002/jcb.23369
   Wang HC, 2015, NEUROSCI BULL, V31, P491, DOI 10.1007/s12264-015-1546-4
   Wu WD, 2014, INT J MOL SCI, V15, P12778, DOI 10.3390/ijms150712778
   Xiang SH, 2017, BIOCHEM BIOPH RES CO, V484, P719, DOI 10.1016/j.bbrc.2017.01.095
   Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530
   Zhang SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169585
   Zhou CX, 2017, ONCOTARGET, V8, P14736, DOI 10.18632/oncotarget.14718
   Zhu LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084175
NR 57
TC 9
Z9 9
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 12
PY 2017
VL 8
IS 39
BP 65329
EP 65338
DI 10.18632/oncotarget.18649
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FG4YC
UT WOS:000410291200053
PM 29029434
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kim, WK
   Pyee, Y
   Chung, HJ
   Park, HJ
   Hong, JY
   Son, KH
   Lee, SK
AF Kim, Won Kyung
   Pyee, Yuna
   Chung, Hwa-Jin
   Park, Hyen Joo
   Hong, Ji-Young
   Son, Kun Ho
   Lee, Sang Kook
TI Antitumor Activity of Spicatoside A by Modulation of Autophagy and
   Apoptosis in Human Colorectal Cancer Cells
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID STEROIDAL SAPONIN; LIRIOPE-PLATYPHYLLA; ANTICANCER AGENTS;
   GROWTH-FACTOR; PATHWAY; INHIBITION; CLEAVAGE; THERAPY; P53; MITOCHONDRIA
AB The antitumor activity of spicatoside A (1), a steroidal saponin isolated from the tuber of Liriope platyphylla, and its underlying mechanisms were investigated in HCT116 human colorectal cancer cells. Compound 1 induced autophagy and apoptotic cell death and inhibited tumor growth in a nude mouse xenograft model implanted with HCT116 cells. Treatment with 1 for 24 h enhanced the formation of acidic vesicular organelles in the cytoplasm, indicating the induction of the onset of autophagy. This event was associated with the regulation of autophagic markers including microtubule-associated protein 1 light chain 3 (LC3)-II, p62, beclin 1, lysosomal-associated membrane protein 1 (LAMP 1), and cathepsin D by inhibiting the PI3K/Akt/mTOR signaling pathway, regulating mitogen-activated protein kinase (MAPK) signaling, and increasing p53 levels. However, a prolonged exposure to 1 resulted in apoptosis characterized by the accumulation of a sub-G1 cell population and an annexin V/propidium iodide (PI)-positive cell population. Apoptosis induced by 1 was associated with the regulation of apoptotic proteins including Bcl-2, Bax, and Bid, the release of cytochrome c into the cytosol, and the accumulation of cleaved poly-ADP-ribose polymerase (PAR?). Further study revealed that cleavage of beclin 1 by caspases plays a critical role in the 1-mediated switch from autophagy to apoptosis. Taken together, these findings highlight the significance of 1 in the modulation of crosstalk between autophagy and apoptosis, as well as the potential use of 1 as a novel candidate in the treatment of human colorectal cancer cells.
C1 [Kim, Won Kyung; Pyee, Yuna; Chung, Hwa-Jin; Park, Hyen Joo; Hong, Ji-Young; Lee, Sang Kook] Seoul Natl Univ, Coll Pharm, Inst Nat Prod Res, Seoul 151742, South Korea.
   [Son, Kun Ho] Andong Natl Univ, Dept Food Sci & Nutr, Andong 760749, South Korea.
RP Lee, SK (corresponding author), Seoul Natl Univ, Coll Pharm, Inst Nat Prod Res, Seoul 151742, South Korea.
EM sklee61@snu.ac.kr
OI Lee, Sang Kook/0000-0002-4306-7024
FU National Research Foundation of Korea (NRF) - Korean government
   (MEST)Ministry of Education, Science and Technology, Republic of
   KoreaNational Research Foundation of KoreaKorean Government
   [20120004939, 2009-0083533]; Ministry of Food and Drug SafetyMinistry of
   Food & Drug Safety (MFDS) [12172MFDS989]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MEST) (No. 20120004939 and
   2009-0083533) and a grant (12172MFDS989) from the Ministry of Food and
   Drug Safety in 2012.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8
   Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hong JY, 2011, J NAT PROD, V74, P2102, DOI 10.1021/np2003512
   Hur J, 2004, BIOL PHARM BULL, V27, P1257, DOI 10.1248/bpb.27.1257
   Hur J, 2009, EUR J PHARMACOL, V620, P9, DOI 10.1016/j.ejphar.2009.08.016
   Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294
   Kwak MH, 2013, J ETHNOPHARMACOL, V148, P880, DOI 10.1016/j.jep.2013.05.036
   Kwon G, 2014, NEUROSCI LETT, V572, P58, DOI 10.1016/j.neulet.2014.04.034
   Lee YC, 2005, J ETHNOPHARMACOL, V101, P144, DOI 10.1016/j.jep.2005.04.030
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Lim H, 2015, ARCH PHARM RES, V38, P1108, DOI 10.1007/s12272-015-0581-z
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Man SL, 2010, FITOTERAPIA, V81, P703, DOI 10.1016/j.fitote.2010.06.004
   Milner J, 2011, CELL CYCLE, V10, P3049, DOI 10.4161/cc.10.18.16994
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Park SH, 2014, PHYTOMEDICINE, V21, P172, DOI 10.1016/j.phymed.2013.08.013
   Rosen N, 2006, CANCER CELL, V10, P254, DOI 10.1016/j.ccr.2006.10.001
   Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9
   Stankiewicz M, 1996, INT J PARASITOL, V26, P445, DOI 10.1016/0020-7519(96)00003-3
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   Sun KY, 2013, INT J MOL SCI, V14, P4461, DOI 10.3390/ijms14034461
   Sun YJ, 2013, FOOD CHEM TOXICOL, V51, P53, DOI 10.1016/j.fct.2012.09.012
   Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tsai YC, 2013, FOOD CHEM, V140, P305, DOI 10.1016/j.foodchem.2013.02.069
   Wang YH, 2013, BIOCHEM BIOPH RES CO, V441, P825, DOI 10.1016/j.bbrc.2013.10.148
   Wei SH, 2014, PATHOBIOLOGY, V81, P123, DOI 10.1159/000357622
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
NR 40
TC 27
Z9 32
U1 1
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD APR
PY 2016
VL 79
IS 4
BP 1097
EP 1104
DI 10.1021/acs.jnatprod.6b00006
PG 8
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA DK4UM
UT WOS:000374915800053
PM 27064730
DA 2022-04-25
ER

PT J
AU Man, SL
   Lv, PP
   Cui, JX
   Liu, FR
   Peng, L
   Ma, L
   Liu, CX
   Gao, WY
AF Man, Shuli
   Lv, Panpan
   Cui, Jingxia
   Liu, Furui
   Peng, Lei
   Ma, Long
   Liu, Changxiao
   Gao, Wenyuan
TI Paris saponin II-induced paraptosis-associated cell death increased the
   sensitivity of cisplatin
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Paris Saponin II; Paraptosis; Endoplasmic Reticulum Stress; Cytoplasmic
   Vacuolation; Mitochondrial Swelling
ID COLON-CANCER CELLS; RHIZOMA PARIDIS; FORMOSANIN C; LUNG-CANCER;
   ACTIVATION; RESISTANCE; APOPTOSIS; AUTOPHAGY
AB Paris Saponin II (PSII) has been regarded as an effective and imperative component isolated from Rhizoma Paridis saponins (RPS) and exhibited strong anti-tumor effects on a variety of cancer. Our results revealed that human non-small lung cancer cell lines NCI-H460 and NCI-H520 were exposed to 1 mu M of PSII, which inhibited the proliferation of lung cancer cells and activated apoptosis, autophagy and paraptosis. PSII induced paraptosis-associated cell death prior to apoptosis and autophagy. It induced paraptosis based on ER stress through activation of the JNK pathway. Meanwhile, PSII increased the cytotoxicity of cisplatin through paraptosis-associated pathway. All in all, PSII induced paraptosis based on induction of non-apoptotic cell death, which would be a possible approach to suppress the multi-drug resistant to apoptosis.
C1 [Man, Shuli; Lv, Panpan; Cui, Jingxia; Liu, Furui; Peng, Lei; Ma, Long] Tianjin Univ Sci & Technol, Natl & Local United Engn Lab Metab Control Fermen, Tianjin Key Lab Ind Microbiol,China Int Sci & Tec, State Key Lab Food Nutr & Safety,Key Lab Ind Micr, Tianjin 300457, Peoples R China.
   [Gao, Wenyuan] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China.
   [Liu, Changxiao] State Key Labs Pharmacodynam & Pharmacokinet, Tianjin 300193, Peoples R China.
RP Man, SL (corresponding author), Tianjin Univ Sci & Technol, Natl & Local United Engn Lab Metab Control Fermen, Tianjin Key Lab Ind Microbiol,China Int Sci & Tec, State Key Lab Food Nutr & Safety,Key Lab Ind Micr, Tianjin 300457, Peoples R China.; Gao, WY (corresponding author), Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China.
EM msl@tust.edu.cn; biochemgao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673647, 81673535, 81503086]; 
   [18PTSYJC00140];  [19JCYBJC27800]
FX This work was supported by grants 81673647, 81673535 and 81503086 from
   National Natural Science Foundation of China and Tianjin Municipal
   Science and Technology Committee (18PTSYJC00140 and 19JCYBJC27800).
CR Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Cui JX, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12520
   DeSantis CE, 2019, CA-CANCER J CLIN, V69, P452, DOI 10.3322/caac.21577
   Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050
   Gandin V, 2012, J CELL MOL MED, V16, P142, DOI 10.1111/j.1582-4934.2011.01292.x
   Jiang DM, 2018, TRADIT MED RES, V3, P40, DOI 10.12032/TMR201809063
   Kar R, 2009, ONCOGENE, V28, P2556, DOI 10.1038/onc.2009.118
   Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945
   Kim IY, 2019, BIOCHEM PHARMACOL, V162, P41, DOI 10.1016/j.bcp.2018.12.006
   Lee D, 2016, PHARMACOL THERAPEUT, V162, P120, DOI 10.1016/j.pharmthera.2016.01.003
   Li YY, 2014, CHEM-BIOL INTERACT, V220, P193, DOI 10.1016/j.cbi.2014.06.023
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Man SL, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12458
   Man SL, 2011, BIOMED CHROMATOGR, V25, P712, DOI 10.1002/bmc.1507
   Man SL, 2011, CANCER BIOL THER, V11, P592, DOI 10.4161/cbt.11.6.14668
   Shubin AV, 2016, ONCOTARGET, V7, P55863, DOI 10.18632/oncotarget.10150
   Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465
   Sun QR, 2010, J CELL PHYSIOL, V222, P421, DOI 10.1002/jcp.21982
   Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016
   Wasik AM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.106
   Xiao X, 2012, BIOSCI TRENDS, V6, P201, DOI 10.5582/bst.2012.v6.4.201
   Yang M, 2015, ONCOL REP, V33, P2190, DOI 10.3892/or.2015.3836
   Yang YG, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/bmc.3913
   Zhang C, 2015, INT J MOL SCI, V16, P14979, DOI 10.3390/ijms160714979
   Zhang LL, 2016, CHEM-BIOL INTERACT, V253, P125, DOI 10.1016/j.cbi.2016.05.016
   Zhang T, 2010, J PHARMACEUT BIOMED, V51, P114, DOI 10.1016/j.jpba.2009.08.020
   Zheng RZ, 2017, CURR CANCER DRUG TAR, V17, P376, DOI 10.2174/1568009616666161213141608
   Zhou Y, 2018, SMALL, V14, DOI 10.1002/smll.201704403
NR 28
TC 7
Z9 9
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD NOV 1
PY 2020
VL 406
AR 115206
DI 10.1016/j.taap.2020.115206
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA OE4SM
UT WOS:000580522200004
PM 32835762
DA 2022-04-25
ER

PT J
AU Nerome, K
   Ito-Kureha, T
   Paganini, T
   Fukuda, T
   Igarashi, Y
   Ashitomi, H
   Ikematsu, S
   Yamamoto, T
AF Nerome, Kuniaki
   Ito-Kureha, Taku
   Paganini, Tiziana
   Fukuda, Takao
   Igarashi, Yasuhiro
   Ashitomi, Hiroto
   Ikematsu, Shinya
   Yamamoto, Tadashi
TI Potent and broad anticancer activities of leaf extracts from Melia
   azedarach L. of the subtropical Okinawa islands
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Cancer; anticancer therapeutics; plant extracts; Melia azedarach;
   autophagy inhibitors
ID DRUG DISCOVERY; CELL-DEATH; CYTOTOXIC LIMONOIDS; CANCER-CELLS; IN-VITRO;
   AUTOPHAGY; INHIBITION; MTOR; HYDROXYCHLOROQUINE; MACROAUTOPHAGY
AB Plant extracts have been traditionally used for various therapeutic applications. By conducting an initial screening of several subtropical plants, in this study, we evaluated the anticancer activities of Melia azedarach L. The extract from Melia azedarach L. leaves (MLE) show high cytotoxic effects on cancer cells and in vivo mouse and dog tumor models. During the initial screening, MLE showed strong antiproliferative activity against HT-29 colon, A549 lung, and MKN1 gastric cancer cells. In subsequent tests, using 39 human tumor cell lines, we confirmed the potent anticancer activities of MLE. The anticancer activity of MLE was also confirmed in vivo. MLE markedly inhibited the growth of transplanted gastric MKN1 cancer xenografts in mice. To elucidate the mechanism underlying the anticancer effects of MLE, MLE-treated MKN1 cells were observed using an electron microscope; MLE treatment induced autophagy. Furthermore, western blot analysis of proteins in lysates of MLE-treated cells revealed induction of light chain 3 (LC3)-II autophagosomal proteins. Thus, MLE appeared to suppress MKN1 cell proliferation by inducing autophagy. In addition, in the mouse macrophage cell line J774A.1, MLE treatment induced TNF-alpha production, which might play a role in tumor growth suppression in vivo. We also performed a preclinical evaluation of MLE treatment on dogs with various cancers in veterinary hospitals. Dogs with various types of cancers showed a mean recovery of 76% when treated with MLE. Finally, we tried to identify the active substances present in MLE. All the active fractions obtained by reverse-phase chromatography contained azedarachin B-related moieties, such as 3-deacetyl-12-hydroxy-amoorastatin, 12-hydroxy-amoorastatin, and 12-hydroxyamoorastaton. In conclusion, MLE contains substances with promising anticancer effects, suggesting their future use as safe and effective anticancer agents.
C1 [Nerome, Kuniaki] Inst Biol Resources, 893-2 Nakayama, Nago, Okinawa 9050004, Japan.
   [Ito-Kureha, Taku; Paganini, Tiziana; Yamamoto, Tadashi] Okinawa Inst Sci & Technol Grad Univ, Cell Signal Unit, Onna, Okinawa 9040495, Japan.
   [Fukuda, Takao; Igarashi, Yasuhiro] Toyama Prefectural Univ, Fac Engn, Biotechnol Res Ctr, 5180 Kurokawa, Imizu, Toyama 9390398, Japan.
   [Fukuda, Takao; Igarashi, Yasuhiro] Toyama Prefectural Univ, Fac Engn, Dept Biotechnol, 5180 Kurokawa, Imizu, Toyama 9390398, Japan.
   [Ashitomi, Hiroto; Ikematsu, Shinya] Okinawa Coll, Natl Inst Technol, Henoko 905, Nago, Okinawa 9052192, Japan.
RP Nerome, K (corresponding author), Inst Biol Resources, 893-2 Nakayama, Nago City, Okinawa 9050004, Japan.
EM rnerome_ibr@train.ocn.ne.jp
FU Okinawa Institute of Science and Technology Graduate SchoolOkinawa
   Institute of Science & Technology Graduate University; Institute of
   Biological Resources, Okinawa, Japan
FX We thank Dr. T. Yoshikawa and Mr. S. Mukai (Institute of Biological
   Resources, Okinawa, Japan) for their skillful technical help and general
   support. We thank Ms. N. Ohmine (Okinawa Institute of Science and
   Technology Graduate University, Okinawa, Japan: OIST) and Dr. O.
   Elisseeva (Institute of Physical and Chemical Research, Kanagawa, Japan:
   RIKEN) for their technical support. We also thank Dr. K. Kuroda (Nihon
   University School of Medicine, Tokyo, Japan) for useful comments on the
   manuscript. We are grateful to the Kyoritsu Seiyaku Corporation (Tokyo,
   Japan) for their cooperation in the preclinical evaluation of MLE in
   veterinary hospitals. We also appreciate the Okinawa Institute of
   Science and Technology Graduate School for providing partial funding for
   this work. Authors appreciate Dr. R. Nerome (Institute of Biological
   Resources, Okinawa, Japan) for her generous supports for preparing the
   manuscript and figures.
CR AHN JW, 1994, PHYTOCHEMISTRY, V36, P1493, DOI 10.1016/S0031-9422(00)89749-6
   Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.3.CO;2-0
   Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253
   Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108
   Harris J, 2011, CYTOKINE, V56, P140, DOI 10.1016/j.cyto.2011.08.022
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   ITOKAWA H, 1995, CHEM PHARM BULL, V43, P1171, DOI 10.1248/cpb.43.1171
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   JOHNSON IS, 1963, CANCER RES, V23, P1390
   Katanoda K, 2015, JPN J CLIN ONCOL, V45, P390, DOI 10.1093/jjco/hyv002
   Keller CW, 2011, J BIOL CHEM, V286, P3970, DOI 10.1074/jbc.M110.159392
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372
   Maeda M., 1990, MED PLANTS FOLK REME
   Martino E, 2017, BIOORG MED CHEM LETT, V27, P701, DOI 10.1016/j.bmcl.2016.12.085
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   OCHI M, 1978, CHEM LETT, P99, DOI 10.1246/cl.1978.99
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Sivaprasad U, 2008, J CELL MOL MED, V12, P1265, DOI 10.1111/j.1582-4934.2008.00282.x
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sliwkowski MX, 2013, SCIENCE, V341, P1192, DOI 10.1126/science.1241145
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Tada K, 1999, PHYTOCHEMISTRY, V51, P787, DOI 10.1016/S0031-9422(99)00115-6
   Takeya K, 1996, BIOORGAN MED CHEM, V4, P1355, DOI 10.1016/0968-0896(96)00128-9
   Tan QG, 2011, CHEM REV, V111, P7437, DOI 10.1021/cr9004023
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wu TT, 2016, INT J BIOL SCI, V12, P884, DOI 10.7150/ijbs.15194
   Yamori T, 1997, JPN J CANCER RES, V88, P1205, DOI 10.1111/j.1349-7006.1997.tb00350.x
   Yamori T, 2003, CANCER CHEMOTH PHARM, V52, pS74, DOI 10.1007/s00280-003-0649-1
   Yamori T, 1999, CANCER RES, V59, P4042
   Zhang B, 2005, INVEST NEW DRUG, V23, P547, DOI 10.1007/s10637-005-0909-5
NR 48
TC 1
Z9 1
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2020
VL 10
IS 2
BP 581
EP 594
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KS0YF
UT WOS:000518037100016
PM 32195029
DA 2022-04-25
ER

PT J
AU Zhou, L
   Gao, W
   Wang, K
   Huang, Z
   Zhang, L
   Zhang, Z
   Zhou, J
   Nice, EC
   Huang, CH
AF Zhou, Li
   Gao, Wei
   Wang, Kui
   Huang, Zhao
   Zhang, Lu
   Zhang, Zhe
   Zhou, Jing
   Nice, Edouard C.
   Huang, Canhua
TI Brefeldin A inhibits colorectal cancer growth by triggering
   Bip/Akt-regulated autophagy
SO FASEB JOURNAL
LA English
DT Article
DE cancer therapy; ER stress; autophagic flux
ID ER STRESS; CELL-DEATH; APOPTOSIS; MITOCHONDRIAL; STATISTICS; RESISTANCE
AB Colorectal cancer (CRC) is one of the most prevalent neoplastic diseases worldwide, and effective treatment remains a challenge. Here, we found that the macrolide antibiotic brefeldin A (BFA) exhibits considerable antitumor activity both in vitro and in vivo. Induction of complete autophagic flux is characterized as a key event in BFA-induced CRC suppression. Mechanistically, BFA provokes endoplasmic reticulum stress-mediated binding immunoglobulin protein (Bip) expression, leading to increased Bip/Akt interaction and resultant decreased Akt phosphorylation, thereby activating autophagy. Autophagy inhibition or Bip suppression relieves BFA-induced cell death, suggesting a key role for Bip-regulated autophagy in the antitumor properties of BFA. Moreover, BFA acts synergistically with paclitaxel or 5-fluorouracil in CRC suppression. Collectively, our study provides an important molecular basis for BFA-induced autophagy and suggests that the antibiotic BFA could be repositioned as a potential anticancer drug for CRC treatment.
C1 [Zhou, Li; Gao, Wei; Wang, Kui; Huang, Zhao; Zhang, Lu; Zhang, Zhe; Zhou, Jing; Huang, Canhua] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Deans Off 17,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Li; Gao, Wei; Wang, Kui; Huang, Canhua] Sichuan Univ, West China Sch Basic Sci & Forens Med, Chengdu, Sichuan, Peoples R China.
   [Zhou, Li; Gao, Wei; Huang, Canhua] Hainan Med Univ, Affiliated Hosp 2, Dept Oncol, Haikou, Hainan, Peoples R China.
   [Nice, Edouard C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.
RP Huang, CH (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Deans Off 17,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
EM hcanhua@scu.edu.cn
RI Kang, Jeong-Han/J-3541-2019
OI Kang, Jeong-Han/0000-0002-9693-0696; Huang, Zhao/0000-0001-9994-2070
FU Chinese National Natural Science Foundation of China (NSFC)National
   Natural Science Foundation of China (NSFC) [81430071, 81790251,
   81672381, 81602194]; National Key Research and Development Program of
   China [2016YFC1200203]
FX This work was supported by grants from the Chinese National Natural
   Science Foundation of China (NSFC; 81430071, 81790251, 81672381,
   81602194) and the National Key Research and Development Program of China
   (2016YFC1200203). The authors declare no conflicts of interest.
CR B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Gao M, 2014, ONCOGENE, V33, P745, DOI 10.1038/onc.2013.2
   Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Huang HR, 2017, BIOORG MED CHEM LETT, V27, P2286, DOI 10.1016/j.bmcl.2017.04.047
   Huang YH, 2018, GUT, V67, P307, DOI 10.1136/gutjnl-2016-311909
   KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Lee H, 2012, HUM MOL GENET, V21, P101, DOI 10.1093/hmg/ddr445
   Lee SA, 2013, BASIC CLIN PHARMACOL, V113, P329, DOI 10.1111/bcpt.12107
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Moon JL, 2012, BIOCHEM BIOPH RES CO, V417, P760, DOI 10.1016/j.bbrc.2011.12.030
   PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Sausville E A, 1996, Cancer J Sci Am, V2, P52
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160
   Tang B, 2015, AUTOPHAGY, V11, P344, DOI 10.1080/15548627.2015.1023682
   Tseng CN, 2014, MOLECULES, V19, P17464, DOI 10.3390/molecules191117464
   Tseng CN, 2013, MOLECULES, V18, P10242, DOI 10.3390/molecules180910242
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yung HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017894
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang ZD, 2016, GENE, V584, P75, DOI 10.1016/j.gene.2016.03.012
NR 37
TC 17
Z9 17
U1 2
U2 19
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2019
VL 33
IS 4
BP 5520
EP 5534
DI 10.1096/fj.201801983R
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA HR1JP
UT WOS:000462888500071
PM 30668917
OA Bronze
DA 2022-04-25
ER

PT J
AU Shintani, M
   Sangawa, A
   Yamao, N
   Miyake, T
   Kamoshida, S
AF Shintani, Michiko
   Sangawa, Akiko
   Yamao, Naoki
   Miyake, Toshihiko
   Kamoshida, Shingo
TI Immunohistochemical analysis of cell death pathways in gastrointestinal
   adenocarcinoma
SO BIOMEDICAL RESEARCH-TOKYO
LA English
DT Article
ID APOPTOSIS-INDUCING FACTOR; CASPASES 3; GASTRIC-CARCINOMA; PROTEINS
   BCL-2; FACTOR AIF; CANCER; EXPRESSION; AUTOPHAGY; 5-FLUOROURACIL;
   MECHANISMS
AB Caspase-8 and caspase-9 play crucial roles in the extrinsic and intrinsic apoptotic pathways, respectively. The nuclear translocation of apoptosis-inducing factor (AI F) is involved in caspase-independent apoptosis. Microtubule-associated protein 1 light chain 3 (LC3) plays a pivotal role in autophagy. In the present study, we analyzed the expression of cleaved caspase-8 (CC8), cleaved caspase-9 (CC9), AIF, and LC3 in 160 gastrointestinal adenocarcinomas. The nuclear expression of AIF was rare. The expression of CC8 in gastric and colorectal adenocarcinomas did not differ, whereas the percentage of CC9-positive tumors in gastric adenocarcinomas was significantly higher than in colorectal adenocarcinomas. In contrast, the percentage of LC3-positive tumors in gastric adenocarcinomas was significantly lower than in colorectal adenocarcinomas. CC8 and CC9 occasionally co-existed in the same tumor cells in gastric adenocarcinoma. However, LC3-positive tumor cells in colorectal adenocarcinomas were constantly negative for CC8. No correlation was identified between the expression of any markers and clinicopathological parameters. These results suggest that different cell death pathways are activated in a manner that depends upon the primary site and cell type. The extrinsic and intrinsic apoptotic pathways may be mutually regulated in gastric adenocarcinomas. Also, autophagy may function as a cellular guardian to avoid apoptosis in colorectal adenocarcinomas.
C1 [Shintani, Michiko] Kobe Univ, Grad Sch Hlth Sci, Pathol Lab, Div Med Biophys,Suma Ku, Kobe, Hyogo 6540142, Japan.
   [Sangawa, Akiko] Osaka Red Cross Hosp, Dept Diagnost Pathol, Osaka, Japan.
   [Yamao, Naoki] Kobe Cent Hosp Social Insurance, Dept Clin Lab, Kobe, Hyogo, Japan.
   [Miyake, Toshihiko] Kobe Cent Hosp Social Insurance, Dept Diagnost Pathol, Kobe, Hyogo, Japan.
RP Shintani, M (corresponding author), Kobe Univ, Grad Sch Hlth Sci, Pathol Lab, Div Med Biophys,Suma Ku, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.
EM mtshin@kobe-u.ac.jp
OI yamao, naoki/0000-0002-0999-7420
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [20590355]
FX We would like to thank Dr. Masayuki Shintaku for his kind support. This
   study was supported by a Grant-in-Aid for Scientific Research (No.
   20590355) from the Japan Society for the Promotion of Science.
CR Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Grivicich I, 2005, ONCOL RES, V15, P385, DOI 10.3727/096504005776449680
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008
   Jeong EG, 2006, APMIS, V114, P867, DOI 10.1111/j.1600-0463.2006.apm_502.x
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   Kim R, 2002, INT J ONCOL, V20, P549
   Koyama S, 2003, DIGEST DIS SCI, V48, P2290, DOI 10.1023/B:DDAS.0000007865.96569.9a
   Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252
   Lee JW, 2006, PATHOL RES PRACT, V202, P497, DOI 10.1016/j.prp.2006.03.004
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Lorenzo HK, 2007, DRUG RESIST UPDATE, V10, P235, DOI 10.1016/j.drup.2007.11.001
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Marchetti P, 2004, ANTICANCER RES, V24, P219
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008
   Nam NJ, 2002, APMIS, V110, P825, DOI 10.1034/j.1600-0463.2002.1101109.x
   Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Smith L, 2006, ONCOL RES, V15, P441
   Strater J, 2010, INT J CANCER, V127, P873, DOI 10.1002/ijc.25111
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tormanen-Napankangas U, 2001, INT J CANCER, V93, P192, DOI 10.1002/ijc.1315
   Turunen N, 2000, HISTOL HISTOPATHOL, V15, P53, DOI 10.14670/HH-15.53
   Vakkala M, 1999, BRIT J CANCER, V81, P592, DOI 10.1038/sj.bjc.6690735
   Virkajarvi N, 1998, HISTOPATHOLOGY, V33, P432, DOI 10.1046/j.1365-2559.1998.00553.x
   Wittekind, 2009, TNM CLASSIFICATION M
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 30
TC 15
Z9 15
U1 0
U2 1
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15-NISHI 7, SAPPORO, 060-8638, JAPAN
SN 0388-6107
EI 1880-313X
J9 BIOMED RES-TOKYO
JI Biomed. Res.
PD DEC
PY 2011
VL 32
IS 6
BP 379
EP 386
DI 10.2220/biomedres.32.379
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 867KY
UT WOS:000298454500004
PM 22199128
OA Bronze
DA 2022-04-25
ER

PT J
AU Niture, S
   Dong, XL
   Arthur, E
   Chimeh, U
   Niture, SS
   Zheng, WF
   Kumar, D
AF Niture, Suryakant
   Dong, Xialan
   Arthur, Elena
   Chimeh, Uchechukwu
   Niture, Samiksha S.
   Zheng, Weifan
   Kumar, Deepak
TI Oncogenic Role of Tumor Necrosis Factor alpha-Induced Protein 8
   (TNFAIP8)
SO CELLS
LA English
DT Review
DE tumor necrosis factor alpha (TNF alpha); tumor necrosis factor
   alpha-inducing protein 8 (TNFAIP8); oncogene; autophagy; cell survival
ID SQUAMOUS-CELL CARCINOMA; DEATH EFFECTOR DOMAIN; NEGATIVE REGULATOR;
   POOR-PROGNOSIS; CANCER; TIPE2; EXPRESSION; OVEREXPRESSION; METASTASIS;
   APOPTOSIS
AB Tumor necrosis factor (TNF)-alpha-induced protein 8 (TNFAIP8) is a founding member of the TIPE family, which also includes TNFAIP8-like 1 (TIPE1), TNFAIP8-like 2 (TIPE2), and TNFAIP8-like 3 (TIPE3) proteins. Expression of TNFAIP8 is strongly associated with the development of various cancers including cancer of the prostate, liver, lung, breast, colon, esophagus, ovary, cervix, pancreas, and others. In human cancers, TNFAIP8 promotes cell proliferation, invasion, metastasis, drug resistance, autophagy, and tumorigenesis by inhibition of cell apoptosis. In order to better understand the molecular aspects, biological functions, and potential roles of TNFAIP8 in carcinogenesis, in this review, we focused on the expression, regulation, structural aspects, modifications/interactions, and oncogenic role of TNFAIP8 proteins in human cancers.
C1 [Niture, Suryakant; Arthur, Elena; Chimeh, Uchechukwu; Kumar, Deepak] North Carolina Cent Univ, Julius L Chambers Biomed Biotechnol Res Inst BBRI, Durham, NC 27707 USA.
   [Dong, Xialan; Zheng, Weifan] North Carolina Cent Univ, Biomfg Res Inst & Technol Enterprise BRITE, Durham, NC 27707 USA.
   [Niture, Samiksha S.] Catonsville High Sch, Catonsville, MD 21228 USA.
   [Kumar, Deepak] North Carolina Cent Univ, Dept Pharmaceut Sci, Durham, NC 27707 USA.
RP Kumar, D (corresponding author), North Carolina Cent Univ, Julius L Chambers Biomed Biotechnol Res Inst BBRI, Durham, NC 27707 USA.; Kumar, D (corresponding author), North Carolina Cent Univ, Dept Pharmaceut Sci, Durham, NC 27707 USA.
EM sniture@nccu.edu; xdong@nccu.edu; earthur1@nccu.edu; uchimeh@nccu.edu;
   samniture@gmail.com; wzheng@nccu.edu; dkumar@nccu.edu
OI Niture, Suryakant/0000-0003-0613-9399; Chimeh,
   Uchechukwu/0000-0002-1346-4088; zheng, weifan/0000-0001-9025-7229
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01CA194730,
   U54MD012392, R01MD012767]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [U01CA194730] Funding Source:
   NIH RePORTER; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [R01MD012767, U54MD012392] Funding
   Source: NIH RePORTER
FX We gratefully acknowledge the grants U01CA194730, U54MD012392, and
   R01MD012767 from the National Institutes of Health to D.K.
CR Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Brynskov J, 2002, GUT, V51, P37, DOI 10.1136/gut.51.1.37
   Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5
   Cheng Y, 2015, EXP THER MED, V9, P2319, DOI 10.3892/etm.2015.2406
   Chittaranjan S, 2015, BIOL OPEN, V4, P672, DOI 10.1242/bio.20148417
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Cui J, 2015, J HISTOCHEM CYTOCHEM, V63, P206, DOI 10.1369/0022155414564871
   Cui J, 2011, MOL IMMUNOL, V48, P1548, DOI 10.1016/j.molimm.2011.04.023
   Day TF, 2017, METHODS MOL BIOL, V1513, P83, DOI 10.1007/978-1-4939-6539-7_7
   Dong QZ, 2017, ONCOTARGET, V8, P15689, DOI 10.18632/oncotarget.14938
   Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033
   Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134
   Fayngerts SA, 2014, CANCER CELL, V26, P465, DOI 10.1016/j.ccr.2014.07.025
   Gao HY, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12331
   Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137
   Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014
   Gus-Brautbar Y, 2012, MOL CELL, V45, P610, DOI 10.1016/j.molcel.2012.01.006
   Gustems M, 2014, NUCLEIC ACIDS RES, V42, P3059, DOI 10.1093/nar/gkt1323
   Ha JY, 2014, J NEUROCHEM, V129, P527, DOI [10.1111/jnc.12643, 10.1111/j.1471-4159.2013.12643.x]
   Hadisaputri YE, 2012, ANN SURG ONCOL, V19, pS589, DOI 10.1245/s10434-011-2097-1
   Ham Boram, 2016, Trends Cancer Res, V11, P1
   Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117
   Han Y, 2018, MOL CARCINOGEN, V57, P159, DOI 10.1002/mc.22740
   Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102
   HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350
   Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431
   Kim JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06576-3
   Kristensen AR, 2012, NAT METHODS, V9, P907, DOI 10.1038/nmeth.2131
   Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123
   Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973
   Kuo PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093303
   Laliberte B, 2010, J CELL PHYSIOL, V225, P865, DOI 10.1002/jcp.22297
   Li D, 2009, CLIN IMMUNOL, V133, P422, DOI 10.1016/j.clim.2009.08.014
   Li XM, 2014, CANCER BIOMARK, V14, P233, DOI 10.3233/CBM-140402
   Lian KL, 2017, ONCOTARGET, V8, P48889, DOI 10.18632/oncotarget.16522
   Lin L, 2016, INT J CLIN EXP MED, V9, P10384
   Liu J, 2006, P NATL ACAD SCI USA, V103, P15457, DOI 10.1073/pnas.0604871103
   Liu K, 2012, ASIAN PAC J CANCER P, V13, P847, DOI 10.7314/APJCP.2012.13.3.847
   Liu QQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126176
   Liu T, 2013, BRIT J CANCER, V109, P1685, DOI 10.1038/bjc.2013.501
   Liu TB, 2014, TUMOR BIOL, V35, P5805, DOI 10.1007/s13277-014-1770-y
   Liu TB, 2014, HUM PATHOL, V45, P1251, DOI 10.1016/j.humpath.2014.02.005
   Lowe JM, 2017, CELL DEATH DIFFER, V24, P181, DOI 10.1038/cdd.2016.130
   Ma Y, 2013, SCAND J IMMUNOL, V78, P523, DOI 10.1111/sji.12110
   Mantovani A, 2010, ANN MED, V42, P161, DOI 10.3109/07853890903405753
   Monastyrska I, 2009, BIOL REV, V84, P431, DOI 10.1111/j.1469-185X.2009.00082.x
   Monteith JA, 2016, MOL ONCOL, V10, P1207, DOI 10.1016/j.molonc.2016.05.007
   Niture Suryakant, 2018, Oncotarget, V9, P26884, DOI 10.18632/oncotarget.25529
   Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017
   Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6
   Porturas TP, 2015, J IMMUNOL, V194, P5743, DOI 10.4049/jimmunol.1401987
   Qin BD, 2016, J GASTROEN HEPATOL, V31, P1177, DOI 10.1111/jgh.13251
   Rolland T, 2014, CELL, V159, P1212, DOI 10.1016/j.cell.2014.10.050
   Romanuik TL, 2009, AM J PATHOL, V175, P2264, DOI 10.2353/ajpath.2009.080868
   Salihu HM, 2016, MATERN CHILD HLTH J, V20, P1680, DOI 10.1007/s10995-016-1967-3
   Shi TY, 2013, CARCINOGENESIS, V34, P770, DOI 10.1093/carcin/bgt001
   Sidiropoulos PI, 2006, ANN RHEUM DIS, V65, P701, DOI 10.1136/ard.2005.049890
   Sullivan C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179517
   Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026
   Sun ZG, 2016, TUMOR BIOL, V37, P10923, DOI 10.1007/s13277-016-4978-1
   Swardfager W, 2010, BIOL PSYCHIAT, V68, P930, DOI 10.1016/j.biopsych.2010.06.012
   Theiss AL, 2005, J BIOL CHEM, V280, P36099, DOI 10.1074/jbc.M505291200
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang LC, 2014, TUMOR BIOL, V35, P2319, DOI 10.1007/s13277-013-1307-9
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x
   Wang YN, 2016, ONCOL LETT, V12, P3506, DOI 10.3892/ol.2016.5090
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Wu XC, 2017, ONCOTARGET, V8, P78496, DOI 10.18632/oncotarget.19655
   Xi WJ, 2011, MOL IMMUNOL, V48, P1203, DOI 10.1016/j.molimm.2011.03.002
   Xiao M, 2017, HUM PATHOL, V62, P40, DOI 10.1016/j.humpath.2016.12.020
   Xing BG, 2016, AM J TRANSL RES, V8, P1082
   Yang CH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/732307
   Yang M, 2014, HISTOPATHOLOGY, V65, P517, DOI 10.1111/his.12413
   You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200
   Zhang CB, 2006, MOL THER, V13, P947, DOI 10.1016/j.ymthe.2005.11.020
   Zhang CB, 2013, INT J CANCER, V133, P31, DOI 10.1002/ijc.27996
   Zhang HY, 2015, J MOL MED, V93, P1033, DOI 10.1007/s00109-015-1288-9
   Zhang LJ, 2009, J BIOL CHEM, V284, P6156, DOI 10.1074/jbc.M807713200
   Zhang X, 2009, NAT STRUCT MOL BIOL, V16, P89, DOI 10.1038/nsmb.1522
   Zhang Z, 2015, ONCOGENE, V34, P2566, DOI 10.1038/onc.2014.208
   Zhang ZL, 2013, ONCOL LETT, V6, P571, DOI 10.3892/ol.2013.1388
   Zhao Q, 2015, J CELL BIOCHEM, V116, P1121, DOI 10.1002/jcb.25068
   Zhu Y, 2016, CANCER GENE THER, V23, P98, DOI 10.1038/cgt.2016.6
NR 84
TC 28
Z9 29
U1 2
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2019
VL 8
IS 1
AR 9
DI 10.3390/cells8010009
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HM8PD
UT WOS:000459742400009
PM 30586922
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Greene, LM
   O'Boyle, NM
   Nolan, DP
   Meegan, MJ
   Zisterer, DM
AF Greene, Lisa M.
   O'Boyle, Niamh M.
   Nolan, Derek P.
   Meegan, Mary J.
   Zisterer, Daniela M.
TI The vascular targeting agent Combretastatin-A4 directly induces
   autophagy in adenocarcinoma-derived colon cancer cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Combretastatin; Autophagy; Apoptosis; Tubulin and mitochondria
ID A4 PHOSPHATE; DEATH; APOPTOSIS; INDUCTION; MODULATION; CARCINOMA;
   ANALOGS; TUMOR
AB Recent clinical data demonstrated that the vascular targeting agent Combretastatin-A4 phosphate (CA-4P) prolonged survival of patients with advanced anaplastic thyroid cancer without any adverse side effects. However, as a single agent CA-4 failed to reduce tumour growth in the murine CT-26 adenocarcinoma colon cancer model. Furthermore, the molecular mechanism of the innate resistance of HT-29 human adenocarcinoma cells to CA-4 is largely unknown. In this report, we demonstrate for the first time that prolonged exposure to CA-4 and an azetidinone cis-restricted analogue, CA-432 (chemical name; 4-(3-Hydroxy-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)-azetidin-2-one) induced autophagy in adenocarcinoma-derived CT-26, Caco-2 and HT-29 cells but not in fibrosarcoma-derived HT-1080 cells. Autophagy is a fundamental self-catabolic process which can facilitate a prolonged cell survival in spite of adverse stress by generating energy via lysosomal degradation of cytoplasmic constituents. Autophagy was confirmed by acridine orange staining of vesicle formation, electron microscopy and increased expression of LC3-II. Combretastatin-induced autophagy was associated with a loss of mitochondrial membrane potential and elongation of the mitochondria. Furthermore, inhibition of autophagy by the vacuolar H(+)ATPase inhibitor Bafilomycin-A1 (BAF-A1) significantly enhanced CA-432 induced HT-29 cell death. Both CA-4 and its synthetic derivative. CA-432 induced the formation of large hyperdiploid cells in Caco-2 and CT-26 cells. The formation of these polyploid cells was significantly inhibited by autophagy inhibitor, BAF-A1. Results presented within demonstrate that autophagy is a novel response to combretastatin exposure and may be manipulated to enhance the therapeutic efficacy of this class of vascular targeting agents. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Greene, Lisa M.; Nolan, Derek P.; Zisterer, Daniela M.] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland.
   [O'Boyle, Niamh M.; Meegan, Mary J.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland.
RP Greene, LM (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland.
EM greeneli@tcd.ie
OI O'Boyle, Niamh/0000-0001-5660-4944; Nolan, Derek/0000-0002-3742-4304;
   Zisterer, Daniela/0000-0001-5005-1023
FU Health Research Board Ireland
FX We would like to thank Health Research Board Ireland for funding the
   project. Sincere thanks to the following: Dr. Gavin Mc Manus (confocal
   microscope), Barry Moran (Flow cytometry) and Neal Leddy (EM), School of
   Biochemistry and Immunology, TCD.
CR Barnett A, 2011, J ALZHEIMERS DIS, V25, P385, DOI 10.3233/JAD-2011-101989
   Beau I, 2011, INT J BIOCHEM CELL B, V43, P460, DOI 10.1016/j.biocel.2011.01.006
   Biersack B, 2010, EUR J MED CHEM, V45, P4890, DOI 10.1016/j.ejmech.2010.07.061
   Ding XQ, 2011, ONCOL RES, V19, P303, DOI 10.3727/096504011X13079697132790
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Geng JF, 2010, AUTOPHAGY, V6, P950, DOI 10.4161/auto.6.7.13009
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Greene LM, 2010, J PHARMACOL EXP THER, V335, P302, DOI 10.1124/jpet.110.170415
   Grumati P, 2011, AUTOPHAGY, V7, P426, DOI 10.4161/auto.7.4.14392
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Horsman M. R., 2010, Experimental Oncology, V32, P143
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Karna P, 2010, J BIOL CHEM, V285, P18737, DOI 10.1074/jbc.M109.091694
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Nagaiah G, 2010, FUTURE ONCOL, V6, P1219, DOI 10.2217/FON.10.90
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   O'Boyle NM, 2010, J MED CHEM, V53, P8569, DOI 10.1021/jm101115u
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ohsumi K, 1998, J MED CHEM, V41, P3022, DOI 10.1021/jm980101w
   Perri F, 2011, WORLD J CLIN ONCOL, V2, P150, DOI 10.5306/wjco.v2.i3.150
   Pettit GR, 2005, J MED CHEM, V48, P4087, DOI 10.1021/jm0205797
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Schobert R, 2010, J MED CHEM, V53, P6595, DOI 10.1021/jm100345r
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Smith DM, 2010, CELL DEATH DIFFER, V17, P1867, DOI 10.1038/cdd.2010.53
   Spano A, 2008, HISTOL HISTOPATHOL, V23, P717, DOI 10.14670/HH-23.717
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tian Y, 2010, CELL, V141, P1042, DOI 10.1016/j.cell.2010.04.034
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286
   White E, 2008, ERNST SCHERING FOUND, V4, P23, DOI 10.1007/2789_2008_087
   White E, 2008, AUTOPHAGY, V4, P399, DOI 10.4161/auto.5907
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yeung SCJ, 2007, J CLIN ENDOCR METAB, V92, P2902, DOI 10.1210/jc.2007-0027
NR 39
TC 35
Z9 35
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP 1
PY 2012
VL 84
IS 5
BP 612
EP 624
DI 10.1016/j.bcp.2012.06.005
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 987RS
UT WOS:000307435700004
PM 22705646
DA 2022-04-25
ER

PT J
AU Dziedzic, K
   Gorecka, D
   Szwengiel, A
   Olejnik, A
   Rychlik, J
   Kreft, I
   Drozdzytnska, A
   Walkowiak, J
AF Dziedzic, Krzysztof
   Gorecka, Danuta
   Szwengiel, Artur
   Olejnik, Anna
   Rychlik, Joanna
   Kreft, Ivan
   Drozdzytnska, Agnieszka
   Walkowiak, Jaroslaw
TI The cytotoxic effect of artificially digested buckwheat products on
   HT-29 colon cancer cells
SO JOURNAL OF CEREAL SCIENCE
LA English
DT Article
DE Polyphenolic substances; Thiamine; Amino acids; Processing
ID ANTIOXIDANT ACTIVITY; IN-VIVO; QUERCETIN; GROWTH; FLAVONOIDS; APOPTOSIS;
   AUTOPHAGY; EXTRACTS; SURVIVAL; PATHWAY
AB Recently Europeans are showing a growing interest in healthy foods. In light of this fact, the aim of our study was to evaluate the effect of buckwheat products (groats, hull, and bran) after in vitro digestion in an artificial gastrointestinal tract on the inhibition of HT-29 cancer cell proliferation. We investigated the content of individual flavonoids, phenolic acids, amino acids, and thiamine in these buckwheat products. The MTT (thiazolyl blue tetrazolium bromide) assay was used to evaluate the viability and metabolic activity of the colon cancer cells. We found significant (p < 0.05) negative correlations between HT-29 cell growth and the levels of catechin, quercetin, serine, proline, glycine, histidine and arginine in buckwheat samples after digestion. Our results highlight that buckwheat by-products are a rich source of bioactive substances such as: quercetin, catechin, serine, proline, glycine, histidine, and arginine. Therefore, buckwheat can be used as an additive in pro health foods.
C1 [Dziedzic, Krzysztof; Szwengiel, Artur] Poznan Univ Life Sci, Inst Food Technol & Plant Origin, Wojska Polskiego 31, PL-60624 Poznan, Poland.
   [Dziedzic, Krzysztof; Walkowiak, Jaroslaw] Poznan Univ Med Sci, Dept Pediat Gastroenterol & Metab Dis, Szpitalna 27-33, PL-60572 Poznan, Poland.
   [Gorecka, Danuta] Poznan Univ Life Sci, Dept Gastron Sci & Funct Foods, Wojska Polskiego 31, PL-60624 Poznan, Poland.
   [Olejnik, Anna; Rychlik, Joanna; Drozdzytnska, Agnieszka] Poznan Univ Life Sci, Dept Biotechnol & Food Microbiol, Wojska Polskiego 48, PL-60627 Poznan, Poland.
   [Kreft, Ivan] Slovenian Forestry Inst, Dept Forest Physiol & Genet, Vecna Pot 2, Ljubljana 1000, Slovenia.
RP Dziedzic, K (corresponding author), Poznan Univ Life Sci, Inst Food Technol & Plant Origin, Wojska Polskiego 31, PL-60624 Poznan, Poland.
EM dziedzic@up.poznan.pl
RI Drożdżyńska, Agnieszka/AAD-4573-2019; Szwengiel, Artur/V-6832-2018
OI Drożdżyńska, Agnieszka/0000-0002-4580-354X; Gorecka,
   Danuta/0000-0001-8897-7438; Szwengiel, Artur/0000-0003-4570-7221;
   Olejnik, Anna/0000-0002-4385-0051; Dziedzic,
   Krzysztof/0000-0003-1282-7446
FU POIG grant "New bioactive food with designed functional properties"
   [POIG 01.01.02-00-061/09]
FX This research was supported by POIG grant "New bioactive food with
   designed functional properties" POIG 01.01.02-00-061/09.
CR Agullo G, 1996, CANCER LETT, V105, P61, DOI 10.1016/0304-3835(96)04262-0
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   Drozdzyska A, 2012, ACTA SCI POLON-TECHN, V11, P19
   Dziedzic K, 2015, FOOD FUNCT, V6, P1011, DOI [10.1039/C4FO00946K, 10.1039/c4fo00946k]
   Ishii S, 2008, BIOSCI BIOTECH BIOCH, V72, P3148, DOI 10.1271/bbb.80324
   Kim HP, 2004, J PHARMACOL SCI, V96, P229, DOI 10.1254/jphs.CRJ04003X
   Kim HJ, 2010, J AGR FOOD CHEM, V58, P8643, DOI 10.1021/jf101510z
   Kim WK, 2005, J NUTR BIOCHEM, V16, P155, DOI 10.1016/j.jnutbio.2004.10.010
   Kuntz S, 1999, EUR J NUTR, V38, P133, DOI 10.1007/s003940050054
   Li FH, 2016, J FUNCT FOODS, V22, P145, DOI 10.1016/j.jff.2016.01.027
   Liu YB, 2010, J NAT PROD, V73, P1193, DOI 10.1021/np1000945
   Olejnik A, 2016, FOOD CHEM, V190, P1069, DOI 10.1016/j.foodchem.2015.06.080
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326
   Roomi MW, 2006, IN VIVO, V20, P25
   Sathiyamoorthy Jayalalitha, 2018, Pharmacogn Mag, V13, pS756, DOI 10.4103/pm.pm_319_17
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Senthilkumar R, 2013, ASIAN PAC J TROP MED, V6, P11, DOI 10.1016/S1995-7645(12)60194-1
   Shin BC, 2009, J KOREAN MED SCI, V24, pS204, DOI 10.3346/jkms.2009.24.S1.S204
   Tate DJ, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-14
   Vesela M, 2009, BIOTECHNOL BIOPROC E, V14, P84, DOI [10.1007/s12257-008-0083-7, 10.1007/S12257-008-0083-7]
   Yang L, 2016, MOL MED REP, V14, P4559, DOI 10.3892/mmr.2016.5818
   Zhao CF, 2015, FOOD CHEM, V169, P484, DOI 10.1016/j.foodchem.2014.07.091
NR 26
TC 8
Z9 8
U1 1
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0733-5210
EI 1095-9963
J9 J CEREAL SCI
JI J. Cereal Sci.
PD SEP
PY 2018
VL 83
BP 68
EP 73
DI 10.1016/j.jcs.2018.07.020
PG 6
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA GY3ZB
UT WOS:000448494900010
DA 2022-04-25
ER

PT J
AU Chen, L
   Huang, S
   Li, CY
   Gao, F
   Zhou, XL
AF Chen, Lin
   Huang, Shuai
   Li, Chun Ying
   Gao, Feng
   Zhou, Xian Li
TI Pyrrolizidine alkaloids from Liparis nervosa with antitumor activity by
   modulation of autophagy and apoptosis
SO PHYTOCHEMISTRY
LA English
DT Article
DE Liparis nervosa; Orchidaceae; Pyrrolizidine alkaloids; Cytotoxicity;
   Human colorectal cancer cell line; Autophagy; Apoptosis
ID NERVOGENIC ACID-DERIVATIVES; ATRACTYLODES-LANCEA
AB Seven pyrrolizidine alkaloids, nervosine X-XV and nervosine VII N-oxide, together with a reaction product, namely chloride-(N-chloromethyl nervosine VII), were isolated from Liparis nervosa. Their structures were elucidated by extensive spectroscopic analyses. Most of these compounds were investigated for their cytotoxicity in vitro against HCT116 human cancer cell line, and the results showed that chloride-(N-chloromethyl nervosine VII) induced tumor cell death in a dose-dependent mariner. Furthermore, the mechanisms underlying its cytotoxicity were investigated, including apoptosis and autophagy. Apoptosis in HCT116 cells was associated with up-regulation of caspase-3 and -9 expressions by activation of the mitochondrial pathway. The autophagy inducing effect was associated with the regulation of autophagic markers, including LC3-II, p62, and Beclin 1. Mechanistic studies showed that JNK, ERK1/2, and p38 MAPKs signaling cascades play an important role in chloride-(N-chloromethyl nervosine VII) induced autophagy and apoptosis.
C1 [Chen, Lin; Huang, Shuai; Gao, Feng; Zhou, Xian Li] Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu 610031, Sichuan, Peoples R China.
   [Chen, Lin] China West Normal Univ, Sch Chem & Chem Engn, Nanchong 637002, Sichuan, Peoples R China.
   [Huang, Shuai; Li, Chun Ying] Georgia State Univ, Inst Biomed Sci, Ctr Mol & Translat Med, 511 Res Sci Ctr,157 Decatur St SE, Atlanta, GA 30303 USA.
RP Gao, F; Zhou, XL (corresponding author), Southwest Jiaotong Univ, Sch Life Sci & Engn, Nat Prod Lab, Chengdu 610031, Sichuan, Peoples R China.
EM gaof@swjtu.edu.cn; zhouxl@swjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402803]; project of Science and Technology
   Bureau of Chengdu [2015-HM01-00041-SF]; United States of America
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 HL128647];
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL128647] Funding
   Source: NIH RePORTER
FX This research was supported by grants from National Natural Science
   Foundation of China (81402803), the project of Science and Technology
   Bureau of Chengdu (2015-HM01-00041-SF) and the United States of America
   National Institutes of Health (R01 HL128647 to Chunying Li). We thank
   Xiaoqing Gan, Yuning Hou, Xiaonan Sun and Yu Zhou for technical
   assistance.
CR Arnone A, 2009, TETRAHEDRON, V65, P786, DOI 10.1016/j.tet.2008.11.058
   Beniddir MA, 2013, TETRAHEDRON LETT, V54, P2115, DOI 10.1016/j.tetlet.2013.01.052
   BOWMAN WR, 1994, TETRAHEDRON, V50, P1295, DOI 10.1016/S0040-4020(01)80838-3
   BUSH LP, 1993, AGR ECOSYST ENVIRON, V44, P81, DOI 10.1016/0167-8809(93)90040-V
   Castells E, 2014, PHYTOCHEMISTRY, V108, P137, DOI 10.1016/j.phytochem.2014.09.006
   Duan JA, 2008, ARCH PHARM RES, V31, P965, DOI 10.1007/s12272-001-1252-z
   Editorial Committee of the Flora of China of Chinese Academy of Science, 1999, FLORA CHINA, V18, P71
   Flores N, 2008, J NAT PROD, V71, P1538, DOI 10.1021/np800104p
   Friedrich U, 2005, PHARMAZIE, V60, P455
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Hartmann T, 1999, PLANTA, V207, P483, DOI 10.1007/s004250050508
   Hua Y. X, 1999, CHINESE HERBAL, V12, P997
   Huang S, 2016, CHINESE CHEM LETT, V27, P757, DOI 10.1016/j.cclet.2016.01.003
   Huang S, 2013, CHINESE CHEM LETT, V24, P734, DOI 10.1016/j.cclet.2013.04.043
   Huang S, 2013, PHYTOCHEMISTRY, V93, P154, DOI 10.1016/j.phytochem.2013.03.009
   Huang S, 2013, PLANTA MED, V79, P281, DOI 10.1055/s-0032-1328109
   Jiang P, 2015, FITOTERAPIA, V107, P63, DOI 10.1016/j.fitote.2015.10.003
   Kim WK, 2016, J NAT PROD, V79, P1097, DOI 10.1021/acs.jnatprod.6b00006
   Liu XJ, 2017, PHYTOCHEMISTRY, V138, P93, DOI 10.1016/j.phytochem.2017.02.027
   Ndongo JT, 2017, PHYTOCHEMISTRY, V144, P189, DOI 10.1016/j.phytochem.2017.09.013
   NISHIKAWA K, 1967, TETRAHEDRON LETT, P2591
   NISHIKAWA K, 1968, TETRAHEDRON LETT, P6289
   Perez-Castorena AL, 1998, J NAT PROD, V61, P1288, DOI 10.1021/np980077p
   Shi Bao-Jun, 2010, Nat Prod Res, V24, P1897, DOI 10.1080/14786419.2010.482058
   Siciliano T, 2005, PHYTOCHEMISTRY, V66, P1593, DOI 10.1016/j.phytochem.2005.05.002
   Tan SJ, 2013, PHYTOCHEMISTRY, V85, P194, DOI 10.1016/j.phytochem.2012.08.016
   Xu K, 2016, BIOORG MED CHEM LETT, V26, P5187, DOI 10.1016/j.bmcl.2016.09.069
   Xu MY, 2014, J NAT PROD, V77, P370, DOI 10.1021/np401022g
NR 28
TC 15
Z9 15
U1 0
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9422
J9 PHYTOCHEMISTRY
JI Phytochemistry
PD SEP
PY 2018
VL 153
BP 147
EP 155
DI 10.1016/j.phytochem.2018.06.001
PG 9
WC Biochemistry & Molecular Biology; Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Plant Sciences
GA GQ2ND
UT WOS:000441490800017
PM 29980107
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Chen, MX
   Zhao, ZY
   Meng, QC
   Liang, PP
   Su, ZX
   Wu, YX
   Huang, JJ
   Cui, J
AF Chen, Meixin
   Zhao, Zhiyao
   Meng, Qingcai
   Liang, Puping
   Su, Zexiong
   Wu, Yaoxing
   Huang, Junjiu
   Cui, Jun
TI TRIM14 Promotes Noncanonical NF-kappa B Activation by Modulating
   p100/p52 Stability via Selective Autophagy
SO ADVANCED SCIENCE
LA English
DT Article
DE inflammation; noncanonical NF-kappa B signaling; p100; p52; selective
   autophagy; TRIM14
ID RIG-I; KINASE; DEGRADATION; PATHWAY; UBIQUITINATION; PROTEIN;
   MACROAUTOPHAGY; INFLAMMATION; COMPLEX; ALPHA
AB The noncanonical NF-kappa B signaling pathway plays a critical role in a variety of biological functions including chronic inflammation and tumorigenesis. Activation of noncanonical NF-kappa B signaling largely relies on the abundance as well as the processing of the NF-kappa B family member p100/p52. Here, TRIM14 is identified as a novel positive regulator of the noncanonical NF-kappa B signaling pathway. TRIM14 promotes noncanonical NF-kappa B activation by targeting p100/p52 in vitro and in vivo. Furthermore, a mechanistic study shows that TRIM14 recruits deubiquitinase USP14 to cleave the K63-linked ubiquitin chains of p100/p52 at multiple sites, thereby preventing p100/p52 from cargo receptor p62-mediated autophagic degradation. TRIM14 deficiency in mice significantly impairs noncanonical NF-kappa B-mediated inflammatory responses as well as acute colitis and colitis-associated colon cancer development. Taken together, these findings establish the TRIM14-USP14 axis as a crucial checkpoint that controls noncanonical NF-kappa B signaling and highlight the crosstalk between autophagy and innate immunity.
C1 [Chen, Meixin; Zhao, Zhiyao; Meng, Qingcai; Liang, Puping; Su, Zexiong; Wu, Yaoxing; Huang, Junjiu; Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Oncol South China, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhao, Zhiyao] Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Dept Internal Med, Guangzhou 510623, Guangdong, Peoples R China.
RP Cui, J (corresponding author), Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Oncol South China, Guangzhou 510006, Guangdong, Peoples R China.
EM cuij5@mail.sysu.edu.cn
RI chen, meixin/AAT-4971-2020
OI CUI, JUN/0000-0002-8000-3708
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870862, 91629101]; National Key Basic
   Research Program of ChinaNational Basic Research Program of China
   [2015CB859800, 2014CB910800]; Science and Technology Planning Project of
   Guangzhou, China [201804010385]
FX The authors thank Dr. Ryan G. Gaudet (Yale University) for polishing the
   article. This work was supported by National Natural Science Foundation
   of China (31870862, 91629101), National Key Basic Research Program of
   China (2015CB859800, 2014CB910800), and Science and Technology Planning
   Project of Guangzhou, China (201804010385).
CR Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012
   Arabi A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1975
   Burkitt MD, 2015, J PATHOL, V236, P326, DOI 10.1002/path.4527
   Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463
   Cai J, 2018, FASEB J, V32, P5238, DOI 10.1096/fj.201700473RR
   Camacho-Barquero L, 2007, INT IMMUNOPHARMACOL, V7, P333, DOI 10.1016/j.intimp.2006.11.006
   Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025
   Cildir G, 2016, TRENDS MOL MED, V22, P414, DOI 10.1016/j.molmed.2016.03.002
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190
   Du Y, 2018, EMBO J, V37, P351, DOI 10.15252/embj.201796781
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Feng YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11344-4
   Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200
   Fujita K, 2017, INT J MOL MED, V39, P1053, DOI 10.3892/ijmm.2017.2892
   Fukushima H, 2012, CELL REP, V1, P434, DOI 10.1016/j.celrep.2012.04.002
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Harhaj EW, 2012, IMMUNOL REV, V246, P107, DOI 10.1111/j.1600-065X.2012.01100.x
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hu HB, 2013, NATURE, V494, P371, DOI 10.1038/nature11831
   Isogai S, 2011, J BIOL CHEM, V286, P31864, DOI 10.1074/jbc.M111.259630
   Jin J, 2014, IMMUNITY, V40, P342, DOI 10.1016/j.immuni.2014.02.006
   Jin J, 2012, NAT IMMUNOL, V13, P1101, DOI 10.1038/ni.2423
   Jin SH, 2016, EMBO J, V35, P866, DOI 10.15252/embj.201593596
   Kanarek N, 2012, IMMUNOL REV, V246, P77, DOI 10.1111/j.1600-065X.2012.01098.x
   Kim JY, 2011, J CELL SCI, V124, P647, DOI 10.1242/jcs.075770
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012
   Li H, 2020, J CELL MOL MED, V24, P114, DOI 10.1111/jcmm.14642
   Liang CY, 2006, CELL SIGNAL, V18, P1309, DOI 10.1016/j.cellsig.2005.10.011
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020
   Liu KP, 2018, J MOL CELL BIOL, V10, P205, DOI 10.1093/jmcb/mjy012
   Liu XM, 2015, AUTOPHAGY, V11, P2381, DOI 10.1080/15548627.2015.1110669
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Madge LA, 2010, J BIOL CHEM, V285, P38069, DOI 10.1074/jbc.M110.147207
   Munz C, 2010, IMMUNITY, V32, P298, DOI 10.1016/j.immuni.2010.03.002
   Nenasheva VV, 2018, MOL BIOL REP, V45, P2087, DOI 10.1007/s11033-018-4365-7
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Razani B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000778
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Sheng L, 2012, NAT MED, V18, P943, DOI 10.1038/nm.2756
   Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x
   Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177
   Tan P, 2017, MOL CELL, V68, P293, DOI 10.1016/j.molcel.2017.09.035
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   van Beek N, 2018, BBA-MOL CELL RES, V1865, P803, DOI 10.1016/j.bbamcr.2018.03.002
   Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3
   Xu D, 2015, ELIFE, V4, DOI 10.7554/eLife.10510
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zaman MMU, 2013, MOL CELL BIOL, V33, P4971, DOI 10.1128/MCB.00465-13
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   Zhang HS, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0056-4
   Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012
   Zhou Z, 2014, P NATL ACAD SCI USA, V111, pE245, DOI 10.1073/pnas.1316941111
NR 57
TC 15
Z9 16
U1 7
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2198-3844
J9 ADV SCI
JI Adv. Sci.
PD JAN
PY 2020
VL 7
IS 1
AR 1901261
DI 10.1002/advs.201901261
EA NOV 2019
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA KB3PC
UT WOS:000495463400001
PM 31921549
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, PT
   Li, YY
   Li, B
   Zhang, MC
   Xu, C
   Liu, FR
   Bian, L
   Liu, YH
   Yao, Y
   Li, D
AF Zhou, Pingting
   Li, Yanyan
   Li, Bo
   Zhang, Meichao
   Xu, Ci
   Liu, Furao
   Bian, Lei
   Liu, Yuanhua
   Yao, Yuan
   Li, Dong
TI Autophagy inhibition enhances celecoxib-induced apoptosis in
   osteosarcoma
SO CELL CYCLE
LA English
DT Article
DE Celecoxib; apoptosis; autophagy; osteosarcoma
ID BREAST-CANCER CELLS; COLON-CANCER; PROSTATE-CANCER; CHEMOTHERAPY; DEATH;
   CARCINOMA; THERAPY; PATHWAY; PROTEIN; TARGET
AB Osteosarcoma (OS) is the most prevalent bone malignancy in childhood and adolescence, with highly aggressive and early systemic metastases. Here, we reported that celecoxib, a selective COX-2 inhibitor in the NSAID class, exhibits strong antitumor activity in dose dependent manner in two OS cell lines-143B and U2OS. We showed that celecoxib inhibits OS cell growth, causes G0/G1-phase arrest, modulates apoptosis and autophagy and reduces migration in OS cells. In addition, the results of fluorescent mitochondrial probe JC-1 test indicated that the mitochondrial pathway mediates celecoxib-induced apoptosis. Significantly, the autophagy inhibitor CQ combined with celecoxib causes greater cell proliferation inhibition and apoptosis. Pharmacologic inhibition of autophagy with another potent autophagy inhibitor SAR405 also enhances celecoxib-mediated suppression of cell viability. These results were confirmed with shRNAs targeting the autophagy-related gene Atg5. In OS tumor xenografts in vivo, celecoxib also presents antitumor activity. Taken together, our results shed light on the function and mechanism of antitumor action of celecoxib for treatment of OS patients.
C1 [Zhou, Pingting; Li, Yanyan; Zhang, Meichao; Xu, Ci; Liu, Furao; Bian, Lei; Yao, Yuan; Li, Dong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Shanghai, Peoples R China.
   [Li, Bo] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China.
   [Liu, Yuanhua] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Chemotherapy, Nanjing, Jiangsu, Peoples R China.
RP Yao, Y; Li, D (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Shanghai, Peoples R China.
EM yaoyuan@shsmu.edu.cn; lidong@shsmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81370600]; Innovation Program for Ph.D.
   students in Shanghai Jiaotong University School of Medicine [BXJ201731];
   Innovation Program of Shanghai Municipal Education CommissionInnovation
   Program of Shanghai Municipal Education Commission [15ZZ056]; Program
   for Professor of Special Appointment (Eastern Scholar) at Shanghai
   Institutions of Higher Learning [TP2015022]; Shanghai Pujiang
   ProgramShanghai Pujiang Program [15PJ1404800]
FX This work was supported by the National Natural Science Foundation of
   China [81370600]; Innovation Program for Ph.D. students in Shanghai
   Jiaotong University School of Medicine [BXJ201731]; Innovation Program
   of Shanghai Municipal Education Commission [15ZZ056]; The Program for
   Professor of Special Appointment (Eastern Scholar) at Shanghai
   Institutions of Higher Learning [TP2015022]; Shanghai Pujiang Program
   [15PJ1404800].
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Brizzolara A, 2017, CANCER LETT, V400, P9, DOI 10.1016/j.canlet.2017.04.025
   Cha BK, 2016, ONCOTARGET, V7, P57213, DOI 10.18632/oncotarget.11127
   DeVorkin L, 2017, MOL CANCER RES, V15, P250, DOI 10.1158/1541-7786.MCR-16-0132
   Edelman MJ, 2017, J CLIN ONCOL, V35, P2184, DOI 10.1200/JCO.2016.71.3743
   Gandhi J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00538
   Ghosh N, 2010, PHARMACOL REP, V62, P233, DOI 10.1016/S1734-1140(10)70262-0
   Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040
   Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kleinerman E, 2016, LANCET ONCOL, V17, P1340, DOI 10.1016/S1470-2045(16)30270-4
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396
   Lagmay JP, 2016, J CLIN ONCOL, V34, P3031, DOI 10.1200/JCO.2015.65.5381
   Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li L, 2014, J AM SOC NEPHROL, V25, P305, DOI 10.1681/ASN.2013040374
   Liu B, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0260-7
   Liu KS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.422
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   Malka D, 2005, J CLIN ONCOL, V23, P4805, DOI 10.1200/JCO.2005.01.4332
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   McGettigan P, 2017, LANCET, V389, P2351, DOI 10.1016/S0140-6736(17)30980-7
   Minina EA, 2014, TRENDS PLANT SCI, V19, P692, DOI 10.1016/j.tplants.2014.07.007
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mo H, 2016, BIOCHEM BIOPH RES CO, V478, P74, DOI 10.1016/j.bbrc.2016.07.090
   Nataraj V, 2015, J SURG ONCOL, V112, P662, DOI 10.1002/jso.24045
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Schumacher Y, 2016, ONCOGENE, V35, P2602, DOI 10.1038/onc.2015.283
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Swamy MV, 2003, CANCER RES, V63, P5239
   Vosooghi M, 2014, EXPERT OPIN DRUG DIS, V9, P255, DOI 10.1517/17460441.2014.883377
   Wang GY, 2017, BIOCHEM BIOPH RES CO, V490, P969, DOI 10.1016/j.bbrc.2017.06.148
   Wang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.138
   Wolf R, 2000, CLIN DERMATOL, V18, P17, DOI 10.1016/S0738-081X(99)00092-9
   Xue X, 2013, CARCINOGENESIS, V34, P163, DOI 10.1093/carcin/bgs313
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yousefi S, 2009, RESULTS PROBL CELL D, V49, P183, DOI 10.1007/400_2008_25
   Zhang XD, 2014, BIOMATERIALS, V35, P9144, DOI 10.1016/j.biomaterials.2014.07.028
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
   Zhou X, 2015, EUR REV MED PHARMACO, V19, P4087
NR 53
TC 14
Z9 15
U1 2
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2018
VL 17
IS 8
BP 997
EP 1006
DI 10.1080/15384101.2018.1467677
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GQ4GZ
UT WOS:000441629500008
PM 29884091
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Huang, Y
   Li, S
   Jia, ZH
   Zhao, WW
   Zhou, CF
   Zhang, R
   Ali, DW
   Michalak, M
   Chen, XZ
   Tang, JF
AF Huang, Yuan
   Li, Shi
   Jia, Zhenhua
   Zhao, Weiwei
   Zhou, Cefan
   Zhang, Rui
   Ali, Declan William
   Michalak, Marek
   Chen, Xing-Zhen
   Tang, Jingfeng
TI Transient Receptor Potential Melastatin 8 (TRPM8) Channel Regulates
   Proliferation and Migration of Breast Cancer Cells by Activating the
   AMPK-ULK1 Pathway to Enhance Basal Autophagy
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE autophagy; LC3B; transient receptor potential melastatin 8 (TRPM8);
   AMP-activated protein kinase(AMPK); cancer
ID CA2+; INVOLVEMENT; RESISTANCE
AB The calcium-permeable cation channel TRPM8 (transient receptor potential melastatin 8) is a member of the TRP superfamily of cation channels that is upregulated in various types of cancer with high levels of autophagy, including prostate, pancreatic, breast, lung, and colon cancers. Autophagy is closely regulated by AMP-activated protein kinase (AMPK) and plays an important role in tumor growth by generating nutrients through degradation of intracellular structures. Additionally, AMPK activity is regulated by intracellular Ca2+ concentration. Considering that TRPM8 is a non-selective Ca2+-permeable cation channel and plays a key role in calcium homoeostasis, we hypothesized that TRPM8 may control AMPK activity thus modulating cellular autophagy to regulate the proliferation and migration of breast cancer cells. In this study, overexpression of TRPM8 enhanced the level of basal autophagy, whereas TRPM8 knockdown reduced the level of basal autophagy in several types of mammalian cancer cells. Moreover, the activity of the TRPM8 channel modulated the level of basal autophagy. The mechanism of regulation of autophagy by TRPM8 involves autophagy-associated signaling pathways for activation of AMPK and ULK1 and phagophore formation. Impaired AMPK abolished TRPM8-dependent regulation of autophagy. TRPM8 interacts with AMPK in a protein complex, and cytoplasmic C-terminus of TRPM8 mediates the TRPM8-AMPK interaction. Finally, basal autophagy mediates the regulatory effects of TRPM8 on the proliferation and migration of breast cancer cells. Thus, this study identifies TRPM8 as a novel regulator of basal autophagy in cancer cells acting by interacting with AMPK, which in turn activates AMPK to activate ULK1 in a coordinated cascade of TRPM8-mediated breast cancer progression.
C1 [Huang, Yuan; Li, Shi; Jia, Zhenhua; Zhao, Weiwei; Zhou, Cefan; Zhang, Rui; Tang, Jingfeng] Hubei Univ Technol, Minist Educ, Key Lab Fermentat Engn, Natl Ctr Cellular Regulat & Mol Pharmaceut 111, Wuhan, Peoples R China.
   [Ali, Declan William; Chen, Xing-Zhen] Fac Med & Dent Alberta, Dept Physiol, Membrane Prot Dis Res Grp, Edmonton, AB, Canada.
   [Michalak, Marek] Univ Alberta, Dept Biochem, Edmonton, AB, Canada.
RP Tang, JF (corresponding author), Hubei Univ Technol, Minist Educ, Key Lab Fermentat Engn, Natl Ctr Cellular Regulat & Mol Pharmaceut 111, Wuhan, Peoples R China.
EM Jingfeng_HUT@163.com
OI Zhou, Cefan/0000-0003-0680-3843; Tang, jingfeng/0000-0002-5524-4518
FU China National Science FoundationNational Natural Science Foundation of
   China (NSFC) [31871420, 31701228]; Hubei Province Science Foundation
   [2019CFB166]; Wuhan Science and Technology Project [2019020701011475];
   Doctoral Scientific Research Foundation of Hubei University of
   Technology [BSQD2017032]
FX This study was supported by the China National Science Foundation
   (grants 31871420 to JT and 31701228 to CZ), the Hubei Province Science
   Foundation (grant 2019CFB166 to YH), the Wuhan Science and Technology
   Project (2019020701011475 to JT) and the Doctoral Scientific Research
   Foundation of Hubei University of Technology (grants BSQD2017032 to YH).
CR Bautista DM, 2007, NATURE, V448, P204, DOI 10.1038/nature05910
   Bharate SS, 2012, ACS CHEM NEUROSCI, V3, P248, DOI 10.1021/cn300006u
   Bidaux G, 2007, J CLIN INVEST, V117, P1647, DOI 10.1172/JCI30168
   Chodon D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-212
   Colburn RW, 2007, NEURON, V54, P379, DOI 10.1016/j.neuron.2007.04.017
   Cui CC, 2017, ACTA PHARM SIN B, V7, P3, DOI 10.1016/j.apsb.2016.11.001
   Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001
   Feng F, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109441
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Huang Y, 2021, J CELL PHYSIOL, V236, P2934, DOI 10.1002/jcp.30065
   Huang Y, 2017, ONCOTARGET, V8, P115503, DOI 10.18632/oncotarget.23303
   Huang Y, 2016, J BIOL CHEM, V291, P11030, DOI 10.1074/jbc.M115.695080
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kongsuphol P, 2009, J BIOL CHEM, V284, P5645, DOI 10.1074/jbc.M806780200
   Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200
   Lei YY, 2017, CANCER LETT, V393, P33, DOI 10.1016/j.canlet.2017.02.012
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu JX, 2014, TUMOR BIOL, V35, P8969, DOI 10.1007/s13277-014-2077-8
   Liu XH, 2019, FASEB J, V33, P5366, DOI 10.1096/fj.201801583RR
   Liu ZG, 2016, J CANCER RES CLIN, V142, P1871, DOI 10.1007/s00432-015-2112-1
   Montell C, 2006, NAT NEUROSCI, V9, P466, DOI 10.1038/nn0406-466
   Oh HG, 2015, BIOCHEM BIOPH RES CO, V463, P7, DOI 10.1016/j.bbrc.2015.05.007
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Qi ZH, 2019, ADV EXP MED BIOL, V1206, P167, DOI 10.1007/978-981-15-0602-4_8
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367
   Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376
   Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375
   Wang Q, 2017, BBA-MOL CELL RES, V1864, P957, DOI 10.1016/j.bbamcr.2016.12.014
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang ZH, 2009, ASIAN J ANDROL, V11, P157, DOI 10.1038/aja.2009.1
   Yibcharoenporn C, 2019, J PHARMACOL SCI, V140, P273, DOI 10.1016/j.jphs.2019.07.012
   Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855
   Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang L, 2004, CANCER RES, V64, P8365, DOI 10.1158/0008-5472.CAN-04-2146
   Zheng W, 2018, FASEB J, V32, P639, DOI 10.1096/fj.201700599RR
   Zhou CF, 2021, AUTOPHAGY, V17, P3175, DOI [10.6084/m9.figshare.13005452.v3, 10.1080/15548627.2020.1826689]
   Zhou CF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01237-y
   Zhou CF, 2020, AUTOPHAGY, V16, P1786, DOI 10.1080/15548627.2019.1687212
NR 45
TC 6
Z9 6
U1 12
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 4
PY 2020
VL 10
AR 573127
DI 10.3389/fonc.2020.573127
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PG2NS
UT WOS:000599578000001
PM 33344232
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huber, S
   Valente, S
   Chaimbault, P
   Schohn, H
AF Huber, Sophie
   Valente, Sergio
   Chaimbault, Patrick
   Schohn, Herve
TI Evaluation of Delta 2-pioglitazone, an analogue of pioglitazone, on
   colon cancer cell survival: Evidence of drug treatment association with
   autophagy and activation of the Nrf2/Keap1 pathway
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Delta 2-pioglitazone; pioglitazone; 15-deoxy-Delta(12,14)-prostaglandin
   J(2); oxidative stress; Nrf2/Keapl pathway; colon cancer
ID RECEPTOR-GAMMA; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2);
   HEME OXYGENASE-1; MITOCHONDRIAL-FUNCTION; LIQUID-CHROMATOGRAPHY;
   GLUTATHIONE; APOPTOSIS; INHIBITION; PROSTAGLANDIN
AB Thiazolidinediones have been shown to exhibit anti-proliferative effects against cancer cells derived from diverse tissue origins both in vivo and in vitro. We studied the anti-proliferative impact of 5-{4-(2-(5-ethyl-pyridin-2-yl)-ethoxy)benzylidene}-thiazolidine-2,4-dione (Delta 2-pioglitazone), an analogue of pioglitazone, which binds to the nuclear peroxisome proliferator activated receptor-gamma without activating it, on human adenocarcinoma-derived HT29 and HCT116 cells. In HTC116 cells, exposure to Delta 2-pioglitazone reduced cell growth, but HT29 cells reached the plateau phase of growth after three days. Delta 2-pioglitazone treatment did not trigger cells to enter apoptosis but enhanced the autophagy process. The effect of Delta 2-pioglitazone treatment was related to the increase of oxygen and nitric oxide-derived species production and decreased glutathione content. Moreover, pre-treatment with an antioxidant before addition of Delta 2-pioglitazone limited cell growth inhibition, reduced the production of reactive species and attenuated autophagy within the cells. The impact of the drug was associated with activation of the Nrf2/Keapl pathway as demonstrated by the increased protein content of several antioxidant enzymes, notably heme-oxygenase-1.
C1 [Huber, Sophie; Valente, Sergio; Schohn, Herve] Univ Lorraine, CNRS, U7565, F-57070 Metz, France.
   [Chaimbault, Patrick] Univ Lorraine, Chem & Phys Lab, A2MC, EA 4632, F-57078 Metz 3, France.
RP Schohn, H (corresponding author), Univ Lorraine, CNRS, U7565, SRSMC Campus Bridoux,Rue Gen Delestraint, F-57070 Metz, France.
EM herve.schohn@univ-lorraine.fr
RI Valente, Sergio/K-2198-2016
OI Valente, Sergio/0000-0002-2241-607X; CHAIMBAULT,
   Patrick/0000-0001-7588-8751
FU la Ligue Contre le CancerLigue nationale contre le cancer; Ministere de
   la Recherche et de la Technologie; Marie Curie Initial Training Network
   (ITN) in the FP7 People Programme - Natural Products and related Redox
   Catalysts: Basic Research and Applications in Medicine and Agriculture
FX We thank Dr Eric Battaglia and Professor Denyse Bagrel for discussion
   and reading of the manuscript and Professor S.N. Thornton for correcting
   the English. This study was supported by grants from la Ligue Contre le
   Cancer. Sophie Huber obtained financial support from Ministere de la
   Recherche et de la Technologie. Sergio Valente was granted from Marie
   Curie Initial Training Network (ITN) in the FP7 People Programme -
   Natural Products and related Redox Catalysts: Basic Research and
   Applications in Medicine and Agriculture.
CR Alvarez-Sanchez R, 2006, CHEM RES TOXICOL, V19, P1106, DOI 10.1021/tx050353h
   Atarod EB, 2004, FREE RADICAL BIO MED, V37, P36, DOI 10.1016/j.freeradbiomed.2004.04.015
   Brunoldi EA, 2007, CHEM RES TOXICOL, V20, P1528, DOI 10.1021/tx700231a
   Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000
   Cerquetti L, 2011, EXP CELL RES, V317, P1397, DOI 10.1016/j.yexcr.2011.02.014
   Chia AJL, 2010, BIOCHEM PHARMACOL, V80, P410, DOI 10.1016/j.bcp.2010.04.004
   Deguest G, 2007, ORG LETT, V9, P1165, DOI 10.1021/ol070145b
   Feinstein DL, 2005, BIOCHEM PHARMACOL, V70, P177, DOI 10.1016/j.bcp.2005.03.033
   Ferguson HE, 2009, AM J PHYSIOL-LUNG C, V297, pL912, DOI 10.1152/ajplung.00148.2009
   Ghosh S, 2007, MOL PHARMACOL, V71, P1695, DOI 10.1124/mol.106.033845
   Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307
   KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9
   Koeffler HP, 2003, CLIN CANCER RES, V9, P1
   Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200
   Kronke G, 2007, ARTERIOSCL THROM VAS, V27, P1276, DOI 10.1161/ATVBAHA.107.142638
   Lenton KJ, 1999, ANAL BIOCHEM, V274, P125, DOI 10.1006/abio.1999.4258
   Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488
   Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106
   Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869
   Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Niture SK, 2010, TOXICOL APPL PHARM, V244, P37, DOI 10.1016/j.taap.2009.06.009
   Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4
   Palakurthi SS, 2001, CANCER RES, V61, P6213
   Perez-Ortiz JM, 2007, MOL PHARMACOL, V72, P407, DOI 10.1124/mol.106.032458
   Polvani S, 2012, PPAR RES, V2012, DOI 10.1155/2012/641087
   Rao VA, 2010, J BIOL CHEM, V285, P34447, DOI 10.1074/jbc.M110.133579
   Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107
   Schaefer KL, 2007, INT J CANCER, V120, P702, DOI 10.1002/ijc.22361
   Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677
   Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658
   SOHDA T, 1990, ARZNEIMITTEL-FORSCH, V40-1, P37
   Uchida K, 2008, CHEM RES TOXICOL, V21, P138, DOI 10.1021/tx700177j
   Uchiyama M, 2010, DRUG METAB DISPOS, V38, P946, DOI 10.1124/dmd.109.031583
   Wei S, 2009, CANCER LETT, V276, P119, DOI 10.1016/j.canlet.2008.08.008
   Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489
   Zhou J, 2009, INT J BIOCHEM CELL B, V41, P2334, DOI 10.1016/j.biocel.2009.06.007
NR 37
TC 10
Z9 10
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2014
VL 45
IS 1
BP 426
EP 438
DI 10.3892/ijo.2014.2408
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI5BY
UT WOS:000336881600046
PM 24788124
OA Bronze
DA 2022-04-25
ER

PT J
AU Asp, ML
   Tian, M
   Wendel, AA
   Belury, MA
AF Asp, Michelle L.
   Tian, Min
   Wendel, Angela A.
   Belury, Martha A.
TI Evidence for the contribution of insulin resistance to the development
   of cachexia in tumor-bearing mice
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE colon-26 adenocarcinoma; rosiglitazone; muscle atrophy
ID EXPERIMENTAL CANCER CACHEXIA; WEIGHT-LOSS; MUSCLE; GLUCOSE; PROTEIN;
   METABOLISM; EXPRESSION; MORTALITY; ATROGIN-1; SURVIVAL
AB Cancer cachexia is a syndrome of unintentional weight loss that is characterized by wasting of both skeletal muscle and adipose tissue. Glucose intolerance and insulin resistance have been associated with cancer cachexia. However, it is unknown whether resistance to insulin has a role in the development of cachexia. In the present study, mate CD2F1 mice with colon-26 adenocarcinoma tumors underwent an insulin tolerance test before the onset of weight loss. Compared to mice without tumors, mice with tumors had a profoundly blunted blood glucose response to insulin. Corroborating these findings, mice with tumors had decreased phosphorylation of Akt in quadriceps muscle and epididymal adipose tissue at the end of the study. Expression of Akt-regulated genes Atrogin-1, MuRF-1, and Bnip3 was increased in muscle, suggesting a role for decreased insulin signaling in the induction of both proteasomal proteolysis and autophagy in cachectic muscle. Rosiglitazone treatment increased serum adiponectin, insulin sensitivity, and body weight, and decreased Atrogin-1 and MuRF-1 expression in the skeletal muscle of tumor-bearing mice. In conclusion, insulin resistance is an early event in mice with cachexia induced by colon-26 tumors. Rosiglitazone improves insulin sensitivity and decreases early markers of cachexia. These data provide evidence that insulin resistance is not only present in cachexia, but also has a role in cachexia pathogenesis. Correction of insulin resistance may be a novel therapeutic target for the treatment of cancer cachexia.
C1 [Asp, Michelle L.; Tian, Min; Wendel, Angela A.; Belury, Martha A.] Ohio State Univ, Dept Human Nutr, Coll Educ & Human Ecol, Columbus, OH 43210 USA.
RP Asp, ML (corresponding author), Ohio State Univ, Dept Human Nutr, Coll Educ & Human Ecol, Columbus, OH 43210 USA.
CR Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004
   Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174
   Argiles JM, 2004, CURR DRUG TARGETS, V5, P265, DOI 10.2174/1389450043490505
   BECK SA, 1989, BRIT J CANCER, V59, P677, DOI 10.1038/bjc.1989.140
   CERSOSIMO E, 1991, SURGERY, V109, P459
   DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3
   Dodesini AR, 2007, ACTA ONCOL, V46, P118, DOI 10.1080/02841860600791491
   Fearon KC, 2006, AM J CLIN NUTR, V83, P1345, DOI 10.1093/ajcn/83.6.1345
   Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198
   Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42
   Guerre-Millo M, 2008, DIABETES METAB, V34, P12, DOI 10.1016/j.diabet.2007.08.002
   Kim KY, 2007, MOL PHARMACOL, V71, P1554, DOI 10.1124/mol.106.031948
   Lazarus DD, 1996, CANCER LETT, V103, P71, DOI 10.1016/0304-3835(96)04197-3
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   MOLEY JF, 1988, CANCER RES, V48, P2784
   MOLEY JF, 1987, J SURG RES, V43, P21, DOI 10.1016/0022-4804(87)90042-4
   MOLEY JF, 1985, CANCER RES, V45, P4925
   Musi N, 2006, ENDOCRINE, V29, P73, DOI 10.1385/ENDO:29:1:73
   Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1
   PEACOCK JL, 1988, JPEN-PARENTER ENTER, V12, P260, DOI 10.1177/0148607188012003260
   Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213
   Rohdenburg GL, 1919, J AMER MED ASSOC, V72, P1528, DOI 10.1001/jama.1919.02610210024007
   Ryall JG, 2008, PHARMACOL THERAPEUT, V120, P219, DOI 10.1016/j.pharmthera.2008.06.003
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   TANAKA Y, 1990, CANCER RES, V50, P2290
   TAYEK JA, 1992, J AM COLL NUTR, V11, P445
   Vona-Davis L, 2007, OBES REV, V8, P395, DOI 10.1111/j.1467-789X.2007.00396.x
   Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002
   Wendel AA, 2008, J LIPID RES, V49, P98, DOI 10.1194/jlr.M700195-JLR200
   WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846
NR 34
TC 110
Z9 113
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 1
PY 2010
VL 126
IS 3
BP 756
EP 763
DI 10.1002/ijc.24784
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 542SN
UT WOS:000273515500017
PM 19634137
DA 2022-04-25
ER

PT J
AU You, PT
   Wu, HZ
   Deng, M
   Peng, JL
   Li, FP
   Yang, YF
AF You, Pengtao
   Wu, Hezhen
   Deng, Meng
   Peng, Jingling
   Li, Fangping
   Yang, Yanfang
TI Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell
   CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Brevilin A; Apoptosis; Autophagy; CT26; Mechanism
ID CENTIPEDA-MINIMA; MAMMALIAN AUTOPHAGY; MEDIATED CLEAVAGE; CANCER-CELLS;
   6-O-ANGELOYLENOLIN; CONSTITUENTS; CROSSTALK
AB Brevilin A is a sesquiterpene lactone isolated from Centipeda minima and possesses inhibitory effects on proliferation of various tumor cells. In this study, Brevilin A inhibitory effect on proliferation and its molecular mechanism of action were investigated both in vivo and in vitro in colon adenocarcinoma CT26 cells. The results indicated that the inhibitory effect of Brevilin A in CT26 proliferation was dose-dependent and this effect was due to apoptosis. Furthermore, Brevilin A increased ROS levels, decreased mitochondrial membrane potential (MMP) and induced apoptosis of CT26 cell in a dose-dependent manner. Apoptosis induced by Brevilin A was higher than that induced by adriamycin under the same dose. Cleaved-caspase-8, cleaved-caspase-9 and cleaved-caspase-3 were up-regulated after Brevilin A treatment, together with an increase of Bax protein expression, while Bcl-2 was reduced. Further investigation revealed that Brevilin A inhibited the phosphorylation of PI3K, AKT and mTOR and promoted the expressions of autophagy-related proteins LC3-II, Beclin1 and Atg5 and consequent formation of autophagosomes, whereas 3-methyladenine (3-MA), a type III PI3K inhibitor, inhibited autophagosomes formation induced by Brevilin A. In vivo investigation suggested that Brevilin A significantly inhibited the growth of CT26 tumor compared to adriamycin and concurrently promoted the expressions of LC3-II and cleaved-caspase-3 in tumor tissues. Our results demonstrated that the anti-tumor activity of Brevilin A was mainly achieved by the induction of cell apoptosis and autophagy, suggesting a promising potential as antitumor drug against colon adenocarcinoma.
C1 [You, Pengtao; Deng, Meng; Peng, Jingling; Li, Fangping; Yang, Yanfang] Hubei Univ Chinese Med, Key Lab Resources & Chem Chinese Med, 1 HuangJia Hu Rd West, Wuhan 430065, Hubei, Peoples R China.
   [Wu, Hezhen] Hubei Univ Chinese Med, Sch Pharm, Wuhan 430065, Hubei, Peoples R China.
   [Yang, Yanfang] Hubei Univ Chinese Med, Collaborat Innovat Ctr Tradit Chinese Med New Pro, Wuhan 430065, Hubei, Peoples R China.
RP Yang, YF (corresponding author), Hubei Univ Chinese Med, Key Lab Resources & Chem Chinese Med, 1 HuangJia Hu Rd West, Wuhan 430065, Hubei, Peoples R China.
EM yyf0204@hbtcm.edu.cn
OI Wu, Hezhen/0000-0003-3284-8703
FU scientific research program of Hubei Provincial Department of Education,
   P.R. China [Q20162006]
FX This study was supported by the scientific research program of Hubei
   Provincial Department of Education (Q20162006), P.R. China.
CR Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   C P Commission, 2015, PHARM PEOPL REP CHIN, V10th
   Chen X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063697
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Li CL, 2008, BIOMED PHARMACOTHER, V62, P401, DOI 10.1016/j.biopha.2007.10.010
   Liu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021930
   Liu YQ, 2015, ONCOTARGET, V6, P34953, DOI 10.18632/oncotarget.5547
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Su MX, 2011, CHEM-BIOL INTERACT, V189, P167, DOI 10.1016/j.cbi.2010.12.022
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Taylor RSL, 1998, PHYTOCHEMISTRY, V47, P631, DOI 10.1016/S0031-9422(97)00534-7
   Tsai JP, 2015, ONCOTARGET, V6, P28851, DOI 10.18632/oncotarget.4767
   Wang Y, 2017, BIOCHEM PHARMACOL, V129, P43, DOI 10.1016/j.bcp.2017.01.006
   WU JB, 1991, CHEM PHARM BULL, V39, P3272, DOI 10.1248/cpb.39.3272
   Wu P, 2012, PHYTOCHEMISTRY, V76, P133, DOI 10.1016/j.phytochem.2012.01.003
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
NR 26
TC 28
Z9 29
U1 2
U2 20
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2018
VL 98
BP 619
EP 625
DI 10.1016/j.biopha.2017.12.057
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FX5FR
UT WOS:000426104000076
PM 29289836
DA 2022-04-25
ER

PT J
AU Xue, Q
   Wang, XB
   Wang, P
   Zhang, K
   Liu, QH
AF Xue, Qin
   Wang, Xiaobing
   Wang, Pan
   Zhang, Kun
   Liu, Quanhong
TI Role of p38MAPK in apoptosis and autophagy responses to photodynamic
   therapy with Chlorin e6
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE PDT; Ce6; p38MAPK; Autophagy; Apoptosis
ID CELL-DEATH; MAP KINASE; CANCER-THERAPY; CYTOCHROME-C; ACTIVATION;
   PATHWAY; TUMORIGENESIS; GENERATION; HYPERICIN; LINES
AB Background: Photodynamic therapy (PDT) has been undergoing clinical evaluation for the treatment of colorectal cancer. But the molecular mechanism of photodynamic injury in human colorectal cancer cells still remains unclear.
   Methods: Chlorin e6 (Ce6) was used to photosensitize SW620 cells. The inhibitory effect of PDT was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide tetrazolium) assay and colony forming assay. Apoptosis was determined by nuclear DAPI (4'-6-diamidino-2-phenylindole) staining and Annexin V-PE/7-AAD assay. Monodansylcadaverine (MDC) staining was used to evaluate the abundance of autophagic vacuoles in PDT treated cells. The apoptosis and autophagy associated proteins were analyzed by western blotting. Moreover, we applied siRNA p38MAPK and p38MAPK inhibitor SB203580 to dissect its effect on cellular response to PDT in SW620 cells.
   Results: Ce6 mediated PDT (Ce6-PDT) induced apparent autophagy and apoptosis with dependent on ROS (reactive oxygen species) generation. When p38MAPK was inhibited by siRNA or inhibitor SB203580, a marked enhancement of apoptosis and autophagy in SW620 cells was detected after PDT. Moreover, autophagy inhibitor 3-methyladenine/Bafilomycin A1 greatly aggravated PDT induced photodamage in SW620 cells.
   Conclusion: Ce6-PDT induced ROS production to activate p38MAPK probably to prevent SW620 cells from photodamage. Inhibition of p38MAPK activation accelerated cell apoptosis, meanwhile enhanced autophagy may act as a cytoprotective process in SW620 cells. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Xue, Qin; Wang, Xiaobing; Wang, Pan; Zhang, Kun; Liu, Quanhong] Shaanxi Normal Univ, Key Lab Med Resources & Nat Pharmaceut Chem, Natl Engn Lab Resource Developing Endangered Chin, Minist Educ,Coll Life Sci, Xian 710062, Shaanxi, Peoples R China.
   [Xue, Qin] Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Peoples R China.
RP Wang, XB (corresponding author), Shaanxi Normal Univ, Key Lab Med Resources & Nat Pharmaceut Chem, Natl Engn Lab Resource Developing Endangered Chin, Minist Educ,Coll Life Sci, Xian 710062, Shaanxi, Peoples R China.
EM wangxiaobing@snnu.edu.cn; lshaof@srmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472846]
FX This work was supported by National Natural Science Foundation of China
   (No. 81472846).
CR Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788
   Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200
   Burmistrova O, 2011, CANCER LETT, V309, P71, DOI 10.1016/j.canlet.2011.05.018
   Burns CW, 2000, ACADEME, V86, P44, DOI 10.2307/40252335
   Magalhaes PVDS, 2013, AUST NZ J PSYCHIAT, V47, P564, DOI 10.1177/0004867413481631
   De Dosso S, 2009, CANCER TREAT REV, V35, P160, DOI 10.1016/j.ctrv.2008.10.001
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619
   Firczuk M, 2011, FRONT BIOSCI-LANDMRK, V16, P208, DOI 10.2741/3684
   Fullgrabe J, 2013, AUTOPHAGY, V9, P1621, DOI 10.4161/auto.25803
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Hara M, 2013, J EXP BOT, V64, P1615, DOI 10.1093/jxb/ert016
   HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kopetz S, 2008, ONCOLOGY-NY, V22, P260
   Krammer B, 2012, CURR MED CHEM, V19, P793, DOI 10.2174/092986712799034842
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Luo Y, 2011, EXP GERONTOL, V46, P860, DOI 10.1016/j.exger.2011.07.005
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   Noodt BB, 1996, BRIT J CANCER, V74, P22, DOI 10.1038/bjc.1996.310
   Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Peng Q, 1996, ULTRASTRUCT PATHOL, V20, P109, DOI 10.3109/01913129609016306
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Siboni G, 2003, CANCER LETT, V196, P57, DOI 10.1016/S0304-3835(03)00207-6
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Sparsa A, 2013, ONCOL REP, V29, P1196, DOI 10.3892/or.2012.2190
   vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031
   Whitacre CM, 2000, CLIN CANCER RES, V6, P2021
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558
   Yang SY, 2011, ANN SURG ONCOL, V18, pS239, DOI 10.1245/s10434-011-1789-x
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 39
TC 16
Z9 20
U1 1
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2015
VL 12
IS 1
BP 84
EP 91
DI 10.1016/j.pdpdt.2014.12.001
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CD6IR
UT WOS:000351193300011
PM 25528442
DA 2022-04-25
ER

PT J
AU Li, YY
   Guo, F
   Guan, YY
   Chen, TG
   Ma, KQ
   Zhang, LW
   Wang, ZH
   Su, Q
   Feng, LH
   Liu, YM
   Zhou, YZ
AF Li, Yuying
   Guo, Fang
   Guan, Yingying
   Chen, Tinggui
   Ma, Kaiqing
   Zhang, Liwei
   Wang, Zhuanhua
   Su, Qiang
   Feng, Liheng
   Liu, Yaoming
   Zhou, Yuzhi
TI Novel Anthraquinone Compounds Inhibit Colon Cancer Cell Proliferation
   via the Reactive Oxygen Species/JNK Pathway
SO MOLECULES
LA English
DT Article
DE anthraquinone derivatives; apoptosis; 3D-QSAR; ROS-JNK; HCT116
ID POTENTIAL ANTICANCER; IN-VITRO; APOPTOSIS; AUTOPHAGY; MITOXANTRONE;
   DYSFUNCTION; BORTEZOMIB; ARREST; DEATH; ACID
AB A series of amide anthraquinone derivatives, an important component of some traditional Chinese medicines, were structurally modified and the resulting antitumor activities were evaluated. The compounds showed potent anti-proliferative activities against eight human cancer cell lines, with no noticeable cytotoxicity towards normal cells. Among the candidate compounds, 1-nitro-2-acyl anthraquinone-leucine (8a) showed the greatest inhibition of HCT116 cell activity with an IC50 of 17.80 mu g/mL. In addition, a correlation model was established in a three-dimensional quantitative structure-activity relationship (3D-QSAR) study using Comparative Molecular Field Analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA). Moreover, compound 8a effectively killed tumor cells by reactive oxygen species (ROS)-JNK activation, causing an increase in ROS levels, JNK phosphorylation, and mitochondrial stress. Cytochrome c was then released into cytoplasm, which, in turn activated the cysteine protease pathway and ultimately induced tumor cell apoptosis, suggesting a potential use of this compound for colon cancer treatment.
C1 [Li, Yuying; Guo, Fang; Guan, Yingying; Chen, Tinggui; Ma, Kaiqing; Zhang, Liwei; Wang, Zhuanhua; Su, Qiang; Feng, Liheng; Liu, Yaoming; Zhou, Yuzhi] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Minist Educ, Taiyuan 030006, Peoples R China.
RP Li, YY (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Minist Educ, Taiyuan 030006, Peoples R China.
EM lyy9030@sxu.edu.cn; 201723002004@email.sxu.edu.cn; yanning654@126.com;
   Chentg@sxu.edu.cn; makaiqing@sxu.edu.cn; lwzhang@sxu.edu.cn;
   zhwang@sxu.edu.cn; suqchem1984@163.com; lhfeng@sxu.edu.cn;
   liuym1022@sxu.edu.cn; zhouyuzhi@sxu.edu.cn
OI Chen, Tinggui/0000-0001-8455-1317; Zhang, liwei/0000-0002-9247-6334
FU Transformation of Scientific and Technological Achievements Programs of
   Higher Education Institutions in Shanxi (TSTAP), Key projects of Shanxi
   Province [201903D321095]; Research on Key Technologies of Modernization
   of Traditional Chinese Medicine in Shanxi Province Zhendong Special
   Foundation [2016ZD0502]
FX This work was supported by Transformation of Scientific and
   Technological Achievements Programs of Higher Education Institutions in
   Shanxi (TSTAP), Key projects of Shanxi Province (No. 201903D321095), and
   Research on Key Technologies of Modernization of Traditional Chinese
   Medicine in Shanxi Province Zhendong Special Foundation (No.
   2016ZD0502). We thank Prof. Daxiong Han from Medical College Xiamen
   University for software support.
CR Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen K, 2015, ACTA PHARMACOL SIN, V36, P1074, DOI 10.1038/aps.2015.44
   Duan FS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161886
   El-Naggar AM, 2017, MOL DIVERS, V21, P967, DOI 10.1007/s11030-017-9776-1
   Feng SX, 2012, ARCH PHARM RES, V35, P1251, DOI 10.1007/s12272-012-0716-4
   Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033
   Hseu YC, 2019, J CELL PHYSIOL, V234, P17514, DOI 10.1002/jcp.28375
   Hsin LW, 2008, BIOORGAN MED CHEM, V16, P1006, DOI 10.1016/j.bmc.2007.10.012
   Jafari F, 2019, EUR J MED CHEM, V164, P292, DOI 10.1016/j.ejmech.2018.12.060
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim KY, 2011, BIOCHEM BIOPH RES CO, V413, P80, DOI 10.1016/j.bbrc.2011.08.054
   Kim SY, 2014, BIOCHEM PHARMACOL, V88, P178, DOI 10.1016/j.bcp.2014.01.027
   Kwon S, 2018, EUR J MED CHEM, V148, P116, DOI 10.1016/j.ejmech.2018.02.016
   Li R.F., 2011, THESIS
   Lu ZY, 2017, CHEM-BIOL INTERACT, V277, P62, DOI 10.1016/j.cbi.2017.08.011
   Luo J., 2018, OXID MED CELL LONGEV, V10, P1155
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Magnus B, 2008, EUR J HAEMATOL, V80, P477, DOI 10.1111/j.1600-0609.2008.01062.x
   Malik EM, 2016, MED RES REV, V36, P705, DOI 10.1002/med.21391
   Opoku-Temeng C, 2018, BIOORG CHEM, V78, P418, DOI 10.1016/j.bioorg.2018.03.031
   Pang MJ, 2016, ACTA PHARMACOL SIN, V37, P1623, DOI 10.1038/aps.2016.98
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Pooja T, 2014, EUR J PHARMACOL, V742, P55, DOI 10.1016/j.ejphar.2014.08.028
   Priault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008755
   Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167
   Ramirez-Prada J, 2017, EUR J MED CHEM, V131, P237, DOI 10.1016/j.ejmech.2017.03.016
   Rossato LG, 2014, CARDIOVASC TOXICOL, V14, P30, DOI 10.1007/s12012-013-9230-2
   Vittar NBR, 2014, PHOTODIAGN PHOTODYN, V11, P182, DOI 10.1016/j.pdpdt.2014.02.002
   Satoh M, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-19
   Schattauer SS, 2019, J BIOL CHEM, V294, P16884, DOI 10.1074/jbc.RA119.009592
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song XX, 2015, MOL CANCER RES, V13, P1533, DOI 10.1158/1541-7786.MCR-15-0237
   Song Y, 2011, TOXICOL LETT, V202, P55, DOI 10.1016/j.toxlet.2011.01.020
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Suzuki M, 2015, FREE RADICAL BIO MED, V89, P369, DOI 10.1016/j.freeradbiomed.2015.08.015
   Szwed M, 2014, POSTEP HIG MED DOSW, V68, P198, DOI 10.5604/17322693.1091102
   Tian W, 2019, ACS MED CHEM LETT, V10, P732, DOI 10.1021/acsmedchemlett.8b00624
   Wang B, 2018, CHEM BIOL DRUG DES, V91, P957, DOI 10.1111/cbdd.13154
   Xie MJ, 2014, ASIAN PAC J CANCER P, V15, P5201, DOI 10.7314/APJCP.2014.15.13.5201
   Xu B, 2017, EUR J MED CHEM, V130, P26, DOI 10.1016/j.ejmech.2017.02.036
   Yang K, 2019, MOLECULES, V24, DOI 10.3390/molecules24050884
   Yeap S, 2015, DRUG DES DEV THER, V9, P983, DOI 10.2147/DDDT.S65468
   Yuan DT, 2017, CANCER CELL, V31, P771, DOI 10.1016/j.ccell.2017.05.006
   Zhang L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/696107
   Zhang ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027441
   Zhu CP, 2014, SCI REP-UK, V4, DOI 10.1038/srep05029
   Zhu X, 2014, TOXICOL LETT, V227, P65, DOI 10.1016/j.toxlet.2014.03.015
   Zhu Y, 2017, MBIO, V8, DOI 10.1128/mBio.01179-17
NR 49
TC 8
Z9 8
U1 7
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD APR
PY 2020
VL 25
IS 7
AR 1672
DI 10.3390/molecules25071672
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LL8VZ
UT WOS:000531833400197
PM 32260423
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Onodera, R
   Motoyama, K
   Okamatsu, A
   Higashi, T
   Kariya, R
   Okada, S
   Arima, H
AF Onodera, Risako
   Motoyama, Keiichi
   Okamatsu, Ayaka
   Higashi, Taishi
   Kariya, Ryusho
   Okada, Seiji
   Arima, Hidetoshi
TI Involvement of cholesterol depletion from lipid rafts in apoptosis
   induced by methyl-beta-cyclodextrin
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Apoptosis; Methyl-beta-cyclodextrin; Cholesterol; Antitumor agent
ID RED-BLOOD-CELLS; CANCER-CELLS; DEATH; BAD; CASPASES; PROTEINS; CAVEOLAE;
   CHANNEL; BCL-2
AB Methyl-beta-cyclodextrin (M-beta-CyD), which is widely used as a lipid rafts disrupting agent, is known to induce cytotoxicity at high concentration. In the present study, we investigated the potential of M-beta-CyD as an antitumor drug. M-beta-CyD markedly caused apoptotic cell-death in KB cells, a human oral squamous carcinoma cell line, Ihara cells, a highly pigmented human melanoma cell line, and M213 cells, a human cholangiocarcinoma cell line, through cholesterol depletion in cell membranes. The DNA content and mitochondrial transmembrane potential in KB cells were significantly decreased after treatment with M-beta-CyD. Additionally, M-beta-CyD elevated the caspase-3/7 activity in KB cells. Meanwhile, M-beta-CyD did not induce the formation of autophagic vacuoles in KB cells. M-beta-CyD drastically inhibited the tumor growth after intratumoral injection to Colon-26 cells-bearing mice. These results strongly suggest that M-beta-CyD induced apoptosis in tumor cells and had the potential a novel antitumor agent and/or its lead compound. Copyright (C) 2013 Elsevier B.V. All rights reserved.
C1 [Onodera, Risako; Motoyama, Keiichi; Okamatsu, Ayaka; Higashi, Taishi; Arima, Hidetoshi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Kumamoto 8620973, Japan.
   [Kariya, Ryusho; Okada, Seiji] Kumamoto Univ, Div Hematopoiesis, Ctr AIDS Res, Chuo Ku, Kumamoto 8600811, Japan.
RP Arima, H (corresponding author), Kumamoto Univ, Dept Phys Pharmaceut, Grad Sch Pharmaceut Sci, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.
EM arimah@gpo.kumamoto-u.ac.jp
RI Okada, Seiji/F-5785-2013
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [22790040]; Ministry of Health Labor and
   WelfareMinistry of Health, Labour and Welfare, Japan [24100701]; Japan
   Science Society
FX This work was partially supported by a Grant-in-Aid for Young Scientists
   (B) from Japan Society for the Promotion of Science (22790040) and by a
   Grant-in-Aid for Third Term Comprehensive Control Research for Cancer
   from Ministry of Health Labor and Welfare (24100701). This work was
   supported by the Sasakawa Scientific Research Grant from The Japan
   Science Society.
CR Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
   Ayllon V, 2002, J IMMUNOL, V168, P3387, DOI 10.4049/jimmunol.168.7.3387
   Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643
   Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X
   Grosse PY, 1998, BRIT J CANCER, V78, P1165, DOI 10.1038/bjc.1998.648
   Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022
   Irie T, 1999, ADV DRUG DELIVER REV, V36, P101, DOI 10.1016/S0169-409X(98)00057-X
   Irie T, 1997, J PHARM SCI-US, V86, P147, DOI 10.1021/js960213f
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787
   Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252
   Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571
   Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X
   Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200
   Motoyama K, 2006, EUR J PHARM SCI, V29, P111, DOI 10.1016/j.ejps.2006.06.002
   Motoyama K, 2009, EUR J PHARM SCI, V38, P249, DOI 10.1016/j.ejps.2009.07.010
   Motoyama K, 2009, BIOL PHARM BULL, V32, P700, DOI 10.1248/bpb.32.700
   OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x
   Onodera R, 2011, J INCL PHENOM MACRO, V70, P321, DOI 10.1007/s10847-010-9843-z
   Rosenbaum AI, 2010, P NATL ACAD SCI USA, V107, P5477, DOI 10.1073/pnas.0914309107
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Taatjes DJ, 2008, HISTOCHEM CELL BIOL, V129, P33, DOI 10.1007/s00418-007-0356-9
   Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p
   YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
NR 28
TC 45
Z9 45
U1 0
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD AUG 16
PY 2013
VL 452
IS 1-2
BP 116
EP 123
DI 10.1016/j.ijpharm.2013.04.071
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 179CQ
UT WOS:000321496200014
PM 23684659
DA 2022-04-25
ER

PT J
AU Wilfinger, N
   Austin, S
   Scheiber-Mojdekhar, B
   Berger, W
   Reipert, S
   Praschberger, M
   Paur, J
   Trondl, R
   Keppler, BK
   Zielinski, CC
   Nowikovsky, K
AF Wilfinger, Nastasia
   Austin, Shane
   Scheiber-Mojdekhar, Barbara
   Berger, Walter
   Reipert, Siegfried
   Praschberger, Monika
   Paur, Jakob
   Trondl, Robert
   Keppler, Bernhard K.
   Zielinski, Christoph C.
   Nowikovsky, Karin
TI Novel p53-dependent anticancer strategy by targeting iron signaling and
   BNIP3L-induced mitophagy
SO ONCOTARGET
LA English
DT Article
DE cancer; p53; BNIP3L; mitophagy; gallium complex
ID CELL-DEATH; PERMEABILITY TRANSITION; MITOCHONDRIA; P53; APOPTOSIS;
   AUTOPHAGY; INDUCTION; GALLIUM; METABOLISM; STABILITY
AB This study identifies BNIP3L as the key regulator of p53-dependent cell death mechanism in colon cancer cells targeted by the novel gallium based anticancer drug, KP46. KP46 specifically accumulated into mitochondria where it caused p53-dependent morphological and functional damage impairing mitochondrial dynamics and bioenergetics. Furthermore, competing with iron for cellular uptake, KP46 lowered the intracellular labile iron pools and intracellular heme. Accordingly, p53 accumulated in the nucleus where it activated its transcriptional target BNIP3L, a BH3 only domain protein with functions in apoptosis and mitophagy. Upregulated BNIP3L sensitized the mitochondrial permeability transition and strongly induced PARKIN-mediated mitochondrial clearance and cellular vacuolization. Downregulation of BNIP3L entirely rescued cell viability caused by exposure of KP46 for 24 hours, confirming that early induced cell death was regulated by BNIP3L. Altogether, targeting BNIP3L in wild-type p53 colon cancer cells is a novel anticancer strategy activating iron depletion signaling and the mitophagy-related cell death pathway.
C1 [Wilfinger, Nastasia; Austin, Shane; Berger, Walter; Paur, Jakob; Zielinski, Christoph C.; Nowikovsky, Karin] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.
   [Wilfinger, Nastasia; Austin, Shane; Berger, Walter; Paur, Jakob; Zielinski, Christoph C.; Nowikovsky, Karin] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria.
   [Scheiber-Mojdekhar, Barbara; Praschberger, Monika] Med Univ Vienna, Dept Med Chem, Vienna, Austria.
   [Reipert, Siegfried] Med Univ Vienna, Cell Imaging & Ultrastruct Res, Vienna, Austria.
   [Trondl, Robert; Keppler, Bernhard K.] Univ Vienna, Inst Inorgan Chem, Vienna, Austria.
RP Nowikovsky, K (corresponding author), Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.; Nowikovsky, K (corresponding author), Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria.
EM karin.nowikovsky@meduniwien.ac.at
RI Austin, Shane/AAI-4896-2021
OI Austin, Shane/0000-0002-8698-6055; Reipert,
   Siegfried/0000-0002-2043-3562; Keppler, Bernhard/0000-0003-0877-1822;
   Berger, Walter/0000-0003-0014-1658; Scheiber-Mojdehkar,
   Barbara/0000-0002-4114-9413; Nowikovsky, Karin/0000-0001-8435-8410
FU Jubilaumsfonds der Oesterreichischen Nationalbank [OeNB-15423];
   Initiative Krebsforschungsprogramm [IK-04024]; ASHO (Austrian Society of
   Hematology & Medical Oncology) fellowship
FX The project was supported by the grants OeNB-15423 (Jubilaumsfonds der
   Oesterreichischen Nationalbank) and IK-04024 (Initiative
   Krebsforschungsprogramm) to K. Nowikovsky. N. Wilfinger is a recipient
   of an ASHO (Austrian Society of Hematology & Medical Oncology)
   fellowship and S. Austin is a DOC fellow of the Austrian Academy of
   Sciences.
CR Allen GFG, 2013, EMBO REP, V14, P1127, DOI 10.1038/embor.2013.168
   Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662
   Bisio A, 2014, HUM MUTAT, V35, P689, DOI 10.1002/humu.22514
   Brand MD, 2011, BIOCHEM J, V437, P575
   BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209
   Chen CY, 2012, BBA-MOL CELL RES, V1823, P1459, DOI 10.1016/j.bbamcr.2012.01.003
   Chiara F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.184
   Chitambar CR, 2013, ANTIOXID REDOX SIGN, V18, P956, DOI 10.1089/ars.2012.4880
   Chitambar CR, 2012, FUTURE MED CHEM, V4, P1257, DOI [10.4155/FMC.12.69, 10.4155/fmc.12.69]
   Chitambar CR, 2000, BIOCHEM J, V345, P681, DOI 10.1042/0264-6021:3450681
   Collery P, 2002, CRIT REV ONCOL HEMAT, V42, P283, DOI 10.1016/S1040-8428(01)00225-6
   Comel A, 2014, FEBS LETT, V588, P2600, DOI 10.1016/j.febslet.2014.04.015
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Diwan A, 2009, J CLIN INVEST, V119, P203, DOI 10.1172/JCI36445
   Enyedy EA, 2012, J INORG BIOCHEM, V117, P189, DOI 10.1016/j.jinorgbio.2012.08.005
   Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187
   Fiskin E, MOL CELL, V47, P797
   Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478
   Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598
   Gogna R, 2012, BRIT J PHARMACOL, V166, P617, DOI 10.1111/j.1476-5381.2011.01780.x
   Hofheinz R D, 2005, Int J Clin Pharmacol Ther, V43, P590
   Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111
   Hoshino A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3308
   Jungwirth U, MOL CANC THER, V13, P2436
   Khan AA, 1813, BIOCH BIOPHYS ACTA, P668
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Kitsis RN, 2010, P NATL ACAD SCI USA, V107, P9031, DOI 10.1073/pnas.1003827107
   Krajka-Kuzniak V, 2013, FOOD CHEM TOXICOL, V51, P202, DOI 10.1016/j.fct.2012.09.033
   Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819
   Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916
   Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1
   Lim CS, 2012, J VASC SURG, V56, P1069, DOI 10.1016/j.jvs.2012.02.067
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nakajima Wataru, 2007, Journal of Nippon Medical School, V74, P148, DOI 10.1272/jnms.74.148
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Park S, 2014, AUTOPHAGY, V10, P1906, DOI 10.4161/auto.32177
   Pflaum J, FRONT ONCOL, V4, P285
   Praschberger M, 2015, BIOMETALS, V28, P35, DOI 10.1007/s10534-014-9801-0
   REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376
   Shao S, 2014, INT J ONCOL, V44, P1661, DOI 10.3892/ijo.2014.2313
   Shen J, 2014, CELL REP, V7, P180, DOI 10.1016/j.celrep.2014.02.042
   Sinclair P R, 2001, Curr Protoc Toxicol, VChapter 8, DOI 10.1002/0471140856.tx0803s00
   Sturm B, 2003, EUR J BIOCHEM, V270, P3731, DOI 10.1046/j.1432-1033.2003.03759.x
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Trinh DL, ONCOTARGET, V1, P396
   Valiahdi SM, 2009, MELANOMA RES, V19, P283, DOI 10.1097/CMR.0b013e32832b272d
   Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang EY, 2013, HYPERTENSION, V62, P70, DOI 10.1161/HYPERTENSIONAHA.113.01028
   Wang Y, AUTOPHAGY, V8, P1462
   World Health Organization, 2011, GLOB STAT REP NONC D
   Xavier JM, 2014, ANTIOXID REDOX SIGN, V21, P1009, DOI 10.1089/ars.2013.5417
   Zhang J, 2012, AUTOPHAGY, V8, P1325, DOI 10.4161/auto.20764
   Zhang J, 2011, ANTIOXID REDOX SIGN, V14, P1959, DOI 10.1089/ars.2010.3772
   Zheng R, 2015, ONCOTARGET, V6, P17417, DOI 10.18632/oncotarget.4002
   Zhu JH, 2013, AUTOPHAGY, V9, P1663, DOI 10.4161/auto.24135
NR 56
TC 14
Z9 15
U1 1
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 12
PY 2016
VL 7
IS 2
BP 1242
EP 1261
DI 10.18632/oncotarget.6233
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GP
UT WOS:000369951100014
PM 26517689
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shan, YL
   Gao, Y
   Jin, W
   Fan, MM
   Wang, Y
   Gu, YH
   Shan, CX
   Sun, LJ
   Li, X
   Yu, B
   Luo, Q
   Xu, Q
AF Shan, Yunlong
   Gao, Yuan
   Jin, Wei
   Fan, Minmin
   Wang, Ying
   Gu, Yanhong
   Shan, Chenxiao
   Sun, Lijun
   Li, Xin
   Yu, Biao
   Luo, Qiong
   Xu, Qiang
TI Targeting HIBCH to reprogram valine metabolism for the treatment of
   colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID III COLON-CANCER; PROMOTES CELL-PROLIFERATION; AMINO-ACID-METABOLISM;
   BCAT1 PROMOTES; BEVACIZUMAB; OXALIPLATIN; CETUXIMAB; PROTEIN; MTOR;
   FLUOROURACIL
AB Valine catabolism is known to be essential for cancer cells but the detailed mechanism remains unclear. This study is to explore the critical roles of 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) in colorectal cancers (CRC) and to develop a new therapy returning valine metabolism homeostasis. High HIBCH expression was first confirmed to correlate with poor survival in patients with CRC, which was then linked to the increased cell growth, resistant apoptosis, and decreased autophagy in CRC cells. The functions of HIBCH in CRC were dependent on its mitochondrial localization. High HIBCH level was further demonstrated to promote the metabolism of tricarboxylic acid cycle as well as oxidative phosphorylation in CRC cells. Based on above findings, we further discovered a novel valine catabolism inhibitor SBF-1. The pharmacological blockade of HIBCH mitochondrial localization with SBF-1 resulted in decreased cancer cell growth and increased autophagy, collectively contributing to the antitumor effect both in vitro and in vivo. Moreover, anti-VEGF therapy with bevacizumab increased HIBCH level in CRC cells, which in turn caused the resistance to the therapy. The interference with HIBCH function by SBF-1 significantly increased the antitumor efficacy of bevacizumab and led to a robust survival benefit. The present study identified HIBCH as a critical enzyme of valine catabolism in CRC progression and resistance to anti-VEGF therapy. We also provided a novel HIBCH inhibitor SBF-1, which highlighted the combined therapy using valine catabolic inhibitor along with anti-VEGF drugs, to control progression of CRC.
C1 [Shan, Yunlong; Gao, Yuan; Jin, Wei; Fan, Minmin; Li, Xin; Luo, Qiong; Xu, Qiang] Nanjing Univ, Nanjing Drum Tower Hosp, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
   [Shan, Yunlong; Gao, Yuan; Jin, Wei; Fan, Minmin; Li, Xin; Luo, Qiong; Xu, Qiang] Nanjing Univ, Sch Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
   [Wang, Ying; Gu, Yanhong] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China.
   [Shan, Chenxiao] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
   [Sun, Lijun; Yu, Biao] Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China.
RP Luo, Q; Xu, Q (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.; Luo, Q; Xu, Q (corresponding author), Nanjing Univ, Sch Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
EM qiongluo@nju.edu.cn; molpharm@163.com
RI Yu, Biao/G-9952-2017
OI Yu, Biao/0000-0002-3607-578X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773743, 81730100]; National Key RAMP;D
   Program of China [2017YFA0506000]; National Science AMP; Technology
   Major Project "Key New Drug Creation and Manufacturing Program"
   [2018ZX09201002]; Natural Science Foundation of Jiangsu ProvinceNatural
   Science Foundation of Jiangsu Province [BK20150590]; Nanjing University
   Innovation and Creative Program for PhD candidate [CXCY17-25]
FX This study was supported by National Natural Science Foundation of China
   [Nos. 81773743, 81730100]; National Key R&D Program of China
   [2017YFA0506000]; National Science & Technology Major Project "Key New
   Drug Creation and Manufacturing Program" [2018ZX09201002]; Natural
   Science Foundation of Jiangsu Province [BK20150590]; and Nanjing
   University Innovation and Creative Program for PhD candidate
   [CXCY17-25].
CR Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711
   Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855
   Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430
   Ananieva EA, 2016, ADV NUTR, V7, p798S, DOI 10.3945/an.115.011221
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909
   Choudry HA, 2006, J NUTR, V136, p314S, DOI 10.1093/jn/136.1.314S
   Curtin JC, 2013, EXPERT OPIN DRUG DIS, V8, P1153, DOI 10.1517/17460441.2013.807249
   de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032
   Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849
   Ferdinandusse S, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-188
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Graff JN, 2014, CANCER IMMUNOL RES, V2, P399, DOI 10.1158/2326-6066.CIR-13-0193
   Greening DW, 2015, ONCOTARGET, V6, P38166, DOI 10.18632/oncotarget.6241
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314
   Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63
   Kimberly WT, 2013, STROKE, V44, P1389, DOI 10.1161/STROKEAHA.111.000397
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lukey MJ, 2017, DRUG DISCOV TODAY, V22, P796, DOI 10.1016/j.drudis.2016.12.003
   Mayers JR, 2017, CANCER RES, V77, P3131, DOI 10.1158/0008-5472.CAN-17-0165
   Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171
   Mayers JR, 2014, NAT MED, V20, P1193, DOI 10.1038/nm.3686
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Panosyan EH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3148-1
   RENDINA G, 1957, J BIOL CHEM, V225, P523
   Reuter MS, 2014, AM J MED GENET A, V164, P3162, DOI 10.1002/ajmg.a.36766
   Rhee EP, 2013, CELL METAB, V18, P130, DOI 10.1016/j.cmet.2013.06.013
   Schottmann G, 2016, MOVEMENT DISORD, V31, P1733, DOI 10.1002/mds.26704
   Schulte ML, 2018, NAT MED, V24, P194, DOI 10.1038/nm.4464
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi BF, 2004, ANGEW CHEM INT EDIT, V43, P4324, DOI 10.1002/anie.200454237
   SHIMOMURA Y, 1994, J BIOL CHEM, V269, P14248
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Stiles AR, 2015, MOL GENET METAB, V115, P161, DOI 10.1016/j.ymgme.2015.05.008
   Taieb J, 2014, LANCET ONCOL, V15, P862, DOI 10.1016/S1470-2045(14)70227-X
   Taniguchi K, 1996, HEPATOLOGY, V24, P1395, DOI 10.1002/hep.510240614
   Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Cidon EU, 2010, CLIN MED INSIGHTS-ON, V4, P55, DOI 10.4137/CMO.S5214
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307
   Wang WZ, 2016, NAT MED, V22, P869, DOI 10.1038/nm.4130
   Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048
   Yoshikawa R, 2006, WORLD J GASTROENTERO, V12, P5884, DOI 10.3748/wjg.v12.i36.5884
   Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101
   Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178
NR 54
TC 11
Z9 11
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 13
PY 2019
VL 10
AR 618
DI 10.1038/s41419-019-1832-6
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IS2DD
UT WOS:000481962300004
PM 31409769
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shin, SY
   Hyun, J
   Yu, JR
   Lim, Y
   Lee, YH
AF Shin, Soon Young
   Hyun, Jiye
   Yu, Jae-Ran
   Lim, Yoongho
   Lee, Young Han
TI 5-Methoxyflavanone induces cell cycle arrest at the G2/M phase,
   apoptosis and autophagy in HCT116 human colon cancer cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE 5-methoxyflavanone; DNA damage checkpoint; Apoptosis; Caspase; Autophagy
ID MALIGNANT GLIOMA-CELLS; DOUBLE-STRAND BREAKS; NUCLEAR-DNA DAMAGE;
   DIETARY FLAVONOIDS; BIOAVAILABLE FLAVONOIDS; INTESTINAL-ABSORPTION;
   METABOLIC STABILITY; LIPID-PEROXIDATION; IN-VITRO; DEATH
AB Natural flavonoids have diverse pharmacological activities, including anti-oxidative, anti-inflammatory, and anti-cancer activities. In this study, we investigated the molecular mechanism underlying the action of 5-methoxyflavanone (5-MF) which has a strong bioavailability and metabolic stability. Our results show that 5-MF inhibited the growth and clonogenicity of HCT116 human colon cancer cells, and that it activated DNA damage responses, as revealed by the accumulation of p53 and the phosphorylation of DNA damage-sensitive proteins, including ataxia-telangiectasia mutated (ATM) at Ser1981, checkpoint kinase 2 (Chk2) at Thr68, and histone H2AX at Ser139. 5-MF-induced DNA damage was confirmed in a comet tail assay. We also found that 5-MF increased the cleavage of caspase-2 and -7, leading to the induction of apoptosis. Pretreatment with the ATM inhibitor KU55933 enhanced 5-MF-induced gamma-H2AX formation and caspase-7 cleavage. HCT116 cells lacking p53 (p53(-/-)) or p21 (p21(-/-)) exhibited increased sensitivity to 5-MF compared to wild-type cells. 5-MF further induced autophagy via an ERK signaling pathway. Blockage of autophagy with the MEK inhibitor U0126 potentiated 5-MF-induced gamma-H2AX formation and caspase-2 activation. These results suggest that a caspase-2 cascade mediates 5-MF-induced anti-tumor activity, while an ATM/Chk2/p53/p21 checkpoint pathway and ERK-mediated autophagy act as a survival program to block caspase-2-mediated apoptosis induced by 5-MF. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Shin, Soon Young; Lim, Yoongho; Lee, Young Han] Konkuk Univ, SMART Inst Adv Biomed Sci, Med Ctr, Seoul 143701, South Korea.
   [Shin, Soon Young; Lee, Young Han] Konkuk Univ, Res Ctr Transcript Control, Dept Biomed Sci & Technol, Seoul 143701, South Korea.
   [Hyun, Jiye; Lim, Yoongho] Konkuk Univ, Div Biosci & Biotechnol, BMIC, Seoul 143701, South Korea.
   [Yu, Jae-Ran] Konkuk Univ, Sch Med, Dept Environm & Trop Med, Seoul 143701, South Korea.
RP Lim, Y (corresponding author), Konkuk Univ, SMART Inst Adv Biomed Sci, Med Ctr, 1 Hwayang Dong, Seoul 143701, South Korea.
EM yoongho@konkuk.ac.kr; yhlee58@konkuk.ac.kr
FU Korean Government MESTMinistry of Education, Science and Technology,
   Republic of KoreaKorean Government [NRF-2009-0084183, NRF-2010-0014208,
   NRF-2009-0093824]
FX This work was supported by the Disease Network Research Program
   (NRF-2009-0084183), the Basic Research Promotion Fund
   (NRF-2010-0014208), and the Priority Research Centers Program
   (NRF-2009-0093824), through a National Research Foundation of Korea
   grant funded by the Korean Government MEST.
CR Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021
   da Silva J, 2002, FOOD CHEM TOXICOL, V40, P941, DOI 10.1016/S0278-6915(02)00015-7
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701
   Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V390, P141, DOI 10.1016/S0165-1218(97)00010-4
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   GASPAR J, 1994, MUTAGENESIS, V9, P445, DOI 10.1093/mutage/9.5.445
   Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371
   Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   KANDOUZ M, CELL CYCLE, V9, P398
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550
   Knekt P, 1997, AM J EPIDEMIOL, V146, P223, DOI 10.1093/oxfordjournals.aje.a009257
   Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478
   Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu QH, 2000, GENE DEV, V14, P1448
   Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Paglin S, 2001, CANCER RES, V61, P439
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Prasad S, 2010, PLANTA MED, V76, P1044, DOI 10.1055/s-0030-1250111
   Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   SAHU SC, 1994, CANCER LETT, V85, P159, DOI 10.1016/0304-3835(94)90269-0
   SAHU SC, 1991, CANCER LETT, V60, P259, DOI 10.1016/0304-3835(91)90122-X
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   Shin SY, 2010, EXP MOL MED, V42, P395, DOI 10.3858/emm.2010.42.5.041
   Shin SY, 2006, EMBO J, V25, P1093, DOI 10.1038/sj.emboj.7600987
   Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000
   Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004
   Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0
   Walle T, 2007, MOL PHARMACEUT, V4, P826, DOI 10.1021/mp700071d
   Walle T, 2007, BIOCHEM PHARMACOL, V73, P1288, DOI 10.1016/j.bcp.2006.12.028
   Walle UK, 2007, DRUG METAB DISPOS, V35, P1985, DOI 10.1124/dmd.107.016782
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wen X, 2006, DRUG METAB DISPOS, V34, P1786, DOI 10.1124/dmd.106.011122
   Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7
   Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026
NR 60
TC 34
Z9 35
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD AUG 1
PY 2011
VL 254
IS 3
BP 288
EP 298
DI 10.1016/j.taap.2011.05.003
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 795AO
UT WOS:000292944100008
PM 21616090
DA 2022-04-25
ER

PT J
AU Liu, GY
   Bu, XX
   Yan, H
   Jia, WWG
AF Liu, Guo-Yu
   Bu, Xuexian
   Yan, Hang
   Jia, William W. -G.
TI 20S-protopanaxadiol-induced programmed cell death in glioma cells
   through caspase-dependent and -independent pathways
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID COLON-CANCER CELLS; REACTIVE OXYGEN; IN-VITRO; GINSENOSIDE RH-2;
   APOPTOSIS; MACROAUTOPHAGY; INHIBITION; MITOCHONDRIA; METABOLISM;
   ACTIVATION
AB 20S-Protopanaxadiol (1) is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponins. In the present study, 1 was used to induce cytotoxicity for two human glioma cell lines, SF188 and U87MG. For the SF188 cells, 1 activated caspases-3, -8, -7, and -9 within 3 h and induced rapid apoptosis, which could be partially inhibited by a general caspase blocker and completely abolished when the caspase blocker was used in combination with an antioxidant. Compound 1 also induced cell death in U87MG cells but did not activate any caspases in these cells. Monodansylcadaverine staining showed that 1 induced dramatic autophagy in both cell lines. Elevated levels of superoxide anion in both cells and reduced levels of phosphorylated Akt in U87MG cells were also demonstrated. These results showed that 20S-protopanaxadiol (1) induces different forms of programmed cell death, including both typical apoptosis and autophagy through both caspase-dependent and -independent mechanisms.
C1 Univ British Columbia, Dept Surg, Vancouver, BC V6T 2B5, Canada.
   Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada.
RP Jia, WWG (corresponding author), Univ British Columbia, Dept Surg, F233-2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.
EM wjia@interchange.ubc.ca
RI JIA, WILLIAM/AAE-4322-2020
CR Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bae EA, 2002, BIOL PHARM BULL, V25, P58, DOI 10.1248/bpb.25.58
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4
   Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Fei XF, 2002, ACTA PHARMACOL SIN, V23, P315
   FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5
   Galindo MF, 2003, J NEUROCHEM, V84, P1066, DOI 10.1046/j.1471-4159.2003.01592.x
   Gilaberte Y, 1997, PHOTODERMATOL PHOTO, V13, P43, DOI 10.1111/j.1600-0781.1997.tb00107.x
   Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200
   Gu YP, 2004, FEBS LETT, V577, P357, DOI 10.1016/j.febslet.2004.10.040
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   Jia WWG, 2004, CAN J PHYSIOL PHARM, V82, P431, DOI 10.1139/Y04-049
   Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0
   Kim HE, 1999, LIFE SCI, V65, pPL33, DOI 10.1016/S0024-3205(99)00252-0
   Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008
   Liu ZQ, 2003, J AGR FOOD CHEM, V51, P2555, DOI 10.1021/jf026228i
   Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100
   Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020
   Oh M, 1999, INT J ONCOL, V14, P869
   OTA T, 1991, J PHARM SCI, V80, P1141, DOI 10.1002/jps.2600801210
   Park JA, 1997, CANCER LETT, V121, P73, DOI 10.1016/S0304-3835(97)00333-9
   Popovich DG, 2002, ARCH BIOCHEM BIOPHYS, V406, P1, DOI 10.1016/S0003-9861(02)00398-3
   Sanchez-Carbente MR, 2005, CELL DEATH DIFFER, V12, P279, DOI 10.1038/sj.cdd.4401560
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tawab MA, 2003, DRUG METAB DISPOS, V31, P1065, DOI 10.1124/dmd.31.8.1065
   Tsang WP, 2003, LIFE SCI, V73, P2047, DOI 10.1016/S0024-3205(03)00566-6
   Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0
NR 33
TC 48
Z9 52
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
J9 J NAT PROD
JI J. Nat. Prod.
PD FEB
PY 2007
VL 70
IS 2
BP 259
EP 264
DI 10.1021/np060313t
PG 6
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA 138VH
UT WOS:000244390900019
PM 17261067
DA 2022-04-25
ER

PT J
AU Ji, L
   Zhong, B
   Jiang, X
   Mao, F
   Liu, G
   Song, B
   Wang, CY
   Jiao, Y
   Wang, JP
   Xu, ZB
   Li, X
   Zhan, B
AF Ji, Lu
   Zhong, Bing
   Jiang, Xi
   Mao, Fei
   Liu, Gang
   Song, Bin
   Wang, Cheng-Yuan
   Jiao, Yong
   Wang, Jiang-Ping
   Xu, Zhi-Bin
   Li, Xing
   Zhan, Bo
TI Actein induces autophagy and apoptosis in human bladder cancer by
   potentiating ROS/JNK and inhibiting AKT pathways
SO ONCOTARGET
LA English
DT Article
DE human bladder cancer; Actein (ACT); autophagy and apoptosis; ROS and
   JNK; AKT
ID CELL-CYCLE ARREST; CASPASE ACTIVATION; BLACK COHOSH; COLON-CANCER;
   IN-VITRO; CIMICIFUGA-RACEMOSA; SIGNALING PATHWAY; INDUCTION; CDKS;
   EXPRESSION
AB Human bladder cancer is a common genitourinary malignant cancer worldwide. However, new therapeutic strategies are required to overcome its stagnated survival rate. Triterpene glycoside Actein (ACT), extracted from the herb black cohosh, suppresses the growth of human breast cancer cells. Our study attempted to explore the role of ACT in human bladder cancer cell growth and to reveal the underlying molecular mechanisms. We found that ACT significantly impeded the bladder cancer cell proliferation via induction of G2/M cycle arrest. Additionally, ACT administration triggered autophagy and apoptosis in bladder cancer cells, proved by the autophagosome formation, LC3B-II accumulation, improved cleavage of Caspases/poly (ADP-ribose) polymerase (PARP). Furthermore, reduction of reactive oxygen species (ROS) and p-c-Jun N-terminal kinase (JNK) could markedly reverse ACT-induced autophagy and apoptosis. In contrast, AKT and mammalian target of rapamycin (mTOR) were greatly de-phosphorylated by ACT, while suppressing AKT and mTOR activity could enhance the effects of ACT on apoptosis and autophagy induction. In vivo, ACT reduced the tumor growth with little toxicity. Taken together, our findings indicated that ACT suppressed cell proliferation, induced autophagy and apoptosis through promoting ROS/JNK activation, and blunting AKT pathway in human bladder cancer, which indicated that ACT might be an effective candidate against human bladder cancer in future.
C1 [Ji, Lu; Zhong, Bing; Jiang, Xi; Mao, Fei] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Urol, Huaian 223300, Peoples R China.
   [Liu, Gang] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Orthopaed, Huaian 223300, Peoples R China.
   [Song, Bin; Wang, Cheng-Yuan; Jiao, Yong; Wang, Jiang-Ping; Xu, Zhi-Bin; Li, Xing; Zhan, Bo] Far East Biol Prod Co LTD, Branch Raw Mat & Nat Prod, Nanjing 210009, Jiangsu, Peoples R China.
RP Liu, G (corresponding author), Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Orthopaed, Huaian 223300, Peoples R China.
EM 1345297715@qq.com
CR Biers S, 2017, CURR OPIN UROL, V27, P307, DOI 10.1097/MOU.0000000000000391
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chen CY, 2008, FOOD CHEM TOXICOL, V46, P2694, DOI 10.1016/j.fct.2008.04.024
   Chen K, 2015, ACTA PHARMACOL SIN, V36, P1074, DOI 10.1038/aps.2015.44
   Chen SN, 2002, J NAT PROD, V65, P601, DOI 10.1021/np010494t
   Chowdhury IH, 2003, INT J CANCER, V107, P603, DOI 10.1002/ijc.11316
   Duan FS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161886
   Einbond LS, 2013, FITOTERAPIA, V91, P28, DOI 10.1016/j.fitote.2013.07.025
   Einbond LS, 2009, FUND CLIN PHARMACOL, V23, P311, DOI 10.1111/j.1472-8206.2009.00673.x
   Einbond LS, 2004, BREAST CANCER RES TR, V83, P221, DOI 10.1023/B:BREA.0000014043.56230.a3
   Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356
   Gubern A, 2016, MOL CELL, V64, P25, DOI 10.1016/j.molcel.2016.08.015
   Hagen RM, 2013, INT J ONCOL, V43, P194, DOI 10.3892/ijo.2013.1920
   Hiles GL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150138
   Hojeij R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071125
   Hsiao YC, 2007, J BIOMED SCI, V14, P107, DOI 10.1007/s11373-006-9117-3
   Huang AC, 2013, INT J ONCOL, V43, P485, DOI 10.3892/ijo.2013.1952
   Huang SY, 2012, J GEN VIROL, V93, P139, DOI 10.1099/vir.0.034405-0
   Hwang EC, 2017, INT BRAZ J UROL, V43, P615, DOI [10.1590/S1677-5538.IBJU.2016.0274, 10.1590/s1677-5538.ibju.2016.0274]
   Ishaq M, 2014, BBA-GEN SUBJECTS, V1840, P3374, DOI 10.1016/j.bbagen.2014.08.019
   Jeong JW, 2015, PHYTOTHER RES, V29, P1516, DOI 10.1002/ptr.5402
   Jiang B, 2006, J AGR FOOD CHEM, V54, P3242, DOI 10.1021/jf0606149
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Kang N, 2016, MOL CELL BIOCHEM, V415, P145, DOI 10.1007/s11010-016-2686-1
   Kovacs LAS, 2008, CELL CYCLE, V7, P2626, DOI 10.4161/cc.7.17.6515
   Lei FR, 2012, CHINESE MED J-PEKING, V125, P4076, DOI 10.3760/cma.j.issn.0366-6999.2012.22.030
   Li WL, 2016, EXP THER MED, V11, P1259, DOI 10.3892/etm.2016.3054
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Lin MH, 2014, CHEM-BIOL INTERACT, V218, P42, DOI 10.1016/j.cbi.2014.04.015
   Ling H, 2009, MOL CARCINOGEN, V48, P498, DOI 10.1002/mc.20487
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Mazeron R, 2015, BRACHYTHERAPY, V14, P300, DOI 10.1016/j.brachy.2014.10.005
   Ming PH, 2016, ONCOTARGET, V7, P41843, DOI 10.18632/oncotarget.9731
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Sanchez-Carranza JN, 2017, MOLECULES, V22, DOI 10.3390/molecules22040666
   O'Donnell JS, 2017, SEMIN CANC BIOL
   Orsolic N, 2016, J ENVIRON SCI HEAL A, V51, P776, DOI 10.1080/10934529.2016.1170465
   Rao PC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694565
   Ren SX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131750
   Risal S, 2016, METHODS MOL BIOL, V1336, P155, DOI 10.1007/978-1-4939-2926-9_13
   Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007
   Shi LY, 2015, CANCER BIOTHER RADIO, V30, P33, DOI 10.1089/cbr.2014.1704
   Suh KS, 2017, J SCI FOOD AGR, V97, P207, DOI 10.1002/jsfa.7713
   Sun ZL, 2017, BIOMED PHARMACOTHER, V85, P303, DOI 10.1016/j.biopha.2016.11.030
   Tian Z, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-237
   Tsai JR, 2014, ARCH PHARM RES, V37, P548, DOI 10.1007/s12272-013-0232-1
   Wang YW, 2015, ANTI-CANCER DRUG, V26, P428, DOI 10.1097/CAD.0000000000000203
   Watanabe K, 2002, CHEM PHARM BULL, V50, P121, DOI 10.1248/cpb.50.121
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Wong CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159352
   Wu DS, 2016, MOLECULES, V21, DOI 10.3390/molecules21081001
   Wu GY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-167
   Wu YR, 2016, AUTOPHAGY, V12, P1105, DOI 10.1080/15548627.2016.1173798
   Xi R, 2017, BIOMED PHARMACOTHER, V88, P242, DOI 10.1016/j.biopha.2017.01.038
   Xiao W, 2015, TUMOUR BIOL
   Xie ZZ, 2017, CHEM-BIOL INTERACT, V264, P1, DOI 10.1016/j.cbi.2017.01.004
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xu Dong-Wei, 2015, Asian Pac J Cancer Prev, V16, P2167
   Xu LM, 2016, TUMOR BIOL, V37, P8721, DOI 10.1007/s13277-015-4737-8
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130
   Yang ZC, 2018, BIOCHEM BIOPH RES CO, V497, P1177, DOI 10.1016/j.bbrc.2016.11.162
   Zepelin HHHV, 2007, INT J CLIN PHARM TH, V45, P143
   Zhang JY, 2017, ONCOTARGET, V8, P29125, DOI 10.18632/oncotarget.16250
   Zhang LL, 2011, PHYTOTHER RES, V25, P1551, DOI 10.1002/ptr.3534
   Zhang SY, 2016, TUMOR BIOL, V37, P5165, DOI 10.1007/s13277-015-4375-1
   Zhang X, 2015, SCI REP-UK, V5, DOI [10.1038/srep09803, 10.1038/srep09940]
   Zhang YH, 2017, ONCOL REP, V37, P3509, DOI 10.3892/or.2017.5582
   Zhao RL, 2015, J CANCER, V6, P623, DOI 10.7150/jca.11291
   Zhu X, 2014, TOXICOL LETT, V227, P65, DOI 10.1016/j.toxlet.2014.03.015
NR 72
TC 20
Z9 21
U1 1
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 22
PY 2017
VL 8
IS 68
BP 112498
EP 112515
DI 10.18632/oncotarget.22274
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1WP
UT WOS:000419569800030
PM 29348843
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, J
   Jiang, ZL
   Lam, W
   Gullen, EA
   Yu, Z
   Wei, Y
   Wang, LH
   Zeiss, C
   Beck, A
   Cheng, EC
   Wu, CF
   Cheng, YC
   Zhang, YX
AF Wang, Jing
   Jiang, Zaoli
   Lam, Wing
   Gullen, Elizabeth A.
   Yu, Zhe
   Wei, Ying
   Wang, Lihui
   Zeiss, Caroline
   Beck, Amanda
   Cheng, Ee-Chun
   Wu, Chunfu
   Cheng, Yung-Chi
   Zhang, Yixuan
TI Study of Malformin C, a Fungal Source Cyclic Pentapeptide, as an
   Anti-Cancer Drug
SO PLOS ONE
LA English
DT Article
ID DNA-DAMAGE; CELLS; TROXACITABINE; ACTIVATION; METABOLITE; EXPRESSION;
   CANCER; KINASE
AB Malformin C, a fungal cyclic pentapeptide, has been claimed to have anti-cancer potential, but no in vivo study was available to substantiate this property. Therefore, we conducted in vitro and in vivo experiments to investigate its anti-cancer effects and toxicity. Our studies showed Malformin C inhibited Colon 38 and HCT 116 cell growth dose-dependently with an IC50 of 0.27 +/- 0.07 mu M and 0.18 +/- 0.023 mu M respectively. This inhibition was explicated by Malformin C's effect on G2/M arrest. Moreover, we observed up-regulated expression of phospho-histone H2A.X, p53, cleaved CASPASE 3 and LC3 after Malformin C treatment, while the apoptosis assay indicated an increased population of necrotic and late apoptotic cells. In vivo, the pathological study exhibited the acute toxicity of Malformin C at lethal dosage in BDF1 mice might be caused by an acute yet subtle inflammatory response, consistent with elevated IL-6 in the plasma cytokine assay. Further anti-tumor and toxicity experiments proved that 0.3mg/kg injected weekly was the best therapeutic dosage of Malformin C in Colon 38 xenografted BDF1 mice, whereas 0.1mg/kg every other day showed no effect with higher resistance, and 0.9mg/kg per week either led to fatal toxicity in seven-week old mice or displayed no advantage over 0.3mg/kg group in nine-week old mice. Overall, we conclude that Malformin C arrests Colon 38 cells in G2/M phase and induces multiple forms of cell death through necrosis, apoptosis and autophagy. Malformin C has potent cell growth inhibition activity, but the therapeutic index is too low to be an anti-cancer drug.
C1 [Wang, Jing; Jiang, Zaoli; Lam, Wing; Gullen, Elizabeth A.; Cheng, Ee-Chun; Cheng, Yung-Chi] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.
   [Yu, Zhe; Wei, Ying; Wang, Lihui; Wu, Chunfu; Zhang, Yixuan] Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Shenyang, Peoples R China.
   [Zeiss, Caroline; Beck, Amanda] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06510 USA.
   [Wang, Jing] Beijing Univ Chinese Med, Dept Hematol & Oncol, Dongzhimen Hosp, Beijing, Peoples R China.
RP Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.
EM yccheng@yale.edu; zhangyxzsh@163.com
RI Beck, Amanda P/H-9573-2017
OI Beck, Amanda P/0000-0003-1867-4110; Wang, Jing/0000-0002-2735-7283
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA-154295]; Yung-Chi Cheng's lab at Yale University; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA154295] Funding Source: NIH RePORTER
FX Yung-Chi Cheng is a Fellow of the National Foundation for Cancer
   Research, USA. Part of his salary is from the NCI grant from CA-154295.
   Most of the research support is funded by a trust fund to Yung-Chi
   Cheng's lab at Yale University. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderegg RJ, 1976, J AM CHEM SOC, V26, P6
   Beidler DR, 1996, CANCER RES, V56, P9
   BODANSZK.M, 1974, P NATL ACAD SCI USA, V71, P2791, DOI 10.1073/pnas.71.7.2791
   Chen HX, 1993, CANCER RES, V53, P4
   CURTIS RW, 1958, PLANT PHYSIOL, V33, P17, DOI 10.1104/pp.33.1.17
   CURTIS RW, 1958, SCIENCE, V128, P661, DOI 10.1126/science.128.3325.661
   Ferguson PJ, 1988, CANCER RES, V48, P9
   Gaj CL, 1998, BIOCHEM PHARMACOL, V55, P13
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Gao WL, 2004, CANCER RES, V64, P678, DOI 10.1158/0008-5472.CAN-03-1904
   Giles FJ, 2002, J CLIN ONCOLOGY OFFI, V20, P8
   Grove KL, 1996, CANCER RES, V56, P5
   Hagimori K, 2007, BIOL PHARM BULL, V30, P1379, DOI 10.1248/bpb.30.1379
   Harrington HA, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-26
   HERBERT JM, 1994, BIOCHEM PHARMACOL, V48, P1211, DOI 10.1016/0006-2952(94)90158-9
   JOHN WW, 1974, EXPERIENTIA, V30, P1392, DOI 10.1007/BF01919652
   KIM KW, 1993, BIOSCI BIOTECH BIOCH, V57, P787, DOI 10.1271/bbb.57.787
   KOBBE B, 1977, APPL ENVIRON MICROB, V33, P996, DOI 10.1128/AEM.33.4.996-997.1977
   Koizumi Y, 2002, J ANTIBIOT, V55, P78, DOI 10.7164/antibiotics.55.78
   Koizumi Y, 2011, BIOL PHARM BULL, V34, P1426, DOI 10.1248/bpb.34.1426
   Kojima Y, 2008, J ANTIBIOT, V61, P297, DOI 10.1038/ja.2008.42
   Kojima Y, 2009, J ANTIBIOT, V62, P681, DOI 10.1038/ja.2009.100
   Lam W, 2009, MOL CANCER THER, V8, P415, DOI 10.1158/1535-7163.MCT-08-0692
   Lapointe R, 2005, ANN ONCOL, V16, P289, DOI 10.1093/annonc/mdi061
   Lee Y, 2004, J MED CHEM, V47, P5555, DOI 10.1021/jm049949c
   Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Morimoto-Tomita M, 2005, CLIN EXP METASTAS, V22, P513, DOI 10.1007/s10585-005-3585-0
   Park SY, 2002, CANCER RES, V62, P7
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   SUDA S, 1966, APPL MICROBIOL, V14, P475, DOI 10.1128/AEM.14.3.475-476.1966
   Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277
   Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021
   Zhan JX, 2007, PHYTOCHEMISTRY, V68, P368, DOI 10.1016/j.phytochem.2006.09.038
NR 36
TC 13
Z9 25
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 5
PY 2015
VL 10
IS 11
AR e0140069
DI 10.1371/journal.pone.0140069
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV5IS
UT WOS:000364303800003
PM 26540166
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Martinez-Reyes, I
   Sanchez-Arago, M
   Cuezva, JM
AF Martinez-Reyes, Inmaculada
   Sanchez-Arago, Maria
   Cuezva, Jose M.
TI AMPK and GCN2-ATF4 signal the repression of mitochondria in colon cancer
   cells
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE ATP synthase; cancer; cellular stress; glycolysis; mitochondrion;
   translational control
ID ACTIVATED PROTEIN-KINASE; BETA-F1-ATPASE MESSENGER-RNA; BIOENERGETIC
   SIGNATURE; TRANSLATIONAL EFFICIENCY; MAMMALIAN TARGET; GENE-EXPRESSION;
   ATP SYNTHASE; ENERGY; BIOGENESIS; INHIBITION
AB Reprogramming of energetic metabolism is a phenotypic trait of cancer in which mitochondrial dysfunction represents a key event in tumour progression. In the present study, we show that the acquisition of the tumour-promoting phenotype in colon cancer HCT116 cells treated with oligomycin to inhibit ATP synthase is exerted by repression of the synthesis of nuclear-encoded mitochondrial proteins in a process that is regulated at the level of translation. Remarkably, the synthesis of glycolytic proteins is not affected in this situation. Changes in translational control of mitochondrial proteins are signalled by the activation of AMPK (AMP-activated protein kinase) and the GCN2 (general control non-derepressible 2) kinase, leading also to the activation of autophagy. Changes in the bioenergetic function of mitochondria are mimicked by the activation of AMPK and the silencing of ATF4 (activating transcription factor 4). These findings emphasize the relevance of translational control for normal mitochondria] function and for the progression of cancer. Moreover, they demonstrate that glycolysis and oxidative phosphorylation are controlled at different levels of gene expression, offering the cell a mechanistic safeguard strategy for metabolic adaptation under stressful conditions.
C1 [Martinez-Reyes, Inmaculada; Sanchez-Arago, Maria; Cuezva, Jose M.] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa,CSIC UAM,Inst Invest Ho, Ctr Invest Biomed Red Enfermedades Raras CIBERER, E-28049 Madrid, Spain.
RP Cuezva, JM (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa,CSIC UAM,Inst Invest Ho, Ctr Invest Biomed Red Enfermedades Raras CIBERER, E-28049 Madrid, Spain.
EM jmcuezva@cbm.uam.es
RI Cuezva, Jose M/F-8381-2011; Cuezva, Jose M/AAR-5392-2020;
   Martinez-Reyes, Inmaculada/P-9140-2018
OI Martinez-Reyes, Inmaculada/0000-0003-0479-1535; Cuezva Marcos, Jose
   Manuel/0000-0003-1118-248X
FU Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission
   [BFU2010-18903]; Centro de Investigacion Biomedica en Red de
   Enfermedades Raras (CIBERER) del ISCIII; Comunidad de MadridComunidad de
   Madrid [S2010/BMD-2402]; Fundacion Ramon Areces; Junta para la
   Ampliacion de Estudios (JAE)-Consejo Superior de Investigaciones
   Cientificas (CSIC)
FX This work was supported by grants from the Ministerio de Educacion y
   Ciencia [grant number BFU2010-18903], the Centro de Investigacion
   Biomedica en Red de Enfermedades Raras (CIBERER) del ISCIII, and the
   Comunidad de Madrid [grant number S2010/BMD-2402]. The Centro de
   Biologia Molecular Severo Ochoa receives an institutional grant from
   Fundacion Ramon Areces. I.M.-R. is the recipient of a pre-doctoral
   fellowship from Junta para la Ampliacion de Estudios (JAE)-Consejo
   Superior de Investigaciones Cientificas (CSIC).
CR Acebo P, 2009, TRANSL ONCOL, V2, P138, DOI 10.1593/tlo.09106
   Baba Y, 2010, BRIT J CANCER, V103, P1025, DOI 10.1038/sj.bjc.6605846
   Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x
   Berlanga JJ, 2006, EMBO J, V25, P1730, DOI 10.1038/sj.emboj.7601073
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717
   Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99
   Buckendahl AC, 2011, ONCOL REP, V25, P1005, DOI 10.3892/or.2011.1162
   Cuezva JM, 2002, CANCER RES, V62, P6674
   Cuezva JM, 2009, BBA-MOL BASIS DIS, V1792, P1145, DOI 10.1016/j.bbadis.2009.01.006
   de Heredia ML, 2000, J BIOL CHEM, V275, P7430, DOI 10.1074/jbc.275.10.7430
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167
   Gong YQ, 2005, AM J PHYSIOL-CELL PH, V288, pC1023, DOI 10.1152/ajpcell.00443.2004
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hao WS, 2010, J BIOL CHEM, V285, P12647, DOI 10.1074/jbc.M109.084194
   Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Izquierdo JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P481, DOI 10.1016/j.abb.2004.10.007
   Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255
   IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Lopez-Rios F, 2007, CANCER RES, V67, P9013, DOI 10.1158/0008-5472.CAN-07-1678
   Margeot A, 2002, EMBO J, V21, P6893, DOI 10.1093/emboj/cdf690
   Martinez-Diez M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000107
   Ortega AD, 2008, CARCINOGENESIS, V29, P2053, DOI 10.1093/carcin/bgn185
   Ortega AD, 2010, J CELL SCI, V123, P2685, DOI 10.1242/jcs.065920
   Ouchi N, 2005, CIRC RES, V96, P838, DOI 10.1161/01.RES.0000163633.10240.3b
   Sanchez-Arago M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-19
   Sanchez-Arago M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012
   Sanchez-Cenizo L, 2010, J BIOL CHEM, V285, P25308, DOI 10.1074/jbc.M110.146480
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200
   Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300
   Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824
   TVRDIK P, 1992, FEBS LETT, V313, P23, DOI 10.1016/0014-5793(92)81175-L
   van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002
   Willers IM, 2011, BBA-BIOENERGETICS, V1807, P543, DOI 10.1016/j.bbabio.2010.10.016
   Willers IM, 2010, BIOCHEM J, V426, P319, DOI 10.1042/BJ20091570
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
   Yun H, 2005, J BIOL CHEM, V280, P9963, DOI 10.1074/jbc.M412994200
NR 49
TC 49
Z9 50
U1 0
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD JUN 1
PY 2012
VL 444
BP 249
EP 259
DI 10.1042/BJ20111829
PN 2
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 950IQ
UT WOS:000304643200011
PM 22435535
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Ma, D
   Tremblay, P
   Mahngar, K
   Akbari-Asl, P
   Collins, J
   Hudlicky, T
   McNulty, J
   Pandey, S
AF Ma, Dennis
   Tremblay, Phillip
   Mahngar, Kevinjeet
   Akbari-Asl, Pardis
   Collins, Jonathan
   Hudlicky, Tomas
   McNulty, James
   Pandey, Siyaram
TI A novel synthetic C-1 analogue of 7-deoxypancratistatin induces
   apoptosis in p53 positive and negative human colorectal cancer cells by
   targeting the mitochondria: enhancement of activity by tamoxifen
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Colorectal cancer; Tamoxifen; Combination therapy; Apoptosis; Autophagy
ID BIOLOGICAL EVALUATION; 1ST-LINE TREATMENT; ENDOCRINE THERAPY;
   OXIDATIVE-STRESS; DNA MUTATIONS; BCL-2 FAMILY; COMPLEX-I;
   PANCRATISTATIN; LEUCOVORIN; ROS
AB The natural compound pancratistatin (PST), isolated from the Hymenocallis littoralis plant, specifically induces apoptosis in many cancer cell lines. Unlike many other chemotherapeutics, PST is not genotoxic and has minimal adverse effects on non-cancerous cells. However, its availability for preclinical and clinical work is limited due to its low availability in its natural source and difficulties in its chemical synthesis. Several synthetic analogues of 7-deoxypancratistatin with different modifications at C-1 were synthesized and screened for apoptosis inducing activity in human colorectal cancer (CRC) cells. We found that a C-1 acetoxymethyl derivative of 7-deoxypancratistatin, JC-TH-acetate-4 (JCTH-4), was effective in inducing apoptosis in both p53 positive (HCT 116) and p53 negative (HT-29) human CRC cell lines, demonstrating similar efficacy to that of natural PST. JCTH-4 was able to decrease mitochondrial membrane potential (MMP), increase levels of reactive oxygen species in isolated mitochondria, cause release of the apoptogenic factor cytochrome c (Cyto c) from isolated mitochondria, and induce autophagy in HCT 116 and HT-29 cells. Interestingly, when JCTH-4 was administered with tamoxifen (TAM), there was an enhanced effect in apoptosis induction, reactive oxygen species (ROS) production and Cyto c release by isolated mitochondria, and autophagic induction by CRC cells. Minimal toxicity was exhibited by a normal human fetal fibroblast (NFF) and a normal colon fibroblast (CCD-18Co) cell line. Hence, JCTH-4 is a novel compound capable of selectively inducing apoptosis and autophagy in CRC cells alone and in combination with TAM and may serve as a safer and more effective alternative to current cancer therapies.
C1 [Ma, Dennis; Tremblay, Phillip; Mahngar, Kevinjeet; Akbari-Asl, Pardis; Pandey, Siyaram] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.
   [Collins, Jonathan; Hudlicky, Tomas] Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada.
   [Collins, Jonathan; Hudlicky, Tomas] Brock Univ, Ctr Biotechnol, St Catharines, ON L2S 3A1, Canada.
   [McNulty, James] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
RP Pandey, S (corresponding author), Univ Windsor, Dept Chem & Biochem, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.
EM thudlicky@brocku.ca; jmcnult@mcmaster.ca; spandey@uwindsor.ca
RI Pandey, Siyaram/AAI-5491-2020; McNulty, James/E-7871-2011
OI Collins, Jonathan/0000-0002-5591-5772
FU Knights of Columbus Chapter 9671 (Windsor, Ontario); NSERCNatural
   Sciences and Engineering Research Council of Canada (NSERC);
   CIHRCanadian Institutes of Health Research (CIHR)
FX This work has been supported by the Knights of Columbus Chapter 9671
   (Windsor, Ontario), NSERC, and a CIHR Frederick Banting and Charles Best
   Canada Graduate Scholarship awarded to Dennis Ma. Thank you to Carly
   Griffin for providing the pancratistatin results presented in this
   manuscript. We would also like to thank Colleen Mailloux for the
   critical review of this manuscript.
CR Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005
   Andre T, 1999, EUR J CANCER, V35, P1343, DOI 10.1016/S0959-8049(99)00150-1
   Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200
   Baum M, 2005, EUR J CANCER, V41, P1667, DOI 10.1016/j.ejca.2005.05.006
   Berridge MV, 2009, MOL NUTR FOOD RES, V53, P76, DOI 10.1002/mnfr.200700493
   Borst P, 2004, DRUG RESIST UPDATE, V7, P321, DOI 10.1016/j.drup.2004.11.003
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Bruning A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2602
   Carew JS, 2003, LEUKEMIA, V17, P1437, DOI 10.1038/sj.leu.2403043
   Chatterjee SJ, 2010, MELANOMA RES    0317
   Chen G, 2010, MITOCHONDRION   0814
   Chen G, 2009, ANTIOXID REDOX SIGN, V11, P1083, DOI [10.1089/ars.2008.2321, 10.1089/ARS.2008.2321]
   Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Collins J, 2010, J ORG CHEM, V75, P3069, DOI 10.1021/jo1003136
   Corsi L, 2008, CURR CLIN PHARMACOL, V3, P38, DOI 10.2174/157488408783329878
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015
   Fang YJ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-132
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Griffin C, 2011, MOL CANCER THER, V10, P57, DOI 10.1158/1535-7163.MCT-10-0735
   Gueorguieva D, 2006, FASEB J, V20, P2636, DOI 10.1096/fj.06-6306fje
   Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Janakiram NB, 2009, CANCER PREV RES, V2, P52, DOI 10.1158/1940-6207.CAPR-08-0140
   Kekre N, 2005, CANCER CHEMOTH PHARM, V56, P29, DOI 10.1007/s00280-004-0941-8
   Kim GJ, 2006, MUTAGENESIS, V21, P361, DOI 10.1093/mutage/gel048
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259
   Leber B, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001572
   Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057
   Maindrault-Goebel F, 1999, EUR J CANCER, V35, P1338, DOI 10.1016/S0959-8049(99)00149-5
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   McLachlan A, 2005, APOPTOSIS, V10, P619, DOI 10.1007/s10495-005-1896-x
   McNulty J, 2005, BIOORG MED CHEM LETT, V15, P5315, DOI 10.1016/j.bmcl.2005.08.024
   McNulty J, 2008, J NAT PROD, V71, P357, DOI 10.1021/np0705460
   Meffert G, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-9
   MIYASHITA T, 1995, CELL, V80, P293
   Moreira PI, 2006, J BIOL CHEM, V281, P10143, DOI 10.1074/jbc.M510249200
   Murphy Janet E, 2010, Expert Rev Anticancer Ther, V10, P1371, DOI 10.1586/era.10.123
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Palmieri D, 2009, MOL CANCER RES, V7, P1438, DOI 10.1158/1541-7786.MCR-09-0234
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Patel BP, 2007, INTEGR CANCER THER, V6, P365, DOI 10.1177/1534735407309760
   Pedersen PL, 2008, J BIOENERG BIOMEMBR, V40, P123, DOI 10.1007/s10863-008-9165-7
   Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998
   Siedlakowski P, 2008, CANCER BIOL THER, V7, P376, DOI 10.4161/cbt.7.3.5364
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
NR 55
TC 14
Z9 15
U1 0
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD JUN
PY 2012
VL 30
IS 3
BP 1012
EP 1027
DI 10.1007/s10637-011-9668-7
PG 16
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 940GT
UT WOS:000303878700016
PM 21494837
DA 2022-04-25
ER

PT J
AU Li, XN
   Wong, CC
   Tang, Z
   Wu, JL
   Li, SF
   Qian, Y
   Xu, JY
   Yang, ZY
   Shen, Y
   Yu, J
   Cai, ZW
AF Li, Xiaona
   Wong, Chi Chun
   Tang, Zhi
   Wu, Jianlin
   Li, Shangfu
   Qian, Yun
   Xu, Jiaying
   Yang, Zhiyi
   Shen, Yang
   Yu, Jun
   Cai, Zongwei
TI Determination of amino acids in colon cancer cells by using UHPLC-MS/MS
   and [U-C-13(5)]-glutamine as the isotope tracer
SO TALANTA
LA English
DT Article
DE Amino acids; C-13(5)-glutamine isotope tracer;
   Glutaminolysis-inhibition; Hydrophilic interaction liquid
   chromatography; Mass spectrometry
ID TANDEM MASS-SPECTROMETRY; COLORECTAL-CANCER; UREA CYCLE; CHROMATOGRAPHY;
   METABOLISM; DERIVATIZATION; AUTOPHAGY; STANDARD; TISSUE; FLUIDS
AB Rapid and simple quantitative analysis of intracellular metabolites is a critical tool for monitoring the alteration of biologically significant metabolites in cell lines or in vivo. We established an ultra-high performance liquid chromatography (UHPLC) method, equipped with hydrophilic interaction liquid chromatography (HILIC) column coupled to tandem mass spectrometry (MS/MS) for the simultaneous determination of 19 amino acids and 2 related derivatives in human cell lines. Chromatographic separation was achieved within 20 min using a BEH amide column, with aqueous mobile phase containing 20 mM ammonium acetate and 20 mM ammonium hydroxide, and acetonitrile as the organic mobile'phase. Amino acids were analyzed in positive ion multiple reaction monitoring (MRM) mode without the need of derivatization. Intra- and inter-day precisions were less than 13.7%. The method was successfully applied to simultaneously detect the 21 compounds in a human colon cancer cell line DLD1. Moreover, metabolite fate of glutamine-derived carbons into amino acids in DLD1 cells was successfully traced by using [U-C-13(5)]glutamine as the isotope tracer. Metabolic consequences of glutaminolysis inhibition on amino acid metabolism were evaluated. Analysis of C-12- and U-C-13-labeled amino acids revealed the significantly decreased incorporation of [U-(13)C5]-glutamine derived carbons into aspartate, alanine and ornithine, indicating impaired metabolic flux via the tricarboxylic acid cycle and the urea cycle.
C1 [Li, Xiaona; Tang, Zhi; Li, Shangfu; Yang, Zhiyi; Shen, Yang; Cai, Zongwei] Hong Kong Baptist Univ, Dept Chem, State Key Lab Environm & Biol Anal, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Chi Chun; Xu, Jiaying; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Chi Chun; Xu, Jiaying; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, State Key Lab Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Wu, Jianlin] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Qian, Yun] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China.
   [Qian, Yun] Zhejiang Univ, Inst Gastroenterol, Hangzhou, Zhejiang, Peoples R China.
RP Cai, ZW (corresponding author), Hong Kong Baptist Univ, Dept Chem, State Key Lab Environm & Biol Anal, Hong Kong, Hong Kong, Peoples R China.
EM zwcai@hkbu.edu.hk
RI Wong, Chi Chun/C-4636-2016; Cai, Zongwei/ABD-4001-2020; Jun,
   Yu/D-8569-2015
OI Cai, Zongwei/0000-0002-8724-7684; Jun, Yu/0000-0001-5008-2153
FU Hong Kong Baptist University [IRMS/13-14/03]; Hong Kong Research Grants
   CouncilHong Kong Research Grants Council [GRF14114615, C2014-14E]; Hong
   Kong PhD Fellowship
FX This work was financially supported by Interdisciplinary Research
   Matching Scheme of Hong Kong Baptist University (IRMS/13-14/03) and Hong
   Kong Research Grants Council (GRF14114615 and C2014-14E). Xiaona Li
   would like to thank the Hong Kong PhD Fellowship Scheme.
CR BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8
   Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016
   Buiarelli F, 2013, TALANTA, V115, P966, DOI 10.1016/j.talanta.2013.07.009
   Buszewski B, 2012, ANAL BIOANAL CHEM, V402, P231, DOI 10.1007/s00216-011-5308-5
   Choudry HA, 2006, J NUTR, V136, p314S, DOI 10.1093/jn/136.1.314S
   Delgado-Povedano MM, 2016, TALANTA, V146, P310, DOI 10.1016/j.talanta.2015.07.066
   EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Guerrasio R, 2014, ANAL BIOANAL CHEM, V406, P915, DOI 10.1007/s00216-013-7456-2
   Harder U, 2011, J CHROMATOGR B, V879, P495, DOI 10.1016/j.jchromb.2011.01.010
   Hou W, 2016, J CHROMATOGR A, V1429, P207, DOI 10.1016/j.chroma.2015.12.031
   How ZT, 2014, J CHROMATOGR A, V1370, P135, DOI 10.1016/j.chroma.2014.10.040
   Johnson DW, 2011, J CHROMATOGR B, V879, P1345, DOI 10.1016/j.jchromb.2010.12.010
   Kvitvang HFN, 2011, ANAL CHEM, V83, P2705, DOI 10.1021/ac103245b
   Leichtle AB, 2012, METABOLOMICS, V8, P643, DOI 10.1007/s11306-011-0357-5
   Luo B, 2007, J CHROMATOGR A, V1147, P153, DOI 10.1016/j.chroma.2007.02.034
   Mayadunne R, 2005, ANAL BIOANAL CHEM, V382, P836, DOI 10.1007/s00216-005-3083-x
   Michalak KP, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964321
   Mitchell S, 2009, HUM MUTAT, V30, P56, DOI 10.1002/humu.20813
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547
   Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003
   Poinsot V, 2010, ELECTROPHORESIS, V31, P105, DOI 10.1002/elps.200900399
   Rebane R, 2012, J CHROMATOGR B, V904, P99, DOI 10.1016/j.jchromb.2012.07.029
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sriboonvorakul N, 2013, J CHROMATOGR B, V941, P116, DOI 10.1016/j.jchromb.2013.10.005
   Tang Z, 2016, TALANTA, V152, P119, DOI 10.1016/j.talanta.2016.01.056
   Thiele B, 2008, ANAL BIOANAL CHEM, V391, P2663, DOI 10.1007/s00216-008-2167-9
   Trygg J., 2005, ANAL CHEM, V77, P8086
   Turkia H, 2015, TALANTA, V131, P366, DOI 10.1016/j.talanta.2014.07.101
   Ubhi BK, 2013, J CHROMATOGR B, V934, P79, DOI 10.1016/j.jchromb.2013.06.026
   United States Food and Drug Administration, 2001, GUID IND BIOAN METH
   Waterval WAH, 2009, CLIN CHIM ACTA, V407, P36, DOI 10.1016/j.cca.2009.06.023
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Wong CC, 2016, GASTROENTEROLOGY
   Yatabe J, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-203
   Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024
NR 37
TC 15
Z9 15
U1 3
U2 91
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD JAN 1
PY 2017
VL 162
BP 285
EP 292
DI 10.1016/j.talanta.2016.10.013
PG 8
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA ED7YN
UT WOS:000389088700039
PM 27837831
DA 2022-04-25
ER

PT J
AU Breininger, SP
   Malcomson, FC
   Afshar, S
   Turnbull, DM
   Greaves, L
   Mathers, JC
AF Breininger, S. P.
   Malcomson, F. C.
   Afshar, S.
   Turnbull, D. M.
   Greaves, L.
   Mathers, J. C.
TI Effects of obesity and weight loss on mitochondrial structure and
   function and implications for colorectal cancer risk
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Summer Meeting of the Nutrition-Society / Conference on Getting Energy
   Balance Right / Postgraduate Symposium
CY JUL 10-12, 2018
CL Univ Leeds, Leeds, ENGLAND
SP Nutr Soc
HO Univ Leeds
DE Obesity; Colorectal cancer; Mitochondria; Bariatric surgery
ID C-REACTIVE PROTEIN; ADIPOSE-TISSUE; SKELETAL-MUSCLE; DNA MUTATIONS;
   FECAL CALPROTECTIN; RESPIRATORY-CHAIN; OXIDATIVE STRESS; HUMAN BREAST;
   LIFE-SPAN; EXPRESSION
AB Colorectal cancer (CRC) is the third most common cancer globally. CRC risk is increased by obesity, and by its lifestyle determinants notably physical inactivity and poor nutrition. Obesity results in increased inflammation and oxidative stress which cause genomic damage and contribute to mitochondrial dysregulation and CRC risk. The mitochondrial dysfunction associated with obesity includes abnormal mitochondrial size, morphology and reduced autophagy, mitochondrial biogenesis and expression of key mitochondrial regulators. Although there is strong evidence that increased adiposity increases CRC risk, evidence for the effects of intentional weight loss on CRC risk is much more limited. In model systems, energy depletion leads to enhanced mitochondrial integrity, capacity, function and biogenesis but the effects of obesity and weight loss on mitochondria in the human colon are not known. We are using weight loss following bariatric surgery to investigate the effects of altered adiposity on mitochondrial structure and function in human colonocytes. In summary, there is strong and consistent evidence in model systems and more limited evidence in human subjects that over-feeding and/or obesity result in mitochondrial dysfunction and that weight loss might mitigate or reverse some of these effects.
C1 [Breininger, S. P.; Malcomson, F. C.; Afshar, S.; Mathers, J. C.] Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Breininger, S. P.; Malcomson, F. C.; Mathers, J. C.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Breininger, S. P.; Turnbull, D. M.; Greaves, L.; Mathers, J. C.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Breininger, S. P.; Malcomson, F. C.; Turnbull, D. M.; Greaves, L.; Mathers, J. C.] Newcastle Univ, LLHW Ctr Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Afshar, S.] North Cumbria Univ Hosp NHS Trust, Cumberland Infirm, Newtown Rd, Carlisle CA2 7HY, England.
RP Breininger, SP (corresponding author), Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Breininger, SP (corresponding author), Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Breininger, SP (corresponding author), Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Breininger, SP (corresponding author), Newcastle Univ, LLHW Ctr Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM s.p.breininger@ncl.ac.uk
OI Greaves, Laura/0000-0002-8071-5916
FU Newcastle University Centre for Ageing and Vitality (Biotechnology and
   Biological Sciences Research Council)UK Research & Innovation
   (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC);
   Newcastle University Centre for Ageing and Vitality (Medical Research
   Council)UK Research & Innovation (UKRI)Medical Research Council UK (MRC)
   [L016354]; Wellcome TrustWellcome TrustEuropean Commission
   [203105/Z/16/Z, 204709/Z/16/Z]; UK NIHR Biomedical Research Centre for
   Ageing and Age-related disease award; Northumbria Healthcare NHS
   Foundation Trust; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [MR/L016354/1, MR/K000608/1, G0800674] Funding Source:
   UKRI
FX This work was supported by the Newcastle University Centre for Ageing
   and Vitality (supported by the Biotechnology and Biological Sciences
   Research Council and Medical Research Council L016354), The Wellcome
   Trust (203105/Z/16/Z and 204709/Z/16/Z), UK NIHR Biomedical Research
   Centre for Ageing and Age-related disease award to the Newcastle upon
   Tyne Hospitals NHS Foundation Trust and by Northumbria Healthcare NHS
   Foundation Trust.
CR Afshar S, 2018, OBES SURG, V28, P945, DOI 10.1007/s11695-017-2953-6
   Afshar S, 2014, OBES SURG, V24, P1793, DOI 10.1007/s11695-014-1359-y
   ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Aravani A, 2018, CANCER EPIDEMIOL, V53, P99, DOI 10.1016/j.canep.2018.01.002
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bach D, 2005, DIABETES, V54, P2685, DOI 10.2337/diabetes.54.9.2685
   Beeken RJ, 2017, OBESITY, V25, pS95, DOI 10.1002/oby.21984
   Bellam N, 2010, CANCER TREAT RES, V155, P85, DOI 10.1007/978-1-4419-6033-7_5
   Birch-Machin MA, 2010, MUTAGENESIS, V25, P101, DOI 10.1093/mutage/gep061
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026
   Brookheart RT, 2017, BBA-MOL BASIS DIS, V1863, P1255, DOI 10.1016/j.bbadis.2017.03.014
   Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296
   Cakir Y, 2007, FREE RADICAL BIO MED, V43, P1279, DOI 10.1016/j.freeradbiomed.2007.07.015
   Camastra S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08444-6
   Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   CASE JT, 1981, SOMAT CELL GENET, V7, P103, DOI 10.1007/BF01544751
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Cheng ZY, 2014, CELL CYCLE, V13, P890, DOI 10.4161/cc.28189
   Choo HJ, 2006, DIABETOLOGIA, V49, P784, DOI 10.1007/s00125-006-0170-2
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   Coen PM, 2015, DIABETES, V64, P3737, DOI 10.2337/db15-0809
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Das N, 2017, FOOD FUNCT, V8, P1577, DOI 10.1039/c6fo01326k
   de la Escalera LM, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0797-5
   de Mello AH, 2018, LIFE SCI, V192, P26, DOI 10.1016/j.lfs.2017.11.019
   Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359
   Devarshi PP, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040831
   Edwards RA, 2009, CANCER RES, V69, P6423, DOI 10.1158/0008-5472.CAN-09-1285
   Ejarque M, 2018, INT J OBES
   Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2
   Erlinger TP, 2004, JAMA-J AM MED ASSOC, V291, P585, DOI 10.1001/jama.291.5.585
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Fernstrom M, 2016, OBES SURG, V26, P1391, DOI 10.1007/s11695-015-1932-z
   Gao CL, 2010, MOL CELL ENDOCRINOL, V320, P25, DOI 10.1016/j.mce.2010.01.039
   Gilkerson R, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011080
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Grady WM, 1998, CANCER RES, V58, P3101
   Greaves LC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004620
   Greaves LC, 2010, EXP GERONTOL, V45, P573, DOI 10.1016/j.exger.2010.01.013
   Gunter MJ, 2006, CANCER RES, V66, P2483, DOI 10.1158/0008-5472.CAN-05-3631
   Guo CA, 2017, J ENDOCRINOL, V233, pR131, DOI 10.1530/JOE-16-0679
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Heinonen S, 2015, DIABETES, V64, P3135, DOI 10.2337/db14-1937
   Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jahansouz C, 2015, OBES SURG, V25, P2376, DOI 10.1007/s11695-015-1708-5
   John BJ, 2006, ALIMENT PHARM THER, V23, P1511, DOI 10.1111/j.1365-2036.2006.02915.x
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kant P, 2013, INT J OBESITY, V37, P317, DOI 10.1038/ijo.2012.38
   Kant P, 2011, GUT, V60, P893, DOI 10.1136/gut.2010.230755
   Karahalios A, 2015, AM J EPIDEMIOL, V181, P832, DOI 10.1093/aje/kwu357
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Keum N, 2015, ANN ONCOL, V26, P1101, DOI 10.1093/annonc/mdu563
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kras KA, 2018, METABOLISM, V89, P18, DOI 10.1016/j.metabol.2018.09.006
   Lakhdar N, 2013, INFLAMMATION, V36, P1239, DOI 10.1007/s10753-013-9661-8
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lee JY, 2014, J CELL SCI, V127, P4954, DOI 10.1242/jcs.157321
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liu RH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092810
   Ma YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053916
   Machado AMD, 2010, BBA-REV CANCER, V1806, P58, DOI 10.1016/j.bbcan.2010.01.007
   Martin-Montalvo A, 2013, ANTIOXID REDOX SIGN, V19, P310, DOI 10.1089/ars.2012.4866
   Mathers JC, 2018, NUTR RES NEW YORK NY
   McKiernan SH, 2011, EXP GERONTOL, V46, P23, DOI 10.1016/j.exger.2010.09.011
   Moreno-Castellanos N, 2016, OBES SURG, V26, P1757, DOI 10.1007/s11695-015-1995-x
   Mundade Rasika, 2014, Oncoscience, V1, P400
   Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544
   Nimri L, 2015, ONCOTARGET, V6, P38195, DOI 10.18632/oncotarget.5561
   Ning Y, 2010, OBES REV, V11, P19, DOI 10.1111/j.1467-789X.2009.00613.x
   Nishida K, 2017, CARDIOVASC RES, V113, P389, DOI 10.1093/cvr/cvx012
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Omata F, 2013, SCAND J GASTROENTERO, V48, P136, DOI 10.3109/00365521.2012.737364
   Otani T, 2006, CANCER EPIDEM BIOMAR, V15, P690, DOI 10.1158/1055-9965.EPI-05-0708
   Padidar S, 2008, BBA-MOL BASIS DIS, V1782, P532, DOI 10.1016/j.bbadis.2008.06.002
   Pendyala S, 2011, AM J CLIN NUTR, V93, P234, DOI 10.3945/ajcn.110.002683
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Poullis A, 2004, CANCER EPIDEM BIOMAR, V13, P279, DOI 10.1158/1055-9965.EPI-03-0160
   Prior SL, 2006, CARCINOGENESIS, V27, P945, DOI 10.1093/carcin/bgi326
   Putti R, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00109
   Raffaello A, 2011, BBA-MOL CELL RES, V1813, P260, DOI 10.1016/j.bbamcr.2010.10.007
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Reznick RM, 2007, CELL METAB, V5, P151, DOI 10.1016/j.cmet.2007.01.008
   Rogge MM, 2009, BIOL RES NURS, V10, P356, DOI 10.1177/1099800408329408
   Sainsbury A, 2008, CANCER EPIDEM BIOMAR, V17, P1401, DOI 10.1158/1055-9965.EPI-07-2874
   Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482
   SHADEL GS, 1993, J BIOL CHEM, V268, P16083
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Sousa JS, 2018, SUBCELL BIOCHEM, V87, P167, DOI 10.1007/978-981-10-7757-9_7
   Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Stewart LK, 2009, DIABETOLOGIA, V52, P514, DOI 10.1007/s00125-008-1252-0
   Sutherland LN, 2008, AM J PHYSIOL-ENDOC M, V295, pE1076, DOI 10.1152/ajpendo.90408.2008
   Szabo N, 2018, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00138
   Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0
   Tan DJ, 2008, CARCINOGENESIS, V29, P1170, DOI 10.1093/carcin/bgn034
   Toledo FGS, 2008, DIABETES, V57, P987, DOI 10.2337/db07-1429
   Valerio A, 2006, J CLIN INVEST, V116, P2791, DOI 10.1172/JCI28570.
   Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001
   WARBURG O, 1956, SCIENCE, V124, P269
   Wei EK, 2005, CANCER EPIDEM BIOMAR, V14, P850, DOI 10.1158/1055-9965.EPI-04-0661
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   World Cancer Research Fund American Institute for Cancer Research, 2018, DIET NUTR PHYS ACT C
   World Cancer Research Fund and American Institute for Cancer Rsearch, 2007, FOOD NUTR PHYS ACT P
   Yehuda-Shnaidman E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074843
   Yin X, 2014, J CLIN ENDOCR METAB, V99, pE209, DOI 10.1210/jc.2013-3042
   Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034
   Zinovkina LA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P233, DOI 10.1134/S0006297918030045
NR 119
TC 10
Z9 11
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
EI 1475-2719
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD AUG
PY 2019
VL 78
IS 3
BP 426
EP 437
AR PII S0029665119000533
DI 10.1017/S0029665119000533
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Nutrition & Dietetics
GA IO0OP
UT WOS:000479078500019
PM 30898183
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Bertin, S
   Samson, M
   Pons, C
   Guigonis, JM
   Gavelli, A
   Baque, P
   Brossette, N
   Pagnotta, S
   Ricci, JE
   Pierrefite-Carle, V
AF Bertin, Samuel
   Samson, Michel
   Pons, Catherine
   Guigonis, Jean-Marie
   Gavelli, Adolfo
   Baque, Patrick
   Brossette, Nicole
   Pagnotta, Sophie
   Ricci, Jean-Ehrland
   Pierrefite-Carle, Valerie
TI Comparative Proteomics Study Reveals That Bacterial CpG Motifs Induce
   Tumor Cell Autophagy in Vitro and in Vivo
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; IMMUNOMODULATORY OLIGONUCLEOTIDE;
   EXPERIMENTAL-THERAPY; COLON-CANCER; LUNG-CANCER; DNA; DEGRADATION;
   SURVIVAL; PROTEIN; TOLL-LIKE-RECEPTOR-9
AB Unmethylated CpG dinucleotides, present in bacterial DNA, are recognized in vertebrates via the Toll-like receptor 9 (TLR9) and are known to act as an anticancer agent by stimulating immune cells to induce a proinflammatory response. Although the effects of CpG-oligodeoxynucleotides (CpG-ODNs) in immune cells have been widely studied, little is known regarding their molecular effects in TLR9-positive tumor cells. To better understand the role of these bacterial motifs in cancer cells, we analyzed proteome modifications induced in TLR9-positive tumor cells in vitro and in vivo after CpG-ODN treatment in a rat colon carcinoma model. Proteomics analysis of tumor cells by two-dimensional gel electrophoresis followed by mass spectrometry identified several proteins modulated by bacterial CpG motifs. Among them, several are related to autophagy including potential autophagic substrates. In addition, we observed an increased glyceraldehyde-3-phosphate dehydrogenase expression, which has been shown to be sufficient to trigger an autophagic process. Autophagy is a self-digestion pathway whereby cytoplasmic material is sequestered by a structure termed the autophagosome for subsequent degradation and recycling. As bacteria are known to trigger autophagy, we assessed whether bacterial CpG motifs might induce autophagy in TLR9-positive tumor cells. We showed that CpG-ODN can induce autophagy in rodent and human tumor cell lines and was TLR9-dependent. In addition, an increase in the number of autophagosomes can also be observed in vivo after CpG motif intratumoral injection. Our findings bring new insights on the effect of bacterial CpG motifs in tumor cells and may be relevant for cancer treatment and more generally for gene therapy approaches in TLR9-positive tissues. Molecular & Cellular Proteomics 7: 2311-2322, 2008.
C1 [Pierrefite-Carle, Valerie] Fac Med, INSERM, U638, F-06107 Nice 2, France.
   [Bertin, Samuel; Samson, Michel; Pons, Catherine; Guigonis, Jean-Marie; Gavelli, Adolfo; Baque, Patrick; Brossette, Nicole; Pagnotta, Sophie; Ricci, Jean-Ehrland; Pierrefite-Carle, Valerie] Univ Nice Sophia Antipolis, Fac Med, F-06107 Nice, France.
   [Samson, Michel; Guigonis, Jean-Marie] IFR50, F-06107 Nice, France.
   [Gavelli, Adolfo] Ctr Hosp Princesse Grace, Serv Chirurg Gen & Digest, MC-98000 Monaco, Monaco.
   [Baque, Patrick] Hop St Roche, Serv Chirurg Urgence, F-06107 Nice, France.
   [Pagnotta, Sophie] Ctr Commun Microscopie Appl, F-06108 Nice, France.
   [Ricci, Jean-Ehrland] INSERM, U895, Ctr Mediterraneen Med Mol C3M, Cell Death & Survival AVENIR Team, F-06204 Nice 3, France.
RP Pierrefite-Carle, V (corresponding author), Fac Med, INSERM, U638, Ave Valombrose, F-06107 Nice 2, France.
EM pierrefi@unice.fr
RI Pierrefite-Carle, Valerie/N-6329-2017; Ricci, Jean-Ehrland/I-7117-2016;
   RICCI, Jean Ehrland/AAS-4379-2020
OI Pierrefite-Carle, Valerie/0000-0003-3399-2934; Ricci,
   Jean-Ehrland/0000-0003-1585-8117; RICCI, Jean
   Ehrland/0000-0003-1585-8117
FU INSERM, Fondation de l'Avenir, France CancerInstitut National de la
   Sante et de la Recherche Medicale (Inserm); Association pour la
   Recherche sur le CancerFondation ARC pour la Recherche sur le
   CancerAustralian Research CouncilEuropean Commission
FX This work was supported by the INSERM, Fondation de l'Avenir, France
   Cancer, and Association pour la Recherche sur le Cancer. The costs of
   publication of this article were defrayed in part by the payment of page
   charges. This article must therefore be hereby marked "advertisement" in
   accordance with 18 U. S. C. Section 1734 solely to indicate this fact.
CR Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje
   Andersen JM, 2006, BIOL REPROD, V74, P824, DOI 10.1095/biolreprod.105.048629
   Bertin S, 2008, INT J MOL MED, V21, P309
   Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225
   Cayatte C, 2006, MOL CELL PROTEOMICS, V5, P2031, DOI 10.1074/mcp.M600165-MCP200
   CHANDLER CS, 1983, BIOCHEM J, V210, P845, DOI 10.1042/bj2100845
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200
   Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Deretic V, 2006, CURR OPIN IMMUNOL, V18, P375, DOI 10.1016/j.coi.2006.05.019
   Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1
   Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   El Andaloussi A, 2006, GLIA, V54, P526, DOI 10.1002/glia.20401
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784
   Jego G, 2006, LEUKEMIA, V20, P1130, DOI 10.1038/sj.leu.2404226
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Kuo CC, 2005, PROTEOMICS, V5, P894, DOI 10.1002/pmic.200401144
   Lenaerts K, 2006, J PROTEOME RES, V5, P2113, DOI 10.1021/pr060183+
   Li J, 2004, AM J PHYSIOL-LUNG C, V287, pL552, DOI 10.1152/ajplung.00436.2003
   Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   MARTIN F, 1983, INT J CANCER, V32, P623, DOI 10.1002/ijc.2910320517
   Massey A, 2004, INT J BIOCHEM CELL B, V36, P2420, DOI 10.1016/j.biocel.2004.04.010
   Massey AC, 2006, AUTOPHAGY, V2, P325, DOI 10.4161/auto.3090
   Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Pedersen G, 2005, CLIN EXP IMMUNOL, V141, P298, DOI 10.1111/j.1365-2249.2005.02848.x
   Pierrefite-Carle V, 1999, J NATL CANCER I, V91, P2014, DOI 10.1093/jnci/91.23.2014
   Platz J, 2004, J IMMUNOL, V173, P1219, DOI 10.4049/jimmunol.173.2.1219
   Rayburn ER, 2007, INT J ONCOL, V30, P1511
   Rayburn ER, 2006, PROSTATE, V66, P1653, DOI 10.1002/pros.20485
   Scheule RK, 2000, ADV DRUG DELIVER REV, V44, P119, DOI 10.1016/S0169-409X(00)00090-9
   Schmidt C, 2006, J NATL CANCER I, V98, P574, DOI 10.1093/jnci/djj198
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Song SW, 2007, NAT CELL BIOL, V9, P869, DOI 10.1038/ncb0807-869
   Takeshita F, 2004, SEMIN IMMUNOL, V16, P17, DOI 10.1016/j.smim.2003.10.009
   Wang H, 2006, MOL CANCER THER, V5, P2106, DOI 10.1158/1535-7163.MCT-06-0158
   Wang H, 2006, MOL CANCER THER, V5, P1585, DOI 10.1158/1535-7163.MCT-06-0094
   Watts JA, 2004, J MOL CELL CARDIOL, V36, P141, DOI 10.1016/j.yjmcc.2003.10.015
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
NR 46
TC 22
Z9 26
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD DEC
PY 2008
VL 7
IS 12
BP 2311
EP 2322
DI 10.1074/mcp.M800100-MCP200
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 378NK
UT WOS:000261328200002
PM 18632594
OA hybrid
DA 2022-04-25
ER

PT J
AU Martinez-Useros, J
   Garcia-Foncillas, J
AF Martinez-Useros, Javier
   Garcia-Foncillas, Jesus
TI Obesity and colorectal cancer: molecular features of adipose tissue
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Colorectal cancer; Obesity; Overweight; BMI; Adipose tissue; Cytokines;
   Inflammation; 4-HNE; MDA; MPE
ID BODY-MASS INDEX; GROWTH-FACTOR-I; MECHANISMS LINKING OBESITY; ACTIVATED
   PROTEIN-KINASE; NF-KAPPA-B; COLON-CANCER; LIPID-PEROXIDATION;
   PHYSICAL-ACTIVITY; MISMATCH-REPAIR; UNITED-STATES
AB The huge part of population in developed countries is overweight or obese. Obesity is often determined by body mass index (BMI) but new accurate methods and ratios have recently appeared to measure body fat or fat located in the intestines. Early diagnosis of obesity is crucial since it is considered an increasing colorectal cancer risk factor. On the one hand, colorectal cancer has been strongly associated with lifestyle factors. A diet rich in red and processed meats may increase colorectal cancer risk; however, high-fiber diets (grains, cereals and fruits) have been associated with a decreased risk of colorectal cancer. Other life-style factors associated with obesity that also increase colorectal cancer risk are physical inactivity, smoking and high alcohol intake. Cutting-edge studies reported that high-risk transformation ability of adipose tissue is due to production of different pro-inflammatory cytokines like IL-8, IL-6 or IL-2 and other enzymes like lactate dehydrogenase (LDH) and tumour necrosis factor alpha (TNF alpha). Furthermore, oxidative stress produces fatty-acid peroxidation whose metabolites possess very high toxicities and mutagenic properties. 4-hydroxy-2-nonenal (4-HNE) is an active compounds that upregulates prostaglandin E2 which is directly associated with high proliferative colorectal cancer. Moreover, 4-HNE deregulates cell proliferation, cell survival, differentiation, autophagy, senescence, apoptosis and necrosis via mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PIK3CA)-AKT and protein kinase C pathways. Other product of lipid peroxidation is malondialdehyde (MDA) being able to regulate insulin through WNT-pathway as well as having demonstrated its mutagenic capability. Accumulation of point mutation enables genomic evolution of colorectal cancer described in the model of Fearon and Vogelstein. In this review, we will summarize different determination methods and techniques to assess a truthfully diagnosis and we will explain some of the capabilities that performs adipocytes as the largest endocrine organ.
C1 [Martinez-Useros, Javier; Garcia-Foncillas, Jesus] FIIS Fdn Jimenez Diaz, Translat Oncol Div, Oncohlth Inst, Ave Reyes Catolicos 2, Madrid 28040, Spain.
RP Martinez-Useros, J (corresponding author), FIIS Fdn Jimenez Diaz, Translat Oncol Div, Oncohlth Inst, Ave Reyes Catolicos 2, Madrid 28040, Spain.
EM javier.museros@oncohealth.eu
OI J, Garcia-Foncillas/0000-0002-7591-8006
FU RNA-Reg. CONSOLIDER-Consortium of the Spanish Ministry of Economy and
   Competitiveness [CSD2009-00080]
FX The authors wish to thank Ana Martin for valuable assistance during the
   preparation of this review. This work has been carried out with the
   support of the RNA-Reg. CONSOLIDER-Consortium (CSD2009-00080) of the
   Spanish Ministry of Economy and Competitiveness.
CR Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Alliot C, 2005, ANN ONCOL, V16, P1557, DOI 10.1093/annonc/mdi261
   Alliot C, 2005, ANN ONCOL, V16, P1558
   Amato MC, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/730827
   Arem H, 2013, GYNECOL ONCOL, V128, P181, DOI 10.1016/j.ygyno.2012.10.029
   Ashktorab H, 2014, OBESITY, V22, P1387, DOI 10.1002/oby.20702
   Ashwell M, 2012, OBES REV, V13, P275, DOI 10.1111/j.1467-789X.2011.00952.x
   BAKER SJ, 1990, CANCER RES, V50, P7717
   Barcelos RCS, 2014, FOOD CHEM TOXICOL, V69, P38, DOI 10.1016/j.fct.2014.03.031
   Bartoli ML, 2011, MEDIAT INFLAMM, V2011, P16
   Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T
   Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102
   Blair IA, 2008, J BIOL CHEM, V283, P15545, DOI 10.1074/jbc.R700051200
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Bozzetti F, 2013, CRIT REV ONCOL HEMAT, V87, P172, DOI 10.1016/j.critrevonc.2013.03.006
   BRAMBILLA G, 1986, MUTAT RES, V171, P169, DOI 10.1016/0165-1218(86)90051-0
   Brandstedt J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098964
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Caan BJ, 1998, INT J OBESITY, V22, P178, DOI 10.1038/sj.ijo.0800561
   Campbell PT, 2010, JNCI-J NATL CANCER I, V102, P391, DOI 10.1093/jnci/djq011
   Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chan DSM, 2014, ANN ONCOL, V25, P1901, DOI 10.1093/annonc/mdu042
   Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]
   Chia VM, 2007, CANCER EPIDEM BIOMAR, V16, P2697, DOI 10.1158/1055-9965.EPI-07-0467
   Choe EK, 2013, WORLD J GASTROENTERO, V19, P8349, DOI 10.3748/wjg.v19.i45.8349
   Cleary MP, 2009, ENDOCRINOLOGY, V150, P2537, DOI 10.1210/en.2009-0070
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Comstock SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095232
   Comstock SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085939
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Cupul-Uicab LA, 2012, ENVIRON HEALTH PERSP, V120, P355, DOI 10.1289/ehp.1103789
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   DEVERDIER MG, 1990, INT J CANCER, V46, P832, DOI 10.1002/ijc.2910460514
   DGSP, 2007, S 1 LEITL VORS SPORT
   Di Caro G, 2014, EXPERT REV MOL DIAGN, V14, P387, DOI 10.1586/14737159.2014.900443
   DIETZ AT, 1995, CANCER CAUSE CONTROL, V6, P30, DOI 10.1007/BF00051678
   Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045
   ESTERBAUER H, 1990, MUTAT RES, V238, P223, DOI 10.1016/0165-1110(90)90014-3
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fedirko V, 2014, INT J CANCER, V135, P1949, DOI 10.1002/ijc.28841
   Fenton JI, 2008, MOL CARCINOGEN, V47, P9, DOI 10.1002/mc.20357
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Flanagan L, 2014, EUR J CLIN MICROBIOL, V33, P1381, DOI 10.1007/s10096-014-2081-3
   Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355
   Franco M, 2013, BMJ, V2013
   Fruhwirth GO, 2007, BBA-MOL BASIS DIS, V1772, P718, DOI 10.1016/j.bbadis.2007.04.009
   Fuchs MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099816
   FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1
   Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Garcia SC, 2013, DRUG CHEM TOXICOL, V36, P306, DOI 10.3109/01480545.2012.720989
   Gilbert CA, 2013, ANNU REV MED, V64, P45, DOI 10.1146/annurev-med-121211-091527
   GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777
   Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967
   GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Guiu B, 2010, GUT, V59, P341, DOI 10.1136/gut.2009.188946
   Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Ho GYF, 2012, CANCER RES, V72, P3029, DOI 10.1158/0008-5472.CAN-11-2771
   Hursting SD, 2012, ANN NY ACAD SCI, V1271, P82, DOI 10.1111/j.1749-6632.2012.06737.x
   Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008
   Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897
   Ji HP, 2001, HUM MOL GENET, V10, P2737, DOI 10.1093/hmg/10.24.2737
   Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174
   Kim HW, 2014, ENVIRON RES, V135, P354, DOI 10.1016/j.envres.2014.08.032
   Kinnunen PKJ, 2012, BBA-BIOMEMBRANES, V1818, P2446, DOI 10.1016/j.bbamem.2012.04.008
   KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x
   Koshy G, 2011, EUR J PUBLIC HEALTH, V21, P286, DOI 10.1093/eurpub/ckq173
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Krzystek-Korpacka M, 2013, CANCER LETT, V337, P107, DOI 10.1016/j.canlet.2013.05.033
   Kuchiba A, 2012, JNCI-J NATL CANCER I, V104, P415, DOI 10.1093/jnci/djr542
   KUNE GA, 1990, NUTR CANCER, V13, P9, DOI 10.1080/01635589009514041
   Kwon KA, 2015, CANCER RES TREAT, V2015, P024
   LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69
   Leclerc D, 2014, PROTEOMICS, V14, P2558, DOI 10.1002/pmic.201400280
   Lee Chun Seng, 2015, J Gastrointest Cancer, V46, P243, DOI 10.1007/s12029-015-9709-0
   Lee EY, 2009, AUTOIMMUN REV, V8, P379, DOI 10.1016/j.autrev.2008.12.002
   LeMarchand L, 1997, CANCER RES, V57, P4787
   Leung C, 2015, WORLD J GASTROENTERO, V21, P1189, DOI 10.3748/wjg.v21.i4.1189
   Liesenfeld DB, 2015, AM J CLIN NUTR, V102, P433, DOI 10.3945/ajcn.114.103804
   Lin PC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0601-y
   Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Luo FJ, 2011, J PATHOL, V223, P390, DOI 10.1002/path.2790
   Lynch HT, 2008, FAM CANCER, V7, P27, DOI 10.1007/s10689-007-9165-5
   Malietzis G, 2015, EJSO-EUR J SURG ONC, V41, P186, DOI 10.1016/j.ejso.2014.10.056
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2011, NAT MED, V17, P285, DOI 10.1038/nm0311-285
   Marnett LJ, 2002, TOXICOLOGY, V181, P219, DOI 10.1016/S0300-483X(02)00448-1
   Martinez ME, 1999, J NATL CANCER I, V91, P950, DOI 10.1093/jnci/91.11.950
   Merendino RA, 2003, MEDIAT INFLAMM, V12, P127, DOI 10.1080/0962935031000097745
   Meyerhardt JA, 2012, JNCI-J NATL CANCER I, V104, P1702, DOI 10.1093/jnci/djs399
   Michael J Morgan, 2011, Cell Research, V21, P103
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377
   Mirza RE, 2015, CYTOKINE, V71, P409, DOI 10.1016/j.cyto.2014.09.005
   Miyamoto S, 2008, CARCINOGENESIS, V29, P1057, DOI 10.1093/carcin/bgn080
   Morikawa T, 2013, CANCER RES, V73, P1600, DOI 10.1158/0008-5472.CAN-12-2276
   Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193
   Murphy TK, 2000, AM J EPIDEMIOL, V152, P847, DOI 10.1093/aje/152.9.847
   Murray AR, 2007, CHEM RES TOXICOL, V20, P1769, DOI 10.1021/tx700201z
   Nagata N, 2014, INT J CANCER, V135, P2273, DOI 10.1002/ijc.28872
   Newton K, 2014, J MED GENET, V51, P789, DOI 10.1136/jmedgenet-2014-102552
   Niedernhofer LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/jbc.M212549200
   O'Toole A, 2014, BRIT J CANCER, V111, P927, DOI 10.1038/bjc.2014.367
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Ogunwobi OO, 2007, DIGEST DIS SCI, V52, P1934, DOI 10.1007/s10620-007-9784-6
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Orlich MJ, 2015, JAMA INTERN MED, V175, P767, DOI 10.1001/jamainternmed.2015.59
   Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289
   Pang T, 2015, MOL CLIN ONCOL, V3, P308, DOI 10.3892/mco.2014.482
   Paola D, 2000, BIOCHEM BIOPH RES CO, V268, P642, DOI 10.1006/bbrc.2000.2164
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   Park J, 2013, EXPERT REV ANTICANC, V13, P111, DOI [10.1586/ERA.12.164, 10.1586/era.12.164]
   Park J, 2012, J CLIN INVEST, V122, P4243, DOI 10.1172/JCI63930
   Park SW, 2015, J GASTROINTEST SURG, V19, P242, DOI 10.1007/s11605-014-2682-2
   Park-Min KH, 2005, IMMUNOBIOLOGY, V210, P77, DOI 10.1016/j.imbio.2005.05.002
   Parkin DM, 2011, BRIT J CANCER, V105, pS2, DOI 10.1038/bjc.2011.474
   Parkin E, 2014, OBES REV, V15, P434, DOI 10.1111/obr.12140
   Patel GS, 2015, CANCER MED-US, V4, P1461, DOI 10.1002/cam4.490
   PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Pongnimitprasert Nushjira, 2012, ISRN Inflamm, V2012, P481432, DOI 10.5402/2012/481432
   Poulogiannis G, 2010, HISTOPATHOLOGY, V56, P167, DOI 10.1111/j.1365-2559.2009.03392.x
   Prendergast GC, 2014, CANCER IMMUNOL IMMUN, V63, P721, DOI 10.1007/s00262-014-1549-4
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161
   Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11
   Rosati R, 2012, J ONCOL, V2012, DOI 10.1155/2012/105949
   Roth C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015923
   Russo A, 1998, INT J CANCER, V78, P161, DOI 10.1002/(SICI)1097-0215(19981005)78:2&lt;161::AID-IJC7&gt;3.0.CO;2-X
   Sahin IH, 2013, GUT, V62, P1670, DOI 10.1136/gutjnl-2013-304781
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sanchez-de-Abajo A, 2007, CLIN CANCER RES, V13, P5729, DOI 10.1158/1078-0432.CCR-06-2996
   Santarpia L, 2011, J CACHEXIA SARCOPENI, V2, P27, DOI 10.1007/s13539-011-0022-x
   Satia JA, 2005, CANCER EPIDEM BIOMAR, V14, P429, DOI 10.1158/1055-9965.EPI-04-0486
   Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591
   Schneider HJ, 2010, J CLIN ENDOCR METAB, V95, P1777, DOI 10.1210/jc.2009-1584
   Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147
   Schoen RE, 2005, GASTROENTEROLOGY, V129, P464, DOI 10.1053/j.gastro.2005.05.051
   Schulz MD, 2014, NATURE, V514, P508, DOI 10.1038/nature13398
   Sekharam M, 2003, CANCER RES, V63, P7708
   Shah MS, 2015, CANCER-AM CANCER SOC, V121, P2968, DOI 10.1002/cncr.29440
   Shah MS, 2015, CANCER, V2015, P29440
   Shanmugam N, 2008, DIABETES, V57, P879, DOI 10.2337/db07-1204
   Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008
   She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006
   Shi Q, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2066
   Shu L, 2015, CURR STEM CELL RES T, V2015, P30
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Simpson ER, 2004, SEMIN REPROD MED, V22, P11
   Slattery ML, 2012, CARCINOGENESIS, V33, P2398, DOI 10.1093/carcin/bgs305
   Slattery ML, 2000, J NATL CANCER I, V92, P1831, DOI 10.1093/jnci/92.22.1831
   Slattery ML, 1997, CANCER CAUSE CONTROL, V8, P872, DOI 10.1023/A:1018416412906
   Song MY, 2016, INT J EPIDEMIOL, V45, P871, DOI 10.1093/ije/dyv177
   Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006
   Sram RJ, 2009, MUTAT RES-GEN TOX EN, V672, P129, DOI 10.1016/j.mrgentox.2008.11.005
   Tahara T, 2014, CANCER RES, V74, P1311, DOI 10.1158/0008-5472.CAN-13-1865
   Tandon K, 2015, WORLD J GASTROENTERO, V21, P1371, DOI 10.3748/wjg.v21.i5.1371
   Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001
   Tchernof A, 2015, J STEROID BIOCHEM, V147, P56, DOI 10.1016/j.jsbmb.2014.11.011
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Thrift AP, 2015, CANCER EPIDEM BIOMAR, V2015, P14
   TRICOLI JV, 1986, CANCER RES, V46, P6169
   Trojan J, 2004, INT J COLORECTAL DIS, V19, P538, DOI 10.1007/s00384-004-0597-1
   Uchida Koji, 2003, Molecular Aspects of Medicine, V24, P213, DOI 10.1016/S0098-2997(03)00016-5
   Vazzana N, 2012, CURR MED CHEM, V19, P5837, DOI 10.2174/092986712804143349
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Volgyi E, 2008, OBESITY, V16, P700, DOI 10.1038/oby.2007.94
   Volkova E, 2011, BRIT J CANCER, V104, P51, DOI 10.1038/sj.bjc.6606005
   Volkova E, 2014, ONCOL LETT, V7, P311, DOI 10.3892/ol.2013.1710
   Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064
   Wang MY, 1996, CANCER EPIDEM BIOMAR, V5, P705
   Wang XH, 2014, MOL CELL ENDOCRINOL, V382, P8, DOI 10.1016/j.mce.2013.09.003
   Wang ZG, 2012, MOL CELL ENDOCRINOL, V349, P222, DOI 10.1016/j.mce.2011.10.027
   WHO Expert Committee, 1995, WHO TECHN REP SER
   Wong SC, 2010, EUR J IMMUNOL, V40, P2296, DOI 10.1002/eji.200940288
   Wu SJ, 2014, CANCER CAUSE CONTROL, V25, P1489, DOI 10.1007/s10552-014-0450-y
   Wu YP, 2002, CANCER RES, V62, P1030
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Xu KM, 2007, CANCER RES, V67, P6121, DOI 10.1158/0008-5472.CAN-07-0141
   Yamaji T, 2010, CANCER RES, V70, P5430, DOI 10.1158/0008-5472.CAN-10-0178
   Yang CM, 2009, AM J PHYSIOL-LUNG C, V297, P28
   Yehuda-Shnaidman E, 2012, OBES REV, V13, P1083, DOI 10.1111/j.1467-789X.2012.01024.x
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241
   Zarkovic Neven, 2003, Molecular Aspects of Medicine, V24, P281, DOI 10.1016/S0098-2997(03)00023-2
   Zhang XH, 2015, CANCER EPIDEM BIOMAR, V24, P690, DOI 10.1158/1055-9965.EPI-14-0909-T
NR 201
TC 89
Z9 94
U1 2
U2 60
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JAN 22
PY 2016
VL 14
AR 21
DI 10.1186/s12967-016-0772-5
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DB8JM
UT WOS:000368763000001
PM 26801617
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Gao, GY
   Shi, XY
   Shen, JF
AF Gao, Guangyu
   Shi, Xinya
   Shen, Jiaofeng
TI HS3ST2 and Its Related Molecules as Potential Biomarkers for Predicting
   Lymph Node Metastasis in Patients with Colorectal Cancer
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE microRNA; colorectal cancer; lymph node metastasis; prognostic signature
ID GENE-EXPRESSION; MIGRATION; PATHWAY; CELLS; COLON; HSA-MIR-125A-3P;
   DIFFERENTIATION; PROLIFERATION; INVASION; TARGET
AB Background: Lymph node metastasis is a major cause of cancer-related death in patients with colorectal cancer (CRC), but current strategies are limited to predicting this clinical behavior. Our study aims to establish a lymph node metastasis prediction model based on miRNA and mRNA to improve the accuracy of prediction.
   Methods: GSE56350, GSE70574, and GSE95109 were downloaded from the Gene Expression Omnibus (GEO) database and 569 colorectal cancer statistics were also downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed miRNAs were calculated by using R software. Besides, gene ontology and enriched pathway analysis of target mRNAs were analyzed by using FunRich. Furthermore, the mRNA-miRNA network was constructed using Cytoscape software. Gene expression level was also detected by performing qRT-PCR (quantitative real-time PCR) in colorectal cancer and lymph node tissues.
   Results: In total, 5 differentially expressed miRNAs were selected, and 34 mRNAs were identified after filtering. The research of KEGG indicated that mRNAs are enriched in many cancer pathways. Differentially expressed miRNAs were most enriched in the cytoplasm, nucleoside, transcription factor activity, and RNA binding. KEGG pathway analysis of these target genes was mainly enriched in 5 pathways including fatty acid elongation, MAPK signaling pathway, autophagy, signaling pathways regulating pluripotency of stem cells, and Th17 cell differentiation. The results of qRT-PCR indicated that hsa-miR-100 and hsa-miR-99a were differentially expressed in lymph node metastatic colorectal cancer tissues and lymph node non-metastasis tissues which all target HS3ST2. Besides, we also found they have a significant difference in colorectal cancer tissues compared with normal tissues.
   Conclusion: By using microarray and bioinformatics analyses, differentially expressed miRNAs were identified and a complete gene network was constructed. To our knowledge, HS3ST2 and related molecules including hsa-miR-100 and hsa-miR-99a were firstly identified as potential biomarkers in the development of lymph node metastatic colorectal cancer.
C1 [Gao, Guangyu; Shi, Xinya; Shen, Jiaofeng] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.
RP Shen, JF (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.
EM jfshenzz@163.com
OI Guang Yu Gao, Guang Yu Gao/0000-0002-1317-6764
CR Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x
   Ahmadi A, 2017, GENE, V620, P15, DOI 10.1016/j.gene.2017.03.032
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Balch C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00267
   Chen Si-Xiang, 2018, Zhonghua Nan Ke Xue, V24, P442
   Dankova Z, 2018, INT J MOL MED, V42, P3318, DOI 10.3892/ijmm.2018.3872
   Dienstmann R, 2017, ANN ONCOL, V28, P1023, DOI 10.1093/annonc/mdx052
   Djamgoz MBA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0092
   Eyvazi S, 2020, J GASTROINTEST CANC, V51, P579, DOI 10.1007/s12029-019-00290-1
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hellec C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194676
   Hwang JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079634
   Ikeda N, 2003, CLIN CANCER RES, V9, P1503
   Jiang LL, 2013, CANCER INVEST, V31, P538, DOI 10.3109/07357907.2013.820314
   Jin S, 2018, ONCOL LETT, V15, P9703, DOI 10.3892/ol.2018.8564
   Kania EE, 2020, MOL PHARMACOL, V97, P159, DOI 10.1124/mol.119.118315
   Kitahara O, 2001, CANCER RES, V61, P3544
   Kumar AV, 2014, INT J CANCER, V135, P2579, DOI 10.1002/ijc.28921
   Lechner S, 2003, GUT, V52, P1148, DOI 10.1136/gut.52.8.1148
   Li B, 2017, J CLIN INVEST, V127, P3702, DOI 10.1172/JCI94012
   Li L, 2017, EXP THER MED, V14, P1065, DOI 10.3892/etm.2017.4597
   Ma X, 2019, J CANCER, V10, P6865, DOI 10.7150/jca.31952
   Notterman DA, 2001, CANCER RES, V61, P3124
   Okada R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121535
   Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001
   Pollock BE, 2017, J NEUROSURG, V126, P852, DOI 10.3171/2015.11.JNS151300
   Ren P, 2016, TUMOR BIOL, V37, P3215, DOI 10.1007/s13277-015-4150-3
   Sin TK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020237
   Steele SR, 2015, DIS COLON RECTUM, V58, P713, DOI 10.1097/DCR.0000000000000410
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Tominaga O, 1997, JPN J CANCER RES, V88, P855, DOI 10.1111/j.1349-7006.1997.tb00461.x
   Veenman CJ, 2005, IEEE T PATTERN ANAL, V27, P1496, DOI 10.1109/TPAMI.2005.182
   Vogel JD, 2017, DIS COLON RECTUM, V60, P999, DOI 10.1097/DCR.0000000000000926
   Xu XL, 2019, EUR REV MED PHARMACO, V23, P7375, DOI 10.26355/eurrev_201909_18845
   Xu X, 2016, BIOCHEM BIOPH RES CO, V479, P893, DOI 10.1016/j.bbrc.2016.09.087
   Zuo QQ, 2014, INT J BIOL MARKER, V29, pE354, DOI 10.5301/jbm.5000107
NR 36
TC 1
Z9 1
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2021
VL 14
BP 3881
EP 3894
DI 10.2147/OTT.S311038
PG 14
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA SY3XP
UT WOS:000665824600001
PM 34234457
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, Z
   Gao, W
   Zhou, L
   Chen, Y
   Qin, SY
   Zhang, L
   Liu, JY
   He, YJ
   Lei, YL
   Chen, HN
   Han, JH
   Zhou, ZG
   Nice, EC
   Li, CL
   Huang, CH
   Wei, XW
AF Zhang, Zhe
   Gao, Wei
   Zhou, Li
   Chen, Yan
   Qin, Siyuan
   Zhang, Lu
   Liu, Jiayang
   He, Yujia
   Lei, Yunlong
   Chen, Hai-Ning
   Han, Junhong
   Zhou, Zong-Guang
   Nice, Edouard C.
   Li, Changlong
   Huang, Canhua
   Wei, Xiawei
TI Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on
   Inhibition of ER-phagy
SO THERANOSTICS
LA English
DT Article
DE Brigatinib; ALK independence; ER stress; ER-phagy; Colorectal cancer
ID UNFOLDED PROTEIN RESPONSE; SELECTIVE AUTOPHAGY; STRESS; APOPTOSIS;
   RESISTANCE
AB Rationale: The sustained and severe endoplasmic reticulum (ER) stress in cancer cells may contribute to apoptotic cell death, thus representing a potential target for cancer therapy. Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). However, it remains unclear if brigatinib has alternative model of action to exert antitumor effect in ALK-negative cancers.
   Methods: ALK-positive NSCLC cells and various human ALK-negative cancer cells, especially human colorectal cancer (CRC) cells were used to examine the tumor suppression effect of brigatinib alone or in combination with autophagy inhibitors in vitro and in vivo. A variety of biochemical assays were conducted to elucidate the underlying mechanisms of brigatinib in CRC cells.
   Results: Here, we show the significant anti-cancer effect of brigatinib in CRC through induction of apoptosis by sustained ER stress. Mechanistically, brigatinib induces ER stress via promoting the interaction between ubiquitin-specific peptidase 5 (USP5), a deubiquitinase, and oxysterol-binding protein-related protein 8 (ORP8), leading to ORP8 deubiquitination, accumulation and growth inhibition. Furthermore, we find that brigatinib-mediated ER stress simultaneously induces autophagic response via ER-phagy that acts as a protective mechanism to relieve excessive ER stress. As such, combination of brigatinib with autophagy inhibitors significantly enhances the anti-CRC effect of brigatinib both in vitro and in vivo, supporting the repurposing of brigatinib in CRC, independently of ALK.
   Conclusion: The unearthed new molecular action of brigatinib suggests that therapeutic modulation of ER stress and autophagy might represent a valid strategy to treat CRC and perhaps other ALK-negative cancers.
C1 [Zhang, Zhe; Gao, Wei; Zhou, Li; Chen, Yan; Qin, Siyuan; Zhang, Lu; Liu, Jiayang; Han, Junhong; Huang, Canhua; Wei, Xiawei] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Zhe; Gao, Wei; Zhou, Li; Chen, Yan; Qin, Siyuan; Zhang, Lu; Liu, Jiayang; He, Yujia; Han, Junhong; Li, Changlong; Huang, Canhua; Wei, Xiawei] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Zhe; Gao, Wei; Zhou, Li; Chen, Yan; Qin, Siyuan; Zhang, Lu; Liu, Jiayang; Chen, Hai-Ning; Han, Junhong; Zhou, Zong-Guang; Huang, Canhua; Wei, Xiawei] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Lei, Yunlong] Chongqing Med Univ, Dept Biochem & Mol Biol & Mol Med, Chongqing 400016, Peoples R China.
   [Lei, Yunlong] Chongqing Med Univ, Canc Res Ctr, Chongqing 400016, Peoples R China.
   [Chen, Hai-Ning; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Dept Gastrointestinal Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Nice, Edouard C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.
RP Huang, CH; Wei, XW (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH; Wei, XW (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH; Wei, XW (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
EM hcanhua@scu.edu.cn; xiaweiwei@scu.edu.cn
RI Chen, Hai-Ning/AAR-8059-2021
OI Chen, Hai-Ning/0000-0003-0104-8498; Zhang, Zhe/0000-0001-7509-6965; Han,
   Junhong/0000-0002-3371-8698; Lei, Yunlong/0000-0002-7918-0221; ,
   Zongguang/0000-0002-7616-1199
FU Chinese NSFCNational Natural Science Foundation of China (NSFC)
   [81430071, 81790251, 81821002, 81672381]; National 973 Basic Research
   Program of ChinaNational Basic Research Program of China [2013CB911300]
FX This work was supported by grants from the Chinese NSFC (nos. 81430071,
   81790251, 81821002 and 81672381), and National 973 Basic Research
   Program of China (no. 2013CB911300).
CR Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Bernales S, 2007, AUTOPHAGY, V3, P285, DOI 10.4161/auto.3930
   Breckenridge A, 2019, NAT REV DRUG DISCOV, V18, P1, DOI 10.1038/nrd.2018.92
   Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013
   Chen Y, 2019, J HEPATOL, V70, P66, DOI 10.1016/j.jhep.2018.09.022
   Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183
   D'Arcy P, 2014, CLIN CANCER RES, V20, P3908, DOI 10.1158/1078-0432.CCR-14-0568
   Das M, 2017, LANCET ONCOL, V18, pE310, DOI 10.1016/S1470-2045(17)30342-X
   Dikic I, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0603-7
   Du XM, 2018, SEMIN CELL DEV BIOL, V81, P149, DOI 10.1016/j.semcdb.2017.07.017
   Du XM, 2018, J BIOL CHEM, V293, P3806, DOI 10.1074/jbc.RA117.001558
   Fagone P, 2009, J LIPID RES, V50, pS311, DOI 10.1194/jlr.R800049-JLR200
   Garcia-Navas R, 2012, AUTOPHAGY, V8, P1557, DOI 10.4161/auto.21315
   Grumati P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.217364
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Howell JJ, 2017, CELL METAB, V25, P463, DOI 10.1016/j.cmet.2016.12.009
   Huang WS, 2016, J MED CHEM, V59, P4948, DOI 10.1021/acs.jmedchem.6b00306
   Jacquemyn J, 2017, EMBO REP, V18, P1905, DOI 10.15252/embr.201643426
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Lagace TA, 2013, BBA-MOL CELL RES, V1833, P2499, DOI 10.1016/j.bbamcr.2013.05.018
   Li JW, 2016, J LIPID RES, V57, P1845, DOI 10.1194/jlr.M069906
   Li X, 2016, AUTOPHAGY, V12, P1521, DOI 10.1080/15548627.2016.1191722
   Lipatova Z, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005390
   Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017
   Liu XJ, 2016, CELL METAB, V24, P728, DOI 10.1016/j.cmet.2016.09.005
   Ma B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0889-x
   Mahoney E, 2012, BLOOD, V120, P1262, DOI 10.1182/blood-2011-12-400184
   Markham A, 2017, DRUGS, V77, P1131, DOI 10.1007/s40265-017-0776-3
   Matzke-Ogi A, 2016, GASTROENTEROLOGY, V150, P513, DOI 10.1053/j.gastro.2015.10.020
   Mizushima N, 2018, DEV CELL, V44, P133, DOI 10.1016/j.devcel.2018.01.001
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Niessner H, 2017, CLIN CANCER RES, V23, P6203, DOI 10.1158/1078-0432.CCR-17-0098
   Olkkonen VM, 2013, PROG LIPID RES, V52, P529, DOI 10.1016/j.plipres.2013.06.004
   Ovaa H, 2004, P NATL ACAD SCI USA, V101, P2253, DOI 10.1073/pnas.0308411100
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Schuck S, 2014, J CELL SCI, V127, P4078, DOI 10.1242/jcs.154716
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766
   Siaw JT, 2016, ONCOTARGET, V7, P29011, DOI 10.18632/oncotarget.8508
   Song SL, 2018, J CELL PHYSIOL, V233, P3867, DOI 10.1002/jcp.26137
   Viswanath P, 2018, CANCER RES, V78, P2290, DOI 10.1158/0008-5472.CAN-17-2926
   Wang JW, 2018, AUTOPHAGY, V14, P2007, DOI 10.1080/15548627.2018.1501133
   Wang SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.450
   Yamamoto T, 2016, AUTOPHAGY, V12, P801, DOI 10.1080/15548627.2016.1159376
   Zhang L, 2012, EXPERT REV ENDOCRINO, V7, P369, DOI [10.1586/eem.12.28, 10.1586/EEM.12.28]
   Zhang Z., 2018, REDOX BIOL
   Zheng YF, 2018, CANCER LETT, V431, P31, DOI 10.1016/j.canlet.2018.05.026
   Zhong WB, 2015, J BIOL CHEM, V290, P8876, DOI 10.1074/jbc.M114.610188
   Zhou L, 2019, FASEB J, V33, P5520, DOI 10.1096/fj.201801983R
NR 52
TC 22
Z9 23
U1 10
U2 17
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2019
VL 9
IS 17
BP 4878
EP 4892
DI 10.7150/thno.36254
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA II0MD
UT WOS:000474898900004
PM 31410188
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Meng, SS
   Xu, JS
   Wu, YT
   Ding, C
AF Meng, Songshu
   Xu, Jiansheng
   Wu, Yantao
   Ding, Chan
TI Targeting autophagy to enhance oncolytic virus-based cancer therapy
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE autophagy; cancer therapy; oncolysis; oncolytic virus
ID HERPES-SIMPLEX-VIRUS; CELL-DEATH; MYXOMA-VIRUS; IN-VIVO;
   ANTITUMOR-ACTIVITY; COLON-CANCER; STEM-CELLS; REPLICATION; ADENOVIRUS;
   GLIOMA
AB Introduction: Autophagy is a conserved catabolic process crucial in maintaining cellular homeostasis. On infection, oncolytic viruses (OVs) perturb the cellular autophagy machinery in infected tumor cells both in vitro and in vivo. Currently, pharmacological modulation of autophagy in OV-infected tumor cells has been shown to augment OV-mediated antitumor effects in preclinical studies. Combination of OVs with autophagy modulators can, therefore, have many potential applications in the future research on targeting autophagy and novel anticancer therapies.
   Areas covered: This review provides a detailed description of known interactions between OVs and autophagy and summarizes the roles of autophagy in OV replication and cell lysis. The recent literature on targeting autophagy with either the autophagy inducers, such as rapamycin, or autophagy inhibitors, such as chloroquine, to increase OV-induced cytotoxicity is reviewed to help researchers in further investigations. The major challenge for investigators is to understand the molecular mechanism underlying the interplay between OV and the autophagy machinery and its effect on oncolysis.
   Expert opinion: Targeting the cellular autophagy machinery could be explored as a new therapeutic strategy to enhance OV-mediated antitumor effects in the future.
C1 [Meng, Songshu] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian 116044, Peoples R China.
   [Xu, Jiansheng; Wu, Yantao] Yangzhou Univ, Coll Vet Med, Minist Educ, Key Lab Avian Prevent Med, Yangzhou 225009, Peoples R China.
   [Ding, Chan] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China.
RP Meng, SS (corresponding author), Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, 9 Lvshun Rd South, Dalian 116044, Peoples R China.
EM ssmeng@yzu.edu.cn; shoveldeen@shvri.ac.cn
FU State Key Laboratory of Veterinary Biotechnology of China
   [SKLVBF201109]; Program for Changjiang Scholars and Innovative Research
   Teams in UniversityProgram for Changjiang Scholars & Innovative Research
   Team in University (PCSIRT) [02738960345k]
FX This work was supported by grants from the State Key Laboratory of
   Veterinary Biotechnology of China (SKLVBF201109), the Program for
   Changjiang Scholars and Innovative Research Teams in University
   (02738960345k). The authors have no competing interests to declare.
CR Alain T, 2010, P NATL ACAD SCI USA, V107, P1576, DOI 10.1073/pnas.0912344107
   Alkassar M, 2011, J NEURO-ONCOL, V104, P715, DOI 10.1007/s11060-011-0606-5
   Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400
   Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958
   Amaravadi RK, 2011, SCIENCE, V334, P1501, DOI 10.1126/science.1216428
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Baird SK, 2008, ONCOGENE, V27, P3081, DOI 10.1038/sj.onc.1210977
   Belov GA, 2007, J VIROL, V81, P9259, DOI 10.1128/JVI.00840-07
   Botta G, 2012, HUM GENE THER, V23, P623, DOI 10.1089/hum.2011.120
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Cattaneo R, 2008, NAT REV MICROBIOL, V6, P529, DOI 10.1038/nrmicro1927
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Cloonan SM, 2010, LEUKEMIA LYMPHOMA, V51, P523, DOI 10.3109/10428190903552112
   Colunga AG, 2010, GENE THER, V17, P315, DOI 10.1038/gt.2009.126
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Dreux M, 2010, CELL CYCLE, V9, P1295, DOI 10.4161/cc.9.7.11109
   Eager RM, 2011, CANCER GENE THER, V18, P305, DOI 10.1038/cgt.2011.7
   English L, 2009, NAT IMMUNOL, V10, P480, DOI 10.1038/ni.1720
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Fu J, 2010, NEURO-ONCOLOGY, V12, P328, DOI 10.1093/neuonc/nop005
   Fu XP, 2011, INT J CANCER, V129, P1503, DOI 10.1002/ijc.25808
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gregoire IP, 2012, AUTOPHAGY, V8, P1136, DOI 10.4161/auto.20339
   Gregoire IP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002422
   Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309
   Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161
   Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102
   Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10
   Joubert PE, 2009, CELL HOST MICROBE, V6, P354, DOI 10.1016/j.chom.2009.09.006
   Kanai R, 2012, J VIROL, V86, P4420, DOI 10.1128/JVI.00017-12
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kraft C, 2012, CURR OPIN CELL BIOL, V24, P496, DOI 10.1016/j.ceb.2012.05.001
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948
   Kudchodkar SB, 2009, REV MED VIROL, V19, P359, DOI 10.1002/rmv.630
   Kumar S, 2008, CURR OPIN MOL THER, V10, P371
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lukashev AN, 2005, HUM GENE THER, V16, P1473, DOI 10.1089/hum.2005.16.1473
   Lun XQ, 2007, CANCER RES, V67, P8818, DOI 10.1158/0008-5472.CAN-07-1214
   Lun XQ, 2009, CLIN CANCER RES, V15, P2777, DOI 10.1158/1078-0432.CCR-08-2342
   Lun XQ, 2010, CANCER RES, V70, P598, DOI 10.1158/0008-5472.CAN-09-1510
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   McFarlane S, 2011, J VIROL, V85, P4212, DOI 10.1128/JVI.02435-10
   Meng CC, 2012, ARCH VIROL, V157, P1011, DOI 10.1007/s00705-012-1270-6
   Meng SS, 2012, ARCH VIROL, V157, P661, DOI 10.1007/s00705-012-1226-x
   Moloughney JG, 2011, AUTOPHAGY, V7, P1434, DOI 10.4161/auto.7.12.17793
   Nakashima A, 2006, VIROLOGY, V349, P254, DOI 10.1016/j.virol.2006.03.029
   Nguyen TLA, 2010, CYTOKINE GROWTH F R, V21, P153, DOI 10.1016/j.cytogfr.2010.03.002
   Orvedahl A, 2010, CELL HOST MICROBE, V7, P115, DOI 10.1016/j.chom.2010.01.007
   Ottolino-Perry K, 2010, MOL THER, V18, P251, DOI 10.1038/mt.2009.283
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Prestwich RJ, 2009, CLIN CANCER RES, V15, P4374, DOI 10.1158/1078-0432.CCR-09-0334
   Rajecki M, 2009, INT J CANCER, V125, P2441, DOI 10.1002/ijc.24608
   Rodriguez-Rocha H, 2011, VIROLOGY, V416, P9, DOI 10.1016/j.virol.2011.04.017
   Schache P, 2009, GENE THER, V16, P849, DOI 10.1038/gt.2009.39
   Shacka JJ, 2006, AUTOPHAGY, V2, P228, DOI 10.4161/auto.2703
   Stanford MM, 2008, MOL THER, V16, P52, DOI 10.1038/sj.mt.6300348
   Sumpter R, 2011, AUTOPHAGY, V7, P260, DOI 10.4161/auto.7.3.14281
   Tazawa H, 2012, INT J CANCER, V131, P2939, DOI 10.1002/ijc.27589
   Tysome JR, 2009, CURR OPIN MOL THER, V11, P664
   Ulasov IV, 2009, INT J ONCOL, V34, P729, DOI 10.3892/ijo_00000199
   Wong J, 2008, J VIROL, V82, P9143, DOI 10.1128/JVI.00641-08
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yokoyama T, 2008, GENE THER, V15, P1233, DOI 10.1038/gt.2008.98
   Yoon SY, 2009, AUTOPHAGY, V5, P388, DOI 10.4161/auto.5.3.7723
   Yu LT, 2010, NEURO-ONCOLOGY, V12, P580, DOI 10.1093/neuonc/nop056
   Zhang HY, 2006, AUTOPHAGY, V2, P91, DOI 10.4161/auto.2.2.2297
NR 80
TC 19
Z9 23
U1 1
U2 34
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUN
PY 2013
VL 13
IS 6
BP 863
EP 873
DI 10.1517/14712598.2013.774365
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 142LL
UT WOS:000318798800005
PM 23488666
DA 2022-04-25
ER

PT J
AU Wang, PQ
   Zhu, LJ
   Sun, DJ
   Gan, FH
   Gao, SY
   Yin, YY
   Chen, LX
AF Wang, Peiqi
   Zhu, Lingjuan
   Sun, Dejuan
   Gan, Feihong
   Gao, Suyu
   Yin, Yuanyuan
   Chen, Lixia
TI Natural products as modulator of autophagy with potential clinical
   prospects
SO APOPTOSIS
LA English
DT Review
DE Natural compounds; Autophagy; Disease; Drug therapy
ID ENDOPLASMIC-RETICULUM STRESS; ACTIVATED PROTEIN-KINASE; CELL-CYCLE
   ARREST; COLON-CANCER CELLS; INDUCED APOPTOSIS; ER STRESS; OXIDATIVE
   STRESS; PROSTATE-CANCER; SIGNALING PATHWAYS; MITOCHONDRIAL ROS
AB Natural compounds derived from living organisms are well defined for their remarkable biological and pharmacological properties likely to be translated into clinical use. Therefore, delving into the mechanisms by which natural compounds protect against diverse diseases may be of great therapeutic benefits for medical practice. Autophagy, an intricate lysosome-dependent digestion process, with implications in a wide variety of pathophysiological settings, has attracted extensive attention over the past few decades. Hitherto, accumulating evidence has revealed that a large number of natural products are involved in autophagy modulation, either inducing or inhibiting autophagy, through multiple signaling pathways and transcriptional regulators. In this review, we summarize natural compounds regulating autophagy in multifarious diseases including cancer, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and immune diseases, hoping to inspire further investigation of the underlying mechanisms of natural compounds and to facilitate their clinical use for multiple human diseases.
C1 [Wang, Peiqi; Zhu, Lingjuan; Sun, Dejuan; Gan, Feihong; Gao, Suyu; Yin, Yuanyuan; Chen, Lixia] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China.
   [Wang, Peiqi; Gan, Feihong; Yin, Yuanyuan] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
RP Chen, LX (corresponding author), Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China.
EM syzyclx@163.com
RI Chen, Lixia/ABH-1629-2021
OI Chen, Lixia/0000-0003-2196-1428
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [31270399, 81603275]; Key Projects of
   the National Science and Technology Pillar Program [2012BAI30B02]; Fund
   of the Educational Department of Liaoning Province [L2011177]; Liaoning
   Baiqianwan Talents Program [2013921043]; Liaoning Province Natural
   Science FoundationNatural Science Foundation of Liaoning Province
   [201602689]; Scientific Research Foundation for the Returned Overseas
   Chinese Scholars of Shenyang Pharmaceutical UniversityScientific
   Research Foundation for the Returned Overseas Chinese Scholars
   [GGJJ2015103]; Career Development Program for Young and Middle-aged
   Teachers of Shenyang Pharmaceutical University [ZQN2015015]
FX We acknowledge support from the National Natural Science Foundation of
   China (NSFC) (Grant Number 31270399 and Grant Number 81603275), Key
   Projects of the National Science and Technology Pillar Program (Grant
   Number 2012BAI30B02), Fund of the Educational Department of Liaoning
   Province (Grant Number L2011177), Liaoning Baiqianwan Talents Program
   (Grant Number 2013921043), Liaoning Province Natural Science Foundation
   (Grant Number 201602689), Scientific Research Foundation for the
   Returned Overseas Chinese Scholars of Shenyang Pharmaceutical University
   (Grant Number GGJJ2015103), and 2015 Career Development Program for
   Young and Middle-aged Teachers of Shenyang Pharmaceutical University
   (Grant Number ZQN2015015).
CR Abderrazak A, 2015, CIRCULATION, V131, P1061, DOI 10.1161/CIRCULATIONAHA.114.013730
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Armstrong JL, 2015, J INVEST DERMATOL, V135, P1629, DOI 10.1038/jid.2015.45
   Aryal P, 2014, FEBS J, V281, P4644, DOI 10.1111/febs.12969
   Bai X, 2016, RESPIROLOGY
   Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680
   Blanchet FP, 2010, IMMUNITY, V32, P654, DOI 10.1016/j.immuni.2010.04.011
   Bridgeman BB, 2016, CELL SIGNAL, V28, P460, DOI 10.1016/j.cellsig.2016.02.008
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cai H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7619
   Chakraborty A, 2012, MOL CELL ENDOCRINOL, V355, P25, DOI 10.1016/j.mce.2012.01.009
   Chan ML, 2015, N-S ARCH PHARMACOL, V388, P1223, DOI 10.1007/s00210-015-1152-z
   Chen ML, 2013, AUTOPHAGY, V9, P2033, DOI 10.4161/auto.26336
   Chen RJ, 2012, J AGR FOOD CHEM, V60, P11533, DOI 10.1021/jf302778a
   Chen TP, 2013, FOOD CHEM, V138, P1034, DOI 10.1016/j.foodchem.2012.11.102
   Chen WL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1988-0
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen Y, 2016, MOL NEUROBIOL
   Chiu HW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040462
   Chow SE, 2012, J CELL BIOCHEM, V113, P3476, DOI 10.1002/jcb.24224
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Dai J.F., 2013, J NANOMATER, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0061026
   De Leo A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.156
   DECKER RS, 1980, J MOL CELL CARDIOL, V12, P1175, DOI 10.1016/0022-2828(80)90064-4
   Deng Q, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.324
   Dengiel J, 2008, AUTOPHAGY, V4, P1057, DOI 10.4161/auto.6824
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Duan WJ, 2013, MOL NUTR FOOD RES, V57, P1145, DOI 10.1002/mnfr.201200662
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Dupont N, 2009, CELL HOST MICROBE, V6, P137, DOI 10.1016/j.chom.2009.07.005
   Dyshlovoy SA, 2015, ONCOTARGET, V6, P17328, DOI 10.18632/oncotarget.4175
   Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Filippi-Chiela EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020849
   Filomeni G, 2012, NEUROBIOL AGING, V33, P767, DOI 10.1016/j.neurobiolaging.2010.05.021
   Fu LL, 2015, ONCOTARGET, V6, P8071, DOI 10.18632/oncotarget.3513
   Galli A, 2013, NEW ENGL J MED, V368, P1754, DOI 10.1056/NEJMc1302511
   Gandhi S, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/428010
   Gao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046092
   Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125
   Geng YD, 2015, CANCER LETT, V366, P19, DOI 10.1016/j.canlet.2015.05.032
   Glembotski CC, 2007, CIRC RES, V101, P975, DOI 10.1161/CIRCRESAHA.107.161273
   Goldman S, 2010, AUTOPHAGY, V6, P179, DOI 10.4161/auto.6.1.10814
   Grossi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071702
   Guan F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146553
   Guo JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140745
   Gurusamy N, 2008, J CELL MOL MED, V102, P13807
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Hahm ER, 2014, PROSTATE, V74, P1209, DOI 10.1002/pros.22837
   Hahm JR, 2014, LIFE SCI, V100, P125, DOI 10.1016/j.lfs.2014.02.001
   Hamacher-Brady A, 2006, J BIOL CHEM, V281, P29776, DOI 10.1074/jbc.M603783200
   Han J, 2012, AUTOPHAGY, V8, P812, DOI 10.4161/auto.19471
   Han XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100380
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hau AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065250
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7
   Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014
   Hsui CM, 2013, INT J ONCOL, V43, P338, DOI 10.3892/ijo.2013.1942
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang CQ, 2010, J CARDIOVASC TRANSL, V3, P365, DOI 10.1007/s12265-010-9189-3
   Jansen HJ, 2012, ENDOCRINOLOGY, V153, P5866, DOI 10.1210/en.2012-1625
   Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jin HR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.169
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104
   Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013
   Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0
   Kanamori H, 2013, AM J PATHOL, V182, P701, DOI 10.1016/j.ajpath.2012.11.009
   Kim H, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/596496
   Kim J, 2014, J CLIN INVEST, V124, P3311, DOI 10.1172/JCI69625
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kim NY, 2016, CANCER LETT, V370, P19, DOI 10.1016/j.canlet.2015.10.008
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   King FW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007283
   Klappan AK, 2012, HISTOCHEM CELL BIOL, V137, P25, DOI 10.1007/s00418-011-0869-0
   Ko CP, 2015, ORAL ONCOL, V51, P593, DOI 10.1016/j.oraloncology.2015.03.007
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kovsan J, 2011, J CLIN ENDOCR METAB, V96, pE268, DOI 10.1210/jc.2010-1681
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kristensen AR, 2008, MOL CELL PROTEOMICS, V7, P2419, DOI 10.1074/mcp.M800184-MCP200
   Lan L, 2015, MOL ONCOL, V9, P1406, DOI 10.1016/j.molonc.2015.03.014
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee Y, 2014, INT J ONCOL, V44, P1599, DOI 10.3892/ijo.2014.2339
   Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025
   Leng SL, 2013, INT J CANCER, V133, P2781, DOI 10.1002/ijc.28301
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li HB, 2007, ARCH PHARM RES, V30, P1566, DOI 10.1007/BF02977326
   Li W, 2011, PHYS RES INT, P1, DOI [10.1155/2011/791545, DOI 10.1155/2011/791545]
   Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Lian JQ, 2012, MOL CANCER THER, V11, P416, DOI 10.1158/1535-7163.MCT-11-0559
   Lian JQ, 2010, AUTOPHAGY, V6, P1201, DOI [10.1038/cdd.2010.74, 10.4161/auto.6.8.13549]
   Lin HS, 2009, BIOMED CHROMATOGR, V23, P1308, DOI 10.1002/bmc.1254
   Liu B, 2012, CELL DEATH DIS, V4, P377
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Loos B, 2013, AUTOPHAGY, V9, P1270, DOI 10.4161/auto.25560
   Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009
   Luccarini I, 2015, NEUROBIOL AGING, V36, P648, DOI 10.1016/j.neurobiolaging.2014.08.029
   Maday S, 2012, J CELL BIOL, V196, P407, DOI 10.1083/jcb.201106120
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinez-Vicente M, 2015, SEMIN CELL DEV BIOL, V40, P115, DOI 10.1016/j.semcdb.2015.03.005
   Masini M, 2009, DIABETOLOGIA, V52, P1083, DOI 10.1007/s00125-009-1347-2
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X
   Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246
   Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208
   Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396
   Ogawa M, 2011, CELL HOST MICROBE, V9, P376, DOI 10.1016/j.chom.2011.04.010
   Ortiz LMG, 2015, ACTA BIOCH BIOPH SIN, V47, P824, DOI 10.1093/abbs/gmv077
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Papandreou I, 2015, EXP CELL RES, V339, P147, DOI 10.1016/j.yexcr.2015.10.014
   Park IJ, 2014, APOPTOSIS, V19, P615, DOI 10.1007/s10495-013-0929-0
   Patergnani S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00173
   Peng X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.297
   Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524
   Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]
   Poornima P, 2013, FOOD CHEM, V141, P3598, DOI 10.1016/j.foodchem.2013.05.138
   Pua HH, 2009, AUTOPHAGY, V5, P745, DOI 10.4161/auto.5.5.8702
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rasul A, 2012, INT J ONCOL, V40, P1153, DOI 10.3892/ijo.2011.1277
   Ren GW, 2015, J NAT MED-TOKYO, V69, P522, DOI 10.1007/s11418-015-0918-4
   Rigacci S, 2015, ONCOTARGET, V6, P35344, DOI 10.18632/oncotarget.6119
   Rodriguez RM, 2012, ADV EXP MED BIOL, V739, P237, DOI 10.1007/978-1-4614-1704-0_15
   Ruela-de-Sousa RR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.18
   Ryter Stefan W, 2010, Proc Am Thorac Soc, V7, P40, DOI 10.1513/pats.200909-100JS
   Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Sasazawa Y, 2012, ACS CHEM BIOL, V7, P892, DOI 10.1021/cb200492h
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Schapira AHV, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/159160
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Sengupta A, 2011, J BIOL CHEM, V286, P7468, DOI 10.1074/jbc.M110.179242
   Shao FY, 2016, ONCOTARGET, V7, P6790, DOI 10.18632/oncotarget.6828
   Shen SY, 2014, INT J BIOL SCI, V10, P212, DOI 10.7150/ijbs.8056
   Shi LY, 2015, MOL CELL ENDOCRINOL, V409, P92, DOI 10.1016/j.mce.2015.03.009
   Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228
   Singh SB, 2010, NAT CELL BIOL, V12, P1154, DOI 10.1038/ncb2119
   STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112
   Sun LD, 2015, BIOCHEM PHARMACOL, V95, P156, DOI 10.1016/j.bcp.2015.03.014
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tan HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.271
   Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800
   Tsai SC, 2012, INT J ONCOL, V41, P1431, DOI 10.3892/ijo.2012.1579
   Tsukamoto S, 2008, SCIENCE, V321, P117, DOI 10.1126/science.1154822
   Ushio H, 2011, J ALLERGY CLIN IMMUN, V127, P1267, DOI 10.1016/j.jaci.2010.12.1078
   Valentim L, 2006, J MOL CELL CARDIOL, V40, P846, DOI 10.1016/j.yjmcc.2006.03.428
   Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038
   Vitaglione P, 2005, MOL NUTR FOOD RES, V49, P495, DOI 10.1002/mnfr.200500002
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wen X, 2013, FREE RADICAL BIO MED, V65, P402, DOI 10.1016/j.freeradbiomed.2013.07.013
   Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405
   Wildenberg ME, 2012, GASTROENTEROLOGY, V142, P1493, DOI 10.1053/j.gastro.2012.02.034
   Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3
   Wong KK, 2009, RECENT PAT ANTI-CANC, V4, P28, DOI 10.2174/157489209787002461
   Wong VKW, 2015, MOLECULES, V20, P3496, DOI 10.3390/molecules20033496
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026
   Xilouri M, 2010, CNS NEUROL DISORD-DR, V9, P701, DOI 10.2174/187152710793237421
   Xu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055080
   Yan J, 2012, J NUTR BIOCHEM, V23, P716, DOI 10.1016/j.jnutbio.2011.03.014
   Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102
   Yang CS, 2012, CELL HOST MICROBE, V11, P277, DOI 10.1016/j.chom.2012.01.019
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yao DH, 2016, APOPTOSIS, V21, P683, DOI 10.1007/s10495-016-1237-2
   Yeganeh B, 2015, AM J PHYSIOL-LUNG C, V308, pL270, DOI 10.1152/ajplung.00011.2014
   Yeh PS, 2016, CANCER LETT, V370, P66, DOI 10.1016/j.canlet.2015.08.030
   Yoon JS, 2013, PHYTOMEDICINE, V20, P1013, DOI 10.1016/j.phymed.2013.03.024
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Zha QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124355
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang J, 2013, BIOCHEM PHARMACOL, V86, P317, DOI 10.1016/j.bcp.2013.05.003
   Zhang L, 2015, CELL PROLIFERAT, V48, P385, DOI 10.1111/cpr.12191
   Zhang L, 2013, J NUTR BIOCHEM, V24, P903, DOI 10.1016/j.jnutbio.2012.06.008
   Zhang SF, 2014, ASIAN PAC J CANCER P, V15, P10557, DOI 10.7314/APJCP.2014.15.24.10557
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
   Zhao C, 2013, AUTOPHAGY, V9, P196, DOI 10.4161/auto.22805
   Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185
   Zhao YQ, 2016, APOPTOSIS, V21, P517, DOI 10.1007/s10495-016-1236-3
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou Z, 2009, AUTOPHAGY, V5, P321, DOI 10.4161/auto.5.3.7406
   Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523
   Zhu ZY, 2013, J NEUROSCI, V33, P13138, DOI 10.1523/JNEUROSCI.4790-12.2013
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 204
TC 26
Z9 27
U1 5
U2 32
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD MAR
PY 2017
VL 22
IS 3
BP 325
EP 356
DI 10.1007/s10495-016-1335-1
PG 32
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EL1GG
UT WOS:000394367900001
PM 27988811
DA 2022-04-25
ER

PT J
AU Zhou, J
   Ji, Q
   Li, Q
AF Zhou, Jing
   Ji, Qing
   Li, Qi
TI Resistance to anti-EGFR therapies in metastatic colorectal cancer:
   underlying mechanisms and reversal strategies
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Review
DE Metastatic colorectal cancer; Anti-epidermal growth factor receptor
   targeted therapies; Drug resistance; Reversal strategies
ID GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; WILD-TYPE KRAS; CETUXIMAB PLUS
   IRINOTECAN; K-RAS MUTATIONS; COLON-CANCER; MONOCLONAL-ANTIBODY; 1ST-LINE
   TREATMENT; ACQUIRED-RESISTANCE; TGF-ALPHA
AB Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration, RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.
C1 [Zhou, Jing; Ji, Qing; Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai 201203, Peoples R China.
   [Zhou, Jing; Ji, Qing; Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Canc, Shanghai 201203, Peoples R China.
   [Li, Qi] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China.
RP Ji, Q; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai 201203, Peoples R China.; Ji, Q; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Canc, Shanghai 201203, Peoples R China.; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China.
EM ttt99118@hotmail.com; qili@shutcm.edu.cn
OI Ji, Qing/0000-0002-1899-0204; Li, Qi/0000-0003-2004-6885
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81830120, 82074225]; Clinical Research Plan of Shanghai
   Hospital Development Center [SHDC2020CR4043]
FX This work was supported by National Science Foundation of China
   (81830120 to Q.L., 82074225 to Q.J.) and Clinical Research Plan of
   Shanghai Hospital Development Center (SHDC2020CR4043 to Y.W.).
CR Akkaya M, 2018, NAT IMMUNOL, V19, P255, DOI 10.1038/s41590-018-0052-z
   Alonso V, 2018, NEOPLASIA, V20, P678, DOI 10.1016/j.neo.2018.05.004
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Arai H, 2021, EUR J CANCER, V150, P133, DOI 10.1016/j.ejca.2021.03.048
   Arena S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5640
   Baba Y, 2017, MOL ONCOL, V11, P1065, DOI 10.1002/1878-0261.12074
   Bagchi A, 2018, MOL CANCER THER, V17, P521, DOI 10.1158/1535-7163.MCT-17-0575
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bellier J, 2020, CELL REP, V30, P1400, DOI 10.1016/j.celrep.2020.01.012
   Bennouna J, 2015, INVEST NEW DRUG, V33, P138, DOI 10.1007/s10637-014-0142-1
   Berasain C, 2016, HEPATOLOGY, V63, P371, DOI 10.1002/hep.28246
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463
   Blons H, 2014, ANN ONCOL, V25, P2378, DOI 10.1093/annonc/mdu464
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Borner M, 2008, ANN ONCOL, V19, P1288, DOI 10.1093/annonc/mdn058
   Bowles DW, 2016, CLIN COLORECTAL CANC, V15, P337, DOI 10.1016/j.clcc.2016.03.004
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Calemma R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-232
   Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen P, 2020, THERANOSTICS, V10, P5107, DOI 10.7150/thno.44705
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261
   Cohen AS, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100828
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cuneo KC, 2019, TRANSL ONCOL, V12, P209, DOI 10.1016/j.tranon.2018.10.005
   Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943
   Damiano V, 2007, P NATL ACAD SCI USA, V104, P12468, DOI 10.1073/pnas.0705226104
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Angelis ML, 2016, STEM CELL TRANSL MED, V5, P511, DOI 10.5966/sctm.2015-0214
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Delord JP, 2020, INVEST NEW DRUG, V38, P1774, DOI 10.1007/s10637-020-00928-z
   Deming DA, 2016, INVEST NEW DRUG, V34, P168, DOI 10.1007/s10637-015-0314-7
   Dienstmann R, 2015, CANCER DISCOV, V5, P598, DOI 10.1158/2159-8290.CD-14-1432
   Ding CB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2834-8
   Du ZG, 2018, CELL REP, V22, P2677, DOI 10.1016/j.celrep.2018.02.037
   Duldulao MP, 2013, ANN SURG ONCOL, V20, P2166, DOI 10.1245/s10434-013-2910-0
   Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430
   Elez E, 2016, BRIT J CANCER, V114, P372, DOI 10.1038/bjc.2015.480
   Eng C, 2016, INT J CANCER, V139, P177, DOI 10.1002/ijc.30049
   Foster P, 2015, MOL CANCER THER, V14, P931, DOI 10.1158/1535-7163.MCT-14-0833
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Gao LL, 2019, AM J CANCER RES, V9, P2531
   Han Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202000112
   Hong CS, 2020, CANCER SCI, V111, P3268, DOI 10.1111/cas.14526
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hong S, 2016, CANCER MED-US, V5, P248, DOI 10.1002/cam4.591
   Houot R, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.941740
   Huang F, 2012, CLIN CANCER RES, V18, P1156, DOI 10.1158/1078-0432.CCR-11-1135
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798
   Ishiguro N, 2020, ARTHRITIS RHEUMATOL, V72, P166, DOI 10.1002/art.41052
   Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744
   Jacobs SA, 2021, CLIN CANCER RES, V27, P1612, DOI 10.1158/1078-0432.CCR-20-1831
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   Jung SA, 2016, FREE RADICAL BIO MED, V95, P200, DOI 10.1016/j.freeradbiomed.2016.03.009
   Jutten B, 2018, AUTOPHAGY, V14, P283, DOI 10.1080/15548627.2017.1409926
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Kloth M, 2016, GUT, V65, P1296, DOI 10.1136/gutjnl-2014-309026
   Kohrt HE, 2014, J CLIN INVEST, V124, P2668, DOI 10.1172/JCI73014
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Lee HW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235894
   Lee J, 2011, JNCI-J NATL CANCER I, V103, P674, DOI 10.1093/jnci/djr070
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826
   Lim Y, 2016, MOL CANCER THER, V15, P251, DOI 10.1158/1535-7163.MCT-15-0679
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Loupakis F, 2014, TARGET ONCOL, V9, P205, DOI 10.1007/s11523-013-0284-7
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Luca T, 2014, CELL PROLIFERAT, V47, P435, DOI 10.1111/cpr.12125
   Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T
   Lutterbuese R, 2010, P NATL ACAD SCI USA, V107, P12605, DOI 10.1073/pnas.1000976107
   Maddalena F, 2020, MOL ONCOL, V14, P3030, DOI 10.1002/1878-0261.12814
   Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Medema JP, 2017, NEW ENGL J MED, V377, P888, DOI 10.1056/NEJMcibr1706541
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595
   Mimeault M, 2007, J CELL MOL MED, V11, P981, DOI 10.1111/j.1582-4934.2007.00088.x
   Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Modest DP, 2015, J CLIN ONCOL, V33, P3718, DOI 10.1200/JCO.2015.61.2887
   Molinari F, 2009, BRIT J CANCER, V100, P1087, DOI 10.1038/sj.bjc.6604848
   Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137
   Montagut C, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.5245
   Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6
   Mortara L, 2018, TARGET ONCOL, V13, P657, DOI 10.1007/s11523-018-0586-x
   Mutsaers AJ, 2009, CLIN CANCER RES, V15, P2397, DOI 10.1158/1078-0432.CCR-08-1627
   Napolitano S, 2015, CLIN CANCER RES, V21, P2975, DOI 10.1158/1078-0432.CCR-15-0020
   Negri FV, 2010, BRIT J CANCER, V102, P162, DOI 10.1038/sj.bjc.6605471
   Okada J, 2018, CLIN COLORECTAL CANC, V17, pE45, DOI 10.1016/j.clcc.2017.09.005
   Oliveras-Ferraros C, 2011, J CELL BIOCHEM, V112, P10, DOI 10.1002/jcb.22952
   Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d
   Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078-0432.CCR-11-0239
   Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Poindessous V, 2011, CLIN CANCER RES, V17, P6522, DOI 10.1158/1078-0432.CCR-11-1607
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price T, 2020, CANCER BIOL THER, V21, P891, DOI 10.1080/15384047.2020.1798695
   Reidy DL, 2010, J CLIN ONCOL, V28, P4240, DOI 10.1200/JCO.2010.30.4154
   Rimassa L, 2019, CLIN COLORECTAL CANC, V18, P125, DOI 10.1016/j.clcc.2019.02.004
   Rosa R, 2011, CLIN CANCER RES, V17, P6531, DOI 10.1158/1078-0432.CCR-10-3376
   Sanchez-Martin FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schirripa M, 2017, INT J CANCER, V141, P383, DOI 10.1002/ijc.30715
   Sclafani F, 2013, ANN ONCOL, V24, P3123, DOI 10.1093/annonc/mdt408
   Sclafani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv258
   Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777
   Shin Wookjin, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276-018-0102-5
   Shinozaki E, 2017, BRIT J CANCER, V117, P1450, DOI 10.1038/bjc.2017.308
   Sidaway P, 2019, NAT REV CLIN ONCOL, V16, P527, DOI 10.1038/s41571-019-0259-4
   Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695
   Skvortsov S, 2004, MOL CANCER THER, V3, P1551
   Rocca YS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00413
   Song N, 2014, INT J MOL SCI, V15, P5838, DOI 10.3390/ijms15045838
   Subbiah V, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90380
   Tabernero J, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.13.2183
   Troiani T, 2015, CLIN CANCER RES, V21, P4153, DOI 10.1158/1078-0432.CCR-15-0211
   Troiani T, 2014, CLIN CANCER RES, V20, P3775, DOI 10.1158/1078-0432.CCR-13-2181
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423
   Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/JCO.2005.09.100
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00087
   Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185
   Vincenzi B, 2007, PHARMACOGENOMICS, V8, P319, DOI 10.2217/14622416.8.4.319
   Vlacich G, 2011, CANCER CELL, V20, P423, DOI 10.1016/j.ccr.2011.10.006
   Wang F, 2017, CELL RES, V27, P540, DOI 10.1038/cr.2017.7
   Wang JY, 2003, INT J CANCER, V107, P387, DOI 10.1002/ijc.11417
   Winder T, 2010, CLIN CANCER RES, V16, P5591, DOI 10.1158/1078-0432.CCR-10-2092
   Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013
   Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Ye H, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00584-z
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
   Yoon J, 2011, CANCER RES, V71, P445, DOI 10.1158/0008-5472.CAN-10-3058
   Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500
NR 153
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD OCT 18
PY 2021
VL 40
IS 1
AR 328
DI 10.1186/s13046-021-02130-2
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WI6PP
UT WOS:000708480300001
PM 34663410
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wu, JP
   Liu, SL
   Chen, XM
   Xu, HF
   Tang, YP
AF Wu, Jianping
   Liu, Sulai
   Chen, Xiaoming
   Xu, Hongfei
   Tang, Yaoping
TI Machine learning identifies two autophagy-related genes as markers of
   recurrence in colorectal cancer
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Colorectal cancer; machine learning; regression; autophagy;
   autophagy-related gene; recurrence
ID BREAST-CANCER; EXPRESSION; MACROAUTOPHAGY; REGULATOR; CELLS; SCORE; RISK
AB Objective Colorectal cancer (CRC) is the most common cancer worldwide. Patient outcomes following recurrence of CRC are very poor. Therefore, identifying the risk of CRC recurrence at an early stage would improve patient care. Accumulating evidence shows that autophagy plays an active role in tumorigenesis, recurrence, and metastasis. Methods We used machine learning algorithms and two regression models, univariable Cox proportion and least absolute shrinkage and selection operator (LASSO), to identify 26 autophagy-related genes (ARGs) related to CRC recurrence. Results By functional annotation, these ARGs were shown to be enriched in necroptosis and apoptosis pathways. Protein-protein interactions identifiedSQSTM1,CASP8,HSP80AB1,FADD, andMAPK9as core genes in CRC autophagy. Of 26 ARGs,BAXandPARP1were regarded as having the most significant predictive ability of CRC recurrence, with prediction accuracy of 71.1%. Conclusion These results shed light on prediction of CRC recurrence by ARGs. Stratification of patients into recurrence risk groups by testing ARGs would be a valuable tool for early detection of CRC recurrence.
C1 [Wu, Jianping; Chen, Xiaoming; Xu, Hongfei; Tang, Yaoping] Hunan Univ Sci & Engn, 130 Yangzitang Rd, Yongzhou 425100, Peoples R China.
   [Liu, Sulai] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Hepatobiliary Surg, Affiliated Hosp 1, Changsha, Peoples R China.
RP Tang, YP (corresponding author), Hunan Univ Sci & Engn, 130 Yangzitang Rd, Yongzhou 425100, Peoples R China.
EM daiqilai1988@163.com
OI Liu, Sulai/0000-0002-5257-3922
CR Bednarczyk M, 2017, J BIOL REG HOMEOS AG, V31, P923
   Boga JA, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12534
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chen D, 2018, ONCOL LETT, V15, P7104, DOI 10.3892/ol.2018.8206
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7
   Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3
   Duan X, 2018, APOPTOSIS, V23, P587, DOI 10.1007/s10495-018-1489-0
   Feldmann A, 2017, BIOCHEM BIOPH RES CO, V486, P738, DOI 10.1016/j.bbrc.2017.03.112
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gil J, 2017, MED ONCOL, V34, DOI 10.1007/s12032-016-0869-y
   Gray RG, 2011, J CLIN ONCOL, V29, P4611, DOI 10.1200/JCO.2010.32.8732
   Guillaume JD, 2019, METHODS MOL BIOL, V1862, P151, DOI 10.1007/978-1-4939-8769-6_11
   Han Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04994-x
   Han YY, 2018, INT J ONCOL, V52, P1057, DOI 10.3892/ijo.2018.4270
   Ianniciello A, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00120
   Jiao YN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0646-4
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Li WL, 2016, EXP THER MED, V11, P1259, DOI 10.3892/etm.2016.3054
   Liang ZG, 2018, CANCER MANAG RES, V10, P4125, DOI 10.2147/CMAR.S176536
   Lin P, 2018, INT J ONCOL, V53, P603, DOI 10.3892/ijo.2018.4404
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Ma C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189452
   Ma YB, 2018, EXP THER MED, V15, P4671, DOI 10.3892/etm.2018.5999
   Marcuello M, 2019, MOL ASPECTS MED, V69, P107, DOI 10.1016/j.mam.2019.06.002
   McGuire S, 2014, ADV NUTR, V5, P456, DOI 10.3945/an.114.006171
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Renehan AG, 2016, LANCET ONCOL, V17, P174, DOI 10.1016/S1470-2045(15)00467-2
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robertson DJ, 2019, GASTROENTEROLOGY, V156, P904, DOI 10.1053/j.gastro.2018.12.012
   Sanz-Pamplona R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048877
   Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623
   Specogna AV, 2020, LANCET, V395, P314, DOI 10.1016/S0140-6736(20)30034-9
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285
   Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1
   Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
   Tie J, 2019, JAMA ONCOL, V5, P1710, DOI 10.1001/jamaoncol.2019.3616
   Tie J, 2018, EXPERT REV MOL DIAGN, V18, P1, DOI 10.1080/14737159.2018.1386558
   Venook AP, 2013, J CLIN ONCOL, V31, P1775, DOI 10.1200/JCO.2012.45.1096
   Wang C, 2018, CELL DEATH DIS, V9, P1, DOI 10.1038/s41419
   Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365
   Wu YQ, 2018, ONCOTARGETS THER, V11, P5621, DOI 10.2147/OTT.S176744
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang HX, 2017, ONCOTARGET, V8, P60987, DOI 10.18632/oncotarget.17719
   Zhao YX, 2019, ONCOL REP, V41, P27, DOI 10.3892/or.2018.6780
   Zheng LQ, 2018, ONCOL LETT, V15, P4837, DOI 10.3892/ol.2018.7971
   Zhu FX, 2019, ONCOL LETT, V18, P5310, DOI 10.3892/ol.2019.10881
   Zhu HS, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1211-7
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
NR 49
TC 0
Z9 0
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD OCT
PY 2020
VL 48
IS 10
AR 0300060520958808
DI 10.1177/0300060520958808
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OK4XO
UT WOS:000584655500001
PM 33076720
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, XH
   Li, XH
   Ma, WJ
   Xu, JL
AF Zhou, Xihan
   Li, Xiaohui
   Ma, Weijin
   Xu, Jiali
TI Baicalin Improves Intestinal Injury in Mice with Experimental Colitis
   Via Regulation Autophagy
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE autophagy; baicalin; Beclin1; LC3B; UC
ID INFLAMMATORY-BOWEL-DISEASE; CURCUMIN; CANCER; MAINTENANCE; MECHANISMS;
   EXPRESSION; PROTECTS
AB The objective was to observe the expression change of autophagy proteins Beclin1 and LC3B in colon tissue of mice with experimental colitis induced by sodium dextran sulfate (DSS), and to explore the role and possible mechanism of baicalin in colitis. Sixty BALB/c mice were randomly divided into normal group, the other group, Model group, baicalin gavage group and mesalazine gavage group, with 15 mice in each group. Except the normal group, the other groups received DSS method to establish colitis models. From the first day of modeling, the baicalin gavage group received baicalin, the mesalazing group was administered with mesalazine suspension, and the Model group and normal groups were gien with normal saline. Modeling period lasted for 21 days, and the mice were sacrificed on the 22nd day with taking the specimens. The general condition of the mice and the pathological damage of the colon were observed and the apoptosis cell number were measured by TUNEL assay. The expression of Beclin1 and LC3B in the colon tissue were detected by immunofluorescence and Western Blot. By HE and TUNEL assay. The histopathological damage score and the positive apoptosis cell number of model group were significantly increased compared with those of normal group (p < 0.001, respectively), and Beclin1 and LC3B proteins expressions were significantly up-regulation by IHC and WB assay (p < 0.001, respectively). With baicalin supplement, the histopathological damage score and the positive apoptosis cell number of baicalin group were significantly improved, and the Beclin1 and LC3B proteins expressions were significantly depressed compared with Model group (p < 0.001, respectively). In conclusion: baicalin improve intestinal injury in mice with experimental colitis via regulation autophagy.
C1 [Zhou, Xihan] Wuhan Fifth Hosp, Dept Gastroenterol, Wuhan 430050, Peoples R China.
   [Li, Xiaohui] Wuhan Fifth Hosp, Dept Paediat, Wuhan 430050, Peoples R China.
   [Ma, Weijin] Wuhan Fifth Hosp, Hosp Acquired Infect Control Dept, Wuhan 430050, Peoples R China.
   [Xu, Jiali] Wuhan Fifth Hosp, Discipline Inspect & Supervis Room, Wuhan 430050, Peoples R China.
RP Xu, JL (corresponding author), Wuhan Fifth Hosp, Discipline Inspect & Supervis Room, Wuhan 430050, Peoples R China.
CR Ali T, 2012, DIGESTION, V85, P249, DOI 10.1159/000336720
   Ananthakrishnan AN, 2018, NAT REV GASTRO HEPAT, V15, P39, DOI 10.1038/nrgastro.2017.136
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   Camacho-Barquero L, 2007, INT IMMUNOPHARMACOL, V7, P333, DOI 10.1016/j.intimp.2006.11.006
   de Bie CI, 2013, INFLAMM BOWEL DIS, V19, P378, DOI 10.1002/ibd.23008
   Gong WY, 2017, EUR J MED CHEM, V126, P844, DOI 10.1016/j.ejmech.2016.11.058
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hao XQ, 2015, INT J CLIN EXP MED, V8, P21098
   Hooper KM, 2017, J CROHNS COLITIS, V11, P118, DOI 10.1093/ecco-jcc/jjw127
   Jia W, 2011, J IMMUNOL, V186, P1564, DOI 10.4049/jimmunol.1001822
   Ke P, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00695
   Kozuch PL, 2008, WORLD J GASTROENTERO, V14, P354, DOI 10.3748/wjg.14.354
   Lang A, 2015, CLIN GASTROENTEROL H, V13, P1444, DOI 10.1016/j.cgh.2015.02.019
   Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791
   Long AG, 2017, CURR COLORECT CANC R, V13, P341, DOI 10.1007/s11888-017-0373-6
   Negroni A, 2016, INFLAMM RES, V65, P803, DOI 10.1007/s00011-016-0964-8
   NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Peng LY, 2019, INT IMMUNOPHARMACOL, V72, P467, DOI 10.1016/j.intimp.2019.04.046
   Qu WL, 2013, INT J BIOL SCI, V9, P766, DOI 10.7150/ijbs.5711
   Sandborn WJ, 2019, CLIN GASTROENTEROL H, V17, P1541, DOI 10.1016/j.cgh.2018.11.035
   Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910
   Sudirman S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205252
   Tsuboi K, 2015, J BIOL CHEM, V290, P20511, DOI 10.1074/jbc.M114.632257
   Wang SF, 2016, J ETHNOPHARMACOL, V194, P861, DOI 10.1016/j.jep.2016.10.069
   Wang YQ, 2018, IMMUNOPHARM IMMUNOT, V40, P476, DOI 10.1080/08923973.2018.1469145
   Yamaguchi M, 2019, EXP THER MED, V17, P4312, DOI 10.3892/etm.2019.7452
   Zhao J, 2017, JPEN-PARENTER ENTER, V41, P824, DOI 10.1177/0148607115609308
NR 29
TC 0
Z9 0
U1 1
U2 1
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326-2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2021
VL 40
IS 9
BP 2092
EP 2098
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WC7SP
UT WOS:000704454400014
DA 2022-04-25
ER

PT J
AU Zhao, HZ
   Xi, HQ
   Wei, B
   Cai, AZ
   Wang, T
   Wang, Y
   Zhao, XD
   Song, YJ
   Chen, L
AF Zhao, Huazhou
   Xi, Hongqing
   Wei, Bo
   Cai, Aizhen
   Wang, Ting
   Wang, Yi
   Zhao, Xudong
   Song, Yanjing
   Chen, Lin
TI Expression of decorin in intestinal tissues of mice with inflammatory
   bowel disease and its correlation with autophagy
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE decorin; inflammatory bowel disease; autophagy
ID CROHNS-DISEASE; BREAST-CANCER; IBD; INFECTION; FIBROSIS; THERAPY;
   SURGERY; INJURY; ALPHA
AB The aim of this study was to investigate the expression of decorin (DCN) in the intestinal tissues of mice with inflammatory bowel disease (IBD) and its correlation with autophagy. The IBD mouse model was created by intrarectal injection of trinitrobenzene sulfonic acid. The pathology of colon tissues of the mice was examined using hematoxylin and eosin staining. Expression of DCN and the proteins associated with autophagy was detected using immunohistochemistry. Normal human colon mucosal epithelial cells (NCM460 cells) were transfected with DCN expression plasmid and the expression of DCN and autophagy-associated proteins was detected by western blot analysis. Cell apoptosis was studied using an Annexin V apoptosis detection assay and intracellular autophagosomes were observed using electron microscopy. The IBD mouse model was successfully established. Thickening, edema and inflammatory cell infiltration of the intestinal wall were observed in the IBD mice. The expression of DCN as well as the autophagy-associated proteins beclin 1 and LC3B, was increased in the intestinal tissues of the IBD mice. Furthermore, in the NCM460 cells transfected with DCN, the expression of beclin 1 and LC3B was upregulated, while p62 expression was downregulated. Intracellular autophagosomes were increased and apoptosis was decreased in the cells with DCN overexpression. Inhibition of autophagy reversed the effects of DCN on apoptosis. Therefore, DCN is able to induce autophagy and protect intestinal cells during the occurrence and development of IBD.
C1 [Zhao, Huazhou; Xi, Hongqing; Wei, Bo; Cai, Aizhen; Wang, Yi; Zhao, Xudong; Song, Yanjing; Chen, Lin] Chinese Peoples Liberat Army, Gen Hosp, Dept Gen Surg, 28 Fuxing Rd, Beijing 100853, Peoples R China.
   [Zhao, Huazhou; Wang, Yi] Chinese Peoples Liberat Army, Hosp 309, Dept Gen Surg, Beijing 100091, Peoples R China.
   [Wang, Ting] Beijing Chaoyang Hosp, Med Adm Div, Beijing 100020, Peoples R China.
RP Wei, B (corresponding author), Chinese Peoples Liberat Army, Gen Hosp, Dept Gen Surg, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM weibobj301@sina.com; sdc1678@126.com
OI song, yanjing/0000-0001-7104-0649
FU National High Technology Research and Development Program of
   ChinaNational High Technology Research and Development Program of China
   [2012AA02A504]; Army Medical Science Youth Development Project
   [13QNP185]
FX This study was supported by the National High Technology Research and
   Development Program of China (grant no. 2012AA02A504) and Army Medical
   Science Youth Development Project (grant no. 13QNP185).
CR Agilli M, 2014, J GASTROINTEST LIVER, V23, P462
   Annese V, 2016, J CROHNS COLITIS, V10, P216, DOI 10.1093/ecco-jcc/jjv190
   Araki K, 2009, ONCOLOGY-BASEL, V77, P92, DOI 10.1159/000228253
   Bryant RV, 2015, SCAND J GASTROENTERO, V50, P90, DOI 10.3109/00365521.2014.968864
   Chen JYF, 2015, INT FORUM ALLERGY RH, V5, P119, DOI 10.1002/alr.21456
   Chen M, 2015, SURG TODAY, V45, P1002, DOI 10.1007/s00595-014-1093-z
   Cheng XQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10397
   Connelly TM, 2014, SURGERY, V156, P769, DOI 10.1016/j.surg.2014.06.067
   De Salvo C, 2014, DIGEST DIS S1, V32, pS26
   Dunkin D, 2014, DIGEST DIS S1, V32, pS61
   Esmaeili M, 2014, NEURAL REGEN RES, V9, P1653, DOI 10.4103/1673-5374.141797
   Hildner K, 2016, DIGEST DIS, V34, P40, DOI 10.1159/000447281
   Kasamatsu A, 2015, BIOCHEM BIOPH RES CO, V457, P71, DOI 10.1016/j.bbrc.2014.12.093
   Katz LH, 2014, CLIN RES HEPATOL GAS, V38, P491, DOI 10.1016/j.clinre.2014.01.010
   Latella G, 2015, SCAND J GASTROENTERO, V50, P53, DOI 10.3109/00365521.2014.968863
   Liu H, 2015, J MOL MED, V93, P159, DOI 10.1007/s00109-014-1241-3
   MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692
   Murthi P, 2016, PLACENTA, V45, P58, DOI 10.1016/j.placenta.2016.07.008
   Nata T, 2013, J GENE MED, V15, P249, DOI 10.1002/jgm.2717
   Nemani N, 2015, J BONE MINER RES, V30, P533, DOI 10.1002/jbmr.2371
   Obba S., 2015, PLOS ONE, V11, P1114
   Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329
   Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1
   Tomasello Giovanni, 2015, Acta Biomed, V86, P92
   Zatorski H, 2016, PHARMACOL REP, V68, P809, DOI 10.1016/j.pharep.2016.03.006
   Zeng TS, 2015, ENDOCR J, V62, P615, DOI 10.1507/endocrj.EJ15-0046
NR 26
TC 8
Z9 8
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2016
VL 12
IS 6
BP 3885
EP 3892
DI 10.3892/etm.2016.3908
PN B
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EG5IC
UT WOS:000391076500010
PM 28105121
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Liu, ZZ
   Liu, XF
   Li, Y
   Ren, PW
   Zhang, CF
   Wang, LJ
   Du, XJ
   Xing, BC
AF Liu, Zhenzhen
   Liu, Xiaofeng
   Li, Yuan
   Ren, Pengwei
   Zhang, Chunfeng
   Wang, Lijun
   Du, Xiaojuan
   Xing, Baocai
TI miR-6716-5p promotes metastasis of colorectal cancer through
   downregulating NAT10 expression
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE miR-6716-5p; NAT10; colorectal cancer; CRC; liver metastasis
ID N-ACETYLTRANSFERASE 10; MICRORNA EXPRESSION; RIBOSOMAL-RNA; HOUSEKEEPING
   GENE; LIVER METASTASES; COLON-CANCER; WEB SERVER; E-CADHERIN;
   NORMALIZATION; PROTEIN
AB Background: Human N-acetyltransferase 10 (NAT10) plays pivotal roles in cellular biological processes, such as senescence, autophagy and cytokinesis. The expression of NAT10 is dysregulated in colorectal cancer (CRC) and is associated with the prognosis of patients. However, it remains unclear how NAT10 is regulated in CRC.
   Methods: The microRNA(miRNA) regulating NAT10 was predicted by bioinformatics analysis and further validated by real-time quantitative PCR(RT-qPCR), Western blot and dual luciferase reporter assays. The expression of the miRNA regulating NAT10 in CRC tissues was examined using RT-qPCR. Cell proliferation, cell apoptosis, cell migration and cell invasion assays were performed after transfection with miRNA mimic and inhibitor.
   Results: Here, we report that miR-6716-5p inhibits the expression of NAT10 in CRC. The NAT10 protein level was downregulated by the miR-6716-5p mimic, and was upregulated by the miR-6716-5p inhibitor in CRC cell lines. In addition, miR-6716-5p bound to the 3'-untranslated region of NAT10 mRNA and decreased NAT10 mRNA levels. Significantly, the miR-6716-5p level was higher in the tumor tissues of the CRC patients with liver metastasis than that in the non-metastatic CRC patients. In addition, the miR-6716-5p level was correlated with poor overall survival of CRC patients with liver metastasis. The miR-6716-5p inhibitor inhibited CRC cell migration and invasion. Consistently, the miR-6716-5p mimic significantly promoted cell migration and invasion, and this effect is dependent on NAT10. However, miR-6716-5p had no effect on CRC cell proliferation and apoptosis. We found that miR-6716-5p negatively regulated E-cadherin protein levels. In addition, E-cadherin was upregulated by NAT10 in CRC cells, confirming that miR-6716-5p downregulated E-cadherin levels by inhibiting NAT10 expression.
   Conclusion: We demonstrated that miR-6716-5p acts as a crucial regulator of NAT10 to promote cell migration and invasion in CRC by inhibiting NAT10 expression. Our data suggest that miR-6716-5p/NAT10 might act as a potential therapeutic target for CRC treatment.
C1 [Liu, Zhenzhen; Liu, Xiaofeng; Li, Yuan; Wang, Lijun; Xing, Baocai] Peking Univ, Sch Oncol, Hepatopancreatobiliary Surg Dept 1,Peking Univ Ca, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.
   [Ren, Pengwei; Du, Xiaojuan] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Cell Biol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Zhang, Chunfeng] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Med Genet, Beijing 100191, Peoples R China.
RP Xing, BC (corresponding author), Peking Univ, Sch Oncol, Hepatopancreatobiliary Surg Dept 1,Peking Univ Ca, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.; Du, XJ (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Cell Biol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM duxiaojuan100@bjmu.edu.cn; xingbaocai88@sina.com
RI Du, Xiaojuan/AAY-1186-2021; Liu, Xiaofeng/AAR-2488-2020
OI , Xiaofeng/0000-0002-3264-122X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672735, 81371868, 81621063]; 973
   ProgramNational Basic Research Program of China [2013CB837201]; Chinese
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2018M641118]; Innovation Team of Ministry of Education [IRT13001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81672735, 81371868 and 81621063), the 973
   Program (Grant No. 2013CB837201), Chinese Postdoctoral Science
   Foundation (2018M641118), and grant from the Innovation Team of Ministry
   of Education (IRT13001).
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Arango D, 2018, CELL, V175, P1872, DOI 10.1016/j.cell.2018.10.030
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cai SY, 2017, BIOCHEM BIOPH RES CO, V483, P624, DOI 10.1016/j.bbrc.2016.12.092
   Caradec J, 2010, BRIT J CANCER, V103, P1475, DOI 10.1038/sj.bjc.6605851
   Caradec J, 2010, BRIT J CANCER, V102, P1037, DOI 10.1038/sj.bjc.6605573
   Chang KH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-173
   Chapman JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141853
   Chi YH, 2007, J BIOL CHEM, V282, P27447, DOI 10.1074/jbc.M703098200
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   Helling TS, 2014, ANN SURG ONCOL, V21, P501, DOI 10.1245/s10434-013-3297-7
   Hur K, 2017, GUT, V66, P654, DOI 10.1136/gutjnl-2014-308737
   Hwang M, 2014, EUR J CANCER, V50, P1747, DOI 10.1016/j.ejca.2014.03.277
   Ito S, 2014, J BIOL CHEM, V289, P35724, DOI 10.1074/jbc.C114.602698
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Kida Y, 2008, JAMA-J AM MED ASSOC, V299, P2628, DOI 10.1001/jama.299.22.2628-a
   Kong RR, 2011, J BIOL CHEM, V286, P7139, DOI 10.1074/jbc.M110.173393
   Larrieu D, 2014, SCIENCE, V344, P527, DOI 10.1126/science.1252651
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li QJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3570-4
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Liu XF, 2018, NUCLEIC ACIDS RES, V46, P9601, DOI 10.1093/nar/gky777
   Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505
   Liu YQ, 2008, CANCER INVEST, V26, P575, DOI 10.1080/07357900701837168
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Lv JJ, 2003, BIOCHEM BIOPH RES CO, V311, P506, DOI 10.1016/j.bbrc.2003.09.235
   Ma R, 2016, AM J TRANSL RES, V8, P4215
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Monzo M, 2008, CELL RES, V18, P823, DOI 10.1038/cr.2008.81
   Mullany LE, 2016, CANCER EPIDEMIOL, V45, P98, DOI 10.1016/j.canep.2016.10.011
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Oh TI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091924
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Schwarzenbach H, 2015, CLIN CHEM, V61, P1333, DOI 10.1373/clinchem.2015.239459
   Sharma S, 2015, NUCLEIC ACIDS RES, V43, P2242, DOI 10.1093/nar/gkv075
   Shen Q, 2009, EXP CELL RES, V315, P1653, DOI 10.1016/j.yexcr.2009.03.007
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siriwardena AK, 2014, NAT REV CLIN ONCOL, V11, P446, DOI 10.1038/nrclinonc.2014.90
   Slattery ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134406
   Sullivan-Gunn M, 2011, BRIT J CANCER, V104, P1055, DOI 10.1038/bjc.2011.35
   Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823
   Tan YQ, 2018, BIOCHEM BIOPH RES CO, V499, P1032, DOI 10.1016/j.bbrc.2018.04.047
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wu J, 2018, AM J TRANSL RES, V10, P256
   Zhang H, 2014, CLIN CANCER RES, V20, P4717, DOI 10.1158/1078-0432.CCR-13-3477
   Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1
   Zhang QY, 2018, AM J CANCER RES, V8, P280
   Zhang XM, 2015, INT J CLIN EXP PATHO, V8, P14765
   Zhao H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19458-z
   Zheng GX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083025
NR 63
TC 11
Z9 11
U1 3
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2019
VL 11
BP 5317
EP 5332
DI 10.2147/CMAR.S197733
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IC1EY
UT WOS:000470703200007
PM 31239781
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Dabrowska, M
   Skoneczny, M
   Rode, W
AF Dabrowska, Magdalena
   Skoneczny, Marek
   Rode, Wojciech
TI Functional gene expression profile underlying methotrexate-induced
   senescence in human colon cancer cells
SO TUMOR BIOLOGY
LA English
DT Article
DE High-dose methotrexate; Colorectal adenocarcinoma; Drug-induced
   senescence; Expression microarrays; Signaling pathways
ID NITRIC-OXIDE; CELLULAR SENESCENCE; DNA-DAMAGE; DOSE METHOTREXATE;
   SALVAGE PATHWAY; TETRAHYDROBIOPTERIN; CONTRIBUTES; INVOLVEMENT;
   ACTIVATION; RESISTANCE
AB Cellular functions accompanying establishment of premature senescence in methotrexate-treated human colon cancer C85 cells are deciphered in the present study from validated competitive expression microarray data, analyzed with the use of Ingenuity Pathways Analysis (IPA) software. The nitrosative/oxidative stress, inferred from upregulated expression of inducible nitric oxide synthase (iNOS) and mitochondrial dysfunction-associated genes, including monoamine oxidases MAOA and MAOB, beta-amyloid precursor protein (APP) and presenilin 1 (PSEN1), is identified as the main determinant of signaling pathways operating during senescence establishment. Activation of p53-signaling pathway is found associated with both apoptotic and autophagic components contributing to this process. Activation of nuclear factor kappa B (NF-kappa B), resulting from interferon gamma (IFN gamma), integrin, interleukin 1 beta (IL-1 beta), IL-4, IL-13, IL-22, Toll-like receptors (TLRs) 1, 2 and 3, growth factors and tumor necrosis factor (TNF) superfamily members signaling, is found to underpin inflammatory properties of senescent C85 cells. Upregulation of p21-activated kinases (PAK2 and PAK6), several Rho molecules and myosin regulatory light chains MYL12A and MYL12B, indicates acquisition of motility by those cells. Mitogen-activated protein kinase p38 MAPK beta, extracellular signal-regulated kinases ERK2 and ERK5, protein kinase B AKT1, as well as calcium, are identified as factors coordinating signaling pathways in senescent C85 cells.
C1 [Dabrowska, Magdalena; Rode, Wojciech] Polish Acad Sci, Nencki Inst Expt Biol, PL-02093 Warsaw, Poland.
   [Skoneczny, Marek] Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland.
RP Dabrowska, M (corresponding author), Polish Acad Sci, Nencki Inst Expt Biol, Pasteura 3, PL-02093 Warsaw, Poland.
EM m.dabrowska@nencki.gov.pl
RI Rode, Wojciech K/A-4891-2008; Skoneczny, Marek/S-5390-2019
OI Skoneczny, Marek/0000-0001-9922-2276; Dabrowska,
   Magdalena/0000-0001-7487-8930
CR Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707
   Bartek J, 2008, NAT CELL BIOL, V10, P887, DOI 10.1038/ncb0808-887
   Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Choi K, 2010, CELL DEATH DIFFER, V17, P833, DOI 10.1038/cdd.2009.154
   Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Copeland NG, 2009, TRENDS GENET, V25, P455, DOI 10.1016/j.tig.2009.08.004
   Cosentino F, 1999, CARDIOVASC RES, V43, P274, DOI 10.1016/S0008-6363(99)00134-0
   Crabtree MJ, 2009, J BIOL CHEM, V284, P28128, DOI 10.1074/jbc.M109.041483
   Dabrowska M, 2007, EUR J PHARMACOL, V555, P93, DOI 10.1016/j.ejphar.2006.10.052
   Dabrowska M, 2009, PTERIDINES, V20, P143
   Dabrowska M, 2009, CANCER LETT, V284, P95, DOI 10.1016/j.canlet.2009.04.015
   Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236
   Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40
   di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440
   Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213
   Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910
   Fumagalli M, 2009, NAT CELL BIOL, V11, P921, DOI 10.1038/ncb0809-921
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Gewirtz DA, 2009, AUTOPHAGY, V5, P1232, DOI 10.4161/auto.5.8.9896
   Hasegawa H, 2005, MOL GENET METAB, V86, pS2, DOI 10.1016/j.ymgme.2005.09.002
   Herman S, 2005, INFLAMM RES, V54, P273, DOI 10.1007/s00011-005-1355-8
   Hong Z, 2007, J CELL PHYSIOL, V210, P567, DOI 10.1002/jcp.20919
   Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x
   Khan EM, 2006, J BIOL CHEM, V281, P14486, DOI 10.1074/jbc.M509332200
   Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164
   Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Longo GSA, 2000, ONCOL RES, V12, P309
   Manoli I, 2005, FASEB J, V19, P1359, DOI 10.1096/fj.04-3660fje
   MARITTO S, 2004, NEUROENDOCRINE IMMUN, P291
   Martin SA, 2009, EMBO MOL MED, V1, P323, DOI 10.1002/emmm.200900040
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022
   Novakova Z, 2010, ONCOGENE, V29, P273, DOI 10.1038/onc.2009.318
   Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110
   Passos JF, 2006, FREE RADICAL RES, V40, P1277, DOI 10.1080/10715760600917151
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Ramsey MR, 2006, NAT CELL BIOL, V8, P1213, DOI 10.1038/ncb1106-1213
   Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078
   Robaey P, 2008, DEV DISABIL RES REV, V14, P211, DOI 10.1002/ddrr.29
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x
   Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200
   Swanton C, 2009, BRIT J CANCER, V100, P1517, DOI 10.1038/sj.bjc.6605031
   Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Woo HA, 2010, CELL, V140, P517, DOI 10.1016/j.cell.2010.01.009
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zelcer S, 2008, PEDIATR BLOOD CANCER, V50, P1176, DOI 10.1002/pbc.21419
NR 56
TC 21
Z9 21
U1 1
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2011
VL 32
IS 5
BP 965
EP 976
DI 10.1007/s13277-011-0198-x
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 808FO
UT WOS:000293962800014
PM 21678067
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Lai, HH
   Lin, LJ
   Hung, LY
   Chen, PS
AF Lai, Hui-Huang
   Lin, Li-Jyuan
   Hung, Liang-Yi
   Chen, Pai-Sheng
TI Role of Dicer in regulating oxaliplatin resistance of colon cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Oxaliplatin; Dicer; CHIP; Ubiquitination
ID COLORECTAL-CANCER; BREAST-CANCER; AUTOPHAGY; FLUOROURACIL; LEUCOVORIN
AB Colorectal cancer (CRC) is a major health problem due to its high mortality rate. The incidence of CRC is increasing in young individuals. Oxaliplatin (OXA) is an approved third-generation drug and is used for first-line chemotherapy in CRC. Although current standard chemotherapy improves the overall survival of CRC patients, an increasing number of reports of OXA resistance in CRC therapy indicates that resistance has become an urgent problem in clinical applications. Dicer is a critical enzyme involved in miRNA maturation. The expression of Dicer has been reported to be involved in the resistance to various drugs in cancer. In the present study, we aimed to investigate the role of Dicer in OXA resistance in CRC. We found that OXA treatment inhibited Dicer expression through decreasing the protein stability. OXA-induced Dicer protein degradation occurred through both proteasomal and lysosomal proteolysis, while the CHIP E3 ligase was involved in OXA-mediated Dicer ubiquitination and degradation. We established stable OXA-resistant clones from CRC cells, and observed that the CHIP E3 ligase was decreased, along with the increased Dicer expression in OXA-resistant cells. Knockdown of Dicer resensitized CRC cells to OXA treatment. In this study, we have revealed the role of miRNA biogenesis factors in OXA resistance in CRC cells. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Lai, Hui-Huang; Chen, Pai-Sheng] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan.
   [Lai, Hui-Huang; Chen, Pai-Sheng] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.
   [Lin, Li-Jyuan; Hung, Liang-Yi] Natl Cheng Kung Univ, Dept Biotechnol & Bioind Sci, Coll Biosci & Biotechnol, Tainan, Taiwan.
RP Chen, PS (corresponding author), Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.
EM bio.benson@gmail.com
RI Chen, Pai-Sheng/G-2130-2012; Hung, Liang-Yi/AAG-4174-2019
OI Chen, Pai-Sheng/0000-0003-0513-1467; 
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 107-2320-B-006-009, MOST 107-2320-B-006-068,
   MOST 106-2320-B-006-038, MOST 106-2320-B-006-021]
FX We thank Dr. Ming-Derg Lai for the technical support. This study was
   supported by the Ministry of Science and Technology, Taiwan (MOST
   107-2320-B-006-009, MOST 107-2320-B-006-068, MOST 106-2320-B-006-038,
   MOST 106-2320-B-006-021).
CR Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Blagosklonny MV, 2004, CELL CYCLE, V3, P1035
   Cai LQ, 2016, TUMOR BIOL, V37, P6359, DOI 10.1007/s13277-015-4416-9
   Chang TY, 2016, CANCER RES, V76, P3916, DOI 10.1158/0008-5472.CAN-15-2555
   Chen X, 2017, CARCINOGENESIS, V38, P873, DOI 10.1093/carcin/bgx059
   CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4
   Diaz-Rubio E, 1998, ANN ONCOL, V9, P105, DOI 10.1023/A:1008200825886
   Fang ZJ, 2018, CANCER LETT, V415, P58, DOI 10.1016/j.canlet.2017.11.040
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406
   Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Kuang Y, 2013, ONCOL LETT, V5, P1149, DOI 10.3892/ol.2013.1158
   Lai HH, 2018, J CLIN INVEST, V128, P625, DOI 10.1172/JCI89212
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
   Raymond E, 1998, SEMIN ONCOL, V25, P4
   Selever J, 2011, CLIN CANCER RES, V17, P6510, DOI 10.1158/1078-0432.CCR-11-1403
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Swahari V, 2016, CELL REP, V14, P216, DOI 10.1016/j.celrep.2015.12.037
   Wang YM, 2014, CARCINOGENESIS, V35, P983, DOI 10.1093/carcin/bgt393
   Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Zhang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082895
NR 30
TC 6
Z9 6
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 17
PY 2018
VL 506
IS 1
BP 87
EP 93
DI 10.1016/j.bbrc.2018.10.071
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HC6UI
UT WOS:000451936800014
PM 30336979
DA 2022-04-25
ER

PT J
AU Kim, SM
   Ha, E
   Kim, J
   Cho, C
   Shin, SJ
   Seo, JH
AF Kim, Sun Myung
   Ha, Eunyoung
   Kim, Jinyoung
   Cho, Chiheum
   Shin, So-Jin
   Seo, Ji Hae
TI NAA10 as a New Prognostic Marker for Cancer Progression
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE acetyltransferase; biomarker; cancer prognosis; NAA10
ID N-ALPHA-ACETYLTRANSFERASE; ARREST DEFECTIVE 1; TERMINAL ACETYLATION;
   PROTEIN; ARD1; EXPRESSION; APOPTOSIS; KINASE; IDENTIFICATION;
   TUMORIGENESIS
AB N-alpha-acetyltransferase 10 (NAA10) is an acetyltransferase that acetylates both N-terminal amino acid and internal lysine residues of proteins. NAA10 is a crucial player to regulate cell proliferation, migration, differentiation, apoptosis, and autophagy. Recently, mounting evidence presented the overexpression of NAA10 in various types of cancer, including liver, bone, lung, breast, colon, and prostate cancers, and demonstrated a correlation of overexpressed NAA10 with vascular invasion and metastasis, thereby affecting overall survival rates of cancer patients and recurrence of diseases. This evidence all points NAA10 toward a promising biomarker for cancer prognosis. Here we summarize the current knowledge regarding the biological functions of NAA10 in cancer progression and provide the potential usage of NAA10 as a prognostic marker for cancer progression.
C1 [Kim, Sun Myung; Cho, Chiheum; Shin, So-Jin] Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu 42601, South Korea.
   [Kim, Sun Myung; Cho, Chiheum; Shin, So-Jin] Keimyung Univ, Sch Med, Inst Canc Res, Daegu 42601, South Korea.
   [Ha, Eunyoung; Seo, Ji Hae] Keimyung Univ, Sch Med, Dept Biochem, Daegu 42601, South Korea.
   [Kim, Jinyoung] Keimyung Univ, Sch Med, Dept Internal Med, Daegu 42601, South Korea.
RP Shin, SJ (corresponding author), Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu 42601, South Korea.; Shin, SJ (corresponding author), Keimyung Univ, Sch Med, Inst Canc Res, Daegu 42601, South Korea.; Seo, JH (corresponding author), Keimyung Univ, Sch Med, Dept Biochem, Daegu 42601, South Korea.
EM sun7@snu.ac.kr; eyha@dsmc.or.kr; takgu@dsmc.or.kr; c0035@dsmc.or.kr;
   sjshinhope2014@kmu.ac.kr; seojh@kmu.ac.kr
OI Kim, Jin Young/0000-0002-9597-9834
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2016R1A6A1A03011325,
   NRF-2020R1I1A3071851]; Korean Government (MSIT)Korean Government
   [NRF-2019R1C1C1005855]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2016R1A6A1A03011325, NRF-2020R1I1A3071851) and the
   Korean Government (MSIT) (NRF-2019R1C1C1005855).
CR Aksnes H, 2019, MOL CELL, V73, P1097, DOI 10.1016/j.molcel.2019.02.007
   Aksnes H, 2015, INT REV CEL MOL BIO, V316, P267, DOI 10.1016/bs.ircmb.2015.01.001
   Aksnes H, 2015, CELL REP, V10, P1362, DOI 10.1016/j.celrep.2015.01.053
   Arnaudo N, 2013, NAT STRUCT MOL BIOL, V20, P1119, DOI 10.1038/nsmb.2641
   Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071
   Arnesen T, 2009, P NATL ACAD SCI USA, V106, P8157, DOI 10.1073/pnas.0901931106
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chaudhary P, 2019, ARCH PHARM RES, V42, P1040, DOI 10.1007/s12272-019-01195-0
   Chien MH, 2018, CANCER LETT, V433, P86, DOI 10.1016/j.canlet.2018.06.033
   DePaolo JS, 2016, ONCOTARGET, V7, P71417, DOI 10.18632/oncotarget.12163
   Dorfel MJ, 2015, GENE, V567, P103, DOI 10.1016/j.gene.2015.04.085
   Drazic A, 2018, P NATL ACAD SCI USA, V115, P4399, DOI 10.1073/pnas.1718336115
   Gottlieb L, 2018, STRUCTURE, V26, P925, DOI 10.1016/j.str.2018.04.003
   Heron Melonie, 2018, Natl Vital Stat Rep, V67, P1
   Hua KT, 2011, CANCER CELL, V19, P218, DOI 10.1016/j.ccr.2010.11.010
   Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147
   Jiang BH, 2010, AM J PATHOL, V177, P1095, DOI 10.2353/ajpath.2010.091178
   Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5
   Kang J, 2018, REDOX BIOL, V19, P364, DOI 10.1016/j.redox.2018.09.002
   Koncina E, 2020, CANCERS, V12, DOI 10.3390/cancers12020319
   Kuo HP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000590
   Kuo HP, 2009, BIOCHEM BIOPH RES CO, V389, P156, DOI 10.1016/j.bbrc.2009.08.127
   Lavery DN, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/862125
   Lee CF, 2010, J CLIN INVEST, V120, P2920, DOI 10.1172/JCI42275
   Lee D, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0106-1
   Lee KE, 2016, MOL CELLS, V39, P169, DOI 10.14348/molcells.2016.2329
   Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0105-2
   Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171
   Liszczak G, 2011, J BIOL CHEM, V286, P37002, DOI 10.1074/jbc.M111.282863
   Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937
   Lozada EM, 2016, ONCOTARGET, V7, P20425, DOI 10.18632/oncotarget.7966
   Markopoulos AK, 2012, OPEN DENT J, V6, P126, DOI 10.2174/1874210601206010126
   Merriel SWD, 2018, ADV THER, V35, P1285, DOI 10.1007/s12325-018-0766-1
   Minguez P, 2013, NUCLEIC ACIDS RES, V41, pD306, DOI 10.1093/nar/gks1230
   Minguez P, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.31
   Mughal AA, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0432-z
   Neri L, 2017, ONCOTARGET, V8, P40967, DOI 10.18632/oncotarget.17332
   Park JH, 2014, COLD REG SCI TECHNOL, V99, P1, DOI 10.1016/j.coldregions.2013.11.002
   Park YH, 2017, INT J ONCOL, V51, P573, DOI 10.3892/ijo.2017.4039
   Pavlou D, 2016, APOPTOSIS, V21, P298, DOI 10.1007/s10495-015-1207-0
   Qian X, 2017, AUTOPHAGY, V13, P1246, DOI 10.1080/15548627.2017.1313945
   Qian X, 2017, MOL CELL, V65, P917, DOI 10.1016/j.molcel.2017.01.027
   Raychaudhuri S, 2008, HUM MOL GENET, V17, P240, DOI 10.1093/hmg/ddm301
   Ree R, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0116-z
   Ren TT, 2008, CANCER LETT, V264, P83, DOI 10.1016/j.canlet.2008.01.028
   Seo JH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12882
   Seo JH, 2010, CANCER RES, V70, P4422, DOI 10.1158/0008-5472.CAN-09-3258
   Shim JH, 2012, DIGEST DIS, V30, P603, DOI 10.1159/000343090
   Shin DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007451
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P2020, DOI DOI 10.3322/CAAC.21590
   Starheim KK, 2009, MOL CELL BIOL, V29, P3569, DOI 10.1128/MCB.01909-08
   Vo TTL, 2020, MOLECULES, V25, DOI 10.3390/molecules25030588
   Vo TTL, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0100-7
   Vo TTL, 2017, ONCOTARGET, V8, P57216, DOI 10.18632/oncotarget.19332
   Van Damme P, 2016, MOL CELL PROTEOMICS, V15, P3361, DOI 10.1074/mcp.M116.061010
   Varland S, 2018, GENE, V644, P27, DOI 10.1016/j.gene.2017.12.019
   Wang ZH, 2011, ASIAN PAC J CANCER P, V12, P1973
   Wang ZH, 2012, P NATL ACAD SCI USA, V109, P3053, DOI 10.1073/pnas.1113356109
   WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3
   Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920
   Yang HJ, 2016, ONCOTARGET, V7, P2709, DOI 10.18632/oncotarget.6458
   Yoon H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6176
   Zeng Y, 2016, TUMOR BIOL, V37, P6719, DOI 10.1007/s13277-015-4563-z
   Zeng Y, 2014, CARCINOGENESIS, V35, P2244, DOI 10.1093/carcin/bgu132
   Zhou Y, 2015, J MOL ENDOCRINOL, V54, pR15, DOI 10.1530/JME-14-0203
NR 65
TC 2
Z9 2
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8010
DI 10.3390/ijms21218010
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OQ7KW
UT WOS:000588958400001
PM 33126484
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, Z
   Oh, S
   Li, DP
   Ni, DJ
   Pirooz, SD
   Lee, JH
   Yang, SH
   Lee, JY
   Ghozalli, I
   Costanzo, V
   Stark, JM
   Liang, CY
AF Zhao, Zhen
   Oh, Soohwan
   Li, Dapeng
   Ni, Duojiao
   Pirooz, Sara Dolatshahi
   Lee, Joo-Hyung
   Yang, Shunhua
   Lee, June-Yong
   Ghozalli, Irene
   Costanzo, Vincenzo
   Stark, Jeremy M.
   Liang, Chengyu
TI A Dual Role for UVRAG in Maintaining Chromosomal Stability Independent
   of Autophagy
SO DEVELOPMENTAL CELL
LA English
DT Article
ID COLON-CANCER; DNA; PROTEIN; CENTROSOME; MECHANISM; GENE;
   PHOSPHORYLATION; INSTABILITY; MUTATIONS; INDUCTION
AB Autophagy defects have recently been associated with chromosomal instability, a hallmark of human cancer. However, the functional specificity and mechanism of action of autophagy-related factors in genome stability remain elusive. Here we report that UVRAG, an autophagic tumor suppressor, plays a dual role in chromosomal stability, surprisingly independent of autophagy. We establish that UVRAG promotes DNA double-strand-break repair by directly binding and activating DNA-PK in nonhomologous end joining. Disruption of UVRAG increases genetic instability and sensitivity of cells to irradiation. Furthermore, UVRAG was also found to be localized at centrosomes and physically associated with CEP63, an integral component of centrosomes. Disruption of the association of UVRAG with centrosomes causes centrosome instability and aneuploidy. UVRAG thus represents an autophagy-related molecular factor that also has a convergent role in patrolling both the structural integrity and proper segregation of chromosomes, which may confer autophagy-independent tumor suppressor activity.
C1 [Zhao, Zhen; Oh, Soohwan; Li, Dapeng; Ni, Duojiao; Pirooz, Sara Dolatshahi; Lee, Joo-Hyung; Yang, Shunhua; Lee, June-Yong; Ghozalli, Irene; Liang, Chengyu] Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   [Costanzo, Vincenzo] London Res Inst, Clare Hall Labs, Genome Stabil Unit, London EN6 3LD, England.
   [Stark, Jeremy M.] Beckman Res Inst City Hope, Dept Radiat Biol, Duarte, CA 91010 USA.
RP Liang, CY (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
EM chengyu.liang@usc.edu
RI zhao, zhen/A-2080-2012; Lee, Joo-Hyung/ABB-7759-2021
OI zhao, zhen/0000-0001-8967-5570; Lee, Joo-Hyung/0000-0001-5345-1102; Lee,
   June-Yong/0000-0002-4476-725X; LIANG, CHENGYU/0000-0001-6082-2143;
   Costanzo, Vincenzo/0000-0002-2920-9508
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [E14TG2a.4,
   AC0571, R01 CA140964, R21 AI083841, R01 CA120954]; National Cancer
   Institute Cancer CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [5 P30 CA014089]; USC; Baxter Foundation; American
   Cancer SocietyAmerican Cancer Society [RSG-11-121-01-CCG]; National
   Institute of Allergy and Infectious DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [NIAID
   U19AI083025]; Norris Cancer Center [P30CA014089-34]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA014089, R21CA161436, R01CA140964, R01CA120954] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19AI083025, R21AI083841] Funding Source: NIH RePORTER
FX The authors acknowledge the National Institutes of Health
   (NIH)-sponsored Mutant Mouse Regional Resource Center National System as
   the source of genetically altered UVRAG<SUP>+/+</SUP> (E14TG2a.4) and
   UVRAG<SUP>+/-</SUP> (AC0571) mouse embryonic stem cells for use in this
   study. We thank Victoria Bedell and the Cytogenetics Core of the City of
   Hope (Duarte, CA) for the SKY analysis. We also thank Ross Tomaino for
   mass spectrometry analysis. We acknowledge the University of Southern
   California Broad CIRM Center Flow Cytometry Core Facility, supported by
   the National Cancer Institute Cancer Center Shared Grant 5 P30 CA014089
   and the USC Provost Funds in BCC CU Accounts, for flow cytometry study.
   We thank Drs. J.U. Jung, M. Liber, B. Levine, S. Virgin, S. Field, T.
   Yoshimori, and Y. Ohsumi for providing reagents. This work is supported
   by the Baxter Foundation, the American Cancer Society (grant
   RSG-11-121-01-CCG to C.L.), the NIH (grants R01 CA140964 and R21
   AI083841 to C.L. and grant R01 CA120954 to J.M.S.), and core services
   performed through the National Institute of Allergy and Infectious
   Diseases grant NIAID U19AI083025 and Norris Cancer Center grant
   P30CA014089-34 (to C.L.).
CR Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197
   Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166
   [Anonymous], 2010, J NUCLEIC ACIDS, DOI DOI 10.4061/2010/389129
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110
   Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3
   Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021
   Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249
   Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Illuzzi J, 2009, J NEUROSCI RES, V87, P733, DOI 10.1002/jnr.21881
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang CY, 2010, CURR OPIN CELL BIOL, V22, P226, DOI 10.1016/j.ceb.2009.11.003
   Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202
   Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015
   Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Muller C, 2001, ONCOGENE, V20, P4373, DOI 10.1038/sj.onc.1204571
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924
   Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358
   Perelman B, 1997, GENOMICS, V41, P397, DOI 10.1006/geno.1997.4623
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Smith E, 2009, NAT CELL BIOL, V11, P278, DOI 10.1038/ncb1835
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 40
TC 63
Z9 68
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD MAY 15
PY 2012
VL 22
IS 5
BP 1001
EP 1016
DI 10.1016/j.devcel.2011.12.027
PG 16
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA 945QS
UT WOS:000304291700013
PM 22542840
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Feidantsis, K
   Georgoulis, I
   Giantsis, IA
   Michaelidis, B
AF Feidantsis, Konstantinos
   Georgoulis, Ioannis
   Giantsis, Ioannis A.
   Michaelidis, Basile
TI Treatment with ascorbic acid normalizes the aerobic capacity,
   antioxidant defence, and cell death pathways in thermally stressed
   Mytilus galloprovincialis
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
   BIOLOGY
LA English
DT Article
DE Ascorbic acid; Antioxidant response; Cell death pathways; Energy
   capacity; Heat stress; Mediterranean mussel
ID SUPEROXIDE-DISMUTASE ACTIVITY; COLON-CANCER CELLS; OXIDATIVE STRESS;
   VITAMIN-C; INDUCED APOPTOSIS; REFERENCE GENES; CLIMATE-CHANGE; BCL-2
   FAMILY; AUTOPHAGY; OXIDASE
AB Considering temperature's upcoming increase due to climate change, combined with the fact that Mediterranean mussels Mytilus galloprovincialis (Lamarck, 1819) live at their upper limits [critical temperatures (Tc) beyond 25 degrees C], we cannot be sure of this species' sustainable future in the Mediterranean Sea. Deviation from optimum temperatures leads to cellular damage due to oxidative stress. Although ascorbic acid (AA) is a major scavenger of reactive oxygen species (ROS), its capacity to minimize oxidative stress effects is scarcely studied in aquatic organisms. Thus, treatment with 5 mM and 10 mM AA of thermally stressed molluscs had been employed in order to examine its antioxidant capacity. While 5 mM had no effect, 10 mM normalized COXI and ND2 relative mRNA levels, and superoxide dismutase (SOD), catalase, and glutathione reductase (GR) enzymatic activity levels in both examined tissues: posterior adductor muscle (PAM) and mantle. ATP levels, probably providing the adequate energy for antioxidant defence in thermally stressed mussels, is also normalized under 10 mM AA treatment. Moreover, autophagic indicators such as LC3 II/I and SQSTMl1/p62 levels are normalized, indicating autophagy amelioration. Apoptosis also seems to be inhibited since both Bax/Bcl-2 and cleaved caspase substrate levels decrease with 10 mM AA treatment. Therefore, treatment of mussels with AA seems to produce threshold effects, although the precise underlying mechanisms must be elucidated in future studies. These findings show that treatment of mussels with effective antioxidants can be useful as a strategic approach for the reduction of the deleterious effects on mussels' summer mortality in aquaculture zones.
C1 [Feidantsis, Konstantinos; Georgoulis, Ioannis; Michaelidis, Basile] Aristotle Univ Thessaloniki, Sch Biol, Dept Zool, Lab Anim Physiol, GR-54124 Thessaloniki, Greece.
   [Giantsis, Ioannis A.] Univ Western Macedonia, Fac Agr Sci, Dept Anim Sci, Florina 53100, Greece.
RP Feidantsis, K (corresponding author), Aristotle Univ Thessaloniki, Sch Biol, Dept Zool, Lab Anim Physiol, GR-54124 Thessaloniki, Greece.
EM kfeidant@bio.auth.gr
RI Giantsis, Ioannis A./D-4382-2013
OI Giantsis, Ioannis A./0000-0002-6323-2955
FU European UnionEuropean Commission; Greek national funds through the
   Operational Program Competitiveness, Entrepreneurship and Innovation,
   under the call Special Actions AQUACULTURE -INDUSTRIAL MATERIALS -OPEN
   INNOVATION IN CULTURE [T6YBPi-00388]
FX This research has been co-financed by the European Union and Greek
   national funds through the Operational Program Competitiveness,
   Entrepreneurship and Innovation, under the call Special Actions
   AQUACULTURE -INDUSTRIAL MATERIALS -OPEN INNOVATION IN CULTURE (project
   code: T6YB Pi-00388; Project acronym: SmartMussel).
CR Abele D, 2002, J EXP BIOL, V205, P1831
   Abele D, 2001, ANTARCT SCI, V13, P111, DOI 10.1017/S0954102001000189
   Adam H., 1963, METHODS ENZYMATIC AN
   Anestis A, 2007, AM J PHYSIOL-REG I, V293, pR911, DOI 10.1152/ajpregu.00124.2007
   Azqueta A, 2013, NUTRIENTS, V5, P1200, DOI 10.3390/nu5041200
   Barros V, 2014, CLIMATE CHANGE 2014: IMPACTS, ADAPTATION, AND VULNERABILITY, PT A: GLOBAL AND SECTORAL ASPECTS, pIX
   Bayne B, 2017, DEV AQUAC FISH SCI, V41, P505, DOI 10.1016/B978-0-12-803472-9.00008-X
   Betancor MB, 2012, LIPIDS, V47, P1193, DOI 10.1007/s11745-012-3730-x
   BETHOUX JP, 1990, NATURE, V347, P660, DOI 10.1038/347660a0
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Bourens M, 2013, ANTIOXID REDOX SIGN, V19, P1940, DOI 10.1089/ars.2012.4847
   Calvo N, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015226
   CARLBERG I, 1985, METHOD ENZYMOL, V113, P484
   Cassel M, 2017, J MOL HISTOL, V48, P243, DOI 10.1007/s10735-017-9723-6
   Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6
   Childs AC, 2002, CANCER RES, V62, P4592
   Chung DJ, 2020, J EXP BIOL, V223, DOI 10.1242/jeb.227801
   COHEN G, 1970, ANAL BIOCHEM, V34, P30, DOI 10.1016/0003-2697(70)90083-7
   Connelly AE, 2003, CANCER EPIDEM BIOMAR, V12, P559
   Curole JP, 2002, MOL BIOL EVOL, V19, P1323, DOI 10.1093/oxfordjournals.molbev.a004193
   DAROS L, 1985, B ZOOL, V52, P223, DOI 10.1080/11250008509440522
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9895
   DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961
   Dickinson GH, 2012, J EXP BIOL, V215, P29, DOI 10.1242/jeb.061481
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X
   Feidantsis K, 2020, AM J PHYSIOL-REG I, V319, pR264, DOI 10.1152/ajpregu.00066.2020
   Feidantsis K, 2020, J COMP PHYSIOL B, V190, P403, DOI 10.1007/s00360-020-01278-1
   FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6
   Galati D, 2009, BIOCHEM J, V420, P439, DOI 10.1042/BJ20090214
   Gambaiani DD, 2009, J MAR BIOL ASSOC UK, V89, P179, DOI 10.1017/S0025315408002476
   Georgoulis I., 2020, CEUR WORKSH P, V2761, P51
   Giannetto A, 2017, MAR BIOTECHNOL, V19, P614, DOI 10.1007/s10126-017-9780-6
   Giantsis IA, 2014, INT J MOL SCI, V15, P11614, DOI 10.3390/ijms150711614
   Green D., 2011, MEANS END APOPTOSIS
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Heise K, 2007, J COMP PHYSIOL B, V177, P765, DOI 10.1007/s00360-007-0173-4
   Heise K, 2006, COMP BIOCHEM PHYS A, V143, P494, DOI 10.1016/j.cbpa.2006.01.014
   Heise K, 2006, J EXP BIOL, V209, P353, DOI 10.1242/jeb.01977
   Hernando M., 2018, Mussels, characteristics, biology and conservation, P155
   Hochachka PW., 2002, BIOCH ADAPTATION MEC
   HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709
   Hofmann GE, 1996, MAR BIOL, V126, P65, DOI 10.1007/BF00571378
   Hung TH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012202
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kawada H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062717
   Khan MA, 2006, FOOD CHEM, V99, P605, DOI 10.1016/j.foodchem.2005.08.001
   Kim GU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55303-7
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Kobayashi S, 2015, BIOL PHARM BULL, V38, P1098, DOI 10.1248/bpb.b15-00096
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Lamprecht W., 1963, METHODS ENZYMATIC AN
   Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01
   Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544
   Lesser MP, 2006, ANNU REV PHYSIOL, V68, P253, DOI 10.1146/annurev.physiol.68.040104.110001
   Lockwood BL, 2010, J EXP BIOL, V213, P3548, DOI 10.1242/jeb.046094
   Marba N, 2015, FRONT MAR SCI, V2, DOI 10.3389/fmars.2015.00056
   Mehrpak M., 2015, IRAN J TOXICOL, V9, P1360
   Merchie G, 1997, AQUACULTURE, V155, P165, DOI 10.1016/S0044-8486(97)00115-4
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moreira R, 2014, AQUAT LIVING RESOUR, V27, P147, DOI 10.1051/alr/2014015
   Nagappan A, 2012, FOOD CHEM, V135, P1920, DOI 10.1016/j.foodchem.2012.06.050
   Nicholls RJ, 1996, OCEAN COAST MANAGE, V31, P105, DOI 10.1016/S0964-5691(96)00037-3
   Niizuma K, 2010, BBA-MOL BASIS DIS, V1802, P92, DOI 10.1016/j.bbadis.2009.09.002
   Nimse SB, 2015, RSC ADV, V5, P27986, DOI 10.1039/c4ra13315c
   PALADINO FV, 1980, REV CAN BIOL EXPTL, V39, P115
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209
   Passonneau J. V., 1993, ENZYMATIC ANAL PRACT
   Portner HO, 2007, SCIENCE, V315, P95, DOI 10.1126/science.1135471
   Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156
   Portner HO, 2002, COMP BIOCHEM PHYS A, V132, P739, DOI 10.1016/S1095-6433(02)00045-4
   Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010
   Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200
   Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143
   Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0
   RIBERA D, 1989, MAR ENVIRON RES, V28, P279, DOI 10.1016/0141-1136(89)90244-4
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Salach J I Jr, 1978, Methods Enzymol, V53, P495
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Sokolova IM, 2000, J COMP PHYSIOL B, V170, P91, DOI 10.1007/s003600050264
   Sokolova I, 2018, INTEGR COMP BIOL, V58, P519, DOI 10.1093/icb/icy017
   Sokolova IM, 2013, INTEGR COMP BIOL, V53, P597, DOI 10.1093/icb/ict028
   Somero GN, 2010, J EXP BIOL, V213, P912, DOI 10.1242/jeb.037473
   Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021
   Takle H, 2007, J FISH BIOL, V71, P326, DOI 10.1111/j.1095-8649.2007.01665.x
   Tomasetti M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052263
   Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235
   van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028
   Volland M, 2017, AQUAT TOXICOL, V185, P86, DOI 10.1016/j.aquatox.2017.01.003
   Vuyyuri SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067081
   Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020
   Wang J, 2018, J MOLLUS STUD, V84, P285, DOI 10.1093/mollus/eyy027
   Wang J, 2018, COMP BIOCHEM PHYS A, V222, P7, DOI 10.1016/j.cbpa.2018.04.001
   Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079
   Wenzel U, 2003, INT J CANCER, V106, P666, DOI 10.1002/ijc.11294
   Wheeler G, 2015, ELIFE, V4, DOI 10.7554/eLife.06369
   Wilson JX, 2005, ANNU REV NUTR, V25, P105, DOI 10.1146/annurev.nutr.25.050304.092647
   Wilson MK, 2014, ASIA-PAC J CLIN ONCO, V10, P22, DOI 10.1111/ajco.12173
   Woo S, 2013, ZOOL STUD, V52, DOI 10.1186/1810-522X-52-15
   Yabu T, 2003, FISHERIES SCI, V69, P1218, DOI 10.1111/j.0919-9268.2003.00748.x
   Zhong XL, 2017, J OCCUP MED TOXICOL, V12, DOI 10.1186/s12995-017-0161-x
NR 109
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1096-4959
EI 1879-1107
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD AUG-SEP
PY 2021
VL 255
AR 110611
DI 10.1016/j.cbpb.2021.110611
EA MAY 2021
PG 11
WC Biochemistry & Molecular Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Zoology
GA SJ4NX
UT WOS:000655511800014
PM 33965617
DA 2022-04-25
ER

PT J
AU Maclean, KH
   Dorsey, FC
   Cleveland, JL
   Kastan, MB
AF Maclean, Kirsteen H.
   Dorsey, Frank C.
   Cleveland, John L.
   Kastan, Michael B.
TI Targeting lysosomal degradation induces p53-dependent cell death and
   prevents cancer in mouse models of lymphomagenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID MYC-INDUCED LYMPHOMAGENESIS; CYTOCHROME-C RELEASE; BCL-X-L; SIGNALING
   PATHWAYS; INDUCED APOPTOSIS; TRANSGENIC MICE; AUTOPHAGY; P53; ATM;
   PHOSPHORYLATION
AB Despite great interest in cancer chemoprevention, effective agents are few. Here we show that chloroquine, a drug that activates the stress-responsive Atm-p53 tumor-suppressor pathway, preferentially enhances the death of Myc oncogene-overexpressing primary mouse B cells and mouse embryonic fibroblasts (MEFs) and impairs Myc-induced lymphomagenesis in a transgenic mouse model of human Burkitt lymphoma. Chloroquine-induced cell death in primary MEFs and human colorectal cancer cells was dependent upon p53, but not upon the p53 modulators Atm or Arf. Accordingly, chloroquine impaired spontaneous lymphoma development in Atm-deficient mice, a mouse model of ataxia telangiectasia, but not in p53-deficient mice. Chloroquine treatment enhanced markers of both macroautophagy and apoptosis in MEFs but ultimately impaired lysosomal protein degradation. Interestingly, chloroquine-induced cell death was not dependent on caspase-mediated apoptosis, as neither overexpression of the antiapoptotic protein Bcl-2 nor deletion of the proapoptotic Bax and Bak affected chloroquine-induced MEF death. However, when both apoptotic and autophagic pathways were blocked simultaneously, chloroquine-induced killing of Myc-overexpressing cells was blunted. Thus chloroquine induces lysosomal stress and provokes a p53-dependent cell death that does not require caspase-mediated apoptosis. These fmdings specifically demonstrate that intermittent chloroquine use effectively prevents cancer in mouse models of 2 genetically distinct human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia, suggesting that agents targeting lysosome-mediated degradation may be effective in cancer prevention.
C1 [Dorsey, Frank C.; Cleveland, John L.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL 33458 USA.
   [Maclean, Kirsteen H.; Kastan, Michael B.] St Jude Childrens Res Hosp, Dept Oncol, Div Mol Therapeut, Memphis, TN 38105 USA.
RP Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, Div Mol Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM jcleve@scripps.edu; michael.kastan@stjude.org
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA071387, R01 CA076379, CA21765, CA76379, P30 CA021765, CA71387] Funding
   Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [R37 ES005777, ES05777, R01
   ES005777] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA021765,
   R01CA071387, R01CA076379] Funding Source: NIH RePORTER
CR ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   ASKEW DS, 1991, ONCOGENE, V6, P1915
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0
   Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009
   BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658
   Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001
   EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T
   FANIDI A, 1992, P NATL ACAD SCI USA, V59, P554
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ferraro E, 2007, ARCH BIOCHEM BIOPHYS, V462, P210, DOI 10.1016/j.abb.2007.02.006
   GESER A, 1989, AM J EPIDEMIOL, V129, P740, DOI 10.1093/oxfordjournals.aje.a115189
   Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973
   GLAUMANN H, 1987, EXP MOL PATHOL, V47, P346, DOI 10.1016/0014-4800(87)90018-9
   HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491
   Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kundu M, 2005, CELL DEATH DIFFER, V12, P1484, DOI 10.1038/sj.cdd.4401780
   LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2
   LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686
   Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8
   Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003
   Maclean KH, 2007, MOL CANCER RES, V5, P705, DOI 10.1158/1541-7786.MCR-07-0058
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103
   Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4
   Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563
   Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471
   Stoka V, 2007, BIOL CHEM, V388, P555, DOI 10.1515/BC.2007.064
   Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Williams-Simons L, 1999, TRANSGENIC RES, V8, P253, DOI 10.1023/A:1008994831937
   Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 59
TC 232
Z9 244
U1 2
U2 29
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2008
VL 118
IS 1
BP 79
EP 88
DI 10.1172/JCI33700
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 248AE
UT WOS:000252122900011
PM 18097482
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Duan, L
   Deng, LJ
   Wang, DB
   Ma, SC
   Li, CM
   Zhao, D
AF Duan, Ling
   Deng, Leijiao
   Wang, Dabin
   Ma, Shoucheng
   Li, Chunmei
   Zhao, Da
TI Treatment mechanism of matrine in combination with irinotecan for colon
   cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE matrine; irinotecan; colon cancer; HT29 cells; apoptosis
ID CELLS; APOPTOSIS; PROLIFERATION; MITOCHONDRIA; METASTASIS; INHIBITION;
   AUTOPHAGY; P38
AB The inhibitory effect of matrine (MA) was studied in combination with irinotecan (CPT-11) on proliferation of human colon carcinoma cell line HT29. We also explored the mechanism of cell apoptosis induction in HT29. HT29 cells were treated with different concentrations of MA and CPT-11 alone and in combination. The growth inhibition in HT29 cells was evaluated using MTT assay. Apoptosis was detected using AV-PI double staining flow cytometry. Transmission electron microscopy was used to detect structural changes in cells. Topoisomerase (TOPO) I, Bax and Caspase-3 expression levels were evaluated using western blot analysis. MA and CPT-11 alone and in combination, inhibited the proliferation of HT29 cells, whereas the combination treatment exhibited higher inhibitory effect (P<0.01). This suggests the existence of synergistic cytotoxicity. Compared with each treatment alone, the combination treatment caused more significant damage to cell structure, and caused a significantly higher apoptosis rate (P<0.01). Additionally, the combination treatment increased TOPO I, Bax and Caspase-3 expression levels (P<0.01). In conclusion, MA in combination with CPT-11 synergistically inhibited HT29 cell proliferation and induced apoptosis in these cells. The mechanism may be related to upregulation of the TOPO I, Bax and Caspase-3 protein expression.
C1 [Duan, Ling; Ma, Shoucheng; Li, Chunmei; Zhao, Da] Lanzhou Univ, Hosp 1, Dept Oncol, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
   [Deng, Leijiao] Lanzhou Univ, Hosp 1, Dept Pharm, Lanzhou 730000, Gansu, Peoples R China.
   [Wang, Dabin] Peoples Hosp Gansu Prov, Dept Anesthesiol, Lanzhou 730000, Gansu, Peoples R China.
RP Zhao, D (corresponding author), Lanzhou Univ, Hosp 1, Dept Oncol, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
EM zbo662@163.com
CR Chen MC, 2017, ENVIRON TOXICOL, V32, P669, DOI 10.1002/tox.22268
   Chui CH, 2004, ACAD THI MED U, V26, P778
   Fang XL, 2009, CHIN J CLIN RATION D, V2, P8
   Gordon MB, 2016, CASE REP ENDOCRINOL, V2016
   Heit B, 2011, AM J PHYSIOL-CELL PH, V300, pC33, DOI 10.1152/ajpcell.00139.2010
   [黄建 HUANG Jian], 2007, [中草药, Chinese Traditional and Herbal Drugs], V38, P1210
   Indran IR, 2011, BBA-BIOENERGETICS, V1807, P735, DOI 10.1016/j.bbabio.2011.03.010
   Ismaili N, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-154
   Jeong JC, 2009, NEUROCHEM RES, V34, P991, DOI 10.1007/s11064-008-9868-5
   Lee YS, 2002, CANCER LETT, V186, P83, DOI 10.1016/S0304-3835(02)00260-4
   Li HL, 2010, AM J CHINESE MED, V38, P1115, DOI 10.1142/S0192415X10008512
   Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053
   Lujan HJ, 2002, DIS COLON RECTUM, V45, P491, DOI 10.1007/s10350-004-6227-8
   Phelps MA, 2014, J CLIN ONCOL, V32, P2287, DOI 10.1200/JCO.2014.56.3387
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Ren HT, 2014, ACTA BIOCH BIOPH SIN, V46, P1049, DOI 10.1093/abbs/gmu101
   Sileri P, 2009, SOUTH MED J, V102, P733, DOI 10.1097/SMJ.0b013e3181a93c39
   Venkatesan P, 2012, LIFE SCI, V91, P789, DOI 10.1016/j.lfs.2012.08.024
   Zhang JQ, 2010, WORLD J GASTROENTERO, V16, P4281, DOI 10.3748/wjg.v16.i34.4281
   Zhang JQ, 2011, ONCOL REP, V26, P115, DOI 10.3892/or.2011.1277
   Zhang LP, 2001, LEUKEMIA RES, V25, P793, DOI 10.1016/S0145-2126(00)00145-4
   Zhang Ming-Qian, 2015, Asian Pac J Cancer Prev, V16, P1993
   Zhang Y, 2009, CYTOTECHNOLOGY, V59, P191, DOI 10.1007/s10616-009-9211-2
NR 23
TC 15
Z9 18
U1 2
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2017
VL 14
IS 2
BP 2300
EP 2304
DI 10.3892/ol.2017.6407
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FE0IS
UT WOS:000407904600152
PM 28781667
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

EF